<SEC-DOCUMENT>0001641172-25-000070.txt : 20250320
<SEC-HEADER>0001641172-25-000070.hdr.sgml : 20250320
<ACCEPTANCE-DATETIME>20250320163124
ACCESSION NUMBER:		0001641172-25-000070
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		104
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250320
DATE AS OF CHANGE:		20250320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Processa Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001533743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				451539785
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39531
		FILM NUMBER:		25756942

	BUSINESS ADDRESS:	
		STREET 1:		7380 COCA COLA DRIVE
		STREET 2:		SUITE 106
		CITY:			HANOVER
		STATE:			MD
		ZIP:			21076
		BUSINESS PHONE:		443-776-3133

	MAIL ADDRESS:	
		STREET 1:		7380 COCA COLA DRIVE
		STREET 2:		SUITE 106
		CITY:			HANOVER
		STATE:			MD
		ZIP:			21076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Heatwurx, Inc.
		DATE OF NAME CHANGE:	20111028
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:PCSA="http://processapharmaceuticals.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_PCSA_processapharmaceuticals.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001533743 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_070_SO_Z%2D%2D\2025 OPERATIONS\EDGAR\02 FEBRUARY\PROCESSA PHARMACEUTICALS, INC\02%2D26%2D2025\Form 10%2DK(December 31, 2024)\Draft\Production\form10%2Dk.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001533743</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0087" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0090" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:DueToLicensor" contextRef="AsOf2024-12-31" id="xdx2ixbrl0119" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0122" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0140" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0141" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0146" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0147" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0259" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:FinancingLeaseLiability" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:NonCashLeaseLiabilityNet" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:NonCashLeaseLiabilityNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0591" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0603" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember" id="xdx2ixbrl0655" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember" id="xdx2ixbrl0657" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember" id="xdx2ixbrl0659" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember" id="xdx2ixbrl0661" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember" id="xdx2ixbrl0663" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember" id="xdx2ixbrl0665" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_RestrictedStockAwardMember" id="xdx2ixbrl0671" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_custom_RestrictedStockAwardMember" id="xdx2ixbrl0673" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2024-12-31" id="xdx2ixbrl1001" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">http://processapharmaceuticals.com/20241231#OperatingAndFinanceLeaseLiabilityCurrent</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl1003" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2024-12-31" id="xdx2ixbrl1004" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">http://processapharmaceuticals.com/20241231#OperatingAndFinanceLeaseLiabilityNoncurrent</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-31" id="xdx2ixbrl1019" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">http://processapharmaceuticals.com/20241231#OperatingAndFinanceLeaseLiabilityCurrent</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-31" id="xdx2ixbrl1022" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">http://processapharmaceuticals.com/20241231#OperatingAndFinanceLeaseLiabilityNoncurrent</ix:nonNumeric>
  <ix:nonFraction name="PCSA:DeferredTaxAssetsStartupExpenditures" contextRef="AsOf2024-12-31" id="xdx2ixbrl1097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:DeferredTaxAssetsStartupExpenditures" contextRef="AsOf2023-12-31" id="xdx2ixbrl1098" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1106" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1107" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2024-12-31" id="xdx2ixbrl1109" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2023-12-31" id="xdx2ixbrl1110" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2024-12-31" id="xdx2ixbrl1112" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-12-31" id="xdx2ixbrl1113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2024-12-31" id="xdx2ixbrl1115" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2023-12-31" id="xdx2ixbrl1116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_us-gaap_WarrantMember_custom_PurchaseAgreementMember" id="xdx2ixbrl1201" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="pcsa-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-222024-01-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-22</xbrli:startDate>
        <xbrli:endDate>2024-01-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-272025-01-27_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-27</xbrli:startDate>
        <xbrli:endDate>2025-01-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-27_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-27_custom_SeriesAWarrantsMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesAWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-27_custom_SeriesBWarrantsMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesBWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-12_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-10_custom_TwoThousandAndNineteenPlanMember_custom_OriginalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:OriginalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-28_custom_TwoThousandAndNineteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandAndNineteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-282024-06-28_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-28</xbrli:startDate>
        <xbrli:endDate>2024-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_JanuaryOneTwoThousandTwentyFiveVestingMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:JanuaryOneTwoThousandTwentyFiveVestingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-28</xbrli:startDate>
        <xbrli:endDate>2024-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_EmployeesMember_custom_ThreeYearVestingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:ThreeYearVestingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-28</xbrli:startDate>
        <xbrli:endDate>2024-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-282024-06-28_custom_FirstPerformanceBasedRSUMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:FirstPerformanceBasedRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-28</xbrli:startDate>
        <xbrli:endDate>2024-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-282024-06-28_custom_SecondPerformanceBasedRSUMember_custom_NextGenerationCapecitabineCAPMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SecondPerformanceBasedRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:NextGenerationCapecitabineCAPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-28</xbrli:startDate>
        <xbrli:endDate>2024-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-16</xbrli:startDate>
        <xbrli:endDate>2024-07-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySixteenTwoThousandTwentyFiveVestingMember_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:JulySixteenTwoThousandTwentyFiveVestingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-16</xbrli:startDate>
        <xbrli:endDate>2024-07-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_FirstPerformanceBasedRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:FirstPerformanceBasedRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-16</xbrli:startDate>
        <xbrli:endDate>2024-07-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_FirstPerformanceBasedRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:FirstPerformanceBasedRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_SecondPerformanceBasedRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:SecondPerformanceBasedRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-16</xbrli:startDate>
        <xbrli:endDate>2024-07-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_SecondPerformanceBasedRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:SecondPerformanceBasedRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-032024-09-03_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-03</xbrli:startDate>
        <xbrli:endDate>2024-09-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember_custom_OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ConsultantMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-172023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:SpartanCapitalSecuritesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-17</xbrli:startDate>
        <xbrli:endDate>2023-04-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:SpartanCapitalSecuritesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-182023-11-18_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-18</xbrli:startDate>
        <xbrli:endDate>2023-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-18_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RestrictedStockAwardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:RestrictedStockAwardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember417832562">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_RestrictedStockAwardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:RestrictedStockAwardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RestrictedStockAwardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:RestrictedStockAwardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_RestrictedStockAwardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:RestrictedStockAwardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RestrictedStockAwardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:RestrictedStockAwardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-292024-01-30_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-29</xbrli:startDate>
        <xbrli:endDate>2024-01-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-30_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ATMOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:ATMOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ATMOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:ATMOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PurchaseAgreementMember_custom_PlacementAgentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-142023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:AccreditedInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-14</xbrli:startDate>
        <xbrli:endDate>2023-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:AccreditedInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-142023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-14</xbrli:startDate>
        <xbrli:endDate>2023-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-17_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember417833750">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember417833750">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_FacilityLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">PCSA:FacilityLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FacilityLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">PCSA:FacilityLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ElionOncologyIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:ElionOncologyIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OcuphirePharmaIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:OcuphirePharmaIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AposenseLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:AposenseLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_YuhanCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:YuhanCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CoNCERTPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CoNCERTPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">PCSA:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CROsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:CROsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_SeriesAWarrantMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesAWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_SeriesBWarrantMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesBWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_ChiefExecutiveOfficerAndCertainBoardMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ChiefExecutiveOfficerAndCertainBoardMembersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_SeriesAAndBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesAAndBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_us-gaap_WarrantMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-272025-01-27_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-27</xbrli:startDate>
        <xbrli:endDate>2025-01-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-27_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-30_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-12_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-272025-01-27_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-27</xbrli:startDate>
        <xbrli:endDate>2025-01-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>PCSA:Segment</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001149" toRefs="Footnote001169"/>
  <ix:relationship fromRefs="Fact001150" toRefs="Footnote001169"/>
  <ix:relationship fromRefs="Fact001155" toRefs="Footnote001174"/>
  <ix:relationship fromRefs="Fact001156" toRefs="Footnote001174"/>
  <ix:relationship fromRefs="Fact001161" toRefs="Footnote001179"/>
  <ix:relationship fromRefs="Fact001162" toRefs="Footnote001179"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_905_edei--DocumentType_c20240101__20241231_zlNaNKids3Lf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000013" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--DocumentAnnualReport_c20240101__20241231_z072BKcRyi6b"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
<b>Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_900_edei--DocumentPeriodEndDate_c20240101__20241231_zbACp3hMLWLe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate"><span id="xdx_90D_edei--CurrentFiscalYearEndDate_c20240101__20241231_z9muUqVb2Ij8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000016" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90F_edei--DocumentFiscalYearFocus_c20240101__20241231_zCJ6FEnYb3h4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000017" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>or</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--DocumentTransitionReport_c20240101__20241231_zqRp6mv7J6rl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000018" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
<b>Transitional Report under Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number <span id="xdx_90E_edei--EntityFileNumber_c20240101__20241231_zS6pXP2vzQu8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000019" name="dei:EntityFileNumber">001-39531</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_906_edei--EntityRegistrantName_c20240101__20241231_zWGdfKpN1h6f"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000020" name="dei:EntityRegistrantName">Processa
Pharmaceuticals, Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20240101__20241231_z9oc6M11KOr7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000021" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20240101__20241231_zuoGk6LAE6S6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:EntityTaxIdentificationNumber">45-1539785</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20240101__20241231_zA2UGiS8SLNl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000023" name="dei:EntityAddressAddressLine1">7380
Coca Cola Drive</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20240101__20241231_z5CpRJHzV8Qc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityAddressAddressLine2">Suite 106</ix:nonNumeric></span>,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityAddressCityOrTown_c20240101__20241231_zqfoMgWIy1Bi"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000025" name="dei:EntityAddressCityOrTown">Hanover</ix:nonNumeric></span>,
<span id="xdx_903_edei--EntityAddressStateOrProvince_c20240101__20241231_z6w22YGgWzei"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000026" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_908_edei--EntityAddressPostalZipCode_c20240101__20241231_z3d5y5Myrhuk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:EntityAddressPostalZipCode">21076</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_901_edei--CityAreaCode_c20240101__20241231_zTmLACZUkpMh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:CityAreaCode">(443)</ix:nonNumeric></span>
<span id="xdx_90F_edei--LocalPhoneNumber_c20240101__20241231_zzim0kH7JiWd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000029" name="dei:LocalPhoneNumber">776-3133</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--Security12bTitle_c20240101__20241231_zsStVByHwWOl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000030" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20240101__20241231_zFkjG6yesuZd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000031" name="dei:TradingSymbol">PCSA</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--SecurityExchangeName_c20240101__20241231_zgmOYd0Zxofa"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:exchnameen" id="Fact000032" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_90E_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_zVWMk9WfpOQ8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000033" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_903_edei--EntityVoluntaryFilers_c20240101__20241231_z6lsyLDQXbB1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000034" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_90E_edei--EntityCurrentReportingStatus_c20240101__20241231_zGHabob1muE7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000035" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span id="xdx_90F_edei--EntityInteractiveDataCurrent_c20240101__20241231_z77qidsATD4c"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000036" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityFilerCategory_c20240101__20241231_zoHxawfNkhXk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000037" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntitySmallBusiness_c20240101__20241231_zQKgHJfQMl3i"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000038" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityEmergingGrowthCompany_c20240101__20241231_zxL3HHU7bSq1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000039" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its managements&#8217; assessment of the effectiveness
of its internal controls over financial reporting under Section 404(b) of the Sarbanes Oxley Act (15 U.S.C 7262(b)) by the registered
public accounting firm that prepared or issued its audit report <span id="xdx_900_edei--IcfrAuditorAttestationFlag_c20240101__20241231_zWZ99z5H8xDj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000040" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_905_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_zhNq1dA4seTj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000041" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_904_edei--EntityShellCompany_dbF_c20240101__20241231_z16fxUzf9Xx9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000042" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the voting and non-voting common equity held by non-affiliates on June 28, 2024, the last business day of the
most recently completed second quarter, based upon the closing price of Common Stock on such date as reported on Nasdaq Capital Market,
was approximately $<span id="xdx_901_edei--EntityPublicFloat_iI_pn5n6_c20240628_zE70LJpfyiv8"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-28" id="Fact000043" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.8</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of outstanding shares of the registrant&#8217;s common stock as of March 12, 2025 was <span id="xdx_904_edei--EntityCommonStockSharesOutstanding_iI_c20250312_zLn9iRzayAsd"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-03-12" id="Fact000044" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,269,240</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED BY REFERENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--DocumentsIncorporatedByReferenceTextBlock_c20240101__20241231_zV14nhrNup0g"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000045" name="dei:DocumentsIncorporatedByReferenceTextBlock">None.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Part
    I</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Business.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Risk
    Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unresolved
    Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">52</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Properties.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Legal
    Proceedings.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Mine
    Safety Disclosures.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Part
    II</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Market
    for Registrant&#8217;s Common Equity, Related Stockholder Matters and issuer Purchases of Equity Securities.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">[Reserved]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_001">Quantitative
    and Qualitative Disclosures About Market Risk.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_002">Financial
    Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_009">Changes
    in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_010">Controls
    and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_011">Other
    Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_012">Disclosure
    Regarding Foreign Jurisdictions that Prevent Inspection</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_013">Part
    III</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_014">Directors,
    Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_015">Executive
    Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_016">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_017">Certain
    Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_018">Principal
    Accounting Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_019">Part
    IV</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_020">Exhibits,
    Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_021">Form
    10-K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_022">Signatures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLOSSARY
OF CERTAIN SCIENTIFIC TERMS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
medical and scientific terms used in this Annual Report on Form 10-K have the following meanings:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Active
Metabolite&#8221; means a drug that is processed by the body into an altered form which effects the body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Agonist&#8221;
means a chemical/drug that binds to a receptor in the body and activates that receptor to produce a biological response.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Analog&#8221;
means a compound having a structure similar to that of an approved drug but differing from it with respect to a certain component of
the molecule which may cause it to have similar or different effects on the body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;cGCP&#8221;
means current Good Clinical Practices. The FDA and other regulatory agencies promulgate regulations and standards, commonly referred
to as current Good Clinical Practices, for designing, conducting, monitoring, auditing and reporting the results of clinical trials to
ensure that the data and results are accurate and that the rights and welfare of trial participants are adequately protected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;cGMP&#8221;
means current Good Manufacturing Practices. The FDA and other regulatory agencies promulgate regulations and standards, commonly referred
to as current Good Manufacturing Practices, which include requirements relating to quality control and quality assurance, as well as
the corresponding maintenance of records and documentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;CMO&#8221;
means Contract Manufacturing Organization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;CRO&#8221;
means Contract Research Organization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Deuterated
analog&#8221; means a small molecule in which one or more of the hydrogen atoms are replaced by deuterium.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;EMA&#8221;
means the European Medicines Agency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FDA&#8221;
means the Food and Drug Administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;IND&#8221;
means an Investigational New Drug Application. Before testing a new drug on human subjects, the company must file an IND with the FDA.
Information must be produced on the absorption, distribution, metabolism, and excretion properties of the drug and detailed protocols
for testing on human subjects must be submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Indication&#8221;
means a condition which makes a particular treatment or procedure advisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Moiety&#8221;
means an active or functional part of a molecule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;NDA&#8221;
means a New Drug Application submitted to the FDA. Under the Food, Drug, and Cosmetic Act of 1938, an NDA is submitted to the FDA enumerating
the uses of the drug and providing evidence of its safety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;NGC&#8221; means Next Generation Cancer therapy, referring to the
drugs in our pipeline that change the metabolism or distribution of existing cancer drugs to increase potency and reduce toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;NL&#8221;
means Necrobiosis Lipoidica, a rare chronic and granulomatous disorder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. All statements other than statements
of historical facts contained in this Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements
by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221;
&#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221;
&#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the
negative of these words or other comparable terminology. We have based these forward-looking statements on our current expectations and
projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short-
and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including those described in &#8220;Risk Factors&#8221; and elsewhere in this Form 10-K. Moreover, we
operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management
to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of
these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Form 10-K may not occur, and
actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these
uncertainties, you should not place undue reliance on these forward-looking statements. These risks are discussed more fully in the &#8220;Risk
Factors&#8221; section of this Annual Report on Form 10-K and are summarized below under the &#8220;Summary Risk Factors&#8221; section.
These risks include, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain funding for our future clinical trials, preclinical activities and our operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to meet obligations under our license agreements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to contract with third-party suppliers, manufacturers and other service providers and their ability to perform adequately;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain regulatory approval of our product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential market size, opportunity and growth potential for our product candidates, if approved;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize our product candidates,
    if approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to advance product candidates into, and successfully complete, clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to recruit and enroll suitable patients in our clinical trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, timing, progress and results of clinical trials and pre-clinical studies for our NGC drugs; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing or likelihood of the accomplishment of various scientific, clinical, regulatory filings and approvals and other product development
    objectives;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    pricing and reimbursement of our product candidates, if approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate and degree of market acceptance of our product candidates by physicians, patients, third-party payors and others in the medical
    community, if approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    implementation of our business model, strategic plans for our business, product candidates and technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    relating to our competitors and our industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    accuracy of our estimates regarding expenses, capital requirements and needs for additional financing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    financial performance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    risks and uncertainties, including those described under part I, Item 1A. Risk Factors of this Annual Report.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected
in the forward-looking statements are reasonable as of the date of this Form 10-K, we cannot guarantee that the future results, levels
of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake
no obligation to update publicly any forward-looking statements for any reason after the date of this Form 10-K to conform these statements
to new information, actual results or to changes in our expectations, except as required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this Form 10-K and the documents that we reference in this Form 10-K and have filed with the SEC as exhibits with the understanding
that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we
expect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this Form 10-K, &#8220;we,&#8221; &#8220;us&#8221;, &#8220;our&#8221;, &#8220;Processa&#8221; and &#8220;the Company&#8221; refer to
Processa Pharmaceuticals, Inc. and its subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>Part
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>Item
1. Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated under the laws of the State of Delaware on March 29, 2011. Our principal executive office is located at 7380 Coca Cola
Drive, Suite 106, Hanover, MD 21076. Our telephone number is (443) 776-3133.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make available free of charge on or through our Internet website (<i>http://www.processapharmaceuticals.com</i>) our Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and, if applicable, amendments to those reports filed or furnished
pursuant to Section 13(a) or 15(d) of the Exchange Act, as well as our Code of Ethics and Code of Conduct, as soon as reasonably practicable
after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (SEC). The SEC also maintains
a website which provides online access to reports and other information regarding registrants that file electronically with the SEC at:
www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained on our website and social media channels is not included as a part of, or incorporated by reference into, this
report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (&#8220;NGC&#8221;) small molecules,
two of which are in, or have completed, Phase 2 trials, and one is in pre-clinical development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our strategy reduces clinical risk, regulatory risk and commercial risk. Our risk-mitigated strategy is to identify existing
cancer therapies where the mechanism of action is well understood and that are cornerstones of current treatment regimens, but are highly
toxic, with side effects that are often treatment limiting (see Our Strategy below). We devise technologies to change the way the body
metabolizes them, or the way they are distributed within the body, to improve the therapeutic effect and reduce toxicity. We then efficiently
develop our pipeline of Next Generation Cancer therapies utilizing our proprietary Regulatory Science Approach (see Regulatory Science
Approach below), which we believe will further increase the likelihood of regulatory approval. Since the underlying drugs are already
commonly used in cancer therapy, we believe, that if our clinical trials are successful, and are showing better efficacy and tolerability
than the currently used drugs, the commercial adoption for our NGC therapies will be rapid and broad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NGC treatments in our pipeline are as follows (see Our Drug Pipeline below for a more detailed discussion of each):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS6422,
                                            also referred to as NGC-Cap, is a combination of PCS6422 and a lower dose of capecitabine.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capecitabine
    is an oral prodrug of the cancer drug 5-fluorouracil (&#8220;5-FU&#8221;), which is further metabolized into cancer-killing metabolites.
    It is used in many solid tumor treatment regimens, like breast cancer and colon cancer. Millions of doses of capecitabine are used
    annually. In 2021 Medicare Part B alone reports over 9.2 million dosing units used. Significant side effects, such as Hand-Foot Syndrome
    (&#8220;HFS&#8221;) and cardiotoxicity, typically occur in up to 70% of patients treated with capecitabine. These side effects frequently
    result in decreased or interrupted doses, or discontinuation of treatment with capecitabine, which undermines its effectiveness to
    the patient.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS6422,
    without having any clinically meaningful anti-cancer effect itself, alters the
    metabolism of 5-FU within the body, reducing interpatient and intrapatient variability in DPD, raising plasma levels of bioavailable
    5-FU, and lengthening the time of pharmacologic exposure to the drug. This results in increased 5-FU distribution to the cancer cells.
    NGC-Cap has been found to be up to 50 times more potent than capecitabine alone, based on the systemic exposure of the capecitabine
    metabolite 5-FU.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    clinical trials, NGC-Cap has shown a better safety profile than capecitabine alone. Since a much smaller amount of these metabolites
    are formed with NGC-Cap, the side effects appear in fewer patients and are less severe. Like capecitabine, NGC-Cap could potentially
    be used to treat patients with various cancers, such as breast, colorectal, gastrointestinal, and pancreatic.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    2024, we started our Phase 2 trial of NGC-Cap in advanced or metastatic breast cancer patients. After 20 patients have been treated,
    an interim analysis will be conducted.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">PCS3117, also referred to as NGC-Gem, is a cytidine analog similar to gemcitabine
(Gemzar&#174;), but different enough in chemical structure that some patients are more likely to respond to NGC-Gem than gemcitabine. In
addition, we believe those patients that are inherently resistant, or who acquire resistance, to gemcitabine are likely to not be resistant
to NGC-Gem. The difference in response occurs because NGC-Gem is metabolized to its Active Metabolite through a different enzyme system
than gemcitabine.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
                                                                              <p style="text-align: justify; margin-top: 0; margin-bottom: 0">PCS11T, also referred to as NGC-Iri, is an analog
of SN38 (SN38 is the active metabolite of irinotecan). The chemical structure of NGC-Iri is designed to influence the uptake of the drug
into cancer cells, resulting in more NGC-Iri entering cancer cells than normal cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">Irinotecan is widely used in lung, pancreatic, ovarian,
cervical &amp; other solid tumor cancers. Onivyde&#174; is irinotecan in a liposomal formulation. Approximately 15-35% of patients respond
to irinotecan across the solid tumor cancers. Major drawbacks are the side-effect profile, including black box warnings for diarrhea and
myelosuppression. Dose limiting side effects result in fewer patients being able to benefit from treatment. Despite the black box warning
for severe side effects, Medicare reported a total of more than 1.8 million doses of irinotecan and Onivyde&#174; in 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">Our preclinical study in mouse xenograft models showed that after NGC-Iri
administration, there was greater accumulation of SN-38 in the tumor compared with other tissues than after irinotecan or Onivyde&#174;
administration. Additionally, less SN-38 accumulated in non-cancer tissues, such as muscle, after NGC-Iri administration than after irinotecan
or Onivyde&#174; administration, supporting the potential for a better NGC-Iri safety profile.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are currently evaluating options
to monetize two non-oncology drug assets, which may include out-licensing or partnering these assets with one or more third parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS12852 is a highly specific and potent 5HT4 agonist that is Phase 2B ready as potentially the first meaningful treatment for diabetic gastroparesis patients. Gastroparesis is a chronic digestive disorder characterized by delayed gastric emptying of solid food without obstruction. Gastroparesis symptoms include: nausea, vomiting, postprandial fullness, early satiety, abdominal pain, heartburn and poor appetite. Global prevalence of gastroparesis is over 30 million, with a diabetic population of over 8 million.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We have completed a Phase 2A trial for PCS12852 in gastroparesis patients
with positive results.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">PCS499 is a drug that can be used to treat unmet medical need conditions
caused by multiple pathophysiological changes. We are presently defining the development plan for the use of PCS499 in a primary glomerular
disease. We believe that PCS499 could be successfully developed in a primary glomerular disease such as focal segmental glomerulosclerosis,
or FSGS, and IgA. We intend to design a development program with the next study being an adaptive designed Phase 3 trial, meet with the
FDA, and then find a partner to take the drug to approval.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our strategy reduces clinical risk, regulatory risk and commercial risk, while addressing a critical need in fighting cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
cancer therapies targeted rapidly dividing cells because cancer cells tend to divide and grow more quickly than normal cells.
Unfortunately, most of these drugs do not distinguish between cancer cells and normal cells that also divide rapidly, such as those
in the bone marrow, digestive tract, and hair follicles. Prior to FDA&#8217;s Project Optimus Initiative, oncology drug developers
would begin human clinical trials with dose-escalating studies meant to identify a Maximum Tolerated Dose (&#8220;MTD&#8221;), which
they hoped would be high enough to impact the cancer. If approved by the FDA, the recommended dose would be at or near the MTD,
resulting in many patients suffering from severe side effects from treatment. Developers were defining the &#8220;optimal&#8221;
treatment dose by the highest dose that may potentially be tolerated and then assumed that the highest dose would also provide the
greatest efficacy, which may not have been correct. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
risk-mitigated strategy is to identify existing effective cancer therapies where the active cancer-killing ingredients are well understood
and that are foundations of current treatment regimens, but are highly toxic, with side effects that are often treatment limiting. We
then devise technologies to change the way the body metabolizes the drugs, or the way they are distributed within the body, to increase
potency and reduce toxicity. By modifying the drugs in this manner, we believe our treatments will provide improved safety and efficacy
profiles when compared to their currently marketed counterparts. We believe our approach will extend survival and improve quality of
life for many patients fighting cancer. We also believe that we can develop these drug candidates at a lower cost with a higher success
rate than is common in the industry. We call our drug candidates Next Generation Cancer (NGC) therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
Risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
already know these drugs work. They have been used in cancer treatment for decades, and there are hundreds, if not thousands, of
scientific publications looking at all aspects of the drugs. In many ways, these drugs are better understood now than when they were
first approved. This improved knowledge, added to the data from prior human clinical trials, leads us to believe clinical risk is
significantly reduced when compared to a potential drug that is focusing on a new mechanism of action or new target. By modifying
how an existing anti-cancer drug is metabolized or distributed within the body, thereby making the existing drug less toxic and more
effective, we do not rely on finding an MTD that exceeds what is safe for many patients. Instead, we seek to merely increase the
amount of the proven anti-cancer ingredients in the cancer cells, while reducing those ingredients in healthy cells, often with a
lower dose of the approved drug, which we believe results in less clinical risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
Risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy is to efficiently develop our pipeline of Next Generation Cancer therapies utilizing our proprietary Regulatory Science Approach
(described more fully in &#8220;Regulatory Science Approach&#8221; below), including the principles associated with FDA&#8217;s Project
Optimus oncology initiative and the related FDA draft guidance (Optimus, 2025). Part of the development includes determining the optimal
dosage regimen, rather than an MTD, based on the dose-response relationship. By changing either the metabolism, distribution, and/or
elimination of already FDA-approved cancer drugs (e.g., capecitabine, gemcitabine, and irinotecan) or their Active Metabolites, we believe
that our oncology drugs represent the next generation of cancer therapy with an improved safety and efficacy
profile, thereby potentially benefiting more patients while maintaining the mechanism of how the drug kills cancer cells. By combining
these modified, approved cancer treatments with our Regulatory Science Approach and our experience using the principles of FDA&#8217;s
Project Optimus initiative, we anticipate that we will be able to increase the probability of FDA approval, improve the safety-efficacy
profile over the existing counterparts of our NGC drugs, and more efficiently develop each drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial
Risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the underlying drugs are already heavily used in cancer therapy, we believe that, if our clinical trials are successful in demonstrating
greater efficacy with better tolerability, our NGC therapies will be rapidly and broadly adopted. Why would an oncologist use the older,
more toxic drug?</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have data that we believe suggests our NGC treatments are likely to have a better safety-efficacy profile than the current widely
used marketed counterpart drugs, not only potentially making the development and approval process more efficient, but also differentiating
our NGC treatments from the existing treatment in the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory
Science Approach</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Regulatory Science Approach was conceived in the early 1990s when the founders of Processa and other faculty at the University of Maryland
worked with the FDA to develop multiple FDA Guidances. Regulatory science is the science of developing new tools, standards, and approaches
to assess the safety, efficacy, quality, and performance of all FDA-regulated products. Two of our founders, Dr. David Young and Dr.
Sian Bigora, developed trade secrets and know-how developed from the regulatory science research initially developed in collaboration
with FDA and later refined by Drs. Young and Bigora over the last 30+ years. They also expanded the original regulatory science concept
by including it in pre-clinical and clinical studies to justify the benefit-risk assessment required for FDA approval when designing
the development programs of new drug products. Our regulatory science approach defines the scientific information that the FDA requires
to determine if the benefit outweighs the risk of a drug in a specific population of patients and at a specific dosage regimen for a
specific drug product. The studies are designed to obtain the necessary scientific information to support the regulatory decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently,
the FDA took steps to define some of the regulatory science required for the FDA approval of oncology products. Historically, most cancer drugs were dosed at the MTD, which lead to many patients experiencing significant side
effects and lower quality of life. What was ignored was that a lower dose may result in the same efficacy as a higher dose while providing fewer side
effects and/or less severe side effects. Through the FDA&#8217;s
Project Optimus Oncology Initiative (Optimus, 2025) and the related Draft Guidance on determining the &#8220;optimal&#8221; dosage regimen
for an oncology drug, the FDA chose to make the development of oncology drugs more science-based than in the past. Since the principles
of the FDA&#8217;s Project Optimus and the related Draft Guidance have been used by our regulatory science approach in a number of non-oncology
drugs, our experience with the principles of Project Optimus differentiates us from other biotechnology companies by focusing us, not
only on the clinical science, but also on the equally important regulatory process. We believe utilizing our Regulatory Science Approach
provides us with three distinct advantages:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greater
    efficiencies (e.g., the right trial design and trial readouts);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greater
    possibility of drug approval by the FDA or other regulatory authorities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greater
    ability to evaluate the benefit-risk of a drug compared to existing therapy, which allows prescribers to provide better treatment
    options for each patient.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Drug Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_001.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
oncology pipeline currently consists of NGC-Cap, NGC-Gem and NGC-Iri (also identified as PCS6422, PCS3117, and PCS11T, respectively) and
two non-oncology drugs (PCS12852 and PCS499). We are exploring options for our non-oncology drugs, which may include out-licensing or
partnership opportunities. A summary of each drug is provided below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Cap</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Cap
    is a combination of PCS6422 and a lower dose of the FDA-approved cancer drug capecitabine. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capecitabine
(NCI, 2025), as presently prescribed and FDA-approved, is an oral prodrug of the cancer drug 5-fluorouracil (&#8220;5-FU&#8221;) (Casale
J, 2024), which is itself widely used as an intravenous anticancer agent in many types of cancer. Capecitabine is metabolized into
5-FU where it is then further metabolized to anabolites (which kill both cancer cells and normal duplicating cells) and catabolites (have
no cancer killing properties and may cause side effects) (Yen-Revollo, 2008). In 2021, Medicare Part B alone reports over 9.2 million dosing units of capecitabine used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dihydropyrimidine
dehydrogenase (&#8220;DPD&#8221;) is an enzyme that helps the body break down thymine and uracil, and inactivates 80&#8211;90% 5-FU (Yen-Revollo,
2008). This means the dose of capecitabine must be high enough to account for the DPD effect. However, DPD enzyme activity has been shown
to vary among individuals in a Gaussian pattern (i.e. normal distribution or bell-shaped curve), with as much as a sixfold variation
from the lowest to the highest values. This wide variation in DPD activity is likely responsible for the wide variation in the half-life
observed in patients in population studies (Diasio, 1998). This may suggest a source of the high incidence of moderate to severe side
effects experienced by people taking capecitabine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
side effects occur in up to 70% of patients treated with capecitabine (Yen-Revollo, 2008) (Xeloda Package Insert, 2015), including myelosuppression,
cardiac toxicity, mucositis, diarrhea, and hand-foot syndrome (&#8220;HFS&#8221;). These side effects frequently result in decreased
doses, interrupted doses, or discontinuation of treatment with capecitabine, which limits its effectiveness to the patient. Approximately
30% of patients will experience toxicities above grade 3, and approximately 10% to 20% will require hospitalization to treat these toxicities
(Meulendijks D, 2016).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HFS
occurs in 15.5% to 68.3% (median, 53.5%) of patients treated with capecitabine (Yen-Revollo, 2008). The molecular pathophysiology of
5-FU-induced HFS remains unclear, but since combination therapy of 5-FU with a DPD inhibitor significantly reduces the occurrence of
HFS, it suggests that the toxicity may be due to a byproduct of DPD catabolism of the drug (Yen-Revollo, 2008).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS6422
is an orally administered irreversible inhibitor of the enzyme DPD. When capecitabine is given in combination with PCS6422 (&#8220;NGC-Cap&#8221;),
PCS6422 significantly changes the metabolism of 5-FU, which results in a change in the distribution of 5-FU within the body. Due to this
change in metabolism, and the overall metabolite profile of anabolites and catabolites, the side effect and efficacy profile of NGC-Cap
has been found to be different from capecitabine given without PCS6422. Since the potency of NGC-Cap is greater than FDA-approved capecitabine,
the amount of capecitabine anabolites formed from 1mg of capecitabine administered in NGC-Cap will, therefore, be much greater than would
be formed from the administration of 1mg of existing capecitabine. Therefore, a lower dose of capecitabine would be expected to accomplish
the same, or greater, cancer-killing activity. Importantly, chemically inhibiting DPD activity also reduces interpatient and intrapatient
variability, raises plasma levels of bioavailable 5-FU, and lengthens the time of pharmacologic exposure to the drug (Yen-Revollo, 2008),
meaning that there should be less variability in response and side effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 2, 2021, we enrolled the first patient in our Phase 1B trial in patients with advanced refractory gastrointestinal (GI) tract
tumors. Our interim analysis of Cohorts 1 and 2A found no dose-limiting toxicities (DLTs), no drug-related adverse events greater than
Grade 1, and no adverse events associated with the catabolites of 5-FU such as HFS. In this Phase 1B trial, it was demonstrated that
the irreversible inhibition of DPD by PCS6422 could alter the metabolism, distribution and elimination of 5-FU, making NGC-Cap significantly
(up to 50 times) more potent than capecitabine alone and potentially leading to higher levels of anabolites which can kill replicating
cancer and normal cells. By administering NGC-Cap to cancer patients, the balance between anabolites and catabolites changes depending
on the dosage regimens of PCS6422 and capecitabine used, making the efficacy-safety profile of NGC-Cap different than that of FDA-approved
capecitabine and requiring further evaluation of the PCS6422 and capecitabine regimens to determine the optimal NGC-Cap regimens for
patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
an effort to better estimate the timeline of DPD inhibition and formation of new DPD, we modified the protocol for the Phase 1B trial
and began enrolling patients in the amended Phase 1B trial in April 2022. On November 1, 2022, we announced that data from the Phase
1B trial identified multiple dosage regimens with potentially better safety and efficacy profiles than currently existing capecitabine
regimens. Since 5-FU exposure is dependent on both the PCS6422 regimen and the capecitabine regimen, safe regimens were identified as
well as regimens that cause DLTs. One of the regimens in the Phase 1B trial did cause DLTs in two patients,
one of whom died from complications of his condition in conjunction with the treatment. The Phase
1B trial completed enrollment in early 2024 and the last subject completed the study in July 2024. Data from the Phase 1B showed, that
although 5-FU exposure at therapeutic doses was 5 to 10 fold greater than for monotherapy, adverse events from 5-FU catabolites were
minimal while anabolite associated adverse events for the highest dose cohorts were similar to those reported for monotherapy. In these
evaluable subjects with refractory or intolerant cancer, the combination of PCS6422 and capecitabine showed an efficacy with a partial
response rate of 11%, stable disease rate of 44%, and a median progression free survival of 93 days. This safety and efficacy data supports
the inclusion of the 2 dosage regimens of PCS6422 in combination with capecitabine (from Cohort 3 [75 mg BID] and Cohort 4 [225 mg BID])
in the Phase 2 study. The safety review committee determined the MTD and RP2D as (capecitabine 450 mg/day; 225 mg BID), the Cohort 4
dosing regimen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
parallel with the Phase 1B trial, we had discussions with the FDA which clarified that the major goal for the next Phase 2 trial would
be to evaluate and understand the dose- and exposure-response relationship for anti-tumor activity and safety. The specific dosage regimens
for the trial were defined following the determination of the MTD from Phase 1B trial. Following the FDA meeting on December 11, 2023,
we determined the next NGC-Cap trial would be a Phase 2 trial in breast cancer. This decision was supported through discussions with
the FDA, where we agreed with the FDA that the development of NGC-Cap in breast cancer would be a more efficient development program
than metastatic colorectal cancer and improve the likelihood of FDA approval. The FDA agreed that the data generated from past and existing
studies could be used to directly support the Phase 2 trial in breast cancer. Capecitabine is already approved as both monotherapy and
combination therapy in breast cancer, which contributes to the logic and efficiency of our current direction. In addition, the FDA&#8217;s
agreement that our present data would support a Phase 2 trial in breast cancer makes the expansion seamless. The objective for the Phase
2 trial is to provide safety-efficacy data to preliminarily demonstrate the benefit of NGC-Cap over monotherapy capecitabine. Based on
this expansion to breast cancer, we expanded our Oncology Advisory Board to include key breast cancer oncologists.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IND for the evaluation of NGC-Cap for the treatment of breast cancer was cleared by the FDA on July 24, 2024, and allowed for the Phase
2 trial to be initiated. The Phase 2 study (NCT06568692) is a global multicenter, open-label, adaptive designed safety-efficacy trial
comparing two different doses of NGC-Cap to FDA-approved monotherapy capecitabine in approximately 60 to 90 patients with advanced or
metastatic breast cancer. The trial is designed to evaluate the safety-efficacy profile of NGC-Cap versus monotherapy capecitabine, to
determine the potential optimal dosage regimens of NGC-Cap as required by the FDA Project Optimus Initiative and to evaluate the possibility
of personalizing NGC-Cap therapy. The first patient in the trial was dosed on October 2, 2024, and the trial is currently enrolling additional
patients. After 20 patients have been treated, an interim analysis will be conducted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breast
cancer is the most diagnosed cancer, representing approximately 15% of all new cancer patients in 2023. It has a prevalence of more than
3.8 million patients, with nearly 300,000 new diagnoses last year. Over 150,000 women are currently living with advanced or metastatic
breast cancer. The NGC-Cap annual newly diagnosed incidence rate for breast, colorectal and other cancers is greater than 250,000 patients
per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>NGC-Gem</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS3117,
    also referred to as NGC-Gem, is a cytidine analog similar to gemcitabine (Gemzar&#174;), but different enough in chemical structure
    that some patients are more likely to respond to NGC-Gem than gemcitabine. In addition, we believe those patients that are inherently
    resistant, or who acquire resistance, to gemcitabine may not be resistant to NGC-Gem. The difference in response occurs because NGC-Gem
    is metabolized to its Active Metabolite through a different enzyme system than gemcitabine. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemcitabine
is widely used in pancreatic, gall bladder, lung, and other solid tumor cancers. Approximately 20%-40% of patients respond to gemcitabine
across solid tumor cancers. Resistance to gemcitabine is a key problem with 55%-85% of patients are inherently resistant or acquire resistance
(Gemzar PI, 2019). In 2021, Medicare Part B alone reports over 840,000 dosing units used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS3117
has completed a Phase 2A trial in patients with progressive metastatic pancreatic cancer after previous chemotherapy treatments, including
93% refractory to gemcitabine, with the following results:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31%
    (14 patients) had progression-free survival for 8 weeks or more</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12%
    (5 patients) had stable disease for more than 4 months</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    patient had a tumor reduction of 40% after 28 days of treatment</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mild
    to moderate adverse events were reported with a better overall safety profile than gemcitabine.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Like
gemcitabine, NGC-Gem could be used to treat patients with various cancers such as pancreatic, biliary tract, lung, ovarian, and breast.
We estimate more than 275,000 patients in the United States were newly diagnosed in 2022 with pancreatic, biliary tract, lung, ovarian,
and breast cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Iri</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">PCS11T, also referred to as NGC-Iri, is an analog
    of SN38 (SN38 is the active metabolite of irinotecan). The chemical structure of NGC-Iri is designed to influence the uptake of the drug
    into cancer cells, resulting in more NGC-Iri entering cancer cells than normal cells.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Irinotecan is widely used in lung, pancreatic, ovarian,
    cervical &amp; other solid tumor cancers. Onivyde&#174; is irinotecan in a liposomal formulation. Approximately 15-35% of patients respond
    to irinotecan across the solid tumor cancers. Major drawbacks are the side-effect profile, including black box warnings for diarrhea and
    myelosuppression (Camptosar PI, 1996) (Onivyde PI, 1996). Dose limiting side effects result in less patients being able to benefit from
    treatment. Despite the black box warning for severe side effects, Medicare reported a total of more than 1.8 million doses of irinotecan
    and Onivyde&#174; in 2021.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our preclinical study
    in mouse xenograft models showed that after NGC-Iri administration, there was greater accumulation of SN-38 in the tumor compared with
    other tissues than after irinotecan or Onivyde&#174; administration. Additionally, less SN-38 accumulated in non-cancer tissues, such as
    muscle, after NGC-Iri administration than after irinotecan or Onivyde&#174; administration, supporting the potential for a better NGC-Iri
    safety profile. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Accumulation of SN-38 in the tumor
compared with other tissues was greater after NGC-Iri administration than after irinotecan or Onivyde&#174; administration:</p></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left">&#160;</td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tumor-to-muscle
ratio of approximately 200 for NGC-Iri and less than 15 for irinotecan and Onivyde&#174;</span></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td>&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tumor-to-plasma
ratio approximately 10 for NGC-Iri and less than 7 for irinotecan and Onivyde&#174;</span></td></tr>
     </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The muscle-to-plasma ratio was less than 0.10 for
    NGC-Iri and greater than 0.4 for irinotecan and Onivyde&#174;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">We are defining the potential paths to approval, which
    include defining the targeted patient population and the type of cancer. In 2025, subject to available funding, we plan to expand the
    preclinical analysis, including additional preclinical efficacy and toxicity studies; evaluate manufacturing options for NGC-Iri; and
    conduct chemistry, manufacturing and control (CMC) activities and pre-IND enabling studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Like irinotecan, NGC-Iri could be used to treat patients
    with various cancers such as lung, colorectal, gastrointestinal, and pancreatic cancer. We estimate at least 200,000 patients in the United
    States were newly diagnosed in 2022 with lung, colorectal, gastrointestinal, and pancreatic cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Non-Oncology
Pipeline for Out-licensing or Partnership</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS12852
                                                         is a highly specific and potent 5HT4 agonist that that is Phase 2B ready as potentially the first meaningful treatment for diabetic
                                                         gastroparesis patients.</span></p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The
target indication for PCS12852 is the treatment of moderate to severe gastroparesis in diabetic patients. Gastroparesis is a chronic
digestive disorder characterized by delayed gastric emptying of solid food without obstruction. Gastroparesis symptoms include: nausea,
vomiting, postprandial fullness, early satiety, abdominal pain, heartburn and poor appetite. Global prevalence of gastroparesis is over
30 million, with a diabetic population of over 8 million (Delveinsight), with 60% experiencing moderate to severe symptoms. Eighty percent
of patients are female.</p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS12852
                                                         was initially evaluated in clinical studies in South Korea for gastric emptying and gastrointestinal motility in healthy volunteers
                                                         and volunteers with a history of constipation. In October 2021, the FDA cleared our IND application to proceed with a Phase 2A trial
                                                         for the treatment of gastroparesis. We enrolled our first patient on April 5, 2022 and completed enrollment of the trial on
                                                         September 2, 2022. Results from this Phase 2A trial, which included 25 patients with moderate to severe gastroparesis, demonstrated
                                                         improvements in gastric emptying in patients receiving 0.5 mg of PCS12852 as compared to placebo. The results indicated that for the
                                                         patients in the PCS12852 group, the mean time for 50% of the gastric contents to empty (t50) compared to their baseline value
                                                         (&#177;SD) decreased by -31.90 min (&#177;50.53) (compared to the change seen in the placebo group of only -9.36 min
                                                         (&#177;42.43). Significant gastric emptying differences were not observed between the placebo and the 0.1 mg dose. Adverse events
                                                         associated with the administration of PCS12852 were generally mild to moderate as expected, limited in duration, and quickly
                                                         resolved without any sequelae. There were no cardiovascular safety events or serious adverse events reported during the trial.
                                                         Additionally, the 0.5 mg of PCS12852 showed a greater improvement than placebo in the gastroparesis symptomology scales used in the
                                                         trial, including both total scores in the scales, as well as sub-scores such as nausea, vomiting and abdominal pain. With the trial
                                                         now complete, we have the data necessary to finalize the development plan for the treatment of diabetic gastroparesis
                                                         patients.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are exploring options for PCS12852, which may include licensing, partnering and/or collaborating opportunities.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS499
                                            is an oral tablet of the deuterated analog of one of the major metabolites of pentoxifylline
                                            (PTX or Trental&#174;). PCS499 is a drug that can be used to treat unmet medical need conditions
                                            caused by multiple pathophysiological changes. We are presently defining the development plan for the use of PCS499 in a primary glomerular disease.</span></p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">PCS499 was previously evaluated in a Phase 2
                                                         trial for the treatment of diabetic nephropathy and successfully demonstrated a positive change in proteinuria. Unfortunately, the
                                                         primary endpoint for diabetic nephropathy was not proteinuria, so the development was discontinued. We do not believe that
                                                         ulcerative and non-ulcerative necrobiosis lipoidica (uNL and NL, respectively) are potential target indications and do not expect to
                                                         find a partner to develop PCS499 in these indications.</p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">However,
within the last couple of years, FDA has approved drugs based on the change in proteinuria for the primary endpoint in glomerular disease
IgA. Since diabetic nephropathy is not a primary glomerular disease, diabetic nephropathy is still not a viable indication given the
endpoint required and the potential size/cost of a study. In evaluating the previous data, we believe that PCS499 could be successfully
developed in a primary glomerular disease such as focal segmental glomerulosclerosis, or FSGS, and IgA. We intend to design a development
program with the next study being an adaptive designed Phase 3 trial, meet with the FDA, and then find a partner to take the drug to
approval.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capecitabine</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Market
Drivers:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasing
    Cancer Prevalence: The rising incidence of cancers such as breast and colorectal cancers in the U.S. is a significant driver. The
    American Cancer Society estimated that over 313,000 new cases of breast cancer would be diagnosed and over 42,000 deaths in 2024.
    They also estimated over 152,000 new cases of colorectal cancer would be diagnosed and over 53,000 deaths. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aging
    Population: The growing elderly population, particularly the baby boomer generation, contributes to a higher incidence of cancer,
    thereby increasing the demand for capecitabine. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Market
Size and Growth:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022:
    The U.S. capecitabine market was valued at approximately USD 408.2 million&#160;(GMI Insights, 2023). </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2032
    Projection: The market is expected to reach USD 652.9 million, reflecting a compound annual growth rate (CAGR) of 4.9% from 2023
    to 2032&#160;(GMI Insights, 2023). </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    2021 more than 9,200,000 dosing units of capecitabine were reported by Medicare Part B, suggesting a total that may exceed 17,000,000
    when considering non-Medicare patients.</span></td></tr>
  </table>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemcitabine</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Market
Size and Growth:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023:
    The U.S. gemcitabine market was valued at approximately USD 727.5 million&#160;(Fact.MR, 2023). </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2033
    Projection: The market is expected to reach USD 1.43 billion, reflecting a compound annual growth rate (CAGR) of 7% from 2023 to
    2033&#160;(Fact.MR, 2023). </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    2021 more than 840,000 dosing units of capecitabine were reported by Medicare Part B, suggesting a total that may exceed 1,700,000
    when considering non-Medicare patients.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Market
Drivers:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasing
    Cancer Prevalence: The rising incidence of cancers such as pancreatic and non-small cell lung cancers in the U.S. is a significant
    driver. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aging
    Population: The growing elderly population contributes to a higher incidence of cancer, thereby increasing the demand for gemcitabine.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Market
Segmentation:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    Indication: The market is segmented into pancreatic cancer, non-small cell lung cancer, breast cancer, ovarian cancer, and others.
    </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irinotecan
/ SN-38</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Market
Size and Growth:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    global irinotecan market is experiencing significant growth, primarily driven by the increasing prevalence of colorectal cancer and
    advancements in cancer therapeutics. In 2023, the market was valued at approximately USD 9.2 billion and is projected to reach around
    USD 14.7 billion by 2032, reflecting a compound annual growth rate (CAGR) of 6.5% during this period&#160;(Dataintelo, 2024). </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    2021 more than 1,800,000 dosing units of capecitabine were reported by Medicare Part B, suggesting a total that may exceed 3,000,000
    when considering non-Medicare patients.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Market
Segmentation:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colon
    Cancer: Irinotecan is a cornerstone in the treatment regimen for metastatic colon cancer, often used in combination therapies.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rectal
    Cancer: Employed in cases where the disease has advanced or recurred, enhancing patient survival rates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other:
    Includes applications in treating small cell lung cancer and other malignancies where irinotecan has shown efficacy.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Key
Market Drivers:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rising
    Cancer Prevalence: The global increase in colorectal and other cancers necessitates effective treatments like irinotecan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
    Effects: Common side effects, such as neutropenia and diarrhea, can limit patient compliance and pose challenges in treatment management.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>References</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Camptosar PI. (1996). Camptosar Package Insert. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020571s048lbl.pdf</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Casale
J, P. P. (2024, 2 16). <i>StatPearls</i>. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK549808/</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consegic.
(2025, Jan). <i>Capecitabine Market - Size, Industry Share, Growth Trends and Forecasts (2025-2032)</i>. Retrieved from https://www.consegicbusinessintelligence.com/capecitabine-market</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dataintelo.
(2024). <i>Irinotecan Market Outlook 2032</i>. Retrieved from https://dataintelo.com/report/global-irinotecan-market</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Delveinsight. (2019, Oct). <i>Gastroparesis: Market
Insights, Epidemiology, and Market Forecast-2028</i>. Delveinsight</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diasio,
R. B. (1998). The Role of Dihydropyrimidine Dehydrogenase (DPD) Modulation in 5-FU Pharmacology. <i>Oncology</i>, Vol 12; Issue 10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fact.MR.
(2023, April). <i>Gemcitabine HCL Market</i>. Retrieved from https://www.factmr.com/report/4646/gemcitabine-hcl-market</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt">Gemzar PI. (2019, May). Gemzar Package Insert. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020509s082lbl.pdf</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GMI
Insights. (2023, October). <i>Capecitabine Market Size - By Indication (Breast, Colorectal, Gastric, Pancreatic), By Synthesis Type (Chemical
Based API, Biological API, Highly Potent API, Mode, Global Forecast 2023- 2032</i>. Retrieved from https://www.gminsights.com/industry-analysis/capecitabine-market</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
Data Forecast. (2024, June). <i>North America Capecitabine Market Research Report - Segmented By Application, Drug Formulation &amp;
Country (U.S, Canada &amp; Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, &amp; Forecasts (2024 to 2032)</i>.
Retrieved from https://www.marketdataforecast.com/market-reports/na-capecitabine-market</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Meulendijks
D, C. A. (2016). Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase
activity &#8211; Ready for clinical practice? . <i>Cancer Treat Rev. </i>, 50:23-34.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NCI.
(2025, 1 2). <i>National Cancer Institute - Capecitabine</i>. Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/capecitabine</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt">Onivyde PI. (1996). Onivyde Package Insert. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrieved
from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/207793s016lbl.pdf</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optimus,
F. (2025). <i>FDA Project Optimus</i>. Retrieved from https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yen-Revollo,
J. L., &amp; Goldberg, R. a. (2008). Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?
<i>Clinical Cancer Research</i>, 14:8-13.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Our Team</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug development efforts are guided by our knowledge and experience in applying our regulatory science approach to decrease manageable
risks, costs, and time toward achieving marketing authorization from regulatory authorities including the FDA. We have assembled a seasoned
management team and development team with extensive experience in developing therapies, including advancing product candidates from preclinical
research through clinical development and ultimately regulatory approval and commercialization. Our team is led by our President of Research
and Development and Founder David Young, Pharm.D., Ph.D. who has extensive experience in research, regulatory approval and business development
and who served at Questcor Pharmaceuticals for eight years, initially as an independent director on its Board of Directors and, subsequently,
as its Chief Scientific Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
execute our strategy, we assembled an experienced and development team with a successful track record of drug approvals and successful
exits. Our team is experienced in developing drug products through all principal regulatory tiers from IND-enabling studies to New Drug
Application (NDA) submission. Throughout their careers, the combined scientific, development and regulatory experiences of our team members
have resulted in more than 30 drug approvals in indications reviewed by almost every division of the FDA including the oncology divisions,
over 100 meetings with the FDA and involvement with more than 50 drug development programs, including drug products targeted to patients
who have an unmet medical need and cancer patients. In addition, the FDA Project Optimus Oncology initiative and recent FDA Oncology
Guidance applies our regulatory science approach and principles used and refined by our Founders over the last 30 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in large part on our ability and that of our licensors to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    and maintain international and domestic patent and other legal protections for the proprietary technology, inventions and improvements
    we consider important to our business; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prosecute
    and defend our existing and future patents, once obtained; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preserve
    confidentiality of our own and our licensed methods, processes and know-how; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operate
    without infringing the patents and proprietary rights of other parties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we rely extensively on licensing patents from third parties, we intend to seek appropriate patent protection for product candidates in
our research and development programs, where applicable, and their uses by filing patent applications in the United States and other
selected countries. We intend for these patent applications to cover, where possible, claims for compositions of matter, medical uses,
processes for preparation and formulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current patent portfolio consists of the number of patents related to our drug candidates licensed from each third-party licensor. In
addition to the international patents and/or international and U.S. patent applications licensed from our third-party licensors, we have
licensed at least the following number of U.S. patents:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">CoNCERT</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Yuhan</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aposense</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Elion</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Ocuphire</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">U.S. patents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
provisional patent for NGC-Cap has been filed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Besides
relying on patents, we may also rely on trade secrets, proprietary know-how and continuing innovation to develop and maintain our competitive
position, especially when we do not believe that patent protection is appropriate or can be obtained. In addition, we continuously evaluate
opportunities to obtain exclusivity through our regulatory filings with the FDA. We seek protection of these trade secrets, proprietary
know-how and any continuing innovation, in part, through confidentiality and proprietary information agreements. However, these agreements
may not provide meaningful protection for, or adequate remedies to protect, our technology in the event of unauthorized use or disclosure
of information. Furthermore, our trade secrets may otherwise become known to, or be independently developed by, our competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following descriptions of our license agreements are only summaries. You should also refer to the copies of such agreements which have
been filed as exhibits to this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreement with Elion Oncology, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 23, 2020, we entered into a condition precedent License Agreement with Elion Oncology (&#8220;Elion License Agreement&#8221;),
pursuant to which we acquired an exclusive license to develop, manufacture and commercialize PCS6422 globally. The license grant was
conditioned on the following being satisfied by October 30, 2020: (i) our closing on an equity financing of at least $15 million in gross
proceeds and (ii) successful up-listing to Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 6, 2020, all conditions were satisfied, resulting in the addition of PCS6422 to our portfolio, and we paid $100,000 cash and
issued 41,250 shares of our common stock to Elion. As part of the Elion License Agreement, we agreed to issue to Elion 5,000 shares of
our common stock on each of the first and second anniversary dates of the Elion License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
additional consideration, we will pay Elion development and regulatory milestone payments (a portion of which are payable in shares of
our common stock and a portion of which are payable in cash) upon the achievement of certain milestones, which include FDA or other regulatory
approval and dosing a patient. In addition, we must pay Elion one-time sales milestone payments based on the achievement during a calendar
year of one or more thresholds for annual sales for products made and pay royalties based on annual licensing sales. We are also required
to split any milestone payments received with Elion based on any sub-license agreement we may enter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 17, 2022, we amended the third Milestone Event of Section 6.4 of our License Agreement with Elion Oncology, Inc. changing the third
Milestone Event from &#8220;1<sup>st</sup> Patient in Dose Confirmation Study&#8221; to (a) determination of the maximum tolerated dose
(MTD) or (b) determination of the recommended Phase 2 Dose. Prior to this amendment, the third milestone was not considered probable
since it was unknown when, or if a dose confirmation study was going to be conducted. As a result of the modification, we consider it
probable that the recommended Phase 2 dosage regimen could be determined in connection with our current Phase 1B trial for NGC-Cap. We
recorded an expense and related liability of $189,000 representing the value of the shares we anticipate issuing to Elion at the fair
value on the date of modification. No other terms or conditions of the License Agreement were modified. We determined the dosage for
our Phase 2 study on January 25, 2024 and issued 5,000 shares of common stock to Elion for meeting this milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to use commercially reasonable efforts, at our sole cost and expense to research, develop and commercialize products in
one or more countries, including dosing a first patient with a product in a Phase 2 or 3 clinical trial by October 6, 2024. We dosed
our first patient in a Phase 2 clinical trial on October 2, 2024. Either party may terminate the agreement in the event of a material
breach of the agreement that has not been cured following written notice and a 90-day opportunity to cure such breach (which is shortened
to 15 days for a payment breach). See Item 3 &#8211; Legal Proceedings herein for additional information regarding the status of the
Elion License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>License Agreement with Ocuphire Pharma, Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">On June 16, 2021, we executed
a License Agreement with Ocuphire Pharma, Inc. (&#8220;Ocuphire Agreement&#8221;) under which we received a license to research, develop
and commercialize PCS3117 globally, excluding the Republic of Singapore, China, Hong Kong, Macau and Taiwan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">As consideration for the Ocuphire
Agreement, we issued 2,235 shares of our common stock to Ocuphire, a cash payment of $200,000 and assumed $66,583 in certain liabilities.
Additional consideration includes future development and regulatory milestones payments to Ocuphire upon our achievement of certain defined
clinical milestones, such as dosing a patient in pivotal trials and receiving marketing authorization by a regulatory authority in the
United States or another country. In addition, we are required to pay Ocuphire one-time sales milestone payments based on the achievement
during a calendar year of the highest annual Net Sales for products made and pay royalties based on annual Net Sales, as defined in the
Ocuphire Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">We are required to use commercially
reasonable efforts, at our sole cost and expense to oversee such commercialization efforts, to research, develop and commercialize products
in one or more countries, including meeting specific diligence milestones that consist of: (i) first patient administered drug in a Clinical
Trial of a Product prior to June 16, 2024 and (ii) first patient administered drug in a Pivotal Clinical Trial of a Product or first patient
administered drug in a Clinical Trial for a Second Indication of a Product prior to June 16, 2026. We are currently in discussions with
Ocuphire to extend these deadlines. Either party may terminate the agreement in the event of a material breach of the agreement that has
not been cured following written notice and a 120-day opportunity to cure such breach.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreement with Aposense, Ltd.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2020, we entered into a condition precedent License Agreement with Aposense, Ltd. (&#8220;Aposense License Agreement&#8221;),
pursuant to which we were granted Aposense&#8217;s patent rights and Know-How to develop and commercialize their next generation irinotecan
cancer drug, PCS11T. The Aposense License Agreement provides us with an exclusive worldwide license (excluding China), to research, develop
and commercialize products comprising or containing PCS11T. The license grant was conditioned on the following being satisfied within
nine months of May 24, 2020 (or the Aposense License Agreement shall terminate): (i) our closing of an equity financing and successful
up-listing to Nasdaq and (ii) Aposense obtaining the approval of the Israel Innovation Authority for the consummation of the transactions
contemplated by the Aposense License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 6, 2020, all conditions were satisfied, resulting in the addition of PCS11T to our portfolio, and we issued 31,250 shares of
our common stock to Aposense. As additional consideration, we will pay Aposense development and regulatory milestone payments (up to
$3.0 million per milestone) upon the achievement of certain milestones, which primarily consist of having a drug indication approved
by a regulatory authority in the United States or another country. In addition, we will pay Aposense one-time sales milestone payments
based on the achievement during a calendar year of one or more thresholds for annual sales for products made and pay royalties based
on annual licensing sales. We are also required to split any sales milestone payments or royalties we receive with Aposense based on
any sub-license agreement we may enter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreement with Yuhan Corporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 19, 2020, we entered into a License Agreement with Yuhan Corporation (&#8220;Yuhan License Agreement&#8221;), pursuant to which
we acquired an exclusive license to develop, manufacture and commercialize PCS12852 globally, excluding South Korea.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for the Yuhan License Agreement and related Share Issuance Agreement, we issued to Yuhan 25,000 shares of common stock.
As additional consideration, we will pay Yuhan development and regulatory milestone payments (a portion of which are payable in shares
of our common stock based on the volume weighted average trading price during the period prior to such achievement and a portion of which
are payable in cash) upon the achievement of certain milestones, based on a Yuhan affiliate purchasing 37,500 shares of common stock
for $3,000,000 in our October 2020 underwritten public offering. The milestones primarily consist of dosing a patient in pivotal trials
or having a drug indication approved by a regulatory authority in the United States or another country. In addition, we must pay Yuhan
one-time sales milestone payments based on the achievement during a calendar year of one or more thresholds for annual sales for products
made and pay royalties based on annual licensing sales. We are also required to split any milestone payments received with Yuhan based
on any sub-license agreement we may enter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to use commercially reasonable efforts, at our sole cost and expense, in conjunction with a joint Processa-Yuhan Board to
oversee such commercialization efforts, to research, develop and commercialize products in one or more countries, including meeting specific
diligence milestones that consist of: (i) preparing a first draft of the product development plan within 90 days; (ii) requesting an
FDA pre-IND meeting for a product within 6 months; (iii) dosing a first patient in a Phase 2A clinical trial with a product within 24
months; and (iv) dosing a first patient with a product in a Phase 2B clinical trial, Phase 3 clinical trial or other pivotal clinical
trial with a product by August 19, 2024. Either party may terminate the agreement in the event of a material breach of the agreement
that has not been cured following written notice and a 60-day opportunity to cure such breach (which is shortened to 15 days for a payment
breach).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreement with CoNCERT Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2017, Promet entered into a License Agreement with CoNCERT (&#8220;CoNCERT License Agreement&#8221;). On March 19, 2018, we,
Promet, and CoNCERT entered into an Amended Option Licensing Agreement (&#8220;March Amendment&#8221;) that, among other things, assigned
the CoNCERT Agreement from Promet to us and we exercised the exclusive commercial license option for the PCS499 compound from CoNCERT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CoNCERT License Agreement provides us with an exclusive (including as to CoNCERT) royalty-bearing license to CoNCERT&#8217;s patent rights
and Know-How to develop, manufacture, use, sub-license and commercialize compounds (PCS499 and each metabolite thereof) and pharmaceutical
products with such compounds worldwide. We are required to pay CoNCERT royalties, on a product&#8211;by-product basis, on future worldwide
net sales, or pay a percentage of any sublicense revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will incur royalty obligations to CoNCERT on a country-by-country and product-by-product basis that expire on a country-by-country and
product-by-product basis on the later of (i) expiration or invalidation of the last patent rights covering such product in such country
or (ii) the tenth anniversary of the date of the first commercial sale to a non-sublicensee third party of such product in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to use commercially reasonable efforts, at our sole cost and expense, to develop and obtain regulatory approval for one
product in the U.S. and at least one other major market and, subject to obtaining regulatory approval in the applicable major market,
commercialize one product in the U.S. and at least one other major market. CoNCERT may terminate the agreement if, following written
notice and a 60-day opportunity to demonstrate a plan to cure, it believes that we are not using commercially reasonable efforts to develop
and obtain regulatory approval for one product in the U.S. and in at least one other major market for any consecutive nine-month period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the CoNCERT License Agreement continues in full force and effect until the expiration of the last royalty term. On a country-by-country
and product-by-product basis, upon the expiration of the royalty term in such country with respect to such product, we shall have a fully
paid-up, perpetual, irrevocable license to such intellectual property with respect to such product in such country. In the event of a
material breach of the CoNCERT Agreement, either party may terminate the agreement provided such breach is not cured in the 90 days following
written notice of the breach (which is shortened to 15 days for a payment breach). In addition, either party may terminate the agreement
upon an assignment for the benefit of creditors or the filing of an insolvency proceeding by or against the other party that is not dismissed
within 90 days of such filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
and Clinical Supplies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely, and expect to continue
to rely, on multiple third-party contract manufacturing organizations (CMOs) for the supply of current Good Manufacturing Practices (cGMP)-grade
clinical trial materials and commercial quantities of our product candidates and products, if approved. We require all our CMOs to conduct
manufacturing activities in compliance with cGMP. We have assembled a team of experienced employees and consultants to provide the necessary
technical, quality and regulatory oversight of our CMOs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that these CMOs will have the capacity to support both clinical supply and commercial-scale production, but we do not have
any formal agreements at this time with any of these CMOs to cover commercial production. We also may elect to pursue additional CMOs
for manufacturing supplies of drug substance and finished drug product in the future. We believe that our standardized manufacturing
process can be transferred to a number of other CMOs for the production of clinical and commercial supplies of our product candidates
in the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our potential competitors may have significantly greater financial resources, a more established presence in the market, and more
expertise in research and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement,
and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may
result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also
prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These potential
competitors may also compete with us in recruiting and retaining top qualified scientific, sales, marketing and management personnel
and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary
to, or necessary for, our programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key competitive factors affecting each of our products, if approved, are likely to include the efficacy, safety, convenience and price
of the products relative to other approved products used on- or off-label for each unmet medical need condition. Although preliminary
clinical data exists to support the possibility of improved efficacy and safety profiles for our drugs, more in-depth randomized, controlled
studies are required for our products to determine if our preliminary findings will support the approval in the designated unmet medical
need indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
NGC-Cap, the competitive factors will be related to the efficacy and safety of the product when compared to capecitabine. The market
penetration will depend on how much improvement will occur in the efficacy and/or safety profiles when administered in combination with
PCS6422. Currently, there are no other reversible or irreversible enzyme inhibitor products approved in the US and no irreversible enzyme
inhibitors approved ex-US, which may make PCS6422 the first DPD irreversible inhibitor available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">For NGC-Gem, the competitive
factors will include establishing market penetration against other cytidine analogues, such as gemcitabine, which is currently used as
first or second line chemotherapy either alone or in combination with other chemotherapy agents. The market penetration will depend on
the potential for an improved efficacy profile in patients who have developed tolerance to other agents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
NGC-Iri, the competitive factors will include establishing marketing penetration against the existing irinotecan product (Camptosar&#174;)
and the newer liposomal irinotecan product (Onivyde&#174;). The establishment of that market will be based upon improved efficacy and/or
safety of NGC-Iri.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
PCS12852, the competitive factors will include establishing marketing penetration against the metoclopramide products (the only approved
drug to treat gastroparesis) and other 5-HT4 receptor agonists used off label. The market penetration will depend on the potential for
an improved safety profile due to the very selective 5-HT4 receptor binding by PCS12852 and similar or greater efficacy in the treatment
of gastroparesis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
PCS499, there are currently no FDA-approved drugs for the treatment of patients with NL, and few drugs are used off-label for NL given
the lack of efficacy and/or side effect concerns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity for any of our product candidates could be reduced or eliminated if our competitors develop and commercialize
products that are safer, more effective, less expensive, more convenient or easier to administer, or have fewer or less severe side effects,
than any products that we may develop. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more
rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are
able to enter the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements
upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those we are developing.
These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture,
quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval
monitoring and reporting, sampling and export and import of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
Government Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations.
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes
and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements
at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative
or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold,
issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions,
fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of pre-clinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice
    (GLP) regulations; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND application, which must become effective before human clinical trials may begin; </span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an independent Institutional Review Board (IRB), at each clinical site before each trial may be initiated; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with good clinical practices (GCP) requirements to establish
    the safety and efficacy of the proposed drug product for each indication; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, if applicable; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance
    with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity,
    strength, quality and purity; </span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to commercial marketing
    or sale of the drug in the United States; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (REMS)
    or to conduct a post-approval study.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pre-clinical
studies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
testing any biological product candidate in humans, including our product candidates, the product candidate must undergo rigorous pre-clinical
testing. The pre-clinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability,
as well as studies to evaluate toxicity in animals, to assess the potential for adverse events and, in some cases, to establish a rationale
for therapeutic use. The conduct of pre-clinical studies is subject to federal regulations and requirements, including GLP regulations
for safety/toxicology studies. An IND sponsor must submit the results of the pre-clinical studies, together with manufacturing information,
analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human
clinical trials may begin. Some long-term pre-clinical testing, such as animal tests of reproductive adverse events and carcinogenicity,
may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises
concerns or questions before that time related to one or more proposed clinical trials and places the trial on clinical hold. In such
a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission
of an IND may not result in the FDA allowing clinical trials to commence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
trials</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the
supervision of qualified investigators, generally physicians not employed by, or under control of, the trial sponsor, in accordance with
GCPs, which include the requirement that all research patients provide their informed consent for their participation in any clinical
trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures,
subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol,
and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must
be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals
participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the
informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical
trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results
to public registries. Information about most clinical trials must be submitted within specific timeframes for publication on www.clinicaltrials.gov.
Information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the
clinical trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the results
of their clinical trials after completion. Disclosure of the results of these trials can be delayed in some cases for up to two years
after the date of completion of the trial. Competitors may use the publicly available information to gain knowledge regarding the progress
of development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to
    a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism,
    pharmacologic action, side effect tolerability and safety of the drug.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At
    the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety
    risks are identified, and a preliminary evaluation of efficacy is conducted. The goal of the Phase 2 trial is to also determine the
    &#8220;best&#8221; dosage regimen(s) to evaluate in the Phase 3 trial. The &#8220;best&#8221; regimen(s) means the regimen(s) that
    is(are) most likely to provide a safe-efficacious regimen that appropriately balances the risk-benefit analysis that the FDA is required
    to evaluate in each drug approval. The ideal way to define this &#8220;best&#8221; regimen for FDA is to evaluate the adverse event-drug
    exposure and efficacy-drug exposure relationships, which has also been previously called dose-response relationships or studies,
    and which has now become the foundation for both the FDA&#8217;s Project Optimus Oncology initiative and the draft Guidance to determine
    the optimal dose for an oncology drug.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3 clinical trials generally involve a larger number of patients at multiple sites and are designed to provide the data necessary
    to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk
    relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo
    and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow
up. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of a biologics license
application (BLA).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse
events occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time, or the FDA may impose other sanctions on
various grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Similarly, an IRB can
refuse, suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance
with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with clinical trials, companies usually complete additional pre-clinical studies and must also develop additional information about the
physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities
in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product
candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of
the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted
to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketing
Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of the required clinical testing, the results of the pre-clinical studies and clinical trials, together with detailed
information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted
to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of
an NDA is subject to a substantial application user fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
review process typically takes twelve months from the date the NDA is submitted to the FDA. The FDA conducts a preliminary review of
all NDAs within the first 60 days after submission to determine whether they are sufficiently complete to permit substantive review before
accepting them for &#8220;filing.&#8221; The FDA may request additional information rather than accept an NDA for filing. In this event,
the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the
FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews
an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured,
processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity. Under the current
guidelines in effect in the Prescription Drug User Fee Act (PDUFA), the FDA has a goal to review and act on the submission within ten
months from the completion of the preliminary review of a standard NDA for a new molecular entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Pediatric Research Equity Act of 2003, as amended and reauthorized, certain NDAs or supplements to an NDA must contain
data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations,
and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on
its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval
of the product for use in adults, or full or partial waivers from the pediatric data requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also may require submission of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include
medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution
methods, patient registries, or other risk minimization tools.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be
approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect
one or more clinical trial sites to assure compliance with GCP requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding
the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter.
A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of
the NDA and may require additional clinical trials or pre-clinical studies in order for FDA to reconsider the application. Even with
submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria
for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter.
An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
drug designation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic product intended to treat a rare disease or condition,
which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals
in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in
the United States for this type of disease or condition will be recovered from sales of the product in the United States. Orphan drug
designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic
agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten
the duration of, the regulatory review and approval process. Orphan drug designation entitles a party to financial incentives such as
opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market
the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, by providing a major
contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different
product for the same indication or the same product for a different indication that could be used &#8220;off-label&#8221; by physicians
in the orphan indication, even though the competitor&#8217;s product is not approved in the orphan indication. Orphan drug exclusivity
also could block the approval of one of our products for seven years if a competitor obtains approval before we do of the same product,
as defined by the FDA, for the same indication we are seeking, or if our product candidate is determined to be contained within the scope
of the competitor&#8217;s product for the same indication or disease. If one of our products designated as an orphan drug receives marketing
approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status
in the European Union, or EU, has similar, but not identical, requirements and benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expedited
review and approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has various programs, including fast track designation, accelerated approval, priority review and breakthrough therapy designation,
which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment
of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these
programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat
a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine
that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially
superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on
a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of
the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required
user fees upon submission of the first section of the NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may give a priority review designation to drugs that offer major advances in treatment or provide a treatment where no adequate therapy
exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of
ten months under current PDUFA guidelines. Under the new PDUFA agreement, these six- and ten-month review periods are measured from the
&#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months
to the timeline for review and decision from the date of submission. Most products that are eligible for fast track designation are also
likely to be considered appropriate to receive a priority review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful
therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and
well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to
predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably
likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity
or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require
a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible
morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
under the provisions of the Food and Drug Administration Safety and Innovation Act, a sponsor can request designation of a product candidate
as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one
or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the
drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial
treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated
approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development
and review of an application for approval of a breakthrough therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for
qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, priority
review and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process.
We may explore some of these opportunities for our product candidates as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-approval
requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion
and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications
or other labeling claims are subject to prior FDA review and approval. There are also continuing annual user fee requirements for any
marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications
with clinical data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing
testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness
after commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register
their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state
agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA
approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements
and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to
use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain
cGMP compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained
or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse
events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials
to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include,
among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
    withdrawal of the product from the market or product recalls; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safety
    alerts, Dear Healthcare Provider letters, press releases or other communications containing warning or other safety information about
    the product; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters or holds on post-approval clinical trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals; product seizure
    or detention, or refusal to permit the import or export of products; or </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted
only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce
the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label
uses may be subject to significant liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA), which regulates
the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug
distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose
requirements to ensure accountability in distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Reform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States government, state legislatures, and foreign governments have shown significant interest in implementing cost containment
programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement, and requirements
for substitution of generic products for branded prescription drugs. For example, the ACA was passed in March 2010 and substantially
changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical
industry. The ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed
by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries
and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter and have in effect a national rebate agreement with the HHS
Secretary as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid
patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217;
rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price
(AMP), to 23.1% of AMP and adding a new rebate calculation for &#8220;line extensions&#8221; (i.e., new formulations, such as extended
release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying
the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical
manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug
benefits. Additionally, for a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs or to be sold directly
to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program.
The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the provisions of the ACA have yet to be implemented, and there have been judicial, Congressional and executive branch challenges
to certain aspects of the ACA. Additionally, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers
set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state
legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and
manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, at the federal
level, there is a &#8220;Blueprint&#8221; to lower prescription drug prices and reduce out-of-pocket costs of drugs that contains additional
proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers
to lower the list price of their products and reduce the out-of-pocket costs of drug products paid by consumers. At the state level,
legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) into law, which among other things,
extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also
eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary
maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the Affordable Care Act will be subject
to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the current
administration will impact the Affordable Care Act and our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) established the Medicare Part D program to provide a
voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans
offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage is
not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription
drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies
which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic
category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part
D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs
of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our
products covered by a Part D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the
MMA applies only to drug benefits for Medicare beneficiaries, private third-party payors often follow Medicare coverage policy and payment
limitations in setting their own payment rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Regulatory Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states
and foreign jurisdictions in which they conduct their business. Manufacturing, sales, promotion and other activities following product
approval are subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including Centers
for Medicare and Medicaid Services (CMS), other divisions of the Department of Health and Human Services, the Department of Justice,
the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp;
Health Administration, the Environmental Protection Agency, and state and local governments.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, in the United States, sales, marketing and scientific and educational programs also must comply with state and federal fraud
and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws. These
laws include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting
    on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals,
    including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal
    healthcare program, such as Medicare or Medicaid. Moreover, the Patient Protection and Affordable Care Act of 2010, as amended by
    the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), provides that the government may assert that a
    claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent
    claim for purposes of the civil False Claims Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    civil and criminal false claims and civil monetary penalties laws, including the civil False Claims Act that can be enforced by private
    citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting,
    or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement
    to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which prohibits,
                                            among other things, executing or attempting to execute a scheme to defraud any healthcare
                                            benefit program or making false statements relating to healthcare matters;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, which also
    imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of
    individually identifiable health information;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm
    consumers;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Physician Payments Sunshine Act, which requires applicable manufacturers of covered drugs, devices, biologics and medical
    supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific
    exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians and teaching hospitals
    as well as information regarding ownership and investment interests held by physicians and their immediate family members; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
    state and foreign laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements
    and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers;
    state laws that require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines
    and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information
    related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws
    that require biotechnology companies to report information on the pricing of certain drug products; and state and foreign laws that
    govern the privacy and security of health information in some circumstances, many of which differ from each other in significant
    ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
and rebate programs must also comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and
more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General
Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements
under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to
federal and state consumer protection and unfair competition laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing,
storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending
on the circumstances, failure to meet applicable regulatory requirements can result in significant civil, criminal and administrative
penalties, including damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare
programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished
profits and future earnings, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial
or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Patent-Term Restoration and Marketing Exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of FDA approval of any future product candidates, some of our U.S. patents may be eligible for
limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years
as compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however,
cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent-term restoration
period is generally one-half the time between the effective date of an IND or the issue date of the patent, whichever is later, and the
submission date of an NDA plus the time between the submission date of an NDA or the issue date of the patent, whichever is later, and
the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise
due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must
be submitted prior to the expiration of the patent. The United States Patent and Trademark Office, in consultation with the FDA, reviews
and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term
for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of
the clinical trials and other factors involved in the filing of the relevant NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year
period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical
entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety,
which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept
for review an abbreviated new drug application (ANDA) or a 505(b)(2) NDA submitted by another company for another version of such drug
where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may
be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years
of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability
studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application,
for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use
associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original
active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting
a full NDA would be required to conduct or obtain a right of reference to all the preclinical studies and adequate and well-controlled
clinical trials necessary to demonstrate safety and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>European
Union Drug Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory
controls. Although the European Union Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory
framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed
and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the
current regime, before a clinical trial can be initiated, it must be approved in each of the EU countries where the trial is to be conducted
by two distinct bodies: the National Competent Authority (NCA) and one or more Ethics Committees (ECs). Under the current regime, all
suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the
NCA and ECs of the Member State where they occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU clinical trials legislation is currently undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial
authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency.
Recently enacted Clinical Trials Regulation EU No 536/2014 ensures that the rules for conducting clinical trials in the EU will be identical.
In the meantime, Clinical Trials Directive 2001/20/EC continues to govern all clinical trials performed in the EU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>European
Union Drug Review and Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Economic Area (EEA), which is comprised of the 26 Member States of the European Union (including Norway and excluding Croatia),
Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (MA). There are two
types of marketing authorizations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal
    Products for Human Use (CHMP) of the EMA, and is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory
    for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicines such
    as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated
    for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral
    diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or
    for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public
    health in the European Union.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are
    available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized
    for marketing in a Member State of the European Union, this National MA can be recognized in another Member State through the Mutual
    Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved
    simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure, an identical dossier
    is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the
    applicant as the Reference Member State (RMS). The competent authority of the RMS prepares a draft assessment report, a draft summary
    of the product characteristics (SmPC), and a draft of the labeling and package leaflet, which are sent to the other Member States
    (referred to as the Member States Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential
    serious risk to public health, to the assessment, SmPC, labeling or packaging proposed by the RMS, the product is subsequently granted
    a national MA in all the Member States (i.e., in the RMS and the Member States Concerned).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the above-described procedures, before granting the MA, EMA or the competent authorities of the Member States of the European Union make
an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.
Similar to the U.S. patent term-restoration, Supplementary Protection Certificates (SPCs) serve as an extension to a patent right in
Europe for up to five years. SPCs apply to specific pharmaceutical products to offset the loss of patent protection due to the lengthy
testing and clinical trials these products require prior to obtaining regulatory marketing approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and Reimbursement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health
programs, commercial insurance, and managed healthcare organizations. There is significant uncertainty related to third-party payor coverage
and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products
are typically made by CMS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private
third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, no uniform
policy of coverage and reimbursement for drug products exists. Accordingly, decisions regarding the extent of coverage and amount of
reimbursement to be provided for any of our products will be made on a payor-by-payor basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasingly,
third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the
prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and
reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and
reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known
as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic
studies to demonstrate the medical necessity and cost effectiveness of our products. As a result, the coverage determination process
is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products
to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements
governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its
Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and
to control the prices of medicinal products for human use. A Member State may approve a specific price for the medicinal product, or
it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the
market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will
allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union
do not follow price structures of the United States and generally prices tend to be significantly lower.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 12, 2024, we had 10 full- and part-time employees. None of our employees is subject to a collective bargaining agreement
or represented by a trade or labor union and we believe our relationships with our employees are good.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent upon the principal members of our small management team and staff, including our Chief Executive Officer, George
Ng; President of Research and Development, David Young, Pharm.D., Ph.D; and our Chief Development and Regulatory Officer, Sian Bigora,
Pharm.D. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate
their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements
may still allow these employees to leave our employment at any time, for or without cause. Our success also depends on our ability to
continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior
scientific and medical and scientific personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our common stock involves a high degree of risk. If any of the following risks actually occur, our business, financial
condition, or results of operations could be materially adversely affected, the trading price of our common stock could decline, and
you may lose all or part of your investment. You should also refer to the other information contained in this Form 10-K, including our
consolidated financial statements and the notes to those statements, and the information set forth under the caption &#8220;Special Note
Regarding Forward-Looking Statements and Risk Factor Summary.&#8221; The risks described below and contained in our other periodic reports
are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also adversely
affect our business operations.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
are providing the following summary of the risk factors contained in our Form 10-K to enhance the readability and accessibility of our
risk factor disclosures. We encourage our stockholders to carefully review the full risk factors contained in this Form 10-K in their
entirety for additional information regarding the risks and uncertainties that could cause our actual results to vary materially from
our recent results or from our anticipated future results</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Financial Position and Need for Additional Capital</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    need to raise additional capital to fund our operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred a history of operating losses and expect to continue to incur substantial costs for the foreseeable future. We are
    not currently profitable, and we may never achieve or sustain profitability. Our financial situation creates doubt whether we will
    continue as a going concern.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have limited cash resources and will require additional financing.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will need to raise additional capital to complete the development efforts for NGC-Cap, NGC-Gem, and/or NGC-Iri. If we are unable to
    raise capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    financial statements contain a statement regarding a substantial doubt about our ability to continue as a going concern.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to use our net operating loss carryforwards and other tax attributes may be limited.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Relating to Clinical Development and Commercialization of Our Product Candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    licenses are subject to termination by the licensor in certain circumstances and any termination of a license agreement would result
    in a loss of important rights and have a material adverse impact on our business and prospects.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently do not have, and may never develop, any FDA-approved, licensed or commercialized products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend entirely on the successful development of our product candidates, which have not yet demonstrated efficacy for their target
    indications in clinical trials. We may never be able to demonstrate efficacy for our product candidates, thus preventing us from
    licensing, obtaining marketing approval by any regulatory agency, and/or commercializing our product(s).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    must successfully complete clinical trials for our product candidates before we can apply for marketing approval.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have little corporate history of conducting clinical trials. Our planned clinical trials or those of our collaborators may reveal
    significant adverse events, toxicities or other side effects not seen in our preclinical studies and may result in a safety profile
    that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
    at the FDA and other government agencies could hinder their ability to hire, retain or deploy key leadership and other personnel,
    or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which
    could negatively impact our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we receive regulatory approval for any of our product candidates, we may not be able to successfully license or commercialize
    the product and the revenue that we generate from its sales, if any, may be limited.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are completely dependent on third parties to manufacture our product candidates, and our commercialization of our product candidates
    could be halted, delayed or made less profitable if those third parties fail to obtain manufacturing approval from the FDA or comparable
    foreign regulatory authorities, fail to provide us with sufficient quantities of our product candidates or fail to do so at acceptable
    quality levels or prices.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we obtain marketing approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory
    review, which may result in significant additional expenses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
    and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
    regulatory approval of our product candidates in other jurisdictions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently
    enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our
    product candidates and affect the prices we may obtain.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    could face competition from other biotechnology and pharmaceutical companies, and our operating results would suffer if we fail to
    innovate and compete effectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely on third parties to conduct clinical trials for our product candidates. If these third parties do not successfully carry out
    their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize any of
    our product candidates and our business would be substantially harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may
    not be predictive of future trial results.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    though we may apply for orphan drug designation for a product candidate, we may not be able to obtain orphan drug marketing exclusivity.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
    we may pursue expedited regulatory approval pathways for a product candidate, it may not qualify for expedited development or, if
    it does qualify for expedited development, it may not actually lead to a faster development, regulatory review or approval process.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
    coverage and reimbursement, health care cost containment initiatives and treatment guidelines may constrain our future revenues.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal,
    regulatory and legislative changes with respect to reimbursement, pricing and contracting may adversely affect our business and future
    prospects.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance
    coverage for those claims is inadequate.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    any of our product candidates are approved for marketing and we are found to have improperly promoted off-label uses, or if physicians
    misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products,
    product liability claims and significant fines, penalties and sanctions, and our brand and reputation could be harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may choose not to continue developing or commercializing any of our product candidates at any time during development or after approval,
    which would reduce or eliminate our potential return on investment for those product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in U.S. and international trade policies, particularly with respect to China, Europe and
                                            India may adversely impact our business and operating results.</span></p>
</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Intellectual Property Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    cannot ensure protection of our licensed intellectual property rights.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product candidates may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our
    development and commercialization efforts.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
    and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
    imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
    </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Company-Related Risks</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation or legal proceedings could expose us to significant liabilities
and have a negative impact on our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to identify and develop
    new or next generation product candidates will be impaired, could result in loss of markets or market share and could make us less
    competitive. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience
    adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, interruptions
    or disruptions to operations or clinical trials, reputational harm, litigation, fines and penalties.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are exposed to cyber-attacks and data breaches, including the risks and costs associated with protecting our systems and maintaining
    integrity and security of our business information, as well as personal data of our guests, employees and business partners.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Ownership of Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    failure to maintain compliance with Nasdaq&#8217;s continued listing requirements could result in the delisting of our Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
    equity offerings, license transactions or acquisitions may dilute our existing stockholders&#8217; ownership and/or have other adverse
    effects on our operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock price is expected to be volatile.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to us as such may make our common
    stock less attractive to our stockholders and investors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not currently intend to pay dividends to our stockholders in the foreseeable future, and consequently, your ability to achieve
    a return on your investment will depend on appreciation in our value.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    securities or industry analysts do not publish research or reports about our business, or if they publish negative evaluations of
    our stock or negative reports about our business, our stock price and trading volume could decline.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
    in our corporate documents and Delaware law could have the effect of delaying, deferring, or preventing a change in control of us,
    even if that change may be considered beneficial by some of our stockholders.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
    in our bylaws provide for indemnification of officers and directors, which could require us to direct funds away from our business
    and the development of our product candidates. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Financial Position and Need for Additional Capital</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
need to raise additional capital to fund our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred recurring losses since inception and had an accumulated deficit of approximately $87.2 million at December 31, 2024. At
December 31, 2024, we had cash and cash equivalents totaling $1.2 million and prepaid expenses with the clinical research organizations
of our Phase 1B and Phase 2 trials of $1.7 million. Following our January public offering, we believe that our cash on hand will allow
us to continue our Phase 2 trial of NGC-Cap and satisfy our capital needs into mid-2025 under our
current business plan. In 2025, we will need to raise additional capital to fund our operations and continue our planned development
of our NGC drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred a history of operating losses and expect to continue to incur substantial costs for the foreseeable future. We are not
currently profitable, and we may never achieve or sustain profitability. Our financial situation creates doubt whether we will continue
as a going concern.</i></b></span></p>


<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage biopharmaceutical company. Processa itself as an organization has never had a drug approved by the FDA or any regulatory
agency. The likelihood of success of our business plan must be considered in light of the challenges, substantial expenses, difficulties,
complications and delays frequently encountered in connection with developing and expanding early-stage businesses and the regulatory
and competitive environment in which we operate. Biopharmaceutical product development is a highly speculative undertaking, involves
a substantial degree of risk, and is a capital-intensive business. If we cannot successfully execute our plan to develop our drug pipeline,
our business may not succeed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">We will incur additional
losses as we continue our research and development activities, seek regulatory approvals for our product candidates and engage in clinical
trials. These losses will cause, among other things, our stockholders&#8217; equity and working capital to decrease. Any future earnings
and cash flow from the operations of our business are dependent on our ability to further develop our products and on revenues and profitability
from sales of products or successful joint venture relationships.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that we will be able to generate sufficient product revenue to become profitable at all or on a sustained basis.
Even if we generate revenues, we expect to have quarter-to-quarter fluctuations in revenues and expenses, some of which could be significant,
due to research, development, clinical trial, and marketing and manufacturing expenses and activities. We also expect to incur substantial
expenses without corresponding revenues, unless and until we are able to obtain regulatory approval and successfully license or commercialize
our product candidates. If our product candidates fail in clinical trials or do not gain regulatory approval, or if our products do not
achieve market acceptance, we may never become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may never be able to obtain regulatory approval for the marketing of our product candidates in any indication in the United States or
internationally. As we commercialize and market products, we will need to incur expenses for product marketing and brand awareness and
conduct significant research, development, testing and regulatory compliance activities that, together with general and administrative
expenses, could result in substantial operating losses for the foreseeable future. Even if we do achieve profitability, we may not be
able to sustain or increase profitability on a quarterly or annual basis. Our stock price may decline, and you may lose all or a substantial
part of your investment in us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
have limited cash resources and will require additional financing.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have not generated any revenue, have incurred net losses, have used net cash in our operations and have funded our business
and operations primarily through proceeds from the sale of our securities. We expect to continue to require significant future financing
to fund our operating activities and to use cash in operating activities for the foreseeable future as we continue our research and development
activities to develop products that can be commercialized to generate revenue. Our ability to obtain additional financing will be subject
to many factors, including market conditions, our operating performance and investor sentiment. If we are unable to raise additional
capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development or commercialization
of one or more of our product candidates, restrict our operations or obtain funds by entering into agreements on unattractive terms,
which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we
have business relationships, at least until additional funding is obtained. If we do not have sufficient funds to continue operations,
we could be required to seek bankruptcy protection or other alternatives that would likely result in our stockholders losing some or
all of their investment in us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to raise additional capital to complete the development efforts for NGC-Cap, NGC-Gem and/or NGC-Iri. If we are unable to raise
capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to raise additional capital to fund our operations and continue to support our planned development of our next generation cancer
therapy drugs. Our estimates of the amount of cash necessary to fund our activities may prove to be wrong and we could spend our available
financial resources much faster than we currently expect. Our future funding requirements will depend on many factors, including, but
not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing, rate of progress
    and cost of any clinical trials and other manufacturing/product development activities for our current and any future product candidates
    that we develop, in-license or acquire;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of the clinical
    trials for our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of, and the
    costs involved in, FDA approval and any foreign regulatory approval of our product candidates, if at all;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number and characteristics
    of any additional future product candidates we develop or acquire;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish
    and maintain strategic collaborations, licensing, co-promotion or other arrangements and the terms and timing of such arrangements;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the degree and rate of
    market acceptance of any approved products;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs under our third-party
    manufacturing and supply arrangements for our current and any future product candidates and any products we commercialize;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs and timing of completion
    of any additional outsourced commercial manufacturing or supply arrangements that we may establish;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of preparing, filing,
    prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights associated with our product
    candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs associated with prosecuting
    or defending any litigation that we are or may become involved in and any damages payable by us that result from such litigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of operating as a
    public company;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the emergence, approval,
    availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing products or
    treatments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs associated with any
    acquisition or in-license of products and product candidates, technologies or businesses; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">personnel, facilities and
    equipment requirements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that additional funding will be available on acceptable terms, or at all. In addition, future debt financing into which
we may enter may impose upon us covenants that restrict our operations, including limitations on our ability to incur liens or additional
debt, pay dividends, redeem our stock, make certain investments and engage in certain merger, consolidation or asset sale transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to raise additional capital when required or on acceptable terms, we may be required to significantly delay, scale back
or discontinue the development of our product candidates, restrict our operations or obtain funds by entering into agreements on unattractive
terms, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom
we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds to continue operations,
we could be required to seek bankruptcy protection or other alternatives that would likely result in our security holders losing some
or all of their investment in us. In addition, our ability to achieve profitability or to respond to competitive pressures would be significantly
limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we are unable to secure sufficient capital to fund our operations, we may have to enter into strategic collaborations that
could require us to share license rights with third parties in ways that we currently do not intend or on terms that may not be favorable
to us or our security holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
financial statements contain a statement regarding a substantial doubt about our ability to continue as a going concern.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had no revenue during the year ended December 31, 2024 or in prior years, and do not have any revenue under contract or any immediate
sales prospects. Our primary uses of cash are to fund our planned clinical trials, research and development expenditures and for operating
expenses. Cash used to fund operating expenses is impacted by the timing of when we incur and pay these expenses. Our consolidated financial
statements have been prepared using U.S. GAAP, and are based on the assumption that we will continue as a going concern, which contemplates
the realization of assets and liquidation of liabilities in the normal course of business. We face certain risks and uncertainties that
are present in many emerging pharmaceutical companies regarding product development, limited working capital, recurring losses and negative
cash flow from operations, future profitability, ability to obtain future capital, protection of patents, technologies and property rights,
competition, rapid technological change, navigating the domestic and major foreign markets&#8217; regulatory and clinical environment,
recruiting and retaining key personnel, dependence on third party manufacturing organizations, third party collaboration and licensing
agreements, lack of sales and marketing activities. We currently have no customers or pharmaceutical products to sell or distribute.
These risks and other factors raise substantial doubt about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to continue as a going concern is dependent on our ability to obtain the necessary financing to meet our obligations and repay
our liabilities arising from the ordinary course of business operations when they become due. The substantial doubt about our ability
to continue as a going concern may affect the price of our common stock, may impact our relationship with third parties with whom we
do business, may impact our ability to raise additional capital and may impact our ability to comply going forward with covenants in
our debt agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
ability to use our net operating loss carryforwards and other tax attributes may be limited.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we had net operating loss (NOL) carryforwards of approximately $36.0 million for federal and state income tax
available to offset future taxable income, and federal and state research and development tax credits of approximately $1.2 million,
prior to consideration of annual limitations that may be imposed under Section 382 of the Internal Revenue Code of 1986, as amended (Section
382). NOL carryforwards prior to 2018 will expire in 2037 if not utilized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
NOL and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under Section 382, and
corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than
50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and
other pre-change tax attributes, such as research and development tax credits, to offset its post-change income may be limited. We have
not completed a Section 382 study and as such our net operating loss carryforwards may be subject to such limitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership, including
through completed or contemplated financings, some of which may be outside of our control. If we determine that a future ownership change
has occurred and our ability to use our historical net operating loss and tax credit carryforwards is materially limited, it would harm
our future operating results by effectively increasing our future tax obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Clinical Development and Commercialization of Our Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
licenses are subject to termination by the licensor in certain circumstances and any termination of a license agreement would result in a loss of important rights and have a material adverse
impact on our business and prospects. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
rights to practice the inventions claimed in the licensed patents and patent applications are subject to our licensors abiding by the
terms of those licenses and not terminating them. Our licenses may be terminated by the licensor if we are in material breach of certain
terms or conditions of the license agreement or in certain other circumstances. Our license agreements each include provisions that allow
the licensor to terminate the license if (i) we breach any payment obligation or other material provision under the agreement and fail
to cure the breach within a fixed time following written notice of termination; (ii) we or any of our affiliates, licensees or sublicensees
directly or indirectly challenge the validity, enforceability, or extension of any of the licensed patents; or (iii) we declare bankruptcy
or dissolve. The majority of license agreements require us to satisfy due diligence milestones that relate to the development of new
products containing the licensed drug or the agreement may be terminated by such counterparty. Our rights under these licenses are subject
to our continued compliance with the terms of the license, including the payment of royalties due under the licenses. Termination of
any of these licenses could prevent us from marketing some or all of our products. Because of the complexity of our products and the
patents we have licensed, determining the scope of the license and related royalty obligations can be difficult and can lead to disputes
between us and the licensor. An unfavorable resolution of such a dispute could lead to an increase in the royalties payable pursuant
to the license. If a licensor believed we were not paying the royalties due under the license or were otherwise not in compliance with
the terms of the license, the licensor might attempt to revoke the license. If such an attempt were successful, we might be barred from
producing and selling some or all of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed, on May 7, 2024, the Company received notification from Elion purporting to terminate the license agreement by
and between us and Elion as a result of the Company&#8217;s alleged breach thereof. The Company believes that Elion&#8217;s claims
are without merit and disputes that the license agreement has been validly terminated. We are now in litigation regarding our
license agreement. The Company intends to enforce its rights under the license agreement and will pursue such other remedies as it
determines are appropriate. Any termination of the Elion license would have a material adverse impact on our business and
prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Additionally,
we have not met certain specific diligence milestones under our license agreements with Ocuphire and Yuhan. Although we are working to extend the deadlines, there can be no assurance
that we will be successful and that such agreements will not be terminated, resulting in a loss of important rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">If
we are unable to maintain our license agreements, our business and results of operations will be adversely affected.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently do not have, and may never develop, any FDA-approved, licensed or commercialized products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet sought to obtain any regulatory approvals for any product candidates in the United States or in any foreign market. For
us to develop any products that might be licensed or commercialized, we will have to invest further time and capital in research and
product development, regulatory compliance and market development. Therefore, we and our licensors, prospective business partners and
other collaborators may never develop any products that can be licensed or commercialized. All our development efforts will require substantial
additional funding, none of which may result in any revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
depend entirely on the successful development of our product candidates, which have not yet demonstrated efficacy for their target indications
in clinical trials. We may never be able to demonstrate efficacy for our product candidates, thus preventing us from licensing, obtaining
marketing approval by any regulatory agency, and/or commercializing our product(s).</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates are either in the early stages of clinical development or late stages of preclinical development. Significant additional
research and development activity and clinical testing are required before we will have a chance to achieve a viable product for licensing
or commercialization from such candidates. Our research and development efforts remain subject to all the risks associated with the development
of new biopharmaceutical products and treatments. Development of the underlying technology may be affected by unanticipated technical
or other problems, among other research and development issues, and the possible insufficiency of funds needed in order to complete development
of these product candidates. Safety, regulatory and efficacy issues, clinical hurdles or other challenges may result in delays and cause
us to incur additional expenses that would increase our losses. If we and our collaborators cannot complete, or if we experience significant
delays in developing, our potential therapeutics or products for use in potential commercial applications, particularly after incurring
significant expenditures, our business may fail, and investors may lose the entirety of their investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
we submit an IND or foreign equivalent to the FDA or international regulatory authorities seeking approval to initiate clinical trials
in the United States and other countries, we may not be successful in obtaining acceptance from the FDA or comparable foreign regulatory
authorities to start our clinical trials. If we do not obtain such acceptance, the time in which we expect to commence clinical programs
for any product candidate will be extended and such extension will increase our expenses and increase our need for additional capital.
Moreover, there is no guarantee that our clinical trials will be successful or that we will continue clinical development in support
of an approval from the FDA or comparable foreign regulatory authorities for any indication. We note that most drug candidates never
reach the clinical development stage and even those that do commence clinical development have only a small chance of successfully completing
clinical development and gaining regulatory approval. Therefore, our business currently depends entirely on the successful development,
regulatory approval, and licensing or commercialization of our product candidates, which may never occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
must successfully complete clinical trials for our product candidates before we can apply for marketing approval.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we complete our clinical trials, it does not assure marketing approval. Our clinical trials may be unsuccessful, which would materially
harm our business. Even if our initial clinical trials are successful, we are required to conduct additional clinical trials to establish
our product candidates&#8217; safety and efficacy before submitting an NDA. Clinical testing is expensive, difficult to design and implement,
can take many years to complete and is uncertain as to the outcome. Success in early phases of pre-clinical and clinical trials does
not ensure that later clinical trials will be successful, and interim results of a clinical trial do not necessarily predict final results.
A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during,
or as a result of, the clinical trial process that could delay or prevent our ability to receive regulatory approval or commercialize
our product candidates. The research, testing, manufacturing, labeling, packaging, storage, approval, sale, marketing, advertising and
promotion, pricing, export, import and distribution of drug products are subject to extensive regulation by the FDA and other regulatory
authorities in the United States and other countries, which regulations differ from country to country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not permitted to market our product candidates as prescription pharmaceutical products in the United States until we receive approval
of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
have little corporate history of conducting clinical trials. Our planned clinical trials or those of our collaborators may reveal significant
adverse events, toxicities or other side effects not seen in our preclinical studies and may result in a safety profile that could inhibit
regulatory approval or market acceptance of any of our product candidates.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations to date have been limited to financing and staffing, conducting research and developing our core technologies,
identifying and optimizing our lead product clinical candidates, performing due diligence on other potential drug in-licensing
opportunities and further moving the clinical product candidates through the development programs identified. Some of the activities
in the development programs include receiving FDA IND clearance on one indication for two product candidates, completing a Phase 2A
trial for PCS12852 in gastroparesis patients, conducting a Phase 1B trial for NGC-Cap in patients with advanced gastrointestinal
tumors, completing a Phase 1 healthy human volunteer trial, completing a Phase 2A clinical trial and conducting a Phase 2 clinical
trial in patients with NL and receiving FDA orphan designation on PCS499 in NL. Other activities include improving the manufacturing
of PCS499, PCS6422 and NGC-Iri final products and developing regulatory strategy plans for each of the products including expedited
review plans, as applicable. Although we have recruited a team that has experience with clinical trials in the United States and
outside the United States, as a company, we have only conducted four clinical trials in any jurisdiction and have not had previous
experience commercializing product candidates through the FDA or similar submissions to initiate clinical trials or obtain marketing
authorization to foreign regulatory authorities. We cannot be certain that other planned clinical trials will begin or be completed
on time, if at all; that our development program and studies would be acceptable to the FDA or other regulatory authorities; or
that, if regulatory approval is obtained, our product candidates can be successfully commercialized. Clinical trials and
commercializing our product candidates will require significant additional financial and management resources, and reliance on
third-party clinical investigators, CROs, consultants and collaborators. Relying on third-party clinical investigators, CROs or
collaborators may result in delays that are outside of our control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we may not have the financial resources to continue development of, or to enter into collaborations for, a product candidate if we experience
any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
preclinical studies and early clinical studies of our product candidates have been completed, but we do not know the predictive value
of these studies for our targeted population of patients, and we cannot guarantee that any positive results in these studies will translate
successfully to the larger targeted population of patients. It is not uncommon to observe results in human clinical trials that are unexpected
based on preclinical testing or early clinical studies, and many product candidates fail in clinical trials despite promising preclinical
or early clinical results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and
many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless
failed to obtain marketing approval for their products. Human patients in clinical trials may suffer significant adverse events or other
side effects not observed in our preclinical studies, including, but not limited to, immunogenic responses, organ toxicities such as
liver, heart or kidney or other tolerability issues or possibly even death. The observed potency and kinetics of our planned product
candidates in preclinical studies may not be observed in human clinical trials. If clinical trials of our planned product candidates
fail to demonstrate efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur
additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our
planned product candidates which may result in complete loss of expenditures which we devote to those products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may have difficulty recruiting patients to the clinical trial, patients may drop out of our trial, or we may be required to abandon the
trial or our development efforts of that product candidate altogether. We, the FDA, an Institutional Review Board (&#8220;IRB&#8221;),
or other applicable regulatory authorities may suspend clinical trials of a product candidate at any time for various reasons, including
a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics
developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies have later been found to cause
side effects that prevented their further development. Even if the side effects do not preclude the drug from obtaining or maintaining
marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other
therapies. Any of these developments could materially harm our business, financial condition, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
if any of our product candidates obtains marketing approval, toxicities associated with our product candidates may also develop after
such approval and lead to a requirement to conduct additional clinical safety trials, additional warnings being added to the labeling,
significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product
candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical
studies or early-stage clinical testing. However, any such event, were it to occur, would cause substantial harm to our business and
financial condition and would result in the diversion of our management&#8217;s attention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disruptions
at the FDA and other government agencies could hinder their ability to hire, retain or deploy key leadership and other personnel, or
otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could
negatively impact our business.</b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA and other government agencies to review and approve new products can be affected by a variety of factors, including
government budget and funding levels, statutory, regulatory and policy changes, staffing cuts, the FDA&#8217;s ability to hire and retain
key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine
functions. Average review times at the FDA have fluctuated in recent years as a result. In&#160;addition, government funding of other
government agencies that fund research and development activities is subject to the political process, which is inherently fluid and
unpredictable. The ability of the FDA and other government agencies to properly administer their functions is highly dependent on the
levels of government funding and the ability to fill key leadership appointments, among various factors. Delays in filling or replacing
key positions could significantly impact the ability of the FDA and other agencies to fulfill their functions and could greatly impact
healthcare and the drug industry. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics
or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely
affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory
agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If disruptions at the FDA or other
agencies occurs, such as those resulting from a restructuring of these agencies, a prolonged government shutdown, or uncertainty regarding
U.S. federal government funding, could significantly affect the ability of the FDA to review and process our regulatory submissions in
a timely manner, or other factors prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews
or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review
and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a reduction or delay in government funding of research and development may adversely affect our business. Government funding
of research and development is subject to the political process, which is inherently fluid and unpredictable. For example, the NIH announced
on February 7, 2025, a policy significantly reducing research grants by limiting payments for indirect overhead. While, as of the date
of this filing, the order has been temporarily stayed, there can be no assurance that it will not take effect or that other adverse actions
will not be taken. Government proposals to reduce or eliminate budgetary deficits have sometimes included reduced allocations to the
NIH and other government agencies that fund research and development activities, or NIH funding may not be directed towards our products
and studies, both of which could adversely affect our business and our financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
in June 2024, the U.S. Supreme Court reversed its longstanding approach under the Chevron doctrine, which provided for judicial deference
to regulatory agencies, including the FDA. As a result of this decision, we cannot be sure whether there will be increased challenges
to existing agency regulations or how lower courts will apply the decision in the context of other regulatory schemes without more specific
guidance from the U.S. Supreme Court. For example, this decision may result in more companies bringing lawsuits against the FDA to challenge
longstanding decisions and policies of the FDA, which could undermine the FDA&#8217;s authority, lead to uncertainties in the industry,
and disrupt the FDA&#8217;s normal operations, which could impact the timely review of any regulatory filings or applications we submit
to the FDA.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Even
if we receive regulatory approval for any of our product candidates, we may not be able to successfully license or commercialize the
product and the revenue that we generate from its sales, if any, may be limited.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved for marketing, the commercial success of our product candidates will depend upon each product&#8217;s acceptance by the medical
community (including physicians, patients and health care payors) and the potential competitive products available to the patients upon
commercialization. The degree of market acceptance for any of our product candidates will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
    of clinical safety and efficacy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
    convenience, dosing burden and ease of administration;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any adverse effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of physicians to prescribe our product candidates, and the target patient population to try new therapies;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy
    of our product candidates compared to competing products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    introduction of any new products that may in the future become available targeting indications for which our product candidates may
    be approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    procedures or therapies that may reduce the incidences of any of the indications in which our product candidates may show utility;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing
    and cost-effectiveness;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inclusion or omission of our product candidates in treatment guidelines;</span></td></tr>

</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our own or any future collaborators&#8217; sales and marketing strategies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings contained in approved labeling from regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care programs, including Medicare
    and Medicaid, private health insurers and other third-party payors or to receive the necessary pricing approvals from government
    bodies regulating the pricing and usage of therapeutics; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement or government pricing approvals.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, health care payors and
patients, we may not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the
medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be
successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we obtain regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize
our product candidates successfully. For example, if the approval process takes too long, we may miss market opportunities and give other
companies the ability to develop competing products or establish market dominance. Any regulatory approval we ultimately obtain may be
limited or subject to restrictions or post-approval commitments that render our product candidates not commercially viable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are completely dependent on third parties to manufacture our product candidates, and our commercialization of our product candidates
could be halted, delayed or made less profitable if those third parties fail to obtain manufacturing approval from the FDA or comparable
foreign regulatory authorities, fail to provide us with sufficient quantities of our product candidates or fail to do so at acceptable
quality levels or prices.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have, nor do we plan to acquire, the capability or infrastructure to manufacture the active pharmaceutical ingredient,
or API, in our product candidates for use in our clinical trials or for commercial products. In addition, we do not have the capability
to formulate any of our product candidates into a finished drug product for commercial distribution. As a result, we will be obligated
to rely on contract manufacturers, if and when any of our product candidates are approved for commercialization. We have not entered
into an agreement with any contract manufacturers for commercial supply and may not be able to engage a contract manufacturer for commercial
supply of any of our product candidates on favorable terms to us, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or comparable foreign
regulatory authorities pursuant to inspections that will be conducted after we submit an NDA or BLA to the FDA or their equivalents to
other relevant regulatory authorities. We will not control the manufacturing process of, and will be completely dependent on, our contract
manufacturing partners for compliance with cGMPs to manufacture both active drug substances and finished drug products. These cGMP regulations
cover all aspects of the manufacturing, testing, quality control and record keeping relating to our product candidates. If our contract
manufacturers do not successfully manufacture material that conforms to our specifications and the strict regulatory requirements of
the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. If the FDA
or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it
withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact
our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contract manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies
for compliance with cGMPs and similar regulatory requirements. We will not have control over our contract manufacturers&#8217; compliance
with these regulations and standards. Failure by any of our contract manufacturers to comply with applicable regulations could result
in sanctions being imposed on us, including fines, injunctions, civil penalties, failure to grant approval to market any of our product
candidates, delays, suspensions or withdrawals of approvals, operating restrictions and criminal prosecutions, any of which could significantly
and adversely affect our business. In addition, we will not have control over the ability of our contract manufacturers to maintain adequate
quality control, quality assurance and qualified personnel. Failure by our contract manufacturers to comply with or maintain any of these
standards could adversely affect our ability to develop, obtain regulatory approval for or market any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
for any reason, these third parties are unable or unwilling to perform, we may not be able to terminate our agreements with them, and
we may not be able to locate alternative manufacturers or formulators or enter into favorable agreements with them and we cannot be certain
that any such third parties will have the manufacturing capacity to meet future requirements. If these manufacturers or any alternate
manufacturer of finished drug product experiences any significant difficulties in its respective manufacturing processes for our API
or finished products or should cease doing business with us, we could experience significant interruptions in the supply of any of our
product candidates or may not be able to create a supply of our product candidates at all. Were we to encounter manufacturing issues,
our ability to produce a sufficient supply of any of our product candidates might be negatively affected. Our inability to coordinate
the efforts of our third-party manufacturing partners, or the lack of capacity available at our third-party manufacturing partners, could
impair our ability to supply any of our product candidates at required levels. Because of the significant regulatory requirements that
we would need to satisfy in order to qualify a new bulk or finished product manufacturer, if we face these or other difficulties with
our current manufacturing partners, we could experience significant interruptions in the supply of any of our product candidates if we
decided to transfer the manufacture of any of our product candidates to one or more alternative manufacturers in an effort to deal with
the difficulties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
manufacturing problem or the loss of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally,
we rely on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may involve
several risks, including a potential inability to obtain critical materials and reduced control over production costs, delivery schedules,
reliability and quality. Any unanticipated disruption to a future contract manufacturer caused by problems with suppliers could delay
shipment of any of our product candidates, increase our cost of goods sold and result in lost sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that our future manufacturing and supply partners will be able to reduce the costs of commercial scale manufacturing
of any of our product candidates over time. If the commercial-scale manufacturing costs of any of our product candidates are higher than
expected, these costs may significantly impact our operating results. In order to reduce costs, we may need to develop and implement
process improvements. However, in order to do so, we will need, from time to time, to notify or make submissions to regulatory authorities,
and the improvements may be subject to approval by such regulatory authorities. We cannot be sure that we will receive these necessary
approvals or that these approvals will be granted in a timely fashion. We also cannot guarantee that we will be able to enhance and optimize
output in our commercial manufacturing process. If we cannot enhance and optimize output, we may not be able to reduce our costs over
time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Even
if we obtain marketing approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory
review, which may result in significant additional expenses.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for any of our product candidates for an indication, the FDA or foreign equivalent may still impose
significant restrictions on their indicated uses or marketing or the conditions of approval or impose ongoing requirements for potentially
costly and time-consuming post-approval studies, including Phase 4 clinical trials, and post-market surveillance to monitor safety and
efficacy. Our product candidates will also be subject to ongoing regulatory requirements governing the manufacturing, labeling, packaging,
storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of adverse events and other post-market
information. These requirements include registration with the FDA, as well as continued compliance with current Good Clinical Practices
(cGCPs) for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject
to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations, requirements
relating to quality control, quality assurance and corresponding maintenance of records and documents. Compliance with such regulations
may result in significant costs and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or
maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may
have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product
candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of
the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative
review periods different from those in the United States, including additional preclinical studies or clinical trials, as clinical studies
conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the
United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some
cases, the price that we intend to charge for our products is also subject to approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and
costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory
requirements in international markets and/or to receive applicable marketing approvals, our target market will be reduced and our ability
to realize the full market potential of our product candidates will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product
candidates and affect the prices we may obtain.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval for our product candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell our product candidates. Legislative and regulatory proposals have been made to expand
post-approval requirements and restrict sales and promotional activities for pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Medicare Modernization Act (MMA) changed the way Medicare covers and pays for pharmaceutical products. The legislation
expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices
for drugs. In addition, this legislation authorized Medicare Part D prescription drug plans to use formularies where they can limit the
number of drugs that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal coverage
of drug products, we expect that there will be additional pressure to contain and reduce costs. These cost reduction initiatives and
other provisions of this legislation could decrease the coverage and price that we receive for our product candidates and could seriously
harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage
policy and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA
may result in a similar reduction in payments from private payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010 or,
collectively, the ACA, is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare
spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries,
impose new taxes and fees on the health industry and impose additional health policy reforms. The ACA revised the definition of &#8220;average
manufacturer price&#8221; for reporting purposes, which could increase the amount of Medicaid drug rebates to states. The law also imposed
a significant annual fee on companies that manufacture or import branded prescription drug products. Further, on August 16, 2022, President
Biden signed the Inflation Reduction Act of 2022 (IRA), into law which, among other things, extends enhanced subsidies for individuals
purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221;
under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating
a new manufacturer discount program. It is unclear how such challenges, and the healthcare reform measures of the Biden administration
will impact the ACA and our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not know whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will
be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased
scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject
us to more stringent product labeling and post-marketing testing and other requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
could face competition from other biotechnology and pharmaceutical companies, and our operating results would suffer if we fail to innovate
and compete effectively.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are used for indications where we believe that there is an unmet medical need. If existing or newly approved drug products,
whether approved by the FDA for the indication or not, are able to successfully treat the same patients, it may be more difficult to
perform clinical studies, to develop our product and/or to commercialize our product, adversely affecting our business. Since the biopharmaceutical
industry is characterized by intense competition and rapid innovation, our competitors may be able to develop other compounds or drugs
that are able to achieve similar or better results than our product candidates. Our competitors may include major multinational pharmaceutical
companies, established biotechnology companies, specialty pharmaceutical companies, and universities and other research institutions.
Many of our competitors have substantially greater financial, technical and other resources, such as a larger research and development
staff and experienced marketing and manufacturing organizations, established relationships with CROs and other collaborators, as well
as established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result
in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial
applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or
with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are
more effective, safer, more easily commercialized or less costly than our product candidates, or may develop proprietary technologies
or secure patent protection and, in turn, exclude us from technologies that we may need for the development of our technologies and potential
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval of any of our product candidates, we may not be the first to market and that may negatively affect the
price or demand for our product candidates. Additionally, we may not be able to implement our business plan if the acceptance of our
product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to
our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for
use in limited circumstances. Furthermore, for drugs that receive orphan drug designation at the FDA, a competitor could obtain orphan
product approval from the FDA with respect to such competitor&#8217;s drug product. If such competitor drug product is determined to
be the same product as one of our product candidates, we may be prevented from obtaining approval from the FDA for such product candidate
for the same indication for seven years, except in limited circumstances, and we may be subject to similar restrictions under non-U.S.
regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
rely on third parties to conduct clinical trials for our product candidates. If these third parties do not successfully carry out their
contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize any of our product
candidates and our business would be substantially harmed.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into agreements with third-party CROs to conduct and manage our clinical programs including contracting with clinical sites
to perform our clinical studies. We rely heavily on these parties to execute clinical studies for our product candidates and will control
only certain aspects of their activities. Nevertheless, we will be responsible for ensuring that each of our studies is conducted in
accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on CROs and clinical sites will
not relieve us of our regulatory responsibilities. We and our CROs will be required to comply with cGCPs, which are regulations and guidelines
enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities
for any products in clinical development. The FDA and its foreign equivalents enforce these cGCP regulations through periodic inspections
of trial sponsors, principal investigators and trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data
generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to
perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA or
other regulatory authorities will determine that any of our clinical trials comply with cGCPs. In addition, our clinical trials must
be conducted with products produced under cGMP regulations and will require a large number of test subjects. Our failure or the failure
of our CROs or clinical sites to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory
approval process and could also subject us to enforcement action up to and including civil and criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we design clinical trials for our product candidates in consultation with CROs, the CROs will manage all of the clinical trials conducted
at contracted clinical sites. As a result, many important aspects of our drug development programs would be outside of our direct control.
In addition, the CROs and clinical sites may not perform all of their obligations under arrangements with us or in compliance with regulatory
requirements. If the CROs or clinical sites do not perform clinical trials in a satisfactory manner, breach their obligations to us or
fail to comply with regulatory requirements, the development and commercialization of any of our product candidates for the subject indication
may be delayed or our development program materially and irreversibly harmed. We cannot control the amount and timing of resources these
CROs and clinical sites will devote to our program or any of our product candidates. If we are unable to rely on clinical data collected
by our CROs, we could be required to repeat, extend the duration of, or increase the size of our clinical trials, which could significantly
delay commercialization and require significantly greater expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-party CROs or clinical sites terminate, we may not be able to enter into arrangements with
alternative CROs or clinical sites. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines,
if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere
to our clinical protocols, regulatory requirements or for other reasons, any such clinical trials may be extended, delayed or terminated,
and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial
results and the commercial prospects for any of our product candidates would be harmed, our costs could increase and our ability to generate
revenue could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not
be predictive of future trial results.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing of drug product candidates is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure
can occur at any time during the clinical trial process. The results of pre-clinical studies and early clinical trials may not be predictive
of the results of later-stage clinical trials. We cannot assure you that the FDA or comparable foreign regulatory authorities will view
the results as we do or that any future trials of any of our product candidates will achieve positive results. Product candidates in
later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical
studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced
clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Any future clinical
trial results for our product candidates may not be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a number of factors could contribute to a lack of favorable safety and efficacy results for any of our product candidates.
For example, such trials could result in increased variability due to varying site characteristics, such as local standards of care,
differences in evaluation period and surgical technique, and due to varying patient characteristics including demographic factors and
health status.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Even
though we may apply for orphan drug designation for a product candidate, we may not be able to obtain orphan drug marketing exclusivity.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that the FDA, EMA or their foreign equivalents will grant any future application for orphan drug designation for any
of our product candidates, which would make us ineligible for the additional exclusivity and other benefits of orphan drug designation.
Even where orphan drug designation or equivalent status is granted, there is no guarantee of orphan drug marketing exclusivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally
a disease or condition that affects fewer than 200,000 individuals in the United States and for which there is no reasonable expectation
that the cost of developing and making a drug available in the Unites States for this type of disease or condition will be recovered
from sales of the product. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation,
the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does
not convey any advantage in or shorten the duration of regulatory review and approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other applications to market
the same drug for the same indication for seven years, except in limited circumstances, such as (i) the drug&#8217;s orphan designation
is revoked; (ii) its marketing approval is withdrawn; (iii) the orphan exclusivity holder consents to the approval of another applicant&#8217;s
product; (iv) the orphan exclusivity holder is unable to assure the availability of a sufficient quantity of drug; or (v) a showing of
clinical superiority to the product with orphan exclusivity by a competitor product. If a drug designated as an orphan product receives
marketing approval for an indication broader than what is designated, it may not be entitled to orphan drug exclusivity. While the FDA
granted orphan-drug designation to PCS499 for the treatment of NL and to NGC-Gem for the treatment of pancreatic cancer, there can be
no assurance that we will receive orphan drug designation for any additional product candidates in the indications for which we think
they might qualify, if we elect to seek such applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Although
we may pursue expedited regulatory approval pathways for a product candidate, it may not qualify for expedited development or, if it
does qualify for expedited development, it may not actually lead to a faster development, regulatory review or approval process.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe there may be an opportunity to accelerate the development of certain of our product candidates through one or more of the
FDA&#8217;s expedited programs, such as fast track, breakthrough therapy, accelerated approval or priority review, we cannot be assured
that any of our product candidates will qualify for such programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, a drug may be eligible for designation as a breakthrough therapy if the drug is intended, alone or in combination with one or
more other drugs, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints. Although breakthrough designation or
access to any other expedited program may expedite the development or approval process, it does not change the standards for approval.
If we apply for an expedited program for our product candidates, the FDA may determine that our proposed target indication or other aspects
of our clinical development plans do not qualify for such expedited program. Even if we are successful in obtaining access to an expedited
program, we may not experience faster development timelines or achieve faster review or approval compared to conventional FDA procedures.
Access to an expedited program may also be withdrawn by the FDA if it believes that the designation is no longer supported by data from
our clinical development program. Additionally, qualification for any expedited review procedure does not ensure that we will ultimately
obtain regulatory approval for such product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Third-party
coverage and reimbursement, health care cost containment initiatives and treatment guidelines may constrain our future revenues.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully market our product candidates will depend in part on the level of reimbursement that government health administration
authorities, private health coverage insurers and other organizations provide for the cost of our products and related treatments. Countries
in which any of our product candidates may be sold through reimbursement schemes under national health insurance programs frequently
require that manufacturers and sellers of pharmaceutical products obtain governmental approval of initial prices and any subsequent price
increases. In certain countries, including the United States, government-funded and private medical care plans can exert significant
indirect pressure on prices. We may not be able to sell our product candidates profitably if adequate prices are not approved or coverage
and reimbursement is unavailable or limited in scope.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal,
regulatory and legislative changes with respect to reimbursement, pricing and contracting may adversely affect our business and future
prospects.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
and state governments may adopt policies affecting drug pricing and contracting practices outside of the context of federal programs
such as Medicare and Medicaid, which may adversely affect our business. For example, several states have adopted laws that require drug
manufacturers to provide advance notice of certain price increases and to report information relating to those price increases. There
can be no assurances that future changes to Medicare and/or Medicaid prescription drug reimbursement policies, drug pricing and contracting
practices, or government drug price regulation programs such as the Medicaid Drug Rebate Program or 340B Drug Pricing Program will not
have an adverse impact on our business and future prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory
developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect
on anticipated revenues from product candidates and may affect our overall financial condition and ability to develop product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance
coverage for those claims is inadequate.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater
risk if we commercialize any products. This risk exists even if a product is approved for commercial sale by the FDA and manufactured
in facilities licensed and regulated by the FDA or an applicable foreign regulatory authority. Our products and product candidates are
designed to affect important bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated with
our product candidates could result in injury to a patient or even death. We cannot offer any assurance that we will not face product
liability suits in the future, or that our insurance coverage will be sufficient to cover our liability in any such cases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a liability claim may be brought against us even if our product candidates merely appear to have caused an injury. Product
liability claims may be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise
coming into contact with our product candidates, among others. If we cannot successfully defend ourselves against product liability claims,
we will incur substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability
claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial participants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    of clinical trial sites or entire trial programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment
    of our business reputations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recall or withdrawal from the market or labeling, marketing or promotional restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    costs of any related litigation or similar disputes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">distractions
    of management&#8217;s attention and other resources from our primary business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to patients or other claimants against us that may not be covered by insurance; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenue.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have obtained product liability insurance coverage for our clinical trials. However, large judgments have been awarded in class action
or individual lawsuits based on drugs that had unanticipated side effects and our insurance coverage may not be sufficient to cover all
of our product liability related expenses or losses and may not cover us for any expenses or losses we may suffer. Moreover, insurance
coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost,
in sufficient amounts or upon adequate terms to protect us against losses due to product liability. We will need to increase our product
liability coverage if any of our product candidates receive regulatory approval, which will be costly, and we may be unable to obtain
this increased product liability insurance on commercially reasonable terms, or at all. A successful product liability claim, or series
of claims, brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease
our cash and could harm our business, financial condition, operating results and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
any of our product candidates are approved for marketing and we are found to have improperly promoted off-label uses, or if physicians
misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, product
liability claims and significant fines, penalties and sanctions, and our brand and reputation could be harmed.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about drug products. In particular,
a product may not be promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected
in the product&#8217;s approved labeling and comparative safety or efficacy claims cannot be made without direct comparative clinical
data. If we are found to have promoted off-label uses of any of our product candidates, we may become subject to significant liability,
which would materially harm our business. Both federal and state governments have levied large civil and criminal fines against companies
for alleged improper promotion and have enjoined several companies from engaging in off-label promotion. If we become the target of such
an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially
harm our business. In addition, management&#8217;s attention could be diverted from our business operations, significant legal expenses
could be incurred, and our brand and reputation could be damaged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is
changed or curtailed. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject
to FDA regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil
fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they
consider our business activities constitute promotion of an off-label use, which could result in significant penalties, including criminal,
civil or administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the
curtailment or restructuring of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot, however, prevent a physician from using our product candidates outside of those indications for use when the physician&#8217;s
independent professional medical judgment deems appropriate. Physicians may also misuse our product candidates or use improper techniques,
potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If our product candidates
are misused or used with improper technique, we may become subject to costly litigation by physicians or their patients. Furthermore,
the use of our product candidates for indications other than those cleared by the FDA may not effectively treat such conditions, which
could harm our reputation among physicians and patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may choose not to continue developing or commercializing any of our product candidates at any time during development or after approval,
which would reduce or eliminate our potential return on investment for those product candidates.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any time, we may decide to discontinue the development of any of our product candidates or not to continue commercializing one or more
of our approved product candidates for a variety of reasons, including changes in our internal product, technology or indication focus,
the appearance of new technologies that make our product obsolete, competition from a competing product or changes in or failure to comply
with applicable regulatory requirements. If we terminate a program in which we have invested significant resources, we will not receive
any return on our investment, and we will have missed the opportunity to have allocated those resources to potentially more productive
uses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in U.S. and international trade policies, particularly with respect to China, Europe and India may adversely impact our business and
operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. government has recently made statements and taken certain actions that may lead to potential changes to U.S. and international trade
policies, including imposing several rounds of tariffs and export control restrictions affecting certain products manufactured in China.
Both China and the United States have each imposed tariffs indicating the potential for further trade barriers, including the U.S. Commerce
Department adding numerous Chinese entities to its &#8220;unverified list,&#8221; which requires U.S. exporters to go through more procedures
before exporting goods to such entities. Further, the current administration has imposed tariffs on foreign imports into the United States
from China, signaled intent to negotiate and enter into a new trade agreement with India by the end of calendar 2025, and is expected
to issue a plan for reciprocal tariffs broadly. It is unknown whether and to what extent new tariffs, export controls, or other new laws
or regulations will be adopted, or the effect that any such actions would have on us or our industry. Any unfavorable government policies
on international trade, such as export controls, capital controls or tariffs, may increase the cost of manufacturing our product candidates
and platform materials, affect our ability to commercialize our product candidates if approved, the competitive position of our product
candidates, and import or export of raw materials and finished product candidate used in our preclinical studies and clinical trials,
particularly with respect to any product candidates and materials that we import from China. If any new tariffs, export controls, legislation
and/or regulations are implemented, or if existing trade agreements are renegotiated or, in particular, if either the U.S. or Chinese
government takes retaliatory trade actions due to the recent trade tension, such changes could have an adverse effect on our business,
financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Intellectual Property Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
cannot ensure protection of our licensed intellectual property rights.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend, in part, on the ability of our licensors to obtain and maintain patent protection for our licensed technologies,
products and processes, successfully defend these licensed patents against third-party challenges and successfully enforce these patents
against third-party competitors. The patent positions of pharmaceutical companies can be highly uncertain and involve complex legal,
scientific and factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in interpretations
of patent laws may diminish the value of our licensed intellectual property rights. Accordingly, we cannot predict the breadth of claims
that may be allowable or enforceable in our patents. The existing patents and patent applications relating to our drug product candidates
may be challenged, invalidated or circumvented by third parties and might not protect us against competitors with similar products or
technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection for our proprietary rights is uncertain. We may not be able to adequately protect our rights, gain or keep
our competitive advantage, or provide any competitive advantage at all. For example, others have filed, and in the future are likely
to file, patent applications covering products and technologies that are similar, identical or competitive to any of our product candidates,
or important to our business. We cannot be certain that any patent application owned by a third party will not have priority over patent
applications licensed or filed by us, or that our licensed intellectual property or intellectual property that we develop in the future
will not be involved in interference, opposition or invalidity proceedings before United States or foreign patent offices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may rely on know-how and trade secrets to protect technology, especially in cases when we believe patent protection is
not appropriate or obtainable. However, know-how and trade secrets are difficult to protect. While we intend to require employees, academic
collaborators, consultants and other contractors to enter into confidentiality agreements, we may not be able to adequately protect our
trade secrets or other proprietary or licensed information. Typically, research collaborators and scientific advisors have rights to
publish data and information in which we may also have rights. If we cannot maintain the confidentiality of our licensed or owned proprietary
technology and other confidential information, our ability to protect valuable information licensed or owned by us may be imperiled.
Enforcing a claim that a third-party entity illegally obtained and is using any of our licensed or owned know-how and trade secrets is
expensive and time consuming, and the outcome is unpredictable. In addition, courts are sometimes less willing to protect trade secrets
than patents. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to obtain or maintain patent or trade secret protection for our product candidates or our technologies, third parties could use
our licensed or owned intellectual property, which could impair our ability to compete in the market and adversely affect our ability
to generate revenues and attain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also rely on the trademarks we may develop to distinguish our products from the products of our competitors. We cannot guarantee
that any trademark applications filed by our licensors, us, or our business partners will be approved. Third parties may also oppose
such trademark applications, or otherwise challenge our use of the trademarks. In the event that the trademarks we use are successfully
challenged, we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote
resources to advertising and marketing new brands. Further, we cannot provide assurance that competitors will not infringe the trademarks
we use, or that we, our licensors, or business partners will have adequate resources to enforce these trademarks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
product candidates may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development
and commercialization efforts.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on avoiding infringement of the proprietary technologies of others. The pharmaceutical industry has been characterized
by frequent litigation regarding patent and other intellectual property rights. Identification of third-party patent rights that may
be relevant to our licensed technology is difficult because patent searching is imperfect due to differences in terminology among patents,
incomplete databases and the difficulty in assessing the meaning of patent claims. Additionally, because patent applications are maintained
in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization of
any of our licensed product candidates or any future product candidate. There may be certain issued patents and patent applications claiming
subject matter that we may be required to license in order to research, develop or commercialize any of our product candidates, and we
do not know if such patents and patent applications would be available to license on commercially reasonable terms, or at all. Any claims
of patent infringement asserted by third parties would be time-consuming and may divert the time and attention of our technical personnel
and management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may hold proprietary rights that could prevent any of our licensed product candidates from being marketed. Any patent-related
legal action against us claiming damages and seeking to enjoin commercial activities relating to any of our product candidates or our
processes could subject us to potential liability for damages and require us to obtain a license and pay royalties to continue to manufacture
or market any of our product candidates or any future product candidates. We cannot predict whether we would prevail in any such actions
or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition,
we cannot be sure that we could redesign our product candidates or any future product candidates or processes to avoid infringement,
if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses,
could prevent us from developing and commercializing any of our product candidates or a future product candidate, which could harm our
business, financial condition and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of companies, including several major pharmaceutical companies, have conducted, or are conducting, research within the licensed
fields in which we intend to operate, which has resulted, or may result, in the filing of many patent applications related to this research.
If we were to challenge the validity of these or any issued United States patent in court, we would need to overcome a statutory presumption
of validity that attaches to every issued United States patent. This means that, in order to prevail, we would have to present clear
and convincing evidence as to the invalidity of the patent&#8217;s claims. If we were to challenge the validity of these or any issued
United States patent in an administrative trial before the Patent Trial and Appeal Board in the United States Patent and Trademark Office
(USPTO), we would have to prove that the claims are unpatentable by a preponderance of the evidence. There is no assurance that a jury
and/or court would find in our favor on questions of infringement, validity or enforceability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid
to the USPTO and various governmental patent agencies outside of the U.S. in several stages over the lifetime of the patents and applications.
The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment
and other similar provisions during the patent application process and after a patent has issued. There are situations in which non-compliance
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the
relevant jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Company-Related Risks</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Litigation or legal proceedings could expose
us to significant liabilities and have a negative impact on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The per share price of our common
stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject
to securities litigation, including class action litigation. Litigation of this type could result in substantial costs and diversion of
management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition and results
of operations. In addition, from time to time, we may be party to other various claims and litigation proceedings. We evaluate these claims
and litigation proceedings to assess the likelihood of unfavorable outcomes and to estimate, if possible, the amount of potential losses.
Based on these assessments and estimates, we may establish reserves, as appropriate. These assessments and estimates are based on the
information available to management at the time and involve a significant amount of management judgment. Actual outcomes or losses may
differ materially from its assessments and estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On December 3, 2024, two of the
investors in our February 2021 private offering filed a lawsuit alleging fraud and negligent misrepresentation in connection therewith
and seeking monetary damages.&#160;In addition, on May 10, 2024, we filed a lawsuit against Elion Oncology, Inc. disputing the purported
termination of a license agreement, which lawsuit is subject to counterclaims by Elion.&#160;We intend to vigorously defend ourselves
in these lawsuits and cannot at this time predict the likely outcome of any litigation, reasonably determine either the probability of
a material adverse result or any estimated range of potential exposure, or reasonably determine how these matters or any future matters
might impact our business, our financial condition, or our results of operations, although such impact, including the costs of defense,
as well as any judgments or indemnification obligations, among other things, could be materially adverse to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Lawsuits may divert our management&#8217;s
attention, and we may incur significant expenses in defending any lawsuits. The results of litigation and other legal proceedings are
inherently uncertain, and adverse judgments or settlements in any legal dispute may result in monetary damages, penalties or injunctive
relief, or the termination of license agreements, which could have a material adverse effect on our financial position, cash flows or
results of operations. While we maintain insurance for certain potential liabilities, such insurance does not cover all types of potential
liabilities and is subject to various exclusions, as well as limits on amounts recoverable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to identify and develop new
or next generation product candidates will be impaired, could result in loss of markets or market share and could make us less competitive.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent upon the principal members of our small management team and staff, including George Ng, our Chief Executive Officer;
David Young, Pharm.D., Ph.D, our President of Research and Development; and Sian Bigora, Pharm.D., our Chief Development and Regulatory
Officer. The employment of Drs. Young and Bigora may be terminated at any time by either us or Dr. Young or Dr. Bigora. The loss of any
current or future team member could impair our ability to design, identify, and develop new intellectual property and product candidates
and new scientific or product ideas. Additionally, if we lose the services of any of these persons, we would likely be forced to expend
significant time and money in the pursuit of replacements, which may result in a delay in the development of our product candidates and
the implementation of our business plan and plan of operations and diversion of our management&#8217;s attention. We can give no assurance
that we can find satisfactory replacements for our current and future key scientific and management employees on terms that would not
be unduly expensive or burdensome to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment
with us on short notice. Although we expect to have employment agreements with our key employees, these employment agreements may still
allow these employees to leave our employment at any time, for or without cause. We do not maintain &#8220;key man&#8221; insurance policies
on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to
attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific
and medical and scientific personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience
adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, interruptions
or disruptions to operations or clinical trials, reputational harm, litigation, fines and penalties.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we, or the third parties upon which we rely, process, collect, receive, store, use, transmit, transfer,
make accessible, protect, secure, dispose of, disclose and share proprietary, confidential, and sensitive data, including personal data
(such as health-related data), intellectual property, and trade secrets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyberattacks,
malicious internet-based activity, online and offline fraud and other similar activities threaten the confidentiality, integrity, and
availability of our sensitive information and information technology systems, and those of the third parties upon which we rely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to, social engineering
attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced
persistent threat intrusions), denial-of-service attacks (such as credential stuffing), personnel misconduct or error, ransomware attacks,
supply-chain attacks, software bugs, server malfunction, software or hardware failures, loss of data or other information technology
assets, adware, telecommunications failures, earthquakes, fire, flood, and other similar threats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety
of contexts, including, without limitation, cloud-based infrastructure, drug suppliers, data center facilities, encryption and authentication
technology, employee email, content delivery to customers, and other functions. Our ability to monitor these third parties&#8217; information
security practices is limited, and these third parties may not have adequate information security measures in place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized,
unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive
information or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption
could disrupt our ability (and that of third parties upon whom we rely) to perform our research and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are exposed to cyber-attacks and data breaches, including the risks and costs associated with protecting our systems and maintaining
integrity and security of our business information, as well as personal data of our guests, employees and business partners.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to cyber-attacks. These cyber-attacks can vary in scope and intent from attacks with the objective of compromising our systems,
networks and communications for economic gain to attacks with the objective of disrupting, disabling or otherwise compromising our operations.
The attacks can encompass a wide range of methods and intent, including phishing attacks, illegitimate requests for payment, theft of
intellectual property, theft of confidential or non-public information, installation of malware, installation of ransomware and theft
of personal or business information. The breadth and scope of these attacks, as well as the techniques and sophistication used to conduct
these attacks, have grown over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
successful cyber-attack may target us directly, or it may be the result of a third party&#8217;s inadequate care. In either scenario,
we may suffer damage to our systems and data that could interrupt our operations, adversely impact our reputation and brand and expose
us to increased risks of governmental investigation, litigation and other liability, any of which could adversely affect our business.
Furthermore, responding to such an attack and mitigating the risk of future attacks could result in additional operating and capital
costs in systems technology, personnel, monitoring and other investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we are also subject to various risks associated with the collection, handling, storage and transmission of sensitive information.
In the course of doing business, we collect employee, customer and other third-party data, including personally identifiable information
and individual credit data, for various business purposes. These laws continue to develop and may be inconsistent from jurisdiction to
jurisdiction. If we fail to comply with the various applicable data collection and privacy laws, we could be exposed to fines, penalties,
restrictions, litigation or other expenses, and our business could be adversely impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
breach, theft, loss, or fraudulent use of employee, third-party or company data, could adversely impact our reputation and expose us
to risks of data loss, business disruption, governmental investigation, litigation and other liability, any of which could adversely
affect our business. Significant capital investments and other expenditures could be required to remedy the problem and prevent future
breaches, including costs associated with additional security technologies, personnel, experts and credit monitoring services for those
whose data has been breached. Further, if we or our vendors experience significant data security breaches or fail to detect and appropriately
respond to significant data security breaches, we could be exposed to government enforcement actions and private litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Ownership of Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
failure to maintain compliance with Nasdaq&#8217;s continued listing requirements could result in the delisting of our Common Stock.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Our common stock is currently listed for trading on The Nasdaq Capital
Market. We must satisfy The Nasdaq Capital Market&#8217;s continued listing requirements risk delisting, which would have a material adverse
effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 4, 2025, we received notice from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price
of our common stock for the prior 30 consecutive business days, we were not in compliance with the requirement to maintain a minimum
bid price of $1.00 per share for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550(a)(2). We will have 180 days from
February 4, 2025, or through August 4, 2025, to regain compliance. If we do not regain compliance during the compliance period ending
August 4, 2025, then Nasdaq may grant us a second 180 calendar day period to regain compliance, provided we meet the continued listing
requirement for market value of publicly-held shares and all other initial listing standards for The Nasdaq Capital Market, other than
the minimum closing bid price requirement, and notify Nasdaq of our intent to cure the deficiency. If we do not regain compliance within
the allotted compliance periods, including any extensions that may be granted by Nasdaq, we may be subject to delisting. In order to satisfy the bid price requirement, we may be required to complete
a reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our common stock were delisted from Nasdaq, trading of our common stock would most likely take place on an over-the-counter market established
for unlisted securities, such as the OTCQB or the Pink Market maintained by OTC Markets Group Inc. An investor would likely find it less
convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors
would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from
trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock would
be subject to SEC rules as a &#8220;penny stock,&#8221; which impose additional disclosure requirements on broker-dealers. The regulations
relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker
commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit
the ability of investors to trade in our common stock. In addition, delisting could harm our ability to raise capital through alternative
financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers
and employees and fewer business development opportunities. For these reasons and others, delisting would adversely affect the liquidity,
trading volume and price of our common stock, causing the value of an investment in us to decrease and having an adverse effect on our
business, financial condition and results of operations, including our ability to attract and retain qualified employees and to raise
capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Future
equity offerings, license transactions or acquisitions may dilute our existing stockholders&#8217; ownership and/or have other adverse
effects on our operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into
or exchangeable for our common stock at prices that may be higher or lower than what our existing stockholders paid and other securities
in the future could have rights superior to existing stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may engage in one or more potential license transactions or acquisitions in the future, which could involve issuing our
common stock as some or all of the consideration payable by us to complete such transactions. If we issue common stock or securities
linked to our common stock, the newly issued securities may have a dilutive effect on the interests of the holders of our common stock.
Additionally, future sales of newly issued shares used to effect a transaction could depress the market price of our common stock and
have a dilutive effect on our existing stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also issue equity securities that provide rights, preferences and privileges senior to those of our common stock. If we raise additional
funds by issuing debt securities, these debt securities would have rights senior to those of our common stock and the terms of the debt
securities issued could impose significant restrictions on our operations, including liens on our assets. If we raise additional funds
through collaborations and licensing arrangements, we may be required to relinquish some rights to our technologies or candidate products,
or to grant licenses on terms that are not favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
common stock price is expected to be volatile.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical,
biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the
market price of our common stock to fluctuate include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relatively
    low trading volume, which can result in significant volatility in the market price of our common stock based on a relatively smaller
    number of trades and dollar amount of transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in estimates or recommendations by securities analysts, if any, who cover our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">our ability to remain listed on The NASDAQ Capital
Market;</p>
</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and results of our current and any future preclinical or clinical trials of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    entry into or termination of key agreements, including, among others, key collaboration and license agreements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results and timing of regulatory reviews relating to the approval of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation of, material developments in, or conclusion of, litigation to enforce or defend any of our intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of any of our product candidates, if approved, to achieve commercial success;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    and industry-specific economic conditions that may affect our research and development expenditures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of clinical trials conducted by others on products that would compete with our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issues
    in manufacturing our product candidates or any approved products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    introduction of technological innovations or new commercial products by our competitors;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    sales of our common stock by us, our insiders or our other stockholders;</span></td></tr>

</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    negative outcome in any litigation or potential legal proceeding;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    and departures of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    publicity or announcements regarding regulatory developments relating to our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated fluctuations in our financial condition and operating results, including our cash and cash equivalents balance, operating
    expenses, cash burn rate or revenue levels;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    filing for protection under federal bankruptcy laws; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual
companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In the past, following periods
of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation
against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and
resources, which could significantly harm our profitability and reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to us as such may make our common stock
less attractive to our stockholders and investors.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;smaller reporting company&#8221; under the federal securities laws and, as such, are subject to scaled disclosure requirements
afforded to such companies. For example, as a smaller reporting company, we are subject to reduced executive compensation disclosure
requirements. Our stockholders and investors may find our common stock less attractive as a result of our status as a &#8220;smaller
reporting company&#8221; and our reliance on the reduced disclosure requirements afforded to these companies. If some of our stockholders
or investors find our common stock less attractive, there may be a less active trading market for our common stock and the market price
of our common stock may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
do not currently intend to pay dividends to our stockholders in the foreseeable future, and consequently, your ability to achieve a return
on your investment will depend on appreciation in our value.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to
finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying
dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.
There is no guarantee that our valuation will appreciate in value or even maintain the valuation at which our stockholders have purchased
their shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
securities or industry analysts do not publish research or reports about our business, or if they publish negative evaluations of our
stock or negative reports about our business, our stock price and trading volume could decline.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about
us or our business. We do not have any control over these analysts. We may never obtain research coverage by industry or financial analysts.
If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage,
there can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrades
our stock or changes his or her opinion of our stock, our stock price would likely decline. If one or more of these analysts cease coverage
of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our stock
price or trading volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Provisions
in our corporate documents and Delaware law could have the effect of delaying, deferring, or preventing a change in control of us, even
if that change may be considered beneficial by some of our stockholders.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence of some provisions of our certificate of incorporation or our bylaws or Delaware law could have the effect of delaying, deferring,
or preventing a change in control of us that a stockholder may consider favorable. These provisions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
    that the number of members of our Board is limited to a range fixed by our bylaws;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    advance notice requirements for nominations of candidates for election to our Board of Directors or for proposing matters that can
    be acted on by stockholders at stockholder meetings; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorizing
    the issuance of &#8220;blank check&#8221; preferred stock, which could be issued by our Board of Directors to issue securities with
    voting rights and thwart a takeover attempt.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Delaware corporation, we are also subject to provisions of Delaware law, including Section 203 of the General Corporation Law of the
State of Delaware. Section 203 prevents some stockholders holding more than 15% of our voting stock from engaging in certain business
combinations unless the business combination or the transaction that resulted in the stockholder becoming an interested stockholder was
approved in advance by our Board of Directors, results in the stockholder holding more than 85% of our voting stock (subject to certain
restrictions), or is approved at an annual or special meeting of stockholders by the holders of at least 66 2/3% of our voting stock
not held by the stockholder engaging in the transaction. Any provision of our certificate of incorporation or our bylaws or Delaware
law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium
for their shares of our common stock and affect the price that some investors are willing to pay for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Provisions
in our bylaws provide for indemnification of officers and directors, which could require us to direct funds away from our business and
the development of our product candidates.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws provide for the indemnification of our officers and directors. We may in the future be required to advance costs incurred by an
officer or director and to pay judgments, fines and expenses incurred by an officer or director, including reasonable attorneys&#8217;
fees, as a result of actions or proceedings in which our officers and directors are involved by reason of being or having been an officer
or director of our company. Funds paid in satisfaction of judgments, fines and expenses may be funds we need for the operation of our
business and the development of our product candidates, thereby affecting our ability to attain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>Item
1B. Unresolved Staff Comments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>Item
1C. Cybersecurity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#160;</span></span></p>

<p id="xdx_98B_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-OQG_zSuqKVHvZnT9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000049-01" escape="true" id="Fact000049" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risk Management and Strategy</b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C02_gBFCRMPFAIAMT-OQG_zvKpY2E1CTRl"><ix:continuation continuedAt="ConU000049-02" id="ConU000049-01">&#160;</ix:continuation></span></span></p>

<div id="xdx_C07_gBFCRMPFAIAMT-OQG_z1yjPtWj7AD7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><ix:continuation continuedAt="ConU000049-03" id="ConU000049-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zlQ1SODAGDP3" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000050" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">We
have established processes to assess, identify, and manage cybersecurity risks. These processes are <span id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zODYREMUV9F4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000051" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">integrated</ix:nonNumeric></span> into our overall risk
management program and are designed to protect our information assets from internal and external cyber threats</ix:nonNumeric></span> and include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify; width: 0.25in"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing
    physical, procedural, and technical safeguards;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and maintaining comprehensive response plans;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">engaging
    with <span id="xdx_90D_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zkxK7PJMcqs3" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000052" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">external cybersecurity experts to enhance our oversight and keep pace with evolving threats</ix:nonNumeric></span>; and</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>considering
    the cybersecurity capabilities of partners and <span id="xdx_90D_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zTEDx5rvv61k" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000053" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">third-party service providers</ix:nonNumeric></span>, both prior to engaging them and on an ongoing basis.</span></span></td></tr>
  </table>
</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_C00_gBFCRMPFAIAMT-OQG_zfJ0BoE5oRG6"><ix:continuation id="ConU000049-03">&#160;</ix:continuation></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_98B_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240101__20241231_gBFCRBODOTB-ITRMTVGL_zzPBmK2Bv7Se" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000057-01" escape="true" id="Fact000057" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Governance and Oversight</b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_C09_gBFCRBODOTB-ITRMTVGL_zJa52yo6NEB5"><ix:continuation continuedAt="ConU000057-02" id="ConU000057-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span>&#160;</span></span></span></ix:continuation></span></p>

<div id="xdx_C0C_gBFCRBODOTB-ITRMTVGL_zCrFLOfXihMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><ix:continuation continuedAt="ConU000057-03" id="ConU000057-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_902_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zL4l5kD4iNy2" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000058" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Our
Board of Directors provides direct oversight of cybersecurity risk and has delegated to its audit committee the responsibility of reviewing
and discussing with management our risk exposures relating to cybersecurity</ix:nonNumeric></span>. <span id="xdx_908_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_ztIFLCO5Ykqk" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000059" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">The Board of Directors and the audit committee will receive
regular updates from management on cybersecurity matters and are promptly informed by management about any significant new threats or
incidents</ix:nonNumeric></span>. In the future, management and our third-party service providers will conduct reviews at least once annually of our cybersecurity
readiness to ensure continuous improvement in our cybersecurity strategies.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>We
have implemented mechanisms to monitor and manage cybersecurity threats and incidents, including utilization of tools for continuous
monitoring of our IT environment to detect and mitigate threats, a fundamental plan for responding to cyber incidents and training for
employees to recognize and report potential cybersecurity incidents and to foster a culture of cybersecurity awareness and vigilance.
Our Chief Administrative Officer, along with a third-party service provider, are responsible for operational oversight of our cybersecurity
strategy and policies. Any identified cybersecurity incident is reported to our Chief Administrative Officer who evaluates the severity
of the incident. Based on this assessment, further steps are taken involving other members of management and, depending on the severity,
the audit committee and the Board of Directors. We believe this structured approach allows us to effectively manage and mitigate cybersecurity
risks, safeguarding our systems and data against various digital threats. Additionally, our proactive stance is supported by cybersecurity
insurance, which further reinforces our preparedness against potential cyber threats.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Incident Reporting and Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>During
the years ended December 31, 2023 and 2024, we have <span id="xdx_907_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zEtOM1mwRRW3" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000060" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">not</ix:nonNumeric></span> identified any risks from cybersecurity threats that have materially affected
or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. However,
we remain vigilant and prepared to respond effectively to any incidents, should they arise.</span></span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C03_gBFCRBODOTB-ITRMTVGL_z9FVR5TOAjS3"><ix:continuation id="ConU000057-03">&#160;</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>Item
2. Properties.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive office is located at 7380 Coca Cola Drive, Suite 106, Hanover, MD 21076. We currently lease approximately 6,500 square
feet of office space at this location until September 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>Item
3. Legal Proceedings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal
proceedings. Regardless of outcome, any litigation that we may become involved in can have an adverse impact on us because of defense
and settlement costs, diversion of management resources and other factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
May 7, 2024, the Company received notification from Elion purporting to terminate the license agreement by and between the Company
and Elion as a result of the Company&#8217;s alleged breach thereof. The Company believes that Elion&#8217;s claims are without
merit and disputes that the license agreement has been validly terminated. On July 5, 2024, the Company filed a complaint in the
Commercial Division of the Supreme Court of the State of New York, New York County seeking monetary damages,
declaratory judgement and injunctive relief. On August 14, 2024, the Company received Elion&#8217;s answer and counterclaims. On
October 10, 2024, the Company filed its response to Elion&#8217;s counterclaims. The Company intends to enforce its rights under the
license agreement and will pursue such other remedies as it determines are appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 3, 2024, Jason Assad and Marc Gyimesi, two of the investors in our February 2021 private offering, filed a lawsuit in the Supreme
Court of the State of New York, New York County alleging fraud and negligent misrepresentation in connection therewith regarding alleged
company communication and statements and are seeking monetary damages. In addition to being an investor, Mr. Assad was a former investor
relations and communications consultant to the Company from September 1, 2021 through June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to vigorously defend ourselves in these lawsuits and cannot at this time predict the likely outcome of any litigation, reasonably
determine either the probability of a material adverse result or any estimated range of potential exposure, or reasonably determine how
these matters or any future matters might impact our business, our financial condition, or our results of operations, although such impact,
including the costs of defense, as well as any judgments or indemnification obligations, among other things, could be materially adverse
to us.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>Item
4. Mine Safety Disclosures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>Part
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and issuer Purchases of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is traded on the Nasdaq Capital Market under the symbol &#8220;PCSA.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2024, we effected a 1-for-20 reverse stock split, reducing the number of our common shares issued on that date from 24,706,474
shares to 1,291,000 shares. There was no corresponding reduction in the number of authorized shares of common stock and no change in
the par value per share. All share and per share amounts and conversion and exercise prices presented herein have been adjusted retroactively
to reflect this change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 12, 2025, there were 5,269,240 shares of common stock outstanding and 184 shareholders of record. One of these holders
of record is Cede &amp; Co, a nominee for Depository Trust Company (&#8220;DTC&#8221;). All of the shares of common stock held by brokerage
firms and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and are therefore
considered to be held of record by Cede &amp; Co. as one stockholder. The actual number of stockholders is greater than the number of
record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
Agent and Registrar</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is Continental Stock Transfer &amp; Trust Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not previously declared or paid any dividends on our common stock and do not intend to do so in the near future. We intend to retain
any future earnings to fund ongoing operations and future capital requirements of our business. Any future determination to pay cash
dividends will be at the discretion of the Board of Directors and will be dependent upon our financial condition, results of operations,
capital requirements and such other factors as the Board of Directors deems relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below provides information as to our 2019 Omnibus Incentive Plan as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of
    securities to be issued upon exercise of outstanding options, warrants and rights</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted-average
    exercise price of outstanding options, warrants and rights</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of
    securities remaining available for issuance under equity compensation plans (excluding securities reflected in column (a))</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(a)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(b)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(c)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Equity compensation plans approved
    by security holders</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">507,185</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;462.07</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;353,641</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Equity compensation plans
    not approved by security holders</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,389</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">397.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">509,574</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,326</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    stock options to purchase 358 shares of our common stock issued under the prior equity compensation plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of shares available for issuance under the 2019 Omnibus Incentive Plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the quarter ended December 31, 2024, we issued a total 7,986 shares of common stock to Berg Capital Markets, LLC in connection with a
consulting agreement. The shares were issued pursuant to exemptions from the registration requirements of the Securities Act of 1933,
as amended, in reliance on Section 4(a)(2) of the Securities Act, Rule 701 promulgated under the Securities Act or Regulation D promulgated
under the Securities Act, relating to transactions by an issuer not involving a public offering. All of the foregoing securities are
deemed restricted securities for purposes of the Securities Act.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Repurchases
of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not repurchase any shares of our common stock in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>Item
6. [Reserved]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>Item
7. Management&#8217;s Discussion and Analysis of the Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should read the following discussion and analysis of our financial condition and results of operations together with our consolidated
financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some
of the information contained in this discussion and analysis contains forward-looking statements that involve risks and uncertainties.
You should review the section titled &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K for a discussion of important factors
that could cause actual results to differ materially from the results described below.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (&#8220;NGC&#8221;) small
molecules, two of which are in, or have completed, Phase 2 trials, and one is in pre-clinical development. Our risk-mitigated strategy is to identify
existing cancer therapies where the mechanism of action is well understood and that are cornerstones of current treatment regimens,
but are highly toxic, with side effects that are often treatment limiting (see Our Strategy above). We devise technologies to change
the way the body metabolizes them, or the way they are distributed within the body, to improve the therapeutic effect and reduce
toxicity. We then efficiently develop our pipeline of Next Generation Cancer therapies utilizing our proprietary Regulatory Science
Approach (see Regulatory Science Approach above), which we believe will further increase the likelihood of regulatory approval.
Since the underlying drugs are already commonly used in cancer therapy, we believe that if our clinical trials are successful and
are showing better efficacy and tolerability than the currently used drugs, the commercial adoption for our NGC therapies will be
rapid and broad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Next
Generation Cancer Therapy Pipeline</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(see
Our Drug Pipeline above for a more detailed discussion of our NGC programs)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PCS6422, also referred to as NGC-Cap, is a combination
    of PCS6422 and a lower dose of capecitabine. Capecitabine is used in many solid tumor treatment regimens, like breast cancer and colon
    cancer. Significant side effects, such as Hand-Foot Syndrome (&#8220;HFS&#8221;) and cardiotoxicity, typically occur in up to 70% of patients
    treated with capecitabine. PCS6422, without having any clinically meaningful anti-cancer effect itself, when used with capecitabine, has
    been found to be up to 50 times more potent than capecitabine alone. NGC-Cap has shown a better safety profile than capecitabine alone.
    Since a much smaller amount of these metabolites are formed with NGC-Cap, the side effects appear in fewer patients and are less severe.</p></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS3117,
    also referred to as NGC-Gem, is a cytidine analog similar to gemcitabine (Gemzar&#174;), but different enough in chemical structure
    that some patients are more likely to respond to NGC-Gem than gemcitabine. In addition, we believe those patients that are inherently
    resistant, or who acquire resistance, to gemcitabine may not be resistant to NGC-Gem. The difference in response occurs because NGC-Gem
    is metabolized to its Active Metabolite through a different enzyme system than gemcitabine.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
                                    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">PCS11T, also referred to as NGC-Iri, is an analog of SN38
(SN38 is the active metabolite of irinotecan). The chemical structure of NGC-Iri is designed to influence the uptake of the drug into
cancer cells, resulting in more NGC-Iri entering cancer cells than normal cells. Irinotecan is widely used in lung, pancreatic, ovarian,
cervical &amp; other solid tumor cancers. Major drawbacks are the side-effect profile, including black box warnings for diarrhea and
myelosuppression. Our preclinical study in mouse xenograft models showed that after NGC-Iri administration, there was greater accumulation
of SN-38 in the tumor compared with other tissues than after irinotecan or Onivyde&#174; administration. Additionally, less SN-38 accumulated
in non-cancer tissues, such as muscle, after NGC-Iri administration than after irinotecan administration, supporting the potential for
a better NGC-Iri safety profile.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focused on drug products that improve the survival and/or quality of life for patients by improving the safety and/or efficacy of
the drug in a targeted patient population, while providing a more efficient and probable path to FDA approval and differentiating our
drugs from those on the market or are currently being developed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Drugs in Our Pipeline</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white">PCS12852 is a highly specific and potent 5HT4 agonist
that is Phase 2B ready as potentially the first meaningful treatment for diabetic gastroparesis patients. Gastroparesis is a chronic digestive
disorder characterized by delayed gastric emptying of solid food without obstruction. Gastroparesis symptoms include: nausea, vomiting,
postprandial fullness, early satiety, abdominal pain, heartburn and poor appetite. Global prevalence of gastroparesis is over 30 million,
with a diabetic population of over 8 million. We have completed a Phase 2A trial for PCS12852 in gastroparesis patients with positive
results. We are exploring options for PCS12852, which may include licensing, partnering and/or collaborating opportunities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white">PCS499 is a drug that can be used to treat unmet medical need conditions caused by multiple pathophysiological changes.
We are presently defining the development plan for the use of PCS499 in a primary glomerular disease. We believe that PCS499 could be
successfully developed in a primary glomerular disease such as focal segmental glomerulosclerosis, or FSGS, and IgA. We intend to design
a development program with the next study being an adaptive designed Phase 3 trial, meet with the FDA, and then find a partner to take
the drug to approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"></p>



<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Public
Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 27, 2025, we raised gross proceeds in a public offering of $5.0 million (net proceeds of $4.5 million) from the sale of
1,030,972 shares of our common stock, pre-funded warrants to purchase up to 7,019,700 shares of our common stock, accompanying
Series A warrants to purchase up to 8,050,672 shares of our common stock and Series B warrants to purchase up
to 4,025,336 shares of common stock, as described in Note 14. Since the offering closed, pre-funded warrants were exercised in
exchange for 525,700 shares of our common stock and, as of March 12, 2025, pre-funded warrants to purchase up to 6,494,000
shares of our common stock remain available to be exercised. We plan to use the net proceeds from this financing for continued
research and development for NCG-Cap, and for working capital and general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ATM
Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the &#8220;Registration Statement&#8221;),
including a base prospectus relating to the offering of up to $50,000,000 in the aggregate of the securities identified in the base prospectus
from time to time in one or more offerings; and a prospectus supplement relating to the shares of our common stock that may be issued
and sold under a sales agreement dated May 21, 2024 (the &#8220;Sales Agreement&#8221;) between us and A.G.P./Alliance Global Partners
(the &#8220;Sales Agent&#8221;), through which we may issue and sell in a registered &#8220;at the market offering&#8221; shares of our
common stock having an aggregate offering price of up to $2.4 million (subject to adjustment) from time to time through or to our Sales
Agent (the &#8220;ATM Offering&#8221;). We expect to use net proceeds, if any, from the ATM Offering over time for continued research
and development for our portfolio of drug candidates, especially our oncology products, and working capital and general corporate purposes.
The shares under the ATM Offering will be sold and issued pursuant to the Registration Statement. During the year ended December 31,
2024, we received $1.5 million in net proceeds from the sale of 800,994 shares of common stock under the ATM Offering, of which 426,804 shares of common stock were sold during the quarter
ended December 31, 2024 for net proceeds of approximately $575,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the year ended December 31, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our operations loss during the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Change</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research and
    development costs</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,269,146</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,799,518</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,469,628&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,782,060</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,657,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(875,483</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(12,051,206</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,457,061</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other Income (Expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    income, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">201,088</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">335,541</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(134,453</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,850,118</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,121,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenues.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had no revenue during the years ended December 31, 2024 and 2023. We do not currently have any revenue under contract or any immediate
sales prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development costs are expensed as incurred. Research and development expenses include (i) program and testing related expenses
including external consulting and professional fees related to the product testing and our development activities and (ii) internal research
and development staff related salaries and other payroll costs including stock-based compensation, payroll taxes and employee benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the years ended December 31, 2024 and 2023 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Preclinical, clinical trial
    and other costs</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,450,963</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,817,669</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Research and development
    salaries and benefits</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,818,183</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,981,849</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,269,146</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,799,518</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, our research and development expenses increased by $1.5 million to $7.3 million when compared to $5.8 million
for the year ended December 31, 2023. This was primarily attributable to an increase of approximately $2.0 million for ongoing testing
and related expenses related to our Phase 1B trial for NGC-Cap and the IND/initiation of our Phase 2 trial for NGC-Cap. Expenses include
costs related to contract research organizations, regulatory filing and maintenance fees, drug product testing and stability, consulting,
and other clinical fees. The increase was offset by a $352,000 decrease in professional fees and in employee stock-based compensation
of $195,000. While we have increased salary rates for some personnel, we had fewer full-time R&amp;D employees in 2024 than 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
funding necessary to bring a drug candidate to market is subject to numerous uncertainties. Once a drug candidate is identified, the
further development of that drug candidate may be halted or abandoned at any time due to a number of factors. These factors include,
but are not limited to, funding constraints, safety or a change in market demand. For each of our drug candidate programs, we periodically
assess the scientific progress and merits of the programs to determine if continued research and development is economically viable.
Some programs may be terminated due to the lack of scientific progress and lack of prospects for ultimate commercialization. We anticipate
our research and development costs to increase in the future, subject to obtaining sufficient financing, as we finalize our clinical
trials; plan/conduct future clinical trials, including the cost of having drug product manufactured; continue our evaluation of the remaining
drugs in our portfolio; and expand our development team.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trial cost accruals are based on estimates of patient enrollment and related costs at clinical investigator sites, as well as
estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct
and manage clinical trials on our behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accruing service fees, we estimate the time period over which services will be performed and the level of patient enrollment and activity
expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will
adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related series
are recorded as prepaid expenses until the services are rendered. At December 31, 2024, we have recorded $1.3 million in prepaid expenses
for advanced payments made to our CRO and other vendors for our NGC-Cap Phase 2 clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses for the year ended December 31, 2024 decreased by approximately $875,000 to $4.8 million when compared
to $5.7 million for the same period in 2023. This was mostly due to a $1.2 million decrease in professional fees and approximately $201,000
decrease in employee stock-based compensation. The decreases were primarily offset by increases in salaries and other payroll-related
costs of approximately $443,000 and net increases in taxes, travel, and other office expenses of approximately $50,000. We share office
space with CorLyst, a related party, and during the years ended December 31, 2024 and 2023, they reimbursed us approximately $110,000
and $112,000, respectively, for rent and other costs we incurred on their behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Income.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
other income consisting primarily of interest income was $207,567 and $335,541 for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Tax Benefit.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not recognize any income tax benefit for the year ended December 31, 2024 or 2023. At December 31, 2024, we recorded deferred tax
assets totaling $19.9 million, including $9.6 million of net operating losses that are fully offset by a valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sources
of Liquidity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">At
December 31, 2024, we had $1.2 million in cash and cash equivalents. On January 27, 2025, we closed a public offering where we sold
1,030,972 shares of our common stock, and/or pre-funded warrants to purchase up to 7,019,700 shares of our common stock,
accompanying Series A warrants to purchase up to 8,050,672 shares of our common stock (the &#8220;Series A Warrants&#8221;) and
Series B warrants to purchase up to 4,025,336 shares of our common stock (the &#8220;Series B Warrants&#8221; and collectively with
the Series A Warrants, the &#8220;Common Warrants&#8221;) for net proceeds of $4.5 million, after deducting placement agent fees and
offering-related expenses (see Note 14 to the Consolidated Financial Statements for additional details). On January 30, 2025,
pre-funded warrants to purchase 525,700 shares of our common stock were exercised. As of March 12, 2025, pre-funded warrants for the
purchase of 6,494,000 remain outstanding.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses and net cash used in our operating activities during the year ended December 31, 2024, which we expect to continue
for the foreseeable future. We have incurred losses since our inception, devoting substantially all of our efforts toward research and
development, and have an accumulated deficit of approximately $87.2 million at December 31, 2024. During the year ended December 31,
2024, we generated a net loss of approximately $11.9 million. Based on our current business plans, we believe these funds will satisfy
our capital needs into mid-2025. Our ability to execute our longer-term operating plans, including unplanned future clinical trials for
our portfolio of drugs depend on our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic
transaction or other funding transactions. We plan to continue to actively pursue financing alternatives, but there can be no assurance
that we will obtain the necessary funding in the future when needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"></p>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
estimate of future cash needs is based on assumptions that may prove to be wrong, and we could utilize our available cash sooner than
we currently expect. Our ultimate success depends on the outcome of our planned clinical trials and our research and development activities,
as disclosed above. We expect to incur additional losses in the future, and we will need to raise additional capital to fully implement
our business plan if the costs of our clinical trials are greater than we expect or they take longer than anticipated. We also expect
to incur increased general and administrative expenses in the future. In addition, there may be costs we incur as we develop these drug
products that we do not currently anticipate, requiring us to need additional capital sooner than currently expected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on many factors, including but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of our current and future clinical trials of NGC-Cap and the cost of third-party manufacturing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, progress, timing, costs and results of drug manufacturing, pre-clinical studies, and clinical trials of NGC-Gem and
    NGC-Iri, as well as any other future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and characteristics of product candidates that we pursue;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    outcome, timing, and costs of seeking regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with hiring additional personnel and consultants for our pre-clinical and clinical activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    emergence of competing therapies and other adverse market developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in preparing, filing, prosecuting, maintaining, expanding, defending, and enforcing patent claims, including litigation
    costs and the outcome of such litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we in-license or acquire other products and technologies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of operating as a public company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time as we can generate substantial product revenues to support our capital requirements, if ever, we expect to finance our cash
needs through a combination of public or private equity offerings, debt financings, collaborations and licensing arrangements or other
capital sources. We currently have an effective shelf registration statement on Form S-3 on file with the SEC, which provides us flexibility
and optionality to raise capital, including pursuant to a future at-the-market offering, but there can be no assurance that capital will
continue to be available to us on acceptable terms, won&#8217;t be limited, or be available at all. To the extent that we raise additional
capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted,
and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our sources and uses of cash and cash equivalents for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash (used in) provided by:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Operating activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,245,042</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,063,346</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Investing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,244</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,776</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Financing
    activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,733,414</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,268,724</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net decrease in cash
    and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,514,872</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,797,398</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
cash used in operating activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
used net cash in our operating activities of $11,245,042 and $8,063,346 during the years ended December 31, 2024 and 2023, respectively.
The increase in cash used in operating activities was primarily attributable to increased costs related to closing our Phase 1B and commencing
our Phase 2 trial for NGC-Cap, including the prepayment of expenses to our CRO for the Phase 2 trial; increased salaries and other payroll-related
expenses; and professional fees during the year ended December 31, 2024. As we continue our Phase 2 trial for NGC-Cap and evaluate the
other NGC drugs in our portfolio, we anticipate our research and development efforts and ongoing general and administrative costs will
continue to generate negative cash flows from operating activities for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, our prepaid expense and other consisted primarily of $1.8 million for advanced payments we made to the CRO and other
vendors related to our Phase 1B and Phase 2 trials of NGC-Cap that have not yet been applied and approximately $85,000 in various insurance
policies, such as directors&#8217; and officers&#8217; insurance and product liability insurance for conducting our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
cash used in investing activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
used net cash in our investing activities of $3,244 and $2,776 during year ended December 31, 2024 and 2023 to purchase property and
equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
cash provided by (used in) financing activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, we sold 476,000 shares of common stock, pre-funded warrants to purchase up to 1,079,555 shares of common
stock in lieu of shares of common stock, all of which were exercised into shares of our common stock, and warrants to purchase up to
1,555,555 shares of our common stock pursuant to a public offering for net proceeds of $6.3 million. We also sold 800,994 shares of common
stock under our ATM Offering for net proceeds of approximately $1.5 million. We used cash, classified as financing activities, of approximately
$16,000 to pay income taxes owed on stock-based compensation, approximately $9,000 for the settlement of a stock award, and approximately
$5,000 for payments owed under a financing lease obligation. During the year ended December 31, 2023, we raised net proceeds of $6.4
million from the sale of 421,611 shares of our common stock and used $31,000 in legal expenses related to our January 2024 raise and
$53,000 for the settlement of a stock award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations and Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our contractual obligations at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="18" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Payments
    Due by Period</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Less than</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">1-3</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3-5</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">More than</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">1
    Year</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Years</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Years</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5
    Years</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">77,432</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">76,861</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">571</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">77,432</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">76,861</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">571</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into contracts in the normal course of business with CROs, clinical supply manufacturers and vendors for pre-clinical studies,
research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice
period, and, therefore, are cancelable contracts and not included in the table above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also entered into license and collaboration agreements with third parties, which are in the normal course of business. We have not
included future payments under these agreements in the table above since obligations under these agreements are contingent upon future
events such as our achievement of specified development, regulatory, and commercial milestones, or royalties on net product sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off
Balance Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the periods presented we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Use of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial
statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires
us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent
assets and liabilities. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and
stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that are
believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different
assumptions or conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the following accounting policies and estimates are most critical to aid in understanding and evaluating our financial results
reported in our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Accruals / Research and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our consolidated financial statements, we are required to estimate expenses resulting from our obligations
under contracts with vendors, CROs and consultants and under clinical site agreements related to conducting our clinical trials. The
financial terms of these contracts vary and may result in payment flows that do not match the period over which materials or services
are provided under such contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites as well as estimates
for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage
clinical trials on our behalf. During a clinical trial, we will adjust the clinical expense recognition if actual results differ from
estimates. We make estimates of accrued expenses as of each balance sheet date based on the facts and circumstances known at that time.
Our clinical trial accruals are partially dependent on the accurate reporting by the CRO and other third-party vendors. Although we do
not expect estimates to differ materially from actual amounts, our understanding of the status and timing of services performed relative
to the actual status and timing of services performed may vary and may result in reporting amounts that may be too high or too low for
any reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until
the services are rendered. We expense research and development costs as they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense is based on the grant-date fair value estimated in accordance with the provisions of ASC 718, <i>Compensation-Stock
Compensation</i>. We expense stock-based compensation over the requisite service period based on the estimated grant-date fair value
of the awards. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period
for each separately vesting portion of the award. No expense is recognized for stock-based awards with performance-vesting conditions
until management believes it is probable the performance-vesting condition will be met. We value restricted stock awards (RSAs) and restricted
stock units (RSUs) based on the closing share price on the date of grant. We estimate the fair value of stock option and warrant grants
using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent
management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. We account for
forfeitures in the period in which they occur, rather than estimate expected forfeitures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 3 &#8211; Stock-Based Compensation for information concerning certain of the specific assumptions we used in applying the Black-Scholes
option pricing model to determine the estimated fair value of warrants granted during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements
of operations based upon the underlying individual&#8217;s or entity&#8217;s role.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. We have recorded a valuation allowance equal to the full recorded amount of our net deferred tax assets since
it was more-likely-than-not that benefits from our deferred tax assets would not be realized. The valuation allowance is reviewed quarterly
and is maintained until sufficient positive evidence exists to support its reversal. As part of an evaluation of our tax attributes in
2022, we recharacterized approximately $7.4 million of startup costs previously capitalized as an IRC Section 195 asset as net operating
losses. The recharacterization has no impact on total deferred tax assets since we had previously and will continue to provide a full
valuation allowance on our unutilized net deferred tax assets. Deferred tax assets and liabilities are measured using enacted tax rates
expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect
of changes in tax rates on deferred tax assets and liabilities is recognized in income in the period such changes are enacted. No income
tax benefit or expense was recorded for any periods presented nor is expected in the foreseeable future since we expect to generate future
taxable net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing
authority, based on the technical merits of the position. Our policy is to record interest and penalties related to income taxes as part
of its income tax provision. At December 31, 2024, we had no unrecognized tax benefits and as such, no liability, interest or penalties
were required to be recorded. We do not expect this to change significantly in the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2 of our consolidated financial statements for new accounting pronouncements or changes to the recent accounting pronouncements
during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_001"></span>Item
7A. Quantitative and Qualitative Disclosures about Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
7A is not applicable to us as a smaller reporting company and has been omitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_002"></span>Item
8. Financial Statements and Supplementary Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#fin2_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB: <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">00<span id="xdx_907_edei--AuditorFirmId_c20240101__20241231_zjpzlw24HeNk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000061" name="dei:AuditorFirmId">677</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Financial Statements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_004">Consolidated
    Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_005">Consolidated
    Statements of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_006">Consolidated
    Statements of Changes in Stockholders&#8217; Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_007">Consolidated
    Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gk_008">Notes
    to the Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 63; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="fin2_001"></span>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and<br/>
Stockholders of Processa Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet of Processa Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December
31, 2024, and the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for the year then ended, and
the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present
fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and
its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prior
Period Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company as of and for the year ended December 31, 2023 were audited by other auditors whose report dated
March 29, 2024 expressed an unqualified opinion on those statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Substantial
Doubt of the Company&#8217;s Ability to Continue as a Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 1 to the financial statements, the Company has incurred net losses since its inception which has resulted in a cumulative deficit
as of December 31, 2024 that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to
these matters are also described in Note 1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe our audit provide
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be
communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and
(2) involved our especially challenging, subjective, or complex judgements. We determined that there were no critical audit matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emphasis
of Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have audited the adjustments to the 2023 financial statements to retrospectively apply the change due to the adoption of Accounting
Standards Update 2023-07, <i>Segment Reporting</i>, described in Note 2. In our opinion, such adjustments are appropriate and have been
properly applied. We were not engaged to audit, review, or apply any procedures to the 2023 financial statements of the Company other
than with respect to the adjustments and, accordingly, we do not express an opinion or any other form of assurance on the 2023 financial
statements taken as a whole.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
<span id="xdx_909_edei--AuditorName_c20240101__20241231_zigUuJatLv0f"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000062" name="dei:AuditorName">Cherry Bekaert LLP</ix:nonNumeric></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have served as the Company&#8217;s auditor since 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--AuditorLocation_c20240101__20241231_z9pgK7w7QDk8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000063" name="dei:AuditorLocation">Tampa,
Florida</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 20, 2025</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="Gk_004"></span>Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Balance Sheets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_111_zIECHBMFYkxf" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20241231_zyZKTqT4PqAk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20231231_zOB2U2BcRMib" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_zz4mUocwYPF8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsCurrentAbstract_i01B_zSyVamp5tJ49" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzWzj_zAm9DjfSFPlh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Cash and
    cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,191,325</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,706,197</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzWzj_z1O0qFTcMdEe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,294</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">926,300</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrent_i02TI_mtACzWzj_maAzM7p_zm682eApbvLh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Current Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,873,619</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,632,497</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p0_maAzM7p_zZwIixEh8gq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Property
    and Equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,016</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,554</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AssetsNoncurrentAbstract_i01B_zKdFtAyG95y6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-current Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseNoncurrent_i02I_maANzCvY_zMhZYXyJt7a3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="AsOf2024-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,274,442</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0087">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AssetsNoncurrent_i02TI_mtANzCvY_maAzM7p_zL9ceaDq0gf2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 22.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Non-current Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,274,442</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0090">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--OtherAssetsAbstract_i01B_zl3k5Kd9OTub" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_pp0p0_maOAzPng_zvx2I9xlBTId" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Operating lease right-of-use
    assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,677</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">146,057</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssets_i02I_pp0p0_maOAzPng_z1DcjI7Uvyhi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2024-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,535</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2023-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,535</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_i02TI_mtOAzPng_maAzM7p_zfUO5qXnpxY6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Other Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,212</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,592</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--Assets_i01TI_pp0p0_mtAzM7p_zp7GFILfqTY3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,229,289</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,786,643</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zKM23KveBWD1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES AND STOCKHOLDERS&#8217;
    EQUITY</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrentAbstract_i01B_z0cKQ3PSsF0k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--OperatingAndFinanceLeaseLiabilityCurrent_i02I_pp0p0_maLCzBSp_zRlgkrRrzN52" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Current maturities of lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,020</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,649</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCzBSp_z6lKWOsBqB2a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">880,880</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">311,617</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--DueToLicensor_i02I_pp0p0_maLCzBSp_zbIit6jaXDA6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Due to licensor</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0119">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:DueToLicensor" contextRef="AsOf2023-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">189,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OtherLiabilitiesCurrent_i02I_pp0p0_maLCzBSp_zA6kYnOQrLth" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Due to related parties</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0122">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCzBSp_zeKv77wP2kCh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">578,731</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">146,274</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i01TI_pp0p0_mtLCzBSp_maLzkcd_zjwHZABE57Jj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Current Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000128" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,532,631</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">730,579</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zcnQbvTHsDl6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-current Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--OperatingAndFinanceLeaseLiabilityNoncurrent_i02I_pp0p0_maLzkcd_zdOtvOG5JEAk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-current lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">487</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">66,905</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--Liabilities_i01TI_pp0p0_mtLzkcd_maLASEzjgB_zwnfzqdieGWk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,533,118</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000138" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">797,484</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0_maLASEzjgB_zbiHdpdYy7t6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Commitments and Contingencies</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0140">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0141">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217; Equity</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--PreferredStockValue_i02I_pp0p0_maSEzsZQ_zGQHpANPxAmh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify">Preferred stock, par value
    $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zfcn42dnXx6f" title="Preferred stock, par value"><span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_zT04I0urnL9k" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zckGVWKLrmCj" title="Preferred stock, shares authorized"><span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zSiYNKVMxga9" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_do_c20241231_zvo41kyoHIIf" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231_zxBMkQLnefvl" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231_zlqjvG3s3HL7" title="Preferred stock, shares outstanding"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zJdk6GBhcE0c" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000157" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000159" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000161" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000163" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued or outstanding at December 31, 2024 or December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0146">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0147">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzsZQ_z7NyuE5jzGm8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Common stock, par value
    $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241231_zi4nugaaIVP8" title="Common stock, par value"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_z8e3eEsSc6l7" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zOoKNiGvJRY7" title="Common stock, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zlSdK5sB0Fyd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20241231_zfbLtSXtfFK8" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,707,628</ix:nonFraction></span> issued and <span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zdzKTVRqy4f2" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,702,628</ix:nonFraction></span> outstanding at December 31, 2024 and <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20231231_zZw7VLgvCuw6" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,291,000</ix:nonFraction></span> issued and
    <span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zR6ULQLVaPpi" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,286,000</ix:nonFraction></span> outstanding at December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000165" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">371</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">129</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_pp0p0_maSEzsZQ_z49sth6sLnI3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Additional paid-in capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-12-31" id="Fact000184" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,214,999</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,658,111</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--TreasuryStockValue_i02NI_pp0p0_di_msSEzsZQ_zUgsCNwRv8yh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Treasury
    stock, <span id="xdx_906_eus-gaap--TreasuryStockCommonShares_iI_c20241231_zvm97RrnGqT2" title="Treasury stock shares"><span id="xdx_90F_eus-gaap--TreasuryStockCommonShares_iI_c20231231_zhEB4oxziwMl" title="Treasury stock shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2024-12-31" id="Fact000190" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2023-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></ix:nonFraction></span></span> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2024-12-31" id="Fact000187" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2023-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzsZQ_zmPbKMozgvE8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">87,219,199</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">75,369,081</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzsZQ_maLASEzjgB_z4hvIqNftWF6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Stockholders&#8217; Equity</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,696,171</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,989,159</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_pp0p0_mtLASEzjgB_zlCo4cGqU8qi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Liabilities and Stockholders&#8217; Equity</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,229,289</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,786,643</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="Gk_005"></span>Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_113_zeUeoNYWIp1k" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240101__20241231_zksxiwmMwF4b" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230101__20231231_zmROm7HBeazc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Years
    Ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingExpensesAbstract_iB_z784IvvSc5qd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_i01_msCz2YV_zCquhcV9kICb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research and
    development expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-01-01to2024-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,269,146</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2023-01-012023-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,799,518</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_i01_msCz2YV_zytUkhZ5fOl2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,782,060</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,657,543</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_iT_mtCz2YV_maCz4Lw_z0cf2wEYSTSk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,051,206</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,457,061</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OtherIncomeAndExpensesAbstract_iB_zixKxlleISDa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other Income (Expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--InvestmentIncomeInterest_i01_maCz4Lw_zanhAYtf2uW2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    income, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2024-01-01to2024-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,088</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2023-01-012023-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335,541</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCz4Lw_maCzyio_zTsEycDZkdk6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Operating Loss Before Income Tax Benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-01to2024-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,850,118</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,121,520</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msCzyio_zcR9L8hW0dm9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Income Tax Benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0225">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iT_mtCzyio_zi4e69YEBjVe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,850,118</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,121,520</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net Loss Per Common
    Share - Basic and Diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20240101__20241231_z54UcnI5FN3l" title="Net Loss Per Common Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zkqHYGwERwf7" title="Net Loss Per Common Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.87</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zHRzANHq2U2d" title="Net Loss Per Common Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zNkGPwWnzNhi" title="Net Loss Per Common Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">8.48</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Common Shares Used to Compute</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    Loss Per Common Shares - Basic and Diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zDjNdkdRqDR7" title="Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_z0Fqn8T2jrdk" title="Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000238" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,059,906</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_z8cotl4MFJXk" title="Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z5nzRgSnRqHk" title="Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000244" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,311,572</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="Gk_006"></span>Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Changes in Stockholders&#8217; Equity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
Ended December 31, 2023 and 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_114_zCNyRdofhckf" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zav9UdWqTym1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_ziM0HkfaBGE9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockCommonMember_zHaZwnWn2dbl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z77OXcj9DI92" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B5_zblcbfCorI0d" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Paid-In</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Treasury
    Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_430_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zx5X2UQu7qAb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 37%"><span style="font-family: Times New Roman, Times, Serif">Balance, January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEVEvc3Zf5H1" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000252" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">806,774</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000247" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,018,222</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zRe5lrMFBVhl" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000254" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000248" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000249" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">64,247,561</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000250" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,470,741</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zymxul7tXYh3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1YbV7vxS2F4" title="Stock-based compensation, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000262" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,945</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,060,338</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0258">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0259">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,060,339</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zEYO8tNofpHi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issued in connection with capital raises,
    net of transaction costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDuVNGUUFhF" title="Shares issued in connection with capital raise, net of transaction costs, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000270" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">421,611</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,352,035</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact000268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,352,077</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zifyw9fWrWTa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant granted in connection with a consulting
    agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,310,875</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0274">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0275">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31" id="Fact000276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,310,875</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_zRTq3TMTtyjc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Settlement of stock award</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000279" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,746</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0280">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0281">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2023-01-012023-12-31" id="Fact000282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,746</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_zeb39cQ41Ms1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTyYaABs5KY8" title="Other, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000290" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,670</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000285" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,613</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0287">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31" id="Fact000288" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,607</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zJ5JurAHsaDd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0292">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000295" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,121,520</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000296" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,121,520</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_432_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zNUTHsV7NmQ8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpjGYHHu79wd" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000304" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,291,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,658,111</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zYWLM66u4vK7" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000306" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000300" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000301" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,369,081</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,989,159</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_433_c20240101__20241231_eus-gaap--StockholdersEquity_iS_z8RGJCWPi0K" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb0X3Do9sno9" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000314" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,291,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000309" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,658,111</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000310" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000311" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,369,081</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,989,159</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zz1wslIBPQMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zySnHeJzQDV8" title="Stock-based compensation, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000322" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,502</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">629,508</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">629,514</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zfMS8z8lRoVd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issued in connection with capital raises,
    net of transaction costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNm7U7toFQ99" title="Shares issued in connection with capital raises, net of transaction costs, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000330" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,356,549</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000324" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,762,843</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0326">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-12-31" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,763,079</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zHRfgSyVmn8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issued in connection with license agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFviOHstTXLg" title="Shares issued in connection with license agreement, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000338" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000333" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,999</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0335">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-01to2024-12-31" id="Fact000336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_z3oIQLjgNDq8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Settlement of stock award</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0340">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000341" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,561</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0342">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-01to2024-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,561</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_iN_di_zvTbNUIGSqYb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares withheld to pay income taxes on stock-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxOdwtURPye2" title="Shares withheld to pay income taxes on stock-based compensation, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000352" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,423</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,901</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000350" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,902</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zbsGYUrxHpg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000357" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,850,118</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000358" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,850,118</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_43E_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zCrTCFJtlShd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9VE1AKLyOHl" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000366" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,707,628</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">371</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,214,999</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zWkj2S18h191" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000368" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000362" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000363" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">87,219,199</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,696,171</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_433_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zyxCAibhAsQf" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVJoUNC6UeQ4" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000376" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,707,628</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">371</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,214,999</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000372" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000373" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">87,219,199</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,696,171</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="Gk_007"></span>Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Cash Flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_zE1rIJmumKw5" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20240101__20241231_zSKWahTsdVgc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zCoQT0p8B3be" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Years
    Ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zZnRXtFrpQs8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash Flows From Operating
    Activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_i01_maNCPBUz4D6_zaNNoRRClosh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000381" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,850,118</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000382" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,121,520</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zefKlHJ0FOo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile net loss to net
    cash used in operating activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--Depreciation_i02_pp0p0_maNCPBUz4D6_zKWZRkb6puaj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000387" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">782</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000388" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">222</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--OperatingAndFinanceLeaseExpense_i02_pp0p0_maNCPBUz4D6_zMakhnFWCMK5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-cash lease expense
    for right-of-use assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000390" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,184</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseExpense" contextRef="From2023-01-012023-12-31" id="Fact000391" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,530</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_i02_maNCPBUz4D6_zpebPuhq2ZLh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">629,514</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,060,339</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maNCPBUz4D6_zbnj0LRTxQN" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Warrants
issued for consulting services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0396">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2023-01-012023-12-31" id="Fact000397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,310,875</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zvSsUWljoCC5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net changes in operating
    assets and liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUz4D6_z4m6jhM0HjL8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses and
    other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000402" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,030,436</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000403" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">956,834</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUz4D6_zcSNl8LPvBL9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Operating lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000405" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">83,649</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000406" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">78,896</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUz4D6_zSyOkO7TDd38" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000408" format="ixt:numdotdecimal" decimals="0" unitRef="USD">569,263</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact000409" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,931</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_408_ecustom--IncreaseDecreaseInDueFromToRelatedParties_i03N_di_msNCPBUz4D6_zKqXofPyLESd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Due from related
    parties</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:IncreaseDecreaseInDueFromToRelatedParties" contextRef="From2024-01-01to2024-12-31" id="Fact000411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:IncreaseDecreaseInDueFromToRelatedParties" contextRef="From2023-01-012023-12-31" id="Fact000412" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maNCPBUz4D6_zLC378JtkjM1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,457</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000415" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">256,787</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUz4D6_maCCERCzvwO_z1NG7RKZbtYb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000417" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,245,042</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000418" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,063,346</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zG6HFnMBCTt7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash Flows From Investing
    Activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzVgI_zemt40WELHhj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Purchase
    of property and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,244</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,776</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzVgI_maCCERCzvwO_z52Z0ZBLbZ9b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in investing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000426" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,244</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000427" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,776</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zn9scj8RWDO5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash Flows From Financing
    Activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pp0p0_maNCPBUzBRF_zXFKh1eZ9zOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net proceeds from issuance
    of stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-12-31" id="Fact000432" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,763,079</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000433" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,321,470</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_i01N_pp0p0_di_msNCPBUzBRF_zNbXR2ujfauh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Shares withheld to pay
    taxes on stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000435" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,902</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0436">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--PaymentsForSettlementOfStockAwards_i01N_pp0p0_di_msNCPBUzBRF_zRuWzvtBZxHa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Settlement of stock
    award</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:PaymentsForSettlementOfStockAwards" contextRef="From2024-01-01to2024-12-31" id="Fact000438" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,561</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:PaymentsForSettlementOfStockAwards" contextRef="From2023-01-012023-12-31" id="Fact000439" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,746</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeasePrincipalPayments_i01N_pp0p0_di_msNCPBUzBRF_z170r2O8zkhg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Payment
    of finance lease obligation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2024-01-01to2024-12-31" id="Fact000441" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,202</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_pp0p0_mtNCPBUzBRF_maCCERCzvwO_zinzxE75xmzg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000444" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,733,414</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000445" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,268,724</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCzvwO_zHOw3OLmjO3c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net Decrease in Cash and Cash Equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,514,872</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000448" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,797,398</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0_zOpCVJKPq4w3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and Cash Equivalents - Beginning of Year</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000450" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,706,197</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000451" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,503,595</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0_zGZAMdhJOyXb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and Cash Equivalents - End of Year</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000453" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,191,325</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000454" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,706,197</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Cash Flows (continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Years
    Ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Supplemental Cash Flow
    Information:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--InterestPaidNet_i01N_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Cash paid
    for interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000459" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,204</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0460">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxesPaidNet_i01N_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Cash paid for income
    taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-Cash Financing Activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_i01_pp0p0_zyU6MHbTTelg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zod5YjHuTUXg" title="Shares issued in connection with license agreement" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ2FzaCBGbG93cyAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000471" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span> shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" contextRef="From2024-01-01to2024-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">189,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0469">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_i01_pp0p0_zDlNlh0QXCij" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Right-of-use asset obtained
    in exchange for financing lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000473" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,804</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0474">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--FinancingLeaseLiability_i01_pp0p0_z4FYihWiFXm2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Financing
    lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:FinancingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000476" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">11,804</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0477">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--NonCashLeaseLiabilityNet_i01_pp0p0_zbMs2lGiyG5k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0479">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0480">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="Gk_008"></span>Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000482" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zHII7B87Rjee" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
1 &#8211; <span id="xdx_82C_ztVTq4A1fvoj">Organization</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Organization</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next
Generation <span style="background-color: white">Cancer therapy </span> <span style="background-color: white">(&#8220;NGC&#8221;) </span> drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing
FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known and established
existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our NGC treatments will
provide improved safety-efficacy profiles when compared to their currently marketed counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended with the Secretary of State of
Delaware that effected a <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20240122__20240122_zB3orY3QwZR4" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-01-222024-01-22" id="Fact000484" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-20 reverse stock split</ix:nonNumeric></span> of our common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240122_zPTQ3p56BSo2" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-01-22" id="Fact000486" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share (the &#8220;Reverse Stock Split&#8221;).
Pursuant to the Certificate of Amendment, our issued common stock decreased from <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20240121_zFd6vKWntT6i" title="Common stock shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-01-21" id="Fact000488" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,706,474</ix:nonFraction></span> shares to <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20240122_ztMcbhUbOiNi" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-01-22" id="Fact000490" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,291,000</ix:nonFraction></span> shares and our outstanding
common stock decreased from <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240121_zMReQH9Q8hel" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-01-21" id="Fact000492" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,606,474</ix:nonFraction></span> to <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20240122_zO1T4DtizU4d" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-01-22" id="Fact000494" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,286,000</ix:nonFraction></span>. The Reverse Stock Split did not affect our authorized common stock of <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20240122_znzi3Hs2tYJ5" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-01-22" id="Fact000496" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span>
shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, and restricted
stock units, as well as exercise prices and per share information in these consolidated financial statements give retroactive effect
to the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization
of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception,
currently devoting substantially all of our efforts toward research and development of our NGC drug product
candidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated
deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zCBBEnE2a7bi" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">87.2</ix:nonFraction></span> million at December 31, 2024. During the year ended December 31, 2024, we generated a net loss of $<span id="xdx_903_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zpqInEsbLdr7" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000500" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">11.9</ix:nonFraction></span> million and
used $<span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zN2rqougPdF9" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000502" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">11.2</ix:nonFraction></span> million in net cash for operating activities from continuing operations. To date, none of our drug candidates have been approved
for sale, and therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have financed our operations primarily through public equity issuances, including an offering we sold on January 27, 2025 where we sold
<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250127__20250127__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIdsXD0naTpf" title="Number of shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-272025-01-27_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000504" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,030,972</ix:nonFraction></span> shares of our common stock, pre-funded warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zogXEA8VMUKl" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-27_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000506" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,019,700</ix:nonFraction></span> shares of our common stock, and accompanying Series
A warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0ydKH27MuKa" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-27_custom_SeriesAWarrantsMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000508" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,050,672</ix:nonFraction></span> shares of our common stock (the &#8220;Series A Warrants&#8221;) and Series B warrants to purchase
up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zS6kZ31q4Me7" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-27_custom_SeriesBWarrantsMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000510" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,025,336</ix:nonFraction></span> shares of our common stock (the &#8220;Series B Warrants&#8221; and collectively with the Series A Warrants, the &#8220;Common
Warrants&#8221;) for net proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zr0lZ2YRTCba" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-272025-01-27_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000512" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million, after deducting placement agent fees and offering-related expenses (see Note 14 for
additional details). On January 30, 2025, pre-funded warrants to purchase <span id="xdx_900_ecustom--ClassOfWarrantOrRightExercised_iI_c20250130__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0HyrCDWJfJa" title="Warrants exercised"><ix:nonFraction name="PCSA:ClassOfWarrantOrRightExercised" contextRef="AsOf2025-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000514" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">525,700</ix:nonFraction></span> shares of our common stock were exercised and, as of
March 12, 2025, pre-funded warrants for the purchase of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250312__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrFY2Q82gPZd" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-03-12_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000516" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,494,000</ix:nonFraction></span> remain outstanding. We will continue to be dependent upon equity
and/or debt financing until we are able to generate positive cash flows from its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, we had cash and cash equivalents totaling $<span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_z6OOfwSGf4z2" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000518" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million. Together with the $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zepT5e4MYsB8" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-272025-01-27_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000520" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million net proceeds we raised in January
2025, and based on our current business plans, we believe these funds will satisfy our capital needs into mid-2025. Our ability to execute
our longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend on our ability
to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<ix:exclude><!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absent
additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year
or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our
projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial
doubt exists about our ability to continue as a going concern within one year after the date that these consolidated financial statements
are available to be issued. The accompanying consolidated financial statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might
be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000522" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zqtUGwYB1k1g" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
2 &#8211; <span id="xdx_829_zxnPYDg6pXh6">Basis of Presentation and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000524" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJwbA0ZS79Z8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zfmt3sv6MuK6">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange
Commission (the &#8220;SEC&#8221;), and reflect all of our activities, including those of our wholly-owned subsidiary. All material intercompany
accounts and transactions have been eliminated in consolidation. Operating results for the year ended December 31, 2024 are not necessarily
indicative of future results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000526" name="us-gaap:UseOfEstimates"><p id="xdx_84C_eus-gaap--UseOfEstimates_zvfbiAHSVea5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_z6qoGM74IBTa">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and regulations
of the SEC, we make estimates and judgments that affect the amounts reported in the consolidated financial statements and accompanying
notes. Estimates are used for, but not limited to stock-based compensation, intangible assets, future milestone payments and income taxes.
These estimates and assumptions are continuously evaluated and are based on management&#8217;s experience and knowledge of the relevant
facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates
and could impact future results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000528" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zKoo1C6jtf03" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z3lz7d9cpfM4">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash on hand and money market funds. We consider all highly liquid investments maturing within three months
from the date of purchase as cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000530" name="PCSA:PrepaidExpensesPolicyTextBlock"><p id="xdx_849_ecustom--PrepaidExpensesPolicyTextBlock_z3qevoN2fMUi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zVQDTR4r1B4k">Prepaid
Expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments made to third parties under
these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.
The majority of our prepaid expenses relate to advanced payments made to CROs and other vendors for our ongoing clinical trials. We allocate
the prepaid expenses between current and non-current assets based on the anticipated timing of utilizing the advances. At December 31,
2024, we determined that $<span id="xdx_90E_eus-gaap--PrepaidExpenseNoncurrent_iIP1custom--AccountingPoliciesLineItemsAbstract_pn5n6_c20241231_zE498icFARu7" title="Prepaid expense"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="AsOf2024-12-31" id="Fact000532" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million would not be applied until after December 31, 2025.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000534" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zS4wfLdYwof4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zvh4Vi9h7wea">Property
and Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
is stated at cost, less accumulated depreciation. Costs of renewals and improvements that extend the useful lives of the assets are capitalized.
Expenditures for maintenance and routine repairs are charged to expense as incurred. Depreciation is recognized on a straight-line basis
over the estimated useful lives of the assets, which generally range from <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iIP1us-gaap--PropertyPlantAndEquipmentLineItems_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_zoCtbnHRkXe8" title="Estimated useful lives of property plant and equipment"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000536" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iIP1us-gaap--PropertyPlantAndEquipmentLineItems_dtY_c20241231__srt--RangeAxis__srt--MaximumMember_zLZpDmG39177" title="Estimated useful lives of property and equipment"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000538" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years. We amortize leasehold improvements over the shorter
of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related
accumulated depreciation are removed from the accounts with the resulting net gain or loss, if any, reflected in the consolidated statement
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000540" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z1prFuGxIT3c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zkoqXS1iLQ5g">Impairment
of Long-Lived Assets and Intangibles Other Than Goodwill</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for the impairment of long-lived assets in accordance with ASC 360<i>, Property, Plant and Equipment</i> and ASC 350, <i>Intangibles
&#8211; Goodwill and Other,</i> which require that long-lived assets and certain identifiable intangibles be reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to its expected future undiscounted net cash flows
generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which
the carrying amounts of the assets exceed the fair value of the assets based on the present value of the expected future cash flows associated
with the use of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000542" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbm5AT6BEZh4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zL2TdenAtji6">Fair
Value Measurements and Disclosure</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
apply ASC 820, <i>Fair Value Measurements and Disclosures</i>, which expands disclosures for assets and liabilities that are measured
and reported at fair value on a recurring basis. Fair value is defined as an exit price, representing the amount that would be received
upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or
liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; Quoted market prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access
at the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; Quoted market prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or
liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Fair value determined
using models or other valuation methodologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; Significant unobservable inputs for assets or liabilities that cannot be corroborated by market data. Fair value is determined
by the reporting entity&#8217;s own assumptions utilizing the best information available and includes situations where there is little
market activity for the asset or liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
asset&#8217;s or liability&#8217;s fair value measurement within the fair value hierarchy is based upon the lowest level of any input
that is significant to the fair value measurement. Our policy is to recognize transfers between levels of the fair value hierarchy in
the period the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 1, 2, or 3 during
the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000544" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSwxTtKBlKua" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zDdSubbyF0yf">Stock-based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
measure compensation expense for stock options and other stock awards in accordance with ASC 718, <i>Compensation&#8212;Stock Compensation</i>.
Stock-based compensation is measured at fair value on grant date and recognized as compensation expense over the requisite service period.
Generally, we issue stock options and other stock awards with service-based and/or performance-based vesting conditions. For awards with
only service-based vesting conditions, we record compensation cost for these awards using the straight-line method over the service period.
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For awards that contain performance vesting conditions,
we do not recognize compensation expense until achieving the performance condition is probable. We estimate the fair value of stock option
and warrant grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based
awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.
We value restricted stock awards (RSAs) and restricted stock units (RSUs) based on the closing share price of our common stock on the
date of grant. Stock-based compensation costs are recorded as general and administrative or research and development costs in the statements
of operations based upon the underlying individual&#8217;s or entity&#8217;s role.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
of fair value are not intended to predict actual future events or the value ultimately realized by employees or consultants who receive
these awards, and subsequent events are not indicative of the reasonableness of our original estimates of fair value. We account for
forfeitures in the period in which they occur, rather than estimate expected forfeitures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000546" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z4qzW1m203ec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zsAvmqMEF221">Net
Loss Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average common stock outstanding (which excludes unvested RSAs) and
vested, but unissued RSUs. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted
weighted average number of shares of common stock outstanding during the period. Since we have experienced a net loss for all periods
presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the years ended December 31, 2024 and
2023 excludes the impact of potentially dilutive common shares related to outstanding stock options, unvested restricted stock awards
(RSAs), unvested RSUs and common stock purchase warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<ix:exclude><!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
diluted net loss per share for the years ended December 31, 2024 and 2023 excluded <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_iP1custom--AccountingPoliciesLineItemsAbstract_pid_c20240101__20241231_zjF4WhW5Lk6k" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000548" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,013,154</ix:nonFraction></span> and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_iP1custom--AccountingPoliciesLineItemsAbstract_pid_c20230101__20231231_zlt27ixgXgc1" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact000550" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">296,326</ix:nonFraction></span> of potentially dilutive common
shares, respectively, related to outstanding stock options, unvested RSAs, unvested RSUs and warrants since those shares would have had
an anti-dilutive effect on loss per share during the years then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000552" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_znxOJ7ZTbKK4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_z342kDdpre2c">Segments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">We have one reportable segment, which is focused on discovering and developing a pipeline of Next Generation Cancer
therapy drugs. Our Chief Executive Officer, who is the chief operating decision maker (CODM), assesses segment performance and decides
how to allocate resources based on net loss that is also reported on the Consolidated Statements of Operations and Comprehensive Loss.
See Note 11 for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000554" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zNouNC8tTmg4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zjEuC6PXltOe">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, accounts receivable and accounts payable approximate their fair value because of the short-term
maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000556" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zW9LuNaeVIn9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zjxmExykSpx6">Research
and Development</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred and consist of direct and overhead-related expenses related primarily to clinical trials,
including development personnel salaries and related costs. Expenditures to acquire technologies, including licenses, which are utilized
in research and development and that have no alternative future use are expensed as the acquisition of in-process research and development
when incurred. Technology we develop for use in our products is expensed as incurred until technological feasibility has been established
after which it is capitalized and depreciated. No research and development costs were capitalized during the years ended December 31,
2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000558" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zHxivy8XX6Ub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zqu3ysScCQ1a">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. As of December 31, 2024 and 2023, we recorded a valuation allowance equal to the full recorded amount of our
net deferred tax assets since it is more-likely-than-not that benefits from our deferred tax assets will not be realized. The valuation
allowance is reviewed quarterly and is maintained until sufficient positive evidence exists to support its reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing
authority, based on the technical merits of the position. Our policy is to record interest and penalties related to income taxes as part
of its income tax provision. As of December 31, 2024, we had <span id="xdx_903_eus-gaap--UnrecognizedTaxBenefits_iIP1custom--AccountingPoliciesLineItemsAbstract_do_c20241231_zkuwbJhRSg02" title="Unrecognized tax benefits"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2024-12-31" id="Fact000560" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> unrecognized tax benefits and as such, no liability, interest or penalties
were required to be recorded. We do not expect this to change significantly in the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000562" name="PCSA:RecentAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_849_ecustom--RecentAccountingPronouncementsPolicyPolicyTextBlock_zHPKtuk6v6Vb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i><span id="xdx_861_zB4GDa2ri0Oe">Recently Adopted Accounting Standard</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">In November 2023, the FASB issued ASU 2023-07 &#8211; Segment Reporting (Topic 280) &#8211; Improvements to Reportable
Segment Disclosures, which improves segment disclosure requirements, primarily through enhanced disclosure requirements for significant
segment expenses. The improved disclosure requirements apply to all public entities that are required to report segment information, including
those with only one reportable segment. We adopted this standard effective for the year ending December 31, 2024 and the primary impact
of which was the additional segment disclosures included in Note 11.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000564" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z51Qe2P6ysXl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_ztahQYnCPzBa">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our financial statements. We have <span style="background-color: white">considered
all recent accounting pronouncements issued since the last audit of our consolidated financial statements. We believe that these recent
pronouncements will not have a material effect on our consolidated financial statements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide
enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and
for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption
is permitted. We are evaluating this standard to determine if adoption will have a material impact on our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense
Disaggregation Disclosures (Subtopic 220-40), which requires disclosure, in the notes to the financial statements, of specified information
about certain costs and expenses. This ASU is effective for public entities for annual reporting periods beginning after December 15,
2026 and interim reporting periods beginning after December 15, 2027. We are currently evaluating the impact ASU 2024-03 will have on
our consolidated financial statements.</p>

</ix:nonNumeric><p id="xdx_858_zzQRomPClUQ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<ix:exclude><!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000566" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zpLYO7qj0VH" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
3 - <span id="xdx_82A_ztEoIkXfszYb">Stock-based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">T<span style="background-color: white">he
Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) allows us to make grants of stock options,
restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors.
The 2019 Plan originally provided for the aggregate issuance of <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220710__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember__us-gaap--AwardTypeAxis__custom--OriginalMember_zwuerPj2XEW5" title="Maximum equity available for issuance under the plan"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-07-10_custom_TwoThousandAndNineteenPlanMember_custom_OriginalMember" id="Fact000568" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span> shares of our common stock. </span>On June 28, 2024, our shareholders
approved an increase of shares available under the 2019 Plan, which now provides for the aggregate issuance of <span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240628__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zNbHqIt1mtCe" title="Maximum equity available for issuance under the plan"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-06-28_custom_TwoThousandAndNineteenPlanMember" id="Fact000570" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,000</ix:nonFraction></span> shares of our
common stock. At December 31, 2024, we have <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zkkZDKpzyOg3" title="Shares available for future grants"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-12-31_custom_TwoThousandAndNineteenPlanMember" id="Fact000572" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">353,641</ix:nonFraction></span> shares available for future grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Compensation Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000574" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zlEUr9SVxlF" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the years ended December 31, 2024 and 2023 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B0_zOokHVYXHBB1" style="display: none">Schedule of Stock-based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20240101__20241231_zVJKGeD5iRTc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zScrTcXsxnQj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended <br/> December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXsVE2UNk0g1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,414</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,956</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z42I0Er24F7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000579" format="ixt:numdotdecimal" decimals="0" unitRef="USD">460,100</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000580" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,007,258</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_zZPgq9e56vU3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000582" format="ixt:numdotdecimal" decimals="0" unitRef="USD">629,514</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact000583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,371,214</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zGvd0ZePmG9a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">No
tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for all net deferred
tax assets relating to this expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" escape="true" id="Fact000585" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrAcclmb4UH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes our stock option activity during the years ended December 31, 2023 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_ziFTZbmuS8H9" style="display: none">Schedule
of Stock Option Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total
    options Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual life<br/>
    (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zrGZbbB4faIi" title="Options outstanding, beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" id="Fact000587" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,943</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zHUwAVbHUVUf" title="Weighted average exercise price, beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" id="Fact000589" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">341.34</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_z9DN332ZIQxb" title="Options, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited
    or expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231_zAtzSQrUPqk6" title="Options, forfeited" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2023-01-012023-12-31" id="Fact000593" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,951</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zrbtHTTNqPji" title="Weighted average exercise price, forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31" id="Fact000595" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">257.28</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTzQJ6MkYlG7" title="Options outstanding, beginning balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact000597" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,992</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zhFKS0JEgZLf" title="Weighted average exercise price, beginning balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact000599" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">364.72</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zbh8yDbnm0oi" title="Weighted average remaining contractual term, ending"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact000601" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.1</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_zPTWYcH5toE3" title="Options, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0603">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited
    or expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231_zrTTPNrvRx55" title="Options, forfeited or expired" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact000605" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,245</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zAqysptNg5W2" title="Weighted average exercise price,  forfeited or expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="Fact000607" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">336.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding and exercisable as of December
    31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zdrJ9top9x8i" title="Options outstanding, ending balance"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zTTIIMLMS9I6" title="Options exercisable, ending balance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact000609" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact000611" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,747</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z2FPO341OJ92" title="Weighted average exercise price, ending balance"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zF0kKGejBLoh" title="Weighted average exercise price, exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact000613" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact000615" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">409.09</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zLQxr5HEKPZb" title="Weighted average remaining contractual term, outstanding"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zCMdEWqF3l1d" title="Weighted average remaining contractual term, exercisable"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact000617" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact000619" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.7</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_z7T4Ai5nuFcl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
forfeiture rate was applied to these stock options. The aggregate intrinsic value of outstanding options, all of which are exercisable,
was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDFKWPh4OO0k" title="Aggregate intrinsic value of outstanding options"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRzwHyeFJT63" title="Aggregate intrinsic value of outstanding options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000621" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000623" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> at both December 31, 2023 and 2024. <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z028FAoYJ3b8" title="Stock option exercised"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhsWAfBbA6ub" title="Stock option exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000625" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000627" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></ix:nonFraction></span></span> stock options were exercised during the years ended December 31, 2023 or 2024 and there
is no unamortized expense at December 31, 2024 since the options are fully vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Awards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember" escape="true" id="Fact000629" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zTUUuDHmtpX6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes our restricted stock award (RSA) activity during the years ended December 31, 2023 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_z1gVx5R7HU79" style="display: none">Schedule
of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted-
    <br/> average <br/> grant-date fair <br/> value per share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Unvested as of January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zHpjhP2ZJb" title="Number of restricted stock, shares outstanding" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_custom_RestrictedStockAwardMember" id="Fact000631" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,095</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zvDtXH6wKy01" title="Weighted-average grant-date fair value per share, Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_custom_RestrictedStockAwardMember" id="Fact000633" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">94.44</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zBUNAWaUSTS2" title="Number of shares, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember" id="Fact000635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,750</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zDiKjrXzSbK6" title="Weighted-average grant-date fair value per share, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember" id="Fact000637" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.59</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zG6Gh8y9hnE4" title="Number of shares, forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember" id="Fact000639" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zcvkQywoHq93" title="Weighted-average grant-date fair value per share, forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember" id="Fact000641" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">133.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zYiyJ9hVSuic" title="Number of shares, cancelled" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember" id="Fact000643" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,555</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zn1xW8o7KVYi" title="Weighted-average grant-date fair value per share, cancelled" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember" id="Fact000645" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.13</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vested and issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zj6DtCTV8uv6" title="Number of shares, vested and issued" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember" id="Fact000647" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,790</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zfzhoPcljnXc" title="Weighted-average grant-date fair value per share, vested and issued" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember" id="Fact000649" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.44</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Unvested as of December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zjcDEBXwowyi" title="Number of shares outstanding, Beginning balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_custom_RestrictedStockAwardMember" id="Fact000651" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zilrWwqCxmWd" title="Weighted-average grant-date fair value per share, Beginning balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_custom_RestrictedStockAwardMember" id="Fact000653" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.26</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zideJL0eB3J5" title="Number of shares, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zgIOp8FB0jg8" title="Weighted-average grant-date fair value per share, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0657">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z5n5dSliOvqj" title="Number of shares, forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zR5gOnMVpmud" title="Weighted-average grant-date fair value per share, forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0661">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zWpr9dJBfmAi" title="Number of shares, cancelled" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0663">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z2C3Qvxl48o" title="Weighted-average grant-date fair value per share, cancelled" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0665">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vested and issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z6eoJ079nVs4" title="Number of shares, vested and issued" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember" id="Fact000667" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zPK10SK2ydB3" title="Weighted-average grant-date fair value per share, vested and issued" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.26</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested as of December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z9tt9Iq8ImZd" title="Number of shares outstanding, ending balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zUXL4psXllCc" title="Weighted-average grant-date fair value per share, outstanding" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0673">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zOqgk4IXrrPe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" escape="true" id="Fact000675" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zy3iLyAGdEYe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes our restricted stock unit (RSU) activity during the years ended December 31, 2023 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zaOCKzHQqr42" style="display: none">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted-
    <br/> average <br/> grant-date fair <br/> value per share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUh97PPNY936" title="Number of shares, Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000677" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,741</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4hMt2jDQga" title="Weighted-average grant-date fair value per share, Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000679" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">73.81</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8lbwStdwJo8" title="Number of shares, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000681" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">116,078</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOodBTN4AX85" title="Weighted-average grant-date fair value per share, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000683" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.18</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOHHyEcHKati" title="Number of shares, forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,296</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaCdhNLohGXa" title="Weighted-average grant-date fair value per share, forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000687" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">21.69</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFzyblqRBRmi" title="Number of shares, cancelled" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000689" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,801</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyeq0B0XBxQj" title="Weighted-average grant-date fair value per share, cancelled" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000691" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">71.36</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTxaoyJSVlec" title="Number of shares, issued" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000693" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,093</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbUE9VovGPXc" title="Weighted-average grant-date fair value per share, issued" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000695" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">110.59</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLGvR1SLePC5" title="Number of shares, Beginning balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000697" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">222,722</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0KgHqINrAj7" title="Weighted-average grant-date fair value per share, Beginning balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000699" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">45.82</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1x1hbnWfSC6" title="Number of shares, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000701" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">192,026</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwSYF57PFWD1" title="Weighted-average grant-date fair value per share, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000703" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.63</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdl41hLqzvnf" title="Number of shares, forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000705" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,019</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZoGrtkvNO1k" title="Weighted-average grant-date fair value per share, forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000707" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">71.68</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTA62TKWj5ah" title="Number of shares, issued" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000709" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,093</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zf2oPqvFDvKc" title="Weighted-average grant-date fair value per share, issued" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000711" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">110.59</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbNZUhfAXpS6" title="Number of shares, ending balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000713" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">383,636</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBIYi8aRsFZ8" title="Weighted-average grant-date fair value per share, ending balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000715" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.87</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vested and unissued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdSXGwQWf9Nl" title="Number of shares, vested and unissued" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000717" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">149,013</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaTLvyHdpMG1" title="Weighted-average grant-date fair value per share, vested and unissued" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">43.10</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB626M0FokK2" title="Number of shares, unvested" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000721" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">234,623</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJVlZu6FfKQi" title="Weighted-average grant-date fair value per share, unvested" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.11</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_8A7_zfnE5a5W7f9j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, we granted the following RSUs:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            June 28, 2024, we granted RSUs for the future issuance of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z2Ic12qVaul5" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-06-282024-06-28_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember" id="Fact000725" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,202</ix:nonFraction></span> shares of common stock to
                                            our employees which vest accordingly: RSUs for the future issuance of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockUnitsMember__us-gaap--VestingAxis__custom--JanuaryOneTwoThousandTwentyFiveVestingMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zTYANXC7WJL" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_JanuaryOneTwoThousandTwentyFiveVestingMember_custom_EmployeesMember" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,969</ix:nonFraction></span> shares of common
                                            stock vest on January 1, 2025; RSUs for the future issuance of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240628__20240628__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockUnitsMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--VestingAxis__custom--ThreeYearVestingMember_z1KMfj5WnySk" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_EmployeesMember_custom_ThreeYearVestingMember" id="Fact000729" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,173</ix:nonFraction></span> shares of common stock
                                            vest over a three-year period upon meeting service requirements; RSUs for the future issuance
                                            of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240628__20240628__us-gaap--AwardTypeAxis__custom--FirstPerformanceBasedRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z73xb1N8OkWe" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-06-282024-06-28_custom_FirstPerformanceBasedRSUMember_custom_EmployeesMember" id="Fact000731" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,030</ix:nonFraction></span> shares of common stock vested upon grant due to regaining Nasdaq compliance; and
                                            RSUs for the future issuance of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__custom--SecondPerformanceBasedRSUMember__us-gaap--TypeOfArrangementAxis__custom--NextGenerationCapecitabineCAPMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z4hvvWFRSRL9" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-06-282024-06-28_custom_SecondPerformanceBasedRSUMember_custom_NextGenerationCapecitabineCAPMember_custom_EmployeesMember" id="Fact000733" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,030</ix:nonFraction></span> shares of common stock vested on October 2, 2024 when
                                            we dosed the first patient in our Phase 2 study in NGC-Cap.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            July 16, 2024, Russell Skibsted was appointed as our Chief Financial Officer (&#8220;CFO&#8221;).
                                            In addition to cash compensation, the Compensation Committee awarded RSUs for the future
                                            issuance of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zeGrUrOHlOsd" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember" id="Fact000735" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,000</ix:nonFraction></span> shares of common stock to Mr. Skibsted, which vest accordingly: <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__custom--JulySixteenTwoThousandTwentyFiveVestingMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zRafHYryhzC1" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySixteenTwoThousandTwentyFiveVestingMember_srt_ChiefFinancialOfficerMember" id="Fact000737" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,000</ix:nonFraction></span>
                                            vest on July 16, 2025; <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--VestingAxis__custom--FirstPerformanceBasedRSUMember_zKN49MW9ovg4" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_FirstPerformanceBasedRSUMember" id="Fact000739" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000</ix:nonFraction></span> vest upon reaching a market capitalization (i.e. total value
                                            of Processa&#8217;s outstanding shares of stock at the then current market price) of at least
                                            $<span id="xdx_902_ecustom--MarketCapitalization_iI_pn6n6_c20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--VestingAxis__custom--FirstPerformanceBasedRSUMember_zk0qaH9a03r6" title="Market capitalization"><ix:nonFraction name="PCSA:MarketCapitalization" contextRef="AsOf2024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_FirstPerformanceBasedRSUMember" id="Fact000741" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">30</ix:nonFraction></span> million; and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--VestingAxis__custom--SecondPerformanceBasedRSUMember_z7JGgu9UBLV8" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_SecondPerformanceBasedRSUMember" id="Fact000743" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000</ix:nonFraction></span> vest upon receipt of cumulative financing(s) of at least $<span id="xdx_902_ecustom--PerformanceVestingCriteriaValue_iI_pn6n6_c20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--VestingAxis__custom--SecondPerformanceBasedRSUMember_zM9F8ODzd8f1" title="Performance vesting criteria"><ix:nonFraction name="PCSA:PerformanceVestingCriteriaValue" contextRef="AsOf2024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_SecondPerformanceBasedRSUMember" id="Fact000745" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">15</ix:nonFraction></span> million.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            September 3, 2024, RSUs for the future issuance of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240903__20240903__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zuhaLftduwVh" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-09-032024-09-03_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember" id="Fact000747" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,824</ix:nonFraction></span> shares of common stock were granted
                                            to our independent directors and vest on the earlier of June 28, 2025 or the next annual
                                            shareholder meeting.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
                                            December 31, 2024, unrecognized stock-based compensation expense for RSUs of approximately
                                            $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLWIN50N7gRf" title="Unrecognized stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000749" format="ixt:numdotdecimal" decimals="0" unitRef="USD">613,000</ix:nonFraction></span> is expected to be fully recognized over a weighted average period of <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVogPNmBEA99" title="Weighted average period for recognition"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact000751" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">0.7</ix:nonNumeric></span> years.
                                            The unrecognized expense excludes $<span style="background-color: white"><span id="xdx_90B_ecustom--UnrecognizedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zombOCEZmphe" title="Unrecognized share based compensation expense"><ix:nonFraction name="PCSA:UnrecognizedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000753" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">432,060</ix:nonFraction></span> </span>related
                                            to certain RSUs with a performance milestone that is not currently probable of occurring.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Holders
of our vested RSUs will be issued shares of our common stock upon the satisfaction of the distribution restrictions contained in their
Restricted Stock Unit Award Agreement. The distribution restrictions are typically different (longer) than the vesting schedule, imposing
an additional restriction on the holder. Unlike RSAs, while employees may hold fully vested RSUs, the individual does not hold any shares
or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts
into one share of our common stock. The RSUs contain dividend equivalent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" escape="true" id="Fact000755" name="PCSA:ScheduleOfWarrantValuationAssumptionTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfWarrantValuationAssumptionTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2Jl7pxRbsei" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes our warrant activity during the years ended December 31, 2023 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zRzQRMec8UTj" style="display: none">Schedule of Warrants Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total
    warrants outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual<br/>
    life (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGqRSYw9p3yb" title="Warrants outstanding, beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact000757" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,283</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGJURedJKvch" title="Weighted average exercise price, beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">205.01</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCsQTmCVI6l7" title="Warrants, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">173,007</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeIqhRO1dMv2" title="Weighted average exercise price, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.27</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9NrC0pskkui" title="Warrants, expired or cancelled" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,783</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zC2GvJUrZnQd" title="Weighted average exercise price, expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">266.96</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt">Not exercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Warrants, Not exercisable" id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zurrmhM9Fjgc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Weighted average exercise price, not exercisable" id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNHnrmsmBqAf" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000771" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.40</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zB77ppbgMXah" title="Warrants, exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000773" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">7,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zb45yKNXNDXf" title="Weighted average exercise price, exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000775" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.40</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding and exercisable as of December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpjNwCfzuASi" title="Warrants outstanding, beginning balance"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5tzx0izZMgl" title="Warrants, exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000777" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000779" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">173,007</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDVSyUcHtNr7" title="Weighted average exercise price, beginning balance"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.41</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zF7XqKZb5Bze" title="Weighted average remaining contractual term, ending"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zX4BhSkIDDK4" title="Weighted average remaining contractual term, exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000783" name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000785" name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1">2.2</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6gNJTXjpyLh" title="Warrants, exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000787" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">7,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPQuxIhoW21f" title="Weighted average exercise price, exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.40</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zHIALzkmJBX9" title="Warrants, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,617,777</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWA7T7CXdLr1" title="Weighted average exercise price, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000793" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.54</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Expired
    or cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4ai87IdmVWh" title="Warrants, expired or cancelled" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000795" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYaY4v1ZICFj" title="Weighted average exercise price, expired or cancelled" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">54.62</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding and exercisable as of December
    31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRvIcHK539f" title="Warrants outstanding, ending balance"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4jhRbRLuT55" title="Warrants, exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000801" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,775,784</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7rJNa6M9UAf" title="Weighted average exercise price, ending balance"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDndxQAR2JKj" title="Weighted average exercise price, exercisable"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000803" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.95</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGVC8ehhNS78" title="Weighted average remaining contractual term, outstanding"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zuS1NksCppE1" title="Weighted average remaining contractual term, exercisable"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000807" name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000809" name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1">3.8</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_z2stNADCw70h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, we did not grant any warrants to purchase shares of our common stock other than warrants to purchase
<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__custom--OfferingMember_zfevzV3v7PQa" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_us-gaap_WarrantMember_custom_OfferingMember" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,617,777</ix:nonFraction></span> shares of common stock as part of the Offering (see Note 4). Warrants to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zrYpgHEgE61e" title="Warrants, expired unexercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-01-012024-12-31_custom_ConsultingAgreementMember" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500</ix:nonFraction></span> shares of our common stock expired
unexercised. We also repurchased a warrant issued to a consultant in 2023 for the purchase of <span id="xdx_902_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFPK6NQa2ug3" title="Warrants repurchased, shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-01-012024-12-31_custom_ConsultantMember_us-gaap_WarrantMember" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></span> shares of our common stock in exchange
for a payment of $<span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodValue_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoNhqFqqryel" title="Payment for warrants repurchased"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-01-012024-12-31_custom_ConsultantMember_us-gaap_WarrantMember" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">10,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, we amended our financial consulting agreement with Spartan Capital Securities, LLC (&#8220;Spartan&#8221;), our placement agent for our registered direct offering in February
2023, by extending the term until February 10, 2024. We compensated
Spartan for financial consulting services provided under the amendment by granting warrants to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230417__20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zUvZNAFHp7R8" title="Warrants, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-04-172023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember" id="Fact000819" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">158,007</ix:nonFraction></span> shares of our common
stock on April 17, 2023, with an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zID4DcWFAuwf" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember" id="Fact000821" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.40</ix:nonFraction></span>. The warrants expire on <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zCnI83kq7I0c" title="Warrants maturity date"><ix:nonNumeric contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember" format="ixt:datemonthdayyearen" id="Fact000823" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April 17, 2026</ix:nonNumeric></span>, and contain both call and cashless
exercise provision. We also granted warrants to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20231118__20231118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zjQP6caa7y75" title="Warrants, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-11-182023-11-18_custom_ConsultingAgreementMember" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></span> shares of our common stock to a consultant on November 18, 2023, of which
warrants to purchase <span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_c20231118__20231118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zPD1xtoKC8uj" title="Warrants, exercisable"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="From2023-11-182023-11-18_custom_ConsultingAgreementMember" id="Fact000827" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500</ix:nonFraction></span> shares of our common stock were exercisable, with an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zEamF6yt1VJa" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-11-18_custom_ConsultingAgreementMember" id="Fact000829" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.40</ix:nonFraction></span>. These warrants expire on <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_dd_c20231118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zL3jW7ixPSVb" title="Warrant expiration date"><ix:nonNumeric contextRef="AsOf2023-11-18_custom_ConsultingAgreementMember" format="ixt:datemonthdayyearen" id="Fact000831" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">November
18, 2025</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember417832562" escape="true" id="Fact000833" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z187qcKGfGgk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
used the Black-Scholes option pricing model to calculate the grant date fair value of the two warrants granted in 2023 with the following
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zpzqMzlWJHif" style="display: none">Schedule
of Warrant Valuation Assumption</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Average risk-free rate of interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zFFa3YACrxN8" title="Warrants, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" id="Fact000835" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.32</ix:nonFraction></span>-<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zAKeD9yxN461" title="Warrants, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" id="Fact000837" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.88</ix:nonFraction></span>
                                            </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_z3cdHYYbNIi7" title="Expected term (years)"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000839" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.00</ix:nonNumeric></span>&#8211;<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zCgxZ3Mye4Wf" title="Expected term (years)"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000841" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.00</ix:nonNumeric></span>
                                            &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected stock price volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zvN0Na7wW7ph" title="Warrants, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MinimumMember" id="Fact000843" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82.85</ix:nonFraction></span>-<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zpitNuAAUAad" title="Warrants, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MaximumMember" id="Fact000845" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">108.47</ix:nonFraction></span>
                                            </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zk12iZhMWC1a" title="Warrants, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact000847" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zssuzqLdxQI2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000849" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zUrcz5lh6kPk" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
4 &#8211; <span id="xdx_828_znkqnzsR8Wmk">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Financings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, we issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJd7pqRHNTW5" title="Stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000851" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,356,549</ix:nonFraction></span> shares of our common stock through several fundraising efforts described below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Public
    Offering &#8211; </i>On January 30, 2024, we closed a public offering (the &#8220;Offering&#8221;) for the sale of <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlVtb3XifXQh" title="Number of shares, sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-01-292024-01-30_custom_PurchaseAgreementMember" id="Fact000853" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">476,000</ix:nonFraction></span> shares
    of common stock, P</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">re-Funded Warrants to purchase
    up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z031sVAES4j6" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000855" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,079,555</ix:nonFraction></span> shares of common stock in lieu of shares of common stock, and Common Warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zbXyJ3AXuhwb" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-01-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember" id="Fact000857" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,555,555</ix:nonFraction></span> shares
    of our common stock. The Common Warrants have an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjafoz1qP2e9" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember" id="Fact000859" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.50</ix:nonFraction></span>, are immediately exercisable and expire on <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrO0qwpZmoU6" title="Warrants, maturity date"><ix:nonNumeric contextRef="AsOf2024-01-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember" format="ixt:datemonthdayyearen" id="Fact000861" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">January 30, 2029</ix:nonNumeric></span>.
    The shares of common stock were offered at a combined public offering price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zqKo0Wyz9Rv" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-30_custom_PurchaseAgreementMember" id="Fact000863" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.50</ix:nonFraction></span> per share and accompanying Common Warrant and
    $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240130__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zzCU2Zym2Bgd" title="Warrants, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000865" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.4999</ix:nonFraction></span> per Pre-Funded Warrant and accompanying Common Warrant. The Pre-Funded Warrants had an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240130__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zvlrk92jKLwk" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000867" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> and were
    exercised in full simultaneously with the closing of the Offering in exchange for <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesExercised_iI_c20240130__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlsdrklOLHMl" title="Warrants, exercised"><ix:nonFraction name="PCSA:StockIssuedDuringPeriodSharesExercised" contextRef="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000869" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,079,555</ix:nonFraction></span> shares of our common stock. Gross proceeds
    in connection with the Offering were $<span id="xdx_901_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zvVjzGumwdJh" title="Gross proceeds"><ix:nonFraction name="PCSA:GrossProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-292024-01-30_custom_PurchaseAgreementMember" id="Fact000871" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.0</ix:nonFraction></span> million. We received $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zl8TrhpbuAR9" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-292024-01-30_custom_PurchaseAgreementMember" id="Fact000873" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.3</ix:nonFraction></span> million in net proceeds from the Offering, after deducting the
    fees of the placement agent and other offering-related expenses. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ATM
    Offering</i> &#8211; We sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zkBogvc6ePCk"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_custom_ATMOfferingMember" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,994</ix:nonFraction></span> shares at an average price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zPkN04OMsy9l"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-31_custom_ATMOfferingMember" id="Fact000875" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.93</ix:nonFraction></span> per share for aggregate net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z3346w7zcbt4" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31_custom_ATMOfferingMember" id="Fact000877" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also issued to the placement agent warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zUr0bCKip20h"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_PurchaseAgreementMember_custom_PlacementAgentMember" id="Fact000878" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,222</ix:nonFraction></span> shares of common stock, exercisable at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zk14eQ3OsRY2"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_PurchaseAgreementMember_custom_PlacementAgentMember" id="Fact000879" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.625</ix:nonFraction></span> per share that expire on
<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zqqnB4wqbuze" title="Warrant expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_PurchaseAgreementMember_custom_PlacementAgentMember" format="ixt:datemonthdayyearen" id="Fact000881" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">February 1, 2027</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, we issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2mIJnw4q8ac" title="Stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000883" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">421,611</ix:nonFraction></span> shares of our common stock through several fundraising efforts described below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ATM
    Offering</i> &#8211; On February 5, 2023, in connection with our Registered Direct Offering discussed below, we terminated our ATM
    and suspended the Sales Agreement with Oppenheimer &amp; Co. Inc., but we may reinstate it in the future. During the year ended December
    31, 2023, we sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zuwk64KHNYMl"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_custom_SalesAgreementMember" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,483</ix:nonFraction></span> shares at an average price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zkOJarHcptNi"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-31_custom_SalesAgreementMember" id="Fact000885" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.40</ix:nonFraction></span> per share for aggregate gross proceeds of $<span id="xdx_905_ecustom--GrossProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zyZXoLwWd1e5"><ix:nonFraction name="PCSA:GrossProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31_custom_SalesAgreementMember" id="Fact000886" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,000</ix:nonFraction></span> (net proceeds of
    $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z2lC1V4B6tkb"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31_custom_SalesAgreementMember" id="Fact000887" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,000</ix:nonFraction></span>) prior to deducting sales commissions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Lincoln
    Park Capital Fund, LLC Purchase Agreement</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;
    <span style="background-color: white">During the year ended December 31, 2023, we sold <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zEq7FyfcsIu7"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500</ix:nonFraction></span> shares at an average price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zLLNVV8bf3l2"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" id="Fact000889" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">21.60</ix:nonFraction></span>
    per share for aggregate gross proceeds of $<span id="xdx_905_ecustom--GrossProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zBNg3idhBHae" title="Gross proceeds from issuance of common stock"><ix:nonFraction name="PCSA:GrossProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" id="Fact000891" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,000</ix:nonFraction></span> under the purchase agreement with Lincoln Park.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Registered
    Direct Offering &#8211; </i>On February 14, 2023, we closed a registered direct offering (the &#8220;Offering&#8221;) for the sale
    of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230214__20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_z3CjSM9w2bwf"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-02-142023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember" id="Fact000892" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">390,628</ix:nonFraction></span> shares of common stock at a purchase price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zFwNYLv0iO3a" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.00</ix:nonFraction></span> per share for gross proceeds of $<span id="xdx_900_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20230214__20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zL886pzNPTA5"><ix:nonFraction name="PCSA:GrossProceedsFromIssuanceOfCommonStock" contextRef="From2023-02-142023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember" id="Fact000895" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.3</ix:nonFraction></span> million (net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230214__20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zqjtW0CVP5vj"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-02-142023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember" id="Fact000896" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.6</ix:nonFraction></span>
    million).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
paid <span style="background-color: white">Spartan</span> a cash fee of <span id="xdx_908_ecustom--TransactionCostsPercentage_iI_pid_dp_uPure_c20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zxnR4dQUflil" title="Cash fee percentage"><ix:nonFraction name="PCSA:TransactionCostsPercentage" contextRef="AsOf2023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember" id="Fact000898" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span>%
of the gross proceeds from the Offering, excluding proceeds received from our insiders, and reimbursed Spartan for legal fees of
$<span id="xdx_908_ecustom--ReimbursementFees_c20230214__20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_z9LargEDUAmj" title="Reimbursement fees"><ix:nonFraction name="PCSA:ReimbursementFees" contextRef="From2023-02-142023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember" id="Fact000900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></span>.
The engagement agreement with Spartan required us to indemnify Spartan and certain of its affiliates against certain customary
liabilities. On February 14, 2023, we amended the consulting agreement with Spartan originally entered into on August 24, 2022,
extending the term of the consulting agreement until February 10, 2024. As compensation for services under the agreement, on April
17, 2023, we granted Spartan warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zpR7kli7VJG2" title="Warrants, granted"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">158,007</ix:nonFraction></span>
shares of our common stock with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zij7yQ6U1vAd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember" id="Fact000904" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.40</ix:nonFraction></span>.
The warrants will expire <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zjGnp0U8w2Ah" title="Warrant expiration date"><ix:nonNumeric contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember" format="ixt:datemonthdayyearen" id="Fact000906" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April
17, 2026</ix:nonNumeric></span> and contain both call and cashless exercise provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000908" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zpRHUrmyAeo4" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
5 &#8211; <span id="xdx_829_z0X4jL8t1nvg">Net Loss per Share of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average common stock outstanding (which excludes unvested RSAs) and
vested, but unissued RSUs. Diluted net loss per share is computed by dividing net loss by the diluted weighted average common stock outstanding,
which includes potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants. The treasury-stock method is
used to determine the dilutive effect of our stock options and warrants grants. Since we experienced a loss for both periods presented,
basic and diluted net loss per share are the same and, as they would have an anti-dilutive impact on diluted net loss per share, any
dilutive common shares outstanding were excluded from the computation shown below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000910" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ztC0TQL72M1g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the year ended December 31, 2024 and 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zof6YcQ0I1Ng" style="display: none">Schedule of Net Loss Per Share Basic and Diluted</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20240101__20241231_zD7hGGrZtbYb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230101__20231231_ztCaIABrWzKc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net loss
    per share:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zvISSDNk0s4g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss available to common shareholders</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000912" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,850,118</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact000913" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,121,520</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number
    of common shares-basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zAXRoHMtpuKi" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zDAcUSp6rggj" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000915" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000917" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,059,906</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_znY8l3lNV6C6" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z3UrPgxgOuO6" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000919" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000921" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,311,572</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net
    loss per share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20240101__20241231_z4x0DgFmBZeh" title="Basic net loss per share"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_z74TIldS6lO4" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000923" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000925" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.87</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zdM1LxYB6f4f" title="Basic net loss per share"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zPdcntEirbpf" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000927" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000929" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">8.48</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number of common
    shares outstanding &#8211; basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuNa5O8XU0qc" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgRRORPEjkj" title="Weighted average number of common shares outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000931" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000933" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,912,539</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8kcd3MpdFAd" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXt8aX7sTIPg" title="Weighted average number of common shares outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000935" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000937" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,186,952</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number
    of vested RSUs&#8211; basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_ziUYKHxO80j4" title="Weighted average number of vested RSUs - basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zOz4sF7jb7G2" title="Weighted average number of vested RSUs - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember417833750" id="Fact000939" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember417833750" id="Fact000941" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,367</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_ze1IAvsJxQFc" title="Weighted average number of vested RSUs - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0KpRQcUpNk6" title="Weighted average number of vested RSUs - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember417833750" id="Fact000943" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember417833750" id="Fact000945" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,619</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number
    of common shares-basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z6MJcpcwggpe" title="Weighted average number of common shares-basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_z4zDITZyKKw7" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000947" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,059,906</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_z7dvCnzjGdPb" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z7pUlJLy7xZh" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,311,572</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zwOrTfoFSMsa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 3, we issued various equity instruments during the years ended December 31, 2024 and 2023 which impact our EPS calculation.
All granted RSAs are considered issued and outstanding for purposes of our financial statements. Unvested RSAs are included as dilutive
securities, but are excluded from our denominator of basic EPS. At December 31, 2023, <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9IbvdijZrsa" title="Shares unvested"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember" id="Fact000955" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250</ix:nonFraction></span> RSAs were not vested and were excluded from
the EPS calculation. We had <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zZTn5E4vXSU6" title="Shares unvested"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember" id="Fact000957" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> unvested RSAs at December 31, 2024. Vested RSUs are included in our computation of the weighted average
shares for basic EPS and unvested RSUs are included as dilutive securities. At December 31, 2024 and 2023, <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwIu6txRUIB" title="Shares unvested"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000959" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">234,623</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfXZPYv89od9" title="Shares unvested"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">102,623</ix:nonFraction></span> unvested
RSUs were excluded from the EPS calculation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000963" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zplRa7HBS542" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outstanding stock options, unvested RSAs, unvested RSUs and warrants to purchase common stock were excluded from the computation of diluted
net loss per share as their effect would have been anti-dilutive for the periods presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zy0gGxkf4Eia" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20240101__20241231_zvgAKxGK8DF6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230101__20231231_zzInmJVIHRGe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zUIMPvmE7EHk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options, unvested RSAs, unvested
    RSUs and purchase warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000965" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,013,154</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact000966" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">296,326</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z2DUNhfCbqO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000968" name="PCSA:LesseeOperatingAndFinancingLeasesTextBlock"><p id="xdx_806_ecustom--LesseeOperatingAndFinancingLeasesTextBlock_zVi78KPqPmPa" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
6 &#8211; <span id="xdx_822_z6yTFOVp4tVf">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under an operating lease. Our leases do not provide an
implicit rate and, as such, we have used our incremental borrowing rate of <span id="xdx_90F_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20241231_zoMaAm0GSjjf" title="Operating and financing lease borrowing rate"><ix:nonFraction name="PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate" contextRef="AsOf2024-12-31" id="Fact000970" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% to determine the present value of the lease payments based
on the information available at the lease commencement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs included in our consolidated statements of operations totaled approximately $<span id="xdx_904_eus-gaap--LeaseCost_c20240101__20241231_zhbK1hb52Yla" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact000972" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,000</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--LeaseCost_c20230101__20231231_zf6Jn2Goq64f" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-12-31" id="Fact000974" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,000</ix:nonFraction></span> for the years ended December 31,
2024 and 2023, respectively. The weighted average remaining lease terms and discount rate for our operating leases at December 31, 2024
were as follows:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000976" name="PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock"><p id="xdx_894_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_znFw21XxbQ15" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B1_zL8HvYp8x371" style="display: none">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year Ended <br/> December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Remaining lease term (years) for our office lease</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_902_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zqXsky4jypj3" title="Remaining lease term (years)"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_FacilityLeaseMember" format="ixt-sec:duryear" id="Fact000978" name="us-gaap:LesseeOperatingLeaseTermOfContract">0.8</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_z4vZEn4XDTn6" title="Remaining lease term (years)"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_FacilityLeaseMember" format="ixt-sec:duryear" id="Fact000980" name="us-gaap:LesseeOperatingLeaseTermOfContract">1.8</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Remaining lease term (years) for our equipment lease</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zOaMetDFtdX2" title="Remaining lease term (years)"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_EquipmentMember" format="ixt-sec:duryear" id="Fact000982" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm">1.1</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z5zJxd4m6F1" title="Remaining lease term (years)"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_EquipmentMember" format="ixt-sec:duryear" id="Fact000984" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm">0.3</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted average discount rate for our facility and equipment leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20241231_zUB8zwPiP7Fa" title="Weighted average discount rate for our facility and equipment leases"><ix:nonFraction name="PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate" contextRef="AsOf2024-12-31" id="Fact000986" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20231231_zmEmpJsdLcsi" title="Weighted average discount rate for our facility and equipment leases"><ix:nonFraction name="PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate" contextRef="AsOf2023-12-31" id="Fact000988" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8A7_zKBHHoeqTpSj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000990" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMRYa9vAdA78" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the operating lease were as follows at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zeWKMtOwI9Af" style="display: none">Schedule of Annual Lease Liabilities for all Operating Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_490_20241231_zoEmIJPyAWFk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_ztLma9CsyeDh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact000992" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,040</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zOEtXm9V4krb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact000994" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,040</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z0N10jlv7Ldg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    Interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact000996" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zT0heS5JvJ2f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000998" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">66,905</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zEeJVhEdNdeh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zDKtp7BckTHa" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl1001">Less:
    current maturities</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact001000" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,905</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zeAKPPrOxFMb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zB1x3vZ13zq8" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityNoncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1004">Non-current
    lease liability</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zcyoHwCUbVO9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001006" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock"><p id="xdx_894_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zNGtCiTI2OZ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the financing lease were as follows at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_z4ICQeLz6p74" style="display: none">Schedule of Annual Lease Liabilities for all Financing Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_499_20241231_zFfHPZTHX9f7" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_zu77aSb5E7l8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact001008" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,821</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzELQ_zMeY740iJsda" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact001010" format="ixt:numdotdecimal" decimals="0" unitRef="USD">571</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_zJgKN8wrwWR5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact001012" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,392</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_z3WtNPt2hZId" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    Interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact001014" format="ixt:numdotdecimal" decimals="0" unitRef="USD">790</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zThN1ikNiGwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001016" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,602</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zoEv3801EW8d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zC8VrVM0EHMa" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl1019">Less:
    current maturities</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact001018" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,115</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zNmJYSo5KRoi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_z0jUbRXiOgnb" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityNoncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1022">Non-current
    lease liability</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact001021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">487</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_z8umzddRKmZ4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001024" name="PCSA:LicenseAgreementDisclosureTextBlock"><p id="xdx_80C_ecustom--LicenseAgreementDisclosureTextBlock_zO0cQGBZrDZe" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
7 &#8211; <span id="xdx_824_zkDXlM5abXlf">License Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into license agreements which allow us to develop, manufacture, and/or commercialize the following drug assets:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001026" name="PCSA:LicenseAgreementsTableTextBlock"><p id="xdx_89E_ecustom--LicenseAgreementsTableTextBlock_zuW2fUIKpKUd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B0_zDFwIjQmexUg" style="display: none">Schedule of License Agreements</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Licensor</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Drug
    Asset</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Agreement
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amendment
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elion
    Oncology, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Cap
    (PCS6422)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--ElionOncologyIncMember_zZHD3RtVvUGb" title="Agreement Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_ElionOncologyIncMember" format="ixt:datemonthdayyearen" id="Fact001028" name="PCSA:LicenseAgreementsDate">August
    23, 2020</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--LicenseAgreementsAmendmentDate_c20240101__20241231__dei--LegalEntityAxis__custom--ElionOncologyIncMember_zPgIpyDVHN07" title="Amendment Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_ElionOncologyIncMember" format="ixt:datemonthdayyearen" id="Fact001030" name="PCSA:LicenseAgreementsAmendmentDate">May
    17, 2022</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ocuphire
    Pharma, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Gem
    (PCS3117)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--OcuphirePharmaIncMember_zArfmSPmtob2" title="Agreement Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_OcuphirePharmaIncMember" format="ixt:datemonthdayyearen" id="Fact001032" name="PCSA:LicenseAgreementsDate">June
    16, 2021</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aposense,
    Ltd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Iri
    (PCS11T)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--AposenseLtdMember_zbMYJ3AAwpm5" title="Agreement Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_AposenseLtdMember" format="ixt:datemonthdayyearen" id="Fact001034" name="PCSA:LicenseAgreementsDate">May
    24, 2020</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuhan
    Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS12852</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--YuhanCorporationMember_zpBvzCkuV2y5" title="Agreement Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_YuhanCorporationMember" format="ixt:datemonthdayyearen" id="Fact001036" name="PCSA:LicenseAgreementsDate">August
    19, 2020</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CoNCERT
    Pharmaceuticals, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS499</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--CoNCERTPharmaceuticalsIncMember_znHExZHEkPXg" title="Agreement Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CoNCERTPharmaceuticalsIncMember" format="ixt:datemonthdayyearen" id="Fact001038" name="PCSA:LicenseAgreementsDate">March
    19, 2018</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_z0YMxZkksEed" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"> For more information, you should
refer to the summaries described in the Business section of this Annual Report and the copies of such agreements, which have been filed
as exhibits to this Annual Report.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001040" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zfZapyG0kJb9" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
8 - <span id="xdx_823_zuZlvlWoD9ah">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred net operating losses since inception. At December 31, 2024 and 2023, we had available federal and state net operating loss
carryforwards of $<span id="xdx_901_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20241231_zu2k74JD3bHc" title="Deferred tax assets, capital loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001042" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">36.0</ix:nonFraction></span> million and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20231231_zwPyrmTyV034" title="Deferred tax assets, capital loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001044" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">28.6</ix:nonFraction></span> million, respectively. The federal net operating losses generated in 2018 and later of $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--TaxCreditCarryforwardAxis__custom--FederalMember_zbExmqLhP4wl" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_custom_FederalMember" id="Fact001046" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">29.3</ix:nonFraction></span>
million will carry forward indefinitely. Net operating losses generated prior to 2018 will expire <span id="xdx_907_ecustom--NetOperatingLossCarryforwardExpiryDate_c20240101__20241231_zXojIORC0Ovh" title="Net operating loss carryforward, expiration date"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact001048" name="PCSA:NetOperatingLossCarryforwardExpiryDate">2037</ix:nonNumeric></span>. We have not recognized any deferred
tax assets related to the federal orphan drug or other research and development tax credits as of December 31, 2024 or 2023. The federal
research and development tax credits have a <span id="xdx_902_ecustom--NetOperatingLossCarryforwardTerm_dtY_c20240101__20241231_zurUtY1C19Lj" title="Net operating loss carryforward term"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001050" name="PCSA:NetOperatingLossCarryforwardTerm">20</ix:nonNumeric></span>-year carryforward period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231_z8IRnB35ZVC" title="Income tax examination description"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact001052" name="us-gaap:IncomeTaxExaminationDescription">Pursuant
to Code Sec. 382 of the Internal Revenue Code (&#8220;the Code&#8221;), the utilization of our net operating loss carryforwards could
be limited as a result of a cumulative change in stock ownership of more than 50% over a three-year period. We have not completed a Sec.
382 study and as such our net operating loss carryforwards may be subject to such limitation.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001054" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwt2GrubCQIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of our effective income tax rate and statutory income tax rate for the years ended December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zJABXTlKqHO4" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zwtvD2OueJRd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20230101__20231231_zdLvUfSOZch4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_zfEZgCXxUCD6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Federal statutory income tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001056" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001057" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zAbAVBiqBEr3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State tax rate, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact001059" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.58</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001060" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.77</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential_pid_dp_uPure_maEIT001_zJzhlselhuj4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="PCSA:EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" contextRef="From2024-01-01to2024-12-31" id="Fact001062" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.04</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" contextRef="From2023-01-012023-12-31" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.25</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msEIT001_z8lFLos2qbXc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Federal orphan drug tax credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2024-01-01to2024-12-31" id="Fact001065" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.05</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2023-01-012023-12-31" id="Fact001066" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.41</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zqt7BJVx8Hgf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Deferred tax asset valuation
    allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001068" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">26.59</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001069" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">27.93</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zcOl9omLdlP7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Effective income tax
    rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-01to2024-12-31" id="Fact001071" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-012023-12-31" id="Fact001072" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zjJJH1oc9f4f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<ix:exclude><!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001074" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zwQXe0HxRsVg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant components of our deferred tax assets and liabilities for Federal and state income taxes consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 21.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zw9z2aDyk6Sa" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20241231_zSzN8iRkrpXl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20231231_zn2bWa0RGskl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Non-current:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_maDTAGzhSD_zTh70Z6GDAH5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net operating
    loss carry forward &#8211; Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2024-12-31" id="Fact001076" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,566,071</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2023-12-31" id="Fact001077" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,012,941</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_maDTAGzhSD_zW9YDjrfqMK5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carry
    forward &#8211; State</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31" id="Fact001079" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,074,542</ix:nonFraction>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2023-12-31" id="Fact001080" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,672,436</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzhSD_z4FqIL4VIpR6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact001082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,794,226</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,453,799</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzhSD_z7fRjgnCxBQf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation and other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact001085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">238</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact001086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">999</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected_iI_maDTAGzhSD_zGfvk5GSnpIk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Purchased in-process R&amp;D</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" contextRef="AsOf2024-12-31" id="Fact001088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,477,193</ix:nonFraction>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" contextRef="AsOf2023-12-31" id="Fact001089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,562</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsFederalOrphanDrugCredits_iI_maDTAGzhSD_zSfvfuU57t0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal orphan drug credits</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:DeferredTaxAssetsFederalOrphanDrugCredits" contextRef="AsOf2024-12-31" id="Fact001091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,209,202</ix:nonFraction>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:DeferredTaxAssetsFederalOrphanDrugCredits" contextRef="AsOf2023-12-31" id="Fact001092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,202,955</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_iI_maDTAGzhSD_zbtbcRxTIGUd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Capitalized research and
    development costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" contextRef="AsOf2024-12-31" id="Fact001094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,781,193</ix:nonFraction>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" contextRef="AsOf2023-12-31" id="Fact001095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,795,379</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsStartupExpenditures_iI_maDTAGzhSD_z0OVEdAjESwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Start-up
    expenditures and amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzhSD_maDTANzhKZ_zwKhCno95VK8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total non-current deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,902,665</ix:nonFraction>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,639,071</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzhKZ_zuiwq3AZK1pd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance for
    deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,902,665</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,639,071</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzhKZ_msDTLznZn_zUpYY4GNVbXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1106">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred Tax Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Non-current:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzSHY_zWFnpWlHTZu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Intangible
    asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzSHY_maDTLznZn_z3jxlwImi8rj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total non-current deferred
    tax liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLznZn_zwMFvmmOLge9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax asset
    (liability)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zTuvhC4Qy5Dk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in 2022, the Tax Cuts and Jobs Act of 2017 (TCJA) eliminated the option to deduct research and development expenditures in the current
year and requires taxpayers to amortize them over five or fifteen years pursuant to IRC Section 174. During 2024 and 2023, for income
tax purposes, we capitalized approximately $<span id="xdx_907_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization_iI_pn5n6_c20241231_z5GYIHJbIjb" title="Capitalized research and development net of amortization"><ix:nonFraction name="PCSA:DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization" contextRef="AsOf2024-12-31" id="Fact001118" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.8</ix:nonFraction></span> million and $<span id="xdx_901_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization_iI_pn5n6_c20231231_zBoS4puIgsih" title="Capitalized research and development net of amortization"><ix:nonFraction name="PCSA:DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization" contextRef="AsOf2023-12-31" id="Fact001120" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.2</ix:nonFraction></span> million of research and development expenditures, net of amortization
of these costs in each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation allowance generally reflects limitations on our ability to use the tax attributes and reduces the value of such attributes
to the more-likely-than-not realizable amount. We assessed the available positive and negative evidence to estimate if sufficient taxable
income will be generated to use the existing net deferred tax assets. Based on a weighing of the objectively verifiable negative evidence
primarily in the form of cumulative operating losses, we believe that it is not more-likely-than-not that the deferred tax assets will
be realized and, accordingly, a full valuation allowance has been established. The valuation allowance increased by $<span id="xdx_906_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zYtD407Q6euc" title="Valuation allowance deferred tax asset"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2024-01-01to2024-12-31" id="Fact001122" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span> million
and $<span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231_z7KaIjxstrdg" title="Valuation allowance deferred tax asset"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-01-012023-12-31" id="Fact001124" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize potential liabilities for uncertain tax positions using a two-step process. The first step is to evaluate the tax position
for recognition by determining if the weight of available evidence indicates that it is more-likely-than-not that the position will be
sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit
as the largest amount that is more than 50% likely to be realized upon settlement. We have not recorded any uncertain tax positions.
As of December 31, 2024 and 2023, we had <span id="xdx_903_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20240101__20241231_zwcpn4NhdAR3" title="Penalties and interest expense"><span id="xdx_904_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20230101__20231231_zbE4XGrJwUE1" title="Penalties and interest expense"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001126" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="From2023-01-012023-12-31" id="Fact001128" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> accrued penalties or interest related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file U.S. Federal income tax returns, as well as state tax returns for California, Florida and Maryland. There are currently no income
tax examinations underway for these jurisdictions. However, tax years from and including 2017 remain open for examination by federal
and state income tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001130" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zGbXBtfiGVWe" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
9 &#8211; <span id="xdx_820_zZjW4RWdDjyj">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CorLyst,
LLC (&#8220;CorLyst&#8221;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred,
which are recognized as a reduction of our general and administrative operating expenses in our consolidated statements of operations.
We recorded approximately $<span id="xdx_908_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20240101__20241231__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_z3AV2FCnoFU6" title="Rent and other costs reimbursements received"><ix:nonFraction name="PCSA:ProceedsFromRentAndOtherCostsReimbursements" contextRef="From2024-01-012024-12-31_custom_CorLystLLCMember" id="Fact001132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,000</ix:nonFraction></span> and $<span id="xdx_90C_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zxuogKjgmsUi" title="Rent and other costs reimbursements received"><ix:nonFraction name="PCSA:ProceedsFromRentAndOtherCostsReimbursements" contextRef="From2023-01-012023-12-31_custom_CorLystLLCMember" id="Fact001134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,000</ix:nonFraction></span> in reimbursements during the years ended December 31, 2024 and 2023, respectively. At
December 31, 2024, $<span id="xdx_902_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20241231__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_z5wEpLThZvYk" title="Due from related parties"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-12-31_custom_CorLystLLCMember" id="Fact001136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47</ix:nonFraction></span> was due from CorLyst and <span id="xdx_909_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zJuxQlB8JlEl" title="Due from related parties"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31_custom_CorLystLLCMember" id="Fact001138" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> amounts were due at December 31, 2023. Our President, Research and Development is
the CEO of CorLyst, and CorLyst is a shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001140" name="PCSA:LitigationDisclosureTextBlock"><p id="xdx_80E_ecustom--LitigationDisclosureTextBlock_zlbGTNK0EM71" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-style: normal"><b>Note 10
&#8211; <span id="xdx_82E_zfQbsmeXJKJf">Litigation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white">On
May 7, 2024, the Company received notification from Elion purporting to terminate the license agreement by and between the Company and
Elion as a result of the Company&#8217;s alleged breach thereof. The Company believes that Elion&#8217;s claims are without merit and
disputes that the license agreement has been validly terminated. On July 5, 2024, the Company filed a complaint in New York State Court
seeking monetary damages, declaratory judgement and injunctive relief. On August 14, 2024, the Company received Elion&#8217;s answer and
counterclaims. On October 10, 2024, the Company filed its response to Elion&#8217;s counterclaims. The Company intends to enforce its
rights under the license agreement and will pursue such other remedies as it determines are appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white">On
December 3, 2024, Jason Assad and Marc Gyimesi, two of the investors in our February 2021 private offering, filed a lawsuit in New York
County Court alleging fraud and negligent misrepresentation in connection therewith and seeking monetary damages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white">We
intend to vigorously defend ourselves in these lawsuits and cannot at this time predict the likely outcome of any litigation, reasonably
determine either the probability of a material adverse result or any estimated range of potential exposure, or reasonably determine how
these matters or any future matters might impact our business, our financial condition, or our results of operations, although such impact,
including the costs of defense, as well as any judgments or indemnification obligations, among other things, could be materially adverse
to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001142" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_z3Ver1nv0cti" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 11 &#8211;
<span id="xdx_826_zJcrXtO9w3ab">Segment Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt">We
manage our operations as a single segment, focused on developing the next generation of cancer therapy drugs. As our CODM, our CEO manages
and allocates resources at a consolidated level. He assesses performance, monitors budget versus actual results, and decides how to allocate
resources based on net loss that also is reported on the consolidated statement of operations and comprehensive loss as consolidated net
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt">The
accounting policies of our single operating segment are the same as those described in the summary of significant accounting policies
in Note 2. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. In 2024 and 2023,
all our long-lived assets were held in the United States. Expenditures for the addition of long-lived assets are reported on the consolidated
statements of cash flows as purchases of property and equipment. We do not have intra-entity sales or transfers since our only subsidiary
is currently dormant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001144" name="us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"><p id="xdx_89B_eus-gaap--ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_z25iEhybPU2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt">The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B0_zLIfRicpOYJb" style="display: none; font-family: Times New Roman, Times, Serif">Schedule
of Reportable Segment Profit and Loss, Including Significant Expense Categories</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zAnLjiL2NMwc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_z5DpZyRfuHSf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PreclinicalClinicalTrialAndOtherCosts_msNILzaqM_zJgImA2CqUx9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify">Preclinical, clinical trial and other costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="PCSA:PreclinicalClinicalTrialAndOtherCosts" contextRef="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact001146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,450,963</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="PCSA:PreclinicalClinicalTrialAndOtherCosts" contextRef="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact001147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,817,669</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_ze2sg5BHQyE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development personnel expense<sup id="xdx_F45_zI38usS3yZ05" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact001149" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,818,183</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact001150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,981,849</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_msNILzaqM_zAxhz0moFkLb" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expense<span><sup></sup></span></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_z6WgPoxEZaN4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative personnel expense<sup id="xdx_F45_zgShVznxBUTa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact001155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,981,756</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact001156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,737,792</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_msNILzaqM_zh7jxUMLZp61" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expense<sup style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AdministrativeAndFacilitiesExpense_msNILzaqM_zAhzTBc9TFVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative and facilities expense<sup id="xdx_F4F_zwJTbuSjIAc2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="PCSA:AdministrativeAndFacilitiesExpense" contextRef="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact001161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,800,304</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="PCSA:AdministrativeAndFacilitiesExpense" contextRef="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact001162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,919,751</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InvestmentIncomeInterest_iN_di_maNILzaqM_zCkaNoOQbq32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Interest income, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact001164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,088</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact001165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335,541</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtNILzaqM_zahXuwdY0E32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact001167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,850,118</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact001168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,121,520</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><sup id="xdx_F0B_zmU81x7sUVcd">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zPsqjYqgI5r5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><ix:footnote id="Footnote001169" xml:lang="en-US">Research
and development personnel costs include employee stock-based compensation expense of $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqBDe7kz9TZ2" title="Research and development personnel costs include employee stock-based compensation expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,414</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zZEE1TTtC5Ja" title="Research and development personnel costs include employee stock-based compensation expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,956</ix:nonFraction></span> for the year ended December
31, 2024, and 2023, respectively.</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><sup id="xdx_F07_zP9lRgsLHKZj">(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zJFW1grtFjYh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><ix:footnote id="Footnote001174" xml:lang="en-US">General
and administrative personnel costs include employee stock-based compensation expense of $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_zCX8mmnoY3n6" title="General and administrative personnel costs include employee stock-based compensation expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_custom_CorLystLLCMember" id="Fact001176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,925</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_z490ruzWdrCi" title="General and administrative personnel costs include employee stock-based compensation expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_custom_CorLystLLCMember" id="Fact001178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,854</ix:nonFraction></span> for the year ended December
31, 2024, and 2023, respectively, and are net of reimbursements received from CorLyst, LLC.</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><sup id="xdx_F09_zEzn2b7zhIq6">(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zcOiJ6oVqRI7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><ix:footnote id="Footnote001179" xml:lang="en-US">Administrative
&amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and
other administrative costs.</ix:footnote></span></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8A8_zfSCKHyaa56f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001181" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zbNWT4PynzGb" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
12 &#8211; <span id="xdx_82B_z0d6S1detV75">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Purchase
Obligations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter contracts in the normal course of business with contract research organizations and subcontractors to further develop our products.
The contracts are cancellable, with varying provisions regarding termination. If we terminated a cancellable contract with a specific
vendor, we would only be obligated for products or services that we received as of the effective date of the termination and any applicable
cancellation fees. As of December 31, 2024, we are contractually obligated to pay up to approximately $<span id="xdx_90B_eus-gaap--PurchaseObligation_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--CROsMember_zuJLWgOG4oZ" title="Purchase obligation"><ix:nonFraction name="us-gaap:PurchaseObligation" contextRef="AsOf2024-12-31_custom_CROsMember" id="Fact001183" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.2</ix:nonFraction></span> million for future services
under the agreements with the CROs for our clinical trials in NGC-Cap. Our actual contractual obligations will also vary depending on
the progress and results of the remaining clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001185" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_805_eus-gaap--ConcentrationRiskDisclosureTextBlock_zrg4QKCv4zNh" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
13 &#8211; <span id="xdx_822_z5VupWP4iq48">Concentration of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at December 31, 2024, exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001187" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_z3L1q01Inzg8" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
14 &#8211; <span id="xdx_82D_zqr7bkDBZ4j1">Subsequent Events</span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i><span style="text-decoration: underline">Public Offering</span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 27, 2025, we sold, pursuant to securities purchase agreements (the &#8220;Purchase Agreement&#8221;), <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zemSGCgLLC41" title="Number of shares, sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-272025-01-27_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact001189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,030,972</ix:nonFraction></span> shares of our
common stock and accompanying Series A warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z7esswsEqYbb" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_SeriesAWarrantMember_custom_PurchaseAgreementMember" id="Fact001191" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,050,672</ix:nonFraction></span> shares of our common stock (the &#8220;Series A Warrants&#8221;)
and Series B warrants to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjdkB6fQqNg2" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_SeriesBWarrantMember_custom_PurchaseAgreementMember" id="Fact001193" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,025,336</ix:nonFraction></span> shares of our common stock (the &#8220;Series B Warrants&#8221; and collectively with
the Series A Warrants, the &#8220;Common Warrants&#8221;) at a combined purchase price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zHff3iUiYJh3" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember" id="Fact001195" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.615</ix:nonFraction></span> for institutional investors and $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndCertainBoardMembersMember_zEnldQHctb9d" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_ChiefExecutiveOfficerAndCertainBoardMembersMember" id="Fact001197" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.7975</ix:nonFraction></span>
for the Company&#8217;s Chief Executive Officer and certain board members. The Series A and Series B Warrants both have an exercise price
of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAAndBMember_zSMNu24czw91" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_SeriesAAndBMember" id="Fact001199" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.65</ix:nonFraction></span> per share of common stock, and will be exercisable beginning on the effective date of stockholder approval of the issuance of
the shares upon exercise of the warrants (&#8220;Warrant Stockholder Approval&#8221;). The Series A Warrants will expire on the <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zTeIE5PAYmcd" title="Warrants, exercisable term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1201">five</span></span>-year
anniversary date of stockholder approval and the Series B Warrants will expire on the eighteen-month anniversary date of stockholder
approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also sold pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zY046aFfT4Y2" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember" id="Fact001203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,019,700</ix:nonFraction></span>
shares of our common stock to a purchaser whose purchase of shares of common stock in the public offering would have resulted in the
purchaser beneficially owning more than <span id="xdx_90D_ecustom--OutstandingSharesPercentage_pid_dp_uPure_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zDaE3QiKW3O6" title="Outstanding shares percentage, maximum"><ix:nonFraction name="PCSA:OutstandingSharesPercentage" contextRef="From2025-01-272025-01-27_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember" id="Fact001205" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>%
of our outstanding common stock immediately following the consummation of the public offering. Each Pre-Funded Warrant is
exercisable for one share of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zK19Kj8JuNu" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember" id="Fact001207" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
per share of common stock. The public offering price per Pre-Funded Warrant, is equal to the public offering price per share and
Common Warrants less $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEyldy0iO96a" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember" id="Fact001209" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>.
Each Pre-Funded Warrant will be exercisable upon issuance and will expire when exercised in full. On January 30, 2025, Pre-Funded
Warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zFkI624LWxrb" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-30_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember" id="Fact001211" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">525,700</ix:nonFraction></span>
shares of our common stock were exercised and, as of March 12, 2025, Pre-Funded Warrants for the purchase of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250312__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zox4kV6cRIS6" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-03-12_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember" id="Fact001213" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,494,000</ix:nonFraction></span> remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
proceeds in connection with this offering were $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_za3Ru8kSC2i8" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-01-272025-01-27_us-gaap_SubsequentEventMember" id="Fact001215" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million and we received $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMkAYfauTM7e" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-272025-01-27_us-gaap_SubsequentEventMember" id="Fact001217" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million in net proceeds from the offering, after deducting
the fees of the placement agent and other offering-related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Amended
and Restated Bylaws</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2025, the Board of Directors (the &#8220;Board&#8221;) of the Company adopted the Amended and Restated Bylaws (as
amended, the &#8220;Bylaws&#8221;). The Bylaws, which became effective immediately, amended Section 2.4 to change the quorum requirements
for a stockholders meeting to be the holders of shares of outstanding capital stock of the Company representing one third (1/3) of the
voting power of all outstanding shares of capital stock of the Company except if business is to be voted on by a class or series of stock
voting as a class, then the holders of shares representing one third (1/3) of the voting power of the outstanding shares of such class
or series shall constitute a quorum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Executive
Employment Agreements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">On March 19, 2025, we entered into new or amended employment agreements with all members of our executive team
that continue until terminated or modified pursuant to the terms of the employment agreements. The agreements establish their base salaries,
target bonuses, eligibility to participate in our 2019 Omnibus Incentive Plan, and severance benefits, among other things.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

</ix:nonNumeric><p id="xdx_817_zC2EibRBARRk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_009"></span>Item
9. Changes in and Disagreements with Accountants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_010"></span>Item
9A. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under
the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms,
and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer,
as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures,
management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance
of achieving the desired control objectives, as our controls are designed to do, and management was required to apply its judgment in
evaluating the risks related to controls and procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the preparation of this Annual Report on Form 10-K, as of December 31, 2024, an evaluation was performed by management,
including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure
controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Our Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures were effective as of December 31, 2024 to provide reasonable assurance that information
required to be disclosed by us in reports we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported
within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inherent
Limitations on Effectiveness of Controls</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).
Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records
that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts
and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material
effect on the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management,
including our Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls will prevent or detect
all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control
systems, no evaluation of internal controls can provide absolute assurance that all control issues and instances of fraud, if any, have
been detected. Also, any evaluation of the effectiveness of controls in future periods is subject to the risk that those internal controls
may become inadequate because of changes in business conditions, or that the degree of compliance with the policies or procedures may
deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 83; Options: NewSection; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Annual Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f)
and 15d-15(f) under the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation
of consolidated financial statements for external purposes in accordance with GAAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assessed our internal control over financial reporting as of December 31, 2024. Management based its assessment on criteria established
in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework).
Management&#8217;s assessment included evaluation of elements such as the design and operating effectiveness of key financial reporting
controls, process documentation, accounting policies, and our overall control environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on this assessment, management has concluded that, as of December 31, 2024, our internal control over financial reporting was effective
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements
for external reporting purposes in accordance with GAAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm, Cherry Bekaert,
LLP, regarding internal controls over financial reporting. Management&#8217;s report was not subject to attestation by our registered
public accounting firm as we are a smaller reporting company. We are not currently subject to Section 404(b) of the Sarbanes-Oxley Act
of 2002.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 23.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes to our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d)
and 15d-15(d) of the Exchange Act that occurred during the year ended December 31, 2024 that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_011"></span>Item
9B. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 23.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Rule 10b5-1 Trading
Plans<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 23.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the quarter ended December 31, 2024, none of our directors or executive officers <span id="xdx_908_eecd--Rule10b51ArrAdoptedFlag_dbF_c20241001__20241231_zbqKRAgRa54c"><span id="xdx_903_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20241001__20241231_z91znhGzkLf2"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact001218" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact001219" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span> or <span id="xdx_909_eecd--Rule10b51ArrTrmntdFlag_dbF_c20241001__20241231_zi1thbsfS6Pc"><span id="xdx_904_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20241001__20241231_znYIz0pLrV62"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact001220" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact001221" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a Rule 10b5-1 trading plan or
a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Amended and Restated
Bylaws</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2025, the Board of Directors (the &#8220;Board&#8221;) of the Company adopted the Amended and Restated Bylaws (as amended,
the &#8220;Bylaws&#8221;). The Bylaws, which became effective immediately, amended Section 2.4 to change the quorum requirements for
a stockholders meeting to be the holders of shares of outstanding capital stock of the Company representing one third (1/3) of the voting
power of all outstanding shares of capital stock of the Company except if business is to be voted on by a class or series of stock voting
as a class, then the holders of shares representing one third (1/3) of the voting power of the outstanding shares of such class or series
shall constitute a quorum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preceding description of the Bylaws is qualified in its entirety by reference to the full text of the Bylaws dated March 18, 2025,
which is filed herewith as Exhibit 3.2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Executive Employment Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">On March 19, 2025, we entered into new or amended employment agreements with each of George Ng, Russell Skibsted,
Sian Bigora, Wendy Guy, Patrick Lin and David Young. See Item 11 Executive Compensation &#8211; Employment Agreements herein for a summary
of the employment agreements. The description of the employment agreements is qualified in its entirety by reference to the full text
of the agreements, which are filed herewith as Exhibits 10.11, 10.12, 10.13, 10.14, 10.15 and 10.16.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_012"></span>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 84; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_013"></span>Part
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -49.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_014"></span>Item
10. Directors and Executive Officers of the Registrant</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning our executive officers, as of March 12, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 54%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position
    </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive Officers:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George Ng</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Sian Bigora</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Development and Regulatory Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wendy Guy</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Administrative Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick Lin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Business and Strategy Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell Skibsted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. David Young</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President of Research and Development</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Employee Directors:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Khoso Baluch</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Neal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geraldine Pannu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin Yorke</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>George
Ng </i>&#8211; Mr. Ng has served as our Chief Executive Officer and as a director since August 8, 2023. He has served as a member of
the board of directors of Calidi Biotherapeutics Inc. (NYSE:CLDI) (&#8220;Calidi&#8221;) from October 2019 to September 2024, and was
Calidi&#8217;s President and Chief Operating Officer from February 1, 2022 until June 23, 2023. He has been a partner at PENG Life Science
Ventures since September 2013; a member of the board of directors and co-founder at IACTA Pharmaceuticals, Inc. since January 2020; and
member of the board of directors of TuHURA Biosciences, Inc. (formerly, Morphogenesis, Inc.) since February 2020 . His experience further
includes serving in various executive-level or board of director positions for multiple publicly-traded and private global biotechnology
and pharmaceutical firms. Mr. Ng previously served as a member of the board of directors of Inflammatory Response Research, Inc. from
May 2019 to April 2020; Invent Medical Corp from July 2019 to January 2020; ImmuneOncia Therapeutics Inc. from June 2016 to 2019; and
Virttu Biologics Limited from April 2017 to April 2019. He was also the Executive Vice President and Chief Administrative Officer of
Sorrento Therapeutics, Inc. (Nasdaq: SRNE) from March 2015 to April 2019; the Co-Founder and President, Business of Scilex Pharmaceuticals
Inc. from September 2012 to April 2019; and the Senior Vice President and General Counsel of BioDelivery Sciences International Inc.
(Nasdaq: BDSI) from December 2012 to March 2015. Mr. Ng holds a JD degree from the University of Notre Dame School of Law, as well as
a B.A.S. (B.A. and B.S.) dual degree in Biochemistry and Economics from the University of California, Davis. We believe that Mr. Ng is
qualified to serve on our Board due to his experience with pharmaceutical companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sian
Bigora, Pharm.D.</i> <b>- </b>Dr. Bigora has served as our Chief Development and Regulatory Officer since October 4, 2017 and has
over 30 years of pharmaceutical research, regulatory strategy and drug development experience. From 2009 to 2015 Dr. Bigora was Vice
President of Regulatory Affairs at Questcor Pharmaceuticals (acquired by Mallinckrodt Pharmaceuticals in 2014), including leading
efforts on modernizing the Acthar Gel label and in obtaining FDA approval in Infantile Spasms, events of material importance to
Questcor&#8217;s subsequent success. During her time at Questcor, she assisted in building an expert regulatory group to address
both commercial and development needs for complex products such as Acthar. Dr. Bigora&#8217;s role at Questcor included heading up
the development of a safety pharmacovigilance group and a clinical quality group. Prior to her position at Questcor, Dr. Bigora was
Vice President of Clinical and Regulatory Affairs, U.S. Operations of AGI Therapeutics, plc. In this role, she was responsible for
the development and implementation of Global Phase 3 studies and interactions with regulatory authorities. Previously, she operated
her own consulting company, serving as the regulatory and drug development expert team member for multiple small and mid-sized
pharmaceutical companies. Dr. Bigora held multiple positions in regulatory affairs, operations and project management ending as VP
of Regulatory Affairs at the Strategic Drug Development Division of ICON, plc, an international CRO, and at GloboMax LLC, a CRO
specializing in FDA drug development, purchased by ICON plc in 2003. Prior to GloboMax, she worked in the Pharmacokinetics and
Biopharmaceutics Laboratory at the School of Pharmacy, University of Maryland on the FDA funded Clinical Pharmacology contract and
UMAB-FDA contract as a clinical scientist and instructor for FDA reviewers. Dr. Bigora received a Pharm.D. from the School of
Pharmacy at the University of Maryland at Baltimore. She also completed a Fellowship in Pharmacokinetics and Pediatric Infectious
Diseases at the University of Maryland at Baltimore.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Wendy
Guy</i> <b>- </b>Ms. Guy has served as our Chief Administrative Officer since October 4, 2017. She has over 20 years of experience in
business operations, management, contracts, human resources recruiting, and finance roles. From 2009 to 2014, Ms. Guy was employed at
Questcor Pharmaceuticals (acquired by Mallinckrodt Pharmaceuticals in 2014) as Senior Manager, Business Operations in charge of the Maryland
Office for Questcor. During the five years she spent at Questcor, she built a dynamic administrative and contracts team, grew the Maryland
Office from two employees to just under 100, and expanded the facility from 1,200 sq. ft. to 15,000 sq. ft. Prior to her position at
Questcor, Ms. Guy was Senior Manager, U.S. Operations of AGI Therapeutics, plc. In this role, she was responsible for the day-to-day
business and administrative operations of the company. Previously, she held multiple senior level positions with the Strategic Drug Development
Division of ICON, GloboMax, and Mercer Management Consulting. Ms. Guy received an A.A. from Mount Wachusett Community College.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patrick
Lin</i> - Mr. Lin has served as our Chief Business &amp; Strategy Officer since October 4, 2017 and has over 30 years of financing and
investing experience in the Biopharm Sector. He is founder and, for more than 15 years, Managing Partner of Primarius Capital, a family
office that manages public and private investments focused on small capitalization companies. For 10 years prior to forming Primarius
Capital, Mr. Lin worked at several Wall Street banking and brokerage firms including Robertson Stephens &amp; Co., E*Offering, and Goldman
Sachs &amp; Co. Mr. Lin was Co-Founding Partner of E*Offering. Mr. Lin received an MBA from Kellogg Graduate School of Management, an
M.S. in Engineering Management, and a BS from the University of Southern California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 85; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><i>Russell Skibsted</i> &#8211;
Mr. Skibsted has served as our Chief Financial Officer since July 16, 2024. He has nearly 30 years of experience in the pharmaceutical
industry including expertise in financial management, global business development, capital raises, investor relations and operations.
He has worked with public and private life sciences companies at all stages of development. Most recently, he served as Senior Vice President
and CFO of Alimera Sciences, a publicly traded global ophthalmic pharmaceuticals company that was acquired by ANI Pharmaceuticals from
January 2023 to December 2023. Prior to that, he was Executive Vice President, CFO and Chief Business Officer at Rockwell Medical, a
public company providing hemodialysis products from September 2020 to November 2022. From July 2017 to May 2020, Mr. Skibsted served
as CFO of BioTime, a publicly traded biotechnology company now named Lineage Cell Therapeutics, where he also was CFO at various times
for several of BioTime&#8217;s public and private subsidiaries, including Agex Therapeutics, OncoCyte Corporation and Asterias Biotherapeutics.
Prior to BioTime, Mr. Skibsted served as CFO or Chief Business Officer for several public and private life science companies, including
Aeolus Pharmaceuticals, Spectrum Pharmaceuticals and Hana Biosciences. Mr. Skibsted holds a BA in economics from Claremont McKenna College
and an MBA from the Stanford Graduate School of Business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>David
Young, Pharm.D., Ph.D. </i><b>- </b>Dr. Young has served as our President, Research and Development and a director since August 8, 2023.
He also served as our Chief Executive Officer from October 4, 2017 until August 7, 2023, as the Chairman of our Board until July 11,
2022, and as our President from July 11, 2022 until August 8, 2023. He has over 35 years of drug development experience serving as CEO,
President and VP in different drug development companies. He served as our interim CFO from October 4, 2017 to September 1, 2018. From
2006 to 2014, Dr. Young served as a Questcor Pharmaceuticals Board Member and later as CSO, where he worked with FDA on the sNDA approval
of Acthar for infantile spasms, an ultra-rare orphan indication, and other indications. In 2014, Questcor was acquired for $5.7 billion.
Dr. Young was previously an Associate Professor at the University of Maryland, has served on FDA Advisory Committees, and was involved
with two FDA-funded contracts as co-principal investigator and investigator. Research from these contracts resulted in multiple FDA Guidances,
which became the basis of our regulatory science approach to drug development. Dr. Young has served on NIH grant review committees and
was Co-Principal Investigator on an NCI contract to evaluate new oncology drugs. He has met with the FDA over one hundred times and has
been a key member on more than thirty FDA indication approvals. Dr. Young received a B.S. in Physiology, M.S. in Medical Physics, and
Pharm.D.-Ph.D. specializing in pharmacokinetics-pharmacodynamics. We believe Dr. Young is qualified to serve on our Board due to his
pharmaceutical experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Khoso
Baluch &#8211; </i>Mr. Baluch has served as a director since over July 2022. He has over 36 years of experience across global geographies
in the biopharmaceutical industry. He serves on Relevant Bio, a private US company, as a member of the board of directors since February
2024 and Longeveron, a US public company, as a member of the board of directors since June 2023. Since 2012, he has served as an independent
director of Poxel S.A. (OTC: PXXLF), a French publicly traded biotech company, and chairs its compensation committee and as of March
2023 became Chairman. He also served as the Chairman of the Board for Da Volterra, a French privately held company, from December 2021
until November 2022. From 2016 to 2021, Mr. Baluch served as the Chief Executive Officer and a member of the board of directors of CorMedix,
Inc. (Nasdaq: CRMD), a publicly traded pharmaceutical company in the United States. Mr. Baluch also held various senior positions at
UCB, S.A. between January 2008 to April 2016, including Senior Vice President and President Europe, Middle East &amp; Africa. Prior to
joining UCB, Mr. Baluch worked for Eli Lilly and Company (NYSE: LLY) for 24 years, holding international positions spanning Europe, the
Middle East and the United States in general management, business development, market access and product leadership. Mr. Baluch holds
a B.S. in Aeronautical Engineering from City University London and an MBA from Cranfield School of Management. We believe Mr. Baluch
is qualified to serve as on our Board due to his business expertise and significant executive management experience in the pharmaceutical
industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><i>James Neal</i> &#8211; Mr.
Neal has served as a director since July 2022. He brings more than 25 years of experience forming and maximizing business and technology
collaborations globally and in bringing novel products and technologies to market. Mr. Neal served as the Chief Executive Officer and
member of the board of directors of XOMA Corporation (Nasdaq: XOMA) (&#8220;XOMA&#8221;) from December 2016 until his retirement in January
2023. Mr. Neal joined XOMA in 2009 as its Vice President, Business Development. Prior to joining XOMA, Mr. Neal was Acting Chief Executive
Officer of Entelos, Inc. a leading biosimulation company. Previously, in 2007, Entelos acquired Iconix Biosciences, a privately held company
where Mr. Neal served as Chief Executive Officer and established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs, Eli
Lilly and the U.S. Food and Drug Administration. While Executive Vice President of Incyte Genomics from 1999 to 2002, he led the global
commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis and Schering-Plough, as well as
sales, marketing and business development activities for the company. Earlier, he was associated with Monsanto Company in positions of
increasing responsibility. Mr. Neal also serves on the Board of Directors of Akari Therapeutics, a pre-clinical stage biopharmaceutical
company. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and
holds an Executive MBA degree from Washington University in St. Louis, Missouri. We believe Mr. Neal is qualified to serve on our Board
because of his business expertise and significant executive management experience in the pharmaceutical industry.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 86; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Geraldine
Liu Pannu</i> &#8211; Ms. Pannu has served as a Director since February 13, 2020. Since May 2022, she has also served as an independent
director on the Board of Royal Business Bank (Nasdaq: RBB). Ms. Pannu has over 25 years of experience in investment and financial management,
fund operations, consulting and marketing. Since January 2020, she has been the Founding and Managing Partner of GLTJ Pioneer Capital,
a firm that specializes in land acquisition, entitlement and vertical development of multifamily, student and senior housing in the San
Francisco Bay Area. From September 2018 to September 2019, Geraldine was the Managing Director of Business Development for Golden Gate
Global (GGG), a leading investment fund company in the Bay Area, CA. During this time, she was also the President of Golden Wealth Management
Group (GWMG), an affiliated company of GGG that provides professional wealth management services to high net worth individuals and families.
From March 2007 to December 2016 , Ms. Pannu was the COO and Managing Partner for ChinaRock Capital Management, a leading hedge and venture
capital fund company. She previously worked at McKinsey &amp; Co., Monitor Company as a management consultant. She has successfully raised
capital for several hedge, venture capital and real estate funds. She also helped start-up companies expand and diversify business categories
and client verticals and grow revenue. Ms. Pannu was born in Shanghai and grew up in Hong Kong. She received her BBA from the Chinese
University of Hong Kong and an MBA from Harvard Business School. She is fluent in English, Mandarin, Cantonese and Shanghainese. We believe
Ms. Pannu is qualified to serve on our Board because of her extensive investment experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Justin
Yorke </i>&#8211; Mr. Yorke is currently the Chairman of the Board, a position he has held since July 11, 2022, and has served as a director
since August 2017. Mr. Yorke has over 25 years of experience as an institutional equity fund manager and senior financial analyst for
investment funds and investment banks. For more than 20 years, he has been a partner at Arroyo Capital Management which manages the Richland
Fund whose primary activity is investing in public and private companies in the United States. Since March 2020, Mr. Yorke has served
as a director and Corporate Secretary of Splash Beverage Group, Inc (NYSE:SBEV). From 2006 to 2007, Mr. Yorke served as non-executive
Chairman of Jed Oil and a director/CEO at JMG Exploration. From 2000 to 2004, he was a partner at Asiatic Investment Management, based
in San Francisco. From 1997 to 2000, Mr. Yorke was a Fund Manager and Senior Financial Analyst, based in Hong Kong, for Darier Henstch,
S.A., a private Swiss bank, where he managed their $400 million Asian investment portfolio. From 1995 to 1997, Mr. Yorke was an Assistant
Director and Senior Financial Analyst with Peregrine Asset Management, which was a unit of Peregrine Securities, a regional Asian investment
bank. From 1990 to 1995, Mr. Yorke was a Vice President and Senior Financial Analyst with Unifund Global Ltd., a private Swiss Bank,
as a manager of its $150 million Asian investment portfolio. Mr. Yorke has a B.A. from University of California, Los Angeles. We believe
Mr. Yorke is qualified to serve on our Board because of his extensive investment experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Policy
Statement on Insider Trading</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have <span id="xdx_905_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbT_c20240101__20241231_z66Oo0qFZsm3" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact001222" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">adopted</ix:nonNumeric></span> an Insider Trading Policy that governs the purchase, sale, and/or other dispositions of our securities by directors, officers,
employees, and consultants that is reasonably designed to promote compliance with insider trading laws, rules and regulations and NASDAQ
listing standards. A copy of our Policy Statement on Insider Trading is included as Exhibit 19 to this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Board
Composition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
our Board of Directors is comprised of six members. Each director has been elected to hold office until the next annual meeting of shareholders
or special meeting in lieu of such annual meeting or until his or her successor has been duly elected and qualified, or until his or
her earlier death, resignation or removal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors may consider a broad range of factors relating to the qualifications and background of nominees, which may include
diversity, which is not only limited to race, gender or national origin. We have no formal policy regarding Board diversity. Our Board
of Directors&#8217; priority in selecting Board members is identification of persons who will further the interests of our stockholders
through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture
among Board members, knowledge of our business, understanding of the competitive landscape and professional and personal experiences
and expertise relevant to our growth strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Director
Independence</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nasdaq Marketplace Rules require a majority of a listed company&#8217;s Board of Directors to be comprised of independent directors.
In addition, the Nasdaq Marketplace Rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit,
compensation and nominating and corporate governance committees be independent and that audit committee members also satisfy independence
criteria set forth in Rule 10A-3 under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Rule 5605(a)(2) of the Nasdaq Marketplace Rules, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion
of our Board of Directors, that person does not have a relationship that would interfere with the exercise of independent judgment in
carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3 of the Exchange Act,
a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the
Board of Directors, or any other Board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee
from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has reviewed the composition of our Board of Directors and the independence of each director. Based upon information
requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships,
our Board of Directors has determined that each of Khoso Baluch, James Neal, Geraldine Pannu, and Justin Yorke is an &#8220;independent
director&#8221; as defined under Rule 5605(a)(2) of the Nasdaq Marketplace Rules. Our Board of Directors also determined that the directors
who serve on our audit committee, our compensation committee, and our nominating and corporate governance committee satisfy the independence
standards for such committees established by the SEC and the Nasdaq Marketplace Rules, as applicable. In making such determinations,
our Board of Directors considered the relationships that each such non-employee director has with our company and all other facts and
circumstances our Board of Directors deemed relevant in determining independence, including the beneficial ownership of our capital stock
by each non-employee director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our directors or executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Committees
of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the below committees has a written charter approved by our Board of Directors located at our website: www.processapharmaceuticals.com.
Each of the committees&#8217; report to our Board of Directors as such committee deems appropriate and as our Board of Directors may
request. Copies of each charter are posted on the investor relations section of our website. Members serve on these committees until
their resignation or until otherwise determined by our Board of Directors. In addition, from time to time, special committees may be
established under the direction of our Board of Directors when necessary to address specific issues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors met 20 times during 2024. All directors attended each meeting, with the following exceptions: Khoso Baluch missed three meetings, James
Neal missed one meeting, Geraldine Pannu missed three meetings, Justin Yorke missed one meeting, and David Young missed two meetings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Audit
Committee</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee is comprised of Khoso Baluch, Geraldine Pannu, and Justin Yorke, with Justin Yorke serving as chairman of the committee.
Our Board of Directors has determined that each member of the audit committee meets the independence requirements of Rule 10A-3 under
the Exchange Act and the applicable Nasdaq Listing Rules, and has sufficient knowledge in financial and auditing matters to serve on
the audit committee. Our Board of Directors has determined that Justin Yorke is an &#8220;audit committee financial expert&#8221; within
the meaning of the SEC regulations and the applicable Nasdaq Listing Rules. The audit committee&#8217;s responsibilities include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting a
    firm to serve as the independent registered public accounting firm to audit our financial statements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensuring the independence
    of the independent registered public accounting firm;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing the scope and
    results of the audit with the independent registered public accounting firm, and reviewing, with management and that firm, our interim
    and year-end operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures
    for employees to anonymously submit concerns about questionable accounting or audit matters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">considering the effectiveness
    of our internal controls and internal audit function;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing material related-party
    transactions or those that require disclosure; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving or, as permitted,
    pre-approving all audit and non-audit services to be performed by the independent registered public accounting firm.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee met four times during 2024. All the committee members attended each meeting, with the exception of Khoso Baluch who
did not attend one meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Compensation
Committee</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee is comprised of Khoso Baluch, James Neal and Geraldine Pannu, with Geraldine Pannu serving as chairman of the
committee. Each member of this committee is a non-employee director, as defined by Rule 16b-3 promulgated under the Exchange Act, and
an outside director, as defined pursuant to Section 162(m) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;).
Our Board of Directors has determined that each member of the compensation committee is &#8220;independent&#8221; as defined in the Nasdaq
Listing Rules. The composition of our compensation committee meets the requirements for independence under the Nasdaq Listing Rules,
including the applicable transition rules. The compensation committee&#8217;s responsibilities include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and
    approving, or recommending that our Board of Directors approve, the compensation of our executive officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending
    to our Board of Directors the compensation of our directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending
    to our Board of Directors the terms of any compensatory agreements with our executive officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering our stock
    and equity incentive plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving,
    or making recommendations to our Board of Directors with respect to incentive compensation and equity plans; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing all overall compensation
    policies and practices.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee met one time during 2024. All the committee members attended the meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Nominating
and Governance Committee</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and governance committee is comprised of James Neal, Geraldine Pannu and Justin Yorke, with Justin Yorke as the chairman of
the committee. Our Board of Directors has determined that each member of the nominating and corporate governance committee is &#8220;independent&#8221;
as defined in the applicable Nasdaq Listing Rules. The nominating and corporate governance committee&#8217;s responsibilities include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
    and recommending candidates for membership on our Board of Directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending directors
    to serve on Board committees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending
    our corporate governance guidelines and policies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing proposed waivers
    of the code of conduct for directors and executive officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating, and overseeing
    the process of evaluating, the performance of our Board of Directors and individual directors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting our Board of
    Directors on corporate governance matters.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and governance committee did not meet in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leadership
Structure and Risk Oversight</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 11, 2022, Justin Yorke became the Chairman of the Board of Directors. Prior to that time, Dr. David Young, our former Chief Executive
Officer (now President, Research and Development) also served as Chairman of the Board. Our Board of Directors does not have a policy
regarding the separation of the roles of Chief Executive Officer and Chairman of the Board of Directors, as our Board of Directors believes
it is in our best interest to make that determination based on our position and direction and the membership of the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors oversees the management of risks inherent in the operation of our business and the implementation of our business
strategies. Our Board of Directors performs this oversight role by using several different levels of review. In connection with its reviews
of our operations and corporate functions, our Board of Directors addresses the primary risks associated with those operations and corporate
functions. In addition, our Board of Directors reviews the risks associated with our business strategies periodically throughout the
year as part of its consideration of undertaking any such business strategies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our Board committees also oversees the management of our risks that fall within the committee&#8217;s areas of responsibility. In
performing this function, each committee has full access to management, as well as the ability to engage advisors. Our Chief Financial
Officer reports to the audit committee and is responsible for identifying, evaluating and implementing risk management controls and methodologies
to address any identified risks. In connection with its risk management role, our audit committee meets privately with representatives
from our independent registered public accounting firm and our Chief Financial Officer. The audit committee oversees the operation of
our risk management program, including the identification of the primary risks associated with our business and periodic updates to such
risks, and reports to our Board of Directors regarding these activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee Interlocks and Insider Participation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the members of our compensation committee has at any time during the prior three years been one of our officers or employees. None
of our executive officers currently serves, or in the past fiscal year has served, as a member of the Board of Directors or compensation
committee of any entity that has one or more executive officers serving on our Board of Directors or compensation committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Code
of Business Conduct and Ethics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a code of business conduct and ethics that applies to all of our employees, officers and directors, including those officers
responsible for financial reporting. Our code of business conduct and ethics is available on our website at www.processapharmaceuticals.com.
We intend to disclose any amendments to the code, or any waivers of its requirements, on our website or in a Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Involvement
in Certain Legal Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, none of our current directors or executive officers has, during the past ten years:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been convicted
    in a criminal proceeding or been subject to a pending criminal proceeding;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">had any bankruptcy petition
    filed by or against the business or property of the person, or of any partnership, corporation or business association of which he
    or she was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that
    time;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been subject to any order,
    judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state
    authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business,
    securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons
    engaged in any such activity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been found by a court of
    competent jurisdiction in a civil action or by the SEC to have violated a federal or state securities or commodities law, and the
    judgment has not been reversed, suspended, or vacated; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been the subject of, or
    a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended
    or vacated, relating to an alleged violation of any federal or state securities or commodities law or regulation or any law or regulation
    respecting financial institutions or insurance companies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth above and in our discussion below in &#8220;<i>Certain Relationships and Related Transactions</i>,&#8221; none of our directors
or executive officers has been involved in any transactions with us or any of our directors, executive officers, affiliates or associates
which are required to be disclosed pursuant to the rules and regulations of the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>








<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_015"></span>Item
11. Executive Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table for 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the compensation awarded to or earned by our Chief Executive Officer and our two other highest paid executive
officers for the years ended December 31, 2024 and 2023. George Ng joined as our CEO and a director on August 8, 2023. Up until that
time, Dr. David Young served as our CEO. Dr. Young, who continues as a director, is now President, Research and Development to focus
on drug development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Name and Principal Position</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(2)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Other Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(3)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 37%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George Ng<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">400,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><sup>(5)</sup></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><sup>(4)</sup></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">21,033</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">521,033</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Executive Officer</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">159,091</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">312,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">471,091</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">David Young</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">290,940</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(6)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,484</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">305,424</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">President, Research and Development and former Chief Executive Officer</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">160,200</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26,433</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">186,633</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Sian Bigora</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">290,940</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(7)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,484</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22,827</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">328,251</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Development and Regulatory Officer</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">160,200</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">136,837</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">24,665</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">321,702</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Ng joined the Company on August 8, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    the aggregate grant date fair value of RSUs granted calculated in accordance with FASB ASC Topic 718. Assumptions applicable to these
    valuations and other information can be found in Note 3 of the Notes to Consolidated Financial Statements &#8212; Stock-Based Compensation
    contained in the Processa Pharmaceuticals, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and Annual
    Report on Form 10-K for the year ended December 31, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    reflect the dollar value of group health insurance premiums for the named executive officer.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$100,000
    discretionary bonus received during the year ended December 31, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes$16,259
    of salary that was voluntarily deferred by the executive.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    $181,733 of salary that was voluntarily deferred by the executive.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    $11,664 of salary that was voluntarily deferred by the executive.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
to the Summary Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Overview
of Our Executive Compensation Philosophy and Design</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that a skilled, experienced and dedicated executive and senior management team is essential to the future performance of our
Company and to building stockholder value. We have sought to establish competitive compensation programs that enable us to attract and
retain executive officers with these qualities. The other objectives of our compensation programs for our executive officers are the
following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    motivate our executive officers to achieve strong financial performance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    attract and retain executive officers who we believe have the experience, temperament, talents and convictions to contribute significantly
    to our future success; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    align the economic interests of our executive officers with the interests of our stockholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive compensation philosophy in 2023 and 2024 centered on providing the majority of each executive officers compensation in common
stock. This allowed us to conserve our cash and utilize it in our clinical and other operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Setting
Executive Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee has primary responsibility for, among other things, determining our compensation philosophy, evaluating the performance
of our named executive officers, setting the compensation and other benefits of our named executive officers and administering our equity
compensation plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is our CEO&#8217;s responsibility to provide recommendations to the compensation committee for most compensation matters related to executive
compensation. The recommendations are based on a general analysis of market standards and trends and an evaluation of the contribution
of each executive officer to our performance. Our compensation committee considers, but retains the right to accept, reject or modify
such recommendations and has the right to obtain independent compensation advice. Neither the CEO nor any other members of management
is present during executive sessions of the compensation committee. The CEO is not present when decisions with respect to his compensation
are made. Our Board of Directors appoints the members of our compensation committee and delegates to the compensation committee the direct
responsibility for overseeing the design and administration of our executive compensation program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not historically utilized a compensation consultant to set the compensation of our named executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Elements
of Executive Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the most effective compensation package for our named executive officers is one designed to reward achievement of individual
and corporate objectives; provide for short-, medium- and long-term financial and strategic goals; and align the interest of management
with those of the stockholders by providing incentives for improving stockholder value. To accomplish that objective, our named executive
officers have, and it is anticipated will continue to receive a significant portion of their annual compensation in the form of RSUs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Base
Compensation &#8211; </i>We pay our named executive officers base compensation to compensate them for services rendered and to provide
them with a steady source of income for living expenses throughout the year. In 2024, our named executive officers received base salaries
ranging between $298,000 and $400,000, depending on their position and responsibilities. With the exception of Mr. Ng, our named executive
officers received $290,940 in cash and the remainder was paid in salary shortfall RSUs that cliff vested on January 1, 2025. During 2024,
the named executive officers voluntarily deferred a portion of their base salary for the benefit of the Company: Mr. Ng deferred $16,259,
Dr. Young deferred $181,733 and Dr. Bigora deferred $11,644.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
2023, with the exception of Mr. Ng, our named executive officers received base compensation ranging between $160,200 to $244,000, depending
on their position and responsibilities. These two named executive officers received $160,200 in cash and with the remainder paid in salary
shortfall RSUs that cliff vested on January 1, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
to base salaries are expected to be determined annually and may be increased based on the executive officer&#8217;s success in meeting
or exceeding individual objectives, as well as to maintain market competitiveness. Additionally, base salaries can be adjusted as warranted
throughout the year to reflect promotions or other changes in the scope of breadth of an executive officer&#8217;s role or responsibilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bonuses
&#8211; </i>During 2024, Mr. Ng received $100,000 in bonus compensation for meeting the following conditions: (i) $50,000 was earned
on February 2, 2024 when the Company&#8217;s closing stock price was about $1.00 per share for at least ten consecutive trading days,
thus regaining Nasdaq compliance; and (ii) $50,000 was earned on October 2, 2024 upon enrolling the first patient in the Phase 2 trial
of NGC-Cap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
Awards &#8211; </i>In addition to the salary shortfall RSUs awarded to our named executive officer&#8217;s for the difference between
their base compensation and cash compensation paid, we have used equity awards to align the interest of our named executive officers
with those of our stockholders, as the value of the awards granted thereunder is linked to the value of our common stock, which, in turn,
is indirectly attributable to the performance of our executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have traditionally made an annual equity grant to our employees, which include our named executive officers. In 2024, with the exception
of Mr. Ng, we granted RSUs other than the salary shortfall RSUs for 6,466 shares of our common stock to our named executive officers
totalling a grant date fair value of approximately $14,000, which vest accordingly: RSUs for 4,850 shares of our common stock vest over
a three-year period upon meeting service requirements; RSUs for 808 shares of our common stock vested upon grant for regaining Nasdaq
compliance; and RSUs for 808 shares of common stock vested upon dosing the first patient in our Phase 2 study in NGC-Cap, which occurred
on October 2, 2024. In 2023, we granted RSUs other than the salary shortfall RSUs for 3,627 shares of our common stock to our named executive
officers totalling a grant date fair value of $80,000, which vest over the subsequent three years from the grant date. Upon joining the
Company, we granted Mr. Ng 40,000 RSUs, as described below, with a grant date fair value of $312,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure compensation expense for RSUs in accordance with ASC 718, <i>Compensation&#8212;Stock Compensation</i>. Stock-based compensation
is measured at fair value on grant date and recognized as compensation expense over the requisite service period. For awards with only
service-based vesting conditions, we record their fair value as compensation cost using the straight-line method over the service period.
For awards that contain performance vesting conditions, we do not recognize the fair value of the awards as compensation expense until
achieving the performance condition is considered probable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Retirement
and Other Benefits &#8211; </i>We maintain a defined contribution employee retirement plan for our employees, including our named executive
officers. The plan is intended to qualify as a tax-qualified 401(k) plan so that contributions to the 401(k) plan, and income earned
on such contributions, are not taxable to participants until withdrawn or distributed from the 401(k) plan (except in the case of contributions
under the 401(k) plan designated as Roth contributions). Under the 401(k) plan, each employee is fully vested in his or her deferred
salary contributions. Employee contributions are held and invested by the plan&#8217;s trustee as directed by participants. The 401(k)
plan provides us with the discretion to match employee contributions. We currently do not match employee contributions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>George
Ng Employment Agreement</i>. On March 19, 2025, we entered into an amended employment agreement with Mr. Ng that continues
until terminated or modified pursuant to the terms of the employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Ng&#8217;s employment agreement entitled him to, among other benefits, the following compensation: (i) an annual base salary of at least
$400,000, reviewed annually after December 31, 2024; (ii) RSUs previously granted under our 2019 Omnibus Incentive Plan along with additional grants made at the discretion
of the Compensation Committee of the Board; and (iii) participation in welfare
benefit plans, practices, policies and programs (including, without limitation, medical, prescription, dental, disability, employee life,
group life, accidental death and travel accident insurance plans and programs) made available to other executive officers of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Russell
Skibsted Employment Agreement. </i>On March 19, 2025, we entered into an amended employment agreement with Mr. Skibsted that
continues until terminated or modified pursuant to the terms of the employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Skibsted&#8217;s employment agreement entitled him to, among other benefits, the following compensation: (i) an annual base salary
of $400,000; (ii) a $50,000 base salary increase upon a cumulative (one or multiple) financing of at least $15 million that he leads
and substantially participates in; (iii) RSUs previously granted under our 2019 Omnibus Incentive Plan along with additional grants
made at the discretion of the Compensation Committee of the Board; and (iv) participation in welfare benefit plans, practices,
policies and programs (including, without limitation, medical, prescription, dental, disability, employee life, group life,
accidental death and travel accident insurance plans and programs) made available to other executive officers of the Company. He is
also eligible to participate in an executive bonus pool with a target bonus of 40% of his base compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sian
Bigora Employment Agreement.</i></span> On March 19, 2025, we entered into an employment agreement with Dr. Bigora that continues until terminated or
modified pursuant to the terms of the employment agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">Dr. Bigora&#8217;s employment agreement entitled her to, among other benefits, the following compensation: (i) an
annual base salary of $387,920; (ii) RSUs previously granted under our 2019 Omnibus Incentive Plan along with additional grants made at
the discretion of the Compensation Committee of the Board; and (iii) participation in welfare benefit plans, practices, policies and programs
(including, without limitation, medical, prescription, dental, disability, employee life, group life, accidental death and travel accident
insurance plans and programs) made available to other executive officers of the Company. She is also eligible to participate in an executive
bonus pool with a target bonus of 40% of her base compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Wendy
Guy Employment Agreement.</i></span> On March 19, 2025, we entered into an employment agreement with Ms. Guy that continues until terminated or modified
pursuant to the terms of the employment agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">Ms. Guy&#8217;s employment
agreement entitled her to, among other benefits, the following compensation: (i) an annual base salary of $325,520; (ii) RSUs previously
granted under our 2019 Omnibus Incentive Plan along with additional grants made at the discretion of the Compensation Committee of the
Board; and (iii) participation in welfare benefit plans, practices, policies and programs (including, without limitation, medical, prescription,
dental, disability, employee life, group life, accidental death and travel accident insurance plans and programs) made available to other
executive officers of the Company. She is also eligible to participate in an executive bonus pool with a target bonus of 30% of her base
compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patrick
Lin Employment Agreement.</i></span> On March 19, 2025, we entered into an employment agreement with Mr. Lin that continues until terminated or modified
pursuant to the terms of the employment agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">Mr. Lin&#8217;s employment
agreement entitled her to, among other benefits, the following compensation: (i) an annual base salary of $325,520; (ii) RSUs previously
granted under our 2019 Omnibus Incentive Plan along with additional grants made at the discretion of the Compensation Committee of the
Board; and (iii) participation in welfare benefit plans, practices, policies and programs (including, without limitation, medical, prescription,
dental, disability, employee life, group life, accidental death and travel accident insurance plans and programs) made available to other
executive officers of the Company. He is also eligible to participate in an executive bonus pool with a target bonus of 30% of his base
compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>David
Young Employment Agreement.</i></span> On March 19, 2025, we entered into an employment agreement with Dr. Young that continues until terminated or
modified pursuant to the terms of the employment agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">Dr. Young&#8217;s employment agreement entitled her to, among other benefits, the following compensation: (i) an
annual base salary of $387,920; (ii) RSUs previously granted under our 2019 Omnibus Incentive Plan along with additional grants made at
the discretion of the Compensation Committee of the Board; and (iii) participation in welfare benefit plans, practices, policies and programs
(including, without limitation, medical, prescription, dental, disability, employee life, group life, accidental death and travel accident
insurance plans and programs) made available to other executive officers of the Company. He is also eligible to participate in an executive
bonus pool with a target bonus of 40% of his base compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Potential
Payments Upon Termination or Change in Control</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
executive employment agreements provide that either party may terminate the agreement at-will, and regardless of the manner in which
such executive&#8217;s service terminates, the executive is entitled to receive amounts earned during his or her term of service,
including salary and other benefits. In addition, the agreement provides that in the event of the executive&#8217;s termination for
good reason or if Processa exercises its right to terminate the executive, the executive will be eligible to receive the following
severance benefits: (i) an amount equal to one-year&#8217;s annual base salary; (ii) 12 months of continued health coverage; and
(iii) the vesting in full of all RSUs or other equity awards then outstanding and subject to time-based vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following definition is contained in the employment agreements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;termination
    for cause&#8221; means a termination of the executive&#8217;s employment by Processa due to (i) refusal or inability of executive
    to perform or observe any of the material duties, responsibilities or obligations set forth in the employment agreement following
    the Company giving written notice that the specified conduct has occurred and the executive fails to cure the conduct within thirty
    (30) days after receipt of such notice; (ii) any act of the executive involving fraud, theft, misappropriation of funds, or embezzlement;
    (iii) the executive&#8217;s commission of, or being charged with, a felony and/or convicted of any felony or misdemeanor involving
    dishonesty, violence or moral turpitude, or which in the reasonable judgment of the Company, reflects materially and adversely on
    the reputation of the Company; (iv) failure to comply with any of the Company&#8217;s policies, including but not limited to by engaging
    in the illegal use of controlled substances, the knowing abuse of prescribed medications, or the misuse of alcohol; or (v) breach
    of fiduciary duty.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
severance benefits payable to the executive under the employment agreement are subject to the executive signing, not revoking and complying
with a release of claims in favor of Processa.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee
Non-Competition, Non-Solicitation, Invention and Non-Disclosure Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our named executive officers has entered into standard form agreements with respect to non-competition, non-solicitation, invention
and non-disclosure. Under these agreements, each of our named executive officers has agreed not to compete with us during his or her
employment and for a period of one year after the termination of his or her employment, not to solicit our employees, consultants, customers,
business or prospective customers during his or her employment and for a period of one year after the termination of his or her employment,
and to protect our confidential and proprietary information indefinitely. In addition, under these agreements, each named executive officer
has agreed that we own all inventions that are developed by such named executive officer during his or her employment with us that (i)
are related to our business or our customers or suppliers or any of our products or services being researched, developed, manufactured
or sold by us or which may be used with such products or services; (ii) result from tasks assigned to the executive officer by us; or
(iii) result from the use of our premises or personal property (whether tangible or intangible) owned, leased or contracted for by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Processa
Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain an Omnibus Plan that currently provides us with the authority to issue up to 800,000 shares of our common stock to eligible
participants. The two complementary goals of the Omnibus Plan are to attract and retain outstanding individuals to serve as our officers,
directors, employees and consultants, and to increase stockholder value by providing participants incentives to increase stockholder
value by offering the opportunity to acquire shares of our common stock, receive monetary payments based on the value of our common stock
and receive other incentive compensation on the potentially favorable terms that the Plan provides. The following is a summary of the
material provisions of the Omnibus Plan:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administration.
</i>The Omnibus Plan is administered by our Board of Directors, the compensation committee of the Board of Directors, any other committee
of the Board, any subcommittee of the compensation committee or one or more of our officers to whom the Board or compensation committee
has delegated authority, which are collectively referred to as the &#8220;Administrator.&#8221; The Administrator has the authority to
interpret the Omnibus Plan or award agreements entered into with respect to the Omnibus Plan; make, change, and rescind rules and regulations
relating to the Omnibus Plan; make changes to, or reconcile any inconsistency in, the Omnibus Plan or any award or agreement covering
an award; and take any other action needed to administer the Omnibus Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eligibility;
Participant Award Limits</i>. The Administrator may designate any of the following as a participant under the Omnibus Plan: any officer
or employee, or individuals engaged to become an officer or employee, of our company or our affiliates; consultants of our company or
our affiliates; and our directors, including our non-employee directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Types
of Awards. </i>The Omnibus Plan permits the Administrator to grant stock options, stock appreciation rights (SARs), performance units,
shares of common stock, restricted stock, restricted stock units, cash incentive awards, dividend equivalent units, or any other type
of award permitted under the Omnibus Plan. The Administrator may grant any type of award to any participant it selects, but only our
employees or our subsidiaries&#8217; employees may receive grants of incentive stock options within the meaning of Section 422 of the
Code. Awards may be granted alone or in addition to, in tandem with, or (subject to the repricing prohibition described below) in substitution
for any other award (or any other award granted under another plan of our company or any affiliate, including the plan of an acquired
entity).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shares
Reserved under the Omnibus Plan. </i>We have reserved an aggregate of 800,000 shares of our common stock available for issuance under
the Omnibus Plan. We may issue all reserved shares pursuant to the exercise of incentive stock options. The number of shares reserved
for issuance under the Omnibus Plan will be reduced on the date of the grant of any award by the maximum number of shares, if any, that
may become payable with respect to which such award is granted. However, an award that may be settled solely in cash will not deplete
the Omnibus Plan&#8217;s share reserve at the time the award is granted. If (a) an award lapses, expires, is canceled, or terminates
without issuance of shares or is settled in cash, (b) the Administrator determines that the shares granted under an award will not be
issuable because the conditions for issuance will not be satisfied, (c) shares are forfeited under an award, or (d) shares are issued
under any award and we reacquire them pursuant to our reserved rights upon the issuance of the shares, then those shares are added back
to the reserve and may again be used for new awards under the Omnibus Plan. Shares that are tendered or withheld in payment of the exercise
price of a stock option or as a result of the net settlement of an outstanding SAR, shares we purchase using proceeds from stock option
exercises and shares tendered or withheld to satisfy any federal, state, or local tax withholding obligations may not be made available
for re-issuance under the Omnibus Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transferability.
</i>Awards are not transferable other than by will or the laws of descent and distribution, unless the Administrator allows a participant
to (i) designate in writing a beneficiary to exercise the award or receive payment under the award after the participant&#8217;s death,
(ii) transfer an award to a former spouse as required by a domestic relations order incident to a divorce, or (iii) otherwise transfer
an award without receiving any consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Adjustments.
</i>If (i) we are involved in a merger or other transaction in which our shares of common stock are changed or exchanged; (ii) we subdivide
or combine shares of common stock or declare a dividend payable in shares of common stock, other securities, or other property (other
than stock purchase rights issued pursuant to a stockholder rights agreement); (iii) we effect a cash dividend that exceeds 10% of the
fair market value of a share of common stock or any other dividend or distribution in the form of cash or a repurchase of shares of common
stock that our Board determines is special or extraordinary, or that is in connection with a recapitalization or reorganization; or (iv)
any other event occurs that in the Administrator&#8217;s judgment requires an adjustment to prevent dilution or enlargement of the benefits
intended to be made available under the Omnibus Plan, then the Administrator will, in a manner it deems equitable, adjust any or all
of (A) the number and type of shares subject to the Omnibus Plan and which may, after the event, be made the subject of awards; (B) the
number and type of shares of common stock subject to outstanding awards; (C) the grant, purchase, or exercise price with respect to any
award; and (D) the performance goals of an award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any such case, the Administrator may also provide for a cash payment to the holder of an outstanding award in exchange for the cancellation
of all or a portion of the award, subject to the terms of the Omnibus Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may, in connection with any merger, consolidation, acquisition of property or stock, or reorganization, authorize the issuance
or assumption of awards upon terms and conditions we deem appropriate without affecting the number of shares of common stock otherwise
reserved or available under the Omnibus Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change
of Control</i>. To the extent a participant has an employment, retention, change of control, severance, or similar agreement with us
or any of our affiliates that discusses the effect of a change of control (as defined in the Omnibus Plan) on the participant&#8217;s
awards, such agreement will control. Otherwise, unless otherwise provided in an award agreement or by the Administrator prior to the
change of control, in the event of a change of control, if the purchaser, successor or surviving entity (or parent thereof) (the &#8220;Successor&#8221;)
agrees, then some or all outstanding awards will be assumed or replaced with the same type of award with similar terms and conditions.
If applicable, each award that is assumed must be appropriately adjusted, immediately after such change of control, to apply to the number
and class of securities that would have been issuable to a participant upon the consummation of such change of control had the award
been exercised, vested, or earned immediately prior to such change of control, and other appropriate adjustment to the terms and conditions
of the award may be made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a participant is terminated from employment without cause (as defined in the Omnibus Plan) or the participant resigns employment for
good reason (as defined in the Omnibus Plan) within 24 months following the change of control, then upon such termination, all of the
participant&#8217;s awards in effect on the date of such termination will vest in full or be deemed earned in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Term
of Omnibus Plan. </i>Unless earlier terminated by our Board of Directors, the Omnibus Plan will remain in effect until the date all shares
reserved for issuance have been issued, except that no incentive stock options may be issued if the term of the Omnibus Plan extends
beyond 10 years from the effective date without stockholder approval of such extension.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table lists the outstanding equity awards held by each of our named executive officers as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Stock Option Awards</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Restricted Stock Units</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Name</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Grant Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Securities Underlying Unexercised Options (#) Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Securities Underlying Unexercised Options (#) Unexercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Option Exercise Price ($)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares of Stock (#) Not Vested<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market Value of Shares Not Vested ($)<sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: left">George Ng</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/08/23</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">31,109</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">27,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">David Young</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">06/28/24</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(3)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,233</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,858</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">06/28/24</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(3)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,425</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,144</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">01/01/23</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(4)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">801</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">708</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">07/01/21</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(5)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">215</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">190</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Sian Bigora</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">06/28/24</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(3)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,233</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,858</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">06/28/24</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(3)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,425</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,144</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">01/01/23</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(4)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,616</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,429</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">07/01/21</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(5)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">215</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">190</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Not included in the above table are RSUs representing 47,844 shares of our common stock that have vested but have not met the distribution
requirements as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Market value is based on $0.88 per share, which was the closing market price of our common stock on December 31, 2024, the last trading
day of the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Stock awards in the form of RSUs for 6,466 shares of our common stock granted to each of Dr. Young and Dr. Bigora on June 28, 2024 contained
either service or performance vesting conditions and must meet distribution requirements before any shares of common stock will be issued.
These stock awards had the following vesting conditions: (i) RSUs representing 3,233 shares of our common stock vest on January 1, 2025;
(ii) RSUs representing 2,425 shares of our common stock vest one-third on January 1, 2025, and the remaining vest monthly afterward;
(iii) RSUs representing 404 shares of our common stock vested upon grant for regaining Nasdaq&#8217;s minimum price requirement; and
(iv) RSUs representing 404 shares of our common stock vested when we dosed the first patient in the Phase 2 trial of NGC-Cap, which occurred
on October 2, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
On January 1, 2023, stock awards in the form of RSUs were granted to Dr. Young and Dr. Bigora. One-third of these stock awards vested
on January 1, 2024 and the remaining vest annually on January 1, 2025 and 2026.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Stock awards in the form of RSUs for 215 shares of our common stock granted to each of Dr. Young and Dr. Bigora on July 1, 2021 vest
when we cumulatively raise at least $30 million.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Director
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 3, 2024, our compensation committee recommended, and our Board of Directors approved, an amendment to our compensation plan
for non-employee directors effective July 1, 2024. Each non-employee director will receive annual compensation for serving as a director
totaling $100,000, consisting of an annual cash retainer of $56,000, payable in quarterly installments and an annual RSU award representing
31,206 shares of our common stock equal to $44,000 total value, which was based on the closing price of our common stock on the date
of award. These RSUs vest on the earlier of June 28, 2025 or the date of our 2025 annual meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors are also reimbursed for any reasonable out-of-pocket expenses incurred in connection with service as a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below shows all compensation paid or earned to our non-employee directors during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Name</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fees Earned or Paid in <br/> Cash ($)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Awards($)<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Total ($)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Khoso Baluch</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">49,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">44,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">93,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Jim Neal</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">44,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">93,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Geraldine Pannu</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">44,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">93,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Justin Yorke</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">44,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">93,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    the aggregate grant date fair value of RSUs granted in 2024 calculated in accordance with FASB ASC Topic 718.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table lists the outstanding equity awards held by each of our directors as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Option Awards</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    Stock Units</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    Date</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Securities Underlying Unexercised Options (#) Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Securities Underlying Unexercised Options (#) Unexercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    Exercise Price ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares of Stock (#) Not Vested<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    Value of Shares Not Vested ($)<sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Khoso
    Baluch</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/03/24<sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,206</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,586</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Neal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/03/24<sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,206</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,586</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geraldine
    Pannu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/03/24<sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,206</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,586</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin
    Yorke</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/03/24<sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,206</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,586</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Not included in the above table for each of our non-employee directors are RSUs representing 5,069 shares of our common stock that have
vested but have not met the distribution requirements as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Market value is based on $0.88 per share, which was the closing market price of our common stock on December 31, 2024, the last trading
day of the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
On September 3, 2024, RSU awards were granted to each director. These RSU awards vest on the earlier of June 28, 2025 or the next annual
shareholder meeting. These RSUs also have distribution requirements, such that they will be distributed on the earlier of: the end of
their appointment or reappointment as a director; the third anniversary of the grant date; a change of control; or their death.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 95; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_016"></span>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BENEFICIAL
OWNERSHIP OF COMMON STOCK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information with respect to the beneficial ownership of our common stock at March 12, 2025 for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    of our directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    of our named executive officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of our current directors and executive officers as a group; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    person, or group of affiliated persons, who beneficially owned more than 5% of our common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock beneficially owned by each entity, person, director or executive officer is determined in accordance
with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such
rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well
as any shares that the individual has the right to acquire within 60 days of March 12, 2025, through the exercise of any stock option,
warrants or other rights. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the
table have sole voting and investment power with respect to all shares of common stock held by that person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
percentage of shares beneficially owned is computed on the basis of 5,269,240 shares of our common stock outstanding as of March 12, 2025.
Shares of our common stock that a person has the right to acquire within 60 days of March 12, 2025, are deemed outstanding for purposes
of computing the percentage ownership of the person holding such rights but are not deemed outstanding for purposes of computing the
percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as
a group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Shares beneficially owned</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Percent</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name and address of beneficial owner <sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Officers and Directors</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sian Bigora <sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">54,141</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wendy Guy <sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">43,086</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick Lin <sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">160,703</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George Ng <sup>(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">259,671</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Russell Skibsted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Young <sup>(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">475,666</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Khoso Baluch <sup>(7)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,467</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Neal <sup>(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,790</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geraldine Pannu <sup>(9)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,951</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin Yorke <sup>(10)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">71,038</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.3</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total for all Officers and Directors</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,084,513</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
represents less than 1%</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Unless otherwise indicated, the address for each beneficial owner listed is c/o Processa Pharmaceuticals, Inc., 7380 Coca Cola Drive,
Suite 106, Hanover, Maryland 21076.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Consists of (i) 21,878 shares of common stock held directly by Dr. Bigora; (ii) 6,668 shares held by CorLyst; and (iii) restricted stock
units representing 25,595 shares of common stock issuable within 60 days of March 12, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Consists of (i) 11,857 shares of common stock held directly by Ms. Guy; (ii) 8,335 shares held by CorLyst; and (iii) restricted stock
units representing 22,894 shares of common stock issuable within 60 days of March 12, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Consists of (i) 29,059 shares of common stock held directly by Mr. Lin; (ii) 43,500 shares and warrants to purchase 65,250 shares of
common stock held by Lin Family Trust Feb 4, 2024, of which Mr. Lin is a trustee and has investment and disposition power over the shares
and warrants; and (iii) restricted stock units representing 22,894 shares of common stock issuable within 60 days of March 12, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Consists of (i) 20,000 shares of common stock held by Ng Cha Family Trust, of which Mr. Ng is a trustee and has investment and disposition
power over the shares of common stock; (ii) 87,200 shares of common stock and warrants to purchase 130,800 shares of common stock held
by George Ng IRRA FOB George Ng, of which Mr. Ng is a beneficiary and has investment and disposition power over the shares and warrants;
and (iii) restricted stock units representing 21,671 shares of common stock issuable within 60 days of March 12, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
Consists of (i) 205,405 shares of common stock held directly by Dr. Young; (ii) warrants to purchase 186,750 shares of common stock;
(iii) 18,851 shares held by family entities; (iv) 41,464 shares held by CorLyst, LLC (&#8220;CorLyst&#8221;) (22,920 shares held on behalf
of entities controlled by Dr. Young and 18,544 shares held on behalf of other stockholders); and (v) restricted stock units for 23,196
shares of our common stock issuable within 60 days of March 12, 2025. Dr. Young is the Chief Executive Officer and Managing Member of
CorLyst. Dr. Young disclaims beneficial ownership of a portion of CorLyst shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
Consists of (i) 1,398 shares of common stock held directly by Mr. Baluch and (ii) restricted stock units representing 5,069 shares of
common stock issuable within 60 days of March 12, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
Consists of (i) 721 shares of common stock held directly by Mr. Neal and (ii) restricted stock units representing 5,069 shares of common
stock issuable within 60 days of March 12, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
Consists of (i) 2,882 shares of common stock held directly by Ms. Pannu and (ii) restricted stock units representing 5,069 shares of
common stock issuable within 60 days of March 12, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)
Justin Yorke is a manager of the Richland Fund, LLC. The shares of common stock reported for Mr. Yorke include (i) 3,737 shares of common
stock held directly by Mr. Yorke; (ii) 12,400 shares and warrants to purchase 18,600 shares of common stock held by Directed Trust Company
FBO Justin Yorke IRA, of which Mr. Yorke is a beneficiary and has investment and disposition power over the shares and warrants; (iii)
restricted stock units representing 5,069 shares of common stock issuable within 60 days of March 12, 2025; and (iv) the shares held by
the Richland Fund, LLC which total 31,232 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Delinquent
Section 16(a) Reports</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires our executive officers, directors, and persons who beneficially own more than ten percent of our common
stock to file reports of their beneficial ownership and changes in ownership (Forms 3, 4, and 5, and any amendment thereto) with the
SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
solely on our review of the copies of such forms furnished to us and written representations from the directors and executive officers,
we believe that all Section 16(a) filing requirements were timely met in fiscal year 2024, except three late Forms 4 were filed on April
12, 2024 and August 2, 2024 for each of Sian Bigora, Wendy Guy, Patrick Lin, and David Young.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Options: NewSection; Value: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_017"></span>Item
13. Certain Relationships and Related Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Related
Person Policy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee has adopted written policies and procedures for the committee to review and approve, or ratify related party transactions.
These transactions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transactions
    that must be disclosed in proxy statements under SEC rules, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transactions
    that potentially could cause a non-employee director to cease to qualify as an independent director under Nasdaq Stock Market listing
    requirements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
that are deemed immaterial under applicable disclosure requirements are generally deemed pre-approved under these written policies and
procedures, including transactions with an entity with which a director&#8217;s sole relationship is as a non-employee director and the
total amount involved does not exceed 1% of the entity&#8217;s total annual revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Criteria
for committee approval or ratification of a related party transaction, in addition to factors that the committee otherwise deems appropriate
under the circumstances, include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    terms of the transaction are no less favorable than terms generally available from an unaffiliated third party, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the case of a non-employee director, whether the transaction would disqualify the director from (1) being independent under Nasdaq
    Stock Market listing requirements, or (2) from serving on the audit committee, compensation committee or nominating and governance
    committee under Nasdaq Stock Market and other regulatory requirements. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the exception of the transactions set forth below, we were not a party to any transaction (in which the amount involved exceeded the
lesser of $120,000 or one percent of the average of our assets for the last two fiscal years) in which a director, executive officer,
holder of more than five percent of our common stock, or any member of the immediate family of any such person has or will have a direct
or indirect material interest and no such transactions are currently proposed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CorLyst,
LLC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CorLyst,
LLC (&#8220;CorLyst&#8221;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred,
which are recognized as a reduction of our general and administrative operating expenses in our consolidated statement of operations.
We recorded approximately $110,000 and $112,000 in reimbursements during the years ended December 31, 2024 and 2023, respectively. At
December 31, 2024, $47 was due from CorLyst and no amounts were due at December 31, 2023. Our President, Research and Development is
the CEO of CorLyst, and CorLyst is a shareholder. Dr. Young spends a nominal amount of effort related to CorLyst activities. As of March
12, 2025, CorLyst beneficially owns 56,467 shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_018"></span>Item
14. Principal Accounting Fees and Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
and Non-Audit Fees Billed to the Company by Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the aggregate fees billed to Processa for the years ended December 31, 2024 and 2023 by Cherry Bekaert, LLP,
our auditors as of October 31, 2024; and BD &amp; Company, Inc., our auditors from January 1, 2023 to October 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Service Type</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Audit Fees</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">128,750</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;<sup>(1)</sup></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">94,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Audit-Related Fees</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax Fees</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">All Other Fees</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">42,461</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,657</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">171,211</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">95,657</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Fees</i>. These fees were for professional services rendered for 2024 and 2023 in connection with the audit of our annual financial statements
on Form 10-K and review of the financial statements included in our Quarterly Reports on Form 10-Q. The amounts also include fees for
services that are normally provided by Cherry Bekaert, LLP and BD &amp; Company, Inc. in connection with statutory and regulatory filings
and engagements for the years identified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>All
Other Fees.</i> These fees were primarily for services related to our Registration Statements and related comfort letters in 2024 and
2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    fees incurred in 2024 were billed accordingly: $39,500 by BD &amp; Company, Inc. and $89,250 by Cherry Bekaert, LLP.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Value: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Audit
Committee Policies and Procedures for Pre-Approval of Independent Auditor Services</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following describes the Audit Committee&#8217;s policies and procedures regarding pre-approval of the engagement of the Company&#8217;s
independent auditor to perform audit as well as permissible non-audit services for the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
audit services and audit-related fees, the independent auditor will provide the Committee with an engagement letter during the first
quarter of each year outlining the scope of the audit services proposed to be performed in connection with the audit of the current fiscal
year. If agreed to by the Committee, the engagement letter will be formally accepted by the Committee at an Audit Committee meeting held
as soon as practicable following receipt of the engagement letter. The independent auditor will submit to the Committee for approval
an audit services fee proposal after acceptance of the engagement letter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
non-audit services and other fees, Company management may submit to the Committee for approval (during May through September of each
fiscal year) the list of non-audit services that it recommends the Committee engage the independent auditor to provide for the fiscal
year. The list of services must be detailed as to the particular service and may not call for broad categorical approvals. Company management
and the independent auditor will each confirm to the Audit Committee that each non-audit service on the list is permissible under all
applicable legal requirements. In addition to the list of planned non-audit services, a budget estimating non-audit service spending
for the fiscal year may be provided. The Committee will consider for approval both the list of permissible non-audit services and the
budget for such services. The Committee will be informed routinely as to the non-audit services actually provided by the independent
auditor pursuant to this pre-approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure prompt handling of unexpected matters, the Audit Committee delegates to its Chairman the authority to amend or modify the list
of approved permissible non-audit services and fees. The Chairman will report any action taken pursuant to this delegation to the Committee
at its next meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
audit and non-audit services provided to the Company are required to be pre-approved by the Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27pt; background-color: white"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_019"></span>Part
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -49.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_020"></span>Item
15. Exhibits, Financial Statement Schedules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)(1)
and (2) Financial Statements and Schedules:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Part II, Item 8, of this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 99; Value: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3)
Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of the Exhibit</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315224020879/ex1-2.htm" style="-sec-extract: exhibit">Sales
    Agreement, dated May 21, 2024, by and among Processa Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners (incorporated by reference
    to Exhibit 1.2 to Form S-3 filed on May 21, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315220017927/ex3-1.htm" style="-sec-extract: exhibit">Fourth
    Amended and Restated Certificate of Incorporation of Heatwurx, Inc. (incorporated by reference to Exhibit 3.1 to Form S-1 filed on
    September 17, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315220017927/ex3-1_1.htm" style="-sec-extract: exhibit">Amendment
    to Fourth Amended and Restated Certificate of Incorporation of Heatwurx, Inc. (incorporated by reference to Exhibit 3.1.1 to Form
    S-1 filed on September 17, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315219012368/ex3.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to Fourth Amended and Restated Certificate of Incorporation dated August 8, 2019 (incorporated by reference to Exhibit
    3 to Form 10-Q filed on August 14, 2019)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315220017927/ex3-1_4.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to Fourth Amended and Restated Certificate of Incorporation of Processa Pharmaceuticals, Inc. dated June 25, 2020 (incorporated
    by reference to Exhibit 3.1.4 to Form S-1 filed on September 17, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315222000543/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to Fourth Amended and Restated Certificate of Incorporation dated January 1, 2022 (incorporated by reference to Exhibit
    3.1 to Form 8-K filed on January 6, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315223022920/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Processa Pharmaceuticals, Inc. (incorporated by reference
    to Exhibit 3.1 to Form 8-K filed on June 29, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315224002835/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on January 18, 2024)</a></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex3-2.htm">Amended
    and Restated Bylaws of Processa Pharmaceuticals, Inc., dated March 18, 2025</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315220017927/ex4-1.htm" style="-sec-extract: exhibit">Specimen
    of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Form S-1 filed on September 17, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315225004298/ex4-1.htm" style="-sec-extract: exhibit">Form
    of Series A Common Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed January 30, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315225004298/ex4-2.htm" style="-sec-extract: exhibit">Form
    of Series B Common Warrant (incorporated by reference to Exhibit 4.2 to Form 8-K filed January 30, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315225004298/ex4-3.htm" style="-sec-extract: exhibit">Form
    of Pre-Funded Warrant (incorporated by reference to Exhibit 4.3 to Form 8-K filed January 30, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315224011976/ex4-5.htm" style="-sec-extract: exhibit">Description
    of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference
    to Exhibit 4.5 to Form 10-K filed March 29, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315220017927/ex10-1.htm" style="-sec-extract: exhibit">Amended
    and Restated 2011 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to Form S-1 filed on September 17, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315220017927/ex10-2.htm" style="-sec-extract: exhibit">License
    Option Agreement with CoNCERT (incorporated by reference to Exhibit 10.2 to Form S-1 filed on September 17, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315220017927/ex10-3.htm" style="-sec-extract: exhibit">Amendment
    to License Agreement and Securities Purchase Agreement with CoNCERT Pharmaceuticals (incorporated by reference to Exhibit 10.3 to
    Form S-1 filed on September 17, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315220017927/ex10-5.htm" style="-sec-extract: exhibit">Processa
    Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.5 to Form S-1 filed on September 17, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.5+</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315224028733/ex4-1.htm" style="-sec-extract: exhibit">Amended and Restated Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit 4.1 to From S-8 filed on July 22, 2024).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315220017927/ex10-9.htm" style="-sec-extract: exhibit">License
    Agreement with <span style="background-color: white">Aposense, Ltd.</span> dated May 24, 2020 (incorporated by reference to Exhibit
    10.9 to Form S-1 filed on September 17, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315220017927/ex10-11.htm" style="-sec-extract: exhibit">License
    Agreement with Yuhan Corporation (incorporated by reference to Exhibit 10.11 to Form S-1 filed on September 17, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315220017927/ex10-13.htm" style="-sec-extract: exhibit">License
    Agreement with Elion Oncology, Inc. (incorporated by reference to Exhibit 10.13 to Form S-1 filed on September 17, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315221006807/ex10-15.htm" style="-sec-extract: exhibit">Addendum
    No. 1 to the Aposense Ltd. License Agreement (incorporated by reference to Exhibit 10.15 to Form 10-K filed on March 25, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315221014623/ex10-1.htm" style="-sec-extract: exhibit">License
    Agreement with Ocuphire Pharma, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed June 17, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11*+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-11.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement dated March 19, 2025 by and between George Ng and Processa Pharmaceuticals, Inc.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12*+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-12.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement dated March 19, 2025, by and between Russell Skibsted and Processa Pharmaceuticals, Inc.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.13*+</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><a href="ex10-13.htm">Employment Agreement dated <span style="font-family: DengXian; font-size: 10pt">March 19</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, 2025, by and between Sian Bigora and Processa Pharmaceuticals, Inc.</span></a></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.14*+</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-14.htm">Employment Agreement dated March 19, 2025, by and between Wendy Guy and Processa Pharmaceuticals, Inc.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.15*+</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-15.htm">Employment Agreement dated March 19, 2025, by and between Patrick Lin and Processa Pharmaceuticals, Inc.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.16*+</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-16.htm">Employment Agreement dated March 19, 2025, by and between David Young and Processa Pharmaceuticals, Inc.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315225004298/ex10-1.htm" style="-sec-extract: exhibit">Form
    of Securities Purchase Agreement, dated January 27, 2025, by and between Processa Pharmaceuticals, Inc. and each of the Purchasers
    (as defined therein) (incorporated by reference to Exhibit 10.1 to Form 8-K filed January 30, 2025</a>)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315225004298/ex10-2.htm" style="-sec-extract: exhibit">Placement
    Agency Agreement, dated January 27, 2025, by and between Processa Pharmaceueticals, Inc. and A.G.P. (incorporated by reference to
    Exhibit 10.2 to Form 8-K filed January 30, 2025)</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">19*</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex19.htm">Insider Trading Policy</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21-1.htm">List
    of Subsidiaries</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of Independent Registered Public Accounting Firm, BD &amp; Co. Inc.</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-2.htm">Consent of Independent Registered Public Accounting Firm, Cherry Bekaert, LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification
    of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification
    of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification
    of Principal Executive Officer and Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315224011976/ex97-1.htm" style="-sec-extract: exhibit">Processa Pharmaceuticals, Inc. Restatement Clawback Policy (incorporated by reference to Exhibit 97.1 to Form 10-K filed on March 29, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Labels Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management contract or compensatory plan or arrangement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_021"></span>Item
16. Form 10-K Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 100; Value: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gk_022"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROCESSA
    PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    George Ng</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Russell Skibsted</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell
    Skibsted</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Financial Officer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 2.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons in the capacities
and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capacity</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    George Ng</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Russell Skibsted</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell
    Skibsted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David Young</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    of Research and Development and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Young</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Khoso Baluch</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Khoso
    Baluch</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    James Neal</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Neal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Geraldine Pannu</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geraldine
    Pannu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Justin Yorke</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin
    Yorke</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 101; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>ex3-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
3.2</B></FONT></P>

<P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMENDED
AND RESTATED<BR>
BYLAWS<BR>
OF<BR>
PROCESSA PHARMACEUTICALS, INC.<BR>
(THE &ldquo;CORPORATION&rdquo;)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
I<BR>
OFFICES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.1. Registered Office</B>. The registered office of Processa Pharmaceuticals, Inc. (the &ldquo;<B><I>Corporation</I></B>&rdquo;)
within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware
or (b) the office of the Corporation or individual acting as the Corporation&rsquo;s registered agent in Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.2. Additional Offices</B>. The Corporation may, in addition to its registered office in the State of Delaware, have such other offices
and places of business, both within and outside the State of Delaware, as the Board of Directors of the Corporation (the &ldquo;<B><I>Board</I></B>&rdquo;)
may from time to time determine or as the business and affairs of the Corporation may require.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
II<BR>
STOCKHOLDERS MEETINGS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.1. Annual Meetings</B>. The annual meeting of stockholders shall be held at such place, either within or without the State of Delaware,
and time and on such date as shall be determined by the Board and stated in the notice of the meeting, provided that the Board may in
its sole discretion determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication
pursuant to <U>Section 9.5(a)</U>. At each annual meeting, the stockholders entitled to vote on such matters shall elect those directors
of the Corporation to fill any term of a directorship that expires on the date of such annual meeting and may transact any other business
as may properly be brought before the meeting in accordance with these Bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.2. Special Meetings</B>. Subject to the rights of the holders of any outstanding series of the preferred stock of the Corporation
(&ldquo;<B><I>Preferred Stock</I></B>&rdquo;), and to the requirements of applicable law, special meetings of stockholders, for any purpose
or purposes, may be called only by the Chair of the Board, Chief Executive Officer, or the Board pursuant to a resolution adopted by
a majority of the Board, and may not be called by any other person. Special meetings of stockholders shall be held at such place, either
within or without the State of Delaware, and at such time and on such date as shall be determined by the Board and stated in the Corporation&rsquo;s
notice of the meeting, provided that the Board may in its sole discretion determine that the meeting shall not be held at any place,
but may instead be held solely by means of remote communication pursuant to <U>Section 9.5(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.3. Notices</B>. Notice of each stockholders meeting stating the place, if any, date, and time of the meeting, and the means of remote
communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting and the
record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining
stockholders entitled to notice of the meeting, shall be given in the manner permitted by <U>Section 9.3</U> to each stockholder entitled
to vote thereat as of the record date for determining the stockholders entitled to notice of the meeting, by the Corporation not less
than 10 nor more than 60 days before the date of the meeting unless otherwise required by the General Corporation Law of the State of
Delaware (the &ldquo;<B><I>DGCL</I></B>&rdquo;). If said notice is for a stockholder meeting other than an annual meeting, it shall in
addition state the purpose or purposes for which the meeting is called, and the business transacted at such meeting shall be limited
to the matters so stated in the Corporation&rsquo;s notice of meeting (or any supplement thereto). Notices of meetings to stockholders
may be given by mailing the same, addressed to the stockholder entitled thereto, at such stockholder&rsquo;s mailing address as it appears
on the records of the Corporation and such notice shall be deemed to be given when deposited in the U.S. mail, postage prepaid. Without
limiting the manner by which notices of meetings otherwise may be given effectively to stockholders, any such notice may be given by
electronic transmission in accordance with applicable law. Notice of any meeting need not be given to any stockholder who shall, either
before or after the meeting, submit a waiver of notice or who shall attend such meeting, except when the stockholder attends for the
express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully
called or convened. Any stockholder so waiving notice of the meeting shall be bound by the proceedings of the meeting in all respects
as if due notice thereof had been given. Any meeting of stockholders as to which notice has been given may be postponed, and any meeting
of stockholders as to which notice has been given may be cancelled, by the Board upon Public Disclosure (as defined in <U>Section 2.7(a)(ii)</U>)
given before the date previously scheduled for such meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.4. Quorum</B>. Except as otherwise provided by applicable law, the Corporation&rsquo;s Certificate of Incorporation, as the same
may be amended or restated from time to time (the &ldquo;<B><I>Certificate of Incorporation</I></B>&rdquo;) or these Bylaws, the presence,
in person or by proxy, at a stockholders meeting of the holders of shares of outstanding capital stock of the Corporation representing
one third (1/3) of the voting power of all outstanding shares of capital stock of the Corporation entitled to vote at such meeting shall
constitute a quorum for the transaction of business at such meeting, except that when specified business is to be voted on by a class
or series of stock voting as a class, the holders of shares representing one third (1/3) of the voting power of the outstanding shares
of such class or series shall constitute a quorum of such class or series for the transaction of such business. If a quorum shall not
be present or represented by proxy at any meeting of the stockholders of the Corporation, the chair of the meeting may adjourn the meeting
from time to time in the manner provided in <U>Section 2.6</U> until a quorum shall attend. The stockholders present at a duly convened
meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than
a quorum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.5. Voting of Shares.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Voting
Lists</U>. The Secretary of the Corporation (the &ldquo;<B><I>Secretary</I></B>&rdquo;) shall prepare, or shall cause the officer or
agent who has charge of the stock ledger of the Corporation to prepare and make, at least 10 days before every meeting of stockholders,
a complete list of the stockholders of record entitled to vote at such meeting; provided, however, that if the record date for determining
the stockholders entitled to vote is less than 10 days before the meeting date, the list shall reflect the stockholders entitled to vote
as of the 10th day before the meeting date, arranged in alphabetical order and showing the address and the number and class of shares
registered in the name of each stockholder. Nothing contained in this <U>Section 2.5(a)</U> shall require the Corporation to include
electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder,
for any purpose germane to the meeting for a period of at least 10 days prior to the meeting: (i) on a reasonably accessible electronic
network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii) during
ordinary business hours, at the principal place of business of the Corporation. In the event that the Corporation determines to make
the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only
to stockholders of the Corporation. Except as provided by applicable law, the stock ledger shall be the only evidence as to who are the
stockholders entitled to examine the list required by this <U>Section 2.5(a)</U> or to vote in person or by proxy at any meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Manner
of Voting</U>. At any stockholders meeting, every stockholder entitled to vote may vote in person or by proxy. If authorized by the Board,
the voting by stockholders or proxy holders at any meeting conducted by remote communication may be effected by a ballot submitted by
electronic transmission (as defined in <U>Section 9.3(c)</U>), provided that any such electronic transmission must either set forth or
be submitted with information from which the Corporation can determine that the electronic transmission was authorized by the stockholder
or proxy holder. The Board, in its discretion, or the chair of the meeting of stockholders, in such person&rsquo;s discretion, may require
that any votes cast at such meeting shall be cast by written ballot.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Proxies</U>.
Each stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to corporate action in writing without
a meeting may authorize another person or persons to act for such stockholder by proxy, but no such proxy shall be voted or acted upon
after three years from its date, unless the proxy provides for a longer period. Proxies need not be filed with the Secretary until the
meeting is called to order, but shall be filed with the Secretary before being voted or the delivery of a consent action in writing to
the Corporation pursuant to <U>&lrm;Section 2.9</U>. Without limiting the manner in which a stockholder may authorize another person or persons
to act for such stockholder as proxy, either of the following shall constitute a valid means by which a stockholder may grant such authority.
No stockholder shall have cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) A
stockholder may execute a writing authorizing another person or persons to act for such stockholder as proxy. Execution may be accomplished
by the stockholder or such stockholder&rsquo;s authorized officer, director, employee or agent signing such writing or causing such person&rsquo;s
signature to be affixed to such writing by any reasonable means, including, but not limited to, by facsimile signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) A
stockholder may authorize another person or persons to act for such stockholder as proxy by transmitting or authorizing the transmission
of an electronic transmission to the person who will be the holder of the proxy or to a proxy solicitation firm, proxy support service
organization or like agent duly authorized by the person who will be the holder of the proxy to receive such transmission, provided that
any such electronic transmission must either set forth or be submitted with information from which it can be determined that the electronic
transmission was authorized by the stockholder. Any copy, facsimile telecommunication or other reliable reproduction of the writing or
transmission authorizing another person or persons to act as proxy for a stockholder may be substituted or used in lieu of the original
writing or transmission for any and all purposes for which the original writing or transmission could be used; provided that such copy,
facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Required
Vote</U>. Subject to the rights of the holders of one or more series of Preferred Stock, voting separately by class or series, to elect
directors pursuant to the terms of one or more series of Preferred Stock, at all meetings of stockholders at which a quorum is present,
the election of directors shall be determined by a plurality of the votes cast by the stockholders present in person or represented by
proxy at the meeting and entitled to vote thereon. All other matters presented to the stockholders at a meeting at which a quorum is
present shall be determined by the vote of a majority of the votes cast by the stockholders present in person or represented by proxy
at the meeting and entitled to vote thereon, unless the matter is one upon which, by applicable law, the Certificate of Incorporation,
these Bylaws or applicable stock exchange rules, a different vote is required, in which case such provision shall govern and control
the decision of such matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <U>Inspectors
of Election</U>. In advance of any meeting of the stockholders, the Board shall appoint one or more inspectors, who may be employees
of the Corporation, to act at the meeting or any adjournment thereof and to make a written report thereof. The Board may designate one
or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting,
the person presiding at the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before entering upon
the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality
and according to the best of his or her ability. The inspector or inspectors may appoint or retain other persons or entities to assist
the inspector or inspectors in the performance of their duties. In determining the validity and counting of proxies and ballots cast
at any meeting of stockholders, the inspector or inspectors may consider such information as is permitted by applicable law. No person
who is a candidate for office at an election may serve as an inspector at such election. When executing the duties of inspector, the
inspector or inspectors shall: (i) ascertain the number of shares outstanding and the voting power of each; (ii) determine the shares
represented at the meeting and the validity of proxies and ballots; (iii) count all votes and ballots; (iv) determine and retain for
a reasonable period a record of the disposition of any challenges made to any determination by the inspectors; and (v) certify their
determination of the number of shares represented at the meeting and their count of all votes and ballots.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.6. Adjournments</B>. Any meeting of stockholders, annual or special, may be adjourned by the chair of the meeting, from time to
time, whether or not there is a quorum, to reconvene at the same or some other place, if any. Notice need not be given of any such adjourned
meeting if the date, time, and place, if any, thereof, and the means of remote communication, if any, by which stockholders and proxy
holders may be deemed to be present in person and vote at such adjourned meeting are (i) announced at the meeting at which the adjournment
is taken, (ii) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy
holders to participate in the meeting by means of remote communication, or (iii) set forth in the notice of meeting given in accordance
with <U>Section 2.3</U>. At the adjourned meeting, the stockholders, or the holders of any class or series of stock entitled to vote
separately as a class, as the case may be, may transact any business that might have been transacted at the original meeting. If the
adjournment is for more than 30 days, notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at
the meeting. If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board
shall fix a new record date for notice of such adjourned meeting in accordance with <U>Section 9.2</U>, and shall give notice of the
adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of
such adjourned meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.7. Advance Notice of Stockholder Nominations and Proposals.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Annual
Meetings of Stockholders</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) At
a meeting of the stockholders, only such nominations of persons for the election of directors and such other business shall be conducted
as shall have been properly brought before the meeting. To be properly brought before an annual meeting, nominations or such other business
must be: (A) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board or any committee
thereof; (B) otherwise properly brought before the meeting by or at the direction of the Board or any committee thereof; or (C) otherwise
properly brought before an annual meeting by a stockholder who is a stockholder of record of the Corporation at the time such notice
of meeting is delivered, who is entitled to vote at the meeting, and who complies with the notice procedures set forth in this <U>Section
2.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) In
addition, any proposal of business (other than the nomination of persons for election to the Board) must be a proper matter for stockholder
action. For business (including, but not limited to, director nominations) to be properly brought before an annual meeting by a stockholder
pursuant to <U>Section 2.7(a)(i)(D)</U>, the stockholder or stockholders of record intending to propose the business (the &ldquo;<B><I>Proposing
Stockholder</I></B>&rdquo;) must have given timely notice thereof pursuant to this <U>Section 2.7(a)</U>, in writing to the Secretary
even if such matter is already the subject of any notice to the stockholders or Public Disclosure from the Board. To be timely, a Proposing
Stockholder&rsquo;s notice for an annual meeting must be delivered to the Secretary at the principal executive offices of the Corporation:
(x) not later than the close of business on the 90th day, nor earlier than the close of business on the 120th day, in advance of the
anniversary of the previous year&rsquo;s annual meeting if such meeting is to be held on a day which is not more than 30 days in advance
of the anniversary of the previous year&rsquo;s annual meeting or not later than 60 days after the anniversary of the previous year&rsquo;s
annual meeting; and (y) with respect to any other annual meeting of stockholders, including in the event that no annual meeting was held
in the previous year, not earlier than the close of business on the 120th day prior to the annual meeting and not later than the close
of business on the later of: (1) the 90th day prior to the annual meeting and (2) the close of business on the 10th day following the
first date of Public Disclosure of the date of such meeting. In no event shall the Public Disclosure of an adjournment or postponement
of an annual meeting commence a new notice time period (or extend any notice time period). For the purposes of this <U>Section 2.7</U>,
&ldquo;<B><I>Public Disclosure</I></B>&rdquo; shall mean a disclosure made in a press release reported by the Dow Jones News Services,
The Associated Press, or a comparable national news service or in a document filed by the Corporation with the Securities and Exchange
Commission pursuant to Section 13, 14, or 15(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;<B><I>Exchange Act</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Stockholder
Nominations</U>. For the nomination of any person or persons for election to the Board pursuant to <U>Section 2.7(a)(i)(D)</U> or <U>Section
2.7(d)</U>, a Proposing Stockholder&rsquo;s notice to the Secretary shall set forth or include: (i) the name, age, business address,
and residence address of each nominee proposed in such notice; (ii) the principal occupation or employment of each such nominee; (iii)
the class and number of shares of capital stock of the Corporation which are owned of record and beneficially by each such nominee (if
any); (iv) such other information concerning each such nominee as would be required to be disclosed in a proxy statement soliciting proxies
for the election of such nominee as a director in an election contest (even if an election contest is not involved) or that is otherwise
required to be disclosed, under Section 14(a) of the Exchange Act; (v) a written statement executed by each such nominee acknowledging
that such person consents to being named in the Company&rsquo;s proxy statement as a nominee and to serving as a director if elected,
and (vi) as to the Proposing Stockholder: (A) the name and address of the Proposing Stockholder as they appear on the Corporation&rsquo;s
books and of the beneficial owner, if any, on whose behalf the nomination is being made, (B) the class and number of shares of the Corporation
which are owned by the Proposing Stockholder (beneficially and of record) and owned by the beneficial owner, if any, on whose behalf
the nomination is being made, as of the date of the Proposing Stockholder&rsquo;s notice, and a representation that the Proposing Stockholder
will notify the Corporation in writing of the class and number of such shares owned of record and beneficially as of the record date
for the meeting within five business days after the record date for such meeting, (C) a description of any agreement, arrangement, or
understanding with respect to such nomination between or among the Proposing Stockholder or the beneficial owner, if any, on whose behalf
the nomination is being made and any of their affiliates or associates, and any others (including their names) acting in concert with
any of the foregoing, and a representation that the Proposing Stockholder will notify the Corporation in writing of any such agreement,
arrangement, or understanding in effect as of the record date for the meeting within five business days after the record date for such
meeting, (D) a description of any agreement, arrangement, or understanding (including any derivative or short positions, profit interests,
options, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of the Proposing Stockholder&rsquo;s
notice by, or on behalf of, the Proposing Stockholder or the beneficial owner, if any, on whose behalf the nomination is being made and
any of their affiliates or associates, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes
for, or increase or decrease the voting power of such person or any of their affiliates or associates with respect to shares of stock
of the Corporation, and a representation that the Proposing Stockholder will notify the Corporation in writing of any such agreement,
arrangement, or understanding in effect as of the record date for the meeting within five business days after the record date for such
meeting, (E) a representation that the Proposing Stockholder is a holder of record of shares of the Corporation entitled to vote at the
meeting and intends to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice, and (F)
a representation whether the Proposing Stockholder intends to deliver a proxy statement and/or form of proxy to holders of at least the
percentage of the Corporation&rsquo;s outstanding capital stock required to approve the nomination and/or otherwise to solicit proxies
from stockholders in support of the nomination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility
of such proposed nominee to serve as an independent director of the Corporation or that could be material to a reasonable stockholder&rsquo;s
understanding of the independence, or lack thereof, of such nominee. Any such update or supplement shall be delivered to the Secretary
at the Corporation&rsquo;s principal executive offices no later than five business days after the request by the Corporation for subsequent
information has been delivered to the Proposing Stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Other
Stockholder Proposals</U>. For all business other than director nominations, a Proposing Stockholder&rsquo;s notice to the Secretary
shall set forth as to each matter the Proposing Stockholder proposes to bring before the annual meeting: (i) a brief description of the
business desired to be brought before the annual meeting; (ii) the reasons for conducting such business at the annual meeting; (iii)
the text of any proposal or business (including the text of any resolutions proposed for consideration and in the event that such business
includes a proposal to amend these Bylaws, the language of the proposed amendment); (iv) any substantial interest (within the meaning
of Item 5 of Schedule 14A under the Exchange Act) in such business of such stockholder and the beneficial owner (within the meaning of
Section 13(d) of the Exchange Act), if any, on whose behalf the business is being proposed; (v) any other information relating to such
stockholder and beneficial owner, if any, on whose behalf the proposal is being made, required to be disclosed in a proxy statement or
other filings required to be made in connection with solicitations of proxies for the proposal and pursuant to and in accordance with
Section 14(a) of the Exchange Act and the rules and regulations promulgated thereunder; (vi) a description of all agreements, arrangements,
or understandings between or among such stockholder, the beneficial owner, if any, on whose behalf the proposal is being made, any of
their affiliates or associates, and any other person or persons (including their names) in connection with the proposal of such business
and any material interest of such stockholder, beneficial owner, or any of their affiliates or associates, in such business, including
any anticipated benefit therefrom to such stockholder, beneficial owner, or their affiliates or associates; and (vii) the information
required by <U>Section 2.7(b)(vi)</U> above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Special
Meetings of Stockholders</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Only
such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation&rsquo;s
notice of meeting. Nominations of persons for election to the Board may be made at a special meeting of stockholders called by the Board
at which directors are to be elected pursuant to the Corporation&rsquo;s notice of meeting: (i) by or at the direction of the Board or
any committee thereof, or (ii) provided that the Board has determined that directors shall be elected at such meeting, by any stockholder
of the Corporation who is a stockholder of record at the time the notice provided for in this <U>Section 2.7(d)</U> is delivered to the
Secretary, who is entitled to vote at the meeting, and upon such election and who complies with the notice procedures set forth in this
<U>Section 2.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) In
the event the Corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board, any
such stockholder entitled to vote in such election of directors may nominate a person or persons (as the case may be) for election to
such position(s) as specified in the Corporation&rsquo;s notice of meeting, if such stockholder delivers a stockholder&rsquo;s notice
that complies with the requirements of <U>Section 2.7(b)</U> to the Secretary at the principal executive offices of the Corporation not
earlier than the close of business on the 120th day prior to such special meeting and not later than the close of business on the later
of: (x) the 90th day prior to such special meeting; or (y) the 10th day following the date of the first Public Disclosure of the date
of the special meeting and of the nominees proposed by the Board to be elected at such meeting. In no event shall the Public Disclosure
of an adjournment or postponement of a special meeting commence a new time period (or extend any notice time period).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <U>Effect
of Noncompliance</U>. Only such persons who are nominated in accordance with the procedures set forth in this <U>Section 2.7</U> shall
be eligible to be elected at any meeting of stockholders of the Corporation to serve as directors and only such other business shall
be conducted at a meeting as shall be brought before the meeting in accordance with the procedures set forth in this <U>Section 2.7</U>.
If any proposed nomination was not made or proposed in compliance with this <U>Section 2.7</U>, or other business was not made or proposed
in compliance with this <U>Section 2.7</U>, then except as otherwise required by law, the chair of the meeting shall have the power and
duty to declare that such nomination shall be disregarded or that such proposed other business shall not be transacted. Notwithstanding
anything in these Bylaws to the contrary, unless otherwise required by law, if a Proposing Stockholder intending to propose business
or make nominations at an annual meeting or propose a nomination at a special meeting pursuant to this <U>Section 2.7</U> does not provide
the information required under this <U>Section 2.7</U> to the Corporation, including the updated information required by <U>Section 2.7(b)(vi)(B)</U>,
<U>Section 2.7(b)(vi)(C)</U>, and <U>Section 2.7(b)(vi)(D)</U> within five business days after the record date for such meeting or the
Proposing Stockholder (or a qualified representative of the Proposing Stockholder) does not appear at the meeting to present the proposed
business or nominations, such business or nominations shall not be considered, notwithstanding that proxies in respect of such business
or nominations may have been received by the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) <U>Rule
14a-8</U>. This <U>Section 2.7</U> shall not apply to a proposal proposed to be made by a stockholder if the stockholder has notified
the Corporation of the stockholder&rsquo;s intention to present the proposal at an annual or special meeting only pursuant to and in
compliance with Rule 14a-8 under the Exchange Act and such proposal has been included in a proxy statement that has been prepared by
the Corporation to solicit proxies for such meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) In
addition to the provisions of this <U>Section 2.7</U>, a stockholder shall also comply with all of the applicable requirements of the
Exchange Act and the rules and regulations thereunder with respect to the matters set forth herein. Nothing in this <U>Section 2.7</U>
shall be deemed to affect any rights of the holders of Preferred Stock to elect directors pursuant to the Certificate of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) Notwithstanding
anything in <U>Section 2.7</U> to the contrary, in the event that the number of directors is increased and there is no Public Disclosure
of the appointment of a director, or, if no appointment was made, of the vacancy, made by the Corporation at least 10 days before the
last day a stockholder may deliver a notice of nomination in accordance with <U>Section 2.7</U>, a stockholder&rsquo;s notice required
by this <U>Section 2.7</U> and which complies with the requirements in <U>Section 2.7(b)</U>, other than the timing requirements in <U>Section
2.7(a)</U>, shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it
is received by the Secretary at the principal executive offices of the Corporation not later than the close of business on the 10th day
following the day on which such Public Disclosure is first made by the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.8. Conduct of Meetings</B>. The chair of each annual and special meeting of stockholders shall be the Chair of the Board or, in
the absence (or inability or refusal to act) of the Chair of the Board, the Chief Executive Officer (if he or she shall be a director)
or, in the absence (or inability or refusal to act of the Chief Executive Officer or if the Chief Executive Officer is not a director,
the President (if he or she shall be a director) or, in the absence (or inability or refusal to act) of the President or if the President
is not a director, such other person as shall be appointed by the Board. The date and time of the opening and the closing of the polls
for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting by the chair of the meeting. The
Board may adopt such rules and regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the
extent inconsistent with these Bylaws or such rules and regulations as adopted by the Board, the chair of any meeting of stockholders
shall have the right and authority to convene and to adjourn the meeting, to prescribe such rules, regulations and procedures and to
do all such acts as, in the judgment of such chair, are appropriate for the proper conduct of the meeting. Such rules, regulations or
procedures, whether adopted by the Board or prescribed by the chair of the meeting, may include, without limitation, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) the
establishment of an agenda or order of business for the meeting;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) the
determination of when the polls shall open and close for any given matter to be voted on at the meeting;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) rules
and procedures for maintaining order at the meeting and the safety of those present;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) limitations
on attendance at or participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted
proxies or such other persons as the chair of the meeting shall determine;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) restrictions
on entry to the meeting after the time fixed for the commencement thereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) limitations
on the time allotted to questions or comments by participants. Unless and to the extent determined by the Board or the chair of the meeting,
meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
secretary of each annual and special meeting of stockholders shall be the Secretary or, in the absence (or inability or refusal to act)
of the Secretary, an Assistant Secretary so appointed to act by the chair of the meeting. In the absence (or inability or refusal to
act) of the Secretary and all Assistant Secretaries, the chair of the meeting may appoint any person to act as secretary of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.9. Action by Stockholders Without a Meeting</B>. Subject to the following paragraph, any action that is properly brought before
the stockholders by or at the direction of the Board and that could be taken at an annual or special meeting of stockholders may be taken
without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall
(a) be signed by the holders of outstanding shares of capital stock entitled to be voted with respect to the subject matter thereof having
not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled
to vote thereon were present and voted (as determined in accordance with Section 9.4 hereof) and (b) be delivered to the Corporation
by delivery to its registered office in the State of Delaware, its principal place of business, or an officer or agent of the Corporation
having custody of the records of proceedings of meetings of stockholders. Delivery made to the Corporation&rsquo;s registered office
shall be by hand or by certified mail or registered mail, return receipt requested. Every written consent shall bear the date of signature
of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein
unless written consents signed by the requisite number of stockholders entitled to vote with respect to the subject matter thereof are
delivered to the Corporation, in the manner required by this <U>&lrm;Section 2.9</U>, within 60 (or the maximum number permitted by applicable
law) days of the earliest dated consent delivered to the corporation in the manner required by this <U>Section 2.9</U>. The validity of any
consent executed by a proxy for a stockholder pursuant to an electronic transmission transmitted to such proxy holder by or upon the
authorization of the stockholder shall be determined by or at the direction of the Secretary. A written record of the information upon
which the person making such determination relied shall be made and kept in the records of the proceedings of the stockholders. Prompt
notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders
who have not consented in writing. Any such consent shall be inserted in the minute book as if it were the minutes of a meeting of the
stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
III<BR>
DIRECTORS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.1. Powers; Number</B>. The business and affairs of the Corporation shall be managed by or under the direction of the Board, which
may exercise all such powers of the Corporation and do all such lawful acts and things, including, without limitation, adopting rules
and procedures as it may deem proper for the conduct of its meetings and the management of the Corporation, as are not by statute or
by the Certificate of Incorporation or by these Bylaws required to be exercised or done by the stockholders. Directors need not be stockholders
or residents of the State of Delaware. Subject to any limitations in the laws of the State of Delaware, the Certificate of Incorporation
or these Bylaws, the number of directors may be changed from time to time by resolutions adopted by the Board of Directors and/or the
stockholders. No reduction of the number of directors shall have the effect of removing any director prior to the expiration of his or
her term of office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.2. Vacancies</B>. Unless otherwise provided in the Certificate of Incorporation, and subject to the rights of the holders of any
series of Preferred Stock or as otherwise provided by applicable law, any vacancies on the Board resulting from death, resignation, disqualification,
removal or other causes and any newly created directorships resulting from any increase in the number of directors shall be filled only
by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board, or by a sole remaining
director, and not by the stockholders, <I>provided, however</I>, that whenever the holders of any class or classes of stock or series
thereof are entitled to elect one or more directors by the provisions of the Certificate of Incorporation, vacancies and newly created
directorships of such class or classes or series shall be filled by a majority of the directors elected by such class or classes or series
thereof then in office, or by a sole remaining director so elected, and not by the stockholders. Any director elected in accordance with
the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred
and until such director&rsquo;s successor shall have been elected and qualified. A vacancy in the Board shall be deemed to exist under
this Bylaw in the case of the death, removal or resignation of any director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.3. Resignation</B>. Any director may resign at any time by notice given in writing or by electronic transmission to the Corporation.
Such resignation shall take effect at the date of receipt of such notice by the Corporation or at such later effective date or upon the
happening of an event or events as is therein specified. A verbal resignation shall not be deemed effective until confirmed by the director
in writing or by electronic transmission to the Corporation. When one or more directors shall resign from the Board, effective at a future
date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies,
the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold
office for the unexpired portion of the term of the director whose place shall be vacated and until his successor shall have been duly
elected and qualified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.4. Removal</B>. Subject to any limitations imposed by applicable law, any individual director or directors may be removed with cause
by the affirmative vote of the holders of at least 66 2/3% of the voting power of all then-outstanding shares of capital stock of the
Corporation entitled to vote generally at an election of directors. Directors shall not be removed without cause pursuant to this Section
3.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.5. Compensation</B>. Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, the Board shall have the authority
to fix the compensation of directors, including for service on a committee of the Board, and may be paid either a fixed sum for attendance
at each meeting of the Board or other compensation as director. The directors may be reimbursed their expenses, if any, of attendance
at each meeting of the Board. No such payment shall preclude any director from serving the Corporation in any other capacity and receiving
compensation therefor. Members of committees of the Board may be allowed like compensation and reimbursement of expenses for service
on the committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
IV<BR>
BOARD MEETINGS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.1. Regular Meetings</B>. Regularly scheduled, periodic meetings of the Board may be held without notice at such times, dates and
places, within or without the State of Delaware, as shall from time to time be determined by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.2. Special Meetings</B>. Special meetings of the Board (a) may be called by the Chair of the Board or President and (b) shall be
called by the Chair of the Board, President or Secretary on the written request of at least a majority of directors then in office, or
the sole director, as the case may be, and shall be held at such time, date and place, within or without the State of Delaware, as may
be determined by the person calling the meeting or, if called upon the request of directors or the sole director, as specified in such
written request. Notice of each special meeting of the Board shall be given, as provided in <U>Section 9.3</U>, to each director (i)
at least 24 hours before the meeting if such notice is oral notice given personally or by telephone or written notice given by hand delivery
or by means of a form of electronic transmission and delivery; (ii) at least two days before the meeting if such notice is sent by a
nationally recognized overnight delivery service; and (iii) at least three days before the meeting if such notice is sent through the
United States mail. If the Secretary shall fail or refuse to give such notice, then the notice may be given by the officer who called
the meeting or the directors who requested the meeting. Any and all business that may be transacted at a regular meeting of the Board
may be transacted at a special meeting. Except as may be otherwise expressly provided by applicable law, the Certificate of Incorporation,
or these Bylaws, neither the business to be transacted at, nor the purpose of, any special meeting need be specified in the notice or
waiver of notice of such meeting. A special meeting may be held at any time without notice if all the directors are present or if those
not present waive notice of the meeting in accordance with <U>Section 9.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.3. Quorum; Required Vote</B>. A majority of the Board shall constitute a quorum for the transaction of business at any meeting of
the Board, and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board,
except as may be otherwise specifically provided by applicable law, the Certificate of Incorporation or these Bylaws. If a quorum shall
not be present at any meeting, a majority of the directors present may adjourn the meeting from time to time, without notice other than
announcement at the meeting, until a quorum is present.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.4. Consent In Lieu of Meeting</B>. Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required
or permitted to be taken at any meeting of the Board or any committee thereof may be taken without a meeting if all members of the Board
or committee, as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings or electronic
transmission or transmissions (or paper reproductions thereof) are filed with the minutes of proceedings of the Board or committee. Such
filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained
in electronic form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.5. Organization</B>. The chair of each meeting of the Board shall be the Chair of the Board or, in the absence (or inability or
refusal to act) of the Chair of the Board, the Chief Executive Officer (if he or she shall be a director) or, in the absence (or inability
or refusal to act) of the Chief Executive Officer or if the Chief Executive Officer is not a director, the President (if he or she shall
be a director) or in the absence (or inability or refusal to act) of the President or if the President is not a director, a chair elected
from the directors present. The Secretary shall act as secretary of all meetings of the Board. In the absence (or inability or refusal
to act) of the Secretary, an Assistant Secretary shall perform the duties of the Secretary at such meeting. In the absence (or inability
or refusal to act) of the Secretary and all Assistant Secretaries, the chair of the meeting may appoint any person to act as secretary
of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
V<BR>
COMMITTEES OF DIRECTORS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.1. Establishment</B>. The Board may designate one or more committees, each committee to consist of one or more of the directors
of the Corporation. Each committee shall keep regular minutes of its meetings and report the same to the Board when required by the resolution
designating such committee. The Board shall have the power at any time to fill vacancies in, to change the membership of, or to dissolve
any such committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.2. Available Powers</B>. Any committee established pursuant to <U>Section 5.1</U> hereof, to the extent permitted by applicable
law and by resolution of the Board, shall have and may exercise all of the powers and authority of the Board in the management of the
business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.3. Alternate Members</B>. The Board may designate one or more directors as alternate members of any committee, who may replace any
absent or disqualified member at any meeting of such committee. In the absence or disqualification of a member of the committee, the
member or members thereof present at any meeting and not disqualified from voting, whether or not he, she or they constitute a quorum,
may unanimously appoint another member of the Board to act at the meeting in place of any such absent or disqualified member.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.4. Procedures</B>. Unless the Board otherwise provides, the time, date, place, if any, and notice of meetings of a committee shall
be determined by such committee. At meetings of a committee, a majority of the number of members of the committee (but not including
any alternate member, unless such alternate member has replaced any absent or disqualified member at the time of, or in connection with,
such meeting) shall constitute a quorum for the transaction of business. The act of a majority of the members present at any meeting
at which a quorum is present shall be the act of the committee, except as otherwise specifically provided by applicable law, the Certificate
of Incorporation, these Bylaws or the Board. If a quorum is not present at a meeting of a committee, the members present may adjourn
the meeting from time to time, without notice other than an announcement at the meeting, until a quorum is present. Unless the Board
otherwise provides and except as provided in these Bylaws, each committee designated by the Board may make, alter, amend and repeal rules
for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same manner as the Board
is authorized to conduct its business pursuant to <U>Article III</U> and <U>Article IV</U> of these Bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VI<BR>
OFFICERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.1. Officers</B>. The officers of the Corporation elected by the Board shall be a Chief Executive Officer, a Chief Financial Officer,
a Secretary and such other officers (including without limitation, a Chair of the Board, Presidents, Vice Presidents, Assistant Secretaries
and a Treasurer) as the Board from time to time may determine. Officers elected by the Board shall each have such powers and duties as
generally pertain to their respective offices, subject to the specific provisions of this <U>Article VI</U>. Such officers shall also
have such powers and duties as from time to time may be conferred by the Board. The Chief Executive Officer or President may also appoint
such other officers (including without limitation one or more Vice Presidents and Controllers) as may be necessary or desirable for the
conduct of the business of the Corporation. Such other officers shall have such powers and duties and shall hold their offices for such
terms as may be provided in these Bylaws or as may be prescribed by the Board or, if such officer has been appointed by the Chief Executive
Officer or President, as may be prescribed by the appointing officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Chair
of the Board</U>. The Chair of the Board shall preside when present at all meetings of the stockholders and the Board. The Chair of the
Board shall have general supervision and control of the acquisition activities of the Corporation subject to the ultimate authority of
the Board, and shall be responsible for the execution of the policies of the Board with respect to such matters. In the absence (or inability
or refusal to act) of the Chair of the Board, the Chief Executive Officer (if he or she shall be a director) shall preside when present
at all meetings of the stockholders and the Board. The powers and duties of the Chair of the Board shall not include supervision or control
of the preparation of the financial statements of the Corporation (other than through participation as a member of the Board). The position
of Chair of the Board and Chief Executive Officer may be held by the same person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Chief
Executive Officer</U>. The Chief Executive Officer shall be the chief executive officer of the Corporation, shall have general supervision
of the affairs of the Corporation and general control of all of its business subject to the ultimate authority of the Board, and shall
be responsible for the execution of the policies of the Board with respect to such matters, except to the extent any such powers and
duties have been prescribed to the Chair of the Board pursuant to <U>Section 6.1(a)</U> above. In the absence (or inability or refusal
to act) of the Chair of the Board, the Chief Executive Officer (if he or she shall be a director) shall preside when present at all meetings
of the stockholders and the Board. The position of Chief Executive Officer and President may be held by the same person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>President</U>.
The President shall make recommendations to the Chief Executive Officer on all operational matters that would normally be reserved for
the final executive responsibility of the Chief Executive Officer. In the absence (or inability or refusal to act) of the Chair of the
Board and Chief Executive Officer, the President (if he or she shall be a director) shall preside when present at all meetings of the
stockholders and the Board. The President shall also perform such duties and have such powers as shall be designated by the Board. The
position of President and Chief Executive Officer may be held by the same person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Vice
Presidents</U>. In the absence (or inability or refusal to act) of the President, the Vice President (or in the event there be more than
one Vice President, the Vice Presidents in the order designated by the Board) shall perform the duties and have the powers of the President.
Each Vice President of the Corporation shall have such powers and perform such duties as may be assigned to him or her from time to time
by the Board, the Chief Executive Officer or the President, or that are incident to the office of Vice President.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <U>Secretary</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) The
Secretary shall attend all meetings of the stockholders, the Board and (as required) committees of the Board and shall record the proceedings
of such meetings in books to be kept for that purpose. The Secretary shall give, or cause to be given, notice of all meetings of the
stockholders and special meetings of the Board and shall perform such other duties as may be prescribed by the Board, the Chair of the
Board, Chief Executive Officer or President. The Secretary shall have custody of the corporate seal of the Corporation and the Secretary,
or any Assistant Secretary, shall have authority to affix the same to any instrument requiring it, and when so affixed, it may be attested
by his or her signature or by the signature of such Assistant Secretary. The Board may give general authority to any other officer to
affix the seal of the Corporation and to attest the affixing thereof by his or her signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) The
Secretary shall keep, or cause to be kept, at the principal executive office of the Corporation or at the office of the Corporation&rsquo;s
transfer agent or registrar, if one has been appointed, a stock ledger, or duplicate stock ledger, showing the names of the stockholders
and their addresses, the number and classes of shares held by each and, with respect to certificated shares, the number and date of certificates
issued for the same and the number and date of certificates cancelled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) <U>Assistant
Secretaries</U>. The Assistant Secretary or, if there be more than one, the Assistant Secretaries in the order determined by the Board
shall, in the absence (or inability or refusal to act) of the Secretary, perform the duties and have the powers of the Secretary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) <U>Chief
Financial Officer</U>. The Chief Financial Officer shall perform all duties commonly incident to that office (including, without limitation,
the care and custody of the funds and securities of the Corporation, which from time to time may come into the Chief Financial Officer&rsquo;s
hands and the deposit of the funds of the Corporation in such banks or trust companies as the Board, the Chief Executive Officer or the
President may authorize).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) <U>Treasurer</U>.
The Treasurer shall, in the absence (or inability or refusal to act) of the Chief Financial Officer, perform the duties and exercise
the powers of the Chief Financial Officer. The Treasurer shall perform other duties commonly incident to the office and shall also perform
such other duties and have such other powers as the Board, the Chief Executive Officer, the President and the Chief Financial Officer
(if not the Treasurer) shall designate from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.2. Resignations</B>. Any officer may resign at any time by giving notice in writing or by electronic transmission to the Board or
to the Chief Executive Officer, or if no Chief Executive Officer is then serving, the President or to the Secretary. Any such resignation
shall be effective when received by the person or persons to whom such notice is given, unless a later time is specified therein, in
which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any
such resignation shall not be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the
Corporation under any contract with the resigning officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.3. Term of Office; Removal; Vacancies</B>. The elected officers of the Corporation shall be appointed by the Board and shall hold
office until their successors are duly elected and qualified by the Board or until their earlier death, resignation, retirement, disqualification,
or removal from office. Any officer may be removed, with or without cause, at any time by the majority vote of the members of the Board
then in office. Any officer appointed by the Chief Executive Officer or President may also be removed, with or without cause, by the
Chief Executive Officer or President, as the case may be, unless the Board otherwise provides. Any vacancy occurring in any elected office
of the Corporation may be filled by the Board. Any vacancy occurring in any office appointed by the Chief Executive Officer or President
may be filled by the Chief Executive Officer, or President, as the case may be, unless the Board then determines that such office shall
thereupon be elected by the Board, in which case the Board shall elect such officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.4. Other Officers; Duties of Officers May Be Delegated</B>. Such other officers as the Board may choose shall perform such duties
and have such powers as from time to time may be assigned to them by the Board. The Board may delegate to any other officer of the Corporation
the power to choose such other officers and to prescribe their respective duties and powers. In case any officer is absent, or for any
other reason that the Board may deem sufficient, the Chief Executive Officer or the President or the Board may delegate for the time
being the powers or duties of such officer to any other officer or to any director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.5. Multiple Officeholders; Stockholder and Director Officers</B>. Any number of offices may be held by the same person unless the
Certificate of Incorporation or these Bylaws otherwise provide. Officers need not be stockholders or residents of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VII<BR>
SHARES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.1. Certificated and Uncertificated Shares</B>. The shares of the Corporation may be certificated or uncertificated, subject to the
sole discretion of the Board and the requirements of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.2. Multiple Classes of Stock</B>. If the Corporation shall be authorized to issue more than one class of stock or more than one
series of any class, the Corporation shall (a) cause the powers, designations, preferences and relative, participating, optional or other
special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or
rights to be set forth in full or summarized on the face or back of any certificate that the Corporation issues to represent shares of
such class or series of stock or (b) in the case of uncertificated shares, within a reasonable time after the issuance or transfer of
such shares, send to the registered owner thereof a written notice containing the information required to be set forth on certificates
as specified in clause (a) above; provided, however, that, except as otherwise provided by applicable law, in lieu of the foregoing requirements,
there may be set forth on the face or back of such certificate or, in the case of uncertificated shares, on such written notice a statement
that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative,
participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions
of such preferences or rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.3. Signatures</B>. Each certificate representing capital stock of the Corporation shall be signed by or in the name of the Corporation
by (a) the Chair of the Board, Chief Executive Officer, the President or a Vice President and (b) the Treasurer, an Assistant Treasurer,
the Secretary or an Assistant Secretary of the Corporation. Any or all the signatures on the certificate may be a facsimile. In case
any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased
to be such officer, transfer agent or registrar before such certificate is issued, such certificate may be issued by the Corporation
with the same effect as if such person were such officer, transfer agent or registrar on the date of issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.4. Consideration and Payment for Shares.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Subject
to applicable law and the Certificate of Incorporation, shares of stock may be issued for such consideration, having in the case of shares
with par value a value not less than the par value thereof, and to such persons, as determined from time to time by the Board. The consideration
may consist of any tangible or intangible property or any benefit to the Corporation including cash, promissory notes, services performed,
contracts for services to be performed or other securities, or any combination thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Subject
to applicable law and the Certificate of Incorporation, shares may not be issued until the full amount of the consideration has been
paid, unless upon the face or back of each certificate issued to represent any partly paid shares of capital stock or upon the books
and records of the Corporation in the case of partly paid uncertificated shares, there shall have been set forth the total amount of
the consideration to be paid therefor and the amount paid thereon up to and including the time said certificate representing certificated
shares or said uncertificated shares are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.5. Lost, Stolen or Destroyed Certificates. </B>The Board or the Secretary may direct a new certificate or uncertificated shares
to be issued in place of any certificate theretofore issued by the Corporation alleged to have been lost, stolen, or destroyed upon the
making of an affidavit of that fact by the owner of the allegedly lost, stolen, or destroyed certificate. When authorizing such issue
of a new certificate or uncertificated shares, the Board or the Secretary may, in its discretion and as a condition precedent to the
issuance thereof, require the owner of the lost, stolen, or destroyed certificate, or the owner&rsquo;s legal representative to give
the Corporation a bond sufficient to indemnify it against any claim that may be made against the Corporation with respect to the certificate
alleged to have been lost, stolen, or destroyed or the issuance of such new certificate or uncertificated shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.6. Transfer of Stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) If
a certificate representing shares of the Corporation is presented to the Corporation with an endorsement requesting the registration
of transfer of such shares or an instruction is presented to the Corporation requesting the registration of transfer of uncertificated
shares, the Corporation shall register the transfer as requested if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) in
the case of certificated shares, the certificate representing such shares has been surrendered;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) (A)
with respect to certificated shares, the endorsement is made by the person specified by the certificate as entitled to such shares; (B)
with respect to uncertificated shares, an instruction is made by the registered owner of such uncertificated shares; or (C) with respect
to certificated shares or uncertificated shares, the endorsement or instruction is made by any other appropriate person or by an agent
who has actual authority to act on behalf of the appropriate person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) the
Corporation has received a guarantee of signature of the person signing such endorsement or instruction or such other reasonable assurance
that the endorsement or instruction is genuine and authorized as the Corporation may request;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) the
transfer does not violate any restriction on transfer imposed by the Corporation that is enforceable in accordance with <U>Section 7.8(a)</U>;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) such
other conditions for such transfer as shall be provided for under applicable law have been satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Whenever
any transfer of shares shall be made for collateral security and not absolutely, the Corporation shall so record such fact in the entry
of transfer if, when the certificate for such shares is presented to the Corporation for transfer or, if such shares are uncertificated,
when the instruction for registration of transfer thereof is presented to the Corporation, both the transferor and transferee request
the Corporation to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.7. Registered Stockholders</B>. Before due presentment for registration of transfer of a certificate representing shares of the
Corporation or of an instruction requesting registration of transfer of uncertificated shares, the Corporation may treat the registered
owner as the person exclusively entitled to inspect for any proper purpose the stock ledger and the other books and records of the Corporation,
vote such shares, receive dividends or notifications with respect to such shares and otherwise exercise all the rights and powers of
the owner of such shares, except that a person who is the beneficial owner of such shares (if held in a voting trust or by a nominee
on behalf of such person) may, upon providing documentary evidence of beneficial ownership of such shares and satisfying such other conditions
as are provided under applicable law, may also so inspect the books and records of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.8. Effect of the Corporation&rsquo;s Restriction on Transfer.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) A
written restriction on the transfer or registration of transfer of shares of the Corporation or on the amount of shares of the Corporation
that may be owned by any person or group of persons, if permitted by the DGCL and noted conspicuously on the certificate representing
such shares or, in the case of uncertificated shares, contained in a notice, offering circular or prospectus sent by the Corporation
to the registered owner of such shares within a reasonable time prior to or after the issuance or transfer of such shares, may be enforced
against the holder of such shares or any successor or transferee of the holder including an executor, administrator, trustee, guardian
or other fiduciary entrusted with like responsibility for the person or estate of the holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) A
restriction imposed by the Corporation on the transfer or the registration of shares of the Corporation or on the amount of shares of
the Corporation that may be owned by any person or group of persons, even if otherwise lawful, is ineffective against a person without
actual knowledge of such restriction unless: (i) the shares are certificated and such restriction is noted conspicuously on the certificate;
or (ii) the shares are uncertificated and such restriction was contained in a notice, offering circular or prospectus sent by the Corporation
to the registered owner of such shares within a reasonable time prior to or after the issuance or transfer of such shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.9. Regulations</B>. The Board shall have power and authority to make such additional rules and regulations, subject to any applicable
requirement of law, as the Board may deem necessary and appropriate with respect to the issue, transfer or registration of transfer of
shares of stock or certificates representing shares. The Board may appoint one or more transfer agents or registrars and may require
for the validity thereof that certificates representing shares bear the signature of any transfer agent or registrar so appointed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VIII<BR>
INDEMNIFICATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.1. Right to Indemnification</B>. To the fullest extent permitted by applicable law, as the same exists or may hereafter be amended,
the Corporation shall indemnify and hold harmless each person who was or is made a party or is threatened to be made a party to or is
otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(hereinafter a &ldquo;<B><I>proceeding</I></B>&rdquo;), by reason of the fact that he or she, or a person for whom he or she is the legal
representative, is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving
at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture,
trust, other enterprise or nonprofit entity, including service with respect to an employee benefit plan (hereinafter an &ldquo;<B><I>Indemnitee</I></B>&rdquo;),
whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent, or in any other
capacity while serving as a director, officer, employee or agent, against all liability and loss suffered and expenses (including, without
limitation, attorneys&rsquo; fees) actually and reasonably incurred by such Indemnitee in connection with such proceeding; provided,
however, that, with respect to proceedings to enforce rights to indemnification, the Corporation shall indemnify an Indemnitee in connection
with a proceeding (or part thereof) initiated by such Indemnitee only if such proceeding (or part thereof) was authorized by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.2. Right to Advancement of Expenses</B>. In addition to the right to indemnification conferred in <U>Section 8.1</U>, an Indemnitee
shall also have the right to be paid by the Corporation to the fullest extent not prohibited by applicable law the expenses (including,
without limitation, attorneys&rsquo; fees) actually and reasonably incurred in defending or otherwise participating in any such proceeding
in advance of its final disposition (hereinafter an &ldquo;<B><I>advancement of expenses</I></B>&rdquo;); provided, however, that an
advancement of expenses incurred by an Indemnitee in his or her capacity as a director or officer of the Corporation (and not in any
other capacity in which service was or is rendered by such Indemnitee, including, without limitation, service to an employee benefit
plan) shall be made only upon the Corporation&rsquo;s receipt of an undertaking (hereinafter an &ldquo;<B><I>undertaking</I></B>&rdquo;),
by or on behalf of such Indemnitee, to repay all amounts so advanced if it shall ultimately be determined that such Indemnitee is not
entitled to be indemnified under this <U>Article VIII</U> or otherwise. Payment of such expenses actually and reasonably incurred by
such person, may be made by the Corporation, subject to such terms and conditions as the general counsel of the Corporation in his or
her discretion deems appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.3. Non-Exclusivity of Rights</B>. The rights provided to any Indemnitee pursuant to this <U>Article VIII</U> shall not be exclusive
of any other right, which such Indemnitee may have or hereafter acquire under applicable law, the Certificate of Incorporation, these
Bylaws, an agreement, a vote of stockholders or disinterested directors, or otherwise. The Corporation is specifically authorized to
enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advances,
to the fullest extent not prohibited by the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.4. Insurance</B>. The Corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer,
employee, or agent of the Corporation, or is or was serving at the request of Corporation as a director, officer, employee, or agent
of another corporation, partnership, joint venture, trust, enterprise, or nonprofit entity against any liability asserted against him
or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the Corporation would
have the power to indemnify him or her against such liability under the provisions of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.5. Indemnification of Other Persons; Other Indemnification</B>. This <U>Article VIII</U> shall not limit the right of the Corporation
to the extent and in the manner authorized or permitted by law to indemnify and to advance expenses to persons other than Indemnitees.
Without limiting the foregoing, the Corporation may, to the extent authorized from time to time by the Board, grant rights to indemnification
and to the advancement of expenses to any employee or agent of the Corporation and to any other person who is or was serving at the request
of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other
enterprise, including service with respect to an employee benefit plan, to the fullest extent of the provisions of this <U>Article VIII
</U>with respect to the indemnification and advancement of expenses of Indemnitees under this <U>Article VIII</U>. The Corporation&rsquo;s
obligation, if any, to indemnify any person who was or is serving at its request as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust, enterprise or nonprofit entity shall be reduced by any amount such person may collect
as indemnification from such other corporation, partnership, joint venture, trust, enterprise or nonprofit entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.6. Amendments</B>. Any amendment, repeal, or modification of this Article <U>VIII</U> shall not adversely affect any right or protection
hereunder of any person in respect of any act or omission occurring prior to the time of such repeal or modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.7. Certain Definitions</B>. For purposes of this <U>Article VIII</U>, (a) references to &ldquo;<B><I>other enterprise</I></B>&rdquo;
shall include any employee benefit plan; (b) references to &ldquo;<B><I>fines</I></B>&rdquo; shall include any excise taxes assessed
on a person with respect to an employee benefit plan; (c) references to &ldquo;<B><I>serving at the request of the Corporation</I></B>&rdquo;
shall include any service that imposes duties on, or involves services by, a person with respect to any employee benefit plan, its participants,
or beneficiaries; and (d) a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the
participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &ldquo;<B><I>not opposed to the
best interest of the Corporation</I></B>&rdquo; for purposes of Section 145 of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.8. Contract Rights</B>. The rights provided to Indemnitees pursuant to this <U>Article VIII</U> shall be contract rights and such
rights shall continue as to an Indemnitee who has ceased to be a director, officer, agent or employee and shall inure to the benefit
of the Indemnitee&rsquo;s heirs, executors and administrators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.9. Severability</B>. If any provision or provisions of this <U>Article VIII</U> shall be held to be invalid, illegal or unenforceable
for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this <U>Article VIII</U> shall
not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this <U>Article VIII</U> (including,
without limitation, each such portion of this <U>Article VIII</U> containing any such provision held to be invalid, illegal or unenforceable)
shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
IX<BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.1. Place of Meetings</B>. If the place of any meeting of stockholders, the Board or committee of the Board for which notice is required
under these Bylaws is not designated in the notice of such meeting, such meeting shall be held at the principal business office of the
Corporation; provided, however, if the Board has, in its sole discretion, determined that a meeting shall not be held at any place, but
instead shall be held by means of remote communication pursuant to <U>Section 9.5</U> hereof, then such meeting shall not be held at
any place.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.2. Fixing Record Dates.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) In
order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof,
the Board may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the
Board, and which record date shall not be more than 60 nor less than 10 days before the date of such meeting. If the Board so fixes a
date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board determines,
at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination.
If no record date is fixed by the Board, the record date for determining stockholders entitled to notice of and to vote at a meeting
of stockholders shall be at the close of business on the business day next preceding the day on which notice is given, or, if notice
is waived, at the close of business on the business day next preceding the day on which the meeting is held. A determination of stockholders
of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however,
that the Board may fix a new record date for the adjourned meeting, and in such case shall also fix as the record date for stockholders
entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to
vote in accordance with the foregoing provisions of this <U>Section 9.2(a)</U> at the adjourned meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) For
the purpose of determining stockholders entitled to consent to corporate action in writing without a meeting, the Board may fix a record
date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board, and which
date shall not be more than 10 (or the maximum number permitted by applicable law) days after the date upon which the resolution fixing
the record date is adopted by the Board. If no record date has been fixed by the Board, the record date for determining stockholders
entitled to consent to corporate action in writing without a meeting, when no prior action by the Board is required by Chapter 1 of the
DGCL, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to
the Corporation by delivery to its registered office in the State of Delaware, its principal place of business, or an officer or agent
of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation&rsquo;s
registered office shall be by hand or by certified or registered mail, return receipt requested. If no record date has been fixed by
the Board and prior action by the Board is required by Chapter 1 of the DGCL, the record date for determining stockholders entitled to
consent to corporate action in writing without a meeting shall be at the close of business on the day on which the Board adopts the resolution
taking such prior action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) In
order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment
of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the
purpose of any other lawful action, the Board may fix a record date, which record date shall not precede the date upon which the resolution
fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed,
the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board adopts
the resolution relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.3. Means of Giving Notice.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Notice
to Directors</U>. Whenever under applicable law, the Certificate of Incorporation or these Bylaws notice is required to be given to any
director, such notice shall be given either (i) in writing and sent by mail, or by a nationally recognized delivery service, (ii) by
means of facsimile telecommunication or other form of electronic transmission, or (iii) by oral notice given personally or by telephone.
A notice to a director will be deemed given as follows: (i) if given by hand delivery, orally, or by telephone, when actually received
by the director, (ii) if sent through the United States mail, when deposited in the United States mail, with postage and fees thereon
prepaid, addressed to the director at the director&rsquo;s address appearing on the records of the Corporation, (iii) if sent for next
day delivery by a nationally recognized overnight delivery service, when deposited with such service, with fees thereon prepaid, addressed
to the director at the director&rsquo;s address appearing on the records of the Corporation, (iv) if sent by facsimile telecommunication,
when sent to the facsimile transmission number for such director appearing on the records of the Corporation, (v) if sent by electronic
mail, when sent to the electronic mail address for such director appearing on the records of the Corporation, or (vi) if sent by any
other form of electronic transmission, when sent to the address, location or number (as applicable) for such director appearing on the
records of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Notice
to Stockholders</U>. Whenever under applicable law, the Certificate of Incorporation or these Bylaws notice is required to be given to
any stockholder, such notice may be given (i) in writing and sent either by hand delivery, through the United States mail, or by a nationally
recognized overnight delivery service for next day delivery, or (ii) by means of a form of electronic transmission consented to by the
stockholder, to the extent permitted by, and subject to the conditions set forth in Section 232 of the DGCL. A notice to a stockholder
shall be deemed given as follows: (i) if given by hand delivery, when actually received by the stockholder, (ii) if sent through the
United States mail, when deposited in the United States mail, with postage and fees thereon prepaid, addressed to the stockholder at
the stockholder&rsquo;s address appearing on the stock ledger of the Corporation, (iii) if sent for next day delivery by a nationally
recognized overnight delivery service, when deposited with such service, with fees thereon prepaid, addressed to the stockholder at the
stockholder&rsquo;s address appearing on the stock ledger of the Corporation, and (iv) if given by a form of electronic transmission
consented to by the stockholder to whom the notice is given and otherwise meeting the requirements set forth above, (A) if by facsimile
transmission, when directed to a number at which the stockholder has consented to receive notice, (B) if by electronic mail, when directed
to an electronic mail address at which the stockholder has consented to receive notice, (C) if by a posting on an electronic network
together with separate notice to the stockholder of such specified posting, upon the later of (1) such posting and (2) the giving of
such separate notice, and (D) if by any other form of electronic transmission, when directed to the stockholder. A stockholder may revoke
such stockholder&rsquo;s consent to receiving notice by means of electronic communication by giving written notice of such revocation
to the Corporation. Any such consent shall be deemed revoked if (1) the Corporation is unable to deliver by electronic transmission two
consecutive notices given by the Corporation in accordance with such consent and (2) such inability becomes known to the Secretary or
an Assistant Secretary or to the Corporation&rsquo;s transfer agent, or other person responsible for the giving of notice; provided,
however, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Electronic
Transmission</U>. &ldquo;<B><I>Electronic transmission</I></B>&rdquo; means any form of communication, not directly involving the physical
transmission of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly
reproduced in paper form by such a recipient through an automated process, including but not limited to transmission by telex, facsimile
telecommunication, electronic mail, telegram and cablegram.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Notice
to Stockholders Sharing Same Address</U>. Without limiting the manner by which notice otherwise may be given effectively by the Corporation
to stockholders, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate of Incorporation
or these Bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders
at that address to whom such notice is given. A stockholder may revoke such stockholder&rsquo;s consent by delivering written notice
of such revocation to the Corporation. Any stockholder who fails to object in writing to the Corporation within 60 days of having been
given written notice by the Corporation of its intention to send such a single written notice shall be deemed to have consented to receiving
such single written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <U>Exceptions
to Notice Requirements</U>. Whenever notice is required to be given, under the DGCL, the Certificate of Incorporation or these Bylaws,
to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be
no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting
that shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect
as if such notice had been duly given. In the event that the action taken by the Corporation is such as to require the filing of a certificate
with the Secretary of State of Delaware, the certificate shall state, if such is the fact and if notice is required, that notice was
given to all persons entitled to receive notice except such persons with whom communication is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
notice is required to be given by the Corporation, under any provision of the DGCL, the Certificate of Incorporation or these Bylaws,
to any stockholder to whom (1) notice of two consecutive annual meetings of stockholders and all notices of stockholder meetings or of
the taking of action by written consent of stockholders without a meeting to such stockholder during the period between such two consecutive
annual meetings, or (2) all, and at least two payments (if sent by first-class mail) of dividends or interest on securities during a
12-month period, have been mailed addressed to such stockholder at such stockholder&rsquo;s address as shown on the records of the Corporation
and have been returned undeliverable, the giving of such notice to such stockholder shall not be required. Any action or meeting that
shall be taken or held without notice to such stockholder shall have the same force and effect as if such notice had been duly given.
If any such stockholder shall deliver to the Corporation a written notice setting forth such stockholder&rsquo;s then current address,
the requirement that notice be given to such stockholder shall be reinstated. In the event that the action taken by the Corporation is
such as to require the filing of a certificate with the Secretary of State of Delaware, the certificate need not state that notice was
not given to persons to whom notice was not required to be given pursuant to Section 230(b) of the DGCL. The exception in subsection
(1) of the first sentence of this paragraph to the requirement that notice be given shall not be applicable to any notice returned as
undeliverable if the notice was given by electronic transmission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.4. Waiver of Notice</B>. Whenever any notice is required to be given under applicable law, the Certificate of Incorporation, or
these Bylaws, a written waiver of such notice, signed by the person or persons entitled to said notice, or a waiver by electronic transmission
by the person entitled to said notice, whether before or after the time stated therein, shall be deemed equivalent to such required notice.
All such waivers shall be kept with the books of the Corporation. Attendance at a meeting shall constitute a waiver of notice of such
meeting, except where a person attends for the express purpose of objecting to the transaction of any business on the ground that the
meeting was not lawfully called or convened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.5. Meeting Attendance via Remote Communication Equipment.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Stockholder
Meetings</U>. If authorized by the Board in its sole discretion, and subject to such guidelines and procedures as the Board may adopt,
stockholders entitled to vote at such meeting and proxy holders not physically present at a meeting of stockholders may, by means of
remote communication:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) participate
in a meeting of stockholders; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) be
deemed present in person and vote at a meeting of stockholders, whether such meeting is to be held at a designated place or solely by
means of remote communication, provided that (A) the Corporation shall implement reasonable measures to verify that each person deemed
present and permitted to vote at the meeting by means of remote communication is a stockholder or proxy holder, (B) the Corporation shall
implement reasonable measures to provide such stockholders and proxy holders a reasonable opportunity to participate in the meeting and,
if entitled to vote, to vote on matters submitted to the applicable stockholders, including an opportunity to read or hear the proceedings
of the meeting substantially concurrently with such proceedings, and (C) if any stockholder or proxy holder votes or takes other action
at the meeting by means of remote communication, a record of such votes or other action shall be maintained by the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Board
Meetings</U>. Unless otherwise restricted by applicable law, the Certificate of Incorporation or these Bylaws, members of the Board or
any committee thereof may participate in a meeting of the Board or any committee thereof by means of conference telephone or other communications
equipment by means of which all persons participating in the meeting can hear each other and be heard. Such participation in a meeting
shall constitute presence in person at the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.6. Dividends</B>. The Board may from time to time declare, and the Corporation may pay, dividends (payable in cash, property or
shares of the Corporation&rsquo;s capital stock) on the Corporation&rsquo;s outstanding shares of capital stock, subject to applicable
law and the Certificate of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.7. Reserves</B>. Before payment of any dividend, there may be set aside out of any funds of the Corporation available for dividends
such sum or sums as the Board from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies,
or for equalizing dividends, or for repairing or maintaining any property of the Corporation, or for such other purpose as the Board
shall think conducive to the interests of the Corporation, and the Board may modify or abolish any such reserve in the manner in which
it was created.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.8. Contracts and Negotiable Instruments</B>. Except as otherwise provided by applicable law, the Certificate of Incorporation or
these Bylaws, any contract, bond, deed, lease, mortgage or other instrument may be executed and delivered in the name and on behalf of
the Corporation by such officer or officers or other employee or employees of the Corporation as the Board may from time to time authorize.
Such authority may be general or confined to specific instances as the Board may determine. The Chair of the Board, the Chief Executive
Officer, the President, the Chief Financial Officer, the Treasurer or any Vice President may execute and deliver any contract, bond,
deed, lease, mortgage or other instrument in the name and on behalf of the Corporation. Subject to any restrictions imposed by the Board,
the Chair of the Board, the Chief Executive Officer, the President, the Chief Financial Officer, the Treasurer or any Vice President
may delegate powers to execute and deliver any contract, bond, deed, lease, mortgage or other instrument in the name and on behalf of
the Corporation to other officers or employees of the Corporation under such person&rsquo;s supervision and authority, it being understood,
however, that any such delegation of power shall not relieve such officer of responsibility with respect to the exercise of such delegated
power. All checks, notes, drafts, or other orders for the payment of money of the Corporation shall be signed, endorsed, or accepted
in the name of the Corporation by such officer, officers, person, or persons as from time to time may be designated by the Board or by
an officer or officers authorized by the Board to make such designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.9. Fiscal Year</B>. The fiscal year of the Corporation shall be fixed by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.10. Seal</B>. The Board may adopt a corporate seal, which shall be in such form as the Board determines. The seal may be used by
causing it or a facsimile thereof to be impressed, affixed or otherwise reproduced, as may be prescribed by law or by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.11. Books and Records</B>. The books and records of the Corporation may be kept within or outside the State of Delaware at such
place or places as may from time to time be designated by the Board. Any records administered by or on behalf of the Corporation in the
regular course of its business, including its stock ledger, books of account, and minute books, may be maintained on any information
storage device, method, or one or more electronic networks or databases (including one or more distributed electronic networks or databases);
provided that the records so kept can be converted into clearly legible paper form within a reasonable time, and, with respect to the
stock ledger, the records so kept comply with Section 224 of the DGCL. The Corporation shall so convert any records so kept upon the
request of any person entitled to inspect such records pursuant to applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.12. Surety Bonds</B>. Such officers, employees and agents of the Corporation (if any) as the Chair of the Board, Chief Executive
Officer, President or the Board may direct, from time to time, shall be bonded for the faithful performance of their duties and for the
restoration to the Corporation, in case of their death, resignation, retirement, disqualification or removal from office, of all books,
papers, vouchers, money and other property of whatever kind in their possession or under their control belonging to the Corporation,
in such amounts and by such surety companies as the Chair of the Board, Chief Executive Officer, President or the Board may determine.
The premiums on such bonds shall be paid by the Corporation and the bonds so furnished shall be in the custody of the Secretary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.13. Securities of Other Corporations</B>. Powers of attorney, proxies, waivers of notice of meeting, consents in writing and other
instruments relating to securities owned by the Corporation may be executed in the name of and on behalf of the Corporation by the Chair
of the Board, Chief Executive Officer, President, any Vice President or any officers authorized by the Board. Any such officer, may,
in the name of and on behalf of the Corporation, take all such action as any such officer may deem advisable to vote in person or by
proxy at any meeting of security holders of any corporation in which the Corporation may own securities, or to consent in writing, in
the name of the Corporation as such holder, to any action by such corporation, and at any such meeting or with respect to any such consent
shall possess and may exercise any and all rights and power incident to the ownership of such securities and which, as the owner thereof,
the Corporation might have exercised and possessed. The Board may from time to time confer like powers upon any other person or persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.14. Amendments</B>. The Board shall have the power to adopt, amend, alter or repeal the Bylaws. The affirmative vote of a majority
of the Board shall be required to adopt, amend, alter or repeal the Bylaws. The Bylaws also may be adopted, amended, altered or repealed
by the stockholders; provided, however, that in addition to any vote of the holders of any class or series of capital stock of the Corporation
required by applicable law or the Certificate of Incorporation, the affirmative vote of the holders of at least sixty-six and two-thirds
percent (66-2/3%) of the voting power (except as otherwise provided in <U>Section 8.6</U>) of all outstanding shares of capital stock
of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required for
the stockholders to adopt, amend, alter or repeal the Bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 9.15.
Exclusive Forum</B>. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of
the State of Delaware (or, if the Court of Chancery lacks jurisdiction, the federal district court for the District of Delaware
unless said court lacks subject matter jurisdiction in which case the Superior Court of the State of Delaware) shall be the sole and
exclusive forum for (a) any derivative action or proceeding brought on behalf of the Corporation, (b) any action asserting a claim
of breach of a fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the
Corporation&rsquo;s stockholders, (c) any action asserting a claim arising under any provision of the DGCL, the Certificate of
Incorporation or these Bylaws or (d) any action asserting a claim governed by the internal affairs doctrine, except for, as to each
of (a) through (d) above, any claim (A) as to which the Court of Chancery determines that there is an indispensable party not
subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of
the Court of Chancery within ten days following such determination), (B) which is vested in the exclusive jurisdiction of a court or
forum other than the Court of Chancery, or (C) for which the Court of Chancery does not have subject matter jurisdiction.
Notwithstanding any of the foregoing to the contrary, unless the Corporation consents in writing to the selection of an alternative
forum, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any
complaint asserting a cause of action arising under federal securities laws, including the Securities Act of 1933, as amended.
Notwithstanding any of the foregoing to the contrary, the provisions of this Section 9.15 will not apply to suits brought to enforce
a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. If any
action the subject matter of which is within the scope of the preceding sentence is filed in a court other than a court located
within the State of Delaware (a &ldquo;<B><I>Foreign Action</I></B>&rdquo;) in the name of any stockholder, then such stockholder
shall be deemed to have consented to (i) the personal jurisdiction of the state and federal courts located within the State of
Delaware in connection with any action brought in any such court to enforce the preceding sentence and (ii) having service of
process made upon such stockholder in any such action by service upon such stockholder&rsquo;s counsel in the Foreign Action as
agent for such stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Adopted
March 18, 2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 26; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>ex10-11.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.11</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex10-11_001.jpg" ALT=""></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Executive
Employment Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Employment Agreement (the &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of March 19, 2025 (&ldquo;<B>Effective Date</B>&rdquo;),
by and between George Ng (the &ldquo;<B>Executive</B>&rdquo;) and Processa Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;
or &ldquo;<B>Processa</B>&rdquo;) (collectively referred to herein as the &ldquo;Parties&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires to employ the Executive on the terms and conditions set forth herein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Executive desires to be employed by the Company on such terms and conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants, promises, and obligations set forth herein, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Term</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
This Agreement shall be effective for the term beginning on the Effective Date and continue until terminated or modified pursuant to
Section 4 of this Agreement. The period during which the Executive is employed by the Company hereunder is hereinafter referred to as
the &ldquo;<B>Employment Term.</B>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Position and Duties</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
During the Employment Term, the Executive shall serve as the Chief Financial Officer of the Company. In such position, the Executive
shall have such duties, authority, and responsibilities as shall be mutually agreed upon by the Chief Executive Officer and the Executive,
which duties, authority, and responsibilities are consistent with the Executive&rsquo;s position and prevailing industry standards. During
the Employment Term, the Executive shall devote substantially all of the Executive&rsquo;s business time and attention to the performance
of the Executive&rsquo;s duties hereunder and will not engage in any other business, profession, or occupation for compensation, which
would conflict or interfere with the performance of such services either directly or indirectly without the prior written consent of
the Company&rsquo;s Chief Executive Officer (&ldquo;<B>CEO</B>&rdquo;). Notwithstanding, the Executive shall be permitted to (i) manage Executive&rsquo;s
personal, financial and legal affairs, investments and holdings, (ii) participate in trade associations, (iii) serve on the board of
directors of not-for-profit or tax-exempt charitable organizations, (iv) serve on the board of directors of for-profit organizations
that do not directly compete with the Company, with the prior approval of the CEO and (iv) conduct business and other
matters that were previously disclosed to the Company prior to the Employment Term, in each case, subject to compliance with this Agreement
and provided that such activities do not materially interfere with Executive&rsquo;s performance of Executive&rsquo;s duties and responsibilities
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Compensation</U></B></FONT><B><U>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and Benefits</FONT></U></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Base Salary</U></FONT>. The Company shall pay the Executive an annual
base salary of $400,000, less all lawfully required deductions and withholdings (&ldquo;<B>Base Salary</B>&rdquo;), which will be paid
in periodic installments in accordance with the Company&rsquo;s customary payroll practices and applicable wage payment laws, but no
less frequently than monthly. The Executive&rsquo;s Base Salary shall be reviewed annually and may be increased based on an assessment
of Executive&rsquo;s performance, the performance of the Company, inflation, the then prevailing salary scales for comparable positions
and other relevant factors; provided, however, that any increase in Base Salary shall be solely within the discretion of the CEO and Compensation Committee of the Company&rsquo;s Board. Executive&rsquo;s Base Salary may not be subject to reduction from
the level set forth above, unless pursuant to a salary reduction program of general application to employment contract executives of
the Company, provided that, unless agreed to in writing by Executive, the percentage reduction of Executive&rsquo;s Base Salary shall
not be greater than the percentage reduction applied to any other employment contract executive of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Bonus</U></FONT><U>. </U>This is a non-qualified plan used by the Company
to provide special compensation to key executives. The Company&rsquo;s contribution to an executive bonus plan is considered salary to
the Executive and is therefore subject to taxation. The Executive is eligible to participate in the bonus pool with a target bonus equal
to 50% of Executive&rsquo;s Base Salary, as then in effect (the &ldquo;Target Bonus&rdquo;), as may be awarded pursuant to any annual
executive bonus plan and related corporate goals approved solely at the discretion of the Compensation Committee of the Board. Any such
Annual Bonus shall contain such rights and features as are typically afforded to other contract executives of the Company. <U><BR>
<BR></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Equity Compensation (RSUs, RSAs, Stock Options, Other)</U></FONT>. The
Compensation Committee of the Board (the &ldquo;<B>Compensation Committee</B>&rdquo;), and pursuant to Processa&rsquo;s 2019 Omnibus
Incentive Plan, or any such additional incentive plans that may be in place at such time, (the &ldquo;<B>Plan</B>&rdquo;) has previously
granted new hire RSUs to Employee. Any additional equity grants will be at the reasonable discretion of the Compensation Committee of
the Board. The specifics of the grants will be described in the Award Agreement to be provided to the Executive. Notwithstanding the
above and any other sections in this Agreement, all unvested equity granted herein, any additional unvested granted and any other unvested
equity-linked securities that may be granted in the future shall immediately vest upon a Change in Control (as defined in Section 4.5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Incentive and Deferred Compensation</U></FONT>. Employee shall be eligible
to participate in all incentive and deferred compensation programs available to other executives or officers of Processa, such participation
to be in the same form, under the same terms, and to the same extent that such programs are made available to other such similarly situated
executives or officers. Except as otherwise provided herein, nothing in this Agreement shall be deemed to require the payment of bonuses,
awards, or incentive compensation to Employee if such payment would not otherwise be required under the terms of Processa&rsquo;s incentive
compensation programs. The Company reserves the right to interpret, amend or terminate any incentive compensation program at any time
in its sole discretion, subject to the terms of such incentive compensation program and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">3.5
<U>Employee Benefits</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. During the Employment Term,
the Executive shall be entitled to participate in all employee benefit plans, practices, and programs maintained by the Company, as in
effect from time to time (collectively, &ldquo;<B>Employee Benefit Plans</B>&rdquo;), on a basis which is no less favorable than is provided
to other similarly situated executives of the Company, to the extent consistent with applicable law and the terms of the applicable Employee
Benefit Plans. The Company reserves the right to amend or terminate any Employee Benefit Plans at any time in its sole discretion, subject
to the terms of such Employee Benefit Plan and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.6
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Paid Time Off</U>. During the Employment Term, the
Executive will be entitled to earn and use paid time off (&ldquo;<B>PTO</B>&rdquo;) in accordance with the terms of the Company&rsquo;s
PTO policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.7
<U>Business Expenses</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
The Executive shall be entitled to reimbursement for all reasonable and necessary out-of-pocket business, entertainment, and travel expenses
incurred by the Executive in connection with the performance of the Executive&rsquo;s duties hereunder in accordance with the Company&rsquo;s
expense reimbursement policies and procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Withholding</U></FONT>. By signing this Agreement, the Executive hereby
authorizes the Company to withhold from any amount payable hereunder any Federal, state, and local taxes in order for the Company to
satisfy any withholding tax obligation it may have under any applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<FONT STYLE="vertical-align: baseline"><B><U>Termination of Employment</U></B></FONT>. The Employment Term and the Executive&rsquo;s
employment with the Company may be terminated upon the following conditions or events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Death or Permanent Disability</U>. The Executive employment under this Agreement and the Employment Term shall terminate immediately
in the event of the death or Permanent Disability of Executive. &ldquo;Permanent Disability&rdquo; shall be defined as (1) Executive&rsquo;s
inability to perform the essential functions of his position, with or without reasonable accommodation, for a period of six consecutive
months or for an aggregate of six months in any twelve month period, as determined by a physician licensed to practice medicine and designated
by Employer and acceptable to the Executive, having reviewed and considered information provided by the Executive&rsquo;s healthcare
provider(s); (2) if the Executive is subject to a legal decree of incompetency; or (3) the Executive receives benefits pursuant to a
long-term disability insurance plan, and the person or persons required to make disability determinations under the long-term disability
plan determines that the Executive has a disability that, if Executive qualified for such disability benefits, would provide coverage
for the longest period of time.. Any refusal by the Executive to submit to a medical examination for the purpose of determining a Permanent
Disability shall be deemed to constitute conclusive evidence of the Executive&rsquo;s Permanent Disability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Termination by Executive</U>. The Executive may voluntarily terminate their employment with the Company by providing at least ninety
(90) days written notice to the Company of such termination. Once such notice is given, the Company may elect to terminate the Executive
prior to the conclusion of the ninety-day period. The Executive shall be paid their Base Salary through the end of the 90-day period.
The Executive may also terminate their employment hereunder for &ldquo;Good Reason.&rdquo; For the purpose of determining Executive&rsquo;s
right to Severance Pay and other payments described in Section 5.2 and elsewhere in this Agreement, the Executive&rsquo;s resignation
will be for &ldquo;Good Reason&rdquo; if the Executive resigns after any of the following events: (A) a decrease of more than 5% in Executive&rsquo;s
Base Salary or annual target bonus opportunity other than a reduction in Executive&rsquo;s Base Salary or annual target bonus opportunity
that is implemented in connection with a contemporaneous, temporary reduction in annual base salaries by the same percentage affecting
other senior executives of the Company or (B) a material decrease in the Executive&rsquo;s authority or areas of responsibility as are
commensurate with such Executive&rsquo;s title or position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Termination by the Company Without Cause</U>. The Company may terminate the Executive&rsquo;s employment hereunder for any reason
other than Cause by delivering written notice of termination to the Executive at least ninety (90) days prior to the date of termination.
The Company may elect to earlier terminate and pay Executive their regular Base Salary and benefits through the end of the 90-day period
as an addition to severance pay in lieu of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Termination by the Company for Cause</U>. Employer may terminate the Executive immediately for Cause. For purposes of this Agreement,
&ldquo;Cause&rdquo; shall mean:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
the Executive&rsquo;s refusal or inability to perform or observe any of the Executive&rsquo;s material duties, responsibilities or obligations
set forth in this Agreement (other than any such refusal or inability resulting from Executive&rsquo;s Permanent Disability); provided,
however, that Employer shall not be deemed to have Cause pursuant to this clause unless the Company gives the Executive written notice
that the specified conduct has occurred and the Executive fails to cure the conduct within thirty (30) days after receipt of such notice;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
any act of the Executive involving fraud, theft, misappropriation of funds, or embezzlement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
the Executive is convicted of any felony or misdemeanor involving dishonesty, violence or moral turpitude, or which in the reasonable
judgment of the Company, reflects materially and adversely on the reputation of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
the Executive&rsquo;s material failure to comply with any of the Company&rsquo;s policies, including but not limited to by engaging in
the illegal use of controlled substances, the knowing abuse of prescribed medications, or the misuse of alcohol;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
the Executive&rsquo;s material breach of fiduciary duty of care, loyalty, and good faith, ensuring diligent, company-focused actions
and legal compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Termination of Employment Involving a Change of Control</U>. The Executive&rsquo;s employment with the Company may be terminated in
the event that a Change in Control occurs, and the Executive&rsquo;s employment with the Company is terminated by the Company Without
Cause or by the Executive for Good Reason at any time within the three (3) month period before the date of and in connection with such
Change in Control or during the twelve (12) month period following the date of such Change in Control (&ldquo;<B>Termination as a Result
of a Change in Control</B>&rdquo;). For purposes of this Section, &ldquo;<B>Change in Control</B>&rdquo; shall mean and include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Acquisition by any &ldquo;Person&rdquo; or &ldquo;Group&rdquo; of securities entitled to vote generally in the election of directors
(&ldquo;voting securities&rdquo;) of the Company that represent 50% or more of the combined voting power of the Company&rsquo;s then
outstanding voting securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
A change in the composition of the Board occurring within a twelve (12) month period, as a result of which a majority of the incumbent
directors are replaced by directors whose appointment or election is not endorsed by a majority of the incumbent directors before the
date of the appointment or election;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Merger or consolidation in which the seller&rsquo;s shareholders no longer control the surviving entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of substantially all assets to an unrelated entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Resignation of All Other Positions</U></FONT>. On termination of the Executive&rsquo;s
employment hereunder for any reason, the Executive shall be deemed to have resigned from all positions that the Executive holds as an
officer or member of the Board (or a committee thereof) of the Company or any of its affiliates (and shall confirm such resignation in
writing upon the request of the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">4.7
<U>Termination Date</U>. The final date on which the Executive is actually employed by the Company pursuant to this Agreement shall be
the &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B>Termination
Date</B><FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">5.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Compensation on Termination
of Employment</U></B><U><FONT STYLE="font-weight: normal">. </FONT></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Earned and Accrued Payments</U>. In the event that the Executive&rsquo;s employment is terminated, the Executive shall be entitled
to receive: (a) any accrued but unpaid Base Salary, which shall be paid on the pay date immediately following the Executive&rsquo;s Termination
Date, unless earlier required by applicable law; (b) any accrued but unpaid target annual bonus or any other granted bonus where such
bonus was determined prior to the Termination Date, which shall be paid on the otherwise applicable payment date; (c) reimbursement for
unreimbursed business expenses properly incurred by the Executive, which shall be subject to and paid in accordance with the Company&rsquo;s
expense reimbursement policy; and (d) such employee benefits (including equity compensation), if any, to which the Executive may be entitled
under the Company&rsquo;s employee benefit plans as of the Termination Date; provided that, in no event shall the Executive be entitled
to any payments in the nature of severance or termination payments except as specifically provided herein. The treatment of any outstanding
equity awards shall be determined in accordance with the terms in this Agreement, of the Plan and the applicable award agreements. For
clarification purposes, if the Termination Date occurs prior to the date of payment of the prior year bonus, the entire unpaid bonus
from the prior year plus the pro-rata accrued but unpaid bonus from the year of the Termination date would be included in 5.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Severance Pay</U>. In the event that the Executive&rsquo;s employment with the Company is terminated due to death or Permanent Disability,
by the Company Without Cause, the Executive terminates employment with the Company for Good Reason, and/or there is a Termination as
a Result of a Change in Control (each a &ldquo;Separation Event&rdquo;), the Executive shall be entitled to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>a.</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    year of Base Salary and Target Bonus (&ldquo;<B>Severance Pay</B>&rdquo;), paid out in accordance with the normal payroll practices
    of the Company following the Termination Date and paid out over the twelve (12) month period. Payment of any Severance Pay shall
    be conditioned upon the Executive executing and not revoking a separation agreement reasonably satisfactory to the Company (or its
    successor) and to the Executive, including a general release of all claims that is reasonably satisfactory with terms substantially
    similar to typical agreements to the Company (or its successor) and the Executive; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>b.</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the twelve (12) month period following the Separation Event, (or, if earlier, the date on which the applicable continuation period
    under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&ldquo;COBRA&rdquo;) expires), and the Executive has
    elected COBRA coverage then the Company shall arrange to provide Executive and his eligible dependents who were covered under the
    Company&rsquo;s health insurance plans as of the date of the Separation Event with health (including medical and dental) insurance
    benefits substantially similar to those provided to such dependents immediately prior to the date of such Separation Event. The Executive
    will be responsible for any portion of the premium associated with such coverage that he was responsible for during employment. If
    the Company is not reasonably able to continue health insurance benefits coverage under the Company&rsquo;s insurance plans, the
    Company shall provide substantially equivalent coverage under other third-party insurance sources. If any of the Company&rsquo;s
    health benefits are self-funded as of the date of Separation Event, or if the Company cannot provide the foregoing benefits in a
    manner that exempt from Section 409A of the Code or that is otherwise compliant with applicable law (including, without limitation,
    Section 2716 of the Public Health Service Act), instead of providing continued health insurance benefits as set forth above, the
    Company shall instead pay to the Executive an amount equal to twelve (12) multiplied by the monthly premium the Executive would be
    required to pay for continuation coverage pursuant to the COBRA for his/her eligible dependents who were covered under the Company&rsquo;s
    health plans as of the date of the Separation Event (calculated by reference to the premium as of the date of the Separation Event),
    which amount shall be paid on the Payment Date. Eligibility for this benefit is contingent upon the execution and nonrevocation of
    the separation agreement referenced above.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Section 280G</U></FONT>. If the Executive becomes entitled to any amount
in the nature of compensation payable by the Company that is contingent on a change in ownership, effective control, or substantial ownership
of a substantial portion of the Company&rsquo;s assets within the meaning of Section 280G of the Internal Revenue Code (&ldquo;Covered
Payments&rdquo;) and constitute &ldquo;Parachute Payments&rdquo; within the meaning within the meaning of Section 280G of the Internal
Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), and that is subject to the excise tax imposed by Section 4999 of the Code
(&ldquo;Excise Tax&rdquo;), a calculation shall be made comparing (i) the Net Benefit (as defined below) to the Executive of the Covered
Payments after payment of the Excise Tax to (ii) the Net Benefit to the Executive if the Covered Payments are limited to the extent necessary
to avoid being subject to the Excise Tax. Only if the amount calculated under (i) above is less than the amount under (ii) above will
the Covered Payments be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise
Tax (that amount, the &ldquo;Reduced Amount&rdquo;). &ldquo;Net Benefit&rdquo; shall mean the present value of the Covered Payments net
of all federal, state, local, foreign income, employment and excise taxes. In the event reduction is required, the Covered Payments shall
be reduced by the Company in the following order: (i) cash severance payments hereunder to the extent not subject to Section 409A of
the Code in the reverse order of payment; (ii) any other portion of the Covered Payments that are not subject to Section 409A of the
Code in the reverse order of payment (other than any acceleration of vesting of equity awards); (iii) Covered Payments that are not subject
to Section 409A of the Code that arise from the accelerated vesting of equity awards, and; (iv) Covered Payments that are subject to
Section 409A of the Code in a manner consistent with Section 409A of the Code. All determinations pursuant to this Section 5.4 shall
be made by tax accountants selected by the Company and reasonably acceptable to Executive (the &ldquo;Accountants&rdquo;), whose determinations
shall be binding on the Company and the Executive absent manifest error. The Executive shall provide the Accountants with such information
and documents as the Accountants may reasonably request in order for the Accountants to make their determinations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<FONT STYLE="vertical-align: baseline"><B><U>Return of Property and Employee Non-Solicit</U></B></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Return of Property</U>. Upon termination of Executive&rsquo;s employment with the Company for any reason, upon request, Executive
will use reasonable efforts to promptly deliver to the Company all equipment, correspondence, drawings, manuals, letters, notes, notebooks,
reports, programs, plans, proposals, financial documents, or any other documents or property containing material information pertaining
to the Company&rsquo;s customers, business plans, marketing strategies, products, property or processes..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Non-Solicitation of Employees Covenant</U>. Executive acknowledges that the Company&rsquo;s employees and consultants are a valuable
asset to the Company, especially because such employees have access to and knowledge of the Company&rsquo;s confidential information
and trade secrets. As such, Executive agrees for a period of one-year from the Termination Date, with respect to any Company employee
with whom Executive had material business contact during their employment with the Company, Executive will not (i) induce or attempt
to induce such employee of the Company to leave employment or contracting with the Company; or (ii) directly solicit the services of
or hire away such current employee of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Notification of Future Employers</U>. Executive hereby agrees to notify any future employers or prospective employers of the foregoing
obligations and authorizes the Company to provide a single notice of the terms in Section 6 to Executive&rsquo;s actual or future employers
(or persons or entities that contract or seek to contract for Executive&rsquo;s services).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
<U>Remedies</U>. In the event of a breach or threatened breach by either party, each party hereby consents and agrees that the non-breaching
party may (as determined by a court of law or proper judicial authority) be entitled to seek, in addition to other available remedies,
a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of competent jurisdiction,
and that money damages would not afford an adequate remedy, without the necessity of showing any actual damages. The aforementioned equitable
relief may (as determined by a court of law or proper judicial authority) be in addition to, not in lieu of, legal remedies, monetary
damages, or other available forms of relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B><U>Assignment of Inventions and Rights</U></B><U>.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Work Product</U>. The Executive acknowledges and agrees that all designs, devices, discoveries, processes, proprietary software, writings,
inventions, improvements and documentation, and any other works of authorship (collectively, &ldquo;<B>Work Product</B>&rdquo;), and
all related know-how, produced, made, conceived or authored by the Executive, solely or jointly with others, in the course of his employment
with the Company together with any intellectual property rights concerning the Work Product produced, made, conceived or authored by
the Executive, including any moral rights relating to any of the foregoing, are works made for hire and the property of the Company if
such works (i) result or are derived from, at the time the Work Product is produced, made, conceived or reduced to practice, the actual
business, research, or development of the Company; or (ii) are result from any work performed by the Executive for or on behalf of the
Company; or (iii) are created or developed with the use of Proprietary Information or Company equipment, supplies, facilities, information,
materials or other Company resources (&ldquo;Company IP&rdquo;). The Executive shall disclose in writing any such Company IP promptly
to the Company and hereby irrevocably assign any and all rights in their entirety, throughout the world, in and to such works to the
Company or its assignees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
To the extent that any such Company IP may not, by operation of law, be deemed works made for hire, this Agreement shall constitute an
irrevocable assignment by the Executive to the Company of the ownership of, and all right, title, and interest in and to such items,
including an irrevocable assignment of all moral rights relating thereto, and the Company shall have the right to obtain and hold in
its own name, all intellectual property rights, including without limitation, patent, trade secret, copyright and similar protections
which may be available in such Company IP throughout the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
The Executive agrees that all work product made by them after the end of employment with the Company, whether created solely by the Executive
or jointly with others, that is based on or contains Confidential Information of the Company, shall belong to the Company; and the Executive
irrevocably assigns any and all rights in their entirety, throughout the world, in and to such future Work Product to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
The Executive agrees to use reasonable efforts to assist the Company, or its designee or assignee, to secure and perfect the Company&rsquo;s
(and/or such designee&rsquo;s) rights in such Work Product and any copyrights, patents, trade secrets, mask work rights or other intellectual
property rights and/or moral rights relating thereto in any and all countries, including the written disclosure to the Company of all
information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments
which the Company shall deem necessary in order to apply for, obtain and protect such rights and in order to assign and convey to the
Company, its successors, assigns, and nominees the sole and exclusive rights, title and interest in and to such Company IP, and any copyright,
patents, trade secrets, mask work rights or other intellectual property rights and/or moral rights contained therein and/or relating
thereto. The Executive further agrees that their obligation to execute or cause to be executed any such instrument or papers shall continue
after employment with the Company ends. The Executive shall be entitled to reimbursement for reasonable expenses in providing such post-employment
assistance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
In the event the Company is unable due to Executive&rsquo;s subsequent disability, incapacity or for any other reason whatsoever to secure
his signature to any lawful and necessary document required to apply for, register or execute any patent, copyright or other applications
with respect to any such Company IP, the Executive hereby irrevocably appoints the Company and its duly authorized officers and agents
as its agents and attorneys-in-fact to execute and file any such application and to do all other lawfully permitted acts to further the
prosecution and issuance of patents, copyrights or other rights thereon with the same legal force and effect as if executed by the Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
In the event Company should not desire to secure and perfect its rights to any Company IP, but should desire to keep the same secret,
the Executive agrees that they will do everything reasonably in his power to assist Company in this and will not disclose any information
relating to such Company IP except with the prior written consent of Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7
In order to permit the Company to claim rights to which it may be entitled, Executive agrees to disclose to the Company in writing and
in confidence all inventions or Company IP that Executive makes or conceive of, either solely or jointly with others, during the term
of his employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8
All Work Product that was made by the Executive before his employment with the Company (collectively referred to as &ldquo;Prior Inventions&rdquo;)
are excluded from Section 5 of this Agreement. The Executive agrees not to incorporate into a Company product, process or code, or other
Company Work Product, a Prior Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">8.
<U>Acknowledgement</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
The Executive acknowledges and agrees that the services to be rendered by the Executive to the Company are of a special and unique character;
that the Executive will obtain knowledge and skill relevant to the Company&rsquo;s industry, methods of doing business and marketing
strategies by virtue of the Executive&rsquo;s employment; and that the restrictive covenants and other terms and conditions of this Agreement
are reasonable and reasonably necessary to protect the legitimate business interest of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">9.
<U>Governing Law: Jurisdiction and Venue</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
This Agreement, for all purposes, shall be construed in accordance with the laws of Delaware without regard to conflicts of law principles.
Any action or proceeding by either of the parties to enforce this Agreement shall be brought only in a state or federal court located
in the State of Delaware. The parties hereby irrevocably submit to the exclusive jurisdiction of such courts and waive the defense of
inconvenient forum to the maintenance of any such action or proceeding in such venue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">10.
<U>Entire Agreement</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Unless specifically provided herein, this Agreement contains all of the understandings and representations between the Executive and
the Company pertaining to the subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations,
and warranties, both written and oral, with respect to such subject matter. The parties mutually agree that the Agreement can be specifically
enforced in court and can be cited as evidence in legal proceedings alleging breach of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">11.
<U>Modification and Waiver</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
No provision of this Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by
the Executive and by the Company. No waiver by either of the parties of any breach by the other party hereto of any condition or provision
of this Agreement to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition
at the same or any prior or subsequent time, nor shall the failure of or delay by either of the parties in exercising any right, power,
or privilege hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such
right, power, or privilege.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Severability</U></FONT>. Should any provision of this Agreement be held
by a court of competent jurisdiction to be enforceable only if modified, or if any portion of this Agreement shall be held as unenforceable
and thus stricken, such holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue
to be binding upon the parties with any such modification to become a part hereof and treated as though originally set forth in this
Agreement. The parties further agree that any such court is expressly authorized to modify any such unenforceable provision of this Agreement
in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting
any or all of the offending provision, adding additional language to this Agreement, or by making such other modifications as it deems
warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law. The parties
expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against each of them. In any event,
should one or more of the provisions of this Agreement be held to be invalid, illegal, or unenforceable in any respect, such invalidity,
illegality, or unenforceability shall not affect any other provisions hereof, and if such provision or provisions are not modified as
provided above, this Agreement shall be construed as if such invalid, illegal, or unenforceable provisions had not been set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">13.
<U>Captions</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Captions and headings of the sections and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement
is to be construed by reference to the caption or heading of any section or paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">14.
<U>Counterparts</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
This Agreement may be executed in separate counterparts, each of which shall be deemed an original, but all of which taken together shall
constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Section 409A</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1
General. The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt from Section 409A
of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively, &ldquo;Section
409A&rdquo;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2
Separation from Service. Notwithstanding anything in this Agreement to the contrary, any compensation or benefits payable under this
Agreement that is considered nonqualified deferred compensation under Section 409A and is designated under this Agreement as payable
upon the Executive&rsquo;s termination of employment shall be payable only upon Executive&rsquo;s &ldquo;separation from service&rdquo;
with the Company within the meaning of Section 409A (a &ldquo;Separation from Service&rdquo;) and, except as provided below, any such
compensation or benefits described in Section 4(b) shall not be paid until the fifty-fifth (55th) day following Executive&rsquo;s Separation
from Service (the &ldquo;First Payment Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3
Specified Employee. Notwithstanding anything in this Agreement to the contrary, if the Executive is deemed by the Company at the time
of the Executive&rsquo;s Separation from Service to be a &ldquo;specified employee&rdquo; for purposes of Section 409A, to the extent
delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid
a prohibited distribution under Section 409A, such portion of the Executive&rsquo;s benefits shall not be provided to the Executive prior
to the earlier of (i) the expiration of the six-month period measured from the date of the Executive&rsquo;s Separation from Service
with the Company or (ii) the date of the Executive&rsquo;s death. Upon the first business day following the expiration of the applicable
Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to the Executive (or the Executive&rsquo;s
estate or beneficiaries), and any remaining payments due to the Executive under this Agreement shall be paid as otherwise provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.4
Expense Reimbursements. To the extent that any reimbursements under this Agreement are subject to Section 409A, any such reimbursements
payable to the Executive shall be paid to the Executive no later than December 31st of the calendar year following the calendar year
in which the expense was incurred; provided, that the Executive submits the Executive&rsquo;s reimbursement request promptly following
the date the expense is incurred, the amount of expenses reimbursed in one calendar year shall not affect the amount eligible for reimbursement
in any subsequent calendar year, other than medical expenses referred to in Section 105(b) of the Code, and Executive&rsquo;s right to
reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">15.5
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Installments. The Executive&rsquo;s right to receive
any installment payments under this Agreement, including without limitation any continuation salary payments that are payable on the
Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment
shall at all times be considered a separate and distinct payment as permitted under Section 409A. Except as otherwise permitted under
Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional
tax or interest pursuant to Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">16.
<U>Successors and Assigns</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
This Agreement is personal to the Executive and shall not be assigned by the Executive. Any purported assignment by the Executive shall
be null and void from the initial date of the purported assignment. The Company may assign this Agreement to any successor or assign
(whether direct or indirect, by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets
of the Company. This Agreement shall inure to the benefit of the Company and permitted successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Notice</U></FONT>. Notices and all other communications provided for in
this Agreement shall be in writing and shall be delivered personally or sent by registered or certified mail, return receipt requested,
or by overnight carrier to the parties at the addresses set forth below (or such other addresses as specified by the parties by like
notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If
    to the Company</B>:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Administrative Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
    Pharmaceuticals, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7380
    Coca Cola Drive, Suite 106</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hanover,
    MD 21076</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If
    to the Executive</B><FONT STYLE="font-weight: normal; vertical-align: baseline">: </FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">Mr.
    George Ng</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">6411
    Lilac Mist Bend</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">San
    Diego, CA 92130</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">18.
<U>Survival</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. </FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the expiration or other termination of this Agreement, the respective rights and obligations of the parties hereto shall survive such
expiration or other termination to the extent necessary to carry out the intentions of the parties under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Acknowledgement of Full Understanding</U></FONT>. THE EXECUTIVE ACKNOWLEDGES
AND AGREES THAT THE EXECUTIVE HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE EXECUTIVE ACKNOWLEDGES AND
AGREES THAT THE EXECUTIVE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF THE EXECUTIVE&rsquo;S CHOICE BEFORE
SIGNING THIS AGREEMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>[REST
OF PAGE INTENTIONALLY BLANK</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>SIGNATURES
TO FOLLOW ON NEXT PAGE]</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROCESSA
    <FONT STYLE="text-transform: uppercase">Pharmaceuticals, Inc.</FONT></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MR.
    GEORGE NG</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Justin Yorke</I>&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/
    George Ng</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin
    Yorke, Chairman of the Board</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>4
<FILENAME>ex10-12.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.12</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex10-12_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Executive
Employment Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Employment Agreement (the &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of March 19, 2025 (&ldquo;<B>Effective Date</B>&rdquo;),
by and between Russell Skibsted (the &ldquo;<B>Executive</B>&rdquo;) and Processa Pharmaceuticals, Inc., a Delaware corporation (the
&ldquo;<B>Company</B>&rdquo; or &ldquo;<B>Processa</B>&rdquo;) (collectively referred to herein as the &ldquo;Parties&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires to employ the Executive on the terms and conditions set forth herein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Executive desires to be employed by the Company on such terms and conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants, promises, and obligations set forth herein, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Term</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
This Agreement shall be effective for the term beginning on the Effective Date and continue until terminated or modified pursuant to
Section 4 of this Agreement. The period during which the Executive is employed by the Company hereunder is hereinafter referred to as
the &ldquo;<B>Employment Term.</B>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Position and Duties</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
During the Employment Term, the Executive shall serve as the Chief Financial Officer of the Company. In such position, the Executive
shall have such duties, authority, and responsibilities as shall be mutually agreed upon by the Chief Executive Officer and the Executive,
which duties, authority, and responsibilities are consistent with the Executive&rsquo;s position and prevailing industry standards. During
the Employment Term, the Executive shall devote substantially all of the Executive&rsquo;s business time and attention to the performance
of the Executive&rsquo;s duties hereunder and will not engage in any other business, profession, or occupation for compensation, which
would conflict or interfere with the performance of such services either directly or indirectly without the prior written consent of
the Company&rsquo;s Chief Executive Officer (&ldquo;<B>CEO</B>&rdquo;). Notwithstanding, the Executive shall be permitted to (i) manage
Executive&rsquo;s personal, financial and legal affairs, investments and holdings, (ii) participate in trade associations, (iii) serve
on the board of directors of not-for-profit or tax-exempt charitable organizations, (iv) serve on the board of directors of for-profit
organizations that do not directly compete with the Company, with the prior approval of the CEO and (iv) conduct business and other matters
that were previously disclosed to the Company prior to the Employment Term, in each case, subject to compliance with this Agreement and
provided that such activities do not materially interfere with Executive&rsquo;s performance of Executive&rsquo;s duties and responsibilities
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Compensation </U></B></FONT><B><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
Benefits</FONT></U></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 <FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Base
Salary</U></FONT>. The Company shall pay the Executive an annual base salary of $400,000, less all lawfully required deductions and
withholdings (&ldquo;<B>Base Salary</B>&rdquo;), which will be paid in periodic installments in accordance with the Company&rsquo;s
customary payroll practices and applicable wage payment laws, but no less frequently than monthly. The Executive will be eligible
for a $50,000 base salary increase upon a cumulative (one or multiple) financing of at least $15 Million that he leads and
substantially participates in. The Executive&rsquo;s Base Salary shall be reviewed annually and may be increased based on an
assessment of Executive&rsquo;s performance, the performance of the Company, inflation, the then prevailing salary scales for
comparable positions and other relevant factors; provided, however, that any increase in Base Salary shall be solely within the
discretion of the CEO and Compensation Committee of the Company&rsquo;s Board. Executive&rsquo;s Base Salary may not be subject to
reduction from the level set forth above, unless pursuant to a salary reduction program of general application to employment
contract executives of the Company, provided that, unless agreed to in writing by Executive, the percentage reduction of
Executive&rsquo;s Base Salary shall not be greater than the percentage reduction applied to any other employment contract executive
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Bonus</U></FONT>. This is a non-qualified plan used by the Company to
provide special compensation to key executives. The Company&rsquo;s contribution to an executive bonus plan is considered salary to the
Executive and is therefore subject to taxation. The Executive is eligible to participate in the bonus pool with a target bonus equal
to 40% of Executive&rsquo;s Base Salary, as then in effect (the &ldquo;Target Bonus&rdquo;), as may be awarded pursuant to any annual
executive bonus plan and related corporate goals approved solely at the discretion of the Compensation Committee of the Board. Any such
Annual Bonus shall contain such rights and features as are typically afforded to other contract executives of the Company. <U><BR>
<BR></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Equity Compensation (RSUs, RSAs, Stock Options, Other)</U></FONT>. The
Compensation Committee of the Board (the &ldquo;<B>Compensation Committee</B>&rdquo;), and pursuant to Processa&rsquo;s 2019 Omnibus
Incentive Plan, or any such additional incentive plans that may be in place at such time, (the &ldquo;<B>Plan</B>&rdquo;) has previously
granted new hire RSUs to Employee. Any additional equity grants will be at the reasonable discretion of the Compensation Committee of
the Board. The specifics of the grants will be described in the Award Agreement to be provided to the Executive. Notwithstanding the
above and any other sections in this Agreement, all unvested equity granted herein, any additional unvested granted and any other unvested
equity-linked securities that may be granted in the future shall immediately vest upon a Change in Control (as defined in Section 4.5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Incentive and Deferred Compensation</U></FONT>. Employee shall be eligible
to participate in all incentive and deferred compensation programs available to other executives or officers of Processa, such participation
to be in the same form, under the same terms, and to the same extent that such programs are made available to other such similarly situated
executives or officers. Except as otherwise provided herein, nothing in this Agreement shall be deemed to require the payment of bonuses,
awards, or incentive compensation to Employee if such payment would not otherwise be required under the terms of Processa&rsquo;s incentive
compensation programs. The Company reserves the right to interpret, amend or terminate any incentive compensation program at any time
in its sole discretion, subject to the terms of such incentive compensation program and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline"><U>3.5
Employee Benefits</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. During the Employment Term, the
Executive shall be entitled to participate in all employee benefit plans, practices, and programs maintained by the Company, as in effect
from time to time (collectively, &ldquo;<B>Employee Benefit Plans</B>&rdquo;), on a basis which is no less favorable than is provided
to other similarly situated executives of the Company, to the extent consistent with applicable law and the terms of the applicable Employee
Benefit Plans. The Company reserves the right to amend or terminate any Employee Benefit Plans at any time in its sole discretion, subject
to the terms of such Employee Benefit Plan and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline"><U>3.6
</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid Time Off</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
During the Employment Term, the Executive will be entitled to earn and use paid time off (&ldquo;<B>PTO</B>&rdquo;) in accordance with
the terms of the Company&rsquo;s PTO policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline"><U>3.7
Business Expenses</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Executive shall be entitled
to reimbursement for all reasonable and necessary out-of-pocket business, entertainment, and travel expenses incurred by the Executive
in connection with the performance of the Executive&rsquo;s duties hereunder in accordance with the Company&rsquo;s expense reimbursement
policies and procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Withholding</U></FONT>. By signing this Agreement, the Executive hereby
authorizes the Company to withhold from any amount payable hereunder any Federal, state, and local taxes in order for the Company to
satisfy any withholding tax obligation it may have under any applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<FONT STYLE="vertical-align: baseline"><B><U>Termination of Employment</U></B></FONT>. The Employment Term and the Executive&rsquo;s
employment with the Company may be terminated upon the following conditions or events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Death or Permanent Disability</U>. The Executive employment under this Agreement and the Employment Term shall terminate immediately
in the event of the death or Permanent Disability of Executive. &ldquo;Permanent Disability&rdquo; shall be defined as (1) Executive&rsquo;s
inability to perform the essential functions of his position, with or without reasonable accommodation, for a period of six consecutive
months or for an aggregate of six months in any twelve month period, as determined by a physician licensed to practice medicine and designated
by Employer and acceptable to the Executive, having reviewed and considered information provided by the Executive&rsquo;s healthcare
provider(s); (2) if the Executive is subject to a legal decree of incompetency; or (3) the Executive receives benefits pursuant to a
long-term disability insurance plan, and the person or persons required to make disability determinations under the long-term disability
plan determines that the Executive has a disability that, if Executive qualified for such disability benefits, would provide coverage
for the longest period of time.. Any refusal by the Executive to submit to a medical examination for the purpose of determining a Permanent
Disability shall be deemed to constitute conclusive evidence of the Executive&rsquo;s Permanent Disability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Termination by Executive</U>. The Executive may voluntarily terminate their employment with the Company by providing at least ninety
(90) days written notice to the Company of such termination. Once such notice is given, the Company may elect to terminate the Executive
prior to the conclusion of the ninety-day period. The Executive shall be paid their Base Salary through the end of the 90-day period.
The Executive may also terminate their employment hereunder for &ldquo;Good Reason.&rdquo; For the purpose of determining Executive&rsquo;s
right to Severance Pay and other payments described in Section 5.2 and elsewhere in this Agreement, the Executive&rsquo;s resignation
will be for &ldquo;Good Reason&rdquo; if the Executive resigns after any of the following events: (A) a decrease of more than 5% in Executive&rsquo;s
Base Salary or annual target bonus opportunity other than a reduction in Executive&rsquo;s Base Salary or annual target bonus opportunity
that is implemented in connection with a contemporaneous, temporary reduction in annual base salaries by the same percentage affecting
other senior executives of the Company or (B) a material decrease in the Executive&rsquo;s authority or areas of responsibility as are
commensurate with such Executive&rsquo;s title or position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Termination by the Company Without Cause</U>. The Company may terminate the Executive&rsquo;s employment hereunder for any reason
other than Cause by delivering written notice of termination to the Executive at least ninety (90) days prior to the date of termination.
The Company may elect to earlier terminate and pay Executive their regular Base Salary and benefits through the end of the 90-day period
as an addition to severance pay in lieu of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Termination by the Company for Cause</U>. Employer may terminate the Executive immediately for Cause. For purposes of this Agreement,
&ldquo;Cause&rdquo; shall mean:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
the Executive&rsquo;s refusal or inability to perform or observe any of the Executive&rsquo;s material duties, responsibilities or obligations
set forth in this Agreement (other than any such refusal or inability resulting from Executive&rsquo;s Permanent Disability); provided,
however, that Employer shall not be deemed to have Cause pursuant to this clause unless the Company gives the Executive written notice
that the specified conduct has occurred and the Executive fails to cure the conduct within thirty (30) days after receipt of such notice;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
any act of the Executive involving fraud, theft, misappropriation of funds, or embezzlement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
the Executive is convicted of any felony or misdemeanor involving dishonesty, violence or moral turpitude, or which in the reasonable
judgment of the Company, reflects materially and adversely on the reputation of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
the Executive&rsquo;s material failure to comply with any of the Company&rsquo;s policies, including but not limited to by engaging in
the illegal use of controlled substances, the knowing abuse of prescribed medications, or the misuse of alcohol;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
the Executive&rsquo;s material breach of fiduciary duty of care, loyalty, and good faith, ensuring diligent, company-focused actions
and legal compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Termination of Employment Involving a Change of Control</U>. The Executive&rsquo;s employment with the Company may be terminated in
the event that a Change in Control occurs, and the Executive&rsquo;s employment with the Company is terminated by the Company Without
Cause or by the Executive for Good Reason at any time within the three (3) month period before the date of and in connection with such
Change in Control or during the twelve (12) month period following the date of such Change in Control (&ldquo;<B>Termination as a Result
of a Change in Control</B>&rdquo;). For purposes of this Section, &ldquo;<B>Change in Control</B>&rdquo; shall mean and include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Acquisition by any &ldquo;Person&rdquo; or &ldquo;Group&rdquo; of securities entitled to vote generally in the election of directors
(&ldquo;voting securities&rdquo;) of the Company that represent 50% or more of the combined voting power of the Company&rsquo;s then
outstanding voting securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
A change in the composition of the Board occurring within a twelve (12) month period, as a result of which a majority of the incumbent
directors are replaced by directors whose appointment or election is not endorsed by a majority of the incumbent directors before the
date of the appointment or election;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Merger or consolidation in which the seller&rsquo;s shareholders no longer control the surviving entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline"><U>d)
</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of substantially all assets to an unrelated
entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Resignation of All Other Positions</U></FONT>. On termination of the Executive&rsquo;s
employment hereunder for any reason, the Executive shall be deemed to have resigned from all positions that the Executive holds as an
officer or member of the Board (or a committee thereof) of the Company or any of its affiliates (and shall confirm such resignation in
writing upon the request of the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline"><U>4.7
Termination Date. The final date on which the Executive is actually employed by the Company pursuant to this Agreement shall be the &ldquo;</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B>Termination
Date</B><FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">5.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Compensation on Termination
of Employment</U></B><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Earned and Accrued Payments</U>. In the event that the Executive&rsquo;s employment is terminated, the Executive shall be entitled
to receive: (a) any accrued but unpaid Base Salary, which shall be paid on the pay date immediately following the Executive&rsquo;s Termination
Date, unless earlier required by applicable law; (b) any accrued but unpaid target annual bonus or any other granted bonus where such
bonus was determined prior to the Termination Date, which shall be paid on the otherwise applicable payment date; (c) reimbursement for
unreimbursed business expenses properly incurred by the Executive, which shall be subject to and paid in accordance with the Company&rsquo;s
expense reimbursement policy; and (d) such employee benefits (including equity compensation), if any, to which the Executive may be entitled
under the Company&rsquo;s employee benefit plans as of the Termination Date; provided that, in no event shall the Executive be entitled
to any payments in the nature of severance or termination payments except as specifically provided herein. The treatment of any outstanding
equity awards shall be determined in accordance with the terms in this Agreement, of the Plan and the applicable award agreements. For
clarification purposes, if the Termination Date occurs prior to the date of payment of the prior year bonus, the entire unpaid bonus
from the prior year plus the pro-rata accrued but unpaid bonus from the year of the Termination date would be included in 5.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Severance Pay</U>. In the event that the Executive&rsquo;s employment with the Company is terminated due to death or Permanent Disability,
by the Company Without Cause, the Executive terminates employment with the Company for Good Reason, and/or there is a Termination as
a Result of a Change in Control (each a &ldquo;Separation Event&rdquo;), the Executive shall be entitled to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>a.</U></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                            year of Base Salary and Target Bonus (&ldquo;<B>Severance Pay</B>&rdquo;), paid out in accordance
                                            with the normal payroll practices of the Company following the Termination Date and paid
                                            out over the twelve (12) month period. Payment of any Severance Pay shall be conditioned
                                            upon the Executive executing and not revoking a separation agreement reasonably satisfactory
                                            to the Company (or its successor) and to the Executive, including a general release of all
                                            claims that is reasonably satisfactory with terms substantially similar to typical agreements
                                            to the Company (or its successor) and the Executive; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>b.</U></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the twelve (12) month period following the Separation Event, (or, if earlier, the date on
                                            which the applicable continuation period under the Consolidated Omnibus Budget Reconciliation
                                            Act of 1985, as amended (&ldquo;COBRA&rdquo;) expires), and the Executive has elected COBRA
                                            coverage then the Company shall arrange to provide Executive and his eligible dependents
                                            who were covered under the Company&rsquo;s health insurance plans as of the date of the Separation
                                            Event with health (including medical and dental) insurance benefits substantially similar
                                            to those provided to such dependents immediately prior to the date of such Separation Event.
                                            The Executive will be responsible for any portion of the premium associated with such coverage
                                            that he was responsible for during employment. If the Company is not reasonably able to continue
                                            health insurance benefits coverage under the Company&rsquo;s insurance plans, the Company
                                            shall provide substantially equivalent coverage under other third-party insurance sources.
                                            If any of the Company&rsquo;s health benefits are self-funded as of the date of Separation
                                            Event, or if the Company cannot provide the foregoing benefits in a manner that exempt from
                                            Section 409A of the Code or that is otherwise compliant with applicable law (including, without
                                            limitation, Section 2716 of the Public Health Service Act), instead of providing continued
                                            health insurance benefits as set forth above, the Company shall instead pay to the Executive
                                            an amount equal to twelve (12) multiplied by the monthly premium the Executive would be required
                                            to pay for continuation coverage pursuant to the COBRA for his/her eligible dependents who
                                            were covered under the Company&rsquo;s health plans as of the date of the Separation Event
                                            (calculated by reference to the premium as of the date of the Separation Event), which amount
                                            shall be paid on the Payment Date. Eligibility for this benefit is contingent upon the execution
                                            and nonrevocation of the separation agreement referenced above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Section 280G</U></FONT>. If the Executive becomes entitled to any amount
in the nature of compensation payable by the Company that is contingent on a change in ownership, effective control, or substantial ownership
of a substantial portion of the Company&rsquo;s assets within the meaning of Section 280G of the Internal Revenue Code (&ldquo;Covered
Payments&rdquo;) and constitute &ldquo;Parachute Payments&rdquo; within the meaning within the meaning of Section 280G of the Internal
Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), and that is subject to the excise tax imposed by Section 4999 of the Code
(&ldquo;Excise Tax&rdquo;), a calculation shall be made comparing (i) the Net Benefit (as defined below) to the Executive of the Covered
Payments after payment of the Excise Tax to (ii) the Net Benefit to the Executive if the Covered Payments are limited to the extent necessary
to avoid being subject to the Excise Tax. Only if the amount calculated under (i) above is less than the amount under (ii) above will
the Covered Payments be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise
Tax (that amount, the &ldquo;Reduced Amount&rdquo;). &ldquo;Net Benefit&rdquo; shall mean the present value of the Covered Payments net
of all federal, state, local, foreign income, employment and excise taxes. In the event reduction is required, the Covered Payments shall
be reduced by the Company in the following order: (i) cash severance payments hereunder to the extent not subject to Section 409A of
the Code in the reverse order of payment; (ii) any other portion of the Covered Payments that are not subject to Section 409A of the
Code in the reverse order of payment (other than any acceleration of vesting of equity awards); (iii) Covered Payments that are not subject
to Section 409A of the Code that arise from the accelerated vesting of equity awards, and; (iv) Covered Payments that are subject to
Section 409A of the Code in a manner consistent with Section 409A of the Code. All determinations pursuant to this Section 5.4 shall
be made by tax accountants selected by the Company and reasonably acceptable to Executive (the &ldquo;Accountants&rdquo;), whose determinations
shall be binding on the Company and the Executive absent manifest error. The Executive shall provide the Accountants with such information
and documents as the Accountants may reasonably request in order for the Accountants to make their determinations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<FONT STYLE="vertical-align: baseline"><B><U>Return of Property and Employee Non-Solicit</U></B></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Return of Property</U>. Upon termination of Executive&rsquo;s employment with the Company for any reason, upon request, Executive
will use reasonable efforts to promptly deliver to the Company all equipment, correspondence, drawings, manuals, letters, notes, notebooks,
reports, programs, plans, proposals, financial documents, or any other documents or property containing material information pertaining
to the Company&rsquo;s customers, business plans, marketing strategies, products, property or processes..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Non-Solicitation of Employees Covenant</U>. Executive acknowledges that the Company&rsquo;s employees and consultants are a valuable
asset to the Company, especially because such employees have access to and knowledge of the Company&rsquo;s confidential information
and trade secrets. As such, Executive agrees for a period of one-year from the Termination Date, with respect to any Company employee
with whom Executive had material business contact during their employment with the Company, Executive will not (i) induce or attempt
to induce such employee of the Company to leave employment or contracting with the Company; or (ii) directly solicit the services of
or hire away such current employee of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Notification of Future Employers</U>. Executive hereby agrees to notify any future employers or prospective employers of the foregoing
obligations and authorizes the Company to provide a single notice of the terms in Section 6 to Executive&rsquo;s actual or future employers
(or persons or entities that contract or seek to contract for Executive&rsquo;s services).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
<U>Remedies</U>. In the event of a breach or threatened breach by either party, each party hereby consents and agrees that the non-breaching
party may (as determined by a court of law or proper judicial authority) be entitled to seek, in addition to other available remedies,
a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of competent jurisdiction,
and that money damages would not afford an adequate remedy, without the necessity of showing any actual damages. The aforementioned equitable
relief may (as determined by a court of law or proper judicial authority) be in addition to, not in lieu of, legal remedies, monetary
damages, or other available forms of relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B><U>Assignment of Inventions and Rights</U></B><U>.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Work Product</U>. The Executive acknowledges and agrees that all designs, devices, discoveries, processes, proprietary software, writings,
inventions, improvements and documentation, and any other works of authorship (collectively, &ldquo;<B>Work Product</B>&rdquo;), and
all related know-how, produced, made, conceived or authored by the Executive, solely or jointly with others, in the course of his employment
with the Company together with any intellectual property rights concerning the Work Product produced, made, conceived or authored by
the Executive, including any moral rights relating to any of the foregoing, are works made for hire and the property of the Company if
such works (i) result or are derived from, at the time the Work Product is produced, made, conceived or reduced to practice, the actual
business, research, or development of the Company; or (ii) are result from any work performed by the Executive for or on behalf of the
Company; or (iii) are created or developed with the use of Proprietary Information or Company equipment, supplies, facilities, information,
materials or other Company resources (&ldquo;Company IP&rdquo;). The Executive shall disclose in writing any such Company IP promptly
to the Company and hereby irrevocably assign any and all rights in their entirety, throughout the world, in and to such works to the
Company or its assignees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
To the extent that any such Company IP may not, by operation of law, be deemed works made for hire, this Agreement shall constitute an
irrevocable assignment by the Executive to the Company of the ownership of, and all right, title, and interest in and to such items,
including an irrevocable assignment of all moral rights relating thereto, and the Company shall have the right to obtain and hold in
its own name, all intellectual property rights, including without limitation, patent, trade secret, copyright and similar protections
which may be available in such Company IP throughout the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
The Executive agrees that all work product made by them after the end of employment with the Company, whether created solely by the Executive
or jointly with others, that is based on or contains Confidential Information of the Company, shall belong to the Company; and the Executive
irrevocably assigns any and all rights in their entirety, throughout the world, in and to such future Work Product to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
The Executive agrees to use reasonable efforts to assist the Company, or its designee or assignee, to secure and perfect the Company&rsquo;s
(and/or such designee&rsquo;s) rights in such Work Product and any copyrights, patents, trade secrets, mask work rights or other intellectual
property rights and/or moral rights relating thereto in any and all countries, including the written disclosure to the Company of all
information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments
which the Company shall deem necessary in order to apply for, obtain and protect such rights and in order to assign and convey to the
Company, its successors, assigns, and nominees the sole and exclusive rights, title and interest in and to such Company IP, and any copyright,
patents, trade secrets, mask work rights or other intellectual property rights and/or moral rights contained therein and/or relating
thereto. The Executive further agrees that their obligation to execute or cause to be executed any such instrument or papers shall continue
after employment with the Company ends. The Executive shall be entitled to reimbursement for reasonable expenses in providing such post-employment
assistance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
In the event the Company is unable due to Executive&rsquo;s subsequent disability, incapacity or for any other reason whatsoever to
secure his signature to any lawful and necessary document required to apply for, register or execute any patent, copyright or other
applications with respect to any such Company IP, the Executive hereby irrevocably appoints the Company and its duly authorized
officers and agents as its agents and attorneys-in-fact to execute and file any such application and to do all other lawfully
permitted acts to further the prosecution and issuance of patents, copyrights or other rights thereon with the same legal force and
effect as if executed by the Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
In the event Company should not desire to secure and perfect its rights to any Company IP, but should desire to keep the same secret,
the Executive agrees that they will do everything reasonably in his power to assist Company in this and will not disclose any information
relating to such Company IP except with the prior written consent of Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7
In order to permit the Company to claim rights to which it may be entitled, Executive agrees to disclose to the Company in writing and
in confidence all inventions or Company IP that Executive makes or conceive of, either solely or jointly with others, during the term
of his employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8
All Work Product that was made by the Executive before his employment with the Company (collectively referred to as &ldquo;Prior Inventions&rdquo;)
are excluded from Section 5 of this Agreement. The Executive agrees not to incorporate into a Company product, process or code, or other
Company Work Product, a Prior Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">8.
<U>Acknowledgement</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Executive acknowledges and
agrees that the services to be rendered by the Executive to the Company are of a special and unique character; that the Executive will
obtain knowledge and skill relevant to the Company&rsquo;s industry, methods of doing business and marketing strategies by virtue of
the Executive&rsquo;s employment; and that the restrictive covenants and other terms and conditions of this Agreement are reasonable
and reasonably necessary to protect the legitimate business interest of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">9.
<U>Governing Law: Jurisdiction and Venue</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement,
for all purposes, shall be construed in accordance with the laws of Delaware without regard to conflicts of law principles. Any action
or proceeding by either of the parties to enforce this Agreement shall be brought only in a state or federal court located in the State
of Delaware. The parties hereby irrevocably submit to the exclusive jurisdiction of such courts and waive the defense of inconvenient
forum to the maintenance of any such action or proceeding in such venue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">10.
<U>Entire Agreement</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Unless specifically provided
herein, this Agreement contains all of the understandings and representations between the Executive and the Company pertaining to the
subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both
written and oral, with respect to such subject matter. The parties mutually agree that the Agreement can be specifically enforced in
court and can be cited as evidence in legal proceedings alleging breach of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">11.
<U>Modification and Waiver</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. No provision of this
Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by the Executive and by
the Company. No waiver by either of the parties of any breach by the other party hereto of any condition or provision of this Agreement
to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or
any prior or subsequent time, nor shall the failure of or delay by either of the parties in exercising any right, power, or privilege
hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power,
or privilege.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Severability</U></FONT>. Should any provision of this Agreement be held
by a court of competent jurisdiction to be enforceable only if modified, or if any portion of this Agreement shall be held as unenforceable
and thus stricken, such holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue
to be binding upon the parties with any such modification to become a part hereof and treated as though originally set forth in this
Agreement. The parties further agree that any such court is expressly authorized to modify any such unenforceable provision of this Agreement
in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting
any or all of the offending provision, adding additional language to this Agreement, or by making such other modifications as it deems
warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law. The parties
expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against each of them. In any event,
should one or more of the provisions of this Agreement be held to be invalid, illegal, or unenforceable in any respect, such invalidity,
illegality, or unenforceability shall not affect any other provisions hereof, and if such provision or provisions are not modified as
provided above, this Agreement shall be construed as if such invalid, illegal, or unenforceable provisions had not been set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">13.
<U>Captions</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Captions and headings of the sections
and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference
to the caption or heading of any section or paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">14.
<U>Counterparts</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement may be executed
in separate counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same
instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<FONT STYLE="font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline"><U>Section 409A</U></FONT>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1
General. The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt from Section 409A
of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively, &ldquo;Section
409A&rdquo;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2
Separation from Service. Notwithstanding anything in this Agreement to the contrary, any compensation or benefits payable under this
Agreement that is considered nonqualified deferred compensation under Section 409A and is designated under this Agreement as payable
upon the Executive&rsquo;s termination of employment shall be payable only upon Executive&rsquo;s &ldquo;separation from service&rdquo;
with the Company within the meaning of Section 409A (a &ldquo;Separation from Service&rdquo;) and, except as provided below, any such
compensation or benefits described in Section 4(b) shall not be paid until the fifty-fifth (55th) day following Executive&rsquo;s Separation
from Service (the &ldquo;First Payment Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3
Specified Employee. Notwithstanding anything in this Agreement to the contrary, if the Executive is deemed by the Company at the time
of the Executive&rsquo;s Separation from Service to be a &ldquo;specified employee&rdquo; for purposes of Section 409A, to the extent
delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid
a prohibited distribution under Section 409A, such portion of the Executive&rsquo;s benefits shall not be provided to the Executive prior
to the earlier of (i) the expiration of the six-month period measured from the date of the Executive&rsquo;s Separation from Service
with the Company or (ii) the date of the Executive&rsquo;s death. Upon the first business day following the expiration of the applicable
Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to the Executive (or the Executive&rsquo;s
estate or beneficiaries), and any remaining payments due to the Executive under this Agreement shall be paid as otherwise provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.4
Expense Reimbursements. To the extent that any reimbursements under this Agreement are subject to Section 409A, any such reimbursements
payable to the Executive shall be paid to the Executive no later than December 31st of the calendar year following the calendar year
in which the expense was incurred; provided, that the Executive submits the Executive&rsquo;s reimbursement request promptly following
the date the expense is incurred, the amount of expenses reimbursed in one calendar year shall not affect the amount eligible for reimbursement
in any subsequent calendar year, other than medical expenses referred to in Section 105(b) of the Code, and Executive&rsquo;s right to
reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline"><U>15.5
</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Installments. The Executive&rsquo;s right to receive
any installment payments under this Agreement, including without limitation any continuation salary payments that are payable on the
Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment
shall at all times be considered a separate and distinct payment as permitted under Section 409A. Except as otherwise permitted under
Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional
tax or interest pursuant to Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">16.
<U>Successors and Assigns</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement is personal
to the Executive and shall not be assigned by the Executive. Any purported assignment by the Executive shall be null and void from the
initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect,
by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets of the Company. This Agreement
shall inure to the benefit of the Company and permitted successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Notice</U></FONT>. Notices and all other communications provided for in
this Agreement shall be in writing and shall be delivered personally or sent by registered or certified mail, return receipt requested,
or by overnight carrier to the parties at the addresses set forth below (or such other addresses as specified by the parties by like
notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If to the
  Company</B>: </FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa Pharmaceuticals,
  Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7380 Coca Cola Drive, Suite
  106</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hanover, MD 21076</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>If to the Executive:</B></FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Russell Skibsted</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">306 Trinity Overlook</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canton, GA 30115-7579</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">18.
<U>Survival</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Upon the expiration or other termination
of this Agreement, the respective rights and obligations of the parties hereto shall survive such expiration or other termination to
the extent necessary to carry out the intentions of the parties under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Acknowledgement of Full Understanding</U></FONT>. THE EXECUTIVE ACKNOWLEDGES
AND AGREES THAT THE EXECUTIVE HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE EXECUTIVE ACKNOWLEDGES AND
AGREES THAT THE EXECUTIVE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF THE EXECUTIVE&rsquo;S CHOICE BEFORE
SIGNING THIS AGREEMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>[REST
OF PAGE INTENTIONALLY BLANK</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>SIGNATURES
TO FOLLOW ON NEXT PAGE]</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROCESSA
                    <FONT STYLE="text-transform: uppercase">Pharmaceuticals, Inc.</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MR.
                                            RUSSELL SKIBSTED</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/
    <FONT STYLE="font-size: 10pt">George Ng</FONT></I><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/
    Russell Skibsted</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng, Chief Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>5
<FILENAME>ex10-13.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.13</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex10-13_001.jpg" ALT=""></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Executive
Employment Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Employment Agreement (the &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of March 19, 2025 (&ldquo;<B>Effective Date</B>&rdquo;),
by and between Dr. Sian Bigora (the &ldquo;<B>Executive</B>&rdquo;) and Processa Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;
or &ldquo;<B>Processa</B>&rdquo;) (collectively referred to herein as the &ldquo;Parties&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires to employ the Executive on the terms and conditions set forth herein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Executive desires to be employed by the Company on such terms and conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants, promises, and obligations set forth herein, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Term</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
This Agreement shall be effective for the term beginning on the Effective Date and continue until terminated or modified pursuant to
Section 4 of this Agreement. The period during which the Executive is employed by the Company hereunder is hereinafter referred to as
the &ldquo;<B>Employment Term.</B>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Position and Duties</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
During the Employment Term, the Executive shall serve as the Chief Development and Regulatory Officer of the Company. In such position,
the Executive shall have such duties, authority, and responsibilities as shall be mutually agreed upon by the Chief Executive Officer
and the Executive, which duties, authority, and responsibilities are consistent with the Executive&rsquo;s position and prevailing industry
standards. During the Employment Term, the Executive shall devote substantially all of the Executive&rsquo;s business time and attention
to the performance of the Executive&rsquo;s duties hereunder and will not engage in any other business, profession, or occupation for
compensation, which would conflict or interfere with the performance of such services either directly or indirectly without the prior
written consent of the Company&rsquo;s Chief Executive Officer (&ldquo;<B>CEO</B>&rdquo;). Notwithstanding, the Executive shall be permitted
to (i) manage Executive&rsquo;s personal, financial and legal affairs, investments and holdings, (ii) participate in trade associations,
(iii) serve on the board of directors of not-for-profit or tax-exempt charitable organizations, (iv) serve on the board of directors
of for-profit organizations that do not directly compete with the Company, with the prior approval of the CEO and (iv) conduct business
and other matters that were previously disclosed to the Company prior to the Employment Term, in each case, subject to compliance with
this Agreement and provided that such activities do not materially interfere with Executive&rsquo;s performance of Executive&rsquo;s
duties and responsibilities hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Compensation</U></B></FONT><B><U>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and Benefits</FONT></U></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Base Salary</U></FONT>. The Company shall pay the Executive an annual
base salary of $387,920, less all lawfully required deductions and withholdings (&ldquo;<B>Base
Salary</B>&rdquo;), which will be paid in periodic installments in accordance with the Company&rsquo;s customary payroll practices and
applicable wage payment laws, but no less frequently than monthly. The Executive&rsquo;s Base Salary shall be reviewed annually and may
be increased based on an assessment of Executive&rsquo;s performance, the performance of the Company, inflation, the then prevailing
salary scales for comparable positions and other relevant factors; provided, however, that any increase in Base Salary shall be solely
within the discretion of the CEO and Compensation Committee of the Company&rsquo;s Board. Executive&rsquo;s Base Salary may not be subject
to reduction from the level set forth above, unless pursuant to a salary reduction program of general application to employment contract
executives of the Company, provided that, unless agreed to in writing by Executive, the percentage reduction of Executive&rsquo;s Base
Salary shall not be greater than the percentage reduction applied to any other employment contract executive of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Bonus</U></FONT>. This is a non-qualified plan used by the Company to
provide special compensation to key executives. The Company&rsquo;s contribution to an executive bonus plan is considered salary to the
Executive and is therefore subject to taxation. The Executive is eligible to participate in the bonus pool with a target bonus equal
to 40% of Executive&rsquo;s Base Salary, as then in effect (the &ldquo;Target Bonus&rdquo;), as may be awarded pursuant to any annual
executive bonus plan and related corporate goals approved solely at the discretion of the Compensation Committee of the Board. Any such
Annual Bonus shall contain such rights and features as are typically afforded to other contract executives of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Equity Compensation (RSUs, RSAs, Stock Options, Other)</U></FONT>. The
Compensation Committee of the Board (the &ldquo;<B>Compensation Committee</B>&rdquo;), and pursuant to Processa&rsquo;s 2019 Omnibus
Incentive Plan, or any such additional incentive plans that may be in place at such time, (the &ldquo;<B>Plan</B>&rdquo;) has previously
granted new hire RSUs to Employee. Any additional equity grants will be at the reasonable discretion of the Compensation Committee of
the Board. The specifics of the grants will be described in the Award Agreement to be provided to the Executive. Notwithstanding the
above and any other sections in this Agreement, all unvested equity granted herein, any additional unvested granted and any other unvested
equity-linked securities that may be granted in the future shall immediately vest upon a Change in Control (as defined in Section 4.5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Incentive and Deferred Compensation</U></FONT>. Employee shall be eligible
to participate in all incentive and deferred compensation programs available to other executives or officers of Processa, such participation
to be in the same form, under the same terms, and to the same extent that such programs are made available to other such similarly situated
executives or officers. Except as otherwise provided herein, nothing in this Agreement shall be deemed to require the payment of bonuses,
awards, or incentive compensation to Employee if such payment would not otherwise be required under the terms of Processa&rsquo;s incentive
compensation programs. The Company reserves the right to interpret, amend or terminate any incentive compensation program at any time
in its sole discretion, subject to the terms of such incentive compensation program and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">3.5
<U>Employee Benefits</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. During the Employment Term,
the Executive shall be entitled to participate in all employee benefit plans, practices, and programs maintained by the Company, as in
effect from time to time (collectively, &ldquo;<B>Employee Benefit Plans</B>&rdquo;), on a basis which is no less favorable than is provided
to other similarly situated executives of the Company, to the extent consistent with applicable law and the terms of the applicable Employee
Benefit Plans. The Company reserves the right to amend or terminate any Employee Benefit Plans at any time in its sole discretion, subject
to the terms of such Employee Benefit Plan and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.6
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Paid Time Off</U>. During the Employment Term, the
Executive will be entitled to earn and use paid time off (&ldquo;<B>PTO</B>&rdquo;) in accordance with the terms of the Company&rsquo;s
PTO policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.7
<U>Business Expenses</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Executive shall be entitled
to reimbursement for all reasonable and necessary out-of-pocket business, entertainment, and travel expenses incurred by the Executive
in connection with the performance of the Executive&rsquo;s duties hereunder in accordance with the Company&rsquo;s expense reimbursement
policies and procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Withholding</U></FONT>. By signing this Agreement, the Executive hereby
authorizes the Company to withhold from any amount payable hereunder any Federal, state, and local taxes in order for the Company to
satisfy any withholding tax obligation it may have under any applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<FONT STYLE="vertical-align: baseline"><B><U>Termination of Employment</U></B></FONT>. The Employment Term and the Executive&rsquo;s
employment with the Company may be terminated upon the following conditions or events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Death or Permanent Disability</U>. The Executive employment under this Agreement and the Employment Term shall terminate immediately
in the event of the death or Permanent Disability of Executive. &ldquo;Permanent Disability&rdquo; shall be defined as (1) Executive&rsquo;s
inability to perform the essential functions of his position, with or without reasonable accommodation, for a period of six consecutive
months or for an aggregate of six months in any twelve month period, as determined by a physician licensed to practice medicine and designated
by Employer and acceptable to the Executive, having reviewed and considered information provided by the Executive&rsquo;s healthcare
provider(s); (2) if the Executive is subject to a legal decree of incompetency; or (3) the Executive receives benefits pursuant to a
long-term disability insurance plan, and the person or persons required to make disability determinations under the long-term disability
plan determines that the Executive has a disability that, if Executive qualified for such disability benefits, would provide coverage
for the longest period of time.. Any refusal by the Executive to submit to a medical examination for the purpose of determining a Permanent
Disability shall be deemed to constitute conclusive evidence of the Executive&rsquo;s Permanent Disability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Termination by Executive</U>. The Executive may voluntarily terminate their employment with the Company by providing at least ninety
(90) days written notice to the Company of such termination. Once such notice is given, the Company may elect to terminate the Executive
prior to the conclusion of the ninety-day period. The Executive shall be paid their Base Salary through the end of the 90-day period.
The Executive may also terminate their employment hereunder for &ldquo;Good Reason.&rdquo; For the purpose of determining Executive&rsquo;s
right to Severance Pay and other payments described in Section 5.2 and elsewhere in this Agreement, the Executive&rsquo;s resignation
will be for &ldquo;Good Reason&rdquo; if the Executive resigns after any of the following events: (A) a decrease of more than 5% in Executive&rsquo;s
Base Salary or annual target bonus opportunity other than a reduction in Executive&rsquo;s Base Salary or annual target bonus opportunity
that is implemented in connection with a contemporaneous, temporary reduction in annual base salaries by the same percentage affecting
other senior executives of the Company or (B) a material decrease in the Executive&rsquo;s authority or areas of responsibility as are
commensurate with such Executive&rsquo;s title or position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Termination by the Company Without Cause</U>. The Company may terminate the Executive&rsquo;s employment hereunder for any reason
other than Cause by delivering written notice of termination to the Executive at least ninety (90) days prior to the date of termination.
The Company may elect to earlier terminate and pay Executive their regular Base Salary and benefits through the end of the 90-day period
as an addition to severance pay in lieu of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Termination by the Company for Cause</U>. Employer may terminate the Executive immediately for Cause. For purposes of this Agreement,
&ldquo;Cause&rdquo; shall mean:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
the Executive&rsquo;s refusal or inability to perform or observe any of the Executive&rsquo;s material duties, responsibilities or obligations
set forth in this Agreement (other than any such refusal or inability resulting from Executive&rsquo;s Permanent Disability); provided,
however, that Employer shall not be deemed to have Cause pursuant to this clause unless the Company gives the Executive written notice
that the specified conduct has occurred and the Executive fails to cure the conduct within thirty (30) days after receipt of such notice;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
any act of the Executive involving fraud, theft, misappropriation of funds, or embezzlement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
the Executive is convicted of any felony or misdemeanor involving dishonesty, violence or moral turpitude, or which in the reasonable
judgment of the Company, reflects materially and adversely on the reputation of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
the Executive&rsquo;s material failure to comply with any of the Company&rsquo;s policies, including but not limited to by engaging in
the illegal use of controlled substances, the knowing abuse of prescribed medications, or the misuse of alcohol;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
the Executive&rsquo;s material breach of fiduciary duty of care, loyalty, and good faith, ensuring diligent, company-focused actions
and legal compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Termination of Employment Involving a Change of Control</U>. The Executive&rsquo;s employment with the Company may be terminated in
the event that a Change in Control occurs, and the Executive&rsquo;s employment with the Company is terminated by the Company Without
Cause or by the Executive for Good Reason at any time within the three (3) month period before the date of and in connection with such
Change in Control or during the twelve (12) month period following the date of such Change in Control (&ldquo;<B>Termination as a Result
of a Change in Control</B>&rdquo;). For purposes of this Section, &ldquo;<B>Change in Control</B>&rdquo; shall mean and include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Acquisition by any &ldquo;Person&rdquo; or &ldquo;Group&rdquo; of securities entitled to vote generally in the election of directors
(&ldquo;voting securities&rdquo;) of the Company that represent 50% or more of the combined voting power of the Company&rsquo;s then
outstanding voting securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
A change in the composition of the Board occurring within a twelve (12) month period, as a result of which a majority of the incumbent
directors are replaced by directors whose appointment or election is not endorsed by a majority of the incumbent directors before the
date of the appointment or election;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Merger or consolidation in which the seller&rsquo;s shareholders no longer control the surviving entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline"><U>d)
</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of substantially all assets to an unrelated
entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Resignation of All Other Positions</U></FONT>. On termination of the Executive&rsquo;s
employment hereunder for any reason, the Executive shall be deemed to have resigned from all positions that the Executive holds as an
officer or member of the Board (or a committee thereof) of the Company or any of its affiliates (and shall confirm such resignation in
writing upon the request of the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">4.7
<U>Termination Date. </U>The final date on which the Executive is actually employed by the Company pursuant to this Agreement shall be
the &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B>Termination
Date</B><FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">5.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Compensation on Termination
of Employment</U></B><U><FONT STYLE="font-weight: normal">.</FONT></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Earned and Accrued Payments</U>. In the event that the Executive&rsquo;s employment is terminated, the Executive shall be entitled
to receive: (a) any accrued but unpaid Base Salary, which shall be paid on the pay date immediately following the Executive&rsquo;s Termination
Date, unless earlier required by applicable law; (b) any accrued but unpaid target annual bonus or any other granted bonus where such
bonus was determined prior to the Termination Date, which shall be paid on the otherwise applicable payment date; (c) reimbursement for
unreimbursed business expenses properly incurred by the Executive, which shall be subject to and paid in accordance with the Company&rsquo;s
expense reimbursement policy; and (d) such employee benefits (including equity compensation), if any, to which the Executive may be entitled
under the Company&rsquo;s employee benefit plans as of the Termination Date; provided that, in no event shall the Executive be entitled
to any payments in the nature of severance or termination payments except as specifically provided herein. The treatment of any outstanding
equity awards shall be determined in accordance with the terms in this Agreement, of the Plan and the applicable award agreements. For
clarification purposes, if the Termination Date occurs prior to the date of payment of the prior year bonus, the entire unpaid bonus
from the prior year plus the pro-rata accrued but unpaid bonus from the year of the Termination date would be included in 5.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Severance Pay</U>. In the event that the Executive&rsquo;s employment with the Company is terminated due to death or Permanent Disability,
by the Company Without Cause, the Executive terminates employment with the Company for Good Reason, and/or there is a Termination as
a Result of a Change in Control (each a &ldquo;Separation Event&rdquo;), the Executive shall be entitled to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>a.</U></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                            year of Base Salary and Target Bonus (&ldquo;<B>Severance Pay</B>&rdquo;), paid out in accordance
                                            with the normal payroll practices of the Company following the Termination Date and paid
                                            out over the twelve (12) month period. Payment of any Severance Pay shall be conditioned
                                            upon the Executive executing and not revoking a separation agreement reasonably satisfactory
                                            to the Company (or its successor) and to the Executive, including a general release of all
                                            claims that is reasonably satisfactory with terms substantially similar to typical agreements
                                            to the Company (or its successor) and the Executive; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>b.</U></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the twelve (12) month period following the Separation Event, (or, if earlier, the date on
                                            which the applicable continuation period under the Consolidated Omnibus Budget Reconciliation
                                            Act of 1985, as amended (&ldquo;COBRA&rdquo;) expires), and the Executive has elected COBRA
                                            coverage then the Company shall arrange to provide Executive and his eligible dependents
                                            who were covered under the Company&rsquo;s health insurance plans as of the date of the Separation
                                            Event with health (including medical and dental) insurance benefits substantially similar
                                            to those provided to such dependents immediately prior to the date of such Separation Event.
                                            The Executive will be responsible for any portion of the premium associated with such coverage
                                            that he was responsible for during employment. If the Company is not reasonably able to continue
                                            health insurance benefits coverage under the Company&rsquo;s insurance plans, the Company
                                            shall provide substantially equivalent coverage under other third-party insurance sources.
                                            If any of the Company&rsquo;s health benefits are self-funded as of the date of Separation
                                            Event, or if the Company cannot provide the foregoing benefits in a manner that exempt from
                                            Section 409A of the Code or that is otherwise compliant with applicable law (including, without
                                            limitation, Section 2716 of the Public Health Service Act), instead of providing continued
                                            health insurance benefits as set forth above, the Company shall instead pay to the Executive
                                            an amount equal to twelve (12) multiplied by the monthly premium the Executive would be required
                                            to pay for continuation coverage pursuant to the COBRA for his/her eligible dependents who
                                            were covered under the Company&rsquo;s health plans as of the date of the Separation Event
                                            (calculated by reference to the premium as of the date of the Separation Event), which amount
                                            shall be paid on the Payment Date. Eligibility for this benefit is contingent upon the execution
                                            and nonrevocation of the separation agreement referenced above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Section 280G</U></FONT>. If the Executive becomes entitled to any amount
in the nature of compensation payable by the Company that is contingent on a change in ownership, effective control, or substantial ownership
of a substantial portion of the Company&rsquo;s assets within the meaning of Section 280G of the Internal Revenue Code (&ldquo;Covered
Payments&rdquo;) and constitute &ldquo;Parachute Payments&rdquo; within the meaning within the meaning of Section 280G of the Internal
Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), and that is subject to the excise tax imposed by Section 4999 of the Code
(&ldquo;Excise Tax&rdquo;), a calculation shall be made comparing (i) the Net Benefit (as defined below) to the Executive of the Covered
Payments after payment of the Excise Tax to (ii) the Net Benefit to the Executive if the Covered Payments are limited to the extent necessary
to avoid being subject to the Excise Tax. Only if the amount calculated under (i) above is less than the amount under (ii) above will
the Covered Payments be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise
Tax (that amount, the &ldquo;Reduced Amount&rdquo;). &ldquo;Net Benefit&rdquo; shall mean the present value of the Covered Payments net
of all federal, state, local, foreign income, employment and excise taxes. In the event reduction is required, the Covered Payments shall
be reduced by the Company in the following order: (i) cash severance payments hereunder to the extent not subject to Section 409A of
the Code in the reverse order of payment; (ii) any other portion of the Covered Payments that are not subject to Section 409A of the
Code in the reverse order of payment (other than any acceleration of vesting of equity awards); (iii) Covered Payments that are not subject
to Section 409A of the Code that arise from the accelerated vesting of equity awards, and; (iv) Covered Payments that are subject to
Section 409A of the Code in a manner consistent with Section 409A of the Code. All determinations pursuant to this Section 5.4 shall
be made by tax accountants selected by the Company and reasonably acceptable to Executive (the &ldquo;Accountants&rdquo;), whose determinations
shall be binding on the Company and the Executive absent manifest error. The Executive shall provide the Accountants with such information
and documents as the Accountants may reasonably request in order for the Accountants to make their determinations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<FONT STYLE="vertical-align: baseline"><B><U>Return of Property and Employee Non-Solicit</U></B></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Return of Property</U>. Upon termination of Executive&rsquo;s employment with the Company for any reason, upon request, Executive
will use reasonable efforts to promptly deliver to the Company all equipment, correspondence, drawings, manuals, letters, notes, notebooks,
reports, programs, plans, proposals, financial documents, or any other documents or property containing material information pertaining
to the Company&rsquo;s customers, business plans, marketing strategies, products, property or processes..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Non-Solicitation of Employees Covenant</U>. Executive acknowledges that the Company&rsquo;s employees and consultants are a valuable
asset to the Company, especially because such employees have access to and knowledge of the Company&rsquo;s confidential information
and trade secrets. As such, Executive agrees for a period of one-year from the Termination Date, with respect to any Company employee
with whom Executive had material business contact during their employment with the Company, Executive will not (i) induce or attempt
to induce such employee of the Company to leave employment or contracting with the Company; or (ii) directly solicit the services of
or hire away such current employee of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Notification of Future Employers</U>. Executive hereby agrees to notify any future employers or prospective employers of the foregoing
obligations and authorizes the Company to provide a single notice of the terms in Section 6 to Executive&rsquo;s actual or future employers
(or persons or entities that contract or seek to contract for Executive&rsquo;s services).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
<U>Remedies</U>. In the event of a breach or threatened breach by either party, each party hereby consents and agrees that the non-breaching
party may (as determined by a court of law or proper judicial authority) be entitled to seek, in addition to other available remedies,
a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of competent jurisdiction,
and that money damages would not afford an adequate remedy, without the necessity of showing any actual damages. The aforementioned equitable
relief may (as determined by a court of law or proper judicial authority) be in addition to, not in lieu of, legal remedies, monetary
damages, or other available forms of relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B><U>Assignment of Inventions and Rights</U></B><U>.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Work Product</U>. The Executive acknowledges and agrees that all designs, devices, discoveries, processes, proprietary software, writings,
inventions, improvements and documentation, and any other works of authorship (collectively, &ldquo;<B>Work Product</B>&rdquo;), and
all related know-how, produced, made, conceived or authored by the Executive, solely or jointly with others, in the course of his employment
with the Company together with any intellectual property rights concerning the Work Product produced, made, conceived or authored by
the Executive, including any moral rights relating to any of the foregoing, are works made for hire and the property of the Company if
such works (i) result or are derived from, at the time the Work Product is produced, made, conceived or reduced to practice, the actual
business, research, or development of the Company; or (ii) are result from any work performed by the Executive for or on behalf of the
Company; or (iii) are created or developed with the use of Proprietary Information or Company equipment, supplies, facilities, information,
materials or other Company resources (&ldquo;Company IP&rdquo;). The Executive shall disclose in writing any such Company IP promptly
to the Company and hereby irrevocably assign any and all rights in their entirety, throughout the world, in and to such works to the
Company or its assignees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
To the extent that any such Company IP may not, by operation of law, be deemed works made for hire, this Agreement shall constitute an
irrevocable assignment by the Executive to the Company of the ownership of, and all right, title, and interest in and to such items,
including an irrevocable assignment of all moral rights relating thereto, and the Company shall have the right to obtain and hold in
its own name, all intellectual property rights, including without limitation, patent, trade secret, copyright and similar protections
which may be available in such Company IP throughout the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
The Executive agrees that all work product made by them after the end of employment with the Company, whether created solely by the Executive
or jointly with others, that is based on or contains Confidential Information of the Company, shall belong to the Company; and the Executive
irrevocably assigns any and all rights in their entirety, throughout the world, in and to such future Work Product to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
The Executive agrees to use reasonable efforts to assist the Company, or its designee or assignee, to secure and perfect the Company&rsquo;s
(and/or such designee&rsquo;s) rights in such Work Product and any copyrights, patents, trade secrets, mask work rights or other intellectual
property rights and/or moral rights relating thereto in any and all countries, including the written disclosure to the Company of all
information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments
which the Company shall deem necessary in order to apply for, obtain and protect such rights and in order to assign and convey to the
Company, its successors, assigns, and nominees the sole and exclusive rights, title and interest in and to such Company IP, and any copyright,
patents, trade secrets, mask work rights or other intellectual property rights and/or moral rights contained therein and/or relating
thereto. The Executive further agrees that their obligation to execute or cause to be executed any such instrument or papers shall continue
after employment with the Company ends. The Executive shall be entitled to reimbursement for reasonable expenses in providing such post-employment
assistance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
In the event the Company is unable due to Executive&rsquo;s subsequent disability, incapacity or for any other reason whatsoever to secure
his signature to any lawful and necessary document required to apply for, register or execute any patent, copyright or other applications
with respect to any such Company IP, the Executive hereby irrevocably appoints the Company and its duly authorized officers and agents
as its agents and attorneys-in-fact to execute and file any such application and to do all other lawfully permitted acts to further the
prosecution and issuance of patents, copyrights or other rights thereon with the same legal force and effect as if executed by the Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
In the event Company should not desire to secure and perfect its rights to any Company IP, but should desire to keep the same secret,
the Executive agrees that they will do everything reasonably in his power to assist Company in this and will not disclose any information
relating to such Company IP except with the prior written consent of Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7
In order to permit the Company to claim rights to which it may be entitled, Executive agrees to disclose to the Company in writing and
in confidence all inventions or Company IP that Executive makes or conceive of, either solely or jointly with others, during the term
of his employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8
All Work Product that was made by the Executive before his employment with the Company (collectively referred to as &ldquo;Prior Inventions&rdquo;)
are excluded from Section 5 of this Agreement. The Executive agrees not to incorporate into a Company product, process or code, or other
Company Work Product, a Prior Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">8.
<U>Acknowledgement</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Executive acknowledges and
agrees that the services to be rendered by the Executive to the Company are of a special and unique character; that the Executive will
obtain knowledge and skill relevant to the Company&rsquo;s industry, methods of doing business and marketing strategies by virtue of
the Executive&rsquo;s employment; and that the restrictive covenants and other terms and conditions of this Agreement are reasonable
and reasonably necessary to protect the legitimate business interest of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">9.
<U>Governing Law: Jurisdiction and Venue</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement,
for all purposes, shall be construed in accordance with the laws of Delaware without regard to conflicts of law principles. Any action
or proceeding by either of the parties to enforce this Agreement shall be brought only in a state or federal court located in the State
of Delaware. The parties hereby irrevocably submit to the exclusive jurisdiction of such courts and waive the defense of inconvenient
forum to the maintenance of any such action or proceeding in such venue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">10.
<U>Entire Agreement</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Unless specifically provided
herein, this Agreement contains all of the understandings and representations between the Executive and the Company pertaining to the
subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both
written and oral, with respect to such subject matter. The parties mutually agree that the Agreement can be specifically enforced in
court and can be cited as evidence in legal proceedings alleging breach of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">11.
<U>Modification and Waiver</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. No provision of this
Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by the Executive and by
the Company. No waiver by either of the parties of any breach by the other party hereto of any condition or provision of this Agreement
to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or
any prior or subsequent time, nor shall the failure of or delay by either of the parties in exercising any right, power, or privilege
hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power,
or privilege.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Severability</U></FONT>. Should any provision of this Agreement be held
by a court of competent jurisdiction to be enforceable only if modified, or if any portion of this Agreement shall be held as unenforceable
and thus stricken, such holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue
to be binding upon the parties with any such modification to become a part hereof and treated as though originally set forth in this
Agreement. The parties further agree that any such court is expressly authorized to modify any such unenforceable provision of this Agreement
in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting
any or all of the offending provision, adding additional language to this Agreement, or by making such other modifications as it deems
warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law. The parties
expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against each of them. In any event,
should one or more of the provisions of this Agreement be held to be invalid, illegal, or unenforceable in any respect, such invalidity,
illegality, or unenforceability shall not affect any other provisions hereof, and if such provision or provisions are not modified as
provided above, this Agreement shall be construed as if such invalid, illegal, or unenforceable provisions had not been set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">13.
<U>Captions</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Captions and headings of the sections
and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference
to the caption or heading of any section or paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">14.
<U>Counterparts</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement may be executed
in separate counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same
instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Section 409A</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1
General. The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt from Section 409A
of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively, &ldquo;Section
409A&rdquo;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2
Separation from Service. Notwithstanding anything in this Agreement to the contrary, any compensation or benefits payable under this
Agreement that is considered nonqualified deferred compensation under Section 409A and is designated under this Agreement as payable
upon the Executive&rsquo;s termination of employment shall be payable only upon Executive&rsquo;s &ldquo;separation from service&rdquo;
with the Company within the meaning of Section 409A (a &ldquo;Separation from Service&rdquo;) and, except as provided below, any such
compensation or benefits described in Section 4(b) shall not be paid until the fifty-fifth (55th) day following Executive&rsquo;s Separation
from Service (the &ldquo;First Payment Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3
Specified Employee. Notwithstanding anything in this Agreement to the contrary, if the Executive is deemed by the Company at the time
of the Executive&rsquo;s Separation from Service to be a &ldquo;specified employee&rdquo; for purposes of Section 409A, to the extent
delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid
a prohibited distribution under Section 409A, such portion of the Executive&rsquo;s benefits shall not be provided to the Executive prior
to the earlier of (i) the expiration of the six-month period measured from the date of the Executive&rsquo;s Separation from Service
with the Company or (ii) the date of the Executive&rsquo;s death. Upon the first business day following the expiration of the applicable
Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to the Executive (or the Executive&rsquo;s
estate or beneficiaries), and any remaining payments due to the Executive under this Agreement shall be paid as otherwise provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.4
Expense Reimbursements. To the extent that any reimbursements under this Agreement are subject to Section 409A, any such reimbursements
payable to the Executive shall be paid to the Executive no later than December 31st of the calendar year following the calendar year
in which the expense was incurred; provided, that the Executive submits the Executive&rsquo;s reimbursement request promptly following
the date the expense is incurred, the amount of expenses reimbursed in one calendar year shall not affect the amount eligible for reimbursement
in any subsequent calendar year, other than medical expenses referred to in Section 105(b) of the Code, and Executive&rsquo;s right to
reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">15.5
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Installments. The Executive&rsquo;s right to receive
any installment payments under this Agreement, including without limitation any continuation salary payments that are payable on the
Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment
shall at all times be considered a separate and distinct payment as permitted under Section 409A. Except as otherwise permitted under
Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional
tax or interest pursuant to Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">16.
<U>Successors and Assigns</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement is personal
to the Executive and shall not be assigned by the Executive. Any purported assignment by the Executive shall be null and void from the
initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect,
by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets of the Company. This Agreement
shall inure to the benefit of the Company and permitted successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Notice</U></FONT>. Notices and all other communications provided for in
this Agreement shall be in writing and shall be delivered personally or sent by registered or certified mail, return receipt requested,
or by overnight carrier to the parties at the addresses set forth below (or such other addresses as specified by the parties by like
notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>If
                                            to the Company:</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
                                            Executive Officer</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7380
Coca Cola Drive, Suite 106</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hanover,
MD 21076</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>If
                                            to the Executive</B><FONT STYLE="font-weight: normal; vertical-align: baseline">:</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. Sian Bigora</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11608
Periwinkle Drive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">Naples,
FL 34120</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">18.
<U>Survival</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Upon the expiration or other termination
of this Agreement, the respective rights and obligations of the parties hereto shall survive such expiration or other termination to
the extent necessary to carry out the intentions of the parties under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Acknowledgement of Full Understanding</U></FONT>. THE EXECUTIVE ACKNOWLEDGES
AND AGREES THAT THE EXECUTIVE HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE EXECUTIVE ACKNOWLEDGES AND
AGREES THAT THE EXECUTIVE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF THE EXECUTIVE&rsquo;S CHOICE BEFORE
SIGNING THIS AGREEMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>[REST
OF PAGE INTENTIONALLY BLANK</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>SIGNATURES
TO FOLLOW ON NEXT PAGE]</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROCESSA
    <FONT STYLE="text-transform: uppercase">Pharmaceuticals, Inc.</FONT></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DR.
    SIAN BIGORA</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    George Ng</I>&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sian Bigora</I></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng, Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>6
<FILENAME>ex10-14.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.14</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex10-14_001.jpg" ALT=""></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Executive
Employment Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Employment Agreement (the &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of March 19, 2025 (&ldquo;<B>Effective Date</B>&rdquo;),
by and between Wendy Guy (the &ldquo;<B>Executive</B>&rdquo;) and Processa Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;
or &ldquo;<B>Processa</B>&rdquo;) (collectively referred to herein as the &ldquo;Parties&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires to employ the Executive on the terms and conditions set forth herein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Executive desires to be employed by the Company on such terms and conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants, promises, and obligations set forth herein, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Term</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
This Agreement shall be effective for the term beginning on the Effective Date and continue until terminated or modified pursuant to
Section 4 of this Agreement. The period during which the Executive is employed by the Company hereunder is hereinafter referred to as
the &ldquo;<B>Employment Term.</B>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Position and Duties</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
During the Employment Term, the Executive shall serve as the Chief Administrative Officer of the Company. In such position, the Executive
shall have such duties, authority, and responsibilities as shall be mutually agreed upon by the Chief Executive Officer and the Executive,
which duties, authority, and responsibilities are consistent with the Executive&rsquo;s position and prevailing industry standards. During
the Employment Term, the Executive shall devote substantially all of the Executive&rsquo;s business time and attention to the performance
of the Executive&rsquo;s duties hereunder and will not engage in any other business, profession, or occupation for compensation, which
would conflict or interfere with the performance of such services either directly or indirectly without the prior written consent of
the Company&rsquo;s Chief Executive Officer (&ldquo;<B>CEO</B>&rdquo;). Notwithstanding, the Executive shall be permitted to (i) manage
Executive&rsquo;s personal, financial and legal affairs, investments and holdings, (ii) participate in trade associations, (iii) serve
on the board of directors of not-for-profit or tax-exempt charitable organizations, (iv) serve on the board of directors of for-profit
organizations that do not directly compete with the Company, with the prior approval of the CEO and (iv) conduct business and other matters
that were previously disclosed to the Company prior to the Employment Term, in each case, subject to compliance with this Agreement and
provided that such activities do not materially interfere with Executive&rsquo;s performance of Executive&rsquo;s duties and responsibilities
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Compensation</U></B></FONT><B><U>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and Benefits</FONT></U></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Base Salary</U></FONT>. The Company shall pay the Executive an annual
base salary of $325,520, less all lawfully required deductions and withholdings (&ldquo;<B>Base
Salary</B>&rdquo;), which will be paid in periodic installments in accordance with the Company&rsquo;s customary payroll practices and
applicable wage payment laws, but no less frequently than monthly. The Executive&rsquo;s Base Salary shall be reviewed annually and may
be increased based on an assessment of Executive&rsquo;s performance, the performance of the Company, inflation, the then prevailing
salary scales for comparable positions and other relevant factors; provided, however, that any increase in Base Salary shall be solely
within the discretion of the CEO and Compensation Committee of the Company&rsquo;s Board. Executive&rsquo;s Base Salary may not be subject
to reduction from the level set forth above, unless pursuant to a salary reduction program of general application to employment contract
executives of the Company, provided that, unless agreed to in writing by Executive, the percentage reduction of Executive&rsquo;s Base
Salary shall not be greater than the percentage reduction applied to any other employment contract executive of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Bonus</U></FONT>. This is a non-qualified plan used by the Company to
provide special compensation to key executives. The Company&rsquo;s contribution to an executive bonus plan is considered salary to the
Executive and is therefore subject to taxation. The Executive is eligible to participate in the bonus pool with a target bonus equal
to 30% of Executive&rsquo;s Base Salary, as then in effect (the &ldquo;Target Bonus&rdquo;), as may be awarded pursuant to any annual
executive bonus plan and related corporate goals approved solely at the discretion of the Compensation Committee of the Board. Any such
Annual Bonus shall contain such rights and features as are typically afforded to other contract executives of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Equity Compensation (RSUs, RSAs, Stock Options, Other)</U></FONT>. The
Compensation Committee of the Board (the &ldquo;<B>Compensation Committee</B>&rdquo;), and pursuant to Processa&rsquo;s 2019 Omnibus
Incentive Plan, or any such additional incentive plans that may be in place at such time, (the &ldquo;<B>Plan</B>&rdquo;) has previously
granted new hire RSUs to Employee. Any additional equity grants will be at the reasonable discretion of the Compensation Committee of
the Board. The specifics of the grants will be described in the Award Agreement to be provided to the Executive. Notwithstanding the
above and any other sections in this Agreement, all unvested equity granted herein, any additional unvested granted and any other unvested
equity-linked securities that may be granted in the future shall immediately vest upon a Change in Control (as defined in Section 4.5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Incentive and Deferred Compensation</U></FONT>. Employee shall be eligible
to participate in all incentive and deferred compensation programs available to other executives or officers of Processa, such participation
to be in the same form, under the same terms, and to the same extent that such programs are made available to other such similarly situated
executives or officers. Except as otherwise provided herein, nothing in this Agreement shall be deemed to require the payment of bonuses,
awards, or incentive compensation to Employee if such payment would not otherwise be required under the terms of Processa&rsquo;s incentive
compensation programs. The Company reserves the right to interpret, amend or terminate any incentive compensation program at any time
in its sole discretion, subject to the terms of such incentive compensation program and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">3.5
<U>Employee Benefits</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. During the Employment Term,
the Executive shall be entitled to participate in all employee benefit plans, practices, and programs maintained by the Company, as in
effect from time to time (collectively, &ldquo;<B>Employee Benefit Plans</B>&rdquo;), on a basis which is no less favorable than is provided
to other similarly situated executives of the Company, to the extent consistent with applicable law and the terms of the applicable Employee
Benefit Plans. The Company reserves the right to amend or terminate any Employee Benefit Plans at any time in its sole discretion, subject
to the terms of such Employee Benefit Plan and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.6
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Paid Time Off</U>. During the Employment Term, the
Executive will be entitled to earn and use paid time off (&ldquo;<B>PTO</B>&rdquo;) in accordance with the terms of the Company&rsquo;s
PTO policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.7
<U>Business Expenses</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Executive shall be entitled
to reimbursement for all reasonable and necessary out-of-pocket business, entertainment, and travel expenses incurred by the Executive
in connection with the performance of the Executive&rsquo;s duties hereunder in accordance with the Company&rsquo;s expense reimbursement
policies and procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Withholding</U></FONT>. By signing this Agreement, the Executive hereby
authorizes the Company to withhold from any amount payable hereunder any Federal, state, and local taxes in order for the Company to
satisfy any withholding tax obligation it may have under any applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<FONT STYLE="vertical-align: baseline"><B><U>Termination of Employment</U></B></FONT>. The Employment Term and the Executive&rsquo;s
employment with the Company may be terminated upon the following conditions or events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Death or Permanent Disability</U>. The Executive employment under this Agreement and the Employment Term shall terminate immediately
in the event of the death or Permanent Disability of Executive. &ldquo;Permanent Disability&rdquo; shall be defined as (1) Executive&rsquo;s
inability to perform the essential functions of his position, with or without reasonable accommodation, for a period of six consecutive
months or for an aggregate of six months in any twelve month period, as determined by a physician licensed to practice medicine and designated
by Employer and acceptable to the Executive, having reviewed and considered information provided by the Executive&rsquo;s healthcare
provider(s); (2) if the Executive is subject to a legal decree of incompetency; or (3) the Executive receives benefits pursuant to a
long-term disability insurance plan, and the person or persons required to make disability determinations under the long-term disability
plan determines that the Executive has a disability that, if Executive qualified for such disability benefits, would provide coverage
for the longest period of time.. Any refusal by the Executive to submit to a medical examination for the purpose of determining a Permanent
Disability shall be deemed to constitute conclusive evidence of the Executive&rsquo;s Permanent Disability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Termination by Executive</U>. The Executive may voluntarily terminate their employment with the Company by providing at least ninety
(90) days written notice to the Company of such termination. Once such notice is given, the Company may elect to terminate the Executive
prior to the conclusion of the ninety-day period. The Executive shall be paid their Base Salary through the end of the 90-day period.
The Executive may also terminate their employment hereunder for &ldquo;Good Reason.&rdquo; For the purpose of determining Executive&rsquo;s
right to Severance Pay and other payments described in Section 5.2 and elsewhere in this Agreement, the Executive&rsquo;s resignation
will be for &ldquo;Good Reason&rdquo; if the Executive resigns after any of the following events: (A) a decrease of more than 5% in Executive&rsquo;s
Base Salary or annual target bonus opportunity other than a reduction in Executive&rsquo;s Base Salary or annual target bonus opportunity
that is implemented in connection with a contemporaneous, temporary reduction in annual base salaries by the same percentage affecting
other senior executives of the Company or (B) a material decrease in the Executive&rsquo;s authority or areas of responsibility as are
commensurate with such Executive&rsquo;s title or position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Termination by the Company Without Cause</U>. The Company may terminate the Executive&rsquo;s employment hereunder for any reason
other than Cause by delivering written notice of termination to the Executive at least ninety (90) days prior to the date of termination.
The Company may elect to earlier terminate and pay Executive their regular Base Salary and benefits through the end of the 90-day period
as an addition to severance pay in lieu of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Termination by the Company for Cause</U>. Employer may terminate the Executive immediately for Cause. For purposes of this Agreement,
&ldquo;Cause&rdquo; shall mean:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
the Executive&rsquo;s refusal or inability to perform or observe any of the Executive&rsquo;s material duties, responsibilities or obligations
set forth in this Agreement (other than any such refusal or inability resulting from Executive&rsquo;s Permanent Disability); provided,
however, that Employer shall not be deemed to have Cause pursuant to this clause unless the Company gives the Executive written notice
that the specified conduct has occurred and the Executive fails to cure the conduct within thirty (30) days after receipt of such notice;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
any act of the Executive involving fraud, theft, misappropriation of funds, or embezzlement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
the Executive is convicted of any felony or misdemeanor involving dishonesty, violence or moral turpitude, or which in the reasonable
judgment of the Company, reflects materially and adversely on the reputation of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
the Executive&rsquo;s material failure to comply with any of the Company&rsquo;s policies, including but not limited to by engaging in
the illegal use of controlled substances, the knowing abuse of prescribed medications, or the misuse of alcohol;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
the Executive&rsquo;s material breach of fiduciary duty of care, loyalty, and good faith, ensuring diligent, company-focused actions
and legal compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Termination of Employment Involving a Change of Control</U>. The Executive&rsquo;s employment with the Company may be terminated in
the event that a Change in Control occurs, and the Executive&rsquo;s employment with the Company is terminated by the Company Without
Cause or by the Executive for Good Reason at any time within the three (3) month period before the date of and in connection with such
Change in Control or during the twelve (12) month period following the date of such Change in Control (&ldquo;<B>Termination as a Result
of a Change in Control</B>&rdquo;). For purposes of this Section, &ldquo;<B>Change in Control</B>&rdquo; shall mean and include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Acquisition by any &ldquo;Person&rdquo; or &ldquo;Group&rdquo; of securities entitled to vote generally in the election of directors
(&ldquo;voting securities&rdquo;) of the Company that represent 50% or more of the combined voting power of the Company&rsquo;s then
outstanding voting securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
A change in the composition of the Board occurring within a twelve (12) month period, as a result of which a majority of the incumbent
directors are replaced by directors whose appointment or election is not endorsed by a majority of the incumbent directors before the
date of the appointment or election;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Merger or consolidation in which the seller&rsquo;s shareholders no longer control the surviving entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline"><U>d)
</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of substantially all assets to an unrelated
entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Resignation of All Other Positions</U></FONT>. On termination of the Executive&rsquo;s
employment hereunder for any reason, the Executive shall be deemed to have resigned from all positions that the Executive holds as an
officer or member of the Board (or a committee thereof) of the Company or any of its affiliates (and shall confirm such resignation in
writing upon the request of the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">4.7
<U>Termination Date. </U>The final date on which the Executive is actually employed by the Company pursuant to this Agreement shall be
the &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B>Termination
Date</B><FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">5.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Compensation on Termination
of Employment</U></B><U><FONT STYLE="font-weight: normal">.</FONT></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Earned and Accrued Payments</U>. In the event that the Executive&rsquo;s employment is terminated, the Executive shall be entitled
to receive: (a) any accrued but unpaid Base Salary, which shall be paid on the pay date immediately following the Executive&rsquo;s Termination
Date, unless earlier required by applicable law; (b) any accrued but unpaid target annual bonus or any other granted bonus where such
bonus was determined prior to the Termination Date, which shall be paid on the otherwise applicable payment date; (c) reimbursement for
unreimbursed business expenses properly incurred by the Executive, which shall be subject to and paid in accordance with the Company&rsquo;s
expense reimbursement policy; and (d) such employee benefits (including equity compensation), if any, to which the Executive may be entitled
under the Company&rsquo;s employee benefit plans as of the Termination Date; provided that, in no event shall the Executive be entitled
to any payments in the nature of severance or termination payments except as specifically provided herein. The treatment of any outstanding
equity awards shall be determined in accordance with the terms in this Agreement, of the Plan and the applicable award agreements. For
clarification purposes, if the Termination Date occurs prior to the date of payment of the prior year bonus, the entire unpaid bonus
from the prior year plus the pro-rata accrued but unpaid bonus from the year of the Termination date would be included in 5.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Severance Pay</U>. In the event that the Executive&rsquo;s employment with the Company is terminated due to death or Permanent Disability,
by the Company Without Cause, the Executive terminates employment with the Company for Good Reason, and/or there is a Termination as
a Result of a Change in Control (each a &ldquo;Separation Event&rdquo;), the Executive shall be entitled to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>a.</U></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                            year of Base Salary and Target Bonus (&ldquo;<B>Severance Pay</B>&rdquo;), paid out in accordance
                                            with the normal payroll practices of the Company following the Termination Date and paid
                                            out over the twelve (12) month period. Payment of any Severance Pay shall be conditioned
                                            upon the Executive executing and not revoking a separation agreement reasonably satisfactory
                                            to the Company (or its successor) and to the Executive, including a general release of all
                                            claims that is reasonably satisfactory with terms substantially similar to typical agreements
                                            to the Company (or its successor) and the Executive; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>b.</U></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the twelve (12) month period following the Separation Event, (or, if earlier, the date on
                                            which the applicable continuation period under the Consolidated Omnibus Budget Reconciliation
                                            Act of 1985, as amended (&ldquo;COBRA&rdquo;) expires), and the Executive has elected COBRA
                                            coverage then the Company shall arrange to provide Executive and his eligible dependents
                                            who were covered under the Company&rsquo;s health insurance plans as of the date of the Separation
                                            Event with health (including medical and dental) insurance benefits substantially similar
                                            to those provided to such dependents immediately prior to the date of such Separation Event.
                                            The Executive will be responsible for any portion of the premium associated with such coverage
                                            that he was responsible for during employment. If the Company is not reasonably able to continue
                                            health insurance benefits coverage under the Company&rsquo;s insurance plans, the Company
                                            shall provide substantially equivalent coverage under other third-party insurance sources.
                                            If any of the Company&rsquo;s health benefits are self-funded as of the date of Separation
                                            Event, or if the Company cannot provide the foregoing benefits in a manner that exempt from
                                            Section 409A of the Code or that is otherwise compliant with applicable law (including, without
                                            limitation, Section 2716 of the Public Health Service Act), instead of providing continued
                                            health insurance benefits as set forth above, the Company shall instead pay to the Executive
                                            an amount equal to twelve (12) multiplied by the monthly premium the Executive would be required
                                            to pay for continuation coverage pursuant to the COBRA for his/her eligible dependents who
                                            were covered under the Company&rsquo;s health plans as of the date of the Separation Event
                                            (calculated by reference to the premium as of the date of the Separation Event), which amount
                                            shall be paid on the Payment Date. Eligibility for this benefit is contingent upon the execution
                                            and nonrevocation of the separation agreement referenced above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Section 280G</U></FONT>. If the Executive becomes entitled to any amount
in the nature of compensation payable by the Company that is contingent on a change in ownership, effective control, or substantial ownership
of a substantial portion of the Company&rsquo;s assets within the meaning of Section 280G of the Internal Revenue Code (&ldquo;Covered
Payments&rdquo;) and constitute &ldquo;Parachute Payments&rdquo; within the meaning within the meaning of Section 280G of the Internal
Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), and that is subject to the excise tax imposed by Section 4999 of the Code
(&ldquo;Excise Tax&rdquo;), a calculation shall be made comparing (i) the Net Benefit (as defined below) to the Executive of the Covered
Payments after payment of the Excise Tax to (ii) the Net Benefit to the Executive if the Covered Payments are limited to the extent necessary
to avoid being subject to the Excise Tax. Only if the amount calculated under (i) above is less than the amount under (ii) above will
the Covered Payments be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise
Tax (that amount, the &ldquo;Reduced Amount&rdquo;). &ldquo;Net Benefit&rdquo; shall mean the present value of the Covered Payments net
of all federal, state, local, foreign income, employment and excise taxes. In the event reduction is required, the Covered Payments shall
be reduced by the Company in the following order: (i) cash severance payments hereunder to the extent not subject to Section 409A of
the Code in the reverse order of payment; (ii) any other portion of the Covered Payments that are not subject to Section 409A of the
Code in the reverse order of payment (other than any acceleration of vesting of equity awards); (iii) Covered Payments that are not subject
to Section 409A of the Code that arise from the accelerated vesting of equity awards, and; (iv) Covered Payments that are subject to
Section 409A of the Code in a manner consistent with Section 409A of the Code. All determinations pursuant to this Section 5.4 shall
be made by tax accountants selected by the Company and reasonably acceptable to Executive (the &ldquo;Accountants&rdquo;), whose determinations
shall be binding on the Company and the Executive absent manifest error. The Executive shall provide the Accountants with such information
and documents as the Accountants may reasonably request in order for the Accountants to make their determinations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<FONT STYLE="vertical-align: baseline"><B><U>Return of Property and Employee Non-Solicit</U></B></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Return of Property</U>. Upon termination of Executive&rsquo;s employment with the Company for any reason, upon request, Executive
will use reasonable efforts to promptly deliver to the Company all equipment, correspondence, drawings, manuals, letters, notes, notebooks,
reports, programs, plans, proposals, financial documents, or any other documents or property containing material information pertaining
to the Company&rsquo;s customers, business plans, marketing strategies, products, property or processes..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Non-Solicitation of Employees Covenant</U>. Executive acknowledges that the Company&rsquo;s employees and consultants are a valuable
asset to the Company, especially because such employees have access to and knowledge of the Company&rsquo;s confidential information
and trade secrets. As such, Executive agrees for a period of one-year from the Termination Date, with respect to any Company employee
with whom Executive had material business contact during their employment with the Company, Executive will not (i) induce or attempt
to induce such employee of the Company to leave employment or contracting with the Company; or (ii) directly solicit the services of
or hire away such current employee of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Notification of Future Employers</U>. Executive hereby agrees to notify any future employers or prospective employers of the foregoing
obligations and authorizes the Company to provide a single notice of the terms in Section 6 to Executive&rsquo;s actual or future employers
(or persons or entities that contract or seek to contract for Executive&rsquo;s services).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
<U>Remedies</U>. In the event of a breach or threatened breach by either party, each party hereby consents and agrees that the non-breaching
party may (as determined by a court of law or proper judicial authority) be entitled to seek, in addition to other available remedies,
a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of competent jurisdiction,
and that money damages would not afford an adequate remedy, without the necessity of showing any actual damages. The aforementioned equitable
relief may (as determined by a court of law or proper judicial authority) be in addition to, not in lieu of, legal remedies, monetary
damages, or other available forms of relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B><U>Assignment of Inventions and Rights</U></B><U>.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Work Product</U>. The Executive acknowledges and agrees that all designs, devices, discoveries, processes, proprietary software, writings,
inventions, improvements and documentation, and any other works of authorship (collectively, &ldquo;<B>Work Product</B>&rdquo;), and
all related know-how, produced, made, conceived or authored by the Executive, solely or jointly with others, in the course of his employment
with the Company together with any intellectual property rights concerning the Work Product produced, made, conceived or authored by
the Executive, including any moral rights relating to any of the foregoing, are works made for hire and the property of the Company if
such works (i) result or are derived from, at the time the Work Product is produced, made, conceived or reduced to practice, the actual
business, research, or development of the Company; or (ii) are result from any work performed by the Executive for or on behalf of the
Company; or (iii) are created or developed with the use of Proprietary Information or Company equipment, supplies, facilities, information,
materials or other Company resources (&ldquo;Company IP&rdquo;). The Executive shall disclose in writing any such Company IP promptly
to the Company and hereby irrevocably assign any and all rights in their entirety, throughout the world, in and to such works to the
Company or its assignees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
To the extent that any such Company IP may not, by operation of law, be deemed works made for hire, this Agreement shall constitute an
irrevocable assignment by the Executive to the Company of the ownership of, and all right, title, and interest in and to such items,
including an irrevocable assignment of all moral rights relating thereto, and the Company shall have the right to obtain and hold in
its own name, all intellectual property rights, including without limitation, patent, trade secret, copyright and similar protections
which may be available in such Company IP throughout the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
The Executive agrees that all work product made by them after the end of employment with the Company, whether created solely by the Executive
or jointly with others, that is based on or contains Confidential Information of the Company, shall belong to the Company; and the Executive
irrevocably assigns any and all rights in their entirety, throughout the world, in and to such future Work Product to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
The Executive agrees to use reasonable efforts to assist the Company, or its designee or assignee, to secure and perfect the Company&rsquo;s
(and/or such designee&rsquo;s) rights in such Work Product and any copyrights, patents, trade secrets, mask work rights or other intellectual
property rights and/or moral rights relating thereto in any and all countries, including the written disclosure to the Company of all
information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments
which the Company shall deem necessary in order to apply for, obtain and protect such rights and in order to assign and convey to the
Company, its successors, assigns, and nominees the sole and exclusive rights, title and interest in and to such Company IP, and any copyright,
patents, trade secrets, mask work rights or other intellectual property rights and/or moral rights contained therein and/or relating
thereto. The Executive further agrees that their obligation to execute or cause to be executed any such instrument or papers shall continue
after employment with the Company ends. The Executive shall be entitled to reimbursement for reasonable expenses in providing such post-employment
assistance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
In the event the Company is unable due to Executive&rsquo;s subsequent disability, incapacity or for any other reason whatsoever to secure
his signature to any lawful and necessary document required to apply for, register or execute any patent, copyright or other applications
with respect to any such Company IP, the Executive hereby irrevocably appoints the Company and its duly authorized officers and agents
as its agents and attorneys-in-fact to execute and file any such application and to do all other lawfully permitted acts to further the
prosecution and issuance of patents, copyrights or other rights thereon with the same legal force and effect as if executed by the Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
In the event Company should not desire to secure and perfect its rights to any Company IP, but should desire to keep the same secret,
the Executive agrees that they will do everything reasonably in his power to assist Company in this and will not disclose any information
relating to such Company IP except with the prior written consent of Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7
In order to permit the Company to claim rights to which it may be entitled, Executive agrees to disclose to the Company in writing and
in confidence all inventions or Company IP that Executive makes or conceive of, either solely or jointly with others, during the term
of his employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8
All Work Product that was made by the Executive before his employment with the Company (collectively referred to as &ldquo;Prior Inventions&rdquo;)
are excluded from Section 5 of this Agreement. The Executive agrees not to incorporate into a Company product, process or code, or other
Company Work Product, a Prior Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">8.
<U>Acknowledgement</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Executive acknowledges and
agrees that the services to be rendered by the Executive to the Company are of a special and unique character; that the Executive will
obtain knowledge and skill relevant to the Company&rsquo;s industry, methods of doing business and marketing strategies by virtue of
the Executive&rsquo;s employment; and that the restrictive covenants and other terms and conditions of this Agreement are reasonable
and reasonably necessary to protect the legitimate business interest of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">9.
<U>Governing Law: Jurisdiction and Venue</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement,
for all purposes, shall be construed in accordance with the laws of Delaware without regard to conflicts of law principles. Any action
or proceeding by either of the parties to enforce this Agreement shall be brought only in a state or federal court located in the State
of Delaware. The parties hereby irrevocably submit to the exclusive jurisdiction of such courts and waive the defense of inconvenient
forum to the maintenance of any such action or proceeding in such venue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">10.
<U>Entire Agreement</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Unless specifically provided
herein, this Agreement contains all of the understandings and representations between the Executive and the Company pertaining to the
subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both
written and oral, with respect to such subject matter. The parties mutually agree that the Agreement can be specifically enforced in
court and can be cited as evidence in legal proceedings alleging breach of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">11.
<U>Modification and Waiver</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. No provision of this
Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by the Executive and by
the Company. No waiver by either of the parties of any breach by the other party hereto of any condition or provision of this Agreement
to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or
any prior or subsequent time, nor shall the failure of or delay by either of the parties in exercising any right, power, or privilege
hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power,
or privilege.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Severability</U></FONT>. Should any provision of this Agreement be held
by a court of competent jurisdiction to be enforceable only if modified, or if any portion of this Agreement shall be held as unenforceable
and thus stricken, such holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue
to be binding upon the parties with any such modification to become a part hereof and treated as though originally set forth in this
Agreement. The parties further agree that any such court is expressly authorized to modify any such unenforceable provision of this Agreement
in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting
any or all of the offending provision, adding additional language to this Agreement, or by making such other modifications as it deems
warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law. The parties
expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against each of them. In any event,
should one or more of the provisions of this Agreement be held to be invalid, illegal, or unenforceable in any respect, such invalidity,
illegality, or unenforceability shall not affect any other provisions hereof, and if such provision or provisions are not modified as
provided above, this Agreement shall be construed as if such invalid, illegal, or unenforceable provisions had not been set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">13.
<U>Captions</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Captions and headings of the sections
and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference
to the caption or heading of any section or paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">14.
<U>Counterparts</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement may be executed
in separate counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same
instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Section 409A</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1
General. The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt from Section 409A
of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively, &ldquo;Section
409A&rdquo;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2
Separation from Service. Notwithstanding anything in this Agreement to the contrary, any compensation or benefits payable under this
Agreement that is considered nonqualified deferred compensation under Section 409A and is designated under this Agreement as payable
upon the Executive&rsquo;s termination of employment shall be payable only upon Executive&rsquo;s &ldquo;separation from service&rdquo;
with the Company within the meaning of Section 409A (a &ldquo;Separation from Service&rdquo;) and, except as provided below, any such
compensation or benefits described in Section 4(b) shall not be paid until the fifty-fifth (55th) day following Executive&rsquo;s Separation
from Service (the &ldquo;First Payment Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3
Specified Employee. Notwithstanding anything in this Agreement to the contrary, if the Executive is deemed by the Company at the time
of the Executive&rsquo;s Separation from Service to be a &ldquo;specified employee&rdquo; for purposes of Section 409A, to the extent
delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid
a prohibited distribution under Section 409A, such portion of the Executive&rsquo;s benefits shall not be provided to the Executive prior
to the earlier of (i) the expiration of the six-month period measured from the date of the Executive&rsquo;s Separation from Service
with the Company or (ii) the date of the Executive&rsquo;s death. Upon the first business day following the expiration of the applicable
Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to the Executive (or the Executive&rsquo;s
estate or beneficiaries), and any remaining payments due to the Executive under this Agreement shall be paid as otherwise provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.4
Expense Reimbursements. To the extent that any reimbursements under this Agreement are subject to Section 409A, any such reimbursements
payable to the Executive shall be paid to the Executive no later than December 31st of the calendar year following the calendar year
in which the expense was incurred; provided, that the Executive submits the Executive&rsquo;s reimbursement request promptly following
the date the expense is incurred, the amount of expenses reimbursed in one calendar year shall not affect the amount eligible for reimbursement
in any subsequent calendar year, other than medical expenses referred to in Section 105(b) of the Code, and Executive&rsquo;s right to
reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">15.5
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Installments. The Executive&rsquo;s right to receive
any installment payments under this Agreement, including without limitation any continuation salary payments that are payable on the
Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment
shall at all times be considered a separate and distinct payment as permitted under Section 409A. Except as otherwise permitted under
Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional
tax or interest pursuant to Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">16.
<U>Successors and Assigns</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement is personal
to the Executive and shall not be assigned by the Executive. Any purported assignment by the Executive shall be null and void from the
initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect,
by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets of the Company. This Agreement
shall inure to the benefit of the Company and permitted successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Notice</U></FONT>. Notices and all other communications provided for in
this Agreement shall be in writing and shall be delivered personally or sent by registered or certified mail, return receipt requested,
or by overnight carrier to the parties at the addresses set forth below (or such other addresses as specified by the parties by like
notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>If
                                            to the Company:</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
                                            Executive Officer</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7380
Coca Cola Drive, Suite 106</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hanover,
MD 21076</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>If
                                            to the Executive</B><FONT STYLE="font-weight: normal; vertical-align: baseline">:</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ms. Wendy Guy</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">4245
Amelia Plantation Court</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">Vero
Beach, FL 32967</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">18.
<U>Survival</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Upon the expiration or other termination
of this Agreement, the respective rights and obligations of the parties hereto shall survive such expiration or other termination to
the extent necessary to carry out the intentions of the parties under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Acknowledgement of Full Understanding</U></FONT>. THE EXECUTIVE ACKNOWLEDGES
AND AGREES THAT THE EXECUTIVE HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE EXECUTIVE ACKNOWLEDGES AND
AGREES THAT THE EXECUTIVE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF THE EXECUTIVE&rsquo;S CHOICE BEFORE
SIGNING THIS AGREEMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>[REST
OF PAGE INTENTIONALLY BLANK</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>SIGNATURES
TO FOLLOW ON NEXT PAGE]</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROCESSA
    <FONT STYLE="text-transform: uppercase">Pharmaceuticals, Inc.</FONT></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MS.
    WENDY GUY</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    George Ng</I>&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Wendy Guy</I></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng, Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>7
<FILENAME>ex10-15.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.15</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex10-15_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Executive
Employment Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Employment Agreement (the &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of March 19, 2025 (&ldquo;<B>Effective Date</B>&rdquo;),
by and between Patrick Lin (the &ldquo;<B>Executive</B>&rdquo;) and Processa Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;
or &ldquo;<B>Processa</B>&rdquo;) (collectively referred to herein as the &ldquo;Parties&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires to employ the Executive on the terms and conditions set forth herein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Executive desires to be employed by the Company on such terms and conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants, promises, and obligations set forth herein, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Term</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
This Agreement shall be effective for the term beginning on the Effective Date and continue until terminated or modified pursuant to
Section 4 of this Agreement. The period during which the Executive is employed by the Company hereunder is hereinafter referred to as
the &ldquo;<B>Employment Term.</B>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Position and Duties</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
During the Employment Term, the Executive shall serve as the Chief Business and Strategy Officer of the Company. In such position, the
Executive shall have such duties, authority, and responsibilities as shall be mutually agreed upon by the Chief Executive Officer and
the Executive, which duties, authority, and responsibilities are consistent with the Executive&rsquo;s position and prevailing industry
standards. During the Employment Term, the Executive shall devote substantially all of the Executive&rsquo;s business time and attention
to the performance of the Executive&rsquo;s duties hereunder and will not engage in any other business, profession, or occupation for
compensation, which would conflict or interfere with the performance of such services either directly or indirectly without the prior
written consent of the Company&rsquo;s Chief Executive Officer (&ldquo;<B>CEO</B>&rdquo;). Notwithstanding, the Executive shall be permitted
to (i) manage Executive&rsquo;s personal, financial and legal affairs, investments and holdings, (ii) participate in trade associations,
(iii) serve on the board of directors of not-for-profit or tax-exempt charitable organizations, (iv) serve on the board of directors
of for-profit organizations that do not directly compete with the Company, with the prior approval of the CEO and (iv) conduct business
and other matters that were previously disclosed to the Company prior to the Employment Term, in each case, subject to compliance with
this Agreement and provided that such activities do not materially interfere with Executive&rsquo;s performance of Executive&rsquo;s
duties and responsibilities hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Compensation </U></B></FONT><B><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
Benefits</FONT></U></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Base Salary</U></FONT>. The Company shall pay the Executive an annual
base salary of $325,520, less all lawfully required deductions and withholdings (&ldquo;<B>Base
Salary</B>&rdquo;), which will be paid in periodic installments in accordance with the Company&rsquo;s customary payroll practices and
applicable wage payment laws, but no less frequently than monthly. The Executive&rsquo;s Base Salary shall be reviewed annually and may
be increased based on an assessment of Executive&rsquo;s performance, the performance of the Company, inflation, the then prevailing
salary scales for comparable positions and other relevant factors; provided, however, that any increase in Base Salary shall be solely
within the discretion of the CEO and Compensation Committee of the Company&rsquo;s Board. Executive&rsquo;s Base Salary may not be subject
to reduction from the level set forth above, unless pursuant to a salary reduction program of general application to employment contract
executives of the Company, provided that, unless agreed to in writing by Executive, the percentage reduction of Executive&rsquo;s Base
Salary shall not be greater than the percentage reduction applied to any other employment contract executive of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Bonus</U></FONT>. This is a non-qualified plan used by the Company to
provide special compensation to key executives. The Company&rsquo;s contribution to an executive bonus plan is considered salary to the
Executive and is therefore subject to taxation. The Executive is eligible to participate in the bonus pool with a target bonus equal
to 30% of Executive&rsquo;s Base Salary, as then in effect (the &ldquo;Target Bonus&rdquo;), as may be awarded pursuant to any annual
executive bonus plan and related corporate goals approved solely at the discretion of the Compensation Committee of the Board. Any such
Annual Bonus shall contain such rights and features as are typically afforded to other contract executives of the Company. <U><BR>
<BR></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Equity Compensation (RSUs, RSAs, Stock Options, Other)</U></FONT>. The
Compensation Committee of the Board (the &ldquo;<B>Compensation Committee</B>&rdquo;), and pursuant to Processa&rsquo;s 2019 Omnibus
Incentive Plan, or any such additional incentive plans that may be in place at such time, (the &ldquo;<B>Plan</B>&rdquo;) has previously
granted new hire RSUs to Employee. Any additional equity grants will be at the reasonable discretion of the Compensation Committee of
the Board. The specifics of the grants will be described in the Award Agreement to be provided to the Executive. Notwithstanding the
above and any other sections in this Agreement, all unvested equity granted herein, any additional unvested granted and any other unvested
equity-linked securities that may be granted in the future shall immediately vest upon a Change in Control (as defined in Section 4.5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Incentive and Deferred Compensation</U></FONT>. Employee shall be eligible
to participate in all incentive and deferred compensation programs available to other executives or officers of Processa, such participation
to be in the same form, under the same terms, and to the same extent that such programs are made available to other such similarly situated
executives or officers. Except as otherwise provided herein, nothing in this Agreement shall be deemed to require the payment of bonuses,
awards, or incentive compensation to Employee if such payment would not otherwise be required under the terms of Processa&rsquo;s incentive
compensation programs. The Company reserves the right to interpret, amend or terminate any incentive compensation program at any time
in its sole discretion, subject to the terms of such incentive compensation program and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline"><U>3.5
Employee Benefits</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. During the Employment Term, the
Executive shall be entitled to participate in all employee benefit plans, practices, and programs maintained by the Company, as in effect
from time to time (collectively, &ldquo;<B>Employee Benefit Plans</B>&rdquo;), on a basis which is no less favorable than is provided
to other similarly situated executives of the Company, to the extent consistent with applicable law and the terms of the applicable Employee
Benefit Plans. The Company reserves the right to amend or terminate any Employee Benefit Plans at any time in its sole discretion, subject
to the terms of such Employee Benefit Plan and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline"><U>3.6
</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid Time Off</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
During the Employment Term, the Executive will be entitled to earn and use paid time off (&ldquo;<B>PTO</B>&rdquo;) in accordance with
the terms of the Company&rsquo;s PTO policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline"><U>3.7
Business Expenses</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Executive shall be entitled
to reimbursement for all reasonable and necessary out-of-pocket business, entertainment, and travel expenses incurred by the Executive
in connection with the performance of the Executive&rsquo;s duties hereunder in accordance with the Company&rsquo;s expense reimbursement
policies and procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Withholding</U></FONT>. By signing this Agreement, the Executive hereby
authorizes the Company to withhold from any amount payable hereunder any Federal, state, and local taxes in order for the Company to
satisfy any withholding tax obligation it may have under any applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<FONT STYLE="vertical-align: baseline"><B><U>Termination of Employment</U></B></FONT>. The Employment Term and the Executive&rsquo;s
employment with the Company may be terminated upon the following conditions or events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Death or Permanent Disability</U>. The Executive employment under this Agreement and the Employment Term shall terminate immediately
in the event of the death or Permanent Disability of Executive. &ldquo;Permanent Disability&rdquo; shall be defined as (1) Executive&rsquo;s
inability to perform the essential functions of his position, with or without reasonable accommodation, for a period of six consecutive
months or for an aggregate of six months in any twelve month period, as determined by a physician licensed to practice medicine and designated
by Employer and acceptable to the Executive, having reviewed and considered information provided by the Executive&rsquo;s healthcare
provider(s); (2) if the Executive is subject to a legal decree of incompetency; or (3) the Executive receives benefits pursuant to a
long-term disability insurance plan, and the person or persons required to make disability determinations under the long-term disability
plan determines that the Executive has a disability that, if Executive qualified for such disability benefits, would provide coverage
for the longest period of time.. Any refusal by the Executive to submit to a medical examination for the purpose of determining a Permanent
Disability shall be deemed to constitute conclusive evidence of the Executive&rsquo;s Permanent Disability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Termination by Executive</U>. The Executive may voluntarily terminate their employment with the Company by providing at least ninety
(90) days written notice to the Company of such termination. Once such notice is given, the Company may elect to terminate the Executive
prior to the conclusion of the ninety-day period. The Executive shall be paid their Base Salary through the end of the 90-day period.
The Executive may also terminate their employment hereunder for &ldquo;Good Reason.&rdquo; For the purpose of determining Executive&rsquo;s
right to Severance Pay and other payments described in Section 5.2 and elsewhere in this Agreement, the Executive&rsquo;s resignation
will be for &ldquo;Good Reason&rdquo; if the Executive resigns after any of the following events: (A) a decrease of more than 5% in Executive&rsquo;s
Base Salary or annual target bonus opportunity other than a reduction in Executive&rsquo;s Base Salary or annual target bonus opportunity
that is implemented in connection with a contemporaneous, temporary reduction in annual base salaries by the same percentage affecting
other senior executives of the Company or (B) a material decrease in the Executive&rsquo;s authority or areas of responsibility as are
commensurate with such Executive&rsquo;s title or position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Termination by the Company Without Cause</U>. The Company may terminate the Executive&rsquo;s employment hereunder for any reason
other than Cause by delivering written notice of termination to the Executive at least ninety (90) days prior to the date of termination.
The Company may elect to earlier terminate and pay Executive their regular Base Salary and benefits through the end of the 90-day period
as an addition to severance pay in lieu of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Termination by the Company for Cause</U>. Employer may terminate the Executive immediately for Cause. For purposes of this Agreement,
&ldquo;Cause&rdquo; shall mean:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
the Executive&rsquo;s refusal or inability to perform or observe any of the Executive&rsquo;s material duties, responsibilities or obligations
set forth in this Agreement (other than any such refusal or inability resulting from Executive&rsquo;s Permanent Disability); provided,
however, that Employer shall not be deemed to have Cause pursuant to this clause unless the Company gives the Executive written notice
that the specified conduct has occurred and the Executive fails to cure the conduct within thirty (30) days after receipt of such notice;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
any act of the Executive involving fraud, theft, misappropriation of funds, or embezzlement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
the Executive is convicted of any felony or misdemeanor involving dishonesty, violence or moral turpitude, or which in the reasonable
judgment of the Company, reflects materially and adversely on the reputation of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
the Executive&rsquo;s material failure to comply with any of the Company&rsquo;s policies, including but not limited to by engaging in
the illegal use of controlled substances, the knowing abuse of prescribed medications, or the misuse of alcohol;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
the Executive&rsquo;s material breach of fiduciary duty of care, loyalty, and good faith, ensuring diligent, company-focused actions
and legal compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Termination of Employment Involving a Change of Control</U>. The Executive&rsquo;s employment with the Company may be terminated in
the event that a Change in Control occurs, and the Executive&rsquo;s employment with the Company is terminated by the Company Without
Cause or by the Executive for Good Reason at any time within the three (3) month period before the date of and in connection with such
Change in Control or during the twelve (12) month period following the date of such Change in Control (&ldquo;<B>Termination as a Result
of a Change in Control</B>&rdquo;). For purposes of this Section, &ldquo;<B>Change in Control</B>&rdquo; shall mean and include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Acquisition by any &ldquo;Person&rdquo; or &ldquo;Group&rdquo; of securities entitled to vote generally in the election of directors
(&ldquo;voting securities&rdquo;) of the Company that represent 50% or more of the combined voting power of the Company&rsquo;s then
outstanding voting securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
A change in the composition of the Board occurring within a twelve (12) month period, as a result of which a majority of the incumbent
directors are replaced by directors whose appointment or election is not endorsed by a majority of the incumbent directors before the
date of the appointment or election;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Merger or consolidation in which the seller&rsquo;s shareholders no longer control the surviving entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline"><U>d)
</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of substantially all assets to an unrelated
entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Resignation of All Other Positions</U></FONT>. On termination of the Executive&rsquo;s
employment hereunder for any reason, the Executive shall be deemed to have resigned from all positions that the Executive holds as an
officer or member of the Board (or a committee thereof) of the Company or any of its affiliates (and shall confirm such resignation in
writing upon the request of the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline"><U>4.7
Termination Date. The final date on which the Executive is actually employed by the Company pursuant to this Agreement shall be the &ldquo;</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B>Termination
Date</B><FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">5.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Compensation on Termination
of Employment</U></B><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Earned and Accrued Payments</U>. In the event that the Executive&rsquo;s employment is terminated, the Executive shall be entitled
to receive: (a) any accrued but unpaid Base Salary, which shall be paid on the pay date immediately following the Executive&rsquo;s Termination
Date, unless earlier required by applicable law; (b) any accrued but unpaid target annual bonus or any other granted bonus where such
bonus was determined prior to the Termination Date, which shall be paid on the otherwise applicable payment date; (c) reimbursement for
unreimbursed business expenses properly incurred by the Executive, which shall be subject to and paid in accordance with the Company&rsquo;s
expense reimbursement policy; and (d) such employee benefits (including equity compensation), if any, to which the Executive may be entitled
under the Company&rsquo;s employee benefit plans as of the Termination Date; provided that, in no event shall the Executive be entitled
to any payments in the nature of severance or termination payments except as specifically provided herein. The treatment of any outstanding
equity awards shall be determined in accordance with the terms in this Agreement, of the Plan and the applicable award agreements. For
clarification purposes, if the Termination Date occurs prior to the date of payment of the prior year bonus, the entire unpaid bonus
from the prior year plus the pro-rata accrued but unpaid bonus from the year of the Termination date would be included in 5.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Severance Pay</U>. In the event that the Executive&rsquo;s employment with the Company is terminated due to death or Permanent Disability,
by the Company Without Cause, the Executive terminates employment with the Company for Good Reason, and/or there is a Termination as
a Result of a Change in Control (each a &ldquo;Separation Event&rdquo;), the Executive shall be entitled to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>a.</U></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                            year of Base Salary and Target Bonus (&ldquo;<B>Severance Pay</B>&rdquo;), paid out in accordance
                                            with the normal payroll practices of the Company following the Termination Date and paid
                                            out over the twelve (12) month period. Payment of any Severance Pay shall be conditioned
                                            upon the Executive executing and not revoking a separation agreement reasonably satisfactory
                                            to the Company (or its successor) and to the Executive, including a general release of all
                                            claims that is reasonably satisfactory with terms substantially similar to typical agreements
                                            to the Company (or its successor) and the Executive; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>b.</U></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the twelve (12) month period following the Separation Event, (or, if earlier, the date on
                                            which the applicable continuation period under the Consolidated Omnibus Budget Reconciliation
                                            Act of 1985, as amended (&ldquo;COBRA&rdquo;) expires), and the Executive has elected COBRA
                                            coverage then the Company shall arrange to provide Executive and his eligible dependents
                                            who were covered under the Company&rsquo;s health insurance plans as of the date of the Separation
                                            Event with health (including medical and dental) insurance benefits substantially similar
                                            to those provided to such dependents immediately prior to the date of such Separation Event.
                                            The Executive will be responsible for any portion of the premium associated with such coverage
                                            that he was responsible for during employment. If the Company is not reasonably able to continue
                                            health insurance benefits coverage under the Company&rsquo;s insurance plans, the Company
                                            shall provide substantially equivalent coverage under other third-party insurance sources.
                                            If any of the Company&rsquo;s health benefits are self-funded as of the date of Separation
                                            Event, or if the Company cannot provide the foregoing benefits in a manner that exempt from
                                            Section 409A of the Code or that is otherwise compliant with applicable law (including, without
                                            limitation, Section 2716 of the Public Health Service Act), instead of providing continued
                                            health insurance benefits as set forth above, the Company shall instead pay to the Executive
                                            an amount equal to twelve (12) multiplied by the monthly premium the Executive would be required
                                            to pay for continuation coverage pursuant to the COBRA for his/her eligible dependents who
                                            were covered under the Company&rsquo;s health plans as of the date of the Separation Event
                                            (calculated by reference to the premium as of the date of the Separation Event), which amount
                                            shall be paid on the Payment Date. Eligibility for this benefit is contingent upon the execution
                                            and nonrevocation of the separation agreement referenced above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Section 280G</U></FONT>. If the Executive becomes entitled to any amount
in the nature of compensation payable by the Company that is contingent on a change in ownership, effective control, or substantial ownership
of a substantial portion of the Company&rsquo;s assets within the meaning of Section 280G of the Internal Revenue Code (&ldquo;Covered
Payments&rdquo;) and constitute &ldquo;Parachute Payments&rdquo; within the meaning within the meaning of Section 280G of the Internal
Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), and that is subject to the excise tax imposed by Section 4999 of the Code
(&ldquo;Excise Tax&rdquo;), a calculation shall be made comparing (i) the Net Benefit (as defined below) to the Executive of the Covered
Payments after payment of the Excise Tax to (ii) the Net Benefit to the Executive if the Covered Payments are limited to the extent necessary
to avoid being subject to the Excise Tax. Only if the amount calculated under (i) above is less than the amount under (ii) above will
the Covered Payments be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise
Tax (that amount, the &ldquo;Reduced Amount&rdquo;). &ldquo;Net Benefit&rdquo; shall mean the present value of the Covered Payments net
of all federal, state, local, foreign income, employment and excise taxes. In the event reduction is required, the Covered Payments shall
be reduced by the Company in the following order: (i) cash severance payments hereunder to the extent not subject to Section 409A of
the Code in the reverse order of payment; (ii) any other portion of the Covered Payments that are not subject to Section 409A of the
Code in the reverse order of payment (other than any acceleration of vesting of equity awards); (iii) Covered Payments that are not subject
to Section 409A of the Code that arise from the accelerated vesting of equity awards, and; (iv) Covered Payments that are subject to
Section 409A of the Code in a manner consistent with Section 409A of the Code. All determinations pursuant to this Section 5.4 shall
be made by tax accountants selected by the Company and reasonably acceptable to Executive (the &ldquo;Accountants&rdquo;), whose determinations
shall be binding on the Company and the Executive absent manifest error. The Executive shall provide the Accountants with such information
and documents as the Accountants may reasonably request in order for the Accountants to make their determinations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<FONT STYLE="vertical-align: baseline"><B><U>Return of Property and Employee Non-Solicit</U></B></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Return of Property</U>. Upon termination of Executive&rsquo;s employment with the Company for any reason, upon request, Executive
will use reasonable efforts to promptly deliver to the Company all equipment, correspondence, drawings, manuals, letters, notes, notebooks,
reports, programs, plans, proposals, financial documents, or any other documents or property containing material information pertaining
to the Company&rsquo;s customers, business plans, marketing strategies, products, property or processes..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Non-Solicitation of Employees Covenant</U>. Executive acknowledges that the Company&rsquo;s employees and consultants are a valuable
asset to the Company, especially because such employees have access to and knowledge of the Company&rsquo;s confidential information
and trade secrets. As such, Executive agrees for a period of one-year from the Termination Date, with respect to any Company employee
with whom Executive had material business contact during their employment with the Company, Executive will not (i) induce or attempt
to induce such employee of the Company to leave employment or contracting with the Company; or (ii) directly solicit the services of
or hire away such current employee of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Notification of Future Employers</U>. Executive hereby agrees to notify any future employers or prospective employers of the foregoing
obligations and authorizes the Company to provide a single notice of the terms in Section 6 to Executive&rsquo;s actual or future employers
(or persons or entities that contract or seek to contract for Executive&rsquo;s services).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
<U>Remedies</U>. In the event of a breach or threatened breach by either party, each party hereby consents and agrees that the non-breaching
party may (as determined by a court of law or proper judicial authority) be entitled to seek, in addition to other available remedies,
a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of competent jurisdiction,
and that money damages would not afford an adequate remedy, without the necessity of showing any actual damages. The aforementioned equitable
relief may (as determined by a court of law or proper judicial authority) be in addition to, not in lieu of, legal remedies, monetary
damages, or other available forms of relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B><U>Assignment of Inventions and Rights</U></B><U>.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Work Product</U>. The Executive acknowledges and agrees that all designs, devices, discoveries, processes, proprietary software, writings,
inventions, improvements and documentation, and any other works of authorship (collectively, &ldquo;<B>Work Product</B>&rdquo;), and
all related know-how, produced, made, conceived or authored by the Executive, solely or jointly with others, in the course of his employment
with the Company together with any intellectual property rights concerning the Work Product produced, made, conceived or authored by
the Executive, including any moral rights relating to any of the foregoing, are works made for hire and the property of the Company if
such works (i) result or are derived from, at the time the Work Product is produced, made, conceived or reduced to practice, the actual
business, research, or development of the Company; or (ii) are result from any work performed by the Executive for or on behalf of the
Company; or (iii) are created or developed with the use of Proprietary Information or Company equipment, supplies, facilities, information,
materials or other Company resources (&ldquo;Company IP&rdquo;). The Executive shall disclose in writing any such Company IP promptly
to the Company and hereby irrevocably assign any and all rights in their entirety, throughout the world, in and to such works to the
Company or its assignees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
To the extent that any such Company IP may not, by operation of law, be deemed works made for hire, this Agreement shall constitute an
irrevocable assignment by the Executive to the Company of the ownership of, and all right, title, and interest in and to such items,
including an irrevocable assignment of all moral rights relating thereto, and the Company shall have the right to obtain and hold in
its own name, all intellectual property rights, including without limitation, patent, trade secret, copyright and similar protections
which may be available in such Company IP throughout the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
The Executive agrees that all work product made by them after the end of employment with the Company, whether created solely by the Executive
or jointly with others, that is based on or contains Confidential Information of the Company, shall belong to the Company; and the Executive
irrevocably assigns any and all rights in their entirety, throughout the world, in and to such future Work Product to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
The Executive agrees to use reasonable efforts to assist the Company, or its designee or assignee, to secure and perfect the Company&rsquo;s
(and/or such designee&rsquo;s) rights in such Work Product and any copyrights, patents, trade secrets, mask work rights or other intellectual
property rights and/or moral rights relating thereto in any and all countries, including the written disclosure to the Company of all
information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments
which the Company shall deem necessary in order to apply for, obtain and protect such rights and in order to assign and convey to the
Company, its successors, assigns, and nominees the sole and exclusive rights, title and interest in and to such Company IP, and any copyright,
patents, trade secrets, mask work rights or other intellectual property rights and/or moral rights contained therein and/or relating
thereto. The Executive further agrees that their obligation to execute or cause to be executed any such instrument or papers shall continue
after employment with the Company ends. The Executive shall be entitled to reimbursement for reasonable expenses in providing such post-employment
assistance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
In the event the Company is unable due to Executive&rsquo;s subsequent disability, incapacity or for any other reason whatsoever to secure
his signature to any lawful and necessary document required to apply for, register or execute any patent, copyright or other applications
with respect to any such Company IP, the Executive hereby irrevocably appoints the Company and its duly authorized officers and agents
as its agents and attorneys-in-fact to execute and file any such application and to do all other lawfully permitted acts to further the
prosecution and issuance of patents, copyrights or other rights thereon with the same legal force and effect as if executed by the Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
In the event Company should not desire to secure and perfect its rights to any Company IP, but should desire to keep the same secret,
the Executive agrees that they will do everything reasonably in his power to assist Company in this and will not disclose any information
relating to such Company IP except with the prior written consent of Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7
In order to permit the Company to claim rights to which it may be entitled, Executive agrees to disclose to the Company in writing and
in confidence all inventions or Company IP that Executive makes or conceive of, either solely or jointly with others, during the term
of his employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8
All Work Product that was made by the Executive before his employment with the Company (collectively referred to as &ldquo;Prior Inventions&rdquo;)
are excluded from Section 5 of this Agreement. The Executive agrees not to incorporate into a Company product, process or code, or other
Company Work Product, a Prior Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">8.
<U>Acknowledgement</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Executive acknowledges and
agrees that the services to be rendered by the Executive to the Company are of a special and unique character; that the Executive will
obtain knowledge and skill relevant to the Company&rsquo;s industry, methods of doing business and marketing strategies by virtue of
the Executive&rsquo;s employment; and that the restrictive covenants and other terms and conditions of this Agreement are reasonable
and reasonably necessary to protect the legitimate business interest of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">9.
<U>Governing Law: Jurisdiction and Venue</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement,
for all purposes, shall be construed in accordance with the laws of Delaware without regard to conflicts of law principles. Any action
or proceeding by either of the parties to enforce this Agreement shall be brought only in a state or federal court located in the State
of Delaware. The parties hereby irrevocably submit to the exclusive jurisdiction of such courts and waive the defense of inconvenient
forum to the maintenance of any such action or proceeding in such venue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">10.
<U>Entire Agreement</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Unless specifically provided
herein, this Agreement contains all of the understandings and representations between the Executive and the Company pertaining to the
subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both
written and oral, with respect to such subject matter. The parties mutually agree that the Agreement can be specifically enforced in
court and can be cited as evidence in legal proceedings alleging breach of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">11.
<U>Modification and Waiver</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. No provision of this
Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by the Executive and by
the Company. No waiver by either of the parties of any breach by the other party hereto of any condition or provision of this Agreement
to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or
any prior or subsequent time, nor shall the failure of or delay by either of the parties in exercising any right, power, or privilege
hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power,
or privilege.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Severability</U></FONT>. Should any provision of this Agreement be held
by a court of competent jurisdiction to be enforceable only if modified, or if any portion of this Agreement shall be held as unenforceable
and thus stricken, such holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue
to be binding upon the parties with any such modification to become a part hereof and treated as though originally set forth in this
Agreement. The parties further agree that any such court is expressly authorized to modify any such unenforceable provision of this Agreement
in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting
any or all of the offending provision, adding additional language to this Agreement, or by making such other modifications as it deems
warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law. The parties
expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against each of them. In any event,
should one or more of the provisions of this Agreement be held to be invalid, illegal, or unenforceable in any respect, such invalidity,
illegality, or unenforceability shall not affect any other provisions hereof, and if such provision or provisions are not modified as
provided above, this Agreement shall be construed as if such invalid, illegal, or unenforceable provisions had not been set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">13.
<U>Captions</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Captions and headings of the sections
and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference
to the caption or heading of any section or paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">14.
<U>Counterparts</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement may be executed
in separate counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same
instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<FONT STYLE="font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline"><U>Section 409A</U></FONT>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1
General. The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt from Section 409A
of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively, &ldquo;Section
409A&rdquo;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2
Separation from Service. Notwithstanding anything in this Agreement to the contrary, any compensation or benefits payable under this
Agreement that is considered nonqualified deferred compensation under Section 409A and is designated under this Agreement as payable
upon the Executive&rsquo;s termination of employment shall be payable only upon Executive&rsquo;s &ldquo;separation from service&rdquo;
with the Company within the meaning of Section 409A (a &ldquo;Separation from Service&rdquo;) and, except as provided below, any such
compensation or benefits described in Section 4(b) shall not be paid until the fifty-fifth (55th) day following Executive&rsquo;s Separation
from Service (the &ldquo;First Payment Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3
Specified Employee. Notwithstanding anything in this Agreement to the contrary, if the Executive is deemed by the Company at the time
of the Executive&rsquo;s Separation from Service to be a &ldquo;specified employee&rdquo; for purposes of Section 409A, to the extent
delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid
a prohibited distribution under Section 409A, such portion of the Executive&rsquo;s benefits shall not be provided to the Executive prior
to the earlier of (i) the expiration of the six-month period measured from the date of the Executive&rsquo;s Separation from Service
with the Company or (ii) the date of the Executive&rsquo;s death. Upon the first business day following the expiration of the applicable
Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to the Executive (or the Executive&rsquo;s
estate or beneficiaries), and any remaining payments due to the Executive under this Agreement shall be paid as otherwise provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.4
Expense Reimbursements. To the extent that any reimbursements under this Agreement are subject to Section 409A, any such reimbursements
payable to the Executive shall be paid to the Executive no later than December 31st of the calendar year following the calendar year
in which the expense was incurred; provided, that the Executive submits the Executive&rsquo;s reimbursement request promptly following
the date the expense is incurred, the amount of expenses reimbursed in one calendar year shall not affect the amount eligible for reimbursement
in any subsequent calendar year, other than medical expenses referred to in Section 105(b) of the Code, and Executive&rsquo;s right to
reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline"><U>15.5
</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Installments. The Executive&rsquo;s right to receive
any installment payments under this Agreement, including without limitation any continuation salary payments that are payable on the
Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment
shall at all times be considered a separate and distinct payment as permitted under Section 409A. Except as otherwise permitted under
Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional
tax or interest pursuant to Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline"><U>16.
Successors and Assigns</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement is personal
to the Executive and shall not be assigned by the Executive. Any purported assignment by the Executive shall be null and void from the
initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect,
by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets of the Company. This Agreement
shall inure to the benefit of the Company and permitted successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Notice</U></FONT>. Notices and all other communications provided for in
this Agreement shall be in writing and shall be delivered personally or sent by registered or certified mail, return receipt requested,
or by overnight carrier to the parties at the addresses set forth below (or such other addresses as specified by the parties by like
notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If to the
  Company</B>: </FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa Pharmaceuticals,
  Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7380 Coca Cola Drive, Suite
  106</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hanover, MD 21076</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>If to the Executive:</B></FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Patrick Lin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">45 Coachwood Terrace</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Orinda,
  CA 94563</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline"><U>18.
Survival</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Upon the expiration or other termination
of this Agreement, the respective rights and obligations of the parties hereto shall survive such expiration or other termination to
the extent necessary to carry out the intentions of the parties under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Acknowledgement of Full Understanding</U></FONT>. THE EXECUTIVE ACKNOWLEDGES
AND AGREES THAT THE EXECUTIVE HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE EXECUTIVE ACKNOWLEDGES AND
AGREES THAT THE EXECUTIVE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF THE EXECUTIVE&rsquo;S CHOICE BEFORE
SIGNING THIS AGREEMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>[REST
OF PAGE INTENTIONALLY BLANK</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>SIGNATURES
TO FOLLOW ON NEXT PAGE]</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROCESSA
                    <FONT STYLE="text-transform: uppercase">Pharmaceuticals, Inc.</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MR.
                                            PATRICK LIN</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/
    <FONT STYLE="font-size: 10pt">George Ng</FONT></I><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/
    Patrick Lin</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng, Chief Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>8
<FILENAME>ex10-16.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.16</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex10-16_001.jpg" ALT=""></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Executive
Employment Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Employment Agreement (the &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of March 19, 2025 (&ldquo;<B>Effective Date</B>&rdquo;),
by and between Dr. David Young (the &ldquo;<B>Executive</B>&rdquo;) and Processa Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;
or &ldquo;<B>Processa</B>&rdquo;) (collectively referred to herein as the &ldquo;Parties&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires to employ the Executive on the terms and conditions set forth herein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Executive desires to be employed by the Company on such terms and conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants, promises, and obligations set forth herein, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Term</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
This Agreement shall be effective for the term beginning on the Effective Date and continue until terminated or modified pursuant to
Section 4 of this Agreement. The period during which the Executive is employed by the Company hereunder is hereinafter referred to as
the &ldquo;<B>Employment Term.</B>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Position and Duties</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
During the Employment Term, the Executive shall serve as the President, Research &amp; Development of the Company. In such position,
the Executive shall have such duties, authority, and responsibilities as shall be mutually agreed upon by the Chief Executive Officer
and the Executive, which duties, authority, and responsibilities are consistent with the Executive&rsquo;s position and prevailing industry
standards. During the Employment Term, the Executive shall devote substantially all of the Executive&rsquo;s business time and attention
to the performance of the Executive&rsquo;s duties hereunder and will not engage in any other business, profession, or occupation for
compensation, which would conflict or interfere with the performance of such services either directly or indirectly without the prior
written consent of the Company&rsquo;s Chief Executive Officer (&ldquo;<B>CEO</B>&rdquo;). Notwithstanding, the Executive shall be permitted
to (i) manage Executive&rsquo;s personal, financial and legal affairs, investments and holdings, (ii) participate in trade associations,
(iii) serve on the board of directors of not-for-profit or tax-exempt charitable organizations, (iv) serve on the board of directors
of for-profit organizations that do not directly compete with the Company, with the prior approval of the CEO and (iv) conduct business
and other matters that were previously disclosed to the Company prior to the Employment Term, in each case, subject to compliance with
this Agreement and provided that such activities do not materially interfere with Executive&rsquo;s performance of Executive&rsquo;s
duties and responsibilities hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Compensation</U></B></FONT><B><U>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and Benefits</FONT></U></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Base Salary</U></FONT>. The Company shall pay the Executive an annual
base salary of $387,920, less all lawfully required deductions and withholdings (&ldquo;<B>Base
Salary</B>&rdquo;), which will be paid in periodic installments in accordance with the Company&rsquo;s customary payroll practices and
applicable wage payment laws, but no less frequently than monthly. The Executive&rsquo;s Base Salary shall be reviewed annually and may
be increased based on an assessment of Executive&rsquo;s performance, the performance of the Company, inflation, the then prevailing
salary scales for comparable positions and other relevant factors; provided, however, that any increase in Base Salary shall be solely
within the discretion of the CEO and Compensation Committee of the Company&rsquo;s Board. Executive&rsquo;s Base Salary may not be subject
to reduction from the level set forth above, unless pursuant to a salary reduction program of general application to employment contract
executives of the Company, provided that, unless agreed to in writing by Executive, the percentage reduction of Executive&rsquo;s Base
Salary shall not be greater than the percentage reduction applied to any other employment contract executive of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Bonus</U></FONT>. This is a non-qualified plan used by the Company to
provide special compensation to key executives. The Company&rsquo;s contribution to an executive bonus plan is considered salary to the
Executive and is therefore subject to taxation. The Executive is eligible to participate in the bonus pool with a target bonus equal
to 40% of Executive&rsquo;s Base Salary, as then in effect (the &ldquo;Target Bonus&rdquo;), as may be awarded pursuant to any annual
executive bonus plan and related corporate goals approved solely at the discretion of the Compensation Committee of the Board. Any such
Annual Bonus shall contain such rights and features as are typically afforded to other contract executives of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Equity Compensation (RSUs, RSAs, Stock Options, Other)</U></FONT>. The
Compensation Committee of the Board (the &ldquo;<B>Compensation Committee</B>&rdquo;), and pursuant to Processa&rsquo;s 2019 Omnibus
Incentive Plan, or any such additional incentive plans that may be in place at such time, (the &ldquo;<B>Plan</B>&rdquo;) has previously
granted new hire RSUs to Employee. Any additional equity grants will be at the reasonable discretion of the Compensation Committee of
the Board. The specifics of the grants will be described in the Award Agreement to be provided to the Executive. Notwithstanding the
above and any other sections in this Agreement, all unvested equity granted herein, any additional unvested granted and any other unvested
equity-linked securities that may be granted in the future shall immediately vest upon a Change in Control (as defined in Section 4.5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Incentive and Deferred Compensation</U></FONT>. Employee shall be eligible
to participate in all incentive and deferred compensation programs available to other executives or officers of Processa, such participation
to be in the same form, under the same terms, and to the same extent that such programs are made available to other such similarly situated
executives or officers. Except as otherwise provided herein, nothing in this Agreement shall be deemed to require the payment of bonuses,
awards, or incentive compensation to Employee if such payment would not otherwise be required under the terms of Processa&rsquo;s incentive
compensation programs. The Company reserves the right to interpret, amend or terminate any incentive compensation program at any time
in its sole discretion, subject to the terms of such incentive compensation program and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">3.5
<U>Employee Benefits</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. During the Employment Term,
the Executive shall be entitled to participate in all employee benefit plans, practices, and programs maintained by the Company, as in
effect from time to time (collectively, &ldquo;<B>Employee Benefit Plans</B>&rdquo;), on a basis which is no less favorable than is provided
to other similarly situated executives of the Company, to the extent consistent with applicable law and the terms of the applicable Employee
Benefit Plans. The Company reserves the right to amend or terminate any Employee Benefit Plans at any time in its sole discretion, subject
to the terms of such Employee Benefit Plan and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.6
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Paid Time Off</U>. During the Employment Term, the
Executive will be entitled to earn and use paid time off (&ldquo;<B>PTO</B>&rdquo;) in accordance with the terms of the Company&rsquo;s
PTO policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.7
<U>Business Expenses</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Executive shall be entitled
to reimbursement for all reasonable and necessary out-of-pocket business, entertainment, and travel expenses incurred by the Executive
in connection with the performance of the Executive&rsquo;s duties hereunder in accordance with the Company&rsquo;s expense reimbursement
policies and procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Withholding</U></FONT>. By signing this Agreement, the Executive hereby
authorizes the Company to withhold from any amount payable hereunder any Federal, state, and local taxes in order for the Company to
satisfy any withholding tax obligation it may have under any applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<FONT STYLE="vertical-align: baseline"><B><U>Termination of Employment</U></B></FONT>. The Employment Term and the Executive&rsquo;s
employment with the Company may be terminated upon the following conditions or events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Death or Permanent Disability</U>. The Executive employment under this Agreement and the Employment Term shall terminate immediately
in the event of the death or Permanent Disability of Executive. &ldquo;Permanent Disability&rdquo; shall be defined as (1) Executive&rsquo;s
inability to perform the essential functions of his position, with or without reasonable accommodation, for a period of six consecutive
months or for an aggregate of six months in any twelve month period, as determined by a physician licensed to practice medicine and designated
by Employer and acceptable to the Executive, having reviewed and considered information provided by the Executive&rsquo;s healthcare
provider(s); (2) if the Executive is subject to a legal decree of incompetency; or (3) the Executive receives benefits pursuant to a
long-term disability insurance plan, and the person or persons required to make disability determinations under the long-term disability
plan determines that the Executive has a disability that, if Executive qualified for such disability benefits, would provide coverage
for the longest period of time.. Any refusal by the Executive to submit to a medical examination for the purpose of determining a Permanent
Disability shall be deemed to constitute conclusive evidence of the Executive&rsquo;s Permanent Disability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Termination by Executive</U>. The Executive may voluntarily terminate their employment with the Company by providing at least ninety
(90) days written notice to the Company of such termination. Once such notice is given, the Company may elect to terminate the Executive
prior to the conclusion of the ninety-day period. The Executive shall be paid their Base Salary through the end of the 90-day period.
The Executive may also terminate their employment hereunder for &ldquo;Good Reason.&rdquo; For the purpose of determining Executive&rsquo;s
right to Severance Pay and other payments described in Section 5.2 and elsewhere in this Agreement, the Executive&rsquo;s resignation
will be for &ldquo;Good Reason&rdquo; if the Executive resigns after any of the following events: (A) a decrease of more than 5% in Executive&rsquo;s
Base Salary or annual target bonus opportunity other than a reduction in Executive&rsquo;s Base Salary or annual target bonus opportunity
that is implemented in connection with a contemporaneous, temporary reduction in annual base salaries by the same percentage affecting
other senior executives of the Company or (B) a material decrease in the Executive&rsquo;s authority or areas of responsibility as are
commensurate with such Executive&rsquo;s title or position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Termination by the Company Without Cause</U>. The Company may terminate the Executive&rsquo;s employment hereunder for any reason
other than Cause by delivering written notice of termination to the Executive at least ninety (90) days prior to the date of termination.
The Company may elect to earlier terminate and pay Executive their regular Base Salary and benefits through the end of the 90-day period
as an addition to severance pay in lieu of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Termination by the Company for Cause</U>. Employer may terminate the Executive immediately for Cause. For purposes of this Agreement,
&ldquo;Cause&rdquo; shall mean:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
the Executive&rsquo;s refusal or inability to perform or observe any of the Executive&rsquo;s material duties, responsibilities or obligations
set forth in this Agreement (other than any such refusal or inability resulting from Executive&rsquo;s Permanent Disability); provided,
however, that Employer shall not be deemed to have Cause pursuant to this clause unless the Company gives the Executive written notice
that the specified conduct has occurred and the Executive fails to cure the conduct within thirty (30) days after receipt of such notice;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
any act of the Executive involving fraud, theft, misappropriation of funds, or embezzlement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
the Executive is convicted of any felony or misdemeanor involving dishonesty, violence or moral turpitude, or which in the reasonable
judgment of the Company, reflects materially and adversely on the reputation of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
the Executive&rsquo;s material failure to comply with any of the Company&rsquo;s policies, including but not limited to by engaging in
the illegal use of controlled substances, the knowing abuse of prescribed medications, or the misuse of alcohol;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
the Executive&rsquo;s material breach of fiduciary duty of care, loyalty, and good faith, ensuring diligent, company-focused actions
and legal compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Termination of Employment Involving a Change of Control</U>. The Executive&rsquo;s employment with the Company may be terminated in
the event that a Change in Control occurs, and the Executive&rsquo;s employment with the Company is terminated by the Company Without
Cause or by the Executive for Good Reason at any time within the three (3) month period before the date of and in connection with such
Change in Control or during the twelve (12) month period following the date of such Change in Control (&ldquo;<B>Termination as a Result
of a Change in Control</B>&rdquo;). For purposes of this Section, &ldquo;<B>Change in Control</B>&rdquo; shall mean and include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Acquisition by any &ldquo;Person&rdquo; or &ldquo;Group&rdquo; of securities entitled to vote generally in the election of directors
(&ldquo;voting securities&rdquo;) of the Company that represent 50% or more of the combined voting power of the Company&rsquo;s then
outstanding voting securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
A change in the composition of the Board occurring within a twelve (12) month period, as a result of which a majority of the incumbent
directors are replaced by directors whose appointment or election is not endorsed by a majority of the incumbent directors before the
date of the appointment or election;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Merger or consolidation in which the seller&rsquo;s shareholders no longer control the surviving entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline"><U>d)
</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of substantially all assets to an unrelated
entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Resignation of All Other Positions</U></FONT>. On termination of the Executive&rsquo;s
employment hereunder for any reason, the Executive shall be deemed to have resigned from all positions that the Executive holds as an
officer or member of the Board (or a committee thereof) of the Company or any of its affiliates (and shall confirm such resignation in
writing upon the request of the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">4.7
<U>Termination Date. </U>The final date on which the Executive is actually employed by the Company pursuant to this Agreement shall be
the &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B>Termination
Date</B><FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">5.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>Compensation on Termination
of Employment</U></B><U><FONT STYLE="font-weight: normal">.</FONT></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Earned and Accrued Payments</U>. In the event that the Executive&rsquo;s employment is terminated, the Executive shall be entitled
to receive: (a) any accrued but unpaid Base Salary, which shall be paid on the pay date immediately following the Executive&rsquo;s Termination
Date, unless earlier required by applicable law; (b) any accrued but unpaid target annual bonus or any other granted bonus where such
bonus was determined prior to the Termination Date, which shall be paid on the otherwise applicable payment date; (c) reimbursement for
unreimbursed business expenses properly incurred by the Executive, which shall be subject to and paid in accordance with the Company&rsquo;s
expense reimbursement policy; and (d) such employee benefits (including equity compensation), if any, to which the Executive may be entitled
under the Company&rsquo;s employee benefit plans as of the Termination Date; provided that, in no event shall the Executive be entitled
to any payments in the nature of severance or termination payments except as specifically provided herein. The treatment of any outstanding
equity awards shall be determined in accordance with the terms in this Agreement, of the Plan and the applicable award agreements. For
clarification purposes, if the Termination Date occurs prior to the date of payment of the prior year bonus, the entire unpaid bonus
from the prior year plus the pro-rata accrued but unpaid bonus from the year of the Termination date would be included in 5.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Severance Pay</U>. In the event that the Executive&rsquo;s employment with the Company is terminated due to death or Permanent Disability,
by the Company Without Cause, the Executive terminates employment with the Company for Good Reason, and/or there is a Termination as
a Result of a Change in Control (each a &ldquo;Separation Event&rdquo;), the Executive shall be entitled to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>a.</U></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                            year of Base Salary and Target Bonus (&ldquo;<B>Severance Pay</B>&rdquo;), paid out in accordance
                                            with the normal payroll practices of the Company following the Termination Date and paid
                                            out over the twelve (12) month period. Payment of any Severance Pay shall be conditioned
                                            upon the Executive executing and not revoking a separation agreement reasonably satisfactory
                                            to the Company (or its successor) and to the Executive, including a general release of all
                                            claims that is reasonably satisfactory with terms substantially similar to typical agreements
                                            to the Company (or its successor) and the Executive; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>b.</U></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the twelve (12) month period following the Separation Event, (or, if earlier, the date on
                                            which the applicable continuation period under the Consolidated Omnibus Budget Reconciliation
                                            Act of 1985, as amended (&ldquo;COBRA&rdquo;) expires), and the Executive has elected COBRA
                                            coverage then the Company shall arrange to provide Executive and his eligible dependents
                                            who were covered under the Company&rsquo;s health insurance plans as of the date of the Separation
                                            Event with health (including medical and dental) insurance benefits substantially similar
                                            to those provided to such dependents immediately prior to the date of such Separation Event.
                                            The Executive will be responsible for any portion of the premium associated with such coverage
                                            that he was responsible for during employment. If the Company is not reasonably able to continue
                                            health insurance benefits coverage under the Company&rsquo;s insurance plans, the Company
                                            shall provide substantially equivalent coverage under other third-party insurance sources.
                                            If any of the Company&rsquo;s health benefits are self-funded as of the date of Separation
                                            Event, or if the Company cannot provide the foregoing benefits in a manner that exempt from
                                            Section 409A of the Code or that is otherwise compliant with applicable law (including, without
                                            limitation, Section 2716 of the Public Health Service Act), instead of providing continued
                                            health insurance benefits as set forth above, the Company shall instead pay to the Executive
                                            an amount equal to twelve (12) multiplied by the monthly premium the Executive would be required
                                            to pay for continuation coverage pursuant to the COBRA for his/her eligible dependents who
                                            were covered under the Company&rsquo;s health plans as of the date of the Separation Event
                                            (calculated by reference to the premium as of the date of the Separation Event), which amount
                                            shall be paid on the Payment Date. Eligibility for this benefit is contingent upon the execution
                                            and nonrevocation of the separation agreement referenced above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 89.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Section 280G</U></FONT>. If the Executive becomes entitled to any amount
in the nature of compensation payable by the Company that is contingent on a change in ownership, effective control, or substantial ownership
of a substantial portion of the Company&rsquo;s assets within the meaning of Section 280G of the Internal Revenue Code (&ldquo;Covered
Payments&rdquo;) and constitute &ldquo;Parachute Payments&rdquo; within the meaning within the meaning of Section 280G of the Internal
Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), and that is subject to the excise tax imposed by Section 4999 of the Code
(&ldquo;Excise Tax&rdquo;), a calculation shall be made comparing (i) the Net Benefit (as defined below) to the Executive of the Covered
Payments after payment of the Excise Tax to (ii) the Net Benefit to the Executive if the Covered Payments are limited to the extent necessary
to avoid being subject to the Excise Tax. Only if the amount calculated under (i) above is less than the amount under (ii) above will
the Covered Payments be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise
Tax (that amount, the &ldquo;Reduced Amount&rdquo;). &ldquo;Net Benefit&rdquo; shall mean the present value of the Covered Payments net
of all federal, state, local, foreign income, employment and excise taxes. In the event reduction is required, the Covered Payments shall
be reduced by the Company in the following order: (i) cash severance payments hereunder to the extent not subject to Section 409A of
the Code in the reverse order of payment; (ii) any other portion of the Covered Payments that are not subject to Section 409A of the
Code in the reverse order of payment (other than any acceleration of vesting of equity awards); (iii) Covered Payments that are not subject
to Section 409A of the Code that arise from the accelerated vesting of equity awards, and; (iv) Covered Payments that are subject to
Section 409A of the Code in a manner consistent with Section 409A of the Code. All determinations pursuant to this Section 5.4 shall
be made by tax accountants selected by the Company and reasonably acceptable to Executive (the &ldquo;Accountants&rdquo;), whose determinations
shall be binding on the Company and the Executive absent manifest error. The Executive shall provide the Accountants with such information
and documents as the Accountants may reasonably request in order for the Accountants to make their determinations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<FONT STYLE="vertical-align: baseline"><B><U>Return of Property and Employee Non-Solicit</U></B></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Return of Property</U>. Upon termination of Executive&rsquo;s employment with the Company for any reason, upon request, Executive
will use reasonable efforts to promptly deliver to the Company all equipment, correspondence, drawings, manuals, letters, notes, notebooks,
reports, programs, plans, proposals, financial documents, or any other documents or property containing material information pertaining
to the Company&rsquo;s customers, business plans, marketing strategies, products, property or processes..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Non-Solicitation of Employees Covenant</U>. Executive acknowledges that the Company&rsquo;s employees and consultants are a valuable
asset to the Company, especially because such employees have access to and knowledge of the Company&rsquo;s confidential information
and trade secrets. As such, Executive agrees for a period of one-year from the Termination Date, with respect to any Company employee
with whom Executive had material business contact during their employment with the Company, Executive will not (i) induce or attempt
to induce such employee of the Company to leave employment or contracting with the Company; or (ii) directly solicit the services of
or hire away such current employee of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Notification of Future Employers</U>. Executive hereby agrees to notify any future employers or prospective employers of the foregoing
obligations and authorizes the Company to provide a single notice of the terms in Section 6 to Executive&rsquo;s actual or future employers
(or persons or entities that contract or seek to contract for Executive&rsquo;s services).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
<U>Remedies</U>. In the event of a breach or threatened breach by either party, each party hereby consents and agrees that the non-breaching
party may (as determined by a court of law or proper judicial authority) be entitled to seek, in addition to other available remedies,
a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of competent jurisdiction,
and that money damages would not afford an adequate remedy, without the necessity of showing any actual damages. The aforementioned equitable
relief may (as determined by a court of law or proper judicial authority) be in addition to, not in lieu of, legal remedies, monetary
damages, or other available forms of relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B><U>Assignment of Inventions and Rights</U></B><U>.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Work Product</U>. The Executive acknowledges and agrees that all designs, devices, discoveries, processes, proprietary software, writings,
inventions, improvements and documentation, and any other works of authorship (collectively, &ldquo;<B>Work Product</B>&rdquo;), and
all related know-how, produced, made, conceived or authored by the Executive, solely or jointly with others, in the course of his employment
with the Company together with any intellectual property rights concerning the Work Product produced, made, conceived or authored by
the Executive, including any moral rights relating to any of the foregoing, are works made for hire and the property of the Company if
such works (i) result or are derived from, at the time the Work Product is produced, made, conceived or reduced to practice, the actual
business, research, or development of the Company; or (ii) are result from any work performed by the Executive for or on behalf of the
Company; or (iii) are created or developed with the use of Proprietary Information or Company equipment, supplies, facilities, information,
materials or other Company resources (&ldquo;Company IP&rdquo;). The Executive shall disclose in writing any such Company IP promptly
to the Company and hereby irrevocably assign any and all rights in their entirety, throughout the world, in and to such works to the
Company or its assignees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
To the extent that any such Company IP may not, by operation of law, be deemed works made for hire, this Agreement shall constitute an
irrevocable assignment by the Executive to the Company of the ownership of, and all right, title, and interest in and to such items,
including an irrevocable assignment of all moral rights relating thereto, and the Company shall have the right to obtain and hold in
its own name, all intellectual property rights, including without limitation, patent, trade secret, copyright and similar protections
which may be available in such Company IP throughout the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
The Executive agrees that all work product made by them after the end of employment with the Company, whether created solely by the Executive
or jointly with others, that is based on or contains Confidential Information of the Company, shall belong to the Company; and the Executive
irrevocably assigns any and all rights in their entirety, throughout the world, in and to such future Work Product to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
The Executive agrees to use reasonable efforts to assist the Company, or its designee or assignee, to secure and perfect the Company&rsquo;s
(and/or such designee&rsquo;s) rights in such Work Product and any copyrights, patents, trade secrets, mask work rights or other intellectual
property rights and/or moral rights relating thereto in any and all countries, including the written disclosure to the Company of all
information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments
which the Company shall deem necessary in order to apply for, obtain and protect such rights and in order to assign and convey to the
Company, its successors, assigns, and nominees the sole and exclusive rights, title and interest in and to such Company IP, and any copyright,
patents, trade secrets, mask work rights or other intellectual property rights and/or moral rights contained therein and/or relating
thereto. The Executive further agrees that their obligation to execute or cause to be executed any such instrument or papers shall continue
after employment with the Company ends. The Executive shall be entitled to reimbursement for reasonable expenses in providing such post-employment
assistance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
In the event the Company is unable due to Executive&rsquo;s subsequent disability, incapacity or for any other reason whatsoever to secure
his signature to any lawful and necessary document required to apply for, register or execute any patent, copyright or other applications
with respect to any such Company IP, the Executive hereby irrevocably appoints the Company and its duly authorized officers and agents
as its agents and attorneys-in-fact to execute and file any such application and to do all other lawfully permitted acts to further the
prosecution and issuance of patents, copyrights or other rights thereon with the same legal force and effect as if executed by the Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
In the event Company should not desire to secure and perfect its rights to any Company IP, but should desire to keep the same secret,
the Executive agrees that they will do everything reasonably in his power to assist Company in this and will not disclose any information
relating to such Company IP except with the prior written consent of Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7
In order to permit the Company to claim rights to which it may be entitled, Executive agrees to disclose to the Company in writing and
in confidence all inventions or Company IP that Executive makes or conceive of, either solely or jointly with others, during the term
of his employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8
All Work Product that was made by the Executive before his employment with the Company (collectively referred to as &ldquo;Prior Inventions&rdquo;)
are excluded from Section 5 of this Agreement. The Executive agrees not to incorporate into a Company product, process or code, or other
Company Work Product, a Prior Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">8.
<U>Acknowledgement</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Executive acknowledges and
agrees that the services to be rendered by the Executive to the Company are of a special and unique character; that the Executive will
obtain knowledge and skill relevant to the Company&rsquo;s industry, methods of doing business and marketing strategies by virtue of
the Executive&rsquo;s employment; and that the restrictive covenants and other terms and conditions of this Agreement are reasonable
and reasonably necessary to protect the legitimate business interest of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">9.
<U>Governing Law: Jurisdiction and Venue</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement,
for all purposes, shall be construed in accordance with the laws of Delaware without regard to conflicts of law principles. Any action
or proceeding by either of the parties to enforce this Agreement shall be brought only in a state or federal court located in the State
of Delaware. The parties hereby irrevocably submit to the exclusive jurisdiction of such courts and waive the defense of inconvenient
forum to the maintenance of any such action or proceeding in such venue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">10.
<U>Entire Agreement</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Unless specifically provided
herein, this Agreement contains all of the understandings and representations between the Executive and the Company pertaining to the
subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both
written and oral, with respect to such subject matter. The parties mutually agree that the Agreement can be specifically enforced in
court and can be cited as evidence in legal proceedings alleging breach of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">11.
<U>Modification and Waiver</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. No provision of this
Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by the Executive and by
the Company. No waiver by either of the parties of any breach by the other party hereto of any condition or provision of this Agreement
to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or
any prior or subsequent time, nor shall the failure of or delay by either of the parties in exercising any right, power, or privilege
hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power,
or privilege.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Severability</U></FONT>. Should any provision of this Agreement be held
by a court of competent jurisdiction to be enforceable only if modified, or if any portion of this Agreement shall be held as unenforceable
and thus stricken, such holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue
to be binding upon the parties with any such modification to become a part hereof and treated as though originally set forth in this
Agreement. The parties further agree that any such court is expressly authorized to modify any such unenforceable provision of this Agreement
in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting
any or all of the offending provision, adding additional language to this Agreement, or by making such other modifications as it deems
warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law. The parties
expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against each of them. In any event,
should one or more of the provisions of this Agreement be held to be invalid, illegal, or unenforceable in any respect, such invalidity,
illegality, or unenforceability shall not affect any other provisions hereof, and if such provision or provisions are not modified as
provided above, this Agreement shall be construed as if such invalid, illegal, or unenforceable provisions had not been set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">13.
<U>Captions</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Captions and headings of the sections
and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference
to the caption or heading of any section or paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">14.
<U>Counterparts</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement may be executed
in separate counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same
instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Section 409A</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1
General. The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt from Section 409A
of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively, &ldquo;Section
409A&rdquo;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2
Separation from Service. Notwithstanding anything in this Agreement to the contrary, any compensation or benefits payable under this
Agreement that is considered nonqualified deferred compensation under Section 409A and is designated under this Agreement as payable
upon the Executive&rsquo;s termination of employment shall be payable only upon Executive&rsquo;s &ldquo;separation from service&rdquo;
with the Company within the meaning of Section 409A (a &ldquo;Separation from Service&rdquo;) and, except as provided below, any such
compensation or benefits described in Section 4(b) shall not be paid until the fifty-fifth (55th) day following Executive&rsquo;s Separation
from Service (the &ldquo;First Payment Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3
Specified Employee. Notwithstanding anything in this Agreement to the contrary, if the Executive is deemed by the Company at the time
of the Executive&rsquo;s Separation from Service to be a &ldquo;specified employee&rdquo; for purposes of Section 409A, to the extent
delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid
a prohibited distribution under Section 409A, such portion of the Executive&rsquo;s benefits shall not be provided to the Executive prior
to the earlier of (i) the expiration of the six-month period measured from the date of the Executive&rsquo;s Separation from Service
with the Company or (ii) the date of the Executive&rsquo;s death. Upon the first business day following the expiration of the applicable
Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to the Executive (or the Executive&rsquo;s
estate or beneficiaries), and any remaining payments due to the Executive under this Agreement shall be paid as otherwise provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.4
Expense Reimbursements. To the extent that any reimbursements under this Agreement are subject to Section 409A, any such reimbursements
payable to the Executive shall be paid to the Executive no later than December 31st of the calendar year following the calendar year
in which the expense was incurred; provided, that the Executive submits the Executive&rsquo;s reimbursement request promptly following
the date the expense is incurred, the amount of expenses reimbursed in one calendar year shall not affect the amount eligible for reimbursement
in any subsequent calendar year, other than medical expenses referred to in Section 105(b) of the Code, and Executive&rsquo;s right to
reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">15.5
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Installments. The Executive&rsquo;s right to receive
any installment payments under this Agreement, including without limitation any continuation salary payments that are payable on the
Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment
shall at all times be considered a separate and distinct payment as permitted under Section 409A. Except as otherwise permitted under
Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional
tax or interest pursuant to Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; vertical-align: baseline">16.
<U>Successors and Assigns</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement is personal
to the Executive and shall not be assigned by the Executive. Any purported assignment by the Executive shall be null and void from the
initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect,
by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets of the Company. This Agreement
shall inure to the benefit of the Company and permitted successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Notice</U></FONT>. Notices and all other communications provided for in
this Agreement shall be in writing and shall be delivered personally or sent by registered or certified mail, return receipt requested,
or by overnight carrier to the parties at the addresses set forth below (or such other addresses as specified by the parties by like
notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>If
                                            to the Company:</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
                                            Executive Officer</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7380
Coca Cola Drive, Suite 106</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hanover,
MD 21076</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>If
                                            to the Executive</B><FONT STYLE="font-weight: normal; vertical-align: baseline">:</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. David Young</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">2716
Vardon Lane</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">Ellicott
City, MD 21042</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">18.
<U>Survival</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Upon the expiration or other termination
of this Agreement, the respective rights and obligations of the parties hereto shall survive such expiration or other termination to
the extent necessary to carry out the intentions of the parties under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<FONT STYLE="font-weight: normal; vertical-align: baseline"><U>Acknowledgement of Full Understanding</U></FONT>. THE EXECUTIVE ACKNOWLEDGES
AND AGREES THAT THE EXECUTIVE HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE EXECUTIVE ACKNOWLEDGES AND
AGREES THAT THE EXECUTIVE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF THE EXECUTIVE&rsquo;S CHOICE BEFORE
SIGNING THIS AGREEMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>[REST
OF PAGE INTENTIONALLY BLANK</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><B><U>SIGNATURES
TO FOLLOW ON NEXT PAGE]</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROCESSA
    <FONT STYLE="text-transform: uppercase">Pharmaceuticals, Inc.</FONT></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DR.
    DAVID YOUNG</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    George Ng</I>&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David Young</I></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng, Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>9
<FILENAME>ex19.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 19</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-19_001.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-19_002.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-19_003.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-19_004.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-19_005.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-19_006.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-19_007.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-19_008.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-19_009.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-19_010.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-19_011.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>10
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
of Processa Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    of Incorporation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent
    Ownership</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
    Therapeutics LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-279588 and No. 333-254983) and Form
S-1 (No. 333-283986) of Processa Pharmaceuticals, Inc., and Registration Statement Form S-8 (No. 333-280952) pertaining to the Amended
and Restated Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan of our report dated March 29, 2024, relating to the consolidated
financial statements, which appear in this Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
BD &amp; Company, Inc.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owings
Mills, MD</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
20, 2025</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>12
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the inclusion or incorporation by reference of our report, dated March 20, 2025, with respect to the consolidated balance
sheet of Processa Pharmaceutical, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2024 and the related consolidated statements of
operations, stockholders&rsquo; equity, and cash flows for the year then ended, in (i) the Company&rsquo;s Registration Statement on
Form S-1 (No. 333-283986), (ii) the Company&rsquo;s Registration Statements on Form S-3 (No. 333-279588 and No. 333-254983), and (iii)
the Company&rsquo;s Registration Statement on Form S-8 (No. 333-280952).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Cherry Bekaert LLP</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tampa,
Florida</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
20, 2025</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>13
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
Pursuant to Rule 13a-14(a) or Rule 15d-14(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
the Securities Exchange Act of 1934, as Amended</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I, George Ng, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. I have reviewed this Annual Report on Form 10-K of Processa Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. The Registrants other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure the material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly through the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
    under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
    Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
    evaluations, and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
    Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
    registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
    internal control over financial reporting; and</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent function):</FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
    all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
    any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    George Ng</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>14
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
Pursuant to Rule 13a-14(a) or Rule 15d-14(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
the Securities Exchange Act of 1934, as Amended</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Russell Skibsted, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. I have reviewed this Annual Report on Form 10-K of Processa Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. The Registrants other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</FONT></P>

<P STYLE="margin-left: -20pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure the material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly through the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
    under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
    Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
    evaluations, and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
    Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
    registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
    internal control over financial reporting; and</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent function):</FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
    all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
    any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Russell Skibsted</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell
    Skibsted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>15
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report on Form 10-K of Processa Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) for the year ended
December 31, 2024 (the &ldquo;Report&rdquo;), George Ng, as Chief Executive Officer of the Company, and Russell Skibsted, as Chief Financial Officer of the Company, each
hereby certifies, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002,
that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    George Ng</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Russell Skibsted</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell
    Skibsted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification accompanies each Report pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required
by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of &sect; 18 of the Securities Exchange Act of 1934, as
amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &I T<# 2(  A$! Q$!_\0
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MX3/6O^>T?_?L4?\ "9ZU_P ]H_\ OV*Y^BCV4.P?6:W\S^\Z >,]:S_KH_\
MOV*LZCXMU>WU.Z@CFC"1S.B@QCH"0*Y8=:NZQ_R&K_\ Z^)/_0C4^RA?8OZQ
M6Y;\SW-/_A,]:_Y[1_\ ?L4?\)GK7_/:/_OV*Q;62"*Y1[B SQ#[T8<INX]1
MTKH[^RTD164-MIZPS7T6])9+IML7USUI2C3B[<I<*E>:;4]O-E;_ (3/6O\
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MB;L8^H(.:T5.37,OZL3S*]CL:*\^L_&?BGQ#%)J/AOP]:S:2KLL4MY<F.2X
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MD X)!Z^]*,4TAMM,Z34]9@TR*SD*F5;JZBM5,9'!=MH/T%7_ #8_,\O>N_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ$L9>0I*@"YQ@$9*DXYY[U1T'7-?U/4;>Z:8+&]Y)%<6\DT018P6&U4^_O&
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M^= %VBJ2W^#\\>!Z@U;1UD4,IR#0 ZBBB@ HHHH **** "BBB@#@_B83<?\
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M10 SR8_[B_E1Y,?]Q?RI]% #/)C_ +B_E1Y,?]Q?RI]% #5C13E5 _"G444
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MX5(R2BH\S?W$_P"^C_A1F;^XG_?1_P * )**CS-_<3_OH_X49F_N)_WT?\*
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M\* )**CS-_<3_OH_X49F_N)_WT?\* )**CS-_<3_ +Z/^%&9O[B?]]'_  H
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M_"@"2BH\S?W$_P"^C_A1F;^XG_?1_P * )**CS-_<3_OH_X49F_N)_WT?\*
M)**CS-_<3_OH_P"%.0N<[PH^AS0 ZBBB@ HHHH **** "BN/^(7BC5?"^FZ?
M+H]I;W-U=78@$<X)!&UFXP1S\M00^/#>:QX7CM4A^P:M;3S3NX.^(QH6P.<#
M!!!R*T5*37,OZL2Y).QV]%><6OC'Q9K]JVK:)8Z-;:0SL+;^TIG66Z .,KCA
M?QJ_JOB[7)-<L_#N@Z?9OJ\EHMW=R74A,%LIXQ\O+<^GJ/6G[*5["YT=Q16=
MHDNK3::IUNVM[>^#,K+;.6C8 \,,\C(['I7(2>,/$6M:IJ$7AJUTJ+3]/G-M
M+>ZI(X664?>5 OIZFI4&VTN@W)(] HKF)/&%MHN@V5YXFD@L[NX)7R;5C/O(
M/\&T$D8P?;-+-\0/#%OIMEJ$FIJ+6]9TAD",<LHR5(QD'M@]^*/9RZ(.9'34
M5QJ_%3P<T<3_ -K >9)Y9!A<&,YQ\XQ\H]SBNQ5@RAE(((R".]*4)1W0TT]A
M:***D845#=7,=G:374Q(BA1I'(&3@#)K)TGQ58:O<QV\<=U;S2P"XB6YA,?F
MQ\?,I/!ZC\Z:BVKH5T;E%(&4C(((]0: 01D$$>M(8M%)N7&=PQZYHR,XR,]<
M4 +12;UY^8<=>>E48=8M;JWM+BT+W4%T^U)85+*.O+'L.,9IV8%^BDR"2,C(
MZBH+^^MM,L9KV\F6&WA7<[MT I 6**Q].\1V^I726ZV>H6[2*7C:YM7C5P/0
MD?H:MZIJ<.E:1>:E*&DAM(FE=8\%B%&2![U7*[V%=;EVBL^PUB#4+^\LXDD5
M[01ERP&#O7<,<^E9P\9:;]O>V:*[1%NS9&X: ^5YV<;=WUXHY9=@NCH:*S]-
MU>WU,7AB5T%K<O;/YF!EE."1STJ_D#'(YI--;C%HJAH^K0:SI<5_ KI%(S*%
MDP#E6*GH?44:1J]OK.F)?PJ\<3LR@28!RK%3T/J*&FA71?HI"P'4@55U34;?
M2-*NM1NMWV>VB:638N3M R<#O22N,MT5E6_B+3KN#2YH)6>/4F*VY"GDA2Q!
M],!3^-:F1G&1D=J;36XKBT4@8$X!&>M+2&%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%13W,%LNZ>:.)?5V"_P ZB@U*QNFVP7EO*WHD@)IV8N97M<M4
M444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% '+^,=%OM7NO#TEG&KK9:I'<S;F P@5@3[]17
M-1^ M1M?B1;W,*1MX=4W,H&_#1--&5= /3=S^)KT/4-1L])LGO+^X2WMX\;I
M'/ R<#]:F%Q"=H\U,L 0"<$Y]JUC4E%61#BFSQO4/ 'B4>&3X5.D:9JMK;EQ
MIVHR3^6]NK'/S+CK]*WY?"WB/P_KNG:]H<-K?3+ID=A>VLLNS=MQ\R,1[#KZ
M>]>D,RJI9B !U)-(9$";RZA/[V>*IUY,7LT<FOAB?Q&MKJ/B42VFHPD[8=/O
M9%C5=V5#8(#'U-<OJ/@O7+#^V--M=(T_7-$U&Z>\BBN)O+>VF;.3SP0">*]4
M,B!-Y=0O]XGBEW#;NR,8SFI562&X)GD#_#KQ!8Z+X6DMUCGO-)CGCFMX;LPD
MB1B04DQP1GFKEIX%U.,^&7&F0VZVNJRWEW$;LS;58#!+-U/'.*]35E90RD%3
MT(--\V/9O\Q=G][/%7[>;_K^NXO9H\LU'P+K-QH?CJWBM83/JUX);3]XHWKG
M/)[?C7J%I&T5E!&_WDC53]0*BN]3L;&SFO+BZC2W@0O(^<A5]3BK$,T=Q!'-
M"ZO%(H9&4Y# ]#6<YRDM2DDMA]%%%9E&?KL;R^']1CC1G=[:1551DDE3@ 5R
M$>@7=CX3BU2X6YU;48M,CMXK.6/8(E(7<NU "2,<]SMQ7?U!;7MI>J[6EU#.
M$.UC%(&VGT..E:1FTM"6DSRR+3]1ELM<MH+:]%I+/8-"(K6:W!^<^:45OF'
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M% '!_$L^?)X7TYS_ */=ZS$LH/0A06 _,#\JX?Q;:1:A\1_%5N^A:EJUR;.
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M(Y&Y0>>AJS-XQUJ>3S&N(E8L[N8[>-/,9U*LSX'S,03R>>37T7_PIGP1_P!
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M/.B\OS/,39_>W#'YU5NM6L;*6TCN+A$:[D\N#GAVVEOY*:=FP+M%5H;OS7N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*VGW_.C:??\ .@#5R/6C(]:RMI]_SHVGW_.@#5R/6C(]:RMI]_SHVGW_ #H
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M_P# @4<U'^8+3[')>*+ZWU'7I+FUD\R(Q0J&QCE8U4_J#6,>E>C?\*0\9_\
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M5'B?^_'_ -\G_&C$_P#?C_[Y/^- $E%1XG_OQ_\ ?)_QHQ/_ 'X_^^3_ (T
M245'B?\ OQ_]\G_&C$_]^/\ [Y/^- $E%1XG_OQ_]\G_ !HQ/_?C_P"^3_C0
M!)14>)_[\?\ WR?\:,3_ -^/_OD_XT 245'B?^_'_P!\G_&C$_\ ?C_[Y/\
MC0!)14>)_P"_'_WR?\:,3_WX_P#OD_XT 245'B?^_'_WR?\ &C$_]^/_ +Y/
M^- $E%1XG_OQ_P#?)_QHQ/\ WX_^^3_C0!)14>)_[\?_ 'R?\:,3_P!^/_OD
M_P"- $E%1XG_ +\?_?)_QHQ/_?C_ .^3_C0!)14>)_[\?_?)_P :,3_WX_\
MOD_XT 245'B?^_'_ -\G_&C$_P#?C_[Y/^- $E%1XG_OQ_\ ?)_QHQ/_ 'X_
M^^3_ (T 245'B?\ OQ_]\G_&C$_]^/\ [Y/^- $E%1XG_OQ_]\G_ !HQ/_?C
M_P"^3_C0!)14>)_[\?\ WR?\:,3_ -^/_OD_XT 245'B?^_'_P!\G_&C$_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH_M'^[^(?ZO+_GY^'_!/#?#<KV'B"SGECD$6_8YVGA6&T_H:]3\+E3H\VCW
MS+8NUM(A[I_"?H5(K?V+_='Y5CZKI-PUXFJZ5(D6H1KL9'^Y<)_=;T]CVKEK
M5U6>JL>E@\#+!+W9<W]?\!,Y77O"EU#<M-#)<7%O!;"/3U8[C;2DX)W#D+C&
M,>G)K7T339].TZ.T$@@R/WTQ823SMW/' _I5Y/%=E%^ZU>&;3)^A6Y0[#]''
MRD?C2MXI\/0G%O=Q7$I^[':*97;VPH-8MU5'DA%?B_UL=M2HJLKSJ.W;1?HF
M:8>#3=.>67$-O"A=BQZ <DGWK$T*.5-(%Q,C)/?327CH1]W>?E'_ 'SMIWV2
M_P#$DT;ZC;M9Z5&P=;1R#).1T,F.B_[/YUTF!Z5%N2/+U+C[TN9*R6QD[C[_
M )4;C[_E6M@>E&!Z5)L9.X^_Y4;C[_E6M@>E&!Z4 9.X^_Y4;C[_ )5K8'I1
M@>E &3N/O^5&X^_Y5K8'I1@>E &3N/O^5&X^_P"5:V!Z48'I0!D[C[_E1N/O
M^5:V!Z48'I0!D[C[_E1N/O\ E6M@>E&!Z4 9.X^_Y4;C[_E6M@>E&!Z4 9.X
M^_Y4;C[_ )5K8'I1@>E &3N/O^5&X^_Y5K8'I1@>E &06/H?RJQ:VS-())!@
M#H#WJ_BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH CGACN8)()D#Q2*4=3W!&"*RM+\*Z)HLXGL+!(YE38LC.TC*OHI8G ]A6S
M133:5D*R,6;PGH4\4,4FGH8X2Q1=S ?,VY@<'Y@6.<'(I]SX7T2[OQ>SZ=$\
M_P I)R0K;?N[E!VMCMD'%:]%/FEW"R*8TNQ!O#]FC/VTYN0PR)?EV\@^W%4K
M+PIH6GN[VVG1*[PM Y8ERT9()0[B<C@<=NU;-%',^X61BP^$]#M[6XM8[$>1
M<((Y$:1V!4'(49/ ]ABK%_X?TK5+N*YO;-)I8\!26(! .0& .& /.#FM*BCF
MEO<+(****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 (RAAA@"/0TB11Q_<15_W1BG44 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%(P)4[3@^N,U'MF_YZK_WQ_\ 7H EHJ+;-_SU7_OC_P"O1MF_
MYZK_ -\?_7H EHJ+;-_SU7_OC_Z]&V;_ )ZK_P!\?_7H EHJ+;-_SU7_ +X_
M^O1MF_YZK_WQ_P#7H EHJ+;-_P ]5_[X_P#KT;9O^>J_]\?_ %Z ):*BVS?\
M]5_[X_\ KT;9O^>J_P#?'_UZ ):*BVS?\]5_[X_^O1MF_P">J_\ ?'_UZ ):
M*BVS?\]5_P"^/_KT;9O^>J_]\?\ UZ ):*BVS?\ /5?^^/\ Z]&V;_GJO_?'
M_P!>@"6BHMLW_/5?^^/_ *]&V;_GJO\ WQ_]>@"6BHMLW_/5?^^/_KT;9O\
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MO1MF_P">J_\ ?'_UZ ):*BVS?\]5_P"^/_KT;9O^>J_]\?\ UZ ):*BVS?\
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M_P!>@"6BHMLW_/5?^^/_ *]&V;_GJO\ WQ_]>@"6BHMLW_/5?^^/_KT;9O\
MGJO_ 'Q_]>@"6BHMLW_/5?\ OC_Z]&V;_GJO_?'_ ->@"6BHMLW_ #U7_OC_
M .O1MF_YZK_WQ_\ 7H EHJ+;-_SU7_OC_P"O1MF_YZK_ -\?_7H EHJ+;-_S
MU7_OC_Z]/0.,[V#?08H =1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME_QKP!HG1$=HV"/G:Q'#8ZXH>)XPA="H==RY'4>HH_L^/\P_[?G_ ,^_Q?\
MD>__ -J:?_S_ %M_W^7_ !H_M33_ /G^MO\ O\O^-?/P&3@#)I61E"EE(##(
MR.HH_L^/\PO]8)_\^U][_P CZ _M33_^?ZV_[_+_ (T?VII__/\ 6W_?Y?\
M&OG[ J=K&Z7;NMI1N7<N4/(QG/Y4?V?'^8:S^H]J?XO_ "/>O[4T_P#Y_K;_
M +_+_C1_:FG_ //];?\ ?Y?\:^?>*7 I_P!G+^87^L$_^?:^]GT#_:FG_P#/
M];?]_E_QH_M33_\ G^MO^_R_XUX%';RS*[11.X098JN<#WI8K2>=&>&"215^
M\54D"E_9\?YAK/ZCVI_B_P#(]\_M33_^?ZV_[_+_ (T?VII__/\ 6W_?Y?\
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MRQ^M)!?:.T<TDZ@2R0!2@BX+[&&1Z<[:UC\+]2R=M_:$=LAO\*3_ (5?J?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex10-11_001.jpg
<TEXT>
begin 644 ex10-11_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !O H4# 2(  A$! Q$!_\0
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M#11G<D3<@MZD=_QI5\;1H+WG\CQ:5"=5Z(SM2\2ZIXA9HM+,FFZ3T:[=<37
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MHH **** "BBB@ HHHH **X;QUJ_C?1C->>']-TZYTRWM6FF>:4B3*Y+ +WX
MKS;PK\6?'OCG6VTS1X='MYEA,I\]&((! /.?>@#Z"HKQ_6_'/Q(\%V?V_7?#
MNG7E@A DGM)2 O.,D<XSD=:Z?0_B-#XP\*7>I>%[,76J6VT-IUQ((V!)[MTQ
MC)!'7&* .YHKQCPG\7M=\0_$VU\,7NDVU@@:>.X0.7<.B,<9X[KBO9Z "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%<V.MV\BF)K:&6/>N><G%=B/B#K-_P# >]UGRIDU>!?LLLH7:0<@>;T]#^=
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MXDMGU75[J%9;B6ZD9MK,,[5YXQG'X4 >FQ2QSQB2*19$;HR'(/XTYF"J68@
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MTRZM3#(UQN$H+9#8.".AZUYAX6^#_P 0O"&N1ZMI=YHXN$4H1)*S*RGJ"-M
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M'E9I9$5RTR.1QC@#L.YH^*OPSU;Q%KECXE\.S1C4K555XI6V[@IRI4^O)XH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
.*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex10-12_001.jpg
<TEXT>
begin 644 ex10-12_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !G E@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBCI0
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MRZ%K%*NH?&;QQ"NIP^$[*!+N)H_#.G:=K'C#67D:&TT**"&ZUC3/X"?VWO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI(]S/+<S,D-O#;QJTUQ/(Z);6R23R&.+]X/XE/\ @LS_ ,'&%_J$_C/]E_\
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M><*$,QE";_M[B:IA5["CCL[QF&E&-/"_O:GU3)<,X8; 1JTZ-2>-;A%?'_\
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M]'U#3M8U,ZS;R2MM/]=\2+'%%&L:1+'&B+%'C9&J*%$:8"C8@ 5<*HP!P.E
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MWSS/>,5/**RK5JL,/B:N94Z>"IXC%\BIX.DZ'UBO/#3G"4,-1PE&FVIM./\
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MA%&FEZS=ZN[Z?J\=TL[Z"+34;B]@9;)XG_-OX]?\&_/CK]J/X9ZQ\'/VA_\
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M++X1_P!MSZ=$UMINIZW8?$+XR6TVL6=FP*VMM<S7.H2V-L'D:W@NGB8[5CR
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MU^R7XX^&O@OPIX/\,PW-K)KWBCQ1XY\6>'/#&CZ>+FTCNM5U."&2X@0-*/\
M1\\-^"?#/@W2+'PYX2T72/"_AO2X4M]+\/>'=*L-%T73K:.)+=+:ST[3H+>U
M@MUMHH8EBCB50T2RCYNG^?G9:-H^O_\ ![%X5T_6]*T_5;!/'?CS64LM0MHK
MNU76/"_[&7Q(\3>'-56"97C2_P!#\1Z)I&OZ7<J!)9:QIMGJ,#)<P(X /UT_
M:A_X+._\%D/V2? E[^T[\7?^".7A[PC^R9HUYIU_XL^W_M$P:]\9?!'A&^U*
MWL1>>,SX=L]2TK1;X33"W7&AWFGP75Q9_;'MK><R#]\/V"/VX_A'_P %$OV6
M_AO^U1\&4O+;P9\0[?4K>[T+69[:37?"'B/0+N72?$_A;Q%':YACU+2-8AEM
MH_+8)J.GR66JQ+%!>QQ+X'_P6D\,Z=XF_P""4W[?&D:IYKV5W^SGXTGG2V*I
M-*-/M[?4TD$B N=]U;0EG.XHD7R%26)_'#_@S5:5_P#@E-\0SN9W7]L'XIA=
M^'"?\6[^$4R^6&(V*TS"3:,(92SXW.Q8 ^A/&/\ P7-^-'[1?[:?Q,_8:_X)
M0?LK^$/VF_'/P,BU4?&?XU_&OXHW7PK^"OA2\T+46T?7=)TU]*TK4=<U2XTS
M7%.B&YB,#WNHQ7T=I8RV^G27$_'3?\%Y?VCOV,OVN?A=^R=_P5Q_8X\'_L_Q
M_':ZL[7X.?'+]GGXE7WQ,^&NJSW5Y:Z/<IJUAXDL=)UH6.FZ_K.A:9J^K1S6
MZZ8=2EO9=/FM[023]?\ $_\ :L_X)I?\$E_CY\3O@M^Q'^SG+\?/^"B7[6'C
M&;Q!XO\ V?\ ]GJXG\1>.-:\4ZVE_P")DU#XH^(M7OKVS^'?ADWVL7?B*_TU
MWCEM;&XNM3N+>-3;D_RM?\',^O?\%!/%/QD_8 \=_MX>#_@?\(=>\00_$^?X
M2?!_X)ZUJ_C'4OAGH5GX[^'":M%\0OB1>K%I7BKQ+J,@T:\M8?#MK;V&DH+B
M.6::Y,J( ?Z&O[<7[4_B[]DGX$W?Q?\  7[,WQF_:TUZ'7-#TJU^&'P(@TZZ
M\3FQU=YQ=>)KNZOY!#:Z%I5I#++-/;VFI32W4UC;K;)#/+>VO\V'[*'_  =@
MZ'^TL?C1X&TG]B'XBW_[2D'C'P_X5_91_9B^'GB;_A)O'OQBN-;DOK36T\=Z
MYJGA_2]&\!Q>!KJS-]XO\0?8[Z&#1S=3)I\=W$()_P"M#X0"6?X4_#"XFN)9
M)G^'?@IGD)&7>7PQH[RNX((=G<,^YP2K2/CK7\"7_!IU\//"OB'_ (*H?\%(
MOB%J&FP2>(OA];^.['PG,T$$B:1#XL^,VN6FJ-:-)$TL$KVEJ+420R1LUO))
M"Y:-BM '[<?\$SO^"\7Q]_:D_:M_:=_85_:I_89OO@%^U+\#OAOXT^)WA?P!
MX!\3SZPGC"3P1+:G5/A]J5UXFBLK+2O$FLKK7AX>&/$UMJ4_AS7A+J$L_P#9
M2P6D=Q\PZC_P=7ZG\+?VW;']F?\ :[_8*\:_LB^$]+TJ[/Q"N/&/C1O'OQJT
M:_U/1S?^"K+PYX+\(>'(-+UV?Q+?2V=M;65OJSRO'="YBN1Y#*_]:MC\+/AS
MI?CO6OBAIW@GPM8?$KQ)I>E>'/$?CZRT'3+;Q?XA\/Z)>7#Z5HNMZ_%:C4M2
MTRR>\F:&UN+AE!*@DA4"_P"?5^W/86&H_P#!X;^SS8ZE96VH6<_C_P#9_%Q;
M7D,-S!.Z?#N]DCDE@FBDA<Q31Q2Q*Z,J/%&0 0" #]>?VCO^"YW_  5R^%WP
M]\1_M3^#_P#@BUXBT/\ 8L\.:3I?BNZ\5?&CXG2Z5\6_^$#N90!XO\0^$?#"
M7=[X1MM06:.^,::#XI;P[8RQ7FO7<MM-%(OT;X-_X./O@W^T#^SS\'/$7[%7
M[.?Q3_:A_;-^.L'BJ'1?V-/"5_8_\)!\-+OP:LB>)/$WQK\?20-HW@KX:VEP
ML,6B^)C:74_B0WEM;:;ID4S71M?U<_X*D0^7_P $XOVZYE*$_P##*?QM15:)
M&581X!ULR0\@YCF11&Z\# !P2JX_F?\ ^#*GP-X1@_8__:>^(EMX>TF#QWK'
MQLT_PKJ/BU+* Z[=>'-&\+:??:;HDFH,K7 TNVO;Z>[%C'(EM)<;9I8WD&Z@
M#V#1O^#C']KK]EC]JSX4?LY?\%8_^"<]O^R-X=^/%WI-KX%^)/@+Q[<>-+32
M1K.N1Z#;ZOJUO;P>(-,\1:;97\@M=8CT76+'6=(D:*ZNM*^QRF1/Z;/VG?VJ
M?@W^QY^SK\3/VH?CEKLWAKX0_"7PS%XE\3ZO9V4^K7L\%_>V.DZ!I>AZ=8)+
M+JFL^)-;U;1M%T>TC:.*34-6LTN+FWA\Z:+^*_\ X/2-UO\ $#_@F!<6[>3.
M/$'QCEBGB4)-%*NO?"&=9%E0JQ82R"0$_,)5,@(:1RW]A'Q/^"'P1_:7_8SM
M?A!^TYH^C>*?@AXV^$WP\N/BEI_B359='T@Z#X:M=#\=#5M9UT7EA'H=MI6M
M>&]+\17>M75S!;?\2:6.:57> $ _%W]GW_@JQ_P5]_;Z^%=[^TQ^P]_P3<_9
MXM?V=]0U37;'X:O^T=^TKJOACXJ_$$>'I6M=3NM-T7P[X?B\.Z>G]JPW>DQI
M>ZY'9&[LIUDU%5601?2O_!)+_@MOX*_X*/>./C+^S%\4/@SKW[,/[;'[.<VL
MK\4O@+K.I)X@TG4=&\.:W9^$_%/B+PCXB&G:?(?^$1\:7=IX=\2:'K%KI]S9
MC5="U72[S6[?5+JWT;YF^%7_  4VE\<:':_L9?\ ! 3]C32?CC\,/@1I4GP_
MG_:(\:ZG<_"K]C7X71VJ3D#0/$5]%-J_Q/U9KJ]'B.Z@TQ_MOB*=+Z>\5DOX
M]3;^?_\ X(9V7Q5TC_@Z*_;+TKXL^)_#NO?%1=<_;DM?B_K?P_L]5T/P1XD\
M8'XD3W/BJ[\,:7JTDNI6WA:/Q?$LNB:=JLUS=6,=I9*7+6@V ']P_P#P4+_X
M*,?LW_\ !-/]GG5OV@/VE?$,^EZ3+=3>'O _@W0_]-\:_$OQG+87=[8>%?".
MGCRG-Q+#9S3:GK%VUMI/A^U47>HW:"2V2?\ (B7_ (*9_P#!;SQ?\%_%/[6G
MP_\ ^"37P8\,_LZ6'A.^^*/A_P $?&C]I:X\.?M&^(OA1IVA)XGC\0S^&+31
M)-%T?4[SPU(NI)HVHP)?6TJRV3V-W>HL$G\^?_!QMXQE_:._X."_V&OV/_BG
M<HGP(\+>+OV0O -UI=Y)<)H;Z)\>OBQX=N?B+JVH6F]H9Y)])U%].NK^%%N/
M[/L([)G*0*I_T6]0L[#4[/4-+O;2'5+'4;.]L]2TF[@2ZM;ZQG273;VVFMKA
MS;R6=S \]O):.VR6.78X\O<H /RV_P""1W_!67X,_P#!73]G[Q!\9OA9X1\4
M?#GQ-\/?%=OX*^)_PR\5W-C>S>%=?FTX:QI%[I/B'3(5M-=\/Z_8AI+.Z:WL
M]0@D@OK6\TVW,$$M]\=>+_\ @M/\9/VCOVJ_BS^QS_P26_9:\,_M8>,_V?YV
MC^-WQ[^*GQ43X7_LX^$]5A>]L[GPSI6JZ'IVN^(?%FN)K5C)H43VCV6FRW]K
MJB+'=6MHMZOTS^VW\-OA5_P3G_X)5?\ !13Q1^QI\._!/[/FKQ? 7X_?$J"?
MX=Z;9Z%<6WQ2U_P5>:-!XX66QA?S-<\--)I*>'UE@\C39M*T^S"QVBEF_D;_
M .#73]A;XD?M8?LW_M/>-?AK^V_^T)^R;-H_QD\/>&/$V@_!-_"[V/C-'\%F
M^T_5M>;6]-OM32[M+>^EM[0-(JR2&343FX(>@#^C/X)?\%ROB-\*_P!N7PY_
MP3F_X*N_LW^$_P!C[X^?$S2M)UCX'_%#X<_$.?Q[^SS\4[/Q1?/I'A6PAUS5
M+*RU?PU/KOB'3?$_ANUU;4_-L(O$?A]]'U$:7-J%DTVW_P %7?\ @NA\3O\
M@E+XUN?^%C?\$[OB?X__ &?K_5M!\-^"?VBM'^+O@C0O"GC'Q1JWAYO$%]X=
M@\/SZ!K&OZ3J&D1V^I6TLM_'+9W<FGR26\^6:-/$?CQ_P;,>'_VI/'GP[^)O
M[2?_  4/_:V^,?C?X5RI'X(\4^([;P39Z[X>TM=?B\31:3IVJV.C6TMI86FO
MHVKV@'F&QO;F]NK=%EN96KY?_P"#SBR_LK_@FS^R]I<FI7>KRV'[4?AJR75=
M3F%QJ6K"R^$'Q M9M1OY1&J7%_>2!KN[N J!KB:21%!?@ _I&^'G[8WB3XQ_
M\$_O 7[;7P0_9\\7?$[Q1\2_@9X9^,'@W]G:R\3Z+H7B[6M4\0Z99WS^!8?%
MFM6\&B175G<7%S;0ZW<6$$=_#:K=C2;0S_98?R3_ &-?^#AK4OVEO^"D&E?\
M$T/B[^P7\3OV8?C-<P^.3K\OC/XH^%O%4G@W4?!?P\U+XC"PU;3- \-6]O=K
MJ^E:>L5OJ%EKGV:W:]M)\3J[1C]$?^"+VY_^"3O_  3[V>6DG_#+OPQ9G9B8
MRATE/FD9B6+28+N@(5)6(7" +7\H?PD1U_X/6?&@8R1M]K^)$H4-Y9"3_L@W
MTFQPH.])8Y2SHW7?U^4&@#[U_P"#I'_@HO\ MQ_LW_ +XA_ ?X5_LP7GA?\
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M-;ZBL482[?0#?7>KI"[-B2>.Y5&=48@'ZM?!O_@K/_P51_;ST'5/C;_P3O\
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M/VEO@Y_P2O\ V/\ X1_M!>!_V./%T7P]^-_QD^.OQLNOAEHGBWXDPP7,^I^
M/A1H.A:/J6M7FKZ>^GZII<^K>($CTZ+5--E"6K0/;27/K/\ P2D_X+"^(_\
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M/\??%7X@7OQ/^'FOZI\'?&FG>"O[&T#P=9Q>)8?%/B[4K.TT_0YDDM(_[/\
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M>$K/QO?VNN_"^_U?3]'U*Q\-K\.]356\.Z?XA46,NFZI/I&F32IIL=JG(?\
M!&G]G;P]\6O^"[/[>/\ P47_ &/OAOKGPD_X)S77@"Y^&WPWOCX,U#X:>&/B
MQ\2/&.@_"6]^(MGX(\):Y%'=3>"9_B5X7\<_%22ZTZSTK1].NKSPO_9]E9V]
MZUBG]F%]X'\&:GI#^']2\)>&K_09;N:_DT2]T+2[K2)+ZXNWO[F\?3I[5[1[
MFXO99;NXG:$R37$LDLC,[LQT['0](TNSM]/TS3[33;&TC\FVL]/MX;*U@BPJ
M^7#;VJ10QJ41(R$108U$9^7B@"Y:[MA)R%. JY4A<#!(VC'SGY\@L&W;@0"
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MJ]&]==$^K[BT445N,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex10-13_001.jpg
<TEXT>
begin 644 ex10-13_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !4 ?0# 2(  A$! Q$!_\0
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M,,U:OBG-.G'^NO\ ;@_X.G_V,O@)=ZYX)_9=\->(/VK_ (@:>MW9)XHT]O\
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MM1KU$[:TZ$Y0IW5U.K+D7NQDU>0"(%LDLQ+/(QY(SU8@'CD< !5';'3\A_\
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MF:1/JFDVDR7,\C7DDD4<$H!^A6Y?[P_,>N/Y\?6@,IZ$'MP0>?2OXD_V!O\
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M,JXJIGF=U,+[107[BCE;K0^L<\</&"D_VU_8F^&OQ*_X*E_$6YF:YU@_LT^
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M!_!SXY_M6?MI_%[]K']H?Q?^U;X/\,7MC>75M\.OV>/ VDZE\-OB]KFLZ?\
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M]!_C3J**^OI-N+NV[2E:^O6_77=MZM_Y2%%%%: %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex10-14_001.jpg
<TEXT>
begin 644 ex10-14_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !4 ?0# 2(  A$! Q$!_\0
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M,,U:OBG-.G'^NO\ ;@_X.G_V,O@)=ZYX)_9=\->(/VK_ (@:>MW9)XHT]O\
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MM1KU$[:TZ$Y0IW5U.K+D7NQDU>0"(%LDLQ+/(QY(SU8@'CD< !5';'3\A_\
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MF:1/JFDVDR7,\C7DDD4<$H!^A6Y?[P_,>N/Y\?6@,IZ$'MP0>?2OXD_V!O\
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M,JXJIGF=U,+[107[BCE;K0^L<\</&"D_VU_8F^&OQ*_X*E_$6YF:YU@_LT^
MM:AM_B+\2[:";0?"-WJ4;079^'/PYT^\CM]2\5>*;FSF234O$YLKC0?#5I*I
MDNY]5EL]/D_K4^#OP3^%'P \(67@+X0^"=$\$>&;4('M-(M@EQJ%U%'Y;ZAK
M%_M:]U;4)=S&:]OKB=@S$!XU(6O*?"4?[.'[%/PD\&?!7P1#IWA7PA\/O#]I
MH?ACP1H26U[X@N(K5%BGU#4(;?R/M&M:M<^;J&KZOJ36S7M_<7-S+(1)L7XK
M^/\ ^W1(UM=:3;79\+Z3<ATM-%TJ1+KQEK:,/W:7ERES''I]E..)!$L:E9&'
MG7C*(SKF-3Q%\4_8X?!X#'83A3"N^6Y?15?"92E2<G]9E2_=_P!I8V$7&3Q%
M:%=483<5BZ44W/\ F#Q4^DWP;X?X'$3X[XLR>6<4HJM5X6R"O&C@\#B.5SCA
MYTU4Q$<!1IRE&$,5F];$YMB'&I6CET_:TZ%#[4^.'[2?AWP'8:GI7A[4K.YU
MZS66/4=6=F?2_#H2-B\LL[1F*[OXSM5+> W CE.90LB")OC_ /9A\!ZW^T-\
M0A\7_%=I>-\+_!VKO=>%7U9B\OC;QA#(T<^KW$$Q,LECI5VADCWJL3RB"%'>
M2.X6+R[X#?LO_$O]I?4M-\<?%^SOO 7P9BEAU#1_"H>:S\0>,F4K-$]S#-$T
MT&F3(I6XU2\6.:ZC)CL+.-6-RW["W\WAWX=^%[/2M*L+72=-TRT2RT?3-/@6
M"VL;>(87RH5>-8XT9MQ8X::9B26=I&/\^^(64Y'D3Q%?B#,,+6R_AV,\=CHR
MJT:F#]KA(N?U>I.,ITJDOK<*$9THNI&=6-"E)MPE%? >%DN.?'+-\MXZXDRG
M&</<#4ZM'$\(<.8S#5L-C>(93E]9P^9XC XN-*M0R.FG'%4:V-H87&YY55":
MPV#RFA3IXGN8<,%>-D9&Y#)RK NI)!R0<$MTYY(R:N5SOAN.>'1-*CN%$<QM
M89)8PY?RY)E25HBS<DHS,#UY'4UT1Z'_ #_0_P C]*O*L54QV6X#'5:,\/5Q
MN"P>,J4*G/ST*F*P>$Q$Z,E44:B=)UU3DIQC)3A43BG%I?U)5A[.I4A=2Y:D
MUS+[7++E<K]6W%W?5W>[/X=_^#WIT_X9F_880N@D?XY_$]UC+J)&2/P#I0=U
MCSO95+H'8+LC+(KL&= W]2__  2Y=Y/^";_["!9F<_\ #)'P"#,[EVW+\-/#
MB;2S,S90*5P2< !>-N*_%/\ X*#?\&W_ ,6?^"E7CF#Q!^TM_P %4/C5XM\&
M^$?%GQ UWX/?#JZ^!WP[BT7X6Z-X\UF._FT'3[C1]?T5M:N+/2[#0=!EUW4+
M5+R]LM"L6\BV^>(_H_\ \$T/^":_[0__  3\L]'\"^+O^"B'Q7_:@^ W@KX9
M1?#GX9_!3QO\+O WA/2? R6>HV%QI6J6GBG2[W6/$VH)HVF6UUHNF:9<W:0P
M6ETH>XDAMX;9/0,S]?J_B-_X(!V5I)_P7^_X+HZA);0O?6GB+QM:VUVT:FX@
MMK_]H&ZEO((9<;HXKJ2PLI)T4@2M:P%@3&,?V%_M!^ ?B;\4/@SXZ\ ?!WXS
M:E^SW\2O$VF6EAX8^,NC>$]!\<ZIX%N$U;3[J_U&Q\+>)BFB:K<7VDV]_HZ?
M;&C:R.I'4;22.\M+>1?YU/V4?^#=;X\?L??M1>,/VM?A9_P5G^-R_%/XM^);
M77?CS>:M\"?AUJMO\9[%_&-GXRU_1O%-KJWB34=.A&OWL%U"-3L]/%YHL>H7
M0TT!)'C8 _/'_@]_\-^.+SX%_L$^+-.M-3F^'6@?%/XVZ)XKO;?>-(L?%OB7
MPKX N_!$.J 3['O;[2_#?CDZ.S6K-#%9ZPHN(_M*QR?VT?#/4]#UKX=^ ]9\
M,7EAJ'AK5_!7A34_#VH:44.EWVAW^@:?=:3>::8P(VL+FPEMYK,H IMWCV@)
MMKQ[]KG]D;X%_MQ_ 'QY^S5^TAX+MO&_PM^(-G%#J=CYWV/6-%U.RF%WHOBC
MPIK2PRW.@^*?#U^L=[HVL6J^9;S))%,EQ97%U:7'Y$?#?_@F)_P5-_9M^&>G
M?LR?LT_\%:=.TK]F?PYI</A/X=7GQ@_9<\+?$7]H/X3^ +;S[+3O"?A?XA6W
MBG1-"UPZ#H0LM,T+4]<\.1OI:VD(TFSTJ&""-0#\#/V/-!\=>//^#KK_ (*=
M>(O@JT]_X>\/?#/]HNU\4ZMH#>9HEEJE_P###P;X1T.+5HK>:%;B1?BD;*U\
ML13R?VU:R?*LH,R^J?\ !E/K5MX>T?\ X*0_"GQ>\VE_&+3OB?\ "C6?$?AK
M7+B9/%:VVB6WQ"\-:_)J>G7(,\$VB>*;A[#5)YY6N)=2U'[/(IDMR3_3]_P3
M9_X)7?LY_P#!,GP-XVTOX3S>)_B%\6_C!KB>+?CS^T+\3;JRU7XJ?%[Q3]JU
M+4C=:YJ-G9VMOI^B6FJZSK.H:7X?LD,5O<ZM?7E_>ZKJ=S<ZC/\ #?[17_!#
M#5;7]LO7_P#@H5_P3;_:HU[]@W]I[Q]!>V_Q>TBU\$:1\2/@5\79=5N!>ZUJ
MOBGX=WT^EK'JNNZC%9ZQK:-<ZGHU_K=A;ZY!H^GZY/?ZG> '[O\ BWQ_X%\!
MR>%QXW\8>&/"$OC;Q7I?@+P8/$NM:;HLGBGQKXC,[:'X0\._VA/"VJ^(=8-E
M.=/T6P$U]??9G:&VE,;@?Y[/_!$W]F7X#?'S_@N+_P %9_@'^W+\%/!'Q=\5
M)XC^,?C71?#7Q8T*R\1M:>(-#^/DBZQJNFRW88M>7>C^*;&Y2XM),:AIDGVS
M]]!$KI_6U\"_^"</Q^UGXX?"S]I3_@HE^V-=_MA_$;X"W&KZM\!_AQX3^%'A
MKX)?L_\ PQ\8Z[ITVC7_ ,2Y/ VEW6N:CXW^(]EI4TMGX5\3Z_JL3>$(K[5#
MI=M)<7-M<V7FW[=O_!%3PS^T7^T]X*_;^_96^._BS]BG]O'P';V]A'\8?!VA
M:;XM\&_$/1K;3[W2_P"Q_B?\/-0EL++7#=:=>-I%_JL-\DNI:*J:?K%EJBVN
MF2:< >]77_!*W_@D1\';WPYX^U+]C?\ 9-^'MYI'BWPJGA;Q/K/A+PSH8M?&
MUWK%JG@^VTJ_U.:&$Z]>ZZUG!H=G"SW-]J4EO!;1RSL$K\8_^"F'_!(?P-_P
M46_:A^-G[8/_  2X_;%N?@7_ ,%&?V:_$.A_#/XZZ!H&K^)O"VAWWC_1O#.G
M7OA_3-=U_3X]*U7PAXFN_"LMC:MKVG6_B;PCXFMXQ;ZG&EU9:C+7Z:^ /^"7
MG[2GQA^)/PF^*'_!3W]M^Y_:^LO@+XTTKXE?"3X"_#;X1>&_@)\ ;7XG>'9S
M/X9^)'Q'\/Z1>:UK'Q/\1>%YFDO/"]CK%Y8:+H.HR2745K=I(;<>:S_\$=OV
MC_A)^UY^UU^W1^QW^WOJGP=^-'[5'Q*LO%'B'X=^.OA%HOQ%_9^U3P79>'=.
MTNR\+^,/"#:UI7B"]\3Z-JT6IZIH?CW0_$.E75I:7SZ5+H\R37-Q( ?!?_!*
MW_@I5\6OB?\ #W_@HY^P9_P6_P#">@>&_B%^Q]\(M0U/]H_XF:MHVGRQ>-O@
M3K.FOX3\07/CL_#RRU;3O$VJ:7I&HZ=<Z/XJ\)VUS+KNC:I:W=G%)J-M/,?S
M5^/'_!,/_@HS_P $3O#NO_MT?\$B/VH-2^/G[ \^BQ?%SQU\ _&.H6VJZ>_P
MEUBTM-1>;Q#X$UNX_P"$<^*7A.YT+67:;7_#%KH_CZVT:+^T+JPG>&YN$_HR
M\$?\$11-\&_^"A:_'?\ :4U?XO\ [8'_  4F\!:I\/OC/^TLGP^TCPUHO@SP
MK)H$&B^&_!WPV^%]GJLEGI_A'PVT$=V+&^U^6ZU1XK<37%J+=1)YE+_P1B_;
M4\+?LZO^P)\+/^"GFM:9^P9KW@^S^'^N^&?'GP*\-^+_ -HWPG\/KBT@M_%G
MP^^&?QDCU_3=/T_PQKO^G6VB/KWA34]3\&:-=Q:/I]U?QVCW%V <+^U%_P '
M%'P2_9[_ ."7W['O[:6G_!F/Q5\:/VO_  A'-\"/V>7E-IHN@^./#"3>'_%U
M]JGB/^S66P\$>!O%<*:58W%C'9ZWKEE?:=%I4-L)+RZL/A/_ (+-?L:?MAZO
M_P $@?VG/VM_^"B?[8/CGQM\;+'P=\,]=\-_LO?!?58_AC^R;\(-4\5?%/X=
MZ1/X8E\/:),VH?'#6=$TO4)H&\0>--2O;*36+0ZUI>G%H+:\;]5/^"@__!NY
M^RA^VI^R+^S-^RSX#\4>*_V=/^&.=+FT/X ^,_#D47BMK'0]0@M1XATKQMH^
MHSZ<?$;^(]3LK?Q'>:W::AI.KVWB0W.H03/;7M[87/+^+/\ @W]O?VG/@-XN
M^%G_  4/_P""A7[5'[9'BO4/!,OA;X9Z[JMSHW@#X>_!?6XQI4FF_$;P]\*M
M%%YIOC+XAP3Z+:6^H>)?'VKZU+?Z3=ZQ96EMI-YJLVJ( ?4G_! :[M8_^"/_
M /P3[LGN;=;VY^ &E7%O9M/$MU-;6^I745S<Q6[,)I8+>2:!)Y8T=(7N(%D9
M3(*_9&OPW_X)5?\ !&_7/^"=^M:3XK^*'[7/Q$_:KU[X;_!VX_9V_9^TGQ#X
M;TSP1X(^"'P7U+QA!XX\1:'X>T#3M0U:?5->\4:]8:*VI:YJ6H&2WTW1+#2X
M(YHHHI8?W!N8I)[:XAAN);26:"6**[A6%YK622-D2XB2YBGMVEA8B2-9X)H6
M=0)8I$+(0#_/2_X/@)8V^(W[ D8D3S?^$(^-,K1>8AD$;:]X+5)#&&\SRW97
M5)"@1BK -E6 _OT^%+%_AA\-W+F0MX!\',7+%R[-X>T]BQ<YWELYW9R00V3N
MX_E9_;/_ .#7?XE?\% _'FA?$/\ :Q_X*M_&OXLZ]X0TO4?#G@EM5^ _P[TZ
MV\+>%[_6;K66T>PM-#\3Z99NS7%PINKV6V-U=M# )9#%!!&G[;?\$]_V)?VE
M/V-M*USPO\:?V_OBE^V5X+A\(>#?!OPS\-?$3X;^"/!G_"MK'PG_ &C ]W!K
M?A^XU#7?$=WJ.ES:5I&=5U!4MK324DE%]<SK-;@'Z4W/-O..YAE _P"_;?G^
M'UK^(O\ X,T#F;_@K%_V<#\(SU!ZO\=/0D'Z@D'UK^N/]K3X._&?XZ_!37?A
MM\"/VE/$?[)_C_6=1T26+XQ^$O!'ACQ]K^E:-8WBSZSHNGZ)XL>+38'UVV7[
M&VK0S0ZAIZ,SVDF6=6_%K_@E!_P0+\;?\$G?B_K7C;X5_P#!0/XD^.OA=X_N
MEO\ XR?!/7_@WX'L='^*6H:=I&NZ?X8U'4?%4NMZUX@T/4/#E_KUUJ]O>:.8
MY[QC-I]TYMKNYD< _,S_ (*ZWNAV_P#P='?\$:09]/BU);3X<0ZB5V+>[=0^
M(GCJTT*.\9!YK)<7;W$.G+(2OFM.%PK.:_6?_@KK_P %AM4_8W^-_P"S]^PS
M^RA\+?#?QL_X*%?M1SZ9I/PQTWQ==IIW@CX3:+XZUJ[\+>'_ !GXRNT5+_4U
MU+6M/U&>U\,6%YI\=WIWA[4[W4K^*-+"TU'YF_:+_P"#</XU?M+?MDZ!^W5X
MY_X*L?%]/CY\._$=GJOP:\26?[/GPQ@7X5:+X>\5:UXJ\$>&M"L+77K32;VT
M\)76MW$=M<W^F//J#^9<WP>2<K'[-_P4+_X-^1^W+XW_ &7/VF--_;(^(GPB
M_;I_9N\&^!?"-Y^TSH?@?P[(GQ+N/ =]=Z[H_C#4O ^E7NAVWA;Q58>)M1U'
M5-.ET35Y=*BLKZXTB^TO4!Y-_" ?@)_P<\_L9?&OX)_L&?!+XT_M7?MG?&']
MJS]H[QG^T)I>B:Y97NI6_@3]G?P/97G@OQAJ^JZ7\(?@5X?2UT/2[>QO+;3K
M!/%.M'5O$L]NLC>?IEOJ<VGI_95\,+RTF_X);^!;.*YMWN[7_@GUX.DNK1)X
MVNK5+G]G&S-NUQ;JQE@68(YB:15$@1MA;:V/RO\ VF/^#;WP5^V?\!/$GAO]
MK7]MK]I3]H;]JN_M]-/@G]I;XAW.DOX;^$TFG:LFHW&C?#?X!Z&=)\$:!X8\
M36R#3O%:-J%WXGU-=MU:^)M/VFU;OOA]_P $1/C_ /#?]F/QQ\)_"G_!3_XV
MZ%\>/C)_PKSPG\9OVC(/A?X)U34-<^!7PF^&NJ?"[X=? SP3X,U#4TT[P#X>
M\/Z'J;W=QXHTO49O%FLWPE^V7Z03,@ /@[_@RXL;*'_@G7\<[^&T@BOK[]IK
M5XKV[2)%GNX[+P7X9^R)/*!OE%L+B=8@Y(C$C!<!CG]R?^"V@S_P26_X* CU
M_9G^(7_I E?%7_!*/_@AG\4O^"4?B^.W^&?_  43^)_C_P#9]U35M6\0^.OV
M<M?^#?@73O"WC#Q%?Z#-HUGK47B8ZYJ^O>%[VQD73KV9M#$7]IMI5M;7;>0\
M@/WA_P %//V#_BE_P4,^ LO[.W@W]K?Q?^RUX!\5IK6D_&.W\'_#CPEX[NOB
MOX.U:SA@B\(W][XBO-.U#PUI]K<Q-<SW&@WD-QJ4<\EI=YC2-P ?F-_P:1''
M_!&#X3>_QF^/JCVQX]O&K\SO^"9Y4?\ !VQ_P5"!9 Q\,?%0J#@,X^U_"XD(
M",D@$,V".!SD=/W#_P""8_\ P1]^,G_!,CX/_%+X"> /^"@OQ#\??"CQ5X+\
M96/PI\+:]\%OA]IT7P0^*7B^6YNG^+.@7?\ :>K7GB.\L]1N!J$OA/69X] U
M&9<7"KPU?&7P(_X-P/B_\#OVXW_X*"V/_!5'XR:S^T-XF\1R:I\5O$\OP%^&
MEK+\2_#^LWVD2^,?"=_ ^N7FCZ1I_B;3=(MM,\^QT5WTJ*&WELHA)"IH ^2_
M^#T'_DAW_!.[T_X:H\29S_V*&F5^U?\ P4X_X*K? _\ X)._L-?#'XP?$[PT
MWQ)^(7C7PUX6\.? GX/0XMI/'?C;2O#>BWMY?:CK<]C?6GAOPWX/M+RUUC7=
M9:&;4 LEGI^CVMSJ5_ J>"?\%8_^"$?CO_@K!\4M#\2?$7_@H'\3?AQ\'O =
M[IVN?"OX$:!\(/!.KZ#X \5IHEGI6O>)[;Q0=;T77=:U+79[:2\#:LLO]F1S
M_8K-_*3>TG[6?_! N#]NS]A7X:_LJ_M;_MD_$OXQ_&7X%^+O$/B7X*?M3W?@
M#PIX<\2>'-)U^TT73)_!7BGP+HE]'HGC+0FTC1+:QFU"YU*Q\1O+!87HU8-9
MRP7H!^>7_!2K]EK]N'XV_P#!(G]JW]LS_@HK^U;XYTSQ9)^SR/B9X&_8A^ =
M\GPL_9U^$-]K4_A^Z\.^'OB5>Z1>7_B;XZ^*-!@UN]T[4H_%&NR^%[K5);=4
ML-4?3-/NU\Q_8ZTSQUX@_P"#.OXF>&/A?+>-\0-3^"/[1^HZ9IVD7*Q:YJ/A
MGP]\9M4UCXB+I]LDB75S##X%AUZ/4A CE;29TDXGC#_J3X9_X( W_P 5_@HW
MP5_X*+?\%!OVJ?VV_!^D>!YO OP\\#-K-M\(/AE\/Q!HZZ1X<\<2>%_#DVJ7
M_P 0_B)X/4&Z\.:W\0];U[1K:1+8WWAS49[6&YKHO^"6W_!"(_\ !/?Q5X1U
MSXF?M=_$/]J;PQ\#_"7Q9\ _LO\ PO\ $/A'2?!?P^^#_A_X]ZU:ZK\:M3O=
M)MM4U^Y\7^(/'T.B^&M.9;^]MM'T*SL-3CMK&_.J6IT8 ^??^#0/Q?X3\2_\
M$>= T'P[+:G6_A_^T9\;_#'CV&+S1.GB74;KP_XWTY[M98HPS2>#/%OA40RV
MSS6[11)&)Q=07=O;_P! /[2GBG27^&_Q.^$NB^*=$M?C3\1?@1\:[OX7>!_[
M9T^T\;>*Y= \'SV5YJ'AK19)EU/5+3P_JWB/P]%J-]96TUOI5SK6F"[DC>^@
M$GX?Z+_P0D^-G[&GQT^*7QA_X)$_MT7_ .QIX+^.&IC7/B3^S7\2/A1HWQP^
M!\>O_:-2F34_!NE7NI:+=:#;Z;%>_8?#]C-%?:AHMC+>64/B"72VL=+L/T8_
M9%_X)_>.OA+\9?$7[6?[6?[2OB+]L/\ :ZU_P'!\+=#\?ZEX,T'X8_#7X-?#
M$W5CJFM^"/@G\*O#DMYIGA6/QKK>F:5J_C[Q+>ZAJ6N^*KS1]+,CV$$%Q;W@
M!_'_ /\ !I!^Q5^QE^U3\%_VTO#_ .U3^SG\)_C#\2OAG\9? 26-I\3_  M8
MZMXG\+:!K'A36;&[M(8+X)J5E9'7]#U"*_A9!%'?QE)@LW _L4\#_P#!.[_@
MEU^S#\3OAI\0/ _[+G[+WP=^+<OB1]%^$?B2W\,>&="\77/B^;2[Z<Z;X(EO
M7%[=Z^NCPZE=K!I*2WEO9PW%T@C19)$^$OB[_P $.?$?P_\ VP/''[>7_!+W
M]JN__80^/7Q=M-2M?CAX$NOAMH7Q6_9X^*UQK=_+JFK:_JGP[O[G1SI&N7NK
M2'7IVM9[VR'B%/[9TFVT*^O-8GU7ZE_9F_X)M?$C0OC[X9_;$_;P_:BU?]M3
M]IWX?^%]6\(_!F1? .@_"7X&?L^Z=XG@%IXRUGX5_"O0)]1B_P"$^\7V$<.D
M:W\0->U.[UA]"B32K&WL=]W=W8!_.9\4K&\MO^#T?X1O<6\D*WOPCT>^M2=K
MB:S/[.7C&W6X7RFDVQM+;3)\^QE*'>JXS7V;_P 'DWB?0=*_X)5>#_#^HZG:
MV>M>*_VJOAI!X<TV63_2M7DT7PMX^U35#:QJ"2EC81/<7,C!8X@8XW<2S0I)
M]R_\%(_^")UW^UO^U9\'/^"@O[+G[2WB#]D#]M_X,:;I>@:7\0;7PKI_COP/
MXQT'2/[5BL;;Q5X8NI].NVO8--UK4]#GF6^O-+U7P[.=(U'0W=8=0@^9/VM?
M^#=KXD?M]_!GQ-%^VC^W_P"-OCA^U/K&L^"_^$(^*UU\,M(\-?!_X%^#-%U:
MVO?&'AKX1? GPUKNF:-I>L>/[>)HO$GC34-6FU2]CMM/L(K6QLO[1.H 'U-^
MU#S_ ,&WWC['?_@E3H8YX_YM\T0?S_#U('->"?\ !I<&7_@C!\'\J_/Q>^.K
M#Y2,K_PGEPV5R.5R"-P^4D, 2V%;],OV7_\ @GSKOPP_89\1?L*_M2?M&^+?
MVSO >O\ @W5_A0GB+QEX,\.?#[5M*^#5_P"$K'PAIOP[MXO#MQJ<FH1Z!I]O
M<G3M?UB_O]3*3VMO*#'8(9OR<_9 _P"#?/\ :2_9-T.\_9V\/?\ !4SXPP?L
M.:3\39OC#X.^#?@OP#H?@SXC7/C>">#4M#LO%OQ/M=2N;@^"HO$.GZ/KGB_P
MGX=L=,TKQW/8SV]W;Z-;:E=H0#XE\:!C_P 'IWPSPIY_9K+$ '@#]E_QL23P
M <$$,5+ '/S$@UX#^T+>:C\/_P#@\K^ >L_&2.-]$\8Z7X(LOA3JNHS/I6G6
M>GZY\(O%7AWPHUG<S1QP:A+%XIBU71%@A9UGU6]\AW\\-7Z7:O\ \&W7[1NN
M_M@Z=^WYJ?\ P6'^.LO[7FDV\=IIWQ>@_9\^&EG-::?'X?N_"S:);^&+7Q/%
MX8A\.R:#J%_IG]A#2VTZ.UNG58&D5)5_2[_@HW_P1O\ A!_P4G^%7P:M/BE\
M1O%7@?\ :K_9_A\.ZA\*_P!L?X>:-HVA?$K1_%.ABVO+V\OM%MC%IUSX8U_Q
M' /%,_A:SU#3CHNN)!>^'=7TN>.:2Y /UYU;4=.TG3;W5=9O++3=)TRSNM2U
M34-2G@M=/T_3["![R\OKZZN66WMK2RMX)+FXN9G2*"&)YG=41F'\^'_!3[_@
MM=H7[/'Q"_9>_95_8@\,_#W]IC]MG]LV'P=<? ._O]9@G^$7@SP)\5+^71_"
MGQ3UGQ=I;/'XBT?7&BNM0T?1=!U:%=4TO3KO4KV]%FUE;7_1V?\ P3)_X*;_
M !F\(O\  S]M7_@K)=_$G]FO4K2'0?'GA/X(?LZ^#?A!\6?BYX+13;ZCX0\:
M?%^34M=U#3=*\56"C3?%TFAZ.+_6M-OM4LFO8FG2[CY/_@I/_P &]/PH_;1^
M)_[-O[0?[//QP\6_L4_'O]EOPCX"^'?PT\3_  _T&V\0^&;#P-\+9VG^&VG6
M'AV74]%E\/ZKX'WM:Z+J&EZB;&?3 FFZEI-VJQ7,0!^ _P#P<^?L6?&CX*_L
M!_!SXY_M6?MI_%[]K']H?Q?^U;X/\,7MC>75M\.OV>/ VDZE\-OB]KFLZ?\
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M]!_C3J**^OI-N+NV[2E:^O6_77=MZM_Y2%%%%: %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex10-15_001.jpg
<TEXT>
begin 644 ex10-15_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !4 ?0# 2(  A$! Q$!_\0
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M,,U:OBG-.G'^NO\ ;@_X.G_V,O@)=ZYX)_9=\->(/VK_ (@:>MW9)XHT]O\
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MM1KU$[:TZ$Y0IW5U.K+D7NQDU>0"(%LDLQ+/(QY(SU8@'CD< !5';'3\A_\
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MF:1/JFDVDR7,\C7DDD4<$H!^A6Y?[P_,>N/Y\?6@,IZ$'MP0>?2OXD_V!O\
M@MA_P68_X*J_LK?$NR_8^^!OP TG]H?X(W7CCQ/\6OCAX^T76;/X4W6D7:?V
MO\'/@Q\(/ MMJ6M7'B'XN^*+.S\0V&M:EXFOK7P]HUAIVCZA.CW6N+Y7W+J7
M_!27_@L;I'_!'"']N/7/V5/@M\)?VAO@_!\4KK]HWP3^T/I7Q(\#:CJ_@CX>
MC3[32/B3\*OAY820W%CJ7B2^FU07?AWQ?J5KIQ32IKG2+I[*]L7(!_4/D>H_
M,49'J/S'O_@?R/I7\AW_  3\_P""E'_!;W_@JW^Q]X"\9?LP?##]F'X):_H]
MWXETCXJ_M:?'S2]??P%\0O%NG>);R*V\,? WX0^&)-8NO(T/19+73_%WB3Q%
M=W.GQZQ9/:V,0NFF#<7^R7_P7Q_X*"M\=/VE_P#@F?\ '[]E[P9\?O\ @I;\
M+/&;^#/@J_P3MM0\,?!+QE+9ZA(OBWQ9\9=?DO-0'P]^'G@;PS-8^+9O$^F6
M,=QK=K)%X;32K'7+^V>@#^R7<OJ/S%*2!U('UK^./]JW_@J#_P %HO\ @D=\
M</V8O%?_  4,_P"&,OCK^R_^TK\1Y?AYJFE_L^>'?%?A;Q'\-KP:IHUQJ+:9
MK7B6>PO]0O\ 1O#5]->Z9+K$&I:5JXAG@O9[&ZBCDK]NO^"O/_!2J]_X)K_L
M7M^TEX$^$FK_ !V\=^,?%_@WX<?"3P7I]MJLNAZCXM\>Q7%SHE]XJN=%AN-2
MAT1;6SF6WM=,7^T]<U>?3=#L'AEOVN80#]8<CU'YBEK^6O\ :J^,?_!?;]BK
M]C?6?V]?'?QX_8G^)MI\+?#/AWXH?&?]EB#]GGQ5X/&E>$-2ET]O$?A;0_B:
M/&D^NWVM>%AJL5M-<7>E:7)=?8[NZ3<\:6MS^SO[#_[?GPO_ &R?V#/AE^WB
M(X?A?\/?%7PX\0>.O'=IXGU6TDMOAJ? 4VLV7Q#CUG6(6-J=*\.W'AS5[^/4
MI?(DET5+:\N[:TF>:"( ^]B0#@D XS@D9P3@'Z$\?7BC<O/S#CKR./KZ5_,1
M^SC_ ,%$O^"CG_!8[Q1\7O'_ /P39U?X!_LF_L3?!KXH:O\ ";1_CM\?_ASK
M?Q?^*_QS\7Z'I6DZIJ=QX<^'^G^(-$\-^&/"T6E:_H&L12WE_)J446L6UA/=
MS:A%J-GIWT)_P2Y_;[_;Q^*?[5G[7/["'[>WP(L;'QM^RJ@U#0OVL/AM\/O&
MG@'X,?&'PY/XAGL],OC8>+&FTZQO=?T.[T[6/#<GA_4I[*_L=+\0_:;.%]/D
MD< _?/(]1^8H#*> P)(! !'(/(/T(!(]<5_+7HO_  5X_:)_X**?M4?M%?!/
M_@GO\;OV4?V6/V:OV5=9LO"/BS]J_P#:4TV#Q[XA^-/Q#>^URPFT+X0?#J\\
M9^#])/@=4T:ZOCXKU:[-\]E!:7<,(&LV]O#VG_!/W_@L?\7]3_X*!?%+_@DS
M^W-KGP(\7_M#Z%HG_"3_ +/7[3_P&+Z9\&?V@M*O?"\7CN'1[S0)]:U$:-XK
MLM U$VK6N@7\MK=ZQX3\6Z$\4>IV5E=ZJ ?TP%E')( ZY)'3UHW+_>'KU'0\
M@_ES7\JWP3_X+'?\% ]"_P""T_@3_@D]^UM\*?V5#%XFT76]?U+Q[\![SXD2
MRV^G7/PX\0^//"4EE-XRO]GVJ-=*M;77;.?2 5=YTM;E"JR5[-_P73_X*6_\
M%&?^"6/A&']I/X2?#3]D?XA?LK7/B3P+\/+:U\<W_P 33\:H/''B33M=O[^\
MU#3](O\ 2?"K^&5N-&:SLGTZ^FU!(9H9;F-79F4 _I"9N/E(W$X X.>F>,C.
M!R<'@<UY1\(_C?\ "OX]>&=3\8_!_P ;Z'\0/"^C>,O&/P]U76=!EFFLK3QE
MX UZ[\,>,= D>:" M>:'KEC=:==% T+2Q>9#))$P:OQ[_P""CG[4/[?-O_P2
M/T;]L/\ 8TU7X&?#/QS>?LR:3^T!\:-7\?VGB?6=5\(>%-5^%>F>-=8L_@A9
M01WNEW7B^'4;^[T_2KGQN)K*SM%@NE=]11"?R,_X-H]>_P""J6L_L _!S5_A
M';_L7:M^S3K'QJ^-6L^+M<^+.M?&9OC[JVL:GXSU+4?%][(-"M9?""SWWB"9
MS93M)),UI.]]=++,VQP#]'/"W_!-S_@I9H?_  78\0?MXZA^V7/J'[#FL:-J
ML:?!F3Q)XE>1O#U]X!E\.:5\(F^&$SMX-MK'0O%QM?%-KX[MYO[3DDM5O1:Q
MZG-,#_1I7\E?[//_  5V_P""H6J_\%S/AC_P3!_;!^%O[+WPM\/W/@;QSXG\
M86/P0?Q;XQ3Q-:'X3^(O'G@37]$\<^+=234M/B^T:;:_;=.DT"RED475K.D6
MZ.6OT*_X*J_\%<];_8W^*?P!_8L_9:^%NC?M"_M]_M5W]M8_"SX<:UJ\^G^"
MO 6A:C>W&F6_Q"^)T^E&368]!%Q9:M=V^G6/V:>ZTS0=;U&:[@M+'%R ?N3D
M>H_.C(]1^8K^6#]K_P#:D_X+K?\ !,'P7\)_VE_C)J'[/'[>_P *-9^(6A^#
M?CA\$/V>?V=_&_A#QMX!L?$@=K75?!/BK3]?UW4]:BBEAGTFRU#Q!X=@L#K,
MNF0ZDB1ZC'CZB_X*9?\ !4W]H[X)?$/]AO\ 9)_8M^!#ZM^U!^WU;Z9JGAKQ
M9\9/#/B.Z\ ? CPE>?8AK.J^-] \-.NHZIXJ\*K>37OB#1)[ZRTW1-.TJ^O-
M2NG$T*, ?O[N7U'KU'3CG]1^8]:_'/\ X+?_  8^*WC_ /88^,?Q7^"?[4?[
M07[,WQ)_9T^&GQ!^*7AVZ^"7CD>$-%\<RZ/H]KJ=WH/Q(M8[*6\UK24L-(ND
MTHV&IZ3=:;=WD]RLL_$9_,?]OC]OW_@K+_P1;;X"?M!_M;?%']F;]M3]D[XD
M_%72?A!\3=$^'7P3U3X%?%'P7J^K:9J?B*+5_"=]_P )?X@T;6)7\.^'/$LV
MG0ZKFTN;W3$LKZ&PANEU"']J_P#@HKXIT?QS_P $LOVO?&WAZ<W6@>,?V-/B
M9XJT.Y;9NN-'\0_#+4]7TR8^6SIF2RO('^1W3G"LRX) /SA_X-7OB9\1/BS_
M ,$C/AWXS^*/CKQ=\1?%VH?&KX]"^\3^-_$.J^*->N5/CR_N!'-JVLW5Y?21
M)+/,\4+SM%#YKK"B(0!_1ON7U'YCU _F0/J1ZU_(O_P;A_'_ ,*_LI_\&Z?B
MO]ICQM:7FH^%?@-J'[6_Q8UK2M.*#4M:M? ^H:QKRZ#I;2E85U379[.'2-.:
MXDBMEO;ZW:XFBA661(M?_P""@G_!;2R_X)J:G_P5S\ ^(?V*OC#\*_%WP=U[
MXK']E+PI\-?&+^)/@/X+UN&6'1O%MM\3;?Q9)/\ $;Q)\&08->^+/A#7K#1;
M231=/\50VT]O=Z;;J #^NW(]1^8HKQ_X!>.-:^)WP*^#'Q(UZ.SM]>\?_"KX
M?^--<ATZ%XK"/6/$_A72M9U)+**9GEAM5O+R5;>"1W>&()&SN5+$H ]="$=^
M .O4GUS]>?7TK\H?^"S?@Z+QE^P9\3+76;'7;OP=I&L>'-8\?W/A@W;:_P"'
M_!23W6F:MXPL8]/9-1EB\'3ZE:>)+^/3UGNHM,TN[NUAG2!XW_6*LZ^T^WU&
MUNK&]M;6\LKV&:VO+.[B2XM;NUN4:*YMKFWFCDBN+>XA9HIX)5:*6-F1T9&*
M'AS' PS# 8S SY%'%X>K0;J0C6IQ]JOB=*<9QFE)17):RC*;CRM1M]-P7Q&^
M#^+^&N*E@UF"R#.L!FM7 ^V6%>.H8>MRXK"+%>QQ"PU3$82OBJ5'$2PV(A0K
MO#UYT:D*$J=3^:S_ ((H_%;]EG]C?]DJ;X::_P#&2X\8^+/%OQ&\7_$77/B!
M::#X@US3=>T[5;B#2O"-A;ZCHXU^[#Z5X6TC3'N[>XBM([?4;W4!$BAFSW'_
M  6*_:B\;?M%?L=>*OV=?V$/B)H%CXU^.-[%X(^)7Q&\1'Q;X-;P-\(KNUFG
M\6#0%N_#:7^K:SXOBBC\),NGF*2PT;5=6O1<Q3K;L?3?C9_P;^_L;_$/Q/JW
MC3X2>)/BQ^R_XAUBYFO;_3?A!XCM(_ 4MW(L:^;'X-UNRO(--B+(97M-&U+3
M+4/+(4B3]WY?\8OB3Q'\5M6_X*K:Q_P2_P#@YXM\;?$.6T_:<F_9VL/B5XP\
M1:IX?NI8O#NI?8/'GBO4/#=E++:QQ>&H=-\2W]G;I=FUU.STFVF,D27HV^KX
M8<.\:+$4X9'PYDV+I\&X"&=UYQQ6"648;"9?5JUEBL3A\QK9<YQIUZ4*RH2=
M55)T8Q<:JII5/Z=XGC]%/CK.\UXWS#Q2XWR;,N(L;6S+,>'^(>$\RHXV&*KP
M@JV"PV,X:H9QEN)ITG&-*C4P-?#4HTHTYRHX=U[4OL7_ ()D?L _#3_@FE\<
M]*_:I^+_ ,1OAK\6_B5X-T'4K7X;Z)KFE3:9X-\ >*M2$%L/'-I:7=_/K_B#
MQ%I&F"^LO#[QZ;:#3;C4)-2B;[7# R?JK\=_^"JNH>.+:Z>\\67OBC3[=I7#
M32+X)^'MD%F=LM#/%9SZIY9"QQS-;F=T2$M-(1D_?VK_ /!(/_@G9^Q]\,OB
M'^T-\<;WXG?%?P]\*/"VL^.?$5Q\2/&5J-+GM="L9;L6$6C:%IOAV"\N]6N8
MH]/L+2^O;@3WMW;6V]6DK^13]G#]GWXC_P#!6K]NJ\\%^#]!@^&W@#Q;XKU;
MQQXJT[PQ9RVWA'X'?!:TOMEM!IMG*]]:C4X=,^Q>'M%\[<^M^*+AKJ0QVAN#
M;?L> XRJ<49IB.)^*Y_VIC,%AJ=.6,Q%.E2PF'I4IU)0P>$I1C:E3_BM0PTJ
M4ISDJE656HHR7\]>)7BOX'^&M7+,C\.^$\\XZXISRL\/D]',7'AO 1:7LOKF
M,JXJIGF=U,+[107[BCE;K0^L<\</&"D_VU_8F^&OQ*_X*E_$6YF:YU@_LT^
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M!_!SXY_M6?MI_%[]K']H?Q?^U;X/\,7MC>75M\.OV>/ VDZE\-OB]KFLZ?\
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M]!_C3J**^OI-N+NV[2E:^O6_77=MZM_Y2%%%%: %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex10-16_001.jpg
<TEXT>
begin 644 ex10-16_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !4 ?0# 2(  A$! Q$!_\0
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M,,U:OBG-.G'^NO\ ;@_X.G_V,O@)=ZYX)_9=\->(/VK_ (@:>MW9)XHT]O\
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MM1KU$[:TZ$Y0IW5U.K+D7NQDU>0"(%LDLQ+/(QY(SU8@'CD< !5';'3\A_\
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MF:1/JFDVDR7,\C7DDD4<$H!^A6Y?[P_,>N/Y\?6@,IZ$'MP0>?2OXD_V!O\
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M,JXJIGF=U,+[107[BCE;K0^L<\</&"D_VU_8F^&OQ*_X*E_$6YF:YU@_LT^
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M!_!SXY_M6?MI_%[]K']H?Q?^U;X/\,7MC>75M\.OV>/ VDZE\-OB]KFLZ?\
M"3X!^'6BT+3A%>:7H]I'XIUU]<\40V27-JM_8V^L7EI+_4M^T#>V,G_!#/XC
MV27EH;NV_P""9%@]S;"YM_/M4N_V>;9;1KF#S!);I<E'%NTJHLQC<1%RC ?&
M'[2O_!M]X(_;/^ OB+PY^UU^VY^T[^T5^U/=+;7G@+]H_P >:I8VWA7X37UG
M<F=M'^'W[/VA2:?X$T;PIK\(6R\5I)=W?BG5!';W=KXGL#;QV@Q/^(?'XZW7
M[./CCX+WW_!5;XZ?\)A\=/#GA?X;?M(?$23X2^!=6'Q(^!_PN\(Z?X+^"GP7
M\.:/J&KI<_#[PO\ #S2F\6W&H:GHVL3:SXXOO&VJ2:[-'#96,*@'@G_!N=J'
MP!TO_@W)\97?[5=UH]E^S2UY^UU9?'F?7X]6FT?_ (5-J=_K&F>.H;Z'0(;G
M79XI_#UY?P"#1;>?5Y))D72XFOVMB/S-^/7_  3H_P""F/\ P0E\,^*/VW_^
M"5/[3EW^T'_P3OBTRX^+GCSX$>.+F'5]'TOX3>*+17%_XJ^'6OW4FA_$#PS;
M>&=<M;B_\=>#8M$\9V6G6<?B76-(AT[2[^[M?VI^ ?\ P;U?%[]G/]C/]I3]
MA?PS_P %(_'OC;]G3XZ?!'XL_#K0?A5XS^!O@NU\,^ O'OQ,FTZ]_P"%DV>K
M:7XCF\4RM8WEI>O=:';ZE;6=[_:UQ,YWPI')Z'K7_!&O]N!?V:I?^">OA;_@
MJ'JG_#!6N> ;7X4ZYI'C7]GSPGXC_:9TGX226/\ 9^N_"WPO\7K?7],T:7PU
MK&FK)H%MJ&N>$[O5M$\+W3:!:--:VD;7 !^O7[!7[3^A_MJ?L:_LX?M3^'O#
M@\(Z=\;/A7X:\92>$H)3-;^%=6FMC8:_X9M;B2WL_M5IH.O6.I:5:74=M%#<
M6UI%-"&C=68KUG]G_P" _P ./V9?@E\+?V?/A%I$N@?#+X.>"-!^'_@G2Y[N
M2^NX-!\/6,5E:RZA?2!)+[4[PH]YJ=ZZ(UY?W%Q<E%,NT% 'LE%%% %=XR^0
M4R"W)W 9'J>_M^7!Y%?S"_'G]D_X6_L:_P#!3F7_ (*.ZU\'K^#QE<S^.+[0
MOBQIG]O77PZ\42_$3PQJGAO4K+XC:9HD&KQ^'?&7A:UU6_&G:_/8:9#K5D]G
M<7%_<26A$']059UY907JSVUW;0W=I=*8[BVN85GMYHBBADFAD#12J2H^61&Z
M=<<5]IP1Q>N$,=F$L3ED,[R;.\NJ93GF4RQM;+JF+P-2I&K;#8ZA&H\/B(SB
MX1=:G5PTZ56K3JP3E&K3^%X\X2S+BK+L(LAXFS#A#B'*L5/&91G6"HPQE&G4
MJT70Q&$S/+:M6E0Q^78NG&DJU-M5Z56C0Q.'<JU+V=7^9O\ ;3_:W^%'[>/P
M%O\ ]GWQ]XPT+P=X'U[Q)X9\0^(I_AUXWO%UO7['PU=R:C!X=O)#87#MH>H7
MXM+C4((86GG%C'$&7YU;Y8_9<U[X$?LDZ1XR\$_LC:'XU?4OB,^C+XWN?"J>
M(=8\3^*&\.K>QZ3:7OB368[K6;'3;1]2OIFT_0H;+3[N:>0W4$_EVQC_ 'B_
M;Q_8/^"_QZ^"NNZ+IW@"S\!>(#?V&JS?$/X1>'=#\,_$S0[>QDDFEU+3M5TO
M3X+W5+2&01?VUH$WGQ:SI3W<1B>9(7C]=^%/Q4^!G@;PIX=T+PAX.-A'H.B:
M3H(NM!T'PE#-<'2["WL3->W&GW]K<M=3&$2W1NHH93<._G1J^17U5?Z2?T<>
M!\;/(Z_AOF&69Q"C1S'!T^*<[R:EE>9JJD_K> QN!R7.\7BE@<;2J87&4X/"
MXK"U'1:I*&(I3/Y2S[Z/WCYQ9Q!*OG_CADV68:E@8X:AG63\/\05,ZG@\3+%
MT<5@:6$Q&;Y%EU"5*A-3E.K4Q5'$>W5.<.6$X/\ *GX>_ #]M#X]72M9^"3\
M$/!]U*!>^*/&K/;:U+;3;'::VLKQ6US47DAD9XVL]/T^T9D5#?POD5^G'P%_
M8"^$'P<N+/Q/XD@F^*7Q%A9;H^*/%"/)IME>@.S3Z1X=:XN+!)RTC!+S41?W
MZA$,,L RC>NZK^TMX6L8WDM=(U!9 ,,VM7>EZ7"BD,=S/;WNH2, 2,)M3()_
M>#/'B&K_ +1/B'QU>-H7A&+4-<NY6$9TCP?:W9BQ(N"FH:P6;S82599/+DCA
MQE)E*.,?C?BO].[*Z^%K9-EF:9?E.#QD50H\+< 8;&+'YM*3=.GA\?G&)IRS
M[,H5;JBZ%"B\.[\L<O<7[-??>%WT+O"3@S-<'Q+G<,Q\3>,,'.&)PW$7B%6P
M>9X'*<2I0E+%Y'PKAJ-'A;*L1"<5*ABYX'-,SH/EE#'4ZR]N_K[Q5\1M!\,1
M31+<6]UJ$$9$D"2QBVLB%*J;^>-O+A"\K]G5FN2J@! /F/E_@JUU;XH:VGB?
M6(YAX:LI@]D\L?DIK-Y;N0/)MRJLFGVKQ$@,66=CF0A]RKS'@?X#>(]=N(-9
M^*<J6UDKBXM?!>G7 EAR<-G6KF-I897."ODP23LX)\R>,@0CZWL[.WL88+6S
MMHK6UMHUA@MX(Q%#%$,JJQHN%4  $@+]>M?SID>2<>>+.:8'B#Q!RZKPIP)E
MV*P^8Y-P'748YEGV+H357 XOB>@I3J8/+<+*,,1_96-E/%9GB84)8K"Y;EZE
MAL5_9RQV"R;#5J&62CB,QQ%-T:V82A:&%HR7)5IX7XHJK44O9\\()1IN2C).
MTH6$1EV@J,#H.,*!\O &/X<8P.N<U/117]'QBHWLV[V;YI.3NE:]W=Z[ON]=
MSYJ[>[OYOKJVV_-MZA1115 %%%% !1@=<<^M%% !1110 4444 '6@@$8(!'H
M>1110 =.E)@9S@9'0XY_.EHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** #&?PY'^?\ /'%%%% !_G_/YT=.E%% !1110 4?Y_*B
MB@ HHHH 3 '0 ?A2T44 %%%% !1_G_/Y444 %%%% !1110 4444 12'D#U_/
MH?\ #_"O%_&'[/GP<\=WKZGXD\"Z9<:I(29=3T^?4M"OYF.<M<7.A7NG/<DD
MDDW!ER3D\X(**\+B#(,BX@PT,#GV2Y3G>"Y:E=83-\MP69X=5HI1C5C1QV&Q
M,(5%&3CST_9R:;3<EH5*$7!7BGI?57UOT[?(YNQ_9,^ -A-%./ :7DB.DB?V
MGK_B;48U92I7,%UK,D$BC^Y-'(F,C;@XKW#1_#VA>'8(M/T'1].T:R155;?3
M;2&SC QGD0*F[W+[B<G).:**\G)N">#.%U5Q'#7"/#'#^(GAX.>(R;A_)\MQ
M$[U:*?-B<)E]/$--2E>/UA1U;Y+ZH3:Y4FTGS72;2=D[7UU^9OA0,8[=/ITQ
M]!_C3J**^OI-N+NV[2E:^O6_77=MZM_Y2%%%%: %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex-19_006.jpg
<TEXT>
begin 644 ex-19_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2* X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLWAJST1K:]\2WVGZ];VJ>,KBSUANE^"?Q%^(.G_%_P#X)*^+_A'\8?B1\;/
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M[?$N.X^&'_!4;_@E]^R_KFF:U\7=1^'_ ()\)67QM\1_LMV'Q)_9X^'?[/\
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MTB'1O#$.IZ?H=OH!T/0-<;Q-XXT73]-\7>*?&/B#6J>M_%/X[?LH^*?CU<?
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MX7:[#\3-1\.:;H2/=:+X/\?:\?"]_P" +/P&UGXA@T;6-<@\16EE>:1J>?\
MLN_\$S(?V8?%7[*WB#3OVHOC1\0=+_9$_9Z^+'[*?PV\,>+/"GP-TW3]1^ O
MQ UWX*:MX;\*>)[WP?\ "[P]J=]KG@V#X!_#Z.^\:V=S8>(O&6J:=/J>H7.G
M6NHZOI&IW4U5H6B[S3F[J\91T<4KN,HS<G%\O,HJ"5N1NH/EBVX\TD]8QE9M
M.,Y64GHFI4XTW-<UO:2J/7F48?+'P?\ VJ_'7Q-_8_\ ^"+/QH_:9^#GP;^.
M?CG]K3XY? /5K#QC?7E[ILWP4^)'Q(_9R^*/Q-TKXO\ @KPEJ'A#6[23Q?IE
MCIWQ#\$65GIOB7PS%X2TCQ19/I6JZW;K?6;?2/B+_@H]J.B_"FU_:YM?!'AN
M^_9!M?VPKW]D/Q/J#ZUJ,'Q3T;3+#]J6[_8KN_VD[6*"VO?#NJ>$;;]I"T.E
MO\(8;5/$,GP-D3XX1_$;_A+UE_9\CV_A_P#\$S=*\ ? S]BCX"1_M"?$[Q-X
M7_8-^,_A#XK_  7U7Q%X7^%\>N7.B?#'P#XO^$_PS^%?BV3PWX1\.V&K^$-&
M^'7C76+?Q-K<5E:?$'Q5XP%MXFM_&'AW2XSX4?M=-_X)X?#[3+7Q;\-T\:^)
M+W]F3QC^T]8_MBWG[/VIZ?I=[8:/\;K3XQZ-^T3<:+X<\9OLU33/@/J_[0>A
MV_QTU?X42Z9>:I/\0KS6-!MOB!9_ W5[[X+RVW!SCK)4E-R4$I-J#> O!MMP
MBW2IXN"<8RE[;DG.4O<FLHJ2IV>M7V:C*=U9S3S!J<592:4ZF#DXR<5R*<8J
M-IQE\\2?\%&_VA(M?^(FNW/[/OP@M?A'\&_^"FOPO_X)[_$.ZM_C9XPU/X@7
M^F_&OQ=^SO\ "_P%\5O!NF2?!S2- N)])\:_M'^#]=\8^%=;U+3C'H>G^)O#
MFAZIJ%QI.D^,/%/Z#_M._M!Z=^SC\/\ PYXHET:/Q+XF^(/Q@^"WP&^''AJ?
M5#H5AK7Q(^.WQ-\-?##PF-;UX:?JSZ)X8T.[\1R>*O%NIVVDZQJT'A;0-9'A
M[0?$7B1](\/ZI\QWO_!.C2KOPS\9?#*_&GQA#;?&K]NGX7?M_P"N7G_"+>$7
MO=%^*WP?\<?!3XB>#_!&A VJ6H^%B^)_V>?AA)J6G:G;ZCXYOM-7QA8OX^C;
MQ#IMSX;^DOVM/V7? W[8?P-\0? _Q_KOC3P?;ZAK?@CQIX4^(WPPUN/PM\3?
MA;\3?AAXRT+XB?#7XG?#CQ'/9:K'H7C#P3XV\-:+KFE7-Q8ZA97"VT^EZK9:
MAI-_?V5SBN=1][5IX=M*RE**I8?ZTDU97=2-?V>RO+=1E%T]7\4K647&MRM\
MW*I^UK^PNG[W*J;H>TM=Z2T<HVJ>&Z_^U%\>/ACKWA3X1?%?X3>$+'XI_&;]
MJ^W_ &;/V:O'>A>*+=OAC\7/!I^ .L_M'>+/CYK7@Q=8UKQ[\-(/AKX/\!?&
M;P=J'P@UK5]2U7QS\2?AOX;L-%^(6@>"?BSI_COP9Y'J?_!17QCX3F^+O@7Q
M3\.?!]S\7?V;_P!N7]BW]DGXLZ5I'B'Q!9^%?%_P^_;B^)GP(\$_"3X__#O4
M+S0[R[T:<^'?CI:>(?$?PIUT:ZWA_P 8>!/''P[M_B/XATJV\/?$OQ)Z5=_\
M$_;WQ9\./ 5K\6_VI?CA\7OVCOA?\:?!/[0O@']J;Q'IGPK\+^*_#'Q*\ :%
MKGA'1M'TOX9?#3P%X(^$EM\(-7\#>+_B#X \:_#B+PHEWXI\*_$WQ_?R>+[+
MXAZKI/C_ $+4\?\ _!/[PM\1/AE\<]#U#XE^*/#?QJ^/WQN^!7[2_BKX^>$M
M \)Q:OH/QO\ V8]>^"WB7X"WWA#P5XLTWQCX<M/AE\.]3^ /P\LK3X:^()?$
MC:UHA\7/X@\4ZGXR\:^(O&M[3347[Z<DU:T7K&^"<6KKXDEC8U-(QESPY$O<
ME&7S-NRY;KW;M*TFL6I*5K^[=X25*W-*/++G<OWD9?"7_!37X\W/QO\ V#?^
M"[/P0\3^"M&LK?\ 9(^&FH^$-$\16FJ75XWC+_A,/V6_AO\ M':!K]UHUU80
M#PUJ_A*]^(%GX=$=KK&MV^KW/AQ?$<;Z0NJGP]IFY_P52^.7B;XU?L9?\%E_
M@S\.?"'@C4_!W[*'[(GQ0\-?%W5_'M_K5MJ?B'XE^,/V5]1^.D^D> 8M*L+F
MTT"7X._#'QE\*OBGI7BG5K?Q-;?$/QSJS_"V/3_AM_85[\3[?Z1\6?\ !,71
M/'GP]_;X\!>,_P!H[XR>(/\ AXEI7@K1_C1K<^A?!^PN?#<?A?X(^"O@1J^K
M_#BRTCX<Z?::/K_BOPCX*L$O7UT>)/#6DF*PET;PM:ZQ'K>N>(:?QT_X)?Z=
M\9-?_:SU;1?VEOC#\(=#_;T^ LWP8_; \!>!M$^&VM>"OB7KMM\(KOX(:'\7
M?"%I\2?"?CC6_A3XYC^&ES:^"/%<7A77FT;QAX4\->#8IK+3/%GAR/QE=S.,
M91J0M\=&FN:[Y?;QHN#E+2[A=:VBN9RIR4%&,XK1R:4'%.\*LY6?Q*E*=&7*
MFFO>TG:[]V*E%2<I1D_OGQ-XFUCP/\$=>\8^&M#TGQ)KGA#X87_B31/#NM:_
M=^$]%UO4-!\*OJ=GI&I>)=/\-^+[WP]87\UJEI<:O9^%/$<^G0RM=0Z+J3Q"
MTE_-'X4_\%$?CCXB^"?[)?Q2^+?PC^%G@6]_;]L/@_?_ +,.D?"WQ'\8/CYK
M_AW2/&7[)OB?]IKXD>(?C-X!T3X1>$M=GG\#67@K6+#P_P"$OA;K'B]/%%WK
MGAW2-=\9^"-'MM>^(5C^G.K_  ]O=2^$.H?"O_A--;N+S4/A_-X"N/'^L:;X
M:NO$MS]JT ^'[OQ3>Z7HFC>&_!S>(;B%Y=2:WTWPWI7AB/5'!@\.QZ4@TD_$
M7C#_ ()K^$_$G[)/[*7[,^@_'+XP_#3QG^PZGPLO/V6_VF?A[+X3TKXN^ ?$
M?P:^'6I_"'PGK6O:9J?AW6?ASX\T[Q1\+=9UKP)\7_!'B#P>W@/XDZ!XA\06
MTOAS0GNM+DT;2<KUJTM94YU(N.B4G"5;$2JRBKIJHH2P\HJ<E%I58Z3DG'"C
M"4*&'INRG3H\DM6X^TA1P\::;2=Z?/&LFXQOK3DTX)Q?B_B[_@IA\1OACX1^
M$TG[1?PL\-_L=:G\0_B'^T'\-8/C/^T6OC;2OV8-7\2?"+6_#,'P1BOO&L6F
M:-KGP.TO]L_P=X@U'QM\-]6^.5GX=O?A9<^!/B#\/=9\._$OQSI?A/3O'7H/
MQ5_;[^)OPCT/_@H#+XC^$7A!O$O[$/[ ?P@_;E32;?QKJ$UIXTG\>>&OVJ]:
M\4_!W4[ZUT2ZM]"N- U/]E;6M%TKXAZ//XHT_4K;QGIVMOX57^PI])UGUZ^_
M8Y^(=_\ #G3/ 6N_M4>.?BHWB#P;\5?!OQ_O/CQ\,OA!\1?#G[0<?Q;A\#:7
MJ&N^*/AAX=\+?#GX;>%M4^'WA3P;/X0^%>@>$?#>G?#*QT;Q+KTOQ.^'OQ7U
M;4]5U+5/#_&W_!)OP%JW@_QC\,_AU\>_C+\*_A=\2_\ @G?X-_X)N?$SP98V
M?PW\9R>,OA!\)O!WQ>\$_!KQ7/XM\;>"=7\7Z5X\\(Z/\=_B9%XEU'2=9MK3
MQV+WP^]U;:/>:#)>ZI%13;2@TK2=W=VDOJ\HQ^*#:MB(PFY))355KV=-0L]Z
M;CSQ=12Y+PYHJU^7ZQ"4[23^)T)5(*+YG%TU)5)RGIE7MW<>(O\ @K-^SUX\
M\/Z7H^F>,?&G_!(S]IS4(?[0DNKG3EO6_:1_8NU7P_I^KW-I';7EYI>EZAKM
MY')/;P07DEK<7)A2-VCCC]\_X)=_&OXO_M(_L$?LQ_M ?'&^\,ZE\0OC1\+/
M#'Q.U:\\*VU]8:8[>-=-M_$$L TR^,G]DBQO[^^T^QTJTNK^ST[1[73+6/4+
MR2*:=^X\+?LB6?A?]H/X._M"/\5/&?B;7?@Y^RYXD_90T_2O$NC^"UB\4^#O
M%WB?X9>-/$'C;Q+=^%?#WA6&/XBWGB/X0^"FCN/#NF:#X&L]';Q'IUKX#BO-
M6L-6T3;_ &,/V7K;]C/]GCP%^S;HWQ.\:_%+P9\*[%_"WPYU/QYIG@C3M<\-
M?#C2BMCX*\$RS>!_#'A:UUQO#6@V]G9WOB;6;6\U[Q%JQU'5[NXM+:[L]'TO
M9NFO;J*DDZD_8WU4:7U_&5HJS;<9.A7H7O=^Y*$I72YLG[22P[DUS1I4XUK6
M]ZHL%AJ4WHDI16(IU=DOC4XI)OE_-[3?VX]?^$;_ +0M]\-/V1O@CX;\3ZQ_
MP69^'O[%/Q BT3XKZQH-KX]U_P"+_@7]FG3;+]I/Q3J]C\$_/UWQ]JVB^-/"
MFA^*- N=*M#X;T3PY:R6?BGXB7GANUTKQ7^@W[(G[07Q+^-=Q^TOX)^,?@;P
M3X'^)W[,'[1U]\!O$_\ PKCQ;K?C'P-XLL]3^"WP4_:%\%>+-!OO$GA?PEKN
MG27'P^^/7A30_$6C:CITYL_%N@Z_/8W]QI-WIZQ>&:K_ ,$U=!U2;QI<-\:?
M&D,WCC_@H-\.?^"CNHLGACPBZ0?%WX7Z=\-=+\-_#N%6LP?^%-S6OPC\$C5M
M-W+\2+N0>(7MOB?9#5[)=&^J_@E^S[#\&/'W[3/CZ'QIJOBF[_:?^,NE_'#Q
M1INI:3I.GV7ACQ3I/P<^%?P&M=+\,2::D=RWAX?#OX*?#U'M]:DU35'\20>(
M=:;5S;:W!I.D84^9*":27(U)65DU1P?+R\J25Z\<8W964)I62<.72IK.3@[I
MU$TVY<W(ZF*YN;FO=JF\*EJW>$G=M/F^<+C]M^]N?VV_$G['UJWPV\'^-_"_
MB3P(-$^&/Q6O?$G@CXE_M _!;Q/\-M$\=>+/VC?V9M?U2"U\$_%70/A?XFO?
M%7PS\;_#'P[!J_B+0[OX8>/_ !?XB\5>'!%X-\&^-.5^$/[=_P 5OCOXG^"G
MBCX0? ?4_'OP!^-VK?%?16\4OX<^*?@FZ^$ND>#X?&4OPJ^+'BCQ_P")?!+?
M#GX@>!/C)>>%]/T+6O#_ (!)\6_"#4O%GAZZB_X6SI@\27/AGVKXL?L:P_''
MXF>&/$_Q3^)E_P"+_AWX!_:(^%W[4?PR\ ZAX+\,KXE^%?Q0^$/A[PKI7AC2
M?AW\4K?R=;\/_#;6-<\/ZMXR\=: VD7WC+Q5J7C/Q7X1?XB:?\)]<UCX=:EY
M?^SQ_P $Z)?V8?'GB2?X9?M5?'UOV<V\<>/OBK\,/V.O$4'PSO\ X(?"OXD?
M$G5_$GB/Q!-INO:5X%T/XV:_\--)\4>)K_Q+X+^#>I?%6'P)X9UZ5]<:RU+6
M[70=3T&XO93NM):J[U4DTGIS)SIRE"*CS*-6FJG-&%7EIQ*_O.._NI)V5O=:
M;CT=IQC.?-RMTZCIVE*ES5/B_7/VZ/C#\<?^">6D?M;_ !__ &+OV9O$?[/W
MQ1\8_L71>"_A%JWQS\6>/_$*^(O'?[7_ (0^&EYXM\;:3JO[/6E>#KBW^%?C
MK4?A9\1/AAI^F:S+J7BM_#>I:OXBG^'.M/IOAG3?K?XS_P#!0'Q1X-\&?MU?
M&?X8?#O0/'?PH_X)O>*+SPY\?=%U+7;K1_'_ ,3/^$*^"OPX_:(^.\_PDO1$
M_ASP]<_!WX1?$S1[WPM8>+8-6/QO^)VC^*OAC<W'P4T#3-$^+7BC5M/^":_A
MBT_8(\"_\$__ /A<_P 0+KP'\/?$WPOU[0OB9>:%X&_X69-:_!_XW^&OV@O!
MFFZDEEH5CX!N)$\=>$=$T;6+Z#P3:#4O D=YI*V=IXINQXVAZKQS_P $_?!_
MC'5OVJ["V^(/B;PY\)?V\-)L+#]K_P"$6FZ?82:+XZU%/AII/P:\7>)/ACKD
MLZZQ\']?^,GPC\/^'/AA\9M0MCXKEU?PIX;T77OAJWPI^+XU?XK:O3>G*I<J
M4^9:3E'F6&PJYI1<N5PE6CBHRM'VCBZ6KBJ?(HIIIRBV^7EFXN$6X_6:[M3?
M(Y<ZH.@US-0]ISMJZJ*?D_Q:_P""C7B'P!I'_!2#7_#'P_\ !_C30?V'OV)_
MA/\ MP^ M9'B?7M(B^,_@OXD>"/VD/'LO@C5K*;PW<3^!-3MM-_9VNK+2O%-
MM+XI@O3XPL-2O_"^F-I%SI%[VGQF_;LN_AU^T_\ #C]FA%^&O@'Q/\2_AO\
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M/$GPZ\+_ +/OQ%M?"?Q,U?PAIDGQOT[Q5>6R7WPPT^[KW_!,CP/K7[/GP_\
MV.IOBCXKU;]D?P1\&/V<O@JGPI\;>'?"OB[Q19V/[-&IW.J>%_B%X#^)8M-&
MOO 'Q5\:"#PII7C?Q7;:#K5KHNE>#-#OO@IHOP=\:QMXR'-W/_!+'3/^%B7'
MC/2_VHOC=I&@6?[>LW_!0GPAX%3P_P#!O5;'PS\7/$GAGQ#X4^(?A^?Q+KOP
MXU3Q5XD\&Z_I'B_Q/9>$]/UK59IOA]I^IVFG:9)J5KX;\++HNB<>>/,VH^U=
M]-Z?M(:M+6+]FZBM%S7NPE%0FY*,>]RRT][V5E:6U50JV:;6J=147+F46E.<
M&YQBI/\ 5VOQE^.O_!4#QQ^S_H'[7E_X\^'/PSTW6_V0_P!J3X$?#GQ9H0\8
M^-;V\\0_LD_'G0_ ?BBP_:]T*TM? POKU/AYX2UWXN>+OB-\-+.VNM(T70_V
M7/CO>-\5DTS0%UBW_1[X!^'OC=X=M_BVGQH^(%]\08-8^-_CK7_@_-K>@^ _
M#_B;PE\&]3AT5_#G@37X/AOIFG>&=1B\,^(H_%MOX-UN:;5O%^K?#6;P3=_$
M75'^(3^*+*Q\Y^*7[#GP'^,WQO\ $/QQ^(ND:IXDU'QK^S-XG_94\>>!;_43
M-\.?&GPZ\0W_ (IDL=4U[PP\1@N/&WA+P_\ $SXV>!O"?BE)8]0T?P1\=/BS
MX<MV6P\8ZK'/#<DXR2YER.3A?E3DH0K0@Y6;CS3@\+4DM(1Q$ZJNJ,5*]&FK
MN-Y*/.ES.,7*=.<XQ;2;C":Q$(R^*5"%-V]K)Q_/_P#X*!>-?%WC_P 3_LHZ
MSI_@GPEK%E\+_P#@KM\ / /P2U9O$%_I2>.]1TGX5^/K?Q[=>(=;.BZL/#&@
M^'OBI>^(_AIKHTC2O%EY!J'PPUG78-$U;6(]&\.P>N^#_P#@I!XCMOA[XXLO
MBY\.- T7X[>"_P!O>X_8!31/AI=^._B+X%\3>-[CPGX=^+VG?$#P];:=X+'Q
M%O-*LO@3XBE\9ZKX+B\-3:M<^+/#.J^"[/7[?3[^U\8VGM&I_L">%9?@O^QA
M\%=$^*'CS2]*_8O^)/PF^+GA[Q5JMOH7BGQG\6_'GPGT'6M(75?B_K&L63?V
MW+\2-2\4>)O&'Q5U30X= \7>)O%^JOK.F^*O#\C7\>I><^._^"6_PZ^(WPZ_
M:.\$:]\7OBGHVO\ QX_:YT']N3PK\5? I\->%?B/^SY^T7X3T/X<>'/"GB/X
M1:D=(U724T30=(^%?AJRATGQAH_B?4=1M=9\=V>M:_J=CXCT^U\.TY<BY$G.
M'MJLV[<LG'FRV//%.7NSJTJ.+3BY-)JBN:+<:D849-N;:C)TH12O*2BU','R
M-J-G"G5JX5II)M.JTI)2IOQ7XT_MF?MDV'@?X,6L'PRT'X0>(O$G_!3;X#?L
MO7'C;Q7X=\>Z#I/QR^ _B?4M)\66/Q*^''@SQ7::=XT^%'_"?/;S?#OQ_P"%
M?']CXOU'P=#I7C[2/"VK^*H]9\&_%"P\0A_:)^(O[&?QO_X*P?%WPE\)_A]X
MK^%7A[_@I!^QO9?' WGCC5O"_BJVT7XX?L<?\$[/A]XCU'X6>'+'P;K.F:[X
MET7Q+\3+CXG:J_C#Q%X9T_7DM;WP[:%]9\3W/B/PQ]_^+?V /$7Q$^"G@'P/
M\2?VN_CI\0?C;X!_: ^$?[2EA^TKXC\-_!:W\3O\0/A#J-C+HFBZ?\+O#/PV
M\.?!GP[\.WT.+5=%A\(:)X*LVCOM=U/QEJNK:[XVU#6=?U?,^)__  3:T3XI
M>&?VP?"FK_&_QYI]E^V?\9O@9\;OB%J>G^&O QUOPMXH_9_\-? WPAX1@\$2
MW6C3Z/!9:_H7[.7PNB\:1^(]#\11WM[_ ,)G>>&(?"(\0Z5;^&*IN,>?GLWS
M12DD_>IO^SG46RDE-4<7S12BG/E<;1G"V=2%233CHK.2BY/W*D89G&F]&TVI
M5L&T_>:IJ:ES3B[Q?&K]NKXD^'_&/QY\-_L]_ +QA\>]:_9;^)_PQ^&'Q%^&
M>A>#/B$_BKXI:WXY^'WPD^,?C*U^&OQ,LM#D^#'@.^^&?P9^-O@?QIHEM\3/
M$QD^+'BR/Q)\-K^+X.Z=8>'OB;XM['X-?M)?M/?&']J+]H/X6V_P8^!OA[X'
M?LQ_M$:K\$/B)\0KCXW>.=4^)FOV&L_LM? S]H?X9^(/ OP\A^"%CX=N-4N[
MGXW:%HGQ$T?Q)X]T'3_#-J;Q_"FN^.[C1"^N8/C7_@G:VM_M/>-/VDOAS^U3
M^T-\!K7X]:1X$TO]KOX,_"R7X;2_#7]H^?X;>%QX(\-Z_P#:OB%X"\>>/O@C
MXMU/P%#I7PW\8>-O@=XR\$>-]5\ ^&?"5MX?\2^$O&OAZS\=GZ2^"G[/0^#/
MQ)_:;^(T/CS6/%,W[47Q<T7XT>*=!U+1=$T_3?"?BO0/@]\+?@-8VGA*YTR&
M'4O[#F^&_P &?A]!?6?B"ZUR\E\1V.KZY:ZC8P:S)I-OG&]XWV4:CDG_ ,_+
M1C!+EW@_>G&[33^-*RC+:5]>6VLH:Z_P_>E*REK&I%\L)-74HWY6[WC\[^)?
MC'\:;_\ X*@>%/V98IO DO[/UU^PUX]^,&O>'+ZPU.?Q#K_BFZ^.7P]\ WFH
M:O>2FZTJZM-'T(R:5X6T"WL=/MXX?$?C2_\ $>IZ^VH>'M.\+_GG_P $H?VD
M?B9\(_@7_P $M/V?->^&G@<?!3]I;P-\?/!'P]\:Z=X]UN^^)^C?$'X06_Q!
M^+<E]XN\)7/A.'PTG@WQ9X5\-^,K"Q?3O&>K>(].U/3/#VJZSYDOBS5-#\'?
MKCXU_98_X2']K+X??M=^&/BEXJ\$>,O!WP3\;? ?7_"-MH?A+7_!OQ \%^)O
M&'AKX@:/'K@UK2)O$6C3^'O%OAQ+F>?PGKVAWVMZ3J%UI<E_I\L5IJ,'@7P?
M_P"";'AWX.Z=^PII&F?&GQWXCT_]@77?BUK7PV.O^'O!4>H>/Q\9/!OC?P#X
MBM?B==:)I.D6MPVB>'/B%XA/A2?P/I_@<6VKP:)?^(X/%%K9:AINKN#<8QNE
MS.T*G,K\T5C,=5C)N-OAHUL-R:J490G%W27-$H-S;OHE.=-Z^[.6%P5.R6OQ
M5*.)531Q:J4Y*UVXP_L[?MU?$K]HOQ9^S/XL\"_ /Q?K_P"S/^U1\._$'Q&T
M_P"(Z^"_B)X*O_@!H$OA&#X@?!75OB3K7C_0=%\&?%+3OCMX/N$@O#\([R8_
M![XBSZ/X,CG^,/@[6G^+>D>_?%7]H/4;7]HOX:_LA?#6Q\+WGQ3^(GP>^*7Q
M\\2:YXX34KWPAX'^$7PP\4?#GP#,;CP_HTMEJGBSQ9\1O'7Q0T#PSX8T<:UX
M<T32/#>C_$?QWK.NWVH^#O#/PV^)OC/[)'_!.V#]C[Q#_8O@C]J/]HCQ5^S+
MX-UGQ1K?[/W[)'C"Y^&4OPQ^ DOC&Y\13WVBZ+XYT?X=Z5\<O'G@GP?9^*=;
M\._";X?_ !&^)_B/P3X#\/W-C)<Z#XF\7>%_ _B_PKZ=\?OV.;?XO?'+X+_M
M,> /C'\0/V?_ (Z?!SPWXU^&8\:^ =)\!^(K3Q_\$_B9J_A'7?'7PJ\=>&OB
M#X6\4:-J>FOKW@;PSXK\&:S!#:ZAX-\8Z5#JR)J^F76KZ#JB>OLUJHM_O+V<
MXJ4';F:3A/DJVYN16G1YK)NT#3_G[W2?L[-\LFI]%+WH<U+1<S]VJKW2?.?D
M?^PAX^TSX=?L<_\ !(CPIXL^ 'PW\7CXF?\ !0;]K'X<Z'?:WXKN=9OOV;_B
M?8:W_P %#?'=AXQ^'$=QX$2'QI>V7A7P-\1_AE'XKN;[P#J=KIWBM-7@T>[&
MJ7VGZ7]T>#_^"E.@:GX__:@L/&-Y\/\ P=I7[(:?M/:O^T'\$];?Q-X<_:F^
M%?PS^ &JZD? 'QZL? _B..RA^,?P2_:/\ :;:_$_P?X[\$Z7I'AWPI9^,? ?
M@VUUOXD:QJ/BK5?!G6^ ?^":_A7X=?#O]DGX<:5\;?B?KNG?LA_M0?$3]J_P
M;K'B[2OA[>ZWXF\=?$JR^.NDZ[X6\22>'?"?A;31X"ATO]I'XJBQM;'38?&$
M6HW'A6^E\9RP>'[NPUSKO$7[ WA+XJ?%+PU\0_VAO&+_ !RL_AW;?M,Z+\-M
M/U_P7X>\/^*+#P)^U7;>(_#_ ,0/A7X[\>Z!);ZEXZ^&/AGX?:_'\/OA_P"%
M;73?":+I>D:/XG^)MY\4?B)H/A;QEX>3<O8PC!\M54IIN5Y0C66#PE.E)1U4
MHJO1:G%^]."YG5<U%SBG'EJ-S3=-SIMJ#BIN'UO$SJJ]DU*5"LN65VH3T4.6
M4N4\*_$C]H?XO^'KNV^*WP)\!P?L^_&K]D74/BG#XQ\.^/+/5;GX>>-?$6GZ
M1;W/[-_CSPWJ,J:G\1)]9\'^)KGQ7I/QD\&:?H'A&0^'?%'A'6O"NBW4?A'7
M_&OQG_P3F_:+\=7W[(7_  3M_90^!>C>"+SXK^$O^"._[%'[2WBW6_BE=^(;
M7P;#HWC#X:^'?AW\)/ D*^%[>?68KKXF^(/AW\54\0^/X$UI?A)IOA'2]6/P
MZ^)UQXKM=$T_ZR_99_8#\0?LP_#Z]^&;_M@_M$?'+PAX5^'>H_!W]G?1?C/:
M?"2\L/V?OA?=:?I6FV.DV,G@+X<^ M:^+7BK3++1-&TJR\<?&76_&NJ:/X>T
MB#P_X2MO"^GZ[X]7QIE?"W_@G!H?P&N/V8?$OP4^,7BOPI\1?V:?V3?#'[##
M>+-=\->'_%.F_&+]F?P+)HDOP[TCXH>%$?0K*;XF?#"\T:[U_P"'OQ#\*7WA
MC3],\2>,OB WB+P5XJ\)>*I/!ME34/;U)Q4HT94FJ<;KVD7SXN=&-233C*5)
M5*$:DTN6HHM^\E44KC*7L(0ERNLJD7.2BU3E:&&A5E3C=2C&KR5Y4X-MT^9)
MM2]G)?/5S_P5ZT;Q3\(?V4/B1X8T'P-\$+W]JKX9_&+4?!EQ^U%XAU#PO\*+
MC]J7X/\ B"U\ W'[#VI_&?1XK;P=X&^)7BOQ_:>/M/T#XC>)Y)[?6M.^&]W_
M ,*\^%WQ.U+Q!?VO@CU[X^_\%!O'GP4MO^"H<L'PM\(>(V_X)X_LU_#K]IW0
M&G\7ZUI(^+?A[QCX#^,_CS5_ ^LPQ>&]3_X0/7-'A^#=_HVF^)+"X\9Z?JTN
MMV6JW>B:.EO<:77<>*O^"=/A'4?V=A^R)X4^(VKZ)^S5KWP"\0?L\_$;X:^+
M/!W@_P"(X\7Z7XNO]2U3Q+\:-/U36[.RA\/_ +2%SJVN>(?$-IX[O-*\2?#Z
MZ\5ZY<>(O&/PB\97>C^$D\-\O\=?^"7G@GXQWG[1ECHGQS^,7PH\ ?M6_LB>
M'_V1/C;X!\)CP1K\'B/PYX#\-_$SP?\ #GQE8^+/'_A?Q7XST;Q%H7ACXM^+
M-+\2P6>N&T\=#3O!\VL- =+\1)XNF7,U/E:C)^U4;7Y%*4*;IR][FE&$:L:T
M87<VZ,Z/M8JM"LY-63C?FE%<C=^7GY54J*2;ARQE*=*5)SM&"C5A4]FW3G24
M>S^(W[4O[2,7[;MK^R!\&?@G\&/$&G6?P0^%_P"T3XD^)WQ+^-WC'P@UO\/O
M$'QLU'X;?$+1-+\&^&/@GXUGN/'6E:%X>U:^\ VDVO#PSXDU*_2?Q3XC\$PZ
M'!I?B_F/V??VZ_B/^T5XN_9N\6?#SX&>)?$W[,W[3/AKQKXHB^(<?@WXD^#]
M0^!7ARR\/7GC#X+^,?&WB/QKX=TSP%\5M!^._AVV@L;ZR^&%]#>_!WQWJOA[
MPY'=?&#PEJVI?$CPW]">'_V67T3]JNV_:MN_BSXO\2>)4_9K\/?LQ:IX9UO0
M?!,&D>(/#7AWQCJ'Q"A^(&JWGAWP_H%Y;?$S4/%NKZF=1FT!=$^'1\/7?]DV
M'PWL-2M[;Q!#XE^RG_P3KM_V1_%US8^!/VHOVA]?_9D\.^)_&'C#X(_L?>)Y
M_AD_PG^"6L>.[WQ)?:QINB^,=)^'FF?&OQCX$\,'Q7K-I\+?AIXZ^)>N>!/
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M)]'\*W]_XPU/1;3PMX>\2:QI'YA>%_V&_P!J+]EF'X5_#;P-\,;K]I#0Y?\
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MO%\&B?DO^V?\(/%C:G_P5]^(/Q2^#6DS_"#]I_\ 8I_8^_9W^#@^(WQ8\#^
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M^ _@KX7^/OCG1_"?P<^,_C;7]/\ @YXAO=3T=/B_+X.^'7@7QMKMI\/[/4-
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M7X8?$/X*_M,^-_#7Q$\3_LN:;\ ?VE-%_9TN/C%\7OV=/BGXKT2X\3:;\2/
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MG[8'_!%;X9?'GX<']FKQ1\./@U\1/^"LG[:OPEU7Q7<65]\'-"^&NC:)X/\
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M^BBN:3NE%67O_7%@XQNW;WI4\54YDW&-/"RG)^RJ4ZQ_4717\\7QF_X+*?M
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MG+#X ^$OPK7QQ\/-+U6'1?B#XR\:_$_P%HG@W3H/&'XX?M\_M-^,/'W[7?\
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M(_CKX,\4^ ?$?PG^)WA#1M.\'ZG\0OA';Z#XCTV\CT.7Q?H6K0^(? 'P_OM
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M,4JV_'SU;;;;=VVVY-MMMN4FVVVV4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7T %%%% !13(Y(Y5+12)(H>2,M&RNHDAD:*6,E20'BE1XI%)W)(C(P#*0'T
M%%%,$D9D:(2(942.1X@RF1(Y6D6*1D!W*DC0RK&Q 5VBD"DE&  'T44$@#)X
M ZGT]S[>I[4 %%("& 92&5@"K @@@C(((X((Y!'!%+0 4444 %%%% !1110
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M)-.;7_$-[X1NM$^(_AC36L/"UAXHUBSU#PGXL;P/#JOC?TG7?^";OP\UY_\
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MN_\ #'P\T"?1=-B^'7A'PW:Z,/&'_"=:E9ZOIAU:[U/49[[4%N<SQA_P3Z\
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M:^NO"[V5CX=N[GP[IVC6FJW.K>+=6N?$C_@F_P#"KXDG]M:"\^)OQC\-Z/\
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M-^(;VR\936=Y86=_J45IY5REOJEQ:WTL0_0CQW_P3Q^'OC+PC:VNE_$WXH>
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MH_C/Q%XD_9N_:8_9F^+'P[^/.HZ1H.LIXQ\"7/BBSU2-/@5\6/AE\1_!^O\
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M2/C!K'P_UO4M4^$=]=:M\*9?&GQ6\8ZA+%(\7Q0F%[!"GQ1@MK6&W7'\>?\
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M_P  _'+Q)\-/$7[*OP\UO5_C)KGBO]GOXRZ9X\^ NG:SX(U[Q'X0^-$WP/\
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M7@/1O'WP?\1?$GQ"MY\$[KQ'\2O"OA(_#Z?QWHWC^&ZBMQX?OK_VGXD_M?\
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M=W[*WQ5^$DGQJ\#?$^75O!MM\5KOX#:CI5YX%^(_AWXHZ+\<]/\ $,/A>_\
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MCJ=I,_PP\4_%WP.O@GX>_#/[M_86^$7QA^"/C']MWPQ\1_ <>C^%OB!^V?\
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MO;VR\/>)OB[XO\)^&=;\,?"_PU(NGWNL:QK_ (YU;0M*\*^$+6Z\>^*[O1/
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M1FHV:]Z=.A*K!-[NG*59;W]SE=W%>TY/]I?_ (*&>!O#/P8_90^)/P#UZ_\
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M--;<O+.I">\*=65T[1;ASKF@Y6<XQE3G"HFHN$G&,[--/]\*^=OCE^TGX6^
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M+6?\$X-&TO4K/X_>,;'6/"7AOQY8?\$H;#X@^%HM;/C8:EI?@:=O$OQIMY?
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M  2I^+/P0_:"\0_LP?%7PW^UKX@U_P#:VTG]G/7? /[9_P"S)H.B6GASQ_\
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M:          ,  <  #@ #H*_D0^%F@_#"W_X)D?L+_M,:;\;/B=JOQ+^,/\
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M@_IM(U?X@>(OAC\>?V?=5C_9&_9:_:/\*_M ?LKP:=JWASQ'XF\6_P#!+_\
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M1@^7[+Y)ZKO9N[5Y%T^5K:5&A-K=J52-;G5_6FK)[+UT****!A1110 4444
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MCI7C/PCJ^H^)/#NKZS8?$"[T7Q7IMMHFN67A_P *7%Q?:+#\U?M7_MH?M6_
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MUX=U2Y\4>-/%GQC_ ,$KOC_\=OA]\)_^"-G[/7BUOA#K?P9_:4_X)5Z)XS\
MZ=X:\)>--)^)OPZ\5_LX?"']DZ*"3Q?\2-4\?:IX6^(.A?$KP_\ %K5]1N=%
MT?X/?#R]^&^M:18Z-#XF^)EC-+KLLJ[=FDOW:G%+6]ZF+@X-6WE'"2E!+XFU
M!\KY6Y=1*7+VE)2;>BM#"24EULI8R$9MVY5[T>:[2_H!-C9$,#9VI#JR.#;Q
M89&BBMV5ALPRM!!#"RG(,4,49!2-%#3IVGG4$U<V%D=5CLI-.CU,VL!U!-/F
MGBN9;!+TQ_:5LI;F"&XDM5E$#SPQ2M&9(T8?C#\"?V]_VB?BO\2+/X3:O>?
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M4TMJ?ENK7Y+_ &L_VY?VO?A+XR_X*=6WPLB_9N3PC_P3[_9!^"'[9FBP^/\
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MUGX)^#+!?%6N^"?$/A_1/##1:!I/AOP]>/XL\;^*?J[2/VCOCI\,OVP/V?\
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MA#X:\1?L#?M/^%?V-?&=O\+-!?Q+\./$&MZ-\6/BSXRMO'GA6XUCQM-<>"/
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M8'N+2VAEW30(WP!H_P"U-^T'X,_: _9*^"WQAB^$6LV/[;GP3^*6O_#SQ/\
M#+P7XQM+/X._'/X1>"/#/Q)U7PEXO.N_$O5V^*/PV\8>"?$.OW?AWQ1I<?PO
MUG3=;^&L]AJ&GWD/Q0TMOAYYY_P2J^'LOCCX+2?&7XS6/PE^)7Q&\&?MD_\
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M8)KC3+J:SN-/FN=/FDC:2RGEL+N[L99K9HY)+.YN+9V,,TB-YI\!?B@GQO\
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MY3E(A0@N6FHQT5.G&"2V2HJE&,;7=E1H1C:[4:5*+:C&*.J_9B_9V\&?LG_
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M%\&?A1H/[%/AOPIXY^,0TK]@B]\;7GP*BU37_!E_+.OCSP1XI^&VL6GCN=O
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M+XL_9-^%27VH?#V_MH_A5XR7X5G5W\1I/\.#+KGBE;CX'?"&\M=:>:WCCN/
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MM)2?)&$8RLX1C;E:C",8\J7N^XE&[:BJ3ING%-OF:A[.*3E*<G%6E)[K\6/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/O\ 2M1BBN'DLM2L;RQN5BNK::)#^OOV^^S^X#H**** "BBB@ HHHH ****
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MW_!7[]HG]E[XX?ME>&?$X^ &H?"O_@GY_P $TOAQ\;/CUJFG^!?B!-J>L?\
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MPW:>*=#\WPSX3U#Q'K6M6>L7>H?>/Q!_X)8_L@?%3Q'^T#XJ\=^$_%NO:O\
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M#HLD_AW2?$]GH%U=Z;<8GQ__ ."='[-G[27Q:\1_&7XAV'CBU\4_$+]G6_\
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M[07QAU#]H?XD_"&P^+?BBW^"VI?'K78+&#Q5\5X?!]M+;ZA_;OC$:=:2>*M
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MOVE+3X6ZM\*O@Y\&_@_\// WBOQ?9>-OBB/$GQ5U?2KG]I_]J/P5\)=9\7^
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M7.E.<8P5:SY8SE[6C*HX-IN,G3C6I0YDZ:]I&JTJD7&7YN^'/^"MG[8?Q)^
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M;?V?:WWB?P#X$O/"'B_Q"FC^$M&BU73OGW_@HO\ $#X5^(?@AX^\)ZB(-/\
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MQ1W$MFE\MO).D4:RO&9%C16"CM*_EJA\/:AX ^)/C^U_88M]-\-?M!?M ?\
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MM[:>U\1:)HGQD\&7J)>V^N6UIU?Q,^*G_!.Z[^%?PJ^*/[/]MI-K^RY^T?\
M\%"OA?J-_P#%GQI<?$?X??L":9\79?V>_B#80>+O%OPRU:W\'^$?'/PA35O
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M22NG))I3Y9;N7NQYO=:Y(3LI:-2BY)7ZR<;-V]W1N-XH_H6_9"_:4TK]KKX
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MZA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'?\ !2;XW_$C]G3]D[Q#\7/A8?!#^)=$^*O[-WAJYMO'OA6\\6Z1<^'?B?\
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M%GA[QCX:_P"$E\,_$'Q7X9_9B.IQ_#W6-.@USPO=QW?C_3=.E\&Z#X@B\0V
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M ']D?]I;1_AE)X#T?X&>()?B#\4?"'Q(_8K^!7QR\,6%[\2-0^,MQIO@O5/
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M)M+L]+^QZ>MHMZ<R;7>RG.&OSIR^5GULA--R2^S+E?KRPEI\IKYIKI=E%%%
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MQ!H5\GC;5O$P\7:OJ>M_#/X;ZW=^,/&Q\2>,)]0\#Z(LVN26$FKV6J<-;?\
M!/[]F^S_ &4_"/[%5MI7CM/V>/ >N>!]>\)^%I?BAX\O/$6D7/PT^(^D?%_P
M!:I\2+[7+GXCW=CX3^)OA_0?%FE0ZAXJNY0VCV'ANZGN?!<;^&I/-_!G_!3S
MX%_%7X;_  B\??!/P3\7OC5K7QH^'O[1'Q$\*?";P'I_PUM?BC%9?LH^-/#?
MPR^/GAZ>Q\=?%#P9X0UKQ5X%^*'BS0O ,.G>"/&7BZS\8ZG?1^(O FI>)_ #
M)XP>7]IK_@J3^RK^RA-XL'Q0US5);/X96'@'6_C-<Z!J?PX?5/A!X;^((MKV
MQU[Q+X%\1?$+PY\3/%JZ#X;O+3QGXH\.?!_P3\3/&^E^$[S3M3A\+7TNK:3:
M7U*7O-J7O3FIN5]9U/:JLJG-=<S]M.-7VG-95)*;DFTQ<L;*/*K0@Z:C9^Y!
M4W0=/E2?(O91E1]G:+<(NFH-)I=7\1/^";_[*_Q-_:);]J/7M ^(>C_%37-&
M\'^'OBPGP_\ C3\6OAC\/OVC-$^'?VH> -(_:8^%?P\\8^&?AS\>=(\)PWU_
MIEMH_P 2/#6NZ3KGA>[;P-XNLO$7@2VL?#-IZCH?[)GPRT;X@>'O']UJWQ#\
M4R^"/BG\3/CA\.?"WC+QQJOB;PI\-_BW\8-.^(.A?$'QMX.MM2$FM6<VJ>&?
MBI\0O"NC>&M2US5/!'@?P]XMUVP\ ^%_"YU2_FN$_;1^)?AGX2?L??M.?%7Q
M9K/Q:T#P9X%^ /Q7\7^*?%OP ?PX/C1X1\)Z-X%UO4?$/CGX47/BQU\+0>.O
M!VAPWOBKPM>:Z+C2X-6TJTFGLM1"K877SS\7/^"D'P\^!-U\9/"]W\$OVH/B
MAJ/[-O[,GPJ_:P^*.H^"O"_PMO$@_9_^(*?%J"Z^(D&L>*OBMX#T;7M7\%GX
M(>.Y_%_@31Y/^%B>));1E^$'@KXD-9ZY!HHM+KX5!O1W2C>%2K4;;M&*C%3E
M)R:4(N<[THJ=R3BVKN+=1*SNG*=I4Z4$DN:4^:4J<(J/,YODC:HW"WU5\<OV
M</AO^T-<_"*\^(A\5FY^!?Q9\/\ QT^&<GACQ;K?A0:-\5O">GZOI7ACQ1J4
M>B7-K%XJM='T[Q#X@LSX/\6)K?@/6HM8N?\ A)?"^M/;::]AG:#^RO\ !S0?
MB-^T/\3VT34O$6N_M5:5X7T/X[Z+XQUJ_P#%O@/QQHW@KPI<^ _#.E-\/=>D
MOO!FA:=9^";V]\+ZM9>'-%TFV\9Z==23^.XO%&JQV^HP>;_$W]NGX5> K'Q[
M?^%?"WQ'^.,?PH^!?A[]I'XIQ?"&R\%3R^ ?@_XRL?%NK^"/$>J_\+&\=_#B
M'6=3\8Z'\/O'^NZ+X,\'3>)O&T6D>%)+O6?#NDCQ/X"3Q;6\)?MW?#3QOXF\
M-^$?#_@'XL7&N>,_V-=(_;@\'V\^G^ +6'Q%\*]6NM"L1X:M;N;XBK;:=\1K
M"_\ $FD6E]I.ORZ1X8+W#S6'B^^LX)[F-3M!34URJ*J\\9*R2E3J^VYHO=2I
M8*LJEXM2CA:D7?V3@G&TW!P]Z4O9NG*.K=JE+V+A)=54QE%TVI)J6)IRBTJJ
MD^M^#W[&GP<^!]OX+M_!<OCJ[;X4?"W7?@=\#[WQCXUU;QMJWP1^#?B&?PK=
MZA\._A[K7B9M1U>33&N? O@HMKWC6]\8^-[NQ\'^%-!U/Q5?^&_#.A:/I_,?
M#_\ 8!_9U^%MK^RC8>!M/\=:+IW[$>B>+/#7[-.GR?$?Q=JMGX!\/^./#$O@
MCQ)I.IQ:UJ6H'XAVMQX-F/AO2W^);>,+GPS91Q7?A>XT;6(UU,>;:/\ M@_"
M;XP?$G_@FQXM\+:Q^T=HUA^V/\"?B3\>O@MX7TBS\%:9\,O%_@S4/@WX"^),
MEG^T-87M_J.MVGB_PKX<\6^'[OP'I?A/5)+:#Q3JFL_;;[5=(LKNYL?#OB+_
M ,%,?A9\5_V'_P!I?]H*W^&?[>?P?^!7@3X0_$+7-5^.O@/PA\)O"?Q(MKKP
M7\3O&/P@\=:3\&!XD^(/B(#XE^!=6\&ZAXGEU3Q-X6@\!P^&[S3[VU\1ZCK5
MOK.@Z13E*[NY<W.^:\G=2A7]ES2;E;F]MB*BNVYRJ5)1YISJJ06BFE9*\4E9
M/6,Z3GRJ*5^7V5&+LER*G"]H0IR2_2GX$? 7X??LX^!KSX<_#&+7K7PK>^.O
MB1\29K3Q%XDUCQ5=KXQ^+WCSQ!\4?B3JD>J:[=7FI*GBKXC>+?%7C&ZL#=-I
M]AJGB#4+;1K73=(2RTRT^>3_ ,$Y?V:$O]6O+6U^*5E;:E^UC:?MN66@6WQH
M^)S>%/#/[1UKKVK>,9?&?A;PK=>)KG0-&TG6/'WB3Q7X^\4^!HM/D\#>,?$_
MB6]D\6>'=:TC3/#.DZ#SO[4__!3[]EG]D'4?'%E\5/$%]=6_PEM_!.J?&F\\
M+ZO\-[F]^$OAWQQ+%/:>(==\%^(/B%X;^)/C*'1/#D]OXU\1^'O@]X)^)GCC
M3_"%YIFJV_A2^DUG1K._]HTC]K#POXF^-/B3X,^#/AW\3O&P\!_%33_@U\3?
MB7X9A^'EW\/?A?X[U;X':7\?]+L_'%O=?$6R^)5CI&H>"_$G@K3K/Q+IOPZU
M7P_/XK\<^&=%CU$H^K7NDQ!I<O)I;EA%1T24'3Y$DFDHQE3I<CM9.$;-20Y?
M:Y^O/.7-JVVI\[UNY-JK4YDKR:J2O%J1Q7C3_@GC^RO\2/AW^TM\*OB'X)UG
MQGX&_:U^)]A\:_C3I>L^-O%RW>I?%O2-*\":'H?Q \(Z[IFKZ=K_ ,./$'A_
M2OA;\,[;PZW@'4_#EAH$G@;1;_1[&RU.?6KW5O9OV>_V=O '[-/@B;P3X%U/
MXE>*'U/5/[>\4^._C+\5_B)\;_BMXX\0?V9INBKK7C/XF_%3Q)XJ\8Z]<VVC
MZ/I6CZ79SZJFCZ#H^G6.C^'],TK2K6"SCC^+_P"T/X0^"GC?]G7P-XLT/Q=>
M7/[3/Q@N_@=X%UO0;30KS0]&\>V_PK^)7QBMK;QA]N\0Z;K=AIFI^#_A+XT-
MEJ>BZ)X@ACU6RL['4ET]=0M9W^9=0_X*7_!?3=)T?4YOAS\=KBXUG]MGQ/\
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M)W2O&G)Q::M&%1QLJ=3D)14;N246N63>SLI1@K_::4IP3NFN:=/F=YP=3/\
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M%GQ1XXU+4OAKX:T?Q'K^GZ;\%=2AN_@O+%X@\52:I\/]1N/&OC6;Q%J?%O\
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M\%_LL_%C]FOXC?$_]EW1M%T;X7^,?"OPN\*_$'Q+\'/&GQ3M_C/X1OO%.O\
MBOQ/XU_X0#X@_"^ZTFS\+_$'P#^UM%0XI\EU=4XJ,(N_*HJ4)15DT_=E"Z?-
M=<U17Y:DXNG=J2N[S;<GU=X2@[^3A+E:M;W8.W-"+/QAU3]@O]I.;P3^T/X;
ML[OX'3ZA\6_^"LGP#_;_ /#LUSX_\>V-G9?#3X+?&/\ 9A^*]SX-UIXOA!J4
MUKXZ\0K^S<-$@2QAU3P_IK>-#J$FLWH\-BSU_@O&7_!/G]M*Q\)_M"_L\_#C
MQ5^S=X@_9^^)G[??P^_X*!?#7QS\1/%'Q+T/XK^#==;]N7X4_MI_%KX">(?
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M &)_@]X2^)NM:7H=UH/A;XG_ +1/A_XI^.'^'^H0QW&GZ<VI_$GX0?!N/6/
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M_A)J7PWTG]H+5/&?Q"\%R#P)K>BVWQ:N[W7+Z27Q5)+T_P"T9\%?#]K\!/\
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M&<9IM.-.G!6=GS4IX"I"I=\WOQE@(\ONM1]K*U^5*?\ *'\5/ ?Q8OOV#O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\\+:=Y]\2/\ @OS^R;\)O"'[7GBGQK\'_P!J*UNOV*_"'[*OBWXL^&;'P/\
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M#XC\5"S\.:#XDN_'=A\-O'<A\-P)^A?Q#_X),>-_B-\6O^"EFM'XF_#SP/\
M#3]K'_@GU\.?^"?/[*Z^'/#'B+4/&?[,GPE\.?#+QWH'BGPQ-I\VIZ/X?O\
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M:&'DN9/E6(<8J%IQF4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPC\&?$3X:Z%JVF:U:^(E\7^(8YM0MO'WB;Q?%<NITO '[;7[2'C/]G#]A/\
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M[8WQ)_9Y\-_%:31=#\/:M\5?AU;> /A1\9/ ?B;Q1I/A+1_#W@N+QKX>\/\
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M%7XO_"3P=^RYJOP=^(UY\.]4\=?MY?L??!GQE-;^&/!GBFV\2?#;XP_&'0_
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M1;HQBYWII0NG&4JD*:ERRE.G33N[1;J1A%:/7DGB+\JYI+VCM%\[O]H_ /\
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MH_[??QF^&OP>^&GQ]GTGQ;I_AJ\^$&CZ)X9T;X??$KP[\-SXJT?4-,T[^S]
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M7?'[6/BMX'\1^&H?ASX8T+X-^/-,\+:%\*T^%UE<_#SQ1IEGXU\6Z5-]Y_M
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M?LW?#_2O@A9?#3X<6'A&Z_9>M?&"_LU^9XB^(NK:%\(+[QMI&H:+KCZ1X?\
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M'7_!1+X;?"[P?^V7K?Q%^%?QF\.>-?V&O@_!^T+\6_A$NG_#R]\;^*?@)?\
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MVG>([-/CI\-Q>:MX@N_^$&^,B>.O#'VKQ;XUN/[+\[QMXL?6?E;P+^VY\!/
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M;V+RV[W5G:W^IW%P8]BSS*S,$_.3]EW]AG]IOX,7O_!-"\\<ZU\"-97]@?\
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M^"W@3X=:A\0?@EKWB/PM_P %8_%G_!0[4=5LM.\>>$-%N_ VO_M<>/?VH&\
MVEK<'QQ?+XNOYO&LN@+>RRIHOAR%(83+XMET^35]8]4UK]A#Q/X\_;*\'_M1
M>(_#_P '?AIXF\+^,?BIIGQ!^+OP6\4>/M"^(_[5_P"S)XL^&OC_ .'_ (%_
M9L_:/^','ACP[X)\26?@N_\ $?PU\:V7Q%\3^-/B9K'AG6/@AH]K\-M#\%/X
MYU#5?"WWCX+^)4USH5_J/Q-U+X3>%+\_$;XH>$-"3PC\45\8:)J6D^"-=\7R
M:2+W6-;\,>!9+#X@Q> _"EYXB^)/@2TT_5HOA_JVE>*]*3Q'XBTOPY<:_+T
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MQ9\./!^E_$'6/$OBKX@>.];\>:G\._!OB?7$\1^(;[P''IGA&'X=VS>%M/\
MAM=2Q^*=;N?B+=1>#?T2\:?$+P#\-]-M-9^(GCCP?X"T?4-5L=!L-5\:>)=%
M\+:;?:YJ;M'INC6E]KE[8VMSJNH.CI8Z=#*]Y=NC+;PR%2!6\7_$[X;?#ZWO
M;OQ]\0O _@>UTZQL=4U"Y\8>+-!\-6]AIFIZW:>&M-U&\FUJ_LH[6PU'Q'?V
M.@6-Y.R6]WK5[::5;R27US# ZFE4@Z<FW"4)4N5:64\/5PT[66E2IA\1.G-K
MWG&<9<JDH33A:G/VD;*?-[1M];5Z6(CS7:O"->A"<4]$XRCS.+G!_",O[)OQ
MEN/!_P#P2VT.?4/AA_:G["_Q!\+^-?B;-#K_ (K33_&$?AO]D7XV?LHO:> P
M_@N6Y1]0A^-=W\0D'B#^SUL)?"]KX/:6_379?%>C> W?_!/?]H6Y^''B+PA_
MPD'P8&JZO_P5J\+?\%&;6?\ X23QPNGP^!O#7[0WA#X]_P#"L;B3_A7\ER?%
MEX?"8\(?\)#';?V/ -2/B/\ LV7["/#][^EFO?M-? KPQ^T!X-_9=USXE>%-
M.^.?CSX<>*/BMX=^']SK>EQ:Y-X*\+>*_!?@J74;NQDO$N[*7Q!XC\<65AX-
MM+BW2?Q>V@^-6\/K?#P9XB^P>I^+O&?@_P"'_A^_\6^/?%?AKP3X5TI86U3Q
M-XNUW2_#?A_35N)X[6W;4-9UFZLM.LUGNIH;:$W%S&);B:*%-TDBJ;E-N52K
M*6M6M.M.6B4JDL10Q$VK627M\/3?*FDFI0T4FDJ<52C&G3]U0ITJ2@KNT*>'
MK4*2:=W=4*]1)O?W9OF<4W^-FO?\$^/VN-=^/6B_$_6?BA\!?%UMX#_X*6V7
M[8G@_P =^*[+XCW'Q7UW]G_4/A3\6OAAHW[/.N0P))H/@_3OV:],^+FNP_"K
M0_"NJ:AX/^*WE'Q'XCA^$/C;7?'?B'QM<\6_\$\/VC]9_92_;#_9<T_QC\$'
MT_XT?MP>+/VI/A)XMO+KQ[97MEX5^(O[8ME^V1XI\/\ Q'TV#P_J-O9^(=%U
MEK_X8>'U\+W&JZ;J.E6]EX[U+4+"\NKCP7:_L%J'CKP3I.B:;XFU7QCX5TSP
MWK%J]]I'B#4/$.D6>B:K8QZ#J'BJ2\TW5;F\CL+ZUC\+Z3JOB1[BUN)84T'3
M-0UAG&GV=S<1Z%GXE\.:CX<M?&&GZ_HE]X2OM$@\2V7BFSU6QNO#EYX<NK%=
M4MM?M=;@G?3+C1+C3'348-5ANGL9;%UNXYVMV$A2DXQ4;VC!Q;344DZ<L/.+
ME[L=8RP=*3YK7<:CES<]1CDE-IO5M2M:^U2.)A)1U>DHXVO'2]E."C90II?E
M-XR_X)]_%/4M$_X*)? SPOXL^'EI^SG_ ,%+]2\3^+/B/J>IWOBE?BQ\!O%'
MQC^"W@_X!?M#VGP_TTZ%JWA3XH:7XR\(>"[/Q9\-[_7M7^&A^&GQ UC6KC6=
M ^(_AM['0[3/^.'_  3Y^+?Q#F_X*EZ5X.UGX4Z!X6_;R_8B^&'['GPRAU#6
M/%ZWGPR3P)\/?C]\.;KQ;XIM+?PC?0ZI9-8?'ZZU/2]#TG4//W^![/3+O50O
MBJ?5/#'Z?:;\8/A+K/@>]^)VD?%'X=:K\-=-^W'4?B'IOC;PU?>!M/&F7!M-
M2-[XMM=3ET"T&GW0-M?&?4(_LEP#!<>7+\M5[_XU_!K2O"&C?$+5/BW\,M-\
M ^(]072?#WCB_P#'OA6S\(:]JK-J"+IFC>);C58]%U34&?2=55;*QO9[DMIF
MH*(\V=R(X<8N/([J*BH-)M>[*E[*"EK=VI+DI-^]R[.=KI[OFTDW+FNTG[RG
MSR::[S]Z:6E[^["[1XQ^U5^S*_[7G['WQ4_9E\7>)Y_AEK7Q5^&4?AM/&W@U
MYO$K_#GQ[8+I^L^%O&&A#4(O"MQXFMO!OCC2-'UZ"RNT\,S>(+3338SRZ(]Z
MT]K\@>*_V1OV[_VE_P!G*^\*_M8_'#]FK2_V@? 7Q*_9^^,/[/&M? ;X9?$8
M?"7PU\5_V8_BUX:^,OA/Q]\3=*\;^-8?$WC"+XH>(O".D>'_ !GX(T5_#NE>
M!/!]UK5GX3UG7]=OX_$%M^GOB#XF?#CPE)X4A\5?$#P3X9E\=ZC::1X'C\0>
M*]!T:3QEJVH26D-AI?A1-1O[9O$6HWLNH6$5I9:0+RYN9+ZS2&)VN80]CQ;\
M0/ 7@%-'D\=^-_"/@J/Q#J]GX?T"3Q;XET;PXFN:_J$J06&AZ.VL7MFNIZO?
M321PV>FV1GO;F5TCA@=V4&Y-N4YOXJM6,Y::>WC/GA*,7>*J1DU%+EDW%J#I
MR31$(PA"G".D*5)PCJ[^QY%!QE--2E3<8W;YE:2<U4B^:_YE?'S]A#XF_M'^
M$_V]?&?BF?X8>"OCY^V/^P/;_L!^%]*T;Q5XN\6_#KX4> UM/C[=7WBZ^\9W
MG@'PAXA\:ZUJ7BS]HG7M;OM.3X=>&[1](^'W@OP]87.EW>J^)?$<F_XP_8H^
M+/Q*^-_Q4\?>)/$/P[\,>#_BQ_P3:_X8?OX=#U+Q+XE\3>'/&%YKOC;7M1\=
M6=M?^&/#&E:WX:MW\;3:?9:9-?Z-JERND1:C/+;'4WTW3?O9?%?C#_A<TW@>
M73OAHG@ _#&V\5V6KK\2]2;XQ3^,!XJN](U/3I?@ZW@%-'B^&EIHITFZ@^)<
M?Q1GU*?Q3>W/A:;P#:VMO!XBO.(\<?M8_LV?#SX._%;X_>)?C=\,U^$/P1TS
M5]3^*/CC2/&6@:_H_A!M%LX;RYT?4YM$O[[R_$UR+JPM-)\+J&U_6=3U32=+
MTO3[O4-4L+:XFKRSISC4=Z<J,X27,[*DZ.,PLUNW#]WC,2G9Z3JQE\?LXNHQ
M2JPG%?O8U*3B^KG"KAL325OADXU,-0:5E[L)0:<'-GP[X)_8U_:6MU_X)1ZK
MXXU7X%IKO[ UAXKLOB5IWA/7_B!-I/C&/4_V6_%/[,FCCP+JFL^"X;QF=?$;
M?$+4I?$&DZ4+0Q+X'M8;_P H^-[GG/@1^P-\>_A7X'_X)Z^$=<U_X0:K-^QY
M^US^TU^T;XUO])\0>,X8O%NA?'[P=^U[X+T[P]X6MKSP)OM]6\,6O[6]]J=[
M-JT\-GJMQ\.;2Q@EL(_&<U[X1_1ZP^*T_BGQ3\(I/ -W\)O$WPN^(GAGX@:M
MJWB:7XK1Q>-X]4\-GPPOAZS^&W@S0O"WB?P[\2],:>^\46?Q'U1_B%X3;P!<
M:7H7V.U\6OK=W!H_=Z-\1/A_XB\3^(_!7A_QSX.UWQEX/2U?Q;X2T;Q/HFI^
M)O"Z7S2I9/XBT&ROI]5T1;MX9EM6U.TM5N&BD6$N8W"U43E.<ZG\2=:=::TN
MZL<3]8J.48_#_M#<VEI:7V8.*(@H>SIPA;V<*-.E3:O94I4%2IJ,GJ_W/+&+
M?O7BOBDI7_)#X7?\$_OVGOA_JG[,'A(>/_@,/A/^R9_P40_:4_:T\(:H^G?$
M'6/B'\1/AA^TEX=_;4CO?#GB/347PUX;\%^._ FH?M>7?A>QCTW4O&&@>*[+
MPU:_$"ZU7PY<13_#/5_3OV7OV4OVU_V:/B?XQ^%>D?'3X%ZK^P5=?&KXK_';
MP#93_#WQG+^U?X5A^,'Q.\4_&;7_ -GM/$5WXED^%S?#;3/B)XPU<67Q+U?1
M?%7CZ;X;S:G\/K'0?#VM7WAGXC^ OT9TCXG_  T\0>(8?".@_$/P-K?BRXT/
M4O$]OX8TCQ;H&I>(9_#6C>(I_"&K^(8=%LM0FU*70]*\6VUSX7U+5DMFL+'Q
M%;SZ)=7$6IQ26RZ^L^,/"7AS4-#TCQ!XH\.Z%JOB>Z>Q\-:9K.MZ9I>H>(;V
M.:SMY+/0[*^NH+G5KI)]0L(7M[".XF66^LXR@>YA5U'W%"VRCR*ZNIKEH17-
M?XW'ZM1<6K6E"]GSU(SII2YW?XI<S:=N5WJR]VWP)^VJJ2ZQDE]B$H_(?[:_
M[.OQ/^.X_96\4_"#6O 6G^-_V8_VM? W[1=MI/Q*?Q%:>%/%VBZ;\-OBW\(/
M%/A^?5?"UCJVKZ1JMMX;^,.J>*O#TT>DWUIJ>O>&=.\.:F^DZ=K=UK^D?+\G
M_!.7Q]?_  E^*_['&O>*_ VM_LD?$?\ ;'?]J_3-?EN]>M?BSX6\*^)?VJ-%
M_;.^(?[.LG@Q/#L_AG7-)UGXSV7BW1-!^+X^).D:]HOPS^(46FR^ K[Q?X @
M\7^-OT_LOBQ\+-2L8]4T[XE^ +_39M?L?"<.HV7C+P[=6,OBG4PK:;X:CNX-
M2DMWU_4 Z&QT99#J-V'4P6T@89\)\:?M9^!/@;I'B[Q/^TKXP^"WPP\-K^TG
MX%_9Z^&%SH'Q:'BS4?$^J_%!_AWI/P_TWQQI^N^$O 0\!?$[4==\::AJ_B3X
M>Z;/XUTOP?\ "_3+3XF7_CFZT";6V\/B?(XM-Z2YHNR=GS8:<5S6OK4H8>K"
M*?O3@FN:+<)-Q33;2NHN+WORJ.)C)V3W5.OB:<I6TA-IVDHRBW]N'X-_&'X\
M_LZ^(OAS\"_&GA_P;X_N/&7PE\4"W\8W_B72/ OQ&\)^ ?BMX-\<^//@G\0M
M;\&6]YXNT;X>?&_P7X>UWX5>.[[P]8:G>-X4\6:M9W.C:YI5WJ.BZA^)7[1O
MP-^)O[(GB7X4:EXK\3_LT:>_[1G_  7$_99^/OP;\*Z)?>(OAYX5T&UM/V.O
M#_P1\0_"S5XM3L[UM(TW1Y_@];:#X9\7^%M.UV&2'7=,\7WO@+26N8OAC9_L
M/\+/VUM \:_M$_M+?!'QM:_#OX=Z'\&O%_[.W@[X5>/Y?BUI^JVWQZU#]HKX
M:WWQ'\+6FAZ=JGAOPI::9XGEM[.;3-'\(:!K?CRZ\01V=QK&G:F]O*MI!]!_
MM"_$[5O@I\"OC#\8]$\+V/C:_P#A1\,_&_Q(3PEJ/B6?P?;>(H/!'AO4O$UY
MI \26_ASQ8^DW%]:Z9-;6EVV@:A"ES)%Y\:0EY4EN-)*O)M17LZ\G)RNJ=&2
MG*R^P[863DG"3BX2GR7DU.X-U&Z</><E4PZBK).=2,J:NU;G2EBE9J<5-.,>
M;EC>'X<_MS?"'4O@-<> ?CUXZ\2?"C2OCK^UK_P6#_X)\>/[GPY/XJOK#X=^
M']$^$&E^!OA+X(^&FG^-=6T31O$/B&'_ (1_P-J?BKQ)\0Y? %M?Z/KWQ!U7
MR?!NJ>'/">C:;J'U1\>O^">?Q2^-_P "?^"D=E_;_P ,?"_[0/\ P4.T/P3X
M+NB-2\4ZS\,_A%X%^&WP[T7X;^#-'/B./PKHGB?XDZE;2KXZ^(FH:Q+X,\"-
M<7_CNV\ Q6L6E^#+7QAK_=? K_@I0GC_ ,??L1_#WXP?!Q?A+J7_  40_9WU
M;]H']EW5_"?Q#F^*_A[55\'_  [\&?%;Q_\ "_XBW%U\/OAMJO@3X@:#X"\=
MZ/XDT::WT?Q/X)\46>E>*K2#Q?INMZ5IND:[^A>G?%+X9:PVOKI/Q%\":HWA
M70[/Q/XH73O%WA^];PWX:U!M:2P\0Z^+;4)3H^AWS^&_$26>K:B+>PN6T#6E
MAN'.EWP@T<94W*$KQE"I4CO_  U1>&HU*=M;.%7 Q]I)W4M=>5N<XC44_9RB
MTTZ=.2;3?M%5=>M3J:VNI0Q;4(I*R237,E"/Y?\ [27A;X8?M:_MC?LW_#KP
M5\16T_X__LR^(M:TO]M#P5X%AOO$.E6O[(GQG^$FG?$?Q?\  ?XMZIK6AZ-X
M?O\ P#\=_BOX/_9E_L?3[V&#Q7XO\.Z+XNN_#GAIM$T+XHMX<_47XE^#4^(O
MPY\?_#Y]0;2$\=^"?%7@U]52V%Z^F)XGT*_T1M02S:>V6[:R%\;E;9KFW$YB
M$1GB#^8MOPSX[\#^-/#$/C?P=XR\*^+/!ES'J$MOXN\,^(M(U[PO/%I%U=66
MJRPZ_I=Y=:3+'IE[97MIJ#QW;+9W5G=6]R8Y;>5$J:#\2_AQXI\)7?C_ ,,?
M$#P3XC\!V$>KS7WC;0?%>A:OX1LXO#[W":]+=^)-/O[C1K>/1'M+I-7>:]1=
M-:VN%O3 89 N<H0E3J4I1]RHJKJQV35>+IS>B3C%TY<D6Y-W<I*2<K%1E*-2
M-12]Z#IJF[)M>Q:G%=I24[R:M\*C%IQC<_*#]FW]A']IO]G36OV1OC19Z]\#
MO%'Q?^#_ .PSX-_X)_?'/X;+XH^('AWX7>/OAK\)=2T76_A!\5_ GQ'D^'_B
M3Q3H/C[PYK]CXYO]<\(:Q\,+K0-=T3XQ7/AE/$MC??"K3/%_Q$^__P!D']F_
M2_V3?V?/!7P.TS7G\4W&AZI\0O&?BKQ.--.B6GB+XC_&+XF>,/C-\4]<T?P^
MVH:P_AKPYJWQ)^('BN_\,>%Y=:UV?PQX=N-,T&?7M;FTY]6O/2Y?C1\'H/ >
MG_%.?XK_  U@^&.KM FD_$:;QUX6C\!ZH]U=R6%JNG>+WU4>'KUKF^AFLK=;
M;49&FNXI;:,--&Z"?6?B]\)O#D?@Z7Q#\4/AWH47Q$B6;X?RZSXU\-:7'XYA
M>+3YTE\'/?:G OB:)X-6TJ99-%-\K1:GI\@)2]MC)K*<ISE*=G.3DI2Y5S7J
M59XF4=%=<]:K.MRI)N51V7L^2$(C&,(1A%M0BHVCS/EM3I1H0>]G[.C3C23;
M:C&"N^=2G+\H3^P)^TW9_#[P;\,K+Q+\![SP_P#"G_@JGXS_ &\/ ^I7>K?$
M*PUGQ'\,?&W[47QB_:EU3P;XL2'PCJ%CHGCV/5?C+=_#O3Y-'36/#EGI_A"U
M\;7-[J=SXIF\&>&(OV\O^"?7[4O[5'BG]JVW\*_$SX)ZA\/?C=^S=\+OA[\&
M8_B_9^.;O7OV<OB%\.O&'B?Q-XWT?P'I'AVQN]#T[PK^TFNJ^%Q\4_BMIM_:
M>/;!? GA+0]<\$_%CPUX4\#Z;X2_7.;XD?#NW\<6GPRN/'O@N#XDZAI<NN6'
MP^F\4Z'%XXO=$A$IFUBT\)O?+KUSI40@G,FH0V#VD8AE+3 1OM[2LHQC&--1
MT5.W)9W^"GAJ"[\W+'!T%Y3IR=TYU8S=E>>FLU:7>SJ8BK;NKO%U^UX5+:J-
M.4/Q8^-G_!//]HGXJ^$/^"H&@6OBOX*Z?J?[?'BO]GOQ'X1O[C4_'26'@-?A
M%\)/@W\+/$B>([&+PE=7%\=;?X32>(M$@TR_<62^(H]$O[NX.BMK.L^M_&7]
MB'Q[\;?VK_AE^T7?>'O@G\+O'7P>^*_PK\2> OVG/A;XH\<:/^T7)\ O#FD^
M$=7^+'[)WQ-T*S\#Z+X?^,'PS^*GC.U^)F@+<>+OB'%X;\*>#_B)9>+-#^&-
MK\1?"7VWQ#[3X _;"U/Q3^U]^UK^S-XH\ >$/ OA/]D_X<? 7XG:[\8+_P"+
M$]Q%XAT#]H*#XJS>&A/X4U#X<Z!IOA=O#Z_!_P 4-XJN;WQYJ%G9QW>B2Z?/
MJ2W.H#3,G]CK]L;Q1^V1:^$_BSX \!?#Z;]EOXB?#WQ3XJ\,_$32OC!;ZU\4
M_"7BW2/'6G:3X0\ ?%'X20^$8;/0[WXB_#/5(OB9;:CI'CO59O!.H:7K'@/Q
M)HUQYOAKQAXDJ$E+EG"WN^SJ)JRY?9?6*$&]FKM8BFU_R\O*,^:$[3)P]G)J
M:<934H-/[:JJAB):7:E=>QJIV]QM2CRSC[GQU\&O^"=W[5_A7XV_LS_%'XN?
M$WX#?$:\^"/Q;_;0O/B=\0_L/Q%?XN?M$_#C]I2SU.#P3XV\7ZC>I%8Z#\0O
M ?AV/PO\)-.^%5O?Z[\/? ?@/0[*3X=>.=/\):%X9^#VE>P?L1_LA?MI?L[_
M  UT7]E3XO\ [0/P;\=_LJ_ ;X>7?P?_ &=-;\%?#OQ1H_[0_C?X<6?AN[\$
M?#/2?V@=3U7Q WPSTZ'X2>![B'1&M/AOX4?4_B=KFA>"_%VH>*? \&@>*?"G
MQ&_1^#XK_"VZT&^\4VOQ*\ 7/AC2[Z#3-2\1P>,?#LV@Z=J5TT"6VGWVKQZB
MVGVE]</=6R06EQ<1SRM<0+'&QFC#7[SXA^ -.\9Z1\.-0\<>#[#XA^(-,N=:
MT#P%>^)M%M?&FMZ/9B\:[U;2/"T]['KFI:;:KI]^US?6=C-:P"QO#+*@MIMD
MN$'"5)I2A.E*C*+5^:$Z:33:2E=04I1E%IKGJ3M+G<HUS/F53F:G&<:BDG9Q
ME"4K6Z*/-+EE%IWY81NG%)_EI\'_ -A[]H[P9\#/^"2?PK\8:[\$KW5O^"<?
MC7P9/XIO_#6N>.TT[QSX'^&G['/Q>_8T\.2>'Y-4\%BY;Q7XFT?XKS_%K6[;
M4;31=(\-ZGI,/PQL;OQ-:SO\3!'IO_!./QTGPC\8?L9:[XB^'FL?L@:O^VE:
M?M:^&-;2Y\46GQ=T3PA-^UWI7[<^L_LZZIX4.D7'AW6+&7XZV.L>'+3XQI\1
M['6A\(?$ZZ*WP^@\:>&8/&VO?J5_PLKX=?9FO?\ A/\ P5]C3Q0O@A[O_A*M
M"^S+XT8*R^$&G^W^4OBAE=&70"XU8AE(M,,,]3J.HZ?H^GW^KZO?V6EZ5I=E
M=:CJ>IZC=06.GZ=I]C!)<WM_?WMS)%;6=E9VT4MQ=75Q+'!;P1R2RR)&C,+4
MFINJI>\YRJ.>FLY3H5G)O2W[RA3K*W*E+F:?)-Q(<4TXN[YDHM7=[*->DK*]
M[\F)JTKM-\K2TG%2/Q\U']@7]H"?P9^T#X;M]<^#LMW\7?\ @JI\"?\ @H-H
MLTWB7QM:V^E^"?@M\7?V:?BP?AQJC)\/[R1O%7B&7]FVST$:W:0RZ1IT?CBZ
MU/['>/X5BL/$WI\O[$GC;Q!^V]\//VO+[1_@_P#"CQSX ^(/Q';QA\9_@GXD
M\<Z-\2?VI_V<]<^'WCOP5\.OV<_VC?AK_P (KH/@/Q1:>!M6UWX8^.++XA^+
M/&'Q/U3PWK'P.T>T^'.@>"V\=:CJGA;]"-"^)WPV\4>&-/\ &_AGXA>!_$7@
MS5M5M="TKQ=H7BS0=7\,:GKE]KT7A6RT;3]?T_4+C2KW5;SQ1/!X;M=.MKN2
M[N-?FBT>*%]0D2W.1<?&[X+VGACPWXVNOB[\,+;P9XRU:#0?"'BVX\?>%(?#
M'BK7+F_ETJVT;PWKTFK+I6N:M<:I!/IL&G:9=W5Y+?PRV<<+7$;QB815.2<5
M[R5.*NF_AH0PU/1]722@M/?<I7C4YN5.24E*[TESN5G9-.M+$3V=K*K*4[W]
MRRM*')S'SY^US^SOX^^//C/]BSQ%X*U+P?IMA^S1^UQX>_:.\71^*;_6K6[\
M0:%HOP@^,GPGE\,^&X](T+5H5U>X7XP3>(8[_5+BULHF\,1:.T$@UY]5T/XO
MN/\ @GO^T')X"\3^$X_$7P:-]KG_  5M\+_\%%[>Y?7_ !PEI%X!\-_'OPA\
M<1\,YBO@224>,+P^#XO"QUY(Y-$@&I2:]]AF-DFBWG[15Y=IGQQ^"NM>%[SQ
MOHWQ@^%VK>"]/UIO#5_XOTSX@>$[_P +V/B-(K>=] O-?M=7ETJVUI8+RTF;
M2IKM+Y8KJWD, 2>(M5[=>JE\U6PU57\O:X6AVORN%_?:9)*5N;71Q2?9T\1!
MI>L,36;W>JEIR(^<?^"C_P"S3X\_;'_8C_:)_97^'.M>$?#'B3X]?#_4OAPO
MBOQM/K*:'X6T_77B74-=-CH.E:G?ZS>V4$1%EHX?2K>ZFE$D^K6R0F*X]O\
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MMX<N_&'P]OM870O!?Q5\%>*4\&^-G\,^)?!D'@K5M \2Z'X@U#Q'9^??$_\
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M/\:?L^^"/'_QR\._&/Q#H'B^7X<6G@W6?Z&+?XG^![OXH:Q\&;?6VD^).@^
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M;]HCX67GQ&_:?U#]COX[?L,>&?"G@;P9<_%74?BC\2?V9+;XJ?"W6?BQ\-?
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M^._A%\(OCEX<OM:\)^%M9UO3_P!G+Q-XA^).@ZKX[^%WB4:C\3/"4GQT\O\
M']I\?;+X7_ OXO?##X,:C\./V@KK]@W]D+PC\9O^"9/C;]GOQWXH_96_:"\
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M=\6+71SX;A\*_LR? S0?"7PA^)DD'B*#7OA]H?P;O?A;K^ER6_C+P'I?CO\
M971_ ?P#_8?\%?&+XSZ_XJ^)<FDZK?2>+/B;\3?BW\1OC+^T)XUM-!7Q)KM_
MX:\':1J?C'6/B#XRTGX9^!-1\<:Y;> OAIX/@M_"OA4:_KNIV&BIJVO^)=8U
M/ZVJH2<5!Z2<%24KJ-TX5</B*4%-1;7LHX6EAU))>UP\)7C%.'+,HQ;G96YI
M5'!ZV:E3KT*DG"Z3]J\34K.#;5.M*.LFI\W\T'[6UIXGTC2/^"J'P=M_@O\
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MJ6CD[*7,DO?7,E:AC*&B>R?UMS<=$Y4H+9MQ_F-\>7/BO4/VK/!VL:3^S_\
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M%.W)4J*/(H4N52BI2<GWOI9-*2QE/65G>26.<83:NI4Z;?,Y33_GP^,_P3^
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M3G*4ZE63BG#V<813;5-R:V3]ZE@Z6G+912C@J;BH1BHN<E%*,*:C_++^QK\
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MNI)HL.L_VMH4EAX%\5^,OB=X33Q!/XS_ &?^)'["O[*WQ@7XR+\3_A8OC?\
MX:!\$?#SX=_%]M?\:_$2\D\8>%OA%K=SXH^%$3R'Q:)-$UKX8^*[[4O%WP]\
M6^''T?Q;X,\7:MK'BKPYKFF^(=7U/4KO&N/^">G['5WX4^.O@F\^"]C>^'OV
MEQX+G^.,%YXO^(5WJ/C[7OA]I/AO1_"OCF\\07/BZ7Q#I/Q.LD\&^$=7OOBK
MX>U72/B3KWBWPOX>\<>(?%6J^,]&T[7K>*?N1]].;7):UK/V=:E4AJTY<W+2
M46VVKM-^T:G*55H^T;4/W<91FI7O)MU:%:E-Z-1MSU>=125E%QCR)P4?@+]K
M;]M?]H']CWXK_P#!0:YTKQ3J?QD\)?LN_P#!(_X3_M7?#OP'XT\*^"A9R_&V
M[^(W[5'@;Q!XR\6ZI\.?"G@;Q/?>%]9L?@_X,\0^.=%LM5LM*T:QM/%MUX.L
MO#4%Y:VNG]?^T1\9?VE_V</BW+\+?#OQZ\7_ !6\)?&?_@G1^V1\>O"WCO7/
M OP=G\5?!/XS?L>Q?!/[#\1M%O?"_@+0?!>L_#[XNQ?M!:7:Z[X2\8^$?%>G
MZ/XK\+^%!X0OM%T7Q%KFDW7Z,:=^RI\ =-\;:[\0U^'EKJ7BSQ3\'-&_9\\4
MW_B37?%7BRR\4?!?P_-K-UI7P\\2:#XGUW5_#VOZ#!?>)?%&HSIJ^E7EU?ZI
MXL\6ZGJ%S=:AXI\07.HX7A3]C#]FWP5X(USX<^'_ (>W,?@_7OAE)\%9M-U3
MQW\1_$=WH_P;DBGMQ\)?!NN>(_%VK:_X ^&5O:SBSLO ?@;5/#OA:PLK;3[*
MRTJWM=+TV&UFJG*G4C!N,W0JTZ<M8VJSI8^$9MQ;E:-3$86NI?%%X94]4H)W
M!I3C)Q7*JM.<E?GO"$L%*27-:/O1H8FFXVY6L0Y7UG;X _8P^.?[3.K_ !__
M &,- ^*_Q\USXO\ A/\ :Z_X)8:I^U=XI\*Z_P##[X2>%-,^'?QE^&.O_L9^
M';[4/AK?_#OP+X3\3Q^'/B#9_M*>)M1\6>'?B!XA^("V&NZ'HT_@R^\+:*UU
MH$GT-^VK\4_B9HGQ+^%WPE^$7Q@\3>#O%GBGX'_M/_$N;X??#'PA\/-5^).L
MM\.H?A-H/A;XK:SXZ^+OA_Q?\.?A_P#!3X2^)/B)&?'EA+X2\3>/OB#XO\6?
M#72?!OACQ?X<T7XC^%=7^DO!/[*'P$^'7BGX5>-/!O@BZT7Q)\$?A%>_ 3X6
M7Z^-/'U]%X/^#FHS^'KJ_P#AY8Z;J?BB]TJ[\.W=SX/\&W,]MJEE?227'@SP
M;.TIE\)^'7TV7XO_ +*O[/\ \>O&GPY^(7Q:^&^F^,/&'PIL_&6D^#-7N=4\
M1:8(_#7Q$LM-L/'O@CQ/IVAZQI>E>/\ X=^,[?1=%/BCX<>/['Q-X$URZT;2
M+[4O#UQ?:787%NZ_-4]M[.U-3JXMTKIWHT:T\9+#Q7+;FG0C7H1W=E2M"3<*
M+C-%*G&BJB=25.EAE5=]*U6E#"QKR?->T:SHU7LKNI>:]ZJI_A'\"M6_:)_;
M8_:'_9Z^)WAS]HW6_P!F/XV_';_@@=^R!\9_$OQ8^%OPQ^%GC.\L?B-\1OB/
MXL\83QV'@WXS^'/B'X#C\ OXLUZZO/$7A<^'1XHU?1;:ST;PU\0? L\-UJU]
M[[^QI^V]^T!^W/J?[+'PJ\8^+-7_ &<?%/Q#_P""8'@_]LGQQXN^$NB^ [O5
M/B+\0O'OQ1N?A%:>(/AB/BUX(^(_AS2OAOX27PI)\4[?2;CPUXC.N6GQI^$U
MGK>J3^&M*U32_'OZ+Z#_ ,$^OV1/"NA_##P[X6^$\WAC3O@_\)#\ ?!$OASX
MB?%30M9'P,^T?:X?@WXP\2:5XWM/$7Q,^%UG=F2[TWP'\2]4\7>%]+NY[FYT
M[2[6>ZN9)?5O&_[-'P2\?W?PSU+6/!(T76O@SIVJZ%\*O$GPZ\1>+/A)XJ\
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M//IO"?M#_"/XP_'OQGX6^%.K:-\#I_V/[MOA]XW^*=]XDN?$FO\ QFU[QO\
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M=,\:2Z_8>+/$-MJ4I63O=_O$UJW:DJMXQO9.4H4+4I.6M62E4DXRG>%];Z?
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M:U2<5M[2,J4H13M"M!N"25W^/>F_M'_MJ/X9^'/Q2'[6WBRY+?\ !9OX^?\
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M5VZ_5Y*]U2;_ ")_;2_:F_:\_9IM?^"BGPL\&?&W7-5OO@M\#_V)/VI?@/\
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M>HV%A=^&Y[73?AAX+UO]H/0+73]2N$\9_ RY\-^*O#E_>:[XHT?PI<8>F_\
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M6?@7H'C_ $?X9ZCJ_P 0O@9X\_X3#6?!5]X_L;4_!+XX?#SXWP:8?"UAXU\
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M%I3G2E=2<913BG'76-O:N[:IVE9Z;N%1PE>S:DI.,:D;.*:;3::9\P?M#?\
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MAZ=X"\&_'6;P]'JOCNS\3_"[Q]JG@^_O/$U]\*+SP=XH\7)XP\+_ $7^V?\
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MO@?P+I]NWBF\\;_37Q;_ &9?&'Q4_:-_8H^/S_$7PSH2?LHZI\8=;\3^$%\
MZMJDGQ-U#XP?"2^^%=U'H'B/_A8&FI\.[+PY_:=WXAA34O#OQ&GUL+;:*\NC
M&.769S[4=5)*I1O)72Y/98EU)KJI*I]7BXN]E*5E)RJ.FTY-2>L?W=7E6C;J
M*>'4(2WBXN'MY*2<;M1^&,:?M/,_AE^WYHOQ(^/_ ,/_ -G3Q=\)?&?PGU[X
MX>#OVC?%OPTTGQ;K+Z+\6;#PW^SGX]\-> M=U/XP?"N;3=$\3_!V#XK:?XMT
M_P"(WP#U.RUKQ</&'P_@O-5\0W'P_P#$B:?X<OL__@D=XE\5^+/V O@[K7C;
MQCXS\?\ B-O%W[16EW?BWXA>+O$7CSQCJMGX>_::^,?A[15UOQ=XLU'5_$6M
MS:=HFEZ=I=M<ZIJ-U/%8V5K:K((((D3PK]G'_@FC\?/@C\3OV4?B!XH_:9^&
MGQ*_X9AU#]LBPU'4+OX#^*-)^(WQS\/_ +6FN^#?%&K>-?BIX\?XXZI;:A\>
M(=<\ Z%)XC^($7A:;0M?AOM>>7P?]KFTF?2/N+]AW]FKQ#^R-^S7X.^ /B7X
M@Z+\4-1\)>)/BGKI\:Z#X'OOAS8:G#\2_BMXT^*0LU\(ZCXX^(USISZ%-XTG
MT W#>+M2&JQ:9%JQATU[Y],M'&UF]>9T81=]^=5Z=357:C)4YU5)QT:CRIM*
M"E4GNELJSE':W*Z%:F[/1N/M(4914O>7/S-7YG'Y<T7_ (*C6NK>(_#QO/V9
M?BMX=^&-[^W;XJ_X)]^*OB/K?BOX7RS>$_C'8^,-0^'/@G68_!_A_P 5:]J/
MB#P5XK^(%A;^']8U:PU"&X\)Q>*/"6H1VGB,OXUL_ OHWB;_ (*(^#_#.AQ?
M&&7P#JE[^RG;_M0R?L@^(?CW#XETJUN?#OQ2@^-DO[,U[XVO/A_J%I:RS? 7
M2/VDH9?@=K'Q"B\5+XM@\51R>,+#X8ZG\%@GQ6?R(?\ !-;XB+X(N?" ^/W@
MCS+G_@J7%_P4F.I'X)Z_L73H?C9:_&U/@1]C_P"%V9.H'5;5- ;XQ?:A:G3F
M:]'P?%UB$;UK_P $W+L?#_XE?LPZO\3-*US]C[Q[^U[:?M>:;X+O/"4T/Q+\
M)?:OVC-%_:\\:?L^6_B2WUE?#.L?#7Q?^T=I^K^(4\87?ARV\4Z#\(_%7B#X
M.PZ1J/B1M#^-F@D/B@IV45[+F:O>5XX!UE;X5RJ68*F[K]Y"FK2BH2GF^>TK
M6NW44=4^5*6/5*5FE=.V7N:;NZ<JK]V3FHV?''_!35/ WB+XR#4_V9_BA%\-
MOV=_VT?@S^QQ\:/B5=^+_A<L/AW4/CSHW[-L_P /_B7X>\*:/XIU[7?%?ALZ
MW^U)\-7\1Z)$-,U_P_X(;5?$MQ!-XIT^Y^'</W'XT^/GPT\)6OCFUL/$OA[Q
MMX]\!^&?$GB6^^$?A+QGX#;XFZF/#&B3:_>Z1I^@>(O%7AZUM-4FL8D:)O$.
MIZ'I=N+B"XU+4[&R9KE?@OXJ?\$Z/B#\2/!?[:?A&W^._@K0G_:W_;2_9S_:
M_P!.U*?X,:]K$?PV/[/-I^R7IUC\/+_3H_C1I#^/!XKL?V0?!PO?%=MJ7@4Z
M1>>,_$]S;^&[^#3=)L9/H7XK?LM_LE>"1\:?VH;;]G']G7PM\?\ 4?AO\1)O
M$G[0NF_!WX<:/\8=2?5_!%_H>IMJ7Q5MO#<'CJ_;5=-$.BW NM<FFU&Q\C39
M5GB*0'"<JD,)4J2_C0H59M)*3]I'"5JD4HI<KBL1"G%QNY-2E&'->+-H)3Q,
M867LI5J<$VVER2Q=*#;E?G4GAISDI64>>*<N5*1\X?!#_@J1<?%[Q;^S)X<U
MW]EKXF?"/1_VW?V<!\>OV/\ Q[XW\:_#W4_"/Q<UO1_A7X;^,/C7X2:^/!.I
M^)_$WPL\5Z9X%\2CQ3X1O?&?AN"S\<>&?#?C*_C@T/5_#TOAZX];^%O[>?@S
MXYS_ +">C6'P]\9Z+H?_  42_9(\5_M.?#[5CXBL[#5_ >@^'O!?P:\7:SX1
M\7_V+>6NH:=X@FT;XZ^&(]!\0^#-9U(+JND>(6EDT/[%HE]K'R]_P3:_9L\5
M_$+]F#_@DI\5_C%XD\.7-K^R5^QA\/=.^'/@;P_X4UKPYXAM?BKXV_9M\(?!
M[Q'K'Q,?6M=U*Z\/>*_A5X#O/B+\'M4\"V5NJWWBK7?$OC#7&\,W]OI'P]\)
M]9^S+_P3E^._P1\2?\$^KOQE^TA\+_&GA7_@GS\#?C)^S)X-T?P[\ /$GA36
MOB)\'/&7A7X)^"/A_=^)M;U#XZ>)K71_B=H.C?!'0-0\6>)-*T>;PIK=Y?:I
MIVE^!M+6ZM]7T[KG&,:]2#M[%5*T%[SDW35?%QIR<HZ.3I?5[J-TTE)-WGS8
MJ4G",E?F=.+>B5JOLL,[*+U4%45>_-JI/EM91Y?G'_@F'_P4 \=^'?V>/^";
M/PQ_:&^%_P >M7\/?M0>&=1^%_@7]M'XD?$?PCX^LOB)^T1INF?$OXB1^#/&
MUOJGC[7OC);#QAX-\">)X/!GQ#\8:>;GQ9XK\.:AHL^BZ;I%QX;\3^(+_P %
M_CU;^"/@_;6_Q?E_:6^+D6N?\%V_CE^SG\//$6C?M$?$31]2\ -;?MH_$#P;
M\(+#XD^)KCXIZ'XR\?? SP?I&E6/AB3X-W\?Q"\%>)-)M-&\,^*/!DOAN*74
MM-^K?V>/^"<FL?"[X=?L9_!7XG?$WP[\0_AI^P9\1==^*7P@N/#?@K4O!WB/
MXB>,F\)_$[P-\.=0^*%MJ?BSQ=I6FV7PT\,?&'QG=7VE^%I9#X_^).E^ _B'
M9ZA\-] \/:M\+/$O/1_\$U/B&O@'1?!;?'[P2TVD?\%3-6_X*4'5!\$]>$=Q
MI^L?'77_ (\W/P)%C_PNO=#?QZYXAN?#\'Q@-[-:KI-O!=R?"*2\>1*2<6HM
MWYI>Q51M)7BJ^5RDVE?EJ0C3QK;BE>,(/WIS:JZ3MS5>56C[2M.ERK2-Z>;*
M"3;O[.;JX&/+*]G*4?=A34J?TG+^V1J.L^+WB^%OP*\>_&'X4^'_ -IVW_9,
M^(GQ$\"7UC>Z]X/^(*3Z;HGBKQ]!\/I;5'UKX%_"?QSJG_"O_C#X[E\5:+XH
M\':_H'C+5M-^'?B?P3X;;Q9??;]?F'\+OV(/V@/@A^T1\8];^%7[5.C:#^R!
M\>OCYJ'[47CGX%ZG\'K[6?C)X:^*OB232]9^)/ACX5?'C_A:-CX?\*?"CXP^
M.-,'BWX@:)KWP<\8^(+&SU;Q?X>\ :YX.U7Q6/&^A?IY4+6,7M)I<R>ZER14
MT[7CR^T4Y4VFVZ<H\UK6%KS271.7*ULX\\G!Z^]S>S<%4322G&5KIA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7BU_\ $/6[#X[6W@"XU?X+VG@1?@SX
M@^(.IVU_\2+RT^.T&NZ3XP\/Z/'JMM\+W\.?V-)\&;31-1OU\0?$>X\96]YI
M?C"7P_X?7PY/::G-JMK[37Y1^-/",L/_  5PMOB+JOPJ\;:K\.F_X)B?%'P'
MXO\ 'UE\&O''BCP/J^NM^T)\/?%NF_#N]\5:1X1U70/$GBFY\*:1XEU'2? ,
M-]J7B"^MOM%MI^BSW.IV]M=Q.3BKI7M"O*VNKIX;$58K1/XITHP752G%Q4I6
MA)I)IW=K.GZOFKT*;4?-1J.6S5HRYK1O*/W]X5_:"^ OCO7[WPIX'^-WPA\9
M>*=.\">'_BEJ'AKPK\2O!GB'7[#X9>+;9+SPK\1;W1](UJ\U&U\">)K22.Z\
M/^+Y[9/#^LVSI/IVH7,3*Q^-/@9^WE-^T?XS\3^,/A+=?L_:M^R]\+OBK^T!
M\(OC?XHUGXTVFE?%/X9VGP2OO%OAK1OCPFD:=IOB#P9KGPM^)WQ!\ ^+O#6A
MZ/K.O^";FR^'\7AWXU:=XU\5VFL:[\._!WYT?L*_"3QA\-I/^" %I-\!?BSX
M U'X6?\ !._X\?#+X]W$WP"^)WA"V^'?Q \0?"_]EF*_\)_%S49O!.FV'A77
M?%'Q"^&/BB^A3QA/9'Q/KGA]=<L9]0;4=(OM1J^'?!7Q[D_9E3Q#H/PH^-RZ
M%\(?^"[WQQ_:R^-'PFUOX-_%?PYXY^*/[*.K?MR?'#XK>%/&/P\^'WB'P=8>
M)/BHOA&;Q?\ "7]J#P]X9\&:5K7B37)_AA#I/AC2=0^(@T7PU>[<B3E>:]V3
MA[VD;O%X?#^U:3NX1A7<[7T<)SYN1<\,%4G)1_=M72F]&Y6^IXG$>SC=)*?M
M*"IWMJYPAR\TN6I^_EG\;/@UJ/P^N_BUI_Q;^&-_\*K"34(K[XFV?CWPK=?#
MZRETG5)=#U6.[\9P:J_ARWDTS6X)M'U!)M21K/5(9=/N1'=QO".0O_VK?V7-
M*T7Q%XEU3]I/X!:;X=\(6WCF]\6:_?\ QB^'=GHOA>S^&'BO2O GQ*N_$6JW
M'B..QT2V^'GCC7=$\&^.9]2GMHO"7BO6-*\.Z^^GZOJ%I9S?A;^VU\ OB'X\
M^"O_  6R^(_@KX3?%7Q9\,_VJ? W[*>G?"#X06GP?^(^L^-/B'\>?ACX2;0/
MBG\8_#'P:7PI<>-+(>)O#4_P3^':^)[_ ,+Z5J.HWGP&O-:D(\-:=X>\1:G]
MQ^(OA+\.M"_X*6_LE>-O"7[/%WI7PQT+]@[]MVWU/Q+X8_9H\66?@WPUXT^(
M?Q=_8D\4>!-"UW5=(^'::/X;^('B'P=\.OC$^F>%M7GL/&")8ZWHLNEV^H^*
M-/T_6\&Y6CHXN4H0L]H.6'Q->4I-)^XGAXQ5K2M6IN7+-<E39^[)KXXI.7-&
MZYE[>A2Y5S+XTJ[E+>/[J?*Y1;G#]&O#_P <O@IXM\:P_#;PK\8?A;XF^(MS
MX"TOXJV_@'P_\0?"6L^-;CX7ZY-:V^B?$B'PKIVKW.NR^ M8N+ZR@TOQA'8-
MX>U":\M8K349GN(5>O9?'SX%:C=?$*QT[XT_":_O?A)IVI:Q\5K.R^(W@ZZN
MOAEI&C7.LV>L:K\0K>#67E\%Z=I-WX<\0VNI7WB1--MK&XT'68+J6*72[Y(/
MYXOV+_@YXW^'G@3_ (-^H!^SE\8?!FO?!Z]_:HTOXRVUS^SU\3?"6H?#.T\3
M?LS?%7P1IME\4[Z^\#Z>G@32?%/C.U^&>CV-QXRNM+TK7+G3/">HP3WFG:#9
MWUAW7_!//3_&T/[2W_!/;Q;J/[.?[0_P/\+Z1_P3Q_;$^ FO_#36?V8_BK\.
M_@[^R[\4;KXN_L(^/-)_9XTSQAXU\(R^--8TO3/"_P ._'5SI_Q^^*OCG6_A
M[^T/XFT'6]9^"_B:#4]4U#X4^$JG[ME!2FWSJR2TLKP;:T>DHQFE]N,VI0C*
MF@:4>;FE%VL[QNU*TI0DDVM.9PE.G?7V<X7C*4:E_P!;/!G[8W@#X]?#C]G?
MXQ_LS_$3X#^+_AK\9OB;X=\/W^I_$'XH'P;J]WX+USPCKGB&.R^'&C:-HWBN
MXU_XW7GF>"-:TCX1>+?^$,OV\':SK&HZ_J'A_6--M=&O?HZ3XN?"F'X@6OPF
MG^)WP\A^*E];SWEE\,Y/&GAM/B!>6EKIJZS<W5KX-?4E\1W%O;Z.Z:K//%IK
MQ1::RWTC+:L)3_.]\&O!/C^3]A?_ (-_?!6K? ;X_P!C\1/V5OVE_P!FGPA\
M:]&\1?LX?&C3/$/PDF^&'[*7QJ^%OQ$U[6X]5\ P7FG?#BR\9>(O#6@6_P 4
MK3?\,O%$-]:ZIX<\5ZSH-K<ZE:]Q>_!/X[>-OV9_&?[*&K_#;XDZ;^V/X._X
M*V6G[0W@SX[:C\,=9?P3J7@G5_\ @HG:?M0Z7^TQX0^-"Z3<_#"+3O"_[%6N
MZ[\*[[P9<>-[+QAIR^&+W]F1- @N-<\)^&M9TY4ZB@G[OM.5U=$G!O+X\][N
M_+'$U:[BHV]G2FHRTDZ>:E+V:G*-INDY.G9WC-/,'R25M')X6E24KWYJL'*.
ML54_<^7]H'X"P>,-"^'D_P ;OA%#X_\ %'BSQ-X#\,^!Y?B3X,C\8>(O'/@K
M0M+\4>,O!FA>&7UH:UJ_BSPEX:UO1?$7B;P[I]E<:QH.A:OI>K:K9VFGZA:7
M$V3^T=^TA\'/V4/A+XB^-?QT\::3X(\">'I-.L/MNIWUA9W.N>(]=O8=*\,^
M$?#T6H7=C!J7B?Q1K%S:Z3HFG&Z@CENI_/O+FRTZWO+ZV_!#5/@[JFF^!_VR
MM2MOV;?BO#XEU?\ X. _V-/CMX+NM)_9A^*T_B'6/A-\.?VA/V'O$WC'XN^%
M/[*^',NJ:KX!\.^#/!W[0%]>>-](2YT%K27Q;;VVHSW/C&&#7?U$_P""M?@S
MQMX]_P""?_QPT+X>>#O%WC_Q1:ZI\$O%\'A'P%X=U?Q;XTUC1OA]^T#\*O'_
M (K3PSX3\/VM]XA\3ZS9^$_#.MZA9^'/#^G:CK^MRV@TS1=.O]4NK6RGRA*\
M8N2Y?>PO,WI%1KQP52=G923I1KUHR;O9TU)J/+4@JGS+VJBFY1IXEP25VYT7
MC(4U9NS=25"A));JK9-\T)'V5J_QU^"/A^W\#7>O?&/X5Z):_%!]/C^&ESJ_
MQ"\):;;_ !$DU>ZTJQTI/ LU[J\,?BY]3O=<T2ST]= ;4#>W6L:7;VPEFU"T
M2;U3( ))  SD]ACKD^W>OPG^(&A^*]>^*7_!4>W^+7P5^,_Q:^%/[=?[)'P=
MM/V7[?3O@Q\3-5N==\ :-\#/B'X"\5?LO^,[2]\(VS? GQII?Q7\;>(OBEIG
MAGXVR_#N*,?M!:]J[3V&I^"OBQ#X,^SO$/@#XO> /^"5&M_"[XI>#9OVOOCU
MX+_X)\W_ ,/OB/X!77]=6?\ :?\ BYX=_9SE\-^,?"7_  D]DUMXG$GQH\8V
M>I:.==LGA\09\1F_M=FI&, G*4*=2=KN,%)+5KFMBE*FTES\].6'I\[C%Q<:
M\7'9.I<4I3A'F5I3Y6TG?E_V=JK&]HN$XUY*"E)2YZ,TU9R]G]6>'_V@_@'X
ML\+>+?'/A7XW_"#Q-X)\ 1F7QWXQ\/\ Q*\&:SX6\%1+I4&NM)XM\0:=K5SI
M/AN-=$NK;6"^L7=DHTJX@U G[)-',U>']H[]GFXB^)4]O\>?@Q/!\&;S1M/^
M,$T/Q1\#RQ?"B_\ $4$-SX?L?B5(FN,G@6\UVVN(+C1K;Q0VES:G!/#+9)/'
M(C-_.7\0O"7Q \?_  K_ ."M5II7P;_:F\:Q_M"_\$./@I\/O@O;>)?V*?BU
M\*+'Q7\5O D'_!1/PI>?!_X;_"^Z^'0\3>"-4^'WBSXN_"S1_!/PI^*NJ>(O
MCI;^'-7TWQP?$?Q%^'UA'\5KO[K\ ?!'PSXO_;E7PMKWP"\5Q?L_?$W_ ((^
M>"O@+\0(=;^!GC_P?\*/$:77Q9\67FI?!SQ5J>I^#]"\,VFO6O@SQYXLDN?
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M@S1?'NE>)'\)ZAXEFU Z+9/96NMW6BWF@3>)O#UP[W]K]*:+XWUK4OC5\0?
M#ZG\)[GPUX5^'WPS\066EZ+X[N]1^-6F>(_%>M_$BVURX^(/PZ.APZ?X6^'V
MIZ3X=\,_\*S\31>(K^^\5ZW8_$BRN]*TZV\.Z?<W_P"!7QV_9E\8^#/V1O\
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MJ/AW+HWQ5\2^,!X]^'OC#Q%Q_P"U5\(IO%/[;/\ P4(\3WOP$\<>--#\8?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4;[I]U*,']J4>L).,NRE%RC)7V;4H23L]&NSC*91110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7Y%_'/_@G/\>/BA_P49^%W_!0WPG^U#\(_#VL? GX*>+?@O\
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M)I5YK6H\U\</^"*:?M :=_P5SL/'/[3^L03?\%2V^#RQ:QH?PJL;/6?@O8?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***\-UO]H_X0>'?CGX2_9MU?Q#K-O\ &?QUX3UWQWX3\(P^
M ?B'?6^L^#?"U[HVF^)_$T/BNP\*77@R#1_#6I^)/#FF^(+V[\16\.BZCXC\
M/V&IM:W>N:7#=%U=+JVTEU;2E)I+JU&,I66MHR>T6T=&^B5V^B3<8IM]%S2C
M&[ZRBMY)/W*BBB@ HHHH **@CNK6::XMX;FWEN+-XX[N".:-YK62:%+B*.XB
M5B\#RP.D\:RJK/"Z2J"C!CQOQ(^(GASX5>$+_P <>*[;Q==Z'IM_X=TVYM_
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M//@9\1OV:OV4[C]I ?%#PK\?_P!K7]H_X72>/_&WBC7OA1J_@[['\)+[XJ_
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M'P>^E^"?A+IGBS3/$'PX\"_%6+_A-_AU//X3@\0^ 8_H+]B/PK#X*_X*%?\
M!5GP[:>)?$OB73[*]_8??2V\7Z_=^+-?T2QG^ 6M2Q^'[OQ5K$U[XJ\1QP7'
MVG4[;4_&>KZ[XE$.K+93:O/I5EI-O:?67@C]@+]A[X:_"3XC_ 3P!^R/^SKX
M/^"OQ?N[B^^*GPL\/_"#P-IO@7XAW5Q,)TD\8>&[?14TS7QI[I"FB1:C;W$7
MA^"UL;70DTZVL+.*#T+X._LN_LX_L^7FM:G\#_@;\*_A5K'B72?#F@^)M?\
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MX9?M<?$+Q5I4?PT^-]O_ ,+4O?A]H7QD^'?A35[WX;6<$7C7QG^G/QU_8O\
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M?P_HNH1>'?#>D6<=I96=GHVA3PZ;I]M#:V.GB**.)?E#]@W]BOPG^R-^S?\
MLZ?#'5_#/@:Y^+'P5_9Q\ _L]:Q\1/"#ZO-;ZII_A7PYX4TCQ?JO@QM8L]-O
MOA_IOQ;\3>#],^)_CWPQX:M=-MM:\?NGB#Q+?^+?$VGQ^*[IOF=><[M0Y:;2
M48)2?-B54@HW<8<\)TN?D344ERRYXPDA<L:,863ES5+W<VXKEH.#<M)249QJ
M<MY)M[QY'*+_ "2^#WQP_:7\._LW?LC?&WQ_^U=\??B#K7[7_P"WX?V'/B1J
MGBB'X1Z;X(^%7PZTS]L']IW1-$\6^$M&\%?"3PI-X8^)7Q;C\ ^#OV;KSQA+
MK7V;3[KXIZ+)\/\ 1_"6J^&?AM9>&C]M;QG\8+'X3_\ !4[]E_7_ !7XA\>?
M"3X'_%C_ ()?^,_@#X]\9RR^*O%OA"/X\_'SX6:GXU^!GB'Q=>O_ &M\0_\
MA5WB#P/IGQ$T+5O&VHZO\0%\)?&KP_H'B7Q)K&FZ9X>OC^\%A^RQ^S7I?P=U
MC]GK3O@-\);+X#Z_=ZCJ&K_!NV\!^&XOAE>ZCJ^O+XLU/46\$IIX\.Q:A?\
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M&T:&Y^%GCB[LOBDFL? '58? >CW$-QX.\8-K*#Q9X[^%ZV5L^L?IA7Y#>(O
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MW^TYJE>Z<;NIR0Y&K-I\ZY6^1<[:ER\S?/'EC+ETY%%U.6S4VE!U)<V_X_\
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M6]A!*8+>WA3Y_P#%_P"QMXX\4^/OV'?B!<_M":EKNM_L;^./B3\2=5U;X@^
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M3]J[X#:5X \)^-(?B'XK^'_@GPW\,-)\>?![XCZ_?V^M?L[>-]?^%_@[PKX
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M^(FO^.?B#\0?B?>ZCX8^$=CX2^%LS^-_"_@[QQXRFMM"U#2-*\&^(.C^#_\
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M:O&WA/\ :N_:/_:@TWXI^&9Y?CY\'/@?\(K/P1?_  OU.6'P7!^S]??'#6_
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MV27UGEG:VD9*C3:3:?[Y)Z.GS>P>'?VAO!T7BW]I23Q'\=_@GXI\)?"'Q_\
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MFI>$O%^E6OQ(@LY/^$#\1:F\UHT_M?BS]H/X/> _&&E> /%WCK3M*\5ZK?\
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M,U2;:5U9^]JN:4&U#F2CI&JDW*#YITXR252,H.I3E%_M3X ^(7@OXI^%-/\
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MFQ^Q!X4_:1^&&IZ?^R+\<OV,-3\2R? S]J;]I#XW^ ?VY_$VK_!?Q+\&=?\
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MB_X5MKRZ3X^:':_$C7]8T+3-)\->);VTLO 6EVFM2ZEK.D6MWI\=IILOZ/\
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M3XFQ>(M!L_@OKWQ%_9XM_'=SXQ^"?BO7&\7Z!\1- 3QYK2:=X+FO(?"JV_\
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M>:+<>.->M- @\5^)K;2D=]!\ ^&7NQJWC;QA>[=+\+Z#;W>K:@ZV\#9[_/\
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MXS\SPC\2]+^&GB"[USPEX.T[P]9^=?M"77Q'^#GPX_X*W:SX%_:1_:MLI_V
MOVM?V7?%'[+\>N?M2?'#Q<O@L?$/X'?L9?%CQ]X2\?:AXN\<ZYKGQ[^&GBSQ
M'\1/&=K<?"_]H;5_BE\/?#GA[7KK3/ GAOPD=MW5PC[6\=+6I\UUS+EJO!I7
M2?\ U&1335I*G)IN-2FYVU.*4DGS*4U&TN1\U/V[BU)[7>'NFM8<T6_>IS4?
MZ:_!_A+0? 7A7P[X*\+6EQ8>&O"FC:?X?T"PNM3U769K'1]*MH[+3K)M3UN]
MU'5KQ+2TABMH9+Z^N9Q#%'&92J*!TF1^F?PKX5_X*7_'+Q]^S7^PI^TC\<OA
ML^J6GB/X<^";36[[Q#H6A1^)-=\ ^!9O$^@:9\4?BGHFAW%AJMAJ>L_"7X97
M_B[XF:5;:OI&L:$;_P )V[Z_H^K:*M_IUS^?WQT^-_@7X5V.CZ]^R]^V;XZ^
M,GP5_:%_:P_X)W?#?XX7.F_'^^^.WAW]ESX._&CQIXA\&7WCGX>?&V[UOQ?X
MU^'FD?M4WFG?#GX3:U=3_$AX? B^)Y?BI\)KCX<>-_%">-94G.<VDN:4JM.F
MVW=NI7]Z,I;RY92DTY^\^=V:DY7<OEIP3TA&-.<TK<L5"C[LHQ>D>:*2:I^[
M[FJ:2LOWKR/7V_'TI,CU'YU_-U^VK\0/CS\%_@5_P73\ _#[XT_&C3_AO^S]
M^SC\#_C1^S[\2H_BCX_U7XF_!GXQ?$7P1\1M;^+_ ,)=%^-VNZ_J_P 0KJPT
M2#P-\*_C!9>'M:\4:CK'@K2?C]_8^B7FD_#[4/ OA[P_U7[3O@?Q5H_QO_X*
MB_"_2OVC_P!KS2/"/A'_ ()F_"K]M7P=;Z)^U5\;M!U;P3^TSKGBS]O'P_J'
MC_P/XAT7QC8:]X'\(RV_P5\!W1_9]\(ZEH?[,,]W8W"ZA\%;ZQDM+*Q2DG3J
MU5_#HT9UIMQ:ERTL/6Q-2T)--VCAZT8._+4DJ;BU3J<].U";G2I67/6KPH07
M,G'GJUJ%"FW-723EB:$I*SE"+J*47.GRS_H<KQ+Q+^T%\./"?QZ^%?[-FL7.
MO1_%+XR>!_B=\1?!%G#X9UN3P[=^%?A#=>"['QQ=77B\V:>&[?4--O/B#X2A
M304U&?79(]7@O7TZ+3V6[;\/M'3QO^U[\6/B'X<^*7[9?[17P(T#Q!_P1P_X
M)]_M53ZU\'_CMK_P6T?X?_&?Q]X@_;+T[QS\>-*A\-7^CV^CZ5HD'@GP;JGB
MSPG'<VWPJ\60Z=IMO\3_  OXHTZTT>"Q] ^!_P 1/BK\7OC_ /\ !!KXH?'F
MWFTWXV_$_P#X)C?M<^.OBM;7&EP>&M0_X6)XL\$?\$\-=\83S^&H++3(O#5_
M/K=_>WEYX;@TVS3PW<S2Z0+:%;':.AT90KNC4MS0G)246[22>9TDXR:_Y^Y>
MY-.%U2E&3=W-4\858U*7M(72=)SBVEHU#+JO+)7UO3QZ2:DUSQ:M;D=3]LOA
MMX^M_B5X6'BJV\+>//!L1\2>.?#8T/XD^$=3\$>*?,\"^-_$7@>;63X?U=$O
MAX<\43>'9/$_@?6F46WBGP1K'A[Q389L-8MC7>5_.E\!_C/XC\3_ +//[#7P
MO\:_'KXX^)/B;\6OV_O^"G_@W1]&O/C5XP\!WOQE^'O[.GQM_;QM4T/XN?M)
M:1?GXI^!_ ?P<\#^$_!>O^'=/^&\FM>)/$.N^"/A_P" YO":?"0>._$/@CS_
M /9V^+'Q>^/OPP_X(9:=XR_:.^-&H6WQQ\:_MO?";XR:WX$^,/BKPKJ7QB\#
M_#KX"?M,V_A$^+/%WA35[+Q+K7B"TT_P'X6U72?B5!KD/Q*T_6XX_B+HOC&P
M^(7V+QC;<M.?/&+7VO8J-VO>]K"+N[7Y>6;M)6=N;W;J*3VJQ=*4HR^S*K%V
M3T]G-JRYDN9..JEIM[RBY-K^FVBOYROAS^U)K_P[\*_L*?!CX^?'/Q]H?P!\
M>?MX?\%5?V6/%/[0'C_XM>)/#WC#Q#<_LK_M"?M0_#[]COX)_$;]H^ZU_1_%
M]IJWC'PA\.C+%XJF\::9\2?BYXT^#GAOPWK7BCQ,GC3QQH?C/L?'_P :M#\%
M^-/V(/V61^WE=WW[-_QG^&G[<MAX7_:H^,?Q"\=C5/B]\7OA;\8/@]I7PS^$
M(_:%^!OQC_9M\5WWBOX??";QE\9?"WA3QAJ/Q-NY/B[-X D\5ZX_C3XK>'M.
M\4JXSYHPE%-JI;DO;XG3IU5&:3?(W&HG%7DIV:BVW%2FZ][7X;MZ25XJ=2GS
M0;2YTI4I*6D7'3FLKM?N3\3_ (9^"/C-\._&OPG^)>AKXG^'GQ&\-:OX-\<>
M&9=0U73+3Q+X4\06<NG:_P"'=2N=%OM-U"31]=TR>YTK6;".\CM]5TJ[O-,O
MTN+"[N;>78\(>%-!\">%O#_@OPQ:W%CX<\*Z/I^@:%976IZKK,]EI&DVL5GI
M]F^J:W>ZCJUXMI:10V\4M_?74XBC1&E8*,?*W[,'@W5_%O[%/@#X=>,_VJ/$
M?[3M]J?PUUGP)>_M;^ K>_\ @YXK^*&G1W6M^&]+^*'A+5_"WB76[C3]<DT>
M&PN='^)GA;Q5J6G^-;VS@^)/A_4KG2_$=D[?AA\*OVO_ -H+X::I^QS\1/'=
M]\8/B5<_LVI\6?\ @E%^VQX?O_BI\7KK0/B?^W?%)XF\,_LU?$J+PHMY?^&I
M?%GQ<\:_!GP990>.?$VFWT,NA_\ !2#X$ZM-=W1\(C4O"-O2<X1=[.+6\?::
M3A%J,^6TO:2HT5&34N;%TK/DDY-*[@I\NW,GM+D=X.2YH\VCA"K5;46N3"U.
M9<T5%?TNZU\0+?1/B%X$^'<GA3Q[J5QX]T;QQK-OXOT3PAJFJ_#WPLO@7_A&
M#/IOCOQE;(VE^$M9\3CQ/'_P@^FZFR3>*CH?B9=.+-H=TIX/QM^TI\)_ ?C;
MX$^ =5UC4M3UO]HSXI^-_@Q\-KSPQH6J^)/"\GQ#^'/@3XF?$/QGX>\3>,=*
MMKCPMX4U31-$^$/C^TDTC7-7M-=NM;\/:MI-AI5U<:-KITKX!UO2O'_P=_;D
M_P""7/[/\OQK^+OBSP[K'[)?[<.F_%9=:^)GCV\MOB_XQ^&5G^RG#H_Q(\7V
MFK>)]5O=0\3V&J^/?'-_H=]=ZG>7'AJ/Q.=/TJY@MM+T1=/_ #6_97\ ^']0
M_9Q_X)%^&K7QA\1[>?Q3_P %>OV^+/Q-?0_%[Q]K7C"WTVS^%7_!:OPU<+I?
MB3Q/XE\0^)/!>I>(K'1M3TS7O&/A.^\/^/+S7Y-=\9V?BNP^*"#QE9%GS1BF
MG[VK3;4O]K>&:B[+E3LI1FE+W6FX<VBSJ3<(.5FKPBU=?!S4%63DD[N2UBZ;
M:]Y-*32;?]4#*KJR.JNC*596 965AAE93D%2"00000<'BOA=]2_8N_X)C_L]
MZA9>!/ WA_X1?!KP7XZ\ >%M5\'_  ;\%7_B"ZT[QU\8?$?A#P!X(?Q3I_AN
MVU'4K.YUN]UWP9HR>)_&MW::?I7AQ?#UO=:Q8Z!8Z1%%P'_!+GQ9XKUSX(_'
M'PAXH\9>,_'=M\$?VYOVX/@1X&U_XB^-/$_Q(\=I\,OAA^T?X]T3X>Z!XG^(
M7CG5_$'CCQO>^$O"YT_PM:^)/&GB#7_%>HZ3H^G/KVMZKJ*SWLWY+?M1^#_#
M^A_#3_@N!?6?B/QG9Z_=_P#!4']A*VMX]7^)_C?Q3;V5GXB\!_\ !'KQ1=ZO
MI_@OQWXD\3>#4N=-\0:Y]F\.:A/X6N8/#OAW^QOASHR6OP[TG1?"%DHM.M2@
MKN-:%*;:7*Y0E6R^T'K[K:QLK7<E&I%2BGHV59N-*I))<T)5X)/WE&I3H9BW
M-)6YDI8**:23E!N+:NC^FKQKXHB\$^#?%OC2?1/$_B6#PAX9U_Q/-X<\%:%>
M>*/&6OQ>']+N]5DT3PEX9TY6U#Q%XFU5+0V.@:%8JUYJ^JW%II]J#/<Q@W_#
MVLQ^(M T/Q!%I^L:1'KNCZ9K,>D^(=,N-%\0:8FJ64-\FGZYHUXJW>DZQ9+,
M+;4],NE6YL+V*>UG42PN!^"GC?Q/\1?A+IO_  7T^$_A+XV_'4Z!\%OV6O"G
M[0WP<USQ7\:?B%XZ\??"#XC_ !-_9E^-'B'Q1>?#GXA>-]?\0>,_"?A8>+_A
M/H'C#PWX%L=;3P'X*UB[UZT\%>'/#WA[49=$6I\;_BO\9OAIX9_9_P#V@O&>
MO_%3XL?LP:)^R?\ L9WOQSM/@=^TAX\\ _M)?LR>,[_Q)XG\0WO[4WB?X6Z=
MK6EZ9^U3\)/C'*?"O@[XF^&_%FM:CXPTS1/A3XPN?!/A3Q_;^)_B-I,1#W^6
MS^/ZNHMII)UI8BG9Z6NJM'D4I.,7S4G>FJWNZ2?+S=>5XE-+>3P\</4=D[/6
M%=2M'F:Y:MXS]E>7]!U&1SR..OM]:_.K_@J'K_BWPI^S5X)\1>"?BEXY^#VN
M6_[:/_!/#P[-XV\!>(X?#>I6GAGXD_MX?L[?"SQU8:K)?6M_HNL^&]5\"^-_
M$FGZSX<\4:;JWA+6+6X^S^)-&U?2A/83_FC\6?B5\9?V*-?_ ."@?PX\,_M"
M?&KQG^S-X2^(G_!*?6M2^*'Q:^)OB;XI>-OV3?#/[6_[1NK?"S]N;1M*^-/Q
M O/$GC2VL/!/[/F@^#/C?HMEK7B&\?X V_Q@T[X@:-#H_@Y]*MXES:VL]9JG
M&T92O-QPTDGRI\L6L3#WG=<R<79SIMC:2;=O=I^TEJE:'-7C=7^)WP\_=5M'
M>[Y9I?OM\:?B[X*^ /PB^)GQP^)%SJ]G\/OA'X&\3_$;QO>Z#X=UWQ;J]CX5
M\'Z/=Z[KU[9>'/#.GZIKFJR6>F65S=/;V%C/(L,4D\OEV\4TT>=H_P 9=$U_
M6?A#I>C^%?B)J&G_ !E^''B+XFZ#XPM/!FIW7@7PUI&@0> +JWT3Q_XMMO.T
MCP?XN\56OQ"M+GP3X>U&8W'BF#PQXXDTV21?"][N_%G]K*^^(OPY/_!9+]GC
M2/%?Q"\;_LWV_P#P2#U;]H.T7XF_$#Q1\3=1^$?QN^(?AC]L'X;^(?"GACQO
MX^U'7O&Q\(_$3P-\(/#WC ^!]4\5:SH_@?7?#NKZSX?T_P .6?Q"FM]0]0U7
MXB?%7P-\?O\ @F[8_#;6?&&O6OB+_@EA^VGXW?X-VOBC7H? 7Q&^(?P?T;]A
M"7X33:KX2L+V+2-1UVSNOB1XNT33=9>TEU6"T\57,%M<JJVXBM+]W.HTVHQC
M5M%-R5.-#-*E1<D;RG-RP"]FH-\ZE%*ZG/D).W(KI.525+5I)R=3+(TWS2:4
M8VQ_O\R]WEDW:48J7[:9'ZD?B,_X&BOQ!_82\>?!O]L/X0_LX?$K1OV[/B]X
MT^*?[1G[#]]I_P >OA7X%_:$U6?53\2M9T_P#??$[XT1^"-'U[4K[]E;Q]\$
MOB=>>,/A^@^$-C\+O!GAOQ%\0]&^'U]HTT'ASX<Z)IG3_P#!/#QE\:/B?J7@
M+X+?&7Q5\2;CXJ_\$V-$^(/[/_[4>OZIXI^)EI8_'OXYWMUI/ASX+?%?5Y]1
MUDZ9\2-+^)_[.&DK^U+JOAWQ='KR>"=0_:,^$4VAS6NJZ'?):CC)2G!\MX<S
M;C)3BX0J3ISJ0E%\M2FFJ+C.+M..)HRB]=94TX1GJE-I*,DXS4I4XSC&<9*\
M)_Q82A+WHSH5$UI=?LO17XM?\%.OBF]OXXUKX6^%?C/\3?!?C;PI_P $]?VS
M?VB[[PMX7^,'BS]GGP1X4T3PIJ7PE\,>&/V@M>^)7P]U32/'GB[QYX#\3:C>
M>&_AY\)(S=?#76+3Q5XR\1?$K7O VL:-\,G\7>1>!=5^(7[6'[1O[$_@?XD?
M'W]H'1?"7Q__ ."*NO?&GXIZ+\'/C9XY^!\>N?%RU^*/['[0?$;2K_X1:SX0
MUCP7XRTW4/'.OXUOP/J7AV\ETZYN_!.H277@+6O%'A/7\G4M"<[:0]H[7B^:
M-.CC*K:=[)OZC6ARRLU)PNTN=PT:Y7"[LIN*O:5TY3PT=8M)M)8JG/FC=249
MI>]RJ7[ZZEJ$&E:=?ZI=)>RVVFV5U?W$6FZ;J.LZC)!9P27$L=AH^CVM]JVJ
MWKQQ,MKINEV5YJ-].4M;*UN+F6*%_*_V?OCG\/\ ]IOX)?"_]H/X47FI:C\-
M/C#X,T7Q_P"!=0UC2KK0]3O_  OXAM5OM'OKS1[X+?:9+=V<D5P;*]CBO+=9
M%CNH()UDA3\//V-/VH?&O[2^O_\ !/OX2?M,_%WQSX=TSQ]_P19_9]_;&B\1
M^'_B/XM^">J_M _'[QI_96B_'3Q3K7C?X?ZUX*U#6;WX)>$](\.^++CP-I&L
MVOA6"/X^:YXQ\7^$M7;P[X U3P9]N_\ !&)K'6_^"1W[ $$>H"]MKG]DWX5Z
M;=7NDZDUK,)5\*6UE?B#4=%N()]-U""99HWET^XM;S3;Q&\E[:Y@4Q[.+C[6
M]FXI.%I*S_VBO0?-;FY6W27NMMPYM;RO%8JHI.CR[34W.Z=U;#T*T$KV;M[2
M7O*RE:R224G^H]<)XO\ 'MOX.UKX;Z+-X7\=>(7^)7C:;P/;:EX/\):GXET7
MP9/#X(\8^-_^$F^)&J:>C6_@GP3+#X-D\,0>*=6*Z?)XV\2>#O#((O?$=H1_
M-)>?M$?%W]FF\\$VWQ%^)O[07BS3_P#@E!^W#XS\#?MR>)]=^-'Q9\2#XE?L
M7_M:^)[>Q_9(^)OQ"\,6,VIW7QJUKP=X!_:%^&'Q7\2:BHUV;P2W[+GQI\,3
M:/#;>*?#6CM^C?Q%M?BW\+O%/_!).'6OB'\6M$\5?%_]NCXG_P#"\?!ES\6?
M&/B'0KRV^*?[%?[<WQ^U7X.:VUUK^H0>*_A[\(?'OA+P;H/PTT>_GN]"T'2O
M &@W.EV4,^Z9HC>2I2V52I2@MKM55&<+VD^5.#J-VO)2P]6-KI7NI+D]HGJX
M0J2;6UZ<G"25TKVDZ6Z2<:].5^5GTQKG_!0[]FWP]\*OCE\9=1O_ (B1^!_V
M>OV@X_V8?B),OPJ\>KK5O\6YM<\ >&(=/L/#L^B0ZR?#,WB'XE^%M,C\<ZI9
MZ5X.>*YDUP:T?#36FM7?W'7\P'QGFB7]A+_@LFYFB"Q?\%== 61C*@6)_P#A
M;7["1"RL6Q&V'0[7*G:RG&&!/Z\_\%8O$OBWP5_P3*_;V\<^ ?&GC'X=^.?
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MC70_'/C#POK_ ,4?"?BC3+.W\)^.-#\*PQ^&D]I^!'QI\5?M%?&K3_&.M?\
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M^'FUG5OB!\/=.U75+#P/XRO[VX\1^$[+4K^UT'4K""\N(Y+/[2'QW\*_LS?
MWXD_'7QG:ZEJ.A?#OP^^J?V+H\$MSK/B36KV]M=$\+^%-'AAAN&;5_%GBC4]
M'\.:6S0O#'?:I;R7&V!)67XPU+]L[]K63PS^U!-\/OV&=7^)'C3X*_#?PO\
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MK*,K;7VLSS:I=12WLKSM^+VG?M/_ !3_ &/?C3_P5"^*%E\'?#?Q ^$GA_\
MX*._L>^'?C=<ZM\<]?TGQ+X#T3X_?L@?\$YO ^KW?P2T*]^&OBN+XCW'@_QI
M\5M6^(.L^'O&.N?!#0;S0U&F>$[^;6=<OK3PG]J_%7_@H7XJ\/\ C[XI>%_@
MC^S=\1?V@[+X!?'SX7_ KXM:9X)\,_%6]\5ZC/XRT+X4^,?B-XJ^&NJ^'_A1
MXF^$%['\%O _QA\->(=3\+>/_BGX"\0>-;SP]\1-"M$\+'0_!&J?$ZN5\T$N
M7GG&FG:2T=1*23E[KY+U(VG+EIOG;O&TA*:E&4FK1C*JTGK=4I.G*7+[UIWA
M)."4IKE4?>=D?>GPZ^#/P?\ A!'JT/PF^%/PV^%\.OSI<Z[%\._ OA?P3'K5
MS'>ZKJ4=QJR>&M+TQ=1GCU'7=;OTEO!-(M[K&JW083ZA=R3<KIG[,'[-6BI\
M8H]&_9Y^!NDQ_M$375Q^T FF?"7P#8)\<Y[Z#4;6]F^,2VGA^)?B;+>6VL:O
M;W4GC4:V]Q!JNHQ2L\=[<K+P'[8_[2/B3]EGX;>!/B)X=^%T/Q;/BK]HS]F7
MX#:EX87QS;>!=9M+;]I'X\> /@+I_B/PW<ZCX=UO0]?UK0->^(>CZE'X8U_5
M? ^CZM9PW:7?C?0!&LS_ !IIG_!3OQUX+\2_&SX'?M(?L[>&OAQ^U-\-OC3^
MR'\)?A[X%^'7QJU?XF?!CXT6?[=.O:KX:^ _C/P[\9O$GP7^%OBS0]#\-:YX
M)^,=I\:X=7^"9UOPOH_P:\2:_P""=$^(-_X@\+>%+W-2@Y."Y>9*-/E;BG+F
M5)JG!.W/I*D_9QNN5)J#5-JGHXR24K-Q=ZG,KM1Y747M)-7Y;251<\K--OWE
M[2\_U'\!?#3X<?"O1[CP]\,/A_X)^'&@7>HR:O=:'X"\*:%X/T>YU:6SL=.E
MU.XTSP]8:=93:C)I^F:;8R7LD#7+V>GV-LTI@M($CXG5?V:OV<M=@\86FM_
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M3W/[%-KXHU'XT^+O%OQ3\!Z+8?M,ZC^QS;_%BST+QW:^*'UWX2^'_P!J1?\
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M6/XB?%W1_ 6N?LH^-/&OPO\ CCXECU'X7?"_6?&OCKP3H7Q%\)Z?I/A>ZMO
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M'_PYOM(TR_2\TG2/$'AGQUX,\3:-XGL[[POK</B'P-H'SA\?_P!O;]IWX?\
MQ7_;&^%OP._8^\!?&N[_ &/_ ()? W]HS5;S7/VF=2^&]_\ $;X;?%.P^/\
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M/4?@U/B[X_U;P78^)]0T3Q+\9?B'+\-_AQ>^(_$-I<>&? -C=^"[&'P)\,?
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M3D\(?"WPW\"_@XWCZ^\3_LS?LJ?&>Z^-W[-7PEU/P[CQ+X(U>V@\=_\ "O\
MP%XQ^)-QXBU%?'_PP^"5]\1=6N_@[I47@OPKXST1/!WPIB\8^/O'=QX/UN]\
M:>^?M?\ [-!_:G^%OASP/8^/+GX9^*O ?QL^ _Q_\ >-8O#MKXOLM(\??L_?
M%KPG\6O"T>N^$[S4M$C\1^'=5U'PJNCZYI<6N:+=R:?J$T]EJMG=P0R5]344
MGJDFV^649IMMOGA['EFY-\TIKZO17-)N35**DY*_,TDKV25XRA9))<LW5<HI
M))*+=:J^5)).I)Q4=%'\N?B?_P $VKSXG>$/VR/"&H_'S4+2+]L?XZ_L_P#Q
MX\4ZU_PK;1Y]:\*^(/V>?"W[/W@WP]8:6(?$EAHVH0^*-%_9E^&DWBJ6;1K.
M ZO?^.[OP_I^@V.NZ!I7A'9U'_@GUXRL/VH_B-\>?A3^V)\:/@M\,?VB=8\)
M>+_VK?V;/!7AGX:ZAX)^+WC[P=X&\+?#5/%_@?QCXL\.Z_X[_9_U3QUX \%>
M&?!?Q5U;X7ZI9>+_ !1HFE6.K^'/%_@GXAZ5H7CW2/TMHHZQEUC:S:3TC3]D
MHNZ=X\EERNZ;C"33E"+%R1Y7&VCYKK7[=3VLFG>Z;G>7,G?WI)-*4D?FQ_P5
M1T+QEXH_9Q^&^A> -&^(&K>*4_;:_P""?'B^&[^'/PP\7?%G6/">@?#']MWX
M"?$[QMX_O?#'A/0/$,C:+X \$^$/$/C'4WU>VATRZMM$?3?,FO+VTL[E_P 2
M/^"<_A;XUV'Q1\9?$SXDZJ?VC?B-X_\ V:_BAX<^.7@/PCI?A>/X.^)_V._$
M4_C/]FJR^&OP\\87WQ$LU\*>#_&&L^/?%'C#0O'VO>-M2\>:C\8/BSH]YKNC
M>#=9\)>%/ OZ245$8*+G+=SG&=[1O%PA3@N67*Y)_NH2;YMXI62OSVVVHK91
MA*#5Y6DI2J2?,N:S5JLX\MMG=MOEY/@'X@?L+Q_%KX<_MD:3\0_B7%=_%_\
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M%6M&*C%*,4DHV7*HV5OE']K;]F*;]ISP[\(;?2/B/J/PK\:? W]H+X9?M$>
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M23YGRVES+E7/+ECM&[MIH?%6K?LL>/[OXT?'GX]:!\>#X+^(?QK_ &;/@O\
ML^V.H^'?AK8S6_P]O/@3XL^,_CSP9X_T>R\0^*]=M=<NKCQ7\?OB-)KWACQ!
M%=Z/JF@Q^$=#::)M&US4O%7S_P"-/^"8.B^./A_^TOH-Q\2]$\'>.?VLOV@?
MV>OVB/BSXD^&OPIC\*^!!XQ_9O\ %OPQ\;^&+GPQ\+[[Q[XA2QUWQSXA^%'A
M^Y^+/C3Q!XO\4>)_&T6H:Q$;W2W@\+3>&/U5HHBW!QE%V<4E%Z/E2J*M973L
MG42G):J3C&Z?+&RY(^\K+WVY3W7-)TY4G)V:][V<I1NK-*4K/WF?"7Q&_8QU
M+XR_&GX8?$GXL?$_2/%GACX'?'K3/VA?@IH]M\+K'1/BA\-/$MEX!M_!VH^
M]!^-%OXMN+T?"/Q1JIU3Q3XM\+OX.7Q+XD357\%ZOXVO/ =E8^'8?!O$G_!+
M637/@QKWPJT?]J/XH> =?\'?MF_$S]N']D?XJ>!O"W@O3_%_[,7Q;^)_Q/\
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M7.U:W-S5ZSO;>I+35<N:IP48P48J,(\D5;2,.6E'E7:*C0HI+I[.%M5K^/\
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M).SJ5.6Z?(JDU%).R_#C_@EE^R?X]UG]CS_@G;??M%7?B[13^R?!KGQ!\"?
MOQS\%->^$GCOP?\ &34?#'Q0^%\%_P#%"X\87$.I>*[#X?\ @CXJ>/-,^&UC
MIG@?P399UG0O%WB#4_'7BCPUHGB6/W"#_@F7JT'BKP6Z?M2^/K;X7_"S]O[X
M@?M__"[X>6/PZ^&L>J>'_&7QBU?XW^-?BM\.]?\ '%_IFIW'BKPAJOQ#^/OC
M_4_!U\V@Z/K?A#PAK-YX6O[GQ9KMKX5\<^%/U7HJDVG&2T<%!1ZVY/86;;W?
M-AJ4[O9JR7*E$37,YRDDW4E4E)I6_BO$\T8V?NQY<75A9/6+NVY>\?A5^W!^
MQ_XY^%'_  39_P""HO@GP3JOC_X[^,OVLO&'Q0^,_ASP?\-OA!K6K^.=(\=_
M%RZ\*66H>$?"'A_P</'&I:]HNG#P[87NCWFK:/<7.ER_VI<^(=4U'2YK:WTO
MZR^*G_!//X?_ +66C_&K5?VFO&&M>,O$/QU^ WAOX":#X@^'_A>\^"^H?!KX
M?>'O'-Q\8O#7BGX?:)XHU7XA:WH?QL@^*S>#_'^N>)O%=WJ&@2Z[\)?A38+\
M+]"MO#GBBR\8?I'14I6V;T]DHM-IP5*C[""CKH^2WOJT]$N:VI3=U%65DZK:
MLK2E6K*O-R3337/=\MG%\TFUJT_B.S_9,\9ZAKGC+XN^-?C@=1_:BU3]FK6/
MV8_AW\<O!GPSTCP?8_"?PWJ^J77BO4?'7A_X<:SXB\=:;JWQ \4>/(/!/BGQ
MY_;&O2^ =<7X5?#S1O#G@+P796_BY_&/SG\0_P#@E!X'^*VG?'_Q1XA^)UY\
M-OVA/CA\4/@#\=--^-7[.'@;2_A1:?"_XY_LQOJUQ\*OC!X8^'7BK7/BOI>O
M^/-4;Q!K>@?%_6/'.M^))?BGX N[+P3>C1K/1-&OK+]:**+:MJZ;32<7R\MY
MJI)PY>50<JD54;BDW-*>DHIJ;+UVNG[R:C"5.*DI<W,E3E*"4K^[)Q;:9\%>
M'_V6/VA]-^&VE>&O&G[8,WQV\<:S>>)H?C5K7QU_9^^'?B'X4?%[P9XF\(GP
MD_PT?X&?#W5?A=HG@WP/I"I'KMC;:3XEO=<U36;S7T\8:[XIT3Q'J>C/Z7\*
M/V//@_\ #']CGPY^PY=66I>/?@=I/P3OO@'K6D^+;Z4W/BOX>ZYX<O\ PMXC
MT74)-(;35TO3=5T;5=1TRTTKP^-+T_P[I$MKH_AV'3=/TW3X;?ZJHH:3C4BT
MN6JK35DE**O:.EK17-)J*=DYS:LYRYFO=<))M.$G*#N[QD^6\TW?WGR03ENU
M"-[\L6O@WX+?L0GX=ZA^S9=_$KXM:M\;S^QGX$\6_#G]FG4_$/A6QT#Q5IVD
M^*O"V@_#L>./C'KFG:O>V'Q,^,6D?##0)? =KXU\*:!\)?#5]I_C?XEZGK'P
M_P!1UCQ%H%YX/]!_9)_9EO\ ]EW0/B]X?N/B(/B';_%G]H?XW?M'S3/X0A\*
M2>'/$_Q]^(&M_$OQKX;L!;:_K:W_ (7TWQ)KUW%X36_+Z[IVD".SUK6_$5RJ
MWZ_6-%6Y2;FW)MU')S;LW*4ZD:LY-VOS3J0C4G)6<Y).5]B5"*4$HI*GRJ"5
MTHJ%.5*$4K_#"G.4(QU48MI6Z?F9\:/^"<Q^+&K_ /!09;'XZZ]X2\$?\%%?
M@3HGP>^*GA#_ (0/P[KUSX3U>Q^%^I? W5_'7@[Q//?Z=?JVH_"6^@L-.\,Z
MG:W=EH_CFPC\83ZAK&DW%UX-EV/BM_P3L\*?'_XA_'[Q;\</'3^*_"_[2G[$
M7AO]A_XE^!?#GA./PI"GA'P[XC^)?B^'Q]X5\077B/Q+J.A>,SXB^+?BZ[L#
M-#J>GZ3#9>$/LL+:GH5_JVO?HW14**2:Z./(^KY;5HI7W5E7JJ+3C*/,G&2E
M&$HNRYN:VO,IW_O*=*=[;.\Z%*3NFI.+YDU*:E\9_LE?LU?&OX"Z1>VWQW_;
M-^+W[8NN66G0^%/ NM?$CPA\,?A_%X1\#V4L,D46J6/PR\-Z)<_$;XC:VMGI
M$?C'XG?$'5=?U#41H-C+X4T;P/<:WX_E\;?&ES\'/C!\4/\ @HI_P4/TK0=>
M^('P:^&?Q?\ V//V,_A!J'Q.N?@9XLO;'Q/_ &'JW[9=I\1?^%%_%/Q$-#^'
M.E?%CX;Z-\6/"U]I.LZA9_%GPG9ZEXJTZYUGX<>*XO#^KZ9%^R]%*45-IS2D
MN2K"46E::K4_9SYU9*5US.2:]]SGS6OI46X1DH>ZY.DU)-IP=*HJD''71IJ*
MCJU%1C92MK^<MG_P3N\,_#3QQXS\2?LO_$.]_9X\+?%G]G/X5_LP?%7P#IGA
M+3O&VE'P/\"?#/B+P'\%_'GPGU#7M6MKKX>?&GX>_#WQ5J/@:T\4>*(OBEX!
M\0>']%\#)XM^%FO7WA*"\O\ T'PE^Q5X6^&GQN_9S^)WPMUZT\%^!?V8/V1/
M&G[&GPR^$(\.7>L:58?##Q?K'P0UJ":3Q1=^*8M9DU'PS)^SK\+]*T3[1!=(
MVAQ^++?4WO\ 5-=TW6?#OVS13DN9\TO>ES.?,]9.3==MN5N9^]B<1))MQ4JU
M22C=KE2]U<L=(\JARK1<J5%6LM/AP]"+>[C2A%MKFY_Q\F_X)/7&E_ CX ^!
M_AQ^U)XZ^%?[07[*OQQ^/7QQ^ ?[3OA;X>>"=2U70KS]I;QC\1_%?QB^'OCK
MX6^+I/$7@GQ]\./%4/Q3\0Z'+HSOH&JVUMH/@'4[?7$UOPYJ6H>(]C]JKX)W
MGQ ^"G@C_@GWK]M^U;\:_B+\4]1\%?$V?]LVPTJS\')\+O'/P\^.7@CX@7OQ
MQU'XS>!-/\'^#_A5\5?AI?6:^./@M\,O!VC:$-8LO">B?#CPE:6/AR&^NM._
M6NBCE5E&R<.:#<&DTU35)12;4G%/ZOAW/E7[Q44IJ7-*3;;<G.[4VII33LTZ
MCJN3]WE4G;$8A1O\'MI.%DE$\FN?A]XETSQ!\&HOAUXVL_AS\*?AK9Z[I'B?
MX1Z/X%\-WFC^.O#K>$E\.^ M L=<G\G4?A[8?#W48;36K"/PO"4U>"UCT&_C
MCTW!7UFBBG=N[;;;<I-MMMN3YI-MW;;=WJW:[MN[RDDDDDDE&*2T2459)):*
MRLM-[*^RL4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***\P^-?QB^'O[//P?^*'QW^+&NKX:^
M&7P=\ ^+/B9X]UXVMS?R:9X3\%:)>^(-<N;73K&*?4-5OQ86,R:=I&G6]SJ6
MK7SV^G:=;7-[<P02)M)-MI);MNR7JW9?UZ7:3;22;;=DEJVWLDOZ_.WI]%8_
MA[Q!HGBS0-#\4^&=6L->\-^)=(TSQ!X?US2KJ*^TO6=$UFR@U'2=6TV]@9X+
MS3]1L+FWO+.ZA=XKBWFCEC9D<$_.&L?MC_!+P_\ M>>#_P!A[6M1\1Z?^T!\
M0/A/K7QM\%Z,_A;5;GPUK_PY\.:E/HVN:Q#XPL8KK0K"[TW5[:XL)M$UFZTW
M6I'2.YM[";3[RQO+JK-3Y&FI\TH\C34N:"J2G'E:3YHQI57).S2ISNO==I33
MCSIIPY8RYEK'EDX*,KJZY9.K32ELW4A9^\K_ %/17RQ\=_VQ_@E^S?\ %/\
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M-3EMS)N5/W?=DL;FU5*Z2B[T<=1BFDK1H4862@H4LY1;IJDI/W81@IJZY_\
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MP-G_ .".?_!/[]J/X[?L\_$3XJZC\1?VN?VWOA%\3?VY_P!J#6+T:;XZ\-^
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M6WQF\:2_&7X33P7'_"RO#?@/QM>/X9T_P?XRTG1-+\,6WPYT_P"'UGI/L_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+/C!I.F:%X@\?:;^T/X,M/%&DOXH\1_$KXS7OBB"P^$-I\"M8\)WNCZU\/\
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M_$'PG=>%]?A\4>$/$.AZ7KWAY]+N?[7L;,>67X?_ (*':)\<];^"?@E/@/\
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MO3EI*=*$:D[+F2Y[2FDDG%N//@5%N_O)NG7K-QE'W)T*B3:A.4OT0U#]JCX
MV/@GX4?$*T^(UAXK\,_'?2+;Q!\$V^'6D^)/BAKWQ;T*Z\+?\)NNL_#?P=\.
M=&\4^,?&FEV_@_'B;4;_ ,/:#J%KI6B,FHZG+:6TB2-VWPA^,WPI^/O@/1_B
MA\%?'_A?XH?#GQ%'YN@>-_!>J6^N>&-;A$<4AGTG6+-I++48%$J(T]I+-$LP
MD@9Q/#-''_.]\)_AG^T%^SS\*?\ @D#X(M/V8/BIJG[9G[+_ .SI^TAIWC+X
M9?#+XK_LAZM\1O!7PN\0K\-_ 7BG2O$'@GXE?M"^ O@GXW^$GCCQK_PK+Q-!
MXS\)?';2_B'X0\4_#/P5I.B^'];\.^(_BKI&A_L7_P $Z]#\#^!_V4_ OPH\
M"?##XP_!ZT^#NH^*/AYXE\"?'G4OAGK_ ,4;3QW;:[>>(_&OB#Q3XK^"7BSQ
MS\%?$^I>./$'B6]\<7U_\)_$UQX-TO4?$5[X6M]"\"ZMX>U;X?>%=%R^];FN
MM4FXM1]ZBI+F3]]0]JX2G'_E]3G#E2NXS>7N-I6:UT:;=JSCI=\CDJ49J$M?
M9U8R3?N\U7PI^VW\ ?#=AXVUKXJ_M@_L\>(=#O\ ]K'Q=^SO\/M5\.:7<?#O
M3/#?C'3=+TF^B^ >O:IK7Q$\>V7Q$^)O@>,:O?\ CKXA:#)X,\+BVDDAOO!G
MA!_#6K2W'JGA']L/]G#Q[\-6^+'@OXDP>)_":>/];^$\EEHWACQI>^/X_BKX
M:OKVQU_X82_"6'PXWQ6B^(VCC3K[4]0\#2>"U\46WARUF\5R:4OAE?[6K\>7
M_99_:Q-[<3G]FGQTT,G_  7YM?VPPO\ PGO[.IW?LQ6_AVTL1\8]K?&\#^RE
MU"U!3P8V/BRK".9?AYA0X] O/V3OB%XHM_VWM'^+?[.?[1>CZ'\8O^"HH_:#
M^#/Q6^ 7QD^#O@KXW?!SP?I_['OP>^%NA_M8?#*^T+XK7NH?;M#\??"SQ+X5
MU'X;:KIUWXX\3^"OB%,NJ_"/QSHU_P")/!5YG%NT+Q:O"#LFDTU#+Y33YE;F
M?UG$QCS.-ZF';G+2LX6])U$G>,9R496;4KSQT8OW7=17L,-)\L96A7O%-.DI
M?I+>_M._#CQ+X^_98TGP1^T!\,] M?C?XS^,&AZ5\,_%?@7Q-<_$_P"-C?"O
MP)\1)?%_A;P$+[Q1X.U/X5ZS\*?%/A&]U[XBZCXQ^'_BY#:>$]2^'\NG>&/$
M&NV&L6_@/[5_[=H^&GQ%_9<\ ?!+Q5X%UZ]^(_[<GPO_ &7OB\/$/@3QWKVC
MKIOB2S\4W?C7PG\.?B?I>L>&_AO:_&GPA)X>BG\0^$9K_P >^(-!T*V\4RZM
MX)TN;1;S5-*\%\,?!;]M[6/%G_!)/Q-\;_!6I?$OQ?\ L]_M*?MB^,/V@/BC
MI9^ _@.?2_AEXS^#W[5'P<^!'CWXC^"/#OCW2=$E^*WCWP[\2_A7K_Q<T#X&
M:/XR\-Z3X\O/B'<Z6(-'M=*COOF7P/\ L\_MN^#/A/\ LH?LK>)_V5/B%XZU
M?]E3_@J#;?M#>)?VD])^(G[/$7PY^,WP3\1_'OXY_%&[^,&BV?B#XRZ9\3;;
MXF3:?\5H[_XG>"?%/@G1K]]=L?%=]H6N^)KG6?"^F>)'#6<4[I>VIMIZ*4%B
M,)":O/2,51JSJ2BV[QC44)<U.K)35NJ,G%WFZ$DN5:QJ.EB91:4;.4G4I1A&
M26CE"4XKVE.,OW7O_P!I;X(:5\1O#WPJU/Q[9:?XP\6^*-3\!^%OMFD^(;?P
MIXA^(ND:)J'B;4?A?H_Q$ETA?AYJ'Q6M?#6CZ[XC?X76OBF3X@/H'A[Q'K,7
MAQ].\.ZW<V&/^T)\6=.^&%Q\#K"X^-_PM^#6I?$SX^_#OX<Z78?$GP=J?CC4
M/B^-=N+TZA\(/AKIVC_$#P%>:#\1/%5K#YNC^/+F+QOHG@JSL-0U;7? >NZ>
M))++\K?V=/V=OC1X&^-'BGX%_&_]@#PK\6-!\)?MR_&3]JCX(_MU^(?'7PD\
M4?"^S\#?%KX^?$O]IG1/%>H>!-:\4V_QL\(_M2?"^[^*OB7X/^%_^$8^$=YX
M?.M6<'BT_$33/!]_<W6J_9O_  4+^%?Q:^*=O^QA'\*/AIKGQ(;X<?M^_LT_
M&'XA#0]>^'>@?\(?\,/A_J?B"Z\6^,;_ /X6%XX\%#5K328KZU+:+X3/B/Q9
M?&4C2_#M\4D"-:J@VG>I4I<^J]V,YT>92B]8NDY585.?]W+V7,G*$G)MW3K)
M-6A3J\CLVY2A3K.-FKJ2J<M-PY??3J6LI145Z</^"@'[&;>.[;X;0_M#_#Z[
M\7W/QL_X9P>RL+R_O],TWXZ2V&DWVF_"[7O$UEI]QX7\-^+/$4VM6&A>$;#Q
M!K.F#QEXR>Y\">%)-9\::=J.@VGAGQ7_ &J_C#XM_:L^*?['_P"SS?\ AKX;
M>/OA'\ O@_\ '6+Q]\9O@9\9O&WPO\8ZO\2OB1\:]#N?!?B?5M D\!Z7X&\
M:=X*_9_\610?$^#QA=6OB#QUXZ\.Q^$Y]9NOA7XU^'?COY \0?LV?M2O\/\
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M)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH7VS3KRXL#!J,_:V?[1?P^OOVE];_90@A\4CXI^'_@IH/Q\U*:X\.W=IX/\
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M?Z7**_FF^('QH\'V/CGX7?L?^-/^"D6L?#W]G7Q9_P $[[;Q-^S'^V=^T?\
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MM:M66-IN47>UJEN:48.6CE:$IO:$ZL9):M^QAC92MM=2>"J<KT>L+VBY\O\
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MWXI_X*W>+/#'Q^^&_BCXMZ[8VWPG^(NA^#?VQ_"6N_L]W/P6UKQ+%X:\$P?
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MK4I='TG4-4ATK5-<DL+66Z72-%CM)=6O_)4NUOI\-]>:?:S73*&,4,MY 9F
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MQNM)'WG1113&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXH\47.LZBFL:O<>(O$&DZ7::MK<^JZM%%JFI2ZE=W,E]J,:7MTTMRBRC\NO
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M.OW,VIZ;IUM>RSZYK$SSM)J=ZT_L*JJ*J(JHB*%1% 5550 JJH "JH
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MLHT$:>%:"$C!B0K^4WQ;_P""EOQA^#7PT_;NTC5/A/\ #?QA^T1^PO\ $O\
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M_P#%?PQ!XLTC]D*W^..AZGX/\$?"SXKV.D7>D7.E:MXXAU2X^)1\16UG\/?
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MQ9B^Q>![B[N?AY!X"USPY\+=(U/7O&^B>"YO$EUX@NF\3:9?:CX%?#\?:?\
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M[6GA[X:65QIF@:Q\4K6?X17]WX$^(ESHEU<^%+WXG?L\7GP6\;Z7X/O+G1/
MVL^#+B#1]3TCZ#^,_P"V?^S=^SY=:U!\6_B)_P (M9>$[_X9Z=X]\1+X6\9:
MYX.^&4WQC\4V_@KX:R_%'QGX>\/ZKX6^'-GXH\27NGVL=[XRU;1K;2=-U"S\
M3Z_+I7A.;^W5N^,?VO/V?_ 'C?P[X"\7>-;S1]3\4?%;0/@5INOR>#/'-S\/
M(/C1XMT^SU'PA\+]:^*%EX;N/AWX=\9^+?[1T[1_#>DZ]XFTY]6\7:KH/@2U
MD?QOXE\-^'M74;*,%'2$6E!?93</96UT:E"2IM2O&HG&,E4DH)4U[TKKWIIN
M6GO-<_M6]%S)QG%U$XV<'S27LTY-_(_QT_X)3?#7XTZG^U?:Z;^T'^TA\&?A
M?^V[HMC'^TG\%/A1JGP@C^'WB_Q[I?@WPU\.K3XN>&F^('P>\?>)_AWX\U#P
M-X2\,Z)XQ7P9XATOPKX^F\)^$M1\7^&]5EL?$$7BG[(_:3_9R\/?M2?LS?%K
M]EOX@>-?'FD>$?C7\+M?^$GCKQIX/?P38_$&X\,^*]%D\/\ BB[TRXUSP3XA
M\%:=K>N:7<WT$]W'X'>SL&OY[C1=/TNXAL);/-T_]K[X :CKVNZ(GC#4[*T\
M.:;\;-6U;QOK/@;Q]H?PHMK']G'Q1;>"_CBS_%_5_#-E\,%N?AQXGGFTK6K"
M3Q9'?W3:/XIO=$MM5TSP=XLOM%S+C]M+]GW3O#_B[Q+XAU[QQX/L/!2_!YM7
MM?&WP6^-/@[7;YOV@O%\W@#X)6GA+PUXC^'^F^(/'FK?$SQO%_PA_AS0/!&F
M^(?$ \6RQ>$]5TO3?$S-I"3RQE!QM>#4$UJTTFHTUW_Y>J,%>[YXJ*DI0!/E
MES749)RUT33MSR?;:FYR=K+D<I--29YS\3_^"?OPR^,OB_\ :)\6_$CXC?%W
MQ"G[47[%5K^PE\5/#27GPWTC0+CX2VTOQ6N6\3Z!)HWPSL/$>B_$NYN_C5\0
M;FXU>+Q#-X35M4LTMO!5M'I&F+;8W@O]@!= ^(/BGXM^,?VI_P!HSXI?$_QQ
M^R58?LA^+/%OBNS_ &?=,&J>$M*\5^//%^C>.X?#OA#X$^'O#&F_$#0-1^(>
MNP:1-9Z0GA2\M6C/C'PMXONU2ZC^J_@Y\=?AE\>M(\6:O\--<O=3_P"$!\?^
M)?A7X]T?6O#?B7P=XG\%?$7PA]ADU_PEXF\+^+](T/7]+U&VL]5TC6=/N)M/
M_LOQ%X:UO0/%GAJ_UCPOK^BZQ?U/CS^T)\)_V9O ]E\2/C1KVL>&?!5_XX\
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M^)_ D?QR^(OQU\-^'?AIK_[/WQ#L[WXZZG\(/AI\53XX^&WB'6/&W@?1]6^
MNN_##7/!NJ_$&<^*E\*:UXEE^'MSX0L[;4+776CE\-_:)_;GEL/C3^Q#X!^
M7BQM0\-_%G]NO7/V:?C#KD_PE\::EX.\0Z?X)^#W[0VO>._!_@/XQZGI=K\-
M_P#A*_!?Q-^%%CX;\56>A7^NZO)?:-XY\.Z7=66L> /']KHHX^VFX27-+$3=
M&:EM/VDY1DYI:6<L14NU%3@JLXQY>=Q4N2H4E)>[3P\%5AR_94(QY5!RMK:A
M!)<SC-TH7YG!,]O\!_L->$OAY\0_V>_B9HOQ@^,UUX@_9K_9'\4?L:^!K?5#
M\(9M)UCX=^+K_P"$>K:MXO\ %]M9?"*PN[[XD-JGP-^&U]!?:'?>'O!<+Z-=
M0)X%%GK&J6UU\1>&/V)?$W[.'[1G_!,SX/\ P*\9?'I_@_\ LE?L7?MG? L?
M&CQ'X.\">,9(9?B7XU_8SO/A+X'^)VH:3\-O"_A+4K?4?#7P=^(=_::MX1T7
MPO?Z5KW@'P9)XVUQX?$4FD>/?T@U[]L+]GKPQX_\#_#G7_'-UIFK_$OXF:]\
M%/ 7B&X\'>-S\-/%?QF\,:3KVL:W\)M(^+47AR3X97'Q$M(_"GBS1H_"A\5K
MJM]XT\)>+?AYI\%WX_\ "^O^&=.S?V?_ -M;]G?]J+5;S2O@=XC\=>,%T^T\
M;7%[K][\#?CMX+\$6U]\./B;K?P>\=>%9OB%X]^&OACP*GQ \,>/_#VJ:;JG
MPW;Q$/'\6D)9^,$\-R>#-4TOQ!>4IR<W/F<G4G5K5+W?M)2>(E5G)K6_M<74
MJ2DFO?G9Z24 E&/)&#]V,%3ITTWI#D5.-.,8NZ_AX=4XJS:C&334HN2XK3?V
M"_AGH5G^R19^'?'WQ7T,?LA?&?XC_M"^'KFWOOA]J%]\7?C%\9/"/QI\)_%_
MQM\:;O7/AUJTVJ:A\2IOVB?C/XN\2P?#MOAK8IXQ\=7FJ:);:/9Z3X=TS1\C
M0/\ @GQ\+O#R^(?!MMXR\?7G[/FO_M-V?[8$7[.FH3^';CP+X=^-EI\4;'X^
MF+PSKJ:##XXTKX6S?M(Z;9_M'O\ #8>(IK6+XJB[TNUUB#X+ZC?_  >N-+XH
M?\%(OV//@UK_ ,7O#?Q%^)'BG0]0^ 'B#P!X>^.-W:_!#X]>(O#WPB;XGZ.O
MB#P7XF^(_BWPS\,M8\+>#OAMJ6BNNHW7Q9U_6+#X8:)!N77?%^FSQR0IZ+X,
M_;,_9S\<:_\ &_PU8>.=3\-:G^SKX5TKX@_%B3XH?#WXE?!S2='^&&N_\)L-
M&^+V@>(/BSX0\%Z%X_\ @WJLGPV\?Q:=\7?A_J/BCX;WK^$-<-MXGECM1)),
M$E[U-)-+GO!)625*:=HK2,50HRBDN6*I1E&*Y)-.=GI/7F:C:3W;]K"WO/63
M]O6C+[4O:RC)OGBGX9\._A6GQO\ VU;C]L+QG^SE\0_@3K7P/^&7CS]FGP=J
M/Q2U'X<S:]\;3>_$:[OK?XG6'A_X:_$7XBZ;IW@?X<:+9^,]/^!GBCQ5?:)X
M\U?1?VF?CA;W/@[PEHUY#<^+U\.?\$YO"'@;]I#XB_'/X=_M!?M(_#[X>_&;
MXGZ;\<_C'^RAX7\4> [?]GKXA_&S2[;2(S\0KI;[X<W_ ,7?";^)]1T+2/$7
MQ-\+_#[XK>$O"GQ9UK2;&S^(FD^(?"%WXE\)^(O0/%W_  4'_93^'NA?';Q!
M\0O'/B[P%!^S5\,_#WQI^,NC>,/@K\<- \9^%_@]XJ;78]!^*5AX!O\ X<Q>
M-_&'@.ZNO"_B;3+[Q'X*\/\ B*P\/Z]X;\1>&O$LFC>(] UC2K+F?%O_  4U
M_8^\#ZE\8]$\1^+OBO;Z]\!_#^C>./B+X=T[]EO]J?Q#XEA^%FNW'BRSL/CA
MX-\-^'?@QJNN_%#]GY;[P-XKL+_X^_#+3_%_P<TN^TI+34O&UK/JVAIJ9I%1
MN[>RIN3;NK0FW4J3DM(J$YP=5W3IQ=/FC94>>F:2<EO[6:7+H[R@E3A"/VG*
MG":IK7G:J<KO[90GC?"3_@G1X4^"7QG\;^/O /[1'[2]A\%O&_QA\3_M#3?L
M=77B[P1>_LZ>'OC;XWU?4/%/B_Q9X6:?X>-\9="\,:Q\0-3O_BHOPET_XN0?
M">U^)NJ:IXF7P=+ ^DZ5HWIWPA_8\T+X<?%KPW\>?&7Q-\>?&[XT>#?V?Q^S
M#X?^*'Q"T[X?Z7XSU+X3S>+-"\>:JWQ!U#X>>#/!=IX]\:ZYXN\.Z3J=UKNH
M:?9>']#CM+D^!_!WA'5?%WQ-UCQ_\>_$+_@I?X1^"/[9/Q0TOXI?$C^U?V1-
M,_8$_9\_:K\!W_PB^"?Q+^-/B""U^(?Q0_:$T7QS\5-:;X*>&_B?XSU+X2Z+
MX(^&'A;7=5^(7_".:#\-O VFZYIK>)=4AO=>TB]U/[U\7_M;_ +P=X%T#XDO
MXSO?&?@[Q5\++GXX^&M3^$?@WQQ\:I]?^#=GIVBZQ<?$[1M*^$GASQIJ^J>#
M6TCQ#H^H:=JUA8W":]%?V]OX>35K^:*S=M.E&/-[BIQE!J6CI<BKTI0G=)P<
M:=&JK2:Y*,+-PA2<:*LIR;2YI5.2:<;M554]C6A*/*[24YUJ<E97G5G=*<JB
M=7YV_:G_ .";_@O]J?QI\=/%>L?';X[?#/3/VEOV/+K]BWXW>!_AQ<?"I?#/
MC?X<V=[\7]1\$Z\;[QK\+?&/C+PYXH\$WOQY^*-Q#_PB/BK0-"\3C5M+L_%V
MCZSIFF7-AJD?C7_@FMX#^(>E?MH:;XQ^/O[0^L3_ +=W[./P\_9B^-NL[O@#
MIVJ67@7X?>"O'O@/^W/ <>D? +3]&T'QCXPT3XG>.)/%5]JFD>(="AO]92?P
M;X=\(0Z7I-M9>D/_ ,%#OV1Y?B-X&^%&A?$CQ!XY\<?$KP1\$OBCX'L/AA\'
MOC;\5=(\0?"7]HG7-0\-_"/XQ6WB[X;_  Z\4^#X/@WXAUW39]+U7XN7FO6W
MPX\$7MQI,'CSQ/X9DU[0EU+UGX=_M-?![XJ^+;+P;X'UGQ+JVH:UX8\5>-O"
MVLS_  Y^(VD^!/&_@WP5XF\/^#_$7B?P+\2=8\*6/P^\8Z1;>(/%&@0Z?-X>
M\3:A+X@T?5M-\7^'8=6\&:EIOB&[EPC).+5URRBT[_!><9)O=1YO:1M?E4N>
M,=4TG=)\VB=XR3LE[UH2B]DN9KV<KV<FN5RO%IGQW\:/^"7/@?XN^(_VE];T
M[]HK]H?X6:=^VG^SY!^S_P#M=^%? 3_!.X\/_':+2_A=X@^#7A_XJZE#XW^#
M/B^[^'_Q6T[X<^(G\*ZGK'PDNO 7A[Q)H^@>#[36/#,I\+:9-'^A>@>![/1_
MAWI'PXU/5M9\6Z=IW@^R\%W^M^(6TFWU_P 16%MHT>B7&H:R_A;2/#.BPZIJ
M=LC37SZ!HFAZ>ES+(VG:=80B*"+SCXN?M-?!_P""-Y?:7XWUCQ+=:WI/@/6/
MBEK?ASP!\.OB)\5_%&@_#?0;M+#4O&NM^&?A?X6\7Z]I>AM>?:K31Y+O3X[K
MQ1=:3X@M/"MKK=UX<UV'3ODK]IW]MK2M$\=?L+_"_P"$?BOQ+>>$OVW?$?BN
MXM_CW\&_AYK?Q?\ [.^$FG_LU_%WXQ>$/&/P6UO3?A[\4/A;XK\1^*?%/A7P
M!.G]IZ!X_P!.M/A3J/B;Q1=>%[?3K[1_&>B$FIQ=-^^JLN1P;34W46(CRN^T
M6GB8)7C!7J02B[P@)*#4U[CI134K-<D8JA9JRWM'#/9SDHTI-R24Y:GP&_X)
MN^%/@+<?L=WFG?M$?M!>-KC]A[X!?$G]F7X,1^,8?@(EE=_!_P"(FG_"/18M
M#\;1>%/@7X8N]:U3P9HWP)^%]IX:\0:9?Z#J=U<:'?WOBN7Q*=>U2";SR7_@
MDA\+]*^"W[*7PU^'G[17[37PS^)G[%7B#XA:U^S]^T_X7U?X.#XV:)I?Q8OM
M1O/B3X$\6Z9<_!E_@EXY^'OC-+K2[;7?"VN_"![>^3PEX1NKB>34=+N[S4OH
M'XS?M$^(/V(/V7?AWXX_:&U+5/C_ /$(^.?V??@3XB\6_"+X.^)O#%AXQ^(7
MQM^+'@OX,:/XWG^'7A_5?BK=>!-!&L^,;+6M8TV#7];.H:A&/"?@>WU'Q9XE
M\'>#K_Y>\._\%(O#_P ,_P!I;]M;PW^TWX_OM ^"GPV\<?LD:)\'[_2_V?\
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MO2R_$C_@G_\ "WXP_#G]I;PE\2/%GCK5/''[5FG_  \L_B3\8]$N/#^A>.-
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M?@9\=K3PCX(\>?#?1_#?B#Q/X4\8_$O4_AM9?#;PMK#:)XN\/ZKX:M]=\6V
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M3QMX/\=>.H8_&=YYKI_[*O[;'P4^"WQI\#?LMZ%\9X?@ WBO]A_5?@Q^R?\
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M/X^?L*V_[5FN^+OV9KS6M$_:,_X*3^%/&?@G3?"WQT\ ^(=>_P"%6_&OX+?
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MXJ_".S^/&J_#G2+[PSJ'B_PW\2/$'AS7O&AET34/%OSQ\%/V1/VZ/AW\-O\
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MIQE-N_O+GIP3@TIPFW)M<MU95)3:MNYRH3E&6J;C)48*UXODG)J2<HRC_/\
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MR:HPI.,).R<K0I1ERMV5ZDHJ+G-/\1=(_9#_ &T?$EO^U1XCUS]GK6] U_\
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M%XCFTG4+/X@:P_B#2/$FJW>A?!KP)I7P^]-_;Z_:!G^&V@?\%\=%@_:#\5^
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M\[W[=VG_  O\,_';_@NK>:QK.G>'_'?BS_@B)\+?$GAG2M4\=ZGI-WXSFL/
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M76B:?^T0UO=^Q2YE[CI_S=_MFZ_\4_A'\#?^"UOA7P7\4_B/X'_9[^#OB?\
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M:U:PW3SZ5K>F:AI5\D%]9W,$?\Q%M\2=*^ 6M?MB:=X;\7W7@CPQXI_X+^^
M?!G[66J:=\2M?TK7_AU^S)\4O G[.=[>>.M?#^)5O/!/@[XC?&G5_AG\/?B#
M\39H--W^ ?B-KT-SXET_2Q;ZAIG]+/PF^#_@CX+:!JOA_P #Z;%8P:_XHUOQ
MIXANUL=&TV;6O$VO/;K>ZI=6/AW2M#T*V>.QL=,TFTM]+T?3[2VTO2K"V2 M
M$\LO5-X)\&/=>++YO"/AAKWQY9VNG^.;MM THW7C.PL-.FT>QL?%EP;0R^(K
M.STFXN-+M;;6'O(;?3IYK*%$MI7B9K2<9V4K4XQE%ZJ4N?"5I1;T3@YT*E/5
M-RISBVN;GA,:O'E=U:<G%IJZ3IXJC&6VDU"M3J)Q=E4C))\KA*/Y[_L=VWCG
MPA^V1_P43^$NC:OKNJ_LN>"=9_9E\0?"+2=3U*^UO0_A/\8_B%\,O$6L_M!?
M!3P'>ZE=WMQX>\$Z)H%C\"/BMI?PULI8?#?@.]^-&IQ>%=/T?0=8LM&T[]+Z
MP?"_A7PQX(T#3?"O@SPYH/A'POHL#6VC^&_#&CZ=H&@:3;/+).UOIFCZ3;6F
MG6$#3S2S-%:V\2&6620J7=F.]36D8IMMQBHW=KNSFTW;312C%:R?+3A>4G=C
M>\FDDFV[+974$[:]7&4GHES3E:,5HRBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\,/BY:?M/>'O^"H'[9FL
M?L3^$OV=;GXOW_\ P3@_8.\8ZRGQR_X3"QT'QSJ6A_M"_P#!1+3;+PQ-'\/4
MTC43XF\::1HFF>$K7XFZ_P");BU^'=EH>@M<^"O'VF!--T7]SZ^2/B)^R%X=
M\=?&SQ;\>-'^+/QE^%OC#XB? CPU^SG\1;;X;:KX#L=.\7_#CP3XI^)?C#P4
MWV_Q1\/?%?BWP;XJ\*ZO\8?B6-*\4_#GQ1X-U-[?Q5))J+7^I:#X1U+PZ7:4
M^6RFZ5:-.32:C4G2E&#DFI7ASJ'M$D^:'-%J2;BYDN;D3LXJK1G-._O0A44I
MI6<??Y7)P;:M.S3BTI+X4T?_ (*1_'[]ICX;>'-=_8A_9[B\5_$K6/V!_P!F
M;]N)/!'C>?P;J>C7>H?M56GQANOAC\!]2\2^(?CC^S\_A&[GU#X$>,?#>M?%
MRPTOXAZ3HS:]H/BA/ &J6&G7.CZO^@'QE6?XF_L8_$V7XJ_#&#PQJ'C/]FSQ
M5J7COX0>,Y_"?CN/PIK6K?#6\U+7/ ?B&^T6XUWP5XJN/"^K2SZ)>ZGHEYJW
MAS5;K3GO](O+S3YK6YD^??BA_P $OO@AXP\<_!;XC_"+XF?M!_L>^+/@C\$=
M#_9CTB\_9.\?Z!\/[+Q?^S5X4G:Z\&_ SQOHWB[P3\0M'NO!G@>YN-5N? VK
M>&K'PO\ $'P9=:[JUYX9\:Z7=S6\]K]I>*/A-H.O?!O6?@AHVJZ_X#\+:G\/
M9_AG8:GX4FTF[\1^&_#4N@_\(S%_8MUXWT?QCI4^H6>C@6UO=>(M&UY68">Z
MAN9\R&,1'VM#$TZ:2E4CB80O=64Z>)A2M*\N6#C5HMQ:E.$X2:E)+FJW1;A5
MH3FVU!T93:L[N,J$IWC:/--2IU6I1Y83C)>ZK\M/^8W_ ()?^$/#OCSQO_P1
MCT3X._#^P_9+^(/[-_\ P36^#_QX_:&UZZA\*^"/$W[=OP*^-?[-?A_X;:3I
MO@C1?A;J7B+1OCC\/?#'QX&C_$WXO>(/CC?>&O&_P4\<S?":^T;P5)XC^,$V
MOZ'^N_C;]L?]J7Q7\0_CAI7[)G[.2_&[0/V8OVE?A_\  'XC^&I=1^%^A:E\
M0H=0\&_ [X@_%O6/"OQ'\<_M'_#!?AGK_P -_!OQPEU?1O#WB'X-_$+3?'5Y
M\,[C2+3Q+I,7Q-TC6?!7=P?\$U?@_I_P;_8S^%6A_$GXT^'/$O[ MOX1TG]F
M/X_:'J/POM/CKX+\)>%O UI\,+_P!J6MR?"F?P+XJ\ ^/_AQ86/@_P")GA3Q
M#\/;_2_&UKIVBZ[JL3>,/#GAOQ)I#?$W_!-?X6ZY^TGXO_:2T/XU?M._#J;X
MNKX&G_:/^"7P\^)^D:'\ OVFM;^'F@V'A/P_XE^+?@J]\%ZMKEAK=WX1T3PU
MX/\ %[?"3Q=\+=,^(/A'PWIWACQYIOB30[O7;#6-7)>U4GK3]M7G)/F:?M*U
M*K3DU>ZING&="I0INGR3_?4G:K.4,Y1?+/E;4G3I1BTXIQY(5H2BGRN/.ISA
M5A5G&?-#]U4M[&"GQ7PM_;5^(?Q:_:B^*?[,LGB3X1_!CXK>!=;^-=C;_L__
M !<^&'Q&T_XM77PQ\.:OXE\.? S]J;X:^*+SXE>%?"'[37P8^(C:)H'C'QGI
M'POT7P]<_#N+QW;_  O\4>-]&\8>$K[6=>^4/V</VR/VX]6_8E_X)+^,;?6?
M@)\3_C!_P4&UB3PSXC\:?$SP_P#$3PMIO@W5?%'[&OQ]_:=TO7;G0_"GBSQ$
M?%!T/Q=\&-7&IZ=I%[X"T77?#.H:1\/_  SHWPVC(\<:#^G.F_L<^%'^+WP\
M^,GCWXG_ !9^+VO?!KXE?'+XI_!33?B/-\-9K/X2^(?CY9^,-!\3Z9X5U_PC
M\-/"/C_4?!WAOP-X]\4?#SP3X1\9^,_%.C:;X5O-+;7(/$?B'P9X!U_PIY)\
M,O\ @FQX ^%/@#]CKX9^'/CS^T3>>$/V%OBG??$SX!V.MW7P+O+C3]/E^%'Q
M ^!VB_##Q-?6WP(LKOQ%\/\ PK\*OBI\0?".B74TMO\ $FZB\1MK7B;XB>(O
M$NC>'-9T>5R\D8NZFY4E.:;M[.-><II7O*,I4YQ;2O9TW"$W%Q45-3<G*'*K
M>T<8O92E1IQCY2C&I"23E9OVG/*":DY?//BS]L[Q'^S-\5/VY?$'QG^#_P
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M>]SS=XNT7'EM!Q4E)Q3;YN2?-[T&I2LXR?B7A7]K?XK?%[QY\-OV=?A)XO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\#Z)\"_BA\6OC)\$%U?QQJGPA^(?Q=GTJYOM8\ ^(/&6M>(-%T_X=W&E^$/
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M:[XLTK6_$7B2QUO3/"UUX/TJP\&:A8:WK]CK6L:!I]_W%?BU^U!XI\#^'O\
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MQM\(>%=>M=%N-$\5>,M,\=VJ_#_7O$%[9]#<>(O@7\!_^"@VA_%RXUSPU/\
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M?Q+X-^'\6I>$-.U_^T/$<=]XKM4L;O2=8\+[V\86,V@I_.M\#OB_\-=#M/\
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MI8&IR\VW-&6.A"6T6ES1;;Y04DWIM><=-7>%7&P>F]G'!3FMVKV:LN8_9FC
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MITYU91NFUS<M-V5WNGLF?I%@9S@9( )[D#.!GT&3CTR?6DP,DX&2 "<<D#)
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M!O\ P5'UWPQ:^"=0\8_L1Z5^S_XY^#_B7XN?"#Q;X.OO&_@KXW?#KPWXRO\
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M]+?!KX]_M'_M%GP]\:_A9JGP0T?X,Z7^V-^T;^SU\3OA?\0H?$^G>++3X/\
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MX1Z#=_$S4-67P)XS\)^+-4\9>!/#>CSZQ97\TOPY\"ZOK%['H7@W4FO[34+
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M9\SE%*;YXR3YI)\JBVE'E:A&+2A_R[4'",>50LX^S7)91E>*4&FN6!Z)KW[
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MQ?C7)X2^&,MUJ=IHVOP:5\,4U+Q7XH\57^K:-X,\%67AGQQ%XS\0^'[OX?\
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M>&["/2= \=>)_C-\-?!'ACQ8MM<Z#>Z[XNT/5Y[RU\":OI7C&^]NTO\ :B\
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M77^)?VZ/V??"'C_P-X)\0:_J-CI'Q'^.%Q^S#X0^*)M+&;X8ZG^TM WB. ?
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MTC4^]@_8:^'_ /Q.-9U;XH?'7Q#\3M0\(?!SX>:7\<-6\<Z2GQ>\,^ ?@/\
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M(_@-JO[4^L_#SQAX*:P\=^)/V;M"GN+?Q!\7O VAVFI7Z^);#PO<6LEKXU\
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MEDW6CAYI.UY^R<5+F@ITW9N[:=N5W;V5.M3MYI4IUX-*Z4754N6TN7?\3?\
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MVG\&?@++\3V\6)XUU[2O@+X(T+XH?M%:]X"\*7/B_3O@'\,O$B>);G2O&_Q
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M4WOA70/&W@[Q/%X-O_#>B>//&/@[Q)8>.?AWX8\8>"X-3\0:?G?#7_@H_P#
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M%\2OA]X:\=1Q:5J%G=7']IZ+ OB'[%I^IW4.FWM\EH\]SI6GNWD+R5C^W5\
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ME.GB*\9*,J;E"7+&<96DLW]G_P"'&K_"KX0>#_!_B?4-(UCQT8M7\6_%#7M
MM;W3_#WB3XO_ !$\1:M\1/B_XF\/:7J%Q>7>C>'_ !+\3?%'BS7-"T.2YF70
MM)U"STB!_(LH@/RYU+_@G_\ &7QK\//VP?V6_'%KX'M_A-^U)^WU;_M67'Q9
MT;Q7=:E=Z;\$[KXH_"3XJ^(OAZO@J]\-Z9JVF?'&_OOA=<>!M$N[>^U+X?\
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M91E"5*[C=I\T(3A:W/HK6:@C\K/VJOV6_P!K7]N_X$?!KP=\?_AO\$O!K/\
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M[XM\.Z'XG\+^$9?&/@WPY#<^+M)\"7/B_P 1^=_&+]A/]K_XS?#W_@J]%?\
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MQ#=_\$O/VY]2\=:1I'A7Q'-^P?\ M2W7B;1="\0S^*]%T'4'^ 7CJ2_LM/\
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MX$A6#7/<OCI\$OC%XB_;7_9!_:"\ :'X'\2?#[X=_!W]K3X!_&"V\1?$'6_
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MF^L4\5"G&-TG&-;#4W3IKX84N2*4=%\>?LS_ +-_[9?A?]H']F_XZ?%WX??
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M$'PWK7PXNO#G@GPU:>#9O _Q'E\4^'M4M?B3<Z[8ZK<>++.U\+:?,_B'PJ?
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MNFG-1E<IREJD[7JRJ)NSE9P4%&3TBVE=<ZC%VY6H\RL?RM_LCZW\*O%.K_\
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M:BXRE!_SN?ML_M5?LR>*_B5^QQ\4/BQ\5+BW_P""7GQH_9W^-/@[3?B?X?\
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M7T]C\6?%/BKX4Z=^PM:_#SQ+XBN[&/4_$?BCXR_"3P:?VA+'X03:[8:[XO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex-19_007.jpg
<TEXT>
begin 644 ex-19_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2* X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOM#_ &<_@1HU[9?$SQ'\:;*\TKX0_#[3[JT^,7C%K5_%_P 6+6XL_#T,MO\
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M7M-\4V/A/XM> ?"?Q'\,V7B;11<+H_B*TT'QCI&LZ5;Z[I(N[L:;J\-HFH6
MNK@6MQ$)I V:?V=_V?S:^';$_ OX.FQ\'^.-1^)WA*S/PR\%&U\+?$K5[^?5
M=6^(7AVW_L3R=$\<:IJ=U=:EJ/BS3$M=?O;^YGO+G4);B:21HIQY9J<FY6FI
M-6C:45BH8A+:_NP4J*3<HR34FE:2=2?-&44DKPG%-N5U*6&J4.96>SG*%9VL
MU*+2;?+)?@MXS\>_&;X;?##_ (+/_M;Z)\=?VD_$GC7]C/\ :;_: \+_  B\
M+3_$OQ7XP^&?PK^&FN_LL?LE>-/&WB;_ (4>;ZW\&?$'_A3ECXN\8?%3X?\
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M4O#'[.FG^,_V5_B5\2? O[/,GQP\'?$;X<?%"'P=?_M#:!\.[W2/%.M?&_\
MMKP4_C_3_A#XG\5R?#6XMO"-K^TP^$?PI'P[U+X0#X9?#W_A4VLZ7KFB:O\
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M_:1^./@+]KKX>?$_]E3P)\,_'/Q.B\(^(/&1T#P=\0_%7_!/WXM>.==_:/\
MB_JOQ>^&?Q:\.>&_''Q$\2S?$7X@7?B#]E_X7?$K_A88M=,^"'@KPOH=S9^(
M/[9>F^&_V&OV'_C/X<^/'BSP/\,?VF?VO=,\$?M6?'#XWV_Q(BU3]G;5OB#I
M7Q\U;QA\/O'^F?\ "W/#WBO]G;PYX#_;"\,?#_\ 97UKPO'\8=*TOX$^&[ZX
M\)GQE?0:0^O:G^R?@K]G?]G_ .&NE?#?0?AU\#/@[X!T/X.?\)'_ ,*BT;P5
M\,O!7A72?A7_ ,)@EU'XM/PXT[0M$L+3P/\ \)3'?7J>(_\ A&(=+_MM+RZ7
M4_M0N)0[8/V=?V?;;P;X_P#AU;? KX-V_P /OBO?:OJGQ2\"P?#'P3%X-^)6
MI^($CCU[4?'_ (8CT1=$\8WVMQPQ)J]YXBL=1N-22*-;R2944!Z*Z4>97I.*
MDVOX4H7BW'F?+5IJ\VW*7M:5%^]3=>$RS=FWRO\ >J7+9_Q8SM**DDN:G-KD
M6D53J5HKDFJ-2/XD6'QJF^ 7Q#_9>^ 'Q:_;]_X71^R_\=?VMOVJ_#&H_'O1
M_%?BWX;6?PX\7Z7\$?"?Q,^ _P"P[KG[3FJ?&KXB^/\ 7+2\\0Z]\4_'7ASQ
MGJGQL@^)7B;6_!_@;]GV36KO0=$\0^"?%/L/A[Q?_P (+^T=_P $MO O@K]K
MSXL?'GX0^-=(_P""A?@/5_B1XS^*4VI6?QFT[X;Z1#XD\":?XHU309-%\*_$
MWQ)\(-/L/$7AKP_\5IM/O?'7B;2/ VK>,];\5>(=2N=>\17WZC:C^R_^S1J_
MP6M/V;=5_9X^!FI_L[6%G9:=8_ 34?A)X O?@M9:?INI#6=/L+3X67/A^7P-
M;6=CJZC5;*VAT)(+74@+Z!$N@):V?&?P!^!/Q&\)^"? 7Q"^"OPE\=^!OAKK
M?A7Q-\.?!GC+X<>#?%'A3P!XD\"VDMAX)\0>"O#NN:+?:/X5UOP=8SS6?A;5
MM"L["_\ #UK-+;Z1<6<,CH1:.+M?EJ7U^W2<7%QFKM.4%)J%M)12527,W(<K
MRC);<T+/:T*BE&2E3=DXJ;BG45]).3A&RC$_GA^#6LM\>? /_!%7QO\ $;XL
M?$SQVT?_  4R_P""F/@Y_'H^/WQ4M[F]\&>!_A+_ ,%7=+\%G5?%WASQ]I[Z
M[=>'/"?PZ\)>'M"\7:S?ZCXDLO!5MK7ABTUU/"_C+QKIOB+Z%^)^B_M/_%?1
M?^"U/A/X%?%KXT7/QA_9U_:O^"7Q%_9<\.V'Q7^(VE1W.H>$_P!B#]CS]HC5
M_P!G+3QX=\6>'FL?AG\>/$7B?XA> M9\*P7,&AZ9+\3Y_%&GVMIXBT+0-6TS
M]B]4_9N_9WUSPQHW@G6O@+\%]8\&^'/B';_%WP]X2U3X6^!M0\,Z#\5[35[O
MQ!:_$[1M!N]"FTK3/B';:_J%_KEOXULK2#Q)#J]]>:E'J2WMS-._8>&?AC\-
M?!.O>,O%?@WX>^!O"/BCXBZG!K7Q \2>&?">@:!KWCK6;:-X+75?&.L:5I]I
MJ/B?4X(I9(H+_6[F^NXHY'CCE57*F(1E"-1<SYY*].=E+V=3V66I5.6=XSM6
MP$JDHR3C.-:49JU2NIE3WZD962@IWG3NXJ=+VF8-T^:#C*-Z6,A!.+O"5)2A
M\%%P_$_XJ?MK:MX@_81^,7_!3KX5^/?&O@SX)?&'Q1^QAHGP_P!7\16WQ'U?
M2_AC^R'>_&_X0> ?VC_CUJ'PAL]=TV^\)^.-+T7XE_M#:KK?B?P-?>'[V^^'
M/PR^%GC:QU>QNM.DUN;[-_80L)M/\9_M(3:3^W5X9_;!^'WBK4OA1X^\'>#/
M";^+/&6A?L^W/B;PEJ=MKVFZ)\9/''QZ_:&\3^*] ^*PT72/B#H_P]U#QM#:
M_#*.>?4/#FEV?A#XA>';>#[ZM_!_A*S\)P^ K3PMX<M? MOX?7PG!X+M]$TR
M#PG!X533_P"R$\,P^'(K5='C\/II0&F+HR6:Z<NGC[$+86W[JN5^$GP5^#?P
M!\'0?#OX$_";X9_!7X?VM_J&JVO@;X2^ _"OPX\'6^J:M,+C5-2@\,>#M*T;
M1(;_ %*<"?4+R.Q6XO)@);F21QNK6ZYJC47&,DE"-^;EBU[T).2O)*3<XS7[
MR[L[+52E+E@G+FDFW.37+S.ZM-*+T;BE&4'^[M=Q_E?X/?&KX^?M!>(?V?/^
M"G7[0_AGQO\ $GPC^UO^Q=^VUK/PT_9\^#VG^,_&^D^![W0/!MU\$(_V?_@]
MK/P1L=;T[P3\5=,_;4\%^/+754UGQOX9\5^,M4U[]HF)OAIXJ\/W?@/X11_#
M_P"JA\/O#>K_ /!;;X@7%UJOCJ&]N?\ @FA\--?DM=+^+7Q1T2U6>[_:,^+W
M@^46^AZ+XTT_2[71TTR".XMM(MM/AT2Q\3F;QC965OXPN;G6Y?TZU#X,_"#5
MOB%9?%S5?A3\-M3^*VFZ=I^D:=\3=0\"^%[WXA6&DZ3/JEUI6EV7C2YTJ7Q)
M:Z=IESK>M7&GV4&IQVUE/J^J2VT4<FH7;2ND^#GPCE^(5S\6Y?A9\.)/BM>Z
M#_PBUY\39/ _AA_B%=>&-AC_ .$<N?&C:6?$D^@^6=G]CRZDVG[!M^S[>*B*
MMR.S]V+3CI;F>"J864HO67[V<XUZJE*W.I*"N^=DUS*2V;FI*6MW&.+IXF$&
MK\MJ<(RHP<8J34DY.RY5_/)X M-8^$O_  2WOO'_ ,,/B'\8/"/BBZ_X+):Q
MX4N]3TWXT_%6_:^\+:__ ,'"WBOX+>)/#SC6_&&K)#I?C7X<^-_$FB^/DL#:
M3?$:ZU277?'EQXDUT_VD?J"Z^//@KXK_ +2G[<_PN^-'[7?C;]F7XP_LQ_M9
M?LUV'P#\$^"OBQ<^#]<U7X%:I\)OV;OB'X/M=)^#5S=R>!_VBI/VG_B[XI^.
M?PCGT_7O 7Q(\2ZC<ZUI'PZ\,:?9^,?"7@.YC_4R+]EO]F6#P;+\.K?]G3X$
MP?#Z?Q';>,9O L/PB^'\?@V;Q?97,EY9^*I?"Z>'ET23Q):7DTMW;:X]B=3@
MN99)XKI)79CT.N_ GX(>*/B=X,^-GB7X.?"KQ#\9?AQI5_H7P\^+>N?#SPAJ
MWQ.\!Z)JB7<>IZ/X,\>ZAH]QXJ\+Z5J4>H7\=_I^AZM8VEY'?7B7$,@N9@[I
M+V<*$&W)TG'FDE&\N3"X.C&24E))QJ86<HQE>#A7FI1<^;VA-2G*M*Z2J*2C
M'WK1YL1B:K3:<7:5.O",I0<9J=&/*^1Q]G^('PH^,_BO]H3X\ZMXAU7_ (*&
M^&?@'\:/V=_^"G'QA^"OC3]F&30_B3?>)O'WP>T3XW^/?AS\*/@IJ/P;U?\
M:+TKX<ZOHGQX_9K'PW^*/A;X[:+^SUJ6K^$==GU?XG:1XCNK7PYXW,B?!3P'
M\=_B)^S]^UY\7/!7[77Q3M_CSI/[;_[8O[+OPGLOC[^T=\4=/_9^'P^\*_\
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M=\1W7Q+^$>K^&O'GACQ_\//$9U&!5TCQJVD'0?"4NER^$]$_(K]IGXD_M _
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^VS^U'\8?V/_ -E7Q;^SS\/O@G^VWHVL?!C5?V@?B)XGU/XE:]^R]\=?C?\
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MG:?$S]F2/XC?M.?LY?M.CX@ZSX?UO]FWPU\8O"GAWP79Z'HE]X8\7Z1\>(/
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M,_:?\$Z-KD<.C?&/X/?%3Q1+X2T33KCX?Z?<:1X&T[Q%8W'B3QW?>,&U_P
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ME&5/D<))2@ZB<HP4=+2IS?=3IRQ3N[WC).-6AR65E*-3FC).T^'O_P#@I?\
M$_1/@7^T/\8KOX8>!M6T']C?]MKPE^S9^TGXQEG^)W@G2K/]GO7/#?P#\=^+
M_P!K_P )> -9\&:UXPL['X2?#K]H#1O'_C;X2^(=5.F:AX.\#^._$OAKXUZC
MH\/ABZ\2?I3\-OB7XB\>_$;XZZ*=(T6W^'_PM\8^'?A]X:\26UWJ,NK^*?%0
M\"^'?&'C\R6\EF-$_L'PM>>+-'\)VNIZ7JU[=S^+]+\=>&]9TK0[OP>D^N?#
M^I? >+]D7PU^TTTO@K]I']OZT_;^^-Z7?Q"^$UIX7^ ;:9I7B#Q5^S5X9^#?
MB;4_'FHR1?"#0M ^$?CC0_@OX<\+>+M:U&;5=$\*W7B30;:W\+VNFR^(M>NO
MK_\ 9!_9^L?V5OV8?@9^SS9ZM=^(I_A5\.?#WAKQ!XJU#4=3U?4?&7C1;47_
M (]\<:EJ>M33ZK?:GXV\;7NO^*]1N;Z0SR7NL3EDB&(DJ"E:3E).RI)))K]X
MZ:C63T2E&+A&K&44ESUY17NQ4(U-J\5!.*;FW>S?(IJ5-WYFTY<TZ3B_>4*,
M9O63E+XZ^,7_  41\2>"_ G[:_Q\^''PXT/X@? [_@GC\2-1\ _'W2I-9OM-
M^)GC_3_ 'PX^''Q8_:(\5_"B:2*/PWHTGP(\$?$"<Z+X8\7PW4GQO\;>#/%W
MA%-?^$/AZ'PS\1O%?EG[0WA6+]JK_@I-X#_9G^*_A_X=_%K]D_QK_P $Y?C?
MXUN?AOXIDU^?2-7C\6_'3]F_POK'CM+:SC@CM/B1I.CHUC\,O&&G7=GK_@:P
MU?7K[PSKOA[4]=U1[OZC\7?\$^? OB75?VK=$L?''B#0/@;^W3J-AKG[5OP2
MM-)T=]-\8:]_P@WASX7^/=2^'_BRW2PUKX=?\+^^%_A'PU\.?C^D\'B^XU_P
M_I":_P#"J\^#/Q1U3Q#\1]:]:O/V88KG]L70?VPHOB!J\&M>'OV?]?\ V;;+
MX;'0=$?P4? WBCQ]X3^)>M^('O8T@\5_\)ZWB3P9HMAIVHC7?^$0L/"XN].D
M\#7FN7 \31Q%?P^=\S33DFM%?"8JG5Z6E%XJ5"=*UI0@F[J4;HFW>7(^5:<K
M5TVEBL/4C;?EDJ$:T)WO&4DD[J2OSWQW_:+B^#'CKX-?L[>"]/U67XA?%+X=
M?%WQ[X<UR^^'_P 6/C3I'A;X>_ "Y^$?A;Q-J>L^%_AE;:M\0/%VN:AXO^.'
MPG\.V4.H:SX7TY=*UGQ9XRU;QM<:UX7T?P-\0?F?P[^V_P#M>>-O%?[,OPHA
M_9#\&?!OXP_M&_LO?M0_&*\\+?&[XR>(+=?A9\1?V:/BY\"_A9J^B:W;>$OA
M1J-]XC^&WBFQ^-^A_$#P#XCM3H?C3Q5H4UAI7BGP-\*[]K^ZM/H']L/]BBW_
M &I-:^"?Q-\%?'/XK_LO_M%?LY:WXRU'X._'GX01>"=:UC2-!^)NBV'A_P"*
M'P\\7^ _BAX6\;_#CX@_#SQY9:+X7U35/#_B/PU+/9^+/!'@GQ%I6I6;Z-=V
M6JZ&D?L>R:%\7_@/\:XOC5\0/%?C3X#_  :^/?PBL]1^(UAX8\177Q&N/VE?
M&'PN^(?Q5\??$)_#NF>"K.#Q#J'CCX,^ =6\/>'?AGIWPW^'/@S2$\1>#O"/
M@O1?"5[X:T?P?=W)IR<O>J3=1W7,XN%>490:3=W.5-34DGS1NDX\S):<4E!1
M248**ULDI4HS@XO32$9.$HNRBY1T?*CX]_9W_P""EGQI^,NJ?\$_/$7B?]G[
MX=^"/AA^WUHOQ1\)^&H-/^+^N^)?B+X ^-GPB^$?CGXL>(%U^U'PUTSPI?\
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MXTIJ?[+7Q'TBTU,V'_"!QV7B3PGXAN\3:?J/AK4O7;+_ ()O>&K[_@F3X/\
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M=*I&,9*TN7=J7)"U[.\E*5[N-E:<7%MQ2E3DN5*K"4FO%_V:_P!NKXG?%/\
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M\HHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\A^-_Q[^$'[-_@.Y^)?QM\=Z1X!\(1:GI>
M@65WJ$=_J&K>)/%6O7!L_#?@GP1X5T.SU3Q7X^\?>*K_ !IOA+P#X)T37_&7
MBO5'CTOP[H>IZA+';-Z]7\W?Q^TGQ9^T!_P<L?L;_"?XG,\?P-_9*_8.^(/[
M8?P9\):P+>3PQXU^.OB/Q[K/P7U[Q=;6\L8M=8\5^"].U_PEJ>A6DWVO6/ T
M_@D^*=);38?$MQ-=I>]4I4T[>TE*\FK\L*5*K7J-+K-TZ4HTXMI2J35_=A,&
M^6%2HTW[.,6HK3FE.I2HTTWJU'GJQ<Y)-QA%V7-.!^SOP=_;+^ _QL^+'COX
M"^&]9\5^%_CG\./"GASXA>)?@_\ %;X=^.OA+\0W^&GB^\NM/\,_$SP[X=^(
M6@>'[GQ?X#U'4;.71]0\0^%CK%MX1\2-'X/\<KX8\8/_ &"/J>OY))/B[<>*
M?V]_^"K'_!<!#-<?L8_L3_L$>/\ ]BO]G+QQ9ZIJGA_3/VH?'W@+4AX^^)%U
M\+_$ND7=A=:YX+\-?'#3_%?PET7Q]X>U-?#OBCQAXAT"\\#^*+S4O"6OC0?+
MOV$/VMOV@M&^*W[ 7PZ^,'[57QL^(WAK]DC_ ()D?M ?\%*_V[_%NI?%/5O&
M+_M$_%/]H&UUK5OAY^SAJDEYJ]Y;^)KS]FKPG8>,=0\,>%-$O[;PU!J?PX\3
M0M:+/X4U0R*,DX1G)\EJ'MJF\E"%L?6C+W4Y)/ X*.*:<5I7HQCS*K%TQQDI
MRBK2_>^RA:T7*2^I4I1LW9VQ>+^K)IM7I5G*WL9\_P#9917\CW[$_P"U9^T?
M^U;^UG_P2PN?%7[3OCJT\3?'WX-?M*?\%.?VT?AIX4^)EYI/P4T#X,^([ZP^
M$_["_P"S1X&\-6]]%HFEZ7\/[SQ5IQ\?^%X[9/&'Q'US0M4\<_%F[\7ZYJ6F
M7WAOG/A7\</CIKO_  3R_;3_ ."S_P 3/VV/VGXO@Y9>)?\ @I3XP_96^!Q^
M(C^'?!7C/X8>)VU3]F[]E:RUYO#UMI&I>%+WPUXS\+:5=?#6/PQ;:/+I'C/7
M;WXDBXU/4O$-I/:5-.G&<IIIPIU9S6C<73J0HQ@K-J4ZE>?L8*+LW&=1.=&,
MJD5!JI*$8-/GJ4H0>RE[2,ZG/9I-0A1@ZTFU\,HT[1K-4W_7E8:UH^JSZM;:
M7JNFZE<:#J7]C:Y!87UK>3:-K']GV&K?V3JT5O+))IVI?V5JNEZE]AO%ANO[
M/U&PO/*^S7EM++I5_)9\!_$W[1G[-6J?L&?\$FO@OKVNZS\6[S]B3XI_\%'/
MVT/&'Q&^.6M:;J7Q7_:#\9^-+_PEXD^&WB#X\:KK^J_$3X8_#/3?VL_$7CWX
MH_M'ZK\'="\4?'#4=&\&VVF:!HSIK_Q93Q#T&B_"O]K7XV_M1_!?_@F9X0_X
M*9?M0S:5^S)_P2=?Q=^TQ^V#\*OB$LOB'QE^T%^T7XAU;PA\(_$;:I<G5+S7
M_$H\!P^(_%'AG4_&6N^(]:D^'-YI7C;PAXQ\'_'GP]X8^,&EU*#C-T[IS4JE
M.UK*4J$:KQ,XMMKV5.5":C+WG.$J4U\=E,9J45.S47"G4O=.T:\J7U=.UOWE
M6%:$G!6Y91J0WA=_T33_ +5_P/@_:LL?V*!XFU:?]I"]^"5S^T:W@:#P5XU;
M3K'X+6_B_P#X0 >.;[QT_A]/ ,5M<^-O^*9M]'B\33^(VU$AI-'CLR+JOHVO
MY)]<U/Q5\9O"'_!RK_P4%\!_$[QUX/\ &/PE^%GCC]D7]EGQYX3\677AKXF>
M"?"__!/'X->+/%/CGQEX0\5Z#]ANU\(?%O\ :8E\;74FH:;Y5GJ]UX.UJPL)
MXIK*:Z/[$_\ !-;4_B1\:-,7]L;Q#\9/B;XT\"?M"_LH_L26.G?#SQ1K]OJ?
MPXT#XP^#_AEXB\1?'#XB?"71;-'T[P]I'C74_B1X6\'>+?LS6>JZI\3/A?X[
M&M6]UH^F>"Y+28KF@I7VC3G)VM=8B.(K8=J+]Y)T:5",DW=5<1'645=MMJ36
MGQ2BE=-J5%X>G63DG:5JE6M*,HKEE3H2LU*2BOKSQ7^UM\#/!G[3GPM_8[UO
MQ)KP_:#^,7@;Q9\3?!'@VP\ >/M3TFX^'O@>._'B?Q9K'C^Q\-3_  [\/6.F
M:A9VVB-8ZSXKLM;GUG7/#MG;Z5*NN6$LMCX@?M6?!'X9?M!? +]EOQ=XDUFT
M^.'[3=C\2M6^#GA.R\#^-]6T_P 1:-\'_#B>*?B1J^H^-=-\/77@3PM:>%]*
MN--$\/BCQ-I&H:A?:UHNG:/9:C>:G;0M_(W^WU\3/C?\5_VB?^"I7[:_[+'Q
M@^(O@3X_?!KXL_L;_P#!&;_@G+!\*+SPS:ZW\6OCYI'Q6\)?'+]JOX5ZIIVO
M^'=<CUS3=(\6ZOJFI^*--BU#3-)U+P1\.?$C>-QJ.AZ*=)M?KW]HG]K^/X5?
MMQ_\%:O^"D.IZ;I7C"T_X)1_L&^ ?V/_ (%^&I&DN_!OCW]H_P"+FHZ%\9_C
M%J]K9QZE'K>G0^#_ !EXS_9]^$_Q)U'2KBVU#2?"^LM9FX-W.IO93M3A4E=1
M4:]6K97E[*%&I7I\D=/?<:F A---1GBZ?,Z+G%1IINI.G"SES4:5.^EJTZE.
ME/G_ +EUC)P:U<<+4:52,7*7]651S2K!#+.XE9(8I)76&&:YF98U+L(K>WCE
MN)Y2%(CA@BDFE?"11N[*I_DX^#W[6'QR^"_[0'[4/Q&\8_M)_%7]I'PO_P $
MU/\ @D!8_M!?M2^"-0^)\P\$?'?_ (*&_''P_P"+?VAO$UWX(T+2#=>%]*^&
M/AGX4_#RX\->$/"7@G1+;X<_!6SUBW72O#FEZC::]J_B7T/XO?&[XW?L_?\
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M%?Q9_M-?&#]K_P"/VM?\%)_BK^S5^U5^U)X-\:^+O^"J/[+W_!.K_@FU\&_
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M;C):-K22E'1V?*VM&B8R4XQDMI)27HTFG\XN+MTO9ZIA1112*"BBB@ HHHH
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M_9[\,Z1KG[4^I?M#:+H^A^(?' ^,?A#Q1X'U_P"&GQ&;3[;Q)IWB?QS%X?\
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M-M%HNR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4/A_I[?$NV\*W'P]N+7Q-/[1\9_VB?@O^SU%\/YOC+X]TSP'#\4_B#I7PK\
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MO6R2=WHR;JU[JS2:=]&G:S7K=6ZNZLM4?1-%?.$?[6W[/K^)M9\,2^/FT\Z
MGQ4;5O&&L>$O'.B?"6T;X'7<VG_&*W/QLUCPS8_!Z>]^&.I6>KZ7XXL+;QS-
M>^&]5\-^+M,U.WM[_P '^*+?2+OP5_:D^!_[0FH:SI'PK\6:GJ^L:%X/^'OQ
M$O='\0^!/B'\.]7G^'?Q8A\0R_#7XA:-I7Q(\)^$M0\1^ O&S^$?%EEX=\:>
M'K;5/#&HZKX6\2:-#JIU;0M4LK1*[V3>C>BVMO?M;=IV:5VU9-H;2=GH[I6>
MCNU=+7NM5:]_N3^@J*\'\??M+?!SX9^-+#X?^+O$6M0^*;ZY^&MK/9:!\/\
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M&GBCX@#X5'QI:Z;KMUKW[.VJ>$K::W\1>,=$\3Z2GWIX$^&?Q9^,?[8_P/\
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MIKQ3^QI\2/V96_:+\):U\%]=M/C;XU\3?V%NL? .I_!;0=0\?>#?V4?BE?\
MA ZQ\3_#'Q1MM"\:Z7#X@\,:79?#OQE<^&=1UBOZ+**J7OQ<6].6RM:\6JM6
MK"<9/FES0E6FDI2E&:Y?:QFTW4(15-WC?X^=W;:DY0HPG%K2-IJA3>D8N#3]
MG*":5/\ )/X+:3^U5\6?V]OA)^U)\7?V1/&/[-OA/3?V$/B?\"?'.G>+_BY\
M O'^H:%\:/$7QJ^"_P 0O[.T5/A+\2/&C^(OAM>Z7X-U]?"/CF8:/XCU)H0/
M&'PW^'TTUM#=Z'[9O[-_CWXY?M[?\$X_'<GP!M_BW^SW\$+/]KFV^.>K>(KS
MX1:AX6TE?C1\*/#G@WP/%<>!?'7BVRU_Q9$-;TBZDU@:3X6U,:;:&"XA6]DD
MDAB_5RBA63@U&*495)<J7NMU)XB<DTW*T>;$U.5)Z+D5VHIN>16FFY-S4$Y<
MSYE[.-",6I*VML/3NW\3YVTN=I?D7^W?^RGXUTG3OV,/'7[)G[*OP=^._@G]
MD/Q_XNLO$'[#$J_"SX4>#?&_P:^*'PZUCP!J$_P@_P"$UTJW^#OA?XC?"77)
MO#OB_P (Z)XE_P"$0\.:YX:'CGP[%XM\/ZCJMBNH<W#^SS\6(?B__P $RO'_
M (+_ &+/ W[/O@KX:?'_ /:5^,?QJ^%WP:U?X'Z5HGP4T_XU?LZ_%;X7:3J'
MC671O$'@O2OB3\4_$'C'QWIGBKXHWWPG\,>)M*TNZOO$>D:3XE^)*^&=,\<_
M$/\ 9BL_5]6TK0-*U/7==U*PT;1-%T^]U;6-7U2[@L-,TK2M-MI;S4-2U&^N
MI(K:RL+&TAFNKN[N98X+:WBDFFD2-&8)-0O)RTC4==N4K6=FY\TFUS0;7.^=
MODE&\913E:G%3LK:\BII)=FN1Q5G:4;\JY%'G4K34G:_X]ZM^S#\>%_;2N/B
MY\!/#'QU_9L\/_$OXU>-+#]KVWG^+?PI\5?LL?'_ .%LWP(\1>"/#/[0OPZ^
M& \;^)_B;\(/VK(=6T;X):/8^-/ W@OX42ZNWA#Q+:?%RU^(7AY]*UW4>+^
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M70?AM-\3?#?B#Q!\>?!&JZM-JGQ^\2_&OPE:?$'4K/\ M+2O@7XZ^(O@'3O
MGPI\._T'UA>*/$_AWP3X9\1>,_%^M:9X:\)^$="U?Q/XH\1ZU=PZ?H^@>'=
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MB;X@?'%?VDO"WC7X-^)?C1<>$?"OC;X3^"-<U?Q5\$]<T6ZO/!'C.X\$:/\
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M4ZYHNJ:)/INN1VFGZMY6F-JOT+X+^%OQS\(_\%"]!^/4_P %/%&H?"WXA_\
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M!/XD_%6P@\,7</QL\*:YI'C/3+[4[%_#MPTFJV.B^*%U3PII7[_TC':I;!.
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M-O[7'QD_9L_X+JZ/;_LR^*O!_C/]OC3-"NOV<_ ?B'XF? 6Z\1ZO/XA_8#^
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M:_LQ=/T4Z3X:BTK0OL>G-9Z#$-+$FBZ3)#;F+3@=%T^[TCSM-LY!$7TVSO\
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M_P""=UB;1_%/A#7M"U**UO9FN-"UO0KG4#IVN6MS>^']9L+VUNKFRD_I3L?
MO@C3/%FM>/--\'>%M/\ '/B6RL=-\1^,['P]I%IXK\0:=ID<4.FV&M^(H+./
M6-5LM.B@ACL;6^O)X+2.&)((XUC0+6;X<?#QXM2@;P'X,:#6+JWOM7A;POH;
M1:K>VD]Y<VMYJ49L2E]=6USJ%_<6]Q="66&>^O)8W62YF9\:=-TXTH\SDJ<*
M<-;)>X\LD^1)+E4WE\I3YG*\L3+1<L_;:3J<\JLG"*]K.4WNVU+^T/B;;NXK
M'0C%I)*-!?S0]C^'GQA_: ^!/BC]K[]N;]F;]KO]I;QO^S5\6/"'C#]DKQ+^
MPC'X3^(^G_"GXN>,/A)JOPX^'_BO3[O]D#0_$,6HV?QB^*'Q'_:KTG]H+X&_
M%31?!WA'QGXD^)7A0^%/@/XPT;5?#,^@:-<?<_\ P5MU;5/#W_!+_P#X* ^*
M- \5^*_ OB7PA^R#^T!XR\*>+O!/C7Q+\/O%.@>+_"?PS\1^(/"E_I'BKPCK
M.A:Y9W$7B#3].#64&HK:ZU&SZ+J-KJ&G:A=V%S]U2^"_!T^H^%M8F\)^&IM6
M\#V]_:>"M4ET+2Y-1\'VFJV$.E:I:^%KU[4W/A^WU+3+>#3K^'29;2.\L((;
M.X62WC2-=/5]%T?7[&32]>TG3=;TR9X)9M.U>PM=2L99+6>.YMI)+2\BFMW>
MWN8HKB!VC+13Q1RQE9$5A=2+G1=._*VK<RO;313:^+GE"RJ6DHMI<JMJLX>Y
M553623O9V;ULW!.RCR1E=TTX<T5)IM_:_G%_;OM)=>\8?\%K=5M?C'\;M$;X
M%_\ !)+]FS]IKX26O@3]I3XS>#-'^''QR\/Z!_P4?U_1/B;X4TGP=\0])TS0
M;[3KSX6?"WQ$VD6-O;^#M6U71='\3Z_X>U?5[F+5)/I?XLIX:\??\%)/^"._
MBGQ3JQN?$/CO]E?]MWQ+ ]EXPUC1(==U?2_"_P"Q[XHBNM#TO1M<L+"YA/\
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MM]@R=/6PC2Q6S)^SBS1+81^2H0,N/A?\-+I=.2Z^'?@6Y32-*\3:%I*3^$M
MF72]#\:[/^$RT;3EDT]A9:5XN\J/_A)].MA%::]Y:?VK#=;%QK.3E*3BE!-S
ME%+[,W5QU2$D[6O"&+I4E9*\:"MRKD48BDJ<(65XQIQE.VLHQHX.G---_P#+
MR>&J5FVW[]7K[[E^/O@:X^#_ (R_X+'>.=>O?&^CRZO\8?\ @E7^RUJ/@K4O
M#GQ7U+0;CX@SS_&S]L?2?%5W\/IO"_BW3?[?&C>%)+'41<^$S=#PE//:^+=-
METC6;Q-8G^;OV&?C+XJ^(_P:_P""$_@3X^>,_%/C3X.?M)_L3?&76/&7B+Q;
MXDUK7[+XW?MB>&?"?P4U?X:>"OBSXOOKBXN/%^KWWPMU#]JOXA:7X)\6ZSJ-
MMXS\9^"#XTETB]\5?";0M1TC^B.Y\"^"+R739[SP=X5NY]&\/:KX1TB:Y\/:
M1/+I?A378M.AUOPQITDMFSV/A[6(=(TF+5=%M6BTW4(M,T^.[MIELK814]3^
M&GPYUOPI>> ]9\ >"=6\#ZA*D]_X,U/PKH5_X4OIXK^'58IKSP[=V$VCW,L>
MIV]OJ4<D]F[I?P0WBD7$22+3G%[4TDJCDHZ6<'7QU50=HZ)1QBLE:'M*$&TX
M.T,HTY)).HW+DBG/7F]HL/@:,I;ZJ4L&Y.]YN->:4E)7G_.)\.M2^*OC3XC?
M\$XOAI\1_BW\:-2^&FL?\%+?^"J7P"^&&LVO[0'QBTCQ+\<OV._AE\ OVS#\
M(+[X@>(-)\?6.O?%&[\*WW@S1M&\&_&/Q!>:MXW\0^&O"WAGQ_:>,[^X\=:I
MXB\3?I+_ ,$SOBGX4\.?LZ)\._&?Q<M9YM(_;K_X*%_LP? JU^)WQ4NO$_CC
MQ-X<^"?[8?[3.D?"_P"%F@>(?B!XDU?QK\0];\#_  +^'ENNDZ?-J>O>)8OA
MWX,_M2X,VE:/<W\?Z3WG@SP?J,ND3ZCX4\-7\_A]((]!GO="TNZFT2.UEMYK
M9-(DGM7?34MYK6UE@6R,"PRVUO)&%:&,K4L?AYX TO\ LO\ LSP/X/T[^Q-8
M;Q%HWV'PSHMI_9'B!M$OO#3:YIGV>RC^P:PWAS4]1T ZG:>3>G1-0O=*,_V"
M[N+>3.'N\R:YE)1C>[YK1EAWS-MM.;5&>NW-6FW>\_::37,X2BW'D<WRKX'S
M*NE&RLU"+JQLMVJ<5I:FJ?84444R@HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^5_VSOBY\3_@_
M^S[XWU7X!>&-&\=_M*^+;"]\ _LT> -?F":/XN^-_B'2-4E\)IKD*W^EW%WX
M0\'VFG:Q\2_B+#8ZEI]]#\-?!'C"^MKZS>S^TQ?5%?$_Q$^$GBGXY_M0Z#_P
ML3PE\1] ^!OP1^'<^N_"WQCX,^,5_P" 8?&7QT^(<M]X?\8ZQJ-M\,?B+X:^
M)NCO\,OAC;KX0\"WU];KI'B;_A<'QIM=9TVPA\/>"-7\33)-KEC+E;O[R2;B
ME&3;2::<M(J*EHV[/0::7O-*5K>Z[VDW**2=FI6U;DT[I*Z/5?V3_P!HWP5^
MUY^S5\#_ -IKX>+);^$_C;\-O"_C^PTFYN8+K4O#-[K6G12:]X,UR6V @'B/
MP1XA35?"/B6"-5%IK^B:E:E5:!E#_BW^T_\ !GX(W.OV/COQ!KKZEX1^'US\
M6/&>D>"/ 'Q!^*.M>"?AE;7.J64?CKQGHWPS\+^+=4\+>'=6NO#_ (HM_#%W
MK=I92>,9?!GCM/",.N-X%\8#1/D#_@G[\!OC+^RE\2?VR?@5>> =?T_]D/5O
MC_KWQT_9$\9:]\2M!\;:SI-C\8M,T?Q7\>?AMK.D3>)=5\::-HR_M!WOQ%^)
M?P[U+5CK-_K&C_$'7(/%=SX>U72M-LM8\)_:A^%_[4?P=_:$_;K^,?@?X6^'
MOC)^S]^U_P#L4>'?"/B7QM=?%+2O _B#]F3QM^S?X$^/=M-:Z]X/U;1-3U?Q
MW\-?B3X>^)Z:MX7NOAY-J_B#0?B/8>(=.\1>$=,\.^)1XXLYQ%7V=.I6C&,5
M]6KXA1YGR4ZE/"U<1&A*4GS*'M:56BIR;DJ<:4F^:JF.A3YZE.E*4I?[11H.
M=ES3ISQ-.BZR25I3]C4IU7"*LZDJL4N6FXGZ!Z%^W#^S-XGD>'P_X[UW5YA^
MS)X7_;&MH;+X5?%Z6;5?V<O&44TOAWXA:!%_P@8D\12W@MY(KCP7H*ZC\0-+
MN0EIJWA6QNI8H7P?%G_!0C]DGP;X&\!?$;4_B=?ZCX7^)?[.>N?M=^$6\)?#
M?XI^-_$%S^S+X9TGP7K?B+XU:KX,\(>"M;\9>&O!6CZ=\0_!KW=SXDT'2K]K
MO6H]*MK"XU>TU"QM/RQ^ 'P2_:'_ .$)_8M^,WPJ^%%K\5/!/Q=_X(@?"/\
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MX-&^'WQ&^),OPR7X=?#2]\8W7BW1+'X=ZOX_\5>&_#GQ+U"34K#X?ZQXEO-
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M=T77]#US2+[3]1TZWG@9:X36?VO_ -GOP[\0O OPTUSQW/IFM_$WXF:_\%?
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M,?VW?B)^TMXA_9XLKCQQ\,S8^(M)^+?['GP=_9M\)3>)-3M_&$\7A":'QAX
MUGQ'K]OJ$,SZ;X+GTZZL&UGQ)-/X8M^3^,G[,G[4'A_XG?LK_M&^$_V,?A%^
MV#I<7[(/A7]DWX]_LN?&3QY\)?"WBGX5>)?"'B&#Q7X*^-7PV\<^+M%^(/PW
MU_1(KO6/'OA7XJ:!8:EI/B+4] N/ .O>'K7Q/J&C7OANPSBVZ4&])N.'5Y)M
MQJ5,-B9U>>,6I.#Q,,/";;2H\ZY733;*E=5&K7@I5VU%I7C3Q&&C349.Z4EA
MYUYQM?VO+)-3DDC]+O'7[='[+/P^^'D/Q9U;XI0:[\.&^"-G^TO>>+_ASX6\
M;?%?2-$_9YU&Q?5-+^-GB27X9>'/%LGASX::SI5MJVK:!XJUN*QT[Q#I7AGQ
MGJ>A2:C8^!_&%QH>?\,OVTOAY\5OVK?C/^RSX6T'QG=7_P '_A9\ _B<?B1%
MX3\5W7PZ\86GQW3XN:AID?A[Q=:Z!+X4;0]/T'X:Z=?:3XNN/$4>B>-]2\0Z
MGH'A&34]1\%>(5B^'+GX,_MN_LP_M.Z5\5_V>?V6/V=/C/\ #+X_?LE?LY?L
MU_%;X0^&/C#;? 'P%^RYXZ_9S\5_';Q#X4U;P/<:W\/-977OV9;S2?VA?$OA
MO6-&\(_#*]^)-I>^&[3Q5HGPX\K6[WPFGT?\'_@W\=/AS_P40_:0^*_B3PG9
M>*?A?\?OV7OV//#(^+^BZOX<T#2-*^(G[.FJ?M+6GCGPU??#N[U[4O'%GJ7B
MF3XO^$?$?A#^SK/6?!]OX>B\3VNM^.K'Q#H>CZ+XKI.[CHTF\0FN:+Y90C)T
MXMI*ZDXQE&:_=U.;DBW*W*KRMYI47?E>JE**J22YG:UVO9R_>02<Y*R?-]$>
M-/VM_@1\/OB9XV^#OBGQ)XIM?B1\/O@/JW[3'B/PUIGPG^+WB21_@MH6M+X=
MUCQ7X9U/PUX$U?1?'-_IVMO%IUWX*\#ZEXB\>17%Q:[O#&RZMWE7PC^UE\#/
MB%X:^$_BOP3XF\4>(/#_ ,=?@9K_ .T?\*=7TWX4?%J>'Q1\'/#MAX'U&^\7
M)%)X%2;2+N>R^)/@>ZT#PAXAATGQIXK37[<>&/#FL-;WRVOA'[9G[,/Q4^+W
MQ6_93^+GP,\30>"_&7P\\4?$WX._&77GUO4-!U"[_8Z_:+\"OI_QMTOPG>:6
M/M4/Q-T7X@_#_P"!7Q)^%.J2BYL=$\;^ ;&YU*QO-'N=4@?G_P!@O]D_Q_\
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MX,U+XB:-X0O_  #I&N6GPUTZ?7'AU;Q)902ZC+9^$+>XF\:WUIX<F\)^&?\
MP4Y_8D^+_C?X4?#[P%\7]6U'7OCCJ'CG0OA3?ZQ\'OCEX.\$^,_&'PTU#Q7I
M_CKX<:?\2_&?PU\/_#FW^+/AS_A"O$6J7OPDU+Q59?$Q_#5M8>++7PI<>%]=
MT'5]3^=8/V8_C?H?[<'ASXY_!#P3\0/V>5U7XQSVW[5^HV7Q0\%ZY^R9^US\
M"=.^#J^%/#OC:X_9_P#^$TUSQ1X"_:;T75_#?PO\,>%O&OA?P3X$U*T\.>%-
M7L_'7CGQWX0DTCPL_P A_L1_!'QS^U#^R3^Q%X)D\ 7WA?P7^SY_P4@^/_[4
M^N?&+5M;\'3Z-J-C\&_VQ?VMM7\.>&/AKI.D^)-0^(,GCOQ9XNUOPSX1\71>
M+?!G@SPEIWP[NOBM<V?C#7=1M/">@^.7!J4H\VD;4W*RU498AT9U/*,8.-6$
M91C4E*%2C*#E:<B5U"4E\2;C'JG)8=UE"V_-[2+IR<7*"C.G54TFXP_:F\_:
MZ_9_T[XB^"OAA?>-[NTU_P")'Q"\7?"+P%K<_@SQTGPU\7?%SP%IWB'5/&'P
MKT/XO?\ "-'X5WGQ&T*#P?XTM+CP8OC%=?N==\#>/O#&GV-YXF\ ^--(T' T
MS]N#]F?6O&N@?#W2?'VI:CXI\:^!OBI\2/AG:6?P]^)-S8_&3P?\$M0T33OB
M?J/P/UJ'PA)HWQINO#4OB3P_=Q:-\+[_ ,5ZUXDT76+'Q%X3T_7?#\K:HGYM
M?LH?LB?M _![XP^)?@E\2OV*OV6_&/PW\,?M$?&KX[?"_P#X*,ZAXB\!ZI\5
MW\#_ !3^+/Q ^+WA_P /2?#5O *?%)/VFO!TOQ NOAFGQ!_X2OPMX$TS0!-\
M2+/Q+XHUO05^'/Q"]K_X)J>"/V\?@C\,?@W^R!^T/\$?A'X6^''['7PTT/X(
M^&OVG/"WQ3M/%;_M+^ _AWX7MOA_\)KOP3\'(-$3Q+\)=0N?"NF:#K?Q;U/X
M@>+@^G^)_#"^'_!?ACQEHOCNY\4?#43;@FE:;H2G9RBOWCA_#M*-HRI5'RN,
MY+VUE*DN63DE)M2FEK%5(P3LW[MW[WNM<T:D4FI17[GFM55XV?V?^QO^U!X8
M_;+_ &;/A+^TKX/\,^+_  ?X=^+G@SPUXXTGP]XV\-^(/#VL:=IGB[0=+\4Z
M-")M;TC2K#Q-$FBZWIJ7'B?P;/X@\#ZAJB:C;>'/$VMV]C)='RGX*_\ !0SX
M)?%_P3\6/B)=V7C_ .'?A7X:?M(^+OV9[(^./AG\2M(U[QKXY\+_ !/U'X+6
MEAX2T";P<M_XG\1^)_B3H&N:?IO@/PDOB+QMH.EOH4GCO0_"6O:E>>'M+K_\
M$O?AA\8/@5^P1^R]^S_\<_AZOPY^(W[/OPB\"_ W6K"+Q=X9\9Z?XG;X5>&M
M+\&GQ[H6J^%;N^LX/#'C:?29]?\ "^G:J]GXIM/#]WIR^*]%\/:^^H:%I_P+
MI?[&G[6>AZ'>7.G?#C3E\2?LS_\ !9+XW_\ !0OX:V#^.?!EQI/[4GP3^/GB
MS]H:;Q-X,\(S/K=H_P /OB)X:^%7[2^OP:%;_%F+PCX?U'XU> ]*T>YUO2_A
MYK9^)VF6U#VDESVI\M/EG9RLI5<*I5-$KR5*=23A96YIMP_<SA#).K[*G)PO
M5YI\\+J-VJ6+<8:MKE]K"C%23UM!*7[U2E^S/PB^.?PS^.5EXPN?AUKE[?7O
MP\\::C\.OB'X:U_PWXG\$^-/ 7CC3-.TK6IO#?C'P3XUT?P_XJ\/7M[X=U_P
M]XL\/SZCI$&G>+/!7B3PSXW\*WNM>$/$N@ZWJ/"_%3]K_P#9[^"FI3V'Q*\=
MS^'K+3/''P\^&GBGQ;%X0\;ZY\//A[X^^+%[H&G_  Z\)_%'XD>'O#FJ^!/A
M?K'BBX\7>"WMX/'_ (A\.IIUEX]^'>I:U)IFF_$/P/=^(/+OV9/V?_$WA+]H
MW]L_]JOQ9I%WX'OOVK];^ MIHWPRO]1T/4M<\.>&/@)\)8? UMXB\<S>%-7\
M1>$(?'GBSQ+K7BRW>V\+>)_%6G+\./#7PPFOM<@\13ZWX6\,?"WB7]D[]H/P
MQ^VE^TVI_8A_90_:S^ 7[8'Q4\"_&KP[^T9\:M;\"R>*/V7=?TCX-?!SX/>-
M?"'Q&^'7BOP3K_BWXM^$]+E^#6F_$CX-Z'\-;[1C<:UJ<O@;Q9XL\"V%W#\0
M/"TQUG14M%.*=1W249IKF@I.\8\T%*<)RO",K4Y-M>_K+2-5K5Q<O9Z/6+C>
M,G&ZE+EDU"486E))SBDG[OZ21?MM_LRS_%FS^"MO\2&N?&M_\9=7_9TM+FU\
M(^.+GP)+\?=!^%EQ\:]8^#1^*4'AN3X:P_$;3_AI9WWB"X\,S^*X[[[9INJ^
M%41_&.DZEX?M-&+]KWX ZA\3/"OP;TSQ^P\=_$3Q5\4_AU\.;V?P3X[F\ ^,
MOB5\%;#7+[XK^ _#7Q&70K3X=^(_&7PYC\,>*U\5>$=-\9IK<-YX(^(>BP1M
MK/P[\>6GAG\H_'?[-_[=GCO]HWP%XX\9?!;3?$UK\$_^"L&G_'CPIXSTCXQ^
M!O#_ ,/-2_8ZU3X*_&+X9^ KCP%\,%GM;[2_B1X NOB;!J'[3>N>.="M?B;X
MTUFQN)_AIXD^+_@H>"O ?PS]R_8-^&_[=_[-HL_V0/B-\$OAIK7P#^"/Q#^+
M?B;P%^V-;?&'2=7\1?%GX5>,?&?CWQU\//"NE_!";PO:^)?"?QPL(/&MCX$^
M*.M^*_$%CX&73-+\1:_X5\6^+K_7+2&!1]Y1N[-QO*]TFTJ4I).R<'&,YM74
MN:5.5.//.+4W+1R4?>2=D^J?-5C%VVG&3A"[4H\L:L9NT'[FW_P3W_X*&Z)\
M8?AU\#/A_P#M"^/S>?M0_&#QI^U3X?T"[T?X-?$3PA\*O'-W\#/CE\<-";PA
MX1^($/A[5/@_!X^T#X4_#7_A)[[X3O\ %#5?BG;^$]#U/Q;JVEZA90:AKDGZ
M3_$;XJ^!OA59^'+GQIJT]I=>,_$]MX)\$Z!I.CZUXG\6^-_%]SI&M>(AX;\'
M>$?#.GZMXE\3:K9^%O#7BCQCK4.CZ7=IX=\#^%/%OCCQ#)I?A'PKXAUO3/QG
M_9W_ &3?VG/ W@C_ ()@:'XN^$%]I6I_LR_MV?MF_'?XPI!XY^&.IVV@_#GX
M[^"?V[O"G@34-.N;3QH7\07ZW7[5/@*[US2=*@GO--L?#WCD0)?7-CX;M_%7
MUA^W3\*_VCI?C1^Q5^U9^SA\/M-^.FJ?LO\ CCXMZ;\1?V?;SQSH'PUUKQY\
M-_CW\.1X U7QA\/?&?C%X_!-K\0_A7K&GZ'K]CH?BRZT/3?%?@W4/'6@6GBG
M1-8O--6_F,I-04ER^_2IREO=/#X1RJ<M_=_>RJ4Y:N/.JE310G%2KKF6K:A*
M:3:UE[;$KD4K=*<83BK7MR06DX2/9/"G[??[*WC0^"$T/Q_XB$_Q"_:+\8?L
ME>&K76?A#\9_#5U_PT9X!\-^(/%OBWX6>(+?Q'\/M*D\':WI&A>%/$MS]O\
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M/_P3-^&/[,WAWXZ2>)O#D>D?"GXL_"G7OVV)CI7C7P++=3^./$FC^*O^&F/
M-[;-X>T"^T*\\.:%\1--U_5]$U.'PUI_BE3;2IRC>2DIN45;FC;"T:B6K3;]
MM.M&,7R\[I0I<RG)MEVY3C:RC.DHSZ2B\35ISDKJR2I0I2D[/EC5<^7ECI]@
M^*/^"@O[*7@73/CIJ?CSQWXJ\"R?LW?"31OCY\8O#_C+X,?&[PWXV\-?!'7W
MU^'3OBOIOP_U7X=6WCCQEX%CN_"OB73M:U[P1X?\1VOA;6- UG0_%)T76=-O
M+"'Q/QK^VK?>+_V@/V"=$^ WB+4Q\(OC%^UI\<_V>OC-:^.O@5\3? 6K>,8O
M _[#G[0/[1/A37/ACXD^*NA>#/[>^'4VO^ O!NLZ/\3/AUH'BWP%\3-,O$/@
M[XC7&EV&N6>I_(>M?L[?M4_'/]A_]M[P-XE_X)N_LL?LD_M$?%S]C'XV_LK:
M"_P7\;?"?Q%K7QD\??%3P;K'AB+Q58^-='\/^"8/AI^SEI6N7T/BN#PQXV\1
M^+_B/K3ZQ>F^\+>'=4^'VFS_ !6^\OV@?AM\7/B=\</^"9?Q+\/_  RUL:+\
M!_CYX_\ BM\9;:_\2_#Z'5/ VA>-/V-?VB?V?[*QEB'C![;Q-J]CXW^-F@7V
MIIX1N]<LU\.:%XEO[&\O]1CT72=;4[\T5'5*IA=8R34E/ZRZLMD_9J,:*:DH
MNFYKGM)QA&J<O>?,K1]EB7[T7=3BJ$:<=&US\TZKBXN2GR>XVHRE+UCPG^VW
M^S?XX^&WBGXL^&?%WBW4/!7@KXZ)^S1XHFF^#7QLTSQ)I'QQ?XFZ!\&V\ S>
M M6^'=AX^FO8?B7XGT3PK=:K:^&9_#UG=7<EY=ZO#I=E?WUK[UXY^(/A+X<:
M39:QXMU*6RM]4UK3/#FBV6GZ7JWB#7?$'B#6)'33]$\.^&_#UCJFOZ_JDT<5
MU?2V>D:;>S6>D:?JFMWRVVCZ3J=]:?E[X ^"MGK'_!3/XM>,/A;\1O"?B3]G
M+Q!X;^&/[4OQH^'>@ZB^K'1/VW= \/>//V8?!?B<7-I<7'A*\\/_ !(^"?AJ
M#5O''A-+>;Q%X4^+7[,7P@^(3W.BW?BB=O$7JO\ P4P_9^^,GQJ^&OP*\9_
M3P#\+?C/\2/V7OVDO#?[0UK^S[\9[K3=*^'_ .T)X6B^%GQ?^"7Q"^$=YXEU
MO2/$.@>#O$NL> /C7XEUSX=>+_$/A[6M \/?$?P]X3OM9LH].2XO;2K^Y2E_
M/R<[2;Y%S*E.5E%R:<HU*L&N=>QG!^^H3<Q_'4C'51YN6[C'F;@ZD(MN7+>,
M90I33<6ZL9KW'.*C[!I'[>?[+7B#P_X>UW0OB'J.L7WBCXS^./V==(\ Z?\
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MW\"_VSOC+H2_$CQSJG[#G@75/&OQ@^%(^$/Q<\!_$:.V'AC7/$O@^_TSP_\
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M-*_N^T44Y*4),FDG'E=U^\<FME=X;V2?6Z52JKZ.7*W)*49179_&;]ISX._
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M\3:S^SS\??!6A:-9_ C7/ASX1\07+)XP^&.BZCJND:MXG^*OA*33?'5A9O\
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M?[J:LKZZ2N]B5>\KZ6E))6L^73EOYM.[:LM596"BBBD,**** "BBB@ HHHH
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M.5<C</ZP:*_ER_9L^+WC;P3^P_\ \$DO^"G]EKGC_P#:2U+P5\#_  G^R?\
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MXVA</9;+V6&S?[4I,&V[FAM6\S;/+'$68?'_ .P+XZ_9^^)O[+_@[X@_LQ_
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M%&C^IWWP9^%NM_\ !4OXH?!70]1UR_@_9V_X)V_L(_&+]GC]GZ']H3XJ^&/
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MXC_9)\':?J'@;Q/^S3JVJ01?#WPMX@@^"'A'X8Z__P )9K*^!_$7C'_!,_\
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M391XNC\1-9^)=1OM3^@?VF?C5^S'XR_:4^-?[._QP_:P\&?LN?!#Q]^R_P#
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MQ7X%\,7ACM9.ZK^4C2O&FG:Y;_"/P_=?'CQZVG7_ /P<L_M,? S4+FR_:/\
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M+FZN9G.R*) 3+/<3.57)DED;EFK\^?V._P!H[XT_';XV_M7>%O$FN_!CXA?
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M@&V\&ZGX2^(UU\8OBQH_BKX?>.O!7C'P5J7AKQ]JNA/H:V6E>%5\/^I?%O\
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MG@H23NH<S<K6<:C;:7*XU(.$E=VCRU:,6FFK5(._+/FB^$^'?[ WP@^'%_\
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MZDZ:4=8*<H<L(2Y7$DU:?,]'RQGS/2].,I14K[2C",W?23@IWE*#DI<C<?\
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M^'\VBZ6OA#5/V?OA!=Z=X?\ %NA>-/#-\_@Y%U[1]7CUWQ.FM[6L_P#!1?\
M95\*CQU:>-?%_BGP;XE^%OQK^"G[/_Q.\$ZS\,_B%=^+OA]\1?VCM2T#3/@3
M)XITOPYX<UV&Q\ _%.X\3Z+%X1^+$5Y<_"Z^U.:_\+R>+X/&6@^(/#NE>R_
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MMO#<MQH<WKWP8_8+^&_P.\3_ +,OBSPU\2/C%KFI_LI_LN:I^R#\/4\6ZMX
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M=^R+\"8?AS<?'KXWZY\+-)^#_P 4_P!KSXM0_&SXD> ;+4-"U[4O!K:;\/\
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M^WK^S7XS\6?LO:OX!^">L?LGZ5\?_CW\:_ ?[5P^+VN7/Q7U;X9_'+XU^/\
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M[CP=+^T;^P9^TG\=_%/_  4TO_"6G?#?P=??M WO_!/;XF_LR:Q\5KBP\:>
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M+O&3?(JCA3FJ<8TA.+::4FDX2ALI;QK1C*[2M*'M;J45'G<(RJ0Y^:H_R?\
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M^#?[7W_!(CXKV7C[P-:_$";QA\0_B#\2/"?Q/_9O>73?VJ/B[I&HZ-IOQO\
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M@@D$8HE#FJ1J;\KG[C^!JI6I59T[:.-*T)\L%JJE1U7>TH346XPE#^917/\
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M];J%1IW:YI)KFY&[)QDINRWE;$QE;6\>?ZQS3Z.<$TDG9?SOZ+\+_!/[6?\
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MV4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!?B"/0]8ELO@/]G+]FC]H7Q5\*/V&_V@O@4?@GXC\'?%+_@C%\&OV2_'UO\
M$OQQXS\*:QX N+[P-X2\>^ ?BAX'T_PC\.O'&F?%G3KB3Q%K^E>*/ VK^)_A
M#*L5GH%_HWCF5;_48M.L>(O^"=_[;NN?L\?LS_LVZIK?[-/C#X:^ ?\ @EYK
M_P"Q9X]\#^)?B-\4;;P-\/\ ]IN/X=>%? /A/]JOP1H5I\%+R#X\P6NF>&_[
M,TGPO\1[?X5:]\++>[U35?A]XJ&J>)_$IO\ ;$QE2EB8TU>5*IB84XRU<W0K
M9M&G&5FK*K'#9?'F32YJTFG!3<J66%G"M3PTZK<56AA)59132A"O0RJ=6<4U
M*[IU,1CY*#3]VA%-2<4JGZ%>(/\ @H7\&;#XQ>!_@;X.\$_'KXO>-O'_ ,,O
M@Y\:M%G^%7PA\0:_X7MO@[\:_'Z_#[0/B7K'B?5)-!TK3O"_ANY$_B/QP\DS
MZIH'ABTN;B/3-0U>,:*_GOP5_P""D7AKQS\,O'7Q.^+7PQ\3_ ZTTW]JWXU_
MLJ?#?PUXL\4_!^;6/B-X]^"_Q'^*OPYUWPSI6IZ7\5M2\.VWBC3A\%?'7C/Q
M9<>(]2\*^"-"\-6]Q=:+XM\6^'O#VJ>,;CFOV6_V4/VD_A;^TG\(_BY\2--^
M"-GX/\*_\$V?@G^R'XLMO!?Q6\>>+/$]K\5OA;XVUOQ1J&I^']-USX&>!=)U
MWP!J=IK'V:TU_4=>\-^(DN;<F;P8L,N^/Y]U3]@?]MK0OA[K$?PG\0?LWZ#\
M7/@/_P %0?VC?V__ -EO5O&/BSQ_XD^'WQG\(?M0>*OVH6^(GP@_:#\/6WPF
ML-5^#D]M\*_VL/''@73O$GP^U'XS7,GB70],\66PT6UG?2UJ:I1E-1FW%3JJ
M$FF_W:Q\Z<)\L8W<_J<:55=9*I5:A>*IK*$J\HTW."C+EIN<%)*\Y8&%24;M
MM<JQDJM+M'V=*\[3]H?46G_\%9/V6M9\"^"_&/A[3_B]XNU;QE^TS\1_V-C\
M./ OP^/Q \=>&?VG?A=X'\9?$+Q'\)?$K^!]9\0^"4U*\\,>"[O5/#'BC0O&
MFN^ ?$^C:QH7B[1O%MWX&N;WQ3I_,^&/VM/B!I?[3_[4WB7Q-I7QYU;X->#O
M^";_ .Q+^UYH'[-=W\//!R_&/X9>(/BCXY_;6TWXJ>&K'P=HEMIOB;6?'Y\-
M?!/P:NN> -6\9>-]:A\8Z+K?A_P++=3:CINA3W_B+^S_ /MJ?&&?]ACQQXZL
M/V9-.\9_ ;]MH?M)?$SP-X4^(GQ%L_!7@OX80_LZ_&S]G^S\ _"[QE<? ^77
M?BYXMCE^+LGQ$OM=\;>#O@]IUW?17W@ZTAT[2H],UF#TZ_\ "&M_!']L_P#:
M:_;8^,/BSX)?#K]E[6/V//V;?A-<>.?%?Q1OO#NN>$=2_9^^*'[47Q%\2^*/
M'ECXD\#Z)\/_  UX,U.V_:/M]-L=7/Q2O[JUF\(O<7NFHNOQPZ3,K*\N:,7R
MXE7DU*G"2PU)4I/6*E&5:<W%N2U3A&2DE4E;YW**492ASX:3Y=)SBZ]5U8;-
MQ<:<87M%W4E.46KTU[7\./VI?A[\5X_V;[KP/IGBG6-*_:C^"6K?M#?#O6X8
MO#+Z18?"O2M+^&>J+K_B2[A\43%'U0?&#X>V>DVGAN+Q-+<W.O>=+]GTW3]3
MU"S^-/VF_P!JOXC_ +/'_!0+X3>'+>Q^/?QA^$_BK]@O]JKXCW7[-WP.^&/A
M[XA>)?$'Q3^%GQ\_8^T'PUXP\/BWT;1/$%GJ5MX(^)_Q TV]_P"$S^)NE^ ;
MC?I6EZ-8P^.-7TFS\1W?^"7OP$\*?#+PQ\8?'/PY\;_\)_\  #Q;\3O&.B?L
M7WEJEM_PC7A;]D=/&OBKXF:%X;\!3VTMY9ZO\/8OC/\ %+XRZ9\(/&VB7TOA
M[QY^S'X9_9PN]":]\.:)X>U.\]F^,'P/^-#_ +:WP*_:P^%>F?#?QCI'@+]F
M;]I/]G/Q=X*\<>._$?PZU6*?XU?$G]FKXE^&/&?A_5]&^&_Q*LM9LM*U'X!3
MZ!XGT74+7P_=V>E>)1XCT6\\0ZAI"^$]6SJIMTG&,X7GS3@[\U.,Z59JG/X'
M+V3E3A.\4Y349.,&[4MJ3C:JI.,U[.4(2MRJ<HU**]I&SER>T2J3C:348MJ\
MDKU/&O%/[85E\:]8_P""3'QI_9A^+NM7'P&_:N_:?\?^ /&.B1>']#LK3QUX
M/LOV*OVR_B:?#WC"R\4>%I?'O@[Q?\.?B]\"-#L-5T;2=9\+W>F:YI'B3PYX
MMT_56AB@L/>/A[^WK\%OB3\6O _PGT?1_B-IC?%?5_VC/#GP?\?Z_P"&].LO
M GQ2\3_LG>-I?A_\=_#WAXVWB"^\:Z#?>$/$=CK8TRZ^(G@KP3HWCK2/#^J^
M(/ &J>*-$_L^_O\ YM\+_L$_%7X5^&?^";_A'P+K'PW\70?LP?MC_'7]K3]H
M+7_$?B#Q+X#;7-<_:/\ AK^V5I?Q*L_@]X5T?P%X]@GL+3XI?MC>(/$/A#PY
MXL\3^'$TSP5X/TSPU?\ BC4M4U*;7++Q7X0?L'?MKZ5^T;^R]\;_ (Y77[.'
MQ#\2_!'XQ_MI2?%3XR6?Q5^*-Q\5?CA\(/VCK7Q#;?"W7+;0]4^!MMIGPRU#
MX0Z%<Z+X*L?V=-'\::[\--(TQ9+[P-\3/#=II*:#KSCS*]TE[]23ASN2O*G1
M48QK-7<*=92C&3IV=-SJ<LK.+CK+6;7)34)<B3?+*JVW24K*4Z;3DN=-34(<
MRTM]W6G[9WP_^*LGA[P=X!M_C#X;L/CS\)/BIX__ &=/VAM)\%>'M6^&_P 0
MM%^']AI+:EXM\#:]<CQS8:-FQ\3Z%XR^&M]\9_ /A[P?\7O#,B^)/AROQ$\.
M17;'RW_@GS^V)??%C]E+]C.[^),WBSQS\2/$7[ W[,'[07[1?QO>W\$:1\-O
M"'B?XB?!'PKXTUN;XBZXVN^';70/%_B:6XO_ !HWA7P_X:G&E>%]4T[Q'=V6
MB^&=0TZZ?A?V)_V=/^"A7[-WP6\*_LI?$?Q1^R_XT^"'[-/PPUGX1? 3Q]X7
MU[XA:/\ %;X\> _"OANX\"_ 3P_\;_#6I?"V\\)? QO!W@U-$'CKQ%\.==^,
MNI^+O$NA:=<Z=8Z)I$>M6/BSY^_8S_X)A_M+?LV? J+]CSQ1XG^$VL?LG_'7
M]ASP;\#_ -J'PKH'Q4^(%]XQ^%W[3^B?!+3/V=_B-\8/V6=4UOX(V46K?#7X
MZ_#_ $#P]XE\6?#SQY>>#H_!7Q3TVZ\8>#HF_P"$F\96GB2)<ZE*4$Y_[+)T
MU*7)"I7BJ\Z<:B;O1<VE3GR\RC:DG-1FINXV=E-\B^L14^5<SA1DZ<*DX26E
M?EC:<.9033JM1<J;@?I+X$_;F^$GC[Q9\*?"-KX?^(GARZ_:*^&&N_&#]EO4
M_&&C^'=!TK]I7P3X;T/1?%>KM\.3+XKFU/PQXLM_!WB?POXR7X=?&S3/A-\0
MY?"VKZAK$?A=K;P+\33X(ROAO_P4"^!OQ4LOV0=2\+:7\1AIW[;L'Q&'P2O-
M4\,6&GI_:_PN\'>*_'?B?P[XR@?7I+WPQJQ\.^"O$EQILTEK=Z)>W&GBS.L0
MW%U:)/XA\%OV.OCO+=_\$[U_:%O_ (8)<_\ !.O0_%UMH_B[X;>(?$&M7WQS
M\:S? #7OV6O#'C*]\/Z[X&\+P_#7P]KOPM\;^,?&_C+P1#K7BZYT/XEW&B>%
M]$\2^)/"OA;_ (3#Q9\__LZ_L#?MB?"G6/\ @G1X7\5?\,V7'PX_X)_?&7]I
M*X_X2;0?B7\3K_QK\8?A%\7?AA\8_AYX(\5KX5O_ (+:/H?PY^(V@1_$?1[C
MQ7\-W\4>/O#6L36FKW&D?%?1XK&PL==VT]I**=Z7M)*G4>DI4?;58PG.-K4Z
MKHNA.5/WN62D]%SP6:;Y(N2:FZ=ZD%JH5O84Y.G"5[SIJLJL8U-'*+BM?=D?
MH1^P[^U1XA_:]^$.N_%37O@WXL^#2:=\:/VBOA=IVD^*-9^'NM/?VWP/_:+^
M+GP++&Y\!>/?'-NFOV?_  K-#XTC::/P[#XGO+^V\":[XW\)6^G^+-2\0\3_
M /!67]F;P?XH\1Z1K_A3]H33_!G@#]IZ']DCXM?&NZ^"OB.R^"_P9^*^KMX
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MRYER+VE&DHI)N;J3A>R52G]/^(?^"C7PA\)_#_Q3\3/$GPU^/>D>&/A#\/O
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ME^(OAS]E_P 0_LB>&O%$K>)OAO\ #^3P-X'N/AAX^\>>,-=\*;=>UI/B'?\
MAS0[77;SPWX(D\2?$"8J:KU$]:7/4A%N5HNG'%8I1JKXFINDJ%2,4DJBDH6A
M!VI2W>E2E;EJ.G3G.*3;C5EA<(YTFM$X*L\13<FVZ?)SISF[U&:5^W[;^';/
M]G^T^%/@O]HO]I#3?VDO^"@G[6?[+]YK_P 0T^#'@?Q-\*O%/P;/[3/CWQC\
M.=,\/:WK7P;N;KP_X=O_ ("^-?A_\'H?$EK+JUCX"\*7%_\ $GQKJ/C2U\+Z
M%\1OK']N/]J'5?V0?@'-\8]'^&6N_%2_N/B=\$?A19Z'HNI^%-*BT?5/CK\7
M_!?P9\/>*->E\6>*O"<5UH6E>)O'.BQ3Z;I%[+JVH7M[86TTF@Z!)KOB_P -
M_!7AK]AS]K?P9X3^!FJ:?I?[.VM_$'X-?\%<_P!KK]O-_"US\9_B1I/@_P 1
M?!S]JD_MLZ='H0\<I^SKJ6LZ1\2? 6G_ +7=CJ$^A?\ "OM5\,^);CP#>V,/
MC/1E\1VUWH_V_P#\%!O@!\1OVF?V5O%7PK^$T_@Q/B3%\1_V;_BIX4MOB!K6
MM>%_!FN:G^SY^TI\(OC^_A?7?$OA_P ,^-]:\-6GB^U^&5QX7C\06/A'Q1+H
M=SJ\&J2:)JL-I):2]"]FG2YI-P5:@JDDKR=%1RUS]Q+3W5BU**YI)\\7*4[2
ME@O;-5O=46Z5945S67M+YBH-R<G9\SPC3;47'DGRJ/-%0ZI^W1X)TWX^VW[,
ML/P7_:6UOXNV^@?L]>+O&>D^&_A.=>\.?#3P;^T;XA^(WA/P[XQ\;^/=.U^;
MP+'X9\%>)/A=XITKX@ZKX9\1>)H;22UN[OPD/&.G>'?&=YX8R_A)_P %%OV=
M_BWJ6D0POXR^'7AKQC^S9KO[8GPS^(7Q7T;2?!G@?XE?LO>%]9\/Z1XF^,^E
M:E+X@OM2\$>'?#\7C3P!KNKZ+\9M'^&'C:R\.^.M"U:7PL(K/Q,GA]O@3X+?
MM"VG[:?QR_:+\36'P@\,>#OBY^QO^RY\#]+/AGXA^,/&_BWPI\4_@;X]_:D^
M(&OWEQX8UKX0>!="U[P-<7O[3!TG0M;_ .$QTK6]2@\!+J6I>#]%/B]M+\+?
MF)X7_P""6?[7/Q+L=(TK]I;4_@!I&M_$C_@F+^V3_P $]/VIOC9X ^*_Q.^*
M7Q@^(OCW]HL?!*6U_:O^V^./@C\/D\8WGB#4OAIKK+\"==UGPOX<^"/AS4],
M\+^!?'GBSPE::9X*\.8MS2LHJ4G3JRYN9<BG?%1IP4;IMKV6'EK**G&JES)U
M%*CO"S;<VXQ]I&*23<G3MAG*3>JCS>TKKX7R2IZQ?):M]J>&_P!K'QU\2?\
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MPX+K39-=L=#\37EIJ%WIKWT>BQV^@ZE]LUK^S[*X2VM+FXOK7@/BM^P+\?\
MQG9_$KXC^&8O@Q'\9/CM_P %+_V*OVU_'GA?Q#\1O&^C>"/!?PO_ &,;[]FW
M0?#O@#0?&6D?"/Q5JOC'QUXM\$?LVVVMZG>WO@7PGHNC>,OB7J_AZ#5]>\.>
M!-'U[Q4DO=3;:YJC@GR[)5,%>VMGRTZV(<Y._+R0E:ZE"I3>L5&U^3GDKK33
M&Q6FZ;E1H.*:7/SRBGRM3A[]\0/^"HW[/OPF^'MY\0/BGX6^+/PXE\(?#;2/
MC'\9_AYXWTCP)X;^*_P&^%VLZWXVTBV\7?$#P!J?Q$M]9\3F*T^&WC[Q+/X4
M^"*?%WQX?"_AM-5MO"ER?$_@BW\3_HEH^L:5X@TG2]>T+4;'6-#US3K+6-&U
M?3+J&]TW5=*U*VBO=.U'3[VW>2WN[&^M)X;JTNH))(;B"6.6)V1U8_E[\4OV
M=OVWOA]^VCX__:*_9&O_ -E[Q?\ #C]I;X9_"CP7\;?!/[3&J_%#0]9^$/Q'
M^"USXPTSP=\:OA%<_#KPOXFM/B+HVK>!_'%QI7C;X,>(Y_AC=ZQKO@GPM=Z%
M\8_"EKXD\07.C?0ND_L!?LPZ?^TU8?MGWG@O7]8_:EMK6RCOOBM=?$SXI6MG
MJU_;?"JW^"\^IW'PITWQI9_!>UGOO $']F36NG?#RTT^&]=M=M;6'7PNJ*D[
MQYG[K;LXK5P<544EK\<9.-&<)WC959Q:DX*R=U)I:I1NF]IMNFTVU\#C&56$
MH<LFW3A+F2FV_LZBCI104%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 445_-M^WMX@^">O_ +;'QR_9
MZ_;[^)GQZ^#G@'XT?!3X&6W[!GBGX6_"32OB#/XK\0Z7+X_'Q-T']G3Q.W[.
MOQP\3>"/VSO!'Q5F\->--'@^&&H>'_C%KNFWGP6UG0]/U9/ OA:?39;?-&*5
MW)3<=;.3A&,N2.DKU)IR5.-GSR@XI-M(=M&V[*/+=VNHJ4G'GE9JT(/E=25_
M<C)2;2U7])->9:EJ/B/6?B)<?#S6/A,NK?">[^'R>(;KXG:EKOA2^T&Z\9+X
MF6P'PUN/ %U-+XGFNH]&CC\5KXFET]O#014TQ;D:J@C'X!_MN:'\(_A_^TI8
M?M8Q^'%\3?!+X?6'[./P%_X*_P#AG4(/!6M:WXMT#Q!XZ\'>./V>/&/B#PEX
M*T?6XO&_Q#_9_P#'USX4\6?M.V'AV"QL/B)^SCXUM_!NC6WQ6B\)Z9X.\&>\
M_&C7?A=<_P#!3+XY>(+OXE:EX*\*:[_P12\7WFM_%+X3ZQ)-XP\.^&O^%R^(
M-:F\=_#F]T&+5Y)O&F@^"Y8_%OA6^T.PU+5KJ+3_  ]>V]MJ%G::4@4G97C:
M;7UA<ND8MTL/BJU-\TM%"M&C"=.;E:*<W4THR55+7XO<5J#;^*455KX6C42C
M'64Z+KRC4@HZV@H:UHNG^QOBOQ;\-?@AX(D\0>)]1\._#WP+I6I:'H\<I@M]
M*TI-<\;^*M-\,>&=$TZPLH5%SK?B_P ;>)-)T#0M)L+:74-?\3:[8Z;8V]UJ
M6HPQ2RQ>)/&K_%*]\(2?#>]B^'4'@'3/$EI\73XH\./I]_XUN_$6KZ7J/PW7
MP6MS_P )=;7FDZ%9:7XG?Q1/9CPW>P:TFE6MRVIV%Y$O\IGQ1T?PQ;_L??M.
M^%OBCX"_8M^*6@_ #XR_\$?/B/J7[;O[)_@C1="_9O\ C1\)]!_;FT*'Q1XM
M^(GPULCXO^'/P;^//P8^"NC_ !!\0_M,Q>$_'OC#0+7X#_%WP1KFHZCX8^&.
MN:'X7L?T%\<3?!G_ (>%?M.#P[-X)LOASJ?_  1(\"V]A;Z1-8:1X1/AFP^+
M/QTFL(=+M;-[+2K&RM/ EUX0E1-/CMG@\)OX1D;;HZ:"RU6:HTJE5/VBIPQ$
MU%)P<HT,!B<6KQ:YXRJ2P_)!22<6[-55'WYIMU*D:;2AS>P3=U)<U7'X;"RY
M)JT)J$,0IRY=)+5.FY>Y^]E%?S$_\$_O"GPP^'WBS_@D'J7P^FTKX=_$?XZ?
M\$,OB5H7Q^\6>%+>VU#XE^-/'7PW\,?\$[++X1?\)]:20ZIK?C7Q]\*(K7X]
M:)\)M!\2V.KZQX5T7P]\1/ 7A/3+3PYH&N>'[+$_X)/^*/V2OB5\:?V'=>L/
MBQ^S;;?'#X<?L.>(_A1>Z!I<7BVW^/7[7?Q4UBW^$WB]_CI\8=)^)_PF\"KH
M7[0'P\\&?#CXL>-/%>@^'O'/QU^)EMK/[0OQ]MKCXHWO@KP;XO\ %7Q3J491
MJRIZ24)UH.::=U1KXJC*48K5Q:H0E;5I5EJXPDW,:BE3Y[2B_P!U[K323JT:
M%5)R=MG5G"Z5FZ3T4I67[^?M=_M-:!^Q[\ /'/[0WBOP+X[^(7ACP NB2:[H
M7PZ7PC)XC@L]=U[3?#D6L-'XT\6>#M+;1]*O]6L[G7&L]2O=:@TL7-UI>AZS
M<0?8I-#XZ_'?PI\+-5^$OPRN=%'CCXF?M(>,M:^&7PI^&RW>GV4'B6]T;P-X
MG^('C?7/%FH:BES!X?\ AIX)\"^%M:UKQSXD;3-;N8TDT?PMX<\.^+/'?B_P
M=X/\1?'O_!:74;#3_P#@F5^U0M]>6]J^H>%_"NG:?%-(JS:AJ$WQ$\(30V%A
M #YU[?2PV\\L=I:I+</%!-(L92*1EQOVP].30/VZ/^"8/[7&K:AI<7[/_P .
M+']L/X2^/_B-<ZE:Q>"_ &I?M(_"KX?Z[\)_'WBSQ)).FA>'_!>OZM\%;_X7
M:;XKU2\@TJX\<_%+X?\ A2VNFU+QEI=O=3#WFTY<J5>E#FM]F6%KUG%W:5Y5
M:=.FINW+[2VK<$5*3B](\W^SSJ6VO..*ITKWZJ%*<IN"NY<E]%S7]ET+_@H-
M\._%?BK]E?PMX:\">-[NX_:2_:*_:&_99U^74+[P393? ;XU_LR?#;X]>._B
M;X#^)>FV/BG5[_4-<AU+]GWQ?X=T*^\$1>)?!&OV,NG>-M+\:W/A36_!]]XL
M^J?C3\5](^"7PT\2?$C5]"\2>+#HW]D:;H7@KP9;Z7=>,O'WC3Q7KNF>$? /
MP]\(1:]JWA_PZ/%/C[QMKN@>#_#]QXF\1>&_"UGJNM6EYXG\2>'M @U+6;'^
M:32_@_X>3Q'\#/BY^T=IMCI/[+_[27_!=']O[X[76H?$*\N_"GPW?]GOXE?L
M,_M7?L[_  DU7XAZOJ<^CZ%;?##]IKQ%X9\-7GA?1_%%ZOA3XR^&/C7X5\*W
M]AXAL/B+)X>U/Z2^$'P?_84^&O[+?QX^!'[;FF_#:R_X)U_%;_@HCX^\,?L%
M^%_VC)F7X/Z/\/M7^%OAC5]$T7P!X@\1&/2_AK\.K_XZ^&?VG-2_9MU_4=;\
M/:!K?A/5O!%S\)-=O]'\<_#5=:R4IOVD6FI)T[/E2A&4J> E*E)MOEDWB:JH
MW4W*<73G'W.9:R4(JF^9--3YM;R:4\;&,XQ^U%*A3=6THI1:G"5IJ+_:WX ?
M%KQ=\:? ;^,_&?[/GQC_ &:=4_MW4M)@^'?QSN/A+/XYGL+"*S,7B0I\&?BE
M\7O"EMH^IW-Q=6NG0W7BJ'6W.FW%U=:1:65SIUS>\S^T3^TSX?\ V<+_ . E
MEXC\#>._%<'[0'Q_^'_[.^BZSX03PB^C^"_%?Q%DOAH>M^.O^$A\6:!K,/AE
MDTN_@-QX2T7Q=J8U$65K=:99VMY_:,'PG^SM\)_VU?A/^RKXY^%_[)/Q1^&^
MNZ5X4_:;\9VG[)7BW]MZP^,?Q;MH/V,9+/3KO2O"-]JOASQWX4^*7BVW\(>/
M[GQCX3^ WCCQ/XQUV/Q!\ -"^'NM&]U[2M4T+4*SOV]-:\<^'?A=_P $S(?V
MB?$WPM'Q?7_@H7^Q_??$;4/AO:ZYX9^&]YKNDWOB5O%FL>#-&\::[X@\4:5X
M+T^>Z@E\SQ#KFISZ3:W-M_:NJ%I4D?9M.=/E5HRJX.+4DU)PKRH*:LVW&<%4
MDJBNO9U8M1YH),QDY1IU'O.-+%23C:45.C&HX:I).,G%2I^Z_:4]9.,KW_9&
MFL2JLP5G*J2$4J&<@$A5+LB!F/ +NJY/S,HR1Y7\=]-L=9^"'QCTG4[9+S3]
M2^%OQ LKVTE:1([BVN?"FK130N\3QRH)$8J7CD21,[D=6 8?SC?\$W/A9\*Y
M/%7_  14^-?[*=_H\OQ.O_V =(TW_@H[K_@SQ$=<NO$OPKM?V1?AMIWPSTC]
MH_41J&H-;_$#P=^T"/A_HGP+\,>,)K'Q3HO@#P]\4/#/P]TN#X=?#+Q%IGA9
M1?-4<+VLH-M:M*<<4U-IV2A&6&Y9R;7+[6#5VFI:27+!3NM9223=KN#P]TG9
MWE)5_=C:[<&MG>/] 7[*G[1.G_M3_!Y?B]IO@KQ%\.XA\5/VA?A3=>$/%M[H
M&H^(=*UG]GG]H+XH?L^>()-2NO"NIZWX=9]4U[X7ZEJ\$6C:UK-C;6M_!;0Z
MMJ0B^VS_ $;7\M_PX^)'P%D^$G[$?@/XJV_AG5= ^(O_  5(_P""O</AWQC\
M2KB^\4_LPZ+XIU?]J+]MOQ)X(\*?$_X::=>6>@_&7XH?';P#\1[&W_96^'?B
M37/#2:OJ'B8_%3P1J?BOQ!X<\(_#;XG^8?L;:7\)/C=8?\$*/!/QOAT#XG:!
M;?L>?\%%OA%\3O"?Q6#ZOH^IVO@/4_@KX,TCX8?%GPKXH":5K]GX7M/#GBKP
MU#\/_'NE7MCH]]X8\3:4NAVNI>&-5@TW/#N56E2E)J,I0I.5U9*4J?--VT<6
MI+F<6DE"<;-V4I.ORTI5.6\HJ=112:;M&I:*OK=*+<7+^>G)-*[4?ZWZP-$\
M*>%O#4EY+X<\-:!H$NH^3_:$FB:-IVE/??9GN)+?[8]A;0-=>1)>7;P^>7\I
M[JY:/:9Y2WYL_P#!&75;>_\ ^"<GP&TRSU>;5M-\$ZO\;?ASX=CN-3NM5FT/
MP-\/OC]\4/"7PS\,17%]/<7L6D^'/AGI/@_2O#-K<2%8?"EMH?V/=I[6;O\
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M]HW2_P!G+2?@CX>\>B6S\.:_J%I=?#+2H/"\7B6XM<__ ()V_#+X/ZM\/O\
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M4_P?\##_ ()T_$SX\:)\#_&2>*?@K>?";PU\//V:_#4OP=^).C>$[GQCX_\
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M\%$/C?\ %#]C^^^.VO?M/_M(>%%_X*0?\%:;[]FS_@F9XU^#OP9_9I\9^+_
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MG!6M?66'Q&NUJ-25VHWE^CE%%% PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *_(_P#X*\?L-?'3_@H?\)O@Q^SQX!U7X3Z/\%K']HKX2_%S]I+3_B%XM\8Z
M+JGQ5^&/PRUR?6-0^"VAV/AOX<^,=/LHO%MY)I^KOXOU:^E70]3\.:9$OA75
MX;J:XM?UPHHZPEUA4IU8[-<]*I"K"Z:::52G3DTU9\J3TNF=)+I*%2F[:/EJ
M4YTYV:LTW"I-*2U7-=:I-?F[_P %!OV,/'?[;NH_L7>#D\2^$/#WP0^#'[7O
MPU_:>_:&T#5Y=;N==^)>C?!;3=<U?P%\,-"T^VTF;1-5T#7?B'J&CZGXQ_X2
M.[T?R--\/V-QIGVJ\#63?+'[=O\ P3L_:^^/7[8?Q2_::_9\^+_PB\(67BO_
M (),_'[]A3X>6?Q#O_'=IXB^%GQZ^)_Q G\:Z5\6_"S>&_"^OZ=I>F>(=-AT
M+PCXL\76<_\ PE_A73]#AO='\,>,C+#I]E^Y-%2X*47!_"YUIM=Y5Z"PT[]U
M["].'6$95%%\M2I&33:DI+>,:<%V2I5OK$=-KNLE4ENI2C"3BI0A)?S<ZI_P
M2*_;!\)7W[..J_!#XJ_L^>%[K]GW_@C1\:_^">G@&SUB]^)]M%\'_P!HWQEH
M^CP>#_CQ\-M2TCPQ<2:S/KB:)HWA7XE_$/5].\,^(Q:Z3/XYTWX:Z[>ZY'X)
M\/>I_"W_ ()4?'#P%\0/^"*0F\1? 9/@S_P3"^!/Q+\-^.?!MC+X[O+O7_CK
MXV^'GA;X=VOQ#\+Z9<>&-.T?X@21:);>-9(?%/B6\^%FH^'/'OBB?XIV'A'5
MHIO^%<6/[YT5HY2<G.]I.K*L[*RYY5,35VO;EA4Q=6I"*2Y)JG.,N>E"1')'
MEY>GLHTO/DC3P]+>U^:5/#4X3?VXNI&2:J22_FGT/_@BY^T+'\.OV;+'Q7X[
M^ .N_$W4?^"M'C#_ (*B_MY:RMQ\0D\.?%#Q<NM_$76?@WX>\!)_PB<>I^*O
M"7PPN-5^'4M_\)_%D?@#PSXF.@ZU'IWBWPE)<B^O_C;XZ>,;?X]_M;_%GXH^
M)/V2/@3^UC^QE^V/^U5^RO\ LX?$;X)^%/CQXP_9V_;?EN/V7?B1=?"[PUKG
M[4'['\M\5^/&@?#7XI:EXZ^*UGX.\2R^'/%>H? O0?!VH_'G0_!WPP^'LMAX
M._LAIGEQ^9YNQ/-V>7YFT>9Y>2VS?C=LW$MMSMW<XSS41]UT_M0IN+46WJHQ
MPE)P;W:^KX.E2@VW*E-U*T7*=2<)N=Y*I9N,ZBE>2Z.4\354E'1)JOBIU)*_
M+4C&G2DHQA&2_!O_ (.$OB!;7_[&7P\_8B\.^+O#WA;XG?\ !2+]I[]GO]CC
MPBFH^*K'PS=V'A#QG\2=!UKXI>*)5:WU'44\'V'@SP_<^#O$VK:?H&MIITOC
MS1-/BTV_UC6M%TG4>J^(/_!-/XX>+O#G[?WQ?\.>)_A%X'_:Z_:F_9-TW]A?
M]G/3K#6?&%W\&/V1OV8O#NDZSHNG>&?#?C2R\#:#XX\4>*/$6O>*O$WQB\0:
MZ_@#1M.TGQ3!X"\!:!H@TGP=J_C?QO\ MTT43EB\<;%XS$Y9%8O$<YC8D'=&
M=QRARIR>.33Z7*G&I&5VZKJ*;O:].=&.'<.^M+VT).3E>.(K1BHJI4YZ3:E3
ME&R5)0Y%;:<*TJZEV2514914>36A2<G+V<%'\-OVL?\ @EA\0?$7[(O_  30
M_9Y_9;U[X>M_P[F_: _9>^,$/@GXG^,/'OPB\(_&O2?V?O!FN^%KVSOOB?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3?AOXG/B*:]XBT_:?_;VA_X)B?MN?MZ:I^T;\,K_ ,7?"#X7_P#!133?AO\
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MMS>_'2WDMG\5V7P*UC0="TWX>Z3/\*-7^'WCO1]>TGXK:^?%FO-;^&M$\/\
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M<>C_ !6\$P? GXIP?'G4?BI^SG?^$M+O=4T3PWH%S\0[/X5>&O@GXGTA=/\
M%LOQ_P# FL^ ]*\+_''3_'_B+Q7X.\8ZC)\4+[P9X2^&<NG>%]!T;Z2\#_\
M!/\ _98^&^C?L_\ A_P=X-\=:;I/[+GQ0^('QG^!UI=?'S]H37/^$1^)7Q3M
M/'NG>/?$FHW&O_%/5+KQQ_PD.F_%/XCZ7+H_Q G\5:!8:7XX\3:;I>E6-CJ]
MY;RL^$?_  3Y_9,^!7QI\8?'OX6?#75/"WCKQKXF\8^.M1TI?B9\5M7^%6B?
M$+XBY3XA?$GP'\#==\;:G\%_AO\ $CQQ:-<:9XG\>^ / 7AOQ7JFCZGXAT>7
M5AIGBSQ7:ZW@E5Y9Q<TI.%J=104O9S5*A%RE%\JJQG56(GRRE[JY-;2:AIHF
MG;F7,N>-W'G@ZE9V4O>=.48.C9Q7O6DGK!.?S?\ L7?&_P#;&^/]G^R%^TKK
M6L?".?\ 9K_:G_9UT_XC>/?"&I^,M&.O^!_B%XW^'_A/XG?#"Q_9OMO#?PLT
M36_$.C6%I<?$GPK\7?#?QC\;Z_XABLM#\*>+O"FJZ//H7C?P]KW,?MK>&OBE
MXP_X*4_L"^&O@Y\3]+^#/CC5_P!C7_@IS:67Q+U'X?V7Q-N_"ML_CW_@G*9]
M0\/^$]7US1/#MWX@646PL9_$Z:[H%O";LWOAW5)&M_(^K/V<O^"=7[(7[)GC
M/7_&_P  /AAJ7@*[UK4/&6IZ;X33XF_%?Q#\*/AU<?$/6D\1>.E^"_P8\5>-
M];^$OP0M_%>M*UWK-O\ "7P7X.CN+9QHBA/#\%II-O[+\4?V<?A;\7O'?PR^
M*/BFT\5Z=\2?@[8^.M'^'GCCP1\0O'GP^U[1?#OQ07PM'\1_"M[)X,\1:+9^
M)/"_C2/P3X2EU70_%-GK5A::OX:\.>*="BTCQ?X;\/Z_I?0IP4DU!QCRU4XJ
M4G*'M8UDH>U=I5%3=1153EA*5.*NN9R,W&34DY*3;IM2<5RR]G*FW+V>JIN:
MA=Q3DHS=T^51/R0^'G[;G[5^B^ ?V.?CO\?O%OA&P^%VB_MD_M&?\$]_VZ=1
M\(> K'1O ][X^\"_'WXM_LH? +]IWP;JWB";4]<\$?#3QU^T!X!\%^!?B5H%
MQJUY9Z/K'Q@T&\TS4_#F@_#SQ1)XJ_5[]E_Q3XV^('P;T?XF>.-9O-5?XHZW
MXM^)'@6UO]&TS0+SP]\&O&/BC5-9^!WA_4M*L-*TRXL_$5G\(KCP7<^-+;66
MU+5K7QQ>^);.34I+*WL;6T\$^.W[,NL^-?AEX;_8B^'_ ,#/@</V+OB!X1O_
M  I\=/$/C'Q_X@D\5^'/"'_"3:1J?B?PKX2^$,OPO\2V_P 2_&GQ<TJ[\2J_
MQ<\4_&KP=K_@GQKJ5_\ %O58_'/BW2K#1O%OZ X & !CT[>WJ !@8XP/2HOS
M1=TKI\JDM'+W*3JRE"R4;UX2=*VBI59QC&,81'RM-*[MRMO5M)N57V<4VW?E
MHSBJFM_:4H.3E*3;_E\U']EWXU_MN?#?_@M)^R7\*!\.?!UC\6_^"O.C/K_Q
MS\7^+?$EEX@^"5CX+^ W_!/CX@:M\0?AUX&\-^#KVZ\7_%+P];^%;.]^%]N_
MC_X?:>/%\R:IK?BSP_:Z!!%XC^SOB]^U=^U+\//CW_P4A\83_%'PP?V=O^"<
MGP:^&G[3$OP7\-_![3)?'WQK\)W?[.GQT^(/BOX37_Q.UOQ7J?\ PC%UK&O^
M"M,U6T\9:-X5FOH[VRT33+32=,T>U\2V_C/]-/@E^R[\&/V=]>^,7B;X3Z)X
MKT76?C[\2;_XO_%FX\0?%;XM?$.W\4_$G5-$T#PU?>*X]-^(_CCQ9IGAV]G\
M.>%?#.@>1X6L]#L(M%\/Z-I<-G'9:=:00R>'?V8/@IX7^+/QN^-NF>%]7N/B
M#^T;H/A#PQ\99_$/C_XC>+O"7C#0/ >E:GH?A72U^&?BOQ9K7PS\-VNFZ1K6
ML:?*OA/PAH3:G;:I?IJSW_VN<R90C*%.,(V4E1E%M7M[=854*,[:J4:<DW?D
M3:E=JIRQIQUG)3J.<KN/MH-+12=!UU5K0YDTXRJ122?,U'E23I\TIR_.'6_V
MR/CS^SKXW_8_\0_$GQ):_M"?##]KO]F7XZ_$OQ?I7A7PAX?\-S_"OXP?!'X
MZ=^TI:W/P6N]"@6^N_@7\0?"]C\0_ ]MX;^*VJ_$?Q[HGB,?"2ZB^+.JB\\4
MV^OZ,'[5/[1'PV_8M?\ X*/>*/B7\-OBU\)M8_X)J>.?VN]4^"*Z+8>&+F+X
MXZ'\'M&_:$\%>'/@%XQT/3(=5O/@UK?@6/XE:%XNM_B=+\0/'MC_ &#\/O%>
MB>((K,^.K*Y^\/@Q^Q]\!/@$?!*_#?PMK5O;?"WP)K'PK^$EGXI\>>//']I\
M)/A9KU[X=U#5/AM\-8?'7B3Q"/"7@V>Y\)>&+>#2=-*?V?X>\,^$_!&FS6?@
M/P5X,\,:!YO^SY_P3>_8T_9=_P"$XM?@U\(&T;PYX\T3Q;X2N_ 'BCQ[\2_B
M9\+O"/@3Q_K)\1^/OAO\*/A9\3/&/B_X=_!SX:>._$)36/&GP_\ A9X9\(^$
MO%,]AH%IK>DWNE>$_"6GZ%I4M/VG(G34O:RIJ\FZ2E4KRA1;N^=0I5:=-57[
MW-0A-)M+GB-XJFI/G<53C5?*E[648T5.JEHH.<Z=23I)J#5:46U]GYQUGQC_
M ,%+_#.G?%/Q9X%N/A!\?O!7B?\ 9X\.>/?A#H&F>-?A]!\9]3^*^G>/O#L'
MQ$_X47;V?@?P7\)]9^$?B;X)^)1XB^$K?%_QAXFU;PQ\:++PSHGCKQOXS^'G
MCT7'A?S&W_;9^+?BC]G&T^+_ ,$[[]J3X]>#?"_[5\WPY_:?T7PW^SOX%\.?
M\%!?V5/AM8_ J/6==\'>(?V;?%?@3P_X=\<_$_P3\==5^'=_XUL/!/PL\6^(
M=5_9V^(,NO\ PI\)_$'5(-%\9S?7'PD_X)<?L7? WP#X@^&7PS\"?$GP]X/U
MN#PC8:;:/^TM^TUJVK_#C0O GC?2_B1X4\*_!'Q7K'Q?OO%GP&\(Z;XYT/1/
M$EQX8^#6M^!M&UR_T311XAL]6M]'TN"T]CA_8]^#=G(VIZ8_Q(T7QA=?%&^^
M-6M?$+0_BW\1]%\<>+?B?J7PSTGX-WGB3QQJ^F^);:#QQ8?\*O\ #_ASP98^
M"/%ECK'P[T72O"O@UM"\(Z9>^"/!]WH1-MR;BERWIN,6K.*4YR<6X-*:491C
M)^Y*?)%TZD%%QJ**:4%)W<>93DG*TVX1CSV:;A)R3G%7E"/-*,X-OGC^3?[0
MW[??Q=TC]F!OC;^SI^U#X"^-UIX!_P""6WQ+_;2TS5?A3\.-$/BSXK^._AYH
MUYJ6B_%3XZ^%OB+H,7A3X,?LR>)+OPAKWAW6?ACHOB'P-^TIK_C-_B3X1^&Z
M+?\ P8\:3>'OV@TGP5X4^)>K?"#XZ>(=*6;Q5X<\&2ZEX1M7^R2V'AG4?'_A
M^WAUK5K&0V4>I2:P-#O]2\-6MY/?-!::+K&N6]K902ZSJ$TWS-XH_P""77[$
M7BZ"UL]3^$VNV.FI^SCXF_9,UK2?"_QC^-_@S2_'OP#\73>*;W6_ _Q7LO"?
MQ&T6'XO//K/CKQWXGB\3?$]?%OBR#QIXV\5>.(]<'C'6;O7&^U_ W@W1/AWX
M-\+> _#3:X_A[P=H.E^&M$;Q-XJ\4^.?$']E:-9Q6%@-9\8^-]9\0^+_ !-J
M*VT$:W6M^)==U;6M0E#7&H:A=7#O*UWAR649<ZJ1E&<FFTN6O&2NDMU4C9N*
M;2?,H-OF5I<RNUR<DHR2NKN]*46XNZT<)7M)J\E9RC%6_,K]B[]J3XK_ !&^
M/_B?X&?M&:_\0/A=^T9X3^&_C7Q=\0OV8OB+\-/"VF>"M7T^T\=^"-&\/?'3
M]COXS^#_  Y::?\ %G]G*T36[[PKK$?B/QMXW^)GAC6_$O@G3?B58>"/$JS6
M6N<MXAUG4_%G_!>'X>^ ?'DDEYX&^$W_  3 \1_&C]GG1-4TV-]$M?C/X]_:
M1N?A1\>OB#X?NYX/+E\?>&?A-:?#/P*E[;2-JWAGP/\ %?Q;IMK+::3\1O$$
M.I?>WPE_9-^"OP5UOPIXA\&:9XQOM7^'WPYUGX0_#C4/B!\4OB9\5;_X>_"[
MQ)J_A'Q!XE\"^$=3^)?BSQ7JFGZ+XBUSP#X)U#69)[Z[U6^@\'>#=!DU'_A&
M/!7A#1-"O?'?]EKX)_M'W'P^U?XG^&M7;QE\)-<U7Q'\)_B=X$\;^.?A1\6_
MAEJ^OZ4^A>)'\#_%7X7^(_"'C[0-)\7:*RZ-XY\+6GB >$O'^BPP:)XXT+Q#
MH\*6 B-X^RDTI.$)1DFG\4J4Z7M(Z_Q8<_M$_@<Y55%0C.FJ-27-[5)RBI34
MHV=](U(5/9RT_ARY>2RM-15/F<G"HZOP/_P60^'W@;3OV&OVQ_B?INBZ-:?%
M#QC\*?@GX)\0:[M2/4?$7A+X:_'K3_$'@/3]7$96YO=,\&^(?B9XUNM*=2&T
MZ7QCK*PR))?J0W_AHG]J/P)X[_X*J_"/6?BCX+\=:_\ LU?LR?!_]J3X&>.-
M7^$]IH]KX1U+XU>#OVECJ'PVU?PIX<\5:6OBWP'X,\5?LY#6/!5QJ^O'QT-&
M\9W&@^,O&GC.ZT6VUR[^S_'G[%/[/_Q3^#/C;X#_ !,TGXB>._ 7Q)7PY'X^
MN_$'QT^.3?$+Q/;>$M9@\1^'M-N?BQI_Q%L/B?IOA[2O$$4^L6/A'0/%ND>$
M;*\U77_L>A6\'B#6H;^]J?[&_P"S]K/BGX^>-=2\-^,;GQ/^T[\)/"WP+^-N
MJ_\ "YOC7 _B[X7>"=/\7Z9X5\.V%M;_ !#BLO!5UHUK\0/'!M_$W@*V\,>+
M)+WQ7K^I7&NRZCJEU=293C4]G6A3DHRJ1JJ,K649RP52E2FK)N+AB91J<R][
MEYWKS.#TINFJU*I5@YPA*CSQ3M*4(8RG5JQO=)JIAHRI6=ES<EW:*G'\W/"W
M[6'[7G[1^A> ?@O\$/%?@OPC^T*__!,+]DG]LX^+]9NO!5A9>-_BS^TK'\8?
M#VG+XC\%:[X$\8-)\#O!GC/X*1M\5M.^'EIX=\9WVF_%;0]-\)>.? 6I:38R
M:YU]WI/Q.\=?\%,OV"M5^)'Q#_LCQ%KG_!,/]K[Q7\0? WPMN/A_XS^"P\0O
M\:_^"8T?Q)\&^!_$GC/X4-XQ\3?"OQUJ]P5E\0:O<:=XPU#1-&\/W7AJ^\"+
M?:[IVI?2/Q _X)=?L5_$K3?@!8Z_\./&VEW_ .S%\./^%.?!OQEX$_: _:'^
M&OQ.T+X0MI^E:5<?"[Q!\6OA_P#%3PW\3_B%X$O+#1-/AO/#WQ#\7>*;.=UN
M[HJ+O5-4GO??F_96^!J_&3X;_'NR\*ZUHGQ'^$/PNUOX*?#:7PS\1/B7X6\#
M^$OA5XCU+PAJ^N^!].^$GASQAI?PEDT35-1^'W@2XNXKWP/=3/\ \(9X6A\X
M0:!I<5KM6Y9U+TUR4_K5:JX-)_N9?75""W27)B*%.5)J4%[%S4FN52QIJ<*2
MC.7-45"C#G5T_:06$]H]];SH5JL:GNS?MDK1:ER_G=_P5ML[O08O^"5-AX%T
M#P\UWHO_  5?_9@LO"GAJ\OY?"'A=!8?"/\ :$M=,TE]1T;P[XEE\/:1!;QQ
MVL;Z;X8U46=O&D,&G&(?)W/[;OQC_::_9W_8@_:H_:BL?#7P9^$W[1WA$^&M
M*T/5_#_]H_&GPYJ/PHT/XCV%CX/@EUWQ!I'PLU'5==&E_$/QEJ,2Z]X+M-'\
M%>+]>UO3K;0?&NB6-KXB\3_;/QY_99^"G[3%W\)+[XQZ!XGU^Y^!?Q5\-_&_
MX6/X?^*?Q7^&Z^&OBEX1MM5LO#OBR6'X9^-_!\'B&?3++7-8LX]-\41ZUHL]
MIJ5[;7>FSP3NAW?V@?V?/A1^U%\(?%GP(^-NA:QXG^%WCF'3+;Q3H&B^.O'W
MP\U#5+?2-7L-=L8#XM^&WB?PAXSLH5U33+*XN8]/\06B7Z0M:7XN;.:>WEE-
MI;MOV[F[W=X.6!<];W<IPP]:$D[IJHDV^:4HOE]]O:/L5326CYE3QT8WMIR0
MGB:,X\O*U*DVM%&+_+/]L_\ :-_;!\$_$7_@I+H_PE^-7@GP%X<_9$_X)W?!
M+]M/X8:;)\&-)\2ZIJ?C6^U+]N&?Q!X%\9Z[XA\3:C;ZGX*\:G]F?P[IOBBZ
MTG0-#\1V.@:L+?P/J/A#Q!IU_P"*?$7(?MQ_M]?'WX6_#_XL?&#X.^,?#2S_
M  1_8W_9N_:G7X+^$_"^D^,;FRU;XB^-_B--X_7]K#Q#XVTW2K#P]\'O%GA'
MPGX2\(_ ;2/@GX[\.?'O7O$,/QS\8WN@ZUX3\':+<Z3^FWCO]B?]G/XEZS\=
M]?\ &WA?QIK6J?M+_ G0?V9_C9(OQL^.>EVOC+X(^&$\;)H?@F/3='^)%AIG
MA?[#_P +*^(<G_"2>#K/P]XMN;CQUXNN;S7KBX\1:M+=^1_$7_@EM^Q5\4_^
M$F3QE\._'-Y:>./@!X,_9E\?:7I_[0'[0FB:+\1?A1\-!KP^%\'Q*T72/BC9
M:5\1_'/PP?Q3XBN?A_\ %;QS9^(/B?X7O=4-_IOBZ*]T_1[C3E#FC&*D^9J<
M9.Z;YE&K6FXW?2=-TJ335E9R2NFYEFY2;;Y7&HHJ+M9RA04+V2TIRC6GIK)R
MBKV=H_ W[5/[97[9OPXU#_@JKXU\%?%KX?Z-X4_X)Z^)_P!F?QW\/O 8^#FG
MWX^(G@[Q7\*? WQ)\??"_P"(OB;5O$^I:F=+\4V7B'Q%IQ\3^$(O"OBK2]<_
MX1;6-%U'2-%T37O"_C/Z\\:?'/X__&_XU?MO?!?]G/XN_#WX(>//V)K7]GAM
M LOB/X8TSQ7X&^(FO_%'P,_QEUS6_CJLL1\7Z=\$=<\)O9_#;PM/\+-9^'GC
M+P[XI\*?%;Q3?^+_ !?;GP_X9\*>S^*O^"='[)?CC0OVCO#?BSP9\1-<TC]K
M;3/AWH_[0T5[^T;^THUY\1+'X5^&=)\'>"TDU>/XNQZOX9N+7PSH>EZ1KM_X
M-OO#U_XTM[=W\:W/B"XNKN:>?XL_\$[_ -D?XW?&'PM\>OB+\.-<U/XI>&O"
M.B_#R_U_1_BQ\8/"%C\2_AUX=UE_$6C_  Z^/'ACPAX]T+PM^T)X!MM=DDU&
M?P?\;M%\>Z!J?VB_T_5K&^TG5M7T^_J.ED]8V@N9IW4E3FG.SUDO:1HMTW)*
M<74UB[J1:7O.^K<FHK;E=6,E#FVC^ZE4BIJ+<)1@[-2]WY'^)O[87Q\\)?$C
M_@K%X<M_BO\  KP;H?[,WP1_91\9?LZ^*/B9X,\4)X'\$:]\;_#OQ:_M2?Q[
M%X(N/%?C_P"+6L:KXC\-:#;^$?"O@S2X=7\7ZU+X=\"^$?"DFN:W)-K'QG^U
MY\?OBS\3?V'?^"V'P8^*%QXLU;3_ -F]O@[I'PYUKXF:!\.O#_Q7NO"/Q5^$
M?P4^*\]E\0+3X30Z?\/;B\T_Q1KNO3^&+C2?#WAK6K+PEJ&A:'XQTIO%NBZM
MJ5]^R7Q(_8 _92^+EY^TM?\ Q#^'>N>)+K]KOPU\-/"GQY-W\5OC EGXETOX
M-3W-[\*9_#.D0>/8M&^%VN> =4NYM<\.>)?A7I_@OQ#9^("FO-J<NKQ17B<E
MJW_!,S]C[7_"_P ??!WB#P?\4M?T+]J30/AOX=_:!&M?M._M0ZCK'Q/MOA/I
M6E:#X+U;7O$]Q\9'\3Q>+;?P_H.@^'-=\:Z7K&G^+?&'AS0])\/^+M:UO1K"
MWL4*;<5'F7,U[)MO5MTZ].LK-KW9?N8IR22=TVM'$MM<UUHKR:M=64Z4Z4E:
M[YHOVLVHMOEMHTW<X7_@LG\0?C-\*?\ @EG^W?\ $3]G_4-=T;XJ^$_V<_'N
MJZ%XB\+W-Y8^)?"6D)8Q0^./&OAW4M.FM]1T;7/!7@*;Q-XKTG7;"XM[W0;_
M $>WUBSN;>YLHY4\Q_X*/^!_@IX$_P""*7[2FC?#272_!WPR^!O[$FI^//V:
M-:\'ZFVB#P+XL^ _P]M/'_[+/BSX=Z]I5Q:76D^(O"WQ$\'?#C6_ FLZ/=V^
MI)KMII5S87(N9(V;];QI5@=*&BW$!O\ 33IXTN:VU::?63>V)MOLDD.IW&JR
M7ESJIN;?='>3:E-=3WV^1[R2>261F^6]%_8A_9VT+1?!'@RV\,^)KSX6_#/7
M_#WB;X=?!76_B5\1M>^"O@K5?!NK1:]X$@T7X6ZQXHO?!S^&/AIK=AX?UCX0
M_#_5-+U'X>?!;5?!_@?4_A#X4\#ZAX*\+W.E0X-JK'F<55E0DIQ^*G[%RUC'
M1\RYE6IOGBHUHKFVYXE[.E+E3=-5TX/13]LH:.5I+E?*Z4[PDW2D[?R/X#TG
M2?BWX[_X*,_\$]M5^+WC?QIX9\9:[_P2F_:F\6?%#X;6VA?"_P#X1C3_ !?-
M\8/^"8T7Q6\!2V&M_#?5M9A\/^,=>G>#Q=$^LGQ!9MH6FVG@[7?"-BVKVFJ_
M(?A?Q/\ %3]FC_@GG_P6._:+^&GQ'CUSXH_LQ_M1_M[>-/A'>?%7X;_"[Q;H
M'A/Q'\'=#D\.:?XFT31O"OA+X>3:9XFU+X>K<^ +9H=3?P9X=\.S1Z5I7@7_
M (1P7_AS4_WXUO\ 9O\ A+XA^/W@_P#:>U32O%<GQH\ _#[Q1\*_"GB*T^*7
MQ5TOP_IO@#QMKOA;Q-XO\.3?#?2_&MG\,M5@\2:_X'\&:KK-WK'@Z_U*_NO"
M?AMKB]==%TY;?Q]O^">W[*4OP;_:-_9_N?!/CB^^$G[6GB[Q]XY^/_A;4OC[
M^T-J<WCGQ'\49H9OB%<6_B34/BI<^+/!FF^+_(6'7/#W@'7?"_AV[LY+JP.E
M"QO+NWF?O7Q,E:+K?67"$+\M-5LQP^+A!-J_)3HTZM):/E;A&*2O.,QC%/#J
M7-.-%X=3<]9552P57#SDU>SG.K.G4EK:5IMN]D_#/&?QR_: ^.'QJ_;<^"W[
M.?Q<^'_P1\>_L4V/[.\GAZT^(WA?3/%?@;XB>(?BGX(G^,>MZU\=DEA/B[3_
M ((:YX5^Q?#?PO/\*M8^'GC/P]XI\+?%?Q1?>+_%L!\/>&O"G'>(_P!HO]KS
MXR?$C]JB+]E_4?A=H$'['/[3WP[^$FI>&OBWXMT7PK\-?'7P_B^$G[.WQI^,
M&M?%F]'PN\<?$OPW=:OX&^,/C^+X->+OAWXFT/PYI^N>#_ .O^,-(\3>'KGQ
MMH$OTW\4_P#@G5^R+\:/BWX0^.7Q#^'/B'5?B=X3\&:%\-KSQ#IOQ>^,WAB#
MXF_#;PUJY\0:/\.?C[H/A?X@Z/X>_:+\"0:XSZE=^%/CKI7Q"T76'N=1L];M
M-1TS6=:L=1=XY_X)U?LA?$3]HZ?]J_Q)\,-2B^-6K:=X(TSQMK'A?XF_%?P-
MX1^+=O\ #.\-[\.&^.?PM\%>-_#_ ,+_ (Y7'@5]EMX9N/BWX/\ &4EAIUKI
M&E$RZ=X=\.6VDU'25-RVC?F5KIRC.\*EKKFC4@E"I0;BES2DJE]6I)N,TKIM
M+E=[-*4.6=/F2=I4YMSIU_>;M%2AT/%OV0_B'^U=\;OVC/VNK_QW\<O!:?!S
M]F?]L#XL_ #1/A'X:^"6GZ3?>+_"]Q\"OV<_B+X)U+7OB-J'C;6M:L-1\":K
MX^UE(ETK3(U\3SZGX@NM<E.GW?A+0? 7??$3XR_$CXD_MH^+/V*?AQ\1+CX'
MW'@+]D'PE^TW>_$;1_#?@[QEXH\3>(_BM\6_B/\ "GP'H-IHOCS2==\.Q^ ?
M A^#_B[5_B;I\&D0^*O%]]XX^'-KX9\>_#JW\.>(HO&WTO\ !_\ 9T^$OP'U
MSXQ^(_ACHWB+2-7^/WQ-O/C'\5I]<^(_Q*\=V_B+XCW^@Z)X7N_$=AIWC[Q?
MXGTWPCYOASPUX=T3^R/!=IX>T%-,T'1K./2T@TRS2'/^)7[,GPA^*?Q'\%_&
M+Q!I/B+1OBQX!\*^+O /AWXC_#_QYXX^&GC'_A7?CZZT6^\9_#W6=:\!>(/#
M]SXC\&:[J'AW0]9BT77SJ4/AKQ3I&E>-_!S>'?&^DZ7XCLDM(TU).7+3Y96D
MXR=1T7%SYDKRY:UJB4DDUT7+R3K6\VI6O4YHW@I+D5524.1M**E2O3DXW=U?
M7GYH?CI\.OVU_P!MO]L&Q_X)S^'? 'Q"^&G[*OBG]K3]F;]M[7/C%JMG\%G^
M+0\+?&O]DSXC?!;X77/BSX66?C7QY86<OP\\2>(_%/BC6_!NA>*8=:N!X-U+
M3FUC6_$&HO97]A_00F[:NXAFVC<P7:&; R0NYMH)R0NYL#C<>M?,]I^QW^SM
MIGCK]GGXBZ)X$OO#/B+]E/X>>)?A/\ [7PEX^^)'A'P;X"^''C#3?#&D^(_"
M ^&_AGQ?I/P[\4:3J=AX)\(1-'XS\+>(I;:7PQH-U9RV]WI5E-#TGP4^#VH?
M"C5/C7J%SXT\:>)+#XL?&;Q-\5-(\.>+?B1\2?B?9_#ZWU_3-#T^]\/^$M7^
M)_B;Q)J'AGPUJVKZ/J'B^R^&O@>#P=\)?AK_ ,)$?!W@'P3;0:3JGBWQG;<7
M9)6UJ2D^6R;;I*/*N:3A%VJR4$W&FIQI\TE34W"4E*3WB^11CS7<8VJ<W,[)
M3DG[).5DY\LIVCSRB_R4_;7_ &W?VK?@E-_P6(7X?>-?A[8#]D']C_\ 9%^.
M_P  1J7PO&JGP]K'Q8U']J&S^(-MXF>X\6#_ (2[4]4_X5)H+:)JMVEMX?\
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MZU^(7_!1[X4?#/PO\3OB1XD^'OQ6_P"%1_L__$#P1\+OVEOB?IL'P\U;P_\
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MH_PE_:%\$_$V7X@:[<_!OXS^!?A/XS^%/A+XF?!?Q/X9TC1$\?\ @WQ3X/\
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MMV<N5>W5TKK2RH25KMJ33:E*4:>FEWU]W3MS6HM>>[K1=VK6NE91E/\ 1#X
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MOV[_ !WX=_9T\8>-OVP_%%QK6DZU^W7\=_V=?V*?BYX[L/A_\'/$?[5WP#T
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M-<_'KX@^(?@__P ,_:'\6?B+I&J>'I8/@K'_ ,*JU#QV/%'PS\-:C\:;*_\
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M(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4F4W%-N+NE"Z3NK^SPDI)-+6[Q,TFKINC*5DFX4_Z"+/XL?"W4?%VL^ -/\
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MYX4^*OCS1TO3_C+\*OC]\1M.^$G@+Q_^UQ^SSXAUO_@HYX\O?@=\5O@WXO\
M@;^T1^RS\6?$&J?$SX@^)[?X.?M+MH?AS1/'_P"S9^V5\9-5\1>%_A3H?B*Q
MU#QDUIXW\ _$SX1?$'QU\*?A;XCTSX?J4FHN2^S'$-J2:=Z,*\XQ]R-1M35)
M+GA&HO:.=+EC-4GB%%WDH]9.C9K5-5)T83E>7(DX.HWR3E3E[/DJWE!U?8?N
M1X.^)OPW^(D_B&V^'_Q!\$>.KGPCJG]B>*[?P=XLT'Q-/X8UK$A.D>(8M%U"
M]DT75 (I2;#4EMKO$<A\KY&PSQG\4?AG\.9]"MOB%\1/ O@.Y\47-Q9>&K?Q
MGXN\/^%Y_$5Y:?9OM5IH46MZA8R:O=6WVVS\^#3UN)8?M5MYB+Y\6_\ !+_@
MF9::_9_M>?"#Q$OPP^.7@;X?ZW_P2)_9X^#^AZ=XD_9;^.WP6^%WPK\3_ WX
MM^.?M?[.>C:A\4_!47BJRA^#WAWQ796_ARZ^,_C[Q?XH\9IX@U?6/"'C'Q1;
MW&M6FC^X?\%*M&^)>C_$GQ9\3?V=H?&?C'XQ6'[,6F^%_&7[+/Q(_9_\=?$_
M]E?]N_X67?C'XF3Z?^SOH7Q,\,Z0G_"G_P!IG2]7N_$VI:+XHTWQ4EEHF@^+
M_#OB7XM> _%GPMTB]\1> M9Q4)PBFVI3E"37*VG"M6H\T5"4XRC+V<)IQG.T
M*O/'VT(*568RYE-JWNQC.-^9)J=*E52DY1BXRBIS@^91O.FX/V4I?N_V%U7X
MC?#[0_%WAWX?ZWX[\&Z/X\\7Q74WA+P3JOBC1-/\7>*(;&UO[V]E\.>&[N^A
MUG6X[.STO4KNZ?3;*Y2WM=/OKB5DBM+AHV3_ !)^'=MXS3X<W/CWP7;_ !"D
MT:X\1Q^!)_%.A1>,G\/6FS[5KJ>%Y+]=<;1K;S(_M&J"Q-C#YB>9.NY<_@WX
ME\/P:Q^U9^UW^S9^UA^S[^VA\2-0^*/[7'P6_:@_93\9?"/PO\7H_P!G;Q]X
M:\(^$OV=6^%>H:E\?OAE&OAK]GWQE^S#\5O@U.WQ"_X6+XI^',ZZ'I^BZ[X9
MA^(3?$N'P_XB]!_96U7S?B5K_P"R[^TG^R1\?_$_[2_P<_X*-_M*_M+> ?C9
MK?PK^($'P.U_P7\4_B1\9O$_PB_:;T;]IS2K&Y^$]Q%X0_99^+=K^SOH?PCU
MOQKJ/Q#TN_\ "-K\'+7P)I?ACPM]N\'1"\_9[KGCS]-(KD4XW;2]K2DY<\&N
M5P@Y*HKI*I/E]IM[C44W?5MRY9-)-JG4BH\DE=\TU%PT=_VAL/B9\.-4C\,3
M:9\0/!&HP^-KG4[/P7-8>*]!O(O%UYHDDT.M6GAA[>_D77KG2);>>+4X-*-W
M+820RI=+$T;A>4\:?%_PWI^E^-=%\">,_@]K?Q>T7P9\0]>\,^ _&?Q2T_P?
MIMYK/@+3K%K^/QIJVD:7XS\3>$/!NAZWKWA2Q^(7BVP\#^*;GP/IWB*QU"?P
M]J5W=:;I6H_@)X?M?%=B_P"QW\()?@A^T,?%7[/W_!?C]L3XH?$J>W_9L^-L
MG@OPO\,?CG\2O^"F_CKX4_$S2/':^ %\%^*/AYX@\&?'3X8ZM?>-/!&MZ_X>
M\#VGBVRM_'M_X5F=H*T?"W[,/@>Z_8L_X+@WB_LA:U!\5_&GQ1_X*8:)\-QJ
M?[)/C?2_B7\1O!_Q/\%K>>"K#X06>K_#&T\7_$GP9XY\66UAJ&B#X9V_B'PS
MX@\2P)J=LUUJZ-<U#D_J[JN+4OJ]2LZ:^+FC2PLXTXNVLI2Q,H7:OS49I1;Y
MU3N"3KTJ=XJ,\1"DYRNH4XRKXBFYU=8VBH4(S=FO=K*\HKEE/]KK#]K7X*VG
MQ7^$O[.GC+XE_##2OVB/BM\&+SXU:=\._#7C[3_$U@_AO2-8\!>%[Z\T+6[V
MT\-:IK&C>(?%/CR&Q^%^IW_A;0+WXE:;X<\7ZKHFBQ-X3\266D]OX6^*B6OP
M[\1_$#XPZ]\'/ ^E>&_&?Q%T;4O$/AGXJQ^)?A[I/AWPS\1=?\(^&[CQ%XW\
M2^'/ 5KHGB]]-L=*MOB#X8N+)[3P7\0)-<\&VFN^(H]*@U>^_*[X7:=XH\(_
MMI?\$R?&OB3X:_%^T\&^(/\ @E'\8/@#<ZW_ ,*7^*EYIW@[XN:G\0/V&O&=
MGX&^+:VW@Z:7X+ZC?>%_ 7C>^@D^+\/@G3YIO"NN:,EVVN64FF'XS\+6GQ1_
M9_\ @Y^R9\2V^ W[4]E^SA\&/^"CG_!5R[^,GPZ^"_P)^+?A[XR_"WP'^T%^
MTC^U1?\ [-7[1W@[X&Q>!M+^('BSX3>&? 'Q M[35G^'_A?5KG1?AM\7[[6=
M)TC5#X:UK1+?2II6G#1153$TU.W[M>SS"KA:;7Q<L94X4IW]I)*-:%I.%JRQ
M@VZ-&;OS3I4*DH?;7/@*>(G&5TKR5252%G"#YJ4[QY_W+_H_U_XP?"7PIX3\
M/^/?%'Q1^'7AOP+XL_LL^%O&FO\ C?PSH_A/Q*-;TR;6]%.@>(]1U.VT?61J
M^C6UQJVE_P!G7ES_ &AID$U_:>=:1/*OH%O<074$-U:S17-M<Q1W%O<6\B30
M3P3(LD,T,T;-'+%+&RO'(C,CHRLK%2#7\\WQ+^"NB?#OX-?!#Q1^Q;9?'7]F
M#Q9X?\#_ +='B7X/_#;]HK]F#XR?M#? KXW_  _^.?Q&^&'Q-^+_ , _VJ?A
M!+H]U\4/@CJG[3_Q/TCPEXQ^!WP[T'7?A[\;-#T=?%^A:%\-;C7!\0?@#:?K
MK\"/CSX?UE_A=\#/%O@+Q9\%OCN_[-O@+XNZ_P#!S5?"WCG4/"?@S3&T[PMH
MGB_P3X5^-\WA>T^%/Q0U3X2^*/$.B>$?%UOX-\6ZMK6E?VIX=U76=*TZS\0Z
M=),+52Z-.*4?M?PG.;\U!QG%M<K7*G.G#VE.]<VJ[-2O+6UU4Y(K96<DXRM[
MR?,U"I+V=1KV*_\ %'B:V^+7A;P7!!\._P#A$-8^'WCCQ-J5Q?>/;VS^*W_"
M0>'?$/@+3-)C\,_#-?"=QI^O^ 4T_P 3:L?&GC:7QOIEWX6U^;P-HD/AK5XO
M%<VI:5:T+XJ_"_Q1X@C\)>&?B/X"\1>*I?#"^-HO#.A>,/#VK^()/!KZQ<>'
MD\6QZ-I^HW&I/X8?7[2[T-->6V.E-K%K<Z8+LWL,D"_GW\3/!L#_ /!6?X"^
M/;GX5^*=6\*2?\$Y?VS_ (:_$'XC6'P=\9^(?!4]]XF^/7[&/BOP%\./%_Q#
MTOPCJ'A2YU36/#O@+XO:GX9\#:OKTFHS16FM166D"X\26$.L_EU^P7\#M:^&
M?AG_ (("W5O^S7\5_AMXU\%^'OVLO#7QRU2X_9A^+?@G5?A]9>(O@/XJT2#2
MOCAJ5Y\.M'D\ :7XD\;^'_AS;Z'!\2KO0-/\2WGA_P *3^'7O[32=+G@RIR<
ME)N,M*DH*R7-.]7$TXVY^2.GL(-7:7+4UG9*I)U'R227O<U.,]-HVHX:I)-+
MF:_C33ZWI-J/Q0C_ $B2_$GPIJ6M>,/ G@KQ;\/O$_Q9\(Z$VK7WPWE\=:;9
M:UIDEW;[]!?Q?9:3;>)/$OA+0]6NY;6!M<F\*ZDT-O<?:K/3=4D$5I/X9^R+
M^UCX6_:>_9I_9D^.^KIX9^&?BC]I#]GSX??M VGPIN?&^G:YK/AS1/&_A'3/
M%=]9VM[=67AS4?$FF>%UU(Z=?>*(_#>DV=P]K)=2V.FAS:Q?F7_P3;\1Z?J/
M@7]D_P"'/[0?[&_[0WAC]MC]A'X;?&#X>_&KXN>.?@]\5K7PKI'B35-+M=-^
M/'QC^'?QM'AX>!/VH=1_;.\?>&O#WQ-32OAKK'Q!\:>+;SQ!>^/]?L;/4M&C
MN]7\2_9OT'QK\%O@U_P;P_$GXD?!7X^Z3I7P#_9C\:? /XT6-G^SG\;/$GQ'
M^#WQ(\:?LR?#[P?HVC>/?A7X=^'^K?%;PQHNI^,OAWK/A:?Q3=>#T\*1:TWA
MH7VKQ6?B'0+V\W459>]>4WAXJ2:Y/WLL1[\+\LG"3A3@^=0DGI:$GIG*<E)O
ME<8QC7DXM>_>G]77)4:YHQE&,ZE1<DI)QUO-)W_H;N_BC\,]/\#R_$V_^(G@
M6R^&T,2SS?$*[\7>'[;P/% ^I+HR32>+)M0304B;5V32ED?4 C:DZV(8W3"*
MOCOX!_MB^-?V@/@IXL^*.C^ _A%X,UGPE^V/\0OV8;G2_%OQSU$> ]8\._"S
M]IJ;X!:[XY\+_$:U^%*3ZYXD\=:/IE_XI^$_@9_!NF6WB7Q/K/A3P'>>*K!+
M^;Q0GX[_ +/G_"WO@1X1_P""9OQ)^)7P!_:'L/V?OA!^U;_P5C7XW>"=.^ '
MQ5\6>.OA-\3_ (Y?'7XTZO\ LH?'2\^$/@3PAXH\;>*OA]+\/O&'Q,\'6'Q-
M^'>A>+O!>E)\<]&U@:Y_8EU<ZO8]#HGPZU4_L1^)-+M?V=OC1;:IX9_X. ]$
M^-_@7PM)^R[\95\5Z%\*5_X+!^$?CE=_%KP?X/7X;R^)M*\ V_[/+>)O$=YX
MST?2K71=/\-2:OX3O+VTU::X\-O"LX<Z]YRA0]W6].53$Y8FGHDW*CBZKLE)
M.G2F[TWSSH75O"?(G=1EB'S):5(T\-F?+;?EM7PE%7;352K"RG%QA6_HGOOB
MO\+M,\0Z9X2U+XD^ =.\5ZUXGN/!.C^&+[QCX=M/$.K>,[3PW9>,KOPCIFBS
MZC'J5_XGM?!^I:=XKN= M;:758/#>H66N26BZ7=074CM<^*GPP\,^*])\!^)
M/B/X"\/^.->TZ?5]#\&ZYXP\/:3XKUG2;6/49;G5-)\.W^HV^L:CIUO%I&JR
M3WMG9S6T,>FZ@\DJK97)B_G)^-WP-EMO!O\ P4_\4>%?V8?B5_PL#4?^"SG[
M!/QB^$^O^$OV5/BI-XSUWP'X#U+_ ()B:G\0_BE\+;WP_P##)]?\3^$O#_B#
MX6?M":OXG\:>!VU31I+[3/%^KWFI70\4P76N6OVHE^$[_&O]O/X1?&"R_:,T
M3X/>,_VV_P!C']JKXB?%'2?V!_VN?V@V\-S?LX?"/]CKXG:G9^!_CG\$?AC\
M1/A!X=^%VNZ%\*O"OA"^D^(.N>$_'?P%N4^.VJ:CX,\8>$OB%X'U#0II-U(T
MI2_=JHUSM[4TZ=*;;3Y9.RG4_ENX0BW%S?(YOEG4C%.7)%N-K/G?M*E-+2ZU
M<:;LN9I5'*TE!<W],\<B2HDL3I)'(BR1R1L'21' 9'1U)5D92&5E)# @@D&O
MB+PY^V?HH_:U_:5_9I^*%E\/_A7H?P4\,_LF:SX!^(VN_%6SB?XLZU^U/<_'
MC3]*\''P[X@\->%+3PYXMTK5/@??6>BZ!H_B;QS>>+8-52\MGTZ>VETT>_>&
M/C=\,_$/Q3\5? W0[KQ%;^.? WA?P]XKN;/4OAU\0?#'A#6O"NNVUC+9ZI\-
M/B%K_A72?AQ\5=/T1=3T:R\7-\+?%'BY? .I:SHFB>,U\/ZMJMA8S_BG^U5^
MSU\-/B)^UM_P4^L?V@OV5=<^.FB?'/\ 8"_9=\%?L[1R_ [5O'Z>/?&_AB;]
ML;3O'/@GX2_$5O#=_P"%_ OQ-TK7/&/PHU:_GG\6^#M8\+6C>'OB?JM_I'A+
MP;=>+M 4Y2C:2A*:5/$R4(Z3J2I0?+"%TE[652G5I1B[)U;PDO<DEK2C":FI
M3C%WH14V[QA[2I!2G+7X(TZD*LFFVJ5I)KF4C]WK_P"(/@+2[W7],U3QOX0T
MW4?"ND1^(/%&GW_B71K.]\-Z#, T.MZ_:7%['/H^D2@@QZEJ,=M9N.5F(KRG
M6OVK?V>- ^,WPR_9^U/XN^ X/BU\8/A]K7Q3^'OA'_A*=!^W^(O 6CZ[X2\,
M1>(K%7U%/M-KXC\0>-=&TKP7';">Y\97$&OOX;AU*W\+>))M+_'9/ ?QA_9S
M^.?[/L'QY\)_%CXQ^,?$G_!%NQ_9$\1_%GX<?"SXA_&+1O'O[4?P\UWPSJOC
M/P_XQ\8>&?#>K6/@>;QU)J>K>+?#OB?XPW_@GP;KEK#XJOKKQ':-HFNFUF_8
MWTOQ?\,O$/\ P0FOO'/PH^.7A>UT/_@D/\5_V6_%B7OP!^-!F^&GQYNHO^":
M5Q9?#WXNVMIX"GG^#-S>6GP2^*UQ8:[\4X_!_A6\M_ NM26FN2QBU-UI)6J\
MD9<\57G2<XV:E&%7-*2FK72C/ZEAJB;T4<7!7:<)SP<G[%SLU/DI24&GHYT\
MNJ2332;Y/K>(@U9.^'DVE*-2$/W=\4^//!'@:U>]\;>,O"G@ZS32]>UMKOQ5
MXBTCP];+HOA;3'UKQ/J[SZO>6D2Z7X<T>*75=>OV86NCZ;%)?ZA+;VJ-*(+_
M .(OP_TKP1%\2]4\=>#M-^',^DZ7K\/C^_\ $^B6?@F70M;6T;1M:B\5W%]'
MH,FDZNM_8MIFI)?FSU!;VT-I-,+F'?\ F;^UO\+]+\9_\%,?^"9WB[6?@OKG
MCWPYX0\"?MKVWBSQU#\%?%/CWP;X*N=5\*_"&_\ A]8^-O'NF>$-:\*^#9=2
MU_0M8O?!ECXLUO26U#7]-:?0H9]7AMF'P)^RQX-^+GPI^%W_  2?\:Z]\)_B
MWX6_9U_9]_:D_P""C&C?%7X<ZQ\%?BOX:\4?!RV^*/C7]HOPM^R'\8M0^$>I
M^![/QQI'PB\&>!/$MYX#7Q-'X:B\+_#GP3\9=(\;:W-HOP\\,^)/$GAF8OFY
M4WRN3=FTK*V(="[V>KY&GHO>U?)^\BY.W-HVHI/UOAXU[+?;WXO1OW)63FO9
MO]U/BY^UI^SG\#?"WPN\9_$KXO\ @'P]X:^-?C+P1X%^$^K7'BWPZMA\0-9\
M?7-G_8]QX3OIM4@LM=T6ST.YG\9ZWK.FW-S8Z5X)TO5?$LTIL+0L_(_MS_M,
M:S^R+^R'\<OVHO"W@71OBM=?!OP'=>/AX,U3QM<^!-/\0Z5836IO_)\5Z?X1
M\=26]Q%IT\M_80+H$\&JSP16#W^EQW1U*V_&KQ=\'?B9\+? NE?$2W^&OQ>N
M/@5!_P %\O#G[5'PV\ >%/A=\2_&WC/X;?LY>)= M_#OCSQ58?!;PAX7UOXB
M:-X4\9?M0ZG\6OBY9Z'HOA">X&B?%6U\;W.F65GK-Z]K^D7_  5ZT+Q1XX_X
M)A_ME^%_ O@GQ]X]\8^-/@5X@\/^%? OP^\!>+_B!X\\0:[KILK73=)TGP3X
M*T77_%&H7KSSH+I+72IH].@CN+S49+6QM+JYA(N\(RDG%^WH1E&5KPIS675)
M*:6MU&OB8N6GNP;:ISA.-.E_&=.ZE#V<G&2NE.2>.A>+=M.:CAW9W]Z:2E.$
MX2G]L7/C+Q5:_&2#P7/;_"R#X>/\*]3\92ZK<_$W48/C&/%.F^*M,TJ6"'X1
M/X$_L27X66NAW_VG4OB8WQ/CU&Q\4S:;X8?P*UI?#Q#%6_X:!^ WV3Q)?GXV
M_"(6'@WP;H/Q%\7WI^)/@S[)X5^'WBJQ;5/"_CKQ)<_VUY.A^#O$FFH^H:#X
MGU-[71-8L4:[T^^N+<&2ORH^/?@.#Q#_ ,%&/B[XW;X(>/O$?@KQI_P1T^)_
M@CQ%XMC_ &=OB7XB\*^,=?G^,=IKV@_"S5M=@^'U_HWB?X@2>'&U&ZTOX/W%
MUJ'CV2TGN+>T\),UR8)/F;]D']G?2O#OC'_@AE-XO_98\8:)/X'_ ."1WQ=^
M'WQ^O]?_ &7?B!8P>$OB_;^'/V =1\,>#OC1JE]\.8[30/B /$GPP^-.I>&=
M&\?W-GKDVOZ5K-YH\+ZKXATM]8JG%STYHTVE-^^WJXSS"U^Z_P!C@E:SY:L5
MK:$JRFU"[UDOW37+:S4J>#DTM_>7UF2>ZYJ<GI><:7[\>*/'NI03?!V]\"W7
MPMU[PS\1?&EEINJZQXE^)$OAJ2]\$ZEX#\7>)K#5_A#'I/A?Q98?%#QC>:GI
M7AZ>Q\)3:EX4TN_\$7'BOQ7#XM27P[::5K/&_!_]J_\ 9W^/6F_%+7/A-\7/
M GC3P_\ !KQ;XB\&?$'Q#HWBK0+S1="U/PDLL?B6]N[ZWU*6.TT'2-4T_P 0
M:'-KNH"RTVYU/PKXD-A/=Z=IW]H3?A'^S+\,_&6D?LQ_\$%K/5_@)\:]$\4?
M []N+XNP^*;'6_V;OC+HOB;X(_".;X"_M[?#K1CXRT[5?AW::Y\)?AC=ZWXS
M^!^@Z3<^)[;PWX/N[&Y\(WUG-)H.AK?Z92U.S^/7@K]GK]H6W\+_  0_:6\6
M7OP _P""W/Q=_:8^.GPC\!?"OXD:/\0?BW^S#XV_:8^(OQ,\)>(_V>-0U;PU
MIOA?X\>(?#5IXD^&7[0NA>&_AEXA\17K7?@32M$OI]"\47^CVSU:*YFY))QY
MHW:3CS5<KBG4>JM2IXVHZB227LJDU+EC/V,-SY^5*_)/EDXIRA-1IYD[T[V?
M[RI@J:IR;=_:TXRBG*'M?Z*XOB_\)KCX>CXN6_Q0^'<_PI:!KI?B;#XV\-2?
M#UK9-4;0WN%\:)J;>&S FM*VD-*-2\M=45M/+"[!B'@?[&7[4FH?M7^"_BOX
MNU#P5H/@D_#?]I+XZ? 2RA\,^.Y/B/H7BC3/@YXOE\*Z=\0-+\3OX4\&+-8>
M.[6%/$MAI\6C/%I=CJ%M8IJNLF$ZE<_D%>V_A#X<?%O]D;]KGX-_L]_M<R_L
M;:_^U]^T3\9/VE;GQC\$_P!HC7?B[J_Q^^)/[+VA_";X3_M:R_LOZIX1O_CG
MX>^&^DW6G>,?AAJNIK\)O"[S^)_$O_"YV\+WGA.^\/\ Q0\2?>'_  2ET:]T
M+X??M:V\_P -_B%\,-.UK_@HA^VCX^\*:/\ $'X5^./A--K/@GXC_%O4?&/A
M;Q;X=T7QQX=\.75[X?\ $NGZI_:4-U86K+97LM[I&JPZ9KNGZEI5G,5=2;W5
M.5XM:PJ0K8-;Z-JI3K5)4VDU*DFY)2C+D)MJ5)+9U$VUJI4Y4<5Y-+DJTJ<9
MW=XU&HIN,ES_ &7\/_VJOV?/BEX\^-WPU\!_%CP/XB\8?LZ^(Y_"?Q@TJQ\3
MZ'+/X.U[3O#GAOQ1K]GJ,2Z@;E(/"FG>+O#UIXKU,P#2O#_B"\N?"^HWT/B+
M1]<TO3?6/!GCSP/\1]#C\3_#SQGX4\>>&IKN]L(?$/@SQ%I'BC0Y;[3;E[/4
M;./5M#O+ZP>[L+N*2UO;=;@S6MS&\$Z1RHRC^?7]H;0/C$OC?_@IEX>\)_"K
MXU^)8[?_ (*7?\$Z/VQ/&W@SP_\ !#XF:Q9_M!?L5?"GX,?\$X]'^.6C?"7Q
M6_A2/X>_%_Q$]Q\$OBKI.J? _P '^+=9^(?Q!A^'/B_X;1>"]:;Q-!HFM_:/
M@C6=/^&/[7?[<7[;-AHOQ,L_V5?&_P"SO^Q_I7B-/!GP1^+WC;Q1\6?VE? O
MB#XWZ1XU^(7@_P"$'@OP9X@^+/C*_P##?P.\5_LU?#?Q)XR\(^ -5T_6K3PW
M;>%-1U9YO@)XDL_"DQ=XJ52T$J7/.4I1C&+5)U6VGM%O]S&]FJE.3D[72J\F
MVE%MNM*$8*+;Y/;*E'563ER_OGI9TYQ45M)_JIJVK:7H.EZEKFN:E8:-HNC6
M%YJNKZOJMY;:=I>E:9I]O)=W^HZEJ%Y)#:6-A96L4MS=WEU-%;VUO%)--(D:
M,PXI?C!\)'3QO(GQ1^'3Q_#*_LM*^)#KXW\,LGP^U34K>VN].TWQNPU,CPI?
MW]I>V=U96>O&PN+JWN[::".2.>)F^'?^"J-WX0^(_P#P2*_X*$>(+ Z'XO\
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MB\.?LD?&3X(67C_XB?!R?PCH?Q=^+\?[-O[27Q/T;XM76B0^&?&&N6#:7/\
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M_:8_9E_:,\3^#OA!K7B+]GSXV^(/'GQ0^%"_#_QGI?\ PJN;P+XW^%GC#7O
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M]3T#XE_LI7'@M;2ZTVPTZR^&/C.;XV07.I>!F_X1&SL(_D7]EWX^?M=_M/\
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MK4HRBKM-<M2FTY2C&#34HRE=Q7ZFT444QA1110 4444 %%%% !1110 4444
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M_9Z\<?!_7O@3XI^'5MJOPW\3>);+QQKMD?$/BZS\5:A\0=,\4Z9XXTOXEO\
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M>$/^"C?P;U_XE^$_A[XM\'?%/X-V'Q$^'/[3GQ8^'WCKXR:)X>\!:!KGP_\
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MB^/?B3:1_#GX6>-9M&N/$_@;PO"GC PZ?H&JS^&/"4CVJHQM6\%^!S9/;?\
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M"NH?$/XX_#Z'5=1\'W?P#^(%MKG@:^&D>/M=FBTQOAUX9\;V4FK7VBWO#?\
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MP;JFAW6DZ;-:^+:O_P %+_!GAWP9^TYXAUS]G7]I&'QC^RE^SI\)OVK/B/\
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M\:OA1XJ\0:+I$5U\2'^(/C?XAZW;_#>ZN[J6U/T]^S;^U/HW[1>K?'3PA/\
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M!\8^'?!NM^ OA[KWPZ\.^'O&7AWP9KVB6<_P^\/ZQ:^%+B_U:/0QK=_^0O\
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MO'XXC^&3_$'P0GQ)FLQJ,7P^?Q7H*^.)=/:UN+Y;Z/PFU^->>S-E:W5V+I+
MPFUMY[@/Y,,CK<IN<W-N\I5:]1V22DZTJE2O3:C9.FYU:DY4_L.5^>*C#DF,
M(PA&G%6A"G0IQ5V^6-&,*=":<KM5(PI0A&H_B46G&;E-3X[X]> ?%'Q$_9^^
M+GPM\'WNDR>+/'GPH\:?#W1-5\97EY9Z1%J7BOPMJ'AF/6M?N-#TB_O'BM#J
M#:G=V^FZ4K7TD)LX#IZW NK;\^_A5^P[\=_@;XN_8P^-W@G6?A)XD^*_P$_8
MATC]@SXW^ ]?\2^-_#OP[^*7P\\/2?#_ ,0^$OB7X#\<6/@CQ+KW@7QGX/\
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M &5_B_\ L\V?QZ_96_8L\$?L%_&_PE\:=%^)GB#X$?'+X3^"M/\  ,.@>/\
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M/66(G%I;Q]M%5.5[.Z?N-Q/DS]AG]AV']B+0/C7X?T'Q1;>,])\3?$SQE=?
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M'U]I/[4_[4M[^T?X;M_!NN^)=2O_  G!<_!;X+?!6/PAK4.N>$M!MK^==/\
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M>'KZ#4)]$N]"\+V-U/:Z-<^+I-"\"^OZ7^Q+\6K;P/\ M:^ _'7@+]E/X]^
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M%EQJ?@+_ (*[6_CS7_!7Q/NO WC?_@G'-X'\/>-?"GPF^)?C[PF?%_P_^/\
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M7\:_B+^Q_P"'O!/AS5$^&W[<'[/GC_X[_ KXK^(-8TS2;;4]3^%L7A*Z\?\
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M7QA_X*%>%?A9HO[3GQ)T[X<Z[X_^!O[$OC'3_!?[5OQ!\-:W9OXA\$7B^!O
M'Q.\?:OX \ IIUW)\3-#^!WPW^)OA?QS\9Y1XD\*:KI6DVWBO0?AYI'Q,^(O
MA74O M>6_'+_ (*H:=\&M7_:\>V_9K^)_C;P%^P[;?!?QC\>/B'I7C+X56>E
MO\'OBKX7?QKJ?Q)^'&E'Q;?:IXTF\)^$_-UZW\(74?AS5/$-CHGB59+O0;L>
M"K7QWT'C7_@GAJVLV_[>GPN\+_$_2M$_9P_X*/ZAJ6O_ !Q\(WGA2ZNOB#\.
MO$GQ!^%'A3X$_M":A\)O%T>NKI=W!\;?A7X-T0:):>*]">/X,_%-_$7Q'MS\
M3?#WB&U^%WAWD/C=_P $RO%/Q9T'_@IKX4T7XW>"_ WAW_@H9\)OA+\(-!M8
MO@MJ^LR? 30/AG\+[WX4W=Y(L'QBT&T^)\VNZ+J-SJ.C65I;?"ZU\)7<5G97
M+^+;6&26;.+FHIR2E))-Q2M>7+1<X-IKW?:*M&DU9N#O*7,HLJ5W*T-(\S5V
M]5&]51DE9J_*Z4IIM^\K1C;F3^G?%/[8EK9_M,ZU^R]X$\%Z;XY^(/@?1O@A
MXO\ B%X:N?B#IGA#XB0?#CXV_$1_ 0^*/PW^'^JZ+<O\2_A[\*XK35O$GQ;\
M2IX@\,V.@VNG-X=\.OXL\9O)X=M_9/C[\8-4^"_@_1-?T/X:>+_BCK/B7Q[X
M,^'^GZ3X9M;I-&\-/XPU9-/N_B'\4O%%MIVL)\//@]X!TX7OB?XC^/[C2-8'
MA[0-/F-AHNMZQ=:9H]]\E_M-?L.^*OVI?'7P]U_X@>)/A%%'\*?BW\#/C!\&
M/BAHOPPU+2/VBOV?=4^&WBGP-XI^+7A;X8_$N'Q9,+[PK^T'#X/NO"6K6FHV
M>CCPIH/B37AXI@^,VER^'O#'A3UK]MC]FWXB?M,>!/A9H'PU^*/A_P"'&L_#
M+]H+X6_&Z_TGQ[X'U+XD_"GXK:1\.[G5;AOAI\5/ VC^-/ &H>(/#!U74=)\
M?Z$L/B6U_LCXD^ / 7B!X;E-(:$N.JCS-I^T49M:^Y[36=E9Q7([."O)*/M(
M2:FX4G?WI62M[-RBGI:?([0>]_>2:GHFY<DXKD4JGSDO_!5#PC??!GX2_%3P
MG\#_ !_\3=3^*'[9WCC]A4>&?AGXN^&>K:1IWQC\ >-/B7X%O]<T?QSXJ\4>
M"M)\5?#'Q7JOPQU'4/ 'C&ULM/DU'0->\/:MXTTCP AUR+0[7C__ (*9CX<>
M&-?OM:_9X\;:K\1_@WHGPCO_ -I_X#>"O$^E_$#XP?#?Q+\4=!T+Q5J/PX^$
MVB^!M)\1:#\?_'GPU\&^)-!^('B_3],\1^!]'U?P/X@T*?X=ZYXW\9SZMX&T
M3A-"_P"":/Q@TGP]X7T&X_:+^&ER?"'_  5(\<_\%(;.]3X ^*(VU6Q^('C;
MXC?$#Q#\&+NW_P"%_P"S3[Q]>^*.OVF@_$F"6^@T#0]*T.UU+X?^+M2;4=7G
M]0\9_L5?M(:'^UG\6OV@/V8/VLM!^#/P^_:GTGX>6?[3WPP\;?!.7XLZLOB[
MX;^%;+X=:9\9_P!G;Q6OQ.\$Z1\,?BUJ?PKT/PMX GF\>>#/BU\/8I_#'A[Q
M?KO@#QB^C1>&+JKJT>[:O=+E36'PDDI)-6A/$?7*<W'F<5[-QCRJ$G.O-/?D
MC\&JYYQ=;$QE?1KGA0^JS@O=4Y>T4G=RBOJG]J;]HO3?V7/A5I_Q=UKPO?\
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MJJFJD92DDK*#JTI+67,N6=.H^:R7[N/-*+Y7*;4:BM*2I.?5_$G_ (*BZ?\
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MGC6;2?#5Y\$_VBOV?-.^(5W\0_V>?B_H,,NKV]G\2)-0^$OQ4\.^$I/"FO\
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MI^I?%GXH?&$VFJ>%/A]\,?!WQ(UI(?$L/AC0KCQE[S\9/V</'GCG]K+]D_\
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M?1M;_:1^'%]=_&3_ (*.?LP?\%#$U6V^ 'B6S32-<_9\U3]F?Q;K'PU.E_\
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M2>-4G^'OB'0KJTF@M?#&A^'!L>S^;?A1_P $R/'?P2\/?L<^(O"GQS\+Z_\
M'+]CGXF?M>>(=.\07OPUUOPK\-OB]\(_VU?B)XD^)/Q>^#?B7PE%\1O&&O\
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M[ -EKG[27PW\4_#[_@GIHOQI^&WPYT32O@)K^B>*/B#\'_B'X&TOX?>$=/\
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M"^,_ ,FF3>,=&BH?'7_@H!^T%\*?%_\ P5E;0?A+\,-<\)_\$^OV0_AS\>?
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MX+_!CQ$VE^+/"WP=OO GPZ\;>*/+OKO_ (32U\)7.E:!X[\83P64O]K:O?\
MB<P>*O%NHFPN+C6-5N=3OYX+FYNY1)^$'[*$7B_6O%'_  0O\,:K^RE^T_\
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M;J2_\3ZGH172_%/B&*XT/PGJ-Y;62^)-1A-EIT4E\)+6/\+?VL_A%XFUP?\
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M:K+;7%\Z6D4KSL(S_/M^S1X&\8I^SW_P1<^$_P 0OV?_ ([0Z_\ LV_M^?&
M?'#1O&7[-GQAET7P(VA_LQ_M]^#M%\;ZIJ6I^ )O#]U\/S\0_C!\'8_!GQ?T
M^\O/AQK6H>([+5O"?C"__P"$5\577AKD;3PW\=OA;\.O"GQ4'[.O[6?C'X-?
M!#_@L[_P4-^)OQ0^#/P<\#?&7X?_ !XD^ O[1&M_M-^'_A?\=/@OX,T:X^'7
MQ&^(_@WP_K?QKTCQ7JOA_P"%S:]>ZSX2\7^)]7T[1-2NO#FHQ:?$=4[MKF<'
M&3:M%5*>7?$TK\D9XJ:BTN:+4^?W(3E0F,I\S4DW:\>51:OR?V@[K764EAH*
M6O*W*'LUS2C&M_3#X2\7^$_'WAG0_&O@3Q/X=\:^#O$VFV^L^&O%GA'6M-\2
M>&?$.D7B>;9ZKH>O:-=7NE:MIUW$1);7UA=W%M.A#Q2LIS7P%X2_;HF^-/QQ
M^*W@+]GS4?V>_&7@[]FKXY:)\*/CXGB?XRVFB>,[CP#>?!/X8?%SQM\>_A?)
MX>L_%>E:CX8^$^J_%WPC\.=6\,^*=/T:Q\7>*--^(T#?$3P)>^!]&TGX@>L_
ML.^#?AOX4^#.L:G\)?@U\7?@7X&^)_Q5^*'QELO!WQVUSXG7OQ4U77/BKXGN
MO&/C;X@>*_"'Q=\1>)O&OPHO/B-XYU/Q)XRC^&>JWNF:CH\&L1ZQXC\*>"?&
M/B#Q)X0T3\I?BAX0^/?B/X3?\%B/^%6?!7XX>)_%VH_\%*/V:?VDO!GP_N/"
M_P 4?@GJ7[2'P%^!/PW_ .":O_"Y_!OPE^(/B30_"UCK<_Q*T']G?XX_"30_
M^$9UFY;Q!>HEK9NVC>(-*U*[F<G"M3C:\/9RG/F7NQE'ZHGSM7]R'MZTGJIR
MC24E%34J<=$N:G)W:DYJ$>1J[5\2UR\R7O3]C27\JE4<>9Q<9S_=7P]\:?@[
MXM\'>(OB)X5^+/PS\3?#_P (7&O6GBSQUX>\=^%M:\'>%[KPM#]I\3VWB+Q/
MINJW.B:+<>'+<B?7H=2O;632(?WNH+;I\U?,O[-G[9^C_'WXB?MJ:#(GPYTO
MX<_LH_$[P;X+T7XJ>%?B99^-?!_C[PEXG^ OP]^.5UX^O_$/]D:%H?AJ+1;7
MQ[)X<US2;>]UW3]$U#PSJ\TGBC4('5[?\C_B)X<L/$?AO0OVR_V7_P!B_P#;
MF\/^%[O]N#]ASXS_ +;7@[XZ:%^TI<_M%?M ?#K]GOPWX[T&SO/"W[+WQE\1
M>+OB)KNK?LR>,=3^ GQ'ANO!/A>UU+XOS_"BWLO![>.Y/AEX3NY<7XG:#\</
M%D__  4P^-?P9_9Q_:;U[PE??M[_ /!-W]KVT^&D/PM^*GP ^*O[2OP!^#WP
M+_9'G^+=E\%+7QY#\)O%4GQ9\,ZO\-/$.O6?@N>_\*>.)O'W@&V\&7]C;^)]
M:@TJZULD[R:LHRC)._[N36%:JR:T=.U6I*'+SRY*5:\'))14F[14;N\Z<DXI
MWG%/%*=))M6G>G2C+F<5S5*/*XJ3O_0WI?QT^"6N>%=)\=:+\8OA7K'@G7O&
M%M\/=#\8Z7\0O"6H>%=9\?7GB(^$+/P/I/B&TU>;2-1\877BP'PO;>&K.\FU
MJ?Q$#HD5D^I#[-6#8_M/?LU:I8_#K4],_:&^!NHZ;\8#;+\)=1L?BUX!N['X
MHM>:U!X;LU^'5W;^()(/&QN_$-S;Z#;#PU)J9GUJ>'2XM]]+' WX8_'7X7_"
M/XJ? /3/B9\(?V,/VO=.TGXQ_P#!3C_@G%\7OBCI'[0/PL_:B^(7Q;\?Q_!C
MXX? O1_C'\5=>^ 7Q2C^(_C_ .%_@?PE\ ?AZ/!&N^*-?\/^")?B=I'A'5[5
MM U[PN_@3Q+\0.6_X*@> O'NJW/[??P8^$7[*WQD\-6FJ?L8_LIW/PIU7]GO
M]G7QY\0?#_[3X^''QO\ CC\0?$G@K4?&'A[P?XF^%WPQNOV<]2\8:WXP\-_!
MKPR/AW^T'\3]?^(6K>(O#MW\3[6Z\+>#-/B[4E&7N^_"$O)>SPU2K).S3Y57
MDX7:4E1GS6DI1A=KQYHM.\*LDNONU*U.FFM&G-TH\R2;3J14>9--_MY\/?VA
M?$WB_P#;%_:;_9AUCP5H.C:%\"_@S^RO\7?"OC73?%6H:UJWC6S_ &BO$'[2
M_AO4K+Q#X>NO#&B6?A"Y\*ZI^SS<Q6-IINM>+HM7T_68-5N-4T^YEDT/3O:/
M&_Q@^$OPSO\ 0-+^)'Q1^'7P^U+Q7/\ 9?"VG^-_&WAKPI?>);H7VG:8;;0+
M37M3L+C6+@:CK&D:>8=.CN9/MNJZ=:;?/O;:.7XA^"D>M7?_  4X_;+\;OX+
M^)6E^"/'/[&/_!/?1O"/C7Q)\+?B/X4\'>(-?\!?$']NKQ-XV\-Z;XJ\3>%M
M)T"X\3^$]%^-'PTNO$'AI=1_MS29_$C:=>Z?#J>A^(K/2/G/_@H-X:^+FC_'
M7Q#\5/V7-/\ BEXJ^.#? ;X->$/'G[.WC?\ 9]\:_$O]CK]MGX76/Q3^-TO@
M_P"#%Q\8-"\,R:7^SU^T#\//$?C+QWXET[XJ3>.]"\/>!M&\?^$O$?QB\*^)
M_AM$=:\&S1<VJ:J73G5G"3<=5'ZS4I*36EDHJ'O6:27.XSA&HQU'%<[@TU&F
MI12;:<EAX5'&]G\3YG:Z;D_9IQG*FC]<=6^*WPNT'QQX<^&.N?$GP#HOQ)\8
MQ7$WA'X>ZMXQ\/:=XX\50VEEJFI74OASPG>:C#KVN16VG:)K6H7$FF:?=+#9
M:1JEU(5@L+N2*&[^+WPFT_QS%\,;_P"*'P[L?B5<:?>:M;_#V[\;>&K;QS/I
M6G:<NKZAJ<7A.;4TU^33['2734[R\33VMK;3F6]GE2V825^%FG> Q?\ [5?[
M17[//[5_[(?[9?QB\6^+_P!NOP;^U?\ LR?&[X>ZW\?K#]DOQ'X6T@_"_P 4
M_!3QIXY^*W@?XAZ!\+?@]X[_ &4+[X:1>$O%GACQ]I6G>*]>\*?#'P='\,O#
M_P 8=2\9:%X.U3T?]ER]U^T^)_B/]D[]H[]B;XY>-/C/\+?^"AO[2O[4GPQ_
M:1\1_#/5+O\ 9RU;P3\4_B]\7?B!\+_VB-&_:-2WN/ ]AXZ\ ?L^_&.'X :/
M\&H]6U?XGZ-?:'IG@"T\-Z/\.=/U+Q%X(N%Y<E[^_#GTM:UH<T+S<4JE*;FJ
MD79.-.4H2UM&)OEY[:\LN76]KWERR?*I/V=6*C[.24GS3491TN_V'TCXR_"#
MQ O@A]!^*OPVUM/B9<:]9_#A](\<^&-27X@7?A9+]_$]KX(:SU28>*[CPXFE
MZF^O0:";^72$TZ_;4%MQ9W!CX'QQ^T=\+['3_'OAKP%\9/V>+_XT:!X&^*/B
M'P]X&\<?&3P]X<T^/5OAG864>O7/CV31O^$D\5^%_ W@[Q#KWA2Q^*/B:Q\*
M:U<^!+#7[*XO-*GOKS3=/OOPZ^ 7A_XD^$[7_@G5\&M6^ 7[1EIXD_9N_P""
MQW[=?C/XRZP?V??BO9_#SPAX%^->@_\ !5X?";XA:?\ $+4?"=AX/\<?#7QK
M;?'/X:7Q^)/PXU7Q?X"\'/XDT_1/B-XC\'>+-2T7P_JO4>#_ -G_ $N;]CG_
M (+?H?V7O%5M\2?B5\7/^"B\7P\@U']F;QGI?CWXI>%OBS\,[.S\&K\-;74O
M %KXD^(OASQQXALXDL?^$.BUG2]2U2VCN9LR^5<-E*<G0G52E=8:M64(W4W*
M%'"2C3C>-^=SQ52'P<W-AFXP;YE#2FN;$TJ+M&,L30HRJ3_AQC4JUXSJ3LTN
M2,:$9-<Z5JJYIQ5I2_7/2_VQ?@A:?%?X*_LX^-/BE\*[3]H?XQ? Z\^-VE^#
M_"7CS2O$'AZ\T#2-7^''A:YNO#>M7YT75M6TGQCXG^(L47PANKKP]IU[\2]$
M\+^-=5T;3U;PAX@M;#LOAQ\9[*Y^#4OQ7^+_ (Y^ &@Z99^*/B)INJ>,?AQ\
M68O%?P:T_2/#_P 4O%/@OPS%)\2?$^D>"[<>*(-*TS1M)^(FE7&G6EKX8^*2
M^*?!FGWFKV^CVNJ7_P"8WPMT7QIX/_:\_P""7OC7Q+\+/C,/!6H_\$I_C7^S
MQJ^JV_P8^*6JZ9X#^+VK^./V#/&EOX/^,7V/PE<1_!6;4?"WPP\?7-GJ'Q=7
MP7I.L7_A/4?"NFWU]XMDTWP_??$7PV\)_&;X)?LL_L$_$;4_V:?VLO$GP6^!
M/[<?_!1^Y^.OP*^"GP]^-_@']H[P/X0_:#^//[4@_9^_:"\!?"'PRWPY^*?C
M/PCX2\/?$'2K#7-&\"0ZEK<'PP^,VNZUH_AG7D\.:WI=IM42C7JP3]V->O2C
M-*U)1CF&(PU.22YK1=*G0G>-2<>2O"TG37M5G3UH4JCUE.A0JNF[NJI3P5*O
M4@V^6\HU)58-.$9<U*2<54?LW_1KX@_:%^ 7A/P7X9^)'BGXX?!_PU\._&NF
M1:UX.\>^(/B7X+T;P7XLT:?3$UJ'5_#/BG4=:MM#U[3)M'DCU:*_TJ^N[633
M9$ODE-JPF/8>/_$&L>%_ /C/Q5X:TC2O$>N^'O">OZ_HFAZSKUUX9T;6]2TK
M2;K4+#3-2\2V&@>++S0M/U">".VN=9M/#'B&?3X)7NX=&U)XEM)OY^/C#\%K
M7P?\&/AUXQ_8G^&_[4'[,_C_ $?X4?ML^-_A5\$_C=^SA\<?VN?@E^T)X#_:
M#^)?@3XJ?&GX"?M>?#S4F\=?$/X'^(/VF/B;H'A[QMX%\/67Q.^&GQ8\%:#X
MC\4R7WA^/68?BE\#]!_<[7-3\177[/&JZOXK\&:AX8\6W?P:O+_Q'\/?#IO?
MB-JGAWQ)=>"I)M6\&Z+)X3T^^O\ QQ>Z1JDEQHEA-X=TNZN/$4MO%+I=C*UW
M#"<JSG'#XB<;JI"G5Y5;FDJD:%64>6+C>=JL.1^ZGS)1E3M5IRGI2Y)5Z$96
M=.=2'.VVER>VI1?,]%!2I3YT^9IIR<9MTIJ/C7P&_;1^&'CW]DO]DK]I7XT^
M,_A=\!;W]J']G_X-_&6Q\,^,_B/X>T#3K35_B=\._!GC74O"WAS5_%EWH$OB
M1/#][XQL=(6ZAM(KFX$VGRW%I:S7\,!^@=;^-?P;\,ZMXJT#Q'\6OAEX?UWP
M)X<B\8^-]%UOQYX5TK5O!OA&XDMHH/%/BK3;_5;>\\/>')I;RTCBUS5X;/3)
M)+JV1+IFGB#?RY>)O 7QENOV&?V=_@(?V2?VBM!^(FJ_\&Z/BC]G6U^(/AG]
MG;XE^+/'GB?XX1_!7PUX3\6_L._$./7O"&J^$/V=-$75?!4/BC5M1^(GAWPM
MXC^.&OW_ (/T3X1_%3PU/X#U3P]\3_T0^)7P0^)_BZ]_8*^-'PK^%7B37+C]
MH3]E77/^">O[6VE^-? NL^&O$?@SX'?%7X6P_$SPM\9OBMX"^*>DZ1=Q']G3
MQ_\ #_QMX?@^'?Q!\/Z;JFMW_P"T5XC\&7EE;ZGXA6*'HJ17-45*VE:K3IQ<
MK0MSXZ%#FF[R474PU"-6;4G&GB(5%&5H^VR4K<O-=QY(SFXJ\DHK"SJ\L=(R
ME[*O5E2AS)SJ8>5-M7E[+]BM/^+/PKU:308M*^)?P_U.7Q5X2OO'_AB/3_&7
MAR]D\1^!-,>RCU+QKH*6VI2MK'A+3GU+3DOO$FGBXT:T:_LEN+V,W4 D=\/O
MBM\+OBUI^I:M\*_B3X!^)FEZ-J*Z/J^I?#[QCX=\9Z?I6KOI]EJR:7J5YX<U
M'4K>QU%]*U/3=36QNI(KEM/U"RO1$;:[@DD_&[]GW]G'QSI/[!7[2'P?_;$\
M&_&K7?#/P3_9V^.G_!/'P-%\.M'N/$WQN^*_[(OPO'C_ ,):/\</@]HWAS3M
M3\32?%O]HCX-W/PPT^_\*Z9IFL:KXK\??!KPMJVG0:S+JNF6%O\ 5G_!/F7]
MI"UU+]HSPY\>KV/XJ:)X>\:^!XOA7^U=K?P(U;]F7XK?M!^'K_P+9W=]I_QK
M^$.IZ/X;L+WXC?!P?V1X'O/BYX&\*^#_ (>_$327TK2=(\'^%O$W@7QCH=EF
MFI2?+S<O(JD7)*+Y9I3IQFM>6K[.<.>GK^\56$)\U)PD7:2O;F53V<DFVKQ<
MH2E%V]ZFZD)\D[_PW3G.*512C^D=%%%,H**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBORK\9_$OXS?'O\
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M +.G@RP\4^$?V?FM_C!\&?VB_$7_  3VU+QKX+^.\^D?!;2[[Q!%H^@?M?\
MQ+\)^!]7^'D_PQUG0[+3O"&MWE[K7B70+35EF'ORA!63J5)4X\UTN:,L)&3;
M5[)?7:#6FJYUO#WJ:DH3FES*$(SE9JZ4EB7%6;5V_JE9:-I6A?26G](-%?A5
M^T9^U)\8_"WQ]N-=^$/QQU[QAX4\)?\ !4+]B/\ 9'\;:-:Z)X0T#X4?#SP?
M\;=!^"/A[XL?LX3Z7?:?XA\5?&#XJB?XJ6?QTUWXNVW_  @^F?#Q?&'@#X:>
M#O'6H:KX ^-OPSUGLH/C9^T7X2_:;_: _8(\9_&_QQJ/Q6^*OQI^#'QO_8[^
M*<OASX06>J:-^Q+XP6+5?CSX+T^STGX9)X7O=;_9VU+X*?'7P&?%WCGPAXWU
MV5OCA^RLGCC7[[6_'MAJ,)!\Z3C]IR275N,:-33H_P!S6=;2Z=.E6:;Y5*2G
M>%^;9).Z[.=6FG:U[>UI>R[J52G>W,XK]3_BY\;/AC\"=#\-^)/BMXG7PIHO
MB[XC_#?X2>'KUM(U[61J'Q"^+GC31OAY\.O#WD>'M+U:ZM&\2^-/$6B:!#J=
M]!;:-876I6\FK:C86I:X7U2OS5_X*OV^I7?[*'@^TT;44T?6+O\ ;I_X)<VV
ME:K+IT>LQZ9J4W_!2[]DN.QU"72)KBTBU6.RNFBN7TV6[MDOA$;9[B%93(OP
MA\4?VJ/VHOV'=<_;:^%GC+]I:\^/G@?X?^,/^"7^O_#W]HGX_:7\&_ /B?X%
M>&OV^_VG?%G[/OQR\.?%/QS\+_A'X1^#\.E?"RS\"W7Q7^&_BS5O@=J=K\-M
M.^*'ABT\>>&O'W@?0='T74)C*[E%_$ZJIT[*3YVZ-"IRV2DXN]=6E*T&K0NI
MN+D2TL].7V?/)O3E_>UH<VNCBE1=TKR6LK.*DH_T,TF1TR,^F:^,OV5]"_:-
M\'^-?V@/"WQY^*?@/QKH%UXB\%^/?@I\/])\3:EX]^(OP6\ ^*?#]WH>L^$/
M&WQ(U/P%\,;_ .('A75_B!X*\6>)OAIKGB#P>_B_3+/4?$G@[6O%?BG3O"^@
M7-I^=WCW]JSXU:7^U%\/=4^'7QRUCXB?#G6_^"K>C?L:^,[-?!WAWP=\)_#W
M@&^_9K\7S>+/V<?#.@W<GBOQ7\2/B!\+OBQX(E^)_P 0/VB'O/AW=6OC37X?
MA-X4U#Q/X$\.>./AYX9M:RA%6;FH.^K4>>I3I)2:6G+.I&,GK'HI2E:(F[1G
M*VD.?3K)0A.HW'UA3DTG9Z:I+WC]P_$WB31?!_AW7O%GB.^73?#_ (8T?4M?
MUS4&AN;D6.D:19S7^H77V6RAN;RY,%K!+(MO:6]Q=3E1%;P33.D;<]\*OB?X
M%^-OPP^''QF^&&NIXI^&OQ<\!>#_ (G?#SQ,FGZKI*>(O WC[P]IWBOPEKJ:
M5KMCI>N:8NKZ!JVGZ@NGZSIFG:K9BX%MJ-C:7<<UO'^1.B?'WXT^'OVD_B+\
M"OVG[[XM>#-=^(<G[:=[^SAXH\.GP)X]_8^_:G^#VDG5_&?PG\-:#KNBZ?'X
M^^!O[2W[._P>M)=#\=?#[Q/9^%M+^(UUX=^*7CN'6?C!$?">J_#_ ,J_X(P_
M'KQ+\0?V3/@CI5WK_P 2O#.K?LF_\$ZOV(?#VE_LA2Z)X"MW^*'A[Q!^RGX+
M\9>"OVH[3Q1;Z)XA\4>*/#?QENH-=^'?POT[PCXXL_#?AB^^'/BW1OB7X<3X
MO6^O^#OAMGS-*I-V]G3H.NY)W:A#VWM?=3YIN/LXIQA!SB^9RBJ?)5G?*N6-
MK\\J\:"3LE)SA"5/WG[L>9R=I3FH222@W/FA'^@BO*[OXV?#"Q^->@?LZW7B
MF.+XR>*/AEXM^,>@^#/[*UV22_\ AOX$\3^"O!OBSQ(NN1Z6_AJW71O$GQ%\
M%:;-I5UK,&N3_P!OVEW9Z9<6$=W=6_X1^%?VT?VOM'_8F\+?\%3H/BS\$?'G
MPNUK_@G1\;?CQXF^!<?CR[\>:7\6/C]X8^"<WQO\'?\ "M=/TSX3?#G5O@?)
M\(]3\#?$?X9_%GX=6WC_ .(RMX*AOY?%BW7Q?\ ZKX\\3?3OPZ\.ZS9?\%(_
MV$_%M_\ 'CQ3\>K/QW_P2V_;9U\>*M9C\%_V#KNMW/QT_P""86I:S\1_"!\)
M>'](@TG1_B/::SH,\/A/2[E_ >@6&@:3<^#M&TF^UKQ7J/B*YJ4)1C+E_C*C
M42;?)-PQ<E'F2Y&W]6<DXRE%PE%M)S@C+G3BW%-^XIP=K*4?:86#EWT6(MRM
M1DI)O:$K_L=)-#$\,<LT4;W,IAMTDD1'N)EAFN&AA5B#+*MO;SSF.,,XAAFE
M(V1NRRY'3//I7Y4?M80>)[__ (*:?\$NM&T_XC>/?#GAR\\-?ML^(=3\)Z!J
M.CKX5U76?!W@#X80Z=J^L:%JVA:O9ZAJK:-XN\1^%X=:G7^V?#^@^(==M/!^
MH^&[GQ%KUWJGS)X9_:X_:1\6_LS_ +.G[=NC^.==L/$/C;_@H]9?LX?$S]F;
M5M'\/R>"V^"/C_\ ;W\0_L,VWPF@TF;2M.\1Z%\6O@C8W^A?%2^^),'B"PUO
MQ)\1_"/B^U\6"3X.ZMI7PZ\(I2O;2S<W#O:^*H82G+35J5;$04K+]W&\I/E3
M95]:BZ0C&5[_ !?[+6Q<TKZ7A2HS:U]]VC%<SL?OE7D_Q3^./PL^"DWPVM_B
M=XKB\+3?%[XG^%O@S\.8Y=*UW5#XF^)GC0W8\,^%8#HFEZFMA<:FMA>RB_U8
MV&D6EO:7-S?ZA:V\,DJ_-_[:WQ]U'X-ZY^QAX$B\76_PY\/_ +5/[8_A;]FW
MQ=\12UA%JOAS3M7^"OQU^*OAKP_X7NM6AO--T_Q1\8/B-\)?!/P+T_4+C3[F
M^L[3XFZC/X3N-(\=KX3UK3_BS]K+0O&OA+PI^R+X*\=?'D?M!:MX4_X++?LY
MVVE:]=>$-,\*>*/ 7@;Q#XCU;QU\.?A!XXN=(U;4;7QQXG^&_@+Q7X<T5_B5
M=6NAZ]XZT3^Q->\6:7/XLN=;UO67%\TH+[,J]*BWK=\U;#TZB6CLXQQ$9)M<
MNC3=W%2I6;FNL:-6KMHE"AB:L&]KJ4L,X-1;E'F3MOR_MWD=,\^E%?B;\)_C
MI^U1^TEXTU'XM^ _C3\'?A=X3^ __!2+XV?LP?'+P3XE^($^OZ3J_P )OAI^
MT%XL_9X\/_!:]^$G_"F[&?P/\8?B?X9?X2_';X<_$!?CEJ/B6]\?^/-$L#)>
M_!;QA:?";2N*^!W[4GQN\8?M3_LC6&A_'_Q!\5_@K^U9KG_!2C0M4\?OX/\
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M*UZ\E2#=M$VUO&1,9<RNMKR2\^64X-KRYJ<UJD]+VM)!1112*"BBB@ HHHH
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M'$'PLT#QUXQBTCQ9\1K;X;^%=/3QGK.AZ/JGB+3]8U#2=+GL_P V_P#@F?\
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MG6=K^:?_  5)_:Q^*WP'U3PQ\1/@]XP.F>$?V%;[X:_M;?M@^"K#9+K?Q:^
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M/%^H^$_"6G?$7R[X[_\ !5#Q?\&]2_;%U32/V-_B'\2?A5^P+\1O">E?M/\
MQ"T'XG_#[3]2T7X.Z[\#OAA\?->^+GPX\$W:SWWQ!U#P9X#^)D/B+6?A_<:K
MX5E/A?PUKFICQ5#KTFD>$]2;?,I)NZNI3;DG'WY4ZJJ3DY.*C.4Z56-6;Y9N
MU53O!R@E96:BTTDH^XTU93I<D5RI\T4IT94XJ\;NDXI349?2'Q1_91UIOA)X
M%_8]_9Q\+?L\?!S]C#Q#X%^)/PF^/?@X^"]>C\4Z5\+_ !G965G=:+\"= \,
MWNC>![7Q#XSTW5_B1I?BGQ+X^&I)I/B#Q3I/Q(ET?QW>Z1KGA#Q;]5>+/A%\
M-O'-_P#"[4_%G@_2=8O?@KXVC^(WPKEE2:W3P3XT@\&>+?AY;ZYH]O936UNL
MUOX+\<^*O#\-M<Q7%A%::O+)':K=6]E<6WQ+\8O^"AEA\//#'[5'Q4\"?"N;
MXN_!+]AV^TJW_:@\9:%X\TW1_%6CVD7PF\"?'_XAW?PB\%W.@:AI7Q0D^%/P
M/^)O@OXA>++;6/'/PY74Q=ZOX1\'7/B3QKH5YH#]/!^W5HGBS]I'6?V=/A1H
M/@;QSX@\(VOP4\3>)M(U;XMQ>"_BEKWPG^,R^'[R+X]?!CX:77@C5[#XN?!+
MP7IOB2)?%?C6U\>^&Y+;Q'X8\=^%(=)?5M&T$>+&N9N_O.7M&VY7YE.,92NV
M]5R0A4E%_8BJDO=M*45>*73EY+)*W*X2E&-HI*SYY3IJ27Q-TUJG&_U-\:/@
MA\*/VB?AYK7PE^-W@?1OB5\,O$QM/^$F\!^)1=7/A;Q-#8W"7MI8^)-'AN(+
M/7],AOH;;4%TG5XKS33J-G8:@UHUY86<\'&ZU^RE\ ?$FO>+O%/B+X?Q:]XF
M\?\ PFMO@/XX\1:SXC\7ZIKGB[X,V<^JW=O\,O$6JWOB">^U?P:E[K_B._;0
M[Z>:SEU'Q/XIU":.2]\3Z]/J/S7X4_X*"#QW\2_AGI/@?X!?%?QO\%/B;\8_
MB9\"[;XR>#?!7Q>\0MX+\3_#?6OB+X5;XA_$'3;3X.#X::-^S_XE\7?"KQ+X
M=TKXK:-\;O$5UIEWXG^%ESXF\':'8^+/$UQX!^4?BE^U'XN_:%^*?_!)/XS_
M  PTO7_"_P"S=\9?VZO&N@^!?'&D?&/Q-87'QJ^&4'[(7[:&J:'>_$?X):7I
M>E>$YO GQ)U;X;^'/C'\';[7/$GCOQ#IGAO2?#&H^)= ^%OC/Q!K7@_35&+F
MXJ,7RUFH2DXRY7&:4+3LM8SA42BI)PJ0J.S<.<4YJ"G)_%13J1C=*2E!J?N-
MOW91E3YI.+YH2IIM*7(S]G/ O@;PG\,_!GA;X>>!-%MO#?@GP3H6F>%_"7AR
MRDN9-/\ #WAO1+2+3]%T+2UNY[B6VTG1].@M]-TJP27[-INFVUKI]E'!9VT$
M$?SS\!_V#_V,OV8%^*47[/G[,7P6^$5O\:I[B3XI6?@GP%H6D6'C*QN#J;'P
MYJ5A':M91>"[9];UR33_  )806G@S2Y=<UR73=!M)-8U)KKS3]NO]HSXV? +
M4/V/-"^#'A3X?>(;C]HC]KGP%\!O$U_XZ\8ZUX5DT;2=2\'>/?B0UMHPTOX=
M?$*!_P#A*;7X::CX6UC7;RS^T^&-.U5KS1-)U/5[JVU'P]R2_MY?%+4/C1^U
M)\._"O[&WQ'\<>"/V./%^N>%_C'XU\)_$+P+JWC77V'[)/A+]J/P#9_!/X.P
MXU_XF>,OB#<>-O"_PTLO"%]K7@P:;JWB7P]K)UO4!)XCT3PNK\RG4:<KJM&H
MVG)N,84JM7F;4G*$HUH73YG4DW%PFW[[32E"FDHO]Q*FE:,>:<JM.BHV<5&<
M71FH_ H))J4$KQ]+^''_  36_8+^#_PO^+7P7^%O[*GP>\ ?"WX\39^,O@KP
MKX9CT?2/B5IZ/J36_AGQ>MG-'<ZQX'L%UK7+?2O -S<-X*TBSU[7['3- M+/
M7-6@O/</&/[-OP.^(=]\&=5\=?#K1O%NM?L]^(!XH^#>O^()M3U3Q%X%ULZ'
M/X;N;K3O$%W?R:U>P:EHT_V36M.UB^U'3=<:UTV[UBSOKW2M,N+3X)U'_@J&
M?"_P[_;T\1^+/@II=[X\_8*_9@\)?M5>// OPQ^-?A_Q_I6L>$O%/A_X[:A>
M^ ;_ ,9:CX3\%2>#OBWX!US]F_XH:)\1/!]]X7U6WT:&/PM>Z)K/B74=<O=!
MT3L+K_@HO>>"?$7[3&B?&7]GSQ7X+7X%?L91_MW>$+7P9XQT;XH^*?B=\%+2
M+X@6OB+PU<Z!IFD:#I_A+XS:)KWP_ET^#P7I7B/Q]X6UO3_%/A;4=.^(;7TN
MO:'H!I:4M+0:O*\>6]"G7<4IN7+*5.G2Q')RSDHPC4<)\C<IG-&ZCUFK*-G=
MJM.C'6*7,E4G6H)J48N4ITU*',N6'MOPS_X)[_L5_!G7O!7BCX4_LX_#CX?>
M(?AM;_$>Q^'NK^%=.N](O? VE?%B_P!/U7QQH'A&6UO4_P"$=\,WVHZ787FC
M>&-)%IX?\'SVR/X-TW0"TF_JO"G[&'[,'@:W^$%KX.^$'A[PU:_ #Q%XS\6_
M!2VT:\UZQ@^%WB3XC1:Q!\0-8\%Q0:NL>AWGC:U\1^)K/Q6]FL:Z_8^*?%5C
MJBW5IXGUZ'4/%+']M?QIJ7PCTGXM>'_A!X ^)OA7QIX\\(:#\//BC\#_ -H7
M2_BC^S3J'PVUKPUJ/B3QA\>O'GQWM_AUH9^'OPH^&1\,^,?#_B[66\ ^([B+
MQ%8>&K*WMVM/%<=_I.1\)O\ @H?H7QL\(_!NU^'W@;2-3^-_QG^)'[5_PRT'
MX?2_$9'^'5E/^Q7\2_%OPI^.OQ'E^,.E^#-5N]5^$"^+?#OAS3OA_P")M"^&
MFH^+O%LWQ8^&,VH_#_PMI5WXXU;P$VOLM-N+2Y;-M-2=O=:NG&2;UY;-.2<G
M>2%**UNES\WO724KQM)N5TFI1E:]WS*7+:SY7]K?"WX/_#?X*Z%JOAKX7^%[
M;PCH6N>*_%'CO5M-L[W5+R"_\9^.-:N_$OC3Q/<'5+Z_E;6_%_B;4=3\3>*-
M1$@N=?\ $NJZMXAU:2[UG5-0O;GR6W_8C_9$M/VF[G]LVV_9R^$</[5%YI*Z
M-<_'2/P9I*_$&6%="F\*?VE_;'D?+XG/@ZYN?!#^,4B7Q;)X%N;GP0^MMX4G
MET=_D?5?VT?VG-4^.G_!.SX<0_LZZ=\%XOVF6_:5OOC7X$^,/Q 2W^(G@^^_
M9ZT2XTG5?#F@3>#/ OCWPOKWA#6;S6+3XG> ?'-KK^A:KX\T#2_".GZGH?@&
MU\4:^-,K_"O]M'X9^$I?VB+;P_\ "KQ_H?Q(\6?\%._$?['OA3P/XV^,OB#Q
MS_PMCX^7WPH^'WC.Z\8:5JWB'5O&6C? _P"$VG?"G2=:^(6L^!/ T%UH_A7P
M=\.O%FL^$O >N?$SQ/\ \(5KBCJXRCJU&<8<MW-*$\-AW&*5GR-8BC%6:7+R
M1<(QC+V0VESQ>B3@YWLH-SA7Q%Y.]N9>PJS?,G>2DU*3DG4^P+G]BG]EV[T_
M6]*G^$.B-I_B3XV6'[2>NVZ:IXFA&J?M!:5>:=J.E?&FZDAUR.5OB=I>IZ-H
M>J:9XT$BZ_I^JZ!X?U.SOH;_ $+2+BSA^.?[#G['_P"TUX]^&GQ1_:"_9Q^$
MGQ@^(7P@F67X=^+O'GA#3-?UGP_%'>'4H=->YO(G_MK0[;5L:W:>'M?75="M
M->5-=MM.BU=$O5^4OB3_ ,%0+'X2_"K]L/7?&7P,UR?XW_L0^._@_P"$?B_\
M%_#'CO1=1TG6?#WQ]N?!T_PC^*?PY^)FOZ-X5B\1?#WQ/HOB^>*XDU?P9X:\
M7:3XV\#?$+P=/X2E@T32/$?B+;U__@I%#\,HOVV+/XZ?!>]^&.N_L;:1\#?B
M!J;6?CRU\<>#]=^"O[2FI>(M"^&/Q0\7>*M&\*VMY\.;7P9K7@CX@-^T=86W
MAKQWI?PD\,^!M=\9>$_$_P 7/#YT^YO1-)IJT7'V=2+TC9JG#V<HR?+:4:3B
MH--.$(N*<%3DH4];Q=VY*<91=W>,ISYU)>]>,JD9.2:DIR:DU-SBY?3OQ<_8
MM_95^//BS7O'/QB^!G@/XA>*?%7PLU'X*>*=4\1Z;+=?\)/\+M2;6W/A'Q)8
MI<Q:=KUEI;>)_%+>&KO5K2\U3PD?%?BK_A%K[1_^$FUW^T-'5OV1?V;=<;XC
M#4?A)X::V^+GPJT'X%_$K3;1]4TS1?&/P6\+6FIZ=X<^$^L:%IFHV>C3?#O1
M--U[Q+IFF>#H[&+0+/3/%WC33H;!;+QEXH@U?>^ _P 5/$7Q>\&7?B_6?#G@
MG2],N-7@_P"$)\4?#'XI6?QD^&7Q.\#ZGX7\,^)M#^(G@'Q[;>&/!CZMX>U)
M]?O-!;[3X<L2FL>'=5>QGU/1I=,U:^_$O]G']N;XE?LO:3\;M6^)?PC^+7Q6
M_9EB_P""LG[2_P"SYX__ &F/$?QPTOQ7KOP*M/B#^U#;_!?X%16W@CQ]XAUG
MX@^-_@_X3\3Z_P"#/ OBZ_@\0Z'J?PST34]*G\%^"O'F@:3JW]BN,;R=-*S2
M5H\KUG5JTZ'(U9<DIO$\KYDKRFZ4DI5+-7]UU59I22E*ZNE"%6LIIJ[FH?57
M)<K;2@JL6U!-?L9=?L<_LSW]Y;W^H?"70-1N[7X&Z[^S-!-J5YKNHE?V?/$]
MM;6OB'X-.E[JT\<OPZUE+'39M0\+RH^EW-]H^B:D\!U'1-)NK-FH?L;?LT:U
M\/?B5\+?$_PJTOQKX,^,'AK1O!GQ*M?B!K'BGX@ZWXK\'^&)=2N/!OA2]\8^
M-==U[QE;^&_ .H:SK.L?#G0].U^STSX<Z]K.K^(/!%KH&M:I?W]Q\\7_ /P4
M*EO/BCX;\.?#?]G;XP?&#X47O[3NK?LG^,?BC\.O!GQ3U^_\#^.?#WBW5OAC
MXO\ B'?Z'9?":X^'T_P*^&GQ=T/6?AY\5_'][\9=%USP1-HFM^*/^$'UCPI8
M)JUS\::G\6]=N?CC^W5\5?VGM+UN?3OV1OV[OV6/A7^S'8_!7]H3XB:-XTM_
M'OQ/^ '[%:_"?]GS2]!TWP3\+O"GB?X<?M"_%7]J+5IOC-)\2?$EUX7U#4/%
M6F:#X]\/Z[X+^#GP^^(7AI*TGYS4I.]W)WG1;]VZE*4ZF)I32;3G*=^;G?NJ
M4E3Y4]&FH06RCRPK*U]5"%.&'J1=E:$864.5+F_1CQC_ ,$YOV'/'^I^(M9\
M9?LS?#'7]4\7>$/AMX'\47M[I5R)M?T3X.WT.H?"RZU8P7L*WOBOP!);P6OA
M;Q[.K^.M(TB)="M?$::(/[/KLO$O[%/[*_C"T^,VG^)O@MX3UG3/VB(/"UG\
M<])O&U9M(^*UAX'TZTT7P;IGCC24U)--U[2O"VA6%AX?\/Z5>VLFG:3X>LK/
M0;&V@T>V@LD^7_BW_P %(+WX!Z-^VOH_Q9^!;VWQG_8X_93G_;53X?\ @?XH
MZ5XG\)_&C]GF*R^(27/B?P+\0O$/A3P+JFE:UX6\2_"SQEX9^('AGQ-\.[#4
M- G;PIJ7AQO&NG^+M,=>PU7]MKXE>&KGPYX*\9_LT7_@[XU?%&\^+7B?X*_#
M2X\=Z[\0K;Q!\"?A+IWPD&L_%_XE>(_@/\)?C!?_  TEC\8?&KP)\/-8\'Z+
MX3^)/]C^)M9LKNT\2:YX7GD\06YK:]G9\KND^67.ZEK;*3<J-6Z6L73ES<O+
M%-IQ4DDTI13=KI2BH>SU[I+VM/E=[/GCR\UY->S_ !#_ &&?V0/BY\9/A/\
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M"QTS=KWB"X^%GC,?"3X=:K!]9_#W_@I/X(\:^#_'US)X7T2Y^(GA/]LGPO\
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M+>E?"G_@FE^Q9^TQ\3OA0/VB=?M_AQX&L_#/Q-_X**K\:-0^$4WC+P]J4?\
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ML=4U:PL[R%/@]^P5^QM\ /$?A/Q?\'?V<_ACX$\4> -,\;Z#X U[2]"$^J>
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MAU"Z\*^)8;DP6W7WW[:_['NF>'O!GBO4/VI?V?;3PY\1O#/B;QIX UF?XO>
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MP_U+X>W=SJFO:CXTOOB#X3^&.C^(]-CT"?4)?%6HZK//X8TN.RNK'3H/?_\
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M[X2\6^.=)^*O@N[\,^ ?%L'P^\=7JZS;Q7?@SXAWA\-C3OAWXJT6<Q:YX?\
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ML^%_B%X@CM;W2O'6BW>DZY#I&IN-3L[6[TF^\@O/V$_'6HVG_!3O3I?VBYM
MB_X*)P2R:%XB\!_#K4/"/Q!_9[UH_LK>!/V5;3Q!I7BT?$_5;;QKJFGZ!\-_
M"_C2QN=.\/\ PWN;/Q4VL-97-K9W6EQZ)].^-?VL_P!EOX;_ !!TSX2?$#]H
MWX&^"_BKK7B3X=^#M(^&?B?XJ>"-%^(.I>+/B[?:AIOPK\-V7@R_UN#Q'<:Y
M\1[W2-9A\#Z9%IK7GBC^Q=9ET:&\ATC49+:;1?VJ?V:?$6I^)M(T;X\_"6^O
M_!WA7Q!X[\1QQ^//#<<&G>!/"&O7/A3QCXZ%[/J$5E>>"?!OBZROO!WC'Q=8
M7%UX=\*>,=/U#PGXAU+3?$5A>:;!G[KA4A=.%2-3VD;IIQE"G"J[_97)0AS.
MZ4>1MV_>7NWOPG;WX2I\CL[J4)SG2275J5>?*K-M5%'6\#\Z-;_X)A_&/Q=X
M$_:X\'^)?VFOA!I__#7?_!.3X?\ _!/[7[/X=_LCWG@+P+\*[/X9I^TCX>\+
M^-OA/X'M/VC]231?",'@/]I;Q1I\OPIU?6]9D@\9:)H_B'0_B#H/@B./X56W
MT+=_L=?&>#X[^(?VA?"O[1/@CPOXYO/V%-._9'\*!?@#J>KV'A7X@:%XIUGQ
MQH7QLN+;4?CD\7B#P]9^*-6$MY\(;F.RN=1T:TCTH_%&UN9I=5/T9\,?VLOV
M7OC5XP'P^^#_ .T/\%?BAXY?X<>'?B_'X1\ ?$OP?XM\13?"SQ9%I<_AWX@P
M:1H>KWM[/X1U6WU[PY<V^NPPOIZVOBCPK=33Q6_BC0)-1Z?P[\>_@IXM^(%[
M\*O#/Q3\"ZY\2+'3O$^KOX*T[Q)IEQXANM*\#>)K;P3X\U+2=/2X\[7+#X?^
M-KVQ\%?$"[T47\'@7QC?Z?X6\6/H^O7UII\U7;5D[<TY5;1TO.2Q$9S5E=MJ
MOB5)JZO*>B<6HPZ<'NKVC&G=MZ1B\/*$;W5K.AAW'5/W8V;YKR_,34O^"46K
MZ9KVO?$/X._%[X6?!'QYXD_;#^"O[8.O^ O"O[/&KW?[)7BGQM\(/AKXP\ W
MM]XO_9PM?CIX<EU?QU\0-?\ %]C\7_$7Q"TGXD^&[V#XL_";X!^.AI%_XV^&
M%SXQ\74I_P#@E7\7M#TOX?>*_A?^V/8>!/VCO@?^UY^V/^TC\&/C-=_L\)XE
M\.O\//VY/B?XK^*/QT^ 'QS^$G_"Z-%T?XKZ3K6L^*PMKXT\(>(O@W=:1>^$
M/ >N^'_#6BZOH%[/K7ZD_#WX]?!;XLZUKWAOX:?%+P-XX\0^&-(\-^)-<T/P
MYXCTW4M7LO"GC-=1;P7XS&G03M=W7@?QH=&UR/P=XVLXKCPIXJFT'7K?P_K&
MHSZ'JL=F[QU\=_@U\,=:T[P[\0_B;X+\&:SJA\.BUL?$>O6&EO'_ ,)CXD3P
M7X+.H27,J0:2OCCQK)%X)\#MJLMDOC+QI+%X1\,G5?$<L>F,7=H13:2Y(TU&
MRMRR7+&'*DVN:/+;W[KFII*+=)-QC>4VDW[[G*3O\47SRFVVD^5W;]S:,V^9
M*H_D[Q-^QC\4=>\??L3?%V3]I-=7^*_[+&N_%Z\^(/BKQO\ ">#Q#I_QCT#]
MH#1(-+^*6C^&/#N@?$#P7#\(+O2YK.PB^#EY-?\ Q,T;X?>'M.L- \4>&/B<
M\,VIW7D%Y_P3&UR]M?BEK)^/VF6?Q/U/_@HY9_\ !23X#>--.^$6I6VC?"7X
MD67@3P_\*Y?A[X[\(R?%^XF^,'@7Q-\,+'Q7X$\:MIOB;X4ZQJ>C>/\ 7KOP
MY=^$-?L= UG2O4/AG^WKX+@_: _:<^!/[1WQ+^ ?PEU_P%^V%X._9E_9ST>^
M\9VWA7Q'\7U\=?LO?LR?'K0-.ALO&&OI/XF\>77B+]H&+P3!;>&--L+"^U5O
M#'A[3K&[U_7-/&K?77BOX_\ P1\"^+M(\!>,OBOX"\+^,-=UGPIX;TW0-<\3
MZ5IU])XD\?7TNE_#WPW<BYN8XM.\0_$75;>[TKX=:'J,MIJOC[5+#4M.\'VF
MM7NFWT%N;*#OR\Z<X6?*U[6="NXQY;.,N?#4).";<+6>E::J"Y7S:72?+/F5
MU)THUJ"E+F34ERXBM!3:M*]U9TH.G\(_'7_@F[J'QQ^%G[7^D7/Q>\.^&/C?
M^V9XD^ NH>/?BFGPIU'7?"GA;P=^SK?>#[KX=_#OPO\ #H?%/0-6NM)LCH'B
M?4[O6M:^(MSJMUXM^)'C#6DCM/#Z^&_!?A[TRY_9)^-FF?M!_M2?M%> OVA?
M /A?Q5^T1\-_V1_AWHVDZQ^SYJ?BS1?!-I^S!XV^)?BC63XABE^.FCR^/=)^
M+FC?%_QYX.U;3-.;X?ZIX4TR[T;4=%\27.KZ5-=:E])>(OVF/V<?"%O\6+OQ
M;\?O@MX6M?@*-";XYW'B/XH^"-#@^"\?BFT.H>%Y?BS+JFN6J?#B#Q+IX^W^
M'I_&+:-#K=BR7FF/=6SI*WD%C^T/X]F_X*#^(OV3KG1?""_#;3?V/O"_[0^E
M^(X%UEO'$_BW6_C)XG^&M_H=^TE\- A\.6>F^'X;^S^SZ=+J=U?7\HGN[6WL
M4BOI2C*2BK-RC)I*UE&.'J7TV2E0A545:TVZC3<I3DK:=I3:;Y>7FD[WNZ]*
MVNFL:U2E?9Q3@FE%13M?L<?L@^%/V/O#7Q@\.^#F\+:7H_QA^.7B#XYOX ^&
M_@YOAU\(?AAJ/B/P1\/O!FI^$?A/X!.O>)1X6\-:K>> 9?B)XCMX]6:TUGXH
M>.?'_BC3M*\.:9KEEX9T?Y_TK_@G'=G2/BW\)_%OQ=TKQ/\ LY_%S]MV;]MW
M6_ \7PTN-)^(L_B&3XU>'OVD8_A5J_Q#?X@ZIX9U3X?CXT>$?#]QJ%Q:_##2
M-9UKX7)J'PXOG&J:A<_$"3M4_;CT;Q7^W1^SY^S1\)_%?PC^(GPW^*_[/7[3
M/Q>\4>(?#VL76N>+](U;X)>,_P!G_P *^%;C0KO3M67PY>^ /&$GQ;\7:?'X
MCMK'6[+4/$OPZ\1:#IFKPZCX>\0V5G-^T1^W!X>_9=_:M^&/P_\ CCXZ^"7P
MB_9E\5_LH?M'_'+Q9\6/B=XG'@[4/#GC;X+?&+]DSX:^'=$;Q%K^MZ3X/M]$
M\5P?M)3VUGI1L]3\2ZUXFTW2K'29K=IQ8ZDU+D]E-/D]H_9TY7LK491E#JTD
MIX6G*FV[7A3LDI0@3I)5H6<E%JI55KMNK&<6]$FVXXFK&HDE93J<SNI3..^%
M_P"PA\;_ (*?M!?%+Q)\+?VR=9\._LB_&/X\:Y^TQXN_9@N_@_I.L>.-"^+'
MC77)/''Q0T[X;?M%7/CE+CP?\)OB[\26E\8>/O %Y\*/$6I*-:\9:=X*\9>#
M;KQ9=:S9Y/CS_@F[X@^*&D_MWZ/XQ^/MEI__  UY^T%\&?VH?AOXB\ ?"67P
MWXO_ &=/C/\ LZ>"/V</"WP5\1VFI^(_B?XXT;XD6OAK6OV6OAGXOUW3+GPY
MX,A\3WESXMT6233="UNWL]+^\=4_: ^"&C_#OPU\6[OXK^ 9OACXUT6V\2>"
MO'>E>)]*UWPQXU\.7?A^X\7P^(?!NK:'<ZC:^*]"/@^SOO&,FK^'WU'3H/!^
MGZEXJGN8O#^G7NHP=KI'CGP5X@\$Z7\2O#_B_P ,:]\.M;\+67CC1/'NB:]I
M>K>#=9\%ZEI,>O:=XNTGQ/I]U<:+J?AG4-#FAUFPUVRO9]+O-*FBU"VNI;21
M)6'[NK;3I1Y.:3?-!1E2FKRDG)2IO#47!R]ZFJ,5'X6FG&$[-J,E*7.E9.,G
M*-2,FHJT7&HJ]5327+/VLF_B3/SN^./_  3X\2?M$>"_VN[KXA?%[P;9?'?]
MJW]BF[_81;XD>&?@_K5OX!^&/PCUBU^)TWBK6O#?PQU7XQ:EXBU7Q?XM\1_%
MKQ!KFIS:E\6(M%MK+PG\*]#@TF6?PIXJU_XB=-^TS^Q?\8_C+JG[+'QC^$/[
M3UE^S]^U=^RW9>,/#^E_%"U^#<OQ#^#_ ,1/ 7Q8TGP79?&?X;>//@+JGQ7\
M/ZE>^#?&NJ_#?P!XET);?XP)XC\#:]X1T;4=.\1:C>6[7+]A\-_^"D/[%7Q%
M^!O@+]HF7]HSX0_#[X7_ !/;QO+X&UCXI_$7P?\ #JZUG3O >FZUXJUN[ETK
MQ=K&D:GI%[8_#?1F^)VN^'M8M+'Q'X0\%7*:IXNTO1!;7J6_LTG[5?[-<=E\
M--3;XZ_"S^R/C'8_#?4_A?K:^-="?0?&UA\9IFM?@W=Z'KJ7C:1/#\8;])-*
M^$[R7L0^)6LQ3:+X)_MS589;-'?9)V:G!Q479J5I2BHI:KFCBYN4+-3]LU.+
M<K"M!WFTI7A.#E+6\$XJ5W+1\DL+'EEHX>RO":2YCNOA3X1\5^!OA]X=\->.
M/B)JGQ5\;6EM=W7BOX@ZOI-AH)\1^)-8U&\UG5[K2_#.ER2V?A?PO:W^H3:=
MX0\*1:AJLGAKPI9:-H5UKVOWMA<:YJ'YW_#K_@G;\1O UW^RK=7G[0?@?6O^
M&:?VX_VROVT+F.U^ 7B#1SXYE_;$/[51UOX<6[S?M!:S_P (I'X(/[7/Q _L
MKQ;*OBA]7'A[P8+SPY:&SUUO$'WE-^T+\#+?XEV_P<N/BUX @^*%UK[>$+;P
M3+XGTN/79_&R^!T^*!\ Q6SW 5_B$?A=(GQ07P LA\9/\-"?B"NB'P>K:T/,
M_@S^VM^SC\=M&^,GB;P+\3/"\GACX'?%KQ)\&_&FNZKK6FZ1:P>*/"FM0^$-
M2NQ;ZC<6U_;:'J'CV/6O!OA+5[ZUMK+QU?Z%/J7@V;7-#U+1]2U"'&$I<S2;
M24E;91A5A)-)/EM&K.GIK\459IW=7Y4HMVO*44GNY3I5$T[ZWE2C4>MMI-6:
M27R ?^":7C]_A'IOPQD_:+\'&\L/^"GMQ_P4?;Q$OP#UI+><W/[4VH?M6/\
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M EM;>'OCEXKU^&_NM)\<RMK6F^'HY+;[!:ZE;ZML:1\<=#\5?M%^'?ASX/\
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MR?3-6TTVGO%N+]8MI_BF2FFDULTG]Z3Z-KKW?J%%%%(84444 %%%% !1110
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M]_ WXX_M(_M ?!GXZWGQM^..D/\ %CQ?,$_:5O\ X9W+_$G6/#GC;X@O\/\
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M'#QA\'/^"P_[(/B'X:>-?&_C7]O#XM^*?BG^RM\89] O)OAI/IOQ7^!7P/\
MAA\/]9\>^.8)+T?"GQ%^QEXM^%5CJ&IZ9XYB\,^*=5^'WP_\ W/P+TOXB>,I
MH_!^F_T$5XY\&OCY\*OV@-/\>ZI\*/$-[XAL_AC\5/&_P4\<?VAX5\7>$;K0
MOB;\.+RWL/&?AJ33O&F@^'M1NVT6]NH;9M6L+6ZT._<L^EZG?0HTHEOF7)+5
M*E",DG*-X4E0@I>ZTX/GI4FYTW%IR<4TI1<&HJ#YD^5N=1QO:24ZDJU64;23
MC/W9U?<DFG&";3Y)<WX8?MX?!/\ :.OG_P""SGPS\#_ /XO?%S4OVV/V$/A;
MX:^!7C'P;IWAJ?PGKWBOP)\)?C)\,_&?A?Q3K]_KN@V'ACQC;ZWX@\,:A8>'
M)K5+KQ7IOBF"[\)VNHVVC^*F\/?0O[3'P2_:$^-G[5?[4[?"_P ,>.?A;J/Q
MJ_X(W>,?V<OAE\8M9@;3_#/P_P#VDO%GC/XHZUX=\/ZIXM\)7VO?8->\&Q>+
MO#_B.]U_PT^L^'H9;6>UT+Q'J>N6J:>WZF_";X\_"OXXWGQ:T_X9^(;W7;[X
M%_%K6?@9\4[34/"GC#PI<>%_BAH'A?P?XTU/PYY/C#0-!DUJ"/POX^\(ZQ:^
M(_#RZMX7U.UUF$:9K5Y+!>1V_L%3R)QDGK[2G4C>R2<*U#&4KJ*CR6]GCZDE
M[KC*T+QY'.,M8SE#W8Z*,X2Y7=M3IU<%5UDVIWY\!23][F2E4][GY9K\*OV<
MO^%V_$#]IC_@F)XQU7]BOXY? #P_^SO^Q7^U_P#LY_&JP\6:3\.-(\&?"/XE
MZS<?L.V^B>%_#NIZ?X^E/CGX=71^"_B6W\!^-_A]I.M^'_%6D3:+=:)&PTGQ
M[;>!?KGX_>%]=\._\%"?V0/VC-4^&GC'Q?\ "GP)^S%^VC\&M7\8>"O ]_\
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M_BOJ?BCQIIT_B&Y,VL1:MXKTM=)\<7D[0OX>O]0,6EW&MR^*]/CTI/DWP_\
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M9U#QM?\ AV+6_&.D6?CFZ\533_C]\'?B3K7[3EA_P0'_ &SO$7Q:U[Q;XO\
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M'5_AGXB\+?&F#XKK;1_%9?C1J&G/;>*H/@+J:_!X>F_$[XM?'7X8_MH_'_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGP\?XB_M]_M'_&/X>?\ "3KH4B^,OA/X_O/#,O@KQQILGA[7-?CTNUU]--U
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M.MK74M/T_0/'_@]EU."Y,6JW6HWATJ.ZT[3CJ-Q\[_M(?M;_ !"TS]IOPO\
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M_!*CXO>'/&WB/Q!9:=H:Z_K?QK_9D^"'ACPG\'/"EOI=_=6WC7PG;6GA6_\
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MX_VB?V=_B3K?@'5O@AI/Q@\ _'B_3X96W@GX1>-/C'>_$?1M1\"?LP>+=/\
M"5Y\0/$=_P# SQS>R_$'Q]\./A'H7BJY&C:--X$\<8.4XT:DDG.<'7<(6LY\
MLL4X0NM6Y*A",&HJZJQBFY2I2=12E7C"3Y(3=*,INW+"+IX53J;=)5JCDF]9
M4I-\L8S2_H#T3]HGX(>)OB!)\*O#/Q-\*^)/B*GPVT7XR)X/\/7QUS6KSX2^
M)96M_#7Q,TRUTN.[_M;P)XDOHKC2_#OBK3&N]%UW6;._T72KV[U73[VS@P]>
M_:K_ &?/#7PX\._%W5?B=HJ_#CQ7X+U+XF:#XJT^TUO6K&]^%>APZ1=>(?BV
MT&BZ7J%_9?"+PQ8>(/#VJ^*_BM?VEK\/?"VB^(= UOQ#XETW2=;TN\N_QVM/
MV/?VKYOV>O\ @DS\1O@WX4UWX+?M&?#3]F/PA^P=^UAI/B#6_!_A[QQX-_9A
M^+_P:\)^$_B5XYLM6\.7_B[3-4^(O[.GQC^&GPZ^-OPA\-VVM2?:9D\3^'-2
M?P[=>*-=CL?6_P!JCX0_%CX-_M=_"_XG^ /V2_BW^U-^R/XL_9,T7]DGQ%\'
MOV9OB;X5^&GCKX(:_P" ?'WB#7_ >KP>$O'/QO\ @'X#\7?"3XB^%O'ESX%\
M;6U_XO%OX1MOA[X;U348X=(#VVH]%2,8SG&$FTJ]>C"4G>,E3=>5&JW33M3K
MTUA(\R5HU:E9)I1I,S@Y2C&4HVO2HU915N://[&-6G:;7[RC-XF7*[\U.G2>
MO-41^N^M_$SP+H'PUU3XP7?B.SOOAKI/@JZ^(DOBOPU'=^,+'4/!=KHC^(AK
MOAV#PG;ZUJ'BN"^T9!?:+;^&+/5[[7UFM8=#M=0N+NUAF_,'3_\ @J/X2UGX
M@?L1>.6USP5X%_9._:P_8=^.W[5&L:E\0O#_ (@TSXJ>$/$WPWG_ &0-2\'>
M%]/U*W\3'0]<.O>'OVH+FQO?"N@^"/$NN:OXE\.6*^$M>U"&]DL6^]?"7PQD
M\/\ [+6A_!WPYX#\)?"N32_@9;?#SP]\,/"&I27O@?X;"'P./#^C> /#FLM8
MV#7WAGP8HMO#FF:NFD:5'>Z=IL5_!HFDQ31Z9;?D=^Q9\'_CYX7UG_@C-JGQ
M)_9P^*?P]M/V0/\ @F;\=OV7/C;=^)X?A]JLO@OXMWOAK]A'PYX?:PL_!OCK
MQ;JVM:'XNG_9P^+MKH6L>'+&_O%L8-"N-=T_1=-\::#<:BHI.K4BVXQA%2@Y
M---N.-34^7W9\KIT=(22YW%IN,H*2FY>RA):RE)*<8)WLJF$=X<RYHIQE5NY
MQ;Y.964HRM^GWQ"_;U_8L^%'@7P'\2_B/^U+\"_"'@7XI?#W5/BQ\,_$>K_$
M?PU#9?$+X:Z+X?M/%&I>.?!*)?R77BGPS!H^I:/(FJZ);WUM<WVO>'-&M7GU
MKQ%H>GZAW6M?M1_L^>'?$/@[PUK7Q8\):??>/=?\)^$O"U]-=S-X8O\ QC\0
M-/L=4^'7@BY\:Q6\G@[1O'/Q)T_4]-N_AMX*US7M-\4_$*'4+$^#-(UQKN /
M^+7[(/[-'[1GP[T7_@B+I/CW]G_QUX?N_P!ERQ_:]TKX\B[G^'>H6_P5N/B+
MX!\7>#?AM/J=UHWC;58-=M?%%QJMKIEC<_"I_'0\/:7J#S^,?^$7TA+^>#NH
MO@E\9_#W[4_[4GP<^,/[$GQ%_:F^$_[0_P"U+X1_:8^!G[0<'Q?\+0_LX^#M
M)7P]\&4O=&_:6^%'B;XQZ!KVE>+OV</'/PMTO7/A7?\ @KX5?$O4OB+H^E^
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M/+3_ (9J_8W_ &DU\8^&-:\5?"B_^%5]XQO=,TS4/BAK/@3X2^*OA%\&M/\
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M(O#-[''K6@1ZQI5QK-E8V^HV<L_XK?'OX5?M<^-_CYK^I?\ #('C]M*^&_\
MP5C_ &4OVA?"VH_!JY^!/@WX8?$']GOP_P"%/AKX3UGXQ^*))OB7X*\7_&C]
MHF]O-*DT/XD7_P 5=.U2T^&/P]^&O@_2? TWA[2=);5_B!]?^*/@!XSLO^"E
M%QI?@_4=(F_9U_:6\+?#[]K7]I7PC)?WXU/PU^T'^QEX@\%>"OA%XGT:VMGD
MCTF[_:"-]\")]7NI/[.M-3T7]@_5M&4:H/%/B2-,H7DJ=]'.4D_>5HI4J5=2
MLTI)<GUFFXN[C6ITTVTYLUG:/-:7-RQC):-7;JU:/(GJG*_U>HG=*5*=2UFH
MGZ#/^T)\'$^).G_"-_'%BOCW5M?N/!^FZ4VGZV-.OO'%IX&U3XGWWP^MO%!T
MS_A$Y/B-IWPUT74OB%J?P\76SXUTWP/ GBR^T*WT&YM+^?BOC7^UC\*O@-\5
M_P!FSX->-IM=;QC^U!XR\=>$O D>D^'M;U73M-B^'?PL\8?%'Q%KWB+5-/TZ
MZT[3+);;PO9Z!IVGS72:YJ^I:^E_I.F7NA>&_&&J:!\':'\'OC9X1_;LTCXE
M? ;1?C1X$\ ?$/\ :*\>WO[7?P-^+5GX2\7_ +->M>$+'X/^/M#\+_MH?LX^
M.;B+4?$?PI^+7CCQ-:?#[P#XI^&/@OQ)8WGC5?$WBC6?'OP;T[1=-NOC9K'M
MO[:?@3XI7O[2W_!-7XS^ OA=XN^*GA;X&?M$?%ZZ^*&F^!;GPC'X@\-Z!\5O
MV4OC7\)/#WBV6S\9^*O!^FW/AW3?&GBO0;3Q%<V^K2WVDV&H#45T^ZM8+IX'
M%MJ@W_R\G&%1:IQ4E-.2=M(\WLU"<K?$U5A3E&:2E=*M;>$'*#W4FI0LFM&Y
M*/M'.$;NZBZ<ZD909]8ZC^TA\#='^(>F_"S5?B9X:T[QKJ_BN+X>Z;8W<]Q!
MI5Y\3[CPR?'%M\)(?%DELOA$_&*Z\" ^/K3X0G7!\2[OP"1XWM_"LGA4C5SZ
M?XH\5>'/!6B7GB3Q9K6G>']"L7LH;G4]4N8[6V6YU._M=)TJQB+D-<ZCJ^K7
MUCI&CZ;;+-?ZMJ]]8Z7IUO<W]Y;6\OX47/[)_P"T7XC_ &7_ (E_L(Z[X+\2
M:/\ $ _\%,1^TYX _:7TVZTVX\&:G\#_ !)_P4DTS]OZZ^.4'BZWN8+OPU\6
M_ GAK4_$7P;7X67MA:^.]1^+&AZ-=:/IMY\!M9N_BWI?W1_P4V^%GQV^)G[.
MWAO4OV=/"TOQ*^)/P9_:!^ 7Q^3X+0>/#\+KGXY>&/A+\1]'\1^+?A?I7Q';
M5=%M?!'BK4]!2\U[P#XDU&_BTO3/B#X<\*SZBT5J)+B$3:I0G*RE*5%22O+D
MA4A0E4F^5/6A.I5ISBD[^Q<OYD/><HQU2C5Y;Z-SISK1A'6RM6C"G.$D]/:<
MO6##]I+_ (*(?"/X3_LR>,_CU\--<TCXAW_A_P",'P[_ &=YM"GL?$MI>^ ?
MC'\2?BO\./A-_8?Q<\'/ING^-_!>J_#V3XGZ%X\\6?#[Q-8>$_&6J^%X[2ST
MO[#<>)]!U&3P+7/VO_VK8_CW)^QQX>\9_LQ3?&SQ_P#!_P".'[1/P.^+FI_!
M7X])\-F\!:#X@_9N\+? 3P!\5_A>GQ%MO$6G>+?%7B7XQ>/;3XF^./"WQ.N=
M"T;PS\/_  SKNF>$M(\1_$2^\%_#KR/XW_"'Q[\7OV,/BEK7P:_8.^,7P9^(
MGQD_:L_87^*M]\-?B/XK^&NM?M*_$C2?V=_VD_V<OB'XV^)OQ?U]/C=X]\"Z
M1>Z/\*/A5?\ A?P)X>USXQ:MXNGT7P9H.C7$.F7NKZ)X0T;[&UOP3\1=1_X*
MJ?"/XWV7PZ\92_!;1_V!?C5\'M4^)K6>FVNB:?\ %#XE?'O]GKX@^%_"%QH5
M[JD'CN.[D\(?#7Q)JFJZX_@\>$M%G&GZ'J?B"#Q!<RZ1;6XI1C=WE*<H22LG
M!+ 3K)Q=VE?%1A&,Y)J\_95%\4#/FES-I+EC%23:;4G]=C2?,O=;_P!G<FXQ
M:22]I!Z*9]4^#OVB?A3XC\::3\)+CX@>#S\7[W0O$&HIX7TVZU1=+\57?P^U
M"P\.?%L?"S7]:TS2M/\ B=8_"GQCJ%KX5^)#>#YM7O\ X;:[?:7H/Q$LO"^O
MZA!IC\#J_P"W7^RCHWAWXH^)I?C%H5_8_"#X.7?[0OBNST33O$.MZ[J?P+M8
M=0DC^,'PZ\/:9H]SK7Q;^&6I7&EW^DZ)X\^%MCXP\)ZYX@M9O#VE:Q=ZRC60
M_%[]G+]C[]H#QE^S5I'[$GQJ_8\\;_#7]HW]F3]FCXY?LR_#_P#X*#^+_C/I
M'C[X$0Q>)OV?O&G[-7@;XZ?LM6H^+_C'XP^'_B/\8?#>H>$O%/Q!\*7/P5^&
MND^"_#3>.-(\0>+K3Q7I7@?P1XF^FOAMH?[3'[2/['_Q-^%_Q-_X)\R_LT?M
M#>$/V!OBQ^R7<^//'FM? .^M_&_Q#\3_  [TCPYI_@7]FCQA\.OB!XW\2']G
MG6_$&@6_BGQ5JOQ*M_A;H]KJ4/PUL]!T7QQ>:5XMUCP+E5E)4:TX*]6-"I5I
MQA&2C.3I8BI!0A-<RY*D:5*5&=JC]HE%2<6WM2BO:483;Y'5A3J2E*/-"*J4
M82<Y1TE[2G*K45:-J:<'S<O,DOUA^"OQD\,_&_X,?#[XW>'X;[3/#GC_ ,#:
M!XYALM6MYH-0T:VUK1;769].OU:*-9[C2A</:W%U9K+97;P-<6$UQ:R0RO\
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M=S_!']HZ+]F'XC?!.X_9I^*UUXG\*_\ !;;3_P!J.SECN_A/=>'/B+\ ;_\
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M%_"/Q\_9Q\5?$+4/%/PCOOA)X"_X)\O\1?!'Q&\'?#F:!/!'P-E^%/QK\._
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M&K0PU=1]U.U3EQ*486DZLH-4VW."/Z1**_FE_:(\<:CI/[$G_!2SXZ?LZ?\
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MA^TM<?%/Q!J/_!0U]0_:K_:,FD^$O_!$_P#96_:C\"^)/AA\2?BC^S?H%O\
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M*HSY?WRHK\5/#FG_ !,^/'_!2FQ\+_%?XH?M _"O3O#/_!/G]AS]J'6OV?\
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M=,\4?$'Q?XS\5/H5UHEUX=\0PV?]LSZ6I\11Z[:I&/$IGO.__P""5'BB6S^
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M:OXBT:UO]5O)8;*Q^W1S7<T, >1?L7X[A=6^.?[$^@6$RSZWI'QL^)GQ,O\
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M I:JZ;<<=3NUI3:;E>+@YQ*22K=Z<:O*WHI2@L:MM[*6!J>Z]9)JUFI\G]2
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MII;G[%865KYOD6L$<>A110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>:7-XBL-.TS4]6U74=/LK34HK:SOM3U"[MXH[B]N))/SC^.W[5-G^SY\<?\
M@HO\0=,_9I\(>(OB?^RY_P $W?@K^TW+XUD^,&L>']5^-_PHTKQ+^VAK>A?!
M[7H4^%WB#3_AC?>!O$OPH^+M]H^M:9'\18?$3_$32WU)M'AL6M[/TWP3^US\
M??$VO_!WX9^)O@7\+? WQ>_:+\+?%/XS_";0[3XY>(O'7AS1/V;?A5X>^":Z
M[X\^*NM0_!GPFNE?%:+XB?'[X;>"[KX-^!6\<^'%@U75O$.C?&GQ!I/AVZN;
MYQ3M%I;7<4M&FY8J+4-4[R6&KMV<6^2I\47"52'.-Y)M:OE;?7E6'^*Z^S+$
M48I-22<X*RDI*G]::Y^SM^S]XGN?']YXD^!?P<\0W?Q7@TFU^*5UKGPQ\$ZM
M<_$JVT$QMH5OX_GO]$N)?&,&BM#$=)B\1-J,>G&*,V:PE%POB7]G?]G_ ,:>
M(_A?XQ\8_ SX.^+/%WP0FBN/@OXI\2_#+P5KOB/X0SP1VL4,_P +]<U31+K4
M_ $T,5E9QQ2>%+K27CCM+5$8+;Q!/E[P9^V#\9;SXO\ [)GP,^+7[+L'P7^)
M/[2?[-W[1_QF\3^&]5^./A[QQ=_"3QY^S?XJ^!?A;6_AT^H^!/!VL^%O'?A+
MQ>_QST?7/"_Q,TOQ)HVK1:)II_M_X8:1K=Y/HFE_/WP]_P""FWQ4^*7@[_@G
M?KGA']F7P*GB/]OF3]H;1+?0M;_:*UNRT/X7>,O@=\.OB?X[T_3KKQ/:_L]W
M^H^*_"7BYOAK<Z??^++;P?HNM^%XM1ANK;P'XHD1K8%G[MEJ^5P2:O?FJTXN
M-NSA5C%IQ<4Y+W%.2=7NI-WLKJ5[]80J-.][W@H2:M)/EC\7+&WZ8?\ "D?A
M!;:I\1_$>E_"GX7Z=XL^+>DR:-\3/$\7P]\*_P!L?$73VLIM/BL?B'?Q:=;7
M_CG2X[2>6U?3/$5[>6TMG)-9_)#,XJ/X&_!3X>_LZ_"GPA\&?A7H=GX<\!^"
M;74+?0]&T[3-#T/3K1]7UG4?$6K-IWA[PMI/A_PCX9L+O6]7U*]LO"_@SP[X
M:\%>&;:XBT'P=X:\.^&=.TK1;'\S?AY_P4M^->L']F'7/B/^S#X!\(> OC%^
MV)\8_P!@#XH:SX7_ &A=5\9>*? G[27PC^('[0WPPF\1?#WPG>? _P +:=\1
M/@+K/C+]GVYTZ/Q5XH\7_"_XE6EOXS_M)OA7-I_A*.X\9^W?!C]N?6/C]\:?
MC7\&OAUX;^$<7C#X&^.OCE\./B)\+O&?Q>UCPA^T#\.M0^'.LW6D?!SXE^,_
MA#>_#6XU&Z^ ?[2UI%9>,/!7Q3\*:EK%CI7@[Q%X'O-%LOB)J/B'Q=8_#%-N
M*;L^5QU2:LXTX1KQTNGRQCB(U(NRC%5U)^SYY-"M*S[:IN^CJ3E0=GJKN6'E
M3E9M_N;>_P L4?9WP^^"7P9^$MQK=Y\*OA'\,?AG=^);NZO_ !'=?#[P#X5\
M&7'B"^O=1O-7O;W6Y_#FDZ;+JMW=ZMJ.H:I=7-^T\UQJ-]>7LKO<W4\KT/"O
M[/OP%\">,/B1\0_!'P1^$7@WQ_\ &25)_B]XX\*_#;P9X>\8?%6>,7 CF^)'
MB;2-%L]:\<RQB[N@DGB>]U1U%S<!6 FDW?F=^RW^W%^T[X[_ &'_ -@?XV^.
M_AC\+=4\;?M8?#GP[XS\6?$J\^*W_",?"WPC=>+/A+9^/O"5A<>&7\%Q?$/4
M?B!\6OB5JUI\+/AU\%?ACX<^)ESHVF-=^()O'WBO4-!LO#7BZ]\.?^"EWQ8^
M/.C?L%O\#OV:?!%YX@_;W_8H^)/[5WA.'XF?M :OX/T'X6^(_A5-^SS!XK^'
M?C:^\/\ P+\::MK7AIF_:"TV+P_X_P#"VB7>NZSJ?A_[#J?PS\+Z1K%UXH\-
MWR3NTHMN%Z<E%I\J]FY2A:^D7&$HV24)<EDI1<&1[2#C&;=HU.6<7*ZYG[10
MC*^J<E*497;<XJ5[J2DE^C5E^SC^SUIOPYUGX/:=\!_@S8?"3Q$[2^(/A;9?
M"_P1:_#G79'OX]5>36?!$&AQ^&=4=]3BBU)GO=,G9K^..\)-PBR"]K/P%^!G
MB/P#9_"GQ#\&/A/KOPNT[4%U?3_AMK/PZ\'ZIX!L-574;O5UU.S\'7VCS^'K
M74%U:_OM46]@TY+D:C>W=Z)?M-Q-*_Q/\$/^"A%[^T;\._V,;KX>_"NT\.?&
M/]K_ .#/Q8^-$G@7QMXSFF\)?"3P[\ [[P!X*^,S7WC/0O#$MWX_D\/?%SXL
M?#CP7X2M-.\.^%+OQOH6NW_C6=?"D&@W^BG%\0?M_?&/2-*T'P%<_LFZ[X<_
M:XB_9RC^/WQ'_9WO?$'CCXK:-X&U#4_%WBSP1X#^'H^+7[,_P=^-VE7MA\5_
M$GPX^(5OX7^)>I>&]"MM!\/:39>(]>\$3:[)J7P_TV&[*]KJRDG'WN:-.//S
M0Y4W-4X)27*FU'E<%K%%Q:;M%K=Q>J7*YSY&I.Z4'.;:?,TI/FYGNS[N^)G[
M/_P'^-,7@R#XQ_!/X1_%F#X<Z[:>*/A[#\3/AOX-\>1>!/$U@(5L?$7@V/Q3
MHNJIX7UVR%O;BTU?0Q8ZA;""$0W"") /7*^9==^/WB73OV/]4_:?@^$/B'0/
M%EA^SQ=?'.;X$_%;4W^'GBWP_K-C\/7\=:C\+/'VKZ?H7C4>%?$^BW$5SX7U
MZ]L=!\2V=CJ]K<2VD&I6:QRR?$?P^_;Z_:K^*'B?X'>"O"W[*7P5M=>_:J_8
MAD_;&_9_U#Q!^U1XJM/#]G;^%;S]G>P^)WA'XY2:;^S/JNK>"'T6;]I?P0/!
M-Y\-]-^,0\87&F:E;ZS_ ,(39W,NK:.-I-QZJ:3UT=2<:C5GM*<X8>I9WO)4
M^7FTBF*S2DE=..CMJHQE33O?6,8RK0NG91<[VOS-?HEX#_9T_9\^%G@WQ=\.
M?AC\"?@W\.?A[\0-0\0ZMX]\"> _AAX)\(>#?&^J^+K-=.\5ZGXN\+^']#T[
M1/$NH>)]/1+'Q#>ZS8WMSK5FJVNI2W,"A!):_L]? &Q^'6J?!^R^!WP?M/A+
MKC0OK?PNM?AGX+M_AUK#VT&F6UN^J>"8=$3PSJ#P6VBZ/;PM=Z9*8H-)TR)"
ML=A:K%\ Z)_P4A\8>/\ ]E/]EG]IWP)\"_#FC:9^T;\ /&GQ@U2W^)_Q@CT+
MPYX'^(O@_P )Z!K^D?LXZ'J'ACP+XJ\=?%7XA_%36;KQCI7@+4?!/PUN)8O!
MGPX\<?$B]\)7FH:7HWPT\3]+\+O^"BUQX_\ B#^Q!#X@^$NA_#CX#?MY?L9W
M?[3GPF^,/B7XL32:[I7Q+T?P/\/_ (MZ[^SIXF\"0_#2'PM::W!\&O&FN_$[
M1O&:?%PPZ[H'PH^*TD?A6SM_"OVV]<E9RC*RY>6+O*/+:,)U(:M\O)R4INFV
MU'EBG%13BVU?=1E>\F[)J2ESQA45M)<_/-*I9.7-=2<FI)?;5Q^SW\ KS4=4
MUB[^!_P@NM6USP/;_#'6M4N/AIX+GU'6/AK:01VUK\/=4OI=%:YU#P/;6T,5
MO;^$[N6;0(8(HXH]/6-%406'[./[/6EW.FWFF? ?X,Z==Z-X"N/A7I%U8?"_
MP19W.E?#"[$PN_AQIL]OH<<MCX"NA<3BX\'VK1>'IA/,)-.;S7W2_L__ !%\
M5?%WX*_#;XI^,_!%E\.==^(?A33O&G_"$6'B/5O%1T#1O$D9U?PM::EJ^O>"
M?AUJB>(I?"]WHUWXIT:Z\)V"^&?$MQJOAJ"^UZVTB'Q!JGQC^S7^WUXH^,G[
M17A;]G3X@_!_P_\ #KQ=XS_9B\6?M(/9>&_BBGQ(U'X4:W\//BGX'^%7Q(_9
MY^+=QIOA#3/!T?Q<\"ZI\1?"-SXE7P1XQ\3P:'KTOBWP7KFDZ5;^&/"OC7XG
MEO><'%J5I-QDK-6C4E.,E)?$E[92@US*7M822E*49I-<JDK..EG&S5N:$5)-
M:<K:I<LD[./LI1O%0</L_1?V>?@#X;O/ &H>'?@=\'] O_A19:GIGPMOM%^&
M?@O2[SX:Z;K;S/K.G^ +FQT2";P;9:N]Q.^IVGAU].@OWGF:ZCE,KELZQ_9B
M_9KTS7?BOXHTW]GKX':?XE^/%N;/XX^(K'X3> K37?C-:%9D-K\5]6M] CU#
MXB6Y2YN$,'B^XUB(K/,I7$KAOEOX^?M<?M%>#/VI8/V4/@#^S9\-OB[XSUW]
MEKQ5^TAX3\1_$/\ :*U7X.^'+B?P7\4_!/PZUWP9XE33/@7\4M2T5KB#QI:W
M_A;6M)@\2PZYKGV?0M?L_ ^BM>^,K+R3X?\ _!5/1/C=\+?V:_$/PB^$WB0_
M%7]HCX$_%+XV7/PY\3Z+\6/$UK\*+GX,>-O#7PC\<^ ?&]Y\#OA'\6O%[ZB?
MC7X@N?A_IWB>W\"6WAV+1_"WC'QI=.VIZ;X8^'_C=)\R<DKJTE_><7*K";47
M[THN>&J0J633E3BIJ2<)#:Y6DU9OEDNB3483IWDO=4E"O"<+M-*<G"S4T?HW
MH/P)^"'A77/"GB?PQ\&_A5X<\2^!/"K^!? _B'0?AYX1T?7/!O@E]V_P=X4U
M;3]'M[_P[X5?>^_P]I%Q9Z0VYLV9W',OP_\ @A\%OA/KOQ!\4?"SX0_"_P"&
MOB7XM>(1XN^*OB+P!X \)^#==^)GBM3=E?$_Q!U;PYI.FW_C/Q"IO[XKK7B.
MXU+4@;V[(N<W,V_\Y?"?[?G[4GQ,^*GP$^#G@S]BC0_ 7C[XO?LD6_[5'BSP
MU^TC\>O$GPGU[X42^'/B]X"^%GQ4^%?B+1?#'[//Q.U*]\0:$?&3ZMX!U^TM
MTTGQU!:++KEM\/X9+0:AT?@'_@IEX)\2:M^U5JWBF+X;^%/ 7[&FF?M1:M^T
MCX>;XD7TW[27P1TS]GCQ1-;>$?$?C;X WW@S3-6O? ?Q_P#ACH?B_P",/@/Q
M[HFN-X?@T2P\+:'H$OQ#'BRZ\1>&1OEYG*RY(UG)I\S4*=22K2]WF<J?M:;Y
MIQYHRGR2DFY4YR46I<JBF[RI1BK->_4C'V4;/E2GRU5:+Y91BY)62G%?9/AS
M]E#]EKP=X#\9?"SPC^S7\ ?"WPQ^(NNW?BCX@_#GPY\'/AWH?@/QUXFOY+2:
M^\1>,O"&F>'+7P_XGUV]EL+&6[U?6].OM0N9+*T>:X=K:$IOW'[/7P"N]1U/
M6+OX'_!^ZU;6O UO\,=9U2X^&G@N;4=6^&MK!';6OP\U.]DT5KF_\#6UM##;
MV_A.ZEET"&"*.*/3UC15'QYH7[</Q&MOB7^R]\-_B1\$O"O@Z_\ VVO@_P"/
MO'?[.]Q8_%?5-<@TOXI?#OX>Z7\5-5^ _P 9+B#X7I;^'+_4_AQ=ZEXQT7XC
M^"&\>://-X2^(?A>X\+P/X7\'^)/BIYI^RC_ ,%)/B9^T#XJ_8;/CW]F_P +
M_"OX;?\ !0#]DSQ#^T?\'->T'XZ7?Q*\;>%?$G@CPO\ !WQCXG\ _$GPC+\(
M/ V@V.A:OH/Q;GNO WC3PUXX\1:E?1^#3_PF'@CP7J?BI=#\+OE?,Z;BU*+=
M.49./NR@ZU!TI>\TI1="M2Y+NT8\B]R45*?:0LI*2M*/M8O5<T9>QJ*K%N*Y
MHR=>C/G6\I7?OQER_>WB3]EK]F3QEH?PS\,^+_V<_@1XJ\-_!;4[/6_@YX>\
M2?"'X?:YH?PFUG3C"=/U?X9Z3JGAZZL/ >IV)MK<V=_X6M]*N[4V\!@F3RDV
M]!KWP'^!WBK6?&'B+Q1\&?A1XD\0?$+PS!X+\?Z[KWP[\(:QK/CCP=;>6;;P
MGXPU/4-'N+WQ-X9MS%$8-!UJ>]TN+RH_+M5V+CY(_:D^/OQX^'?[8W_!/CX*
M?#+3? -S\/OCWXN^/I^)Y\1Z]K&B^(M5L_AC\$]>\2:=H^FW=GX,\66.FZ18
M3WX\73>7 FL>)?$GAWPUX>&K>%?#TGB&]U?RGP/^WG^U7X_\-?M2_$'PY^QG
M\/-7\$_LU_$W]HGX&6VGZ?\ M7VUIX[^(GQ5^"OQ#TGP;HNJ6]KXK^"/A3P'
MX*^"VKZ%>WWC'Q_\0?%/CZ'QCX MM%\2Z?HWPI^($&C^'M9\>I6DK[INJWS7
M5G&=&A4E)R]U*4JU&+DW9P:YY<D'[-W49<MK-*DHVM=J4*M>G&*7O>[&E5FH
MQ5XRBW&/-)<_Z'1? CX'P>(?ACXN@^#7PIA\6?!/1-<\,_!GQ/%\._"$?B'X
M1^&_$^FVNC>)?#_PQUI-'74O 6B>(='LK+2M<TKPK<Z38:MIMI:V-_;W%K;Q
M1)M_$#X7?#+XLZ5IVA?%3X=>!/B7HFCZY9>)](T?X@>$?#_C+2M+\2Z9#=VV
MG>(=.T_Q'I^I6ECKEA;:A?V]EJUK#%?VD%[=Q07$:7,RO^;6C?\ !3[2AX9_
M:-CUKP/X;UOQ[\'_ -K7]GG]C[X4Q^!_'>H7'P[_ &A?'7[6O@C]GOQ;\ _%
MND>+=8\&6VI^#? =])^T)IDOC_7-,\/?$RVT'P#X+\2?$KP#/\5+*^T'0+_Y
MW\%_'_7/V:_VT?\ @J]\3_BYX6:?4X=/_P""57@'PKX9\&>+O'/Q T3Q=XY^
M/7B?XF_ SX6RZ59_\(??^*O ^D^)/B9X\\+:'XI\/>%O!/C+4= M-/U;Q/H6
MC^.=1O;?2]0'=246K)J<TY-6YE&C6MJ_BE[:,I7M*,FI3]YW1=))I;RC3LM+
M*]6#VZ15)J*5U).T%:RE^S?BKX*?!KQWH7A7PMXW^$GPR\9>&? EWI5_X'\.
M>*O 7A7Q#H7@V^T*V6ST.]\*Z1J^E7FG^'KO1K1$M=*N=(M[.;3K9%@M'AB4
M*-CQU\-OAU\4/ ^N?#+XF> ?!7Q$^&WB?3!HGB7X>^.O"NA>+O _B'1E:%UT
MC7/">OV&H:#JVF![>W<6%_87%H&@A819B0K\Z?LQ_M%_$WXT^+_CIX/^(GP!
M\;_"RQ^%>N^#!X!^)NJ>'?B)X=\!?''P?XW\/7.J?VCX5TWXL> /AEX[T3Q=
MX \0:7KGA+XA>%[WPWJ>D6L8\'^*M#\7ZK;^-9M"\+?'G[3?_!3[XA_LR^'O
M^"@>L>)/V:O"=]??L+']G[X@6^F7?QX\4:3'\8?V9/CW=ZAI=I\=M.N[']G3
MQ%<^&KSPOK_A/XH^%[WX=Z=IGCFYU/Q'\*?&%A:^*(+>;PU>Z^.S:3M[ZY_>
M<4G=TTW)R?+S+VD7/F]Z,%*4O<IRDJVU2=XM4URI\UWSN,8VU?,XM1479S<8
M17/.,9?IUX#^#7P@^%E]XAU3X8_"KX;?#C4_%UIX.L/%>H^ _ WACPA?>)['
MX=^%K#P-\/[+Q#=^']+TZXUJT\"^"=+TSP=X.MM2DN8?#'A;3K#P_HB6.DV=
MO:1_)/[<?[ GP_\ VN_AO\1=/\,:9\(/A1^T!\0]!^'O@BX_:=U?X':-\1/B
M1I_PY\#?%CP;\6)O $^IZ9XE^&WC?6/"FLZIX-MK5/#S?$?3="TV^O%U]M-U
M*XT]+"Z^8/\ @I-\4M=\=_ 7QX-(\+V4_A;X,?MQ_P#!)72_!/B_PA\2=2;7
M/B'XO\=?MJ_LA^(O&_A]_#]UX>\)^$K3PJGP^^*7A/1M!\03_$'QAX?\97'B
MWQ##K.F^#)?""3ZIC?M"_MO>(-2_9!_X*U:#^TE^R5\+_&&N_L1>$=7M/BQ\
M$- _:&\5:Q\*?CK\$O'?P!\-?&JV;3?BQ>_ CP?XQ\-:_>^"_$_B+PCKOA^Z
M^%1AA\2^&$N]*\4'2O$5O>:(2O&/M9W3A-R7,Y<Z5/V%24G?WDU*4.:&\H-2
MG>G4G$B+C4DZ*2<)PC&5G'EE[9UZ48))\LHRC&?+.]E/2#4Z<91_4?Q7^S7^
MSW\1/%DWQ%^)?P$^"'CWXE:AX#@^&6L>/?%GPI\$>)?%>H?#V/7(?%1^'\WB
M77]$U'7Y_ 2>*X(O$D'A&ZU&;0X];A@U?[$=2B6ZJEXO_92_9<^(.N^)O%'C
MW]FSX!>-_$WC7PGX;\!>,O$7B_X._#OQ+KOBWP+X.\1Z5XQ\(^"_$VKZSX=O
M=0U[PGX5\7:%H?BGPWX<U6XN]'T/Q'HVE:YIEG:ZGIUI=0_G?\?OBGX0_9[_
M ."G=Y\=_'VHZY8_#SX3?\$=_P!JWXM?$*.PN]1U*"U\)_"7X_? ?Q9K.H:3
MX:FU"/2!J]KH%OK CDM(;&[U,FWM;V[>.&V\CZA^ '[5GQ=^*OQNO?A=XT_9
MG\=^!_!-Y\&+#XJZ#\9U\/?%S2/!&F^+H/$6F^'?%/P*\6_\+?\ @_\ "&]D
M\;VEMK6D^+O!7B;P=#XD\/>-_#T/C:#4;+P3>^"=-D\=$=5!I=:MK*RBX5<1
M3>JLDYJA.>C3;;CK)KVEOW=W>\*4MVVU.E0FM'[S4/;4XNZZ)I)*2I_5_AOX
M5?"_P;XI\8>./"'PW\!>%?&OQ#N;6\\?^,/#?@_P]H?BGQS=V2R+977C#Q!I
M>G6NK>)KFT665;6?6KN]EMUED$3('8'S"^_8]_9)U/X/Z=^SUJ7[+?[.>H_
M+2-;E\2Z5\#[[X(_#.[^#^F>(YM6U#7YO$&G_#2?PQ)X+LM;FUW5M5UJ75;;
M1(KZ35M3U#46G-Y>W,TGS!^WG^WGXP_8LT/XH^-5^#7A_P 4^ _A!^SGKW[1
M%[K7B?XK6GA'6OBW)X.U;66\=_![X+>"M!\,>._&FM>-/ G@'1)_B1XT\9ZW
MX>TWX<^%;/7?A[H^N:Q9:1XL\6^.?A9!^T3^WI\1O@/\2/VJ?AI;? #PIXPU
MOX-_L7']LS]G^"?XV:_X;O\ ]I[1_"^OZWX6^+_PTMK%/@5XA@^'GC7X;^(H
M? .E6XL-2^)EOXFG^-GPB1X] FU_6X/#<N<4G=KW8MM=HTXSK*Z[)4ZE2$5>
M7-!N--3<>=J+<DDFW*2L]=7.4*3=^BO4A"<W:*4TIU.7FY?NQ?@]\)%\:Z#\
M25^%OPY7XB>%?#Y\)>&/'R^"/#(\:>'/"IBD@/AG0?%(TS^W='\/F"66$Z-I
M]_;:<8I)(_LVQV4^4^/?@3XFTCP_JD'[(NM_!7]EWQMXU^(]GXU^*GC5_P!G
M32?B"?'UC/9ZE;>)I;O1?#WCOX1K)\2=4EN=-O-)^)'BK4O&D&E3::\.K^#?
M%-I?26\/A6B_MO>-_B%\'=3^-'P.^ ^E_&_0A^Q-\*?VI?".D^$?C!!H>I>/
M?B+\:M%UWQ-X$^#&AZGX[^'GA7PII?A^/PSHD7B3Q9\3?%GB+P_XE\-Z#XD\
M)W__  IG4CKD44/SKXN_X*N:_P"$_A?^U_XRT?X*^#?BQKG[)GQD_93\ [_
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M2Z+*\M_-/SOPM_:I_:3^,WQJ_:>^&OAS]FSX.VGP^_9A^.GC;X"^+_'7B/\
M::\4VFN>*M6'[-/P:_: ^%FJ^&/ VF_LSZS;-:^)Y/C/H/A+XGVFM^+-)_X5
MO:!O$/A"[^,5Q%>^'+;Y4\$?MWW?PA_X)\_L??%_X'_LJ>"? 7P9\3_\$\YO
MVC/!_@GQ+\<'T_PMX1N? ?PD\ ^//AW^QQ\/KW3_  1XH^)_Q#^(7BOP'?\
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MX5^'>K^)_!\7C:]UO2_"4/@_Q2_X**_'#7?A'XUU;X-^%?A7:^-OA%_P5/\
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ME?Z=X'@U+1;F+PG8WMGH^D6EW::"FGV]S;:5IL$T;PV-LD7Y[_\ !8=K6Q^
M'[/VN.=9@F@_X*"?\$^O#-]<^&V\0#7;_P $_$']KSX0^"OB/X/6V\*'^WM?
MT/QYX*UC5_#'B/P=:P:A!XKT^]_LR;2=0F-K$ORY#\<_VD/V)KC_ (*8?M1:
M!\(_BEXP_8GT[QQ^Q_:?LJ_ OXV>--?^%NKQ^+/%.H6?PM_:>\0_!30?B5X>
MU[QW\*OA-_PD/BGX<W7@KX4^-M&\!> -<\6^'/'&K?#Z+X?>%/$LGBGQ%,)\
MTI12<>2I&%U\/,Z="I3U37)S2Q2IP:4FJCFTHQE.<2;45=ZWI^T??DYZ\*EM
M[\D,*ZD[N*=-15Y24(2_H(HK\]M,_:G_ &A;_P"*L/[,-W\&/@79_M267P9\
M6_M#^+/#FF_M!^/=<^#GA?X9O\3=0^'?P1LI_B3=_LX>&O&NH>)/C-J.@>*[
M749K#X12Z;\,;;P?XFU^\B\8SQ^&/"/B[E/@G_P47T_]J#PS^S':_ [X>K8?
M%?\ :.^$_P"T-\5]0\%_%;Q$^A:5\'K+]E/XC>"_@/\ '3PQXLUCPMHWBB[\
M1>+/#G[0WQ#\,_#31K70].M="\0Z-8^-_'EKXBAB\,:7X:\65?1.VC2:U2<D
MW4C>,6U*24Z56#:5HU(2@W?E<GK=JSTNF[-QBTH.SDDXIN%2%2*;O*G-3BFN
M90_32BORM\6_\% _C1HV@P>#[+]D+Q5I_P"UIX>_97\"?M)?%']FJ_UCQO\
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M^.GQXM?V?OB-\)/#?PZ\;:E^RUX9_:6N+?P?\3A\3H?AYKTGQ"O_ (8?%/\
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M)=(N5\.:]%XRR_CO^P#XH^*WA_\ 9/\ $_P]_:=\:_ ']J3]CO1-:\*_#/\
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M_P!C']CSXM_LM6-OX?\ B3^VS\<OVKO"'@?PE:_#+X'^'_BIX9^%?AB7X?\
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MX?U_7K_3/B9X+\1:C\.]!A^)O@KQ2EM:^*-.GU:QTO4/#<=W ;/[,\2?M2?
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M64$=MXQ,_B7PU!X,^"W@"]N=/N+C1]3N_$?_  E5\FMVNGZYIFD^'/B#2O\
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M-'?>&-:B\6=Y>?\ !/7P\==^#?B_2/B%-IOC/P%^VYXM_;Z^)'B&?PC!>O\
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MU\)^)OBI/;3ZQH&DVMQJ.OPW6DZ4+;[+HM]=!=:2TN+J'4;_ %%IA(GPS;_
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MES-JT7%R5N6<>1R3TG%Q=-WDM).4*GLY2;<I0DH2;5K<!XT_8';XO?%OP?\
M%/XS_%L^)=9^$^J_M,3_  8\;^!OA[I_PS^/G@SPM^TKX9^)?@2_^&FL_&JQ
M\2:Y_P )!\._ASX,^)\]MX'T+1/ _@NZF\6_#SX1_$#Q9J?B3Q/X)GN=>\7^
M#?\ P36^)G[.\?@7QKX1_:R\7>(?B)\&?^"?6N_L*_#O^R_@;\&])TFWT'PO
M+I-[\"_&.C^$;^_L-%/B?P/+H-C/XC\/^(/%EOX.^(?B9;*X6\^&7@J*^\*W
M'UYX#_;[_8V^)^O^*_#7P^_:&^'OBW4/ WACXB>,?&-UHU]>7/A[PUX?^$_Q
M!?X6_$.ZUGQ=]A7PI8W7ACQNL.F7FD3ZTNL3V-_I/B.PL+OPSK.DZQ>^O?"K
MX^?"?XTWWCS1_AYXI?4?$OPN\067A?XD^"M>\/>*/ OQ \ ZUJNCVGB/0K;Q
MA\/O'FB^&O&WAVW\3>'+^R\1^$]2U;0;73/%GAV[M]=\-WFJ:3-'>-*2:YH/
M>#DI)MKEFJBYUJU[RK5/?5KJ=[V:FZ;TY6]%)+E;M[T)0:BUHWRRHQ]V5[.#
MBEO!3_#;PYXWU3X'>"?"?[0<WA[QC\0M2^&.A>'_ (RS:9ID%CX9\3>*+WPS
M;Z=X[-MI,$DUI;Z5J^H2ZFIL[5_L0@N&CM(XK4Q0I\>_L3?L&>/?V.K;1_ =
M]^V;\<OCK^SY\)]#7P=^S)\#OB!X>^&&CVOP=\$P62:1HFB^*OB/X2\*:7\1
MOC3<>!_#2R^#_AZ?&&NV/AKP]X8O)$U+PEXA\1Z-X*\2^$OT<HJOM2GHG)6D
MELTFVM+6O%RFXOE3CSSY>53:2M[L8N[47=7U=[)/7?51BI*[3Y(7NX*3^-/@
M[^PS\$?@UXA_;$U?1]-O-:TG]M'XCZQX\^(WA+6[N\NO#NCZ9XI\*I9>-/ O
MARQ>\DBL/#'C'XD^(_C+\:-?BMH[6>\^('QR\?73N;:6QC@^/_!'_!*GX@>&
MOV8OC)^QWXK_ &]_CS\5OV??%7[/?Q!_9:^!?@SQWX&^$T5[\"_A!\1?!-U\
M-;F36O%GA'P[X7\6?&_Q_P""?A_?W_A;X;>(?'>M6WA3P]:W*WFM> /%.I66
MG7=G^Q=%*V^^L(TW=MWA!24$[MWY%.:A)WE%3FE*TFD_/M-U%HDU.3BY2323
M7,X0E)*T92A"3C>*;^+? ?[)&I^$/VF/"?[2.H_%&/7+_P ,_LG:%^RE-X/M
MO T6CZ7J.CZ+XOMO'#>-TU-_%&JZA8Z]>:Y;^0VF[;K2(-'86B0M?J=6;[2H
MHJFVVVW=MSDWIO4J3K3>B7Q5*DYOSD[65DIC",$E%**48127:G3ITH+_ +=I
MTJ<%UM"-VW=LHHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.G@#]HSXJ_!_XM?L"^!_CSX!U_\ ;?\ &W[6_P "OVV_$'C/X0:E\/\ X?\
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M^T=J_P $?@-X<^)NOWG@#_A#O#?B;XB?\$T?V;O 5AXS^)E[J>OZ=XKMM/\
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M@\+^(=.L-:T#5H;O2M4L[:]M9X4*:]G"G".L::CRMW;TJ9;._1.\\JP\9)?
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M6****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKO\ P3R\(?M ?"7X!:)\7=1UV;Q_X;^'/CK]M672_ANFJ_VSX3T*\L[CQ/\
M!C3=$\"^"_%-E\._#O,?\-"Z)^S+I_[<=QX*^.-CX7^!]]_P7F^'?P[_ &BO
MCGXE\9^*_B;8_!;X.?$3]A+]F;3_  [KOQ!\<:3\4?"'C'PQ\,D_:2T7X:_
M[6_$NH?$[PWI_@OP;=ZUX8U#5XM'\/:EI:_TJW_P+^"6JZ#XV\*ZG\'?A7J7
MACXEVNC6/Q'\.7_P]\)7F@^/[+P[H>E^&/#]GXVT>XTB33_%5KH7AK0]$\/:
M-;Z[;W\6EZ'H^EZ39)!8:?:6\.Q9_"SX8Z=X7USP1I_PY\!V/@OQ/8G3/$OA
M"S\(>'[;POXATT^'K#PD=.US0(-/32=6L3X4TK2_#)M+^TN+?_A'M-L-%\O^
MS;.WMHY491:=W/E224]%-+ZG[D^5N2BOJLE=2G)JO)R4W&7MK;4N;W5!2O\
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MZ)X*\"?$Z[_97TOXO:!KGB_XB_"GPIXM\*V?C?Q=X"3P?8:_X0A/A]O#^I^
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MJ/AW3?T7_P""C+:_+\3?^"9/AW1OB-\5/A]I7Q._;VNOA/\ $.'X8_%+QO\
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M\;>*[[P+^SEJ?Q%^(J>)=-\86?BF630_^$CL_%5GJT<>M1?D3^V)%\.?%?\
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M:_X*0:#X>^+GQ-T[X._ /_@J9^R3\-];^)_Q2^(OQA^/?BSX ?LM?'7X,?\
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MI7P'^U;^R+X9^.%W::G'\18;GQ+HOQF\!?&;]GV:YU/Q7\(/!/[-GC;0;,?
M;QSH%I\+=9\"MJ_@S3K#QOJ\?QQO].^(?R3^R+KD/@7]@7_@AD/AO\5_'VAW
M?BC]O7P1X#^)F@:%\=/B)<Z5KND:Q\/OVIVU;X:^,?"TWC:]TF;PT=6^'GAW
M65^'E_IL6B:=XH\/W&M6FBVFLW.MW%Y_3KH_PV^'7A[QCXK^(F@> ?!6A_$#
MQW!I-MXX\<Z/X5T+3/&/C*VT"W-IH5OXK\365A!K7B&#1;4FVTF+5[V\CTZW
M)ALUAC^6N>@^!'P/MHXHK;X-?"FWB@\:ZS\2H(X?AYX0BCA^(OB.^34_$/CZ
M)(]'58_&NNZE''J&L^*E UW5+Y$N[V_GG59!5.7(X2MLL/SQC;EYJ->G5GR*
M3D^2JH2NIN4E*I+>+DYJ<7+FU_Z"E%RWY<10J4H.3CRKGHN<>5P44XTX[245
M#\'OB3\8?CGK_P"SE^V5\?\ PIXW^(UA^V]^S;_P5'O?@S\-/AM_PF7CW0?"
M4OAJ/]JCX8_"W]G[X#ZI\((=?L_!^O\ P[_:?_94\>?#KQ'J$VM^']0A\0^)
MOB[!\=- O=,\7>'O _B#PGR?QZU;QOX:T[_@HA\:M-^/'[15EXF_9C_X+.?L
M->#O@I8G]I/XU1> ?!?@WXP:9_P2GM_BOX!O? :>/8?!WC+X>^-[;XY?%/2;
MCX;_ !"TOQ5X$\*Q>,=<D\ >&_"&K:KJU]??T5W'PQ^&UWX\L_BI=?#WP/<_
M$[3])30;#XC7'A/0)O'ECH<:ZHJ:-9^+Y-/;Q#;:2BZYK2IIT&HI9J-7U0+"
M!J%V)L*^^!7P1U./78=2^#GPJU"+Q1K,'B/Q-%??#SPC=Q^(O$-LUZ]MKVNQ
MW&D2+J^LV[ZEJ+P:IJ N+Z)M0O6CG4W4YDB-U.E.R2I\CE&.S<*>#I2<>;F2
M]K]5J5JG,I?O<14M[KDYN:<H3@I-.7M4IO>TWBY03Y7'^"\3"%/DY;PH0O9J
M*AV>E^+O"FM:YXF\,:/XG\/:MXE\%S:5;^,?#VF:UIM_KGA.?7M.36-"@\2Z
M3:W,NH:#-K.CRQ:KI,>J6]J^HZ;+'?68FM764]%7,Z/X+\'>'M:\2>)- \)^
M&=#\1>,6T9_%VO:/H.E:9K7BE_#FEQZ)X>?Q)JEE:P7VN-H6BQ1:1HS:G/='
M2]+BCT^Q\BT18ATU5T6^VM[;ZWM;IM:^N_D5_GIZ:;^=[[:6MYA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7YN?%KX^_M.P?\% ?A_\ LA_"KQ#\"/#7@_X@?L<_&?\
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M]&UG1]%U+XHZ/;MK6L> O#2ZY_9WB&;P3H7BOXJV>A7_ ,+O!OC?XA6^CR^
M_AYXV^)5OXK\'#X?^#/'GB/PYXH\9W/C;P-9>&])U.]\:^%K?5_EWX[? 7Q=
MI_[5G_!+>]^"'P$V_ ;]F;Q'\>++Q9<?#^7X0^"O ?P/\%^)OV;/$OPA^'>G
MZ;X(U;QIX/UUM%MM0UBPTC3]$^%W@SQ&FAZ#;W"M96-K%;VUQ\@?%7]C7]H;
MQ-\$_P#@K%^QE>?#[5/&EM^W?\;O&_Q/^!G[0TNJ>#7\#^%_#OQ\\%_"[P?>
M3?$*VO?&$'CO1?%O[(OB'P;<:QI.GVWAR>/QK\/-$^%L'PKU'6?$]IXP\-^
M;NW=I.4KSLE:DI*G5P5-JSYH4W6A7Q&(B^:5.$:$J<74C&3)2:=F^6-H>\[U
M+*I3Q=1-VY9S5&5*AAY^[&I-U54DH2E%/]</BO\ M2_ #X':K#I/Q7^)NB>"
MIA-X(AUB_P!3MM7F\/>"E^)WBJ7P-\,[[XF^*]/TV\\,?"G2/B/XVMKSP?\
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M\0>#_%WAG3=-OM=\4:)XMTK1+WPUX:@/B?78M/\ #SQZF]KP]_P4(_8I\4?
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M\<:_XS\+WMMK/A+7].CD\8:!X2U0V3:-JVBM<X(L.I_X)C^$?C%'\"H?B?\
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ML?$O@[Q-X&\8Z/XML-3L;)O#-UX:UDZXUA%8SR)X%^W'X&^+S_&[_@GO\?\
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M.O+W0]!TZ_UC4-*ENH-5ATVRNKPV?V>"61/F/]FW]MJZUCP?^T%X@_:;\3>
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M.GX45184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%?S>?\%3/VD9O!WB_]M#4?A=^T#\1_!WQ1_9A^'/[
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M?+K*-/W3Q/\ M:^!=!^*LWPFT/P7\6?B;JWA[XA_#3X7?%/7_A1X'?QUX?\
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M6]7ET:!/!L'A'Q]J_C3P_P"$;N'Q&-0:WNM1UC7OAUXXTO\ X1Z"%_$.G?\
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ME35/VCO 'Q$^'OPU^(GCKP#^P%\=?V]_@EXG\+W?BCX=^ /&FD_LXW6CZ/\
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M6)+S2I["&*TEM&MXTC7\H/C9_P %&OVB_ACK7[;.N:;\(/@Q<?##]A;]J?\
M9Q^$?CG[;XY\:W_CKXD_##XY> /V:O&>H:MX5BB\,:)H7A3QWX<TS]HA-?B3
M5I?$.@7-QX3/@2."Y.M_\+"TG>_:W_X*,_%OX'^)OVQM/^&_PO\ !>N7'[&'
MA3]E_P 4#X8^/KGQ+I7Q"_:R/[3/B.]\.:59? K5=&DF@\.V]CKML?AS\/\
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M&J6&I6-G?6MU%=6L$J?BE\>/B)\;_P!F_P#;8_X*#_'CX3^!_@;KWQ+^&_\
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M8TE'P[\)_P!M[6/B;^V!XZ_9ENM3^&'@'QC\.O&_CC3?$W[/'Q#TOQ5X,_:
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M\<_!CX:_L^?'#X7^-?!\WC7QMX3NO 7[1>H_'GPUI'A3QUX=UB;P-K.J^+/
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MZ+QS>>'_ (B_![XO? 'X8Z)IMS+9^,O \NI?#/6['XQ76M>+-!^VZ7XOFO\
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M_MEMXS\2_$#5_A3^W-\./!?@3XS? 9'\"V'P]L]9\"> M(^&/A_XD^"-;LO
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M OQ<^,_QI^!]CXQT[X>+J7PX\1?'+PA\1/AYXF\(6/C/P]X*T+Q9JOPI\-^
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M2$8Z6TOUE.4TXIV;5VFFF][J4I)WZM2E)IN]KVV45'\M/C)\*OBUXP_X*D?
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M/:=H?PK\!_#3X>^&/"V@I+J-UIVD>'O!MA-=:OK?B#Q'XCU'Q!XHU_6M<O\
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M._B!XJ\/>,/&_B/QOH?ASX5>'=1D\:>)M5\,:;;7T/AK6_#?P\AT9KO3-/\
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MM3_M=SVGQ>\)>+_V4?VL_@G#\(;GPSX9\9S_  3F\47_ (K\+?M2:/X@\/\
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M]&I1>N_PU:D]U>I.<W\<HGX&?M(_L@_M5?$GP5_P5XT+PQ\(/M.J_M=_&O\
M90\;_ X'XB?#RVT[7-'^$?PH_9C^'_CFZU2[OO$=E=>&_(UKX*>*+_1EU73[
M>^U;0M1\,W,ECI^JW>JZ+HGZ8_M\?!OQO^TK^P9^V)\!/A[:6D'Q&^.7[*_Q
MT^&'@C3?$%_::?8KXT^('PM\2>'/#FFZUJD$MY8Z?;/KFIV=IJ&I137EG9QO
M+>(]U#$#)]A45$XJ<)P>BG&$7RW5O9TYTXVNVMIMO>[2V5TZBE":FMTYO5W3
M]I4A5E?;>4-&K-)M=K?DKJ/PR_:1\<?M:S?M&:K^S[KGA'PWXC_X)I^-/@9=
M>&KCXC_"36O$GA_XQ>(OBE!X\TKP+J?]G>,UT6ZF@T&TCL=7\2Z1JNH>$;/Q
M+<-8:=KNKZ'%_P )-)\@W?[(?[>(_94_9+_95G^$V@Z_X%\,?\$A?$O[(OC;
M2[+XM^$/!47@;]L31_A+X$^&>F>)?BYXCTVXOO$?Q+_9U\0^'= \1V/@CPIX
M('C'0;KQ9J=GX@^-/PAEO++P+XO^$?\ 1114U*:J*:E=*<*M.23=N6K+'2E:
M]]8RS"LX2>L7"D[-P;E5*3H\CIVO3G1J1;2E[U&."A!N^EFL!04E:TKU%HIV
MC^./[+_[/W[2_P ,/VG/V6OBIXO^#D5EX4N?^"7GP@_94^)\T'Q'\#7U[\%O
MBM\'O&UUXQNM/\3V=IJ$LOB^R\6:5XCGTW0=4^&A\8:5:>)?#^HV>NW^FZ!>
M:5XHN_H[]ISX/?%7QW^V'_P3G^*?@SP;)K_P_P#V>_B7^T!XK^+.NKX@\,:9
M+H.E?$?]F_X@?"+PP=.TC6-8L-4U^Z;Q1XOT^ZU&'3;9Q9:%:ZC>))<WR6FE
MWGZ 45M4G*I-5)6YE6JU]%9<]:MBJ\E:_P *GBZW*M[<J;?*KYTZ<:4'3A?E
M=*G1U=WRTZ.&H)W_ )G3PE!2>S:DTDY,_"+X5_LE?M->&OAO^P#X;UOX0WUK
MK'P$_P""K?[8O[7/Q.C'C?X8W,&C_!OX\Z__ ,%!M2\%W^GW-MXUG&M>(+>V
M_:^^'PUS0;!&N+.3PO\ $%+>:[6Q\*MXP\V\'_L@_MR^"?A;\!OV1[CX*^'?
M&7A[]F#_ (*=Z#^T]HW[35Q\:_!^F^&?C%^SYKW[2_Q*_: N]<OO",VGW/Q,
MT'XZ>%+3XD3^'?B/X/U7PI+X5UK6]);Q+X*^)_C!==GL-*_HFHJ(+DC2@M8T
ME24>:[;]C/"U*7,U:[C/"P=TH\RG4C).,H\M5%[1U7)M.JI*5K*RG'$0DHZ.
MR<<1-:WLXTY)IQ?-^3Z_L2ZM\<E_X*_?";X[^$;_ ,+_  H_;J^*N@:K\//%
M,.J>$-9U6'PYIW[%W[.'[.D'CC2K#2]<U2]\.^-/!OQ.^!^H_$3P8=8M;&>T
M@/@;61):ZZNK:1H7.>)?V6_VJ?%__!(_]J7X-?%*W\*_$#]O;]K_ /9:^+7A
MWXPW'@[4-*\.^!M5_:"^*W[/]M\"-"6UO=:U*QT/2_"W@/PKHW@'PWKNK:>Z
M+J]GX.U;Q/I>D:GK6LK87W[!T4G%.#I])4Z5-M?%RT5)1:>J4G&3C-I7E%1C
MHHI,C%1::O[M2K42;=KUG&4T]KQ4HJ44W[LFVKMW/P'^.7[+W[:5GJW_  4P
MT+X<?!:U^+/@7_@I?^QMI7ACPKJ&H?%'X>^"M=_9F^/7@W]E36OV?;[X:_$R
MQUK7;RV\1?#CQU:Q^'O$?@WQ9\*[OQ?_ &-\2K_Q?I'BW1-)\'ZS#\2+#W#4
MO@'^U%X,_: _9S^+7A_X-Z)X[L[[_@G+XF_8]^).GZ7\5/#&CV7P@^* \2_#
M7QOH7B'Q#JWB2UTC4_%?PUU1-"\4^&[O6?A]X9\4>+].U^TT&0^!+CP_K6H:
M[H'[$44ZB=524_MJ<7;3W9PQ]-P79*&98F*=N;^&W+FA>937LI0E#>FH*-]=
M83P%12>UVYY=AI-?#I422C.T/YLM7_8P_P""@ES^QQ^SQ^R+J/PF\)ZYX2TC
M_@BYKG['VK:;X>^-/ACPOI7@/]LO2/@_I?PPL]9^-FO"QM/$OQ-^#FO^$+,V
M?P\\+^"H?&_@?2/BA+JFI?%#P3?VL7P\^+WPV^^_@]\$?CQIW[47["OQ9\6_
M"J[\,^%OA/\ \$VOB_\ LZ?$R7_A-/ 6MS>#_BM\3/'/['GC'1= G@TWQ$UW
MKEOI&F_LY^+--\2ZWX8M=:T6WU_7/#-OH=_X@T675]?TG]4J*)+FDY.VM5UK
M*_Q7Q32;W:7UNJE=WLJ:NE'WJ3:Z_P#+MT[V7PR^K\SVM=O"TWV3<VE[WN_
M'[1GP=^*GC?]MO\ X)Z_%SPCX.?6OAQ\!-7_ &E[[XJ>(AK_ (9TZ308?BI\
M&9/A_P"$A8Z+JFKV>LZ\[:[)YNJ+IEG*+#35-S&;NX(LZ^)O"W[*/[3=EX!_
M8ST*]^#M_;ZI\'O^"P?[6/[9GQ @G\=?"^1='^!OQP^*/[='CCPCJ=A/:>-;
MN+5_$MMIG[4_@6VUOPU9,+BUOO#WCM;:YO8+'PU/XL_=BBE&/+*,TDW"4I*]
M[>_B*.)=[6_Y>4*:6J]RZU;N3-*HFI;."AII[JHU:'W\E:;O_,HO9-/X2_;;
M\,_M'>(+[]ERX^!_A"[\>>!/#O[0\6L?M&^$_"'CCP_\+OBS??"V]^%'Q/\
M"^B:C\.OB7X@UGPU-X1MO#?Q.\1^!_$?Q('@OQ1X:^(7BKX::7XF\#Z#?ZOH
M_B7Q-X+\6?G3\'_V,_VJO G[/O\ P3]^%NL?!/1M.UW]F'_@JC\?_P!HGQ[8
M>%/B5X#U+PQ:? GQA\0?VU-3\+>)O!E]?W7ABYU6"[TK]HSP3<Z+X8N]!T#Q
M1'HND:X=?T#PMK=O8^';S^@.BG"\'=._O1DN;IR585HQTM[JG#1-MJ,YQ3LT
MTW=KEV7+..B6O/2JT9/6^KA5:NK*\8-I\MG\+_LM_"OXF> ?VD/^"BOCGQKX
M-N?#_A#]H+]I/X:?%+X5:U+KGA74CK_A;PC^R!^S;^SUJSWFFZ)KFIZGH=ZW
MC#X)>(M8L+75K6V>X\+:UX<NI_LFL2ZOH>D?.FD_#[]O#X$?ME_M467PK^#?
MPJ^+G[-O[;'Q7^'WQYL_CGXJ^+4/A'7/V6_'6A? 'X+?L\_$+3/'?POO/#^N
MZ]\:-).@_ KPGXX^#^C> I_#D-]KLMS\/_''BSP#HM['\1?#_P"N=%-MN5.3
M46Z=/V:36DH6BK2ZIMP@VXN,O=LFE.:<J*49Q3:4YNI=/6,G)RO'HTKR2C)2
MC9JZ;C%K\"OB=^S9^W;\0_VA_#GC+Q9\&]&\6V/P;_X*K> /C_X#\9:7\8_!
MOAOP!J'['R_"?QAX \,IX*^&(-O>V'Q6^'VH^-M2U+]HOQ)X]T2V^(GC&2#R
M?ACXQ^*_@F+P1\-/AMT6J_L&_&/QW\6_V@](^&^D_%+]D+X+?M2^$?VV?A_^
MU?X/O/BIX4^*/P"^)6O_ !=L_''A3X6?M3?LY?#6S\<Z]XE^#?Q^\:7OB33?
MBI\7TL-$^$/AGQ$MSXFTCQK8^,OB"-/\>:A^Z=%1R)P=-ZQ<*E.2VYHU:*H3
MYK:/F@DW=-.HHU%RSC&2N[YU46DE*$HZ*T73KNO!K2Z<9MI-23Y)2IOFC)I_
M@+\&?V:/C[XC^ 'C'X7_ +5?_!)[]C.VUC0?@SI?[/OQ/U?X/?$7X9+K_P"V
M%I&K>)_A[I7Q"\3_  :U?3O!'PNU?X+^"M4\,^'-9^+>C:)\3?&O@_QM9_%7
M1_AOH^GW.@/X;7XC6_V?^R?X-_:N_9R\ ^(/"'B+2_C-\?O ^O\ [5.D:;\%
MM,^/OQD^&GBC]HCX"_LJ>)? _@2+Q9J?QI^*MOJFK6/QAD^'7Q@M/BMJ?@33
M%\;?%#XMZK\&];^'&E^)/'FM^+=/U?1?#GZ5T5HY2E.<Y6E*HTYNUE*7/*I*
M7*K13G*<_AC'D4YQI<L9RB9J$8J*C=1C=15[\JY%3BKN\FH14?BE+G<(.IS2
MA&04444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHI"0.20!D#)('+' '/<D@#U)P.: %HJM<7EI9^
M1]KNK:U^U7,5G:_:)XH/M-W,&,-K!YK+YUS*$<Q01[I9 K;5.TXLT %%%% !
M137=(P&=U12R("[!07D=8XT!) +22,J(O5G954%B 74 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\% _@7\:O![:\T_C?X52R_!C_@I/:>%/@_\ %JU,TNH^!9O$&MZ7\.[WX>>
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M_P##5D:PQ?L@?\,.^:OG2R7'QH_X:M\C_A6S%_*@2V_X5$9?^%O[%7?<;/\
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M ,)M^SAX\_X)PO\ "+PQ\-;#XD^,?A?H_P (?@C+8:?^Q3XT\1_!SXC^(O\
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MBGJ=YH-A!XQ^(^CV?B[PAIO@+PP1X(AZ&U_;B_:ETRTFLO"UG^S/HFN^(/\
M@M9XQ_8*UR_@^#WCBTTB]^&,^@76H:/\06TW3_C+#>W/Q6@ET>TNO&&J:KJV
MHZ9XU1KW2-*M_A_]HTW7=!(W;Y6K2YZD.6VJG&OA:"B^TN;%1C-7]V6TG&-0
MJ345*3MR14&Y75K2H8FNWI=_#AI.+ZI:I.5-G[V&.,R),8T,L:21I*44R)'*
MT;2HCD;E21H8FD4$*[11E@2BX=M7<6P Q"J6  8JI8JI/4A2S$ G +-@?,<_
MC'8?MR?M-^$_V;?VP->\8Z;\./'/Q3_9*_;M\)?LK>*OBEX0^&?C/3_AWIGP
M6\6:W^S1XE\7?M->+/@]9_$/Q)XMBTG]G_X)_M":SXT^(OA[1_B,;+4H?A5J
M_B*?7_"'AF_U&Y\/_4O[&7QF^.WQ?\=_M667CC7OA]X_^!'PJ^+^@_#_ /9M
M^-?@CP1>: GQS\(WOPA^&?Q \3^*9O%%M\1/$O@KQO/X \=>-/%'P8\1>)/A
MSX5\->"M2\:?#_Q#;V<6D>(-(\5>"O"Y%J=^5II4X5;O1.-2G"K&UTKR<:BT
MLO>C4BG)PD#?+:Z>LYT[*S]Z%2I2E>SM92IRUN[1<9-)2B??%<Q:^-O!E_XL
MUGP#8^+O#%YX[\/:/I/B#7_!5KK^E7'BW0]!U^>_M=!US6/#D-V^LZ9H^M7.
MEZG;Z3J=[9P6>I3Z=?PV<\TEG<+'^(7[2/[:W[?O@@_\%1_'_P )-3_92?P#
M_P $PO$>@^/+GP%XU^%?Q2F\5?'_ .#</[)7PR_:A\=^ )_'VE_&>WTKX4?$
M#1="\7^*[#PU\2K3P5\0=$\7ZW;^$K'4/AGX"TW1=?U+QOZ'K'Q(N/"W[?/[
M=_QM\$/\/?#NKZ7_ ,$:?V/?BOX>O_CCXB'PS^&6G:KI/QB_X*3^)=!O_C5X
MT2.Z?P/X'TPV6GCX@^*G2[D\+>&;34]0"S)IJ(;4)2BYV?+&E*H]/>:]A4K4
MU&[47S^RJ1?O>ZXV?*W&34GRR4++F<X06NFM:A2DW:\O=6(I27NZJ:M>THK]
M7/!/PO\ "_PZUGQUJ7@Z*YT73/B'XEN?'&O^%+>2+_A%[?QYJV6\5^,- TXP
M^9X?U+QW<);ZSXWL--N8?#VO>+TU/Q\VC6WCWQC\0_$OC$^)OPO\,?%WPP/
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M.?SV_8;^-OB?P'^R[_P38M+KPGX<^+'[1'[37CS]M+PQX"^(^E> / <'Q?\
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M8RI4JT;N%9473=K<RK^Q<='JK0KTYM22NG97:N_T?I  ,D  DY.!U. ,GU.
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M3C.[K6HNHY/W8<[O:[DH5,?&Z2[0R^LVMTUHVI0M^Y>!D' R 0#CD X) /4
MD D=\#/05EZ]KVA^%M#UGQ/XGUG2?#GAKPYI.HZ]XA\0Z]J-GI&AZ#H>CV<V
MH:MK.LZMJ$UO8:7I.EV%O<7VHZC?7$%G96<$US<S10Q.Z_C'^UA^W5^U+\/O
MB?\ M1?#;X.:5\.=)^*?P8\6_LBZ-^S3\"O'7@#Q-XS\1_ME>#/C[>^%K/XG
M_$?PO+H_CGP/JEUI/@C5M4\?>"-,C\&21:5\(]8^!WCCXC_'/7=3^'?BW3K7
MP%^D7[4/B_QS\-/V2_C_ ./] ;P#K/Q"^'GP!^)?C.R'C'P?K&L?#37?$?@_
MP#K&NR6OB#P/9>,])URX\(ZW=Z=+:W>A0^.TOX=,O#;G7KR6)IYW4E[.C.LT
ME&,)3U][2-&I6NU!W:C&D^=1?/%VIM1J2@FZ<?:5J=%)N52<()*RNYU:5)*\
ME9.4JL5!R7*TW--PC)KW7PYK?AWQ/H&C>)_".KZ+X@\+^)],L?$GA_Q#X<O[
M'5M!\0:-KUK%JNFZ]HVK:9-<:=JVF:S9W<.I6.J6-Q<6FHVUS%>6\\T4R2-M
M5^$FF_M??MH^-]:\)?#;X2^)/V9_AK!??\$D/A)^W#I.I^(/@7XY\71:5\3M
M8OYM&UGP0=!T7XZ>"=+;X>7RZ9$-!&GMI.I^#+$WEC-'XTFO].U'PSK_ !3_
M ."EGQ0T']G[]D']H37+31OV;_A'^T[^Q]X%^-#_ +1_BKX7>,/C3^SI\(/V
MC?BMX>^'6I> /A?^TWK?@W7-&\1?!;X&3OX[FC/Q9UB#2/#^L:O'9PZM\3OA
MPOAN70OB;I-*%2=-Z.-65*S:NFJV,H)N2486]K@JU/F3BI5.105JU)/&G452
M$9K7FI1J^ZGM*CA*[M%WG_#QM&;5I.,>?F=Z51G[,V7C+P->^-/$/@'3O%7A
M.[^(GAWP_P"&?%/BOP79:YH]QXTT+PMXLO?$FF>#?$?B'PY!=/KFE^'_ !+J
M'A'Q?I_AG5]2LX-.UF]\,>)+32KBYGT75([9Z>-_!<GC&;X=Q^+O#$GQ M_#
MR>+KCP,FOZ2WC&#PI)?KI2>)IO#"W9UN+P\^J.FFIK3V*Z:U^RV8N3<,(S^4
M/[27[>7B;]E+XI?\%(/$_B3PG\-/%GAK]G+]CK]BCXN_"8:1X?U'PCXR\5>,
M/VA/BK^US\)O#?P_^+?Q'FU_Q-#J7@2P^(_PX\/:CINOZ-X5T9? ?A[QYXVO
MU\/>)=022;4O#?BA\3O&/[)'_!0#]JW]I3XO7?A;XOS? O\ X(F^(OCCJG_"
M"^#9_A;J_BJ#X0_&3XF^/?$W@\1W_B;Q_!::1/?:3>VGP[GN[[5-4\.:)JZ:
M5XHO_&>L:7=^+_$><9J2B[-1O64G9I\U.EC*JC&.LG)K"NZ:ZMI\THQ52=KI
M<KEST(KWE;EJU<)2YG*]N5/%1:DM+K5<L92?[\45^*_QM_:G_P""AOP9^ _[
M8?QZ'@+X5_\ "M_A+^P'\3OVGOAC\0/B)HO@Z;S/C]\(/#E[XSUGX=VWP_\
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M9YIXO_X)O?L^>,M!_:?\,7FK?%_2= _:K^+'@KX]>,-)\/?%#7=+LO ?QP\
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M,.H7D.KZ_>Z7IFLV/@RZN_"MQZQX,_;6^$GCZQ^(-SX;T7XE7%[\+?VF[/\
M9#\<>'KKP9-8>)M(^-MU/X4272H-#N[Z*^UGPO8:;XX\*^+;SQYHD>H^#6^'
MFJGXF6.M7OP]TS6?$^G?-/Q/_;^\)_!'X0_MG?&/PK??&G]H6\^"?[8'@#]F
MO5? 7B3P'X;^'D?PC^)7Q-T3]FSPQH7@WPPNI>&?A9K_ (L^#FEZM\:_!_Q
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ML?&W[/VIWVFVNG>/?!/B;1M(7PCXIL;RUU*/54CT?Q!<R16G]G65SY&O>*_
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M?P/XW^,WP6\.^([#P7X^\0>&M)T+1],2+5++^P?$5GIMK%XST3Q+M8MTFO\
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M246FXKV=./,O<C)3:TE4O>*E-.5[Q]Z2FTFDU)RKU')64G[2H^5KF:V/AO\
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M"U\&^'H?&>J?K[\)OASI?PC^&O@CX:Z/>WVK6G@WPYINB2Z]JWD-KGBC4[>
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M/P]\*?#>']N;_@DG\%?V6OA]X)\?^.-4TSQA\-?C)::9^U[XEU;3?B[I6G^
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MOB+Q5:ZCI?C#PMIL7A)M837$TGOOBI^Q#\=/B3X<_P""H?[/%[I_@2W^%?\
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MA^#M7T_P9H][_P $P/VB/&/PA_9ET/PS<:YXN\)ZY\2Q/^W]XB^'7@*2QO\
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M/#?[1@USPI?>%/@/\'Y/'WP_U3QQ^QY'\6/A]KL5SI/PR_9>UKXH^/M8\?\
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MLM*_9.U7XH^)O#OPS^$/@S5_A]H_@3Q'X9O_  ;X5\ 6WB7X2>,/AU-XF_I
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M;;;;;;;;;;;&DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDBBBBD,**** "BBB@
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MM?%]RGC'0WTCQ9INC:UIO#7'_!/W]G ^#=)^%>FZ3XST/X)67P8^&_[/.L_
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M^#]D_P"*O[-/[1VE0Q:'X[^&>L>!KW1K#]I32M:\9Z]\1/"_Q$^()O[[P?\
M S0O"0\(ZG]57G_!.G]ENY_:;UW]K*U\/?$'0?B;XQUCP;XJ^(OA[PK\:OB_
MX4^"_P 5O'GPWBTJ#X;?$7XK_ CP[XUTWX2?$?QS\/XM%TU_"FN>+O"&K-IV
MHV6G:^\%QXCT;0]7TS>F_89^"&I6UY8^)KSXG^,+"'P-\;?ASX(C\3?%#Q=>
M:E\)O"G[1:QQ_%^S^%_BNUO['QKX;O==M;:QT?PGK,_B34]8^#OA6QC\#_!&
M^^&_@>[U3PYJ$V;BDVTW2DI.+2E&I[-PYZ<G'E]ZHH54JE.48J4X/EE"$I4[
MJ;:LXJ<914K\KBJL9\DXI\S2IN=*3A4C*7+"2YHSGR?EQ\0?^"BOQ3B_8/\
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M&MW<>'?B3HUAX;\*BU\9Z#]@U2W'A3P[:6S0:7ID=@S/B'_P3'_90^*'Q/\
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M9XV_:TNO^""/QZ^*/A#P[X)^*GB+]KO]K/PI\2M#\)2:A<>#X/B#\+OV%/\
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MK=JG4U>59PM&,HU%3CK[LIU,<^9M;-1JX.44M(NA."MHY_FA_P %-_C;X_\
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MEA:+7-;OK>ZO8;GR3QW_ ,$Q/V3_ (A?!/X ? S5])^*VE:+^RE>V]Y^S/\
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M5:C)\0_V+[SX/^'/']];^"OVYO&'[7/[1OQ=TCQ]X6\/?$75O%/B#]D#X_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS?-'WM[QI)<T4VN:I&]I1Y44444#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ex-19_008.jpg
<TEXT>
begin 644 ex-19_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2* X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.[]PHZ)]&FT^C2E*#:])0E'UBUT#JUU5KKJKQC)??&49+NFGU"BBB@ HHHH
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M%_:$^&W[27A?Q3XQ^%UUK]UH?@[XJ_%+X,ZT_B7POKO@[4X/'?P;\9ZK\/\
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MXNG^(?#.OZSX>U6V29#<6&ISK$\-R+>XB\QOO!/A^\_X+A:?JTVJ>,4U1?\
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MG%I-WM%S2EJU5C^[E""A1E#\5/B]^T7\7?@SHW_!3*]7XH>/(_ _AG_@K?\
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M6I.T4H-4(<J345'\KOV[OV@/V[_^&+?^"H%WXQ_9ON/V2/"_P@_9)_:@\>?
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M]?QZ?R%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *_.OQ+\38+7_@I9#\+])_9[^$NI_$V/_@GU\1/B
M3X(_:"U?Q=>Z7X^U31['XZ_#SP_=_ ;6Y;3X8ZQ?>"OAG?>*KO1?&%_KVFZS
MX\FOM3MK>[3P+97.A+_;_P"BE?*6N_LOKJ?[6$/[7&G?$76-)\86'[-?BO\
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M#Q39:?XG^&4GQ)\*>-O#>B^*M%\5#QS)X6T:X\::9X4UWQ5+J7A/XCV'VO\
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M0\)=7^T'^P/:?M"_%;P]\7-3^/'Q.^'VOO\ LO\ Q=_9'^)MCX TGP!)I/Q
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M<LJ;J4>=/E;:;Y:3<?>T=6"E?5<LG&,VDG%QYZ2DHIJ?LZG*HW2H:%_P4/\
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MOX(? +Q#\>?&O[+7CGX3?#?XK?##PEX-^)<VK?%/QAXZ^''PG^,?CW2OA/\
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M3_BEX5^)'@_1]%\,>#=.\8>!?"%GK/Q-U/4/$^M>$>\_:*_:LU/X=?%GPO\
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M[)/A=_A=+\'/B+\9=.L?#>G7?C"'Q'KGPZU?XN> M)\<1>%]-O?BUX1^'OQ
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M[]\4O^">"^+_ -J'Q-^T[\)_VI_VB/V9]0^,?A/P=X&_:C^'OP>F^&,GA/\
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MIIO5?5=%%%,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OE"U_:\\!7W[9&O?L5VGAKXBO\0?"WP7\*?&C7
MO%,OP]\=IX @TCQYKOC'1O"6G6?C&'PO<>%YDNT^'?C1M1\0W^NZ5X<M]<LM
M,\$:/J/B#QM<:_H/A?ZOK\E_CQ^RY\8OB9^VI^T;>V/AOQ'I?P:_:U_X)AZ5
M^QZ?CYX3\0>!1+\#OB-X9\>_M.ZY>ZMXC\):SXT\-_$#47U30OCQH%[X O\
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MW/A/_!3?5-7T/XB?\$IM6T+PAJOCO5;'_@IQH,T'A+0K_P -:9K&KQG]AO\
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M_''A?7-6'ANV\':_I\%QXCM_5OV?/V9?VO/ 5U_P3L^''B+]G#5K'0?V+/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4H^[JM95:=)IW2:<7-W3BFI0E!I--K],Z*^1/V\OVE/$G['W[)/QJ_:5\*>
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M*]#\3_L?_LA?MG>/?"WAFX_:@^,_[&_PAM_B'\:-#U7Q(WB[XP:!XWT#PO\
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MWA;X,_%'X+S_ !0\1Z_\$OBGX.\<> _V<?COX,\60ZUXF^"\6M2:AX?\(?M
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MX+?'+XE:/>OI?@7Q)\0O"]_X]\&^&!X&\%N/!'B/4M+^(NGR:QKFDP^&==U
MJ]Y<B:<KM))_%9P3<79)I*I3DW=)1G%]TFVDKR]VVDN;1Q=I.TE=M.\)JUF^
M:+2Z-_J117YEZG^VQ\9- /P7^#OQ%^!\'PE_:P^*?PT_:&^*&M^"]/@\>_M,
M>!/!GA;]GWXF^"/AC9:_%+^S_P"%]7\8Z]HWQNOOB7\/?$G@R:]TKPM)X"\'
M:_KD_P 0?)^(?A*Q^%OC7[&_9N^)_CKXS_ KX7_%#XG_  7\5_LZ_$;QCX5L
MM3\<_!#QKJ>G:YXA^&OBM'FLM=\-3:_I4-I9^(=-MM1M;B;P]XB73=%N-?\
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M6A17&H/X7\">$? O@#PYH?A;PS-K.NWMNZ:MX@U_Q!XC\8>)?$_B76>8T_\
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M0N?^">>EZQX^L?@I<_LQ:Y^RD?$,&NZ8OQ+M_ 'B+X=7_P -=1UVQUO^P?\
MA'-.\7KI.IW>I::VG^$;7PCHVI_9[71_"-AX<LK+0+?C_P!G3]BGQ'\#OC1=
M_'7Q1^TK\0OC#XOUW]F/X*?LT>+--USP#\'/!7A?6=+^ _BSXM^*O _BC3M,
M\ ^!M$O/#=S!/\:/&D,^AZ9JG]FSO>QRW3W5M8Z18:5E?M]?MK:)^S9^S/\
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MO:>+-:N=:^+_ ( U/2=.M-,^&WBOPO\ $WYVT3_@L-\*M$^,%YXX^,GC[1O
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M_P#P20\!R>%? ^J_![XX_$;]F?\ :1^''[0/QN_:5\&?M _!#PW\/["S\/\
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M5JOPCUOX7^(M1\377B/P+X_^)MYJ'C+_ (61XTO/B+;K\5_^"=_A?XS?!_\
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MX.\/^$KW5KGP)X(^'_A-=)\0Z7=Z+K.M^+Y/%7B'Q-<ZIHNM:-X/\+<=J/\
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MPDXQ24HI148Q<I*RLHJFXZIIZ.E4Y8I:./)R_!"4/JKX9^"Y_@Y\,[+0-?\
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M%SJ-\LE>-2;;O[\VFIM)MN4\5--V<DJD[-)-%SXK?\$YOAI\?/ GQ^TSXO\
MCCQO)\6_VB[_ .!FN>(?CM\*KP_##QO\+/$/[,6N6GC/]G6^_9_+7'BRX^'-
MI\'/B2FM_$[PG;Z[J_CS4KKQGXW\=/XFUK7_  _X@70++Z _9J^"'Q"^"_A;
M4X?B]^TG\4?VJ_B?XAN;1]>^*GQ-\/\ PM\"NFDZ4ES'H7A?PO\ #SX*^!OA
MW\._#.A:4U]JE_+=KH&I^,-=U76=0F\1>+-6TVS\,Z3X=Y_X;_M5?#*_U'X:
M_"?QO\3_  OK7QH\1RZY\.;SQ)X0^'OQ)\'? _XD?'?X6:5J<?QK\#?!KQOX
MKA\0^!]6\2>%]=\'_$:>;X1:?\6?'/Q)\*Z9X \?Z?KC:G??#'Q_?:1^?WQX
M_;;_ &GOAO\  #_@JQX]\/ZW\)Y/&7['/[87P]^$7PFN[_X9Z[/H8^%'C7X%
M_L2?%"YT_7=$3XE1W6J>/]/E_:-\8V=KXTFUK_A'YM6L-)U>;X?#18W\)!)Q
MC.-.#3]K)0BXZTWRU*%%-.WNJ^+I-RY8SE2G>2:Y5)V<O>:?-#5J6E1<U.O6
ML[O56PM6R;Y54C:-GS./J,__  2PL5^(LOC+2_VI/C1I7A_3_P!OJ[_X*%>#
MO!'_  C/P=U6W\,_%;Q7X4\4>$/B/X:N?$^M_#_4/$_B;P=K>D^-?%-GX*M-
M:U"2X^'6FZC8Z392:U9>&O"R:+Y!^Q]^RGXO^+&@?M.^%/C>?B'X5^#>J?\
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M\<_#"XT+QKXCL],>Z^"/BWQ=\-[?4_'?A=?#VL^(/%K6%WHDWC'P[X'UV_\
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M\O-.TKQSI_C;PIX3\;>%O%GAE=&@\/5]S:G^U=\ ]%^(_@_X6:MX[?3O$_Q
M\;Z[\,?!&HWGA/QO!\//%7Q0\,Z7K&L:Y\+M#^+LGAH?";4?B=86/AOQ5O\
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ML\/^SWXK/QW\/?MI?#SXMWGPVC\?? LWTOP_\(?\%1M _;%U'Q#;^*C\6%\
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MR]N?%&BZGJ^AW%\E_P"$+;7%T_1C:WFMV^EW(GLK3R']B+2]6\(:C^PYXO\
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M5%:3O9_!1A=.V_[B$G>]Y.5]):?DM\6?V<?CQ\-OV@?V]?BU\ _A[_PLV?\
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M]%X:\?VWB']J'X"?$']HCX=:M=Z;X;'ARQ\'?#%_@\GBW1?%5Y;>*[G4M/\
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M%R<GV2_(/P=^R[^U)9_"_P#80T'4?V?_ !5I^L?!G_@L=^UM^UQ\2M/G\=?
MV:3PW\!_C-\4OV^_&'@OQ<+BP^+-Y8:Q>?V3^U+\/!JWAG0;O5/$MA=:3XQA
M72K@:=HS^(+W[+_[+7QQ^$OQBU_X/_%O_@G;^SU\5/#G@/\ :N^-G[2WPD_X
M**Z[JWP(\4:[JGA+XD?&'XB_'/PU&/ ^L6.F_'C1_P!K3PL?B=J7PEL/%#6V
M@_#O3DAU'XA#XI:G%9Q^#_'/[ST5G37LHTX0VIPY(WU=E&A&+NG%J498>,TX
MN+;E4A*].2C&JC=5RE-_$W)I))>]4KU)*VJ:E[><;24DE&$HVG%N7\__ .R[
M^R=^U/\ #WP7_P $7= \:? ?Q#HFH?LF?%C]J'Q'^T'(_COX+:E#X!T+XD?!
M7]I'X<>#[Y)=(^)VHOXL35M>^+/A:[>U\&)K][8:3;:M<ZG:VE[9VNG7OHG[
M''P2_;8\"?"B?_@GW\:/@'X=TGX:?"(?'OPGX)_;[M?BKX%UU?B'\,O'L'Q'
ML_A?XN^''PGTVYN/BYX'_:*M-%^)&G^'OBBGCJVT#P9$-"\>Z]X;^(GBX^*M
M(T"3].OA+^T?X,^,7Q4_:5^$'A_0O&6C^*?V6/B#X/\ AQ\0[CQ+IVC6>C:M
MK7CGX6>#?C'X?OO!MWIFOZO=:IHLW@KQYX<N+BZU2QT.ZM]0N;C3S8M+9W!3
MZ"I.G%PE3DKTZM&4)0;:4Z=6%*$6VFI*T:'NM.+?-44EK'E47R24HZ3IU(RC
M+>4*D'.3M>ZU]M%2337NTW%WYG+\5_\ @FG\!?C7\/(/A'X/_:'_ ."</[-'
M[/\ \3OV7?A6?A'??M@^"=7^"/C6[^/<FG:)HW@:3Q%\ (? V@:1\6?AYX9^
M*]CX9T_Q]\34^,%IX"U70WL]!\ V/@KX@G5;WQE\/?IG]K?X9?%SQI^UA_P3
M4^(7@'X7:_XV\#?L^_'SXT?$;XN>)-*\1?#C2(?"GASQK^R)\??@3H!32_&'
MCCPSKVOWT_C+XK>'[NXM?#FE:K]E\/V.M7TDAO8+#3-1_0^N)\+^,+_Q'XA^
M(FA7?@+QMX3M? ?B?3/#FF^)?$\'AJ'P]\2[?4/!GA?Q=+XH^'<FB^)M;U>[
M\,Z5=^))_!6IW/BO1_".J+XS\+^)[.RTB]T:ST_7=4TG*52493DY34W6E+1<
M\U.<ZDI)6A%U)UIRE"G&"<I2<())\DPBJ:DH>ZI1]FE\7)'D4(13=Y24(4U&
M,JDINT8J4WHI?BKJW[%7[2'BO]G#]H7]@?Q%X(O+;PQX[_X*$:E^TG\//VJ=
M-\9>!F\*_P#"E_B'^WEH_P"WQXAU#7-)/BJV^,.C_'WX<7,WC?X:>'K*R^&>
MJ^#]<\=Z=\,/$\?C33?"6N^+KWX>?;/[+GPP^+/@G]L;_@I)X_\ &WPWUKPO
M\//CI\6O@-XR^$/C.\\0_#_5-/\ &FC>!/V8OA9\'O$K1:-X<\8ZWXL\/7-K
MXK\"ZK/!!XK\/:$;W1KO3+R!C=27EC9_H/12BW%**>BAR:W=TJ%'#QD]7[RI
M4*:;^W+FG/FG*Z'"+=[6:G[16W3=6M7:O:[BZE>H[._*FHPY8JS_ #S_ &YO
M P_:+\+>./V5?'/[ NI_M4?"_P"(GPHOIM&^(OB;Q'^SI9?!GPK\3-<7Q9X8
MM-+\6+X\^)5A\=_A_K?A")M \7VGQ6^$'P;^(^LZ!IFLW6H>#EN/&_AVVT#4
M?'O"_P"R/\6?V9/CU^R9^T%H$'C7]JG4/AE_P3R7]@;XXRZ9K?@70/BAXVUC
MP-K?PT^(?PT^.5M%\5/''@WPI>PZWK_A/XLZ/\0=/N_B"?$,>O?$SP)J.G6V
MJZ/I/B[5--_6VBDE:]G9N7-)K1MJG6I)-+W=*=>I%OE<I+DYG[D44]=TFE%Q
M2:3M>=*HVFTVGST8223Y8OF:C>3:^&OV#?V6_%W[+G[%'P\_9\\8>*;*7XF_
M8_BKXU^(OB7P=/<W6C:/\6OV@?B9X^^-WQ(3P1?ZG9:7?ZGX=\)_$'XFZ_I?
M@W5]4TG1]0U;0](TK4M1T;2+NZGTVU_-?]FKX!_MM>%-#_X(Z_!'XF?LHWGA
MRU_X)G?$;5?AW\5?C)H/Q=^".L?#'XF?#7PS^P]^TG^R5\.?C+\']&B\?)\6
M-0T?Q3)XQ\ ^*OB!X;^(OP\^&?CSPAJVNW.DZ!X3\?:;9:CXCTS]BH/VD/!D
MW[4]_P#LC'0?&D/Q$L/@/9?M#GQ%-IFD+\/[OP1?>/I_AS%IUEK*Z\^M3>*H
M_$%K<R76EMX<CL[738X[N;5$>\T^"[^@ZGE@W"2BE&U)0BG)02PU2<*:BN:Z
MY'&=*5US34;3DVE*0Y2;DN9\Z=3GE:/-?$TX3J<WNV?/&<*D5M'F3BMXK^?3
M]EOX"?MOVW[3W["GQF^/W[-&L>#=8^$OA;_@H'\*OVA=?\.?%7X'2?!O1-9^
M,WBCX)>*_A=X[^ _PF\)?$D0^$?V<]9T#X97_A7P_::7X'TG]H*_\3)I>K?M
M"^!M7U^Z\2?&[Q!]/?L?_L^:QX%_; _:HLM&\8Z'XG_95^%GQ1\0_%C]GOP=
MITTM\/AE\>?VSO"_AGXM_M)>%+V.Y06-H/!M[J&I?%OX5ZOX<#6]MX2_;P^)
MG@E[H:?HMK8P?J]JNE:7KNEZEHFMZ;8:SHNLV%YI6KZ1JMG;ZAI>JZ7J%O):
M7^FZE87<<UI?6%]:32VMY9W44MO<V\LD,T;QNRGC_A;\)_A=\#O >@?"WX+_
M  W\"?"/X9^%(KV'PQ\/?AGX2T'P+X)\/1ZGJ=[K6IKHOA;PQ8:9HFF?VEK.
MI:CJ^HFSL86OM5U"^U&Z,MY=W$TEIM<O]RG*$7HV^?V*DY7O;E]BJE-P::JU
M*NJC923U4E?2<X2DGLE3=9Q4;-.\O;RA/F33IPA:\KV_+_\ 8*_9S^.'P-^,
M[7_ASX?_ !=_9V_9*\5_!;Q3K'BS]DSXR_%#X5?&/PI\#?VF-9\:_#N]TO3O
MV.?$_@;QU\2O%7A/X$:EH=K\8+[QY\.O$.M>#_ &BZM=?"74/A/\/] 74O''
MAKP9[Q\7OAQ\6M9_X*/_ +&?QE\/?"WQ!KWPB^%?[.G[9?PT^(/Q"L_$7PWL
M].\.>)_CYXQ_9*USP/'_ ,(]K7CG2_'.K6=O9? 7Q?\ \)!=Z'X4U%+"34_#
MB68U+[7J8TCU7XJ?M>^$/AO\1-9^%F@_#7XS?&SQKX)L/@?XC^*^B?!#PCH_
MC'4_A)X$_:%\>^-OAY\.?B!XKT74O%/ASQ!XCT"35OAK\0=7\2Z3\*=(^(WC
MKPGX1\)WOBS7O!]EH>H>'[O6?K+(]:<&X^SE'54U*$6]4TZ52G9W:=HPJ-4[
M-QC&G"$9RC3Y(S."GSQE=<[C4=M'=5:52^BM=SI1<[I.3E*4HIU'*7X)?"']
MA?\ :(C_ &;?V(OV*/B/X/O[!?V(/VTOAQ\99_VI&\3^ KSPQ\4?AA^SY\3_
M !A\5?AYXE\&Z'IOC75OBI!\2?C%H^H>$?AE\6= \;^#/".FZ#=>(OC3J%AX
MJ\7Z%IG@^?XC6/VBOV7_ -I_QW\ _P#@L5X&\)? 7Q-JOB;]J/\ :Y^$OQ3^
M EA)XY^"FGQ?$#P1X9^ G[#_ ,)M<UE;V^^*,-KX5^P^(/V</'FI_P!G>-I/
M#FKW.@7WABXM-/GU74-1TC2/WEKYD^/W[67PM_9Y\#ZSX]\1)K_C33?"_P :
M_@C\ O&6F?#F/P_KFN^"OB!^T!XS^%G@GP!;^*K'5_$7A^'2K-KSXU?#/6M7
M#7<NJV?A;Q5INO6NE7]K-&'A1]ZDUK.,X<O>=2^74X-Q7NW?U#"0Y8J$&Y5)
M-)S;IW*5HR;?+&*J3>UH0MF%2IK9NR^O8J5Y.4DHTXJ_):K^?/Q0_9N_:1/B
M3_@J_P"!M&^#<'Q.\ ?\%)OAGHFJ?#'Q/=^*_AUH_AWX4_$;5_V1/"?[('C+
MX8?M#Z=KGC.#Q6O@2R_X5_X-^)5KXJ^#WA7XN27WAWQ%\2M(7PT/$WASPO8_
M$CJ_B9_P3]\9P^,OV,;/X?:W#XK\%Z1^S1K7_!/?]M/7O%%Y-I_B#XE_LG-X
M7\*^,K/Q->16VN66H7WC2Z\7?";6O@_HUUH>IGQ-X&T[]KOXE_$#0[]+KPZU
MU'^NU8GB'Q+X?\):8^M>)]9TW0=)2\TK3CJ&JW<-E:G4==U:QT'0]/26=T66
M_P!:US4]-T;2;*/?=:EJM_9:?9Q37=U!"]?94'9Q7+%QEK&45'$484Y1;M*+
MIXRK2DK*56,HQJ2D[<R:2NU[KO*=XW3C-NA5G44KMQESX2E56O+3E"4H1BKJ
M/Y,_ ;]D3X^_"'_@GO\ '[X*^.K=/BE\;(O@C\4?V3_@I+I^I^'+/Q%XK_9T
M^"NC?$?X1_L?6'B;7-7\0:;X43Q=XN\'ZH_Q5\7ZEK&L6,VE^)?BIKVDZ]?+
M-HJV]MS7[.7[/_[1OPR^/W[#OQ"\4_ OQ4GAGX'_ /!'_6?V8?B'+8^,_@O>
MW>F_'F;Q9^S/XBM_ %C9#XHHVJR7=G\%_$]LGBBR=_!27NH>'4N?$D-K=:G=
MZ-^TU%3*//S\TI2<X*G)MMR:6'Q6'<FVY-SE'&5JDY-OFK2=1KWIQ;TY8Q22
MC"<ZD4M$G.KAZKBK6M"+PU.$(Q24*:Y8_#!K^8[X>?#7]I3X%Z+_ ,$SOAE\
M/O@#\1]5_:Z_9A_X)1VGP!_:,T;X(?'S]D#1_C#\.?#GB2Y^"_@;P?'X@T7X
M_P!YXQ^"_B'X4^+OB%^S[\3_ !A\-/'?A+4-7\:P^,/AG;Z5JUAIG@^^^('@
MSQ=^W/["(\%VG[(7P*\)?#OX2>+_ (#^#/A9X-_X4;H?P@\>Z_X5\6^*O $'
MP$U?4_@Q<:!J?C'P3XM\=^&/&B0WO@2YFT[QII?BW6?^$MTN>R\1WLUOJ6I7
MEE;=I\:/V2/V5OVC]7\,Z_\ M"?LU? 3XYZ[X*AN[;P?K7Q?^$/@#XD:OX7M
M-0FAN-1L= U+QAX?UB]TFPU*>WMYM1L+&>"SOY;>![N"9H8RONFDZ3I6@:5I
MFA:%INGZ+HFBZ?9:1H^CZ396VFZ5I.E:=;16>G:9IFG6<<-G8:?8VD,-K965
MK#%;6MM%%!!&D2(HJZ]]V2<Y.3MMK4E-=;VO-OE:^-RFGS2;E*C90CNH04(M
M_$H\JBT^[T^)->ZHQY=+G\_:_LI?M8:'\'M+U:#]G?Q1KGBSX=_\%R/BE^W3
M%\+]+^('P*A\8^.OV>/'OQS^+/BC3=>\&ZMK'Q8TOX;P>)+'PM\3M,US4O"G
MCCQYX+U('0]?TNT:ZU$:-'K'TE#^SM\?-#_;JTGX\? KP-\7_@)H_C/X^ZG/
M^V%H6N?%7X5^//V.OVEOA9:_!+4/"NC?&WPI\*9/&VM_%#X8?M+IJ'AWX-^$
MK+QIX'\#?".Z\01^#]?LOBY9>._"=QINLW7[!44+1Q>CY6FKK=JAAZ#3[Q<,
M-!RB_=<G+16IRI$HJ3F[M.I?FL[;UJ]9-+HXSQ$U&2::2C\5YQJ?F'^W%X+_
M &JO"G[0_P"R#^V%^R_\'+;]I>3X&Z!^T1\%OC!^SQ9^._ WPS\=>+/AC^TG
M)\$M:/C[X9>,/BCK_A;X;0^+?ACXQ^ ?A6YN]!\5Z_HJ^)?"/B/Q/INE:M9:
MF8!,S1_AU^T-J/[9O[$/QE\4? +3_"/A7P9^RQ^W#X#^*[_#OQ=\.KWP3\)_
M&?[1_P 6_P!DGXC_  Z\(R1:AXF\->,/&MYI>@_ 'Q/I7C_Q?X/\ 7.B7_C?
M4]+U?2K;^Q=9U"7P]^G]>"?&']H?PA\$_&_[.7@3Q3H7B_4K_P#:<^,5Y\#?
M FK>';'1;O1-%\;VGPH^)GQE3_A,I]2\0:3J&G:3>>#?A)XT:TO-&TWQ!.=3
MLK6RN;.V2^AN*<'*,H*/O/GFH)J[_?1J1E#W>6Z<IRFG.[C)64E#134A"2DY
M>ZN6$IM.UW1E"49N_-9QC%1:C:,HO6+DKGY,?LV_LK_&WX9_'KQ5\'_BW_P3
MO_9P^*G@W0/VROC/^U3\(O\ @HOXHU/X)>)M1L_"?Q8^/'Q!_:(TF'4O ^K6
M+?M!:=^U1\.+WXF:Q\,/"OBS1]'TWP#9V]I!XVB\>XTL^&O&'*_LR_ ']N"/
M]J']AGXR?'G]F76?".L_",?\%"/AQ\?_ !#X9^*WP/D^#>E7'QK\1?#?Q+\)
MO'_P%^$GA7XDB/PO^S[K&@^!I/"]A!:>!]#_ &BM1\5C3=9^/W@;Q+K]WXG^
M-NM?T& Y ([C/YU\46G[;>@Z]\;/C[^S_P"!?@5\>?B%\1OV:(_A]=?%BR\-
MVOP;T[3M,T[XK>'M5\4_#K4M$U#QM\9O"*>*(/%6B:'J]S;6N@17^J:5/8R:
M?XAT_1]1FM;2>8R5/V:37N4TE>]W"E'63L]U2<8S:5YJ,9SO.[=R7,I]/:2Z
M6T=5Z1BWK9SBY0BVU%\T8VCM^7GPO_93_:W\/?LF?\$Z?@=KG[.GB2R\6?LC
M?\%&]%\>_$:ZB^(WP-O-)UKX.^%?&'QUU=_C1X.GA^*/G7W@S7-,^)7AB71/
M#6KPZ)\8%NX/$=IK?PPT2/3=*N_$/8>-_P!AG]H?Q?\ L]_MW_L(:OX-OM3\
M)?M1?MG>-?CW\-_VH;/Q-X#A\*>#/A9\>?C[X4_: \4G7]!OO&R?%RU^-'[/
M>K6WCG1/AYIFB?#W5/!OB:30_@E<VOCWP[;ZQXV/PP_;OX?^-=*^)'@/P3\0
M]#M-:L-%\>>$?#7C32+#Q)I%YX?\166E^*=&LM<T^TU_0=02._T36K:TOH8=
M5TB^CCO--ODGLKE$FA=1U]5&])J*TY'33B[:N@LOC!-IOX9Y5AI^Y)*4O:Q;
MG2J*,4TI=]%-1WO%5)YA*2LUKIF>)A[\6TE3>DZ;<_P:_:*_9B_:?\<?#_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$KIGPO%MIG[E?M1_LL^%OVB_V>/VCO@9I#>%_AGJ_P"TA\&/BS\$_$/Q,LO
M>FZ[KVCZ%\9O#&J>$_&.KP6MMJ7ABYU76'L=7N=1M/MVN+9/KL%AJ&JVNJ0V
MTEE<8'Q$_9<\/^./V4/C9^R?H>N^ /AWXG^._P %?&_P]\?^.?!GPVTW2S=W
M_P 2_!5Y\.O%/Q2F^'UGXHM;N_UR\LKB[FLKG6_%NIM_:EM:)J.J:O;V<EG.
MZCYJ%1*[KNFX\S=G5D\#BL/S2G_*ZE2A6J7=W6I^UNVY23I6C7HN6E&-:-22
M234(?7<)B)047=M^SAB*<+:>RJ>STLHR_-?]G7P)/X;_ &N?V3;_ .$OQI^-
M7Q%^&W[6?_!-CXF_%7]L>T\2?M)?%'XA>%8-4L7_ &9+']GKX]>#+B[\9W-K
M\"O%WQ!?QG\9/"_@T_"*?X>^#O$?@_PCXFE^'/AC38?@_=W6@_,_[)FI7OA3
M]E?_ ((A_%7Q/\3OB[XQ\#?MXS?LY>$/VZ_BI\3/VB?B[\2])\7^*[#]C'XR
MR?L_?"S5[/Q=X]UOPM\-_#'Q,_:>U#PAX'\;:;X#T?P>GQH\=6/@?X2?&NX\
M?1^.-6T#Q+_0Q\&/@9X2^$GPMT?X=#0_ NHW3^'-'TCX@:UH'@'2O"%A\2]8
MT_0;/P_?^)O$OA]+O6VO=0URTLD_M$ZQK.NW$JN\,M]/"%1?0I? 7@:?PSJ?
M@J?P7X3F\&ZW!?6NL^$I?#FCR>&=7MM3!&I6^IZ"]FVE7\&H!F%]%=6DL=V&
M/GK)DUK6<)U*KC%.#Q$JD'9)ND\9B\0Z7O*3C3=.O",$DG#DBI1E"*A'GHPG
M&%)SE)26'5.I&]U[1X3"T/::-)SC.A*4FG:?,W&2DW-_@SXQ^''[3GBCX!_\
M%+/#/[/WB_XH>*I/V,OVV-!^+W[ ,9^)/Q EG^)5M\)_A1^S_P#'[XT_L8W?
MB#0_$.DW_P 3O@'X@^,FJ_'G]DZ#P)XNUOQ5X3\"SZEJ'PEDL+"W^!7AKP_X
M4E_:Z^*-[\5_^"//_!1/]O?P3XY^+OPXTW]H7]G?7OC3^S=J%CX_^(OPH\6>
M!_A)X-^&6DV'P2UK2X] \4:$WAR]^+6JV6K_ !COH].M]+U/Q1X8^*GAOX>^
M._\ A);+PQ86L?[]Z/H^D>'M*TW0M!TO3M$T31[*VTW2-&TBQM=-TK2].LHD
MM[.PT[3K**"SL;*T@CC@MK6UAB@@A1(XHT10!5O/"_AK4=&M_#NH>'="OO#]
MI'90VNA7FDV%UHUM%IHC&G16^F3V[V4,=@(8A9)' JVHBC$ CV+C"4=)*-E>
M%"*;YF^:E&E"<Y/F;;K4Z,(32>EG+WI3J2GT1=I1E)7Y9U9-*R3C4E.<(6LD
ME2G4G*+Y=>;ETA&$8?S:_MX)>:AXU_X+Y:_!\8/C=HVI_LT?\$X?V:/VDO@G
M;^$_VD?C5X2TSX2_'CP_\,OV[?&/AGQ?X6T#PO\ $32M(T.:X\1_#KX?:Y+X
M26P7PAX@U+3+;4]0\-:A?:MJ-UJ"?\%'/CEX8A^.O[4GPC\=?MD?![X4>,OC
M+^P)^S\?V.O$/C?]L7PM^R*O[&GQQ\1^*/VDK.]_:#LK_7_B)X%U_P 2:9XJ
MU6'P#X@USQO\"(OB3\2;CPC\-+_X.^-O!NG> O&6A-X^_HK;X:?#%"R2> /
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MJ0DK)PE3J5IJ7*DHWM5M"R2IN[2^!0S]FFJ:?PQC4A*+7,I1G3HT[-R<I?\
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M\"_#[PQ^RUHGCSQEKOA2S^+'[8?PV^'&C:<_Q(\,_"/X0^/]9B\ ?%?XB/\
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M_L _ CXT_%/6;?\ 8^US]N'_ (+&_ #5O'/Q.^)GB#6?#WB/Q-^S3^U%\:_
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M:R2G1E2:23:3OR3TT;4KW]SE_F/UK]HR7X!^&/VFO&-S\0O#O@#X":K_ ,'
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M8U?6M3U ZE??TKZ[X8\->*(M-A\2^'M#\0PZ-K>E^)='BUS2=/U>/2?$>AW
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MDV[MMME%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;QN?$7A#XQ>'+WX8/XQ3P)XPTC4_A5X"N+SPY>W_ ,Y_"O\ X*?^/?$^O_\
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MA348]>Y[7M:^,OC'_@HC^S#\7O@SI_[+^K?M"?$O_@CW^TAJS>.E\1Z]XE^
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MB^:#=-MJ/(Z:E=J-F](<EV_?Y?K&,J02E9IRA"K0YI224TII>]SQGY;\.O\
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M'Q0U_P *-JFH^.?&4'B?1M"B\5^&(?"VJ>)K5? _VI^U7^TC:?L?_LM_$/\
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M_@HU\./$NJ_!K4?#0UK5[[]G_P",.F? >_\ VC_#_P +OBT;KQ#;V?Q@\/\
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M'D--_:@_:W\?_M<:G^S[X%^"'P;\%>$_!'P4_8J_:+^)&H?%SXE>*G^)^C^
MOVC?&?[1_A'XD> ;3POX#\&ZYX+_ .%L>"KKX":I;^'_ "?'VK^ [FZLUDO?
M$UY;>+(_^$+^;_A[_P %<K35OV9_CK^TSXFMOAQJ>H_!SP/\+K7QQ^RM;1^-
M?A1^TI^SK^U/\5_&@^'F@?LI?M(^&?B)'J>NZ#;GQ_KGA;P9H?[0MOX!\/\
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M'J_[5'PW_;5^(^N_#\>.O@;IGCGQ!H7CWQA\-?&OPMUKX?:W\2/%WQ&^&7Q
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M2:SHUMH.@Z^]Q?/IWS#_ ,$_]%^-7P8^(/[+%K^T/^RK\5#XRL_V/]1_9P^
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M);^++/POXPM_&OAPZ5XX31I?!2W-U?Z=?:_9ZGX?\1V>D>I_!?\ :?\ @O\
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M/XX?$CQA\0?$_@[PU^S=H7@/Q7\;(/%?P9^-WA_Q9X"\'_%"RFU'X>^,]0\
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M//B5\0_%/AOX9_$"]U+5=.\&^+]<O_"/C*W\/_GE\0?V*/VE=0_9F_9-\-^
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MB^4RA)RI0E-2A*5*A*=H2DJ=2I1G*I%QYDY<M6"C",97<9<DG&JFS]@?B_\
MM??L]_ ::_\ ^%J^.KCPOI.A>(_ 'A/QGXO'A#QOK?P_^&VO?%#5=-T;P-9_
M%3XA^'_#FJ^"?A?'K%[KGA^6YOO'NO>'[#P]I'B7PQXC\3W6C>'/$FAZM?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7A_Q_P""(-,\/Z3^L7_!3CXD>$?A7^PG\7/&?Q(\0_$/PAX7^U_!OPQKFN^
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M?_&GXR^&/'7P2_9^_9C^-?[,]EX1_:-^-?AGQ/\ ##XUW'P2^**_#WQO\&/
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M^G^-_BM\,+WQY>>$/BQH/_!+7]KWXM_#&'XC>-(-%^&47B6*ZLE\+^*_V<O
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ME>WE>S=NUVDW:UVDW=I6****++L 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 56>RLY+RWU&2TM7U"TMKNRM;][>)KRVL[^6RGO[2WNF0SPVU[-ING37<
M$;K%<RV%E),CO:P&.S10!GV^DZ7:&]:UTW3[9M2OUU746M[.VA-_JBQVL2ZE
M>F.-3=7ZQ6-E&MY/YEP([.U02;;>$)/]CM, ?9;;"D%1Y$6%(G6Y! VX!%RJ
MW (Z3JLO^L :K-% %3^S[ #:+&SQY/V?'V:''V?8D7D8V8\GRXXX_*^YL1$V
M[54!WV.T#!Q:VVX,SAO(BW!WDEE=PVW(9Y;B>1FSEI)I7)+2.6LT4 9\NDZ5
M/;3V4^F:?-9W-K<6-Q:2V=M);7%E=Q1P7=G/ \9BEM;J"**&XMY$:&:*...1
M&1% B.A:(UM>63:/I1L]1L8]+U"T.GVAMK_3(K:2SBTZ\@,/E75C':2RVL=I
M.CVZ6TDD"QB)V4ZM% %"72],N+C3;J?3K":ZT=YI-(N9;.WDN-*DN+62QG?3
M9GC:2Q>>RFFLYFM6B:6UEDMW+0NR&:]LK/4K.[T[4;2VO]/O[:>ROK&]@BNK
M.]L[J)X+JTN[6=)(+FVN8)'AG@F1XIHG>.1&1B#9HH HII>F1FX,>G6*&[VF
M[*6ENINBEHE@AN"L8\[98Q162^9NVVD:6XQ"BH/*OC3\-_''Q&\$_P#"-?"[
MXX>-/V;_ !._B#P[J,OQ)^&WA'X1>+?$W]@Z;K4=_P"(O#,.D?&?X>_$OP2D
M/BC39-0T\ZK/X6NM1T:]NH=7LGD:"XLK[V.BDU??NGNULU+=-.UUJKV:;3NI
M23%IMV:V6S375-;/331I-6<8M<;\// ?AWX7^!O"7P\\)07<'ASP7X?TOPWI
M U'4+S5]5GL]*M([5+[6M:U&6XU+7-<U%T>_UO7=4N;G5=;U:YO=5U.ZN;^\
MN)Y/GCX<?LJ6O@;]J#]HC]I;5?%MAXON_CT/A'):>$K_ ,$6%LOPUO\ X-^$
M?$7@;0-5\*^)'UC4+Y]1UOPWXKUNU\474UE!+=O-#'I3:-IOV[3=0^N:*?7F
MZVDKZ+2:BI)))))J$$K)<JC%1Y4DDK>[R]+Q;6NK@Y2BVVVW:4I-W;NY-RYF
MVW";>W,@F,$)E#B02F)#()!$\ D#[=P<0220A@=PBD>,'8[ Y]EH&A:=%;0Z
M?HNDV$-G:06%I%9:;9VL5K8VT_VJVLK:."&-8+2WN0+B"WB"PQ3CSHT63YJU
MJ*!E:.SLXF#16MM&RR&56C@B1EE9'C,@*H")#'))&7'S%'="=K,"RYT[3[R:
MUN+NQL[JXL&G>QGN;:&>:S>ZMI;.Y>UEE1GMVN+2::UG:%D,MM++!(6BD93<
MHH JBRL@Q<6EJ'8HS.+>(,6B,!C8MLR3&;6V*$G*&W@*X,4>VK!H>BVLOGVN
MCZ7;3_VA>:MYT&GVD,O]J:C&T.H:EYD<*O\ VA?0N\5Y>;OM%S&[)/(ZL0=2
MB@"K:6-C8)-'86=K9)<75U?7"6EO#;)/?7LSW%[>3+"B"6ZN[B1Y[JX<--<3
M.\LKN[%C%<Z5I=[:7=A>:;87=C?VSV5]97-G;SVEY9R>=YEI=V\L;PW%L_VB
MXWP3(\3>?-N0^:^Z_11_7]?<ON 8\<<@42(D@1UD0.JL%D0[D==P.UT;E6&&
M4\@@U6_L[3_+>'[!9>3)')#)%]E@\MXI88[>6)X_+VM'+;Q102(P*O#''$P*
M(JBY10!CKX>T!+9[)-#T=;.33+'19+1=,LEMI-'TS[1_9NDO (!$VF:?]KNO
ML-@R&UM/M-Q]GBC\Z3=8TO2=,T/3++1M"TW3]%TG3+2*QTS2]+LK>PTS3K2W
M01V]I96%FEO;6MK @5(K>W2**-%"1A !C0HH_K\_\W][?74_K^ON1\E?LH_L
MK6/[,>D_$FTF\3:;X^UKXB?''X_?&UO$[^";/PSK6A7'[1GQ?\3_ !Q\;^![
M&\36=>O+CP;IGCSQ;JTOAFRN+P7-KI::?#K%SK>JVLNLW7U?%;V\!S#!#"=B
MQ9BB2,^6C2.D>44?(CRRNJ?=5I9& !=B9J*;;;N]79+IM&*BMDMHQ2\[7=VV
MVDK7WU<I.[;;<I.4G=MO64F]]-E9))4['3M/TR&2WTVQL]/@FNKR^E@L;6"T
MAEO=1NIK[4+R2.!(T>ZO[VXGO+RX93-=74TUQ.[RR.[3"VMQ&8A!"(FE:=HQ
M$@C,SSFZ>8IMVF5KEFN&D(WM.QE),A+5-12_K[MONLK=K(9D:CX?T'5X;.WU
M;1-(U2#3M3M=;T^#4=-L[V&PUFPG:ZL=7LXKF&5+74[.Y9KFUOX%2ZMYV::&
M5)"6JY<V%C>2V,]Y96EU/I=VU_IDUS;0SRZ=?/97FG/>V,DJ,]I=MI^H7]@U
MS;M',UE?7EJ7,%S-&]NB@/Z_4PKSPOX9U%=)74/#NA7ZZ!=Z??Z$MYI&GW2Z
M+?:2)!I5[I(GMW&FW>FB64:?<V?DS68DD%L\8=LX'Q*\)^(?&'@/QIX;\#^/
M=5^$?C?Q#X<UG3/"_P 5/#?A_P '>)O$/@+Q#?Z<;/3/%NFZ!X]T'Q+X.UV[
MT>=+2Y_LKQ+H>IZ5J,-JME>0>2RO'WE%)I--.^M[V;3UM=W333T6J=_,:=FG
MV[I-?<TTUY-6\CRGX-?"JU^#_@F'PN?%?B?XA>(;[5=7\3^-_B5XX'A__A-O
MB+XS\07;7FL^*?$Y\*Z%X8\-P7#J+71]%T;P]X>T3PWX3\)Z1X>\&^%M'TCP
MQX=T;2[/TBYTO3+VYM+R\TZQN[RP2[CL;NYM+>>YLX[^)8+Z.TGEC>6W2]A1
M(;M(71;F)5CF#HH O44WKV]$DE:UDDDDDDM$DDDM$K:$I)*R]=VVVW=MMMMM
MO5MN[>K=SY&T[]E'2[7]KSQ?^U3>Z_HNJ0>)O@;\&?@;8?#.Y\"6+:9X8T_X
M$>.?B[\0O ?C#1->GUJYEM?%MMKWQQ\=VES=6VC6MG'H4?AJRTJSTR_TO4]6
MUY-:_93M/$/[8NE?M8:SXML-4M-*^ =Q\!8OA5J?@BPU'1WL9/B5H/Q:LO&O
M_"07>L2W,?B[1O&/AK29-&F32/[/L=-2X1+)M::TUZR^NJ*;;;@VVW33C!OH
MI*HGTU=JM35W:YM[J+B))<Z6U2W.KO7E=-I:MV2=*G[JM'W5I9R4H3;6[2><
MT$)EW(_FF)#)OC1XXWWE=VZ-))$1LY5)'52 [ T3HFBMK*>(VTC2V\0Q:;)H
ML6O&PM#K,>CS74=[+I*:H8OMR:;+>117<E@LXM7NHH[AHC*BN-2BD,88HS(D
MQC0S1I)$DI13(D<K1-+&CD;E25H86D0$*[11%@3&I%6;3=.N+ZRU.>PLI]2T
MV*\AT[4)K6"6^L(=0$ OX;*[>-I[6*^%K:B\C@DC2Y%M )@_DQ[;M% &<^CZ
M3)?OJLFEZ=)J<MM9V4FHO96SW\EGIUY+J.GVCWC1&X>VL=0FFOK.!I#%;7DL
MMU B3R,YLP6=I;2WDUM:V]O-J%PMY?RP0112WUVEI:V"75Y)&JM<W"6-E962
MSS%Y5M+2UM@PAMXD2Q10 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !117X@?MA_MB_M'_";_@KY_P3._8S\ ^/
M=/T?X'?MC^&_C[K/Q0L;GP7X5U;Q5HUU\$?AQXA\;:/%X&\2ZAI\K:7:^)[W
M2;6Q\3)KFG^))ULGN6T"XT2XDBEMU>\Z4%\56?LX]N9PJ3U?1<M*>MGK96UT
M3?+&<WM3@YONTI0CIW=ZD=+K2[OIK^W]%?F'\2_^"Q?_  3]^$?B?XU^$O'/
MQ;\9:5JG[-?Q3^&GP>_:(O$^ '[0ESX6^"7BWXPWUQIGPTN_B)XZB^%Q\$:/
MX/\ &%];^1HGC>+Q#>>%;]KBU^S:I*LZD?0/QV_;G_9M_9S\9:M\/OB3XRU-
M?&OA?X(^*?VFO'GAOPEX/\5^.-4^''[./@G5DT+Q3\;O'EMX5TC5'\/^!]/U
MDSZ=IZ2^;XF\62Z3XHE\%>'?$=KX*\:7'AX33BI+6+VDM5_#]JW=-JRI?O&W
M9*G[[:BFT]FXO22WCUUG[-*V[;J?NTE=N;4$G)I/Z[HKX>T'_@HY^QYXFU3]
MCK1M&^*6HW=_^W]X:\7>+OV0U_X5G\5HK3XPZ!X&\+6_CCQ-=PZG+X(32_ L
M]CX0O=/U^+3/B?>^"=4O[6_M[>PLKG45N;*W^1OV@_\ @J!\"_'G['/PK_:B
M_9=_;+\._!GX=>/?VL?AM\#K'XT?$/\ 8_\ VA_BKI>N:S9?$.71/'?P>NOA
M7_PC?@GX@>"M8\5C1=9\+V/C_P 3:-IOABQOH9-%@U[P_K&OZ'XMT2E&3DH*
M,G)U*=-JSO&56O0PT>96YOXV(HP:2<G*<(1C*I.G"HN:-KW7P3FM?B5.C6KM
M1Z-NGAZLDVU%1A*<I1IPJ3I_LU17YW?&?_@JK^Q!\ _B=\6O@M\1_B?XNM/B
MS\#M+^&7B#XF> O#GP*^/?CC6M#\,?%[5]"T/P/XLL9O!OPTUS2/$_A>[U/Q
M)HEAK.N^%-3UO3_"VI:E9Z-XGFTC6[JVTR?S'X/?M\_#3P_K?_!3+Q[\<OVQ
M_A_XN^$?[(?QUM/"FMZ#:?LX?%?X0:U^S%IZ>'=*TM/A1K^N>(8-2N/VD/&/
MBWQ@K1>"+_X3:1XCN/'&MZSI5IX).L/X]\'^!/#2C>6L4VN24^9)N+4)4XM*
MR;;YJB2T<4TXRE&3A&;>FCW4H1<=FG-3DF[V27+!O5IM-2BI14I0_5^BOAR\
M_P""B?[+FF136.K^+M;T3QY;_M(^$?V0Y_A)KGA/6]%^*$?[1WC_ ,&P?$CP
M-\,SX<U.WM;9I_%_PXN8O'OAOQ:FJ-X UGPLMQJ%AXKG:TNH(/JCX:?$CPK\
M6_!6C_$#P5+K,OAS7'U6*S'B/POXF\$^(+:YT/6M1\/:OI^N^#_&FD:!XN\+
MZSIFLZ5J&G:GH'B;1-(U[2;VUGLM5TVRO89K>,\];:._2TK<K3V:=U9IM:K5
M/07,KVNKNZM?6\?B36Z:ZIJ+\K:G=T444#"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME2G4FFM).GAY851T::C*C.49I--M\RE%I6_ O]H?_@F_X7_;._9.7P%\9O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ';7UWIWAW1]4UN\AATW3[NYA/UV\]]N[T>BN]'IH['_  _R[_BOO1U5%%%
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M\<VD?"73/!]OX%T70M,\3W6I7?BB._T3P]96,.F^(;O5[O7DOK*WU2YU"YU
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M;==LOCI:?$#7OCS\4I_VE?@A\)/@9\;=6\??''QSJ&L>-](^".N>+/$7P_\
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MWW/!R3E:/^T\EUS7:INM2DX.5IQI.#;O$P?AO^T'\4]"_;F\:_L6?%:X\/\
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MVXJ3BW&,HN<8NTDE*"G%-I24IKFYU"-27E$/Q[_;*\=_L@:;^USX<^('[/\
MX6^'_P :/^">OC7]H?0K"P\,ZUJWCWX,?&_Q!\,] ^+GP;T_X;7.JZA?>#/C
M;X%TWX>7OC&T\<ZCXXL/"^H:AXY\(^'_ ![H7AE? GBS6OA;X+X7X.?'GXW>
M'- _X(4>&/%FI?"_XDVO[4'@Z_TOXB^+_%'P^\2W?Q1TZ^T;_@GW\0OC1X;\
M3>#?&NJ?$W7$TCQ7?W?A.?P_\2M?U+1];N_'-AKNK-8+X3AO;JSE^G/V>_\
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MCX7>/?B#X+\!6WQ%\?>#/AIKCZR(;G4D\2>-Y]-U.TT'2=8U36_%2?47QO\
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M=?$GQ/J_P?CUW6_$UYIOA/QBVD:A/X'M-<\2>(+W3=,O]-M=7UO5;FWN;Z?
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M_P -V6K_ &J\O-?]G']L'X5:]^SU\'/%GA3QC\?/COK/QN^*O[0_@CX3:/\
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MX^TV6UN=6\*_#6YOI-+TK4_:!_8<_;%UOQA_P4A/P7E_9[U[P!_P4Z_9EM?
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M-'BC4/CY^UQ\4/V1_%^A:_:?#WP/XC^%'Q"^#/PU^-7Q&\8:%>VGC/XE>&M
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M7_:T_P""?GQ:_:W^./QKUG6O$?@'X<?"KXV?\$R_'_[&<_BG0/%?BKQ%\3O
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M#7@_PCX3\6WVH?%'Q'H=EXJ\N^ '[''[3_PC^*O_  3C^)FJV?P)U"/]GO\
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M-IK-W<WL5R?#]K% \<GP'X._X)\?MS_!KP+^R;\3?A)K?[-$O[3W[+?[0O\
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MZ7K/B:?1UE\,WFL^/M-\+W6GZOH^K:CXCTO2[J:\MOR \'_\%#/C=\5?&?\
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MXOE\(>!(];@\$^'4^>5*HX\L*K@^2,OAA5E1HSAKJZE-5*E6$V[2BZ%G=O\
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M \2?LSV/B[QKIOQ!DU*\U?Q1I6MZ:_BCX<_V;;Z'I&M_$;3]2MF\-?2GQ_\
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MZWUKQ9_PB6C7%OJ_B;^P;*__ +!TR>&_U3[+:RI*W:5^2&@?&+XS_#[XI?\
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M&VB?#7Q+XE_X*?:'\7;+PIK'P%_9Q_X*A?$?XD> %^(-Y8M\._ASJVJ_LS_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^8?'G[)/PL^(?Q
MT\.?M):OJ7Q)TKXP^#_AOXE^$/A/Q/X2^)7BWPG:Z#\-_&FN^&?%'C#PO;^'
M-$U&T\-:A%XE\2^#?"NMZIJVMZ1JOB W?A_2(+35K33M.L[&#Z>HI65T[:Q;
M:?5-J46UV;C*4;KI*2V;#HUT:LUT:O&5GW7-&+]8Q>Z1\>>-_P!AGX$?$CX2
M^._@OXW/Q0\1^#?B?\5/"WQH^(=UJ'QC^);^,?%'Q"\"ZOX$UWP3JC>.D\2I
MXM\/:=X2U;X7_#JYT+PWX/U?PYX<LX?!^F:8=*DTBZUC3]3]$N_V;?A]J'Q^
M\'_M.ZA?>,KOXR^!OA5X@^"FA>(7\47L&C+\-/&/B'PEXN\:^'[KP19);>!Y
MY_%_BOP'X-U_6?$ \.Q^)8[GPWI-CI&L:5HMG%I:^_T4^WD^9>4E3=)27G[-
MNG??D;CJFVRV_P#>3B^[BYJHTWNTZB4[7MS)/HDO@GX _P#!-+]D?]F;Q?XJ
M\3?"3P?XVTKP_P"(KGQM>Z)\%O$'QA^+/C7]F_X67?Q-O=1U+XE77P6_9S\7
M^,M:^#/PGN_'-WK6OQ:O>>"_!>E7=AH7B3Q1X+\-3Z#X&\3:]X9U'.^"_P#P
M2]_8\^!'P]^)OPD\'>$?B+K7PK^)_P /?&_P<N/AS\2/CS\</B=X+^'OP3^(
M]HMIXW^#7P1\/^.?B!KEA\$/AWXG"03Z_I/PNB\+7NO7&F^''UO4]13P9X+C
M\/?H/12Y8VY;+E=/V+71TK->S:ZPLVK.]DVDTFQW=U*[NJGM4[ZJI>_.FK-2
MOJVK7>K4F?(/A7]B+X+^%-5_9=\01:C\5_$/B3]CWP_XR\-_!3Q%XT^+WC_Q
MCK%E8_$3P[:>$_'4GC*XU_6[Z/XA3^(/#EA9:3;+XRAUBT\'V]K"_P /[3PE
M<J9SZ]X=^ OPF\)_&SXG_M$^'O!VG:7\8?C)X+^&/P_^)/C&V,RW?BCPS\'K
MSQY>> +>]MC(;);W2#\1_$=G<:K!;Q:EJVF1>'],U6ZO+'POX>@T[V"BJ;<I
M.3;<FZDG)ZR<JMO:N^]ZEE[1WO/[3E=WE148J*244H145I%1I7]G%+9*G=\B
MM:'V5'2WPO\ #O\ X)S?LM_"CX_^,/VBO .A?$;P]XE\<^/?$/Q?U[X<6OQM
M^+[?L\/\;?&%O<6?C'XX6?[.4OC63X+VGQ<\56EP4U;QM'X+.IB[5M:TXV&O
MW>HZK>?5GPV^'VF_##PLOA+2O$'CSQ/9)X@\9>(4U7XD^//%7Q)\4B;QIXPU
MSQE=:6WBKQIJFLZ_+X?T"ZUZ;0?!NB37\ECX4\'Z;H?A;1XK;2-'LK>+O**E
M))12T48\L5TC&Z?*O).,;+HHQBFH1C"+W;;W<N9OO*S5WYV;OM=RE)IRE*<O
ME[5/V._@5XH\)?$7P%\0_#NI?%/P7\5?C#X.^/?C7PQ\2->U+Q/H^H_%/P'X
MK\#>-?#&NVMI/-"NEZ/I_B3X:> [Y? FFFU^'IB\.K8#PJNGZUXEM=:I^)_V
M+O@/XV^+?Q7^-/C'1O$?B;QC\</@,W[+_P 5;35_&'B&;P=XO_9_6Z\7:A:_
M#*Y\$1WL/A?3M.L-4\>^,]2M?$&B:9IGC4S^)M;@NO$]SI^IWME/]6T465G'
M[+C*#CJHN$J7L)1:32<94/W,DTTZ7[MWA9(LKJ5ES*2DI65U*-3VT9)V;357
M]ZFFK5&YJTFV_P Y?"G["?P[_9.MY?C=^S=X1^*OQB_:!^%W[-%Q\!OAIX7^
M+?[5_P 6%TSXC>"/"E_>>)?AW\+_ !5XG\9W_COP[I5GH>IW%]I7A+Q%JG@W
M5[;PN==U35KBSGU._OM7;W']E7X'S_"?2/BSX\\4>"O O@/XO_M,_%_6?CU\
M:= ^'%_/K'A+3_&5_P"%?!_PYT+3=/UZ[T+PS=^(;_3/AO\ #GP/:^,/$TFA
M:/#XQ^(@\9^.+;2-+3Q0;&#ZIHIW;;DVY-IQO)MN*G+VE1)MW_>U.6=1R<G*
M44[J\^=<JM%)))-.RT3<8>S@VMOW<+PIV248R:Z1Y?GKXG_LX>'/BIX[T7Q[
MJ7Q*_:#\(W.F^$-8\":IX6^&7Q]^*/PZ\!^*_#>LWBW\K:WX/\+>(]/T>P\7
M6-SY@TCXG^$8?"_Q4TNSE;2K3QM'I$=O80,^,/[*_P $_C?^SW>_LK>+?"TF
MB_ 34/#GAOP9/\/?AOJFH_"_3[7P3X0?3)/#7@[0;_P%/H&L^$?#FCG1-%AL
M]/\ !^HZ#Y6G:7;Z()/["FOM,N_HBBE96MTNI?\ ;RDIIZW=U)*2U]UZQ2&]
M7=ZOEY>GPN+BX[6LXMQ:MJFT[IGSM\1_@OXD\:_%']G#Q[I7Q-^(7A>#X):S
MXQU3Q+::)\0O%6A:%\3]-\2^$!X9D\.?$#X7>'VTWX8?$5;N]-OK5AKOCK1=
M4;X;7%CJ-U\-M#T?Q5XEL_&'@ZG^T7^RG\,_VH8_ <?Q(\1?'/P\?AOK6K>(
M_"EU\#_VD/CU^SCJEMKNL:/+X>N-3U#6_@)\1/ASK>LSV^A7FJZ3IZ:MJ-Y;
MZ?8Z[KT-K#&-7O3+]*T465K.S2ESI=I>Z[W\G%-+9.[2NVV?_(J'ERKFTMJM
M>:2>[:LFVDDOD?1OV)?@=H/PWT7X<6;?%'5Y/"WQ3T_XX^$/B;\0OC3\5/C+
M\;O"WQCT6SCTC0OB'IWQA^-'BSXA>.[_ %32?#48\"'1?$6L:WX.UWX87.L?
M";Q7X9\0?##Q)XF\(:SG^+/V$/@!XO\ @S:_ FY_X6WX8\%)\6;WX[:QJ7PP
M^/?QH^#WQ$\7?%_4_&&K?$34_'OB_P"*7PH\<^#/B%KNJWOQ"UB;QP;.X\1K
MHEEXBTWPS<Z7I5A;^$/"EKHWV113>M[ZWM?5Z\O):^JV]G#M=P@Y<SA%Q%I:
MVEKV\K\][7O_ ,_)^G/.W*IR3^<_@I^R]\/?@!X>\7:%X"\4?''6;OQK-;RZ
MOXR^,G[0OQL_:,^(EO#8V<]II6EZ-X]_:%\=?%#Q/HWA[1GO=5U'1_#&GZC#
MX<TW6M<U[6K;2DU/6]3NKKJ?V?\ X$?#S]F3X.> /@)\([/6-*^%WPL\/6/A
M#X?:!K?B'6/%=YX;\*:5$MOI'AZ+Q%XCN]2\1ZK8Z5;J+:PFU[5M5U&&U$=H
M;Y[:WMH8?8Z*=WKJ]5%/7=0<G!-;6BY2<=-')N[;8N6.CLKIR:=MG.W.UYRY
M5S=TDMDD%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-4IQGUM%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ex-19_009.jpg
<TEXT>
begin 644 ex-19_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2* X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q_P#M^?#;X?\
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MH>M0:'\)/$WQ'\1>$+#PGX;L/"!T=OYL_P#@N+^RE^SK^S?_ ,%A?^"*_P
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M  UJGAW1/$TFJ67C>TMM-O\ 0]-UDWL$NG07>.2_:Y\&Q_\ !N=_P5)^%?\
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M]X;U7]G3]F#Q?\(KWQS\8_B=\#[;XTZQX"EA\#_"*\U77)/&GCR\^-=K\/\
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M_%SPA\=_@_X>\,_%#3;.'3?B#HOAS6I/&$6K^&;'QA8+;^((O#.I_;9[B_\
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M*TO;*<AIK2[MH;BUF83+<!I;>9'AD(G59@70D2J) =X!JW118 HHHH ****
M"BBB@"I!I]A:W%W=VUE:6]UJ#1/?W,%M##<7KP(4A>[FC19+EH49DB:9G,:,
M50@$BK=%%%@"BBB@ HHHHL 4444K+^O^' ,?7Z4444P"BBB@"M%9VD%Q<W<-
MK;Q75[Y/VRYB@BCN+K[.ICMQ<S(@DG\B-F2'S6<Q(S*A4$BK-%%*R ****8!
M1110 44446 **** "BBBE9?U_P . 48&<X&2 ">Y S@9]!DX],GUHHI@5[JT
MM+ZWDM+ZVM[RUF"B6VNH8[BWE".LB"2&97C<*Z*Z[E.UU5A@@$3@!0%4 *
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M9:CX7\!O:^,?$EI>64$^A>&]3T76-52TL=<T>>^II^V[^QV?!WC7X@S?M0?
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M6HKY&C_;\_8?G\):9X_M/VM_V=;_ ,":PWB5['QKIOQ>\#:EX3.G^#?%UGX
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MC!J7/S*]VD^4_.__ (*>>#/'WBK]FSPEKOP\\"^+?B;JGP:_:W_88_:+\0>
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M[3;WQY^RM\-?V4O&6NZSX-^)L?[1?PO^+?PETO2]8_9^^&WPX^,_P.E_9_\
MCA\2-/M?A;X[U7X2>-?#?BSXLZ!X9^%'Z+_\%P+FQUG_ ()*_M<WUO8?\)!I
M^I?#_P #7MMIC06RG6[2Z^*?P[N;>P6WUI[*S234XGCMTCU:6SM4DF5;^6VB
M6:2/Z>E_X)Y?L>O\5_%?QE@^$ TKQ5\0/$=WXS^(_A[P_P"/_BAX;^#GQ/\
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M/@/X8-'XT@T[0M2NO'%QX?U2<:'X7\<R^'E_:9TKXV?M8?LWZ[^U!^S_ /\
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M\<ZI\2/"7Q<\5Z)XJ^#ND?"+3/!GQ+U3S+QA\,?VWY_ 7AKXKZ1HOQ9\(?\
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MG5[*"#4[C7[ZZTS3_#'B2[T6'1/"'[6?[/&O_ O]K#2?V8?CW\;/AO\  O\
MX*!?\%B]?^*O[._@3PI9K\<+OX5_MS?M!_$'XB?LZ_M,_![X>?$/Q#X%TSQE
M=>&-#O+'P]KFAV&K6WQ \/>$/CUX]MWT&W.E>/+33_Z<J*OGG[:O7T4\15]K
M+1-1D_9*2A=-J,HTN5IN]YN2DIP@U#IQ<*,-;4:;I*SLY1:J6<FK>]%S4HVT
M3BDXN,II_'_[/?BR/PGI?PA^%FG_ +('BS]F_2_B1X:^-_Q<A\)^$?"'PWL_
MAC\$_L_Q*T;6_P#A#_B]JWPU\1W?@WP]\>?B]/\ %6Y^(VHZ!X(C\:>'-6\8
M:=\8G_X3[Q!)X=3Q1XL^'/\ @IW\-OBKKWBQOB-^S'9?M >&/VLO!W[._B_2
M/A!J/ACX66?QM_90_:I&L^*(]3OOV)OVMO VM:5J7ACPYX2^(MYH&GZ;IOQ<
M\0:_\(;?X76'Q \0^+H_C!HEAI&L:%KO[1T8'I462<'%*"A)N*BVK1M*,8IV
M]U1A+DTBXSC>,X.$G!:)RU;?,Y)<W,KJ3NI2E)7N^::Y])J4)6E"I&:50_G(
MU3X-_$VQ_:^_:D^"?[2/["'[3_[4O@O]K7]I#X6?M+_!GXQ_#;X]:QI_['?A
ME?#7PK_9UT1_#?[3?A^\^.'PZTKP7-^S5\3/@?IFN^#?%,/PB^(/CSXF>#M
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M=^#_ ,8?@%H/QK\.?%+X*_M(?##5?CW\ /!6N?!GXCZ1\;]7:;XJ>-_&FJ^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^&O[66L^&M._X*L?
M"OPO\1?$/[3Q^$'BC_@FG^TYXV\5^ /V=O$?[7M]=ZGX]\$?M"_LP^%/"'Q
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M5?PE\5)^U/\ ''P)\9?C#X+\??L@1>)_AQXLTNR_8\\-?LH?%+X.ZOX7C_:
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M%->T+5?VJO&7AGPGX=T;P(/$,NL_!RRUO0;WQ=K.NZ#?>/M>TOQGX:\[N_\
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M/"^A?$7X9?$KX<#X'^-/CA9_%>ZN/&/P/L5^*&HZSKW@OP_X(^'T_CN;P?\
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M=I'A2Z^B;+_@K+H;_!7]E?X@^+_ASX#^"/C;]I;XM_M#?L^RV/Q_^.<OP_\
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M1.4X6ORN4G.9'O6A=V:3Y^5W3FN1:.R]Q^_*#2C*^ZC%0B?BEI7P(\.>.?\
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MXM_%30M>O+K6/#^LV%_H!7X2ZCI6OE;JPO\ 2;344U?3;3Q#<VHT.[^)IO\
M@K1\3M$\*W&@^+_V-&T/]IOP9_P4,^&'_!/CXN? RR_:(\-ZMX8\.:Y\;_#N
MB>//@Y\<_ 7Q<F^'>D/X]^$_CSX=>,O!'BJVMO$7P[^&7CO2Y]3\0:'J7A.&
M\\-++K'I'_!4_P +_$[Q5XH_X)D?\*HTSQ;)KO@S_@I-\/OB!KWBO0/@OX]^
M-OAOX<^#]._9O_:?\(WWC#XF:%X%^P2:-\/Y?$/CGPMX1UO7]7\4^#K+2QXJ
MBU!/$>F-927MK<\?_P#!-/7_ !R-/\6?\+V\/:9\9=<_;[^"O[?/Q>\??\*2
M>[\/>./%'[/_ (/\#_#+X:_"WPMX+B^*VGZEX%\!Z7\,?AIX+\-7-QJ?CGQ[
MKUSJT7B7Q8E]!J?B>XBL^B$:3A%S<O>J3A)Q<6XQC5P;32U:2I3Q/,W%N3Y.
M2\J:O%3F2C[/D<O9.34F[*7^UQBG;2\I0P[2<E;WF[1F[2>(?^"AOQ?\/^$/
MVC]8C_9;\-^(/%G[#WPX\%>./VR_!/AWX_ZA?W/A/Q#KWPT_X7MXJ^%'[/FJ
MS_ NSC^/7Q"\)? NZ\->-K-O%%C\#/!7BO7O'O@OP38>,+*^;QGJ7@HT[_@J
M/X3O?'WQRT)O _A^3X?^%OV#?AW_ ,%#?V8O'NE_$+Q!J>I_M8_ OQW9^(8+
MR3P]X';X2V5WX,UOPCXLT_P=X7UK0X-;\=>))G^+OPIO+#P_/<>+(]+MN]^(
M_P"P-J>N_%']K7QO\+/C9/\ "KPS^WE\-?#O@']J+PW=>![SQSK[Z[X3^'-W
M\%M%^+?P$\3W?Q T'P_\)/B7+\'KNP\(ZW+XM^'WQB\$ZMJ7@#X6>)!X*LYM
M!\:Z?\1^F^)'_!/#X&>.?%O[!_B#1(=3\ :'^P+JHL?AKX+\,:AK=OH/B#X4
M6'@S0K#PU\'?$"PZ[:27?A+PQ\4OA;^SG\9=-_M<:^'\3? /PO97-G+%J=[>
MP1:+Y=90YE",[<O-3DZ>(C6G'2491C46%J8:-VVG4C56DHMK1/12E%R<=^2<
M8O#SI0D_=G&<U]9I5I)**2IRA9N$E\^>-OVQ_AO\!OVL/V@O%O[0GP;;X=>*
MO@/_ ,$J_A]^U3\8?BEX6^-7BGX@Z1'\.=.^)7QFDUOX+>%?AC>^'_!OA/6O
M$7A/QIX0\<SZ%\28=/T;Q7\1(-:\,:$^GZ?!)#HNB> _$#]I+XC_  4_X*/Z
M5^T!^U-X U/X-_#?X8_\$8?VW/C_ .-_!W@;X^^)?CCH3:3\*?CI^QUXL\1V
MZ_#VZ\,?#WP7HGQ?\%:'-K>D:AJOA'3]:M/&\7B#1])M/'^MV6BV\6G_ &/^
MT#_P3<\+_M-?'3]I3XA_%3XBSW'PM_:<_8,M_P!@[Q?\,/#_ (/ATWQ3H/AB
M#QI\1_&Z?$CPW\3-0\2:UIL7B^UU3XG:RVFV=_\ #2]TJQGTCPW=LES)9:BF
MK>6VW_!,3XH_%#7;'4_VS?VM[7]I#3YOV%?VD?\ @GUXULO"GP$M/@CJOQ$^
M$/[1MY\(KOQ%X_\ $?B&#XK?$6[LOCA,WPHMCXG\3^&K?0_ >L7-]97O@WX8
M_#2XT_5V\3Y55.?(X*G%P]^*O4LFY9BY1UE:Z57"<B?-"2O*;YE6;T@X0<KN
M4U.,82;44[\F!7-HD^6]/$\W*E)-)0O%T4OH3]G3]LCXG?&']H/QI\#/'W[)
M_P 6/A7HFD_"+P_\6O!GQQ;PI\=?^%.^)I[CQ-/X3\8_"?Q!XD^,_P"SQ^SY
M)X8^,?A>]DT7Q#I/A;0+;Q_HGC+P'JEUXFTSQ5:7/A[7=$LN,_:#_P""@OB'
MX ?&FV\ :_\  O3K?X>/\<OV5?@;9^-O%_QAL/"GQ!^)-W^T[\0?AY\,+GXB
M_ ?X.:7X&\93_$/X7?!KQM\8?AMX=^)/BCQAXX^%3IK0^(6D:'8:EJ'A7PM!
M\1>X_8K_ &6?VG?V>+*>P_:0_;O\>_ME6_AOP\O@+X3KXA^%7@_X2OX=\#07
MME<VVH_%&Z\+ZQX@O_C=\9'LM(T/1;_XL^(;S0TFT[3[^YT[P;I.O>+_ !SK
M7B;P3X\?\$U/BM\4_B?^TIXY\$_M5Z!X!\/_ +0/QL_8>_:/M_#'B7]G*P^)
M&N>$OBE^P]XU^!OB?PAX5O/'L?Q:\$ZQXB_9Y\5Q?!2'6;KX1Z99>#O$?A;X
MJ>+O$_Q!\.?%2'1?$GCOX?>-]I<O/!12]GHW)\ZT]M3?O1;=INA*JFDY4U."
MUE.49/#W_9RT3J<MHZQ45/V4[M-+WH>V4&KQC+ED[*,$TNWT;_@HZ/%?QA_:
M&^''@?X4Z-XV3]E?Q5\4_#OQQ^&V@?%.X7]L[PMI7P^^%FJ^/_"GQ TS]DS5
MOAMI8\6?#OX[:S9Z!X:^!_BOPW\8=2L?'%E\0_ FN1?9-0?QMX6\#?+GQS_X
M*'>&?C'_ ,$S/VCOVIM7^"?P>_:+_9GLOAE\(O$^D?\ #.G[:_BNXTOXE1^-
M/&$.G>//A]KGQ T;X.?"WXE?!3XC_!BX7PKK'C'PS<>'9M;EM?$$/A^Y.F>(
M[+Q!X9M/JGXB_L"_$+XK?&?P5\=/&'QY\ 0?$[X&:[^T5K7[-?Q@\+?LTZ-H
MOQ]^'FG?&[X;?&'X;>&/AUX^^)6H?$S7_#_Q1^$GPLM_C'<^*+;P#I_PW^'5
MOXY\7_#3X2:WXIU%[C0/%G_"<^/?%K_@DO-\8_AU^W)I>K?%KX5_#WXM?MZ^
M!O@-X%^+OCGX+_LU7/@+X?3/\#O%_CKQFOQ*U#X5ZA\<O%>L>+?C3X[N?B)J
M_AOQ5\0_$7Q3N!)X,\+?#71(-"^U>%=5U;Q4HM+DO'5*DV[N_-#$X>4Y):>]
M.C&K[J:=%QBZ<JO-%T[O[ST:BW+JM(RHUXI:+:%1T_>U]LIR4XTN1^T^DM-_
M;EG\4?MF_$+]C[P;X+^&U[XD^$'BOP58?$;2O%GQTB\%?'"Y^&7C/X0>%OB/
M'^T%\*/@5<_#?5%^*7P5T3Q=XZ\-_"'7/%-G\1]"FT[QQI/Q%M[G3XI/"&DV
M?B_Y\^!'[='[4>I?!'4/B1\6_@]\%9]2U3]N3]KC]F]?%-K\?-8\'?!/X0>$
M/@+\>OVGOAK:Z_\ &/Q_KWP$MM0\)^&[;_A1W@[X4^!_%%AX6\7ZC\8OBM\1
M_"=UK>A?!Z'Q0WA[PY[?\6/V%/$WQZ^/GPF^+GQA^+'@+7M#^ 7Q[\'?'OX&
M#PS\"IO!_P >/A=<:!\/O#F@>+?A7X>_:"A^+.JO+\'OBOXZT?5O%'Q)\):A
M\-KJ]\4>"?$UY\+M4UR[M-'\.>)])\97_@F9\6='\4?#'Q+X0_:N\.Z?!\#O
MV_OVF_VV_A/X6\2_L]W_ (F\)0Z?^US-^T-J'Q6\ ?$C2;+X\>&6\>>._"NK
M_M*^/KGX'?&;2[GP3#\.+&'3-.USX9>/FGUZ\UN4D^7FTYE:=M6OWU)N2<DD
MG*GSJ4;2<;3=.;A*$2)<SE"45[L>>3B[IMNA6C&+49-27M?9RO=+WHJ45.,I
M/#\!?\%7_&7QA\*?L!ZA\)?V7++6O%W[=\/[5WAK3=$\8_'1?!7AGX5?%;]E
M'2/&L7B71/$/B>#X2>)]?\0_#;Q%XS\":UI=AX_TCP#;^,M/\(>1XKF^#]WX
M@D'P_/K_ ,%?^"AWB/X]^"OV?M/\%? :STG]HSXV0_M?/K/PA\9_%@Z9\/\
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MXO\ Q#KWPE\:RSVAUGX>^-K(I?>%-0U.VAE&E:M&=3TR\FM!:W[_ "_\8_\
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M !1110 4444 %%%% !1110 4444 %%%% !7R+\;_ -OK]BC]FO4_$.B?'O\
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M_P")O%6GZ?/H/A70)QKGB34-+TJ.6[3\:?V,/@[\?O#FM_\ !$;5?B3^S/\
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M(U.5SC%1C):Q>/C3;UO^]>%HN,4KVQ">J4'/]U8OV_OV(YOBM?\ P/A_:L^
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M\(?$6G^%OB7I?@[Q#8ZO?^#M7UC2X]:T$:O:02&=-+\2:2[:AX8\00)-X?\
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M+_ 7_!77XD_$CQAX9\"?#WP/_P %@_\ @H5XC\9>-O%VMZ;X?\*^%M!T;4_
M4^K:QKVO:I<6NFZ5I^FPP3/>75Y<PQ0"-UD96! ^1/\ @GGX;^+/P:_9L_X(
MNZ;$_P 4?@?X#^+/_!2']M6^\'? LZKKO@>VB_9-^+GP)_X*0_M!_ WP%\4/
M ]C>6]KK-CI]CX6^&WQ'\*^&O$T5XO@_SM%@?3M.UC21;Z;FFG*$'S7E'!RY
MDO<YL2XKV;>\9.\ZD&KR=*E4=FXW8Y6A.=E[M3&4[77,HX9S4:B3M=-PC3G]
ME5*L%=+1_P!1.1ZC_#Z^E&1ZCTZ]_2OY8)/BC\3_ (+_ +*?[4?[96M_M3?M
M M=>$/\ @J/\=_V-/%_B7XH_&;XC^-O@I\ ?V-[W_@K5H/PI\6>*)OA5IOB[
MPH6U+X=?"'3-4\+:5\6-+\0:5\<?AWX*\9^(O^$)^)?AS1?#W@^R\+>G:O\
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MC9>7,$VN_&/_ (*4>!KVYDLM7^(&I:7JS:?I-E9ZAH":[IFJVGA7QE-?>/\
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MB?XB\<?M#_MJ?LUR?\%,+#]@?QU^QYXD_98UG]FNX\<P_&?Q7XXUOX)#X(_
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MQ0^-?Q*_9R\'?!/]BO\ 9H^*?[.&O?#+XT^(/@UKVGO\4M9_:9M_C1^TZ?\
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MT?3] T*TO]7U?7KNUTG2K6.RT^UFUCQ!?ZIK6HFVM88H%N=2U"\NW2-1).Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#P9INJV<$-IJ5CX<M]-M;ZVAB@NHI8HT0?EC\%_^"HO[27Q ^%/P/^,7C_\
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M#I%OI7B/5_ %SX9E\*:EKVF0>']!AT_5[W29]0LXM$TB.WN(TTVS6'T_P/\
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MB_XA:?X)TGQ]XK\1_!CX<:WXD\<:5\--9T#Q%\.--\8:YJ?ANZU/Q-I_P_\
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M-":OU335]DUI)0;]ZZ349*#UT5O<6C[N^_9J_9SU/4O$.LZE\ ?@IJ&L>+O
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M4?@]X6/@?X1_$B3X6>!G\??"SP4;"^TL^$/ASXQ;0CXB\$>%SIFJ:GII\/\
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M-;^.-I<V^IVMQ;?&#5;'0(+[XEV\]KK>LVTT/C2?6HI8-7U.%U:._NEE]/\
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M?N/!,&B:U9RZE-\I_$WQ[\5_V"OVC?\ @IM\9O@G\/\ X;?&.[_9T_X)<?\
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M=JSH1A.S:<:\</*$TDTY1Y<33DN75Q:;47S<G[; @]/\_P#UQW'4=Z*^ _\
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MW&I^&-;T+XU_%#X=_$>XM)]1U?0-0TWX+:C9^'&\'#XE>+O!_P!I5^:7Q/\
MV@?VGT_X*.^ /V._AIXF^ _AGX=>./V,OBQ^TR?$'CGX+?$+X@>--+\2?"SX
MT?!#X5R>'?MV@?M$_#+0KS0_$%G\7YM728^'[6_T>ZT&&T:?5HM2>:RB4H1E
M3<K<TIRIT[Q3]ZI2JJ23:?*W3A-*2LTXJS3:N^5RC-)M)1C.5FUI"K3<=FN:
MTY1]UW34I-K2Z_1'Q-8:QJF@:OIOA_6HO#FLW]C/9V&O2Z5#K8TB:X0Q'4(M
M*N;FUM;VYMD9Y+2*\DDLA="&2]M+ZU2:RN/GK]C_ /9FL_V.?V7_ (4?LM^$
M?'&K>-O#'P0\$V/P\^'GBKQGI&E1^)3X6T.T%KX<A\81^&1H&C:]J6EQXMKC
M4=(T[PL-3L(+5+BV35%O-7OO*/#GQ]\7>'=:_9%\%?'#]IW]E2P^)'QQ\9?'
MZ^TGPS\._A]XJ6S_ &H/A3X4\*?$_P ??#76O@M+JWQN\47'PH;PO\)M/\"_
M$[XM>)?$-S\7?"VJW^F:]X0\-ZCH$/BCPWK$74?"S_@HC^Q1\;O&_P ._AW\
M)_VBO 7COQ1\7(/B3)\,(]!DU>XT+Q]>?"#5=6TOXD>'O"?C"32H?!^M^,O"
ML6A:OXDO/ UAKLWC*Y\ V$_Q*T[0KSX?!?$S5'5S4;^]RJ5M>94Y2E%KJE&<
MZB6D7S*::=HIJ45>$FD^52<))725114^65M5*,*;;3E%QY9)VYFO"=)_X):?
M#O3_ -D?X8?LL3?%SXCS:E\ _P!HN3]JOX _'NTTWP1I_P 4_AG\;%^,?BWX
MWVOB+[!_PCEU\.O$>FMX@^(?Q!\ ZWX>U#P5!I7B/X+^+]4\"ZK!+K,]SXSN
MMOXJ?\$R_A?\>/ GQ\M/BUXZ\9)\;OVB/&OP(^)VO_M"_"9;7X9^-OA7\0_V
M8!X>O/V?-7_9^BO9?&]S\/-*^%/B?1-3\:>&],\0Z[X_U.;Q)X]^(LNM>(=4
MTWQ1_9MA]$>&_P!M7]EOQ;XRO_ NB?&/PY)K5GI/Q6UVUU#4;37M"\%>)=)^
M _B.W\'_ !SO? ?Q)UW2--^'?Q&B^"GBN[M_#?Q?7P#XI\22?#+7)!IGC9-#
MO T(S?@S^W9^R3^T+XO\,>!?@Q\;O#'C_P 2^-_A3;?&WP5;Z1:>((=-\8_#
M.:30X;SQ!X3\0ZEHUCX=\277AV3Q/X77QKX;T75;[Q5X"_X2CPR?&NB: OB'
M1S>EN:,5K)2@I0:;=X*--*<'=NSC@Z5YPOS?5H-N;IW;YW!M<RBXRE&2TC:3
ME.<H25H_;Q4Y<DM(O$2M&*J6/F'X@_\ !,K7/BG\+_AJ/'?[:_[26K_M??!W
MXL67QR^%_P"W#9Z1\$?#OQ,\%>/[/P%JWPUG\.:)\,/#7PNTCX)P_ K7O!OB
M#Q#H/C+X)S>")]"\=6GB'7[[QEJNN^(M:U+7[GL?B'^P#XG^)OP8\6? ;QW^
MU3\2?B?X%^,OPH\<?"?]HV3XQ^ /A-XYU;XGR?$&_EGO_BWX6M-&\+>"/!/P
MG^,/@72YF\/?"*7P[X*U+X->%=*M="D\7?!3XB:GX5\+:AHWJ^K?MP_LSZOH
MGQ,L?"W[1/PX\&Z]X3^!GBCXZZ=XV^(6BZ_#\.Q\*-($FE2_'_PU=ZU=_#_1
M/CE\#_"7B"ZT3_A+/%GPH\?77AA4UKPWI=UXV\/7'C3PO?WN1;?MT_LX_#GX
M6?!W7OB]^T3X(\2:KXQ_9\\&?'?6OB!X*^'WCG2/"5_\+=2TOP]#J?[2?B#P
M;I\OQ(U/]GSX :UJ^L+J5OXJ^+OBY/"/@S3YKO2]=^(>HR^&M<U6(TESJR<9
M.+GI!P;<'"S232O"%YQ?(I*,9SNX*I 2E%Q:<E*%W%^]SQM-3YDVF])R]UKF
MY7*4$N63A+G/'W[ ^D_$[Q+X L/'7Q-U+Q9\$OA-\=?V?/VC/A%\,O$W@WP]
MX@\8_![XB_LS:+\/+#X<Z?\ "[XT:K-<^*O#W@O6=9\!W7B?XF0ZGIGB#XB^
M-;GQSX[\,Q_$[0_ /BSQ%X2U;PO]G/\ X)+:7^SEXW_9,\4:+^U=\=O%VB?L
M91?M+^%/A#X.\3^&_@B]E=_"7]I?5_#?B'Q+X$\<>([+X9P>,/%.OV&N^#O"
M][=_$V;7+;Q;X@33;@7#V&H:WK^IZE]3^#OCQ\2=5_X*"_'O]F#63X,G^%_@
M']DW]F3]H'P/=:5X>UG3O&L.O_&;XJ?M/_#?Q9HWBO7;OQ;J^B^(=,LA\ =*
MUCPY+H_A;PG/8KXCU'3M4&M/9VNHORGC_P#:G\?^)?VU[']ACX :?X.L/%7@
M_P" =O\ M)_'[XP_$+2=2\9>%?AUX2\6>,K_ .'_ ,(?AEX<\!>&?&/@?6/$
M?Q*^)VK>'_'GBF[U35O%OA_0?A]X+\"6]Y<:7XSO_'NCVFC:WJJ:ES252NJE
M9ZQ4II*M*I.II9R4859-R3DHR76=C-<G(X*RI4G&DEKRQYE2C"$'ORR<Z<8Q
M3M*4796A<^Y?$&JS:'HNI:M;Z-K'B*YL;26>TT#0(K*76M;O -MII6F_VG?:
M5I$-WJ%RT5I%>:UJVCZ%8&;[;K>L:3I-O>:A;?+7[$O[-US^S/\ !K6=!\1_
MV%-\4/B[\9_CM^TY\;+OPQ+?W/AX_%_]I+XK>*OB[XPT'P]J&I16E_K'ACX?
M'Q18_##PAK]]IFB:AK_A'P1H6MZGH6C:G?WFGV_CG@C]M^^\%?M.?'C]CC]I
M6/1;WXM_"GX$>$OVMO 'BCX)^ OB'J-M\9?V:O%_C'7?AOJVLV7P>TV[^*OC
M;PQX^^$OQ1T"X\"^,O#EAXI\<VOB;0]8\#?$[0[G0X/%7B'P#\._B+P'_P %
M,_CWXS\*_L ?%"^$>E^ /^"D&@> X++P[HW[(/[4.M>.?V;/%^M?LP?%G]J;
MQ1<>!O$EMX?U'PQ^T=X8'A'P#X=^'?A2:V\.V-Q?>+-3\6_'^QD\5_!_P[JW
MPL\*97LW"_\ %ITVO>:4X2J34(M/E5YUZ,X>\D^>ERN23A*3;7+S.+M"<F[Q
M=XRC3AS2WUBJ56,E;F351R6JG&/N/P7_ ."1H^"6D?L_^']&_;%^.?B30?V9
M/@)^T[^R[\)]+\3^ OV>?+M/@9^T7+\-)+7P[XDNO#GPG\/7_B#Q/X"/P@^'
MMW_PG!N[+6/&6K:"UWK4=M9:UXFTS7/5?#__  3#^&-EX5_9B^&_BWQIK/Q
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MOX*?&SX7_M%?#70/C!\&O%,7C3X<^*+GQ'9Z%XDATO7-%2^NO"7BC6O!?B*
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MKW4[2C0Y4^?6G3EM3YHWS651I[N=6=NDK593GHO==G6NUR?'43UJ-2E\<?\
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M?'*> ?!'E>"_#FA6FA:AXQ@\88C?\$I9_"VH_L_^+?@)^VG^TS^S3\2O@_\
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M3/VQ_P!F75-9\1:*?B]X;T63PU\,-<^-UQK/C"#6? O@W7/@MX6>V3Q=\8?
M?CWQII>@^"/B7\*O!HU#1IO&GQ$^'?B'Q1X/\'6WB3PG=^)M9TJU\6^&IM5Q
MBHJ$81M[-1Y(PTE%1C",7"*?/9<D(N4(_$DIRA4NYST=^=R=_:73;U4N:<Y.
M+=E%W<YR4&]8M\D90LH1\*^!/["/B']F/P[:_!CX%_M0_%7PC^RKI-YKEQX+
M^".J>&_AWXK\3?"+1M9\0:EXC'PT^#WQIUCP\WBW1OA/I]QJ=UIFC:'\1=/^
M*?CKPIX<EC\.^ _B5X/TG1_"EMX;/BW_ ,$^O#WQ;OOVTCJ/Q2\4:1H?[;O[
M(_@[]BWQYHMEHFCW<G@GX2>"=+^-NB:5JG@36+^2;43X]DT_]HWXN2W>N^,'
M\5Z5-JEWX-NV\.FS\+ZAIGB?W&T_;$^ %Y8:M=+XE\7VFJZ/XQTCX?3^!-6^
M#OQGT3XM7_C77?"%W\0M+\->'/@SK'P^L?BSXLU2?X>Z9K7Q E@\+^"]8^Q^
M!/#GBKQE>M;^&_"OB+4],YGQ'^WW^R)X3\.>%_%>N_&73;;0O%GPWU+XRVMU
M;>&/'6J7'AWX.:'JUIH7B'XO_$C3-)\+WVJ_"7X4>&=8O8]/\4_$GXI67@_P
M5X8N8-137]<T[^R=4-F^5/EO=N"NFVVTI1=-2<FW)IPBX*4IM)1:<XN+:>NN
MEN9NZ2LKPDIRM%144U.2E)1BKN2]UJ2C+R7Q#_P3?^'OQ"^)7BCQQ\6?'7B+
MXA>&_B#^P/<_\$[OB-\,I=)TGPUX7\7_  :U74=5U?Q#XF;5_#IL_&F@_$?7
MKS6]4L+C4]!\2V'AK3M!FA@T3PKIGB&UB\3UQO@__@FGXIT_]FOXV_LR_%?]
MN?\ :B_:.\+_ !1^ WC3]E?P5XD^,EO\'Y/%/P>^ GCSPS_PAGB2VTZ^^'OP
MW\!#XL?&/5?#<6F+>?&GX\?\++U>/6?#VE:AHV@Z+8:S\1M%\?\ ZF*RNJNC
M*Z.H9'4AE96&596!(96!!!!((.0<4ZG.\W+GN^?F4TTDI<TZTY\T4HKF<Z]>
M[<5*U6I&ZC)Q4QM%0Y-%34/9M?84(4H4U"6K48PHT%%*37[JG+645)^;_![P
M#<_"GX4_#KX877B2X\8'X=>#/#G@>V\47NF66CZGKVF^%-*M="TK4]9L-+*Z
M3'KMWIEC:2ZY+H]KI>CW>KM>W>DZ'H.G3VVC6/I%%%5*4IRE.3<I3E*<I/>4
MI2E*4G9)7E*4I.R2NWHMDHQC",802C"$8PC%;1C&*C&*WLHQC&*7112Z!111
M4E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5^0WQN_9>U[XR?\ !5[X-_%'XE?LGVGQC_9<\*_L)_&_X*:U
MX]\>6_[/GC#X?Z3\6_B1\;_@5X]\.JOP]\;?$";XD7 L/!WPV\9Z7JWB'3?A
MC<PVD^OZ;INGW.HV.J:W-IGZ\T5$Z<9NFY:^SG[2*O9.7)5A[W=<M66G5I7T
MNFU)I22TYH\K?5+GISNMK.].*OT3=M;-?ES^T%^SGXTT_P#:8_X)%M\"/@KJ
M-[\"/V0OB5\99_&UYX;U_P"'6CZ!\(_AI??L5?&#]G?X;:7%HWC'QYX?\7Z]
M'_;_ (Z\+Z;9V7@S0?%4UCH>EZI?ZL]FUO91:E\=?LI_LR_M6?#OX/\ _!+#
MPKXU_9G\>Z!X@^ __!2#]M_]H'XV6\WCS]G347^&_P */CIX=_X*.Z'X%\3:
MK=Z%\<-5MO$DNJWG[6GPQOM4T+X>W/C/7]/L].\8R7VF"]TG2;+7OZ"Z*.1<
MSE=MRJJM+F=VYJM&O=MW>M2.NK;3E=N3YA3]^G"E91A"E[&"A[J4%"4$K+31
M25E917*DDHW3_FG_ &=/@)^W!I'[3?[#7QP^+?[&'COPGJOP-UW_ (*5^&OC
M?I?PO\?_ ++NA_ 30_\ A?VL:)XM^#NL_LU?"?1/CCX<L+7X6>(TT75K#7O&
M7BWP=X:^/_B+QYJUEKGQBA\73ZMK'CC2;7PG_8>_:RE^&G_!&?X5>)?@QX^^
M%-[^SW_P3K_:I_95_:'^(^G^-O@)JDW[/WQ'^*/[/GP?^%7A;6H(O#?QLN=:
M\:6MYXG^'>K:YH]_\,(O%9A4>&[KQ$WARZFOUT7^D[ ]!7G7Q$^(,WP^'@@P
M^ /B+X^_X33XB>%OA]*/AWH-EKI\&P^)Y+N-_'WC<7NL:1_8_P ._#7V42>*
M==M/[3O=-CNK1K?2+[S6$=R]^#I22<9Q5-I7C?FA4IO9M)S=:<F](Q;LG&"L
MDU>K&O=J=-2<6M5&/M*=:S3^)1=&"5VVXII\TI-O\:/V?_"W[:6K?L17'[.?
MQA_X)^6/PU^,/[-O[!WQ$_92TSXE6'Q._9[\86_QZ\11_#70/AWX<T+]D^^T
M[QIHNH^#?AE\8F\">#?B7X]E^.]Q\$]/\$:II7P_^'4GAWQ]J&F:]XY^&'R3
M\8/V3?VX/$7[(NG_ +,T'['OC2^O]8_X()Z)^RMI?B'X=?$/]FOP+X@T_P#:
M_P!!^%7Q(\%Z[\)?VDOBK:_&;2OB!XR^%?AJ2?P;_P *-\!?#S6O%WP"\1^+
M/BI\7]8^,.EZY:Q>'/%?PO\ Z-?B-\8]&\">!?BAXQT#PUXP^,NK_"5X[+Q-
M\,/@M8:1XR^*<VOSZ-X<\36_A/3?#%UKFB6Y\4W'A;Q=X<\40:/JFK:5--X>
MUC3M51C:W]D]QZ[UZ_XTY2G.56<I7G5?[V32O*I)8B4IVTY93>)JU'RIQ4I;
M7;B$4HPA3BK0IMNFDWI&/L(*#>KE&"P].*4K2:6LK),_,KX&> _C6?\ @H/\
M1OCKXL^!'C_X>?"_Q[_P3P_8X^$NG>)/%GB?X'ZC-I7Q7^%'Q:_:K^('CWX>
M:]HOP^^,'CO7(M9T/2/CQX2LQKNCZ?K?@#5-6TGQ3#H_C/4+*ST74-?K>+?@
M%\4/@A_P4=US]N3X<^$=0^*OPK_:!_9I\(_L]?M"?#_PA)H-K\2? ?C3X+>,
M/%7C?X2_''0[?Q=XL\/:5XX\"WWA/QGXY^'7C_P9X9E?XD:3KUK\--9\%>%?
M'EEKWC4^$/T^KEO'/C#1OAYX*\7^/_$:ZDWA_P #>%_$'C#7%T71]3\0ZR='
M\,Z3=ZWJ@TG0-%M;[6=<U,V-C/\ 8-'TFRN]3U.Z\JRL+6XNIXHGJI5E.<:L
MN52A&LEHVN6LL1[1--MZQKSBFK22A3:?.I<\0I1A3=)7<6Z3U:NI4?8>S:=D
MKJ5"$M5:\YK2,ER?EYX<_9T^)OC+]MK]HO\ X*0>-?A+XR\+:Q9?L6VO[$7[
M-WP+3Q7\-K[XE>-O ]I\1?$OQL^(GQ(\60KXM@^&?@[7?B9X]NO!7ACX8>%=
M7^*PDT3P;X*_X23XCW_@KQ'XVU'P3X&\/^#WP)_:A\$_ +_@@3X$US]F'XDI
MXF_8FE\ V/[3-E:^._V;;B'X;1>"_P#@G!\=_P!DF_U$7G_"^$MO&-EJ/Q.^
M*OA_4=(3P!)XJU!_!FG:_JNI6&EZO;Z7H&K_ ''JO_!0WX8Z+XY\9_"^^^$/
M[2K?$OX>_ O2OVE?%_P_TWX1RZYXOTOX*:[K/C#PYH?BZVT/0M=U*\U[4=7\
M0?#_ ,9:+I_@#PW'K'Q+N-2T*>V3P;ON]-^V^Y?"+]IWX9_&WXI?M#_"/P.O
MB9_$W[,GB?X?^$OB-=ZSH4FD:)=:M\2OAMH'Q8\-2>$[VYN#<Z_I<O@WQ/HE
M[-JRV-KI\D]Z(=/N+](II8\G2O.,N5WIPI.RT7+AZ]>LY2:BG)RK5YJ<FV_=
MC"#M3T<I1G%PE--3E.&[=G5I48*G'5J/+3HP<(:*\I2DOWFOXW?&C]EW]MN]
MN_VM?BU\(?@;?7_CCP1_P6'^ ?[?/P8^%7C+XB?"'0=(_:[^"WPQ_9._9S_9
MT\;>!](\3Z;\1?$.G?#/Q'J=_P##[Q]XL^']]\8=/\,Q:1X@T3X::[JND6\T
MVHVV@]I^TU\./VI_BO8?LV?MB^$_V 5EU#X4_M0^.?B#\5OV$-5^)7P0\+?'
MCXN_"7XF?L^WW[.VL?&;Q1XU\/\ BW6?@-<_M)_#S&E>(_!'@67XL:RGB/X'
MZ3:>"-1^*?A+Q[J[^!/"O[R44J</9PITXOW:<HRAS6=I**C-[*ZJ15IQ=TM7
M!Q=N76<G.4I.R<U.,N6ZYHRDY)7NVN23;BUKK:5U>_X<Z9^SI\6XOVI?^":'
MQ6\$_L*6WP"^&/@'XF_MO_$GXS^%?!/BG]GC?\&KOX]_"E?!7ACQ+\8)-'^*
M5I_PL#XO?$7Q$UYXF^(FH_!/3OBOINC7.KWFD77C/QDVEGQCXJ^L_P#@HQ\&
M/C-\3O#G[*OQ$^!_AZ?X@^)?V5/VT_@Q^TQXC^#MCJ_AO0M;^,GPZ\-:%\0O
MASX[\&>%-4\;^)_!G@&#QQHV@_%*?XF^ [?QYXI\/>%-3\9_#W0=)U'7_#LE
M];>(-+_1.N.^(OB]_A]\/_'7CV+PEXQ\?2>"/!OB?Q?'X%^'>DVVO_$#QJ_A
MK1+[64\)>!="O-0TFTUKQCXC:R&C^&-)NM5TRVU'6[RRLY]0LHIFN8]'.2Y&
MGRNE-U(-+FY7>G.WO*=TO9))<ND6U%1:I>SSC"-Y*W-[1*$HMV4KQJ4_LN'*
MW[5MM22<HJ4G*]3G_"']H#]D#]H/Q=K_ .W#^T7\/O@3XW\0ZA^U-^U3_P $
M@/%WAGX'V7B3X/>'_&%[\._V OCM\'?BK\4/C9XJC^('Q3\&^!M!\5>./!NB
M:[X$T;P9J'BIO&-QI'PN^&5OXEM=&GU>^TCP=^S3?&\VW[1FB?L[W_PP^(EC
M)XF^"GB3XTZ#\69;CX<3_#&]'@[QKX/\&>+/AO);V7Q"NOBA8^/-%?Q_X0U\
M7-Y\-8?AWJ6BZI/#I7CV[U[3KO0T],TCQ?HNJS:+ILDW]C^)M:\+P>,$\&:S
M+9VOB[3M%E>RM[F?5-%ANKF6V_L[4-0@TK4)4DGM(M3\RUCNIF0L9?#5_P"$
M?$^GZ=\0/"-UX?UW3?&OAWP_J>E^,M DL-0MO%/A6>VN-8\+7MGKUB94UC0G
MM=<NM2T*:.ZN+'R=7N;NQ(6_E>5MR48TW\-.4EO*5G&$Z7+S<TT^6:G+1[IP
MBO9QBHI<LJDJJ:=2=.$7LDHJ4*D7R6BT^1PC[RNU)2E[[N_AGXE>!OBX/^"D
MWP'^..A?!_QAXL^$?P__ &&/VP/A=XB\<:)XB^$MG9Q?$KXK?%_]D7X@^!/!
M=GH/BGXF>&_&=UJ&LZ-^S[XPM)=97PROA#2]4U?PG#JGB6TL[W6[[P]^?/[(
M_P"RI^U/\-9_^""MCXW_ &<O&'AQ?V.?V//CQ\%/VE]7D\<? #4;'X4>-O$O
MP?\ @WX'\/VUVN@?&35=5\9:1XI\0?#75KBQU#X9Z=XV6WL[K0;SQ-;Z%<R7
M]OI/]"%%137LN91UYJCJN[?QN=>?2VEZ\E;M&*;^*[J1]I.,VVI1INDK;<CC
MAXM-.]VUAX:WTO/2S27YL_M&_"OXO^)/^"C'_!._XR^$?A-XB\8_"?X,?#[]
MM71?BEX^TKQ%\+M/T_P)J_Q@\)?""Q^'\-WH/BSX@>'/'&M_VY=^ ]=TU[GP
M7X5\2PZ7+=Z>^L2V&GW-W=VGP;^RA^RY^UA\._AA_P $B_#OC;]FWQSX?U;]
MG3]NK]N3XQ_'.QF\>_L\:C_PJ_X9?&GP7^WSX2^&NOZG-H/QMU>S\2_VG<?M
M.?#FZET3X;W'C;6='TK3_%1U'3K2\TO2]/UO^ABBE*//&G&6U)J2M=<S6+>,
M7-Y*J^72WN:?%[Q2T<VMZBL][+_9_JVBO:_L]=;^]K\+<3\8?V(_@)\>?@O^
MTVM_X$^'WQP^!_[(GCKX=_''Q9\5?V9OC]XU^$7Q-\(_L\?M'Z_\0_A7J'AB
MQ_8W\;>"_%/CCQGI_P '_BY:+\6/B+XH^'@\2K\+/"LK^&)K#P=\+/'5_JOP
MS\-_+W_!3_\ 9N_;5^/GC']N#P=X!_96U[QUX/\ 'OP?_8TN_P!GGQ]\'/'/
MP"^&>F_$#6O@E\9;WQ_\7O"_[2^L>*OB;\.OB_X]\>^']-U/6++]G;P)XALO
M%O[.]C8ZG>7C7/@3QMXB\2^*8OZ/Z*N+<?96LW2BHQ<ES-\LJ$H-MZWIRP])
M4TKQC3C[*TJ?)[(ZU&M/:.[M=)756,K*^CFJT^=Z.4G[2RFYNI_/]\8_V5?V
MB?B!?_\ !;3X7V_[/>NSVW_!3KP/\,=!^!?Q"UO7OA+/\//!]QK/[$GPV_9=
M\2:E\6KBR\>:OXL\-:C\!_B#HNH>/];LM&\(^(Y?$GAVTL+WX*7WQ"\4-J6C
MZ+Z;K'[,?[0GP^_;$\'_ ! _9?L?C]X'%Y\:/@)X?_:FC^)_CCX<_$?]CS]L
M'X!>"_@;\/\ P;XQ_:)U#P9J?B_4OB%\%?VJO .G>#O!7PS\">*/AWH'@_Q;
MXZ\;?"CP?;^//!WCCX&:KJ_Q,\$_MI@>G3I[5D:;KVAZS=Z]8Z3JVG:E>^%]
M6CT'Q):V-Y;W5QH.N2Z+H_B.+2-7BA=WL-1?0/$&AZREG<B.<Z9K&G7H3[/>
M0.].I)N-^5J+IRY>5:JC"=*"D[<[C&G5E3DG)QGSWDHSY)1F44Y.3;YI*<=]
M^=4Y2LGHI<U"%2+ARN+B]90YHO\ G=_8I_9E_:*^$_PG^'G[/OQI_P"":GA6
M^^,G[&7P?^+WPQ\"?MO:7X_^!&MZ+\8?#ND?"7Q!\&OAWXF_9PL=<^)EQ\5_
M 'QR_:!\/WN@VGQ*TOXH:-\)? FD>&HO'D_BGXFV]]J7A?P;?5]&_84_:N\;
M? '_ ()W_L\:W\+O&/PDU#P)_P $+OVM/^"??QE^*G_":?!G5M+^!GQ^^-OP
M>_8P^'7A*:>W\*?%V_\ %?BNPTS5OV>O'.KIK_PWTGQ3I]N;CP<TE]:2ZCJT
MGA[]E?'W[7?@7P7\4[WX0Z'X'^+?Q=\5^%-3^"MI\7A\&?!MMXZC^!NE?M!>
M(/$?ACX7>*OB1I4.MV/BR[T'4-1\+:KJ'BI/AOX;^(.O?#/P4+3XG?$W0_"'
MPPO;?QD_U96/(G*55I7J4O8R:2BI1=.M#G45%*+E&JVG&#IMT[QBU[2G&W)\
ML:2;2I5HXB*<I2<9QJT:L4W*3DXJ=*-XRGSM3:F[N%27\^6O_!_]O']LK]@O
MXB?L^_$7]C7P7^R5^TGX$_9*T?X2:5\5?&WCGX0>-?"?Q?\ BUX1\5?#OQ7I
MW@'X1WWPA\8>,?%^@_LI_%!_A+&OQ<L_B<GP\UO2X/&O@K1-"\*^.Y_"OBO5
M])]]^%'Q3\3? _X8_%?]L3XA?\$H?%_[,GBG0O W@?P[\3_"'ACQ_P#LM?$_
M]HGQS!HNN:OJ?C&3P[XOT3XPZ-X2\1? SX.RZGJ^H?#ZRU7QM:?%+XO:WXC\
M02>"_@;X1GM] _X6G^R%4K[3=.U-;=-2L++4$L[VTU*T2^M8+M;74;"9;BQO
M[=9XY!!>V5PB3VEU$%GMIE66&1'4,-7.4JDZLK2E5FJE3>*E.4I.M*/+;D]M
M&I5C*,7R)S4HQO!<T*,53ITHJT*4>6FM[1BH^RBV[\RI2ITG&4ES^XTW[S:_
M/3_@J[\&?BE\?/V%?BK\//@OX,O/B'\1D\;_ +-_Q"T7P-IFJ^'=%UCQ78?!
M;]I_X-?&7Q5HF@ZAXNUGP[X83Q%?^$? .NP^'K;7-?T73=0UMK#3KG5+%+DW
M,7Y[_M)?LU_M9_&.#_@N+JGAO]E/XD6-S^VY_P $^?V=O@I^SWI.O>/_ -F&
MWU/Q5\4M%^$/[17AKQ5X2U66P^/^IZ5X7/@/Q#\:O#UEKVN>(]5T[PU?/HOB
MN\\#:QXOLX-!N?$7]$%%92CS4ZE)OW:JFI:*ZYZ=.E*SUM>-*FUH[23MI)I4
MK*4)V]Z%K.\DG:K.JDTNTIS6EKII/6,6?@'\6_V?/C_I_P"V3^TGXG\4_P#!
M/72OVY/V=_VY_ 'P*O\ 08?&'Q&^"'A^V_9H^*?@?X:V7PI\8_"/]I+PSX[\
M=:C:^(_@%KFEZ/IOQ&U3Q;\&M!^,FI^']?;Q[I&B?#WXFZMXI\,6\GW)_P %
M'/V0O&_[4G[.'@#1?A%>^#]/^/W[-'Q\_9X_:U_9\B\4_P!HZ)\,M9^+_P"S
M3XZTGQEH?@_Q?%IJZOJND>#/&^BV_B'P6;NT;4;CPK-KVG>(&BUJ/1)=-U']
M&*^??AA^TM\.?BW\9OVC_@5X4M_%D7C;]EK7?AQX<^)\NN^';C1=#EU3XH^
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MB+XET3PG_P %!O\ @FM^TS\*_%?PE\??LV_#;X:?%_X)_ CQW^R!XD^+.O\
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M_#F=/'K?%SQ=\%)/A;^SOXW\%:=\'_ .E?M$?#CX;?M,:)^TA\4M:^,OPO\
M&?PXN?@E\:O'&O\ B3Q79_#;5TN-4\._ O1_#'Z:_P#!5'2OB1IO[).O_'?X
M0^(/BIIGC_\ 9 \:?#O]KV#PG\+OB7X]^'LGQC\"?L]^,M'^(GQI^!?BS3_
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MZ7K,UY:0-I&K+J5M<O<6T+6%X'BC,0U_A_\ #OX?_"?P?H?P\^%G@7P=\-/
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MY(1?([*,-%))R?*FW"48MN5XJ5"%%QLFH^SE.'MI>ZY\[M&2O*4OB3_@H/\
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MIO,'=M7O+FQE*:<>7WL/JGS1E#^;'P]XO^)/AW3I?CC8_M'_ +2=]XW\"_\
M!Q_?_LB^'[/7_P!I?XP>)? 4G[.OQ+_:[\+_  ;\3_ SQ#\,-<\:W_P]\;>&
M['P9XEU1/!\OC;PUXC\9_#R_@TQ_ WB/P[IVA:1IMA]+-\?/&'[,O[1'Q+U;
M]H_QQ\0?%WPN\;S?\%(?'_[/7[9W[.?QG\8_$OP[I7A7X6#XC_$SXB?LX?M#
M?L>>)%USX?>'OBU^QIX?^'.N_#[X/^//#?ASQQX<UK4OAV/!>L6G@;XA_$?X
MD^#_ !Q^W-Q^S[^SRMG):7?P0^#*Z?<^+XO&LMM<?#7P0+.?Q[<N+2#Q;)#)
MHOD2^+YY+@6T6O,K:S*\XA2[9I K;'A;X)?!GP-XM\3^/O!7PD^&/@_QWXVF
MU.X\9>-?"O@'PKX>\6^+9]:U*/6=8F\3^(](TJTUG7YM6U>*+5=3EU6]NWO]
M2C2^NC+<HLHSUY'"_P#RZ<$VM5-X2G0<N:ZDKU::K7C)-J\9<SFW"U924G>2
M]HYM>ZO=^MU,1"-K2B^6E4E1:E%KX7%QC'EE_(]>?MJ_&#X"^$/C[K7P=^.7
MQ+\9>&V_X(X?L'_M%7FG:C\>;K]ICXR>']!UO]H/QUX:^-?[5^I:A=:KK_A'
M3/VHD_8YU;5?CC\4XOA=I-W\+[?Q/X1\-:A-J7Q6\'^%?#WBS4_K3_@H%J'[
M(WC[]BS]J'QC^SI^V?XS_:&^'-U^T?\ \$G/%WB?1/#_ .UEK?Q:^"WP.U63
M]M?X%^&[S4O"7Q*T7Q=J&O\ AG6/B?X-NA\0_B1X.U_XFZYI^D>)-(\)_'JT
M\.^"O&OBR/QKXI_HB\!_ /X%_"P^'V^&/P7^$WPY/A/PUKW@SPJ? ?PY\'^$
M&\,^#_%7B:/QIXG\*>'SX>T?3SHWAKQ'XPAB\6:]H6G?9M+UCQ+%'KNH6MQJ
MB+="#2/V>O@%H'POUSX(:#\#O@_HGP7\3P:_:^)?A#I'PT\%Z;\+_$-MXJ>:
M3Q1;ZYX L]%A\*:M!XDDN)Y-?BO])N(]8>>9]16X:1RW1[:/M(U%27N5%5BD
MTG+EQ,ZJISDE%.'LY02:IQ:JTU)1C#EC2SJ0=2G.FYN*J4ITI-).W/AW2E5B
MI7M4YG*23FX.$G%MR3E4_##]L?XY_'KX"?&+_@IGJ?[*/CWXB>,-5^%7_!$'
MX'?&WX%>&=2^)7BKXP^'/#_Q,@^*?[9_@[4/C'X3\+_$77/''ASQ#XWM_!GP
MT\&:SK=U-IFJW?Q0U3P3I4?BY?$VIZQ?2:CN_M':QJ/P^\9ZI-^RC\>OB]XN
M_9U^//\ P1[_ &Q_CEX[UBR_:4^)'CC3?!VJ_!W2_@QJ'[)7[3_PU^)NL>+]
M<\<^!O'?Q8LOBQ\4-/G\4>#O&OA^W^-FF>$3XTU>/Q-K'PC.L:5^ZNC?"KX7
M^'?$O_"9^'_AOX"T+QA_8%CX3_X2O1O!_A[3/$O_  BVEV]G::;X:_MVRTZ#
M5/[ TZUT[3[:QT;[5_9UI;V-G#;VT<=M J8GA_X"_ SPEX<\4^#_  K\&/A/
MX9\)>.9KRY\;>%_#_P .O!^C>'?&-QJ,MQ/J%QXJT33=&MM,\0S7\UY=RWLN
MK6MW)=2W5S),SO/*6PK_ +V$HQO!O"SP\9:>[.5+,*2JM0<&WS8VE7MSMQK8
M2G:3]R5+2D^1Q<O>MB(5FE:[A&I@JCIWFIV_W2=)/ELZ>(J72O.-3\6_V -3
M\::%^T=_P3W:7XU_'7Q_9_M2_P#!%S4?CU\:M$^*/QQ^(_Q7\->)/B_\-?$G
M[ ^A>$_B=X?\+^.?$NO^'?AQKM[I'QO^)=KXB_X5AI7@W0?&<^L?VMXATK5=
M;L+?4HOH_P#:"\'2_%?_ (*A_![X%^(OB5\=M$^$?Q,_X)O_ +6/B3QY\/\
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M^S;XOTO6OVD?&NH^*=8^#7AS]H#]OOP_X-^#_P 48];\=WFM>-/"&B>'-,^
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M]!^*OC?4_@U\2/@-XW_X*H?MA6/[2/PWUW]G"#6!\(M2E\)_L_R?%W]IV_\
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M;X>_&Z^\56/AS0/A)XOT_7=-\5VWA:Y\0_;Z^.FA?&?]F'_@L'<?M!?%J_\
MA[\:?V8?V^O@+\)O OPDO?C5K/P^L/ _[-VB^/\ ]E/Q+\&M6NOA&?%VF>&?
M$?@O]H_3-3^(OQ=U#QOXQ\)ZU>>.[O5;[1[+Q'<:3\"OAM8_#?\ J.NO@-\#
M;ZZ^%=]??!CX47E[\"H([7X(WEU\.O"%Q=?!RVATVST:&W^%=Q-H[R_#V"+1
M].T_28X?"+Z1''IMC9V*J+6U@B0\5? ;X'>.?&$7Q#\:_!GX4>,/B!;^&$\%
M6_CGQ5\._"'B#QA#X-BUZV\51>$HO$VK:/=ZW'X8C\46=GXC304O5TI->M;;
M6%M!J$$5PDIJ\96LTX]$]:=?#UJ=5*4II59PH.E6NI0M.]-7C'EN2<HRCMS1
ME'32RJ4*U&I#1*]-2J^UIW?,I1Y9:2DY?G]_P6=\8>)O"'_!.'XN>//AW\3?
M''PN\3:3XX_9GN/#GQ$^%WCW6/ OB'3X?$W[3WP<\+7XM-?T&^M8=2TG7O#W
MB/4](U#0]8CU?PQXAT[4I+'5](U2SG^SM^;'[0?QK^*/[)OQS_;^^%/@GXT?
M%RU_9PT'XV?\$8/$?Q6\3?$W]H#XD>/-7_9K^"?[8'[0OQ*^'G[9WB[PA\6/
MBEXR\3?$3X4^"_$?PZ^'VBV,T_A[QAHEI\$(?$/B7XG?"VX^'>L:=#K^F?TI
M^-/ 7@7XD:'+X8^(G@OPGX]\-37-M>3>'O&GAW2/%.A2WEE)YMG=RZ1KEG?:
M?)<VDO[RVG:W,L#_ #Q.C<UB6WP=^$=GJ/BC6+/X6?#FTU;QQH8\,^-=4MO!
M'AF#4?&'AL6<>G#P]XIO8M,2Y\0:&-/ABL1I.K2W=@+.*.V^S^3&B!*ZO;K/
MF:[PY*"<'>Z7-*BW)ZVYN9)RBU.U;2ZO:FX]+*;J59*HMFW&%5Q2YD[Q2YE%
M^[\*?LU0>./A]_P4"_;2^"'AOQAXY\:?LU:;\%?V4OC)I&F>-_&^M_$"T^"O
M[0GQ,UGX_>%/B5\*_ OB#Q5=:YXFTKP]XA^&OPL^#GQ9U'X7W'B271?A]?\
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MG?EM+\^OV>$UGX6_\%6/C]\%-)^*7Q?\7> ?'7_!/_\ 9E_:/UWPO\5?C/\
M$3XM6=K\8M7_ &@?VF/A]XD\=^"-'\>^)]>T;X4V?BSPQH?AO2=<\&?"/1_
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MKMNRNV[*]E=MV2NWNZ2LDKMV25WN[)*[M97=KNR2NW9(****0PHHHH ****
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M6;+1KCX=JO\ PF?AN;1G>75;F&#1+^VTNVU'6:&L?\%1_&)T7]C674[?X/\
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MQY\0OAYX;TG/[;'[3WQ$^*=CXMT7Q%K7Q8^**_!?6KKQQX:\-^!_%/@GP_\
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M2FY1O4PIPJQG6G.4)2E&BJ;:;45&A3C4CHO=;J1J6:7(Y2524+.T/B;XC?\
M!1']LGX'>!/V.OB+^T!^RCX:^#\'[3USXO\ @#XH\ 7'B1/&WB3X1_MKZE:>
M,-+_ &8O!.M>+?#OB>+PG-\#_P!J7QKX<T[1?#WQ,U.+0E^%MYXI\$:-\5G\
M.)XIU?Q)X%]^^//[77[07A/QSJW[-/P0^'OAKXC?M1^ ?V6/"O[2/C8GP?XF
MU7X7Z]JWC?Q/X^\"?#CX:^'[2W\?>&=>\):7\2O&/P@^*=EJ/Q0US7O$8^$>
MFZ5X3O[KX=_$X^*=0A\+=AX^_P""</PE^+OPG\5?!7XR?$KXU_%_P%XP_9P^
M(G[/FK6/Q$U?X<Z]?+K7Q@U+4-;^*_[2%CJ0^&-K=6G[0_C'6[O3]2TW6(V_
MX5;\*?\ A']*TSX&_"?X7Z%<^(-*UWB?B'_P3%TSQGXM^ ?Q>\-?MB_M@_"[
M]I?X&?!^]_9]U#]J+P;KGP'O?BW\<O@QJ.JV^MS^#OCSI7C'X!^)_@_XYFTS
M6H[OQ+X8UV#X5Z-J.@>,=2OO%J&\UBXEF?/3E:>LG.;3A%1LI0JJ&D[Q:IUE
M";CRVE1J0IW;H5(5=^J:2222:DY24N6I3;=XN,TZE'GIIWO&K"51V]M"5+(T
M[]LC]K?XR:=\6(/V>_V<O >G?&#]F"U_9DL?CK^S9\9/']O;>*O$7Q6^-?PI
M^&WQY^*'P/\ "/Q;\+ZDG@3P%<_!CX3?%+PK_87Q>U;0?B7X5^+GQ*F\1^"T
M\*_#OP]X3B\?^*<'7O\ @H'\5_#O@S]J;Q%=>#/AY>7_ .S)_P %0?V:/V%Y
M8+>/Q+;VGCOX=_M%>)?V)=!C\9Q^9K,T_A3QIX4A_;&%Z\+-XGT/6)?AZUHE
MGIZ>*!=Z!V>O_P#!*[X62?'+5/C5\,_CS^T_\#K?XC_#KX2?"C]I/X:?#GXA
M^'M1\)?M3>"O@EIB^&_ P^,'B7XF>"?B#\6X/&K^!8X_AOXE^*_PZ^)/@3XK
MZ[X$$E@OC6PUR>?Q%(_XF?\ !+[P;\2/%7[1&JQ?M)?M'^ O!/[1WQY_9\_:
MG\1?"KP,?@/#X3\*_M'?L\:U^SSJ?A_XI>%M8\4? WQ3X\NW\06G[+WPHT_6
M_ WC7Q=XN^&R3KXJUVP\(6VN:MHM]X8I<GMJ#:2I*HG7BK\TDJM%R<7J_92I
MQK>SIW56"FH3FW>9+4O95DG>JX?N962LW"=E*[:]I"4HJ<[.G/EYX07NQ/BC
M]I_]ICX[^"/@;_P78\;_ !>\+_LY_M9?"3]DOQ_8>%O _P"SG\5OASJ^A> ]
M3^'-S^R-^R;\?H]"\87-YX@^)NE>,;72D^+WB2?7-'U'P597?Q&\=0?VG;^+
M_ACX3FT'PEX.^TOC'^VU\7CXM_;I\.?LT^!? GC'4O\ @G9X'\ >*OB=X1^(
M,FOV.K_'KQSXQ^$VI_'Z\^"?P[\2:3J5CI_PBNK7X2R?#Z31/B[XBT#XMZ-K
M/C7XDW6@W_P\T'3_ (<7^L^+M7XR_P#!,GP-\;M._;X\)^(_V@OVA-!^&G_!
M1#3/"2?&+X>>$T^ D&G>$_%'A_X5_"KX(ZUXT^&?B+Q'\"O$WC+2]6\9_"OX
M+>!?"^L:5XJ\0>+_  OI<S^)_$'A;0]"\0:QIVHZ#V_CC]@/P9XI^)/QR^)G
MAOXL_%;X::K^U5\&_"_P3_:CLO!2_#NV@^,6E^"/#_B'PIX1^)'V^_\  5[K
M'@+XTZ+X2\2ZIX%7QOX&U#1]'O? MS;Z7?\ @^Y\0>$OACXK^'^3C+DE&/+[
M1X6G3IU'9*&(CAZ\?:5;0<ZM)5Y0DX_$X3DUI%TS2GRI0]K=VQ52K44;VEAI
MU\/+V5-<RC"I["-2*DDH\\%=WG&9\3?$7_@J-\=/%6@_&SQ_^RU\+O@YJGPP
M\ ?\$P_V</\ @J#\/O$'QD\1>.;+Q7XY^&GQGL?VAO%4_P .M>\&^&-(MK'P
MCXOUCP_\"9= TC4(O&&NZ3X*U'6X?%VKCQK%YG@2T_0;XT?MI> ?@=^P?XS_
M &]?%.B:N_@/PA^SB/VAO^$0AFA7Q!JL%]X)MO%?AWP/;WBQ3V5MKFOZCJ&E
M^%;?4;A!I5GJ-_'>WTL&G0SS1^?>*O\ @FY\'-?O_CJ=!\=_%7X;^%_CK^Q!
MX(_X)^W?P^\ +\(K#P7\-/@+\.(?BG;>"C\++37?A'XAUK2/%N@6OQG^(-I9
MW?B?7/%_AAK75;*WN/"<T6AZ&NG^[WG[*OPK\2?LE-^Q=\2H];^*_P &M1^!
M$/[._BL>,[K3K#Q1XT\ +X*C\!75QK6J^ =)\$V&E>*+[18Q<G7?!6D>$WTG
M6_+U?PW;Z'<VMD;;6KR.%14KIMKD<M)V]IB[ZMSBG[%X11OSJ-1<SYN2K[3&
MC[15(NM9Q4I<RB]''DP?*K6BVU4CB^9KEO&2LH\U-4_"]-_:-^.W@[]J7P5^
MR3\:K7X16_BG]H/]G7XK?&KX!_$[P!H_C&;PMH7C?X):[\.?#OQ7^$'CKP1K
MOBLZYXQM?"L'QA^'7C;PG\3=+\3_  VA^)VBOXU\.7_@3X6:QX8T;4_&'RA_
MP16^&-GX_P#V6/@C^V+\6M/\!>-/VD?$=I^U)X?C^,VE^#M6\._$:X\*?$S]
MJCQIXR^(?AKQEXDO?&GB5O&FG:SXY\(:)X@T2VN;/2[#P?;V<.D:!I]O&U_=
MZC]]_"[]DN#P1XK\&?$;QW\9_BI\<?BG\,/@GXB_9]^&'Q,^) \#0^*/"W@+
MQGK'@O7O'VNZA!X1\'>&_#?BWXH?$O5/A?\ "B[\?^-/$&@7.G7<OPTT!?"'
MA7P5;ZY\0K?QML_L;?LJ>%_V*OV>_!7[-_@CQ_\ $GXD^$/ 5SXKN-#\1_%B
M7P!<^-)%\7^,?$'CG4K;4+KX;?#_ .&?AF>"WUGQ+J,>GF#PM:SQ6"VL%Q/=
M2Q/<RN\(QJ)*\I1BHRY4E[N+Q$XV3<I1?U:I"$I.3E*3E&4GRRE4$IODYGIS
M-RCS7^+#48M-VBI)8B$Y)**27+*,8W48?@#\3O'OQ\^-OPT_9F^)7QJU;X5_
M%_XC_#7_ (.)M7^$'PB6Q\$ZK\*['P[;_ W]HK]I+X!V%LNO7OB?XN7/AWPQ
MKOAGP5X>;R-#\/WNMZ-;)J]QKE[\2_$.IOJ;?H/X"_X*0?&*72O$/PE^(GPU
M\&W_ .TYHW_!0[XD?\$_=-U+X2V/B7Q!\,?$%]X-_97U#]MVS^,EIX#\0^(-
M(\;064/P @31M6^&_P#PG=W<W/Q7MO[,M_'^G^$M4_X2/1O5?^'6?@0RBS'[
M1_[2%MX2TG_@H+=_\%&_!7@FR3]GE='\&_%[6_'GCWXJ>,/ UKJNH?L_ZGXM
MUOX6>,OB-\3/%>OZK8>(/$>H^-M+L4T#0?"?CCPY8:9?G6J_Q(_X)._!WXC^
M&_C983?&W]I+PMXX^+'[9^A?M]^$?B]X,\6?#WPS\0_V?OVD/#?PY\)_!_2]
M:^#MSHOPOL-!D\)3?"CPC#\.=<\)_%/0OB9!X@\+Z_XJ74[Z;7-976[2*C=J
M<::2IJ2<U)<THI4\MA+V;YXIU)NABG*4FXS3BY-3G&<*IQY54=1J55Q<83C>
M,6_K&95%S+E?N1AB<,HQY;PE&2BN2#A/ZI_9-^)WQ]^*7P\\4WG[1OP3N_@K
MX^\(?%/Q]X"TB5Y='BT+XP^ O#>H0'P)\>O"?A:P\9^.==^'6@_$O0+ZUOI_
MAAXY\2:CXS\ >(K+7_#&HZKXCT^PTGQ;X@_)SX>?MS_MP>!/@5\!M7UQ?@-^
MT'\3_P!IG_@JA^U[^Q#H^I:Y9>//@;X;\"6/PT^.O[</A_PSK#6FFZQ\:+K4
M_"]EHG[-^C:7HNBP-9:YX9\,Q6^G:QJ_Q1\67VH>,G_9WX#_  =N/@GX(E\-
M:O\ %3XF_&_Q=K.O:EXJ\;?%GXO7WA:?QOXU\1ZE%9V*WEYI?P_\)^ ?AQX7
MTS2-"TK0_#.A>&OA_P" _"7AVPT;0[*>;3;WQ#>:[KVL?%EO_P $O/!<$W@B
MW7]I3]I&/PS\*OV^/'G_  4(^$WA""']G-=)\!_$KXG^(_C3XQ\?_#6+4+G]
MGJ[\3>(_A)XC\2_M#?%NZ:V\4:]JWQ&TC3M<TC3= ^(^E'P[8W;M).M%R:]E
MR0A-14E=JI2<Y15KING&>JY?>;Y%!.,5,U-P7L])J524>9I[T:D::D^J5246
MXNZM:[DXW/&/B'^W[^U1\"OB#\-O!GQG^'W[/<FJ)\>/V"?V</B1X3^%VM^/
M?'5_XLO?VPKKX5_#GQ1^T-X<\6:2^H?\,V_"[P7\>?B'XN\&_"/X:_M-^ M-
M\9?M#Z'\"_'VI^%O&>B3:QIG]D\Q9_\ !2K]J>7Q!XF\5:C\%O@'8_!GX8_\
M%8?#/_!-OQ]IUC\0OB!JWQ*US0/BK\0OA-\&OA_\5O!^IW/@_0_#6FZIX0\<
M_%WPIXE\9^&=:TC4(/%OAVX\1^&M#U#PG>>$=,\8?$#Z&^*G_!+KPI\3O'_Q
MH\8Q_M/_ +3'@70?C-^TM^S;^V)<_#CPE-\"[GPGX*_:3_9H?X$VGA?XD>%M
M1\9_!#Q9XVU&UUK0/V</A?I.H_#WQ[XK\:?#&QN;76=7TOP;;7=UHB>'M9_^
M"8/PT?PQ\1/"@^._[1*6/Q+_ &_O"'_!1G6;Q)_@*-1T_P",O@3X@_#WXG^&
M?!6C2'X"&SB^$EAXP^%O@F^DTK4K'4_'U[;:7-I]]\1KFSU+48;G-.K[[<:*
M?[KV<8IN,7[7#.LY7M=.FL0HI;.45'E]SEV:A:"7.[.ISMNSE%TZZI<MM$U-
MT+W71N3E:;?'>'/V_/'OBW]JWXO?LWZ-IOPQTWXH_"76?B+(/V1_B%%K?PP_
M:(^)OPDT#P+XWU'X6_M!?!'XD>+_ !3;?#'XO_#[XN_$#P]X<\-W</A7PB=+
M^$.G>)KX?$CQO8^)/#-YH5Y\[>'/^"P^O^#?"_QZUGXT>#?A[XOU'X8?L2?L
MT?M>^'7^#UWKVB?#_5O&/[2/Q'^(_P %],_9\TGXK:[J7COPA\6/"V@?%3P;
MX<TC3_VO?AG-+\+/&>B>*]5UK3_ FE1^"[B+7?LWXT_\$W/ 7[2$\]A\?/C'
M\8_BCX/L=7_:?UCP+HNKM\-M)\3?#6']K7X.?%WX!?$CP7X2^)GAGX>Z+XZ'
MPV\._"_XT>+]*^&WA?5]5U34] U1= U'Q'XF\96G@GX>Z5X.\HL_^"/?P>UO
M3_%^B_&SX[_M ?M#>'OB1^Q#X=_8)^(_AOXD6_P!TC1O%GP?\#>*_&OB_P"&
MVNJ_PS^!/@+7?#?Q"^&VH_$#Q&/"OB7POKFD":9M*UGQ39^)O$>B:5K-KI#E
M4?>CS25.RBGRJ4DI-MS=^2<Y1BM(SA3E-3BW3BZ!+U>CY4ZE[VYN6/NJW*FN
M>"3D[7ISFH.,VIRC57-?MQ?''_@H-\%?@E\6+P3? [P=:Z=\>/\ @GOX1^&?
MQ\\)>'_$>HP>.O!W[4'[5/@7]G_XV_"^^^%&I_$IO$OP\\=?"8>)M$UN#XL)
MXRUG0_B+X/\ 'MOIOA'PQ\/?'&A:EXA\.4?B[^W/8_LC_%7_ (*1^-OB1\"_
MA!J?BS]G#]EO_@G[XHMOB-\.EN?"/CS]I[QE^T%X]_:7^%'PO^'GQ%US4M!U
MZ]^'7@W2/C+X<7P_X'L+S5_B[;_#7P[\1O$OBVXUW7I[^_T&S]EU'_@F/9^*
MOV;_ !I\!/B?^V1^U_\ &;Q-X@U+X(7_ (1_:#^*GB+X-^(?BU\+X_V:OBOX
M/^-7P5M?"^F6/P7T?X3:U=:=\0_ OA[Q#\3?%?CSX:^+?'WQOND>W^)WB[7M
M)T;P'I?@GM/'G_!-CX,?%[4?VI;OXU^.?BQ\7]._; _9R^"G[-7Q@\.^+IOA
M7I6C-X=^ ;_$/4O 7C_PD_@#X4^"M:\,_%.#Q=\5/&_CV;Q!:ZQ+HFG>+]2T
MZ\\+>&?#FG>&O"^E:-$E;V7*N9QKSJ5MH2G1=%1C3IRDI>SFVIP;:Y4ZD)SE
M6C";DH7=2I*I90E0I4Z<5=J%:.(E4G4FDXJ<6G"=E[UH5(05)SIJ/@O[2'_!
M07XZ_LCWG[6'P_\ B+\._AO\3?B!\)?^">?QQ_X*'? _QGX4'B?X9_#?QYX5
M_9XN[/0_C#\'O'6A:KK?Q1\3Z!XR\$:GXF^&NM^'?%6C:Q?:)\4=&\?7.EW&
MC_"R]\&3ZIXD]:_9T_:\^.7C7]K.Z_9Q^-G@7X6:+9>-OV/_ (??M?\ PJUG
MX8ZUXJU.ZT'1=4\:2?#GQM\/?B#-XGMK.'7M9@U>Y\.>*O#OB7PYI?A[3HM.
MUK5O"=[I&HW/AF#QAXGW_'__  3L\%_&;P;\9-"^./QF^+_Q,\;_ !H_9*\9
M_L2:M\8Y[3X1^&?B#X9^ _Q&^V+\25\(V'AWX76?PXTCQ_\ %9SH&K?$_P 3
MKX"DT+6/$/@[PI=^%/!W@C1-!TOPY9[]E^PEI6C?%ZS^.OA[]HCX^Z)\2M'_
M &*W_8F\.ZK!:?L^WFG:#X:CUN#Q/IOQEMM&U#X"W5I>?&;2O$UG8ZU;KJ9O
M?@Y<26B6-]\'[K2Y9[*72/)&+YDISYJFJBXQ]FZ>*]DDG)VJ1J/"J4M$[/22
MC4E5F2DYKE?+#V=/F4FF_;*KA?:.ZCK3E26)Y59:M?#S4HT_NZBL#PGH^I>'
MO"WAK0-9\5:YX[UC0] T;1]6\;^)K7PU8^)/&6I:9IUM97WBKQ#9>"_#_A/P
M=9ZYXANH)=7U:U\)^%?#7AJWO[RXAT+P_HVEI:Z=;;])I)M)II-I-)I-)M)I
M.S2:2:32:3LU=,I7:3:LVDVKIV;2;5UH[-M76CM=:-!1112&%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\'ZY+IS:A:65Q<6MIXC\/ZOI\=XL'V2^%I]LT^>ZL)[:ZF]5K\H_^"*2._\
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MT^2%.+<-?CI*JG]E1?L5:3WNG6A%M*S=^6Z<>;]VS\=OA&/CG!^S2/'6C/\
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M._A'=VZ_#..PUK0)8?VJOBS%H'BV_M+CXIZ?!?:"S?$.]FT6"XF\"_: U_\
M:>^#FG_\%QOVNOV=?VE[_P"$VL_LF?M>^%/C9:?!R\^'/PP\6?"[]H9OA_\
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M;37/C;\'-(\8_#KXC>*X/%?COXJ?=G[ WQO^.?C?]HO_ (*%? _XO:IXMO\
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M3;:#X[T>32TNY>U^)W[1W[<7P6L_^"N_PD^'?Q@\0?M!>-?V:]"_8_\ B3\
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M*_FG\$OCA\9/VI]:^+?Q6T']J?3_ ($6'[-7_!3CXC?LL^-O@OJWPZ\$^,?
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M<V*IPBDVY/739_N117\T7[,_[5/[:W[3]Q_P2J\#>)_VI_&/PSNOVG_V>O\
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M%7/XD\7/I'_"ISIG]@_\*V.I/K[>(CX(_P"$:_XI+_A&3K']C_\ "&_\4?\
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M<+;Y<^,W[<OQ!TOQK_P6(\&?%;X21:U^S/\ L-_LG^!_&6H6WP>^,_B7P?\
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M?B?X%?$+1]0\8?"WQMX0U#P%XR\.:[XJ\77UQXL\&ZQ9OINN>'?$GB637?\
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M,/>Z5:6$LGAKPQX5\/.6T;PQH%EIWKU%%EV6\WLMZC3J/;>;2<WO)I.38_\
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M[DVVWNVVW=MME%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK^-_B)X6_9J_;3_:^_: \!? '3-8^&5O\)M"^-NA?MM?M1:S\'OBKXF?P_\
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M^+7B'2/&7I/Q,76M=B_X*,_#7_@HA=6L'[5UE^Q[^SMXC_8:UY)-"_X3Z_\
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M+Q7]]XD_9TM?$_CF[^,'QN^%'_",Z;\,QH'@;XY^*=)^+FEZ?=_%?PC:_/\
MXS\3?$_P.?VO=&_9%?X5?MC_ !+^('[+_P"W_P#$'X,_M8_LHK?>&?V_?A-H
MU[^T9\-?'WQP_9<_:F\)Z)%XE&O?&>?2]2C^'O[)OQ?TA] ^(D/Q%^":>$O^
M%*Z?XBU&_P#$%S_7Y15RFY3<VHJ\JLE"*M3C[2NZ\::B[WHPE:/++WY4N>C*
MI.C-4Z403A%1YFTHTHMM+F;ITE2<[K:<HW;M>'/R55&-:'M*G\N'@^3_ ()Z
M?&#]GO\ :=^+G[(/[=^O^$OAS\6M2_8WTOXD>/\ XH? ?X:^"_V(_!7QL\&?
MM!>#=<^&'@3XQ_"SP/\ !;]E;1=:^(?QO6[TCX _M3>&W\3GQ"/@/?>!_#/Q
MPO?!VFW'P9GUOQ3XA^,O#?B/]EWX:^)=7^'O_!/GX=>-/A$?^"B.@>)_V#OB
M7XLN;O\ 86_X*!>$Q\1?@GJ?[2OQJ_80^,MQ'IMS\.?&.IZU<W=C\ _%%]X!
M\6ZAX&\4_&'XM_"O6M &DP^(O'5K_7U16<E=22NE)65_>Y/=FG92^-7J33A4
M<H3IM*7LZL8UTXOE<9/WFIJ;=W!STC&5W!KDE*,(-5*:C*E.+<%4A*5)_P L
M7[6WCSXNZK\2_P#@HOXD_9*\+_$+PM^T=XM_X(Q_\$[/&MQ\'M'U%M,_:@\/
M:6_[07[5]]\??!^A:1H^KKXJT?\ :1\(_LWZW9:1HD'A.ZA\::1X]O/AK/X9
MG37]3\(7-WVOQY3X):EJ'[;7Q"_8IUOX<K^Q'XV_X(N?M):E\<7^ DWA+1/V
M?+G]HZ+4+$?LO>)[2?P.NGZ+;_'>^^%TGQMT7Q/=Z!+!XVM_!OA_X0Z;\05B
MM;#X.Q0?TT456(:KQJ*WL^>-:-XR;=JT,="4)RDG*K3OC55<9.,I5Z,:CDG4
ME**PZ]@X-VJ\M2G/WXI:TY8&2<5%\L)I8)THRBK0HUYP2:A&,OYM?^"?>B_!
MSX;?MR?L&CX47/ACP]K/[1'_  0_7Q9\=4\/^)%FU/XS?$/X6^.OV/M+^#_B
M[XF!M3NKSQUX^\%^#?%/QP\.>"O$_B0ZGXGTSP-%XJ\,:9?Q^%_#+:=I?U7^
MTY=_!?5?^"C%_P##;]O"T\"3?LE^/?V$-"M/V?9/C]=>%-.^ 5_\=[/XS?%
M_M0Z#IU_XLNK+0?^%ZW7PDN/V=];\+QWDO\ PF5C\/?#GQ!UCX936>F6'Q<N
M!^S]%.<N>I4J-)JI5Q<^22YHPABJN)J<D-5;V*Q+5*6EI*4E&//:"A'DITJ:
M<E[*CA*7/%J,JDL+3H4_:3T:?M70C*I'=KECSR45?^4/X>>%]0O?&/\ P;>V
M7[?.F^&/%G[2=_HW[4-AXSU+]H/PWH=U\:=8\ :3^S7\5[OX!)\:!XZT]_%D
M/Q#M-.U+P)/XOMO&7E:Y#\>+[73J:#X@75[YG[??M_W7PGOM!_9T\ ?&/4?
MX\%_%/\ :5\+_#S7O#'CS4](LM&\<>&O%W@'XD>&/%7A2YLM7N8(M7L-;T;7
M)]&U2P02B>UU/[-*O^DHK??U%*34^12BI1C6=6479J:<Z,G&2LE>:HN,Y6M)
MUJLE&*DH)I<KDXOE<J2IQ<6_W;4:T8N#OS*,'5BX1O=*E33DVN8_D,^+_@CX
MV^#?^"6_[>_[.7[3<.KV'A+_ ()7_LM?MD_LG?L^?$_QW>^%;>W_ &J_$GQ0
M^ FN>'OV5?B7X833)-/NK?QS\-?V'_B1X;^".LZ:B:U;^/?B?\??B5I<:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME.G3FJDIMJ,E&:7+JH?M[XH^*7A+3_@YXK^+4?Q$\"> O".C^#/$WB5_B?\
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MCKX8_LJ'P+XNTPW>E7>I:7J=K9:_H%_'8:QHU_J&DZQ8+;:GI-Y=V-U;S/\
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M? ,E[!:VGQ(^'FC^*[JU\(:_X\\ 7/B7PEX?\87,'A/6]9L/$4T6FMR/BO\
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MQ3:_LO\ QD.DZCHUC=726*>&X]:M-)'CKP_%J'QU\!/V=/VPOV7/@K_P2?\
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M:-X)\!^'1906,USI+ZYXK\0Z1IEWJ6K6]KI^@0W$^H:S+:VMG<,O+ZA^W_\
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MF]\,_M5>/O!NE6MEI&FQ6VI_#?[)W[*'[2W@_P"'G_!#'PGXE^!_Q%^&6O\
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M-IVIZ?!K6CW+&XTO5(K=;[3YR9;2>&0EJYSPW^SS\ ?!OC_7/BOX0^!WP?\
M"OQ2\3WVLZIXE^)7AOX9^"]"\?\ B+4_$?V3_A(=1UWQCI>B6OB+5K_7OL%C
M_;-W?ZC<7&J?8K3[=)/]FAV?/G_!1O\ :K\6_L6_LC?$+]H#P-\.)?B?XIT+
M7OA?X,T;0?[7T31M/TO4/BU\4O!WPHT_Q9K,FMZKI":GIGA;4/&=IJY\-V%[
M:7OBB^M['P]-K'A/2M2U/QIX;S;G]NJY3]H#6OV<-/\ V1?VJM;\<^#?!/[/
M?Q2^(^I:1;_L[7GA;X=_"O\ :$U?XK>'K#QYK6I)^T0;W7XOAWX@^#/CG1O&
MW@GX?Z9XR^*.N3Z:U[\(? GQ1T>.YU*WFZBG+9<THM_#K[!UINZMHJ,>:HV[
M*,;2YDDD/62BU=N,9+9JSK>QBK7^)UG:*MJW=6;;/K#Q1\'_ (2>./%GA3Q]
MXU^%OPY\7^.O =MKMEX&\:>*/!'AGQ!XL\&6?BBR;3?$MIX4\1ZMIEWK'AVV
M\1:<S6&NP:/>6<6K63-:WZ7$!,=<9H'[+/[,7A0?#=?"_P"SE\!_#:_!N_UK
M5/A"N@?"'X?:./A5J?B-I&\1:C\-QIWAZV_X0:_UYII6UJ\\,?V7<:H99#?2
M3EW)^%)?^"NGPAT7PC\7/$WC?X&?M#>"]9^$W["-A_P4?OOACJVE_"R/XIZE
M^S)<1:S/K'V[PM<_%2QMO GQ>\&VVAR7_BOX6_$+6/#-W'::MH]KX;UKQ-XB
MB\4^'_"O5#_@J9\(]"F^/\7Q5^#WQ]^#*_ G]DI/VXK*;QUHOPWND^,'[-21
M^((-3\;?#N/P=\3O%-QH.L:%K7AUM)USP/\ &B#X3>,=$7Q#X6U/6-&T_3[W
M6I?#U*,DE)1:BV^67PQYE[1M)WBE).G5NKJ2E&;=G=L<DI.#:YN52Y;Z\LG"
MFI6UO!NI3BFKQ:G'5Q9]Q_&3X#_ []HKP@GP^_:"^#/PH^.O@*/5[+Q!'X(^
M,GP[\(?$[P@FO:;%=P:=K:>&O&VCZYHRZO807]]#9:DMD+RUBO+N.":-+B97
M?J/P+^"6L>.?"7Q/U;X._"S5/B5X!TLZ'X$^(>H_#[PE>^.?!6B'&='\)>+;
MG2)=?\.:6<#.GZ/J%G:<#]SP*\'G_:ZU*V\.>&]1;]G3XUZCKWCSXP^$_@]\
M-].\+Q>!_&GA+QROC+X61_%ZQ^,]A\2_"/B_6?".B?L\Z%X8AU^Q\5_$GQ3<
MZ'J5IXG\'Z]X;\-^#_%FJZQ\.+?Q_P %\*?^"BGPV^.W@;X-:[\'_AU\1?%W
MQ!^.$/[2]YX6^#\E_P##.S\0Z1I7[(7Q4;X&_'SQ'XF\;67Q U?X2GPMX5^,
M-]X/^'^CZWX.\?>,AXSU+XB>#-=\*6VJ^"CXJ\5>%9;L[/1W;4>9*3E%2A)J
M-U)N*4H2:C=>]#9N+:]Y-I-I*S=FXI-QE9RMRI-\LUK9^[-;*2^IO"_[/'[/
M_@C0/'WA3P7\#/@[X0\+_%:?7;KXH^&_"_PR\%:!H'Q)NO%%K-8^)KGQ]H^D
MZ)::=XQG\165S<6>NS>(K;49-7M;B:WU!KB&5T;!T_\ 9._98TGX)7W[-&E?
MLT_ #3/V<-3^T_VE^S_I_P &OAU9?!+4/MFN)XFO/MOPIM_#<?@2[^U>)(H_
M$-S]HT&3S]<C35I=]^BW ^-O!W_!0GQU\1?VJ?V6/@_X;_99^-_AKX?_ +0G
M[$/Q9_:IUBW^*?A_PM\+?C=\._$_@OXI_L[^ H? 7CWX7^/_ !YX9U3PE-X$
MC^*FMZ?\01$GB.37O$.L^#KGX;S>)?"&F>(?$K9/['W[<'PN\8?L]?LNZ=\%
MO"_[4'Q1\:_'[PY^T?\ $/X??#SX\^,O"GB#X\V'P_\ @=\7+GPC\5?%_P 8
MOB3KGQ UKP=8:+X7^(7C;P#\./"VGV'CGQ5K<C>// 6C:'I5SX4\.>-_$/@I
M)IJ?]UJG*.EVXU)0Y&N9W473;C[LHWB^5*RDW9KEE9Z^^I).RYH*?/S65I2C
M)*5VI6?O-IM+[\OOV=OV?M4T3X1^&M3^!?P<U'PY\ -8\,^(?@/X?OOACX*N
M]$^">O\ @JP&E>#=<^$>E7&B26'PWUCPEI8&F^&=3\&P:->Z#8 6>E3VEO\
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M0>$_B>_X:?M;^"O!OQ#^"5I\2%_:W\2_$GPQ_P $>[_]J_7[GP_K#^._@O\
M$KP)X4U/X--\0+W3?A7HWC'5/'?C_P#:LC\1WNGV_AC5)_AVFI:CX<\2Z[X>
MT;Q)J5[XDFTTI)N,I;*,N775R_=8JK)Q2^)16$JIVO=)S@YQBTS5RC%)MR@Y
M]$DE4PU-<U[<O,\53:O:UU&2BY)K]CZ*_'#]H_\ X*L:A\,OV<_^"A/C#P5^
MSWXYTW]H?]AK]F[X>?'[6OA1\2=>^%@L(-"^.GA+Q_X@^&&J>)]1\%?$OQ"N
MG7GA%_AUXO3XL_#FZN-+\:6U]X7N;+P*/%_AGQ3X%\>^)/5OV@/^"JOP$_9N
M'C:S^(GAOQ7;>+_A-X/\(?$#XQ_#"'QI\ !\4_ OA7QG=ZXEA%I/@Z3XTJWQ
M2\8Z;X?T63XB:MX%^%FH^+O$$GP]DAGT&'7O'^L^#?AWXMGGCS2A>/-!I27-
M&RUG%WDFX^[*G-3?,U!Q?/)*TG7++E4N65I*Z]V5WI!KW>7F]Y5(.":3GS>Z
MFTXK].:*_"Y_VWM=_9K^.?\ P6<^.'Q /Q]_:(^ W[,'A?\ 8X^*NA?#'X:7
M'@GQ!JOPZ^&GB#]GS5/&?Q2U_P"&_AKQWXS^%_A:#P[8VUM??$?QD'\2/XDU
M#3['4)K5=;N++2M'B_6+P[\=-"\5?&.[^#VA>&O$VI2:;\$? ?QSU/XBV=_X
M O/AU9Z'\3_%/C+POX"\,I<V7CFY\8:GXF\3'X=^.-<L+_0_!NJ> %T+PW<R
M77CF#5+_ $72M3MQDE'1ZPC.6C7(Y*N^63:MS)8>IUUV2YO=<MI-JZ:O[K33
M4XVH-2C9W<7]8I*]NM[\OO'M]%?FA^TM_P %,?#'[-GB#]J7P[=?LQ?M,_%.
M;]CWX'?#?]IOXQZM\.(_@!#H$'[/GCNW^-=[JGQ)\.ZC\0OCWX$DU5_ UK^S
M]\1X=7\!W=II?Q(\0ZE:::G@3PEXIT6?5-?T?O\ XL?M]_#_ , R?&"+P!\-
M_BE^T/)^SU\$O!O[0_QML_@Q;>"KW5O!_P -/B#8^+]9\'6FD:3XS\9^#KSQ
MI\3->\+>!O$_CVS^&'AY)_$:^!]+MK^Y%OXB\;?"?PK\1Y33@JBLX-RBIW2C
M>',YW;MRJ"A-RE+E@E"5YKE=JLW)P2;FN7W5K+WW!122U;DZM-1BKR;G%*+;
M1]X45^9'@/\ X*$77Q<_;/LO@1\(_A5KWQ'^!FJ_L'?"C]M+P;\;/"NN?#Q;
M?XC:'\>/$GCVU^&USI.C^+_'?@W6=#\,7FE_#"[T;1[F[TR^UC7?%_CBVD\2
MZ3\/?!'A2+QEXL^.M._:WOO&?P"_X(YZ!^S_ .'?VS?'/P$_;/\ &&JZ5XA\
M3^-OBWX MOVGO'?PNT3]CK]JSXNZ%X-\8_&#4_CSX:\?Z%\69O&/PT\"?$?Q
M7XT\)>.-,AF\,^$M<\)6WQ%OK[7QX/\ $E2C*$5*:<5*5*"NMI5:U>A!3=_=
M3J8>HD_>NE?33FB,XR<HIZQ4V]]5"C1KMQT][]W7IV^'5]DVOW\HK\M/V=?V
MNO#7@#]GSX@>$;CPK^VK\3O%_P"R3^TYX+_89\2:7^T)=? '5_VH?B1X\\;^
M)_A)I?P[\87&N:#\1O#7@+Q;X*U+P?\ ';X>^,M.^)?B_6?#'B[Q1\++&\^(
M'B6U\1^(Y+S5O$7K?_!0#]K+QU^R+\/_ (&^*?A_\*+SXKZI\6_VP/V5/V=-
M1LK;6?#&DMH'A[XX_&OPCX"U_5;.#Q/XE\+6VK^);[2-5O?#W@RS?5M/T>R\
M5ZQI.O>*]4T_POH^JF=/I;6,G34)?S.K&G*%E>35U5AN]+ZV>BJ-VVK+F7M+
MJ^WLY3C/5VV=.5KV;Z7U9]X45^!.G?\ !07Q-^S!^T[_ ,%0?$?QM\*_M*?$
M_P" ?PK_ &A_V.-#U#4-&O/AUKGAC]C[P%\9/V7/@)J>HZEJNAZ]\2?#-SJ_
MA>'XH?$+5M9\6Z3\"-,^+GC#2=/74_$>M:7<:8?"LWB#[%^/?_!5;]F?]G_X
M@>*O VO7&H^*6^&7Q?\ A-\$OC'/X0\1?#6Y\3_#GQ;\8;;X?ZEH^J1_";6/
M'6C?%WXA^#O!.@_%7X=^)/BIXC^&7@CQ:GA30O%#3:/9^+-0\$_%73?A]7))
MN"2YI35.RC;2=1<T:>K2;UBE)>Y)SCRS9*DK3DTXQ@YWD]N2#2<[JZBM7>,K
M3CROFBM#],:*_./_ (*,_M*_$GX*:1^RQ\'/@KJ%OX:^+G[;'[67PZ_9;\/_
M !(FM=)U.Z^#/@[6M!\8?$3XN?%_P[H'B70/$GA'Q/X[\)_#+X>^(]/^&F@^
M,=*U+PB?B/X@\)ZWXN\/^+O".A^(/".N>O:C^S/XTT;Q9\)M3^%_[1?QP\,>
M%-'\2>+YOCIX5\6_$#4_BHOQ>\-Z_P#![X@^$- FTS5OBA;>-=;^&/BOP5\3
M]<\%_$71$^%FJ^!/ M['HVLZ7XF\&^(8CX63PW-FXN:2MSSIJ[7O3IPA.:\E
M%U:4')Z<]163A&<HNZY^2^JA&I+2_+&<IQA?K>2IU)12WC!ZJ3C%_7U%?AY_
MP2P_X* ZSXZ^!G_!.'X'?'+P1^T#=?%/]HO]@[PU\9O!/[2/Q'N? VL^#_VA
M_&?PR\#_  JOOCCI5O=Q?$G6/C!I7C'3I_B9I&N6.M_%+X<>"O"_Q!L+/Q1J
MW@SQ'K6E6&C7WB'U?X1?\%"?V>/ OP*^'>IC6OBM:>)/C#\8OVY[7P?X'_:Q
M^,OPKT7XE6FK? #]IWXD^"OCA9:W\1O&7Q3OO -A\-/AM\4+W1OAK\+M#\.^
M-O%>H:%\/_$7PHT'1]"?0M(UVZ\.$_<G[-ZNTFK)WFH3C"3BFKVC*33ZW2CR
MWE%M4Y>TIQJ)-*7*VG;W5*$ZD6VFXZQA?1VLW[UXRBOUL_S^=%?@Q\1/^"A-
MU^U=XT_X)@>&?@=X _:.M?V>/VW=0_:<O/B@?#7B3PM\#_C!(?@I\,?B9X4U
MOX1KXQTOXX^!_'/@75/AC\4K/_A-_&7C/X3^*[;3O%-MX)\*S?!_XK?$/PKK
MNLZ-XD]0_P""CVK?$#]EO]FC]A[2O#/[0'QYN[O2?VW?V"OV=OB-\4]1\3B;
MXI_%GX/_ !,^,G@WX8_%B'XAS?#_ ,->'K+Q#XN\9^#[J[FN?$GA#PCH7BZR
M\1.VK^#;C1]5O+H7DSER4U4E\+J*FDM9-NI2I-[I)*5>E)7^*$FU:4>1TO>F
MZ:WC"4Y-Z*-J=6KRN_5QH5$WHHRC[UXMR7[+T5^*W[0/QH^"OPC_ &2_^"@/
MQ_3XN_MY^._@5\-?"?A/X;_$3PA\-_&6O^%?CA\(O$GAG1XO&WC+XE? ?X@_
M&GQ-\._B!H^J^(/!_P ;?AR_B6>7QG)IEC;_  [M[CP'I$FJ76O0:[[O^T?_
M ,%,_"_[./B+]JWPY=?LR?M+_$Y_V-/@Q\,_VD?C3K/P\3]G^#P_:_L__$"Q
M^-.JZI\3?#E]X_\ CWX'N=7C\"6'P!^(T6M>!I['3OB5K^J6NFP^!?!_BC1I
M]1U[2"_O*.TI.,8IZ7<J7ME[S?*E[-J:;:3@_:745))V]SG6L/>3DM5>%3V<
MEW;4[P:4=)KE]YM-_IE17Y[_ !:_X**?#OX1>,7TG5_A1\:-3^'6G_%3]E#X
M,:Q\:X] \/>&?AU<^._VR?$VA>%_A;;?#R;QYXG\*:U\8=+\(S^+/!^J_&G4
M/AEI7B27X?:1XNTS^S[+Q9K'A[XE:/X XC4O^"HO@K3/%7CK1[C]FS]I./PE
M\)?VW? ?["?QA^*4J_ "'P1\-OB3\5[CX Z3\*O&>I6[?'H^,_$GP[\>^(OV
ME_A9IEG=>!_"7B?Q7X7L[K6]7^(/A/P?!I]A#J]-24H0<6ISE*,8NR;E%Q4H
MN_PM.45:7*[RBDG=$\RY93NG"$8SE)-.*C).4973:<6HR::NK1D[Z,_3^BOB
M>X_;<\,W7C6+1/ _P;^.OQ7\!V?[2L/[)OB[XN_"WP;8>-/"'@CXLE([/6]3
M\0:3I6NR>-4^$GPX\8+<?#/XQ?%>W\,R^'?AC\0R-/UI)O#6A?$3Q9X!\)^!
M?[8W@UX?CK_P@'PT_;!\>>+;[_@HS\7/V6[_ ,'?$_7?#7BV+PE\5?"_POL_
M'_B;7-#\1Q?$/Q/X2^#G[(6C>$?"MWKGAV6\U>TNM/U'49=+T?P'<^-_&FA^
M$]52]Z]EM%3MI=IRI*+LVFHR56$E)^[9Q>TN:---7NGI+E?9.U1M-ZKF3I3B
MX_%S*2MS1Y7^IU%?BW<?MF0_M0_$G_@CC\<?@5XN^*G@7X4?'?\ :N_:^^%7
MQ$^&.IZOX<L+7Q/)\)?V2OVW=,\0>&/B+;>!-?\ &7A+QB/ 7QL^!*WOAG4?
M#/CKQ3X!U&\T>S\6^'M1UZWET#6X/VDJ834W-+_EW/D>S3?)2J*46FTXRA6I
MR3ZIE3@X<O-HY1YK--.+4ZM-QDGJI*5*:?;;S91115D!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?&
M7[>?[!'[-_\ P4B_9YUS]F?]J'PMJ/B+P!J>LZ9XJT;4_#VJG0?&/@7QOH=O
MJ-IHGCCP3KOV>]BTOQ'IEEK&L:<CWNGZII6H:3K&K:-K.E:GI&IWUC/?_89_
M89_9V_X)U_L[>%?V8_V8O"MYX:^'/AJ]U/7+V\UO4WUWQ=XS\7ZZT#^(/&WC
M;Q!)#:G6?$NLFULX)IH+/3],TW3+#2]!T'2](\/:1I6E67U]11&\>?E;2J<O
MM$M%/DUCS=^5ZKS2;NTFA^]R7U]GS<E_L\_Q<O;FZ[[NUKNY2$ XSV(/XBEJ
MEJ6I:=HVG7^KZO?V>EZ3I=G=:CJ>IZC=06.G:;IUC!)=7M_?WMU)%;6=E9VT
M4MQ=75Q+'!;P1O+*Z(C,$VDFVTDDVVW9))7;;;2223;;:22;;23:+7TM=MI)
M+5MMJR26K;=DDKMNR2;:3_+[]F?]D7]I3]C_ .!/B;]C_P""_B#X*W/P:MO'
M?QUUSX)_&KQ#JGCFT^*?PE\&_';XG^-OBROASQ+\&X_"NN>$?BQXE^%.O?$#
M7M&\-^*[;XR_"[2?&>AV/AIM:\&>'KW3M6D\0?/_ (V63X/_ /!6S]C3X._
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MSZI:6NNZAI\=C?<WHO[.7[1,O[17[2?QMU/QQ\./ UY^T!^QK\ _V>-,\2>
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M4OA_HFJZ_-I\7Q)U+[(_8._;@\$?MI_L_P#P(^*$\G@CX=_%OXS? [P_\?\
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MWT4XJ/LXSC3O"JJFU3]W)2LGRV6'JTYI-2C&WU:BU)I*Z<)7]K*$OB3X+?\
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MU^'7[37[.WQ371[SQ/IG@CXQ_#*35+;3'\8>"K+Q)X0?Q_\ #SQ9X7\1>*_
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MDTI*$PDU=-_$J;>E^9TH3;U2UE&,W-0WE>52G"Z<X+X<_9U_X)V?'/X,7?\
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M!GB<_%O6?%VB_#KX1Z;XW;2?CQX@^%WB7P=X]T/PO\B_!?\ 9%^(?[$VN?\
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MWE9:27UJ5O[L(QO9NSJ1]HTVW&U2-31MW<7A7RZO9_58WZ^\^RO^/_Q(T_\
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MZWI/@O5%\0S:CH/PML-2U'Q/\$O%'A?P7^XBJJJ%5555 554 *%  "@#
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MKWPGX?FO?'$&E7VB^'FTP)X1UBPT#]+- ^&GQC^./_!-KX/?"_PCX]N_@?\
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MK'@+Q_X0T=O&UW?>,[_1M5B\7_#VUT.Y\"Z[U'[=O[-7Q"\7?M0_#?Q)\._
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M3:W1E["+C.,I3:FZ#WLTZ#IRA9OF]UNG%RB]+-I-7NOY3_V /@GXQ^&^D?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^)?%OAC18==O=).DZ99W=E'!KUY]N?L%?\$TOVDOV"O@+\7OV*_"'[1GPO\
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M?%>J>)=%^'$UY\.K'XA^%?'G_@JG>?M ?L1_M>^(/@]\'?VG?@I#KW_!*/\
M:5_;[_92_:>2UDT?PE>Z'\.=/\:Z!X,CU;QKX2U4V_P]^-K^(]%\*?%S0_A(
MVJ^*3J?P7\3^'-0\=WF@^(=1\4_"[1O6/V%/^"5WQ7_8_P#@7\9_V!/$7QZ\
M#_%;_@G9XHU/X\V/PI\&77PZ\1Z+^T)X6^$G[0\'BZ3Q'\%?$'Q"A\<S>#9=
M+\)ZMXPU76[3QWIO@^7Q%XPUK4=8O)=.\%Z9>6/A[2^?^ 7_  3&_:Y^%?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>:YXCUG2M#TN&ZU/4;.UF_##0_V^?VK=%UR]\.:YXI^'/BEO!O\ P7&\,?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ?#/Q _P"4EO[)7_9C/_!0_P#]7[_P3 K[FK\UOVS?
M O[:MG^T+^SE^T)^QK\.O@5\3]5^'WP7_:B^#/COP[\</B7XF^'%E:67QN\<
M_LF>.- US0+CPUX0\4RZM/:3?L]:OI^H6]S+IJVJ:M931+>^9)]E\E7XK_\
M!<;RY-W[(?[ GFYC\DK^T_\ %3RP,MYOF@_"K<21M\O9T.[=D8H_K^OT ^A/
MVR/^3BO^"3O_ &?_ /$?_P!=9?\ !2RO<_VOO"WP2\<_LK_M$^"?VE-071_V
M??&/P9^(OA7XTZV^H_V,F@_#+Q#X6U+2/&?B!M<V.-!&@Z#>7NK_ -OLA30O
ML7]K/A+-B/SR\/>$?^"I/QS_ &E_V,/%'[3OP,_9,^%WP@_9O^/?COXW^(=>
M^$OQR\=>./&5_/K'['G[57[.VB:'8^'/$'P]T2PN8;CQ!\?=)U*]N6U:T>SL
M-*NY4%R^VW?]?O$OAGPYXS\/ZUX2\8:!HOBKPKXCTV\T;Q#X:\2:78ZYX?U[
M1]0A>VU#2=:T;4X+G3M4TR_MI)+:]T^^MI[2[MY)(+B&2)V0J45*+C)*49:2
MB]G%N/,O)N*DD^DG"7V1IN+33::U35FTTGRNST=I<K:>C2E%_$?@[X&^)/[=
MO[!7Q]\#?LG_ +0>L:+_ ,%#O#OQ ^ W[4?B7]AK]I*W\.R^%_VL=+U7]G[P
M;H?CG5O@A^UAH.E)-X:\>67C/0KGP'X.\/\ [0O@:32M<\8^/M TY_B=X4;Q
M3\1M#O=+T/V%_B1XR^./P^_9]_:AM?V]/ WQ<T']I7]B7Q!JWQ*^ VCS^)_'
MEU\0/BQ8>"_!VM^*/BEHNFZC\7?%.B_LT>(?@?XWOO&/PX^*O@KX8^!_!_PL
M.M_$;1?AWXO\(^'?&GASX76NG?L?X#_9_P#@;\+M=G\4?#CX0?#;P-XDGT*/
MPH=>\*^#/#^AZO;^$8KBTO(O!VGZAI]A!=:7X.BU"QM]4B\):;+:^'8M6635
MH],74I[BZEY#P;^Q[^R9\.]6^+VN^ ?V8?V>_!6L_M ?VFOQUU7PK\&_AYH&
MH?&2/6Y+Z;6H/BA=Z7X>M9_'=KK%UJNL7NJVGB9]3MM2U'6=9U&]BGOM8U.X
MNIJQ56E5IOXJM#$4_:65^>K#%4HRG%.,)KV>(IJK)Q4ZDZ$)_'%2;@U"=.:5
ME&K1J2BF]53EAYM1D_>@E*A)TXW<8JK4@VH2<5^(_P"PX"?$O_!M5C.!_P $
M1OCP3[#_ (5%_P $JAD_B0/J:_0GXX?$'Q7XZ_X*/_ O]C/Q1J_COP+\!O&?
M[%W[1/Q[35/ GC_QA\)M<^+7QB\"?%_X _#ZS\):5\1_AYK7A'Q_8CX2^ /'
M_B#Q=K'A?PKXLLTU]OB%H&OZ[:2VW@G3V;[&\._LN?LR^$=3^%FM>$_V=?@5
MX8UCX%^'M5\(_!'5?#WPB^'^BZE\'/"FO*5USPQ\*[_3?#UM=?#WP]K2DKJV
MB^$I=(TW45)%W;3 XKK?B/\ !SX4?&"'PU!\5/AQX*^(2^#/$ \5^#I/%_AO
M2M=NO"7B;^RM2T&3Q!X7O-0MI[OP]K-SX?UK6_#M[J.D3V=U?>'-<UOP_>2S
MZ/K&I65UK.7.J"LTJ*JQDG]M5)U91?NM6<'4C+=KGIJUURN.4(N$J\M&ZJA;
M1^XXQI1?K=0E%-6:C-];W_G>TKXD_M7_ +047_!+WX0^//VL?CGX(M_BS^TS
M_P %5OV4/BO\4O@;J'@/X:^)?V@OAK^S3X5_:R\#?"3XTG4K+P3J@\+>.O$N
MC?!_PSXRM/$?@N+0-%B\0:GJGQ \ Z%X<NIO NJ>%?TM_P""BOQL\8?LT_"/
M]D7P5X>\8^*]$T+XZ?MG_LJ_LF_%7XWW%XDGBWP3\+?'FIZC_P )5XGU/Q5%
M8Q0>&]?^*L_A/3/@G+\1;:/1-2\':[\88?&/A+5/#GB[2O#NJ6'VSJ/[.O[/
MVKZM\(]?U;X%_!S5->^ %L+/X$:WJ/PQ\$WNK_!2T73+311;?"/4KG0Y;SX;
MVXT>PL=)$'@V;1HAIEG:6 46MO#$G7_$;X:_#KXP^"?$7PT^+7@+P9\4/ASX
MNLETWQ7X"^(7AC1?&?@SQ+IZ7,%XEEKWACQ%9:CHNKVL=Y:VUW'!?V5Q%'=6
MUO<(JS0QNJC)Q5.\?:.$XSJ<^GM^5T+\[BKQ<U"OS1C^[4JVD7#GBZLN:;3Y
M8RA.--)+]US1KI<NJYE!SHN+D^>U&W,I<DC^7S]H;6O'O[.7@+_@XKUSX$_&
M/XH>!?&_PP^*G[#VK>%O'=KXTN?%_P 2](M]0_9;_9A>^\/ZCXZ\?CQCXOOX
M-0TW5]3TM=9U+5'\:6>A7T%MI'B2Q:QTZ\A_0SXM?%?XM_"']OG0[KXV2_%^
M]_9Q^+'[2_PJ^%?[.GQV^ 'QJNM9^'GP;\9>+_@9X9\'6/[)G[9/[*L1TFST
M^Q^)'QBD\=_$GP)^T9::%\4+Z/Q1\5/@UX,\?:YX \&^'_#5A<_?.G_L$?L-
M:5X*\8?#;3_V-/V5K3X>?$.P\&:5X_\  D7[/OPG'@_QUIGPX,!^'VG^,O#;
M>$FTCQ19>!WM;>;PC;:Y:7T/AVXA6YTA+.?,A]$3]G/X$Z7XZN?B[H7P0^$T
M'Q9^VP:_!XUC\&^'])\07GBK2_ <?PQT3Q!?^(K+1;G4$\0Z;\-K>#X8Z=XM
M-O?^(=$^&YF\%:9,OA>231)AR7-"ZDX0C06K2FU2HSI32LG;G<U--2O&4??5
M3FFI"3Y9*T5*<J\I/7_E[4I3IZN]^1TW&7,K.$FH>S:BX?SF?LZ?$#]KG3?A
M?_P33_:XLOVN_P!H?XU?$3XN_P#!1GXT?L5?%?X)?$/Q)X2U?X2_$_\ 9[N?
MVFOVM_"GB?6[;X?^&_!?AXV/Q?\ @3X*^$D?QKL_B/H^HVVH:-X3^'OCGP9<
M6%O\((=%\#^$?8/A)^U#^TIXP_9K_P"":W[=&G>,O'9^/?[3?[=^A_L__M+_
M +/>O:QXJO\ X=M\./B-\<OB_P#"WXM_!?P]\&+N[@\-?#[Q;^Q1HW@\>)]/
M^)'A+PUX>^)E_I/[-_BR^^,WB3QM:^-?BM>>)/TF_P"">_[ WAG]CWX2Z%H7
MC7PQ\'/%?QNT7QW\?_%<WQG\&>"X]+U?4K7X[_&/QM\6-1CMY]9LY]?T/4;;
M3_%^F?#S7[R#6M0NO&6B> /"M]JU]'9VVC^%_#'UWX?_ &>O@/X4\>ZY\4_#
M'P9^%WAWXD>)M=U#Q5X@\<Z'X$\-:5XIUCQ9J^DQ>'];\6ZAK5EIL-]<^+=?
M\/6UCX>\1>*))CKWB'0-*T71-9U"^TK1-)M+(4KTZ4)17,O83G427M%*,,#*
MK2CS-PE"I.EB85'4C)WJR<$XV3TJ<KK5I02Y)3KQA'50E"4L9&E-I<LH.G&I
MAYTU3Y;^R2F^9)K^>+XK?M=_M3_LC^&?VM]:^)DGQ.O_ -H+1_V-OVV_VB_V
M9/C?X$^+;?'+]C/]J/X.^%O%WP9\6:5\>]!^#7B76;I?@-\6?V3O GCSPS'J
M7P?TKP?8_#3QIX:U3QGJMC\1?B;I^I:)=Z-^J_['0OQ\7_&/B/PS^VQX%_:(
M^#'Q?^#7@+XG^!_A)X7UWQQ\7SX5N'U[7+"+XZ^&?C1XX^,WQ5UK2/A_\9/#
M5WHGA^P^&),'@.[U_P"&NL^-/A:UA?7'Q6MK[ZW^'7[,_P"SM\(=1O-5^%?P
M,^$OPXO[^Q\1:7<3^"/A_P"%_#&W2O&&NQ>*O&&EVD>CZ99PZ?IGC#Q7!%XL
M\7Z=81VUEXI\5J?$VO0:AKC-?EOP+_9A_9M_9?T77/#?[-GP ^"W[/\ X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !16;J.LZ1HZQ-JVJZ;I:SEU@;4;ZULEF:,
M*76(W,L0D*!E+A-Q4,I. 167_P )KX-_Z&WPS_X/M*_^2Z .FHK#L_$_AK4;
MF.ST_P 0Z'?W<V_RK6SU:PNKF7RXVED\N""X>5]D2/(^U3MC1G;"J2-R@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7AZW_8F_9&\1^*M7TOQ/^RII?_!8[]N&Z_;=:UNDUCPMH7PE^)/[0_[?.L_
M?QA\;HK>673-,^ 0^//C#]FOXG>+/$/BKRO!UMX=;PEXW\27/_"MXO$&H+M4
MY8UZE-744W!7>E.4,;'!U)3D[/DYU/D<N52A.G--\RDN>,INE1E;G<VY2Y4V
MYP>"EBZ48Q5TIR3CSVORN%2-DTXG]5U%?RZ?$']D;QA\1_A+_P %&O%W[,?@
MSPEXF^&?[*'[:7P0_;>_X).^%M,LKW6?AY??%GX)?!/X)?%[]ICX<? Q-/U2
M+P__ ,*0_:!^+5M\5OA!<Z%X*O;;X=:5\:_&GQEOHM'@UO1;R0=Q^TUXYM_"
M?[+GP2_X* _$#P_\5_A=\!?VL?VT_!O[2/[;=[X-^%7@[QQX]^&'[&.O?LM_
M%?X9_LM7WQG^&?BOP;\5]-N/"GPOU33OV4?BA\?O!UYX;^)(\ _%G4?B5X@\
M)65RUO%*BM:UVD_W#>JM%8B,73O*3@DU)5HU$^7DY*4KVKQY=7I>RDU^]2M%
MMMT6W-)+F=G"5*46N;F<JL;/V3<OZ4Z^-_"/[6\WQ?\ $WQ6T_\ 9^^$'BSX
ML^#/@;\0O$GPK^('Q)EU[PMX$\,^)OB3X&9K+XA_#GX&CQ/?QW7Q,\6_#OQ
M/^$1\7ZSX@7X;?!ZT\91:OX.TSXN:MXJ\'^/=%\*>0?\$K_!7[//@S]FWQ%+
M^R?\2?C/\5/V=?'/QM^)?Q-^%WB7XJZ/X?\ #7@^+3?'T^D^(?$.E_LT>%/#
M/PV^$VC^%_V:+;QM=>)[CX?Z/I7@?3/#0UN\\87_ ($GU'X>7_A&_N/A_P#X
M)&?%_P"$_P#P3\_9DT7_ ()Q_MD_&/P=\%OVH?V?/BY^T5I5O9_&WQ5I'P]G
M_:;\&_$K]HGXL_%[X?\ QX_9ZN_&.K6DGQJ\&>/?#7CBR759_!TNL>(O"/CR
MS\0>!_'.B^'/%%@NF3#3524;NRI*:3CRR<Y2I1:46W=TXS<N2*E*:<:G*J:D
MD7CR<U[MU>16NUR*-27,VERQYG!0O.2C%\T5)SLW^V7P0^*]E\</A5X,^*EC
MX1\:_#]/%^F2WEUX#^)&F6&B?$/P1JMEJ%[I.M>#_'6BZ7JNN:;H_C#PQK&G
MWVB>)=+L-:U>TT_6+&\M+?4[Z.%;F3U6OQ(^.^N?";QE_P % ](T?]N+PKX:
MM?V+OBA^P5;67[/L'[4&G>$?#_P8N/C\_P ;/'4_[0OAO5=$^($]M9Z/\<O%
MOP1F^ ?B;P=X?\:V5A\1-/\ AYX<^*B>%-.T*ZT?XWZ;:?$O[+GPKMO&GQ%_
MX)2> /\ @HQI7AWXF?$/5/\ @EK_ ,%!=%^)WAK]IJTL-0\3>+_A79_M(?L4
M>)_V:-'_ &E? /CT!/$/CJU^">A:OXG\7Z#\5-"OM73XE>"OB1XKUVP'C7P%
MJVJ:$6NHN\5S-*W,[1DOK49PEII4A]4=6<+WA1Q%%MOE<IRWRINTI<KBG>/+
M)J?L)0G%:\U.V(]FJFBE4H25DY\L/ZD:*_CR_P""?V@_"CP_I?\ P;I_$O3%
M\.V_Q8^)UI^U3^SE\:_'E_J[7GQ$\?\ P.\+?LP_'RR\ ?!'XI^(-9OKCQ)X
MH^&GA#X@>"_@YIW@#X?^+KB]\.^$/%&F>#]+\):7I-_?6MK>4?\ @FO\-/@W
MJ7PP_P""'?Q>_98GTB__ &SO"WCGXA^%/VL-?\->)_$WB3XD1_L56WPA_:,'
MQ0\%_'S24UJ]O6^%\?Q3\/\ P L?@U;?$:PD\-^'_BWK_@#5_ADVG7OC+4=8
MU2^1<TH\\4HR2E*5U&,'+6;LINT*<J<ZB4923]K&"DXT^?6I3E3AS/EFWS)1
MIRY[RBZT7&ZLO?GAZBI-M*4)49NRE4Y/[&Z*_C ^!'Q&_9XUB/P;XC\':[X
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M+)K&E76BS)XY^.G[0_P]O;.2P\.Q!_)/^"QC>'-+\<R>.X]=_9N^./B+X?\
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MU3\9M>UKP]X(_P""K7ASQ)X?_P"&?_VMH_B+^UG:>&?$_@N;3_\ A'_V^_\
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MMMO=MMMMMZMMMMZMMNX48QZ_B?\ /^?K112LAB8]SUSU/Y?3V_\ K86BBBR
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M13_/_AO\E]R[!_75_BVV_5L**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /#OC!^TM\ ?V?[SPQIWQI^+G@;X:ZEXUM?$-_P"$
MM,\5:Y;:=J?B/3_"4WAZV\4ZAH^G,6O;[3_#MSXM\*VNM7T$#VFF77B30;>\
MFAFU:P2?R#_AXI^P]_T<Y\*?_!__ /:*R?B!_P I+/V2O^S&?^"AW_J_?^"8
M%?<U 'RSX&_;>_9(^)?C3PQ\.? G[0?PR\3>.O&M]J.E^$/"NG>(K<ZSXFU3
M2/#6O>,]3TW0K.<0OJ>HV/A+PKXF\2W%C:>;=1Z'X?UG5#%]CTV\FA^IJ^ /
MVR/^3BO^"3O_ &?_ /$?_P!=9?\ !2ROIW]H3X[?#G]F#X&?%O\ :)^+NK/H
MGPS^"OP^\4_$GQKJ%O'%<7XT+PGI-SJUU9:/92SVHU37]5^S)I7A[1HYX[C6
MM<O=/TJT)NKR%2I24(RE)I1BFVWLDMWU_)N[22;:3:3DU&*;<FDDMVWHE_5D
ME=MI)M>Q45^?MI\4?V]+WX"67[02_![X-VWBO6O!.D^.$_8XNKGQI)\2_"%A
MJB0W][X<U+X_Z9JFI>%O&?Q5\/>&)CJUS\/=&^!7A_PMK7Q!M;CX2:7\7DT*
M2T^-UQ],77[1_P !++XG1?!>\^,'P\M?BG-K]OX/C\#S^*=)BUP^.+SP6GQ*
ML?A\8'N1&GQ%U#X9O_PLS3OAZ\J^--0^&T<_C^RT*?PA;7&LQ6XR3:::DIN$
MH_:C-*[BTK[:Q;BY+G4H7YDTX4HO5.\7%24_L.+=DU+1:Z25[-PE&:7)),]J
MHKXA_:+_ &T/ '@#X,_M/:U\&/'_ ,)O'7QX^!GP!_:'^,7A[X::UXD:2V\0
M77[/6ES6OC5;BVT6YBUG5_#'@SXA3:+\-OB7JWA5[Y? ?C;58O!OB*XTGQ6K
M:2K_ -G']LKX>?M)_"BVB^'_ ,5?@=XH_:7T/X$_#SXA_%/X5>&O%]IJ<GPS
M\9>/O UOK=I:>,/"FF:WK/C'PYX:7Q.-1TGR;^:?4X/[.O-)FOWUBTG(AR2I
MU:M[PHKFG;WGRJE5K.2C&[E&-.C-S:TC>"DUSQ;K[<(;2J.T;Z1OSTZ:3D[)
M.4ZL5%/XK3:OR21]MT5\$_L[_MP^ _$O[#O[(O[5'[2_COX6_![7/C_^RI\'
M_P!H;QC%-JS>&?!GAX^+OAAX#\;_ !'US3T\1:QJVI:%\+_A_?\ C:S/B#Q9
MXDUFZT7P/H%YIE_XU\46EO-_:,OT;K?[1WP$\-^*?#G@K7OC!\/-)\3^+KCP
ME8^&]*O?%6DPOK&I_$&Y>T^'FC6ETUS]B;7?B)-!?'X>Z$]RFL>.H=(UVY\*
M66KVV@:U-85;6V[YN56N[NUTEIJVM4K7:U2$I)I-;-<VNGNW:N^RNK7>G=H]
MIHKR+PQ\?O@GXT\>ZA\+?"GQ3\#Z_P#$33;/Q=J,W@[3/$.GW.O7.F?#WQ+I
M/@GXAZII-BLWF:[I7P]\=:[I/@+Q]J>B?VA8>"O'E]%X)\3W&E>*1)I*0_%S
M]H7X&? /3X]7^-?Q:\ ?"O26M)=3GU7QUXGTOPYIFF:';ZAIND7GB?7;_4KB
M"T\/^$-.U?6M$TC5/%^N3:?X8TK5M=T+3-1U:UOM:TNWNTFG:SO=I*VMV[62
MM>[=U9*[U7=7?];/_+R?W/L[>QT5X+J7[5/[,6C:U\2_#6L?M%? S2?$GP8U
M#P#I/QA\/:E\6/ =CKWPIU7XK:II^A_"S2_B3H]SKT6H^!]1^)VLZOI.D_#J
MR\36VF7/CG4=4TZR\+1:K<7UK'+M^/\ ]H#X(?"K7=&\,_$KXK>!/ NN:]>>
M%[#3[#Q3XDTS16%WXZUR\\*^ HM1N+ZXAM=$_P"$^\76%WX,\!2:U/I\7C;Q
MK%_PAWA9]6\321Z4YO9K5-I)I.S;=DD[6;;:22;;;22;:3'I>^EDV[Z622;;
MO:R2:;;LDFFVDTSU^BOFK3?VS?V1=9^*(^".D?M/_ '5?C$?$7Q \(?\*OT[
MXN>!+WQY_P )9\*/#FF>+_B?X8/A:VUV761XA^'GA;6-/\0^--&-H-1\,Z/.
MVH:Q;6=M;W,D/E_Q@_;8^"$/P,^/7C3X0?M9_LC^#/%GPF\*^&]3N_'?QV\9
MVD_P;^'=Y\1X))_A)XG^*EEI'C?P+KTOP[^)\=O<2?#O7=&\3Z38_$JWC>X\
M ZWKJ0N&5TTI+WD]4XV::YHPNFG9I2DDVFTG=7YK1;L[\K33O:S333LY)-6;
MNTKI<MVK.UG<^Y:*\?\ %/[0/P0\$>-M(^'/C#XK>!/#/C?7M2\,:+I/AS6_
M$>G:=?W6O^.-0FTOP)X;(N9XX8/$WCV^M=1@\">&[F:'7?&IT7Q!)X7T_5HO
M#VN/I['_ &AO@7%\4='^"<OQ;^'\/Q9\13^(++P[X!F\4:5#XC\1:MX2T:/Q
M)XN\/:!8R7*MK?BGPEX8GM?%7BKPII;77B3PWX4OM/\ %&MZ78Z!J%EJ,[6M
MK:WO:VMW'XDK7OR];7MU%M>^EK7OTOM?M?IW/8Z*X#XA_%3X=?"?3-/U?XC>
M,-$\)6>L:E+H^AKJET%O_$&KP:1JOB*ZTGP]I,"S:KX@U.S\.:#KWB6^L-&L
MKZ[L?#>@:[X@NX8='T74[VU^,_VL?^"@OPC^ G@7]EKQ+X3^)'P@U^W_ &QO
MC3\,OA9\'OB'J'CCP]JGPM7PEXZT?5O&>K?&QM2TGQ-IL/C+X>:'X%T"[O-.
MOO#OB&ST?6_$'B#P5IMSXGT33-?&M6XM6DM6Y1@E=?%-\L4VVDKOK)I))MM)
M.P]$V]$HRF_\,%S2:6[LNB3;NDDVU?\ 0NBOGGP)X_\ ''P[^".C>*OVN_&'
MP4L/&]MJNHZ/K/BOX0IXLTGX:>,AJOC?4="^%-UX*\+>,[_Q!XQT_P 6_$GP
M]<^#6'PJM/$'Q%U*P^(>O7?P_P#!WC#XF1V^C>)=?\WOO^"@/[)L7Q7_ &=?
M@YHWQG\!^*O%7[4$'Q4OOA7=^&_%.A:GX:U33_@YK-KX-\:LWB6&_.C-K%O\
M2]2TOX9:;X4@O)?%.L>,WUS2]-TBY?P?XM.C"3;Y4FW=*R3NFXN=FK)Q:C&3
M:ERM.,D]4E*7*,8N4G:*ZO:W,H735[Q;E&S5TXRC+2+;C]G45XWX>_:'^!7B
MOXA7'PH\-_%SX?ZU\2($\821^#+#Q1I4^O:D/AUK\/A3XDC0K);G?XBD^&7B
MNZLO"OQ-BT$ZE)\.O$^H:;X>\:IH6L:E865QD7W[1?PBU3Q;J?PA\%?%WX4W
MWQPN-*\>'PGX&U/Q59O<ZOKOP]\FS\:65M8:?=?VCXAE^&VJ:CH<?Q3T3PRU
M[K_@.'7-!7Q3;:"WB/0I;U2DHQ<G=I1G/1-MQIQE*;22?-RQC)NU[6U:*6KM
M=?%&.K22E-I03;T3DVK7U?1,][HKX8_8G_;(\-_M#_LW?L6>-/B=XS^$WA7]
MHO\ :E_9.^%/[24OP:T#Q%::5K-Y:>+_  3X3UWQCK'@3P'KWB+6?'%YX!\-
M>(?$]MHLFL2SZU!I<EWI=CJVLO?WL!N/J#XD_%_X7_!_3;+5OB=XZ\-^"K/4
MI+^+2_[<U&&VO-6;2=-N=;UHZ3IJF34=4CT#P_8ZCXD\13:?:7,/A[PQI6K>
M)=:>QT+2=1U"U<K1;3<=).+?,FN9;J^BNNJ=FK.Z5G91?.DXIM22DM'?E=[.
MUKV=KIVU35KW5_1Z*^:?''[9W[(7PT\/>"?%OQ!_:C_9\\&>%_B5X U'XL?#
MGQ#XC^,7P_TG1O'_ ,+=)T33_$FI?$KP5J-WX@BM/%7@&RT+5]&U2?QCH<M_
MX>6TUS0G_M$G6M+%WYWXE_X*'_LB:!JG[)-I9?&OP%XLT3]M;Q3XS\-_ OQU
MX0\6>'=>^'NNVO@+X9^/?B5XC\2W/C6TU,^'(="M_P#A Y/ ]NT6HSZE>^/?
M$.B>';33YKA-7?2QZ;IKWE'5->]*4H*.J7O.<)P4=).<)Q2YHRC%_P"3E_V[
M&*E*7^&,91E*6RC*,FTFF_MJBODSX5_M'^$M4\,?&[QSXX_:#_9G\;>"O ?[
M0_BGX4Z-XE^#>M,VD^"C#?>$O#_AGX+_ !,U"[\:^,;;6?VCK/Q=XAA\+Z_H
M7AHZ'-JOB77_  SX3T?P)8>))7L;WM6_:L_9EC\#^$OB5<_M ?!VQ\!>//B!
M;_"7P=XLU+XB^%-,T7Q'\6+GQ1=^"!\+-+O-0U2V2X^)=KXTT[4_"&I^ 5QX
MMTCQ/I.KZ!JFD6>JZ3J-K:IM)7;2LHR=VE93C"4;WM:ZG&W1N2Y934HRF;NR
MUUDEYN#DI6[VY)-]4HR<E'EDH^_45X]\%/VA/@1^TEX8U?QK^SY\9/AE\;O"
M'A_Q=KO@'7?$WPJ\;^'/'FAZ/XU\-?96UOPOJ>I^&M1U*TLM;L+;4-,U)]/N
M)8[B;1]7T;6[9)M(UC3+V[\3U#]JS1M;U3]KN+PQXP^%O@#P+^R!8S^"/B5\
M;/B]K$5C\-/#?QTNOA9X>^,%WH_B>Y/B'PI!I?@#X3> /'_PN\2?$KQ)/K]M
M:ZG=>-M1\':=JWAO7O 'BBXHD^5-M/2$IM6L^6,5*_O<OQ<T%&[7-*<$G[R:
M:5VEWE&%];*4I.*3LI/=2;T;2A-V]VS^S:*^(+?]O7]E3X<?#CP-J/[07[8O
M[).A>-;CX%_#CXR>--5TCXI>%_"7@[4_#'C73=-AM/BKX.\/^*O&.L>)M)^$
M/CC7YKV;X;ZEKFJZNVI:.C01:]KESI6JWJ?0VE_'OX&:Y\1--^$.B?&7X5ZS
M\6-:^'5I\8-'^&&D_$#PIJ7Q#U;X1ZA>QZ;8?%33?!=GJTWB.^^&U]J<T.EV
M?CNUTV7PM=:G+%IT&JR7LB0-<HN+DFOAE*#:3Y6XN:=FXQO?V<VKJ,N6$FXQ
MY9J$1E&2336L5*UU=)J&]I.UO:4T]6KSBN9\\'/UFBOGC7OVM_V7?#/@W1?B
M)K?[0?P?M/ 'B'2_&&OZ/XV3X@>&KSPI>>&/AUJEKHOQ)\8_\)!8ZC<Z5!X'
M^&FJWUE8?$KQO=74/A/X>W-W;)XRUG1//B+>)?&S]K'Q-\,?VP_V*?@II<7P
MZNO@Q^TE\._VJ_'7CGQ[JMWJ3:WX?A^ ?@GX?>+_  Y>^&-3M-5M_"T?AS6K
M;QG>W>O:MJL.HB*PTNV_L]42^EO[.5JTM%=M7;2BG[.K5UD]%>G1G)7>NEM'
MS*EK>VO+%R:6KY8RA!M+=VE.*=D[.ZW7*_O2BO%O#7[2/[/'C3PK\-?'7@[X
M[_!SQ;X(^,_B&Y\(_![QGX8^)G@S7_"?Q8\5V=GXCU&\\,_#3Q'I.M7>C>.]
M?M-/\'>,+^ZT?PM>ZKJ%O8^$O%-W-;I;^'=9DLO$_AY^V=\"[+X=^$?%7QC_
M &N/V.[Q_B7XT_:+C^&'C'X?_$[PYX=^'7CGP-\&_&WQ'N;R/PU>>*_'NOGQ
M%XB^$?PN\(1P?'[6]%UNY\-:'XY\->-[^*W\.^'TL=-M$VHMJ7NM;\WNZII<
MMG9\WO)VM>SONU%BU2:UOVUTM)WTNK>ZU>[U3Z)R7VK17@F@_M3_ +-WBKX-
M^%?VAO"WQS^%OB?X(^.[O3M,\#?$_P -^--#U[PCXUU[5_$4G@W2/"OA#5-)
MO+N/Q-XTU;QK%+X'TSP5H@OO%FH>.(W\&6>C3>)U.E#HOA'\>_@?\?='U+7_
M ('?&#X9_%[1]%U"72-=O_AMXX\-^-(?#^M6\]U:7>A^(?\ A'M2U!] UVQO
M+&^L=0T36$LM5T^^L;ZQO;2"[L[F&)]6K.\?B5FFK6O=-)JW-&]TK<T;VYH\
MQT3Z/9]'OL]G\,MFW[LM/=ER^LT5XQ8?M%_ ?4_&VH_#>Q^+OP_F\<Z7:>-+
MZZ\-?\)/I<6HO9?#2^T[2_B;=V"S7$<6JV_PPU;6=%T;XFRZ7+>)\.]:UO1-
M'\9G0]3UC3;2Z^6?VCOV]/A]X?\ V-OVT/V@OV5OB5\%_C+\0OV5_P!F/QU^
MT/'X:D\0-XCT*72])^%OBWXI_#C6/$&F^%]8TS7[CX>_%O0O!^J7OPX\::5?
MVGAKX@:-#<:YX,\1ZMI5I/>(F]&TG+3F]U-MI.UUT:OI>]KIZZ K-VND[\KN
M[6;5[/=K1IV:O9K1W5_T-HKY]\0_M-?!3X:Z'X,N_C+\6?AQ\-M4\4:-X&O9
MD\4>)=-\-Z?8W/CZ[BT#PQ/J,^K7QA\-Z/XK\9L?!?A#4?$5]:6/B'QA<:?X
M-TC4-2\4:A8Z;=>R^)_%'AKP3X=USQAXS\1:%X1\)>&-*OM=\2>*/$^KZ?H'
MAWP]HFF6\EWJ6L:YK>JW%IIFDZ5I]I%+=7VH7]U;VEI;QR37$T<:,PN<7"4X
MRWA.=.36L>>$G"24K6=FO5IQ=K21,9*:BX_:A&:6TN6<5*+<=U=/[TU?1F[1
M7Q[\7?VY?V>_A9^S-^TE^U#:^//#/C;PC^R]X0^(FN?$?0=%\1Z3I_B73/%_
M@#P&/B!_PJ?6--UF>SO/"?Q*\3Z/>^'&\-^%?$]GINLZE!XO\*:E:V%QIWB#
M2;B]J?LD_%KXT_%GPAJ7Q>^)WC#]F7Q/\&O&?@7X9>./A5X@^"$_BVTU/PKJ
M>H^'=4F^,O@#XFW/B'Q-XP\+>(;?P%KUII!\-?$GPYKGA:XUZ'5/$?A_Q7\*
M? U[X'MM<\<3]F4OL1MS3?PIRA.<;N]M84YRYOA2CK)-Q3JZO&.\I<W+%:R?
M+*$9:+7252"M\3<M(NTN7[-HK\U/VL/^"@/A?X>? +5OBK^S/XW^#7Q6\2^$
M?C?^QCX"\;Z!J>K7FLKH?@']J_\ ::^&GP+TOQ=)I/A_6]$U:UAU[P]XWU3Q
MK\+O$E]<Q>$_&FE:,OB#0[CQ%X=GBGN?I[PM^V#^REXX^'7C'XO>#/VC_@CX
ML^%OP]\8GX>>./B#X<^)O@_6O"/A7QZVH:)I5IX+UO7=.U>XT^P\4ZMJ'BCP
MM;:!H,\ZZGXB?Q7X5;0K;48_$NAO?OEER\UFES.*ONVHQDVHVYG%<\8\UK<]
MX?$FB>>/-R7U45)]DG*<4N;X>9^SG+EO?DBY_#J?1M%?,>K?MJ?L@^'?!6G_
M !&\4?M/? 7PAX'U3Q+XP\%6OB3QG\5?!7@_3T\;_#JWU>\^)'@B^;Q-K.E2
MZ7XT^&EIX?\ $5S\2O".IQ6?B+X>V_AWQ#-XRTW1(]"U9K/0B_:^_9;GLOA;
MJ</[0'PFETGXUVOP\O/A5K4?C?0GT3QO!\7KNYTWX1'1M:6\.EM+\6=7LK[0
M?A=;W-W;W'Q$\16&H>'O!L6M:W87=A"6:U:=KI7MI=\K2OW:E%I=>:-K\T>9
MII[-/=[]%>[]%RROVY97MRRM]&45X_:_M _!&]^)$7P@M?BKX&F^)US>ZSI=
MCX)7Q%IXU[5-7\,Z5'KOBO1-&M&F7^VM>\':)<6&L^,]#TEKS5_!^DZOH.H^
M)K+2K/Q!HDU_PWQ$_:Y^!GPM_:)^"?[+?C+QII>C?&#X]^'?''B[P)H6HWUC
MIMO<^'O FH>%M!O9IK_4+BVMWU;7?%7C;PUX;\(^'+5I]<\47\^KR:197-OX
M>UB2V2UY;:\[:A;[32E)V>SLH2;L[)+5JZYB345)RTY;<U_L\THQ5UNKRG%+
M3KV3<?IFBO'/#7[0OP,\8_$"[^%7A;XM> ->^(UI;>+;P>#=-\3:7<Z[J%K\
M/O$=OX-^(MQH=FEQO\10_#;QE>6/@[XD2:"=27X?>+K_ $_POXR.B:[?VFGS
M?/\ ^W)^VCX1_8[\/_ ^'5M9\$:7XP_:'_:&^%WP!\#S>/->L=(\.^'T\::[
M"GC/XE>(+2;6-$U'5?#/PX\(0ZEK%[9Z??Z;#J/B&Z\*>&]3\0^%K/Q&WB+3
M1._*EKSRC&%K>\Y2459W2W:N[V2U;2U'MS7TY5*4K]%&+D[K>]D[*UWLDWH?
M<=%?&_P9_:7T&Q^#]_XA_:3_ &B?V/[OQ=X(^+NJ?!3Q]X_^#?Q"@\._""+Q
MOK/BJU3X0>%M5TSQ_P"+M>U7X6?%OQ_X"\8?"O5M4^"VO^.?&>JZ/XM\;V&@
M>%_&'C[2-3\,^(]=ZS7_ -M7]CWPKXVM/AMXD_:E_9\T3X@WOQ+LO@S;^"M1
M^+_@*U\3_P#"W-2@TJXL/AC/HLFO#4+3Q[=Q^(/#20>%+J"'6WN/%7A*T%E]
MJ\5>'H=2.UM;V2:NTVU!V6GQ+GBG'=-V:O;F5U9MZ6O?FT:MSW;3>BM"4KNR
MY4Y:)2Y?IRBOSM_X*3?MS:%^Q9^RQ^TM\2?"/C;X*K\?/@_\ /%/QI\'?#OX
ML:]=0Z1J:Z;:>(/^$1B\3Z7H6K:/KEK8_$;Q%X7UGP)\.TGUCPVOC[Q_;GP9
MX7U:[\01RV*??FM:[HOAG0M6\3>)M8TKP]X=\/Z3?Z[X@U_7-0M-(T30]%TF
MSEU#5=8U?5-0F@L=,TK3+&WN+W4-0O;B&TLK2":YN9HX8G<)23<HJ]X\K>C2
MM-2:L[6?P2O9Z.R>Z'V_O<UNK]UQ3NMU?GC;357MMKK45\U7G[9?[)>E>'-;
M\7:_^TG\$?"?AOPQX^TOX5>)]6\:_$OPGX)MO#'Q,U^RM=5\-_#_ ,2CQ;JF
MC2^'_&7BO1=0TSQ!X0\-ZO'9:OXM\-:OHOB3PW::IH6LZ7J%WZ9%\9?A#/IO
MCW6(/BG\.Y])^%?B6X\%_$[5(?&GAR73_AWXRM;;2+VY\(^.+R/4FM_"GBBW
MLO$/A^\F\/Z[)8ZM':Z]HEP]F(=6T][A^?3O\HO\IP?I.#^U'F/Z_P#2E^<9
M+UC+^67+Z317RS>_MQ_L::3X3'CG7_VJ/V?_  KX47Q9XU\ W.L>,OBSX(\&
MPZ;X]^&NC77B/XD^!=:@\4ZUI%YH?C7X<>';&^\0_$'PGK%O8^(/!&@V-[K/
MBC3M*TRTN+J/<7]KK]EYX?AC=)\?OA,]E\9M.^&FK?"[4D\;Z$^E>---^-5W
M<Z=\%[S2-66\.FM%\9-7LKW0OA(;FZMV^)GB&QOO#W@A==UJRNK"(_S2^;2:
M7:[4HM:ZJ46KJ47)75[75TFVNJ2O=M:-)<LKNUERRNU9V^BJ*^6? _[17A":
M+]HCQ-XP^.G[/7BGP-\,OCZ/A+H=Q\*]6GOM7\ ZG_PAGPL@'P5^+^WQ1XI3
M5?VCKCXG^+-5M=.\&^%-/T75=3T3Q=\+O#%EX*E\9WEVVK[^I_M;_LP:-\/+
M+XMZC\??A-#\,M0A\:W5MX[3QQH-SX7_ +/^&6NS^&?BEJ]QJ]K>SVEGH?PI
MUVTO=-^*NNWDD&C_  RGT_4F\=7OA^+3KZ2W2DFKK:T7T=N;9.S:N^GO-.ZL
MV-Z-IZ-.2>_V?B>R=EYI-=4MCZ'HKYCU;]HS2O"_QT^"_P ,==.D7_@C]I_0
M?$\_[/\ \2_#=V=1T;7/'O@?P>WQ&UGX9:U+!->6EQJ/B_X4Z?XL^+?PP\4Z
M)/+H.O>%OAQ\3=*UV+P]J>@>#+OXE_3G6GWOHTY1:ZQE%\LHR6\91>CC))JZ
M=K-6.W9I23W3C)7C*+5TTU>S3:T:Z:E%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?#/Q _Y26_LE?]F,_\%#__
M %?O_!,"ON:O@7]M7_@GSX+_ &V==^$OBO6/VA_VP?V;/&/P<TKXE>'_  [X
MS_8Z^/>J?L_^+M9\,_%>[^'.H^+_  MXM\1:'H^I:IK?ANYU7X4^"-7@T47%
MI8C5-&MKZZBNY[:R:T^,O^'&VA?])7/^"X_T_P"'E7Q'Y^O_ !3>>/8CWS0!
M]D?MD?\ )Q7_  2=_P"S_P#XC_\ KK+_ (*65TG_  4B_9)F_;M_85_:?_9)
ML=?M?"NM_&SX6:SX;\*>(M1DN8M'TCQQI\]GXD\"7OB![&RU&_\ ^$:C\8Z)
MH?\ PDR:?8W>H2: =1CL()+MH5/S%\"/^"/7@#X(_'SX.?M!ZM^W'_P4X_:*
MUWX%^(_%GB[P)X!_:I_;&\0_'3X36_BCQ?\ ";XC?!>]\17?@CQ/X96)==T[
MP1\5/&-IHNM:5?Z5JMA-J,L7VR;2[O5-,U#]>*F<%.$H2O:47%V=G9VV:V::
M33UU2T:NG4).$HSC:\6I*ZNKKNNJ:;36FC>J=FO@[X!_M8?%CXA^"_"/A/XF
M?LF_'GX4?M0VVA:%8_%+X?>)?!TH^#?AGQ4MG;V?B7Q/X<_:9T6YUWX'^.OA
M>-;%SJ.@#P7XTU_XQ7GA2>PN-4^#^C^)%U3PUI?Y%?'GX>?M1>./VDWO$_8W
M^+&C:=\*?^"T_P"R]\<[8?!GPI\/="^$7C?X V_PZT'P"G[4OB7Q2?%'AO7?
MC?\ &?QA=30:)\7;O57UG2_@7X"^'OA'2M3\,^"#H.L_$3XG?TS48&<XYZ9[
MX]*J_P"\A5:BYQDI[**<E5I5;Q45:FG*E;EAHHSE%62I\DKW83IQ]V,H\BU<
MG&'LZM*UY.\GRU%[T[MN$6[N53G_ )J+[X,?M&>'?"_[6?P_^ /@C]HOQ#^S
M9\6/V(_V]K"]_9U_:#^%\2^//V5?VH_B5JEE_P (+\,/V1?C7-H&D:Y\6/@K
M^TWK/B;Q+K,OP_;Q+\0O GPCL_A=X7\2ZS\0_A5#K.@_#6?W7]G[X6_$KP1^
MU/\ L5?$+4O@K\3?#?@;X6_\$2/%/[/7CJ]B^'.L11>&_C%;^._V8O$^B?"&
M33M,LIIKKQ#9:%\+_B0^E6VE07GAU;BUATK2]6EU#Q1H%IJ_[Q?Y_P _E1C_
M #^?^)J)QYZ+H?#%QY7-/WVOJN+PC5Y7]WV6+DHQ;ER*G1@G*%-).,G&HZN[
M:DN5MJ/O5L/7;LK+F=3#1<FE%2<ZD^6,Y-R_E/\ A]\&OVBOV??!G_!/_P 0
M_%O]C']L?]H[X+:O_P $F_V5/V#/C%\&?V9/B+KOP_\ C!\!_P!I;X#'6[/Q
M-#\0_A_)\?\ X ^$_&GP6^,VD_$+6/#.O?$"?Q'XD\)>'Y/@]H-_K=YIGA?Q
M7I.H:M]26O[/7Q1^#OQP^$4_[(WPU^,_P&O=+\;?L#_#SX\_L>^*_!4GQU_8
M*^,OP ^&O@_X/^#_ !3\4/A_\8?$(M--^"7QY_8\^%)CTKPA\2]-^(?A'Q-\
M8/$W[(OP]\,7/P1^)UQXA\'W:_T&4?Y_*M5+WHRY8\T'+E:T?LY.4G2E9+GB
MY3J-N5Y24[/WH0K*%%J+AS2Y912:;NN:,8P51)M\LE&$.7ELHR@I)\LITI?B
M=^P_\-_C/\,?VI;;3_AMI'QSL?V./$?PO^/?B'QI\'?VK/AW;:9XJ_8K^/&N
M_&'P/XATCP!^R_\ '6XT'3]=^+?P)^/]KJGC7Q%>?#FT\0?%'PI\++;X.>$-
M4?Q[X F\2>%?A9?^=?MI?##Q_P"'/VZ?BEXI^(W[&7[6G[</[*W[9O[*GP._
M9N_L7]E;XN1^$!X"\9?#+QA^T@OBSX7_ !]^'6K?'[]G[P5KWP,^+7@WX_W6
MJ/\ $KQ[XJO?"OA35;3Q+X4U_1XM+\4MJT7[[45G;2FDVO9P=.]W><7",'=N
M]G&,8*D_?]DH0C%RC"*5W=YM_;:DULDU)SO96^*3<JB7*JCE*3492DW_ #\_
MM"?!3XN^$OCA\"OVO/@C^S+XNU$?L.VWP%_9;^)7[-G@R#Q+JS?M@? ^^?0=
M:U;6OAE/XRN?#'ASQYHW[!OC+Q5%\3OV6/%GQ4/A?5M?^)'@_P"/UO<:=X./
MB7X1?$?7>6_:#^#GCR]_:W_:\\ _&;]A']IK]M3]FS_@H!<_!?QM\$=9^%OQ
MJ\7>!?@=X/O?#O[/_P ./@_\0/@U^VC\/M=^.?PJL/A;X0\/^)?A-HOQ@TSQ
MJWPL^(FJZU9_$OQ'I&AZ'XD^(OA1/!!_HOP/2C ]/\CI^56Y-_$E-.564E+W
MN=5VIU8N4E*:YJJ5534I33<HWE"3B0HVMR>XU&DHN%X\KHIQI2M%QC+E@W!Q
M:49*SO&48R7X%^./V7?CO\:?V=/^"]_P@\ ^$/$'@/XE_M:?&CQYK7P'U;QM
MX>N_"N@?%KPA>_L2?LO_  9L-*DU_4UM+,>$O&_C_P"$OQ2^'6KPZI>P7&G^
M'=9F\47^G+X?\2Z7?:OQG[7VN?'#]OS_ ()S_M\W.A?\$ROCE^SW\?\ XD_L
MP1?L]6NF_%OPM\()?CA\7_'MEK^LW>D^ / VL_#_ ,:>*-9U[X"_"SQ#XA\9
M:WX?\>_$F;P'X=UNY\<7?BGP-X<MH;OQ-=3_ -$]%90I\D.1-M*--1;=W"5)
MJTXZ*RE%<LZ=U3:4=-'&6JFU4C42BI1J2G:VDD[-1DNKC)<RJ?Q-9+FUYH_B
M%\9/A[\7(OVU8_C!^RM8?M"^&?$'CGX_?L?C]HKX&_%3X077CC]C#]J[X(:1
M;?#*R\<?M&Z'XF\5VVE6_P"RY^TI^S;\--1?4=$URW\=>#/&'CGQE^RSX$^'
MVH_!'XGW^J^%+I?#OV0?@G\1/#'QNL?V:_VD/V&?VH_B)\0?@A^V5\?_ -I[
MX9?MH^)/CEJ6I?L2W?A3XD?&WXR?$SP?\=](\,7GQ^F'A3]HB\\&?%[Q1\.=
M2^$?@[X%>*-6'B_7+S6?%&NZ!\.O%WBWQ%X7_HNHK6+E%Q<6URJ2LI-;U/:Q
M2:M*/)-R:M+55*L/<A4M")>\I*23YN6]TM>6'LWS*UI7ARK5:<E-OGE!2E^;
M/[0OAKXC> ?V_?V4/VK1X0\9_$7X$^&OV=?VI_V:_B':> ?#&I^./$OP;\6_
M&?QO^S9\3?!/Q7B\ ^%=/UOQ_P",O#/BF3X 7GPJ\4R>!_#^MZOX,OM=\'^(
M=6TZ+P'+XW\2^%OSKNOV6?CI\*/A5^PMIT7PO^(NL6VG_P#!;[XX?MPZM\-_
M!GA2VUA/V:OV6OB[\0OVQ/%OAK2]:M/"UU=Z'8#PII?QM\ 7_BSP9X6O-<UB
MR\5^+/%NE>#M+\5Z1X4U'5T_HZHHI/V3NE&3Y^=.2;DE[:.(<%)\THQ=6,9/
MDE3]U<CC):DU(^TNI.23@Z;2E96=&5"_*DHW]E.2]Y3]YN:<6VG\)_\ !0#X
M=^'?B=\*/A[HNOV?[2VEW&E?&SP5XL\+_&#]DN"[U#XT_LZ^+?#>C>+-1T7X
MQZ7X;L] \8W'B_P[&Z3?#;QIX.E^'OQ%T_Q%X8^(^IZ;K?@C6=#FU+[/^;/P
M]\ _MMV7QQ_X)6_%7X[_  V\2^-?$?@_P[_P5(^ 'Q,^,_PA^$WA3X?B1_CE
M\5?A+JG[-?[47QC^"">*5M_@O??'[X8?!B^^-7Q:T#==1> _BMXIF\%^)_#_
M (/\8>(;+P#IW]"5%*+<>=6NIW4ES2CI*E4HSLXM.$Y4ZLH>U@XSBE!J\J=.
M4')<Z2;?NK1Z.S52G5C=--2BJE*,_9RYH-\VL5.I&?\ /9\"/V</V@?$7P4_
MX(X?LY^(_AMXQ^#OQJ_X)L?'#P3JW[1GQ"M](OU\!:AX%^"O[,OQY^!.JZY\
M-OBM=66F:#\7-+_; N_&?@O4K_1O"=_J/B30O"_C[Q7<_&+1?!_COP;J'A-^
MA_X)V6OQR^%G@GX0?LH_M1_L#?$#4_BY^P?<_&>6^_;CUWPG\+O&'PK\<:3X
MC7XI6&F_&?\ 9<\6Z;XO\6?&_P 5_'']I?PSXCTJ?XH>&K+P#X4UO28O&?Q0
ML?BIXAT_7_[*\%^,_P!\<#^8_/\ _52T3_>4YTI*'+4C-3M&*O.2@E4CHW%T
MW!2A!2E!.ZT5G$BN24)1<KP:Y6Y-OD3J<T).Z<U-591E*2YMI*[YE/\ GV_X
M(Z_#[]J/]D7PS\%O@;^T#\-_BEXP\-?$K]CW]E4:1\6?$/PZ@M?&'[,7Q'^!
MOPB\-?!SQU^Q%\3]2\.VUO8WWP>\,>*]%\4_%C]F_P ::'I"Z%!+\1_BZ?B'
MJNI^*?$FG?%#XL_97QR\-?%+X:?\%*_V>OVK[SPY\1_B)^S@_P"R'\?/V7?$
MMI\-_".K_$35?@=\4/'7Q;^!OQ;T'XAZEX"\*R:IX_U;P;\6M)^%'_"O?$^L
M^ O!/BNY\,^(O"7PXO/&$.D>#;C4?$N@?I_@>G^1THIN3E*$FE>#ELDE*+A4
MII25K-J%1QYU:<I1A4DW4C*550CR1E'5J22UM>+YH2;C9+EO."ERV<4I5(QM
M"2C#^8/PO\(K_P#9!^,__!&3PW\3?AKJ^DVFE_M$?\%A/B]H/PL\&>%E^*6N
M_ CX?_'&+XQ?&;X5> +#PU\-M-\2:EJ^N?#+P-\0/"G@;Q)IWPMM_'-MH?B4
M:Q:^$M5USX>:1%XBB[;X9_LJ?'/X!>*/V,/B_;?!3XEZEX%_X? _M^?M/2_!
M?P7IVE:MXF^!/P6_:X^!O[6OPO\ @NNH>'3K=AHGA#0=9\5_$#P?X[\=:;+J
M.F:/\%[SXLZMI?BM])LO"NOW]I^ZOCS]G'X0?$SXN_!GXZ^,_#NKZG\4/V?)
MO%\_PB\06?COX@Z!9>%)O'NBCPYXQ>3PKX=\4Z3X0\1GQ!H(&DWX\5Z!K@:P
M'V>,1Q\5[CCMVJ4OW<*;3M&:LKO2G3K82I3AS:SDY?5(>TG)\U[\M^;W=)2Y
MI<RT?(TV[/\ >3CC5.<4[I13QD^2-VG9)V2M+^;#X>_ ?]HWP3\3+[X^R?!3
MXGWG@GX._P#!=/\ :>_:J\3_  T/A-H_$_CW]FWX\?LK^._V;=!_:&^'7AY1
M=:MXXG^&>O\ Q)O/B!)\.M#LY/BAKWAC2_%+^'O".H^.1X,\->)^O^+?[,GQ
M8U.#]IKXIZ%\-/B!?^ ?VH/^"PO_  30_:<\&?!ZW^'MXNK:#\&?V:M:_8@M
M/V@/C;XT\!PVAUGPUJ7Q C^ 7Q+\8:AX6\0Z5%XZUW0-$\$+J?AZ/X@>+[OP
M?IW]$%&!G/>ERKD<++:E'FWFE3^I7Y92YG#G^H4+NG[-QO446^9<JE)SFYRO
M=N;<;M0]_P"M6O%64E'ZW5TG[13M&ZC[W-^<G['_ (0\<>'/VO/^"I?BCQ+X
M-\8^'O"'Q=_:5^"/COX6>(=>T#5-)T+QOX<\+_L3_LU_!3Q1JWA^>^@A\W^S
M?B-\*O%V@W"S0VTU_::9IVOZ8-1\.:MHVJW?QG\ ?A?XY\"? K_@N;\ M8T'
M6/$OQ1\3_M7?MI_%7P9X8TO3[C4?$/Q%^'W[8/P5\,^/_@AJWAK39MLNL:!>
MWVOZY\$[+6U\OP[%XT^$/C[PS)J,#^"=>_L_]YZYZ7PIX<E\3VWC1M'LU\66
MFCS>'H_$$*&WU.709[K[<VBWES T;ZAI45_NO[73[_[3:V5_)->V<4%U-+,[
MJWJTZE*6D:V%EA)\ME+D<4HRBVG:2>K2:5GI?EY64&\/*$X>]*&+IXR//>WM
M(5?:.+Y6GR/9=5:U[M2C_/+^S?\ !#XP>#_BQ^SKXB\<_ 'XJ6FB>"/^#?7P
M+^ROXMOKWX>7FI#3OCWI'B'PEJ?BCX'O%;)>75[XC>R\.74DQLH;GP9K+VEE
M;VGB._N9["&76TS]E#]KGPA^Q7_P1M^*G[.OAS4? W[:'[*/[./P7_8R^,'A
MCQ<&TB#1OA+\<_@E\.?@'\=9_&OAZ\TRZMO'5G^S#\?/!GP@_:EL-,\^71O%
M>A_ ?Q+8^%=3OK#QU;:C=_T2_P!**=7]]7G7GI*<YSE&-U!NIC,;C*BMO:<L
M?B*#]Y26'ERQG&?[Q337LJ2HQ;<$H)<S;?[O"87"0?6-XQP="JO=:]M&[BX-
MP?Y(:5\*-<_9%_;1G\1V'P@\:_$#]DOQ;_P3\_9X_91^&%[X%\/Z]\6O%/PN
M\:?LP>/_ (X:E!\+_%?ABPL=5\16WACXV> ?C'H=U:_%;7)I/!A\0_"B[T3X
ML^)_"<EQ\/9O$?R=^S#^R/\ M$?LW>*/^"#?PY^('A7QUXUG_9:_9F_:K\!?
M'3QMI-N_BWPC\&=:^)OP\^%]C\,_AKJGBVWN9H]7T;PO-H6H?"GPSK6BQ:E9
M+H_@G3=9UM?#^C:GIEQ-_1!CC';I151G*-G:+:E>]DFTJF-JI.RTM4Q]>7N\
MJM[."IQC3299+FMIS1E%W;=G.EAJ,FG)MZPPE+1RE[[G-RDY*WXX?L3?L@_&
M#X#?M(?&_P"'?B[1H+7]C7]G3XN?%;XT?L%BVDT22SNIOVT+>W\<_$GPW%X4
MT?3+.Z\(S?LE^+M0_:&^&'PNO6N]5?Q-\*/VF[O0WL=('@NREUGYP^!_P8^+
M>GZE_P $U%\0_!'XHZ99_";_ (*J_P#!5+X^_$5=8^'FMQV_@;X7_M WG_!1
MN\^!7C36(_L4R0VWBJY_:7^"D]B+%;N[\-7&LZI-XBCT(^"/%LFA?T/8_P ?
MS_\ UT5A*DIRI2;E>C"G"-G:_LZT:JD^MW[.E3;NGR4HJ[E[Q?,[5%I^\G4J
M2NKJ]2E*DTEM9<]2HDT_?G*_NM17\P_C'0/C+\+/@/\ "K4]+^!_[0.K_'/P
MI_P7(_;:_:?^"O@_P9X/\ ZQXZG^&_Q,\??MO_$+2OB%#\$/C-\1_@=;_&#X
M<>./@7\9)O!OBOPMX?\ BY\*OB#\,+WXJ0_$F74H_$'PMU'P#XF_3G_@EJ?"
MFG?"SXUZ/;_"W]H?X/?%7Q!^TO\ %SXY_'GPA^TA\/O#WPV\2WGQ2_:-\1W'
MQ9UCQ-X$\.>!_B-\7_ %C\)[]=:_L7P-IWA[XH>-M:TNS\-W5G\1=>UGXD+X
MI\0:U];_ +0G[*/P!_:FT_PG9?&[P"OB:_\ A_K%YX@^'?C+0?$_C/X;?$_X
M;ZWJ=@^DZOJGPX^+?PP\1>#OBA\/[S6](=])UV;P=XNT1M<TH_V;J_VRR @'
MH'PL^$?P\^"OA5/!OPV\.IH&C&\DU34)KC4M9\0^(?$>MSVMI8W7B3QCXQ\3
MZCK7B_QMXJO;/3["TU#Q5XOUW6_$6H6UA90WNIW$=I;K'T>UFXU(2TC)))1N
MHVBL-9_W;O#J52&L)2C3=/DY&I8JG"/)RWO%RDY/XFY3Q$FI6=I<JQ#A2E92
MA!S4E+F37X*>)_A+^TUX0\:?M1:/^RI\&?B%\:O@M\6/#/\ P4O\7_$[]AS]
MM[X8:5=?!GPQ^T+XXLOB9=^$M=_9M^.OB)?";>(_@]^WG\8;J77/&?P,3XH>
M,?!FA^ ?C?XV\5:K=_ #5DN_ 5>.Z_\ "_\ :#^(WPN_X*/0:1^S?^UO]L_:
MA_X(1?"_]G[X8W'Q2^%_@GP!<ZS\>- MOV[_  LWPALOA9\/]?/AKX*'1KOX
M]?##PQH'@'2?"OAS0-%TF#7O'_B&YFT275OBEXN_J5HI1G*,(Q=FXQE'FNU*
M7-3=*\DFHOEB_<3@Y124'4E3C3A!RAS.]VDI1FHJUN:,HR3UBW[W+:23C%_$
MH1FY2E_-/\6/A7\4M/\ VE/C9I'QE_82_:]_;0_9P_;N^"?[..A?#6Q^#OQ9
MUOX9>"?AIK_@GX1W/PS^*'[/G[7_ (%UK]H'X0Z+X.^&LM_I\?Q+@\>ZUX/\
M8:>TWQ&\9:%I=IXK\00_\(_;_J%_P4<^$7QC^(O[,'@)/@UH&I^-_&'P._:5
M_8R_:1UGX0>&M5TFSU3XT^#_ -F']H_X6_&?QE\+?#VM>-]8T;1T\0ZOI/@>
MXU7P4_BG6+&RU?Q?H7A[2M8U/38=3N-5L_T6P/\ /US_ #H_I14DZKDVE&3J
M>TYHW6L:]2O3BTG%2C"56I&[?/.G+EDXN\YN$5#E^THTO9<LK--.C3HS:NI<
MKG&E"32BXQFN9*2M&'X'?M3? +XB_&O1_P#@L%\>_A%\.?B)::'^U;_P2I\/
M?L@_"_P#J/PV\0^!OB)\>/VA=!\,_MBQ6WC'5OA]XGT70_'?AZPTNS^/?PO^
M$?AKQ+\2=(\)S,=-\<7NJVFE_#CPQX8\8Z_^EMEI5KXB_8(/AKQS\'?&_CZU
MOOV4+WPEXX^ 5W9W/A7X@^./+^$\_A_Q7\(XH=0U#1&T[Q'XIDBU'P?8WZ:[
M8Z=)>7]OJ6G>(3ILMKJ[?8E%#DW0EA[1]FW%J\4VN6&)A9JT8RC+ZU5<E)-N
MZCS<O-<4;58UN:?/'FL^9[REAW=-N4HN/U6DHN.D;-J*=K?S"?$7X"_M4ZE^
MS!^T'\#K>+]H3]KGX$6OQ1_X)0:Q^SCXP_:'^ <GAO\ ;$'AKX.?ME^%OBA^
MTW^SS\8-5O\ 0_"&O?'WP'\!OAE\,[/XH^!_C1X\^'^@GQEJWQH\;_#6Q\>?
M&CQIIUS>GT;XY>$_VB_!_P >?^"FGQ1\!_LJ^//B-X4^)W[27_!*WQIX:\1)
M\*M.\6^)8? OP<LO .A_&_\ : _9\\ ^+-,U"P\=_M _LYR>&K'Q%\*M+\5>
M'KR!/''AOPKXNMO"GQ-\*^%KOPEKW]&M%.524XJ,DFDY-MN4I2YU0C+GE)N4
MVUAX7FWSMN4I3=1NI*8TU&<IIM.4:<>56C"*IRK3CR0BE&*4J\GRI."M%1C&
M"5./\KGA_P#9Y_:!LO'.F)XD_98_:%.CZ+_P<3:!^V7)=^,]$T'XAWI^ &I?
ML?6WAFW^-%QK&A^,/&EGJ%OX4^(&LZ -1M]%O+G6/#^M27&E>$-"DO/ 7B?2
M/"'O?QA^!'C2Y_;#_;)^"'QZ_8+_ &C?VO/@;^VO\8_A!\;?@-\1?A[\==4T
M']E+P[=^#?V?OV??A?KG@[]L+P#_ ,+F^&NB?#&T^#WQ$_9W\.?$WPWXYTKX
M=?&KQEX^\/:Q;MX#\.:Y\1_!&C^"=8_HHP/3V_#THI*37L;)7HJT97DI-*&&
M@M4X\DH_5*+C."4HOGY5'F3A<DY2JRNTZJ2=G[JM*O+1/FNF\35YH2DXR]SF
M;Y??_$OX,_#'XQ?#[]NC3]3^!5E\?=)_9U\>?M)_M7>,OVGOV:OVD?AC_;_P
MH^#'B'7=&^*DVC_MA_L4?M":P;";PK+^T-\7;73=7\2_ 3PGXR^*FF:EH'[5
M/Q1\;7'P]^#>J:)XJ#>X?M8^#/BK)_P4#_8(^)O@[P'\2=;\$0? K]O3]GWQ
M/\2OAYHNB^(;7X-^.?CS>_LC>(_AMXO\=V.J:_HTVF^#8M/^"/Q"U&;Q"L%_
MI\.MZ'HOAF5#KWBSPSI^J?J)CI[=**2;45'=<E6G;FDG[.K3JTY14DU./+&M
M/V<E)R@VK2?+34%.*G=N]W.G4OI\=*I2JPDTTXR;G1@YIQ4:B3YHWE.4_P"?
MG]GS]G/XX^(_A!_P1>^ NO?"[QG\&/C%_P $R_B/X3;]HOQQ=>'''@Z7P3\&
M?V0OCI^S/J47PL^*DUK9:!\4]$_:RUWQEX \4C3_  'J.KWVA^ -9\0R?&*S
M\%?$CPBO@BZ^P/\ @IOX2^('BZX_X)_OX ^'/Q ^(:_#S_@HU^SQ\8/B&W@3
MPW=Z_P#\(7\*/ NF>/K;QEXZU\0/%G2M"E\1Z*CZ1I?]J>+M9%U*WAOPUK::
M=JAL?U&P/3_)ZT4U)ITG:-Z=3VVD5'GJ7HMRE;WFG["FE%SGRI-1<4THC@FJ
MB;DU4IRI:R<FH255:-_:7MIOFY4Y.SDFW)R_FY_;*^'/[1FJ:=_P4W^"W@K]
ME3]H#XDZY\<O^"@'_!.']K_X2^+/!VB^!S\//&_PB^':?\$Q_!OCRTL/&/B;
MQ_X<T[2O'G@WQ#^RM\5+77O _B;^PM7TS1(_#WCB^6U^'>I77BW3,7]KG]GK
MXU^,_ __  72@\*_L]?$_P 4>)?VE_VAOV'O%/P+@TKP'))J7Q/T3X0?!C]D
M+PCXAO\ 0=6NS:6(MOAWX\^$GQ+EAN=6U73K.-]+3Q%X4N-2M/$_A^_UG^E_
M ]!Z=.WI2TZ=1TJ*HP24$XM-N3E>,\/-:W7_ $#4T_\ %-JSY>69TE4E&4I2
M]V5222:2O5A7A/97M;$3:UT<87OROF_FW_;$\"_M)GPM_P %O?@+:?LH?&7X
MVS_\% _@WKWQ"_9-^+?P]\->']7\.W\"_L0_#;X"-\#?B4WB76_#-Q\(O$_P
MO^(G@#5?'/A'1/$(67QW%X_UG4_ UIJ7Q'?6/#-S^H/_  4>^&'QV^/_ .PA
M\1?#7P \)7$OQTCN_@3\7O"7PI\1^/T^&VH^--2^"?QO^%OQVUWX$ZE\2O!'
MBD6'@W6?BAH7P_UGX2'Q9HWCB#P[I.J>)TU"3QA:Z!%-KL7Z#X'ITZ45DH\N
ML=)J-"$9/W[+#NHZ5XS4HR:=2\G+XW%/EAS2--V[W<6ZK<;M:UU%5+23C**:
MC[JCK%.RE)1C;\!M"^%GP]_:6^!/[2NGW/\ P34_:@^$DO[=UM\)OV7_ (F:
MC^V=K_B+XC?%O6[+07^(6GK\7_'^FV_QM^-/B?PG\+_V8=/\17OB/X.>*&\>
M^!O&?C/XD7EE9>'9/A7X>T_PS\8QY[XQ^%/[;.I?\$\;7X%P?![XD?$+XY_L
M(?MJ_#3QKXAM]%U?Q#\%M0_X*3?!3X0?M CXAZG\:?!'Q(;Q]IM[X>^.?QFT
M2YN?C'XXGO\ QM;ZDO[57A/6]=T>RU/P;XK\ 7_B#^CNBGLVX)05Z<U%:Q4Z
M52-6G/E=E=3]JI*WOTZTZ4I6A3G$5].9N5E--MZN,X3I3BWJ]8.GRM64)T85
M(Q3E.+_F^UOX6WGQ3U3]AKX[?#S]@/\ :M^"VEWW_!4GX2?M'?&31OVD;C4/
MBE^T3J?AGX<?LB?';X$V_P ?OBYI-S\6_CNWA#3_  =KGB_X->"?!FCZKX\?
MXL-HWA*;Q+9^ [+P]X5TJ^7W!+'XX?"G]KC]M+]GKXA_L!^._P!K;X0_MM?M
M+_";]I[X(_'-;#X,^+/V;/ \_A'X#_LR?"R[T3]I_3?B-XMT#5_AI)^SQXZ_
M9O\ #7Q'\ WOA3PS\3O&'CK3_P"S=2^&?AM?B#X:M-(O/W1HK1S;]CI94/:*
M%ISO:I[#2ZE%Q<)8>$H2@DX)SC%1YE.,*"3J/?VO)S*T;7@Z[3MRM2O]8J*:
MDVI-0E)RY>67X%ZS\"[[Q#+^WY;_ !-^'7[7O@32_B-_P56\!?'GX,_&7]F_
MPUK%I\8/AAI7A?\ 8U_9J^&VA_M(>!=)7PYXN/C7PQ:?$WX*_$'X;^+?!TG@
M7Q_+X@\'^)9KS7OASKG@_P 4:=)J?S&W@S]NGX8^.?@-\>?VJOV:/VD_VR_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKZ^UG5BBGS8=U&KI4/;\UVW+ZWA?:.3BO93C[#ZUS*G""<))K14HTK/[)/\
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M=:TRR\4:%X6UM=0TBQ;9?';Q1\(?!WP'\"_&;3/$7Q._:X^._AW6O$\_P?\
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M;1G.<4EHX<YX\_X*/>(/V2/VY/\ @I-;?'%?VF/C9^SC\$OA=^PI\1-+\/\
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M )74 ?K=17Y(_P##^3_@CM_TD-_9O_\ "NG_ /E=1_P_D_X([?\ 20W]F_\
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MW45^2/\ P_D_X([?])#?V;__  KI_P#Y74?\/Y/^".W_ $D-_9O_ /"NG_\
ME=0!^MU%?DC_ ,/Y/^".W_20W]F__P *Z?\ ^5U'_#^3_@CM_P!)#?V;_P#P
MKI__ )74 ?K=17Y(_P##^3_@CM_TD-_9O_\ "NG_ /E=1_P_D_X([?\ 20W]
MF_\ \*Z?_P"5U 'ZW45^2/\ P_D_X([?])#?V;__  KI_P#Y74?\/Y/^".W_
M $D-_9O_ /"NG_\ E=0!^MU%?DC_ ,/Y?^".W_20W]F__P *Z?\ ^5W'XT?\
M/Y/^".W_ $D-_9O_ /"NG_\ E=0!^MU%?DC_ ,/Y/^".W_20W]F__P *Z?\
M^5U'_#^3_@CM_P!)#?V;_P#PKI__ )74 ?K=17Y(_P##^3_@CM_TD-_9O_\
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M"Q"@%CN8@ %F"JH9B.IVJJY.3M51T %+10 4444 %%%% !1110 @ 4!5 50
M     .@ '  [ 4M%% %2^T^PU2UEL=3LK34;&?9Y]G?6T-W:S>5(DT?FV]PD
MD,GES1QRIO0[)$1UPRJ1SW_"!>!?^A+\)_\ A.:/_P#(==910!R?_"!>!?\
MH2_"?_A.:/\ _(=/3P+X)C+&/P=X50M')$Q3P]I"EHID:*:-BMF"8Y8G:.1#
M\KHS(P*D@]310!R?_"!>!?\ H2_"?_A.:/\ _(='_"!>!?\ H2_"?_A.:/\
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M:/\ _(='_"!>!?\ H2_"?_A.:/\ _(==910!R?\ P@7@7_H2_"?_ (3FC_\
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MND=W8:-IUG=(DJE)$2XM[:.55D4[757 =?E;(XKH*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***_E^_X.=OV8?@!X;_X)*_\ !1+]
MHS3_ (1^ 9?CQ\1-;_9/O_$/Q@U+PGH&I_$E(?#WQX_9R^&FCZ)HOC:]TZ;Q
M+H/AFQ\*:7/:P>'-*U.UTB.\\1>,-06T%UXMU^2_SJ3<$I6NN:,7K9^_.$%;
M376:;O;1.UW9#BN9VZV;\M%*3OUVC96ZO6RNS^H&BOY\?VMO''@+_@D!_P $
MQ?BW_P %)?V4/V>_@=H_Q@;X'_L.:+\2_#H\(/X2\(_%;2=.\>Z1\-/"]UX@
MM?AY?>$C%XM\.+^T3XFU"/Q?/#JFI:II.E:3X5U!)-.L-&N-$^COB1^U_P#M
MZ? _P%:_$;XT_ W]G/PMX#^)W[5OPQ\ ^$OB#H/Q1DOO#_[+?[+'Q"\#6-[<
M?&+]J6#XD^(O@_I/CCQ[H7Q0$/PXD\$_"KQKX:M]>U+QEI&G^!Y_&7B;1O#&
M@?&+IE2E&I4AH^2M*BI-J*E-3G",5=MWGR-Q326C3DGR*KC"K&=.E45U[2A"
MORVO*,94Z<YW2LFJ;J*,FGJK246N;D_8"BOY7I?^"]O[0T__  3 ^$7[:^A?
M WX0ZA\7M2_X*#V'["OQ(\"^(7^(_@KP%XBG?Q-K_AZ3QQX16[N]9\=?"Y]2
M2VT*[?0/&%C\0]1\)SW&LZ=?V^OSV,#7'J>L_P#!9_\ :3^'/P+_ ."Q7B3Q
MC\!_!_Q0^*/_  2Z_:$\&> H+WX'^$_&MSX<\2?!+XB:]H*W'Q3\0?#+7/'M
M]XEO-2^!GP_F\6_$+XD6-A\2_#/AOQ1I_AEQ-XC^$_AE-;\:Z%GRMIO2W)&I
M=M).$Z. Q"G=[1]CF6#J2<N7EC4DI6E3G%:-\K<6GS1DX227,U-5L;A^7W;W
M;K9?BH1LVI.G%Q;52#?])U%?@39_\%:_B%X]^ O[.WQK^#6H_LY>._@S^T#X
M]^/_ (/E_;*L[;Q(?A3\+KGP/\.)]<^ '@?Q/^R_K_Q.\%_M >)/C]\?_BC-
M9_"*P^!7A/Q9=^,+'Q?IU_IWA<>-X/$?@/5?$G(_ ;_@MSXF_:0_9B_X)(>)
MO"_PX\"_#7]I#_@JG\0?C#\/M'M?%]SXA\7_  F^$MC^S)>^/--^-WQ#_LG2
MM1\(>)/'']N:KX*T/2?AM\,Y/&G@Z\2?XE6-QK'Q!U#_ (0B\M/%U>SGS.'*
M^>,J,'&Z3YJ[DJ:U=KMP=];17+)ODG"<DIQ</::\G+4ES-.W+2LYRV5TDTU9
M2>O*XQFG37]$E-#*Q8*RL4;:X!!*,55PK '*L4='P<':RMC# G^8[XA?MC_\
M%4=1_;?_ ."%?P"^+&C_  ?_ &/?'G[3ME^V]XJ_:1^"&F1:C\:_#-WXY_9J
M^#_Q3LM(FU3QAX%^+^A6?BGX3?$;P;K_ (9^*WP_^'-MKR:I\+OB!+X?O?B!
MXD^).J>"K/1[3Q3]G+_@I#X>_9CTC]L31_A1^S?\+/ 'QG_:3_X.5/B#_P $
MZ+'7]%U'XJ^(/ ?B[XW_ !-UWPCI/B_]KCXK>%?&7Q.UK7+2#^R=,O=;U/X1
M_"[Q?X+\-W^N'1M'T&3PO'JOB3Q;#G!\\936L8RG&+37O.%:A0;M+EDE[2M;
M5*24)2<>5-*YIQ<4]Y*,FK-\JE"O4:O%R3E&-&]E>+<XQC-R:;_K>HK^7O\
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MX;$8N6G:%'"UY73U]FTE=Q4OZM1(A=H@ZF1%1WC##>J2-(L;LF=RI(T4JHQ
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MX?ZGXL^-WCWX(>(/"FKZKKGPV\4WNLZQJ\_B&!]0U?PWH,_AV9(M8^L/$_\
MP7+^(7[/'PE_X+.^*OVBOA+X$\<>+O\ @EE\7OA7X'\(-\&Y/$/@KPW\8-*_
M:0OM*T'X+Z7X@T[QKKOCC5?#.K>%_$FK6T'Q/\5Z9JNIV>HZ&UWJ_A7P3:WF
MGQ:)JC2O"4EJXNZBK7E#V6$J7U<;5%/&4:<J4N647*+<E=J*UYU"VC44Y-Z*
M<ZV*I1CHFG!QPE6:JIN+Y6DM$W_2717X&?$;_@J[^T'\"KVR^&GQ6_9_U-/$
M_P 7_P!O7]C+]A_]E3]HO6?@O\2?@5\&OBXW[7&BW.H^)OB?>? KXJ>/+KXR
M:;!^S/JOA/XA^&?&'A)O&=F?BAJMO\-[KPYXG\':)\0;O5?"/P+_ ,%8_B#\
M<?+_ ."-GQ%_;Z^&WP>^ _CWX,_\%X_AAX>D^)&B^*_#0^'/BSX!^#_$'B#5
MM$^/VF7>I^+/%^I?!CP;\1/#'AW1O%>O_#GQMX\U37O#-QX9L[OQ;=075M86
M6EEO?A!RBE*I0A*;E'E2K.S:?-[TZ:<74I^[.*E=^[&337O1<K2^"K)1Y6I-
MTU>SB]8J;NHR=U)JRNVD_P"NVBOC3]AW]H?Q!^UE\(+_ /:.@\3?"CQ7\$/B
MGXU\6:O^R]K7PRLM:M]1UKX#:;K5[H7A/Q)\2VU?Q7XA73OB#XCGTR_U#5O!
MATWPGXB\!0&U\,_$;PGX.^)EKXP\ ^#?R#_:!_X+I^+/A-<_\%#OCCX>^&/@
MO5OV3/\ @F3^T[\ /V7OC'I%]#XEN/CI\7];^(GBS2_ OQE\;?#W6X]=T;P3
MX @^$GBCQ=HEMX1\&:]X6\>?\+6LO"NO7EYXY^' \5:5'X:+/FY6K248SDI>
M[R1<\/3]^]N7EGB\/":?P.;<O<A4G!77*Y)WC=Q3CKSOEK22A;67-'#UG"R]
M[DLK2E!2_I'HK^7;]N+_ (+6?M@?LX_%O_@KIX'^&7PK_9KUOPI_P3'\&?L<
M?%?3-;\=1?$^7Q!\4?"_[1;?#FX\3> K[2- \5:9IVBZ]9:9XVUR;0?B-;ZO
M-I^C7WA32;/4/AEXJ@\:W=]X%^G/V@?^"N?Q8MOV@;S]G;]D[X'Q?$SXC^#_
M -@GPC^W-JW@O4/ ?Q=^(_B/XH:QX_\ %.CV7@7]F7PI/\++*'2/A'J_B'PT
M-6N-4_:$^(DWB3P%X2U[7_ ]C+X$UZ"3Q$^FEGR\UG:R=DG)I.G7JW:BI.RI
MX:O)I7DO9M*+;CS-:MI-;R2;:47*,L/!Q4FU%OFQ>'2NTFZB]ZRDU^]@96&5
M(899<@@C<K%6&1W5@58=0P(/(-+7XI>'_P!H7Q'\+O\ @L-\)?@I::3KWA'X
M2_\ !0/]A+6_CYJ?PI\2V4L&N_#W]I[X(^*]/;6/$UW8Q:W>:/X7UGQK\(?%
MT7@_XKZ7I5O=6NK^+/A9X'U:"Z74?^$FU'Q!^UM-Q:46[.[JP=M4JE"M/#UH
M)IM24*L&E.+<9QE&46U=M)W;5FO=I35TTW3KT85Z4FFDXN5.>L9+FC*+4DGH
MBBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %?$_\ P4&_85^&W_!2#]F'QK^R
M1\9/'OQ6\!_"KXBZAX1OO&<WP?O_ (?Z1XJUJ+P1XR\/^/M TTZQ\0/AU\2+
M73K*+Q3X7T74+F32-,T_4KF.T:QDU#[#=75O-]L44I14E:235T[/O%J2?RE%
M->:0TVG=:/5?>FG^#:^9^?G[6'_!.GX7?MF?L(ZC_P $^_C#\4?C7'\*-=T'
MX7>'/$GCSPC?_"O0_BUX@TWX1^+/"GC3PP+W4KCX3:GX L9KG7?!/AV769-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZNMKI7\W%32?9N#4DFDW%J2TV.MNMF[>2DX-^:4TXMJZ4DXWN%%%% !1110
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M+^V\D<8!;S1)"87:8R#:(RL\ B(9F68,%4_K^M]>WYH#Z<_;(_Y.*_X)._\
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M#[PI;_$SXS>,O"G[%/\ P4"\+^'OL'QGTGX9Z,UWJ.B_";P;+\%/B/XE_:4
MT#Q)X9OB?V)OC%<:=J4>N^)_#ENO[@:[\$/@OXH\4>#/&_B;X0_"_P 1>,_A
MQ;0V7P\\7:[X \*:OXG\!V=OJ&FZM;VG@S7]0TFXU;PO;0:KHVD:G#!H=W8Q
M1ZAI6FWJ(+FQM98O+=-^!GQ)U?\ :'U'XO?%CXQ:1X]^'7@V_O-5_9M^#6B_
M"NS\&Q_"37?$O@BR\#^,/%OC?QW<^,/%NI?%?QFND'QEI'P^UK2M%^%EEX.\
M*_%OXJ>'=?T;Q^VK^$]5\$Z*WNQ<8M649MJZG3C3K0G'1IJIB?:493E%14)T
M&X32U>+6DFG+FYI2A9I<DI3HSIVT:=/#RI55%2NYPK<LXMIGXB?M!_%K4?%7
M[1G[:/[+FL?\%,+7]@+QY^RSXE_90UG]E>;QRWQH\1_$CQ-\%D^"WP0\::-\
M0?"^C:]^U%\/O"'[:,GCO]H6Y^./P4^*7AOQI\-OCMX@\6W</A_P)XPFU#Q!
MK?@^R;7^%WQTUS]H+]I749?$/_!2KP]^SQ^T#^SE_P %2OB_\*/$_P"R6^A_
M$[_A87Q1^#.E?&;Q]\/_ (2?!>Z^!WB#]I*P^&_B[X=?';]E2?X>_$C0/CSX
M9_9CU&3P=KUKXA^-.D^+&U/P1X_UI?WS\7? SX)>/_'G@'XI^._@[\+/&OQ/
M^%,U[<?"[XC^+OA]X2\2>//AM<:D@349_ /B_6=(O?$/@Z;4$ 2]E\.ZCISW
M2 +.T@ %#? SX)O\6X_C^_P=^%C_ !WA\,MX+A^-;?#[PDWQ;B\'.YDD\)Q_
M$@Z0?&*>&7D_>-H*ZR-+9\N;4MS51E;E<KMKF<FN5WE>\:B4HV<IW<:L)?NT
MFW33?N@UHU&Z2244[;.*C*$FM>6%N:G)/GOI.VLSX9_;:^*WC70?VL/^";/P
M#O=2\4>#?V?/VE/BG\?_  ]\5O&_A3Q)XC\"WNM_$7X?? #Q)XZ^ _P-O?'_
M (7U'1==\,V'Q*U.R\<>/8[/0=<T#6_&>L?!/2/ [ZAJ/A3Q#XN\'^*ORV\0
M>)/CIK%_\$?@5KO[1'[1-A\)]+_X+Z?%?]C;X??$OPE\;OBEX1^('Q3_ &0[
MG]B;XW_$?7/A%XP^,%OXI?QA\49/AE\>;+QC\!8?B?JFN7OQ<\/ZU\%;:XT_
MQ]IOQG\,7OCUOZ4O'GP]\ _%/PMJ'@;XG>!_!_Q&\%:O+IL^J^#_ !YX9T7Q
M?X6U.?1M4LM;TB;4/#_B"RU#2;V72M:T[3]7TV2YM)7L=4L++4+4Q7=K!*G-
M:O\  GX(>(=.\":1K_P;^%6N:3\+;ZUU/X9:9J_P\\(ZEIWPZU*R\G[%J'@2
MRO='GMO"-]:?9K?[+=^'XM/N+?R(?*D3RDVJDXPE%S3E%2DY12C:I&4Z<H\_
M,I/FHJ$X4U%PBXU9*=TK,JISA*,7R2<(QC47-S4Y1C43E'E<4_:.<'/F4G%T
MHN.KT^)/^"DFEZU\$_\ @DE^V5:?#?XE_&'PWXE^"/[#?QAU+X?_ !6M_BUX
M^/QLLO$7PE^#^L:KX2\7:E\8WU[_ (6'K/C.?5?#VGW_ (A\5:EXAGU[Q->3
M:A/J]]=3:C=O)\&?MY1^--1\:_\ !9"XM?CY^TQX(L?@3_P28_9X_:<^$NE_
M#3]I7XS?"O1OAU\=;#2/^"E<</Q%\/0_#WQMX8GLQ<)\(/ <_BOP=+>R?#?X
MC7&B6-Y\4?!_C2?2?#LVB_OYXS\$>"_B-X9U7P7\0O"/ACQYX.UV&.WUOPGX
MST#2O%'AG6;>*>*ZB@U70=;M+[2]0ABN8(+B.*[M9D2>&*95$D:,//I_V;_V
M>+I_$3W7P%^"]R_B_P (:7\/?%CS_"[P/,_BCP#H<%E:Z+X'\1-)H3'6_"&C
MVVFZ=;Z7X:U(W.BZ?!8645I90QVL"QXRIS<IS5646T^6RNX3^KUJ49J_NWC5
MJ4ZR]UJ]&.C>JN+C&5%R@IPIS@YTWI&K36*P]>=-M--*I2I5:#=[J->334;I
M_A9IWC#XG^&OVB[S0[7X^?'W4=*_:<_X(9_%W]K'XE66O_&[X@:WI^E?M#>!
M/%OP7T/0_BO\&-'OM>D\/_LZWW]E_%[Q5!J7ASX Z3\-OAW>30^&;X^#X;[P
M[IURN)^R/X1\5_$_5/\ @DAIWCK]H_\ ;#\0:7^V]_P1S\4?%O\ :7L_^&O_
M -H?27\>_$?X0^%O^";<G@7QMX9U?0?B)IFO_!?Q;&_QF\<W7B[Q=\ =8^%G
MBSXI7=_/=_%37?&SZQXM/B3][F_9O_9W:XM;MO@+\%VNK#P)<_"VQN6^%O@<
MW%G\,;RW>TN_AS:S'0O,M_ EU:RRVUSX0A9/#\]O(\,NGM&[*9=/_9V_9^TF
M[\*7^E_ OX.:;?> _#-_X*\#WNG_  Q\%6=WX,\&ZJEW%J?A+PI<6^B1S>'?
M#.I1W]]'?Z#I#V>E7B7MVEQ:2+<S!^R56G*I4FJ,8PE4K2ITTVE3IU*F9SIT
ME;1QI0QV'I+2SC@X=J:AG)-TZ<$W&48T%.=[NI.G3P<*E1W]Y2JSPU2H_>T=
M:5[N51S_ )</V=/VQ?B?\7OA!_P3P^!W[3G[:EI\ /!WQF_X)Z_&+7/#?[0O
MQ=\=?$SP5K/Q\^,_PM^.47P@\2VE[\<?AK^TG^S)XNN?C;\*_A%8^"/&MO<2
M^-M5O_%E_P#$#QI\0/$FEZAXET31=9TKZ7_X7!>_%?5?VG_V;?C_ /MD>(_&
M6F_ _P#X(Z? KXP? GXT^"/B/JG[,T'[5*>/M#_:)TG]H/\ ;@MO"?@KQE:6
M/BGPT=6^'WP0TJU37]9\??";P<-4O]4T&V'ASXR7T6L?NWK?[)W[+'B;X<Z)
M\'O$G[-/[/\ X@^$GAKQ+;^,_#GPMUOX-?#K5OASX?\ &%I<7=W:>*]$\$7_
M (<N/#.E>);:ZO[ZYM]=L-,@U2&XO;N:.Z62YF9^K^(OP)^!_P 8-7\$>(/B
MW\&_A5\4M>^&>HZEJ_PXUOXB_#SPCXWU?X?ZMK-K!8ZOJG@C4O$VCZG>>%-1
MU6RMK:SU*]T&:PN;ZUMX+>ZEEBBC1>:LO:PJ1ORNI"M3DTE:7M:%2"JN-K*I
M3JU)S2BHPE!I22E&*AM&:C55102C&I&=."O:FHUX5/9*5TY0E2IP@W)N49)N
M*<92Y_YX_@9\;;CX/_!C_@G9X\N/CK\3/AO\(]#_ .#9_P"/OQD\=R^!M4F\
M:>%_"&J? 'PK_P $[KW1?C/X>^#6JR:M\./%GQ1^&NA>./B+'X=N-9\.:G<:
ME!=W/A.\\_2+V^T^X\"^+'C7Q!KW[,__  5H^"^N_%SXC^)? 5W_ ,&_'PK_
M &A=!\+>*?VM_'_QV\80?$'6? W[<]W'XS\1>-T\97>G:5XX^*WPU^'_ ,)/
M%/QP^'GPKU"Y^"'BFVG%B9OB;X*U^^\7^.?ZF+7X#_ ZQU7PSKME\&?A39ZW
MX*\'S?#SP;K-K\._"%OJOA+P!<6LUE<>!O#.H0Z.EWH/@^>RN;BTF\,Z5-::
M++:SS6[V312NC<WX*_96_9@^&MG8Z=\.OV</@+X!T_2_ASK7P>TRP\%?!_X>
M^%;/3OA)XD\1WOC#Q%\+;&UT+P[80VGPZU_Q;J6H^*=:\$6Z1^&=4\1W][K=
M]ID^IW4]U)HY7>*DTY/$5<74C=IJFL14KU(0LXR;]E*I"TN9*T9<L.:,)'.H
M-1H04N54H8:+<5K-T*=&E)WYHJU2%.>C3?-).4FG-'X*?';XO:=JOQT^+O['
MFO\ _!1'PQ^P?\/O#G["WP-^*G[+GQ6^)_QH^+MUJ^J:]XL\4_M!GXT?&_PI
M\89?VP_@TGQ)U?X1>-?"7PUTK7_AM\;]9^*_@S2_!_A>RT*W\,VGP[\9?$[1
M==_1[_@IYI,_BK_@C=^W.?%?B#Q#K>KV_P#P3J_:+\2ZCXCT^T\8?!K4O$/B
M+1_V;?&6L/J6K^#;#5=,UWPYIVMZI;FYU_X7>)+B]TT65S=>#O%FFZK8K?V4
M_P!EW'[*7[+MYHOP>\-W?[-OP#NO#O[/.HV.L? '0;GX._#R?1?@=J^F?9_[
M-U7X/Z7)X=:Q^&>I:?\ 9+7[#?>"X-$N;3[-;_9Y8_)CV^J^,O!'@SXC>&M4
M\&?$+PCX8\=^#]<A2WUKPIXRT#2O%'AK5[>.6.>.#5-"UNTOM+U"%)XHIDBN
M[69%ECCD"AT4ASGSJ>FLJTZCNHV:E4JSBVTG+G4:JA/EDJ<G1IS4>:4E$IPY
M(THWTIT*5%-75W3I4*<G:_+:4J+J)M.<?;3A?EBG+^9[]O'XE7?PH^"7QN\.
M?"']HKXX>$_&?[.?_!&B]_:D\-Z9K7[5OQ!\ ^$/AGK_ (IU;XJWWPW^+WAW
M7;7QG>?&+]IGXP>/OBK\,M(^%WASX<_$CQ#J/P+^&7@K1-.\-%/+^,"_##XE
M^R?MPR^*/%_C;_@K-?Z=^T+^T?X/T7X6?\$@_P!GW]J+X66?P?\ VF_C#\+/
M#W@#X[6DG_!2JQ'Q)\(GX:>-_#C:<2GP>\"GQ+X3COY/AQX_N-!LI_BAX0\:
MSZ3H$FC?M7K/[*W[,'B)_#4GB#]G#X"ZZ_@OP+XQ^%_@Y]9^#_P]U-_"?PT^
M(NE3Z%\0?AWX::]\.SG0O OCK0[JYT;QCX2TLVN@>)]*N9].UO3[ZTFDA:XO
M[-'[.*Q:O"O[/_P26'7_  -HWPPUZ)?A3X$$6M_#7PY96.F^'OAYJ\8T$+J7
M@;0=.TO3+#1O"5X)M TNRTZQM;'3X(+2WCC563J.I).4)2EB)0>G[N56&,C3
MDK))NG+$8>HN:,FYX5>\U*'(4(>R^K*;52%%82-2%G&-:&'E@W4C)J3:]O##
MUZ<FK6CB&[7C+F_%3X3^)OB3;?M8?#SP_<_'CX^:SH?[7'_!%+XE?M0_%^P\
M0?&OQYK.BV?Q[\(^.?V;?#NC?%+X-Z!?:V_AG]G/45T7XU>-K>\T'X :/\-/
M 5Y*/#VI2^$QJ?AW3;V+B?@7K^M_%3Q!_P &T>M_$GQ?XL\5^+_BE_P33^.^
ML^-?&6L>-/$A^(?BWQ%XN_8O_94U'Q9XJO?'D>L0>-I_&.K7^HWVLW_C"VUM
M/$ZZQ<R:XNJQ:GB]'[T)^SE^SU'<Z?>I\!_@REYI/@:Z^&&E7:?"_P $+<Z9
M\-+ZVFLK[X>:?.-#$MEX&O+.XGM+KPE;/'H%Q;3S03:>\4KHU.Y_9U^#=AI_
MA63P/\)/@OX.\5_"WP]K^B_ [Q+%\(O!UXGP;FUNVN5,G@G3K*TT2XT+2&OY
MUO=7T+PSJ_AN+6XUFMI[RW:X-RDU'?$SQ$8VIJ5:5/#02M"$\1F=:G3BW*,;
MTZ6.IX:+=DXT(KF47%0Z8SC[&%%1C&I[*G3J5VW>=18?!4)UIZ2E:=3#2KR2
MN[S=DYJ3G^2?["VJ_&#4?BIIG_!/_P"*/Q"^/_B/QU_P32^,WQ/\=_%?XR>*
M_BS\4M8\1?M'_!GXCZ=KEQ^P1J/Q*\87VK:8WQ2TGXI_#SXM>,-0^(^CSZGX
MG\.>'?CS^Q/XM\/:GX7TOPUJOA&-_;/V^9?$VK_MQ_\ !*7X5V/Q4^,7@+P'
M\;OB%^V5X"^*WA?X6_%_Q_\ "NW^(7A;3_V+_BKXMTZQUFX\!^(- U5-4\/Z
M]HMGK7A7Q7HM_I?C'P1K,4?B+P=K^@^(;+3=7L?N7]G+X+^./A3H?B/6?C'\
M5;3XY?'+XA:CH^I?$CXHZ;X M?A?X>OH_#/AW3?"WAGPSX$^'R>)?'-[X%\"
M:/8Z==^(H_"EWX\\71?\+#\9_$CQC:7UB/&<VCZ?ZGXC^%_PS\8^)?"/C/Q=
M\._ OBKQAX N+N[\!^*_$?A+0-<\2^";O4(TBO[GPCKNIZ?=:IX;N+V*...[
MFT:ZLI+F.-$F9U50*32E2YDI\B_>:MJI)TJU*4KN,7JI8=M-6YZ51I>^F8]:
MC2<5/F4$K+D3E":M9NRY_;-6?,HSIQO[A_-WX0\0_%#X;:+_ ,$_?B79?M&?
MM->)?%5E_P %NOVJ/V ;M?B#^T9\6?&?A;QA^RQX0^/7_!03X2>%_AW\2_ .
MM>*Y? OQ<\4:1X=^'7@K5-.^,_Q1\.^,OCW%XC\.:-=Q_$[^R=+TO1;/M/V2
MOCCXC_:@^*O@;QIXZ_X*'>$_A5^T5X$_;=_:J^#_ ,8OV(],O/B?<?%3Q3X8
MT/XB?''X?:?^SI=_"&Q_:O'@&VTKPK\*]&^'WQ<\(_'OP-^S3:>-_!_A+X9Z
ME\5M9\56T6M_';7]=_=FV_9B_9KL]/T;2;3]GKX'6NE>'/&DWQ'\/:9;?";P
M%!I^@_$.X,)G\>Z-91: MMI?C28V\!F\4V,<&N2&"$O?,8TV[*? 3X%Q_$WQ
M+\:X_@O\)X_C+XT\)1> ?&/Q;3X<^#U^)OBSP)"+58?!7B7QZNCCQ5KOA*);
M&R6+PYJFJW6CQBSM0MF!;Q;&I^[!.*;A'XM&^;V>&BVW)/F52I1KNHJG/[N(
M;C:I%J:<?=Y5HW\4DY+F7ML1/9-<KA3JTHPY.7WJ"4O<<>7^8C]C6]^*7Q"^
M&/\ P0B\7^*_VJ_VO_$6M_MLZ?\ M/\ P-_:9N;W]JOXS7%M\4OAYX5_9S_:
M3^+OAZ:"QB\7IIW@#XDZ!XN^%GAB+3OCS\)[7P+\>;;19=1TI_B;(L]I-9>S
M>%[+7OB[I7_!.#X4^.?BO\8[[3_"'_!:7_@K)^SAI7Q D^+?C:Z^-Y^$/P@^
M$_\ P5Q^%W@CPS<_'76M:U7XL?\ "2P?#'PYHWP]3XI6OBVT^,=CIZ0>)/#7
MC_0_B/;:7XVLOW_TC]FO]G3P^O@--!^ 7P5T1/A9?ZCJGPQ32/A7X%TU?ASJ
M>KS&XU;4? :V>A0CPA?ZI<$SZC>>'QI]Q>S$RW,DKG=4$_[,7[-=UX)U'X:7
M/[/7P.N/ASK'BJ'QUJ_@"?X3> IO!.J>-[:\M]0M_&.H^%9- ;0K[Q5!?VEI
M?0^(;FPEU>*\M;>Y2\6:&-U51QGS>XE>K3J1M9M*G6H5>6SO&]J=91=M/;.Z
M:<[VW9P<?=Y:5>G.S?ORK1Q$5/IK!5**Y7HU0BU9QA;^<Q_VBOC)^SQJ/A7]
MG;XA_M;^)="_9#O?^"KO[4/[,W@7]L;]I;Q+X_\ $LEUX&\*?LKZ+\3OAY\
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MY%.:O5@XKDTL1;5MM^]4G*]M8QFH\EO>BG*C)3<(M*G)3?.T[I_@[^V7H/P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?F7^TK\$_@S\=_^"AO['OA/XX?"/X8_&7PKIO[&/_!0CQ#I
MWAKXK> ?"OQ$\/Z?K]K\</\ @F?IMMKEEHWB_2=8TZTUBWT[5-3L(-3@MH[V
M*RU&^M4G6"[N$D]G_P"'<?\ P3S_ .C#OV,O_$7O@A_\PU8WQ _Y26_LE?\
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M\):!K>@^$O'?P]TCQI=PZ+X\\<>#8K_0K_6OU!S7\=_A_0K#6OV(?^"$>L_
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ML>_TOQBVI:9#\,/C-^UY^UK\+O&O[+WAOQ%\*(/"FK:/\'?%OPJM_@%'\/\
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M6N+^R/X#^)?BSXI_\$F=9^*2^,?"?Q6^,'BC]O;_ (*K>*/"5AXA^)>GZ?\
M#3X.>/X_&%I\.OV9+[0Y9M+TBU\46]S^W]\);3Q9'XETRWM/#_AK]G:V^#IO
MKSP_H'AZ[UM1Y6DY3C'=2Y?WEFE*7N*-I54XPJN+A&T_8SE#GA*E*9)R5W&+
M:TY7)\E[Z+FYE)0?,Z2<92O'VU-2M)5.3^GRBOYE_P!B/XZ>"?C;X)^'_P#P
M4 _:H^.FE>'_ (B?LH^&_P!H?]J']L+PYX&\*_&OQ/\ %3X&>+[+X9_$+0OB
M!^SA^T#=:OX.TC6/V=?@5^S?X)\3>)]'\&_L*:'\/[_Q;\9_B9\)_ ?[3EM\
M0?BSXCL?B7K_ ,2_WB_:0^-.L?"3]E+X]?M#_#'PG)\6_$'PR_9Z^*/QH^'W
M@;21J,\OQ,UCP9\.-<\<>$_"FFC2;._U69_&=[IUAI%F-,L+W49#J,8LK.YN
M3% \R;A3YYIJT;R2M**O!5(I33Y9.4>9K51?)*49.G:HB+4ZG)&4=6E%R;BW
M[_LW*4)14XQC+EO[K:4TI14TX/Z&HK^9GPY\7O@Y8_'O]DOXEZ+\4?B!^T'X
M3_9Z_8B_:P_X*'_M3_M8^$=(UZ_\/?MG^-O#?@'1?AYH.EZ79V%S)%XX\#>%
MU^,/Q_\ &'PW\#Z-H=S\'/V?==TKP1\#_A#)H6OZ?JW@GP[\^:1IWQ]_9 \*
M?LR>+M?L_B5\0/VP?V,/^"4_[:'_  4#^)WPT%U\3=9\%77QP^-.F7UI\._V
M>9/"VF^,$L-4^'<OQ)\2?M'^./C"PN-5\83>,/AE\&=,\/Z_IGAO0_@5X!\*
MW->SYW)KEIRJ)RBG+F5-XI2E!6BW%O"S:;Y?<<9R4%**''W^3EO>I&$HJ2Y?
MXBH.*EK*TG]8HJUG[TW%.3IS1_2E^TW^T0_[.VE?!V\MO"$7CK5OC'^T5\&/
MV>]"\-Q^(Y?#^KO?_%KQ7#HFH^)-)1/#OB"/6;?X<>%8O$GQ1\7Z9,VD,GP_
M\$>+=2L]0EU"PM=-OOI<'/-?SU_ O2OA9\8O^"B7[$,?P]\9>(_CEX:^ G[*
MGQE_:M\7?M?W5_JMT_[7_P ?_BFEE^SU\/\ XB7MQIL<?A3Q'\/_  QX"^('
M[6DOP^DT1IOA)\(D\?V7P@_9^TOP!X TZW\+W_K'_!1#X_>(-"_;5_9E_9T\
M=^)/ ?PN_9X\;? SXQ>/='U_XQWOC%?A/\=_VGK?Q9X&\&?#WX/:SX-\%Z9:
M7W[05W\.O >K>._B-!^R/<?$/P!_PT%KWB+P?<:?JIO_ (:1-$G%QY$VW.I4
MJQ2Y6DE3YH)*ZA.2E/#UY1O%3DY4XQIKFC%I/FYG91C"E3F[M-MU>6:ORN48
MM0K4$[-QBO:2E-J+DOV\HK^2_P#:(^"'C_0?AU^TO\+/A?KGQ\^)7AS]GO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%5-0MI
MKRQO+2VO[O2KBZM9[>'5+!+"2^TZ6:)HX[ZSCU2RU+37NK5F$T":AIU]9-*B
M"ZL[B$O$W\^'_!,_]J_XF_M8?L^_LS>(?B!_P4I<_M9>-?CI\6['Q#\!4\,_
MLDW,/C;X;?L_?M.?%#P_XQ\/Z[\-?"7P2TWXJ^$;?Q/^SQ\.R9?'EAXO\*V>
M@>/M?\+Z[!>-9ZMIW@K7R/O3<-FHJ3>K]URE&]HWD^5Q;E:+M'WG9)V'I'G;
M27-R:NWO.*DKMKE2=TDVU[S2ZH_H:HK\J=#_ ."CW[-OPNT/XH^*?%_Q>_:;
M^*NF:E_P4*\1_L<Z)8>(?V;]:N-<\!_&ZZT3PM<6_P !_A_X7^%'P1\&>*-0
M^&.A227'_""^+OB3IGBKQ[X^UK5;S3-&\=_$>34_ ]M=WO$'_!7#]G#PIX6^
M)_B?Q'\,/VN]"D^!7P<^"GQ\^/GA;7/V6OBIH7C#X(_"CXU6GQ-U2'Q;\0M"
MUK2=/DM[#X;:'\(O'6M?$Y_#\_B :5!HM[IGAD^+/$6F:UHNEINRBWIS<MKM
M*[E"%1).]FU"I"3M=*$E-\L&I#MK):MQO?1II*4HMM-)KWHRBDTFY1<4G*R?
MZD45\D?"/]M3X-_&7XX>,?V??#MI\0] \?\ AKX<Z%\8_#I\=^ M:\'Z%\6/
MA!KNO7?A)?B=\*=3U5$?Q-X1TSQ=9GP[JES>VFC:@DM_H&NV.G7WA'Q5X7\1
M:QRGQY_;_P#@S\ OBOJWP*U3P=\?/B1\8]*^ 7B']I6/X??!WX(>.?'FI:U\
M+?"_BS1O!^M7WA_68+"P\):OJ]CJ>LQO<Z/;>(S<VGEV>F7QM?$?BGP+H?BI
MR]SXTX>[.7O>[[M/VG/)\W+RJ'L:O/S<KA[.ISJ+A-14?>TC[SO!+E]Z[J<G
M):U^;G]K3Y''F4_:0Y7+FBW]Q45^=_CK_@J%^REX-\*:%X[TO5_''Q'\%:C^
MR;HW[>/B'Q)\/O!&I7]M\/OV,M>C%SIO[0_C/3/$,GAGQ /#-S80ZMJ<'@KP
MOH_B?XPWFG>&_%%UI_PVNT\/ZI]G7XX?\%./V<?@+X@_:&\.^)M"^/'B:?\
M92\"?"7XK_'[5/A_\"_B!XI\/?#_ .$OQ<M_B1JEC\4Y==CTRTTWQ'X$\'>&
M_A3XR\3^-];\(3Z^+/3=+O=.\/P>)/%&C>)/#^B$O==I+E;DXJ]E=Q<DTGL[
M.$TVFTN2;O:$W$6JNM5RJ>G\LDG%VW7,I1LFDWS15KRBG^A]%?#NA?\ !0S]
MFW4O&WQK\%>(]5\8_#!O@;\$9/VFM=\4_%;P5K/@7P=XM_9QL9=<L_$'QQ\
M:SJL8DU[X>^%=4\.ZKIWB#4+NSTC4;=/[)UVSTN^\)^)O"_B#6J"?\%#?@N^
MK_&_P2OA#XRW?QC^!_P@TS]H"]^ 'A_P'!XW^-_Q)^"VOZSK_A?P]X^^$7@3
MP#KOBFX\9IJGC#PMXA\&7G@UKO2_B3X-\4:?;Z5\0_!?A"37O#+ZV[232<9)
MN+DDXM/EBY1D[-)KE<9*::3ARRYXPY9.*NNZUE&*U5FY).*3O9\RE%Q:;C+F
MCRRES1O]XT4@.0#Z\\@@^V00"#Z@C(/%+2'OJ%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M #8T?\.F/^"=_P#T;+X6_P#"G^(G_P V- 'Z*T5^=7_#IC_@G?\ ]&R^%O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 44Q)(Y5+1NDBAY(RR,K@212-%*A*D@/'*CQR*3N2161@&4@/H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSX?_ ."DGQ/T'6/'_C]OAEXS\2?M8>,_A)X:^%>GW_PH\3?#MO@9XN\#>(=
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MF24K:O\ GU6]N:JHQ=[J]O83A)?"E4C/WF^?Z-HHHJ"PHHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/A3IA\+Z[9?%7X<_\*YT2P\!Z1I,6G^"OAC!\+R%\6:2(/"?B,>(;LKH-@/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKP?XM>+?VC/#NK:3;_!;X)_#3XHZ-<:=+-K6I^.?CSJ_PDO=+U-;DI#86.DZ
M;\$OBE'JUK+:XN'U&34]+>*8FV%A*H^T'WBB@#XO_P"%F_MY?]&B?L^_^)I>
M*?\ Z$*C_A9O[>7_ $:)^S[_ .)I>*?_ *$*OM"B@#XO_P"%F_MY?]&B?L^_
M^)I>*?\ Z$*C_A9O[>7_ $:)^S[_ .)I>*?_ *$*OM"B@#XO_P"%F_MY?]&B
M?L^_^)I>*?\ Z$*C_A9O[>7_ $:)^S[_ .)I>*?_ *$*OM"B@#XO_P"%F_MY
M?]&B?L^_^)I>*?\ Z$*C_A9O[>7_ $:)^S[_ .)I>*?_ *$*OM"B@#XO_P"%
MF_MY?]&B?L^_^)I>*?\ Z$*C_A9O[>7_ $:)^S[_ .)I>*?_ *$*OM"B@#XO
M_P"%F_MY?]&B?L^_^)I>*?\ Z$*C_A9O[>7_ $:)^S[_ .)I>*?_ *$*OM"B
M@#XO_P"%F_MY?]&B?L^_^)I>*?\ Z$*C_A9O[>7_ $:)^S[_ .)I>*?_ *$*
MOM"B@#XO_P"%F_MY?]&B?L^_^)I>*?\ Z$*C_A9O[>7_ $:)^S[_ .)I>*?_
M *$*OM"B@#XO_P"%F_MY?]&B?L^_^)I>*?\ Z$*C_A9O[>7_ $:)^S[_ .)I
M>*?_ *$*OM"B@#XO_P"%F_MY?]&B?L^_^)I>*?\ Z$*OI/X::O\ $?7/"5EJ
M/Q7\$>&?AYXTEN=0CO\ PMX0\?7GQ+T.TM(;V:+3+FW\6WW@CX=W-[-?V"P7
MEU;/X6LUT^XFDLDN+Y81=R][10 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !15:\:[2TNGT^"VNK]+:=K*VO+J6QM+
MB[6)C;075]!9ZC-9VTLP2.>ZAT^^EMXF::.SNG00/^6/[(G[=/[4O[77[-7@
MO]IOPS^R7\%=#\->(_B/\1/ ^K^$/^&O/&>K>,M/T[X0_M'>,O@#\0]:\.17
M/[(&@:%XGU18/ /B/QCX)\-W^N>%1XJE;1?"VH:UX7NM2GU73YYESJ%_>:4D
MMM'.--.]K?'**?9-R?NIM-IJ$JC3Y(NS:UUY)U+)+5MQA)I)7;M%>]**?ZKT
M5XOX@_:0_9W\)^)M*\%^*OCU\%_#/C'7?B'I7PBT/PGX@^*7@;1O$NL_%C7=
M)L]?T3X8:5H6HZ[;:IJ/Q#UC0M0L-:TKP5:6LWB34-)O;34;33)K.YAF>WX<
M_:!^ OC'1?B9XD\(?&WX1>*O#WP6U_Q+X4^,>O>&_B3X,US1OA-XH\&62:EX
MP\-_$S5-,UJZL? >O^%-.DCO_$NC^*9]*U'0K*1+K5+>U@99#5_R<O\ MU.*
M;]$Y13>R<HIN\HJ2_P TOF[M+U:C)I;M1DTFHR:]=HKYN\6?M!^$]5^&/A[X
MC_ [XJ_LW>,=&UWXN_#?X<VOB[Q9\9=-TSX8ZHVK_%OP[X&\>^%?#WC;PA9^
M,+75?B[_ &9/XC\/?#?P/'"#X@^+:^'?"&LW6D6]Y?75KX[X,_;9TZ7]H?\
M;S^%GQDL?AS\%?A9^Q1X?_9]\47/QF\2_%*WMM!USPO\9O _B[QKJ_BGQ]=^
M*?#_ (,\._"ZS\*'P\FD26<OB#Q/I[0PRZ[<^*(AJ*:-I DVY+;EC*;YO=]V
M$:4Y-7M>T:U-I:-\VB:5V:]$W\*]U<UN><Z<;VN]9TY1V=FM;7LOO.BD!# ,
MI!4@$$$$$$9!!'!!'((X(I: WU6J"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH ^T**^+_P#A37[9W_1Z_AO_ ,18\(__ #Q*/^%-?MG?]'K^&_\ Q%CPC_\
M/$H ^T**^+_^%-?MG?\ 1Z_AO_Q%CPC_ //$H_X4U^V=_P!'K^&__$6/"/\
M\\2@#[0HKXO_ .%-?MG?]'K^&_\ Q%CPC_\ /$H_X4U^V=_T>OX;_P#$6/"/
M_P \2@#[0HKXO_X4U^V=_P!'K^&__$6/"/\ \\2C_A37[9W_ $>OX;_\18\(
M_P#SQ* /M"BOB_\ X4U^V=_T>OX;_P#$6/"/_P \2OI/X::#X]\-^$K+2?B5
MX_M/B;XMAN=0EO?%]EX.L? =O>VUQ>S3:?:KX;T[5-8M;5M.LGAL7G2_D:]:
M W4B1/*T:@'>T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;?%?5O#.G_$3X\?LX_#CX=Q>((OAW\./'7BJUT:^\56NHZIIWA?51I=M>W,
MMV^WZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ?\ #WP/XX\._'W2?V8]?\ ^,?B#>_!>W\%^%O'^B?&?7M"\.ZMX&U[7M/\
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M,K?4?VC? 6G^)?@=I<^CQ1W_ (^MVUOPZ-7_ #__ &Q/V-/VJ?C3'_P6UM/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ?F9\>/^"F7A?X)^*?V@UT_]G;X^_%CX/?L;+H[?MC_'WX?VOPYC
M\$_ MM5^'?AWXOZK;6'AOQ9X_P##?Q%^+U]\-/A%XQ\(?%CXO6_PN\)>($\(
M^!?$NG1Z)<>,/'UOJW@+3?TMM[BWO+>"[M)X;JUNH8KBVN;>5)[>XMYT66&>
M":)FCFAFC99(I8V9)$971BI!/\U__!2WX0P>+-7_ &^?@1^RGXP_X*5>'OVB
M/VW_  *GPZ\=_ /X9_LS37W[#OQ>^(_Q&^ /A/X&:=\<?'7[3OQH_8_^('PS
M^&G@#0OA;<^"?#O[0^K_  8_:@^&NNZEIWPJN/#VE:#<?&JW2/Q!_17X$\*6
MW@3P1X.\$6=W/?VG@[PKX=\*VU]<JJ7%Y;^'=(L](@NIT0LB37$5FLTJJS*L
MCL%) !IQ2]GS-^_SPC:SL_W=2562DVTXQFJ,8)132E)2<I749;DJG+9<G+.5
M[ZI<]-4DU;24H.HY>\TW%.,8QLY=71112*"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ex-19_010.jpg
<TEXT>
begin 644 ex-19_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2* X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?S
M*_\ !RM\"/AM\,_^"5__  4)_:J\*:*]I^T-XNU?]E.>#XN3W!F\<^!=-TGX
MY?L^_#%/#7PO\2!4U?X=>&M1\-QZTVOZ7X7O-/'B#4?%_B^?69;ZVUI[2'^F
MJOAO_@HK^PSX0_X*0?LK>._V/_B7X_\ %_P\^%WQ0OO!]WXXU7X>V?A]O'%W
M!X#\;^&OB)X=LM#U?Q3IVOZ)HL+>*?"FCS:O--X;U6ZOM.BFL+2;3?/EN&SJ
MQE*/NZ2YH:WM[JJTI35_.$))I?$O=>C:*BTGKM:6F^O+/ETZVDTU?9Z[JZ_/
M[]I3XI?#7_@D#_P3E^*/_!2OX,_ CPUXC\5)\#_V*]*^)?PITS77^&'@WX@#
M_A/+3X?Z3XIMQX?\/:QI/A[X@_VC^T9J6K>+?&1\*ZMJGCG1O"?AOPWK,B?V
M3H^JZ5[S\1?VY_VN/A%X0L_&_P 7?V0M!^'W@3XC_M0^ OA7X%^)VC_%!?B7
MX4^!?[-/C;X/GX@:M^UG^U[ VC_#G3/AQX=^%GB/3]2\(_$SPY_PFVC^&--\
M3/+X<T3XJ:WI%OX(^(?Q9]<_:Y_X)X>$?VTOV M6_P""?7Q<^)_C+3_ 'B;P
M[\*?"GBKXB>"=*\-:+\0-3T?X.^,O!_CCPQ<V$6I6.N^$M(UW5-8\ >&%\47
MJ>'+O2+RU;7XM"T#PX-3TPZ#I?M:_L%Z;^UWHW[(5EXH^-GQ&\ :M^R/^T7\
M(?VE-&U/P%IG@R32O'OC/X1V]Q'I5OXJ\'^-M"\8>&6@^V7+ZQH-VUA>W7A'
M6EAU/2=]U!"\?34G3E5JRC%R4\7%KF<HQCA95*LYN,8V<6HR@E%/G7-.--)7
MY>>C&I&G1C.6L,)R3:LY2Q$*5&%.\FK2NXU&YR]V3495')O7\F6_X. _%TW_
M  39^$G[=.A_LO>&?$?C/Q%^W/9_L+_$'X4'XNZGX?\ "[>*)-?\0>'5^(WP
M]^(-U\/-4U*70=5?3M U:U\.>+/!6F7NDQ:_J>E7>N7[^&+?5?%/=>(O^"X7
MQ%^''P(_X*M^._B3^S'H]Q\2?^"8W[0OP^^$_B71?A/XV\2_$#P9XB^'?Q:\
M7^'=(TCXJ->:KX'\&>*;AOA7X4UG6O%OQ!\/1Z)H]GKZ>$W@L_$G@K2]<N==
M\+=I!_P0#^#4'[)4O[')_:8^/LOPYM/VZ[W]N_PYX@DTSX32>-M%\;)<W6HZ
M'X'NM2E\!2:7KGA:VUJ[?7=>OK_1AKVN:A'';6%_X<T/S-'D^L/A3_P3"\/_
M  ;^(O[;WQ4\&?M!?%FT\7_MU?&?X9_'#XC--HOPVN-%\,:W\,O$5QJ"^!/#
M6C3^$98=4^%?Q!\'W5Q\+OB;X8\9S>)M<USP3=W\F@>+?"GBN[/B9(3CR].;
MV5.]U)KVRPN4<^D7!^SEBX9O=PY9>RJT_9<O[E0UE\<G%2Y%5;@DTFZ3Q6:6
M3<^9<RPE3*^3FO\ O*-15')^U=3PF_\ ^"L7B'6?@Q^SW\6OACX4^&'CWX0?
MM&:S\>(-&_;?\-Z]XBUO]C[X5>$/A5\/1XB^%'B;X\6NIP^#/B+\)_B!^TK\
M2IM'^ 6D_ +QC<Z-XI^%/QNU7Q%\-I/%OQ8\2>#_  C:_&;CO@E_P6TTW]I'
M]G+_ ():>.OA]\+-+\"?'+_@J?\ $+XK_#WP#X'\>>);W7_!_P )+/\ 9\N_
M'NG_ !V^(VK:EH6EZ)J'Q%TOPQ=^";2+P/X)MI_AYJOCZ]\9^&M.U'Q-X%B3
M6=4TWH?!/_!"/X ?#35/V:]:^%_Q:^)GP??X!_M(_M8_M2ZIX+^$>C> ?#GP
M:\8?$C]K_P &+X$\8V'ASX1>)_#GCCPU\,/"?PE\)VUGX'_9RL-#?5==^$?P
M_;6-.MO$>M^.=9F^(T'/:%_P0,^#7A#]CG]C3]F+P3^TA\=/"7Q&_P""??QM
M\8?'?]DK]J#3-+^%TOQ'^'?B3QEX_P#$?Q U?PKK?AB^\%7/@GQS\.=9U/7K
M9_%WA7Q!ILC^+I]#TZWU'4XO"[7/A25MT^:6LG!RPK2BFI1A&?\ M2BVDFYP
MFN65HJ2HMPC2J5$FHWY+.ZJ<N(2D_>CS2C)X>4HJUXQE%)QNW%SCSNI",CQO
MQ_\ \%#O^"D^I_MF?\$2/@5XB_9X^''[*WB+]KM?VU?%_P"T)\!/&WQ5O_%>
MO)XF_9J^$_Q3TRS\(ZK\1? GA37_  VGPLU?1]5\+?'3P<^@Z;XA\0>(_%D'
MA+PYKU]X0T?PQJ>I>,_-/@#_ ,%-_A5^SGI/[84/PN_9KN/"_P 8_CQ_P<.^
M-/\ @F[I-MK'QT^(GC_P#\1OVH/B+K/@WPUXF_:A\5Q>,4U/6?A'\-8/#^EW
M7B2Y^"WPUM];LK>[T;PU\/- UO0=*US_ (2WPG^M_P 8_P#@F_9_&GX]?L&_
MM0Z_^TI\9K'X]_L):Q\<+GP]X\M- ^#;Q_$SP]^T3X.@\$_$GPYXJ\*O\-5\
M*:((-!L;+1?!>I^&='L9M T:76'U6W\3>+]0L_&6D^!:=_P1&^!%GHGQ:AN?
MBC\2-2\7>/?^"EEC_P %;_ 7C"ZLO"Z2?!C]M.Q\21^(_P"TO"^BVVG0V?B;
MX.7R6\7A74OAEXXFU[5)O"-_KD=IX[LO%]SH7C+PU$/=4[N//*=6[BI\CA+%
M82<59NZC]7IU8V3234DESRHU(U)J3A[LE&,8[N-U*-+%)/SDJM2FW*2EHTW>
M*K0E\T_M ?\ !>S4?@9^R?\ MP_&.Q^ WAWX@?&;_@GO^VQIW['GQA^&C>/=
M3\$>&_B/8Z_XIMO"O@GXR>!/$+>&/&-QX0L/'"ZA;ZT_@#Q!%XFN_!E]H_BG
MPE<^,?$]M9:'XX\0_?O[#_[>GQ'_ &D/VL_^"BO['WQ>^$_@?X?>/_V#?&GP
M#M9/$?PU\?Z_X\\'>-_!W[27P\U[XB^"H5N?%/@;P#K=OXG\)Z=X=N=.\5W1
MT2UTG4[^]B;1[.VMK1IKSPKXN?\ !#3]GWXT_LP?M+?LY^)_B?\ $C0=4_;*
M_:NF_;&_:4^+?@S3_!]CXM\4?%%_$%MXIT[PUX(T_P 4:-XQTOP3\*O">J:9
MHNG^"_">I'QGK.E>&K"\M=9\6^(_$WB#Q#XMU+[(_9R_80\*?LZ_M9?MK_M?
MZ7\1/%?BSQ]^W9>?!74/BOX>UK3=!LO"7AFX_9_\*:YX&^'<7P[@TJTM]6TV
MR/A?Q#?VWB>+Q-JOBR\UG4X-.U*SU#1EAO;/42+MI)7O32D]&O:?5L,FX**@
MTGB8XAZQ:M)NRA*"@*W++XD^:\%?WN5UZSM4;O%VP[I;/FNDFW*,G+\-_P!M
MCPAX5\5?\'0__!-[X<>*/#NC>)/AU\2_V)OC5K/Q&^'VO:?;ZQX#\>ZSX9\.
M_M,/X=UGQEX-U!+CPUXEUG0WT[3#I>K:SI=YJ-D=)TCR+E/[(TS[)XY^S]_P
M5,\8_P#!,OQO_P %^/A;\7]7^*?[27[,_P#P35\4?"KQ]^R]I/BSQMX@\6^-
MO"L'[1'B ^%? O[,6H?%_P :3>,_%;?#[3_&?BOX>^$/"&N>)W\7ZY\.O"'A
M_P 8ZLUIXO6UM]$@_=?XV_\ !,;0/C+_ ,%"/@K_ ,%(D^._Q#\"_&K]GOX4
M>)?@U\,?"OAWPUX!U+X;)X3\8:=\1+#Q%J/B[3/$^AZSXD\0>*[G_A9FN266
MHZ;XI\-Z'8KI'A:/_A&9C:^(Y/%/+S?\$6/V+=6_9=_;%_9C\9VGQ&\?R_M]
M>*M4^(O[5_[07BCQ#X;C_:$^*OQ0D\5GQSX/^($_B#PSX-\.?#OPU/\ "CQ?
M'9:]\*_A]X0^&.@_!?PE=V<\<?PQO+/Q#XOMO$2A>,(IMOEI8V+@K+GG7Q-*
MKAVI2BXKV$8SD^:WO25*-X2FD/6I)M)J53 R4G=\D,/AZE+$1<4XR?MY.$?=
M:O%.I*THQ9^<'_!33_@K'^VS\%_^"=W_  4:\9^ _@7XB^#GQ5_9JU?]G'P+
MX3_:6\=_"3XZ_"?X6?%'P5^U;::'H&M>/_V9M ^+O@[P]XFUKXK_ +/7CCQ!
MJGP[UW3_ !)=3>%;&_T;PU\8;R=T\5VGP2L_J+_@HC_P5I^/'_!/CP]XXU#Q
MY^S7X.,WPL_9X\(?'RX\7ZMXZ\1V'P3_ &@O%^K_ !FU+P)XD_90^ WQ)O\
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MI6I)JIRU;.;6C<<U]CSO6\XN64\\HIQO#$/WO?<^)_:+_P""QG[2?PN^-?\
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MG<:1\7?"^M?##Q!H/A#QUJ+>+/A=:W.B:'X0TGXV>/YO@W_P5=^/'@O]F_\
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MG_ .?PK?7K>,9_A]#>>,KFP\)_$#6;;5?BGH>B:6TWCOPQ=^++0CPW'\H?\
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M1T?_ #\5""KOK>];=IN,I1DXZ7<BBBBD,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#*US6+;P_H^I:W>6VJW=II5G/?W-MH>C:KXBUB:"V0R2I
MIN@Z'9ZAK.L7A13Y&G:58WFH7<F(;2UGG=(F\ ^#7[7?[/W[0WP'F_:4^"?C
M6_\ B/\ "6U;Q=;WNH:#X&^(">,=-U3P#JNH:+XS\-:M\*=3\+:?\5M(\9^'
M=2TN]MK_ ,#ZGX*M/&.^.'[-H<_VVQ^T_2+@G;CLZD_3/_ZJ_F/\,^$?$?\
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M%_P3]\1S3W.@^,_&WB'0KOQ!%J5Q+9V7BBZTZ;Q/I/AV.T\%:7J]CX.TW3M
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M#^,-EXE^*_QH^"'[;FA^ OA#\-5^,7PG^/?[./Q#\+>)M(^!VO?%2Z\)V/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB+X4ZUK[2OKVL?#:/3_#MNG@75-;>>9]7U#PN-+N]2::5KR:8R.3T/@SX!_
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M2T$DELDKMMV25V]6W9*[;U;=VWNV%%%%(84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5\]?&3Q+^U=H>L:/!^SY\%
MOV>OB?H$^FS2^(-3^,G[3OQ(^!6L:9K"W12WL='T/P3^R-^T79:YILMEMN)M
M6O?$/AVZ@NB;--%N(E%\WT+10!\,_P#"P/\ @I;_ -&E?L,_^+#_ (^__2P*
M/^%@?\%+?^C2OV&?_%A_Q]_^E@5]S44 ?#/_  L#_@I;_P!&E?L,_P#BP_X^
M_P#TL"C_ (6!_P %+?\ HTK]AG_Q8?\ 'W_Z6!7W-10!\,_\+ _X*6_]&E?L
M,_\ BP_X^_\ TL"C_A8'_!2W_HTK]AG_ ,6'_'W_ .E@5]S44 ?#/_"P/^"E
MO_1I7[#/_BP_X^__ $L"C_A8'_!2W_HTK]AG_P 6'_'W_P"E@5]S44 ?#/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 'Z&T5^>7_#$W[07_26;_@H;_P"$9_P3$_\ I;U'_#$W[07_ $EF_P""AO\
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M 'Z&T5^>7_#$W[07_26;_@H;_P"$9_P3$_\ I;U'_#$W[07_ $EF_P""AO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>)+NUM/'/C3P5XA\:^)=$\#:5/\ &C6_ 'A32=4\;CX5:IH5_HNC:]XY\6^
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MGQ1X0_X*._ 3X-_&?X(:C\!O^"D'@ZY\1^+_ !+\:-#\8Q?%WX3_ +05_P#
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MI0IS^C3_ ,%:_AU\//V>/ACX_P#C+X,U:W^-6J_LC^ _VK/B#\&-'\:_L_\
MA7Q>?!OBO3-3_LO4OAYH_CCX\V&F>,;WXH:GX,^)4_PC\#>'_%VN^)KFV\'7
M>C^.Y/!GB"^T*RUK]0_A?\2/!_QD^&GP[^+WP]U*?6? 'Q5\"^$OB1X'UBZT
MK5]!NM5\'^.= T_Q/X9U*YT/Q!8Z9KVC3WVBZI974VE:WINGZOITDK6>I6-I
M>0S6\?XQ^%/V'_\ @I?\&]0_9I^,GP!^./[(GAOXUZ-^Q[\%/V(/VJ/A;\4/
M!_Q@^(G[.'B3P-\ -=\8:]\)?C?\*-2\+ZM\+OBM+\6/ VH?$7XH)+X1\47V
MA^"O&/AKXDWOA>ZU/PWJ_A32O'NJ?MOX4TS5]$\+^&]&\0>([KQAKVDZ#H^F
M:WXMOM/T[2;WQ3J]AI]O:ZEXCN]+T>&VTG3+G6[V*?4Y]/TNWM]-LI;I[:Q@
MBM8HHUZ*OL_:5G2^#V]54UJK4U5KNFXIW;A*B\.U)R3C)3AR74[<U'VBI455
MUJ>PI.J[\UZGLJ*J)NR7.JT:][)J4)0DG9J^_11161J%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%5I[VSMF5+F[MK=V7<JSSQ1,R@X
M+*LCJ2H/&0",\=: +-%4/[5TO_H)6'_@9;__ !RC^U=+_P"@E8?^!EO_ /'*
M +]%4/[5TO\ Z"5A_P"!EO\ _'*/[5TO_H)6'_@9;_\ QR@"_15#^U=+_P"@
ME8?^!EO_ /'*/[5TO_H)6'_@9;__ !R@"_15#^U=+_Z"5A_X&6__ ,<H_M72
M_P#H)6'_ (&6_P#\<H OT50_M72_^@E8?^!EO_\ '*/[5TO_ *"5A_X&6_\
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M]@#_ ,0W_9U_^=S7W_10!\ ?\.G?^"67_2-/]@#_ ,0W_9U_^=S1_P .G?\
M@EE_TC3_ & /_$-_V=?_ )W-??\ 10!\ ?\ #IW_ ()9?](T_P!@#_Q#?]G7
M_P"=S1_PZ=_X)9?](T_V /\ Q#?]G7_YW-??]% 'P!_PZ=_X)9?](T_V /\
MQ#?]G7_YW-'_  Z=_P""67_2-/\ 8 _\0W_9U_\ G<U]_P!% 'P!_P .G?\
M@EE_TC3_ & /_$-_V=?_ )W-'_#IW_@EE_TC3_8 _P#$-_V=?_G<U]_T4 ?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8Q]Z<%*[6=FXQNUK*45&W-3A*7,_=4(.K!U)-I4X\\I>[3FX_LQ17XF^!?\
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2WHU;??O[U13U<'3N_9NWN7?+HJD8VU3O&-6HD[W2G+6[;#[2F]9K:;MS?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.UHQA%*'MH*-H_#1BFM(<FY1115#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_./XB_%CXQ:1_P %0/V;OV?M(^)FJ:=\%_B3^R?^TI\;_%?@>/PQX!N3=>,/
M@C\1_P!G'P1X<M;3Q/?>%;GQ58Z#K6G_ !LUZ^\1V4.K_;9=2T30FT?4M'LO
M[4L]0_1ROSQ^(/P7^,>M?\%+_P!GC]I/2/!>GW?P9^%O[+7[1/P'\4:W)XOT
M>T\32>*OCI\0_P!GKQQHVMZ+X2EC8W_A3PS:?!.^TSQ'=7FLZ7KKW_B"UDT/
MP]JUIITL][+YO:T+?#[27M/Y>3ZMC+<W=>U="W]_D*T]G7O\7LH^SM?FY_K.
M$ORVZ^R]O?IR>T\CZN^)WQN\'_"_5?"WA2\MM?\ %WQ'\>6/BS5? OPK\"Z?
M!K?C[Q9HG@&STV_\=>(['3;J]TS3-*\*>#XM;\.V.N^+O%&L:!X7MO$_B[P#
MX#BUB?Q_\1_A]X7\4?-E]_P4J_9(_P"%'VO[1_A3QUKGQ)^#2? C2OVIO%/B
M[X=^!_%OB*X^'7[-&K2^(((OC7\0?"C:59>-/#OA^*;PCXTC7PBWAVY^*^J'
MP!\2V\/_  \UA/A=\1V\*^=?MH_"7]KW2/VDOV9/VS?V./!_PI^-'B?X/?#C
M]H#]GWXL?L\_%KXCZO\ !J+XA?"G]H;6_@CXN@\5?#SXNV7@_P"(VE^"/&7P
MV^(WP&\#ZUK=AKWP_P!>M?&W@&[\2Z-IU[I'B*ST/^T/ECXQ_LC?MJVW[5?A
M[]JRV_9C_8._;3O_ (W?LZ_"/X)?'7X4_&OQQK/@#3OV<_B;\*?B9\9/B!X.
M^(GP6^+/B/X"_&*\\9?!O2O#OQU\5?#OQYH\?P;\&?$WQOJ/@SP#\2]/TK3;
MC5?$7@S1FKN/1/GG%:WMRJ4J?N\JYE52BN;FC3IR:4ZB<G&"]V_VFN6#T<5S
M7<54]YMJ'L[R:3C*<UK&#23E]SW_ /P4E_9I;XJW_P &?!-O\<_C)XWTW1/@
MIXHNI/@?^S;\=?BQX+7PC^T1X>\=^)/@]X[7XF^#O 6I_#=OAKXQM/A_J]E!
M\4?^$K'PWTW5KBWL-9\5Z?)IWB9O#_FOP9_;S\(?M)?#;_@G#\7#K_Q?_9[N
M?VR?%1USP1\,YOA)<>(-$^*]K>_LS_$?XRQ?"?Q?\2-;\ :UH'A#2;'PK;1_
M$S2?&?AWQ'X*UCQ[K/PHU70?!VHZOX<D\6Z8O3_LY?L\_%WX8?MM?M/?%[Q9
MH7A6/X;?%+]F7]B;X+^#=>\)'2?#]M<>)_V7Y?VBY?&FH?\ "L[:_P!2?P#X
M2\1R?'?2D^'VAV6O>)Y-.L/#&LV6M3Z6$T1]6^4/V<_V1_VM? _[/'_!&SX3
M_$3X8> M'\0_\$]/BQI-O\5;GPK\7[;Q9I?B+X>?#S]B_P"/_P"Q_I?COPQ<
M:CX-\(7#ZIXW\2_&73_B7IO@J>T,^A_#G1;VWUO7X?'ES!X.0IW<HN:<5[>D
MM9)VI/%XR$IV2M>.'IX:4G).#59R]DHN"IXU7--*"YHJA5<FDU>M]6P<HQUE
MS6=:>)Y5%IIT^3VDFI.</C7]O[Q):>//VNOC)X^^,WQ<_9K_ &=OV _VN/A]
M\-_'.B6O[)]Q\2_ _P 3/@EJG[.G[-WC7Q;#\5+EO"FK?%OPKXXU/XE_M&W]
MWX=\<?#;Q=X7\/\ @/X=^%_A]XX\:_#_ ,0>#4^(.J:_^P>G_%KPGJ7Q;USX
M(VZZY_PGWAGX;>$/BOX@MFT+43H>D^$O'GB/QCX3\)-<^*8HI?#IUG6];^'G
MCF"UT"#4IM6%MX7U+4I;:/3FLKJ[_.[PK\._"WPJMO\ @IQ=?MUVGPI^&O[,
MG[:O[1=QX@@U;XE?%SP9HO@S7?ACX_\ V5?V<?V0;OX<?$#4]4U7PU%X>\6>
M/;[X2:W=V&BZ7J.KVESI'C#2M)M/$)\20S61[G_@EA\)_'WP]_95\)>)/BU\
M0KSXP?$/Q];:6--^*NL6FI6NN^-/@-\-]&L_A7^R]K^K6_B"YOO$NCZ]X]^!
M/A+P?\;?B9X:U>_D.E_'KXO_ !DU""RTE]<NM/A5%MTESI\\80G)Z6YJL90=
M.35^6I&<(UG!M+V+;C%/FE+25U-M;2J5(16WN4Y1DJD5HI0<)2I\RN_:\O,V
MK*/@W[;'_!0OQIX=\*?\%;_@_P#!;2OB%\*?B[^PE^P+9_M+^"?CG<^"=$\1
M^'M1\=>*/A=^TS\0]'&FZ3XJT3Q/X1D\,:))\"-(T2+4?&>F[?%>NZMXPTK2
M-"ELO#-EKVK_ %?X/_X*&_LT7MG\=K+Q9XT\6>#]2_99^!.B?M$_&74_B+\*
MOB/X"MKWX%W>@^+]0O/CK\/HM=\'Z3+\3?ADNI?#?XBZ._B/X>:;K-G+JWA6
MX&FVUQI6N>#[_P 0_&7[6?[&/[3OQ"^)/_!6&/X:>$/ WB3P7_P4+_X)K^!?
MV9/!/BS6/B)'X7O/ 'Q=\$^$?VM_AY!8>)/#,OAW4[C4_#>IO^T?X8\57?B+
M3M1A.E^'/#/BV&VTW6?$L?A_P]X@U/BY^S3^W'KO[0'Q[^/'P"L_ WPK\=>,
M_P#@DOH_[*?P<\8^-_$F@^)QX(_:K\.^._B=\0]&U;7/"\.D>(=(U'X?6,GC
MO2K&R\6WEKX@;_A)=)O'UGX5ZUX55/[9J+M0E)K]Y:<G'[5X4L9R*,9/9U(4
M5*$7^\]I&6Z@3)/ZS%1;=+D@D[VAS3K8/VJD[7;5.5>49M?N^24$FN9/U[X_
M_P#!5;X/_!CX$_M,?$VP^'GQ?UWXD_LV:-\$M2\3?!'5? FH>'O&"V?[3VJ_
MV#^SYXVOKJYF?01\,_%]^NI7GB#6]'UG5_$W@^+PGXU\':QX1A^+GA^7X;S?
M5O[47Q!\6>&_V0/C]\6?AOK&M> _&?A#X!_$WXE^#-4U3PSI[:KHOB#P?X&U
MKQ9HD>M^$_&6DWMLT,E]I4%IK6CZGI\-XUC-=V\%QIE^8+ZV_#7XF?\ !.+]
ML;XF>$/^"BEQH/P.^$OPPU']K#]D_P#X)]6W@+PIK'[37B/XJ>+[OXT_L@_%
M[XL?$;Q/X$^+?Q8\0_#IM;\7^,?&NB^*=-T6^^-'B+6/%, U-?#YN];\56;:
MS?\ AC]P_P!H?PS\5/BY^QQ\:_ NG>"-(LOC#\5O@!\1? NG>"(_&MK=^'='
M\;?$'P+K'AC3K'5/'EYH^D(_A_1=2UF";Q%KUCX;N[R+3+34+C0?#_B"\2QT
MW4<\0I_5L3[)2C7Y:BHI3C*2?L,7&FXR7NMRK4Z$M?AE.+=J<XQCO1Y%BL*Z
MDE*@W0==N+4?X^$E6C*.LHQC1GB(W5^>,))-S@Y3YS]@KXB?$+XZ_L&_LD_&
M/XE>,+S6/B;\=/V6O@A\7?&7BBST?POH_P!C\8?%GX5>&?&VMMX=T33="@\/
MV.E:+J^OW,/ARPU#3-6>'3[6R@UNZUZX6ZNKOXK_ ."5_P#P4FTC]HG]GW]A
M[P5\>O&?B_6_VJ_VA?V:6^+,OC+6/A!K/@/X;?%KQ-X3AT^\^*6B?#OQGI/@
M[PW\)O$'BKP'9:]HE_XE\*>"9I/[(L);^$?:=5\,>,[;0?N#]ASX8^//V?/V
M'/V5?@A\0= !^(OP!_9B^"OP<\5Z7X?U71]5L==\5_"+X6>&O!&L7'A#5Y[[
M3K*[T3Q!JWA^XN/#%[XA;PS>2:?=V4WB'3?#MPUW:6GY??LJ?L'?M6?!S0?^
M")WAOQ=X1\%QR?\ !/\ ^'G[0/@/X_:OI?Q"LM7T^6\^(GP<O/A=X(UCX;V;
MZ;I=_P"--,_M8VNL^)[76U\"7^B:%)*NDIXDU6%-.FZY^R53$N%G2>(:I)?%
M[%5<?*FZ?-9JU..$4E*SESPA-IW<>:*FXT;\RJ*%1RN[1YO9X16FE=.\WB.6
MVL7&<H75E+] O!/_  4I_9A^(5A+K/A*\^)NM>'=3^ ?Q)_:D^&WB'2OA'X^
MUO3OC=^S_P#!WQ/X>\&_$_XC?!N#0=%U75_&(\*>)/%OA.RB\#G2].^)WC'3
M_%?A+Q/\/?!/B[PEXL\,Z]JWJ?AO]LW]GSQ5X3^!7C[3/&,\'@3]HOX'>(OV
MEOAOXSUG1M3T'PW%\!?"WA/P?XWUKXJ>.]3UFWL8?AEX2LO#7Q"\#7EW?_$'
M_A'&TV\\5:/HFK1:?KLTNF0_FA^QG^R]^W9X/_:2_9)^/'[3'PP^%MWX]\$_
MLH_M8?L[_M2?&2R_:&O/B!XM^(WQ&^(WQ8_9<^(&A?%;POH\GP>\)VVA_"OQ
M9J?P0\7ZG\+_ (": WACPE\$/#GCJX\-Z7HO@N'1HM"\0]%\'/\ @E'K7A3]
MGC]OS]E#Q5\0-*TOX1_&/P/^TI^RW^QA)X?TNYUN3]G+]D3]I"R\;?$.^T&#
M2-;OUG7Q%X4^*7QN\3_#M](L-=M-#\1_!W]G/]FZRN'LKS0I#:\SYESZ:1C5
M<&GS^T=-VBK)Q:E6]I"<(V@K4JT;P<HI;*SY=&KRIJ5W;E517D]5)6I.%2,W
M>;_>4G:2YF?HQ\./VN/A!\2OB_?_  #M9/%_@[XP1_"O2/CSH/@#XD>#M;\$
M>(O&?P,US6XO#%C\5/#.GZQ;QSMH]GXIGM_#/B[PKKJ:'\3OAMKE_H5C\3/
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M-]57P]-JNA6LFK? WQ!JO@N^TWPYKU]XBT/7?#+Z]HG@O5'UO2M&ZRV_8O\
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MMM*LM5%KD]4^-O[3OQ/\8_M6?M+?L_\ ACX[>)OV.O!/[*W[.O[-_P"T1?\
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MQ2O[BTU&WUSR:S_9>_;PUK]JKX)?%[XG_#3X5^/+CX$_\%*OV@/BWIWQ@O\
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MEW2O$GQ8_:!U3]L#1O!7QFT[Q)^S+^V;\,_$'A?Q7X4^!7Q#D^!4L-[/X/\
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M_C5\-?AA^S;X\\'?M#_LD?"C]G3XW_"SPU\0=:^$/AO]F[XB?!CQU^T-\1O
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MS%XEL]=T;J_A+^V=\-/!VB_ /X4_&3XUWOQ/\9^+?&^H?LH6O[5A^$LOPO\
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M\-?%&I6'ASX3^(/B%XBUS7_T9^ 7P/\ VB/ ?_!0']J/X_\ B_P'X&M/A?\
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M]_;6M^$A<W&F^+?$&DZM^\7_  6 T'PW\2_^"2G_  4+@DT30/B#I%Y^Q/\
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M5IEU:P>&YO#MG]IB$,EM?3/<V\4NE\#_ /@H7\%/VDO'W[-?A_X)V7B3QO\
M#G]JC]ESXL?M4?"OXVV[:!9>"-0\.?!SX@_!?X;^-? 5[H5SK0^(>D?$/0-=
M^-_AE/$&E^(/!^BZ7I$]M?Z1'J^HZ_IVN:5HOYO?%33[+XH_\%^_%?PP\,?M
M&>,/@7XLU3_@C;I_AUO%'P>U'X/S?$;3]2F_;$\4:E/I&EQ?%KX=?%CP_9Z_
M:Z)>0^(8H8_"QUNQLVM-741V30RG=\3?LH?L._!S]KW_ ()Y?L(WOA?X9G]G
M7X:?\$U/^"BOANV^"GQ)\26&K:%X@\.W'QM_X)W:XEQ\2/#7B'4ELOB#%XDD
M\+_$CX@WB^,M,U72=2\2^$/$?C^VLH]8\"KJN@S*RC0=[RJMM:KEDH?VI[2[
M5^1)8?#6=FU)5'+W).TSE-.I964)0BVHRE)*H\LY'&+LI-O$8E-W4>1PM><$
M?OKGV/3/_P!;US^%+_G_ #_G^E?PYR?'#X=?&/\ X)R_L4_#;XI>($\1?&76
M_P#@@]^U7KWPW\7?&.]U+Q_X)\<^./!&F^!_"3^ _P!G#X>6=W9ZAXX_;^\(
M2>!K;6F^(^B^*6^)WP+\$V$MQ8?#[XC)\1_$FI_#G]$OV>M)_9X_:]_X*'_L
MW:C\:/%'A[XVWEQ_P1@_8=_:#T:#6/BIJVM:;JOQC\#_ ![\4>,X/BY'H^G>
M*TT37?&WAN^MM#U]O%DUC>ZE:VUQ%<S7?]G:G+]JU]DU*<7.*Y)S2V;E3A3K
MU.>REI+_ &><90>D7*#YN5IR;J6A"7*VY<J<4G[LY5*5*S=O@O5C)3LO<4FX
MII17]/5%?QT?LB>"?V8M6^"O_!';QYJ][X)OOB#\3/\ @IG_ ,%$_P!F_P 8
M>+[_ .(UU-XN^(7[.'B&\_X*@^)A\!O$OB"?Q0VM^,/@EXB\=Z;\"M??X7ZO
M>:EX$\0>*O$GAS4;C1+[5/B7>R^)]?X2_%#]FWPY;?#W]FCQ9=?#_3/@Q8?\
M%K_^"DWP>^"%A\0;W2[[]A'X0^'M%\&?%#7_  #\&/B)\)[6ZTWPCX\F\57'
MC[4K']D/]GE_$?PXT*+QG<2^,_ >MR7_ ,+_  Q\,?'*]G)K24>9V<5=6:O@
M[W?1J.,BXJS<Y4YQ2O*FI:=:C^S2:4F[*3YEB[.,6_>2>$ESOF7(IQ;NXS<?
M[ ,_C_D_X?G17\?O[+/[57PB^'/[)_\ P1\U;]O'Q0GB3]AJZ_9[_;,_9_\
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MG*-64'+2/+]7S"=.+J*R56E5P:]K#D:4*D)2LVXNXQERR]HXJ<8Q^%W?-[3
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M7+?3?@-\1=1^'7P2\9_L_P"L_ 2W\.6GPS^&'AGX\^!(]7^'FJVWQEN=+O?
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MMD?$#7_V<?A/:>+OAM\'_BA\/_\ @L_K7[ _[06M>'_AMXFUSX=_&WP[X?\
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M'OAC\3O!ME\;]=3PI\1W\%_$?PMXLO=+TC3]7^$WA.WL[[5]=_17_@H'\?\
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M[4OP%\&_ V'QCH7Q,_91_:?M?B!<_!'XI>+?^%AZ[H5Q\6?A]8>%;_Q1\*_
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M=64(RM"I"H$+S<E%:)\O,]N:,8RJ0=KVDH2]I3NK5*<:C7O4YP7]#=%?CO\
MM%_MB?M8_LJ>-/BG\,O&<WP%^(.I:Q_P3U_:>_:Z_9Z^(VB_#'XB^$=&T_XK
M_L?1>!A\6?AE\5/AT?B_XPO-9\">*X?B_P##CQ!X#\3Z)\2?!FKZ':V7BOPE
MKH\3:M)H7B*\Q/@?_P %!?COI7Q-^'%O^U6?@S/\(/C!_P $P=6_X**6&I?
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M%[S/&^OZAJ_Q EL=9M]3^*&M^"[WQ=X'\/Z&9?!LL\7_  BES-<WMM>^;?\
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M P.@X%%?A[^U'^V;\8_V2OVM/^"@'Q7\5>+]%\:?LY?LE_\ !,?X%_M.Z'\
M8?"&MZ3K.O\ BCQ9X\_;3\.WVC:;\2;7QMJ.G^'O$OC7QC\%_ UEK?CG6?AC
MXOTC3?!,>CZ'I/A#P]?Z+XG\8^-OJ[0OVA_C]\+_ -M;X+_LH_'^[^$?CS0_
MVEOV=?BU\5?AEX[^%'@KQM\/]4\'_$S]F[7OA/I_Q@\$^*_#OB+QM\3K'7?
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MVA/ ?CSQIX2\?^)M'^/W_!1;3?"_@G5-.^&OCWX5:OH#^,+C3]#TG6/C)?\
MBKQ7=?#[P[X;LM-L/A+X_P#[8@O?!6C@US.;453IUZDTK3E'V"ES1DH\UK2A
M)RLYWIQ<J:J-Q4H<U=):N52E"+?NP?M6K-2:2:Y6K?"E-VFX)2:_=7 '08ZG
M\2<D_B>3[T5^%ND_\%*/VJ_VI?A?X7OOV)OV>M.?XR>)?^"=/[+_ .W!I_AC
MQO%X.\9^"8_&W[6D?QH3X=_"#Q/KOBOX_P#[+.NZ3X/T'6/@%XGT77_B7X3T
M/QS?:S8>--!\3VGA?PP/"[>'O'OI6E?M\_&^/]K/P)^SK\<] \"_L=>(_B'?
M_!R_^%/P_P#B_P"!/&7C_P +_M'>&_%'P/\ "?BSXX>#/@U^U_X)\=:)\%$_
M:#^"GQHUWQ7X!'PIU'POJ&N>+?"'PVM/&'A[0]9T+XRZ+XJ^&1R2NXKE<E4E
M3LIQ;<HNI&3@MYQ4J4XN4%*UKN-K\K4HN'/?W>53U332:A)<R^R[5(_$XIMM
M<U[.7[$45^:O_!*OQU\>OB7^S+XC\:?'WXH:!\4_$$W[4O[<O@_2M8TOP)JW
M@O4+/2_A?^W)^TG\,;*QO/[0^(GCFTN=!L]'\):)IO@30M/MM(/@CP?INE^%
MM0U/QI>V$GB>]^=],_X*0?&?Q)\"?A)^W7X5T+X9:A^RIX[_ &YI?V6O%7PM
MOO#/C*V^,/A[X3ZY^V/KG[!/@;XSZ)\1K/Q;?Z/K/C.;XO6_A3XL^*/A?<_!
M^TMX/AWXKU#X7Z7XB/C#P0/B+XZRIS56-.4-?:PH3C=[?694H44]+WE4K4Z=
MU%I2E>3C'WE4TX>TYM%3E5C)]+48U9SE?16]G1G-)V;2Y4G-J,OUZUWXG?#;
MPMXL\(^ O$WQ"\#^'?'/C^>[M? G@S7?%F@:1XL\:W.GV%_JM_;^$O#FH:A;
MZQXDGL=+TK4]2O(M&L[V2VL-.O[R94M[.XDB[BOQ9_9*^'NO?%/]O;_@JS#\
M=Y?@_P#%_P *?#+]KC]E;4_!.A>(?@W?WNJ>"_%O@?\ 8V_9:^+/P9\1^!=<
M\7?$[QMIOA#_ (5EK'BSQ%XALK?2O"@U9OBOK_B/XH^&_$7@YM?NO"L%;]L'
M]M3]LGX4^*?^"G>G?!S4?V:-*T']@W]BKX*_MK>$)?B/\(OBCXZUGQSI_B+P
MQ^V5K/COX0>)5\-_'_X:V%G=>([[]F;1!X5^)VE>3%X L-5U>UU3X;?$F[U2
MRU'PQ53]TZ<9NSJPC-.SM%2INJ^;=KD@FVUS<R3Y8\R49JD_;<_LE*3A5E1Y
M;+FE-58T5RJZOS5)J*3Y;-QO*TKP_:^BOQZ\(?M8?MI>+OVE/%7[-UI=?LO1
M^(/C/_P3\E_;5_99UJX^&_Q7BT;X.^*X/'GA_P !2?"/X^RQ_&*:^^//AMK[
MQYX0O8OB=\/=-_9XU5[;2/$YD^&<$FHZ3;6'I/[%_P"V3\6/VL=*_97O6LO
MWAO6KC]GGQMXU_;H\%S?#WQIIGB+X4_M!>&O'B_ 5/@UX6CUSXBQS^!H]/\
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M ++]DWBSQ3X*\8^+O#OQ7\&Z'X^^"M[\-_ O[1OC/P[INE>#O!'C'Q;H_P
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M0<[TO9\_.E.7R+FD[)V7,^KC!5Z>K3]Y0C]8C*SDH1555.6,7R\KXZ_X)U_
M_P <>"O WAN/Q)\5?!GB_P "?M3VW[:-I\:?!/BC1=+^+FO_ +14NG>)/#7B
M?QQXJU;4?"VK^%=9@\9?#[QCXG^%>H^&CX/M_#7A;X97^E^#_AAI7@'3O!7P
M_P#^$4]G_:D_9B\"_M;?!J]^!GQ%U[QMH/@[4/%OPP\:7=YX'U32-/\ $<NL
M?"#XB>%OBMX'!U3Q%H'BB-;6Q\>>"O"^MWR+9B?5%TH:;?7$VE7^J65[R%I^
MVM\(KOQ-K5B+'Q?;_#CP[XS^+GPZUW]H"ZM/#<'P0T#QW\!-'\9:O\9O#OBK
MQ&?%+>)/!"?#O_A7WC+2]:\3^-_"/AOP1=ZUH5WIV@^)]7E,+2^<Z=_P4U_9
M17Q%\2O#GC;Q/K_PIN/AI^S?>_MAW5[\1-"6RLO$O[+FF:@='UCXP^'X_#E_
MXFU.QBT#6GLM%\2_"[QKIW@_X[>&-3UGP[;>(OA5I9\2Z VI'/)<KYI)P<:L
M->7E<53Y)03<>5VI4G3C%+F4(2ITYVN/ENW[MY2YJ<G9MRNY\T9-;ZUJBDY2
M?*ZDHRG#FL9OQ/\ ^":'P6^+>C?MB:!XJ^(?QLBT[]N/QK\+/'OQO31?$'@/
M3)QK?P=\-> /!O@V/P;<I\.)9O#E@GA;X6> =&U6!GU";4X?#RW4MRNI:IKE
M[J=?_@J)\&OBO\<?V.Y/A+\(O!WCSXF>-=1^/W[%OBJ\3P1XK^&7@7QG9>$O
M@Q^U_P# GXT?$7Q=IWB'X@>*_AWX2T[Q#IW@;X<^([[04L+I;B?Q4^D6NGZ3
M';2O):>?_!W]I_XP?$7_ (*E_$/X*ZM)\4O OP:LOV!?AA\;-$^"'Q1\%?#?
M0]1T7QUXF^/OQ!\%2_$/3M?\)V^M>);NP\7^$/#.E6C>$_%'CN_U+P?JNG:Q
M;:WX0\':U=3:</6_B#^WEI?PW_;!\<?LS^(/A1\16\)?"K]CV[_:[^(?Q8T+
M2=/\86D/A2Z\7>(O#.BVGASP5X3US5OB5K\MO+\//'FGZII6D>!-5\3ZCKUQ
MX7BT+1;C1FU+6%:J2A*E4<K.'[]<^T5@W53YWTC"&&J1^*-H7BFIKW<W&$XU
M*:CHY*B^1:REC%2LXJUVYSQ--N\97J6DU*,FY;7BC_@G_P#!+XH>!?C=X;^,
M.J_%#XG>*?VB(OA8WQ ^+/B3Q9IOA7XOZ4WP+UEO%WP#C\!>(OA#HOP_T'X:
M-\"O'MQJ/Q$^'$?P_P!"T:TTSXD:WXH\<:@-<\0^+/$NI:QU#_L=Z#/IGQ!O
M[OXT?'6?XR?$Q?@=;>)?VD;?6OAWHOQB_LC]G3QM<_$/X4>%]-M/#GPST;X/
MV'@O1O%6L^-;[6/!,?PG;PGXPA^)/Q&L?%VC:W9^+M3A?P[X>_\ !5+X"_%C
M2OA1>_#KX8_M-:[JO[0::%>?LY>&-:^"VH_#/4OV@=!U/X$6W[1&M>+_ (6:
MW\7-6\ >!=5\$>"/ <ES9>*/&>L>+]"\-2^+K:S\->%=2\3W?BKP+)XJZD_\
M%-/V9M4TS]G6^^'L7Q=^+]]^UE\ ?%_[2'[/6@?#'X/^-M<U7XD> /!4?@(Z
MQ96<^HZ=HN@Z!XM@N?B7X2L]0T#Q=K7A]_"LFH?:_'5UX5TH1:C*<LH<UHRB
MDVI*,6DG%3C+2,?B2I5(R:7-[DH3E?W9:-IJ/,TT]8N?6\H6UGK9RG3<8MJ-
MY*4(I)RCT6F_L+:#X<UO7/&/@O\ :!_:(\$_$+QYXF^('C#XQ^-]"U#X,WC_
M !N\2?$+P;\$_AS<ZQ\0_A]XG^"OB+X,6VH^&/A_^SO\)O!_@Z^\ ?#+P+>Z
M1I>AZ_=W%QJ&N?$3XDZOXN\5\3?\$>_V3K[Q?\(?%7PV\1_M)?LYV?PN^"?P
MO_9I\1^#/V=/VB_B3\,?"?Q^_9Z^">DW.@_"+X3?M"+::KJ'B3Q_IWP_T74=
M7T;1/'%EXD\._%NXT36+_0=;^(FK:']DTZU]3M?^"D7[/GB7X7?"GXJ_"W3_
M (E_&>R^,'P%^(7[3GAGP5\-/"-K>?$ZV^"/PDN/".E?%#Q9J7@7Q1KOA76)
MM8\%>*O'?A+P/>_#?P^FO_%/7/&6K2:'X/\ !'B2;1]?DTKH_%G[?OP&\&_%
MF+X5ZM'X[EMH?V@?AW^R=XB^)^G>%A>_#/P=^TU\6_AWX3^*OPT^#/B._34D
M\6C6?&'@GX@?#R\L_&>B^#M9^$^EZWX[\-^#?$?Q"T;QI-?^'K"5%*<$HI33
MY8)1@G[MZ:C#2TH>^X*,>>E-SY;5)3M)\S:>LFI7G+6;NU[SG+JIQY.;FDHU
M8*%[P4+PFU#]ASP'X@\6Z)X@\9?$_P"-/C;P[X'^)OQ&^,GPF^&WB/7_  5_
MPAWP<^)7Q,\!?$OX8ZKXB^'VJ:+\/]&^)*6OA[P1\9/B?HG@3PIXL^('BOP7
MX,7Q6E[H7ARUU#PIX$NO"WG7BC_@F?\ "+XA^"OC5X7^*_Q4^._Q6\2_'K]F
MC2OV/?'/Q>\9ZY\-$^*W_#.>G7OBG4;SX=Z=KGA;X5>&="9_$=]XV\47?B;Q
MGK?AK6OB!J]WJBWDGBN.[TW2)]/]7O?VW?@]:^//"W@VVT[QYK&B^-_C+XS_
M &;?"7Q4T7P]97WPNU[]H[X?Z9XSU+Q9\%;+7/[:BUE?$.BR_#GQ_P"&M4\9
M7/AVW^#^D?$7P7XF^%.L_$O3_B?I-UX/C^// '_!2+PK\<_V5OV:?VD?&T/[
M0G[*>D?'G]MOP/\  OX;:;X6\&_#OXA:MXYNM5_:HUWX.?#[X>?$^_MM'^-7
MA7X?>"OB-;:+IWA[XP^)1J_@75-"UBYUO2OA-\2I[RX\):OXB3]Z$K)RBU&F
MTWNJM14U&\G=RE*:35^><913<U.":BE&<8Q7+-WDE&.O[J#J[06D8Q@Y+3DA
M*$G:$H2M]1^./V!?A)XY\:_$?QY/XN^*'AC6OC[\'M ^!7[5*>"-6\'>&+;]
MJCX?^%]'UWPWX?\ ^%L2V7@8ZGX<\9Z1X9\7^-?#&G_$OX%:E\&_B+:>'?$X
MT:#Q1'8^#OAM#X)C^(7[ 'P=^(FI?M"W-SXE^(GA31?VD_V3_"O[%?C7P;X&
MG\ >'/"?AWX!>"D^)L7AOPW\/;"/X>W-]X4O]+@^-'Q5MK35(]2O)+6V\9SP
M6L4$?AWP8OAK4\5?MZ? CP?X@,&J?\)K<?#:R^.VD_LO^)?C_I'AI=6^"/@O
M]HC7=<T?PEI7PM\6>)++49/$&FR2>.O$.A_#+5?B1!X4O/@MX4^+VHGX.>,/
MB9X?^*FFZSX.TW@M6_X*<?LY:/XV\3>#[G0?CP-/\!?M7^#OV,?B5\1)O@7X
M_P!,^&GPU^-/Q&T[X3R?#J+QEXHUS3-*^Q>#_'7B7XW_  Q\$>'O%^GV.IZ7
M)K7BS1_$-^;#X;:II?CN^+W48ZM5%4A&+3]]5(VJ02MK&4,3;EMR\F)]Q1A6
MO,LEK9+V+IU-;?NY4FO9S5V^64)89)27O*6'Y9-NCRQ^J++X"_#QOV?H_P!F
M7Q;83_$CX3S_  C;X'>(]'\=_8-0F\:?#BY\(MX%U30_%9TC3]$L+]=;\+23
M:7J[V>G:>MY%/._EQR2,U>2_"+]C'P1\([SP7K4?Q(^+_P 1O%GPH^#GB/X
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M.46WXD?\$X_@C\7/%G[8/B?XA^*_BOXBL_VXO@?H'[//QS\(2:]X3T_PO/\
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M7P"LO'6I_%CX8:9XETV\O=8T77?#>F?"OXI7NG^(/&7AOPS\//&H^'/BJR\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB?P%+I;WD_QE7XIPZY\$]-\7Z5XP@\&3?#'6;'XWSZE8^.- D^!.O?L/X/\
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M3:>UXMR>CV6B:UNUHYR6CG!0D_)1Y%:][-1ZK1O5IL_#/QI_P3=^-&L?!_\
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M,TY1C'EC)*32_##XN_\ !/C]J'X@>.?^"XVMZ0/@A::+_P %+_V1/AC^S;\
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M5CX$\<W/@6+7[S7OB'\4/%]_J4.A>!?VWB:1XHVEC$4K1HTD0<2"*1E!>,2
M 2!&)7>  V-P !Q4E%6YR<5%VY5)R244K-Q47;5Z-*_+LG91M%**B-.,9N:N
MY.*@VVW>,9N<5TV;>N[U<KMMGYN?LS?LP?&OX4_M_?\ !1G]ICQM!\-E^%G[
M77_#*@^%]OX9\;>(]:\?:-_PSW\)]8^''B$_$'PWJ7P[\.>']$_X2*^U.+4_
M#H\,^-?&G_$OAE75SI5X8[9O!H/V0?VY_"/[.O\ P5/\*?"#QS\*?A3\=_VL
MOVHOB;\?/V;?'&@>/O&&J1Z!X5\<>$?A#X-E\/>--<D^&'A_5/AC\0M6\/\
MPT\0:?#XF\$6?Q B^'NI^,=(\3^'-<UO5/# ,W[.45"NDDG:U-4EHG[JJPK*
MZ::;]I!-W5I1E.$HRA.2*22=[*_M'5ZZ3=.5)VL]$X2?FI*,HM2BF?S2:_\
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M-Z.SL]G9V;L[%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\-__  *_Z$/]MG_Q6E_P4<_^A4H ^V:*^)O^&_\ X%?]"'^VS_XK2_X*.?\
MT*E'_#?_ ,"O^A#_ &V?_%:7_!1S_P"A4H ^V:*^)O\ AO\ ^!7_ $(?[;/_
M (K2_P""CG_T*E'_  W_ / K_H0_VV?_ !6E_P %'/\ Z%2@#[9HKXF_X;_^
M!7_0A_ML_P#BM+_@HY_]"I1_PW_\"O\ H0_VV?\ Q6E_P4<_^A4H ^V:*^)O
M^&__ (%?]"'^VS_XK2_X*.?_ $*E'_#?_P "O^A#_;9_\5I?\%'/_H5* /MF
MBOB;_AO_ .!7_0A_ML_^*TO^"CG_ -"I1_PW_P# K_H0_P!MG_Q6E_P4<_\
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M5KUGXG^)7Q"\;>,=5M?BUJGB#7/B--J7Q/\ &/B77?B7J>K^*M9\6>)=5O\
MQ%J7BR\\1Q:AK5U<V6K6LD=F;;\XO&?_  3TU#P/^TO_ ,$PM&_9W\,_$[PQ
M^S#^Q3\+?VJ_ 5MXHL_COJ>L^+?A1;?%OPM\*/"?PH\-^'IOBMXR\5>,/B)X
M,\)Z7X$\0:/=>%/&L'B[PKX6\/7G@VT\.Z'JQ\/Z5:>#W"WN0:O%34N:[BGS
MT,0L1%K>*=94*L9<[;J1BHJ%[#=KSGL_95(I-<SO"I1>':=]7&#K4W!0249R
M<G/E=_GGX>_MT_MY?%*#]B?X/)X^^!_@3XL^/OVW/^"BO[ _[0/Q07X">(_$
MGAKQ;XJ_8V^&G[4-YX4^-_PL\,7OQAT6#0]&US4/@GI6NZ]X)U"?4H[CQG=7
M&F6VO:+X7T#4_"WB67P/^VA_P4%\6Z9\)/V?]0^)'P-\-?'CP[_P5'_:$_X)
MI?%[X[2_ C5]:\,_%?0?!7[$?QD_:K^%'[1?@WX8P?%O2K#X?^(+GP[H/@7_
M (3GX9MXD\5:#-\2[?6K+3/$NB^#;&Y\-ZK];_M!?L3:O+\7?^":.C? +P1X
MK\.?!W]F#X_?'KXO?$CQGX8^)=I9>.=!U+XO? +X^>!6\=RZ[X[\5WOC/XK_
M ! \3_&SXT#XI?%S5?&Y\9O\38+CQ_J?Q(C^(^J^*-5\+^*/JV#]AK]G6UM/
M@U;6OAWQ;93_  (^-WC#]I3P#JNG_$_XD:=K4OQ\^(4'CJS\>?%3QOJNG^*+
M6\^)?B'Q?IGQ/^)&BZ[8_$&3Q+X:N]!\;Z]H(T*/1Y+.RLR$HR<W4@U%U7&R
MYN;EC]4?M(M>SY83MBFH1M?VJC>"IQ4%6C^ZIQI2M5]BI<[=XQG*IBO<G%J7
M-)4_JL;MR45!5'><I\_YL>)OVS_VKM*_9O\ ^"B7Q^\._$3PQXB\1?\ !*#Q
M%JOPY\7>$=;^%VE>"/!G[6NJ?LX_LN_!']H+]J+QIXLM4U#QCXO^%DOQ13Q_
MXUT/]GS2?AWXPBTCX8WVD>%/%_CM_C1H6L7_ (%LNS\;_MH?M#>"_P!H[]J'
M]F:_\265AXU^,/P5_9[^+W_!,QM4^'<:7I'QG\:GX)?$C2_BOHXTZU'BQOV8
M?C)KW@CQY\8=*T&__P"$AT3]F?Q5I>L7-O\ \))I&N>++W[\\:?L2?L]^//'
M/Q2\<:]X9U<?\+\L_!EC^T3X*L/%&NV7PU_:#@^'5E9:3X+'Q<\!I>-H'B-[
M#P[I]CX*\3/:6VE'XK_#.PTKX3?&8?$3X6Z'H?@W3?4/&G[/OP<^(?Q>^"OQ
MZ\:> ]&\0?%S]G:#XF6WP5\;WRSOJWP]C^,7A_2_"GQ).A;)DMXI?%?AS1[#
M1]0EF@FD%C$\,#0B>8R*F[-.I>=VO:122C9TI^T<-$TYUXT9QL^6E2=:G&*3
MC93N^;DM!)/DUDWS*I#DYVW9Q5)UHS7+><_92<I6:?Y/_M)?MI?M$?!O]H'1
M[3P?\0O"WQ$\!:)_P4(_8B_8W\3^"O#7@;3M0\'^&/AI^U%I'P8\+^);CX__
M !%UNW\':S:_M>1>/?B9XB^(G@[PE^SYK'BOP'X&^#,'P6N/C3\,]%N?B]IG
MB"?WG_@F\D:?%[_@KJJ(D:G_ (*E>)G(151=\G[#/["4DKD* -\DC-)(Y&7=
MF=B68D^@>//^"77[('Q&\??$/XC>(?#7Q/M-9^)WQL^#_P"TGXET?PK^T#\=
M/!7@>#]H'X)W'@UO"?QI\-> /"7Q!T;P=X2^)^H:;\//!&@^*/&_AO1M-\1:
MYI'ANU$FH0:C>ZOJ&H_3WPB_9Z^%_P #=>^-/B7X=:;KNG:O^T)\4[SXU_%F
M?5_&/BSQ5%XB^)VH>&?#?@N\\365KXGUG5[;PNDG@_P9X.\,P^'_  I%HGA>
MQTCPMHT&G:):/#/+<1'F?)*:CSJ%:+Y8M?Q/JKBKNUTI4*C;LOC325W&.KE!
M4YPA&?O2IN\I)WY)UW>RVM"K&*6KT=V[<TOQ'_;!T/\ :"_8TUO]OKX\?\*L
M\*_\%!/^"8/[6EWXB\=?ML_!#PWJNF:1^U;^SI+HG[/W@+X _&;Q7X!_X2S5
M1X ^/?PJLOA-\%-,BUGX2ZIK'@/QUX6U&32[;PO<#P]HOB'4+[ZK\8_MI_'&
M_P#VO;_P=^SSI7@3X\?"_P 2_P#!)+XB_MK?L[^ ;31;KP7XT^+/Q@L_B)X*
MTCX;:!J?Q1\2:X]EI?A'XBZ7KVCZ;I=K+X-\*OX;N]:O-6\376L^180:+]>>
M-/V(/@=XYM_C3I.J2_$VQ\)_M*:OJ6K_ +1'@;1?BU\0-/\ !_Q@_M;PEH_@
M74--UC2!KLK>"]*U/PEX?T;0/$-K\)+GX=/XSTBQ_LOQQ/XETZ[O[2[X+]IG
M]B/PKX_T?XR?$WX,^$_!MM^T]XA_8M^)?[&WPN/Q(\6_$K2_V?K/X:^,;>74
M[#X>^+OAKX(OY_#6F^$+CQ;;Z1>:OXK\->!;OXB6&E6$&DZ7J5SH5K'X<F&K
M4VHJ]14Y4XNRBXQEA,13BG.TN?V.+K4:E&HXNK"C"IS>UM3IL@X>TO-7CS*3
M6KBVL3A9N2AS1495,/2KPK034*E2=/E=-SG.'YN^&_VW_P!N/4OA_P"/_BQ\
M/_'O@7XG?";PU_P2=\1?ME>._B+XX_9ZU72=/^$W[;L7AB\U_2?V9=/LM \:
M_#@Z=X3.AVVK^,-9^"?C6?QW^T+\'=.\-:-%\7?BI<6?Q=^'EU==7\/_ -M7
M]L?PYXGT2W^(OQ?_ &:M8L/C=_P1M\??\% ?!6K?%#P;JGP>^$/[/_QF^#"_
M!;2+]?B9X[\.^(=?U_4O@'XG7X[:-XH^*>O7.GIXB\*KX$\2:WX,MM%T/7K+
MP9X?] _9T_8(\::YI]]X6^+GP[^/?P'^$6M_"GX@?!'XK_"CQ7_P5>_;#_;6
MTGXN^ O'?@6[\":KX.\/^'?B=XBD\+_"3P]9B]M?$OA'XS_#?4_AU\<-*D\/
MCPI8^'O!_AOQ3KT+?9'B#_@F[^R+XMTK3-!\6> ?$WB?0])_9 \7_L%6FD:W
M\6/BQ>69_90\>VGAZS\7?#&Y'_":)-=ZCK:^$/!UQ=?%*YFE^,0O?">@7D7Q
M!CN+(R2[5I7YW2C"'-*:C&W,HTY+'VL^:333KX-4DINI&GAHN<Y5%*5;&DFG
M%U'*5J>NMKU4\$TVM(M?NL4JBMR2==QC%0:5+\>?VI?VK_VM+S]CG_@L/\/+
M_P"*_P 1?"^J_!+_ ()N_ C]I_X2?&'4/A;X1^#_ ,:8[SX_:%^U-IWQ!T2R
M\-Q01ZAX*^']^W[/%M%\/;3XB?##X7_M2_"ZS\:>+;'Q==6WCG0O!WBW2?NC
M]H']IK]H7X*^*/\ @H]\/?#_ ,1;?7Y/V8_^"7?P^_;+^%'BGQ1X)\(S:O:_
M%O7O$'[<-A?:5XBL?#VF>'-#UWP#<6_[-?@..70ETW3M=V:EXK^P^*K">_TJ
MXT/Z!T__ ()A?LFPZ+\8=#\0Z9\8OB+#^T%^S+HW[)/QNO\ XJ?M'_'SXD:S
M\4?A#H+>/VTP>+]5\7?$75;O4O'.G_\ "S?&4>A_$3S(O&/A"UU>XL/!.K^&
MK":YM9Y?'?\ P3-_9?\ B7-#>>-W^.FOZE>?LX:W^RAXZU:]_:9^/LFI_&7X
M(ZT?%\X\+?'.Z/Q"W?&!M%U'XA?$#4_#E[X]&MS:)<^-_$EO9"/2[U-.AYW&
M=\3)3UJ4ZL:"4&HTIR6/5&?*[IJE[3!MI)\SIMWE[-NKI%QYL,Y1TI5:$JRO
M=U:<)X)UZ=U:7[Y4L5:4G=<Z5H^T?L_D;PG^TS^VM\;?VLOA'\'O"7Q>^$'P
ML^',G_!/O]D/]N7XB2+^S]JWQ"\:>*;[QE\7O$&D?%SX7:%<7?Q;T33="L/'
MOAGP7?Z'H'BB+2]0U/P%'K4DUKH'BK6%L]6TWM_V.OVC/VV_VG+']D3]I"ST
M[X?Z5^S5^UE\ ;WXC?$+1O%WB3P'+??!SQ=XT^&^A?$7X'V7[.MKX'M)O%GQ
M)71I9?%W@CX_Z!\:->TS5=1NM(TKX@^!C\.;?3/%'PPD^U_AC^Q5^S_\'OBC
MX3^,?@#1/&^F^//!/[.OA#]D_P /ZAJ_Q?\ BWXPT^/X!^ =5N-?\(>"M6T+
MQGXV\0:+XFU/0]>O+_5K;XB^)K'5_BE--J.HV-WXVN-'OKG39/,O@#_P3+_9
M!_9A\9>*/&'P2\&>//!=KKU[\0-3\/\ PXM_CC\;+_X*?"#5_BO?7.I_$G7/
M@!\$]2\?W?PN^!'B'Q;>W^IK+XB^%?A7PMKOA_2-7UKPIX.U'PWX0UG4] N^
MFM*G*I5E3@XTY?6)0IVLXNI7QLJ=-R4F^58:MAJ<))I4:E!32GRKVF5.,U&*
MG).2=).6K7+&CA5*23M>7UBE7J.+3]I"MR-QO)1^POAEHOCGPW\./ 7A[XG>
M.+'XG?$?0O!WAK1_'OQ'TWPA;?#_ $_Q]XQTW1[.S\2>,[/P+9ZQX@L_!MMX
MFU>&[UF+PO9ZYJ]IH27@TVUU&[@MHYF[BN1\ >#+'X=>!O!_@'3-8\7^(=.\
M%^&=$\+V6O>/_&'B/X@^.=:M=#TZWTV'5O&'CGQ?J.K^*/%_B;4$MQ=ZWXC\
M0:G?ZOK&HRW%]?W4UQ,[GKJS>[ZZO6UK_+IZ=/F4METTV;YOQZ^O^04444#"
MBBOFSXI_M6_"_P"#WBMO!GBWPM^TGJ^KKIECJQO/A9^QG^V!\<_"AM=0>Y2"
M)?'GP3^!?Q!\#OJ<;6LIOM%3Q$VLZ8CVTFI6%I'>6;3@'TG17Q-_PW_\"O\
MH0_VV?\ Q6E_P4<_^A4H_P"&_P#X%?\ 0A_ML_\ BM+_ (*.?_0J4 ?;-%?$
MW_#?_P "O^A#_;9_\5I?\%'/_H5*/^&__@5_T(?[;/\ XK2_X*.?_0J4 ?;-
M%?$W_#?_ ,"O^A#_ &V?_%:7_!1S_P"A4H_X;_\ @5_T(?[;/_BM+_@HY_\
M0J4 ?;-%?$W_  W_ / K_H0_VV?_ !6E_P %'/\ Z%2C_AO_ .!7_0A_ML_^
M*TO^"CG_ -"I0!]LT5\3?\-__ K_ *$/]MG_ ,5I?\%'/_H5*/\ AO\ ^!7_
M $(?[;/_ (K2_P""CG_T*E 'VS17Q-_PW_\  K_H0_VV?_%:7_!1S_Z%2C_A
MO_X%?]"'^VS_ .*TO^"CG_T*E 'VS17Q-_PW_P# K_H0_P!MG_Q6E_P4<_\
MH5*/^&__ (%?]"'^VS_XK2_X*.?_ $*E 'VS17Q-_P -_P#P*_Z$/]MG_P 5
MI?\ !1S_ .A4H_X;_P#@5_T(?[;/_BM+_@HY_P#0J4 ?;-%?$W_#?_P*_P"A
M#_;9_P#%:7_!1S_Z%2C_ (;_ /@5_P!"'^VS_P"*TO\ @HY_]"I0!]LT5\3?
M\-__  *_Z$/]MG_Q6E_P4<_^A4KZO\#^,M(^(7A+0?&N@V?BJPT?Q'8)J.GV
M?CCP)XW^&/BVWMY'=%CU[P#\2?#WA/QWX6OPT;%]+\3^'-(U.-"DDEFD<D;,
M =51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%?@__ ,%!/AI\+_$G_!5K_@FI?>+OV8_#
M?[1\^M_LM_\ !3"#6_ S^"_@OK^L^,(/#:?L:KX>M;Q_C1K_ (.\(WZ:,GB+
MQ#8Z*FM>)(4TS_A*-7BM?LUCJVM3TXKFG&-TN;VFMF[<E&O5T23;O['E\N:^
MMK.*DU3@YM-VE3BDG%:U*U&E>\FDE'VO-OKRVTO=?O!5&VU33+R\U'3K34;"
MZO\ 2)+:+5K&VO+>>\TN6\MDO+./4;6*1IK*2[LY([NV2Y2)I[:1)X@\3JY_
MG5^!?B7_ (**_L.?!'_@GW^Q_9>'O@^/BG^U;\9?VV_"_@CPU^T?\1O'OQ6C
M_9&^'&B_##X[_M'_ +,?P5U?QI\/=3U*[^+>F_!?PCX1T#P1XJ33?&L^GG2=
M,M_A3\-_%ECX3L= ^(^A=3\6_P!NOXJ_LTZ;_P %B/BEX9_9U_93@^.?[)U]
M^Q##XH\7Z!I7B/PV_P"T'K'Q'^"GPMNM2\0_%CQ1864?B_Q.W@&Q\7W7A'X5
M:1J=TUQH7A+1M*T>Z\4?9YY?L:@N?EWBY17+!\M_:?[$IP;U3=&>-A2JRIN4
M>>,W3<X0<BI7BI2M>,6VY*]N12Q:4]=4JL<'4G34DGRRASJ+DD?T'T5_/=^W
M7^VY^VQ\+/V>?^"R'@9-;^"7@#XN?LH_LL?"3]HWX'?%SX;>%_'NJ#2_AK^T
ME;_'/PT/!.KZ%XC\>:=-+\:OA3K7P$\<P>&OCCI^J:=X,\1SZ]X(\=7W[/FA
MKH>M?#G6?U=_:D\#V?C']C'X^>$OC?HWPY^+(F^!?Q1D\3Z?>_#](/A_X@O;
M'P;X@O;6:/P)XLU_X@-9VT$D-M)%;WWB/6YXKF'[5#>QL8TARG54:-6LK25*
M$IM)ZMQI5JLH;64HJA4A+=*:6LHOF>T*4I5:--^[[:K&E&5KI.52A34FKIN+
M^L4YJUFXW^&2LOK2BOY9]4US7/V8_P!D/XV_\$O?VQH+'XR_!KX@_L6_&'QY
M_P $TOC[\3K?2O%LGQ(\$^#_ ()ZQXLU/]D7XSVNM:6NFQ_M*_LR6D4>K?"_
MQ9IL4FF_&CX(6.D^(=-L?"WCWX=^,-%O/T0_:Z_;P^+W[*/Q-\0Z%HW@[X.V
MWP@^&7C']@[P;IO@BPTSQ-X[^)?COP;^U5^T#H'[/GB;Q=J>H^ ?$NE>%OV1
M?#?@*]\1F'X/+\8O!WB2Q_: USX:?$;PWX%N+,:3?W?AKK]C)U'3A:5Z\J%-
MMQBY3AI.,O>DH3IU)1ISA=M.2J*]*4)RY(UHNDJLO=7L(5Y[NU.I%5*<HZ)R
MC.FW-2LOAE!_O(3@OV(HK\(OVF?^"D?[6GP=B_X*(^./"/@']G?4/A[_ ,$Z
MOVCOV>O"/B7PYXA;XDW/C3XV?![XM?";]G#XF>)=)T+Q+IVLZ3H7PN^)6DZ;
M\=K_ %#0_&>H>&OB5X7EO?#5IX-O_A\T&J3?$&Q]1\3?M_?M!_ SXA_M;_"C
MXV>!/A/X_P#&'PVUK_@G@_P"?X*1^)?#D.KQ_P#!2;]H+QO^S!\/OAUX_L/B
M5XL>RUSQ!\&?B9X!U36_$?Q*TKQ1\/=!^*O@;4K&YM?A_P#"'6K2[TY\97@H
M.=H*?*H<S2<I3IPK0@O[TZ4U.*;2LI)R4DHRWBG-2E%.48N:E))\J]G4=*H[
MZ74*EHRY4W>4;)IMQ_8RBOC?]E7XD?M=>,O$GQT\,?M1_ 2V^&NB>"?%'A.3
MX'_%K3+OX?:-IGQO\%>*O#":MKMM=_"GPI\??VB/$7PW\6?";Q7#J'@SQ!=>
M(_&\FC?$*RF\/^-?"%OID6H:WX7\,?9%-JUM4[I2T=U[RO9]FMI)ZQ::?1N4
M[]&M6M5;;KN]'NGU7;5(HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***CFAAN(9;>XBCG@GC>
M&>"9%DAFAD4I)%+&X9)(Y$9DDC=2CH2K J2*&!)4%U=6UC;7%[>W$%I9VD$U
MU=W=U-';VUK;6\;2SW%Q/*R10001(\LTTKK''&K.[*JDC^/;]GK]E/QQ\5/!
M'[0.E?L@_LYVOPZ_:!\%_P#!P%^UOX@\+_MN>%Y_@O\ #W3?V<_A5\-OVQ+Z
MZ^).FZH++QGI?QB^(_A3Q7\&M.\3?!&'X&V/@'7_  #XOM_&-CI?BR#3_!FE
M2:I9?JIXV_:Q_:\\>Z'_ ,%0KK4/A/\ L<>*?V>?V*M?_:L^$?B;X=^/A\4/
M$7B#X[:/HG[$WP4_: ^&^A^(8[BPE\#Z5X=U&\^*NL>'/C':ZAX>\46?B_PU
MK:>'= TCP])X-N?$GQ-5=QH*:E.,90A*=Y*2BX0P5#%SJ*R<E"#K>Q=TISG"
M3IJ4=8K#\V(=/DA)J<XT]'%M3EC:^#A3NVH\\_8JJM>6$:D54<6G?]M;6ZMK
MZVM[VRN(+RSO((;JTN[6:.XMKJVN(UE@N+>>)GBG@GB=)89HG:.2-E=&96!,
M]?AUX+_:]_:I\4^*/V6_V8_V8OAW^R1\*!\4_P#@DGI7[8/@?4?%?ACXBWGP
M]^&OC7POKWP)\(:7\,=*^$W@'Q#X(CM_A##IWQ%C\*Z#H^D>.M,U7PQ8-:^)
M8]0U&W\%Q^ /'VE\"?VOOVC/VG/VK/\ @FMXKT+Q1X)^&GP/_:C_ ."2_CK]
MLWQK\#9_!?B#QCJ%MXTUKQ[^PQ<W-BWQ(B^(GA*UU2]\-Z'\8KWPW\.M=;X=
M:=!X9MY_B!J'B30?'DGCKP[:_#)UG&C6E1DVI*M4HVENG3KXW#WDXIPM[3 5
MX-Q;3DDXITY1D*FW4IQG&SO2C5LG:Z=+"5GRJ7O?P\91E:232;4FIQ:?[9T5
M^-?_  4^_99\4?'7XP?L<^,OV>/$_AGX+_MG_#+7_C%XV_9[^.U_H=M)"GB3
MPE\-+K4$^$7Q<U/3M*O/%VM?LZ?%BSN-1\&_%CPEHUQ]H;2=6B\2Z;9:CJWA
MZRTN_P"*_9[_ &EO!W[6_P"TK\'/CG!^SQ8> OVP_@I^R=^WG\)?V@/@%XT;
MPE;_ !0^#O[0O@+XD?L(S7GPAO?BE%97-EJ/@G7_ .V9-7^$WQ7T^9O"GC3X
M7>-=,\<V-GIZ:OK>@Z>1M*%2>J]E'$SJ*UW[+#Q4G4IJ+O-.4E3E'EYJ<Y0O
M>%:E(IZ2C%6;G[&,7=12J5N9JG-R5H^Y%SC/FY9Q4TDI4JB/W)HK^?31_P#@
MK+\>]/\ AS^UWJ^O^%/@7XY\9? O_@E%X:_X*4^#-2\!:5\1O#_PDN]=N]/^
M."^+/A#IWCK4O$_C#3?VA_AUINH_";3[OP#^TU\'M2T'X??%;1=;GN/#VDV5
MK!!J\OKVC_M@?M_^,OCUI_[.?AS3OV/=#\3?'/\ 8+TW]M3X&^/=<\-?&C7/
M#OPCO/"GBSP;X'^(7PT^+/A'3_'VB:I\;+?Q?J_Q'\!:CX-\8^#O$_P(D\ Z
M7J/B^WUOPO\ $F[\%:*_Q%NI3J4HRG.*Y8*<I2C*,E:G3Q-:I9Q;OR4\'B9.
MUTU3]UR]I2YR-YRY8IMNSV:]V4L/",G=:1;Q6'LW9VJ*\8N-10_:VBOQ&T#_
M (*0?M2_M&?"#X;ZI^R'^SCI&O\ QQ\4_P#!.K]EW]O35_!WB:\\):_X)FUS
M]JW3?BK)\,_@19^(/$GQV_9ZU/0;6_\ $/P+^(?A_6_C&UCXNM?"%KJ?@[Q!
M=?#37A<:EHT?[#?#C7_%?BKX>> _%'COP'>?"SQQXD\&>%]>\9?#'4?$&@>+
M-0^'/BO6-#L=1\1>!+_Q3X4NK[PMXEO?"&KW%YX?NO$'AJ^O= UF?3GU'1[N
MXTZYMI7EIJZ=DTW&U]=')<R5M8WC))WOM>*NK)24DFG=-)W5FDVHOE=F[22D
MKJVZ:O>+1V=%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R9\1/V1O
M#OQ(_:N_9_\ VN=2^*GQ9T;QC^SAX.^+G@;P/X T%OA:GPRU30?CBO@,?$9/
M%=OK/PMUKX@7UUJS_#/P5):7.D?$+0VTE]'8::MM'J.J1WOUG133<9*2;4HW
MLUNN:,X/[X5)Q=T])/K9I-*2<9)-.UTTFO=E&<7KU4H1DFK-.*=^_P O_&C]
ME?PS\;?C;^RO\==9^(7Q+\*>(OV2/'7CCX@^ O#G@Z7X>Q^$?%>M?$+X9^)_
MA#XCMOB##XJ^'GBOQ)?Z7)X$\9^)]*M+?PIXF\'W%M<:I_:@NWU.PTNZL?FK
MXQ_\$M/A'\;+3]NVQ\2?&C]H31;7_@H+J7P3U+XN1^&=0^"L!\%'X#Z#X8\,
M^$[3X4/KGP0UZ32;35M$\(:-9>)AXX?X@7-T4N;K1[G0[RYDN*_36BDM+-:6
M<I+R<I49R:WLW+#T9/SIQT2YE*FVTT]4U&+71J/M5%-6LTE7J[W_ (DKWTY?
MSR^,G_!-SX3?'J\_;,F^)GQ/^-NL6'[<7[,GP]_97^*>BV>I?"[1].\+^"OA
M:OQ4F\%>+/AO/IGPHMM9TKQ_IFM?&CX@^(I;WQ7JWC+PI?ZIJMK;7WA"?0-*
MTS1;7ZCUWX.7?BCX!Z[\"O$WQ;^)VNW7BCX=ZO\ #WQ'\9;R#X70?%?6!X@T
MFYTC6O%TUKIOPRL?A#9>)[^*\NK@6VD_";3_  9832B'2O"%AI\%M8P^U45/
M)#EG#ECR334XVTDG[1-/U5:JGLVIM-M<JBU.:E"2E)2IR4H.[O&4?9M->:=&
MDT[.S@GOS.7QW\<?V'/@?^TQ^S'H?[+'Q_@U[XJ>#_#*^ M1\.^-M>D\-Z9\
M3= \<_#"[LM0\"_%#0=<\*>&?#N@:#X\T*^L(G>ZT7PMI^@:UIEUK/A;Q%X>
MU?P=XC\1^'M5\ ^.O_!*CX4?'3QO^TIXTE^/G[3?PR@_:I\2_LX?$?XF^"_A
MOK_P:D\&0?&?]E'6OA/JGP8^,_AJR^)'P/\ B-K.G>+M%L?@MX#\.:UX8U#7
M=7^$/BK2-.:]\0_#+4/%$>G^([#]0Z*U]K43DU.:<JCJRM)QYJDN2\VHV3D_
M9TW=K1TX-).$6LU""C&'+'DA!4XQ:3C&$4TH13O:*4I+EV:E).ZE*_YF_%C_
M ()=_"SXP^%?VX_!_B7XX_M$Z?IG[?GC7X6>.OC!/H-]\#K>_P#"^J_"3P1\
M,_AUX?M/AG<:G\"M6CTG3-4\(_"+P-INOQ>+H/&UY/)IMU?Z5?:1J&IZA=7&
M]\:_^"9_P3_:(UK]J/4_B_X^^-'BFP_:R^"GP#^"OCOP[:Z]X$\*:?X1C_9B
M\:>-_B9\$?B;\,M:\&_#GP_XW\-?%3P/\3/B%XE\?V&M:CXMU_P[)XAETU)_
M"LFBZ)I.D6?Z*45$KRY>9M\K3C=N\7&G[&,HNZ<91I6A&2:E%)<LHRC&4:7N
MIQ6D6Y-Q^R^:I&K*\7=24JD5.:DFIM>\I)N,OF#]F+]F*+]FS0-;L=2^.W[0
MG[27C#Q%_85IK'Q7_:6\:>&_&'Q"N?#_ (5L[JS\*^%83X&\$_#?P5I^B:"=
M2UO4$ETWP99ZYKFM>(-;UWQ9K/B'6+YKU/I^BBFVV[MW?HEMZ)+\+MMMMMMB
M225E^K_-ORZZ))*R04444AA1110 4444 %%%% 'D/Q<^.?P\^!UCHNH_$*7Q
MI':^(+RYL-,_X0SX5?%3XIW#7-G;K<SB^LOA9X+\9WND0"%@8KO5[>QM+B3,
M%O/+.K1CPW_AO[]FO_GY^.G_ (B%^UW_ /.,K[0HH ^+_P#AO[]FO_GY^.G_
M (B%^UW_ /.,H_X;^_9K_P"?GXZ?^(A?M=__ #C*^T** /B__AO[]FO_ )^?
MCI_XB%^UW_\ .,H_X;^_9K_Y^?CI_P"(A?M=_P#SC*^T** /B_\ X;^_9K_Y
M^?CI_P"(A?M=_P#SC*/^&_OV:_\ GY^.G_B(7[7?_P XROM"B@#XO_X;^_9K
M_P"?GXZ?^(A?M=__ #C*/^&_OV:_^?GXZ?\ B(7[7?\ \XROM"B@#XO_ .&_
MOV:_^?GXZ?\ B(7[7?\ \XRC_AO[]FO_ )^?CI_XB%^UW_\ .,K[0HH ^+_^
M&_OV:_\ GY^.G_B(7[7?_P XRC_AO[]FO_GY^.G_ (B%^UW_ /.,K[0HH ^+
M_P#AO[]FO_GY^.G_ (B%^UW_ /.,H_X;^_9K_P"?GXZ?^(A?M=__ #C*^T**
M /B__AO[]FO_ )^?CI_XB%^UW_\ .,H_X;^_9K_Y^?CI_P"(A?M=_P#SC*^T
M** /B_\ X;^_9K_Y^?CI_P"(A?M=_P#SC*/^&_OV:_\ GY^.G_B(7[7?_P X
MROM"B@#R?X2?&SP!\;](U;7/A])XQDT_1-4&C:@?&7PP^)_PMO1?-9VU^!9Z
M5\4?!_@W5=3M/LUW"3J6F65YIHG,MH;L7=O<01>L444 %131M+#+$DTEN\D;
MHEQ"(FF@9E(6:);B*> R1$AXQ/#-"74"6*1-R-+10!\C_LC?L?>$OV.]'^,^
MB>#OB5\5?B-;?'']H7XN?M,^*)OBG/\ #:XN=(^)'QP\477C+XA1^&F^'/PT
M^&\-MX<U'Q%>W%_9:7K$&MW&EJXM++4(K-%@''6/[!?@FR\(?MV>"F^,7QNO
M=+_X* ^*?&?C'XIW-S-\'8]1\ :UXZ^"_@_X ZW)\(Y;'X.65MIMNGPS\ >#
M=*LH/B#:?$<0W^A1ZS*UQJ6HZS<:E]TT4IQC5O[1*IS4W2?.N:]-PA2<'?HZ
M=.$'U<8VYM9<S@W2M[-^SM455<GNVJ1J2JJ:MLU4G*:Z<SO:]K?G]X!_X)Y^
M!?AM\1_@Y\4_#/QM^/4?BKX'?L1W'["'@M[V7X(W>GR_#&XU3P5K8\=:W9-\
M$$%]\58-7^'?@^^AU"WDLO 1?23;S?#R:RU#4[:\I_";_@G'\.O@KJ?[$FK^
M!/C5\?;2^_8;_9Q\1?LE^#Y;V]^#5Y_PM_X Z[/\'+RV\"_&H?\ "EHO//AR
M_P#@-\-;W1_$?PD/PB\57CZ3?VGBC6_$>F:YJ]C>?H;13E[\W4G:=1R<W.24
MI.<JM>M*5VGJZN)Q%1NVLJU1O1V4I*,5&*Y8J*@DM$H*G2I*.EG94Z%&&[]V
ME#6\;OQ#Q[\$8/'OQ:^#'Q:E^(WQ"\,W7P5N?%]UIG@SPW'\/#X-\9/XTT)_
M#NIIXU;Q'\/O$7C-HK;3G;^ST\'^,?!YCN-L]TUXR(%\5^*'_!/?]E[XM?%W
MXQ_'#Q-X*O;'XA_M"_LG>.OV+OC?JWA?6KOPX/B9\$O'%QIT@A\1KIPCG'C3
MPE9VNI:)X0\<Z7<:;XAL= U^[T;5;K6;'0_!,7A3[9HI65G'HXUHM=XXB#IU
MTWO:K!N$]?>CIII:DW&2E%M23INZWO1DITGV_=R2E"Z?*TFM3\C;;_@CY\+'
M\+>/O#'B7]J+]KOQPWQ-_8%U+_@F]XT\0^*=:_9T?7]6_9V>^\9R^%ID?0OV
M;-"TC3_B'X"T?X@>+?#.@>*].TBUM]>TW53JWQ*T;Q[XSL['Q5;?17AW]@_P
MGX8^,_PV^.^F_&[XZ-XX^%G['FL?L6^&H[IO@E-H<WP_UO7/!?B6\\<ZKIJ_
M!..2[^)XU_X?>%-4AO(;NT\!H^FO9M\/Y--OK^RN?NBBKE.<U-3G*2FZDIJ4
MF^9U8UX56[N[=2.*Q*GJN;V]5O6;8HI0MR>[:,8+ETM&+HN,5;I'ZMA[+9*C
M22LH)'Y#P?\ !'#X.>']*_9<?X8?M-?ME?!+XB_LK?LX:-^R'X?^-7PC^(GP
MJ\+?$OXJ?LU^%W$O@_X3?&F*X^"6J?#OQ7H_@RX:ZU#PIKN@_#_PEXST36M0
MU#Q%:>)5\0W+:J/U9\*>&-$\$^%_#?@SPU:S6/ASPCH&C^&- LKB_P!1U6>S
MT70=.M]*TJUGU36+N_U;4IK>QM((I=0U2^O=1O'1KF^N[FYDEF??HH<I2W;=
MVY:N^KWLW=I7N^5-13;DH*4I-I1BK625DDK::+;;=VTN[RLDG)J,4BBBBI&%
M%%% !1110 4444 %%%% !7SE\3_VK?@U\'O%+>#/'$_Q/CUY=-LM6*^$_P!G
M_P"/_P 2-(^Q:@]REL1XE^''PQ\6>&FNBUI-Y^GKJYU"S B:\M8%N+<R_1M%
M 'Q?_P -_?LU_P#/S\=/_$0OVN__ )QE'_#?W[-?_/S\=/\ Q$+]KO\ ^<97
MVA10!\7_ /#?W[-?_/S\=/\ Q$+]KO\ ^<91_P -_?LU_P#/S\=/_$0OVN__
M )QE?:%% 'Q?_P -_?LU_P#/S\=/_$0OVN__ )QE'_#?W[-?_/S\=/\ Q$+]
MKO\ ^<97VA10!\7_ /#?W[-?_/S\=/\ Q$+]KO\ ^<91_P -_?LU_P#/S\=/
M_$0OVN__ )QE?:%% 'Q?_P -_?LU_P#/S\=/_$0OVN__ )QE'_#?W[-?_/S\
M=/\ Q$+]KO\ ^<97VA10!\7_ /#?W[-?_/S\=/\ Q$+]KO\ ^<91_P -_?LU
M_P#/S\=/_$0OVN__ )QE?:%% 'Q?_P -_?LU_P#/S\=/_$0OVN__ )QE'_#?
MW[-?_/S\=/\ Q$+]KO\ ^<97VA10!\7_ /#?W[-?_/S\=/\ Q$+]KO\ ^<91
M_P -_?LU_P#/S\=/_$0OVN__ )QE?:%% 'Q?_P -_?LU_P#/S\=/_$0OVN__
M )QE'_#?W[-?_/S\=/\ Q$+]KO\ ^<97VA10!\7_ /#?W[-?_/S\=/\ Q$+]
MKO\ ^<97U/X)\9:%\0O"FA>-?#+:N^@>([%-1TMM>\->)/!^L&UD=T4ZAX8\
M8:3H7B;1;C=&VZRUK1]/O47:SVZJZ,W4T4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%%T 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/>&_A]\.?@GX6UKQ)XEUZ]\"6'AZXU7XHZAXDUR_^-WC+XG:_>C7H?.?'/\
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M/)_!US:_#S6O&/P=UFQ\2W/P\\,>![/2M5T3Q]X7C^)%[^B?@WPGXYT#Q?\
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M5\ ?\/8O^"67_22S]@#_ ,3(_9U_^>-1_P /8O\ @EE_TDL_8 _\3(_9U_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"(7BOX+>'M9M?$_P .M/TGXB75QXB\02^#.MLOVUO$?C?Q7J4OP/\ V?\
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MKN\HK32\DN:]^7]8J*_%_P#X*.?M@ZYXG_9E_P""EOPO_9IL=:O_ !-^S/\
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M,_'#2-#M]-\)^,]=\"W.F^(K?5O#5FUIXHU :5I6JG@_V0_^"@.O>"/V1?\
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M]GC4/''[/'Q@\7?'CX>>!_C;;_$&*UFT3Q+\%G^(>GZ1XS^*_@>+P9?MX*^
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MG9_&C]IWQM^SU\,O WAW5%^$7C/PKX4^-EEXI^)DW@']HCX8Z)XY_9Q\/_M
M>#_BSJW[+_BCP!9^*W^$&O:AXV\#_"&U\47OBO2-97XBZEXEM'\+_8O!&N7
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M<F\:?$+3OA?H%SX-U'3O!&M_"_PEKMWXY^*7BB/2-$/B7P/H'PJ^S_@7\:/
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M,GSJ<'%N4^52<W.GO027ON4W!+23K5I4Y225US.M*2]R49J3M!2T@?(NL_\
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M/0_ ?[-'QQ\?P?%7Q7I'Q3^$_P &='\=66N:9%/X*T6[\2?%#P+X#^(FF0>
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M.FN-XC3Q#:^$9;/Q)=:/+IR7]KHVJZ'?SP1V^O:*]_X'\6/VQ;[2OVY/A_\
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MJ-H/W;+FE--:6E[6:J5*<HNZG&<Z3E*FU*+Y9KE474B_S^^(O_!.;]J+X[_
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MN:0]YZ_^W+^S-^T+^TAXC_X*O:'^S_X%\3Z?JGQ]_8"_8(\(_"6\\3>'M1\
M>#OC;XL^ /QE_:T^)OQ<_9]U+7_%5MH>E:1_PLCX:?%;P-\(-;?QG-I.A?V?
M\2=9TO4YVT_P?XVAT+]N_@C\<_A/^T?\.=,^+GP1\::;\0OAOK.N^.?#>D^+
M=(@U&WTS4M8^&WCSQ+\,O&EO9#5++3[FX@T;QQX/\1Z&NH16[:=J9TTZCH]W
MJ&DW5E?W,WP\^-/PT^+-YXDMOAMXD;QI8^%=9UCPYJGBK0M$\17GP^N/$/AK
M5[KP[XJT'P]\2ETE?A_XNUKP?XHT_5O"/C32O"?B76K[P=XRT+Q%X0\30:5X
ME\.ZWI5@M).BU+WJ/+5I./(W[E)TJ=1WC)24%.G)73A*<5=-5)Q9;E<W9KGG
M::<IQ3;G"I.GHXN+FZ4T[/GC%NS7LH27XL?M8?LY?%?]N+6/VKOCA\%?A%X]
M\"7WQ,_X(I?M;?L.0^&OC+H%S\'/''Q%^/WQXU.#Q)\*/AKJ.A^+I["W:Q^
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MCX^^.O@UI_P%^.?QY^!C_##X63Z%XI^/OPKTK1O"\MI\4?A[XM?QI^S_ /\
M"77_ ,//A9J7Q/\ !WP=\(>/[;X::-H?B'0]9\2?EUX/^ GQ:C^#'_!-_1=0
M^ GQ,76/A=_P7#_:P_:E^)VCWOPSUH7G@[X._$#XI_\ !1#Q+\//BOKJ7.G"
MV-G-HW[0_P #;^U:RGOO$.E-K%Q;_P!GPZAX"\8VWAG^DNBKA+DKT\0G>5.*
MC9O25I1FY3LDVY.-W9*-VWRW%]B4/=M)S>L5+EYZ<Z=HJ7,DHQF^75M6C[UD
MK?S7^'/!/[1'PRU[XOZW'^RY\5]3\,>,?^"ZOQ+^-Y\:^'?@YX?\:_&7X;?
MKX@_LNGX>^$/VB?V?O"GCY)O#5A/XN^*UO)\(OB)XXU/1]9\4?#CX,_$'XJ>
M,%\':/=ZKH'Q#\.U_#?P-^-'PU_X)I>'_BOI_P '/'7P[_:X_P""?/[?7[8W
M[4/P'\"_%SQ!HFE>*/C%I/CS]M+]H[5->^!%E\09;KXJW7B2']KS]F7X[:[\
M%?"WB.+4-=C\2?&#QAX#\9:7J/BM] T+6-0_I8/0YZ=Z\&^(7[,?P)^*_P 6
MOA-\<?B-\/;#Q=\2_@=!KT/PNUK5]4\02Z7X9?Q'J?AG6[V_;P?'J\7@K7=9
ML-=\&^&->\+Z[XD\/:QK7@O7M&M-;\'W^A:IYEW)%KRI2<Y)TH0IPG%Q4J<(
M+#*\8.+C*<OJRC[SY;8BKSJI&*C*Y3<O:^[%*K*<Y0L^64Y*LK2:E&48?OKO
ME?->E#E<')M:?[/OPPOO@_\ !_P9X$UO5;/Q!XOMH-5\1_$?Q/I]O-96'B_X
MM>/O$&J^/_B_XTL=.G=SI-GXR^)WB?Q;XHM-'B*6NCV^K1Z98PP6=I!!'^!7
M[(/['/Q<U#]G[_@DQ\!_$'P:\<?!/XS?L"?M@?$KXW?'GQGKW@^/P_IG@_P>
M+/\ :>M=6\*^ /B3ITLGA'XR0_M,W_Q3\ 0:TGPI\3^,_#9\(WGB7Q#\3[_0
MO''A/2?".J?T*?$KXL^ OA)I^@7OCC6GL+CQAXEB\&>"- TW3-4\0^+O'?C*
M?1=<\3)X4\#^$/#]EJ?B3Q;X@C\,>%_%'BN^TW0M,OIM*\(^%_%'B[5A8^&?
M#>NZMI_ ?L^?M3?!;]J'P+J'Q*^#^M>+KWP7IOBEO!<^K^/_ (3?%OX*S3>)
M8K;1I;G3=.T?XU>!OA]KNJFRO=<M/#FH76FZ9=66G^,[76_ ][<0>+_#FOZ)
MIND*CA)SBH_\NY;>['V-1SI\M[^[&=2,6FY72A%RYG*4\Y:TG3D_=E*3YW\3
M<Z4J4]7H^:FIMNR49<TE91C&G^+_ /P3&^"'C;P]K?[*/P@_:;_8)_:,T+]I
MO_@GGX'UKX:7/[7WQ.^/'B7XB?LJW.FI\,M:^#%O\1?V2+OQ!\;O$^I>)=>_
M:(\$6OA/5_%W@*V^!OP[T3X8Z?JWC#1_%^KZ%XF\$^ ?#_C7^B;L,^W^>:**
MBZ<8IV]V-FUHF]+RY4U"#:C&\8)1NK_RJ!;63ULV^5-M\L;R:CS-N4DG.5G+
MWK.SN^:4_P 0?VO_ (2?$'QE\</^"J6JZ)\'/'GC"Q^+O_!'7X=_LV?"_5=-
M\!:AJECX]^+&F^(_V\]3\2_"WP[JDUFMG<75W;?'WX-/=R7%U:^%KR35+M;S
M5@W@CQ4?#_SUK/P1^.]MJ?P.U3P?^R?>?$J^\%?\&]/[2_[+H^%/Q4^']Q8_
M"CQ?^T=XBB_9@UCP#^RW\3Q?77AW1(M \<K\(/'GACQ#%=^(M%\&PZ3YFF2>
M+M+F\4^'I=2_I#HI27-3C3YFN5Q:E'1WC#'P2ZI)K,*G,EO[.F]W)NZ4O9<_
M*D^>523YE=IU/J/-9Z.R^H4^5.Z7M*F]XV_DZ^,OP-_:6^.GP,_X*1Z-X)_9
MS_:QFU?]H[_@C)^RS\/OAM<_&'X=>!/A9=>(?BC\&/'7[9VJ^+?A%HWPQ\'>
M(H/#'PDUS1M%^*O@;PWX+^#VA>&=!%W)%J.N/#JXUP_$+QS]AZ[JWQT\/?M9
M_M5W'C__ ()U_&7]L#]G3_@I=\.OV<+KX/6.M^$/@[?>#_A3-\./AOKG@3QC
M\!/VT_#GQ:\?VEQ\(_A=#JBVGQST\W/@WQCY%Q\6_B'HMCX.UKXP6VN^ %_9
MCQG^T-\(_A_\9?@S\ /%OB6]TKXK_M!6OQ"N_A'X='A/QE?V'BN#X5>'X?%/
MCX-XNTWP_>>"] N= T&YM]0-CXF\0Z->ZDD\46D6]_,QC'M56YJ4I3<4XU'4
MC*+DW&2G.LZL.9J4]\0H\SE*<73IMRG*4W+.*<(*FI-.+A44G924N6DJ=2T5
M!--4)/E2C":G4C:$8QY/YIOVT_V>?CE\1=+_ .#@O1?"WP&^)'B?7/VHOV;?
MV9/AW^S[J.G^ KLZ?\8O&/@GX-^+_"6K:=X2U*4S+!;>#?'7B2S!O/$=UI.G
M637=YKVBW^H:;:ZEJT73_&?X-^+_ !%^UE^V!\(_CG^P-^TS^UY^SY^WA\0_
M@I\:O@!XT\"?&GQ;X,_9K\.W7AK]G'X!?"KQ5X#_ &U?AMJ?Q=^%%M\&(/AC
MX_\ V?\ P[\5=&\6K\+_ (M^-_%NC>)9[7PGX;UGXH^!=-\ ZG_1E14JRJQJ
M;N-.C3Y+M1Y:*J)3BDTX57[1-U8WE%02A:[<;;_=RIK1.=2HI7;DI5?9\V^D
MH6@UR-*+YW?97_F ^+/PW_:XT#X3_MU_LIZG^R9\=OBI\2?'7_!5?X)_MN?"
M_P",/PXL_"/B#X;_ !B_9JU3]OW]F7XRZ+'=?$3Q=XQ\'6GA[XI? 7X7_#\?
M W6_A?XNET[4M#\(_#KP;XH\.7E_\&[/5O%7@W^GN)F>-':-X6=5=HI#&9(F
M903&YBDEB+QD[&,4LD9924=UPQD_S_G\J/ZU;J.4(QEROE<?>24;J-&G0BK1
MM%6IT:>V\E)V2DT9\B]I*JKWDFK-N25ZLZS=Y-R=YU)VNW:+2UY4S\X/^"FW
MA?QKXS^%/[/FB^ _ _C;QWJ6B_M[_L#?%3Q#9>"O#6J>(YM#^&_P-_:U^$OQ
MA^)WBO5X]-AE>/3_  [X'\&:UJ,-E MUK.N:A#::1X?TO5-4NHK8?"OQN^ '
MQEU_X;?\%L?V5];^$/CGXF:Y_P %&=2\2_$+]DOXES^#)=4^&NI7'Q8_8T^"
MW[-GASPU\2?$2VUU8?!'4/V5OB%\'--\5ZM>?%!_#6H:SX$N/#/B+X.V7CSX
M@Z?XA\%Z'_037DWCWXX?#/X8^.O@M\-O&VNWVD>,/VA?&/B'X?\ PBL8O"OB
M_5].\4>,O"WP]\6?%;6M N_$NB:#J7ACPI>P_#[P)XP\2V7_  F.L>'X=9MO
M#VI6FB2ZCJ<(LFPC2@JDIZRE5FHRBWI.\*5-4TE]I_5X2BVI24E)16L7#651
MJG:ZC&G%SY]G!QG4G[1RM=)>V::O&-N5N5[J7Y]_L@?"_P"(/@/_ (*(?\%!
M_%/C#PGX]N/#WCOX0?L%^$_!WQM\3^$)M*TGXQZM\#? /Q8\._$FZL];1'#W
MVB:]XSTFZN+74396NI3^(=0N_!SZ[8:=XAO-._5VO&O@C^T!\)_VB_#OBCQ7
M\(/$=[XET3P7\3_B3\&?%$VH^$_&/@V]T?XE_"'Q7J'@;XC^%KK1?'&@>&];
M%SX7\6Z3J6B75ZFG/I=Y<V4TNEWU]9^7<O[+6\VV[R2C*R;]R-._.ZE92Y8Q
MA&/,L1S*T4G%P:25DLXJ*346[7MK.4[.$84FN:4I2=O8)-.3LU)7W"BBBINN
MY045Q7Q"^(W@GX4^%;OQM\0?$-GX9\-6>H^'=%.H7:7-Q+>^(/&/B32/!G@S
MPQHNFV$%WJOB#Q9XU\9^(- \'>#/"NA6.H^(O%OBW7=%\,^'=,U+7-6L+"XY
M?X,_'/X<?'SP_P"(?$?PWU#7KJV\(>.?$_PT\7:9XJ\$^-?AWXG\,>._!MS#
M;>(O#FM^%/B!X?\ #/B.SGM?M-G>6&H'3'T;Q!HNH:9XB\-ZEJ_A_5=-U2[%
MK=+6RN_)72U^;2OW:3M=7.WF[+S=F[?<F_D^SMZ[1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^*_P"T!X>_
M:-^._P"W+^U7^SMX*_;H^-7[+_@3P=^PM^R=^T+X!N_AUI/P62+P3\5_%/Q@
M_;/\'WNI:IJWC+X:Z]J.I?"JZ;X+^!]?^(_A2^O5UOQ6EA)X?B\?>&? USJO
MA75_VHK\WO$_[#%C\4/V[?BU^T?\7_!GPJ\;_"3X@_LC?!W]EVS\-ZAJ_B2Z
M\67FE?#KXF_'KXC>,]&\::$OAC3O#7BCX2?%M?CA9^'_ !U\)M>\1>(/!OB6
M+X9^&]2\6Z+XG%[9Z7X6:2:J)OEDZ%>-.6ON594G&G-6^U&;4H73M**M9ZDM
MR3IM*Z5:BZD4HOFIJJG4C:6C4H74E=7B[.ZNE^:/P5_;/_:1^+NDZWXO^(7Q
M*UOP!/X__P"#>C]G?]NG5=!T.]TS0]#\%_M(^,'^,;^*OBUX*_M"#4+SPG;2
MV'ACP?<S>$9]3O/!>EVUI:+K_AZYU34_$EYKG0? GQO^U-^U3\=?V!/ 'B/]
MM+]H7X:^$OB3_P $</@'^V%\0[?X2Z9\ M%U'Q?\>-,^*/P N=<UZ_UGQ1\$
M?&,T6B_$*'6]1T_X@^&K>);&]T:4Z)X2D\%Z%K/C;2_&/[7?%?\ 92_9K^.?
MBWPCX]^,7P-^&?Q)\:> =&U_P]X.\4>+O"6DZSKGA_0?$XMFUO1M.U"ZMWN$
MTV[N;&PU.*R=WM['6]/T[7=/2TUFPL[^!?"7[+7[.GPU\3>%O'OPQ^ _PF\$
M>.?A[\+Q\&?AYK?A/PAHG@ZZ\(_".WN?[3M/A!X=O= TN-O#7PJ&MI!KC>!M
M(LQX5AU^&#Q*N@3:Y:V]VM<ZYY2Y5;FDXK2\5S8Z5/1047*,<3A[JW*Y8=17
MN>R4%R/V<:?-K[CE)W;;4,)&I&[DVHR=&M:5U)*MS-*?M)2_GY^"WQ@_;5TG
MX7_L$_M>/^V#\:_C)XF^)'_!3OXO_L._%?X >/-)^#'_  JOXF_ '6/VX/VI
M/@IJ7B^P\-> OA%X.\3Z5\9?@SX-\!>'/C!9>,?#/B;2?#VC>!_A=XL\-3>#
MK?P!>:GIUOZC\(OVNOVA/&/[/O\ P2:_;F\,_$7Q;XQ\?_MJ_M:>%_@G^TU\
M QJ<=W\,1X,^+5S\;;?QMX%\'^ +[3IV^'?BW]@_4?!$S_\ "2>#CX8\:>*O
M!OP:^(J?M#WGQ(\2WUWXAT?]"_\ @G[^P7IW[+OPQT6T^+'AGX9>)?C5X>^,
MG[3OQ1TCQSX1O_$6O:-IDW[1/QL^*OQ1GUG0M-\4Z'H-MX:^(5EX-^*1^#7B
M;QQI&BIXI\8>!?"FDZ5JGB-O##V'A#P_];^$?V9O@#X"\;ZS\1O!GPF\%^&?
M%^O>+?%/Q!O]1T?28[.TC^(GCR*X@^(7Q&TK0HV&@:!\1/B3#<S1_$OQYH6E
MZ;XN^(J%!XVUG71%%L*,U&G352*E47U><I-)M<M+"^WHN]U)5:D<1S3;<HRJ
M-P]WE2TKJ$JM:5-N,'+$1@HN2C)2J8A4:BO:4/90E0=.$8Q4E%JI>7*U_/Y\
M0_VX/VG_ -E3X=_M1:K\8?\ A;VF_M,>"/V1_C;\>_ /CC1O$FF?'#]B/]I[
MX2VGQ<^"/A:Z_;'^ ZV$'B/4/A1JW[+7A'X@:#JWCK]FF[\#Z#9IX/\ &-AX
MGGA^,EO?3?$.]^K/&MA^VEH^@?&#4_V>OV@OA_\ 'BP^+6@?LY_&+X-_LIZ=
M^TK>ZOXW\6>!+7Q-XFU[XVV_P2_;'\3>'_#^M^ ;3]KGX3Z1=0_":35Y+SPC
MX-U_P#XVUSX+^-_A=X:FUSQ!\-OU#\ _LE_LU_"^"\LO OP7\":%I=UX/USX
M=PZ&ND+J/AW1/AUXIO+;4_%GPZ\)>'=6>_T/P7\/?&&L6=IKOC'P-X1T_1/"
MOBWQ!;0:_P"(](U/68DOAYYX&_X)X?L,_"[P'J7PR^%_[*7P/^&?@C5?B#I7
MQ8N]%^'/@+1? A3XG^';VXU'PG\0;#4_"EOI&L:5XQ\$7ER\_@#Q%I>H6>J^
M 6BLU\&W6AI86*V^:T23U:C22=D]8*$91E%^Y*,E!5')V<ZKJ74(UG[,D[NZ
M25YU)-)M:2;E&S7O1<6W!)-\M-P7--TE[3GOV&_CGHWQ9_97N?'_ (3G^._B
MG4?"_P 0/VB?#6N>!OV@K'2-.^/O@+QIX(^+_P 0K;4?V?\ QN=*U37M+U/6
M?A++#:?"?P]XD7Q+XMF\5>&_#OAWQ-JWB_Q3JVK:AKVH?G-\$_VH?CEKWPI_
MX(M?M=>'OB?XK^+FO?\ !17Q]X/^'?[5'PPT_5+*]^%2_P#"W/V6/C?^T!KV
MH?#;PO-!J,'PDG_8W\7_  ;U'P=IUMX*NM)U/QG\--)\;V_[0-]\5?BO%I/Q
M(T7]U? G@'P9\,?#-GX.\ ^&]+\*^&K&\US5(]+TJW\I+G6_%.O:GXK\6^(M
M4N',EYK/BCQAXLUK6_%WC'Q/J]Q?>(/%OBS6]:\3^(]2U/7M7U'4+GA?!7[.
M?P,^'/BW5?'/@7X7>$/"WB;5]7\7^(9;W1],2UM--\0?$74H=;^)FO\ AG1E
M8Z)X0USXJ:]:VGB+XK:QX4T[1=1^*'B2SLO$7CZY\1:U9VU_%<7%5.>2YHJ-
M-*#?NMQY_;)OX^6MS\J7/>$80YI3DN=Q)-Q<4WJZCYOAE:2C[)KD2@IT914M
M(J,VY)1C&;BOS:_X(^>$(_#^G?\ !0:\'B+QIK+C_@J'^VYH2P>)O%.IZ]:B
MWT?XB6$=O?I!?R.HU:Z1@M_J>3<WJI&)G98XPOSO^UMX"^/O[*>N_MT?MU_L
M1^//AI^T7\ ==N/%WC7_ (*+?\$Z?CRYT'0M:USX:?!#PEX>^*7C?X!?&'1M
M)N]=^%_Q;USX(>!/ L&I^ ?B/X>\:_#KQUH6K2^)[>6&23P3ID/[?_"SX%?!
MWX(#QF/A!\-_"7PW7XC^,]8^)'Q!3P?I-OHD?CCXD>(S$WB;XC>+8[-8X_$7
MQ"\4M;6C>*O'&K+=^*?$S65@==U;4#8V?D\9XI_9(_9H\::CXOU3Q+\%/ 6H
MW'Q(U6'6_BO;KHT=CI7QHU&TTZQTG3I/CEH>G/::+\;K?1M,TO3+#P_8?%C3
M_&.G^'K73;"'1+6P2SMA',M7%JR:H0I7<5-.U/#TYJ<&U&I1J*E-RIMQD_W=
MJE.2<X53]U24KRC*O*K**DX-QE6K55RS6M.K#VD5"HE))J;E"<9<LOR#\>?M
M/_&3]L/XO_M-_"3X)_'6V_8\O_A?^R/^RG^U)^SUXT^)'C6]^&WB'P5X2^+?
MA+QMXZ\2_M'^-?A5J7@WQ%X*^.?P[\+:Q%HWPC^+?P]^)6O7_P ._ \_@^]@
MO)/"GBOQKHWB^+U;P+\<O&O[1OQ(_;/NM:_:KN?V;?'_ .P]^V%^S?X)T+PM
MIEI!?^%I_@%XA^$_[-7Q.U9?'_P*U76-/U;QPG[<5SX\^,?PW^$_B?Q8U_XH
M\#7 \%CX&6@^)GP^\57/Q _1KXT_L:?LE_M'>-OAU\2/C[^S;\$_C)X^^$EX
MM]\-_&'Q)^&_A7QAXA\'S1SRW<46D:GK>F7EU'80:C+_ &Q;:7+)+IMMKL%G
MKT%I'K-C97UO8\6_L>_LI^/?CMX,_:?\;?LY_!?Q9^T3\/-/CTSP1\:_$'PY
M\*ZK\2O#-G;S_:=/72O%M[IDVKP3Z+.]S)X=O/M+7GALZEK T&XTY=:U87M7
MAS)\K4?:3?+S<[C'VDI4I<\N5SG[/DHU8R2IU.5U=&^0EJ7+9-7]G".BY8M^
MSA"I'EC?D@YJ52G)-SIIJG';G/P4^'WB[XL_"K]EO]MWXK> OC?\7]+\9I_P
M7U\/?"?4-0U7Q3!XU;6_AAXE_P""D7[/O[..M^!+B7QUI7B:^TG1+SX4^-[G
MPO#-X4O/#VMZ9IWA[PIHFDZO8^&M&&A7'N?QT_:<_:$USX-?\%D?VCO"_P 1
MO%/P>^+?_!,[XO\ CC2OV??AM>7"W'P^UCP!\$OV6_@7^T,]I\5/AH5TRU^)
M^E_M>7/C+QEHEIX@\0>?KO@_P/XA\)/\"=;\"?$#PYJ'CG7OUFOOV)_V1=3O
M?BCJ%_\ LW_!VZO/C9X_\,?%7XN32^!-!/\ PL;XD>"S83>$?&_BZ,6@BUKQ
M+X9U+2].\1:'JMXDEUIGBZSM_&5H\7BJ-=8KM-=_9O\ @3XF^(2_%;7?A;X2
MU+XA21>#(=5\33:<%O/%2_#37&\4?"Z3QW;Q21V'Q N/A1XJDG\6?">[\;VG
MB"Z^%_BNZO?$W@&;P[KM[=ZA,I-2A3BER.*@G.-FX^SP^"HQ<%+25GA:MH33
MARXF5X\RJ.J1BXSJO2<9RFU&2=O?Q&*K24N5JW,L13BY1?->A&S2<.3^>O\
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M%?B)!^T)_P %,?#X\<: =1BUWX;>"_&__!6G]I+P/\6/BIIE[I5Q9:IH]_\
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MU?PK\ ?$%MJ-GXLO?@C\.OCE%=>,/AOJ_P 5_ _PV\=ZE9>/M5^$%_\ M#>
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MB^)_Q%T+]I7P=X\^,WQ6UW2_A'_P<1_\$Q/AS\.I+3Q!8^"KKP]\,?&>K?\
M!,#QXGPX9?A[HWA*QUOP?X7\2?&CQCK?ABU\066JZA_;Z>'O&/B'4_$/C31+
M3Q&?W?UO]FWX!>(O^%2#5_@_\/KA/@$MH/@5%%X9TRQ@^"S:?H\?ARQF^$\%
MA!:P_#JYL_#<4?AJUNO"$>CW-OX<!T"*5=(9K)N<\3_L??LN>-/"WQ=\$^*_
M@-\,=?\ "?Q]\4Z3XZ^-6@ZGX6TZYT_XG^.M OM&U+0?''C.)XLZYXTT*]\-
M^&)]&\67C2>(=*_X1;PO'8:C;Q>&]#CL.>5"HU%*M)6G*<GRI.;;RNTFHM14
MG]2Q4I*/N)XOEBG'VEZC*,959>S7O^SY%?\ AQBLS4H*3O)IK&8:*=U)K#<T
MFI>S:_.?Q7\8/C)\$?V]_"'A_P"/%[\8!^SI\2_V@/AQ\-?V5OV@?A+\1;#Q
MI\'1/K7[.EUX(U+]CC]L[X+SSVFN>"?'>N?'_2?%?Q?\"?M&Z/X?\9:EXM\3
M^,_A9\.O$OQ-\"^%-"OOAG?^G?MN>+/C&?VW?^":GP0\#?'7XE_"CX9_M!ZC
M^V#X>^+FB_#VW\ 6UWXC@\"?LZZIXP\(:G;^(O$G@;Q+XBT+6M#UA9A83Z7J
MD&F)'>3:B=(;Q5IOA;Q+X;^W]$_9;_9Y\->.(OB+X?\ A%X,T7Q5!K6G>*+:
MXTS3?L>CV?C+1OA]9_"/1?'MEX4@E3PG9?$31/A'86WPET7XA6NB0^-=(^%:
MR_#C3M=MO!=S<Z'-UGBWX*_";QYX\^'/Q2\9?#[PMXD^)/P>D\1R_"?QYJNE
MP7/B[X9S>,M+70O&4W@+7V']I^$I?&.@JOA_Q=+H5S8OXG\/JNA:ZU_I(%G7
M5%V]FY1C)QE4YTM%.,J=2G&ZU7.G-3E)<JDTGRQJ*4YYM7<[.R<(1C;[,HRC
M*ZVTM%*SO)7E[TH.,(_@!\*?B]^U!X$T7_@FI\1=<_:K^-OQ4OO%W_!4W]K3
M_@F_X_\ #?Q#7X;/X4^(OP%^$_Q"_P""@_PX\(>*?'6F>$?AWX4O=8^-MC:_
MLO\ PF\07/Q1CU*SU"YUO3=?2:Q_LGQ=XKT_5\S2OVZ_C'X?^/'[-7Q@^&_Q
M-^(/[27P>^-^I_\ !7=-<CN/L_A'1/VA]/\ V3H?B#XX^$'A?X)? 6.X^(-G
M\+O#?P5NO!EC^SKX2^,&D:YX-\??M#W>G^)_B-\6/AKXF3Q9X"\:7/[I6G['
M_P"R[8:1X-T"R^ WPQM="^'?Q1O?CCX!T:#PMIT6E^"?C5J-U?7U_P#%_P *
M6"1"U\/_ !0O;_5]=U"Z\?Z5%:^*Y]1\2>*;^35FO/%'B";4N6\._L#_ +$_
MA+QSIWQ-\,_LJ? 70_B'H_Q3\0_&S1_&FF_#+PK;>)=(^*OBO3]4TWQ'XVTK
M5TTT7NG:OJ\6MZO>7GV*6"T?6M2O/$*VRZ_.^I&+2]E"/,U5C3J0G62B^:56
ME"G*;A*+C)QFG6C\#51+5*<XQTO2<Y2]DN1SO&'/+2,:]2I"-TU:U.4*#:O>
M";UE&+?XO_"7Q5X@^+'QQ_X-]OVHO$GQ:\4?%7QM^TG\"_VGOC-\1+"76;.Y
M\&7?Q \=?L9Z!XPU6V^&_A1TCL_A?H'@*]U74_AOI7@[PU_9<$FF1:?<_%63
MQA\3["_\;ZA]"?\ !.[XU_M!?M0>'?V"_P!LRZ_:>^$L7@+]I'X3^)[;]H/X
M-6OC3Q'\2H_B;\;-0^&\7C&+P9\)_"M_I'A?0OV9_&/[*?C+PA\2?"'BKPWX
M5N?%H\:>!8=7T_XNR>,/B;X9T7XIS_HQ\/?V /V'OA/XUT[XC_#;]DG]GGP5
MX\T3Q5XD\<>'?%OA[X3>"]/USPIXL\7V7]G>)==\'7\6D";P??:Q9R7T-X_A
M@Z2C?VYXFD1$E\5>(Y-4HP_\$^_V+M#\0?M#>/?!7[*G[.'A;XG?M1>"_'?@
M;XX>.8/@WX5;4/BEH'Q)C:7QUHGQ$.DQZ#J?B?PSX^U=;;7/B7H,>MZ2OQ$U
MBVCUCQ+?7.O1V^LV]-KFE*,5&-ZTJ=)/FC3]K4YU33DN:<(Q;I*51RG:G2J/
MFJ<R6=K[MZ^R4Y62E)4X2ASV32C*]JG+&T+RJ0TCRM_0_P 7'UJ/X5?$J7PW
MXCU?P?XAA\!>+I]"\5^'[3P[?:YX;U>#0-0ET[7-(LO%^@>*?"MWJ6F7:0WE
MG;>(_#6OZ)-<0QQZGH^HV;36DO\ .K\#OCG\??#_ ,+?^"0EM\2OVG?BY\4;
MC_@JM\ /AWXV^(VL_&SXHZ1\(O!^B?%SP_\ L8_#_P 2>'/@=\(OB;\#/@QH
M/CSX7:C\<O$7C+7OB0C_ /"1W/CKQKXR^#L&BZ)XSANO&/BS1/&W[_?##]G[
MX=_"[]GWP9^S1IVG/K?PM\&?#72_A1;Z)K8ADM=1\&:;HJ: ="N=-L8K+2+'
M0)]*#:7!X4T6PTSPGHV@F'POH.B:7X9LK'2+;D_'7[%O[)7Q.^ VD?LN_$']
MG/X/>,?V=O#L6FP^%_@SK_@70=0^'OA"/18KFWT$>#/#<]FUAX.;P]:7MW9>
M')/#,>E2>'K"XFL-&:QLW: RE*-5S4N:'+"/LW=*24JCJ/9J+:G#E:3NZ,>:
MT)V5\R=-0<;2O4?.K7BW""I[6;Y90DVG)<JJRY;SCK^64WB/]I7PAXB_90^
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M*<ZK2T7/_,Y%-:IJZ2C423;?*I8BK6C%/JH0G&FFTG[NGNJ*):***H84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M^:'[1/[>?Q#^ WQ4_:>^%MO^S[X?\7:A\'/V&M?_ &W_ (*7-U\9M5\)O^T3
MHGPYUO4/#_QE^&L(NO@OJVA_#KQ1\--2'@Q+W49?$OC33;Z#XO?"BZNTT.#7
M/$<GA']+Z^3OV@/V1? W[07Q>_95^,NO:MK&@^*/V6_B/XA\8Z8^AS75K)XX
M\)^)/#@;4OA;X@NK74+)X_!]Y\5_"?P.^,.IVS17\6JZ]\#_  MH]W:-INH7
M\B)IMVNDFI1;:;Y'*$U&HHJ47)TYJG+DO::YHO>Z-%=VNURR4;V4^6<&Z;=G
MRJI#G@Y)7@W&2U5G^<7[9G[5]_\ M,_\$MOVN?&O@#1Y/#?A#Q/_ ,$:?&G[
M:&G_ !)\"_&#X@^'?%7A+Q;\4/@Q\1O&/P?\)^'5TKP/X!U;7-&\KP#XHU;Q
M+KE]XE\+:@L.D:9X5\7_  IGT7QK=1VWNNM_\%*!\#O&'[37@']I#X-+\/V_
M9^_9F^#?[47P_7X=_$.Y^,'BKXL_#OXR_$3XF_!GP1X%UKPW%\._!>E>!?CU
M=_$WX<:;X2D\#>%?%OQ?^'\^H>._#TND_%_5+*'4;F#:L?\ @F1X,\&?L&?M
M;?L*_"GXAWG@_P .?M5?\-4Z9)XLUWPU/XPM/A7X,_:;OO%FDV_@;P/X.3Q;
MX<6'PW\&_A9XBT[X<_#/3/\ A)+32[$>&-+UR]TV>":]T";%^./_  2]TC]I
MSXD?'CQ7\=/BRNI^$?VA?V$OAY^Q3XM\+_#OP%=^!/$GAF\^&_Q&\=_%GPU\
M;_A]XXU7XA>.(M#\7Z%\0/']_P"(?#.A:QX4\2:7I-SX>\)+J%YKR:?K']OW
M[G/5DHN,9\LE!2;:?LJDW"$Y:WHRF\-2G-)5+0JU8M3E*GDHSYXMRNHP<%)V
MNW]8HIRE!:)5:477J1BVX2O2IR7+&,_"?VBO^"E/[57ACX5_&!_!?[+-S\-/
M&7@;XT?L*^#/#/Q,^)%I^T5H'P:\<_#?]K+]ICP3^S[XKG\&^)?BY^R3\)=5
MD^-OP[US7);+Q%X&N/!6M^&/"OA3QGX%^+NG^)OB5=6VM?!MO"?$G[8/QD_8
MO_:8_P""O_[0&I_">Y^,'P_^"UG^P+\2/CUX5O?VDO$T=E\(?ASJ/P'U*[^+
M<O[-UKXL\!>(T\=ZUX?O;K4?%>E?#2^T3]G7P3XQL[?4M4'BSPUXNU0^';K[
M4UK_ ()Y?M2_%+]EWQW\%OVDO^"AFN?'7XM:CXJ^ ?BOX7_%J?\ 9N\ _#GP
M!\/]2_9O^.'PZ_:"\$:IXF^!O@/QAIC?$WQ)XR\=?#7P_8_%G6K_ .*'AVUU
M7PG:6^C?"K1O@W=WGBW5O%V9\:/^"7/C;XV^&O\ @I)H/B+]I3P_87'_  4=
M^$_P6^&'BS4=/^ UYCX9O\*_AL_PVUCQ#H-F_P :P-?D\765YJFK6>F7]QI\
M/AB_GL8VNO$%I8SPZ@-J$$X+GJ)5>9.\8U(RAA?9P:;]U2Y*L:BBURSBIJHY
M-38H3G63FU&C>@TD[RA*-3$^UDFE[SBJE*5.4D^:#<7#EBH'<?M+?\%)M;^#
M?B[XS>&?@Y^RM\:/VJ+G]FSQ3\,?#'QNT'X1>"?C=X@\=-?^.?#/@CXEZ_X<
M^#VG>"/@'\1/AQX]^(G@[X._$CP+\0E\'>/OBS\&;+Q /$ECH5OXHTZ?S;Z/
MTCX(?M<?'3XW_M(?'CX2:5^S)X:T'X2_LW?M'>,/V?\ XF?&C4OV@K>XUJX:
MV_9X^"_QZ^''B;P9\)[3X4O<ZY<^*%^,>F>&_&_A[6O&OA:#X?0)H^N:)XB^
M)%YJ/B3PUX*\J\>_\$[OC9/^U5XV_:1^ /[<OCG]F[1/VD?#_P .M,_;4^$_
MA?X2^$O'&D_&'Q+\+_"VE^ /#7Q1^"7B?QWX@U35/V8/B=)\.--@^'VL>(='
MLOB+8:QX=TKP?>:AHL_BOP7H?B:/ZF_9O_9O\2_ CXB?M<^-]8^(VA^-[#]J
M7]H2#]H*'1--^'VH>$+SP%JD/P6^$/P*;PY+K5W\0_&,7BVP?PC\$?!>H_;Q
MHWAFZ7Q'=^*+QHWTW4]*TG0,_>4Z=K.'+6553TESI*,'%P=G"3;G3U3M%>TC
M'6,]G9QDM5*]-Q<;_"VI24E-.THI.-1JZ?,N1M-2C\$?M=?M$?M!:Y^T7^W)
M^R5!IWA;P[\#/A__ ,$K[W]H.S\;^#_BIX]\%?&FW\2?$^Y_:/\ "%MXGTZ^
M\+^#+&^TS5_#?B+X'6^B:!H_AGXC>$9-$T75]4\>W7B[Q7K.J:5X#\$\O^Q9
M_P %!-7^%/P5_9W^''[3?PSC\ ?#;P__ ,$A_"'[<?A?X^V_Q4?XD:[XI^%G
M[//PV^!6A_M R_%SP"G@O2+CX>^-='U'XH^&/$OA2W\+^//C3I_CGPM=ZAJ>
ML>(/"'BJSN?"-?7GQV_86\5?%/\ :)^+?QY\&?&_2O =M\=?V&]0_8G^)/@O
MQ!\)Y/'P?2],\0?&#Q5\./B)X/\ $5E\2? DWA[4O#>N?&[QE_PEOAW5-)\3
MV7C;2K;P_8Z;J7@>[T^\U/5/._#/_!,.S$GP T'XH_%+P_\ $[X8?"3_ ()K
M?$__ ()H^/? 9^%FK^%;CXN_#+XMVWP5L/%_BN?Q):?%K4V\':C>:9\"?"NG
M#1K'1]9CC@UKQ<\6K137VB2>':JMJDHT$N=J"GSV^)0S7FFFW9RC4J8%4TWR
M.,FIQ<(34)I17MG*M_#4I<K@Y74)/+/=LN\:6,<U_-9Q:E).7IG[-?[;?Q(^
M.?QP/PK\6?LD_&/X6>#M=^!UI\:/!7QFU+PE\:H? D>H0>(-%T7Q%\&_B=J7
MQ1^ ?P9T3P?\78+7Q5H7B'PAI'@#Q'\8O"WC30-(^(=[%XNT;_A#].3Q7Y[^
MT1^WK^T;\,OBY^U3\)?@A^Q3:?M :A^RU\!_@-^TEJU[/^T;I7PUN?'?PW^+
MLW[26GZWH'A307^%/CC4O^%L:-JW[.VH6W@+P==?\4Q\0K;4M7G\1_$'X67N
MC^%]+^(7>_L._L<_M%_LLV-EX4^,W[=WQ$_:Q^'/PW\'Q_#']G_PIXH^%'@#
MX::IX1^'=C/IUOH$_P 9?&'A.XU#5OC_ /%?P[X7T'0O".G_ !,OHO MO>6!
M\3:WKO@W6/%_BBY\16G@?B#X9_'CXB_\%'_VY=-^&WC/Q#\#O!GQ'_86_8P^
M%%Q\5_$'[-7C[Q?HVMZ]X;^(7[=ESXS'P6^*.M:UX)^%,/Q-^%GA_P"+WA#5
MHTOXOBQX?AU/QMHLVO>"-8@\.:YH<N==RYX+#I>_]9<%54FHVI5:F'A7E'9Q
MDJ,*THOEDO:6?,U;2DHVDZVT?J\9.F[7O4ITZ\Z2D[OF7M9THM7B^1<MD[R^
M+O\ @KKH>N^"QX[_ &5/V<_B]^U'I^F?L_?L^?M*:_X;\*^"OC<?&M[X*_:*
M\(/\4_"/P_\  FF_##X!_&WPWJOQXC^$<5IXO3P!\2?%WPA\*ZCJ?C'X?>'(
M?B3!'K/BO7? O1ZY_P %(OBS;?&3]L7P7X4_8XU[QO\ #']B'PKX:^(/Q5\;
M:5\4Y+;XJ^+_  AXR_9>U_\ :,\,Z3\(_P!GFX^%K>*/%'Q9O]3TG3_A;-\,
M_$_B7P.(M>\0Z;J=MXHOA;:II%CCW'_!*_Q1\)OBSX*\=_L(?M>^./V+?!$G
MP&^!/[,WQR^&&G?"CX<?':S^)/PN_9GT.]\&_!+Q+X"\1?%M=1N?A5\<O!7P
M]UC5? P^(>MZ7\6/!WB#2+/PE/XH^%.M7_AVZN-=]U\&_L6_$CX<_%/]O7XK
M> OVB;?P[KW[8G@KX<:%\/[N;X5W/B77/V?_ !A\)/@S<?!_P%X[N==\6?$_
M6Q\99[*(:9XKUO2O$^F^'W\0:UISQ76K0VNH72G9J'O6;M:MRW4E[R<U3TUE
M[*:=.4%*7M4XSA-I^]+*\O<:6SH\T6XW<7R.K>27*JD6JD&XQY.64:D4[*,?
M.O!'_!2>/QQ\/?A5XY\+>$O@C\4[/]ICXO?#SX*?LJ^)/V??VE[CXM_"KXI>
M,_$W@CXA_$+XA6?C3Q_>_!/P)K7PDNO@IX/^$/Q+\1>/](U+P!XDUM+30]-T
M'3].G^(>M-X$T[F/''_!4K4_AYX+_:)M]?\ V?(+_P#:"_9._:H_9*_9U^-G
MP3\-_%^WNM'N/#'[:/Q%^$7A'X(_&3X3_%'Q'\.O"MEXVT/7M"^,>DW;^'O%
MWA3X8W-AX\\&?$CP)K&KZ3H_A_2?B!XCS]3_ ."36FZKXU\<_'NV^*OA/X>?
MM/>(/C_\ ?VG_#7BWX,?!K5/AW\"-+^-OP#\/?%KPE)XZ\:_ .X^,GBC6/B'
MKGQX\%?'CXI_#7]H_5F^,GAG6/B)\.;CP+::'J7@GQ_X$MOB1JO>_%7_ ()M
MW'Q0\&_':>;XNZ!H_P <_P!I;]HS]D+]H#XM_%)?A-J%_P"%/LW[%/C+X->+
MO@]\+O ?PW;XKVFL^&O!?VKX)Z9>:]+XA^)_C?6+CQ)\1?BYK>FWFEZ?XB\)
M>'? =0]DYT_:*48\\?:J,N9<GM<*THNR<K4UC%6ERP;4J/)'GC(BJJRI5E1<
M)5?9S]@Y)P7M/98A)55)R45[1X9T^5S2<*G,^25CW3]EK]JGQE\;/BC^U?\
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M:!U)/B1\2_'GA.[U'X9Z'XZL?'G@_4_AAX.U.ZTSPW'>Z;'8:799R2YY\O\
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MY-*+5FXNC+E=U3]]QE,M\MIZ-M3DZ:O[J3I05F[:VDIQ4M'.\5*,$KE71?\
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MX8Z!^R)X6O\ X7?LM?$_XD_!OXC_ !)U/]J"+0-9\3/%^R5\*?VDOA==^"/
M^F_""_OVN_',OQ?T+P+X\@UCQ=X9@^%EM>Z1XP\-^(?BC>R>)O"?@SY8M/\
M@I7#^S=^P#^S1\:/A[^RC;^'O@)I'_!,3X4?M9V-C\2_VFK[3;+3O#&G_!_2
M/&NG?LJ_!?QSK_@+XC_$?]I#]H+P?\)?#'B[7M6O_&VB?#[3=1T_2/!NN^*/
M&]M_PFWBC5O ?Z%?#7]ESQW\/-=_;HUW_A;/A/5YOVQOBD_Q:T: ?";5]/C^
M%GB!/V>?A-^SA:6.I,?BW?M\1-(B\)?!3P/K=S#;CP#=W/B.X\52Q7MIIFKZ
M3IOAW\^M9_X(V^/;OX.:)\%-$_;#M-$\,S?\$F(?^"3OCN^NOV<M+\1:Q>^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ex-19_011.jpg
<TEXT>
begin 644 ex-19_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2* X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***\8^*W[1W[/?P(%F?C=\=/@_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8_9@L?%]S<:QK>H_$BXO_C1\=]1EO8IKA=7U?P9HWB"PT][^_N#;_;+?Q?\
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M%?KI_'H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(_X*M_%:Z\9_ ;PIK]]/^RC\%?B7K&F:3\*_&/C#PU>W.FZO\7-1^&8M]/\
M ]MX*\%ZS8S:3X#T:TTHWGBWQII6I^)-:B71?#VB#QCYK\1?C-\%_P#@IO\
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MTFYU'6_%UQI&A1:;J;7KZA'!IFHO#_>G\1?'OASX6> ?&OQ,\8/J\?A3X?\
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MQ#XX\=-:Q^*[Q? -PWPWMM3A\4Z5>6VK^/(= T+3K+[9<>)=5T 6DJ5]E_\
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M:U:^%39_)GPV_;6O/VK_ -HC_@H5\)?CQ_P4L_:._8#_ ."J_P -OVJ?C1X
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MN;X7V<NK:KX;73[W0-(L]89_R:_X*.^%/VHO&O[6'_!,O_@XF^"?[*_QTN/
M_P %+[7?AO\ '/\ 9Z/AO4M1^/6C?LE^'OC%\8K3P9\=X?AS;6NE>)[.7XO_
M  (^)7BSQAK?@^\L)+SX7/KWA"P\5/JNBP>(]=M?VOA_X+:?L_\ [1>G^%_
M/_!.+2_&O[67[2OCKQ;X)\/V7P^U'X-?'OX:> _A-X=U77K!?B)\2?VA_B3X
MP^&V@^'/AKX1^&7A%-=U&]L1J6H^+/%7BN+P]X,\'Z#K6H>(8)H #\F?VO\
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MAJ_^,WQ9\3^*)-+O=>L?#48\+> ? T%WJFNZ]-KFJZ3HJ@'XZ_\ !'+]H_\
M:QE_X+5_\%0OV%?BY^UA\<OVDO@=^S+X&BB^& ^.NI>#==\6VM]8>-_ ]C#K
M>I:OX0\%^"=.FU>73_$NJ6-[)IVBZ78WL1M7FT_SK2!X[EC\5OVLOV:_^#EO
M]G3]AW_AMG]I;XX_LT_&O]EWXB_M ^)_AY\<=4^&>M6FG^)]9L/VA/L?A[0I
M/ _PS\ PV'A3PO??#CP]J'A:W2T&KV 6;3[W6-3L'DBF^8_AS\3?"7_!)?\
MX.+_ /@H[\<?VV='^*'PJ_9^_;,^&FF7?P ^-]C\(_B?\3?A_P"-_$=_J?PL
M\0WOA&SU#X6^#O%NHCQ%!>:3XHTYM)32)I]-GT6.#5I;8:OX?N=9\<\??M?^
M)==_X.7OV//V[OBQ^S9^TQ\)?V7=6_9-U?P/\&M<U3X"_$GQ'\0]=^&FLO\
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MFOQ9^PU^P3^Q]XBT7P+^U?\ \%%_C)X7^%>E_&C7?#UKXPM_@+\.]<\8>$O
M&J?$+3_"<Y>ROO$]UK_C2SET:ZU;3=5T;3]!\,^-9QIK:PFCWVFWOCM_P2W_
M &_?@L/V?OBE_P $VO\ @HS^T[XO^.W@;XL>'&^.'A__ (*&?M3_ !<^-?[/
M_P ;/A!J\MPWCH:U\*H]'UCPCX>\06VI)I36=C\,/#?PRGL?!MSXHM_!7B'P
MWXJL_#<EQ^>/_!97X4?$;]L>'_@FW_P6_P#V /AG\5/C#=?L(?%/2_$GQ*^
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MK)AU/PA%XIO8?$OC/1O#UWI>B^1I'B.TU&RTY=)U+3KBX_?Z@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4445]D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2C_)/Y2C&2:M=-.,X233::DGUT$U))Q::=[-;.SE%_C&2]4_5E%%% PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9KLM5+)8:G?Q+_8947D0;/+\F+R_-\_9Y:;//\[[3YVW;M\W[3_I'F8W^?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4N6+:5W><4N[A2Q%1)63;YY4%"#BG?VL)?#<_K>HK\3?BQ_P4"_:5^#6N_\
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M]I-KLU%4V_FE5@[?WMVT[>A4444P"BBB@ HHHH **** "BBB@ HHHH ****
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M7XX^.7PVF\66_C;X1:%\1)--'AH^-=)N_ WB_3=.@U"\T_2?&7B#PQXF\*>
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M\4:)XFTZUN/'^M:QX'^'S^._&'C"T^'G@:T\/>I_#?\ 82L_A;X-\,:%X?\
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MC:;K%C=>(_A]K-RGA?6]2^'^A>*O$'@ZZFN]#.K&YT+0;?0?A]%IG@G3O?\
MP-^V1\!?B%\3/ WPHT'Q+JT'B;XM?#/7_C)\$K[6_"OB+1/"GQR^&'A*^\-:
M;XL\7_"7Q;J.G0:!XNM/#L_C'PG?7NF07UOK]YX4\3>'?B%HFD:K\.=>T?Q;
M>\#\?O\ @HE^S#^S9XV\8_#;XCZK\6;_ .('@#X8:%\:_%O@_P"&?[.G[0/Q
M?UO2OA#K^O:QX<3XF)#\,/AIXK@U/P/H6I>'=?C\:^)=(N+_ $GP$^FPVOC2
MZT+4=?\ "UEKKLH<KMR*SG%M.*M2DIN2YN5)4Y4U*3LN5T[SMR/DKXN:/Q:I
M22][6HN5*25[N:G:-TW+G2C=S7/I_$[]A[X;?%?Q+^U5XE\1>-_BE93?MA_L
MZ>%OV6_BSINAZGX*L].M?A-X.3XJ1:)9^#GNO =_JVAZY%'\</BXDVN7.J:I
M=3'QO=2;5ET#P?)X<\L^*O\ P2[_ &?_ (UV,VE?$OQ;\8O$6EW7[&7B;]A6
M]L5\3>%-'CN_@QXKU#PKK>H:G)<:%X%TV_A^(5MXC\#>#_$.F^)K2[MK6TU#
M08;?^QI-'U'6]+U3V?7_ -N7]G'2?!]CX]T/Q;K/Q,\*7/P*\._M0WNI?!_P
M7XN^*<VA_LX>+K?4;OPI\9M6TGP5H^KZTOACQ=;Z+XAF\#:/I^G:AXY^(D7A
M+QU+\/O"/BB+X?>.G\.>8W'[1?B'6OV[_P!FOPKX#^)FD>,?V8?C7_P3Z_:@
M_:,L;#P?H^@>*]*\7:]\./C#^Q)IOPW^)/A3QIH=GJOB+Q#I6L> /C]XLCTG
M2O#=^^@:]:ZAINJ0V.KWW]F7%K$G&FE!Q<4ZG(XI-*,W'%.\K-.+M]:2DM>9
MS:E>/-"HMRO*,KOD]I=/XH\V%6F\97MAFT]'&,.96?+/F-;_ ."5O[/GCO3?
MVB--^,?CCX[?&_\ X:J^#OP1^$WQQOOB-X\T6.^\3ZE^SQKWB3Q+\*?C#HDG
M@3P?X(@^'OQ;\,:WX@M]5L+_ .'%OX2\#Z?K/AS0O$6D> ]-\2R:_K.NU_$O
M_!*GX&>//V?;/X'_ !)^+_[6'Q+\7Z-\0_"'Q<\)_M6^-OCYKVI_M:^ _BA\
M.K/5]*^'/C3X?_%6UTZPTOP5<>!=$\1>)])T+PYX<\':?X(N/^$P\>:YKWA?
M6O%?Q"\=^(/$G<?L]_M@?"C6_P!GGX+^+M*^,WQ+_:GU;XL:+\7_ !9\/M:3
MX+W'A+XS?%/P?\+?&]_IOCOQ1)\%O#O@;P!+X3\/?#5]4\->";S4M:\'>$1<
MZQJ_P[\,7:W_ ,4/B7X3T+Q3Z3\%_P!N;]F+]H?Q=X,\#_!SX@ZAXSU[XB?L
M[>%/VK_ CQ_#_P")&A:#XK^ ?C6^L-*T#QSHOBWQ/X1T3PK=7)UG4[/1==\%
M_P!LIX_\(:M(;'Q?X6T*52*T3?O)75U%R4>96LG73]VUN7FG)2C:\8RY93I*
M,5F^56;MHY<KE9MW?L'\=VU+DC#EDI6=DXQJ<S/-[C_@G=\,GTKX!3V7Q?\
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M\=_$'P_)\,/C7H/P"^,'B>X_9]_:!D^'?P1\>>+=$^'>N>#+WXU_$J#X92>
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M5*4VYJDIN#E%2^)7YYN5FK\TY2BG9+=RG""Y8JTJBA[CJ<O-TO[0W[ GP?\
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M]\-C6%\.^-O#>B>+- 'B'PYXA\'Z\=%\1:;;:OI3:SX2\6Z9HGBOPOJCV-W
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M+7O[KPI%\/M>J? +X7>#?&G_  40^/'Q?^!OQ7\"?$']EVZL_AG^T7XD\/>
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M F\#Z"]RNA:GK/@_X=7_ ,28O!EMJ\6G>$KKQA:>'YO%+Z!X6O\ 7Y])T_\
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M_9<^ >J^"O&>K:K^U3XB^*/AKPMXVTEO"H\%^$=2^%?PH\3_ !;U.S\6K?\
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M;>"/A'XLNOV8_P!H3]C?XS:=X'\.?LM_&GQMXZUOQ4WPJ^+]AJ6@_#VW^/\
M^RI=3Z)\,-7^-VFW_P &OB+9_$C59OB5?^'O@7I6K7OA:]T[]"/VXO#'[3/B
MGX 6VD?LT_V=J_C^#XF?!35?'WA^W\3_ /"L?$'C_P"#.@_$KPQJWQO\#?#3
MXB7$MVWPJ\?^-/ -EKFB^$O',6IZ=KWA">]:_P#"?C3P9XT@\/\ COP_]FT5
M36C2T7M%4LKV34H2LM;\LN11FKIU%=S;E[SE*S3NVU!PN[;24M=%:\7-N&C5
M-Z02C>)_/WX?_P""?WQ)D\+?M'?#WXW_ ++-IKG@;XC_ +?GCS]J;X4^)?V6
M?VFG^'?Q]^ ]WXE^ GP[T'P5\8/@7\0KH_ N_P##WQ%\)>,M%\1>"O$Z7OC#
MPM=>)K#Q'XMU;4H_%GA$S>&?B9^C&D_#C]M/2?\ @G1J/PKG^+/@SQ+^WI#^
MRYXM\'^'_C#XFTS3=3\%3_M!3^ ]8TWP-XG\6V\_A*31?$%AIGB>70F\5:Q/
M\.3HWB6>SU+7I_ATNGZB_A ?=E%)Q_=RIIM*481;3M)<D(TXM/I+EBHRFDI3
MBE&3<5'V;UYU4>LE*<]4N5N<N>2:MK#FO*,'>,92E*-FY<_Y-?L4? ']H#X=
M_M6_&;XU_$3X(Z3\+_!GQM_9!_8W\!W\^J?M"2_'7XIP?%CX">-_VKM3\7VG
MQ*\57GAJWU+Q]XBU'2?CCX9@A\:2>(M4TQ= \.:5I]AJ+JD?AKPL^+X8?M\?
M _\ ;-_:<U/X'^!_@9\2OV;?VW?'?PS^+VH?$_QM\4];\ ^.?V2?B7X0^ 7P
MM_9P^(=Y?_#*W^'?C?\ X:*T#Q'X)^"OPW\9_#/PYHWB_P"& ;QG:>)/ WC/
MQ!X.\,ZO8_$+2_UBHII)2322M[3W5?E:JSE4G%KI'G:Y5#D<(QC&+47)23C=
M--MO]VU)_%&5*G&E&:?63A'WG)3YY2E*2;:M^&/C;_@G]\<O$WP3_P""@?["
M^I6&EZY\&OVU/VG?'?QS\#_M!P>)-)MI?AC\.?VA_B)X-^)/QR\'^-_"-]+'
MXP3XK_#+Q%%\3)_@#>^#=+\6^"O%UE<?"ZU\9^)_A;/8>([C3)/VAOV-OVF/
MB#X+_P""IOA[PCX T:]U#]KG]K;]E#XS?!LZIX]\.:3ITW@WX)_#/]C+X?>-
M9/%MPLE_<^'-3NKK]F'Q=JOARRM[#66U.P\3^"8=2?0[R;Q+#X8_<JBJ3:>C
MWC2B[J]_8K#JE?;X8X6E'2RDN9RO*5TIPC47+):*5:22=K.O'$1J[?S_ %FJ
M]6^5N/+91L_YZOCU^Q7^W'=?#_\ X*=_LY_"[X;?#?XC> /VZ/B]8_M._"CX
MM>-/C7%X&U/X>>)?$WA_X&^&O'WP4^*7A>V\">+-28^&;WX2_P!H_#OQ9X.N
M?&&B:AX-U)](UB?P_J?AO2-+\0>]?M%?L:_M!_&S7?\ @K[%I?A[PMH4/[;W
M_!-;X:?LI?!C5M2\96MSHR?%CP5X&_;*TC6'\5?9=/\ [>T3PA>:U^TUX3MM
M#UR/P_?7UU8^&?%VHZKH>B2QZ!I^O?LW163IQE%0=[**COKRQH/#03?50I<L
M5>S;IP<FWS<VBDU.4U9.?Q:?]/UB));V4JR<G;;GFHV37+^)7[0/[%_[0'[8
M_P 1M5O_ ![X-L/@5X/^,_\ P2._:X_8:\:ZC8>/-!^(^N?"OXG_ +37BKX5
MZKH-Q)8::OAB'QGHOA+PU\/]23Q;=:->0V=UXJU+3_#NBG6_"\NH>-;3VKPO
M\"?C_P#%'XV_L9?M$?'CX=:7X%\<?L4? CX_^%->T/P=XS\/>(;#XQ_&SXQ^
M%_A1X+U"Y^%6J+=V+P? Z32O GB[6--?XJV?PX\:WVO:U\/)=7\&^'T\+ZS+
M+^I=%6U?GU:524YNWV95'BVY1;U7*L=B(Q3O%J4.=3=.+<**2@DE[E*%!?WJ
M4(86"C+NVL'0;DN65U/E<?:2/P__ &6OV-/VDOA)!_P1AT7Q?X(T-8/V%?V3
MOBC\!OCWK%AXYT&^MX_%?B3X4_"7X;^'-3\!6P,=]XJ\.7.H_#75-5U*>^A\
M.:EI6B:MH1@TO5-4;5M+TCZU^*/P2^+?A#]OGX;_ +:/PZ\-S?%;P5J'[,/B
M[]E;XO?##3/$GASP[XW\.I)\3] ^+'PT^*WP]C\:WWA_P9XCMK;4X_&/A+XG
M>'-6\:>$-5.CZMX2\2^&9?$E[X8NO"VI_H7152;E)3VDJE6I=75W6BHU$]7[
MLHKEMT76Z1,(1A%Q2NG3I4]==*+;IM?WHN5[]7NK7/QA\'?L1?&GX+^%_P#@
MF_X4\/>'-!\;G]G;]MO]IS]L?X[3^'/%>FZ1H/A]OVG_  /^W%#KGP\^%47B
M>WT+4/%UEX$\?_MDVUCX=U+6-*\"IKW@+X?7FMZA9:%XFUNV\,Q_5'[?_P %
M/BC\<?"7[.&E?"OP[9>(;WX:_ML_LF?'[Q?%?>(-+\/BW^'OP*^+NA_$7QDN
ME2:FZ1:GXGO](TB73_#&C.]C8:AJT\,>K:YH5@)=03[VHJ(Q4%%07*H5(58K
M>SIK"QA'5OW8QPE&-G=NTVY-S;5/WI3G)N4JD'";?VN9XAN6EK2;Q-5Z67P)
M)*-G^&?[2'[&_P"TS\2_AO\ \%3_  IX0\ :/<:K^US^UO\ LM_&GX--JWCW
MPWI>GS>#O@Q\+OV+/AWXQ_X2^YCFU"?PWJ-U>?LL^+M3T&TMK+6VU#3?%G@F
M._.DWDGB>V\,^F_&WX<>%_C?_P %"O@CJ/P@^*_A!]3O?A[J7@#_ (* ?"#2
M=>MM?UZ]^#GP%\=>$_CS\ X/%T/A[7]0\.^%O&?A#X]>))?AC=^$_&.GZB?B
M/\!?VD?VA=/TNSN8M#C\0>'/U_KD_#_@'P+X3UGQ?XB\+>#/"?AKQ!\0-6M=
M>\>:[X?\.:/HVL>-M<L=-MM'LM9\7:GIME;7WB35K/2+.TTJUU'69[V\M]-M
M;:QBF2U@BB6^:5Z;?O>S=-J]KMTJ$L/34MDX.G4E[16O*4*327*[%O=E%?:Y
MUY)5:\*]1K=\RG3C[-[14ZB;=U?XX_X*/?LV_$G]I_\ 9GN/!WP9E^'<_P 7
M/ ?Q8^"'QW^'7AKXQVUW>_!OX@^(O@A\4_"_Q%?X9?%>TL+#4[]_ WQ&T?0M
M6\(:G=V-E/=Z+=:O8:_;QO)I*QO\7:Q^S3^T_P#$WPS^R9XND_8S_9P_94UK
MX>_MU?!#X_>//@E\%?B5X1\3R:/\,?A5X2^)>@>(/$'B/XEZ;\,_A'H/C/XC
M:]J/CZSA\+?#_1O"]QX?T7PSX>FU._\ BD=8\33^%O#_ .XE%*'N2YH[^TIU
M4GJE.FX:]':2ITU*+;C[MXJ,FY,DN9*+V4)P_P"W9\]_G%U)N+5G[S4N:*27
MX7?$O]C/]I;Q1\+OV]O"VE?#[3)-=_:'_P""I_[)_P"V/\-(9_'/A:'3Y_A#
M\!_$_P"P3K7B>W\1W[7IET/QAJEE^Q_XXBT?1(+'5K!KOQG\/8;K68+>X\87
M7@[D?$'PE^)?[4=[_P %V/V0O#G@&V'AO]IG]J#P1\)]2^+NL>(O#;Z!\*K'
MX@?\$QO^"?/AKXC^)-?\(7%VGBC4O$O@KP/=Q>*OA'9^$=.\3:;XX^)5O8>%
M_&.M?"GPU:2?$$_O_7!^$_A9\,? >M>+O$O@?X<^!/!OB/X@:FFM>/=?\*>$
M/#WAW6_&^LQ1^3%J_B[5='TZSOO$FIQ0_N8[_69[VZ2+]VLH7BDE>,:<TITX
M0E"TDFW>&%@DVN7W>7"P4K6D[M)I2E8ES2FZJDXU)3C*ZT4;/$-N*L[23KOE
M;NE9-IM*_P"/O[0_["W[2?Q?^+W[>?B[P)#X0\(2_$9_^"97Q+_9E\0^,?%;
MW?AKQ1\4O^">7QJU;X\2^$/BWIF@VVI^)?"G@GX@^(E\,>%K'Q)IVF^--1TZ
MP?7_ !;?>&_[1T'0O#GBCVOQ%\"_ GC#XZ_'O]K?]LO1_"7P8^#WQA_8P^'W
M[!NL?"SXQ?$#P+:6NO\ A?Q#\1OBSXB^)$/Q*\0Z!XIU'P$]CXTO/BCX?\ ?
M#32-)\8WNM- /&-U>+8W_C*QT73/U3KD_&W@+P-\2O#\WA/XC>"_"?C_ ,+7
M%]I.IW'AKQKX<T?Q5H$^I:!JEGKFA:A-HVNV=_ITM]HNM:?8:OI-V]LUQIVJ
M65IJ%G)#=VT,R"NDTG?F4HRYKZJI3JT:KNG%MSH5ZL+-J-^27NR7.F[.2E;E
M:45[NFE.5*I25GS)*-3#T972YK*4=8M1/P?T_P#8_P#VC/BU_P $B_B-\-+'
MQ?I_[07Q^^.=E\.?#GPZ^*7BO5F\(V_C7]G3X'_$'PKX?_9L\7>)M>UXZSKN
MFWWQ$^ G@#3_ (]^.-,DMKZ6/X\?''XEO8Z/H]CK-PNG?0'[2G[+'[0/Q<\0
M_P#!5N_\+^ K:"T_;,_X)I_"K]DOX,R:OXQ\*6DD/Q2\):1^VM9:M<^.(K;4
M[T^'/"D=Y^U?X3\O5M+/B6\EM/!7CRYBTN2X3PE8^*_V,HI5(^UOSN4KRE)\
MS3DY2PKPDIR<5&\ITYU:DVDDZ]:K5M>5ATI2H\KI\L'%P:Y8^ZN3$0Q,(I.]
MH0G3I0BKZ4:5.G=)77X"ZW^QQ^UE\/OVAK;XH^#_ -D;]D;]J[P-^T!^S]^S
MA\.?B'X=_:4\>:)X8\0_LJ?&/X'^$=7\#:KXQT+68_@Y\7#\2?@WXM\,7>BM
MJ?@_PL=.\43>*M#DO[%=%M-:U.ZDT?CE^P_^T]XN^'/_  58\%>$O OAC4M0
M_:[^,?[*7B[X*7,WBWPQX1T&ZT+X*_!?]EKX4^-KOQ-IUM-JS^!([C4_@%XE
MUGPIHVG6_B0W&A:]X1M;YM&OWURRT#]Z:*U=23<V[7G*<I:?SXF.*Y4KI6C6
MB^6Z<N24H2G)*#CC[&#C&&O+&$86ONHX>>&;;LW>5*>MG&*G%3C"+<D_SW^
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_GY_:O\
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MBO[)MY\&_#&A_P#!*'XR>&_&F@'XI>,?^"O7_!3']GW5O'EW\3[SQ'XB\3?
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M^'GP@T'PMXF^*7@JPLOB/\:K*SDU;Q5X,^-/@#]G_P")4OA&X^)<*>%/&?\
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MKC4/A7\%O^#D+XSV'B77/BII^BGP=\'?ACK_ .T5\:]"LM/U^X\=VJZ;\-?
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MT^+]%'LOQ&^*W[ >A>'?V8[;X+^--.N_V7?VE_\ @H5\0M2\)^/?BGXR<?\
M!-VT^(5Y^R;\3/[?\+QZ3XL2R\"?$?X+ZEXQTZ\\0?"3X&^!O$_@GX?^(/VY
M%U/Q#X<\;Z7XR\ >(/#K_P!%_P#G_/\ G%-V(%"!5"+M"J  J[""FT 8780"
MN,;2 1C H=I<MXJT72LEUC!14X-]5)PC4IW3Y*CJ.7,JC8TG'FL[<ZJ7712E
MK"45]EIN49M6<X<D4TX)'\KO[&/Q7T36]._X():1XC^)=AK?BCPU^U-_P4O^
M%GV+Q%K\L7BG1HOAU\+_ -KKP!X5\"7^@^)-2N?%/ARZ\'^&6\!>$=.\&:YM
MUCPM87'A7PS<0132Z?!-] _LD_&3X:_ /]ICQ+XB^(WQ&_9H^,_P;U3X&_M=
M_&[PS_P4&\!>)X? _P 1/ OPKT_XU_!SQ#X^^$__  42\*W5U>>')OB+X/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6E\-O^"I_A/6/V6OV??CU\1?@C\7=+\8?&']BR;]N;7_ (<>!+/P+XID\,_
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M\L? =U\$Y-7O[GX:_%;Q!J6O>(=2NO4_"_[!7[7-IIGQA;6;+]G6SU+XB?\
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M0]6\/^//V=/A=IVCZW\2O'OA[3O GB#QEXUT'5/!'AWQ-X3\1:Q\,?B7X2\
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MLIW3>_,FM/>Y)MTU'DG.2I>H?L=?MVS:?^SUXD\4_M$^.O%/CGXD:_\ MO\
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M/%GC:U\#Z;\-?B=XO2;]M_\ ;>U+4_V#_P!N+QE^SWXU\?? +]I']D^_\/\
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M2+;:;DJ;;<'+E5W>UU)**EROWK6DGRSE&7+'GA.G)1C?ECW?PN\<1>&OV9_
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M?M[_ !&\?0?#Z/PM^TU^T=X$^,'PR'@_QAXC\1>(++PWX3_93_9X_9SNM/\
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MI_;.T'XJ7?@K7KZRCU+6?$?A/X:^)_ASHOCE](O9]4TSP3KO@S3-9V:'>Z/
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MD?$BWU;Q=IG@_4]>\6>'-=T6R[7_ (*7?%?X7?%#]F[X(ZEX;\6V>K> [_\
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M,[O05LM:U&PTQY?$OA*YO/#^HC6=(M;#7HUL+B1K&'5(].O0E_:74:?S8?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6DN_'X^*,O@+4I/$?@;1-&\2:CXK\=>%?#NJ_*FH?MK>/?$?[5G[)WC?X;^
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M:%)X8\-0RW?Q)U'4;'Q->:E=_!G3+OXL:#HVL>"I]*U;4OH#XM_&?PM\'H/
MD&M6>M^(/%'Q4\>VOPQ^%_@7PM!ID_BKX@>.9_#'BKQY>:%H(UW5O#_A^W?1
M?A[X#\>>/]<U#7]?T72M,\)^#/$&H37QEMH+6Y+Z)])."3[NI"G4@EKKSPJT
MYQTU4X[.ZB;MKJN:Z[<DIPE>]K<LJ=2+\X2WT;]<HKX"N/\ @H-X13P_I=U:
M?L\_M3W7CV\_X:6FU?X07OP[\'^$?&/A33/V3M;TCPW\6O$&N>+_ !_\1_"7
MP+O/#,FM^*?!-I\/?$7A;XP>)-'^*-KXRTW6_ -YK_A[1?&VK^%,&T_X*9?"
M3Q3XO^!W@SX1_"#]H[XX:A^T/^S;\*_VMOAOJ'PV\!>%H=$N/@/\6/%OA'PK
MIOC#7]1^(/C_ ,!+X:F\,0^--*\4^+]!U>*WUZR\,PWSZ/IVN:[';:%=59\R
MC9\TFDEI=\T7)-:[.*<N:ZBE&;<ER3Y5S+E<K^[&_,[.R:=FGI\5[)1LY.\>
M6,N:/-^C=%?F]X+_ ."IO[+OQ$^,OPS^"?@?4-8\5Z_\<_#_ ,3]9^ NO>&M
M>^$7B+PW\8M2^%&@W?C#6_"6A1:%\5-2\7>!]=U[P+INK>./!>H?&?PG\,/!
MGBGPWI5[/8>+!J"PZ=-\B_LG?MA^*O'-Q^SE^T+\<;W]J#PAJ_[0W[87[9G[
M'/A[P3HVJ?!C7OV=_%EUX>^.?[34?P5L/%O@Z+QMXH\2>!]7^!_PN_9JU+P?
M<_$7X9Z?X.N_'_C2\UJ[\=W'Q0T'5/#.MZ-,6I-)/XHJ2=KI\TU2@E9IMRJR
MA"VEO:0D_=DAR]U2;5W%M..S2C"52<G=62A3A.3ZODG%>]%V_=NBOR#_ &FO
MVR=4\>_"70?$_P "?$7Q0^$6M_"3_@K9^Q;^QY\7=-U+3? 4%QXPL]9_;)_9
MW^&_Q6\)375O)X\2?X?^,O WQ1WVVJ^&M;\+>*+I)%L-2FL+%M;T'4,2P_;?
MUO\ 9R^*7_!4CQC\<]0^*WQ7^#?P%_;$_9=^%WA6U\.V?PU_XLCX"^-_[+7[
M+OB674M275];^&6EVWPO\._%3XNW]]XM\67=[KOB#PSX>U>3Q3XMN;KPOX;\
M0^)-'*;=24HQ5N50:O\ ;]I'"RI<MGK[3ZW246^57>MKHJ<73ASRVNU):WAR
MU*].?,FOL/#U')*[LKJ]F?LO17E^A_%33?$'Q;\?_".Q\.>)_MOPX\*> O$^
MN^,W3P])X&GN_B#<^+(].\&6%[:>(KKQ /&^C:=X47Q#XDT35/#>EQ:9X<\4
M^"=7BOKRW\3Z?N^*K[_@H9I?@S]HO]MGX<?%CX<>(/ /P5_8U^$/P&^(FN?&
M.6[\)ZY_PD%]\6K7XL:G);Z?X3\/>--7\=ZL?$8\(^&/!_PK\(Z!X&U#Q[XF
M\>)XBTF]T6U77/ *:V)W<4MY0G-;ZQ@XJ5K)W=Y12C\4FU&*E)Q4HNDF^BE&
M#\I2NTG>UM(R<GM%)RDXQC*4?TEHKYC^&G[4WA/QY\9_%?[.WB3P5X_^#GQO
M\,?#OP_\7[;X=?$X_#Z?4O%_PF\0ZW?^$T^(?@O6?AA\0?B7X3UK1=$\;:7?
M>#O%NER>(;+Q;X2UA] O?$/AO3_#?CGX?Z]XJ\?_ &J_^"DO[-?[(-]XVT[X
MEZM?ZK>_"SP)X?\ BE\6;#POKGPPMM8^'?PV\17WB&&U\677AWQY\1O WB7Q
M[+::1X.\8^*;_P #_!W1OB3\3H_#V@0RV_@BYU/QA\.]+\8C:5FVDI)M-M6:
M3<6[WLE&2:DW;E:?-R[C7O723;B[-)-M-I-*UKW::<4D^:ZY>9M(^_**_,+X
MJ_\ !5KX&_"C5/CTEW\*OVA/&?@[]E_4?@G<_'OXI^!/"OP]U3X<_#[X8_'7
MPM:>,_#OQR_M75OBCH6L>,_AGX:\.ZAI^I^-;/X<Z#XQ^)^FZ?=2ZKI/PWUS
M1]*US4-,^D3^UKX5O_C'XY^#7@[X=_$_XAZC\*?B1X%^$_Q?\6>#H_AS-X:^
M%7C;XC?#7PU\6/"EGXPTG7/B/H7Q);1K[P=XY\!73^+/#GP_\0>$X;SQA:6+
M:T9?#GCL^$G9OH]^5JSNF^:RDMXZQDKR45S1E&_-%Q24HM74HM6YDTTTTN6[
M33M+XXNT7)VE&5G%J3^K**^$_ __  4#^$GCS0OV9?$>G^"OBOI>F_M3?M&_
M'/\ 94\''6=)\$)/X0^,G[/Q_:'7QMHWQ ATSQ_JAM=*OG_9=^+:^&]?\'MX
MSTN_.F:0VH3Z4FN6+-YYX9_X*D?!O7=)\9^+]9^$?[0GPY^&'@CQM\2/@_J'
MQ>^)WAOX:>#?AOJ7Q_\ AO\ M.-^R?<_ ;1=7OOBQ)J5UXT\2_$K9J.@^+KG
M1[/X):?X/BUO4_''Q9\':KX*\?:%X52=TI*[BX\RE;1QO22:>S3=:DHZWFZD
M5!3;LAM*3@VE-/E<;^]>U1M6WNE2JMZ>ZH2<G%*[_2^BOD_]EO\ ;*^#W[6Q
M^+UC\-I[^R\3_ KX@VWPY^)OA/5=8^'_ (CO=#U36/"NA>._"6L67B7X4>./
MB5\._$GAKQIX*\2Z+XAT+5/#7C75WLWGU'POXHM?#GCGPWXH\+:)^;'Q4_;T
M^,?Q1^!/Q/\ B3X>\+_%3]F^#X"?\%9_V3/V7)3H_P#PKCQOJ?Q/^&Z?MX?L
MY_L]_&+P7K-EX0U'XG^++S4?%6E>+?&FI76E^!-&\+:FVF:[X-\*>'/$?C*>
M#Q=#K"<K6TWC3FO.G4JT*,9J]DUS8B#LO>LI63<6A.22D]^5U8M+?GI4:U:4
M'V;C0FDVN52<>9J+YC]UZ*^ ](_X*%?#^]\/?%B?6O@S^T!X4^)7P:_:.^%W
M[+7B[X$:AX=^''B;XH?\+.^-MA\+==^$]U8ZC\-?BGX\^$2>!?&'A3XP^"_%
MK>.M8^*FC^'O"6B/K4?C^Z\)ZUX?U;2+;R;Q-_P4YL[\_LV1?"3X!?%/Q?J/
MQB_;A^,'[$/Q*\-:Q>_"70O%7P?^)7P'^'_QQ\>>-O#EY'>_%RT\&^*/$/B&
M#X)ZB_@[4_#'CC6/ 1\,W6H:WK'BRU\3VGA[P!XMN*<FE%-N7):VUJG+RN_\
MOOQ<G]GF2DHOW0G)0C*4G91YT_6G?FCO\7NOE6G-9N#DM7^JM%?F1_P6(^,7
MQ?\ V?/^">/QZ^-/P&^).N?";XK> I?A7<>%O&N@:-X&\1W6G_\ "1_&?X=^
M#-;@ET'XD^$?'7@W4[?4/#OB/5[%DU;PU?M:27$=_I[V>I6MI>0?8?[0/QI\
M-_LJ_L[?%KX_^-M+\:^,/!/P"^%OB_XI^.;?PNGA_4O&MUX+^'/AR_\ %'B[
M5;"V\1:[X1T;4]2L/#^DZCJCV)U>QN-0-L]KID%Q?36UG+-_=E)Z*$XP=^\J
M:J)^EG9^?EJK<6E!])J;7_<.<8-/YR5O*_6R?NE%?#WQ9_;X^$OP:\1?'CPS
MXK\'_%2[O/V??V05_;;\57.@Z'X4U*S\0?!6.^\::?J*^#A+XUL[Z]\8Z/<>
M ?$7V[P]KMEX=CFCAM7TK4=2%W%7.^#?^"D'P1UOQ%\1M&^(/A+XM_L_Z1\/
M_P!EVP_;0MO''QM\/>%-$\(^.?V9A:W<WC'XG>&9?!_CCQQK^AP_"^[MX--^
M(7A+XH>'_AUX\TV75-'U31_"VN^&]3MM<9NZYKJW*I.5]+<CKJ=[O>+PV(NE
M=_N:K46H-N4T^6SOSJ#C:_O*I['D:\I?6*%F[)^VIZKF5OT#HK\:KS]M#Q5H
M_P#P4,\.WGQ1D^./[/?[,>@?\$N?VG_VG/'?@7XV:)\,]*\(:>/AG\:?V8&3
MXP(?AYJWC7QA!XB\+^ ?$OCG3/%_A+QOKMOKG@ZRFLQ;^!]$O-?OI]7[?Q'_
M ,%B_P!E?PIIW[2T^KZ+\2KG7?V8/V;&_:W\4^$/"5Q\&/B/K?C7X$Z?JMYH
M/BOQ3X!U'X;?&7Q?X-_M3P'KMF-,\:^#?'WBOP%XRT07^CZN="N?#VLZ7J]V
MD]&VG&WM.9.R<53J3I2<M6E:4&[-W2OS).,K/=I)\U^3E<;M2]I"%2/+HKW5
M2*35TVURM\T;_J]17Y]W_P#P4%T>PU+Q#X7'[+W[55Q\1M$\)?%GXH:?\(SX
M?^"FE_%7QE\%?A/JGA/1I?C-X,\%>(/CKH^IZQX3\;ZGXQTO3?!WA:9;'XO6
MNKI)H?C[X9^!==N]'TS5.4T[_@H?)I_Q$_;ST3Q[\!?BIHW@?]C'XG_"_P"$
M&EZOX4L_!_C[Q)\5?&GQ/^'_ ,$_%_@[2]#\,^%_'>H:]8ZG\1]2^/O@RR\&
M+J^AZ7X.\,^&K.Y\4?%SQ_\ #^[EU[PWX,:3;22;NF]-=%*G![-Z^TJPIVW]
MHW3:C.,XQERBDG?1RC'T<HU)J][67)2G.[M[B4]82C)_I?17YVZY_P %*_@Y
MX5T/6M3\5?#?XY:+K7A+]L_X7?L*^.?!%OX9\$>+_%G@KXR_&33?AAX@^'^I
M:JGP_P#B+XN\/ZSX'UGPM\9/AWXC?4O!?B#Q3XBLH=>?PY=^%8O'.E:OX5L-
M_P +?\%!OAAKG@3Q[XA\2?#?XR?#+XC_  [_ &CM!_9*UG]G?QUI?PZF^-&H
M_M ^,_#OP_\ &WP_\!^&!X%^)OC;X4^)8O'/P]^*/@?XD:=XQTGXJ7'@/PU\
M/=2UCQ?\1?$_@K1?!'CZZ\+RIQ=K-.]K6UYK^RMRVOS/]]2TC=VG%M6NU7?I
M:][V5K>TOS7:Y?X535V7N2UVO]YT5^:7["OQD^*WQ3_:$_X*7Z!\2;WXBV>D
M_"?]J/X7^$/AO\/OB8GP]37/A=X3\0_L??L[?$V^\*6S_"^]U?PC>Z/=>+?'
M7B+Q+HNIP^(?$FKWFC:YIR:_KEWK%O=QP?I;56TB_P":$9KR4U)I;+7W>UM=
M--28R4G-)/W*DZ;OU=-Q3:\GS*U]=/0****"@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^#O'7[/?Q@\0?
M\%$?@)^U5I"?#;_A5/PI_9J^/OP&UNPU'QAXHM/B%J&H?''QY\!_'/\ PD>E
M:!;?#K4?#;V?A=O@=%I0T^\\9VDVM+XIDOS=:4=#2QUG[QKY2^-O[7'PW^%#
M_&/P;H6J>&O'7QU^$/[//BK]HV\^"P\6VGA[6[SPAH5EK]QH4.J:B-/UR?PX
MWC>Z\+>);/PY=S:%J(GC\/:[J#6OV+3996B<H0M5F[>Q56K?5V5.A7=27*M9
M*%&5:32O9+FW44Z2<DZ:_P"7SIT7JE=SKT/9QYGI%RK0HQ3;5W[MTFVO*OVM
MOV>?C]\9/C3\ /$O@'4?A'XE^"OA;PA\:_"7Q5^$_P 9M8\;6?ARQ\:?$ _#
ME_A9^T;H7@_PIX<US1?C-XT^!Z>%O&>G:#\*O'NK_#S0[Z'XB:GKNA_$WP1X
MNTK1M>LO@S]GS]@K_@HS^R;9_LK>(?@+X\_8[3Q?IW[!7[*?["7[6W@[XI3_
M !D\8_#V";]CRV\=:7\)?VC/@AX@\->$O /C'QIKQTSXF^-4\4?!?Q;:_"/0
M-=M;S3-+B^)NEZAI<?BJ7]@_V=?CEH7[07P?^%OQ,L5T?1->\??"/X3?%3Q!
M\/[+Q-9^)=5\ K\6/ ^E>-M)T35[F&TTJ]D1;?4)[?3=5OM"T3^WK>QEU&VT
MZVC9[>'U#0_%_A/Q/=^(-/\ #7BCP[XAO_">KOH'BJRT/6]-U:[\-:[%#'<2
M:)X@MK"YN)M&U>.WFBG?3=12VO$AECE:$(ZL;=+V522E%*I3J55*_O-24ZE.
MK!OF:<+J<-%I%14*D5&#6:J*K2C*,FZ=2%.<+>ZG>$)4YI-)J7*X32?VFW*G
M)RFG^+_QK_X)S?M1>(OVLOBC^V5\&_B7\,/#?QX\-_#G]CGPS^S+\0O&?B#Q
M+<3ZY>_ 76/CC:_'OP3^TGX3\,_"[3])OO@_^TYX"^.NI:-XDT#P)JCZCX8\
M8^ O 7Q&\+/HWBK0/"][X.]2^._[&O[27QHU?_@HUK<47P/\-7'[:_\ P3D^
M&7[''A&UD^)?CW6(?!/Q!\'6O[7,>K^)O$<Z_!;2GU#P=)-^U=,--FTR!=;N
MHOA[$USI&GOXQ=?"GZI:KXJ\+Z%*(=;\2:#H\QN-"M!#JNL:?I\IN_%&HW&C
M^&K81W=Q"YN/$6K6EUI>A0@>9JVHVUQ96"W%S#)$K-=\7^$_"UQH-KXF\3^'
M?#MUXIUFW\.>&+;7=:TW2+CQ'XAO$DDM-!T&'4+FWDU?6;J.*5[?2]/6XOIT
MBD:*!E1B,W"$H\CUC^]BE?9XBG5IU8QL[1YXUI>XDDGR2C%.*E+3F:E&>G-%
MT9IV5W]7G"=*4NL^25->]*]TYQE)QE:/Y=>#/V,_VD/@U\3OC!\2OA3J?P4U
M=OVJ/V8/@/\ "SXR>&O'_BCQQ'IOPI^-_P"SYX \2?#'P[\3_AM=:1\.KQ_B
MQX#\8^#?$^F:?XJ^'/BBT^$>I6=]\-M+U32O&3#Q]J]AX2V]0_X)IZ-HGA[_
M ()T>"/AIX]O-)\+?L6?#-OV6_B+/X@M[>_U#XZ?L<ZC\)O"FA^-?A!XBTR'
M3WT6^N?B5\4_@;^SMK?BN6\2UTZ#PAI'Q!T_38UO-<M(&^H;_P#:3U#3_P!M
MWPE^Q_-X @;3/&'[+/Q(_:2L/BBGB\FXANOAM\6/A/\ ##4? <_@,^&1A+Q/
MBOI^OP>*AXP"Q_V=+I0\/S-</?V?HG@SXHWUK\(_#7Q!_: 7X6?!KQ!>10VO
MC#3-&^+]MX[^''AKQ'<ZQ-HUOH.D_%?Q#X1^%J>)I);T6]BD]QX-\-W$FL2R
MZ5#I\LL"37&K?/+VSY.:4^=2M&[<<1C&HI.]XPQ&)Q5H6WJ1NY15)+-4U3A&
MBN90C35-1YF[0>'PL4W+>\J&%PR<KI_NV_=DZC?P9\*O^">_C#X*_L-_M/\
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MA^.?''P#^+^H_M[_  \_:J\-1?#:^\!>!/V-_CU^STV@:[XQ\4:%XOU7QO\
M%KXI_ SXF:1J8@L/AUXDT6Q\*Z6?@A!H>I7IU6\U=O\ A+)M5M=%E_X1U-,U
M_P#-^V_X)G?MEVG[.7[*G[,]YXW_ &<_%_PW^%?_  32\;_L2>-O#'BWQ!\2
MKKPC\.OCW_PAWAGP=X$_;"^&/ABT^&\=I\7_ !/<^'?#]UX2?PSX]F^%?B'X
M-Z/XA\0:A\,?B5J8\3>/= \;_O/H_BWPKXBN;JR\/^)O#^NWECI^B:M?6FCZ
MSIVIW5GI7B6WGN_#NIW5O97,\MOI^OVEK=76B7LJ);:M;VT\]A+/%%(Z\/\
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M=8L/A)H^E^#+N_\ "?@L> +S4/A[X5\0^'_ACXE\,Z)HGB/P3INJ?#31M?\
M"_@_6M)T;5/"\&IZ9<VE?2U%6Y2DI\SO*I5G4E)6C9SJUJKLE?[5:2L^:*U<
M>7F:997@TK*$(P2>ND84X?=:G%Z6;LD[V3/@3_@F/^S+\4_V.?V,_AC^SC\8
M-0\ :SXQ^'NL?%&[GUWX;:WXCUGPSJUGX_\ BWX[^)MF\/\ PE'A/PCJME<Z
M=;^,X]&N;=[.[BFETUKV*Z5+E;6W^:_A5_P3B^)O@SX-?!/]C;Q)XG\!:K^S
M'^S-^U[X4_:0^%7Q%M-;\13_ !M\1^ _A7\=]2_:;^"OPC\6^"+GP/9^#O#V
ML^!?B))X2\">)OB7I/Q#\2+\0_AOX%O-07P-X-\1_$.X@\%?L?14V79-<M*+
MBUS1:H2I3HMIMW=.5"G).^K3YE)2:"W9M.]62:=FG6C5C52MTG&M4C;HI>[9
MI,_%#QS_ ,$_/VD_%'P)_;&^&%GJ'P.BU[]H3_@I5\(_VT_!5W<^._'L6D:5
M\//AI\:/V8_BQ=>%/%-Q%\([F]MO&FKP_LZ2:) -(T_5M#M)?&27LFI3IX=-
MMKOJ7PH_99_;=^ 7[2GQPT[X4_%#]GV3]BG]HKX_:E^U'XBN/&6E?$/4/VGO
MA%XU\=VWAZY^-?PD^'=AI\=K\*_%_@#XC>)_#M]XB\)^/_$6J^&?$_PHF\>^
M)8)O!GQ*_LC09Z_5VBJ3:4$G=4XJ"3U3C&G2IJ,_YDE0I2UM[\.;:4X3))3<
MI2UE)RDWLU*52I4E*-OA;=6I%V^Q+E^S"4?R&_9I\+_![X_?MX_&?]K[]G7X
MP:1\5?V;=3\'?#37]3M/!EQI_BCX2ZO^W/HWA_X@_ ;Q1\6O!WC?3]2N%/Q(
M\(?LJV'A'X+_ !/\.V$0\/KI6M^#'O\ [3XPT;4$T7Z$_;T_9Q^.?QMT/X!_
M$G]EKQM\._!7[2W[*/QWMOCO\)8_C#8:[>_"/QX=2^%WQ.^"'Q!^%WQ(N?"]
MKJ?B;PYX<\;_  S^+WBVTA\8>&-$UOQ#X7UVTT;4]-TRY"W"'[UHJ.7W:<=O
M9.$H[.TXSE4O&Z:454G-0@U)1IM4WS*[']JHWK[1R4EM>+BJ=GRN/O.$8.<D
MXN51.IH[(_)OXD_LR_MT_%SQ1^SOXL^)OBW]F;QQIUIX2^/6B_'KX,WM[\4-
M+^!WP\\<?$Q/AA#\&_BY\)?#'_"-:UJG[1&O?LZZ7X*\6:99^'?C+JGPGB\=
M>(/B?XT^(7A7Q/\  V[D\)>%O!/+_L-?L.?M*?L[^._V,/$/Q/G^!]QH_P"S
MM_P2X^'O[!7CD>!/B%X^\1:KJGCKX=Z_X(O;3QSX4@\0_![P7:WWA/6=-\!V
MS7-KK%WH>LZ=?:[<0Q07]OHD=SKG[&44TDI.223;F^K^.%2G)*\GIRU9I)W:
MYM'9))-<T5&3;BN1V;ZPE"49:):WA%NUDVK\MVV_R@_8-_9I_;\_90T;P?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQR\6?LO?#/P;\&O@Y^T-X@U#2/#?B34?VA/#7[4^FZ5\4UTOXAO<^-OAA9^
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M3?V=G\'_ /@XPN?B%\*?#=G\+]8ALOAE\"/^'H_B7XIP?$SP'I]OX=%KX/\
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MMKO6V"YF[ZRK3OLG(HHHI&H4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<EI=K#.C1C\ O%NG?MD?'3_@G!\3/VOO'/P>\0>+_P!J?5?&O[&MI\4/@7\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-<]5U6WS2<I2L[1DY.;U6JM'VDU%*UE*TN?DIN!1113&%%%% !1110 4444
M%%%>4_&?X'?"7]H?P+=_#/XV> ]"^)'@*_U#2]6O/"_B.&:?2[C4=%NTO]*O
M)(X)K>0S6-Y&EQ 1( )%!(8<4 >K45^=7_#I+_@FW_T9[\(/_!7J7_RTH_X=
M)?\ !-O_ *,]^$'_ (*]2_\ EI0!^BM%?G5_PZ2_X)M_]&>_"#_P5ZE_\M*/
M^'27_!-O_HSWX0?^"O4O_EI0!^BM%?G5_P .DO\ @FW_ -&>_"#_ ,%>I?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **/\ /^?_ *WXT47 **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#\.OC)\$/@M\3_ /@NU\%[?XE_"#X7
M_$2WOO\ @E-^TAKEY;^.O 'A3Q=!=ZYX?_:M_98\/Z%K-S#X@TG4(IM6T70/
M$WB70])U*1&O=/T?Q!K>EVD\5CJM]!/XM#\6OBA_P3__ &VO^"AW[./[-VB6
MWQ+^ WA_]@_X5_M__"[X,_%#XP>'_AS\#OV5OB?K_P 5_B)\(OB;X$\.?$OQ
M_>QZ-\#_ -GC7_#'@N/]H+4_AS=Z]8> _A[!X9\:CX1>&O".G^)+JPN/U/\
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M/E2:;3=TK:M:.3M>36C;NDM4;]9?XI6[-7T<4]5'^6+UBM'?0****8!1110
M4444 %%%% !1110 4444 %%%% !117A'QY_:;^ W[,&AZ#XD^/GQ+T'X9:'X
MGUF3P_H&I:^FI/!J>LQ6%SJDEA --L;^03)86ES<DRI''Y<3 .7*J0#W>BOS
MJ_X>U_\ !.3_ *.P^''_ 'Y\4?\ S/4?\/:_^"<G_1V'PX_[\^*/_F>H _16
MBOSJ_P"'M?\ P3D_Z.P^''_?GQ1_\SU'_#VO_@G)_P!'8?#C_OSXH_\ F>H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ex-19_001.jpg
<TEXT>
begin 644 ex-19_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2* X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;'5M"T=OA?X0NK?\)?\ @GS\6I?^"4'_  6J_;7_ &*/VWOBKX]\:? [Q/\
M"3XC^*?@1\7_ (_^//'?Q+7PQ\)_!OAS7OV@/#UPNI^,=4O=,ATKQ5\![#Q]
MX3^+6O:7I*OXB^+?P8TSPGI5HPN9+,@']TM%?!7_  3?_9^N?@-^S%X:G\3^
M'?$/A3XH_&C6/$OQ\^*/A/Q7XCU_Q3K'PT\0?%_Q#JGCW2_@+9ZAX@UO7GLO
M"G[.?AGQ!H_P/\)Z1HUS:Z$FF>!CK<=B-9U[6]0U#[UH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT=AJ7CWQ1\,=0^'OQ)EU_P 8^ +J-?B5';VOB?7/#/BFU\3&;3/$6C?T-T4
M?FW^RC\&_P#@HCX*\&:]\2/VR/VAOA+^T!^TO%\/;KP5\._AQ\+M)\4?!3]E
MOPM-)<VFHZEKWBBXM-(UWQ5\1?'OCO5-$\,R:[\0]<\!6]E\/="TFY\,_!?X
M<>!8/%_Q3U'XD_"'_!!W_@DQ^T;_ ,$EM!^/'P\^*_Q#^"7Q:\'_ !BU+P;X
MNL/$WP\N?'FC>)O#OB7P?I-QX=;1KSPSXD\+_P!DZOH6N:9?'4$UBW\3Z7J&
M@7^E_86T?Q%;Z\+WPW_0G10 5\D?MT?"GXO_ !\_94^._P"S_P#!F#X;0^(_
MCW\(?BA\%[[Q-\3O$_B?0-$\$:3\3O FO^"[GQ=::9X5\$^+[[QAJ.BC6OMD
M'A>:\\(6VH>5MD\3V6-LGUO10!^ G_!#?_@E]^U#_P $H? _Q:^#7Q+\8? /
MXN?#_P"+'Q(M_BB?&7@;7?B)X>\9>$]8MO ND^#IM&_X1#7_  '=Z'XJTS4A
MX9T&>*]_X2_PG=:(9=8E>V\0^;96MMN?\%W?^"7?[0/_  5A^#?P;^!'PD\?
M?!SX6>&OA]\2KSXL>(/%WQ&G\:ZCKNHZXO@;QC\/]+\.:-X<\,^&[FPBTI=.
M\;ZIJ^H:W>^(#=R7MI8:=;Z-%!]HOY?W?HH \;^%'AGXBV'P*\&>"OB/-X:\
M,?$C3/A_9>#]>U+X7:UJ?B'P[8:MIFE'0;?Q%X2U'Q=X9T#4B)X;>UUVVT[6
M] F_L:^G;1IKSQ%;V UK4_Y*O@I_P;A?M_\ @#]AC]N#]AGQ)^W-\!1\-/VA
MO'/AKXJ>$[?0_A'X@U_Q%\2/BAX&\2>"_$&C>(_C/\3O%4<?BWP#X9\5-\.O
M#$_BWP9X,T_XF:QI_BI8/%.B?$.2PM_'7A+XM?V<T4 ?SHV'_!$3Q[\8/^"+
M'@;_ ()A_M5_%_X6_P#"T/A3?V_B3X+?%GX,^"?%MQX9^%GB/PSK.L7_ (/E
MU>#QKXEL]3^*UQ>:;XE\9^&/&VN0:+\)X-2\'>-KO1-"\*:%XAT"W\<ZU\C_
M +1'_!$'_@J'^V+_ ,$]?V5/V#_CS^U3^Q]X;\._LG>-? .E>$+_ .'G@?XI
MZY+XN^&?PZ^$GQ$^%/A/QKX\\1>(K+1=4U'XE^%_"_B+0/"6C^"?#>D>$?"F
MJ6MYXV\;>,_'/B?Q#-X3TGP]_7-10!_,5_P5/_X(K_M@?\%"/V3/V+_V4K#X
M[_LWZ;+^R_X;EA\6?&+4O"'Q+\&/X_UZ/P=+\-]&LM"^$5CJ'Q+A\)Z7IGA*
MVT[4-7UJ\^+'B&X\2^)KB];3_#?@W2;6"SN^P_X+._\ !(_]KK_@K+\$?V6/
MA78^-_V;_@KJGP:LO$^N_$+6;K7_ (G^--/UCQKXE\-V_@Y]+\%V47P]\/W,
M/A6RTZR.MKJNNW)UBYO=370SI4$&AMKWB+^D6B@#^:G]O3_@DI^VG^V9_P %
M#/V(?V\['QA^R[X);]CVR_9XU>[^%MWXK^+&J#XC>,/A9\6O^%V>-K*W\:0_
M"V ^#_#6M:Y=3^"/"U])X5\4ZI8:3I\7C;5K&[O-7?P/HGR%_P %C/'G[=/Q
M._X*@^'O@U^S5^S5^S-_P4]^%GP<_91T?Q'XU_8>^,'@?2OBU\*_@/\ %3XA
M>,+B:/XX?&;PWXH\3?#WP=:?'#Q'X/LM)\/_  "O_$?BO6-:TWX1ZM\6)/"O
MPX\.1^,?$/C3Q+_8G7PS\7_^"=?[,WQ>^-\_[3?]G?$WX1_M(7_A&Q\ Z]\;
MOV=_C7\5_@-XW\9>"M,E2;3O#7Q'B^&?B[P_X7^*.G:<8+--*;XD^&_%=YHL
M.F:1#HMWI\6D::MJ ?BA_P $Q?\ @H[^VQ\.?VKO@3_P39_;6_X);_##]A3P
M_P#''P;\5M>_9PNOV<_"T'P_^%>G3?"/PQ>^._&FEMX+T3Q%X]\#/I(TF)+?
M5=1\,^,=,U7PMXEUSP39:UX2NK/X@:;JNG?TW^,;KQC9>&]3NOA_H/AGQ-XO
MB6V.CZ'XQ\6:IX&\-W[O>6Z7BZGXJT7P7\1-3TE8-/:[NK9[7P;K1N[R"WL)
M4LX+J74;/YT^"W[%?P*^!WQ!U+XQ:-;_ !%^(/QKU;PDO@*[^,WQV^,/Q2^.
M_P 1['P.VIP:U>>#/!^M?%7Q;XIMOAEX.UC6K33]:\1^$/A=I_@KPOXFUO2M
M)UOQ#H^IZOI=C?0?6- '\Q'_  2+_P"".'[9_P#P33_:N^/7Q_\ &'Q#_9B^
M,/AK]IJW?3_'OA_PQK/Q4\"ZSX&DU#XH3>/KOQ'X2FU7X>^+K/Q4NDV>M>)-
M/M/!NKS>%QK=Q+H\EQXWT..SNC>?TF>._ _A/XG>!_&7PV\>Z'9^)_ OQ"\*
M>(O _C3PUJ/F_P!G^(?"?BS2+S0?$>AWWD2PS_8]6T?4+RPN?)FBE\BX?RY8
MWVN.KHH _E)\._\ !"O]LKX,_L3?M2_\$KO@A\>/V?-6_9 _:9^..G?$G2OV
MB?BG!\1%_:4^#?@&]N_AQ/XL^'EQ\%O"_A<_#'XS:U=6?PQT&PL_'1^,OP;@
MN+C4?%NJR>$--77-"TKP9[K^WS_P0V\3_&/_ ()E?LL?\$P/V//&/PY^&_PR
M^ /CO2?B#KOQ(^,FI>*M2\4>)];TK1OB-_;MW_PC?@_PG<:;<:]\4?'WQ7\5
M?$GQ?KL>M:!I7A_5(9-#\/>#[G2]>BE\+?T@T4 ?S*?\%$?^"./[7_[=O_!.
MC]A3]A:V\>_LV?#C5OV5]-^'C^.OB1/X@^*'B6P\8:[\*O@QXH^ ^AGPEX:C
M^'.BW&DZ1XKT#Q%+XYU=-9U>^O?#&L-%X+LI?$UC82>,]7ZO_@IA_P $.O&_
M_!1O]E3]DC3Y_B7X#^!G[;/[(W@JU\&^'O'?A:Y\7^(?A1XQTB+3O#VGZCHU
MYK<>D>$?B-X9%QJ_@OPQX^\%>);33-;U3X7:S/XF\/6FG^,8]9F\5-_2!10!
M^7W["_P<_P""C/PTT2+QO_P4N_;*^%'Q9U7P-X(O?#^D>$?@7X!M?AU\-"L7
MV6[UOXR_&GX@:YI7AO6_'_CJ/2=-;3]'TO0/"7PB^%/@ZQU'Q;K>K>$/&WB'
M4/"&M_#C\]OV[OV.OV/?^"J'[<7_  2(_:.^%GQ-^&_QATO0/&'Q<\8^.=>^
M&&K>&/B3X'^,7[,/[,NIZ7XPN8;_ ,7:-J>J>&]:T/X=?M7ZQ\,/@[K/ANVF
MGE>S_:/^(T=]&UQH<MK%_19XJ\+^'?''ACQ)X*\7Z-8>(O"?B_0=8\+^*/#^
MJVZ7>EZ[X=\0:?<:3K>C:E:R QW-AJ>FW=S97ENX*36\\D;##&OBS]B/_@FK
M^R'_ ,$\M)\3Z-^RWX!\1>%+/Q01:S-XM^)OQ)^*-SH/AV+6];\26O@SP=<?
M$CQ3XGD\'^$8=?\ $>MZY>:1X=.GCQ%KNH3>(/%<^OZ\L>I( ?>-%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%?SF_M[>.OB3H?_  7I_P""-?PI\/?%KXS^&/A3
M\:?"'[5M[\6_A7X2^-'Q6\)?#'XDWGPT^$7BSQ-X&N?&GP[\->,=*\&>()]
MURUM+U9=1T2=]46UM;'6SJ>FVUO9QI.]2C3ZUJGLT^D7[.M4NUNU:C)::WDN
MB8I/EA4G_P ^X.;75VG3A9/9.]1.[TLGU:/Z,J*_GD_:(_X+SW'[/6M_M\2:
MI^R+>>(_A_\ \$YOV@_V9_A+\=_&5G\=-.L-2U[P)^TSJZZ5H'COX7^$I?A?
M=3^(/&GAC[=HMWK?PV\3:OX,\/W,-UJ::?\ %>6;3+9-6^D?%7[:O[4!_P""
MV/A'_@G_ .$O GPHF^".F?L&ZK^U9XEU35OB3X@T7Q1XBT[Q%^T'\./A"_BI
MXK?X+^*!:^+?A>VE>/-/\*?"2QUNP\*_$33?&<?BSQ5\7?"NJ:1I7A'34I<R
MIN*NJK2@[I73H/$\SO9I>P7/JKM.R5TQOW>>^G(G?1ZM5H4'&+2:<E5FHM)Z
M=]5?]BJ*_%']E+_@KEXW_:BB\2>.+?\ 8WU[P-^SQ\$?CC^US\$_VN/VB-3^
M.?@F]\'_  !G_9=\!1^,K+Q;H_A"\\.>'OB7\8="^(5ZPT2X?PGX1T^'P,M]
MI-[?7NN7J>*=%\)V/V>?^"SWPW^+OB/]D:+XE?"C4?@;X$_;X^#?[1?QT_94
M\5ZMXW@\8:UJ?@S]F<S>)/'.F_&GPOI?A/2].^%GBZ[^$DEC\3]*T_PSXO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDHR;;T2BVVDFSZ[HKY#\1?MR?L_>%9?"UKKMW\4])OO&/[0WP]_9=T/3]?\
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M_5;+0M"TR.>ZEBB?4-;UO4M.T;2+)6-SJ6JW]EIUG%-=W4$,AY :%% .>E%
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MPAXRO_"VL:S\(_!7C?QS\1]#\6>)9-"M]&^'7BOPA8?#SQ9HFM> _'=YX?\
M']GXMT76/#4WA9-3\.^*(M#^P:/\VNF\>6ZNFUISPOJ])1:;4HMG6W71VU3U
MO:Z:37PRW2=XR32<6D4449'K_G_)% !1110 4449'K0 45GZEJVE:-;QW>L:
MGI^E6LU_I6E0W.I7EM8V\NJ:]JEGH>AZ;'-=211O?ZSK6H6&CZ59JQN-1U2^
ML]/LXYKNYAA?D?#7Q"L?$_C3XD>![?PUX^TF\^&=]X8L-0U_Q+X&\1>'O!?B
MM_%/AJT\3VUU\-_&&IV4&A?$&PTBWO%TCQ/>>&+R_A\-^);>\\/:LUMJ=M)
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M"_A^^TS^@SQC\'_A+\0]/\*:3\0/A=\.O'.E> ];TCQ-X'TSQCX)\->)M/\
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M$T-O<1QRR*T?Q8_9X^ 'QZD\&S?'/X&_![XT2_#K7T\5?#Z7XL?#/P5\19/
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MD^!=/T6?0M-D^*_C<^)^0^-GQL\;?&S]H3]N#X4K_P %!] _88^(?[+'C_\
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MA[XY^$:>'_#?P%^%>AZ(GPH^)^HMK'Q+^&":5IGA2UL%^'GQ#U=WU7QSX+$
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MK22>E2=1PQ%3E:]Z+Y6Y/F?Y=?LY_'+PE^T)XUU+Q9XY_;!\=?"W]IGX+_\
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M;PI=SZ8N@>#?$WQ,]N_:.^.GCKX.ZA\+M*\&_#CP_P")8/B'KWB+1=9^('Q
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M27P+XFN+S6?BG\1?!7Q!T7P7XND\+:9X?T_P=X4G^(GBJVTK^U?#7@_Q#O\
M[2_[#_Q)^->K_LX_&#X5_M4>)OV:OVK?V<?#GB_P/I?QI\#?#3PQXM\%>/\
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M6_C,W[-'Q"\7_#'P7!^TIX5^*GCE=(^+B>"O$2:'X=TB?X@?%#6/#O@N^O\
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M\'_\$Y/BS_P37\6>$;'P3)X7U#QU\*OC/:_":S\8^-(_$]OXTU*?PKXT%O\
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M\(_A-/\ !72/!FAZ_-:?#30/A;XP^+\QUWP5I6L3R>/?%Y^TM _:_P#C=?\
MB_X0?"/Q1\ ?AUX-^-7[0EA\7/BC\*?"]O\ 'O5O&7AK3/V:?A)X9^$5UK/Q
M+^*OBFQ^"NBKX:^)J>//C?X!^'E_\'/!5A\1M 2]OK_Q#X=^,_BGPWI5[J"?
M17[3'P,O?VEOV6_CG^S9K/C"W\+R?'SX*>/_ ()^*?&VD^&I+T:1I/Q/\'ZG
MX'\6:YX>\-7OB("'4H='UO5+CPY!J6O:G::9J9L+C5$\06MI<6%_Y/XX_9 U
MCQ-XA_9.^+>@_%2V\,_M$?LF>&_&'@?P]X]D\#7>J_#SX@> /BEX9\*^&_BQ
MX'\??"JV\>:)J%SH/B>Y\"> O'/A^71?B-I&M>#_ (A> _"FIPZMJ_A3_A*O
M!?BL37+&,N9\DH4[KXG3MBY2G>UFXU:M!6;YE0IJ$.;EU34^:3C9*:J3][95
M.;"1C!+I&5&GB'=>[[::E*R9Y5\,O^"CVB_%;1OA;X1T7X>0Z+^TKX]_:<^/
M7[(?BGX1:SXPN)?"7PS^+G[+FC>.O$WQRUG4/B1;^$(M2\5?#*U\*^!K?7OA
M5XBT?X?V>O\ Q'C^)?PC@\0^%/AC;Z_XWU+X;[VN?ML?$KP?#\)?A[\0OV==
M4\#?M+?%6Q_:1\16WPQL=6\>?&3P=8?#[]F[QWX0^'NJ?$RQ\8? ;X0_$?QE
MJ7A3Q[J?Q7^"NM>$(-=^%_@W6;+P[\0K@^,+/PWXC\-GPUK/!?$[_@EYHGB7
MX<>"3\)?CGXR^!/[4/PW_:A^*G[9?@W]J#P[X2\*>*;^'X[_ !T/CFP^+MMX
MC^&OB59M#\4?!_Q1X*^(6L?#"T^'%]KD6JZ9\/=!\"Z5/X[U75O#5SKFM7_C
M%_P3O^(_Q$T7]G?Q[X/_ &U?BY\/_P!M#]G/5OB)JFA_M977@3X;>+H?'.F?
M&NR\/:9\9OAS\0?@$VE^'OA7JGPG\4:;X/\  T'A?PEI%OH>K^ K[X<?#[Q-
MIWBS4?&&C:QXB\1PME>][PC/E2L[PI<U2GM91J>U512;]WEE2C+1+1[OE:M[
M[BY73MSU.6-2R:;</9N#BDK\RJ-:R?#Q_P#!4'Q9/9?L]>%=>_9QB^ O[0_[
M07PC\>>-O!?P'_:U^)VJ?L^2_$'XL?#[Q^/AKJG[.WP:^(.M?"G6=&\:?$+5
M=2$/C?PK;^*='\ >)_$GPP\5?##Q=9?#]+'Q=XVG^$GO>E_MP#Q)^V=X^_8\
M\.>'_AM%XP^%OBGPA!XN\,>-?B[)X)^-'B#X/^+O@UH7Q&3]HWX.?"K4/ =U
M;?%OX5:%X_\ $NG_  4\0W>B^,K$:-XJT/X@7NIZG9:AX5TOPGXMY'X\_P#!
M/WQ1^T5\"_$W[,_Q9_:#'Q6^#WQ/^$4_PY^+?_"Y?@SX0\??$2\\<:KK_C+7
M=9_: ^$/B;2]:\%>#_@[\7["?QG]H^&\T?PV\9>!?A+JO@GX:WW@CP58V/A.
M31]6[CXG?L5:C\:/C5\,/B)\3OB;HGB/P=\"?CSX9^/OP)TJ+X71V'QE^%NJ
MZ#\/](\(ZG\/]&^/G_"<W5[=_#/QWKNG:AXG^(>D7?@,^(O&&G^(-2\#ZOXJ
MG\+V^E6VG4OBBI?#SSYG&]N2\%&23UTO/EAM4A=\]"LJ:E+YK2Y4U[BY4W&Z
ME:3LVN_NIS=W3EHX5:7,UP?PE_X* ^)O&O[47PR_9M^(/P/L/AKJGQ>\)_M4
M^)M$L[?XJZ1XY^(/PTO/V:?'_P +]%TSPM\</"_AOP])X/\ "/B7XL_"[XM>
M%?B[I6D>'_B3XKU+P=:7=KX;UFPU.UU+3_%]Q[G\<_VF?%7P6_:'_9/^$$WP
MST#5?A[^U-XA^*/PTL?B[J?Q)OO#LO@WXT^#?A-XO^,7@/X>7/@N'X<^(+?6
M+7XH>%OAYX^^P>)7\::(=&O/"US8)H>N:KJ>A:;JGR9^SA_P2\\2?L^^.?V3
M?$[?M4^)_'NC?L@Q?M8^$/!&C:U\*O!VGZWXS^%G[4GBCPQX[U.U^)7C&VU6
MYU#Q)\9[#QAX1T6Y\9_&B.QL8/B7I:7\UU\//#/CS6]?^(6J_;/[6G[+WA#]
MKOX26WPG\7^(/%'@V/3?B9\(/BEH'C?P)?#1O'GA/Q%\)/B7X8^(-I=^$/$*
M#[5X<U/7K'0=2\%:AK%@5O(?#?BG7;>,2I=202FCA1W4EI63NKI^SC?[5G%5
M*L_=O[U!))J<8RK:57K'EO3>[YE[9VZ73=.C&TK+EK2U3C*4?FO]C_\ ;]\1
M?M:^ _@;XBTKX3_#[P]XQ\?_ !)_:7\&?%SP-I/QUU'QI%\(?#/[-'BK7O &
MO>-]"\3I\&/#MI\34\1>-+SX-KHVBRZ?X!%UX(^-7A_Q_HNK^(-&TN:&_P#E
M/PC^UK\4M$^&?[#$7[./P(^%OPGTS]HO_@J+^W)^SC\7_A]XB^,WC#Q';1^)
MOA;XT_X*#>,O&^J>&/B#)\(M7OK>Q^,/Q;_9R\0_$35]4D\&@^#M-U^+X:>'
MO#EQIVL#QKX*_2OX+?L@_#7X#_&_]I7XX> YM2L]2_:6UGX>:_K/@UC#'X#\
M":OX#^&/A+X5W=[\/_#EL(;+PW/X^T'P#X%G^(#Z7'9'Q3>>"_"LNJ&XET'3
MI8?F2U_X)Q>(M)^%WP(\&Z!^T*=&\;_L^?MX?&C]N;P;X^A^$NFWUA>ZY^T/
MXB_::U?XJ_#_ %KP7JOC:]M[C36T[]K?XN:5X%\06^NVUSX7FL_A_J>L:5XP
M?PYKMIXO4?XM)N[IJ%-U;KE;J*M3YHVC=NG:$JKBI2C:K*-Y>SA>*BDZ-10=
MJCG45/\ E5-T*EI7>JGSS5*,K1E^[C)J*J3M\I^%OVFOB%^R)\5_^"CWC*P^
M&5C\1_@;;?\ !7/]G'X9?$[Q-XP^.7BG3?&W@#3OVH/V:/\ @F+\*='NOA)X
M.O? ?Q(C\>6_A;XC_&3_ (3/Q5X2\2>./@YX<T+PE<S6?@#4=>U!I- T;]/_
M -N/]IK6?V//V:?&_P"T-HOPT3XNS^!]8^'=A=> U\:6W@*]U:R\=_$CPG\.
MY)])U^_T'7M+.JZ7-XL@U.TTS5DTC3=5%I)977B+0UE%]'\[?$[_ ()SZK\2
MO"?[6?A*;XXVFD6G[57[8_[/W[8NH7L7PL:\O/!7B/\ 9U_X9BC\)>#+ /\
M$6WM=9T35[;]D;X31>(-1NK>ROYI-1^(4U@EC_PD'AV/P9]*_MF_LU7G[77[
M.7C']GX?$#_A6P\9ZCX#U"^\96GA2'Q5=6)\">._#/Q!M4T[0[[7=)M ]_K'
MA73K2>2]O+V.'3)[Z%('NY+>]M9I)1H4(ROSQG24]6W[)2I.HKMV=H^VBK>]
M[S2D_<E%SYW4K.*5I0KRA>R7MG[54GHKI/\ <RE=-7C>R7,I?+/Q(_;T^/GP
MXF^(WPRE_98T7QO^U#\+?@[;?';7?@[\(_''Q\^+7A#7_"'CGQY\9?"/P)\,
M^&_BOX._9!N6TSQO\5;;X"?$:>_C^(?@3P1X?\%ZO'X:TZ+5O%VGZMKFL^$^
M@B_X*'-X@_:"^'_[._ACX9:1X/\ B7XX^''[.'Q=L/A-^TE\0KC]G_XX^)/A
MU\9];U!OBKJOPR\":AX(\6Z%\1/$W[+?@O1=<UGXK_#_ $7QI_PD<?BS2-3\
M&ZK_ ,(;:#PQXK\8Z?[0G[#'Q0^)7[07@O\ :E^ ?[87Q"_9/^-2_"?1?@%\
M;-1\%_#CX>_$WP-\9_@]H'BCQ'XY\.:<_P .?B[;^*?#O@[X@> ?&/C3QOK'
MPR^(\2^(KSP[;>,O$7A_Q)HWC?P[J=UIDM[XV?L'W/QZE\$^$?B#\5[;Q+\&
MOAQ\3_V:_C%\/])\4_#S_A)?CS\./B!^S7X@\&>*-+U[X:_M'7GCB'6/"NI?
M$;4O UE8?$7Q%<^"=<\:7WA[Q5\1=+T+Q3H-UXO.J:74?L<UE[[C4=GI&-XJ
MHFKW4HN%2S2YJL:D'&E"4)Q)77,XIOW.:&JUDUS<DDTFK24J=XM\E.4)J55P
ME"7S-XO_ ."K'Q:\!Z7\6?BGXE_9#T*/]F_]G/\ ;8N/V0?VA/B=I7[1;:IX
MV\(:1>^-?AWX%\/_ !Q\%?"I?@E;CQYX/T_5/B5H-_\ $[P_J?C?P-XC\$Z.
M\E]X9@^)%K9ZS<Z1[OJ__!0C7K[XF#P[\)/V<_B3\9/AYX?_ &I[?]EWXB^+
M_"'A;XQW.J^&[FT\0V'@+X@_%71WL/@EJOPFUCP-\&?B/<WNB?$C3]6^,?AK
MQ#%X5\.>-_&6BV]_>^'-!\'>.OEC]F3]EOQK\?O^&]OAU\6I?&W@;]G[QM_P
M5!\:_&C4OA]XW^ 7CSP!XO\ BOX5\':U\$O'?@\>"OB1XYN?#NBZK\#O'_BS
MX96-IXQ;3/AQXPU#Q+X>?QMX?T3X@^'H/$&B7GAOZH\+_P#!/OQS\-?VG/B5
M\5O@]^V'\6_AC^SC\</BK'^T!\9?V2=+\&_#C5]%U[XWSVV@P^+=>\"_&+6M
M&NOB/\,_ GQ6N?#&DZW\6/A]HTE_)K_B"\\5:AX5\4^![?Q3?V"$-52YN9<T
M*4Y2NG9NAA9S516NE*HL1&"@N>#J)22M#V=U%:5;V;349U815W:RJXB$'![-
MQBZ$I.3Y)J$K-^][3T'X??M9?%/XS7_A'QC\%O@!9?$/]GWQ%^T)\=OV?M;^
M(,7Q7T?P]XY\%)\!=?\ BM\+_$'QEUGP#K7AR'0M6^%^J?'7X0:WX"TZR\)?
M$#Q#\09/!OB?P/\ $ZT\)7\FH>(_ OA3'_X)F?M ?'+]IG]F"+XM?'G2_ EC
MXGU+XT_M0^%]/F\!:YJNIZ<^B_#;]J;XU_#+2=(;3=4\&>%I-,M/">C>#M)\
M+Z-J#WVO:GXMTO2X/%6O_P!B:WJE[HUMSWP,_8 \9_ +XV>/=;\&_M<_%C_A
MDOQ?\7?'O[0NE_L;2^$/AVGA_P *_&/XH>,=5^)/C=-+^,?]D2_$RS^#-]\4
M-=U;XH:=\'?#EQX7M;7QG.]KJOBC7?A]JGBOP#XG]Q_8X_9?U#]DCX;>*?A+
M'\3+GXA^"IOC#\:_B/\ #JUO/"6G>&=1\%^'/C1\8/'?QLU#PIKFI6FJ:K)X
MVUO2/%?Q'\0:8OB]8O#%E?>&=.\+V:>#M/UFPU_7O%$QYK)R23="%[7TK>TI
M.HNUK>V]G)73IN*E:=E&97N^6]E5G;:SIN$_9N[2DTG[/VB=FJEW&\;M_&_A
M+]OCXN^"[C_@HWXJ^-7@WP1K7A']GO\ ;G^'7[)WP"T#P+XQU1/$/B'Q9\9?
MAA^Q5I7P6^'NL)J_P\TVQL[3QC\5/VE+'5/&'Q)N]9OSX)D\2ZUI4'A36O"G
M@>Q\2ZY]<?"O]J;5]?\ VHOBA^Q]\6O VB> _B]X+^$G@3]H3P5>^$/&&I>.
MO!?Q-^"GC?Q+XF\ 7NL66IZKX+\#ZEX=\:?#WXC^$-3\-^-/"-]I=_9G0O$'
MPX\8Z)XDU!_%VN^%_ OB'CC_ ()KZ'\18?VX_"OB3XR^+;'X:_MD_%[X9?M'
M:3H_A+P]HVA^/?@=^T7\+O"7[/V@^&/BEX5^(E]=:[!XB_X1GQ%^S!\(O'?@
MOPKJW@ZST/3-<A\7Z?XQ7X@^'O$.FZ5X;^E/A=^SI>^'/C/XG_:4^*GBW0OB
M%\=_$_PC\#? MM>\(^![SX<^!_#_ ,./ _BCQEXZ-EX8\':QXW^)FNZ?K/B_
MQEXZU'4_&NIWOCW4[75;'PU\/]-L=)TI_#%Y?Z\4DU&"J7YE!*33OS/V$UK_
M -/%BE&4FK0="2Y;.\(U4LYS=.ZBY7BGNFJU-ONO92P[FHKXU6B[[J3^HJ**
M*L04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7RC?\ [8WPBTO]I_Q5^RKJ;>)](\:> _@=I/Q]\<>*
MM;\(^*](^&_ASP+XCU?Q5IGA_4+KX@7FB)X,73[A/ 'CV;5O$%UK]EH&CWV@
M1>''U&[\2WESI.E_5U?FO>>!_B_X+_X*E>-?CA:?!CQQXV^#WQ,_8#^%/PFL
M_B#X2UGX7QZ3X9^(WP1^-?[27Q'UGPIXJTGQ;\1/"GBR&^\7Z/\ %[P98>!+
MS0O#NOZ-J&KS:NOB#5/#.D:'JFL6TO?=)*G7DKIM.<:%65.-UJKU(PVUEI!:
MR5U*_+HFWST5I:_+*O3C4=GH[4Y2?]U>]M%V]3\'?\%&/V)/B+I5QK/P[_:)
M\#?$&TC;X606$/@5->\8ZMXGU'XU^'?$7B[X8Z#X%T'PYH^I:Y\0O%'BCPSX
M.\8ZXGA3P-IWB'Q)I.G>#_%MQKNE:6GAG7/L'JUK^U)\ ]4^&7@CXNZ!\2M'
M\4>!_B;JUWX;^'%WX.LM;\:>(/'GBW3(/$USKO@GP?X#\*Z9JWCSQ-X[\*6W
M@CQU=^-/ FC^'+OQ?X+M/ /CVY\5Z-HT'@CQ5+I'Y0?#?X/_ +5'P@_X)Z_\
M$@?A)>_LI^+=?\7_ +/,GP(^'O[4G@SP;JW[-&K?M _"'3?!G[,'Q)^$FL^-
M_@-XX\6_%*V^%_AZX\4?$;4O#_@+QW\4OAU\3[#XP:#^SA\4/BA<^ [GPEXT
MU"[\0>"O%?V?O@%^VA^S7<_L3?%V[_92^)OC[2/V??C[_P %=/AW\6_@SH/Q
M/^#_ (C^*4G@/]M_]J_4?CE\"_VG/AOJ?COXQ:+X8^(>C^&K'P]I7@3QRWC_
M ,?>$_C+#HGQ-\6>*].\)ZY8VVK-KU^[[25.\E&,N1U;+E;5M8*,I-J;G"*D
MKJ$FY-\D*CC*<G2C4:7.TG[+7F5^>_-)I)."@Y./Q2327O2@I?=GP _;HU?X
MJ_LT>"/BY\0/CK^S=\,]<\8_\% _B?\ LK>#?%$G@3Q3+X)^-WAGX>_MP>/_
M -G3P3X0^%_A&]^,I\1:;\4_CEX!\%:;)HGB*3Q9XYT3P?XHU^]\6WG@G6?"
MFDRZ+;_4^J?MW_L>Z/XWG^'%]^T+\./^$TLOC+HO[/6K:+9:N^J'P]\:/$FG
M^&+_ ,._#[Q3J&EV]YI7A36]>E\:^$]!T5O$=]I=CJOC3Q#I7@*PO+CQM=Q:
M ?RUC_9Q_:HU']D3PWX%F_9L\=:;X^TW_@N!=?M=7WA"?QO\!Y+N']GB3_@K
M+KG[9LWQ%BU6W^+S^'KBUM_A!J20KX7CU8^/;WQ7"^EV'A*YT^2WU>6]^T5^
MS-^TWXT^'7_!4C1O"W[//C/Q%K?Q^_X*,_L1?';X*V47B_X%6,OQ!^%7P/\
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M'ACP-JI\7:QI>L>*_A][A\!-;_:!_8D\+?'OQ#\4+']J3]I/]E_0M6^!FF_
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M;BITG+1J<_UU^,'[0GP@^ MBNH_%7Q:WARV_X1OQ;XTN19^'O%/BJ[TOP+X
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MM$\'ZDWPN^%_P&^%7C;P#XLN_'?Q+\*>)M!^(46H_"#5]9TII_"DG@C5]/\
M$.A3ZCXT\/6J>(KW0/3_ (T_LQ_';QQXA_X+)_#Z'X":IJMM_P %&_@U\,/
MWP*\9ZUJ?P_N?AQ8:M<_LIV_P \0CXNZAIGC"^\5>"[3X/>-+J3QMXE-OX<U
M2YUSPG')=?!%_B3XZ%QX4M6FDI25IM4YJ,&U%U)>S4DH\R_=3=6DX4Y5+QIJ
MJW4YXQ<I:))IJ3Y'SP]Y>\H1]M&+DU&_M8*C5YZD86E-45[/EE)1C]V:I^TG
MX[\._P#!0/5_V=O$FH_#;2?@/8_L1:C^TH^OW^E:IH_B_P /^+-%^,=EX!UN
M;Q+XTU'QFWA*3P);^')VU2.W3PEH=]IUVEY<ZAXAO+-88H>Z^'/[3'@&#]GG
MX(?%+QS\9O!?Q;F^*7@C2M<\.>//@C\-/'<.D_&IV\./XEU#Q5\(O@SI&L?%
M_P"),_AZ70+>Y\4-I]AJWC671O#L,VKZAJW]F1-=)\V^$_@?\7/AM_P4%\"?
M$"#P#XY\=?!OX>?\$SH/V?C\8Y=>^&GG>*OBOX>^+OA_Q/:^%I_#^I_$"Q\>
M/XF\1^&M$FUB3Q#=^%K?P$NI7:V%YXS@OWD@B^$/V?O@?^W!^QS\,_\ @C_\
M5+?]D_QS\:=6_9N_8/\ 'G["O[4W[.'@GXF? 6S^+_PUU3XAR?LS>)M.^+/P
MUO?%GQ7\/_ _XA:+;^-OV9=-\*>,;.'XS:)J$7A7Q=X<\5P07B^'O$%EH1))
M1:A-3M.=.,W"4>:/US,E2JR@WS14Z5+"*R7-&%:FZCY8QFI;?/#W&DZ-.I.*
ME?EJ?4\!*K2C+X6XUJF)U;LY4:BIWDY1?Z9WW[7UWK/[67[(_@;X8>)_AG\1
M_P!F3]IK]D?]J7]HFP\:^#M*UGQAXFU:\^!?BG]E:Q\(:KX$\8>&?%FH>'?$
M?@KQEX;_ &B=1N9-&T_P)J.O7&J>'=(FTCQ%+#J-SI ]]\$?M5_L^?$OP#\+
M?BE\/OB=HOC/X>?&WQ</ OPG\7^&[/6]7T3QYXHWZ^LFG^'[JSTN474%N/"O
MB:6\U5ECT>RM_#^LW-W?P6^FWDL/QKH_P=^,5O\ MC?\$^?B5#^SKI'PX^&'
MPJ_9'_;6^'/Q!TWX::M\,[3X>? OQ+\=O'?[('BOX5_#2WT:+Q/H>O>(_P"R
M]!^!GB[0O$/B/X<^!=0\)CQ#!8:E!!H^B:[$FF<[^RS^SMXH^'G[:G[2G@VU
MUK2-<_93^#_Q/U[]I/X$>'+66>\F^&/[1W[:'ARZUOXZ?#><CRH=%N_AO<3_
M !5^-.@Z9&T]O)X/_P""AT.EK8V%EX2\.S3U+D3A%67NUI2?,I24J=9.49/9
MMTI<M)I6;CIS)W(BY6J2;NU*C&*Y9*,E4HM*44]5:I'FJQ;NDW\,E8^TOVE/
MVK?AU^R_/\$;'QUIOC;5-4^/WQF\/?!+P!9^#_ WC/Q@DOB?5M*UKQ1J+ZK<
M>$O#OB#^S!IO@SPMXIU[3M.N(EU+Q/=:.VD:';SRF\NM.YBZ_P""@W[$MEX^
M\5_#&]_:?^#MIXU\ W7Q,M/'^F7'B^PAL? $OP:^'^D_%3XI/X[\0R,GAOP9
M:>!_A_K,'B;7[[Q-J^E65I9Z=XFA%P][X/\ %=KHOE/_  42^'7Q8\7R?L/^
M//A1\+?%/QBE_9]_;P^%_P 9_'G@KP1J_@'2?%\OP^7X3?'+X6:EJ^A'XE^-
M?A_X3OFT37_BCX;U'5[2\\5:;-#X=@UG5+=;IM.:VF^==6^#_P"U;I/P<_X+
M=V_@K]FKPYXK^(?[1WQB\=?$7]F/P+\<KOX-^+OA9\?]!U/]AO\ 9D^ %OHG
MB7PV/'GB'0QI6M>-/@YXTTR7P7\9H?!6BZ[I&H^'8_%#Z9H.M:Y)HV#E)+6-
M[.O>UU91A@_9=TU*=>JW*S;C2J)+W)*.JC>;3ERIQH<M]4Y2J8E5GIK>,*5*
MT797J0E=\RYOTF\(?M2_ #QKHOQ3\0:9\3=#T73O@;91ZM\:$^(%OJ_PKU3X
M3Z#/X6/CBT\4?$;0?B;IOA'7/!GA#4?!BS>*]*\7^(=.T_PQJWAZTO\ 6--U
M:ZL-/OI[?Y@^%W[;O_"=_MH_M.?!Z_\ $'@K2/@'\#?V4/V?_P!H$>(?%/@?
MQU\(_'W@G6OB1XZ_:.\.>/K+XKW'Q0UG2X+?PGI/A;X*>&O'_A?7'\"^!K9?
M#7C&XU&YO_$6CIIFMR?EG\1_V2_VTOBS8_\ !2#6/ 'P(^,6A^(OCS\(?^":
M?Q5^#K_M.?%KX/2ZU\8?'/[(?QI\5?%?XL? /XFW7P\^)OC/PY\+?$GQJLK2
M3P?'X<\*Z-8_L_>%M$\<+%.?!&C3W?@W3_6?C[\!OVN/VS?&_P"W7XL\'?LZ
M_$S]FUOVB/\ @F%^SU\&_A-J/Q]\1_ Y;<_'/X*_'_\ :R^)M]\*/B9I'P<^
M-WQ,UG3/#7C;3/BGX0T#6=:T=M9T=?"^K^*'GO(KJ+3=/UK5<J7,[WC"HY0L
MY-+DJ1YURV4W&4&X4XWG)JT8WK46\I\[Y(QZU*7OIJ*:4Z4I0UNXQE&HU*<D
MHJ*;;_=U4?L;H_[5?[/>L6GQ<NV^)^A^'#\!=.T[6_C-IWC^VUCX::]\-/#6
MMZ=J6J^'?&'B_P .?$/3?#'B#2/ _BJPT779_"'CBXTQ?"7B[_A'O$47AK6M
M4G\/ZS'8_.O[,W[7?B?X[?MH?ML? IKCPQ<_#/\ 9]^'7[(OBWP-"/AS\0_A
MM\5_#^O?'6'X_P GC7PM\7]%^(FKIJJZG;VGPO\ !WBCP>G_  @7P^F?P?XO
MT[5GLM=T[6=(UNX_/WXG_!+]HW]HKX"ZO\7?AU_P3>N_V8/VE/AY\3?V)OBM
MKGPO^+/QF^!?B+XE?M1S?LE?M8>#/VD?$_[/7AWXT>"?'WQ"\,Z/\'K.\\)Z
M^?A%XM^)FL^#+/QC\2/$<.M:GX#^&7@M;SQ=XF^S/V3-!^-VO?MT?M@?M(^/
M?V;?B;\"?AG\>?V<_P!B?P[X!E^)OB+X(WOBB7Q1\%]:_:BN/'/A_P 5>&OA
M9\6/B/>>']:M;#XO>#KNP=Y=2T>YL/M5K<:Y8Z]I]YX>M)5^9<W2-5.THN+?
ML(SA-6;;BY<T87<6IQG>+C.DG7->*MNY0WC)/E51QG'79V:E*U_<Y?>NJC7V
M3\8?VH/@%\ ?M#_&+XG:!X#M=,TO2/$'B;5-634I=$\ >$]?UNX\-Z-XY^*.
MO:=87NC?"GX>ZEKUEJ.DVOQ"^)%]X6\$R7VDZS!_;P?1M5%FGQ!_:@^ GPJ\
M1'PQ\0OB5HOA?4+:_P#!FEZ[>W]MJ\GACP3J7Q(UB+P[\-[+XD^-;/3KGP=\
M,+GXC^([BU\.?#V+XAZ[X9?QQXAO++0_"HU;5;VUM)OSK^)O@S]I[X4?MM?M
M0ZSIG['TO[:_[.'[=/P8^"'@>UE7QO\ !C0/#/P;\=?"S2/B'X(\3_#G]H;P
M[\7_ !-8:CJ7[-?CKPSXQ'CJ[\2?#;PG\5?$&B:G+\0O#]O\'/&VO^+]$L=4
M\W^+/[+/[2&I?#[_ (+)?LMW?PXNOB5%_P %&_\ A)_%WP ^.":EX<'PZT7Q
M'\9?V//A%^R9K'A?XKZ7JVNR^+?AO9?LZ>)/@_8?$JWO;33O%J^(?A#J/AO3
M_A7=^-?B[H6I_#RV47*7*[+6,FTWR6G&7*Z5W>S:M.-7EY'%ZW2E:Y65U>UI
M15[<ZY)1355*-KJ+YHSIWYDXV6LHM_H]\5OV]/V._@AKGQ$\,_%+]H/X>^$_
M$'PBL/ &K?%72+C4+K4K_P"&VB_$^7Q*G@W7O'<&BV>I/X4T"]M_"'B'5=5U
M[7!8Z1X5\/V">)/%E[H>@7VG:E=Z5I^V]^R3=ZC\9M,'[0'PWLY_V?/!</Q)
M^+]SJ^N)H>D>$/AS-+KEJ?B$VO:S'8:'KO@2UU/PQXCT'4O&'AK4-9\.Z5XF
MT'6/"^IZE:>(=.N],B_-7]H']EK]I'7K_P#X*[Z+X8^%GCCXC6?[1'_!)_X$
M?LH? CQIJGB_X1P7/QF^,_@+P=^W+H/B73+L:Y\2--U/PU-/J'[1?P_N;_Q+
M\0].\'^&[^[?Q7<VFJ7%MI<,^H<;^T1\&OC;I.M_$+XM:U\'?%/A?X7>&/\
M@@M^T#\ _$_C"_\ $'PJGLO"GQFE'AWQ@/AU>Z'X<^(FM>*KV_LM!\+ZQ-+X
MD\->'M<^'?GV\5G8>,[NXN8(Y(G4Y*%>JVI>RCBI024H*:HT,RJTIM3]Z,*C
MP-!--*2^NP3:<8>TTI4U5JT*=^5U9X:,XZ3E!U:V74ZD5**4)2A]=K6LVF\)
M*5G&4_9_JI\*/VZ/V/\ XX^./&OPU^%/[1'PO\9^._AYX'TSXF>,/#&G^(H+
M;5-(^'FIE8CXU$6I+8IJ/AG1-18>'_&.LZ5)?6/@7Q8'\(>-)M \4(^D*:7^
MW+^R7JO@KX@_$9?CCX/TGP+\+OAIX=^-/C3Q1XK&K^"])L/@OXR@UVX\$?&7
M3+CQ?IFA_P#"4_"/QVOA?Q+#X"^)WA1=;\#>.+S0-9L/"FO:O?:;>6\/Y4>!
MO@?\:/C;\//V#?C=\+?@/I&D:S^RU_P2I^-_@#0/"7QL;PC!\//C1\7/C]\"
M/@'H7PK^ &K:;X5\4:G#XB^"32?#Z\\3?%'Q'/-IGA?3HKKP%H'A*\UW7;KX
MDVGPT^>+O]E3]L3QIX$_:]6T_9/^.^E:]^T7_P $(K?]D'PW8^/O'7[+.D+:
M?M1:')^TEHTOPWM?"?@;XW1_#3X0^![^'XM>"I?A[I?P\T/PQ\*-$T&Q\03:
MGI_@N_M1'KW36@J=2O!2NZ4L7"*:UDZ-3&PHRM9?Q5AJ2E3TG"<VFO?I-<U&
M?M849OW546&DWTBJT<&ZT>MG2^LU)*>L91IZ:QJ'[Z^#/VP/V:/B;J/Q.T#P
M#\</A_J6M?"7P=HWCWQU+=WTMCI7AGP/XFMM:DT+X@SWVKG0]-USP"]SX<\1
MZ=?>*]!U>Y\/6.N>&?$OAC4=:TWQ#H6K6-CE>!?VE_ &G?L\?!;XJ^._B[X8
M^*A^(OPG\/\ Q!T[QY\%OAAX_?2OBOHLGAC1M>UGXF_#?X.:#>?%GXCZ=X F
MLM9TW7I5?4O%</A72M:TE-<\0N;NVN+CY)\ _"?XW:%^V]X/^,=Y\"/&MA\.
MM%_X)::!\$K[7H]?^#+2)\:-(^*-IXS/PBCT>S^*DNLRZ]:Z-'="U\21V#_"
M87LSVD'Q%#3,[?#_ ,//V<OVO?V<OA;_ ,$C/'&L_L@?$/\ :$M/V?O^"?EK
M^Q'^U%^S?X ^+_P:\,?&3X.^/)--_9TU/2OC#\--2UKXQ>$O@_\ $S0)/%_P
M*N_!_C33;+XSZ!>)H&L^!?&UNU];^&_$&FZ/G/2I*,&G&\H1G*\HWABLQHPG
M[OV:L,/A9WC=J&)C-MTW2DE3G*4*<IP<9.,9R@M&N;"Y=6E'5VYJ=3$8NG[S
MUEA91C'VBJ1E^VVJ_M<?LXZ5I/A'Q"GQ6T#Q#X9\<^%O WCKP]XL\"VVL_$7
MP>W@3XHZBVD?"_QUK7BWP#I?B3PWX5\$?$W58;W3OASXP\4ZIHWASQW>Z3KE
MMX4U/5YM!UE+#OOB[\9OAE\!?!Q^(/Q=\66?@?P4FO>&?"\OB34[34[C3+;7
M_&FNV/A;PCIEW-IEC?&SN/$_BK5='\*Z#]J6&/5?$^MZ'X=LI)M9UK2[*[_%
MOXN?LE?&3PQ;_#SQ-^QE\!?&?['_ .T1X)^ ?PI\'^"?"_PIU[X5>)/V$OB=
MX.?XQ?%+Q5J/[%/[5WP@U/6TT>3P?\&_#/C'QEXCU3XW>"/"G@[Q+HEU\:O&
M]Q^SCXZ\8>*6F^$OB7]??VH/@)X8_:E_9U^-G[.GC"ZN--\/_&CX9^+_ (>7
M6NV,,4^K>%KKQ)HUW8:1XRT$3%%A\2>#-9DT_P 5>&KQ9(9M/U[1].OK>:&>
MWCE0F^6,YI2ER5&E37)[2=.*C-J+NZ;G.*JP@VU&-;V<:EX2]H[@W)QBW&/-
M!7FXSY(S;<+RBTI\D6X3:2<I4N>4+2CR&?=?M6_L^V>I?'K1[CXD:>NJ_LO:
M;INL?M!::FD>))K[X3Z3K.B2^*-'U/Q=:PZ+)-96.K>%89?%NF74:3P7_A.)
M_%%J\N@J=1'E_P 4?VOOAK\%O$G[37BGQM\8?"FL^ OV9?V:/"?QQ^*/P6\"
M?#7Q=XL^//PTTJXNOB?K%_X_\576@^)=6:X\.^-/"_A:"V\,>!)_AKH&M>'9
M/!GB?QAKGBV[\-:Q%%H'Y_\ P7_9(_;4UOX^_L\?M&_'C3?#6C^(/VF/@#X
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ML@?&WX0Z;XD^%_B?QC\"/$GQ*_: ^&OQJ\!?%G2+3PC\0O$GA7QQX*\;:?\
M"JS\ >.K7X<^)-=\6:!=W7PFUC4/#\_AG0O'E]X"[7X*?L8?'SX._&C_ ()U
M:X?A-J]QX(\!_'__ (*L_'WXHQ:+XH^%\N@?LUZ%^VUXV^)/Q)^#GPMN-.N/
M&>EZMK^I>'+7X@6?@CQ,?A%I'Q'\-:=XOL?$^I6NOOX)O-'UN\4?>DD_W<96
MW?,Z;:F^236DFER3YU:+M*#2<ERTVTF[.3CS)Z<JERMKG6K:3Y6E!*4O?4KM
M1][]+OAU^WM^QW\6_$/PB\+?#7]H+P!XSUKX\:+JVM?"6#0[R]NK7QD= T?4
MO$.N^&[35?L*:3I_Q!T70-$\0:YJWPQUF^TWXC:=I'AOQ/J5YX6ALO#6NS:?
M]=5^ '@7]F']J'3?A;_P3_T+4?V=_&6F:S\&?^"RG[7_ .U9\3M(E\9? J:?
MP7\ /C)\1_\ @H=XE\$>/[BYT[XN7>D:TL^C_M0_#)]3\)^#]2\1>.;!QXFM
M1X7GDT98[W]_ER  >W^1^E*#YJ5.;7+.=W*FW=T[T\/-1=TG=2JU*;;2NZ3T
M4E.,:DN6I."DIQBM)I-*356O3NMU:4:4*J2;M&HE=IPE):***8!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'OVJO^">VC:#^U;\']6^,WQ&U[X::;\'/ _[#?PYUOP;\8?AKX'C\16WA?\
M9WU;X6_&.Y^!_P &HO%OP4TKP'?^(X_C%;S^-KKQ)X]UV^\6ZAV'[$G[27B3
MQIJG_!OJNM?M&^+?%WB/XT_\$X?B[JGQLTC5_C9XB\0-\5/B'X<^$/[.$]IX
MA^)?AR_\4WEGXQ^)&D^-8_BG&OB;Q)IU_P",H=;LO'-H^I&?3M;AM^MPBZDX
M1VC6J4KM?R5<5!--:336'B^:.C]H[).$N;GYMKI:T76NFFN51P\G&^MIOVS7
M*W>T+WM./+_13KVJ_P!A:'K.M_V;JNL_V-I6HZK_ &/H-F-0US5?[/LYKO\
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M1Q4*D&F^:-T[2Y8K^B6BOYB/AI^V1X[\8_!#_@C1X6_:1_:@T'X,>!_VL?\
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M_:U_X(A?$_XR_'[Q3\7OC%\1/BWX2;XF?"#P+_P3FO\ P5\:++X>>/?%.J^
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M]Z-M&U=I7NI*"<DKW:C:7+[S2UY%.VK_ )7S6=G;5I)Q<OMFBN#M/B7X.O\
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M]CKX*^)OB5X/^)7QLTKP_P"(/@S+\-C\8+.W\,>//$4'PHTGXM/J<?@KQ?\
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M9--75U=-76FJNE=>]&]KVYHWM=7TJ*_,_P#;9_:?_: _9%^,_P"RW\1=3O\
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MWTWQ<JZCMT_26UW]EH8HK>**"WCCA@AC2*"&%%CAAAB54CBBC0*D<<:!51%
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M#X#UWQ%KNH>*?"^D^"9/ )MM0T#Q9KWB:8>$:^@?VOO!'[3?Q2^*OP#D\'_
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ME\[IW2@L1'1)2A\*?LD_ ?\ ;2_9<\7?L _%+6?V9/&OQ!T/3O\ @E=^SO\
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M9L?M'_!G]H+]I'X">*?A9^S'^R)XKT3]F_XB_P#!(CXO_LO? G2-*^)_P1\
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MFST'X)_\(GXKU7Q+_P *X^)EYXXB^,UE>?$#P[X&UC1/#7@GPWX6\3>%]/\
M&5_>6'A[]9_AMX[TCXI?#OP%\3?#]OJ-GH/Q%\%^%O'6B6FL16L&KVND>+M"
ML/$&FV^J06-YJ-E!J,%EJ,,5]#:7]]:QW*RI;WES"$GD[6M)1Y*DU*/+.,X<
MT7IRU<-[>G%M*WO1=2MSKX92;;5M'G"49TX.$N:G*G-PDM5*EB51F[-_9E&%
M%P?Q1BDDVW=?G3_P3>^&/Q?^%'@+]I;1/C#\*_$'PNU/QM^W7^V=\;O!UMKG
MB3X:^)!XA^&_QS^/WC;XF^!-:@F^''CCQM!IMU)X<\0V$6LZ/KDFF:IINIBX
MMEM[J"-+N3XP_:A_98_:>^(-A_P7BTSP9\#O$>M/^V5^R9\-O@[^S5=Q^-_@
MUIUK\3/&5E^SO\3/A3K<*?VO\3M-NO!VFZ)XD\:Z;-J-]\0;;PHEWHUOJ-SH
ML>KW4=K87G[3ZYXXO]&^(/@/P+#\/?'VNZ?XUT?QQJU_\1=#LO#LWP^^'\G@
MU/#;6>D>.[V_\3:=XEM=8\=-XAGC\#V_AOPMXGMKU_#?B0Z[=^'H[73Y-3^2
M;;_@HA\&;CX<?#SXG-X/^+UKHGQ&_;1U?]A'3M.N?"V@+KF@?&K0OC]XO_9M
MU2_\5VT7BZ6QTCP):_$CP1K:?VY'J-YJLND?89X/#\FIWL6DU$X^U2B[N])4
M%RZ>[)8;"IZWM.4J5*,;V3G.5DXM.-Q?)S6ZU?;-/76,L1BVEUY4JE64K7:A
M%)M->]\S?&3X"?$SXC?M3?M8_$+QG^R%XK^,'P$^,G_!+;X4_LZ:A\/[SXB_
M!?PQJ/Q6\7:/\5?VB/%GQ'^!T-Y'\8+*_P#"_B6\\$_&+3M,T#QK?:GX?\"0
M^)TU-[3XDZ/;V=EXAN?G[XC_ +*7[<-]^QO^T;\!;.T^./[07AB7]K/]B?QS
M^RSH?[0?Q#^!>M_M2Z%\(/A9\<_V<?C5\:M%^)GQD;XA:7X6^)/AGPCJ'@/Q
MU:_"+7OB+XUUOXYZI#O\.^,M<\3:7;^%?%-W^[OQ$^('@WX3?#_QU\5/B-X@
MLO"?P]^&?@[Q/\0/'?BG4O/_ +.\->#?!FB7WB/Q1X@U#[-#<7/V+1M$TV^U
M&[^SP33^1;2>5#))M1O,?@O\?#\8];\<:'+\&OCE\*Y/!VG^ =<T[6/BMX-T
M?2?"GQ%\-?$;0[S6M$U[X<>+_"GBCQEX9UU]+ETS5-$\:^$;_5='^(G@/5K7
M3Y/&'@W1M%\6>"=8\36I-2YDDVFGJM%;$/$I.]M5._*[J:ASJ%XN<5FJ<5!1
MN^5KE6MW_NRPC:ZI.ER\ZLX.?(Y*,N1O\4_VJOV:?VX9_AS_ ,%C?V;_  #^
MS9XB^/.C?\% -8N?CE\ ?C=I?Q?^!_ACP_X8UWQ#^S=\$_@9XA^!GQDT+XD?
M$+PIXY\,:YX'E^ FF'X8:]X$\+_$OP)XJ\/>)-!T_P 3>*?AK-H^JS6GI7Q/
M_9O^/%K^UW^U--KW_!.;X&?MN?L^_MQ7?P@^(OA_QS\8-5_9\E@_9@^('ASX
M)?";X ^,_AQ^T#X0^)E[K?B?QM\'#:_"3PW\5-,E^ ND_$?4+37[_P ;:7!X
M:O[[6['6HOWAKYH_:!_:N^%G[.?@#7?B)XK.N^*])\*_%OX-?!/Q;IOP\M](
M\0Z]X3\=?'?QG\-_!'@*T\26%[K>C0Z1;37_ ,7/A[JVJ-=7:7ECX:\3:;KJ
MV5Q9W,#2Q"*CRP23YG3I\K2?.E#ZO3@]&[VJ4X\\7&;DHRE*TJE[FU[U23Y>
M52FY)N*@XREB)S25E;]W5DX-2CR\RC&\86\*_9<^&/Q;\%_MF_\ !2/Q_P"-
M_AEK?A;X>?&_XE_L^>*?A'XZO-?^'>HZ7XZTGP%^S5\._A/XH:TT3PWXWU_Q
MGX=EL?%?A#4Y(+?QEX;\/&[TJZL;NT>::2ZMK:3X^?#7XMS?\% /V$OC[X.^
M%^N_$/X:?#[X2?ME?!7XH:OX;\1_#K2;SX;7WQ^\0?LE^(?!'C?7=(\=^-?!
M^I:]X(M8?@7XOL/$*_#ZV\9^-;"_O= -EX,U.QN[Z\TW]"**M3:=-IJ]."@O
M.-J\7==&U7J*ZM:T6EH[RZ<6IQUM.3F]7I)RH2NGY2P]-V>C]Y/1V7X@:;\)
MOVR/"/\ P3^^(7@?PC^SKK8^,3_\%&?C#\<V^'.M:Y^S)X@\?:]^S_\ %+_@
MJ5XO_:LNO&7P5U/Q9\2O$?P'T;X[>'O@EXVAU[X:7GQ5\7>%T\"_&3PW%JMG
M=0:IH/A?6=1^<?#?[)_[:WPL^*>I_M >#OV:?B!XDL/A-_P5BU;]LG0?@7K?
M[0/PGU_QS\</V>OCM_P3GT#]C+Q)J/ACX@>./B_J6E7/[1?P(U?6_%OB#6/"
M?QL\=^!O!OB)[;Q!H/@;XT>+=)O=!\4:K_2;16<81ARV;]V%*,;NZBJ,*$(Z
M:)J2H*4XOW7*<WI[BIZ7LG'3EDZKDK*[]K.O-ZV;3BZ\E%K51C#JI.?\\'Q-
M_9>_:\^(/['W_!6+PE;?LQ^*]'^(O[67[:O@7XZ_!3X=W/Q,^ -SK&M?#MO
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M)^%VF_$[3?AMX F;P'X]\*Z"?IW_ ((AS^")O^"47[!G_"%^)+7Q$T/[+/P
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MG=QWD-['XJ7[)#::Q;746HW\5TNKBXBFCO[Q)0RW4PD?+\-?AS/X$_X5=/X
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M8^+/$7B3Q981W7I_[-O[2,MIX<_X)4^%_%'[2WBN;XCC_@JU_P %#O@'\6M
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M#XC?&/QEXY^)/BI-5\:ZC'86:>(_%^I-I>DS6?A[2'T_0M-TS3[/^;63X_\
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MBW4+;S++0]1UZ[@_=ZOE76OV3_#NM_M?^"?VS9/B;\4[+QUX$^"?C;X :3X
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M_AWQ1H_!_$K_ ()G?#7XMP>/=>\:_&CXYS?&GQUJ_P"R#X@_X:%T0?!'P_\
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M;_'GP9XS\,:OX8\/> O^$(ETOQ-X&U.P\=I!I?C[4??_ -K;XG?'CP[^VO\
M\$WOA)\-_B!X2\*?#7XR>-?VC9?BAH&L^ =9\3:AXN7X:_ #Q/X@TK2KO5]/
M^)'A.UB\--%JM]=IHLNAWLB>--.\(>*I]2NM/\-W7A77_2OA+^PGX$^#_P 0
M/V8_B'H?Q4^,FN:A^RI^R=X@_8W\!Z-XFN?A5-H?B3X5^)=1^$6J:EJOCK^P
M_A/H&N7_ (W-W\"_AF]OJOAO6_"NC0KH5P@\/,NM:U]O]$^.O[+?ACXZ?$?]
MG+XM7/CWXE?#CQ]^S'X[\3>-? VM_#F\\$H-=T_QSX+U/P!X]\ ^,M/\>^!O
M'NF7G@_QCX:U-K;4+K0+/PWXZT>[L[+4?"'C;PU?1RW$_55G[3$2J[PEC<15
M=XZRP]3$XZ=/VD=I2]E7H^TBNL.764%S<U.FX8:%):3AA,-3T;LJU*C@X5>2
M6\8N="JH2Z*:E9)R2_'W]A3XU_$W]FGP9^RA\.]#\*_!ZS_9?^/?_!47_@J?
M^R?IOA?1-)\1V?Q*\&:];?M6_P#!1WXT> _&6A7]G?:3\/\ 1O NE'X&ZI\,
M;_X7P^#=3O$TW5]$\<Z7\0=/6RN_AZOVU\%OVQ?VF?C_ .*OA#\2?A5^SU#X
MN_90^)'Q9^,7PV\4^($U+X>Z%XH^&W@GX>^*?B;X%\,?'F/Q5JWQY%[X^TW7
M/%OPUTNR\6?!>R^!7A?QQX1M/B<EQIWB?Q7)\+M2A\?=?X<_X)N?#GPWH'P
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MS6M*?LU)W7)1A*TKR9^=_@/_ (**_M'?%#PQ_P $_P"/PM\//@UHWBO]K/\
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M/P5^%/BKPQX@?X?_ /"#:7H'P%O_ (EZIX(O_#EIX?\ A]H'BBUUN?4OB_\
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MJ14G3@K3I2DG)I1:4SNW+ET5U:S2ERM-I*ZE&-2$FO:2;E"I&+4%=GA>B_\
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MQ>MOBQJFL^);#X@K\4;Q_$GAV\TKP1J<\/C:_P!WPC\#/VWKCX]?%37M+O\
M_@HG\!_'?B?X_P#Q2\;:9/;?$K_@GC\6/V!&\+7OCJ^M? FLW&I^/=%\8?MJ
MZS\,_%7PY\-^#;CQA\(+:'P;XV\.^(9]1\&?#BV^#?@.P\#>*?"_W5\0O^";
MOPZ^)/AS]IOPQK7QK^/MAIW[5/[4?P5_:W\;OHUU\$X;KPO\2O@$?@&GP_TG
MP')J'P0U&.T\%QVO[,OP<M-9TOQ7#XOUG4X?#=W(?$,-WX@U^ZU(@HN6%JR5
MHQ5JBUY^6<<O<U:UVI>SQ4I*7(U.;I**4*3@5+_OH1?5N#7P\T5CU3>[2E&5
M3"I-<R=.,IMN4ZBEQGQ'_;$_:DUWQ]\>M%_9'_9Q3XZV?[+7[0?PU^!OQ$\'
MW&I?#OPYJ?Q,GUWX>_ CXM?%"X\'_$OQS\??AIIGPQUCX>_#?X^6&LZ%9>)_
MACX_TOQUKW@'5?"Z:OX?B\8Z7X@\/2?#C]MCQS\4/VK/B1^S ?$7PF^#GQ2\
M%>(OBQ8I\ /B]\.O'VF?%O4OA/H,?BK2?@_^U+\*O%MU\1O#7A#]I?X2>/\
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MNW>+JUI1>NJ]R5/1ZQMROX0HHHH*"BBB@ HHHH **** "BBB@ HHHH ****
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M3P9JNNZU8?#3QS??$[P3\.]>\0>'U\0WL%A8_$2[@T/4+2V\,'Q7:UKX0?\
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M/'QW\6Z7\.M.^.&G>-+_ ,!>)?'OCWPE\.]<^'GAKP%/+\/_ !3I.O?$V_\
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MB#\,/"EUX')>TO/%UI)J_B[3M3U87-IX>O-,T&VOI+>SU/58[;1[KT#]G/\
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MM0>$/B#<7]A\+_#>MBTUC6O!OA[XF_$C5+72+2]31]0TGX:Z7I\Z1:IK\?\
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MB+^UE^W[\ ?!/C:'X'^,_#WPJ\3:I^SC^U+^U+X<\ _#:?XE^&/!2?!7P_\
M$J?]G[X&W?B;3/!6H^,(_%VO:-X/U36+U+[5]6TV;7O9OVLO@Q\8_%W[3O\
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M?@WJ'A;0-7\2ZC\6]/UF\^'FCZ1I][)J'B.&ZLKRUM_C'XJ?LE_M8^$OC_\
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MAU.ZU;4-/T&Y\2Z;K'@31M8U3QYX9\5^&="ZWXE_&7P/\*[OP9HOB*XU._\
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MK?P1U[]GR?P%J$OB#XJZ7X^^(?BCP7/\3'^*'A7P0/A]J-CXWL]/OO&/AT^
MO$TTWS*//[K?,VKI.UJ,E%W4E"24ZNK;4I4G37--KVE3T<N5WM9+2Z3;JQNK
M-.:O"D]$K1J\SY8KW.FTS]O[P%\9?@:GQ*3Q/\9_V6;.+]N[P_\ LIZ?KFI?
M /Q7XLU'7?$OA/\ ;8N/V:XO 6K#7OAKXB\(:!H_[07B?P-K/PNUSQ6TUO-\
M%3\1M)AUOQ+X/^(]EIBCZ<^*W[:7[/7P5N_&J_$'Q?J&F:!\*];\#^'?C1X]
ML/"WB77/AW\#]7^)*:+<^#;7XO\ C31M+O=#\")=:5XE\,^*?$]YJUTEE\,/
MA_XI\*?$[XLW/@7X;^*O#OBS5/SEF_91_:IB_9G^(?P'?X5>'KG4=&_X*Y:?
M^V%X)\0:;\4?#LUO\0/@K/\ \%6%_P""B>K:JVG:E9:.WA+7+#X<M#\+[#P[
MJU_=WNJ?%6&_,[Z5X!BL?&NH=%\3OV,?C_=^&/\ @K'^SCX9T#2O$WPT_P""
MG<_C'Q1X&^,M_P"*M($GP(\3?&S]EKX??LK_ !=TKXM>%-3N-.\0ZWHG@&Q^
M&FB?$GX-)\-K3Q;)XU&KW_PQ\877PJM?#6E>/M?B'-HFE=QI/62M*?U7 RJ1
M;5^7FJSQ<>=*,(3I6<;INI*;U<KKXUI&_+%XO&1B^6ZYE"C'"R4?>J3A/25I
M?NOKKXR?\%'/V5/@-XC^-_A3XB^(OB=;:S^S=X6^''C_ ..">&OV>OC_ ..+
M#X=?#;XGQ>.[S0OBAK>L>#/AGKND/\,-(TKX9>/-6\:?$+3[Z]\(^#+;PW?6
M?B'5['6GM=*N/8O'7[4'PF^'WC6;P!J]WXJU?Q#IND?"SQ#XHC\%^!O%OCBV
M\%>'?C?XZU_X:?";Q'XME\*Z1JTFE>'?&7C7PGXKTT:ZL-SI/A72?"_B+QIX
M\O/"O@31=2\3VWYC?'K]B/X[^*5_X*T^&/ /A$:CH/[7'_!,GX,?L5?L_:WK
M_C?PV;J]\>?#OP#^V!X(U#6_B'+=7\.HZ+X?:?\ :5\'WYUF*QU?5=0L_"GC
MJ[;18-13POI7B?IOVF?V4?CA\4?B'\+/B?\ !;X>>,_@1^U!\//AA\!O"_P\
M_:R\!?&C0=&T*+0=.\>:KKOQB_9Z_:[^$L/B9=-^.7P/\/V$*>(_ NC0^$?B
MA)?^+?'7B;_A#]0^"FJP:AXZ\1:0L[7D]:_)=P=-^R<ZT54<7*7*N2%*K)<S
MFE4G&/-*G"-53<D[**_@.;L^=1K*G2DZ:DE%2;G*K"+Y5%N$+\L9RE3_ &9H
MKSOX?>(?B'X@D\=K\0/AS:?#R/0OB'XA\/>!)+3QMI_C3_A/OAYI]OI<GA[X
MC726&DZ4?"%WXAN+K4[:;P3?'4]0T4:4DT^K7:ZA$L7HE"V7FD_O2?R=GJGJ
MG=.S31??R;7W.VG=::-:-:JZ:"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^6/$?[7?PV\)?M6_#W]
MCKQ%H/Q TKXK?%CP'XO^)7PTU6^\/6-I\.O'/A+X>C1X_B!+X9\;7.MPZ?JO
MB/P/<^(-#C\3^ ;6*3X@:;IVK:=XJ;PN_@J]MO$LOU/7Y5_\%E?"5A;?L*?%
MG]IO1=6D\&_'']@_0M>_;/\ V</B-92M!?\ ACXK_!'PWK.O1^&K]%O;"/7/
M GQD\+'Q%\%OBAX-OYIM.\6> O'VMZ=]D;6$T:\LIE*,+3G_  XM.I;=0;Y7
M)=W!SA4Y5K-0G33C*<9)J,IWC"W/)-4[_"YKWE&71*:A*',](.<9M-0E%_='
M@GXYZ#X]^+GQ>^#^B>%/'D>I?!&?PQIWC?QCJ&BZ?;_#T:_XO\-:1XST/PMH
M?B2+6;A];\4'PCKND>)M9T*ST\WWA71=8\.WOBN/1(_%W@_^W_;*_*?]J#6_
MBC^S-_P2<_:(^*7[-MSJ_B?XZ6G[/'CGXUOX^TVRL-;\8:[\1?&^DOXQ^)WQ
MJTG2IH]0T+4O$VC1:SXC\>^"/!MMIUWX)TE=!\,?#_PSX6C\":/HOA.#Y-_:
MIO/$G@_Q#\;H/V0OBW\4O$GP5^+W_!&/]K'XZ:X_@;XU?$GQG;^$OBK\/D^'
MC?L;?M!_#/XDP>)]=\8^%/B7\>-*\:_&QH?%GA;QEH^H_'I_A+-X[U._\5>)
MOAG<:LBJMT/;1J1O+#>UC6Y;/]Y1P^,Q-2W3DM@J]*%2ZC*I&G=+VK]FJ=JJ
MI..BKNFZ::?P5:^%H0;:O>5\72J2C\482E9OD7/_ $%45^&W[+G[1VD_$7]O
MO]E'0O#W[1%Y\0- \>_\$@8O'>N>%+'XV:QXP\'>*?B-9?$O]GV]L_'DW@__
M (2O4O"E_P#$D>#_ !7JEU?>,H=(;QK=^%M=#ZOJD^BW=EG&_P""LOQE\,Z-
MXV\>?#.U^,WCKX>_$KPK_P $T_VP_C;X>TV\^+<_PB^%7AF6"_\ !FB^"OC#
MX,B\*W'AGXC?$G]J[PYX_P! TSPI\(TT;QUH.B_"+PQXK\<>,)=3TWQ;XB\'
M>'?B)6(MA_:<WO>SEC(OELF_J<\=&?+??GC@9S@KW4:D.:]GS/#IXCV*C:+K
M0P<US;1^N1P<H*;2TY)8R$)O:].=K:<O[Q45_/U\#+B#]JW]N/X#1^/_ ([_
M !G\3:#J'_!*;]D?]J27P1\._P!I[XL_#_P%KOQLTOXY^);#4_B3=^$/A-\0
M/"VD:E&]_I-OHGC/PW% /AWXQEM[&S^(GA7Q-J&@>%I-!X[]A/X_Z=^T9\5O
M@;XL\?\ [<GACP9^V)X#^.G[2G@'X]_L3:'_ ,)?;_&;Q#J6FZS\3M \4?"'
MXJ_#76OC_P"(]'G^$'PE2UT3XC?"CXCZ=\$_#T'@[2?#VE3^&O$NEQ_$/X@:
M-XTTG3<*LJ+LY1G5BVMG&EB\3@Y3BOBDO:8=SDE'FC2J0FVFI&,*JJ4E52:C
M*-*23NG>KA<-C(P;MRQ?L\2H*3DHRJTYP70_HVHK\LO^"AN@KXO^.G_!,GX>
MWOQ)^+G@+PO\7OVL/C'\*_B+IOPK^./Q/^"\OCKP!J'_  3^_;(\;S>&M7NO
MAMXO\)WUP[>-? ?@B\T7Q!:3V_B[PEJUO;W?@?Q!X<UR]2_;\]/$'Q.T#5_V
MC?VD/V6_B+^WQ;_LA?%G]F#]I#]F+3_V3? WBOQ)\3?%G[2GCOX$:)\)OV>]
M;^&EC\'=2\;?M"V=M^U=9?M,>.8_BE\,/C+X?\1?#GXY_$SXE>-/$&J>#_B'
M?:IXCTOX0'P]E3E&I+E?NOVDJ>JE*ZI_5^>2Y4^9Q^M4Y>SBI5'"-25E:-]9
M^[%R2YK4XSMHFW/V_)%7T7-]7DN>3C#FE!7=W;^EBBOPV^&WB/Q]X9_;3LOA
MM\7]0UCXR_#C]H_XR_MQZ%^SY^U;^S[^T)\0M'FTZ3PXWC[5_&7[)O[5?P-M
M=?L[#PEJ_P"S-:^%O'/PN^"_Q^^%^LZF?#&N?#?0M$G@^#OQ)^)WC.W^(OQU
M^R%/\7=+^%W_  10_:B^#'[0'[0'QX^/O[37[)GB73OVG_AO\0_VB/B3\7/A
MY\9?"G@C]@[Q1XULO&_B3P%XH\5:SX ^&.J_!K]KCPW\#OA/J/Q-\!^'_!'B
MN]\7_'G6-$^+WBCQ=XZ^)VMZSJZ<E&$JDHRY8QO+DA*I-.^(CR>SBE+F3P\N
M9.S7/3<54C--F]3V::N_A<I*,)*U!\W._=2?MURMZ/DFGR.+1_4=17\]W[-7
MC_Q[XO\ !G_!$CX]?#KXK?$+QS\5?VI='UOP5^W3H-]X[\0ZIIWCK21^RE\4
M?'?[1_CKXC>")+Z^T7X<^.?V=?VQOA_X&^&&E:KX6TCP;_PI3Q!XQC_9?T!_
M"G@[Q9I7@"O)_P!CG5/$5CH'_!)_XT2?''X\>*O&7Q/_ ."D7_!1K]F#QI<>
M-_VDOC-X_P#"WCGX&^'K7_@JGXD\,>$?$/@WQ9\0-9\%^)KWPSXJ^!'P;NM!
M\:ZIHE_X[M)_!^AZ6WB>?3\:?);34^1I7]HZ3:E&2<E65!2@U;VE.4I0E"HK
M*=-\T8M\JE$IJ,'.T^514O@DK)TW4M*ZM&:491E%M\LXM-V4G'^F:1BD<CK&
M\K*C,(H]@DE*J2(T,CQQ[W(VKYDB)DC<ZKEA\F:/^V#X/NOB)^RQ\)/$_P ,
M_C+\-_B5^UE\)_B!\7/!_A#QYX8\.V6H> -/^%^C>!=8\<^#_BO=:'XPU_2?
M#WC[0O\ A8GAS39]!\/ZCXKMI=2;4%@U22RT^XO5_.7]EOQ/XVLOVH&^$WQO
MUG6?BCIOQX^!?[7_ ,3OV?OVO_@'^T/\2_\ A7?QL^$UM\;OA8WCC2OCY\(D
MU;3+KX%?M(_L^VGC3X6^ _AM\2/!&L:OX+T/PGK?BCP)\/M=^$US##\*K#Y#
M^#6D6W[3NC_\&YNC_&WXC?$[6[SXS?\ !,_]HJ\\?^*M'^-?Q$\ _%7XD>(]
M3_9__8V\2>(TN_C)X)\6>'/C NOZQJ%MJ/B3Q/J/A3QSHOBO7%TK5;?Q!JE_
MX8NO%FDZJJ?ON#M[LH49V;2?[R.*]V]FU*,Z45)M2C)0_=2G"M&I*W9.4;V<
M8UW=+F7[KZJXR2O[T9QJR<;--7?M%"=*5./]"/QG_:*\#_ OQ7^SYX0\8Z9X
MLO-1_:5^,\'P(^']WX>TFTU#2['QS<?#[Q]\3H/^$LO+K5-/.CZ/+X5^&OBR
M:*]MXM1GEO;."QBLGENHS7O=?S0>"M6^)"_"G_@E1IWQ0\?^*_B7H/A3_@N3
M\>_AO\ ?B[\3_%$OBOQ_\7/V;/!7PZ_X*0^#OV>?''BCQOJ$GG_$.]\2?#[2
M]%3PO\13YC_%;P=#X6^(EM=ZS'XKAUK4^K^#/QSL?CS^TQ/I'Q"_;U\.? _]
MKCX ?\%*_CSX$U3]E?1]/\66?[0'Q2^#6E_%?XB>'OA%\([_ .%NO?&G_A'O
MB)^S;\0/V/\ 5/AK\6CX^\%?LXKX:\*W?A_6OVC#XFM/B!X'^)?Q FOEUA%:
MN;E)27_/MPP<E:*5Y3IO$M5(PYI+5Z146TVE'FT5HV<;K2:JXR'Q+2,:BPRE
M!SY%JMWS)?O1\7/BWX+^"/@J3QWX[O;FTTB3Q1\/O FDVUC:M>:GXA\>_%KX
M@>&/A3\+_!ND0;X;?^V/'/Q)\:>%/!VDW&IW>FZ'9:AK=M>Z_J^C:';ZAJMG
MF_!?XMR?&+PYKNMW?PM^+WP>U7PSXX\5^ M9\&?&CPC;>%O$:ZCX5OQ:C7="
MOM$UGQ1X+\;^!_$EC-9:WX4\<^ ?%WBGPOJ]A>FR;4[7Q%I6OZ'I'P9_P5RT
M+P[K'[/WP)D\1:IK&F)!_P %$/\ @F/8VKZ;XZ\5^"$D36?^"@W[-=IJSN?#
M/B'04O[VST5=0OM+O;O[5?>%KBVD\3>'Y](U?3H-6M?C+]H3QUXVU3X<?\%J
MQ>?$KXK?#W]HS]AJP\,Z[^Q):>'OB+XTC\2^%/ &C?L@?#/XD_LP>*O#FD/J
M%Q!\8G_:'_:OLOC?X"\>+XIL/'>H_M 76DZQ^S=X_E\8Z5X-L?".FX1JWE5C
MR2ER-V<8MZ1I8>M)K5<U1JORQI*[DDFO><>:N7X/>C'FY?B=KN=6O2C=M6C3
M3I*4JC:4=>9\JDE_0]17XP>&_"6O_&'_ (*G>)?"_P 9O'_QH\.2>!?V"?V
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M+6\<5%N#7-S<T8OVD5?]YJ*_%[X/Z=^QO^W!X+^+]C^Q9_P4 ^.VO67QZ_9
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MFK-6E9W35U:6CT=GH]=&%%%% PHHHH **** # ]**** "BBB@ HHHH ****
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M42*&)$CC144 6:**?KKYO5OS;=VV^K>K>K#;1:):)+1)+1)):)):)+8****
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M&U^:-QM*]VE9N+NTK-)MIZZ-*,F[[*+O:SM]T45^4?[6?[<MQH'CC]D?PO\
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MK"<I:*T8.C-3?V6N5KFNC]F:*^"_BI^UG\/?@W\;_P!H=/$/Q2^)OB1_V?\
M]C73/V@O&7[+_A7X)7E[);^$[;Q5\0Y(OB]X+^)%YX5TF/QOXC\<#PYJ'P[C
M\&67Q%N/"GA:;P-<:QXDM_"LESJNLO[_ /L[_&^R^/?[/GPI^.\?A_7?#,7Q
M%^&GA3Q[>^&M0\/>+K74M'N]>\-6&NZAI6G66O>&]!\0>(;*SGNIK71M9L=
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MQ\+^ -/^*GAGQWIM[:WGPIN?$D?Q&E\/PCQK:^&)_!<]OK\W6ZA^T[\)]/\
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MM>SJ)\W*DZ<TVN2?(KKNOA4]U\+Y+25KW3]I3LTW?VD+7YX\WV517PE\7O\
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MW/"R;E%2^BZ*^&O&_P#P4:_91\#:G:Z+-XL^(/C+5]2_9XT_]JW0]/\ A/\
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M%X7^Q>*;[0[31_%\GC3X>V'@2Z\4:K\2_AWI_BGSN\_X*/?LAKI_P,U'P_\
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M/XK?LB_'O]F7]FG]G[]J+PM^SO\ ##XR?LZ^,/V1/C'KNA_#W1;[X5?%^_\
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MM*\E*497Y9QTA)-JZCHG*DXJ-KKEI2HI22=U&5)JBDH\D6K<T):R7\Y?@O\
M8%_;3^!WP@_X)T^.8OV7OV9OVJ/'_P"S?\!?C;^S1\>?V4OB5\5M(B\/WWA?
MXN?$KX=?$/PC\6_A%\4O%_PLU;PEHGQ%\!:K\.;>#QGHVK>&+_3O$7A+Q'JF
MA:#KD^K:3I6LS?I)X(^ 'QB\,_M>?LB_%*?X0_#/P7\/OAA^QW^U=\&/'NC?
M!?5M!T_X<?#OQW^T3\9/V5_BUX<\,> -(OK#P5K_ (Q\&^![']G[Q)X5U_Q^
MW@'P%J7C+6]<\->,[7X:>&8==\1^'O!7Z:UP?B'Q5XGT?QK\//#6D_#'Q5XK
M\.^+Y_%,7BSXB:1K/@&Q\,_"F+0M";5=%N?%^E>(O&&B^-]<C\::H%\,Z$GP
MZ\*^-)M/U-_MOBJ/P]H2G5JE1C[BW4)J4%=I)JE*'*]5[NDI^\[J;LI*$E!E
ME9[_  M-WN[.HJEU?KJHV6C@M8MIR7XJ>$?V7OVZ];_:G_9-^-'QC^%_@;7M
M5^ /[='[9WB[QQ\3K/XS6$-AK7[/'QQ^%W[1'@GX)ZK\(/A/#X?GT[P!X7\%
M^$/'?PN\(?$/PE'=Z'X^\=?$WPU??$3QE:_$+6O$/B7XNR?>7[ 'P<^*?P4\
M&?M#Z+\5/"L/A:^^('[:_P"US\>/"4=OXAT3Q"M]\//CQ\;/%/Q.\&/?R:+=
MW4>E^(K+1?$%OI_B71G>XMK#5[:XCTS5]:L#%?R?>M%5'W8<FZY7&[^+66'G
M)W5ES2EAJ<I.VKE4>]1M#5VVW:\XSLK))PCB(P2W=HQQ-2*UVC37V%?\)=0_
M9N_;I\4?M+?!CXC_ !#^$_A3QBGP'_X*B_%OXU:-\2'^/.EVFAS?L??$'X"_
MM1?"7X4:=\,/A4OA&*W\ ZOX&TKXU>!(OVA-.EM[#Q=\2_B-X&NO&-OJGQ2M
M=8TK5_!FCH?[(_[2]KX'_92T.X^%\46H_"C_ (+#?M1_MN^-8IO'?@8QV'P,
M^-OQ?_;/^(_AAM+FM];N4U3QMI^F?M/>#K#6O#$8MK.+4O#7CG['KUW:VWAB
MY\5_N312C9<C27N<MM+)N-3#U4VE:[<\+2E)WO)NHVVZC:F5.,G-OF]]33]Y
M[3IUZ32OM:&(FET5H.WNVE_/%X _8Q_;K\!?##]F']D^?X6?#CQ?X0_9!_X*
M-Z1^T)H7[1U_\<K;2++XQ_L]ZA\5?C#\4;;5]0\#)X$U?QGX<^-7AG3_ (E)
MX:^(?AC4;2\\-:WXGTJVU[PCX_\ $>F^)-4?PE^L_P"VG\(]*^.7P:@^&WB;
MX"M^T3X-UCQYX-OO%_@G2OB /A9X]T+3?#NH/XATGXC_  G\?+XH\#7?AKXH
M_#[Q?I?AGQ'X3U'3/'?@C5X9K2Y.E^*]%O?)NT^MJ*7*N10^RG!W>K;ITL-1
MC=_]>\'05URR4H>TC*-1\T;VG*I=\TE*.FB2E4Q%5I+73GQ==V?,N6?))2@D
MG^(OA3]E+]MCPG=_\$T_&?C'5M3_ &B=<_99_:3_ &J6\1W/Q3^(_AJ+XTZ-
M^S5\:O /QJ^&7P U/XL?$&TL'\,?%3XI_"GP-XB^&NF?''6/"\6H:MXAU1->
MO_#5[\5-4TR?Q5XRY#X/_LO?MX7/[47['GQR^//PT\"ZQXF^"?QU_;KLOC)\
M3[7XSV$]IK_P[^.&G:];_!_Q;\'_ (;6WAE[3P-\*](\(67@_P +/\.;:;0O
M'=_\0_[0\4?$32/$6M:IXO\ CAXG_>FBJ3M)26ZE*:3U5Y<MV^K;<7S.]Y<T
MN9O1$\JY91VYTE)Z7:5[6O=)).*BE914(J*6K/YM8OV"_P!M'P1\ OV:WT;]
MGSX$_&GQ_P#L2_M9_MD>)F^ 'Q8^)/AH_#K]K?X"_M-?$CXU^))-;\+^(-2\
M#^+-'^%_CW0=/\>_#K7_  ++X^TRWNK/6]"\?Z!XAM=/T>;2;SQ=^XW[,'A'
MQ1X/^$>D6WC+X/?!WX >(M9U+5_$FH?!OX&7%KJW@3P =7NO-AT<^*K+P=\/
MK3QGXGF@CCU3Q?XDL_!6@:?+XBO]0TO2AK.E:58^)-9XWX-?M8V/QV\4Z8OP
M^^%/Q$UCX/>(+[XY^']"^/MN?"S> T\7_L\?%K6/@UXY\/>)-+E\06_C#1(_
M$_BG0M8O/A-KMGH.NZ-XXT#0/$&IZC=>$Q%X>A\3?6V<TH6C3C%?"XQY6][1
MIX:#?V6^>-##5&Y)IW4Z7+"K(;LYMO>+E=+;6=>22NY+W'6KP7*T[+EJ.4J:
M9_/M/_P3<^-GQ \'_M3?"SX<V/BS]B_X0?M7?L?_ +3?P\^,_P !-8^*.B?%
M[]G/2OVQ_BWK_A[5_AO\>/V5_!NEZUXGUGX9> Y)]8^.5U^T-X05?A#X8\?6
MOB?X=PZ;\(=3\4+XF\9>'MC4_P!CS]L#]I?]DKXV^!O$O[*/[$'_  3\_:1A
MT'X;S_#?QG\(->M?B9H'Q=^.'P/^,GPX^/O@[Q-XFO/"?PJ\":_\+OV:]?\
M'WPFT*RN/!NI:E\6OB/J.B^.=;N-:TC0=0^&.E#XN?OC7,>,/&GA3P!HJ^(O
M&>O:=X;T236_"OAF'4=4G$$%QXB\<^*-&\$>#=!MN&DNM8\4^,/$.A>&- TZ
MW26[U77-7T[3+*&:[NX8G$N5)1;34*4(R5E)2I-*E-/5<T?=A&+3IJ/)!4^6
M%.$!V=W-\RYJDY*;O%QE&7M8S3LG&2YI5)>[4?ORE4YI3F_RC^-?@S_@H%^U
MO^QSXZB^(_[.WP=^"?QBT#XL_LB?%SX8?L[Z5^T(GQ-?Q?>_LJ?M3_"O]I+Q
MI9>(_C;#\-?"/A7PO>_%NT^&H\!_#+1X_#VL:5X7DCT[Q;X\\769\6:IX9^'
M?AOQM_8\_;$^-/PL_P""T>G-\)?!7A?6_P#@H/\ "+X:^#O@7X?D^+VD:KJF
MCZ[%^S+IGP<UB'XE7,6A6GA[0K'PQJBQW>NZAX?UWQ.]S>P:WI?A:P\3Z1I^
MB>+?%G[Z @YQVX-0W4TEO;7$\5K/?2PP2S165JULES=R1QLZ6MN][<6EFL]P
MRB*)KN[M;99'4SW$$6Z1233C+[*M)OE6J;A2C.45:3YI?5Z;LE)*4;0C9\K<
M%RR36LKP5V]U"K4J4XO96C*K-7T<D_?DVG)? '[1/PC^+7Q3_:@_X)L?&#PS
MX$N(_"'[/OQ7^,OQ$^+\>K>)/"5GKGA;2_B7^RS\6?@EH>FV6G6VMWUIXDU;
M3?%OQ)TR^U]-%U.YT^V\.Z3K5[I&H:YJ8TO1]3^)=6_8_P#VK&_96_:2_9Y3
MX5:%>:MJ_P#P5?T_]K[X:>)-.^)OA>33O'WP?U3_ (*=^&/V_P#6;VYL=431
M[KP;K&A?#W2[CX90Z-JTMY?:O\4XW$<=EX >'QO)^VG@/7M?\4^"/"'B7Q5X
M(UKX9^)_$'AG0]9\1?#KQ)JGA;7/$'@36]2TVVO-5\(:UK7@?7?$_@S5M4\.
MWTT^DWVI>%/$>N^'KZYM)+G1]6O["6"YD\IU3]H;0M)_:H\#?LHW?A#QBGB;
MX@_ 'XK_ +0?A_QYCPPW@&;0?@Y\0_@O\.?%WA5S'XDD\90^+8=1^.W@G581
M=>$+;PW<:1+<FS\0W6I6UUIULXS]BTDTN>K=1=FG4=6CB4D]=%+"II<VL?:)
MR;<>6:E-5X6ES-0I<KDO=DH>RKX>3=^KCBY)OET?(U%6=_R^UG]DC]I#P?\
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M/I_@/P1X3\'^(_AQX/\ %W@J&YT#Q]XN^)>BWWC[QWIWCG7=>\6?&C4OTO\
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MXW;E*TE>,]&DIT2M=^ZJC;2UM6IRI5-(Q^U";2Y8WB[.+33;^,/V9/@]\6O
M'[8?_!1'XH>-/!*Z)\._VC/B7\#/&7PG\0Q^)O#FJW>HZ;\,/V=/AS\%O$<'
MB/0=-OYM0\.7=[XD\&7^M>&U!U2+4/"]W9W.L2^'==\_P]%\1_\ !1C]EO\
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M::IJFL2ZUH6B<!^SW^RQ^TC\'OB]_P $Q/'>I?#W0M4TSX'_ /!,[QA^P_\
M'F*+Q_H5JWPZ\=3ZQ^Q_XG@\8::RQ7LOCKPGJP_9Y\9Z-H,>@6J:Q)J^L>#V
M\1V/A?1]0U[5O#'[+45"BERV;;@J*3>NE&EB*,+Z+>&)J*6UVH-6Y7S7=VDE
M[JDZS=NCKSHU)VO?[5"+5[VYIKJN7^>SQ;^PU^UC:_ #X/>*O"OP/^$7Q3^+
MW[.O_!1?]NK]JN3]E[XX^,O"P^&7[0/P._:]^+G[57BM?!J>,K;2/'7A_P %
M_%GPUX,_:'\,ZCX;U_Q#I%WX>T#XB>"_$&F78USPEJEKJFJ>M?&;]CWQY\6O
MA1\(S?\ ['FF? #XP:)9?''X@?"_QC^P/\>?"7PM^*?[%?Q=\7:?\.O#WA32
M[7XF7EC\#_#OQ>\+_%K0K7Q1J_[2-O)X(\0_#^?5/#7@[X?7GPF^.FB:%HOQ
M.E_;FBA02AR*4HQ2@DXR<9QY*5*E>,U:2D_84JBE[SA5BYP24YTY#=Y<[2;Y
MIR::4HR]I5K57&4'>+A>O5@X^[S4Y*$I-QC-?#7[07P"^.GQZ_X)K?&W]EWQ
M7XQ\!:[^TM\9_P!AOXD_ /Q)\0&M]2\+?##6/CG\1?@+K/P\UCQBUKI>B:GJ
MWAWP%J'C[5[G6C;Z=X<U#4=(\/3>7::)=W-O'8OP>B?#S7]8^/OPJ_;)^/WA
M_1_V<_"'[.'[)'Q<^ UUHGQ%\9> ]0U;7M=^.?CGX$>*?B#XI\6^+?"WB?6/
M >E?"SP)8?L]^%M.^']QJOB&?7_&>J_$GQS>^)_!WPU3P9X>D\??I#7,^,O!
M?@[XB^%=?\#?$'PGX:\=^"?%6F76B>*/!WC+0=+\4>%O$FC7J>5>Z1KWA[6[
M2^TG6-,NXR8[JPU"SN;6X0E98G7BM)R<G*5H7E4=51Y4H1FX5Z3Y8JZ452Q5
M>$86E&*E&R?+9YJG%<B;G[L(T[\S<G&,Z55<S=KR=6A2FY-IMJ6W-=?F;_P2
MW^!-Q\+?!OQ)O(/'FF?$KX/>#/''C']GK]BK6M-EU*[@T#]C;X7_ !$\9ZQX
M'\*FZUF^U2:ZU/P5XS\7^+O@59^+-!GL?#GQ(^"?[/O[/?B6VLM1DMD\3:WL
M?MS?!S]JSXQ?%+P?X9^'?A'PC\0/V<O%'[-?[2WPW\7>']6^(R_#%/#?QZ\=
MVW@NU^&/C[XHW5MHFN>(_B+\&K'PGIWCSPW-\,]"T[Q'H=QXW\1Z#XP\;?#[
MQ1=>%O OBOX:_IEIFF:;HFFZ?HVC:?8Z3H^DV-IIFE:5IEI;V&FZ9IMA!':V
M.GZ?8VL<5K96-E:Q16UI:6T45O;011PPQI&BJ+U9U(1J05-N7(J;I;VE*#HU
M*#<[7O.4:DJCE=OVJA4O*4;RTA)PE[1<JDZBJJRO&,E6A6BHII)1BZ<8*-DO
M9N4+1C*T?PV_9B_97_:F^&/C3]F/QCXY^$5E:P?"K_@C?X9_8T\5Z7HGQ*\%
M:U>Q_'CP_K?@76(]%M9)[W2;.[T&YT[P=/:W7BB&=]/L]?U""QMDU+1(9O$I
M\V\4?LZ^,O W[(/_  27^ OAOXJ^"_@W_P %(OV2?!/[,/P$\/Z9IOB'P]XI
M\67OP]\;?"B#]E[]K.\T;0-*UC^UO$/PZM/A+X4^)'[3G@.^NK.ST^Y\=?LS
M?#K7/$EGI=UX0UO2=-_;/QA\3_$/@V?XI7EW\(?'FK^$?AQ\+['XAZ7XMT+5
M_AC+!\2-9'_":S^)/AKX/T36/B!HFN:?XM\,:=X9T"_GU/QW9^#O NK?\)SH
M]KI'BZZN-(\3+H_&?L[>)/A#^T;\/_@C^V]X2^&.CZ!XJ^/W[-_PM\3:!XO\
M0^%_"T?Q?TSX1_$K0])^+6@?#3Q#XOTH:C?G2=(U#Q*-2OO#%AXBU#PO#XF-
M[J5C]IFD%]+4FIUG5DDVY.=1:I?O,5C<5;E35E4K5\5!IO\ @.4$M8RG,(>S
MI<D'**MR1EH]88;"X>]VG>4*-'#SBTK>VC&;=U*,?F'Q9^S7X[^"O[97P#_:
M8^!/P^_X3OX/>#_V0_$W[%?C#X(>%_$GAGPSXH\ ^%[+QWX%^(/P?^('PQM_
M'VJ^'?!WB#2]$/A;7/ ?Q#\-ZQX[\*:Q_86I>$/$?AV7Q+>>%[OPYJ'SW\$O
MV%_C?\!OC3^P3XEB\.Z)XE\,?!MO^"G?Q!^-MSX3\4Z7;Z1X1\<?M^?&O3/C
MUH7P^^&^G>)9?#VJ>+O"?P[UI_$'@>7Q+=Z3X,?4]-LO#?BI?#=I>Z[KNB^&
MOTDTO]I?PSJG[6?C']D$>$/&EAXV\&? ;P3^T+<>,;]/"_\ P@FN^#O'OCGQ
M=\/M'T_P]-I_B?4/%+Z]I^O^!/$J:];:_P"%O#UI:V\6FW&EWNM0Z@[VA\0_
MVEO#GPX_:,_9U_9MU3P;XVO_ !#^TGI?Q@U7PGXVTU/"Q\!Z /@OX:TOQ-XD
MTKQ-)=>*+;QA%K6JV>MZ<?#T>D^#]5T:YCCU-]2UW2KBSMK34'&ZG">KJ3=1
MTY2=Y/GJXNK42NTM:SQ-2SM+FBXJ\7%3)13C.#5HQ5-SBKI)0I8:$)_*BL/&
MZYH\LE+?F<?Q/L_V"?VO_A_\!/V)/'>C?L]? [X[_%G]E'XE_MO67Q._9$^,
M/CCP?;^"?C#\&/VPOC)K7Q,M=:^'GQ2U'PMX[\)>&OBW\-M1TGX5ZMIK>*O"
M^F:=>Z<OQ5\+)KUG'>:+>>)?W,_9N\)^(_!GP=\*:1XN^%_PC^"OB2=];UO5
MOA1\#&CNOAGX"N/$.O:EK2>'=$UB/PKX'7Q/J-I;7L#>*_%J>$/#5OXJ\7R:
M[KUCH>E:??6EA![IG_#_ #^5<KKGC?PGX;U[P9X7US7M/TWQ%\0]6U30_!.C
M7$I_M#Q'J>B>&]8\7ZQ!IULBO(Z:9X<T'5-3O;J01VEND$-O).MW>V%O<D=$
MH+5/E44]TH4Z,.56LY7CA:<WS*;4HS<.2,IQ2:C=2V4;]=-9U9)N][<KQ,XI
MIQ34H*?-*,&^JHHZT4%!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %?B)^WM\(-4L_VJ=)T_1]!UC5O
M!?\ P4V_9M^(/[!GBV[T;3[JXD^&?[0_A2*X^)_P1^.MK<:5J>B:MH,OASX(
M1?M(>+?'/B?1]:\.>(KU_P!G?X&:5H_B6Q\0:#X.GT[]NZ,9_P ].W'IQ2:3
M:;U5IQ:NUS0J4YTZD;IIQYH3TDO>BXQE&TE%Q-;.VC]UQ=D^6<)PJ0E9II\L
MH:Q>DE*497BW&7\UC7_BCQ;_ ,$@/VXOB_\ 'OPQ8^ ?B7\!?^":O[3G_!/_
M %ZYU6RT_1M'UGXF?LT^!?C%\,OV@?B'X(U2./3["^^'GQ?^,NAZ3I7@JP,=
MU';MX"1M$NF_X22]CN?(OB3XF\7?"GQK^T1I/[ WB:?4_CU\8O\ @@,WQQ\/
M>'? OCG4?'OC?XE_'#P5XEN/#WP\^+7AO0_[:\0:EXS^+^D>#/%FK:/\/M<M
MK+5+_78M/\#^#P-3\/>'_#VBV?\ 5!I.K:3KVF6&MZ%J>G:SHVJVD%_I>KZ3
M>6VHZ9J5C=1B:VO;"_LY)K6\M+B)UE@N;>62&:-@\;LK G0HGS34VY6G47O2
MT]YSH8B%5R5HIQK5\0\1.$>2#7[N*@O93I1""BZ=OAIM62_EAB,-4IQ3?,TZ
M='#+#QFW.=O?;D_:1J_C)\"KKX7ZI^W3^S%X[_8+USP]K7[,7Q:_8=^,WBC]
MI8> ->U#6/ %YJ&F>./V>C^R#\0/&=A;7EU::=^T%XQ@\0?M$:%'XM\9K'\2
M?B7X-\&>/]-\6:AKT_PCTR/PWW'[7OB;1M$_X*=?\$D=*NO&K:-J/B74_P!M
M6Q7PE-XWO=-L/$D%K^SI+/8W)\#OK$&D:[J5CJ,AAT_66T6[U:P%U<6-I>PP
M7EQ!+^K5M9VEGY_V2UMK7[5<RWES]F@B@^T7<^WS[J?RE7SKF;:OFSR;I9-J
M[V.!5FKE*\J;44E3J3G:[DY*<L3)1<GNH>W48^[%<M/2$.;EIN,;1J)OF=2G
M&%[)).,</'G44W9R=#F:YF^:?QRY>:?X*_\ !+OQ7'IWQRT_X=/??!?]I72_
M$G[*DOQ4^%?_  4*_9X\0L+[]H'X5)X^\"Z+:6_[<_PZ<W]QX9_:ZUO6]7N?
M$^D_$^?Q)KME\=UL/CCJMGIW@CQ#X&\;>$-.\5_X+4?%/X9Z=XC_ &N?!%WX
MV@\(?'CP!_P2-^,WQO\ @K+\2_$\MUI47B?3;OXU:KX>UW]C#X::1=>'?$UI
M^U/X5\0_"ZW\7?%3]H/2/%K7WP.\&^'/@3-9^ _%NE^*O%/B#P#_ $=R7OA_
M2-1M+"6[T;2]6\4WMU)8V4D]E9:CXBU"QTU9KV2TMF>*YU>]L](L$ENFA2XG
MM]-LE>8I:VP*/U;4-"TI;6[UR]TG34N[RST&RN=5N;.S6YO]?O;2PL-&M9KR
M2(37>M:BUC96FG0LT^I7K6MM##/.84K-KW816G)&=.+;=]5.,'>*BN>'-"]E
M'GE%S?LZD[NK:S;^W.,Y)):KFA*:M+FM&?).WQ*"DH+FIP45^!O[5GPXD^(/
MQNMK#X:WS^+?AC_P6-_8Q7]G2U^+'@.=O$_ACX4?M&?"J*X^(/P\_:1\(^(=
M URST:QNM0_9O\>_&?XN1:EH7B/PO:^/=?\ V.?A!X4T;Q-9^*O$7AK41Q-Q
M\5)]4_X);_M ?M=?M,>"/B/\-?%OA+]G/P3^Q'\0-)^"VM6?PA\1^'/%'P%\
M>W'P:_:.\0^%OB!I^A^)KWX/?"&;]IO6/B!X7\=^--.\*Z['X2_9_P#@S:?$
M[0_#FN^38Z;/_1/8:_H.K:AKFDZ7K6D:GJOA:^M=,\2Z;8:E97NH>'-3O])L
M-=LM/URSMYI+G2+Z\T+5M,UFUM+^.WN+C2=2L-0AC>SO+>:34>-)$:.1%DC=
M61XW4,CHX*NKJP*LK*2&5@0P)!!!I_\ /QQ44IU.>$6DE"*KRJP@N6.RIU,1
M0;Y;.%52Y9>QC3G,8M*DI2;=.G&$I7;<Y*C"G*;YI.TI5*5"O:^DH27,O:RJ
M0_C\^,_QA^'.E?LQ?\%MO"&@_M ?"C1/ 'A+XT?L#_$CX8)^SU\0I/A#\)_#
MWA+XK?#3]E.;5?%'P@T_P[\0KNWL/ASX[\36/BPZMK?A_6)/ OQ)\>V/CW7;
MBQ?7;WQ-I]O]=_M=#]D;]G']H'P=^S3^T/\ $F']FG_@GY\<OV8OB)XJ^"7Q
M*\6ZIIWBWX1:O^U?XV^+GC#QO^T%<ZQ\4OBY%X_MO#GQPUGP-K'P[^(/P)\<
M:IJUCK6EW'_"TU^&6NV&K^(]7TKQ!_2)-+;6D;3SRP6L*!5>::2.&)5SA%:1
MRJ* S;4!( +87KBJPO-+O'2U%U87<C"&ZCM_/MYW81,ES;W*1;W8^6Z1W$,R
MJ=CHDJ,"JL&W=6:3OR*;E=N4(X>O0Y;IQ:DO:TZL)<SY:E"#U?+4I"C:3DG9
MV;BDERPFZU"MS).+33=.I3FN7WJ=>:LKRA4_/CXWCXZ^!_\ @E1\4X_V6M>^
M.7Q$_:%\)?L-^++;X#^+?BQI-SJ/[2WC7XAZ'\%[VW\ ^+?&>@7?AS3-0U/X
M]Z_J-KI^O7FAZUX/TS4]1^(UTNF^(O"UAJ$]_HT/R=\)'^"OBW]KK]DWQE^Q
M9?>%/$O[)GQJ_85_:#UC]L>RL=:NO$O@'7_#=IJ/P$@_9L\7_'+3=3U/4-.C
M^/VOZAKWQQ\+S^)?B=:M\3_B5X2T3XVZ3XPU/Q /A5?0>&OVWTK5])UZP@U7
M0]4T[6=+NC,+;4M*O;;4;"X-O/+:SB"\LY9K>4P7,$UO,(Y&\J>&6%]LD;J+
M%O9VEH;@VEK;6IN[F2\NC;P10FYNY51);JX,:KYUS(L<:R3R;I76- S$*H G
M:I.I\3F[I2M9+V>(@U)1C%253ZQ&K/9.I2IRC"*<7 Y?<A%.RBG%\M_^?E":
MDKR;4Z;H.$&VVH5)QDV^92_'W_@A7#\(I_\ @G]X4U[X5P_#:1]9^,_[6<?B
M+6?AY!X7/]JQZ;^U]\?H/"::Q?>&D O8K#PM)I\7AM;R26.V\/R62:6$TR2W
M#?EC^T!=?!VS\"_\%0OB]<?$U;+XD? ?_@N?^QW9?"SX@3?'3Q(OB+X26?CN
MS_X)?>$_BC9^#];N_'$DG@VS\0^'-7^-_@[Q?9Z?)8VI\+Z=XN\(WL,&@^#3
MI>A_ULT5,5RU,/4^)4(48N$GI4]E_9WQ;Z26!FK6;7UF>ME)5;3M"K!)?O'4
M>NR4WC'9I6NT\5![I/V,=+N+I_RY?%'XC? #]F[Q]_P5P^$T'BV[\+_ ?0_C
M#_P2<\0ZOX(\)?'9?ASX'\'^*OCY\0O!_A3XG^+/C7XYU6V\>1_"_P#9\^*U
M[HGA"T_;6\1W/AR]/CGX2ZE\1YM4MM2\9>.;O4]3\M\0>(_@;KG[*/[=&A>/
MO&7P"\<?"?\ 9M_X+G?\$Y/B!X>EN-+\/Z+\$?@O\!?'_P 4?^"97BKQ%\0O
M ?A+QQXG\:Z1\(/@%XVM/'/[0NMKXGL?$0^'7C#PUXJ^+NOZ7K-[X/\ $WB,
M2?UE#4M$U&^U3PZ+_2K[4K"RLI]:T,75I=7UEIVM_;X=.FU33!(]Q;66K_V=
MJ<5E)=P)!?\ V&^2!IOLMP([[6\#I/&\,3I=!A<HT:,MP&B6!A.I!$VZ%$A;
MS V8D6,Y10 N5OE3D[1C1C&*44OW-:E63=DG)/V*@KN\(OEARJ*3)VDJB48Q
M=3VB<E?FC[6E.E)QN])/VCFWM*6LN9R9_,O\2?B3^SCX\_:H_:4_9W^/7[1_
MC?\ 9W^*6B_%[]F/XF?\$V[+X)^%_AW:_$#QW^S>GP:_9SU#X7Q_L&>-/$GP
MS\6)X@L?%'QP\)?'7X??%[P5\.+G4O#NJ^&/$WCGPUXXM;?X=ZS>2Z=],_ 7
MX??LU?$/]K+_ (*W?$CQ9XT/B'QA^SQ^U3>CPIJ]Q^T1X_C3X)^$_B5_P3/_
M &4-'^*.HZ3IUG\2+?3/A[INL>)[[XI:)J&MQ6>E)H^L^%+C2=,O-+O/ACH]
MOX9_=$PQ-)',T4;31+(D4K(K2QI+L,J)(07193'&9%4@.8T+ [5Q)1*#E3E#
MF:DZ.(I*?53KTU25=]?:J"O4<904YMRAR<TF2E^]A4T2C5HU'!*RE&E)S=)]
M'3YOX:<9."TDI62/Y'%^-/PA\6_L,_\ !*?X4?$#QIH]WXO^('_!#SQUXH\&
M:E\7?$\7B+X/^-/B3X=^#W[*>A:[I?PR^'MO+8^)?C-^W_H'B.UO]$^&%QX2
M\=Z)X^^"_A7Q-\:=3M]"\8:SXL_L ?=?['WQO\/?%#]I?_@CGXHUGXM>'O'O
MCGX@_P#!$;]HK5]7UJZ\=:3XE\2^,?&6M?$'_@F!>^(-0O+P:G=:AKNOZGK?
M@GXCW&I7+&>\O-2\'^-GF+W'AW7?L7[ZO'&[1L\:.T+F2%F56:*0QR1&2,D$
MHYBEEB+*0QCDD0G:[ T+C4='TF71]/N[_3=,GUF];1_#]C<W=M9RZKJ%MI6H
MZR^E:/;2R1O?7EOHFC:MJK6-DDLT6E:5J-\8EM+&YEB'!.UW9>VC6TMJXK%1
MBNR;CB(1DU\7L4TO>4:;3Y4DDM*<J=];M2^KMMO>RE1E**>WM9:JS<_S,_X*
M!^(]"\-_M'_\$BWOO&:^&M3U_P#X*"Z[X972;CQK<Z#8^)]!U+]AC]LII;"\
M\,OJ]GI'B<#QW#\.+72Y[[3-1O-.\2ZEX?TW2)[6_P#$45KJ/XV>#?$/PKT#
M2OA9\<[+XKQ-\5?#G_!QQ\=/@7X8\?:M\;M:U_7;#X5>._VHOB_X%\3_  DL
M[W7O&6I'_A#/&/PPU/37USP:=VG^(;.P\&^);^RO+CPWX2U#3?ZV**N#Y5&R
M5U4]IS+1O_:,)6:NT_BAAI46_P"6M+1Q4H3SG3<W)\[5X<BZ\O\ L^*HW6J6
MDL1&JE;XJ2UYG&</Y=_BM=MX?^(W_!Q=KO[&^B>#K_\ :S\$^#?@9?\ A6/X
M-V/AAOCYX>B\1_LR>&[_ .,FH_#H>&E7QA:_$Z\5/%NO:%!IN_5]<^+MEI.;
M35/$KQ6T_P!BZ)=_!F3]J1O%O[)GCWPG;_L6?$?_ ()I_&'QK^TC=_"?QK#X
M<^"VF^+K?QO\)W_98^+4WB7PEJ>EV_@_XO>//AMKO[2-EJ7CZUU?1/%_BWP#
M\.=,D\::Q?#X;_#QM%_<.J]M9VEFLJ6=K;VJSW$]W.MM#' LUW=2M-=74JQ*
MHDN+F9WEN)W!EFE9I)&9B364Z;E2=-2E!NC*DI1V7-AL=AY*VEZ;>,A7Y$XO
MVN%HOF6DH:PM&?.XJ2]LZMGNG[?!UDT]4IQ6%G24G%KV6(J1M:\9_P GGP<\
M#? /0?V0O^#>GXC:3XYU.S\8?M9?%+]B_2/V@O$__#1/Q'DO?B]JOAW_ ()C
M?M'>&=6T/Q)-=?$B6"YNO"_CE?#W@3^Q=/CM6\,:E%H'@&TM=-6WTG18LS3(
M_@#\.?AK\1/&?A/Q_H7AN\_96_X.$O@/\$O@'J5K\9-1M=,^ GP9^)/[6W[,
M]I\9_A!\.+)O&":-X*^&GB[X?_%'XX:?\0/ .F6EKX<U+P')?Z=KFF2>&? '
MAZ#PQ_6]6=;ZQI%WJ6HZ-:ZIIUSJ^CQ6,VKZ5;WUM-J6EPZHMP^F3:C8Q2M=
M6,6HI:73V$ES%$MVMM<-;F00R%=IOFNE[K<I24HOWXKZS@\0N5VT<(X>M23T
M2AB9.R3JQK3&T;WC"7,HJTD[75+%TWI?52=>E-IW;>&@KMJ#I?R^:E^T+\(D
M_;G^#WC#P=\4=#\&>+]+_P""V7Q2_9U^-=M\5O&^FW_[2'_".ZE^R;^U+X*T
MGPEXPUJ2\\.P_"[]DWXB_$?P/X)'[+'P"U;2_%VE_$&/0_A1\8-&\9MX_P!;
M?P+X/\B\?W7P&^%W_!,S_@LYH7A76/AS\)/B-X!_X*)?&]_&.G>!]>T;X6>,
M_"_AG7_VQ=)U?X/:9XZ3PG?>'=9L?"'B[PQK&M7_ (#\/^*BOAWQCX:U#69=
M&L-5T>74L?UDWWBSP7I%_KEAJ7B;POI>IZ%X>3QOXDLKW6M*LK_1O"KG4+&+
MQ?KEM/<Q7&G>'W.@:M9Q^(+](=.)T74;=;O_ (EURD/10"W96N+80LMV4N6G
M@$96Z+0Q1QW#2Q\3EK>*&-)2S9ACB56V(@ G94TDER12NKW:5;+ZV]NL\OFK
M;?OY:2E"4JTN"<Y2;OS2E+E:5O>HX^@[]VH8Z#3233H4]HS2I_SN_M5>*O#'
MCSQ7_P %AO!7QL\1ZQH7QG^'GP=^'OQ'_P""<.M:9J=]I?Q&T?P!??LPZ!=?
M#SXC?L7RZ'<6VOZS\6)OVY8_B?X;\07OPLBOO'OC#Q5_PJ+X7^,H_$'AF?X5
M>'[OY?\ VK+;3O$6F_\ !8B__:.\8Z;'^T7\'O\ @BC^Q;\;;W2--^,FN0:;
M\)OVQO"W@/\ ;]UN\\?_  V\.:?XT_L/P=XU\'?$K3_A9J/@;5O#>F65WH%]
MK7AG4?#YMKGX@W-QXD_JIT75?"_C+2M"\6>'M2T'Q5HE];)J_AGQ+HUYIVN:
M7=VE_:O%'J>A:S8RW5I/;WEG/+$E[I]R\=Q;32(LKQ2,&WZSE%N,8Q?+RIJZ
MWYO8UJ<:E[*7M'[:%6H[M2G0H2AR.*DM(M1;;7/>5VI._N^UHU)4^WLU[&=.
M$>6\85JL9N:O&?R/\3_BQI%C^PC\1OCCJ>L^/_$6AV'[)GC'XI:IKW[/MWI=
MW\5-:TZQ^$&I>*M1U3X*7UO(VC3_ !$OH(9[GX=7$4ATUO$TFCNKBVYK^6/X
MJ?$?P!K'[./_  4E^'_P;^)/P@\1> _'O_!#O]E7XS>%?!?P,\6P^-M#UCQ1
MX9^*O[67A/XM>.[CQ,LT+?'KXK^#O#^E^ O"_P"T!^T-9^!O!&H^()-&\%6_
MQ$\%^#;S1M*T.S_M4J.*&*%$CABCBCCCCBCCB18TCBB7;%$B( JQQJ2(XU 1
M!PH%;2FG4JU(PBE4ES1B[V@O:2J**Y4E9/V:NN5VB[13]G.GG3BX0H0<W)T5
M!.36M1QITZ;D[MM2FHU&]9:U-6USJ?\ ,7^T+X,^)WPA\2?\%&/'/_!*GQ!\
M0O&?@;QK_P $T-7^(WQ 3X:?%'QK\9;6_P#VPM9\<-<>!OB5\%?$FM>*?&EY
MJ7[5'BO]FD?$_P 3Z]:>"]7O?$?B75=-_9R\6^,-%U/5_'/@C4?%/H7Q_P!!
M\$>.]2^-5U_P3\O]'\<?L]?&3_@CA^USXF^)_AGX(71UKX>ZG\9;/_A6MS^P
MM\2=(L?#'GI8_M'>/=-USX^V6C^+8FLOB#XX\._#C3QXEU#5;_X8?#K^P/Z+
MK6SM+& 6UE:V]G;*\LBV]K#';PJ\\KSSNL4*HBO-/++/*P4&2:225R7=F*6U
MG:68F6SM;>U6XN)[R=;:".!9[NZD,MS=3")5$ES<2LTD\[AI9I"7D=F.:PJ0
M<Z<X*<H\U.K3C*]Y)5*.-H\KLHWIP>+A4C%-6GAJ33BU&5/6$N6I";C&7+5I
MU7&UDY0JX2IS:\UIS6%E"<N5WAB*B_F57^<#X+?&+X%_M,_M0?!'0?!'Q$^'
M_P >_"/Q>_X(;_$?P]XLT32=<TWXD^#?BCXST;X@? K3-6\*>*--$NK^&/&W
MQ \/:3JNO:=XF\(ZQ%J?C/PYI&M7EIXCTK3].UI4O/T#_P""+&J?"/6O^"57
M[!%S\([[X>:II\7[)/[.6E?$"X^'<_AR\LA\7='^"7@'2?B=8>+9O#;26[?$
M32O$UG=Z3X\M]79O$ECXALKS3?$*Q:I9W$$7Z@1P00EC%#%$6SN,<:H6S)+*
M=VT#.99II2#G,DLLGWY&)>J(@*HJH"SN0H"@O(YDD;  &YW9G<]6=F9B68DZ
MU&IU:U6W*JTJDG!-<J=3&8W%\NRO&*QLJ44X_#2@[).4%G!.%*C2T?L8THJ;
M3YVJ6#P^$YMW:53ZM&K-IZRG->]:,G_))H#?LN>#OV7O@M\,_#&K?!7X9^)/
M#_\ P<3?$;X;_$SPS\.M?\'?##QIX/MH/^"E'[7U]\+O!OB)/!-]X>\3^"[N
MQ^$]YI=[\-M+DDTC4='^'5WI&H>#4L?#TFFW->A3?%7]GGX+_#[]KWX*ZSXR
MMO#OP$\#_P#!='X9_!_P!X>3XK6/AK]FSX*^'?&/[/G[.WQSU3P_^T+=WK:[
MI_A[]DZX^,DWQFO-8^$4:^&O"GC_ .,.J:3\%)]=^'FE>)M=\2^%_P"IA8HT
M:1TC1&F<22LJA3+((XXA)(0 7<1111!VRPCCC0':B@9^IZIHVF_V?'K.HZ98
M?VKJ=KI>E1ZG=VMK_:6LR^9=6.G:>MW(GVS4Y!:2W%I9VPDNG%M)+#&?)9ES
MIQ=.-*/,Y*"IQDF[>T4(993BI6YM5_9\I1TDU+$.R]UJ;LE[1]9J=I.UX.4\
MPFY)Z/\ YCE&5VDXT5=^_P"[_(^GB7X*>(OV:/V>KKXU^(_@AXK^'O[,O_!P
MS\>/ASX@UKQ?9^$K3X:_ [X-ZI\9?VGM/\&^%IM-\9:GK]G\%_A!JOAKQ%\/
M]/\ A]X/UW6X= M/ >L_#O0]&N;WP[)X9,W[A?\ !4_XI:U\&/V4O#OQ0L8O
M$<'P3\(_M!_LPZQ^U5?^#=*UZ_UGP_\ L?V_QD\(2?'/6IM!\,65[XFU'P-I
MGA!5?XNZ1HVCZC<S_!@_$*WO+%=+.H3VWZ6O%%(H22.-U$D<H5T5U\V*19HI
M,,"/,CE1)8W^\DB*ZD,H(DJVY-)*W,JM*K=ZQDZ=+!TY1G'[4:CPEY:W<:LH
MMR<(RG*@E*4ME*G4IVCHX1G5Q=2+IO7E=-8IJ-].:E!KE3E&/\]_C7XF_LN:
M/I'[.WCS]FGQ[+XJ_P"";'Q;_P""C]N?VK?%_AW6=0UC]E71+?Q?^S!\0O!O
M@KP3X$U2UBA\&>'?V8-3_;'TGX":A\9SX>N?^%,W/Q_\;^)O!'BC6KRZUSXQ
M^ M)\3^-31_#SX<?M1Z-#X\F\$?L?^'?^"TG_!+?3/V1=5TWXM>)O!'AC3=#
M\3_&G]A?4OVL?!'PG\2Z7XPTC2[WX+>#/B)K?QRM;;PMX<O9?!WPG\7:-\8O
M#FBZ9X8/PECMO"G]+MGJOA;4+S6/"6GZEH%[J'ARUTVW\0>&;.\TZYO-"LM9
MM)9-'@UC18)'FTNUU6QMYWTV.]MH(KZTAF:U66&-R-J""&UAAMK:&*WM[>*.
M"WMX(TBA@AB01Q0PQ1A4BBB152.-%5$10JJ%  E))-*[3E!KF?-:$:F#FHI)
M15H?5)JE)N?+[>I=M*49MIR33:3<9*\4TU-QQ47-:Z.:Q4755ES^R@TDW&4?
MY"?VM=%^!/PN^'?_  7F7P+XMTGP?>_L=_$/]F_XV_LY:9I/Q9U738?V=_CI
MXH^ _P %/&6K?$;X=:0OBN.W\$^/_%WQ0TR^O=8UFTM[?5?%&O:KXWT>_DOH
M_&?C33M;]E_:]\)? /XJ?&W_ (+16?Q ^*OC6W\<>"_V=?V5OC/^R9!X2^/7
MQ.TKQEX7^.-U\#OBJ/A1\1OV;O"?A+QS8WGB'XFO\4(_!6D?#71/!FFZT^H>
M)_$J^#O#6@O+\7?%.E>-_P"I:OE?X:?LQ6WP\_:6_:,_:2E\:W7B34?VB;;X
M2P:AX/O_  YI5KI/@27X,>&O$?@[PK>^$-4@F?5_MFK^'O%FMP^,9]9FU)M2
MO)+5]!_X1C2TOM'U$M=*%W!>QG#GIOEG"I]75&%2FVFHU%/DJ0FU+V<L/1;4
ME%*.KE&S?LX.3J0ERR5XSC[>-6<)ZIN#4:D9Q33FL36MRN4G/^<']N_X[0Z'
M<?&^3XL_$72OAQ^VC^SI\)O^"2'C7XB:E\1O&FFP:_HNN_\ "\/".O\ QB\=
M?L2>'=&N_#/_  JOX/:=_P )5XCTW]J;XZZ-K?B[PMX\MK35?ACXZ\+>$_ _
MP_M_$/B'9_;UU?X6:E>?\'!/Q#/Q3,_C;]GCX _LC?''X":O!\</$#3_  ?^
M->D? [QGXL^&OQ!^&U@GC-K+P;XO'C*'P_%X3O-!L[":X3Q#JGA_18S8^/\
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M2U8>+/&'PDT07VJ6\GB[4OA?HWC;]K\^!8Q/XHN_!&H?L!? 2SN- L=1\9^
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M5_"#:O>R%)/'^CO;I>2=7\4/C[XO_:I^ '[%WB3X\_#WP#X:_:(_9W_X+;_
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M\+M4L-%U^P\&"XUNV2^NX8_2=&_8%^#GA;Q5^R=XH\&^(_B5X2'['S_%>[\
M:'IFL^&-1TOQMK7QRL[R#XN>)_BU?>)O!^O^*O&/BGQ_J&J:SXF\2^(+7Q)H
M>I:CXMUS5_$TLYU>]DNA-/F=G-OE=6:DN5J?+&K747&2>D'3E25N6\G&,DU[
M-SJ$V]5"RDHTW%[QUIT7-25M9N<:MGS-04G&2]]1A\@>/O\ @HS\8/!GP)^-
M/[8]KH'PUUO]GO\ 9@_:P\2?LW_%[X>P>%/%D?Q?\6^%/A'\;M*_9E^/?Q<\
M%>+$^(TWA?PG?^$_B4WC7XA>!_A?K'@?QI)XW^&7@G2-%OO'_A;Q3\0_[0\"
M_*GQ@^-'Q<_8V_: _P""TW[3OP(T/X)1Z'\&M?\ V(OC/\;?"OCKPEXIU+5_
MBYX.L?@'IEMX^\,^#M4\&>*O!-K\._B1JGAL2:AH/Q8\4VGQ<TP:MIUGH>L_
M"Z\LKIM?LOUGD_8 ^";:_P#%%H=5\=6OPH^-7QL\.?M'_%/]G2"[\'?\*7\7
M_'+P]K_A/Q=/\0+J&?P3/\2],_X2_P 9^ / WC'XA^!M ^)6D_##Q_XCT#4[
MWQ7X'U2/XC?%N#X@<Q\6_P#@F]\(OC/:?ML:;XL^)'QJMM,_;UT+P#X:^-.G
MZ)K'PYM(-)T3X=>&H?!VBV7P\FO/ACJ%[X>-WX;B.F:M=:I=^(;R?S9+^SN+
M'5!%?1VGM+EM+EUB]8^]#!1JTY)64J=6I2Q-2,=J=.=.D[.*<9E%M*/,GRRN
MI-/7E>,]C-+649TX5J$9MMN<X3FKN3O^??\ P50\>P^)=&_X+%_ ;Q'\+/@O
M?Z9X9_X(7^+?C7I'Q-/@5)_C%J$^IO\ MAZ5H7@CQ'XNO[ZZM[[P=\//%GPP
MD^(O@'3;72[1_#_C'Q5J>M64UOJ<+7M[]H?"?]H#]K;PU^UOI'[*_P =O#WP
M!G\)_&O]EOQ_^T)^S)X]^$]K\1([GP/>?!/Q=\(/ OQ(^#WQDL?%>LW)^)5Q
MIJ?'OX7>(_#7Q<\*V?P8L/%%I;^)]&O/A?X6U Z9/7KWQ)_8(^$/Q@\=_'KQ
MU\3/%'Q-\5G]I3]CV/\ 8?\ BSX6EUGPKHWAG6?@JLWQ%NIY=.;PUX+T3Q+H
M?C.\O?BU\0[NXU_2_$EM;"3Q$8K?2K>TTCP_;:3Z)\//V8-#\$>)1\1-=^)/
MQ,^*WQ@L_A5)\%_#GQA^(Z_#(^,/!OP]N]3LM?U;2/".B> _AGX$^&>C3>)/
M$VD>'/$?C#44\ 37WC74/!W@6U\73ZUHG@7PCI.BM62:N[.*YK)WERPS"*Y6
M_AFI5\+*G4:M&,)Q<&W-3&GSN2T5H*-]7%_['*IHE9TY>RQ$7#5R<H/F24.3
M\@/V7_VGOCW\4XO^"%Q^'S_!#]GGX4?M,?L[?'#XL_$+X#?"KX/ZKI7PYL+[
MX>_#KP5=Z5X3\)6^F_$S06T/P3I.A_$36;;POX=>TOM*TOQ=;:7XUUFP\2-I
M&B:%I/ZX_M7?&+QQ\'="^$\W@:]^&^C3_$+XS:+\.]?\2?$2S\1^+9O#^@7G
M@GQ]XK\SX??!WP1JV@>/OCO\2/$>O>$="\#>'_AKX'UJQUNRLO%>L?$Z[74_
M#GPYU[1=2\3\!?\ !-+X0?##PK^P]X7\"_$[XZ: W[ MGXG\,_!_Q#!X@^'L
M_B'Q-\,?&_A^W\+^,?A-\2Y;SX8W.DZQX2\0:)IGA^VFU[PMI'@SXIZ5<^&]
M)U7P[\1=&U=M4O\ 4_>OVC?V7/#7[1FH_ WQ-=?$'XG?"?X@?LY_%D_&+X5?
M$3X47W@F'Q'HWB&^\ ^-OA7XGT?4-+^)/@3XE>!M<\,>,OAU\1/%_A/Q!8:M
MX/N[^*QU9KSP]JN@ZS;VNIPN;7N\JNO;R<K\R7LI2PMVM7)\L8UN6GS)K1<U
MG%,46I57>23IKV:NF^>*Q2BI>[RWDY4'*HHV;NW&ZDU^:WPZ_P""A_[4OQ;\
M+?\ !/"#PSX9^!7A;QE^UQ\??V\/V9_B5JOBSPI\1K[1_"?BG]D?1OVJM*T3
MXF>$O!-C\0],U:TTK6_%'[.4/BW7_A+XA\;ZEJ;:1K5Q\,;3XK:-J(7XK6'3
MZ!^WQ^T=IGP?_9C^-?Q+TWX)6?@./]O#XT_L)_ML>(_#7@OQO'I_AS4?!7[3
MGQ=_8X^%WQQ^%B:S\62_@3P#X\^/G@;X::/XNT'QS/\ $F[^'F@?&,ZW/XFU
MK3_ASJM]XC^B/AK_ ,$TO@_\*K[]GRY\,?$[X\3V/[,/[0O[3G[1WPDT;Q#X
MI\#^(X--\3_M87/Q1G^)'A3Q!K>K?#BX\8^+_!^G1?&CXF6GA:Y\3>)M3^($
M:^)WO_$_CSQ3K.EZ'JFF><_%_P#9-U3PK^S?\2/V%?AQ\+?BG^T#\.?VU-6_
M:ZN_BG\9/'GC+X$:3X6_9UU_]J#QIK'Q$^('C/Q?I%I=?"SX@>)=/U/QK\5_
MB/X[^&NA_"#P'XWU_2O%F@V/A?4M?^&GAJ]\/>*_#N<5)\KD[R]Q\J:C&4O:
MX)N#;5H1=)8^,I744Y4IO2$$JG\;Y=*7[R]TY5(P]GBE"44FN><9O"3Y?BER
MSA%WE*3W[[]LWXFW/Q-^"'P?T5/AY:>(_P!K7X]_M.Z!\"/%&L^"_%,^B>$O
MV>?V5_"6IW/BGQ_XKT*T^(]I_P +8\2_$3QQHFFP_#.?PGXP^'/AK5?A/\3?
M#_Q3*W%SX+U'P7XR\(U?_@HI^TCIV@Z-X0C\"_!O_A=7@;_@JMX-_P"";_QF
MO=4LO'&G?#GQ;H/C;P5X=^*OA7XS?#'3;+Q1K/B+P7=^)OA7\1/AOKMQX)\4
M:YX\B\'>)K[Q/X6;Q)XQL-'TSQ5KGZ#_ !-_8Z^$7Q$\.?L^:3I+>)/A1X@_
M90U[1?$'[-WQ#^&%YHMEXW^$3Z7X&U3X6:AH>A3>,- \:>&=<\)>+OA7KNN_
M#SQAX2\;>&?%7A[6]#U*'5&T^#Q?X>\)>)O#_"^)?V /A!XET7P%IK^*OB9I
M.K^#?VKM&_;3UOQII.H^"?\ A+?BE\?M#$D%EXC^)5WJG@+5-+U'2H]*&G>&
M[7P_X9TCPIIFB^$O#WA?PGX=AT;PYX<T?3+2K).*O>*G%3;C+FG3C6PS4XVE
M[DI4(XM58-2E.56BHM2A[12^9QDTN6;A)P5TXPJ2I5^:,O=M-1K2PWLI*T8Q
MIU&U*,W!_*7AG_@H3\;_  G\/?BOX.^+GACX;^/OVD?A_P#\%%M _P"">WA/
M6OA%X=OOA]\-/B5KGCOX;?"SX[^%_B';_#_XI_&;5;SPA>:-\(OB;=6=[\/=
M5^/FHP>,OB1X-30M)^(/AJP\;V-UX;^Z/V5/'7[4GC+1_B?9?M4?![3OAAK_
M (3^)^I:-\-?$FBW'@VRTOXN?"F]T#P_KV@^-)? GA7XU_'VZ^&_B#0]9U7Q
M#\.O$7AW6OB/KIUV[\%Q?$'1I=)TGQG!X2\+>,^.?^"9GP"^)?P__:D^'?CG
MQ3\8M9L?VJ?C_P"'?VI=:\3:?XSTKP7\0/@]\??!&@?#'P]\/?B;\ /'/P_\
M+>%/$7PZ\2> +7X,_#*X\,W<][X@Q=>&)!K*ZQ9^)?&%GXA^DOV<_P!GS3?V
M=O!$OA<?$_XS?'#Q1JEZNH^+?C#^T#XWB\>_%3QE=6]M%8:9'JFHZ;H_ACPG
MH.C:+ID$-GI/A3P#X.\&^$+6ZDU?Q(V@2^,/%7C#Q%X@4+N/O_'R03M\+;HT
M8R:LERSA6IU9.5^6<:UTKKEC<[<RY+\O-)ZZ-)3JM)W;O"5.I3BH_%"5%7E:
M5Y?E1XF_X*4?M#?#.UTW3_B1;?!&W\4_"?\ X*@Z;^Q?^U;8Z7\-?B!;Q^&/
MV<_B7=>!-0^"?[2GA:UD^-.K/X4T35/!OQQ_9NUOXB^*O&>H:UX%\&ZA\7-1
MT)9[S7/!.GZ5X^N?MD:Y\0/B9XC_ .":WQ&N+#X;2>()/^"N'B'1/@#K-UX7
MUG3(=)^%4/[,G[9?A+0/$6OZ@GB3Q/>^,K?QDGA7_A9]I<^$KSP+H?Q"\)7W
M@321#X0N5E\76OWW\7/V!OV;_C9K?[4'B+QSX6OKC6?VNOV;M,_9;^+E_I][
M;6<Y^'6F1>/H!JWA9VT^=M \?7L'CFRAO_&"F[O;A/AK\)ML,3> M*9NL^*G
M[)7PZ^*0_9@MSK?C/P#I/[(_Q4\,_%SX3Z#X NO#%GI!U_PA\/?%OPKT#2/$
M<7B;PIXJNM0\,67@3QUXIT,:7IUWH\[#4TOS?#4M-TF\L+@TO9.7Q1J492<4
M]%%0522=[\UZ*G!Q46I8G$I/2">=2,I*K&-N65.M&*D[WE)2=-27*EROVLH2
MO=<M##-WM-OX1^&7_!07XV:MX7\(_"KQUI7PCO/VFO$O_!2/XR?\$\;?Q]X7
M\+^,?#GP0O9OA)X%^)GQ\NOC._PPUKXB^)O&VAQ7_P "_AU/I4/PR7XQ>)+B
M;XMZCI]C'X^C\*W-SJ&E_6'[*7[2_COXG_%3]KG]G+XPZ1X7B^+?[(OQ,\#>
M'M3\9_#W2M<T'X>_%+X<_&7X8^'_ (N?"[QKHGACQ)KWBS6_!>O6%CK.N_#S
MQOX2N_&/C&%/$7@2X\7Z5X@31O&>G>'?#W*W'_!-CX*77ACQSHDWC?XP'Q!X
MI_; F_;L\)?$B+6_ UKX\^#'[2DB6UK'XQ^%ES:?#R#PU%I2Z/%?^&-0\'^/
M_#'C[PMXG\'>(O%7@_QEI7B/PSXFUK2[WZG^$WP/\(_"*\^)&OZ7=ZUXF\>?
M&/QC9^//BQ\1?%3Z,WBKQ[XET?P9X6^&WARYU.#PSHGAGPII%CX:^'G@?PCX
M1T;1/"7ACP[HJ6VC2Z]?6%_XR\1>+?$OB!1=U[Z]YTTI6TC[1TL+K%:I*-6&
M*YMHS56#BDE:%M.[L]/:-QT=U!5L2[2;^)SH3PRBK7A*E/F;YKR_.C6_VGOB
MCX%^-7_!5T_#W]G/P'X]\;?LY^$_V2O$'AA_@]\-=2U?X[_%[1_'G@+Q)J^L
M7OC[3+/Q'IVK_''7O@_H-OK6H_#7X4^&-1\+^(/&5AI5S\/_  OK^F>(/&^G
MW6C?6O[$G[26G_M4?"OQ#\4O#_QB^#7QO\)'XB:QX<\*^+?A#X-\=?#"ZTO3
M](\.^%)=6\&?%SX4?$OQ3XM\=_"[XQ>$O%]]XETKQ+X,\47FF:U;:)%X7U;4
M?#?AZ\U>?2[>"]_8J\,'XC_M*_%GPY\9OCKX%\>_M/7/P'O?%&N>$-:^'-L_
M@B]_9TNK>X^'D_P^M=7^&.LVB6UQ#%/I?C#1?'D/CSP]XQT74M4TC7-(NK"]
ME@KUKX)_ #PE\#IOBMJ^C:QXE\6>,OCC\3%^+GQ9\=>+V\-QZ_XS\<6WP\^'
M_P )=+U&YTWP5X:\&>"]%M](^&WPL\ ^%K6P\,>$]#M+M=!D\0ZU'JOB_7?$
MOB+69C\+3W]G32?:<9UN9+IRN$Z;E+W7SQ]Q.$JB">LKQNE[2;U;U@X4;7TO
MS*<:BBKM.$O>M*,)'P3)^W+\:](_:S^$WPEU_3_@W>_#[XJ?MH_%K]D^;PYX
M%T;QSXP\1^ -)\)?LT?&OX[_  ^\:>+_ -H&V\56_P *4^*/BH? RXU/Q?\
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M\Y^(7[!OPF^)GP$_:>^ OB3Q5\24M?VRI=;E_:2^)VF:AX*LOBA\2CKWP_\
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MA+Q7\1_!GQ=^"-WI7AOP\?A3XE\+KH&JZC\3=0T72?B3?_0GQT_;P^,_P?\
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M5*<U:\XRUY.:*<;V?*L7AJSYNDOW*Q%.UU+11C4CS0G#RF/]IS]HOX=_M*_
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M7Q-IT&H> [K2D\9:?XD_LV\ACNO"-SHB>)K35/,T:;2UU2-K0?C%X,_X)_\
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MM7^#?[07QN\/?!;X5>)_B!X(\$>'/AEI_P 0-;^$WPONI-(MY7_M37;W1/\
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M\46?@'PA<:/)%X@\4V%OJOAR[UKA_%/P0_:%@_:Y_:<^,?A;X?\ @[7?AO\
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M:Z3O"G*<KJ+WY(3>EFG**BX.-VT^>%2I%O>E.E:ZM*>C1114EA1110 4444
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M/Q1A^P7@W]K?7?BAIG[6D7PP_9]\?^)_'7[*?[2MK^S;?_#K4O%OPN\-:O\
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M=7O@VQM]#W/V._A?_P $Z/V^8?V@KGX"?%[]H;QWH/Q\_9)F_9^_:B^%5YX
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MA_X.)?@)\&/"/A+4/"OC?_@ES\+?CE9?"3PA:6?B32_%?[2WBCX9?MT#Q?\
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MN^#'QP_X)0_LQ:S^QUXS^)-Y)XC^&OQ1_:-UO4OB/;_M7V7@#Q7+'=VOC/\
M:S\2:5>?LV2^"]&\.7FM_%Z_\.1:I>?":'[1XA\>1ZER?[)FM>!I]/\ ^#9>
M35-:TB$1_P#!-KXH^&?$5OJ>J#3[<+H_[&WP'T35+'6+"\GM[8RZ7J^E>*M*
MBGO(#-:26_B2ULIDB?54?:490Q$J=U*,9RIJ2BXQ4Z6)S.@W*5^:+E]1A54+
MIPI5:512:ES5,(S4Z4*B3BY4?:N,OB<:E#+:J45:TK/&SI7LU.I2K0:7(HT_
MZ=+RSM-0M+JPO[6VOK&^MY[.]LKR"*YM+RTN8F@N;6ZMIE>&XM[B%WAG@F1X
MI8G:.161B#SG@KP%X&^&V@P>%?AUX+\)^ ?"]K/<W-MX;\%>'-'\*Z#;W-Y(
M9KNX@T?0K.PT^&>ZF)EN98[=9)Y"7E9F.:_E=_X)X:/\*/!"_P#! CXG^%)]
M"T?XO_%C0_VN/@Y\7/&\6OS3^//B#\-+'X3_ !<\9:/\,_B'KE_J5SKOB'P?
MX;^,7AWP/K'A#PCXCN;K1_"'CJ6$>%]/TG5_$%['J.I^RCK_ .RMXN_:G_9F
M\*?$?]HG]FU_CY\#OVY?VZ;OQ-XO^(-SXR\-_M4?M7:UXH^(WQ^\&?"3X+_%
MKX<>/_AQX6T7PWK?A+QAKW@KQOX(TG6?B7XZOO#>M?LY_!C2_A'X!\)7'BFR
MT#X2D?><4E*\M)*UGHZ#=EO)06(BW%KF<E.,(W5RDTXSDW;DMRW3LW*-?K:T
M;O#N-[I)2CS/1H_HH^.W[26D? CQ[^RWX$U?P9XG\0R?M3_':?X!^'?$6CW/
MAZ'0O!OB>'X0_%/XS17GBJ/4=7MM>FM-1\,_"+Q3;::- T35XO[2BBBU:[TA
M)K-[SZ2K\D/^"K^D>!M1U#_@FY>_%F>UTWX,:'_P43T:?XO^(];\07_A#P9X
M?\&>(OV+?VUO -N?B!XNM-2T:ST'P=XL\8^,/"GPZOH=?U:R\.^+K_QIIGP^
MU:/58/%XT/5/A;1OV)]4/[.7[86H?LH>"8-8\$_LF?MZZ-^UU_P2<\#:IJ&L
MZAX1U.R^%OPE^ OCCXV? _X52:I?26^A_LX?'KXZVG[2WP:\%:-I?D> ] O_
M !+)\1_ =@^CZ'\/=?%2Y8TU.322]K.I.Z:A"%3"QE=)>[RTJM2M&[O45*O_
M "4VTG)U.2*NY*G&$;<J<YPQ,E[[:34ITJ=.;^&FZE*3LI3M_2Q17Q=^Q&NF
M^/?AWXB_:P7PK/X6US]M#7M*^/D5AJ^E6^E>*-/^%EUX.\.>$/V?-%\26;>=
MJFC:\/@GX9\%^+?&GA#4=2U&/PK\5?&GQ(L["6&"X>)?R\U#XH_LZZ]^W!^U
M7^S=^VYI7CD_M5R_M<_ SXO_ + 5CH7ACQ_;_$7QK\!?"_PP^ >H_#>U_9>^
M)?A[2HIM"\#:3\9O"?QNT[]I6+2?%F@^!_"<'BSXP:Y\:==\.?#GQ-XKU#3U
M9JI&G)6DT^9*S:E&5.-2$;:2J0C.4N6ZYE0K).T'* Y+DE46L5LWHFFJCA.3
MU<:<I0C'FL[>UI-I<RC+^A2BOYB_'+^(/'/PR_:(L-,:/2?^"O'PM_X*F27'
MP<N;QDL?CK_PJK6/VU/"_P#PI'4_!=E%);^*]<_8TUS_ ()^ZO:>'?B=)H]M
M??">Y^$^A_'BZ^(D3^)_"OQ3NM-\F_;,\,?!.?PU_P %NOB1<-X8_P"%F?!3
M_@H/^QAX_P#@9XXB\2RQ^-_@[XX;X ?\$^T\0>-/@YKUOJPUKX9^*]2\9Z9\
M3O#WB[Q+X!GT'6M=DT;QEX,\27]]IV@ZEHVGU3CS\KYH1YO9-W>J57ZC9KHU
M3EC>2L^:U.I0J1>K2B2ERRY>5W<JD5?W4G3^M_&]7%5(X53I:>_"M!K9\W]9
MM%?R7_MP>%?@[\+?"_\ P<!?#'X-VGAKP7\/KC]A?]BW]H)/!7PXU$66DW_Q
MLUWQ%^U+%\6OB]#H>@W;IJ?Q,\6:'X=^!=U\4_$ZVMUKWC8+X U/QU+K=SKV
MGW.J>F?'W0_@C\ _%_\ P4S^-/[,-GXX\:_L<>*?^";6K^(/VN+#]F'XL:Z+
M7Q?^UGKGQ$UW2_#GQ)T_XS:$WQ"OM ^-US\%I/'GB;]J;XG:%:>,OB%X<^'4
M7PY^+/Q*\+^*=5\1>$/^$NSC+FBW9*T=>;11G[.K-<[:]RDZE&5)3E9J4Z=U
M%^TY-9P<'&[34I*W+JW%RHJT5KS55"M&;IK2T)V=N1R_IFC\*^&(?$UWXUA\
M.:#%XRO]$LO#5]XMCT?3T\37OAS3;V]U+3M N]>6W&JW&B6&HZCJ%_9:5-=O
M8VM[?WMU!!'/=3R2;U?QQ_%;Q9\)QX2_X*/>#/"7Q+^$$_PYOOVHO^"&_P :
MOAE'^SS-<_"3X+76A^/OCM\!/#OQ$^+GP#L/#GC/4;:/PEXE\&>"M=L_$WQ9
M\!>*[[2/$0\%^*M5DU^U;PQJEKH/Z-?#;]E3]GGXZ_%O_@ME^P3H5MX=\"?!
M'XEK^SQKMEX1^&:Z5INE_#/XJ?%#]GH6GB[XU_#WPSIKPZ+X>^(L7C/POX.\
M=ZUK>FVEK)K7Q&T6+Q%XG:^U_5=6O+^FK4^:*YFX5)0A&UVZ5/VLX2;:C!N\
MXP;23J.//R1G.4<N9*HH2NDYTXRJ6;BE5J>SC.R3;C%<LIZMJ*<8\TE%/^@*
MBORP_P""<FI?$OX\:>/VD/VA?ACIOP]^-?PQ\!1_L0:MI]IX?TK3M&E^(7[/
MOC?Q'X<_:I\??"J_L LW_"FOB?\ ''1(M!\ :3.9;:#PU\&M%U[33;)XHO(&
M_4^G)6=KJ6[36SBVW"2O9^_3=.I:24H^T4))2C.,"+YE>S5M&GNI))3B^CY:
MBG!--QDH<\6XRBY%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBOR:^.7Q7_;Z\9?M<?M'_LP?LM?$
M7]FKX?GX:?LC_LU_M+?#G6OBQ\%?'?Q O=6\6?$SXE?M4>!M3^%?BEM%^,_@
MNP3P_P"+M2^ &A?:?B386UOJ/@+PWK&LZ9IOP^\8:_?6/C+PRGHI2LVH0J5)
MM:\L*<'4F[)\TK1BVHQ4I2:Y8KF:N:72;2<I0A&[M>52:A%7>B7-)7E)J,5[
MS:2=OUEHK\-_ G_!0K]IG]KSP!X-M_V8OA>/"/QG\2_\$WOV2/VY]"TG44^'
M_B/P-+\3?VMH?C1'X*^'/Q)E^(7Q!^&'BE_@%X6U;X)ZE9>-O$/PHTR_^)7B
MK3/&^AZKH'B'X;7OA,Z'\2O;?#7QK_;<^*/[:T_P%M/&/[/?P<\$^!?V7?V%
M/VK/B-X>7X8>*/C/XJNI/C+\2OVDO!?QL^!OAKXEVWQ>\ >&KRUOS\"9(?!?
MQM7P*J>'H+^RNG^%WBII+FY+<9<THV3:<U=--2C3]KSS@[KG@G2FKQ5[N*M>
M5HPYQ482;24^1+JU*HX*$))7Y9/G3M)V24G?2\OU;HK^?:W_ ."K/Q$^&'P%
M_:6\?_&M9/"?[5'[/OP#\,>)_BM^Q'\8/AM<?#?Q!\-OC=XY^)</PD\-^-OA
ME\1M$N[KP[\>/V$-8\=ZA;6&E_%WP3K'CC6M"T#1[C6_$_C>]\2>-;#P#X#]
MG_:G_;"_:E_9&\2_M,_#A]=^'/Q-OM(_X)F_M*?MZ_ ;XB>*/A[>6*^'/B)^
MRAJ'A/2OBW\*_B#X,\(>,/#<'B7X:^*I?BO\,=2^$^HV&O\ A[QAX/M+7QAH
M?CCQ-\3[Y]&UL9RFH0YY?#RN2>K4K4*V)Y8O[3='#UIII\K<'!N-6]..L8RE
M/D2]Y2Y6NW[VE0YFMU'VM>E&]KVDJB3I_O'^T7^?Y8_S[T5^,GAC]K/]KG0_
MB?XV^'_C/Q=\$_$TWC+_ ()HS_MO?"J^LOA+XGTS3?A?X^\*:Q8>&-:\$^*=
M/@^*]MJ7Q5\':T/$WAG6&O[?6OAIK0U;2O$WV+^Q-(U_1M%\*</\%_V^OVE?
M#6A?LZ_%W]H/6_AM\1/AM^T#_P $@/BC_P %#-1\$?#CX7ZOX'\6_#_Q_P#L
M[>&_V2O$GC#PUHOB>^^(?BRV\9:+\2=-_:?U&-(KWPOHMSHFL>"-'DTF*"PU
MC4M/2JK5%U54:2I.JJC2D[.C+'QJ+17;4LMQ:5EKRP:=JD;94IJLJ;AK[54G
M!.R;5:.!E3W=E=9EA;W:LY33_ARO^XFJ:IIFAZ9J.M:UJ-AH^C:18W>IZMJV
MJ7EOI^F:7IMA!)=7VH:C?W<D-K96-E;12W-W=W,L5O;P1R332)&C,,[PEXL\
M*^/?"OAKQSX%\2^'_&G@GQGH&C^*_!_C'PGK.G>(_"WBOPMXBTZVU?P_XE\-
M>(='N;S2==T#7-)O+35-'UG2[NZT[4].NK>]LKF>VGBE;\X/V>_BQ^UK\6[G
MP?XX\>^&O#%[^S#\;/V5(_'=]JFMGX66>IZ/\:-=TCP]X@T'3O@N/AS\3OB(
M?''P!\:_#[5O$M^UM\2(/^%@^&]8\.V6K+XM\4>'_%\V@^!_0/\ @D[_ ,HL
MO^":?_9@'[&__K.OPYHES0K3HSCRRA%\ROK&<,16P\X-;:2HMQDF^=.Z]UHN
M+C.G&I%W4FK.VCA*C2K0DGOK&JKII.+]UKFN>T?&']F71OCIXPT+4_B'\2?B
M7J7POT6\^$GB6;]GFW/P[MOA+K?Q(^!7QK\.?'SX6_%#5-2'P\D^,<7B?P_X
M^\(>%VOM%TCXLZ7\._%.B:!I^C^*? ^L6[ZD=1^EZ**KHE=V3;2N[7E:[^=E
M\DDK+0+*][:M)7\H[+Y7;\WJ[O4**** "BBBE;^O7^OET ****8!1110 5Y]
M\5/!&L_$?P!XC\%>'OBA\0?@OK.NV]I!8?$[X5IX"D\?^$Y+74K._>[\.1_$
M_P "_$SP&]Q>0VLFE7:^(_ OB&U;3;^\$%M;WWV6^M?0:*35U9_FUV>Z:?1;
M-?G<3L[_ *)]ULTUUZI_E;SSX5_#30?A%X%T?P'X=NM8U*TTVXUS5=2UWQ%=
MP7_B/Q5XK\7>(=5\8^./&GB2[M+33M/F\1^-O&>OZ]XL\0-I6F:3HXUC6;Q-
M'T?2=+6STVU]#HHI_KV27X))+9))))))): E;^F_Q;;?JVV^X4444 %>:?%[
MP#K_ ,3O &L>#/"_Q>^)?P(UW4KO0;RP^*/PAA^&ESX_\.2:%XATK7I(M'MO
MC!\./BU\.KJTUV'3)/#VOVGB7X?^(+>[\/:KJMK;1V5]-;:C:>ET4FD]_P V
MNJ?1KM^CNFTS^OT_7^MUQGP\\!>'?A?X+\/> _"D-Y'HGAVR-M#<:IJ%WK&N
M:M>W%Q-?ZQXB\2Z[J,L^J>(_%?B?6;O4/$7BOQ-J]S=:SXE\1ZGJFNZQ=W>I
MZA=W,O9T44]_Z2[)622222222222222222222T2_X+\WNVVVVVVVVVVV8^O7
M/7_/'M1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H'  ]*
M**+ ?-G[0_[-.B?M%:K^S[JVM>.O&O@J?]G/X]^&OVB?"D?@V/P@\/B7QEX4
M\,^+_".G:!XR'BOPMXGDG\%7FB>.O$<>KV/AJ3PQXEN+F33[C3_%>E"SFBO/
MI.BBCIR]+N5O[TE%-][M0@KWVBEZF[N]U%17E%2E))=+<TYO;>3NWT**** #
M'7WZU\V?L\?LTZ'^SKJO[06KZ)XX\:^,IOVC/CWXE_:)\50^,(_"*6_AGQEX
MK\,>$/".IZ#X,7PIX6\,RV_@NVT?P+X>_LNQ\2R^*/$L-X-2NM1\5ZJ+Z.*T
M^DZ*5E>_7E<;_P!URA)Q]'*$'ZQ7S+NW+TYHRM_>BI*+]4IS7I)[]"BBBF 4
M444 %%%% !1110 4444 %%%% !1110 4444 (RA@5)(!!!VLRG!!!PRD,IYX
M*D,#@@@BOA+X-?L,#X2V'@WP=J_[57[47QJ^#/PTE\(2_#7X'?&.[_9^U3PA
MX/'PWU/2M8^& F\<^"OV?? OQ\\>R_#K4M"T.^T"^^*OQC\>:EJ>H:-INL^-
M+WQ9KMJNJ'[NHH6CYENU:_DFVM'=:-MIVNGJF#ULNS;71IM6=FK-722:3LUH
MTPKP;X]? J3X]Z-H'A:]^+_Q=^&?A"WU/4/^$_\ #'PLO_ FCVOQD\%ZUHE_
MX>\0?#+Q]K7B?P!XN\7:-X2UO2]3O(IM7^$OB3X8_$C2;MX=5\,^/="UBQT[
M4+/WFBDTG:ZO9IV>JNMKIZ-=XR4HM:2C):!=J]M+IK31Z]FK-/M*+C*+UC*+
MLU#;V]O:6\%K:P0VUK;0Q6]O;6\206]O!"BQ0P00QJL<4,4:K'%%&JI&BJB@
M* *FHHIO75W;O=MMMMZN[=[MMMMW;NV[W!))))))622T22LDDE9)))))))))
M))))%%%% 'SK^UG^S=X;_:^_9V^*?[-7C/Q;XR\#^#OC!X;D\)>*?$?P];PO
M%XTL]#N;FWN;V+P]=>-/#'C/PU97MXMLMH]YJ7A?6!!:S7#6L$%Z;:]MOH*S
MBG@M+6&ZN3>W,-O#%<7C11P-=SQQJLURT$($,!GD#2F&("*(OLC 10*L44DD
MKV^TTWJ]7&+BGONHMQ35G9VULK#=[7^RI)>2DU*7WR2?75:6UN5YM\7/ >O?
M$SX?ZUX+\,?%OXD_ K7=4N-!N=/^*?PCA^&US\0/#,FB>(M)U^5-%MOB]\.O
MBS\.;JWUV#3)?#>O6OB?X?>(K:Y\.ZOJT%I%8ZE)9:I8^DT4[?UKWO\ U]VV
MC#B?AS\/_#OPM\%:#X$\+)?'2="M[@&^U>_N-7U_7=5U*^NM8\1>*?%.N7C/
M?^(O%_B[Q#J&J>*/%_B74I9M4\2>)M7U;7=4GGU#4+F9^VHHIMW;;W?HNRV2
M26B222222222222222T2V_KYM^;;;U;"BBBD,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORZ\3?LJ^/_B1
M_P %%/CO\6_$-M\5_!'P0^(?[#?P _9J3QE\/_B;X:\+?\)G=>"OB[^U-XX^
M*?A'4M+TO7[[QYX:M=9\.?&WP/9^$?BIX4TKP=\6?!VK:/XV7X?>/_ $>I2Z
MGXM_46BFG:^B:E"I3DI)23C4CR233T:LWHTXN[4HRBW%IJ]M7%QE"2E%V:<)
MJI&SZ>]&+NK25DXRC))GP)\9_P#@F=^R=\:?%/P;\<2>'_B/\&/&7P*^'UI\
M%_ OBK]ECXV?%S]E7Q$/@!:76FW\?[/>MZU\ /&/P^U+5?@S#?Z-I5[I/@Z2
MZB7PI=6LTW@R]\./JNMG4_=/"G[+_P *O!'QMUCX^>%;/6-"\9:W\'/ '[/U
MSHVF:I]@^'UM\'OA5JOBW7OAOX)TOP!9V\'AG2[3P7KGC_QUJ.AZG8V$&O0)
MXMU;1IM5G\.+I^C6/T/12;;YFVVY.HY-MMR=9255RNW?VG//GO=2<YMKFG.4
MCEC9*RM%0459>ZJ?+[-+33DY8J%M8J,4GRQC%?$>F_\ !/W]GF;PSK7A'XE6
M?C+X]Z)JW[/FL?LH0I\<O%=UXYU/2?V<?$<>BGQ/\++;Q MOI?B#5H/%5[X<
M\/ZMXJ\=^+-4\1_%?Q+JN@>'+K7/'U__ ,(SX<CTK4U']AOX.>)? /Q'\ _$
M'5_B9\4%^*/P(U#]EOQ+XU^(/CBZUSXDQ_LYZM#J]IJ_PITOQS#:6.MV<?B"
MQUS4+?QC\2GFN/C;\0+J'P]X@^('Q/\ %/BKP3X&U[PU]D44FD[W2=TT[I:I
M^TYD]->;VM52;NY*K44G)5)J36EK:6::MTMR6MVM[*DTE9)TZ;23A!Q^-Y?V
M&O@U-XHM?&<NJ_$Q_$EG^S%J7['EMJ!\=WZK%\ ]7N=/O[_PR+)($L#XAGU/
M2=,U'_A8YM3\1TGLHH(_%:Z?)<V4]OP'^Q%\#_AWJ/P#OM!B\7W-O^S1^SUX
MA_94^$NB:]XGN-=T'2_@%XKA^'5MXA^'^OZ9J-O-%XTBU6U^#WPEM[[Q%XM;
M6?%UTOP\T22XU^6XU'Q5-XA^O:*<DI-RE[SDY.3E[SDYNM*3E>ZDY2Q.(<N9
M/F=>LW?VD[I)1BHQ2C&/*HJ*245!48PM9*W)'#T%&S7*J-)*WLX<OP'^S7_P
M36_9J_9)L_%.F?!&Y^-NC:)J_AS7_!7@CPSXK_:!^+_Q,\(? 7P-XGGLK[6_
M!?[._@SXD>+O%7A/X.Z!J&J:?8ZK=IX4T:VU&\NK#2X+W4;G3=&T:PT_VCX3
M?LK_  [^"6A_L\^$OAWX@^*FC>!OV8?A5JWP7^%O@#_A:'BZ;P._P_N].\$Z
M'X=T_P =^&CJ":;\2M5^'/A[P'I&@?#?Q-XZBU[Q)X3TZ_\ $C6NJRZAXDU>
M^NOI2BCJGU45!/=\L>;E5W=M+GGNV[R;;;LXEDTU;1MRMLN9\MW962OR1V22
MM9))M2****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117R9XK_ &HI/"_[
M8/PL_9!_X5OJ6HZU\6?@_P#$WXXZ)\0(?$NCV_AC2_!/P>\2_#/PAX[L];TR
M:$^(T\5)KOQ;\&1^&]+TS3=3TG6K&[O+R\\0Z(^G7EM$KJ\8]9MQBN[49S:7
M_;E.I+II!];)G24K.T$I2>_+%RA!-^7/4IQZZS72[7UG17G_ ,,OBGX ^,GA
M5O''PQ\4:9XR\)#Q5\0/!::_HTK3Z9<>)/A;X_\ $WPO\=6%K<E%CNUT/QUX
M.\1Z$]Y;&:RO)=->ZL+BZLIK>XE/#/B+QQJ7C#XFZ/XG\ V_A7PCX6U;PY;?
M#KQDOC'2]=E^)FBZEX1TG5_$&N7/AJTL;:^\"#PYXLNM:\'1Z?K%YJ,VMQZ'
M_P )':RV]CJ,%K$)W^[FO=)6LGN^ZDFNZ=TVM0_SMMK>[6V^CBT^S6MCT"BH
MH)X+J&*XMIHKBWGCCF@G@D26&:&5%DBEBEC+))'+&RR1R(Q5T964E2">'\(>
M(/&VK:O\2K7QCX#M_!6C>&/&R:+\/=<3Q?IOB3_A9/@<^"?!VN2^/;C3K*QL
MYO [P^,=9\7^"#X5U>;4-0:/P4GBD7HTWQ+I]K;%];>3?EHTM^_O*RW:4G:T
M96/\TOON_NT=WLM+[J_>T5$9X57<TL:J)$A+,ZA1-)(L,<18D 2O*Z1)&3O:
M1U0*68 N:2-.7=5Y1?F8+\TCB.,<XR9)"$C Y=R%7+'%%U_7_# /HJ&2X@A>
M".::**2ZE,%LDDB(]S.L$URT-NK$--,MM;7%P8HPSB"":4KY<3LKWDCCV[W1
M-Q55W,JY9W2-0-Q&2TDD<:@<L[H@RS*"77<!]%<#X(^*/@#XCV/BO5?!'BG2
MO$>D>"?&OC'X=>)=7TZX672M-\:?#S5)M \>: ^H<6LM[X.\1VFI>&?$@AED
M31_$>C:UHEZ\.HZ3?V\'=1S0RQ1SQ2QRPS)')%-&ZO%*DH4Q/%(I*2)(&4QL
MA(<,-I.13NG9]&DUYJ24HM=U*+33V:::NFFU=/KLVGZQ;C)>JDFFNC33U1)1
M7 ?$'XI?#_X5Z)HGB/X@>*=*\,Z+XE\<_#CX:^'[Z_F(CUGQU\7/'/A[X;_#
MGPUIRQ+))=ZEXJ\:>*="T73XX591)??:IWAL;>YN83XI?%+P!\%/A]XK^*GQ
M1\4:9X-\ ^"=)EUGQ'XBU>8Q6MG;+)%;6UO#&BO<ZAJVJZA<6FD:#HFG076K
MZ_K=_I^BZ-97VJW]G:3"=W9:MN,4EJW*32C%)=9.44ENW*-K\T>9MV3;T23D
MV]%RQYG)WMM%1DV]DHR;M9V[^BOE[3?VF;34/VR/&7[(,O@76-.OO"'[.G@'
M]H9?B->:QHYT'7].\?\ Q(\;_#:S\,Z3HMK)<:M%?:5J7@74;C4;[5FTU)#>
M6%OIME?12/>I]-37-M;M EQ<0P-=3"VM5FE2-KFX,4LPM[=78&:<PP32B*,-
M(8H99 NV-R#I%]))N/FE.=-^GOTYJSL]+VLTVKIN2OK!J,O)N$)I>?N5(.ZN
MO>MNFE/17"Q?$OP+/\2[[X.V_B33KGXEZ5X&TOXE:OX0MY3-JVC>!M?U_5_"
M_ASQ'J\,88:;IWB77_#GBC3/#LMVT1UJY\*^)UTX7 T#5#;=U2NK)WT=[/H[
M-Q=GMI*,HOSBUNFD75VKZIV:[.RE9]GRRB_22>S045#<7-O:1&>ZGAMH0\49
MFN)4AB#S2I#"ADD94#2S21PQ*3F261(T!=U!FIW&%%%%%T 44P21ES&'0R#.
M4# N-HC+97.?E$L1;C@21DX#KGYA_:F_:8MOV9-!^$^NS^!-7\>Q?$[]I+]F
M[]GFZCT?6]$T<>"A^T9\9?"7P9TGQ]K:ZG*U]?:)H.N^+]/>33=%TZ^OM3NF
MALC)I=K)=:O8)R2M?K*,5_BE)1BOG*45T5VKM+4$KWMT3?RBG)OY*+?RTN]#
MZAHJ W-N+A+0SPK=R0RW$=JTJ"XDMX9(HIKA(2WF/!%)/!')*JF-'FB1V#2(
M#()8B_E"1/,PQ\O>OF801ESLSNP@FA+''R^;'G&]<ET ^BO/?&WQ6^'?PZLO
M!E_XQ\6Z-HL'Q%\;^$?AQX"$]W'+<>,O&WCFZ^S^&O#WAFUMS+<ZW?7EO'>Z
MW<)IT5PNG>&=(UWQ1J#6OA_0]6U&S[O[5:BY6R-Q +QH&NEM#+&+EK9)$B>X
M6W+>:8$EDCB>8(8UD=$9@S %^?2[5^ETDVK]TI1;6Z33V:%=7:OJDFUU2;:3
MMV;C))[-Q?9D]%,$D9<H'0N,Y3<-PP$8C;G.0LD;$8X#H3PRY^9_VH_VDK?]
MF?PU\,O$D_@75O'L/Q#_ &C/V:?V?[R'1]:T31SX.7]I+XZ>!/@1I'C[61JD
MQO;[0_#OB/Q]I$EQIVBZ??ZAJ-Q)!9%M-M9;K5]/ER4;-NUY1C\Y2C"*^<I1
M7S5[+4:3>BU=F[+M&,I/M]F,G;=VLKNR?TW17G_Q3^*?P_\ @G\.O&'Q8^*?
MBC3/!GP^\!Z+=Z_XH\2:O*8[33]/M=J*D<<:R7-_J-_<R6^FZ-H^GP76JZWJ
M]Y8Z/I-G>ZG?6EK-Y-X(_:0A\7_M3_M"_LQ77@;5O#=U\!?A;^S;\4H_'.IZ
MWHESI?C[3/VCM?\ C[X;TJVT32-.EN;[2!X<U?X!ZU87$FN7%MJ&KWFJ1BUT
M>VLK:TO]7?,KI7^)R2\W&'M&K]U#WK.S:U5^AW\DF_).?LT[;VY_=;5TGH['
MTS14$US;6QA%Q<00&XG2VMQ-*D1GN9 S1V\.]E\R=U1V2)-TC*C%5(4D?.W[
M87[0\?[)/[+/[0/[3T_@;5OB39? +X2^.OBWJ?@K0]8T;P_J6NZ1X"\/7_B3
M5K>#6-=E2PL%CT[3KFXFF$&HWWDQ.FF:1J^H-;:=<J4HQBY2=HQ5V^R5O7NO
MO0XIR:BE=MV2[WOW]']S/I"BHHI5E!PR%T*K,B.',,K11S>6^,%6\N6-P&56
M,;H^T*ZYCDO;.&"XNIKJVBM;6-I;JYEGBCM[:)(EN'DGF=Q'#&L#+.SR,JB%
MEE)V,&JGIH^CM\]OZ[]-R4TTFMFDUZ-)KTT:WM;9ZIEFBHIKB"V19+B>&WC>
M:"W5YI$B1I[J>.VMH%:1E4S7-S+%;P1@EYIY8XHU:1U4Y/B35YM"T+5=6M-+
MN==O[.QN9],T"RO-*T^_U_4TA=K#0].N]<OM,TB#4-6NA%8V3ZEJ%G9BXGC-
MQ<11!W692C&,I2:48IRD]791BY-V2;TC%NR3>FB>B=)-M);MI+9:MI+5M):M
M:MI+=M)-K;HKY&_9R_;#^'?[0/P>_9)^(J1+X/\ &O[8/[-VA?M,_#SX/7.K
M6NL>+HO!5WX*^'OB_P 5?Z5'#IMG>67@>X^*7@7PUKGB&6+3=*&N^*?#]J6M
MWUBU0[7['7[2]I^US\ ?"WQUMO!&J?#7_A)O%/Q@\+MX'U[6=*UW6M'N/A#\
M9?'GP=U%K[4=$SI5Q-?7_@:35)8],FOK&P_M*.PAU/5$@34;NNK5M8J\O+W_
M &>^SM/W79NTM'8A3C)1:>DOAZ7]WGV>JO#WE=*ZU5SZ?HJ.66*"*2::1(88
M4>6665UCBBBC4O)))(Q"I&B@L[L0JJ"S$ $UXK^T1\?O O[,_P "?B7^T)X^
M_M2_\%_#/PE=^*KZR\,V]KJ.N^(7!AMM#\/>&X;N]T_3)]:\5:U>:9H&AR:I
MJNE:(NHZG:3:OK&E:4EWJ5L7^;;226[<I1C%+SE*<(I=92BNNE;7;T23;;T2
M48RE)M]%&,92;V2C)O1,]NHKR+X4>+_BSXGE\?:?\6_@[:_"J_\ "GC-]$\+
M:IH7Q'T7XE^#?B?X1N-!T76].\;^%M4ATCPCXOT7[/=:I?\ A/Q+X;\>> /"
M6I:9XK\-ZR?#\WB_P=<>'_&>N>K075K="4VMS!<B">6UG,$T<PANH&VSVTIC
M9O+GA;Y987VR1MPZ@\4K_BD_DU=>CZ-.S3T:3W2=[^3:U36J=GONNS5TUJFT
M3T5YU\3OBU\.?@U\-_&?Q=^)?B[1_"?PZ^'^D:GK7BSQ1J-R#8Z9::3*]K=0
M*L FN+W59=05='T_1+"&YU?5==FM=#TVRNM6NK>SEE;Q%X['Q4A\*#X?P'X9
M2?#^Y\0O\5#XQTQ;J/QW#XCM=-B^'X^'QL/[9EMYO#\\WB-O&2ZF-,@D@71'
ML#=7$=P'\G:]K]$^5SLWT;BKI/?1*[:"ZVOK:]NMN90NENTI.S:VUO:SMZ!1
M17@OAGXVFQT7X.V?QUT/1O@K\6/C7XU\4?#[P;\*AXVT[Q_=ZKXK\.:+\0_'
M)TG1?$>AZ=I]EK5P_P *_AOX@^(FI^58VT6A:=9:AIU]*UYIY>Y5TO\ R7?2
M[E+E25[7;?17:6K5M1^?36_6RBKMNU[)+J]+Z7OH>]45P?@W7_'&LZO\2+/Q
M?X"A\&:3X;\<IH?P[UB+Q;IWB9_B7X);P5X.UQO'<^F6-A9W'@B9/&.L^+_!
M'_")ZM+J&I-'X+3Q0+W^SO$NGVMMV!U'3Q9+J1OK,:<T23K?FYA^Q-!)@QS"
MZW^08I-R[)!)L;<NUCD9+Z)]TG]^U^SZ-/5/1J^@?HVONWMW7FM"Y10"#T(/
M)''/(."/J""#Z$8KXKU;]MSX?3^-_P!D#0OAOI<OQ4\"?M=?'3XW_ 30_BUX
M:UW1X?!_A3Q5\"_A5^T)\1O$,S0W#OJ_BZSU;4?V<?&WA;1-0\/V;>'+I57Q
M#'XCET^71X-<&TK7ZRC'YSDXP3WMS23BF[)M-7OH'^4I>=H)2DTNO*FFTKNS
MO:Q]J455EOK*&T;4)KNUBL%A%RU])<1)9K;E0XN&N6<0K 4(<2EQ&5(8-@@U
MQ7BWXI_#_P #>*OA=X'\5^*-,T;Q;\:O%>M>"?A?H%U(W]I>,/$OASX?^,?B
MEKNGZ7;QH[L-)\"> O%.O7]W,(K*VAT^.VEN%O=0TZWNBZ[]4OF[V7KH]-]'
MV=C_ (?Y+?[NIW]%(3@$GH.O^//&!W)Z56^W6/V(:G]LM?[--K]N&H?:(OL/
MV+R?M'VS[7O\C[+Y'[_[1YGD^5^\W[.:=P+5%,,B!5<LNQBH5MPVDN0J8.<'
M>S*J8SN9E"Y)%1S7-M;V\UW<7$$%K;1337%S-+'%;V\-NK-/+-,[+'%% J.T
MTCLJQJC%RH4X )Z*X+Q)\4/ 7A'QE\.?AYXA\3Z9IWCCXM7_ (ET_P"'GA:2
M<2:YXF;P;X9O?%OBR^L=.A$ET-&\.:-9QMK6N311Z1INH:OX<T>[O8M5\2Z%
M9ZAY[=_'./P'8^)=9^/>BZ+\&=!?X_>"_@;\*-4O/&VG>*C\5I/BGXA\ > _
MA/K-O8Z5IUK=>%]:\=_$CQS_ ,(A;>";];_4=*72QX@U#45T>^,MDK]>CO9]
M&U*,&D]G+FG%<J;=WMHP6K:6K5KI:M7C*:;2U2<8MWM:RW/?Z*/\_IG_ #[U
MP&D?%+P!KWQ+\;_![1_%&FZA\2?AOX3^'WC?QSX3M9&EU+PSX8^*FH^/]*\
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MBZOXH_L[XT>#/BC#<^,/&&H_;?$NJ?CU^T[X>\#']EW_ (+7:+8:1I*PWO\
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MS9HEB7U+Q-^TTE]#X8TCX<:O\-]/OOBDDNMV7AKP[(-/\9WVF:S_ %3U\V>
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M0)=-^%4J_&_4+CQ-^S5XET6._M-'^%]SH_=_#_X":)\3?V]/V%O!O[>'P_\
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M^T#^U[\1OB;J6A^,M(\3?M#GXS?!CPEX3\+?'[PQ8>#/&7Q:\?\ AS1_B_\
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M=8\.>,I=9?QI\,=&\ >,/%?V0OB=X6^&O@'_ ()C:?\ M0:?K<7[&W@;6?\
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MMZT-W+I=U)!#?Q1/:O<6XE\^/\!_A;_P5!^*>F:Q^PKKWQX\2IIWA7Q+\/\
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MKFN:IKVF:CXG\.>-=*U&.'PS-'-X7N_"VB^&[K1-:N?%7ZT_"?\ X)V?LG_
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MB:;LY^"?\%"D"?M/_P#!'6\D54@B_P""AGBZS:ZD 6*.XO\ ]@/]M1;6U,[
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M?P\^(^F:AJWA>[UWP5XH\C2/$OB?P=K%EXD^'/C;P[\1_ ^O:/XI\%ZQX?\
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MXU%44;7]QN<DF[MPU*\K-6E3J1;L^;GFJ:A.][IT^1MM6<[).R:BO@/]J/\
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M(\2_$;PO\)_%OA#QA-X'\!7WPGN_#NN^$?'G@KQMX@U7Q%\1M*B'@GP_M?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KX)^-=A^WM+KG[1"_![1?A'K/A^?PM\)-0_9]NM;^-7B'X=7U_+I?B
M?P]-\:_A7XDT>R^ _P 04\%>*_&?A>T\?Q^%_P!H2/Q)XUL?#USK_P ,-*T_
MX.Z//X6\<>+O%/WM1_G_ #UI-:I]E)6Z>]%1NULW&UXWT4M6I*\6?);Q?_@+
M;LM5;FO:5M6K).+2:_#G]HO]L>3X$_MC>)_AU^W1\2?BC^QW\#_B)X!^$^D_
ML3?M.^"-5DMOV8-%^,&I:!XE3XO>'_BY\3=5\)W?@2#XT+XGG^U>"-%_:K\.
MW7P&U[X:>!]!UC0?!WA[QO=>,CXUW?VKOB=\7_@Q\?O^"/\ \,_&7[0OBKP_
MH7QIU3XW?#7]JS7_  7>6NG:+\4KSX8_L8?$+XG:-XDL@^@7FH>%K@_%_P +
M6.OV=]X,C\-WFJZ9?/H'B--4T06FG6'VG\7/A-\>O'%G^T7X$UCPY^SC^T'\
M$?CA'9:9X>^%OQSN/%V@Z3X'\/S?#3PQX1\5Z#XL@TSP=\2M)^*OA/Q+XLTO
M4_%]MX4ATKX;WVASW>K))XTUR3Q/8GP)\E/_ ,$\?C!\,YO^"1&F_"/Q7X#^
M(GA__@ESX*\2>&+V\^*_BKQ7X%\1_&6?6/V3_$G[+%BT$GASP'\3;/P7:6-G
MXC?QPWFMXCVBPMO!EI:V]LP\20J]U"ZU5>DW:Z<J;>,E)2BV[.FYTDY1FXUJ
M:H*4'4HMCBHJ;=W9T:T?>U4:BIX90<;)<WM)0DXIQ3HS]LXR]G52,/\ :'_:
M[U;X&?!71[W]G'XX^)OBEXE_:\_;M^"O["?P'\7_ !7\.VWBS2/@+\3_ !WK
MZ?#CXK^*+:*:T\'ZOXY\)?#O1_ GQ"^(>AZ#XKDU!=6^*-E>Z/'KM]\.=;T?
M3-'_ $!;X"_$3PUK'PNUSX??M#_%F670/&^G:Q\:])^(^N:5XXTGX^^&7\-Z
MOX=U2SU&VU3PW<6'P;U;3M8U.R^(^DVG[.FD_"'P;J6OZ!'X2UCPP/!^K"'1
M?G?]HO\ 8Z^+O[9G@#Q1H?Q9\4?#CX$^,/!?Q4^ ?Q[_ &2/$?PHM[WXQ3?!
M/]H7]G_7[CQAH7QI\87OC+PG\(_^%FIXJU":Q\ >*_A?<:/HVER_"K2]3TO2
MO&FF^(O%\FN>&?I?X5R_M>:U)I,'QWT3]G_X?PZ&UNVKZI\%/'OC[XES_$J:
M"T5)9(-%^(7PH^&\7P=TJ]U-#J%SHJZ[\:=333)O[ M/%UM>0?\ "4W%1TML
MIQG3E[S34H1I0LE:-K>U5;VE*3E.:G1;E*,$J<._FTXU$^5./ORJRU2<G*_L
MG24*D>6,73J\L8RG>IX)X4_9F_:CTC5OA=+K'[7WQK\0Z)X1_: ^,?C+7M-\
M2Z]\*+AO%GP%\?:/+!I'PS^)-[X2^ W@[5/&?B#0?$*W>J_"^7P'J'P</P:T
MGQ?)I6J>-OC,_P (_#$GQ$]%_92^/>K?$#QK^U3^SUXYU:'7?BA^Q[\;-*^&
M6N^)5MX;&Y\=_#[XD?"GP!\=_@QX\U'3K*RL]*LM>E\"_$B#X>^-I-)BM-)U
MOXC_  U\;>*=#T+PKX=U_1?"^D?8]S<V]G;SW=W/#:VMK#+<7-S<2QP6]O;P
MHTDT\\TK)%###&K22RR,L<<:L[L%4D? ?[&_P?U73/C5^W5^U=K=A?Z,O[7G
MQS\!ZC\/]%U-)+;4[?X,_ 'X&?#WX%^"]>U73Y;:&2PN/B)XM\+?$GXGZ!"\
MLMU_PKKQIX#75H-*U]-7T>P([N+VC2DU9+XTL+3IJ]FVY>REIS:WK5'>4IR9
M+[+7Q.I!7[Q;Q,ZEU>UDJD=5%6M2A=*,(KH/B?\ MY_#?X2_$R'P!XL^'?Q>
MAT'_ (:/^!G[)MY\5AH7A:P^'\?QP_:*T#PIK_PT\/Z+#KWC/1_'/CC1'7QY
MX'T;Q5XK^'_@OQ3HGA;7O%=O:7UQ)9>$?BGJ/P\\OL?^"HGPMNO%$&CWOP*_
M:3T7PE!^V?=_L%^*OBOJOA[X2CX?^!?V@)_$NA>"_!5CXBBL/C+?^/-2\'_$
MSQCXH\.>&/"/C'P-X&\8Z1IVK:U8P_$!_ \;3R0?/W[0'_!/[]K'XK_&;XL^
M.;'QY\ O$NBZA^V7^P]^U+\%O%/Q,E^(MQ\2?!/PV_9I\:_L_P#BGQM^R=86
M^DZ)=:!\//AK>>)/A#XG^+?AOQ)X5OM?'C+X@_$/Q%8>-? FCZGJC?$[3M+4
M?^"?7[0D_@3XA^%+?7O@R]YXN_X*W?#O_@HGI]S-XF\<0VUO\/O /QY^%OQN
M'PYO?+^'MQ*GC/5?^%7P^&3J\,=QH=C_ &]+K(BNSI":5JD1DWRN4;:QYHMJ
M^M7"1E%V=HN-*>+E=/\ Y=P:<E;VER2NU&5]9)R2T25+$RBXIJ[YJD<-'7^>
M2:3?[L_X*;_MF>(]+_9E_:5MOV;;SXQZ5KWP(^,_[/?PE^(?QU^%TGP\MO#O
M@KQ]XK^)WP2U3Q3\-;B7Q)KP\=ZK96_P_P#B7X9TGXC^*?AQX.U&T\)7?CRW
MT*U\5P>(/"'Q8M_AQ]K_ /!07]IKQ-^QS^QU\=_VD/!W@(_$CQ-\,/!LVK:+
MX:EU'2]+TL:E?7EIHUAK/B"XU/5M&>?PYH-[J-OJVMZ9H]T_B#5["UETS18T
MO;N.ZMOST^,?_!-K]JS4?#'[=?P%^#/Q)^ K?L_?MD_M >'?VM/#WB#XJP?$
M9OBG\%_BS?>-_A+XL^+GPX?0?"EF_ACXC_#'Q?J_PSN/&G@CQ0WB?P)XH\ :
MAXCU3P-J?AWQUI#:7XLT/]%/V\_V<?%/[6_[%_[0O[-WA;Q-X?\ "_C?XK_#
M#5?#?AKQ)X@L=1E\*6?BZ)K75=#?7K33I;G6+?PW>:UIMK9ZM-IS:AJFG:5=
M7%W96VIWEM%:W+3]QMW;=7"SE'1R453HQQ,5%;1BU7C&TKU%[.HESR3,Y*3J
M2Y=E0KP@[M1<W5K3H2;WNU*BY2<?<:G#X8-2^#_BO^VI\3OV>_VV?VF_%'B;
MX<?M/?%/X2_#G_@FW^S_ /M&:E^S=X!/P.O=>^%;)\:?VLM)^+WCJV.N?%'P
M-\-]7U8>$/AIX6N+O0K3XK^,_'_B=K*6P^'&CZ[9Z=JNG:+]1_'K_@IM^S5\
M"/"]WXGEU#4?B,VG_L_^&OVHKKPQX.USX:^'_&M[\%/&P\42^"/$/A3PM\7?
M'_PQU3Q[KWC.T\!?$*Z\.^"?!$6O^*IG\$ZGI>I:9I>O:YX%TGQ=YA\2/V/_
M -I/XH_%;]J3XK:S>? _1KW]I#_@F[X8_8XBT'3/%OCZ]M?!WQ&TOQ)^T#XK
MN_$$FJW7PZMI=?\ !-G+^T!<>'[:_33M&UW6H_ L/B63P]X>;QF_A7P9YOI/
M[$O[>/P)\<? GXJ_LI?%[]F'3?$TO['/[.O[&_[4_@#XZ^$OB7XQ^'&JVO[-
M4OCR]^&GQV^$.I^!M0\#^-I_&/A^Z^*GQ"T_4OAQXCU#PQX6\:^&M6L+"[\3
M>&]=TFR\3Q4]HQ3CHDE)7:3E4QLN67P\T;J@Y5'*\(58I-P2]B1NI3DU)Q<G
M)JZ3<5# I<JM+EDXO$I0BK.=)NW.[5OT0^+/Q TSQS^R)\0/BY\*_&&K6NE^
M(?V??$'Q5^&/CWPXU[H>KPV]U\/[CQOX%\5Z;!J]A%<6\F#I.JC2/$>CRVEU
M$6TCQ-H5Y83ZCI4WP'_P3O\ B[+\?/A#_P $]O&>K_M6?%_Q3\>O&/[(OPX_
M:4^//@:XAT34/!/Q3D\0? KP9H/C[3M>M;KPA8:1X'^P_%[XQ>%_'WAZV^'N
MH>'IH]1\,+H:1'P;+JFF2?I)\4_ 7C;Q/^SQX[^%^AZWIWB?Q[XE^$FN?#ZV
M\4>.)E\.Z?J^O:WX4G\-7'BGQ(?"/AZ^BL#<7%U/KE]8>'_#L=H]P6T_3[?3
M;62.6UX/]BKX(>*OV<OV1_V8/@#X\D\):SXT_9X_9\^%?P'G\3>%;O4KW1_$
M,/PP\ ^%? S^(-/FUG0=&U;1;?Q:WA.QUR]\/O;WR:3,T%BVJZX=/AU":-JU
M5J_L^6'(N92U53%7M=+F:A*@Y-TX\\4M(MVIWJZ5)7C[3GFZGNV]UT\/NE)\
MJ<E54%SSY)-M.5N:?RC\+/V]/AEX.^$'P$U?2? /[8WQ,_X::_;'_;$_9O\
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M5.JT]6HIW7.[M14:C<^6^L:."E#FBG9QE-8FA&2Y6ZE2DFMG+]K?@Q\5M/\
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M!/XF>&?C)\ _M,\'PY\7?M!>*/%/P%OM%_:.T&SCM;V'P3X]\2^!?@\OP_\
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M:\%WWP%BMO#?A/7_ (@>)M5O-"\4P:7J_C&?5?"TWB7Q9X-XY_X)^_'#XF>
M?^"AW@VX^)W@SX1^)?VIOVMOA!^V1\ /BCX&EU7QQJ_P<^*7[.WA7]D.R^#1
M\7^$/%7A'P]HWB?3K/QY^QYX.\;>*+:RUA$U#3/%.L^#K5(3IMMXGOYJ/EG2
ME37NI8F557YFI+$8=4K:+VDHT98CV2Y5SQCRRY7-)S'G:FIVU>'C%Z03BZ&(
M]JW;F<(NLL/[35\LI76D;Q]B\!?\%/\ ]G/X@:I\3/".D6OBZ;XE?#?XO?"C
MX,6WP[TBY^'?C+4?B=XF^.'A^_\ %/POU+X3^,? _P 0/$?PM\5Z!KF@>'?'
M^I:]<77CS1=2^'=G\+?B/J/Q(TKPGHWA^#5-1Y+XR?\ !17Q9X)T/X-OX6_9
M4^.UMXM^(7[=NB_L7>*O"OQ+T?PAX"U/0+RUM-4\8ZIXR\#7/B/QUHW@_P"+
MGA7XE>!]"D/P@\<^#?&TW@6277FOO&.NZ)XF\&:_\-;K@/BG^R9_P40_:-^!
M_@?Q/\6_CG^R_P" ?VSO@!\>?A9^T7^SA;?![P%\3-0_9=TCQC\+=&\=>$]?
M\/?%$>,O$$?QB\6^&OC_ . _B?\ $#P+X[ET'4_#,_PZ\/:GX8E\%V>O>(O#
M&N^(/'W<?%W]F#]L[XU?"3]G;Q%X^\>_L]:Q^TQ\%/VQ?A1^U//X3T2R^(7A
M#]GN#P_X*T76O VK?"+PMXGN+/QG\2OW'A?Q3KOBVU^('B'PU?W7B;X@M-:3
M^%?!O@[4M/TSPI6B<=4^6K04]?==-SH<\XNRO[KKQJP=O9V33=M25W&:BG>5
M*JX.[4HU(QJ\L9[I*ZI.E-7YW*2DE</B!^W)\-/V??&/_!2GXE:QX,_:_P#B
M!-^QS\,?@'\2/C5\.]*N?A?K_A#3OA[J?@CQ]XM/C3]G#POKGQ1\.64/V+PE
MHOB/Q)\:$UW5_#^J:O-X8L%\.Z;KNH6"V<_U-XK_ &P_A!X&/CC5/%<VJZ7\
M/_AE^S'8?M9?$3XKP7'A/7O 'A+X8:U=>*8O#EO/+X:\5:SXIU_Q#XHL? ?C
MS6?#2^#?"WB7PUK>G^#M5BL?$TNK7>@Z9K/GOPD_9B\<>%OVM?VU_C;\0Y?A
MQXF^&_[4O@C]G7P=IGABS_MB^U*&#X+^#_'7A7Q+%XPT#7-#?09M(\:KXZNG
MATNWUO5UT^PL/[/OY=7&H23VGSW\+/\ @ECIGA+_ ()W_'3]@KQ9\8/$^NK\
M6/"'Q&^#_A?XN*B7GBOX:?!C1-/O/AI^R/X=T;":'/>W'P!^"_A[X8Q7=C<7
MJ6/B+XDZ=XZ\2M>+_P )GJ%Q+";4-5=JG%J,>7XO:5X3IKF:]Y0E3Q$.:T6X
MJE*:C4DH:.SDDFU%U'%RE_+[/#3C-V3:7,JU"?*FU?VBBW33J?3G[/W[=?P?
M_:'^,GQ#^ _AFTU?1_B)\//A_P""_BG/!/XC^%/COPSXC\">-M6U_P .PZEX
M>\:?!GXD?$_PJNL>%O$_AO4/#GC;PAK^JZ%XJT2]GT;5[32=6\'>)/#?BG5_
MM.OC']D;PS^WEI.D7<G[<GQ-_9T\8>(-#TV#PMX7M_V:_!/C;PSI'B]()(7U
M#XJ?$R\^(.J7]Q9^,=>BLM/BTOX>^ -*T'P?X'DN?&-Q=^(?B+%XE\*V?PS^
MSJUE;W>6S]U7:;=W>6MI1BX7CR7@[N+33?,Y*,1<GS<RM[SLFE=*T=+IM2M+
MGM-64E9I647(HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)I*"3YHMN4?T6_9O_:3\._'C]D_]FW]JC7[32OA5I'[0_P #O@E\9(?#VO\
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MGX+^+.A?%;5?A?X5\6W>E^.]*\9Z]%X.^(/B;1M4\!>*?K_]@+XN_LD^!O\
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M+RYT_5H);J&5X(YM,O[*\L=1B:0/97EI<VURL4T$J)\M_L__ +4]O\>?C/\
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M (*&^$V^$T/@'X\_"_QK^U9K3^./@+XT^%E]X6_:*_8;^)'A_P#9+USX,O\
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MBG\,/B-\(/'NL_#[QYX!^(%AX9\5^"5U[2[ZP:YT+Q!9WW@SQWXR\+:UX/\
M'WA_QAX#\0:-XCOX-<\+:C+'8S6>[\(?@QI'PDL]1E;Q?\0?B;XT\06^DVOB
MSXG?%3Q#!XB\<>)[7P^=2_L"PN?[)TSP]X2\/Z+HO]L:M+IWAKP/X4\*>&(=
M1U?7=>;1G\1>(O$.KZK[%11W\]_P7RT23M:Z23>B!ZVOT5EJ]KMVT:NKMM)W
M2;;23=PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7HDEJ]-7<V_IO\6VW\V_P5BBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***_/7QU^W=IMK^W*?\ @G_\-]/^
M&EW\<K+]G73?VC9;3XN?$[4/AI;>,=*\0>*?%GAG0?!/PNLM'\!^/-8\7ZQI
MT/@7Q+XE^)VNQV$5O\//#MSX0N](T'XAS:OXM@^'QNU%*\FIM)-7:A!U)M)M
M7Y81<G:[MLGT3:2<GHDXIOHG.:A&^CMS3DHJ]E=ZM=?T*HKYY\'_ +0.DP?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWN;HI.H[;V=3$T\3UZ1E3<5U:DY-\RM+^%;X(?L^?MI?"_\ X)J_L!^)+/\
M9W_:JT72?V9/^"RGC7X^_M%_!;PW\ /%D'[0-E\'?$'C+QG-X+^-W@7X(_$#
MX<ZKJOQ1M?AU%XPT[Q9I6BZ)X%\8/%KMSIVJC2K6[\$ZUJWA+[-_;O\ V*O%
M?@_X&?!+XM_\$YM<_;3\+_&;X)Z9^WE\</AAX-^+_P"S-\1_B=\+/VE/"_[2
M?B_X8>-/VF/V6?C/\$)?AAIVI?""Y_:%\:7\>K_!KX<_$CX4>#O#/B35]+^)
M>FW7A?PFD7@/XG^!OZW,=??K132:44G;D5)*2MS\M/"X/#.+<HS4HS6"I5)0
M<?9WG6I2A4HU'!.;<YRG*SYYU:DHM7AS5,1BL1>*NG"4?KE2G&<9*HE&E4C.
MG6IJ;\T^"\/BFV^#OPGM_'/A33/ ?C:#X:>!(?&'@;1-7?7]&\&>*8O"^E)X
M@\*:1KLEW?R:WIGAW5EN]'L-7>^O7U*ULXKQKNX:8S/Z7115SESSG-I)SE*;
M2O9.4I2:7,W*RYK*[;LE=MW;B$>2$()MJ$(03:2;4(Q@FU%1BFU%-J,8Q3;4
M8J*211114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6X.K"6OPNKS_ (D_:UT[]H?XI?\ !&?XU? +X@?$?0OA'^T/^T1^T;X3\<>
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M%Q\0M3UK5?&%_JWA@2>+?)?V?O\ @GW^UO\ #K5O^"=N@_$KXZ? 7Q9\/?\
M@G!+XZ\#>!]:T'X9>/K3XA_&CX/:A\ =9^ ?@"7QE;7GCZ/PUX!^(^C>%=1T
MV#Q1<:2_CC0=;U31;CQ/:+8C76\+Z/4.95->7ECB*DH.[473<\;&\U[TDW&>
M%E%/FYXRG)Q4Z:B\ZBYJ?NWYW3I*2TNIJ&$E+E=DK<T,1%M<KB^6%W&;D>_?
M#;_@J#\!/BY\3_A)\._AQIVM_$"Q_:%\!_$#QY\"_&'P^\0_#CQIIOBNW\ >
M'D\:6VA^.-,T?QJ^K_!/6?BGX!D?QU\'G^+%OX8T?7-&T[5] \>:M\-/B/:6
MO@/4/6/V+/VQX?VVOAKHOQJ\)? #XX?";X/>-O ?P]\?_"WQU\9#\(M-'Q.T
MWQS9:M>ZE9Z#X4\!?%?X@^,]!N? KV%CI_B"[\=Z!X3TC7[O5[;4?AOJ/CGP
MGY/BBZ^?/V(/V3_VV?V2-"\,_L_^)/VCO@[\5_V1_P!G7PYJ/A/]F+2HOAAX
MI\(_M%^*O VGZ7J>B_"3X7_M"_$Z;Q=XI^'<?A7X->&;W3?"=KX@^&?PDT_Q
M;\06\(>!O%.JW/AM-*\8>#_B)](_L"?L\^,?V2_V./V>OV9/'?B'PSXO\0?
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M&B>&O$NG_!F/6=5\3>)?&6D:Q\0]%\5>"M'\2^!_#^M_%#X=64>C>(?%.N^
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M &187\UO>>-+[X>VGA-M7GBF@\/6FL7.NC3M;FTZ'1[WX4^*G_!.W]J3Q_\
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M(/QG\<:H="U;0?=O"O[*'[5NJ?'CXR?M)?%CQW^SV?%_QA_8.^''[*U_\/\
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MX(/Q4NI/&W@_4M>^".L>([BQT+XH>#]+M?&'_"6>&M1NM#U3PI?Z3>W<MO\
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M2-%^'GQ#\=ZMX5TJ[?6;C3%\.?$NS\$?$"QFTYWUSP=HTTS6=O\ -8_X*<_
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MRMITX<SO?WYXK'4H[M0BW[/#*4I35-4JBJ/DIP=:HHMM3E>_[RIR*S2Y(83
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M5([B%G_G1^$7[(EUXG^'7[-_@K2/V>?$WP^_:_\ @Q_P6.^.7[1OB[XO:O\
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M7_@&]\">))=5M-2\0W6C6/X8_LC?L>Z]X!^,'_!)CX7?M5? 34/B)XF^#_\
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MK3]/N(+:UT^]N)Y$AM9WCR!\;_@N?%^A_#X?%[X7GQ]XGUOQ;X:\-^!QX_\
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MF36O!%W=:7)?+!?:AJ/C?QRTDUD]XD5W=W6J1M<+'-*ZCY9^%'B#Q):?M/?
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M\3O!OQ@\(6_CKP%?:IJ'AJZUSQAX<ANM9\+^*O!NH'5_ ?C+7_ /B>WD\/\
MC71?#WB&""S\4^&=9L['4)]*CT[7;&WMM>T"[U3P_J>EZI>?GKJL<DO_  5)
M_8PA2::U>3_@EM^W9&ES"L+36\C_ +1'_!,91-"MS#<6QFA)61%GMYH2ZJ)H
M9(R4;X__ &5?VR/V@?BAHW_!.GX'_%#XM>)+_7OVGOBQ_P %4[/XC?&Z+1/
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M)X-\#_"&/P/X#_9<_:H\4VOP7\ Z#>6?B;XD>*O&7P%^,/[.3CXG_'^^\0^
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M5_LZ_&?X._ ;Q9^P[XU^ ;:3JWQ-\<K8^$[#P!XE^!GPS_:$UCXC_&/X93_
MOQE<^,?A?\4V\3_%OX+:GK=E\8/ +^'M.^$VJZQX G\"?$/PYJ'C75.\U/\
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MOA9JOB'P+')X>UZ?P'HN@1ZA#JOBV],4>J?$#X@WWBK\*OB/XV^,WP0\5_\
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M_P %/VJ;'XP?"GP#\)KWXX?M ?#?XU?"3Q-XXM]8:32]!\4_%#P#X3^#\?@
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M  _!<Z7I>FMX1\/>*=>T[X>-X.DUW5[F_P#T_P#VW?B9\3OAU<_LIVG@V_\
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MT>^TW\*/B?\ %SQ_^U=\ ?V6OVF/$7Q#\2Z0+G_@N)\'OAG+\"X-+\'P>%/
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M\<M4E\0^(-:'C;XK6?PML?%,-IK>IS:C;>&H8/A!\,_A1X2&@>'5F.GZ#O\
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M_P"U##XTG_X*V?\ !.6/P+J/AG2]8_X8^_X*4L]WXMT75]?TH6(\=?\ !/\
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MUE%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO@O2?B7K7PO^)NCZ>D5W\+/C1)\,M2U#XD:)X3BG\:^%-4\(>#O'"S>/]/\
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M3=?V.='LOBO?^$]%AQ;WWCRW\(V%IJLUM:33@DG%.HXW5URNK6H4JL^5)/\
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M;3VOA3P]%IOQ+8_\%/;+5O!7[+&LZ'^RU\=->\>?M0?&#]I[]G2Q^&FE:_\
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M>J;BI5:E.,KI:2;>-4I15Y25:;2;G4O]-?M#_L%_L:_M:>)_AUXT_:5_9O\
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M]2^(_@'_ (*)>*_"GB?]D_PG8_LD?&1/A-\*_BUX_P#CA<#]F[Q1;:E^S=\
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MUHW[7/Q)_:._9I_:;\#_  :\(_M3^"_AEX8_:O\ AUXU^#VK_%W5K3Q+\*=
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MG^ OA;XJ_%73I]2UBW\':MH_P=UOQKX7\7>$O"M]XKT3QEXQ\7WGQ)TF_P#
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M/P]XEU/XC_HE\*OC-\'_ (Z^&9_&OP1^*WPV^,?@VVUO5?#5QXM^%?CKPO\
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MJ4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7Y;^*_#&LV?\ P5NT?XI7WPX\=W_PVL/^":?Q-\ ^(?B!IWPO
M\9>(?"%QXIF_:&^'OCC3/ )\0:/X=U'3]:\37'A?1/$NJZ9X2LIK[5;H"2SL
MK"34=4L[.\_4BBIE'FMZ5(VLM?:4:U%W\DJSE;9N*3T;'>R:[\FO5<E6E637
M9MTE&^Z4FUK8_FS_ &/O@7XO\':+_P &\&F^+/V>/B1H.I_LX?LD_&CP?\9'
MU/X$>-;./X,_$/6/@-\+?#]S8>-+V7P@EOX3UOQ+\2?!VJ2PZA=2P?\ "1ZM
MIMOXAAO;V"^TS5+S/_9L^"_CW2[;_@D78^(/@!\5M*M_@Q_P4M_X*F?$3QA;
M:Y\!_B'IUK\+_AE\4F_X*$S? WQ7K<>H>#8(?!_A3Q%=_&;X&7'A&ZN186=C
M+JMA.5T]_!?B%O#G]%.H>/O#FF>/O#/PTNAXA/BKQ?X9\7>+M%^R^#/&6H>&
M?[$\#W_A/3/$+:QX\T_0+KP)X9U1+SQMX>31O#WB7Q)I'B'Q1#-J=WX7TO6;
M/P[XCGTKL_K5SDYR4W96J2FDK[^W]LU=ZVC).">C2>FJ3%!\D/9I1=J<:=W%
M<UE1JTTW:UW*-5S=[IN,;Z71_,UH/P=\?:;\(?A7%I_[/OQ>TS7-,_X.(?BY
M^TE?6]M\ _B/I^MV'P3\3_M;?'3Q=I'QDNX$\&0ZA;>#-0^#WCO0\^)IUCBB
M\.:M<>%;F2*:UU/1+;T+X1?#6YO?VE/%/[.7[4?[$W[8OQ&^)/@+_@HQ\4/V
MQ_V?OVB-.^(WQK_X8TN/A[XO_:$\=_&OX0_%R[\;:;\3-&^%/A3XC? GX=^.
MI?A!JWP$U/P?>^(/%X\*:/X<M]'\1^#/%NNZGH/[D?!KXY_"[]H#PYXA\5_"
M;Q'<>)=#\*?$;XB_"3Q%<7?AOQ5X4N](^(OPE\7:IX#^(OA>[TGQCH?A_5UO
M/"_B_1-5T*]N4L'T^>\L9S87EW HF/JL]S;VRH]S/!;I)-!;(\\J1*]Q<RI!
M;0(TC*&FN)Y$A@B!+RRND<:L[@%\S3@VDDE%I*\59T,#"FX6UAIA*-2+@GS*
M;BDE[*<%*TN9NR=YIM))7=;%SFIKX9?[S5I-2::Y4[MRJ0G_ #">#?"_QWLO
MA-^R/^S-\4/V:_VB->_:._9C_P""QD?QO^,OQ&T_X(>,M<^$WC/P)X^_:&_:
M#^)1_:Q\ ?'(::?ASXE\*>+_  ;\6K)O%VAZ/XF_X6M\,]0U37_"/CCX=^&]
M'L;>ZO?>OBEIWQ+\!Z7_ ,%0/$/A_P#9D^(GCW2O%O\ P53_ &'OBSH:I\"/
MBEXKO;#X6>"OAC_P3J\+^./VH?@_\-- \/VVN_'[Q)\!OB-\#/B)XZ\,>$_
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M>:A\,+/7_!^G7OBOP[HMG<?FK^T%X$^(7Q?_ &-_^#@BQ\$_LV_'R.X_:?\
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MX1O_ (#?$;]K?XQ?''PS\5="\0P>$]0\(^-OAVOP]\5^']9U[Q!X9U'6=/\
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MC]JSX>_!WXR^"O!>G?\ !+[]J3X$_%_0/B+\#_'W@GXA?$'QC\4?&'PA\6_
M;X-Q?##7_"\7B3QUJ'PF?PI\>[R^U+PSI_B#P]H=_P#$JVTGP=K>NV/C_P 1
MRQ_M9143I*I"I!RE:I"4;I_"YX7%8-R2V?[K%3?++W74A3DU[LE*HR<)4Y)+
M]W*+MJN91Q&'Q*3:U3]IAH+FC9\DIK5\KC\-?\$TOA]!\-OV!OV./"MW\-[K
MX7>,-"_9<^ /A;XA^$]9\#7/@#Q7IGCOP?\ "[PWX;\6:=XKT/4-*TG4QK&F
M^(]/U:VEN[R&:+4"&U+3KN^T^]M[VY_'[0_@UX\T[X:^'Y;?]GKXN6'B9?\
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M\<ZS\%_!?BCQ'9:IXKT?5OB]X=U6?Q!K?BO2M+O+GAOVI_V@_P!JSX#^%?\
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MKU[9/%>^*OAG>7UQJMU\+O'OV*:UA^(GPNFUB[N=;;X:^.HO$7@8:[-)KBZ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME/Q/^V[_ ,$^OCE^RGK6L>'_  /\1/C+\$AX<@UBQFU2Y\%^'/BG86NF>(=
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M1[;I/:VZ3\ELBBBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX?T[0_ /A"[UO7O#[ZI/>>'='^Y]*^)EUXZ^!.D_&'X<:3:37?C/X3Z=\2O
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MO%1DXJ3M-2C"DG=K;V;J)Z:VHUJ[5KWTIT92T3;BI-*\;2_9:BO@#X4_MO\
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MXIU/QM[U7S!\0_VT_P!E3X4_%?1_@5\0/CKX!\._&37=1^&&EZ9\,I=4DO\
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MSX3:1>RV'B#Q7?\ BN72_$'A[P[XT\3^&M1]O\*_\% _V*?&W@[X^?$#PO\
MM-?"/5?!G[+LC_\ #0'B%/%5I:V'POL6TJXUO2_$'B$WPMI6\)>*M)M+O4/
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M$CXW:9\.O#,UUX0^%NE^+=5TSPUX:\.W<;:]X=\7^(_"WPX\1^!??[G]M?\
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M:FNSLH^V4W9<JD[P@DO9?)'[,G[+7C;X^#]O;X<?%R?QQX)^ 'C?_@IYXO\
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M<JDI*][Q4DHJ*NE9):;J*A""@E9Z*%.$%&*=E",;+6,FN1N?V3-3G_;TTO\
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M$_@6\E^(?QA\$ZUH'BW1M:\"^)/$%^-?T&P\*2>$;>SN;7Q/=:YJ^D>'K_\
MH:HIW=XRNKQCR7LGS)2HSO*]KRYL/3;E9.2B^:[E*4DXQE&46KJ4G*R;C9N-
M6#4;7LN6O5LOLN2<;<L(K\4/VF?@Y^UAKOQ'_P""IWC_ .$/[,_A_P"(-Q\=
MO^"=7[*_PA^!VA_&F?X'^)/AE\6/BE\+?$W[:6L?$3X;^)O FN^.]7MKUH?#
MW[0GA&QTNW^*OAW1_A7XNU^WU31=;U\^$[>74;_Y#^*7[*/[6OQ*\$_\%67T
M']FWX^QW?[3?P9_88\:?!_\ X7-\4_@5KWQ$\?\ BSX$ZSJ>J?$WP#XA;0/C
M/K_ACP/\2]2N+6ZOM"\)Z+-H?P4TJUU+2+'1]:\&1W9\*Z+_ $"^&/CU\._%
MWQQ^*W[.^BW/B$_$WX+^"/A1\0O'=AJGA'Q-H>BP^%OC5J'Q*TOX?ZCX=\2:
MUI=AHOC.WU&^^$GCFSOKSPE>:SINDZAHUQI&HWUOK5M?:=:>S5G2BJ:4J;6[
ME&32E9JO[1VV3BJU*/NRTO2<6[2FBIOVBE";;3]V<;M;TN3HWRMTJLK-;*HF
ME[L;_+/[1X^*WQ$_8P^/<7PW^"7AOQ-\9_&W[.'Q4M/ O[//[0$/@/7O"/B;
MX@>(/AWKMKX;^$_QAL;+Q5K7PSUSP]K^LW5GX8\;Z5_PF]UX)U33KW4-.NO%
ML>B7$VLQ_P \/[8'PU^-WA[X$?\ !1[XM>-_V=?V@/"W@/XT?L+?\$T_#&B:
ME\>/B%\!/$OB[6?B;\$/VJOCS<?$'X>^,O"_PY^+'B3P)\-=?\3V/QK\):WH
MG@WX4^'M(_9Y\/Z7=:M#'%\-KV8>"1_6)7EWQC^"_P +OV@? &K_  L^,GA#
M3_'OP[U^?3;C7?"&KW&HQ:-K3Z/J%MJ^EIJUMI][9'4;:QU:QL=5M[.\>:T3
M4K"PO_)-U8VLL-<JYXSU]VI3J**D[1Y)TV^5/1MPC+XD[SY&[14HR<6XJU[^
MY.+>W,Y1J)-VVM.4=8ZJ'.DG+EDOQ+_X*&?!GQAXG^'G_!7[]LG5/!GB'X8>
M$KO_ ((G?&K]E_1='\53Z GB7XA^)?#/A+]ISXH^+?$^J:+X:U[Q#;6'AKX=
M+XKT3P9X(UG4;U=3\6ZOK7Q-OM(TU/ %CX%\8_$+ZO\ AE\+?&/CS]I[]F[]
MJJU^"GBOX7Z!^SU^P#\5O@=JNDZG/\.=-\7_ !3\7?&WQ5^S=XT\-?##PU!X
M?\5ZGH&I>%/@Y9_ /Q1/=:SK/B30OA]>>*?BSX/E^'_B'7K/3/B!=^'?T6\?
M_"WP'\4_AMXE^$/Q$T(>+_AQXS\+WG@KQCX7UK4]8N;7Q9X1U2P;2M:\.>)[
MO^T%U+7M'\0Z5+<:5XEL=5O;N#Q+IEY?Z=KJ:C9ZA>P3^=? SXO?!_QEJ_Q<
M^"OPIF\1+=_LH>,O#_P3\?Z1XAT/QGI3^'?$5S\.?!WQ&T+2--U'QQ;P:GXI
MTEO /C;PCJVF>)K";5-!U/3M4LY-(UC4;4"5;;4Z+H\ND7*<+)-1C*GBZ52;
M34N5J685'&[<8N:L]+2RDES*<FK3:C)N3BY2<L+*%/W;)IQP,4W?FERRNK6<
M?R ;]G;]H+X,_P#!*C_@F;KFE>#-#^&G[>G_  3\\.?LB^$_ W@KXC>(/"M[
MH'B7Q[K&@^$?V2?BQ\ ?$OCCX;:A\0M(D\$?'?PSX]UGP_H.K:%K%Y9:=XW_
M .%5^/-7CL-0\&+!IO[=_"#X;V'PA^%W@3X9Z=J=]KR>#/#>F:->^)M62!==
M\8:Y!$LGB/QOXEDMU2.\\5>-M?DU/Q9XIU(AIM5\1:QJ>I7,DMS=RROC:[^S
MU\"O%'QH\$?M&>)/A#\.=?\ CS\-?#&N>#?A[\7]8\(Z)J/Q#\%>%_$C2MKF
MC>%_%-W9RZMHEKJ*7>HVTQT^Y@E6RUG7["*6.R\0:W;W]:P_:"^&>I_M"^(O
MV7K/4-;;XO\ A3X3^'?C7KFDW'A3Q+8:'!\/?%GBC6?!WA[5=/\ %VH:7:^&
M=?N+_P 0>'-?L9M.\.ZIJUWI+Z3<#7(],DFL8[LNY.=U[U6I.JXK5)1A&_)?
MWDG&DJU5-\JJ14HW?-)THJ*AJW&E3C34GNW*I*W-:\?==3V--V3<).,K-QBO
MQ4^$O[-G[7'PT^#7[)<\G[/_ (KO?%7["7_!4+]K7XX^*?AW-XS^$QA_: ^!
M7[2OC;]N#P?%\4?@==VGC^^L[W6OA[\.?VN- ^*6G^%?BI/\*O$VK'POXT\'
MZ9I,WBUO#MCJ_P"D_P"R5\#_ !GX)^.?[>7[0?B:TU7PIH7[67QT^&?CCP#\
M.-6N;0ZEHWAGX6_LT_!WX(7'CGQ+I.FWNHZ;X>\6_$SQ#X"UK5#HT5]<ZK!\
M/M)^&\WC"'P]XYG\3>"_"WOX_:'^&#?M&C]E1;_7_P#A<G_"F[WX]/I<O@_Q
M5:>&O^%;V?C+2/ 3:E:^.;S2+;P=K&J/XEUB&TF\/:%K6JZWI,$+7FOV.DVU
M]HTFI^X5%-*$$HV:Y7!2;;;4:>$PU2S;:U_LZE=)14)QJ\J3F[-J\G?=2BVN
MS4\1B*>EKIKZ]4:=[SA*GS7M=_DUXX^ 'B>/_@I59KX)U31A\#OVD? '@;]I
M#]JOP=)<:NNJZ=\:?V)/&'@G0/V>_&^B-:7-Q9:5J_QL?Q'\,M&\6RWUOI,?
MB/P1^Q'IGA_3Y-5BD\4PP_/OQ:_9 _:!\0?";_@K]^R#??#C4OB#:?\ !0CX
ME>-?B#\!/CU=:CX2E\">'+'X\_ [X1_!>YM_BG;WWB9?&7AS6OV1O$7PY3Q1
M8+#H-ZGC;X5:7\-[#X23>(?'>F^)/!/A']A?A9^SU\"_@?JWQ,U[X/?"/X>?
M#37?C-XXU;XE?%G6_!?A31] UCXC^/==U#4-5U;Q7XTU/3[6&]\0ZS>:GJ^K
M7[76I3W!BN]5U.>!8I-0NVF]BHY4XQB[M*$H3NWJI5:5;E4DU)1ISHPC2:<9
M1I\R7+S1=,5TY232<IQFK):.%.I3NU9Q<IJI.=16<7/EE[S4O:?ST_MQ_LR_
MM8^(+G_@KQ\-/A1^SSXV^,MI^WC^PM\-/ /P5^)FF_$#X-Z!X3L?B'\._A7\
M:/AKXF\"_$Z;QQX_\*>+M#\6ZI=^)O".J^$]1TGP5K7@GQ(_BA8M8\5>#K#0
MO%^K^'?U$_;JTOXT>//V(/CKI/P0^#7A7XD_&3Q7\+'M_#?P5^+FF_#7Q+I6
MJWNK2Z9_;_AK5]&\7ZEK/P<\0^+-(T*;69?#6E^+-8U;X7ZOXYTW1;/Q%J-_
MX1N+VXF]E\4?M"?#+P?\=?A7^SCK>H:W!\5?C-X1^)'CKP%ID7A7Q)-H.I>&
M/A*?#*>.[VX\9KI@\(V=]HT_C+PM"= EUH^(IUUNSO(M);33+>Q^VT*/NZ/=
MQM.V[HU:LMERQTG7E&=N5[*+@[3BU*SY;JT&Y.';VU*DDVW>5G3HQE"[DM&W
MS^]&7\J/[6'PM^-/@C]G'_@L3\0/'GP$^-GAKP/^T%8?L">.OAOJ'QI^(GP=
M\<>*_&U[X3O?A1X!\>>"/%__  C?Q>\=6GAGQFWB[3=0$_A^%+/X2:1X<U71
M4T#6=)T^2?POH/L7_!5CX,^,_$WPN_X*??MCW_@+7_ /A34O^";WPU_9?T/P
MKXKN?#5OXB^*GBCPI\;_ (B?$[Q;KFL:1HFOZ_I>F^%O!D?C+0OA_P""M<UV
M]BO?%.J:S\3[^RTV/X<6/@?QC\0/W\^,?P7^%_[0/@'5?A;\9/"%AX]^'FNW
M.EW6N>$=7N-1BT;69=$U*VUC25U6VTZ]LCJ-OI^KV5CJUK:7CS6D6J6&GZ@(
M/M=C:30P_%?X(?"WXY_#+6/@U\7O"5M\0OAAXBL++2_$G@_Q+J&LWVF^)M-L
M9(9H;#Q,YU%+SQ%9O-;6]Q>6VM75]%J-S"EQJ"74ZB2JYFDK63C.DX62]V$(
MJ$EKO*5.52"37);D;5XL=]5=MZ5>?7XIS<91:WY4I4Z<G)/GOSI2M*Y^9?QA
M_9Z^+'QE^/'[67[3WAWX/^,?#5UJW_!,;Q=^QCX%\#ZWJGP[TSQU\:?B1XI\
M7>/O'\ED\;>.F\(:)X?^%VJW%CX2\'>*?%7B_3-!\3:W\2?B+J^C7T'@'3=%
M\:>-.!^*'P+^/G@C]E/_ ()??$#X:PV7P@_;6_9Y\._!#]F!?"WC+4-(U\7'
MA7]HCX>^!_@'^T-X$UJ/P)XB\2^&?&5A\)-4T?PA^UW)#X?O_%>C:C=_LGZ5
M<F[/AB36K^+]OK*SAT^RM+"![J2"RM;>TADO;V]U.]>*VA2&-[S4M1N+O4=0
MNF1%-Q?7]U<WMW*7GNKB:>1Y&^$X?%?['?B;]LW0?&VF_!J'QE^T7;#Q?^R[
MI_[4VA_!R?Q?IW@[Q%\._#.J_%KQ7\ -4^,>E:9J=UX N=-\,^*/$FIS:CJY
MT/X=ZCXEN/$WPFA\;7GQ8L-7^'=LM/=@U[EX/EO+F4:=3%3Y4^9-1JSQU:C4
MO.*5.MR1:DXJ2?-R2UU]]I\L6E*I3PU-MZ.[IPP=*K"T9/VE-S:<5+E^Q_A_
MX&\.?##P'X)^&O@VR?3?"'P\\)>&_ WA33I+FXO)-/\ #7A+1[+0-"LI+R[D
MFNKM[32]/M8'N;F62>X:,R3.\CLQ_ C]GO\ 9C_:S^#[?L3^,O$/P,\?R67[
M%_[8W_!26/XH^ ['Q#\)=8;XF_"']LGXG_'/Q-\/?VE_@O#9?%*1M>3X9:7X
MO\(G7/"/BRQ\&_%JY\%>-OBKIG@CP3XF\7Z=I7@_QA_1-11K[3VM_?TU=K75
M6=6]DDM74JQ:2BN6?N\LH0:32<.3[-FMVW:5.$-VY-M>SI24FY-RA[SDISO\
M*_L._ ;Q;\&YOVO/&OBK1AX/7]J']LSXE_M(^'/A[)<Z;=W_ (%\-ZYX ^$_
MPOMH-8ET/4-4T)-=\?ZE\*-4^,FM66E7]RFFZE\2[C3M4D?Q#::P[?/ES^SM
MXFT__@IEXLL_".MZ3=?LW?&_PS\+_P!LW]HGX<&6>YNO#?[4'[/\\7P?^#_B
M.;3T,4.D:=^T'I^D?"WQS87T4L6[QC_P3NOW^R:B?&/B6:']#_$GQJ\+>$-6
M^*5AXCT'XEV.E_"'X8Z#\6/$_B^U^%?Q U[PCJOA[6IO'R7.C^ ]7\.>'M8?
MXB>._#%M\/KW4O%G@'P5:ZYXMT33_$G@:>729'\7:3%+YO\ L@^$_P!EV#X.
MZ#\:?V3_ (7>"/AO\/?VK+#1_P!I^>^\)^!-.\!ZK\0;WXV:1:?$&W\;^-K&
MVLK/4;GQ/J]AXB@GNTUHRWFE+)_9,2VUM:1VT2@E&4'%>[2IJ$=6WK"5*"DV
M^9)^QE4YKINK1BHQ4%I4G)J:;UJU+ST26DE5ERI*W,N>,$E\-.K)N3E*[_*7
MXE_L7_M%>,?V=_\ @I;^PUJ_@;7M<D_:]_:S\:_&;X)_M(V^J^$7\&^'_AW\
M=?''PY\;R>)O$4]SXLC\;>'OB/\ L?ZSI>J6/AWPW-X:AE\7:)X*^$US\+-7
MU>5_%]K\-LK]KCX ?M8ZTO\ P5)^&7P\_9<^(/Q+@_:<_:B_8@_:>^#_ ,0?
M#OCGX%Z+X'\0>&?A/X-_8,^'/Q!\!7I\<?%;PMXMT/XDZ-??LQ>/];MK35O"
MEKX(O_#]]X<NY?'5A/?W%M9_T*T<?B/TS50;@XM.[C[)7?6-!4(T596C'E6&
MHIN,4Y\KYG[SM,DI.[TM*K.-M.65?VWM7>S<N;ZQ5LI-J',G%7BF_P [?V=_
MAI\5_#G[?_\ P4 ^*_BSX4>(_"GPR^,G@_\ 9 LOAC\0]3UWX8W^F^-+OX5^
M!_B%I7C?2;71_#'C[Q!X[T:3PYJWBRTMU?Q?X4\.:;J4DE_<^'[O5+0?:IXO
M^"@?PU^+OQ&U_P#8*OOA3\*O$OQ.MOA)^WK\*?C-\3Y/#OB#X::%_P (7\,?
M#/P]^+?A?6_%5XGQ%\>^!Y-;2RU+QOHS?V'X03Q)XGN[9;Z6QT.Z>W2*;]%Z
M*%=>RM;]TZ;BK;^SJU*T4WN_>J-.UFXQ5[/F;3BG&K%WM553FUU_>PA";7:Z
M@FEJDV[75DOYX/%'P._:]\4_M,?#'QKK7[)'C73;'X,_\%A=?^./]I_"OQ1^
MSMX/^"?B+]EKQ+^S_P#'WX2>%_C-H_@Z/XO^%?$_COXOW]UX]\!^+OVB/%WQ
M<\,WOQ5A\0ZCXYT/X8:AJO@G2O#_ ( M[=E^RQ^U+;_"#P%X=N/V;/&4VOZ9
M_P %Z/B+^V9J>ECQK^S])+IO[-OB7]L7XI_&W1_BU)=R?&,:=/#%X%\7Z(T_
M@^PO;KXI6^JI=Z;%X'E6V2>;^A3_ ":\0^!W[0_PP_:)M?B;??"^_P!?O[7X
M1?&'QM\"?&I\1>#_ !3X)N[+XC_#L:4OB[3+;2?&&DZ)K-UIVG7.K06MIKBZ
M<FDZX(WU'0;O4]%GL-4O+A.<5&*Y7[-TZFVRI5<+)-J]K.I0HQET]^27*Y04
M!QO)U+_%ST^CBO:T\7%Q5UORXFM*-W?W(O7DES?CC^T9^S!^U+XT_9O_ ."R
MO@;PG^SUXSU[Q;^T[^V?\*_BM^S]HD/C?X#V$WQ.^'^@_!+]A;X::UXBL+[6
MOC#IFB^$TTO7/V>OB%?/I7Q(U3P3KUUHL>ASV&E76I:I_95K]S:9\*/B;>_\
M%/OB3\8M:^$VL-\!O&'[ 'PE^"\7C_5-6^&U[X<U#XA^&_CI\:_&_B;P#J'A
M&/QK>^/V<>$_B'HTKZI<^!G\&7S#4M-3Q#+=0QV]S^B]<1\2OAKX ^,G@#QA
M\*OBIX0T#Q_\./B!X>U/PKXT\%^*=.M]6\/^)?#VL6SVFHZ5JFGW*O%<6UQ!
M(1G"R0R".>"2*>*.1,(05.')%1DN5JTW=.^&JX9\VC5G3K5&URM.32LX<T7I
M.<IR<G)J[=W!+F2^L4<3[MWNJE"FD[IJ-[-2M)?FA_P3*^ 'C#X20_$GPQXJ
M\36'CGX8_LL^*O'O[&O[%>OQ7ESK$]A^S)X4\:MXQFTRZUFZ6&XE\3^!+NY\
M!_L>>/+>5+L7>J_L/:3XE:^.H>(=4M8/5/CS\*_BOXA_X**_L%_&;PS\--<\
M2_"CX/?"#]MGPU\2_'=AK?P^M+#P;X@^,-C^SZ/AY97&A>(?&FB^-=9?7G^&
MGBFR:[\(^%_$-II$LE@=<N-,LKZ2ZA^ZO!/@CP9\-?"/AWP!\._"?AKP)X&\
M'Z39Z!X4\&^#]$TWPWX7\-:)IT*P6&D:#H.CVUGI>DZ;9P*L5M96-K!;PQ@+
M'&HKJ*UYFI0DI.3@DE*>\FJ=6FYRLW[TG5E4E9ZSLVW>;J9M74T[+VC;:C:T
M;U(5%&.BTCR1@M/AO:WNJ'X$_LY_LR?M/^"/A+_P2O\ #?B;]G7QGX<UG]G[
M_@HQ^V)\=_C7I#>-/@'=O\.OA5\7_!__  44\-^!_%E_<:'\8]1TKQ(-6OOV
MH?AI>W>B?#^^\8>)=-T]O$\FH:-!J&D1:=J.S^Q5\ /C=\,/%/AWX"_'[]A"
MU\9:W^SM\>?B[\1OAM^WQK?Q"^$_BSX:^,_A_P")O%_Q0\5>!OB1X*\!W7Q"
MN?C/X._:H\0>'?'E[\+/&.@W?@'1O#.AW-YXW^(-Y\6;W0-<T#P'XS_6_P",
M/[0OPQ^!6L?!G0?B)?Z[8ZG\??BUH?P1^&::3X2\3>(+'4_B'X@TK6==L-*U
MK6M&TJ\T/PC:OHOAW7-134O%FI:-97BZ9/8Z9+?ZM);:?/[:#D9J8)P]Y.^\
M;M6]ZG#!J+3C9QE3^KT)OE<;^TFG[LX\A.TY34FKRM-Q5M(U)8IO1IIPG[6K
M%<RE;V46O>@U+^?C]EO]EO\ :E\!?"[_ ((N>'_&?[.GC+PWK?[+?[2_[4?C
M_P#:&L[KQM\!-0?X8>$OB1\"OVT?AGX2UJ^NO#OQAUJS\6_V_P")/CQX$OVL
M?AM=>-M4LM).M7>NV6FZAIJZ=<S> /V:OVE_!.E_ OQ?XE_9X\=,GPC_ ."X
MW[='[8_BCPKIOB+X,>(?%4_[-_[0_AW]OG1_A[\4_#NFZ3\5+W3M933[S]I3
MX<ZGXB\#P:I'\6["VM/$QT/X?Z]K&F:7INM?T!5XE^T)^T)\,OV7_AG=_%OX
MNZAKFE^"K/Q)X(\(RWN@>$_$OC"Z7Q!\1O&&B> ?!UI<6/AC2]4GTVRU7Q;X
MBT71Y=>U<:?X=TF6_@GUK5M.M29PX-P;Y;7G.BTK?;A/!QII6M=R>'I0UU;J
M2U3<.1U&IT^6;2IPC.4GHK0BL94E)RLVE!5ZTV[?#2C=-*?-^+7Q@_8Y_:6\
M*OXJ_:I^%7[/-A\1]5U#_@JKJ7[;NO\ [%-A\0?!_@+Q7XM^"GB/]AI?V ?&
M]QH_BM];M/AL/CWK+2ZO^U7%I.H^.M$T76/[7N/ >L>)CXS\Z*^]NN?@3\0K
M[6?V"?'GPU_80O/@1X?T'_@I!X\_:J^-/PZT?Q%^S]%X\\&^%_%W[&_[37[/
M]W\7_CQ<:;\6Y_"OC3XO>+/B/\5_"/B3Q)!\*O%OQ@\01>"X(KB]U/5_%VC7
M.E77[2444VZ?*H[0<.2[=U&$8IPNFFXR<8S:;M&?,Z:CS6BJL554E-_$IJ5N
MKE*4E*SYK2CS.*:^*'*IM\MY?D!X]^ _QVTK]N9OC3^S7H?QI^&3^-/VA/A"
MW[4/A7QKXH\ >._V,/VIO@?H7PC\%^'/$_[0-IX2U+Q'JOC?X(_M(?#'3?#W
M@SX4^!-9\ 6'@GQGXZ\4?!_P9;>// ?CSX(W$_Q/\'_3O_!0GX+?$#XO_L]C
M7/@GX>L/$_[1?[/'Q)^&W[4?[.>AZAK47AJ+Q-\5O@=XFM?%'_"LSXFNKFTL
M?#=E\=_ /_"=_L^Z_KNISQZ7I?ACXK:Y=:B\=I'+(GW%14I6C&*=N2:G&2LI
M*2E3FK-+1*=/F2LTG4JJ*4)^SB[7<FW?G@X-/9Q<:D'=*VO)4Y6U9M4Z3;<X
M>TE^2?[)_P"Q;\9?@5^U9\8]1\8:SIWBSX!^*-8\-_MCZ+K3WT_VQ_V\OC/\
M.]9^!_[37_"):/<ZIJ.L>'/AK9^'/!^I?$K2_#5\UKX6MM=_:=U/2O"UFZ^"
M&31OES2?V7?VJ+?X??!C2Y?V</&UKK7AS_@O'\;OVQO$=I_PF_P :;2?V:?B
M%^T'^T5\1=$^+$]W!\99+2\M3X.^*/AFWU'P;I=UJ'Q2@NO[3TR/P)<V]HDU
MQ_0#INJ:9K-C;ZGH^HV.JZ;=J[VNH:;=V]]8W*)(\3O;W=K)+;S*DL;QLT<C
M!9$=&PRL!\T^#/VOOA-\2/!&L^/_ (=Z9\5/'&A>'OVB[O\ 9>URU\/?"'XA
MS^)M'^)>B_%:P^#GC&\UCPA=>'[3Q1HO@/X?>+KN]N_'?CS6-)L/#GAOPEH.
MO>,KN\/ANQ349Z3=E;515%JU](T\50J4KM-MQYUAZ";D[TU3C>]ZLIE!2NVW
M>3K)ROO*IA:U*I:R23=/V]9I)?O/:2LU>G'\N/#/['_[1-]^S!:?L*^,O _B
M"/Q7X#_X*8:;^TWX=_:KEU_PG=>$?$?P=L_^"C!_X*$2?&73M3CU>\\:Z!\8
MM7\*W>N? 75?!=YX8D\3P_&[4+OQ([W_ ,#=3D^*#_>'_!2KX;?%#XM?LQ:?
MX+^$7PRUSXM>+X/VGOV'OB/<^$?#^M_#O0;V3P7\#/VT?@'\=_B+?"_^*/C;
MP#X5DDM/ 7PT\1C3]-EUY+K5M9ETW3(+?R[J:YMOONBBF_9>SY++V<Z-1::N
M5"GAJ,.9Z-KV>%I1>M[N<U:4DT5(*JJBFY-585:;]YZ1K2KSGRK5)\V(J..F
MRA%W4=?Q5_:O^$OQLT']MOQ9\7!^Q)K7[=W[-7[3G[)OPN_9_P#%_@SPG\2/
MA-X6\5?"#X@?!CQM^T-KEK8^.?!_QF^(/PR\%>+?@=\:?"O[2FL:3XNU#3?$
M'B[5/#UYX)U.#4/!FJ6'B#2[/5\SQ]^S)\;?!_QR^&7CS]EGX6^./@%\1_"&
MJ_L;?"_XB^'O!.N_#?Q%_P $_P#]I3]G+P1JGPVM?B5!KGPW\3:D?%/PL\;?
MLM^"?^$XT?X)>/-!\%_#CXHZI%H/@'0/#^I?$KPS-JWA3X=?K_\ %+XAV'PG
M^'WBKXBZIX:\?^,+#PGIC:I<^&?A;X%\2?$SX@ZS&)X8!9^%? ?A"PU3Q+XF
MU-GG5UT_2+"YN?(2:X9%AAE=>^I1]WDL[^SFWJWJI<TE3GK[\+3J1:DI<U*7
MLIVC&GRU)<W-?3G@H^CBHP<XZ7A).,)1<7'EJ152-VYJ7\_OQI_9@_; U"^_
M:U^)'@'X*>(-6N]%_P""Q'[*W[>'@'X77WCCX0Z?)^U7\!O@E^S?^R5\)O%G
MAOPO?_\ "R;C1/"7BZR\:?!OQ/X_^'^F_&.X\ Q2^(_!?P\O;YM*DU&671<'
MXG?LZ_MD?':T_P""GOC[P-^S/KOPR\5_&+X@_P#!-_\ :/\ V</"'QT\<_"7
M2[;XO:_^QCJGP<^)GBCX+>.9_A-\5/'5SX"U/QYJ7P@?X<RZMJFHQ^&K/3_&
M&EWEYXHA:P\2Z3X>_H@HJ:<?9148O2*ERMI-QE*%&G*5FN65_J]%\LXRA>,D
MERU)Q":51WDMY\\DFXJ5IUII-IJ22^L5HWC*,K3B[J5.$CX'_8B\/W%[/\3_
M (P:O^PO<?L2>*OB+9?#;P]XGL?'OB/X5>+_ (Z?$O4/AWIOB-$U#QGXE^$/
MCCXG:!J?PU\&?\)5-X:^#\NO^.4\8RJ?&][?^!/!.@WOAIM?^2_VO?\ @G9\
M3/VAOCE^TYX'\+ZO%X(_9F_;H_9S\-:O\:_&FC:Y=Z?XM\ ?M>_LQQZAX5^
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M:)=_$DS:?XPUSQ1X>M+>/2]2\2:/B?\ 9K^+GA__ ()R_M4ZYXP\(7WP3_:
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M6*BGHG&3VUE&E[%2;M=?N[)QBXQO%.WV44444B@HHHH **** "BBB@ HHHH
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M>>-_CCJ7C.?]BCXA>+_C'XZ^,7_!.7XJ?&#QC\8/B#J_Q#\4V^K_ +2OPO\
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M^%O[.'CK06G^%6B_M-?#+P+^T)X;_::\2^*OC)\,;*'Q9\)_B!X_C\3^+8]
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M6T5?E;:C?EYG&/NIMVNW*4RBBBD4%%%% !1110 4444 %%%% !1110 4444
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M<\"ZI:_"'XE?%'X%Z-X)\'^)_',?PWT/PEJGQE\&GQSXGMI]+>P\1:'[3_\
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M+/'G_!*6[\2_#CX^:UXBG@\<?"U/ W[/?[(D?Q"\$Z+X;/@^_2#2/BO%XJ\
MSZQXEM?&/VB%/!DNG7/AB[5[.]?U#X6?\%,?C?XB^"?AG]H;XI_L^?"KP1\/
M_BC\9-9_9H^$GAOP#\8/BO\ &#XI:Q\=?#G[4GQ0^ FOPZQX1T3]FK1XY_AS
M9>#_ (<:Q\2]-UKPS?ZSXYUNWT*]TEOAYI&HZY:6>B?0WPN_X)ZZ-\)-2_8%
MOO#WQB\8ZS%_P3Z_9N\;?LS_  YA\5^'?"=Y/X]\)>.O"7PL\'7NI^/[GP_8
M^&8_[1T#2_@QX#3PPOA:T\/>7Y>OGQ-/XIN-7MKG2N6G_P""8'@/5OV*1^QG
MKWQ@^):Q>'_C3X@_:'^%OQW\'P^'/!OQC^$_QDU3X_:_^TSH7CGPG>V^FZEX
M835/!OQ1\4:U;:(LGAU+>Z\!30^%=<AU6];4_$6J]%6:E4G*-YP=2K)1U34*
MF8>T:BI-*,_J<JG)9QIJJH\UYM36-.#4*<;\C5*E"3=G[]/!.FFVE+]W]:C3
MYU9SY'+EM#F@]#PQ^V]\5))_#OP]\=_ G4O"/Q0^*7[6$W[,G[/_ (FU_2_'
M7@+X;?&#PW;_  (\8?M):M\>'\+_ !$\->'_ (J^!M-\*_##X8?%C2-;^&&J
MZ)JMU??%WP9I/@?1?B1=>"O'6F?%O2^&^)O[2O[;.A?%O]@3P%J_PL^'?PFO
M/C!^VA^TI\#/B-H^J^-H?$VF?%SX<?"[]EO]J'XI?";XH>!]<\+6_B2\\ >$
M?B7#\+=$^)&H>!_%6G/\1?!^OP:;\-=4N[[1[?6/&&O=/XY_X)Q>*?BQ\"?"
MG@[XL?MK?M%>,_VF_AU\9?"'[1'PM_;(M=%^#G@WQQ\,OB]X T37/"WA63PG
M\(O!_P .M(^!DGPS;PCXK\;>$/&'PR\2^!_$5E\0/#GC_P ;0>+-9U'5=6L-
M7TCMM:_82U[Q#H?[,6IZY^U/\8?$'QU_9T^/E]^T%>?M!>(/#/PCN?$_Q'\2
M>*?@O\1OV>O'.B7_ ,/])\!Z)\'O!GA^[^$/Q-U;PQX+L/!W@/3X?"=]H'A;
MQ1K4/C?Q-_PF>J^-,FG[J33M4H\TM>6=->S<Y)63YKJ?M(VA%W7LXM-<MJ]I
M\U[.%7E2:4HR?M%&+;TM9P=.2;E%K]XT^;FX;P3_ ,%!/&?Q1^(/PVO/A5\
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M]%:>']#;43X=\,^&/AU\%O!7@'P'HMG8R:OJ^IZKX@OM)UWQ[XHUC5[E=?\
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MQX9L-+E_X1V/P/<>'?$OC+4/$NF7.I:CXJTWP'JD2>&8OCWXP?MN)^S)KO\
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M[\JE)XATW/1S;BOJRFUI93Y8N3FCY^\>_M;?&GX*ZI:^!/BW\$M MO%_Q/\
MVI?A7^S-^RSXUT7QUIT/P[^/;?$GX=WGQ2\3>.=2T**;Q+XZ^$J_!;PWX/\
MC#9>)?"GBBWU&?X@7OPRTN^\%:]!;_$FTLO"'B/C_P#X*4_$3X82_M!?#O6?
M@CX1\4?&S]F7]J#]A?X)^,],TSXC:OX6\'^/_A%^WQ\5OAW\*O@Y\=_A]=:G
MX(UZZTW6?[>\9>(-)\5?"'Q5?06GACQ!\/?%MM:_%GQ5H:^'-?\ $WINH?\
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MAS<>&8?!GP?\#O;1:I'=:R-?_P"$DU.ZUF[L]7T_2M"SC?F3E_SZE'=MIN.
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M5[T97DE*+<93J3LVEJO:12T?\.4(24KVL[2<^?6,H>[>,E=1^B_''[5_[/\
M\./%,_A+QG\0H=&O=.\8>"OAYXDUS_A'/%^H^ / GQ ^)"Z"WP^\"_$SXHZ3
MX?O_ (:_"[QEXV_X2_P,OA;PO\1/%GAC7-=?XB?#2/3;&YD^)'@9?$'-WW[;
MW[+MA\>Y/V8'^*=O>_'BU\3>%/"&I_#O1?"GCKQ#J.@:WXX\'^(O'GA5?$^I
M:#X7U+0/"VE:QX8\+:O>0^(O$>K:7X=AO1IFAW>JV^O:_H.F:G^9'Q0_8G_:
M+\1?!S_@JW^QG)X"F\;^%/V^?C%X[^)OPA_:.N/$G@-?"?P[T#]HGP-\-O!?
MB2P^)?AC6/&6G_$P>,/V9?$7@W7/$/@RW\)^%/$>A^,O =E\*=,T3Q%HGB&+
MQ/I'@_[5_9Z^%GQ9\(?M]?M\_$WQ5\-O$&A_"OXO>$OV2M-^%WQ'U'Q'\/-3
ML?&EY\(O!?CW0/&ELNB:%XSU;QUHTMI?^)]/DM)_%7A30K?4E&H2V\@,<*W3
MC=N-[I<GM'KK)_5X5)4K;P=.LYT>:2?M+)PC=.ZDY*_*D_?Y%H_=C[6<%5>M
MIQG34*BC&W)=J3L]/JOXO?'[X4_ NPCOOB1XBO["27P]XL\80Z'X9\(^-/B+
MXPF\&^ H=*F\<^,X? _PX\/>+/&4W@WP8?$'AJT\5^+(]";P]X>U/Q5X1TG5
MM2M-4\5^';/4_@+X@?\ !130OAO^UEX3MM<^(W@7Q!^Q;XS_ ."?'B+]KCPE
MXH^%WPY\??%?X@>)[^R^*_PPT2S\7>&KKX77_P 0=6^)?PVE^&'C"[\;Q1?#
M_P"%R-X<\,6OB#Q]XG\1:CX0T]K_ ,.6_P!J+PI^UK\)/VW_ (4_M?\ [//P
M N?VMO &N_LX>,OV8/BY\'= ^*'PR^%'Q!^'.HM\1-%^*GP^^,O@_4_C%K_A
MCP-XH\,ZE<VWB'P/\4?"\/B/0_%4$+^!/$^A6OBY-"O=#AH-\%_V@-+_ &UO
M 7Q8NO@/8CP%X9_X)C_$KX#:I<_"/Q+\-(/A[H?Q>\0?%/X:^-]#^$7P\T7Q
MAXM\ ^,;SP]I>A>"[_P_H/BW5_ G@WPM<K'H<VI1^%(KR]L-#SE*:@ZD8\SC
M#%/V;37-.GA\9*E"V\E5E##2ISBDU.JHIRE%0=V3E&#;BI3PMZB:=J=2OA55
MEK\,J<9XB,XN]X4^=I1;FOJO5OVA_ VN?&C]D?0O!'[1OPXC\/?M!> ?B?\
M$;P;\.K/P1J/CG5?VCO!&F^#/"OB;0O'7PW^*>C>)K/P_P"!?#'@>PUNR\1Z
MKJ&I:#XHLO'FG^*M#TO3+K1+K[-<ZAXM^RI^V=J'B?X.?$SQS^TKXC\*V?B/
MP[^W)^UO^REX*L_AQX'\6_;/'?\ PHWX^_$[X8^"=(\$_#+2M0^)'C_Q5XRU
M+P3\.;[QEXCTCP])XGOK73]+\7>*9(+#PGX?U&XTOY,_9M_9<_:9\!C_ ((/
M6/B_X)>(-(3]C/\ 8Q\=_!+]I6_?QK\'K^U^&OCRY_9P^#7PGTFU*Z5\2K^]
M\8Z9K/B;X>ZW+9:EX M/%4-OI5QI5UJZ:9//=6EAY'X4_9?_ &U_A1XC^#'[
M1.B_LY>+/'%]\!O^"G__  4P^.?B/]FJS^)?P"TSQM\4?@%^W'XP^,B^!?B]
M\+O$>N?%RQ^$EK\2?AAH/Q$TJ]G\$_$KQW\/[S4= UGXF>&K77-.OY])?7.A
M<MY)Z)SJP3?O.$/K5)0GII)^S]V4OA47.<5&DII3JXKK)1H2LKQ4I/#8EU8.
M[LDJD8/5WYG3@W*HXM_9O[,G_!1_PEJ?PK^./Q8_:N^*?PW\#>%O#G_!0KXD
M_L=_#'Q+;>"O&?PVTJ9+3QIX9\ ?"_PQXK\,^*M2\4^*?"_CM]>U:31_B-=>
M+[G0[/PWXIAUQO$&G>!-,TR;2-'^HI?V]OV5K?X7Z;\9;KXAZY9?#B]\+Q^.
MM7\07WPF^,EC-\._ 4GB/7_"@\?_ !IT&[^'\/B3X$> 4UKPCXSCG\;_ !HT
MCP'X5M]/\$>.=<N-7BT/P7XHU+2?RSN?V9OVM[KX&_%'3)?V9O%L'BKQ;_P6
M\^"W[;6B>#;/XD_ *ZU63]G7P;^U?\ ?CYK?B?4]2G^+&F>%;+Q+;^$?AOXC
MTNX\&P>(-0U)O&7V&PTZXU;0KD^*4]5_:6_9Z^.6C_MN?%'XGVO[ OPE_P""
MB/[/O[5GP(^$?PQU33?B'XP^!7AW5/V<O'OPLOOB9H>J6'C;2/CAI5^GB/\
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MY^S<]B?CY:>*/ /Q,\,^,_A!8ZKI$/B#2=?^('PVU[P;IWQ&\->$M8\/S_\
M"0:-XQU+PK#X5U;0;>^UK3M8N=,TW4+JV]ITCXP?#K7?BOXV^!^F^(3)\5/A
MWX0\#_$#Q;X1N='U[3KG3_!/Q)U'Q?H_@CQ19ZAJ.EVFC:[HNOZQX \;:-;W
MV@:CJD-MK'A;6]*OVM;_ $^>W3\@?VMOV*_CS^U?H_\ P4O^)WAGP9JWPQ\4
M_M,_\$R?!O[&/PD^$/C_ ,5>!8M8\3_$KP;JG[3GQ(N?$_CB[\ ^+?'7P_TC
M2I]1^.?A+X:>#-9D\9W6I:=>Z7\2[_5K"V\)S^%-7UWZ8^ GASX_^)_V_OC'
M^TM\0/V<?&OP0^&/Q4_8;_97^%OAZ/QYX]^"/B/QCH7Q$^#7Q[_;)\4>+O!G
MC30?A)\3/B1I5CJ\NA_&KPKXATC5/"GB7QIX*N_#]U9";Q;:^+W\0>#?"]12
M;:D[6I<^B=O:<F(?)S/27OTJ5[:_OE#I"<E-M13C%MNHH_\ </FH7E9:IJ-6
MIOH_9<R7QPCQOQL_X*.^&/V5_P!MOXQ?##]I;XA^#/ W[-W@G]CGX)_M ^'-
M2TSX>>/?$/Q!LO$7CSXP?'#X?^/+[Q,G@Z;QSJVM> O"&B?"C3/$>K^*-+\"
M>&_#GPZT?6;_ %+X@:PFF0VVLI]Q^//VI/@/\._!&A?$;6O'D>N^#?%'@6]^
M*7AO6/AGX<\7?&4Z_P#"W3+'1-3U/XGZ/IOPBT#QQJVI?#;3=/\ $WAJ\U#Q
M]:6$WA*RM_$>@2W6L1+K6FFZ^2?'/PW^-O@C_@HC\1_VC_#OP(UKXT_#'XD_
ML$_#/X":8OAKQ?\ "G15TWXF?"WXU?'[XA7_ (?\>V'Q'\9^%-0LO#/C#0?B
MWX>MM%\0^%](\=0)-IGBB#Q%I>E-;:#'XD_/?2/V!?VAOV,F_8CCT/\ 95\
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M6?'_ (+\-_$6TN?&?P?\(>#_ !I\2K76O#_BGP7IEMX-\9V6NRZ!\3/"VO\
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M#X(@\!^*?%FBZ/X0\4GQ3HCZ-K]Y'?PNWY=^,/V>/VEOC_\ LP_$[QA\/O\
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MLL>+=.US]L6^_8[\1? CP3??%/\ 9\D\1ZU#X%^$_P (O#'CW0?%=W%\6/\
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M"/&_@_XE^#/"?Q%^'OB?0O&O@/QWX<T7QAX+\8^&-3M-:\-^*?"OB/3K?5]
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M6)=9BU=/%,&J?'#P%=66GVN@7FGS:9=WMQ<ZK9W%M%:W/XL?M1_"?X9?%/\
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M_EW;'-\S:2V<7RP<OWF'/M]:\*^,_P ?_#'P:O\ P#X7E\/^*OB%\3?BS?\
MB[2_A5\)? +>$4\;?$#4/ O@C7/B#XGATJ[\?^+? ?@71;/3/#^@S)<:[XT\
M:>%_#D.L:IX>T2;6(M4\0:3;77X]?\$MOC3\+?VB?%7P ^,W@;]O+P[\6/BE
MK_[*DNE?M ?LQ>#(_$Z>-(O%2OX)NM9^(G[67@/Q-\<_BE)\/?C-\+?'>GZW
M\.-+\80>#/AK=>);3QA?^"K<>)/ ^A^ [+P=[[^V3X=\):M_P5$_X)-Q:WJN
MIVFKZWIO[<=MIVGVGC_Q3X9FU"/PO\&O"^M_\2G1]&\1Z5%/+$;V1O$,UA9-
M-JVD_9=.\1R7NCV=G:0;SC*-2G3NGSU94W*'O1:B\3%5*<U>,Z<_8QJ0FFXR
MIR5W>5XX*I>$YJ+?+3A-1E>,KR^K>[./QPE!UI0J1:3C.#^S%\WZB?#'QW;?
M%'X<^ _B19^&?'/@JU\>^$/#OC"#P=\3O"6K> OB-X4C\1:3:ZJ/#GCSP3KL
M4.K^%/%^B?:CIOB+P_J$?VG2M6MKJS=Y/*$C]S7\XGA7XG?&3QW^SE\+OVB+
M+QOXPTW]OWPI_P %=+SX _$CX<:;XUUBY2[\*:M^W;K/PO\ 'O[+GBWX<0WN
MJ^'Y_@_X"_X)_P"MCXZ^%]./AN4^&O"'A32/VPK6X'C;4/$7Q.US[*_8[^&O
MAWQO^VA_P40^(7B+XE?'#Q7KW[/'[<TOA;X3^$]2_::^.NI_#?P+X:^)W_!/
MW]C'Q3XPTB;X1#XDM\._$6B7WC/QQXZU#PYH?CGPOXCT#X>:Y%+<?#+3/!NJ
M:9-,)C-2<?=<(SC.:WE:*H83$KE=DYIPQM*#DU'DJ1J1E=J/-<O<O%MRDI1A
M=))2DZN*HN^MHVEA*DDH\W-&<'&RYN7]<:*_%[]H#P=HOQ?_ ."I5[\"O'GQ
M*^,%A\+_ !5_P2U^(WC?Q#\//!?[17QC^%6C0ZWHO[2OP]\/V?C[3=/^'?Q
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MS6:QXH_:&^&_[)/B_P#:RD^(WQD\3?#O_@FM_P %*OCWXI\.,/B7\4/$5_\
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M]M+_ (*3:A9_L^?M.?'KXB:,_P"V7\-/A+^UI^V%X%L?A;9_M!3R>//%D7Q
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MTT2X\566FCPG>Z-I.J>)_P!*O^"HGQC^+WP%_8O^(7Q*^"/B'0/"_CNV\;?
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M[2OS3PM.\G-I+EJ8NFFTVHJ49WC'G]G]\:;\,?AMHMQJ-WH_P]\#Z3=:O?\
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MUW=^NK<G=[MMMN\G)ZO6SL))+966BLMDDN5)+9)))6BDM%I=(****0PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M56<6K14*4H+6[YE+G;>J>O)HK<JE%6U;=RBBBD4%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ex-19_002.jpg
<TEXT>
begin 644 ex-19_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2* X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M40_9/_:Q^(FH?#7X!_$'4_'^IP^ _$7Q/T+Q/I_@;QO;?#CQSX \'_&/Q?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_GE_X)6_\$]?#7QT^!/_  1Y_;C^,_Q.U;Q/J7[*O["_A;PW^S/\*_!.@1^
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MB9-XM]?_ &D/VU/VR-._X(H?\%%OB1IOQJ^+G@WQG^R?_P %;OB+^S1^RO\
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M#?\ "$P^+?&NMZKX,\ :O\1/$'AKP1HGB:^^'VC:;XNMO%<UM_P@/BR]T_\
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MX[&@^+?A=XV;X5>,M-OM<^'WC/P[XJ\&:SJ=O)X=O],\1^'/%MK8>,?#<_\
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MOPGT/7]+O+*Q^%>N1'0[;XHQ>.]9-_;3:/\ #+7/"<6DW!\237^E_F]^S?\
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M^*7[6^@_ S0H+S7C\%/&7Q2T=OA'\.8/@;>2Z[#+XCEUSQ7-\1H_['T32_\
MA'+^76M:JA3C4]FU4:YFE=3E>G',(Q<7'V<7&4Z6%<HQ2]I[>+IN/[JTPE*:
MI\T7%\Z3T<8N$U@)-24N9QE%5<5%3;:INA)3C)<Z?Z5Z1^V]^S-K;^,[>T\>
MZQ:ZEX%^$J?'G6/#^N_##XL^&?%6J_!5GEBE^*O@/PEXC\"Z5XF^*/@*RN(X
MK+5?%'PTTGQ;I.D:A?Z/I^J75G?:YH]O?=/H'[5OP'\5ZSX$\/\ ACQG>^(-
M8^*'[/FI?M3_  WL]'\$?$#4#X\^!.C3^ [;5?&OA&:U\*RVWB"YL9_BA\/(
M9_!NES7/CM9/&?AY/^$9SJ5ON^#?%?[/G[0W[8'Q0^!/QI^*/POOOV8O$OPB
M_8O_ &Q/@IXN\,Z[XX\">+K#Q3\8?VLM*^!GAQ;+PGJ7PN\5^-4UWX+^"&^$
M7BGQ-=ZKXTL_!'B[4[G5_A1>Z?X,@U*V\::3X:\]_8K^#'[5_A_XM_\ !-_Q
M)\5/V9?$/PE\.?LU?\$ROC-^QG\6-1\1?%/X)^)KRP^+MSXA_83O]*US0=)^
M''C[QH=;^%OC.#]G3QA+X$\21WT'C*9)-OQ)^'/PLGBTN+Q!C/F4N6%I7G;F
MWBJ:GC8^TYO=BVXTL+44;1O[9Q45&I#V6D-8J4_=_=IM+XE4<<+)T^6\I+EE
M/$P<O>2]FFY.4)^T_1K]CK]JOP5^VE\!?"7[0GP]\.^-O#/A'QO+K%QH&G^/
M/"7BCPEK4VAV^KWUOH&JF'Q'H6C07YUC0H]-U2_;P[-KVA:+J]WJ/A:/Q%JU
M_H-_<'\F/C5_P4P_:T^ _P %?^"E7[26KI^SCXS\#_\ !/']M/PS\"X_A='\
M-?B)X)\7_&GX5:SX,_9:\63:7IOQ.F^.?BS1O#?QOOY?VCY?#_@^\A^%?B#P
MOXH\2>&]$T3_ (0O2G\:?;?#7WQ_P2N^%GQ@^ G[$?P>^ 'QO^&>I?#;QU\#
MK/7?AM>?;/%'@3Q3I?CJWT?Q-K5U8?$7P9>>!/$_BA(? OBK3=0L;S0+;QD/
M"?Q#MI1J-EXH\!>'&M+*;5?(_P!CO]D);3X__MS_ !6_:/\ V4/"-MK7C[]O
M";]I7]FSXB_$/1O@5\0_$FD>&;+]GK]GWX3:'KGAC6= \2>-_%7P_P#%=AXJ
M^%OC'6K"(IHEUIVD:[IUY;WR:MJ6KZ=8#O[:GRNT/8*<G92CS>RRV;34G%.?
M-/%P4)..OM$TO9VA,6U3]Y7DJS@^C<.?,()WC=J-HX:3G!._N-?'[WUW?_MQ
M?LQ:;\=KG]F:X^(E]/\ '33]:\"Z#K?P_P!)^'OQ-\0WGAB]^)/A?Q-XQ\&7
MGBW6O#W@[5/"_A3PYJV@^#]>E?QAXAUS3?".FZC!8:%JNN66N:[H.G:GU'PS
M_:Q^ /Q@\6Z5X(\ >.Y-4\0^)? 3_%7P-%JGA'QSX3TKXH_#"&^TG3[OXC_!
MWQ)XO\,Z#X;^,O@/3Y_$?A*35?%WPLU;Q?X?TJQ\<> -3U+4+73?'W@V[USX
M3\3_ +)_QB^+OQT_X*Y^&]:T#Q#\+?AI^VE^R7\(/@)\*/CE%K?@75HX-?T;
MX4_'KX>>+];L_#&@^-YO'6F3^&KSXM:)K&AMKFB:#%JSZ3JRI>6#Q:?)J/$Z
M;^R1\??VCI/V"O\ A<_P_P!2_9M\1?L;_ GX^_#_ .('C#2/%G@'Q+9^-OB%
M\5/V<8_V7Q;?!)? WC'6];N/A!>-JOB3XSV6J_$JQ^%_C*QG\%_!W3;[X?PZ
M_JGBB+X?C;]GS1CS5.3G]E?D3YHY@U%3GHG"IAL'3DI)RDL:JCBH03*BO>Y9
MRY8\SA[3EY_@>"7,X0=VJL*^*G'E:C!X5PNW)H_1/P=^V+^S9X\\80^!O#?Q
M0L)-<U#X::Q\9_#=UK&@^+?"WA/Q[\(/#^IZ?I6N_%/X7^/O%.@:-X$^*WP[
MTB?6O#UWJ/C/X;^)/%/AVST7Q5X/\13ZBGA_Q?X9U/5<O3_VW?V8K_5_&_AY
M_B3/HGB/X?\ @/PQ\4-9\,^+_ ?Q)\$>)M9^'?C36)?#7A'QE\.O#GC'P?H6
MM_%OP_XF\6)#X*T/4?A58>,X-3\=:AHW@>T:7Q;KNC:-?_FA\&O@!^W3\9?V
M!O'7_!/7]HK]GOX:_LYZOX,_84^)_P"PYI_[4FF?%/PE\5-!^+UWK_P?;X'>
M%/B#\%?!G@^PT[QSX%^'6OVFDZ)\4?B'IWQ3@^'OBG0M7TCPSX%T#P'XP@N;
MSQKX)I_#?X$?$WXJ_!GXEVW[4'_!%_\ 9Y^'7C6?X/V'P&^*VG_!_P"(7[/.
MG?$;]I/2O$7Q+\ 7OCW4?V=OB9X"UOP+JOPO^%^GZ=X:U/XT>%-$^*_Q,^%7
MQ"C^*>D_#:TTZ?PIK?@^/XB2W*RE/EDIQ2YH2LX.I3<Y*-11DG[.?)R<U";]
MI&4]8J,)RC,7)Q3G'DD])13510J*$7*'-%Q<X<_/RUH)0E&/NM2E&+_52+]K
MCX%RZ/+JQUOQM;3I\46^"T7A/4/@O\:],^)=]\3T^'J?%I_"6D?"?4/AY:_$
M[6KQ/A:TGQ&:[TCPC>Z6O@>TU'Q2;X:)IFHWMKQ/C/\ X*!?LD_#[PCX;\;^
M*_BC?:?H/B;X+:S^T; EK\,_BUK?B#P[\!O#<NC0>)?BY\1?!VA>!-3\7_"G
MP#X:GUZQ@\1^)/B=H7A'3M!GAUB'5YK.3P]KZZ9^=\/[(?Q\UKX"2?![XZ>'
M?VR_C=H/AS]KB^\5_LH?%G2?VC_@GX-_X*#_ +*7PSM?V:D\.Z#\5_%WQPTW
MXE^%?!GQ1\8Z/\5-5^,/PLTI=8\;_%'Q9XM^!7Q)\(CXSVGCP?\ "=^&-.\<
M^/W[.O\ P5#^+GP.U/X+_%7X:Z7\;M=^*O\ P2S_ &C/@EJ'Q4^'7C3X+_!'
M4[']KKQE!\0['PPO[4LUAXD\+ZWKW@[Q%\-M4\&:79>"_@0GCG]GQ_V@]8^*
M>K_$/P._@9/A%\3/AO+=E-J+DHIR4?AE-*A*KR)VE:;G#V;5I1]^#HU)N\%<
M$I2A%R4%*:A*;3:@G7I4_:6T<J<:=255-6;]G.-2$+<[_H'\:?$'PSX$^'OB
M;XHZO+JFI>$/"GA/5/&VHW'@_0-<\=ZM>^'])TN76;BX\.>&_!NGZYXA\4W<
M^GPM-INF^'=,U/4-49HHM/MKB26-6_)BU_X*>7?B?QM_P3A^).G:=J_A#]G+
M]L']EGXZ_';Q?\/[WX*?%3QA\>E\5^"/AW\"/'O@[PO\-M-\,Z9?>)_BO"]A
M\6]8@ATKX2?"KQ??^/+GP]%K7@K7-6T,W=F/T0\'^$?&'B3]DSP_X"UWPW=?
M#[QWKG[/UAX,U+PIXIU+0=1O?"'B6^^'L>@2Z/XCU3P/JWB_PS<W6CZA)]GU
MBZ\):[XHT4S0W#:)J^N60MKVZ_*K]E+X ?M6>%KC_@BU>?$#]FCQGX"3]C;]
MBCXP?LZ?'NVU'XC? +7+OPMXU?X2?LX_#?PW?6J^$/BWKUGXD\.^-=>^"_BG
M5O#MWX9O=8O;'POJW@Z^\9Z;X1\0ZAXB\+>$K:4<34@I*5*G42A.R<90_P"%
M*$I2L^65U2PLDDTHRJPDN9.-\;SGAZ<^5PJ3IQE4@G:49\V7SY%?WHV4\5&3
MLW*-.<79MGZ9P_MP?LNWWPW^!_Q6T+XH#QAX2_:4L+S4O@1;^ ?!GQ"^(7CC
MXGVVE>$]5\;Z^/#'PM\$>$_$'Q/N;OPIX<T35+GQII\_@^WU#P5J%HV@^++;
M1M?DATR3A8_^"A'P%UKXM?LD_"[P!)XP^)=C^V1\(_%OQU^%/Q+\#> ?'_B/
MX;S_  P\,3?#G3H=<N?$^B>$M3L(+G4=6^*O@X:E::C-I=IX!T*YN=?^)>I>
M#X;SPK:^*/SE^ 7P"_;A^#WP:_X)Y?#G5/V<M9U#PIX*^+_[8S_M*Z!X1^*G
MP4\+_&7P-;?%7XH>./&7[/?C#2OBI;_$:"XTOX&0)XIDU+X_Z-\#/&Z?'#4S
MI_@WP]IWA3XB^ (OB-\,_&]3]BS]E7]K3X%:;_P1CO?'/[/&NQ77[*W[+?[5
MG[)OQ^T;2OB-\$KZ\^&^M?%#6OV99?!GQ5FGC^)":7XJ^%.I1? +Q-<F/P#?
M>*OBA8Z=XF\%2:E\,K'4KCQ3H_A,I\DK.=Z>L'RN2?Q4DW2D^5.\:M2,7.Z3
M]DV^52GRNHYJ+Y-7[R^'7W:FDUJXVE3IR]S5WJ+E<FH7_1K]L[]I'QE^SG\2
M/V$UT[7/#.E_#/XX_M4^(?@G\7K/4O"&L^)/%^IZ(O[)W[37QK\*V_P]N=(U
M<W2^);[QO\%M!\.V?A73/!?B_P 4^/;WQ%I_AWPDMGK4L&GZ[Z)HO[<'[,.O
M_"/PI\;=.^)-R?!/C?XG:A\$?"^GW_@#XEZ/\3]5^-6B^*?$/@O7_@ZGP-U?
MP;8?&RU^*WAGQ#X0\76_BKX<7WP]M?&7A>P\)^*-=\0:+IN@^'M8U*RX#]L/
MX:_%'Q]\8?\ @G9XD^'O@#5_&.@_ []L[4OC'\5M5TW7? ^CQ>$O %W^R)^U
M3\"$U.2U\6>+?#FIZY<-XP^.GA2ZDTOPQ8ZW?_\ "/:;XDO/(-[:Z7INL_ &
MA_ G]LSX<_#3Q5%H_P"SIXOUV+Q)_P %?_V@OVA?'/@[P?\ $+]GC2/C7JO[
M)'QAN?BWJFE^+_@9X]\4?$_3O"7PX\?2>(O$_@6R\9RIX_\ AQ\5[/X6WGQ8
MT7X>>(_#WC35_#^NQJ*3C%-ZN<[R;2Y4Z^#IV?,K<KIU:LH/:'LYR?-%S]FF
MYJI-M2<.2FDDKW_<8V;E%)IW56G1A4N^:2J0246H<_ZIZ;^V'^S[K?@7P;\0
MO#OBWQ'XJT;Q_?\ C[2_"^B>#_A7\6_%WQ*NM2^%'B#4O"'Q5L-1^#WAKP+J
MOQ:\.WGPO\::3=^!_B1;^(_!.DR^ _'4FG^"O%::1XIU?2=(O?1KWXV_"[3O
M@I+^T5?>*X;;X,P?#5/C!-XWDTS6_LT/PWD\-IXO'BB725TQO$,=LGAMUU6:
MS?2%U2"$/'/8QW$;PK^&WA7]BOXOS_ 3PU\+_B/^S+^TMX!^*'PS_; _X*1_
M&+X-?M%_LG_M,_!#3/C%\%9?C1^U7\0OC%\)_%?@CQ'X_P#C%X-L_BC\(/C3
M\*_BK?>$_'O@KXW:/=W>O:]X-M[#XP? .WM+K0?&&C?IWXG\!_M&>)?^"<&M
M_"_XF67A_P ?_M8^)/V++_X>?$&S^'L^@>'O"GBO]H'7O@E+X8\6#P?<ZY)X
M/\-Z/X9U+XA7E_)I$]\/#6F6>D20R_8M,AC2QBQG.<<-5J1@Y5HTN>%-)VE-
MX55532OSMJO>C-.S3Y>64VY^SV@E*M"$GRTY5'"4FTG&*Q+I.HWK!1=&U6#3
M:?O<T8I1<^O^$7[<_P"RO\=/%>I^"_AK\4TU/7M-^$?AGX^0_P#"0>"_B'X
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MX3_;'_;MT/X]^%?V@?\ A*_AU?\ PX\-?![5;C]F[6?$&M+HZ>+T^,5E\:O
MEO\ !GQ6/!>A?\*J;PQ<?%"?X<R?\)Y9>$+GQ+XS\)6]1_94^.'AG]L/]ISP
MSXI_X)^_LW_MA? G]JSXY>#OC_X!_:K^+&K_  8U0_L[W$/P^^$OA#Q/X$^,
M_P ,?'N@R?%/QM#\.?$OP?B^(/P0@^$L/B2TURXU3POX4U[Q=\)?L5UXQ\)*
MG:7L8RTO&BI2VYK4,,ZL6WI3JJ?UB/M*GN3J0UBN9*>M;W76=.S2E5Y%9R4?
MWM54Y:-2G3</9/DIIU(QEHVE[GZEZK^U[^SIH?Q*\,?"?5_B/!I_BWQI\2+_
M .#7A:ZN?#7C)/ >M_&+3?#&I^,KSX1V7Q7_ .$=/PL;XI)X=T36[Z+X>/XR
M3QA<S:)K.FVNC3:II6H65O)HG[6_[/?B+XB>'OA=I/Q \[Q3XQ\0^/O!W@B\
MN?"GC;3? GC[QM\+&UH?$;P'\/OBIJ7ANS^%_CSQ_P""U\+^,9_$/@7PAXQU
MKQ=IUIX#^(5Y-HRVGP_\9S:'\&?LF^"?VW?@5\3/B%^RYXM_9J\#>)_@!!^U
MM^T?^TM\-/VU;WXJ^#M2TK_A6O[1?QZ^)'[26I^!]2^#D\[_ !>D_:+T'Q+\
M6O%'PSBU^/2/#OPN7P]))X_3QIJ-_HT?P^\<^-_!7]AK]H5/V<O^"?/[&7Q/
M\&W>BC_@G[^U7\-_B=?_ +3$?B7P)=^$_BQ\./V<KSXA:E\,M?\ ASHND^-M
M9^*=O\0/C)I.N>!?!GQ9\/\ Q$\%>"-+\-P:W\=&L/%7C+3](\#3_%!QM)4V
MWRRDJ3DM_=G4A&OK:*A+#1<GR2N\1R-T[QUE$FTZB2TC[11=KV<*<YTKI-\\
M<1*,8J4&E1<TJEI:1^^?^'F/[$2^(=#\.S_&^&RDU_XN_$3X V_B34OA]\5M
M+^'6D_'#X6SZY:>+?A)XP^*NH^!K7X9^ _B(]YX9\06/A+PCXW\6^'M<^(U]
MHVHV7P[LO%-U:RPKZE\.?VQ/V>/BI\./&'Q4\)>-M6A\+_#[XAGX1>.=-\9_
M#GXG_#+XB^$OBO)=^%[+2_ACX@^#_P 2O!GA+XMZ5\0O%%QXY\"KX'\&7?@B
M+Q'X]C\=>")_!>FZ]!XP\-RZG^2,/[*/[5D7P=B\,-\ ?$LFOK_P74O_ -M@
MZ8/'WP1+1_LWS_MD7GQZB\:B[?XI?8/[0/@BX6 ^#TNQXI'B#S-/.EBSQJ;:
MG[0/['O[5GCZU_;W\7> O@MX;\0^*+K_ (*1_LR_ML_ OX6?&/Q;\-[?X:?M
M8?#CX(?LP?LJ_!#Q[\(O$.J:9JOQ#_X5[J'C63X-_$L^"-3^(O@ZVTW2-?N?
MA7X@UJWTZ!_$,GA-:+DUT<4YOE?N?N\MG*7*M79XK&0Y$G)_5)6O4C.#IZ;:
MOFFE'_#/'0@G)VC[ZP^&ESMJ*^L1NU"491_9KX0?'3X7_';3/%>I_#+Q#=ZL
MW@/QKJOPY\=Z'KOA?Q;X$\9>!O'.C6.EZO=>&/&G@/Q_H7ACQMX4U6X\/Z]X
M=\5Z-#K_ (?TX>(?!GB;POXST!]2\*^)="UC4/6Z^+_V*_!NI:-X.\7^-=;_
M &*_A5^PGKGQ'\0V&J:K\(/ \OPHUOQ[JMQH.AV>@)XQ^,GC#X)6R?#;5O$U
MY!:1:%X9T7P_KGCW^P_ V@:!J.H^.O[4\2WGP\^'/VA3M:R=K\L>:S37-;WK
M--^[>S5VVD[-W6B3O=].:7+HT^6_NW32]ZVDK))M72L]2BBBD,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***_$?
M]H7P+XC^.G[=_P"V'\#==_;"_:0_9V^&OAW_ ()U_LK?'3PY=?"7XXZM\*K+
MX:?$C5?C)^W+X4UKXP6=YIDUC/;:7X=TGX;^!+WQ?X<NK]/A[XVATJRM?BGH
M?BG2XK&UMU)M1G+[-.G5K3=U=4Z-.56;2;5WRQE9<T5=+FE&+<HBM>,;^].I
M2IP5F[SJU8TH+1-I<\XWM&3LWRQE*T9?MQ7C%]\?/AWI_P"T+X7_ &7[F?Q#
M'\6/&'P<\?\ QVT2U;PGXBB\+77P]^&GC/X9^ ?%5S%XXGTZ+PI>:[8^(_BU
MX,AE\,:;JM]KME8Z@FIZM8Z;8WFDSZG^"OP@_:9^/OC72]1\3_'SXH^.? /C
M#XC?\&]O[/\ ^U)XW\-2>.=>^&^F^'/VA=4NOBA:>/OBAX3\.66I>'[;X5>*
MS=/X,M_$EOX1MO#O_"/7ESH6DZE$EZ\+W/4> _!^J?M;?%S_ ()/67CSXS?&
MO0=2^*/_  0Z^/\ XM\>?$CX0_%'5_AQ\5?%NK:_XX_X)5:MJ.IK\6?"QA\=
M>'[O4O$]_#XLO=:\$>(?#>M:OJ6FQ:7JNJZAX/U;Q3X9\0S5<J;25FU65*2=
MU>\LQA:-[.+Y\ _BC=*I:45*%3E=/EG!R;:7L^>.SL^7 5+M)OFCR8Y+W9--
MQYHR<90YOV]^(G[0/PV^%_Q3^ 'P;\777B"W\<?M,>+?&O@OX4PV'A'Q+J?A
M^_UWX?\ PM\:?&+Q+;:]XPL],E\*^%YHO!'@+Q#>Z78:YK%GJWB">VDBT+3M
M1@L=8N=,Z[P-\0K/QY=^/[.T\,>/O#;?#WQ]J/P^O+CQSX*UWP=9^*;S3=#\
M/:[)XH\ 7.MVMM'XU\ 74?B*+3-.\:Z&;G0M0US2?$.DVMU)=:+>JGX&? WQ
MM\6?B!I7_!!K7_C5XWU3XI>,;7]N+]N[PAH_Q;US3[33M6^,OPI^'G[)W_!2
M[P!\"/C1?"P@MK#5+CXP? [PQ\//B4?$NGPI8>+D\4+XJL@;76(B<Z[_ &M_
M&_PAE^-]K\5_CA\0-+^!>N_\%Z[[]EOXH_%GQ%XSUI+KX%_L]>)?V5O!WCOP
M9X3T;QY]KMHO@S\.->_:%3X<?"O4_$EE<Z#;^$_#?Q7\37VF:WX=\7:K;>,+
M$IM5)*,6GSN7(Y1=+W95<OC3<XS]Z$W'&QYH3UYGRI.?LU4JI'DIJ;3TBG-1
M_>-22Q[FH<B2G'_8I6DFE9<[:ASN'[I?&_\ :'^&?[/4'PPG^)5WX@LU^,'Q
MG^&OP#\#'0O"/B7Q-!<_$?XL>(;?PUX0L==U#0],O-+\(Z/<7]P3<^(O%=]H
MVC(8UL+:\NM;O=+TJ_\ <*_!7]I2S\(:+\%OV>M%\#_M)>-/VE_".F?\%J_V
M.5T7Q/XZ\8V/Q'N_AXFN?M'> O$D_P $=$^*202:W\1?#?PVU+7;G2='UCQE
MXE\<>--":YF^'VN^++JX\&II.D=C!=?%OP'^U9\<?^"?^L?$+X[Z];?M*?%O
MX7_M:_L\_%74_B=\6-5UGP/^RUI]WHEW^UK\'].\>66H6&K^"]+^%GC[X81?
M#_0&T#Q+976EZ7^W#\ M-N?[572O$=])4?>M%Z.524(W32=J&#K.%K/WHPK8
MBIS)N$X8>7+O&3F?NQ4MUR<TK-:?O\51C*[:]V4J5&'*US1G7CS;22_;FBOB
MG_@H+\0[;X;?LPZYJ=Q\0_B!\,KGQ1\4/V=OAAI>O?"PZ%9^/-9U7XL?M"_"
M_P"'5G\.=!\2^)=5T/1_AX/BP?$K_#'5?BQ)KVAZA\(M$\6ZE\3= UC3O$/A
M32KJ/\?M7\6?M-WG[-G_  4:\;^ OBG\4?$7CS_@F_\ \%)+'XF>!_A?X!_:
M/^*/Q _X3OX'?"']G_\ 8[_:#_:1_9&U+XD:V+3X@_%O2/$MM\0_CQX<\,Z7
MXXL9-4\,?$74_#7A#2;7P_X9\.Z;X5LY<X*_-)1C&W.VG:G']S*<YNUE&G3K
M>UDDW)4X5)-)*/,U"37NKF;7NQ37-.4G5C3A!7NY5*E)TXMVCSS@DVV^7^E>
MN$^(/CZT^'6EZ%JEYX9\>>*DU_QWX!\ PV7P^\&ZWXWU33;OX@^+M(\'VOB;
M7=/T*VN9]&\">%I]837_ !]XQOUBT7P;X1T_5_$FLW$&GZ=.X_)#XC_'6S\3
M?LW6_P"T;8?&CXQ^%O#'[=7[9?[*_A+]EC2_"?B?Q-H=SXV^$WB3XA_#7P'\
M,O _AS6]>U?1XO@?X _:T\/>&O&?Q@\6?%/P=8^%?BIX7^%7QA6+PWI?C'XL
M>%_!/A'6ODW0?CK\<G_9MOXC\<OB FH?"7_@X)^ W[.&C7V@_&#Q3XWOI?@C
MXD_;B^!'A;Q%\$_$OQ4UT6_CWXJ^ X-*^(WC/P3,WCFX;4M6T&VM/#NL6\>C
MZ5;Z#:.[3::Y7&5)-.UU*=7#4YP=G>,H?6J7-?767+>48J8ES6LT^;VBB]5?
MEI8FI&2TU4OJM6UOY8W]V3</WM\"_M#?#3XC?&;XX? 7PM=^()OB)^SO:?#&
M[^)UGJOA'Q+X?TFQ7XNZ7XCUOP6/#^MZ[IFG:?XQM[K2_#&H7%YJWA675M"L
MYV32GU5M9M=6T[3>"_;"\3_LT^#/AEX8\1_M4^"M.\<?#U?C1\$/#7AFQU?X
M;WOQ,T[2?C#X_P#BEX5\ _!C7SI\.D:O8>%M2T_XF^)?#"Z!X_U<Z1;>$M?N
M--OK+7=.UA]-,WY,?'CXF:7\)OVAO^"ROBO5/BAX^^$,,_@3_@E%X%A\:_"J
MW\+S?$>'5/BQXN^(GPKT'POX2U#QEJ_A_P ,>#=7^(^M^,++X=VWQ)UOQ'X6
MLOA>OBB;XC?\)5X9D\*+KVG>)?'+QI\0/$7[-O\ P4;^$7B?Q_J;6WP9_P""
MOO\ P2I\!_#M;7XOZ_\ M"7OPKL_$_Q=_P""2WQ*\9^'_#/Q/^-NBZGXA\76
M_A;XO?$7QQK<%A\0/#=[I/A;7=5O?!J^&K7PEI.F^&+36A3=9T4T[3]DY.RL
MY>W2FH-Z1DH^S<?B=.;4W9>S;RQ%2-#VBNG9323>L4\-[2+G%:N+E[1-*RG&
M+CJW-+^B+X]_&[X?_LS_  2^*/Q^^*=QKME\-/@SX$\1_$3QU?>'/#'B+QIK
M&G>$_"6EW&KZYJ4'A_PQI^JZU>PZ=IUK/>W]REK]CTRP@N=5UB[L-)L[Z_MO
M5K.ZCO;2UO(0XAN[>"YB$@"N([B))4#J"P5PK@,H)PP(!(Y/\W7[4>@?$7X0
M?!#_ (. OV>;3XR_&?XX_L\:!_P2R\1_&KPK>?'#X@:M\6?$'P9^./QA^"'[
M9&C_ !7^#>@?$CQ2=1\97WAZ^\&?#/X1?%ZV^'FN^(K^V^%]O\1]/?PSI7A_
MP?XZ\.V3^N_M4_&#7_'O[47QL_9%\1_ML^$_V$;7P_\ L)_!#XS?L\>/?$VN
M>,?"M[+XB\0^(_VA=*^*WQO\-:IX4_:,_9_\,>.H_@]J_@?X,2^*OAI\7H/B
M-X%31M/B_M'P_'X/^(GC^SUK..JO_-[-QLEHG2Q52LG>23E%X:;@DTYP7-%)
M2E[(YG[24$K*"DFW=<S=7#TZ=DD[1?MXJ3L^63Y7=J'M?WPHKSOX7:^=9\$^
M$H-2\::;XY\6VG@KP5=^+-<L_#TW@>[U74]8\.V=Z?$=[\.=0OK_ %OX?)XH
ME%SK-CX3UJXFOM$@G.E2W-U+82SMZ)527+*4;WY92C=)I/EE*-TI)22?+=*2
M4EM)*2DDXOFC&5K<T8RLVFUS1C*S<7*+:YK-QE*+WBW%Q<BBBBD4%%%% !11
M10 4444 %%%% !1110 4444 %%%% 'F7CWX*?!OXJZW\/?$OQ/\ A-\-/B/X
MC^$?BF'QS\*=?\>>!/"_B_6OAGXUMS ;?Q?\/]4\0:7J%]X-\3P-:VKPZ]X=
MGT[58GMK9X[I7MX63TVBBA::+17;LM%=VN].KLKO=V5V[*Q_DE\E>R]%=V6R
MN[)7=RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH /\_Y_.BBB@ HHHH ****+( HHHH **** "BBB@ K
MS'X1?!+X,_L_^#H?AW\!OA'\,?@E\/[?4-0U>W\"_"+P%X5^&W@Z#5M6E6?5
M-3A\,>#=)T71(M1U.95FU"]2Q6YO9562YEE=01Z=11MMI?1^:3ND^Z3UL[J^
MN^H?H[KR=K7];-J^]FU>S:91110 4444 %%%%%E^OS **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *^#-=_8;\'^//VT_B'^U/\6-&^#OQ4\*^,OV</@S^S[H?PT\=_![2?%>L
M>#9/@[\1OCA\1XO&VF>-?$NJZQIY;Q?=_'35M&UOPU9^"]*\FW\(^%]2_P"$
MCOYA/8Q?>=%--Q=T[.TE\I*S]'97333B_>BT]12BI*SVNGNU?EDI).VZ;7O1
M=XR6DDUH>3?$'X!_ KXM>)/!?C'XJ_!;X2_$SQ=\-X?$]O\ #SQ5\0?ASX/\
M9^)/ 5OXWTR+1?&<'@O7/$>C:EJ?A:'Q=HT$&D^)XM#NK%-?TR&*PU5;NUC2
M(9VO_LV?LZ^*M!\!^%?%'P"^"OB3PO\ "R.6+X8^&]?^%G@;6-!^',4^F'19
MXO >CZCH5QI_A".;1V;294\/V^G+)IC&P<-:DQ5[512LNRWOLM[WOMO=MWWN
MV[WU'=[W>BLO);6796TMM;2UM#S_ ,0?";X5^+-:\"^)/%7PT^'_ (E\1?"Z
M]DU+X9Z]X@\&^'-9UKX=ZC+;1V<M_P"!=4U'3;F^\(WLEI%%:R76@3Z?.]M%
M' TAB15',S_LX_L\W7ACXF^";GX#_!FX\&?&K4-0U;XR>$9_A?X(E\,?%K5-
M72./5=2^)N@2:&VE>/-0U..**/4+SQ5::K<7J1QK<R2JB@>S44-7O?6][WUO
MS-.5[WOS.,7*]^9Q3ES-)H6EK:6M:VEN5-1M:UN5-J-K<J;4;)M/Q8?LV_LZ
MCP'X"^%@^ ?P5'PQ^%6H:1JWPO\ AR/A9X&'@/X;ZIX?DEFT'4O 7A :$/#_
M (/U#1)9YY=(O/#VGZ=<:;)-*]G)"TCEN1^%OP9^).D_%#Q=\7OCE\4/"'Q6
M\7"#Q7X(^#<7@OX477PIT7X3_!GQ/XOM_&&H>%[N#5/B1\4=7\:?$'Q+=:+X
M#TSXA?$!=;\+>&?$NE?"GX:_V#\+?!>L6'C#6?''TO11U<KN[3OJWK)).6K^
M)Q2@Y.\N3W+\MN565DK*RM:R2V;:6B^%-N7+HN;WM[WXSXA_#CX>?%WP7X@^
M&_Q8\!^#/B?\._%MDNG>*O 7Q#\+Z'XU\%^)M/2XANUL/$'A;Q)8ZGH>LV2W
M=M;W2VNHV-S +BWAF$8DBC9<;P)\%O@Y\+;WQ)J7PQ^$WPS^'.H^,K/P=I_B
M^_\  G@3PMX0O?%5A\._"EAX#^']CXDNO#^E:?/KEGX&\#Z5I?@SP=;:G)=0
M^&?"FFV'AW14LM(L[>SC],HHLK-65I*TE96DK6M);25M+235M+6T'V_NN\?[
MKWO'L[I.ZL[I.]TFO+/&GP,^"7Q(^%<GP+^(GP=^%GCWX)2Z5X?T&7X.^-/A
M]X2\4_"N30_"=SIMYX6T:3X>ZYI%]X2?2O#5WHNCW7A_3FT@V>C7.DZ;/IT-
MM+86K1<W-^RU^S'<6VK65Q^SG\")[/7_ !MX?^)>NVDWPA^'\MMK7Q'\)Z-I
MWAWPK\0-6@?P\T6H^-O#/A_1](T+P_XJO$FUW1M&TO3M,TZ_MK*QMH(O=Z*.
MKE]IOF<OM.6CYG+XF[I.[DW=)WNDT=+=$K)=$M=$MDM7HDEJ]-7?QCQ#^S?^
MSQXNE^)T_BOX"_!?Q//\;-$L_#/QFF\0_"[P/K4OQ<\-Z?"+:P\/_$Z34M"N
M7\>Z)8VZK!9Z5XJ.K6%M"HBAMT0!:S]/_9:_9CTG1?''AO2OV<_@1IGAWXF^
M%?!?@7XDZ#I_PA^'UEHOQ"\$_#?PW%X-^'?@[QQI=MX>BL?%GA7P%X0MX/"O
M@OP]KT%_I'A;PW#%H>AV=CI<:6J^[T465K65FK-65FM=&K6:U>EK:O35W//J
MG=/JG=.Z[.Z3NM;I.]TFO*5^!'P/3X=:M\'U^#7PI7X2:_')#KOPM7X=^$%^
M'6M13&V,L6K>"!HX\,ZC'*;*S,B7FF3*YM+8L"8(MF-XV_9E_9N^)=O\,K7X
MC_L^_!#X@6OP4U.RUKX-6WC;X4> _%=O\)-8TU;!=.U;X90Z[H%_'X"U.P72
MM+6RO_"JZ5=6JZ;8""6,6=N(_;Z*=W>]W>\7>[O>/PN][WC]EWO'[+B*RM:R
MM9JUE:TOB5K6M+[2M:7VE(XO1/AM\.O#7C'QQ\1/#G@'P5X?^('Q.7PPGQ)\
M=:)X6T/2O&/Q"3P3IMSHW@Q?''B>PL(-;\6+X1TB\N]*\,+KU]?C0--NKFQT
MH6EK/+$W:444OT5EY+71=EJ]%IJ]-7=]WU>K?5O17;ZZ)+6^B2V22**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?\ "+3?CIJ]E\*;1/AP;GXIBZ^&FL:5JWABZ^'D7B6S\;ZYJ%IX%\%W.O\
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M]*T5\:_!?_@H'^R'^T+XL^'/@SX/_%Z+Q?JWQA^&>L_%WX2W_P#P@_Q)\/\
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M)_BOQ/>^*O@QH/[07P[TKPU\!_VAO$.M?&/X3^(+70+I/$'P%T/1_A1>ZO\
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MC)NHI1<9I1B5.$IN<DVW-3<;M1=ECDXV5FHRCF%>+M)2M[-IJ46Y?B=^T?\
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MIW=W%/!T59N[3G>3;37\Y-[^Q;^U-9?LI_L9:'\,/@S\:O@A^WE^S#_P3M^
MWP8\ ?M#_#KXU? A?A?+\4_"'@[_ (0_QE^S/^U[\.-:^)VH^'OC+^S(OB[P
MWX4\?3:CI7P[^+^LZ;H'B#Q=K7PJG\%_$JR?1?&/]&BAPJ[RK/M7<54JI;'S
M%5+.54G)52S%1P68\EU>+?M'_'/PO^S%\ ?C/^T;XXT;Q3X@\$? KX8^-OBW
MXTTKP39:5J7BN?P?\/?#U_XJ\43:'I^MZUX=TJ]OK'0M+O[Z.UO-;TY;@6S0
MQ3FX>&*36<VW4G*WOU:E:5KVC*K.4YJ*U<8N=24G%-WE:33G><HA34>2,;OE
MIPHQN]U!1C#F=TG)1@HINW+'W4^2T8_,_P#P4Z^$_P 5?C?^R1JWPX^#'@34
M?B)X[O/CE^R/XS@\/:;KW@OPW,/#GP@_:Q^"OQF\;7[:IX\\4>$="5[3P;\/
MM=^P6?\ :OVS4=7ETZP@@$=Q/=6OQ!^U/^RY^TY\38?^"XUAX-^!OB+41^V;
M^Q3\+?@;^SK>MXW^#5A;^._'VE?!CXY?#S7;6[74/B;9W7A+2]'UOXGZ#+>:
MGXO@T6.[TJQUNXTB/4[FWT^QU/\ 5:+]I?P9)^T-\-?V;&\-^.8/&7Q4_9W^
M(G[2OACQ%-IFACP.G@WX7^-O@UX$\5^'=0U6/Q%)J\?C>#5?CKX%O;;3K'0+
M_0Y=*DU*>;Q%;W5O9V5_]%5+UC4I-Z.=>$UIS1E*%+#58WULX_5HK6]I\WQ)
MJUPFXN%2-M849Q=KJ4.>6)I25[:2]K>ZM>'*K)W/YZ?^"A'P _;?_:)U+]K/
MPSX7_9>\1>)_"'CCX(_L=>(?V=M2\'_%7X#?#BQG\4_"GXLS>/\ XX?"W]H:
M&]^*WA_Q-\0/C9 C10_!2+Q _CO]EK0M-MXI=!\?_"CQGK/CKQ/XQ[GX[?L;
M_M0_&+Q3_P %;/!'A;P);>#+3]L_X;_LW?$;X!?&#QEXA^'^K_"F+XE_!3X5
M^$_"\GP.^+WA/1_%.L?$R'^W/''@K3[+QA>:;\//$7PXU#X4Z_KMS9>+M7\2
M6L/@G5OW=HHULU??FUTNG)64E>^L'&G*+::<J4.>,HN<90HI>S5KJFH**>S4
M+73LU=33G&236E6?*XM0E'^>?XK?L_\ [0_QX_8S^/3>&_\ @E#\*OV0?V@/
M&]O^SQX5E\!^!/'O[*VM?%3XHGX=?';P7\5?$\LWQ5\#ZOX*\ 6?P6\&:?I6
MO-\/K7QCXQE\=^,O$?B+7+K4?AK\*HM%M;CXB?H/^T3\+/BYX[_;6_X)O?%K
MPK\-=:U3X>_!;6?VEM6^+GB)O$/P]L1X!B^*/P)N_ GA.VOM)U#QG:ZYX@N9
MO$=XMM?CP1IOBBWLK>&:[:XDA\EI?T1J"YF>WMKB>.VGO)(8)98[2V-NMS=/
M&C.EM;M=SVMJ)YV BB-S<V]N)'4S3PQ[I%&[>]LHS573F=G"AB*-HKWFH\N(
MJS4(IVGRJ":7+,4=U=WE3E1;=KN,ZM&K=O1.2E0IQYY:N-^?76'X)?L;_!#]
ML_P]^T3^Q)\8?CO^R]XM\&ZU\/OV4_VT?@%^T%K&F?%WX"WOPS\.?$_Q]X__
M &/?'G@?4_@I\(? WQ+'AWP!^S)XBT7X'^+?"GP=TWP3X3M/BI'J$.E+^T?X
M*T351?\ QE\8?>G_  2^^$_Q4^!O[%7PQ^%?QH\!W_PW^(?ACQ/\:[O5_#&H
MZ_X+\32PV/C#XY?$;QYX=O(]7\!>)?%GAZ>.]\.^*-+FEABU9KJSO/M5I<P(
MT*R2_6OA'XGZ7XA\+?"G7/$VA^(/A3XD^+FC:7?Z)\+?B7_PC^G?$C1=<O?!
M]SXWU7P/XATSPUX@\5:#_P )AX3T73]6'BBT\/>)/$.DV-SI&H"TUK4+:.&Z
MGN_#_P ;:GXXM/%%UJ?PY\>_#9_#OCWQIX*LK/X@0^$H+OQ=IGA+6[C1['XC
M>%T\(^+O%\+^ O',, USP9-K\^@>+)]$N+>;Q%X2\-W[MIZ-+E4DDDN7D>R6
ME:%1\MI-756R:3GRJ5GI:2>CZMWJ*H[ZOF=&=.-[I-)TG)ZJ*DXJ6[<9=ZQ(
M5B%+D D*I4,Q SM4L57)Z#<RKGJP&2/P=O/V;OVH5_X)U2?!:']GGQE<_%F7
M_@J1<_M-#P.GCKX#QW:_!U/^"R;?M^Q^))-?F^+R>#Q=7/P3VZ3'H,?B*37D
M^(;?V'/IL6B#_A)J_>.BHY%[2-7[4>1)=/<Q%'$*Z6]YT(1>J]QR2M)J2)I5
M*4J,O@GSWMH_?H5<.[/I:%:36GQ*+=TFG\C_ +<>C?'KQA^QE^T)H?[-?@OP
MAXK^/?B+X2^(+'X>> _B7;^"-0T+6->U&R2.Z\/W=MXWBUWX5W?B233)-2M?
M"B?$&'6/A5)XT70_^$]BU'P,=:6;Y;_81^#7QG^'G[5/[;7Q/\=_!/XH?##X
M=_M">&_V3O%/PZU/XL?%[X?_ !:\>MJO@+X8:YX,\>^"_B/J'AGXL?%'5++X
M@>'-;,<]VNDZWXK^%[:!?:)%X'^(&K"+4- \._J)XA\0Z'X2T#6_%7B?5K#0
M?#?AK2-3\0>(-=U6YBLM+T70]&LI]2U;5M2O)V2"TL-.L+:XO+RZF=8H+>&2
M61E1&(\^^ _QN^'?[2?P5^%/[0'PDUH^(/AE\9_A_P"%/B7X&U>2$VEU=>&_
M&.BVFN:8FI6$C-/I6LVEO=BRUO1KO9?:+JUM>Z5?Q0WEG/$CCI*33N[>\M/=
M52#HKI=*7)>-W9S@[-^]%-ZQBGHG)-/;F=.:JV[-QY_>LKJ$U>RY6_AK2/V?
M/BUXE_;2_P""CFO:]X3\4> OA+^TO^R;^R_\%/AQ\9[+7_ %\7\3_#6T_:FL
M?'-UIOAS2O&]QX[TFYT:/X[^%[_PW=Z[X;T:TU.]T;Q INK%;729]:^*OV</
MV<OVM-!_9E\6_#?Q%_P3$_8R^$'[6/[/_P"QU\6/@9\.?VE]2NO@%\2/ G[3
M?Q1?X63?#WP9)\/](\,>'M)^(G@[X-_&O7/#_A[QC\<M-^.5MX"NM-T=-,^'
M(\#?$*'6-3\:_#W^A.BER6BXIM*5%46^MHO$N,KJWO16,KQLFH3A-*I&5DQM
MW:>W+5]LK7MS6P_,K.ZM)X6C*]N:$HWIRC>R_GQ\+_LS?&CQ+XO_ &GM:^-O
M[!WQS^(_PI_:1_87_87^%?B;X?\ Q"_:9^ &H_%;6O'WP7_:*_:=OOC?HMQX
ME\%?'?1/"OPO^)^@^'/CCH7QG^!Z?!'Q%X,^".EVWA738?!GCKX$^/18_#WP
MMU'A[]E7]N+P5!^SE\2=0U#XM?M#6G[&W[??BCXF?"7X7_'/XF_""Y_:;\>_
MLB_$O]C?7/V8==@^(7Q*T76;7X3_ ! ^._PF^('Q=^*OC/X:ZYX_^)<>L^-?
M@?H^CZ-X_P#B):?$KQ!>:;9_M/X\\;ZGX+F\"Q:9\./'WQ$'C+Q_HG@G49O
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MO-M<S<6XU(U%;FNFD_AYG%)O5Z<_LTW'F4$X^ZDG9?EO^TU\!_VB?B?\0_\
M@IOK_A/X$^+;W2?VE?\ @DW\)OV8_A(;[QC\%;%/$7QM\.WW[=.I:YX-U"&?
MXIM+H46FI^U#X$LY/$>L06WA:YNM'\;'3]9O;2PT&Y\2P_'#]B/XY?$G3O\
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MLZ'I_@_P+X>\2>%[+7=3U?\ X1/]&_V<?VC_  9^TYX1\;>,?!.A^,?#MEX
M^-GQJ^ ?B'3?'%AHNG:NGCKX"?$;7_A9X[>UAT+7_$=E/HA\5^&M5CT2_:_B
MN-1T^.&^>QM4GC0GPO\ VCO!GQ8^,7[2'P1T+0O&6E>+?V7O$WP]\+>/KWQ#
MIND6GA_6;WXF?#O2?B?X;N_!=]I^O:I>:OIJ^%];TTZC<ZEINB/:ZG-+IJ07
M$]G>_9Y:NU=>\XTZVUN:5*,IPKM1<5?EQBE*"4824X\U/2455K)ZOE4JE)IZ
M\L:LXPE2NU*5G/#<L92;G%Q:4_A;_(+]D+]DO]J;X7^$_P#@AUX<\=_ S7=$
MOOV.?AC\=/!_[1EZWCKX-ZI9_#W5?%7P2N_AUX:,3Z/\2]0O/%^GZUKQAN(9
M?!=KK\MGI30W.KVVFW:R64$WP@_9-_:>^'_PQ_:.\"_"[X3_ !C^$_[.7Q/_
M &&_B;X<\)_L3?&?XM?!'XJ/\$/VJ/&VCV>@Z+\/OV0_B=H7Q2\7GPI^SFVC
M1^)K?Q=X#^(_C7PSX!\*ZN/AGJ/P<T'0-%O/&_ACPI^_%>"^$/VA?"?C+]HK
MXV_LS6/A_P 9Z;XX^!/PZ^!GQ1\2:WK&FZ1;>#?$7A?]H'5?C+HG@U_!NHVV
MO7NM:C>:7JOP*\<67B>/5O#^AVMG+_9(TJ[UI;B];3XFHRC.E)M*O#$4FE)K
MFC7H1IU$D[IN%.G&<&XMPG%5$[IQE5*]*<*T-71J8:JFUS*,Z%>52D^C2E.;
MA-*24X-PDK/F7X__  ;^ 7[:G[./B;2M8C_9N\0_&3PS^T!_P2Y_8^_9+\7:
M1HOQ;^">B^(_V7_CW^R=H7QHTI=-\<VWC#X@Z-X>UWX$_$!OV@?$&L7'C;X+
MZY\6O&^@>)?#.JK_ ,*HU?3]?L=1/F/AG]D/]K#X&>$?^";GCO5/V%? W[:-
MG\.?^";/P=_8;_:6_9@\4^.OV>;'QM\&/B7\*M&\*W^B?&7X8^)_BOK%W\'_
M !OX5U34[;QSX'^).B:5XTT#Q'?Z-/\ #CQ1HZ>(WT/4_#-M_2115R]ZI*J[
M<TYSG+JFIU,;4E"TN:\7_:&)@FVYQ@Z:4KTHMQ&/)3A33?+"G"FNC_=T\)3A
M*\5&TE]2P\G;W9351M6J24?RH^ G[/GQ5^&7[>.C^.!^SSX+^%7P,L/^"=7P
MH^ 6GM\%]1^'>G?!/X>_$;P?\9_B'\0;_P"%G@+PA!JGA;Q^_@_P[X>\9Z;H
MOA_Q7'\(/"&BZ[/I-Y?-X<\'Q75KHUOZS_P46^%?Q4^+OPM^!6A?"3P!JOQ#
MUKP?^W%^PY\:O$NFZ7KW@?P_)IGP[^ O[4/PR^,?Q!UEKGQWXK\)6%Y<6WA/
MP5JD.E:3IUY=ZIJFM7&G6<=I':RW5]9_?U%$O>44]H34UJVVUB/K"3;<F_>M
M%N_,X)7?,W)U#]VY.-DY)IZ*RO0]@VHI)+W?>M\*ELN70_._]G#X6_%[X9?M
MR_\ !1'Q1XG^&FJQ?"K]I#QS\!?B]\,OB[:^)? -UX6OH_!'[,7PA^!/B;P!
MJ7AN+Q8WQ0TKQSI_BCX<ZEKL<MYX!C\!WWA*_L;JT\<R^(%N/#<? ?M%?!7X
MX>)?VZ+3XP>#_A1K_BGX;Z;_ ,$SOVNOV?SXGTSQ1\,=.%U\8/BS\4/@)XV\
M#^$;/1_$WC[0/$ ?4M*^%'B"WN/$%WI5IX7TW4=0T*&^UR"UN-2O-*_4^BLZ
MD%4A[.;;7LJE%VLFXU:.*H2?6TE#%U+-?:C"33]Y2=.7LY2E&UYSC4:>J4HU
M<-6TV=G/"P;U=E*:32<7'\1OV7OV<?VDOACXH_X(YW7C'X(>);"R_9)_X)>_
M%_\ 9E^/-[:^-/@YJ$'A/XP>)_#?[#NG:#X>LX[7XFO>^)]/U&\_9D\<JFO>
M&[/5-'MAK/@V2_N[1;[7#X<^7_V5/ GQS_9<^,?_  2*^&GQ&_9^\:WWQ2\$
M_L<?\%=--\6_#OP[XP^"&H:_HVGZ[^T[^PCXJTOQ)9ZY>_%;3_A_JEE=6FK:
M#9R6=CXV_MNW;6W:;31%I^HB+^CSQ%XH\.^$;"WU7Q1K>F:!IMWKOA?PQ;7V
MK7<-E:S^(O&_B;2/!?A#1(IIV1'U/Q+XMU_1/#FBV:DS:AK&JV-A;))<7,:-
MS&K_  D^&.O_ !%\*_%W6O OAG5/BEX%TC6_#_@KXA7VE6UQXO\ ".@>)VLW
M\4:%X:U^1&U'0]&\4OINE/XHTO3;BVL?$;:1H[:U;WQTG3C:]3Q%252525GS
M>VYK+EM[:MB<0^75IVK8F6C>E-):R2<L727L_9IZ*5*:N]W3I4*"NU9K]U1O
MI_R\U?NMI?C9\+?V)?VA/V>?$'[#'QS\.>!(_%LGPI^+?_!2CQ-\9?V;/ OB
M7P3::EX&\#_\%*/C?J?Q\\/6OPVU;QIXK\#_  SUS6/V8M?L?!7@#Q7;?\)-
MHEEXD\(:M\4O%/P\GU?5(] \$^+,V;]BCX_^"]5^"WCCPY\+M9\2W?C7_@M/
MX[_X*%_%'P-HOC#X8VB? WX1^,O@Y\4O@]9VMS=^(_'>@:3XB\4WBZSX/^)/
MQ T'X?77BFWMO&WBKXDV7A[4O%UMI6DZ_P"*_P!</VB/VA/"G[-7@WPKXZ\:
M>'O&?B#0_%?QF^!7P/A'@G3=(U*ZT;Q+^T+\7_!GP0\"ZWKJZUKWAZVM/"EK
MXZ\?>&K?Q#?6MU?:I9V-X]QIVC:M/']D?UWQ+XE\/^#?#FO^+_%>L:?X>\+^
M%M'U/Q#XCU[5KJ*RTO1=#T6SFU'5M5U&\F98K6QT^QMY[NZN)65(H(GD8A1F
ML:<W3Y.1JU&5.G35E:$8/"5HT=%#F3>&P\KR4IV;49KGY(U-1E[2,GK4A*=3
M765UBJ;JMMRY6OK%=.TE%M*4HOE<I_E#^TW\(_VK5_:0_;A\<_ KX(Z'\11^
MT+_P2Z^'OP.^$'B_QQJGPGU#X0:9^T#\%O%O[<GB>T^'OQE\!^-/%UEXJUKP
M[\0/^&B_AY::3)8>!/%?@#4[:U\7:;\0M7\+V%O:_P!L?!7QD_9"_;(^)/@[
M_@H8?#G[*WQMMM2_:R_8A_8*\"^ 8/BO^T'^SGXS^(4_Q;^ ?QZ_:4UGXN^%
M?B?J5A\;)? O@W77T;XL:%XR\,Z?\++S4?@3_P (4J67A?4/!?BDS?"#P_\
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M^T^%[J#5/$>GVGB"WOX?/T29;N.ZBWVLB4[2?V9OV5/CCX[_ .&EOB/^P_\
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M3M:G""LFH_PX4ZD6HM/V3<?:4TI>TA)V]HES2E_-%XV_:+@\ ^%_C3X3UO\
M:(\0>$O'OPZ_X.$OV</#VF^'M8^-_BC2/%7@S]GOQI^TI^R1)XA\)OIU[XMA
MU/1_V=]<^&7Q&UJ*?P??10_" ^$_%D=E!I,5E=Z; /MCX'_"OP7\1OVJ_P#@
MJ;XN\8?%7X\ZKJ?[/G[4=QX?^&6B6_[6_P"T+H?A+X6^%_B__P $TOV2M=\=
MFP\$^'_BOI/ARVLKSQ9XY^(6J^$IO$&F7^G_  M\2VC:O\(HO FO^'?MUO\
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M<^,?AM^U=_P67^*?[,5OJ^M_M4_#;_@DM^R_\0_@YHNBZ]KOB_7$^+/]L?\
M!3Y[*YT_X9W6H:YI'BW4].#>$=2\/> ;_P *ZKI-SJEWH=OIFA17?BPR:G[+
MHE]H,G[5'[*P_96^)'BWQ9^RK^TK_P $\_VA?B%^T%J5K\9O'VIZ9<^&O#L_
M[/W_  S/^TLOC5?%@U[PK\=_B!-\0/BCX=U#XM66O:1\1/C-HEAXAUWQ'K7B
M74O@)H^K>"/V)@\%^#K;7)/$]OX3\-6_B662>67Q#!H6EQ:[)+=0K;7,DFK1
MVJW[O<6Z);SNUP6F@18I"T:A:H:5\-_AYH5IXGL-$\!^#-'L?&VIZAK?C.RT
MOPMH>GVGBW6=6).JZOXGM[2PAAU_4]3))U"_U5+N[O23]HEDR:S5.U.4+MMT
MZD$[M1BZD<PC\*<7RI8V$W[ZE[3#4VK)QE3+^_S:6]HIM65]'@6K2U]Y/"3B
MFTX\N(DG>THU?YE? 'A>ST'_ ()Z_P#!%3XV6GQW_:/E^)7[8/QF_P""4&F?
M'[QEJG[87[1.JGXF7FL_!#5;'Q'X1&D:I\5[KPKH4.IW=[?P:]HG@S1-!O-7
M\2Z)HGBK6?MGQ"\'>'_$^CI\4M-7X0_"']O/QEX)^,OQQTF[_8G_ ."S/['7
M@?\ 9YN]2_:<^-FMZ3\,? WQEU[_ ()C:]\7_!6JVNO?$>_TOQOX/\6ZG^T1
M\=] UGPW\4H_%^D:;X<\;>(O!VEVNE:*ATZ'^FB7X?\ PXDMM/T.?P3X)>SL
MI+_4M*T>7PWH36UI-<3P/JFH:?I[V1BMY9KB>V:_NK:%'DGFA-R[221DI-\,
M?AK<+>)<?#SP-.FHW:ZAJ"S>$] E6^OT_M'9>WBOI["YNT_M?5MMS.'F7^U-
M1PX^VW/F[IVJ4YKX8595'#W;2BW@7&F].1*#PE=JT;)XJ;27[SVDI-4I0=I2
ME!1YY7NI*.-C*>C4FY?6:-[R=UAH)M_NW3_G3_:Y_:=\%Z-^U!XH\0>"?COJ
M?@GQI\)?^"MG_!/3X)_$%?B9\7)=$\9Z7X-\<:%^S?H7Q:^&?P@^&MG?^%+3
MP;^QMXA^'?Q.7Q9XP\1^/6\=67Q<^..O_%35V\,:!8_#OX._$.7A?V@[CP7\
M,OV9?^#FJX\%?$77?AC\:_"_Q8^*7Q/\-Q^#/C7XV\"?$?1[67_@GE^PGXTT
MCQUIUEH7C72O$%MIVN_$J^DMY-?A@2Q\2"_D\#W-S?Z!<CP^?Z:[CX<?#V[O
MM0U.Z\">#;G4M63PG'JNH3^%]#FOM3C\!ZH-;\#)J%W+8/<7J>#-95=7\*+<
MR2KX=U15O]'%G=@2U/>> O NHWNMZEJ'@OPG?ZAXFCT.'Q)?7GAS1[J\\01>
M&'NY/#<6MW4]D\^K1^'I+^^?0TOY+A-)>]NVL!;M<S%\'3DXP7.[QC5C?1)^
MT6#Z)WY>;"N3C?\ Y>R5Y-.=36,TIJ7)%KGISL]6_9RQ#6ZMS<M?E3L]*<;*
M*?)'\6_C?XK3XH_M$?\ !57X4?'CXD^*?A%8_!']D#X,_%?]DWQ)X=\?ZS\/
M]5\"_#:\^'OQ3UGQ_P#M6_"B_P!(U:PN%\?^$?CIIFI>!?&_C6P^UKHOACPE
M\/\ P3K\$'AGX@:II?C?Y \6S_&'XN7G[0"_M4?$7XW_  Z^+&E?\&^?[)G[
M4GQ)^'?A;XZ?%;X-:/\ #']KF4_M:K\2?B#HO@_P7XXT#3_ NM>%?%W@#PZM
M[IVCQV/A2/7/"^B:OXBTC5M>T31-4L/Z7-3^'/P]UJ7P?/K'@3P;JT_P\NX-
M0\ 3:GX7T._E\#7]M;Q6EM>^#Y+NQF;PS=V]K##;07.BFRFBMXHX8W6.-%$V
MH> / FK7U_JFJ^"O"6IZGJD*6^IZCJ'AS1[V^U*"-+.*."_N[FSEN+R%(]/L
M(TCN))$5+&S0*%MH0EN+<*L5)ISH5:4)*R<)SIXVG#$*VKK1^M4Y2DI1YGA:
M/+ROEE2F_O4WRQ]VM1JS6ZG"G4PDY4-594I?5JD8J4966(J*7,G)5/C?1=8U
M#XZ_\$Q]$\1>-[J3QIJWQ=_85T?Q%XJN[222(^+]5\<? .UU?6YXSH+VN^+Q
M!>ZE<.]MIC16]U#>-;11M;3>4WXU_L_:1\'_ (G>"?\ @W"\ V7C7^V-!\6_
MLK_$_3/%5IX,^+NNV6N7FMV7_!/SX<77BSPM;>)_"_BJ#QCX=.ERO9G6O#OA
M;7-"?3+#9HM[;0>'=0U'2=0_IZTO2M+T2PM]*T73;#2-,LU9+33M+L[>PL+5
M'D>5TM[.TCBMX%>6225EBC4-([N069B>/MOAA\+=)M=(M;/X>> =-LM!:2/0
M;>V\)>';.UT5[_5)M2DCTB*+3XH=.:]UJ_N+]TLUA:YU2]GNF#W=Q)(^DVI5
MZM7E2A4K*JJ>EHJ,\PDJ>EH\O+CE%6C&WL5IRRY8XPIN-&C2<W*5*E[)U&O>
MD^7 ?O-6VI2E@FY7;TK.SYHJ3_G)^ _QR\&ZE\"?^"=GP:^,/QL\8:A=^+?C
MK_P52^'_ ();XQ?&Y-/^!7B_X7?LJ_M _&[X(^%[C]H3Q?XG-_\ $+X]^+_@
MW\-+GP'J?P/^&L'Q"\+ZMXQ\6>';OXJ>(_'>EZO\+=/\9:%Q7[)_Q0\-?&"[
M_P"#;_XU_&_XN1^,?'.N_LA_M(^$_$_Q/\7?%>^&N>(?BIIGPN_9\G@T#Q-X
MFD\403:_\2M;U;3;J;Q9I6MW=_XK\::C8WK>+[?6KFSN##_3HOPT^'"6VE6:
M?#_P2EIH/B2T\8Z':IX5T);?1O%UA9-IMCXJTF$6 CT[Q)9Z<[Z?::Y9K#JE
MM9.UK#=) Q0V(OA_X#@LO#NFP>"O"4.G>$-:D\2>$K"+PWHT=EX7\12IJL<F
MO>';5;(0:)K4D>NZW&^JZ9':WSIK&J*UP5U"[$RIOEC#G7M*D949SJM^].5.
M#A.5FGRRJ*4Y2?-*\G[SLY1=U8^T4E&T(M348I:14I*<8NS2<(N,%9)6C?EL
M^5K\\/\ @I1^T%IO[/.I?L0ZW\5O%T7PZ_9&\;?M<0?#[]K7X@:E?W.B>#M%
M\&ZW\ _CG<?!_1_BMXJMO)7P9\(/%/[2MA\'-)\>Z_K.J:'X)U*#^SO 7Q,U
M.Z^&GCCQ?X<\0?+'PZ\9_"G4OVD_V._@1X.^.?C;X]_L _&[PO\ \%"?$GPM
M\9^*?B/'\1/AG\5?VC]-^)/P>\:?#KX"^#OB=X?M++3_ (@_!OX&?!SQ1^U%
MI_[._@+7/$7BK28].^$][=Z;<^)]<_9N\'^)?"G[GZ[H.A^*-&U/P[XET;2O
M$/A_6K.?3M8T+7-.L]7T?5M/ND,5U8:GIFH0W%E?V5S$S1SVMU!+!-&Q21&4
MD5BZ]\/O 7BKPHO@3Q/X)\(^(_!"0:9;)X.U[PUHNL>%4MM%EMIM&MU\/:C9
M7.D+!I,UG:2Z9$+/R["2UMI+58G@B*RH[WN_WG,[-+F@U_#FW"3M"7O4^7EN
M]*DN5).G=[67N<NJORR3NIQ7-'6:;C/F;LM8*^W\^WP^^,GQ,\!>!/\ @G)X
MJ^+_ ,:/%>E_#;1?^"P_[8W[.G@[XS>/OBSKL4OQD_8PT7X:?\%&/"W[,TOQ
MJ\=ZSKL%I\5],\5:QX#^"<'@;QQX^N]<N/BUJ&@_"WXG1ZQXD\5>,[?Q-KO%
M6OQ<TKX@?LB_%*1OBQ_PL#3O!_\ P<7_ +.OA'P[<:K\1;KQJOA;P/I__!7+
M]FC6O WA30[K6=;U6;1/!>G>!Y[75O OA[3Y+7PY8>!I;"]\+64/A9K&4_TF
M:_X1\*>*]!E\*^*?#/A[Q+X8G_L_S_#FOZ+INLZ#,=)O;34=*,NCZC;7.G2'
M3-1L+&_T_?;-]BO;.TNK;RI[>%TI7?@KP'K6G'3;WPEX2U;21J^KZL;"ZT'1
MK_3AKVI7FH-KVIFUFM)K8:O?ZA?ZJVL7IC^V75Y>:@U[))-<7)<DE*$J=K7Y
M%=:MJ-7+JCE*[DW-O S][FWQ$Y-_'&HHIQE*2U;;:3VA^[Q]-1C:UH6QD&U:
M]J$8K3V;I?RW?M0_'_X:?$/X)_MM7W[0WQ6TOPC^U#\"_P#@LC^R_P" (?AY
MXT^)USX%U?X>?LZ>#?V_?V5IO@9)H7P_U3Q%I4<WP2^*/[.-GI/[0VNZE/I&
MH>!/&OC:X\0?$Z_N)]<^&FB7W@?]@?\ @LMXFO\ PG_P3#_:W\:Z!\0_%/PR
MU;PU\-['7M#^('@;Q_K7PYUO0[V+Q7X<6TNK;Q5H&K:3(;"\%Q]CU#2-0N+O
MP]XDT^[GT37]*UC1]0N].N?T-N_ ?@#4_$8\4WW@WP?J'BVVTO2=%'B*[\.Z
M)=^(K?1M'U^U\6Z'I(U>:SDU.+3-+\46%EXFTFP^T+:6.O65KK-G#%J-M%<I
MM:UH&@^)+,:=XBT72=?T]9XKE;'6M-L]5LQ<P[O)N!;7T,\(GBWOY<VSS$W-
MM8;CF[KDA%1C%QG0F^5M1DZ*PT7?7FO46'<IMR;YJU1:KXI<$ZDY\TK3I5:7
M1RBJLJ\TU=<O[OV]H+E2M3IMV=TOY^_VL]?^$/[+'[37P]_99^*G[06B?LR?
MLD_&W]GOX\?$'PA\4OVMOB_\>_B#X(\2_M)ZS\3]%O\ XI:9%\=/B+^U3X"U
M[X;_ !/\(^#M1\/>//@?+/X_AM_".IZUXWUGX86_A[Q9#9S3_+O[?'QNT3P/
M^SM\<_#?AK]KWXF^+?CM^SW_ ,$>?AO\:OAO\9/C)\23\+]4\2:R-<^.-S\)
M_P!HG]G?X8>&[OPAXY\8?M.?%K4/A#>6_P </BE?^)K#P[X \&CX3>&X_!?C
MR#XL?%[P(?ZD=8\!>!O$6B:5X:\0>"_">N^'-"NM'OM$T#6/#NCZGHFCWOAY
MHVT"\TK2KVSGL-/NM#:*)M'N+2"&73&CC-D\!12#7O 7@;Q5>?VCXG\&>$_$
M>H?\(]KWA'[=KWAS1]8O/^$4\5);Q>)_#'VG4;.YG_X1[Q'%9VL>O:+O_LW6
M([:W34+:X6&()'O<MD[2N_?TORIRE1O>]ITFU24H63H1C&]XI.[+G4FDU9-P
MV3D^155I:\*G+*I::DU6G)VM)M?BY\9OB-XB\+?MC:=\4X]=\(_M.?LR>.?V
MFOV,/A=%XD^#7QEU3PC^T=^Q-\3?BEHOPPT[X?\ A*;P9!JT_@#X_P#[(/QR
MU#Q?\-?BE\2=(T:^T'QMI6C?%CQ9\1=7\/?%/PC\.?!NI_#+Q+PU\1_C!XY_
M9S^'OQ_LO&'BG2_^"A?@W_@KQ=? /XB> =,\7ZK+<7?A75?V[]2^'7C7]EWQ
M=X$@N]3TC4/@=X-_X)X:_'\>?#&AG0KBR\/>"O#6B_MDV,J^/+C7/BIJO] <
M?PQ^&L7BVR\?Q_#WP/'X[TRP?2M.\:IX3T!/%MAI<EE%ILFFV7B1=/&L6M@^
MGP06#V=O>1V[6<$-J8S!&D8T8_!'@N'Q?<_$&'PAX7B\>WFBQ>&[SQO%H&DQ
M^+KOP[!<B\@T&Y\2K:#69]%ANP+J+2Y;UK&.Y G2 2@-1%6E%VO&$^:*T4E;
M$4Z]FU\7/&$Z%5M*]&JX+F5.+DI)RC-72E./+*2O;6C4I72E?EY'.%6%KI5*
M:G:#G)1_F/M]6U32K7Q9\:K'XY?&J_\ B+\-_P#@XO\  W[-?@V\U?\ :1^+
M?B/1].^$WQ,_:?\ @M\(O'WP2O/!^L^/=0\+>(O#EY\-_'?BO2K?PWXFT;6K
M_P -6,>C1Z ^D:9X*\(6?A_J/BW^U/X0L_VP?"WBGP-^T!KOAW5O#O\ P6;\
M&?L[?$Y/BQ\7])M_'K^#F_9KNO!_Q$^#GA7X<Z,/!NE_#;]B[2-8M_"?BOPE
MH?Q MOB#<?%/XW^+M0^- 'A;Q#_P@7BWQC_1H_PK^&$D,MN_PX\!O;SW'VN:
M!_"'AYH9KKRIH/M,L1TXI)<>3<7$/G.ID\J>:/=LE<-;G^'G@"YU;5->N/ _
M@^?7-;U/PMK6M:S-X9T275M7UCP.XD\%:KJFHR6+7E_J7A"0"3PO?W<TMUX?
M<!M)ELV&:*:G"5-M\T8>Q:76\(8*%35W5JKPM24DU9NM=MM355M)QJ*VL_:J
M[2LN>>,G3T5G>E]:IJ+NK>P5K)Q]G_,!X&^'>HVWP]\<?M"? [XH?&2Q_:Q\
M&_\ !?;]H3X2_#_X>^$?C?\ $.+X<>+?!/C[_@J%KC?M ?"3QY^SOH_B$_#+
MQ%X<U#]F+6?B7\=OB%XFUKP--\3O#?@SP;:?$^/QSI?@;X?Z##I/UMX@^#7B
MO]I#XX_\%T/A/\'_ (F:S\-OCE:>+_V.?$_PF\5^$_'_ (C\$WOAGXL>'OV.
MOA_XB^&]MXVOO!6J6&OR?#;Q;K6FP^&_B+X=G;[-XL^'>K^)]*6)GN(KFW_=
M"V\"^";/Q?J/Q"L_!WA6T\?:QI%MH&K^-[;P]I$'B_5="LY8Y[/1-2\2Q6:Z
MU?:1:31136VFW-[)9P2QQR10JZ*1Y3\8/@WXI\6>'KF+X&?$RW_9J^(FJ>)]
M U77_BKX4^%7PT\<^)-8\-VVLIJ'BSPU/I_CO1-2T9[GQ39FXA@\07UKJ%QH
MFK&UUG[%JB07.F7U2DW&R3B^648SBUS0E*C@Z,9QY^:*4)X58EQ<91<VTX3B
MIPKN]YU)-)QG*,G&2;C*,*V)KN$E#E<G.->6'34HN,'=3A+EE1^</V"?BM?_
M +6NCZW^VO=>%_'?PRT?XH^$O 7PM\(?!_Q?J/B6R?P(_P (H]=3XR)X@\#:
MNNF:?HOQ/T?]HKQ-\5?@EXK\36?AVR7QOX/^ OPTU_2-0U7PE<^'KR7X*_:D
M^$WPB^+/[<'_  4LM/B[\9_BW\$;'P/_ ,$U/V%?BAH/C'X._'WXF? ?Q5X/
MU/P;\2_^"F<]G\7K>X^%WB[PCJOC.7X3:W<:-K&C:)XG_P"$F^'\?B74-)'B
M'PIK.H7&AI!^YOPW\#>'/ACX#\)_#CPFUX^@>!= TKPO82ZIJ$NKZW=1Z590
M0'4/$.L7+->:SXDU9@=5U_6M0>34M:U:]N]7U"6:[O9II+NO>!?!/BG5O#.O
M^)O!WA;Q%KW@J^N-3\&:WKOA[2-7U?PCJ5VD,5UJ'AC4M0L[F\T&^N8[>WCN
M+O2IK2XF2"%))&6) N=:G[7EM+V?+&JE*FOAG4H3I>TIJHVX\E6I.M24VY14
M:,93YJ<I-TI>S337/S2IMJ<K\T:=:-10FXJTN:G"%*JU%1DW6FH<LU!?S&>-
M?VAO''BJ[\$_L\?\%*?VO_!O[ ?COXD?\$IOV,_B)X3\>?%O^U/A-X@LOVGO
M$%C\3M-_:^^(/P#^(ND_&+X-> _ _P"U=\(?B,?A7%%X7NX/&OB/P[H,VC-X
M3\&'P#XI^*>G>+/V2_;=^)/QH^%'_!-#XW_%/X67GC?Q7\8/!?[-;^)D\0CP
M8= ^)TXLO#NG3^/O'-G\.[)O#;:-\2-)\+'Q+XPTSP5:#1SI_BZPMM"M[>U,
M*6Z_=6N^$?"GBB?0;KQ-X8\/>(KKPMK-OXC\,7.NZ+INKS^'/$-HDD=IKN@S
M:A;7$FD:S:QS2QV^J:>UO?0I+(L<ZJ[ ]#5R<I1FM%*5251-I-/][*I%3M&G
M*7NR5&HH^SC.E&Z49R_=Q%*,HMW:C!0LO=LN2$'R7<TK.'M*;G[249NSE*,?
MWG\]G@W4/V3?C_\ "?\ :\\3?#+_ (*0S?$/X;?&3X*?"72)H_V&?'7CWP8/
M@'\</$6KZMX:^"WCKX9ZDGQ\^)'C+X??ME_'+Q1XQ\+^%;WX.GQ/X7O?CEXM
M\,^&M.^)?PPUGQ)XK\6S>.O!OB5\=_B'>?\ !+#_ (*'W'QF^*_BWX3?\%!_
MV<O''PG\-?M@:?\ #KXM^*O!&F_"?6_#M_\ !_3/AAXX^$6D6'C.]C\*?LX_
M'7X#1:7\6;.SG6;P-\1=>\8?%[3?&^BWNIV'C;PAH?\ 2K8?#+X;Z5I+Z!IG
MP^\$:=H3Z]<^*GT6P\)Z#9Z2WBB\G>ZN_$;:=;V$=FVO75S))<7.L-"=1GGD
M>66Y:1V8_-G[8G[)6A_M9?L_?$SX0^&O$'AGX5:S\6[;PU!JWQ5L?A]I_C#6
MAI6C>+_#?C8K'#;:_P"$9M2;4[SPSID8N+O79[6.+_2/LES-';O"[VDFE:/-
MA]'9N/LL30JMW2C*2Y/;TY+24Z*A#W9642*2MS.]O;/3:7M*%:GRN+<DO?\
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M=U54U*3N_9RYY*2:YO:?SH_M<7?['/C/X0^!/B-^S]^T3_PNWX!K_P %?_\
M@F[X]O\ Q!X8^->B^-/V8_V??$.J?%OX._#_ ,<^#O@1X\\$7\&B> =#_LJV
M3X@^.?"L/B_5M,\$?$+XNZ[XCT&7PK?^-;G2[4^)'QV\'_$O]J?]J3X#?%+]
MO/PI^R9\4_A9^T3^R]XK_8HT2SCUV;X__$+X$7OP>^ ?C'X=1_LCWVI_%W1/
M!G[0WAC]HCXMVGQI^%?QA^'_ (?^%/QIUWXC7.J:A\,OB(VH6UI\(M.\+_T/
M+\-?ARG@J/X;)X!\%+\.X;>*TB\!+X5T)?!<5I!>KJ4%K'X6%@-"2WAU%$OX
MH5L!''>HMTJB=1(-*_\ "WA'4_$F@^*-3\.>'+_QAX;MM6B\,>(K[2-,NO$N
M@6>K10VFN1Z#J]Q;R:II5MJ<#06NJII]Q!%>Q&&&\$J%%II\LD]XQFIQ3Y?=
MM2PT$TN5QYHSPRY;WBZ=6I&JJDK735U*[2E*'(VK[>TQ$FKM\RC.-?WN5QDJ
ME.$H.,;I?S!?&_X]?"7XC?"CX^Z_\?\ XPZ9X9_:I^"'_!<G]EWP1K/@7QO\
M3;SX>ZI\/O@7\/\ _@J3^S?IWP*T[3?A]K7B'1H)O@5XL_91TWP9^T'=WAT>
MY^'/C?QT^M_':Z,_BOPQ#K7AS]/_ /@MYIN@ZI_P3&_:.N/$!C_L;1;GX*^)
MKNZFU*ZTW3K"WT/X]_"_49]9U*[MKNSACT[1;2&769KJ^F^P::;&/69&@ETV
M"[M_TUN_ '@74/$4GB^_\%^$KWQ9+8:1I<OB>[\.:-<^(9-,\/Z[!XHT'3I-
M;FLGU-[#1/$UK;>(M(LVNC;Z;KMO!J]G'#J$,=PNUJ>F:-XDT;4-'UC3],U_
MP_K^F7>F:KI6IVEKJNC:UHVJVLEK?:?J%C=1SV6HZ9J-E/+;7=I<Q36MY:S2
M0S1R0R,IFWNQ6G,IX>H^D7+#PPD;V6J=66$]I4?2=>I92Y8MIP;E4;D^6=.M
M26B<HQK/%.Z>D7[-8KE@K6Y:-->ZG)+\6_$'B3P/\8/VK/VRO@5\8?BQJ/@7
MX"^!_P!@?X%_%;]DKQQX7^-6N>&UT?P;<:S\?]/_ &EOVK?AW\2='\6IJ;_$
MWX1^*['X0>&]>^*3ZS=ZQ\(_#R^!#I5_X=L?C+XPD\??0_@?XU_%+1/^"/VA
M?M$_M>ZG\4/A[\7]$_X)VK\8_P!HO7OAMX:\.Z-\</"'C'2?V=Y/&?Q(\1>#
M?!?B71;'PAH7QBTB]M]4UC2?!^N>'[;POH?CR&+0=0TQ=&LY;>OOO4? 'PZ\
M20^%%U?P5X+UZ#P#JEKJ7@<:CX;T+5(O!>M:(K:?97_A07-E.GAS5-(2)K*U
MNM'%E=V"QM;0R0A"@[1E5U974,K JRL RLK#!5E((*D$@@C!&<\4G#]W5IK>
MI#DO+;26*:FXQ<7SRCB(TZCC))PH4^5IV<-$VJE.H[)0?-RQVVPZ<4Y*5XQE
M0E.',G:5:=TU=3_GS_8>^(G@C7OVCOVEOA%+\:O!7B#X5^)/^";'["OQCM/
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MP^-/!OQP\!P_"'XAKJGB#5_&2>.[?3=1\.?#/Q%X7]8^ O[07P$^-7QY\7^
M/C5^TSXX^&?_  4&^!__  4N^/OAJP^ _AGXC:=X0^,?Q"^"6B^-O&>C_ #P
M'9? W6[;4=;\<_L7^*OV./$/PI^-_P 0+WP=X4MO"%YXG\->)_VBKSQ/I/Q
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MC]H;X,_M6?"C3+WQ#KUM\$]'_9FN/$FG^/?$>@:C>7&AW_B+2==U/5/V>/\
MA!_$^H:?I]OKOA/]I;X;>/4\-C2KEM/E]._X* ?$RT^%O@/]GG5]4^#7PO\
MC/I/B?\ ;H_8@^&<]C\4#Y\7P]U/XH_M,_#?P#X;^+W@C2W\,:_!J/Q(^&GB
M+Q#IOB?P9++J/A1]$U>RB\06VO27.EQ:-JN7^R-\)H=<^,7Q_P#VX/$/P%\=
M?LY^.OVG=,^$^AGX7?%/4O!U]\1=.T3X9>#;70I_B#XYT;X?^./B3X$\#?$?
MXD1)X9\%^*=&\(^--9?5_AI\!?@%/XTGL_%FBW'A?PI[O^TS^S7X<_:A\)^
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M0+KQ+/(OA'Q3\,]2U+PI\2_"WC3Q9X,\?Z-<^$O&_@Z^TF9)K2W_ $.^/?\
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MDN:;2>EG%QE#E2]^/(DW\<I_E%XY_P""G'[57@30OCK\=M3_ &>_@9/^S/\
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MQ?"SQ5X!\#^'_$.I?#[2_#?C+Q-X\\8>'?$-E;> J^*=2_:G^+L?P%^%.M_
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M;'XK\/ZUJ7B>YL+34/%_@NWU.^6YL/%MO]X>$/\ @FK\-?!G@?\ 9I\!:?\
M&7XZ7VF?LM_M;_%+]LWP/J.IS?!Q]8\2_%#XOZK\=M8\7Z!XZ>P^#FGZ3>>
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M'FD?L^_$*W_: CT7XAZWX>\5:C=^$_AI^T7X:L3\!-%\7ZEXR^)OQ8T$^!_
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M4J>K;CU]AY-J-.$:EV[M6?,XZM.SARPC*G*G];T445H 4444 %%%% !1110
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M!I?B*TO'O+&30-8UF: P_57@3]J+X)?$W0?V=_%'@3Q/K7B3P]^U9X-;XA_
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MP?\ "O\ X)N>%O$WP=OK#7/V=/\ @I9^UG^TU\6+>'QQ\+[^UT+X3_&G3?\
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M:AHOP<^.7C#PQ\./#OQBTS4-:^'OQ!\9>,O!OPVU_P )>'_A-K&EZ7>WM_\
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M]%:R^,/AZ.[TF\\+^'?%VDZ+HVJWNI>%-.UI;'PM=?H#^S9\+OC!\,?VQO\
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M#_!D6ECQWX/\+7/PE^+/[/UO\7]!M]#\;:?XTN]):Y^"'Q0\/?%32]2E\0^
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M]+T/Q1X7\3>%?%F@ZYX7\4^%_$VBZ1XA\-^(]'U30];TRPU.PNK6+YB_;?\
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M.?[/?QC_ &?/@Q=?"G3-/\0WGC_1-<^)^E>/_ NO_%/0?B9X1\'Z;X7LM/\
MBIX'TK6_&%O-X2\6^(B7+[>4?=C2]RTEJK-N-1I6L_91C"I9RO/F<4I-WB4^
M=4(-W=3EGS<S5^:*<J::;N_:2;A=:02BY-+?]$_@1^VS^SI^TOXJU;P?\%?$
MOCKQ=J6@Q_$9-;U2Z^!GQX\(>"=(UGX2?%"]^#OQ&\%:G\1_&_PT\-_#VQ^)
M?A3Q[8S6>H?"RY\3Q?$=_#TMAX\L_"USX"U33/$UWY]X;_:#\6:-^VQ^VK\-
M_BCXX\':/\ _@1^R;^Q[\?\ P]>WVDV7A2#P##\3O%_[;NC?%O6O&_C/4=8N
MTU;38=+_ &>_#.LG5+K^P-%\/:3;W$*Z6DT>J:WJ]_\ X)__  W^)WPF^"GC
MKP=\5O ]_P"!O$&I?M8_MN_%O2;*]U[PCX@%_P""?VC/VP/C?^T5X%NENO!_
MB'Q#:6VH6?A/XJZ1HOB33KNXAEL?%.EZW!8OJFCKINM:C\I_M2?L8_&S]I#X
MD_\ !3CP]H=DGP_\-?M7?\$_?V;OV=/@]\6-:U7PMJ7AN'XM_!CQ;^V3XPU#
M_A+O"MAJ>L>+E\"WMU^T7X"TV]%QX4N?[<TO1/B%83V,,"^'I/$G/)S_ -GE
MRR3Y%.M&+NDY8:E.2Y6XW<)SJ*%-RYI5*2I\W/-N.\+-55)I/VBC3OII'$U(
MQ?-K92IPIN=2W*H5'-KDC9_<=O\ MJ?LY-JGQ%\/ZGXQ\0>%/%?PMT7X:>(_
M%G@GQU\+_BMX#\>2Z#\9O$5UX,^$FJ^$/ WC#P3HOBWXC6_Q(\=6-W\.O"$?
MP]T?Q1=ZO\3K6Z^%\5N/B':W7AB'03]KKX)O!&HO?B&-?D\;^(/AY_P@3_!3
MXS+\3O\ A)_"?A+3?'?B<1?#-O 0\<WOA[1O"&M:'KK^-=/T&\\%ZG;^(?"]
MOH7B#5=0\6>&+/6/S?\ !GP%^)/Q<_9]^,%C^T?_ ,$BOV7/A9JWB_PMX(^$
M'Q$^#WP@^)OPLO?'OQ_\.2_$OPSJ/Q \7^!_BEX4TKX5V7PO\*_#W2(M9^*/
MP)TCQ-\2[;XC:U\3UTVXO=5^!6M^"='\9>.N2F_8K^-^O?"?3/AI\;O#O[87
MQDT7P;\>/BCXZ_9%^.OAW]IGX3>&/^"D'['?@^^^$/@'PGX43Q%\;Y?B'X6\
M(_%/5-2\::O^T7HC2>)?B3\9QXF^"^I_!O1_CCI_C_5U\6:/X9UD[.VZY:>L
M6I)MRFIN+?*E[OLYPC425E4C5E1FZ<5FFVNSYIJSBTTE&#C>SE>TO:0G*#;3
MY)4XU8*HS]J/#7Q-\(>,?A=X?^,GABYUO6O 7BKP#I7Q,\/7=GX0\8-XCU;P
MAKGAV#Q5I-S:^ 9-!C\?MK=_HMS;RP>$'\,)XP-]*NC-H*ZUG3Q^1,/_  4]
MU/XEG_@EG\>/ ,/B7P)^SK^U[XA^-,WQ+^'WB/X(?$#7_B[K?A_2/V/OBK\?
MOAA9> X[#2+G7/&6HOJ/AWPNLFG?!;P=\05\=^)9)_#/@;Q?KT.G:A8ZQ^HG
M[-.C_''P_P#L\? S0OVF?%'AOQM^T1HOPF\ :9\<?%_A#3K;2O#/B?XK6/A;
M3+7QUKNB:?8:=HNGV]AJ?B2/4;N%=,T+P[I<GFF73/#GAZPDMM%L/QW_ &5_
MV4/VLOAY\-O^")O@;Q]\"Y= O?\ @G[JWQ'\$?'"_L?B9\,->L;GP_I_[(OQ
M._9M\,?$3PD+3Q/!=:QH7CKQAXWT[Q5I&AO;VWBS1? =K=W7BC1='\7+#X/F
MII*<ES?#5I**7O1Y&\6JDF[1<TE[!.]K/EE;=DWFXQ?+:].JY:I/G4<*X)+5
MIMK$.-KW3<=VDOU*T/\ ;;_9L\3_  P^$OQ;\-^.-8UOPM\=?''B7X8_"?2[
M'X<?$X_$3Q?\2_!2?$)_'/P]C^$T_@Z#XGZ'XR\ CX3?$[_A8.@>)O".B7_@
M$> O%C^,HM#BT+47M^,?_@HW^R VE_!K5--^(WBGQ)_PT)X)^)7C_P""^B^#
M?@A\>O&WC#XA:-\'+FSLOBKI&A^!?"/PQUKQF?B%\/;Z^BL?%OPFN]!M?BGH
M=[!J=K?^#H9M&UA+'X5\*_ O]MCX?_#'X%>&=(^#NJWOA>W_ ."F'[=/QQ^/
M?@;PW\4_AMX,^+EY\"_VE?C/^UK\7?@IXD\!_%"R\<6\'@^P\)Z]\<?AU=_'
M72?!'C7PW\4M8T7P_P",O OA>3QQX%UOQ)X3^)/!?L:_L:_M5_!7QA_P3J?Q
MU\$K#0=$_99NO^"J&A?$>;PC\1_AWKFAVVF_M,_'*R\<?!34_!L#ZMX=U35_
M#FN:#I$DGV>YT#0-<\/6=WH*Z_X<T;4IM8T?P]%-N=N>U-R5-M6;]FY4E*I%
MN3]_EE))/1^[*,DI714FXQ;BG)QE-<KLN:,:KA&=XK3FA&4K*^\9)M-,_;CX
M*_&CX9?M$?"KP/\ &SX->*K?QK\,OB/H<'B+PCXDM[#5](>^T^66:VF@U#0O
M$.GZ1XC\.ZWI=_;7FD>(/#/B32-(\2>&]<L-1T+Q!I.F:QI][8P>4>$/VT?V
M</'_ ,2-"^$WA+X@7%_XO\8:W\:?"O@>[N/ _P 0+#P1XX\6_L[>(9_"GQN\
M+^"OB-J?AG3_ (?^,/$7PU\06>IV'B#0O#_BF\U&8^'O%\NDQ:A;^"/&4^@>
M9?\ !-#X/_%#X"_L@^#/A7\8O")\$^/-#^(G[0NOW^B+KWASQ);KI7Q*_:&^
M*7Q3\,3V^K>%]4U739BWAGQMI$%_ 9HIK/5[?4;01S6L%K?WOY^_##]F_P#;
MGU']J3]CWXS?&KX)Z?<:S\#/VM/V\KWXL>/=(^,'@=/!-]\*/CSX<^+>F?!?
MQS\"?A-8ZD;;PG\.K3PIJ_P^\,?$#2+G2O!WQM\6_$VQ?QE\2_#GQ,U>_P#$
MWQKN1.\Z::Y8RA3E-:MQE.G!RBIKW;TJDW&2<;M1ONFE6T)-_&I345H[\DYJ
M+<5TJ0BFFG9-]FF^PT[]L_\ :C/[(O[-_P 5[[QMX&N?'WB__@KIK/['OQ-U
M2V^&L-GIWB/X,:;_ ,%1OBQ^R:FE>%-&D\2WEOX*U23X9^$M"MCK=_-XTU5/
M(O93>OX@O5\36WVO_P %-_CS\3OV6?V"OVH_VE_@YJ&@67Q'^ GPE\5?%/PS
M:>+= /B;PCKUWX3L9;U_#_BC2+?4M#U2;2-4MQ+&9]#\0:%JEE?+97B7MQ9P
M7FDZE\(0_LG_ +3J?L?_  .^%_\ PIJ__P"$]\#_ /!7G5_VP_$F@/XZ^%RB
MU^!VI_\ !3#XE?MG+J]KJL?C:71[[Q#%\+_&NG>'SX:2^CNY/B!:W^E^<GAM
M+;Q9=?;_ /P5,^"WQ2_:0_X)[_M8_L\_!;PH/&'Q/^./P<\7?"_PAIMQKOA[
MPUI5IJOBVPET^'6-=UGQ'J>FVMGHFF>8;B_-G_:.JR($CL=+NG9C'@O:_4US
M<_M[0;M_$N\-ECEM>_[UXJZ6T_:K=-+H?LGB86Y?9.57FW4++$XU1O?9>S5#
MEUUI^R:T:;\DM?VVOB%\&/V[/B1^R?\ '?5O!WCWX3^%?V![C]N8_&+P3X$\
M5Z-\0?A9I?A'XH2?#GQEX-^*W@?P[J?C^T\96GC.&XNO%WPHUWP3I'@[7(=-
M\!>.O"M]X.\;WNF2^-%^C? 7[?\ ^RY\3_#/AWQ?X"\6^.O$&A^.-3\,:1\-
M;@? GX\Z/-\7+SQA\-;GXOZ'+\'+3Q#\--(N?BSI'_"M[*_\5ZYXC^'L7B/P
MWX1T[3M2/B_5]"ETZ^CM]'Q1\$O#&D_LV_';2?@M^SYX5^&WQ ^,7PJ\86>J
M^"_"/A_X6^!]=\2^.=7\#ZGX9T6+Q=K?AG4;;PAJ>IV;W<%E_;5[XFU"UM-/
M5EM[]HE6%OAGPE^RY^TE\/O#'_!(/XR6/@*?7/'?[#G[/OB#]G']H/\ 9[LO
M%G@5?$'B#P]\4/@M\*OA[XE\9_#'Q=JGBO2_AKKGB+X>_$CX+>#M<TNQ\2>*
MO"D/B+X2^)O'<L&I:7XYM-*\#Z]U)>_*,I))2A%2459^TJ8QWO%M2C2C3PU+
MF>K595*MDH6XXN?)"7*[NES2C)^]STZ6#BXM.S4ZLIXFLTKQ4J3I4OB9^BFA
M_M:_ #Q/\._"/Q.\.>.I=;\/^//'>M_"KPCHUEX3\:#XC:S\5O"USXKM?&7P
MK'PDN?#MO\4M-^)G@!O 7CZZ^)/@/6?!^G>*/AII7@'QYKGC_2_#>B>"O%.H
M:3G^&?VQOV??&_P^\,_$KP1XMUWQGH?C#5/B+H6@:'X6^&WQ-UKXDW&N?"+6
M]7\,?%/1;_X26?@^3XHZ#JGPZ\4Z'?>%?&EEXA\(:5/X;\4R:5X:U5;77-?T
M*PU+\H?%/[#O[6OP5UCP[^V)^SWX(\,?%+XT:9_P43_:4_;.\6?LB:[\1]&\
M!6'B/X3_ +2?P5?]G*\\!^%_B7J%GJG@;1?C?X>\)Z#X(^+^KR7]Y;_#P_$?
M6?BMX0TWQ_XAT";2_%7BWT/]J7X'_ME^.O$7['W[7MO^R#^SI\>_''PKTC]I
M+X?_ !E_83\1>/\ P=/:P?#']IW6_@CXGLM>^'/QM^(W@ZR^&^H_&WX5^+/@
M#X.\1>+KC6/"VC>'/%%GXR^)G@_PIXLEAMM#\6>(9OHK^ZVX1DOBY)2C3=TX
MW52FY2G%M)>S<;U)<OO/1Z.R]ZW/)27NJ<8RFK-/6G)*,6DVW54KTTF^6/W?
M;?\ !0#]D[5?AOX<^+OA?XEZAX^^'GB7X87/QHBU_P"&GPV^*?Q*F\/_  PL
MM2OM#O?%?CO0/ O@KQ!XF^'L5AXBTCQ#X;U'1_&^C:!XCT[Q!X/^(&DW^CVU
MW\-OB"GACTVX_:;^#UO\4/\ A3ZZSXEOO&<7CZR^%>HR:/\ #CXCZYX0T#XD
M:E\,8OC-8>#/%7Q#T;PG?> O"6M7?PSNM,\3P)XF\2:3:NNO>%]&%U_PD7BO
MPUI&J_D[\??V-?C?XI\$^!=2^!'[.,'[(_[6OP[^"/BR3]G+XW?L6_%;X;>
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M@S\;/@]J/A6PU_Q#X,^./P1^(UWXZ^&%WX=^)'@3X@Z?X2AMKK1/B)X4U?\
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MA_Q?8Z%=7/C^+X::WJ_QO\">%-4UM? YO-5\/Z=\1I5T%&A\-VGB>?\ :?\
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MS]E;P?X$_9\N/V<?V,OCK\?_ (1^-/BW\*?%&G^(O%OACXY^$_A)\8-6\?\
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M !$MM&^'7_!:2&U^-_BW04\ ?\%2?^":NG:3J-K\=_%VF:EX(\/_ !!\(_\
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M4)25X*[^]**_FG_9]^/7PN^*_P"QIXD^//[!WQ9^(?Q$_P""F/A?_@EI\8M
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MFZZBN5QO*>=.Z6ZE3@[NRO6I*K2U7,K2M5BWHH^SOJI^[^Y-%?S(?\$_]?\
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M[/4D^*7[/NA^%O"GB&X^%6J:1J7AP>#?&6L?#>^USX:Z_J/B7PM\5=>^;?\
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M]H@VTYM(O&?P;U'PI\4/B1J?P:U:ZB,=U'X4^-WB?X<>%_AIX[T^*>.U\8^
M=>\4_#C5TO-&\;7]C<OE?/3IZ)U9T81;327MU"4)2TNER3YG=)WM%VE)$\\>
M2=1:QA&K)VU;]BYQG%6O=\\'%-76\M8Q9]D_&/P#X._:R\!77A/X7_M#ZO\
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M)T_4M#TRX\<?&?\ 81U*?P3<^/O'GPC\)^!/VJ/B!I/@+]HOX5V.N>.=-LO
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MX*^*B?&+XF_L^RP? :YU'QCX"\62?%A?"'@GXG_#+2OBS?\ B"_L-:\'>.M
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MAX^\*ZGXGUB]\*?$&S\4^&Y[D/I9AB_/3P+_ ,%&/BMKOPR_X)^_M7ZOX=\
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M !K^)N@?!+_@C5^S?H[^!!X ^,'_  11T7XQ'4=2\+>(+SQAX<^(?P \!_L
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MS$E]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/P7HGB>_UO5-/^#?PM@C\3:+XAT#5K(^#;>:TFAGUWQ;+XA\]^&__!*SX%>
M(]$AUCXG_M%?%:WTO]CKQ'^P?J=M\3OB'H-];^+?V<-8F@30/#'B*#PCX(\&
MQQZYX#T1+KPYX=\6^'5\/^(->M-1NM>^)M[\0/'$6G>++#]-**<US\_/[_M?
M:>TYKOG=;V_M7.[]YU/K.(YV]7[:HKI3:%%<O+R^[R>SY+-KE]E[+V?+KIR>
MPH\O1>RIZ-Q3/S"\9?\ !*KX0^,O!7[,ND'X]?M;^#_BS^R?X3O?AU\,OVH?
MAO\ &#2OAY^T%J7PKU>T\.:?X@^%?CW5O"?@?2_AOXP\!Z_8>#/!<=_I5]\,
MH[JUU/PM8^*]%U#2O&FI>)/$FN?1'@C]C3X8?#KX]>'_ -H'PEXB^)5GX@\-
M_ &Q_9NLO"NI^*K;Q-X6OOAY8^*I_'*WWB/4O%.CZU\2/%GC_4/&5W>^)M?^
M(GB;X@:MXO\ $^LW^I7WB35=6EU*_-Q]:T4[MRE)MN4ISJ2DWJYU5)5)-]ZG
M/-SZ2E.4Y)U)2J.>6*2BHI1C&$(JRM&--Q=.*714^2*A;X(QC"+4(QIK\Y=7
M_P""9_PDOX]5O=(^+7[0/@[QE<_MJW'[?/A[XB>%?%/@&V\6>!OC]J?@/5/A
M3XC?PW;:K\,]7\'W_@+Q7\*M=\0?#KQ#X%\;>$_%^CW7AW7-2FM19:])#K4%
MFP_X)I_!G2O 7A_X;:?\2?C['X7\)_MG:S^W/X7CO_'>@^(=5T7XNZU\6?$G
MQQFT7^V_$_@S6M5UOP+%\4?&'B?Q3+:>)[O7/&&MSZQ/9>*?&FOZ;!8V=I^B
M-%):**6BCR\JZ1Y'2E&RV5I4:,M%K*G"3YFKMM)N4FES2<G*7VFYJI&=WN^:
M-6I%Z_#.4=$[+P3]J#]G7P3^UI\ OBA^SA\2=4\5Z1\/OB_X8NO!OC2?P3J.
MFZ1XDN/#>HO%_:FG:?JNJZ-KL&G?VC;QM9SWD%A]OAMYI6L+JSNO*N8_&OB5
M^P;\-?BQJ'[4NH^,/B)\7IYOVP_V9O"'[)OQG33]3^'^GQ7GPF\&67Q2L-.3
MPV8/AQYWASQ+>1?&_P"+TFHZW:3.&G\>7LEA9V T#P8OAG[@HJ7"+O>*=[WN
MK[TW2>_>G*4-OADUU97-)6LW[K3CKLU.-1-=FJD(S3_FBGTL?(UY^QUX+O\
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MQ5ERWDE:*LEI):)6MYI/=7/CW]C_ . 5E\(-,^-/Q(OOAKH?PG^(O[5?QO\
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M7_#72/AAX+U'Q-9:9HFDWUA:>)-9U^\\9^.+O5=4GO-0U?QGX@\5>-SXCO\
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MO[EHIN[2C"THN%-P_+KQ'_P22_9LUCX,_##X2:#X[_:0^'.O_ WXU_&#X^_
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M'?P[\"_%CQ;X6NO"GB_3;2Q^'WQ+UOQAX<\$>)=.\5ZGH-GX/\2VFN:]\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO#XGT+QWX-O?$W@_7$^!?_!,K]G/P;\/?B=X*^)O[./['</AGXS2_#2Z\:_
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ME^']&F\2ZW\.[;3O&UMK*KXX\/Z][C87'Q>U'QQ_P4'_ &8Y/VHOV@?!]_\
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M!5))V;E!5(X6I":C)M*K\4VZDI_D=\"_CM\<=;\"?\$8OVB= ^,OBKXAW_\
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M"TCQU\2=3T.RN(]!\/ZEJVAZW;6\.GQZUXA2WTF^U>YT&#0XEU)_U5K\9/\
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M$#Q7XYU_Q;HB+X+AC\#7OA[5;K1--UG6[;Q#JFFI:Z#?:+:>)=:\/>6>%_\
M@K7^Q5XB\3+HUY\2K'PQX>U3]G_XC?M0^#?B)K/B+X<ZIX0\:?!+X1:1HWBG
MXF>*[:Q\$^._%WC[P'J'@WP/XG\+^.M2\'?&3P1\,_&UUX7U>[N-'\.ZEJ7@
MWXBZ9X/Z+P#^R?X]LOVI/V\?'OCN'P&OP*_:L^$WP!^%_A2U\*^-/%%S\2=,
ML_A1X*^(_@KQ*/$FCZCX TK0=&CUNQ^(3RZ)>:/XT\2W5E)I*M>02-?C[#\K
M_#7]A;]NSQK^QC\2?^"=7[6_QB_9UNO@';?LO^./V4_AQ\<_@GI'Q&N_CI\4
MO#6H^ ;_ .%/PT^(/Q?\!^.[;3O!7PT\0>!/"?\ 9OB?Q9X:\">._B(GQ-^(
M-O8SP^,_ 7A32];\.^.S5+2\FJ3J*]HN4V\5!T]6X0G#DPM6$6Y*K[2I!S@K
M3IBYK^]97K*#2;DHT_\ 9Y*=TE*49J6)ISFDG1]G3FJ<W>%3[2U_]O/X?>!=
M)^,VJ_%#X1_M&_#+_A2_P;\+?'>_L?$7PL&O7?CCP#XRU/Q#X?T&'P'-\.-?
M\=:9=>.I/$_AN\\.ZG\+_%.H^$OB1X?N;O2=7\0^%M+\+:G;>('K0?\ !03X
M0Q6WQ9T_Q%X2^)7@OXD?!OX]_![]FOQ/\'_%$?PV@\;:C\6?V@=&^'/B'X+Z
M+X:U[2OB5J_PEU:T^(6C_%+PM<Z1J#_$VT@L;HZGHWB :/KVGRZ6WSMK/P@_
MX*Y_%?\ 9&^,7P[^)GQL_99^%O[2-S\.]$\#?"SQ?^SWJ_QDTWPMXZUBSU[P
M]J?CKQ_\1_'>H>#O#GQ$^!^J_%#PMHVJ?#S0[+X':)K6M_ 9O&/B?XE>&O'/
MC_Q3!X$TOP#YSX2_X)^?&2SN?VVM*\??LY?L$^.O@K^V7XV_9A\5:_\ LSZC
MXV\>M\+M)\/>!/@IX2^%WQ6\#/=-^S0MG_:G@[Q7X&T#XI?";XGZ?X'M+WQS
MXA!.K>!_@KK6GV7B@VU%<Z6MDN1\TK._+)-MPO%R3=.=XOV37.X-J4'*<K1;
M33<O>7+%N*ORR2M.TE#XXM27M5[JE;ED?4/Q#_;O\5^%OB;^Q'\/M'_9A^,2
M7/[5OQN_:"^%7B/3O%\_PE\.^)OA]!\ /AQ\;/$6IR)8R_%\:9K%_P"+-:^&
M.G>*_".LZ-J>N^"=;^#W]N:];^((_%FJ>!?#/B/WKX8_M4^%_B[XWN_#/@GX
M??$_4?!]MXS^./PWC^-!T_P7)\+9OB)^SMX_O_A;\4/!5PUEXYO/B%H.M:=X
M\T#QCH6C/XK^'V@:7XF_X0KQ!JN@ZE?Z)+H&I:Y^?'A#_@G[^TU\+[#]@*^\
M+^/_  ;\1KW]CW]KC]I#XAP>"_C+\8_BUXH3P5^R_P#'SX>_'WX5^#?A=X,^
M.?B#X?>-_B=\6=?_ &<_"7Q1\(V_@RT^*6B:#)XYT/PW-X(O_B/X(L-.T/7Q
MZQ\+OV)?B-X5_;<D_:RL-$^$_P"SXVOZK\<[/X^Z?\ ?B5\0]5\-_MD^%M4U
M>^L?V=_$'QM^".N_#KP5\._#/QP\%Z%/IWB_Q5\9]$UKQ=XYM]?L]>^&MKKO
MBSX?^,!J/A>8I\UI-N+G5?,]&H<M*5).*;3MS5(2Y)-J:YDZL(R2<G+5I6?+
M3M%>\KJ4XU/>?*TVE&<%.-G#?V<W&_VM\4_V@/#WPU\9^#/A=IWA7QE\4/B_
M\0?"WC[QWX2^%/P\'@Z+Q5J7@3X87'@_3/'?C*?4_B+XQ^'O@71]!T#Q!\1?
MAUX8DFUOQCIUW?:]XXT*UTNROH$U>ZTKX _:2_X*!3>(O@'^QY\2OV8?#OQ"
M\5>$_P!JO]K?X7_ /Q1J.GV?ACP/X_\ !-A9?$;5_#_QE^$.HZ-\2?&7@/6_
M WQAO]5\ ^.O@UJ-Q&D,_P /M6T[QEJ$/BWP9XJTOP7XAF^C?C+^SC\4)OVQ
M_@3^V;\$[GP!K'B3P5\&/BY^S+\5OAQ\3O$'BCPAI'B;X2_%'Q9\-_B=I?B[
MP7XR\,>%O'TNB>/_  !\0?A1I-LNA:MX(O\ 1/&OA+QKXC@N/$7A34_#NBS:
MG\N>)/\ @GQ\8]&^$_[-'A+X;W_PEU?Q?X1_X*8^(O\ @HG\>[WQ9XM\;>%-
M!N-3^)/QK^+_ ,</'7@?X9'2OA]XXO-8&@ZA\6AX(\'ZAXBL_!\6J:%X1L-?
MURWL=8UJ_L[4C=N+EHO:T[JU_=6,A&::;LZ<L&YU).SESIP5MFYMI2Y%K[*I
M9MKXWA9RARZ74UB5&$5MRM2=])+[?G\76?['7[.#>)?BQXX^,_QDM_#WB+3=
M(T>ZU_1= \8_&36+_P"+OQ5L/!_P;^$?_%#:?I6C^(]8TG6O'?@GX367CKQ+
MJ'EW<%G%X[^+'Q$>'_A*O'(\EUG_ (*2_!+PSX,\1^+/%/@?XWZ'J'@;]L?X
M8?L,_$3P+#X%TOQ;XS\"?&[XP:I\)[;P&VK0_#_Q3XN\-ZYX0UG0_CC\*_%D
M.L>!O$OB[4I-+\76F@VVB7/Q!L]4\%V/K7[:7PT^//Q;_9U\1^"/V<_%F@>#
M_BK=^*/A/K47_"2^,_&OP\\.^,/!WA+XJ^"O%?Q1^%.K?$WX=:%X@^(7PZTW
MXN?#?1?%GPSNO'_@KPWJGBGPQ;>*9-7T>P%]!%)#^9__  [I_:>MO#_QJ\.Z
M#X<_9,\':/\ $7_@J/\ L+?\% _"/ASP5XZ^(7AKPOX0\$_L[:%^QM-\2/A
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M_LJ> YOB%\+]#UKX3:/IFK:+H=A^S3<WJ1>)]?\ "^I-=>.8$%C(GA9SXC]
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MC&%HTW3DVI.:7-&--N"?*G+EH.K&,O?2^+$2IIN4ERTZ<Y2G[U1?$7_!5?\
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MAX<\)ZQ/)J#7HL;&]^$/@5^PEXW_ &</CG^PC/X"U'P=XB^ ?['G_!.SQ_\
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M^(GAOPKX('@S4/!OBWP_XA;XE^+/!;6/BC18O#0276_$O@NQ\2XW@[_@J!\
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MMJ5M\2-$\5^+])M]2\*>#=0UI]5T3PI>?\)-KG@3P5XD^^?$7A'QQ=_ K6_
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MN2/-7A!N*M)QBOJ]?GU=1*K34(N4$L7]L_\ :N^'?P[^ G[9%]XDU?\ :/\
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M4<4Y<E)7DYPNFE&%575K2O/#2A*25[3E%5FX.4_9V=-2LN:MKT444RPHHHH
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MT_\ M'? C]JGPW^U[:?L_?M5?"O]F&;]B.#]G;]F?4_&.B?$#PEX,\)Q32_
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MY(M.L;.PBFF:XECLK:"UCEN'1(WGD2!(U>9DBC1I6!=DC12Q"*!<HH ****
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M]%>]KO97::5VKV=KV=GUMU?3KTZ;]5TZKNK]S17!WOQ3^&.F^']"\6:C\1O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^2[_@N?\
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MY^,]I:?LZ_M%MX8\>_\ !NQJ/[//@[X8W7[%7[1?AKPCX,^*7PEG^(5KX?\
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M!HWA72?".M^,?A5XI^(]CX&_L2UU;XGQZ5??-'Q%?]N2Q^%_Q"U[7O!WC/\
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MJ^(_%?P[DU>VLO$/AW4_%6KW\4=_I^KZAZ+^TI\$_B[_ ,+'_P""P&C?LK?
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MU[3H?%MQX8\*?&WP;:^(/#UA]/?$7X>?$CQO\:/^"JEQI7[/WC[P;XR^/?\
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MWB3PE\ OB-\2_P#@HW:>!_&/BI+;X7:5J_A7X+^)/AO\7OA%INF>(?$$.F^
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MJ%%U4FO>I4Y0:E!29RJ[>OO/$<UFDVJ]6K52;LT_8NM55)R3O&I*,TXNT?P
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MSQ:BH23]I'F>,::C&E'FDXTJ$:"U2;A'"4,'&3T<5-0P].=^5IS<TUR2LOP
MU#X3^ +?X??#_P"(W[)VH?M>?L:>.=?_ &I/VAOVH?A#\4OC-^S_ /'GXR>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%=-\/^/=+T'0=,U/QG8>&X_$]]],_L_?MC_M??M+Z]\!?BM\,/V?-'O/V/\
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MTBYMM6E^Z_$'_!/KX0^(/ _P\\&/XQ^*>F77@;]JK0_VT=9\<:=JG@B3QO\
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M>&?!!^'7Q6T[2O!OPV;POXV\4Z?XFT#6O$'AO0M0TS4/GR]^+GQ!_:R^(/\
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MR5WLY0=/*M"I.E4A&4+SISA)<LHIRES6E%W]VG:-/FIRO)NS]Z,91GYOX?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:7;0PZ>=*>U@%@ELEI'&L,,8'X!^#_@W^T-X2^(ND?'7_A3_ ,6+[P1\%O\
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M^)?#O@#P+K%UX[M="UC7/)U'P/\ $7Q';6VF^%]$NTTKBOB-^UMJ&G?M!?\
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M9-PG*T4_>C)<CE*,G)*-K3FIPD_<:***!A1110 4444 %%%% !1110 4444
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M_:BL=0U?X:?"+2="^(_CS]JO]D/5/''@N;2/@QJUG=?#;X967@_]O'Q#\/\
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M\!?#KX<?%W3O@%\$]7_8@_9)_;3O_!.I?!?0/&/Q*GN?B!\:O&]CX[^%6O\
MB;Q)KJ6NDVOBGP5X33P?JNJ:=X=M]:\*W-S+JGAYK?5K8W<WH7_!1RZ^(2?$
M[_@F3H'@KXQ?$;X6Z/\ $?\ ;YMOAWXZT_P)'\/Y;;Q7HH_9/_:F^*>AS:W#
MXY\!>-XKZ7PKXS^$_AS5M%TZ2,>'7N9;G4M8T35=<TKPAJ_A?9TIQG&G**C-
MU94G%M-Q=.O5P]1MQO%J-3#U4DI-RY4U[LE(Q]M!TYU(OFC"DJB=FE)3HTL1
M"*OJG*G7I-MJT>9IW<6C]1**_'[P5^T)^V'^T?\ $#Q;\1/@+XL^"WA#X7?
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M\0:OX-U/2-3\/7OAWPUX4UKP_JNJ>*O2_P!E7]I[]I/XK_';X(_#7QC\8?\
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M.C:AK^FZMXU^S1^T;^VK\0?V2?V-/V@OB=^U;X3O_$O[:&O?"GPW'\,O 7P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M $BP^*?Q+B\3?&G7(?AMX+\3>*/'6H^,;"366=X'_8#_ &5OAQI?[*6B>#?
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MK6]V,YQ6C2C.4;-2:;>K;>KDI*3>K:FXRDF][2E"$GJO>A&2Y7&+7PS\1O\
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M@\1@VEZ4JU6<='[\4W>,7%M:2YUTA"+3VY88NCBTW_W%IPBWMR2:W::_$/\
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M:6&'DOV>_P!I?]KF\M?V /BCX^_:5\4?$+3/CQ_P4B_;N_8=^(OPSO\ X:?
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M_P!F#1O#_P 2OV>?"VAZ'9?%+P=\!_&'@G]HV_M?"FC?'3Q!K?Q UWPWX?\
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M\,O&6F?$'5OVH/V8_P!I/]IFU\7?&WQ1%XAN]?\ 'D,W[)MY\.?AI\$?V?\
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M@U[.+=TY+F:M91M?W84X-<U[\LW[W,_>;4'>;E?VDHJUD^4^@J***104444
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M-'XZ?M]Z;<ZQ^PUX\^"'Q)URP^''BS_@H+\4/V1/VG/ R_#"YU_QNFN?#/\
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MP=XC^&=MXW\7>$?%WBGP1XTK?L[?L5?M.?"SP/\ L!>#?$GPU^'6C1?LJ?\
M!2/]N3]H_P 5VO@'XAZ??>'U^"GQ[L?V]O#WP['@VSO/"_@_9J%L_P"U_P"%
MKM?"1T_38=,\%>!];DFN-/\ $=WI7@LY7DU&T9)R>'4FVK14_9>VLNT%.;4I
M7LX237N.,[>D:CWE'VWLXK7G475]E)M;.2A"\5:_/&VLKQ_0[PE^W9^SWX[^
M%OP[^*/A/5O%^ICXJ_&#Q?\ L[^!OAQ=> ?%7ASXO:E^T%\/M2^(6D_$#X,:
MI\._%6G:%K7A'QEX#NOA/\2;OQI=>,E\/^$?#'ACP3K_ (^UKQ/9?#ZS_P"$
MJ:Q\-_VY/V>OBWX,;QCX UOQEJSM\7_%7[/-CX0U;X8?$/P1XZUCX^^!;SQ;
MI_CGX/Z'X;\?>&_"\VK^*_!%UX"\;R>-;ZPGG\(>#=#\'>*?&GBGQ/I'@7P]
MJ_B:S_&+XN_#[XN? /P[\*OAY>:+\%-#_:5^*'_!7#]L#]L/]F^Q\;?M/6GP
M(\1CX;^,=.^/?C>XU+X=?%,_"_XR>"++XMV'ASXL>'/A[\5?A/XX^%'Q:\%^
M+OAMXP^*6AZ#%J<XTGXD^#>F_P"&?/C/\<_V>_ &M_!S]FC]G!OCC^QS^W[\
M1OVA_'WP4^(_[0>G?M!_L_?MJ^(/C1\-_BG9_M&OJ/Q^TGX0>%K/PS\7/$=S
M^TMXMU;0[K6O@):>"?@I\4_!VC>!-%\#6GPDL-#MM&OHV[V]S6+YN33">U;M
M%NI[*5:I"I&-I1;IM*?)4C)7>UM;U+)NTI)2Q:I7NU&/MXTJ4Z<F^5Q]HI.'
M-3E'];/!_P"W?^SU\1O#NBZO\.M9\3>./$>L>/?BW\+I_A;H?A'5X_BSX<^(
M/[/VH7.F?'CPKXM\":Q'I6J>&]2^$]S:@:__ &F8;;Q!_:O@Z'X?7'C.Z^)'
MPV@\7_1OA7XC>&?&?PT\.?%K0/[>N_!_BOP+H_Q&T4/X3\4P>*+GPSKN@6WB
M;3=_@:72%\:0Z]-I=W!N\)R:"/%$>H,='?2!JRFRK\I_B5^R-XJ^-'P6^$_A
MWXO_ +&7@;X=ZC'XA\?_ !)TW3/V%/CQ;?"OXX?L6_$R\\*^'?!WPX\7?!'X
M^1:9^SG9>-_&-YI4GBZZ^*NL1Z7X,\.117^E?#]O"WQI\&^%VO\ QY^D/P T
M+XU>!_V<O@SX=_:!\5:9\6_V@O"'P<\!Z1\9/&/@ZUL],TSXC_%G0O!VF6GC
MG7_#<&H6OA+3K>W\4^*K;4KS3I+O3/"&G2"]CN)-&\+6KG3-/72=W:2DDOM)
MKV:;LENU44[J[BXRIJ%2352SN[Q:3<7>Z?NM6G*UV^DH.*323YE/FA%.#/CG
MX0_\%"OV>=(^#_[+=E>?&GXV_M.>,/C]^SWXD^-OPA\;6'[,WCO_ (6%^TAX
M*\ 7?A73_%7C#3? OPH^$/AKPAHOBAKKQUX/NKWX?V'A_P +:OX=T37K+Q%K
MWAW0_#=KJNMVOW)\%?C-\./VB_A%X ^.'P<\3)XJ^&OQ2\*Z=XO\%>(UT[4]
M*FO-(U:#S(/M^AZ[9:;KFAZO83"6QUGP]KVFZ=K>AZM:7NCZSI]EJ5G=6L7Y
M!?L9_L4?M+_  _\ !)]?'7@O0+H?L3?L1_M0_LY?&9O"_CK0]334?&WQ9U7]
MFB]\&WWP^_M)=#?Q%H#Q?L_:V=:N=>3PC=:7)XI\+""SU+9X@;1/NG_@FQ\$
M?B=^S?\ L7_!SX(_&+1]&T7XB> 4\<6NOVOASQ#%XI\/2_V]\1O%WB[3;G1]
M=2RTJ>]MGTKQ#917'VW1]*NH-2AOK<6LUK%;7]YI-1N[._N\VZ^+VT:;A[L8
MQ:]G>IS)1O9R2M)HSBY\R2B^13E'F::;@J<YPG:3<DY348M-OEYN1ZQ3/D#]
M@S_@IOX5\3^"?@Y\*_VH_B#XYU'X_?%G]H3]L+X,^"_B=JWP%\8>"_@GXZ\5
M?"C]J+]I#PI\,_@_8_&;P[X T;]GFS^+]W\&OA/#/I'P_3Q=#XLUX>&[I+Z.
M_P#&&IQ0ZQ]ZZ7^VY^SIJVC_  BUZV\5>(8M+^-_[0GQ%_93\ SWGPZ^(5E-
M-^T'\*?$'Q3\*^._AMXAL;CPQ'?^$;S1?$'P2^*FE_\ "1>)K72_!E]<>#[C
M^S_$ETFL>&WUG\^/A=^P=\;9_A!\"?V6_B=X?\.:'X8^ ?\ P4:\;_MNZK\8
M-(\3Z;KVD>-O#-O^U[\8OVQ/@]X8^&FD^3:>,]*\:S>)_&G@/P3\7$\;>&_#
M&@:-X;T_X@6_@WQ%X[&J:+=R\W8?L>_MFV>L?!/X?0?#3X0MX'^ 7_!8+X_?
MMP6WQ+OOC9J-L/'_ ,#OVAO'?[8OQ;\JP\(V?POU+6/#OCKP"W[3MIX*UC0=
M4EGL-<\5>%(6T75SX1\1W?C/PGG2N_8JI>*<:/.V[-^[EZJ2:L_9M>TQ?,G=
MRG1E42M*49;5K*I5]GK#FQ#C:-[6^O2HQC>2YXS=/"I.RY8UHQO?E<?U/\/?
MM2_"_P 4^,(?"F@0>-]6L[[QC\5?AUHWCK3/ _B'5?A[K7Q#^!M[XCTGXO>!
MK/Q1I=I>PVOB;P-KWA'Q1X<GL-9M]*7Q-XA\->*]%\"S>*K_ ,&^,(=!^6O@
MW_P4!_9[TKX0?LU:CK/QP^-OQ^N_VG/&/[0_A[X+^/=4_9B^(&D>-_B3JGP>
MU/XP^,?%/A&_\!?#+X+>%+#PEKG@KPE\-_$GACPEX9UOP?X9\>>-]+\'0:F^
MBZ]X@?Q)J@X#X;_LI_%KP3^VW)^T1\,? 6N_LV>'_%'Q,_:%UO\ :W\$^$/B
MWI/BG]G/]K[P?K.D>)M ^!GQ(\/?!F[O9(_A]^UI?:GH/P<\>?%'XF67AGX4
M":U@^)/@KQ-XL^,?_"2:?K^E^,?LZ?L1_M-_#;P__P $L],\8^"O#4%W^R%^
MU+^VQ\8_C,=$\?:1J]N/"W[0W@[]KCPI\/H_!4MS;:1)XFU&TN/VC_"U_P"+
MX-1@\-?V/:>&?&":.?$MS%X<A\1RG+W+IIM0C-VO:]>K&3BKVLJ:IS3:C*SD
MJD6HVD[)\SOHI3<(O1V6'C**D[7;=7G@U%RB_=<))N\?TT\!_MB_!+XF_"3P
M!\7_  7J'BK4-.^*'COQ=\)?!'@C5?!/B7PE\5-5^,OP^U?Q]X?^('P@O/AY
MXRT_P]K_ (=\>> M;^%7Q+L_&UKXFAT;1O"5AX#\5^*M?UO3_!>B7WB.'CO"
M_P"W_P#LZ>/?#VC:S\.]3\;_ ! UO4YOCU;ZC\,_"?P[\67WQ@\)W'[*_C#0
M_A_^TEI_BGX77.GV?C+3]>^#GC?Q1X6\+:[X3M=*O_%WB?6/%?A&U^&V@^-S
MXM\--JOYF^,OV"_VJE^"WP^\4^%?A+\#OB5\7O@)_P %+/VX/VQM-_9S^.7B
MW3YOA%^T%\#/VO/B;^U!XBN?AQJGBVR\,>,;'X?_ !?\/^"/VA=&N_#7BC5?
M#'B?PIX8^)W@>[M;E/$W@W6/[5?U?XT?L<_$3XU?"+X2V7B[]D7P3\'?BAHM
MG\:?&_PX\4?L+_'ZP^$_Q:_8?^,'B?1? /@[X?0^ ?C5)X5^"UO\1O"WCCP\
MGC#6/VBKU_!$WA6>[T'P;X'D^"/QX\/Z%IGB*>I.T9M<SDHTW%147K*C1J2Y
M8R<74?-.M35-SIM5**IU*M-U(U'G!R;@I)13E-2;;LDJM6$7)PYG"/+"E.4^
M6=Z=5SITY\C@?HA>_M>_!Z#6]&T;39?&/B==0?X&0ZUJGA'P3K_B33? ]S^T
MKX@L?#/P1M_&PTNUGU/1SXSU"_CN[^X@TV_L?A[X=%MXM^*-WX(\+:UX=UC6
M?6/B=\5O"GPHTSP_>^))+ZZU+QGXLTOP#X#\+Z+;1WOB/QSXZUNVU"^TKPIX
M<M+BXLK)K^?3M(UC5[V_U74-*T#0- T?6O$OB76-&\.:-JNJV?Y-^.OV.OVH
M?%WQ-^ WQ7CB'@O]M#X9V/[(_ASQK^W)\'?B(G@?X6_'[X<>#+[PEJ/[6_PR
M_:>_9RAU'2[?Q_X0\217?QCN_P!GC0$\!^+;CPUXS\5^$)-(\9? &TTS7_&%
M_P#=O[;/P8TGX^?"71/AOXI^ 5C^T3X'OOB-X8UGQIX3MO'\WPN^(GA73?#-
MKK.O:!\2O@EX\M=?\&7OAOXP>#/'MAX/N_"^IZ?X_P#A[J%M97&M36/C31KE
M(C.3TORN]JTH:-M2IJO**G3DXIVE22Y95*<6I-3G%TI*4"#;LI)J]*,KN-N6
MHZ46XSBI/55+N4:=22<+PA)5(-3X?7OV_/ =K\8/V1_A+X=\ ?%C5Y_VIO$?
M[0&D)K>I?#CQ=X>B\ P_LZ0:UH?C:R\1Z+JNEV_B6W\12_$.WTO2+.W.B'P]
M!X2M_$?C75_$>EZ4OA+_ (2S,@_X*C_L=SV7Q5UP^*OBE9^#/@C?^/\ P[\4
M/B+JO[.7[0NB_#GPKX_^'/Q3\/\ P6UKX23^-=8^&5AH5_\ &C5/B3XDT[P_
MX/\ @_I-U?\ Q'\:120:WX9\-ZEX?U30M4U;Y@\$?LE?MH^"?$O_  30\=^+
M/$*?M$:[^S!X[_;+\(>/=:^+'Q2LX/B[IWP"^/D^O:=^SWK/C_QS8>#+K1OB
MS\5/A)\*=#^''@3XT:KI-FE_XX\=#4_$VE:WXRB.I^+=6M:)^SK^W#X _8S_
M &TO OPGT?P[X2^/7Q+_ &VOCC^T/\*X!\4=.T<^*_@?\9/VKK3XS>*O L'Q
M!L?#7B(_!_XS^)/@E?\ CCX;Z5XFLM*UK3_AM\3-7\/^,/#/CN2/3H_$^BTH
MJTG*6TII?9;B\1@HQ=K3:4:-;$SDU&IR^QGI5]FXU9<I\UE%M/D[.R6'Q<IM
M:P3<J]*A!)RA=58N]/GO3^D_B[_P45^&_P ./AGXM\:Z-X#^)_BCQ3\.OVM?
MV?\ ]C;XI_#5?!NJ6_BSX7?%+]H'QO\ !'P_X=N?$L5I'J&FZYX=3PE\?OAS
MXZT+7? &J>+M"\=6_B?P]X?\*ZQ>:UJ=Q#IOK/Q<_;9^ 7P-T76?%?Q+USQ%
MX>\#>"9OA]!\7/'C^#_$-SX3^!DOQ3ETR#P/#\8M0@LFN/!<]V^N>'[WQ7;3
M6=W<_"KPOXC\.?$+XNP^ OAOK^D>+[S\NM6_8G_:MC\#_MT1^&?@?\,-"O/B
MK^WG_P $[?VW_A!X(M?CS-JMSXQT_P#9<N?V!=<^*?@#Q/XOU?X?6YTKXC^)
M[K]D_P =7<WCSQ+<:Y9^*/'WC>TO-:U:^LGU;QQ>]KXP_9&_:N\._MD?'+XE
M^'/V7_V(?VB/A9^VA=?"7Q_XC\9_&[Q%'#XX_8N^,'@OX%?#_P" 7Q"_LZPO
M_@;XIU7]I/X2:SX3^%/P]\5^ /">DZ[\&=5U'QW!XUT3Q'>?#O1/%47C:Q26
MJ3?Q.G:^EOW$)3A)KF5-2JQKI3FY*$O9IMKE]J<TVY/E:48R\V_W\TII/XY*
MDZ,N2'*Y1Y[+FYE3^Z_'_P#P4&_9H^&NO^(-(\1:]XWOM*\)?'/P1^R_XI\:
M>"_A7\1OB-X2T#]I'XD:=X2U3P+\%+RX^'_AOQ-K5SXN\10^._!^F1ZEI6AZ
MAX*TCQEXDT3X;>(O%>C_ !*U;3O"%S;LOVE?A?H7Q\_:XT+Q%\<?&4EO^S]\
M*?V=_%GC_P"%/B/X4WF@^%/A1:?$*X^-3Z#XO^'OC*'X>Z9XK^,FK?&G_A%)
M=!NO#N@^)/B39Z/XA^'FC^&O!^GZ1XM\2:[HNH_B9K?C/5F^.?[5?Q(\"?"#
MX$?';]EKP[_P4-M/BCXD^'G@3]NK3OA9XT\5?M1?LS3?"GX;75X_[+_BC]FF
M]\6Z_P#M)Z%\>/@S:W/@SX61?M#?#+X6?'OXH>&/A_XUT_P_JMOXVL_B5XY^
MT?VJOV!?CQ^T=\0O^"D]QX;NO!O@:U_:._9Z_8/\-?L\^,?%MS9^)_#;?&;]
MB7XO_&[XYV-M\7/!EK:WM_#\+O&?B_XA^!?#>IP6EEXGNM4\(Z;\0CJ>AVTG
M_"/Z3XES]ZU*;3Y7=R45)SC^XH3E>/-%-MSK2HK7F@J*YO:R<WNE%^UC>S22
MA>4>64O;5(KWE&5HI1IJK+:+=25G3@H'WDG[</P&AO/BSX>UO4/%7A7X@?!;
MQ/\ !/P=XW^&7B?PEJND^.%UW]ICQ+:>#?V<5\/VKI)H?B?2?C9XLOH?#'@[
MQ)H6O7OAO3_$MIXB\->-=6\)Z_X)\<Z;X:]#T?\ :)\(:UI/@G5K7PC\8U/C
M3XO>(/@A)IO_  IOXBWNJ>"O&_A9O&EOKE[\1[;2= U&+P/\.8-0\#:GI^G_
M !@UJXA^$WB!M8\%ZEX;\::QH/CSP?J^M?G3X>_9Y^+7Q7_9D^*O@K]I+_@F
MK^QSX%TOXD7_ ,*/"'C']F?X&_%73[^\^(/A7P[X^M]5\=?%C_A;VG?#/X)6
M?A3QQX1C-O\ $/\ 9L\):??0:YX6\:>%++4]3^-'@_Q+XHL=9^&?HWP/E_:E
M_8^^$?PB^'_C?2_'G[3</Q"_:[U#P)X>3XG?&S2/$O[17P-_9=^(FN7[>"-0
M\<^++K3-?N/VF?&?P<0P:O\ $T67B>[UGP[\*G\0:]=?$KXC1?"R]\1^,M(K
MWFI--IP2L[1J.4HI*,FKQ;B^:3DG%)33]G.#IRQ;D]DTKRO>/O1487NU=1DE
M-2A[LN9MPM[2,O:+]2Z***"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI:E?^(M3(OFBI;7=&UTU_'DZ5)MVY4I5X5*.^DH.6L)18Y^Y)Q=FTJCT:?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR:3XRLM"\.Z5IFB:/:^(K348=-TNPM+*S2&W@CC6K^TU^U1\/?V4M$^&6O\
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M8V'C*2Y?3=/G\8PZW-X334O";Z1JEU3U_P#;Y^#OAO5--O-2\-_$W_A4%_\
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M)]2\577PN@\=:_;?%F>^T^T\1:/X>N?!\.O#1HI/$7Q3T>?PYI?AC2[SQO\
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M:T*BF[1YVTIQGRRG^K\G[+O[-]U\-_$OP>U3X$_"?Q!\*_&L.FV_C7X>^*?
M?AOQ7X0\:6NBVFG:=H5IXPT+Q)IVJZ?XIL_#^EZ-HFD>'[37H-0MM!T;0M"T
M?2(K+3-%TNTM.NT3X-_"'PUX[U+XH^'/A9\.= ^)NL^%-$\!ZQ\1M&\$^&M+
M\>:MX&\,R2S>'/!FI^+[+3(/$-_X3\/S3SS:)X=N]1FT?29II9;"SMY)&8_
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MGZ7>W%I)%=_LG_LMW\K3WW[-OP%O)W^#6I?LYO-=?"'X?W$S?L]:Q;_9-6^
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M\(=-Y'P-_P $\OV\?@E\'/V1+_X*^./V8K7]H_\ 84^(G[1OA+P%I/C;Q/\
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M.%.E"4N=TXPBY/1R<<)@\/*5D_BG4PDJLKWO[:5VYQ<I_@S^P;^T3\(/VF/
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MLI-,TS2_'6JC31?^+=.T[3I9=/L;+7Y]0MK2RDDM+>*.!VC,>E?![X1Z%?\
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M\KA:3HJG25&W(DE%R23VFITY/F49I\BIZ-W][DE3NI+DC5<ZGM4^;F?Y\_\
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MV-X6F^"G[2?QB_:RLOB5^U5\2?CKX\_:-^%EMXDNCXVUS]E']G+XD?M!:?\
M'KP+;WEIIOPJL]:^&WB?5].^*,?@[QS\;/@U)<W_ /PE-WXLUW5-=]#TFSGO
M?BC_ ,$E/A)I7[<7QD_:2^%WQ)\:_P#!0SP+K/Q7\!?''XO^ ]/^-?@'P_\
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M:#J'CZT^,WB73=,\8?&/P;)\"/$7PRD_:.O] G^%_@3P%;>%/BU\.?BWX2^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPR^)E[KVA:)]L^#?C/XC^-?@Q\8O"WB/PQH'B?4[O5O#"_&#XF^$O&/PTO\
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M>= \(R:3K7C7QKXAU67PIHOA_0=>3PA96>K:O96GAS0-4M_#=BEAIMU!9O\
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MA5'^SIXO\#^,]/U>W\?_  F\*^,?B#XX^'6O:);>(O'6JI\\_LKZ5XU^/?Q
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MB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN]>\$_!SXF_':\\&:?\ !WP5\1M2L)'U&QUWQQ=?$CX<S3VN@:1XB'P^\/\
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M5^&>F_#?XF^&?#>@:U>>$)CXH\;^$38^*K]SX%\6^'_%G@OQ9X \4>+O#/Q
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M'J-%?#>O?\%"OV>O!>A^/=2^(G_"QO >M_"CX\_!7]F[XH^"+_X>:]XO\4^
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M/B.X\*4G[9'[5"?LE^!OA;XN_P"%>^)_B-<?%#]IO]F?]G2VT_PX+%(] ?\
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MQEXL7X>^,/#?Q'_8=T3XD>%/A#\0KRY;2]?T9/@_\3?#'Q1UB+XN)X?MM?\
MB#\-_$'AO2=<\"^ ?BY#XQUK2O"7UU\#_B?\&?B=^T;^UMX;\*_!5_ OQ?\
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MU+_@M%H7_!06W?\ X6-<?9U_9ZTC]H_PS\;GTF1SX.#+\:)M#\/S:*G@8(?
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MS7Q0K4Z\>RK4YX2I&:5]W+!4.9.\6E-67.[?-GP&\ _$[X6_LB_"'X6Z]8^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG:I*?)/F:DG9J:FVF2X74E?XE-6LN5J=2,^22T;@HJ<%%.+2<7%QM)/\IO\
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MTM--TRSM;.V5G=EA@0,S$$G:AMK>W55MX(8%2&&V188DB5+>W#BW@4(JA88
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MOA1XE&MVUKJOA&XT/3]6^&_Q?TGXJ?#;Q+'<^*O".N7MU^&5]>_![_A7>O\
MQ?E^+UY;_$?P9_P<<W'P5\*_$N/]HCQC;^,_"/PP^*/[8?A3X:?%OX<>'?%Z
M?$!=;\.^'O&?P.\2^)=*\8:/I6HV1O/">GZ)JUULC\!^$;_P[_7/;6UM96UO
M9V=O!:6EI!%;6MK;11P6UM;0(L4%O;P1*D4,$,2K'%%&JQQHJHBA0 )ZI/WX
MSLGRQHJUK)NG6PU6325U%3C0G!16D55:U@G"3225K)KFJNSU3]I2Q$$G=7?+
M*M"I=[NDF_>:G'^7_P 7?%CX _LW>%?^"HWPCC\0Q>'/V??AQ_P5A_8-\(:-
MX,\/?%32_!?P=^#FD_&GX:?L#^,/'MI\</$.K6/C+3OAG^QYXX^-UW\5(/VE
M/#,VC6?A;QM8^)?C!\.5?0-7\:^(=5L,GX5^']7^(?[,7[9GC'X(^(?#GQ8^
M+_\ P3=_X*=>//VDOV??AO\ #B:[T'PKXA^%'AWPU\*_BOXK^ /@+P!<:YXV
MF\,_!_\ :4\!Z]\64^!_AY=4U#X>/\1=8^'7Q<\(W=]:>$/#^IVO]1]R;9;:
MX:\,"V:P2FZ:Y,8MA;"-C.;@R_NA (MQE,G[L1[M_P N:^9?BM\+],_:L\'^
M#'\&_M%^,?#?P7\1_P!KM\1-*^"<WP;UWPG^TE\,_$VB2Z#JW@77_'WB#X?>
M//%GASP]J=J'LCXP^!GC3X;^/K33[K58M$\9Z7K T+7/#LMN]Z?+"HH48QE9
MN$)4O8>RJSA>\XQJ4)<\$U.=*K5HP<6TQ**MR3O*#G5G)7Y9SA/VW/2A+:$I
M0KJT[.,*E.E5FFKIX/[&=K9>*_AWX@_:3&D7>CZG^UUXL;X^6]IJ6GWFD:M9
M?#76/#^A>&?@+IFJ:%J<2:KX4UO_ (4?X:\!>(O'G@Z\=O[$^+?B;XD7&R*Z
MU2]#?A?^V%\:/AC\,?#'_!5GX4ZQ\3_#/@3XE^%O^"J'_!.KXV> ? +^+;?0
M_&OA;X+>+=+_ ."3NE>,?BUX5T"VO8-;\/?"KQ#XPN_C7H'B_P <:7;V7@^_
M\4:O\1?#NOZD^KZWKVGWO]1D44<,<<,,:10Q(L<44:JD<4:*%2.-% 5$10%1
M% 55 50  *:8(#(TIAB,KK"CR&-#(Z6TDDMNK.1N98)99985)(BDDD= K.Q-
M/E]O"K!.,:<O<@W>T%4P\X1D]G)+#13=K.56K-).R8E)TW&33E+6;2]USE2Q
M%*;2;NHWQ,I15[I4Z<9:<UOP>\8>*!X'_P""F.D^*HKWX)?M7^#?B1^UEX!^
M'D5AX8UZ^\._MO\ [!WQ5U/]D.RTNW\-0:"+K5-(^,_['&O^ -+O?C;XM\)Q
M+\/-4^&ES\;/&GQT33?B?IFFSZQH'B/_  35^(OP8^//Q<_9X\2_$?\ :'^+
M.E?\%/\ X-7/QP\%?MC?LRZ'HWA7PYXPO?%<VE:]IGQ//[3^G:=X'_X2OQ'^
MRWX;\6S>&_&'[,_BG7_%-OX \*:YJ?P?\%?#;6;>XU6#X?77])7V*R^V+J'V
M2U^WK;/9K??9XOMBVDDR7$EJMSL\X6TD\:3O '\IYD21E+J&$XBC61YA&@FD
M2..24(HD>.(R-$CN!N9(VFE:-6)5#+(5 +MF8+E26CLG:2NI)\RE&S;:Y;.<
M)WBY3IRC%RDZ<9R<KRYG?XN5-67*THRB[I*]U[DH6DE&I&4DHJK*,?QZ_;QL
M_A;XO_X*%?\ !+/X8_$_4_#T^C^-+3]NBSU+P3K7B6+1T\:Z)-\"_#\%]H&J
M:0NI6-QXG\+:PADT[Q#X;NH[W0?$>FR76B:_8:CI-W>V$_YN_!/XK>'YOV4/
M^"+4:?&1KRQT'_@L=\?O@'X8\[XOZCJ5IJOPH^&_B_\ X*%> ?A3X!U*2Z\4
M7,'C?2?"_@OPK\%=&\%PZ^VMW%E:P^"WT:5)-5L'O?ZJJ**:Y)1=[I5%4:VY
MFL33Q$>^L8QE23ULJDFM+Q:E%24^\Z;AJK\M\+4PS:M9M7E&K:_Q02?24?Y+
M/ ?B#X4>'M+^!OQQT_XK0/\ %/1/^#BS]I/X#^'/'VK_ !MUGQ%KUO\ "7QO
M^T]^T-X,UOX16M_X@\8ZH\G@OQA\-K_P_>:KX.):P\1QV7@GQ=>V=]?:'X5U
M2RT/BU\</V?_ !CX3\9Q_M%>.?"7A_\ ;^^#'_!<O]FA/&GA?X@^)(O#/Q6\
M$?L[^'_^"K/P&@^ .H:#H&ISZ3J]O^R/-^R%J7PI\7:%X@M],M_@?XG^(-WJ
M_P 3[VYOOC7J&N:_/_4]XN\:>#O &BMXE\=^+/#7@KPXNJ^'=";7_%VNZ7X;
MT1=;\7^(=+\(^$]';5=9NK*Q&J^*/%FN:)X7\.Z>9_M>M^(M8TK1=-AN=2U"
MTMINA$42RO.(HQ/)'%%),$42R10M*\,3R ;VCB>XG>)&)6-II60 R.63BY**
MNTHNG:RMR<BRV4O9NWNRJ/ 3YKO6GB9)IRC*=44;<]I.\XU%9VL_:2S%)S6\
ME!8]*-K>_AX.ZBU&E^"OA?Q/8>%?^"DOAV0:M\%/VI_!/Q?_ &J_C9X2\.?$
MGP1KMSX7_;*_8T^+O@[]GCXM1>/_ ()_'W0+,7Q^)?[*^F^&_#6H1?#_ %:^
MO/A\WP]USQG\([J[\*>.8;SX??$.]^6M&^,/PT\+_P#!.7]GSQKXH_:"\"VG
MP9\&_P#!9?\ ;$T;XG6GQ6^)VIW_ ,*?C+\*[']MG]NN;2/A1\9OC7JE]XGT
M?PSH-IX0N/!'QH\"ZC\8-0N/!/Q2\6_#KX3_  KUO58(_B]H>LI_2C\0?B)\
M*?A%I;^._BKXY^'OPPT66:P\/OXR^(/B;PWX*TN2XN9YY-+T1O$7B.^TRT>:
MXN9+E[#36O"\L\D[6\+2/(3Y+^T?^SIK/QWE^%FO>$/CY\7OV?/'GP;\8:MX
MT\&^*_A>OP\UW3-1O-=\'Z]X%U?2/'7@'XL>!?B'X&\6Z+=>'?$NJP6ET-$T
MKQAX?N+B:X\*>+M!%]JT>I2HN,J4D[NE&--^[%QLJU*LN:+;4^2%/EM)>UG&
MHISE4E34JENTN=/3GE*HDFU*[H5:#:DM8\TJBEH_90E3<81@JCC#^>634/V=
M3^S;^S9K7@S]JGX%?%'P5\6_^"Z_PUU/1A\!_P!H6R\5^#_@7X2\1_$#Q;KW
M@#]F;P=\0M!US1[[P[=_#CX<ZSH>K6_A3PO;>%+'X?VOC%/#WPWMW^'ND^#/
M$>J9WQ"M?V>](_9O_;:\":[-\)KC]GK]D+_@X0_85G\-Z/XSU+PMKWPS_9K^
M$?B+XS_\$Y/%?Q9-C-XKNM1T+X3_  U&O_%#]H>W\41I/H7A71=)\4_$[PK=
M)8^'Y?$.DK_3-\(_A"OPPMM;O]:\=>+?BQ\0O%LNFR^,_BEX]L_!&G^*O$D6
MB6TUGX?TI]-^'/@_P'X,T;P]X;M;J\@T+1M#\+Z?%')?:GJ^J3:OXDUK7-<U
M/U^2-)4>*5$DCD1HY(Y%#I(C@JZ.C JR,I*LK A@2""#3G!R7+SM+W+VZ^S>
M6^S3O9RY/[.^.5IR>(JR;NG*M,4ESOEMSIQ6R<4UCU*4;7Y7-8Y^ZFX1]C!6
M<6HT_B']N/4/!VG?\$Y/VL=6\.>(;'PIX(L/V.OC/J/A+Q)X*\3R^"-,T;1;
M7X/^(+GPE?>%/%'A74M%;0].ABCTPZ'=:'J5G;BU-M#:.;:18V_&SP;IG[/?
MQR_:(_93^'WQJ\<Z'XP^&/BS_@@+%XP\7^#-=^,VJV_@75;6P\;_  (-OXUU
M'PY!XRM?#JKI>GQ:WX@M?%0LHEM=6\/V7C(WYUWP3H&L:#_3G4%S<VUE;7%Y
M>7$%I:6D$MS=75S+'!;6UM!&TL]Q<3RLD4,$,2-)++(RQQQJSNRJ"0JD>:-7
MWW%3A-<S=G"^%Q^'YV^:.L7C%6OS12E06J;52G2_Y<KE5Z<XRM%?%^_P57D2
M:E[K^JR@E:3_ 'VS2E"I\(?\$P?'6J?%[_@F9^P'X[\3>,]1\?\ B;QO^Q7^
MS5J/CCQM=>);O6O$/B#QK>?!?PA%XZU+6_%$5]-JEQXN;Q4NLKXCOYK\:W!X
MCCU'[;-%JD,^S\9OV;OB/X9^$7[,7_!"_P"-_P 6/B5I_@#P)H7[8_[8/@?X
MH?&7XI?$$:)HEMX>\7_!'_@HSI?A'0/B7\2O&VN1)=Z;XH^*&F_#VSTE?&6M
MW,>M_$.#P='')<^*)=&\W^B[Q)'<_&OX<^#O$GP1^.\_A'2?$-YX ^(_A7XH
M_#"V^&?Q'\.?$#P(UWIOB:/28;GQ5X?\9^&]=^'?Q/\ #,@L+GQ%X-N=&\2M
MH6K1:SX'\;Z%?BTU.E^!?P,^'O[._P '? /P.^'.G7$/@?X=Z1!IFD+J\T.H
M:IJ%X-0FUO4O$>M726UK;7/B'7O$EW?^)]7N[2RL;5M<U"ZN-/L=/@\BU@J:
M<YSE+F7OT96EJY2IXBI6GS?"US1J3@[J[F]8N',F4VH4X1C:5HUE=;1C4P\:
M$$M[VE"$TD^7E6DE-*W\U/P]_:+\&>$K']G[2OC+XRT+1OV$/^'O7_!7SX=_
MM&ZWXWU>'2?A/X#UK1/C7^T:_P"QI\)/CO;^(9K71O!WP:O9M2MKKPOX4\:6
MFF>"]+\;>&O@I:SV]A%!HUM)C>%_BO\  /X>_LY>,O$*_&CX3^&?V=O"G_!?
M7X\OXW\)^./&4OA_X#?%?X1ZQIGQ2US1_ACX[^(3+J'@CP1\-[33[C0?C/\
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M0_B3X7\,^(E^$%QX7_90^%.I?&_5?B_\,_ FM^,M3UV/7OB7X%USX3:/X?\
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M &J]#^'MO/9^ M/_ &F_AUX+U#2/#WQ3M_"VG7=_H$"74&FKKW@K4M1^''C
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M_!)G_@GK&(XX=G[*WPF3R8F)BB*^'+53%$Q5&:*,@I$6169 NY5)('2^'O\
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MBYXTTS7(/!'CGX+:)K^O?%&QU;X=Z=J?AWQ=K,DWA'PK'H,#/](_$K_@G/\
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M*5G_  ?HSX4:Y\6?%_P3\!Z]\3?"GAWX4_'+7/AUH=UX]\&V>J0_$3PE\/\
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M,OC._P##_P  ;+5+G3[=]/\ $_C/Q5H%O/JM[X&L'NUUG[%H;Z?J/B^U@MM
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M$VOVBOA1J7[/_P )?VEOVEO^"$OCCXP>+?%OC+X5^-?B%\+_  ]JGQ ^*?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME!$4DL:2%6=0?CBZ_:H\7>(/C;XW^%'P8^!NI?%S2?@A\9_A7\&/VCO$D/Q
M\,^!M;^&M_\ %3X9^$OBW'XM\*>%_&%I9:3\3/#/P^\"?$GX:^*/B);VGC?P
MWXJ71?$6J6_P[\-_$;Q?X?/A#4_P=_8U^&GP;\!>&_\ @DG\3_"W@7P1X2^+
M5O\ \%2/^"B_P[\0^-;#PYINE>/M._9Q\8#_ (*GZCX6\#:MJS6<6OZ5\$_$
M'BSQ7^SSKGA;PU=RVO@6[\4>,/A3XAT2R;6?%/AF_P!0[;XI>!-1LM-_X+[7
M_P"R?\,],U#XU7'Q]^ NHZ'I?P=\):99?%OQ_P#LY0_LS_L+Q_M;^$/@U?\
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M/#;W,EN&\Y+>>:UNHH9F01RR6TZ(S-#(%_E%^'7PN^"'PZ\)?L'?$3X>^!?
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M4CL]4L?B!K>B:1^RK\*4_9"7]D/QB7M-:C\4?"#]MSPW\3/$WBRR^'FJV?\
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M"IK\493A'F4O=24H3DU9VY^7G@N1M4_#OA?^T;\+_B[\2?CU\+/!OBKPU?\
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M!^*7P'_8,\1:$GP[CDUGX=>,?VW=-^/7Q"M?B9XY^"<?A1I]#G\;67P#TO\
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ML[4I5(+WE1JODE=RYX+,DII*.MGA:4IP=E'G@DY*3C4_HDT/Q#X[OOB+X_\
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M ,%T?VN)?%PU+P#:^(_"_P /_@_\3_VJO^"A%MX%?6=*&B:G'H'P^\>1^/\
MX&OX=>XLK?0->M/%WPSU"U,]EJOAZZDWK*,,8\/!?NU4]GSN3E>"Q_U=3;2L
MY3ISARR5H2235.\[OFA*<L)&O+2I*FY^SY;6G]26(<%%OFY83C-.+]^+4DYM
M0L?T_P#Q1U[QSX6^'/C?Q)\,_ =I\4?B%H?AG5]4\&?#F^\86/P^L_&WB.SL
MY9]*\,W/CC4]-UG3O"D.KW21V;Z]?:5?VNFB7[3/:RQQLM=H;NV2Y@LY+BW2
M]N8+BYM[1IHQ<SV]H]M'=SP0%A+-!:R7MG'<3(ACA>ZMED*-/$&_+W_@M'H.
ME^+_ /@DY^WCH$OA^+Q!<:S^S%\1[?PCX>GT26_U'4/&TWA^4^ [+0M"DM)-
M0F\5-XE.E)X=L+2S.KKK0LX;2 7BH@^5OVFK[3;/]M_0/B7\/-5^"O[5VE^*
M?C9^P=X:^(O[)7Q*\.,G[0/@4V?C/PQJ?PW_ &L?V#_BSHIN-3UKX>_">T^)
M>G_&OXP_#[5]#U7X3IX<^'WQW\61?$_X:WFI_$6#7LX-RJNG_>A%/LYTIR2M
MHDN:#4I-R4':<G&GS..\TH48U>9.ZJ/E5[VA.FF]FW[L[P5HRG:4(J53EC+]
M\6=$ +LJ LB LP4%Y'5$4$D#<[LJ(O5G95 )(%(DD<J[HW210SH61E=0\3M'
M(F5)&Z.1'C=<Y1U9& 92!^2G_!6[P]X1\0^%OV&(?%&C:=JT>G_\%+/V.]2=
MKVS:YETOPY;^/)U\::I)<PJT^E^'(/#TES'XOU":6VT:/0IKB#Q!,--GECD_
M.G6/#B?"+PI^U]X'^"G@*STK]D'X6_\ !<?]G/Q1\=_A!\+?"Q3PGX=_8GU;
M]F_]DB^^,.M>&OAQX4L=@^!NC?M4IXE\=_'?2_"&C2>$M1\.>#_VC+?Q;I^I
M:%9_$K39%&?--0M9RJ2II_97+]2<IS>G+!1Q>C3^*DTY*,G*">B;Z1IQG;K+
MF6+2A#HY<V%UONJBLG))5/Z/_B1\6_AO\)/AOKWQ<^(?C#1/#/PZ\-Z7;:MJ
M/BF]O8FTYX-0N+6PT6VTUX6D?6-5\1ZKJ&FZ)X7T;2EN]4\3:]JNE:'H5I?Z
MKJ=C:3^BU_+5^V7\(]/U#X&?\%@?''PO\+Z1XM_8M\3:W^P-\9_AI9^$_#MG
MXK^%G_"Z_!/CC3->_;7^+WP@T31=,U+1KWPG)\+8/A1JGQ.\;> (+SPSJ?Q%
MT+XUG5+F7X@Z5\5=W[E_M'MX0U/]@#]H3_A57B+QG\-O ]]^R5\94\ ^,?V=
M_!U_<_$'P1X?G^$?B=?#WBWX$>!]!N?"=_JOB[0;,VVN_"W1/#^H:"^N:O;:
M%#H6JV*WMG?HW*U*K4LTZ:A+DFN1I/#UJK4DVVEST)*$G;FIRC)QC)M(BG*O
M3I7BXS32E'WE?ZQ2I+E>B;4*T7.'V9Q:4Y)IK[!MKRTO5F:SNK:[6WN9[.X:
MVGBG6"[M9#%<VLQB9Q%<V\H,<\#[989 4D56!%%O>V=W]I%K=VUR;.X>SNQ;
MSQ3&UNXDCDDM;D1LQ@N(XY8GD@EV2HDB,RA74G^4?X+#P%\6[?\ :=\=_LH^
M(O@M\/?VZ%_X)":W^SQ^S9\'?@%\//C#\+SK7QA^&G@CQ_\ V/\ ''P+XH_:
M"^ G[/$ECXET7Q!XX\ _#[PKH7A;2M6U;P)X-$<GCWQGK.CWWAW3?"7+?%"#
M]C?]HG]A+_@I'\8_V>[7]J'5_B1K?_!+WXG? GXI_"'XI?L]:5\#? GP]^*7
MAS2K_5?@C\%?&7P^T/\ 9[^"GA[X@?M;_#/XAZQXF\,?#F\\(_\ "Q]?\&:7
M<ZU;IJ^GZ1X_^&%WXHJM:DJKB_:>SA.>B:<HQJU:4)13][EER4W-V;HRKPI3
M7M(M3FG+G]G=<O/*G'5IVE*G1J2BVM.:/M*BBM%45&4X>Y).G_7,DT,K3)%+
M'(]O((;A$D5V@F:&*X6*95),4AMYX)Q&X5C#-%*!LD1C%!>V=S'-+;7=M<16
M\]S;7$D$\4L<%S9R/#=V\SQNRQ3VLT;Q7,3E9()$>.5592!_-?\ M ^!]0^'
MWQX_X*>Z-_P3\\*:=H?CKXN?\$B?@K\0-%L?@9#:Z+K?QL^.&F?%7]K:YU_Q
M'I?BO0K*[;QC^TSK_P *_%GAJ#3O'^HW.O?$F9O%?PUUW5]0NK2Z\-W<GA'Q
MVL_V-OC]_P $Z_\ @J/\:?V6[K]H3X@:G\2_V&KCX5>./"_Q"_9XTKX$> M+
M^,/P\L/$I^"OP_L_AKH/[/WP1T3QI^U9X/U/7;WP?<7_ ($M?B#XK\(>'_#_
M (!\*>)]:TW2;CX,0ZJY6@FW*R48MW5MZTZ/-N[4N:G).H_A;BIQ3DE)4Y.I
MR>[;FE&-[Z)2I4:V]E>:C63Y-&U"HXR]U\O]8EQJ%A:+ UU?6ELMU=QZ?;-<
M7,,*W%_-(T,5C TCJ)KR65'BCMHRTSR*R*A8$5\RZE^TTNG_ +9.B_LA?\*[
MUJ:[US]E_P <?M*V/Q#77=#32[R+P1\3_A[\-+KP)8^'VD.I'5)[CX@V.JRZ
MWJMUH^EP1PPV=JFHF>\NM*_#+_@H_P##S]E3PMJOQ+^"GPA_9X\(>%9OC)_P
M3(_;R^)?@+QUX,^&GB#QWX,^/GC?XFZ?X//C7PE\%O /@?2]0^'_ (N_:I\6
MS^"/AU\5OBO^T#XBLO%OQ3M?A7X=T1X=+\3Z'KOB3QW\+/J3]GCXAV'B_P#;
MR_8<\>:EXBO-3CUO_@B]XNNM6\6^(1JMN-1U[6OB[^RUXH,NJZSKT%L9-9\0
MZ3X:\6>+K)+^X&HZ_P"']#UWQ58I>Z+I]]J44QM)QN[*]2,KI+58?'ZJ\KQY
M*^$32FDW&<%-)O\ >:*UIWM?V:G!*5]?;8&R>BYN:CBY?#UA)QNH^Y^F?[&_
M[2=M^UY^S;\-?VB;3P5J7PZM_B-%XIFC\%:QJ]AKVJZ!_P (UXV\2^#'MM0U
M;2H8=,NKN>3PX][.+#S[.VDN3:6][J$4*7UQ].5_+A\*?AI9Z+_P2U_8<_;Y
M\)^ K?Q+\<O^"9GQ#^,WQXGTS_A%;"X^(.N_L]7WQ+^,'AK]KKX2:7:Z^NG:
MI;>(->_9U\5^(/B=\-=#,ME+K7Q<\!?"&YMW%A?">?\ ?[]E7X4W'PK^$R/X
M@\-:)X8^)OQ5\7>-/CO\:;'1+71PJ?%SXQ^(+SQMXMT>ZUC1[> >+(_ ?]IV
M'PO\/>*-2>[U;5/!G@;PPMY>3?9XMC?P\VB:A3YHZ_%/#X2JN6^Z?M,0Y=:<
MH>S>KB3)I5)0B^9*=91>GP4\1C*6K5TVE2P_*UI4C4]HMG?,_99_::@_:;LO
MCQ>1> ]5^'\GP._:9^+G[-MY8:SK>DZW=Z]??":[TFSNO%J-HH>PTRSU^35#
M/8:0+[4[FSLXX6OKN.]FN+"R^GS-"'$9FB$C2&$(9$#F40_:#$%SN,@@!G*
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MXQ^'HK_]G#X0?\%0?^"P/PS^-%M\7_A_>?#_ .%7@OX?^)]3_P""B/AWX,^
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ME_0%^RS\>+#]I[]F?]G?]H[3] E\(V_[0'P$^#WQWMO!EUJL&LZAX5T_XO>
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MU*?*U9N+C4IQ]K3:=W3=VO=DUX+\*_VKE^)_[6/[3O[*47P[U#0M8_9;\/\
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MOQAII3Q/K&M>%;[Q-XN^P_VY]?\ BWI?QU_X)E:!\-OBM??#S0OB7^V;XV\
M_$#1;?P]8:YIWC/2;']AS]L'XL:'#KZW-Y8W5QI^A^*/A9H]_::1;W5M9SZQ
M)8ZW?&[G\/:9;LKK]W:S]I4A35F_==3V,DY)I.WLZ]*:M=M32TDI**<N6,Y6
M=H4Y5/\ $H.I%I--Z\]*<'>R35]8M-_>'A'XB?#_ ,?S>+;?P'XZ\'>-KCP!
MXNO?A_X[@\(^)]%\23>"?'FFZ7H^N:CX)\71Z-?7K^&_%UAHOB+P_K%[X;UD
M66LVNEZYH^H3V26FIV4T_8U_.AH_Q9^-G[-WQ _X*+?&7X5^)?AYI_P^TO\
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M^FZQK^B:9>7D-[JMA!/^'WP]_P""IGCWQ?XW_9\UK-IJ/P>_:6_X)X:M\5_
MFBV?@RUT[X@V7_!0/PGH^@>(-?\ V1K[Q5+X@U'PXGQ)U7P?J&LZII7PANO!
M\'B?1O%'A?5'N_$NN:)K_AWP[;?8T7Q5_: TO]O+X-?LN>+/%/PIU:T\6?\
M!.7XW_%K6_'_ (=^$^H:)XNM/CK\//C)^S+\/-5UW1+C5_B!XELK7X5ZPWQ-
MOM:TKX8RV$FI6%UI&G+XA\>>+VBM9K%S7*[1Y9>_5A[K4HSE16(YHPDFHZJ@
MIPG_  YTZM":;5:+A,)*=]U:$)M2T<5-T4G*.K34JKIR@O?C4I5H.SI24_O;
M5OB)\/\ 0/%_A/X?:[XZ\':+X]\?1:U-X%\#ZMXGT33O%_C2'PU8/JGB*;PG
MX:O+Z'6?$<>@:8CZCK<FCV5XNEV"-=WQ@MU,@3QE\1?A]\.8_#,OQ!\=^#?
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MU9M7C?E<HR-U;I=.WFMG\KW2=TG:5N9*2****8!1110 4444 %%%% !1110
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M_!?P//JWQHUW_A1GQGT#]HOPWXY\:?&[XC_$'XJ^+?CGX8T"Z\*Z'\2/BO\
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ME.FO2$5>T4BFVVVW=MW;ZM^_J]-?XE3RO.3M>384444Q!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !117PY\2_P!K#XA>%OVO?"'[(/@7X+>&O&GB?QM^SO\ $/\ :2T3
MQ9XA^+UWX'T8^$OA9X^^&/PX\7>'KJRM/A9XTO(/%LVO_%OPE-X9@WOH.JZ6
MFLW.K:_X=N+""SODY).*;LY-J.C=VHSFUHG]FG-_]NM:MI2.C?2*3;[)RA!?
M?*I!>LETNU]QT5\O_LC?M7^ /VQ?@/I'QY\$:-XK\$Z9-XB^(?@CQ;X,^(EM
MHNG>,/A[X_\ A+XW\0_#GXC^#_%!\/ZYXC\,2WGAKQ;X6UBS.J^'_$>M:!J=
MC';:KINJ7%G=1N,G]IO]JO3O@-\$?"GQS\&Z!H?QE\+^)OC=^S3\(A-HGCVR
MTG2ET_\ :._:(^&W[.MGXQTCQ!IVA^+K+7E\*>(/B7INM7.BP16J:O9:=J%F
MFM:;<".0TDW*,8^\YNDH<K34O;.FJ4DTW%PJ*M3E&:?(X34U+ENU/,DI2;LH
M^TYKW3C[+VGM4TTFI0=*I&4;<RE!PMS63^MJ*QKWQ'X>TW6-%\.ZCKVC6'B#
MQ(NI/X=T.]U2QM=8U]-&MTN]7;1=,GGCO=572K66.YU)K&"<6-O(DUT8HW5C
M''XH\-3>([CP?%XAT*7Q;9Z5#KUWX6CU?3W\1VNAW%R;.WUFXT-;@ZG#I4]X
MK6D.HRVJ6<MRK0),THV5-U^?X;_=U[=;%?U]^WW]._2YNT5@V7BGPQJ>MZQX
M:TWQ'H.H>(_#WV;^W] LM7T^[UO0_MEK:WMI_;&E07$E]IGVJRO;*[MOML$'
MGVMW:W$6Z*XB=Y='\1^'O$1U9?#^O:-KK:#K-YX=UU='U2QU,Z+X@TY87U#0
MM6%E/.=.UFQ2XMVO-,O/)O;59X6G@02H6>_W7^7?T\]O,/\ .WS[>OEOY&S1
M6-K/B/P]X<&EMXAU[1M!76]9L?#NBG6=4L=+&K^(-4,@TS0M,-]/ -0UC43#
M*+'3+3SKV[,4@MX)-C8^<?VAOVF[+X+^,/@=\)?#^B:#XM^,W[1OB3QYX8^%
MWAGQ5XSG^'O@Z*7X>?"?QO\ %;7]?\=^-;+PGX\U?PWX62U\'6WA:*]T+P+X
MQUF7Q)XJT-8?#\VE0:YJ>DIM:;MM\J25VY6;LN[M&3M=.R;[7--;M*RNVVDD
MKI7;>RO**OW:6^WU/17SV_Q&^.DO[/'AWXDI\!_#WAKXYW_ASP-J_BOX#_$3
MXV:'H7A[P/JNJ:GH4/Q'T74_C=X,\)_$?0=3A\ Z-=>(]6T?6M(\*W-CXUGT
M/3M-D3PJNNS7VB>V7WB+0-,NK6QU'7-'T^]OKZRTRRL[[4[*TNKS4M2BO9]/
MT^UMYYXY;B^OX--U&:RM(4>XNHK"]D@C=+6=HWU:T=G;1IW=E*ZMNK->\M+Z
M;W25U9/575]5:VKC9WV=T]'K975UJ]BBOA[X^_M=>*? ?Q5U+]GGX!_"+1?C
MY^T/I?P"US]HH_#3Q!\7-,^"UCK'A/2O&NB^"]'\'Z#XRU7PEXSTM_B5X^OK
MKQ&O@C3/$-KX:\$B[\-!/'?Q \!Z+K%GX@C^PM&\4^'=?N]8TW1]<T?4=6\-
MW-M8>)]'L-7TS4=4\,:E=6D=]#IGB"TTZ\NWTK4'M)8[A+:Z*-- RSP&6!TE
M9)W5^EVD^]G*,FENXJ491<EHI*SM>+D75VNJM?K:ZC))O9-QE&2BW=Q::5K\
MN_16&OB?PV\U];IXAT-Y],A%SJ,"ZM8--I]N=3U+11/?1"X+VD)UG1]7TD2S
MB-#J>E:E8;OM5C<Q15_^$R\("/SCXK\-B'_A)/\ A#?-_MS2_+_X2_[5]A_X
M13?]JV_\))]M_P!#_L//]J?:O]'^R^=\E/\ K9]=/Z_X*'_7Z_D=)16'J/B?
MPUH^JZ%H.K>(=#TO7/%,M]!X9T;4=6L+'5?$<^F6PO-3AT+3KFXBO-7ETZS9
M;N^CT^&X>TMF$]P(XB'KR^/XZ>#/$_BSXT_"OX6:WX5\??&CX)>'=!O_ !5X
M /BB+2;72/%'C70=8U_P+X/\7>(+#3O$<_A+4-;L-/T[5M4630-6U7P_X6\3
M>&O$\N@WUEKFD1:@FTDWJ[1G*R3E)J"3E:*U;2<=$KWE!;RC<ZI72O*,4VTE
MS3;44V]%>TK-V5HR>T7;VRBO./#?CY1X"^''B3XG3>"?A]XG\<:5X-M[W0;'
MQ_8^)O#$'C_Q1I%M=S>"_!?CG4-*\(?\+ B34VO;#PUK%KX;T.^\6V-I%JUO
MX<TTW+:?;==K/B/P]X=MYKKQ!KNC:%:V]C=ZI/<ZSJECI=O#IEA+907VHS37
ML\$<5C93ZCI\%W=NPM[:6_LHYI$>Z@5V]&T[:-Q=FI*Z;3M):-:736C3BUI*
M-TFFD]=4FDU9V:NKIZKS3V::>J=MFBBO&_AA^T'\&/C)\-;OXQ?#GXB^%?$G
MPMLM7^(6D3^/K36+!?"F[X7^-_%'P^\7ZK%KLEPNF3>'+7Q'X-U\:?XDBN7T
M/6-)M8M<TN^NM)N[:\E+K7R5WY+:[[*^B;LKZ7OH/LNK=DN[M>R[NVME=VUM
M;4]DHJI87]CJEC9ZGIE[::CINHVEO?Z?J%A<0WEC?V-Y"EQ:7ME=V[R075I=
M6\D<]O<0220SPR))$[(RL?@W]J#]O_X>? OX&?M1_%GX:V.A?'CQ-^R1XH\+
M^"OBM\.=*\<VWA.?2/%?B$?#?4+S0;SQ$-!\5+::GX=\+_%/PGXCU>WBT2^,
M*7HT9FCUM)[*!7U4?M2:275MSITUZ+GK4TVU:/.G*RN)M1BY-VC%.3?2T85*
MCVW?)1J-):OD=KNQ]^T5FZ=K.D:P=0&DZKINJ'2=2N-&U4:=?6M\=,U>S6)[
MO2M0%M+*;+4K5)X'N+&Y\NZ@6:)I8E$B%JWA[Q-X<\6Z<-8\*^(-$\3:2;J]
ML1JGA_5;#6=.-]IMU+8ZC9B]TVXN;;[5I][!/9WMOYOG6MU#+;SI'+&Z!_\
M#_+OZ>>WF/\ X;Y]O4VZ*Q=1\2>'=(N(+35M>T73+JZN])L+:VU'5+&RN+B^
MU^YNK+0K*"&YGBDFN]:O+&]M-)MXU:;4;FSNH+-)I;>9$LV.KZ3J<^J6NFZI
MIVH7.B7PTO6K:QO;:[GTC4VL[345T[5(8)9)+"^;3[^QOQ:7:Q7!L[VTNA'Y
M%S"[JZ_7\O\ -/T:>S39_7Y_Y/[GV=M&BL71/$GAWQ*FI2>'-?T77X]&U>^\
M/ZO)HFJ6.JII6O:6R)J>B:DUC/.MCJ^G/)&M]IMT8KVT:1%N(8RR@_+'@?\
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M+'^U/\%_A]_9O_!7SXA:+\&[2?XIZ3_P4N_84^*/P"\4>'OA?J5_X]M;G0_
M7_!-V?XB?$3X(W&B^'[G77N+7XC_  V^,-Q\3O%OPY62>?6/ GCR?QY?S1>&
M=6>R]7^/G@SQK\0/AE_P60^"?CC0]<UC]L/XK_&K2/BS_P $\/$.B:?K%IX@
M\9V>E_ _X,6_["GB_P#9W\?0V=E;V%O^S;\?/"_B'4OBA?>#M9@T[]G_ %P>
M/OCK\5+CPIX6^*5_XY\4_P!(M%9J*2C%WM&%.&CY&O9QHI3@XJ].HW1B^>-V
MDW%7:@U2CRN34FVY5)>_[Z_>5*U1QFF[3BE6E&SW48O2\T_RA^%^AZ/X/_X*
M\_M.W/BWP9*GBGXJ_L1_L-W?P]\=6/PMUV30_$NL?#'XA?MVV'QJO;7QWIV@
MZCH'AJ]T6T\:?##3_$=KKWB?3]1DM/%GP_T=CJ']K>'X+G;^*/A[PJG_  5L
M_9X\8:EX9TS^S[G_ ()R_MN_#WX@^,KSPVC:/+'K/QX_8A\6>!/ _C/Q7+8'
M2F&H>'/!OQK\1>&?#&N:EF71]!^(6J:?8_8X=9F;]0ZX'Q/\4_AUX,\9?#7X
M>^*O&.A:#XW^,>J^)-#^%WA?4KU(-8\=:MX/\*:IXY\46'AVT(+W]QH7A#1-
M6\0ZDJ8%MIMC/.YX4&733]G=I\M6K444DHRE5EC9\D8+2$%]:FE"*:Y*2BER
MW4:VC-*_O4Z47)MN25)81*<I;RD_JT&YRL^:HY-\UK_RU?L<_LV_"2V^&W_!
M!L^(/V>M TWQ.OCC]J?P)^T,GB?X.76E:Y9_#*__ &=/VE=/\-^ _CU%X@\,
MVM_IO@*^^)UG\"]/\%>#OB@EMX=O/%%A\+++PCI<MU8^%8H>KT[X4^#I_@9^
MQS\/;SX36LG@KX;?\'!?[6ESX?\ !D/PSO?^$9\!?LR^+?V@/VV]7\-:KIFA
MV7A\:9X8_9P\1_#WQ]\/6M]=@M[+X0ZKX,\9>%]-N;^?0M=L;.Y_IG^&OQ8^
M&7QDT&_\4_"?Q[X4^(_AC3/$_B;P7>^(_!>MV'B+0HO%?@O6+GP]XMT%-7TN
M:YL)]1\.:]97NBZS!;W$IL-5LKS3[@I=VL\4:>*?BS\,O!'C+X:_#OQ=X]\*
M>'?'OQCU?7M"^%7@S5M;L+/Q1\0=5\*^%M7\;>)K7PGH<LPU+6O^$>\)Z%JN
MO:W/96\MMI6GVOFWTT!GMEFWC4<;<RC)3G1G%233;4\+6CJVW+VOL&]O>6)J
M22ESN56)Q4^5IJ/LX5H/E6EI1Q-.3E:UG3=:*U^'ZO3@W'EBJ7\R/BSX"?"G
MPM\+/VX];\%_ OPUHGB?X8?\%R_V.?'?[-]YH/PD2W\2^ _A/#\:O^"='C3X
MP^,?@#%:>&AK6@?"^:XT;]J'Q1XWU_X80P>#-1.G?'#5]2NKI(?&TX]L\/R>
M&O%W[8OQ>_9V_:ZT3]L&Z^-UE_P4)T#]J;]EN+X=? J;6?@[\2?AUHM_X-U+
MX#_&'0_VG_#/P(U > /#?P8^'KGX0_&S2_%OQ^\+6\OAO0_%WP]@TWQ/!X_D
M\ ZK_0#\1?BW\,/A%;>$[SXH>/\ PEX!@\>?$#P7\*?!#>*M<T_1G\8?$OXB
M:Y:^'/ _@3PS#>SQ3ZYXJ\3:S>0V>E:+ID=S?3@7%T85L[2[N(/0\Y_E4QG9
M4X/EE[+E3>S;A2PBC*_-)PFIX2C4YG=M2G%IIPG%U(<\JDO@59.T4O=2<L0I
M)*R4HN.(JP<5RI349)I\\7_*1::W?:U\.?V=?AC\9OA#\5M7_;F^"?\ P6^T
M?XP_'[4+3]GCXO\ BK5FT/Q1^U?\2[OPM\<=!\?:)\/]2L-?^#>I_LR7_@'P
MEX"\1V&M7F@^%_A+X*TWX:V9T_P]\)'T_P .^^?%27PC\,['_@LEJ&J_ N^\
M:_#[Q3_P4G_88\9OI^F^#/B*_@O3?#\WPH_X)Z:!X\_:;\0^%_A5_87B_P",
MGPK^!?Q@\$_$;XC?'+P5X'U+R_BE??"_XB_#'Q]KWAW3->\9>(M(_H[HJ87A
M%)2]Y*/O62:<89;!N-M(.:RV$Y<MOWM:I4C9QI<JG!3GS.Z5VU&^EKY@TG?X
MN5YA-)N]X4H1DFI5.;^3OQ)H:3?#C]K#5?$/@?XE>(_"GP__ .#@G]B?]HW6
M]5\8?L\^,O#KP?!#Q;;_ +"GB+XA_$W2?!1^&NA9\(ZCK$?Q$USQ>OAS0+[5
MDT^\U'Q-\0I=2OO$6I>)M>]K^)\'@SQC^UC^U-^SA^U9X?\ VWH9?C/^T)^S
M!\>?V$]-^"WP \02>!OB1X*^%OP?^ VH_"C2/!7Q_P! ^!_B;Q;^RWXN_9S_
M &AO 'Q UGXDZ;\1/BO^SYX-^'$?CO4OB!K!B\,?$CXE:K?_ -+->;GXP_"H
M?%N'X"#XA^#I/C7/\/\ 4/BL/A5#K^G3>/8?AKI?B#1O"MWXZO/#$,[ZK8>%
MCXD\0:7H=IK-];6]EJ.IS3VFG2W4MAJ"VI"\'&S;Y6FOYOW='#04E:Z4X?4Z
M,XS46H1]K'E<91E"I+FYV[)S5FTE;WJE>3B[ZN$_K56$HMQ<Y.G+F4E*,_R*
MM/V6_ G[97B3_@N;^S+\5M/O;+PA^T%^T'\*CX4\4W7AR2X;3KG2?^"?G['G
M@7P]\8OAO<:S:Q:+X@UOX/?'3X9ZT=,U+3+J]M=!^)GPWNM%U9[:_P!.NK0?
M2'_!.J\^+'QI\-ZY^U9^TQ\/-)\!_M%ZQH>D?LM>)]+L(;![6S_X97\3>,_!
M'Q<U7P[-#-J,D/A+X@_M37/QV\3^![NTU5K3Q7\%K/X(ZW?:?9ZM!/$GVG\;
M?A);?&[P!=^ +OXA?%KX7PW>M^%]:/B[X)?$#5OAGX_M_P#A&/$6F^(3I-IX
MKT8-?6^B>(ETYM \46"+C5?#NHZEIZR6TL\5W!V?@KP;X:^'7@_PMX!\&:6F
MB^$O!7A[1O"OAG2$N;R]&FZ#H&GV^EZ59&]U*YO-2OGM[*VACDO=1O+O4+R1
M7N;VZN+J669[YV[WLO<I02764(2IRK+^5RI2]@XMRO'WKV443R)-6UO.K.3V
MLISC.-+^\HU(^V4G:ST2NY,_ ?\ ;9^!?PE^(G[4G_!5.\\<_!?PQX[M/$7_
M  2#^"=AX<N=9^&B^*;/Q+\=/#7B']O^RN+/PU(VA7]KXB^-^@^$O'GP9TW3
M(-&-]\2],T'QAX%TW1$AL==TVWN>!\"_"OQ98?%KX%ZO^S+X8A^'GQ_^,'_!
M!C]I'PSK_P 3(O#=WX5U/Q'^V)JFN?LK:Y\&Y/CIXWOM/L[S6/C3IWBH?&[Q
M9$GQ*U2Z^(MF\7Q>UR\CCD?Q;<O_ $NU6O;VSTVSNM0U&[MK"PL;:>\OKZ]G
MBM;.SL[6)Y[FZNKF=XX;>VMX(WFGGF=(H8D>21U121$[2I*FVH)4G2E.'NR<
M'3S.G)W35FXYBY-MM.6&I2=TWR:TY.G)R2C-NI[2*J+GM)SR^:5M6U%X%**2
M37MZEK.W/_+S\)_%/P+^(O[+OQX^,NB_LV?M[?%G]H7X/_\ !+WXN?LV_'C]
ME_QQ\&_%?[+ATS0X/"^F:I?_ +(5KX_\ _ #X.?\+&^(EYXJ37Y?ACXM^%EW
M\7/''PU\+:KX_P#%7AV7P]K_ ,1-,\-_$'Y[_:)T?2OB#X2_X*@V^B>%_&7Q
M,\._%/\ 9V_X(V_$/X4ZEX;_ &5/BM\+_!7C'7/A]\=/B=X8\0^(_@9X*O/!
MMSXELF\(>"-%\'0:+<W?BCQQ\4='\#^%1,?'&K>%/AZMWX:_K7^&/Q1^'/QI
M\">'?BA\)/&WAKXC_#CQ?:SZAX3\<^#=7L]?\*^)]-@O;K3FU3P_KFG2SZ?K
M&ERW=G<I::GI\]Q87T<8N;*XGMI(IG\_C_:F_9SG\ :M\5;3XU?#G4?AKH7Q
M0TSX*:OX\TGQ/IVK^$K'XKZQ\1]!^$%CX"FU[3);O3O^$B;XH^)M$\!7-DD[
M_P!G^*;W^R+][:ZMKM+>FY.K*=G&3G&<J<$X1C.5>E4ERP2YH1G7=-4XN[@Z
MBIP<G."ECRP5)PYKQ=.5)5)23G[.-"I2BW-OEE.%%3<YV2FH<\DE&3/A#]CW
MP+X&^&__  4A_P""B6D?"?P/H7P_^%/BOX+_ +!OBK0[+P-X2@\'_#3Q7\1;
M&V_::T?XG>(?"PT?3=-\)>)O%&G>%'^".E?$'5/#C:A?:;83?#JP\33V[3:'
M _G'[0NGZ!X/_P""I/C#QOXH\$ZI%9^/O^"5GCCPUX$\<VOPR\2>(=,U'X@>
M!_BMXLU3Q9I$7C'0O#6JZ?I'B;2/ WB30/,MM3U33M0O-'UK3]/TY;U;E;6O
MVRHK&5/GI>S<W;V->AS63:A6P^-P^EV[.G#&-PU2_<PC:,6U'5.TG*VKK4:[
M5]'.E7PM>ST5XSEAK2O=VJ2;E*2O+^:G]AWX2Q?#CQ-_P2,U'X8_#S0OA?\
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MM-\&_$+X>_\ !7G]MCPMJ/B32_AE-HGQ"^'_ .R=K-[_ ,%//"WPLT#6+]=
M@\7>#/V=KGP5X[_9TT?PCIVJMI?PUM_#GBSX0QV,=OI^K>%&E_JEHK>$W"<9
M*S493?+)WNI5_;*+>B7+&])6@ERRE913=.425Z;IVBN:,%S<NJ<:,Z3<5=6Y
MG)5&N9^]"%W)Q4U_,#\*/$FG^*_VS?V%O$VE_!7XH_":QT+_ (*!?\%4_A[\
M3OAE/\$_C#KL?@2\^,GA+X_Z[-J7QG^.'B;POXB'C75_VD/%F@>%?CU!9:)X
MNTCX*>!OAWK/PU\'Z?H&JZ%\)?"_Q+U;C_A]X+\-6_\ P3>_8U\#3_"G4]*^
M*GP*_P""R'P)U7QUI>I?!OQ+H>O> +OP5_P5 U?Q5XR\72WU_P"$;*.WT7P?
M\#I+_6O$WCO3;R;PYX>^&EX+O5-<L_#NI6S7/]5U<#\+?BE\._C9\/?"/Q8^
M$WC#0OB!\-_'NC6WB'P=XS\-7J:AH7B+1;LN+?4=,O$ 6>VD:.1 VU65T='5
M71E&48N,8I-OD5*\FM+T\3AL0GH[14YX:<>6]K5;1?[F,9.33GSV47>MRI?]
M/,/B*,KWUE*,:\)\RUO3=U:K)Q_GH^)?@SXG^-O@?^V%\"KKPSKVC?\ !1BV
M_P""IL?QK_9S\8:MX>DO/%VI>#=1_:E\ ZU^S3^T?\.O%?V&X74O@E\)/V-]
M0TCX'?%?Q'X>O[C3?!7@7P%\5?@-XYV:E=ZMX5USR#]MKX)>!]:?_@OSXNL?
M@I'KOQ0^T_LJ>,?V>/$&D?"?5]<\9:A\6/#OP-^&?VCQ9\ [S2_#EYJ>M_$#
M1/B=X:TVU\6>(?A>U]XBT[Q5X7T_3_%][#>>&K.VT_\ IP\<_%SX7?#/5?A_
MH/Q!^('A'P;KOQ7\7V_@#X8Z'XBU[3],UGX@^-;JSNM1C\,>#=*N9TO_ !'K
M,>F6-]JMU9:5;W4MCI-C>ZI>BWT^TN+F/T2M$VDFM&N1*2NESTJ6 I75K6DX
MX*E.HE*[JU74?*^2\.$6W%N^LI-77,X59XZ5I-\S:7URM"DW&RA344I+G1^8
M7_!81+CQ1_P2\_:[T_PI9ZSXMU/QA\(GTWPAI7@73=:\5^(?%5]K6K:*VE6W
MA'2O!]MJ6O:Y?7T3_:K+_A'[:ZN1;))J$+);V\ES%^>/[3/AOX3?"3QK_P %
MCI_ ?[, ^)?P4^)W[!7["FH>(/A/\%-$\=>!O!_QD\177Q,_;#\,?'+Q)+J7
MP#M-*\2^+Y/!OPE\<?!KQ-\>8/AO<ZAX\UOX/P>&?#UVEW!J^@V<W])=<]XM
M\7>%/ /A?Q!XW\=>)_#W@KP9X2T?4/$/BKQ?XMUK3?#GA?PSH&DVTE[JFN>(
M-?UBYL]*T;1],LX9;O4-3U&[MK*SMHI)[B>.)&<9.*3Y^?E49<[ULFE1C2Y9
MM2C[B<54>JM)*2<90A.-I-M)7;:C'35NU:57W59^\^>4+ZWC9--.<9_S<:!I
M^G?$;5/^"L&B^(OC#\9/A!I'Q-_:"_X)M_'KX7?M)>'OV9/%FB>!],^(&G>#
MOV8H? WQDTOX:>-O!A\*^(/@+%\</A3X;\.?$G3?%>MZ[=7WP%\)>)-1^(?Q
M/;PMH^I?%VP_6O\ X)Q^)/B'XG^!WC.Y^)OPU^%/@;Q-9_'_ .-,$GC/X#:9
MXA\/? []HV&_\4OX@G_:9^%OA7Q5>ZKKOAO0?C!JNMZGJ^LVUSKWBJQUSQQ:
M>+?&/A_QKXX\-^)M'\8:Y]K^"O&7A;XC>#?"7Q"\#:[I_BCP3X[\,Z#XR\'>
M)M)F^T:5XB\+>*-*M-;\/Z[IEQA?/T_5])OK34+*;:/-MKB-\#=BNFK76-XM
M6:BJ:35I1<)R;NK*2E:].<6^5I+F@ITZ<E%KM2YDTY.IHE9\U*G!I:M.+<54
M4K<R<FHR<:DU+^7CX?\ [*_P\\4V'PBO?!GP8BT#_@HQ\)_^"TWQO^*&H>/5
M\%ZAX-^.7P]_9AU3_@IC^T/\7OB)JGC7QM?Z7IWBBQ_9?^-/[$?BWQE9>#;&
MXU)O@U\8/$_Q/\):;X936_'/B.WF'H'[-MIX:\;_ +2^D_!?]I[2/VV/^&VO
MV=_^"@G[3G[0WP\TK3/@IJWA[X-:MX$\>_%#XJVO@C]H+1?VL_#/P9AT+5_V
M?]>_9/\ B!I?PMU7X:_%#]HZWNM2?PA;_L_6'PTN=9\*?"OPY'_2/16=*/LN
M11E)J$(12<OA=.G0IQE32]VG*3H<U1QC>I[2:>L:<UI4?M7-RLG4G4D[+=5:
MN(JRA-N\IQC]8<::<ER*$+:.<#^=[_@G_K6B?$70/@C\'_BG\!/C-X>_X*I?
ML:_\-1Z?\1?B;XT^%/QQ\*?#SP5\3?BY9>.M'^('[06N?&HZ%HGP'^.?PX_:
MG\1:?X)\8^%_!.G>*/B/JWB$:QX7\>>&_ <6G_"&]\6>"<S]F_P9KWC#X=?\
M$6(/#WA?7?!W[5G[+NH:WX,_X*'/XUT34M+\<>$?AW<_LJ_&/P_^V!IG[0]_
M?^5;^)M+_:0_; T[X1?$WPGJWBF]UL_'_P 62>&_VH? 1\8^&?"_B/X@Z+_1
MI2,RJK,S!54%F9B JJ!DLQ.   "22< <FJBU%QD^67+&G=22Y.>DG'F4%[L5
M43_?0O*,VN;R):;YDFTI2J-6=Y<M1MN+FUSR=-M^REHX*R=[7/Y1/V4_V;_@
MI#\&O^".LVN?L\^%].\46/[>'[;O@SXK?VQ\&9M&\4Z5^SYXL^'?_!1_3_#G
M@SXIPWWABSUW1_@CXH\6^*OV<;+0_"GCB.T^'VOCQ!\)+>PTZ\TC4O#2RZ6D
M7WC/X$_ G2O$?A7PK\;_  S^RU^SU_P7 _;&\8_%CPO^SW\'E\8>(?AO^RUX
MWF_:1D^#_P 9/A]\$-9\ >,]*\=?L^> _C7\1/AS\:UD^'WPR\>6.G6%@/B]
M\,](N];\!6VK:5_35\,/BM\-?C7X-L_B'\(O'?A7XE> ]0U?Q7H6G>,O!6M6
M/B+PSJ6K>!_%FM^!?%MIIFMZ9-<:?J/]A>+_  WKOA^]FL[B>W74=+NXHYI!
M'N/H%$797BXN_(T]XM1^HM)I.[C+ZGS.TE[V(G4BU*,95'+5ROIS-W_FBTL=
M%V<DTI+ZWROF@[JA&G).,I*G\%_\$\/ WP8\+_L_:W<_ ;3OC8GP<^*'Q9^*
M'Q>\-S_'OPGXA^'6L^)KOXL:ROB_Q]XG\*?!KQ?X*^&FM_"'X<>*_B)JOC'6
M= \#3?"_X>Z'J%Q?:OXZ\'>&F\#>-?#>M:Q^#'[)?[._P7\7?"_]@C6OV<_A
MMX3\-?MF_!O_ (*K_M$ZOJOCWP3X(M]!^(?@/]D?PC^VQ^V78?&+PUXQ\766
ME6VKZ+^S)XQ^!MQXF^%_A+0)M0C^%/B#XI>(?"?A3P_92>-('M[#^M::-Y89
MHHYI;9Y(I(TN(1"TUN[H56:);B&XMVEB)$D8G@FA+J!+#(FY&\!_9B_9P\)?
MLI_"B#X/>!?$OC;Q1X9MO&_Q0\?P7WCZ]\.ZCKT>N?&#XC^*?BSXVC%YX;\,
M^%+)]/N_'?C7Q-K%A;2Z<\FF0ZF-*M)TTFQTVQLR+Y:JJ)V4(4%#57O1KJI&
M+:2M!TU[.222E3<J27*]6[.DX/5SJ592;5U:K1G"4O>;O-5)<\6[OG2J2=U=
M?SS>+[)/#MI\4_@M/\(_B9=_$7P?_P '$/P-_:BO- \-_ 3XC^)H=*^$?C+]
MJ#X/?$RP^-6F:OX<\%ZEHM]HVO\ @ZY\2ZC+KGAV_O\ 6+J33O']O<P,?"WC
MEM'SOB+^RKX<^)NF_MW>']'^#UMIW_!1&7_@K+HOQ0_9#^(FJ?#N;3_C=\._
M!%W\1_V:/$6E_'OP+XYUK18]?T;]F+1-#T7XAZOX^\4^%M5'PT\0I9>./ :'
M6_BCXC7PIK']-GQ'^+'PR^$&F:!K'Q1\>>%/ &F^*_&OA#X;^%[OQ7K=CHR>
M)/B!X_UNU\-^"O!6@)>312ZQXG\3ZW>V^GZ-HFG)<ZA>S,[10&*&>2/T&BE[
MG)JI.DZ2OLU*DLOE"S3;C)K+Z/,KZTZM9)<DXH)RYH5*>RJ<\[/6ZJ3Q_-=.
MRG%2QU51;5E.C1;;E&5OYVOVD_#2^+D_X.._#EYX/U7Q+%X^_9,\ :5X#TNY
M\&:UJMI\1O%6E_L;>.?#5CI/PX272)K7XA^*-&^)5QX?\-)IG@=M=UO1?B#=
MZ#H#V]GXIN],LI8?'OQ%^''@+XH> O"_[9OP4^./Q0_8[_:K_P""5/P2_9I^
M%^L?#_X$?';XZZ)H7Q<NM?\ BCIW[4G[/VH>$O@+X/\ &OQ/^&'Q#_:'^'/C
M+X"30:G<Z%X47Q5%\ Y-&BUZW\1_#F*"U_HKHIV]Q0:3BHPA)/52A&GC:;O'
M;F<<;-QD[J+A%<LHSFA2;E/GORR4I3BXZ-2;P+BKZMP3P,'*.G-[23O&48-_
MB,GP-\ ?&']O;XN? GXN?"O6W^#7Q._X(]?L_? GQ7X-\8W6M>,M-BDA^,G[
M0<WBKX3ZG\6)+O7=,\1_$[P?X2\5^'=9U&X@\9ZKXV%KJ&C?$2*ZGMM0L/$$
M_HO_  32\(_&'7[:VU+]I3PW9M\0OV&_"_BW_@GM\._'<VDZ1;2?$^Q\#^+]
M)?XD_M%^%+S2+N]A@\+?M'^!O /[+5UK7A>X_LV\\!_%;X8?%+PI#I%GIMO;
M7.I?I=\7/AQ%\7?AMXO^&TWC7XC?#A/%VE-I?_"<_"/Q?>> _B3X8?SX+F+5
M?"'BZQBGN-%U6"6W0+/]GNK>>!Y[.\M;FSN)X)+7PS^&WA/X1^"=%\ >"K2^
MMM!T4ZG<+-J^L:KXCU[6-8U_6-0\2>)_$_B;Q+KUYJ&N^)O%GBWQ/J^L>*/%
MGB;7+^^UGQ%XCU?5-:U:\NK^^N)WKF;E*3O=Q:=Y2DYSG6Q%9U6VU:=-8FO1
M3DI.<*TG>-FG+2:A%**4>1*T5'DA2H4*$:<4KKEF\/1JM*T82HQ23NF^\HHH
MJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *_#S_@HG^V-\?_@/XD_:%\0_!7XJ6FI6W[-O@/\ 8^\;7OPL
M\(^"?!.MZ#X=NOBE\=?$^@^/K;]JGQ3X^TLZPVE?%/X?Z?HVE_!_PC^SUXLT
M;XI>$Q9>(O'/Q L+#PUXH^'6NWO[AU\1_&G_ ()T?L>_M!^,OBEX]^*WPMU?
M6_$7QN^'?@[X7_%T:'\6_C3X!\/_ !%\-?#G6;[Q!\-M2\5^#?A[\1/"O@[5
MOB)\--7U&[N_AM\7KC06^+'P_#Q6W@[QKHMI;6L$*UYZ<K7C"7,X\UN9J5%J
M+5G&49*-6#3V]I%ZI2L;QFKV<HN*=KV;C5C>]TTXRG2FFM7[-KK&_P H_M ?
MM1?'S]G?]KWXQ_!37?'TFM:%^TW^R_HWB?\ X)UZ;J&@?#O1++1_VI=!^(VF
M_!+XC?"#4M9@\/W&O>*87\1_&?\ 9M^*&EZIXBM=:@\.?#ZZ^,NL:QI^I:!\
M/[R^MO+?VW?VL_VE/V>M:^+5[\-/CLGCY/V;+?\ X)]:?XC\(Z!\.OAK/I=I
M?_&;X\6'@?XK77[6?B+Q!H6G7">(/C3X$UBUU#X5^!OV8-3\.>)OAFEM8^.?
MB%X?T7P9X[^']WXA_8WQ%\&/AEXNU_X.>*_%'A.T\0^*/V?_ !'J?BWX0>)-
M8O-4U#7_  9XCUOX<>+?A+K6JVVL7-])J&J7&L?#_P =>*-!U5==N-4AU%M1
MCUB\BFUW3=*U.Q^;?C'_ ,$XOV.OCYXT^*WC_P")_P +=;U7Q-\<?"GP^\(_
M%F7P]\8?C?\ #[1O'-O\)=;M_$/PK\4:UX4^'?Q(\*>%&^*7PSU.TM3\/_C-
M;:);_%SP;86T&C>'/&^FZ-%'8*0]UPYDI*,Y-W6LH1G"5)23;O)QEB(3?\OL
M-9.-1H?O<_V>:,4DG\,W3G"HTU:T5-4*D$E>ZKK3G@G\M?M(_%CXHZSXT_X+
M!_ SQ'XJM-7^%7PZ_P""8WP@^*OPU\,0^&])TRX\*^(?C-X?_P""@/A/XAFZ
MUZ!)-;\2?VW%\"_!=W$-4O/L.E&&:WTG3;)I]0N-0^5_C'^U!\=O@;^Q-X(U
M#X&_%^/1=;^ G_!%UOVL(?A=X#\#>!O%'C:/Q7X ^$^GZIX-^(GQ[U[XLZ/J
M?@S0OV<+ZZ\#:EX&L?!G@74?#OQ\^)NJ7?Q(U'X<_P!JZ;\+_%&M^ _V4U[]
MC[X >)_$?QJ\6:YX6\3WVO?M$?!KPW^S[\8KS_A;'Q?MHO%_PA\'P>+;;PUX
M16PM/'EOIOAW^QT\?^.Y+77_  I::'XG^T^-?%MY+K4EYXDUF>]\I\7_ /!,
M[]BGQY;^';3Q7\(]6U2T\-_LUZI^Q\EJ/C!\<+"V\4?LT:IINIZ8OPA^)D&F
M?$FRB^+OAG0DUG5-2\%O\4T\8ZKX!\2WT_BWP1J/A[Q2PU@334X1DG)2DVFF
M]KP_M%T^;F3NHO$X9;.RIS=I*"52W*,G&\6H*;DXWUY9K+8U(Q:UBY+#8K5-
M:U86:<FX? OC?2/VF/C!^VW^UUXA_9O_ &A=$_9D^(S?\$P_^";?Q$M?$=[\
M+?"OQ.TO4_$2?%__ (*8Z_H7A#Q$OCVXO=)TCX5ZC>2:C8_$#^R=#B^(-YIL
M^GWO@[Q_X%N]'U#_ (2*#0/VF=8^+_QO_P""/W[9'BGP6^G:_P#$O_@D%^W?
M^TCXA^'WAK[3.;75O%V@_P#!,CXF:MX2\-M?-/>SPB\OI]+T)[TO=SPFS>[!
MG>1:_3B]_87_ &9]2N+&ZOO!_C"YFA^"?AK]G/6VD^-GQS*_$7X*^#I_$-SX
M:\!_&:/_ (60(OCE8:3+XP\:>1J/QB3QSKDD7CCQU;7&J36WC7Q5#J_IFL_L
MZ?!_7OB_\*OCO?\ AB^C^)OP1\&>-?AY\+M7TKQAXWT'1/"O@KXBOX7E\:^'
M8O NA>)-.\!:II_B&3P1X,DO%USPSJ<JOX3\-M;2P-HFFFVTOR^U5-\BDL0J
M+4(R='VLLT=.:4F^91CC,(G1<N1O#2E=N2<\(QE:G[1*I)*C[75Q55PAEBJ)
MM)6YIX3%353EY[8B$=%%J/P9^Q3\4_VU/C0?V6OVD?&OQ!_9_P!:_9H_:=_9
MRTWQOX@\'V/Q"6_\0:-\4_&7A#PM\3OA_/\ LZZ5IO[-'PYU4>%4T67XG:/\
M0O _Q9^+WQ5\4:;H&B>"]9T3Q4=5\*>/Y_&_ZODX'OE0?Q(']:^(_@!_P3C_
M &,/V6?$GCWQ5^S[\%X/A;J?Q$M?%>GZE:>'?'?Q./AKPCIOCK6_^$D\::5\
M&O!FH^-;[P?^S_I/BK7X[+6=?TKX%:%\.M.U74M&\.WEY;33^&M ?3?JKP5X
M \-_#[X?>%?A?X777H/"/@OPAHO@;P\FK^,/%_BGQ+!X>\/Z/;:%I::CX\\5
M:[K7CO7]9BTZT@6X\5>(/$FJ>*M1O%;5-1UJ[U266\=MQ?PPY(VE)0YN?E<Z
MDY^R]H[2J1HQ<80J22E*"2<4U*3J,9*_-+F;:3=N5-0A&*FH*Z@ZC3E.$924
M97:DTTE_.]\"_C+\:?@M_P $^?A-K?P5\::1X.\0>._^"Y7QA^"7B6\U_P &
MV/CBPU3P#\;O^"QGQF^&WC+1I=.O]0TV2TCO=*\27+SW^DWNGZ[&B21Z-K.A
M:A/'K-GZ5^TQXS^-OB/_ ()S?\%^?@S\2?CGXP^(&I_LF>$/VG/ W@CXLW'A
M3X3>%?'OC#X9^*?^";OPB_:BL?!OQ!L?!OP]T/X?SSZ3JGQP\1_#NX\4>!_!
M'@/Q!?\ @K2- O;:\TKQM'J'BN__ $TTS_@GE^R9I'PVT+X16'@+QBGP]\,_
M'VS_ &H="T"?XZ_'^]?3?CQ8?$.\^+<'Q"AUF^^*%SK[7K?%'4+WXAW>D2ZI
M)X<U#QI<R^)+_1KG5F^U5U7B#]B?]F_Q3X:_:B\'Z_X.\3ZEX;_;0O+B^_:8
MTJ7XO?&:.'XFRWG@#0_A3?PRR6_Q!BN?"FGZE\,?#'ASX>ZII/@:;PQI>I^"
M]"TGPUJ%G<Z/I]K9Q81@U34)-/EH4Z271NG@\LP\=&M(JKA<7-+K"M%-24YP
MC<Y2E6=2#Y%+$U:S5KRY:F+S&O9--6GR8G#)M?:I22:Y83E\B^%O%OQ5\9_M
M#:K^QGX,^/'B?X8:W\-OV#O@A\?)?C2O@;X&^(OBK\0=<^-?Q2^/'@CP3HVI
M:/JGPKMOA\?AC\"X/A)JL=YI6@>#-(UOQ5<_$?1XI/%GAJ_T76;_ ,:?+?PJ
M_:[_ &T/VU$_X)N:=X5^+^D_LCZK^UW^Q!^V!\4OC$_@OX0>#?B4=#^,/[,_
MQ5_91\!VGB[X1O\ %E_$=O9^"/%NI?%3Q;J'AW3_ !;;>,K:X^&6KVMM,UWX
MNNM%\>>'/UOUK]C[X!Z]K'PV\3W7A[QE8>-/A)X"U_X6>!_B'X;^,OQI\(_$
MZU^&WB=](N-<\!Z_\3?"OQ"T;Q]XX\)WNH^'M UU="\<^(_$>GV?B?0=$\5V
M$%KXDTC3M5MM*#]E#X V'Q!^!WQ.T7P%_P (OXG_ &;/AKK_ ,'/@=:>#?%/
MC7P7X'^'7PK\46OA.RUWP#HWPO\ "GB/1OAG/X8OK3P%X$@&EZIX1U"WM4\$
M^#Q9K;GPQHAL>J<X3K5:CC)JI5K5%=^\G.OCJL)NTK->SQ&'I3I:QO0=7GFV
MU4YXTYPHTZ<9I2A3HP;45RVA1P5.I!65]9T,14C5=I6K^SY8I+D_&C4OVKOV
MV8]&\1?%S3_VB='CM_A[_P %IK3]@NW^&%_\$_A]>?#SQ?\  [XM?M)_#O\
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M'ASQ5I/]H-)#+?/<36=E);]'X._9+^ _@+XC_#_XM>%_"WB&S\?_  M^"/\
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MC&:A634XNHE96DS\;O%W[:7[6_QR\._M ?$7X6_&#4_V;/#^C?\ !%_]DO\
MX*6?#/P);_"_X8>-/%/@CXO?%K3OVL_$FI_#GQCK_P 0O"WB"#Q#X!O?^%*^
M%O#WQ#TE/#.C^+[S3S>)\/?&/PLUI;G6M0]M_:1_;5^./P\\/? WXV>.]1^(
M?P)_93^*'[-?PF\:ZG^T;\&/ 7P_^+7@CX%?'OQH=4\1>)(/VP/!_C+PSXW^
M)'AW]FF]\/OX"TCP9\5OA?9:/I_@[4I_B:OQB\6:':ZC\/?$?A[]%_&?[&_[
M._Q \5?%WQGXJ\&Z[>>(/CO\#=)_9K^*<VG_ !/^*_A[3O$GP0T&;Q9<:-X
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M\9=7_9U_X(]_ '5/CEXZ7Q?^VI^R5\7_ -ISX@?&[Q#9_#'7OB5;W'PA\'?
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M+YKN\+4KQNXN/M+/E=2FJTYRI*6O(YTYJ*JJ,I4Y4XV4DSS']I?XL>+?%_\
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M\/Z+#8?07Q@^%;77[+_Q+^"'P<\+^&="^V_ OQ;\(_A?X0M/LGA#P3X>COO
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M\2OBA=_#GX83WNAW]Y\//AU??%'Q?XRO? 7@O4;CPIX+75O#7A&XT;2-6M/
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M]&U#XLW5G\3_  CHUAXAU[PWH]A\1X_%3:5X(UK5? .GRV_@G4+O0)K'C_\
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MX>\8?#3XE^ ?'7A;7O"_C37+*\T;Q-;V>H-IGB+3M<T/2_-?B!^WE\)?AO\
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M[>,?B+^RSH_A72O@WXQ\+?![2O%?B7X7?$3XBI\9O!NO>-]6^(^N^,;+P?\
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M"TOQAX=\'Z)X<\,Z'X@\.> _"'AKPWJFDZ'H>EV%A=:3);06D8C.?B[X^?\
M!0'XT>-O@#^TYXW\%^%_B;^SG)^S'_P4Z_90_9?@\064/PP\:7WQ&^'^K?M3
M_LE?"?XO^&M6T;PYJOQ7\2R:CXMT7XN^.=1TRV\#:%H?B"/P]?\ @'3](UZ;
MQ@GB_P -']$/V"?@-\4OV;?@#J?PN^+^H_#_ %?Q9<?M"?M;_%B'5?AK>>)+
MGPY=Z!^T3^U+\8/VAM$B>V\4Z1I6J:3JVDVGQ3&@ZII(FUVTM+C2M]KXDUF.
M;[37PGXZ_8$_:LU'P#^V9\*?"\_[/=_X:^-W_!2']GS]N;X6>)]>^(_Q(T'7
M9?#O@7XX_LS?'3X@^ _B!X<T[X*^);#PGK6F:A^SW>^$?!NJ^'/$?CVQ\8V?
MC6T\2:W#X G\*3>'O%-8:RJ8?VUE!4</*IS7FE5A6RMSYFM9M0^M\Z=U-0JJ
M7,VU.<3S2A6]C?FE/$J-K0DX3H9DJ?*MH7JO"\LERNGS4Y1Y4DH?:&A?\%"/
M@K+X<_:)UGXBZ'X_^!.M?LQ?%3X??"+XE^"OC%#X!T?7E\2_&>'X?R_ B_T7
M7/"WQ!\7_#BX\-_&E_BAX(L?".L:IX\T<>'M6U2]T?XI0?#S5?#OB6ST?L?V
M7/VVO@?^UOK7QL\)?#'5)X?'7[/'C'P]X.^*_@S4-:\ ^)+[0)/&OA.P\=>
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MBE>:EX=\2ZEX2^,?A!OAYXGTSQO\+/#6N0Z=I>H_+W[6_P#P3X_:3^.^J_\
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MK^(?A=^SWX6T_7/AE^QUX9M5>+PK>:U=?!CX267@WQ!XET2:^M--UCXLZO\
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M\?\ AGQ-:^"]%\6/INHZ5HMC9^I?MV>)+;4?%7_!9[X>_'CX=^+?';_M&?\
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M-^"-II^M^#_$!^!?BG6K/X _!?PE\9O'/ASQQ::WJWPZOM$UCXF7OA'PO?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:_$S0K7QKK<5WXNU_6-1:[U[7=6UB^U*\N'@U&'ZM^#7[=?@WXW_  W^!GQ
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MM(\1WFCR:#KL5UI>ORZ9-97A@=FKW37*[2NFFFY3AJK7_B4JE-]ITYP:4HM
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M)QYHRCC!TZL8U8^\JU)33:LY0Q"PU2$G&R:D_8X9TWRIQE2C&-VIQE^6T/\
MP3S^.<7[.N@?!O5?BQ\)?$?B+2?^"H5U_P %![CQ!IW@CQEX(T:?P\G[?.J?
MMSCX91:=<^+OB'>KK>N:W>R>#O\ A)VNQI_A+2=1C_XDGC:]\/OJOBFQXB_X
M)^_&75?!W[5OAFT\;?#!+G]HG_@I5^SM^WQH]]<KXK2W\+Z'\ /&G[(_C*V^
M%^IVD6G22ZIJWB:7]D/1=.N/%]I=V-GIL?Q)U6ZB\.73>";.W\8?H[??M _
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M7C#0OAY+\9?A3'X_\4^(/%/A/PSX'D^(GA!/&'B+Q3X&TS3=:\;>&M"\,MK
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M#[QQX,\+?LL?'CP[+HEOX3\9>$O!7B7Q#X#^)FG>-/%'B7QU!INM_"+1-/\
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M)U6TDY*<*G+HG'G]K+9\KCSUE-36D9.,HRA.$91_)/\ X=J_'OP]HWA[Q_\
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M\_2G]DWX;?%3X+_LP?!?X2?%/5/A[XE^(GPL^%G@WX=W>H?#ZU\2:)X)U-O
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M ."?NKZMX/\ !'PU\8?%?4;SP5X!_;P_9Q^)OQ+U+5?"?@KP[XGU&7PSX?\
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M 7'BF23XV?%CQ'\</B$?$WB.[\1#4OBCXPM=,L?%7B33!?*?^$=M=9M-#T2
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M8A\-7FI:AHU_'X9NM6DLSX,N)= I_MNC1?$OQD_:^^'>O^$_VN-6\$_MP?\
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MW\"_#LZ)XR^&_P"TA\-O&/PV\6_#KX@_!34_#.F7WB'PQJT7P4^)X\0Z+>^
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MZ5:E)\K;3DG6E43;;<US2;<I,_FPU73/&7P]MOVNKV;]E'XU>)O"VL_\%V?
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MV=X4'/E?NNI9-J+;CK3:C=.S4O:MR:3G>K4JU='OI.:BGNH.5KRLG^0?C;X
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M::S"JD[/D4812G%SC)7>]VI<SFI1;BXSM@N22<7>\7@:3>MYN4[RBU!Q^/\
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M>6TVK?F9X@_9U^&7_#U[X!VR_LR6-Q\'O '_  3@^(GPM\+Z[!^SKJ-Y\#_
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M/U2XU2V^#<OPW^)]E\6?''Q \/Z_XT^)MAK_ ((L?AO83:#X&TW^B3P-\./
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M'"Z^!G@7Q_X_\2_'CXT?M0>'-%UGQC\,O _['_C3X?>/OA?\$H_A#\,? 'B
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M\??O+XZ_\$^?V,_VE_C!\/\ X^?'+X ^#?B!\7?AII"^&O#?C34)M?TV\O\
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M9\<_#[XM?L_^#_"_PH^/'P1^+^I>#]9A\"^.?"U[KT$6L?#KQA#<IX0N;I_
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M3^$/[*?QV^(VA_%CPA\"_$'A[X?:J?#7Q9\<>"M<^)6@>"/$^KFWT3PUJO\
MPKCPPEQXB^(6NOKNJ:?8>$? NA:?K.J^+_%MWH?AZP\/^(KG48]#U"OXV_8G
M_9G^(UU^T->>-/AU=:W+^U?X1\.^ OVAHY/'WQ*L[/XH>"_">GW^D:!X7UK3
MM.\8V=A9Z)8:/JVL:.;#1+;2X+S2-:UO2KY+G3]9U.WN_3/BO\!_A+\=/@SX
MK_9\^,/@ZU^(_P (?''A/_A"O%GA/Q9J6MZL^N:$L5O' ]YXBN-3/BK^W[.>
MTL]5T[Q?#KD7BW3?$%G9^)+#7+;Q!:6^I12U*\FDE%^S<::;;C:==U(^TDKR
M3I3HTXN5^9TN>:7--S(IKDYI<TE[3FGRI<W-&A[-\B;BN6I"M-Q6RJ<L6THJ
M/QA^P[\;OC9XZ^/G[>7P7^+VJ^+M8TKX#?$;X"M\-T^)FF_".T^*'AOP]\6_
MV<_ OCW7?!OC&^^!5AIWPPUI=)\8MKNJZ)>Z.NLZA!8^('T[4O%&KPV>G6VE
M>5?\%<K&SL/"'_!/Z&PM+:RBG_X*_P#_  3TOIX[.WBMHY[R_P#CK%>WUY,D
M*(LES>W<LEU=W#@RW-Q(\TSO([,?OCX._LH? 7X">,?'7Q"^%O@R_P!#\<_$
M_1/ NA_$CQ;JWCGXA>-M?\>I\.-(FT+POKWC'4_'7BOQ+=>)/'9TF5++Q-\2
M-7DN_B!X[CLM)?QSXF\1RZ-I,EEK_'#]FWX-?M'VW@"T^,OA2\\6VWPN^(OA
M?XN> 88/&'C?PLGAOXF^";T:EX-\;VG_  AWB3P^9_$7A340-1\.:A?&ZET6
M_P WNG?9[DF4N2O[*S5X3H2D[6YO95W4DUU;G&--:V]Z.OP\S5KJJGHIQJJ*
M^+E]I0C!*^FBG[1Z?9EIORG@/[27C[QO\+OVF_\ @GIH7@'Q$?#GA;]H[]J;
MXI?#?XX>&K7PWX,GLOB)HVA_L'?M0_%CP]J.KZQ?^&;OQ?8>(M \6? ;X<QZ
M?JV@>)=':XT#29?#NKPZII+6UO:?G_X)_;B_:1N]"^$GPOOO'&D:WX[^-G_!
M5#_@HC^R#HGQ1\:3>#?AB;#X<_LO^-/VI;OX5^!M/\0:!\%_'?@2P^(GB32_
M@]X1\+V>I:Q\(=?F\7:-I_C.PLHK'Q[K6A>*M'_8'XW?LZ?"']HKP[X1\,_%
MGP]J^M6OP_\ '6@?$WP%K/A[QUX_^'7CCP1\0/#5CJVDZ5XN\'_$?X;>*/"/
MQ!\,ZX-#U_Q%X;U*]T7Q-8OKOA;Q)XD\+Z[_ &EX?\0:SIM[XAXJ_P"";G[#
M?C7X(^./V<O$O[./@6_^#/Q"^+7B3X\>(?!L4GB#3?LOQD\5^([SQ9J_Q(\'
M^(=+UJR\5?#KQ6NMZC?S:-JGP]USPO+X9L;VZT7PU_9.B3R:<Q!./M.9NIS3
M3BGIRTU.A)P4M7%N,*B3ULVH_P *<U&WJHI6BU&*O9OWE#$1;<5RJ2<JE)M7
M5U%R_B0AS?%GQ&^*7_!0WX!_"GP3<_%:_P#$?QXT7P'\2OCYH?[1/C#]A*'X
M/_$C]K#P7\,+Y=$\1_LS?$#6OA7\3_@AX.\#?$W5? _@CQ-!!^T?X,^"?P5T
M#QKKNMZI\,_B5\+/ =_X(D\9_#36O!_BI^U!XN_;%_9W_P""DG@+P#^T5>W'
M@3]G7_@F%\*O&VA^._!_@/P%8I^T]K/[47[)OQ-^,L_QH\7^'/&W@K6]2T3X
M3^,O#&E>%O#_ (+\&> 6^&^L:3J3_&B'4O$M_JG_  @Q^&?Z\Z7^Q%^S5X=\
M+?"OP;X-\%>)/AUH?P7\/^.O"_P[_P"%6?%SXR?"O6M,T;XGZOHGB3XD0:UX
MH^'7Q \,>*/&UWX]\5>&]%\9^,=5\<:QXDU?Q'XWL5\:ZO?7?BJ:XU>;F/B!
M_P $Y_V+/B9J'AK4?$?P'\/Z<WA3X%W/[,&GZ?X U[QK\)_#^I?LX3:;-I=G
M\!O&'A?X6>)O!OAOX@?"#PY!<37/@KX=^.]*\1^%/ 6L.=?\%:5H&NA=1$UH
M>TIUZ:Y7[6G6IQ;C91E4PDJ,)R@FXRC&K:;IZ.2J5G/G?*HE&7LYT:CO>G4I
M3:4F^94\5&M*"DTG&4J2</:*]N2FH\B4I2_)7]I']KKX]? C]DSQ-XA_9]^+
MU_;Z_P#LJ_\ !+']F+]HUOA=X4\!?#O5]&\)>(+VW\>ZA+X@_:7\8_$S0=:N
M]0\"?%CPM\*!X"^&?PW^"4VD?$^)M&^+?B;Q-JOA6SU3X:^//#/VS^TA^TI\
M8_V5/VM/$&A^+?'FM^+?A)^U-^SEK.E_L8>!+K3_ (<>'M/T/]N7X:7S6DOP
M TSQ?;?#%]<U#Q!^TEX<\8^#?%/PE3XA>)?%6G:-?_"WXZ3WMC<Z"-!TW1??
M/'G_  3/_8>^)=K>:=XS^!&FZGH^J?L[:=^RAK?AZU\:?$K0O#'B3X"Z#'J:
M>$/!7BGPQX?\9Z5X?\4WOP\FUK5=2^%OC?Q%INI_$#X5ZWJ%UKWPZ\5>&-:E
M:_K4O_@;\4/'OQU\ 0?$3PO\%;;]F/\ 9D\6^'OB?^SG=VGB7QK\1?CCXN^)
M,'P;\1_"][_XGV'COP9:^'? MOX$E^(/C_4="\0^&O'GQ)\:^/;^7PAKVK:W
MX%GTCQ-HWC+>M)5Z]:I*\8UL3B*K2;35&O+&N<>?>-7DKT)4YJ[AB8.=-QY8
M,QHP=##T::2E.AAL/34GKS5:$,%&#]F[1=+GH5E5@[*6'J<LKWD?5?@'0_$?
MAGP/X.\.>,?&NH?$CQ;H7AC0M(\3_$+5=&\/^'=3\<>(-.TRVM-9\6W^@>$]
M.TGPQH=UXAU"*XU6;2/#^EV&CZ:]TUGIUK#:PQ(/S2UI?&VH_P#!:+P;I8^*
M_P 0[3P5HW_!.?Q?XPM/AQ;-X*F\#)J>I?M(> _#VOJ+/4/!5]KEN_B:+1_#
MM]K>J6?B"V\02S^%="LK#6-/T."^TB_^V+/X :39_M/:W^TY!XA\26FMZU\&
M-/\ @QJ/A6U\4>-Y?"FNZ=IOB[_A+]*\1:[X4U'Q9?> (M=\*SR:KI?@[4?#
M'@CPYXALK+QAX_\ ^$G\2^+K;Q#H6G>#=#QC^S?\&O'GQ@\#_'SQ'X4NW^+O
MP[\&>+_AWX8\::)XN\;>%+P>!_'%[HNK:YX7\16'A3Q'HFC>-='M_$'AS0?%
MGA>U\::;X@7P+XUTC3_&W@C_ (1[Q9;1:RN;<G4A4T3O5E.,5RQ3J4\3345%
M+DY8N=&:CR\L4^6*_=IRKE7(X7=E[%1E)N4G[.I0J-MM\W-)0J0<K\TGJ])M
M1_!+_@F;\1OC?\)/ _\ P1D\-6/QAUG6_@S^U1\._P!I;X8^+?@3J'@KX;VW
M@OPC?_"_P=\0OC+X)^)/@OQ59>%(OC'%XX:3P=?>%/%]IXD^)OB7X=Z_IOB&
M:_T'X?>#=2L+*6/Z_P#V%OCY^V?^U-I7[$/[7\WQ6^ =O^S/^TG\,?%&J_%7
MX.77CO3?$>OZ?XT\3^#;_P :>&/"GP0MM$_9Q^'GB'2_B5\#O&WA;Q5\,_BA
MX6\=_&CXE:=+X*T/QUJ5Q:R>-?"D6LO]U>"/V&/V6_AQ!^S]:^"OAK=Z%:_L
MK7OB_4/V?K2+XA?$^[M/AG<^/=-U/1?%QT>UU'QI=V][!K>BZUK&BW%IK<>J
MV<6CZIJ.E6L%O87EQ;R9OP>_X)\_L:? 'XW?$']HOX.? /PAX"^+_P 3]1UW
M6?%OB;1[KQ$^GG6O%<MM/XPUOPQX-O\ 6KSP-X!UOQK/9VLWC?6? 7AKPUJ?
MC.:WBE\476K.@:G&UU>S48N,79.R4,-&,9)_&FJ=57E*]).G;FBE&F<K46DU
MJXZ6M?WL1*4E).\6G4IRLHM3:FFTVY3^=_\ @H;X5U_Q!^T-_P $GSI'Q.\=
M^!4NOV\_&.D11>$]/^&%['8ZBW_!.?\ X*":C'XJMO\ A//AOXW=]=@L[*[\
M/QP7CW7AP:-K6JW']@?\)+#H7B+1/E3]IG]KC]J;X>?"S_@N9JW@/XRS:#K_
M .QOX_\ @P?V;M5G^'GPOU>/P#I7C7]F+]G?XS^)]!OM-NO!\=GXTL=1\8?$
MGQ<HO?%PU;7K73+RSMX-7%S8"[F_9;XH?L__  J^,OB/X6^+?B'H6KZQX@^"
MOBZX\>_"[4-/\;^//"O_  B/C.Z\/:UX2N/$UE:>$?$VA6-WK$GA/Q+XE\+F
M\U2VOI1X<\2^(]#4KI>O:O:WGF/C+]AK]EWX@Z;^T7HWC+X:W.NZ5^UIJ?AS
M6/VBM/N?B!\38;3XHWWA/0](\+^'VUJ&T\96Z6-MIWA?P_H'A@6&A#2=/N?#
M6A:+H%Y:W&D:3I]G;D-$U*\O?JRBKZ*,ZN732UO9\N&Q,;I/E]LDKQG4LI0;
M<W%I.<*,5*VL73IX^$VTK<R;Q&'DDY*[I-NSC!GP%^VA\3?VL/V//#R>)?%G
MQW_:1\7?LY1> OC?XB^+O[5?P?\ @Q^S/\1/B1^R;XJUWQ!X9NOAIXW^)W[.
MUE\'GU?QQ^R=\)O!]OX[O;[7_AKX9\:_%/1;+PYK&H_%>Y\5Z9+;>,/"WI?[
M,U]XE\3_ /!4[_@H?JH^,GC?Q7X"T?X%_L!WO@WPD]WX$U/X>PZ'XUT7]IG6
MK:'P[/8^#8]:M]'M;\W_ (CTN[TSQ.MUK-]XHU2X\2:CXCT^/P[9Z']J_$C]
MDOX%?%VXBN/B'X=\5^(=WPXF^$&M6A^+7Q>TK2_''PRNI)9;[P3\4='T3QWI
MNE?%G0=3^U:A%JUG\3++Q8-6MM7UVTU)KJUU[6(;[HM._9R^#.C_ !SU;]I#
M1_!HTGXP:_\ #SPQ\+=>\1:7X@\4Z?HVN^#_  1?>)+[P5%K?@&SUR'X>:OX
MB\'#QEXOTKPKXYU#PK<^.?#OAKQ5XD\):/XCLO"^N:GH]THJSBV[\OMXZ)?!
M.FH4W+?FE%PC9M<T(RDI2JR@JM2I)M66FM*3NV[RA-RDD]XJ2G+F2;A*48<L
M:<92IP^&/B-%XUO_ /@LK^S7HUE\6OB+H/@\?\$Z?VN?%EQX TEO!$G@V[U3
M1/VFOV(-)N9;JQUCP1JVJ23^)++6X(=7U,ZR-:L(/#VDVO@W4_"EIJ/C*'Q9
M\C?#O]K#]KCQA^SG_P $VM>O?V@-1MO'/Q\_X*A_M7?LE?&+QG#\,_A"]SXM
M^$7@#Q7_ ,%#=*\)16>A-X(3P]X8\3^&=._9U^&T>A:]HFG6\<MUIUQ=^,]-
M\;1ZCJMGJ/[2>-OV>/A#\0_BO\,/CAXK\+75U\4_@[I/C+P_X"\6:9XJ\8^&
MIK/P[X_N?"^H^*O#?B#3/#'B#1]$\=^&[W7/ _@OQ59>'O'FF>)=&T'QIX0\
M+^-O#]CI?BW0-)UJT\QT/]A3]EOPWX;^$WA#1?AOJ%CX<^!GQD\3_M!_"C3%
M^)/Q5FC\&_&;QG=^+K[Q7X_LI[GQO-=7NL:_>?$'Q_<:E'JT^H:?<2>//&Q:
MR_XJSQ -15*/))<_O14W)Q75/%SK:MV;_<3]DTW;W8Q345'ETJ2YHOE5I\BB
MI7TNL,Z6VJ5JW+432ZN33E=2_)30?V@OVT/"GA'Q%XKUW]KKQAX\;]F?_@L-
M\&_V#K_3M>^$/[.NEQ?M$? WX\?M-?LV?#2[U+XZ7/A+X3^'I=.^)O@#P9^T
M9=V7@CQ/^SXGP%\-S:CX(T/4O&_@?QD^J:S%<?0^D?'_ /;)_:$^)?QR\3?
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M[(O[._CGX/\ Q ^!7C#X=Q^(OAU\5-:L?%/Q$AU3Q/XSN?&?B[QGH]YX8O\
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M%S5+'Q!\3(=>\3>,M4\9^-O%>CCPLGAOQQX@^*EWXBE^*=]\0?!D7@/P!;^
MOB"_C,>-/ %I\/O %IX+UW0K;P/X5BTC@Y/V:[3]G/P_\7/'_P"Q-\(/A9>_
MM%_%2Z^$[>+;[XZ?%GXM:-HOQ2C^'Z>'?!DVJ?$KXKQ>'?CGX_E\76WPRM==
MN+?Q9+X1\4:UXT^($D6O?$"\U35-?\1>)97;W'&3;ER2@IQ45+FE3IPA.ST3
MISA&;<K\UIRFGSUU4%I-S233E3DJ<G)Q2A5G4J1O=-JM"<H.*Y>7W80:4:3I
M^?\ [%'[4%W^VK<V'Q\\ >)O$]A\"K7X&?"WP[J?PXU^Q\$)J^C_ +3/BFWE
M\<_%_P )_$%K;PG:>+=(^(OP(\.7OP^\!>)-,T7Q%9>!QXQ\4^/_  _?>%T\
M2^"!+I_D'Q'^/GQW^+OQJ_X*0?"#X0_%ZY^ .N?L/?!GX*ZW\-RGA3X=^)],
M\>?$;XI?#'QY\8H?'7Q4B\?>%/$5]J/P7N9=!\/_  LB\.^!-1^'GB",>%?C
M5?0_$,>(=5\':A\,/T!_9\^#EC\#/AI:^#8Y-%N]?UGQ9\1_BG\1-8\.Z$OA
MK1/$?Q:^-7Q#\3_%WXM>(](T-KO4[O2=&UKXB>-?$E[H6F:KK7B#6-+T*33=
M,U7Q'X@OK.?6+S%^)O[*?P"^,'C.7X@_$#P FJ^+K_X?W/PE\3:IIOB7QCX4
MC^(7PHN=0U'53\+?BOIGA'Q#H6D?%WX;6VH:WXDN=.\!_$^P\6^%-*?Q?XV7
M3-)M(_&WBQ-8*B<N;DM3;IUE!KWXTJU2FW3J)-_O:=#$2DX0FWST80B[MRYE
M3]U1YTYI3I.:;Y95*-.:4H-K^'4K4(QYYQ4>6K.<ERJW+^7GP:_:,_:C_; _
M:+_9>@T7XX>+/V:/AE\9/^"8?[,7[=GBGX4>%?AS\'O%>LZ5\0_''Q+T:?Q;
M\/7\8?%#X=^)M:M?"FM^$=0O/ _B.W^P1>);.>*WU_PIKOA'5;>X2\^\?VZ?
M'G[1?PT^''@/QK^SWX'^('Q(M?#_ ,4;;4_CSX+^"L?PNO?V@M6^ UK\/OB&
M^MS_  %T#XR1R> ?%OQ TCXB'X9ZM?\ @^^,6O>*?A]9^-]#\"R?\)[?^&(I
M?;X_V>?A##\<8/VD(/"US!\9;;X;I\(8/%<'BKQC#:1_#2/5O[>B\&KX1B\0
M)X*_L>+7/^)S%&?#AEBU4#48YENP)AJ?%3X+?#_XS1>#$\=VGB9KCX>>+CX[
M\%ZMX.^(?Q$^&/B'P_XH?PKXG\$3ZC9^)?AEXJ\(>(&AN_"?C/Q/H5_I=QJ<
M^D7]EJ\ZWMA/)';R0N;3^!**]I4G9I.T98BO.$;)I-0H3HTG!2C&\'RM<L)R
MF$9*_/+F]RG%6;5N6C1A/5IZRJPK5%-Q<GSKF2O**_'?PM^V%\9OVG]?^%O[
M.?[)O[1UIKNM>)_V$M0_:+T+]H;QK:^#O@U\3OB3X@D^,?B3X&W^JZA\-O$7
M[*/Q@\&Z-X@^!?BGPC:6?QV^'D7PM\"_8/&OQ"T#2!:>'K&PGT.X]*^$&I?$
M;5_^"FG[-VH?&#5OAKK_ ,6;C_@D%XJ_X6CKGP:N]6OOA)K'Q&B_:1^!4'C?
M4_AK<Z]#!KC>![_Q+%J=UX7BUA6U2VT:6TMKZ:YNHI;F7ZP^,7_!-?\ 8=^/
MO@[X-^!?BM^SUX5\1Z'^S]J&KZI\';JRU?QAX3\5^![OQ,J_\)J+#Q]X-\2>
M'_'=]:?$:5%O/BGIVL>(]1T[XIZBJZG\1+7Q-J(%U7LUC^R]\"=)^)WAWXPZ
M'X#A\-^/_"'P=D_9^\):GX6U_P 5>%])\+_!B2\T_45^'GAWPAX>UW3?!NB>
M'[?4-(T:^LHM,T"UN-/O-%T6YL;BWFT?37M4DDXR2UBZVG,Y74Z->G"2<DG%
MIUE3DFFW"G"<FYN2=ZVE&]U*--7LDTXU:,Y)V;4D_8N:::M.I*$5R*#C\@?\
M$9<C_@F5^RB",?\ %)^,.,8X_P"%H^.L?I7Y6_#[]E'XL_MS_"?_ (*G?LJ^
M&M7\#_#OX7>/O^"V?Q'\3_$OXQW7BCQ.WQ:\$Z/\)/$_[+GQA,7PC\!Z=X(?
M0+OQCK.H^ ]'T+1_%VN?$WP_!X1&L7_B--"UZ[TFTTC4?Z,_@C\"_A;^SE\,
M= ^#?P9\,R>#/AKX5&I+X<\,+X@\3Z_#HT>KZE>:QJ$%CJ/BC6=;UB&WFU._
MO;U+8:CY%M-<S-:QPAB*Q?@K^S5\&/V=Y_B5<_!_PG>^%)OC#\1-=^+?Q+:?
MQCXX\4+XN^)OB>*R@\1^.=1C\7^)=?BC\1Z[!INFV^JZE9):SW]OINGP7)DA
ML;5(J3Y9J2^Q1HQCV]I0EELXR:_E4\ I+5.[A?3G%47M.;ISUL1-K_IWB%F,
M913_ )E#'<M[-:3:UY&?DC\8OVG_ -J7X7^/?^"O/QLA^.7B;7/A9_P38\+0
M?%?X;?LVV/PV^#UOX>^)UKJ'[!UK\9[[P'\4/B++X!U#XF#P=IOQ-U&P\5:1
MJ_@?7/"'C#1-.LM:TWQ#XB\:Z+?V&F:'V_QK_:V^/O[&GQ'^&%[>^.=<_;'^
M&GQ9_8'_ &P/VA+_ $6;PO\ #GPIJV@?$O\ 8\^'_P ,_B?HWB7X>ZQ\,_!V
MA/'\-/CIIOQ$U+P-KFC>+[3QU=^'?%9^$=WX5\2VBZEXIT[Q7^G?AC]F[X+>
M$/'OQK^)>B>#,>,/VC#HW_"[+S5_$7BSQ+I/Q"'A[P\GA'14UCPKXDUW5O"D
M,6G>$XH?"]M#IFB6,2^'8+?1&1M,MX;5,[X/?LL? CX#1:/!\,/ \FC0>%_!
MLGPV\%0:UXL\;>.8?AW\,Y;S3;V3X8_#"'Q[XD\3Q_#'X9M+H7AB#_A7GP_7
MPWX,&G^#? NE+H@TOP-X1L]%S<7[.44[2='E4]W&HZ..IR?=WJ5\'64F[Q>$
MY8QO).3C93YI7E'VKER623I^UP=2*O=6<84<51<4K2CBN9R]VT?SB\:_M)?'
MWX%?L<>,OV_+;]IKP9^T-X-NO^":VO\ [2GAOX.:O\+?"^G:)>_%K1/"GA[X
MCV/QD^''B/X;3Z#XV3]G"+0_&4.F>/O OB1OB/XGT[P]%X"U?1OBA9:]+XCE
M\:;'BC5/^"FOA?1OBWXC^&_Q)^"?QPT?QO\ "3X/^-?V>/AY!\6_A5J?QIUG
M4_#7Q:\+6OQ^N_A-X]G_ &8?V?\ X(7&B?$?X!^+=*'PFU?XI:)XY\+>$/VB
M=4\)7'BG77^$GB^+0-"^M/@!_P $Z?V(OV6[?XFV'P(_9O\ AYX#TCXP6FM:
M3X\\/QVVI^(O#%]X6\1W>H7^N_#_ $+POXMU+7O#W@CX7:K?:KJ-Y>_"KP-I
MGASX<375Y/<-X7\U]]<Y\*/^"8?[#/P,^&WC7X3?!_X%V_PZ\%?$#Q)X"\5>
M(8O"WQ!^*^F>)H=4^%?C>V^)/POMO"OC^+QU_P )_P" O#OPW\>6Q\5> O!_
M@3Q/X;\(^#]8OM9N?#VAZ<=>UI;_ $?+SU9**C&=W3AI-4E.4Y.BN9KGC3YH
M>SK.2FHTW"W+--0E)0IQ;4IP<5.;O!U>2,(JK)05HRG:;G2C%0<JBDFN5H^(
MH?VROCMXO^ 6A?%OX%_\-??&GP[X!_:0^)OA;]K?X5VOP>^ 7@W_ (*,?L\^
M'M'^%2Z[#\-(_@=XD\#VGPM^*NI_#3QMXK\!ZOK&F?#S2M7\>^._AEXQ\ Z_
M\.?$'Q59]07QYY5^TQ^W-\:=*_96\9_&W]EO]KG4OC9_PI__ ()/>$/VR-'\
M1>#/@C\-_#:>-O$ZZ7\2_$=O\?OVG)/B=X.;3/!WP_\ C9%\&-7\(^#_ -G;
MX/\ A;P3\6M*\06_QTM]63PA!X<\,^)_AI^P\O[&W[/S0Z,;7PYXTT75]%\3
M^*_&:>,_#/QI^-OA3XE:WXH\<:/I/AWQ1K7C3XI>&OB+I/Q'^(%WJ?AWP]X8
M\.C_ (3KQ3XBBL?#_A'P;H>G1VFE>#_#-II7G/CW_@FI^P_\2[6'3?%WP#T.
M?0T_9OD_9%N?#&A^)_'_ (.\(:Q^SFB:F=&^&'B3P?X.\6:#X7\4Z7X*OM9U
M;7OAGJWB32-5\2_"OQ7J-WXO^&^M>%O%$\FKF)*3B^5J,G\+:YN5JC&-TY>\
MX^UA>"FI5(1E+FE6YFU:LI*ZO&_O)O5Q=5RT2LHSY)-2<9*G/EBE&DTCZ'^/
M]S\6[?X#_&2Y^ 2>&W^.R_"OQXWP6@\87<%EX6G^++^%M37X=6WB&]NH;BUM
MM'N/%[Z/!?SW-M<6Z6\CM/;S1!XG_&BR_P""BGCRT\-Z!X%M/&'Q9\,?'GXC
M_MY_!S]DWQ[\,_VR/#7PB^$/Q&_9(U;XA?!;Q7XR\.^'CXN^#_PD\:_"?XE^
M#_CWXE^$<FF? CXQ:+X5^*GACQ5XG^-]MI>G:M<P^';7PYX>_:KQ#\'?A[XK
M^$6K_ KQ%HU]JOPRU[P1=?#O6=%N?$_BO^UM2\*WVE-HM[;W7C2+6X_'$FL7
M=E)(USXJ/B,>*Y]1DDUB76VUB1[YO%_%_P"PK^RC\1?A3\6?@K\3/A%I_P 4
MOA[\=&T63XMV7Q4\3>-_B=XD\<S^%[;3;7PC=:O\0?'GB;Q#\0A>>"?[(TZ\
M\"WEGXIM;KP1JUL-;\)S:/K$DU]([6G-I<T;QY8MN+:C.+M=<R@I14E.+4TV
MX2C*,E44Y2DX04G::3YI)77,Z<HMV]URY9N,XV<-I*46O9N'PQHWQL_:_P#A
MA\8/V>/V1/VB_C9\.9_$W[1W[37[2=EX.^+_ ,,YO"_BGXAZ#\%OAA\ -'^-
MW@CX'^-;G5O@K\-_A?!\?]6U[Q!JUS'XCL/@E9:7J/[.G@2#R-!G^*'BBX^)
MFD]LOQ)_:4^%O[1O_!.WX%>,?VFK+XS1_$O7/VV/ GQN\1Z'\-?AKX2L?B*/
MA3X.UKQI\)M6U:PTW0]2E\*_$[P5I7]@:+\0D\ ZUX;\#:]XPL?$\Z> M!TZ
MXM/#6A^\Z]_P3+_86\3_ +-VD_LE^(/V>O#6K? S0?&6G?$G1="N_$'CE_&6
ME?$_2)';3OBI8?&(>*5^,UM\5;:WEFTM?B;%X_7QV^@7%QX<E\0/H-Q/ITG?
M:[^P]^RSK_@3X)?#=OA1:>'O"G[.'B1?%OP1B^'_ (I\<_#'7OA[KTVCZ_X>
MUVZTGQE\.?$_A;QE<VWCG0O%7BC2/BAI>JZ_J&D_%?3O$OB"T^)5CXKAUG4D
MN11LXW;:C5BV]?WE'ELU.+;M*%VE9MU4E*4HS;:;NU+9<T)62M^[J73]V22O
M"?+=W5J3DU!2BK/\K_!7[1/[8'Q4^"O_  3ZM[+]I[Q'X'\8?'S_ (*4?\%!
M_P!C_P"*/Q%TWX4_ S6O$FM?"KX-P_\ !3;_ (5MJUAHVM?#F3P+H7Q#\%6'
M[*OPSET'7M/\))X:O?$5M<:M\0/!/Q!T"YUCP=K6[^U1\6_VE_ .I?\ !2'X
M"Q_M,_$B^L_@?_P10^'/[07@SXA:?X<^$?@[XB67QZN;K]LSP?XW^*=EK?@_
MX;Z/#H^L>/(?@'X1U>\TS2;.UT/P=J^HZ[=_#73_  8[:,=&_2OP_P#L*?LJ
M>$=)^%V@^$/A3%X0T+X*_&/QO^T!\+=$\)>,?B#X8TCP=\8?B/<>+Y_&OC?3
M],T+Q9I]E/?:[#\0?'FDS6.H07FC6OASQKXL\+V&FVGASQ%J^E7?>:Y^S#\"
M_$_Q$^(_Q5\2> X/$'C7XO?""T^ 7Q+O-;UWQ3JNB^,?@U8S^)+JS^'>K^#K
M[7)_!K^'+:Z\9>,;N&UAT"&2.[\7^*[E9A/XDUJ2^APOAZE)ZU)T,134GLJE
M3 TL/3FWORQKJM4<4DH\[FHRG)I5=K$*JK*DL1AZD::TY:5+&3K58+2S<Z#I
MP5W9\O(VHQ3?YS>!OB3\8_A/X]_X(P?!W0_BOXCU7X;?&WX0_&&T^*^@>(/"
MOPPEO?%T7@7]F'2OB%\.H!K6A^ _#][X>@\$ZI)_9]E'X8_L:XUS3K'3(_$]
MWK-S'JESJ_+?L>?M!?MT_M->!?V/_P!L?1OBY^S%8_ ?]I+X#^-_$'C3X2^+
M_B%:^(+?2OBKXF^'%_\ $'P)H/PL'A/]G+X=>+=(\1_!'QYX6\5_#GXR^$_&
M7QJ^)@'PZT+QOJ@5O'O@YM9O/T2\(?L3_LV>!7_9WG\.^"->6\_91TS7]'^
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MOV99]:^._P -?$L?[-W[?O[9W[:=NUM\'_%&BW_C71_VO'_:RM]2^'=_=O\
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MSPGXZ3Q_>>%O!'PWM-9']F^//CCX@T7X:^)?$&D_#S7=9^'WAU='G\+W&O\
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M+XNT73?$%EJ^GL6N5TW6;:(DS"'YOA#PE_P33D^$OBBY3X/?$/0M&^%VA_\
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MA*V\'>+;^QTKQTOBWX"_$+PUJ'@?Q+JNG6UGY_@W6!XIGT_7]3;PWYM\=_\
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M7:MKS*G]9Y4DY2]G3TYY14_KCX3?M7ZWXU_:0\?_ +*7Q ^"/B7X<?%7X?\
MP?\ AI\?-1U;3O&/@WQW\,[OX9?%_P 1_$;P?X)%OXCM[[P[XN3QQ!XJ^$GQ
M!T'Q;X;;X?-H6CW.BVM]HGC+Q5H>KV.K/LZ]^U1I_A7]KSP_^R=XH\$ZAX=D
M\;?L_>//V@O /Q:UCQ%H5EX"\8:5\+/%7@SPE\3? NGPR/\ V];^// 4WQ"\
M%>*?$-G=Z?'H8\!^)M.\0Z5KVJWMCXGT3P[\*_\ !-0>,[+X@Z^GACQ3^S;\
M9/@QK?PPALM>^+OP<_9$_:J_9O\ $GA[Q#\.]9T'1O@Y\*+WQ[^TQ^TM^TC)
M\5/".C^%/$GQ1&A_#;PGJN@V?[/2Z/'9R:9I=I\2=-LKOO\ ]O#P+\*/VN_B
MQ\#?V5+>/XHVGQS^&GQ(\#_&W4O%GA_X8?$*Q\$>%/V=O&^A?$KX7_M ^'?%
M?QGO?!J?#:YT#]H+X#W7Q?\ V?$\&^%_'%UX_P!/\?\ C?P-XX30]+3P5'XG
MT'62CS4U&_O\T6GO[SK)5'%6:C0BZ-6<5)N=.C6?.W4A;)-\M24OLJ+7+;HJ
M5X)RNG*K-5:<6XQY)U:2Y$H23]D\/_MMZCX^3X8>$OAM\%]2U_XY?$?]F^+]
MK&Z^$7B'QOI7@\^"/@[JNNZ=H7@J#Q7XKN-'U2+3_B-\3+N^U"S\!>%)]#@T
M"35_!OCZQ\9^-O!5GX<@U75:7P*_X*&_#7]I'6_V<-/^%/A/Q-<:;^U-^S?\
M>/C_ /#G4O%<MKX;O/"VJ_LV?$+X._"GXO\ P>^+FA1)K&H>#O'_ (/^(?QI
MT3PEJIT ^-](@UCPKXZ@CO)X])TB;Q!U'Q#_ &7O&"?MA^$_VT?@YXM\-:9X
MU;X :I^S#\6? 'CS3=8NO"GC_P"&\7CMOB5\-/$VC:WH-]#J/A+QO\(?&FK^
M-KVVAET;Q!HOQ!\+^._$GA#43X2U,>'?'?AOP/P/_P $[/&WP%UO]BGQ'^SS
M\7O ^FZO^S9X)_:J^'7Q4?XH?"S7/%.F_%G3_P!L_P"*'PK^/OQR\>^&M,\*
M_$[P7-X"\;7/QP^$]GXC\.:3<ZKXF\,V'AWQCXB\/W"SRZ=I.H-*LVOB4;M/
MF:YOCQ,5K%-<CI?59RGHU5=5*/)[B<N90;BTY^Z[)/EY>2C*HES-/G]K]8A"
M.J=/V?-)3]]_9_[)G[1OA[]KC]G#X/\ [27A7PUXA\'^'OC%X/M/%^E^&/%;
MZ1+XBT."YN+JU;3]7DT'4-6T>2[@FM9 TFG:C>6KJ5:.8@D#YW\$?\%!M(\3
M_'GX?_ GQ!\&/B!X"\2?&?PY^TOXG^$/AWQ5<Z=H/Q9U#2_V7O'-EX(UV^^)
MGPE\4Q>&=2^%VD?&B&]'CS]G#7[C7O$FB^/OAW ^L^-KWX7:W/8>&;SU;]@[
M]FKQ'^Q]^R1\$?V:?%7C_2/B?JWP@\*OX6'C;1?"%SX&M-8L5U74-0T\2Z!=
M>)_%C"_L;2]BT_4-4@U&RM-;N[675[7P]X;@O(]"L/A3X!?\$U/VC/@Y\4?V
M8?B-X@_:1^%'Q'E_9K\9_MD:C>ZEJ7P4\7Z9\1?CKHG[5]UI6KWGB[XL^/?^
M%Q:G!=?&C3KSPOX6T6_\66OA:;P])H5OJ#Q>&KD+H&DZ":.HKW4.2+=D[*4J
M=II/XN:%36*E>+2M>5V4](SMJU4J<FJNX1J-T[[)J=.RDU:2;3M&]EZ3\'O^
M"I^A?%/X0?#CXYZ_^SW\0_@I\-_V@9_AUX;_ &8_$/Q;\=_""PA^,7Q#\9:7
M\5_$_BOPQ>6?@[QIXSUCX=:/\)/ OPHUOQ_XU\5^*=+\O7_#%IK8^%&D?$;7
M['P_H7BW[#_98_:4L_VF_!WCCQ!'X#\5?#[6?AK\6?&OP;\4Z=KT$]UX:\0:
M[X+&EW2^.?A'XV:PTNS^*'P<\:Z)KFC>(? 7Q!L-,TB34K&^GTCQ%X>\*^,M
M#\2^%=%^$+/_ ()D_%;0OV"OV2_V:/!W[3>E^#?VC_V&OB%X6^*W[/\ ^TAH
M'PLO4\&7?C'PE9?$'P?)8_$'X+:I\0]6O]4\%^/?@_\ %;XA?"CQYX?LOBBD
M\\'B.?Q7I&IV4D-OX:B_2#X#^%OC9X8\$$_M#_$[PC\4OBSKNIRZSXDU3X:_
M#_4_A;\*O#X-AI^F6/A7X:>!_$/CCXG>+=,\.Z?:Z:E_J.H>,/B-XOU[Q%XN
MU3Q+X@BG\->'M2T#P%X1;LG*S;LH+R;]GAVY0>[_ 'CQ,)QE&*48TY1O=.4+
MFLK]7*]FM+5,1%*2LM'26&G%QD_?E4B[6<8_"6C?\%1]+U7Q)H"W?[,_QC\.
M_#2[_;F\1_\ !/\ \5?$O7/$'PG:/PC\:K3Q?>?#KP=J)\*>'_'.OZQK_@OQ
M9\0+2T\/WVMZ3,Y\,P^*?"-]);ZK.WCC3O ?I7BC_@H9X(\,:-'\6Y_ ^LW?
M[+=O^T^W[('B#X]PZ[I%L?#GQ8B^,TG[-U[XQOO NH1VEU)\!-&_:/C?X"ZU
M\1H_$(\66OCN.;Q/:?"_4/@;&/C&_B@_X)O?$P>"+WPB/C1X"\V\_P""J-M_
MP4G.H'X:>(S''HMK\;K'XW)\!OLO_"Q0S:LVI6$?AQ_C+]H6Q-C(^ICX."X"
MV1W[?_@F]J!^'?Q+_9:U?XBZ-KW['_C_ /:^MOVN]/\ #-[X;N8/B9X2@O\
M]I#1OVO/'/[.4.IVU^/#.M_#KQA^T/8ZUKL/Q!N;&P\4^'?A)XKUSX/Q>&-6
M\4)HOQQT=0UE34[1BO9.;7,Y3O'+W6C;X8N/-F"@[I>TA35I14)3'S)2MJVZ
MJB]'RVECU2DU973ME_,M^255^[+G4?<?V<OVD_BG\8?VI?VZ/@YXI\!^&_#?
M@7]ECXF_#?X7^%-?TGQ5)J^J>(YO%OP(^%?QQCUG6=,GT#3GM+S6M+^+=O!+
M;6U_/I^@Q^'+6PB;4KV]U#43@_M>_M]:1^Q^WC77_&7PB\::A\+?A5X<^#?B
MCXA?$V_O]/\ !FAZ[!\9_'GC7P18^#O@!)XBMX]'^./Q8^&UEX#U7XB?&#X<
MP>(O!M_X4^'>M^!]0T#4/&/B?Q;:>$[?NO@Q^S7X\^$7[5W[8OQM3XA^$=;^
M%O[5OB'X5?$C_A!&\":S9?$#P?\ $CP!\$OAK\!+Z,^/1X[N/#FJ^!KOPI\)
M="UZSTT?#ZTU]O$?B;5X9]=ATS0;*/7/CW]M?_@FS\</VH_&O[5^J^%/VC/
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MP4I\!?%;QU\'M%^&_P -_&'Q,\ _M&>"?B/XT^"'CWX9:AI'BJ:\A^'WA/\
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MKWA[P39>(=4U*#PGX:O_ !SXQ\5>*#X=T!-/T6WU77M1FL["W298UX?X\?\
M!4C3?@=X@_:\M)_V9/C)XI\(?L,W?P?U;]H7QW8^(OA+IVFZ?\,/BCX<A\7Z
MA\1O ^CW/CJ?7?%X\(^&+A]:F\(366@^)-2M=!\4QSV^C7:>"K;QW]/_  $_
M9Q\2_![X_?MJ?&/5?&>A>(](_:T^+/PW^*>E^&M/\-ZAH^I?#V7X>?L__"S]
MGPZ+J&N7/B#5;7QA%KVD?"71?%@OK;1?";Z)J6KZIHAM=<M8;35A\E_M ?\
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M7O@+Q/X4U;2?$C2ZWX48>)(M(M3]B^+/VS4\'Z1XLT+X/_!+XE_M ^(_@/\
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M[-KLVK!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^VS^QG8:7XAUR^_:X_9CL]$\(V/C#5/%>L7?Q[^%5OI?AC3/AYXOT+X?>/\
M4?$.H3>*TM-%L? WC[Q3X9\$>,+O4IK:W\,^+_$>A>&M:DLM:U?3[*X_%_\
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M4.H? _P3XK^*GBCX7?'3]FCXY^(?@[X"\3S^"_'_ ,7/AU\$/CW\/OB?X_\
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MUQ>V<B3'\H_VL_!?C'QC^V=\0OB!X<^$GQ4\1^$/$G_!&']J7X4P>);#X/\
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M),J2<&E%.5W33=K\MZ]&$_A;5G3JN4973BHN3U5U]%?"3]MS]EGXS_ ;P_\
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MPT;P5\<+OQ_XLUJ32_ ]E>/)=?#[7_A=?^2=:U^[MZ[+PE^T9^SWX_\ #'Q
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M1G**^RZ-:?,KWM[\::3:T]V+3<GS?H)H7Q]^!/BB/X=2^&OC5\)?$47Q?O\
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M*?$#6/"GC^XTCPCK'0?LK_#76!\:[']G/]IG]C3]L+Q9\<?@#^W%^T!^T_\
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M)>MJ]YX3AU74=/TR7Q';V<FCQZA?V5D]X+FZ@BD_$W]GSX"6W[2'QW_X*B>
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MU*+:DFNC33371IKH---)IIII--;--)IKR:::\F@HHHI#"BBB@ HHHH ****
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M#7P'_P %']<^'M_JL8^%+Z/H>M>#+WX&>!'\-V?A#2O#?@VU%BQO/"&HM8Z
MVB9\ZLI6NI62C9:2>,K8-/FN].>BV]+J,E*TFI1+2;YM/ADU=.]^7"T\4THZ
M:N-5)-RMS1:T34C^BS '3_.:*_FP\#_&/]J/PEX+^!GC_4/VI_C+XWNOAO\
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MFKSJS5*%[Q3A'VCY)2FH\DDU*-TXG[$P^'M"M]=O?%$.CZ;'XDU+3K'1K_Q
M+*W_ +:NM&TR>\NM-T>;4S&;UM(L+S4=1O;/3/.%C;7VI:E>PVZ76H7DTVQ@
M?Y_SU]^M?A/\'?B7^T[^UU^U9^S_ &?C#XZ_&W]FKPEXN_X)H?L8?MN>-/@)
M\,-.^%.EVNA?&KQ3\6M4U'QW\-=7UWQY\*/&7C9O NM0Z!#X*\?>'KS5O^$D
MO=)M+C3M!\3>$+>^\0VVN?<G[=^O?M!>'- ^%.M_ WP1XE^,N@^'/'-_XI^/
M?P$^$_Q/T[X2?M$_$OX-:;X:U/2KK4O@=XGU37O"=KJNN_#CQ[X@\">--9\
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M5W;7<>G:OHUAJT(E6&ZL(+@-"OS_ .%_^"@O[(/B[7V\.Z9\7HM.O%^-M_\
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MX(>,_A_\8_"VI>'M,L;OP_X9_:"N_C/:_#SQM\,_ ,F@?"/2M4U#X9:E\'O
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M_IUSJW[+<O[1:_'#XG^&-8L9]$^*O@CX@>.K_P 3?!;Q!X9\<6VO>"-.\*_
M_7)OA['X'^)]SXH\8Q\C9>*?VJOVR?VDM!^%-W^TO\=_V-]*^)?_  2M_9K_
M &IK_P"'_P *-&^$<7B;X2?'OX@_$3QQI7B+3;;6?'WPR\4:]<Z)H]YH^CV?
MB_P[K$]SJFK7'ARTT;3O$GA/PUJWC;P]XS.72]DVX1J635W"5'$UX/6T;N.$
MKQY7).,U!3<5.\'>]^B4G%R>BYHU<-2DK6YK*6+HRNH-2BYN-W!*?[Q_Y_S^
M=%?S@?L[?MD?M3?ML^&OV9O@9XI\>:'\&/C?\:?^"4/P=_:Q\&>,M'\<ZO\
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M;5+OX=>)]6T+0M'TZX^*OPOUGQ+%I&F:@T^FVWZK?\%*H-3\,?\ !,7]NMM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\T_VP/\ @H^O[%][
MXG\7?$G]D;]I[6_V8/A;J?@S3_CC^UKX8@^"Q^&7PUM/'=UX,T_3_$NE^ M<
M^,.C_'WXI>$?"5]XYTC_ (6?XE^&_P )-?TOPC:6GB+^S)_%.K>$_%.C:+^E
ME?SZ_P#!1+X[:C\;?VH+/]C#XO\ [/O[9%A^PM\&]3^$OQ>^/_BWX8?L&_M5
M_M(6/[;_ (YT^ZTKXH_#;]G7X=^*_@]\%/B-\/\ 0/@#\/O$6F>%/%W[2WBW
M4M?MO&GCOQ3I>D? #PMH=CX97XN>(D_?^PO8M2L;+4;>.[B@O[2VO88K^QO=
M+OHXKJ%)XX[W3-2M[34=.NT215N;&_M;:]M)@]O=6\,\<D:M)>SYNKJ25]?@
MY7925DE)S4G!13?LH\TVG."D-KF45I[EWJFKN2MR[MV@TZC<N53FH17[N;5N
MBBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>ex-19_003.jpg
<TEXT>
begin 644 ex-19_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2* X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?A[XE\5?M'Z)\*]:^'>F>+/#OPVU*PU_PI\'H[J]\=_$OX8KX;N?%7QEMO\
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MVI-'%SXOU+]L7X8_MA_ [Q7\0?&_BS5/'WQB?XDZ_P")/ACX4\$?!W7+S2O
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MZTFV^*/PLLK/1OV9O /A.PNOB]\$_!]Y:^))$\+ZIXBO?&WQ3\.ZUJ/Q&G\
M^']-\5:'X/E\':YK_A'5;CQ7X?\ <_AS^R+^VY\,?C+_ ,%(?CY\._V;=/\
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M_P!G[_@GS_P3Z_9;\:?LN>*/VCO^"B/@/]K[0O\ @JE\=O@[\/\ XS?#./\
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M\9>+_%GB;5]/TG0_#/A70M8UJ_GF>2&Q:WM[J:'^83]AO_@GC_P4/\,^)/\
M@DO9?M1? 33X].^ W[0O_!07]L#]M;Q==?%CX0>(Y?B#^U]\7?%?B_3_ (-?
M&_QA-X?\4ZMKNOY\"_$3Q!KWP^/@[1_$&MP>)-!T/P_\3[;X?Z;,FKZ7^SG_
M  5*_9NN_P!L;X"W?[+^O? 7QO\ %SX7_$O1?%>H:QXX^%/C'X9>$OBW\!/B
MQX&_X1[Q+\!_B;\/T^*'Q'^&6CZOJ-MXJ@U6WO;&#Q#;17%HG]FZ],OAC5-9
MT[58FW"E&5N>;D[Q@T[QC]7<N5/E:E+FQ2I>TY(S]GAI/D]O.%&XV=246^6"
MB[2:>DFZRCS;WBK8>510YI14Z\8\SHPE5^K;3]K/]G^[\ :#\2V\>OIGACQ7
M\4=>^"/A2#Q#X2\<>%_&/BKXP>&/%?BCP5K_ ,,O"_PW\1^&M*^(OB+QQI?B
M3P1XSL[GPUHWA6]U46OA/Q+JZ6SZ-H>IZA;>6:/_ ,%(?V*/$/P4^#O[0GA_
MXZ:3KWPN_: T;QCXB^#M]HOA/XA:KXN\=^'OAQ#J%Q\2]>TOX6V'A*X^*<&B
M_#"#2[Z;XGZKJ?@NQL?AQ'$C^-I]!6XMC-^-7BS]B7_@H3J'QX_X)F^-?VDO
M"'Q&_:G\$_![_@GU\0?@3\?-6_9B^,/P9^%?Q'\$?M>?&:+PYX9^-/QCN_$O
MQ;\<?"+Q'=:+\2?A:=6\":S\6/@+XGT3X[Z;J$GBSQCX./A&^UJ'3M?]]\+_
M +'?QE^!W_!1&_\ $>F?L4>#_BI^QMXQ_P"";?PR_8E^$GAKP%X]^#L'PA_9
M?L]*\8:SK_Q;^$?Q,\'?%C5O!/C7Q;\&OBE>W.AZAXJ^(7P]^$_Q1\7^(-%\
M,>'K#7_A=K-U;KI>F6UK*"E%R<L1"$]?9IX>-5Q<U92Y<5*-)4FFU#FJ)SER
MPE.8RNE*49<JC1G./NJ;5>4$XPO=.6'BYNK=)R<8-07-.$/TT7]OS]D&3XB?
ML_?"NW^-6C7OC/\ :F^$M_\ 'CX"V^GZ!XTU'0/B!\&],\%ZA\0[_P")-OXV
ML?#=QX(T#PE;^$--EU9M6\5>(M"MV>[T;3(R^K^(-"L-1XW4?^"H'[!6C_!W
MX'_'_6?VD?!^B_"#]H^ZUN#X+^-=9TGQEI-GXTM?#']K2^*M?33M1\-6VMZ!
MX/\ ">G:#K7B'Q;XW\4:9HG@_P +^$=*O_&6OZYIWA2UFUE?Q&_;]_8,_P""
MB?Q'_:-_X*2_%K]FSX!^&+?3(_\ @F9\*_\ @G__ ,$_I_#GQ.^#_@NWN_ O
MQ U^RU_]I#1/"/A+6]1TJP^&OBG1I-5U;P_I/BWQ1=?#ZVT_P+X;MM&\"7]]
MJ6O:;?\ @[['\+_\$^?BU<?M2_\ !(KPOJ/PXM?"O[&7_!,G]D7Q=JFG7%YX
MO\(:W=^*_P!J'4/#/@WX(?#3POXA\,:7J!U-_$WPZ^'N@ZS\4+GQQI.G7/A2
M/Q9XCUK0;'QAXE%R\]XDG+56BI5$ES6;A3E4S*7--*R<HT,+A(/E=GB,5#2-
M*:Y!OEZ.7+!M\NG-.,, K1;V4JV)Q$E=-JAAJGQ5*<E/Z/N_^"B_@3XA?M*_
MLA>&?@+\>?A#J_P9^*'[)OQ*_;4^*W@OQ!\%?VE-5^.7C3]FS4_!ND:A\#/B
M]\&]3T3PM9^#_!GA^/Q5)J5CX_TGXJ:</%>HW#Z?X"\,^'%\?7IL[#Q#_A[S
MX/\ VA_AM^S?X^_94\>>"OAAI'[1W[?'A[]G'X*Z[^TK\#_VC]93]I[X/^$-
M:\-V'Q=\1_!W0/ /A;2[WP9X@\2'5M6G^&'BCXAWDO@.Q\+>&M6U?XFWGP^U
M>W\::=\*/GKXE_L:?MRVWQU_X+6?'WX4_ 70[#QIXX_8@^&7[%'_  2[ETGX
MD_"[PQ8:5\,-"^%=_-K^B> K2'7;.W^'ZM\9O$NJ>+&TKXCV?PQT'P]K'@WP
MAIV@W/BKP]K&I>)=!W_@C_P3[_: \%_MC?\ !(JSU7X(1:?^R7_P3?\ ^">?
MC'PSX.\4W'Q"^&YO='_:Z^)5OX>^$/BL_$3PCHFN:AK.L^)3\$/#D_BYK_P=
MI7BWP#9_$_Q=KNF:5\2;BSM5\6:HX.+<&T[<U*HTW[RC.KCL4X._*IN.&P>%
MPS@[*%?'.E42ARS<SNE-)W:C4@G&+2;C2PF'4HV;:YL1C*]=23<G1P7M:;F^
M:"_8SQ?^VA^S'X%^+7@[X'^)?BMIEO\ $KQU\4=.^"&A:1INA^+/$.CVOQFU
M?X<:M\7M(^$_BSQKX=T#5O _@'XCZM\+]'F\>:7X+\=^(_#?B+4?#&I^&-5L
M].FMO&/A-];/@5^V;^SC^TM>Z79_!+QYJ/C:#Q!X0UKX@>%=>7X>?$[P]X.\
M;>!O#_B]/ NJ>+_ /CGQ7X-T+P;X^\.1^)I;:TM-8\&Z[KEAJEC?:;KNESWF
M@:GI^IW/X;?\$T?V*OVJ_P!G?X Q^+/VCOV-O%/Q3_X*"_L_S?MH_$?P9\1_
MB=\?_@7?_!3XM?'O]HGQG\0_$=_\1/@[%X \:ZQX@;Q=\;]/O_"7A#XD_%G]
MIGP5X#^*'@#X>WGB#PAX%UM?"5_K/@+5OMS_ ()-_L3?$G]B;4_VN? UOH_B
MOX>?L;Z_\9=-\9_L1?L__$_Q)X)\;?$7]G[P]XW\*:;XE^/_ (4TWQ!X#\5>
M/] T7X1ZW\6KB'_A7'@NW\;:CJ5FGAC5_$WBJVNO$_B?4?%GBPC:WO--^SYU
M*#O!R<:,E#5*5USU;/E][V3A4C1G*+')R3?+:RJ*%FGS.*G6C*:LW&UH4FTY
M72JJ<)5(IQ/N[Q1^VC^R_P""?B/\8?A)XP^+V@^%_B#\ ?@=>_M+?&#0=?T_
MQ%I2>"/@-IRW3:A\4M0UF]T:'0;SPK8_8;Y+N\TG5-0DMY;&^AEA26SN4B\B
M^.'_  4*^ 7@/X0?MW^*O OQ)\.ZS\1/V%/@"OQE^*GAK5?#OB=[?PFWC7X,
MZ[\8/@L-2LK]_!D/BVT^(6C:5&^F:5X5\607=_=>?X9EU?0O$6Z*U_-G_@IO
M_P $H_BS^V;\:_V\OC=H4\=YI_CC_@D';?L=? WX8PZSI&D/\6?V@['XK?'+
MXYZ#<>*-=OM8TZU\*^$_!OC*3X.G1XM9DM--\1>*=3DU36]1TWPUX(O;#Q=)
M^UI_P30_:<^+'[ _P_\ V3C>^'/B)\5_VI_B[^Q'\-OV_P#XO^"]8T_P5H_P
MX_9.^ [>'+WQA9?"!?'%Z/%/B;1/#$'@1;#1] O%O-8\?^-OBM\3_'4_A;P9
MH7C*^\#^&8:<Z3CS.G4G&%-26G).M/$4W5ZM1P\84ZL[WLK27-*<*+J,K54W
M%2IPE.;B]Y1I1HS4+OE4G6?M*<;.-Y/EO&,953[7_P""?G_!0CPU\?\ X4>&
M/!/QR^)/P[N/VXO!O[-7PX_:5_:H^#?PM\$^/]*T_P"$>E_%VQU#Q1IWA72]
M)U-_%\^K:KX MBG@/Q3X=T?QAXR\8:5XETF)?$EEI]]XCT:VO?B:3_@IY^TC
MXG^!7[ VM_!/XG?LI_';XB?\%!/^"C/BWX%_#+QGX ^#'QZT?P1%^QGX.\5_
M%2X^)'Q2T?P=\3_&/@'QA<?$#X/^ _A\)];\1W,>K?#O5-9N;2WT2P\6>'9X
M?'FH^9^(OV,/V_M'TS_@OK\8?A[\ ]+B_:!_:O\ #&@_LR?L-::OQB^&]G;S
M?LV_"_X3VWPC^'&M> M2N?$)M_AQJVHP>,OB!\2?$6D_$7Q#X&DD^(/A_P ,
M17&F7MM=OKUKZO\ L]_\$_\ X\_#/]LS_@G8TWP:LM"_9B_X)_?\$L?$OPG^
M"GBV]\8_#S4(_"?[87Q5UW2? 7Q)U#QCX=T+Q&WBW4_%>K?!7P-X>OO$EWX:
M\-ZMX O?$/COQC;:?\5=4GTB&X\1Z.4'-U%%J%J-7V2M?E4\PQDJ2C*22FZ&
M$P&"FE-R]OBZ\'>E5BX1RRC#V;G>2=>G[35^\J>!PL:CDD[Q]OB\;BJ;Y4G1
MPE&<?WE.<9?KKKW[:/[,7AKXR>"_@#JGQ8TH_%/Q]\1M3^#WAW1-*T7Q5X@T
M5/B[H_PTNOC'J/PI\2>.M T'4_ '@CXEP?"VVA\=IX#\:^*/#_BJY\.:QX8U
M"UTF>/Q;X7_M?TCXP?'/X5_ 70_#NO\ Q4\5Q^'+?QEXTT#X<>"-*M-)U[Q3
MXN\>_$#Q.+R71?!7@#P+X0TO7_&OCKQ1<Z=IFM:_/H?A+0-9U'3O"GA[Q/XN
MU*WM/#'AG7]7TW\/?^"-'["/Q;^"G@3X*:A^VS^S1\0(OVM?V?[K]I:XO/C[
M\5OC3\&_B3X'U/QK^T=\6/&/C/XE?%O]GS1?A1XS\7Z]K/C?XS:5JFGVOQ*^
M*7[0'A+X>?&G1/#%U/\ #'P[K^J?#Z?4O#3>A_\ !0'X!?MW>*_V_OA-^TM^
MSW\*-*^+'@W]GO\ X)[?MK:7^SE+=>/_ (<^%8OAC^WS\3]&AT7PAXCU_0O'
M&LZ3<Z[;>._A]I]O\./#%]9Q3^'](U#5=<A\;^(O /A?4]0UR\S;<%33M4;Y
MY3=/X7&-&=:,8<]FI3E2E1C*HH)RK4I2IQ<9PE:]YSM[J7+&/.E?F=:%)RE9
MV<8QJQK2492:A2K*,Y7A)???@W_@H_\ L3?$*/X&7/@KX^^'/$>G?M,?$WX@
M_!WX":UIVA>-9/#WQ3^(WPMFUJV\=^'O"GB-_#,>A7JZ)<>'M9MTUJ34(?#^
MKS6+Q:)JNI22P++W^A?MF_LQ^)OB%\*OA9H'Q;T35?'7QOU#]I;2?A3H]IIO
MB22#QIJG['OCN/X:?M(:=IFMG11X?BOOAEXUD?1[VUO]5LY]?CM-1U;PBFOZ
M+I>I:C:_C#\,/^"4/Q>F_92_X(=? )[&?X#+^PSX[L/CE^TA>0>,- USQA:^
M+T^#_CNV\>:#X8U/PCJ.H6#>-/BG\:OBAX@OD\1>&?$&J:9X&\.R:]XGL?&.
MH^*--\-Z?K_S[HO_  22_;B^%7_!)K]JWX#_  \_X0>3]H2PT+]M'X9?L.?"
M7PWKFC:1;>!O@Q^U#^T-/XO^(:ZQX]U_7$\(6WQ<^)WPE@/A/P7>P:EX?T3X
M6:'?OHLOBJWU'QGX^U&U=2\/:VM/V+KV4;VK*F\-2I^S:YN5U*M:M56D^:AA
MY6Y;J;4'SNFM8>U]EK+>CSK$U*GM%[JER0I4*;UA:K63M+6$/WI\ ?\ !17]
MBWXI^-=/^'OP_P#CQX>\3^*-8^''C_XRZ%!8Z'XSCTCQ%\%_AEK\?A;Q7\:?
M#7BF[\-6WA7Q)\&CXB=]'\+?%C0]:U#X>^/[ZUU"+P#XD\3'3-1-KC_!7_@I
MQ^P3^T-;?$#4/A)^T[\.O$6C_"CX5P_'#XF>(M3DUOP5X6\!_"*Y\1>//#5M
M\0O%?BKQUH_AKP[H?ABZN/AMXJUZVU'4-3@CN/ *^'/B;"'^'/CCP1XI\1?C
M=9_L<?MZ>#/'/_!13XI_"O\ 983P5XJTK_@EE^S/_P $_/\ @EYI]A\9/@E:
M#P)X3T[X;:AJ/C[PU+J5GXKC2QUKX<?&CQ5IVL:OJGB6U\(^'[N+X6Q:;X"U
M?QYH]WX>UF3T/]K;_@F+\9/ O_!-3_@GY^RE^RK\-[;XGW/[._QN_8/NOVN_
M!?@K5_A+X0\<?M&_L_\ [.FJ>(O'7Q \-:'JOQOO-#^%WBJ[B^-^KV7Q=\,>
M _BMX@TSP))?IK,;*?MDVCZOI*,8R:YKP4J=/FT;?M,1B:?M;1<H^SIX>A2K
MSBFWSXBG0<H6=92I2E%/E:E*,Y\K7PJ&'P]7V;=U^\J5JTZ$7M%4:E5*HK4S
M]O?@I^U!\$/VAM=^+'A?X3^+K_6_%'P-\3>&_"'Q8\,:[X)\??#_ ,2>"]=\
M8^!O#WQ*\*0:CH/Q$\+^%-6N+'Q%X'\5:'X@T?6]-L[W0]0M[N:VMM1DO]/U
M*TL^3^,'[;O[*_P%\37WA+XL?&#1/"NL:%=_"^T\:NND^*-?T3X6?\+M\81^
M ?@_??&GQ3X9T+6?"_P1T7XF^,7DT'P-X@^+FL>"]#\2WEEJK:3J-U;Z/JLU
MFG[(7P7\+?!OX<>(7T'X/:[\'=<^*OQ"\3?&#XC6?CWQUIGQ*^,/C7XA>-(]
M.?Q%XY^-7C+0];\6^&[SXA:@UC;Z.VB^#O''C/P%X/\ "FA^%_"'@#5M.\&:
M)H?A;P]^ 5Y_P3!_:9^)6B_M3? _]I9-#\!?"7]I[_@K]X@_;)_:H_:=\8^/
M_ ^I6/Q;_8W^&VO^ -:_9>_9R^%>F:?XNU'QWHNKZUK7A[X=^!+:Q^)UCX)\
M._!O1_"WC]_#?_"=3WO@+2?&,Q5ZM.$O=C:BZSOS7<J^'I5HTI6Y;PIU:U=<
MR;E&A&$8RG74:3;:IU)+65ZOLTTTDHT:]2G*HF[^_*G3I6324JS<I1C1E*I^
ME7[1_P#P4.\52_\ !07X-?\ !,+]F6*'2/C/XI\'>*?BW\?OB_XZ^#?Q7\<^
M$?@Q\*K'PE<7G@&#PEI.BVGAGPSXJ\2?%#QA<V>B1_$;6O'$/PG^&::)KNC>
M((_%OQ#OM*\ I]C^/_VLOA5^R]9?LY>!_P!K;XM>$_#OQ@^.+Z=X$T74O"_P
M^^(NF^ O'GQ2T7PY8ZE\0;[P[8P_\+%/PV\$6&-3\62O\1?'=S9>!_ UM=ZI
MXJ\:W>F^']:\1)^>W_!-/0=8^-O[>7_!6;]OC6[*]_X17Q7\=O"?[#'[/5SJ
MMM.%'PS_ &(=)U+P5\6M?\&:A)&EOJ/@KQW^T1K?CL&\L9KFUE\0>!]3@C8&
MS>2XYK_@HG^R?^V'\>OVY/AS^T)\*?AU:^(?!O[$'[!W[5GC#]D:5O'7@+16
M\;_\%'?CQ:Q_#KP/H7B+0_$6MZ?/I_A'X?>#-"T3QM!XSUR33-+T[Q!/'!I-
MU<3IJ=K<QS.-.B^5RE.#KU+:ODE#%5Z5.'\DI48X2DOBO4Q2G-3A!3-$N:I5
MC=1C"2HPOI[\98>C5G)OXHJK/$S:5K4\,U!J3<']V_"[_@J'^P3\:=5_9HT+
MX8_M'^%/%.M_MA3?%B']G31X-#\<:=JOQ#_X4CJ/C?2/B1<'3]9\+:==^$+'
M2M5^&WCO3=&U'QW#X8L/&U_X7U6T\#7/B2> 1OUU]_P4&_8ZL/BSI'P/D^-^
MB77Q,\0?&>[_ &=M T+2?#_C77-/UWXX:1H \3>*?AEHOBS1O#5_X/U7Q5\/
MM&>"?XI6%AK]P/A3<WFGZ9\2)/"VJ:C8V5Q^&_[,?_!)[]I7]FOXY?\ !/K0
M/"7P[\/Q?#;]A/\ X);_ !H3X??%O4/&O@ZYT.V_X*G_ +3SW7A_XU^(O%/A
M\WVH_$#Q-X?7PYIFG6/AZ\_X1&\\,6'A#7TTNT\6"7PE!X8UC)_X)R?\$^OV
MW/AE\8/^"13_ +07[.E[X,^&W[$G[)/[4_B3Q?KFI?&KX4>--;LOV[_VH?B9
M<Z/\6?%?Q%O/#/CCQ3KGC2Y\6_#+4/''BOPG>^&-/\9:/8:AXSL;#Q#XYT;5
M=3\067A751C[3DE)6C.2<E\,HJKB*:<)7:5XX2I4U3TQ6">L9R<LG*3@Y1B]
M8*44T[ING2G:47RMV>)I0=K/FP^,LE*$(K]F_AU_P4S_ &9OB;\9?VN_AKH^
MOW_AOP/^PUHFDO\ M'?'KXF:-XB^%_P?\(^-KV]\1?VYX$L_&/CK0-#\.WUW
MX \/^'[?Q/X[UZ\UO2M%M]*\8>";GPA-XSLKWQ/?^$>DU3_@I7^Q1H/@_P"(
MOC?Q%\:#X9T?X4?''0?V:O'>G>*/AO\ %OPUXUTGX[>*M#\,>)/"_P ,[/X;
MZ[X#T_XA^(O$?B71?&/AR\\/Q^&?"^L6FM&_>VTVZN;RPU*WL_Y^8O\ @GU_
MP4:?]B;X*3>(O@%XKD^-WC?_ (+2:C_P48_;^^!?@/XQ?LY3>,?B=X6E^*OC
M+Q%HB_#C4_'GC[_AG7Q9X:\$:5X8_9\\3>&_AO\ %'QEIUEXBUKP7:6>MZ#X
M9B\.VEM?_=?QI_X)R^+OB=+_ ,$]/@E\-OV=F^%7[,8_;J\8_M\?MX:GXS^*
MOACX@?%CQ5XU\%>&-6\5> +7X[ZG=^)O$%_\6_B'\<?BEX@TZQ\=3>$_$GQ,
M\-?#W3? 'AW2O#?C2#P9X8\%VUMG33:I<[6KP\*FZ<955A:U:H];*G2IU<31
MBH^T?M,/%R=VXRN;M[3E3T]O*GLTXTGB*5."ZRG5G2H5>9N$73KRY4THN/U'
MXW_X*2_#+XI>(_V M._8V_:4^ >OV7[6O[27Q \+::?&OPP^/GCF#X\?!7]G
M74/B!X6_:<LOV>=?^'>C66@Z=XY\$^)?"L%UI?Q"\=WR?"-/"L9\?'4M=\(:
MEX=D\3_3T/[?G[(5U\8_#/P!LOC3I&H?%?QM\3_'GP8\$^&]-\/>-=2L_&OQ
M/^$_A^[\2_%_PAX.\5V'AJX\&^*M0^#5A8W-E\9I] \0:AI_PB\31CP9\2+S
MPQXOEBT.3\U?VB/V/OVN_&__  4R\<?M"_";X7>$_#GP[^!__!,_]H'P!^Q/
MX\N/%W@72?"^@?MT?M'^)?&7B'X@?$2Y\(6,\_C+2O&>JW4?@S1M>U'4O!R^
M#O$'AW7?&'B[4?']SXLMH/"&J_-?_!.G]@']KOX1_'__ ()A7_QF_9CM_ 'P
M:_8:_P""8/Q \):2;KXL_"#Q+>>&/V^_VA/B! G[37B/6)?!WB;Q%K>K:S\0
MO#?AN;6;6]T+3/$/@K^SOB/<WE[\1U\5P:_X6+IM.,7/F2M4JS:2YDN:O!12
M>J:C@>>-**E.^.HVYHN]53YDY<MG\$(K6W-R49N3>S7-C%!U':,OJ=:_)*T:
M?ZD_L@_M:_&?]I?]MK_@I#\/)8OAZ_[*O['WQ%^$WP ^%'B;PUX8UZT\8>,O
MC7>_#+2?'W[0^D^,_$VH^,]8T:^;X2ZOKOAGPMI]IH'A7PSYCZ]=G5$NI=-M
M+R_[?XS?\%3/V"_V>M=_: \,_&;]H#3O >N?LN:-X$UWXYV&I^!/BG=/X+L_
MB=;3ZA\/K:";2? VH6WB[7/%^CV6J>(="\,^")O$GB.^\,:%XD\41Z5_PCWA
MK7M3T[R#_@C!^SE\<?V;_P!BFWL/VI/  ^'W[4_QH^-_Q^_:1_:4LG\2^#O%
M5UK7Q>^-7Q1\0>*-5UFXU3P!XA\7^$I(8O#K>&- TE],\5ZS+=Z)H6FW^IIH
MFJW5[X=TG\B_VA?^"6_[:'QP\#_MW^)O%7P977_B1_P4F_X*F_ ;P_\ &S2-
M)^*?PNTSQ!X'_P""2?[.WB/PC!X(N=&UG4/%-OH%KXTUS0?AKHLWC;POH'B#
M4/$&JZ5K^FV,OA[4;_P[>6%V)-2I4WRW5"DJLV[Q]M.>%A-\T6^90J8JO*3A
MS/V&"<HI1G#E&U:K.TFG6J>S@E:7LH1Q$E926DIT\-24.;EO6Q<8N[C-/^C'
MXV_MI_LQ?L\6(O\ XJ_%;3M+5?A?XE^.-S8^%]!\7_$S7-,^!_@T:>?%_P ;
M-;\.?#'P]XQ\0:%\&_"S:MI47B+XJZSIECX!T:XU/3K;4?$-M<7MM%+SWQ,_
M;^_8_P#@]X[\"?#CXB?&W0M!\3?$SX5>(OCAX%E@T3QAKWA3Q%\)?"NES:OK
M/CVU^('ASPYJ_@&#P^MLEG:Z;<WOB:U?7M:UWPGX=T&+4M?\8^%=,UG\6OV@
M/^"</[:_QE^-O_!6KPSI6C:5X?T?_@HUIO['?[/7P[_:=U+Q3X-U3P%^SK^Q
M%X(\ 7.G?M&> O"_PZ3Q#%\5KCQU=W-W\0]'T7P)IO@[PO\ #OQYXS\?^"_'
M.M^/= LK3Q=_PCJ?M)?\$Z/VM;CXM?MV?&'X"_"E9[KX%?\ !*SX??\ !.;_
M ()1^'#\5_!6E-XBD\9>&]:N_C'\4KJXU;Q!IMOX$\??#O4KGPWX3\%ZEXZO
M/#MCXB/AXWTSQV2:9JEO,I6A*:3;:J3A&UY**P^+G"G/E_Y>QQ"P%*4HWA4=
M3%\D5"C3JSJ*O*,6U;]W"<OA3FZ^%A.I'FVI.C+&U8IWG"-+#.<G.M.G#^@W
MX"_'CX2?M/?!WX??'[X$>,[+XA?"+XI^'X/$_@3QC86.L:5!K>C3S3VIEDTG
MQ#IVD:_I%[:WEK=6&HZ1KFE:;K&E:A:W6GZG86E[;3P1_)7QQ_X*P_\ !/O]
MFWQY\4_AG\;OVB-.\ ^-/@A#\-;OXN:5?_#_ .+.I6WP]TWXOZMH^B?#O6O$
M^MZ#X"U70--\/^(=1\0:+&?$,FJ'1-'M]2M;_7K_ $O3Y/M0\%\$_P#!+CQ
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M*K4JJ)*6DI04G[E5TTTUK-XV>'557OS*.&P=*HG9TZF,J^\Z4*4I?L[\:_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!& D42* *Z"BBC^OZ^Y?<NRL?U_7WO[WW84444 %%%% !1_G_/YT44 %%%%
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MOQ*T[PIX?\;?LZ>'O&7P<;PT/"5K'I7@WQ-J'COP+XWDUFV\=ZG=7FO>#[2
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M5UI?Q(L/A%\?_"'@2RL9[7Q%IO@EO!*7]EJGC,6-I%JGT!\3OVI?A_\  /\
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MHR5DVXRA))J29]T45^-[_P#!3+XH+\&/B1XST'X(^"_&GC;X0?\ !2CX*?\
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M:=DI+246FJC<KIIJ5O95)2OL^9^Q<VMVH.H[6;[#Q5^Q;I/COXQ>$OC!XO\
MB-KU]>^'?V0OB[^QOJ6@:7H>C:1INN>!?CAJWPS\0^/O%JW0^V:AI7C5];^$
M'@=]!D@GN/#FD:6OB&PE\/ZA=ZO9ZKH^9\"OV'-(^$"?L[OX@^(VJ?%*[_8^
M^"VI_ /]F.Y\0^&=)T6+P?X-U'PWX.\'2^,?'6GZ!=6UAXZ^,U[X0\#:+X2U
M7QSHMOX \/1^&KKQ-IOA+P#X.;QCXKN=9X#]H'_@HO\ #?PW^RU\'_VBO@-?
MZS\1_#WQ]_: _9^^!'@SQ%IOPJ^*^LIX<D^*?[4OP_\ V<_B;>>*O"=MX/A\
M3^$_B)\*O^$A\:6]M\*_'ND>'/%^J?%KP@/A9=>'7\3#4=#A[+PQ^U?X(^!6
MAZUH7[3_ .T7H_BN_P!*\<Z-$GQ(_P"%&?$+X<:=\-/ GQ?U2RE^!7AC]JK7
M-/TK5OAK\)/BO/IFMZ)IGB36_&I^!>BZ[<:IX=UR/X9?#^#Q+INDSN+YIU9)
M^^ZEY.[;G5JN59N-N:+G_MLZG,K)1Q,E"7OJ#)+EA3@T_9Q@E%;1ITZ48TDF
MFTU!+"0ARN]WAXN:]QR7 ^$_^":FF>!?@C^R=\(?"/[0?Q+T/5_V/?VD?&G[
M17PW^*,/A?X8W_BO5KWXFZ/\?_"OQ#\)^*=$UKPEJG@2[LM2\(_M,_%'1_#F
MK:=X5TV[\-7<'@C69[?7+OP_K">*-KX??\$[S\)OVC?B-\5OAG^U3^T/X-^
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MW6BY7+%5N9**UK5'9)RY?1=$_9FN=._:YU?]KR^^(U[>>)O$7[.W@S]G#7?
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M\!:KX@$?Q%^/GBC]G34/#-[/%X=_::_93_9A_92\7:3\5IM>TEK&^^&7@O\
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MWKZJ+YIR[-2DVXIZJI6;Y9VO=0L]'>*C[MM&VHJ/=V25[:'Y6>/?V+M!T_\
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M+P3H&K6GU[X6_;!_9W\;>%=8\6>%/'\VM0^'_BKX@^!FL^%;7P7\0!\5-/\
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M?J^M^&7B,$OCCPEX=^*7QN\"^%O%22+J.D^"/CC\4_#MNZ6'BS4X[CB?$/[
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M7]J/]D+]H'X%Z=\2/A _BWP'8_'/XL?!WXN^%?C+\/[NZ^(5E\*?%6G66L?
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MSX??XD7'Q=>XU.7XK> /$/Q3\(^/_ 7@WQGHWB+6KNU\):;\1M+CUGQ)H?\
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MN_"NI&RC\1Z)>^%O$GC/P5XP\$>*;%[/7O"7C#P9XO\ $.BZGIM\+.ZN=/\
M$6FZ]H6D^O4TK1C%.W+##J+T?\"="M1GRN\.:U&A&:Y4IQ@_:1]I*?*K)SE-
MJ[<Z_,KM?QH5:56',K3M^]JN#YVX.2]G+D4>;\*/%/[.WQE\>^&_V6/'?@/_
M ()T^ _V3=8T_P#X*(?L^_'KXM_"3X>>(?V:H?B#9_#SX3^#_&'A77OBC\9O
M%W@'Q3X<^&_BWQ&QUC2M"\'^#/ FO_%'7=.\":#I6JW?B;^U?$%W\.?A[Q_Q
M _9-_;0.C?M:_%#X6?"*V;XH>$_^"O7P[_X*"? ?X4^-OB+\.]!T+]J+X3>
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M ,+[7P3XA\.:MIWA?Q#X</PJOM%EO/"^HP]1\8="USX4_L"?M^_#67XB^/\
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MZW_W>-K/D]GG**E)R^%/DT5OBB\"^;7K+ZI4O:W^\2U^/G_FN_8W\<V'P_\
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M<E/%?6)I.S:]I!RIRZ+234H\T7_(1I7[:'CSP;X/G^)?[&7QGU;QUXI^(O\
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M33?BG\%[M/&-QX>MO$=_X8UCXE6?@[Q//-J?B9;";QO'X3UZQ_MF_P#["O\
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M[/'[+'Q5\2^'[GXK>*?$VL>+_"_PUUW]JWXI:=X(\9WFK>)EL_"?@3XJ>+]
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M4U[U-MR@[RN?G1X)_P""C'[2T_PC7X]_$SX1_L]:!X&\:_M/>*/V&_A!X/\
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MUOX;:#X T_PS9V^G>$;KP=X]^(_C_P"*VG>(I$UGQ-+\1_%MW>W&L/X3\/>
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M^*? /AJ+0?AGJ6D^$_B9J<7P5O-$\%W>LW>J>#M%O[C2=2UW4=>M_$VH:=X
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M;>#OB5^S9=^*?#7@OQGHOC2^74M6B\4^#?\ P4W_ &H_$NF?L3?&GXM?L_\
MP1\._LV?M?\ QT\4_LIW<OP_^*7CSQ1\7OA?\:I/%WQ@\.?#3QE?Z=K'PXT/
MP?X@^$/BC7_A5_PKW5(XM5TGQCI=SXE\-_$B6UMXM0UKX6^%/>OA/_P2W\"?
M CQ;\!/&WA_]HW]I/5M#_94^)G[1OQ(^$/@+5H?@]KVB:-X4_:6?Q)K7Q2^%
MNH2V'P6;XA>.-(O/$&OR:EHWB36?$FL_%>SBLH-&TOQ<O]I:Q+JOE?\ P3:_
M8^\1Q?LP?LOO^T>OQ8T?5/V<_C1\>_C-X1^ _CWPUX?T.W\+_$OQ5\2/CI'X
M3\4:S)I?A]-8\<:+X>^'?Q2F\0?"W0WU?4++PYXH\2W.N>(KOQ+XT\(^ X/A
M@4VO<4VWR0IRJ76K3KTU4BVMZGLI5X*4;)2A2JN*@U%74LU)P5G*<HP5]FJ%
M5QE9WM3=54)-/7EE5IJ\[MYN@?\ !1W]K:.P^"WQF\<_LZ?!6U_9K\:?MX?$
MC]@+XFW'@?XK^,O$?Q7\%^-X_P!MWXD_L4_"KXMZ#::YX"\*^&=:^&#_ !$\
M+>#-"\:6&H/I?C6]E\97/BW1]&T72]$7P]J/@_QD\:^&?@%\-?\ @XD^(C?L
M_P#P9^.OA7PG^T]\*/%OBCX)?%O3[.+X5^.[?5?^"=W[ ^M>*)?%6B1^$O%%
MEXBN+K6-5OO%MSI=[I=M_P )/XC,CWWB#1+R_EUZW^I?V*?V2?$'BWX6M9?'
MO4/BQI/ACP;_ ,%%/VQ/VL/"WP)\9^$-%\):1<ZIXA_;?^//QY_9R\17FJ-X
M8LO$^N^"-/L/%WPY_:$T#PW/JTGB#0OC/''!XL\0G2/#J?"W0?>OBI_P3=^&
MOQ=\$?MY_#_Q'\8/CEIVA?\ !0OQ3X8\5_%^70;CX/P:EX)O/"WPO^&7P:M;
M+X2W&J_!_6+?2;#4OAW\(/ ^BZNOCRS^(EVUQ9W^KZ1>:/JNI3W:JC)JE:I'
MFE4H4EK'WFIK*:M6%1S=KSE3QMDHQ4$XPEK[-4)FN:JG%M1C5J7Y6TER2S*G
M3G"UG[L*F$OJW-J<XNSG[7G?CU^V?\;].\>_M"?#C]E#X'CXX^/_ -ENT^%-
MSXL^']]9W]E)\7?$_P 1_#\WC^Y^%?AOXA#7M&\-?!?5;'X<W/A;5]!^(WC/
M2?B%X<U[Q)XKF\/ZKX9\*Z=X7NO$FL3Q_MSZIJ'[;]_^R+<W7P[^%/B[3?$7
MA%_"OPF^-&D>+_"OQ*_:/^#.L_!GP]\1_%WQR_9H^(5QJEA\,OB-/\,_'.M^
M)?A7X^^#7A;3_&7B?PG%\'_'GQ \1>*]*T[7?"7AZXWOBA_P3OT+QU^T;>?M
M->!/VE/VF/V>/''C_P"'GA#X4?M&Z3\#/$GPZT'PQ^TIX&\!R:U-X3'CVU\5
M?#3QAJG@[QYH<.OZOX?T?XN?!S5OAO\ %/PYX.UC5M#\)>+?#UZVCZWHGHWQ
M _8T\-_%3QWX3UWXA_$+QCXK^'_P\^/7PS_:4^&7PHU'2? <>C_"WXF_"+PA
MIGA7P58_#SQ78^%+3QMX<^'J7MC?>.=?\-KK=UX@UOQ9KVO:&?&EI\'=?\1_
M"76G'['->RDO:==%*<6XV6L9Q=.HH27-S0J4VZ3E&H*5_?Y5O!\CO9QDU3DE
M)/7FC)5:;E%\J4X5$JBBX'V2,XY&#7X(_%3PSJ7_  3(_;IN_B5\"?A9X5\1
M_"?_ (*L:QHGP/M/!R6FB>'].^$?_!0G0/"?C3Q)\,?$5_?6-Q9ZSIG[.7[0
M7@71/&>K?'&U\-^'/%.J>#/'_P -I_B#H6E:IK_Q1U?1M3_;CX>>%_$7@[PV
M=$\4_$?Q3\5=6_M_Q;JJ^+_&6F>!](UTZ5K_ (JUG7=!\-/9_#OPGX)\,'3O
M!&AZCIW@S1;V/0(M8U+1]!L=1\2ZAK/B*ZU35[WP;]IK]DGPS^U%K_[-_B'Q
M/\1OB7X&N/V7OV@?#'[2O@*S^'Y^'J6.N_$7PGX5\:^"M,M?&X\;_#_QO=ZA
MX4F\-?$+Q5I]_I7AV\\+ZG(U]#?6FNV.H6-E=0.'+[2E*?-R?!5Y;*3I586J
MPTM>SY-8ZJI2A4IO1.3E=PG%;ZR@W9VJTW)T9I/17=[J2_A5:E.:U:C\]V(\
M"_L#:;^R+^QE\"?#O@Z+XK?M5?$OXE:;_P )EJOAJ+2M"O?$WA7X7^._CU\>
M?V@_'7A;PI<Z -=O=9U/08=)TCX<^&M>\+6&G:EX\\+^'?"]SX4^&G@UX-#\
MYM/^"C'Q+LO&G@_X5^)OAIX.M/B1X8_X*3:3_P $]?CM:VVHZQ'H5]8^-?V?
MKG]I+X8?M ?"FY-Q?W>GZ;XP^&>H>!=1U/X8>+HM2OO"OB+Q'XI\)IX[\16G
M@;3/&/Q!^Z/VA/V9?"GQ_O/@UXKN/$'B+X?_ !4_9V^)\?Q=^"GQ1\'QZ'+X
MA\(^*)_"OB3P#XIT2_L_$.D:SI7B+X??$KX>^,?%/@#XD>$KRU@DU?PYK;ZA
MX>UGPGXZT+P=XU\,^(?$'_@GK\/_ !WX,GLK7XF_$[P5\7KC]JKP]^VG+^T!
MX7_X0:?QVW[0/A?PUIGPYT77'\.>*O!OB7X9W/A73O@OHNB_ RQ\(W_@N\M4
M^&FBZ4;V]O\ QY#=^.KV8N2E%RLTIVE"*LO9JKA/9JGJE&,,/'%4Y0;U2HJ#
M3C!Q)*\6HNTN1VDVW>I*GBN=S>K;E6EAYQG;1^T<D^::EZ'^R5^T3XJ^/U[^
MU/I'BWP]X>T.]_9T_:S^(?[.>GWWARYU*2T\6:)X2\%_#7QGI?BJ\L=3\V;1
M=5O(?B"VG:AI4%_J=G%+I0NK:_=+OR+?PQ/VTY_%'[<_BK]BG6Y/A;X&U'2?
M$EMIEO\ !_XS:!XL\.?$7]HSX"ZQ^SZ/B%JW[0/[-_B[5]0M?AM\9/#V@_%&
M_P!0^#OC[X3^%M"\4:UX+T?X?_$'QKXW\5:#<R:/X'?Z-_9D_96\/_LP3?'6
M[T/XD_$_XC7G[0?QLUGX^^-;GXEW?@J[;3_'WB'PKX1\(:]+X:'A#P1X..G:
M1K-CX)T74KK1;MM1TO2M7>_A\(6GA?PP^G^&-,YCQ_\ L<Z1\5?B/X.\:?$G
MXH^.?&WAWX9_'K3OVEOA3X'UW2O 4D?PO^*.A^ =4\!:%9>#?&5IX3L_&EI\
M/-/?7-:\<S^&-0UC4=?U3QAJEYH5_P"-9O@O=WOP?NCK233E'V<(U=M9J%.-
M27+)/F<I1G)1=H24Y1DZ<G"4*E_R\Y/=O.;IZZQCS.5-76JLFHN2O*+BI)5(
MIQE^3G_!*7]H/XG?!;X'?\$J/V?;OP!\-(O@#^TIX0_:+^&G@74=$UW7U^)?
MA'QY\'8OB;\8M.UK5]-?1[?P<_@/Q/X-\(^,?#2>&=.E;7/#6K:9X:UV7Q-K
M=OXFU+PSX0^M/#?_  4D\6ZUX%_8D_:=E\&>%)?V5/V]?C-X<^"GP^BLH]>3
MXM?"/_A<<OC*U_9A^*/C>XGU&3PYXZT?XM7_ (=\):3\0?A]I.B^!-8^">N_
M$[3M/M?&'Q8TSP=K7B'5/7OA-_P33^&GP?TO]B#1]%^,WQVU^T_8*\2?%KQ+
M\*W\3S_!N2Y\;W/QD\)>.?!'B2T^*\GA[X->'8]3L]'\._$3Q+;>&!X"A^'5
MS;7#V%YK]QXCGLMTNQ\)?^"=/PF^$6C_  J^'>E^+O'.O_ ;]G[XU>(_CS^S
M[\#_ !$?#%SX8^%/B[7I?&]WH_AJSUNT\/6?B?Q+\-?A/J7C[7]6^"'A'Q-J
M>H77P]OY-*%QKWB.P\&?#6P\#5!KW?:7DXNG%RO*TJ<%A(U.9?$ZDJ<*T:4F
MURRC!S3OS/.S5^6R5JC44OMR>+E"2;]V,55G1E.-GS0E.,;<KB>1^$O^"@/Q
M'UCPG^QUXBU;P'X(%S^T+_P46_:G_8(\;V>G7NO0P:+%^SYXO_;5\+:7\4_"
MEU<S7,BR>(/^&08[N^\&:Q;7JP?\+!=+?Q2G_"*K_P )%\Y_ _XZZ!^R5J'_
M  4MG\*^$M"N_%WQB_X+8^#/@+\)O!XD'AGPYJWQ;_:&_9K_ &$]%&M^(KW3
M;"ZDL]"T'^U_%/Q2\<W%G9SZWJ^C^&]=M-%AO?$VIZ9;7/UM8_\ !,CPEI_B
MGP-JMO\ M'?M"Q^$/A3^W%X^_;P^$_PS@C^!D/A3P!\1_BS/\>=9^*O@FTOS
M\%G\7>(_AYXY\6?M)?%36KFV\8>(_$'B?PU8:EIFB>!_$WAB/3!>W&GXW_X)
MC?!_Q]X._:0\*ZW\3OC7%J7[0O[5O@[]M?3?'FEZG\.-+\<? ']HOX=:1\+-
M$^'_ (T^!.IV'PSM[#2H/"-C\&O L5CIWQ"TOXC-J<4&NVOB6\URQ\2:M:SQ
M"ZA1]I[U14U"O*&CDG4RN=11>B3E[''.#BHJ+E"[C[2+HZMK]XE=)RYH*6L5
M)?VBH/1<RBHU<&I)\S?+/1\DE5\D_85\/>(?#_\ P42_X*SQ>+;/P&/%.HZE
M^P_J>L>(?A[H-[X6T;QI/<_ CQ&J^*+SPOJ>J^)-1\.ZPXC?1+[3[OQAXP>[
M71(->&NQ_P!M_P!AZ-U_[1W[='Q;^ _QMN/#%Q\/_ $GPZTKX_?L1_!>UT9M
M5U?Q;\2_B#X2_;'^+7@+X(S_ !QN=2\ W>MZ1^SEX5^'7Q#\?:CH?A#PY\=_
M"-E+^T)JWPC^)&C^!/%.A&;1M27Z&_9S_8_3X!_%7XV_&W6?CU\8_C;\1_VA
M-%^$>F?$G4/B19_"'2=#FO\ X.>'=4\->'M=\.>'_A?\+/A_#X=O;W3=8NK/
M4["VNIM!EM;73)TTI?$']M^(->\3^+7_  3*\,_%+Q_\?/&EM^TM^T5\/=*_
M:"^./[*W[3'B'P%X,3X%77ACPU\?/V2]2^!,W@/XB>&KKQQ\%/&'B>X&IZ/^
MS;\)='UCP5XLU_Q-\/#)I.KZO'X5.H:I;'3*5TJ,;JT(1C)I-)N-=MI)W=G1
MJ5+-*RF_@5XNEC:25=I+FJ5:E2%W=KGIKENUU52%-23?PIVD[-3S?$_[</Q5
M\'_&#]MGX :[X-\ 6?Q5^#NA_LZ^*_V3=-FDUU-.^/\ X9_:G\57WPE^%NJ^
M)I$U:>^\-:?I7[15A>_!/XE:OIEK=V/@BTL].^*>H*=(\5Z;X4T_#^+O_!0/
MXA^$_AW^W7\>/AIX,\%>._A3_P $W/&FI>#OCIX9OO[:T?Q[\7H_AE\'?AC\
M<_VC-;^%>MR:RN@> )?A9X!^)-RG@OP_XNT;QJ?BQX]\#:YX-NM>^&WAO6-#
M^)DGV3XZ_9+^$?Q%_:7_ &?/VL?$MIJ\OQ>_9L\'?%WP3X!U.QU"/3=/U'2/
MC-:^$K/Q&OC*RL;6#_A)TTA/"@N_"=A?2C2?#VK:YK6LV6GKJ<]M<VODOC3_
M ()_?#3Q;KW[444'C3Q[X>^$_P"VXNDR_M6_ [2IO#Q\#?$K5+;P3HGPL\8Z
MWH=]<Z))XJ^'FJ?&OX0>&?#7PF^-T_AG7$'B;PEX=TG7/!:?#OXHRZ]\1]=5
MI6A[R4DIJ3<7)-PJ4U2E)*5YJI2=5U8KDM44%'EYDX7UGHW%N#BE*TE&4).K
M%.S47"HH*E+WO<G+F3Y'[3Y@_: _;I^%'[-W[3O[1?Q9\6? OX:ZKI/P=_X)
M>>&OVEM*^/GANVM9/V@?BGX*U+XP^-],\*_L\Q:KJWA?1YO#7A'4O&U@M_X6
MT?4?%6J^'Y_%WC:/7M7A\+FTU*2:MX T+XD67_!:#PSKWQ:TKX2KXU\0?\$L
M?&\E[KWPLT[7K"/-M^U-\)S=^!=4N/$LMYJWBFR\"7%PJ^'_ (A32^&O^$UM
M]?O6?X7_  \?1?)UOZI^.7_!.[X'?M&_$GXS^/?BUJ_COQ%H/QX_9"E_8J\=
M_":.Y\&Z?\.O^%52>+/$7C6+Q#H=Q9^"H_B/HWQ)L->\3ZC-I?B&W^(+:)I<
M<&F3V'A>WUC3K;5UJ_ []A"Y^$WQO\%?M"^-?VK_ -I;]H/XE>!?@-XD_9OT
M^^^+I^!45AK?PSU[QGX9\:VS^*X?AU\$O FHZSXTTK4O!VA32>-8M5L-9\17
M\VNW?BEM9M+W2-,\/O>I"7O<L)5.7F?,U3G#,8*+:LO:+VV$YI12IN//:"E&
M;FI)N#6\I.A*36B<Z;P$IN*=WR.5+%<D9-RC[EY<KCR['[0_[4'C+PA\8]"_
M9M^#&@V6K?%[7/@?XY^.SZGK?@WQ)X^T#1M#\+^-/!G@'PWHFH^%?"GB3P;K
M4L7C;Q!XHU?[3XJM/$4D?@NR\)3R7/AKQ)<Z_IEK!\_:9_P4(^*O@CXI_#;P
MS^UE\%](_9:\+_%7]A#XB_M4V&G:WKD'Q%\9^"?B_P# !?#EW^TK^S[J-YX.
MUHZ'X]E^&WA3Q)I7Q-\'>*?#%II5]\4O!4WB&.'PMX1O_ FKRZG]#_M1?L0:
M-^T5\3/@U\=_!_QV^.?[+?[07P/T_P 9^%/"WQD_9_O_ (<#7-?^%_Q*N?#5
MW\0/A-\1?"7Q=^''Q6^&?Q#\"ZQJ7A#PQXIT73?%G@G4Y?!_COPYH?BSP_/;
M3PZG9ZOK_$[]ACX(?&#PU^R_X;^(#>-?$+_LF_&;P?\ 'GX=>)K_ ,5W=QXR
MUWXA>%=#\4Z'?7GQ#\32PMJ'B_3O'\/C+7[GXFZ1=-!I_CBXOI8]8MY+%WLV
M(;+F;3=249V5VJ<G6BJM-:1YZ=.I1FH3NI5<.TUR5I23E>[Y=E!2CK9.I%4I
M>SF]9<DZD*D'*"3C2K\R?-2C"7@OCG]K_P#:1TZXL/@;X0^$OAJ__:_\.?LD
M^!OVG?BAX+AT7Q)XR^'6F^*/B-K/C;PMX%^!^CZMH/BG1[ZRM/$GC3X6_%'P
MOJ_QMU'4=1TWP3!X:\/^)(?AAXWMO&-UI7@_PGXQ?\%&OVO?!FB?M?ZYH_[-
M/P@\$7_['G[ G[-'[>?CCX>?%+XJ>)=7\<2VOQ'\-?M->+?B[\ ;^[\">$9?
M!VF>/?#LG[-WB'P)X:\;:1X@\5>#K'57L?&-Y;>*M.UR;PMX7^Q/VE/V#='^
M/'QO^'/[2_@#]H/X^_LI?M > / NN?".\^)_[/\ >?"NXO?'_P &_$6M6_B*
M\^&WQ \)_&OX6_&'X>^(M,T7Q EYXC\#:G<^$?[6\&^)=4U'6-/N97G\A<;Q
MI_P3?^%GC2T_:LTN?XJ?'+2]$_:\_9 ^'O[$GQ TRV\0>!M<N/#/P>^&NB?&
M#P_H6K>#/$_C;X>^*O&EY\2;^Q^/7Q2G\1^-/B9XD^)$FN:IK]OJEUIWVG2K
M(IG/VC:=/W;.NY0DU)7Y:CH<LK)N',Z,9QE[SY*CES*;E*X\J:4VY+]S>44T
MVN:DJZ<7*RDTJ\H2BVDIPC%IP27V'X@\5:QJOPAUOQKX N=+TK7M0^'%_P"*
MO!=YXOT6\UW1M/U2[\,RZOX?G\3>'M'\0^'+_5].M;F2T?6-'TSQ5H=W?6Z7
M%G9Z]ITLL=_%_/;\%_%_[0OQ<^(W_!"WX_W5Y\)O&O[4/QR_X)0?M-^,;[XB
M>+= UKPMHGG>./ '_!.OQPVI>/+7P_?:YKGC.70_$WBCQ#JKZ!X>U'P+I.L7
MFOZC#HC_  _M;V]N*_HJ\->"[+P]X T+X>W6HZGXET[1O".F^#I]5UK^S;?6
M==L-/T>'16O=6_X1S3M!TB'4]0M8?-OFT/2=%T];J65M.T[3K<0VT/PA\!_^
M";GA;X#S?L;7-C^T/\?/'$W[#'P.^)7[./P4B\8VWP(BLKOX0_$/1_A3X;MO
M#WCJ+PC\$O"][KNH>"?#_P $OAM:^&?$&E:CX>U>\OM*U34/%MSXF37+JSCV
M=EB*DH.2H^\J?_/Q1YL=%6;5XRE2JX>,FWK[U_AGS8)5)8:G&HHNORTW5M;V
M<IKZC.HG:R<?:4:\H)))/D>EUR^2?"#_ (*2>,_CW\+/V0H/"/P_L/"GQW_:
M<^ OQO\ C3X@L[?PWXD^,O@KX:P_LX_$;X6_!CXDI9>&]"\0?#;Q7XTTO6?B
M?\6-!A\)3R^(/";V_A"SUG6=6F?6K/3?#>N_H3^S=\1/BI\5/@1\./B%\;?@
MCJ_[//Q=\0^'FN/B!\$]5\4>'?&EWX'\46-[>Z9J&F67BWPW=2:)X@T749+$
M:SX9U7.G7MUX?U32I-<TG0-9.HZ/I_P:/^"2/P[\/_"S]E?P9\+?VFOVI/A-
M\4OV-M;^+%Y\$OVE/">L?!J3XL+X5^.FOS^(OBS\,OB%X9U/X+W7P&^(WP[\
M6:BOA^[;0?$/P:DDL-2\"^!M7M[UM1TK5;C7OT1\)?"/1/"WPC@^#]UK_C3Q
MAI4OAS6=!\1>+?%WB.>Z\?\ C"]\4?VA/XO\5Z[XBT>'1([3Q-XGU;5]6UR[
MD\+:?X;T71;^_:U\(:)X;T2QTK2=/AN7LZC2C[5QTBKQA[14X23IMJ7)"51U
M*<E-34>6$H1E$TBO?@FWR)M-WYGR^TJ17,K1<Y*FJ4XN+BVW.,FI71^3/A7_
M (*??&J2[\?Z+XF^%/PBU;QG8?\ !.WXE?MTZ/X:\*>-_$G_  A?P^\=?"#7
M=!\-_$O]E[Q'\>-"TKXD_#?X\W'@KQ#XOTWPKK/QX^!D:>'8/%_A+QMX>O\
MX=:3=)IS+U?PH_X*!?M27OQ/_9Y\*?&7X$_!+2?"G[:_[)OB_P"/W[+NJ^!?
MBGXZN-2T3XB_"SX??#[Q_P"+_A-\?WU+X:ZAIOAZU\:>&?'\7BKPQXO^'Q\:
M0^#G\-^)?!%SIGQ$>VTGQSK7(:]_P2YL_P!GOX#:EJW@3XZ?M-?'+Q?\$?\
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M7\4/V2OVD/V>8_%T%_XKU#3;"[TGP9XM^+GA?7O%VG:6VI^+9?"-MKEWX/\
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M)3<G9KFYHM*:O"G*=11]I^@MU^V?\ ;;PWH7B6/6/B#J \1V7QLU32?"FD?
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M)?@1\'?'R? ?Q?&OQA^'GQO_ &5OAAXUU&3X2>-OB)X'\&7/QM^,GP9T?4_
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M+2[MJ_=?[1R[:)R5.G-+X73GS)N\2'X3_P#!0[X*_$I/VC=1U;3?'WPZ\/\
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MG_5+7Q%X-_X)V_'/]F[]H+6X?C/\*?$NKZI\?)/B;^S?X[L;[X=^"=&U[3_
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MP- UI-&T+Q3%<_8G@3]IKX/_ !*\=+\._!NL^)=7UVXLOBC?Z;JA^&_Q(L/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!117X!_M4?&/]GO4OVU/VM/V8_V]OC)XA_9_T?Q;^SI^SSKW[ OBO1_&>J^
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JI<:?87=Q8W=U96ES=:7/+=:9<W%M#-<:
M==3VEQ837-C-(C26D\UC=W=E+-;M')):7-Q;.QAFD1K=% &7>:)HNHW^DZKJ
M&D:7?:IH,MU/H>I7EA:75_HL]]:O97LVDWD\3W&G2WEE(]I=26<D+W%J[V\Q
M>)BAN/9VDCEY+6V=S()2[P1,YE7R-LA9E)\Q?LUMA\[A]G@P?W4>VQ11_7]?
M<ON79 9=UHFBWS6;7VD:7>-I[W<M@UU86EPUC)J%I<Z??R69FB<VSWMA>WEE
M=O"4:YM+NYMIB\,\J.^]TC2=3DMIM2TO3M0FLA=K9RWME;7<EHM_:R6-\+9Y
MXI&@%[932V=V(B@N;662WFWPNR'1HHLNR^Y?Y 4[W3M/U)+>/4;"SOX[2\M-
M1M4O;6"Z2VU"PF6YL;ZW6=)%AO+*X1)[2ZC"SVTR++"Z.H8.>QLI+VWU&2SM
M7U"TMKNRM;][>)KVVL[^6RFO[2WNF0SPVU[-IVGRW<$;K%<RV%E),CO:P&.U
M10!7M+.TT^UMK&PM;>RL;."*UL[.T@BMK6UMH$6*"WMK>%4A@@AC58XH8D6.
M-%5$4* !8HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK7[*D6NZR/CKH7PFM?CG=^#[GP5XUL=/NOA7>>(QX/@\5Z+XYO\ P_:_#_Q
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M+?ZL45\E>+/VX?V;_ ME^T=>^,/%GBOPZO[)/P<\#_M _M!6VI?"/XNQZCX
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M5>*=.\*^*-2EN/#_ (9U?5];T'Q38:"S2O\ @HA^RYJ'@SXM>/;SQ/XV\/\
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MM^2<)J3^RX34N5PDH_4E%?*^K?MG_L^Z%\0_A[\/-8\6WVGR?%;XL^+?V?\
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MIX3\$:+INK^(? _A&[6+QWXZ\*:!X@NZ1_P4-_97\6?#GP_\6OAUXUU_XJ>
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M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K\]/\ @J!\"_BU^TK^R9JWP9^"OAG3O$?CC6/C'^R_X]A&N^)=,\*:
M!9Z-\"OVG_@Y\>?$<6H:M>K=W:7FM>'_ (::GH/A^.PTC4D?Q!J.G#5'TS2A
M=ZE;_H713C)PG3FG:5.I2JQO9KFHU:=:%T]USTH<RZQNKJ]U,XQG"<):QJ0J
M4Y:M/EJ4ZE*5FMGR59V?1V=G:S^!/VYOA%\6/CCX?_9//PR\&IJ=[\,_VS/V
M:_V@?'FF:UXF\/Z!>:-X ^%7B2;Q#XNLK*9KV^TW6_&+6\ZV.BZ-::@FAZE?
MQSBZ\4Z98B"^N/B3XT_L6_M,^-_@5_P4U\!>'/ >C3>*/VK/^"@?P+_:3^$<
M.I>._#EAI4WPS^'6A_L1:%X@_P"$HU..:^GT#Q&X_96\;7FGZ/#INJV]PGBO
MP%!)J4,EWXL;P?\ M5X;\=>$/%^K>.]#\,^(-/UK5_ACXLMO OCZPLI&DG\*
M^+[SP5X/^(UMX?U4,BK%J,O@CX@>#/$@B1I%&G>(=/9F65I(H^LJ$DG&2>TY
M5%V;F\'+YQ_V'#N.NW/J^?W:OI)?S05.3ZN,5BXKO9I8VNG9+7DTO#WOR,^+
M7[+'Q;\5_MG:)^T9\%? 7BK]G7XJ6/Q=_9^C\9?';P3\7?#\/PE_:9_9.\(:
M5X7E^+/PO_:R^!3ZEJ,?C7XJV&D>(OC)\./@5XITWX?:UXA\#:A9?"WQ;IWQ
MS\+^&=/U7PC%L?\ !3[5-;T7QM_P2XU/P[H#^*M8M/\ @IUX!EMO#<.K:?H=
M[K5M_P ,D_MCC5[/2=0U>2#2/[=&B'4;C0;'6+_2-'U?68+'2=7\0>&M,OKK
MQ#IGV9^U3^TIX?\ V4/A3:_%OQ5X/\7^,M!N/BC\$_A3<6G@T^&A?:1JOQW^
M+O@OX*>$M?U5?$WB'P\C>&M/\:>/?#L>O/HIUO7[:PNGO;'P_J,-O=-!ZGXT
M^%GPQ^)%WX5U#XA_#GP'X\O_  )KD?B?P1>^-/"'A_Q1>>#?$L*>7#XA\*W.
MN:=?3>'M<B0!(M6TA[._1 %6X"\5<;PY))/DA63WT4DXUI1AS72]VTE&W)SS
MG)VG.<6FTW).SE*C..O52A4HJ4G'5VE+EN_?Y(Q@FXQ@U^/GQ1_8F^/'BU?B
MM\6-#\$6<7CS]H3_ (*C_L*?MHZ]\-9O&WAJ!_AS\%/V,YOV5]!?0-3UM;MO
M#6O?%WQSX6_9OUCQ-+IOAZ^N?"6G>*O'VD^!)O'.I:#X.F^)&O>V^)/V=?C]
M\._VG/VY?B-\/?!F@_%_X=_MX?!;X6Z-IUKKGC'2?#0^"WQT^%7PX\8?"7[)
M\1]/U>%[G4OV??'OA34_!&L:CXA^'">.?B)X3\1Z-XXA@^$WBNT\2:;?6OZI
M45G**G&4)7<)PG3<>9I>RJ8>.%G335FHRI16J:DI^_%Q^$J+<9*2MS1G"HFT
MG^\A7>(A.SNG)3=M;J4/=DFVYO\ "C0?^"??QJ^#@^(_PS\ :5'\0/AYI7_!
M%+X#?\$V_AEXZU?Q)X:\-:WXQ^*OP0L_CCI5OXC\1>&9+^\/AOPEKVE?%+PW
M/-JZ7^HZA8:MI?BRRB\.W.GVN@ZIX@]D^''[+GQ[T#XN?\$E_%NL>#=+M]$_
M9$_8W^,WP*^.ES'XQT*ZETSQY\1/ /[-GA;1)/"-O&XG\7:!:ZI\#_$LVK:I
M(FAW<&EZ[X5NK/3+^^N->TKP]^N><?AS[?G7C.C?&&#QQ8? ;Q?\(_"^H?%O
MX2?'/3H_%,/Q@\*>(/!EIX/\&_#O6?ASJ'C[P-\0=3L_$7B+1O%7BC0_']R/
M#GA?P];> ?#_ (HU:WOO%5AK>O6.D>&;'5=7M-)5+R<I*+<K7M%VNY8Z2=HM
M\JYL?B-;J*_=K14[RS5-)-)OX9IMR5^64<$I;VNVL!A^E[^TMK4:C^8_[*'[
M%GQQT/X1?\$J?@Q\:/"V@>!Y?^"8-G8WOBGQGI/BK3?&.F_&[Q[X-_99^(_[
M*/@Z+X.W&F/IWB33OA3X@T?XN^+/B;XMU3XH^'OAWXQTG5_!G@'P+:?#OQ3I
MWB7Q'XK\&^7M^Q3^U9I'PFTB?2?ASX7U?QQX"_X+3?$C_@H%I/@6]^)>AZ0W
MC#X&?$[XW?%7Q7:6%OXFCL=6T;0_'_AGPI\6(-4\1>'M1\S2I+OPOK.D>'O$
MFN2WFCW-[^]U%/GDY.5US2J*JW:WO^UPU9R2V7-+"48M6:4$XJS?,E[./+R:
M\KCR-7O>*I8BBE?>T8XJLU9KWY*3O:S_  V_:*_8(_:1^/WCC_@I1J.A#P5\
M.[S]H#PW_P $[O%W[-WBOQ#XD;7?#%Y\8_V#_B/J7QL@\/\ Q/T[1=-?Q/X<
M^'7C/X@6GA/PM+X@TG1?$6NCP7<>*_$$GA:TUG3]&\,Z[T'[3O['7QP_:JA_
M;&^-B?#L?#+XG?&#_@E;\6?^"??PK^%?B3QKX0OKZZ\<_&?4/&NM^)?%WC_Q
M/X3U37O"5M\._"^NW7@"'P7JEAJ>I^,'T2?XIZG?>!],U.YT#P]K/[4UR?B/
MQWX/\(ZOX"T#Q+X@T[1M9^*'BR\\"_#[3;V4QW7BWQ?I_@;QG\2[WP_H\:JW
MVC4;;P%\._&_BJ6$E ND>&=4N-V8 C19<GL_LI327;VE'$4)VZ^_1Q%6%FVE
M[LHI2CS/2[4_:W]^\&WIK[.IAZT+K;2IAJ4KI*]I1=XRLOSV^%'P%^->C_MM
M_"OXX>(_!%IH_P .O#G_  3NT+]FO7M0?Q=X?U'6[/XLVGQ-\.^.[VWBT33[
MB=KWPG#I>D7-A'XEAOOML^MO!!_PCT>F,^KQY7QW^'/[;WPJ_;B/[4W[*'PR
M^"_[0?@3XX_LY?"K]F?XR_"[XI_&?6?V?M5^&OB#X(?%/XT?$;X5?&S1O'EA
M\+/C2OB;P,VG_M"?%#PO\1O NF>#(O%UK/#X/\1^%D\2L-8T:/\ 4JBJE)SF
MYMVDZE><K:)O$U:]6K%K6RE+$5.6S4H)0<)*4%)YPI0IP4(KW5&A&/-=M?5Z
M5"C2DG=>]&&&I7NN63Y^:+4VE^5D'[/7[27P>_:<_:B^+GAWPYX:_:'T3]L?
M]G/X$^"=<GN_$>E?#BQ^'O[0WP)\*_$+P*VI^*O#&N-J\]E^SG\5M$\:Z1K&
MM7/@35/B3\1_ASKF@Z_:Z;\,/B);>*H]0TGRCXB_\$NO&VF_!#_@FK\,/@M\
M5(K'Q3^QS\,-"_8U^,OQ!U)];\/7_P 6OV(OB+\%-#^#7[2_AS1;71]7FN?#
MWQ U6_\  WPR^+GP@O)M6U/3/AW\0O 6A3+;:QID5WIVH?M514*,4XNT6XN%
MKJ_N0J8BK&DT[KV=\5B(N-GS4ZKIR<H)*6CN[ZO53ZZ\U2G0IRJ)JS52V&H3
MC)6Y*M.-6')/X?QK_:Q_98_:!TS]LKP]^TS\"?V6/V3OVQ/AM\0/V</AK^S#
M\1/@E^T#XITGX1:A\']3^#/Q+^+?C_X4_&+X=^.]0^#/QPL)O \NF_';XC^$
M?BKX%TCP;:>)Q%IGP\USPK!XF;3;_1+?W;X1_ #XP>!/V\M;^+^J^$/!UM\)
MK[]@+]FW]F>+7?!$VD>%M$M?B;\%OB9\;_'>O)X8^%:7VH7WAKX77>C_ !<T
MS2/!J'5[K4]&OM!U+0[G2#HD6E^)]3_1ZOG'0_VD_#^N?M7_ !#_ &2%\'>,
M=,\7_#KX&?#/X^W7C'4O^$9_X0KQ)X0^*GC/XB^!-"M?#+Z=XBU'Q(=5TO7_
M (6>+K;Q#;^(_#_AP6HATZ?3#J]EJ,=XEQ;3LO>D_;/FEK+EG"I*I>5XW<8S
MJ34I\U2[MS348Q6<XPLF_=BI459.T>:-2FJ5EKRWE"G%QCRPTORP;;/A_P#8
M2_93^+/P"^,^I>*_#O@GQ)^S#^SUXT^#>K3?%G]CV7XLZ-\5_@/X>_:SU[QY
MX?\ &+?$3]CG2K2^UZ_^#?PE%CJGQATOQQX3@/PK\,^,=0U_X<ZQI'P1\,:C
MX:US4K_T7]O3]B_QY^TEX[_9D^)/P@\86?@+Q9X!\2?$+X-?'+4+F]U:PE\<
M_L/?M*>$?^$7_:3^'&C3Z)<6=U;>/_[6\,_"SXB_";Q'<W$MKX-\?^ =-U>2
MPU*TFU#3+[]*:*FR7L]$_9.+BFN967,N5IWO#DG.ER:Q5&7L5>FE%:7?OZZS
M4E)K1WDHWDFK>^I1C5]HK2]M%5KJI>;^#?B?\%OB'J'[>/[(7QV\*>#K6Y^%
M'P*_9L_;#^%7BIK+6/#VE7UMKOQX\1?LL:[X!L/#/A^[O;/[98:9:_LZZ_IF
MNO+)I-IIDWB?P?\ V:VIVA\12>'?B71/V./VHM)_X)-^"_V;)/A_X8NOVA?A
M3^TI\(_CK!X%'Q)TB/PUXYT7X1?\%'?!7[93^'M ^(;:;)8Z9K7BGX;^')_"
MVFS>)=%TG3=,^(+MI^HW*^%HH?%UW^YE%5S2TO+F<7%IRU;<,7'&1;U]YJM%
M7NW>+<9-M\QDZ-.2DG'W9J46DW%<L\,\+)*UN5.C9*R]V23C9+E/PW_;"_9/
M_:]^).O?\%'4^&OPM^'GB2Q_X*%?\$M_"_[,MOJFH?&&'P];?!WXX_#KPC^V
M'H4_A[5H+[P8VH>,_#?C'_AIGPT/!OBS2K/28%O?"GB>/QI8^#K&;1-0O^(_
M;L_9(_;]_:/\.?M&_#6#X?\ PK\=>"?&'[)?[/FC_ 33#\;[CPUX,^&'QJ^'
M?C#4O%/QRT+5M*O_ (>VEY\3O'?CR\@\&VOP:^*WC'0M(\/^!O#.B:S;:4?@
M[JOBKX@+\2OW_HJ8^XH1B[*%3VD5=OWE.4X;O:$I-KKW>K-&N:3DW=R@Z;V^
M&45&?3>25GV3TV1^87C/X$_'?6OVI/VN?C'!\/\ 3)?#OQH_X)R_!7]FWPI'
M:>.-"=W^,?PV\:?M:>-=<L'-^FFW<7@N\B_:1\.:1I'BV^T_3]0FO_"OBJ:]
M\*V-@= NM:^1_B7\%_%?@_\ 9-_X)?? KPS\4_AU\'_^"EW[+.C_ +*7P^^'
M>B6VN>$_'7BAM"\3>!8OV5_VI-2TCP?%<IXF\<?"+_A25K\:?C/I&H+I.FV:
M:K\#?"WCSQ)I^CWOPXU;3-(_?6N4/@3P.?&X^)I\&^%3\2%\*GP,OQ!/A[2/
M^$W7P2=6_M\^#QXL-G_;P\+'7/\ B='P^-0_L@ZM_P 3$V?VS]]1+WFN:SBO
M9)K:\:-3$5(*]UN\35IS=US49RB[MW;5XQE%/=U))NVDJM.A2F]GHHX>E4BK
M/EJPC).VB9X1\%Z%\.O ?AGX>> -.LO#OAGP-X2T7P9X)T@K=WFG:%H7AC1K
M;0O#6FE9;M;Z[L],T^QLK8K)?+=3PP8>[$K&:OQ8_9 _9J_;A\&?M&?LE_M
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M0'A?QG<?$'P)\/M8T31M>^'^IZ9<?#WXDZQXRT+6(_$?P^TGTSX7?"3]O?\
M9T_:J_:3\(?#?P)\%/B'^RG^U3^T/_PTO:?'SQ=\7-7\-_$K]GF;Q3X+^'7A
M7XN_#>X^#EO\-]=B^+&H7FH>![S7/@W?VWC+PQH.CIK\EOXZU66RT:QT*[_0
MM_C&GB'PY\+_ !G\&O".J?'7P7\1O'.G>';KQ9X#\1>!=/T3PEX(N5U^+4?C
M!=7?C7Q1X77Q;X$TC4=&M+%8?AZ/%GBCQ##KVF:SX3T#7M"%UJ,'M%*+<%!+
M:,8PY7M.$:.&A34H[M1I4L+RRCR\W+S.4W.I>FHR37=SG%K[$IU:\ZC@[:-U
M*E=.+ORI\JC!0A;\1?V5/V0_VD_@)\=O&'PP\2_LL_L;>-/@O;?M(_&G]H;X
M=?MY:CKUK=?M"6G@3XO?&OQ?\=K7X3^(OA#>?"B^U[Q#\:_"?B'QGJWP[L?B
MS!\9_!_@RQ\!'1O'MOIFJ^+_  K-\/O&E+X5?L9?&+X?ZK\;-5\$?L^67@SX
M*?&3]F'X[Z)^T'_P3U^(/QLT+QS^R#\9?VIOB+XK\+Z]HGB']GC2Y4\=R? S
MX;^/_#VK?M ^$_C];3:%\./"/B23QW\-]6'P*\6:SH7B/Q);_N/14J*48I;1
MI>QU2:<+4XVDMFN2E3C:UGR*H[5E[4IZ\SN_>G[1M-W4[SES)N[4N:I.2E=M
M*3@KTG[,_!G2?V3OVZO@U\,=2\$_LZZO\5;K]GBR_:L^!'B+P;^S+\;/VDS?
M_M(>"?V3-$\&:CH'QJ^$_P .?VI4\0_$K5O".E2_$"7P9XE^&WAF^^,.N>)-
M%^$7A#QKX*TOXI^$[[Q_HWACPE]K_P#!-WX"?%S]G'X9?'?P%\6/ W@/P+_P
MD7[9?[6GQF\!6/P\\8KXL\.7'P^^._QP\8_%[PO!8Q+X0\'-H5MX>TOQA:^%
M4L+K2[2]GNM$O;QM)TBQFT^&;]#Z*T4FDU=/FBHMM)R:3IM-S?O2=Z:=Y-O5
M[OWG/*M.B4W-):13_>K2*5DK59*T>5;622Y5^&.K_P#!/7XH?$3XH?M#V/@S
M3O&_['OPG_:M\ ?MK_#S]K_PCX?^*]A\1O@)\9O$/QRTO7? _P *OVD_@C\'
MSXANY?A3^T'J]A<Z=\4?C?XCL=%^$<&LZ[<:SX3\0CXR:YJ7_"T[#C/!G[#?
M[6WQR_8__:&_9;^/7[-?[$_[)'Q$\1?LJ^-/V=;#]IG]G/6[3Q9J_P <?B?J
M>E:':Z)\5H_#&E_!GX;:C\+?@I=ZOX=M_$?B[X<>(=9\6^+O%5]J5MI:6OA2
MQ\(Q7GB[]GOCK\;_  ?^S_X'T_QOXS%]/;Z]\2/@_P#"'PQI6F)#)J&O_$;X
M\?%7P=\%_AGH%M]HF@M[>'5?'GCOP_;:IJ=Q*MIH6BG4M>ORMAIERPO_  A\
M>>+_ (@^&M3U'QU\)O%?P<\2Z'XN\4>$;[PUXIU/PSKMOK">&]3DL+3QOX,U
M[POJNH0:W\/O&5JL6M^#M2UJQ\*^+)=)N8XO%7@KPGKD-[HMKFDG&4%)M0IQ
M@WS6E%J49TYQE9252G)J4(QE*,(S3=+V:A&FVK.+:5I3E))QO"2Y.2I&4?@<
M:D8\LY2C&4W%VGSN;G^77Q=^&7_!1W]MC]A;]I7X0?'OX._L[?L_?%K7OAA:
M^%_AWX3\$?'#7OBMX6^*?Q0\,Z]H_BFX\9:UXFN?AAX6G^$7PY\4:AX5L]'\
M$^'<_$;Q5I>F^*]4U3QO<0WOAW3K#4^?^(_[,?[7_P 8[S_@J+XYU7X1> O!
M%U^VY_P3:^$G[,WPL\%O\8K+7_$GAGXL>%-*_;+T:33?'U]9^%+;PI::#:']
MI/0=1\3^)?#WB#78]+AT6^L_">F>/YW6>OVYHI2A&?/S)6J1E&26D??H5*$F
MDGHY4ZDE9/EBU'DBE%)U"4H<KBW>#C9OWFU&M3KQB[[I5*46W\4DY<TFY-K\
MN_BW^S[\<?'OAC_@E4--\#VD.L_LJ_M&_#/XN_&_2[KQAX>*:-X=\*?LJ_';
MX":_:>&]3^TB+Q7J_P#PEGQ>T;6]'AB@TZVU+PIHNO75_=:)KHTKP_JGRE\8
M_P!B;]K/Q)^SK_P5G_9Z\+_#OP3JLW[5_P"U!/\ '+X%>-;GXHZ?I6E>(=&\
M<:/^S]_:>E>)M)GT";5/"%SX*G^%_BNPUF>Y&H_VK=S>&W\.VNJ6&JZK>^'/
MWOD8HCNJ/*RJS+&A0/(0"0B&1XXPSGY5,DB("07=5RP^=_V6/VC=$_:J^#MI
M\8M \&>,/A[9S_$?X[?#"\\'>/CX:/BW1/$?P ^.GQ(^ ?BZ#5V\'>(?%GA@
MM<>*OAEK5[9'1O$FLVC:=<VC"^ED,F-*E5U*C<FN>4JU9I*R_?XK"UYNVONK
M$86CRJ_NIR@VXR36<*2ITZ<8WY*4*5"%W?EC3P^)HQC?=N5#$UE)M.[49+EE
M&S_,?XM?LF?M.:#^VK\:_B[\.?V5/V0?VJOA!^V/IOPCUG6-4_:;\0:/X<\;
M_L??%3X>_#;2OA%XFU"XTA/A9\4IOC)\)_$?@CPGX%U^Q\">"?%_A75)?B+I
MWB_3)-7\-Z)XE'CL^IP?LI?%RS_;F\-_M$_"?PAXD_9UU"\^+NOC]J3Q)X=^
M+5GK/[/'[8W[.]A\*=;\*?#_ %'QC^S]%K<HTG]J_0/%-C\+].T;X@Z=X%\'
MW.B> _#GBF35_BUXNTB70/@Y)^M^<?RZ$_R_GTKE? _CCPE\2_!_AKX@^ =?
MT[Q7X)\9:-8^(O"?BC1IOM6C>(_#^JP+=:5KNBWH41:CHVK6<D-_I6IVIDLM
M3T^>VO[&>XL[F">11]UQ:U]DI6;O\,Y2M&35KQ3E.%I)\\7R5'44*;IN24G*
M[LZBL_-QC"\E>[4K1IR3BU[.2YX*#G-3R/A?K_Q"\3>#K?5_BC\/;#X7>,I-
M<\96-SX.TSQM:?$*SM]#T?QEK^C^#M=3Q39:+X?M[B7QGX-L- \:7.D?V7%/
MX7N?$$WA:[N=1N]&GU&[] .>,>O/T[TM?-OC?]I?P[X%_:>^ W[+>H^#_&%U
MXF_:!\ _&KXA>%O&UH?#/_"#:;IWP)/@&/Q?HFKF3Q$GBY/$5P_Q+\*3:1';
M^%)M"N;*>_ED\00WEB=/F23?+%7<GHK;MQA*3?1:QI3D]M>9):QB-M)2D]$K
MM^2<DE;=V3J0BMW:U[^](_/?XL?L>_%O]I_6OV&?B!\7_@9X(^'G[;'[,?Q7
M^ /Q'\5?MJ_#GQSH*:38>!_ 'B>'6?C?\+? 6KZ+:>%?C'XST7]H;P9+XH^&
MWB3X+^.OA]X<^#/A7_A:'BCQ#_PEOCT^ =!M_B+SOP:_9#_:8^"'[5_Q6\./
M^S!^QO\ &7X"?$G]J[QS^U=X&_;,\;ZSIUC\>_@WH/Q7^(J_&3Q_\']2^%K_
M  EUG7_'/Q$\,_$G5?&>G_!/X@:?\7?#_ACPUX+U7PAKNM.-2\$+\.=:_;RB
MB/NNZVO-N-WR2=3V7,^7[#YJ-.=Z?LG*HI2GS<\T$ES)J3W44G972A[6RO\
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MM+TG4_M>F6GUM113;NV^K;;]6VW^+?WC2LK:OU_X"7Y!1112&%%%% !1110
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MC2-/N[+_ (7-/\/-0_:_\6P_'_X>_$&,R2Z]J_[*,'["FLW'Q&^%&D:Q+?\
MPXM/A=X9^ /C'X< :]X;^%^HVGZ%_P#!8.?0M.^ /[/.M>)O%6K>"O#NE?\
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MTSX777A/Q+\8KK1-:?P'X:UG7_CGH^J2:4=.\?Z1IW+_ +6/QB^%7B/X.?\
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MC;H<4_@3XB6_BCQUI>F?%/X=^-?$FD^([FV\%^.K]HHOZH&56&&4, RL P#
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MJ-J?O.,DIN$9):1A2;3<'$_E_P#VMOBM_P $^O'_ .P7^UE\=/V'?B3HE_\
M##XJ?%#_ ()OR^+=7\,:AK&A_LL:5\0_#O[5_P );NU@\(^#K_\ X1GPGX5^
M-LO@673;[]HCP]X5M-'\9V_AKPU\,I/B?::+JUKI$\_WE^QC^UE^S1\/_ G[
M3GCG]JGQW\#O@#^UU\(/B=I^B_\ !0[Q!XQ^('AG0/#FC>-?$3^"O#GPJ\<>
M#?%'BE] FT[]D_XH>%M?^&$W[-%QJ$=FBZ1K]IX<^(-[JW[0EM\6]4U+]D@
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M9^U!J>F?&K6OB/\ "N[N?%UCX#_;1NOV:(OCWX^\1:YX<\8_$RR^+^F^*?\
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M4HX=U&W=.I&4.;FY4I+E5H-J:_EP^._AC]A_2/V,?@3JOPM^+T/QY^ OB_\
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MPU76=$N+#0]>M?ZVR >" 1P<$9Y!R#^! (]#S7(>+_'W@#P':VT_C[QKX/\
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MZEX2USX=_!_1?$W[0W@G2=$_M7QYX$\'3ZCI7@SQMX=M] T?^P>FJB( $14
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MQ<N+_3;V74DUZ']C34OA!KGQ6OYKNXM_&'Q _:0\:7NHH/$7@FVOQ^ZP
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MMW%IMZJ,(\BB^]TH.[YFG&34VJDDA)WB]-%-:)ZN<_:/=NUI.>W*I*2O"/)
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M&/&NN_'/QA9:=8W&F?L=Z5X<UWX>ZGX1UV1QXVUC78?',US8Z=IT'UC\.?\
M@E[^S=\*O%_PD\8>#==^.-A-\!?B]\:?B]\&?#LWQC\4W/@WX<S_ !^M/%G_
M  LCP!H7A9W&E7'PYU+7O&>M>*K;2=;AU;7+?46M=!E\27'@*W'@YNR\#_\
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MENU3N-US-WUIU(Q5TTO:8;%TI*?N^]^]JX><972A&G)+FLO:?GC_ ,+%\2_
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M5CU_7+O:;C4M5M_"WAGPYX9M;NZDDEM/#V@:+HELT6F:796L/KO[6/B_XR?
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M>)M&N_V:="OO#>I> ;SX8_$KQ=%IO@OQ5XL\6:Y+>>*W;X677PR^*7LO[/\
M_P $_P#X0?L[?$?PQ\6O#7CGX]^-?B!X:_9\\+_LS2:_\4_C!XB\:_\ "2?#
M#P'XBUGQ#X!@\3:9.MGH]]K/@P^(M>T[2-1M-/T^&]CUG4]=\166N>-+R?Q2
M_>_'#]DCP-^T#>^-[?Q[XS^*/_" _%?X7Z5\&/C#\'M*\2Z5'\+_ (I?#73=
M1\;WUQX>U[2-4\.:MK?AJX\0VOQ#\3Z#XK\2_#+Q#X"\6^)?#DNDZ-JVO7-K
MX=T :;I4<7.$H)J"J3;BTXW@\15<$U%SM:A."M%R49TXP?M(.4Y3%249*5KR
MIPBFG=QG[&FIRBVHWO7C-WDHWA4E)>SGR1A\@W'[7?[5OQ:^)'Q?B_9?^%6D
M>)_!W[.7[8&B?L\>/;'Q;)\-M.\/>)?!'AK3_AEJ'[0&L:OXRU#X[>'_ !]\
M//B+X9TKQOJ_BCX2PVGPB\6^%]:T7P]H]OXEL=3A^*5EK_PN]*^%7QW_ &E/
MVA+J'XK_  DU7X$Z/\)O"O[:G[0/[-7Q-^&GQ%B\4V/BVT^%/[/WQ/\ BE^S
MAXC\:>&_&^@MJ\4OQUU_XU?#K2?'W@CP7K_AG1/ M]\'O%Z>!-9N+/QW_9_Q
M%&_X@_X)K_LX:]^U!KO[5MOJ'QM\)>+_ !WJ'A/7OC#\-O 7QW^)W@GX!_'G
MQ9X!TS2]%\"^+?C7\&_#OB&P\(_$#6/#.C:)I&D"UU*U3P]XFTO3X=.\<Z'X
MILVGAFM^$O\ @G'^SAX#_:3\;?M+^#YOB_X=U+XC>-I?BYXW^"6C_&OXD:=^
MRUXG^/-S;V%K=_M :[^SI9:_!\,M:^+UXFD:-J-SK^KZ+?:9)XRT+P[\41H:
M_%;PYH/CC3IAHH*2N^5.;U=JD?9IO1QYJ=7DJ24$DZ;J6E+E24:E=RFXOW;M
M1C:UX2Y[)-\W).ES03G[RJ*FK15WS?,7PS_;S_:!\2^"/V$/$?B*P^#L^H_M
M$_\ !2K]LC]B+XKKHO@CQKI-A_P@_P"SWK?_  4#TWP3XS^'UK??%37KGPGX
MLU*#]C_P<_BB'Q'J'C_1KV7Q7XG.E6>C(FDBRP=+_:7_ &V/&OP__P""EOQ.
MOO&7[*H\#?L=>-?VR/A+X2^&6I?LY_$K7F^(LGPN^#_@?XC_  V\0>.O%$G[
M3&F0V.G6PU[4O#'C[P=I?AB_C\:6\UYK>E^)O!JW]CX;\.?5&E_\$T_V>=(\
M8^%_%=KKWQR&G> /VL/&?[9_PW^'T?QH\9Z?\._AU\:_B58?%U/B1/X2\/Z1
M=Z=/;>$/'?B/XZ?$_P ::_X1U'4M3TL:SXIU30M*73/AYJ.J>"+_ -%\/_L4
M_"OPYX"_:I^'%EXB^)5QX<_;&\6_$'QS\9?M_B>QN-1?Q+\5?"FG^!O'U[X.
MOUT**3P?;Z]X3TC1]'CTO2E32M".FIJWANRT?7KW5M5U&)1?U9PBVZ[PM:'/
M+6/UF=/#1ISDI)WC&4,5+X;+VJ]V5^6.D9+ZS"<HVH+$T9SIQ;YG0A4K2J0B
MTX\LI0=%+WKM0MS1:<I?"'P(^-GQ_P#B1^VU^PWIQ\?^%O#?PQ^(7_!(B^^/
M?B'X0Z+X N;3P9!XYUKXD?LMV6LZGHD=CXTT^:UO8(->AT;P8VK)KFE^!O"L
M&M:-I6D7-]XKUC6ZH_!K]O;XJWOP<_9:\(MX"\&7/QQ_:8_:^_X**_!62'X(
M>#_"_@KP[#H'[)?QU_:KTKQ)XQ\">"?BQ\8=)T.7XD>,--^%?A_Q'J-AXF^(
M^M0RZKKWQ!^(5]9>)8M!D\*ZO]Z>'?V&_@_X2\=?LW?$;PYKGQ0TCQ3^S!\#
MM4_9P\%7ECXYN;2'Q7\&[Z?P+?Z?X.^)EO;V44?B^W\.ZU\-O!VNZ5>-_9^H
M7M_IMU;^)KKQ!H^MZ]I>I^7>,?\ @EU^S/XY_9\T+]G;6=1^,-CHW@?XZ^.?
MVF?A7\3?"?Q1UGP-\<?A!\=?B1XW\=_$;QC\1OAM\4/!D.A:UHFKZOXR^*/Q
M(U62UO4U31X[;QGJF@1Z:OANST+1](NI[U9SBFJ7M,0^2]I2IU,?7K4E=WM*
M&%JTH>])V="5/F?M%465).-%0FTZOLZ"<]>6-2&!HTJKLK74\32J3O&*NJRJ
M<J=.5-_,'QB_;:_;)_9Q^%GPL\1?M3>%?#'P%T6_D_:@\._%3]I[PY\'/$'Q
MV^$/PE\6>$?$'A!OV.?&'[0_PO\ A/\ %CQKXE^#?P:^-/@'6/%.N?'#5+#X
MC^)-!^&'C3PSI?@^;XW^"]"\8:)XZ?\ 9WPQJB:YX:\/:W'J6BZQ'K&AZ3JB
M:OX;ODU/P[JJ:A86]VNI:#J47[O4-%OEF%UI=]'\EW8RP3I\L@KY%/[#/@"U
M\$>&O .@?%?]HO0=&TOP-\2?A[XTOKCXNZCX]\2_&G0_B[=^&;WQ_J'QC\4_
M%K3OB'KWBWQGJ+^%K2R\/?$*TOM%\=_#G0-0UGPI\,?$/@SPIJ+Z(GUAX+\&
M^%_AUX.\)_#[P1HMGX;\%^!?#.@^#?"'AW3E=-/T#POX8TNUT30-%L$D>21+
M/2]*L;2QM5DDD=8($#.S L:35I76MXJ+2:YHQBXRE).]I2:C+W>5/FFI4X.,
M92$FG'5M6G>[3:;FI02LE?EBY1=T[<L7&<U*2CTU%%%(H**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ)V<:L+N4E+WU-^_[J?+*=65VOLNIB+1Y5;V=OW+@[-2ISLHQY;4_B7X0_\
M!5_]FKXS^+/@!X?T#PE^T'X;\-_M0R>,_#_P.^+/Q ^#.O\ @WX0^-OBKX%A
M\8:KK/P-C\;:I<+!HWQ8N?"_@/Q5XGT32=>M-,\.ZVFA:[X-T[Q1-\4?#/BG
MP%H?KF@?MZ_!C7]%^ .O)HWQ%TVP_:*_:9^,7[(7A :EH&C_ &CP_P#'CX':
MY\<_#OC?PKXSAT_Q)J!T^Q&J_LX_%J#2/$VBGQ!X<OE\/V;RZG:KKVB?;_RP
M_P"":_P,\9_M1_L3?\$T[WQ OPWL/@S^SE^T9\2OVG-.\6>&?&VJ^*?%GQ U
MGP%XW_:5\%_#3P;:>'F\%Z3H_@Z2S\5>/E\4>/?$T7C7Q-$FG^ XO VC:+JP
M^)>KZ]\,/:]%_87_ &P-)UGX >$HX/V<3\+_ -FW_@J_^T!^W)H'BF;XI?$N
M3QW\1O@_^TEXD_;;\;:YH>J>#XO@?#H'@/XB_#/4/VLM/\.Z5I%MXS\<>&_B
M3#X:O]=N_%'PU"6NCZM<-9T5+2$HPE-WLTIQP%3?7E<88G$)IK6-&G->^YP;
ME9.JDVU&5>,;)-\U+Z_3@MTI*=3#89N2TBZU2/PJ$E]8^'?^"F/[/_B+6/C#
M&OA3X]:)X$^ OB'XQ>"OBC\8_$GP;\3:/\+]!^(7P9\5>$?!U_\ #73M0GW>
M*/%OQ$\?ZWXQL;;X2^#O!WA/7]<^(%Q:7&EZ5:+KNH>'-)UWY_\ V[_VV_&.
MF?LL_M477PFD^-W[,OQ\_9G\;_LMKXMM_%_P\\$ZG<7W@;XU?%SP!H\5[X3\
M1Q67Q@^%GCOPQXW\':AXY\-W5W\-_$U]\1/!'B31+RUO(_!OB.'1CJ&3?_\
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MYHR;BY)->ZY*-N;F<N7[F\1_MK_#?PAX5\':IXJ\)^.O"OQ!\?:K\7-(\)_
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MVI_%CXIWWQ5\?_LK?&[X3_M2?";X;^ =*T._^"-QH?P;E_9P\&?&[P)H&D?
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M_"/PZ'PB_:;^'?A;]ECXI^/?!/C?PUXA:+7_ (I:'IMEXFT;PKXO^'S:O/\
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M\.:MXC\-G7?!6G:=K5C?R_9?PL^)]S\2XO&::C\-/B3\*]8\#>+T\'ZMX?\
MB78^%(;V_N)O!_A'QK;:YX;U;P-XO\<^$_$OAFXTWQE8Z<-8T;Q)=I;>)-+\
M2>';^&TU;0=0MH_@;X3_  X_X*4:M\"O'7P[_:R\*_\ !/\ ^*>N6OPEN?AA
M#X8T;5/B7J/PQ_:YO-8N=.TOQ5K_ .T!#XJ^"A3X*:#XK\ 6&K^&-=\">%?!
M?[06@W^L>/\ 7=:NXKK0/"VD^"_$'+? OX)_'?\ X)\_#3X@:+\'O!?AWQC\
M,/&?[2'PT3X&_LD^(/VA?BKXLC_9^^#>I^!/!GA7XB>$_@;XYU[X3>/->U.\
MO_'&B>)?'G@_X(:ZW@CX#_"[PYJ.N^)-2^,'PN\ Z9XBM] /=<YI.\;Q]E)I
MKF4I\L>=.TH3DITY3;2A2Y*L:D8/WHB<N2+E&TK-U%=-1<8.4^1IM2C&4)J"
M^.HI4W3E4OR/V_\ X*G_ !/^*/P7_81^.7Q3^#7Q UGX9?$/P;'\/[W1?%.A
M:5X1UF]CMM2^*/@K0-<TI[/QKX;\4Z0EIKF@ZOJ>E7-[:Z=;:[IJ70U#P_J^
MCZO;6FH0>G?&G]M#X5_!*]^*EMJ>A_$'QU:_L_>!- ^*?[1NI_#30-,\2V_P
M(^&OB2+Q/J&F^+/&.G76OZ1XB\47"^&_!'C+QC?^ _A%HGQ+^*>F^$M#L];O
MO D$'C;X;KXSYW_@HQ\ /BA^U)^QO\8_@+\''\!1?$'XA6_@ZTT6Y^)GB;Q#
MX1\&VJ:%\0/"OBK4)]4UKPKX(^(>MPO_ &=H-U%906GA:\%S>RP13SV4#274
M?B'B7]DK]H#PQ\;OVY/B#\))OA1KGAK]OOX2_#RP\66/Q%\7>)["7X)_';X=
M_"/4/@;_ ,)%I6D:1\.]6B^*7PL\6?#R'P9<ZAHD^M_#[Q%I'BWP+<6\"ZCI
M/Q.O]8^&6<G-4ZW(E*I>4J,96Y93C@FZ<)2;7)2JXA*G.:?NS<965W,VM!NC
MS-J-^6M**NXTYXN"E-*SYZE.@Y5(1L^:*E'72!ZO\4/^"C/[._PNU35$N#XT
M\:^"_"NA_LV^*_B'\6OA[H^C>(OAE\/O"'[6_CJ_^'GP$\6ZCK<WB/3=4\:Z
M#XRU[3;F[O+GX0:%\29O"/AIK/Q5XRMM \/ZGINH7?._&K_@IQ\ O@7XF_:+
M\.^*/!OQZUJ#]DFS^%'B3]HWQ3X4^%5]?^$_A=\-OBM8:SJL/Q9U#5=4U+19
M?$?@3P1IFBW&I^-AX(L_$_BY-,&H:IX1\)^+M.\*^.+KPO\ GC\</^"5O[5F
MI_#'Q;^S5\+]?^!'Q-^ O@;]FG]A?X1?L>:K\=?B5\1?"WBWX#ZM^R!K?A2Y
M\:Z'+X'\*?!3X@>#Y[W]H/3O"=NVO_M#:1K]E\1/#PN]/\)ZIX#\<^"O!_A[
M21[G^T=^P;^U+\8]._X+ V?AY/@#IDG_  4&_96^$GP)^$#ZS\5OB+&GA;Q/
MX9^$?Q)^&_C#5OB0+'X"WITK0;.]^(TFH^&Y/#'_  E^H>(K31$AU2P\*2ZJ
MW]EW4:CSNG>HHSK.":<74A%ITDU9.+ERRBVE>TXRT:5LU=NFG[O,J2J/1J#E
MI.2NVFDI1E:\E%PE&\HW<OT1U_\ :K\&Z5\5?$'PET+P9\1/B#JW@7Q+\'_"
M/Q3UOP)9^#]3TGX4:U\<]3TVP^'J^--&U/QKHWQ FTN\M-9TOQ#J_B#PAX)\
M5Z!X>\-7%UK&LZG9P:'XB72.T^./QX\(? 71O!FH^)]-\4^(M7^)/Q)\*?"+
MX=>#_!>D0:KXC\8_$'QC_:$^DZ'92ZG?Z+X9T2WATG1M=U[5?$'B_P 1^&_#
M6E:1HE_->:Q'<M96EY\$_'O]C+XO?&K]I'X<_M!:)X/^$'P4^,'PR\?_ +/U
MUX7_ &H?A5\8_B9I7Q1U7]GWP[XH\!^+_P!H[]F7XV> ['X9^&_#?QT\"^,F
MT[XD>%?AA;>,O$MYX9TF#QY!X_C\*_#KQ?X6N[;Q[](?MN_"_P#:,^*G@SX0
MZ=^SOJ'@&['ACX_>"/&7QL^%WQ,\>>+OA=X-^/7P-TO0?&5CXC^$6N?$+P)\
M/_B=XET'2[SQ?JO@3QMK.CIX-UGP[\2="\#ZK\)/B!8:G\._'WBS1]3%M#F:
M3=7EF]UR>TM[1<JDXQ<+6O%RBU*=ITW!Q3;O.T6U[/FCT]_D?N/F:YI*:O=-
M0<7&-X3C-2YD?\%%_@8WAOX'Z[%X8^,U[J?QZ^//QM_9?\,>#='^'%UXC\3^
M'OV@?V>K3XV-\4OA?XUE\-ZEJ_A;2-7T;6?V??B9X=L=9L/$VK^$=<GT@>*=
M)\17?PY34/&UAN>"OV]_@WX[^$GA3XFZ3H'Q)M?$GC+XY^,_V8=%^!&IZ!H4
M'QND_:-^'&M^.='\?_!R;1+;Q3=^"U\0>#;7X9?$#Q=XA\21>/)OAQIWPX\(
MZ[\2Y?&__""6$WB ?$7P>_8(_:?^&Y_9>T6XTC]FJU\,_L__ /!5;]L[]M:^
M/A/XE?$'2(+WX(_M*^'OVTM+\(^&_"G@U_@&=/T'QQX0N/VNX+:\\#S>)I_"
M4&D?#>-=-^(=Q)XJ6U\+<TG_  3Z_;$\))X5^,G@2[_9UN?C]\#_ /@J#^U5
M^VY\,OA[XA^)GQ-_X5'\5?@M^U3HGQ8^'GC'X9^.O'EE\%X?$GPI^*>G_#KX
MOZM>>%_%VC?#?XN^&M"\8>';2TO-.UO0O$VHW.BI>;T;CK;E<8WP?,U'WW)O
MVN)3BVW%4G*+E[-JK*=1NSBDES6U34O<QCCK>-ES4\*KZ?Q;22Y_W?UC_P $
MXOC=\4_C5J?[?@^*'B+Q]K"_"O\ X* ?$'X3^ =!^)GAWP-X;\6?#?P)I/P!
M_9O\61_#6>V^'>E:=X:U73/"_C#QEXP70_%5K>>*?^$NT>\LO$D'C?QCI^IV
M/B&_[#QQ_P %&_@;X(\2:OI(\,_%CQ?X8\/_ +2GA#]CG7?B?X)\+:)K/@#2
M?VHO'G_"*6OA7X.W4MQXKT[Q:=0U#Q!X[\&>";KQS;^$I_A-H?Q \0P>!?$'
MQ!TKQ3IFOZ5I$W[$'P&^.OP6U_\ ;+\4_'*W^$UIJ'[2_P"U;<_M&>&--^%'
MC/QCXSL_#6D:W\!/@1\*;[P=KU]XQ^'?P\FNM2T'6?A%>RVGB+3K,6OBK3-4
MM=5FT#P9=&;PY;?C'=?%C2Y?VHOVD=;\!:!_P3T^-NB6/[>>N?%6U_9HU;]N
M3XQ_ 7]J#7?C]^SSIGACX2Z=/'^P4OP.^(7@[Q1^T+%XM^%-_P"._A'K_B/Q
MMI7A3XWZY>?"G]HB[LO"-U:_#?QEX&4+N5&G=<SHTDTVY>^GAH5.:6C;2G4]
M[K4<)S?LXU.;1:1K3DI-*K5Y6K)\LGB9T[*RC;W:6CY4H<T(KG<'']B?$/[4
M>A>$OBQ^WU9^$;SX\?%+X@_LR_ SX#_$#Q'\$=9TCX?>%OA7X?L_%FE?'#5O
M#NM?!SQ#K^G^ ]9UZ\\7Q>#=?O/C!JOB;Q[XFT2UM?!?AO3?AW%:Z];ZYH.I
M_%/[.W[8WQ_T'_AV?XI\=:!\?OBMJO\ P4H^&G@J3Q=X2U>[_9KL/AY\/_&O
M@W]E+QK\>?B%\6OA;]F^(MEXUT:'XM7B>$CH_P ,=3U=O OA;P!X&\8:HFB^
M$_BGK6FZ!\1?J'Q!^RK^T%/^T%_P4H^*^C6WP<NO#O[6/[*GP$^"'P:L]3^(
M_C;3-:M_&/PCT']HS3M5OOB=:VOP<U:Q\(^&=5N_CK:?V??^%=2^(VJ);>&[
MF>XT2.74XK:R\\T#]BW]IOPKX"_X([-I\?P)U3XA?\$]K;1O!WQDT"[^)7Q
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M&^*OA?=V>L:;INK?##6+3QI%XBU+P!X^T#PZ[X__  41\9?M&?L8_P#!)?\
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MH/AVQ\$WOVA^W7^RW=_M6Z/X#\$ZG\'/A=\3/!V@CQ?XGM?%^K?&;XB_L_\
MQ_\ @E\9+'_A&!\'/BC^SI\6?AO\/?&VN>#=5TMSXSMO'&KV&I>&]:MM*GT9
MK"V\<:<==\":^I-^SIN*;DT^=:<S]VG).,9)1C)NI)*,GR<U&4)2BI>T*7\2
M:?P*W*]6D^:HFFU:4HKDB[Q7/RU8SBI./(,^-'_!2?\ 9O\ @1X1NO&7CJ?Q
M5!8>&O@UX)_:%^*&CI!X2TGQG\(?@SX[MO$FH:9XS\8>!O%_C'PQXN\076G:
M7X(\>ZGKO@/X4:-\2?B;IUMX,U.+_A"I[_5O"%GXEZSXD?MX_!/X>P:]K%AI
M_P 0_BOX,\"7'PBC^+'C[X*^%8OB3X:^$]K\<IO#TGPXO_$]MHNK?\)7XD74
M- \5^&O'FO:3\*_#/Q$\2>!_AEXB\-_$OQOH?AWP-XG\-Z]JWQ5X<_9(_P""
MCOP ^,'A'XI?!_XH?LQ?M%:E\6OV5OV9O@G^UWK?[3DOQ/\ !.M6O[07[-_A
M_7O#D/[5OPHM_AQX;\86?BW3_B+I_C3Q%=^.?@5KTWPWFO=:\/\ A9]#^,?A
MFWUO7KO1_0K;]FK]OGX-_M7?M >-O@!\2/V?_%/P%_;#O/@[XV^*NN?&*;Q9
MH7QA^ _QD^'?P<^'G[/'C'XB?"?P-X*^'NL_#SXO6?CWX7?"7P!J]OX-\9>+
M?A?I?A[Q]ID\RWE[X7:;1-1TCRN2YG9.I-<NJ2Y932@Y^\U3J0C&<,19V<E&
M4&[D-S2T5[0@V_M/FC"\HQ5DZD)RE&5!\MU%R4DK7^B_%?[>_P &O!/AGXT^
M*O$F@_$BQT[]GW]J3X5?LC_%.%- T.\OM!^)7QJB^ TWPXUBU@LO%%PFM^"-
M=A_:7^#DLNK:--?:QI,?B:Y?5_#]B- U\Z;8N_VY_AN/VF?%7[*>@?#3]H3Q
MI\1_A_J'PIB^(NM>$OA!K>H?#SP#H'QA\.?$'Q#X3\;^(_&5Y<:?9?\ "(+)
M\.]1\/WM_H\.K7\WB+5-/L]#TO6K32_&-_X5^%_VC?V%_P!K[Q[+^W-X&^%T
M/[.<_P //VGOVP/V,_VT/!OC'Q_\4/B3H7B_2_$G[/<O["6B>./A#XD\$>'?
M@EXFTC3M&U31OV/-3\3>&OB=IOCK7KU[_P 6Z9X.U'X:V\*7OC;3_M#X0_ ?
MXS^"/VXOVS/VAO$-G\,6^&'Q]^&'[+WA3X>PZ-X[\5ZAX\M_$'P(L?BU!KO_
M  F?AR^^%^D>'M#T?6YOB=$FDW^A^-/%E['%H;S7NE1OJ2V]A%)MP@ZEE/EJ
M.:6S<:,90BE]GFJ\\=VY62BTG&94]&U"[7-;6WNQ=5I23O[S5)QDUI;5RU4H
MGS%\+_\ @H/9VOA;_@G9HOPJ\._M(_M/>&?VT_C1^TMX$B^+?Q@@^!W@;XEZ
M/IGP>\,?M&>/M6M/$'AFTU+X,Z?;:_8ZY\,[?1/"&F1> --L;?X/^%]<D\9:
MU'\6T\.Z#X[^E?"7[6OP8\-']L7QAXB^)GQ7N=+^$/[67A#X!^)-%^+6B^%O
M">E>$OBOXS^%G[-T7@?X7_!-3H?@V[D^'?C>Z^+?P]UK3/$_Q,U>[@?QOX^\
M9^)+[QMIOPQAT^_TGXE^#G_!/[]K+X3?"[_@F7 /^&>-:^)?[%7[4G[37Q,^
M)'AW_A:GQ(M? OB+X8_M)>%/VI/!\NI>"?'!^ TFOW_COP/!\>/#VM)X+UWX
M>>&] \52Z'K6C'XA^&UEL-9DZKXK?L!_M/\ COP]^W7J/@SQA\%?AW\5_B-_
MP4"^!'[>_P"Q[XCU+7/'?CSP;'XE_9\^#_[*OP[T3P+^T;X6MO!'@+4](\-_
M$"Y_9MU?3_%2_#_Q%XUNM"\/?$LWVE76K:OX-AMO$>:<U[-N.EIJK;5PCRY5
M91C>TG%3QO+9.=1X=KG4N9UJDE>?*[^^N2_NJ7O9GK)V2BIN&#;UY(1KJ7+R
MM*C]0^#/^"DW[/7Q EU'PUX3A\4ZS\8-,^/EK^S3-\"K&_\ A?>>/[CXJZG\
M&?$'[2&AZ?8^);+XEW/P5O=!\0_L]>%/$OQ=T/Q5;_%I] U#2="UCP5'?K\7
M-,O_ (=6_P!E_#CQO#\2/ _AWQO!X;\6>#QX@LFN9O"GCO2H=#\9>&[R"YGL
MK_1/$NDV][J5M8ZQIE];7%I>P6NHWUJ)8F:VO+F!HYG_ #I^(O[.W[1?[4'P
M%TSP#^V5^SO^QE\3;3Q)\2-%O?&?P+\'_%;XL:;X:^%W@CPUX,\8R:5\2/@G
M\?6^$'A?XDR_M*'XH7OAK4M.UFQ\.?!W3? _@F?4M+\)>-HO%FAS^,OB#W_[
M.=E^U-^SGI/[(O[,WQ)OK+]I*";P;\1M/^,/QZ\0?%3QAXA^+O@9M&?7_$GP
MO?Q"=3^$MCIOQ@\-:1HL.A?!77OC/XR\:?#WXH?$[QI)HWQ#D^%\[7WCY?#F
MRM?ENKV@D[^[*7+)U&M%RJT')1DY*S24U4_=D7>C::2E4YKJS4;P5/>3YOCY
M6XJ+<HMN'):;^A/C9^TGX7^"WB;X?> #X,^(OQ/^)WQ2TSXBZ_X(^''PRTC0
M;G7M5\-_"?2-(U;Q_P"(+G6_''B;P+X T:QT-O$OA/2HK76_&>G:SKNL^*=(
MLO#NEZN(]6ETOR.'_@H'\$_$7A/P%XQ^%&A_$CXW:=\0/V9_"'[8=AIGPVT/
MP_%XLTO]G/Q]:&]\'?$2_P#!GQ \5^ _%6J_V]';ZI!!X1\&Z1XJ\=V>H:1<
MZ7JGABPU*_T&TUBM^U=\&?VBOBC\8OV;M6^',7PB\;? +PQ8_&+2?CY\&?C'
MXQ\9>%_#>O>(/&%O\/8_A%\73X<\*^ /&^E?&J;X+QZ'\2!I_P $OB%>>$/!
M&O>(?'F@>.8_$_A_QU\._ _BOPM^;\O_  3&_:2\0_L7_LA_L^^(/"G[/'@O
M]HS]D;]COX;?!KX"_MF?"'X_?&+P]\8/V=?VA? GAV^^'6I>/O#&L:?\#?!^
MI_$OX$>-?".A?#_QAXM^"NOWWAS1/$WB2SUCX7>,='\6>'9]'^+'AJ(MN237
MN\Z36BE;VDHO6344E#DJ7O:47)*=.IRQBY-JZBM>234MTI*$91T7O/FESPM9
MN,E%N$X-M_L=^U!^TAX(_9+^#/B3X\_$O1_&&J_#[P;>^'8/%UUX+TS3-7U#
MPWI?B3Q!IOAF+Q3JUIJ>M:'';^%-%U/5]/F\5:VMS);^%M">]\4ZX++PQHNN
M:OIGG.J?MM?#C2O''[57PYG\$?%>3Q?^R)X,^&_CSQ]I$6@>&EG\9^'OB];>
M*IOAI+\(UN?&%NWCN\\9W7@CQ9H&AV,*Z?<7GB_0[[P5&I\71C16^A?BQ\,/
M!_QL^%/Q)^"_Q&TTZ[\/_BY\/O&/PO\ 'FD>:;8ZQX.\>^'-1\*>*-.\Z,;H
M#J&BZK?6WF1C=$9MZ#*BORD^"'_!,[XO^#OB3^Q[\:_B[\:_"GQ#^+/@_P"#
M7_"N_P!O'Q)9:%K5FG[57B#X;:G\)_&G[*_B#3TN)U_L2^_9\^(?PLL]9T_7
MFCTJZ\30ZWXTEU71_-^('B.V6HZRLVE'F2YK/X90FKI6^Q5I)MO[&(A[K=-W
M4G+E3C&\G%OE;5U)3INSW7O4ZDHKE?\ $H2]Y1FI+ZE^.7_!23]F+]G;7-=T
MSXH>(Y]&TGP%X[^&'PT^,?BM=9^'JZ5\$_&7QAC^'\G@73?'VA7WCNP^(.HV
MEVGQ9^%MSK>N_#?P5X_\/^$=)\>Z1XE\6:IHOA;3O$^MZ!\"?M0?M*_M+^"_
MAE_P<":GX3^//C#0=9_8_P#A;X:\=_LTZO9^&?A1-=_"B<?L9Z-\<;W0=-@O
M_AW>Z9XBTC5?'%SJ37NH>-=/\2^+HM(U)K'3O$UA-INAWFF?25I^S9^W3\'_
M -K/]I#Q'\ _$O[,FN?LP?M=?$7P=\:O%&L?%>Y^(=E\>OV:_BA;_"SX;?!+
MXG3?##POI7A#Q;X"^-/A[Q=X+^$/@WQ+X2TCQ=XR^$MKX2\:ZAKJZM#XFT"R
MBT_Q%Y_\??V#_P!ICXI>$_\ @M/X7\.M\"K4?\%$OAEX:\ ? :^UKXE_$"S/
MA^YM_P!F#3?V>=;U/XNVUC\$=5'AF"RO+2;Q5I5MX,N/B))K%KY>D7DVA2R-
MJ,42NZ,FDU4E0Q"23LXU&L+RP2_FC4C5]E54ESTW+17F:P<54M)IQC5P_*W'
M1Q4Z_M)MIVLZ<H>TIN+Y9*._N'ZV_$?XA>$/A)\//'?Q5^(.KG0? 7PS\&>*
M/B#XVUT:=JNKMHWA#P7H=]XD\2ZL-)T*QU/6]4.G:+IM[>#3]'TW4-5O3#]F
MT^QN[N6&WD^1-._X*%_!1=(^+%[XX\.?$SX2ZW\(?!?[/WQ#USP?\2=(\)Z;
MKFL>#_VJO$7B/P/^SYK&AZGH'C7Q'X(MQ\2/B+X/\5?#U+'Q5XN\,:GX+\2:
M%=7/Q)L_!GAFXTWQ%?>^_'+PY\:_'O[-OQ>\)?"3Q9H'PA_:(\9?!3Q[X=^&
MGC@7-SXF\,?#+XQ^(/!&JZ;X/\4K>W?AJVN]<T;P?XRN]/U5+VY\')/?6FGK
M<3^%W>1]);\M?A]^Q#^TUH7C#]HWQCXG_9X_85U_P[^TK^R'^R#\#_'?P2\6
M_&OXP_$KPIXI\6_ WXT_M":I\9+/XM^/_&?[-%[XF^,S_&+X1_M :UJ[_'+Q
MQH.I>.%^)NC:7H7CGP)\1M/DU+XE7PW+F:232W;=D_=D_=:33O.*AS6?+SQE
M[.<%)K._NQ:3NVM.R<HQ?,FTTXPDZEFUS\DH<\9M)_K=\+_B5+\2;/Q3)>_#
MWX@_#+6/!WBN3PAK?AKXC67AJ#4S?#P[X<\56^I:1J7@SQ3XT\)>(=!O=(\4
MZ6;?5] \2ZE;1:C'JFBWWV/6='U.PM?G?QA^WM\#O ^JW-QK5MXW?X4Z/\=M
M$_9D\7?M#:=HFE7WP4\#?'CQ'XET3P'I/@'Q3K$6OCQA;VX^)GB;PY\*-=^(
M6E^"=5^%'@SXHZK-X$\;^//#?B'P[XOLO#U/]@S]F3Q=^RA\-OB+\--5\1ZM
M/\-[WXO:GXF_9\^%^K_$WQI\99?V>?@K<> /AUH.F_!6P^)OQ M;3Q5XCT/3
M/'7AWQ]XW\/Z9>)<V'P_T3QW8?#+0M6U[0O!>G:[J7R%K7_!.OXQ^)/@]^U#
M^QAXCU[X=:S^S%^T-^V?KO[3>F?$HZ_XBM/BQX0^&OQ8_:0T/]J_XW_!Z]^'
MZ^#9="U+Q>WQ*/COPE\+/B;:_$B"TTSPEXVT?Q=XD\,2^(OAB/#/Q2T7*YQ4
MFU!QIM[7;=7#JHG).48N-"6(J1LY1E4IQIII.PKRY6TDW>HKN^B4,0Z3C&R<
ME*K"A!W<91IU)3=VN9<1^VU^WO\ '"?]G7_@KO9?"/PY\2OV<O&/[!%O9^'?
M"?QNAE^!OBE-?\2#X2_!WXW"Y71=6UCXCSV.G>.?!OQ?TI_#\$G@!-0TKPM:
M7FHZIXJ\$_$JZB\'^%_T#T?]O+X(OJ7[3>F>/[#XC_!.;]E'POX(^(_Q&;XO
M^";GPV-9^$/Q/C\;K\,?BOX$MM*O/$&H>(?#_C_5/AI\0?#&A^$[BRTKXN6G
MC'PGJ'A'Q'\-M!\176CZ=J?PU^TM^P9^U3\3O"__  6#^&_P^A^ $WAO_@H3
M'\.?%?PB\7^,OBM\0_#.L>%/&.C_ +./[/O[.'B?PM\1/"6A_ CQI:V'AW3[
M+X+:GX\T3QAX;\5^)-1URXU[3/"-[X-T&."]\4P=O^TQ^P-\<_VF_B!^W%J5
MUXJ^'OPET3]I']CO]CWX1_"3QSX9\6>(O&WC3X<?'[]DWXS_ +17QZ\.>+_$
MG@;6/A?X7\.:O\/E\=_&?PM$(+;QI<:MKFD>!M4AO]%TH^+(XM EOE4>52E%
MQI.;WG%QPTG5<(WBI2]KS0C3]V,YJEU:FTN=N3E9-3J*"NN1PEB8J',TFU%4
MG&3E9RA%U5KRN)ZCKG_!6#]E;PIX2_:;\2>+#\0-(U;]DO2?AMXI^+7@72-&
M\,_$KQ2/ GQ?U6]T'X=>/_"M_P#!_P 8?$/P'XC\*ZYKNC>)=(U*2V\:Q:QX
M)O/#6HGX@Z/X4MK[P[<:Y]J?";XO6GQ5\%:EXZN? 7Q.^$VG:9XC\8:&^E?&
MOPDWP[\23Z9X2U>\TV/QHFBWU_=7%GX/\46-HGB3PU>ZN=-U1]!O+:37='T+
M5([[2K/\R/C9^SW_ ,%)?VJ_V%/V@?@K\:=(_8C\#?&_XB^%?!G@[P=X9^$7
MQ&^,TGP8O-4TCQ1H?B/QM\4/%_Q'\4_ ZX^(&B#Q#)I:6/@KX5:+\-O$*>$K
M"RNKKQ/\4O'6H>++6'X=?J+\3OAW!\9?@S\0_A-XPFGT"V^*_P ,O%OP\\4W
M'AC4GN;K1(/'?A;4/#>MS>'M7N]-T^2XGTV/5;I](U*ZTBQ>:2"WNI].M69[
M9%+GC3JN*C.K&*]E%2M"I+V%6HG?=*56-*E).SI\\F]4E"XVE4IJ3<*4F_:2
MM>4%[6G!JW5JG*I535^?DC%:7<_S+OOVTO%GQ4_;6_X)OVOPFU7XL>&_V9OV
MD/ /[4_CFW37?"'P[A\ ?M$^$?!_PM\)^*?AE\3?#>I6\7B#XO\ A>WLX_$U
MKKOA[PYXQN/A?<>,]!\46&MQ>!_$3>'+^\\-^D>%?^"@'P,^'/P*^'OQ,U;6
M_P!J/XIZ1\:/VQ?CY^S7X$'B;X1+K'Q43XN>'_CK\<O"NI_#FZ\+> O"GA>'
MPWX*\'^(_ACXL\!?#(>)]+MO%A\&Z#X3M/%5SJWB9M7U%_!?V>OV/?V\?#'C
MC_@FQ_PNV']E:Z\+?\$_/!'Q7^#.L^-_A]\4?BK?>*_CAX)\1_!?PW\)O GQ
M*M?A[K?P+\/Z%\-/&:P^%--O_&WPY;QYXVT"2^U/5[CP]\0+*STO3],UIVE_
ML+?M86'P?_9L\&/9?L\'Q1\(?^"L7QP_;J\6(GQC^)+:#=?!_P"+/[1'[3/Q
MLLM \.ZL?V=H]1U#XDZ-IO[0EOH%UHFI:!HOA>[OO"DU]%XTBM]:2WTNVH\\
M80DW2]I6BJK2YW2GF&&]G.<7I"7U252JZ=I>Q<9PYG"+ISQO4M.;C[]J;5-/
MW%.& KJ<8N_O1>*C"G[33VJ<)\JE.-2'T1\3_P#@JI^S-\%? ]OX]^+5A\1?
MAYIV@^%?A=XR^..@>*=.\$Z9X\_9DT;XLQV4^A0_&GX?R^/CXPGU_0;._MM5
M\=>%?A%H_P 5_$_@OP]<6'BG7=(M?"^M:#K.J^Y>-_VSOA?X)\7:SX;_ .$=
M^)7B_1O!OQ?^%OP%^*'Q!\">%[3Q+X.^%'Q8^,T/@:X^'OA3QG;P:U#XWNCJ
M4/Q4^%<^M:WX*\&>,/#O@JR^(OAW5/'&K^'-)M_$5_H7RKXG_9K_ &Z/A?\
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M--9M/$MWX+^'_B+P[\/?B9KG@SM?AI\<OAY\3-;\0^!=%U=;'XH^ /"/PO\
M%?Q2^%6K/%'X\^%EM\7-"U'7O!&G>.M.MY+FVT[5=3M-$UR)8K>]O(FN-&U
M),\<:22?ECJWBO1?V*/^"LO[1OQT_:5UN#P%^SI^VK^S%^S5X4^%G[1GC>YA
MT7X+?#'XH?LOZS\9+?QA\!?B%\0]1N1X<^%>M?$71OBMI/Q&^&EQXYO?"WAS
MXDZEI_B[PUX2U'6?&NB7&CW%2BXU8TWHKUU)WC9RI4ZKA%2O*-JE6G*FI1E*
M[@U3<I2BW*ES4G4CO:BTFI72JU**G)Q<8R_=TJBFXRC%I23G&*C)+]/?A?\
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M!3XWV7C71D\-:MK=G9^&]<\.?&W0ET>TOM0&N""T:?6M/T74;B;1=/\ YO\
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M?#V.YO=;U/Y._9V_;(_;O^-&D?\ !+37M8^*?P-T>V_X*2?LD^*O&VO6>F_
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MI+>W5K9QW&H7UO"]U<V]NKF6:-&_FJUSQ#\:/B!\&/"WB'QS\5G^(?C/3?\
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M\4K?EYKWQ^^-WPY^-_[-GP1^*OB;PU\9/!'[;7[,?[0'B:YU7P[X&M/#=O\
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M3GAO9TX*TY*M!O6G4)O)SA",;RJ-\J<DF_\ :,+1BNJ34,2ZDY:Q7L9J*:G
M_>:BOPX^ 7[7/[7&L?L]?\$XOB-\7OBI\*-?\4?\%3)/V5]+\&?\(A\$[WP%
M8_LUV_BS]C+XB?M2_&J]_M+5_B7X[L/BMXM\::?\+M0\,_"P:QHWA70O!'C_
M ,5V/B'5_"GQ&\&:)<_#V\U=1_X*$?%?X<?%'XG?LE^.+OP]J?Q+\-_M]_LP
M_LB?#WX_ZAX8AT7P[K/PU_:E^#D7Q^\,>)O%_ANQU6/0IOC?X:\*:#X\^$;1
M:%%H'@7Q7\59_AGXZM_ /ASPMXPN_AEIMJ,G)P5G)2E#1Z>TA*A&I"[5KP>)
MHN72TI--^SF#DDFVFE&*G)VUC"2K.$FDW*T_J]5123=XQ32]I%K]LJ*_+#X@
M?'C]I[X#:S\(O@'\0O$'A/XI^.OVCOVN?B3\(/@]\0_AAIWA?2?B1I7[/_AO
M]F?XB_M":-JGQ"\/^.Y/"GP<B_:6%_\ #?7/!2_V=;6GPKU/P[/IOQ1LO!-Y
M?6FH_":\\8^+7[5_[;'[.WPO\(>)/VH_#NJ>!/AMH/BS]I32/BY^TY^SA\,]
M+_:%USX4>%/"EWX4\1_LE?$W]I+X#>'I_%VI^%/ ?B[X4W_C:[_:WG^#-OXR
MM?!GCOPIX=U#P=XM^&7PR^(/]N^#(O[KEHXK2]TKRO!2A[SBE*+G!24I12<K
M^TY;3=?:4>O9)MI>\U*T4VXR4).+49-I:0<O=/VVHK\=?B-^VM\1O OQK_9\
M\/\ COXA6'P[^"WQG\-_LFS_  3_ &G?"7PW7XK?L@_M#>.OB+X\TV#XT_#/
MQI\5]"M]5U/X.^+OB!X(N=&M?V1-3UG4_AY\/O$6K>+%URY\8?%G4C'\-/#;
M=-_:_P#V@[7]KKX%^#+KQ=\.O'GPN^,W[<G[3O[)/B"S^'7A>;4?A9X%\*_"
M7]G7]HWXU?#^#0OBGK[^#_&OB/\ :?T;7O@%'X4_:-LO#NF_$[X#^!O$.H?$
M'X,Q7GA7XI_#274-9IIIV=DE4E2;?-I.-25+E:Y5*,G*-^6<:<HQE3G)<LXD
M\T>7G;27LXU;:7Y)0C44E9M22C*W-"4XN49QB[PE;]C**0'(S2T%!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7R_\1OV1OA1\2?B?XD^+^H7GQ#\->-O'OP<TO\ 9Y^)]WX'
M^(?B?PO8_$KX):'KGCGQ-H/@/Q#IUG>M;:+-H'B#XE^/-2T'XA^ %\&?%S11
MXJUO3-,^(%KHFH7.F2?4%?*WBO\ :R\+Z#\9M9^!OAKX=?$_XI^+_!K_  &D
M^)LWPYA^'=[:?"S1_P!HKQUK'@7P%XH\8Z/XF^(WA;QO<^%K23P]X@\4>*=<
M\&^$/%EIH?A'0=<U(M=7ND:EIEJG9^Z[/FC-6>J<>6U1-.Z<.25IJ2<.65II
MQE9FVNUG%I[-2YKP:>C4N:-X.+4U*-XM-77G'QP_X)M?LG_'?QA\)/B#JWA7
MQW\*_'/P4\"-\(/!'C#]F7XR_%S]E?Q+'\"Y;G3KZ;X"ZOK?[/?C/X<:EJWP
M<%]I&F7NE^"+FY^P^%[FWN)/"$GA_P#M;7!J?KL7[)?P.@^,(^-D/A5X?$Z_
M *']EQ?#D=].GPN7X!6^L2>((/ANOPF7'P\33(=9EDN(]43PZOB-=.8^%AK7
M_"'8\/#Y[\3?\%1_V4_"GQF\!?!O4/$=W>2_$/\ :'O_ -E'2?'6BZY\,=8\
M-Z5^T!9:GKGA6+X?>)?"%C\19OC?HAU#XC^&=>^%5KXNN/A&W@.V^(6GIH^K
M^*=,LM3T;5-2]'\'_MO>!?'_ (P^&^@^#?A;\=O$W@OXT6/Q6G^#?QQT/P/H
M^K?!3XC7_P )(9[O4]*MO%NG>++O4? T/C;3].U[5/A+XR^+>@?#SX:_%33=
M"FN_!7C?5H];\('Q(_B762FZDG?WN:52,U4;YN:[J1J5%+F_B>TG93=2?M"W
M+_=<5"*M[ME3E#D22Y;*FX0MR_P^2'P1IPY.C^"/[&7P3^ )^&T/@FU\6ZCI
MOP/\#:]\+/@%I'C?QAK/C2S^!OPM\2R>&I-5^'WP^N-<FN=7;11%X/\ #>DZ
M5J7C#4_%GBWP]X3TBQ\!^'O$FE^ [6W\,Q,UK]AW]EKQ!;?%2TU?X1Z!=VOQ
MJ_:-^%'[6/Q*MVEU".'Q)\=_@K>_"'4? 'C.5([M%M([*^^!W@*ZUKP_8BV\
M.>*ID\4MXFTK5?\ A._&8UWSWX5_\%#?@S\7K/\ 8LU+PSX3^*MIIG[=_ACX
M@>)?@W?ZWH7A2UCT9_AOX+U#Q[K^@?$*VLO&VHZCH>MS^'])U&32VT2R\3:'
M<W=L;2?6[62:V,WS;X__ ."E7PV^*O[&_P"UC\9K+X3?MX_"SX*_"[X)_M,7
MWB_X\^ O"?PA\+>/?#FK_ KXF_$CX%?%;0_@Q<>(_B3KBR?&/P)?^ M;^(OA
MW6M8\*S_  UAT&.R>Z\42^--&\5^!- 3DE>5]8QE+F<EI%5*$Y2YVW_R]>'F
MY<SE.HJ,DYS]G*):]DT_?E&-N5M-N->$5RI/["Q$$K*,8>VC:,'4C+]<M8T?
M2_$&D:KH&MV%MJFBZYIU]I&KZ9>Q+/9ZCI>IVTMGJ%A=PN"LUM=VL\UO/$P*
MR12.C9!-?GE\/O\ @E5^R7\,K;PA;>%8OC@J^!/V=/B-^R7X7DUO]I#XX>)7
MTK]G;XD2^&DN?A9;)K_CG4;>#PWX/TCPEHNA?#R*""&X\'V]K%K>G3GQE:V'
MB>S[S3/VLO%U]^W1\2OV08/@EXSNO#GPQ_9H^$'QWN/BE#K'PVFBU^;XN^)O
MCAX=TN"+1IOB%IFOV.D6VH? S6/"5I)'X:O=8U3QOJEW-JND^$? .DZ+XS\8
M^#_!/_@H5^SUX7_9-_98\9:?XR^-/Q0NOCE\)?&OQ'^%&F?'SQE\ ? _[0WQ
M%\$_#S6M"T?Q/XB\:>(_B)\0_@U\%(O$5IKWCWP!X>31U\9:5K5U)XMT>XCT
M5M.T7QIJOAM2A&TN:,;2A9IJ_/3=3$X>SB[^[*V)C9I\T)U8VY9RYE"IS<K@
MW>,E9IZ1FJ6&Q-U)-)M*>'E?3EE&$K7C'E^F/#_["?[.GA^;X2@>&];U_2O@
MG^S1XI_8\\">%_%_BC6/%OA%?V:_&]KX&L?%OPM\5^&=?GO](\>Z=XCLOA=\
M,[37->\;6NO^+]7@\#:/'J7B&[%YX@_MKB_@7_P3:_9G_9X\5_!CQA\/YOCI
M>:C^SIX)^)'PO^!5CX[_ &EOCW\0O#_PQ^%'Q.?P$-8^%FB:!XP^(.KZ7J7@
M+1K3X9>"-/\ "VA^*+;7UT6T\-^'BL\]UX8\*W.A\]X._P""G/P"^+/@3X>^
M//@#X9^*?[0<7Q#_ &=W_:DM/"/PTTOP'8?$+1?@_%XCO/!USJU]X*^)OQ$^
M'>M>(-<L/&&C>)O"6K>%?AY!XW\0:-XE\.R:-J]A8WWB7P%#XO\ H#]M#XB^
M'/A%^R)^T[\4/&.L?%GPUX0\ _ /XM^+?%OBOX#OX>B^-'@WPMH/@/7M2\1^
M-?A9/XL8>&;?Q[X-T6WOO$_A6XUU+G3H=9TFS>>PU+"Z?=5)RINI4:<9\U5S
M;^*4W.HZK;]YRE*=2KS3]Z\JD_??/)245"HH4THN-J?)&WNJ*C"-.T79)1A"
M"C'W7&-."Y8\D7'H_'/[.WPZ^(7QF^#WQ^UX>)(OB=\!M%^).@?"[5M)\2:E
MINEZ%IOQ?LM TWXC1:CX8AD/AOQ:WB.R\*>&(HW\8:7KQ\/2Z);WOA0:%J%W
MJMWJ'D/A+]@7]GKP/X;^!7A+PY:^/[30/V;/CAX^_:,^#UI<_$KQAJ5SX<^+
M_P 4/^%FCQYXHU+5M1U.ZUCQ?#XAC^-GQCM[C0/&.H:]X=M;/XDZ_8Z?I5I9
M6/A>#P_Q'Q%_;\\)?";Q;8?!S1O@;^U#\=OB;#^RI;_M4Z7X?^''AOX67^L^
M+/AII?B70/!VNQ+XA\;?%7X:^"$^(6ERZP=>U30]1UO0[+6;>QN]-\(7NN^*
M]4\+^%==^J_ ?QK\)_%CX#>"OVB?A/9Z_P#$7P/\3/A'X;^-'PUT_0[.RTGQ
M/XY\)^-/!UEXX\'6NDZ?XRU+POIVFZ[XET?4M.CL;+Q3J_AZTL[^\B@UK4-+
MBCN;B E:DY7;C[&4U?5./+6K\S44W+^/AZS=HSM5IS3;FK2(M581LE*-50=K
MWB^:C2<4WI%OV.(I\K?+>G4BTE%OE^5? '_!,3]E/X6>,/AEXZ\#:5\5M-U;
MX)_%CXL_&'X/Z&_Q]^,I\$?#W6OC;!XE?XD^$/#'@P^,9?"^D_#7Q5K?BS6/
M$6J>"X]%FTJXU*6UM+F*[\.:?9>'X>F_9>^%'Q!U/XE_$C]K[]H3X)_#;X'_
M +0_Q?\ AM\)?@[J7@7P#\0!\86\,_#?X.:G\1/%.C0:Y\4F\"_#Z+7O$>N>
M,_BSXRDU%=$\/V^D-X0\/_#6VNIKC5M*NH;#&^$__!1?X,?&/Q!^Q?HGA?PC
M\3K*T_;N^!WC7X\?!'Q-KL/PUM=!M]#^'FC^&->\8>"/&J6/Q,U+7]&^*6B:
M9XS\.W%YX*TK0M?N8?.UY)+I&\"_$$>%/F?Q%^V5\3)OVQ?V8?&'@+P;^T?\
M1?A3\;/^"<W[5?QG\/\ [)OA*R^ [>)_%'BGP1^T!^Q3IW@'XDV.KZIX[\-^
M =+U35/A?\3_ !=JMC)\1?V@M,\.1Z#JNF>'='T[1_BCXCD\):_$G[/D5G9J
M=./6,$J=JCC9MZT\/"E+E<KP5.T7"2G*DE5<K-.2Y:DKW4IM2;A&5TE=3JSJ
M14E&U1SO*,TX1_2;XP_L_?#KXYZQ\&==\?1:_-J7P!^*UA\;OA?+HGB/5/#Z
MZ+\3M+\+^*?!.G^(KZ/2IK=?$,%OX1\<>-/#\OAO7QJ7A34++Q-?S:KH=]?V
MFC7FE^*R_P#!/W]G"71?%>E'2?&8U#Q/^TU+^V;:>+O^$_\ $\GC/P/^U'/:
MII\WQ>^'/B">^EN/!=W<:5&WAZ_\!:0D7PFU?P=J'B3P%K'P_P!0\"^-O''A
MOQ)Q$W[7GP=^+6I_\$P?B!X-\4?'NT\)?MG>(M9\9?!*7P38^&=)\!>,;;4O
MV//C)\9K'PE^TO9^('FU^S\/IX TGQ#XKT#0/"(?6K/XQ>"O"#ZO<Q:'I>IK
M<>C^%?VS/ OQ'\;_  \\'>#_  +\;KWP1\:=9^+_ (-^%_[2&@^"=&UOX)ZU
MXK^#T/B ^);4Z_I^N:]XB\)66ICPAXWN/AIXY^(WP^\/_"WXHKX/EF\$>*O$
MUGXK^'A\;5>SE&]I0G.+2E9QGS46[RB_=<YTZ5O>7-*G3M*7NW5E)*5E*,X0
MDFXW4HN-9+1IN2C"=5.R=HSJ)QC[S-;QS^Q7\"_B+\'/B+\&/%-AXMFT[XM?
M$;PE\:OB'X^T;QMXA\*_%OQ)\</ 'B?X>^,_ ?QBF^(?A:\T;6M/\:^!_$7P
ME^%[^"8M'.G>%/!WAGX>>"?AMX8\,:3\+O"VA^";'U3XF_ CX7?&;X'>,OV<
M?BEX?O\ QO\ !_XA?#K4_A3XV\.:YXL\8SZMXE\$:SH;^'=5L-4\=1^((O'\
MVK7^ER.MSXL'BA/%TE\[:P==_MAC?U^5?_!-C]OC7?$/PM_8\^$/[0ME\>/&
MGQ-_:+O/VF-$\'_M/^+_  [\/K?X;?$WXE?![XD_&?Q%K'PMN&\.:]H?B[1O
M'.G?![P)J/B_2[^W^"WASX):IH'AC5-#\%^.+G7]'E\*6WZ0_&+]ISPE\$?B
MW^S3\)/%WA#Q_=3?M3>/_$GPL\!>/]'M/"1^'/A_X@>'OAWXL^*=OX6\=ZOK
M7C'1=:T?5/%7@[P'XRN_!T6D^'=?77]0\/W>B0O%J]SIEE?&DHPM[T:KI\J2
M>LG2HRC'E2NI0A.G"S4;<L5%N/LI,B]7))QE!3;E]I152KS2YMW%RISG=2E:
M[NHR51*K8_LC_!J?2_B/8?$'2]4^-=[\7OA1%\!OB7K_ ,8]0C\9:SXP^"=O
M;^);.#X6ZIBST[2E\*2V?B_Q%'K:6>E6NJ>,[W4[C7_'6I^)_$KMK+<]^RE^
MQ!\"_P!C72+[1?@_-\6]5MI]*TCPMHL_QD^._P 8_CS?>!?AYX:,Z^$_A9\-
MKSXP^-O&<WP]^&GA:WF6UTOPCX2.DV%TEIIUQKG]L7^G65Y!:O\ ]L'P#8V=
MO(/"/Q"O=9\2_M&^,/V7/A/X7T^W\$76M_&[XF?#W3/%^M>.I/AQ.OCM?#UO
MX;\(:1\-/BW?^(]3^(>N^ ;K1H_A+X[AO]-@O+31K;6_,K3_ (*-?!J2V\/Q
M:GX(^,/ASQ3=?M>>&OV(/'_@#7O#OA&U\8_!;X[>-=/TS7?!5I\1[:V\=WNC
M:AX,\8>%/$7A'QGX:\=?"S6_B5X=UCPKXQ\/ZM:73H^IQ:8*2;]U^])1C9-7
M:E*+BK)K>>(C?12B\0E-Q]LXU!Q26JLHN3NULXQDF[O72-"5E=IJ@^12]DG#
MQ;P3^Q1KGCW]JW_@I%XF^._A3QE8_ +]J;Q?\!!I_A>W^(F@3^!/CK\.?AC\
M O!7PR\1>#_B7X+T;6M3UK2M U;Q;X?UYM=T2S3PS'\7?AGJT7@'XPR^*O E
MYJ'PUM_H+XX?\$Z/V7?V@?CCI'[1/CG0_B-H_P 4+?P9:_#/QGJ7PO\ C;\7
M_@_HWQH^%FGW^I:MI_PL^//AGX8^-?"N@_&/X=VFJZM?W;^$_'5AJ^EZG:W-
MQX?UN+4_"MU>:#<>V_!+]H7PC\==;^/WASPYH?BWP]K7[-_QSU']G_X@V7BR
MTT&W-QXQL?AI\,/BW;ZKX;N/#WB+Q)::EX7U?P/\7O!FHZ?>75QINK17-Q?Z
M;JVB:9?6$T)_-'0OV\-<_9Z_:!_X*(6GQRMOCQ\6/@S\-/VZ?V9_@[HWCG0M
M ^&\W@W]F+P+^T+^S#^QOJ/AC_A*4N=<^'&LZ]X$C^-?QMUF'4?^%8>&?C'\
M3_"FBZC!XK^)FEV_AZ6T\6:C4$Y^SY$GR0C*G)6NVVH0M?=U%B>75J#BU"4?
M>4)%5\CFZB:<Y\M16MRV@YMR6EE36%4[J]2_OQEHY1_2;P5^S3\./AY\1_V@
M/BQX0N/&6D^.?VFKKPMJ'Q7U'_A,-8O=/O-5\"^"K'X<>"=6\+>'-0FN_#?@
M74/#7@;2M*\.QR^#])T:/7HM+T_5/%\7B/7[6+5AY?X"_8'_ &>?AC'^RE;^
M"+'QSHMI^Q)X1\5> _V:+)OB)XKU2S\ >#_&GAJU\%Z_H.HV^L:AJ"?$*UE\
M'Z?IGAS2IOB6/&%[X:LM-M;OPS=:/K!N-3GJ_%+]N_X8?";XCZOX"U_P'\8+
M[1?"GQ7_ &</@AX[^+&G>&O#5A\,?!?Q._:J\2>'?"GPB\.37?BSQGX8\9>-
MUN]:\<_#FW\4:O\ ";P5\0]#\&)X^TB7Q'J5@N@^/O\ A#JVD?M[?#?5K#]I
MXK\./BYI_BG]E/X^^!_V;O''P[U:U^&-AXX\5_$7XI1_"RY^%4WP_L)/BBVD
M7_A?XG6/QG^'=]X%U_Q1K?A*#74UN:RBACU?2=6TZR2;=N7F>D;6YM%!M0].
M5XJ7*W9VK3DFXRG**:C%NZ2:YKZ)?&DY;6OS+#Q4DD[NE"+2DH1=_P /_L _
MLZ^&/#7P8\(Z/I_CJ#0OV?\ ]HCQU^U7\*K>;XC>+KRY\/\ QU^)=]\2]3\<
M^,KS4KO4IM3\26WB*_\ C3\8;F]\*>);O5_!X_X63K\$&@16MCX8@\/Y7B__
M ()T?LS^-='_ &F/#^JV/Q-M-$_:M^(GA#XP_$G2=!^,GQ,T'3-%^,7@34OA
MYXA\+_%?X::=I?B6VL/AWX^T_P 7?"CX=>,6USPY;6SWGB'PM:37L-Q87NK:
M?J'.?'#_ (*=_LL? #QWJW@GQQXDEFB\'?%;X9?!?XH^)]*\1_"M+/X5>._B
MV? R^$+;Q/X*\0?$GP_\8O$6B!_BG\+E\0^*/A;\,?B'X=\*Q^.(KOQ!J>GV
M/@OXHW7@/ZF^./QOT#X$^'/#&N:SX8\>>-M2\;_$;P1\*O!OA#X<>'H]?\2:
M_P",?'NKIIFEP--J6HZ%X6\-:)IULFH:[X@\5>-?$WAGPQHVC:5>/<:NVI3:
M7INHJ*]V#A=)2]G3<;JTI+#VA"SNG)4<,XI-75*BXOW(R3=G*:EK-Q]I-2U;
MBG7;G+F3T3K8CF;ZU:JDO?<7\U?$O_@F=^RA\5OB]X8^./B;1OBO8_$+1_AY
MH'PB\9ZCX0_:%^.W@JR^/?PK\*F_E\/?#W]IO3?"_P 0M+MOVB_"UG<ZG?RZ
MEI_Q=7Q6?%MI>7>@^-I?$OAB\N]$GB^-?_!,C]DWX^^,?C=XQ\>:#\2K-OVF
M/!FE>"/VBO"O@+XW_%WX:> _C;9^'=%LO"_AC7?B'X.\">,M T;6/&/AKPC8
MQ>$=*\616]IK;^&TL--U.ZU%/#WA9]#RX/\ @I=\'+OPG\%O$EE\,_COJ&J_
M&W]J3XS_ +%VD>!=+\+>"=6\6^$/VD?@5%\:SXT^'_CB73/B+=^$+.UFO/@%
MX_LM)\;^'/%GB;X?-%#IWB'6/%6C>#Y;[Q'IU70_^"FOPDU;PA\(_%VH_"/X
M^^$Q\2OVO-9_88\6Z%XFT3X71:I^S_\ M(:5XRU7P':>$OC9J.C_ !;UGPA:
MZ+XJ\2Z9!IG@CQM\,?%'Q/\ !_B^_P#$?@G1]#UJ[U[QSX2TG6:Y7HN5I<VG
MV5S5I46[:Q352=2A)\MZ?/.E)J,Y0DUS1=U=/W5=:MVIQK)75F^:$*5=:KVG
M)3JQO*$917V'\6?@9\,?CE\%/''[/7Q4T"Y\8_"CXC> ]3^&_C#0M3\0>(VU
M35_"^K:6VD78?Q?'JR>,(->6W*W5KXMM]=B\56>L10:[:ZS%K4$5^OS/+_P3
M?_9FO]&^-^E>(T^,'C.Y_:4_9VT#]ECX_>(O&GQ[^+_B7Q'\5_@YH-Q\09ET
M?Q5J.I^,)HSKM[;?%7XA:/\ \)AI5MIGBC0/#WBG4O#W@O5?"^C-#91?47@'
MXJZ;\0_%7Q@\+:5X=\4::OP;\=Z?\.]5\1ZQ%H">'?%>OWG@/P?\0;R3P5/I
M?B'5=4O]-T'3O&^CZ+K=WK>D^'VM_%-OK6B6T-Y-HU_)#\D>)KW_ (*(0Z_X
MS_X1_P"'OPBUG0]+_:L^'<WAZX;X\R^%I?'G[)6HZ;=6WB.+1M.?]GWQ(WPM
M\9_#W6+CPMK'C71_$.I?$S6/C%!IOQ<M/!'CWX5V6O?";1?!D63DER_Q$I.4
MK*+3Y*:;;V<H5G9I)NG&HVU"+N[V6FT&XV3=URJ=1I);I3HI6U2JRIJW-*Z]
M6U']BCX!^(/&GB#QUXRT+7/'FJ^,/V9G_8\\9Z7XV\3:MXB\(>,?V=9[G5+Z
M]^'WBCP5>3'PMK3:IJ&N:U=:QXMO-)D\;ZQ#JMYHVI>)+KPZT>CQ>??"#_@F
MW^R_\&/$7@CQ3HEG\7/&>J_#?X1_$+]G_P %1_%[X_?&GXNZ+H_P)^)5_P"$
MKS7_ (/W'AKQ_P".-=\.>(O <$/@3P=IVEZ3XJTK79+>S\.:5/<W5YJMLNI5
M\2?LG_\ !1ZY\ 6MSX&_:9TW]I3QWI_C'_@I5^V=^R-X=_:PU+X<>';CX+>#
M_$^C_MG?&/X.?LW?";Q_K'AVX\,:UI4WBC2?#W@GP!X>\<^#/A)J?P8L/&6L
M:/X3\7^//"WBZYU'2K/Z]\<_\%0?V5?A_P#&+PI\']9\17E[/XH_:$T3]E>3
MQIH.L_#;6- \-?'7Q-?0^'?#O@OQ%X1MOB%_PNI+;4_B#=V'PPN?&6C?"?6O
M GAKQW>-IWC#Q-X=TS2]=UC2KFGS<LK3E.UU?F3G5BJDHR4M'-O,)Q;E#]X\
M1/DE.G77/,7%)N*Y%"]FERVC2<J<9)QLU%1P*:2F^2.'BI*$Z#4(_A%_P2R_
M9&^!_P ,?B;\&_ 6F_&/_A6OQ,^'/B[X+KX2\8?M%?'+XBZ3\+?@EX^M[>U\
M:?!_X VOC_Q[XEB^ W@?Q/#:VIUR/X5)X6U_4[C3/#=Y>:]->^"/ MQX9^X/
MAOX!T'X5?#[P3\,?"KZL_A;X>^%M"\%^%UUW5[[Q!K%OX;\,:=;Z/H-EJ.OZ
MK+<ZQKMU8:59V=E)K6MWFH:[JIM_M^MZGJ>JW%Y?W/P?X/\ ^"GGPC\7^*_A
MGHG_  IW]HKPUX3^)O[4OQE_8LM/BQXI\(_#_3_A]X7_ &E_@OXC^*7A?4?A
MUXFAL_BCJ7Q EM/&6K?"'Q;9^"OB!X2\!^*OADVJ'2_#/B_QGX/\7WK^';;1
M\6?\%1/V5/!WQE\$?!S4O$=W>2^._P!H;_AE.Q\<:)K?PSUGP[HWQ]EU+4/"
MVG^ O$?A&Q^(DOQMTU=1^)&E7_PI3Q?%\)+OP)IGQ#MSH_B'Q/HUC)%JLAK:
M.[YU",;W]Y047!.[O=+$0<>>TK5HM74TQKEU:M[O.VU;W>:4U.UE9)RP]3F4
M?=O1GHG!G42?\$Y?V9_M^NWEO:_%&QM=9_:OTS]MJ#P_:_&?XF_\(EX;_:.T
MK7[WQFOC7PMX4N/$MQX?T;3-6^(.K^(/B#XJ\$1:?)X'\9^*=?O'\7>'M;T;
M3_#^CZ+L^,/V OV<_'OP_P#VGOA=XJTSQSJ'@G]L;XAVGQ2_:$TRW^)7C32+
MOQGXTM- \#>$UU'3M>T75].\0>"+6;PK\,/AOX<GTGP)JGAO2FTCP9IMNEG&
MVH>(Y-;_ "W^(O[3WCOXB?#[_@J!\>?C#XH_;E_9S^'O["7QI^*_A.*Z_9:\
M1_L^-XOA^!?AC]C[X)ZQXS^'4GA3Q)XJ^(O@36?B=!XO^)OBO]H#1OBK+X?L
MO$/@LV'A7P[X<^,6DZ9I>O> M2_6'XU?MB^"/@M>?$;1K;X?_&#XT:W\%/AC
MX7^,/QHT3X+^&_#?BGQ%\-_AQXPU'Q98>&?$.IZ#K7BWPEJGC+5-:M?AW\2-
M=MO WPHL/'WQ".C^![Z4^#X[SQ/\.[#QG"<6HNZOR4Y176-.I3HSIR>ONIPH
MT;WMR^PI\TE&G3D.[4I))V<IIR6BG.%2I":2LG)JI6K);\SJU.5-U))[&N_L
MD?#7Q5XTU+Q;XJU[XD^)M/UWXF?"GXU>(/A[KGC>^OOAOJ_Q>^!UM\/D^$_Q
M 3PN\"_\(]>^#=6^%W@CQ=;>&/!U[X;^'VL>.]#LO''B3P?K7BFTL]5MO"_^
M"@?P&^)WQYU[]A5?AWX;\1:KIOP5_;;\&_'OXC:]X7\:^'O!6N>$?!GA;X-_
M&_P-!K&AW&MZ[I4FO:U:^,/B5X5U,^%#::IX?\2>&=)\4Z/XLL=6TB\/A3Q1
MI>+_ -JKX5?##]I#]J"?Q;KW[1D;? /]AOX8?M%>.O!*>']-UWX01?"F7QA^
MT+=V7CGX8^"]$M;OXJZI\;_$-WX%\;>$_&FD7=G%;WNC^!/ >FZ9H\.HI+>:
MGXM^U?\ MO:AKW[''_!5.S^%T/Q:_9M_:@_8K_9-^(?Q.O;+Q39_"?4_%7A#
M5M8_9Z\:?%WX0^,=$U/PEXF^-'PSU;2=;N_"6M:-=6DNK-XFTRZ\/:T\VE:)
M#=^$_$>IMMPM)*\HKZQR[-JE.:NV[-I.B[M.\8QM%**3DZ:YY<D;+VCCAN;=
M)XB$()6LTFUB(V<DTW+F;DVTOK7Q-^P_^SUXU^&^O_#GQ=X;UG79O%'QC\/?
MM'Z[\2I?$^LZ9\8+G]HSPCJ'AG4?"/QSL?B-H-SI.N^'O'OA'_A"_"/A_P (
MKX9DT;PIX5^''AG0O@SX=\,:9\&=*LOA]#%XY_8>^ WQ.^$/QD^#/Q"L?%WB
MC0/VB_$&B^*_C[XD'C+6?"WC_P"+'B/P_IO@[1]*U+7/&'@67PKJ7AZ.RTCX
M?>#-(L='^'W_  AN@:7HF@6V@Z3I.GZ'<:AIUYXUXH^#W[6'Q%\.?$/Q!\.O
MVI?C'X%LOB7^S=\*+#X>V.F7?P!$W@3XW:5-H&L)XL\":IXN_9W^(%QX6\'Z
M_9VVIZ;\;=1^)MK\??$'B[3O&FJ2?"[PA\.M2^'?A8^,_L;XE_%;PI^SU\&M
M?^*WQJ\606_A[X=^%;74?&7B2QT.[2;6=2C2TTU+?PWX1TR76-5O]?\ &'B*
MYM-(\(>"=%?6=;UGQ!K.D^&-%35=5O;..XNI%T9U*<I*].K*DU!2^*E6G07*
MDNLL)AW!1]YQGA8I2G!0A$)*I&G-)VG!33;6BG3C5?,W+MB:]VWRIPQ+;C&7
M-+@_$/[(WP3\9_%?Q=\9O'6@ZAXY\8?$']GJ7]E;Q]8^*]5N-5\">-/@1=ZK
MK.O:EX%\1?#-EB^'U]%K&N>(_$.H:OK?_"-Q^(M0MM:O?#EQJS>$%M/#UMX5
M\-?V/?"W[ ?P>\9S?L7_  P\??'#QY8:)X3\*_#GX9_'O]KKXO>(+'0_AQX?
MUJRLM*^$/PT^(WQMU#XSQ?!KX<>!?"]WJ-_X<\(^&M MM*\07N@Z#I7B2[>Y
MCT_Q%H_0^)?^"@'PQ\ Q_M%:;\3OAS\7OAO\0OV:_P!GV\_:I\5?"7Q!9_#+
M6?'GC3]G_3K?Q*NI?$?X82^ _BCXQ\$>++/2==\'>)O">N:!-XTTGQ=X>\06
M6C_V_P"'],T7QS\.]9\7>V?LY_'^/]H[P;>^/=/^$/QF^%'AJ2]T<^#[CXS>
M'O"_AB_^(WA;Q!X.\,^,]&\?>$M&T'QGXLU>S\+WMIXFCT=K7QO9>#O&&G^(
MM&U[2]5\*6/V&*>ZA;/E;^"S<=N252K*W\NM2-=-+WN;VT='SQ=-JZ4K-\VB
ME>_-&G3BG9^][M.5"S^'E]B[VY&O/O@?^RIH?P^^ GQ8^&FIVMK\//%?[2?C
M7X__ !<^-VL_ 7Q1XC\%ZIIGQ-_:6\2>(_$?C/4_ 7Q0T2T\%>-%\3^";/7]
M/\*>%/C'9:1X%\9:Q+X.T7X@'0/!_B&[?2M-^KM#TF#0-%TC0K6YU2]MM%TO
M3])M[S7-6U'7M:NX-.M(;.&YU?7=8N;W5M:U2>.%9=0U;5+R[U'4;MYKR^N9
M[F:65_BN3_@H+\%(M9^',TNA?$5?A#\6?V@-;_9:\ _M'QZ7X3N/@OK7QYT;
MQCXE^&4'@6=K7QI/\4-$M?$_Q:\%^+?A3X*\>:_\,=+^&?C#QUI>D6'A_P 9
MWVF_$'X7:MXX^"_C-^WO\9?B!\._C#XD\.^&/BE^SU8?LV?\%>/V*OV5KC4-
M"7X<^,KWXM?#'6_VI_V/_AW\6/!VO:7X7U+XG>,I[_QKHWQ<\9ZE;:7X TCP
MWJMQX5U#P3X<BUW4?$;^-O"MRI3M%6NU:FDETBIX7#1?O2NE".*P]HMJ3I3C
M*"G%PD%E&[MK^\MI9RERXBO.*LE%N4L/63:3C&I%QFX-21^JO@#]F'X7?#3X
M[?&_]I#PNOBN/XK?M&6?P]T_XP:IJ?BW6M7T/Q-8?"72-4T#X96FG^$;^XF\
M,>#HO!VB:WJ^GV[>"-*\.3>(&U&ZU3QG+XFUMQJ:^9ZA^P-^S[J>C_$[0;J'
MXA'3/C#^TOX'_;!\?Q1?$GQ;#<:K^T1\-M9^'7B'P+X\LKZ/4%O]!M?#6N_!
M_P"%&J:=X'T&YTWX>+<?#[0TE\*2VUWXA@UO'\._\% _@_<^!/V@/&'Q)\,^
M/O@)K'[,WQC\%_ ?XK_#SXP7/PJM?%.D_$;XJZ9\)M8^#6GVOB'P#\4O'WPE
MN-)^+EG\<_A6/"7B.?XFVFAZ1<^*3:_$.^\#W&@^)X]%\;A_X*]_LOSZ1X[O
M;;P_\6-8USX8_M-_L[_LM>._!G@O3/AS\3M>T/Q3^U7J_AG1_@9X\L]4^%GQ
M.\;>!O%OPS\9W'BJP5-0\#>,/$WC#2]2M-8\)ZKX)L_'.DWOA:,45:+4=(QI
MN-E?EC.I2J4[):V=5T9Q5F_:.#<5+8=O>37Q2FIIK>485(5$]-;4U5C)[.',
MKRBTW]-ZQ^Q;\&=8\6_'WQX;KXEZ1XQ_:5U#X,:O\4O$/AOXI>-O#NH3ZK^S
MU?:=??![4/")T?5K2'X?S^$CIEO;72>"H=#MO&5L]R/'UOXIGG><^L?";X+^
M$/@__P + O\ 0)M9UKQ7\6_'"?$OXK^.O$MW:W?B;XA^/(?!'@OX:6GB/6UT
MJPT?P[ITFG_#[X<^!/!VFZ3X5\/^'?#NG:)X6TR&ST>"<W=Q=7/AG\1M7^(7
MPNT/XC:O\)OBA\*=9U?2]1U"Z^$7Q+MO ]O\4?#]UI]Y?V:Z+K<'@KQSXW\!
MC5-1^PI=Z<^D>/=7TF:SO[":;58/,G2W_-[X _\ !0_X7Q?!O]BKPS\.O!G[
M:/[2WB+]J/\ 9N^)WQK^!-WXRTKX-W/QD^)7ASX+7W@:U\5V'Q2\4ZM\0OAA
M\+O"/Q&O8OB5X4N;&\\4:MX.\#W27::??^)]+U\Q:7=4KIRBKW481<8WEHY5
M'&*Y6U;W:DE9M.TD]4)N-E-VUE)J4M&I*---MR2=[2IQULTFFO=9/^Q]^Q/K
MFG7W[1>H_M&>$_&6DZ5XL_X*'?%_]K_P!\--2^(F@^)/AQX@NKWXAZ1XZ^!?
MQ'UG0/#.M:W)9^*/A]?:#HGB.V\"7.J6WP_TKXDZ'X=^)S>%]=^)7A[0?'6E
M?<O@[]E[X0^"]1_:(O[?1M1\26W[5OBFX\9_'KP]X[UB]\<>$/'FOW?P]\-_
M"2]EN?"7B5]1\/Z7I>H?"SP9X/\ A_J7AS1=/T_PUJ?AKPSI5MJ&D75TES=W
M/R%=_P#!2G3/%VG_ /!-SQ?\"_@O\1OB/X#_ &_?B'XW\*O/J!\!^#O%_P ,
MX? W[.GQS^,.M>$M<\-^,?B)X:,7Q/TCQ5\(;OPYKUE#<ZIX)L-)\+_$1K?Q
M?>>(?^%=:3XX[23_ (*>?LL)\;/AW\%8_$<]Y/\ %+XV^-_V;O"/CO3_ !%\
M+-0\-2_'7P#)XUL-8^'>L^#K/XDS_'/PU-?>(OAG\1O">@>,/$/P?TWX<:UX
MB\)QVMGXS:S\:_#.^\;S[L[4[*3C%X=1M&3DHTJ,91M>7,JE-4;M7A54H^S<
ME*,95)N+E5DW'FE]8<]8Q3E6K-235N5TZJJJVDJ;4G.S4I1]1^&W[$?P4^%>
MC>'M#\.3?$*_MO 'P?\ $?[/?PAO_%7C_7_%/B+X,? SQ7)X7EUKX:?#KQ5K
M,]UXEM["\D\$>#!/XL\3:KXG^)-Y:^#_  AINH>-KS2_"/ABQT@^'_[#WP'^
M%VH_LT:GX(L_&6D3_L?_  5\3?L[_L\QR>.?$&IVO@3X.>+=/\":5K7@NYM=
M5NKV'QI;RZ;\*_A=9VNJ^/E\4:]8#X?^'[BSU2"]FUVYUGP_P7_P5&^#GBWP
MEXH^)6K?"/\ :$^&7PD\+^)O&GPTD^+?Q7\-?#;P5\/]7^.7@S]J75?V0Y/@
M5H^J7?Q7N-0;QQKOQ6T^VN-*\4:II.E_!C3O"VIO?^,/BKX6U?PI\0]"\&7?
M!?\ P5(_9I\>P>*--\/CQ%<?$?PQ^T-X._9B/PHC\1?!34?$&O\ Q1^(W@"7
MXM?#JV\->/\ 0_B_JWP"U+1_'GPMM-3\8>&=0D^,EK/=WVDZC\,)[&U^-D47
MPRGI2YG[1-RE*$9\Z?-)PJ2:C)M2<GSRQ5W>\I?6%.2:JJHYDHI<DDE%2<>6
M2M%2IJ[232C[BH65O=C['EC9PY5WOA__ ()Z?LZ>#?!'P2\%>!X/B%X0D_9L
M^)OQ)^,'P%\9:?\ $;Q-K'C?X;>/OC%-X[E^*6IPZQXONO$MIXYTSQP/BA\1
M;?6/"_Q4TSQYX6CM/%EQ:Z9HNGP:)X33P_U_B+]B7]GWQ'X'^'/P\G\/>(--
M\-_"[X]:1^U#X;71?&GBC3]6U#]H#1/'>H?$^R^)_C37EU.36?B!K5Q\0]5U
M'Q?KNG^-KW7O#OBO5KHCQ7HNM64%K9P>.>)?VZ?%]C^T-^QM\#=,_9D^+6E'
M]IH?M%ZAXKN_&MY\*-)U_P"'5G^SO?6?A/Q'I$NBV_Q9ELM5N&\0>(] \;/X
MK\-ZQXK\.:K\,[83^ H?'.L>*;0>'?T7I15HIK2/.U&VEI4945=*^G+*%!QM
M97ITW\5-<K<N>4DVW)13DW=WC7C6EN]^>-2NI7L_WE164:C<_C'QO^P3^SQ\
M0K_]K6Y\26?Q'DTO]N#PG9^#OVDO!^G_ !@^)ND^!?'&G)\.O#/P=UO4[+P=
MI_B>WT#PEXI\7?"/P1X)^&OB7Q;X3LM&\1S>%/"]E;Z7J6E7^I>(]0UOH?%O
M[''PD\7^+W^($VH?$?P_XWUGX-6O[/'Q#\4^$/B#K_AK6/BS\$[*YU:^L/ _
MQ$N-.GC6_OM%U'Q!XCU'PC\3=!C\/?&3X?7/BGQBOP\^(WA2U\:^+K;7.(\2
M_M__  ;\*7T6J:KX;^)C?!E/VAXOV5M9_:3L]%\+W7P4\+_'&?Q]#\&H_"WB
M.X3QD/B59:1'\?+B#X!:GX^@^&UW\//#OQ7>;1?$WBK1M(T_5->L='P%^VOH
MGQ*_:*^(?[.GA+X!?M(WM[\(/BUK/P<^+7Q9N?!W@C3?@S\/?$=M\"_ '[07
MA/4=7\27_P 2+?Q'K&B?$CP9\2/#FF^%/^$-\'^)]=TGQ'/;0_$?0? 6A>(/
M!VO^)3E3LN6ZDFDFM'&%)IQ?,K<JH8E^[+W94:]N6=.HDSFC%WO%24E:S5^:
M51--<KOS>VPR?-'6-6A?FC.#9V<O[('P4B^)^F?%[0-)UOP5XOT#]GF^_94\
M,0>!O$%]X4\)>$_@-?:II6N'P-X4\":28/!OAQK'6M!T+4-&\3:3H=KXOT*+
M1K#0]'U^Q\,QR:)+Z=\%/@YX%_9^^#_PV^!'PSL;_3?AE\(O _AWX:_#[0]6
MU?4?$5SH/@/P?I5MH'A/PTVM:U<7NLZK:>'_  _8V&B65WK5]J.JSV-C;G4M
M0O[LS74WFOQ7_:AT'X;^-=;^&7ACX:?%7XZ_$_PM\*X?C3XL^'7P9T_P/?\
MB?PU\.M4UO7_  WX4UG4A\0?'WP[T>:]\>Z]X/\ '6E> _#>DZMJ?B;Q7=^
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M875M<6EDJ"UN(9(TD7YW\-?L#_!#P7;? 6Z\'ZU\8-!\>?LX?#[Q!\(_AO\
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M$9QNK/EG&,XW71VDM-?5[LHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@
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MU):<R;Q56Z;5XN,;I*Y^<?QF_8M\6S>&_P!B7Q+\"?$OAFY^,O[#'Q<'Q/\
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MVVG]J+<JTWRR^)<TJ]:]W+2=ER\E-P_%;1OV!/VE;#P)\)O#,]Y\#1J'@?\
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MJ22:VMKUTG&HM;7TE%VU?*IU%&WM),_$NW_X)^?M+CP-H/AJ>_\ @6-1TO\
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M815WJ[1C%7>KMKK=LHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]H7BCQ/<^&8O%6N:'\+[J]U+Q+>>'/[9U73O#DVDR7-P_P 9?LJ_!/Q'\/\
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MRN^LN>3UGH]>MKVC>UVKJ,(NS>MKQ?+?X8<D-H(****8!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/B?]GS2_%_[2=U\<_P!G[5_VH_AQX8^%]MH&G:_JGP1T:W\+D^)-53XD^(/
M=AX8UW7]:\9>'_!'A'P/XFO=)\7:WXYN-8TJXTG2]'\"?$[Q%X&\L^+_ /P5
M/_9\^#O@@^+];\/?$.XUK2OV=? 7[4GC3X1:I'X#^&WQR\&_"[XC6GB*_P!
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MH.[?,E>.ONJ6C4KQDMDFG&49P3]G*7*6?_!0?X6:'XH_:=\)_&/P'\5OV?\
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MHZ)K&BZ%\2/"WB_P#H'S5\,_V6/&G[0NI_M+_'CX7^*]'T/5_"W_  6$T/\
M;O\ V1_&]Y<)J_PE^.OA3PQ^PY\ ?V:O%6G7NOZ#%J]U)\,_BEX=O?CU\+[#
MXB>%+?7)_"?B*/3?B)I6A>.M/\.?\(EXF]Q^/O\ P3M\??'#X&_\%+K&/7_A
M[X6^/O\ P4>\#^$OAMJUP=0\2:S\._A)X)\!_"FR^%?A'2HM=C\,Z+XA^(M]
MIMS??$#XB7.K3>#_  -)?WOC>T\"_9;;3?"5MXJUF8W5.',I*HJ<7.#C:SY<
M!*ERIM2;;>-C6C*SI.G233?\31\OMI*,H^RYURS4N;F3>*C5YG:R4?\ 994Y
M04E4YJEG:_)Z7\>?^"FW@3X">)_VL?#>J?L\?M)^.(/V*_AS\+/C7\>O$_@7
M3O@I+X<T/X'_ !,T?XH^(;OXKZ+)XJ^-WA76?$.B^ -%^#_C2Z\7>%-/T9OB
M==R6MJ/!W@3Q59O=W]EZ?HG[57C#6_\ @H!X^_8^A^$FM#P1X$_9F^#GQU?X
MM6VM>"+BPU"X^,?C;XY>%[&2\TF;QE:>);'PSIL_P.OO#FF2Z5X;\0:_J_BO
M6M0GUK1O"W@W1]$\5>*_F3X[?L'_ !S^,=[_ ,%3+FVU[X3:#%_P4,_8D^&?
M[*'AF.;7_&%_)\,=9\+> /V@? _B#Q?KTB>!K9?$VF.?VB-5U/1M.T^+1KJY
M'@73[.^FL3XPN;KPC]$>&?V=OC/H'[=3?M3)JWPO7P'\0?V./@]^SO\ %7PB
MUQXLO?%_ASQ?\#_B/\<_B)X=U/X>:HNF:9HOB'PSXJN?C]K.GZY>>);/P_JN
MAP^"-*DT_1]7?Q;>_P#"+73Z>T=FHO392G*EBU9V;7+"=/#RBU;WZBNY1:C#
M"IS\S5-)PYH--/WE%5L*VK-)\TJ<ZZDG>ZIM*SBW/N?VF_VNM#_9E2\;4OA1
M\6OB.NC?!+XS_M">)+_P/IOA/3?#'A[X<_ D^"QXNM=1\=?$CQ=X#\#1>/M?
M?QSI<'P^\#2>(XM1\2M8Z[J&H7'A_P .:)J6OVW+^*/V[? $'A<^(OA'\-?C
M#^T=J4'[+WAO]L.^\#?!OPWHMYX]A^"/CJUUV[^&<UEX:\8^)/"%UK'Q ^+X
M\&?$'3OA3\/-*:ZUSQ1KOP_\4Z3?'07M[*>^\P_;,_9%_: _:(^+WA;7O!/Q
M(^&2?!^;]FW]H/X)Z_\ #WXKZ-XJUS3_ (<?%#XJQ^'$\(_M/?#OPQX>NK+1
M_&OQ.\-Z!I?B'X96T?BC5_!^J^"O!WC?Q9>^!/&]G%XJ\>>$O&WSUX/_ &%/
MV]?@9KG[,/Q2_9S^.O[,VB_$O0_V)?@#^P[^U3X)^+OP^^)WCWX+ZWX=_9\U
M#QAK_P ,?C/\(T\'^+/AGX_O_B!X U7XE_$S29O"_BS7O#/AGXE>&?%C17%_
M\-]7TVQU"&(.34E)\K<FHNR]VZQ$8N4>:S@Y1P\I3NG&%1W5W/V6LK+E<4I6
M2<TVU=+V$I*+2;51QE7C&-N5S@M7[BJ_:'CC]N_P7X:L_&VH^#/@U^T5\:[;
MX3Z-\'O$'QBTOX3?"V\UKQ]\-['XTP:9J^@Z-J/PEUF_T#XJZY\0_"O@G7-&
M^*7Q%^%GAOP;JGQ!\)?#:\BU*30+WQ7J7AGP9XC@^,?[?WPL^#EE\??%5WX,
M^)?C?X7?LE^(_#/AG]J?XH^ ]+\.:MH7P2N]9\)>#_B3XHO=5\/7OB?3/'?C
M#2_A!\)?B#X&^+?Q=NOA]X5\4R:#X'\30P^&+?QGXUT+QCX-\-?/]]^QE^VC
M\+OVI/B;\4OV8?VEOA=9?"G]K#P]\&[?]J*+X[_#GQ!XN^+W@[XE_!?X<Z7\
M'?\ A>'[/-[X'\0>#?A[<>,OBE\*_#_A+0_$OAGXD>&I_!_A+QMX(\/^/]-M
M/$^A7.M?#"_E^(/[ 'Q-U6T_X*,_!OP3XP\!6W[.O_!3,^(-:^(U]K<GB.T^
M*GP'\7_%#X$^$OV;/CMJ7@#38-)UWPU\4+'QY\/?!'A[Q3X(M?$>O_#N+X8_
M$@:[=ZE:_$GPMK5IX=T&WJTXV2DZFDF_=G&:4:;T3=&<&W"L^6;:NX1;Y"5L
MU*[:Y/>BE[T)03E-1;:5:$[J5%-P3:49N'OGJWQ8_P""DWPD^$'AW]N3Q-KO
MPR^-&N:=^P+X4^'OCWXJ_P#"*VOPEU"3QSX'^(_@NX\?:5XH^$DNH_%[2;'7
M+'3?#EE?SZM8^,+SP)KKSV;P:'I&MFYT]KS#^/7_  4V\"_ /Q/^UCX;U3]G
MC]I+QS#^Q7\-_A9\;?CSXE\"Z?\ !.3PYHGP.^)>D?%/Q#>?%;19?%?QN\*Z
MQX@T?P!HOP<\:W7BWPG8:,?B=>2VUHO@SP+XKLY+R_L?G7]J#_@FI\=/B1%_
MP4 ^'?P.\=?!7P=\'_VZOV6_A9\'6G\=:;X[U'Q?\(_%_P (? GBOX6:98:/
MI&B.-*\4^"/$_@[6O#]Z^OZCXCTSQ#X-UCPYJ5HOAKQO;>)[>_\ "W>?'7]@
MGXZ_%R\_X*DO#XN^$MNO_!03]B#X9?LD>&]1DN/&.F-X$UKPAX#_ &A? _B#
MX@:YHBZ%KPNM+U!OVB=5UO1O"NG^(+F[M%\$Z?HU]XCNCXJN=:\,0W)7<4Y)
M*;BIJ*<^55.1349^[SN--2Y967/)0DE%256O%)V4W)<UI-Q49>ROR-QO)QYJ
MMN:-[0BYJ[<9>U>/?VYKSX??MG^+?V?_ !!\,==M_@U\,_V+]3_:U\=_&G3[
MWPUKJQZ0?%NN:4MS;>$[/Q)%XR_X1WPWI?@#Q-8SQZ#X:\7>+?%OBGQ+I,-A
MX8T3P]X<?Q#XI^BO@'^T%%\?-,&OZ7\-/'/A3PGJ?@;X;_$GP3X\U;5_A=XL
M^'GQ*\)?%&T\0:CH<_@/QK\*_B)\0-$UK4_#]AHD#^-;)Y[6TTR77O#]WX=U
M/Q;X:UK2O$E]\R>*?V9OVDK?]K*P_:C^&/B?X+Z-J6N?L*ZA^S%XHT3Q>OC3
M7!X.^)?ACQ?K?Q(^&?C#PJ^F:;I4/CCP;>^*O%&I:1XUT_7D\%ZM8:'I&FZG
MHRZK>:G>:187OV*/V+#^RW\1OC_X[\/>%OAU\!_ ?QRTWX5W#_LL? CQ;XP\
M4? 3PE\5_!MQ\2)?B5\>/!FF>)?"WP[T#X>^)/C=I/C#P!X4\7>!?AY\-?#6
M@!/@KH?C77=>\9>*?&>H#PU;LG**=U%5K3ZMQQ6(5-M?:]IAW0<7'EY;-SBX
MR_=XQ=3E4I1M*3HN4$TU%2PN'=2*;=X^SQ"Q$9)\W-=<DDU^\Z_XU?MY_#?X
M*VG[0GB2[\!_%'QU\.?V17\.?\-3_$7P%I/AS4M'^#%OJ_@SP_\ %+Q+<7NA
M:IXHT;QGXT;X4_!CQAX-^-OQ0L?A_P"'/$VI:;\-O%.E/X1L_&OCA;[P/9GB
M#]N71K/]I^#]E3P-^S_\??C!XO\ ^$ ^!GQBU+Q[\.$^",OPDT;X)_'7QSX[
M^'VF?%F\\7>+_C9X1O+OP]X+U[X=Z\_BOPUHVA:I\3-6TB2TU_X9>!/B'H%G
MXEU3P[X9\3/V$?BMJUS_ ,%$_AW\/?&_@>V^!O\ P4OT:ZN?B%<>)'UFV\>_
ML^_$7Q9^S[X8_9=^*OC'X>Z+:^'M=\/_ !<TSQO\,/ _@3Q'H/ACQ9XA^'*>
M!?B'X;UN:YU3QOX6\:VNA^!_8_AG^RGXI^%_[:VO_'+PVW@?3_@9+^Q;\ _V
M2?"GA"+5_$ESXZT)/@)X_P#B_P"-M%UR7[5HAT:XTG4K'XOW'A=M.DUJ?4K-
M?"5EKSZI?2>(+C1M%=*SBG4:4[7<5=1YE2K.4;OWK>UC05.6G.IU+624E=1R
M3:@KKFM>Z=H.I1496T3DJ4JSG%WY73A>[;4O>/C7\>(?@[JGPS\.6GPW^(_Q
M*\3?%;7O%6BZ%:>"='LH_#?AJU\%_#_Q/\1=>\3?$OX@^)=2T'P-\//#0T_P
MROAW1[SQ#KL-]K_C+Q%X=T72--NK637-4T'P[X;?\% ?A1\;OAO^S7XW^"?A
M+X@_$3Q+^U5\$O%'[0?PR^%$47@WPUXXL/ACX#C\$V/C[5_&FH>)O&.F^ -%
MN/"/C;XE?#OX975IIGC37VUKQKXSTRZ\+/KO@'2O%WCKPU:_:Q^ 'QS^+_Q4
M_9-\;_"_QI\.SX"^#7Q%\8Z[\7O@O\6K'Q1=>!/B%:^)?"#:-X#^)26WA:<+
MXF\=?L]^+(8_''@'X?>+;:#P=XGUC4I=6/BKX>>.O"?@+Q[X>_//X9?\$U_V
MVOV<?AG^PMXF_9]^-O[-D?[37[(/PI^-/[,7B^R^)/@OXDZK\!_C?^SI\8/'
M_@;QDPU.;1=8L_B#X/\ B/X6UOX5^"O'VAW>@(NG?VO?>(/ &JWNL>'!'XEU
M"$W9III\[5^L8\THQDD_=DM:<I:JT%.3:<90*?2VKM=IZ)^XI--[IW4XI:7D
MX132<9GZ#-^W?X9U3P=X4UCP1\!_VD?&GQ'\1?LVG]J?5?V=E^'VE^"?C_X"
M^'7_ ![6?AOQWX"^)'BCP>FA_%7Q3X@LO$G@?X?^ TU6[;QOXS\)>)8-*U=/
M"FC:EXPL\KQ9_P %#OAIH7A?XD>,O#7PK^.OQ"T;X'?!?X>?'SX]V&@^#-(\
M->-?@[X$^)'A'4?B#I^B>*OAU\3/$_@3QQ-\7?#?PZTVX^(OC7X*:9H5W\2]
M \)"UME\/WWCWQ)X"\">,O&/BI^Q]^VWH/[0'PL_:Q_9E_:(^!%[\<]0^ =O
M^S+^U+I7[0OPH\?W/P9^(7A*S^(FO?%OPA\4/A7X0^&WQ+TWQCX&\3?"'QQX
MW^)6E^"_AOXE^(/B[3/$OPQ\<IX0\1_$RR\3^&8/B)K.I=_L0?'/P5\1OVKO
M$OPO^*O@SQ7IW[<_P1^&O@;XUZ[\6+'4-/\ $/PZ^.?PS^#EQ\ D_:)\&>&O
M!^B3^'OB7IGCGX=Q^#;CQ7\#-3U;X265EXD^&T<^A?%.VT[X@7UKX-<V^6<H
M)<_+7Y*<Y-1=:"G+#TW4LY?5ZO[N$J[CSQDI>[%O0C:\(S;47*AS5(Q3DJ4W
M&->?)?E]O2?/*-)2<)1Y4G+KZOXH_P""BGP9\/Z5^TGX@TOPE\3/'?AO]FS]
MCOX7?MTWGB/P.GPSU+1/B]^S]\7=/^.&I^$];^#M]J?Q.T9-2UAK/]GSX@3W
M>F^/1\/()(3H%QI.H:K:ZQ'/#%XS_P""@&B:%\1?!'PD\#_LX?M&?&7XB_$W
M]E+6?VNOA[X?^'T/P-T^+Q-X%\/^+/AAX1USPJ=:^(_QP\!:+H7CG2;KXL^&
M-2NK;Q)?:3X9O=.CU"V\.^)]>\0_V=H.H_*WQ/\ ^"9WQ6T'1OBC\*/V7/&7
MPJT/X(_%S_@E/\._^":-Q;_%Z/QGJ'COX:V/[/.A_M%:+\&/&>@77A:V_L;Q
MQ;^+=$_:,U[PQX]@UA/"ESX-N?#.A>.M$A\?+/J/P_G]^\%_LE_&_P %_M*?
ML[?'B;7OA1XIM_@A_P $^_''[(NK:7#<^+_!LWBKQ]XN\8_ SQRGB_3;>31O
M'*>'_!UI>_ VTT,Z==:IKNMM:^+;G6O.>;PY%HOB!U;)5/9-RM4JJGS17,X1
MCFCI.4;Q2<W3ROF5UK6JQ5DY2IS#G<8NIRJ;2<DFN57_ +/NDUS._OY@NJ7L
MX.[Y8>UJZ-_P4.7XE?&;_@GGX7^#?PF\6^,/@_\ MV_LQ?$+]JO1_B-<7G@;
M2-7\.^"?#EM^S\^C:9J/A77/'6CW]K<:18?M":)XF^(TEI_:^K:9!ING^'_
M^@^/-2U'Q(_@[Z#_ &>OVN/"_P"TPVBZW\-O 'CZ]^%?BW0OB!KW@WXV+<?#
MW5?ASJY^'/CO3?AYK'A36AX=\>:SXR\"_$:^U>\OM6TWP)XT\(Z+K%GH6AZ]
M9>*1X9\?^&_%G@+P[\6? ?\ 8"^//P-B_P""34VG^,_A#K-[^P1^R[\1_P!D
M#XNQ7O\ PFBVWCCP!X\\/?LY:8WQ(^&TUOIEM+:>,H;K]FC0XQX-\40P:':V
MWC_6+O\ X2K4)O!]C9^*_2/V:OV)/&/PP_:GU;]JG7M&^#WP>\7>.?@_XQ\#
M_M&^'_V</$'CI?A[^U]\6_$'C/X>>)O"?[1_Q,^&6M>'/!G@OP#\3OAM9^%O
MB3IEEK>GV7Q(^('C2U^/'B#2_$OQ2BT7P'I=CXKI\BERQ=U:N[MO27M(RI)7
M5Y1]DU3@E:2:YY.:56*S@ZO+>:M)_5]%:UO9RC6ZVC+VB523]Z+3Y5R-TY'T
MW\4OVG]/\">.?%?PM\#_  K^)OQX^)_@+X06'QS\;> _A6G@>'6M"\!^(M=\
M5^&_ -NES\1/&G@/0]3\8_%76?AY\3=/^&_AFRU=UU.Y^&_BH^)-4\*6QT&Y
MUOX6^/?[:G_"X?%G_!,/1_V>;;XD_$+]FK]O+5_'GBW6/'/PF\4:'\,_$WQ!
M^&-I^R?\9OB5X8\'>&_$^J?$SX6?%CX6>)-&\3V/@SXC^,+O3YO 7B;3+;P>
M_@8^()M4OO%7@#4OI[Q5^SM\7_!W[8?C#]K/X#ZO\/M6_P"%S_L]^ /@)\8?
MAI\3M4\1>&M-AU3X*^,OB7XR^#'Q@\)^)O#'AGQC?7]]H</QC^)?@[QM\,[_
M $K0M/\ %^EZKX4U_2?'W@[4?!^JZ;X[^?O!?_!.CQ5\$F_X)4^$/A!XC\%Z
MO\-_^"=EG\04\6WOC2YUW0?&'Q9U;XA_ 3QM\&-:US1[#0]$\0:#X7NKW7_'
MNM?$[4+2:[O=/DN<>#=+M]'L98M>LLX7:ASVO[6FIQ2?+R<^,4[MN[A[+ZG/
MF7_+R4U'X9<NLN9<_)9>Y)QE=-_!A7%VLU[3VGUN*BT_<4&VN:+?T'\2?CQI
M/[!W@#]E3X6^,;;]IK]J7Q!\5/'.G_LT> O'"V_PI\5?%3QK\2K'X7>/OB'X
M:?XJ:C_:?P:\/+JWC70?AAXATN3QW9^&]/\ "MCKZ6VN?%#5_!OAV?6_&MGR
M'@K_ (*;_ CQ!\+_ !IXY\>>&/B-\!/&_P -/VBX_P!D_P"(GP)^.)^&G@[X
MG>$_CI=:3HWBW2O#L^LVGQ)UKX.ZUX:\0_#77]+^+OAKXB^&_BKK/@+7?AE-
M-K]EX@:]L-2T>S\B_P""JOBB?PYXZ_X)6'1=9\!V'BZ3_@IIX*O/#^G?$'Q#
M)X;T#65@_90_:[TN^L+S5+.VU+4])AU277-/\,66OV>B:^NB^)/$GAR6;0=>
M:>#0=4SOBO\ \$X_B[X^\-?%?XQ>"/BUX)^$G[;WB[]M/X8_MV?#WQ1!HOB#
MQW\$O!_CKX+? OP?^R]X/^"GB[3GN/!/C+QW\+/&O[/?AGQ'X)^)GB>Q/@SQ
M/+XE^*?B_P :>&=$TS3](\.^!XKNFI3FY.]249.$8N2M/!M\L4XIM4ZF(<DE
M=6@TN>RJ#5N2,+)NGS)2>E_]LC%2?O.,7.G0LWH[R5^1-T^SB_X*T_!V_P##
M7A+5?"_P5^/_ ,1?$WBW]K#Q9^Q3:>"/AI;_  7\47H^/7A_X1>(OCAX;M+#
MQ;<?&C1OASKWPZ^*GP]\.G5O ?Q6T3QC>^!]$DU:ULOC1JOP@O-"\?0>#/>O
M O[;&D_$/QSK'PY\/_!#XP2>,OAWKOP/\(_M!>%'O_@U=>+OV</%?Q[^''A;
MXH^%K/XF^%]*^+>I:KJWASP]X?\ %^C:?XP\??"R+XB>"8?$+ZO:>$M;\8:3
MX%^*>M_#_P -\7?LS_ML?%^T_8S\9?&OQ_\ LXZS\5/@'^V'I7[37CK1?A_I
M7Q$\'?"_3/"&E? WXJ_!&'X5?#-];B\9^+_$&JS+\7-:\?7_ ,1?&]SI1N]:
MT]?#MOX/T[0KZQE\-VOCG^Q!XR^.'[5_P[_: GT;X-_#[Q7\&/C%\*O%7PJ_
M:C^'>N^-?#/[2UM^S_X5L_!^K_%7]E7XD^'-+\+V7A_XK_#?XQ^)K7XJ>'KU
M/%/Q1?PCX4\(_%.#Q)H_PSF^('@F'5/$J:M[*\HRO5<:CCTA[.ERR6RLYNHV
ME)R:4HTVY1@JBNVZEDXKD3I-ZOG<ZMXR6]U!4U%V2O)2FN1SY?3)/^"AGPAC
MN_ASKO\ PB?Q&F^!_P 5OVD=8_9*\&_M%V5CX6O_ (87'QNTSQYXB^$.GZ=J
MEA:>*YOB+I/@CQI\;O"VK_!3P#\1KCP.?"WB?Q^NE7D5U:_#KQAX!^('B[SW
M1/\ @J/\-=6\2Z/IM[\ ?VDO#?@V]_;+\1_L&:]\5M=TCX.?\(1X)_:'TGQ4
M? _AW2/$5EHWQHUCQYJ/A3X@^+Y=,T#PGXW\$>"_&'ANTU#7M'M?&E]X1NTU
MZVT'SSX>_P#!.;Q[X5^$'AW]C76_%G@+5/V3/AQ^V'H_[4_P^\3VC^)/^%SW
M'A#PM^U)_P -F>"/V?O$OAC5=+U#PC'#X6^,\&D^&+_XPV'C6ZN_%WP8T9_"
MW_"K?"_B_69?'FF\U)_P3U_:!/@'6_":>)O@X;[5/^"M>C?\%&8[AM:\;"TC
M\":1\>?#_P <?^%7N1X+:;_A+KA_#\?A4^)5B;1HEO'U\:3(;9=#N)AS/E<K
M6?LKJ^MI2P"K*;6D73=3,%%QNI4\/2J.[DE4*E]?9J]O:J[?5+&>R<4UK&:I
MX-RYM5.M.GHDW3^[O _[7'ACXE_%?Q)\-OA[\/\ Q]XTT?P3\9_%7P!^('Q*
M\.W/P]O?"_PS^)7@OX<7'Q(UJV^)7AV3QW;_ !,\'>';V#^S?"/A;7K[P+(W
MB7Q9K.B75KI\/@#Q/X+\>>*NZ^*?Q\T+X;>./AI\*-/\.>(?B!\6_BYIWQ \
M0>"? 'A>30K*]D\'_"RT\.R?$#QWKNL>*-8T'1-%\(>&-7\;_#OPI?7AO;O5
M9O$_Q&\'Z?8:->P7FHWNE_',_P"Q'XT\1_MN_#G]KO4M)^#_ ,+?'7PX^(/Q
M(D\3_&GX+:]XUT7XG?M0?LY^(/A]XZ\%?#_]FS]HOX=_\(OH?@?Q1IO@?6->
M^&OCJQ^(/BKQA\3=2\/:S\$=&M/AWX:\%S^.=3USPQ[5\??V=?B#XE_:/_9K
M_:S^#>N>&5^(?P&\*_&SX2>)OAWX[U'4_#W@WXK_  :_: ;X;:IXHTJ3QIH7
MAKQGK7@?Q?X*\>?!WX:>//"NLV_@[Q3INN66C^)_ 6L:7IA\8:=XY\$N_NT6
MWOI5:5W&RFE*VRYI^S<HM-TX.I=U%&,I-MWJ<JV2=/F=D_>BW&Z>KC#VG+*Z
MC4G[/2FW.,?+;K_@IS\*IO ?P&\9>#_@M^T/\1];^/GQV^+O[*^G?"SP9HGP
ME'Q+^&_[4/P1\&_&?Q7X\^ _Q9T[Q3\8_"_AKPOXIL;SX!_$GPJGB_3O%6O_
M  @@OM-T[QEJWQ*TOX0ZWIGQ*N/K;QA\>_"GPO\ V?[S]HCXR:7KWP@\-:#\
M/--\?>-/"WC67PO-XQ\#W&H:98W4G@/7#X3\3>)_!M_XYLM8OX/"#6OA7QAX
MC\/:IXI*6GA[Q'K-A<V6I7/P3I'_  3[\>>"=3_9M\1^$-<^'U_XD\%_\%&_
MC[_P41^.]UK%_P")-'LO$?B;]H+X:?M)_"G4OA]X#M;#P[K):U\">$OVB;"P
MT/Q3K3Z/+XE'PBTNXUCP]IU_\0=6O/"GV;^V/^S?;?M=?LR_%_\ 9WF\;ZS\
M,[_XC>&H;?PO\2O#UG'J6L?#KQ]X<UG2_&'PY\?66DS7FG0ZT_@SQYX>\.>)
M)="EU+3$UR#3)=);5-,%Z;Z EI!-7<KKF24;I*.%<U!-\LE>6+]G*4[2E"FI
M<L5S34>9U)J5E37\.3O[UY8GE<[7<=%A>=*-U&4W%.3Y8_)6L?\ !6SX :!;
M?%&2\\"_%37+KX2^/_V6/!GB2W^'%Y\&OBK:WVC?MA_%:P^"?PE\>>&M:^'W
MQ>U_1O$FD:/\3]1B\&_$[P;H]]>?%SP?JL']HZ=\.?$_@_7/!/BSQ=S?QY_X
M*A:AX"_9/_X*'?%KPI^SG\3O"WQZ_8+TB[B\6?!+XS:C\*+20W'B'X9^'_B9
M\./B.WB?X8?%7XB>"/$/PQU7PUXIM-7U"R\.>-)O'RWGAOQ5X0D\-:?KMOI\
MEY5\;?LO_P#!1;]H7]FZ?X=_M._%?]DW5?B59_&W]DKQ]H%I\&/"?Q2\"_#<
MZ)^S#^TU\,/VCM:\1^)=4\777C[Q3JOC?XM2_"K1_!UMX=TC2/#OA+X76NJZ
MIK$&H?$&98K!Z_QW_P"">'Q<^.'AO_@KCX8G\:?#CPQ;?\%"_AEX(\'_  PO
MH9?$^L3^ -;\!_ ]/A593>/K9]#TN.^TK6M7L[36[J7P[<27FE:;<7.G0VVJ
M75M%?7)*RC>_,U=OET;C'ZM4BXQ=KRG!XBFX.2:G&UXSM:4ZCFURI0?)RN36
MCE]8A-2:=FH25"?,DDXR;2E!/F^BYOCWH\O[:WA/X9WO@7]J'1?B[<_L1?%[
MXRZ'\-;CQ?\ "U?@GXA\,>'?C'\)/#&L:5J6B:3\6=5T&X_:&L?$6L^%]-\(
M^)[Z6U\(Z3X)\5>)[&X\<6W]IWMM;_.7P3_;HC_:*^"G_!*CXX?%?X=_'WX1
M:_\ MB?%;3-0\ :9\,?&G@&+X97OBKQ'^RA\:_C#I/AGXNG3OB5+XH\8_!"\
M\ :9XZN?#MGJ'A.+Q%??%CX8^#_$GB_P/X&1-"^U?1>A?L\?'/4_VW/@_P#M
M<^/[_P"$UI:>%OV-?B=^SOXV\(>#]4\87=S!XU^*7Q8^$OQ7GU3PM?ZUX=M(
MM9\+^$O^%4VWA"*\U9/#NK>+O[:G\8/HO@_[#'X-N/F+X'?L ?M&?#7X _\
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MI\ECX;T.YUV[TPZSJES>ZC!8V%C:1O?WTTL$<5J9IDC/X??M6^"_B-XAO?\
M@XFTKP_\(_C;KMU\6_\ @G9\-_AY\(Y-%^"'Q;U33OBYXZ;]F;]ISPE)X1^$
MFKV/@R?2?BCX@L?$?C?PII&JZ7X!O?$-SHU[K,$6JI9F"\^S4OC_ '$&E_'@
MZ/\ M.? C]M3XE?L??M=_P#!-CX-_ +PW/\  +X-?'#QNOASQOX<U/X^0?M
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M5"M*496YZ5:G_9TE2=O==2/UC$PDDG&:IRE'96_;>R^+'PLU+1+#Q-IWQ+\
M7_AS5==L_"^E^(++QEX=NM$U+Q-J#1I8>';#58-2DL+S7;YY8DL](M[B34+E
MI8UAMW+J#XE^T-^TCJ'P'^)W[(_@V7PAH.L>$?VEOC=XR^#7B3QKJGC>?PW=
M_"]O"O[-7QX_:1B\5IH#>$]4TSQ1HEQH_P !/$&@ZY+?^+O!I\-MJFGZRO\
M;5K#>VMO\'?L_? 7Q?\ #/\ ;,^*_P"R'9:!9+^Q]\,?B59?\%(_A5):76C2
M:3X9U_\ :7U'XIZ9_P ,TWW@V6UMGAT#PS^U5X9_:!_:\\%ZSIUK+8>$-0G^
M%/AG1)[23PIL@]@_X*0^ ]&\7^+?^"=.M>.?AM??$GX._#G]NRY\7?&>V7X:
MZ]\5?#GA7P5J_P"Q)^V?\-M#\7>/?#.@>'_%$MGX'L_BAX^^'NE:SXJUG2?^
M$4\)S:S9:]XMU+1?#UEJ&K6<-/\ <-M?O*E'F34N6,9>[-3TC))554C?W;PA
M2FG'VJ8Y/2LHIODC42:MS.4;2BXK6.M)PDD^:TI5(M/V=C[TB^,OP@G\,^%?
M&L'Q6^&TW@WQV81X(\6Q>.?#$GACQD;E'DMQX4UY-4.E>(C<1QR/#_9%W>>:
MB.R;@C$==9^)?#FHZWK/AK3_ !!HE]XC\.PZ;<>(/#]GJMA<ZWH4&LQ2SZ1/
MK.E0SO?Z7#JL$$\VFR7MO E]%#+):M*D;D?AOX*_X)XS>.?V9?\ @H#\//A=
MX.M_@!HGCS]N"]_:V_X)R:5XB\,R>'+?X"?%WX3> O@!K?P^^+.F>!-6T5K_
M .&?@OQ3^V;\)_B3\2)O FGZ'I UOX1^.]64:;I]G\2-4TX?H-^P7K'B+XL_
M!>Q_:U\>>"9/AYX__; L/!WQJO? MWJ>F^(;WX=> ;KP)X;T/X3_  ]3Q'8*
M3>6MEX,TVW\=:OIPF-AIOQ'^(OQ$GTZVLEU.>&G'5-ZQ2C3DXR24E[6E&48M
MI<KE&K&I"HE9J"I3:C*<HP;=FHZ2O*I'F37*_9U&G)*[DHRING*#=U*7M(J3
M4(N7U GQ5^%\EGXKU"/XD> GL/ <\EMXYOD\8>'FL_!ES%<W5G+;^*[E=1,/
MAV>.[LKVUDBUA[.1+FTNH&42V\JI)JWQ0^&F@:YX3\,:[\0_ VB^)?'QV^!?
M#VK>+= T[7/&C>49L>$])O-0AO\ Q&?)!EQH]O>'RP9,; 37Y-?%SX$>-O#/
M[>_B+X4^!/#EOJ7[-G_!3/P3IOQ)_:<M+6ZTK[-\/_'/[)6K?#OP]\6->UOP
MG?W44OB;P7^VQ\!/$_PQ_9@^(@T:V;_A'-0\(Z-XCU!C>^,;S^T/"OVD?AS\
M2/$_A'_@N%^SOX^^$_Q!\=?&+]J6ST_QO^PQXLL? VM:QX;\<Z?+^RE\*OAQ
M^S9X)\ ?$K3;'4?#7PW\7?LW?M@_#GQC\1-5M?%6N^#H_@WK?BT?M0ZNWAWP
MEXOU7XA2RI2:@^5MR51N,7&_-2<(S@G*2M*<JD70YTE."DY*/+.4*:]Z2YHI
M)TTI2YN51K<[A.5HM\L%"2K<M^22LKW@I_NY?_$WX;Z6GBF34_B#X(TZ/P/)
MIL7C62_\6:#9IX/EUE_+TB+Q2UQ?QKX?DU63Y--35C:-?.-ML)6XK67Q=X4?
MQ+#X+3Q/X>;QA<^'I/%UOX376M-;Q+/X4BOX-*D\3PZ$+DZI+X>CU2YMM-DU
MI+5M-2_N(+-KD7$T<;?SH_MI^%/BMX3OO^"O/P]U[X<?&?XK_$W]K'_@B1\+
M?AG\*_$_PJ^ 7Q1\;>%_C!\7OA)\-/\ @H;X=^*VDGQ9X'\%ZIX#\'^++35?
MBM\.KW3O!GC#Q#X?\0^)(?'?A;1? >D^)-8O[+1F_97X??$SX#R?%GX2>"+W
MPIK6A_M&>*/V7]/\5^&-?\6? #XE^$=5G^$5KJ^BQ>(/  ^,/B?X>:5X9TWQ
M-I/BE-.U[Q-^SU>^-K3XF:/ EGXUUGX>6NC1Q:VNBC[LFI*7+6E27*G[ZB\8
ME./.HR<9?5H5$N6ZI55>TE&^;G:44XN/-1A5?-:\'+ZJW"7+S137UB<+\VLZ
M>W+S6^NJ***184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %>#_#?]G+X>?##XB?$KXJZ3J7Q.\4>-OB=K.JZI?:E
M\4?C%\4_BU9>!].UR\L]4UCP5\&M"^(_B[Q-H7P4^'FJZQI^GZMJG@7X6:;X
M3\-ZI=Z3X;BU'3[JP\&^#++P][Q11UOULU?R=DU\TDGW6E[-J1TMTNG;I>-V
MG\FVUV>N]FBBBB@ HHHH **** "BBB@ HHHH \(^ /[.GP]_9P\,:EX:\#:C
M\3/$]QKFJ?VOXB\;?&CXO_$_X\?%#Q'=16Z66G0:Y\3?C#XK\:>-]0TK0M.B
MCT_P_H<FMC1M$MS<OIUA!=ZEJES>^[T44?Y)?)*R7R7ZO5N3D62VZMOYMW;]
M7_ET22\1^/'P \$?M&>&-#\&_$'6OBEI?AO1_%5GXIO-.^%WQC^*/P:?Q=';
M:3K6B7/@_P >ZA\*O%GA#5/&OPYUJPUV\7Q%\/O$-[?>%-=G@TVZU/2[BYTN
MPE@]FM+2UL+6VL;&VM[*RLK>&TL[.TACMK6TM;:-8;>VMK>%4A@MX(42*&&)
M$CBC141550!8HH6B:6S=VN[M:[^6BULM;)-R<CJGU2LGV5[V797U??2[=DH^
M#?#3]G'X>?"WX@_$OXHZ/J7Q0\4>-?BAKFK:OJ.I_%/XR?%3XN6O@K3]<U"'
M5]5\$_!W1?B3XN\3Z)\%OAS?ZQ;6FJ7G@'X6Z=X4\+WD^F>';>\TZXT_P?X.
MLM ]YHHHZ)=$K)=$E=V7;5M^;;;;;;9NV^K=V^[T5W\DEZ))62216$WAG0I/
M$L/C&738)_$UKH5QX:L=7N#+<7.F:%?:A:ZIJNFZ2)Y)(=)@US4-.T:Z\0G3
M8K27Q#)X>\,?VW)J"^&/#RZ9NT4 %%%% !1110 4444 %%%% !1110 4444
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MRY)^UC^SKX[^*FE_"O3?#OQ+\"Z/IOP=U3QQX:M])\'?%GQOX[\,>-/ MO\
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M_P#!0;X0Z?/X2\12>%?B-<_ SQG^TIJ/[)&E_M'V&G>&+WX66?QOT_XBZO\
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MAK\&/C)XPT#P/+\/%U?PM\*_CC\3O&'PK\-^.FT3Q;X^\+:QXFT;POK'P_\
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M717YKN6GO\T^:[G*3_+KQ5^R'^T$GAG_ ()K>*? ^L_!V;XQ?L,3_P!C^+=
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M]J*?##X?Z'J_@+Q)XZU;4;_6?$D&B/I.EZ#Q3_\ !,WQ,GPN_;K_ &/=%^)
M\,?L9?M3>%]3UGX-Q)XI\;>+/C#^S7\<_'&BBY^+'C#P^_B"%;'7/!OCGXOK
M'^T&OAF;QG9W>E_%O4OB9J[:C?:3\58M&^'G[!44Y7G*4Y-N<U)3GM.3DXS<
MG**BU/VL85^:#@U7A"K%1<5%J,5%1C%)1BXN,%\$5%.*BHMN+BJ3E0Y9*:="
M<Z3NI.2_(;Q7^R#^W[^U+^R3\4/@A^V#^TM\"/"'Q9D/PRU/X&_$G]E;X6^*
MK/2]!^*OP+^*W@;XX?##X^_$W3?BAXBU$Z]KDOQ)^&/@2]OOA)X+L?!_A+P_
MHZ^.]./B[QH_B_PQ/\,]OXG_ ++?[=/[3?['?Q*^'G[1?Q7_ &9]-_:-UGQ9
M\ /B%\--)^#?@SXFV7[./A?Q/^S'\;_ WQ_\)6GB2\\:^(M9^*FN+\6?&G@*
MRT7X@^(+)=-A\$^";K1-+\*>#_$6O^%-9\4?$7]7J*:E).33LY.$M%%<M2#B
MU4BK6C-\D5)I<KBE%0C&R2Y8Z:;*47O>4)J473E*_-*"4Y<J<N9.3ESN3;?X
MI?%G_@G1^T?\<_ W_!4FS\9_$CX)>&/%/[?_ ,'?@SX;\#Z/X9TGQUK?A_X7
M^/OA;\,;KPX;'Q5XJU1]'U'Q9X-DU][#2O[?TGP9H&NZMI%M?>+_ /A&O#MY
MJ-MX"TCUQ/V0/VD_#WQ9_:C^+G@GQ-\%K74/V]/@O\.?#?QX\-:_>>-M0T/X
M$?'7X<_#[7OA1I?Q3^$LT7AJ.Z^.7@Z\^'.K^$_#_B'X<>,H_@9=Z]JWPDL/
M%&G>,O"4?Q,U?PWX&_5&BI<4XS@TG"=-TI0:;C*DZ=:E*#U3Y94Z]2$GS*5N
M5J491YG2<E.-12?/"<:D9Z<RG"=*I"6UKPJ483BFN5-S3C*,G%?FI\'?V&]<
M^ ?[2_[,/BSX<:AX;;]G?]F;_@GN_P"PEX;T7Q%K^N7GQ6N=-TSQ)\']:\*>
M*[J6W\+Q>&;\:;I7P:TSP_JUI)J-E<ZM<>(KKQ%#<Z<-%30=<^JOV?/&/QO\
M8:=\4W^.'@SP?X4N_#GQM^('A?X9:GX)G\7_ -D^//@]ITNF7/@GQC>:9XZT
M30?$6D>((S?ZKX.\2 6<WAKQ'K/A&\\<^ =1U'P!XK\+WDOT#1_G\Z;;;;>M
M_:/9*TJE>>(G)**BDW.I-))*,82Y8Q45&R22VT^"[NVVH4HT8W;;;?+"#;;;
ME*/-)MN5_P @?"__  3F\>Z3\'=1_8NUOQ)\/-6_9$L_VS=-_:N\'^(K>Y\5
MP?&.T\'6'[7=A^W/!^SWKOA6YTJ[\+WMM9_'*QE\*'XOP?$%+_4O@Q??V"OP
MVT?QK91>-KCZM_9._9_^(OP/^('[:OBCQO>>"KW2_P!IG]JN\_:*\(Q^%-7U
MV_O_  _I5Y\#O@E\$_\ A%_$EOJ_AG1+=M1AA^"-GXI_M33+VZMII?%UUH(L
MH$\-1:WXC^T:*25E%)NT8\B5W:RAAZ:NKV;C3PM""=KVIIMRE*4I-ZN3=KRE
MS-V5[\]6H[/=)SK59-;7E9<L8QBOS)_:._9=_:YC_:[\-?MA_L5?%CX&^%_%
M?BKX&:+^R_\ '[X<_M*^#/'WB_X=:U\.O!_Q!\7?$SX7?%3P,OPQ\4^#?$L?
MQ1^%WB+XC?$O3W\)ZQK=IX3^(GA;QU>:5<^(? ^K:/IGB.O&/VF?^"?'[2_Q
M*NOVW='^&OQ3^$VJ:'^W;_P3C\,?L<?$;QO\7;/Q1:^-_"OQ*^&G@[]I'PEH
M/C_2?#7@/1HO#.NZ%\4+7]HJ^?Q:9-6\.3_#/5/#$.M^'_#?Q&L=7;PIIG[.
MT4G%-13]Y1]IR\UVU&JFITT[IJG=N2BOAEJI6]T.K:LN;DYDDDFZ;3C-I;SM
M%1<G\4-&K^\?DY^UI^PG\3_VHM9^%TVI:?\  30/&7PET7X/ZO\ ![]KSPC?
M>._ /[3O[-_Q1T'Q)J,_QHU#X7Q:;X>\1+XQ^%_Q$\)0^'-*M?A3XI^*/A[P
MSJMPNOVOQ,MO'>EW&BPZ/B_%O_@GK\9OB9J_[=>GZ5\2_AOX*T+X^?M.?LN_
MMP?L[>/!I'B?Q+XU^&_[2?[,O@C]DK1/"VD?$;P8\F@>&M=^%<7B?]D/P_JF
MI?V'XH7Q-XI\/?$OQ#HD)\%:IX0TGQ%XA_7VBFUS-MZMSJ5+M)VJ5)TZDII-
M.*ESTJ4U:%G*G!SC4<;N%"*459M0C""3;=X0C."A)W4I1Y*M2#O*ZC4FH.FG
MI^/O[2?_  35\5?MFVG[2WCWXK>+_#7P2^.'QE_9W_9[^!?PNO?A?J.J?%;P
MW\%M2_9M^//B3]JCP9X[O=:\5^$_A7??$E=?^.>J>$I?%'A.[\(>%;0^"?AU
M8Z3I6KV>H^+==O[7IO"/[+7[9'B+XY_%W]I#XU:W^S)IWC'XI_L#^$?V4[KP
M!\+KGXJZAX;M/B+X-^(?QL\60^,+?QSXKTG3M3M/!.NQ?%--2FTB7P-JFO:'
M)*?"D=_KB>&3XW\:_JY11-<\)4Y-NG*$Z?)K91J4J]"IRZW4ITL36C*5VVY*
M22E"#5IM3A-?'3G3J1EUYJ-6A6I7Z.,*N'I2C&R7NN+O&<XO\)K_ /X)I_M6
M3?!;]E?X$)\6/@AK7@'X1_\ !,_Q)^POXM\/^,K#Q[K7AGP-\9X?AWX1^'?A
M;]L'X2^%[*TTJS\7>.M5\+>'-6\$3Z1XSNO"'B#X4>%O%NO_ /"OOB+JMIK_
M ,0O#7Q#[#PQ_P $^OVD=/T7XK1ZWXB^![ZY\2O^"2?P*_X)X1?V5KWC[^R=
M&^(7PEA^/[W?CUS>>!A>:AX,O)OC_=V5O;#['KMU%X&MM4EM-,?QE+I'@_\
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MU8TDM%WD_G*<YO[Y5)OYVZ(****!A1110 4444 %%%% !1110 4444 %%%%
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MWGQ'\$^&=,TKP%\0?$&I'Q7XR\,:WXHM+'6+;I++]B']F6PTWP)I%M\/+_\
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MJ_OH_&6F>#]"T*RUK3[RZTFZ@;2KB:R?FOAE_P $^?V._A#=K?\ @KX):/\
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MP+\.O$WB#X:V>L:7X'^(UQ'?GQ5XQ\(Z1XEU+Y>\<?M<_M6?#KXA_$_X)/\
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M?E=^Q]^TQ^TA\4?V@/V=_ _B+XY>)_B%\+_VGO\ @G5\??VC=.^)[_#7X7>
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MUYI4X5U.#U<7SU<.IT[/EC&JZ<I<B4VLJ2J.C#VC4:[A3YVK.$:DZ/)/9/\
M=TJ[56\;RE2C4BE)N$3SK]KGX^^/KWXH_L$>*/ >F?$G3]+M/^"H7Q&_9X?P
M]\.OBG=:;I7[17A'PI^QO^V/?^)M(\2^%Y]?\%>$;W1=#^.GPNL=-DT[XHPW
M \-^*OA1J?B?PU=76@W6CZUXDZ?7OVZ?!_Q-_9U\(?$'QW\&?C-X8UK1?^"B
M7P8_8T^)7@7X?_%^/PS>?"[XYV7[8W@+X%Z7KFN?$+P?XP\#7_Q%^"DWC76?
M"FN:AHFC:;K*?$GP-XAM_#'CKX>VFBZCXMM=$][^)?['.K^+E_8.MO#'Q.LM
M'M/V+OCQI?QSUB\\6>"9_%GB'XTZI:_ GXR_ S78=6U;1_%_@NU\,^)_%\/Q
MS\7_ !!\0>-I=+\5M>>-;>UN+KP[>0ZAJ;2>"/\ \$X?B&?A1\2OAQ'\>O!*
M7_C_ /X*:^#O^"BUKKS_  5U^2TT.V\%_M+_  T_:=T_X*SZ./C5'-K%S<^)
M?AAIGA6^^*4>KZ/#)H.K:A?6WPQM-1M[9&B:M!0@XRE&=^:UDY1Q67IU(W2;
MC4HQQ=1<R3@J=.U.%3W*BBI.4IM-*<$K-IN*>&S%J#2;CS4ZT\)3;B[3<ZC<
MYP7-#Z,UK]L*^F\:>--)^%OP2\<?&;P3\(OVA?AQ^S1\:/%/@2^M+KQ-X2\>
M?$6T^&U[>>(/"O@)K.1_'?PZ^#UE\7/!6L?'KQ0/$GAVZ\!Z##XWOM#T3QM?
M?#_Q+I-K^=W[)7[97C#X(7?B_P '?$KPK\9?BE\-?B'_ ,%=_P!J_P#9.TKX
MX>,?BI%XUN?ACJGB;XR^+]#^ ?@BQTSQUXIUOXA^(_A[I=QHNG_#NXN+:73K
M'X?IJ_A&WT+3_$^EQ^*IO"/UMX>_8E^/WPQ_:;^.OCWX*?M3:%X'_9?_ &IO
MB;X=^.7QN^!NL?!>X\2_%'0?BOIGA/P1X%\=W'P%^.]G\3_#D/P\\-_'7PWX
M#\.+\0;;Q9\-_B/J_@[4;+7]6^$&I>"?$7C&'Q#X-\__ .':OQ$/@ZU\+/\
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MC?PMX_T'PYXSCC\:PZWX>\4Z'X>N=1]H^$7_  35^,O[-VO?L9^//@5^T?\
M#Z#X@?L]?L.?"[_@GK\:I/B1\#O$WB/P%\<_@G\&;O3-3^&7COP[X1\.?''P
MGKGPP^*OA+64\6WR"Y\;^._#.LZ=\0M?T.\M+=].T;68-OX$_P#!-CQ_\'_
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MHBFZC;NH2I>ZGLJBGBN532NTFI89.2YFZ:<I+GC*#Y+4/VR=7\'37'@WXH_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[5KS1?CC^PWIWP7U?1_%MCXD^'>D>#[EO G[1:_'G3M \9> ='LE\,>']?\
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MH9I=CR^5$&(,DGE122;$RVR-WQM1B)*_+7]N_3?$.I?M>_\ !(RST;XC^/\
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M*/A#]H?XL^!OBSXH\+_&GQ5;>#YO"5^VN>(?AY\+->T#PCXS\!?"KXJ>*O\
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M*+IRNKM.<D_9\\?>?W;17Y _$OXR?&OXS?'#_@IC\'O WQC\0_L\:O\ L7?
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M*=^5N3P=2,5S+WITE+E<I*'[E5P_P_\ B-X4^)^BZEX@\'7&LW.EZ1XS\>^
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MX\_:QM_@]XE_X)N_M1^/_%/PW_9_^)G[9"VVH^.? 7Q__97\->%O&&G?"_\
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MZKJW]HZK=ZYHMCK\MZ=;C.H-P/['/[6VA_M<>&/B[JFF:'I.B:Q\$?CQXR^
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MFOHGB[4/ 'A"\3Q%8^*?"U_H=MJ'AFZEN/BN+]O'X1_ KP?^WK\6=>\!:O\
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M\'7/A7X?>*=4TGQMXFTE]5\(_!/Q%KEEJOBS3/!NH:KJ'@/3+CQEH/T]=_\
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M?"?A2#PG?:-%X9T)=/\ "-4_;HUJW^-OP^_9OL_A-X8T_P"/?B+X%? SX_\
MBSX/>/\ XWZ'X'^($?A+XK^-/&'A+Q]IGP6TA/"'B&S^//B#]G.V^'GB[Q%\
M9[;2=4\)V.C:9=_#V+3K^_N_'UG%IN=XD_X*#/X+_:2^'7P-\:_!F^\':'\5
MOVF=5_9?\!:UXD\=66F_%/Q+K%G\&O&WQ8TKXVZ3\%6\-N;S]FGQ)JGPW\:?
M#31/B?%\03K%SXQTZS8>!_[)NKR^TLC%3]R,8M3;A9<O++EG*-KW49+VG,E9
MMN;V3=P<K>^[IQ49MM2YDI033>G,FJ:3=U[L(WO9'V/\$/@1\'/V:_AIX=^#
MGP$^&_A+X3_##PHEX-!\%^"])M](T:SGU*]GU/5M1ECA4SZCK.MZI=W>K:[K
MFISWFL:YJUW=ZIJU]>7]U/<288_9F^!"_$75OBJGPVT2'QIX@\3:)XZ\0W$$
MVJ6_A[Q%\1?#6E6&@^'?BAXA\#P7\?@;7?BOH.@:1HGA_1OBGJWAR\^(6F>'
M]!\/:'9>)8=*T#1[.RXS]K']I.\_9:\)?#7X@77@*+Q?X&\5?'OX(?!;XA>(
MI?&-IX3A^$^D?'7XD^'/A+X>^)NK1WNBZK'K7AK1/''C#PQ8>([:"XTV?3=/
MU;^VY[A-(T[5KRQ\/\%_MZ:AXX\8_M+?##2OA7X;/Q6_9X_:R^%W[,$?@:#X
MPVVI7?CJQ^*'A_P-X]M/BW876F> KMM*\+Z!\-/%?B?Q;KNB?8M7UW3KKX-?
M&7P]J,5A=^"FN;\YN:5]7-.2N[\RLJ'-J]E:M0=[I6::_A^X-*$;.T8-)VT2
M=W6M9=7>G63TO=M/^)[_ -=^&_@/\)O!_P 4_'OQL\,^#[;1_BK\4K/P[IWQ
M'\:6NI:X-5\<:=X.@U.U\&:=XG634Y++6=/\%VVM:W;^#;&]M9K7PG#K>LQ>
M'HM-35M0%SA?$7]F+X%_%GQ3=^,OB%X"MO$>N:MX1TSX>^)Q+K?B>PT3QY\/
M=&U7Q!K>F_#[XE^%=)UNP\+?$[P';:IXL\3W@\%_$'1O$OAF5_$.LI/I<L6I
M7<<OY=_M(_MJ^)O@C\*/^"O/Q.^ /PIDT;XT_LT_%SX3>"O%&J?%7XR>+=?\
M&>(_$?CC]GC]G*_\-?%3P1X*.F_$#PQX)M/#'P\^)7@6>/X8>'-*\+:%X_\
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MRYIKWDYU+V=2;=.SNW:Z:N]$U=*,8M[J+48I1;L^2%K\D;?FS\3]+^*VI?\
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M%\,OB7\!/B%^R!\5OV./VO/VCF^/OA+QI:>(],@U_P#95^./[-'PI\0R6OQ
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M4EI;DIJ24;-1I)2I^ZHN,;4N>-FY.]H6E?FO>I&SOKS3:E)Z.53FC4U<HM_
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M5-KH_;E^'GAKXO0>&OV;_P#@H?J%WXA_:"^%]U\/AJ_C/0_%'COX9^&?@?\
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MG:=-5%[[FYCC%WNEJV[I)-.52M5DXM:QYI8BO?E:O&HX.\5%0****!A1110
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MU_7])^'7P_\ %6M:7X>L[H:MX@N].CT?18+S5[VRLY_R[_:P^"'QS^)O@?\
MX+D'PI^SI\6;CQ3^U#X*_9.MO@-ITW@_3SJ_Q"U?P1\%_".@:QHVEZM;:G>:
M+;W?P[\=0ZM97=UJ^N6&AV^H07NO^%]5U;1;F+7+K^D2BA*U[=9<]W?1VPJT
MZ?\ ,)3:M;XJG=<K<$Y<VM^51=FTFE]:2VUVQE7KNJ;WC[W\_?[1GPR^(L?[
M7O[3N@_%?]B;]IG]M7]F;]NKP-\&4^%EQ\(/BQJO@3X;>#=1\.?#8_#;XB?
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M(O&/A/PAH4"1H+2P75?$&K:?82:OK5SIN@:2MP;[7-5TW38;B\B^@_BGXH\
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MW/&4+)?"G[;:[=VE6DM;748M^]S2G_.[J?P2^+D7PP_:]L++X%?$VWU;QO\
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M35:$W[J2C*I*I6E4<5I4^%)0Y3\=/&>C>./B!^W3J7QU'P*^+^G_  Z\1?\
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M\&/@K\6K&^_X)T+XA^"GQ(L+3X4?\%9?^"I7[0WQ!&K^!-2%OX+^%7Q_N_\
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MTW3=#T'5_/L+/3-&UKQ'I&CPVXTW1_$?B73K2UUO4/QQ_9:^'7[1/PP^%_\
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M-JS=[7M:_NN-U=<T)PG'F7VH-Q<9QNN>$Y1;2/QQ_9R_:"^,/[17[&?Q&_:
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MOAOK-_XTUN_^$'B#6?A\K/B/^T%XK_9ON?\ @J3XK\*:T/!$WQ _X+*_L&?
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M?AAX?OOVDOV</$ME=27?P:UGP8_C/P5HWC#]G/5?#W@2/PQHWQ?\)ZMH-O\
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MX4>)]5\;?"72?!GABP\%GX1^,M?FU:?Q!XK^$NH>%$T?5?AAXC\0R>(/$?\
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MVE]XN;7]4\0^-/%>F>%+SP[]2^./!WCKXK?\%*OVG_!W@[QWXB^!'Q)\9?\
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MG<ZM)R:O/EYY^]5O\+?M5_'+XOVG[ /[0O[7_P &OC=XV\-VGQ-^/OP-U_\
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M#WQ#^TCHJ>+Y;/QQXATR2TUS0O GB/X/_#*YT?X]_$?X;^,_ W[5?$S]D/\
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M^VU?$_Q _95\>ZK^TIXY_:0^%'QQMOA=K?Q6_9M\ ?LT>/[+4OAC!X\U33=
M^%GCCXT^.O 7CKX4:W+XU\,Z5X.\>Z7J7Q]\>C4)?'/A+XL^$=5DL/!<K>$K
M6'1=<L_%1>RG9+G]E6C3;2<54E2E&FI7VA*:C&;Z0E+57YHS)7Y$]8JK1E45
MVFZ<:B<[<MFY*+<H+9R2T=DG\]>'_P#@I1XP^-/C_P#9M\*?LK_LX6/Q5\._
MM/?L8>$_VW?!?C#XC_&ZP^#JZ!\.-;^(/PL\+:]X:\6Z%IWPZ^*=W:^,_#WA
MOXGV^NV]GH]UK.GZMXDTJ3P=<:AHMI<3^+=-Z#5_^"D=GIO@SP[^T';_  HM
M-3_8]UC]K.\_9'U;XU6OQ,MH_''AKQ#'^T+J'[(%A\5+[X47/@V+0+WX07W[
M4&GKX+;6=/\ B[/XJ@^'VK:)\4D\'W5M<:EX:TCO_A5^P9X?^!_Q]^ 'Q*^%
M7C"R\,_"/]G3]BP_L1>!?@K<>$M1UK44^'EMX@^'GB#1M=N/B??^.3?SZ[I$
MGPO\,:?NU#PMJ+:I8SZ]-JUU>:QJ5IJVF<5H'_!.'3M$\->(O@5/\4XM7_9
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M\4_\%0?VFOV5/%WB+XJ_M$>(U^#>@_$[0=>^*^J^(OC3\1OC#XB\$>(A\)_
M_P 4_%GPXD\,>"/#$/A<>%]'\=?$#X=^"8)M @UV633/?G_:7_:BNOVQOV,_
M@K??#'X3>$?!_P 9_P!DC]HWXX_%S0A\7=8\3:UH'CGX1?%#]DOP1>V'A#Q1
MIWP=&D>+?"WA?1OCMJFH^%+LGPH_Q:GU:.\UIOA3!X*L[+Q_)X$_89^)?PW^
M'WQ/^'^@_''X9>(]%^,_[6'[1'[1/Q2\-_$_]FI?'WPZ\=^ _P!I'_A-M3\7
M_ KQ)X'G^,NE2WNC:7XL\5:7K>D^*HO$=M-=Z;X9B\->(/#NL:?K>LRW%#X/
M_P#!.<_L_:[^POJ/PA^,;:/I'['WPB^/OP(UWP_XH\ S>++;XA_"K]H3QM\&
MOB;X@\+^![I_'NDR?!R#P7XS^!O@S1?AJEQ%\3M/\+?"-M0^'?\ 9M[J4.A>
M-]%A7;IW:7+[%2N]&OJTX3325THUO9M.+:<7*/LXNG3<BHI-34+ZSJN-K1?*
M\3"<'S=7*BIQ::4N:S<Y1G-+E/ G_!4S2O%U]\+?B#??L_\ Q5TC]D'XM?!?
MXF_'2P_:KA\&?&V3PG\,O '@7X?2_&3PWXM^-]OXE^ _@[P/X3\$_$WX36.I
M:SX0\3>!/BO\4II?&?\ 8O@231&F\06.MKY)!\9/BM\8/^"A7_!+;XC^(? V
MI?"CX??&;]E3]M#XB^&?!D'QH\1>*[J[TJ_T#]F?Q'X1M_C'\,8/#7ASX=>%
M?BMX9\/^-%BFN?"&N_%>RT[4]3\;^&+'X@ZAH6DZ'K?BOTSX ?\ !+SQ-\'?
M!GC+]F;Q?^UU\1/B]_P3_E\'?$[X<?";]DK7? OAC0-5\!?##XK>&_$?@_5/
MA1XU^/VF:E<^/?BU\-? WAGQ?X@T?X3^'[_3O"VH^$+0^'4U;7?%8\%^$1H^
MK\ O^"=OQB^%?Q"_8\\6_$C]L&;XR:)^Q#\/OC7\%_A1IT_P+T;P?XP\9?"#
MXH>'OACX;\,67QE\<I\0?$T'BSXF^!].^&&CVNJ?$7PAX3^'>F>.[=+2:_\
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M5O=DVY)V4H3A*$E*G40^9\ME;WGS*Z=H\KL^;K::V:3<9QG&45&=-_-^D_\
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M:?X,>%]:\'?!Z[\!_M ^ (M>\5>+_@KH<7A+X@7K^%O$:V'AA7^(4?4>/O\
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MWQ8\&ZIX7M?%.MZ?X&\:^%/B#:^'/",?B+P[\1O!-GX?^(.C2OX;TFYL-/\
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M-\0/&GQ+_:76QTOX;:-=VFL^ -,T:+7/BW\2/B1X.\!W]]?^-K+PC\-[72=
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M&](^(OASX&>&?VA_^$N^'GPU^+UEXA_:J\+?&3X(^+I?#WAG]G+XH_LY^)_
MW@2?X8_%OXQ:=I7BG4O!UIJ/C_5_#RWOA^."/7-4\,^(?#OC+4?HC]BC]GGQ
M3^R;^R[\%_V:O%'Q-T[XMQ? KX?^$OA'X,\8:=X /PW:;X;?#?PYI7@KX>6&
ML: WC'QU]L\4V?A/0M+'B_Q+%K=M8^)_%,NKZWI'AKP?HUYIWA31OCKXC_\
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M&OPLUKP=X^\8?M&_$']IKPC\?OV>]/\ C=\-_P!HCQE^T]\0M5^+7Q!U+7_
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M['X$C^-%YX-O+/QM:_!U_$8^)MQX)N[;QC#X4?PS/%JC_D/H'[.OQ^M/A_\
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M^&_@#7_AOXCTS2OB#I_CKXIS>,_!4?PF\'3>&%\2?%1O&W@K_A7FF>)1XO\
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MOC]X1U'X_7W@[3_VB?V=M1\':;^S?9_&?4OA?IQ%[\7](T;4/% 33OCKK/Q
MM?B;/X3TKX#ZUX:D&FZ#::A\,K2XUG6[/4_$NE_$B]T;3K_0K/J_#/[3/P+\
M6Z=XOU72OB'I=O:> [3PUJ7BT>(['6_!UYHVE>-KG4+3P-K,^G>+]+T/49]$
M\>W&EWJ^ M:L[2YTKQO''%/X5N]7@NK62?\ -CQ9\ /B!!^U=XR\1:[^RK;>
M,_@F/^".]_\ LU:K\/?A;?>&/#WPF\6_$FV\=ZQX@U']EGX=/JNI^#M>T70]
M9\$W!\/^$/%6I^$O"GP^T[2KRQTVY\0:%KUO/X?L_E_Q3^S!^W1'\$/C+X0^
M$%[\:OVC?AO\&/B3^P%\>?V6O!'[4^O:#\'_ -J7Q_'\"?C1KWQ$_:&_8J\5
M?M$64N@Z]XJ\,>!]*T#P?KG[./Q^^)MO?ZA%\4?%VL:?>_$WXD^%O#UI\1W3
M:6W,HI2U?*Y17UVK2<I\BLW&A[.LN524DJD8VC&BZCU\FWR?"I)-O"4JO+!2
MU5Z_M*4N9Q<7R2DN9U5#][_A9\9?AE\:M*U_5_AEXNL/$T?A#Q7J?@/QKIBV
M^H:/XG\!^.M'M-.U'4_!/Q \':_9Z7XL\!^,+/2=:T/6YO#'B_1=%US^P=>T
M#7EL&T?7-)O;STZOS9_9JU^X\)Z1XD^,^B?\$^_VA?@QJG[0?Q=^$/A+Q9H7
MC3Q!\(_%O[2FKP0Z58> ?^%_?M!WA_:%\;Z/:?#+X8>&8=$\.V=G8_$SQS\7
M=,\">%7%A\.6M(O#WAR#])J=K675*/-M;F<5*233=XZIIMWM)*5I)QBTVU=[
M-RY=[\JDXIM.S3T:>B3:O&\;291110,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9QCAZKDH\O*?H[17Q5KW[7&LZIXI\?:3\"O@OXA^.OAKX,?&'X=_ _XP^*-
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M3UU32:=TTFFD4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7S5\7?V6_AU\;OC9^S5\:O'_VW5KW]EC6OB'XT
M^&_A5V3_ (1Q_B1XX\.:=X/TSQUK=OUU/4/ WAQO%47A6PN5ET^RUWQ-!XK6
M*/Q!X6\.WMG]*U\L6W[7'PZOOVO=:_8QLM$^(<WQ+\,_"'PW\8O$6MO\-_B!
M'X#L=!\;:QXHTGP=!;^.%\+2^#[F+5F\!>.8[G7)_$%EH-IKVB6_@JSU#5?&
MESJ>@Z&OM12^)-SA;=.G"<W)=G&'.[^;2NVD)M*,FW:+M"7I4G""3MK:4^2.
MGE>RNSDOVS/V/8?VKH/@-KFD>/H/AO\ $G]FWXSQ_&CX::]KGP^\._%WP%J.
MI7_P\\>_";Q9X4^(OPL\4W>FZ;XL\,>(_ /Q*\3VMO<Z7KOA7Q=X6\21Z#XG
M\,^*=.N-,NK/4^3_ &@?V)O%/[2'PL^(GP/^)7[0>M>*_A9\:/A;9?"WXK:-
MXN^&O@S6-5C*>)?$^OS?$[X-W>B/X2\._";XO:#%KNAVWPW\6W/A+QSIG@S5
MOAWX \::EX:\7^-=&NM>U+Z#^'7[47P%^+'BNQ\%> ?B)I^N>(=<\&2_$GP9
M!+I?B'1=/^)_PTM[W2=/N_B9\&]?U_2-+T#XT?#:PNO$7A5=1^('PHU3QEX/
MTZ+QGX&N;[6K>U\<>$IM9Y/X]?M<_#S]GOXK?LP_"#Q9H7Q%UKQ/^U-\0?&O
M@/P=+X,^&_Q!\9Z7HO\ P@GPA\?_ !:US6-=U+PEX5UW3H7%MX)M=&M/#8O$
M\4WL&MWWC&RTBX\$^!?'^N^'$E%622]^HI)+[51\JTU5V_8Q;5[WIIVC**3;
M>[;^"'*W_+#WGKHVDO:2L[6M-KWDV8NH?LIZG+\?OVDOVA-%^,7B3PYXM^//
M[.'PP_9Z\.G3_#F@3W?PD@^%EY\<-8\/^+/#^K7_ -HEUF:V\3?'#7?%5IH=
MY:V-JVMQ3R>(;WQ/8KX5L/!GG7P,_P"">O@7X+-^Q&Y\:ZQXN'["'[+OC']G
M#X/66H^']!LM)M]2\<Z/\(O"VI_%F.R1+RXT_P 8:+X&^$\GP_\ "TAOM0U"
MV\(?$+XAVWB77_%FL>*M7UN\\X_90_X*(>'/&GB/QO\ "O\ :3^(_P +O#OQ
MEN?VX/VH/V6OA)H_@_PQXM\,^'?$UC\%_%7B#3O 6D:Q=ZMKWCS2O#'Q)\<^
M#_"FMZ_I.A^*/&ND7OQ'U'1?%K_#70;RQT"]TS2OM37?VH/@1X9^)'AKX4>(
M/B%8Z/XQ\8>,&^''AHW^D^(K?PEJ_P 3QX>N/%L7PHMOB.^CCX=+\6KSPK:7
MGB33?A9-XJB^(.J:#97NK:;X<NK"SN9XFDW&"BY6G!<G+*5VN2K/1IWYX+&U
M;M>]"=16?-&DQ*2]YNRY934N91TY90I/1IKDDL%3Y?LRA3OHI5;?E-\2?V4O
M%_PT^"O[*'[#EKJ_BQOAW^SEX'^'WQ$\/?M-:M^R);_M>^&_C;\?/",?C+PG
MX@\,_%WX$^#-$UO6_!%JTGB"#XV:_P",I?$?@W7_ (@>+_%5G9>'OBL\OA7X
MGZ?XJ_3+]C6Q^*.D_L\^#-!^+?@/X5?#KQ#X;U+QOX:\/^'_ (+> -5^$/PZ
MN_AAX>\=>(](^$7BK0O@OK?B+QEK/P5/C7X9V?A3Q;??"+6/&7B?6OAY>ZS/
MX9UW4;;6K#4-&TOU?XG_ !@^''P:TO0M6^(OB6/0U\5^)['P1X-TBTTW6?$G
MBWQSXTU+3]4UFU\(> O!/A?3M:\8^.?$[:#H/B'Q-/H'A+0M9U6T\*^&O$WB
MF\M(/#WAS6]2L/.O!_[7G[-_CZ[^$UAX,^*NA^(KSXZ>'?'OB?X2V^FV6NRR
M>-['X577]G_%#3=*#:2@C\7?#?4Q)I'CWP'?FS\;^#]:AN-%\0>'M/U6VGLX
MVKVDK74GJTGO'2*22LN6%.--*-TJ=)+E4DVTTKIW:LFU=WT;]Z[E=VE4J.I)
MMINI4;YFFHKXQ\0_L4>$/@C\._!>@>(]8^+7Q9_9B^#_ .UU<_M.>$/V>OA5
M\.;S7O'FJ_$CXQ?M1:I\8M.UGXPZGI/B&_UWXR?"C]FOXT?%K5/CMH/AGPAX
M1\+>*;70/A?X2U?QHGQS\5^"[FW\=_27['?P>\5^!A^T1\9?B78+I?Q1_:Q_
M:&\4_&O7M%E2S-_X/\ :)X7\'?!/]G[P+J4MHK10ZYH7P#^$_P .M4\=:1;7
M>I:7H_Q6\1_$6WTC5]=LI$U[5.?\=?\ !1+]G3PIX?\ V;/%/AV_\;?%'P]^
MU1\:?$_P-^&6M?#+X8?$[QO8+XP^'UA\1=2^(]EXAC\+^#-:U71-9\)0_";X
MA:=_PB-[I<?BW6=>\,ZS9:?HYTOP[XPUSPS[-J/[5O[/FC?$/2?A;JWQ*TK3
MO%FN>.A\*M)EN].U^'P;??%M]$?Q)#\'X?B6^D+\-_\ A;]UH$<NLV7PI;Q6
MGQ"OM-AGN[/PW-#!,R*"44HQ6EO9PM>[M##<R2^TW2C@X<^O[J-*E"34W&HY
MN\FY/6+52;EO>4\1RMM_"E4>*FXNS]HZE2:3@I0\LNOV,=%\6?M ?M-?&;XL
M^*--^)OAK]I;]G+P?^RKJOPOU'P1;Z7IOA'X,>$M4^*^K7?AK2/$5OK]U?ZD
M/B#=_&GQK-\2[C5+&23Q!)8>!X](_P"$;T_PFNGZEX!XA_X)IZ]K'PW_ &&-
M$7]HN75?BW^P/%<>'?AI\5?B+\'/#/Q(TCXA^ =2^']A\,-:T?XO?#;5_$=E
M8:]XSU#PMH^A7\/Q*\+>(_!NMZ;XPTE==L[-=.U77O#^J_1WB/\ X*$_L7>$
M_$>K>%=>_:%\"66K>'/C/IW[/?BR2-]7OM#\$_&'6-+\(ZKH_@SQ[XIT_2[O
MPOX#FU<>//".C:5K'C'6-$\.ZCXOUVT\#6>KS>,UGT&'H?#W[;W[*/BCP?\
M&GQ[IGQM\(V_A3]G?4X=*^-&I^(!J_A*3P%-J&CZ=X@\/7VIZ9XJTS1=6N]
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M31[:Y\!^/M?MO$VI'4+K3/C;(Z6NNZ5J=M<:OX0T"\\7/XSTVTTK1-$](?\
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M[=Z4M_X&L_$6CP^(YO:M+_:X_9^U_P $6WC_ ,,^.;OQ?I-UKWCCPFF@>"_
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MWSMRX_X=?\$]- ^&_P#PQZFF?%GQ9J,7[+?Q4^/OQ_\ $LNI:!X<EU#XZ_M
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M(O[;/[*<OQW'[,=I\;_!NI_'I/%X\!7OPRT674=;\0Z-XN;X=7WQ831?$?\
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MP%\$_$+PW\+_ !9\1-.T+Q9XL\9Z7\--$DO],\01^$)?BCKV@P>*/#OPHO\
MXCKI#?#O1/BQXH\-WEAKOA3X7ZWXJT[Q]XHTG5-(O_#_ (=U*VU;39+KF-4_
M;._9WTH^. _BWQ-J)\ > _BG\3-5/A[X3_%WQ-'K_@OX(ZUHGAOXLZM\-;CP
M_P"!-2M?B])X"\1^)= \/^(M+^%4_C+5K'6]7L=+>Q-[,(0G)13J2EI3IN\Y
M:VITHR4G*5F^6,)-.[LXJ-^91BP45+W(J_/--16SG4<6G%)VYI2BFG'7F<FG
M%RE?H/VC?V>M!_:'\->"+*\UW4O"'C/X2_%;P/\ '/X1>.-,M;/5)/!_Q0^'
MMQ>G1[W4O#^I Z;XG\+>(-#U?Q)X%\<>'9Y-.U'4_!/BWQ#'X4\2^"?&B^&_
M''AN]X6^%/BU?&$/Q/\ B;X[T;QE\2=(\$:W\/\ PA-X3\%7O@'X?^$=$\3Z
MKH>O>++^Q\&ZAXW\=Z]JWB+Q?J_A3P6NNZCXC\?:O86&C^"/#^F^"-(\&3ZK
M\0]2\>?,VD_\%1/V/K+X$? ?XZ?%OXE0? RV_:!^#9^-/@OP'\2-%\5:;X_O
MO#>F>!M"\=^+5T+PLGAW^WO&EOX;T_Q!8VEOK?A#2=6T;Q?>36D?@N[UU]1L
M8Y_5?!7[2OP\O?&W[4M[JW[2?P=\4> O@I=?#)]9\,Z)X4U'POKO[/L7B;X=
M:;XCGT3XL?$'4/'>OZ)X[U[QO)>6_C#PU8:3X/\ A[JOA/1-9TKPMJFD^)-3
MN;+6KQN#7/!IQY95'-7:<:B4:-3X;N-2SC!M6:<8J\9^SYTI1ER334N94^1Z
M>]!N56&CLI0OS5$FFFG)I2CSJ'EGP7_X)X^!O@==?L-P^%?'>O77A[]B3X-_
M&/X>Z;HVIZ%H4]Q\5OB5\;/^%:2>,OV@O&.IB/&F_$_6;SPM\3=2\0ZCHMA%
M/KU_\=_B&[7UA;WMQ;:CQUE_P3;^S?#31OAY<?'_ ,57LL/[?OB+]O7Q7XAG
M\#>$//\ &GBC4_CCX\^.OAKPEJVF9:REE^'?BKQ'X"O/ _B346U?3])U7X)?
M#"5_!DWA;2KKP7=>I_%7_@HA^SQ\,OAUJWQ @N?'OC2?P]^T%\$OV9?%?@3P
MU\*/BK+\2/ /Q4^/GC/P%X3\ Z?\3/AW+X''CSX=:7JEG\1_"OBW1]5\6>&-
M-@\::#KGA>W^'J^+?$/COP#HGB?V;Q;^U5\!_ =WH-IXU\;S>%1KNI^!-#DU
M'7?"'CG3=!\(:_\ %&ZT[3_AOX=^*GB2Z\-1^'_@WXD\=ZOK6A>'_"?AWXLZ
MGX+UO7?$_B#P]X7TVPN/$.O:1IEZ+=*._-%12U7-.5#$P48ZIW='#R@HQ<>6
M%*"O'D@QRC=MRU492E)RV2C7PTG*5TXV57$0E=Q?-.I.RES37EMS^R'J'B;X
M\?!?XT?$CXJ-XX;]G/XH_'7XJ_!A7\":9I'Q#T"?X[>%?'_@'6?A?KWQ,36[
M\Z]\#]#\'?$%DT[P%8>$?#NK:GXJ^'OPB\2^(/&.J6_P_L]!OOI?X;^'/'7A
MC1=7L?B#\1G^)^KWGCCX@Z]I.N/X2T3P8=%\%^(_&>MZWX$\ C3= =[345^'
M'A"^T?P.OBBZ*ZOXN&A#Q+K4<6JZG=QK\%?\%"_V[5_9J^$_BZZ^#'B;P5JO
MQD\%?%;]G#P)XHTGQ3X"\?>.?!'AZ#XU?%[X6>#M1\)>)_%WA#5/#?A#X>_%
MJ]^'?Q*M?'7P]\->-?%R:SJ<5[X0U3_A!/$>@^*]'.H?H7XU\;>%OAWX:O\
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MHOG:&I6E=/WH>RG=)-Q]C5<Z4GH[.G5H2:OJO9OF7(F?,'P[_P""?"?#N/\
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MXD_X*R?'/Q%\-O$'C7X0^%]?_P""<W[.7PJ7XL:K^S[XE\<?#[4O%FA_'_\
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M'Q0:Z)TP^!2AWUWOP-_9V^-?@;X^>/\ X*_&7_@GS\//C+X)M?V[OBM^UO\
M K]N+6_%OPAUKX=>&/!7Q8_:#\;?M46=]XF\!>)?%=Q\<O#O[2?P0U[XA>(/
MAA\*]3\&?"W4_#MUJ^F^$]=/C'PAX5M=6UI_W:HHC[MMFK133UORT<-1BT]X
MM?5:<[PY6Y.<6_9R48+E5[IM.\FFI25N>KBJLE:]FF\75A:2?NJ#^.+<_@/]
MNW2/C9?R_LIZC\)_@IKOQH\,>&OVEH-6^-4'PSNO@SI7Q]\!_#K4_@E\:/!D
M'B_X'^)_CEXR^'?AWP-JVI>,/%?AKX=_$_QSX)\<>'OC'H?P*\=_%"V^%]_I
MVN:I)K^B?F7^SK^S;^UQ\ [;]@[QMK?[*WQ'\47'[-O[57_!5+2?B-X#\*?%
M/X%^(?&<OPY_;&^-_P 3_B5\(?C9X6\1?$'XT^%])\:> [>RUGPYHWBX>+?%
M/ASXT1WNJW/B"[^'5]96E[?3?T85D0^(-"N=>U+PK!K&FS^)='TC1-?U;0(K
MVWDUC3=#\2WGB#3O#VKWVG+(;JUTW7+_ ,)^*++2KV:)+>_NO#VLP6TDDFFW
M:Q3"/)-33<FIQFE)R<4HM^ZDK*,7S36EFG4;3YE"U2?-!TW91E'ET23;W3OU
MDG&+MJGR6:47)/\ G^^'_P"S9^UK\//V8_\ @GDNM_LS>,M;^('[+_\ P57_
M &C_ -H;XG_"WP5\0O@9JOB*Z^#OQDU/_@H+I/A7Q[X*U[Q3\4/!/@O6M*A3
M]J+X::WJVC^(?$'@[QWIVA0^)IKOP9;ZMHRZ/==</V/?VE=>_9C\?_L%^(/!
M6O:=J$'_  4I@_:8\#?M76GBWPG=>$M9^">O?\%&]/\ ^"B^K?$=[R/7(?B/
MX<^-?AG2;_Q5\#U\)/X#EFU#XR6GA_7;/4KCX+ZSK?Q)T#]TIO$&A6^OZ;X5
MN-8TR'Q+K&D:YK^DZ!+>V\>L:EH?AJ\\/Z=XBUBPTYI!=W6FZ'?^+?"]EJU[
M!$]OI]UXAT:"ZDBEU*T678JXR<?9-6?L>10NFU>F\#*+:ORMJ>7T9WY6_>J0
M3]G)**G%3E5D]ZKFYV_Z>?75)*ZO9PQ]:%KV:5.;O.+YOP#_ &A/V:/VI?&7
MP>_X*G^%_#?[-OCCQ)K?[0'_  4C_9+^//P7TQ/'/[/-HWQ$^$?PH\*?\$\?
M#?C/Q;8SZ[\:]-TWP['I-U^RW\2+NST'QY>>$O$^H:=<>$WL-#DO=4OK#1][
M]H;X*?MAGXJ?\%5/B3\)OV9(_''_  NKX6_\$\M#^"B>-[O]F[Q5IGQ$;X*>
M-_'EQ\>6\#^#?'WC[7?#=E\5_AUX)\<W'B;X*S?'GPCI'PTU'XPZ#X9GUB'7
M_#-E=6^H_N]14TTZ4(0BU:&JYES7;ITJ;OK'2U&$K)QUNKI-.--M\R>TKW22
M37-5E5E9V;UE)I74DE;1ZJ7\W?Q%_9,_:J\2_![_ (*N:1X>_9F^,5I?_'G]
MI+]@[]IOX'Z#\0?C'\%_&WC;XC>'?@EX#_8DC^)W@&7Q3<_'WQ@;+XK:%J_[
M//C_ $I+#QGXBT?X:SW%WX4TWP3\1=7\/2O-HGT/^T9^RE^T/^U/\>/VW?L?
MPQ\0_"#P7^UA_P $9(/V0_"7Q-\;^*/A5J.E^"?CGXI\4?M*:C>^#_&.A^ /
MB/XQ\:"Y\'Z;\9_#,^NZUX8\/:_X(O+C3_$=GX6\:ZV+;2K[5OV??Q/H?]JZ
MWX>M=1L]0\3^'M!TGQ-JOA>PN[2?Q#:Z'XAN?$5CX<U&;2S.D]O9^(M0\(^)
M].T2[NA!::C?:!K%O;SL^FWGDY/PX\8R_$3X>^!?'\_@_P :?#V;QOX/\-^+
MI? 7Q'TFTT'XA>"I/$>CV>KOX4\=:'8:GK5CHWC#P\;PZ3XDTJSU?5+;3]8M
M+RTAU"\CA6XD;ES*46TURJ+Z-+ZO7PL6FK:JE4>EFE.G"32BY0G$8J#YDWS-
MWN];VQ-#%M6Z+VM*.MU)PG.*DY*,X?'7['?CW]IWXLR:9XO_ &F?V)=._9-\
M?^&/A;I'@;QKK6M^./@[\1==\=^-(]4MKS4-/^$&O?"3QAXTO+3X":/<V>M:
MO:+\2I?"7BG5M7\1Z,;'P58P:'JFL:U\A_M#_"+]JWP;^TY^WWXA\$_L_>+O
MVD_AC^WC^QI\-?@]\/\ Q5X,\<?!SPY+\ OB3\'_  A^T)X:_P"$ ^)VC_%;
MXC>"=:E^$OC2X^,+>/="\6?#C3?'-]H7B;4/'FF:EX(FO=;T:YU7]$_C?^UA
MX)^">O7O@V/P3\5_C'\0=&^';_&#Q'\-?@5X/@^(/Q$T#X2P>*K+P?=>/9/!
M_P#;.D:SXBM_[7N-071/!O@BW\4_$[QROAKQ3:_#OP+XNU30;W3D^H001GGL
M>00?4<$ @_49!X/(J*L574U*UJE/$4:BC[JDL33K4JS2^RVY3<73?+"I3Y4W
M:HI72;H.*@VG"5"<+ZN/U>=&I13>CDE&%-/G?-.$E)K6$H_SF:5^SI^U#\(_
M$?[/WBGQI_P3UD_;!^&7Q/\ ^"9G[*/[(7QL^#G_  M#]G>R\>?L^?&7]F5/
MC.UU:^)K3XB_$W1/A%X^^"GQ<TS]H3Q%X>\87_@OQIXZU.Q;P-]IF\.ZSINK
M:=I.H9?QH_9:_;(\%?!C_@K/^R7\.?V-]/\ B'X6_;E_9PM+K]G#QI\"/'OP
M*\%_!SX3^+[7]@CX;?LA:K^S5XH\/?%;QS\)?%W@GPQX&\0_!?PYJWP,O?!_
M@;Q;X2UKPCX]CC\2ZI\/]1\/^)YK3^C+4M>T31[O0K#5M7TW3;[Q1JTN@^&K
M.^O;>UNM?UN'1=8\23:1H\$TB2ZCJ,7A[P]KVN2V5HLMPFD:+JNHO&+2PNI8
MO'OV>_VB/ 7[3'A#Q7XU^'=KXIL](\&_%[XP?!'68/&&@R>&]73QO\#OB'K_
M ,+_ !W&FDW%Q->1:=!XM\,ZO;:=/?1V5W=VL"74MC;+*B&JO[Z55RWJ/$3J
M<KE\&(K^TG'5M6C5J?NYRYJL(R5-/V=[YTXQHQHPB]*<:$*2D[OFP]%4X2Z-
MMT:7OQTIR<7.RFDH_F5^U)\(OVE=8_:)_:,^(_@']F_QQX_\-?M7?\$J=._9
M>T>?2_&_P2T63X1?&KP1XD_:<\7V^@?%Z'Q%\4-,N5T7Q/;_ !]T#1]*\2?"
M2U^+5M;:SX<\1+?6T6F'1]2U/SCP!\.OVV?V:_'GP2\=V7[$NJ?M(?#WXS_\
M$R?V5/V/?CI\(['XJ_L^:)XV^ _QH_9=OOC-J=F/&TOCOXCV'PR\9?!+XDZ=
M^T3XNT/Q9JOPY\1_$77],F\#Q74/A/Q#!JVD:/?_ +YT4]]TFFW=/9P;Q5X:
MW5G'&58\S4IV4)+WXOVC4;1C%-KEY7%WLU.-/"PC.ZMJOJ=&7+=0;YTU:2=/
M\O/"?PY^.7PS_P""B7B#XLWGP(U+Q+\-?B#_ ,$Y_P!G#X,/XS^$.K?"W2OA
MUX*^+/[/'Q4_:I\>^*_ (\,^._B1X.\>:=I7BC3_ (T>"]*^$MSI/A77=!DD
M^W6WC'6O!NGZ)>ZJOQ[^Q3^R]^U9^R_9_P#!*CXF>.O@QXQUA?@E_P $U?$'
M[!/[0GP=TCQ=\*-8\8_ [XA76L_ /QOI7Q;\/MIWQ$O_  /XZ\">+M5^!5WX
M#\:KX'\7W_B^S_M'X/>)+CPY>^']*\<S^ _Z!:X#P_X[FU_QW\1/ \G@3Q_H
M,/P_3P@\/C?Q#HMA9>!/'_\ PEFDW6J2I\/-8M]7O+[6W\*-:C2_%XU#2=&_
MLS5;FUMK0ZC%(UQ'3J2:47RZ/F7Q?9EBI/>3O[N.JQ=VY-*F[RG&;E*IQBW)
M.2;3B[-6O.&&ALHJUW@Z<K12BFYJT82BH_BS\$/V,_V@/@S\</\ @GIKY^$>
MLZAX)\$?&'_@J_\ '7XIG0?%WPG;P[^SI9?MO_$OQ;\6/A'\*)-,U+QYHFM:
M[?\ AFQ\8IX*\17'PJT3Q[X6MO%VG^(=3L]=;PIJ.FZG-]O_ /!,/X6?%3X,
M_LE:9X ^,OPYUCX5^.+?X[_M@>,F\(ZYKO@#Q'>P>%_BY^UU\</C%X#OO[2^
M&GC+QUX6 O\ P/X_\/2W%C#K\EYI=^+W3;NVA>U1Y?O75]0;2=)U35$T_4=6
M;3-.O=032M(@BN=6U-K*VEN5T_2[:>>UAGU&\,0MK&&:YMXI;F2)))X48R+A
M^ /%<GCSP)X*\<3>%?%O@67QGX2\-^*Y?!'C_3+71?'?@Z3Q%HUEJ[^%?&NC
M6.H:O9:3XM\/->'2/$FF6>JZG:V&LV=[:V^H7L427,N<8J*45M&$::6ND>:C
M*"O97:^JQC?5N*DY^])-VU>3F[WG-S;NW>7)4A)V;=KJLWY.RB[*2/PR^$?[
M$_[13_LR?L._L8_$;P1K6F^)_P!BK]N7X>?&;6_VEY]=\$7?A'XA?#'X$_%W
MQU\5_"GQ*\'_ -G>,]4\>W7C3]H7PQ>:?\*_B1X3\1^&_#VO^%M;\:?%>]UX
MZCX)C\'>(OB5]P?LK_#;XP>#_P!MO_@I9\0/''PD\3^#OAM\;_B/^SQXD^#_
M ,0-3\2?"W5=&\?Z5\/?V;O ?PK\42V&B^$_B'XC\=>'I;/Q1X7U!H(?&_A+
MPM)>Z9+9W=L))))K>W_1JBJA>-M;ODE%MWUYZ.$P[E96BFJ6"H)*,8QYN>35
MY)0)+GM?1*:G%+HU6Q=>UW=M.IC*S]Z4FH\D4URN4_R!_;3^ 7QU\2_M$V7Q
MN_9/\._&CX;?M&Z-X3^ /@VT^)^G>,_AUK?[(G[27PVTOXQ>+-6\5? G]K3X
M*>+_ !5)JPT/X/\ ACQ5\1O&&C_%;PCX+\/_ !6\-VGQ;O(_@AX^\9>+K;6/
MA3=>#^*?V;_VIKCP3^VG8:?^S;X]O-4^)O\ P6N_8Y_:X^'5G:>._P!GB*Y\
M6_L_?!+XI?L ^*_''Q%L[B^^-MC9:.(-%_9D^(KZ/X7\3WFA>.]1N+CPK;#P
MS;C5+YM'_?:BHC!)):-*2ELM;5\/7M>VD74PM-R2T=ZDK1E.7,37.FI.6L)0
MNI--1E2KT=.EU#$346U=)05Y**M_/%^T9\"OVS_'_P ??'>IC]E+Q?K6A>!?
M^"H?[%G[37PY\4?"?QY^SSX%^%GQ*_9O^'.F? '2O&GC#7/#]Y\6/!7CSXI?
MM4Z9?^#-;T3QE??M!>&+72O#GPN^'G@S1O@UXUCT_3-(T/QEW^J?L@?M2?$7
M]E7_ (*U_"72?A\WPE^)WQW_ &S?'_Q[_9PO?B1XB^'FK>"_BWHNEV/P*UWP
M1;>(G^&7C_QCJ_A_P7\1=:^$%]X#\667C&U\->*-.\):^US<>'ROF6<7[O5E
M:-KNB^([*34= U73]9L(=3UO19;W3+N&]MH]7\-:UJ'ASQ!IKSV[O&M[HNOZ
M5J>C:G;%O-LM2L+NSG5)X)$6HIQBX1=O=M>R<D^?!S535./,JF P\M8N$FIQ
M<7&;C%MJ4XRE9M-M1NTFN7$QE'1IM>SQE:+LU**E"2:E%2E^,UC\'KWX_? 7
MXO:O\5O^"4WC;]FWQ/X]_P"&=O"WB[P?X!^.WP)TK]K'Q#XC^'7QBT/QU8_$
M_P"&WQX^#OQ8T[1=)\&?LC^+G/QC^"FKZS\4?#7Q%\;>)O#_ (HN?#/PO\&7
M/_"*V7Q9^UOV$/"'[2'@7X/^)?"_[2?C+Q%\1M2TKXN>.[7X0_$#XD:5X"T?
MX[>,/@#:R:9:?"_5OVA8OA;;6/P^U#XLQ65OJ&DSZ]H.F:)J?B/P/IO@?7?'
MWAOPM\3M0\;>&M(^PM0UW1=)O="T[5-5T_3[_P 4:I/HGARSO+N&WN==UBVT
M75_$EQIFE0RNLE_?0>'_  _KFM2VMLLDT>F:3J%ZR"WM)G36H6G-9)*24;+5
M1Y9*24;WMRMR6C34:DH/F3CRSRIO63;4N9_"FVX<KYFDFU**C)\UTW",H\EG
M?\+/#_[(OQM\9?"'1OV9O%GP6U'PAJ/A#_@K]X__ &WD^->OZO\ #;4O!VF_
M"?3_ /@I1\0OVZ_ _B[X:S>&_&^M^,[OQI\2?A_=Z?\  J71M7\,>%?$O@C4
M_%OC'4O%>FV_@^Q\.7GCSVFZ_9W\267_  4T\5V_A+7]*NOV<_C1X3^%O[8_
M[1GPS,EQ=7.@?M/? .;_ (4[\%O$\]@)([?2=-^/^E:1\.?&EI?1&-_^$Q_X
M)UHZV][_ ,)5XDEC_5+3?$&A:S>^(--TG6-,U/4/">KPZ!XGLK&]M[JZ\/:[
M<:#H?BJWT?68(9'DTW4YO#7B;P[K\5E=K%<2:/KFE:BL9M+^VED\\^$WP#^"
M'P%@\96WP3^$7PX^$\/Q%\;:]\2?'Z_#WP;H'A)O&OC_ ,47<E[KWC'Q5)HE
MC9R:_P"(M2GDVS:KJCW5VEK';V,,D5C:VUO$H)0<-/X<$DW?F;CAJ&$@G>UH
MJCAZ,_=LW5IPDTU)M4VW&23TG)W5E:,98BKBI\N[YG6K58IM>[3J3BFK6E\J
M?\%6?A7\5?CK_P $YOVQ?@9\#_AYJ_Q2^*_QE^ OQ!^%_@7P?H^O> O#$M[X
M@\::!>:)I]U?:[\2?%_@?PKIVD6$]TEUJEQ<:Z+Q+..4Z?8:C=".UD[74?@+
MX&\+_ GXX>(_A%^S3H7@?XT_&+X(ZCH/BC0O#6@?"/PW\5/&NM:9X(U[1_!'
M@GQ5XUT_Q1!X.U63PU=:U>Z9X;AU3XES^"O#2ZE?+I6LV&GW-S._VC143HQG
M'$0;DEB*?LIM.S4/8UZ#4=+*\,1/FOS)M0NG%.+<9<LZ,TDW1?-%.[BW[:C6
M3DNO+.A%1:LU&4];M-?AW\.OV;_VE_AKX"_X(H_%*Z^%'BBXU3]BC]GS4/V?
M_P!IO]GC3_$7PQU'QIX?B\?_ +.?P]^%]Y\4/"5U8?$23X:>,[_X2>./A=:1
M76D^&_&FH>(M8^%/Q"\;W7@6R\0>,K6S^'WB3@/$G[(?[6OP:LK7]JGX,?"*
M+XE?$'0O^"N?Q:_X*!7O['\GQ \%>&/$.H_!CXQ_LT>.?V+?&'AWP;XNU#7H
M_A3'\93X:\:ZM^T['H^K^--(\(7?BSQ'XO\ !TWBR^UNY@O=8_>W1M=T3Q%:
MSW^@:MINM65KJVNZ#<7FEWEO?VT&M^&-:O\ PYXDTB6>VDEB34=!\0Z5J>AZ
MQ9,PN--U?3K[3KR.&[M)X8]:MIRE4G.JVN:=6K6TORIU\13Q-6*BFE*$ZM-:
M3<[0E*$7;D<(A%0IQIQOR1I4J+UO)QH4:F'IMR=Y1G&G4:<H<K<HQE)7YXU/
MPH^-_P .?VJ)_B_^RY^V/HO_  3XLOB!X7LM,_:I^%OQG_8R\,_$SX"^'_CO
MX#\/_M$^+OV>OB-X:^/J:_J?C[P[^SQXY^+T?CC]G6:'XNZ3H_QK^RIHOQ,T
M*+1?%/C:Z\'^(/%-US/QC_9$^-.E^'O!7B+]CG]F7Q%^Q?\ M)^ ?@!IVG_"
M-O@-XE^!-[^QMXJ'BKXH_%[Q==_L2?M??!'5?$FFZ-XD^''@R'Q/-XX\<_%G
MP9X!%WH7B+XJ?$C7?V<_'U]XV=/ _P 0/W]HI+2UE\,U*.LKQ2:ER)WO*+ES
MZ34TH5:M*,%3GRP;3=[N[<'&6D;2NFN9Q<;*5FM8N+<H4ZCG[2/-+\?)?@)\
M<O#G[>%C\;?V>_"/QI^#F@^/OVAI9/VOO!'CGQE\-/'/[(/QZ^%VC_ W6_"N
ME?M-_#?PNWB[7_B#\&/VA+B[T;X4?#II/ 6B_#C5_&&I^%M2_P"%L?#WQ?X#
MGA^,-]X#^Q3\&/VO-'_:(_8-^*GQJ_9(\>?"BZ^'O[+?[;GP(^/IT+QU^SE9
M? [X:?$?XE?$C]D/QMX''P.^"_PX^-%YH_@G]FBXL/@QXT\'?#.Y\%^"[GXR
MZW::;X5U7X_:!JNNS:E\5]<_<;XC>-YOA]X=M?$$'@CQU\07N?%W@#PH?#_P
MZT>QUSQ%;1^//'7AWP/+XJNK'4=6T6WC\(^!H_$+^-/'^J+>O<Z)X%T'Q%K5
MGI^JW5A%IEWY5^TS^U5\)_V4_@M\:_CI\1[G7M8\,? #P./B%\1] ^'^CGQ?
MXWTSPW)'>RVMTOAVVN;8VZ7D.FZA<17>KWFE:7#9V-Y?WVHVEC;37**$N115
MT^1J";5I7:LHW7*U!+$*T4G"+G%1E33]D*<%-N_,G+WK)NUT[WM9ISO2:NVI
M2C!\T9M.H_G;]OKX:_%_XA^.O^">FK_"OX3>)OB=IGP7_;O\'?&KXJW7A[Q'
M\+M '@OX;:5\"OV@/AQ?^(;F'XC_ !"\#7.NO!X@^*'AR4Z/X3A\0:W+IEOJ
MUS!ITL]M:VE[XY!^R[\;_BBG_!<'X9:OX4\2_!#3_P!N#7[S2_@%\9]4UWX>
M:OIVHZ3XD_X)W? ?]E%O&FGZ;X ^(/B+QWH-SX2^)'PS\2ZXNG>+M!\(:G/H
M4^@:AI?F7][J5EH_Z/\ Q^^-?@W]FWX'_%W]H/XB0>(9_ /P3^'7C#XH^-D\
M*Z)<>(O$2^$_ VAWOB+Q!/I6BVS1RW]Q:Z5I]W<^69H((XHI)[JYMK:*:>/T
M/PWKMGXH\.Z!XFT^.XBL/$6BZ5KMC%>)''=QV>KV,&H6T=U'#+/%'<)#<(LZ
M13S1I*'5)9% =FKNE5I;PFJL)O6Z^LPI)I.UKJ.%O!<LUK-S4O=BU:*K4JE[
M5*;I5*:OH_JU2JTVM+KGQ5I^]%_!RM:R/R3^&WP/^/'Q3^)O_!-'XN_$OX(:
M[\"O$W["WP7^->E?%C1F\2_#?6K?QA\0O'OP;\'_  :_X5)\++_PIXSU6T\2
M?"S7[[3I_BY8^+?$,OA"T@C\&?";2]=T+2?&\OC/P[\-?G']D[]E7]JGX<_#
M_P#X(4^&_''[.'C#0=5_9"N_CVG[2+3>.OV?M2A^$Z>+/V=?C#\*O#E]=S:'
M\9=6;Q=!XB\3>-=%GMQ\,U\;7EKH\EU=Z];:3=0-8M_0;<SI:V\]RZ32);0R
MSM';02W5PZQ(SLEO;0))/<3N%*Q001O--(5CC1G8*?$/V;_VB/ '[4WP'^'W
M[17PRM_$\'P^^)FAW?B+PS#XJT&;1?%/]F6FIZCI1;4O#D<U_>6%Y--ID\L>
MF2,VI1QR0PW5K;WWFV<5^TG*4ZC:E+VGUBI*WVZM?$5)R:V2JU:U5*,=(\J4
M.75R<8Q@H1BN6*I/#TUNE"-"E344VKN5.C3@U*3YG\4K[+P/_@G9\._BC\+_
M ()?$SPY\7/AQX@^&/B36_VS/V\?BOH^B^(M<^'GB"ZU'P#\>_VR/C=\=?AS
MKT-[\-O''CW1[<:CX'^(^@C4M+U'4[+6])UV#5M.N]-$%M:7]_X-H7[/'B31
M/^"F?Q/TWPGK6AG]FCQ]H?PL_;I^+_PXBF4:GH7[6VBZ=XM_9U\%7]QH']E0
MZ5/\/OC;X8\"^&_B]'<0ZA<:MX?^/O['_P#PF$L O?B!=WP^M_@Y^V%X'^/G
MPM^"?QB^%GP]^,OB3P3\;?BIXZ^%EE<'P3::=J7PYF^'FJ?%K0/$'C?XLZ5J
M.OVMYX-\"+XF^$.I>%[;4%CU37E\0^+? VF7WARQFU?4#HWK'P<^ /P._9XT
M+7_#'P&^$/PV^#?AWQ5XQU_XA>)]%^&?@SP_X*TWQ#XY\4S13:_XMUNT\/V%
MA%JFOZF+>SM9M3O5FNDTW3],TJ&2+3-,T^TMHCHZ<EM"C&G!JS4E&AAX0YKI
M^[R1H8B,HM/VT:4H6BI.)9.,H+6]24G=?#>M7E/E:M[RDZU"S37LW44TWRI_
MCD_['O[2OB']F/XE?L%:_P""=<TV]/\ P4G3]I?P'^U98^+/"=SX2U?X)>)/
M^"C.F_\ !175_B-+=1:[;?$;P[\:_"6F:CXJ^"<7A)_ <CZG\8;'PUKECJ5S
M\&M8USXC>'N5^(/[//[7>GZA^U!\+/#O[+/C?QQI/B3_ (+!?L<_M^>$/BIH
MOQ(^ >D^!O&OP)\$_'']BOXE>/=%\-67BSXKZ#XY@^+?@JV^#7Q%L]5\(>-O
M"/@GPKJ-CX>_M3PU\0M<O];\(^'/$G]"=>$_M.?M#^ _V3?@!\6OVDOBA9^*
M[[X>_!?P1K?C_P 8V_@CP]/XH\3GP]X?M6O=3FTS1H9K5)VMK6.2XN)[V]L-
M-LK:*:\U&_LK.":XCAQBH1@[<D5"+NW>7(\#"#E)MR<G]3P\6^9N3G-O6:Y=
M%S.=X_&Y3<;):.I];<E%))6OBJSC%JT;12TB^;YD_9@^&GQ9\'_MN?\ !2?X
M@>-/A1XB\)?#KXU>._V<=?\ A'\0]2U_X8ZEH_Q#TKP!^SMX0^&GBA=.T?PM
MX^\0^/M!DT?Q3X?U%1!X\\'^$EN[*[M[S2C>^=<I!-\:_AK\5]<_X*/_ +#/
MQ>\._"OQ%XD^$7PO^ _[:O@3XC?$JPU_X9V>C>!?$_QKU3]F'4? $&H>'_$/
MCW1/B'J\.HV_P:\76EY>^"_!?B>/3+C4-"CO&BM;W4;G3/LQ?'<Q^*4GPR_X
M03Q^+>/P!#X[_P"%FG1; ?"V2:;Q%<>'_P#A!(_$7]KG4V\?PI!_PD$VBG01
M8)X=G@OAJ[7#M9+QW[2O[0'@C]E7X!?%[]H_XE67BO4/A_\ !/P!XE^)/C.U
M\$:!-XG\4'PUX3TRXUC6IM+T>*:UCGDM=/M9[F::]O=/TVSMXI;S4M0L;*">
MYBOGY%3FVE&E#EN[I.*6(IMR=[IWQ$[VMJH63BVYY^S4_:02;=6ISM)ZJ4I8
M>I:/E^XA9.]DYIM/2/Y+?"/]GCXZ_#S]I7XN?"7XJ?L$^"OV@?A[XI_;<\5?
MM:_ C]MOQ!XT^#][X"^'7A7Q]\4'^.\]G\1?A[XG\4S_ !MTSXW?L^>*K[5?
M"WP*U+X?_#;Q'HWB.^MOAT\WBKX9:%HGBCQMI-OX4?LN?M$>'/B%\5="^$7@
MSXP_!?\ 9N^./P%_:X_X6;^S=^T#XY^%_P 1OAW\&/VE_B-K_A&7P3J7[)/C
M;PMXI\<^//"WPR^+^IZG\3_B%XP^'JZS'\*?#VG76A74'P^^$/C\3_#NS_<Q
M6W*&"MRH8 XSR,XZ[<]C\V,]\<U\F6O[8G@:/Q%^R%X*\5_#WXS_  Z\>?MG
M6'BZZ^'W@GQWX&@TK7? =_X&^%NJ_%OQ+X:^,$UCKFJ:%X/\56'AS1KZQ&@Z
M?K/B*]GUR*2W@233K6^U2TSE34X2I2_Y>4)X6=DDYPJ4J]%)I1492A34W#W=
M*E&-?W:B<JMQG[\:T7M4CB([M1<:E*NY)_%&,IN+E[R3A6G2:E"25/\ -CX!
M?!+]J*PO/^"'5QXO_98^)/@V+]DOX ?$OX1?M#RZUXZ_9OU+_A5?B'_AFGP'
M\'-$UN]C\-?'/7KKQ1H7BOQ-X7U:?0I_AM;^--:MO#EW97?BO1_#%]=7FCV?
M-_M!_LH?MC^+_'7_  4Z\>_"7X/*WB36OVEO^"9G[57[+]AXZ^(OPYT#P-^T
MY??L+S? SXC>)_A=+J7A_P 7^*/$WP]D\5^)O@]>>$-#U?XG^$_!>EVWB'4/
M#6OSWL.@6^HZOIG[6>&_BSI>KV7C+4O$OAOQ=\+-/\(_$^Z^%UO>_%*QTGPQ
M:^-+\ZOHGA_P[XH\#SPZUJ<>L^$/'>NZ_I^B^!KVZ;3=7U_5I/[/31(+N2VB
MG]4SGI[C\C@_K6M2<JLI3DXJ4YUZ]X])XNK0Q,Y<MVN7GHQ<:<KQY)SIS4EH
MLZ<(THJG&_*HX>FTWJX82%6A35]&GRU'&4XZN<(5(24[M_C?^T-H7[2O[1?[
M*?B_QYI_[#OB+X3_ !('[4?_  3_ /C?'\ I/&/[/&H?M'?$[P_^S!^UO^SM
M\8?B=K?B;QAX?^+"_ J7Q WPV^'&JZ%\)_"VN_&$ZE+IOA'3X/$&O^'=1\4V
M/@KPEY%XA^ 'QT'[3_[6'AWXC?\ !.;PG^UA\#/VU?B#\'_C[\/_ (H?$CQQ
M\!]3\*_ 3Q/!\$/@'\&_&?PF_:J^&OBSQE_;6LZ+\)]>^ &@?$[P;JGP+T7X
MWQ:Z=7L](T*\MM7TAM9TC][:*F,5&;G%)7DI.-Y<KY:5.FDM;QUHTZBE%J<)
MQ?(XJ<[MQNFFVVX\G-I>RJ3FM+6?\2I!IIQG&2YTW&-OYO?C7^SE^VUI7PG_
M ."@_P"S#I'[+WCGXYGXY_MZ^"?VR/@K\=O"GQ#_ &?M&\%^(_AMJ'[0W[.7
MQ8U;X9>-;;XE_&/P=\0O#OQ-^$'A_P"'?B#P'X723P5>>"==\+^%_ XL?&&D
MP"[&D_LY^V+\/M-^+W[-OC+P%K_P3\=?''3O%.I_#&._^&GP[^(7A_X6_$VQ
M%K\4?!&JCX@>!?B'JOCKP%I?AGQW\#IK)/C+X7U#3?'VA:Q)XA^'UC:^$M6;
MQ%<Z.LWU-11;W%!VDDJ:N[IM4J2HTT^5QM:E&";CR2<H1FG&=V-K]XZBNFU-
M65K+VE5UIV4E*]ZDINTN9<LY0:E"R/P=TWX(_MP>$],_9#\0^.?#OQ=_:PTS
M]FG_ (*<Z_\ $3P;K.O3_LZ>%?VK/$'['GB3]@OX\?LZ^#_'/QY,_COX6?"G
MQ=\1?!?Q@^,?]C:MK&GZOIGQ'\2? O1_"?C?Q?X*MOBC'XS\(66-XX_8K_:0
M\9_LZ?MY?L):YX#U6ZM?VCOVY?%OQ]^$7[3>G^(O!C>#=#^$GQK_ &C?!?[1
MFH>*=7@O/%J?$70_B[^RYJ<>O^%/"?A0>#WM?%=[X0^$FI>!_$0T"\\:WOPL
M_?NL;5?$.AZ'<Z'9:OJMCI][XFU.XT3PY975Q''>Z_K-IH.M^*;G2-$M"?M&
MJZG#X<\-Z_KCV%C'/=#2M&U.]$1@LIW1Q<HNZ>KDIRO=N<HSP=5-M)._M<!1
MJ-QLY/VL9*4)-1GEBN9M)-I13V4;PQ=+W4VXZT\;5II24DOW;C:4;2_(;X7^
M"/VM_@M^TO\ M3_!;6/V3=.^//P-_:._:WT3]K#X5?M8:QX^^$G_  K?X6Z?
MJGA_X4OX@\-?&CX7>)O$L/QFN?B1\ O&/PKMM3^ US\./"/B_2O'BW'PNTR7
MQ=\%;;PGXE\8^$?G[]G+X"_MP?LW_M;_ !:_:6LOV=_B)XV\ ?'']M']I;P3
MX[^#>H^._P!E^YUCP=^SW\4]2T;XA_#;]L?X(:MJ7QHM;3PHMWXS\*67@3]I
M3X1W7BO3?'WQ9\%K\'/%:?#^;Q%^SUX?TKQ!^S?[-?[1/@/]JGX2V'QG^&MG
MXKT_PEJ/C3XN^ H;/QMH,GACQ+!KWP4^+WCOX)>,TU#09KBYNM-C_P"$S^'G
MB Z=#>M!J#Z4;&?4;#3+Z6XTZU]XI4_=4'%J5J,*2;NU.E:BXI[)ITHTH*25
MW'DFFJD8253C=S3O%NI*;2]UQJ7J<UMVOWLIS<6[<W-%IPE*+_/_ /X*#_!K
MXO?%/PC^S7XW^#&C7/C/Q/\ LR_MA_!#]I76_A'::OX=T+4_C'X$\%IXJ\*>
M.? >A:KXP\0>&/!$'C*P\/\ CR\^(7P^A\9^)O#WA/4/B#X$\+Z;K'B;PS:W
MA\2:3\ ?M<?L<_'_ .*WPS_X*Y_$_P"&?P:\4:QXQ_;>^&_[*WPN^%/P)/B/
MX5>'O%/B5O@-H^K6^L?%;Q3=>,?B'X;^'_A74/%MOX^?PC<:-X@\70>)(?!W
MP@\,RZE:)J.HV?A?3/W_ **$FG>^JDYQVM&4OJO,TM%)26#H*T^9*TG&W-[K
M>J<7M*FJ<[:.4$\0XJ^K@T\56M*'*VG%-^[[U+3KF>]T^QO+FPO-)N+NTMKF
M?2M0>PDO],FN(DEDTZ^DTJ^U/2Y+RS=VMKE]-U+4+!YHW:ROKNW,5Q)_.O\
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M2!I8BT4C1.3&9(V,;E2R$J0:FHHH_K^KZ_?KW+6B2\E^7EI]V@4444 %%%%
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M!QN^9N_,KZ)QR].R;<M9X.M/XEKB'HOWGM/YTOV)/&WQ&U'3O^"$_P 3-?\
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M)5/>5U?6\82<9\VDJEII-IR/YB?V7O%OPE^%W[./[-GPFC^)?Q#TGQ;\4_\
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MZ\T;6_\ @JQ^UQ\(?&=[X:^+7B&[TGXF^"[G3/\ @IYXY_L'XI1:%XA7P_\
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M23Q%\./ GQM_:'^)GP&^.G[#/C/XL_M#>&O'WQQ^)?Q+TSX??&]OC;X*\+_
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MQSXDAA,NIWOA[PSJ.CZ+)<>(+_2XI_C/XT_M8_'70_#/_!2#]G76+[P3X/\
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M$;P=\;_#NK_%[]H*P\3_ !<_;#T3]NWPI\5= \0?#70/B-^SS^T;X8\*>#O
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ME1-.2;YW"@X2<E%*7+.%9-I1NJBM&SM3\=_9J_X*&?M+?%F]_8=\8_$7X4_
M[P[\*_VP_CQ^U=^S%<:5X*\8>/-:\>^!/B+\ =+_ &J_'/ACQQ;ZMKGA_1]!
M\0>"?$7A?]E/Q;X0U?PW)HFD:[!K>M>'?'MOKUI9W^I?#;0?"/$'[47Q=L/A
MMK]U\!/ W[/?[*WB'6O^"[?A7]E7XK/X"^']]XKA^)VF:K\<_A_HWBWXG>(M
M3TC5_@\^I_$KXL/%8K\5_$.M:+JFH^(/!UUK/@RTOK'6Y=+^(^F?H!\+_P#@
MFY\//A3X7_9,\)Z)\</C_J^G?L>?M _&3]I'P#-X@F^!DE[XQ\<_'+2/CKH'
MC+2_B-)HWP+T2WO/"EOHG[1_Q9TW0K#P7;>!]6LH]<L;J[US4-1T+1[VSR=4
M_P""8WPWO_AU\1O =K\<_P!H#3-2\=_MPV/_  4!T;XA6\_P1F\8?##XYZ=X
M]\-_$&SL? MG<?!&3P-J/@*VU+PW%IT6@_$OP;\0]3DTK4;^.]U^\NQ8W=EE
M#FNG.UDZ-[64G%5,JG54FK*5W3S*R>C@Z2Y>9TI0<E[LTGJ^;E>MDW3S.$79
MZJSGE[35I)JH[Z58SKZ9^V[X@O?VZ]2_8WUG6?A=\.?%?A_Q+HD.B?#GXH^%
M_'?@SQ_^TS\&[GX Z=\2/$7[0W[+'CO5/$$7P[^(UAX/^*NJ:O\ "[QG\&_#
MECXV\7> ]%^&/COQSXR\6:3]O\/^'V_3+J!GKP>.QKXX\9?L<:)\2_B!X'\6
M_%#XJ_$?XC^&/AG\=O"/[27P[^'WBFS^'3:?X&^*G@;P#+X$\/-X5\5Z/X%T
MCQSI7@_[7>ZS\0M6\/KXAEU/5/&^NZSH[>)8/@WJFI?"*]^D?A_X4U[P=HE[
MI7B/XC>+OBA?W7BCQ=KUOXB\:6'@?3M6T[2/$?B74];T7P;:0?#_ ,(>"=$?
M0/ ^E7UIX4\.W5[I-WXDO-&TFSNO$VNZ]K<M[JES2^%7^*\K[6>L4K62L_B;
MCK%**Y9+G]E2+/FO;W7&"2O=Q:4^9MOXM5#WE:3<FG%J#J5/Q#_: _98_9N\
M"_\ !3__ (),_#7PY\#/A1;>"M=^$'_!2";Q7HEQX!\*WUMXYU3P_P"#_P!F
M^^TSQ#X]^V:5,WC;Q1#JFKZUK,GB7Q.=4UN?6]<US5YKY]1UC4;BYS?B7X)\
M0_LQ?\%"O'H_8S^'?P4\/>(?A]_P2 MYO#.G?$1-?T[P+IGA7X9_M'>,-8\*
M^!6L/!%I#X@O-$MM/A'@#PE;0:QI6G_#GP]<6VKVUMXCM/#%GX%\0_JG\3_V
M1?"_Q4_:D_9L_:PU3XF?%30/&/[+VA_&+P[X&\$>&Y/AFGPY\0Z7\=-*\*:1
MX^B\;6VO_#/Q!XXO9+BW\$^&Y=,F\.>._"\FFW%@YC9X;N\AGSO'W[&GA;Q_
M\?O''[0]Q\5_B]X>\4>._P!E?5_V2;SPOX>/PF;P5H_@?6/$^I^+I/&.BV_B
M/X3^(?%'_"P[35]5N#:7.M>*M9\$FV2&"]\#7FV1Y(DJBI)4K1J0IXY0VY5.
MI0JPPB>EG!5'2YHM<L:?,I+E]T2C%U92J>]3E5P$I+6[A2JTI8JUG=2E351I
MW3G*SOS<K7R%;_\ !1KXM_''P-HVH_LE? T^*_B;<?L*?LR_MQ'X>>)+?_A(
M+'Q!+^U;H7Q8UWX1?L^#Q=:^,?AY:_#_ %?7[CX+>*O#^M_&G6].\3^'O!DN
MN>&=?;X<>*;*/7--T_[/_:"_:"\=?!S]B'XP?M2VWPLBT_XA_##]F/QK\?+G
MX,_$+Q39Z<=(\0>#/AE?_$'5_AYXJ\5^"+?QMIK:AHL^GWF@:CJ'A<:YI-_J
M-H_]EZHVGW,6K1_*J_\ !)KP!X:?]FO5_@S^U-^UU\ ?'?[.?[,/@O\ 8TN/
MB1\+_%OP@7Q+\;_V<OAU"%\ ^#/C+H/B_P""OBOX9:CKW@>ZN->U#P=\0?!'
MP_\  WC3PY>^,?%MQINKQ3:C8R:7]!_MP?#/5-2_X)Y_M8?!?X4>$]<\4Z]K
MO['OQK^#OPO\#Z4VI>(-=U_7_$7P>\0^ ? 7AB&]U2]GO;JXU+5;_2-,N=>\
M0ZO%;6J2S:WXFURSL;?4=6ANN_W>)=)6DWB94E9N22^M.A&#;EI*$L+%PGS3
M52G/WN67/4O#1O6PJKR]QO"PKNZ4-986.(E)\JLU)8F:FK1]G.%XWCR0^7?!
MW[='[5>D_&SP?\,/C5\%/@;IVD_M)?LB?$_]IW]E35? WQ+\<S3VWB'X&Z?\
M+;CX@_"'X\3ZAX#U.'2KW6=/^+_A#QAH?C/P-8:MI.BVT/B;P4FF^-KO1++Q
MCK_+?L^_\% ?VG?BMX2_8/D\=>#/V=_!?C+_ (*3?"[P1\7O@+#X4U+XF>-K
M+X6_#[2?V6+'X[?&KQ)\5M&UJ'P&?%VJP>+=:\#>$O W@GP?XNT)K.Q^(LMU
MK'C#7H_AO?:GXW^EO@9^R1#JG@;X3?$#XD^/_B_J?Q6\-?LC2_LW^!M4\7Z)
M\/- \6_!#PU\1-*\ W7Q@EL-"MOAY:^&M8^)7B[Q%\-/AU#XC\1>,O#GB;PY
M#9?##PO:>"_#.AZ=K?Q#NOB-;T?_ ()W?#/PM\%OV*_A5X5^(_Q2TWQ3_P $
M^['PKI?[,WQPO_\ A6VI?$_1="\+_#2\^#-UX0\:Q6_PZTOP)XP\%^._A+>S
M_#[XB:/'X,T/4=:TM;'Q/H6N>%_B=H/ACX@:%K54(UZB@KTE5G!*Z:=/ZWCD
MI0DM7*-!X/WU)^UC&2A:;<Y94G*5"$I7]K*G3GJFDI_5<*Y*2DKI2K_6+1<4
MX2E>:Y$H1_.']J'X]:Y^T3X=_9WM/&'PL\(V?[17[''_  6]^ '[.VOVSZA+
M9^"-;\;:;H%EXY\*_$3P)XCNM*\4>)_!7@WXL?![XM?#WQ7JNC7&F^)=?\!7
MVM^(? +7_P 1?^$5L_%OB?T[XP?MI>.-9_8V_:[E^/W[._[-_P :_%W[*W[>
MOP;_ &3OB-X0UVWUC4O@5\0;7Q-\4/V4_%_P[^+VC^!O&>B^,M2MO$/@S1OV
MAOAOXFM_!.N:W?1Z9\3O E]K.C>/88+?12GVOXH_X)X_"[Q1I/@^U/Q'^+GA
M[Q#H/[97AO\ ;J\8>-_#L_PO_P"$F^+OQO\ "B6VGZ+#\0_^$D^%WB715\$V
M'A;2?"O@.RT;P1H_@S6;'P5X*\*:/9^)89["[O[_ )KQQ_P3.^&7CSX=_M5_
M#;4OC7\?]-TK]KO]J#X?_M9>/]5TBY^"":WX5^(?PUE^"#^'-"^'[:E\#=3T
M>S\$-!^SS\,;34M/\7:-XS\07D&EZC(/$T-YK.H7<N5-R@Z?,XNU2-2I*-U[
MZ_LA3G3LU*/.L/C5+E<6_<E'V;G1]C4HQ;JO5J5-PIJZYE'ES51A-R3C+EEB
M,')-J5DIJ2GR5%6_/;Q]\0/VCOV=?VW?^"Q/QH_9,^#GP'^(6H?#[X1?L0_&
MWXO^$_B5XP\3_#O6/B;X>\"?"/X\ZOKO@WX?ZAX,\#^)K2+XJ>,/#>BWUGH'
MCSQ[,_AO0M7TKPUHVJ^']=TO7]1UWP1]A>$OVF=+^-'[8GA>[^%7PA^#6@ZM
M\5?^"5%I^TM\'/VGO&G@V3Q+\:K;POXX^)'AFX\-_"KQQHNF2>#=8@^%.F:K
MK.D^.-=^'^B_%P1^)O$<;/#JGA*_L(M6N_>_'_[!7@GQ[\2?VC?'K_%/XL^'
M=*_:\^%'@'X,_M'>!= O?!MII'C7P;\/-,\7^'K&3PUXE/@YOB!\-_$'B7P?
MX[\3>"?%FM^#_%MC/'H-]'J_@*/P#\1+*Q\>6W?V/[(7P^TK]IW2/VGM'\2>
M,]&U#0?V9C^RCH_P>T>W^'>F?!?3/AFOC.P\;6]SIVDV7P^@\>Z?X@L;_3;+
M2[!+'XB6_A6ST.!+*#PJDRK=B9*3HJ$7:I&E.$)7LZ<GA\SA%W2=X>VKX*<+
M+FBH5U)2@W3EK)Q=24^5\KE3ERJUI6JY;*7-%_:]G0QJDV^63E2Y;2M./YQ?
MLV?M&?%+QE\&/^"#?C;X]^$/@M\<O'7[8.G:!XBOOC'K?A6[T;X@_![QIXF_
MX)M?&7]H"Y\3_#[2;R3Q;8+XR\51^$?&7@?QIXYT3Q)X#L5\)^+]0\.Z)\.X
M=*UBX72?5/#W_!1_QAK?PU_9M_:SM?!?A75OV3OVF?VJ='_9?T72=*BUB#XM
M^ ]+^)7QS\1?L[? GX\ZMXBO=:/ACQ5H?CWXCZ=X&_X3#X40^"_"6M_#?PW\
M4SJD7C[QIJ?PTO\ 0?''KOPJ_P""</A'X6>"/V$O 4?[0O[0OB_1O^">'B>X
MUGX#2>)H_@!#>:EX=@^!/C#]FCPM\/\ XBS>&?@+X>'B#PUX0^"_COQ/X:T_
M4M$7POXUU;5-4E\3^)?%>LZS::1-I?0>!O\ @GE\)? 5IX?\#Z;XJ\<W_P
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M]L_X2?'[4M1M;C3#\'?AM\6?VV?&_P /?#'Q-\/6^G:MHVCIH'AKXBZWX/\
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MM;74-!\#:9XQMKBZL_%]K;:;\=_\%<-*M+[]DWP;J?\ PCNB>(M>\,_MT_\
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MK\?O"FI_M-?M/31?M%?M,_LX_M<>,];6;]GB37]/^-O[-,'P E\+^(= FO\
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ME/$/[,7Q._8*U[P1KVF:H_\ P4G7]I;P%^U38>*/"MQX0U;X)>)_^"C.F?\
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M4,VN6EG)H;ZUI_Q+GL/"UMX:@U&7Q'K-QK&@7^AZ5J6D^(=#U#4.VTW]K+X
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M!_\ :R\%^/OB#\4?C+\3_P!HWP,_QMT+2?@-H&FZ+I7A3Q+\3_B%\#=<^/\
MX0\'^/="EL_BI\9O@9X?LM?\70_L_?#[XB^$=!^(^G>.;WQC)X#\,11ZRUW]
MO'X5?%CXF^./^">NJ?#'X;ZWX_TSX.?M\> _C+\5+[2->^'NB)X'^&>D_!#X
M^_#_ %/Q7>P>.O&OA"\UR&SU_P")'AP2Z/X-M_$OB>;3_P"T;FRT.[>U2WN-
M$DITUHXNI33>C24O9\]U+1."J7DIZ1<91;DX\S5[PF]5)4ZLDM;N454Y$N75
MJ<J:C%QUDIQDE%2LO2U_X* ?L9OX[M?AM#^T/\/KSQ?<_&S_ (9P>RL+R_O]
M,TWXZ2V&E7VF_"[7O$UE87'A?PWXL\12ZUI^A>$;#Q!K.F#QEXR>Z\">%)-9
M\::=J.@VGHGB_P#:F_9^\ ^/=#^&OC'XG:'X?\5>(/'OAKX46)O[?5U\,6OQ
M9\:Z-:>(? _PFU[Q['ITG@/PM\5?'6B:GHFI^!OAKXG\2:1XW\96OB3PI)X9
MT'5?^$K\.#5/R)\0?LV?M2O\/_VU],M/V;O'>HZQ\4O^"V'[(O[6OP[L[7QS
M^SU%=>*/V?/@M\8_V!/&OC/XD6ESJ'QLLK'2$A\._LS?$.+1_"WB6^T'Q]?W
M$_ABS/A6UCU*\DTOUWX,>!_VM?@U^T'^TC\!O%G[)-C\</@M\;?VSKK]K3X0
M_M::QXV^$,WPO^'7AGQ5=^"?&VMZ%\6_AWXB\7'XV1_%[X"^+_"3Z?\  >[^
M'_@#Q5HOBV<?#**7Q7\)]'\)^)/&7A_*FW-1YDXR<8/5M)R=+#5)P]Y1Y'#V
MF(2<G:4J/(_?O&3DVI25FXQ<E>ZV53$TXR25^=/V=!M1U2K<Z]RTH_1GP?\
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MW4_8F^"G[0/[/OQ)O9_!WPV^/?@C]DB[_9X\9Z]+^Q]\;/%OP-^)'B7]FO\
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M/[9?P]T3]L?PYX/_ &4]8^(5OXN_X*Q?#K]J?1_$MEJ/[,VOZYXM_9S\0_\
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M\%V+30/@/XLU&W_:P_9A\&?#G]FK4QXS^"5K8_&+Q?:_LH>._A-J6DZ1'?\
MQ6MM2\&IIGC/Q!IUG=7_ ,6-/^'VFSVKS7^FW>H6L1D)-\JG*/O_ .RXB<%9
MKGJ?5Z-2BK/WH3E4<H1A)\\).<)<TH2D[I)3<8U'[/FQ.&A*3U]G3>)J4ZTK
MVM.$*-JDI)<LX1C**CS**_0OQ!^V5^SS\+-$\'1_%KXW^#;?6-2^'/P\^(7B
M3Q'IGASQ1IGA;0O!WQ"U%?"_A7XL>/K:$^+XO@)\*?'OBZUUK3?!WB7XP>*=
M)\.376B>)-%A\7ZS>^#O$]U8_*'C'_@I=\/?V=?VR_VK?@Y^UW\8?@S\)/@I
M\-/AI^QIXQ^#GB+4M(\1>'_$7]H_M :W^T9X<^((^(NN2^)?%&EWOA;PSJGP
MH\%SOX^C\.?#_P '>!;3Q9:V?C74/,U'3=4NO@/]M3]FW]MKXO?!'X]_ [P[
M^R5XTU*+XB?\$IO@=\+?A?XB\ >._P!G3P1<77Q\\!P_&8_$+X2_M3>.H?BW
MH_Q*\8CP%'XKT&#]G;X<^&+KXA?LQZCKGQ3^+NN^*]3?5-3_ .$H\!_97C_X
M3?':Z_:-_;^\:_\ #+WB+QYX0_;5_8$_9A^#_@#1M=\2_")?"]M\2OA_'^V#
MI_Q ^$OQVEC\?:M-X7TRRT_X^^%KO6_$_AW2?B#X)U?0+/Q;8^$=8\6^+(_#
M_A+Q.5VXU*SI0E44*F,5.%X0590AB'04>5\L/:3HQA2DWR+V\9-<OLXAAE&5
M&'MI1A.='"2E\4I493GAE6OS+FFZ<*U252-G*U"2NY.<C] +GXQ:3??M.:+\
M%M!^.WPE.M:A^SKXO^*B? A?"6HZ[\4KRTM_'?@'PYHGQM?QMI_Q#M-'T[X6
MZ2WB"3PK+X+N? D>K>,]<\26>MZ)\0+&Q\+ZKI-S\9_LR_MJ>./BS^RQ^Q#\
M5OC#\:/V?O@[\6/VA?CYXF^'FK^')/AIXKU+2/C6OAKQM\9/#,_PL^!_AF?X
MQ6WB3P+XPU/2O!NC>)X/&^OZW\5],\+:5X?U_P#M[PKJ\6L0ZGHW,? ']DOX
MR?L]?M9_L/V8\+^)_B-\(?V7_P#@D?X@_8Y\2?'LZU\.["R\3?%?3O'/[+-S
MH5N_A/5/B"GQ(.H>*=!^!WB;6[S4QX4NO#.G7FIZ38W?B9I[B\>S^</A;^RW
M^U?HG[(/_!*3X>:W^S;XXTOQY^SW_P %$)_C+\;/"D_CW]GJZOOAU\*3KO[4
M[Q^.;_5--^-5[X7\1V,EI\5_!]Z=#\ Z_P"+_&:VUU?1MX9-[836AN,8JK.*
MESP]JH1E+5.,<SQ%'VD>9))3PD:59Q:Y%3DFDH<A,G>BI:*I[-S:49+5Y93K
M>S<4W*ZQ3G13OSJHDFW-2O\ =7B'_@HA\)?%?P8_;0\:^%_BGI_[--G^RO\
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MWW7*[_9UBXSDJD(KN****8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3;2Z)R:<FELG)I.32NVDVVTK%E=NRN[7?5VNE=[NR;M?:[M:[N4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 445^:__!5NRT[Q]^R@?V99[2UU'5/VV/B_\'?V/["P
MGL;2_N5\+_&/QMI\/QT\1Z/%=@K!KOP[_9FT3XV_$[1K^WV7NG7_ (*AOK*>
MTN8([N!.[LHVYI3A"-W9<U2I3IJ[2;27.Y-I-VA*RNT&B3;O:,9SE97?+"$Y
MNR;2;:@DKM*\E=I)M?I13))$B1Y976.*-&DDDD8)'&B#<[N[$*BJH+,S$!5!
M)( K\MOBS.OQS_X**_#;]DKQ!HMI-^S1^S7^R@_[6GQ:\&W]MIDOP_\ B'\1
M_BE\0_$GP2_9C\,>-_#UU8R:3KW@CX::'\*_VC/B/:>$]8%QX>A^)>F?"'X@
M1:=#XF^%WA;5=-_,GX;^(OB-^TK^RK_P1]^$FB_#?3/'VO?%SX^_&G]OSPAX
M0\>:I+X)\-^%?V-_V6/B3X]^,?[)=G=^-#X0\>Z]\._!FD>+OBC_ ,$^?AW9
MR>'/ WBS5/\ A6^IWGARR\.ZAI,MW'&*[:Z1E*'*W:[IRQ-7#N32?Q6P^(JQ
MBG:4:33E%RBQ-V4M8N48SO9Z>TCAZ=?D3M>R=:A3DVE*,JJ]UVDE_4%17Y/:
M_P"(_CS_ ,%)O^"='BX?#30?@?\ !_XO>)OB!\8/A!X]^''Q=N_'WQJ^ 7B[
M4/V9_P!H[Q_\%/BO\,;WQO\ #K4/@IXVU?X0?&?6OA)K&@R^.+;PVFH3?"[Q
M5?P:C\-KZ^OIM,@K?LB?M>?\$_/V=_V'/V0_%7BSQ+^S%_P3E\)?M!?"ZW^+
M'A#X&?%/XW?#3X:V=AXE\31Z=XF^*.E>$-6\=:_X7D^(=GX>\7>*O)N/%6F6
M@6_L=3T'4I['1X=6L-.B<?>YM5_RY]FEJZBK14H2CLY1DFHQY8N?.^65.*<9
M,;MRZ/5U5*Z:Y'2;4HO322:;:DU'DUC.3NC]:J*_,[]M?0M%^,_[4O\ P3?_
M &<KW0[+6Q9_'3QK^VOXODN;2UGGT;X??L;>#($\.:EIMW<6MQ+IFI1?M5?&
MW]E>Y\RUEM)K[1+'Q!8!WBEG,7Z!?$'QOX6^&7@+QM\2/'.IP:+X)^'WA'Q)
MXW\8ZS=C=:Z3X5\)Z->Z]XAU.Y!!!M['2+"\NI@>#'$PJ7)1A*I*45&+JW;?
MPQHQBYRE:[23<TU9NU-R5[\JI)N<81C)RDJ=E;>564E",=?>;2@[Z:S4=U=]
M?GZ_E32Z!UC+J)'5W2,L [)&461U7.YE1I8U=@"%,B!B"ZY_F7_8O_9/^,?C
M[]EO]@GQ1X*_9N_X9U^./C?]HKP7^WW\>?VK)Y_A-X"OM!^&?Q5^,FN_M-_$
M;]GGP-9_"_QQK/Q<\41>-/ /C;2?V5=/^&/Q$\$>$/A9IGP>_MO4/%TEKJW@
MOPMX!\3?9OPI^,6@:+^TW^V#^T+X;\&6WC?XJ?M,_M/^%OV ?V8/"6GOI_A%
M?B-H/[#WP\\6W7Q6\6^./%Z:=JH\,^#?A3\>=?\ VR+?XD_$*^TOQ!J\?A#X
M7^#_  9X.\.^.OB=K/PQ^%?B*N6:ER3C*,XJ2G&R;C4C##IPT[8FM5PS<E!N
M6%K5(Q=*+E".:+7-&2E%N+C+:,H2G7M)-VWP]*GB5R\RY<12@VJC49?L[17Y
M-^,?^"E'BOP-\)OVC_B-JWP5\&7MU\"?VU_@A^P]X9M++XQ:^=(^,GCOXJ^+
M?V?? ?B3Q7X7N['X,ZUKMC8^ /%_QWN] O/!^G>'/%WB"^UCX5_$#3)+K3FL
MH+ENH;_@H)X]TKX<?\%%?B)XD_9KG5/V$->M]'M?#O@WXE7'CS6/'DEQ\!?A
MQ^T!J&C^+DT'X<2/X+\7?#[P?\4O"L_Q6TCX9VWQ]TC1!+JUE\.O$7Q8UW19
M-&O5S+E<[I1C%3<FTDH.%*HI/FY;+DK4IZVM&7,VHIR5:W4;-R<G!))MN2E4
M@TE&[;YZ4X*RE>4>5)R:B_T\HKQ7X#?$KQ%\6O!"^.=6TSP /#>NS:1K'PM\
M;_"WXD1_%#X?_%_X6^)?!OA7Q;X4^*WA77E\/>&Y+/2/$H\07UG:Z1);ZI#&
MFCC4=,\1>(=%U/3=6NJ?QC^ /P7^+E[HOC+XI_#+P5\1]:^'?A3X@:3X,_X3
MKPYI/BW3- A\<+X7O/$=W8:+K]IJ&E1:M>-X(T&WBU@6G]I6=@FHZ?:7,-GK
M&J0W4U9>RIU9RB_W5.I4E':7[NG4J.&OPR_=N+4E[LKJ23BT.FO:RIQB_P")
M.$$[.WOSA!2[N/OWT^)+3=,]VIJ.DB+)&RNCJKHZ,&1T8!E964D,K @JP)!!
M!!P:_EJ^'O[./P(OO^#;"]^.=Q\*/ 2?%G4/^"%7QATC7/'D'A718/$/B6#Q
M-^S5IGQ#U&^\5W\%G%/XIUJ#QQ\,O!OBS2=<UV2^UC1M?TIM4TN^M+V]O9Y_
MU-^"O[2_QK/QA\9_LJ?$+X:_""\-G^P_\-OVF?@N-#\6>*5TZ^T#4-6\2_"[
M7_AG\7M9U3PEJ227?]L>'] UR'QAX3\&-IZZ-XIU70'\':E<^$X=<\6Z54J2
MK-R5Z7/NFHOV>'K8B>JO*ZA1E)147*2A4L^90C/*E4]K[%J+2JQB]US1<\12
MPT%9V33G5BG.ZBI3@FK.<H?J+!/!=00W-M-%<6UQ%'/;W$$B303P3()(IH98
MRT<L4L;*\<B,R.C!E)4@U+7X06'_  49M_@]^QI_P36\5:'X-^ ?[)7@?]J?
M]BOPQ\1_ OBCQYX1\7:1^Q;\+?BU-\*/@UXD^$/['NI>-_!EYX;\-?L]Z;\1
M;;Q[XHC\ ?$3XA:A:^';'0?A)JWA_P ->#O'7BC58-*TC](?V\?VBO&7[)7[
M%7[2?[3_ (-\&^'/&WBKX$?!CQG\5;?P?XL\0:EX=T/5!X.T*XUS4;2YU31=
M'\07LDL-I:W,EGI\,%G%K-Y%!I<^O^'K:\DUZPENR<G?E4N2]M>;FA&UE?52
MG&ZWY9*:BX2C.5P]]P4=93CS)*^WOVWL]>25N[3C=23BOKZBOQR^(G[?W[4O
MP$^(_P"UC\*OC5\!_@Q/XG\"?L0_&7]O7]E[4_A_\3O&MQX,\:^ /@9JFF^&
M/B1\(_C#K>N> (=:T#XD>%-<\5_#G5(O$GA#PKJ/A;Q7H'CD06=EHFH>&[^6
M][;P#^V1^TIKNL?LQ?"WQ]X3^ G@KXN_MKZ-XW^+?P5N/"VI_$+XA^%/AI^S
M[\+?@G\+?&7CG7_B?I6J0?#:\\;_ !._X6M\3/"O@C3/!7@_Q3X6\/1^$O&2
M^+_^$TU.\^'NH:%XWJ*<OAL]MFG[S==<F[7.GAJZDF[+V;;E9P<R4E%I2NKI
MR5T]8+V/[Q;-P_?T;2MJYVY5*,U#]56=$P794#,J*68+N=CA5&2,LQ("J.2>
M ":9--#;H))YHH4:6&%7FD2-&FN9H[>WA#.5!EN+B6*"&,'?+-)'%&&=U4_S
MW?$S]HWQ+^TO\0O^"?>L7'PJ\#Z#^U!^RY_P6.^/G[(OCO3[[6KP>"!XQ\*?
M\$Z_VV_$0\3^#?&W_"-ZEXMM?AE\4_A]J_PC^,A\*R:2^L:;=7EE\/\ 6-0U
M75_"4/C*X]C\7?MJ^*O'/[$7B'QY\9/@!\"OB=XN^%?_  4=^%W[&'Q>\&:V
MVJZA\([WQ+X=_P""A'PO_9X\._&_X?>'?$NB>)]2N]0T36]?\!_&'PAX4\2Z
MG97O@[Q3I^Z'QKJE_P"%-/NM=(QE)0:L^>2Y4M;TY5,'",TVTFW]<@W%\J@G
M'F=O:*GG*JH2JJ7NJE'WFWM-4L75E%I)M)1P=3E:YG.TN6W[MS_;%71F=5=6
M:-@DBJP+1N460*X!)1C&Z.%;!*.K 88$L$T+326ZS1-<11132P"1#-'#</-'
M!-)$#O2*9[:X2*1E"2/;S*A8Q2!?YP[G]H;X]_L0:Y_P6'_:*^#_ ,$_@UX[
M_9S^"'_!1%?BY^TUX?N?%VO^$/B]?_#^?_@GY^P!KGQ7U[X.:!I?A"3P)/XM
M\*Z?>ZI\5=4G\:^)H_\ A8MRNO>'XH=#URYMO$5_]5_M=?M,>./A'\0_^"G^
MH_##X:?!/P;\:/V:/^"5?@#]ISX??M!:EX;F\<>-_&NE_P!L?MHZAH7PY^(-
MBL/@B[C\)^"?%'P4\6ZCX2\,1^+?$6BV>J>/K_Q9<^?)J&J>%&P5:]%U;)N%
M&I6G",HN48TZ%6OU:2C.-*:C*6[C*/*IQ<7T2ARU52NKSK0HPDTU&4IUJ=&V
MB;YHRJ1YHI62<9<SB[K]DFEB22.)Y(UEFWF*-G57E\L!I/+0D,^Q2&?:#M!!
M; (J2OR1@^+6JZ#\<?\ @E!X4^+7PT^"GQ6\9_%'X-_M!^)8/VE]=T*YMOBC
M\)=1\+_ _P )>(_$-O\ #>RUR#Q=J6@'XE>'M3T_2/B;XLM?B3;2^)8M$GMK
MGPJ++4[:/1%\)?\ !1+QWJ7A;]@G]H;7_!/@J/\ 9I_X**^./#'P]^&.F6,W
MB.V^+7P=U'XQ> ?&7Q(_9J\1?$+5!+KGA3QOIWQ3T3PC9:#\1=$T/1/!=U\$
M/'7C30]%TS6?C/X?TO6?%Z=,Z<H5:E&ZE.G7K8=\NBYZ6)J85*TO>3J5:4XQ
M4E9MQM*SYGA"HITJ=6SC&K0HXB*>LO9U</'$.5HW34*<U*36R4KJZL?K;17X
MP? O_@HE^T=X_OOV._&'Q$^%'P0\/?"G]J+]L3]L']B;4M,\%^-/'WB'Q]X.
M^(/[/>N_ME/X.\?V&IZYX5\.>'];\&ZUI7['VM>&/$6A7.DZ7K<^H^+])\>:
M?J.D6MI>_#F'[\_:2_: OOA#K7[//PQ\'Z;I.J_%K]JCXT2_!7X9?\)'+<)X
M4\-2Z%\+/B5\</B'\0/%EMI]S::QK.D^"OA5\(_&NHZ1X5T:[TR[\<^.YO!?
M@2Y\3>!-(\3ZG\0?"F7,G"G47PU7!4W=+F=14G!>\XVYHUJ<E=K26MG&26K5
MIU*;TG33<UORI>T3;LGHG2FM+WLK74HW^H%D1S(J.C-$XCE56#&-RB2A) "2
MCF*2.0*V"4D1\;64E]?S_P#[*OQFU[]FWXA_MP_#V3PI\/1\8OVF/^"VX^ 7
M@M?"MEJ.B_"FU\6^)?\ @G#^RS\;/%GQ:US16N6UZUAE^%'PP^('Q3OOAY;Z
MW>WVO?%*]L/A1)\4+:SUR?XPV/TO/_P4AU[X?ZE^T7\&?BOX(T*\_:&^ W[3
M'[+/[.FB2> TUR+P#\7-,_;.E\'3?!7XL:)H6M7%YKOA=M+L-=\;P>._A9=>
M*O$=]'K_ ,)M;TGPW\0-6M_%WAK4XR#<X1DDGS135FFG)JAS1@W9R<'B:"E:
M*:]HG:RGRD[0E*+?PO6ZUBK57&4TN904E1J\K<K/DLG[T.;]::*_(CXC?M\?
M'OX _#KQ%XL_:4^#A^#G@/0_VC/#WPPF_:WO?AOXO\4_!S0O@=XJ^#WB+XCV
M/[17Q#^ _@SQYXA^*WPX\.>&OBQHFG_LK>/X/%WQ"TSPEX6\1^*_#7Q_G^(<
MGPRN-4\,Z1^B/P=\=>*/B'\#O!?Q#>]^%/C'Q)XL\&1>)-(UGX7>-)=;^"WC
M<:C;S7?A?Q'X'\>6=KXEN;OX>^,M/?2];T;Q!!8:W=Q:'JL-T+"_N(C:R._N
MN5G:,82=E=KGBY1BTKVFTF^27+/39K53=72V<G-*^B?LY*,G=VO&[24ES1=]
MUU]FHK\2_P!FO_@IW\8/B#IW["'Q.^.?PV^$G@+X+_MP?LH_%+XZ6DW@?Q)X
MU\1^,/A3XE^#_P /_"?Q9UN3Q%+JFBV.G^(/!_B3P1KOB&WL]+T;28]?\,:O
MX4L)I]5\4Q^+Y-.\)>P_#;]O;XC:O%_P3Q^)WQ \#>#=/^!?_!2^UT^P^%\>
M@7&K1_$#X#>./&_P#\4?M,?!KPI\2;RYU/5M#^*%K\0_ACX&\:Z-XH\0>$=(
M\"VWPQ^)6DZ!H5I:?$KPIXLNO&_A)V?,HVO*4N5):OGYG%0=D[3DTU%;/1\T
M4[I*<6I-/2*3>RM%QYN:S:]U1NY/=6:Y6]_U3HK\^_\ @G!\2?CO\6O@U\2_
M%_Q[\=>#_'/B'3?VM/VVOA7I-WX1\"ZOX&MK+1?@/^V/\>?@CI%N+'4O'GC:
M(:0/#GP_\/0^'=-B>+4-'T^V:+Q#KWC37KJ_\2W?D7Q,_;\^*7PP_:@\&?"K
M7O ?@!/!7B[]M'P/^R/:^&]-U6^\6_$2+PK\1O@)_P +2\)?M#^)O'/@W6=;
M\#_"NXU?QTFH>"M$_9K^*'A?P[\1O%'@'1KKXR:+XQ?3;_3?"LBB^?V26KJQ
MIRCT7[V%*<$V]%)^VIQMK[SW44Y)IWC4ETIRJ*75VI3JQG)+1M)49SZ/E6SE
M:+_6&BOQ&T3_ (*-?M<V]A\(OC1XV_9W^"5O^S5XE_;V^(_[ 7Q3E\%?%3QE
MXA^+'@_Q?'^W#\0OV)?A9\7_  ];:WX'\+^&=7^&B?$3PYX,T?QMI6H_V?XT
MU,^+[OQ7HFDZ%INB1^']3H6__!2S]J^RT?1_CKXH_9[^!]C^R_X8_P""@_CG
M]@GXUW&A?%;QGK/Q;\/W8_;0U/\ 8K\!_&;P=8W?@/1_#FK>#-'^(,G@VX\9
MZ!J2VWB_Q#9>)=8O= TOP[:^%;/_ (2T@W4BI05T_9KSBZWL/8J:7,XNJL30
M<%:5U43?+RSY"34>9R>D5-M]&J?M_:..U^1X:NI;6=-I<SE#G_<421F1H@Z&
M5$21XPRF1(Y6D6-V3.Y4D:*548@*[12!22C8?7\_MW\4?'W[*_Q:_P""Z?Q[
M^!_PZ\)>+M2^%OQN_94^+/Q#\'75A>P3Z[\.=+_8J^!NL?&KQ-X?M= N]-N=
M6^('AWP6/$/Q#TC0S]HN?B)K'AY_!<<NGZQXMMO$6E_KK\*/C/??%WXH?$VW
M\':AX*\3_ _P5X3^$<6A^.?#TMW=ZAXD^)?Q!\+2?$_7-*@NQJ4NCW/A'2/A
M%XK^"'C3P_X@TJWOK7Q*WQ5N=/COK2;P9>_VK5KQ36ON0E/^ZYPJS7_;K5*2
MA+3FDI02YX22<O=DXRW4FHM;22=%?^!+VT>:/V5:=^246_HVBOQW_:"_;5^(
M_P"S=^V5^UGJ_P 0O%.CWW[*G[)G_!,KP[^V3J?PX\.^!;S_ (6%X@O]6\<_
MM!Z/XETNP\4W?Q$L- O_ !3>2_ ;0H?"EYJ_A^WT>QL=;OO#8L].N=3U3QE/
M]$Z#^T]\7? G[57P*_9G_:&\._#5)_VI/@Q\4?B=\*O$OPKF\5M;^#?'WP/D
M^'UY\4?@AXO3Q$;Z/QA:P>&?B3I?B/P#\:-.;P%%XS3PSXQTW6/A%X&N;;0)
M->F-Y.*6\DVHZ77O8E13WUG'"5JD=DXQLVI-1<\R7->]HM*^]URX:3DE:_+%
MXNC"3:T<KV<5*4?O^BOSE_:I^+?QS\)_MK?\$Y/@_P##CQKX2\+_  Y^-/BW
M]H^\^)^FZMX(UGQ#K?B0?"SX$:[XAT+2$UBR\?>&K*S\.22:S=ZC/IS:)=7X
M\7:/X.\0+K#:5H>J^%?$OAGA/]N3]M'QAX+_ &O?B_IOP*_9CM_AM^S%\2?V
MIO@M:Z3JW[0&K^%O$.N>,O@?\3O#/A;1/B'XJ\=?$'PGX'^%_@7X.Z#X"7QY
MX\^*FHZSK$7B",Z/::9X9LRD/VW6!.Z;6R=1.[4;>SJT*,FVVHJ+J8BDDVU9
M2<I<L8SE <DI<KW_ '=K:W=2E5K)))7;5.C4;23^&T>:4HQE^QM-#H7:,,I=
M0K,FX;U5RX1V7.X*YC<(Q&&*,!G:V/QZ\.?\%,/$=SJWQ#^$%[X9\/>(/C+8
M_MV?!_\ 8=^$OBM/"7C_ .%G@'QSJ/QC_9C\$?M;R_%'Q#\._&U]K7COPGIW
MPR^$.J?$V^;PE_PE&I0?%_4/AIX=3PUXY\%Z9\6K+4_!'AOP2^-5_P#LE?%3
M_@K5XK\7^&O!VM?$#Q9_P4L_8I^#^CZ5\-]*OO#?A3Q;\2?VE/V7?V"OA?X9
M\61Z#?7>IZII O=4^(47Q$\=^'Y->\0ZQ<:A;^*--TCQ/XGUG4-.U34[Y);M
M.*<'*-T[RDWAU&"3Y;.7UB*U5U+W;7YN6742:4;2?M%"23ORQ<<0Y3]WFNE]
M7;5G:47S)V<.;]^:*_(;XC_M[_M!_ /P#XZ\5_M%_!*Z^%7PX\*?'CP;X"7]
MKNY^&WB;Q'\)-(^"/C+X3>(/'UU\?_'_ .SWX.^(WBCXP>!O#_P[^*>AVG[-
MGQ#C\0>/-.\,Z1J'BWPO^T ?&D7PV/B/PWX>_0_X(?$#Q!\2_@GX.^(DVJ_"
M?QIJWBSP_=Z[H7B3X1^,/^$A^#?CK3+JZOW\&>*_!7C.R/B5[CP;XUT!=&\0
M66HVXUZ6QL]5*(-3DMMLT]'+=14&[.[7/'FBFEK&32;Y9*+T>]G:[ZI.ZYG)
M*ZLGR249-/9J[6J<EJF^5--^U45^%WP/_P""D?[7?QDT+_@GOXN'P9_9UT/0
M_P#@H;X5^+7AWPCI_P#PGWQ'O=2^$_Q7^'/@'QI\7;7Q3XFOO^$4M[?QE\.;
MWP/\/?&FAMX,TC3O#OBBZ\4Z=X5OY/&^BZ5XUUBR^'/NG@3]N3XV^,_V?OA/
MXNU?P?\ "3P1\1=9_:W_ &E_V/OC5XT&K:EXO^&W@3Q1^S+XZ_:2^%S^-_A9
M\([OQ)X!^,OQ\O/CA\2?@-X8\)_#WX(>!=4?XE>'4^+;^(;Z[\6:3\+]</B8
M::3;3LFD[:_%.E33TZ<U:C=[6JP>MW%%[.*>G,I25]+J*J-V^5*JO6G-:63?
MZNTR.2.52T4B2*'DC+1LKJ)(9&BEC)4D!XI4>*12=R2(R, RD#\COV=/^"B/
MC']K/PQ^R+X(\&>#? _@+XW?M*?!C]HSXU^/F\6P>)/&GP]^&7@#]F#XL^$/
M@#XXN[#PH+SX<^,O&6K?$?XJ_$'PG8^!O"FM:MX&&@>#6\<^(/%FO7&O^"-*
M\$_$#Y<_X)T_M :E\"?V+OV6O@#X1\#Z)I'Q8^-W[37_  50L- T'PMH&I?$
M#P+\,=$^#/[:O[4OB'QI<:'X6TR_^&&J_$#1=$U_4O!W@?P_HMOK7PWN;G1/
M$,_C*6>R'AB7PGK$*7-)Q3C+W4X\LDW-N:C91WLE)-M\MFI1<4XME-.*NTUJ
M[W5E&*C)MMWU?-%Q2BI)[J3O%/\ H7HKYW_9F^(?QO\ B7\$]&\4_'GX+Q_!
M'XR1:AXRT+7O 3^);/6=!U(^%_%&M:#X9\<Z#JU@=3O])\*_%#P]I^C>/=-\
M/ZY;7'BOP-:^(V\)>($U?5] N-2U/\M/A%_P4U_:K\2:-^Q;\:?BG\!O@9X9
M_9R_:[^/7B_]DJ\G\!_$?Q_XO^+?PJ^-<GC;XQ^$/A;X\O\ 1]7\#>&/"/BK
MX/>(_$OPKA^'^N:?#KOA_P :6,WB?P[\1\V46H:U\,/"-K62@M9-4VNB?M9<
ME-7:LG.=H*,N5J<HPGRRNHIZ0<W\*<XM[M.FG*>BU:C!2GS*\7"+E%R7*Y?N
MG17Y/?";_@H#\2?'?@W]AOQ7K?@3P-92_M/_ +<W[6'[%OC?3=)N]?>+P^_[
M.T?[<4FC?$CPI?WDY<IXB'[&R#4_".L6%XUM_P +#8VOB4?\(L!X@X7PW^WW
M^UYK'PZ_:?\ CWJ'[/WPL?X-_LZ_&?\ :%_9^O-$^&.L?%WXR_&ZZ\0?![]I
M_P ,_!F?XOVWP_T/P!X=;Q7\-_ 7PK3XD_%WQ[X&\+S'XF^+Y_"%EX6\#6UE
M-JBWH2=X>T6D.3VG,VHQ4/\ 9K3;=N6+^MT-96LIMRY%"HX*349^S>L^?DY8
MIR;FE7DXKEW=L/6=E>_(E'F<X1G^S=%?EI\-_P!O#7?'%S^Q3KGA'QK^SC^T
M!\(OVO/VFOB+\"O#_P 7O@;J6M_V'J'A;PS^R/\ '']I#2/&EEIESXJ\7R>$
M?%^D>+?@3XE^%/Q ^%GB74]2U?0-0N'O+C5].U#2[C1+BCX5_;G^,GC+X57W
MB.V\)?";PSJ^D_\ !0']HK]BWQ5X]UO6;ZZ\+>$?"OP0\6_&3PAX9^*&C?"*
M3Q'H/Q#^-'C_ .+GC'X;^!OAAX4_9Y^&'BRZ\</XQ^+^GZOI.J>)-"\$ZU;Z
MH+7FM]AJ,KOELW*C&WO6ZXBEUM[RLWU7,O-VY;V3?Q*O*.U]UAJVBU7+:7*W
M9?JS17XU?#S_ (*/?'/XL?#3_@GSXE\%_!SX5V7B;]L/]HS]J7]F/QHOB_QI
M\0-#TSP5XO\ V:/ _P"U[J$_BWP]H#?#Z3Q%)H'BS7_V5-3UI_#GBN?2/%'A
MG2]<L? M^EWK%Q?^-?#GG7B3]N/]J3XB_"W]CB?0=2^%WPG^(_BG_@JQ\0_V
M"?VB/[*\)^*O&WA#Q%-^S_XS_:,T2]\2_#>:?QYX-\0Z!X.\?ZG^S_H^N:IX
M8URXU77(_#WBW4? LWB4C3KKQ#KQ"2F[1=_?IP;6R=66&C%V=FTOK>';LKVJ
MJUW&:@YOV:;EHU&I+EZ_NXUY2C?5)VPU=+6UZ;O92@Y?NU17Y[?\%//B]\8_
M@9^R%JWQ ^"?BKP_X1\:R?&;]E?X<7VLZYX7O_$RKX5^./[3?PC^!WBP:'#9
M>*?#4^B:]%I'Q&N+_3=>:ZU.73Q9S0V5I;ZK=6&OZ-S7CW]KOXV7'BS]KCX?
M? CPO\-/'WCC]A#X5_"[QA\5M*\50>)O#%M\=/B=X]^'GB3XKS?!WX>W5GK^
MJ-\%()? 6D>$[[2?B7XDA^-MC%K7Q-MM%N_!]Q'X U?4_$J<E&%2I+2%-2E*
M3V4*=%8BI4T^Q3IM.6G-NXQE9H(WE.%.*;E44.175W*I6="G3U:]^=16CKR_
MS2CN?I=17S!H_P"TFOQ*_8QTO]K_ . W@._^(\?C[]F&R_:3^#/PR\3^)_#7
MPJU/QZOBKX4Q?$_X=> _$/C/Q)<WO@_X;W_BD7^C^']6\3Z_>77AOP=<7UQJ
MNJW,^EZ?/*_AG['/[8GBOX]_&G]H?X(>+8_ 7B-_@S\-_P!F3XN^&_BW\,-%
M\;>&/ OQ#\)?M+6GQ@@T^T\-Z1XVNM?'B;1O#FK_  3UV\\._&+P5XT\1_#S
MXL^%/%7A_6/#,6D/INHPW-/24HMQ4H\R:YH[POS6LWS)6=FKQE;W9-M)B=XJ
M24N5J+ORM64K)<R:3B[R2<6N9/>*2;7Z)45^<WQ8_;6\0_ C]J[Q_P#!7XL:
M)H.A_"V?]C3X@_M4_ WQUI&D:MK7BCX@:M\$M=TG1/CO\+QX??Q'IT.M^,/A
MY9>+/AIXOT30-!-OJ/Q T3XE)96$FB3^!-:U#6/#?VP_V_/VCOV/_AOXB\>^
M-_AM\&)+_P"#W[*G@#]HSXA^$=)\1>(_&6N_%WQ5)XH\3:5\>?A;\-M&\)7E
MYXT^"_@7X):1H'AF3_AJ+XL>"?%'PG\6>)_C'X!\*RV'AG4M)U])4G=1>B4F
MHJ[2]YU)4^5WM9J4;M:M1E"=G&2:'HVK-N*YFDKW7)&::L]4XRT>B;C.-^:#
M1^Q!DC$BQ%T$KH\B1EE$CQQ-&LCJF=S)&TL2NP!5&EC#$%URV&:&YABN+>6.
M>WN(HYH)X9$EAFAE0/%+%+&622.1&5TD1F1U(9200:_*?2]*33?^"S'Q^UGP
MQH&@R^*]6_X)<_L\W+_;)CH%OXCU>P_::_:=L]'B\1:]8:/K5_!;^5;6>F2Z
MJ-&UN\L-,AB6#3[Y+*VLCYU^QK^V-%\9O@Q_P3V^!GP'^$_P.^!7B/\ :)_8
M1D_:[UKP%8>$+V_^"?P#^"6C7'PL\(V'@#PA\-_#&H^ 6\27GBWQA\6;3P_X
M:LH=?\*Z!I'AOP=X[\2:T9;Z'PQX1\5O7DC))OF7172E[7%P:TU:C#"RJ-I7
M4>;F_P"7?.-VFX.VBOUO;V.&J]K)WQ,8*[]YI<OV^7]GXY8I5+Q2)*BO+$6C
M=74202/#-&2I($D,T<D4J?>CE1XV =2 _/UY]OYU^4__  1+TX:3_P $T?@'
MI9T+1_"[:=XL_:6LI?#/AZZ^W:!X=GM?VK/C?%<:'H=__9FB&_T?29TDL-,O
MVT71WO;*W@NGTK3GF:SA]/\ A'^QM\8OAIJG[+5[K?[5=S\0K7]GC5/VA;?Q
M7;Z[\%?"5E??''PK\9/)E\)ZMXOU.S\0N=&^/O@:\T^TOO%G[0&D6LNM_%NX
M\4?%YM<\,:$/BKJO]F)7;CT4J=*?-NE[2G1J6]W>RK+WDK-+F2M)123;CS):
M\U2/+L[0G6A?7NZ/PWNG*S=H\S_0G_/^?\_UHK\F?V3[M/A]^TE_P6JU;1--
MN]4_X1;]J+X4>)=/T5KV_O;C4+W_ (=N?LC^,+S3K>XNY;VZ0ZQX@U#4KLQ1
MET6^U2ZFBAWSN&^$?V?=2U+P)\#/^"!O[3VGRS^(/CA^W/\ $'PAX=_:V\7*
MEH^K?'G1?VO/V(_V@OVF_B4?B1(+<'7[#P'\8/ ?@7Q3X#M9@+;X:>'/" \
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M'P^/!VD>)+GQ;9?$8V%O\(+>[;XJ+KMW/=23?VC_ ,*SDA86I^&(@55'6/\
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M%+X[W?[0%YX[T7QTVG?!73;&[\",_P"TY\7XM&TKPI8>#]>TR'6M,V^)II]
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MMV-OJMOK>J>-AXYU?QOX_P!2\5^T?%W]KW]G_P""/A36_'/CGQM=7/A'PO\
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MO=V5:JDVVU&<E&RM;\W_ (5_\$T_AW\)]._9KTC1OC;\>=4TS]E3]I_]H?\
M:F^%]CK=U\(KV.Z\4_M(V/QPTCQAX-\8Z@WPB'B#Q!X+TK2OVB?BNFB31ZWI
MWC=]3\2G5-8\9:I_9'AVTT6E??\ !,CP"_P^TKP3HGQZ^/WA[6?#G[=7C/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:K<QSS6^F:>+B6,WFH3PVUS+#96XDN98[>>1(F6*0KH4?U_7WA_7]?<%%%%
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MB75O$WBV[@U_7M8\3Z;K$]O?Z>DGAB/PV=;\8'Q-X;\:/^"7OPX^,GCGX_\
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MJ3@HW@HO$J%2<94H\L83KSBI:/FE2S"%*47>5IN57#>TE)MRCSJ;E:HY1_\
M!47XM?'SX4^!OV3%^ ?Q$\-_#?4_BE_P4$_8U^"_C/5=>\#ZOXTGU#P5X_\
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MU^T7>ZS\=_VG/ O@_P#:F\9? OXL?$_X7_#SQ1\+M(\%?\+H_9\N?@:GP_\
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M6@M6N:,?;\DXV5I4U!)PBH_+7BO_ (*?_%OX ^.?CQ??M ^!_AAXD^%FA?\
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M$G)5/91]H[JWMW@U&3C:.E+ZWSOE5I<O)*%HW4?&OVKOVPOVTO OP4_X+/\
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M5&Y-2E4YN6JZ5)2<?:*EA_:VO[]6$<"ZW))**BI588Z2=K.%2G#2+4*?B7Q
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M:^/;:^^)/A+3)/A$FC16\WQ<^*.F_%WPKH7PP\^^-O[&G[2_Q!NO^"Y\6A^
M=&6T_P""A/[+W@/X(?LZW=YX[\.0O_PDVG_LP?$'X$:[J7Q'M!*W_"'Z%IGB
MCQO9:Y;S:7<>++_4_"FG:G=)I]KKWV#PY?>@>-_V3?CUX^_:<_9T^)]UX%M-
M,^'OB'_@F]^T3^PI\=Q'\2=$TKQ;\&=9^*/C'X!^++?QUX?FT^PUVW\=V4^G
M_"WQ1I7AJ/0TM+]=<O?#-UXBB\-:;=ZM<Z)A)I45**YJW(ER-V7-]4S&2BYV
MLHSQ-+"1G-WE3=:"<VFF;)-XB492<:%I-58Q3:E]8RY)J*:<G&A4Q?+#2,U2
MF^3FYCZZT[_@H%^RU<:W#I>N>/KKP'I.L? 3QC^U+X)\?_$;PWKW@?X7_$?]
MG?X<1:)<?$?XL^!OB-X@L;/PEJ?AWP!9^)?#VM>*K&_U32_$VG^#M>\/_$:/
M09_AOXBT'Q=J?SM\./VOOB!\2_\ @J;%\ M+U3Q[X=^!MS_P3RD_:!B^%GQ(
M^"]_\-O$D?C?4/V@O#_@[PS\0SJWB_PSIGC9;77O ]W?V,OP]U&\TO6_ NIP
M:AI_Q*\%^&O&8@TK3/SA\)?\$R?VROBA^PA\9_V"_BE^S9^PG^S?XP\/_LLW
MW[/G@O\ ;?\ @WX@M]3\7_M/>+O#^CZ!8_#WQ+K_ ,/M#^!?AK7?@[\/_%R>
M'=//[01UKQEXYUK7;^35],\)?#F3P[J\<^E_<_P[\"?M[^)?VQ[/]M?XD_LQ
M?"?X?7OA[_@GG\1/@(?A-9_M-0^)M7\1?'4_%_0OB5H>E:3X@TWX42:!IOP[
M\7W/A5K+3_&.L7D>M:#H.M:5J^N^$5UR/5O">F$N2,KQ<Y0C[5IM6<Z<J.+=
M*HZ:O*-3FA1A.@_>A5E&<7RN*"TW&WNJ<ITHV4E[DHUL-SQ<VU%P<956JJ:C
M*G&2D[J2?[(T5S7@O4?$VL>#O">K^-?#-KX+\9:IX:T+4?%O@ZQ\01>+++PG
MXFOM+M;G7O#-GXI@T[2(/$MKH.JRW>EV_B"'2=+BUF*U348].LDN1;1=+0U9
MM.UTVG9IJZ;3LU=-76C3::LUHT-.Z35[-)JZ:>J3U3LT]=4TFG=/5,****0P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_$4GQ3^+WC'PC_PQQ^SO\,/B;XRN='B^+_Q%\5>!/$5@_P >O'OA3X;'X&^
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M1J2E2OR64FYR<5'E:DK4J-9N2:NFEB:%/ELW[6<J3M4I581_3VBOY:OV3O\
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M7IQ3YFG=M747?^B"BOYI/V.O^"HW[=GBSXJ_L#Z1^UE!^S#I_@G]J;_@F_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9_X):_LS:U^QWXF_88^)NJ?&OXV_ 7Q-\.?"WPG_ +,^+7Q@\5>(=:\.^!/
M%]I&K?#C2?"5WIDNA:3X>OO .K^'O#VIZ'XEL]$_X2C4KGP]H,7B[6O$UCH^
MGVEO^CU%%M''I*,8R2;2:BY.*=FMG.;4OCO.;YVY2<DG9IK1QDY)]5)J*;7J
MH05OA2A!**48J/YF?M(_\$\?AW\4?V2;GX.>)KKX_P#[2WB#X;ZWX&^-W@.#
MXA?M->*O#?CSXI?%_P" "R^(OA%X7\3_ !2FM+_0?"FB^(]<L+#0/$>JV?@D
M:<EQJ,_Q#U/2]1\=VQ\2/SW[&'['WQ!T7]HC]LS]M+]H30O^$)\?_M5:+\%O
M@]\./A#:^.E\::Y\!/V;O@3\.U\-Z=X6O/B7X?DA\SQK\1OB/KGCSXB^*)?"
MOB'6K"R@E\$W%MXC?Q%;ZM%8?JI119/GNE+VBG&=TM?:TEAZKLE%7J4$J$GO
M[)R@M)R%;X+-KD<'&S?_ "[JNO36M_=A7;K17_/RTF_=BC\I=$_X(V_L=^$_
MV?/V7?V>/!,_QJ\$Z9^QE\29_BQ^SA\3?#/Q<UZT^+WPW\8ZC/JS^(6TOQ/<
MPWFCR^&O%UIKFK:=XN\#W/AJ7P5XA@O[R\U'0)M:N[K59OTM\-^#-+\+^$[?
MP=97_BB_T^"TO+235/$'C#Q3XA\67AU"2XFO+R\\9:QJ]YXHEU!Y;F5K6\75
M8Y=*C%O:Z,=.LK&QMK;K:*;]Y24FY*;<I)MOFE*,82;OUE"$(R::YE"/-=Q3
M322<6E9Q246M+)2E-)>2E.<DG>SG*UE*2?YW_LS_ /!+O]DO]E35_@UJWPY\
M-^)M97]FCP?\1/ '[+^D>/?$C>)]"_9Q\)_%W7[GQ)\5(OA;IGV*PAC\7?$2
M_N7LO%OQ9\9'QA\8]7\-M<^#Y_B%_P (GJFLZ+J/!Z1_P1X_8UT7X)? OX!V
M5M\9$\%?LY?M5']L7X4ZFOQK\>VWCG0/C%)XM\?>+[J5?&]AJ5IXA'A_4+SX
MF>+K+4["TO+/4=0M;Z"_N]8F\265MKT?ZF447?,I7?,K6E?5<M2-9-/>ZJPA
M4ONY13;=K":3BXM)Q=[Q>VL)4GIM;V<YPMLHR:25[GY:7/\ P1X_8QN?V;_B
M!^R[_9OQ7M?A]X[_ &A-5_:FL=8L/BYXOL/'7PS^.E[\0=0^)FE>/OA)XDM+
MJ(> M8\+>)M2N#HESIMA)<7>FK#8>*)_$<<>X_0'C3]A3X(?$^+]GC_A:][\
M3_BI>_LS?'?0/VFOAYJ?C[XF>*-=NKSXY^%-!U+P_P"%_'GB:W-U;Z5>R>'+
M?5]3O?#_ (9TK3=%\%Z%J=[<WFD>&[(S2(WV710O=MRMKE=-JSM9T:<:5)KL
MX4H0IQ>_)",9.:C&S?O7YM;JHG?JJU256JGY3JSG4DM%SSG)<KE)R_,72O\
M@D3^QIX;^&FD?#'PEH'Q \+Z?X0_;&B_;O\ AEKUE\1-=UC6_A'^T39>,O$O
MC+1M8^'%CXN/B3P;HG@G0YO&?C#1K'X7WGA/5/A]=Z=XK\2ZGK?AW5O&&OZO
MXIO.@^(7_!*G]C;XD_L_Z=^S9K'@[QGHWP_A_:/T[]K?Q%K/@[XG>.?"?Q.^
M(?[1$'C2X\>ZW\4_B+\5-&UFV\>>+/%WBWQ!>7$FM:Y>ZXNJZ=:Q:);^#KWP
MJ/!_@E_#?Z-44*Z2BFTH^RY4FTH^Q]C[*R322I_5\/RI:)T*3U=.#2LKR=M9
M>TYGI[WM?:JJY:>\ZBKUU)N[:K55HJDE+\R-5_X)(?L>ZKX&_;B^'1TWXGZ?
MX6_X*"WJWWQ[T_2_BGXILH()8O#_ (?\.VD?@&T2X;3?#%M8VGAO3VL[>>QU
M>**WDO?#Y5_"%W)X<KI/V\?AE\=-(_X)Q_'CX _L5^!-=^)/QF\7? [Q/\"_
MA/9:M\1= T.\\.R^/O#]]X*G\=ZQXX^)'BC1;>"+P+I&K7WB#3K6SN[RX.HZ
M?H^B:-H4.D#R]._1.BHG!3ISINZC.$*<DK*\*<9PA'9Z1IU:M.*M90JU(VM*
MRN,N2<:B2<H2E.+=W:4Y0G*6Z=Y3I4IO765*FWK&[_.S]C/_ ()[?!K]F[P/
M\"K^[T;Q5XH^(?PH_94\"?LO^$Y?BAJ'AS5I/A7\*M/TC1+OQ;\.?"OAWP?Y
MGP_TN?Q;XITY-3^)?B^UD\6^-?B'<Z7X?TCQ1\2_&'A+P9X&L=#B^ /_  3!
M_9W_ &;/@'XM_9@^&OBK]H-/@3KW@[XI?#WPI\/-=^.OCG4])^$/@GXP#7#X
MOT/X7S)>6E_I]S%/XAU.Y\,>*O%5WXN\;^#Y;BX3PWXFTVWO]3@OOT8HK2;]
MI*I*27[U34XI6@XSG4J2ARNZ<.:K4LI*3M)^\^:3>=.*I1IQBW>GR.,K^_S4
MX0A&?,K-2M"-VN576D59)?!'Q+_X)L?LL?%']B?P#_P3]UGP[XJT3]FWX::9
M\%M(\)^'O"7C'5]"UV"P^ WB#PQXE\$1:KX@C:>X\0/<ZIX4T^Y\33:[#J$V
MNWL]WK4SQ>(?L>L6=;XB?\$S?V4_BG\1/B?X_P#&OAGQ-K-M\>?!?P2\!_M$
M^ ;SQ9J%[X)_:$T']G'6[O7_ (+1?%TZFE_XR\1#PI>7MQ9Z]86?C#2M$^+/
MAQV\(?&O2OB1X3DFT63] **3U;D]7*3G)O5RFZ<:3D[WNW2A"F[IIPA!--1C
M9I))12248J*2T2C&I*K%*UK)5)2J*S34Y2::<G?\U?VF_P#@D_\ LB_M9^._
MC)\1?BEIGQ*LO$/QZ_9DTS]D[XEP^ _B;XD\%Z!KOPNT'QG)XZ\.3W'AK2I1
MH5[XI\.:S//#HVK:M8:E9VNG2?97TJ9HX9HN^^)O_!._]G_XOZ=/X7^(-W\2
M_$WPWUKPO\!_!7COX5:WX[O/$'@3XD^%OV:?B#JOQ7^#VD^,+?Q)::SXAC_L
M'XBZWJ7B3Q!J7A7Q%X8UGXBV\EIX1^).I>+O 6E:1X5L/NRBA>[:S:Y6I1U>
MC4JDDU=O:56K+6_O3E+XG<'%/=)Z-;):24(M:);QI4XNUO=A%7LK'SE^U1^R
MK\'/VS?@_J'P&^/FCZMXE^%6M>*O 7BWQ'X5TW7]3\/VWB>Z^&_C/1?'_AK2
M?$$^DS6]SJ/AU?%7AW1=2U'1GE6VU$Z?!%<9C4@_-GQ/_P""5'[(7Q=\,?M'
M^&/&6@^/9Q^U;^T+\+_VF/C3K]E\1?$EKXD\1?$'X-7O@FY^'.EV^IFXF2P\
M!>&;7P'H^E:7X*CMGTC3[&:^FTY+/5OL&IV'Z044DK.ZT?,I73:]Y.BU+1K6
M^&P[TMK1INS<$P:35FDU9QL]K-54U;TKUUZ5:BO:32_+;]HO_@CY^QM^T_X@
M_:*\2?$BT^,%O?\ [5/P7^#_ ,#/C;!X7^,_CG2--\9>%_@9XNL_%WP]U[5-
M/N-0U*WU;QSIKZ?9:!/XGU]=8N9_#R7UM'%!J&O^)=3UGF[C]C3Q9^U5^TW\
M!/C'^T]\)G^$/@W_ ()Y?$O]I32OV9]!TKX_7?QFU?\ :8T3XF:#X6\!^%?C
M/\6M6F\,:'KGA/0;WP-I_B&Y\0_![7O$/C'7/$WBS7EM?&_B74/"/AZ^TWXE
M?K;13C[EN6RY9*4=/AG&52<9QM;WHRK5G%NZ4JLI<O,H.!)<R:=[23C+^]"4
M:<)PE=.\9QHT8RZN-*$;\O,I> _M2_LS_"?]L;]GKXK?LQ?''2=1UKX5?&/P
MM/X4\766CZM<Z'K$=LUW:ZGI^IZ/JUKNDL=7T36M/T[6M+FEBNK/[?86ZZA8
MW]@US97'XJ_\%$_^"4VLC]G[]JS0/V(O!GQR^('QR_X* :1^RG^S[^T-XN\0
M_M#Z;?0>&OV>_@(WAWPUXD\3M;_&?X@^';3Q5XXU_P"$6E>*/!J7-S>:[K^K
M>)/'6MZE+J?AS3-;\3S:E_1112Y5>]D[N#FFDXU(P<7R333YH3C%TYQTYJ4Y
MPNN;FB[NVC::C.,9)M2@YI^_!K:<9N-6#?,E5ITY.,N7EE^&/_!03]@7QYI'
M[#O[8/A']ASX9^*/B_\ M=_M7_ WP?\ LE1>-/'WC[X>Z9=^!?V=+**3PE-\
M/-+U#Q5X@\!^#? 7PQ\"_##7OB!'X?\ "7PTT9;_ ,7_ !0\1P>,?'*Z]XDU
MSQ1\1;7[A^ ?_!/O]GOX):8E_I.C^-]9\73?LU^!_P!DK1?%OC[Q/;77CWX:
M_LR^!='%CX6^ _@'5/!::/HO@3P]I-Q)_:OB'5_!B)XK\>>*M/T+Q%X\\;>-
M]1\'^"=1T'[MHIR]]5%-N?M6^=R;;<73K4Y0U=N6:Q&(=1I*525>JZDIN<FU
M%<G)R>XJ:7*HI17,IT9QG9+XH/#T%"[<81HTXP45%)?AGK'_  3*_P"$H^%?
MPY_X)DV?PM\1_#[_ ()^_LX^*?V9?BWX!_:"/[3&H>(_C)\3M1^$_BNX\=:M
M\)[+P;IOA/0?$7PCN;/Q/X>\.V6H>//#_C#3XIO#VNZKXA\%'2/',LTNG?MY
MI.DZ5H&EZ;H>A:9I^BZ)HVGV6DZ/H^DV5MIVEZ3I6G6T=GI^F:;I]G'#:6.G
MV%I##:V5G:PQ6UK;11P01QQ(JC0HHN_>;=Y3FZDY/XISY534Y/17C2C"DK))
M0@K\TY3G(44FK))1BH0BM(P@I.;C%;V=24ZCNVW.<K6BHQB4444#"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN897@S$4)]VJFFFT]&M&ON_S0HR4HJ47>+5T^ZNUUMV84444AA1110 4444
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M3SS]K?X3_L\?$OQY_P %X_#FJ6MA/^V%X8^)'P:\<_L%:9HOB/5M)^,GAO\
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M35/C/*UN_A#4_&[7ME%J/C&\M;;^R)O%:WEWIT:P_9MOX2_LJ)\,O G[/O\
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M+VN7$\GB#Q);>!_B5X6D@\!^%/&EU=Q?#W5M+U7PWX'T[0;:/4M*']6W^?\
M/Y5DZ[HMEXCT/6?#VI2:E'I^O:5J.C7\NCZSK'AS5X[+5+2:RNGTKQ!X>OM+
MU_0=22"=VL=9T/4M.UC3+D17VFWUI>P07$=\[C!*,(N47*2][E<TY8F?LW)1
M?+";K0C-VE94U+EE:,8S*'M)\TI.*<8QDTN9II4(NIK*\I)4I-*Z;4N7FB[S
M?\J?_!.+5/V7_B!^T'^P2OB+XZ? :?XW?!3P1^T;X7U/4->\._$[PO\ M/\
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M^"GQX^%'BCQY^Q1\"_$?A7]H+]E>\\%_MK?!7X<Z7JG_  3F_;,\3:+I>O\
MB[P+X-_:!^"*>+[;PSX.\1W7@WX?:5X%^.?@;1_C)<+X9UGQ3\!O%OP]^(@O
MY? OANU_IQQTY_/Z?Y-*:>VB<K6:3E).<;UI5E:?*I+V;ERTU:5-PM&K2J1T
M4VONHK6+:C&T9-4E2DY0YFI>T2O-^[.,K.E4A+67\J'B'XY^!_"'P^_8<UO]
MK?X<V/[)/[#'B*/_ (*.?!_XNR_!GP1X7_:%_8YL_P!J2^_:<\#0_#/XL6R?
M&#X'>.M(L/V:OVE/#>D?M)^(OV</&]_\*=#GT3PY\5G\%0ZG;^!_$RZWK-OX
MU^#_  !\"_AC\&'^$7CA?VM?#_PD_8^\+:+#^PQ_P41T::+]JCX\?L]W'Q:^
M+E_\(_B!^Q'X^?0?#?C?X>?M>ZBVA'P=X7\ 6WPLU;Q9\0?#^A_LQ>$/B;HG
MPH^*'A3P#KDO]-WC#XE?#GX>W/A&R\?>/O!?@B\\?^*M.\"^ [3Q?XIT/PW=
M>-O&VL"0Z3X/\)6^LWUG-XD\4ZF(9FT_P_HZ7NK7BQ2M;VD@C<K+H/Q#^'_B
MKQ/XY\$^&/'/@_Q'XR^&%_H>D_$OPCH/B;1=7\3_  \U3Q1X>L/%WAK3?'.@
MZ?>W&J^$K_Q#X4U33/$VA6>OVNGW&K>'M2L=9L([C3;RWN9*3O=J+]VM&JVO
M>BN1PDU)24E>+G*-/WH*E3K4XKWJ="1+6G*Y)\U.5-IV3?.IQ7+9QE:48WE[
MLG4G2G)W4Z\3\.[C4=)\&?\ !4+0?$'AV7X%_M7Z7\2OVL-:T;7/#<^F-X;_
M &Z/V"?BI;?LFWO@"Y\6:/JMO->6WQ4_9 U?X>Z#K46MZ3XDT[P/=^ ;SXRV
M.M^'/$_Q&C_L[POI?T5_P4YT/P-X@^+_ /P2@TOQG;:->V=[_P %#YM-UFPU
M6Z6"&_\  VL_L5_MA:)K>EZS"+B 7W@O7O&&I?#GPUXCTO41-X<\0:EK?ACP
MMKEM?C7K+3+[]:Z*5-J'L;PC-TY)M2M:2CHHI--6C>7*Y*4K249RJ*,9MS3G
M[5J3BZD'&ZW3=_>T:W]U2C%QC>+E&-.4Y17\C>D_#7]G'X=?#7Q-XM\#>'/A
MUX/UO]F;_@X+^#O@/]G+6M%EL-'F_9]_9\\>_MB_L]ZC\:? 7P.>*X@A^%?P
M'\6^ ?&'QOO/B)X,^'Z:%\,]7\'77C6ZU_2Y]&T>[ET_TRZ^+'PBNOV[/@OX
MU\,FS\ _$/PE_P %M_C+\%?C-9^+;?Q3XI_:+BTOQ+^R'^UAX!\-W?Q0^)&K
MQ1R^"O@%^T/K/A_X/)^Q[^S_ &%I+X0\6>!_#WP[\0>#O$/B[Q'IMYX.^%']
M,NE?$;X>Z]XT\7?#;0_'G@W6?B)X!TWPSK'COP%I/B?1-1\:>"M(\:?VQ_PA
MVJ^+?"UG?3:YX<T[Q;_PCVOGPS?:S8V5KKW]A:Q_94MU_9E]Y#1\2?ATWQ"/
MPC7Q]X+/Q67PE+X_/PR7Q3H9^(2^!(-6L] F\:GP8+X^(QX2AUW4;#1I?$9T
MW^QDU:^M-.>\%W<PPN4VX34VN>\::46WROV=&A2JS25U)U_JTYU6[^\VYNHX
M3;JK:I"4%&-/6I=Q2NO:5*M2G%WM94G7BJ:5O=;45#GC;^7&P\2?#?X ?LF>
M.)?!OAV7P5\,?@G_ ,%J?VP+'_@HQI?[/WPH\&:Y\1/AC^R?K/[3W[<&K?!+
MQ!X^^'#_  X\<-XA^&7P\U/QQ^S5\83X8F\ ^+7M_P!G-&USPSH#^$[ZPFEZ
MOQI\//V+[KX/_L)V?PB\?^/_ (O?LP_%S_@L3I/CG1M2^+MEI7@WX:ZEX2^(
MOP"^*=G\3/#GP*\+>%/ 7PA\/Z=^R3XA^(6H6T&N>'++PE#\+_%7Q*\6^.+>
MZ_MW1?$]G'>_U,5Q7Q$^)/PZ^$/@W7?B-\6?'W@KX7_#WPO:B_\ $WCOXB>*
M="\%>#?#MB98X!>:[XH\27VF:)I%H9Y8H1<:A?6\1EECCW[W4$32Y;Q4E%X;
M1V]]48X>#A-OF4U-X>#A[L>656I%J:E%3S]F^1PC*:;59<U_>4JL\1-3BU9J
M4?K$E)WESQITVG&4;P_GE_:7@^#W[+W[1G_!1?0O 'PO\1'X<_##_@@Q\)?"
MNC_![]G/6[CX=>-ET;P9\1/VOM&F\*_#7Q#X<L-4U'P#XD\,?#_4?A_)+XJT
M71-<\0> O"S>#O$_]@ZQ;VGAW3K_ ,&N?%WP[B^%G_!??PK\-?&/PAU3X>?$
M'_@E5\)OBE\+]+_9\\*2^!/@+XTU'QQ^SE^UQ\+]1\9? OPY!J&LZ7XVM?$E
MWX7^&7PTU'X@^&]6\0R>,?%GAS1/!LMY::KX?T_P7X>_K(ZY_(]J/\_Y_P \
M]\U$ES0E'^>A5H-IZVJK$7;;;NE*MSI.]FI*_O7CO"?LZD*D8Q3IU\/64;63
M>'EAI*UOA=18=QG))74T[7@D_GKX:7_@G7?V5? 6H:[J/A^_^'VH_ 7PS+KN
MI:A?V8\,7'A:7P#9#6)M2U&2:.Q31SIWVD:A//-';QVHG,[HBOC^=?\ 8.\,
M>$?AK=?\$+_$?P;TWP/X6^/7Q:_X)&_&GP)\6?$4[(GB/XA^-O!WP=_9#N_A
MOX+^.>O^;+XF\11?#OX@^&_&.D>!_"GBN_N)OAQ::)XX\'^ =-\/Z7I>MZ-:
M_P!5O8?A15U6ZM:O6O*#KN=U"7+*"J2Q[ERSM>_^VI)N-KT(-J5THX0I\E*A
M3NI>PC&*;7NS<%@>5RC?:^"=TGM6FE)6O+^:O]E2TM/&/A__ ((Y>,_A2BZ5
M^VWX+UV]\ ?\%06U*+4='^+T?ABQ_94^,*?M?V/[8>F(+3Q!JEYK/[9.A_"C
M7O!FL?$ZUN8M3^)FO^"O&_@29_#'B*[UB?Q?]E;PM\%_ N@_\$J_BUX0T_P/
MH?Q7O/\ @L%_P4C^$NJ^/K6>P?QNG[.'B_Q=_P %5=;T3X92Z]<SSZS8_!'Q
M!XAUSX$>,=$\&K<6_@2_\;^+/AWXYT[3I/%WC+1]:U?^KS']/T_S_GFBFI6J
M0J<D%RN3<(JRO*K"K)1?,W&$>64(0U48U))WBY*I4H\U.I#F=YI)3=G**C"I
M%.R44YOVB<Y:<WLX6LU%T_C_ /9XT[]OJS\>?$.7]K#Q?^Q_XA^&$R3#X3V'
M[/'PX^-'@WQYISG7+MK?_A8FK?$GXJ>._#^LJOAHV$$P\-Z+H+-KJ7ETA2PD
MALXOL"BBDM%%?RQ4;]96ZR?VI/K*ROV1763_ )I.5ND;VTBOLQ5M(IM*[U=P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OR6^.7Q._;V\<_M>_M'_LO_LP?%;]GSX91_#?]D7]FG]I
M+X<:U\2?@CXI^(-_J'C'XE?$W]JOP/J7PU\4RV?Q:\,:>?#?BW4?@%H U#QY
M865KJ7@SPQJNK:9HO@O7/$5Y:^--"_6FOR_\2_LH>-?B3_P4-^._Q>\4V/Q,
M\*?!'XC_ +#OP#_9FC\4^!/BGI_A"7Q7=>!_BY^U#X[^*'AG5-)\/^)6\9:%
MIVO>'OC=X(T_PE\3/#MAX8^*GA'5M"\<P^"/&'@*TU:35/&)R\RFK\LO8U_9
MR;:4:OLG[*35FI<M1QDHM-2<6N6=W&2;<>5VO'VE'G7+S-P]M#VB5I1:3I\Z
M<DU9->]'2<?F[X-?\%$OCO\ 'G1;OQGI=MX=\ Z-X\_X(P_ K_@HGX2\-W7A
MO^W=2^'_ ,:?B6?B=_:OAM-8N;K34\7?"SRO!>AOIUAJ6D6/B34$N-9U*W\5
M6%MJ^DZ=X;XV/Q/^T9^TO^TC_P $S?B1\-/B7\-_@I\=_C?_ ,$8?VFOB)XA
M^(VL?"._^*/A?PQJWCKXG_\ !+7Q;X@D\,_#63XC>"_M9CU_6#%H5IK_ (TO
MK#2M.EN3>1:S<HGG?IC\2/\ @G_^S)\2_$?A3Q)=^%/$7@E_"7P,U+]F:#P_
M\)O'?C#X4>"M=^ -XJ-IGPB\6^"? >KZ'X7\3> O"ETC77A/PUJNE3Z5HL5Y
MJ^B1VTOAG7]?T/5+^G_L,_ GPVG[/4O@'_A9/P[UC]ESX2>(?@#\'/$OAKXK
M>/-0\1:/\#?%\?@"+Q;\+/$.H^--;\6_\)SH&MK\*_AW+!JWC2'7?&?A34?"
M&BZYX#\4>%->M%U,S52J2NE&*C7YXK:T(SS'EMROW6Z>)PJ:3ER^Q<;U%"#J
MU3;A!J3O*5+E;6JYG3P%TU)>\E5P^)DI-+F]JI6BYS5/\OO!OQ^^(O[3WB+_
M ((=_%GXS>&_!WAKXQV?[>/[>WP?^*-I\/I-1G\"7/Q!_9Y_9._X*3?L]^.=
M?\"/K<MWK5GX*\9^)OA1>>+O#FE:IJ&I:AIFC:IINF7^JZO=:>VI7/J7A']O
M'XP1>*?B'\,O&FH?#/2O$_CS_@L9K_\ P3W^''Q \/\ @^?POHG@KX>Z9^RQ
MI7[1]OKNJZ#KGBGQ4WBSXL:YX9\&^+/AMX7UK5-8FT"X^*_C'P7XAO/!5]X)
MT23X7ZA^B7_#'7P#@G_9DDT;PKJ7AJU_8]UK5?$7P!TKPWXI\2:5I'A/7=?\
M#>)?AGXAU?6+"'4VB\=ZEK_@+QKXU\/:Q?\ CT^);R\;QAXC\0/./%FHOKZ^
M8>-?^";?[)WQ$^'/QP^%WC+P=XIUKP[^T!\>;3]J3QIJ+?$GQ[8>,M!_:-TQ
M?"BZ+\9/A7X[TOQ!9>+O@_XN\/KX$\'1>'XOAIK'ACP_HMMH;6.GZ'!8:]XJ
MM=>(*49)SM42<G.*_=*I*4\!*4DH\RI<ZH8KW4VH>TIPO:4I4G-J4%&-X2C&
M,82?[SD26/LG=ISY'7POO-7E[.<DN:,8U?=O@%;?'+2M"\<^'_CSXT^'7Q!U
MWP[\4O&&F^!?%/@6UN-+US4?A#.VGZO\-1\8=%6PTS0-+^--OX?U..W\='P3
MIVE^!M<DBT_Q7X9T/PU8:^/#.C_E7XC_ &T_VK-(\(_M9:IH6M_ ^T\3_"7_
M (+/?LJ_L4Z%<R_"'Q&=&U3X%?';Q+^P7X,N8=5LX?BPNH_\+&TVT_:1UJ;4
M_'USJFKV>J1Z-]AT7P;X4AN]%?PK^MOP.^!O@3]GSP!8_#OP$_C'4K"&\N]7
MUGQ5\2OB%XY^+GQ.\;^(M0$*7_BCXA_%/XF^(/%7Q \=>(9[:UL=*M]1\2^(
M=1.C>&])T'PAX?CTGPCX;\/:%I?A^I?L#?L[ZMIWQ*TJ\L/'OV/XM_M.> OV
MQ_'@@^)OC>VFU;]HOX7W_P /-5\ ^/K>Y@UE+C2+3PQJ?PA^$]_I_@;2)+'X
M>&?X=^'OM'A2>*76X]8512E)<LE:T$VERI\M;"2D^5+[5&EB(O5-NJFU%R;I
MS&RIS5O?;FX-OFY>:CBXI-O=1K5,-)*SM&FTF^6U3\^OBY\<OVB/$/[)7_!<
MKX.?$?XDZ'JOCG]D'P+\5M-\!?&#X?\ @=?AYJ&K^"_B!^PEX+_:.TW1]1\+
MS>(O%EMI>O>#M=\>^)?!6F>*-*UA+V[\*:?X5U.YB'C"SU?7M7['X!^-_&6K
M_%#X3_LC_#GQ?X>^&OQ(T?\ X)B_ 'X^^+?CW%\*_ >J^./%6DZOXU\6^ ?V
M?/A:NF7-I#INI_";X5:EHGQCU7QWX>D^R^(;L?$;P_'X!\9_#;5=9\5:UK7W
M?K?[%'P)\1VG[6UCK%CXRNK7]N/3[?2?VEX8_'_BRR7QQIMO\---^# M-'^P
M:G:_\*Z,_P )-'TSP!=WGPV_X1+4;O3+&WUBXO)/%T8\1T7'[%WP;&K_  4\
M6:)<^/\ PG\0_P!G_P"&FK_!+X=_$[PWXXU:U\??\*3\0)X:BUWX3^,];OCJ
M,7Q&\*:@O@[PK>077CVR\1>*]"\3:%8?$#PQXET3XCK-XOFN-DG=-N4*,6E)
MKWX4<;!SO[VL9UL.U:W.H5)/_GW6CEDYW;5HRK..BE:,Z^"J1BXNRUIT<1!O
M[+J02T7/2_+3P%^W9^VY^U9H_P#P3W\-_"[Q)\#?V:O'/[6/P=_;EL_B_K?B
M'X,^*_C38^ ?CA^QOXZ\(?";7/$_PST:Z^+WP]CU_P"&_B3QA>>*=7\(>&_$
M][%J:>'[CPUJNK>+-;%G>Z%K=_\ :%_;6_;7^&^G_P#!1?QYX:\=_!!M"_8'
M_:U_9R\#Z+X,G^#NOP'XM_#+XK_!C]D+XC>(?!GB;Q+<?$W6KOPCJ%LO[0WB
MR&V\::#IFI7\VO:3X9U--'TWP_I^K^$?$?ZDZ9^QE\ = \7?LU^,_#'AK6?"
MNH_LC>"/&'PY^ NF^'?&'BG3?#?A3P=\0M+\/:)X[TC6O#L>JMI7Q!;Q3IOA
M+PRM]J?Q%M_%>K6.IZ-!XET*_P!)\4W6IZW?<IX\_8"_9R^)>B_M+^'/%^E^
M.[[1/VOO'/@;XC_'^RL?BAX]T)_&/BWX:Z+X%\->"-0TO4=#UW3M6\!QZ+X;
M^%_PV\/R6GP^O_"UMK6D^"M(MO$,>K?:=:?5KBX)Q<H\WO.4^5<J;^L9?)\L
M7)J,94:6/C&#;5/ZS3IMSY/:13C-R=FU!M)1YO>4?88V#7M.5-R56I@I.=DY
M>PJ2LN;EG\8^)OVKOVJ?A/XR_P""BWPD\7_&/]F_4O$'P ^%_P"QG\9_A#\6
M/B#\-O&_P[\%^&T_:R\<_&CX<:[\-M4\$> O$'Q1\9?$S5M U;X)33_ /PEX
M<6\^(OQ4\>?$'PK\'KZ]UK5KJQ\27?SQ^T;^U;^TMKG[)_[?OA)?'WC+P'XI
M_9I_;[_8G_9T\+^/]1\)^ -"^*WC'X(?M'7G[!?BOQ%I?Q.TCPT=3\"6?B'4
MM)_:@\:^'CJG@K1O .I2>!+?PM8:MX9\)>.XO%5Q<?J9\7?^"?/[.'QSNOCM
MJGQ(T_X@:GKW[1OA#X'^#_B7XBT?XH>./"&M&']F;QO?_$[]GOQ#X-N/".L:
M'#\//%WPA^)6KZSX\\*^(O!%OH5Y/XDU:[N?$7]NVRVEI:X6J_\ !-7]E[7/
M!_[1W@G6+;XPZMIG[5&M_"_Q?\6K[5_V@OC5K&OW7Q#^#&B_#G1?AI\3_#.M
MZKXXO;[PE\1O#'_"HOAEJ4/BS1)+74;Z_P#!'AV/5&OM*T^'3!%.RBO:>])<
MEK-Z^SK4JD6WIJXTW&3>C;3ES-S159.=U2M",HS3YO>=ZE"K3F^MHJI54XQ3
MNHP<8N'N6^5?VHOV^OBA^QY\6/V[I?$^F^$?B=X&_94_X)=_"G]KCPCIUCX8
MF\)>-/&GQ)USXA_M)> KK0?'WB^UU76K)?"=_K?PCTK48;OP_P"%M%MO!FE^
M*O$EPVCZ]/I\-Q=]=\?/VF?VG/V7/BK=?"+4?&G@;XJ3?%;]A/\ :T_:5^&/
MCK6_A9=6MO\ #7XZ?LC+\*;CQIX>U_P?X.\8>&%UO]GGQ[IOQJ\+3^ -'U#Q
MHOQ1\#:UX4UO0O%7Q=^)B^.]!U'P5]F7/[&'P U3QMXX\>^)_#6M^.M8^)O[
M.&C_ +)'Q&L?B'XR\5^/_#OCW]GS0KCQ=?67@#QGX?\ %^K:SIGBDSZA\0/'
MMYK/BO78+_QKXB_X3+7K#Q!XCU/2)[?3K;.T;]B7X(Z7X/O_  7?GX@>+K&7
MX'^(/V9/#^M^-?B)XH\3>-O W[/'BA-.C\0_"GP9X[U"]?Q=IEKXABT;P^OB
MSXA7>L:C\9?'<OA+P#>^/?B5XHU#X;?#N[\*Q4BY4ZBA)QF\/6A"6R56=/'Q
MA*3?._=K5L%64E%2C&A*FMDJM1LJD)27N*K2E*+?,^6$L$YI)<J:E"EBX<CD
MTW6C)_$W3^-_V.OVH?VH_&?QS_9-\)?&KQK\-_&W@[]KS_@FC=_MB6^E>%?A
MK=^"-5^%7Q'^''B']E;P_P"(=#T_7CXPUQ?&/AOQUI_[3\=]J$FJZ1I5SI>O
M^!Q>:#;:-HGB!_#6E?K_ "9*.%8HQ4A7 #%&(P&"MPVTX.#P<8/!KY&\/?L5
M?!;P1J?PK\2^$+;QU9^(_@3^S3XC_9,^$=PWQ4\=6?\ PC?P-\11^"GOO!K7
M\.H7=U<ZI=7OPP^&%V_Q-U.#6?BA!>> M U >*+JY&JKJWJW[/GPRU_X._!S
MP3\-/$_CWQ9\2]8\+66HVDOB_P <>*-?\<^*KFRO-;U/5-'T;5O'/BZYOO%W
MCB3PCH]]8>$;7QIXRO+WQAXMLM"MO$/BNZN?$&I:E,^DVI3K<JY:;JUY45:S
M5&IBL1*C3;3TG1P\J49-MWLHQDW!2<04HTZ,9/FJ*C2C5EJTZM/#T(U:BOKR
MU:T:DDM'JY-+G<5^ /A#XA_&GX)?LM?M@?'GPKXF^'/C[XG>"_\ @MGXE\!^
M$;[XU?"NQ\6V?AVY^*?[:7@3]CCQ#XL\.7N@:UX7UWPQXK7X3_%[5?#&F:W8
MWU[#H?@Q=2\%V&COH^LRK;_I#X8^(?[4NO?'CQ=^Q'J_[07@N#XN_"3]F#0/
MVE/$/Q_\.? G3= T[QWX@^/?QY^/7@SX'>$;?X+^(_'OC:WLOA;\(O"_P3U3
M1_C/!I/C^W\=?%J_U_PA?>#?B;\$[ZP\0V^M^OW/_!._]FV]^%GQ-^#%W:?$
MJ;X>_&']H.']JCQ_I8^+OQ$@U34_CS%\2M"^,A\<Z3XJM=?@\5^#HF^*OA7P
MKX[B\'^"]:\/>!-/UGP_:P:3X7T_1[_7=,U?U?XA_LN?#'XB_$_P?\;[J;Q=
MX2^,_@[P'XD^%$'Q1^'OB>]\&^+?$'PG\9:AI.K^*?AOXMFTE$TSQ!X<OM:T
M6QU_0+JZTP>)OAIXD;4?$OPE\0> O$&LZSJ=^DER0C[UU",':5K<N!C1C*+=
MU'DQ4?:6Y6Y0C"3NHJBY49\TGS))SG/:[?-C:E:2EJF^;#35*[E934DDN;VL
M?RW^#'[>?[4W[66H_P#!.O3/!-_\-O@&G[9G[&_[7WQ)^)<>I?#35_B%K?PY
M^-'[,GQ#_9T^&NLZG\/KS4O'^BZ3K_@K4M4^*_BN[\"V7B'16 L['P]XE\07
MGBRQN9O"DE;]EK]MG]L'X@R_\$N_B'\4?&/P@U7PG^VCXZ_:!_9S^)OPU\)?
M"G5_#W]C>+O@;\%_VD?B/9_&KPKXWO\ X@ZSJ<&I>*O$G[,6J6NH^ [W19_#
M.E>%?B3;:-8S7.O>!SXS\7_J!IG['WP)\/>,?@!XX\'^&M0\$ZM^RW\(?%?P
M(^ UAX3U[5=)\+?#[X5^-[+P1I_BCPI:^#Q<3>&-;M=2M_AC\-O+G\4:5K=U
MI<O@;0I]'FT^9M4?4N*\"?L!?LY?#71?V;?#OA#2_'=CHO[(_P 0/'OQ.^ =
MG>_%#QYK<O@_QE\3]*\>Z!X[U+4]2UO7=0U;QU%KWA_XJ?$O0A8^/[_Q19Z/
MI7C;5[30(-*6UT,Z34VG;D7*W*FY.WNNU>HZKC!N7+&I0G:%-/\ =-PI\TG1
MC5EI!)*7.I2TDH>_JE["U-2DHQYIQK*#G5LO:*,Y<J5:5./C7_!2[Q3\4?#S
M_L':+\-OBAKOPUM/B3_P4)^ ?P[\>#0M*T#4'\5>%;K1OB!XSMM%U&76M/O;
MFVTRV\4^"/#VL7-MI-QILFL'3X])UBXO?#EWK&BZK\K_ +37[=/[47P>\,?\
M%AM9\$ZA\&DUS]B_7/V7X_@U=ZI\,-;GBOO#OQ8^&7P]\6>)X_'@MOB';2^(
M/&L3^,;_ $W0/%<$EGX8T=--T.ZN/AOK-O;:GH^L?K+^T-^S9\+OVGO"_A'P
MK\4;?Q4L'@'XF^"OC!X)UWP-XY\7?#CQAX4^('@*\GGT37="\6^"-8T37M/D
MEL;_ %C0-4AAOA#?Z#KFK6,BJUQ'/#X]\0?^">O[-'Q1L/VH-*\;:-X]U73?
MVR9/AJ_[0UK!\6/B-I#>,T^$.BZ+X;^'T6E7NC^)+#4? (T?P_X<T+2=1G^'
MEYX5O/%T.G"[\:7/B+5+W4K^]F"46N;5*K*=M[QE_9FFNSMA<7&VUJZTM.;B
MI)MMIV;ITHQ>JY94Y8_F;2^-26)P[75.CJ[QC?X+_:&_:)_;T^$VJ?\ !2[P
MOH?QV^"5]=?LB?L??"W]O+X;^(+W]G+44GOK+QA8_M=K?_L]:[I2_&2:SN/!
M4FL_LCK<'QV+A_']MH7Q%U?2(+YM5TC1_$EGZ%XE_; _:F_:!\2_&3X<?L?:
M!I&A?%WX-_LZ?LN?&;P]I/BF/P'K'P\\0?$K]HWPO\1O&VB^$_C;-XC\4>'/
M'MO\"[C3?"&E>%X_$WP?L-)\?QZZ/&^LVFHWH\)6WA#7OM[QQ^QA\$_B1K'Q
M_P!>\:1^-]9U3]J'X#:#^S-\<9E\>^)=*M_&7P5\-1>/X=)\(6FG:+>Z=IG@
MV:V3XM?%=D\3>!+/PSXLCG^(WB2[@UR&\719]'\G^(O_  3!_9+^)WBSX5>/
M->TCXM:)XU^%'PETG]G^U\6?#G]H/XW_  H\0_$7X Z'<-?:9\$OC;JWPT\>
M^%+WXS?#6'5"NK3Z!\1)M>;4-0-])J5W>1:[XCAUB8)J,8R=WS).2O=)?6%&
M6OQ\J>'<X67M4IM^_&]2G:\FDTVVTKZ.+6';AVBW)8GEG]CFIKX':GV^F_MA
M:+XD^-EC^S%_PJ7]J'P[\1==\-VMP/C!HW[-'QA\4_LJZ)J>J?"B/XF_:=(_
M:KF\ P_ CQ%9Z9#<?\(Y8WT^NP6FK^/;>/P3)81^(;C^QQ^87[#'[6GQMU7]
ME_\ X)'?"GQ/\5-7U_XP?\%!O#/QC^(WC?XW>(- \+W'B7PWX?\ AS\,=:^*
M7CQ/"-F^ER>#[_XF>*/'>N^';C0Y_$_AC6O#&F>%Y_'=Y_PBMS#H&AZ0G] ]
MK:VMC:VUE96T%G96=O#:VEG:PQV]K:VMO&L-O;6UO"J10001(D4,,2)'%&JH
MBA5 'PYX1_X)T?LT?#_X5_"[X2>![+XE^&]$^ OQ/O?B[^SYK\?Q>^(FM^,O
M@-XMN++Q!HEI8?"[Q!XJ\0:_)HOP^L/!WBC7?A]-\)M0M]7^%OBGP!JNK>$?
M'O@_Q;I&NZ_;ZK>G--V]V3I^[=KW8UZTW%*\N6T*D&FI7E[+V<IVGSJ.65J?
MO>_"-5<S5_?G0HP4KV5U[2G.Z<?=]JJD8WAR'S_\,O\ @HAXH\">"/C]I?[1
MGPI^-/Q:\>_LV_MF^.?V1M1U[]D+]FOXP?'2]^(&D67PN^'OQ]^&GQ4USX9?
M"?0O'NM?#QM1^$WQ:\%>&_B%-+<2>$3\6=,UZ;PY_8.A^(M \*Z/J?";QU\6
MOB5_P4<_:".C_%#QMH?PVE_X)\?L-?&'X=?"'XG?#,Z+%\/_ !#\;?'W[<>A
M:E'XE\$:FGA#X@:!K\=W\+O!>L>/?#VM:GHGC*;4M-/@O5=0T.S\/:7::;^B
M'PQ^%/@KX0Z%JFA>"M-EM1XB\5^)?'OBW6-0N[C5/$/C'QUXRU.75_$_B[Q/
MK-X\EWJ>KZG=R)! A:+3- T*QT;PEX7T[1/"'A[P_H.F<'J7[,_PTO\ ]H6Y
M_:AMKGQ]H/Q>U#X0Z5\$M9O_  Y\2?&VB^$O$?@GPQKGCSQ'X&/BGX<6FM+\
M/_%&N_#[5_BK\3KWP9K7B#PWJ5UI,_CG5IY!=W%CX<FT.%%^YS2YI1A-.27)
MS2EA726BNM:S<_:.TES.7LT[I5-<S?)[D74A+E?O>['$*K;F>JM3]WD5XOE4
M7-QLW^1/[/\ ^VW^UW\=/A__ ,$>;71O%?P8^'=]^WI^S1\;OB!\6-4L/@]J
M>L_\(?XM^'WPT\(>+-"N/AKI4WQ'T_1=/\.V1\3WEE8^&M<L=7F2\LM!U;4M
M?U?2]-UGPEXIT/@-^VK^V/J^F_\ !/#XB?$_Q]\(O%/AO]H#]M7]J#_@GY\7
M_ OACX.:GX0DUG6/@%'^V_HFD_M"^'/%MS\2_$EUX;\1>(?$_P"QQI.L:A\/
MUT:^\(6GAWXC>)/#EL7U71]!\5P?HG\.O^"?_P"S=\)X_P!E:'P!H_C;0K?]
MBKPMX\\$?LVVTGQ*\;ZU;^ _"?Q+TFST#QAHFI1:_K6J+\0K:]T'3=,TC2Y?
MB6/&%YX6M=.M9O"MSHE^)KR5?#W[ /[.?A;PY\%_">BZ;X[M]"_9]_:"\=?M
M3?"BVG^)OC>^NO#WQT^)E[\2]1\=^-;[5K[6;C5_%,7B6]^-/QAFU#POXLO]
M;\'E?B3XAMX= AM+;P]!H>L7356+E%NFI/FBM+Q]K!JRO?2E[2*7-HW&-VU&
M<4TW3FE=3;_=MRORKEK:2;7O/G=!\W+KR3>TG&7S1\!OVGOVL/VC]5^$GQY^
M%V@>'D_9Z\0_M%?'CX1_%GPMX_NO .@Z#I'P@^&_Q5^,OP2\+^,_AEXDT7Q%
MJWQ1_P"&B;+XD>!/ Q\:>"?'6@R_#OQ!H^O>./!>@6?@_P 4^'?#GC'Q+B_\
M%A&>/1_^";EU!I_]J7=G_P %=/V'KJSLEDMHII[E-:\:*L5K<7CQ6UO<S(\D
M$<LTT$7[TI-/%"\CCZ?\!_\ !.;]EGX9?M!>,?VC_ OAWX@^'?%?CWQ_K?QA
M\3_#VP^-?Q@3]GK4/CCXHMI++Q3\=&_9P;QLWP3'Q@\1VKQMJGCD^"&U4ZI
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M#S?!?X/I:^'?!VHZ#X9GM_AOH%G>Z/=6EYXD@U[Y@_X*$?L$GXG? ;]L2Y^
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M=?$_BK54USPCI'PAU&\^&'AKPIXC75]!\-^&+FZN]&L+/Q5?ZAXDN^?\2_\
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M]?U?XQ>#M1\?>%=7T#X5^/=-^#EWI?ARU_M?X??"/P[9VMS\08?A[XBUZ_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>ex-19_004.jpg
<TEXT>
begin 644 ex-19_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2* X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%4-[\-O%%]$FE^.M,T>'4ET/Q+?:)+-%H/BFRU'P_?\ EWUG(M'EY-_)6O\
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MJFH1V[PQ-$J-&A&EXX^#?PA^)NO?#[Q5\2/A7\-_B!XH^$OB)O%_PK\2>-_
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MKPE\,/$/@6TU#4?@\W@72[,^%?&/CGPIXI_?]/@'\"8]6U37HO@M\)4UW6O
M]M\,-:UE/ASX.75M6^&MG MO:?#S5-171A>7_@>UMU2&V\)7<TN@P0JL45@L
M8"U#_P ,]? (?#/_ (4L/@=\'Q\'?M-A>CX3#X9^"_\ A6@O-*U:RU[2[L>!
M/[$_X1;[3INNZ;IVM6$_]E>;9ZM866HV[1WEK!-'I=76C<;4E*-TN94Z^-J6
M?I3Q-*$+WM*A%2;I\J6?LY<RESZJ-1+3X93H8.FY+UJ8:K*2TO'$2:M--O\
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M9Y\3:UX3\2>(_@/\&?$'B+P%HFC^&? VOZW\+_ ^K:UX+\.>'M0@U?P_X?\
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MPY\7M*/QV\,^-/AWXA\/?%.T\>?"B30/V?V\(7OA&*#Q'\3(?&/ZV:[^SU\
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MI;71;CPW;2ZAXWATA/$UY);^';NZT"![C4Y&AT6YGTJ,K8S2P/4O_P!G_P"
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^=?B7XFP6O\
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M&T4^6,*D:%)73K0IRC4;;?/5^IT:<9RD_CBL11;;E>;A.+;=YVY/XS?M^_M
M_LW7WANV^-WP=^$.FW>B^(/V&?!'COP_X"^)^H^/-1^(^J?M;?&7PC\ _B-\
M2OA.UIH]AXL^&?P=^ 'C_P 7V4'ASQ!^T)\-?"1_:'URRUWX?:#??#?5-,T?
MQ%XK^9?^"FGQ^US]I3]D#]L&+P'X4\%7WP;_ &<_VPOV=OV?-;UK7M5U2+QO
MXJ^)'@?]I#]FV[^)7C'P=]FLI-*\.Z!\+_$GB6]^&D_AW6H+S5?BA>:9XYGA
MU?P9X;TW0!\2OL+XZ_\ !+W3/C1X\_:6\6V/[3?QG^'6A?M/^/?V3/C%XO\
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M#0],?QO]:?\ #$UEX4^*FD?&SX-_&'X@_#KXFW7P'\/?LV_%'Q'K46D_$O\
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MO8#\C^#_ ()?MF> OA'^SSX<C_9Y\97OA^P_X*<?MZ?&CX^>#_!?C_X Z/\
M'ZP^ _[2'Q<_;,^)_P '?&_PE^(VH_&+1/#G@R"VNOCI\/-+^-S^"/BEX/\
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MXAV&KZ-J?A7XXOH-S\&=1\)7=YX[L/&M]X1T36-5L_S2^(/[(O[6WB;X5_\
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M:Q\/O!WQ!^)$FB0^ ?!7Q*^*&A>&=3^&WPL\3^,;CQ5X+M?#FB_$CQ7X5O\
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M-"O_  =:>(M#3PUJ'@#QO!XEUCQ%I.D:%X=7PGK]QK6IV-MI=W-%HV'[6'P
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MI\9_%7PO^T'\?O!G[/'@U_A_\/OB+KM]H_C76?'%YX.\<Z;X[T32?!NJ>)_
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M7V4E)2Y)VJ4G&%=Q7/RTW*EHU*I.%3,4DE>ZYX4<)S0=K^U4HN/- _6GQO\
MM5? ;X<^,M,\"^,O'$VDZQJ7C[P=\*IM5C\(^.-5\">&_B=\1+;1[KP!\._'
MOQ0T;PUJ'PU^&_CCQPGB;P=%X1\*^/\ Q9X:USQ)>>/OAQI^CV-Y?_$;P/;>
M(.5\#?MO_LQ_$OXT:]^SWX"^(M]XJ^+/A3QCX^^'_BWP]I/P[^*$^E^$?&7P
MST#PGXH\6>'_ !;XU/@M/ OA>]30O&N@7WAS^WO$NGP^.=VLVW@>7Q%>>%_%
M%OH_YHZ5^RK\</!_[7'[1/@[QI_P3]_9Q_:M^"7[1/[1FD?M)_#']L7XGZQ\
M%M0N?@%!J^B_#^3Q-X"^+_PN\8^'[SXN>*O$OP>\;^ +_P 6? >;X52^(M"\
M5PZCX#\-ZYXY^")TO4_%GAG[9_8<^%WQ8^&OQ#_X*#ZI\3/ASJ_@?2/C5^W!
MXA^-OPKU/4?$'@+6X?%_P[U3X!_ 'X7VNJ+;>#O%WB74-"O5\1?";Q#/)I/B
M:TTB^71;_P /W0C-Y<ZIINC$-5%RZTY3:V:DO8Q=)MM^]"I.K[R5JM.G&5.Z
ME*45.ZDU&UE.,>9ZWB_:R4U:RY9PC3T;YJ4YR52SC&+]F^+_ .V/^SU\#/'D
M?PL^(7B[Q(OQ.NOA1XI^-^E_#GP-\*?B[\6O'?B#X9^"?%/A'P=XLU[PKX1^
M$_@3QMX@\67N@ZWXY\.-?^%_#6GZKXMBT.;5/%8T)O"OAOQ)K6D\[\*OV]_V
M2_C=XZ^'7P\^%OQ;A\6:[\8?AA=?&'X0ZK;^#/B)IWP^^+'@;3+;P_>^()?A
MC\6-:\(Z;\+?B!XJ\'V?BG0KSQW\.O"7C'6/B+X!M;[[3XS\*Z%#:WCV_G?C
M[X:_%A_^"E?P3_: T?X9^(/$/PB\!_L,?M4_!_7O%FE^(/AU:A?B1\5/C/\
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MN>(-)^$/C#1_@1X=^%6@6_B;1H;2VTSXR_#'X>WJ1>.?&'BG@S]EC]LSX5_
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MH>MWEYJ_A.;P7XF\6+J'TG\9OB_\=?V7OCW^SA\0'^*/C7X^>%_V]?V2;?\
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MBDXWUC)RC-I+FQE54?:))MT^=7VBY06'FTOM*+IUU)2:5FK2@O>Y?Z>*^?\
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MQM+^)7Q$LOVJHO\ @JG+^S?\5/@/#X_\0W7@*]\ :S_P4,\0?LI>-OV:=?\
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M_P!"TR]TSPCHUUJU_&MSXD\5WNC:)$56Q@O;G6;S3-+O_P .-._:'\?6NM_
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M)?#'P=K7Q"^(GB2+1K&:]?1/!/@?PY;W>N^*_$^I"+[)HV@Z5;RWNI7LL5M
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M8_!_]D:?XC?LE?"_0?B?K_A_X6?M9?#G7_$.?B1\5]1GT75-'T#Q;\0/A?\
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M:\.Z;H6M_";Q+?:Y=:Q;VYR/V7OC_P#$74O"G_!%>3Q+\=O'FK^)_BA^VO\
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M0_BCH$+ZQX&@\1ZQX7N+?4[KP!K?B"SLM!^(6C)YCZGX.U+68K!K'65TS5;
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MY$T+1KZ3PAH7A_\ MF8WMW+'HVF3M<LMQ<-%80!Y"I_&W]D[]H_XN?&'X?\
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M[JIN2T7M(0325FIQQ34E'W4W*5&FTG*"<9R<I;-?TAT5^"7Q2U?XUP_M3_\
M!5[X@>!OB3^T'XY\0?L7?L\? +]H+]F7]F;P_P#%/QIIOPJ\3?%Z[_9R_:4O
M++P/K_P[\'76F7GC?PE\0_$OAW0H]2\!:A>7>BZYXDAT[6AI\OB#1]!O-+=H
M_P 7OC3X \3?\$YOB5^S;\0/B1^TYIO[7'[&/QY^)'QC\*>.O'GBWXA:5\1+
MCP%^SCX,^,GPI_:"\)^'[S5+C1/A'=:C\:?$WAKX1^(-'^$&C>!OAYK$'[1V
M@:%>>$1<>%/A?'X6;:4%5:;CR\]HKGFHRACIP?)&\GS++Z\6XJRG*C!.4JC4
M%"\Y<BLI<TH7;Y8.4)8.%2TY))*+QU%QOK.$:LN6*@N?]JOB/\)_AC\8=&T_
MP[\5O 'A#XCZ!I/B#1/%NEZ)XVT#3?$NDZ=XK\,:A#J_ACQ19:=JUO=6EMXC
M\,ZQ;6NL>&]<AA35- UBUM=5TBZL]0MH+F/OU4(JJN<* HR2QPH &68EF. ,
MEB2>I)-?SP_"_P#:IL]?_8/A_;?_ &=/VP/%_P >/VJ-9_X)2?&GXNZI^SN?
M'P^+N@>._P!I3P1\+="^(-[\1]9^!=OJ6NCX*:_\-OC7!K_PG\0> OA9I7PY
M\!_VO\3-)^%=_P"'UN/#OPYT73-;P1J'CKXG^&?'7Q$_9+_X*Q?"3XGQ?M#_
M +*?@.;X7?"WQ)>?%NZ\&M\2;CXN^!M!\(?$?7OBEK?[1OQP^)?[.5]\8;/Q
MC>_LT>*O"?PK\/>!?$%KXQ\3VOC_ .'WA6+XL?"6\TZZJ47"52+M>G)J;A:<
M7)2G3C.,H7YX2A3<HU8IITU%7U411DIQA))KGBG#G3A*SC";A)27N3C*HHRI
M2E>,^9R2UD?T%45^ >B_$;]I/XD?!;Q#I7PA^'GQ7\)?M!? W]MJ^T/]I/\
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MXBU+4K71EUC1WNGGO+.WUC1VU&?4(\/]D_\ 9"^&7[,?P#\ ?""V\$_"2_\
M$FC?!SX>_"+XI>.O!_PJ\/\ @6/XT1> ?#!\,MKGB[18Y-:OKN#Q USK>M3^
M'_$7B/Q8NF77B76[3^V-6-W=ZA??&7@'_@I'\6M7\=:U\-_%WP5^'$/C^;]B
M+XR_M?6/A+0OBIJ5YH?PU\<? ?Q]X,^'7Q*_98^(OQ@\->#_ (@_#[QMXP\*
M:_X^T'3O%?Q+^$7]O6?A'Q5IGC+P;KGPUA?1O#VO^,NH_9F_;I_: ^./B?\
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MA#6?BEX%T;4UOTU+2/!OQ U'1[GQ9X8TS4$U34UOK#1-7L;6[74;]9XI!>7
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MX9?LY_L]_!1],D^#7P(^#7PDDT7P9:_#G1G^&7PP\$> GTGX>V7B;Q#XULO
M>F-X5T/2FL/!EIXR\7>+/%MKX7M3%H=OXF\3^(=>BL4U76M2N[G;UOX,_!_Q
M+XPE^(7B/X4?#77_ !]/X0U'X?3^.-;\"^%]5\83> M7,K:MX(E\37^ESZU)
MX0U1IYFU'PT]Z=&O3-*;FRE,CY_$7X#_ !>_;E_8C_9^\!Z'\1/A)<_$&?\
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M)M0TVXUK3="UN.65-7TBRO8=/U)))%O+>978'XM\+?MP2^,OVT_&O[)>G?\
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M=J;ZWI^O:1X(.A?\(SINLV.LR2:O9ZI9:9#?6VIR/?P3I=.TIU?%WP)^"'Q
M\$>'_AEX\^#?PJ\;?#?PE?\ AG5?"OP^\7?#SPCXD\$>&=4\%213>#=2\/\
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MJ-.2E;FYDVV^>?//+'EY.5<EV^6VBYHU(R272+C6J1<5:/+)))<L.3P3X*?
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M^'G[0%G\*_"8\ >"M435OB#\/O&?COX*>,9_AS;Z-\,O&/CWX(>*/ _C36_
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M3)['Q)KOA/P?+XFU[P-8^)?BC)HU[/\ 9_[2O[/_ (1_:I_9S^,_[-7Q*O\
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MA_M,W?[4U_XZ^,?C#0+O]JS]F7X-?LT^*_\ A!- T#2;;PMI?P&\=_$_XG^
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MI*,I3FW'WY)S962M=*'LTG=^XHJ"5VV_=@HQB[\T5&"3]V+7YB>%O^"9F@>
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MJ;3O!JHN5R_=_O-:?OH2;=DFWKHEK[LG"5T[-6FG!W4;5%[-VG[A]^45YO\
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M]+W6KZI7Z7L[%%?*'QH_:X\*_"'Q7KW@/1_AA\:?CIX[\%>"?A]\4/B+X(^
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M&$K/9?5*B;6ML0[)J+C4O1\U]Y0C!/2\&EC$YPNOB:Q,&E)VO1Z<RE3^)O\
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M?]G[3_'7BWQ9X7M/BK^U[\#/ACH=GI7Q%\/_  D^'7CGQ!=S^(_&EO\ #O\
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M8^ O"6O:?JJ6?Q4N?%7@'Q1XRT?7/;Y_"/@'QAK'_!.'X8>&_P!N/XG?M)?
M/XX_M^_ME^"_^$P^#_Q[^)_PV^&>M_"+Q=^P9^U3\0M0^ _PF\??"SXQ:AJ7
MQ%^$7P@^*^AZ=X.^'/B=?B;XY\5?!G5-,U'X(>%O'/AV3P9/H%E_1,O@CP&;
M+Q;H*^$?"7]G>-KF_P!6\=:*N@:-]A\77>OV::3J>I>+=.%IY&OW&MZ?IT>F
MW]YK,-W+J5G81V=Q)-!:K$B-\/O 3P^'[9O!'A!K?PE9V.G^%8&\-:,T/AFP
MTLVC:98^'XC9%-&L].:PL6L;;35MH;0V=H;=(S;P[,XTVH0BVVX?5TY.S<XT
MJ5"G.#3TY7*AS0T;M5G&JY)+GUE/FG*<4H\WMVHK3EG5G6DI\T;2<DJMIZ[P
MC*'*V^7^:3]KOPW;:"?^"\.EZ)\8_P!H/2S^QC_P3R_9;^,G[.\-G^UE^T.N
MH_![XL_#W]G3]JOQ'X#\66%ZWQ6?5[S5K[Q)\-_ _B'6+/Q7=ZS8>/O$MC=^
M)?$]AKWB'Q/XFU36_JO4)(_A]^VY^V#\+/#GQ@^*D'@WXI_\$FO#O[3/BJTO
MOV@/B3J-_;?%*#XH?&SP9-\9? .M7?C5]4^$NH3^%TTC1;C4?A)=>"/#5OI_
MAOP9:V-A8VWA+PU%IW[7W?P\\ 7]UJ-]?>!O!U[>ZQL_M>\N_#.BW-UJGEW5
MG?)_:-Q-9/-?;+W3M/O$^TO+MNK&SN!B6V@=(5^&OPY5WD7P!X)6233ET:1Q
MX4T)7DTB.SAT]-*=A8!GTU+"WM[%+(DVJV<$-LL0AB1%J:E.E4@W:=2C4I>U
MNW)2J8;'T'5U=W+GQ=&MI*+YL)3LTU3E24&H583Y5*$)T9*F[<MJ6(P5915D
MTDX8:K1LXM*.(GHTZD:G\^/P%AO_ (W7G_!!GP3\1_BK\9M4\+_'[_@CE\6/
M$?Q?\/Z7\??BSX5M/B]XB\*_#7_@GCJ>B>(/%A\,>-](O=;\3J_Q)^(%UJ?B
MRTN;?Q9XBTW7-8TCQ'KFK>%KK4M'N?"_A7^V+>6W[//_  2BT;]I[]J'P%X)
M_9K^-?[//[9G@/Q%\?OVGKSQ-XP^%/C[X^?"#XE_#GPI\#O#'QA^+&G?%OX0
M6EIX\D^!VA_''6_ _B/XE_$^2T\9?$'P[?>)8M.UKXR^&? GB+P__4$/AK\.
M0;0CP!X)!L+2XL+$CPKH6;*QNY=1GN[*T/V#_1[2ZFUC5YKBVAV0S2ZIJ,DB
M,]]<F5+WX9?#?4O#-SX+U'X?>"+_ ,'7MW!?WGA.]\*:#=>&;N^MKFWO+:]N
M=!GL)-+GN[>[L[2Z@N9;5YHKFUMYXW66")EUJ24YRDH1BI3J2E36D&JF*KU]
MDD[PIU_9P:M9TH;4VZ<<80<+>_)N,(Q4FDY>[AJ%"[O=/FG1]I+_ *^2M^\B
MIR^=_P!D+PCI=Y^QI\*O E[\?OB!^U5X7N?AS>^$]/\ VCO%NJZAI7CKXS^!
M9+G5](\-?$*'QUX;U"UU?Q ->\(G3+SPE\9M%\0W>L?$713HGQ6LO%^LZAXD
MC\2WWX.>$/C?^T?\!=3_ &7_ !AXJ'QR^*)_X)P_'+XA_P#!-G]LBRU'Q+\2
M=1N_VEO$/Q\U*_\ !7["WQ:N-,NO$=WH'COXO>*&UC]D#Q_XN\9^)/#_ (CO
MM,M_VZM1GLM4M9]%UN*T_J;%S;-'YHN(#%YQMC()8S']H%R;-K??NV^<+L&U
M,6?,%R# 5\T;:K-INE2/=(UAI[O<WMCJ]ZC6MLS7&H67V-=-U.Z4QDRWEH='
ML%L;V8-/;G2[,6\J?8H!%#^/GOVYE:*;:E9/F46HOV=2O!M1MS583M*5&*G=
MER<K2O[UGK9<R;:MS)M<\*,[7O:G."<55DX?B5XI_9O\)ZA^W1^P]^S/\4?&
M7C?Q=;VG_!+?]O72_B%JNC?%SXH>#/%OC_6=0_:+_P"";D_BG4;OQ=X=\;Z=
M\2M.T#Q5XA;Q%K%KH&G^*[/3+/3[1/#=C&GAC1?[&B^'/AK^V=K-W^S'_P $
M63^UK^TQX ^'/P)_:5_X)]_$6+XC?'G]IR7Q5XA^%?Q&_:L\+>&OV=?^$%T;
MXR?$ZP^+?P?M]&^).I?#4?'_ ,7>"M:^)'Q-BLO%'Q&TK6=>LM+U?XQ>%O .
MN>&_Z@-5\$>"]<OVU76_"'A?6-4>RETUM2U70-)U"_;3IK:]LYK!KR[M)KAK
M*6TU'4+66U,A@DMK^]@:,Q74ZR4]0^&_P[U;PS+X*U7P%X+U/P;/=17TWA+4
M/"VAWOAF:]@OH]3AO)=!N;&32I+J'4HHM0BN'M#+'?1QW:.+A%D"A'EC.+C&
M2G6=2UK1493K-PTO*T858JF^?25*%VX-V'=RC)2:Y:;A=^])RY**4G>T-:E.
M<Y)05_:S<>621^!7[/WA_P"'/@W_ (*%_P#!/&]\4?M(^)?V@_MO_!*[]I;P
M;\/?VG_BIXLN?#_B7]H^'P;^UK^R,OPQUB+5HM;M=+^*RZWX4UF37]!\16T_
MB,?&31-1TWXM:E>^+;GQ%;^([CQK_@F-(OPRB_X-_;OPE\1?'6[]IG_@F9\4
MO#'Q2\*ZQ\6O%WB#P/XOMO@[\'/V9_%?@*TT?X9ZMX@O? ?AK4OA;JUYXDM-
M(O\ P/X7T/6]-L_$OC2'7KS4;SQ-XCN=0_IKUSP=X1\376FWWB3PMX<\07NC
M0ZS;Z1>:WH>F:M=:5;^(M-DT;Q!;Z;<7]K<36,.NZ1-+I6LQ6KQ)J>FRR6-Z
M)[5VB.?:?#OX>:==Z;>V7@;P98WVER.VD7=KX8T.UN].D>:YO7.FSPV,<UH[
M7%U>7;FU>-C-<7,[$R2RNU1;4>5MO][*?->-[2J8J;BURN-VL1&+LFKTD^5I
MF<J=Y<Z:3]GR-6O[W+A4I7;O9?5Y**NFHU6KKE2/YU_^">?QH\(_M6O^S?X\
M\;_MWZ?I7[6>G?!WXS^ /VY/V/\ X;?\)G\-/CE>?$J/P=JVB?'9OVJO#5U\
M<_%/C'X5:7^SW\<M!O1\"_C1X;\!_!73/ABVM^%_A=\(M=\(_#_XJ>'O -]^
MA7_!''P!H-M^P+^R7\?)/''Q8^(_Q2_:._8]_9%\7?&'QE\3?CQ\6_C#%K?C
M#1_@EH,=S<:+H/C[QSXG\'_#^^@O]9U>P\31_#_0?"UWXDOK*UF\=OX@U[1[
M>_@_2;_A _ _V_Q5JO\ PAOA3^U/'5M86?C;4O\ A'=(^W^,;/2K.33]+M?%
M5Y]C^T>(;;3;"66QL(-7DO(K.SDDMK=(X79#KZ/H>B>';)=,\/Z/I>A::DL\
MZ:?H^GVFF62SW4K3W,RVEE#! LMQ,[S3R",/+*S22,SL29BK.^S=*%/E5W&+
M4W.HXN3<^6;Y=')R5K2E**2EHTVUJ[*<Y:V3DI1C&',HVBY4[.S22:=THMVC
M_-%\1?VJ/",'[8_P\\5> _V@==T*_P!*_P""T,W[-?Q5C^+'QCT>/X@W7A*T
M_9;\;>$O'7P9T3X;Z,G@_1_AG^QKX>\6:#X+\3_#SPOXZM?B!>_$WXP^*T^.
MT<_A3Q5JGA?Q'XXYR+5-3TZV\>_&FQ^./QKO?B)\,?\ @XO^&O[.7@N\U/\
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M$4OA?XO:D_C#Q1X\M/B[XIF^*GC_ .)_[#,'[>OAOX=_%GXGM^PI\*_VQO\
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MS;7/-4ZT/>FG=0A"4FX\Z_GCU_\ :&^#WP'\ ?#OXA^'OVV_#GQO_8,^)_\
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M?\)_M>_%CP7\%?@WKG['GA3_ (+"?M">$/V@/*\9^)/#OQGT31_C5^T!\/\
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MG*BX0=]%5BY+W7*3^8?BS^WY^TS\#O /['?Q?^,_[+EG\)_"7[0ZO\)_B_\
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M1?&GQ$TF[^(.NZ+!XKFT;PQI/B'4O#NF>*[^UT[2M4\#^(?_  3;\&:]\:]
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MWC+1=6TWQ-X#^(%M%%*WB3X=Z1[?_P $Y?@/X#\ ?L]_!?XQVGA#P'I_Q?\
MB]^RU^R]H7Q(\>^#/#6H>%M0\>>&_A[\/I]0^'4/C>*\\2>(V\3^*/"X\?\
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MAO\ VG>?$O7OB)\+O"'B6U3P[J?AGX9^'UM;S0/#WPUTOPQ>?V-%$N:VC?\
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MP3O^'/QBO_V[+SQ!\6/C1I,'_!07X!^#OV;_ (P:=X>G^%$%IX/^''@SPO\
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M+#PIK?P[U;XH6%Q\9?%_@RQ\$0V_B3P(MWX%UW5?%NIZK;:UX8C\%>(_O?\
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MFE/#>UY=6X*&%==QO96<Z>*35DY1K1=-)Z4^)^'O[9/[8?B?X&?LQ_&7QYX
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MQO=1@I;\TI?3]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\K?%C]M?]FGX(^,-
M<\"_$CXB3:-KWA"P^$>K^/GT_P &>//$^A?#/1?CQXZUCX:_"'7/BAXI\+>&
M-:\,_#C1?''C3P_K>E:;JOC/5M%L;.STC5/$FLSZ;X5TV^UNW^J:_!3_ (*1
M_LU?MP?M%:S^V/X#\'_!_2_B7\-?&GP+_9LN?V8]4T7XL>"_AKX?L_&/PP^*
M^J^.?C5X+^+7A_5[_2M?\=_%KQ/-;^%;SX&:OXUM?$GP5\$Z387!T3Q9\#/&
M>K_$/5_B8K^_33T@YKG=GI!2HJ5FKI2Y)U)1NFFZ;72TQ_#-KXE%\BTUERU>
M71[ISA3BTFFE44KV3<?T,^+'_!1K]D#X(>)OB[X0^)?Q'\4:)KGP#A^'6H?&
MM-/^"7QY\5Z7\+?#7Q5L_$.H>#/'_CCQ%X0^&6O>'?#_ ,+9K/PKKT_B'XKZ
MAJL/PW\$?85B\;^*?#T]Y8175GXX_P#!0S]D_P#9R\2?%3P?\6?'/C32?$WP
M1^&OA'XT?%71O#/P(^/_ ,2KOP9\&O&ESXWL],^+VI?\*T^%_B^&?X7:1<_#
MCQK!XY^(&G2WOA/X;3:(8?B%JWAB74=)CO\ X&_:4_91_:<^*3_\%I8_#OPC
M>9OVX?V#/A/^SO\  F4^/?AVECJ'Q*TCX1?M%> ?$R:])?>);&\\/^'-#USX
MV^'[E=9O].CN-4TG0/$US8Z8;Z+0M.UST#X__L\?M"_$CXH_\%!_&/AGX0:P
M=)_:1_X)1?"O]E7X:0ZGXR^%]E/<_&OPQK'[9VLZMH&NQQ^.KM=(TFTB_:<\
M'V1\2'[5IDMUX;\<&S>ZM+7PS<^*L^>HHR;AS.-&I4Y5=.I4C0QE2-%;J+G5
MP]"FI)2=\5%)74.97_>4XV?).M"G*=U:G2E7PT)57HK\M*O5J6=DE0;>GM%'
M[Y^*?[7W[/OP<M-9O_&/C:]O++PO\,;+XV>,+GP!X*\>?%B/P1\'-4N-8M=%
M^*7C4?"WPSXP?PGX$\02^&O%LGAKQ'KJ6.G^)K#P/\0]6T"74M(^'7CN_P##
ML=]^V+^SG9>(_&7A5/B!/J^L>!?@!HW[4NM?\(OX)^(/C#2M0^ 7B*?6;;1/
MB1X)\0^%?"FL^'OB3I>I3>']66VT[X=:IXIUYEMHY&TE8[NR>X_/CX%?L[_M
M,_LW_%3QM\18?@K+\8/#_P"TA^PY^R/\'?$7@^3XD?#O2+[X*?'3]E;P?\3/
M!MUX:\8_VYK$.F:M\#?B9IGQ,MK[_A*OAMJGC_Q3X8\1:!XLF?X9:O:^*[.\
MB\E\)?L&_M+?LMM\'? /PX\'6G[1'ANS_P""._A3_@G9K/C^+QYX;\!0>$/B
MQ\&/[8U#1_&'BG1?&FHMKP^&?Q+M/%FLZ7X43P)#X]U_P?K>@Z+H'B70=-\*
M:I-XVT.Z_-3^L>RM4]FL3[%Z/VDZ<<S]C%J+MRS>%P,E--*:QR@N62BXE!^T
M^KNJO9>T>%]NKZTHU99;[=IM:NDL3C8M/6+P?,U-<_-^DNM?\%#/V4-%_P"%
M>1+XV\<^)=2^+G[/ _:K^%?A[X?? /\ :$^)GBOXC_ K^T/ .FS^+_!/A/X>
M_"SQ-XD\2:E82_$_P1>ZOX%TK2[GX@Z)H6K7/B;6/"MCX<T+Q#JNE=Y=?MB?
ML\1_#OX8_%+2?'5WXR\)?&?X67WQP^%P^'/@GQ[\2/%'C7X.Z3X?\->)];^)
M>C> O OACQ!XZE\'Z%I/C3P6FLZO+X<AAT[7O&W@GP?<!?&/C3PKH&L?G[^S
M%^S5^T=\(/BK_P $Z_%WC?X4/+IO[-/_  20\;?LF?%)O"?CKP#K4=K\;=;U
MS]CC7M,\/: =:\0^%KS6]-EM?V:_%MA<>(_L%EHT&L>(O"4(NI=*FUW6M!^:
M?@'^RY_P4&_8R\$?\$VOBC\-/V?O"WQT\:?!3]@RV_8+_:9_9QU3XZ^"?AMJ
MF@7NG^(/A]XJ\*_'#X8?$6]LO$W@?Q!X>T[7?!>NZ9XUT*ZOM(\3W_A'7O#6
MI:1H&LZ_HT^@Z?<TN:O&,O=AB*U*C)KFYJ4:N-IT*LHIQ<HU(TL)*<HN*BJT
MIV5-\U-)NU%N-W*C3J58I\O+-T\-.K!2:DE*+GB%&$DW+V2@WSJU3]@/%'[<
M7[,?A7X4:7\<)?B)>>)_A9JOP9T[]HJ/Q9\-_ ?Q%^*=OI_P)U;3EU?3/BQK
MVG?#CPGXIUGP[X+U+2EO]2TW5-<TZP.IV6@>++C38;M/!_BDZ/X-^WC^W?X4
M^"W[)?[3WCWX#?$#2?$WQC^'W[&OC?\ :<^'FJ^%_AYXQ^.G@/1M N_ _C;6
MOA#\0?'&H?#NTOO"^@^ /B!J_@W6$\*>)O%/B32_#^K:7H'BGQ?%_:_@[P1X
MRN=.^7?V@?V;/VL-(_:B\'?M%V/[%?[)_P"W-X<^,'[*'PC_ &:_C9\'O%7C
M/PEX$L_V?OB#\(?B%\<OB#X6\>_#?QA\6OAWXEM?%?P-OK/]H;QA\/?'>E:;
MX%TOXEWNG>$_!?C/3?!^L7*WW@H>;?&/]C7]LGP1I/\ P4P^$/PI^!_PZ^*?
MP[_X*&?L3:/\/_A[J7PU\7>"O@YX'_9G^-OP^_8RE_9<N?A1>> _&VKV^I6?
MP'\86F@^'/$/P9NOAY;>)Y?"7B?5-:\*^/=#\,^%KMOB-I^=2[IUN6\9<N(4
M(Q?-+GA"HZ=/F2BKU+0E"LDJ<G[B?-.T;INTZ?-9I2P[FY1M%PG4I*I-Q3D[
M07/ST;^T47S;0<G^[_PSUG4?$7PX^'_B#6)A<ZMKO@CPIK.J7 BAMQ<:CJ>@
MV%[>S""W2.WA$MS/*XB@CCACW;(D5%51\1_M5?'KXO\ PQ_;(_X)R_!3P+XD
MT72_A_\ M8_$CX]> _BG;:EX5L]9U^PL/A%^SA\2/COX?U/P%KDUY;0:!JFK
MZSX)A\,^)_\ A(-(\8:?=^'KU)-"LO#>M6<NJ:A](?!C4/BMI$?@_P"&?C3X
M2'PWH'A;X!?">^NOB18^/?#7B/0KWXGR_P!O:!XV^%5AH<$>G^+7D\#Z?X?\
M.Z^?'%YHECX:\2V_C"&PT@B_T/58D^7?VM?@Q\8?B#^VM_P3.^+O@3X>7OBC
MX=?LQ_%#]H3QM\7/$%OXE\$:5/I>E_%;]F3XF_ WPU;Z+HOB+Q-H^JZ_?6OB
M;QOINM:]':VT<%EX8M+ZXTZXU?6EM]"N-<1;ZPW2M[-XN=N2W+['VV+2TZ0M
M&E:]O<Y'\+UC!K_9X+$7]HL"E+G;Y_K"PN%>ZNW4]HZNJ;O/G3]ZZ7,^!OVD
MOBW^TK^V%^T7\'?AAX]\0_!K0?V._C/\$O#&KZ/XB_9S\6>)/"7QQ\&:Y\+O
M!'Q.^,FF>+O%GBO0?"$W@/Q'J>E_$[3=!^"ESX7\<:'>V%_X5@^+-[X9^-7P
MS\0CPP?MFS_:/^$%_P#M!>(OV6K?Q!K8^.7A;X7:3\:-6\(W'@#XB66G-\,M
M;UVX\,:;XIT?QU>>%+?X?>)(9?$-G>:+-IWASQ5JNLV6I6EU:7VG6TUO,J?-
M/[+'PG^+7@']KW_@H_\ $;QO\/KWPY\/OVB/C%\%?'GPE\3R>)/!FJ_V[HOP
MY_9?^#WP,\0)J>B:)XAU'6_#U[<^*?AUJ^L:)#J%ELO/"][IEUJ$ND:T]WH%
MIY%_P40^%MW\3?BY^R=>_!#XMZ#\/OVEHO'7BW]GGQ-IEKKES;>+O$W[(/[3
M7@35V_:6TJS@T:^@O/#_ (F\!Z!\+/#_ .TS\'O%7B!%T.#XL?L_>%_#JIJ0
M\776AZQ%FO81BTW.,%-MR:52HJT5-I*4HQA-T)UHI-JDJC2C*F^83O[:4[Q4
M)U''W5K3INBU%:I2E.'MHTI-J]5P4G*,_<^J[K]NC]FN#P)X9^(UKXJ\::YX
M<\6_""3]H#2K7PQ\%?C;XG\96WP45HEM_B9X@^'&A?#R_P#B)X6\+ZLLDLOA
MJX\2^%M*NO%\-AK$OA2TUI-$U<V/4:=^UW^SSK?B_2_ WAKX@MXPU_Q!^SV?
MVJ_";>"/"/CGQOH'COX ?;M!TV/XB?#KQAX2\,ZSX0^(MG=77BCPV+#1/ ^N
M^(/%&HV^O:1>V.B7%EJ%K<2_.-Y\(_C'\!_VX/''Q^^%GPL/Q6^"/QJ_9*^!
M_P  K[P-X-\1^!/"'B3X->.OV7/'?QT\4?#633=)\=^(/!?A<_!?QSX7_:$\
M6:/JZ^%=1U+Q7X(\7>$M"FLO!'B30/&.JZEX*^._V>OV$?VB?V)O$O[!FG^"
MO!NF_'W1_A9_P3I^(_[%7Q/UO1O'VA>#=%\ ?%#Q+\0_@_\ %?3_ !LZ^.9+
M/Q)?? B34?"?C;PCI47@[P[XS^)'A:P@\#P-X U?3[K5]1T.9RDH3E%>\E5Y
M(O5\T88_V49VLES.A@Y2:;A_M3IJ?NQE&HI\T5*R7-3YFFFE!O">TDGO[OM<
M5!1:4[8>-1PUE%_M)\)OBEX$^.7PL^&GQK^%NN_\)1\,OC!X \'?%'X=>)O[
M,UC1?^$B\">/_#NG>+/".N_V-XBT_2/$&D_VOH&K:?J']F:YI6F:Q8_:/LNI
MZ?9WL4]M'X%\/?V[OV7/BM=1VWP_^(6J^)H=1^%GC_XW^$M6T_X:_%)O#WQ+
M^$?PN\5:1X)\?>/_ (0^(Y/!::%\7= \.>)_$7AFPGD^&^H>)[N^M/%O@K7]
M*M;_ ,->./!VL:[3_P"">'PL^)7P,_8'_8Q^!OQ>T#3?"OQ1^"G[+7P)^#WC
M;1-,\06GBO3K+Q+\+_ACX9\#:B\&N:;%;V%_'=7.@M>,+![FT@,YM;;4=0CA
M6^G_ #,_9=_9_P#VXO#/QI_94^-GQU_9SU!_'?@/]B[]M']GC]H7Q3IWQU^%
M6O6VL_%WQUX__9-\:^"=8^#O@6SU;0_"W@/]G/Q?:? GQ39?!+P'X?A\)7W@
MF[\2O8?%7P-X"N+?4OB!XY*LI1510CS2C3G*"OS1<E#$N*337/[].C%J+5_:
MK=SBX$6FH-W]Z<4TE9J+G04KW^%\M2I)73_AMZ6:G^F'PD_;_P#V6?CKX0L_
M'OPJ\9^-O%/A#6].^%FJ>#-??X$_'SP[IWQ/M_C+X:U/QAX'A^#MQXK^&.A)
M\9-0C\.Z'X@U'QUI?PN/BW4?A(OAOQ-;_%FU\$77AK78-/\ :?@?\?OA-^T9
MX1U/QM\(/%7_  DNCZ!XU\9?#7Q59WVB^(/"?BKP5\1?A[KESX<\:>!/'/@G
MQAI6@^,?!?BWP[JMJRWF@^)]#TK4)-/NM,URS@N=#UG2-2OOQU\2?L9_M367
M_!-+_@EGX)\-_!'X6_$W]HC_ ()T6W[/&J>.OV7OC-XG\)O\.?C]!\,?V3_B
M-^R/\5/ NC>/(&\7>"=!U77/#_Q/U[QY\'?&?BO3;[2]*U[1?##^+]!TB2?4
M;73OU"_9 \&>(/"?PKO;_P 3_LU?!O\ 9)UOQUXPU/QQ?_ _X.2>%M5M_#3W
MVE:#HT=W\0_%_@C0/#/A#QO\4=7BT%+[Q-KGAS29-'TNQDT3P38:]XQM_":>
M-/$.CM[]E;D:BES)WOR.,T[)2C)2J)J%W3E3]ZR;4H3E:G?>2;?NM6LZB<6K
MMQ<>6FTYV4U-\M].73NOVP/V>;+XC>#_ (7W/CR:+Q!\0?B=XK^"7@G6O^$1
M\;/\./%'QE\#>'_$?B;Q?\*-'^+4?AQ_A?=_$+P_IW@WQK9ZCX53Q=_:L?BC
MP1XX\#I;OXV\&>*/#VDTO#'[:/[-WC#QEX*\"Z!X_NKK6?BCH?CGQ%\(+ZX\
M$^/M/\)?&O2?ANJW'C";X)^.M0\+VO@SXO75AI#/XKTO3/AWKWB/5/%?@*VO
MOB)X0L]>\":??>([?X1_9/\ @]^W'\&-1^)W[&7B_P"$'@"7]FL?&W]IOXK>
M ?VWM-^-=J?&MW\,?VD?B]\4/C6?!=O\%T\+3^+X_P!HGP]K7Q6UCP%J?C2^
MUGPI\.;;PX)_B)I^N^*_$6E+\/O&F!\ OV._VA9_A-_P2J_9Z^,/@F'P#_P[
M \>^%-6\1_%KPYXU\,:IX/\ CIHGP(_99^,W[*WPIF^%ECI6JW7C_28_B?I_
MQ.\,>/\ XCZ-\2O"'@F/PK;:!XS^'FGR>+8K_0/%]U-/WG!2M34H4Y2D]6N=
M/VL>16][#R333DE55I17*TW4[QY[>\XRG&,4M'RZTWSWU59-6<8?N[M2:<7$
M_0OX9?MI?LY?&/X;_"7XM?#?QEXB\2>!?CE\3M?^#?PRU ?"?XP:3J^O?$?P
MGJ?CK1_%GAZ_\(:[X"TSQCX33PG?_#'X@IXJUOQCH&@>'O#=OX/UZ^UO5K&Q
ML)KD:4_[7?P!M?B%X7^&4_C'58_$?CGQ9\0?A[X'U$> /B))X%\9_$CX4V7B
M+4?B)\,_"OQ,A\*2?#O7OB3X7M?!_C,W7@+3?%%QXKO[GP-\0-.T72=3U+X>
M^.;3P[\K_L[_ +%GCWX-_MG?M(>.;[6-&NOV5]=\>ZU^TS^SKX'AGO;W4?"/
M[27[3&AVOAW]JR_U&UU'4;F#2H=)U3P#K'CWP!?:-I]BD][^V3^T%IMU<72>
M1;V?S%^QA^RA^T3^S_\ $63X,?$S]AW]EKQMX,^#OQ?^*WQ2^%W_  4);Q!\
M-]7^*?CCX?\ BWQUXY\<^!_#]E\,KKP%IGQ&TC]IG3M*\90_"_Q5XNU_QQX7
M^'MEIBZYXZT[QYXRO(8?!WBTB[\E_=4J<9R5KN+34*E.][<T>6I6IMZ3INE"
MSJ.40E=*5K2:FXQL]&FG*G/I)QDI0HS22E"I&I-M0M(_0+X2_P#!0_\ 9,^.
M?AFX\:_"[QWXS\3>#(X/#3V'B^3X$_'_ $'PMXFU#Q;XUUCX=:-X9\#>(/$O
MPOT?2?'_ (X_X3CP_K/AK6/ '@J[U_QMX:U33KJ#Q)H&D^4[#K]#_;5_9M\1
M>"M6\<Z5X]OI;70?C+/^SMK/A.X\#?$"Q^*FG?'BVDLVE^$L_P 'KWPM!\4C
MXV;1]0L?&MOI</A&5;WX87EK\6[*>X^%UQ%XP?\ )JW_ &'/VLQ_P3&_92^'
M-C\(_ASJ_P"TM^QS^TC)^T O[.?Q@\6^#]4^%'[0_AVU\;?&:S\2?"C5/'>D
M0>/?#7ARX\;?"#XT:Y-X'\2^(/#>J6'A'XNZ)X7N==TN'1+!O$<7H'BG]GK]
MJ0^'/V3?VHOA1^Q'\$?@9\2?V>OVO]=_: \7?L,?"[XC?#;0]5^)7P\^(/[,
M7Q$_93\7ZMKWQ/T/0/!WP4U_]IWPQH7Q+U+Q1X'34M;T[X?S>%-$L/ >I_%:
MWN;R2^M$FW:]D^:C&HMN55:>&G*HG[RDH3JXBC.,5*5-T5.:LJBF*]M=W&K*
M-K.[ISQ,8P=FFI3A3P]6,FXQFJSA%W4.7Z__ ."?O[2GC[]I+4_VZ)?&GB&R
M\0Z-\%/VZ?'7P-^&#VWPWU_X57VC?#KP_P# O]GKQI;^&_$/A3Q<%\6CQ+H7
MB_Q]XPL=:U;Q&D%YJUW&UW86>G:$^D:=:>!_"O\ X*;^!?AY\8_VP?AA^V#\
M5[/0AX&_X*!6O[-OP8\2:)\%OB5;_#?P;X*\8_L__LH>+OAGH/QD^)GA70_&
M_P /OA5J/BSXE?&/Q5X?\+>,?CCX]\#6GQ(UFUUBW\()'9>&[_0_#OT#^P;\
M*?C9\.O%7[=?C#XR?#S3_AQ!^T5^V7J'Q]^&^C0>.-#\:ZPG@75_V<?V<_AE
M#;^*F\.PMH^B^)K'7/A5K,6KZ7I^K:]IT%W))%I.N:[I$-AX@UCY!^*?[#WQ
MN^*7@?\ X*H?LIZOX#AB\$?\%#_VE=)^)7ASX\KXA\$W_@+X>?"3Q3\!/V5?
M@SX[N=5\/7?B&W^*?_"[_ D7P(\>>)OA]H.E_#?4_ FL>+M1^%<-]\3/#^EW
M_C+7? BCS)T%)-IT*2J)R7QN6"52\[.,:D8/%3NTU>G*/++FM+1.+IXC5*7M
MI>R?*V^3FQ;BXQ3BW!VPT6DU[LU9Q:O'])E_;-_9U-U^U19/XR\06UY^Q58)
MJO[2EK>_"SXMV$_@#2YO!%S\2+74=-BO? MN_P 1;&_\#6DWB33+OX7CQI!J
ME@8?[/DN9[FVAEV_VD_VD?"'[,O[+WQE_:L\5Z#XUU_P5\&/@]XM^,NL^'/#
MOA779/&^IZ)X4\,77B:73(_#=YI]OJFA:A-;VPAU.X\46FC:;X.A-YJ_C:[\
M/:)HVM:AI_PC^T'\%[;XD_\ !0_X):M\)?B3X32U^)'PUU7X??MY_"ZUU$ZA
MJGBOX,_LR_$#PE\;_@9KMU9V5T^B6.N>&OB[X\OO@9XM\,^+;2ZN/'OP)_:J
M^)EM!I=S%X2MM4T#[)_;N^#OB_\ :'_8?_;)_9_^'@TL^/\ XY_LJ_M#?![P
M.-;O6TS13XP^)GPC\7^"_#0U?45@NFT_3#K6MV0U"^6VN&M;3S9Q!,8Q&P[N
MBY)VFU4C[JNTZ;E%U(IQ::FG"=-+G2<*D??<;.595>7245R2L]%[ZC)4Y.ZL
MX6FJCO'2=-^ZF[?&GBO_ (*!ZKX _:[^'5GXZU#Q1IO[-'BS]@'XH_M WOP_
M\.?LT_'+Q7\;K3XG>!?CO\%/ %YJD7@C0?!.M_'+Q)X<TWP[XT\13QV.C?"+
M1K*QT"&X\=ZW+J'A^73M5TK[AUS]KWX :+\.?!GQ6M?&.J^,_!/Q#^$\GQW\
M$7OPM\ _$3XMZOXG^#4.C^'O$$WQ)T?PI\,O"GBOQ9>^%DT;Q7X<O(KV+1&D
MOI=:TS2]-@O-9O[/3I_C#PK\-_VCM8_:Z^"/[27B7]GCQ)X-\,Z%_P $V_BQ
M\#?%7A>7XB_!W7_%/AOXO>,/BQ\'O'7A_P $3?V5X\&@ZK*= ^%VIVVI^)-'
MUB\\)V7B#6M%L;?6K_2?[5U[2_A7PE^Q'^UW\!/!/_!.CQO!^QK\%_VRKOX5
M?\$ZO@O^P3^TI^S/\4_B%\)_#FK?#KQM\&[?19O"OQ\^$7CSQGH?CSX?^(?"
M%YJ,GC_0OB%X?CN] \8:CX2O_AUK>EZ5K>M:+J?A+3*F[5)P@ER>TKJ%1J4D
MN;%9E&C&23O*')3P;]I=<E&K!M\K52.5+FY*<JBDYNG1E4BG&-FL+ETJUFU:
M,^>>,]VUG5I327-:G+^A'1/BK\-/$?PNTGXW:)X]\(W_ ,'M=\!6/Q3TKXGQ
MZ_IL?@2\^&VI>'XO%EEX[7Q1/<1:/'X3G\,31Z^->FNX].32&_M"6X2V#2#Y
M<\<?\%&OV1OAEIOQFU'XC>/?&7@>7]G_ .%7AKX[?%7P_P")?@9\>M.\;:#\
M$O%>IZKHNF_%S3?A^_PS;QSXN^'6GZMH6LZ=XP\5^#_#VO:5\/+W2[ZW^(%Q
MX8EMW43_ !G_ &7M:^,G_!//XO\ ['EA!\-/@EXB^+7[*/Q&^ UC9?"G2+BS
M^$'PKUKX@?#+6O!MKIW@[1[?2_#MW>?#SP??:Q'96L":#X;NM=\/6#.="T">
M_.F67SG^Q_\ !#XD?$/0O'MC^UY_P3=_9 _98N=>^#WB'X!_%&?X3:SX!^(-
M]^T;I_BZ2TMO',F@W_@OP=X8U+P+^SSXALK.\U"V\!^/=;U[QUKNJ^)+>VUO
M2/"[?#V#7_B*2O>JH<MXP<J:G+23Y963FERM1J*%.2C>;C4]K",E&Q<7I2<[
MVE)1J.*UBN:-VH-N7O0<YQN^52A[.<XMZ_H+JWQ\^$WA[7KOP[XC\5-X9NM+
M^$&I_'K7M3\3Z!XG\.>$O"GPGT>[2SU/Q7XT\=:WHMAX*\$_8Y#<W$FA>+/$
M&C>)#IVD^(-631VTOPWK]YIO@'C7_@HU^R%\,[;XG3_$SXC^(_AO<?!SP[\,
M/&?Q$T;Q]\'/C9X1\3:%X%^,OBJ[\#?#?X@1^%==^'=EXCU?P#KWC2PO_"%]
MXUT32]1\->$_%5AJ'ASQIJ?AW6["]L(/BGX9_P#!.#X\7?\ P37_ &GOV2OB
M[\5],U7X\?$_X#>/OV-_A?\ &2\MS,;/]GKX-:-X]^$G['EQ\1%M+C6AXANM
M=\.:E=?&?XO0BVEU2\\2?&7X@>%KCSUL;-8?#OB+^S+^US^T!^QO\<O#>H_\
M$T_V6OV4?V@]?T3X2> %B^#7C_X0:WX@^,5[X3^.WPY^)?B_Q/I7CG2M \#6
MGP\^!UEI_@S5-9\(^#?&?B+Q;\0?%/B;Q+#;Z]H'@0^!HM=^(]+E<Y+50O2<
M>:T9.%6K2NV]8\]"E4Y:]-7E[2-2<+PIN\R<U3NDG4M4C9*\7.G2J6M[W-R5
MJM/GHRE9>SG3A.U2>GZ7^/O^"D'[-_@[X*_MD_&329_B1XLE_8:\$:]XV^.'
MPR_X4]\6O WQ1L;#3O!^K>-/#UWI'@[XE^"/!^KZMX,\=:5HVHS>%/B[I]I=
M?!^^T_3/$'B!_'4?A[PKXGU32/L#X:^-[7XD>!/"WCBTT[6](B\1Z3!?MIOB
M'PSXL\(:K97(+P7L$V@^.- \+^*+6!+R&<:?=:IH.G?VMIWV36+&*73;^SN)
MOR0_:#_9'_:$^-?B7_@LK:Z%X#@\/:9^VQ_P3<^&_P"S)\"/$'B;Q;X033]1
M^*GACX:_MB>'M6L_%-IH.M:[K7AG1DU?]HCP9:VNL3:9>07,>C>*[@K#!9Z(
MVO?3^C?LGW'QQUG]G+]HOXJ>*_VQ_P!G;XF?#;PE\,H[[]G3P#^V)X[\-?"!
M+_X?^);[Q3;Z3\7/AI\&?',WP2^*NH:U/>?V)X^EG_X2C1O%?A2VT_PA>ZEJ
M^A:; &4+.GS/2HY44XMKW4HXR-222W4ZE.@W&[<%.+5X-2D2<E522_=\M5IK
M6\KX:5--[IJG.KJTN9Q:DE.+C'UT_MJ_L[+_ ,)5,?%'BY])\(>!/C)\3-2\
M3V_P?^,=]X-U'P-^S_XHT7P9\7=>\*^,K#P%=>%_&0\)^)/$&FV2:7X5U;6-
M;\2VCW.O>$=,U_P[8WNKP<_\#_\ @H'^R5^T9\1M-^$_PC^)^HZ[XY\0?"C2
M_CGX.T_7?AA\7?A]I7Q%^$FJ#1$/CKX6>+/B+X#\)^$?BKHNAWOB/1M&\9-\
M.==\3W/@/Q)=MX8\;6_A_P 0VE[IEM^:R?LT_&SX1S?M/>/_  )X)^(_[-?[
M._C_ /99_;2UC]H[]G'Q;\5O!GQ7^!&L_M"^)KF7Q5X'^,?[)'AW1_%_B[Q3
M\%I_&DNJ_%[Q1\9-#"_#3P'KS>)/"ID^%FH^/(M1\7:3/^R_^S3XW_:K^%/_
M  2L^(OBKP?K/P;\)?LU?\$\/$'@Y?&5QXA\&ZEXE\=>*_VEOV8?@[\*;!/A
M='X/\1>(;Z'X=:-X<TSQ=XT\1:E\1;7X=>)F\4Z;\'$TGP7J>_Q;/X+A2ER.
M7+S2]E3ER)\OOSH8R23D[J*=?#T(P32FZ=>7M(0J4:AJXK3WN6+JSASN/,N6
M,\)=J*:DY1I5ZSG9N*G1BX3G"K _471OVU_V9-9\2VGAC_A9]KH,VK_"?Q7\
M=_"WB/QIX=\7^ _AWX[^"_@2;2(_&WQ1^'?Q2\::!H/PW^('@GPC;>(?#FM^
M(]<\'^*M9MM(\(^)_"7CJ],7@CQ?X7\0ZQP'C?\ ;B_9\OO _P"T7INE?&/Q
M%\(_&GP>_9M?]H'Q-JWBKX&?%)/%WPZ^$7B[2/&UOX3_ &@M(^%/C#P-IFN?
M$_P9H&K>"O$USJ=MX>TC6K6SU/PM>>'/%D6D75S%;S?E+\(O^"?7[37Q(_8Q
M^*_[$/QK_8Z_9"_9P^(7AO\ 8U^*G[(F@?MX?#S6O!7BS7/CK?\ BSX13_"+
MP]XZ\%>#?"?P]\._$/X;>%?&EO%IGBOX[P?$#Q)INK7+:8W@3PWX$\5:;XPE
M\7_#C[8N6_X*#_M,?L:?M3>"/V@/V5OAG\#/BUXI_9?^*_P0\-^$O!?QQ\,_
M$YOC1\5_&/@36O#$'CG1==_L[PYHOPH^#-MJ5\;SPOI7C#Q)XG^(&J6WBO6E
M\3:#X+N/ .F2_%%UK*GB/9\U1QHU94FOW;K7CB/9-1^.G)N-"$Z+DJT9UG*+
MC&FII4=:V'56U*$\11A5DTJBHP<Z"K7:?+.,(RK3C5471E&DHR3<W!VOB]^U
M_P"(3\1/V&OV8_A[\1OB!::A^UI\%?B-\2+S]IWPC^S[XD\0:RNG^#/ 7@!?
M"'B#PQX,U?X:^+?A[HUWXQ\8_$S0O%_C>W\2Z1J>F?#'PAHUUH?BS3?"K>,O
M#GBK2O8?V>_VF/#6G^!/C5JGQ@_:ATKXU>(_A3^T5HO[/'CV_P##_P"SQXV^
M"MIX+^-Y^'/P2TZ_^"?P_P#AO>#Q;XV^(#>)_&WBY/'_ (.N](UGXD7]Q:_%
M.T\$Z?XJ\3Q>#&U ^"^'OV?OV@-.^/?_  28\9W'PGOU\*_LQ?LH?&SX1_'7
M5/\ A,_AT9?!OC/XG> ?V>_#&@VVG:<GBN2\\6V&G:I\(?$4GB#4-!6>.UT_
M4O#]QI*ZY<W&J6&C_.?C?]CK]M.R;]HGXS?"7X=^&Y?BUX#_ ."OVB_\%$/@
M/\,/''Q"\+Z)X;_:/^$5G^RAX$_98\;_  MU'QKH=WXKB^%/C3Q7X57XH:IX
M*UCQ9X?O]&T#Q.OPVU#78DM;GQ"/#6M50C6FE*\'6Q:=2*YE[*.84*=&2A!*
M*YL-.I.')%7A%M1=.+B8T74E1BY14:BH8-QI-N-ZL\#5G7@YR<I7CBH0IR<W
M)J4E>2E+F/V<^"/[0?PC_:*T+Q;K_P (_%?_  D<'P^^(_C#X/\ Q!TN]T7Q
M!X7\3> OBEX!NX+3Q;X$\9^%/%6EZ+XD\.>(-+%YIVI0P:GI=O#K/AW6= \6
M:!/JOA;Q#H>L:C^:_P"SY_P4V\&:%\2/V@_A7^UU\5K+2O%%E_P40^(O[*OP
M3UK0O@K\2=.^&&EZ3_8GPR/PD\ _$+XF^'-"\9_#7X<>-O&.L^)=7L?"G_"X
MOB/X6UKXFZL;G_A#[*XM8;?2-._1G]GG7OCAXN\"3>+_ (__  M\+_!'QKXH
MUN?4[3X3>'O&MC\2=0\$>'8]+TG3M.T_QM\0-&TW2?#OB?QS>75AJ&K:S+X5
MMKGPUH=GJ&E^%-*UOQ0OA^7Q7KOY-^+_ -A;X\?$7X;?M\?LD>)_ -K9>"_V
MO/V]=(_:,TCX\6_BSP?J/@3P[\$M3\4?L^^,/$4<6B2ZS:?%6P^/'AJU^$/B
M;3?"FEI\-[GP-:>.]1\#:\GQ$N-#CUVZT6(K]XHS^%P@IV::YGB,$JCC)/EC
M*-&6*J1NY>[3=)\[;OK=.E4:^)3O3NFI<JHXQQ3CIS)U(X:$E[EW-37*K-?5
M%I^V1>?##]JW_@HIHW[17Q)\'^%OV:OV6O@=^QQ\5/"VI'PO<:9>>$X_C))^
MT78^-+;5[ZRN]?\ $'Q \1>(M9^''A73_"NCZ)IL-_J6H76E^%?"GA.]\0ZD
M\FN?3N@_M>_L_P#B#P]\6O$<7C2^T:+X&?$+0?A-\5-"\6>"?'GA#QMX7^)G
MB_2/ 6M^!/ D?@'Q+X9TOQGXD\3?$FQ^*7PXC^%NE^$M"UZX^*&J^-_#6@_#
M]?$>O:K:Z:_YR_M#? ?]MN/XM_\ !3CXJ?LY_#K19?$?QL^!G["OA+X#ZKXC
M\4_"^-/&=_\ L^>/OB[K'QRT#2+7Q2_B;2O!/CK5_AY\5+G3/@=XK^(_A6[\
M%6/Q-M+;6_&EOIOA[1[>36O /$?[#7[96KV_[<'B[X8_"O2/A_XOUS]K_P#X
M)^_MU_LP>&OB[\<K7QI:_%*\_9<^%'[-FC^)/@7\:_&FG7OQ \3Z;X[UO4?@
MAXJTKQCXWU?5?%F@6?C;Q-X3UWPQ\1/B'I-CJ_C.P4&O9KG=FJ<+Z-RO[67/
M*4>7WVJ4G+E4E)JFHQBY652JJM-^SL[O17M%OV<$HJ5[03J1U<DXKGDW)+6G
M]K_M!_MW--XI_9BT;]G'QS8VTE]_P4>^%_['_P"U!X.\;?##Q3H?Q \-VGBS
MX2^+OBE/X8&C^/;?POJGA"YUG1(/!/B;2/%B^&=>TSQ5X0U^VU'P=K"V]Y'K
M"_8=A^UU\!=3\'OX[LO%'B)_#<WQ.N_@YX=N;GX8?%73;WXA_$6S\0:OX:DT
M3X1Z-JG@JRUGXQ6$U]X?UZ_LO%7PNL/%W@^_\*:'K'CFRU^?P3I=_P"(+?\
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ML'B#P]K_ (3UJ**4$JFI>&_%.F:-XBT:Z&/WECK&EV-[%QYMNF1GR9/VCOA
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M9"_:ET7_ ()[_LP? B\^#%[+\4OAK_P4L\!?M/>-/#UIX^^%LEOIOPF\%_\
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M?YO_ (*?&#3/$_[)G_!''_A+/BUI?BW6_"/_  6J^-/P=.HZ[XKN)]4T^V\
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M[KC^#_ D/@B7X;:A;6&F>&-6A_6O_@EA>Z'I;?\ !0GX1>#O$TNL?#WX#?\
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M#'[%6L:A\)?!'_!$O6_V</$T>J?&C]H7_@BQ\?M'O?"&O?%+5==\._%GXB?
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M6D";6]%U+6_!OBV1-#LKC2-1UJ[LK[$D^)_Q[^&G@?\ :JL?@,?!G[1_QO\
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M$"2+X%7&K^,_@9=?#>/P=;^.OB!INH?#O6M1T6WLM(\4>+N^\??'/XE^&O\
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M03!!-"-RG$4HCC$D8^1PB!E.U<?@G^R[\3/$?[/GP4_:AN/A;%\(_"-MK_\
MP6?_ &JO >K7OCBTUVYLM \+>)_C3JMWKO\ PK+X3?#^*U\6?&CXO>([BUC\
M,?#WX4^$;W3-7UKQ+XF7Q(3K-KX<OO#.O>U_ S_@H3\5/C%_PS[\'[[3/AYX
M3^/GQA_: _X*)_";5?%FH^$/$EIX#L?!W_!/CXU>-?A+XC\4:+\,9?B3?>(E
M\>^/98?AM<V_P]OOBIJ%AX3MM6^(>OS>+/$L'@73] \5"3DHN*NW"C)K2]ZM
M&%5KM:/-)7;3<8\UKW03:ISE&32Y9UHI]&J565._=.5HZ)/5VO:S7ZS7>I>%
M=/UC1=#OK_P]8^(-=&JS^'-'N[K3;76-972DCO-<FT73YG2]U$:='>Q76JR6
M,,PLTNXY[LQK.K/XAX5^ .MZ9\<O%/QG\;?&OX@?$[3U6_L?@M\*/$&@_##0
MOA[^S_HVOZ-X5T_Q7!X0_P"$)\">&_%?C#Q!KMYX;G-MXP^)WB3QAK_A?PWK
MFM>#_"EQHVDZ]XK;Q+^,/[5_Q[\8_LU_M9?\$R?CY^V%H_P9T+XV:+\"_P#@
MH1\+_&.M?":Y\2R_""]\3>+OBM^QS\,?@[J>I>-O%NDKK?PF^%GB?4O%WA'Q
M;XTO?B3JLWACX*+XIU[3=6\;^*CI%KXC\3?I7K?QP_:"\*_%?]EC]DG7/$7P
M5O\ ]H3XT?"3X[?&?X@_%/2/AAXWTSX2:'X:^ ,GP:\+>(=)\#_"[4OC)J/B
MZ]U[Q'X[^/?@Q]!;5OBE-:V/@_PWXQU'58#J4FC6,XE=4YK64I5813LO>LY)
M14K>_P"PC.I*Z4J2YE"5Y2O,G9RC*RBE3FWOI=1NVD_=]LX4XJ+<:CY7)6@N
M7Z)_:F^!L/[3O[-?Q[_9NO?$LO@[2/V@/@_\1?@KXB\3VNDIK6I:)X6^*7A+
M5O _BC4-%L)M0TVU.OV^@:YJ+Z!=7\MUIUAK LKW4=*UBRMY]*O/1/A[X-A\
M"^%-+T$C1)]4BMK63Q'K.A>'8/"]OXG\0)96MGJ'B6[TJ&\U)TU+51:0RWDM
MSJ>HW+LB(]Y*D<87\E_@W_P46^-GQ"^)W[)_PO\ $7A3X::/X@\4_MK_ +:W
M["7[3L-AX=\7&RNO'/[*'P7^-WQ/\/?%KX&:M=^.F/A[P9\3+7X9^#O$LO@C
MQII/CO5O#&F>/-3\$OXTU+6/!K>+-?\ -OB;^US^UC\0?@;^R_X@\/\ Q ^&
M_P -/&'B/_@LC\0?V,?B!J'ACX9^*KC0/&7P\^!'[87[0?P>\+,NDWGQ@3Q%
MX>L_%5G\"_#&L?$S1['QI=2>*HM0USPM9:MH/AG5;_3[HBW*T4_=G.EZ7J5*
M%"$DM[7QE)NS7NR;:YH-14W&#;DO?A3K.U^E.-2K4B[7C?\ V::3:?O1BD^6
M:;_=>UTC2;%;I+'3-.LTO=1EU>]6ULK:W6[U:>5)I]3NEAB07&HS311RRWLH
M>YDEC21Y2Z*15U/PWX=UJ*Q@UC0-%U:'2]0M-6TV'4]*L;^+3M4L+F.]L=2L
M8[J"5+34+*\BBN[2\MQ'<6]S''/#(DJ*X^ ?^"H/Q$^,_P *OV2;+Q7\&_'^
ME> ?&5W^TE^Q'\.=?\13^%+_ %XWG@WXS_MA_ OX,>-]*TBTM?&/ARZT-]8T
M?Q_=0WM^FKWFIIX;.M:-H5_X?\2ZIH_CSPOQ/CK]K;]HC5_$/[<'@?X%I\'-
M2\:?\$__ (8_#+4O'%GXZ\#^,A9?'?XR^+/@Y-\?=6\$^%DTGXI64_P:\":M
MX"NO!N@^'/&VIW/QAU/1O&'C36+O4O#GB'3/A:^E_$Y2:C"=65HTZ?.Y3>T8
M4:,:]2J[)M0IPE%MVYGJXQ?*T-/FG&FE>4XT^6.EY3K594:=-)NSG.::2OR_
MS22=S].K_0]%U2[TG4-3T?2]1O\ 0;N6_P!"O;_3[2\N]%OI[6:QFO=)N;B&
M2;3KN:RN+BSEN;-X9I+6>:W=S%*Z-;>SM)&+R6MM([2"8N\$3,90D<8E+,I)
MD$<,*!R=P2*-0=L:@?,/AW]I6'XF?L3Z%^V#\*]#T;R/B!^RSIG[2GPX\,_%
M?Q?8_#30/*\5_"6#XH>#]"^)7CR>TU?3/ &C[+_3[#QEXNFLM4L?"EE_:.LR
M6E[;V!BE_+KQW_P4L_:6\#_ W_@HYXML(?@?XS\9?L@?L#? S]M/X5^,I_@Q
M\8?A_P##?Q_=?$C3_P!I^#Q9X8N_!?B;XM2^./$O@*+7OV9-2NOAY\1=-U[P
M2OB7P]XRLI8=(U?2]#L?&OC<J/V+J1J6BZ<I1FK\S4HN2GI&]TG"5Y?"^31R
M=AQ?.H2CM4<%&_NW<^7D34K--N<4D]4Y:J-I,_>;[/;^4]OY$/D2>;YD/E)Y
M4GGLSS;X]NQO.=W:7<I\QG9GR6),9L;)C(6L[5C*5:4FWA)D99'F5I"4RY6:
M2252V2))'<89F)_*OQ%^T)^W;#\7_P!M3]FCP3#^S)XM^.G@#]D/X3?M7_LJ
M^9\._B/HW@B76OB9X\_:,\#1?L_?&&>_^.L5_P"-IVU;X%Z5ING?'3PU<?!O
M3E3QO/KNI?!NVB\+G1-=P=4_X*>6L'[,?B3]M?PS::)XQ^ ?PC_X)Y3_ +77
MQ2\-_P#"*ZWX:\>:]\5?$EAJ][X"^$/AWQ#%XS\6:!\/M<T2_P#AG\5?"GQG
M\$>*?#WBWQ!\.?$&K?#E[KQ%+:'7/.4GRQE)V48P4Y.][0?MES62;:52A*BV
MDU[6=&"?[ZG)D6IR48W;E+D6EDYM4)*-[V3=/$0JZN_LE5F]*4TOULGTC2;H
MVINM,TZY-C>P:E9&>RMIC::C:P&UMM0M?,B;[/>V]JQMH+J+9/# 3#'(L9*U
M#)H.AS065K+HVDRVVFZA'JVG6\FG6;P6&JQ3RW,6IV430F.UU"*YGFN([V!8
M[E)YI95E$DCL?RZ^+7[6W[2O[.OQ>T?X*?$O_A1OC+5_C)^QO^TI\>?@QXU\
M%^!/B)X=T7PC\8_V3]-^'VJ_$+P%\1O#6I?$?Q1<>+/AYXXTKXK^']8\$^*]
M'\5^ ==T5_!OB;0-9T?6[GQ/H>J:+Y)\)?\ @HK^T!HFG?!?XH?M+:9\%M2^
M$?QN_P""3OQ)_P""C\.C_!7P3X^T#QY\-M9_9^\/?LM:Q\4_ M[K'C+XG>,=
M&^).B>.K7]I)=9\"S67AOX=:IX'D\,/X3UN?X@M>)XPI3E&G&4IVC&*FW*S:
MO36)<DK)N3_V.O:RM+E@T[5*<FX^^XQCJY\G*G9751X:,'JTDI/%T5J[J\TU
M>G41^T=UHNC7NF#1+W2=,N]&6.UA72+JPM;C3%AL7AELHA82Q/:B.SDMX)+5
M!%MMW@A>((T:%=.OSL_9>^.G[:'Q2^(_@S4_BA\"_#.B?LW?$S]GW3_B-I7Q
M'T?4/AWIVI>"?BQ<7GAC4--\!VZ>'OVCOC'J'Q;\"^.O!?B75=7T'Q];>#/A
M9<^&;_P#/_;.A:M;?$;3+7P)G_M*?M1_M#V7QL^(_P"S'^R9\-M'\8?&3X??
MLQ>#?V@VO/%FD^#O$'AF_P!0^+7C?XQ> _A9X=O=*\0_M'?L[:O9: VN? ;Q
MK#XW\1Z#?^+;G1[?7_"SKI=I-)''JUR4H-QE"2E&56,X)-RBZ+J*HG%7;Y72
MFE;27N\C?-&ZC*,TI1E'EDJ3C)R2C)5E3=-J3LO>52#?6-WSI<LK??%I)X'T
MC7=-\*V+^%-+\3#0M:U?1_#=HVD66N_\(R-7TI/$6J:;H\)BU#^PAKU_HBZU
M>VMO_9_]KWNEK?2_;;BT#],L,*[0L,2A)9)DVQH-LTQD,TRX'RRRF:8R2##N
M99"Q)D;/XD:GXC^*$'_!1OX:_&1?V?M+TS]IS5O^")WQS\6ZW\!K?QKX5N[Z
MY^+FD_'']G'7[#X$WWQEL+1?#^LV>C^.;_4? VG>._+?PW$+R[\265I#I]Y+
M$S_!7_!4V\U_X1>(?&NB^)O GQ.\?WWQF_90_9GT_P""%U\%/'?[,7[0GP$_
M:"_:$\9_\(AXI\$?M)? SXY?&.>_TJ;P[97=MXI^&<;>.? N@?%B\TS5? 7A
M_P"(%Q8R:=\6+M+6RT;]]-1:E'W<74PD>1Q34XSG"%I)**]I"\HJ5-S;TL]>
M64:<DVN5KGPT,5)33:Y7"$I73U?).RDXS4?VFO=$T;4Y))=1TC3-0EFTR_T2
M:2]L+2[DET;5&@;4](D>>*1GTS46M;5K^P8FTO&MH#<12&&/;=6WMTD\U((4
ME_>_O%B19/W[QO/\X4-^^>*)Y>?WCQQL^XHI'RM^R]XW_:F\5S_&+2_VF_A-
MI7P_A\,>/[*'X,^+]+?P=I,OQ-^&6L^%-$U?[=XB\ >%/C9\?1X*\6>"_%L_
MB7P/JTT_Q!N=-\<6FC:5XZT71_"L6O7?A#P]]7T[:+;6*DK6T4E>S[26THO5
M25G>Z;2=[[Z-QU37PNUU?>+T<6M&G==4J5OING6EU?WMI865K>:K-!<:I=V]
MK!#=:E<6UK#86T]_<1QK+>36]C;V]G!+</(\5K!#;QLL,2(L&JZ)HNNQV<6M
MZ1I>L1:?J5EK%A%JNGVFH1V.KZ;+Y^G:K9I=PS+;:E83@365]"$NK67]Y!+&
M_-:E%']?=M]PRO+:6LY8SVUO,71(W,L,<A>..3S8XVWJVY$E_>HIRJR?.H#<
MU'?Z=I^JVKV.J6-GJ5E));RR6=_:P7EJ\MI<17=K(]O<))$TEM=P07-N[(6A
MN(8IHRLD:,+E% %%=,TU#.4T^Q0W,L\UR5M+=3<377D_:9IR(QYLMQ]G@\^2
M3<\WD0^86\M-MB*W@A),,$,1*)&3%&D9,<;2/&A**,HCS2LB_=5I9& !=B9J
M* *1TS36U%-8;3[(ZM'92:8FJ&T@.HIILT\5U-IZ7QC^TK92W,$-Q):"40//
M#%,T9DC1A:,:%Q(40R!2@D*C>$9E9D#XW!69%8J#@LJDC*C#Z* *)TS33J/]
ML'3K$ZM]A;3/[4-I;G4?[-:<73:=]M,?VG["URJW#6GF_9S.HF,?F -3Q86(
MZ65H/W8BXMH?]4! HC^Y_JPMM;*$^Z!;P#&(H]MNB@"K!8V5K/>W-M9VMO<Z
ME/'=:C<06\4,]_=0VEO817-[+&BR74\5C9VEG'-.TDB6EK;VZL(8(D6C?>'?
M#^J:AI6K:GH>CZCJNA3O=:)J=]IEE=ZAH]U);W%I)<Z5>W$$ESI\\EK=W=L\
MUI)#(UO<W$+,8YI%;8HH ^4/@Y^R[9_"SXX?M,_&_4O$FD>,=6_:-^*WA_XM
MI8W'@BUTR[^&VN>'_@7\+/V=38^%/$$VN:S?MI^N?#GX-^"G\0;XK6XO_$C:
M_?12VFB:CI_AS1OJ*?3--NKVQU*YT^QN-1TL72Z9?SVD$M[IRWT:0WRV-U)&
MT]H+R*..*Z%O)&+B.-$FWJJ@7:*;;=KN]HJ*[VBK+UT>[U?5L225[*UY.3WW
MDTV]6[7:3LM%T2*9T[3VU"/5FL;-M5BLYM.BU,VL!U"/3[B>"YGL8[TI]I2S
MGN;:VN)K59!!)/;P2NC211LKULK-2K+:6RLGE[&6"(%/),S1;2$ROE&XG,>,
M;#/,5P9'W6:*0RK'964/E^5:6L7E;?*\NWB3R]GG;/+VH-FW[3<;=N-OGS8Q
MYK[DM=/L+&2]ELK*TLY=2NSJ&HR6MM#;R:A?FVMK(WMZ\2(UU=FSLK.T-S.9
M)C;6EM!O\J")$MT4 9>J:)HNMBP&M:1I>KC2M3L];TL:I86E^--UG3F9]/U>
MP%W%*+/4[%W=K._M_+N[9G9H)4+$F\]O;RL'D@AD<>7AGB1V'E2I<189E)'E
MSQI-'@_)*B2+AU#":B@#+M]#T6TE$]IH^EVLXO;_ %,36^GVD,HU+5,_VGJ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-/A7P/XK\,V?@KQ=\-->USQ#\.M4\*?$?P-XK\(Z9H^D:]8_$KP9XMU>[O\
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M\,Z[9> M)AU[6O$D?P]^&R:_X^^)NG_$#X@^()?AYX8O_$'BC5-3_MN^UE/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=TBBBBD,**** "BBB@ HHKX>^)G[=G@?P=\?=8_9C^&WPL^,?[2?QF\#^"_
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M_P "_L*?L@?'[_@HQXQ'BV\GDT7Q'JNH^+[#X3_".6ST=)79[OX2:QX+\?\
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M1BYR=O949QJ?--ROJIRA?9)4J>(Q.)A3M]IQG5P]*+]U1HX=1M+VM6!^,O\
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M1X\L!0!'A2@V #Y<(S)\N/E)7H2*B'N)*RE%2HWB[N].EBL/7]DV^9.#I8+
MX>-U90H5'.,XXFM3*FN:[3<9<M6S5ERU*F&KT?:KEY6I*IB\77=FGS5**C*+
MPU.<OXZ/VG/VL/&GPJ^*/_!?O_@H[\ ;'2[WXF?L+?!?]G'_ ()F?LM6]CX>
MAU6Y^#GAVW\4^#?$/[1'Q&USP0NEZKID'AKP7\4?C%8>//!Y\0Z=_P (OXMT
M/X(:^9[+6/#/AOQ+!H?[$?\ !+_]GWX:Z1XR^)O[5'@S]IKPM^TG=?$#X0?
MWX$V6N?"3XCZC\9?AM)X9^$ \7ZM<>-/B!^T$OV2Q_:>_:8^)WC;QCXJ\?\
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M)\6?C=^W/\(OC!X]\;^)_A7^RAH?_!/CX6Z#KOC_ ,;?&/5?C5\3)_VAM/\
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M+ITZ,;V[Z\GN:04>5)<BC/"R:CHN5..%C"*A91E5KU9*<ZCM_!1\8O#?C?\
M:Y^./[1,WPP\6>(_#D/[?O\ P6+_ &??V"OV;;+1O''Q%1O#G[-O_!,KPY<>
M)_VD?VC=+?1/$VFW/C#P=JNN^ 6UW4-*?Q-;VWB;QI<ZAXV\0*?&7A[X?>,?
M"'IES^TG\2?!OPO_ ."G7Q\^''QZ^)GPSA_X*!?\%IO@?_P37MOC5=^/->N[
MG]F'X(>![VY^"WQ'_:EA\1:Y+<:=\'/B#X^TO2_B"RV&EV_@EO@ZFJ_"35O
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M>&/ _P 2=(2PMO%/QI^,O@VTUGXF"74_%7PQ@UOXQ>%/%:^)/#'E-G_P3O\
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M-6Y94Z:5I7_>N+;NG%P;]JKJT.::3=ME.DH-MWMS0J3;NK+V=[)QDI?-<?\
MP5&^ ^@?\+[\/^-O!7[0O@_Q9^S?^SIK?[5.L:-X\^$6I>"]9^,7[./@:WMX
MO'OQM^"EEXHU#2)?%GAWPEJ,L6G^(_#VNIX1^(VG:E?Z/:2^!_,\1>'1JOOL
MW[:OP2T_Q_?^ -?N?$_AJ73OV5KC]LN?Q3K&A#_A$_\ A1>G:A:Z;KNM?;-,
MO=2U6'6O#\]Y;OJGAZ[T:VU![9C<:8NHQJQ'R[\9/V(_BQ^UE%XVU[XQ7/P]
M^$'B.]_X)Y?M0?L/> ]#\ ^)]<^+.G:/KO[75K\/(?BG\1_$GBG6O 7PHOM=
MT?PO-\%_AW:_#;1+7PYI%U?:5J7C;5_$T.DZMK&EZ'X<X_X5?LP?MRZ9\:O"
M'QX\=^&_V1]%\0^$_P#@F_XF_9$@\':'\5OBU\1?#%U\7[+QMH'BWP7XKU'5
M-8^!'PZN]6^%?B9_#T-MXPT/^Q-*\3>$K6ZEATJ]\>M,9+/6I*[JN-E+_:91
ME9N#LLQ^KR48\K?/.G@I2HP::57V<7%5$Z,TM(TE-3:Y**DKKGYD\N56+E*^
MT)XU1JR33E3YY*3A:K[+\=OVU_ =E^R/^TM\7_&&E?M4? #P%\/?V>=+^,4W
MQ5^'/A;X5^,_B WPS^(.D^+Y=$^(OP1O]$U3XX?#2_\ $.C6?A/4]7N[;QSI
MXC\'6MQH/B'QAHEAH.K:?J$W3_'O_@HG\'OV>?%7QW\$^(OA_P#'_P ;Z]^S
M5\$O '[1OQ>/P^^%[ZKINA? _P <7_Q4L[GXC6>NZUJ_A?0M?T_P=;?!CQ]J
MOB;1M!O;WQ1J46DW&D_#WP_XW\3V.K>'M,^"O$/_  2]^,]M^RC_ ,%'?V>/
M@3I'PD^ W@3]L/\ 9NT_X8_!_P#977XY_%'QE^S?\!/C7XIL_C#I_P <?B5X
M UFZ^#L-Y\+OAIXVB\>^!3H_PE^&OPITKPS)<_#>;Q$/#W@?4?'5]HOAOZ,^
M/O[(O[3'Q9^(7_!0'Q?HMA\"],L?VK_^"9OPS_8Z^'\&J?%?Q_\ :M"^+/A"
M^_:\U76=6\8Q6GP(N(;3X=R7/[4T-GI>O:+<ZYXEN8/ TMY=>"["3Q,MGH&<
MW*,JTJ<;Q5&=2G!R4I3JPPV)G2HRG%J+YZT*-&52E&G&2K*24)-*BXW<:*DU
MS/$0IU9I<D84)U\-&I7A"5VN6E.K.,*DJDHNDT^>*;J_0W[07_!0;]G;]G;0
M=0U_Q%K%_P",8]$^#EM^T/XBTGP-?^"'\0:)\"[M=<FL_B6-&\:>,_!=YXDL
M=3L_"GC&[\.>$_!">*?B/XR7P=XFL_!?@OQ%JFF/8/I^&/VY_@Y\1M7TR#X.
M:;XS^-GA"Y?X"C7/B7\,;?PEJ_A'P=;_ +2^C^%/%'P=U7Q#I6K>,=#^(]SX
M=\2^#O'?@WQG/XI\+> O$OAK1O#&O'4-6U:S;0?%<&@_&M[^RK^WS\'OB[\'
M/CG^S=-^R;XQU#6?V,?@-^R9^TW\'/CIXR^)VA>$=+US]G#5_B;XF^%?Q?\
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M!\#?C#\(OAE_P4V_:!\32?!^U\&_M&_M*_\ !)C7OA"1\0O%7]H6-_\ "/\
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MQ]X:TKQ7X#@7QM/;?M ^'O'7Q;F\'>!+/1;:[U*PTOX3>$?%B77BBS^'&O\
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MM=J*JTI2<6]83A"K5=KWJ>RC3FG9M*=N2T?CC*;3UU?LZ\8II6C*$YTJ"O\
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M^%/@?Q!X.^!GP=C3Q$=?NO FBPW_ (:.A":?QGKFB:+K?A7P>_8&_;:_9O\
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M]IS]K?XA_$_Q+X9^)/C^QL]'^%_Q[^/'Q[_:%\):KX&T35_A')<:[XZL-?\
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MMU\N_#WQUK:>'/VT;+_@GUJOA2]\5?%+_@AO^S'\1_@7X6_923Q1IY\8^-?
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M?#47RN]G+EQ"K1NU%TH2E=I7C^GEO^VA\/\ 6_C9^R?\)O!>AZWXQ\-_M@_
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M^(?B+XCTF./0UO=0TVULH+?YQ_X)X^*/V-/&7B[X7?$L_'+]G_X?_$7X=?\
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M2/A7XX?$*RN[NXT#XA_&[0/"/B"VO]%^-/BLZW\5--TF^TC6;/Q;#&NF7J^
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M6W@#P7J?BV]U*UN$TS3X);32+NZCUJ[L[&Z_'7]G74?#'@__ (*#:[HEA/\
M #]JOP#\2OB#^W3J<WQT\/Z;%X:_:Z_8ZUM/B)XHU[XU? []K:UGO-2@\?\
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M5_%!J2_#0_&G2/%_AGXM6G@35&\!Z/X_U#]HP_&6UL=,\8_$$ZQ]9_ WX0_
MCXE_\%=?V\_$7C_PKX$\9_$KX6>$/V"/B+X"GO9)=37P9\2=+\!?'KPQXM\:
M^"-)OKVXM-(\2:58:[I.B:SK-A;#6]+T[Q%I=CK%S"/$$ OX@^?ET:3@ZE[;
MQ5&-9QBG;FJ0NZ=6+LH5%;F:T%.\+VM)\_(DGL_:.FI2:NHPG93@U=RB]DS]
MN:***H84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV;7(GC*5WNDY>ZW3GS?K917XA_L6_MF_M7?$;Q;_ ,$Q=4^-7BCX5>*_!_\
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M0?QI_:*_9+\(Z9XXU[3?"7Q)^ 7_  6Z_8]_9)^)NN>#/!BZ;X*^+EY\*O\
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MPIE^(OQPUR;7/!7C;PUX!^$>C_ 6XL?C/HFJS>+;/6+2E=SC36LIU.2/2/\
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MB[\?_B)<ZO/IME)XPG\320EW^$?A-\;_ -KCPY\&O^"DGQ6\/7GQ*_:6\7>
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M[4/Q7_9P;X,>./B#\+[;P3\./#FE>./@?I_[5Z>-=&TRS^,NN:]!#^SGX5^
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M1^-_BJ^\">)O#%U^UWXL\7>'=9M!XC2]\4>&-#M]5LSX0N+WPNWT#XP_:?\
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M-'U?PY?_ !AUY/&_A_6O"//_ !O_ &N?VC/V<OB+^VI\#(_$7AKXBZI\-/\
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M 7MCX5TN\^"_B;4];&MVGQ'\"RZ=X%\%BTC^(FG>*=?T/7?"VB>//#FO:/\
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M]:\;?"[X31Z?J^@>%;'X0?#?PS\/?B+XF\):AXW\3:;-IGPO\!:WJ^K:Y?\
MDZ>^HCC[KA*/N).T;7YN2M2PVRW7/*%.$G*2:C&,+047%*<>9U(OWTX)SO9K
MVE*IB%[S>CY(3G*-HN[DW>7,G[=XU_8K^"WQ#UCXW:_XQD\?:QJW[1O[/.@_
MLK_&6[_X3_Q#8'Q?\#O#:>/AIGA.*'3+FRM_#&H12_%CXJW7_"9>#X?#_C:.
M\^(GB&ZMO$5O-#H+Z+[GH7PM\%:)\*],^"T^CQ>)_AOIG@6W^&;^'/&H3Q?:
MZUX%MM"7PP/#GBC^W8[S_A*;*[\/*-(U8Z^-0GUVU:=M;FU&XNKN>?XOUC_@
MIA\#_#OA?^VO$/@3XY:/XHT?]KKX<?L3?$CX4R>!M&U3XF_"/XU_%J\\*'X?
M-XTTC0/%VKZ'K7@?Q3X8\>^!?'N@>,OA?XC^(FF^(/"/B[1W\/+JWB!=2\/Z
M?[]^S3^TUH/[2NF?%/[+\.OB?\'_ !Q\$/BUJ7P4^+7PJ^,%EX(M_&_@GQU9
M^"? OQ,TZ&XO_AGX[^)OP[\0:-XF^&WQ-\ >./#NO^#?'OB32[O1O%%I:WEQ
M8:_8ZSHVF3>,DXZ.,HW<79QG&W,]'I*/+BW-VYDHXB4FE&<K-)1=U[LHRM=:
M.,FU#=.\9.6$4=6I.5"*NY0BW\]?#+_@E-^Q7\,/@U\2?V?+;P1\0_B!\&OB
M9X$;X33^ OC3\>OCG\9])^'GP?B,;Z5\*O@=-\2?B'XCU'X$^#M!N[72=5T<
M?"6]\(^((=>\+^!_$=UKUWK_ ,/O NI^'/;)?V-_A%JO@_XN^%?&-WX]\?W_
M ,=OA!9?L_\ Q3^('B_QEJ%S\2O$WP4TJQ\9:7I/P[3QAI$>C7NAZ;IVF_$+
MQO&FN^'H])\97VL^*-:\;:MXFU'X@7TWBQN/^(/[>7PM^&GQ5@^&OB7P1\6X
M]'_X:,^$O[)^J?%R+P_X6A^&>C?'KXW^"?"WCOX<>"GBU3QKIOQ*\16NM:=X
M_P#AWI-UXP\#?#CQ7X(T3Q!XUL]-UKQ'8+X8^(5QX-_/OX#?\%(KSX(>(_VC
MM'_:AA_:/^)'P\M_^"GOQ9_9KL?VFW\"^"I_@I^SIHWB/6OAOX-^ O@?XK:Y
MI%UX%U#1?"6M>+/$=IX+TKQCX)^'/CCPWX4UK6=(D^-?BWPKJGB:SUG6J2]K
M>%N=5(.-G>2J>]1H.E9WNY1Q4%[]O:0J<KE/VJC4;]Q.I\/LYQDVM'!M5:RJ
M*UKJ,\+.3Y+\DZ?/RQ]FY4_T1NOV"O@!>7FC7]Q%\0I+SP_^RKXD_8HTFX_X
M61XK5[7]FWQ<WAV3Q%X& 2_5'UO4I?"'A6:3XHR*WQ:BDT"R-OXZB6;4%O=S
MP?\ L3_ 7P5KWP>\0:9I'B34)O@3^SGKG[)7PZTSQ)XMUOQ-X?LOV>O$I\"G
M7_AUK^@ZU<7FF>,HM9/PN^&G]J^*?%UOK7C?5%\#:.FI>);N.[U]-9XSXG_\
M% _@I\*?^%E>(-=T7X@:I\'_ ('_ !5\+?!?X]?'_P /V/@ZY^$_P5\?>*(?
M!4C6GC)M2\;Z5\0M7T#PC+\2_A[9_$?QI\._A]XX\&?#>[\1ZG#XUU[1!\-?
MC _P\S_B!_P40^$'PU\/?M5>(_$G@?XN&U_8Z^-?PJ^!WQ@M-.T?P->7YUGX
MQ^&?@WXP\&>+/"B'XA0VNN>#)/#WQV\ W^IR2W>G^*]/,^JVK>$Y+S3)+>0M
M[2\FG/GFY2<ES<TZLI>]+FO=U)8^<E*:M46+J33E&K4D2G&%HQM#EBHQ4?=Y
M8PBK1CR)64(X%*T7[GU6$)*,J5.!3^ W_!,+]CW]G7P;X]^&W@GP9XZ\2_"_
MQ[X#\7_"(_"SXQ?&CXP?&_X9^!/@KX_BMX_&_P %?A/X#^*_C;Q;X7^%_P +
M_&!M+23Q;X:\&:9I(\6#3M#MO$UUJ]CX8\+VFBXWA;_@E7^R+X3_ &?_ (E_
MLTP6/QK\2?#3XF^&/#7@>XD^(?[2?QZ^)OC/P%X&\ :JNN?"OP3\(/&_Q ^(
M/B3Q)\*/"7PFUB#3]4\ Z!X'OM'T[3]2TO3]1U6'6;^*2YE] ^%?[6'BOXC_
M +;/[4O[*\_P<\1:'X3_ &=? W[/VNVWQ.GU?P+<6GB+6/C#9_%36KNZN=.L
MO'EYXAL_#MSIWA+0M)\(P+X4_MP:UI7C:[\5P:+H]WX/FU&OX\_:G\8:1^W9
M\,?V+=&^%/BVYT+XD?LM?&;X[:G\8]'U7X;J_AF^\#_%/X%_#32SH^C>)/&"
M7T^F^'(_BCJVJ>,Y-4\&:G=7&HWWP_A\&Z-XRL$^(">'%S? U=NK!*GJ_>C3
M]K-+F;]UQ^KU&I2<9+DLIM/E;LGSII6IS;FK7492Y(/1)J2?MXIQBI1]Y^XG
M=KT2+]C_ ."C?%'3?C#K.G^*O&7C2P_9^UC]ERYD^(/C?Q/X_P!#\1_ _P 1
MZUIWB7Q+X0\8>&_&.HZUHGB^[\2>(M(T[5==\7>(K+4?&FI1VQT&X\0MX5N;
MS0;FA\%OV,O@S\!8O ,'@;_A-+N+X-_#?7?@U\!_^$T\8:GXZN/@9\(_$,_A
M:YO_ (>_#Z_\4?VEJ,^D"3P1X/MX-7\<W?C/Q>FB^&/#_A-_$LGA#1=,T"T^
M ?\ @F/^W]K/COX,?L)_"C]H'3?CCXB^+O[2GP6^('BKPQ^TGXR\/>!K7X:_
M&3XB?##4]1U?XB>!;4Z!XDLO&VA>-]*\(ROXLT^XU3X/>#OA'XC\-Z-JT?PV
M\9Z[)H[:1']+_##_ (*C?LI_%SXZ?!_X$>#O$=WJ.J?M#>'/'_B3X#>-]/US
MX9>)O!7Q2B^'&DIXKUW2["V\$?$7Q5\0_!.J7OP^^T_$?PR/BOX ^'VG>*/"
M&FZG+HNHW>MV%QH:U9W23OS)M..ETU[26FCBT\1.Z:C).=1Q252]11DG&[32
M5DU+6UKPC=WDFG&A#5.4>6$.;6G:GWWP\_X)^_LY_"S3OV8-(\%Z?X\L=)_8
MX\1>/_%/[/5AJ/Q+\:>((_!VL?%'0O%WA;QW/J]QKVK:E?\ Q 76O#/C_P ;
MZ#:CXB7GBI_#5CXFO7\)R:#>VFD7>F_0/QS^!_PM_:3^$/Q ^!'QK\)6/CKX
M5_%#P[=^%O&OA349+J"VU;2+MHY=JW5C/;7UC>6EU!;7^FZC8W-O?:=J-K:W
MUG/#<V\4B\O\4_VAO#OPV\=>#_A+I/A+QI\5_C)X[\&?$#XD^&OA/\.6\#VW
MBB[^'?PPOO!NB>-?&EWJ_P 3/&_PW\ Z3H^E^*OB3\.?"5M;ZKXSL]:UG6_&
M=C)HNDZAHNB>,M8\,_'6H?\ !2O1?%GB/_@GTGP'^%'CGXF>!OVVOB/\;O ^
MKZW=Q^$_!?B?X77_ ,"?A7\7]=\?> M<\'^/O&WA#6=,^*_@[XF_#:\\,^,=
M)O["[\/Z)IW@KXCZ:FIWOBY_!6E:_&EXQ25Y32BM+.=XQ3LW:REA80YK<D94
M80DXN,8E-\MY/2T6V]4^6TI-72O=QQ$Y))\SC5G**:E)K[LT#X'?"OPM\8/'
M_P >O#_@_3=*^*OQ0\!?#'X9^.?%5F)HIM>\'?!W5/B)J_P^TV>R60:?%-HE
MU\4O%T3ZE;VL6I:EI\NBZ9J=U>:?X9\.VVF?.NJ_\$\_V;]8^%GQ$^$-Q8_$
M&#PU\2_VD8?VO=:U33_B=XST_P 8Z+^TA#\4-#^,Z_%'P-XNM-5BUKP'J"?$
MKPYI7B2T\/>%;G2_!>DM%<Z7HGAK3-&O[[3KCY*_8X_;FUGP]8>#OA=\?[;X
M\?$/4?BK_P %"O\ @H=^RCX%_::\1:)\-+;X?'QG\'?VIOVMX?A-\)_$T&E:
M[X+\7C5+SX)?! V.A>+?A[\$M0^"UOK.D1>"=4\:^'_&YG\,6_T#XD_X*C?L
MJ>%_C1X ^#-]XBN[R;XC?M"ZK^RGHWCG1M<^&.K^&],^/^F:EX@\,+\/O$WA
M"Q^(TWQOT$ZA\1/"?B3X6V7BZ\^$0\!1?$#3(](U/Q3IUGK'A_4]7I1;4&DW
MSJ/*EKKS4<1R[_%&M5ISZ<U5J<7/GC.<1E%J36BBY-]-$JU!2:[2I4JD5NXT
MDZ;Y.24(=KXM_P"">?[-_CCPW\??"/B6T^).H>'_ -I[QW\+/B7\;+5OBW\0
MDO\ Q=XT^"FD_#G0/AGKD/B)->'B?PW>>'M#^#WPJTJ]G\+ZUHT_BZU\!Z4?
M&\OB2?4/$DVN?;L*-%%%&\TEP\<:(]Q,(EEG9%"M-*MO%! ))2"[B&&&(,Q$
M<4:;4'Q?^R]^VSH'[6&KZS%X%^ W[1WA'P7H5Y\8O#E]\5_B;X0\#^&/AZWQ
M&^!?QX\7?L_^/_A?82V/Q(UWQ;J?BVU\1^#=3\2V&I:?X1N? -WX7=[)_&UO
MX_T7Q7X&\._:E"?-&,D[QG&$XM.ZE'DM"2U>G)*T;V]R2LN62O5DFU:SBYQ:
MM9J7/>:V7VXWE:Z<XW;<DV%%%% PHHHH **** "BBB@ HHHH **** "BBB@
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MH_#;]25U_0FN;&R76M):\U.R.I:;:+J-F;G4-."&4W]C )C+=V0B!D-U DD
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MX'_MI?M=_M3_ !VTWQIJWB[P;X7UQOVZ]-_:.G^+$OPTO]!\)>-]1N[KX/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8D^-_B7X;6.CWGA?XV>)?V!M(^&,WQ ^"7Q8\3^'4T33];LOBL'\(?%OQ?\
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M0/&NC?M0_!R^_;/\+>&OV>]6T?\ :1^)G['7PD_;ZU#QSX[^%6K^#(_ UO\
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M-)<RU@H^S;6J=W:.MF[I.\XQ:;U3M5<&Y.3FW'52<N?\,?V,M9T+Q/XC\/\
M[/WQX_9X^-7_  \;_9F_:U_;&^+VF_%SQ%\'/C1H_P *;&7XQ>(/CYH'A_\
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M?2_C+XG_ &?/@E\7="\(7OP]T"RD\$:3\/O WC+PO<^"?#VA\3W\._"_1?\
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M\.?'WQ"\+?M':=8>#_%:_!GX7^(M7\0?L]I=:WX-^%=_\3=%\0ZI#]<>*/\
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M\#>"?B5X>\'M\2O#5GX%\%Z/IOQ1MM$M_B):Z%X5T'2(/$\=EIEK%'I^.O\
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MUO\ :#_:(\6^)O!NB?"7QA9?$#X1Z!\)?'WBWXJ:YXZ^#/AWX5>-]+TKQ9X
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MX@\4>*=<\1?";XG_ +$2?'7]IG2]?^!$7P_LO@5^UCJ6I_"RTT'X!^ /%?\
M9VB2_P#"&:_IWC/XM>(K'P;XBO?B[\2?#GACX2> ?%FN?%O6?"GQ:\*ZSXV^
MG_%'["OPS\*^ ]$O/V>?#EMH?QJ^!O['WQ1_9-_95OOBS\4?CWX\^%'@SP9X
MS\-^';;2O!_Q+\$WOQ'U&#XB>"+WQ+\//A;<^--0\16>O>/M2T?P/HL-EXBC
MO-(TF2V^8OV)OV%?'OP2\;?#+Q!+X!\??LY:!\)M(N/"]UX3@_X*F?MK?MP^
M!OB+X9M/ 6K^!]&\ V'PE^/FG^&/A5X0\!Z/J.I:!X[\*^-M+\,>'/'.AWWP
M\T?PGIG@/PSX=\2ZR+71M2KUI:P@ZM>=%62C&C*OC)4:,EM)PIU:$9M/G3IT
ME";A3GSS%2C1IP;4I\E&-2>MY5(4,+&K4BVW)<]2E6FKQ4;5:G,E.2</0_VP
M=2^(K_M_?\$N/!GAWXO_ !!\#>"?%OB_]JC6/%G@[PI!\/FT/Q/JW@#]GS6;
M[P]J&MR>)O ?B76[DP6/B+Q'H,FGPZS;:*MEKDVK6^F0>+]*\,^)M"^"OV<O
MB]\<O@1_PJOQ'X7\?Z+)\)?C-_P75_X*3?LQ^.?@]-X%TMQJ^B?$S]L+]N/7
MH?'<OCVYO;OQ+9^,_"'C;P3H5QH-OH/]A^$[GPE=Z_HGB/P[K^MW>E>)M&_<
MGXM_LW?"/XX>+/@UXZ^(6B:_<^,/@!XRU#QW\*_$GA?X@?$'X=ZQH&MZUH%Y
MX8U^RO;_ .'OBCPO<^)?"7B70KV33?%7@3Q/)K/@KQ5:1V]MXBT#4[>!(:\A
ML_\ @GM^RG8:/X.T"U\%^.TTKP!^U#XD_;-\)V\G[0/[1,\FG?M(^,-?\4^*
MO%/Q"GN[CXJRWFK6VO>)/''C'6]3\"ZS<:C\.;K4O$^N7<GA$RZC=-*Z4N2'
M+*[?M7-OXDZ<L3AZLHM:-_NHUX*+?+&<HN/+I*&=6FY3YXM)^S:C=-.,UA:U
M&,DUVK2I5')).4%*+YK.,_C6U_:W_:#LOVL/@CH9^(.@?$+X5?%__@H+^T1^
MQUKMEX"\): /@EX+\*?#G]FK]I#XL>%="T/QUXCT_0/B]XF_:=\%>+_V?]+T
M?XXZOX?G\?\ [.N@^(]7^+OP:M[C2_B;X >S\+>X_P#!*U_'VI?L]?$C7OB)
M\8OB/\8=:F_;,_X*!^#XM6^(Z?#TZA:Z;\*_V]?VF?AIH<UO/X$^'_@53)?^
M&O#&A0WFGSQS>'=#73+/1O &A^"O"-EI_AFS]!L/^";?[)&E^/[7XEZ;X1^(
M^G^)]+_:6\1?M=^'ET_]HC]HG3O#GA'X^>--,\=Z9X^\7>"_!EA\5+;PAX0T
MSXE1_$_XAW/Q1\%>'-$TWP1\3+GQ;JH\=^'?$-K]DMK7WKX*_LY_"O\ 9[E^
M)A^%5AXLT6Q^+'Q.\<?&#Q3H&M?$SXE>-O"NG^/?B7XKUWQ[\0-2\!^%/''B
MWQ%X=^&&F^,/'GBGQ/XUU[PW\.=,\+^&[[Q-X@U/4WTH220B"$G=.[_A.#33
M=I-X62:=K;TZ]VDG:<6]92A3N2DY)W3BJG.DDU9<F)IM:W>BJ46E>WNR7V8R
MG^1_[3?[</[5?PS^&/\ P6P\1>#O&/P^L?$'[#_BKX.VWP#NKOX:?VA8:5X9
M\;?LV_!'XNZS8^(+"X\4;_$/B:76?B-K5I#XEU&[N=&M#!8W<?@F2SADT.?Z
M8T3Q_P#M'0_'7]OW]FWQY\=)-=LO G[,'[./[3/PF^(?@GX=>#? ?C/X:W?Q
MTUW]K;P7XN^'.EQ:C;>-_#NM^$-"U3]E_3M;\#:EXMT;Q%X[TNR\<Z_I7B'Q
MCXIO=-T+6['WWQW_ ,$_?V5/B7I7[4^A^-/ WC#5M*_;5U#PCJG[2ME!\<?C
MWHL?Q!O/ OAW0?"/AE[ Z%\3M,?X>P6GA7PMX<\-WUE\,7\&66NZ'HUCI>O6
M^IV4"P5WMS^R=\$[OQU\6/B7-IGC[_A.?C=\'O!_P%^)7B"#XW_'&TN-:^%G
M@&;QE<^#M!TNVM?B-#8>#]3\/7GQ$\?:CI_C+P7:^'O&Z:IXS\4:I)XCDU#7
M-2N;C*M&<Z4Z<'RN>&G1NT_CE@<31YGHVO\ :JE"LYIJ3C3F[)OV<M(6C5A-
MWY8UX5''=^SCBL/4E'7W?>H0KP4'[L7.,=O?C^.O_!.;QSXLD^#G_!(W]DSP
MQX[\3>$M:^)7_!'/P-^TMXA^-T/@SX1:A\1/#7@KX=>"OV._ASX,^ _PMU'7
M/AOJ7A<>%+;Q!\9-6\8^(+WQWX4\>^);*W\.>'["74=3NO%LVN>'^^TS]L7]
MLSXI_#G]BWPWH?CSX9?"OXK?$7_@HG^V/_P3Q^/?CZV^"M_XI\+^*M0_9B^'
M/[=UI'\9_A%X;\0_$.%?#MEKWB7]E;2/%MIX7UJ]\4VVC>*=6F\+:IJ^O^&_
M"FLZ;XU_1C2_V#?V9O#O@_\ 9M\&>$_"'BCPI:_L@Z._AG]FSQ%HOQ4^*9\?
M?"KP;<>$+#P%J7@'2OB#JOC+4_&6N?#O6O"&D:%H^N?#WQAK7B+P7J\GACP=
MK=[H<OB/P1X.UC0NDU']C7]G?4K3X 6+>#-=TNV_9A^(NI_%WX-)X9^*'Q9\
M(MH?Q0U_1O&>@^*?'WBF;PMXYT>;XI^*O&>F?$CXC)XZUGXKR>-KWQU=_$+Q
MYJ?B^76M3\8^)+S4^EN,JE1R4G&=><TE:*C"6)J5(I<MG[M":HN$90C*474?
MO-264U-Q7LVH24$DW>7O*DH/F;NG>I%5%-QDXI\FRY7^1'[07[3_ .WE\*M&
M_P""I2:5^TCX#NM2_P"";/[)O[.7[1GA?4O^&>?#=O'\:/$^F_ _XK_$CXI>
M%_B)I]SXMU./1O"?QBU?X97\6K'P-<^']?\ !T&MZ#'X%UK0%\+:VWC_ .C/
M&'[3?[2GP0^//[<7PL\4_&WX*Z]9>!O^"=VF?ML?"/QS\;?!\GPR^#?P2^(,
M_B7X]>!KOPY\1+WX>W&H>--3_9WL[SX<^#O%FOWM]J7B7XJ:+IZ^-8['Q1KH
MU'0-.T'[+\=_L'?LP?$N[_:FO?&G@OQ?JTG[:G@'PS\+?VEH8?C9\=='T_XA
M_#_PCH6M>&-#\+6>EZ'\2M-TSP!IR>'O$?B#1M4_X5K:>#[CQ#I^MZM;>(9M
M4CU"Z$L?CW]@C]EGXIZY\2?$/Q(\ ^)/&^I_%_\ 9F/['OQ*_P"$F^,7QLU?
M3?%W[/?G:U=KX-U+0[SXBRZ(FMQW_B/7M3B^)EII]M\5(M7U:_U>+QJFIW,E
MV<VYM2T7,Z+BKI\OM94L7%R]WE:C[2IA9KEUC[%N*6JGK[O-%VERJ47:[ORQ
MK82233;YOW4,7"2;?/[:/,WHZ?XM?M=?M2_M03_LH_\ !8_X67?Q5^+GAR7X
M#?L*_L\_'KX4?%/Q#X ^%_PP^.5S;?M"Z5^T7X?\=:#J&A:/X6%IX0\#Z];_
M  ,@N/#5CXC^'GPV_:8^'47C?Q;INMZIX3\:Z+X3U?PW^A/[3O[6?Q3_ &/?
MCE#:ZYKUU\7O@S\/O^"7W_!0/]L'Q1X6N_#/AG1OBIXY^('[)/C;]E:XTA9?
M&WAW3M,\-VT&N^$_BWXH\/:?HOA_X>>'K*SU$P:MJS>))38PZ5[5!_P3/_9!
M.C_&;1==\'?$?QS;_M$_L^Z/^S'\=K[XD_M#_M#?$;7/BS\*/#\OC&70H?''
MB#QI\4=;UK6O'6A+X^\56?AKXK37P^)WA+2=1&A^$_%NAZ+:VFGP^O:?^R)\
M"[+QU\-?B7=Z/XY\3^.?A-\'?''P#\):]X[^-'QI^(!N?A7\3-3\+ZS\0_#O
MC?2O&OQ!U[0_B=>>-=6\$^#M2\2>)_B1IGBOQ7J=WX6\/2SZV?[&TX6T5%.2
MDH3Y9.:::BTDE0Q]-*R4K)5*V#G9:?NKVE*E'VI'E3@W!M*,5)<UVVJV!J3?
M,^76<*.+A=K3VVG*IR5/X>\/?M(?M+>$/B_^P'X;U[XA>%_BKX8_X*&_!7XF
M7&H:@G@+2;7P]\ _C[X+^!6G?M >&_%7PTM/"UWH&NZ_^SCXET6U^('A/4/!
M?Q-\8>,/B+:ZFGPFEL?C5YMUXJ/B+Q[]B3]L#]K'X@:Y_P $I?%'QD^)OA3Q
MWX<_X*$_L)>,?B[XY\$Z-\,M$\$V'P]^)WP^^'GP$^(>F^*_"&L6%[J&O7Q\
M56WQ+\7:-XWT;6]1N?#KS6_A?4/!6B^#$T_6+/7?TQ^%O[%W[/OP:T_PQI7@
M'PWXIT_3OA]\._$OPA^%5OJ?Q1^)_B&7X._"OQ;)H4VM_#[X1:EKWB_4=6^'
M'ATOX9\.V^CCPKJ&G:EX8T/P[X4\'^%]1T;P5X*\%^'/#^-\/OV#/V7_ (6W
M7[+UUX&\%>+]&;]C'P#XH^%O[-UO-\;?CMK.G?#[X?>,M)T;0=?\+7>E:]\2
M]4TSQ[ITVB>'/#^E:=_PLBT\7W&@6&AZ1:Z!-ID.FV:0[)Q]I*2BXP=24HPN
MYJG2G4Q4E1NW[SITZM"DJKUE[)2T<%S8RC4<8)35XTE&4K<KJ58K#)UFHJT5
M4=.O)TTVHNK:S3:CXG^WTWQ ?XW?\$P-%\&_&3XD?"[1O'O[;WBWP'XXTGP+
M'\/);'Q=I,?[#/[8WQ2T2?7X/''@#QL+^7PSXL^%6AWFBZ<Q3PYYM_?:OJFA
MZEXIT;P)XA\&_-1_;E^/FI?LX^"_V^_#VM^=\.K_ /X* _\ #+WB;]F&\\$Z
M',D_P-U?_@H#J/\ P3VTC6] UNULH_B+9_M'6'B.3PM\9+Q+_P 7:A\.;B)_
M%?P@3P#]KN]!^)6C?JA\=/V<OA7^T9:?#>V^)UCXN>Y^$/Q/TGXQ_#?7? ?Q
M-^)?PD\6>$_B!I/AGQ;X(&KZ;XO^%/BWP9XF^R:KX'\?>-_!?B'0[C59M"\0
M>&?%>LZ5JVG7<-PABXO1OV+_ -G;P]XT\1>,]'\$WEFGBSXRQ_M%Z]X%'B[Q
M?+\);SX_(+>=OC"GPEGUN7X>V?C:?7;.R\?75U9>'[;3KKXOV5K\<9]-D^-$
M0\?5,%RR3E=Q51S<4EK%U,(Y1;=]94:5>AJG[/VBJ0L]85)2?M+-7E3C"+:=
MX.-/%135K;5JM*M_>Y'&5[)39^V7\5?$'P?^":>)?"OCOP?\.M>UOXK_  &^
M'EOX@\5Z3KOB34YM)^)/QK\!>"/%^A?"KPCX=\-^,+[QA\??$'@G6_$FD_ '
MPU?>%]=\*W_Q@NO!K^/=-NO EOXEC/Y.:/\ MR_MDW]I\/\ P1;^*_#?AWQ)
M;_\ !9/Q)^P)XCU_XG_"_P )>(?'>L_!R7]G_P 1?''PU<^+;'X6>/-'^&%K
M\0=$NI-.\.ZYJWP_CL]#\2:7I-E<6%MX9U&ZU:XN/V:_:'_9P^$7[4_P[7X7
M_&?0=7UKPU:>+_!'Q"T&^\,>-/&WPV\:^#_B#\-?$^F^,_ /CKP-\1/AOXA\
M*>//!7BWPGXFTBPU32M<\,>(M+O1Y<^GW4ESI5_J%C=^#:3_ ,$V?V0=$UBT
MUW3_  /X_BU&P_:2T3]KVSD?]H;]HR2!/VCM#\!R?#9?BC=6C_%=K75M:UWP
MI<7UOXWMM:AU+2?B%J>IZEKWCK3O$6N73ZA1"RFW.[BY0NE=^[&6'D[:IIN,
M<13:32M4C*[?-R54NZ;C#2?++EDW9*3C62TUT4I4)W:;]R4;62Y_@>__ &I?
MVS/#?[*'[5_Q+B^)R>//$O\ P3L_;L\6^$/B]KFF_"KP,OC'X^_L6?#.\^&?
MQ+^+K1^'+6#3_"OA[XZ^#O@!\1?$5[X;U?P3HEAH?C+Q=\-+'3HO EM+XWQH
M_P"I/[/?Q(UGXQZW\9_B9I/C2P\6? V\\=V7@[X$3:*OAZ^T#6-$\!^'-+TC
MXC^.-'\0Z59P:KJ=IK'Q?E\<^#+>#5;W5;#[-\.H/$OAK4)M"\5VJQ>=:W\"
MO%/[.OA_XB']B3X/> O%?C/]I3XZZU\2OCC/^T'^T7\:8O"&BZYXV\)?V+XG
M^+EEI>L^'_CA>^)'L#X8\%:0/@9X.;X0>%->TA'AL_%O@[[%]HF^A?@'\%_!
M?[./P0^$?P"^'-FMAX$^#/PX\&_#+PI;BWM+:5M$\%Z!8:!97=Y'806UHVI:
MA'8B_P!4N(H(OM>HW-U=.OF3.2H<W*^9IR4*4;V2?M?8PA7E;K3;IPG3?+']
M[4K-6<I**:]Y)-VYJLNME3=:<Z$;WTG&,Y4ZD6Y7ITZ5W91;_)WXR_MP_'W_
M (4O_P %/OVJ?A1X@TS1M,_X)F_&/X@>#M-^!FO:%X>?PQ\:?!G[.WP5^$GQ
MH^-\7Q-\07>C:CX^\.^+?B!I7C?QYI?P:UKX?^)O#FB^%(+#X5>-?%/A?XA6
M=WXK\%Z]XA^V[J'CWQ'XB_X+PVFK?%GXHW7PZ\._\$5OAGXM\._!W6[/X?6_
M@_P]/\2OA?\ \%,])\0Z;%91^ (?%FG3&Y\"Z7X@O;Q_%4WB;4-?N;G2O$VO
MZ[X+\/\ @7PCX/\ V(\4_L9?L]>,?'WQ$^(FM^#=1?4_C&_@&X^-'AVR\9^,
M],^'?QCO_A<FGVG@75?B?\-M/UZW\#>,-6TK1-)TGPCK&HZIH,EUX\\ Z'X:
M^'?Q'D\7^!?"7A3P[HF5\7OV&?V;/CIXR^*7COXD>%/&5_KGQO\ V?F_9=^,
M-MX;^-/QM^'OAKXE_!))_'TUAX6\8>#_ (>?$3PKX5U?4]$3XJ_$NR\/>-I]
M'_X3K0=,\<^(M+TKQ):Z?=QVT&<H3E!14M?9SC*Z?QSP=6A.2?53KRIUDK+V
M24E"S?*]8RBI\SB[*<)))[1ABJ5:%D[6E"E&I3;C_$;BY-WO'\R-8_;5^/G[
M'DW[0T?CCQ#H'QM\"_"W_@D"O[??P]\%P>";7P,O@KQ=\(HO$OAK6?AS8:WI
M%WJ^OZOX \9Z?8>$M3OM2\877B7Q5X>URQ\5ZK8ZR/#VKZ7X4\-^D?M"_&;_
M (*!_L_?L^_MQ_':V^(_P.\0?#[P+_P3Z^+O[2'P,\2>(;OP]XT\?Z;\>?@]
MX7\1>+M:7PQX,\ >"/AQX0\3?LV>+/!1\'WWAS4?%/BKQ7X\\!>/+B=/$&L?
M$GPCXHT73-%_0&P_8L_9NL?'EK\29_ NL>(O$]O^SF/V2[A/''Q,^*WQ!\+:
MW^SXU\NHW/P]\5^ /'/C?Q%X"\8QZE=(6UGQ-XK\-:SXRUN&:YM=7\17MI=7
M,$WBOP\_X)4_L/\ PO\ @K\4_P!GCPI\-/'/_"G_ (P_#74O@MXM\)>(?VA_
MVC_%[:9\%M8BO[?5?@]\-_$'BKXLZQXH^#WPPU2VU*[MM7\$_"?6O!>@ZU"8
M%UFSU V=FT'15GSSK2L_?E7<-+.U3$XN<(R:;]]4:U#]\GS1G2G%\ZY)/FI4
MY4Z=&#:_=QP\7:]KTL+@Z<VE;6#K4*[5)I1E"M%^ZU**^F_V?- ^,VB^#M5O
M_C=\7M'^+_B'Q?XC;QCH%UH'PST_X7:-X#\*ZUX<\-BW^'&EZ79^(?$][KVF
MZ%KMMX@U/3O$WB+6+OQ+=6&NVVE:M<WTNC)J5[[M6#X6\-Z9X-\-:!X2T5]7
MDT?PUH^G:%I;Z_XB\0>+M;;3]*M(K*T.K>*?%FJ:WXG\0ZAY$,?VO6?$&L:I
MK&HS[[K4;^ZNI99GWJ)N+G-Q5H.<G!-6:AS2Y$]7JH\J>K=TVVWJ[IJ4:=.,
MWS34(*<OYIJ$%.2NEI*:DUHM&M%L%%%%26%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YX?'_\ X*&Z;\#O
MB?\ &;X/Z)^RG^U=\??'7P+^!OPZ_:4\8Z=\$- ^"VIV^H?!/X@:O\8M";Q5
MX3NO'OQP^'XUWQ!X;UGX'>,]'N?A<8[+XK^,=3GT4_"SP3X^T=?$^L^%_P!#
MZ_%_6_%/Q,N/^"P'[4OA;X$:W\#KGQQ>_P#!,G]C71+NR^)GBC7+:[\+:Y;_
M +1?[?5[I_BNU\,^%-+UF_\ &EOX(MO%&D:OXL^'%W=>!;CQ!I_BOPAL^(W@
MJ#48+[4BS:GRVYU1KSIQ=DI5*=)SIQE=Q:BYJ*FTU:,I-RBES13DH\K?PNI1
MC-ZZ0G6A"=K*7O<DI.*L[RBDE)^[+W/XI?\ !5C]EGX?_#72_BAX8U:^^+6D
M:O\ LQ^"/VP]-\/^$=<^'GA+QSKWP$^)EGXCU+X;ZWX,\(?&3QO\,=8\;^+_
M !_I_@CQ_-X8^'_AF&_\2+=^"-5T7Q+!X:U_6O VE>+NPTO_ (*"^#_&/QS\
M/_ KX3? 7]HKXPWGB#X5_LQ_'Y?B/X.T7X4:+\,](_9\_:G\0?$3PUX0^,NN
M7_Q,^+_@#Q?I^B^$-2^&/B0^-_ 1\%R?&J2R$>I^ ?A?X[TO3/%%[X=^6-&_
MX)W_ +4G[)OB_P" &N?\$]/CG\%M*\.>#_V-OV>/V%?C-X,_:Q^''BWQQHWB
M?P%^S#=>.KWX/_'OPO/\(_%/PYUP_&#P_/\ %'XBV_BCP/<ZYX?\ _$'2_$[
M6YU7P9JNEZ7KMM]A_#O]G/XJ>#_VU?B)^T5KGBKPSXI\&>-OV0?V<?V:Y;V]
MO+J#XEZAXG^ 'Q ^/_Q F^(FLZ3I?A#2?!%NGCJ[_:$UFRO]$T>XM[?1)_"=
MEJ>G^=:^))=!\-T^3FFTVXJ6(Y5U:IQK.BE=7E&JU1<)ODDY-PG&#<W#-NKR
MTTDG)J@ZCTLE)T_:NU_=G#]YS07.DM8RE%0<^=\$_P#!1OX,>+O@%J/[6%YX
M9\>>&OV7O^%$G]H?PK\=+G_A!_$WA+QMX,%[/8'PEHVD> O&OBOQQ8?&-;E-
M.@3X4:_X4TGQ)?ZMXATCP=HHU7XAZ=XW\&^#:GQ$_P""C7@#X./^T!HWQ;^#
M7QN\$^/_ ( ?LK^(?VT;OX;O#\)];\0_$W]GWP9)>V_Q!U_X6ZYHWQ7NOA]K
M'B;X7:I;V/A_XC^#_$'C3PSJ6C:WK_A>30Y?$_ACQ9X5\3ZY\4ZO_P $@=;^
M+?AW]J"R\8:E\+/V5]8_:L_9XLO!GQ@TK]DRZ\5ZS\)/B-^UUI/C?PG\2/"W
M[<6J?"/Q3H'PX\.>%/B!X0\8^#EGN/"^E2:[KWQ-T+Q?K>C_ !*^+&LWNAZ)
MKTOOGQY_8@^.W[4WACXR^+_BMJWP:\'_ !V\8?\ !/C]HC]@[P!9> ]7\;:]
M\+](D_:B;PO=?%GXQ>(M5U_PEHOBR2"?4OAY\-KCP7\+++2;N7PA8^'O%FFZ
MC\4O&,WC^VU3P/E+GY).'*Y\D[*35E)4<3R--+WY/$PPJY6H1="M*4XTZD*G
M)O'D<US74'4CM>Z@ZN&YE+>T50GB6Y)SE[:BE!RA.GS_ $E\"OVWO"?QM^,U
M[\#;GX1?&CX2>+;OX&>$?VD_AW?_ !0TWX?P:%\6O@SXKU@>')?%7A!O!'Q$
M\;:]X>O_  OX@N-(T[Q3X,^*^@?#?QQIB^)/#]U'X<N8Y]472/-_V\?C3\2?
M ?Q%_8<^$7@WP=\4M<\*_M'?M-^(?AQ\3KSX7^*/ 7@WQ)KO@_P[^R1^U7\:
M(? 7A3Q=KGQ5^&OBWP=XHO?&?PC\&>)K[Q-HFHZ#;'P1H'BGP]:^+X/$&NZ7
MX?UJW\*OV5?BYX0_:M^#?QZ\1:I\.#X6^'G[!UK^R9K>AZ+K'B>^\07?B]?'
M/@KQO<^+]*EO_"VF:=)X;5O!PTB#3[R2UU24:E_:<DT1LO[-N_2OVFO@9\3O
MBS\7?V*OB!X$G\!0:/\ LO\ [0GB7XY>)K+Q;K/B+3=3\4PZ]^S?\>?V<T\-
M:%_8WAG7;2RDM['X]:EXQ;5M0D=7N_"EAH"Z<L&N7.LZ3I5252*I^]#ZU.+;
MV>&CC,5&G*2:5E/"K#3DK7][X4W.*YX.JZ,G47+5^KTVE%K^,\)A)58Q:NKK
M%/%0CKHHJTFN23\.\"?M?_#/]GKX:>#-#U_6_P!H_P",'P*\(?M#R_L:ZG^V
MC\6+SX=>)(H/BN?BO<_!+38OB7JNCW/@[QKJW@[PW\?KBV_91U'XOW'PTN;L
M?$G2;;7/B%J>M>%6\4?'&X]A\#?MK6OQ'_:=^*O[,?A+]G+]HF^O?@5\2+/X
M:_&3XP7-G\&-/^#?@.^\0_!'PQ\=_ 6O3:G=_&F/QUXJT/X@>&/%^C:)H]MX
M$\ >*?%/A;Q-)Y'Q3\-?#W1M2\,ZWXA^7F_X)R^.;SX3_$_]CG6_%?@C6OV1
M?'_[9)_:RTK6I[G7K;XM>%_"NO\ [5FC_MH^._V<9O"4>@2^&==T?5_C59>*
M='T?XQ#XA:/K^D_##Q\NBMX N?&'@6W\<>,/JC]GG]G_ .)'PI_:5_;H^+_B
MF_\  ]YX._:G^*GPM^)'@S3_  _J.OW/B;PO'\.?V?\ X8_ .XTOQ1'J.@Z=
MI5R^MV_POL_&$%QI-XPTF;7KKPU)'JL>E0^(M2*=I04JC7M.2[CJESJAAN:-
M[<VF(^L1A>WM*<8S;NTZESYDU&"7+[2S=[\M-UL1RR2V;='ZO*:VA.4HI63C
M#H/C1^UQX8^$GQ&3X/Z/\/\ Q]\8OBV/@SXP^/S?"[X9W/P]B\?:K\-O!FMZ
M;X8OKCP5H'Q"\=^ SX^\17GB'5;>R@T'PM=7RZ9'#_Q4VH:!J?B+X>:3XY\H
M^)W_  4>^%/PI\/_ +9'B+Q!\+_C9?V_[#WQ-^%?PS^+=EHFG?"V>_UR7XO>
M$OA=XW\,^+_A\-1^+&EV6K^$[/P[\7/"]WK<?B"]\+>,+:6#5[.P\):E=6MI
M%?<C_P %"OV*?%_[:FCW'@B+P_\ !>*TLO URWP-^/\ JFO^/? W[2G[&G[1
M$]_J9T_]HGX%>+/ /A^XUK5KS0$3P3KS> K'X@?".#Q?J'@1/"WBGQ=/X5\4
M:@NG>"?M,_\ !.3]I;XIW/\ P4#\)?#3XK_!G3_A[^W2G[.GCRY\4_$?P_XQ
MO_B!X%^*?P0\)?"KX6:UH$_AWPDVD^%O$/@GQCX0^$7A7QI;^*;36/#VL:)X
MG;Q'X)3P3=Z5K^E^.?""@U[O/_S\E&6EGRJKAFI:?#^Z>)AKS<\E&I%Q;5.-
M2WTO\,7TWY,0I)=)7J?5YJW*X1YX232YY?=7Q-_;.\-^ =>^)&D>&?@_\=/C
M?:?!'QU\(OAW\;M1^!W@FU^(%_\ #GQ-\81X*U/3]/\ ^$)LM:@^(7C:[\!^
M ?B7\/?C'\4;+P#X4\27?A;X1>++'Q/80Z_J\-UX:B^&O!7[;VO_ +.GQG_;
MQL/C#H7[0WQC^$^@?\%-_@A\!]/^*-K<_#*]\$?LT>&?VC?V9?\ @GYIGPYT
M/5['Q+XY\ >);WP+/\?/CY?QR:3\'/!'Q)\0^$]-\0ZAXP\=V%K#=PZOKOKM
MY^R;^VIX _:W^-GQ-_9^_:&^#6@_L]_MB:Q\-_''[1OACXB?#3Q=K?Q4^%7Q
M/^'GPD\#? O7/&_[+5[H'C#2?":7OQ4^%GPU\"Z5<6OQA3Q;I?PU\;>%M)\>
M0:9\2-';6OAOK?$?&7]@7X[_ !+\#_MQ^$M,\0?"/3KC]JC]O+]E7]K[PI?W
M^O>,G@\+^'OV;+;]BZQG\&^(K6W\#O)<ZUXNMOV,=+EBU'3;A['1I_BA?QO%
MJ,?@.W;QNH*]2A*7P6J*JKRCRWGAX--).\6E4J4II.7*I.T4W%S4<^6:BES*
M2E3M9IVI8J5-MMQ?-SNE3K4V^12FG=\L9+] ?VH_VD/"O[)WP?U+XV>./"OC
M?Q=X5T;Q7\-_"FK6'P^M_"EWX@L7^)_Q%\+_  RT?6WM/&'BWP7IUQHVE>(/
M%^DW&O+9:M<ZU%I7VFXTG1M8NHELI/&/'_\ P4)^"GPL\2_M7>'/B%HGCOPB
MO[(=E^SE?^.O$FNGX=:?X/\ %=O^U-KFJ>%OA7/X0\27/Q%CL-$T[_A*M*FT
M/QCX@^+[?"OPUX)21?$WB+6K+P1;:EXHL>Q_;I_9T\4?M7_LH?%/X&^$?$^A
M>"?'?B>W\%^(?!FO>([#4-<\)V/CKX9?$'PC\5/"-IXFM--FTW5[CPIJOB?P
M5IFC>(KG3&BU:VT*_OK[3K6>^@@LY?F/1_V2?VHU^)7[9GQK\7W/[*?C/5?V
MM?AK^R5X#U7X$>(O#_CG7_A5_8/P=U+QQ9?&?X>>,?&&NZ;?R^*/#'C_ .&_
MQ'\6>!-$\1W'PB(N-3EL_%^N_#^WTM;GP!,M;S3LK<W*W?7]S3<=KW_?*I&Z
M3TDFTU&-[TM?7X8Z*U^;VTU*Z;2THRA-)M)RA)73E*WT7XT_;6\$_"S0M)N?
MC'X-\3?!SQ7XH^+6H_!KP1X5^)/B7X5^';+QWKVE_#R?XHWGC3PQX^?X@S>
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MEK*W.K).SB[^RE"]Y3A*:DU*$F_IBBBB@84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A_QS_:5^ 7
M[,NB>'_$_P"T-\7/ WP6\*^*/$5GX0T+Q=\2M=M?"/A"]\5ZBDDNF>&6\5ZP
MUKX>M->U6"WO+G2M)OM2MK_5+73=6NK"WN;?2=2EM?<*_+O_ (*'?LH>"?\
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MW\,Z]XWT*S>UN_$]OKFA_B#XR_98\>_!CXS?\$?/^"+OP?\ VP_VF_$WPD\
MZ1\=_P!J']IG6=3O_A7JGC+6OV?_ ( ^/=!\9_L_>'?B!=:Y\+=>N-1\ W_Q
MN\1>&O@G8>#CJ,?P\U/X7Z'JOA7Q/X.UYHO"\FAQ'WI1@_=E.JH0UNN6_-.<
MK:VC0IUZSBDY/V2A%-S0Y:)R6L84W.;V?-;EC3C=[RK3P]%2;4?WKE=*#/Z,
M_"GQW^#?CGXJ_%?X&^#_ (E^#_$GQ@^!=MX%N_C#\.-(UJUO/%GPWM_B9HMQ
MXC\ R>+=(B<W&D?\)7H%K+K.CK<*KW.FF"\VK!=6SS>LU_'/)^W;^VO\1OV<
M_B;\?/@1^T _@_XD_P#!2/\ X+->&/V(_P#@G?X_TOX)_LW:U<^&?V2? ?Q%
M\6^#I/BCXHMIO@]_:OQ0\-6OA[PA\9Q<:CX_N?$NK>#8/#_AI=&\6V;W>NOK
MO8_%S]O_ /X*%:3\.?VZ/A[\*OVE=>U3QYXV_P""S?P3_P"";/\ P3O^.VN_
M"/X!SZKX=\0Z_?\ AB?]H;PEKWABV^$]CX"\<?#_ .#]EI7Q$\-V?C#5_"<G
MB*#7]+U7^V_'&H7N@WMI:D+S4.5>].-)I/:4ZBP4E%-74>6.8X52YFDI*NO^
M74E DU!R4FK1E43MO&--XN+DXMJ4KRP&):45=Q]B]ZD.?^M+7==T3POHFL^)
MO$NKZ9X?\.>'=*U'7=?U[6KZVTS1]$T32+2;4-5U?5M2O98;/3],TVQMY[R_
MOKN:*VM+6&6XGECBC=AQ_P )/BY\,OCU\-?!OQB^#7CCPY\2?A?\0M$M_$7@
MOQQX3U&'5= \0:/<M)&EU97<)X>&XAGLKVTG2&]T[4+:[T[4+>VOK6XMXOYA
M/B[_ ,%%/VT/@S^SS_P7/\6:9\=/$/QGM_@1^U!\*/V1O^">GQ E^&_P*M?&
M=Q^TEX_TGP'X3^)?PATSP[I/PTLO GQ#T;X2_%?QWINE?8?%?A'Q%XDN=&T;
MQ9IFL^)]3UZUGU/3\3]I+]MO]L3]E3QU^V'\,O 7[2EAI/P;_P""8'_!&_X0
M3?&[7M*^#7[/VD^#$_X*&_%#2;J/X0W_ (*T+3?A;I:Z9?\ Q(\.6F@W/@OX
M<6]G:_!3PMJ'BW^W-1\ S:/X6T'X<^-E>RE-_![*%2+2:WPU;%SC)-7YO8QH
M14;0DJN)H)J<:T>2DI.48)6DZDX2BVGMB*&%BTXZ6]M4K-OWU*&'KM.,J4E/
M^MNO'_CC^T%\$/V9_ W_  LW]H+XK> _@W\/?^$A\-^%#XR^(OB33?"WAX>(
MO%VK6^B^']*.I:I/!;BYO[ZX4MEQ%9V$%_J]_):Z3INH7MK^*OQ _:)_X*#^
M =._X)=^ ?BIKWQ#LI=7_8P^)'Q^_;^U_P#9X^"FC_$_]IGXE_&CX3?!?X>K
M:?!SP;\*/#WPZ\?K\-]&\6_%KQK>R>)O&OA_X76&D:WXPL?#/PP\,:]\+-1\
M4:+X>\5_0_[,?[,GQX_;-_X)K?!3X<_\%<X5^(7Q7^)%]X-^*_Q[^&OB;P3\
M+M(CTQ_"WBW3?&'@3X;M8>!?"OA_2/#;(/#?AC6?'30V-UXRLM5UOQEX1LO$
M>D6BZ>-'T<6I33<;4ZRI3U=VH8KV%9P7625+$3AJXM1I3;]G5BW"FI*#5_WE
M+VD++9SP[KTN:^BBW.A&;6JYYP2]I"2C^DGPJ_: ^"?QQU'XI:1\'_BEX)^)
M&J?!'XE:[\'?BW8>$=>LM9N_A[\4?#"V[>(O WBF&UD=]+\0:,]REMJ%E, U
MM?17NGR,M]I]_;V_K]?/WP*_9H^%/[/>H?&CQ)\/_#.C:1XQ_:+^+>K_ !U^
M-WB/2=&T[0%\:_$[6]#T#PU=:RNCZ3#!IVDV5OH7AC1K*&TMTEOM6U&/5_''
MC35O%WQ/\9>/?'?BO^=OP;_P5/\ VN/VC8/^">?[0_P7\41Z)X<_X* ?\%4-
M1^#GP*_9AMO"O@O55UK_ ()E? N/XF^'/VC?C7\19-5\.7WC^V^*<,WA2?XH
MZYK/AKQSI'AWX>Z?9_#+P_HNEWVDW'Q$E^)LQ]Z4(Q3NU24V]HSJ35-135K\
MU3FY(_%[.G5J2M"FY-NZC*3M92J<J6[A"$JEWO:U.*YI6Y7.=*G&\YJ*_HK^
M.G[47[/?[,UAI&H?'CXN>#?AE%K]CXMU?1+7Q%J6W5]6T'X?:)_PDWQ%\3:?
MH-C'>:W=^$_AMX7SXI^)'BN'3W\.?#[PNK^(_&.J:)HB/?+[PK*ZJZ,KHP#*
MRD,K*P!5E8$@@@@@@D$$$<&OYW?^">'@?Q7^T?\ \%<_^"I?[;VN_&WXG^-O
M '[.GQ#;_@F_\#-!UZP^$(T"UT7PII?A_P"*G[2'PXN%TGX5:7KMKX7\ _&G
M7?"]OX$O_#FO:%XKURWT9T^,_BCXM:A9:9/HO#_\%5/^"B'[2GP%_;*^)7@C
MX%_&?4/AM\&OV2/^"6?Q]_;#_:+3_A"?A1XN\,:A\5?%MQXI^&/[*GA"74_%
M?@K5_%>D_$#4O'-O%JWAOPY;>*K'PYK-[-X0UWQ+X7\4>#=$\7^&O%4.2C"$
MY;U*4ZZBM>2G&C7KKFO;WG2HPD[)*$\11IR2YO:%J+E4G%-6A.%)R=_>J2J4
M:+Y;)^ZJE9Q2]YRC1JU(N7*X+^ERBOY5?@Y_P4>_;J^$GQBL=0_:X^(J>)/A
MK^QM_P $0?#O[8O[?GPWT;X<?#W0]1@_:=\6PQZKX#\$ZAXFT_0]/U+2/CWX
MTT;PIXOUVZT'0KKPQ\'[/2=1M/#6D>"KG5=(N?'&L^N_L9_ME_MI_%O]LG]F
M7P1\8?VAM-T_P=:?\$[?$O\ P49_;G\!Z-\.?ACIOPV^&FJ_M%:U:6?[-'[-
MFE^++OPMJ/C_ ,)6?P?\!7NJ^,-1O;_QK<^)_&ES\/[OQ1XE\2ZEX>\41^'U
MTDG%R3:7(ZW/)NT8>Q^N\SE+51BXX#$SYGI&G!3GRIW6<9<Z32?O*DX1T<I^
MU6%Y5&-TW+FQF'ARI7E.HHPYFO>_I-HK^//]BO\ ;2_:9\)?"[]D[QUJGQ ^
M.WQJ_:K_ ."XO[1'QM\?>!;SXB>$_A#K7BOX&_L/?LBV?BN_MX_ACHWAWP'\
M.O!"_%+QE\'&\$7'PX\/>)X+']FSPW\2OB[K?QQUCP/H6DP?%?1/B7]?^/?C
M?_P5%\">*O\ @F)^RAXA^/>F^#?VN_VS?VE?VJOBQ\0=+7P'\&OBEHOP:_8Z
M^%MCJ_Q*\-_";XFZSHG@SPSH?C?Q%\--&UOX6> _&/BSX>S_  TD^)=_)\0_
M!G@OXF_VRWA+XME6G[J<)*<E32BUROVLHJ=2CJT^:A&2]M)I4XN%=<W[F3D^
M9/F:E%QBYOF4E).E&4H1JW5TU5E!^SC%N;4Z/NWJQ2_?;QA\=/@[\/\ XF?"
M+X,^-OB1X1\+_%;X^2>.8O@QX UG6+:R\4?$R3X9Z!;^*?B OA#2Y6%QJ_\
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M1U&^\5>"/#7@G0?(\%6VGIW[;7[6'PO^(O\ P4GA^,7[5VJ^+?AC_P $V?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"#?O1C*/G/BSX1?#+QO\)O$_P(\3>"/#]]\'?&7P^USX4>(_AU;V*:3X7O\
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M/"FK^$]!U'4)O!GQ+U3P)I7B;6+*>75=.U9]"MSJU_;+>?JZQ5068A0.2S$
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M#LO^"^VC?M0_##P'X6^%_P 2/&OBKX8_LW^*O#T_ASQEXGT[X.>#_"^N>/\
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MU\4_"VCWGB37_AG=Z]=>&O$GAC3-2\47VG/H-I<6?T%^T5X+\:>+M#_X+9?
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M3^,/@3_P<$?M5?%_Q_\ 9OV;?C3>>%?#7PJ^-_QE_P""AGQ%^%WQ2T;QQ;>
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M]C;PC\5/@=X(_P""4GBWQ5\'_BOX+_9Q^$7QS_X*G^&_BEX+U/X-_$7PC?\
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M9\*_\%-O^"CUEXA\&?$/2[/XL^'_ -D'Q]\._%US\-_'2_#GQ+X;\'_!_5?
MOB4V?Q17P\WP[A\0:3XJM[C2I_!EYXHMO&;*LFHV^@2Z2DU_'Y;\:/AGJWQ(
M_P""Q_PUEO\ 0/V@M"^&I_X)C?'_ .%FM_&+X:Z'\:? _A71_'?CG]I?]G3Q
M/HO@2+X^^"M*T[PWX?\ %VO>"?"'C/5+:SL_&=EXET2#3XM<TV;0_$4?AG5(
M_P!F*X'P)\4/ WQ,F\=V_@G6VUF;X:>/]9^%_C9&TK6M+_L;QSX?L-'U35]$
M#:QIVGIJ:VECKVDSC5=';4-%N?M7E6FHSS6]S'"N6_L4]?8PFK?S1DL53N^W
M*L99M:.487MSM*E[OM6M/;2O_ADWAYNSTO=X7FBGLG+XN5-_CY^TA^Q3^SSX
M%^,W_!&[X$?#[]D[3M<_9S^!WQ6^/WA?4?#FG? SQ/\ %SX<_#OX:>(OV0OC
MEX;TT_%3Q3<>%_&>EZ7I7C+XQZ]X&OM7U[XK:^+KQQ\1[BV\;:]J.M>(K#4=
M?L_FKXH_ KXJZG^S?_P5 _9*'P[\5Z/^U/X]_;*L_BQ^Q!XO\*^ O%.F^%TT
M1'^ T?[$?Q;^''Q&T7PW#X,\*:+^R!;> ?"7@/XA0:5K-IJ7P8TSX0?;O$>D
MV'A_QWX&O/&W])6HZCI^CZ??:MJU_9:7I6EV=UJ.IZGJ-U!8Z?IVGV,#W-[?
M7UY<R16UI9V=M%)<75U<21P6\$;RRND:,P\9^$?[2?P1^.NN^/?"WPM\>6?B
M7Q/\,5\'7/CCPU/I7B#PYX@T31_B)HUQX@^'?BO^Q?%.D:)J>I^!?B!I%CJE
MYX$\?:/:ZAX*\8_V)XA@\-Z]J=SX>UN&P-6VG*[E*=2=GRR;E6P>(34EK&4)
MX."52*Y_95*D4HJ,91+;-*UE",;KFBN6EBJ+3333A..+DY0D^5U(PDW)SE&7
MY)P:FFF_M7_MM?LV?M2_LI_'SXT:Y\;OVM_V=OVFOV2_B'X=^$OQ*U_X'>+?
M OPW\ ?LY6_PNL]0_:&\%:;?>#?@ W[*GQP^$'B3Q;\0M"^)&N^"0\.OR>*/
M"/AKXH:[\7Y-#\;^=?#7P_9^(?VFOB)^SQ^UM\ OVR?%_P <?!?_  4N\2?M
M<_LY>./#OA#XJ-^S?XU\$7'Q"O\ QA\"?C;+^T9X6T"S^%_A"+]GKX ZMIGP
M)^(?PX^)/Q(TS5O$F@>!+;X->'O"OC^X\8:'X N/Z(Z*<?=4(M)\L5&3V<N3
MV?LY)JSC4C[*"E-7=1<UU!M-*5VYN[7,W)=>7F515(ZI\U.7M9N,'90?+9S2
ML?SD>"_ &J$_'3X+:[I_QV^.'[$7Q*_8M_;YN4URZ_9P^(O@+_@H#^Q3IWQ8
M\0_#N^^)W[*^D:VGAKS_ (X7WQJO-5U[QC^S_:VW@+4_B]X@O/A7H.L6WB'X
MY>$KCPQXRU'%\7^)_P!H;0/A]XPL_CA\*$_;"T/PG^VK^P1K/A3]NOX;_LV?
M&;P1XI\1Z)X>U2'QB/C=\;/V4O@T]AJWQ>^+7['_ (M\(>&/"FM:Y\*[!?@Q
MKNN>+?AXOB7X<:#-\"OBE\)M%_I1IK,L:L[LJ(BEW=V"JBJ,LS,Q 55 )))
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M+#XJZ)^V5XP\0?LQ?%#Q=>^/_P#@WU_9:\ ^'=6\5?LH?&-O$7C3X^Z%X?\
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MAI'JUQ\4= U[XI?!&XUOPQX<@'B_PCXAU70HO$%CI&M>&]2BT7=_:!@M=?\
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M5S.\(U%)2Y6Y6<4FVWS+\\/VV_BW^U?HGQ6_X*5Z!\)_VJ_&_P '_#W[-/\
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MGQ%_:J_9\^!7[1>J_$WQ!I&@P?\ !<_]G;X2Q? .+PQ\/H?#WA+P7^S_ /\
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M9?C'^S3\./A.;I['2/BK\/\ XX7&N>&OA'\5=3\5:AX\UJPO]?\ $/B_38/
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MTYTZ+(C&2NI3;UII-*[2A3]G*7+*R;;2K17,OWB4:CG"56_&?LSZ=^U=X?\
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M]A_ /@#P;\+O!V@?#_X?^'M.\*^#_#%D+#1=#TR-TMK6)II;JYGEEF>:[O\
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MUU3^L*,>MU%5**O)N_L];N,92_$70_CK^W/X?^''PI_:DN/VL-5^(>B>'/\
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MO#\'B'X4_#;5/B-/HOB36_''BS19='&LZ=ILLJ:P=,N-&L-+L=7D%[?>*_\
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MLQ^'O@W)X$UW5]5U+PC\7];_ &==5;4;#XBGXBV5OH+>";7]FCP3I&A:5>>
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M:EXU\.^)_P"V?CQ\/_&FFZ]XON-4N_&^D:UXGU;Q'<^&/$6A7>CWWTA\!O\
M@H)X8^//Q+^$OA'0?ACXS'@;]H/X0:I\9O@_\5-#M]8\4Z#I^C:1IO@[7X_"
M7Q^M[?PQIUI\"?'WC'PKXYTWQ/\ #/2+[7/%NA^,+/P[X_T.Z\2^'O&WA6+P
MKK'"?!G_ ()V:Y\,I?V!].\2?%KPIX[\(?L5_L$_$G]A#7]"_P"%6:SH%W\9
M_#OQ'T7]FO0+[QVNI+\5=6B^'L]M8_LP^%!+X4^P>.$O!XM\41)XELFM=(N8
MM_\ 8;_9!_:D_93\/>!O@Q\2/VO]$^.7[-_P \-2> OV>?#]M\#4^'7QGN?
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M8^*GB+]M7Q9H7Q=\3?#_ %_]J.V^%WC_ .&-YH^B6,L?[-7[5'PP7X4W]O\
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M\3[?2?!O@WPKXELOV2KKP3\-?$?A'1O&.BZE\2-:^-GPM/QU\31^-/B'\:?
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MW^QOX$@\;Z7HGQ:^#^G^%K.[\23_ !6^/WP-N/@QX-U#PMI>G:EK&O\ Q3^
MVDZSI#:C)KVG6%HYKE=6SNJ;J<MVDY<E:5));Q]Z%7!55+FY6JF)2=J#E%<W
M\/=J7)=I-I*5-2;TN[J5+&0Y>7F]S#NW[]*7[)?#[XL_"OXM66I:E\*OB7\/
M_B9IVC7T.F:OJ'P^\9^'/&=EI6I7%A:ZI!I^I77AS4M2@L+Z;3+ZRU&&TNI(
MKB2PN[6\2-K>XBD>._\ B_\ ";2OB!I'PFU/XH?#O3OBIK\'VK0?AI?^-O#5
MG\0-;MA8:KJIN-(\&W&IQ^(]2@&EZ%KFI>=9Z;-']@T;5;S=]GTZ\DA^&/\
M@GXW[1]IKO[1/AOXZW\GQ:\->'->^'-M\)/VL?$WP*UG]FGXP?'GP[?>&-1O
MK_PQ\;_A3JVA^$['5?B+\$DET3PM=_&#P1X0\'^ ?B)INMV&C6/A+PWXP\!>
M-]#L/S1_:=LOBMXG_:&^)2V?[.'[0OA./X=?\%AOV ?CAJ>G?#3]G;XL>/\
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M .#A;]E'X[>%KK1_V9?BK+K^J?"'P'^TG^R/XF\6_%_PT=*^'<FI:K\/-$\
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MX[U-H_#L?AGQ,=#N-3@6UU.PL_1_A/X!MM6_:0\8_L]_M5_L:_MF>/\ XQ>
M/^"DOQ"_:\_9^^/6D>)OVB(_V1M;\#>)OC9XT^*WP2^,EW\5= \<:)\"O#'B
MO]G_ ."_BV+X+>(_@;XKM6U_Q;I_@72/ %EX9\9Z/XMFM;1V3<5'R35U[Z5'
M!5&X-JSDUB:DYJ3BG*E44+)3A14922ES*2UD[N.D;U\=349).]E]7I1CRJ34
M:M-R;DXRK?OQXQ\<>"OAWH5QXH^('B_POX%\,VL]G:W7B+QCX@TGPSH5M=:C
M<Q66GVUQJ^MW=CI\,]]>30VEG#)<+)<W,L4$*O+(B'A=7_:(_9_\/Z)X(\2Z
M]\<_@[HOASXF0PW/PWU_5_B;X*TW1/B#;W%SI%G;S^"-5O=;@L/%<,]YX@T&
MTAET&XOXY;G6](@1FEU*S6;Y?_X*#>!I_&O@_P"!4GASX@_'KX,?%;P;\>'\
M7_!#XW? SX'ZI^T59_";XFCX%_'#PJ=>^-GPKL/"WBNUU[X'>)/ 'BOQ[\.O
M%1UB#P]9KK_C3PI:Z7XW\$^*KSP[XFT[\2/VD[7]I_XG_L[?&OP7XS_8C\=_
M"WXZ_&'_ ((Q_M*>!-(\3_LM?L\_%'QOX>^,GQ'UC7/VC[>P_9QC3Q+H?BW0
M?V5/ VK^'E\*_M VGPC^(FG>'OVAO&6O_&WPK\(/"OQ!TKQ]\$=<\ _$V(MR
M4WHN2^\E%22BY/E;3NTXM.*CSJZG&-6%W&V]8I;RTV;M)R@HW22M%J:?-S<C
M:<'*E/?^ESXB_M _ 7X/QZO-\6OC=\(OA=#X?T[1=8UZ7XB_$GP;X)CT32?$
MNMKX:\.:IJ[^)M:TQ--T[7_$;+H&BWUZT%MJNMLNE6,MQ?,(*W-#^+7PJ\3^
M/?&/PJ\-_$SX?>(?BA\.['0-4^('PWT/QGX<U;Q[X&TSQ5:F^\+ZCXQ\'V&I
M7'B'PS8>)+(&\T"[UO3K&WUBU!N-.DN81OK\3/&G@3_A8'[8O[0OQ0U;X ?%
M/Q#X3\>_\$3/ /@'3O$WB3]F7XKS'Q)XVO/&O[1%[XA^&$ZZW\.EU23XE7/@
MKQ[H%OKOPJU*WB\?QV.O2>']7\,0WL&KZ7:<+^SY\&_BCILO_!*C1/!/PT^)
MGP:^(VF_\$1_VHO@5XU^(>J_ OXG^%+'X5?M!^.[3]@K6/!VA_%[Q0_@:WM/
M#7BL_$+X9_&KQHND^+;ZWU2[U[1M>UF.WGU7Q=I$WB&ZD734FG[5Q51J$&E*
M3A_:RC&-VU>3RZDE=[XVDKI<DJJC)2C3D_<4W234KMP52.72E.223Y8+&U$]
M+WPU2ZOS1I_OAX:^*WPN\:>*/%G@CP=\2? /BSQIX">VC\=>$/#7C'P[KOBC
MP6]Y>:IIUHGBS0-+U&ZU;PX]UJ&B:S86RZQ:69GO-(U2UB#3V%VD1\0?BM\+
MOA+IEKK7Q4^)/@'X9Z/?77V&RU7X@^,?#O@S3;V]VAA9VE_XCU'3;6XNBI5O
ML\4KR[2#LP17XP?\$P/#_A/Q/<_LXW?C+]B7]M+X!_M7?LH?LRW7[.GQ1\6?
MM!ZY\>M&^#7@2T>Q^'OASQU\//@=KOBGXE>)_A#^T/X*^(WCCX4>&?%_@'4/
MA9IOB?P9X=\$>#[/Q5K_ (D^'7BJY\&>$?&W>_M:>)/$GPE_;J\1>(/C'^R=
M\=/VK/V1OVG_ -A71?V8M/7X*_"+Q%^T(OP^^)6D?%#XQZU\8/AW\0?A[H%I
M=_\ "#?#W]J/X>?$KX6Z/X@^(VNR:5X"U+4/@GX=TCXB:UI6DZ%INK:8I1<9
M**G&?,ZO+-<RA44?:.BX>ZY)8F,(<G/%.$I\LN:44ID)-W<H3BE[+FC[O/3Y
MO9JMSJ4E%^P<IN7).2G&"DG&+<H_I/K7Q:E\+_&'Q)X=\5>*O@-X<^%/ACX)
MP?$C6-0UKXK-I/QAT+5K?Q7J6G:UK?B3X?ZEH%KX;T7X)V7AZ+39(/B7=>.%
MN6\5OJ6AW?AVUL;:#5[GO--^*GPPUF'P/<:/\1_ 6JV_Q-CU"7X;3Z;XP\/7
MT/Q!BTG3I]7U63P/+:ZC*GBR/3-)M;G5-0?06OULM.MY[VY,=M%)*OY;_"GX
M22:)_P %-O.D_9[UKP'\-+G_ ().?!;X,:@D7P^\0:W\']*UOPQ\:?&]Y<?
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MR_$3PMXH\9_$7_A'O"VO6_@6Y@\=:?\ 9M'OM.T+0+J#C/V?_P!JK]IWXJ?
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M+C66\,:1X#LO#&HZ7X>\8?"[XG?L&^.?%7_"*2^*]$\8^/OA9\5;KQ!I&O\
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M=&=K7YFOWRLXII)-2LW%R_HNHK\.- UK]L#QW^TY^S%^RU\0OVVM=L[GQO\
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M!GP=\3^(/BC\5IHO%'QA\0^)-/\ $NH?&"?]HOP7X&O_  %X-^#.B>&)M/\
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MZ[XB^%GB74?&/PYUK4[""ZU+P7XIU?P7XK^'6J:[X=NY%,NFZCJ'@7QSXO\
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MS\(:YHOC'PAX,\1:;:6&E>(?!6AZ[9>$]>TC3-*TG5]&O-.TK3K6U^GJ*?\
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MS-K7@^;4]+O+*>ZTMI=0U=],^U&:Y\/MX@\3_P!@7&F?\)1XA_M*IX1_98^
M/@/5?A#K7A#X;Z7H.H? 'P#J?PJ^"DEEJ.O^1\+_ (9:S%HMOJGP^\%V,VK2
MV&A^#+ZT\,>$K&?PU9VT>CMI_@OP/IXM!9>"O"L&D?0-%)))II)-7LTK-7<F
M[/=7<YMV=FYST]Z7,/6Z>J=KIZIV44KIW3LH02NG90C:W+&WQCX!_P""=G[#
MGPJ\6_&GQY\,OV7?A!\/?&G[0^EZWH7QC\4>"_"MMX9UOQGH/BBYM;[Q;H$N
MH:,UG<:)H7C+4;&PU7QIHOAM]&TSQAK%A8:OXEM=5U*RM;J+Z8^'7PX\$_"7
MP#X2^%WPY\/VGA/X>^ _#^G^$_!?A/39+MM(\+>%='MDL=$\,Z'#=7%P^F^'
MM!TV*WTG0-%MI(]-T+1K.QT;2+:RTNPL[2#MJ*.56Y;+EY5#ELK<D>91A:UN
M2*E)*-N5*4DHI-W=W>]W?F<[W=^:5N:5[_%*RO+XG97;LCPGX/\ [-'P0^ H
MM1\*O T/AMM-\'Z#\.M"DNM=\3^*)_"OPW\+@#PU\-?!=QXNUO7I_!/PVT @
M2:/\/O"4FC>#M.F5)[318ID602^*?V:_@7XT^*]G\=/$?PWT*]^,6G_#?5_A
M%9_$F!M0TOQ?!\.=;NM1O+KPNNLZ1>V-TUI:W.M^(I=#NG=M1\,GQ3XN7PY>
MZ4GBWQ(NJ>XT4VN;XO>T:UU5I*2DK.Z:DIS4DT^93ES<W-)M+3;35/336+BX
MO2VL7"#5K6<8M6Y8V^6M6_8G_94UWX8?";X+ZM\$?!M[\+O@/XDT'Q9\%_!L
ML>HKI?PNUGPQ9ZAI6AGP.T>H)>>'-*L-!U?5O"P\/:;=0>'KCP?JNI>#KK2Y
M_"]_=Z3-SM]_P3X_8JO_ (>:+\*6_9O^&EAX"\,?%SQ#\>/".A:%I4_AMO!7
MQ>\5Z[JGB+Q'X[\#:MX>N],UOP3K.L7^MZO;7@\*:EH]G)H&I7GA46J^&)WT
M<_8]%&]V]W)2;ZN2<6I-[N2<(--N]XQUT0K+165DG%+HHOF3C;:UIS5K6M*6
MFK/ENU_8F_9.TWP5H_PYT7X"?#SPWX%\/_&27]H?1?"OA/1_^$3T;3/CD_BV
M?QY;?%:TM/#<VE+%XXTCQA.-?\.:\";WPO?VFF/X<DTN/2-+CL[%S^QI^S-=
MZ?XPTF?X4:0=-^('QCT?]H7QI8Q:MXFM[;Q+\=/#U]HNJ:!\7-5BM];B6X^(
M6B:IX9\*:GI/BH@:OI^I>#O!FH6EU%=^#_#,VE?3E%*RO>RO[NO7W?9\NN_N
M^QI<NON^RIVM[.'(^G+]G7W>GO<_-IM[WM*G-I[WM)\W-SSYOPF\8_\ !)23
MXH_'?XS>-OBS\(?V)O%^H?%3XI>+?B'HO[:&A^%/B%\//VQOAYHVHW\'_"NM
M T3PKX62'PD?BE\%_!6F>&_AYX#_ &B-%^,'A2_NK_PCX=^+OBKX5:]XS?Q1
MIOBK]E?#OPF^'7A+X@_$?XJ^'/"FG:5\0_B[!X+MOB3XIMFNCJ'BV#X=Z9J.
MC>"8]266XDM5'A[2]5U"RLC:V]LS0W3_ &@S,$9?1**:T2BMHW2MINHQ>UEJ
MHI.T8\UKRYGJ#U;;;;=F[ZZQ;:U:N[-MJ\G9_#;J4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC.PO?"?_  @]K#+XI/B.TN-%723J,+VZX6I_MJ?L>:/X*\,?$C4/VJ?V=H?
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M[?4/AAJFKZAX7T>?6?B#H^B:IX=\0?!3XF#5/@KJVD^-[SPWJGCIORS^//\
MP7/^._P5T+_@IY\;](^!7P2^(W[-?_!-+]I/X8_LYZIK$_Q!\9?#OQI\>O%W
MC'Q%HWA7XD>%O!%U/H/C?P]X8\:? O7O$V@VGB"RU*UUVQ\8V+WNKVLOA-(8
M[%J=XR49+EER.I)/[$8RHP?M&N:,6G7HZ7FVIKEYG&:BHVDN:+YESQIQMO.4
ME6<5!/E<DU0K:VC;D?-RIQ<OZ;**^5;;]M_]DQ==\.>"O$'[0?P@\#_%#Q'?
M_"[P^/@[XW^)/@?P_P#%O0?''QG6-?AC\-?%'@&?Q!)KNA?$GQI="^L/#/@J
M[MQKGB*[T3Q%_8-KJ=OX?U>XL_0W_:,^ D?Q5LO@;)\8_ALGQ@U'4]2T*P^&
M[>,="'B^\\2:/X-LOB/JOA.WT;[;]JF\8:=\.-1L?B->>$$1O$L'P]NHO',F
ME+X5;^UJ;3B^5JSO*-M'=P<HS2LY*7+*,D^5R7NO5JS:C)2BIQ=XN,9<VJ7+
M)1E%NZ5KJ<6N91?O+1-V/9Z*\BN_C_\  ^P^)=O\&[SXM?#R#XJW.HZ=HJ?#
M]_%FB_\ "51:]K7A?6_''A_PY>:.+PW>G^)?$W@CPOXL\:^%O#=\EMKGBCP?
MX.\9^*?#^GZEH7A#Q+J&EUKS]HOX!Z?\5]&^!5]\9OAC9_&7Q$_B>'0OAA<^
M-O#T/C?5[WP7X7\.^.?%NE:?X>DOUU&ZUOPWX%\7>&/'.M:'% VL:?X*UW3/
M%US8Q^';N+4FFZT=]'S-/NHIN5N_*DW*VR3;LDVGW756OY<UN6_:]TE?=M)7
M>A[-17S!IW[:_P"R%J_A'Q!X^TS]I?X(WO@GPMX=\'^,-=\50?$CPLVA67@[
MXC^(;WPC\,?&"ZE_:0MKSPC\5?%6FZCX;^$_BBPDNM"^*.NZ?>Z3X U#Q%?6
MEQ!'V _:6_9^/@/5?B>/C)\.CX"T/QHGPTU?Q,/%6DFPT[XH2>([#P7'\*[I
M1<_:8_BG)XXU33O 4?PT-O\ \)S)X^O;;P,N@'Q9,FCEM-;IK9ZJVC?*M[;R
M]U=Y-1^)J+5T]FGOU71<SZ](IR?:*<G9)M>WT5YW\,_B_P#";XTZ)J?B7X.?
M%#X=_%GPYHOB76O!FL>(/AGXV\->.]$TGQAX;F2V\1>%-3U7PMJ>JV%AXET"
MXEB@UK0KJ>+5-*FD2*^M8'=5/)Z-^TQ^SUXA^(D_PDT+XU_##5_B9!XG\2^"
M/^$(T_QIH-UXBN/&W@K0;?Q3XY\&6&G17K3:GXO\!>&KW3-?\>^&-.%UKG@C
M1]9T'4?%5AI%IKVC2WP]&D[IM72L[M64KI6NU9III6:::;339=6O=6O:]U:]
MVK7O:]TU:][IJR::7N%%>/:1^T+\"?$'Q1N/@EH/QA^&VM?%VUTGQ'KEQ\-]
M*\9:#J'C&'2_!NM:=X=\8W#Z':7TM\&\(:[K.BZ5XKMA$;OPW>ZUHT.M06+:
MOIWVGF]-_:U_9<U?1O'?B73_ -HGX*W'A?X8>%YO''Q!\5GXE^$(?"?A'P+;
M:KXD\/WGCK6O%$^K1:!:^"-/\2^"_&WA74O&!U$^&]-\6^"?&OA6^U.W\0^$
M?$>FZ8KK>ZM9N]U:T7:3OM9/1N]D]&TQ];=;I6UO>2O%6M>\EJE:[6J31]"T
M5X#X3_:M_9A\=S>%+7P=^T1\$O$E[X[^&NI_&?P1IVD?%'P7=ZIXP^#NC:A)
MI>J_%OPQI<>M'4->^&%AJ$36MS\0-+MKKPE'(4SJ^V6)G\KUC]OS]D74? ?Q
M#\2_#/\ :T_9#\3:KX.^%/BKXI6MWKW[1OP^T;X=6GA[0_%&J?#2T\9>-_'&
ME:CX@C\+_"I/B_IL_P -?$/Q#M]-U?3=(\46&M^'[>'4?$ND76B D^52;3?)
M&<G%)N5J=^?W='=.T6G:TW&,G&4D@5I.*37O2C%-M*-Y_#KJM5[RWO%.24HI
ML^TJ*_+SX0?\%/?@?J&J?L6_ /XS?%3X!S_MF?M4_"FV^)FI_#3]G[XGZ;\1
MOAYX2\-VGP4UKXWZG\2Y/%^L3Z+<V/PQ\1>%=&BG^'DEQ#JGB#QBNN1:IX0M
MO%_P\\)^//B5X;]?_90_:P;XQ?!GQ]\<_BAX_P#V3?\ A6:?'[XA>"/A!\3_
M -GKX]6GQ:^$WC#X56_CJQ\$?"?4-;^(EWI^B>&XOBIXDUR_C\)ZWX3\+ZAK
M^G-XJ?3-,TZ[MO$>K7?@[0:::<ENHJ3<EK%\M6-"24K6;C5ER-6B[QFOBBX$
MJ2M%ZKFM92TDN:G*JFXMW2=.+FGJN5J7PR4C[DHKY77]N3]C9O!/A+XDK^U%
M\"6^'_CGPUX[\:^&/&8^)WA(^&[_ ,$_"O5D\/?%3QM/JXU3[%I7@SX6>)9K
M7PK\3?%NL2V'A[X>^++[3?"OC#4M%\0ZE8:;<^S_ !0^(OAKX6?#3QI\3/%7
MBKP%X)\-^#_#&J>(K_Q9\5/&-E\.?AQHD5I9R2VM[XX\<ZK!<6?A#PW]K-M%
MJVNW-G=G2[662Y6QO)HTM98<DHRENHIM\MF]%>RU2;>B2NKMQ5]47;WE#:3=
MK.Z:UM=IJZ2?Q-K2SNM+'H-%? GP3_;B^'\?[/\ \"_&W[6GQF_91^&7Q:^)
M7P5TSXU^(K#X:?&RP\4_"(>!=3U*PTO3_B=X0\;^)(M$FN?A+K=[K_A+2-+\
M=:DI\'77C'Q5HO@OP[XP\77NK>'-1\0_8WQ%^)/P^^$/@S6_B+\4_&WA;X=^
M _#45I+KWC#QGKFG>'/#FDC4-0M-(TV.]U;5;BULH;C5-8U#3]'TJU,OVG4]
M7U"PTNPBN+^\MK>6VK-K1V?+=:KF]W1.VKO)*UKMZ)-Z$IJ235U=<UGH[:ZM
M7=E[K=[VMK>VIVM%? GQ\_X*=_L0_L[>#_#/BKQO^T#\-KN_\=_%+_A1_@#P
M3HOC/PL_C3Q9\7[;Q#X:\*^(O ::1J>L:8OAK4/AUKGB[P]:_&'4O&ESX<T/
MX,KJ,;_%'4O"C%8V]PT#]K[]E'Q9\1['X/>%?VE?@1XG^*VI^*?%W@;3OASX
M=^+'@;7/&M_XV^'WAQ?&'Q \'6GAO2]<NM5N/%7@+PI+:>)?''AV*U?5_"&A
M:GHVJ^(K/3;+6M)GO4O>O;6SMIKJHJ;2M>]H2C)M724HMM<T5(;2M=I75U?3
M3F</E><912=FW&22?+*WT717B_A#]H[X!>/_ !]K'PL\$?&7X:>+/B-H.F>)
M-:U3P7X?\9:%JOB*'2/!?B^3X>^-]4@TVSO99[^P\"_$&-O 7CN[T];J#P5X
MW:/PCXH?2?$,T6G/Y]X8_;G_ &+O&VI^!M'\&_M8_LZ>+-2^)_Q \4_"KX:6
MOAKXR_#[7'^(OQ(\#:+I'B#QMX)\"-IFOW4?B_Q'X/TO7]!D\4Z;X>?49_#]
MWK6DZ9JRVFJ:C:6<PM;6UNDU;6Z;Y4U:[:<O=32:<O=3<M!O2]]+-IWTLTN9
MIWM9J/O-.S4=6DM3ZIHKY;\=_MP_L:_"WQ'XE\)_$S]JG]GWX=Z]X,UG2?#/
MC*U\<_%SP+X3M_"'B[7_  ]=>+_#_@GQ7JFO:YI^D^&_'?B#P;8ZCXST#P-K
M5]8^+=;\&:9JGBW2]&N_#FF7^IV_R1KW_!2?1/!W_!03]H_]G;X@Z_\ !#X9
M?LI_LD?LO?"+XK?'[]H[XD^.8? W_""?'']H#QI?:;\(O@UJ^H>)M5TOP5IU
MKKWP^\.:YXZAUFZOCJ6KW6K>'_#6FZ1'/%/J&H)--Q5U[RFTVTHVIT_:2]YM
M1OR6<5>\G**@I.2"SLW9^ZXII)MISFJ<=$F_B=F[)1LW)Q1^K=%><>%_C#\)
MO&_COXB_"_P;\3/ 7BOXD_"&+P7/\5O /ASQ9H6M>,?AM#\1]$N/$GP^E\=>
M'-.OKC5O"D?C?P]:7.N^$WURTLE\0:1!+J.E&ZM$:8?&W_!1G_@H/\,?V#_V
M;OVA/BA+XI^'FM_&7X/_  87XM>&O@IKOB5;;Q!XM_MOQ-_P@WP[L+S2=*DG
M\1:5IOQ(\>I=>#/"^M?8)(]0U33/$<VEP:M'X1\1P6*G)03<KZ?949.3U2M&
M"3E)W=K*+=[JVCLXQ<FDK7=K-M):KF3<FU%)QU3;LTTTVFF_T0HK\W-(_;$\
M=Z'\</A+\)OBYXQ_8E\&?\(S^Q=XC_:,_;A\/W'[1$>B_&?X!^)_#VG_  _F
MOO%&F_"[4[6^72_V<--O]>U^#4/B?\0_$>BZ='8K;7EUKFF7.DV&G^//K'P[
M^TW^SOXK\)^//'>A?&SX8W7@WX5:7;:W\4_$L_C+0]-TCX8Z/>>%K;QU9ZG\
M1KO5+RRC\"V-YX$OM-\=6ESXJ.DQ7/@C5M'\80-)X<UC3-3NZ>G-=KW)5(RM
M*,DG2J.E)MQ;CR.46X34N6<+3BU%HE24N6R?O*G*-XM.7M81J1232ES<LDI1
MY5*,KP:YD[>Y45XOI_[1OP#U+P'XJ^*$'QC^&]O\._ FK?V#XZ\9:KXOT31/
M#_@C6V@T2\@TGQEJ.LWEA!X5U&\T_P 3^%]4TZSUYM/N-2T?Q1X9UC3X[G3/
M$6C7=]RGB']LG]DSPA\)=3^/'C']I/X(>#/@WH?BG5? >N_$GQE\3/"/A+PE
MH/Q T'5+[0]=^'6NZMXBU738-%^(VB:_IFI>'M8^'^J&T\8Z7XAT^^T&^T2#
M5[2>SC-KWTLDW?2RDTHMWM92;2C>W,VDKMI-[VMK>Z7FXJ\DN_*DV[7LDV[)
M-KZ3HKP[5_VG/V;?#US\7K+Q#^T%\$O#]]^SY9>#M2^/MAKOQ4\#:/?? S3_
M (AZ6=;\ 7GQCLM2UVVNOAA;>-]&5M6\(S>.(M"3Q'IJ/>Z.;RV1I!@Z'^V%
M^RIXG\"^)?B;X;_:*^#7B#P!X/O/ &F>)_%>B?$/PSJNCZ+J_P 5](\'ZY\+
M-#OKBPU&?R_$'Q+TWXA>!)/A_H"JVL^,[GQAX:T[PY8ZEJ.LV%I.>75:OR3M
M:_:]U;O=6O=7.B?1[/H]&]&[)Z)O2^B;=DFU]'T5\[-^UY^RF/A_XH^*\7[2
MOP&O/AGX*\?2?"?Q=X\T[XM>!-4\*>'/BO'J&F:.?A7J^N:=KMU867Q.?6=:
MT718/A[-.OC"YUG6=(TFWT674=3L;:?0\"_M3?LT?$W2_B1K/P^_: ^#/C#3
MO@U%=R?&:;0/B5X/U&7X-G3AKIU2W^+UG!K#7OPOOM'?PMXHAUK3O'=OX?O]
M&N?#/B.UU2VM+G0]4BM3NOY5=^2M&5WV7+*,KNRY91E?EE&4BZ=K.]]%YN[C
M9=WS1E&RN^:,HVYHRC'WFBOGZR_:N_9GU/P)X\^)VG?'GX47W@#X7^/7^%7Q
M$\66OCGP_/HW@OXH#4?#ND6WPW\17,=\W]F>/=5U3QAX.T_0/!]PJ^(?$5WX
MR\(0Z#IVHOXIT$:A\S?L/_MH>,?VO_C-^WKI5EH'@'_A0'[+G[1=C^S3\)OB
M3X2U35M1U?XF^.?"G@K3/%?QLN-;CNY7TBVT[P9JGC+PAX-TB;0OM%KJ>J:9
MXGU!KUX9K2QTY)W;BM6H2F^RC%TT[O:[=6'+%M2G=\J?++E'HKO;FC#SYI\[
MCIO:U.5Y6Y5I=^]#F_1JBBBF 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?@'_P
M4V_9_P#BG^V=_P %%_\ @EI\(=9^!7CKQC^PW\ /BIX]_:(_:=\=:AX3L]=^
M%6I_%#3O UY;_L[>"M1T+4)9-1\4V%OXAMM3TOQQ?VWAK7/!5CH'Q*^QZYJM
MLFG^*;;3OW\H_P _Y_*E;WJ<K)^SFJB32:<HJ?)>Z>D93YTK:RA"]XIIGV9Q
M_GA*#:;349<O-:S6K4>6]]%*5K-IK\./^"D?[$WB/1_^":_BO]@C]@3X03:)
M8_M7?M&:'X%\92^$;30[3PY\&OAK^T3^T-=?%G]I3XG>(=.>YT1?^%>Z/X6O
M?&'A&+1-!\W5-*T+7_#^B:#:M!I=NT'BW[=O['OBOX8_M-?\$U]+_9Q^ _Q!
MT#]C/PS\6/CY\9?VE]5_95^%WPP\;>/;/]K.U^!GA/X;?LJ?M$?$KP-XP\/:
M_IWCGQ=X2O[&_P!;T;XG>)O!?Q TS1?'F@Z+XO\ B/927.D^&KJ?^C"BA73N
MM7[6E5;>K:I4)4*=.^C4*<9.I37->%90FKJ$::'9JUDE[.I3225DZM55JE2U
MK<\VE";22E3<HNSJ3E+^2?\ :V\ ?$#_ ()P?$'X(_&OX=_ +XF^'/V,/V!/
M^"97[<G[0'PFUCQIXO\ "WCFW\._\%)?BWJ=_I&H^*OVI_$<WQ)U&3QU\1O'
M?AKQ?J.G:1JVDZCXYNM7\<?%?QEI'P_FA\,7/C#5M"7P?^P%^T=\.? /_!NM
M^RQH/[/GCKQQ\$OV4/#_ ([_ &S_ -I&^L;WPG9^%/#O[:6C_#MO'7PIL_&5
M]XA\4^'K[3+/PY^T/\7OB#X@E:UT[5=<\0:<TMGX=TF>ZLM=N]#_ *5_VFOV
M6_@7^V-\)=8^!/[1W@NX^(OPD\1:CH>J>(O! \7^./!^E^(;GPUJEMKFA1Z]
M+X#\2^%]0UG3M,URQT[7+72-2O+K25UK2])U=K)M1TK3KFV]UT^RATVPLM.M
MWNY;>PM+:R@DU"_OM5OY(;6%((GO=4U2YO-3U*[9(U:YU#4;NZO[R8O<7ES/
M<222N+FY9+F<9>UC4@XJ-HJ*Q,XVO&R=.M7HRII15H8/#TFG0C&C235VM$TZ
M<XS3;]Z4O8P;^*[<Z,*ZJ-W;J8NO4BU4G.I5_C2\+?LD?MT:5_P2<_9>TWQ]
M^SW\<M3^('[2/_!6>T_;!_X*U?#/2_"G@CQ#\4?B!\*O&GQ3\4>./%UU_P *
ME_M.6/Q=X(N)O#'P0TGQU\/DTNV\1ZU!X=OH(O MS\.KR^\S[N_:,_X)\>+/
MBCH?[&?[.GPG^&7[0^F?#G]I'_@HQ-^W+_P40_:&^+NO> YOBGXGTOX(Z!+X
MZT/_ (6M%X.U*ST3P;?_ !I\8:3\+_"/PI\#_#7PKX:T7X3Z!X(TC2A\/_AY
M+I5[HUG_ $E452DTTXJ,5&M1JQ2Z+#PPL:5)MW<J<?J5!I.2E>/O3F[20US*
M2DV^:G6IMW_Y_P \3*<U;13?UNO%.S24[14$E%?Q_>)OV1_VS+C_ ()_?\%A
MG\*_LT_%#P#^T7_P48_;N3X/P:)X=\/^$K?4?A_^P=8?$+P;^SIX4M]!\+^'
M_$Y7Q-X2\%?LV:7X\DEO-(L=(TO4](^(D6J:8NH^&M)U74(?Z!_VRK7XL?"K
M_@FK\?-!_8\^%/BR?XP>%/V3_$W@?]GKX5>$)]('C+PMXE'P\?P=X%LM%^QZ
MM?Z5J&K_  X\^RU6+3=%UG4VUF7PV=,\/7FI7=YI\EQ]]8'Y_P"&/Y45G*'-
M0G0;M&=.C2;5K\E'"K"I6UC:498FHTU[L\77C%^S]G&G46XU8UEK*,ZM1)[<
M]7$_66VTN:Z<*%-:N\,/2<ESNHZG\T7PL_X)R^+_ !%\>_\ @D3^SOX[_9^U
M*+]B3_@G?_P3Y^(FN^-M4^(>C^$+SPC\8OVH?BIH_AGX$W'PZ\7>#H?$FMF;
M5I/"VG^./C-KMK<:=?>&[G3/'NI>$?%(:\U74?#EE\9?M=_L8?M>>/\ 7O\
M@I?\(-%_8_\ B:_@#]H+]H'_ ()I?L-_!_7_ (;Z'X$?P)\(O^"5?PC_ +%\
M5>)]+_9SLKOQKHC:!866LMXIN_B3X;6R\/>!-#U[Q2K7FLZ9J6BVP\/_ -E5
M%:RFY5'4:C:4Z\Y0=Y0E+$8BA6GS*5W)1AAX86"DY1CA95*#4H3DC.,%&$8)
MN\8481FGRSBJ%&O2@XM:1<IXB6)FXJ+>)A3JJSBD?Q]_MX_LL?MS_%_XJ?\
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MW)J"^%WHJA&+6W+"ES1C':TY*2DK)?@E^S3^Q5\1_'_[0O\ P5/_ &W/C_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OQ;_:%UNPL/^"O'P6\(>*[[XWZK\,O%/\ P3B_:.\<:_\
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MPEH-KXDU6U;R_P +?\$U?B#XP_9E^*_[+7[9G[:OQ9_:L\%>-/A1=? [X?\
MB"T\%>#O@GXP^&?@>";3+[PWXZOM8\,2^(W^)G[1OA[5_#O@S6K?XQ^,%?2%
MU/P9IEYI7PVT.Y\2?$J7QVF])[2:4G#EO%3A[6:48N5W&O['DY743IJ33J.\
M:JE2YKQNTD^5/2\HS]E"\I-6C*C[534E32J<K?LU:5%QG\3_ /!2OQ#\,O!G
M[2?C7XR?LP_$+X>>&?@);_ ;6M+^)5_I'QTT?X(^+_"'QM^(=K\,-=\3:WX_
M^*/[-GPJ\3>#;;]GC5S>^/\ ]HI=,^&WCNS\#? XZ1\3=%U/Q9<7.O\ A/PM
MT7CK_@HI9?#+P/\  CQ;X]TG]G[PQIW[1_Q8\2?#KX5?%B^_:@\_]D?Q%I4/
M@?6?'OPWU^']IW3O@W?:9::S\8=+TU=,\ ^&-6\"Z99:YXEL?$WA[1/%6MZC
MIWAJ'QIV/PG_ &:/VT?!7PLUS2/B3_P4#N_C9\<'U'P!9^$/BAXB_9I\!^$/
MAWH?@?P;XVT3Q'XET?Q+\$O ?C'0SXU\9?%[PW8:GX)^(WCR3XD:$MA87FG:
MG\*/"_PNO;7Q!'XLX+P+_P $YI/A3\,/&/PD^'7B[X%1?#/XP?$KXT_$3XX_
M 7Q]^RY#X\_96\4I\8-.\'6$OA'P!\"&^,6@_P#"M?"&CW/@J/Q)?>')O''C
M/P]XF\7>.?BGKM]HUH?%NEVOA8;MHO>LH>]LIWG)R3C:]-^SDESP<U&=/EG3
MJ*;FA7O=JWO2NM'9<D4K/3G2J1E:,E!SC4YHSI\B@\G]IO\ X*.>/OV4? 0^
M('Q6_9HTWP[8>%O@E\$?BY\2M(UGX[:79:]>ZY\0O%M[X>^+WPH_9WL]-^'>
MNP_'GQI^S?I6F2>)?B%=:I<_";PY/IWBGX;3)J^F:5XLU;6O"7W+^TS\<=,_
M9H_9_P#B_P#'[6O#^L>*-'^$7@/7_'>K:-HEMJ5U=RZ;H%HUW?7EV-&TG7]7
MM- TBU676/%&K:7X?\0ZAHGAJPU;6+/0-;N+&/2KO\F_%7_!%K49?A/\0?@3
M\//VM_$GASX7_$;]@3]FS]B'4!X_^%5C\5_B#H#?LG/XTG^%/C7PAXSO?B#X
M7T[0O _B*[\<ZK=?%_X0KX2N9O$]PJ77P\^)'PDU!C>C]B?'OAGXD^(?AK=^
M'_!7Q)TWP)\3VM- ET[XC2^!E\3Z#;:YI&J:7J=_+??#^;Q1I$NH>&_$"V-Y
MI&I:!#XST[4HM%U6YAL?$]KJ44&JJ.ZC.SO)5$XMI)\C<^96B[<JM"S4N=0F
M^5N<$I4GK'1I<CYES77,N3ELY*_,TYIMKE<HKF2BVU\8)^W_ &]I\._AWXXO
M?"/P\\8K^T!\=)?@_P#LOZS^SQ\7/$?[2_PQ^-^AV/P,U[X[:W\2M-\8_"GX
M+:GXSL=$T31_AQ\9?"E_IVA?"KQG-#XK\ 6 GOH/#WBG^W]#SOAA_P % /%_
MQ"M_AKX$UG]F/QO\*_VD_B;\7?CU\,] ^%/Q7N_''P\\%:GX3_9ZTV+Q#XK_
M &@/#?Q"\:?"#P[XZ\1? [Q)H&N_#VT\#ZVOP.T[QCJGC?XAZ3X5UCP/H%AX
M>\=>)_"OC_B7_@D?IMQX-^(&H?"CXYG]FK]H?7_VQM)_;K^&_P 5/V?_ (2Z
M-X/^%WPC^/FG_ O3OV==>O-(_9WUCQ9XFT'Q)X3^+OPW'BS_ (7[H.O^,Y+O
MXN^)_B!XK\0ZQK-C))I=IIO>?%C_ ()Z?&GXG>#?@'XVB_;=\9:!^W1^SO\
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M._BM\-OAU\9==U:.P\'> +/XM^ _!?CSP_XS^"?PX\ :'K_QS^'=VT/PJO?
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M0]4\1>#;_7?V7-(T+X-ZM_P4*^)__!.?QAX\M/CY'K?C;0/B;X5^(/BSX7>
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M4_V??A9\8_B?H/P=\0?%CQ/KGPCO-;U[PO\ $V?2O!46I>&O#7ASQU#\+/\
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M\9^%M/'C'4?0?@W_ ,$X=(^&'@[]FWX):[\49/'O[.7[&GQ=D^+?[,G@"_\
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M_M(^,_CA\+/#/B/X5>"KRP^#7PT_X*R?L.? "]^+5I\:O%7@?Q5KWB3X;_\
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M9V-_X5\/VGC;S?QO^P9\>OC)^RUK/P3^/G[9]U\6?BYXH^)W[/7Q!UWXS3?
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M7Q'YFF)\P_\ !,SX??$_X6_LQ:OX+^+GPN\0?"/Q8O[4_P"W1XZM/"_B'5?
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M^$HT^]T?PO\ 'GP#<0:CJ?AZUT2^N[G7M(T_5I]3T+4K-/G_ /:V^#?QJO\
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METF[_;F^%_AW]EKXI?$*/XC?\%9OV"/VY_ /CWPKXC^#5GX(\9?!'P#\4?\
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M\4?"]CHNM:MXG^'$O@]/&OAW1-%UC7=:T.PT;2M0OK;U3P)X\\'?$_P?X?\
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MMNFI4'%R<Y31E&;<54E%J]+F<;N\).I7BKJUY6Y*2DHKVC552LH\C/T_UO\
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MOC)I'BC1_BE^S5XO\/K#\*+?P3\'_&E_\0H_#O@1-/U#P)::+K'CG2N8U/\
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M47=J:E3BI247%76LJ*ONK595(R:MLZ<H)2C*S<I))<LH5)?TRT5^-NIZ%/\
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M>\FZOU=)JR;YN3$1DXQ3E*$)*+DY4XU/Z1*\+B_:*^&L_P"TE<?LI13^(_\
MA;UI\&/^%]7-K-X3\06GA4?#Q_&=MX"@NK/QI>V-MX<UG5Y?$5Q)!/HFA7^J
M7^DV]LUQKL>E+>:4NH?@/XW_ &G?%7PJ_9@_:B_;>_9*_P""CFA_M16&I?\
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M#\'?MC? [7],UWPU\4[[X ^+/$?AKQYX]U_Q%\._$*:U\,-*3P]Z5^R=\=O
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MIMQ]I&24K*:B2ER04I.+O9)P>DVZE*,9P4K2]G4A456#FE+V<HMQNX.7ZZ_
M+X]?#[]I3X;Q?%;X7S>()O",WCCXN?#U&\5>%]<\%Z]'XD^"7Q:\;_!3QW;7
M_A;Q-9:;XBT8V?COX?>)+2WM=;TW3=3-K!!->:?8SRO:Q>S5_.?X<T[XK^'/
M^":U_P#M(_!C6_BD_B_]CW_@I)_P4?\ VD/$_P *OAMXW\5^&H_VA/@E\/\
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M::]%%K=M;6-Y!#!J\4>I1(EXBS"EXL_9U_9]\>>)_$7C?QS\"O@YXS\9^+_
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M_A[X&>-_$&@ZC;7FG7%G>PRV.JV%E>I'YHCE:$0W,4L#RPOX[I__  4,\:?
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MTG[:#=O:3Y;DFE>2=G&<FFF_=INMS*2L[-+"5).#;=Z$[7]G!R_37Q+^SQ\
M/&>H>-=6\8? SX.^*]5^).E:5H7Q%U/Q+\,O!6NZAX^T30I[>ZT31O&MYJFB
M75SXITK1KJTM;G2M.UV2_M-/GMK>:TAADAC9>$^+O[+/@/QYX"^+NC?#:#0?
MV?\ XL?%+X/:I\&[7]H/X9_#[P'#\4O"/AV;1I-(T"VL-6OM"DGU#1/#2?9Q
MIOAZ>[MH+&V@5= O/#^IQ:?J^G_+OA7_ (*%^*OB/\2OAS:_"K]F[XC_ !)^
M"/C+]I/XL_LW>*?B'X=\,?%1-5^&T?PI\4_$CX97GQVUF_O_ (56_P %-?\
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M57WCO]B7PLW@3X+^-_!G[9_Q)^/O@GPM\8_@Q^T8OQ)\!GPM\*?A!\1_C/\
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MG37UN^IZO<VEB+E)+@./GW0-6^-VI?\ !7+]GW5OBE\/?"O@'Q#K_P#P2O\
MVL]5C\.>&/C+XF\>>'1KUI^TO^PK+<>$-8AOO WAO2M/U#P)=:P]F_Q \/Z+
M>KXSMO%%ULT?3HO#5O%JNM9*C6G033=*K6I-I\K5OK;;4$U)>V^K5&XQLY<S
MYG)WY\J,O;T:=9JRK4:-;E=Y:2CA9).5K-4OK$$I-67*G&*7P?I+I'[,W[-_
MA_Q5J_CO0/V?O@CH?C?Q!\1%^+^O>,=(^%'@/3/%6M_%E='UCP\OQ0U?Q#9Z
M!!J^I?$0>'_$&OZ$/&U[>3>)1H^MZOI@U,66I7L,^A8?L^? /2_#'CGP1IGP
M0^$&G>"_B?J%]J_Q*\(6/PU\&6GA?XAZMJFS^T]3\<Z!;Z+'I7BW4=1\J+[?
M>Z_::A<W?EQ_:))-BX_(/X'?\%&?AQ\*OV5?V.-0TKX-?!_]E+PW^TGXG_:O
MT#PG%\4_C3XGT7]F/P)\6_A?\9O%UK:_!O7OVAV^%-^-'^('[2'B%O&/B?X>
M7?B?P9H&ER6WA[XC-HFG^*O%.@>$OAMX\^H?#?[2?[4WB#_@H)XD_9YN?AY\
M+]%\%>%OV!O@]^T'<>$M1^)FLV_B#3_BE\6_'_QE\*ZIIFM^(](^%_BG2M;T
M_0/$WP@T[P18'1#I]MH_A[4?$GQ#^T>.M0UK2? /A64TUHKQ4)W:5X\L<-#%
MRBDMTZ?(XI1UO1;@N9.%3?(_>OS.45KH[RQ,\*G)OX6JJFI7;:Y:J3:C[_W)
M<_ ?X'7FK?"_7[SX-?"F[UWX'Z;KVC_!;6KGX=^$)]6^$.D>*="@\+^)]+^%
M^HRZ.UYX T[Q'X9M;;P[KUCX3FTFUU?0K>#2-0BN-/BCMUP]1_9A_9JUCX3Z
MC\!=6_9Y^!NJ? S6+J2]U;X+ZC\)? -[\)]4O9M436Y;O4?AU<^'Y?!][=2Z
MU''J\EQ<Z/+*^J(E^SF[591\$?!']O\ _:-^,'[,OP$_:IUS]EOX2_"KX5_M
M,:/^SGXB\#^(-;_:PM=:@^%/@WXR?#OQ'XQ\9_$']H%M;^#GPXT7P_HWA3Q'
M9^#/ /PH\,_#SQ/\1/%?QL\2_$GP9I_B2V^!M[=Z_:>&.I^"7_!1>?X\>!_V
M9X/#GPPT[PY\;OVD_'G[77@6U\#Z[XNUQO"/@:Q_8J^*'CGX/?&KXB7?B#4O
M /A;Q=X@\/0>-/#7A>V\)^$[SP#X+\<ZT?B)X?M?$FF^!H]+\6ZGX=J2]YPD
MKR;U@[-R;ES-VO)-\\>=MOXH\]Y.//%1DG%5(NT%&ZFM(I)."2?NVT;@DEM+
MDLN=1E]J:]^S3^SEXJ'@P>)_@!\$_$8^''AN'P;\/!KWPJ\"ZP/ ?A"W_LW[
M/X4\&#4-!N/^$7\-P?V-I'DZ%H?V'2XO[*TW9:K]AM?*]8UK1-%\2Z1J?A_Q
M%I&F:_H.M6-SIFLZ)K>GVNJ:1JVFWD307FGZGIM_#/97]C=P.\-S:74,MO/$
M[1RQNC%3^5\_[6'[8E[^U1_P3V^#WB[X#>!O@9'\>?AW^V!XY^.OPTUSXP6W
MCCQ#HFJ?L]>*_A/X'T]O"7C_ ,&> ]9\-^)_!.H>&?BD?BKX-MKG3O!WBCQR
M^H^$M(\;#X):EX7\3>'=?\E\&?MRS_";P5XZ\0_#K]D;P+H&J>-?^"P_B/\
M8K^(&@:9\>-9%MK7CSQ_\1=!\"W_ .T8-:U#X0,-0O\ Q/J=UI^LZWX".FZ#
M%H>G!X[#Q#KE]9"TU))\R[J;DU&S;E-U\/0NT^M2IBJ:;:Y^:5JB2YW ;Y7+
M3E]GR*4M+1BZ%>NDG%NW+##5'%+W;1]QN\%/]6Y/V=OV?IOAU:?""7X%_!R3
MX36&I:=K5A\+Y/ACX)?X=V6L:/J-OJ^D:M:>"6T0^&K;4]*U:TM=4TV_ATQ+
MJQU&VM[VVEBN88Y5TM;^!WP5\3:=X$TCQ)\(/A=X@TGX6W^GZK\,M+UOX?\
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MR!^PSIEU\/M/\6_!KXV?MR?M=_LW_$+XO^(_BEXLM?$/P3\0>,_VROVH-'^
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M67ASXBKXC\$ZC=^&;70O$TOP]BEU^;1-'XS3?^"F7Q=\4_ O]CGXF^"OV6_
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M\TF9?!<FFV=C8VFGOX;&FM9VUG:P6QCBMX43\_OB=^W[\7O@EXO\$^&/BU\
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MKI:[GS->T]WVC:CSQ7)S1^RKGX-_"&\^(L'Q?O/A7\-[OXM6VGV6DVWQ1N?
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MZ2_?1FG?>-J]>$HMM*,Y1Y4DFN[\0?#9O'GP<\1?"3XC^)-0\2?\)Q\/->\
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M_@HMX/\ @]^U+^TGX*_:.^(/@OX>?L_> _V;_P!C'X[_  QUC4?AM\2O"_Q
MT"U_:!\:?M6>#?B+=?&&PU&[UW5],\*>"Y?@7X2UG7?&.L^ _ACX>^$^E^);
MJ'XGS6"PKK+BJ<D^:+Y95)*G*22Y5*-*K4C&5_=C>E7JJ+M9JIRN2T:)0C)*
M,ES<L>=)W<N256G!RNM9)5:%-SNW9TU+E>SJ>%O^"9_B/PC\3?ASXTTO]J?Q
M:_A3X1_MX_'S]N'P#X&N_A5\.KFZCO\ ]IWPC\?O#WQ;^'7B[QS)$?$OC"*"
M[_:,\>K\-_&=X]GJ/@_PA_9/A'6M(\:W&@^&O$F@\[\,?^"4ES\*8/V;_A_X
M:_:L^)47[/'['7[4-W^T9^S%\(IO ?P[U#6_ &@ZM\/OC7X$O_@9X@^*&O6&
MMZUXU^'/AZT^-FOZ;\,[^YT;2?&'@WP2)O"VKZ]XSU6#P?XO\$?H;\7OVCO@
MS\"-/O=6^*?C,>'-,T?P]<>,_$NH6OA_Q3XGL_!7@.REDBU/XC_$&X\):'KL
M?P\^&6BBWO;G7OB5XW;0/ F@:?IFL:GK/B&QT_1M4NK/LO'/Q1^'7PT^&_B;
MXP^/O&OAOPI\+?!WA2_\=>)O'VL:K:6WA;1_!^F:<^KWOB*ZU?S&M3I<>FH;
MN.XA>5;B,QBV$SRQ*Y"U*-X>Y&'*I/:*=.,.3G;NG*$:,>5SU2A*U_WJ;DE4
M?*_?<TVE>\G&HYWY;>]RU'7E=1TE[2/_ $[:_/O6_P#@F_/K'@']HWP(?C?+
M#%^T5^W7\*/V[M4U-_AQ:S3>%?&7P@\=_ 3XB>&_ 6D6L?C&VBOO"5WK_P"S
M9\-(=5O-1DDUR?2KSQS:P7MO=:[H%_X1\<_;/_99^(_@KP7^VK\2_!/B#XS>
M.[O]M3XF_LJI\2M)^ _PG\ >,_%GP;^&WPCD\%^#O%VLV?PP\>7GC&W_ &B/
MAWXB^&_A6X\._&3X)2>"_&VM_%+PYXM\5>&M*\,R>'M5O-+L/JO_ (;H_9]^
M*E]\(/\ A1W[5WP@L+;Q#^TIH'P<O[/7O GBGQC/\9M2U#X0ZC\3KGX2?">Z
MC\3> %TSQ7=>&=<\*>/5^*MA;_$GP;X;TC0=>\-ZSX;N=5OKNX\-^K:C^VE^
MS%I/C>V^'VH?%C2[?Q!?^/\ 5OA+I5T=$\5R^#]=^+N@6EQ?>(/A%X=^(L.@
M2?#WQ%\6?#UG8ZQ=:_\ #'0_%&H>.M#@\-^+9-5T"T7PCXF.DG(THQ6EGR*+
M3?P0H490::3M*E"G1DHRY^7^6I*+FN:$ISJ.SE93=1.*LY2KU834DVDX3J5:
ML6X\MV_BIJ7)^<G[/WPZ_;,TG]GKXY>'OV<OC3XNM]/U;1_!6L?L^^*/BW^P
M!\)OV2/$'AGXI?\ "<_VC\0=*?X$W^A?!*XO/ASXI\,V\>F^.?$'Q&^$OA?Q
MAH#ZK>^)OA=JWQ/U?R?#VA?MQ")A#$+AHGN!'&)WA1XX7F"+YK11R/*\<;2;
MC&CRRLJ;0TCL"3^6O[*W_!0_P[XM\5?$'X4_M+?$?X6^&_B_)^W+^TC^RS\'
MM*\(>&/%OACP_P")-/\ A-J]_%\/='UZ]U;7O'NE>&?B3XZ\+Z!KNJZ+I7BG
MQGH=S\3=7T3Q4GPRT"[M]!O=(TOZM^"W[6/P_P#CI\7_ -I+X-^$_#_Q)T[7
M?V8_B3;?"KQKJWBOX9?$3PKX;U7Q0?AW\-?B5>GP]XC\0^%-,\.7MBNA_%?P
MK)H176CJ7C'2WN/&WA;3-3^'-UX>\8:]5W)1ZJ5-5%+=\BITY/FERK6$<134
MH[IJ$?><%.:32;;;7[R5.VRYW4JPTC=NTI8:HXR6C7/+W5-QC\R_#C_@E)^S
MI\,;#]F"PT"]\6O'^RG^T)\3/C=X"N+C5+@7>H>%_&6B^(?#W@;X#ZU/%<H9
M/A%\&=%TS]G:P\!:!;K&GE_LH?!1M62\?3]7;4+?QN_X)TCXV7'_  4+CU/X
MSW>BZ/\ \%"_@-X#_9[\9:?9^ +*ZN_AMX0\#>%O'_@N/5?"&I2>)X1J?B/5
M]!^)_BY[NYU^RNM-MM8C\.7MGI<5CI6IZ3K_ - /^V+\+8_VKO%_[(T^G^.K
M'QQ\/_@SX8^-WC/Q;J?P^\=Z?\,]&\*>--0\;6GAJ9_B)-X9_P"$(73YK?X:
M^.Y-2\37_B/3O#-IK.C1^#+'5-5\9KKN@^'NW^&'[3OP+^,?BK4? _P^\?6N
MK>,=/\(:)\1H_#.IZ+XE\):WKOPS\2W=QI_AWXI^#-/\8:+H-SX\^%6NZC:7
M.G:1\3O!4>O^ ]1U&%["T\0S7@\DPXQG%1:<HN%2T6Y.\)>SI5'JW*TOJ=.+
MDVW)4.:\K3JRN]I-WM*,X7=DK3BI586T44U];E)**27M^5I7C37A'Q-_88\/
M?&WXZ7OQ<^+OBVU\6^%_%?[%'Q5_8?\ B5\);7PI<:)X<\:_#SXVZYX7\0_$
MC6(]=@\6W7B/0=0U.Z\)V.E:796]Y>PZ5X<O]7LY+G4-:GL/$.F^+^ O^";O
MQ/T+]F3XR?LP_%#]N_XX_'[PQXU_9[\:?LH_"37/B1X%^$VFZG\&?@?XR\,+
MX*NKC5%^'WASP;+\;?C5'X6MM(TV;XN_%.^U423^'=.U'3O!^D7?B/XI-\1_
ML#]H3]LG]E_]E270K7]H/XS^$/AEJ7BC0/&OB?PQH>L2W][XD\2Z'\/-+BUC
MQA>^'O#.AV.J^(-;;2+*XM5%IIFFW5[J-_>66D:5;7VK7MK93:6M_M8?L]>'
M/&/@_P "Z[\2],TK6_'?BCP[X"\-7UYI?B*+P=/\1O&/ARQ\7^#/A?JGQ$.C
M'X?^&_BKXS\+ZMHNO>#?A?XD\3Z1X_\ %FEZ]X>N_#WAS4HO$&C-?.RE&<=X
MU.>G..\6ZDZLY1Y=8J;E6K)-)32J3IQ:4E +\LH.]I4^2<'>THJE"E"#[N$8
MTJ-T^:#=.$YIN/,>1?#3]C6^\ ?M#?"K]H&]^*O_  D%_P##']CZU_8_7PO%
MX&@T?3]>\/0>*_"WC)_'$^H#Q/J5WI_B275O"&EP"QMXIM$CTRXU*W%H]W/9
MW]AS?[4/[#'B7XS?';X:_M0_ 7]I_P")/[(?[0/@OP!KOP0\6^.? ?@KX6_$
M[2?BA\ _$OB73?&EUX"\3>!OC!X7\5^%K;Q)X3\8Z9_PDWPQ\?V-E]J\)ZAK
MGBNTUS0_&FA:^^CVONU]^UY^SOIOCCPU\/;OXB1IKWC/XCZI\'/!^H1^%_&M
MSX&\5_%[09-=A\1?"GPU\3[;PY-\-==^)7AB;PIXQ@\4^ ]+\6W7BKPS/X'\
M>0Z]I6G2^!_%B:/'9_MA_LV7^E>']<M_BII*Z5XG^.U[^S%I=Y=:5XEL8T_:
M"T[Q%=^$;OX1:RE]HEO+X;\;1^*;&[\.KH_B./2I9]:@?38#+=[8C3;G)3;;
MDZM2HI:INK5JRG5O:UW4J8N2G':7UA0<>6I"+F,80BZ<5%14*<'%6=H4Z484
ME9\UE"EA(N$G9I8?G4KTIR7PO\>O^"3\GQCN?VC+/1OVJ_BEX/\ "W[2G[._
M[.WP5\9:=KWA3PC\3_$]MXB_99USQ/KOPI\9V_CCQ6$U23PYJ=]XP\0:S\4/
M "6MI=>,/&&J:KXOT'QOX(U/Q#XH77/3?BM_P3LG^*\W[?O]K?'+4K>#_@H'
M^S#X!_98\?2-\/M(FU/P5X0\$^#/BGX$N/$_AFZM-?TO3[OQ=XCT3XT^/KJ]
MDU'1_P"P;#6AX5NM,T.WTW1-3TCQ']:^(/VH?@-X4^(_AOX4^)/B'8:+XP\7
M^,8_AMX=.H:5XA@\):E\4+CP\_BVQ^$Z_$9M'_X5U;?%K5/"T<GB31OA9>^*
MK?X@ZUH4;ZMI/AN\L5:<85W^V#^S_:7WC;3D\5^)-4N_ 7@WXK>/M73P[\*O
MBYXHBUKPQ\#->T;PI\7[GX=7/ASP+JEK\6]2^'GBOQ#HOA7Q/X=^%<WC+Q'I
MWB?4(/#TFDG6-]DF4E!0DY65/EJ2D]HJ'+)5'=648*$FM&HQA912BHVM<TI)
M*\I)PBE\3YN9."2=VY.<$]G*4N9R;DY7Z/XV? G2/VA_V9_BY^S-\3M>U2/0
M/CE\#/'_ ,"OB!XG\#V]GX=UN+1?B;X"U;P#XIUWPC;:Y'XPT[1-6CL-:OK_
M $&+5X?$]CI]ZMJM_#J]O%+'<>(#]B70?B-_;%_^U/XFT[X\:SJO[,7Q%_8\
M2TT7PG??"OP+9? OXRR>'I?C79Q>%+;QGXQU5_&_QE7P5\/;+Q_XH?Q<-)MM
M+^&_@ZS^''A3X=R3^.;GQOZU^S5^T%I'[67[-?PJ_:$^'.EZ_P"#+'XS?"KP
M=\1/#6G?$/PCX@LKK0)?'?@O2/%FE17^FWR^%SXOTK3/[<M(GUOPKJZ^&O%,
M5O/-X9\42V<T6HI\3_\ !.7_ (*A?"']K'X4?LQ^&/BA\7_@]IW[9GQJ^!L?
MQ>\0?"#P:-7T#2;FYMA+?^+-%\ 0^(-4\0PZAJ7@W2I;+5O$'@&+QMXG^(7A
M+PQ<67B/Q;96^E7D6K3ZRC*3JQFGS:NI"2M*\EB*4W&*7,I1A+$1J.+BX4YS
MU2NX9P4(QI5(?!'EA3J)WC%0]C5IIR;:Y7*%&5.Z:E.$-6[*?MW[&7['GQ;_
M &7+"#P_\2OVV?CE^U=X2\$>$K;X9_!#0?BIX:^%GA>;X?\ PWTUM*BTP>-M
M<^'/A+PYJ_QL^*D>EZ!H6A7GQ7\>7#7TFF6%[+IF@:-K'BSQSJWBGO-0_9@U
M>+]LK4OVP/"7Q6O?#UYXH_9O\+?L\>.?AGJ'@S1?$/AWQ-:_#/QQ\5?'_P *
M_$\&O/>Z9XCT!M UWXU^/SXJT73;G_BL;9?"<5OJ_A@:%J7_  D5'PC_ ,%!
M_P!BOQ[K'C+1?!W[1WPV\03_  \\*_$?QKXZU*PU.Y?POX2\.?"+X@?\*N^(
M]YKWC*2SC\(Z;<^%O&[VVEWFD7.MIK-Q9ZAI7B#3]/O/#FKZ9J]WX/\ MJ_M
M\6OP]_8>_;C^.G[+GBOPA>_'']D/X4Z[XXU[P!\8?AU\0-.U?PEJ]EX:;QAX
M?L/B%\(?$&I?"/XEZ%8>.O#D%S>>"/$6H"PT76("-?TA?%6EZ=>Z?<+G;:GS
M.4I)+F3O*:KRC2YIR7Q^T>(C*523;E?VC;45)U&E%VIJ,4G-)1:M&,J;YHQB
MMH>S='EC&*2CRN"2O**9\(/^";$?P@\'_P#!/'P;8?&R^U^R_P"">?C'XC>+
M?"%[JO@"P@O?B4WQ%^%WQ5^#=U9>+/[.\3VUMI3:3X(^,GC&6SNM#@BCG\3V
M_AS5[JS?3--U'P_K=6W_ .":UY!X)\*>#?\ A>KE?"O_  43\5?\%&8M03X9
M6J->>/\ QA\8/&/QOU7X;R6K^-I1%X"C\9>//$5G:72W$GBF+PPNDZ=)K4VJ
MV-UKNI?>,7QU^%$GBOXH>#&\7V]KJ_P5TJSUKXLWNHZ;K>E^$_A_I]_X<L?&
M-NWB;Q[J.F6O@73;D>$M2L?$]QITOB/^T;/P_<+K%Y:P:>LEPOE&O_MS_LI>
M#_#?Q7\5^.OC#I'PYTCX'Z=X2UOXHQ_$W0O%_P -=;\+^'?B!>7NF> /%3>%
M_'?A[P]XGUGPAX]UG2M;T#P-XN\/Z/JWAKQAXD\.^)_#GAS5-3USPSK^GZ<1
MER_"^5R<)I=W"=#D:3Z*>&H64;)NG&Z:<FW)MI\TG9*<7JU_$CB'-.V[E'%8
MAMN[7M9-.+Y4O"?@K_P3[\6_ ;XX^.?$G@/]L'XW67[*/C3XN>./VA$_8N;0
M/AJW@SP]\9OB3XRU/XD>-G\/_%Y_#$GQ@\/_  ;UGXFZSJ'Q.?X*>%O$/AW0
MI/&<]Y9:CK.I?#CQ'XY^'?B[V[]I[]C'X3_M,? GQI\$7^W_  <F\2:S\/O&
MOASXG_!NUT/PA\1OAW\4/A!X[T3XH?"3XD^%-7BTN:!/$7@/X@>'-(U[3UOK
M:YM;N%=1TF[C:QU:^23&O/\ @HC^QG9^%;OQL/CAI&H^&=/B^+NHZCJ6@^&/
M'GB5M-\*? /6=)T#XS?$S4K#P]X5U/4M/^#7PXU/Q!X<3Q1\;;RS@^$>GV?B
M;PQJK>-6TKQ)H=[?^F?%+]J_]GOX,V>E7WC_ .)>EV-MK'@37_BM:-X?TSQ#
MX[D@^$GA--&?Q7\8-6M_ 6C^)KG0?A!X53Q%X?;Q/\5M<BT[X?>'AKFC_P!L
M>)+(ZE9>=/+'V<8Z<D.6$7>W+RJ%6FE/1IPC3A.#<DX0I1:Y8TFX"7O-VO*?
M,W&W,I)N5.?N/FC)2E.<)I1?/*I)-2E42E\M:O\ \$^?%?Q(^"OAKPS^T#^U
ME\4/C3^TAX#^,7PM_:!^&W[3MSX'^&'P_F^&_P 4O@GJ-Q>_#N/PG\&O /A_
M1?AZ/A[=V6K>,O#GQ,\,Z\-=\5_$3PO\3_B-HDWQ#T.VG^'Y^'=GXI?\$\[3
MXN>'/BS>^)?B=:6GQG^.OQ=_9#^*?Q+^)VB_#UK?15L/V(_B/X'^*_P/^&?@
M3P+?>-]1O?#G@.U\=>"+GQ#XB3Q+XX\=^)-1U#XF?%K^S_$.CV&N>"M/^'GT
MMXD_:V_9Y\+?#C0/BU??$>UU3X?>*?">N?$+P]K_ (,\/^+?B$VK?#;PP=-_
MX2?XH6>D> M \2:Z_P +/#*:WH%QXC^)ITQ? >@VGB/PU>:MXAM+3Q'HDU_Z
MK+\3OAM!\-I/C--\0O \/P?A\#O\3I?BM+XLT%/AM%\-H]!/BJ3XA2>.6OQX
M83P.GA<'Q(_BQM4&@KH(.L&_&G@W%7S.+<K\KISYKV4?9S7)?HN2ZP\%-.RD
MJ-II\DTIY8SCRVYXU(<MKN2J0;G9:-\ZO7DXV;:=7W;<\>;Y)L_V1/B-X8^*
MO[5/QI^'O[0@\(^._P!IGQE^SMXP#3?"NPUWP]X,B_9_L/#OAI_"<VE3^,K*
M^\5^%OBCX&T6_P#"OCI)-9T'Q#9?\)%J.M^"/$7A/4[31WT[Q/2?^"7.@^![
M#X6:Y\'_ (JV_P (_BM\,/VN_BI^U]8:YX3^%VC'X2Q>)?CM\-?%?P=^+_@+
MPM\#[OQ))IO@[P1X@\!^+]1U+0X;3Q;J.IZ-\4HE^(^L7WBJ75?$^@^(/M'P
M/^UE^SO\0=)^)NMZ)\3]'TBQ^#'AW2O&7Q9'Q"T_7_A/J'PY\"Z]X<U#Q=H/
MQ#\8Z/\ %+2/!VKZ#\.->\-Z-K^L:'\0]0L8?!6KVGAKQ2=.UVY?POX@338-
M!_:[_9T\10?%%K7XF6&EZI\%=7\&Z#\5/"/B[1/%7@3XB>"=8^)2V(^%]AK'
MPS\;:%X?^(*S_%>ZU&STOX3BW\,W"_%'793X?\ MXBUN&;3XU;E:5FG%1LFG
M=1A-R2L]>55'+F5OB<E)1;DFURR3:LU)MMIW3E.FHN5UIS."5I)K1*2<DDSY
M/T'_ ()LMX=\/? 3P[!^T+XOU^#X"_M^_'/]OW2+_P 6>!/!5SJ&N>+_ (Y>
M*OVA_$>L_#N^;PI%X-L[?PK:-^TS\1KN?5%LKG7KSQ(-%U#3;GP_X6TY? [O
MOO\ @G-J%YX0^,OA0?'()_PN']OSX5?\% KK4)?AC;RMX=\>?"'XB_!;XH^&
M_ &GVL7C>V2]\%77B?X _#Z'5KF^E?Q%<:+=>,K*#5+:\UK1-2\+?6N@_M8?
ML]^)? WBKXAZ3\2M.D\/^!_B+_PI[QC8WND^)-(\;^&/C!+?Z%INF_"/6_AG
MK&BV'Q(T[XJ>(;OQ5X1'A'X<W/A2/QGXR@\9>#+WPKHFL67B_P -W&J9>G_M
ME?LSZGX;T/Q9;?%72HM%UWXUZ3^S>K:CH_BC1]3\._'W7M?TOPOHGP<^('A_
M5]"L=?\ AA\1M5\0:[H&E6'A3XCZ9X5U>ZNO$/AX0VK)KVD/>)-.,8J2<8J$
M8I<O*ES824$N71ISPF#Y=97E3IK>;C4?*US*TES\ZDGS7;Y<4IW3UNHXG%7T
M32G4:^%2I_*7QX_X)ICXY7_[<%U=_'+4?#-O^VY8_LTZ9X@@L?A[I>H3?#RS
M_9EU'^T/#8\-7-YXD1-5N?%!>>+Q)-KEK-'&)(WT6#3#$5?)_:L_9J^*_A'0
MOV]_VAOAOXC^*'COXE?M1_LX? O]GFZ\'_ /PMX0T/XG_#?PW\,]>^).B77Q
M:^#\OCSQA<:7XL\9>"/#W[1'Q;^)]W\/]2N(];\?CP=X2\!?#[5-$\7S0WWB
M#[(\4?MC_LP>!K'QKJ7CGXT>#O!%G\.?C1X*_9X\;R^,I[WPH?#?QF^(\'@F
M]\">!=0AU^RTZ<7_ (JT?XC^!_$FC:A#'+HEYX2\2Z=XO34_^$8>75HO'_BC
M_P %(?V9/A]^S!^T7^U-H?B'Q#\2O"'[,USKWAWXB>&?!W@3X@W'C?3O'^FZ
M5H^JZ-X.U?PK/X27Q'X7M?%-KXH\(:MIGCSQ'HUA\/8?!/BO1OB9>>)HOAU<
M#Q-4M1E%15I**BU'5JTXQHQNHM-J<*\::UUC67\T9AS<LG*]I/FO+2_N-U&[
MM-7A.@Y[:2HNZLIQ?SO_ ,$V? ?Q3\"^(M=MO#GCGQ[XE_9EU+PCJUSJ&A_%
M;_@GSX-_8!\0Z!\9K/5/!.E^&7\%^"M#^'7P,\6>(-*F\ V7B73_ !QJ_BOX
M5:OH-R=*^&=OX"\>(-)\6:+-W_[8'_!-Z]_:H\7_ +1VO:;^T9XK^$^@_M5?
ML17G[%'Q:\,:?\// _CB4>'=/U/XN:QX,\8>"?$/BN.34O!D\-U\;/&UA\1_
M#FGI-:?$318O"YL-2\#^*O#&F^+5_0J7XB>#K'P#J/Q1U_5_^$+\!Z-X;U7Q
M?X@\0_$/3]5^'$/A?POH5E=:EK>N>+K+QY8^'-3\(Z=H^FV5WJ.J3^);+2UT
M_3[>6]N_)M5\T_*'Q>_X*"_ ?X2_#35/B/<V/Q:\0KH_QG^!OP$U3PE8_ SX
MVZ;XUT/X@_M"^,?!O@[X<IXG\(ZQ\.K/Q7X<\.:C<^.=#O5\17^@_8-4>ZL/
M"_AG_A(/'GB#PMX2UQRBJC2E'F=N5)W;:G^Z:>UT_:QCKS<JY&Y*W,TI<D7-
M/EBGS<RT2=/FJIZOXE[*4K:<UI)1=['G7Q,_X)\:I\55_;8;Q/\ '2XFN_VY
M/V-/AU^QG\1M2B^&VFP7WAOPQX$T+XYZ%<>.O"L=GXHM-+3Q3KJ?M)?%>]-G
MJ&F76A:9=)X!2*QNK3PQK]MXUP?&W_!-[7=5^(WC/XF?#;]I;Q'\)=6^._[+
M_A?]ES]JG1=)^%_@KQ1X9^,6B?#GP_XRT'X7_$[PO9>*;B]U+X7_ !5\&V?C
M_P 6:))J']L>-?!OB'P=J4&B:IX*_MK2='\66'UAK7[87[.?ASQ?IO@/7_B*
M-&\4W]Q\*;#4-.U'PGXYM8?!&K_';4ET3X+^'?BOJLOAE='^#7BOXJ:_);>&
M_ /A+XL7_@SQ+XI\37^E>&]'TJ[US5M,T^[YKX=_MJ_!_P"(?Q'_ &J_A\D7
MC3P;!^Q_XM'@SXK^-OB)X!\=> _ <&I6GPW\ _%+6[^R\9^*_#.D^$3HMAX7
M^)GA2_TN[F\01WGBW1Y;SQKX8T[4_AVVB>,-='&,H2IN*<)*MSQM>/+.-6%>
M+=G:,X8NI&4;VDJB4(RY8.)S<LH2YFIQ]C"#;?,N65.=&R>J<982G*,[73IM
MRDE*2D^']C;X=:M^PS;_ + _Q(UKQ+\2?A5<_LT6_P"R]XH\0ZH-#T/QAXC\
M$I\.X_AO/K"R>'-'T_1-$\2+I")>:7?:7I$:Z3J<%G>QI/<VYGE\=^"G[#?Q
M6\ _&GX._'OXL?M@^-_COX^^"/[._P 8/V9_#DVM?"WX=^$;+Q=X'^*'B_X-
M^+[?Q)\3)=&CO==\1?$2QOO@IX5E\4^(/#VN^#M(\6ZC!%?Z7X;\%P3>(=-\
M2^S:A^W9^R7H?A;XE^,/%7QI\/\ @33/@WXO\&^ OBIIWQ(TSQ1\-O&/@+Q;
M\2+C2;?X;Z/XF^'OCS0O#OCW39/B.=<TNX^'MU-X:%AXXL+M=3\+76K:=%-=
M1\9K?_!2_P#87\.6'Q U+7?VB?"6EVWPI\86'@WXE+>:5XPBO? K:K9:3JFF
M>.?%.F?\(V=2T;X):AI&NZ-K5E^T)>VD7P(NM#U.RUN#XC/I4Z7AJ3<YRJR=
MYU)<\I.WO3:J>^]%'F4<742E]F-9[1:<4HQA"%.*Y84X^S@E=<L(^S3IIKWG
M&^'IWAJG*DM.;27E/@/_ ()Y^*OAS^S3X/\ V5],^-W@KQY\)]/T#]HOPM\2
M/!?QK_9VT/XD^ OBYH_[0?Q+M_B@UUXG\&P_$'PO##KWP[U2Z\6Z!X4D.J7_
M (4U'PQXRU.V\5^#M=UFRTK7;3K_ (7?L VWP&^+WPH^)WP:^-'BK2],^&/[
M#GPO_8:N_"/Q#\.:-\1)?''@_P" EYXFU+X)>-?$?BV.Y\*Z]!XDT;4O&_BV
MZ^(L6D-8I\1?M>D+9WG@N32;B;5?I7XO_M/_  '^ C,?B[\1-.\%V=G;^'-0
M\2:S>Z;K]_X;^'NA>+]<OO#7A3Q;\6?%&CZ3J/ASX/\ @;Q)K^DZUH^A^._B
MEJGA#P=JE_X?\1V]GKDTGAW6Q8><^,_V_OV-OA]XP\3> O%W[0/@72_%?@?X
MD^ _A'X]TV*75=5B^'GC[XG1:"W@;2/B+JFCZ9J&D> ++7KCQ7X4TJ/Q)XQO
M]$\+V/B#Q5X7\-ZGK5EK_B+1M-O4E?W8WNTJ=HWNTJ7U>,++5VI553BK7]^-
MI-N(Y6:;FU9RE-N35N9U7B)33=K-U*<JC<6O@E=))M?/ND_\$X-5\*_LW_L!
M? OP7^T1K6@^(?\ @G=XQ\!Z[\)?B)>?#;PYX@LO&'AWP/\ !WX@?L^1^'_B
M+\/-3UC^P=4U>\^$GQ)\06MEXOTF^T:]\/>/+?2/'.CZ?"MI<^'[[S6;_@DM
MJ.D_"_X6Z1\.?VO_ (J?#W]H#]GC]IG]J3]HG]GG]I.S^'?PIUG6_">G_M=_
M$CXD>/?C/\)/B+\-=1T(?#OXI^!_&"_$[5X=;;^S/!]\OB'0?!GB;PF?!L/A
MU/#]U]D67[<'P6E_:%_:/_9]UA_%?A*Z_9:^%/PW^+/Q9^)7C'P1XW\*_"C0
M="\?V/Q4U^ZDO/B+X@\,Z9X)M-%\+>$OAD?$5_XTD\1MX.U8ZQJ&@:%K-_XD
M\!>/M*\/>Y_#+XS?#_XO?\)5'X)OO$#7W@C6;+P_XNT3Q;X#\>_#?Q+X>U?4
MM!TKQ1IUKJGA;XC^&?"GB.V%_P"'];TK5K*Y;2_LEU:7L3P3N1(J&DG[3[4V
MZJFM&[2BG.#5K+FHQYN517NR4H\LYJ8K1CR+2$;4N3[.TVH235F^6M-I2;>J
M:?-"#A\IWO[#VN2_$K]CGXPQ?M(?$;5OB;^RY:?'#0_&'C3QMX7\!>)-7^/7
MAG]HR7P5K'Q5MM?M-,T;PMX;\ :S=>*?AQX+O/"%YX%T"R\->!?"=EJ/@3P_
MX-ATBXT6?P[Y;)_P31N)- U'1!\>+H-?_P#!1[3_ /@I";L_#6P81>.M,\9Z
M9X[M_A>+<>+D+^ SK>D6<$M_YZ>*GTDW%JNL)>2IJ,/T-X8_;G^"/B+XN_M3
M_"J^N/%'@JV_8_L/#<_QB^(OQ"\%^-? WPVTB[U?PM'XYU55\<^*?#6D^#1I
M.C^#]8\):[8ZV_B3R?%MGK6HW_A>VU'0_#MYK5Q[1\+?C[\)OC+JGCCP]X!\
M4RWGBWX9W^C:=\1/ GB+PYXJ\ _$7P-+XETY]7\+7/BOX=>/]#\,>.-!TGQ;
MI<-SJ/A'7-3T"VT7Q59V6H7'AZ_U*+3[UH&G?EDK:I58V2LHRJTJRDDDN6/M
M<+3FE9)>SO91DW-6C:47M?V4U*^LH4ZM*TF_BDJ>*J1YKMM5-&Y12A^:7[7/
M[-7Q'^&WP&_;5N_!&L?&+XA7'[:/[4_P:^+7Q(;X$?"SP'XN\;_"/P7IOA_]
MGWX._$!X?A/X^O?&ND_M#_"NZ^#'[/'A;PY\3?@LG@CQ7XE^*FD>+?B7H47A
M[5- \5Q:+X6X_P#9^^'/[9>D_L^?''P]^SC\:?%]OIVJZ-X-UCX >)_BU_P3
M_P#A+^R/XB\,_%0>.%O_ ![I:_ K4="^"$U]\//%'A>V73/'7B'XD?";PQXM
MT!]4N/$OPMU?XGZL!X=T+]-/C'^UK^SK^S_JLVB_%[XHZ-X.U#3_  K;>/O$
MJS6&OZO:^ /AU>:^?"]M\3/BIJ7A_2=6TWX3?#"?7XK_ $R/XE?$N[\*>!C/
MHGB5O[?\GPOXBETO;\9?M'?!SP#XTL? 'BCQ3>6GB6]UCP!X?G73_!_C;Q!H
M6@:[\5?$]IX,^&>C^-/&'AWPYJOA#P%J7CWQ3?V&B>$;+QMKN@7&O7U]91Z;
M'<+=V[23"/(N2"T:4(I7TC&/P[2YN6TJD6U=5)2DY325-5)WU>G+*4W?;FG)
M-R^S9SO&$HW:<%%1A!R<WVWC_P )ZEXZ^&WC+P.NLVNB:GXP\&:[X5DUZ/2G
MU.UTNXU_1KG2;C4X-&EU&S:[6U-W+<6UE/J<88I%'/<.H<O^<'BG_@F3+XV_
M9$\(_L)^,OC1HWC/]FC2_P!DWX7?LE^(_#7C'X(>'O$/BJ+3OA5HVK>%- ^.
MOPH\1W'BV+2OAA^T3'X9N] O--\;:KX5^(OA?PO\0O W@_QYX6\":3)I]SHE
M[]?ZY^V)^SIX;U#Q5I^K^/KJ"/P9I7Q,UC7-=M_ WQ$U'P<;/X+7:Z?\88]#
M\=Z;X3N_!?BO4OA3J@N]'^)&B^%=>UK6?!&MZ/XBT7Q-8:9JOAKQ!9Z9U&B_
MM+? GQ#XG\->#])^)?A^XU[QE\%)_P!HWPG!*;ZQL?$?P-L[OPQ8ZC\3=%UN
M_L[70]1\,:3=>-?"$>M7=KJ4DNBCQ-H<FJP6<6IVCRGNW<[I7<6];1O2=6I%
M6;LE!JI-)V<5"]_W=XNSY53?,^6^CNY>_&G"3;24KRBZ:D]GSI-?O+2ZCXI^
M%?'GBOP<-)^&/Q''PL\8V?B#P;K>F>+;SPM!X\TZ2R\->*M&UO7/"_B#PQ>:
MSH,FL^'O'6@:?J?@OQ UEX@T/Q!9:7K]WJWAS7]%\266E:M9? &B_P#!,?0/
M!/AKX1V_PM^*?_"J?&GPO_;=\=?MPIJ?@GX9^'(/AROC'XM?"_XJ_!3XH^!?
M OPAU?5=6T/X?>#=8^'/QA\6S^&TCUCQ%=Z!\26@^(NMGQC=WWB/1]>^AOA;
M^W_^QW\;M'\0^(?A!\=?"WQ)T3PQHWPUUW4-3\&V/B77;2]M?C#?>(=+^&=E
MX8EL=#E'C7Q%XPU7PKKNDZ7X3\&_V]XI_M:SCTNZT:WO[[3[>Z]R^$7QI^&'
MQX\*7'C3X4>+;/Q9H6G^)/$G@O7 EIJFC:YX4\;^#=5N-"\8>!O&WA/Q#8Z3
MXK\#^.?">LVL^E^)O!GB_1=$\3Z!?1FVU;2K24JI:5FY*[?-"<FTW9J4)1;N
MK1BYPA*UDG*SM%SO4A\LDHMIJSBDGI\$XO9[J$YI.]^7K)0]SY'_ .'>W@3Q
M1\/O^"@/PC^+WBJ?XA_#3_@H5\0/%OC[XCZ)8^'XO"6K^#;GQA\%OAM\![K3
M_"6N_P!LZ_&1HW@_X1>!-<\-ZI>:3_:NE^/+?6_$+W5U87^DZ#X?A\1?L+>(
MOB;H&KS_ !O^.TOQ+^+$'[*/QA_8^\!_%2#X9Z5X2D\,> ?CU'X*C^+?Q!US
MPA8>)K_1?%'QF^(+_#/X<7GB/Q%8S>%/ 5C=^$(8? GPR\#Z-X@\7:/X@^D[
MS]J'X"Z?\2M$^$M]\1=-M/&OB3QA?_#C0([C3=?B\+ZQ\3M,\-7?C.^^%.G_
M !"?21\/;GXLV_@_3M4\5-\+8O%#?$!O#FDZQK4?AQ].TG4;BUAT?]JG]G_7
MOB5I'PCTSXE:5+XX\2ZIX[T#P=;W&GZ]I_ASX@>)_A9/J-M\4?!WPU\>ZAI-
MKX"^)/C?X97&B>(8/B+X*\!^)O$7BOP--X6\71>*='TE_"7B0:7')!P<-'"I
M3=*VK4X*E5H-7O=OV&(JTFU+F]G5<5=.+CHY2Y^9OWX352[2O";J4ZJ;3344
MZM"E-)Q4>>E%Z-2B_B_Q)^QM\0/@KI'@SXU_#;Q7XL^+OQ(_9;_X)P?%S]CO
MX7?"SP3I?A#X;^,/BM+K=C\,/$FD:MHOQ"\8Z_K7A/P'\3M5\4_ 7X9Z?H&N
M:YH6L^!?#[7OB>]U/PSJJ:AIL>A?.'_!-3X3_&7X:>+O#$'P\^)7Q<\2_#,>
M%Y/#O[0&D_M%_P#!-;P1^Q'J<>J:)X5U(>"M:T7Q/HO@/X-^./BW\2U\?W&_
M4-3L7^,?PJN?!^J?$R^U+QSHWC'5? .I^)?T+'_!1K]ATZYX?T+_ (:7^&BR
M>)_'_P 0OA5I.NR:C>Q>!A\2?A<?$P\9>!M5^(TE@O@#P]XGMO\ A"O&1T+1
M_$'B72[SQFOA+Q.W@N+Q N@:J;2]:?\ !0?]B^Y\"67Q*N_VAO 7AOPC>_&&
M]_9^DNO',NJ_#[6-&^-.F1?;-3^&_BOPGXYTSP]XM\&^)]+T9HO%6I67BW0]
M%&G^";JQ\=7DD'@Z_LM<GT3;G4J-\SJN4I-_:E6J5*DY-[/VE;%>TLDOWDZ3
MC:+@GG9*%.E&T8TE&$(K[,:5.%.,4E9KV=+#*%VY>Y":E=J9\0?$W]E9/A5^
MP]>?\$S+;P_\9OV@-7_:;'[3R^ /C)X0^&"Z%X0^"'C_ .(_Q4U/XX:/\2/B
MSX^LO$$^A?";_A4/Q0^*$OQ(^%OB2(OXJU&P^%4.F>"M%\9_%G2-)L/&GZ\?
M#_P/H'PR\">#/ASX5BNH/#/@/PKX?\&^'XKZ[FU"^31O#.E6NCZ;]NU"X+7%
M_?-:6<37M]<,UQ>W)EN9V::5V/YL?M._\%%_"UW_ ,$Y?VI/VR_V%OB=\+/B
M9K7P"TKQ=9S2>+?#'BO6M*\.^/O -_I \7?#WX@^ #KWPS\=>$/&5KI&J6UY
M::7XEDT>]L;?6/#?BB?0]<\-ZI8Q:K];7WQV\'Z'^T3\3/ ^O_M#_![3-!^&
M/[.OAWXL^/?A%J6@RZ3XX^%VE3>*?&HO_C=X_P#B_>^/E\):)\,]<\.Z,=+L
M/"&M> =%U'29_!^O>-)?'&H:)J#:5I!%)1GM%1<.9MV]VGA%4IV5G[L,-"_.
MY6LDYRC&*D.3;E&3O)R<U%))OGJ8GDJ]GS3KRBN1)MO2$92DXOXDA_X)2W>D
MP1_#GPI^U;\1?"O[-/AS]L_PG^W#\+O@O8_#GX8:CK'PQ^(^F_'&;]H?QA\/
M=$^)&MZ3J4M]\&_$GQ2OM;\2^'_#5]X2_P"$K\&W6O:G9-XZ\1^'A8:#9?2>
MC?LB^//!7CS]K[XH?#;X]?\ "(>./VK?C3\#OC0]Y<?#.SU[1O!-U\%O!?P@
M^%DO@F?29_&%E<^*_!WQ*^%?P;TCPEXX5=6\->(X+SQ/XO\ $/@[Q!X5O)_#
MEOX:ZP_MZ?LCP?#WXK_%/5_C3HGA3P1\#_!OA?XB_%/4_'>B>+_A_?\ A3X>
M^.M/U74_ 7CV;PWXW\/:!XGU3P5\08-!\06_P_\ %>A:-JF@^.M5\.^(M$\)
MW^L:SH&L6%EWOPX_:G_9]^+>O?%3PS\/_BCX>UW6?@I;:#J7Q+MI$U+18?#_
M (=\4V>M7WACQM;ZAK]AI>G>(?AUXD@\->)TT#XD>&+O6? >LW?A;Q3I^G>(
MKF_\-:Y;6"35.,H)J"C&TXW2<8TX4X/FO9Q4*>%IQ:DXN%/#\LE&-.IRCBIM
M3:<G.<6GK:<W.<H\O+I+FJ8B<HJ/,I3KWC=U(*7Y\:[_ ,$B_#5IX6\/:_\
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M@&R\,7D/@7Q_X]/B7Q]X)\"26GP]T:PUN]\-0^--?M-"E\=>)X;_ %C1UL/
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M3H_BJ[B^&Z2^)/A=I&@^*O&^C?I3\/?VM_"'Q8^&GAOXI_#KX;_&CQ5H.O\
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MX7\#_$OPUXK\;^#-USJ?ZC?&#X:?$O1O^"=_Q0^$7P.^!'P!G^*UK^R9XU\
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MS1-9\0^.K:WEGTB?[N^%'P@\>^,?V\?B!^VMKW@_Q9\(_"FK?L<?![]F?2/
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M^&OQGL?#%M\0;7['_P -OVK-.^//["7Q*^)7[(GQ-^%/AGX!?\$N?BY^R/\
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MYJB2LX\OYR_M5_#3XNWW[9__  3M^.W@'X6>(OBCX'^$&N_M*^$OBF/">O\
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MVEVC*4W)Q^&+^!*[L44450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OPR_:,\ ^'_C/^WS^V?\'?
MB?\ M6?M&_ CX7:!_P $TOV8OV@-(?X8_M8_%OX&:5\)_'H^+W[=/@SQ7^T9
MH2^#_'?AI=''@+P[X,^'M[XHT62Y3X,^)+_2?#6M_&#P+XSUC2?".I:)^YM?
M#=]^Q5H7B?\ ;5\>?M9?$6Z^%WQ&\/>*?@+\#?@OX;^%_BSX*6.MZOX$U3X%
M?$3XY?$?0OB%HWQ%UWQIK-F-9U74_CSXELKZTL/AYHT]M::)X;DM-86YMKZ6
M_+)J<6^7FHUX1FE=PG.DXPG&S34HS<90>EI17O0^))N2<9+7EJT9.-XKFC&M
M&4XOF37*X*2EH_=D_=GK%_EK^SJ/B_\ M._M"?\ !/;0/VK/B=^T7X9\9_$C
M_@C)X._:(^.'PM\%_'GXU?L]6VH?M">%_BW^S%)/XY\0> _A/XO^'$WA;Q1:
MZCXN\1:9XP\/Z79:'H]VNKW7@[Q=H^JZ;IVF:?911?&#XW>,OV:+7]IC0?B!
MX^MOVZ_AW_P5WG_9Z\3_  BT[XD:\GA:;PMJ7_!0B#]GR3]F?Q=\(SJ%Q\/K
MCP%9_L >+/#WQ;MM2@\(1:C86EKIO[8,.LVWBRXU?XAW?] <WP\\ 7'C&U^(
MD_@;P?/\0+&R;3;+QU-X9T67QC9Z<\%S;/86OB=[)M;M[)[:\N[=K6*^2!H+
MJYA,9CGD5JJ?"_X:1^/)_BG'\// L?Q.NM-@T:Z^(R>$= 7QY<Z1:PS6]KI<
M_B]=/'B&73K:WN;B""QDU%K6&&>:*.)4E<,^;]ZI\JY54G4Y.EWC7B8WMRWO
M1?U6HO=@Z<I<D80:I$J%J;AS-MPA#G>Z4<)]7:6KLE4_VB#]Z?M(QYY2FO:'
MXM:3%\6_!'[;O[0G_!/#4?B%^T)KGAC]I+XI?"3]O/X+_%'4/C7\==<\2?#3
M]F#1I=%M?VKO@KX?^(=YXE@U#P3X2\.?'+X4>#_AWHW@GP5XQT"ZT#P5^W5X
M6N-%TZ]TKP7K21-UG5_C-XE^,G_!9KX:_#C]I:?X<>*]$^,'[ VD? ^Z^,WQ
M+^(^I?"_P?XK^)7PQ^#VL?\ "E;"72_%47B_X0>"OVE/&NM3?##5KWX.7>@^
M,?#=[\5+OQ;\-[8>,[#0(J_=233=.EU&UUB6PLI-6L;*_P!-LM4DM8'U&ST[
M59]-NM4L+6^:,W-O9:E<Z-I%Q?VL,J07D^E:;-<1R26-JT7GNJ?!+X,:Y'XS
MBUOX1?##6(OB/]D_X6''JG@'PIJ$?CS^S[J.^L/^$S2[TF9?%'V&^AAO+3^W
M!??9KJ*.XAV3(KB+>[&+NVJ=2FY*R;3]E"DW=27[JE2A%MJ4IR3G*[G44[N[
MR:M=U*=1<WO*+BZDZJ7PMJK.I)J-TH1?)%VC3<?P5\8_&WQG>_!KX1H=+_:"
M_99^+_PS_P""W7[&OP#^-_PDOOVJ/&?Q5\(:=?>.?&/P#UG7?AW\-OBA8>(=
M-E^*G[+WQ)^%'Q,\(^+O#_P_\7:%HFF^'=0\5^(/!5S\,O!0\,KX6TJQXT^,
M/QM\1_LV_'/]H[PAXW^(]K^W#\"_^"L]S\"-$^&)\<>---\'2>&I/VX_!'P1
M^&7[.FO_  DAU:R\$ZQ\-_C%^Q!X[^'OCBZU*^\,LMWJ_C^Q_:ET?5--\5Z=
MH'C/2?WB'P2^# \,>'O! ^$?PQ'@SPCJ,NL>%/"(\ ^%!X8\,:M/=W=_-JGA
M[0!I/]E:+J,M]J%_>RWNFVEM<R7=[=W+RM-<S.^K)\+_ (:2^/8_BI+\// T
MGQ/ATN'1(?B/)X2T!_'D6BV\>HQ0:1'XP;3SXA32X8M7U6.'3TU$6D4>IZBB
M1*M[<B5PO&:<DI+FA)K:/N/ R]V-W;VCPE6G*+FXQI8JHHWE?G4DI125XVC.
M.]^93^NKWG9-N"Q5.<9)*3J8:#=DXNG_ #;_ +7?B7QYX=N?^"V'Q8T;]H;]
MHGPWXE_8Z_:)_8V\<?L_V.D_M(_%S1_!/PQU/Q%\ /V6?'?BO0)/ EIXTMO"
M7B7X=^/];\5^(%\1?";X@:5XG^&$EEXAUN/P[X/T.Y\1:]=:K]I?&KQU\4?A
M/^W GBWQK>Z[\9_V9?'7[5?[,GP@\-^+O@=\>_&G@WXI?L3?&KQCX#^&7A;1
M_@1\</V=X-4M_AU\:_V=_C5K?C7PC\5-?\1K-/X[\&_\+H/B7Q;\/M8\,?#W
MX5_$7P-^K^I? _X*ZRWB9]8^$'PNU5_&MY::CXR?4OA_X3OF\6ZC83R75C?^
M)FNM)E.O7EE<RRW%I=:J;N>VGDDEAD21V8R6GP4^#6G^.8?B=8?"3X96/Q*M
M[2VT^#XA6?@+PK;>.(;"ST/_ (1FTL8?%D.E)K\5I:^',>'[:V34%A@T0?V3
M$BV'^CT+1PT;4)496=M>2E4IU$GHUSN4))W]UTX.2G:4*B:=ZCYM)QJQMM;G
MK0JP=U_)RR@U9J<9RBG"_-'X?_;1^)_B;0/VJO\ @G)\%=<U76_"?[/G[0WQ
M3^._A?XE^(]'US5O"</BOXG^$/@3K_B[X$_ [Q#XJTB]TZ[L] ^),]G\1/%W
M_".VNHZ;<>//$'PG\/>#+F?5?#VL^(/"7BC\N?C];^.-<_8+_:K\)?%#QY\3
M/&/PW^ G_!:']EWX7?LU_$7Q)\4_B(OB'7O@;!^WO^P[%K&B>)OB-%XOMO$/
MQ0;X(_%GQC\;O@3HWC'QUK6O>+O#NJ?"#3;V\UV3XC^#!XL'])OC'P5X-^(G
MAO4O!WQ \)>&?'/A'61:#5_"OC'0=*\3^&]5%A?6VIV(U+0]:M;W3+X6>I65
MGJ%H+JUE%M?6EM=P[)X(I%Q]:^%/PO\ $GAC1O!/B+X;^ =?\&^'4L8_#_A+
M6O!WA[5/#.A1Z99MI^G)HV@WVG3Z5I::?8.]C9)96D"VEFS6T CA8H:IOV<H
M2LY<M13DO=M42Q&$KQYG9R4J4</4ITG%I6KRY[Q3A,J1]I"<%9.=)TU)W;@W
M0Q5%N*3BFJCQ$)U%+F=Z$>6S:E#P+]LOPCIG_#"W[4'@J.3Q)=:5:?LM?&32
M+=I?%OC"]\3WEOIGPM\0):+?^,9=;F\:ZS?W7V:)-3U'4==O-5U[S+E=8N]0
M-[=_:/QO_9P^%7PT^,OQ2_X)4_#;_A./B)=^"/$'_!$/]H6\\17WPW_:$^*W
MACQA<2:I\2?^"5VJ7.C67Q?\!>/],^*OA/1EN[VWN;/1_!OCKPW:6NF6UKX<
MMHD\'S7N@7O](5I9VEA:6VGV-K;6=A96T-G9V5I!%;VEI:6\2P6]K;6T*I#!
M;00HD,,$2)%%$BQHJHH \HT;]GGX ^'+31;#P]\#O@_H-CX;\/ZEX3\.V6C?
M#/P7I=IH/A;6I=7GUCPUHMO8Z)!#I?A_5I]?UZ;4M&L4@TZ^EUO5Y+JVE?4K
MPS9.#<F[_%*E*SO_ ,NZ>,IN]FM7];C)-:IT^MXM4K)I]H586Z?O)X6=UU]W
MZNU9Z24[.UI7_F^^%/[9OBOQQ\&/^"2W@G]JG]JKPY\#?A_^TQ_P2ZD\=W?Q
MQ^,?B[X@^%M(^-/[2NBV7P6TKQ/9:_\ %WP'^T#^SUXDT+XO>'O VK:AX^\%
MWTWCU)-0\0>)/%WBNWMIO'GA7P5JNA?MOX1AU0_\$Z8[:3]H'Q9\>]2L?V7=
M>MM._:>TB;4?AOXN^+:Z1X#U.'0?C/H>L^$-:2]T^_\ &%K:6'BW1O&GA77V
MMO$"7MIXNT#4I;#5K2=_I/6?@-\#?$?@G3?AIXA^#'PHU[X<:/J]KK^D?#_6
M?AUX0U3P3I6O65W/?V6MZ;X4OM'GT*QU>TOKFYO;74K6PBO+>[N)[F*9)I9'
M;:^*GA'5/B!\,_B#X$T76[#PWJOC3P7XF\*6/B#5-$N/$NGZ+/XAT>\TE=3N
M] M-=\,7.L160NS.=/A\0Z,]R4$8U"VW&0&(YJE'%1IIJI5AB/9NZ3<IPKRI
M7EIRSC4J\BG#DCR*G*2YJ:C&L,HTZV%E5=X4JE#VFC:<(U*/M%RZN<94Z?-R
MSYI<W/%.TW)_S2_#/Q)^U)\+/AW_ ,$T_P!HG]FKXL?'[]I/XU?M+_\ !*'X
MQ_$_XV_!SXI_&7XG_&OP3\3?$WPO_8P^%WC_ .#7Q0T#X?\ B/Q/J/ACX>>(
M+3]H_7?A=\']<UCX::1X3OOB')\;;JZ\;3^(O'.N:OXGU/ZX_9Y\?>+M2^(7
M_!&[XI? OXS?$KXN^$_VN_V=?B;J_P"U9#XI^(?BCQ_I'CGP5HO[.WA[XB6/
M[1>K^%M9UF\\.?#WQ[X%_:/OOAW\(-:U;P1H/A"VT^U^.-I\)-=T9='\.?#;
M0O!7Z:?L;?LJ>$?V0O@#\*/@_I%KX%U?Q=X$^$OPM^%WC?XK>$?AII?PTU7X
MNS?"GPG;>$=%\6^+=-L]6\2ZE/J]U:0W-_,FJ^*_$+6NHZKJTMG=Q17LD(]T
M\+?#+X;^!M4\6:YX*^'W@CP?K7CW59=>\<ZQX6\*:#X?U3QGKDUS>WDVL^+-
M0TG3[.[\1ZK+=ZEJ-U)J.L37EY)<7][.\QENIWDZ:LHNK5E!)Q>(K3IN,5%*
ME.OBZBHJ,HMQHN.(BK6]I!0C%-<L?9XPB_9TU)>\J4(S4FW>K&EAX>V;C)7J
M1E1D[J7)+GDY*7-+G_GGL?%7B#PK^S!^S)JOA3Q_XR\%W>I?\'%_[1W@G6E\
M&^/O$GA"S\7>%O&O_!77]KK3?$7@;QEI_A_6=-L?&?AGQ!I\D3WGA7Q);ZII
M=YY=M<&Q? 9O9_A7^T1\*?C-^T'\;O GQ[_:T^(/P(_;!^ G_!3.Y\%_#_\
M9_\ "7QDB\&^+O&7P:L#X:_X4+\/M-_9\UN35K?XE?L_?M)? W7-.^)7Q/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*I548):<L:F(Y-$VVG3IPY6K\RE'5R<7+]-/^"@/[9MA^Q?X8_9^U[Q#XD\
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MA'XK:]X?\(_$/3W^(%AX%\+>(_ \]S=7]]X5\4Z[K6G:9J]SH"Z-J/X#W_\
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MX6_'_P" _P"UG\2]<U:[LM>G\?Z;XG_9WUO]G#3M&MM)U"'7+/P[9Z#K5O\
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MB(<[GRQC.+C1IS2@K)5H/FY90,HRFVKPM&2YN9JVGLZ$^1P;<HR4JLXWD_\
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M3^Q!XPUSXX_#SX@:/\2_V</B_P# S0/VW?A/XZ^&_P #/B1X$TO]H3X@:YX
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MDK-?MY?_ +97[-FE^+/BUX"O?B7#'XV^!>N_"#PU\5O"<?A7QQ<^(O".N_M
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MXJT7XX?%#3;;P#\0-(\4^#/ L?BO6[SX<Z)X-U75M:U#4OTH_P""J_[0FO\
M[.OPS_9I\12?$G3_ (*_!WQW^V/\,?A3^T?\;-=T;Q7?>$?A1\+/&'@;XL-X
M1\1^/-=\&?$3X2ZUX#^'^M_M%Z5\"/ 'CCQV_P 2/".BZ'X:\9ZE%XCU-M O
MM2L[J:;]I1I5M(QJS]FE)I<LFHM<TFTNMFO=?,DH\W/$J;4*U2B[N5.FZK<4
MWS13FO=24I7?)=:-*+YI649'TOX7_8-_8K\%?%S5OCQX0_96^ OAGXOZWXEO
MO&^I^/-$^&/A/3=:N/'NJW4U[J_Q#7[+ID5I;?$76[J>XFUSX@VEK!XRUMIY
MQJFN7BS2!O4_BM\!/A'\<+GX=7GQ4\&VOC"X^$OCS3OBE\-);S4M<LSX+^).
MC6MY8:+X\T(:3J=@EIXMT6PU'5;#1M?VMJ6DV.LZW9:?<VUMK6JQ7GX'^+?"
M?Q1_X9BMO$/[&/\ P4'\=?MH?M)_#+]MWQ1\4OV0_!OPL^*_C?0/@5\4=*T7
M2?"?Q#^+O[!OQ*UW4/V@?&VB?&O]G;PSX>3Q[=0?$+XJ?&'7KOX'^*M:\*_!
MCPSXEAG\(V'P3\57?B#^V#X)TSX5_P#!*%?"?[4^J>"/V.?VJ],_:!L?B/\
MM3?M3>*?B;K,MU^TAH_@^RUCPI\#/VA/'%I^T5\+=7^%GB;Q)XB/[36G:E\+
MG^+5AX4\"_%/X.:5\$_#?ABTT+PWI?AG3ZBW>,4^2490C&+ER<KG%RBX-N*M
M>$J3]G&ZJ^QAM7H-N22YG?F3C4<I)-MJ%E*,EK*\HS4XJ3]ZG[:=K4:J?](=
M%?S:>"-#U+Q9^T%_P2R^ $W[>?QQ_:F^"OQ1_9U_X*I:3XM^+GPP^.GQK^$F
ME_'K0/A3\4/V<_\ A4$[>+O ?QGU;Q;XJUSX*:7XZ\0_#WPW^T)H7Q,O/BA\
M1-+T2Y\0>(/B5XHM?$_B&77>0_8?\2_$?5_!'_!';XT>(OVA_P!H[X@>-OB_
M^UY^VM^QY\3]0\9?M%?%;Q'X2^(GP.^#7PI_X*31?#O3/%/P[;Q;'\,M7^(N
MAZG^SC\(]6N_C<?"2?&SQ)XA\-3:CXM\?Z]>:OJIN[E3E&,)2T]HJ32?Q)U<
M14PT(M:;5:?OM72A+G7-91FD[JK)6Y:,I1F[_P M%8AM+>SI\UK\KYU&,E'F
M;A_3U7E'B_XN:1X=\/:3XD\-^'?%WQ;L]2^*WA7X27EM\(M.TWQC?>'=8UWX
MFV7PJ\3^(?$D9UC3K?3?"7PCUVXU/5/B]J*7-SJ7@S0/"_BFX?1[[4='ETJ3
M^9;]F"X^.MI\%/\ @D[^T;X*_:=_:?\ B7\:/BC_ ,%%/C=^RO\ $[P/\2?V
MC?BY\2O 7Q6_9HT_XN?MFZ=\1]&UCX<ZYXMN?!Y\;_ GX<_">Y^)NA_%VXT>
M7XFV ^'\OAS7_%>K:/#X9TO0.I^$8L?A/^P-\&F^%7Q7^*OA+QE8?\%Z],\%
M>+]&T?\ :)^+]YJ \$^*O^"\'Q;^$>H^"/%V@ZI\0M3E?PE\1/AKJOB*P\;>
M'M9M/[/^*=U]M\5>.(/%'B*.YUD\]2HH1IS34X3C"7N:NTZF6QBFTVE&4,RI
M7DF^6<*L(WE"+ELZ4E4G2;2E&=:G=WLW2AF*FUL[QJ9?4M%IJ4)0G+E3FH?U
M+T9[?Y]*_FC^+7QJ_:!UK]FC]NC]I#P5XV^)]K^W-^R[_P %2[SX+?"#X63>
M,_B7X8\"W7AU/VGOA#\)OV=_@#J/P5M_$>F^"O%7P]_:M_9E^(/P^UV[U+Q!
MX?UB+Q)XR^,MM\;/#.IZ9XF\,_#_ %;P;B_M.:QX]\':+_P4<^.>B?'S]I*S
M\5_LN_\ !8W]@OPI\$-+7]IGXWV_P[\$^#_C+I__  2@/Q<\"W_P^L_'UIX.
M\;_#KQM#\<?BEIES\,_B1I?B[X>>%+;Q7KA\ ^%O"&HZSK][JN\(.=6C23BG
M6E!*2O-+VE+!UHM<NLERXVG&7+\-2%2.MH<W-4J*E3G5DI<L?:[KE=Z+Q:J)
MJ5N1_P"QS<.9KGC.F[1O*W].U>.^*OV>O@3XZ^+7PY^//C3X/?#;Q9\:?A!I
MOB+2/A7\4O$?@[0=9\=?#NP\6+;Q^(8O!OB34+&XU/P])J<%N;6:ZTRXMKN.
MRO=7LK>>&TUO6(;[X@_X*F>+?$_@+P'^R%XT\,^._'7P]33O^"DG[!?A[Q?K
M7@_Q]XO\"Z3??#SX@?M$>$/ GC7PW\15\-ZWH^D>)OA_XHTCQ WA_7/#OCB'
M5O"MV^HVK3V(OELIXOSU^)?QBUSQ%9?MI:=\.OVFOBF&\#_\%\_^":/P]\&Z
MEX%_:*\;ZMJ7@[X5?'*W_P""7N@_$;X?:0[^,-;MA\(O%GB#XD?'RWE^%6I6
MFH?"<Z]J/C2RMO!__$KO;&TYYU5'D:3;]K.":WIRA]2CSMZN*DLQ2BURRM"J
MDWS13VM[LFVDO9\S3^VO]JDX6NE*SP3;34E>4&U[C:_I+)Q7@_PF_:)\ _&7
MQ_\ M#_#;PE:^*K;Q'^S'\4-%^$7Q*_X2/P_-H-I+XLU_P"%O@/XPZ=)X:-W
M-]MUC0I_!?Q(\+W<&M/8V5I?S74CZ6;_ $\0:A<?SV>/_CSXJ_9?^*'[1O[/
M$GQM^-7AK]E;3_\ @LO^Q5\"?'WQ+\<_''XW_$?QU\#/@)\>OV!?A#\=_$VE
M?\-%_$GQYXO^)?PP^'_Q3_:D'ACP!JWBW5O'%A8>"-*^-_B_3O!FM^"-3U;P
M_J^@\G\0OC_I7[*&H_\ !5R^^#_Q>LO"7PXLO^"M/_!/SP;\=OB]J?COQ7\4
M]1^!'P$^)?[+O[$/A#XB>,=>UE?BEH?Q#TKP+8^,K>\^#FJ7^E>/_#NI?#7P
M?<^*=(^'>J>&-8\ :-'H'7[&2M)M<LJ:<;2BFIS>"4753=X1C];W=E)+VEXT
MW"3YG6NXJ"=_;2A*\9.\*:QO/R-)J3;PRV3<6_9V=3FBOZMZ\V^+OQ<\!_ S
MP!K'Q,^).K7.C^%=&O/#FD,^GZ-K/B36]8\1^-/%&C>!_ _A#POX7\-V&J^(
M_%?C+QSXW\1^'?!?@OPGX=TO4M?\4^*]>T;0-%T^\U/4;6VD_G'\<O%?ZI^R
M3X2^&/\ P4J\9?'WX1_'#_@K9X:^'7BC5?V6?CK\8?!_@WP#\/\ XE?L*?M$
M^*_'?[+6C?&73?VDOC5XFUO1-;\7^ ?"/Q6T/PU%\4(O&O[/ESX\T$_!&Y^$
M]E)\,IM#_8G]LGX-?LOWG[#6J?L]_M+^,O'^@_L_ZBOP!^#B?$O4_BWXM'Q6
M\*^,]1^+GPP\%? +XDO\;O%>N:EXME^)'A7XV7'PU\76GQ#\9ZQK\]SXKTZ#
M6_&$?B.TEU6QU"73FH4Y)-NJ^6,$K3O%T>>*<DH\_P"\<8.SA*3@V^66MJHN
M>I!VBJ45*4Y-\B4O;<DFH^]R_N^::NIJ'-L[,]J\,?M)Z)XB\4>+/AS<_#;X
MO>&/BUX*\!Z9\2M=^&/B/PII::K+X0U[6]8T'0+[PYXZT3Q'K?P7\:WNIWOA
M_6?M&B>"OBAXAUOPT+6VM_&>G^&M0UG0++5?)/A/_P %!?@W\:?AK\'_ (V>
M _!OQOU#X)?';5? .D_#;XL3_##48O"VJM\4/%-CX*\#ZCJFGQ7L_C+PUHFM
M>*-3T[2I-8\1^%=+T_2#?6U]KD^FZ7)]M'R9^Q?XJ_;%^!/[:/BW]@3]J;XF
M>&/VP_"_A_\ 9=N?VA/@/^V,WA#2O _QZ\.?#[_A;>G?#D?!+]JG1?#S77A?
M4_%FO22P7GPU^*&B6_@]/C!9?!OXE>(M:TC6O%FD^)(O!_@O_!''_A-? O\
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M9Q>&LHM*[O&;@O>C/,Y5:5&.]7V5IV<HKVF-PF%7PWNFL2Y-IMI6E%2TC/\
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M?^"0OPMU[2?%G[0<WP\\-> (?B_\9_V<-1\6_"'X-? 7P1JOAVT^('@3XN?
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MVO4BW9QLZ=5TG:,K3:DU=.R2UBVY1:/TSH_K7\RG[1VC?$OX/ZK\<KS]GO\
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M<ZYI=W)K.O:!J>E3AKJ#:_99^+/Q\E^*'[)/[*?QJ^+'QA\;_LL:_P#ME_\
M!7+X&?#KXVZ]XU\>R>/?CY8_LM^(;72_V7OA?\7OCGIVK6.O>*YQX<3]JZWE
M^WZM9WOQFU#]F;P_KT]SJVGZ9K-AKVGL9<]6FIT^>E4KTVG)*\\/B9X:I%:M
MMRE!2HI+FJJ4E&*<'S1S_NJ59QDH5:5*LGRN\8UJ*JP4DTK->]&H[VI.*<VE
M*T?Z=**_FD\)Z]^W1XK\ :]X3^'NO0_M%Z9^SC^W+_P4%^'WPJ_9W^(/[3OQ
M2^!'QP_;+_9$^#%]I7@/P[KO@O\ :MM?$]UXPUGXU?LD?&KQ5J'P3T_7_C+J
MVI>$/B')H,/C/XH^.=!^,.A>#OBYI7C&I_M?>$_V@M5U+X6^)O\ @H9J/[ 7
MPQUC_@G)^PI\?OV)?B3^U%XV\8^&_CMXH\%?$[X?^,O$6L?M%7'C+PY^UI\'
M?"_Q-^/WASQMI6C^%?C+X:\:V_Q>\&^*;/PW!I;:9XD\#_$GXFVGC#))M1:=
M^:*FHI+FY'0HUU9-VE-PJN,80<VYT:L'RR4%4T:LY*\;Q?*]6TI>UG1L[1;4
M>:,9.348J%6$DY+GY?ZPLC\NO^?QHK\(=%^)GQ3^'W[>OPDU/XNZQXP^,WP4
M_:(_:8\2^ /@?\;O@K\;OB-X4E^$_P :-$_9#\06NJ_LB?M@?L3ZCJ7_  C<
M?P^%IX)^-/Q:\'^*_"PUYO _Q)T3PEXH^*OA3PQX@N;GXCZ]]9_M+>--0U7]
MO7]BW]FSQUX@\7^%?@1\9O@M^V!XGM(O"OB_Q)X$'Q3_ &D/ABWP)G^'_P -
MM7\4>"[W0O$9AT3X&>)?VDOB=8>"/^$AMM.\6WGA)O&+Z9?7?PAM[O3%*\7!
M6;]I.4(M)I<T8U)-2YN5Q5H*S=U)5*4H.I&HDI3NF]K0C4:WO&4H15G'F4K2
ME*,K6Y)4JL9J#@V_M'XQ_&KP)\#/#N@^(/'%[<++XP\>>"?A9X$\/:7%;W/B
M+QU\2_B-KMMX=\%^"?#-G=75C9RZKK.I7)EN+W4]0TS0/#NAV6L>*_%6L:'X
M4T'6]:T^S\&_B?\ \+A^'^F>.I/AY\4/A3>W>I>)=%U7X??&/PFO@[Q_X9UK
MPEXEU;PKK%EJ>GVFHZWH&K:=)J6C7-WX<\8^#/$?BKP#XY\-W&E>+_ OBOQ)
MX4UK2=9O/YEO'S>-OB=\!O\ @GGI?QX\<?$OQ%I?PX_X+^^./V7?@+\3]1^.
M/Q'T3QW\6/V</A]\6_VG/AM\)?%?C#Q=X4\7>%]3\>?$FV\-_#^R\(:)\7-8
MDU+XC>*M/\-W/Q A\4ZEJWQ)\6^(O%/]65I;1V5K;6<+7#Q6MO#;1/=W=U?W
M31P1K$C7-]?37%[>7#*@,UU>7$]U<2%IKB:69W=KY7&/-+>4K))II1=#"5XN
M\6TY<N*49QNTI)<LO=;JSS7FX+:,;R>OO/VV*HM*Z5HIX;FBUJ[M22NN2Q11
M14EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7E_C/X=?!?7_ !+H/C#XA>!/AAK?C"/1?$?PR\,>*?&?A?PIJ7B5
M/#OQ!A@'BWX?:#K>MV,VJ+HOCBWT>U'B/PGI]R+'Q+#I4 U.PO4L8_*]0K\3
M?V\O#O[0_P &/VHIOVP_#G[)_AO_ (*,?LOZI^S7X:^ _P <?V9]"TS0O$G[
M5/P.T_PWX[^)7Q!\1?%[]F/P+XYF?P)\7-#^,F@^)=-\(?&SX&63>%_B5\4-
M?^$WP$N=&\0^(-(\%-H^@2WK&]DGS7D[VC[DDKVC)I2;Y&[<J4_?:C)W>K3L
MKO31-)OWHWMS.*;BESJ*?,W!<J<EI^J]A\!/@3ITWANZTSX+_"2QG\&:3JGA
MWP?<6'PY\'6LWA/0M8EU%]:T+PW+;Z.CZ%I.J3:KJS:IIFEM:V=[+J6HM=P2
MO>7)DBTS]GKX!:*GA.+1_@=\'])C\!:O=Z_X%CTSX:>"[!/!>O7\]O=7VM^$
MTM=%B7PYJ][<V=I<7>I:.+.\N)[6WEFF>2")E_)SX3_MM^#=3^%W[&_[.G_!
M+RP7XK^$?&_[%OBCXU?"7QSKFAZ#X^A\'?"#X.^+_AQ\"_"/AKQ1\/OB)^T;
M^RIX@\0:S:^*?%FH:%X[U(_%@>*O!FK?#6Z\.>(_#6IZSXYB\0^&/1_!O[97
M[;'QR/Q3^&'PW^!/PC^#'[6?[-G[-G[.OQ<^-GP#^-'B<?$;3==^-'QV;XK:
ME%\ /#/Q-^%/C_2O#'@G0;?0?@]*^A_'>9/BKHNHW'Q2T.34? &F7GPR\8:!
MK]N,DVI1E&44VU)>\N67+4:M?F]G44E-P;LU&<>95(2E"::C=+WEI;56DG[-
M2;5H.I#E<8S4=YPE9TYH_2O3?AM\%?AAK_Q(^+VC^ ?A=\//%/C:V@UOXO?%
M#3?"OA/PEK_BZS\+V5R]MJ_Q(\:VMAI^HZ_;>'=.-V\%_P")]3NXM(LC<M'+
M;P&4U<U;X6?"7Q?XFT7XBZ[\./AUXH\9:38QP>'?'6K>$/#6M^)M,TV03310
MZ+XGO-.N=5LK%Q>7$L<=C?1P,+J9U!$\A?\ #[XD?M,_M&6#?\' >M_$BZ^!
MWQN^$W[''P0@3P'^SKX_^%NM7OPW\0^%I_V']#_:2U/P5XVF?XAZCH_C'PWX
MKM/'?C3P7\3%U+P0FH?$E;G1)_[3\)^#M$TOP#8?1_AG]L/XW_%74?C1\&?V
M2O"?P0T/QO\ LA_LG?LN_%GQ)X7\<>$O%LW@_P"(WQ$_: ^'_CSQ]X2^ /@*
M#PGXW\(R?!;PKHW@WX<Z%IT'Q.N[/XQ6ME<?%/3X[3X=7G_"J-8TGQZY1Y*?
M/-J,8TU4;;CR4Z7LL15G*ZYFXTZ=*4Y<D7%1GI&4I\K(.4Y-1BW>I.GYSJ*>
M&A%6?+K*5>FK3?,I1]Z48P<X_HN_[/7P"D^''B3X.2? [X/O\(O&1N3XP^%;
M_#3P6WPX\5F]^R"\/B7P.=%/AC73=_8+'[2=4TNZ\_[%:>;O^S0[&3_L[?L_
M75S/>7/P+^#EQ>76O>&_%5S=S_#'P3+<W'BCP9X8TOP3X/\ $D\\FB-+-KWA
M3P;HFB^$O#>L2.VH:%X8TC2]!TNXM=*L+2TB_'.Y_P""FW[4'QZO)9?V2O"O
MP \&>&_%G_!)+X2?\%,OAQJO[0>@_$GQGKEEK?Q"UWQIO^#WC;PW\/O''@&Q
MGT^ZTWP@GAM_&6@^*XY/">JZK-XQAT;XAZ;I,'@_7?V!_9G^,\'[1W[-_P"S
M]^T-:Z!+X5M?CS\$?A3\9[;PO/J"ZM/X;@^*/@/0?'$.@3:HEIIZ:E+H\>N+
MITFH)862WCVYN5M+82"%!PE&[:LTXW5_>^*M3A+3>/-AJD8N^BC!I1C.#$I1
MG:VJ?-9V5M84:DEK>S<<13<E:S;DI-RC)%F]_9X_9[U:W\36.H_ WX-:G:>+
MO$%KXG\96=[\,O!%Y;^)_%5E]KGLO$/B:WGT22/6O$%K_:M]-:ZMJJ7.HP?V
ME=20W"_;)FDT;[X8?!%/BEX6^*.I?#SX5I\:['PYJ'@7P3\1;[PEX27XHVGA
M%8[C4M4\'>%?%UQIX\66_AQ8GNK_ %#P]I&H)I@C>XNKFS"M)(?RC_8N\5^#
M_P!FC2_^"Y?Q,T_PG#!X2^$/_!0CXZ?&#4?"GA6S@TYM3&@?\$__ -C#XD^)
MX-,M;6W>&/5/$>I)JET[I;2&?5=1DG>*5Y&5O'O^";W[0'Q$\"ZC^Q#KG[4O
MP>T#Q!\8?^"NGPHU;XTZ?^USX4^).K^/?$5Q\2U^$'_#4EM^S-XV\ >(_ASX
M;A^ OP6^'7P:N?%&B_L[>%/AM\3_ (I>#G?X9>+=4\7:?IGQ)\=:_P"._B!C
M3FIQC+2"Y*<KMJ,5.M"JJ=*,FHQYY4Z59)*49.$.2,).I&!O5IN$IKWIVJ3A
M=1;NJ:I5:DY).4DH^UI2=U)<S<Y2BJ;DOZ ]3TS3=:TW4-&UG3['5M(U:RN]
M-U72M3M+>_TW4M.OX)+6^T_4+&ZCEM;RRO+666VN[6YBD@N()9(9HWC=E+5T
MG2DU&]UA-,T]=6U+3]/TG4=46RMEU'4-*TF?5;K2M,O;T1BYNM/TRYUW6[C3
M[*>62VLI]8U6:VCCDU"[:;#\>^!O"?Q/\"^,_AKX\T6T\2>!OB'X3\1>!O&?
MAV_#M8:_X4\6Z/>:!XBT6]6)TD:TU71]0O+&Y$<B.89WV.K88?A_IG[%O[('
MBK_@K9^TU\'==_9;_9[O?A;?_P#!*K]DNVE\!#X.?#ZV\,0+XE_:5_;B\-:[
M/IVE6GA^"UTJ^U30=+TG2;O4=-2TOI;'1]'@-QLTG3A;:13E+DV<J=>HK[-T
M*#JM/MS)*"=G9:M->Z83FH<C:;YJM&E=6NE5J<BEW?+K*UU?9--W/U^MO@5^
MS?J/AN]^'-I\'/@C?>#_  _X]T7QCJ/@2V^'O@.Y\-Z)\4-%.@^,?#OBJ]\+
MQ:0^EZ;X]TDMX8\4Z+KD]C#XAL"=!URQNHB=/NJLR_LY_L]S6UW9S? CX-2V
M=_XK'CR^M)?AAX(DMKWQRHE"^,[N!M#,5SXK GG \13(^K@32@7G[Q\_@Y\'
M/BM\6OV3?B1_P40\>_"'0/@=9? J7_@N]\&OA=\:?!.L>%?%*^//$\7[8/PT
M_P"":WP-U/Q=\-=<\+>(?#OA3P)XB\"^-_B]9?%+Q'+XJ\)_%!OC,VH>)M)G
MD^&6L6,/BKQ3]KZ/^VM^V'\7_BM;:I^S1^S!8_$S]G3P;^VGXX_91^,%]K6O
M?"OPMXCTWP;\)OB)K?P1^-?QRT;QMJO[2=CKFD7OPK^)7ASQ'XALO@U=_LU>
M)-9^*OPZT/3YO#OC?P]JWC+39-)FE)U8J44[?NW)Z\M.4U2<.:5DE?FI*,KZ
M<MWRJDW&YVA)TY2CS*+ERIJ[5JCGRQTD]8UMHWG?9RK<LOTPD^$GPJE^(D7Q
M>E^&7P^E^+,&E0Z%#\4)/!GAQ_B)#HEM#J=O;Z/%XV;33XECTJWM]:UF"#3T
MU,6D4.K:G%'"J7]TLN3K_P !_@=XJ\7ZE\0?%'P9^%'B3Q[K/A_P[X3UCQOK
M_P ._"&L>+]5\*^#_%EIX]\)>&M2\2ZCH]QK-]X?\+>.;"Q\:>'=&NKV73M$
M\665IXCTRVM=8MX;Q/F;]MC]H7XY_ WQ/^QSX0^!WAOX5>(=5_:?_:7U7]GC
M4YOBG=>++2P\-M-^S1^T1\;-%\4V,GA5Q/+'I6K?!.%-8TV>&XEUS2[R?1-/
MFT.^OH?$FD?%7@K_ (*2?M-V%^/V7_BQ\(?A[JO[;MA^VQ\0_P!D&YNO@K$E
MW\*/%GA_PA^R'9_MR>'_ (Z^#?A_\7_C%\,;J*+Q+\'/$W@?PMJ_PAUG]HH>
M(?"?B35]=\71>+O$VD>&QX7U:U&5HM1?_+SV:L[OD<%5Y+)V4?:Q<G>FFI-^
M_:2#F5VN97?+S:[7C.4%*[5[QI3Y4E.W*E[MXW_9.T^'7P^T_P =ZS\4K#P)
MX-LOB;XC\.Z1X0\0_$6T\,:);>.]>\)^'[R_U'0?"^L^+H;%/$&J>'=$U#5=
M4OM(T6^U"?3=-O-2O[FRMH9[RX>3D/$W[/'P \:>(?$GB[QC\#/@[XL\6>,M
M*\(Z#XO\3^)OAEX*U[Q#XJT/X?\ B6T\:> ]&\2:UJFB76I:YI7@GQC86/BS
MPCIVIW-U9^&_$ME::[HT-EJEM#=)^3/B/]LG_@IU!X]_94_9QD^ O[.?P:^/
MG[0D'[<NE3^)OC;<ZMK_ ((N8/V9(/ ^J?![XS^'O 7P(^-GQ,N=&\(?&;P[
MXSL]2\4?!_Q#\9KSQO\ #?5EU'0$\=^)[71[+Q'XGZ ?\%1KWP1\4OVH]%^.
M>L> /AHW[(G@S]I_XO?%+]F+7?A9\0_"W[1GBC]FSX'6GCO4/A[^TY^SY\0?
M$_Q#@^&W[1/P]^+'A[X=_P#"5:IHW@/P7"_PJO\ X@Z5\-?&GBR'Q)X*O]8\
M8EG'EDOY:DH.+O+EIQYZG)&+<_=O[T81YE*5I0OSRA*DI<R\Z49<VB4JLN2D
MIN5HKFM>+G)1Y4FII.$9_J-J'[//P!U>+Q#!JOP-^#VIP^+O$=OXQ\60ZA\,
M_!=[%XG\76C7KVOBKQ#'<Z)*FM>([9M2U%K?7-2%SJ<+:A>M'=*;J<R>A^(_
M"OA?QAX:UCP9XM\-Z#XH\'^(=)N] U_PIXBT?3];\-:YH6H6SV5_HNL:%J=O
M<Z7J>D7MG)):7>FWMK/9W-L[P30O$Q4_E[X6_;3_ &A-#^*G[$W@;XN>&?A+
M>6'_  42^$7Q"UWX/2_#S2/%UI:_ ;XZ> ?@K#^T)'\*_B;XIUKQIK?_  N3
MP/XG^'*>-H-,^*OA3P7\'M0L]<^%A-S\.)K?XI6,/PZ\H_8X_P""A7[3GQB\
M2_\ !,_4?C3X:^!%KX&_X*/_ +'/CKXWZ5X>^%NA?$"P\4_"+XE?#+P3\&?'
MMZVH^,O%OCK6=*\:^"?B%H7Q*UP6GA2U\ ^&-;^%^K:'INF3_$'XLV>H3ZW:
MG*W*=)I)TYRI5(-QM"K!UJ<J4DG*/,GAZD$DG"24'&;A.#$ZD5R2NW[2'MJ<
MDG[])JC+VL9:-Q_?TVW=24G)./-%H_6SPU\%_@[X,A\!6_@_X3_#3PI!\*]%
MU+PW\,(/#7@3POH4/PX\.ZS';PZQH'@*/2]*M4\'Z)JL-I:PZEI7AY=.L;^*
MVMX[J"5(8PN'=?LX?L\WWP[\2?""]^ WP8O/A-XRO?[3\8?"ZZ^%W@>X^'?B
MO4C-I]R=0\2>"9=#?PUKMZ;C2=*G^UZIIEU/YVF:?+YF^SMFC^5OVN?VEOCQ
M\+/VFOV&?V=_@SIGPC2W_:\U[]I+P;K?C7XG:=XS\03_  _UCX5_L]^+/BOX
M0\1Z5X5\*>(?"4?BO3+;6M"2;Q-X8O/%'ANZ\4Z9:GPOI7BGP3=:U_PG'ASY
M ^'G_!0;]KV&S_8Q\9?%_0?V;9?"GQE_;Y^./_!-KXO^%?AKX<^*">(;WXH?
M![QQ^U=\,Q^T-\./&/BGX@-IG@?P%K'C']FA)3\!_$W@CXF^((/"WBHZJ/CP
M-6T__A'IB*=245:\JCDE?7F<<1&B[R=U?V\J:]YZRG">MG.G6VR;<8WM%7:2
MH5*VB5K<M"%63LU:,)QZJ-3]B+CX.?"*[U/PMK5U\*_AQ<ZQX&T(^%O!.K7'
M@?PQ-J?@_P ,M9OI[>'?"U_)I;77A_0C82R6)TC29;33S9R/;&W\EV0X%K^S
MQ\"M'LO#MMX;^"?P9T*3P/JU]XF^'_V7X6>#HK+P1XNOFM9YO$WARQL--TYM
M'U:>\L-.N;Z_T6ZTG4[UK"U+ZC'+!!-#^8/PP_X*!_M%>*_VL_A'^SIXLTCX
M&6,/[0&G?\% =(T.7P-X<\?>-M)^!OCG]D7XC>'?#G@>TU_XTVWCZW^%O[2E
MUKGAC6KQ?C;X ^&EO\,/$OP2^*&D:I\+?%6LZ?XDTG5K:S]#_9,_;<^.'[0V
M@?L]^"O$ND_"/PO^TM9?&G]ISX;?MP_#K2]$\47.B_"G3_V4K^_\'_$'_A7$
M]SX_DNFN_$/CKQ]^R_J7PZU?Q'?ZO)XN^#GQOTWXJV_@^VLD?2+%J$I14UK>
M*J.SO)1E.TI223E'EG.,JDF_==6G*4FZB;&U%N+^R^71)Q^&7*D[V:G&$XP2
M7O>SG%)*+2]9_8&_8B\$_L-_"WPW\/=?UKX1?$;XW3ZK\8KFZ^-_ASX-Z1\(
M/'GCCPU\0OBUXB^,-YX6NX+OQM\2?%VJ:5X2N_$EAI;)+XXU"PFL- T"\GTV
MPFMH@/J:X_9V_9^O(?$-O=_ OX.75OXN\?R?%?Q7!<?#+P5/#XG^*4UA:Z7-
M\2O$,4NB,FM>/Y=,L;+3I/&6I+<^(GL+.ULVU$V]O%&GY9?MQ:1\66_X*C?\
M$]=1_9UM/@[I?QOUS]CO_@I;H6E>-/C'I?B75/"&CZ?I/BW]@Z^TRY\2Z#X%
MFT/Q=\0-.T6\UG5H]+\%V_COP!##-XFUG6;?Q;8S17.E:_C?"3_@IA^T?\<M
M"^$?P8\,_!7POH/[9&K:%^V_9_&^Q\)6FE?&'X5^ /&G["'[2W@C]DGQWJ/A
M+0?B-\=?V0-2\8_#[XC?$7QQ#XV\-W=O\51XC\(^&]'?P7K&F>(=4UB/QEI3
ME!QA3EO>FK))KEA3J+#TU%[-16&@Y:QM*,&HS=Z@O:<]2IS.[E4E*3;NY5)P
M>(J2DDO=NZ\^71IQ<U>"M3?[$7'PG^%EY\1++XO7?PT^']U\6=-T=/#NG?%"
MX\&^'9_B)8>'XUU=(]#LO&LNFMXEM='C37]=5-,@U..R1=;U=5@ U*\$W/:C
M^SQ\ -8B\2P:M\#?@]JD'C37K7Q5XQAU'X9^"KV+Q9XGLGO);+Q'XECN=$E3
M7=>M)-0OY+76-4%UJ%N]]>/%<(US,7\7T3XV?M/0_L*ZO\>O'W[*FI>%_P!K
MGP[^S]XZ\>ZE^R%I7CSPIXUN]6^,_@WPMX@O]*^%OAKQ]X!U/Q?X=U2Q^(?B
M+1M/M?">JZ=>:I?VVE^)=,CU>P@UZUU#2H/@/3/^"F_C77/A'\._C%\,OBE^
MS5\?_#'BG_@H/^R9^Q]XIM?#_P )/C%\%_B%\.;+XX_%KP-\$/BIX&^+/P<^
M(OQ5\0>/_@Q\>_ACXL\1ZCXHT[2_&\$MGJ_A:;P_;W'A&%+L>([R6K2</=;A
M*,?=DI+WZL(1<7&_N2J3A[Z7)S/WG&HK.HMS49)2]^]E).+O"G.;3YM%*-.G
M/W7+FLO=3B[K]E/&WP[^'_Q+\%:W\-OB/X&\'?$#X=>)M+.B>)/ /C;PSHOB
MOP5X@T4F,G2-;\+:[8W^AZKI9,,1-A?V%Q:$Q1GROD7',7_P%^!FJZ7/HFJ?
M!?X3ZEHMUK.A>([G2+_X=>#[S2[CQ#X7\-Z;X-\,Z]/87&CR6DVL^'?"&C:/
MX5T+5)(FOM(\-Z5INAZ?/;Z78VMK%^<7C/\ X*&?$SP'XR^//PIN? OASQM\
M1M._X*-_#K]A3]G>W\)Z=::#;ZW!\0OV)/A-^VU=:]X[M?B!\7/#6A:GXC\'
M>!?$?Q1TJRL[+X@^ -.^)&O^%?!^@6'_  AE[XKENM/I:!^VO^V/H_B+X$?L
MV?';X'^ ?@O^T_\ M)_M,?'7X;?!_P 7:S+H_B/X>>(_V;/@=\'+CXZ:O^TC
MJ?PA^&WQU^(FH^&]>OD?2_@2GP2N_P!H^\UF'QE>M\7SXN;P5'_PA%$5*2A)
M)_O5&<&].?W>?1M).4(WE+6\>65FW!I*Z?-9I^S<XR5_AM*49/EW492BU=)*
M5XW5IPO^C[_!?]GWQ#;_ !3T>3X3_!S7+3XEO/H/QMTM_ G@G4[?Q_)<V27E
MSHWQ3LFTJ>+Q4]QIVLQW4^G>+8K]I;+54GDA:"^5I=GP]\&?@_X1\,ZUX+\)
M_"CX:^&/!WB31=-\.>(O"?A[P+X7T7PSK_A[1_".F_#_ $C0=:T'3=+MM+U3
M1=*\!:-H_@C3=+OK6>QL?".E:;X:M8(M&L;6RB_+S_@C9H6H^&O!O_!0'1-8
MLO!]EK-A_P %5?VS(]67P!H=QX9\'WNHRZCX)GNM;T+PW=W^KW?AVW\0O+_;
M]SX?N=;\0S:'?ZE=Z0WB7Q+]B&OZC5L?^"A'QS'[8OP6^ 5[HGP6U7PU\>_C
M]^VM^SOIFE>%M*\=:W=_"'7?V;_!/Q:^(?PK\4>,?V@=&\5Z[\(OB!XB^)/@
M[X,76M?$S]G[P[X3\'_$KX%7/Q/T'PUXQU8>(/A_K5MXR7+K&*M)SHTIZ6::
MG0]IR)V2DE>I""LDU:Z@YN+5.3FI/E:Y*M>/FE2K3IN;O\+<:49RLVU9VYE!
M-?I=8?LW?L[:5X6\!>!M+^ GP6TWP5\*KJ2^^%_@^P^%O@:S\+?#>]EOQJDM
MYX"\/V^A1Z3X/NI-3 U&2X\/6FG2O?@7;.;@>97I^MIX=NX;31?$:Z+=0:]>
MK8V&DZVMC-#K.HV=M=:\EG:6%^&34;VUL]'O=96WABFG@MM*NM1"+%8RS1?A
M?^S'_P %0OVA/%NE_P#!._XM_M':%\ _#_P4_;N_8]^,_P =M5TOX9:#\28O
M&/P3\8? WX:^"_C#JFN7GBSQ%XQUW3O'?@7QGX'U;Q9 _@>Q^'OAWQ'\.]=T
M71TA^(7Q2L]6N7TWS%?B-\2OVE_VP_\ @@!^V!XZ\/\ P:TSPU^T'IG[4'Q4
M^&.B^&_"NOP?%;X3>"OC%^P=XZ^)'A;X=^*/B-JWB;7-,^(JZGX0OM$N/'E[
MX>\,?#'2=-\=>$;7^R]%\5:5J=MJ.@7*,E.,)6O*;C+WK\LOWT6GHTYN5%*U
M[N#YN:T;)1E&=-U(W<5%.+M9234)QM>S4>6<I7M\4;*-W<_=;0O@U^S_ . M
M&U?P%X:^%/P=\%^'OB5=WC:_X+T+P-X*\.:+X_OUTTF_;6/#FGZ79V/BJ\71
M[,F[:]L[^9=-M#YQ%K =N%H7[)_[+/A;7]*\6>&?V:O@!X<\4Z'?P:KHGB70
MO@W\.M(U_1]4MF+6VI:5K.G^'+?4=/O[=B6@O+2YAN(F),<BFOS>_;ET'QA<
M?\%/_P#@EYJ/PE7X=:%\6M3^#7_!1SPWH7COXA^&M5\4:'X<M3X'^ EU::AK
MOAKPUK7@[Q+X^T?1-0N'OT\ V?Q$^'2ZQ)=7BP^.?#,TLEW-B?!C_@I9\?\
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M6ET^H6!M[F)K!;AKF(VXD-?@CK/QS\>^#OVG?V!/VN_VX/@1IO[,OQD\"_\
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M2:E&4L:<O:1IS4;<]&%=1?+*T)T552[2:A-I67+)IJ+34H1^A?@1\(KKX/\
M@V]T_P 1>,;KXE?$CQEXCU+Q]\6OB=?:'IOAJY\??$'6K;3]/N]3M_#VE-<6
M_A_PQX<\.Z-X;^'OPY\-3ZGX@U+PK\,?!G@OPOJ_BKQ=JFC7GB?5^E\>?!_X
M2_%.Y\-7OQ.^%WPZ^(]YX+OKO5/!UWX\\$^&O%]SX3U._MTM+[4?#4_B'3-1
MET*^O;6..VN[O2WM;BYMXTAFD>-54?B?\4/^"A'[<7P-\!?M?>,?'%K^RCXN
MC_8 _:_^ _P;^+TOA3X<_%_PU)^T/\)_C]HW[*?CG3Y?AQHNK_&GQ&G[//Q#
M\!^ _P!IR%+O6O$_B/\ :,\-^.?%_A*73X_"_@31=3CUFU]D^+__  4(^-_P
ME_:Q\#_"Z_\ #?P@U/X;>*/V\?A=^QS=^$= T[QKXM^(&D^#OBY^SW:_$KPQ
M\8?%_P :_#OB>X^%OPL^( \>:E:+#^RYXY^'Z?$C6O@^=%^)EEX@M] \<^&]
M82N6HW3;34JDH*%_=<7*E3J4KJ_[M.$X1IN]DXN-XJ*E)I+EDUK%*K=])^SE
M.-;E?V^5IRFK*ZFG:3DXQ_4+XH?#/X,?$BR\,_\ "Z?A_P###Q[IWA/QCX=\
M1>#?^%H^%/"OBFR\-?$#^T8-*\)Z[X9_X2RPOX-&\8_VMJ-MIOA[5-*^S:V=
M1OX+/39_M-U'&_I]?S4?M>?&WQ=^V;\,OV'OVD=)TOX+W'[/FD_\%POV8_A[
M\*=.U'P?XGO?C+I=K\$?V[-0_9OO/C'IGQ#O_$ \/Z=>?$/Q?X#\6);> ;+X
M;Z1>Z?\ "7QS:/JGQ"FU_3]5\+ZI]T?#O]M3]L/XW_$'X?\ C?X&_LMOX_\
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M5/$%O5?^"AO[,GASP?>^+_%>N>/?"[:#^T=X"_9)\<^$]3^$7Q.N_&OPV_:
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M?LU:+@X\D.912C)$';F<+I4VX2:O9.,IQE%W>MI2G9R4E)SER\S;3\[\>_\
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M+']J+]L+X+?LN_VSK/P8^(-CXR^$ZW_[2-I\&/VAM,\2_#;Q3X0BU?PY\8_
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MX.\#^-M"UW5=2\0:+XGT_6YHM0@]5^+/_!,WX/\ Q3NOCI!9_%#XY_##P?\
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MO4^*TM)13LM$[/DAS1ER1:_"?XH?L&?&WQGXS^/O[16@^"K>P\??M,_M^?\
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M4KUJ%:=VZ"A&-K)N$?9)I]&W&DM;+WM;6NC^;3]FW]C;Q[_P4%_X)N_\$G_
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MO/ L5W\._CY\(/V8_"?P7EMO'&B7GB'7M<^ ?@KXK^'/$UCXIL=1N(&\,_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M16ECJWP_OOB=\9_C(=+TF[UGPO9>._AE;^&/!L&O_$F_T[39EL/AL=OX"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN>%?@CX$_;%U/5-1\._M5_#[6OV"OV[?B[X!_;8_8D\8WGPN_; T_P"&U_\
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M ?Q"UWP=X=\1^)/"FE^/K;PUI/BN'P_J>@>'];U#QFMMX9N?OCP[<_"OP/\
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MTC3;:PT9?B/=_$"5+2+77\0(OY[_ !]UOQGXN^&__!4C2]?U%=!_X*>_"_\
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M.\XV<XJ+]R332_=58HD>61(XT>9E>9U15>5T18U:5@ 9&6-$C5F)(150$*H
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MJIJ:5FHU:<XWC)NFFN5KG32YH)V2YDJD(U(/5V]^FYN#;:<J=2$K.*53](=
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M-XL\,1WMW;G7=*%U2T?X8>&/#GQ%\7?$OP['=:'K/Q#LM(B^(>FZ?)#%X?\
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M:M^,GQ$^(%[^S7\+M)U_X>? K]L^[_9Q^)MEXND^&>G^']1^&GP_U/PQX?\
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M^,EIX,U#1]&BFCMKOX5^,(KJ;4![A\7?CQXO;]K+X+_L;_#O4=,\'>(?B3\
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M=>)/"\GBSQ@GQ(\%<W^UU_P4'_:N_9KC_P""@OANPTKX->(OB?\ LV)^S_\
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M_;7OT]C*:DM7*,^5)N=D[V4I7LDX7>N[JP5-:)ZNK&'+?12CS-I1U] ^&_[
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M"E_[,OP_M_C)%\2KCXA> O$_P#\:_ 7P5\4?!%_X$U+Q=XAT!_VH?%$/@[X
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M\%>,M-E\;:-HOB#X8ZGHG@V_TQ_$WB:U^+6F>(M%B^&VEZ'I=YXK\2>)+T^
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M1$O(8%<ZII6O:%K.BWUI?WNGZ[X:\1Z'K/AWQ!I=U<Z9K6EWUA<36TGRP_\
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MIS1DW%I1GR33T?N_PD_X)[? _P""S_LAOX.\0?%N;_AB'X6>+O@Q\"(_$?Q
MG\01Z?\ #KQQI7A'0/$/A_Q,M_IS?\));2:!\/O FBZ.EUY47A:Q\*:?_P (
MM%HUU=ZU=:KPOPK_ ."57[+'P5O_ (EK\-K_ ./7ASP/X^L/B=:^%_@O!^T/
M\6I?@5^S_J'QGM?$D'Q/\3_LT_".;Q,_@OX+>+?$TGC#Q9<6/B+PMID>H^!4
M\5>*])^&TO@WP[XL\3Z-J_L>B?MP? _QSX)^!?C/X0S>*OC5-^TE\'KSX_\
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MPXDU#QCI_C?PM_;A\._'+X0?\$SOB]XCU#XP?L]ZS^VOJO@/Q)X)^'VC>"=
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M7@6T\)ZKX;\4>)M:OM)E\>ZYJ/C&?N_AS^V;\)?C!X8\(^(/!-G\1/(\=_M
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M^7OSKS<ERV<J[<DO;)>O?"K]DKP%\+_%_@?QU/XM^)GQ-\3_  I^&WC'X/\
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M!/&W@K2?#^D0:/I=W;76M>&YOU-_:&_9G^'G[2UC\*[?QUJ/CK0-3^"WQ?\
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MO[7P#8Q>(-"UD:]XQ/B3DM*_X*@_LJ^([;X/Q^$KOXK^,O%/QQOOCSX=\"^
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M-RPF(DXV]HITY<R4DTOM3Q3^P_\ "KQ;XN\7>-+WQ3\5=.UCXK?!/P?^SO\
M'D:'XQM],@^/'PC\ GQW_P (AX=\<O%HC7WA?4M%_P"%I?$M8/&7P8O?A5XV
MGC\<:O#>>([F"TT"/1N+^.'_  35_9J^./Q3^&_QEDG^,OP6^('PX^'VF_!E
M=:_9?^.7Q._9KD\;? ?1]4N=;TKX$^/#\'?$7A.;6/A=I.L7EUJ>A:1I\^CZ
MKX:N[FX;PWK>D)/*C_;$7B&YD\,'Q$?#'B2*Z%C->?\ "*2P:4OB=I(3(!IR
MPKK#Z.;^8H/)!UH69$B.]W&A8K^)G[,?_!0/69_@G^R?^V[^TO\ %'XXZ/X8
M_;#T?4OAGX9_9E\-_L\Z;\1/!^H_&KQMK6H_$_X9:M\*/$7PE\%ZW\5M)3P]
M\,_#/C7X80Z#X_\ $.M)\6KN#0-1T;2+#Q[I5^_C>-')]&FIOK>565:,=$GS
MN<YUH\EI)^VFG3E&I.#=TE%=&N2*UTA2A1;=W\"ITX46I7C)>RA:473C)?JG
MX%_9G^'7PY^-_C_X]^$Y_$&F>*OB1\-?A9\(M?\ #\%UI5OX#M?A]\$KKQK>
M_"GP]X>\+6>C6L'A^W\%7/Q*^(<FG/I=Q!+>)XOU"VUAM2M=.\.P:+)\8/V;
M_ OQB\9?"?XH7NI>*? _Q>^!MWXOF^%7Q7\!7^EV7B[PMIGQ%TFRT+XC>%)K
M/Q'HOB?P;XK\%^/-+TO11XB\)>-O"?B70FUOPWX/\::79:9XZ\$>#?$V@^+:
MU_P4+^!?AWP%J_Q-U[0?C%HW@SX>>"/AY\0?VB;[5?A?KNF:Q^RCH'Q.\/6?
MBO0;?]HGP;?M;>-O"7B/0O#5];>*?BAX4\.^'/%_B3X+>!;C3OB=\8=,\#?#
M#7/#_C/5F_&S_@HG^SW\"O$?QD\)>)+#XR>*?$'P$^$'@+X_?$RR^''P4^(G
MC2WTCX,?$"Z^(L5C\1]-UC3M$70O$?A;1+'X3^/M3\0:CX?U/4HX#X>N?#VE
MC5O&KP^%W;M'5NW(Y.]VN5WJ59R<D]$^:M4E.4N2476DYS@JMGH]-'S**LTG
MS?!3C%1:=W>-*$8QCS1DJ248S=-RZWQ?^Q#\$_%OPG^'OP74^-/#'@CX;_&S
MP[^T=I,?AGQ/)!K6M_''PS\8G_:&L/B1XRU[5[/6-2\6:_??'>:X^+?B8ZQ-
M/8^,/&EU=WWBNSUFTN[BQD]T^)WPRM?BEX$;P/J7B_QUX6<:QX&\0VOC'P)K
ML'AGQE8:]\/?&?ASQ[H.H6]_#IL^DSV]SK_A?3H_$>@:AHE[X6\4:#<:MX7U
M_0K_ ,.:QJ&ES^)_";]MCX'?&?XQ3_!+P=+X\@\47WPEMOCO\/M9\4?#OQ;X
M5\%_&7X/_P!N:/X7UGX@_"+Q/K>FVEGXO\.^&/$GB7PII>LW&RPEGMO&/@_Q
M-H$&M^#?%.A>([Z7]H7]L[X-_LV:M>^'O&P\7:]XCT3X)?$_]ICQ;H'@;0$U
M[5?!_P"SM\%KSPSI_P 4_B]K$%S?Z6E_I'A6]\8>'[:V\'>%I?$7Q6\;375\
MGPY^'WC%M \1#21I0;YO<;DY2YO=?-24J<G*Z3BZ2P\X3YN54HT)<_(J<I)K
MWTK>^E%)))R]VHXS2BDGS>TE6C*/*INI*K'EYW.,3E;C]@?X,7VH^#/$>I:Y
M\1[[QMX3_:<A_;&U#QS_ &_HFF^(?'O[1-G\*$^!&G>/?'-MH?AC2_#5[!IO
MP6CB^&=IX.T+P]X?\#?\([;V5Q<^&[C7],TS6K+E-1_X)K? 6^CEN;7Q5\;O
M#_B9/VNM:_;>TCQUX6^)MYX<\9^&_CWXN\':Y\-_'NHZ!JVEZ=;Q6?@WX@?#
M7Q/XD\ >*?A_-9W7A.3P[KE^^CZ9H^M&WUB#[6?XA>!H? #_ !5N_%F@:=\-
M8O!Y^(-SXZU;4[72/"UCX&313XCF\6:EK6IR6ECIF@6N@!M8O=3U":VM;+3D
MDNKN2&**1E_-W0_VQ/$7B_\ X*"_!3P=8ZW\2/ /[-_CO_@GQ^TW^TAJ7AGX
MK_#OPMX&\,ZZO@#XR?L>:5\+OC=IOBS5M&'Q \*L_@GXM_%"Q\7_  O\>^)/
M!_BKP19_V#JOQ0^$7@[4-0\+:CJ:F^1QA)<O)-P::48T7'FF^=245!)X)W3L
MTZ.JY85'&;1G%S5IJ<8M-7FZJDX4XN+7,YZ8U6=W[M:R=YTXR];\*_\ !.;X
M$>"=(^%6@^&_$GQGM=*^"O[5/Q5_;&^&\&I?$_5?$UQH'QG^,=]\5[GQI<MJ
M?BFUUO5M3\+W=I\=?C%IC>&]5OKVUU2+XAZ[JWB637O%$>DZ_IB?$7_@FW^S
M9\2?VE=0_:FO9OC'X/\ 'OC+3/">C?&[PK\+_CC\3OAI\(_VG-,^'UG-IOP^
ML/VE_A=X.\1Z3X5^,=EX0TFYNO#MO8>)[.6P\2^"KN[^'7CRU\6_#RZN/"LF
M_HW_  4&_9IO/$^N>&?%'B?4_A?_ &7^SIK/[7ND^(OB=IL/A?PKXL_9@\,_
MV=_PE_QFTO6_M][#X>T;P0-9T27QQX0^(L?@?XH>#K+6](U3Q)X#TS2=0MKZ
M3P/]LC]MZYT[]D7_ (*%S_!S4_BC\!OVF_V;/V%OB1^UGX#;QQ\-M MM<B\-
M)\//BIXB^$/Q)T_0_'.B>./!E]HNO^,/A-XE\-^)?A_XWTFP^)GA%]*O]-\?
M> O ^HZGX=N[MW<.1)-.GS.G%>[RN"5.:BK**<%149P:3C[&TJ:E331:,N=O
ME:J.*G)Z\_.W.#D[MM2=9RA).TO:WA-J;O\ 5\/[(_P_F^(WAGX@>)?%/Q(\
M=VO@+XQ>+OV@OAGX \;>(=*UKP3\-/C+XU\+^/?!.L>-O"!'AZU\9HD'A/XI
M?$;1]#\&:YXRUOX=>'9?%MWK^B>#['Q5I?AS7=%M_&[]DWX9?'CXF? SXP^)
M-7^)7A/XC_L^S_$"U\$>*?AA\1?$?P_U"]\'?%G3- TSXG_#CQ.^A7,0U?P9
MXV_X1#P7JE^D0L?$FCZ[X-\-ZWX3\1^'=2LI;FXY*Z^/'A72?VD/AA\,-:^)
M7Q;3QI>_LA_%CXZ7GPCT7X4/K?P\\;^%?!GC/X&:!KWQ$C\7:=\--0\5:Y\3
M_!FK>-],\.Z#\,?AKXUN);_3/B#J%[XC^'UW?OX#OZYOX"?\%&/V;OVC_%/P
M6\+_  [F^)5LG[1GP1O?C[\"O$_C7X7>,? _@_XJ>"M$@\'WOBVQ\'Z]XCTZ
MQAU'Q1X,TSX@>"M5\0:,8HE:PUV231+O69?#GC"'P[5K2=-.[HU*E.T)-I2I
MSJTI6:M\2I5%RMN3C%PE&3BXI*47%3:Y55ITY^\DFX5(4JJNM=(^VIMM)04I
MJ<6N92=;X8_\$Y_@+\(?#W['WA?P5K?Q;@TC]A>Y\4W'[/<&L?$&Y\1'0H?%
MW@?Q#\+M0TW73KFG7Z>(M(L?AAXHUOP'H.F7R?9-"TJ[75]-B@\7V]OXEBUK
MO_@GM^SAKW[+_P 4OV/?'6E>+/B+\"_B_P"-OB!\1_%F@>+O%5Y_;-OXZ^)O
MQ;U'X^^*?%/AOQ5X<B\/:_X;UD?''5]1^*WA^]TJ^@F\)>+KB*7PNVD:7I^F
M:99;OA7]NG]GSQ;\6/A/\)+#7]2MM1_:%T3Q_K_[-_BZ]L[(^!/V@K#X5Z?8
MZS\0_P#A66MV&IW]Y+)H7AW4K/QAHI\6:3X4@^)O@ W?Q'^$$_Q!^'^E:MXF
ML=3XS_&7PAX(_:,_9%^%NK_%3XI^#?%/Q?\ $7QBB\*?#GPE\.=,\0_#KXS1
M>"/@SXM\8:[I'Q-\?:M\-O$ESX,'@G3],_X37PAIG@KXA?#_ ,8>*O$FGV=C
M=6/C'PA%XBTZTAI/EE;F]KHI7U>L)R:E?FNI8>E-\KC4YJ=.:=XQD]+[J]E3
M3=FG:/QK;E<>5^WJQU4J:]I4C)6<HQ\57_@F)\!Y?A;X#^'VK_$C]J3Q;XQ^
M&OQF\&_'SPC^T;X]_:2^)?Q!_:4TSXD^ ]*\1^%_#MTOQ1\;:IK\A\(V_@;Q
MIX[\#2_#)-'C^&DNB_$#Q]JH\))XS\9^(_%6I5)_^"5W[,:>%+3P_H>L_'7P
MIXA\,_M-_$7]KKX7?%70/C;XV'Q;^#?QG^+FH>)]0^*-[\/?&VL7FL73>$_B
M/_PG7CRR^(?@;QO;>-/"WQ!T_P 9:Q;^.-,\0FWT.31^I^&7_!2?]FSXL^*O
M@WX;\+6_QEL]/^/?Q'^-_P &?AEX[\8_ [XE^!? .L_&/X :O\6-.\<_"J_U
M_P 6^']'?P_XYGT_X%_%OQ%H6D:[8Z<MYIW@76-(O[C2_&;6/A6[[[]L+]JO
M_AE3P]\%-3@^&_BOXDZE\:_VF/@=^SOI-GX:;0XK70+CXK>,[+2=1\0Z]<:S
MKNC2K#9>'8=;C\/6FE0:M=:GXSF\-Z;J5OI/AJZUWQ1H#YKJ#YFXU)0Y+-\L
MI.=+D<;>ZKS]BXRBHJ[A--\[G4B7*N?F2O3C-S5DW&*5534M;[.M&2DWHIQ:
M]SEAX[K/[.&K_LP?##QQ\,/V2_@3+\>1^U/\8?BIXE^-$W[07Q\UK6?!7@S5
M?C#X7UV7Q'\1O&NF?$"?Q1K7C'X>76O6FBZ!XK^&WP[M(O$6NV6LW>K-!J-_
M)K&I2?8OP$^"_@K]G'X(?"'X ?#>TFLO /P5^&O@KX6^#X+J03WQ\/>!?#NG
M^&]+N-3NMJM?:M>6NG1WFK:A*#<:AJ4]W?7#R3W$CM^;/PO_ &^Q\+?C)^V-
MX&_:4\3_ !3\3^$O#'_!1CX7_LW?"GQG!\'[:7P7\$O#'Q]_9F_8J\3?"WP3
M\3O''P\\(:+H&F:1JW[0G[0.J>!-%\3>*KOQ)XIM+_Q=H1\8ZU!X.L5\0Z;]
M?_%7]N7X!?!CQ'/I/CO5];L?#6B?%GX>_ KQ_P#$ZTTN&]^'OPK^+GQ;/@6+
MX9>#?B%?QWX\0:2/%MW\3_AQ8R>+-.\-ZQX#\&7/CCPXWQ'\5>#+6^^TQJG+
MFC%I/]ZZ<8II\S4%R4J227*U!U+045)-UHJ,Y7IQ&^5-JZ2I^T;U7+[S<JM9
MW=TZB@W-RY6E2ESQBU497G_84^ TGB_XB:[;6GB;3O!GQ@^+?@_]H'XK_!.P
MUBUB^#OC_P"/7@;4_!^M:%\6]5\/2Z7/KFD^(KK6OAYX#USQ?H/A+Q/X<^'O
MQ&\0>&(O$GQ%\%^*_$.O^+]4\1^P^(_V>_A%XM^-O@;]H?Q%X-TS5OBO\.OA
MI\2OA'X6\17D23BT\#_%C5_ FL^,-.N+*5'M;ZYEG^'^F6FDZA=1R7>AZ3KG
MC;2=,EMK#QMXE@U&G^T)^T;\+?V7O!&C?$7XP:AX@TGPEKGQ)^%OPIMM4T'P
M;XK\8I9^+?C%X_\ #WPS\$#7%\*Z1JQ\/:)>^+?%&C:;<^(=;-AI%O<7EI8+
M=S:OJ.E:;?\ RO!_P51_9.3X0?M3?&+Q#/\ &/P+9?L8_9KC]HCX=>//@-\5
MO"OQI\ Z+KFE2>(/ WB[4/A/J7A>/Q@G@?XB^&XV\1^$_&L^GV_AB/1K?5[O
MQ1JOAH^%_%L>@&C3CNH:-/51O"-&VJM_"KQI6NVJ-90<51G9MWNGK>;TM>\G
MSNI>RN]:E%U+V5ZM/F3E5BFO4F_81^ 5G^S+\%/V1?"NG^)/ GP2_9^U?X&Z
M]\-M"\(ZZMKJ5CK'[.7C3PQ\2OA1J.K:UJMAJ]YK=UHOQ'\&>&/'>K2:@93X
MK\0:43XI.KZ9J>L:;J&3XV_X)Z?LU_%'3/VO?#_Q6T'Q#\2_"O[<5UX.U#X_
M^%?%/B&==%U75/AYX4\+^"O >L>$!H%OH6H^ =:\(>'_  /X*70=9\)ZCI>I
MV6O>%=&\9?:G\:0W'B&YYU_VOOAYXT^-O[+?@]/$?[4WP6UWXE_%[]H?X?\
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MUU^V3^RG^T#\(WUSXE:_IFF67@CX$>!_V*_ _BZQ^(ES9?#/6;SPUXEU6/\
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M+IDOQ)D\%7'Q&?P=!,;C6K+P/#KMMX9B\2ZI;0+(-)TO4]>N)M+T*?4FM/\
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MT[3PF'DFU=N,[:2J(_$+P-^P[^V-\9?V*_C=^QA^U-X/_8_^"=_XC_96\?\
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MGH'Q!U^];6/$7BKX5_##X;^%=<^$]G>_#W29/%&@S7GP[N]6\0GQ9<?#K5-
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M$_Q)=6/ACX@^&/AM^T%X+\9ZO\0[A?A7;7FF>";+5_CK:7?A?4O#FF^*=?\
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MMMZAI/A+]N'P[\2='E^!7[3]S:^//V&/!?Q$_8R^)VF'1?VI?AW-IGQP.O\
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MX,?!#X+CX:>.+/\ :DT3X+?L4W6C0_L._P#!2'2K^W_:1_:<_9XU3QQXMN_
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M]R_PT_9B_87_ ."CW[/O[:>E_L>_&3XI>.-*_:(^$O@?2;OQ1XA^"_A#X2_
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M;CP#\=/V?M=_X)3_ !!L?%WC]O$_B'XC:E\-]%_:J\ >*M4^,'[,3R/:Z7\
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ML/\ P72O_&>D7/B7XE_"S_@FK^Q]\0/@YK7Q2U#0]5^+OAC]J3X=_ /]JI?
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M;!UDXK[,W]4=-S2?[JO.-M$I?S9?!71?@/\ "3]ISPI=^"]:E^#_ (?^-/\
MP0SU;QQ^T3XX^"][<VGQ"\7^+?AMK?PPL_!OQ6U75-(AUC6?&OQX\ _#WQ#\
M5&^'_BS6K?Q+\04TFUO[*S?4-*T9;*V^JO\ @E(+KPWXX^/GPOO-&_97^)A\
M#?"K]E^/2?VV_P!C'1X/!?PD_:8\(N_QPTCPIH7Q.^&6C7GB#P1\/_VH/AW#
MHFI>*OBAIO@+QWXWT75/!?Q=^%6N*O@?0K_PAX1M?VDH[GGKV]/\_P">M;2F
MYU*M1JWM'7?+S7456Q>)Q48KJHT?K+I04>52BGSQ<9*-+"G2]G3I4U)R]FJ"
MYG%7E['"X;#2?_<58:,Y7YG&<KPDG%NI_/1^W-^QE?\ Q _:9_:4_9M\$^ ]
M-C\%?\%;_P!F'2+O5_B6?!MYKGAO]GW]I?\ 8Y\36]MJ?QF\876FO:-I6I>/
M_A+\7O!2_#)]UU9W'QC^"E@FL69LO''B:[GYGXX-J/[0/_!%C_@H%^UG\;?@
MQ8_";XU?'W_@GUXP^'+?#C5?#EMX<\5^#M4^"GP8\5^&_#_PP2TM))3K1'[6
M>K?%_P 2_!RYM+FZU+Q5X+\7_"R V-IJ4-IX=TK^CVBL7"]*=+;FCRJ76*4Y
M<J2O;2C.=#HW%Q;^"*-K_O(5'KR2YN72S?)%2UM>\JL(5[N]IJ5OCDU^ OQM
ME^!.@_\ !3SQ=\2/$<'PNTZ]^)W_  1\UO4OA!\0=2TWPRMSX[\0>!?B!\0I
M/&%_\/O&+VK2>(=6\(?"CQ=H5YXCFT'4[F\T3X:ZW;ZC?F#PD\UQ'Y1_P35\
M+_"GX;_%O_@CSK/@73?"GA?QU\:_^")/BW1OV@-2TZ>"V\7?$GQW\,+3_@G-
M9_"C3/BK/)<'6/$?C'X<:;:?'WPQ\.K+Q6;K6O!?A?1?B9X.\,0Z7X?\,ZWI
M.F?THT5HW>2=MJDIZ-7M*>93<+W6C_M"T^DOJ]-N+3M#%4^6/*I.[A3@WI_R
M[IY?"]O/ZA=*]X*O42=]9 Z#/I1110:A1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?#/[:?_!0'X-_L-/\ !6S^
M)7AKXG>.=<^./Q*\+> -!\/?"?P]HGB'5?"FA>(OB#\._A1>_%_Q\?$'B?PI
MI_A_X1^$_B9\8O@Y\/\ Q)XA@OM2U=/&/Q;^'NAZ3X>U:?7':S^YJ_F _P""
MGG[&W_!2?5M9_:F^-OPTTS]E[XU6'QG^/?\ P3RT7X>Z?_PA7[17B;X^?#GX
M%_ /]K7]GWQMX$^&VG:#X,N[SPM9?#/PG\67^)7[0G[0?BG2K&;Q'K7A;Q/X
MWU74-8L="^'_ ,-](\"?TO\ A,>*1X6\-#QRWA]_&PT#1AXP?PFFHQ^%F\4_
MV=;?\)"WAJ/6))=63P^VK_;#HR:I+)J*:<;9;UWN1*QM1B\/"H[^TE6G&47[
MO+#V<90BH\TFW%WYYZ)RFHQ5HZPY/VS@E[D:4&I+7FFZDHRE>R235E"*;?+!
MSDE*5CH****@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>ex-19_005.jpg
<TEXT>
begin 644 ex-19_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2* X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _,#]M;_@
MC-_P38_X*)?%/0/C7^V+^S?_ ,+@^)OA?X?Z5\+="\3?\+@^/7P_^P^!-$\1
M^*_%FF:%_8WPM^*/@GP_<_9O$'C;Q/J']IWFE7&L3?VG]EN-0ELK+3[:T*_3
M^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBB@ HHHH **** "BBB@ HHHH **\QL?BMH4_B3XKZ!JVC>,/!^G?!^VT"_\
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MV/QD\ _";XG?!C3]!C^,7@SQYXS\&ZUX5EM6U+P(/!OA2[\=?#[_ (61XO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXB>$YQXS\6_C5^T-\'OV-/V_/AQ\7/$GQ_\ @=^V5\%/V5?V4?B1<_%SP/\
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MUR>75_A]=Z'-X2U.2;6X8=8FDO=(G>35(H]0=FNXTF#/&_[-W[._Q,^%VB_
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M (*>:W\(-6_9;O=)^(9\7>.O@;;_ !(3P5\'_A./@_JW[36A?#;Q]X-_;!^
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MWA[QY\9]!^&_@W1_BQXVT"R&DBST/Q=\1=/T:W\8>)-'M!H.ABVTS6=9O;*
M:-I0B@4:=9^2>!?@#\"OAAK_ ,3?%7PU^"WPE^'OBCXUZT?$GQD\1^!OAQX.
M\):]\6O$1DU28Z]\3=8T#1M/U'Q[K1EUS6I3JOBJYU6^,FL:H_G[M0NS-,;J
M-N5<W)&VLN6-2--TVHWE*7L:NDZBDY3C.\J=Y-S9)IROJH^T;:2C=TW4YULD
ME4I)\E.2M&44O::+E/Y]_P!JWXOZKX[\??M9_#S3_CEXSU[P=XD_X-V?'7QT
MN_!OA?XU^+H=);XBVNIZV^C?%#1=,\,>++5M UW6O#E]I46H>(O#8TQO%OA[
M4;2WUJ;5M-OT2?T[X17VJ>'?B?\ \$(?A%X-^*WQ7L_A;\5OV(/VF7^)?@C3
M/CA\2K[2?&%[8_LW?LX^*/"NI:Q?2^,;S7CJ'@M_'NM7OPZN+76;4>!K'7K!
M_"2Z5;:;X9;2_P!F_AK^RM^S!\&;?2[7X/\ [./P&^%-KHGAC6?!.BVWPV^#
M_P /? L&C^#/$>OW_BOQ#X0TN'POX=TJ.P\,:]XIU75/$NLZ!:+#I6J>(-2O
M]8OK2?4;RXN9#P?^RM^S!\/5^&"> ?V</@+X(3X)6OB.Q^#"^$/@_P##WPTO
MPCLO&-[=ZEXNL_A@NB^';(> ;7Q3J%_?7_B.W\*#28M<O;V[NM32ZGN9I'W=
M2,IRER<JE6E4Y5RM<DJN;35-JR3489C2IQ=K)8;113I*GG&+4::;3E3P_L4]
M5[ZI9;#VU[MJ<IX&=22UO[?5RDIRJ?CK^POXS^/FJ>,-9_8=\=>.?C?\1?B[
M_P $L_C#\=]?^,WQ$\5_%OQC/XH_:=\%>/- U+Q'_P $]+?XC>(I-:&G^+M#
M^-WPC^,FI>*_&VD7.IZW9^!OC!^RE/HVN>&-%\,>*/#EO>X?_!+OXP^(?VDM
M0_8F_:;E_P""E'@GX@^-OBQ^S?XBM/VE_P!CS0=,^*'B/7?%7Q8/A'PAXA\>
M:IXA\$>+?VH_B)X2_9F\0?LY?%U/$FA:YKWPR^ OPH\":W#\0=$^%M[8V>EZ
MO\%=,TW^@JTT'0[#5=7UVQT;2;+6_$"Z<FO:Q::=9VVJZVFD02VVDKJ^H0PI
M=ZDNEVT\UOIRWDTPLH)I8K811R.I\W\#_L^_ 7X9>//B)\4_AM\$?A%\/OB=
M\7KR#4/BS\1O _PU\&>$_'?Q0O[6XNKJVOOB)XOT'1=/\0>-;RWNK^^N8+GQ
M+J.ISQ7%[=S1NLEQ,SQ&34E)ZOV/))KE=ZMIPG4M).-JL'24DTY0E3<Z<HN=
MHU)*2DDK7J\ZM=6A>,HPO%QE[E3VLHVM&4:D:<TU"\O@SXIZ[KWQJ_X*2ZO^
MQSX]\9_%SP#\'K?_ ()_V'QV^&\/PB^(GQ0^!NL^/OB3KWQ[\3_##XPZ\_Q/
M^&/B'PGXCU:^^!/ABP^"*Z+X6T[Q##I.@S_'FYU_QAH>O76J> ;SPY^6WPR\
M1?$W]JC5/^#<7XQ_M0:YXONOC#\1O&_[6UCKWBOP=\0?B+\*],^*7A3P7^R'
M^U3-\+_CCI7A/X>^+O#'AK0M1^.W@72_"/Q9U?4_"NDZ8FJZ!XX?PI$Z_#V6
MV\-I_29\2_@G\&OC1#X?M_C#\)/AE\5X/">IW.M^%8?B5X"\*^.X?#.LWNEW
MFB7FK^'X_%.DZJFC:G=Z-J%_I%S?Z<MM=3Z9>W=A+*]I<SPN>*O@G\&O'?B?
MP5XV\;_"3X9>,O&GPU:Z?X=>+_%?@+PKXA\4> 7OHTAO7\%:_J^DWFJ^%6O(
M8TBNFT*[L#<1HD<N]% "B^7D]U)QG!W5]5"IBI\^KNJLXXF-*7_+OV="G;7W
M4VKJ2NWS1DE>RMS4J%/V?NI)TN>BZMVG4YJD];^\_P">WXV^&;KX7?LY_P#!
MS#\3_A?\3/CIX!^(WP[\7?$/6O!GC'PU^T-\;%USPUK&@_\ !*K]A7XGZ9K6
MD2:CX^U*WTSQ+9^*;".RT_Q?8V]MXPT7PC&OP]T#7M(\$V&G^'[+V_XN_M >
M!OB7^U/_ ,% OV?OCQ^VO\4/V*/'7[-6H?LF^+_V6+OP#\2Y/A;JFJ_"?7OA
MY\/_ (D7?Q1\*_#WQ*=1\$_M8ZCX]_:'G^)/[/?Q \%>*?!/Q8\+/HGACP5\
M-M.\%Z'XO\8WE_XP_7J?]EG]F.ZL_B5IUS^SG\"+C3_C-<F\^,%C/\(?A]-9
M_%>[-U!>FZ^)5K)X>:#QU<F\MK:[,_BA-4E-U;P7!;S8HW6[K?[-G[.OB;Q;
M\+/'_B/X!_!7Q!X[^!EI_9_P3\:ZW\+/ NJ^+?@]8>3!;?8OA9XDO]"N-9^'
MUI]GM;:W^S>$KW2(?)MX(MFR&-5SHQ=-Q<GSI4J%-+K"5*,^:K3NW#F<G"T:
MD91<.=3]Y^\FM))-J]7$5/LVE&M4A*-.?NM\JCSIN#4E+D<7RII?AMKWQT\:
M_'#]J;]KWPCXF_X*$>"/V.?BW^R7^V]\'_"OPO\ @WK4'Q$U/Q=K?P8N_!/P
M!\2^!/#VG_!;PQ^U9\,?A_\ M":#^U[_ ,)K\1/"6A1>,O@/\2_B.?'/Q(&B
M?#K4)?%/P[^#%OX7I?!+P1^T!\5/@O\ MS_%CP5^UY\6X_CGX:_X**?M5_LR
M?"#0/CE^U!\5/#7[/T?PO\+_ +?_ ()AT;X )#X5FN[[P-XF^(W@SPIJ?[.O
MPX^-VD:1XC^.?PRMOC%=P_#[699+7PGHFF_O+K_P!^!'BOXL>#OCSXH^"GPD
M\2_'+X=Z5>:%\/\ XSZ_\./!VL?%?P+H>H1ZK#?Z-X.^(NHZ-<>+_#&E7T6O
M:Y%>:=HNL65I<QZUJR30NNHW8FP/^&5OV8!X,\:_#@?LX? 4?#WXE>*K3QU\
M1? 8^#_P]_X0SQ]XWL-:TSQ+8^,?&OA?_A'?[#\5>*K+Q'HFC:_:>(==L;_5
M[?6](TS58;M+ZPM9XM(M*%N7W^2$>:T7:<9T.:I%34E>K3I2<XO]W[6I*T?9
MSG933E-33LE-M1ULX.%5*F^5Q5H3J1<9+WW&$>9\T$G\W?\ !-CXMQ_%7X*_
M$"VU/P7\>OA7\2/AA\=_'WPU^-7P;_:'^*NJ_'?Q;\'_ (M6^E^%/&OB3P)X
M2^.&K:[XFD^+/PEBL?&^C>(_A;XPM-:GL)/"'B+3M'@T[PT^D2^%=#_)S]FO
M]HWQ-\1OVR?V$=8\ _M*_%_X@_!/]LF;_@K1HVL:UXX^-?B3^V?BYX/^%OQ.
MA@\!^)M-_9T@O[GX;?LVV?P;\5:'=_#SX-:_\,QI'Q+UOP ME-\6=*^'GC[7
MO&7PZL?Z1?!?@;P3\-O#6G^#/AWX/\+> O!^DR:A+I7A3P7X?TGPMX:TR75]
M3O-:U633]"T.SL-+LGU/6=1U#5M0>VM8VO=3OKR_N3+=W4\LGCEG^Q[^R3IV
MKZAK^G_LN?LZ6&NZM\0O%_Q<U76K+X(_#.UU;4_BM\0M"U#POX^^)VH:E!X8
M2]O/B%XX\-:MJOAWQAXTN9Y/$GB70M3U#2=:U*]T^]N;>177.I\MTJ<8.-VD
M_<E"II>249J2<;N4Z?)%*I)VG&U91E%<UY3G)-\K<5*2E&_NIN4&GK'EC+F;
M<%JG_.'\%_B[\1?A+^Q!_P $A?C1\2_VS?B_I%C_ ,%%(O@/X,_:I_:!_:>^
M-OQ2\<?#;PKKFB?LB_'OQQ\*/#>AV^A?%[X+7_P.N?BI\5H?!ND^*_'OPQ\>
M> M?^(^L?#_PA9_&C7/'<WB;QUJ'BC]ZOV ]+U7P]\#-8\-WO[6.G?MFZ1X=
M^+WQ6TOPA\8-*T[Q-/::1X07Q5<WNE?!YOB)XN^*_P ;O$/QIOO@A)>7GPMU
M7XJ:]\3O%GB[4M4\+WGACXB:G/\ $SPIXQED]R?]FG]G&3X.7O[.S_ #X)O^
MS]J5M)9:A\"V^%7@1O@[?V<NJIKLMI>?#%M!/@FZMI-;BBUF2"?1)(GU6./4
M60W:+,/1O!?@KP;\-_"7AOP!\._"7AGP%X$\':-I_ASPCX*\%Z#I7A;PEX5\
M/:3;1V>E:#X;\.:':6.CZ'HVF6D45KI^EZ99VMC9VT<<%M!'$BJ*E)-5E&/+
M[23E#2+44W":C);_ +N<)<KIN#E"K*,V[:Y1@U&@I2<I4H.,I7DG.7[Q.;L_
M><HSIIJ?,HNDG#?W?P!_X)Y?'3Q9XL_:?_8XU"T^/_Q*^*_PT_:D_P""??[5
MOQ[U#5OBS\<=1\6^+_B[>>&OVC/V0-/^$?QV\2_L^:?JVH_!S]E&[UX_&+XP
M^'_ _P +?@N+*TM/"MS'X(\>6>E>*OAU:_#[X;_*W[/VJ?&_0?\ @D5_P3-\
M=?#.'QQ\4OA5X$_8G^,>L_M"?LZ? ?\ :>\3_LN_M0:]X'O==^&=FG[2?[/G
MB?PMJ_AB'XC>+?V9M M_'D;?"7Q5XS\)>%?%NH?%?0Y8=7/C[3/ -C>?T?\
MAG]CK]D;P7JNDZYX._99_9R\)ZUH.N_$SQ1H>K^&?@A\,M!U31?$OQJT?2O#
MOQD\1:3J&E^%[6\T[7?BUX?T'0]#^)FKV<T.H>/-'T;2M,\4W&JV6G6<$,-W
M^QE^Q]?:%X+\+WO[*7[-EWX9^&UEXJTWX=^';KX%_"^XT+P#IWCJ[TJ_\;Z?
MX+TB;PL^G^%K+QC?:%HE[XJM=#M["#Q#=Z-I5SJ\=Y-I]H\,OX)15[R25Y<L
MDK3G.,7%.FI13FXZ.C*UY4W1J<DXZQDT[RU7M54:C[FGLO924/CY92^-2DJD
M8R2C*%6"<9?BQXU_:)\1?M"?#W_@J[\3= _:(^-?PLNOV/?V7/@-\?\ ]C+Q
M-I?B/XC?"?3M$^&_BC]A_3OVH_ /[1_Q,^'B7VC>'/C9!XZ^.EM\4O!7Q#\,
M?%G0/%OP]O\ P[\$[[X67G@_3M0L_B(?$7VM^WA\2OCC<?\ !%#]I#XUZ]<>
M,OV=/VD+?_@GMXK^,.OQ?#3Q+KW@?Q?\(?C3IOP0?QYK&A>'?$MC>+XFT.7P
MGXWMKG16GMM2AU?['9S6QU!)Y7GK]%/%OP/^"WC[QGX5^(_CKX0_"_QI\0_
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M$XI-13J4TK--1II*UHH_FN\"^%_BEX(^%7Q9_:B^!7QZ^/&@_&_P3_P<$?M
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MQ1XB\+Z[\8OAUHFK>)=6T_PE-!/_ $<?$+X;_#OXN>$=6^'_ ,5O 7@OXF^
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M_$6\T'P9XRLI?@K\.;;PC^T/Q%^ 7P)^,'B'X=>+OBU\%?A+\4?%?P@\0?\
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M'PV\.>(_!GA3X8>'?VG-,'QC:X\'75L\_P .]9U;0-0LK/Q9I^G>'/9?&/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLOWDYX."YE=KW)8OEJ0YO=E1KJ<X1I2J/^F?X&_M(?"7]HP_&$?"?6M:UD_
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M@3]E/X:> _BQXOLM"UO]MGXI1>!]-\>?%;PQX#L]?BM+3XC_  8^,/COX+^
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MV^:S44G"K=JW+-1?+-21_3E17XS_ /!%'XE?$'XO_L[^,_$OQFMOCAX1^/\
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M36/".@6NO0>']-T2\^ 7A_PSX9^)7@O3+--!\5:Q>Z=K/C:PU758=(>QJ?\
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MW91_\)5X>TG5= L;S4--T[4=1L]0U&QMKCZ\K^7O_@H5^SQX[_8%^"_[?_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PFA?"WX9>%_&7B[X
MB^&OAUX$\._$'X@1Z9%X\\=:%X1\/Z3XR\;1:+$\.CQ^+O$]AI]OK?B2/289
M'BTQ-9OKU;")WCM1$C$'NZ*/\FOD]UZ/JMGU3#_@/YK9^JN[/=7=FCF==\%>
M#?%.@^+O"WB;PEX9\1>&/B!I^I:3X]\.:[H.E:OH/C;2M9T.+PQJ^F>+M(U"
MTN-/\2:?JOAN"#P]J5GK-O>VU]H<,6DW4<MA&ENM'P#\-_AW\*?#EOX.^%W@
M+P7\-O"-I--<6GA;P#X6T/P=X<M;BX"">>WT/P[8Z=ID,TXCC$TL=JKR"--[
M-M7':44=_.R?FH_"GW2Z)W2Z)!V\KM>3>[79OJU:_6YY7KWP*^"/BGQY=?%/
MQ/\ !SX5^(_B=??#J_\ A!>_$;7OA[X1U?QY=_"75;V_U'5/A==>+]0TBX\0
M7'PZU+4-5U._O_!,NH/X:O+W4K^ZN-,DGO+B21VL? [X*>(OA,_P$\0?!_X6
MZ[\"Y/#MAX0D^"^L?#_PGJ?PFD\):7]F_LSPN_PYO=(G\'OX=T[[%9_8-$;1
MSIEI]DMOL]M'Y$6SU*BAI-6:335FGJFKN5FG=-<S<K6MS-RMS-MFSNM&M4UH
MT[*-TUJGRI1NG?E2C?E22\)E_9<_9EFLOBGITW[.GP)ET_XYZ+H'ASXVV$OP
MB^'\EE\8O#WA3P_#X2\+Z#\4[5O#Q@^(.B^&_"MM;^&= TOQ;'J]CH_A^"'1
MM.@MM.B2V5]K^S!^S396_P 3;2R_9X^!EI:_&OPAH7P^^,MM:_"7P#;V_P 6
M_ /A;P>OP]\,>"/B;#%X?2/Q[X0\.> 43P/H7AKQ4NJZ+I'@]%\-:?96^BJ+
M(>YT47O=/525I)]5KH^Z]Z6CNO>EI[TN86EK:6=U;2S]UW5K6=XQ=U9WC%WO
M&/+Y+H/P"^!/A:\TW4/#'P5^$OAR_P!&^%MK\#='OM!^''@[2+S2O@I8W9O[
M+X/Z;<Z?HUO-8_"VSOB;VU^']J\7A.WNR;F'2$F.^OAC]H;_ ()B?"CXU-\)
M_ EGX9^ 4?[)GPL^'WB[P?IO[#GCO]GK0=>_9HT[Q9XAUJQU'1?C)X \*> O
M$OPN3P%\4?"NE3>+?#&FZQ/:^+;'3]"\8:X/!-AX!UO6_%FO>)_U!HH:YG=Z
MOK?6_P >DKWYE>I.24KVE)SCRU+3!:*RT25E;2WP_#:W+I"*]VUXKD:<+P/C
M3]@;]C+P;^P)^S-X3_9F\ >(-3U_PIX4\2_$;Q-I4=R^O1:#X93XC>/_ !%X
M^F\%?#_1?$WBKQSKWAGX<>#Y_$4F@>"] UKQKXQUZVT>RAN_$OBWQ3XFOM9\
M0ZGZP/V8/V:5NO%U\O[/'P,6]^('Q$T7XO>/+P?"7P"+KQM\6/#<R7'AWXH>
M+K@>'_-\2?$30+B-)]%\:ZR][XETJ9$EL=3@=0P]SHIMMM2;O)**4G\2453C
M'WOBNE1I._,Y.4(RE*4TII)))Q7PMR;71N3J.5UMK[6HK6LHSE%)1;B_/]!^
M$WPK\+>/?'GQ4\,?#3X?^'/B?\4X_#<7Q.^(^@^#?#FD>/?B-%X.TJ/0O",7
MCSQAI^FV_B'Q?'X5T2*+1_#:>(-1U%=#TJ./3],%K:(L(P?'W[/GP$^*NM/X
MD^*'P0^$/Q(\12^ /&'PHDU_Q]\-?!GC#6I/A;\0K8V7C[X:OJOB'1=1OG\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG\+:LFK3=U_,ER2ORW?EH[--/FLU>'Q*ZNG[NCMLWS*U[>NJ/IVBOB[X6?\
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M/BKX?^!NM?$/6['XQ>)4^#EQ8?#)_A/\9)?&UCIOQ[\1:_X1^&.O^)_#UO\
M#Z;4?!GA;5?%'AG5/#_B#Q7XP@T+PU\/]6.E6/Q#U7PK<>(- CU/IOA'^V5^
MS7\=O%%KX/\ A7\3K3Q1K&K> =3^*_A.8^&_&>A>'OB+\+-%\36G@_5_B9\)
MO&'B7PYHWA'XO?#W2_$.J:!9:CXU^&.N>+?#5G#XL\%:E<:G'I?C?PE>ZTKZ
M<WV?>?-]GW>;F]Z_+[O)._O:<D_Y)\C\EJ[I66KN[-*RN[M2BUI]J/\ -'F^
MG:*_,K0_VY4^)O[>'[-/P5^#_BG2?%'P#^,/[*/[37QOO]5N?A5\1/#M_P"(
M=3^%WCK]F/1/AIXY^&_Q0\6#2/"'Q+^$7CGPY\9_$U[H^M?#O0]:T+4QI&E>
M(;+QUK&B>(-)MX_JSP/^UA^S_P#$7QJ_P^\*_$&*X\33?#J;XP:"FL>&_&/A
M30O'GPEM=1T[2K_XH_"OQ?XL\/:)X0^+GP[TJ[USPS_;7C7X8:[XM\-Z+:^,
MO NH:KJ=GI_CKPA=:V-I14I-14O:6NTFO9.2G>[7*URRDXMJ2C&4I0CRS4$G
M>4HI-N#IIZ.UZL8RA;36_-&*:5G.48QE+FBY?1-%?FGX/_;=C^*W[?'P/^"/
MPJ\7:3XC^!/Q+_8L_:)_:"G^V_"/XD^$?$.J:Y\.OB[^R?X2^''C[P?\1O&B
MZ/X;^(7PB\=>%?C9XQD\.ZAX#\-WFCWUUH(UR+QMKVFZGI5II_O'Q\_;F_9;
M_9D\2R>"OC/\3I/#GC8?##7_ (R6O@K0_ OQ)^(?C+6/ASX5\2>'?"OB37O#
MGA3X;>#O%_B#Q/<:+JGBG2;C4?#_ (=T[5/$MMX>36O%TFCCPGX9\2ZWI*4E
M:[O'WJD;2]UWI.2G=.S5N64G=)J,9.2ARR46M92BDVXJ#=E=6J14HV?6ZE%7
M5TY22C*=TW]:45\V^%/VO?V</'6I?!?2_!7Q1TGQ=/\ M%?"KQ+\;/@=<^&M
M+\2:YH_Q.^&G@V'PU<>*?$'A3Q!INBW.A:A<:#%XR\+-J7AW^T8_%%N==T]&
MT7?.%'COB;_@HM^S]ING?LC^(/!@^(?Q3\)?MC_%CQO\*/AKXI^'_P )OBUX
MCT_3=1^&_P /?B[X^\9W?B6QTCP%J.O:5J&FCX-^)_#MGX/N](M_%^J:C#JF
MM6ND?\(9X*^(/B?PI334N5IJ7-R6:L^;G=/EUM9^T3@[VM).-[VO/-%1<[KE
M4>?F6JY>3VB::WO#WU:[<=4G9V^]**X#XB_%#P-\*-&T[6_'>N#2+?6]>TWP
MKX>L;/3=8\1>(O%/BG5UN)=.\->$?"?AK3M7\4^+=?N+2RU'4QHWAO1M4U*+
M1M*U?6I[:+2=(U.]M/!M0_;N_9*T;X0W'QWUWXTZ!X>^%NF_%C3?@5XD\1>)
M-*\5>';OP+\8=4\<Z9\-X?AU\2_"^MZ!8>+_ (8>*+3QGK6D:3K.G?$/0?#+
M^'H]4T[5M>.FZ+>6^HR*Z^YI/R<G&,5ZN4X12WYIP6\X*=/3?31O732*E)OT
M483DWM:$WJH2Y?KBBO+OA'\9/A_\<?AOI'Q:^'>HZU<^!M<E\206-_XL\%^-
M_AIK,<OA'Q)K7A+Q"NJ^#_B9X=\(>,M!^P:[X?U6V4ZYH&G+>6UO'JM@UUI%
M[8W]SX3%_P %!/V."GCV6_\ CMX7\.VWPW^"4/[2OB*^\9:=XH\#Z=??L\7%
MY?:?!\<O VI>,=!T.P^*'PFEO[);%?B!\,[CQ=X6-YJOAJV_M3SO%GAA-7+J
M]NJ5[=;6O>WIKU;6R?1I-[)O51T5]6^5+2^KEIZM*]VK_8]%?EK^V=^WM%X6
M_8=_;<^-W[*'B[0D^-/[)OA6XG\3>%_C%\)OB1H^K^"O$C>&_#?CC3].\5_"
MGQN_PE\;Z>_B;P+XFT_6_!'B34+>7PO=O>VFKQ6/B_3M-U30I_91\=OBE%_P
M4E/[,MS>>$9/@S<?L3W7QYTVRM?#.H6WCB#XA6WQQTGX>7CZOXMG\37NF:GX
M=.@W"OI&CZ=X4T"YL+Z;4I]4U77EGTV+2&KN7+:SNUKI=_5ZF*5M'=.E2J6>
MSG%QOU!IJ+GO%)MV:NDJU*@[K>ZJ5J=UORRYK6T/N6BO)_B9\;?AQ\))]"T_
MQCJNLR^(/%%IXAU'PUX,\%>"O'/Q0^(7B#2?",%A/XJUO1/AU\,?#?C#QUJF
M@^&FUC0++7]>L?#T^CZ/JWB?PGHNH7UOJ_BOPY9:IX+XG_X*(_L8^%/#?PH\
M67WQU\/ZOHOQV^'WBOXH?!9_!&A>,_B1J/Q5\'^"(]%?Q//X T'X>^&O%&O>
M*M>TR?Q%HFF#P7HVF7GC2^US4K?P_IOA^\UPOIZ*]DWK9.S=M+VD]_2,O_ 9
M=4T+K;JU>WEIKZ>]'7;WD[V=S[2HK\_M0_X*4_LT7EC^Q3XD^&>L>*/C9X!_
M;J\<^,?!WPD\?_"3P!\1O'7ARTA\"?"/XK_%'Q/?>(6\,^#=7N])U[1[OX4Z
MEX'U7X;ZI;Z;\1M(UYO$M[JWAFRT;X8?$Z]\*>A^#_VE/AU:ZU^UIK?BG]H+
MPIXF\)?!;XV>$/AMJ'AZW^'/B#P?J?P4\3:]\+_@X^E?!:\UJYO-4G^.7COX
MB>+_ !OI7BSP)-X)T.#5=<O_ (O>$?A-X:T/Q%X@L--DU<3NVEO%S3752A[+
MFC97=U[:ETM[\?>O."FFTDGTERM/HU/VO*TW9-/V-39W]R3LE&;A]?45\B:U
M^WA^RCX8^&GQK^+7BOXKQ^$?!W[..KV.A_':/Q?X,^(GA3QI\*M2U>PT;5]
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M\27F@Z%'J5W93Z[J.BZ8;N^M.*\"^"/CAK?_  4C'[1_B'X%>,O 7PI\6_L
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M,)+#2ISEYR^J4(U(Q<8-1DXQA*3M\#:%\.OCSH'_  3"T_X1^%_ OA-?VFM
M_85A^&7AGX<?%A_"WBKP%<?''1/@&OA+0_"GQ#DT_5-=\'^(_!-]X[M+73O$
MPBU;4=#U7P]/=K-<M;3R@?GSX'_9M^->N^+_ -K/6_C5^PM\:/B#\*?VF?\
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M,))3Y^9751R<HZI+GAB(22DK32MBJSBG.48<R48VBK_G#\+_  C\=+[_ (*
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M\5OB9XV_88\9:'J7@&P^&_Q'\6:WKOP@\0CX!>.-/\#ZYJ6F^'_'"O"5\?\
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MPC=W;2=&,7)MR<6VWS682O-34FW[3F<WHG*4J56DY:*T7:JWRQ2C=)6MS7^
M/VU_A#\8?$_Q _8A_:!^#GANY^)FI_LC_M)ZU\2O&'P6M/%6@>%-3^(GP_\
MBA^S_P#&;]FWQ5J/@S4?&.H:%X)G^(WPWL?C*?'7AO3O&/B?P?HNN:)I7B[P
MXGB73=4UO38[GXL^-?[(?[0>K> OVR/B)X/^%7BC7?&O[5?_  4E_P"">G[3
M^A? ZP\:_"C3]5\#?"S]CWQM^PK%XVUGQ%J.N?$#1?AK%X\\=:+^RIX\\5V]
MIX:\<:__ &A;^(_AAH6JW%EJ]IXIFT7]TJ*=-ND^:"2;GSMM7;O/#5)1ONHR
MEA*5[--)S47[WNS5A&M!TYW<7#V=DVM.3$4T]/M*.*JZVU?)S+W;2\%_:?\
M@_>_M%_LP_M#? .RU^?P1J/QV^ WQ:^#]IXG$9N+GPC>_$_X>Z_X+M]?$5E=
M*9I_#\^N)J/EVEXK2R6FVWN0626ORLDN?^"I'Q-_8A^*_@?7OV&O@O\ "_\
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M;IU*;W2;NJU25V[J;BTUR02;O)\S;YGRWDFT_<G"I'NE9PC&R5G&Z<7S2O\
M!/[ ?PN_:'^#_@_XP>"?C9XR^*_C;P+8_%[S/V:+[]HCQ5X!^(/[26F?!9OA
MC\-X;O0_C3\2OAS?ZQH_Q!U/3/BM!\2;;P3XF\1>(/%?Q(O/AM'X1'Q#\6:O
MXA66.R^]J**U;O;R45YOE25Y/K)VO*3UD]7=W<DE:^K=Y2EKTYG>R[15[1BM
M(K165E$HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP]?WM]8SW-YH=CKLCZU9Z1<2R:?:ZN[:E#;I>,9BJ5J:I)QYW3<'*[MS.%'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M93\)? /7/ .@?%O]J7]L/X5? "+6OB%X=;Q1H_@KX3ZCI?BSQI\=/BU+I_\
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MQO?$5U$L,%IX7DL%T-+OQ=/?P^$-/U#7;7\QO"?_  2:^)/P7^-?_!-_P?\
M#S1-"\<?LS?\$I?V(_C?K/P/U;Q)XHMO#<_QL_X*$_%2>P\-17WC[P5;3ZK>
M^'_"":79^(/B1!KD5]>VGAGQ1XQ&DZ6]]#8W3R>+>$?^"6OQLN_^"0'P8_8"
M^.W[->J>./&7BOP=\<?C9\8?B/X%^+WPMB^/?PD_;VUSQSH?Q4^$_P 7]#\5
M:OXO\%^#=5\KQ=XP^*GASQ'JGA[QAXBU >!?#WA+1I;S4-+\3^(]#M[FXKVS
MAS3C"4G3BDHSG36+A2BH\UHRJ2P]'&5(J\-:F <U356I&)'F?LE+E@YQ7/)N
M\(3>&J5'?ENU"->IA(/23:AC8P<W2A*?])WPI^*_@CXU^"[?Q_\ #R]UF_\
M#5QX@\<>%=_B'P?XQ\ ZY:>(OAOXX\1_#?QMH^J^$?'^@>&/%VC7N@^-?"?B
M'0YXM7T.R^U/IQOK W>F7-E>W/HU>%_LP^#_ (L_#[]F_P" ?@;X^>+M(^('
MQU\(_!SX;>'OC5X]T$3G1_'/Q<TGPAI%G\2?&>GS7>F:)=W=OXI\91:UKJW]
MUHFB76H-?M?7&C:5-</I]O[I3DE&4HJ2DHRE%2CM))M*2\I6YEY22N[7DHMR
MC&3BXN24N5[QNK\K\U>SVU6J3;42BBBI*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H_P _E110 5X]X^_9X^ '
MQ6UQ?$_Q1^!OP>^)/B5-!'A5/$/C[X9^"O&.N)X8%U>7H\.+JWB'1-1OUT$7
MFHZA=C1Q<#3Q=7]Y<?9_-NIW?V&BE9;V5UL[+32VG;33TTVT#^OU_/7UUW(X
MHHH8HX(8XX88HTBBAB18XHHHU")''&@54C1 %1% 55 50  *DHHI[ZO6^KOK
M=O?[^O?K<-MM+:*W1=EY'C$7[.'[/$'C>?XF0? ;X,0_$BZ\1#Q?=?$&+X7>
M!X_&]SXL$:0CQ1/XK30EUZ;Q$(HXXAK<E^VI".-$^T[54#V>BBCI;HMET7HM
MOP#JWU>[ZOU>[^;84444 %%%%%D 4$9ZT44 %%%%%D 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ?H/A_1-.MQNGU#5]9U6XM-.TVR@4@S75Y<PP1#EY%%?@AX#^,'Q._9#O/\
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MW[-MOX4_87_8A^#/[;/AX_$/X;?$_P 6>(O'EIXCTW]LC4/'/P>UEO#?QI\
M:7IESXE_X9CL%\*?%.R62'X<'5;M=8^%WQ7_ +4BD\,S_M>_\%#?B]\)+OXQ
M6GPZL_A1X#U3P1^PUX2_:M^ 'AGXT^%O$WBS6/VU_BCX@U/XGQ:]^S=\#_\
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M*RBXQVLW[SE[J=H0J2DO==_UOK#NO$WANQ\0Z/X2O?$.AV?BOQ%IFN:UX?\
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M4;_]CO2?$?P_D\5?'OP;X$7XH2:Y\,O&GPG^''Q0TKQ_\2=)\;ZCXQLT\*^
MO'_B+_A'/#FK&Q^'UC.M[-<ONTI7E[L>6M*C"+;>B495Z2J-VY%)R=XQE)+F
M3BY+WDI5(M1U?-35:32BM6Y*A4Y+7YW%15I-1/W)HKP'X*_$+QI\2O$_QWU;
M4)_"DWPK\,?%F_\ AI\'I]$T+5K+7M5B^'>AZ/X=^+VJ^*=;O_%6I6>KS:9\
M=8/B/\.--LM.\(^$%TR#X=W%\]QXGM]=LM1MOSU^,O\ P4&^,>D?"C_@H7^T
MA\&?#GPTUCX9?\$V_BUXG\"_$3X:^,=&\33>._C/X6^!7PG^&7QI_:0UOPO\
M0-,\9Z-HWPM\16OAOX@>(?#7PLT;6OAU\0]-O]5^&\'B37]5DT?XJ6=A\-DY
M)6;]U<GM&Y77+#FIPYIZ-I*5:ES:-Q4TW'22C5F[VU][D26\I6G+ECJDW:G.
MVJ3<;<WO1<OU9\8_$+P#\.[33-0^('C?PAX%L-:UO3/#6C7OC'Q+HOABTU;Q
M'K=U'9:-X?TRYUN]L8;_ %O5[V6*STS2K5Y;Z_NI8[>U@EE=4(/B#X"/C;_A
M6@\;^$#\1_[#F\3_ /" #Q+HI\;?\(U;7%E:7'B'_A%!>_V[_8=O=ZEIUK-J
MWV#[!%<7]E#)<+)=0+)^1WB[P]KWQR_X*Q>+OAMXTU'X7_$#X ^(_P#@F#I=
MTWPJ^)/P?U?QAH6H^!/BU\=-<T3QSH&J:5K?Q&M-"GU'QOJ7@?PE=^+;V_\
M!BV.L^$_#GAOP;J7A8:CH,?BF;Y>^!?CCXB?"O\ 9Y^+_P"T_P"//A]X/_:
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MMM:\$/XBL_"#Z1X\MO#W@+FM%_;(_:KTKPM^R3H_C72?A!XW^,G[<=K<^/\
MX6^&_@YX!OM'TWX8_#'PO^SYH'Q5\>:3K(^,O[2O@ZR^,?CS3_&&M6FC:+?:
M9XG^$-I/X(OK[Q?-X/N+[P=?Z!KMN,XRG"4'&=.HJ4HRT:J.6(CR=4Y7PN(U
M3Y;4I/GLX\R4X-0E&2E&=/VL9)^ZZ7+0E[2[Y7RVQ-!6:4^:I&/)=2Y?U\HK
M\=_&_P"UQ^W'X"^$_@6/XF>!O@9\&?CQ??#+]L?Q1K7AS4/#VK_&C5O'>N_
M/7/"-E\%=?\  OP3^$7QXU#4O!OPJ^*/A'Q7:^._C)XM\6?&W7_#?[.6K7GA
M+X0^+/'5YJGQ$\)_$67D?'?_  4\\<Z-\/\ ]D;XD^(H/A_^S#\/OVL_V4/@
MU\9/ ?QQ^,OPY^(WQ3_9K_X:%^+-EHVL?\,T?%/XP^!?&7P_L/V;#;Z/KOAX
M^!OB3\5+"3PU\4;GQ)JW]A2V>N_"V^\#?$11O)Q2WE.G3BM=954^32S>KC*+
M5N937L^1U'&$VW92D[VC&I)^E)I3ZK9-2OI!P:J<_LU*<?VVHK\I-=_;&_:O
M^(?Q(^,MA^RG\!-*^)G@_P#9R_:L\'?L\_$'3-;N/ASIL_C+1+#1OA-XA^.>
MO6/Q \0_M)?#[5?A=XK\$:#\4]0USP5H&H? WXFZ7XNLOA[9Q2:M;CXOV%_\
M+OU:)P">F ?3M^G^>:%K%2Z.S6NKBX1J1FEOR2A).,MF[QTDF@;M)QUO%.[M
MHFI2A*/-MS1E%J4;W2UU6HM%?CG\9/\ @H5\8]&^$?\ P4!_:9^#GAOX;:U\
M*_\ @G)\8_%7@#XB_#+Q9HGB6;X@?&+PA\!OAU\./BC^TKK_ (7\?Z=XVT;0
M_AAXFT_1?&_BC1?A7H>M?#SX@:7JUY\-;37?$&L1Z9\6+:U^&'K_ ('_ &@O
MVJ?BI^W9^T#\!_"6J?L]:!\!_P!G[3OV5/'U[J.O_#;XGZS\6/&_@?X^>$/B
MQJ'B#PM97T'Q7\,^%_"?BG2]<\!:5>:)XNO_  OK]A#H]U?Z/JG@.YU&6#5[
M%1?,TEI>,9.^B4)4E6A.3LTHSI24X[MJZY8M69)J*N_YG%6LW*<:CI2C%75Y
M1J1<9;)/7F:U/T7U#7M#TF^T/3-4UG2=-U+Q/?W&D^&M/U#4;.SOO$.JV>DZ
MEK]WIFAVEQ-'<:MJ%KH6C:OK=S9V$=Q<0Z3I>I:E+&MG8W4T4&@^*?#/BE=7
M;PSXBT+Q$OA_7M3\+:\VA:OI^KC1/$VBR)%K'AW5SI]Q<#3==TF22./4M(O3
M#J%@\B)=6\3.H/YO_MKZ1I4G[;G_  1RUZ33-.DURS_:_P#VB](L]:DL;9]6
ML])U/_@FK^VQ>:EI=KJ31&\M].U&\T?2;N_L89DM;RYTO3I[B*26QM7B^;]'
M_;3^-_@SX-?%[QSX)^''[,^B>*=$_P""U'A']BS7]-T?P'XN\)>'?'O@'XI?
MM<_!K]GG6_B-K<ND>-+W4;?XYZSI7Q*'B+5?'M\OB/15U?3X3=^"O$-O:"VU
M"%47ON6G+*4?_*V$HQ;\G/%P4K?#I*[BIVTE!I4VM>=)V[/DQ=2R[MQPLFGL
MW[MDW%G[FUAV_B;PW=^(]4\'VOB'0[GQ;H>D:+X@UKPM;ZM83>(]'T#Q)=ZY
M8>'=<U31([AM3T_2-?OO#/B2RT74KNUALM5N_#VN6UC//-I-^EO^$WQ=_;Y_
M;M^"OA#]OOQ#K5_^R3XQ?_@G/\:/@TGC:XTOX*_&/PF/VAO@O\6/A?\  _XK
M:AX2\*Z-=_M)>*_^%"?%#P=I7Q)\1Z'8?$K5_$?Q\\*>--2M-&O[GX3>!;2&
M^MK[W;]H[]H#XO\ @3XF?\%6=.^'MG\%O!?C7]G_ /X)K? K]H;X2_&*W^%E
MQK?Q-EU'7IOV\/+\+_$[4-1\70Z7X]\-^!]<^!M[K_PQT,Z=I&B^&-3^(/BJ
MZUC3_%,6HWUC=NK/V5.522]V-*I5LOB<88.IC%NK+FI4JF^O-"4;)\KJ*,7*
M486:E.K3I1<DTN:>)IX;7=_'6I.Z5N6I"6W-&'Z_T5\N?LI7'Q.UO]C[X$ZC
MXG\;:%XA^)FO_ 7P#JD?C>^\+>(9=.FU?6? NEWNBZKXHT#4?B)JGB#Q/>VK
MW5I-XLN%\>Z1=>+KZ/4;VUNO##:E%%I_QQ^S5^W)\:/BQX(^$6B_$:+X3>%/
MC_\ #[XI?M3>$?V]_"NB^!?'C>&?A[X>_9*-[H?CF?X4VU[\1KW6K.[\9Z[\
M0_V8O&_PMU+Q+J'B^7QE\$/BTOC^W\(P/(FG:5K6C[&IB*<W'_9G5]K*[45&
MC4K4ZE39M0I^QE*HVO<BXMWYE?*E/VU*C5C%VKQI.$='+FK4J56G#=7E-55&
M%OBE&22CRNWZU45^/?@7]OCXW:CX6_X)I?';Q;H?PK_X4?\ \%-;SPUX6\,^
M%/#_ (;\9I\2_@!XM^./P"\<?M+_ +/]WXA\3R>,=6\.?%O0;'PGX U'X9?%
MJ"R\*_"N9/&.O:7XX\-:K:>'--O_  M<T?@+^WW\??B7X8_X)@^(/$^D_!^"
M3]LG]H;]J_X$?&"UT'P?XTL4TQ/@9\+?VPO'?@_Q5\-IM0^)VL'PVU_J/[-&
MAVGB70_%$?CL7]EXHU4:7J^BSV-I/+#;5KIJ\E&SO?F=14VO53<4^B4D[M*7
M+:]YV6KY9379QA"4W)/9KEC*W5N+5E>/-^R5%?F__P $]OCG^UA^TSX-U'XQ
M_&G4_P!G?3OAY#X^_:J^#6G^"_A=\._B5I'C.?QE^SQ^V#\8?@/I?CR\\9^+
M/BWXGT2V\,>(?!7PVA6^\ 0^";K5K;Q2)/%<'Q"72=:7P#X:\F_;&_;L^-_[
M.7Q(\:Q^';3X(ZQX%^'WQ(_8-\*3^!XM+\=>/OB9KOA']J/]H[P7\#?B-XL^
M('BWP[XD\,>#/V;KNP7XA6#_  (T#QAHGCO5?BE>^ ?'.LV-EJ>@G5(_ !!\
M[I*-FZR@X7=OC5*45*ZT;5>D[:V4KMKEFHJ5X*JY)KV3FIZ7?N>TYG%)MR2]
ME4LU:_+HGS1O^LFGZ]H>KWFMZ?I6LZ5J=_X:U&'2/$=CI^HV=[>>']6N-+T[
M7(-+UNVMII9M*U&?1=7TG6(;*_2"YDTO5-.U!(FM+VVFEIMXO\)IK^I^%'\3
M^'4\4:+X=T_Q?K/AMM:TU=?TGPGJU[K.FZ5XGU/1S<C4;#P[J>H^'?$%AI^M
M75M%IMY>Z%K-K;7,D^F7L<'\\?BWXQ?M+?L>:U_P6K_:8_9T\*?L[ZM\)/V<
M/VUO#GQT^/'PF\9>'O&5GX]^+/@'2/\ @G)_P3_\;_&FW^%WC+PIXF\+^#OA
M!XYTCP=;>*O&FC^)/%G@OXVV_P 4_'.MS:7KV@^ 5TR3Q+XO^W_BY\0V\8_M
M3_MT_L]^)_AU\'-7\'V/_!,+X3_%.V\82_#R0?%3Q#I/Q)\<_M@>"[OX8_$'
MQ)JVLZEI_BCX>^'+SX97_BGPMX</AK2(=)U;Q]XH%Q'=3SW%W>YRJ-4*E5+F
ME2PM3$SA=)QY,+B,5%-M:0J1P\HPG9N3C-<L915[A'FK0HM\JJ8J&&C.SDO?
MQ>'PCE96]Z,L1&4HZ))P?-)-\OZ7V_Q!\!7;^"8[3QOX0N9/B58S:I\.4M_$
MNC3/X_TRWT>/Q#<:CX)6.]9O%5C!H$L6N37>A"_MXM'DCU-Y%LG6<]?7X/?L
MF?%C7O!WPY_X-ZOAA:>"_A)K_A_XR_L36=I>^+O%O@V^U?XI_#K5/ '[#'@/
MQ78WGPJ\5Q:]967A>W\5Q&70O'"2Z-?7&K:%&NF0SP+>//98?P\_:_\ VR/@
M[^R?I/[4'Q-^)'P=^)WPL\+_ /!2[]ISX/?M2^(M:^#WCO2/%/PY_9CT/_@H
M-\?/V9S\2O!]Y8?'K4-%TKPY\'3I'P[U+4;76="U:S^'?P!TGQ1K>N:AX[\0
M>!;O5_&>\XJ%>=!/F<:U>DI-64O98Z&"5TK\K<ZE-MMN*]I&VE[9*3<(3:MS
MTJ=3ENF[3PE7%MJ]E)*%*HDM)7A*ZO:_[^T5X'\#_'_CGXDZE\:M?UMO#'_"
MN-'^,_BSX=_!L:1H&LZ-XGGT'X6Q:?\ #_XD7WCJYU3Q-K-KJ>I#X\>'OBKH
MGARXT?0_"UC/X'T+PUJXM=2?6C?M^56J_MF?M _![X^_\%,=1\5>,_!WCWPY
M\.?VHOV$/V2OV=/A]?>#-<\.:1X.\3?M=^'/V:=%^'NM>(/$-CX_O;>Z\)^$
M/&?[1FO>+/BW*WAV'QAX\M-+:+P_XJ\):7IOA#P1I,K5J.B<HN2N^K]@H0Z6
ME-XBG%)V46_>=KV<I*,>9[*:@WV5JTI3ZWC&-"HW:[:7NWTO^Z-%?"/PD_:.
M^)\?[:/Q?_8M^,]MX*U_6=!^ GPS_:A^$_Q.^&_ACQ%X-T?6_AWXS\;>./A5
MXN\ ^-O"OB+Q?X^?3?''@3QOX$MM;T[Q'I/BN32/&GA#X@Z98KX:\/:OX$UG
M4?%/W=19VC+I-.47W2E.#^:G3G%KHUYH=]6NL6DUZQA-?)QG&2?9]TPHHHH&
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7R9\<?V._A[\9OB?X"^/FD>+OB1\"_VC?AKX8\0> ?"OQ]^".K
M>&=(\>2_#/Q9?6.K>(OA=XTT/QYX1^(?PL^*?P[O-<TS3O$NE^%_BK\.?&MC
MX-\66@\7> _^$6\3W-]JUU]9U\*?M ?\%'_V5?V9_%OQ&\!_%#7?BJ_C+X1_
M#[P5\7OB-X=^'W[.7[0WQ9U'PM\'?'-_XUL++XP7B_#'X8>+(;OX5>'I/AQX
MY_X3SX@Z7-?^%O 5UH T+Q9J>E>)]<\,Z'K:=KIO=<TD]59*+YG?1)*+ES-M
M147+F?*Y#UUZIVBU:]^9I)6UNW)*RLWS*-ES*)U'Q<_8B^$?[0'P'\:? ?XZ
M:W\2/B?!X^G\)ZMKGQ6U'Q9'X1^,=AXP^'>N6'BGX8^.?!/BKX8Z5X%TCX:>
M(?AGXJTK3O%/@RU^''AGPIX5L?$2:MJ]]X;U*\\7>-9?$?F@_P""<'PXN_A'
MX&^%OBCXZ_M2?$+6?!?QM^$G[0-Q\:OB9\4=&^(/QI\9?$+X$>+-*\;?"1/$
MWB/Q5X)U/PW9>"_!?B30M)U2Q^'G@CPAX.\$7NH+KFJZQH.HZQXX^(&H^*^P
M\4_\%#_V7?#?C3X>?#_3?$'Q)^)OBCXK_"+PM\?OAW:? WX"?'7XZV/B[X(^
M+_%OA#P=IGQ4T#6_A)\.O&&B:OX(L]0\<>'=1\1:WIFH7EOX6T#4=/UGQ'_9
MEIK7A\ZOV>I_MI?L^:/XM\.^&=2\6:E:Z7XK^-5Y^S7X?^)+>%_$+_"/4/VB
M+"\U'2+GX,#XE1:?)X7M?&'_  E&DZG\.[>ZO;VV\)7GQFL+OX"6?B:X^.=O
M+\.5=FF]&I>T2>EG[6C-02MI:=.I!4[>[+FC&C+FY8T5-XM+5-*#:Z_NZL'-
MOJW"<).HKW7+)U8J-W5>+\5OV(/A!\8_C1XF^-/B_5OB"MW\1/V9/$G[(OQ>
M\ :/XCL=.^'GQ?\ @KKU]XOU+3]'\:V0T2;Q58:OX0OOB'X_N?#&N^ O%W@J
M]#>+]3C\0'7X+/08M'\>^'7_  3%^%GP[N8M53XX_M.>,_$I_9 '[$6H^*?'
M/CSP1JVJZS\&-+U+5+OP//J5EI_PST?PX/&OP\TS7-9T'0O$6GZ#80^)(=3N
MO$_Q/TSX@?$0Q^-(_'?B/^U+\4?B9^TA^V-\)O!'QI^(O[,?A3]B;P_^SGXX
MO_%6A_LN:I\;++XA:3K-K\2/'GQ_L_&6AZ[\/=3UN^T?4OASH.C^&O@Y'\+M
M;\+^)1XSLI_B'I=S\9?"EQ+\.9?9/AK^W3X-'B+_ ()[?!2PU+XJ?'BY_:^_
M95N?CYX<_:/O/A;>>'[3QIX1\&^'/@E9GQQXN\*>#?"6D:;X*\5?$;5OC7X1
M\7>(]'L_"WA7P5\,--O+^+7X?"-M>^%M.NY24XJ-E*-6+BH>]*].K''7YEK%
M1G&.-B^:WNSJ07NSY4<R@W-.SIS3<XW352E+!)-/W6Y0D\$[KFLX4YO6GS'I
M?@']A3X;?#36/V5];\*^/_BS;W?['?[-WB[]E?X.K>:EX!OX8_A;XULOA=8Z
MQ_PE(N?AV\NO^)%A^"7PE:SUEIK1(I?!%J\ME<?V]XP'B/UW]F#]G7P9^R=\
M#/ ?[/OP[UGQ=KG@?X<66H:;X9O/'.HZ5J_B6/3]0UC4-;:TOM4TC1/#]O?+
M;WFIW2V\\VG_ &OR#''<7-PR"0^'_P#!0#]J'7?V7OAA\+M2\*Z?JTWB+XO?
MM0_LK_L_QZUI_@GQ'XTC\)>&/C;^T-\,_AE\0O%%K:Z+HVL:<OC32? 7BOQ%
M<?##3M>M=1L]7^(:^'T?PIXXL+34_">J\-\"OVO?!_A/XC^(_P!DWXB?&;XW
M?M(_'/PIX\TN;7?%(_8N^+'@NX^&/P]^->F>+/B1\$[3X^>)?AY\,K+X,^'[
M73/"6AWGA";XS/8?#'P+XCUO26TJ]T31O%^A>.H=.KGYW-N5VW/F<FKSDY1Q
M-57;6J=98B<FXQ]Z4G)--"Y(04>6,4O=LHK6*4'AX-V3T<:7L(I<TFHQCRM*
M-NLO?^"='P0UOPA^T[X(\4^*/BSXHT;]JSXW:3^TCXWN+SQ5HFA>(/!?QV\*
MV?PNL_ 7Q.^$WBCP3X4\*^(? WB/X=GX)_"B^\&>3J5_IVG:IX)L-2N[#4+O
M4_$4NLZ?Q*_8$^%GQC^%?[0WPU^*7CSXL^,]6_:G^&_A;X.?&SXMWFI> =(^
M*'B?X4>#(_%*>'/A]ITWACX=:%X#\)^&]-F\??$;4K:W\)^ M%NH-;^(GC/7
MK>[AUK6#?P]=X)_;A_9V\?>*/ 7A/0?$_B!;WXQ?#'Q'\9O@/J&H^!?&=AHG
MQ_\ ACX0@T:Z\3>)_@MJ<FB&'Q[-IECX@T;6[?PKI@'C;Q#X.U/3?B)X5\-:
M[\.M4TSQ9>>0^#O^"J?[&WQ /PJE\'>)OBSKVF_'?P-XG\>_ W6;/]FS]HDZ
M5\9;+P;;-J?B;PQ\,9Y/A@DWC'XD:+H,=SXCU3X9:/;W'CO2M%TOQ'<:KH-C
M/X/\86V@2HQ4>51M&R2C9JW*G!)*RDI)47#2U2U+D?P1@6Y-RYV[RNWS-IZR
M:DW?5<K=12_D]_G6DG-^^>+OV7/#'C?XU_L^?'_7_'OQ)F^(O[-_A#XF^#_!
MEU;7/@>TTC7;;XP:5X7TGQ_JWC+1X? BVNH:QJ\?@SPW=VYT4>']*TB\T]CI
M&E65M>W]K=>.^!O^"=OPG^'_ (7_ &</"&B_$7XS7.C_ ++G[1WQ/_:E^&XU
M76/A_=WEW\4?C GQC@\<_P#"57<?PVMI=5\-ZA:_M!_&>TM-'LCI3:;!X[N/
ML=Y%-X<\%R^&OIKX"?'CX<?M*_"W0OB_\*K[7+SPEKFI>+O#[VWBGPEXH\ ^
M+O#OBSX>^,=?^'?Q!\%^,?!'C72-"\5^$_%_@;Q[X5\2^$/$^@Z[I-E>Z=K>
MB7T&R6%8;B7RG0OVX?V=_$OQ.T/X5:-XE\07FL>*_BC\8_@9X0\11>!_%TG@
M;Q9\;OV>]'\1^(/C5\)="\6Q:/)ID_C3X?Z/X/\ &%U?6URUII>NW/@OQWHO
M@_5?$?B#P#XWTKP]:;333::?.FMES359--7C:4VJD;.TFUR*5U%RU&47%ZQ>
MC3OKRQ=.S5[MQ@I1;M>*3YG&S:=X&_8]\&^%/B=X!^+/B7XB_%CXO>*?A#HW
MQ6\._!MOBIJ?@C5(_A7H/QFU;P_J'C?2_#FH^%_ 7A+Q+K,,^G^%/#GA?2I_
M'VO^,K[1O"^DPZ987<4D][=76O\ $3]E3P=XW^-NC?M&^'O&?Q$^$/QJT_X8
M7_P4UOQS\,;WP>MSXZ^$=UX@D\8:;X$\:Z+X_P#!?C[PSJ5IX2\9SWWBKP-X
MCL-$TKQQX,U'7/%MCX=\56'A[QSXWT7Q%YI\+_\ @H]^RM\8O%'PA\+>!_$'
MQ,F?X[>+OC%\.OAAXD\1? 'XZ^"? VO?$WX%:K\3=-^(GPNO/''C/X=Z#X7\
M._$S38/@O\6=<M/ ?B/4]*\3WV@> =<U.+35232X]1]0_:G^*OA_X4^$/AK>
M>(/BUXO^#'_";?M'?LV_"_1O%?A+X9M\33KOB#XB?&WP1X6TGX5>(8)_!?C3
M1O!?AKXTW.HCX2ZG\1-:C\.IX-_X3*'6-$\5Z)XG@T2X,7CR0=UR74(OFM&T
MW3IO7F7,I1J4^9-R=6,H)^TYZ;D]I36TDFYJRNE352:NK/EY'2GRZ)4W&;7(
MH34>+N_V%/@O!J7[&\_@F_\ &_PP\/\ [",6I6_[/?@?P1JFA/X4TBWU3X4Z
MY\$;F'Q,GC'PSXNU_P 5D?##Q-XA\-I<ZGK[7C3ZO<^))[F;Q6EKKMOZG^T1
M^SWX8_:4\(>%/!?B[Q-XT\,:;X/^+OP?^-NEW?@>Z\-VFHS>-_@3\1_#GQ;^
M&SW\GB;POXJL[C2='^(?A#PQXCN]-2RA35GT:'2]2EN=$N]3TV^\,\8?\%)?
MV2O GC/QMX&\3>+?B!8:I\+_ (Y^ ?V=OBOJO_"BOCC+X.^%'Q+^*EE\/KOX
M;I\2?'"?#S_A$_!W@SQR_P 5_AM:^%?B/K.L6W@'7G\6V]]IGB*ZT71?%6J:
M#Z1\4_VS/@!\&M8U/3?'7BK4K/3?"_Q#^$GPF^(GC'2O#'B#7_ WPI^)'QYU
M?PMH/P?\&_$SQ5HVGWNF>$]<\::EX\\ 22VEW)(W@G0/B'\._&OQ)/@SP-\0
M/!GB77';GM[KE[2HIQ5F^>K)TZD6E:[E)PHRBK6E:'+%JR#F4;MNW)!Q;NDH
MPC[2,DW>R4>:JI.[:;G>5[L\D^(W_!-G]GKXN:/^USH7Q(U+XG^);#]LKX@?
M#7XL_$&2#QA:^$]9\"?%+X->%/A[X/\ A/\ $/X->)_ VA>%_$_@#Q7X TSX
M2_#.YT+4$UG5%DU3P=9W^K0:G+J_B<:[A:O_ ,$QO@SXI^ VB_!KQY\6?VG/
MB/XV\+_$SP;\:O"'[5GQ ^,4_BG]JCP9\7_AQ'>V7P\\?>#_ !]J&@OX2\,R
M^#='U77-#TWP5H_P^M/A=J6G^*_'LOB7P)KNJ?$CXAZEXI](3_@H-^S$WQ/^
M)GPG?7OB3::Y\$O$'COPW\;O%&I_ /X[:1\)?@K=_#OX0^'_ ([:YJ?Q=^-.
MK?#FR^$_PW\+ZE\+_$VD>)/!'B_Q?XQTCPO\18YVM/ >K^(KQ/))KW_!0G]E
M?P3+\:K3XG>.M9^$FJ_ 'X5^$/CK\0O#WQ.\!>.?"/BD?!;X@ZMK?A[P-\2/
M"GA:]\/OXA\;Z9XF\4^'M6\%0>'/"FFZMX^T7X@0V?P\\5>$= \<:QHOA[4&
MFY)./,^:,)1E'FNXTW&-.491M+W;PC&<7S2CRQYJD%&(K)7NEI*:DG9I2J7]
MI&5^97EJY1EHI-OEA-N3^0OVE_V#_$_A#X4?%!_@N_[3_P"T%XJ_:&_:E_9S
M^/W[2MYX=_:.\%?"?]H>>]^ _@KX>:!I/Q%_9SU'6[7X6_ +3/B-/XF^!7P3
MOM?^'/C'4OAU\)K[PE!XNT_PG<>#X/#OPT\':=J_#+]B'QK\=/V=/VD?@1^T
MGX]_;;TCX&?M'>%?"7A9?AG^TQ\9?@!\3/VC? SV5QXGC^)UQ!\1/@_9?$_P
M9X?\/?$739_ ^G6'A_3_ (H?$4:3%X8U#7]'/@37?$VMVEU]G:9^VE\#-2L/
MB*#J7B33/&7PJ^,?A#]GOQK\+-8\+:II_P 2+#XU?$3PYX(\8?#KP'IVB2H;
M#Q#)XX\(_$?P7XIT3Q=X?UC4_A[;^'=4U+6==\7Z-I_@_P <W'AG?M?VJ/AC
MJ7A?0=?T6Q^(>M:UXGO_ (LZ;H'PSM?AQXNL_BQJ,WP*\7:CX%^+EZ/ .M:9
MI6LV?AWP7XJTZ/19_&6HI9^#==U'Q!X"L/"GB#7K[XG?#:V\6)M).^WN).S7
M*K4Y06C2LE3A*%DG&RDK^Z"5FE'1KF;2W;;ES-W5TY.HU-MOF4K.R;OY?\2O
MV"_AI\6+_P#:IU'Q?\0OB[--^V/^S1X/_9/^-*:?J?P_T^.[^$_@NP^*.G:=
M'X:,/PX\[PYXDO8/C=\76U+6K6:3=-X\O9;"TT\Z!X+'AGX'^.O[+G[0/_#3
M6IW>B^#_ /@H)=^!&^"OP#^"/PZ^,G[%G[7O[.7PRTS6?"GPOB\?:E-?_M3^
M _C1XR^$&H^'?&/A[QM\2_%[:7JOP"\ ?%+3M=\"7=EJ=_;P>)T/@ZR_83X'
M_&_X5?M(_"7P'\=/@CXRT[X@?"KXF:!;^)?!GBS3;?4;&/4M-GDFMIH;W2=:
MLM,U[P_KFDZA;7FC>(_"_B/2M)\3>%O$&GZGX=\2:1I6N:9J&GVWFWQ_^*_A
MWP!\0OV3_".L?%_Q;\*]5^+GQ^N/!WAK0?#_ ,,CXUT7XYZCIWP<^+'BNZ^"
M_BGQA>^"_$VC?"VRFTW0[KXKVWB%-=\$>*=7;X3S^'= UNZT_4/$6DWHHV<8
M).*<_@2=G*:J6=HIRYOWLY1<;ZU')*2:<5*22E-VNHN\VU=1@X73<FE:]*G&
M:E:[IQBVFG?J_#_PDN/%7[-ND_ O]I*[L?C9/XE^"UM\*?CK=^(+?3;C3_BL
MNM^"AX1^)#Z_#HWA[P7H][;>-(KK5QK#:1X0\&Z9?+J-S+I_A7PS:30Z+8><
M?"?]CCP3\*+GP+JR_$/XM?$3Q3\(O@_XC^ WP2\:?%#6O"'B;Q9\(/A;XKN/
M!D^N:%X=U6U\#Z./%VKZD/AE\+X-4\<?%ZW^)7C[78_A[HLOB+Q1J]YJ_C2Z
M\4\+X?\ ^"EG[(_BCQIX;\$:/XN^()NO$_Q]\7?LM6GB75O@3\</#?@+2OVA
M_!=[JVE:G\(/%?COQ)\/=(\+>#_&^H:OH.KZ7X:T?Q-J6E2^*+J'2Y-!-]9>
M+O!-WXD]$_:__:KT7]D?P-\-?&FM>"_%_C:/XD_M'?LX_L]VMIX3T74]7.A7
M'Q]^,W@SX5'Q7K*Z59:A?"Q\/0>*)K^PTNPL+[6/%7B&/1O"6CV;WNMK<6K;
M^WM[1Q2:NE*4E%1M9VYG'$146DI<M?22C4945]A:\JDW%K5*+GS7YE?E3P\D
MXMN/-12<7*G&W8_LN?LY^#?V2?@)\-OV<_AUKGC'7O 'PFT"+PKX+N/'FI:3
MK'B6R\-VDLKZ9H]WJVCZ%X>AU&'2H9?L=G=WEC+J<EK%$+^^O9U,[> >-_\
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MQ ^(J:MI?Q/L_B8?$>G>.M;TKQ9<^(-/L_#=OH/J_C;_ (*-?LK_  _\._\
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MX@MOBY\/_B'XH\&?$'7+7XV:WXYT[Q9X[\:>)I/B;X$T7XDW_P 0+'QCX?\
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MV_BNUUCPQK=]J=C<?#CXB>./#D-KI^I:.;7_ (2.?5[>6/7=.T/5-*^?9/\
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MXL>,OA_X)^'7PXTO6?%4FI^$K[XF_P!G:YX&^$/PQ\*^// VD?$K2_AO\0]
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MA3X(D_8@;1_&GQ7DB_8 \#:M\.?@7:ZAK?A&YAO_  KJ_P -K+X1R6GQ"=?
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M?AU%S=]_P4!_9=T[2?&&MWGBOQU#8> /VK/#'[$GC7/P-^.;7GAC]ICQO>>
M]/\ !/@+5].7X<G4+30_&-]\4OAK:^%OBR]K_P *9U^3Q[X1;2_B'<Q:]ITD
M[E/GDYN3<YN3<KM2<JLZ2D[Q<&I2G6H)647&52@X<C=*2(Q4(**BE"FHZ-7C
M%4HU'&[DI*T8TJU^9NZA74^?][&7J_PN_9_\/?#?QEXI^*.J>*O&/Q4^,/C;
MP=X$^'?BCXM?$1/!5OXLU+P%\-;[QAK7@SPC%I?PV\&?#KP#I&D:5XD^(GQ
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MT/P1\/--TGXA>'=0U[XBZ!X]^S#^Q5^T_P#"GP)_P1C\)^,O 6@+??L,ZO\
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M=J$(-N[]G"$:2IR;LY0E"$8S<FIR]Z3G%SDU^+OPZ^ /[07C_P#9^^+WA?\
M:5_X)F?L#^"M4\1^"-)^$'CSX3?!SQ_I6O:5^U/I&L^+/"B?%;Q;8^)6^$/P
MS?X*^"8?#&FZ[XF^$G@KQ-XA^(/C'4O&NIZ+_P )5XA^'-S\.M.\2>/<&V_8
M<^(UY\ =3^"7QC\ _'K]H/X*6O[6UQ\4OV9-)\2?M.VFG_MW_L2?"_3/@C8#
MP3K7@+]IJU^(^B7VO?$OX?\ [1Z_$72?AY<77[0NO>*-'_9E^*%CX?\ %WQ6
M\;C1=;^$=_\ IK^R;^TGH/[6_P #/#WQU\->#?&/P^TKQ!XK^+7A'_A#O'__
M  C7_"8:'J?PA^+_ (\^#FO0:Y_PAWB'Q9X76YGUWP#J5[$FB>)=<L4M;FW2
M/4KHAI#]'TG[UW=+GC3;Y;)2BK5827*U;F]JI0<''V<9J-*4(-PDDDDDFVH2
ME:^K4D_9R3<HR;_@N$^92]HX-U>>24U_.1\?_P!C#_@IO\6/V</B)^SG\3+K
MP?\ M.6_Q%_X)>_$/X"Z#XL\2_&;3_A_:>%_VLM6OOC58)XO^,WAW2OAI:67
MQSU_4_AOXI^ ^F> /'UW:1>'/"/Q9^%WQ(\<Z=X8^%%S\2CXMK]NOB1HOBOQ
MK^S'X]\.:O\ !GP'\0?%_BWX+>)]"U3]GWQSXFL]1^&_CO4]=\&7NFWWPA\9
M>+[GPU/IL_A+Q6;F7P?XCUZ;PEJ&F)INH7MZ^@ZM9(;*Z]]HHE:2G>UYN+DT
ME=N/.DWHDW)3FIR:O--_!HHBBDXN[]R,HQ3;T4^1M*]VDG"+@DVH627-N_YW
M?%G_  3@_:DB^#&LZ#\%I[C7? 7P"_:C^!7[1O[%W['7[='Q-A^--I;^$_ '
MPX\7?"[XX_L[>-OC U[\<;W0_A7X]\'_ ! UY/V?=+\0>)?C#-\)?%.@>'=6
MO-4T'1-1BT/P+[#X\_9R_;-O?AW^S%^TE\'?V6/V4_@C^T9^S3^TUXA^.EK^
MQ/X0^)\>G_#3XA?#/QU^SWXV_9W\=^"O%'QV\-?"CPGH$?Q^O-%\<7GBWPEX
M]A^'%QX"\+/HV@^ ]2/BW2[;4?%6K?N#10WIJW=2IS3;;DI4TH\U]YN<4HU%
M4=1223TG>;.5=5I::<5I%QG)RY4EI%0DW*'LU!IOK&T%^4'Q3^%O[:GCKQU^
MP5^U!J_PI^%6H_%#X(?%OXPZO\2?V?O"WQ@D.B>!_A_\;O@EXG^$VDC0/C)X
MC\ >&H_'^J^ =9N/#WBKX@3/X#T&2]LM9\7V/@.Q\22>&/#5KXL\'\)?L:?M
M9>%_@U^QMX-UCP!X#U+Q-\#O^"L_[1W[9/CF/PI\4()]-_X4;\6/C5^V/X_T
MV72[KQ%X=\.RW7CY;+]IC0A9^#!')I-SIOAS5+C5O&VA:O=6V@C]2M _:1T#
M7OVK?B7^R6/!_C#2_%WPS^"'PI^/-WXPU/\ X1H^"_$_A#XO>,OB?X&\/V_A
M=],\0ZEXA.IZ7X@^$7C&T\06_B30?#;6YATZ?2UU:PU"&^KZ-IQ7)*%1+[3J
M4T[V7[^G4=DWS-.MADVY/F?O[*2!M3C4I.3::5.JNK:HRA&[M9-4L2K<EH_
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M.]9_9;T+X0?#OXVZ1^W/\._VN/%_A/X*_"FYMO$>F>%M?\*^%/V>?V<KC2/
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MREH/PE^-6G>$=,\<Z7\6?VEO&#Q>"_$M[XIT>70/BY^TE\5_C!X:EEOKW0=
M:TU1-#\>V=KJ6EP)JEM97-LP36;QI)$@Z3X#?M=W'[27P(^ _P"T!\*_@-\4
MM0\,_&GX@ZOX4UKP[K.M_"30_%OP:\*:%XE^('A/6?B)\0X+GXD/H&L:7HVN
M>"+73]4\/?"WQ#\0_%$D_B?3I= TS7],T_5]2M/LD?3%+X4UM%QC%*Z:4(K"
M5*:C9_"HPP[C)WO&32;N^0TO:UFI-O1J\T\32ES)WM)2E6C*.C4HIM=9_@CK
MG["/[61MOC(?#OA_P#'KOPO_ ."M^E_\%*_@%=WWQ,>T\.?M ^#M7N=,F\9?
M![Q);VWA*_U/X9^(8O WB/XB>%])U[7;35]&MOBGI?@G7EBO/!TM_J^G_HE^
MSY\!_$FC?M.?M6?M=^+=%N/ >I_M*^$/V:?AOH_PQU"[\/ZGXD\/>$OV<=%^
M)UQ:>)?'FH^$M5\0>$X_&_B?Q=\:_&^D'1_"WBCQCHEGX"\&_#[57\3+K^O:
M_P"%/"GVY14I)*'7DCRPOT_<4L-)]%S2I4:46[6O#F24I2;?\UM.>3E)+K>M
M4Q"3>KY8U:U645H[3Y6W&,;?DV?A;^WQ\#OVT?VF]<^!/@KX&_$[]G+]N'QA
M\+OBKJGQ%\=?%+6?AYXT_9%^*?@?X#?#C]G'Q_JE[\-+3X<>-_\ AHKPUXH\
M!_!OX8>,?AUX;T;Q?\,KB7QSIWBCP/XR\0>#/"VMV'Q'TOQ;QO\ \$_OCEXD
M^#'_  46_8;O[#2]=^#/[<_[1?C_ .-'@;]H)/$FD)+\*? /[1?B/P5XI^.G
MA+QWX-U)XO%C_$WX8Z]:?$?5/V?KGP9IGB_P7XSM;OX9Z-XX\1?"?^S/$&JV
M?[FUY[XH^)GAKPSKT/@F.27Q!\2]3\ >._B5X6^&6BW.CP>,/&7AGX<W_A#1
M_$\^@?\ "1ZKX?\ #D+6NO?$#P1H27/B'Q#H6E+J7B?3?M>I6MFM[>6A*480
MO)^["#3;W]E2G3Q"C*V\:3PT)II<SC!J<IQYFA+5\J2YIJ22LDJDXU*,IIMZ
M2J*O.,KRY>:2<8Q:/QP_:*_8R_:9^(?A#_@K%X?\'^ M%OK[]L;]I']EGXG_
M  5?5?'OAW2+"7PO\&_A/^R7\-?&LWC"97U"Y\-7DU]^SOXIU?PY:VMEK<NJ
MZ7XB\'IJ0T*_G\06GASU3Q[^S5^TA-\<?^"G7B#PU\.O#VN>!_VU_P!D?X6>
M$_AWX@NOB+H^B:KX=^)_@GX4_&+X77O@'Q7X<DT^^,/FZCXU\->(F\5Z;JU_
MX?B\./K7V>:]U_2K'0=<_0_]FCXZ>'OVG_V=?@3^TCX1T?6O#_A3X_?!_P"'
M'QF\,Z%XD%BOB'1_#_Q,\(Z3XRT;3-=72[O4--36++3M8MK?4TT^_OK)+R.9
M+6\N80D[^TSSPVT,US<S16]O;Q23SSSR)%#!#$ADEFFED*I'%&BL\DCLJ(BE
MF( )HJQ4HU(5-$Z4Z-2[46J<L)/"2N[I1:H5&^;2TTIO1235%J,Z=:EK*-:%
M>F[.7[R&*CBH6C;WE[:%N5I\T).&K<9+\??@#^S+^T/\+/CM^Q[\3?$7PYL[
MK0/@/_P2BU#]D/QI:Z/XY\*W.J7/QQ;Q5\ /$L-EH-O>7FG6U[X*GMO@SKUE
M#XNN[S3[P7^O^&1<>&K6RDUV]T+SWX/?LA_M7_ SP5_P1DU;2OAMX)\;^,_V
M'_V6O%O[(GQW\&3?%.Q\+VEI-XV^$7P0\#Q_%OPIXI;P]KEMXB\$:)XM^ ]K
M/J^D)IEMXZ;P=XUCUC2/"VK^(M!N?"%Y^T/@CQKX6^)/@OPC\1/ VM6GB3P3
MX]\+Z!XT\'^(M/\ --AK_A;Q3I-IKOA_6K$SQPS&SU72;^TOK8RQ1R>3.GF1
MH^Y1U%6W+VLZDM*DJLJDDU:TY8G&8B:Y79Q3JXS$)Q>L8\L59T[O.-.GR0C'
MX8TE2BU*]X*AA*,)<UVFU#!X:2DM)24I-.-1H_F[T;_@GY^VA\*/@Q^PKXYL
MO@%^RO\ M)?%']EJ\_;A^'WQ4_95^)GCRU@\&_$_X,_MB?&_PY\7M+\7?#_X
MK^+/A7XI\/\ @/XQ_#7Q)\+_ (7ZG/H^K>#]9T'5/">H?$7PQ9>/!J,^ESZE
M^\7P!\*^(?!?PC\'Z!XL\#_"OX9^(HH=6U/5OAU\$HG_ .%7^!KOQ#KVJ^(6
M\)^%-1E\.>#)?$T.A+JBZ=JGC>7P5X)D\>ZY;ZIXT;P3X..O?\(SI7L5?.O[
M6_[1FC?LB?LT?&[]IWQ+X*\8_$+PQ\"OAUXF^)OB?PKX!?PLGBJ^\-^$M-GU
M?7;G33XR\2>$]"9=+TNVNM3O8Y-8&H26-I<IH^G:SJS66DWL74(6;7+'D2;6
ML5&%"DE=*[4O94G[RDU)M0<(2<5M9U*CDDW.<INR;M*4YUJK=I-I-.K42Y7%
M.*3DI2BI/\E_V2/V-/VP/V:_#7_!.[QEK?@#PMKGB/\ 8E^%G[3_ .Q_\4?A
MCX5^)&BZQJ7Q8^#/QI\3_"?Q-HGQU^$&M>)4\%>$-%\26GC?X!_#W5+CX<^/
MM8\,7M]\,O$WB:6^\3:?XW\)Z)X)\4_I)^Q#^S=K/[.'@+XO+XHFL5\8?'O]
MJ;]I#]J3Q1HFCWTNH:%X0O/CM\3=8\5Z1X/TR[DMK075UH'A$^'+3Q;J-O"N
MGZUX^_X2S7=+ TW5+15^SO\ /^?_ *^**I-J/+>ZY>6]E>S>'E+RO*IAJ=1N
MVCYHPY82Y2%%7;2M>?/;^\E747KJN6.(J06NJY7/FE%2?XB>'OV#OC@O[..I
M?L">)-,LS\+])_;[L/VH_"G[2=GXQTZYFU+X%VW[?&F_\%!%\)ZQX<+V7CJS
M_:*;Q7'J_P #KR:TT4?#E/#4UA\;X/B->^(FO?@TO4?M5?\ !,OQ3^T=\8?V
MM;:T\<:=X-_9Z_:Y_9[\(ZGXMTW3+O6[;QEH?[=?P8T'Q;\-_@A\>+5+>X&C
MW6C^&_!&M?"OQA/#+:G6++XJ?LH_L]>(=(OK2#0M9L]:_9.BDDXQC&,I0Y%:
M+B[2NL/2PT)WZSI4Z&'G3DU+EK8>C6M[2!3M*4I249.3NU)*2:=:=>4;/[$Y
MU:T9Q5DZ5>K2OR3;/R,^*O[+G[2/BW]GO]AC1[[0O"GB[XZ^!_VR?V=_VN_V
MKKO0_$=KH/A5?$NB>+-1^)'QUL_AO/XBEFU36=(TGQ#KUYX/^"WAS7+XS0>
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M-<EU'QUH.LV5A'X\\":?-K%KXA']N0^-_ EM+>PZR-$1V!\9\)>$/@7\-_\
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MUFX^'B_#/Q)H$4>M:=IOBK3_  ]X:NHM$\?7FF:_]K_&WQ7\.?B/^T?_ ,%
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M_:4'_!OMI?QJ^(VD?%[3?B7_ ,$H_P!IK3/C%H'C#XHW/B/P]\3O$_@WP/\
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M\(OV=_C1^R=^UY\?O^"</QK\=?M1ZCX(\>? /]M?X.Z%IT'@?1_V9K/]HO\
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MD^&?B)X*U;5?$O@7QQXET30?$-FVJ?#_ ,7:GX(OO#/B'3[+4]6T[2]>\/\
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M&\(>.?C;J/AO_A5?[5O@K0_C+XKM?'/PE^/?@Z\M?'T7A/6?"&B6O].X &2
M 6.6( !8X"Y..IVJ!D]@!T J)+:WC22*."%(Y7FDEC2)%CEDN'>2XDD15"N\
M\DCO,[ M*[LTA8L27)N5]HJ5/D<(^["+]K[5^SNI2IQ4G)PA><?>4*L:M*$(
MBY;6:U:J<ZDU>3]QP]^SC&<I1:C*5H22BI4Y4ZCE?^83P_\ %_X+^+T_9&^#
M'QY^$7PE_9[U;Q#\8/\ @H)X'A\,W?C^Y^+_ /P3<^)/Q/\  EY\,])\8>)/
M@-X&FT7P3J7[27C+XN:M\2M6L/V6?A/)<?#/7OA/J5W^U/H5LWB;QC\)=-\
M_$']<?\ @D?\29?BW_P2_P#V /'=]XZ/Q)U_5?V0_P!G^U\8^,IO$8\6ZIJO
MCS1?AAX:T7QU%XE\0M>7]SJ/C'3/%EAK&E>-#J=Y/KEIXLLM9L=?*:Y;:A%'
M^A<<$,4<,,4,445NJI;Q1QHD<")&8D2%% 6)4B)C18PH6,E  IQ7CEU^T?\
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M#Q%=06<_[:FN:KXRUCPUKM_K\FO_ !GUG1=%T_3?&^I-8WOP_?Q#_4QM4'(
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M\3KOX*:'XEU/XE:)\#?'_C#X7W>L^.?$]E/\1;WX4^%;N/PSJEQIZ^(!\:/
M'Z32?$SXL:A^QA)\8OA-#\+?VC?CC>_LP/\ $OX:6_PQUE=.^"_QW^+%Q\*3
MXH\'0_#[Q#K'B.XCL/A?\3_&#Z='X3UG5/%TZVOA36["]OO$<@CEU,\+\.OV
M&?!/P<\$_#OP/\(/B]\?/AS9?##6/C+J_AW4])\7^%=?O[[_ (7YXY_X67\2
M]/\ %5AX\\">+O"WBRSU#QW)>^(]#FU[PY?:MX0N-2O+'PIJ>C:1]ETZV]DT
MC]G'X6^$_P!FRP_9/^'VGZY\-/@YH/P9B^ _@^Q\!^*?$&B>*O _@&R\'CP/
MHQ\)^.GU"[\6Z=XJT#14@GT?QI-JUWXH@URV@\03ZI<ZR)+R3+5TY)_Q'[-\
MR7+K[&C&K9:14?;1K3II*+M-QGI[.=/174HM).,>9--NTDJM25.^CE=TW3A4
MNYJT5*+YN>,_R]\,_P#!4&;5OAUIVI^#O%5M\3OB!X[_ &H_@7^RSI?PG\9?
M!/5_V=OVB?V>?B;\1_!FI^.?&G@#]H_X._%_XD>"+"'Q:NF>%_$\GPAU>T\3
M>"?!OC235_"/AC2=3\=_V+>?$;XB;'CS]I[_ (**_#:\_9X\!>)_"7P+\%>)
M?CY^WOK?[,?@OQ-\2_"DGB'5M3^ VO\ [+7QF^./P^^+7BCP;\'/V@=7T#0O
MB;X(\;?"#7/!WCCP;IWC ^%_C1I.DMJGA;5OV?)/%T8\ ?5?Q'_X)Q?LY_&K
MP7\9O"_QN7QS\5?$?QWG^%-[XV^+FJ^([3P1\6[#4_@'J=[K_P !]8\"^*?@
M]HWPUL_A[K/P=\2:IJ_B/P7JO@W1='OCJ^MZ[+XBGU^WUO5;:\^5OCW^P'XH
M\,:?^P%X(^!,_P"TA\4H_A1^WIHG[1WQS^//CGX_:7X\^.MII&D_LS_'[X/V
M/CG6O&_QU\8_:O%ESI7B+XA?#VT@^'6B>'=9\$R^!=&\1Z'-X$N='NKGP[XB
MTI\KG'G6CE!-*346I6YHJ32</9RC*2G-N\*JA)R=*,Y)II.SNE"JTVKRYHQJ
M.FVHW4^>]*+A!*TJ3DN559Q4/@S]M/\ :JTGP5\?/A;\:?$/[-FE_'C]FC]N
M[X2?LK>,_C#H/A3XI:-X-^*OPC^+'P\^#7QT\/>,_@G\ M/O?BUXYUK]J+Q%
M\*?B]9>$-#^!-CXO\9^'K'XFVDOC276?$/@BRF\%7O!Z1^WW^V1XQ^''[.%C
MX5C^ ?A?XI?$O_@J+^UQ_P $Y_&^N_$/X8^,O$6BVFA_ ^V_:_N_ 7Q8M/"/
M@?XZ:1#:>+K.P_9U\,R_$/P+:^.M7\->.]8U3Q)IWA'QG\*],O\ 2=7\/_?'
MCC_@GM\"O'_@K2O#FKZO\4=/\;:3^TEH?[7\/QU\-^.)/#_QJN_VD-"T(>"8
MOB9J7B/3M-B\/7\EU\+C)\&F\&W'A-OAWI7P=&G_  W\->$-"\,>'O#%CHG/
M^'/^":?[/_A%_"?_  C?B3XVV,'@3]KSQS^V_P"$K:^^*NL>)AH_QZ^(VG^.
M-,\6ZH+[Q=;>(-6U+P]K%K\4_BH=2\/ZSJ&I0:S=_$77M0U^;5K[3?"-QX:(
MN%[34FOW:DTMW%4%.45%P:4^6LG&RU:DM9OD4U/E?LVE)N;CS;14G7Y4[\R;
MBW1=[MV3@](^_P#-7QA_;&_:E^!_CG3_  SK'C'X"?$JX\ _M%_\$W?V>?B%
MI_PU^&WC=X=6TS]K/XA?!3X0?&7XC?%.^U7QZ^A_L[^.'\7?%ZV\5_L^? G1
M?''QF\;:9\/K'0O%OQ&L_&G@OXHZ;XN^&G&ZE^V)\;?V?_'O_!7?XE^._&FC
M_$CP?\"?VI/V5?@)\$_ U[X6CT.#P5=?M#_!;]C"/X?+-X@O?B5H'A[_ (0?
MPUX__:4UG7_B%#K8T+4O$=Q)JVO/\2?!.@+I^@^'OL?XH_\ !-/X!_%?QU\7
M_'>K>+OCYX9N/C=\4?V>?CKXV\,>!/C/XJ\+>"!\=/V8]2^%]U\,OB_HWA>T
M>2QTWQFNE?!;X6>&_$(S/X=U?3_ _A_6AH%KXWT^#Q8G6^*O^"?'[-7CW7/V
MLKSQ]H7BSQOX/_;:\(^'_"G[0_PE\2^.?$E[\+O%MQX?^'_ACX50>-]/T"*]
MMM1\-_$:X^'O@3X?^&_^$VT/6[+6M&/@;0?$'A6?P_XLDUO7]8B+MS.4>:3@
MU"*;BE*2H.:<FI?&Z-2$9\LG35;GY8)2@B<7*4;/EC&<9.]Y-\KKQC)*ZUC&
MK3G*%U&;HN#;<HS-K]FSQ=^UEK/C[XU:'^T)\/--\-?#/3F\"ZQ\ /%]X_@/
M2/B/XCM]8L-:C^*'A/X@>#_AY\5_BYX9B7P)XCL-%NO!GC32];T+_A(_"GC.
MQ\.:YX6B\2>!=4\:>/OR"_;[\6?&'Q7:_P#!Q!\//%OQ#TOQ+\&_AM_P2/\
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MB_XA+XJ\4_$O7/$_@/QEXJ\)E_$6L367AK1=7@M?!-EX7_X1OP>WAWDO$/\
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M\*/!7P6^%>GO\/O 'PT^'OAOX7_#C2]$E%_)X)\'>#/#EEX4\(:?I,WBB/Q
M+UO#FB:;I]K8R^(8];-P;.-]5742\XF^3/!G_!.GX'> /AC^RG\(O#'B;XNV
MG@G]BWXE+\5O@!:W7C6SU35?#?BB+PKXX\#6T6M^(=2\/W>N>+]$M?!OQ/\
MB1X:32?$U_J=O<:9XSOUOC=W&D>%+CP]NO9^UJ2DG[.<Z?+&*Y;0CB*]5NT7
M[MJ=2,5"+W<HJ:4;SRE&I[.FHR7/"-2_,W).<J%"G%MR7OVJ4Y2;E'71M7;M
M\_>(OVJOVJ-2C_;E\%?#7Q'\&=2^*W_!.CX1_"-_&,WB#X9>)-+\(_M&_'_7
M?V?;7]H7QG9PZ##\4]2UKX/_  =\5^$M>\,>'? TUGXJ\<^+/!'CK4]7UG7=
M6^(GAWP)-X1^('F5S^WA^U+\>?&MU9?LVZW\$OA7X$\8_P#!*KX)?\%%/AE>
M_%[X->./B)XST;6_BIK/C8/\._'5CH'QN^'NDZKITFD^&M'5=6TE?#]]X7N+
MC7;6?2_&$E_I>H>&_P!"?B/^Q/\ !KXC_$;XD_$V2Y\;^"];^.OPKTWX(_M%
MZ?\ #_Q*GAW0_P!H+X6:%!XHLO#GAWXBVSZ=?WNFZYX:TKQQXST'0_B?\--1
M^'WQ?LO#OB%_#_\ PL"31M#\*67A^;6_V,?A+JWQ5\7?%^QO_&?A3Q-XP_9M
ML/V3+C3O".J:-HOA+1/@EI&JZ[KNC^'?"_A=?#T^F:'?Z1J_B?7[S3=>MHCJ
MUK'J TM+D:+IVD:;I^<KNE4C&RJ2HU5"3^SB'AL;"$VW=>S^L3P-114/<5&K
M>+4G"KM#E52#E>4%5IN<;_%05;"2E!+1^T]C#&0<W.\_:TU=.*E3^/OV5_VR
MOVCOBK\8_P!B!OB7/\('^%?[?/\ P3Y\9_M?>%? G@KP#XLT7QC\#?%OPZ'[
M(&HW?AG5?B;K?Q.\0Z;\5]%\4Z9^U9>VLMU#\,OAQ=:)>>!-(FM8KR+6-45?
M1?VGO'OQKTS_ (*(?\$XOA=X(^)&G>&?A?\ $#0/VN?%WC[P7>>$)]8A\7ZO
M\,/!GP[MM)GU/5['Q7X=U$+8:#\0_$]MX:T\-+X>TSQ#?KXI\2:#XTO=(\+6
MWASVWX;?L0_"3X5:W^RUKGA76OB&)?V._@+XC_9H^"5EJ7B'3+ZQTWX.>*[?
MX;66M>&?$9.@17_BNYN++X,_"*V3Q!K%]/K\1^'NE7BZD-2UOQG>^*.\^+_[
M,7PZ^-'Q.^ ?QB\0ZCXY\/\ Q!_9QU_Q?J_@'7? OC#4O"KWNC_$'0K70?'?
M@;Q9!9^9!KO@SQ9!I7AV]U2P*6FIQZCX9T>;3=8L(1J-OJ.M25-U8RIPE&G'
M$UI\KNVJ,JV,=&+U:FZ=&O1BU=_PK7DXPD8*%3V=6$I7E*G24)7UYXPPW.[I
M)Q<YT:CYN]3FLDYQ/Q(_9=^-WQP_9N3PY=^$KGX23_L_?&#_ (+E?M]_LN>,
M_AG=>!?$A^(@/Q3_ &M?VI;S1_B-X7^)5CXYT[PSX8?PAXP\/:%9'P!<_"WQ
M+9ZWX4?Q#=2^,=.UC5]'MO"7T[+_ ,%"_C#>_L_>!?V[?#UAX(OOV>M9_;HF
M_9:\4_!BZ\-:VOQ M?@]J?[;.I_L ^&OB?X=\=VFNS_:/BY%\5?^$?\ C+KO
M@^^\&'PQ)\.=2U+X)V5E9^-]$C^-6N?5UO\ \$Z_@A;Z'X9\/CQ-\69-/\)_
MM?\ B']NG2=_BW2EG7]HSQ7XN\3>/O$'B6XDA\,PK-X<U+QCXT\6Z[)X#$:>
M#H)M>N;"TT:WTBSTC3M.Z_0_V&O@CX>\1:]>:<WC,_#[Q#\>T_:FN_@5>>(8
M;_X-6O[1R^*++Q\_Q;TS0;S3)O$>G:@_Q,TZQ^+:>!K?Q6OPFL_C/;+\9].^
M'ME\4Y;CQ?-,6N:'-=PBZ6EK2<(+ J<&];QG&EBZ4+*]/GA-6BU[.N62C-*T
M7)56FKV4YU,?*,[::Q=;"5):I3=.HI)O2I\CV7_!0;Q1X2_:0^*GPE^/5]9?
M!3Q-\-;G]ICQUI?P%\;?";Q+::A^T/\ LR?!OPUJGBKX?_&3]CWX_6_BIOAW
M\8O%=[X8G\->(OCE\+GM)/&?P_N]3UOPQ>^&/ EM\+[WQ?\ %GTO]D?]H/\
M;#^./B#X%_$OQ;\,?#.G_LR_'G]G*P^)U_KKW?PWL=2\#_$WQ%IG@WQ?\/M.
M^%^K^#OCE\2]2^*_PL\8^!=:\2QZE>^*O!/@7Q5HOB'PQ8^+;6ZN/#GCA_ W
MPX^A=,_9 ^'T7C_P[XZ\4^+/B7\2H/ ?Q*^+?Q>^&'@KXC>(-&\0^$OAC\0O
MC=8?$;0O'VM>%I8O#5AXQU"PG\(?%WXE^!O#OA7QKXO\6^#_  9X,\6W?A_P
MGX?T>TT[0O[)\V_9-_X)P?L\?L7ZW?W_ ,&M8^.EQX:M;;4]*^&'PK^(_P ?
M/BE\2_@]^S_X;UN[COM9\,_ ?X:>+_$>I>%_A_IM_<Q!/M\5EJ/B33M+EOO#
MNCZ]IWAK5-5T>]FGHUSZVC9/5WDG53YHZ.\XU*4DXRY*<\/=>[5<%<];N/NM
MSNUV7[MKD>MHQ<*D7&4>><:VKO34G8\??'CXG^,/VP/%'[&_P=\0^#OAOXB\
M!?LG^%_VEM<\?^-O!5Y\1H-2U7XI_%+X@_#+X3^'K#PC8>-O LMYX2T;5/@S
MX_U+XN1)KND:_K.DZYX-T3P7XI\%ZK<:AXDL?SJG_:8^+O[9>D_\$.?COHS^
M$/@]JWQ0_:[^->E^.?A]KG@W7_'VD:)\8/A9^PU_P44\&>-WM=4L_B)X$N/$
MOP^LO$_@;Q2O@>TGL]-U*\-SX4\<W>L++I)\.7WZZ_$K]E_P#\0_BWX,^/MA
MJ_C#X9?'#P5X,\1_#"U^*/PVO]$T_P 1:_\ ";Q;JVE>(M>^%WC"P\3^'O%?
MA7Q1X3D\3Z%H_BC0+C5?#LWBGP'K]MJ-_P##SQ)X3/BOQFGB/E+[]B?X+?9_
MV5--\*'Q?\.]!_8NU1];_9_\.>"]?CBTCPUK$GPT\6?!V?4]<'B+3O$6H>-;
MVZ^&?CWQQX6OKGQ;J&L2ZB/%NM>(+]KGQ9/#K\$R5U3M=2C5H3DW=_P\3B)S
ME&UO=GAZE"DJ=OXE+G;T4YC3:JWUYH58P2T5IX>C",9+7WHUX59NIS)<E3EY
M;-PCQ7[2OQ8\,_L2?#'X!> /@A\/OAUX'NOCI^U'\)/V9OA;H-AX2MM"^%?@
MCQ#\;O&6L>(_&'C#5O"7@VX\*I.EEH&G_$+Q9::)I5[H<OCCXCW6CZ+J.N:*
M/$VH^([#\XOVWOVOOVIO!OP:_P""G/P#A\;:#X5^)G[,^B?L>>-_AS\?/!WA
M-[#5O&/[/7[8GQ U;X>'0=<\.S^))[/PI\8?#FM?#+XN>%-=\?>$KW3+"_\
M#=_X8\7> _#WPZ\82"7PY^T7Q_\ V?\ X9_M+_#BX^&'Q3TO4KS1$\2>#/'/
MA[6/#VN:KX5\9>!?B)\-_%6D^.?AS\1? GBW0KFSUKPOXT\#>,M!T?Q%H&KV
M%RJ_:;$V&IVVI:)?:GI=]X_X[_87^"GQ4^$GQ[^%7Q-N/&WC6]_:8TSP]8?&
M/XLWFNV&@?%GQ%<^!]/TRP^&VJ:5K?@K1/"_AOP8_P ,Y=&T[6_!7A_P7X2T
M#P38^*CKOB[4/"VI^)O&_C[5?%+5U)/=1J0DXV;YJ<'@91A%NT:;B\/B%>TE
M.%:--QY%:F32E"45HYTYQ4ME&I-8M2G)*\JBDJ]%VO&49TI34G)\T_R9_:'^
M(G[0?[-?[27_  6+_:*^"OB+X):=\0_V?O\ @FK^PK^T;\0SXR^$'BKQ#X9^
M+0^"Z?\ !2SQMJW@O2=!T+XP>$-5\"77CZP\(_\ ",CQOJWB[XB7GA'3&MA!
MX?\ $%S#;W5E]K_'3]K;]I_Q;\4?CO\  C]B_P"&VG^(OBK\%/V;O@A\:M&N
M/%MCX&U/P9XC^(WQ\OOC0? '@/XE_P#"3?&SX0^(O"OPODT[X-7%CK7C#X=V
M7C;Q3-JOBN?4]/@TQ?AE=^%?BA[?XG_X)]_!KQK:?M)VGBSQ7\7?$ _:X_9W
M\'?LN?'NYU;QG8WVH>,_A#X*TGXAZ)INE1:E<>'9+[P_J]]8?&#XMIJVN^';
MC2]1N)?B)J\]M+9RZ%X';PIB?&;_ ()K? +XW_$?X5?&/7/%_P"T5X"^+GPO
M^'6F?!F\^)WP*_:%^)GP \<?%;X+Z9JD^OQ?"7XN^(/@[K7@R]\4>"V\27=]
MXEMDTY]!UW0O$&H:AJOA?7-"NKVX>0A>,8Q?V6DGJTERXKWEHGR*I.A*5)IN
M474L^=2YW)RE/F7PNFDTW[W.G0NKKO3C5A&=[1:C=.+BX>;_  H^//[9?QA_
M;8^,_P &I/$/[/OPL^%WP&\"_L9?%CQ)X/N/A3XQ^)WQ"U[2OVA?"?QKD^(7
MPKB^)^E_'?P=X/L=9\,^)OAU:7/AKXMZ;X#UK1;ZQ,-G<?#2>..YU+6>[_;[
M_:M\;?LG0?#+Q?=6>M>#/V>-4L?B>?C5^TOI/P<\3?M!:+^SWXE\/:+H.L?"
M>_\ BW\,/ NO:+XVT[X"^+67QW_PL_XKZ+'<VO@C_A&/#OAG5M6^'L'Q%B^*
M?@?Z#^&O[+GPT^$WQI^*GQR\%R^(=-\2?%_P5\*?AYXG\-+>:5%X T_PC\#[
M7Q'8_"G1_"/A2QT6SMO"5MX.L/&/BVQMH]%GM4U6VUZ1?$*:P^D^&WT3H/BK
M\$E^)^O^%O$]I\4_BS\,M8\+^&_'7@\/\-]=\.6VE^(/#?Q$NO!EYXBL/$GA
MSQEX3\:>&M0OH9_ FB_\([XG@T>S\7^$HKG7X/#/B#2H?$FMQWQ/F<$HI*2O
M*UY1NW.O)1<US34'"5""<5.5-0<HJK.,E6(+ED^:3FGRJ]E=14**<HP:4'-2
MC5E[W+"HY6E[.$H^R_(+XF_MN?%_X(_M&_M$?&[Q5\2O OQ>^ W[.?\ P1C^
M'/[:8^&OPLTVXE\$?$;Q-KOB']H2\\5:O\+/B5;>)KZ/['\1]1^#G@MO#/CC
MQ)X?\;:+I_P^.GVFC:#H]W>>*?%GB7Z:\9_MB_%O]EOXZ?"3P#^T3>^#_BK\
M/OC=^RE^T3\=;?Q-\(/ 6J^&]9\ _$[]E+PWX \=?$OPM8V>J^./$%GXF^%G
MQ(\"^.KF\^%TVHS67B[P?XI\$W>D>*O%'CJT^(^B2?#_ -MM_P#@G5^RUI_B
M?PAK.D>#]9TGPKX4_9'T_P#88O/A!!XHU>^^#WCS]F#P_9:OIG@OX8_$GP3K
M4VJP^,],\#Z9XG\9:=X?FU.],]U:>,==3Q._B)UT>32>Z^$O['GPK^$UWX.O
M1J7CCXE7'PQ^%&N? 7X33_%K7[3QI=_#3X(>)+KP=<Z[\,M%U%](L-3\2Z=K
M:?#KX>6GB+Q=\2KWQW\3O%EIX(\/)XM\=:[+;7,UVYZJ:@W!\M94I.*M%SEF
M3@Y13=_?Q&!K)7M3CAIT;M.*E%-.,DYWE%RI.:4I)OEAER:4FK_#A\;3D]'-
MXF%6RDI./PI\0_'_ .T?\;?V#?B%\:/'VM?L\:S^SY^T?_P2_P#BY\4-0\%Z
M)I_B2+QEX*^+GCCX,Q>.O!'A7P!KM_=:IX9^*WPGF^&.K>+(O%FO^([3POXM
ME\8^$].\8^'M'M_!_C6[\$_#3@/V4_C!KG[1?_!.?QW#I.L_#J7X"_![]BB#
M]G+Q'\-M=^'_ (I3XV/\:?A_^SI$_P 0=6\<WFO^*M)TKP?X"US1-=\$ZK\,
M?!6I?"F[UOQGX&N])^,]EXZO/ OQ2\&:7IOU/\(O^"4?[,'P/\"_%/X8> O$
M'[0R_#GXD?#SQG\'O#_@/Q7^T'\2O'O@WX#_  @^(:1Q^,OAI^SOX6\;:QK^
M@?"GP_K<4<<$FHZ7IUUXNLK2"QT_3?$MEI^EZ5:V/7^&/^";WP$\$:MK^M^"
MM>^*_A'4?&7[+O@K]D'X@-H/C*RM+/XC_"'X:Z1X@\._#J[\=Z6_AZ;2O$/Q
M0\#^&O$FH>&/#?QAN;)?B78>&%@\._\ "32Z,;FRN9KQC4HXRG3CR+$4*D*4
M)WFZ4I4L?&E"=16=14OK4*7M7'F<4ZJC*47$NDY0J8><Y<SHUJ<IRBN15(QG
MA74E"G=^S]JZ$JOLU)I/]TY1BXR/SO\ V1/VOOB[^S'\(/V2_#OQ@OOA_P",
M_P!G1O\ @A_>?MH^'M$\ ?#[Q'H?Q7^'Z_L@> ?V4=*\5^$M1\5ZM\1==\/_
M !5;Q_X=^.JWFF7MKX)^&+Z)K'@V.V%A>6VO2/8?5GP]_:]_:#L?B-_P3>C^
M*EO\,/%?PY_X*._#OQ2MQI_@70]7TF^^!?QITK]GC4_VH?#NF:#XDU'Q'JL7
MQ)^$FN_#'P3\0_">IWFL>']$\5Q^/M+T+Q?8WEMX5\82> ? WTQX!_88^"_P
M]UKX%:OIMWXTUN']G;]F?Q)^R#\/=!\6:MHWB'P_-\ ?%K?#LZ_X+\6Z?=^'
M0_BR34E^$/PKBN]>UBXGUZZA\#6$=WJ-PNN^,AXFN?!']B3X.? 6W^%VF^$[
MWQWK_A[]G[PMXA\!_LT>&_'_ (FC\8:;^SIX$\366DZ1?^%?AM>:AIB^(=3@
ML/#>A:1X,\+>(?BAK?Q%\:^"O -OJ'@#P=XGT+P7XG\7Z%X@TJ3E4K5ZC::G
MB:]2'-'7ZO/$XZHH35U&56=+$8>]1M^SE1<=4DZF=*'LZ-*GUIX>C3?*[+VL
M,-A*;G%N[4(U:%9^S2M.%5/25^7\M?\ @G]\;_$OA/X;?LK?LA?"_P#X1WPA
MK?QZ_:3_ ."T_P 0]3\8ZKH<6KV/@_X2_LX?\%%?C+I'B#0_!/AJ+4=)T^7Q
MYK_BOXV_#2U\-OJL.H^%]#\):3XWU&^T35+NST?3KFM^R!^T%XY^ 'P'^%_P
M3\/^&[+QA\6OVC_^"K'_  5K^%/VCX=^'O#'A[2]*@^&W[4?[<_QA\?:[\./
M!7Q)^)_A[PY:W<]O\-CI7@OPEXG^)FHP>%M(UBX\1ZC+\0H_!%SX6\6_?-Q_
MP3 _9U_X0WX1^'-&U_XQ>$_%GP"^,?Q@^.?P4^,WA/Q]%H?QD^&_C/\ :&\7
M^(_'/Q[T[2?%UOH1M-:\"_&+Q%XQ\57/CSP!XQT3Q-X2U.WU:ULK?2;*U\*^
M"(O#+/%?_!+#]E+Q=\!+W]GR]'QHL- C_:/\<_M<>"_B#I7QZ^*L/QI^$O[1
M?CWQSXS^(.I_%/X3?%:Z\2WOBKP3XAL]>^(/C#[(UC=R6FH0^(==G\36WB#5
MO$/B+4]6BG[M.*:?.J=*G.SNIQA+"749-1<>2%&:5[*<HW:M54J.E;][B)5%
M94W6Q%6"::<'4ABHQYDG+F;E5A)V7NQ?+&WLK5OFK7OVC_\ @I=IWBC]CCX%
M^*;?]FSX*?%3]HKXQ_M@?"?6_&7B/X:ZW\5HH_!WPL^$'Q"^+WP ^,-K\/O
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MXS_#[X(IK7C]O%,7ASP?\>-4T#4O'.A7L?B/2=376[**/P;X%TWPVFJ?:/[
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M4K:*)2O;6UW=NU[)MMV5[/E5[1OK9)O5M(HHHH&%%%% !1110 4444 %%%%
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M]^(_CSXN_LU6O[<^D?$3PM\4/#W[47PO^&?CKP/\--/^$GAO1]:\(V^D>/\
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M5^'=.TWQ&NF^"[6]U#QCXC\,:%K/QK^QY^PM^U#^SR__  2]B\7P_ 35K?\
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MLY_&2[^&,7PY_94_;-\<_M9VWCKP-XJ\2:]XE^*QL/BS\9/BY\$?#4/A36_
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MQ/\ ##]B7PM^T#>? GPKI7PLMO@[XB\#WGC?XCG0?'?PR\:>-+;P1-KGQ?\
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M7T:<E%<R9^87P[_;O\6WLUU^U/\ 'O6?VG/A-X,\'?\ !1KXP_L/V7P?\ >
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M6]M#-*2J4U.UKT%.,7?FC-2R^_/HE%RIXJ4HQ<;3AS5(J*BN55DZ=6---/\
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M\)=9\<_$#Q3\3?$-EXL^,/C3PK'XD\#Z_P#$[Q-;?17[:7A_X,:K_P %3_\
M@E<?'?AWX:ZMKUWX<_;$MKF?Q7H/AK4]3:'3O '@^_\ AQ#>WFJV5Q/!%:^+
M)/$%UX&CNYXE'B1]9?P\#JK7V=G#WX04TU.K*'M*;4HR@EB>2M1DU:<*JI4Z
MM.36L)J+;<I..//[E2:@[PA&7).\6I-X=3IU8IWA*DZM2%1*6C@YJR24OUE^
M'WB36?&/@7P;XL\1>!_$7PRU_P 3>&-"U[6OAUXONO#5]XJ\"ZKJVFVU]?\
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M\#:UXA^'?PWO?BYXPT]])72?A]I_BCPYX,O->2]UO3;#4WA\2>+KJS\/Z?\
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M]&DU^#"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC3P%H_Q-\+>%=<\':3\./$/PZ\1K\*?^$5M_%G]C?''6_F_1OBQ\3?VH]?\
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M(?$*P?PP^NZUX?\ $/AS\^+W]OK]K[4_AIX'\-:%=_!3PY\:_"__  5GO_\
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MLD^7I.+/UEIK@LC*KF-F5@KJ%+(2" ZAPR$J>0&5E)&&!&17X^?&?XL_M\^
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MO[1O[-OQ'\(>"_$7PX;6_@KJ/P:\0:/XC\#>)]?\.^*-3T/6OA[^T?\ !?\
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M:'XSQ/'_ /P4V^$?AS5]8T7X8_"7X^_M,7=E^R7X&_;=\/W'P"T'X9:KHWQ
M_9W\?:QK.F:1XL\#^(_B/\6/AGX>U+4HK'P_J_B,^&=2U32-=US1;:"#P;9>
M)_$&JZ/H6H1I!7TC&FFT[KEA&$9UW):RBHPC3JU8U+.$53JN%2/LZD8:OW[I
MIR<VKIIWE*3A22>B;G)U*<'!^_+VE-2A+GA*7QY^RU^PY^T=X3\9^"M2\:>#
M_BQ\ /'_ (:^+;?%KXI>//AC_P %-_VI?BA^R'XZU7Q#\3-1^)WQ=T3X,?L8
M^-M>D\$6?@;XQWNL>)O#2^!OB=\//"5Q\(='\;7?BG0O''Q ^(G@C2/$'BS[
MX\&_\$X?V5_A]^T3XP_:6\%>'?B%X9\6>/O'NH_&#QE\.-'^-?Q?LOV<O$?Q
MSUBUBL]9^/.K_LU0>-4^"&H_&+58K:RO+OQO>^!Y[\>)K"S\?6Z0?$*-O%;V
MO@I^WO\ "KX[?%/X=?#?POX'^+VA:/\ '+]GZ^_:;_9S^+/C3PYX9T+X<_M!
M?"709?A3;^,M8^']E'XSO_BEX?U'P9<_&SX:IJ>C_%WX9_#&\U^P\20>(O 2
M^,/"T%QKD?IOQX_:9T3X%ZSX1\*#X:_%?XL>-?&GA+XJ>/=)\+?"_1_"2FT\
M%_!K3/#M[XZ\0^(/&?Q-\:_#7X8^&H;:^\9^#- T;2]=\=6'B#Q)JWB6&70=
M(U#1-!\8ZQX;;O224DX>SC5C=J47%4DZ=7FN]%36$DIIJU-T7)<K49"355RM
M:?/*$FDDTW4:J4[:7?-]93CK>2J\NMYQ>W\:OV<?AK\==3^%GBGQ5!K6B?$7
MX%^,[OX@?!?XI>#-5;0/'OPU\4ZIX;U?P;KT^BZB8+W2]8\/^*O"6O:MX=\8
M^ _&6C^)_A]XPTVXMU\3>%=5N-)T:XT[@/$'[$7P!\1>%/AAX-FT?Q3I>D_"
M+X^M^U+X4GT'QSXIT?6;O]H23Q-XD\9W'Q/\8:W::DNJ>.]2U#Q3XQ\5:SK?
MA_Q?=:SX)\13:W/:^(/"^J:;8Z18Z;Y&_P#P4H^%NNWOP-TGX/\ P=_:'^/V
MM?M*?L>77[;OP.TOX8>$O 6F/X\^$%EJOP;L;K3!JGQ;^)OPN\/^$?'$6E_'
M'P=XD_LKQ]K'A30I+&*]\/Q>)7\?W_A3P;XF^O/@5\:O ?[1GP2^$W[0/POO
MKW4OAQ\:?AMX-^*O@>\O[&73]4G\*^.O#UAXET3^TM*<R3Z=JJ:?J$,6HZ9(
MSSV-_'<6<A:2%LBT3MM">MOLSC4DKZ=56H/577M*46[RC"0.SY5+[</=4E\4
M'"^B>Z]G6V:TA4DE9.:6Y\4?AA\/_C7\-_'7PA^*OA72O''PU^)GA37? _CK
MPAK<4DNE>(_"WB73KC2M:TB\$,D-Q''>6-S-$MQ:3V][:2E+JRN;>[AAGC\Z
M^''[-_@KX:ZE=>)K/7O'_B_X@/\ #O1OA%IGQ/\ B1XJF\=_$+0?AEX;O-2U
M'P]X3T[Q#KUK<M>-::EJ;ZIXA\6^(;;7/'_Q/U?3]"UGXP>+?B%JWAW0[W3_
M (S^&7[>?PL\&?"?X*:RFA_M=_%!OVE/VTOVNOV:? %MXZT#X=Z]\2](^-7P
MY^*G[4NK^(/AOKRZ'XFT'0?#?PTT.^^!'Q'\#?!G4[JYO(/#/PW\-^"?^%GZ
MWH-M9>(?$MC['\.O^"@'PH^(_P ./#GC"S\#?%GPW\0/$O[17Q"_9+M?V=_%
M&E>!8/C1;?M#_"EO'FH?$#X<3RZ+\0M<^$%V_A[P-\,_&WQ4D\8:+\6]6^'V
MH_#70Y?$6C^+=1EN;/3[B8I2C[2*34XPO)6]Y3C!)*6CGIB5#FC=<M5*\855
M%CEJX-ZQE-<KZ<LJC=UTN\+.;3UO1;LY4N96=*_X)Z_LY:)^SG\.OV4-*@^)
MMG\#?A/\0O"'Q1\ >&E^+OQ"GUW0_&?P^^)UI\:_ NH7/Q#NM>G^(WB*V\)_
M%VPLOB!I&F^*?%>MZ>FL6.FV%S;7/AS2-)T2Q[_7?V2/AKXJ\::EXN\5:[\2
M?$VGZ[\3?A5\;-?^'FN>-[Z^^&VK?&#X(6OP_B^%'Q C\+O /^$=O/!FJ?"_
MP3XNM?"W@Z]\.?#W5O'NAV7COQ'X.UGQ9:V>KVWB?B?_ (*,^"?"GA?X0ZS?
M?LZ?M:7'BWXT?'7XQ_LS^%OA-:_"SPY#\1+7XW_!GP5\7O'>H^$M1.J?$#3?
M M[H7C71O@IXP;X?_%;PIXX\3?!G5K1]/\4ZS\1/#W@*'7?%VB<E\3?^"LO[
M,/P9MK.Y^*5IXS\#/H^O_!#PA\:=&U_5_@O:^,_V;_&/QVT'X<>(O#_AGXM?
M#D?&%_B-K%QX3T_XP?#%_B)KGP2\)_&'PAX7C\5OJ(\2:AHWA+Q[J?A2E&\E
M%*\IU())6O*IR4(0LF[2<8/#1B_>4%["-X-4TI;A9R;5H0DY/^6#G6G*[M>*
M<UB)N_*Y-5I6DG-OU3X;_P#!.?\ 9<^$?Q]\8?M$?#[0OB-X>\2>-_'GB3XN
MZS\.K?XV_&"7]GJ+XU>-;:\LO&WQLTS]G2X\:R_!C3OBQXML[Z:'6/&L'@P:
MFLS3ZEIC:=J]_JFH7WM'[/G[,_PN_9AT/QCX7^$D7B[3?"_C+XB^//B?+X9U
M_P =^+?%GAWPQX@^)7C'Q!\0O%]EX#T3Q%JVH:;X)\.ZGXV\6>)O$;:'X>MK
M&S6_UF="'M+73+:Q\DTW]N[X8ZC\9_!WP?;P'\8-*M/B)\>?BO\ LR^ _BKK
M_AKPUH/PZ\7?&SX+?#KQE\3?'GA/1=.U3QE:_%F;2[70OAI\3K'2/B!/\+;?
MX:>(-;\!:E::-XQO+7Q#X"OO%[O"/[=_PF\6:-XP^(;^&?B%X<_9_P#!/@K]
MHGQ[K'[3>N1_#^Y^"<6A_LN>.H? 'Q8@O+WPQ\0O$GC[PYK=AJ,?B+5-+T/Q
MEX \-:E?Z+X'\;RR06FI>'Y]+DE-**:TC&G9=%&ES0DD^T>;V3BG_P!.U!**
MA!7;FFUO-SO;[4JC4U==Y->T3MN^=RO)RD^:T/\ X)I?LO\ AKQ[X8^(>@P_
M&+2]5\"_M+_$3]K+X?Z':_M ?&8>!_A]\7OB[I/Q(L/BI-X(\#/XU?PMX:\'
M?$34OB_\3/$OB[P-INF0^&=8U?QIKEC<:>?"MT?#:]5X;_8&_9[\):%\%_#6
MAVGCRVT;]GWX_?$/]J#X56LWQ%\5WDV@_&_XKW?Q/OOB)XSU#4+N_FU/Q2GB
MBZ^-_P 99+WPYXKO-:\*P)\2_$%M8:+9VMGX9@T#*^ /_!0KX!_M$?'CQ9^S
M;X5?6=%^*_AGX4:)\<++2-3UKX6^+-+\7_##5/$;^#=3\1>'_$'P@^)7Q/T;
M3KWP=XO;3?#OC'P?XWO/!_CC2+G7O#^HQ>&KW0=7M-7?<\9_&?PQH'[;?@;X
M2RW?[0%WXZF_8Z_: ^,.A^!/#</A%_@-XV\,^#/BO^SUX;\1WNHPZA<VOBK4
M?CSX<UCQ=X1T;X>+!=Z?X/LO"'CKQ\FNW8U#4-*EM4^6CR2LJ22?*[*'+&G&
M<G:RO[GU5IK>/LGI^[L%G44UK-.SDKN2?.XJ[N^6TEB%)-^ZU5O?]YS&'\"?
MA%\0?%_[0?BK]L+]H;X'?"SX._&2U^%<W[,OPZTWP3X^/Q=\3Q?!W3_BCKWC
MW7-;\3?$L> OAPAT[XE:U;^!M;T#X:1Z'JZ> (O#%QJUQXHN-=\>:_X;\+^S
M?M+_ ++_ ,'/VM?AS:_#/XT:%JNHZ7HGC'PK\2O _B7PIXI\2> /B+\,/BEX
M#U'^U_ WQ0^%_P 1/!FJ:)XO\!^/?">H^9+I>O\ A_5K26>QN]4\/ZO%J?AK
M7-<T;4?G3]G3_@I'\)_VD?$W[.&B:#\+/CS\/]$_:Z_9TO\ ]I;]G/QY\4?#
M/@/0_"_Q+\)^'=.^&^J^./"EKI_A_P")7BKQ[X:\;^";'XJ^%+RZ3QMX*\,^
M#/&NF-J6O_"7QI\1?#E@^L/V7[3?[5_BKX#?'C]B7X->&O@WXC^)4'[5OQ=^
M)?P_UO7]&U?P)IZ^$],^'O[.OQ>^,OE:7:^*_'GA&YO?$VHZCX"TRZ#3VTGA
MJ'P5I7C@2ZM%XTE\#^'O$M23BJ<9*S<HTZ:VO4C-MN_-[LW5C.I-MP4:DKI0
MBZ::C*,O:2C*^DIRM=V@X644K-N"I.-."2DY05FYR4V<WK'_  3'_9$\5?#C
M]H?X6>._"OQ#^(WAC]J;Q1\/_'GQHF^('QP^,WBS7]<^(7PN\(^ ?!G@;XB>
M'O$&J^.9M4^'_CO0=,^&/@>>V\5^ +CPUK+77AO1(9+IM*T/0M,TQ->_X)F?
MLJ^+_P!GM/V=/'&G_%WQ[H\'Q#\+_&>R^+GCG]H'XU^+/VF])^.?@:'3[?P-
M\;="_:5UOQS>?&7P_P#$OP7:Z3IVE>%=9T3Q?I]EH?AFW;P18Z7%X&N[[PW=
M?)/[*?[>NO\ @77O&_@']H>+X]_$_3O'/_!43]J/]DGP1^T-=>&_AR/AM\-=
M4L?B'K.C_ 'X3^-(M+UCP1XJ6V\2V.CP>"_"_B?X;?"3QGX+T[Q//8V'Q/\
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MEI.,M%&*I6O#V2Y.7\1?\$G?V+]>^"WP1^"%EX4^)O@K2?V:_%WBKQU^S_\
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M^'FH^"/VSKKX/^)/"/P@\%?#[XF_#%_!_C74;]M(_P"$I\9_%I_B[>Z+X_\
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MJS49+2Z3K54K6=I6;DTI+X4^./[/_P 7_BO^TQ_P3\^..G)\-](T/]F+Q?\
M&/QC\5M%O?%_B>?5KN?XJ_ +Q;\'HM)^'DL'P[6S\10Z'J?BZ;69-3\2/X*?
M4K#2XK=--L9]1<Z?\G7W["_[4!_9V^+G[/UG+\!+NUU+_@I_IO[;OPS\47/Q
M$^(>FW&L_#6Y_P""D5A_P41U[PUX[TF/X-ZK'X1\<V=W:M\&M(LO#U_XWT#4
M+;;\2+WQ%ILSMX C_9RBB/NN\;+W^>V_O?6,/B5N[VC6PU)I7MRJ47S*6BG"
M-16G>7[MTKW:?(Z-?#R6EM94L353=KW<9+E<=?RDTG]F/]NWX.?M8_'K7_V?
M/BG^SM'^R3^UM\3/#_QN^)D/Q+T;X@WW[07[/_Q*B^'/P]^%OQ&'P,L-.@U#
MX;?$?2OB)X>^&.AZWH#?$K5/"VE?"_QUJU_KUQX.^)WA^RO/!OB>;PE^Q/\
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MT7=Q^O8FWNI5ZL*5E2A"I#Y?_P""-?[5/[07[:'[+GQ&_:$^.OB/P3XT\/\
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M]GIMS<7]M!-<64,%S))=00RS0+)'&[#^?I_B#^V?\.]$_P""6W[0W[<_@/\
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MT^STW6=:U&RTZ^NK^QM;F]LK>UN99KJTMY[F!'ABD=?PK_9Z^ 7@G3_VF?\
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MK_PQXMT*PC\2VOCO1].O+*XTJSM4T^\6T[+_ (*5Z)\);O\ :N_X)':O\7/
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M87'A/PNWA"ZMM+^*-AX<O?#27'BB*'4=$OKZ#Q)>VM[;Q0>9_M!?MN6_P_\
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M\48OV,?V!_@GXC_9C_:.T#Q[>?\ !!_XO?LYWOQ @_9W^.?C;QT/BCJ/PW^
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MUH6B^*O!>HWZQP^)]-,GIZ>/O DNOZWX4B\:^$I/%/AJP.J^(_#2>(]'?7]
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M+T7P9J>B6?CB\\3>*M1U+3],T'PC'X;_ .$IU/4[RVTVUT:2^E2W/R3^R_\
MLP?L<>*]!LOC/^SQXW^-/BCX+^+/&WCGQEHWPKU#X_\ [1%S\#M ^)$7Q*\1
MS?$RSD^ WCKQ=!:>$M3T'XLVGBRT\4?!GQ7X=M/"_P /?'VGZO8+\.?#'B/1
MC#8_F-<?$+XS_M0?L4?\&^'QO^)7QJ\;0_%+XR_M,?LW>)/B+XI\+>'/A%I0
MUWQOXR_97_:)\27OC@:#>_##5_#6G:KIE[87,.D:-INC6G@JWM=7O6N_"UY?
MV?A^_P!$_8_]O'3_ -IV+]E'XC>(/V/_ !MXC\/_ +0?PVT_3_B=X/T70O#W
MPVU_4?C7#\/KN+Q+XK^!,UM\0? /C;P_I&H?&WPU8:SX'T#Q3I&B:9J?A/QM
MK7ASQ'#=MH^FZKH6KMKD<I.2CRU'2<M;1C".$K.I*23O"/UB562Y.:"I.<%*
M::DE)S:IQBV_9JIRNWO2G+&48TXIM)3;PZIW<U&7M.6;C!IQ^S:*_$?X@?M^
M>*_&7PDM?VM/V=OB1JNI?LW_ +17QN_X)Z?LH? KQ#)X;\!:IX3\'V/[1GQA
M\ ^&?CC^U5I6JS^&)]87Q-X?L/CG%\#['P7\2=6\3>!O '[07P%N[3Q;X(O;
M74O%GAR^Y;]K+]I+]JK]GC0/^"N_PU\,?&;Q;JUY^SA_P3AT#]OG]F[XUWW@
M?X47OC/X5^*?$FC_ +5'AR3X/>+DO? 5U\//'GA;_A+OV6/^$W\*7/B+X?3>
M+GT7Q9X]\.ZOXFU*'1?"M[HT3;IJIS*SI*?.KJ\94X0J2@WS6YO9SC.-I24[
MI1<GJ[BU+DLU:HX\KUU4INFI6MS6]I&497C%QLW)+EE&/[PUY5\6OC9\-/@?
MH47B'XD^(+C2;6Z369--TS1O#OBCQMXLUU?#NA:CXH\0#PWX&\#:+XD\:>)G
MT/PWI&J:]J\?A_0-2DT[2+"ZU"\2&UA>4?*_A3XN?%*X_P""G/QF^ M_XWO=
M2^#FC_L,?LX_&SP[X%N=#\'Q6WAKXC>-OCG^TE\/_%>LZ?XBT_PW9>,[RWU[
MP]\-?"RRZ3XA\2ZWI5C>65U=:+::;]KNHW\+_:=\-^(-2_X*V?\ !-::P^)7
MCCPY83_L]?M_WQT71++X=3Z5&/#.L?L;3ZA:!O$?@#Q!JAM_&EKJBZ5XCG?5
M/[4L;'3[,^"=2\(7EUK=UK%.,KTXII.HY*[UY>5XJ-VDTW[^&V3^"3::E9*>
M=*,YM-J,*52R:3DJL<).*3U2?)BE>Z=I1MK&[/U*\$^-?"/Q)\&>$?B)X \2
M:-XQ\">/O#&@>-?!7B[PY?V^J^'_ !5X1\4Z5::YX;\2:%JEH\MIJ6C:YHU]
M9ZGI=_:R26]Y974%Q [QR*Q\:NOVMOV=M/\ "_@OQGJOQ.TO1O#WQ&^.MS^S
M/X%NM<TOQ'HEYXJ^.5I\4==^#$OP_P!&T;5M&LM:O-0/Q&\,ZYH<&I1Z=_8-
MU::?)XDM=6F\+20:W+^7GPI_:Q^.>M_M:_LC:3I'QQU#XP? S]I/XS_\%&OA
MEK'B*#P/\.O"?PDUW2/@1>^-];^%1^!6D6VC77Q:M9?@H_P_U'X/>*O'WCKQ
M0GAGXQ:S%XM\?>$M)^(OP_\ $/PK\<>&_)/%GQ2^*/QA_8;_ &/_ !;\8/&U
M[\1O'6D_\%T/!_PNN/&&H:#X2\-W^J^%O@=_P6 ^)OP5^'T=]H_@;P_X7\,0
M76E_#[X?^%](N;K3M#LI-2FL'U/4FN]4O+V]N,XS4IT59I5905GO%2Q.%HRN
M]4VH8NG*.G*T^:]G%2UY&N:[^!5+M=7'"XJO&R:32<\)4C+=Q^&U[RC_ $4.
MZ1H\DCK''&K.[NP5$1069W9B%554$LQ(  )) %.K\N_^"S%[XHT__@G1\>[O
MPEXX\7^ M1-]\']*O-4\%WFF6&J:MX?\4_&[X=>$/$WA6^N=2TC6 _A_Q+H.
MOZAI6OV%M%;MK.F3SZ+?S3Z)J.K:9J'BGQ+_ &@/VA-;D_X*H:%\/_V@-9\
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M^#_A[XJ\6_!7PWXB\8MX L_A?\-O!>OO;>-=6UU-<\26_CGQ)XUM[/7K>9O
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MO@NYU?1SKMGI6N^*TUO4^$?[27P4^.FN_$#PM\,/&\.O>*OA9-X47Q_X5O\
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MF\>^&?'&H> =#TZSOO%?CGQGX:\,ZYI.E>'[+4D\/MXJUWPOX\T7P?Y#I?\
MP4T_9LUOXS?#GX0:)J-[KL?Q4^+_ ,0_@)X3\=:!XB^&.NZ+%\5OAJGC6/5]
M&\2^#-*^(-W\8?"_AK7]4^'/C;P]X*^(FK_#6'P'X@U[08(I=?TW2_&WPKU?
MX@)6DXI:N:CRV>LE&H^2VJ=E5I2Y'=7JTWRR]I&Z)-14G*RC!OFNO=BY12DG
MHXJ].HE)6_AU%S1Y):^\>*?V0/V=O&_PQ\1?!_QC\/I/$_@3QEXQ\-_$+QQ:
MZYXQ\>ZEXB\?^.?!K^%F\(^+?B%X]NO%$GC[Q]K_ (6C\"> K3P]J?C#Q-K5
MUHVG> ? >EZ=);Z=X*\,6NE+/^QY^S5?:A\?+_5?A/H6OK^U)I-AHO[1&C^)
MK[7_ !/X4^,-EIGA/2O =C)XY\&>(-7U+PCK.J0>#-#TCPN-<FT0:U)H>GVV
MG2Z@]O&$K=^-/QVM_@]JGPO\-VWPY^)/Q*\4?%OQ-XC\-^&].\":+8-HFA+X
M2^'WBOXCZYXB^(GCKQ-JGA[P-\/O#,>E>$Y=$TV_\1Z_;7>N^+=<\/:%HFG7
M[76H76EG[-?[1/@/]JS]GKX4_M*_"NV\0-X%^+_@72_'7AO2O$-GIVF>*K"+
M4('-SX=URUM=6U'0H?$&C:E#=Z'J3Z7XAU;PY+J-E-/H_B'5=%DM-6N2W,IZ
M7C9J>S34K4VFNJER1IM<K3<(Q>T;/9QZ.]X=+-7J7B^C7,Y[II-RV;OXAX,_
MX)I_L/?#OX#W?[,W@?X Z%X8^">H^-/"WQ$U?P?I/B;Q[;7.O>-/ FI:'K'@
M3Q!XB\6CQ6?&WB*[\"ZGX7\*7O@E-<\1W]MX1F\(^$3X=@TT>%?#ZZ=]KW.F
M6UWI5QHTLNH)9W.GRZ9)-;:OJMEJJVTULUJ\MOKUG>P:Y::@L3%XM7M=1AU6
M"Y"WD%['>(LX_,#P1_P59\!>/]/^ &O:%^R_^UDOA;]IGQM\;OA!\)_$=WH'
MP+^RZM\??@>_QSDU?X&ZEIMI\?+S7M"\4>*-,_9V^)6M>&_'>K:59? JRTZS
ML)O&7Q;\*$:V-"]7^'?[?_@_XG?##PQXV\.?!'X_Q>/-?_:9\>?LA:Q\"[SP
MSX/U'X@?#GXX?#+4/'<'CJT^)/B3PAXZ\5_!_P /_#_P]H?P\USQK+\3]/\
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MQ/KOB#7?AOX;L-,^&]YXRU"3QTWA(>,HK?78>C'[$7[,/_"OO#/PK_X5O.?
M7@[XTM^T7X7\/MX\^)+1Z+\;W\<7OQ./Q*LM0;Q@=63Q+_PLS4M2^) N6OWA
M7X@:EJ/C58!XFOKO5)L#_@H/\=OB#^S7^PE^UQ^T'\+_  ]>:G\1OA#^S/\
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M"#6/@'\+;_3/B#\2;6;P1\'=?70!J_@'0O+\7A+?1+Q_"/@RX;>LEY%>>!_
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MR;71+Z/PAX*#H\<MS$_@3P%+;W$,O@;PF^CZ_P >/VA_!/P 7X26GBF*[O\
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M?SQF_P""E\'CG0?V!/''P'^"?CWQ[X*_;*_:0^-'P#UV.^U7X3Z5XN^'FL_
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MC1\5?VCO@G\'_%WB31/!^AZ'\0OB-^RSHOB[7OBA::1H&I>-[;XB6GA*]L/
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MX]1\*^*?'7A[7M-TW3?#?[2%EXE^(#?V1J/B&WGD\,:3X+T+Q7(GC>3PH/\
M=RBFN249.$7=1Y&Z<[VESI1BZ5"2YU+E<*<4IN,:;BFU:3:;4K.7NM\S]I"*
M33C=R52K&\&N=2<KQ4N=2]BUO]@W]D[Q-X#^//PQ\1_"2UU[P'^TYXN_X6#\
M<_#FL^+O'^IV?CWXAI-X7N+/XB7,MYXKFO-$^(.CW'@;P//X>\<^&;G1?%7A
MN;P1X-ET'5].?PKH#:?FS_\ !/7]C>Y\+?&WP9=?!'1KKP_^T;/X%U'XTPW?
MB/QQ=:CXX\3?#6Q\,67@GQ]<Z_/XGDU_2/BCHL_@GP;X@_X6MX>U32/B1J7C
M7PIX;\>ZOXIO_&VB:;X@MO)_AG_P5*_9S^+_ ,3OAO\ #'X<6GBCQK=_''X2
M>/\ XQ? C7_"6K_"SQ-I/Q.T3X?Z=HGB&7PQ=6>C?$F[\1?"+QWXQ\%^(M+\
M=> _#WQWT3X8)K'AW^UK#5[_ ,/>-_#'BKP=H?F%Q_P4)\"?'O\ 9V^!/QWF
M^!_[=?P;^"/QI^,W_!.:X^$/Q.L+CX'^!=5^($G[4OQC^'MO\/K?4=+T'X]>
M(?&MG\(=+\<:EX5^&G[2FE>)O#.C7'C'P)XXNI_A+9?%7P%KT7B]1/D2:O"-
MJ:OK!1A*K&A&R3B]*EH*$>63E&,;*T91J3O*2E[TTJDVG:<FX4IUIMI\[LH1
M<I2::47*3NN:,OK)_P!@+]C^7PE\<? \WP1T&?P[^TQ9^&+#]H*&XUKQ?/JG
MQBL_"'A72?!>D0?$'Q)-XB?Q)XD6?P[HMI:^(VU#5I7\8WEQK.L^+VUS6_$7
MB#4=3]/E_9K^"D_QD\&_M!W'@PW'QG\!_#F7X2Z!\0;GQ)XNN-<N/AZ]_)JL
M'A[Q5YVO/9>/5TO5KG4M6T'4_'5IXCUGP[JVN^)=3T'4=.OO$_B&XU/PWX@?
MMZ?#SX9_%;2OAOXM^&_Q>TW0M6_:=^'/[']K\5;W0_"^E>"+OXX?%CX;:%\3
M?!5AH6FZWXOTOX@>,/!5S8^)_#WA/5/'O@[P7K^A:7XWU9M-=Y]#\,?$+Q'X
M+R/V*?&'CKQ'\7O^"F/ASQEXZ\4^-]+^&7[?%MX+^'<7BB\M+H>"_ ^K?L,_
ML1_%'_A"?#L&GV&FV6G>&=-\8_$?QAJ6G6<5H;@S:Q>7FIWFI:M=WVI7<>TC
MS4[)^_S\LTDDG1A%./1JT,5:*Y5%0J2LDIZTXOEE?:+A>+OJJLG[W6+7/AH\
MSNVY4XW;<-/I?XI?L^_"3XRZUX"\4>/O"T]SXR^%M[KM[\.?'WAGQ-XM^'OQ
M%\%#Q586^F>+=-\-_$/X>:]X6\;:5X>\8V%EIMOXQ\,6NO1^'/%JZ/H;>(]*
MU.30](>RPS^RO\ $\4_!WQE8?#C3M"\0?L^^#/$GP[^"D_A;5/$7A*P^&G@C
MQA8:1I?BGPUX5T+PSK&DZ%I^F:]8>'O#MOJ<0TUWNE\.^'V=S)H6DO9_05%:
M)M:)M*[>C:U::;T:W4I)[7YG>[;9-D]TG=6=^JT=O3W5]RZ))>5?!;X(_"_]
MGCX?Z=\+/@YX63P7X TC4=?U;2_#4&KZ]K%I8:AXIUS4/$WB*XM;CQ%JFKW\
M7]L>(M6U77+Z);L0S:MJ>H7YC%U>W,LOJM%%'^27R222]$HQ26R44DDDDC_-
MOYMMM^K<I-OJVV[MMLHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /B!X;M?\$]_V=/B3^R1^QU\(_V=/B1X@\$^,O%_PHTWQ+X>M_$'@J/7]/\
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M\-_#CX(>';F_U#4-.\+S^+?'GB#Q7KZ0>$]"NM*\+Z7^H*_$OX<O;+>)X_\
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M:I:*,4BBBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M''0ERO\ NK,7S))1G*G1<DM+?SJ_&OX=?&K0U_X+->(_A'^SS\6O%]B_[?\
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MH8G#J]G;;$\RB]'*G!:)Z74?/*,G>+<HR23MS*%2C5:5U?5T6G)=)MV;AK^
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M<L4^7V<D[)):JM0KV:LFGSX=1?POEE4C>ZT_F3_8X\$R>*])_P"#?_PYXY^
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M$C_;M_8Q^)/[0USKWQ \6^"OBEX?_9PM[KXC'XBZ7\0_VEO"/QY7P]HGP?\
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M[0GC.U^,GB"3XU?#KXYR:)I.B?%/]DK]H#XYZGJ-CX \(>*-(U7Q5J.E^-_
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M\(?"[XU?\+>\5^!M*U7X*>-O .O^,])\#>&&MOBAK7B[X0:SXBT'3O%OT/\
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M ,$G;?Q1\1/#/C7PGX!U/P3XMN-&UGX(?%ZR\0>#O#&O:S\1+"Y\">*=3O\
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M.N>+]0\;^+I7\/:5:6&OW>L^(KN\\7N]_?\ BVXUO4M5U2[O>]\1?LB_L_\
MBWQ-X\\9^)/!FJZSXJ^)_P %M._9V^(&O7OQ#^)<FH^+/@KI,FM7&G^ -7G'
MC!3-I4%WXF\4WYN5":K-J7BSQ9J<^H2ZAXHU^YU")*;IU(QERS^KRI49VLH5
M?JV,ITZCCK[L:]?#UFK2DW1FY*4IM2J'+&4&XW7UI5ZL;WYZ3Q.#JSI7TNW0
MHXBC=VC:K%)QC%.'Y8?%G]JO]LGQ]HGA;4?A_>_$KP'_ ,+%_P""5_AK]H[X
M,S?LU?!K1_C??ZQ^VKXY%Y>+X)^+&A:_X+^*MQX&^'-K"G@2S^$$OB]OAQX)
M\>QZ]\<HM>^)%]J?PWL-0\#_ +%_ ZR^)UA\&OA;;_&O5#J_QA/@;PQ<_%*[
M5_#TMM'\0+W2;6\\7:=ILWA70?#.@W&BZ/KMQ?:1H=U8Z)9&ZT>QL;B[-W?2
MW-[<?DU^T/\ \$Q;CQK\;O".MZ%^S%^R'\?_ (&>#_@5\+/@)\,_#_Q8^.G[
M0W[.GQ2^ W@_X?:SXQO]2TNW\:?#GX:?'N\_:(\,:FGB;3Y_"WA3QKJWPOL_
MAX-#N=,\/WCOXJ\2:[>_JW\&?A';?"/X+>"?@TWB/7O$EGX0\*1^%AK=WKOB
M]M3-F$G1+/1]=\1>+?%GQ"LM)T.WG&C>#Y?$/Q!\7^-](\/Z=H\&N>/?%7B&
MSN_$^H]%2<)NM*$/9J=6<J<&M8P>(Q<H0>KY7&C5HQDUS4Y1I48PLZ<G+*G"
M<(T8SFZDH4:4*E1.RG4C0PL*D[:<RG5I5IQ4K3BZM1SOSI+^>']@[]DSXI?M
M?_L:_L$Z;=:CX \ ?!C]E_\ X*B?M2?MC77C.TUWQ#K_ ,8?&/BOX)?M_?MB
MR^'OAKHW@V3P7HWA?P/H'BG5O$MYIOC+QQ_PL?Q-J=SX'@U7PU:>#TD\77-_
MH/KGB+]JS]JWX:?!W]O+]I?Q'^T_XHUS2_@-^W?XG_8V^&WP^U3X:_ ?2OAI
MX,\%_%;X]?LW?![PC\8?'^HZ7\+K;Q_XKU?]G2Q^+WB7QC;PVWCGPEX8\6Z'
MHEOIOCS3M0N(;[Q)<_M[\"?V??A%^S/X#A^&'P0\*/X&\ 6VL>(=?L_"T7B+
MQ5K^EV&L>+=?U/Q7XIO].3Q3KFN2Z=+XD\4ZWK7B?718RV\>J^(M8U77+Y)]
M4U&\NIN9\.?LD_LZ^%_"GQP\!V/POT?4_!'[2?B#Q=XJ^._@[QAJ&O\ C[PO
M\4-?\?::FC>.-1\4:!XZU?Q%I5T_B[2(K?3/$4,5K!;:O86EC:7T,\%A9I!A
M33IQIQ:YU3I4XN/-)*=2/]FPFFVVXQG1P5>BI**E".(YU%S4I1UJWJ2DU*4.
M:I-J7+&3C3DL:X:>ZG*%;$T:\HN3C.5'E;4;1E^6'[6_[</Q]_8/\?\ [8'A
M2Y\3:C\;? WA']@[P[^UG\.?B!\2?#OA)[OX'>/Y?C6_P"\5:;X[M?A5X5^'
M5OXN^$CVVLZ#\<=*T>\BT[Q@J> ?C;X=LO&\'AB[\(V/P[]R_:E^-/Q?_8L^
M%GQ<^*-S^U)HOQ;\)>+O%'[#O@_X?1?%72OA=X*U/X :3\=?VD?!7[.?QB^-
M'B;XJ^!?!-OX1N?A_=Z-\1=-^)/@F_\ %WPB\0Z/X*\9>$_%AGLO&WPXE@\"
M>&/O3PQ^S3\$O"WAKQEX27P1'XOT?XB^#;+X;_$)OBUKWBGXW:UX\^&^FV/B
M'3M-^&_C3Q/\8M<\=>)O%7P[T^U\8>-!8^!-=U>_\*6<_C?QQ>6VD17OC+Q-
M<:KX]\(O^"<W[#_P+^"_Q&_9X^&?[-OPZT?X,_%VPET?XF^!=9M=2\;:?XXT
M!K.YT^R\,>(K[QUJ7B76=0\)Z!87MY9>$?"DFI?\(YX+M;NY@\):9HL4\JO6
MJ3W;C9Q=^5S7/4;I37O1BG3E!>U2E.,H:)KE%:]OLW^))N2C+D@E4@[QF_?4
MFZ3<:<HR5VI<U_D3QIK?_!33X1Z/\8&N=:\(_M!Z=9?&3X+^/_#WP>^"OC[X
M8WG[9F@_LR>(_"OB[1_C!X.\$>(?B5\%O@3\$?%OB6U^(7@IO'GPEA\7^#]'
M\2^,_AQIWQI^&5K\2;'XBZ7\//&6C>,?$_\ ;(^-:?LP_!_]HWX<_%#]J?QK
M^RY-X _:ETO]H/\ : ^'OP$^#-E^UW^S%\0]#^+,7@CP-X[^.G[)?Q ^&=B/
M$WAS]EQ_#'QA\ _M >&_A5\-VUY?%WP]NO%D_P -_$7A+[>VA_H[\-/^"<W[
M&WP9^&/AOX0_"3X/R?#3P;X1^($7Q3\/S>!OB-\6/#'CFQ\?P>$-6^'EOXDD
M^*NC^.K3XI:A=6WP]US5/A_:VVI>,KO3[;P'<KX,@M(_#5M:Z9#UNL_L1_LS
M:YIFC:/=?#[4K'3-&\,_$/PA+9^'?B1\4_"4/BSP_P#%[Q.WC?XM6/Q-_P"$
M6\;:,WQ:D^*?C:6]\9?$G4/B@WB_4O'GBW6/$'B7Q5>:MK7B+7;[45*_O<EM
M53Y>>+LG&G.+4E"7,X.4H.7+*-;FA[6$VU&DQ;Q<EHN9249:\LIP:<%.+@II
M1ER\ZG3<9>SG%7=5?F=^U#^V;\9-"\8^/?B%\!/C^_C?P#\.?CU_P2X\#R^&
M? G@#P##\(_"OA#]J?XZ?L_^%?'OA3XJ^-_&NF>)/''Q+^)WQN^&'[0VG>/_
M  ;;?""Z\*:7\)?AY:?#'Q#KFKZ'KGB9K;XK_J1^U]JG[0>B_L^>.-5_9:T6
MQ\3?&W3M0\!7?AOPM=>(/"/A74O%GAVW^(WA*;XG>%?!?B7XA6>H?#[0_B?X
ME^%:>-M$^$VJ?$"TE\"67Q-O?"=QXT:+PS'JLT7G?Q"_X)R?L5?%+Q1X^\8^
M-/@1H=YKOQ/L_A';^.'T?Q'XZ\(Z7K>H_ /4='U'X+>,%\/>#_%.@^'M+^)/
MPP3P_H^A^#/BGHVE:?\ $C0_!MA#X$L_%4?@HRZ!)]*?$KX2^ ?BWX'E^'/C
MC1[N[\)/JG@S7(++0?$/B7P1J6EZU\._%N@>.O VKZ#XD\#ZQX<\3>'-3\*^
M+O"_A_7=&O\ 0=8TVZL[W2K4QR^4K1-I.4'&T(25JKDO:<CDZ;<O=E[-13:7
M*[7Y6^97BK(B$9IIRE%_NHQ:CSJ/.E%.:YG*5G[Z5VY*T'+F;DS\7O"?[?\
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MP\US3_V:_@YHVD?!#QUHOCO3K#QIIOC:+XLV6A>)Y_A)>:+)8V.M>,[/Q?\
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MVAI/AGX6\#_#F^\-^!O$6J?$3XP7C^(OVC?%_P 1="U[4O$'A+XS^#OA?<>
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M^TL_[)7P%N?&=[\1+CPCK4OCG4/@M'^SO>^*7^)'Q/.M7/P9CGDNT\#RWO\
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M-_9X_P""D?Q*_9A\>?!;6_A]X(\7^"O$/PU^$_CY/@S_ ,*Q\1:I?#PY\0-
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M+FL_#6PF\;^,CX&D\?7%GK7BC2/#?Q,O/AC=0W?PXU?XJ^ M'URP\ _%/7_
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M3]Y^V;!^S[X$M_VE]06TDU#XGV\.J0W6H:MI^D7/A[3_ !;J'AF/4E\%WWQ
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M;_#:Q\%W^C:!\2?B#X[\<1V=E-X-\+7WP[\(ZQ%\4_B'\/=!\2>I:?\ LK_
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M_#ZSN/#'C+POH?PYUWXB?$B?6_ >@>3>&_&S_$#_ (*EW5AX:^)GCC7O@O\
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M? W_  4D^ 7BFW^%6KG0_A)\2/ OPR^&_P &XOASX^\-GXK"[^+?@OQ;\,O
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MST?1=.L(=-['6O\ @IY^U]\%8?\ @L7\5=-\;6?[0'AOX9_M2_LM_P#!._\
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M>+-57Q]HWA3XDWWCJ_TV[L-,_9\\+>#?AU-X(U71_%5YXT\6^-_>_A_^T?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'\FDT_1III[----IIM_\%?--IKU3336Z:::332**^>OVK/C5K/[/G[/GQ/\
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M'5_!_BSQE=^*/$/AGPQJOPBT"\UJZL?"?BFPUO4O9?$OP!^*/PL^*'P5U/\
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M+?!WAWX86'[*4G[1WA/]H'X!?LN>)OA[\!/&GA[P!IOQX^!O[1-HS^'+._\
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MU?2[O3=5O/3/BK^QC^SA\9OB-I_Q>\;> ]2MOBC8Z)I_A>Z\??#_ .(OQ/\
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MRE%1E&,DV^9,HHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG[2?PY^$=Y^SW_P4L^,'[,_QI^'^K>)_$/B+3-4^#G@;]H3Q[\"? O[/&L?
M^73-(\-^%?B/\;? DOPC^.7P_P#C='XGU?X@1^-_%%DMAJNJ?!?7)?A3IOS%
MJH8_L!?M5<')_P"#A'P?@8.2/^'ZG[/8&/7/;'X5^YY_8]_92;]HM/VNV_9Q
M^"A_:CCTHZ-'^T"?AMX3/Q<2R;P\_A!F3QT=+_X2!;\^#9)/!9U<7HU8^"W?
MPA]M_P"$;=M,-B7]DG]F*?PAXD^'\_P%^%4_@7QE\2V^-'B_P?-X+T27PUXJ
M^,4FN6_BB7XK^)-$DM&T[7/B5/XKLM/\6W/CG5+>Z\3W/BW3-*\4SZI)K^E:
M=J-MI0G[&5.3BY<BI-I-:RAB<%5FU)KFM..%E)1:M"I5:5X<\I34BYPJP5DJ
MDFU)W5E[#&TX)Q3<?=>+BG*+3E3IK3FY8Q\9_P""EW[0WC/]EC]BGXR_&[P%
M>PZ)XA\.7'PN\.MXSGT^QU:#X8>'?B=\8OA_\+/&GQFGTW5K/4=#O(O@KX-\
M::]\6'@\2:=J'A5E\&'_ (2FRN_#HU.W?X*_:S^+7[1G[-7CW]OOX4_";XN?
M$B7X=:3_ ,$E/C!^V=\._%OB#4-,^(WC7]G']HOX6ZOXR\/6%OH_BSXBZ/XO
MOM4\(?'2P1?$6D>#O'Z^)].\,ZQ\'_'8^'AT#1-3FT71/W'\0>&O#OBSPYK?
M@_Q7H6D>*?"?B;1-2\->)?#7B73K37]!\1^'M9L)M+UC0_$&DZM%>6.MZ1J^
MFW-QI^JZ=J<%U::E97$]M>Q3PS2(WD.F?LO_ +/>D^ /%?PLMOA%X*N?A[X[
M\)V7P^\:^$]8TI/$&D^+?ASI=C?Z1H_PU\21:\^I2:U\--#T'5=3\,Z#\.]1
MDN/!>A^$]1OO"FDZ%9^'+J?3),I)N%2.TIQJI3LVU[3#5*,5NN54ZTJ>*BX^
M\YTN2Z4KFD6E*$FKJ+@W&Z2]W$4JK:LM7*E"IAVI>[R5.:SM8XS]CWP/XS\+
M?!C0_$?COXY?%KXX>)OBUIO@[XH:GJOQ3F\#,G@R_P#$'PX\%Z??^#_AWIW@
MKP1X.M]#\ V][I,^O:?HVO-XJUR+7-<UV^U#Q-J;W[;/QNT+Q[^V%HWPZ^$?
M[5-K^V5\7/'>N>%/^"NWQ4_8J\0_ OQ9H'PB'PY^+?[.OB3_ (*K_$O]CN[L
M]7TCPC\.?#&O?\+=\ ?#EM!^(OA[X@Z'K>A:)X1\/?#&ZT^+P5;>';SQA=ZW
M_0UX6\)^'/ ?A70O!7@C0=*\->%/">C6'A_PIX8T>WCTS0?#^A:1:QV6C:!H
M]C;1FWTG1-*LH+?3M+TZQMTLM*TZWM[*PM(K2V@MT^&OV,_V)]+^ FG>+-;^
M)?A'X8ZO\4-5_:E_:U_:1T#Q5X4O==UNUTC5/VH?C/\ %GXE'54LO$.@>'K"
MR^)_A/P#\5[SX#7?Q-T_1QXK\3?#/1(M"DU;2_">J/X)TVZDE/$5*D8\D+^T
MI1]UJ"^O1J>R4?@;>%<Z$FXM<CD[W4$L80E"C2IRDZDE#V=26J<I_4W3]LW?
MF7^T1A7BD_C2BU9R<OSWTK]IKX[6WPY^$NIR?&GQ:NM1?\%\/BQ^Q^9+R_T6
MYN==_9WTK]I[XS>!='^#^N1:AIL[:_9Z=\//"^@0V>O7J3_$3['HL6MR^+)Y
M[S6K[4Z/BGXU_M.?#7X:_P#!9?\ ; B_:*^-GQ"US]@7XJ_M:Z)\#?@?K%A\
M*5^"4GAW3?V,OV<?BSX9D^(?A;PO\,/#GC'Q=IOPJ\3>)=4\0:+_ &?X]\-7
MTF@6&HQZMJ&HZ_XD\9>*/$GZ]7_[$/['FK>.O$GQ,U?]F'X%ZQX\\8>._#?Q
M0\4>*-7^&7A+5-3USXD>$([%?#/CW4'O]+N(I_%^BS:3HVH67B%HAJL>L:#X
M>UPW3:QX?T:^LO5?!7P5^$?PXN_B'?\ @/X;^#/"-Y\7/$=WXQ^*ESH.@:=I
MTWQ)\8:A9QZ=J/BWQV]O A\6>*-2TR"UTS4?$.N_;M8O],L=/TV\O9K+3K&"
MWA\SCT4^1I/[/,Z6"IW:7*W&3PM;F>DXK%U)4VJL5-[>[>%D^13;DEI*477Q
M55*[<TI0C7I1C>\']6A&:E2DX+\2?^"D%C86?_!/#]OS7_!?[6VM?'CX9_%W
M_@GOIGQ(\$^ /$EUI?Q"E34%N-;.M_M'Z%\2](N[<6?@OX[:/X@\%6FF?#+0
M]*\,_"K3-0\ ZWKWP=TC1+34_&.EZ?Z5\4?C-\0?V9/'?_!63PQXK_;%^)?A
M3X>?#7]A']GC]J+X?_&;XE> O _QIU?]F[XI_&S6?VW_ (8>)/$G@+X=:+X8
M\$V7CS0;2\_9^^%GB;PE\%-6EE\,WGC2#6M+TZ*QT[Q?J=FWWYX+_P""??[#
M'PY^&7Q%^"O@']D+]G'P;\(/B]JL>L?%7X8>&_@]X%TCP#\1[RWNVO;&/QQX
M3LM$AT3Q1INE7# Z+HVLV5YH^APQPVND6%E:P00Q^F:W^S)^SUXFNOB%?>)_
M@Q\.?$]]\6OAO:_![XIWWB7PKI7B"]^)/PHL;:_M+#X<>.[O6+>]N/%O@K3H
M-6UD:=X:UZ2_TG3Y-<UZ>SM8)]<U:2\4TVY<CE&,KNS:4K.A.FHMQ5O<G-2A
M-)-<J2C&"5$F-TX.7*Y1<.9I.S4:T:DFDVVO:0BXRA=I.3O*<G*H_P ?=#^)
MG[:%UXO_ ."D7P)^$FK7/_"4?"2'_@GI\1_@O\'_ (Y_'Z.X\6KI7QBU75M=
M_:!_9^O_ -HZ/0O&&J?#WXE_'3X=?#K6O!GA'4-+\1_%#PY\%?BY\0H=<^%G
MQ$7P9;>'KW1,GP[^W%J'BC7_ -EG]GW3=2^,_P ,X/C/^TE^UO\  [XM^#?V
MKO'VM_#;XO?##XW_  H\!>'/%_@7]CV\^/\ \,Y/&]WJL?B?2/'S?%/X)?$W
MX>>/=0\0?%CP#X,\":9%\3O$U_XE\6V'BG]5='_8*_8L\/6.J:?X?_9<^"&A
M0ZUX:^&GA'5IM&^'OA[2]1U#0O@WXR'Q&^%D5UJ]C90:K+J'@+X@QVOCOPUK
MAO?[=T[QGIVD>*(M2&MZ-I5]9]%X_P#V.?V5_BQ\(;[X"_%3X _"[XF?"+5?
M$-SXQU;P1\0O">F^---U?QQ?7EYJ6H?$'5[GQ+%J>J:K\1=3U/4M2U35OB%J
M%_<^--5U74]2U/4-<N;[4+RXFN[NKKF2Y59^[S)5*K=[72O3J03BXO\ >4:3
M4HP=2,DU?;W5[S5KMQ;I4HZW:NU4IRDFI+W*U6\935.4:_[(&F?$_P /_ S1
M/"OQC^.&A_M&?$+P;XI^(_A'6OBSH6F6.G+K$/AWX@^)=-TCPYKTFDV>G:/K
M/CCX<:/!8_#7X@^(-.TO1_[;\<^$?$-_JNAZ#K\NKZ+8?A_X]^-'QVM/V?OV
MY_@W^T;KGQ[^'?[2-O\ \$R?VQ/CIX/^(W@#XLS>,OV5_P!J_P ,^!-&T"W3
M]J3]E?XD>$]5L_$GP%\1^!]3\2^ M+\7?L^R:5\.Y?">A_%WPGJ7AV/XA:;+
M/\1]5_HR\#>!?!/PQ\'^&_AY\-O!_A?X?^ ?!NCV7A[PCX(\$Z!I7A;PEX6T
M'385M].T7P[X<T.TL=(T72;&!%AM-/TZSMK2WB4)#$BC%>4^"/V5/V<?AQI5
M]H'@SX,> -&\.W_@B^^&)\-#0;;4/#6G?##5&\W5_AAX?\/:J+[1?#/PSUFY
MW7^L_#WPY8:5X.UC5)9]5U/1;K4;B:Z?.M#VD*T$[^TPU6A%R2=I3I2IPJ22
M^TI.,IN\N=<ZDG.49K2E+DG1DTG[.O2K2BFU>,*T:DJ:;LG%Q4H1345%\KBU
M!.#_ #1^ &NZ_P#$3XH>"?V(;CXK_%#X8>$? /\ P2]_9D_:!^'&K>"?&4VC
M?$SQ-\0_C!XS^*?@7Q/X_C\37\6K?\)#H_[.-O\ #3X>V'A?X=:YINK?"B[N
M_C#=6_Q@^'GQ TB+X<6NA>4_LL?ME?&+]KU_^"=WP:_:&\9:U\%-8_:E_P""
M>OQG_: N?$WPVUIOACJ_Q]^,GPZ\>_"?P7HVO_"KQ'8-9WNGZ79_#CQ#J7[2
MD'P[\+S7D/B'PSXZ\-WVN6NH?#KP3X@TOQ%^M-C^QC^RGI/A3X8>!]&^ 7PS
MT+PM\%]"\1^%?A;I7A_PW9Z"O@KPAXU@L+;Q]X,T>\T<65^O@OXD6^E:7!\3
M?!]S=7'AKXDPZ;81>.M+\01V=NL>G\<?V1OV6OVF/!_A3X>_M"_L[_!CXT^!
MO FJ:9K7@KPC\2_AOX3\8>'O">HZ/#%:6,WAW2=;TN[L]'C73X5TBYM+"*"S
MO]#>?0M0@NM'N;BREVJR52=62C*U6M5G)2=GRU:^/J<RG%IJK"GC*--<KY6\
M'3GI)Q<,*%-T:5*FY7E2I4H1DDK?NJ&"I<KA).+A.IA:E1MISC]:J05TI<_X
M ?%OX[>(O@K^VEX3U3QG\?=6\7^'?'?_  3(_8L^!OQ]_P""C'@GPSX)\%:7
M\,M+\5?M)_M.>&+_ /;(@\#Q7EYX'\/Z)\0_B78^'=&\-^*=.M/%WP'^#MW\
M5-$^-?CC1/''P"\#:WX7\4_TF:S?Z'\+OAOKNLZMXEETGP[X#\(ZWKNK^+_&
M-YJWB=M*TKP_I=YJNI^(O$5U=7W]KZM!I]M;7&HW\:WT,TMO#);VDEJ@A6+@
MM<_9=_9Q\3:MXGUSQ#\#/A7K>K>-?A&WP \87VI^"- O9O%'P&:.ZC;X(:_Y
M]BZ:M\'V^WZC*WPROEF\$M<ZGJEV=#-UJ=_-<>E>&/ /@GP7X)TGX;>%/"NA
M:!\/M T*+PMH?@G3=-M;?POH_A>WM38VGAG3-#6/^SK'PY8Z=MTS3]"MK>/2
MM/TJ.'2[*T@T^"&VCFJW.G*$?=GR5(PE)<J3G+%37,J<DTH3K0DO9N,K.JK\
MT*$UI!<LXRDKQO!SC%MM\JHQERN::O*%.4??4E=4WI%U('\V>B_'_P"/7B'P
M;\8_"5Y\=?C%XD\$?%7_ ((0^(_VN=/^(>M>)9? GQ.\9?&'3_[0T2+]J#PQ
MX2\(:IJ]S^R.?C/8:O)XJT/X'_"[XH7_ (1\ Z#:>$X],\/?#3Q[I?C#1S^W
M_P"PIIUCX4_8?_91C?4]0DT^W_9I^"VJ7%]X@U:>_>R@G^&'AN^N(S?7TA^R
MZ7IZ%DM+8,EIIUC$EO L5M"B+:^'?[!_[%GPDN]"O_AG^RK\ _!%]X9\&^,O
MAWH-[X>^%OA"PN]-\!_$&>QF\8^#8;B/2O.;PUKJ:;96%SHLKR:?%HT T*T@
MM]&>6P?VGX2?![X5_ 7X?>'?A3\%_A_X3^&'PW\(V8L/#7@KP5HMEH/AW1K0
M')BLM.L8HH8]QYDD(:60X,CL0*3VJ*"LY**IN=I->SJXV=-5'!04N6GB:4&X
MJ',Z,E%0A*'(N6\X2>T5)2C&Z5YT\+&<H<SDU>IAZDDI.22JW;E.,N;\:_V%
M/CO\:/$W[4?[*.D:E\;_ !Q\9/A'^U%_P3A^.G[3UWXS\=KI_AZ7XU^*? OQ
MO_9*T;X8?M#^%O@5$OB:']E;P/X]^'_Q\\47O@WX1^&OB/.U[X+U7PI_PMGP
M#X,^+/@_6+63V7_@IG\3_C;\("OQ-TI/BOK'[+W@3X(?$S4/CSJ_[+OCO1M$
M_:0_9?\ $&J03S^!/VN)?A=K>IZ+9?M!?"GP!I'AKQS!K7PSGU34%MI[+5/%
M"_"KXR-I#67@O[-^%_[#/[&GP3U[P;XH^$'[+GP(^&?B+X=KX^C\!:SX(^&/
MA+PWJ/@R'XH7FF7WCRW\,7.EZ7;2:':^(9-&TJUGM=.-O;6FE:?:Z+IT5GH\
M2V-=_P#$;]G+X&_%S7%\2?$GX8>%?&&MMX3U#X?WVH:O9-)+KWPYUB]&I:Y\
M,_%:0RPP^+_AEXAU!(KWQ+\./%$>K^"?$=U;6<VN:#?R6=JT,VE[C35XSE*T
MHKE47?ECRQ<>=1NU?F@T[3IM2C%.EO*Z=I0C%\KM)M?%-.2DHN5D[-33UA-.
M#=OP]_:6\?\ [2/CGQ1_P5V\7?#?]N[XQ?!WP_\ L:_ ?X%_M/\ [.$'A?3_
M ()6W@#1M4D_9R^(WQ>FTOXD0^)?A)K6H^,O@SK^K^$XY_$&@ZS>VVKZAIFM
M>(UUSQ-K4.D> +3P!U^H_M'?M+_M3>,OVF/A98_&#PK^Q%\;?@!^SU^R;\=/
M#$WB_P 7ZWX;M?A/8_$+X2VOQ5^*'QD\8?##4]!D\,_'/X767CJ\\4_ ?XC:
M#\2_$<GA;P5I_P ,1/I1^'OCO7G\::I]P^$?V&[:\_;&_:Z_:%^,?AGX5^-_
M!/Q_M/V=K3P?H0N-?U#7+"#X">'M8TJWTWXD:/?:'I_ACQEH&I:_JEMXZT'P
M[JEQKFB>#_%>B:=K5E87OB&*S\0Z9]'?%K]CW]E+X]?$7X;_ !>^-G[./P4^
M+'Q1^$%U!>?#'X@?$+X:^$O%OBWP1/9WLFJ6!\/ZWK>EWE_91Z7K,K:_I%NL
MS6^D>(TA\1:9%:ZW;P7\>B:48:.S46U=2G3M]92DII14ZB3PSE%I4I.G=<KG
M()7<I/W6U:S47&%3W<*Y1Y6Y.,)26)49)RJ1YTO>C!'Y_P"B_&SQ/\??BS^W
M7I>I_M0W_P"S9XX_8<_:K_9S\)^%M TVWM]0TBT^!&O_  =_9M^,6K7OQ&^#
M>HZG93?$.;]KW4_'GQF^$7@O6_$RWFI^#X--\(GX*Z-I'Q6\&^)=9\<^*_M.
M>,/B-XZ_99_X.0O GCGXD>,O%'AWX(>&_B]H7PHAN;C2-$D\&^#]<_X)7? S
MXZ3^!K"7PCHWAQ+WPU;^.?B5XI<IK$>I:UJNDWZ6?B76-<G\Z\N/UO\ &7[(
MG[+'Q$^-_@?]I;QY^SM\%O&/[0?PTL8M.\ _&GQ+\-_">L_$SPE96EW-?Z9#
MHGC&_P!*GUNS_L2^N[^\\.RI>>=X<NM4UBXT*33YM9U1[O;O_P!FG]GW5;+X
MQZ;J?P:^'.H:=^T1(LGQ]L+WPII-U9?&PKI$7AW9\5[2>V>#X@PMX8M[;PG)
M;^*X]5@E\(VEGX4DC;P[:6VF11*,94:M-Q]ZK0K4G*RY8SJ1A!58I6M=)RE"
M-E&7NP;4Y-*/-&K1J*3Y:5:A4:NTYPIMR=.3Z^\[1F[N47>>L$G^=6G^+OB7
M\-/VC?\ @D)\)_"_Q1\>_P#"K/BI\#_VD;SXE>!M9O=)UZR\8:QX'^"GPZ\3
M>"M8UGQ%JNBW/C<2^%[[Q-J]MI6D6GBBT\,?9I+-KK0;F^TO3;RU^9_@)^UI
M^T3\2?V;?@M_P4DTWXR^#+ZWNO@E^TQXA^.G[)MEXJ\2>+KWXR_&OP;\%_'W
MQ*TK]F;P+X%UG0M#L_V?_BG^S1XX^'&O>$YF\%KK'B'Q[\/-)\4O\7$^)'BP
MZ'\3+#]MK;]G;X%6FL_"3Q%;_"?P(GB#X!:1K'A[X&ZX?#UA)J_P=\/^(=-M
MM$\0:#\,-1DB>[\"Z)KV@66G^'-:TCPS-IFGZKX:TS2O#E_;7&B:5I]A;<MX
M!_8]_93^%?QI^(7[1_PU_9Q^"G@/X^_%>*^@^(_QC\)?#7PEH/Q'\91:OJ5O
MK6NIKGBW3M*@UF[_ .$EUNRL-<\5%KL'Q5K>G:;K'B$ZGJ6G6-U;W7DZKKN+
M=.56>,G3J+6='ZQ6JU*:M\-3V<:JC+FV<%R/EM%3AX*C'#QDHU%1I8.G4@U:
M%9X>A3HU97OS4_:2I*<>7^9\Z4O>?X__  @OM5\<_M3_ /!$/XZZU\9_$GQ=
MU_X_?L=_M8?%7QAK.H:I:77A'Q!XN\9_!K]F+Q1J7BGX>^'(HVM/AQX;B;6I
M=$L?!'@][#PQ!I<>E7&LV&H^,8M3\3:Q]@_MK:M\8=:_;'_8.^ G@;]H?XI?
M!#X=_'[P[^UYI?Q-MOA?;?#>#Q!JS^ /AAX7\1^%]6\/>)/&7@/Q=J7A[Q-I
ML^HZK907UNU[IUMI.HZEJ%AH5EXXL/"7CKP?]-_#C]@S]BGX0>*]$\=?"[]E
M']G[P%XQ\,:YXM\2^%/$GA;X4^#=(U?P?KOCN,0^+]1\&WEKI"2^$9M>B:[C
MOD\-G2X2FK:\D4<:^(==&H^<_M,?LE^(_CY^U1^QG\9''@F7X>_LUGX[W'B.
MPU/7?%FA?$&YU7XQ^"-)\%:9KOPXUKPQI(N/"FO>#X=,GO(]=L_$FD:QJ%MJ
MU]H]I?:+ T]Y>C<92A:"A!XBM4=-/W(4ZWM9^RB_BE"E>%.,IWFU&E)OF4VB
M$7#VSE/GE*A3A&;C[TJM&%*FJC2?*IU+3J24;1@W423BH*7Y@_#[XD?MA>._
M!G['7P7\5?M7?&G1;F3_ (*L?MX_L!>)OCQX1T?X-V7CK]H'X$_ SX!_MZZK
MX*\>^(+S4?A/JF@6'Q4\(>(_@'H7@W5_$?A+1](T9O'G@WQ9XBUC0-7\20:;
M=Z/Z1\??VE_V@_V/;[_@JPVC?%KXC?&/3OV2/^"9_P"PW\5_A5-\3-'\&^);
M[P?XQUZ]_;=\$?$_XR:Y8>!?!'@L>-+N^L_@UX9^+_Q*M=2MVBUC4?#VM:7H
MLOA3PBVDZ'H'["7/[-WP N[/X4Z=/\&OALUA\"=6CU_X*6*>$-%AM/A)X@BM
M;BP3Q!\.+:"TCA\%Z^-/O;_3CKGAY-/U5M.U+5+!KLV>J:A!<[L7P5^$</C;
MQQ\28_AMX*_X3_XF^&=,\%?$;QB_AW3)?$/CSP;HD=[%H?A/QCJDMN]UXD\-
M:''JFKQZ)H6L27FF:.FM:XNFVMJ-:U7[7C.,Y<KC*S4I2E=.U3_9\/2@I\LD
MTI5*5:=10Y>58FI*E:JTX7#W7/FNU)04$K?NDJ]>I/DYU)-J%2E&'.IJ3H0C
M4O2O&7Y1?M2_'/4OV.?A;XT^-/P__;(/Q$^%'Q3U7_@GNL2_$3Q/X8\5Z'\
M?A[\</VH-!^#WQE_:UA^.SIKT.A_#7XT_#GQWIUSX+T_5-!O/A)\.?%/PR\1
M?$+X6>'-1\*-XX\&:;]K_LH>'_BYX+\8_'WPI\1_CGX6^)_A:;6_A]XX^$GP
MWL]<\1_$'QM\!?"/BWP?]AUGPIXG^,GBUK;Q3\4/#?C/QKX8\1_$3X?7/C#3
M#XL\(Z7XBU/P?)XB\1>$=(\&-IW9_##]B/\ 8Z^"OPQ^(/P5^$O[+7[/_P /
M?A!\69-<?XI_##PK\)/ VD^ OB/'XDM)].UJR\=>%+?1%T3Q7IE[I-S+H1TG
M7;*^TRW\/>7X?M+2#18(+"+MO@%^S=\ /V5O *?"W]FWX-?#?X&_#L:O?>(9
M/!_PO\(Z+X.T2\\0ZG#9VVH^(-2M-%M+5=4UV^M-.TZRNM9U$W6I3V.FZ=92
M736MA9PPZKE3E9/56BWRMI22<H2M9/DDN:G42Y[2E!1A!049M)\M[:.[M?5Q
MTC):W3E&\9P?NZ1DY3FYN7XL_M'?'_Q9^RS\>?\ @MG\?/!>+77?AY^R[_P3
M5ODU^33CJ\/@C1=7UW]IGPUXH^)T^F-I6NQ7]I\+/#.LZU\1;NVNM#UO3YK?
MPK,FHZ1J=B;FQG];^(_C;XD_!;1/'FL:G^VD!\._VA?B#^PC;_ 3X5?"K5$_
M:3^+$5Q\7OCK9^%O%/@WX7?&3XCZY\/;K1_"O[=7A:WO?A[\/?''B_Q5:>'/
MV?+RQ^(WQA^$_B[3=(\(2:9X1_5Z/X$?!>+Q7\3?'*_"SP&WC#XU>'M+\)?&
M/Q)-X7TBXU?XK>%="T^_TC0/#7Q'O)[627QKH/A_2-6UC2/#^D>(SJ5AH6DZ
MUK>F:3;V=CK.IV]WX;X<_P""=W["/@[X.>+_ -GOPC^R%^SQX6^"7C[Q/9>-
M?&?PR\.?"GPAHGA/Q+XPTK5;/6]$\4:OINFZ7;)=^(/#FIZ;IEQX6U=V^W^%
METG2;?P]/IEKI6GPVT1348Q=_=C3BFF]8JI5=2-FFES1J*<)6DXU8M.,H3;5
MU'SR<EI=R;3[^SI*$KQ:=U*FX25TG3DFI*46G^4W_"UOVQ]3_8I_;U\;>"?B
M#XZUSXH?\$_?V^?B3?>$?!'AOQS<>,]6^*O[-GP);X2?%OXH?LIZM\0]7\#6
M'C?X@7?BGX7^)/B9\-_ OCJ^TK3?C'8>*H_ [W/C>^U72]5U37?8_C+^VWK.
MC? RU_;"\"?$P6_[.G[47[8W[,GP7^&?Q#\1:]?^&?AU\/OV:=;US0?A_KWQ
MBOM6O] UI_A]IWQR^)UOXJ\+:=\2U0:/I?PW\<?"?XBZ9#X5\10ZGJ]S^L?P
ML^ 'P-^!MSXVN_@Q\(/AO\*9_B1K>F^)/'C?#SP9H'@]/%>N:/X>TOPII6HZ
MS%H-A8PW<^G>'M&T_3+,/'Y=O##(\4:SW=Y+/-J/P(^">L?!J+]G75_A)\.-
M7^ 4'@?2/AG#\%M5\&>'M1^%T?P\T#3;+1]"\$IX%O=/G\-CPOHVE:=I]AI6
MB#3O[/T^UL;.*U@B6VAV%FM=9.V&NI:*3I0IT\0FU?3$0I1M9>[.=2H^:4W<
M=FWIRQO7LEJXJI*I.A;;6A.H^MIPC""Y5"-ORY\::)^W!\-/ ?BWPQX(^(VC
M_M63^&_VL]$\1:M^S5H'QVO?AK\>K7]FKQ/\#=<U'4_V8? W[5OBE?#&M>(O
MB[X0^(4WA[]IGP9=_$7Q#X \;^(O@U83_"SQO\4;/PIXCT3QG>_;G[''Q(\,
M_M%?LA_#_P :>%?&WQGUK2/%VB>.?#5UK_Q;T7_A7_[0GA/Q#X;\8^+? /C'
MP;\2M,M+:WM="^,'PD\6Z%KGP]\77FD0-H\GC+P??ZKH3W.DSV,TN_X6_8G_
M &3/ ?PQ\!?!OX??L_?#+X<_#?X6>+9OB#\,_#?PX\.6WP^'P^^(=SHFO^&K
MOXB>"]6\&G1-=\,?$*^\/^*_$^C:AXZT;4[/Q9?Z;XBUVTO-7GAU:^2?V6U\
M%VW@;X;S>!O@QI'@GX?_ -A>%]1TGX<Z5_PC+#P#X9U065R-!:]\*>&]0\,S
MW7A^UU62&[U;2M(U?0[[4;;[7%;ZM87ER+Z.I-*-16E).$%&RM-\D9*2NIIR
M<XV2?-&HZBC)U;2<81%2<H-N,;2F]WRKVDHN+:<6ER2NW:+@J;<53<HJ4OR:
M_8P^,OQK^(?B_0_V4OB9\0_'WB3]H#]@3XD?&F']L;Q0EWI.EW?QJT1M/N4_
M8_U#Q%H=H;;3M-\,_M6_#;XH^'/VB]&F\+_V1I/A3QS^S_X[^#*PCPU;^)=.
MO/(_@_\ M1?'+QA\%/\ @D%^U]H/Q$\5>.O%W[>?QC\*_##]I_X.V^K"3X<K
MI7Q8^"_QN^)7C'1O '@^:UN)?AAXA_8L\2?"^ZT>RU'P9<^'O$7B7X>> OB&
MOQ\N?B5\0IK?QSH7ZV?LY?"3X@^ M,\5>./CEXE\ >-?VA/BU?>&];^*WB3X
M7^#-6\#?#JQ?PMX3TGPGX<\$?#O1/%/BCQSXU@\$>&K;3]0U>!_%WC37=0U7
MQGXM\=>*;2V\*Z7XDLO!?ASKO"/[//P0\ ^+=6\<^"_A=X.\,>)]9\0^+O%U
MW?Z/I$%G!;^+_B'=C4?B1XOT?2HL:/X>\6?$W4E35/B=XFT"PTW7/B/JL-OJ
M?C>_UZ_MH+B.E[LX\UJG+&CS.-G&<X3DZSLXP7+B*2I4YI1BHRC5E324HV33
MDI<O-%-U>6,F[QC."5)N2<I*5&JZE2.KYHNG&;O&5_QW\+?M'?'.+P+^P;>3
M_%WQ9<ZSXN_X+6?MO_LB^-+G4;O2KJ\\:? +X7_&+_@I!X7\%?#OQ1;W&FFW
MU&7P]X>^ OPDC@\2I:6WC?'A-;B;Q"R^(/% US[D_P""D_C3XD?!K]G[1OVF
M_A_XS\8^&M&_9=^+7PN^-GQZ\/>%([2Z@^(O[*?AOQCI=M^TWX?UVRNXI7^R
M^$?@_?>)_C!IMUHK6'B*;6OAEI_AN#5(?#WB;Q/I^J>Q?\,/?L<_\)OJWQ(?
M]E_X$S>.M<^+&F_'?5O$]Q\,?"5SJE[\:-(L+[3].^*<DT^ER*OCRU34M0OX
M_$\2)JIUZ\N/$LER_B&1M3/T9XD\.:!XQ\.Z]X1\5Z-IGB/PMXIT75/#GB7P
M]K5E;ZEHVO:!KEC/IFL:-JVG7<<MK?Z9JFG75S8W]E<Q26]U:SRP31O'(RF(
MWC3I1^*=)TY\TMJDH0PB<9OWI.-2>'JN=U+W<5-I.<;S:C[TN9OEG&K&3C?F
M7M*V+FI13?*I4Z>(IP@E9)X:FF^27N_AW^S5\?OBQ\1OVE_C5^REK7Q2^(FI
MOXU^.WPW_;3_ &;O'G_";Z+>ZK)_P3$\0Z?JO]E?\(Z^EZ;I]CKW@C7_ (X?
M!WQ)\(M2N-1&J?$?3/A)^T]\*?%&L>);CQQI.EZ_IWCO[:/C?XI^+OV4/^"P
M7ACQ9\7?B9K%E\(_^"E'[+/PR^'-W::[;>#=3\-?"GQWX"_X)G>-M9^%D%S\
M/=,\(1ZCX%EU+XW_ !#L[C3-9M]2NO$FCZY+:^-K_P 4RW.HW5__ $+V7@;P
M7INO6OBG3_"?ANP\2V/A:W\#6.O6>BZ=:ZO9^"[2]74;7PG::A!;I=6WANWO
MT2]@T6&1-.BND2=+=9$5AY5KO[*W[-OB;PU\:?!OB'X'?#'6?"W[1UW+J/Q[
MT+4/"&CW.G?&#5I;"TTO^W?B'!);$>*?$,&F:;I.G67B#5C<ZU86.B:!:6-_
M;V^@Z/'8C5IT91YN6ENI/6JZ>(PLZ,IVO%2]CA5&;7,O;5)S@N5RYR2E.%2,
MFHRJ]8+2"GA\73JJ*=FX^VQ7/"+LW3IPC-\RCR?A%^V"/B3\,OBG_P %NOC'
M\(?C;\5OA/X]_99_X)S_ +&GQW\!:WX2O_#6H7'BKQI\$O!'[=/COPM:_$^7
MQKX7\62>-O"=_J'A6/3O%OAN9[&Q\4:5K.NQ:^VH7$FDW&C?MY^V7XK\8^$/
MV-_VH?'GP_\ %6L> /'G@_\ 9Q^,7C?P=XNT*S\.:CK/AGQ1X7^''B#Q)HFI
MV-EXO\/^)_#5W/9ZEIUN3!K7A[5+*1 ZR6;,5*:#_L??LK26'C[2G_9X^#IT
MKXK>"?"_PT^*.DCP!X<72OB5\.?!%C+I7@SP!X_TU; 6/C+P5X2TFYO=)\-^
M%?$<&I:%HFE:GJ^FZ986MCJ^IV]WZUKGPY\">)_A_J?PI\2>$]#\0?#76_"M
MQX&UOP+K5A#JGA?6_!5[IIT74/"6M:/>K/9ZMX;U+16ET;5-$U"*YTW5-(FN
M-,U"VN;&XG@?.<)NC5I1FXRE2]G2GK^[ER8V/M-/>3OB*$^6+:3H.VLE*6D&
MHUJ=244X1J.=2%E[Z=3"SY-=&E&C6A>2N_:IO1.,?YZM9_:K_:D_9?TK4?BG
MI_Q8\?\ [0>I>*_^"#_QI_;NF^'/Q2M?#^J^$[7]HS]G.U^!K^%M1\):;X3T
M/PMKNA^&_$MA\8M6TSQ]X;LM<NKWQ-:>&] UF>^O/'+:QXCUS[H\)_$/XC_#
MK]LG]ASP1X#^+?CC]H+X+_MA?LJ?'KXA_$_4?%NN:9XFL[3Q1\%K+]G_ %WP
MG^T[X*FLM+@A\%:!\3I/C(? _C7X?>!YM"^"%GJ/BCX6WGPX\ >!;J'73XL^
M_?#?[.WP*\'>)_!_C7PK\)? 7A_Q=\/OANOP;\">)=)\-Z;9:WX-^#Z36-RG
MPF\,:E# MWH?PRCN]+TB\B\ Z=+;^$XKW1=#O8](6ZT72YK1WPJ_9[^"/P.@
MCM/A%\,/!_P]LK31X?#.D6'AC28=/L/#/@^UOKC5+'P'X-L$S9^"OAWIFJ7E
M]JFD?#WPE!HO@K2-4U#4M1TS0;6]U&]GGZ').K5FX^[*K5E3AI:%*=7,)PHN
MR5U&&+PZ<EK&6#@H-PY%'"$)1I4X.?-*-*E"<G=.56%+ 0E63NW=SPN(ERO2
M2Q<^?WE/G^4OVB_C,R_MN?LD_L?>)_&^I_#?X=?M$?!']K/X@PW_ (;\57_@
M'QI\4/BU\#]6_9WM/!OPD\,>-]%O=/\ $VD6]IX$^*'Q7^+VO:9X-U+0?%>N
MR_#/PZ'U\^ ]-^(/A'QE\Y_!WQI\2OC7\=_%7[%_C?\ ; \9>*KKX-?L(_!/
MXD^#/V@OA18>&_A!XT^.OQ@\??&']I+X0_$']HI]%\/?VQX2UC3_ (*ZC\#_
M  #8Z1\.Q8ZQ\!O$?B7XF>)=3^)'@'XA^'-4^&=EX7_2G]H#]F/]G;]JWP99
M?#O]I?X(?"WX\>!],\0:?XLTOPO\5_!'A_QQH^E>)M*CN;>QU_2;37[&]32]
M7BLK[4=+?4+#[/<W.C:IJVBW,DVE:MJ-G<N\3_LS_L_^,(/ -MK_ ,'_  !<
M0?"WPOJO@+X=QV?AVQT9?!_PY\0Z;HVB^)OA=HG]B1Z<;3X4^+=&\-^&]'\8
M_"U2?A_XOTGP[H&F^)?#FJV6BZ9!:Y*.ZDY?%5ORNW-&<*BI/F^*$Z,YJWL[
M.48J3DI1A%:R;;35E94]U>SC.#JQM?EG&M".O.O=DVK.,IR?X=_LP_'7]JG]
MN7QI^PIHOQ0^/'Q@^!VE_M-_\$@?BA\?/B'H7P1;X>>#[>Z^+'A_XV_LO^$-
M ^-/P_UW4OAUKOB?0K;Q]X6\?:AXRT&QEUK4['2= U[1K#04TVSO/%7_  E=
M[X._$;XC_M)^//\ @W;^,?Q2^('CBZ\;?&;]B3XN_&/XF_\ "/>(KWPAX7\6
M_$V?]FK]G_Q)>>--2\"^&O[*\%_VG>ZEXS\5Q1>1H$4&FZ%XFUOPSI,=EX>U
M;4M.O/W+U#X"?!;5?&5I\1;[X7^"9?'VG_#O4?A%IWC1- L;?Q3IWPHU>:"Z
MU;X9:=KMM%#J5A\/]3OK.PU*_P#!UI<P^'KO5=.TW5;C3I-1TVPNK?DI/V1?
MV7)-&^"OAQOV??A"/#_[-^M_\)#^S_H4?@+P[%H_P7U4:==Z2DWPRTR*P2R\
M&6\.G7LMM;Z?H,%CIULL5B\%I%+ING26M+2?,U=*JJB2LM/:8QMV5HPDZ6)A
M'E@_9IP<(VIQHN.4H.2<5)J+IRARN[UMA'%.3?-*,9X:2YI?O)*:J2O4=12_
M%E/C/^T;\&/V(_C_ /MI^)OVN?CAXS\3Z%^UI^T/^QS;P^/]/^"C?"[X/_"E
M/^"P_B;]D\?M(-X4\/?![P_:WWQ0^!/P5M]2\46.M>);F^^%L5EHKZ=XL^'=
MYX-TN&TT[W7X\^+?BA\//BW_ ,%"?V6[+Q)XT^(/[/FJ?\$K/%7[26CGQSXA
MOO&^O?!'XI:M?_&WX7ZGX1M?&^N_;?&VI^#/C3HOAJ7QAX4T/QOXB\23>&_$
M?PU^)%OX.O\ 3_"-W9^%_#7ZL>&_V>O@3X0\ >-?A3X:^#WPVT?X7_$F?QE=
M?$/X<6G@W01X$\=W/Q'2[3XBW/C#PE)8OH/B2X^(7]H:@_CN;6+"\D\8S:A?
MW'B-M3GO;J26OHO[.7P-\/\ @CQ5\.-.^&/A9_!/CKPY#X-\;Z!JED^O6_C'
MP7:Z1/X<L?!/BJ?79=1O?$/@K3/"]U<>$M(\(:O=7?AS2/!\K>$M,TRT\.8T
ML9R@Y8:I0=G*>&J4.=JZ;J9?+"-R5[VCB9RQBDFZDI-QDTY>[O2DZ>(I5W>2
MIXBE6Y4^7^%CX8I6:T;EAX+".+7LXQY9)-1L_C[PC\6_%GP!_P""//A?X[>
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MUJU&K;72\8PG!K5/F3TUL33<:B@^64X4DG_+*G1JTKV2=[RG":>C3BUKI?\
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MG?6</CJ'Q!)XB^(6N>+O._CM^TI^U/\ #?X%?\%I=#\)_$[XB_"?5?V7;?\
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M!KVI_#'XVZ-:)HU]J-C!I!^(GA;7M5\*F&ZEAU'P;JGAS6K.2?3]3M+B;/\
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MXJ-2$$URN-24G*U.GSW*UG9M/GEJM4H+$U%#1J_O89TY2:;DI02<??GR^2>
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M? =]XH\-?"GXG_ /0HYKFPU;QU923[?Q&_X)\2>+M=_;2T?PQ\9;GP9\#O\
M@H1X?@T_]IOX5OX$BUC78?$VH_"?1_V?_'_CSX'?$&R\7>&X?AEXE^)GP1\.
M>%O"_BAO%'@OXIV-OXJ\)Z#X]\/VNCZE+XFL/$J]YQIN+2;C4YG-/E<HRBJ$
M_=?-[.LG4=6RC./LO<BN>FW6G/--2Y5*G=)I22DFZT8MIQ<Z34%3YFXOVGOS
M?)43XGXL_P#!38_#OP7_ ,%$?'7A_P"$&A^/-#_81_9[^%?[36C7UE\6;S2=
M/^.7PS^)OPV\=_$^'[#=M\+-3F\">(+/0O &IQ:=92V?B_2]9GU'1WGUO1H9
MKQ['])?B1XMOO /P[\>^.],\&>*_B/J7@KP7XI\6Z?\ #SP';:=>>./'E]X<
MT.^UBT\&>#;36-2T?2;KQ7XHN+./0_#MMJFKZ5IT^KWUG%>ZE8VS2W47YF?M
M'?\ !,+4OC)=_MAZ#\.?CW8_!3X2_MM_LC^$OV7OBKX&M/@SIOC/7?"\WPV\
M*_$WP1\/_%OPL\5W7CSP_H?ACP\?"7Q+G\/^/O >M> ?%5[K]AX=T2;P'XZ^
M%6K'4-4O/O'X\?!2?X^?LT_&#]GC7O'WB+PS=?&3X)^//@]K/Q-\(0V^D>*-
M"G\?>"=4\'ZAXU\.6L4GV33]8T^359=9TRT68P07,45OYQC4R5,W-*LX)M*+
M5&$G%5&U+&6<I).";A]3;Z.HJG+%1;0X6O252U^9.JX\WL^5QPK<8IVG93^M
MI=5%QO)OE9^?NH?\%1]7T+X9?M]>+-6^"?@36?&O["'[)7@G]KK7O#/PV_:&
M'CSP1XX\+^*?#/Q^U76? "?$]O@_X?C\/_$/P1XA_9H^*'ACQ#::=X1\9>'D
MF;PO+%X@_M:^\2^'O"/I.H_MT_%SPS?>$O OCC]FC2O#GQH^+6C_ !<^)_P7
M^'FA?$KXH?%_3]6^ 7PLL/@;9S>./BIK_P #/V8OB9K_ ,,O'5U\0/C[X0\$
M:QX'T+P)\3O NC#3=?U[2/C-XL@31;#6_*M7_P""8_Q6\9>$OVK_  [X\_:E
M\%7EQ^U__P $]/AS^P1X^3P-^R]I_P ._"/@FP^&\'[1?AO3/'GPG\'V'QDU
M7_A&-%NO!'[27B]3\-M:UOQ2NF?$"QT_Q%I/C2S^'D-C\'],]B_:._8;^+'Q
M;G_9?^*OP>_:LU#]G']K#]E_PSXJ\":/\8_#_P )-+\=_#7XB?#KXFV7@&'X
MM_#OXB_ ?Q/XV@BUOPCXMU3X7^ _%&@0#XCQ:SX$\3^&M-UG1];N+J)VDU:5
MFW*[=9Q2A?EC0<L6HSCS)-R7^R.?-)R4.=I2J*:EDG/F6BY?8IWDUS.LEA&X
MRY;I1;^MJ/*N5OV:;C!PE'ZH_9C^-.M_M"? 'X9_&?Q+\&_B?\ ?$_CCPZVH
M>)/@K\8/#][X9^(WP]\1Z??WVC:[X<UK3=5M-+NIK>+5M,NYO#FNS:?ID7BC
MPS<:-XG@L;"UU>*VA_/[P]_P4V^)_BC7?&OPYT/]D_3M6^.NG_L5^+?VP_ O
MP1TCX^0ZIXQN-4\ ^+/#WAGQE^R_\9IK7X1MIGP<_:0TF?QQX&TT^$='N/BK
MHL'C#4==\/:]XAT#2=(T3Q7XL_2CP?\ #C5] ^$MM\-O$7Q.\?>-O$,_AW6-
M,\1?%K4KW3=(\?ZSK_B0ZA<ZWXMT]]!TZPT'PG>IJFJ7=YX7T;PWH]AX<\%V
M<.E:'X<TJST71["RB_._]D+_ ()M>/\ ]F#X@?LL>-]<_:6T7XDV_P"S'^QO
MXQ_8AL_#FF? 2S^'EEXO^%]UXP^$OBSP#XPN+^/XI>+M1TKXKZ>WPKM+?XK^
M(;F77_#/Q0O=1_MGPMX+^$-W#JJ>()G=SFHM03A-1DES0C-TZZC)*5IODJJA
M)1E[LH2<;I*3+BTHQ;3DU*+<&^63BJE%N,I*Z7-2=:+<=5**EJW%$WA3_@J3
MX5\1?$GX?>&;KP;X,T[X>?%?_@FK)_P4A^'OQ+MOBOK.JS>(/"&E)X8G\4^!
M_P#A!U^$=GK5K_8FG^+-+URS\2->2ZMXAT%=2N]*\!OJ&@>)M*T.]^U5_P %
M%/'W[(7@2^\>_%;]G/P_IFG^"/@A\*?C!\2[.Y^/=K:7FKZOXN\7:OH7Q6^%
M?[-L4?PNOIOCUXU^ >@:!<^,/',^MP?![P\VE^*_AA)+JVDZ9XNUK6O!D7A/
M_@DS\$/".D? [1]/\8>-EB^ G[97Q._:M\%RP316[67@_P >'XI:=H_[*=B#
M-.^F_LZ^$O"GCWPWX7_X0=);G2_$%I\/[*[U#3X+G6[S[+E?MA?\$R?%O[4G
MB_\ :VU;1?VFY_AMX4_; _9-\ ?LU>-?#^J_"&R^)>O^"-3^$7B3XF^*_A]X
MH^&GBK4?B!X<L?#O@35M6^*.M/\ &#X73^$]0U/QZ;:WU'PC\3/A;XA(UR-R
MDN:+2:C[64I1O>,:?-3JQA=VG*T:M?"\VDI?5:-9J+KR:E)V:<KVIQ2EHG*I
M:I2<[).,;NG1Q/*KJ/UBM23DJ,4>M^)OVS?BS8_M;?%_]F_PO^SSX3U3P3\
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M_@H1^U#H&AV^I>)_%6I:OXBUJ:PT73+#3HKW6=5OKU[:TA6>ZD*;J\R_9O\
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MZ/V7H]!\!P0O\6[2+Q%I>OVW[)/PTBUG6Y#HMY%)K/CN:QLH/[5\/)X5\/\
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MM%TR[NK"+0IK7Q/I>JWUO;$^*--M;R2>S^0?&W[2WQV_97_;%_X*X_%7X9_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHO7OB=^U#^S_ /!CQ#!X6^*/Q4\*^#-:-CX5U;58-5N+DVGA#0O'GBF[\"^
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MGP<_;4\2^!?V"X/BMHWB/XVZU\$_^"JM]\7+GXGGP9X ^&OQ*UC]D/1?A_\
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MJ\,_M/\ [1'P1^-'[$_Q#_:0^''Q7_;!M_VJO@'^TXOQA\-#]FWP=X<U;6/
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M7Z;:ZYI4MW^*OP-^&G[9/['7AK_@E!\5IOV2_BO^T%I7PA_X)BZ!^P)^T?\
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MQ%'JKV8TO28+Z2Z:.73M0AMORQ\3?LK?M&>,/V</VD?V%-7\">(]$\9>-?\
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MKPM\*=#ADUS4+Y/"Z&?4=;^C/C7HWQ_/[3/@G]I'4/V$_P!IG]H3]G3]IO\
M8U^''[.?Q$^!O@+XI?#+X>_'KX'?$+X9_$OXU>)=%G^*/@+6_P!IOX8_!WQ1
M\,OCCX+^/^IZ-XU-U\3]>E\#-\/M-L_&MCI*:I<:7-<X\DJB4U))I4V]4VGC
ME9NDI-JI*A0BIQBH+VT7&T:E%N(3E-Q;A*,>1N6B3NW@G=*HXV=.%:O+D<G)
M^RDI^]"JE]Z?MN_MH>#_ -FW]FWXX?$7P3X^^&EU\5_!G[-GQ&^/?PWT?Q-;
M:UXP\&:A8^&?"&O:[X.\0^/O^$)U?29_#/PN\:^(-%C\'Z9X]UCQ/X6\.ZEK
MVH6VCZ)KNH:]+:Z1=_2_PS^(1\0_ _X??%;QQ>Z%X>.N?"KPG\0O%^H/+_8O
MAG0SJ?A&P\1Z_>--JU_<?V3H6FF>[F,NIZG/]@L(=UY?R^5)<-^#OQ(_9V_:
M:^#D/_!17X.^%/V0==\??#O]LO\ X)U_"KX,_LV0_ '7?AMJGPO_ &>]?^#?
M[*OQ%^!^K?LI>(YOB1XO^&?B?1/AQH7B37?^$^^$OB'3/!6H:#XEL_'OC33U
MT_2_' B\,:Q^Y'P!M/$?A3]G#X,Z?XS\)Z]X4\5^%?@SX TWQ3X*O9M U[Q'
MH>N^'O!FE6>L>'Y9O!.N^*O#>L:I:WME<6:/X9\0ZYIE].J_V=J5Y#+'*ZTY
M*KOK>GR\V\+/'1G"T-9.*IX>4Y4[PFZD72;3@Y6^;VE-;QY*G,XZ*;?U&5.5
MY:1NIXA0C.TH<DXU/>4DO$?!G[;7P!\-_"7X(Z[\:/VKOV;O$7C+XK?"FX^)
M>@>)/AM//X0\)?%_0-%@L#KWCOX,?#G6O'/Q*\;ZAX'FO=6TC3=!^S^)_&=S
MJVIZWX?T?3M3U/6?$.D:?<W_ !A^WS^S5X7L?V3=;TOQS%X^\*_MH^+KKPO\
M#?&OP]L=3\9>#==M]/\ A;XW^+U[XANO$7AVRU.PL]-_X17P%K$-A;2.=6U'
M69$L[>P^S:;XCOM#_+C]C/\ 9C_:&^%5C_P0JL/B+\#?&6@R_L@_L=_M'_"?
M]HBXD?P9K4'PB^(?B;X>?!3PAX1L;A]!\4ZO/XI3Q7?> _&%EI>K_#&'QG9V
M.G_9[CQ/<>'K#6[.2YL_!SX%?M(_"O\ 9N_X)>76J?LV_%+4O%'[-O\ P4A_
M:?\ BK\6?A1X<O\ X42>.?"OPQ^-_@W_ (*.> _AYXL@?4_B=HWP^U70TO/V
ME_@]>Z^FA>.M0N?"?AW7=6NM5LK:;PAXIT_2')6E&*UO5BFTXI*FL5"A+1.T
M7*E+VJ:E9)3E9Q:E'/FFH2:C>U.7+I)MS]A*I%J_O22G&4+.*;O&+:EI/]GW
M_:0^!D?Q%T_X4S?$SPS!XYU;Q)?>"-(TV>XN(=,UCXB:5H%UXNU7X6:/XIEM
MX_">J_%O2_!UC?\ C74OA/I^N7/Q&L/!-C>^,KOPQ#X9M+G58N\\?_$/P1\+
M/"U[XU^(?B?2?"7A>QO="TJ35M8N1!%<ZYXKU_2_"7A#PWI<"B2\UKQ3XS\7
M:YH7@_P9X6T>WOO$/B_Q=KNB>%O#>F:IK^L:;IUU^'WAO]DGX_ZI^RWI/[#?
MC'P7XG'Q0^'7_!3K3OVH-!_:6O)-(G\%Z_\ !JT_X*07'[>]W^T#I/BZ*[U2
M?1_BCK_@;4O$/P-U+X:7=M)\34^-^M7NLW?AZ;]G[4;GXPK^A/\ P40@^,TW
MP T2?X(?"*V^,OB/2?CW^SIXC\2Z):^%_AKXV^('@_X=^%OC+X/\2^-?BM\$
M?"GQ@_XMMJ_QX^%VDZ4WC/X13^*!-;^'?&>DZ;XLT_3=>UC0-.\/:KG%OV<9
M.W-*=*/+KHJD,+*4F^5\GLJE>M1DY)I2P[J/W.=+9_'.*ORQC.2DTM7"5=)+
M6\N>-*G4C9)M55%7;@SZD^%WQ<^&_P :/#EUXK^&'BW3?%NC:;XB\0^#=<-F
MMU9ZKX7\:>$=3FT7Q;X(\8>'M4M['Q#X.\;>%-8MY]*\3^#_ !3I>D>)?#^H
MQ266KZ79W"F*OG2#]HWX@M_P4%O/V3;OPOX-M_AJO[(:_M#:3XNMM2UN]\<Z
MAXI'QAM?AO=Z+J.GRVMAH.BZ!9V$CW5NMM)KVH:I>3+/)?:/#:&PO?$_^"9_
MPQ^*GPIE_;DTOXF?"#XD?"NS\=_MQ_$7XP_#F;XC^,_"GC[4/%GP_P#B!\-O
MA*-(O8_$^A?$OXEZMJ>I:3<Z'?:9XDDUS5'AL]82;1]&U77(-+NY;/JV^'OQ
M&/\ P57@^+X\ ^)?^%0Q_L%77P@;XG;=('A@?%.3X^6?Q!C\$BT_M;_A*VNC
MX-BDUH^(AX9_X0995'AX^*_^$L;^P W?FHM7M.$I36CY92P=2?*WWA748QNT
MW)133;L3/F4:B6KC5C&,HKXH1Q<(.:7:=!N3M=<K;5DKKQ?QE_P4GU[0/#G[
M0O[2%CH/@U?V3OV6OVSO#W[&OQ'CU&Q\03?$WQ-]D^(OPR^"OQG^.OA_Q-:Z
MY!X=\,^&_@Q\7OB=J^CWGPVU#P+XGU7Q?X3^"GC#Q-I_CW2=1\=>'O#/AKJ/
M@S_P4L^&,7QY_:1_9[_:F^-'[/7PM^(?A7]NF_\ V6_V:?#)U:;P+K_Q1\-7
MW[/G[.GQ<\'PZG8>+?&/B$:IX]U?Q5\8O$'@C3]2TQ_#6A^,-7TO1O#?A?PZ
M?$TDEKJ/R5\1OV%?C-XD^ /[:O\ P3\B\*ZS>>&/VKO^"B5Q^T=X>^-$::6/
M ^D?LS?'#]HOX9_M1?M#WGB.^?48[C2_B+X UF#XO_"#P1X!2SU#7_&VK:K\
M)/&%E G@*\^*7B/X5'QI_8_^,GQ8^&W_  5]_9-O_@]KT&J_MX?M;>$/B1\%
M/BK=QZ#>_#C1?AIJOP"_8Y^&LOQON_%5AK%Q)X>\7_L]_$'X*^,/&>D?#O78
M-!^).O>(_#OA/4/ &D:IH^JS^*]'KW6Z?+S--4[MVC)\T,O59OFM&,J=:IB^
M6]DJ=*I%*<$I1M*T*SFXQFF^7EO.,4JN,]FX\J4YJ="&&YEHW*I'WH5&HOZ3
M_:1_;W^(EE^W)X$_82_9@^)?[#/A[XMQ^%/#GC/XC^%_VM/'GQ,\,>._%UAX
MRU*XN;'PY^SGX4\$:0MG\0_''@[P)X=UOQQXQ\-W_B&SN9=,\5>!)[(V6EVW
MBW5=+_7//&?Q]>/\_P#ZZ_,G]LSX?WO[:GA_XB?LF:G^SE\6?#>L>$_'_P '
MO''PA_:>\0V_PZL_ '@?Q3X=U?P_XVT?]H[X-^,=$^(.J>.-/\<_![5K75=(
MM/",WAWPEXX\3^((#X<O;*T^$OC#7/'%G]$ZG^S-XPU#]I*S_:!B_;!_:MTS
MPO9RV4K?LMZ;J_P+3]FR]%IX3/AB2&]TN[^ UY\8I(K^[+>,+T1?&:!SXK(G
MM9+71$CT)%%W@KZ-S;YM[P=-R4K:22C-*DZ=K\_[Q-QE*,9EI)N-W:FK0VM.
M,U%INW(W*+=53O\ "N1JZBY<[\!OVC/B!\3_ -J?]MKX$>+?"_@W0O#G[-&N
M_ ;3O FJ^'-2UO5=;\4:5\6OA6_Q U'4O%TVIVNF6-CJ%K?%=/LM'T?3I+>Q
MM+=I9]:UB:\'V+UGXS?M0?LZ_L[W/AVR^.?QL^&?PIU'Q?9>+-3\*Z5XW\7Z
M/H.L>(]-\"Z!<^)O&&HZ'I%Y=)J6J6'AS1[83:K>6=K-;6MU>Z1I;R_VKKFC
M65_\R_LV?#[XB^&_V[?^"C/Q"\3> ?$OAWX??%S4_P!EVX^%7C;4UTC^Q?'\
M/PT^#$G@GQZ^D6]CJ]]KVD_\(YXI=-+QXPT;PPWB*)_[9\'+XC\/1RZPGEG[
M?&N1^&OVUO\ @D3KUQX=UWQ/9Z5^T7^U!=WUCX:TG^W]=L;)?V$OV@XKG7=-
MT"%FU?79M&@EDNY='\,6FJ^+;^U%Q!X:T36]4,&E7:C=K#Q>CJ*$)-K52;Q[
MYFE]IJC0YD^5-3N^5.Z(WOB&TVH2JS@E97A%8/EBF_LOVM6S7,TTTE)JQZ5\
M>?VX],B_9Z_9E_:5_9'\=?!KXS?"[XY?M=_L>?!.;QC%)J'C?POKWPU_:"_:
M?\"?L\>/[GP;JWA+Q7H$>D?$'P?<>*]4CA_MW^U[;PUXK\.ZEH/BOPE<:A97
MNEP?4Y_:8^ X^)T7P=/Q/\-?\+#F\63?#R+1A-=-8/\ $ZW\##XHS?"0>)UM
M3X4'QBB^%C+\4I/A"=<'Q*3X8NGQ#/A8>#676S^.FK?LA_&WP_\ L_>*+CP[
M\)/%,FM?&_\ X+<?!+]OP_"32[KPM+JWPJ^"7A7]L;X%?%+QSK^O/+XCM=#B
MUKQ%X)^#OB;XX:YX0T'4-6\2#QQ\3+GP39:9K'B:&_8\7\0?A+^UCXJ_:3\'
M^);W]C[X@Z98?"+_ (+$:3\<H[KX1?\ "AO!WP9\4?LWZG\$/B#\,=$^.YM;
M?XE>$_%/Q:^-'BRY\3>#]6^-OBGXJZ5JOBGP,=*U[PYX1GT;P[I5AI'BQPUJ
M*+NE*=)OF^*"J4<#SP4K*+]E4KUKO2_LIW<>6K&-SY524DTYQA7ORIM3=.KB
M_9-QUDO:TZ--*S=O:0:3YJ3E^Q'A_P#;D_8]\6^-_"?PX\*_M)_!WQ-XU\=>
M+_&7P_\ ".A^'_&^C:S+KWCKP =;7Q9X/L;O3;BYTYO$VFOX7\61Q:)+>1ZC
MJLO@WQI%H]OJ$O@[Q,FE?55?SP:7^S3^T'8_#?P?H[? 7QR=;LO^"^WQ'_;%
MU!(4\&+-;?LS^)_VG_B=\2M+^-LT\GBJ%I=/D^''BO0_M'@R%I_C+#Y\_AUO
MAN]U87EE!_0\. !Z 4TO=3N[^[?73WL/A:UTMURSK5:3NWK2:=I1G%9*3<Y)
MJT5S<KMO;$8JE;YTZ-&ILM*J:O%P8M%%%!84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?SH_\%/\ ]HOQ
M3X0\6_MDZ_\ !OX^_$_0?'G[)W@+_@G]K%[I"_%?6_A7\.?@]XQ^*/[07BS4
MM&L/#?P\\-W46G?M+^(OCYX/LO[&^)VB_&G2)/AUX;\)Z'X3T;P'J7C76]8^
M*'@WPHEK4IP_Y^246VU[J<Z,')K>23KT[J.K3=M>5,>D9RZ0C*6SUM"M.U]E
M=4)V;TO:]E=K^BZBOYPOVL+?X@^.OB9_P6DU&Q_;(_:6^"\?[(W[.?[.W[3'
MP'?X<_'+Q/X4\&?"GX@:9\ _C5X\B\4ZSX3TJ[CTSQE\+M>U?P#(/'7PG\71
MZM\+_B'I]QKLGB+P[J?B#1O!6M^"NF\4Z+\5?VB?BQ^UCX?^./[4G[1W[)>J
M^'O^"5__  3^_:<U+0?A=\>O%OPD\-_ ']H+Q'=?MZV/Q/\ B':66FZG975I
MX<\%7GPW\+Q>._!&J:C-\-/'<.CV3?%WPWXPFT?PC-X>B511I^T;T5.562BN
M:2IQHXNO*22?O-0P5=<MU:7L;RC&JI1OD?/R:7=2%)/HZE2IA:4(O=I2>,HO
MFL]%52C*4%&?]"]%?SX_ +4_CI^U+^TQ^Q7IW[1'Q?\ VBOAOKOC/_@D!^SA
M^U+\8_A!\-OBGXV^!F@S_M)VGQ;^&^I^+=0U[PAX/O- U+1S/J=]JO@_QGX/
M@N;#1=5\.7-WX-\2Z;?Z>TD#X7P3^.O[07B[X!?\$IOVOM!\=_$W5_VAOVF_
MVN-/^"_[5OP7U_QEX[O?AU<:1XM'QW@_:=^$VF?!'6=9E\'?#76OV.]5^%>M
M^(?#>N^&O#FA?$/P_H_[/>O:!XW\1^)+/Q9\2U\5;.$E)P;2:J>SL]'_ +Y7
MP7/RNTN55J$G4O%.E3E%U.67-!8*HI*Z3:Y.=/H[86CC'%25XMNC67):3524
M9*"<+3?]%>1ZT5^$WP>U?XP:#^UI\<O^":GBCXD_'#7[W2_VD/!7[=/@'XMZ
M]\4_BC<^,(?^"?OBI3XNM?AYIGC^^\3ZK<WT'@W]JSX?7W[)&N> ]3UVVU#Q
M1^SSXN?QB^F:IKEMXG\1+P7P2^-'BG]HCXWP>+=9_P""A/AGX'?&_P" W_!2
M;X__  6^(7[*$>G_ !'UOQ=X]^&&@?&SXL_#GX:_ 37/@[?_ +1-A\,=2TOX
MC?L[6GPO^+/A?X\^#OV<Y=8\,?V+J'Q57Q-=6=I\5[O49BE)PM)6G!3^&5U&
M\*<[KXFX5Y2I2C%.2=.4[.#AS4WR\]U\$G#=*[Y9U(ZO1*=&,:L7*25IQBW>
M,^7]I/C)^T/\-?@3K7P4\/\ Q N/$-OJ?[0/Q?T7X&_#5=&\*Z[KMA>?$#7M
M#\0>);*RU[6=.LI=%\*6!T/POKM^NH>(M0TZ*\-A)8Z6NH:D\5F[_BS^T+\-
MO@KXJ^!'@SQU<Z_;Z[^T?\5?^%,_"U-+\,:WJ^F7_CM? WC'XCR:?KFNV=F^
MA^&(1X0\!>*=4MI-<U&RFU3^R[FWT>WU">"Y2'^=K0_C#'^TA\*_^"6?[4/Q
M-^)/BJ'X]^+O^"Q&J^"/B_\ #76?BAXFL_#'PO\ &'A.Z_:T\(_\,^-\#=3\
M0)X#\%:W\&= T;P%X6L-0TSP3HGQ(\26FCV/CGQ1X@\2:I\3O&6O^-?TL_X*
MD: OBOQG_P $K?"TGB+Q%X3C\0_\%,- T:?7_".J0:%XHL;6]_8=_;FAO8]!
MUR:TO)]#U+4+,W&EPZWI*6GB711>OJGA/5] \46FCZ[IKIQ<Y4ENYUU%J+T<
M)8?!XB"4FG&[ABHWG%22NURN45SIR:G5BWRQIX>4TVD[5(5,=3E=75USX2R@
MVGKNN:T?UHZT5_.S'\/OVMK?X#?M_>"?@G\;/VE?C'=?\$_OVY?"OQ*_8[U/
MQ#\</'NK?$3]H;X>_#_X2_L^_M$?'']B'QY\3--U./Q?\</"VI^)O&7QK_9@
M\->(_B7K?C'Q'X=\8W&D:%XH\27VM_":^M+7]5OV,O']E^T%X?\ '/[6_AGQ
M/XMUKX5?M(:SX=U_X!Z9KVI>-+72K#X(>$/">E^%O#7B?2_ ?B.^?0_"MS\4
M_%5OXY^)T&J^'='T6Z\5^ O%/PYD\313ZMH^(!)M7337+3F]FU&K3C.E=)M)
MSFJM*RE)*5&4KRC.%FY)-1>[E4BM[-TJCA.S:5U&+IU-D[5%%J,X217^(G_!
M0C]F'X4^,/COX'\>>(/B1I&M?LQ^"O"7Q,^/=QI_P$^.OBOP]\,_AGX\A\5W
M7A+XB:YXJ\'?#KQ!X;N?!6IV7@7QIJ%]X@T;5-3L?"NG>$O$^H>,W\.6?A[6
M9K'Z_P##GB/P]XP\/:%XM\):]HWBGPIXIT;2_$?AGQ-X<U2QUOP]XC\/:Y8P
M:GHNO:%K6F3W6FZOHVKZ;<VVH:7JFGW-Q8ZA8W$%W:3S02QR-^&GB3X3?$SX
M\_\ !1K_ (*V?!SX:_%?PG\(1\3/V$/^"?'PZ\6^+=<^%EY\5-=TOP]XWO/V
M_?#VIZAX*L4^)G@#0]%\6Z=H^IZG<Z%J'BO2_'?A^+69=&O]7\)ZSI.GWN@Z
M[K:?^S?IW@C]N+]E3]A3P7\<_P!IKP5^SA\%/^"7&G#PSX!\"_'GQ?\ #YM>
MU']F_P"/_P"S]X%\ >)_%5YX%G\-WFHZY<^&BVA^.+K3/[(T_P 8Z-J.H^&M
M=L)_#>L:CHMYE1DYQIWLG4=2S3;LJ4L;[1\O51IX6+5IJ4JLIPY8QM4BZCY7
M.ROR.*:[NI#!^S5^CE4Q,U-N/+"G&$[RDW!_K-\/?V=/@5\*/B!\6/BM\./A
M5X*\'_$OXYZ[9^)/B[XYT71K:W\3^/=8T_3[73;*XU[5R'O)H+>WM$EBTZ&2
M#31J$U_JQM#JNIZC>W7L^1^N/QSBOYT? /QX^/'C_P#9Q_95_:_TSXD?$G3O
MVJ=>_P""H8_9S^./P+?QSXQU#P)/X(US]MKQS^SI\8_V<-5^ ,NKS_#[PU=?
ML\_ &P'Q$TCQ[I/@C1/B7I=I\#T^+OBGQ7K=CXN^*M[X]]C^!7QZ\"_'WXK^
M.+KXD_MC_$GX,?M2_L__ /!3CXS?!JX_9Z\.?$B30[3QE\,/#WC[QIX!^ _P
MDU#]F;Q*VM:)XV^&7QI_9OO/ _QVU?XL:=X(N?&-GXCF\7?$OPE\3/"7A_P/
M=VWAG2"<E%+3EC!<K33C&4,+4@J<79SBJ>.I2DJ<5[-NI&2YN5U23Y7*ZUDY
MOFW4I1GB:<O:3U4)2G@ZD8NI)N:Y&K14E3_<RC(]:_GB_8-^.?BC]I#Q/^S-
M^T3XK_X*#>&/!_Q>'CC]HCX;_M._L-_8?'.H>)K[QWHMA\2+;QM\ /%'PL\3
M_M(>(_#'PDU/]F_Q9X6TOQMX8^)_A;X!>#?&FK?#?P-9)K^L7WA'XJZ_?:_2
M^#WB_P#:@M_!?QJ_9D\9?$S5? 7[;&K_ +,7P/U[X5?M*>)_VF?B=\8OV&OV
MP-"U3XEV/@O0_BU\-]8CU<>./V4O&_[0'CSQP?A3\1/"7P[\.:#XI\"VGCWP
M!XF_9[U3XC1>"/"%_I\J3:6F\%426MXN%*K[LDW&5J57VC49<SC3JN$:G(T-
MM)R5U[L^1ZVL_:5:7O<UG%>TI<BDX\G-4I*4X<]U_1517\\/A#]H*3QGK7PJ
M_9^\6S_M4_L]_M WW[<WQ:\ _%+]E7QE^U[XG\4^%KO6?AY^P7X=^.?B?0]-
M_;?T3Q%J7Q>M_P!FC2/AS\0?AI^TGX'B\'1VWQ#\1_%#Q-9>"_%/PG\'?#>W
M^(5W\._T _X)(?%7QO\ &?\ X)T_LQ_$#XB^.[[XF>,[[PIXBT35O'>JZD-;
MUCQ/;^#_ !_XL\'Z!JNL:X9;BZU_5;OPSH>C2W_B+4[J^UKQ'<.^O:UJ.I:K
MJ-WJ%RT[J;NK146FK-23G&#:L].6<TK22;2;M&2<(IZ<M_M.4;6::<8RG9W2
MO>,6[Q;2;2O)-3E]O^ /B#;_ !!@\63V_A3Q]X3'A'Q]XN^'\T7Q \(:IX.G
MU^Y\(:D=-F\5^$XM51&\1> ?$#8O?"/B^PWZ7XCTX_;+%S'FN_K^?3P!XD_:
MM\>? 7]H*T^$WQ7D^(WQ)\%_\%=_VO?"7AKX1?&3]H;XA?"C5/VA/@]\+=6^
M)5Y;?LI_#G]H#PO+J?C[X/:QX;\.:'%\0?A_=^&[:?0Y&^$<OA;XDV[_  P\
M5?$N_?\ 3_\ 8;^(/A[XT_LH>#?$NAVWQP\.VMWK?QI\!Z]X:^.WBZ^\3?&W
MX>>,_AU\9OB-\+_B-\-_%'Q 7Q+XJU'Q)J7PM\=^%?$G@#0?&T?C#Q#=ZYH?
MAG1]?B\1ZI+=+J4RN^6]E?V=":BW9R]M2A*ZO;W5.3@Y+FBIIQ]U<CFWI)QW
MM5KTVUM%TJLX6;ZMQCSI>ZW"S;<N91^S**_F*_8CUWX]Q_#K_@AS^TWIO[4_
M[1OQB^(G[5U_JOP6_:=^'7Q(^,FK>//AEX^^%*?LR?'OXHZQX_F^'FJ&Y\->
M#O'_ ,%OB-\'/!D*?%/PIIWAWQKXBN_%=_X"^)/B?Q5_PD^A:-'ZM_P3J^+W
MB3]JJ[_8Y_:$UW_@H=H]O\3_ !WX#^*W@3]JW]B71K'XFKXJU;XNMX(O[_XG
M_#G6O WBS]I#Q9I_[.7B;]F'XMZ'>7FA?$3P)\$OAOJ&J>$(M,\&W=W_ &-\
M1?"TLEN,DD[Q?Q:)JZ:C2<=$W+EE[:E%SY;0DYQFDX-S3:4I1>G*[7UY7:5:
M,ES645).A4:BY7E%0E%M3]W^A_I1D>O^3T_.OY:?A1/\7++_ ()>?\$X?VGS
M^UE^UQKWQK_:7_:2_P""1OAOXI>,O$'[0_C;Q%9:CHGB3]K;P7X"\5Z3I'@_
M4+NX\!:-IWC3P?\ $+4O#GQ)L+'PPEO\5K30O#DOQ6C\:ZE9ZG>ZM8_: N?B
M/\'/AS_P5GUGP-^TA^U;9S_L!_MB?LL>(/V7TUW]J3XY>+E\'0?$;X)?L3?%
MGX@^$/']_P"+?'.MZU\??AKXL\1_$OQM9S_#/]H?5?BIX"\->'-=N-+\!>'O
M"#_Z87"$IR<4TG&4(R=F[>T>7\NBUVS*@]EK"K'I"4R[]G&HE=24W%-J+?)]
M<36NFLL#576T90F]Y1C_ $I6OCZVNOB;KWPP_P"$6\=V]SH'@/PGX^D\;W?A
M+4[?X8ZK;^+?$'C3P]'X6T+QXZ?V-JOCOP])X*EU?Q;X2@<:EX?\/^)O!>LW
M:FU\2V9&Y9^+/"VHP^&[G3_$F@WUOXRLEU+PC/9ZOI]S#XITYM.35UO_  [+
M#<.FM63:3)'J8NM.:Y@-A)'>"3[.Z2'\(/\ @H'K'BW4OB!_P62^&UUX_P#B
M6_@#3/\ @A[X*^+F@>"K'XC>-M'\/>&/B+J>O?\ !0K1M8\2^%M,T+7--C\/
MWWB32_A+X!TSQ/\ V2+6/Q3IV@C3-?34].U#4[2[TO!OP_\  MK^VS_P1R:W
M\5?$!K5?^"<G[7VI6ZS?'WXQ7ME=:QHWB[_@F_XMT&UN(KKXC7%MK-K>3>.]
M5BOO#^I+?Z5XI\*GPOX9UW3M7\)^#?!.E: XTY/EO97C"??W9K,9-OHFE@H)
M)/EM4O)\RL\9UE%R2UM*<==/>C++HZ:[/Z]-NZ4DZ>W(]/WMR/7_ ".OY5XC
MXC_:#^&_A;X_?"_]FG5KG7X_BI\7_A_\3OB=X+LXO#&MOX;O/"'PAU'P-I/C
MBZN/&#V<?AN/4],U#XC^#X?[ AU&YUT1:Q;7UQIUOI\T%W-_._\ !K]K+XQ^
M.O@/X9_;E\)_ML>&_$'[5/@'X)?MJ3?%_P#X)MIHWQ'UGQ'\2?VB?AK\&?BM
MXMU']F#Q1\)M=_:/\4:=\(]8^!GQE\!:->^&_'GP_P#@5X \;^+/A[H=CX;N
M=6DT'XN?:M5]]^!6M?#OQ+^VS_P1[^*?A?X[^*/C;J/QO_X)V?MJ^.-9\:^,
MOBYKGCD^.==UJ?\ 8.U;4/&&@>$M6UZZ\+_#>X\0Z[)XQ?5?!OPN\,^"/".E
MSZ1<>&K#PII&F>!].T?0Y@G-PO;E?)S6E%NU6A6K4W%IM2C)4TW.-XW3@F[\
MRTJR<(SM\2;4;II?N\10HU+II-./M)6BTFTXSTLT_P"A&BLW1]:T?Q%IEGK7
MA_5M,UW1M0B\^PU;1[^UU/3+Z$.T9FL[^REGM;F(2(Z>9#*Z;T9<[E(&E2_K
M^OO7WKN7_7]?<_N?8**** "BBB@ HHHH **** "BBB@#Y/L_V%OV0M.^*VL_
M&S3?V?OAUIOQ&\2>+'^(/B35-.TE[#1?$?Q'>]M]3;XG>(?!-I<0^!M=^*']
MJV=EJP^).K>&[SQPNK65EJBZ^+^TM[B+ZPHHHV271;+HO1=/Z6R21U;ZO=]7
MZO=_-^>^H4444 %%%% !1110 4444 ?*7CW]AK]D;XG?%+4?C3XY^ /P]UWX
MG:]::3I_C'Q6VERZ?<?$?3= L!I.@Z9\6-/TJYL='^+>F:%I(&D:+IWQ+T[Q
M79:3I(_LS3X+>Q_T>OJJ.*.&..&&-(HHD2.**-%CCCCC4(D<:* J(B@*BJ J
MJ H   I]%&RLMNW3KTVZO[WM=W.M^NU^ME;KOT77HNRL4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5XA\0/V9?V;OBQXDU/QE\4_V??@C\2O%^M_#C4_@YK/BKQ_\
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MO[VVWW;;=VVV4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117Y3_P#!
M77]L#]J/]BK]FV3XU?LE_#_X8?&+QQX&'B7XD_$OX5?$31_%5Y<ZA^SQ\-=!
MEU[XO>._#NM^%O''A63PQ-X!M9M"^VZEJ&C>,[663Q%IUM'HCW+Q1W*E)12<
MG9.48W=[+F=KNR;48ZRDTGRPC*7++E:;2;T2N[-I72NTM$KM+FD[1BFTG.4(
MW7,F?JQ17PW\-_VG]3_:3\0_LC>._P!F_P 6^ -0_9V^.OP"\4?M#^+;KQ)X
M&U[7_'LOA>=OA?9_#GP]I6L:'\3= T7X:>)]2U#QUXDCU^T\5^$_',L=Y\//
M%?A^WM+'4](U&6T].^%/[8O[,?QQ\=S_  U^$OQD\)>._&"^$-6^(.E6.AR:
MA)IWC'P%X>\9S?#KQ+XW^&_B2>Q@\,_%#PAX4\?Q+X*\7>)?AUK'BC1?"GBJ
M[TW0?$5[IFIZMIEM=TTXMQDN62E.+B[7O"3@^K33E&2BTWS<DFDTB5)27-%W
MC:#YE>WOQ4HIW2M*TH\R:3BY13M<^EJ*^*?VKOV]?@-^R)XO_9^^%WQ U35=
M8^,?[4?Q6\&_"7X)_"WPOH^JZQXA\3:CXE\6:%X=UWQ9J<^GV%Y8^&? GPZT
MG6+KQGXS\0:Q+!(?#^A:I9>&+#Q)XH?3?#]]J_#7_@H!^Q;\9/BJOP2^%'[2
MGPK^(OQ1DU?XF:%;^%/!WB&/7YKS5/@Y8>"]2^)UM8:GIT4^B:@O@R#X@>&+
M?5[FRU*XM$U6;6=$MYY]9\*>*[#1933O;5)RC==X1YIK_MQ.\^D=I---1;]W
M?32,M>TY<L&^W/)6C?XNB=US?8-%?+?PI_;7_96^./CW2OAA\)?C7X1\=>//
M$'P]UKXO^&?#NB'5'N?%GP=T+Q1IW@J?XR^$+FXTZWT_Q;\'-6\5:M8Z'X1^
M*_AN[U3X>^.KUYU\%>)-?CLKV2W^&O&'_!3-OB+^W%^PK^S3^QMXG^$OQ>^&
MWQQT3]IOXJ?M&^-V\*>-_%=_X5^!'P#TS1='\._$#X0ZUHOBWPGHOB3PU\4_
MC!JTGPK\'_$G2-#^)GP\\1ZOH_BE?#.H:KJ'A74M.>DFY1BDVY.VVBLJC<I/
M[,8JE-R;5URM<K:<4FTHRE=6C'FW6OP)*/23DZD%%)VES+WDFF_V)HK\H/V;
M/^"EOPT\4>'=2\7_ !Y_:+_98UCPK\;OVW?B=^SY^Q#XA_9\TOXW2:/\0O F
MEW?AC3_A_P"#?'FH>/\ P]]EU3X^:3>WWB!/BMK7@.3_ (4YID.FW-QI>K6T
M'A?QC+I7TWH7_!07]B?Q/\!O&W[3_A_]IKX2ZO\ L_\ P\\:Z[\-_%OQ6LO$
MUO-X3L/'_A_6[/PY<>#;*[">=K_B35M;U/1M/\':1X>M]5O/'TOB#PTW@>+Q
M#%XDT*34$M4G_=A*RNVE4]BHIV3U<J]&"2NW.K3C'G=2G[1W_.2[:P]IS;M:
M)4:LFW9*-.HY<JA/D^Q**^??@S^U5^SY^T'KWCOPE\(OB=HGBOQM\++VWTWX
MI?#Z2UUGPW\1_AAJ=Y/>06.F?$CX=^*],T/QMX#U/4/L%U<:;IWBS0=(O=1T
M](]3LH)].N+>ZER?C=^V1^S!^SAJRZ)\;_C1X/\ AYJ4.AZ#XKUN'6)[Z>+P
M5X)\4^-+7X=>'?B'\2[S2[*_LOA=\--9\=W2^$K#XE?$:X\+^!+C7K?4=.3Q
M#]HTK4TM#?EMKS6Y;:\UW9.-KJ2;T33:OU[%U[W]V_-TY;)-J5[--)IV:3U6
MFJO],45\B_%[]O3]C_X!>.O&WPU^-'QY\%_#3QM\./@I>?M&>-M$\6G5]+/A
M_P""-IXFTGP2OQ$N]0ETO^RI-#U3QQKFE^!O#JVE]<7_ (I\<71\'>&[+5?$
ML%SI</T)X'^)'@3XD_#GPA\7? WBK1_$?PS\>^"M ^(_@_QM8W2C0-=\"^*=
M"M/$WA_Q39WMP(%&CZIH%]::M;W4XA LYUEE$8# *ZMS77+WNK;R6][;PFK[
M7A+7W96.MNO;KM%[=[2B[*[M*.GO*_;45\)>$O\ @IU^P#X_;Q=_P@O[5GPD
M\9P> _A/\1?CSXKU#PKK<_B#2=*^"'PF\9K\/?B)\7_[9TJSN]*O_AEX7\9K
M>:!>^.--O+SPU/=Z-XC>QU*[MO#'B*?3/0_AS^V[^RM\7=5^&V@?#7XR>'O&
M/B/XP?!G4_VA_AEX9T?3_$<OB?QG\#])UA= N/BAHWAN718M<E\(76M20:=H
MNJRV$,7B*YN;-- &IB\M3,^SZ-)KS4E-Q:TU4E2J--7NJ<VK\DK%UKJM&T]5
MHXN"DGV<74IIWM9S@G9SBG]545\$>!O^"H__  3U^)+^"E\&?M<?!O54^(O@
M+XP?%3P7=3^(VT;3]=^&/P#U75=$^+?Q%AU+7;73-/MO O@_5/#WBFVF\67]
MS:Z#JW_"&^.)M O]6M_!/BR71_5O#W[:?[*_BSX$?#;]ICPU\;?!NN?!+XQZ
MGHOA_P"$OC339K^Y/Q,\5^(]9O?#F@^!O ?AJ.Q/B_Q7\0M8\0Z;J6@Z=\/=
M$T"]\;7>M:=J&E0Z"]]974$1W?1<M_+FDX1O:_Q33C'JY)Q2<DTCK;KKIU]V
M/-+_ ,!C[S[1]YM1LW]0T5\A7_[??[&6D_##X5_&35_VCOAAH_P[^-WCRV^%
MGPGUK6==_LF^\<_$Z;Q7<>!KOX=:)X8U&&V\5R^.O#WBZRU+P_XS\)3Z'!KW
M@74M'UV'QE8:%_8>KFRY>P_X*5?L-ZQX<\*>+O#W[0OA7Q9X;\9_#._^,^CZ
MMX,T?QCXSMK3X0Z=XTO/AS+\4/%0\*^&]8E\"^ +OQYIFK^$='\7>-X_#V@Z
M_K^A>(=.T.^U&X\/ZTEB).7PIR^%>[[R]]1<-8\R]Y2BXM-J2E%Q;4HN2;2W
M:6DGJ[.T&U/1V?NN,E+2\6FFDTTON6BBB@84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M./%6FZW\+$_9F_::_P""5GB;X=6GQ+^,_@;QO\)-)\3S:OH6O^"_CMXE\>^
M_A/X*F^&UJ=1\6:KI/Q*GLM9\,6%CX[^$/\ 0#10I-.#7+'DJ.I%13C'7V48
M0LI65*G1HT\-"EK#V$5&2]I^]!Q4E/FO+G@H2<K2>]64YZK6I4JUJE>=1I2]
MK*Z?(E32#..<9[XI:**6Q04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<)=1*\4+1)-(D9.]HXGG@61U!5&FB5B#(@)_7W;_ ' 24444 %%%% !1110
M44SS(Q((BZ"5D:01[E\PQJRJSA,[BBLZ*S ;0S*"06&1I(U=(FD19) YCC9U
M#R"/!D*(3N<(&4N5!"[AG&10 ^BH8+BWND:2VGAN(UFN+=I()4E1;BTN);2[
M@9XV91-:W4,UM<1$AX;B&6&15DC=1-0 45#!<V]TC2VL\-S&LUS;-)!*DR+<
M6=Q+:7<#/&S*)K6[@FM;F(D/!<0RPRJLD;J)J "BJ6GZEIVKVJWVE7]EJ=D\
MMU EYI]U!>VKSV5U-8WD*W%M)+"TMI>V]Q9W48<O;W4$UO*$EB=%NT %%%%
M!11423P2230QS1236Q1;B))$:2!I4$D:S1JQ:(R1L)$#A2Z$.N5(- $M%%%
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MV7OV?(?B!\#OCC_P3_\ AWK?BZTU:]\-^+/CUI/[0.G?"7P9HGC/XO>+=&\
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MA:>,='\67FO^%M2^'^K>7_";_@I+\1?BC\-?VD?'?A7P5X5^(/Q7_9[^"WQ
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M]I3X&>([;3M-\1Z%INJZQ^SA^T-\3O@)<^+K#PQXQAA\7^#;;QPOPYC\8_\
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MO=W.J>*-)U 63Z]I5E'K%GXB^?OB5^WY^V3X<\(_\%-OB_X>^%W[,EG\)_\
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M[_(OX9?\%85\6>+/V4[WQ<O@#PO\)OVD_P#@GOXU_:RO=6M_#WCO4/'GP_\
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MM^W'/JEMJOB/0/#WB/Q-;^'S+I.FZ[J6@Z19(/$U]X>TC39[W1W^SZ]I//\
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M>H6O@[4_$,6J>#M U&V\/P:HOBV+QOK%S\+-SQE_P4U\8V_PZ_X*&_$_X?\
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MCFU2/P7J/C'Q#I\,T4,NF1WM_K>IZ/;^3J\S7/VCK/[%=K=_%34?C+X>^/\
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M--^)'Q!\6>*?$UKK_A?3_#'ACP=K%C#XZ\,?#=O#OB'Q-:PZIJWY<Q?L6?M
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MOL]C-_PC>K_9/H6OY\/A-\ OVL_";_L8?"[4_P!ECXAC2?V4O^"O?[8?Q_\
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MJY6BK/F?+B,%3E[CM)N4,7[D5[SG%05Y2BG^VX_:-^'Q_:<7]DL6_BL?%0_
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M*^O(YX72YF5^WHHLM-%IMHM-+::::::6TTVT#OYZOS=[W??776^NN^IY+?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=/\ $FK?"CQ)>Z'X[\-^&M6ATOQ]I?A'Q%JOAN22S2:_T>PAUI8%T?5M$O\
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M5%U#]G&#4[./]ECX"_L9>&_CY^T9<^$?@YX]^+7Q5N?C+\;/C1-\&/@%\)-
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M\/OV4_&?[-WQ#@_9]LOVH?V[].^"'P'O_P!H/]F']HWQW=?M5_!'X<7FB/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K\=O\ @H=^R+\9_P!O/X<_MR_ =/ EGX5T
MGQS^RQX6^"O[-OQ&\;^)O#$OAF?QYKWQ#OO'OQ9UJ_TKPKK6M^,="\,ZC?\
MA#]G\E]5T :K>?\ "M]4DLK"SD>SAUG]B:*F45)-/52C*+5VDU+DOJFFKJ+C
MH]8SFNL7!IN+3B[234D]&TX\S6C36\D]>L8].92_GAT?_@G'\=+7_@IM_P $
M]?B%J_A#5_%G[)W[ OP,^+=O;_%[QIXO^'-[\3/C1^U[\7?!MK\._%7QG\:>
M#+#7YKA/!Y\"^'?!EKX-BM+:QN_AWJWAO0?!O@;X>^%/AKX5\,KIWR_J?_!-
MS_@H=XG\<^,].\=?"_P+XL\%_%?_ (+Z7?[<?QB\6W7QA\*C5_B?^R%\)?#U
MAJ/[+/A+7[:_L-3U#0_A/X+UCP9\._"^H> (+?Q?\0=,73+B31_"::+!=7GB
M+^KZBKYI<\:C:E*,ZE1N2NISJXRGC9N25DKUJ-&*4>5*C1I4TDJ5.4<^2/*X
M)6BX0II+[,*>&JX2,5IK:E6JN\KMU*M6;_B3B_YB_P!JO_@G=_P4 ^.5M_P7
MP\2^!M'\*^%/BQ^VUX.^ _P+_94\2ZE\3]'BTG6/V:_@[X1\+V/B7X=Z/]AM
M=0UCP5<?&NT\3_'?1?B%!XUG\):3:^+M8\-?8SK'A34;[Q3X;].^/W_!/[XS
M?%3_ ()W_'KX)?LW_LSM^S-\=_VR[#]FWX&?&#Q7\4?CMX+\?_%#PG\!/"=W
MX>\)?$C2-4U'P?/KWPTTKX8?#OX1:=XK\%_"/X0?!KQ#;>$+RW\=^(?%%K\.
M? 7B?Q#XLT_6/Z)J*A+W8P:C*,8T8VDM)*C*4FI6M?V_/..(2Y/:1G/52G)O
M1MN3DFU)RJRNMU*K&$8M7OK1=.G*AS<_LW"&DE%(_%_]M7]ASXD_%3]H+_@D
M?X)^$?PN\)W7[&O[*O[0^H_M"_'>V'BO1/"6I:#XU^ GP;LO!?['VH+8W5O<
MZUXTM-"UV\OAJ-OIUEJMY+;>&M!TO4)M(T^6'6]+_-WP+_P39_X*&77CSX1Z
M7\6OA7X,\0>"Y_\ @N-\?/\ @HK^T;XRM_C7X;^W_$K0/"&DW,O[(7BD64EK
M=ZEH?PQT;4K'P5I4?PMM=/\ $OBC3K+PI8?;/"7A*TTVT2^_K"HJU*2GSWYI
M.I*K+G][FG.O0Q$G)6MK/#THOELG3CRM;24."<>3:*I1I14791A&C7HKEWU4
M<14DF[^^U*[=U+\H?V#OV:?CM\._VQ_^"I/[3W[07@G2?#^O_M0_M#>!M&^$
MFN:7XXTGQ+9ZO^RY^S]\,-"\"? IK/0M.2>Z\*:EJ%QJOQ$U[QMI>L3:3>1^
M(]1C>'3=4@F.LM^>7[='_!.C]M[X[^,/^"Q?[1'@;PEX5USXS?'W]G'X(?L'
M_L%:#J?C_P /VK^'OV:-2>WMOVK_ !+?W.J7]CX<\,^)?&$GQ$^*^J^#TU2]
MT[7+&RAO=#BO+)/%^H&]_IKHJ6DU!-)J%&5!)WUA.*A-MIQESSASPG)-<T:U
M:]Y24U=VG.2=G.M&L[6=I1?-"*4E)*$)*G*,=;.E32]V/(?S^?$7]A#]J/X9
M?MB?LI_&+]G3X<^"O&'PP_97_P""5/Q"_9 _9*\%>)OB'I*^$_V7_P!KC6M<
M\#>%]%^+GQ DUFQT'6=5^%NN_!32+'P5XP\3_"CP9XQ^(=_IW@B]TP_#=8M4
MT0R^>?"7_@CU\2O@5\2?^"7_ ,+]#73/B7^S?_P3$_9M_:2^+.D>+?$WBM=
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M?!EE!IUK<ZK+X3^&/A'6-3UG7M16#5/">I:I?>)K:YL-5M/%&MZ3K7-^%_\
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MOFJ3E4:YY2G(HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$_4?']EID>F_$SX;6/AKX>WOPD\0^+;:UTOQQ\2K#P3JE_XGV/!/_!//X:>
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MPG?^ +KP1]@\5^$_BMIGA_2OB)\//'6F^.O OCFWNO"WBB'PGX:N)=1\*_\
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M"+BXRARTI-\LKQ<D[24+7;>MVG>=3%R<H7O&+CST)M234E*I%+G34M#]K_\
M:)^/?PG^,_[&?P8^!GASX1:E?_M6>/\ XU?#6^\1_%>Y\8FS\$ZIX%_9N^*7
MQH\-^([?2?"+6DVMZ99ZA\/GDUW1'U*PO/$ULL/A/3]6\&MKTWQ"\(_$6B_\
M%(_VN=4\"?"KP9<_"GX Z5^T]'_P4M\7?\$U/CR;_5?B&GP8A\3Z)\$O'/QL
M\._&OX306LMYXRN/"7BOP7I_@#Q5;^"O%>HC6;!?$.J^#+SQ%'J%BOB>+ZI_
M;9^$/Q4^*/[4G_!-;Q!\/+/XB:1X>^#/QX^-'CGXG_%+P':>!KMOAKX>\6?L
MI_&KX2^&[B^T_P ?:?X@L=>M_%?C;QWH?A6_L-'\&^++[1=&U+4O%-\?"=MI
M5KXJL.XU;_@GG\*M1TWX+VUI\1/C!H6M_!W]J_5_VT[SQEI=_P##2?Q5\7?C
MYXATWQMHGB#Q!\6;G7?A?K6EWVCZEH'Q!\0^&K;P[X'TCP'I?ACPO'X=\,^"
MXO#6@>$/"FG:-5)IO]Y?D]M*+2NI\D:^&DG%I*T?82Q,+)MS;ARM.G=757NI
M4K*I[%2N]8J<J6)BE).Z;]K&A*VBA:3DK3<9?-OBW]M_]J3PY\%_VS?BAI&@
M_ +Q=K?_  36T;1-)_:4\*VNB_$71[+]H'XF^ _V9/A=^U-^T3I'P%URX\8Z
MA>_!WPQ:^#/BCIGA?X/ZE\0O#GQ;U'6_'.GZK8^*K/2O#]M:>)=3\_\ BG_P
M4*_;)U_4_P!LW6/V4?AK^S?XL\"_LH_ 3]FK]J[PW9_%34/BAIOC3XU_"SXL
M?"WXD?%+Q)\,M/&A-::5X"^)OB'2/ TMOX+\8ZO%K?A;P9J<.EZ=XC\+>-(?
M&&I:K\,_N7X@_L!_"/X@>-?VD/$TWB[XI^&?#'[8W@OP_P"!OVJ_A+X9U[PU
M'\-OC?IFA>$6^&=SJVLQ:YX/USQKX'\6>*/@\+7X.^+?%'PD\:_#W5]8\!:3
MX?;S[;QCX7\+^+M%^5=/_8\\7_%/]M/_ (*,Q^,7^-'PE_9K^/WP-_92^#>G
M2>!Y?ASH'A3XU^$? WA'XQ>%OB_X2TO4IM \3_$KX;'1--\>6?@V/Q-X7NOA
M%XEO](\3ZAK'PRUZ_O\ POH_C+PC/O.-DXJJZ51J3B_90K1HR:<H)MSI.O*C
M*-)-2E"%>FK<R0X\BYG*\H1J4ERIVG*E.O!.,9-*U6-%5HRJ/W5*5&I]FZUO
M$/\ P4$^./QI@\5VW[!_P-'Q7\4>#/V6OV<_VGK7PSXT'@.P/CVZ_:6\.?$'
MQW\._@QJ>J^*/V@O@N_P;U+5_"_P]M-+;XKC2/C3X>TK6_'OV^[\%W$'PVU7
M1_&75^%/VDOVU?C%^UQ\=?@'X$\*_L[_  C\%_ GPQ^S/XS\37_Q3L?'7Q&^
M)D-C^T!\*OBMK%_X5DT7X>^.O#7@.Z\4>!_B-X3T$W=]IGCF\\,ZKX6TK7-&
MTW4KF^\5:;XM\'^@?&;_ ()N?"CXH?&GP?\ 'GP'\7?VD/V5?'6@_"[0O@5X
MPB_93^)&D?"WPS\8/@AX3UB^UGP;\,?B)X<O_!WBO3[*P\#RZYXKLO GC?X9
M)\./BWX(TWQ?KEGX4^(FD)'HK:/[1\)OV3? _P &OCS\:_CUX2\6^/9=0^.'
M@[X.>!M:^'6I-X$7X:>$M ^!.CZ[H/P]A\#6.C>!-'\7Z=)8Z5XEUJUOO[<\
M9^(H+U+N/-O%]AT_[+<N5RFX*48N6)<(2?,XJ]1897C:\>25'G3O)5*4Y7Y)
MI/%*I:"<DY*%!3:5E)VA[?1K27/&HXR24'3G%**FFH?F+^S7^VM^U+X6_8/_
M ."5O[4/QJ\3_#;X@^ ?VG-5^ &A?M4?$6?X?^*-'\4_#6W_ &H_"^CZ3\*O
M%\)C^*MUX;:QNOVD_$7A7X8>,]=_LK2?#/AKP[\5/#_B;2?!.@>'OAUJ^F:S
M^M/P%^(7B_XH:3\0/%VO)X?3PBWQ<^(OA?X3'2=&U;2-5OOA]\/]?F\ MKWB
M9]0UW7=/UF?Q+XS\->+]>\(^(?#;V&A>(OAI?^!_$$.GV5[JM]9VWP'XX_8Z
MO/A'^Q#8?\$Q_A=\/?CK^TO\'/BS\)OB+^SSI'Q1^(WBG]G.T\+_ +*/PVO/
M#FD>$/!$/CV2PU'X(?$CQ3X>\":)J]]J?PRU#X:_#SXM?&"_USP+%%X[\=:-
MJNHZ)XVB_4SP5X.\._#OP;X2^'_A#3DTCPEX&\,:#X.\+Z3'+-/'I?AWPSI5
MIHNB:<DUS)-<3)9:98VULLL\LLTBQ!Y9'<LQ;Y7[24;J,IKV47;W8.EA^:+6
M]Z<Z3C"5VG[6JU*>C1%22IQ;O**DZLE>TI>UKN#5UI[2%52G'>/L:6D+N+_*
M#XC_ /!1GXD^#_@W\1_VR]'\)^ M4_9:^"O[8GB#]F'XB> KC3_$I^-VI^"/
M ?[3$'[('Q/^.'AOQC8^))O"&GW?@[XJKXA\?:+\)M0^'^IS>-_A)X5@S\1?
M"7C#Q=#I?AK.\._#[5_CW_P5$_;V^%WQT?X4_%?X(^&/V8O^"=&IVWPQ\7?"
MC4M4M+2RF^+_ .W1\0?!,NAW>J_$K5=$TCQEX>^(?@WPUXO\2>-E\)7,OBN]
M\*^!$TO1/!=WX(TG5'^J(?\ @GM\%K?5OBA:1>(?B/\ \*@^,?[0V@_M5>/_
M -G.;4_"5U\'=4^.FB^+_#'Q*O?%EF;GP7+\3M&TCQG\6/!7A;XK?$#P!I?Q
M*M?AYXQ\;Z=JTNJ^%G\/^/\ XH^'_'/JG@K]E_P]X&_:>^-O[55A\1/B7J?C
M#X\^!?A#\._%W@K6)/AZ_P .],\-? ^?XD7GP_A\,VVF_#S3/&ME=V-_\6O'
MM]?W>J>.-9?5)M:CBNP]GIFE6ME"WI/[4%-N3;NIO"T(7LM&_K=.K5I2@TZ4
M)QBW>.FNC552]Y37*HI)1:^LSDM'=I+#2C3J1ES*I.+:5I-O\P?^"A?@'X>^
M(/\ @JG_ ,$K[[Q/^S[H7Q\GU#X)?\%*+;4O!3^%?A1K>L>*[;2?!O[-3:5:
M2M\6M;\*^$KN/2VU+4ET^/6O$5K'9'5KX6QBAO=0<\Q\#]0_;M_86_9Z_8[^
M!C>'OAA:^+_VK/V[/VD?A=\-_AG\;O&OB3Q_%^Q[\!?&OPP_:I_:6_9U^#TW
MC#X>:IJL'Q%;X%>%/@_I?A75=&TKQ3>>'&TMH/A3X!\:Z5X6T_0?'N@?JE\2
M_P!DGPI\4/VH?V=?VKM7^(OQ1T;QK^S)H7Q;\.> /!_A^X^'L7P\U32OC=I_
MA+3/B'#XNLM8^'>M>+M2EU.U\#^&A93Z7XST272)+!WTYK?[;?"YZ'XZ_LVZ
M!\>O&'[.'C36O'OQ$\&ZE^S%\:3\=_ ]GX'D\!IINO\ C)_AK\0_A#/9^-(_
M&/@+QE>WOAZX^'WQ6\?Z')9>'K[PS?*_B ZI!J<.KZ7HE]IMQ<$J:ES)-SA4
M2=K0EBE74HVWE)J-Y?Q%!RIQ:4Y\V,X3;J2BUS+DG2;NUSQPWU>2DG?W5=N*
M^!RY9R3<8V_/#Q=^WW^TAX<^ W[:/QXTCP[\#/%MM_P32U&#PE^TYX.L=(\?
M:5)\</$_PB_9X^$O[0O[6&J? SQ5J?B]3\)]'\-Z%\3-6T3X.Z+X^\(_%&^\
M6>(? <UCXCUO1='\6Z?XHT?W77OVL/CK\8/%_P"T3X3_ &*O#/PB\8:[^R_8
M? 2ZUCPO\:+OQ5X;D^-NO_&3P9H_QGN?!'ASQ5HM["/@K8V7P8\0>$Y/#?Q-
M\3>#OBG;:U\0O%6KZ%JWP^\.Z3\.+G5/&WH/C?\ 8!^$/C;Q-^TAJ$GBOXH^
M'? '[8=AH5K^U+\#_#VN^&E^$_QHO--\)Z;\-?$.N:O9:UX0UKQEX/UKXE_"
M'0_#GPB^)]S\,?&G@:#Q=X)\.:///:VOC*&X\6W/-?%O_@F]\)OBE^T=J7[2
MVD_%C]HKX*>)_'O@CPE\-OV@_!'P,^(VD^!OAO\ M1^!/ 5YJ$W@O0OC?I%Q
MX0USQ%)?>&-,UOQ!X4TGQK\,/%7PR^(=OX-\0:IX6/B]]':TMK2(OX>;XKKF
MLDH0G[-\S<4FYTI5DFJ::<:4^5.\6WH[WERV45=).[<X\ZLN9M*%14F_WFJ=
M2-W=27+Y[?\ [9'[4?Q"^)?CM?V8/V<H?BW\+O@A^UCI7[-GQ2L;C5_AEH?B
M+Q#H>C?\():?&OXB>'/&_BS]H;P+)X&USX43^-]9UO1OAMK'P6\=)\4-#^&\
M4.E^._#5Y\5M*G\ I\,OVZ/'OC_]IWXL?L_7D/P\\)?$[X7:O\;I?^&2/'?A
M7Q?\._CUX[^%7@W5/$VB_!'X^?!CXL>+/&5O\,OC=\,?C(/#VA:WK]_X*\"Q
MV/P=N/B-8> _'.O0^)/!&J7GB3T*Z_X)O_"R/]IKQY^TAX3^,7[2WPYTSXQ^
M)/"GCCX]_LU> ?B?IVC?LP_';X@^#?#VD^%=-\=?$#P!=>$M2\3Z?K>M^'?#
M/@W1/B1I_P .O'G@/PK\9-%\(:5H7QA\.>/-$U'Q3IWB'K]8_8;\(^+?''A_
MQ[\0?C'\<OB'K7P]\6?M$^-?@Q/XCU3X:V.J_ [7OVE-#\<>$?%1^&_C+PC\
M+_#'Q _L?P9X$^(OBGP/\-?#_C+Q;XOT;0M#FT2ZURS\3^(?!'@'7/"LZ\BU
M?/[.IS6:YHU'0G!.#<72<774*T(U8RC%5'&<HJDHU'=\\M(\O-3Y=[.*K1FU
M)*U1/V3G2G.$DY>SBX1;JN5/XV^"_P#P4B^(GQ@_9Y^/'Q<\,^)OV;-2\=?"
M;P[\ M/\<_"#XFZ9X[_9+^(O[(GQ3\?^+]9T/XV>'_VN_ OQM\;W_B'3-"^#
MOA9M-\;>!]1M6\ Q?M!S>$?''A7X?ZA;1:AX;\6#[&_8H_:7\:?M#M^U%X?\
M>Z7I=MKG[-W[3$_P,M_$.E_#_P"(/PC7QQH.I_ 'X!?M!^'_ !)?_"?XI7^L
M>./A[J]GI/QXMO!VIZ/K&N:N-7N?";>,K%])L/$]MX;T3@?B#_P33^''Q7T_
MQY?_ !%^-_[0/B/XN>.?"7[,'A%/VA8KOX*^&_BWX2B_8_\ CG=?M)_!+7?#
M4/A/X):%\+9M?T?XUW<WCC5W\5_#/Q1HNL7.S27T2W\/*-(IDW[#GCKX:Z7\
M<=1_9_\ VIOVB]#^)_[1OQW^$GQT\;>+_%&I_ ;5](L?'O@/X8_#/X1^+]>U
M+3[[]G^^N[WP/\2_!OP@\%ZAX]^%'AM=%M-1US2;3P'\&O$7[,_P[\2:[J6@
M4[NIHXQ@VDU:;BN9PBG%RYIJ$+RFU)NKR*493K34;S>2A\-VO>O=.32C.3C)
M148.<VHPC*%J;E:7)1BVH_I!1113*"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^1OB]^W%^SI\#O&
M7BKP3X_\6:K;:A\.-&^#7B3XNZEHOA7Q#XBT'X/>'/VAO'WB'X7_  4U[XCZ
MIH]A=IHVF>/?'7A3Q%I4<EE%JDOA'2-*N_'?Q!B\(_#J/_A+C]<U^$W_  4:
M_90_;F_:9UC]K;P3X6\'_#WXF_";QE\%/V?9/V7T\0?%T_#[1OA[X^^&OQ/E
M\<?&31_$7@?_ (1#6XO%'Q9^(LNG^&8_AK\3?$-S+X<\!^%;;5M!T76_AS=:
MUX[3XHJ_OTT[\CDN=J^D>:BI)-7Y6X3JN+::O3U:LE4'\$VOB47R+1WERU>7
M1[KGC3C*S32J7VNX?<_Q@_X*3_LI? SQ)\;_  K\0->^*-OJ/[-=A\-->^/5
MWH'[/OQW\5Z#\+/!OQ5M_$M_X<^(GBGQ'X<^'>I:%!\-;+2/"'B36/$OQ!L[
M^\\(^'[+1=6BO]734=)U6PL<W]O;]KO3?@1\!OVK+3X=>)]<LOCU\(OV3?B+
M\?8+WPS\.]2^)=I\(M.B\+_$"/X8?$+XD:7;Z1JNE6_AKQ'X[\":UI6EZ1>1
M7>K:]IWAGQSXBM](_P"$+\ ?$#Q3X3^1_P!HG]CS]ISXK-_P60BT?P'X6AG_
M &\OV&?A5^S9\%Y_^%B:7+I5G\0]!^$W[0GP\\6ZAXQN+O3M-U31O!VG:S\;
M]&U#1=5M=$U/6M>T'PWXBN;KPYH&K-HFB:O5^.7[+'[9,7Q+_P""A.I_"7X;
M^"/B1\/?^"DO[(OAKP.__"8_%VR\!>*OV9/CE\/?@3X[^#K>'->TR+POXMTS
MQY\,?'NB>(/#NK:'KG@OQ!_:/A[XDV'B?3]<\/P>$_$Z>/M(PJ>TE1K)*49_
M5ZK@X74G6>'QKA3BV[1_>T:%JFO+*K"+5I0:NFXQK4W))TU6I\U[->R6(PBE
M*2L^;]U4K2E"RO&G/=PG%_I'X9^/FD> OV,O"W[37QTU^_30?"W[-_ACXT_&
M#Q9IWAF_UN]L])T[X:Z=XS\?^*D\)^!=&O-2OUL;5-6URXT;PCX>NKIK>&6V
MT/1IG%M9-KP?M7?!"[^("_"VSU_Q/?\ CJ?]G^/]J+3-"TSX9?$_5IM>^"4F
MK6>@CQ/X=N-+\'7MIKNM#6=0L=-;X=Z7/<_$LSWMFZ>#VM[NUFF\H\3?LY_$
M/XB?\$V_%'[)&NW/A'PG\4O'/[%'B']G'4+[3]:U;Q/X'\/^-?$?P.O?A@VH
MP:[)X:\.ZWK/AS3]7O!>M??\(IIFH7-A&S1Z3'.5A/RS^SU\$_VQ+/\ :5^$
MG[1?Q5^"/P^\":'X(_X)PW?[,7B#P/HGQNM/&OC9OBKI7Q%\'^*;6/19H?!6
MC^$=0\/>(#X3U,6.I7_B71?[,T2]\-ZGJF==U37_  AX+ZL2TJN+=))Q53$R
MH<J?)**AF4Z,8I6]UU:6"@DG%\E91TO&4.?"QG]7PBK.2G]7PZK<[3FJJ>6P
MJ<TFV[N%3&SD_>O.BY7=I1G]7? W_@H;^RQ^T5XL^&'@_P"&'B[QC=7GQL^!
M#_M'_!S6_%7PA^+/P]\%_%3X6:>G@>;Q1J7@#QOX[\%^'?"GB?6_ L'Q-^'<
M_C?PMI>KW'B#PXOBVWBO-/\ M.A>+H/#E;PA_P %%/V7?&VD7_B#1O$GC+^Q
M%_9PN?VP?"^HW/PP^("CXE?LNV=U'9WOQH^&EC;>'[K5?&&A6<UQ8O<>&+"P
M7XD#3]<\(ZTG@EM#\>>!=1\2?#W[/W[&_P"U/\+-._X)!Z9<^%/"-CK'[#?[
M!WQ=_9G^+'B&Z\7:9K.A6?Q1\2_"G]GWX?>"=>\+:3936>K>,_ AUWX)ZOJ_
MB SR^$M=LO#NN>'$L=.O]7FUNP\/^8? _P#8=_;:U_X@_#KQO^T#X&^'GAWQ
M;XJ_X)@?M(_L:?M%?%<?&IOB)XLUWX^^/O&/PCUQ/BK!H%IX$T73K7X8^-M:
M\,>+-?\ AK\+O"&IZ/X4^#_@J_;PAI'A7X<6.FZ%X&N<JW-"-3V2=2<:.)=-
M.2M.K3IXAX=:..E6K3HPE"Z=JB:DO:*5+6C:<J?MFZ<7/#J;2NU&<Z*KV5G;
MV<)U9)M-WA;7EM4_731_VP_@3XEUWP+X6\*ZYXH\3>)OBG^S-K'[7OPOT/2?
MAQ\0C=?$+X$:#=_#_3]3\0^&[F]\,V6EGQ';ZC\5?AS8M\.]6U#2OB"LWB_2
MI9/#*6:WMS:?FQH__!3/Q-\1_&'_  2^^,_ARR^)7A#X#_M>_L\_M$_%KQK\
M#;7X,ZWXV^)?B;5M"^%_P7^(WPHT_P %V^F>#]2\=^+9=(T_XD:HVI:A\-8;
MCPIKPT^ZUZ758O"WAW6KE>F_9"_9I_:^\+_&K]A3XA?&'X6_#'X?^&_V;?\
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M%\;:II'P\UGPGI/Q"OH_"H^/?VP_VX;RU_9F^+?C+]G'QCK7@'XP_ #]K_\
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MC*-.M5:2E**J4XQ4I1F0^94IR27.IRA%7NFW2Q<Z;6BE).="DME)PJRE*,'
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M@TR>UUV^^&GCF>+1I+*9;"Y\=68N_%/PKC\>>#=+U?Q%8? 'P$_8]_:7\!>
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MX(OO%.C>+K+7=/\ "WA74]0\97,VC67S3\;/V=?VXV^*'_!2[XP?LY:/X?\
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M:3BI2LG**_36\_:A^$WAW]H?XM67B_\ :#\4^$-&^%'['?A+]H/XB_!WQ_\
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M946V@EU"^LK*.65'N[NVMQ),G\U_[+WCGX=>!_BU_P $]OC)9^)=>\2?$_\
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M)%]\,2_Q#U/P9X:^!\FI"_\ #'A[PK+96_B_\5_V=_$?CWPW\$/VXOC[XY^
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M^+OVP_VK_P!GS]MV?XE>$/V@M9^-/[+7Q:_X)Z:%967B7PG\9O$OP5LO@U\
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M2;7+%-QCS<UI)OEJ*:47S2I>TE#F46C^C2C/^<'O_G\.]?ST:#XY_:N^.?\
MP3O_ &J_VR= ^$_B[X?_ +8/AS]CWQ!^RGX-^&O@+1K72?'VD?$_]G"+Q=HO
M[5VJ?!"'0?M^M:=XB\0_M$6_Q#^'GP=T*&*^:[7X"?"KQ9X;M#+XQFL&^,?V
MAO'_ .PE\0OV./VF/VA_V-OVL?B3XR\(^/K[]@_2?B;HOAD>!/@5\#? 'C.P
M_;&^%]QI]QXDT?X;?"OX(:CX5_:LUGX=>*?$OAGXGZ1<:K=>*T^$W@KP?;_&
M#P]I5AHGPLO]1N,>:IR1G%^]2CS+^6O4I1HU(Q:C)TYPK4Y.4E#V<YPIS46Y
M1CG*;C3=1P=^6J^5[\U&G4E5IMKF3J1G2G&,8N7M(1E4IN4>63_KEZ__ %_\
M_P"?K1G_ #@U^07[$$7PX\ ?\%$O^"G7P6^$NIZ'I7@2RT+]B[XOM\.O#OB)
M;[2-/^)_Q*\$_%?2_BMX_30QJ%V+3Q9\0K/P;\-]5^(VO")=3\7^(!9>+O%-
MUJ7B/7[K5=1\S_;Q^!&H2?M3:IX5T+PYJ-]X+_X*K_LP^*_V)O&&N:7H:7J?
M"3]HKX7R:E\0OA/\>+?4(]3T:[T?5=$_9YUW]H_XA:Q=V>M>&M4\3:_^RG\"
M_"FB>)=*\62>%-3TW)RERTW&+DZD&U%:/GY<1RP5[JTZF&G",Y.*CSTY3<5[
M3ET5FZB;Y53FHMO;DYJ'-/37W:=>-1QBI.2C-0YKPO\ M5XJU75=#\+^)-;T
M'PSJ7C77-&T#6-5T;P;H]]H>EZOXMU;3].N;O3O#.E:GXGU/1/#6GZEKUY##
MI5C?>(=9TG0[2ZNXKC5M3L+".XNHN#T_XMZ:W_"%^&O$&BZAX9^,OC3X2Z]\
M6[/X$W6K^$]0\?P:;X-_X06P\=:,NIZ9XAN/ %Y?^$?%7Q)\&^#K_5[7QDWA
M.ZUK6[2XT[Q!<Z*9=5B_%'X;3^*_B%_P3-_:B^//Q^\-1?"GXK?##]A#XI?L
M1^(KG3Y;?P7:V/C7]DKPO\4/!'Q[\<?#SQ+H,^B:IX:\&>-_VC-/\0Z)X7TV
MPN;.T?P_\)O!>OZ5<2Q:XD<7GW[.%Y\ M(_;=_X)8_$7XAM\(['5?B)_P1*?
M3/A[X^\5P>$$U/QOX_\ ASXO_9:\02V'A'Q9J<1O/$?BKX?>"-8\9^))+;2=
M0N]3\'^#]0\9>(&33=!E\17M6TO:2@I)QNK32M>G.ACZ].<8R:LYPPU*;A4U
M@JO*[2IU8J;R4(S<4I-R3A>_O0JX*E4BY16L83Q%2,9P5I^S<U>%2DS]Q_V4
M?VBO#'[6_P"SA\&_VF/!>@>)/"OA+XV>!])\?^'/#OC!-+B\5:1H^MB26PL_
M$,.B:EK&D6^L1VZH;^VTW5]4L[>X:2"WU"]CC6XD]-\!>)/$WBC2-3O_ !9\
M/-=^&FHV7C#QSH%EH?B#6O"&O7>L>&_#?B_6M"\)^.[2\\%:_P"(],MM'^(O
MAK3]*\<:/H^HW=GXHT'3]>M]$\6:-H_B*PU#3X/Y:?\ @FS)\*_!C?\ !OEX
MR\#^(?#^E_$#XZ?LO_M-?"CXK:SI_C)IO$/Q&\(>%/A+H_B_P_\ #[Q+YFLR
MW6KZ)\/?B-X7@N_!/A:XC>P^'.MR>(;/PKI^@SZ_X@@O]NV\1_#?5?V8OV0M
M+3XH(WA\_P#!Q7^TWX%MKW2?C/KEE/?>#9OVW/VS)=!T*\\2:5XP@U76;*;P
M+<>"M1T7^TM3O9WT&^\,ZWITOE7VE7\Q\4DDK-NG"SO:,Y8G X=M/XI*^,YW
M=*RC4A;FC&9G[3EC=WDXQG-M)+FC&AC:R5MD[87E]UVO:3?*YQ7]6/\ GD?T
MXK\Q?'/_  5,^%WPX\3_ +8ND^+/@'^TU:>%/V#-3^'R?M-_$[3- ^#?B3PA
MX(\'_$'X=Z-\6(?B=I^@^&OC=JWQ8\5^!?"?P[UN#Q5XU/AGX::IXNT?3;/5
M3;>$]1FTRZB3D?\ @E;)X'\.ZS_P4@^#7PPU#0K7X7_!+_@HQ\1/"WPR^'?A
M;5+2X\*?"OPCXG_9^_9N^(VN^$/!>@6-S+I_@WP>?C)XO^+FIVGA?1[?3] T
M;Q'>^*M+TNPL38W5E:_''P\^"OPY_;6_;F_X+M?L]:S\>O&WAOX??$7QI^QM
MX6^*?@WX->)_AA9ZE\2?AO<?L:_#WPM\0_!6N:UKO@7QIXNT?POXE2'6/AOX
MTU#P%K/A+7[.UNM:T;3?$.@>(E:^MR-YQO!J\L,Z\%/17<<+-<RBW)QBJM6,
MO9W<K1<;2LEI-\CLT_=Q*HS<;OW;XF+<;Z)R=.BXN>D6VG=.[_H:T+7=&\4:
M)H_B7PYJNGZ[X>\0Z5I^N:#K>DW<%_I6LZ-JUG#J&EZKIE];/);7NGZA8W$%
MW9W=O))!<V\T<T3LCJQU<_YP?I_G\^E?AK8_!']G+QG_ ,%>?BO\,-0L?#NK
MR? O]@[_ ()X?$[X*?"BY^(OB:V\-^!?BC\)?C_^V;%X>\6Z3\.=+\41:;;Z
MOX"\.Z=\'H)+W^P;BXT/PUXCTZ*:--.^(6H)XA^9/V9M7UOQYX"_X)(?$7X9
M7US;_P#!0JS_ &@#\/O^"E%G=W4ME\7KO2-,^$'QH'[<F@?M4^&+2Y@U"#P-
MX?\ C3I'A#6?A)+XXTH>#/!OC>^_9XT;X.RZ-H'CGP-IVN:.*<THOW)\LXRE
M9M4ZF)Q-"FY..CE!4%/$.*Y:2G>]D[Q&<N1\T7[2'-&:2:@ZE/#X>O447*UH
MS=:4<.I>]5<-KO3^F6BOYV_V)_C#\#_BOX_TKP?\2=2\16O_  6#^ '[0W[9
ML7Q&^'@A\::+\0;G3]>\4_&33_"EW\9+Z"PL;;Q3^PO)\(_%/P?\5_!K5M8U
MR\^$EHV@_ ;PK\--7U'XAZ/X2\):EX7^PW\0_P!EWXP?#OP7\3-7_:]_:A^&
MG[;?P?\ V*OC-\.?^"A7@GP[X1\ ^!/B+\)/&5I\+=.L_C=\1/VP+;3?@%X?
M^)6M^-/A%\8O!NN^*OV:O&/BOQ1>^,K[QEXE\5:KX)@\3^%_$OQ-BML5*\7)
M?\^/K$5[JYX.BZD>5R:5HS2HUY.7+AZC;J2C"$^75Z2L]%[;V+;O>,E54).4
M4I2NX?OJ,4KUX-*"<Y1O_4Q17\Q7@":.7X'?M4_!/Q-\4/V)_@YXF\)I_P $
M]9O#?[=_P2TM=5_83_:ST_5_CWXTU7X,>"?CS\&M*\5:3HG@?QO\7[CPBGPK
M_:I\!Z%\9/$)\3?#/X\?#>^TOQZ_A3Q'X*T&/.TCXL_!KQKI'[)'P9^.'PC^
M$?[/^K>(O'?_  4C\$Z;X0O/'M_\8_\ @GG\2_BCX)\:_#;2_&/B']G/X?/H
M?@K5?VE?B#\8-8^(^OP_LE_#II?AMXC^$-MJ?[4?AK3+7Q7XG^'.F^!O';G+
MD51KWU3CS*R<937)5G90E:<9?NK.G.*JP<TY0JQLY*#YN1-J+E/DEJI*#;IJ
M[E!.,HVJ-^TB_924&O:4Y/E7]0U&?\_Y^E?EI_P2Z_:J^%'C3]A/_@F%X3\6
M?M!>"O%GQY^-/[#7P8\1:5I&O_$O2M>^)?Q4\1?#3X/^ ]/^..JVHU#5[OQ!
MXS\2^#/%TFJ6OQ+G5]1UG2?$-EXC3Q%Y6H:-KWV*']LGQ1X<TS]MG]BOPC^T
M=#H<G[&OQ%^%W[5/A>^B\>VEM/\ !G5OVO#>? C4?@7H7Q:FUV(^#3<ZA\&[
M#]IR'X3Z-XOE;1]=\7R:E]CL+SQOIG@66RJ5U*,4G[TW33:=DXJHW=JR5O9\
MCUTJ3C!^\XQDHR3@YZZ0C-Q^U:4H1T3UM[SG>W\.,I[)N/ZHY[_T/\NM?-O[
M2_[2NA_LR:/\(M:\0^"?&7C&Q^+O[1?P(_9PL[CPE)X52#PAX@^/GQ%T3X;>
M&O%OBP>(_$N@WK^%--UO7;./4E\*6/BCQ"9;BU$6A#3S?ZKIOX,^#M!);_@F
M)\/OC;XJU"Y^&&J?\%;_ /@H1\/?V;]/\7?%'Q?:WWCS]A6/]GO_ (*$Z5\
M]'U.?4O%RWGQ-^%NLVT'PM\-?#75M7G\0Z1X]^#VL?"'2(KS5_#WQ"AL?$'%
M:5XZ^&_AS]B'P%X*TGQOX.T_X<?!_P#X.,?"'PJ^&.BQ>)M%30/ ?PO\%?\
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M^*'A/QM\5/V-=&_:9^#7PW^"/[%?C_X%_P#!0'PCX=^%_BOQ'I_Q&_9.U/\
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M\2_&GQ.^//C;]L;P9_P2P_:O%WX&M/A-\0_^"L7AF/X;> E\(WS>+?#'P_\
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MP5?:5\0_=OA)^T%^TQ^T3=ZS\0OA#KWP#L? ?PI_;A^)G[+?Q6^'_P 0M/\
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ML:I^REXHUX_%O4O#Q\<ZGX7^*7@?Q'H?PAB\,Z1XTM3=ZU;ZCXUFAT^S:_\
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M>'OB8^B'XG^'-!\9Z;R^E_\ !*_]EW0_$>EZCHFH?'+1?!/A?]I9/VN/A_\
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MCQW\/;/PQKOBI(='N]7N+B]\'^!;CPQN>!OVKIO&W[:?[0G[(T7PM\8:;;?
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M*-2&+?Q0K>\:12DO=4$XZ)QY(TI4[)644N2>&IN*AK3GADTXSI7BSQ_^P?\
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M/V;/$_[,?BOQW^T=\2?#?CSQ'X*\3_$'XF?%CX^>//BC\=?&U]\.?$^A^,/
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M_P $R?V5O&/QTTCX^6.F_$WX9Z__ ,(7X'^''Q(\"?!;XP_$7X/_  :_:#\
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M"WCGXEV/Q(\0?%WP'JW@G5]8'CG5O&OC;XK?V1X*\3:EX1/A>TMO:_@O\?\
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M!XU\8_$Z+XN?%3X%:[\#M*TS0+3XJ>%?BG\#-/T[6OC'X9UZUUSQ1I'@OR_
M7AW6_#_B63Q!I'C75_#'C3P]XI\':K\,M9\<6WC/PFVM?6O@#QII'Q(\"^"_
MB'H%OK-IH7COPEX;\9Z+:^(M&U#PYX@MM)\4Z-9:YIL&N>'M7@MM5T+6(;.^
MACU/1M3MK?4-+OEGL;V"*Y@EC5INRM)V]U1M+3W8T>7E:;3M&EAU>+=O9TDV
MG%('&+;YDN9W<N9>\^:563YE)7]YU:SM)+F]I4:4HR;?XR_'W]D;X^>//VM_
MBUXTN/ O[5=UHWCW0/A3X0^%WQC_ &5_^"B?B[]F'P,OA?P'X(\EI_VKOAO8
M>+?#.J:5X\L?BKXE^)-ZGBCX#_"KXN>&M0^%E_X(C3P#9^-]-\7V_BG]E?AQ
MH7BGPO\ #WP)X9\<>,;CXA^,_#O@SPOH7B[Q_=Z9IVB7?CCQ/I&AV.G^(/&%
MUHVCP6ND:3<^)M6M[O6IM,TJUMM.L)+YK6Q@AMHHHU\>^+W[4O@#X/>(=4\)
MWN@^//'7B3PQ\.)?C%XYT+X;:!9^)=:\#?"F/4=5T6V\=ZSHL^L:7J^K:=J6
MMZ#K>E:5HW@JQ\5^+M0N-&U:YM_#CZ;I>H7UMY[\0_V^_P!G_P"%FC_M4:YX
MTF\=:=9?L8ZSX(TO]H$6O@G5=6G\+V/Q%\-Z%XP\(^)=&BTO[7_PF?A_4/#'
MB71-8NI?"+:SJFB1W<]EKNE:;JNE:S8:<H_"HJS5W:RU;4G#3I\5?EERKE<Y
MJZBU9#UDV][*Z[7C=7=KW<:+:4G?EBW=JS>CH7[!'[*WANS^&&GZ/\+-*M++
MX/?M2?$[]LOP';)-.L6E?M ?%EOBZ?$WBZ9$91?6EE'\:_%UKX4T&Z\S1_"=
MEIW@JQT.TL[3P1X;AT_TBZ_9R\"7?[3&C_M7S7_BL?%/0_@YKOP&L8$UF(>#
MQ\-O$OBO0_'.M:5+X;:P:&34;SQ;X8\.ZS_PD'V@:Y;_ -DPZ5;7\.AW>IZ7
M?<)\>OVU_@I^SJ/B!<^-SXTUC2?@QX7\(>/?CUK7@/PE>^,;/X&_#SQUJFM:
M5X<\<>/K+3)?[=O-+FD\.:[J>IZ+X"T?QMXT\/\ A;2[CQKK_A;3/!KV^O3_
M !%IW_!00_ 3]IW_ (*$>&_VDO&GQ*\4_!KX1_M!_LM^"_ &HZ#\([?6?#?[
M/W@?XW_ ?X1:W?:I\1O%O@+P?I7V/P*?BY\098/^$@\::EXD\7:?I.H&],=S
MX/\ !WBK7]$%'G<8)7TDX+I=TZ-'EBOA3J4I0I1T490I^SYK1BHJ34$VT_>E
M&,K;M.=:LY2W;C"I"=6=VY1E/GY;RDW]+?"O_@F_\"/@YI_[*ND^#/%/QL;3
M?V+=0\9W'[/-CXC^)M_XKMO!FB^,_ ]W\*W\&31>(;#4%UGP=X9^%%X_PZ\'
MZ-J8N#H>D(/$*W-Q\09[SQE=?2/[/_P#\&?LW> K[X<^ ;_Q-?>'=0^(7Q2^
M*$W_  E6IVVKZBGB_P"-/Q%\3?%OXDWD5[;Z=IS"V\1?$GQIXN\6_8G22WTN
MZ\076F:.NG^'[/2-'TW;^-WQI^&W[.GPD^(/QR^+_B+_ (17X9_##PUJ'BSQ
MEKRZ;JVMSV.DZ<BEUL=$T"QU/7=;U2\G>"QTK1-%TV_U?5]2N;33M-LKJ]N8
M87\2M/VW/@W_ &1\6I?$%MXO\&>-?@C\6?A'\"?B#\*_$VG:&OC?3_B]^T%+
M\,[;X!^"M.O]#\1ZY\.M;?XOWOQD^&5AX7\3Z5X]NO ^E:AXGEL?'/B?PC=>
M%O&L7AHT;;W:3YGJW:4J4Y)NS;<I0HSDDW*34)-2NFZY;*.EDVN6RLKI5(JU
MDDK*56*O:*O*":MRK[ HKSKX8_$>S^)_AVZUZV\,>,O!EUIOB3Q-X2UGPOX^
MT6/0O$ND:[X2UFZT/589[>UOM4TS4--N+FT-]X?\1Z#JNL>&?%6@76F^)?#.
ML:MH&JZ=J5UZ+3_X#^35TUW3333#?[VOFFTUZIII^:"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O@;Q'\"/B^?\ @HCI?[5.CZ1X.U/X7Z%^PS\0?V?(;*Y\8WVF>-]2^*7B
M3XR^"OBAI(70O^$2O=%L_ C:/X/ETF^\4R>*IM?M=>U&VBB\#7>D03ZT/OFO
MF?1/VE=-UK]KSXB?LBCP/XCT[7?A[^S_ /"_]H*3QW?WNA-X:\2Z!\4_'GQ,
M\ :9I.@6-AJ%]K4=WHVJ_"SQ -9FUZTT1@\EH-.L[^RFCU&2904_<=]85M%_
M++#UJ=1^JHU:K7G9I2<4F.2@FVTDW2B[ZZ^WI2IK376K3IIOLVFXIW7Y\?LS
M?L0?M&?!Y_\ @CS8^+++X8W5C^P+^QY\4/V<OCE?Z#X_UN_EUGQ7XE^&/P/^
M'WAC7_A397_@#2?^$G\-W%Y\(-0U37SXNN?AYJNAZ;XATI--T_Q+>VNHVL/(
MVO[ '[3A^!UE;(/A;I/QM^#?_!6?XM_\%*O@_H2?$3Q!=_#CXC^$OBE^T'\9
M?B)?_![X@^+$^&L>N^!O$UU\(_CEXU\%S:UI?@CQSH'AOXAV7A7Q98S>*=%B
MO].M_P!S:^6I?VG[1/VN/$'[),/PW\7W/B'0OV9[;]I6V\8QZCX130O$^F7G
MQ"O/AY;^"O#EC/K\6HIXBCU/3[B:]OO%*^%]#A6XTY+2_OX)M0O-+MSDVTI6
M<G.I[JL^:%2&,E);ZQ^K1=M;P4H*,G.YG&E"*5E=14(ZNZY94JF#BGJM''%2
MC?2TY0FVN6S_ #U_:;_8&^-GQZ^'7_!3+QCX0TSP7X9^-7[>/PQ_9S^#/@3P
M-XV\9S:3X:\&>"OV?+;Q+>:/KWQ4\7^$/#'CP6OC/5/$'Q2^)@U.S\$:3X]T
MJ+0='^'NFVNL7$\^MWNE?9WB[X0?%O6OVY_V?/VFK+P[X8_X5]\-/V1/VG_@
MQXLTN;QE+%XU/CSX\_$?]ECXBZ#'H6D#PT^@:GX>T&/]G#5-#US6+WQ7H]W)
M?^,-%NM.T>[L=-U.5?5/V1/VC-&_:Z_9F^"O[3/AWPQK'@O0OC9X%TKQ[I'A
M7Q#=:?>Z[H6G:QYKVFGZQ<Z5)-IDFI10HAO!I]Q=6<4[/%;W=W$BW,OT;4.F
MDTK6Y)0G%)[25&M3B[WE>\,9.3NVG*4):*"B[;YKN5VVG"3=T[1K4YN+3MR\
MM3"QC;E32C./VFU^'/[.G[!7[3_PM\'?\$?/#OBJU^$:ZG^P9J'QZD^.%]H7
MQ!\1:]I>HI\2?@A\5OA'X/N_A6E_\._#%[XS2#4_B#I>O>*;7Q9'\,)=+T?3
M]4MM&F\2:C]BBN[G[(/[)?[;W@C]HW]E#X^?M(>$O@3JWCWP'^RC^U+^SO\
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MFENY+LVUO,NF:=J^IFSTJ]]OTJ^&J:7INIB(P#4;"SOA"7$AA%W;QW B,@5
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M-.][-WNTXN2YG%O>$9QB^J4U73Z;_P"T5&GNO=Z)\WX*?L\_L$?M<? [0?\
M@F\\WA3X":IK'['7[1/[<-QXT\/:'\5O$^B>'=1^#?[3^I_%U_"WCCPE>O\
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M^_P=G?3];\*Q>/M':3X7/HLL#:4D,47C2TO$NK"Q_53QY^TMIG@/]J3]GO\
M9>NO!'B._P!5_:$\"?'/QWHWCZ"]T&+PIH%O\"H_AZ^O:%?V3ZB_B6ZUS5?^
M%D:'-IYBT:#1H[.*\DDUB2\B&GGZ9I-R<E5;NW*'O-;_ %?DIJ+2Z1MR[+2I
M4Y'%23C32<73>UI2M:S7M^:?.G;5MKF6LE>G#F3<9*7X=>+/^"??[2.K:C\<
M_B1H5U\,K#XBZ;_P5P^'/_!2C]GWPY?>.M>3PKX]\%>#OV?_ (3_ +-_BGX2
M_%C7K;X?7=]\/?$_C'P%X6^)EWI>J^'_  ]\2-#\(>(O$7P_U66Y\21Z1KVG
MQWOVF/V OC=\=O#?[=GQ(\'Z5X*\-_&']L+6/V"=!\+^ O&GC272-"\*?#']
MB[XG:?\ $]=0^(OBWPCX8\=PP?$?Q-?>)_BKIJV/@_3?&GAZ*RM/AGIS^(A$
M_B'5M'_7SX>^(O&?B;1]7OO'/P\NOAIJMEXX^(/A_2]$N_$_A_Q8^M>#_#7C
M77=!\#>/X]0\.33V=A;_ !)\(:?HWCRV\-7C)KOA2'Q GAOQ#%'K6EWR#NZB
M"Y53M=J')*"E=\MHX76VEG*.%P\9IZ^Y)6A-S94VZBJ*6U15(5++EYHREB+Q
MNM>6,L17<&GM-.\XJ!^;>F?"7]IWX8_M1?MY?M.> _AK\+/'Y^-OPG_9*\*_
M _P'XG^-.L_#RZUOQ!\"O^%N0>.;;XE^(=.^$'Q#M/AU87L?Q7CG\&W_ (;T
M_P"*3:P?#U['KUIX3:_M"/?/VW?V4/!G[<G[)WQV_9/\?:I?>'_#GQK\"WOA
M<>)]+@%WJ?A#Q%;7=GKW@OQII]DUU91ZC>>#/&>CZ!XIMM,GO+6WU.;2$L+F
MXAM[B21?JBN#T?Q'XTOOB)XX\,:I\.[G1/ GA_P]X$U+P?\ $V3Q1X?U"U\?
MZ[XAG\81^,_#5MX2LIG\2>&I/A[#HGA6XN=6UZ&'3_$__";0Q:"TK^']8*+E
M7*J>MN6T;-J45&4ZEU.+3C+GJ<\974N:,.1IPLQ-Q?.K)\W,W9/FE)0B[Q=T
MTU3M*-N6TIW5I>[\W_!OQ!^W3=^'?"_@GX[?#/X%Z#XVT>PT;3/'OQP^'GQ4
MUWQ-X$\8M96L<.K>,?AY\,-8^&GACQ5H?B#Q3-;R7K_#[Q?JJ^'/AO/JYM[3
MXC?%ZT\-K_PE?QGX\_8-^--[X*_X*@_LQ>'YO"FK_!3_ (*5^+_&OC;1OBMK
M'B*5O%/P$N_C[\&? ?P/_:$TGQ/X)ET6#_A*XO"=AX.N?B?^SS-X:U>]'BGQ
M)X@D^%_Q%E^%?A_PIIWQ,\2?LQ7Q]^SE^U5JO[2UUX>\8^"/@]KH_9N^(G@C
MQ5XR^%O[0!\6>&I;377\(^/SX&&B>+OAW=-IOC#PA=_$"P/_  L/X5WNE1^-
M--U?P+9ZK_PL*Y^%WC6VL/!>JN24Y/F2DW%JI[MHRC4J4Y-345&$5*KAX<JB
MH1YHRA'E4^42]Q)*32NN3WKR4H1FDX.3<Y.,*[YF^=J+A*3?)S/\]_VBO^"?
MW[1OQ*\(_P#!8+P7X"L/A9;6?[=/PT^!?PZ_9[N_$WQ+\3VR:.OPZ^"MA\)/
M%.H?%]X/AUX@U#PS;QW5O)J_AI_"[_$_4/$FF1Q#7AX4U*XEMX?I_P#:2_8B
M\0_&W]J_]F']I+PKKNE^"],TWPIKGP4_;"\)732W%[\7_P!GFW\1>'_V@/AM
MX*CDA2]T/5KGPA^T+\.='\*:K8:K:'2]8^"7QS_:'T)+I9O$5K%-^E5%-74E
M/F;DI0DVW?FE".(C>6W-S?6JKFGI)\C=G"+(4(I.*BHQE&<&E=+DG*C)Q6NB
M3H0Y;:Q3FKM2T_('XS?LM?M7>$_VW?B1^T+^S_\ ##]DO]H'X8_M,?#3X4>#
M_B!X=_:<\3^(_!_B7]GKXK?!Y/%^D:%\7_A]=>'_ (1_$Y?B-\/?$?@CQ#9:
M=XQ^$$EWX#U^_P#&/AC0-0T'XA^%],USQ-?V?J7PT_9T_: ^'?QY_P""AOQ-
M?0/A%XIT3]H+X<? G2O@?;^(/$6H&T\2>+_@U\$M<^'6K:;\9_!.G>![72O!
M7@[Q9XGO;">SC\&Z[X[:X\(2:F-0TWPYJ%O9Z+=_I97$?$OXD>!O@[\._'/Q
M9^)WB73?!GPY^&GA+Q!XZ\=>+=9D>+2_#?A/PKI5UK6OZU?O&DLWV;3M,LKF
MZD2"*:XE$?E6\,LSQQLFDH<C>BA6IIM)M0K)Q<=4TU'GER<T9.\N5^TCRP=M
M<TU*S<N>E-)72YZ37++W6I7E9*5I*]KQY)-R7XK:)^PW^UW\$OA7^T+X6_8Z
ME;X(?#'QCJG[(VN_#G]CGQ%^TQX\N_"_@:?P1\9-?\3?MU?#[]G'XY:5HGB3
MQ-^R]\*/VD/@_>Z+X"^#<?@K2K&;X<^*;/Q!XW\+^!/V?=1\169\-UH_V"/V
MJ=#^#W[8WAWPY\./V<-#U[Q[_P %.OV/_P#@H#\$OA_X0^*OB'1O ^L^'_@3
MXN_8?\>>/_A7JVLCX&:4O@34;Z3]F3Q3H_AGQ?#X3UNW\3^)?$*:QK_AKPAI
MA:\N_P!KM0\1>,K;XD^%/"UA\/+K4_ &L^#O'&N>)?BFOB;0+2T\'>*] U?P
M-9>#_!$_@^ZF7Q/KD_C[2_$'C/68/$.D02:-X:3X?S6&MR)=^)]##=W2<8RO
M+77E5FYV2I5*4HI*4FTE.A3<;MW4='*+N%WRN%]'S.7NQ][VM.K"5VHI>]"M
M44N51UDVU&9^.'[0_P#P3_\ C!^U1XC_ ."D&F^,]4\&_"_PK^VQ^PA^S/\
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MG=;P3Y8SYFR44Y.6TN:;;3T?--SY7O>,9N4H6?VFN:4+)?SI?#SX%^.?VOO
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MI1C3:5Y4[/F5I/GDG&S>_,IXB24E:2=:M*HXSNOL2G45[1J:*#;BN2/YD?\
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M8V'QTO1XI^*0LM8\-^)M1U'Q#%8:$A^(OC+!\*/''[.__!;CP'\)I/@I\1/
MOCC_ ()#_LA_M ?";PG^S[\/KJU^"&MZWX4M?VV-'U_XH_!;2[]-7C^(NJ>!
MK#P9\'_"_BOXZ:8]UK[>+O!'AKP_K$GA+Q'X(T[P)X/_ ++*Y/QEX[\#_#K2
MK77OB!XR\+>!M#OO$'ACPE9:QXP\0:3X:TJ\\5>-_$6F^$O!GAJUU#6KNRM)
M]?\ %OBK6=)\,^&=&BF;4=>U_5=.T?2[>ZU"\MK>2JK=25[\JU5."Y>5.5>K
M5IP>SG&,JE&E"":M&FH4U'GBHU3:@EI%M1@IR=[OV=*A"<]6U&4U1JU*D^]6
M4IRDH2Y_R(UW4_A/?_\ !1;]B[Q/^R_>_")K3Q/_ ,$R/^"@UC\(]3\(RZ+;
M_#K7EU;XU?L,^)_@^^B#PZ8=)U'P=XGFT?XH>+/"6H>&TEL/%WAO2O'/B?PS
M=:KI-CJ.H1?)/[+5KIWC#PS_ ,$=_&?PR2#2OVT_!>LZAX!_X*DMK4-]I'Q7
M3PC8_LH_&)/VQ+']LG2R+77-4GUK]L;0_A5KWA#5_BE:W5OJ?Q)U_P %^-_
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MP$/VUOV_/"_PT\7?";6/AUXM^$?["'QI^']G\ /"+> /V?\ Q+;>(_!'Q?\
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MQKKFC:GX \)Z3\+/ &E> O"'BC3]?T'PU'X8TO5DL;KQ);1ZXL^I_P#!-O\
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M6+<7"6SC6ISLGM&-6E-K=OX8U.51DG&7(KS@YQC^+?[$_P"UM\8?V2?V7O\
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ME4C3:2C*4H2FDTDOMS:^%QFH+HFU4<+QM>\7*-.4[N\8J:BVG?\ (^/_ (*
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M:P2OV7@?]J_XS?!.R_X*-^/_ !'XZUKXKZH__!8#X2_LB_"O0?$FD^&[;0O
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M4[04Y*G\:> _VJ?VDM#^(G_!.!/&_B3P)\0?!W_!2'X7>,4U*#2/"D6GZ=\
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MO_&K]ISXV_%GX2?$2TT'PYKNNV4'B3PG\./B;X?M)/!&I:K)\.O"/QBT:_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>34
<FILENAME>pcsa-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaWH+bP9z5Z8uekhvWB3bdmKzywke3BzaiugQ6z2oe8B -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:PCSA="http://processapharmaceuticals.com/20241231" elementFormDefault="qualified" targetNamespace="http://processapharmaceuticals.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
          <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Organization" id="Organization">
          <link:definition>999015 - Disclosure - Organization</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
          <link:definition>999016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999017 - Disclosure - Stock-based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999018 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" id="NetLossPerShareOfCommonStock">
          <link:definition>999019 - Disclosure - Net Loss per Share of Common Stock</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Leases" id="Leases">
          <link:definition>999020 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/LicenseAgreements" id="LicenseAgreements">
          <link:definition>999021 - Disclosure - License Agreements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999022 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999023 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Litigation" id="Litigation">
          <link:definition>999024 - Disclosure - Litigation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>999025 - Disclosure - Segment Reporting</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999026 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ConcentrationOfCreditRisk" id="ConcentrationOfCreditRisk">
          <link:definition>999027 - Disclosure - Concentration of Credit Risk</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999028 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999029 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999030 - Disclosure - Stock-based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" id="NetLossPerShareOfCommonStockTables">
          <link:definition>999031 - Disclosure - Net Loss per Share of Common Stock (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999032 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/LicenseAgreementsTables" id="LicenseAgreementsTables">
          <link:definition>999033 - Disclosure - License Agreements (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999034 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/SegmentReportingTables" id="SegmentReportingTables">
          <link:definition>999035 - Disclosure - Segment Reporting (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/OrganizationDetailsNarrative" id="OrganizationDetailsNarrative">
          <link:definition>999036 - Disclosure - Organization (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999037 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
          <link:definition>999038 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>999039 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" id="ScheduleOfRestrictedStockAwardsRsasActivityDetails">
          <link:definition>999040 - Disclosure - Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" id="ScheduleOfRestrictedStockUnitsRsusActivityDetails">
          <link:definition>999041 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails" id="ScheduleOfWarrantsActivityDetails">
          <link:definition>999042 - Disclosure - Schedule of Warrants Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails" id="ScheduleOfWarrantValuationAssumptionDetails">
          <link:definition>999043 - Disclosure - Schedule of Warrant Valuation Assumption (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999044 - Disclosure - Stock-based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999045 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" id="ScheduleOfNetLossPerShareBasicAndDilutedDetails">
          <link:definition>999046 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
          <link:definition>999047 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" id="NetLossPerShareOfCommonStockDetailsNarrative">
          <link:definition>999048 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" id="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails">
          <link:definition>999049 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" id="ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails">
          <link:definition>999050 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" id="ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails">
          <link:definition>999051 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999052 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails" id="ScheduleOfLicenseAgreementsDetails">
          <link:definition>999053 - Disclosure - Schedule of License Agreements (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999054 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="ScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:definition>999055 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999056 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999057 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" id="ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails">
          <link:definition>999058 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" id="ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical">
          <link:definition>999059 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999060 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999061 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="PCSA_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PreFundedWarrantMember" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TwoThousandAndNineteenPlanMember" name="TwoThousandAndNineteenPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OriginalMember" name="OriginalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ServiceBasedRestrictedStockUnitsMember" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" name="JanuaryOneTwoThousandTwentyFiveVestingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ThreeYearVestingMember" name="ThreeYearVestingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_FirstPerformanceBasedRSUMember" name="FirstPerformanceBasedRSUMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SecondPerformanceBasedRSUMember" name="SecondPerformanceBasedRSUMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_NextGenerationCapecitabineCAPMember" name="NextGenerationCapecitabineCAPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_JulySixteenTwoThousandTwentyFiveVestingMember" name="JulySixteenTwoThousandTwentyFiveVestingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OfferingMember" name="OfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SpartanCapitalSecuritesLLCMember" name="SpartanCapitalSecuritesLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_RestrictedStockAwardMember" name="RestrictedStockAwardMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ATMOfferingMember" name="ATMOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PlacementAgentMember" name="PlacementAgentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SalesAgreementMember" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AccreditedInvestorMember" name="AccreditedInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_FacilityLeaseMember" name="FacilityLeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ElionOncologyIncMember" name="ElionOncologyIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OcuphirePharmaIncMember" name="OcuphirePharmaIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AposenseLtdMember" name="AposenseLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_YuhanCorporationMember" name="YuhanCorporationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_CoNCERTPharmaceuticalsIncMember" name="CoNCERTPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_FederalMember" name="FederalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_CorLystLLCMember" name="CorLystLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_CROsMember" name="CROsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SeriesAWarrantMember" name="SeriesAWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SeriesBWarrantMember" name="SeriesBWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" name="ChiefExecutiveOfficerAndCertainBoardMembersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SeriesAAndBMember" name="SeriesAAndBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OperatingAndFinanceLeaseLiabilityCurrent" name="OperatingAndFinanceLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DueToLicensor" name="DueToLicensor" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" name="OperatingAndFinanceLeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" name="AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OperatingAndFinanceLeaseExpense" name="OperatingAndFinanceLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_IncreaseDecreaseInDueFromToRelatedParties" name="IncreaseDecreaseInDueFromToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PaymentsForSettlementOfStockAwards" name="PaymentsForSettlementOfStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" name="StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_FinancingLeaseLiability" name="FinancingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_NonCashLeaseLiabilityNet" name="NonCashLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" name="LesseeOperatingAndFinancingLeasesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DisclosureLicenseAgreementsAbstract" name="DisclosureLicenseAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LicenseAgreementDisclosureTextBlock" name="LicenseAgreementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DisclosureLitigationAbstract" name="DisclosureLitigationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LitigationDisclosureTextBlock" name="LitigationDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PrepaidExpensesPolicyTextBlock" name="PrepaidExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_RecentAccountingPronouncementsPolicyPolicyTextBlock" name="RecentAccountingPronouncementsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ScheduleOfWarrantValuationAssumptionTableTextBlock" name="ScheduleOfWarrantValuationAssumptionTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" name="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LicenseAgreementsTableTextBlock" name="LicenseAgreementsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OrganizationTable" name="OrganizationTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="PCSA_OrganizationLineItems" name="OrganizationLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AccountingPoliciesLineItemsAbstract" name="AccountingPoliciesLineItemsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_MarketCapitalization" name="MarketCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PerformanceVestingCriteriaValue" name="PerformanceVestingCriteriaValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_UnrecognizedShareBasedCompensationExpense" name="UnrecognizedShareBasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_StockIssuedDuringPeriodSharesExercised" name="StockIssuedDuringPeriodSharesExercised" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TransactionCostsPercentage" name="TransactionCostsPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ReimbursementFees" name="ReimbursementFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" name="OperatingAndFinancingLeaseWeightedAverageDiscountRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LicenseAgreementsDate" name="LicenseAgreementsDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LicenseAgreementsAmendmentDate" name="LicenseAgreementsAmendmentDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_NetOperatingLossCarryforwardExpiryDate" name="NetOperatingLossCarryforwardExpiryDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_NetOperatingLossCarryforwardTerm" name="NetOperatingLossCarryforwardTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" name="EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" name="DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DeferredTaxAssetsFederalOrphanDrugCredits" name="DeferredTaxAssetsFederalOrphanDrugCredits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DeferredTaxAssetsStartupExpenditures" name="DeferredTaxAssetsStartupExpenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ProceedsFromRentAndOtherCostsReimbursements" name="ProceedsFromRentAndOtherCostsReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PreclinicalClinicalTrialAndOtherCosts" name="PreclinicalClinicalTrialAndOtherCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AdministrativeAndFacilitiesExpense" name="AdministrativeAndFacilitiesExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OutstandingSharesPercentage" name="OutstandingSharesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" name="ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock" name="ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OperatingLeaseLiabilities" name="OperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>35
<FILENAME>pcsa-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Cover" xlink:href="pcsa-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheets" xlink:href="pcsa-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="pcsa-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:href="pcsa-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="pcsa-20241231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="pcsa-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:href="pcsa-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Organization" xlink:href="pcsa-20241231.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcsa-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:href="pcsa-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:href="pcsa-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:href="pcsa-20241231.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Leases" xlink:href="pcsa-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LicenseAgreements" xlink:href="pcsa-20241231.xsd#LicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IncomeTaxes" xlink:href="pcsa-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:href="pcsa-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Litigation" xlink:href="pcsa-20241231.xsd#Litigation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SegmentReporting" xlink:href="pcsa-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="pcsa-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ConcentrationOfCreditRisk" xlink:href="pcsa-20241231.xsd#ConcentrationOfCreditRisk" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SubsequentEvents" xlink:href="pcsa-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcsa-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:href="pcsa-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:href="pcsa-20241231.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LeasesTables" xlink:href="pcsa-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LicenseAgreementsTables" xlink:href="pcsa-20241231.xsd#LicenseAgreementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IncomeTaxesTables" xlink:href="pcsa-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SegmentReportingTables" xlink:href="pcsa-20241231.xsd#SegmentReportingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationDetailsNarrative" xlink:href="pcsa-20241231.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="pcsa-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfWarrantValuationAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="pcsa-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:href="pcsa-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:href="pcsa-20241231.xsd#NetLossPerShareOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:href="pcsa-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfLicenseAgreementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative" xlink:href="pcsa-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="pcsa-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" xlink:href="pcsa-20241231.xsd#ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="pcsa-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" xlink:href="pcsa-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DueToLicensor" xlink:label="loc_PCSADueToLicensor" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_PCSADueToLicensor" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinanceLeaseExpense" xlink:label="loc_PCSAOperatingAndFinanceLeaseExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PCSAOperatingAndFinanceLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_IncreaseDecreaseInDueFromToRelatedParties" xlink:label="loc_PCSAIncreaseDecreaseInDueFromToRelatedParties" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PCSAIncreaseDecreaseInDueFromToRelatedParties" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PaymentsForSettlementOfStockAwards" xlink:label="loc_PCSAPaymentsForSettlementOfStockAwards" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PCSAPaymentsForSettlementOfStockAwards" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Organization" xlink:title="999015 - Disclosure - Organization" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="999017 - Disclosure - Stock-based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="999018 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="999019 - Disclosure - Net Loss per Share of Common Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Leases" xlink:title="999020 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LicenseAgreements" xlink:title="999021 - Disclosure - License Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IncomeTaxes" xlink:title="999022 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="999023 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Litigation" xlink:title="999024 - Disclosure - Litigation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SegmentReporting" xlink:title="999025 - Disclosure - Segment Reporting" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="999026 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ConcentrationOfCreditRisk" xlink:title="999027 - Disclosure - Concentration of Credit Risk" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEvents" xlink:title="999028 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999029 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="999030 - Disclosure - Stock-based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="999031 - Disclosure - Net Loss per Share of Common Stock (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesTables" xlink:title="999032 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LicenseAgreementsTables" xlink:title="999033 - Disclosure - License Agreements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IncomeTaxesTables" xlink:title="999034 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SegmentReportingTables" xlink:title="999035 - Disclosure - Segment Reporting (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationDetailsNarrative" xlink:title="999036 - Disclosure - Organization (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999037 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999038 - Disclosure - Schedule of Stock-based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999039 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:title="999040 - Disclosure - Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:title="999041 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="999042 - Disclosure - Schedule of Warrants Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails" xlink:title="999043 - Disclosure - Schedule of Warrant Valuation Assumption (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999044 - Disclosure - Stock-based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="999045 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="999046 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="999047 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:title="999048 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:title="999049 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="999050 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:title="999051 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:title="999052 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails" xlink:title="999053 - Disclosure - Schedule of License Agreements (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative" xlink:title="999054 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999055 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" xlink:label="loc_PCSAEffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_PCSAEffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999056 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" xlink:label="loc_PCSADeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_PCSADeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetsFederalOrphanDrugCredits" xlink:label="loc_PCSADeferredTaxAssetsFederalOrphanDrugCredits" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_PCSADeferredTaxAssetsFederalOrphanDrugCredits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_PCSADeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_PCSADeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetsStartupExpenditures" xlink:label="loc_PCSADeferredTaxAssetsStartupExpenditures" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_PCSADeferredTaxAssetsStartupExpenditures" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999057 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" xlink:title="999058 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PreclinicalClinicalTrialAndOtherCosts" xlink:label="loc_PCSAPreclinicalClinicalTrialAndOtherCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_PCSAPreclinicalClinicalTrialAndOtherCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AdministrativeAndFacilitiesExpense" xlink:label="loc_PCSAAdministrativeAndFacilitiesExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_PCSAAdministrativeAndFacilitiesExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" xlink:title="999059 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999060 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" xlink:title="999061 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>36
<FILENAME>pcsa-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Cover" xlink:href="pcsa-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheets" xlink:href="pcsa-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="pcsa-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:href="pcsa-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="pcsa-20241231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="pcsa-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:href="pcsa-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Organization" xlink:href="pcsa-20241231.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcsa-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:href="pcsa-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:href="pcsa-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:href="pcsa-20241231.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Leases" xlink:href="pcsa-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LicenseAgreements" xlink:href="pcsa-20241231.xsd#LicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IncomeTaxes" xlink:href="pcsa-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:href="pcsa-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Litigation" xlink:href="pcsa-20241231.xsd#Litigation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SegmentReporting" xlink:href="pcsa-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="pcsa-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ConcentrationOfCreditRisk" xlink:href="pcsa-20241231.xsd#ConcentrationOfCreditRisk" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SubsequentEvents" xlink:href="pcsa-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcsa-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:href="pcsa-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:href="pcsa-20241231.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LeasesTables" xlink:href="pcsa-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LicenseAgreementsTables" xlink:href="pcsa-20241231.xsd#LicenseAgreementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IncomeTaxesTables" xlink:href="pcsa-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SegmentReportingTables" xlink:href="pcsa-20241231.xsd#SegmentReportingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationDetailsNarrative" xlink:href="pcsa-20241231.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="pcsa-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfWarrantValuationAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="pcsa-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:href="pcsa-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:href="pcsa-20241231.xsd#NetLossPerShareOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:href="pcsa-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfLicenseAgreementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative" xlink:href="pcsa-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="pcsa-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" xlink:href="pcsa-20241231.xsd#ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="pcsa-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" xlink:href="pcsa-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:label="loc_PCSAAdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAAdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation_60" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Organization" xlink:title="999015 - Disclosure - Organization" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="999017 - Disclosure - Stock-based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="999018 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="999019 - Disclosure - Net Loss per Share of Common Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Leases" xlink:title="999020 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LicenseAgreements" xlink:title="999021 - Disclosure - License Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IncomeTaxes" xlink:title="999022 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="999023 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Litigation" xlink:title="999024 - Disclosure - Litigation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SegmentReporting" xlink:title="999025 - Disclosure - Segment Reporting" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="999026 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ConcentrationOfCreditRisk" xlink:title="999027 - Disclosure - Concentration of Credit Risk" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEvents" xlink:title="999028 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999029 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="999030 - Disclosure - Stock-based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_RestrictedStockAwardMember" xlink:label="loc_PCSARestrictedStockAwardMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSARestrictedStockAwardMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ScheduleOfWarrantValuationAssumptionTableTextBlock" xlink:label="loc_PCSAScheduleOfWarrantValuationAssumptionTableTextBlock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAScheduleOfWarrantValuationAssumptionTableTextBlock_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="999031 - Disclosure - Net Loss per Share of Common Stock (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesTables" xlink:title="999032 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LicenseAgreementsTables" xlink:title="999033 - Disclosure - License Agreements (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IncomeTaxesTables" xlink:title="999034 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SegmentReportingTables" xlink:title="999035 - Disclosure - Segment Reporting (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationDetailsNarrative" xlink:title="999036 - Disclosure - Organization (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OrganizationLineItems" xlink:label="loc_PCSAOrganizationLineItems" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OrganizationTable" xlink:label="loc_PCSAOrganizationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_PCSAOrganizationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPreFundedWarrantMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesAWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesAWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesBWarrantsMember" xlink:label="loc_PCSASeriesBWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesBWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ClassOfWarrantOrRightExercised" xlink:label="loc_PCSAClassOfWarrantOrRightExercised_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_PCSAClassOfWarrantOrRightExercised_120" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_120" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_120" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999037 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AccountingPoliciesLineItems" xlink:label="loc_PCSAAccountingPoliciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_PCSAAccountingPoliciesLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AccountingPoliciesLineItemsAbstract" xlink:label="loc_PCSAAccountingPoliciesLineItemsAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAAccountingPoliciesLineItems" xlink:to="loc_PCSAAccountingPoliciesLineItemsAbstract_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAAccountingPoliciesLineItemsAbstract_60" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAAccountingPoliciesLineItemsAbstract_60" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAAccountingPoliciesLineItemsAbstract_60" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAAccountingPoliciesLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems_60" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999038 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999039 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:title="999040 - Disclosure - Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_RestrictedStockAwardMember" xlink:label="loc_PCSARestrictedStockAwardMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSARestrictedStockAwardMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:title="999041 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="999042 - Disclosure - Schedule of Warrants Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails" xlink:title="999043 - Disclosure - Schedule of Warrant Valuation Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999044 - Disclosure - Stock-based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="loc_PCSATwoThousandAndNineteenPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PCSATwoThousandAndNineteenPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OriginalMember" xlink:label="loc_PCSAOriginalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAOriginalMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ServiceBasedRestrictedStockUnitsMember" xlink:label="loc_PCSAServiceBasedRestrictedStockUnitsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAServiceBasedRestrictedStockUnitsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FirstPerformanceBasedRSUMember" xlink:label="loc_PCSAFirstPerformanceBasedRSUMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAFirstPerformanceBasedRSUMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SecondPerformanceBasedRSUMember" xlink:label="loc_PCSASecondPerformanceBasedRSUMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASecondPerformanceBasedRSUMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_EmployeesMember" xlink:label="loc_PCSAEmployeesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAEmployeesMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ConsultantMember" xlink:label="loc_PCSAConsultantMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAConsultantMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" xlink:label="loc_PCSAJanuaryOneTwoThousandTwentyFiveVestingMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSAJanuaryOneTwoThousandTwentyFiveVestingMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ThreeYearVestingMember" xlink:label="loc_PCSAThreeYearVestingMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSAThreeYearVestingMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_JulySixteenTwoThousandTwentyFiveVestingMember" xlink:label="loc_PCSAJulySixteenTwoThousandTwentyFiveVestingMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSAJulySixteenTwoThousandTwentyFiveVestingMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FirstPerformanceBasedRSUMember" xlink:label="loc_PCSAFirstPerformanceBasedRSUMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSAFirstPerformanceBasedRSUMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SecondPerformanceBasedRSUMember" xlink:label="loc_PCSASecondPerformanceBasedRSUMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSASecondPerformanceBasedRSUMember_160" xlink:type="arc" order="163" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_NextGenerationCapecitabineCAPMember" xlink:label="loc_PCSANextGenerationCapecitabineCAPMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSANextGenerationCapecitabineCAPMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OfferingMember" xlink:label="loc_PCSAOfferingMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAOfferingMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SpartanCapitalSecuritesLLCMember" xlink:label="loc_PCSASpartanCapitalSecuritesLLCMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSASpartanCapitalSecuritesLLCMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_290" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_290" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_290" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_290" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_290" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_MarketCapitalization" xlink:label="loc_PCSAMarketCapitalization_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAMarketCapitalization_290" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PerformanceVestingCriteriaValue" xlink:label="loc_PCSAPerformanceVestingCriteriaValue_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAPerformanceVestingCriteriaValue_290" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_290" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_290" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_PCSAUnrecognizedShareBasedCompensationExpense_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAUnrecognizedShareBasedCompensationExpense_290" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_290" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_290" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_290" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_290" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_290" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_290" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_290" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_290" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="999045 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_PCSAPreFundedWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SalesAgreementMember" xlink:label="loc_PCSASalesAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASalesAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SecuritiesPurchaseAgreementMember" xlink:label="loc_PCSASecuritiesPurchaseAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASecuritiesPurchaseAgreementMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ATMOfferingMember" xlink:label="loc_PCSAATMOfferingMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAATMOfferingMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PlacementAgentMember" xlink:label="loc_PCSAPlacementAgentMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAPlacementAgentMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_RegisteredDirectOfferingMember" xlink:label="loc_PCSARegisteredDirectOfferingMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSARegisteredDirectOfferingMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="loc_PCSALincolnParkCapitalFundLLCMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSALincolnParkCapitalFundLLCMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AccreditedInvestorMember" xlink:label="loc_PCSAAccreditedInvestorMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAAccreditedInvestorMember_130" xlink:type="arc" order="133" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PlacementAgentMember" xlink:label="loc_PCSAPlacementAgentMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAPlacementAgentMember_150" xlink:type="arc" order="153" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_StockIssuedDuringPeriodSharesExercised" xlink:label="loc_PCSAStockIssuedDuringPeriodSharesExercised_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAStockIssuedDuringPeriodSharesExercised_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_PCSAGrossProceedsFromIssuanceOfCommonStock_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAGrossProceedsFromIssuanceOfCommonStock_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_TransactionCostsPercentage" xlink:label="loc_PCSATransactionCostsPercentage_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSATransactionCostsPercentage_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ReimbursementFees" xlink:label="loc_PCSAReimbursementFees_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAReimbursementFees_190" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="999046 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="999047 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:title="999048 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:title="999049 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FacilityLeaseMember" xlink:label="loc_PCSAFacilityLeaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_PCSAFacilityLeaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:label="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="999050 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:title="999051 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:title="999052 - Disclosure - Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails" xlink:title="999053 - Disclosure - Schedule of License Agreements (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ElionOncologyIncMember" xlink:label="loc_PCSAElionOncologyIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAElionOncologyIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OcuphirePharmaIncMember" xlink:label="loc_PCSAOcuphirePharmaIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAOcuphirePharmaIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AposenseLtdMember" xlink:label="loc_PCSAAposenseLtdMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAAposenseLtdMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_YuhanCorporationMember" xlink:label="loc_PCSAYuhanCorporationMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAYuhanCorporationMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_CoNCERTPharmaceuticalsIncMember" xlink:label="loc_PCSACoNCERTPharmaceuticalsIncMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSACoNCERTPharmaceuticalsIncMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LicenseAgreementsDate" xlink:label="loc_PCSALicenseAgreementsDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSALicenseAgreementsDate_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LicenseAgreementsAmendmentDate" xlink:label="loc_PCSALicenseAgreementsAmendmentDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSALicenseAgreementsAmendmentDate_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative" xlink:title="999054 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FederalMember" xlink:label="loc_PCSAFederalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_PCSAFederalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_NetOperatingLossCarryforwardExpiryDate" xlink:label="loc_PCSANetOperatingLossCarryforwardExpiryDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_PCSANetOperatingLossCarryforwardExpiryDate_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_NetOperatingLossCarryforwardTerm" xlink:label="loc_PCSANetOperatingLossCarryforwardTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_PCSANetOperatingLossCarryforwardTerm_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization" xlink:label="loc_PCSADeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_PCSADeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999055 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999056 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999057 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_CorLystLLCMember" xlink:label="loc_PCSACorLystLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_PCSACorLystLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:label="loc_PCSAProceedsFromRentAndOtherCostsReimbursements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_PCSAProceedsFromRentAndOtherCostsReimbursements_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" xlink:title="999058 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:label="loc_us-gaapReportableSegmentAggregationBeforeOtherOperatingSegmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapReportableSegmentAggregationBeforeOtherOperatingSegmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_EmployeesMember" xlink:label="loc_PCSAEmployeesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAEmployeesMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PreclinicalClinicalTrialAndOtherCosts" xlink:label="loc_PCSAPreclinicalClinicalTrialAndOtherCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_PCSAPreclinicalClinicalTrialAndOtherCosts_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AdministrativeAndFacilitiesExpense" xlink:label="loc_PCSAAdministrativeAndFacilitiesExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_PCSAAdministrativeAndFacilitiesExpense_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInvestmentIncomeInterest_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" xlink:title="999059 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_CorLystLLCMember" xlink:label="loc_PCSACorLystLLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSACorLystLLCMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999060 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_CROsMember" xlink:label="loc_PCSACROsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSACROsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPurchaseObligation_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" xlink:title="999061 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesAWarrantMember" xlink:label="loc_PCSASeriesAWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesAWarrantMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesBWarrantMember" xlink:label="loc_PCSASeriesBWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesBWarrantMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesAAndBMember" xlink:label="loc_PCSASeriesAAndBMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesAAndBMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" xlink:label="loc_PCSAChiefExecutiveOfficerAndCertainBoardMembersMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAChiefExecutiveOfficerAndCertainBoardMembersMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_PCSAPreFundedWarrantMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OutstandingSharesPercentage" xlink:label="loc_PCSAOutstandingSharesPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_PCSAOutstandingSharesPercentage_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_140" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" order="1000" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1001" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OriginalMember" xlink:label="loc_PCSAOriginalMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAOriginalMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ServiceBasedRestrictedStockUnitsMember" xlink:label="loc_PCSAServiceBasedRestrictedStockUnitsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FirstPerformanceBasedRSUMember" xlink:label="loc_PCSAFirstPerformanceBasedRSUMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAFirstPerformanceBasedRSUMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SecondPerformanceBasedRSUMember" xlink:label="loc_PCSASecondPerformanceBasedRSUMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASecondPerformanceBasedRSUMember" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_RestrictedStockAwardMember" xlink:label="loc_PCSARestrictedStockAwardMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSARestrictedStockAwardMember" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" order="50" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>37
<FILENAME>pcsa-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PurchaseAgreementMember" xlink:label="PCSA_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PurchaseAgreementMember" xlink:to="PCSA_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PreFundedWarrantMember" xlink:label="PCSA_PreFundedWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PreFundedWarrantMember" xlink:to="PCSA_PreFundedWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PreFundedWarrantMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesAWarrantsMember" xlink:label="PCSA_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesAWarrantsMember" xlink:to="PCSA_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesBWarrantsMember" xlink:label="PCSA_SeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesBWarrantsMember" xlink:to="PCSA_SeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="PCSA_TwoThousandAndNineteenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandAndNineteenPlanMember" xlink:to="PCSA_TwoThousandAndNineteenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_TwoThousandAndNineteenPlanMember_lbl" xml:lang="en-US">2019 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OriginalMember" xlink:label="PCSA_OriginalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OriginalMember" xlink:to="PCSA_OriginalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OriginalMember_lbl" xml:lang="en-US">Original [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_EmployeesMember" xlink:label="PCSA_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EmployeesMember" xlink:to="PCSA_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ServiceBasedRestrictedStockUnitsMember" xlink:label="PCSA_ServiceBasedRestrictedStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ServiceBasedRestrictedStockUnitsMember" xlink:to="PCSA_ServiceBasedRestrictedStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ServiceBasedRestrictedStockUnitsMember_lbl" xml:lang="en-US">Service Based RSUs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" xlink:label="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" xlink:to="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember_lbl" xml:lang="en-US">January 1, 2025 Vesting [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ThreeYearVestingMember" xlink:label="PCSA_ThreeYearVestingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ThreeYearVestingMember" xlink:to="PCSA_ThreeYearVestingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ThreeYearVestingMember_lbl" xml:lang="en-US">3-Year Vesting [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FirstPerformanceBasedRSUMember" xlink:label="PCSA_FirstPerformanceBasedRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FirstPerformanceBasedRSUMember" xlink:to="PCSA_FirstPerformanceBasedRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_FirstPerformanceBasedRSUMember_lbl" xml:lang="en-US">First Performance Based RSUs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SecondPerformanceBasedRSUMember" xlink:label="PCSA_SecondPerformanceBasedRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SecondPerformanceBasedRSUMember" xlink:to="PCSA_SecondPerformanceBasedRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SecondPerformanceBasedRSUMember_lbl" xml:lang="en-US">Second Performance Based RSUs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_NextGenerationCapecitabineCAPMember" xlink:label="PCSA_NextGenerationCapecitabineCAPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NextGenerationCapecitabineCAPMember" xlink:to="PCSA_NextGenerationCapecitabineCAPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_NextGenerationCapecitabineCAPMember_lbl" xml:lang="en-US">Next Generation Capecitabine - Cap [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_JulySixteenTwoThousandTwentyFiveVestingMember" xlink:label="PCSA_JulySixteenTwoThousandTwentyFiveVestingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_JulySixteenTwoThousandTwentyFiveVestingMember" xlink:to="PCSA_JulySixteenTwoThousandTwentyFiveVestingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_JulySixteenTwoThousandTwentyFiveVestingMember_lbl" xml:lang="en-US">July 16, 2025 Vesting [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OfferingMember" xlink:label="PCSA_OfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OfferingMember" xlink:to="PCSA_OfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OfferingMember_lbl" xml:lang="en-US">Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ConsultingAgreementMember" xlink:label="PCSA_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultingAgreementMember" xlink:to="PCSA_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ConsultantMember" xlink:label="PCSA_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultantMember" xlink:to="PCSA_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SpartanCapitalSecuritesLLCMember" xlink:label="PCSA_SpartanCapitalSecuritesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SpartanCapitalSecuritesLLCMember" xlink:to="PCSA_SpartanCapitalSecuritesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SpartanCapitalSecuritesLLCMember_lbl" xml:lang="en-US">Spartan Capital Securites LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_RestrictedStockAwardMember" xlink:label="PCSA_RestrictedStockAwardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_RestrictedStockAwardMember" xlink:to="PCSA_RestrictedStockAwardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_RestrictedStockAwardMember_lbl" xml:lang="en-US">Restricted Award [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ATMOfferingMember" xlink:label="PCSA_ATMOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ATMOfferingMember" xlink:to="PCSA_ATMOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ATMOfferingMember_lbl" xml:lang="en-US">ATM Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PlacementAgentMember" xlink:label="PCSA_PlacementAgentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PlacementAgentMember" xlink:to="PCSA_PlacementAgentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PlacementAgentMember_lbl" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SalesAgreementMember" xlink:label="PCSA_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SalesAgreementMember" xlink:to="PCSA_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="PCSA_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LincolnParkCapitalFundLLCMember" xlink:to="PCSA_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SecuritiesPurchaseAgreementMember" xlink:label="PCSA_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SecuritiesPurchaseAgreementMember" xlink:to="PCSA_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_RegisteredDirectOfferingMember" xlink:label="PCSA_RegisteredDirectOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_RegisteredDirectOfferingMember" xlink:to="PCSA_RegisteredDirectOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_RegisteredDirectOfferingMember_lbl" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AccreditedInvestorMember" xlink:label="PCSA_AccreditedInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AccreditedInvestorMember" xlink:to="PCSA_AccreditedInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AccreditedInvestorMember_lbl" xml:lang="en-US">Accredited Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FacilityLeaseMember" xlink:label="PCSA_FacilityLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FacilityLeaseMember" xlink:to="PCSA_FacilityLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_FacilityLeaseMember_lbl" xml:lang="en-US">Facility Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ElionOncologyIncMember" xlink:label="PCSA_ElionOncologyIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ElionOncologyIncMember" xlink:to="PCSA_ElionOncologyIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ElionOncologyIncMember_lbl" xml:lang="en-US">Elion Oncology Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OcuphirePharmaIncMember" xlink:label="PCSA_OcuphirePharmaIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OcuphirePharmaIncMember" xlink:to="PCSA_OcuphirePharmaIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OcuphirePharmaIncMember_lbl" xml:lang="en-US">Ocuphire Pharma Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AposenseLtdMember" xlink:label="PCSA_AposenseLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AposenseLtdMember" xlink:to="PCSA_AposenseLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AposenseLtdMember_lbl" xml:lang="en-US">Aposense, Ltd. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_YuhanCorporationMember" xlink:label="PCSA_YuhanCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_YuhanCorporationMember" xlink:to="PCSA_YuhanCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_YuhanCorporationMember_lbl" xml:lang="en-US">Yuhan Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_CoNCERTPharmaceuticalsIncMember" xlink:label="PCSA_CoNCERTPharmaceuticalsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CoNCERTPharmaceuticalsIncMember" xlink:to="PCSA_CoNCERTPharmaceuticalsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_CoNCERTPharmaceuticalsIncMember_lbl" xml:lang="en-US">CoNCERT Pharmaceuticals, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FederalMember" xlink:label="PCSA_FederalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FederalMember" xlink:to="PCSA_FederalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_FederalMember_lbl" xml:lang="en-US">Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_CorLystLLCMember" xlink:label="PCSA_CorLystLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CorLystLLCMember" xlink:to="PCSA_CorLystLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_CorLystLLCMember_lbl" xml:lang="en-US">CorLyst, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:label="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:to="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_lbl" xml:lang="en-US">Reportable Segment, Aggregation before Other Operating Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_CROsMember" xlink:label="PCSA_CROsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CROsMember" xlink:to="PCSA_CROsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_CROsMember_lbl" xml:lang="en-US">CROs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesAWarrantMember" xlink:label="PCSA_SeriesAWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesAWarrantMember" xlink:to="PCSA_SeriesAWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SeriesAWarrantMember_lbl" xml:lang="en-US">Series A Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesBWarrantMember" xlink:label="PCSA_SeriesBWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesBWarrantMember" xlink:to="PCSA_SeriesBWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SeriesBWarrantMember_lbl" xml:lang="en-US">Series B Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" xlink:label="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" xlink:to="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember_lbl" xml:lang="en-US">Chief Executive Officer and Certain Board Members [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesAAndBMember" xlink:label="PCSA_SeriesAAndBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesAAndBMember" xlink:to="PCSA_SeriesAAndBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SeriesAAndBMember_lbl" xml:lang="en-US">SeriesA And B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and Equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total Non-current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_lbl" xml:lang="en-US">Total Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="PCSA_OperatingAndFinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturities of lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DueToLicensor" xlink:label="PCSA_DueToLicensor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DueToLicensor" xlink:to="PCSA_DueToLicensor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DueToLicensor_lbl" xml:lang="en-US">Due to licensor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, par value $0.0001, 1,000,000 shares authorized; no shares issued or outstanding at December 31, 2024 or December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.0001, 100,000,000 shares authorized; 3,707,628 issued and 3,702,628 outstanding at December 31, 2024 and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock, 5,000 shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net Operating Loss Before Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss Per Common Share - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss Per Common Share - Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued in connection with capital raises, net of transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued in connection with capital raises, net of transaction costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrant granted in connection with a consulting agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:label="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:to="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_lbl" xml:lang="en-US">Settlement of stock award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Other, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Shares issued in connection with license agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Shares issued in connection with license agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Shares withheld to pay income taxes on stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Shares withheld to pay income taxes on stock-based compensation, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinanceLeaseExpense" xlink:label="PCSA_OperatingAndFinanceLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseExpense" xlink:to="PCSA_OperatingAndFinanceLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OperatingAndFinanceLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense for right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Warrants issued for consulting services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_IncreaseDecreaseInDueFromToRelatedParties" xlink:label="PCSA_IncreaseDecreaseInDueFromToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_IncreaseDecreaseInDueFromToRelatedParties" xlink:to="PCSA_IncreaseDecreaseInDueFromToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_IncreaseDecreaseInDueFromToRelatedParties_lbl" xml:lang="en-US">Due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Shares withheld to pay taxes on stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PaymentsForSettlementOfStockAwards" xlink:label="PCSA_PaymentsForSettlementOfStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PaymentsForSettlementOfStockAwards" xlink:to="PCSA_PaymentsForSettlementOfStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_PaymentsForSettlementOfStockAwards_lbl" xml:lang="en-US">Settlement of stock award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payment of finance lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Decrease in Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and Cash Equivalents - Beginning of Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and Cash Equivalents - End of Year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-Cash Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:label="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:to="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_lbl" xml:lang="en-US">Issuance of 5,000 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Right-of-use asset obtained in exchange for financing lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FinancingLeaseLiability" xlink:label="PCSA_FinancingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FinancingLeaseLiability" xlink:to="PCSA_FinancingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_FinancingLeaseLiability_lbl" xml:lang="en-US">Financing lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_NonCashLeaseLiabilityNet" xlink:label="PCSA_NonCashLeaseLiabilityNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NonCashLeaseLiabilityNet" xlink:to="PCSA_NonCashLeaseLiabilityNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_NonCashLeaseLiabilityNet_lbl" xml:lang="en-US">Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xml:lang="en-US">Shares issued in connection with license agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="PCSA_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureLeasesAbstract" xlink:to="PCSA_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:label="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:to="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DisclosureLicenseAgreementsAbstract" xlink:label="PCSA_DisclosureLicenseAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureLicenseAgreementsAbstract" xlink:to="PCSA_DisclosureLicenseAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DisclosureLicenseAgreementsAbstract_lbl" xml:lang="en-US">License Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LicenseAgreementDisclosureTextBlock" xlink:label="PCSA_LicenseAgreementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LicenseAgreementDisclosureTextBlock" xlink:to="PCSA_LicenseAgreementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_LicenseAgreementDisclosureTextBlock_lbl" xml:lang="en-US">License Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DisclosureLitigationAbstract" xlink:label="PCSA_DisclosureLitigationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureLitigationAbstract" xlink:to="PCSA_DisclosureLitigationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DisclosureLitigationAbstract_lbl" xml:lang="en-US">Litigation</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LitigationDisclosureTextBlock" xlink:label="PCSA_LitigationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LitigationDisclosureTextBlock" xlink:to="PCSA_LitigationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_LitigationDisclosureTextBlock_lbl" xml:lang="en-US">Litigation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PrepaidExpensesPolicyTextBlock" xlink:label="PCSA_PrepaidExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PrepaidExpensesPolicyTextBlock" xlink:to="PCSA_PrepaidExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PrepaidExpensesPolicyTextBlock_lbl" xml:lang="en-US">Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets and Intangibles Other Than Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements and Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_RecentAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="PCSA_RecentAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_RecentAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="PCSA_RecentAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_RecentAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ScheduleOfWarrantValuationAssumptionTableTextBlock" xlink:label="PCSA_ScheduleOfWarrantValuationAssumptionTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfWarrantValuationAssumptionTableTextBlock" xlink:to="PCSA_ScheduleOfWarrantValuationAssumptionTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ScheduleOfWarrantValuationAssumptionTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Valuation Assumption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Loss Per Share Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:to="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Annual Lease Liabilities for all Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Annual Lease Liabilities for all Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LicenseAgreementsTableTextBlock" xlink:label="PCSA_LicenseAgreementsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LicenseAgreementsTableTextBlock" xlink:to="PCSA_LicenseAgreementsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LicenseAgreementsTableTextBlock_lbl" xml:lang="en-US">Schedule of License Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OrganizationTable" xlink:label="PCSA_OrganizationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OrganizationTable" xlink:to="PCSA_OrganizationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OrganizationTable_lbl" xml:lang="en-US">OrganizationTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OrganizationLineItems" xlink:label="PCSA_OrganizationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OrganizationLineItems" xlink:to="PCSA_OrganizationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OrganizationLineItems_lbl" xml:lang="en-US">OrganizationLineItems [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_5_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ClassOfWarrantOrRightExercised" xlink:label="PCSA_ClassOfWarrantOrRightExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ClassOfWarrantOrRightExercised" xlink:to="PCSA_ClassOfWarrantOrRightExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AccountingPoliciesLineItems" xlink:label="PCSA_AccountingPoliciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AccountingPoliciesLineItems" xlink:to="PCSA_AccountingPoliciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AccountingPoliciesLineItems_lbl" xml:lang="en-US">AccountingPoliciesLineItems [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AccountingPoliciesLineItemsAbstract" xlink:label="PCSA_AccountingPoliciesLineItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AccountingPoliciesLineItemsAbstract" xlink:to="PCSA_AccountingPoliciesLineItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AccountingPoliciesLineItemsAbstract_lbl" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_2_lbl" xml:lang="en-US">Prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Options, forfeited or expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited or expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual term, outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US">Number of shares, cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares, vested and issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, vested and issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of shares outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_lbl" xml:lang="en-US">Number of shares, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl" xml:lang="en-US">Number of shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2_lbl" xml:lang="en-US">Number of shares, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_lbl" xml:lang="en-US">Number of shares, vested and unissued</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, vested and unissued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Warrants, expired or cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_lbl" xml:lang="en-US">Weighted average exercise price, expired or cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable_lbl" xml:lang="en-US">Warrants, Not exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable_lbl" xml:lang="en-US">Weighted average exercise price, not exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xml:lang="en-US">Warrants, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Warrants, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term, exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum equity available for issuance under the plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for future grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value of outstanding options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock option exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_MarketCapitalization" xlink:label="PCSA_MarketCapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MarketCapitalization" xlink:to="PCSA_MarketCapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_MarketCapitalization_lbl" xml:lang="en-US">Market capitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PerformanceVestingCriteriaValue" xlink:label="PCSA_PerformanceVestingCriteriaValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PerformanceVestingCriteriaValue" xlink:to="PCSA_PerformanceVestingCriteriaValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PerformanceVestingCriteriaValue_lbl" xml:lang="en-US">Performance vesting criteria</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period for recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_UnrecognizedShareBasedCompensationExpense" xlink:to="PCSA_UnrecognizedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense_lbl" xml:lang="en-US">Unrecognized share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrants, expired unexercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Warrants repurchased, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Payment for warrants repurchased</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrant expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_2_lbl" xml:lang="en-US">Warrants, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares, sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_StockIssuedDuringPeriodSharesExercised" xlink:label="PCSA_StockIssuedDuringPeriodSharesExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedDuringPeriodSharesExercised" xlink:to="PCSA_StockIssuedDuringPeriodSharesExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_StockIssuedDuringPeriodSharesExercised_lbl" xml:lang="en-US">Warrants, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:label="PCSA_GrossProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:to="PCSA_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_TransactionCostsPercentage" xlink:label="PCSA_TransactionCostsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TransactionCostsPercentage" xlink:to="PCSA_TransactionCostsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_TransactionCostsPercentage_lbl" xml:lang="en-US">Cash fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ReimbursementFees" xlink:label="PCSA_ReimbursementFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ReimbursementFees" xlink:to="PCSA_ReimbursementFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ReimbursementFees_lbl" xml:lang="en-US">Reimbursement fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss available to common shareholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average number of common shares-basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average number of common shares-diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Basic net loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Diluted net loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xml:lang="en-US">Stock options, unvested RSAs, unvested RSUs and purchase warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_lbl" xml:lang="en-US">Shares unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Remaining lease term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Remaining lease term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:label="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:to="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_lbl" xml:lang="en-US">Weighted average discount rate for our facility and equipment leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureLeasesAbstract" xlink:to="PCSA_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Annual Lease Liabilities For All Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current maturities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureLeasesAbstract" xlink:to="PCSA_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="PCSA_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Annual Lease Liabilities For All Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current maturities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:to="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_2_lbl" xml:lang="en-US">Operating and financing lease borrowing rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LicenseAgreementsDate" xlink:label="PCSA_LicenseAgreementsDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LicenseAgreementsDate" xlink:to="PCSA_LicenseAgreementsDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LicenseAgreementsDate_lbl" xml:lang="en-US">Agreement Date</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LicenseAgreementsAmendmentDate" xlink:label="PCSA_LicenseAgreementsAmendmentDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LicenseAgreementsAmendmentDate" xlink:to="PCSA_LicenseAgreementsAmendmentDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LicenseAgreementsAmendmentDate_lbl" xml:lang="en-US">Amendment Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Deferred tax assets, capital loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_NetOperatingLossCarryforwardExpiryDate" xlink:label="PCSA_NetOperatingLossCarryforwardExpiryDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NetOperatingLossCarryforwardExpiryDate" xlink:to="PCSA_NetOperatingLossCarryforwardExpiryDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_NetOperatingLossCarryforwardExpiryDate_lbl" xml:lang="en-US">Net operating loss carryforward, expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_NetOperatingLossCarryforwardTerm" xlink:label="PCSA_NetOperatingLossCarryforwardTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NetOperatingLossCarryforwardTerm" xlink:to="PCSA_NetOperatingLossCarryforwardTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_NetOperatingLossCarryforwardTerm_lbl" xml:lang="en-US">Net operating loss carryforward term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US">Income tax examination description</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization" xlink:label="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization" xlink:to="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization_lbl" xml:lang="en-US">Capitalized research and development net of amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Penalties and interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" xlink:label="PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" xlink:to="PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Federal orphan drug tax credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred tax asset valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Net operating loss carry forward &#8211; Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Net operating loss carry forward &#8211; State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation and other</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" xlink:label="PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" xlink:to="PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected_lbl" xml:lang="en-US">Purchased in-process R&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetsFederalOrphanDrugCredits" xlink:label="PCSA_DeferredTaxAssetsFederalOrphanDrugCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DeferredTaxAssetsFederalOrphanDrugCredits" xlink:to="PCSA_DeferredTaxAssetsFederalOrphanDrugCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DeferredTaxAssetsFederalOrphanDrugCredits_lbl" xml:lang="en-US">Federal orphan drug credits</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Capitalized research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetsStartupExpenditures" xlink:label="PCSA_DeferredTaxAssetsStartupExpenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DeferredTaxAssetsStartupExpenditures" xlink:to="PCSA_DeferredTaxAssetsStartupExpenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DeferredTaxAssetsStartupExpenditures_lbl" xml:lang="en-US">Start-up expenditures and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total non-current deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangible asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total non-current deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax asset (liability)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:label="PCSA_ProceedsFromRentAndOtherCostsReimbursements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:to="PCSA_ProceedsFromRentAndOtherCostsReimbursements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ProceedsFromRentAndOtherCostsReimbursements_lbl" xml:lang="en-US">Rent and other costs reimbursements received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PreclinicalClinicalTrialAndOtherCosts" xlink:label="PCSA_PreclinicalClinicalTrialAndOtherCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PreclinicalClinicalTrialAndOtherCosts" xlink:to="PCSA_PreclinicalClinicalTrialAndOtherCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PreclinicalClinicalTrialAndOtherCosts_lbl" xml:lang="en-US">Preclinical, clinical trial and other costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and administrative expense</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AdministrativeAndFacilitiesExpense" xlink:label="PCSA_AdministrativeAndFacilitiesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AdministrativeAndFacilitiesExpense" xlink:to="PCSA_AdministrativeAndFacilitiesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AdministrativeAndFacilitiesExpense_lbl" xml:lang="en-US">Administrative and facilities expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInterest_2_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">General and administrative personnel costs include employee stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US">Purchase obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants to purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrants, exercisable term</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OutstandingSharesPercentage" xlink:label="PCSA_OutstandingSharesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OutstandingSharesPercentage" xlink:to="PCSA_OutstandingSharesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OutstandingSharesPercentage_lbl" xml:lang="en-US">Outstanding shares percentage, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandAndNineteenPlanMember" xlink:to="PCSA_TwoThousandAndNineteenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_TwoThousandAndNineteenPlanMember_doc" xml:lang="en-US">2019 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OriginalMember" xlink:to="PCSA_OriginalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OriginalMember_doc" xml:lang="en-US">Original [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:label="PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:to="PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_doc" xml:lang="en-US">Schedule Of Share Based Compensation Restricted Stock Award Activity [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="PCSA_OperatingAndFinanceLeaseLiabilityCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityCurrent_doc" xml:lang="en-US">Operating and finance lease liability current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DueToLicensor" xlink:to="PCSA_DueToLicensor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_DueToLicensor_doc" xml:lang="en-US">Due to licensor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EmployeesMember" xlink:to="PCSA_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_EmployeesMember_doc" xml:lang="en-US">Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent_doc" xml:lang="en-US">Operating and finance lease liability noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ServiceBasedRestrictedStockUnitsMember" xlink:to="PCSA_ServiceBasedRestrictedStockUnitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ServiceBasedRestrictedStockUnitsMember_doc" xml:lang="en-US">Service Based RSUs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" xlink:to="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember_doc" xml:lang="en-US">January 1, 2025 Vesting [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ThreeYearVestingMember" xlink:to="PCSA_ThreeYearVestingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ThreeYearVestingMember_doc" xml:lang="en-US">3-Year Vesting [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FirstPerformanceBasedRSUMember" xlink:to="PCSA_FirstPerformanceBasedRSUMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_FirstPerformanceBasedRSUMember_doc" xml:lang="en-US">First Performance Based RSUs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SecondPerformanceBasedRSUMember" xlink:to="PCSA_SecondPerformanceBasedRSUMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SecondPerformanceBasedRSUMember_doc" xml:lang="en-US">Second Performance Based RSUs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NextGenerationCapecitabineCAPMember" xlink:to="PCSA_NextGenerationCapecitabineCAPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_NextGenerationCapecitabineCAPMember_doc" xml:lang="en-US">Next Generation Capecitabine - Cap [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_JulySixteenTwoThousandTwentyFiveVestingMember" xlink:to="PCSA_JulySixteenTwoThousandTwentyFiveVestingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_JulySixteenTwoThousandTwentyFiveVestingMember_doc" xml:lang="en-US">July 16, 2025 Vesting [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MarketCapitalization" xlink:to="PCSA_MarketCapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_MarketCapitalization_doc" xml:lang="en-US">Market capitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PerformanceVestingCriteriaValue" xlink:to="PCSA_PerformanceVestingCriteriaValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PerformanceVestingCriteriaValue_doc" xml:lang="en-US">Performance vesting criteria value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_UnrecognizedShareBasedCompensationExpense" xlink:to="PCSA_UnrecognizedShareBasedCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense_doc" xml:lang="en-US">Unrecognized share based compensation expense.</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock" xlink:label="PCSA_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock" xlink:to="PCSA_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock_doc" xml:lang="en-US">Schedule Of Share Based Compensation Warrants Activity [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Number of warrants outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments outstanding and exercisable number granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments outstanding and exercisable number expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Number of warrants outstanding weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OfferingMember" xlink:to="PCSA_OfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OfferingMember_doc" xml:lang="en-US">Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultingAgreementMember" xlink:to="PCSA_ConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ConsultingAgreementMember_doc" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PaymentsForSettlementOfStockAwards" xlink:to="PCSA_PaymentsForSettlementOfStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PaymentsForSettlementOfStockAwards_doc" xml:lang="en-US">Payments for settlement of stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SpartanCapitalSecuritesLLCMember" xlink:to="PCSA_SpartanCapitalSecuritesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SpartanCapitalSecuritesLLCMember_doc" xml:lang="en-US">Spartan Capital Securites LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:to="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_doc" xml:lang="en-US">Adjustments to additional paid in capital settlement of stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PurchaseAgreementMember" xlink:to="PCSA_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PreFundedWarrantMember" xlink:to="PCSA_PreFundedWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PreFundedWarrantMember_doc" xml:lang="en-US">Pre Funded Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedDuringPeriodSharesExercised" xlink:to="PCSA_StockIssuedDuringPeriodSharesExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_StockIssuedDuringPeriodSharesExercised_doc" xml:lang="en-US">Stock issued during period shares exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:to="PCSA_GrossProceedsFromIssuanceOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_GrossProceedsFromIssuanceOfCommonStock_doc" xml:lang="en-US">Gross proceeds from issuance of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PlacementAgentMember" xlink:to="PCSA_PlacementAgentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PlacementAgentMember_doc" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LincolnParkCapitalFundLLCMember" xlink:to="PCSA_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Lincoln Park Capital Fund LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SalesAgreementMember" xlink:to="PCSA_SalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SalesAgreementMember_doc" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SecuritiesPurchaseAgreementMember" xlink:to="PCSA_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_RegisteredDirectOfferingMember" xlink:to="PCSA_RegisteredDirectOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_RegisteredDirectOfferingMember_doc" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AccreditedInvestorMember" xlink:to="PCSA_AccreditedInvestorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AccreditedInvestorMember_doc" xml:lang="en-US">Accredited Investor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TransactionCostsPercentage" xlink:to="PCSA_TransactionCostsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_TransactionCostsPercentage_doc" xml:lang="en-US">Transaction costs percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ReimbursementFees" xlink:to="PCSA_ReimbursementFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ReimbursementFees_doc" xml:lang="en-US">Reimbursement fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseExpense" xlink:to="PCSA_OperatingAndFinanceLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OperatingAndFinanceLeaseExpense_doc" xml:lang="en-US">Operating and finance lease expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_IncreaseDecreaseInDueFromToRelatedParties" xlink:to="PCSA_IncreaseDecreaseInDueFromToRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_IncreaseDecreaseInDueFromToRelatedParties_doc" xml:lang="en-US">Due (from) to related parties.</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingLeaseLiabilities" xlink:label="PCSA_OperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingLeaseLiabilities" xlink:to="PCSA_OperatingLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OperatingLeaseLiabilities_doc" xml:lang="en-US">Operating lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NonCashLeaseLiabilityNet" xlink:to="PCSA_NonCashLeaseLiabilityNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_NonCashLeaseLiabilityNet_doc" xml:lang="en-US">Non cash lease liability net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:to="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_doc" xml:lang="en-US">Stock issued in connection with licensing agreement which had previously been recorded as due to licensor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FacilityLeaseMember" xlink:to="PCSA_FacilityLeaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_FacilityLeaseMember_doc" xml:lang="en-US">Facility Lease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesAWarrantsMember" xlink:to="PCSA_SeriesAWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SeriesAWarrantsMember_doc" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesBWarrantsMember" xlink:to="PCSA_SeriesBWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SeriesBWarrantsMember_doc" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LicenseAgreementDisclosureTextBlock" xlink:to="PCSA_LicenseAgreementDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LicenseAgreementDisclosureTextBlock_doc" xml:lang="en-US">License Agreement Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OcuphirePharmaIncMember" xlink:to="PCSA_OcuphirePharmaIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OcuphirePharmaIncMember_doc" xml:lang="en-US">Ocuphire Pharma Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AposenseLtdMember" xlink:to="PCSA_AposenseLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AposenseLtdMember_doc" xml:lang="en-US">Aposense, Ltd. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_YuhanCorporationMember" xlink:to="PCSA_YuhanCorporationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_YuhanCorporationMember_doc" xml:lang="en-US">Yuhan Corporation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CoNCERTPharmaceuticalsIncMember" xlink:to="PCSA_CoNCERTPharmaceuticalsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_CoNCERTPharmaceuticalsIncMember_doc" xml:lang="en-US">CoNCERT Pharmaceuticals, Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NetOperatingLossCarryforwardExpiryDate" xlink:to="PCSA_NetOperatingLossCarryforwardExpiryDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_NetOperatingLossCarryforwardExpiryDate_doc" xml:lang="en-US">Net operating loss carryforward, expiration date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FederalMember" xlink:to="PCSA_FederalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_FederalMember_doc" xml:lang="en-US">Federal [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NetOperatingLossCarryforwardTerm" xlink:to="PCSA_NetOperatingLossCarryforwardTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_NetOperatingLossCarryforwardTerm_doc" xml:lang="en-US">Net operating loss carryforward term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AccountingPoliciesLineItemsAbstract" xlink:to="PCSA_AccountingPoliciesLineItemsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AccountingPoliciesLineItemsAbstract_doc" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" xlink:to="PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential_doc" xml:lang="en-US">Effective income tax rate reconciliation, income tax rate permanent differential.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" xlink:to="PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected_doc" xml:lang="en-US">Deferred tax asset acquired inprocess research and development tax effected.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DeferredTaxAssetsFederalOrphanDrugCredits" xlink:to="PCSA_DeferredTaxAssetsFederalOrphanDrugCredits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_DeferredTaxAssetsFederalOrphanDrugCredits_doc" xml:lang="en-US">Deferred tax assets federal orphan drug credits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_doc" xml:lang="en-US">Deferred tax assets capitalized research and development costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DeferredTaxAssetsStartupExpenditures" xlink:to="PCSA_DeferredTaxAssetsStartupExpenditures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_DeferredTaxAssetsStartupExpenditures_doc" xml:lang="en-US">Deferred tax assets startup expenditures.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization" xlink:to="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization_doc" xml:lang="en-US">Deferred tax assets capitalized research and development net of amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:to="PCSA_ProceedsFromRentAndOtherCostsReimbursements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ProceedsFromRentAndOtherCostsReimbursements_doc" xml:lang="en-US">Rent and other costs reimbursements received.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CorLystLLCMember" xlink:to="PCSA_CorLystLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_CorLystLLCMember_doc" xml:lang="en-US">CorLyst, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CROsMember" xlink:to="PCSA_CROsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_CROsMember_doc" xml:lang="en-US">CROs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesAWarrantMember" xlink:to="PCSA_SeriesAWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SeriesAWarrantMember_doc" xml:lang="en-US">Series A Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesBWarrantMember" xlink:to="PCSA_SeriesBWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SeriesBWarrantMember_doc" xml:lang="en-US">Series B Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesAAndBMember" xlink:to="PCSA_SeriesAAndBMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SeriesAAndBMember_doc" xml:lang="en-US">SeriesA And B [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OutstandingSharesPercentage" xlink:to="PCSA_OutstandingSharesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OutstandingSharesPercentage_doc" xml:lang="en-US">Outstanding shares percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:to="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_doc" xml:lang="en-US">Lessee Operating And Financing Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ClassOfWarrantOrRightExercised" xlink:to="PCSA_ClassOfWarrantOrRightExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ClassOfWarrantOrRightExercised_doc" xml:lang="en-US">Class of warrant or right exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options issued in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ATMOfferingMember" xlink:to="PCSA_ATMOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ATMOfferingMember_doc" xml:lang="en-US">ATM Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options issued in period weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultantMember" xlink:to="PCSA_ConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ConsultantMember_doc" xml:lang="en-US">Consultant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PrepaidExpensesPolicyTextBlock" xlink:to="PCSA_PrepaidExpensesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PrepaidExpensesPolicyTextBlock_doc" xml:lang="en-US">Prepaid Expenses [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LicenseAgreementsTableTextBlock" xlink:to="PCSA_LicenseAgreementsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LicenseAgreementsTableTextBlock_doc" xml:lang="en-US">License Agreements [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LicenseAgreementsDate" xlink:to="PCSA_LicenseAgreementsDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LicenseAgreementsDate_doc" xml:lang="en-US">License agreements date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ElionOncologyIncMember" xlink:to="PCSA_ElionOncologyIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ElionOncologyIncMember_doc" xml:lang="en-US">Elion Oncology Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LicenseAgreementsAmendmentDate" xlink:to="PCSA_LicenseAgreementsAmendmentDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LicenseAgreementsAmendmentDate_doc" xml:lang="en-US">License agreements amendment date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LitigationDisclosureTextBlock" xlink:to="PCSA_LitigationDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LitigationDisclosureTextBlock_doc" xml:lang="en-US">Litigation [Disclosure Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_RestrictedStockAwardMember" xlink:to="PCSA_RestrictedStockAwardMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_RestrictedStockAwardMember_doc" xml:lang="en-US">Restricted Stock Award [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:to="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_doc" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operating and Financing Leases[Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than option vested and unissued outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments not exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments not exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" xlink:to="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember_doc" xml:lang="en-US">Chief Executive Officer and Certain Board Members [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FinancingLeaseLiability" xlink:to="PCSA_FinancingLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_FinancingLeaseLiability_doc" xml:lang="en-US">Financing lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_IncreaseDecreaseInDueFromToRelatedParties" xlink:to="PCSA_IncreaseDecreaseInDueFromToRelatedParties_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_IncreaseDecreaseInDueFromToRelatedParties_3_lbl" xml:lang="en-US">IncreaseDecreaseInDueFromToRelatedParties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PaymentsForSettlementOfStockAwards" xlink:to="PCSA_PaymentsForSettlementOfStockAwards_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PaymentsForSettlementOfStockAwards_3_lbl" xml:lang="en-US">Payments for settlement of stock awards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_2_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_2_lbl" xml:lang="en-US">Income Taxes Paid, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:to="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_3_lbl" xml:lang="en-US">LesseeOperatingAndFinancingLeasesTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LicenseAgreementDisclosureTextBlock" xlink:to="PCSA_LicenseAgreementDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LicenseAgreementDisclosureTextBlock_3_lbl" xml:lang="en-US">LicenseAgreementDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LitigationDisclosureTextBlock" xlink:to="PCSA_LitigationDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LitigationDisclosureTextBlock_3_lbl" xml:lang="en-US">Litigation [Disclosure Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_2_lbl" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_2_lbl" xml:lang="en-US">Finance Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>38
<FILENAME>pcsa-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Cover" xlink:href="pcsa-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheets" xlink:href="pcsa-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="pcsa-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:href="pcsa-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="pcsa-20241231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="pcsa-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:href="pcsa-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Organization" xlink:href="pcsa-20241231.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcsa-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:href="pcsa-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:href="pcsa-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:href="pcsa-20241231.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Leases" xlink:href="pcsa-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LicenseAgreements" xlink:href="pcsa-20241231.xsd#LicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IncomeTaxes" xlink:href="pcsa-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:href="pcsa-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Litigation" xlink:href="pcsa-20241231.xsd#Litigation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SegmentReporting" xlink:href="pcsa-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="pcsa-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ConcentrationOfCreditRisk" xlink:href="pcsa-20241231.xsd#ConcentrationOfCreditRisk" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SubsequentEvents" xlink:href="pcsa-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcsa-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:href="pcsa-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:href="pcsa-20241231.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LeasesTables" xlink:href="pcsa-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LicenseAgreementsTables" xlink:href="pcsa-20241231.xsd#LicenseAgreementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IncomeTaxesTables" xlink:href="pcsa-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SegmentReportingTables" xlink:href="pcsa-20241231.xsd#SegmentReportingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationDetailsNarrative" xlink:href="pcsa-20241231.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="pcsa-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfWarrantValuationAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="pcsa-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:href="pcsa-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:href="pcsa-20241231.xsd#NetLossPerShareOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:href="pcsa-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfLicenseAgreementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative" xlink:href="pcsa-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="pcsa-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" xlink:href="pcsa-20241231.xsd#ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" xlink:href="pcsa-20241231.xsd#ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="pcsa-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" xlink:href="pcsa-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DueToLicensor" xlink:label="loc_PCSADueToLicensor" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_PCSADueToLicensor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockCommonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:label="loc_PCSAAdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAAdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinanceLeaseExpense" xlink:label="loc_PCSAOperatingAndFinanceLeaseExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_PCSAOperatingAndFinanceLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_IncreaseDecreaseInDueFromToRelatedParties" xlink:label="loc_PCSAIncreaseDecreaseInDueFromToRelatedParties" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_PCSAIncreaseDecreaseInDueFromToRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PaymentsForSettlementOfStockAwards" xlink:label="loc_PCSAPaymentsForSettlementOfStockAwards" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_PCSAPaymentsForSettlementOfStockAwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:label="loc_PCSAStockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_PCSAStockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FinancingLeaseLiability" xlink:label="loc_PCSAFinancingLeaseLiability" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_PCSAFinancingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_NonCashLeaseLiabilityNet" xlink:label="loc_PCSANonCashLeaseLiabilityNet" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_PCSANonCashLeaseLiabilityNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Organization" xlink:title="999015 - Disclosure - Organization">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="999017 - Disclosure - Stock-based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="999018 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="999019 - Disclosure - Net Loss per Share of Common Stock">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Leases" xlink:title="999020 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:label="loc_PCSALesseeOperatingAndFinancingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_PCSALesseeOperatingAndFinancingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LicenseAgreements" xlink:title="999021 - Disclosure - License Agreements">
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DisclosureLicenseAgreementsAbstract" xlink:label="loc_PCSADisclosureLicenseAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LicenseAgreementDisclosureTextBlock" xlink:label="loc_PCSALicenseAgreementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLicenseAgreementsAbstract" xlink:to="loc_PCSALicenseAgreementDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IncomeTaxes" xlink:title="999022 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="999023 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Litigation" xlink:title="999024 - Disclosure - Litigation">
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DisclosureLitigationAbstract" xlink:label="loc_PCSADisclosureLitigationAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LitigationDisclosureTextBlock" xlink:label="loc_PCSALitigationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLitigationAbstract" xlink:to="loc_PCSALitigationDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SegmentReporting" xlink:title="999025 - Disclosure - Segment Reporting">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="999026 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ConcentrationOfCreditRisk" xlink:title="999027 - Disclosure - Concentration of Credit Risk">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEvents" xlink:title="999028 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999029 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PrepaidExpensesPolicyTextBlock" xlink:label="loc_PCSAPrepaidExpensesPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_PCSAPrepaidExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_RecentAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_PCSARecentAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_PCSARecentAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="999030 - Disclosure - Stock-based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_RestrictedStockAwardMember" xlink:label="loc_PCSARestrictedStockAwardMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSARestrictedStockAwardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ScheduleOfWarrantValuationAssumptionTableTextBlock" xlink:label="loc_PCSAScheduleOfWarrantValuationAssumptionTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAScheduleOfWarrantValuationAssumptionTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="999031 - Disclosure - Net Loss per Share of Common Stock (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesTables" xlink:title="999032 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:label="loc_PCSAScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_PCSAScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LicenseAgreementsTables" xlink:title="999033 - Disclosure - License Agreements (Tables)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DisclosureLicenseAgreementsAbstract" xlink:label="loc_PCSADisclosureLicenseAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LicenseAgreementsTableTextBlock" xlink:label="loc_PCSALicenseAgreementsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLicenseAgreementsAbstract" xlink:to="loc_PCSALicenseAgreementsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IncomeTaxesTables" xlink:title="999034 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SegmentReportingTables" xlink:title="999035 - Disclosure - Segment Reporting (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaapReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationDetailsNarrative" xlink:title="999036 - Disclosure - Organization (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OrganizationTable" xlink:label="loc_PCSAOrganizationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_PCSAOrganizationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OrganizationLineItems" xlink:label="loc_PCSAOrganizationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_PCSAOrganizationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPreFundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesAWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesBWarrantsMember" xlink:label="loc_PCSASeriesBWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ClassOfWarrantOrRightExercised" xlink:label="loc_PCSAClassOfWarrantOrRightExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_PCSAClassOfWarrantOrRightExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999037 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AccountingPoliciesLineItems" xlink:label="loc_PCSAAccountingPoliciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_PCSAAccountingPoliciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AccountingPoliciesLineItemsAbstract" xlink:label="loc_PCSAAccountingPoliciesLineItemsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAAccountingPoliciesLineItems" xlink:to="loc_PCSAAccountingPoliciesLineItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAAccountingPoliciesLineItemsAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAAccountingPoliciesLineItemsAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAAccountingPoliciesLineItemsAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAAccountingPoliciesLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999038 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999039 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:title="999040 - Disclosure - Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_RestrictedStockAwardMember" xlink:label="loc_PCSARestrictedStockAwardMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSARestrictedStockAwardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:title="999041 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="999042 - Disclosure - Schedule of Warrants Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails" xlink:title="999043 - Disclosure - Schedule of Warrant Valuation Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999044 - Disclosure - Stock-based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="loc_PCSATwoThousandAndNineteenPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PCSATwoThousandAndNineteenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OriginalMember" xlink:label="loc_PCSAOriginalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAOriginalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ServiceBasedRestrictedStockUnitsMember" xlink:label="loc_PCSAServiceBasedRestrictedStockUnitsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAServiceBasedRestrictedStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FirstPerformanceBasedRSUMember" xlink:label="loc_PCSAFirstPerformanceBasedRSUMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAFirstPerformanceBasedRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SecondPerformanceBasedRSUMember" xlink:label="loc_PCSASecondPerformanceBasedRSUMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASecondPerformanceBasedRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_EmployeesMember" xlink:label="loc_PCSAEmployeesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ConsultantMember" xlink:label="loc_PCSAConsultantMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" xlink:label="loc_PCSAJanuaryOneTwoThousandTwentyFiveVestingMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSAJanuaryOneTwoThousandTwentyFiveVestingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ThreeYearVestingMember" xlink:label="loc_PCSAThreeYearVestingMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSAThreeYearVestingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_JulySixteenTwoThousandTwentyFiveVestingMember" xlink:label="loc_PCSAJulySixteenTwoThousandTwentyFiveVestingMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSAJulySixteenTwoThousandTwentyFiveVestingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FirstPerformanceBasedRSUMember" xlink:label="loc_PCSAFirstPerformanceBasedRSUMember_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSAFirstPerformanceBasedRSUMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SecondPerformanceBasedRSUMember" xlink:label="loc_PCSASecondPerformanceBasedRSUMember_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSASecondPerformanceBasedRSUMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_NextGenerationCapecitabineCAPMember" xlink:label="loc_PCSANextGenerationCapecitabineCAPMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSANextGenerationCapecitabineCAPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OfferingMember" xlink:label="loc_PCSAOfferingMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SpartanCapitalSecuritesLLCMember" xlink:label="loc_PCSASpartanCapitalSecuritesLLCMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSASpartanCapitalSecuritesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_MarketCapitalization" xlink:label="loc_PCSAMarketCapitalization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAMarketCapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PerformanceVestingCriteriaValue" xlink:label="loc_PCSAPerformanceVestingCriteriaValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAPerformanceVestingCriteriaValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_PCSAUnrecognizedShareBasedCompensationExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAUnrecognizedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="999045 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_PCSAPreFundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SalesAgreementMember" xlink:label="loc_PCSASalesAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SecuritiesPurchaseAgreementMember" xlink:label="loc_PCSASecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ATMOfferingMember" xlink:label="loc_PCSAATMOfferingMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAATMOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PlacementAgentMember" xlink:label="loc_PCSAPlacementAgentMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAPlacementAgentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_RegisteredDirectOfferingMember" xlink:label="loc_PCSARegisteredDirectOfferingMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSARegisteredDirectOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="loc_PCSALincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSALincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AccreditedInvestorMember" xlink:label="loc_PCSAAccreditedInvestorMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAAccreditedInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PlacementAgentMember" xlink:label="loc_PCSAPlacementAgentMember_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAPlacementAgentMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_StockIssuedDuringPeriodSharesExercised" xlink:label="loc_PCSAStockIssuedDuringPeriodSharesExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAStockIssuedDuringPeriodSharesExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_PCSAGrossProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAGrossProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_TransactionCostsPercentage" xlink:label="loc_PCSATransactionCostsPercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSATransactionCostsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ReimbursementFees" xlink:label="loc_PCSAReimbursementFees" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAReimbursementFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="999046 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapEarningsPerShareBasicLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="999047 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:title="999048 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:title="999049 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FacilityLeaseMember" xlink:label="loc_PCSAFacilityLeaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_PCSAFacilityLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:label="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="999050 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:title="999051 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:title="999052 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:label="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails" xlink:title="999053 - Disclosure - Schedule of License Agreements (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DisclosureLicenseAgreementsAbstract" xlink:label="loc_PCSADisclosureLicenseAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLicenseAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ElionOncologyIncMember" xlink:label="loc_PCSAElionOncologyIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAElionOncologyIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OcuphirePharmaIncMember" xlink:label="loc_PCSAOcuphirePharmaIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAOcuphirePharmaIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AposenseLtdMember" xlink:label="loc_PCSAAposenseLtdMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAAposenseLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_YuhanCorporationMember" xlink:label="loc_PCSAYuhanCorporationMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAYuhanCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_CoNCERTPharmaceuticalsIncMember" xlink:label="loc_PCSACoNCERTPharmaceuticalsIncMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSACoNCERTPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LicenseAgreementsDate" xlink:label="loc_PCSALicenseAgreementsDate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSALicenseAgreementsDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_LicenseAgreementsAmendmentDate" xlink:label="loc_PCSALicenseAgreementsAmendmentDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSALicenseAgreementsAmendmentDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative" xlink:title="999054 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_FederalMember" xlink:label="loc_PCSAFederalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_PCSAFederalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_NetOperatingLossCarryforwardExpiryDate" xlink:label="loc_PCSANetOperatingLossCarryforwardExpiryDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_PCSANetOperatingLossCarryforwardExpiryDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_NetOperatingLossCarryforwardTerm" xlink:label="loc_PCSANetOperatingLossCarryforwardTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_PCSANetOperatingLossCarryforwardTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization" xlink:label="loc_PCSADeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_PCSADeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999055 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" xlink:label="loc_PCSAEffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_PCSAEffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999056 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" xlink:label="loc_PCSADeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_PCSADeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetsFederalOrphanDrugCredits" xlink:label="loc_PCSADeferredTaxAssetsFederalOrphanDrugCredits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_PCSADeferredTaxAssetsFederalOrphanDrugCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_PCSADeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_PCSADeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_DeferredTaxAssetsStartupExpenditures" xlink:label="loc_PCSADeferredTaxAssetsStartupExpenditures" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_PCSADeferredTaxAssetsStartupExpenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999057 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_CorLystLLCMember" xlink:label="loc_PCSACorLystLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_PCSACorLystLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:label="loc_PCSAProceedsFromRentAndOtherCostsReimbursements" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_PCSAProceedsFromRentAndOtherCostsReimbursements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" xlink:title="999058 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:label="loc_us-gaapReportableSegmentAggregationBeforeOtherOperatingSegmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_EmployeesMember" xlink:label="loc_PCSAEmployeesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PreclinicalClinicalTrialAndOtherCosts" xlink:label="loc_PCSAPreclinicalClinicalTrialAndOtherCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_PCSAPreclinicalClinicalTrialAndOtherCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_AdministrativeAndFacilitiesExpense" xlink:label="loc_PCSAAdministrativeAndFacilitiesExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_PCSAAdministrativeAndFacilitiesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" xlink:title="999059 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_CorLystLLCMember" xlink:label="loc_PCSACorLystLLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSACorLystLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999060 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_CROsMember" xlink:label="loc_PCSACROsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSACROsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPurchaseObligation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" xlink:title="999061 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesAWarrantMember" xlink:label="loc_PCSASeriesAWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesAWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesBWarrantMember" xlink:label="loc_PCSASeriesBWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesBWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_SeriesAAndBMember" xlink:label="loc_PCSASeriesAAndBMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesAAndBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" xlink:label="loc_PCSAChiefExecutiveOfficerAndCertainBoardMembersMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAChiefExecutiveOfficerAndCertainBoardMembersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_PCSAPreFundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20241231.xsd#PCSA_OutstandingSharesPercentage" xlink:label="loc_PCSAOutstandingSharesPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_PCSAOutstandingSharesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 12, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Processa
Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001533743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-1539785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7380
Coca Cola Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hanover<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">776-3133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PCSA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,269,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Cherry Bekaert LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tampa,
Florida<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,191,325<span></span>
</td>
<td class="nump">$ 4,706,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">682,294<span></span>
</td>
<td class="nump">926,300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">1,873,619<span></span>
</td>
<td class="nump">5,632,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="nump">5,016<span></span>
</td>
<td class="nump">2,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,274,442<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Non-current Assets</a></td>
<td class="nump">1,274,442<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">70,677<span></span>
</td>
<td class="nump">146,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other</a></td>
<td class="nump">5,535<span></span>
</td>
<td class="nump">5,535<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment', window );">Total Other Assets</a></td>
<td class="nump">76,212<span></span>
</td>
<td class="nump">151,592<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">3,229,289<span></span>
</td>
<td class="nump">5,786,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinanceLeaseLiabilityCurrent', window );">Current maturities of lease liability</a></td>
<td class="nump">73,020<span></span>
</td>
<td class="nump">83,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">880,880<span></span>
</td>
<td class="nump">311,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DueToLicensor', window );">Due to licensor</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">578,731<span></span>
</td>
<td class="nump">146,274<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">1,532,631<span></span>
</td>
<td class="nump">730,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent', window );">Non-current lease liability</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">66,905<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">1,533,118<span></span>
</td>
<td class="nump">797,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.0001, 1,000,000 shares authorized; no shares issued or outstanding at December 31, 2024 or December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001, 100,000,000 shares authorized; 3,707,628 issued and 3,702,628 outstanding at December 31, 2024 and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">89,214,999<span></span>
</td>
<td class="nump">80,658,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 5,000 shares</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(87,219,199)<span></span>
</td>
<td class="num">(75,369,081)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">1,696,171<span></span>
</td>
<td class="nump">4,989,159<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 3,229,289<span></span>
</td>
<td class="nump">$ 5,786,643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DueToLicensor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Due to licensor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DueToLicensor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease liability noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,707,628<span></span>
</td>
<td class="nump">1,291,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">3,702,628<span></span>
</td>
<td class="nump">1,286,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">$ 7,269,146<span></span>
</td>
<td class="nump">$ 5,799,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,782,060<span></span>
</td>
<td class="nump">5,657,543<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="num">(12,051,206)<span></span>
</td>
<td class="num">(11,457,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">201,088<span></span>
</td>
<td class="nump">335,541<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net Operating Loss Before Income Tax Benefit</a></td>
<td class="num">(11,850,118)<span></span>
</td>
<td class="num">(11,121,520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (11,850,118)<span></span>
</td>
<td class="num">$ (11,121,520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss Per Common Share - Basic</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="num">$ (8.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss Per Common Share - Diluted</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="num">$ (8.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic</a></td>
<td class="nump">3,059,906<span></span>
</td>
<td class="nump">1,311,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted</a></td>
<td class="nump">3,059,906<span></span>
</td>
<td class="nump">1,311,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Treasury Stock, Common [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 72,018,222<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">$ (64,247,561)<span></span>
</td>
<td class="nump">$ 7,470,741<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">806,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,060,338<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,060,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">6,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in connection with capital raises, net of transaction costs</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">6,352,035<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,352,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in connection with capital raises, net of transaction costs, shares</a></td>
<td class="nump">421,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant granted in connection with a consulting agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,310,875<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,310,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards', window );">Settlement of stock award</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(52,746)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(52,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Other</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">(30,613)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(30,607)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Other, shares</a></td>
<td class="nump">55,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,121,520)<span></span>
</td>
<td class="num">(11,121,520)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">80,658,111<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(75,369,081)<span></span>
</td>
<td class="nump">4,989,159<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">1,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">629,508<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">629,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">62,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in connection with capital raises, net of transaction costs</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">7,762,843<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,763,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in connection with capital raises, net of transaction costs, shares</a></td>
<td class="nump">2,356,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards', window );">Settlement of stock award</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(8,561)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,850,118)<span></span>
</td>
<td class="num">(11,850,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued in connection with license agreement</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">188,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with license agreement, shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay income taxes on stock-based compensation</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(15,901)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay income taxes on stock-based compensation, shares</a></td>
<td class="num">(7,423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 371<span></span>
</td>
<td class="nump">$ 89,214,999<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">$ (87,219,199)<span></span>
</td>
<td class="nump">$ 1,696,171<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">3,707,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital settlement of stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (11,850,118)<span></span>
</td>
<td class="num">$ (11,121,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">782<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinanceLeaseExpense', window );">Non-cash lease expense for right-of-use assets</a></td>
<td class="nump">87,184<span></span>
</td>
<td class="nump">81,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">629,514<span></span>
</td>
<td class="nump">1,060,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Warrants issued for consulting services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,310,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="num">(1,030,436)<span></span>
</td>
<td class="nump">956,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(83,649)<span></span>
</td>
<td class="num">(78,896)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">569,263<span></span>
</td>
<td class="num">(15,931)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_IncreaseDecreaseInDueFromToRelatedParties', window );">Due from related parties</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">432,457<span></span>
</td>
<td class="num">(256,787)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,245,042)<span></span>
</td>
<td class="num">(8,063,346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(3,244)<span></span>
</td>
<td class="num">(2,776)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(3,244)<span></span>
</td>
<td class="num">(2,776)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="nump">7,763,079<span></span>
</td>
<td class="nump">6,321,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay taxes on stock-based compensation</a></td>
<td class="num">(15,902)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_PaymentsForSettlementOfStockAwards', window );">Settlement of stock award</a></td>
<td class="num">(8,561)<span></span>
</td>
<td class="num">(52,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligation</a></td>
<td class="num">(5,202)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,733,414<span></span>
</td>
<td class="nump">6,268,724<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Decrease in Cash and Cash Equivalents</a></td>
<td class="num">(3,514,872)<span></span>
</td>
<td class="num">(1,797,398)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents - Beginning of Year</a></td>
<td class="nump">4,706,197<span></span>
</td>
<td class="nump">6,503,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents - End of Year</a></td>
<td class="nump">1,191,325<span></span>
</td>
<td class="nump">4,706,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="num">(1,204)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-Cash Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor', window );">Issuance of 5,000 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor</a></td>
<td class="nump">189,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use asset obtained in exchange for financing lease liability</a></td>
<td class="nump">11,804<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_FinancingLeaseLiability', window );">Financing lease liability</a></td>
<td class="num">(11,804)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_NonCashLeaseLiabilityNet', window );">Net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_FinancingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_FinancingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_IncreaseDecreaseInDueFromToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Due (from) to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_IncreaseDecreaseInDueFromToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_NonCashLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash lease liability net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_NonCashLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_PaymentsForSettlementOfStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for settlement of stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_PaymentsForSettlementOfStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued in connection with licensing agreement which had previously been recorded as due to licensor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with license agreement</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (11,850,118)<span></span>
</td>
<td class="num">$ (11,121,520)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risk Management and Strategy</b></span>&#160;<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zlQ1SODAGDP3">We
have established processes to assess, identify, and manage cybersecurity risks. These processes are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zODYREMUV9F4">integrated</span> into our overall risk
management program and are designed to protect our information assets from internal and external cyber threats</span> and include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify; width: 0.25in"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing
    physical, procedural, and technical safeguards;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and maintaining comprehensive response plans;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">engaging
    with <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zkxK7PJMcqs3">external cybersecurity experts to enhance our oversight and keep pace with evolving threats</span>; and</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>considering
    the cybersecurity capabilities of partners and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zTEDx5rvv61k">third-party service providers</span>, both prior to engaging them and on an ongoing basis.</span></span></td></tr>
  </table>
&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We
have established processes to assess, identify, and manage cybersecurity risks. These processes are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zODYREMUV9F4">integrated</span> into our overall risk
management program and are designed to protect our information assets from internal and external cyber threats<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Governance and Oversight</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span>&#160;</span></span></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zL4l5kD4iNy2">Our
Board of Directors provides direct oversight of cybersecurity risk and has delegated to its audit committee the responsibility of reviewing
and discussing with management our risk exposures relating to cybersecurity</span>. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_ztIFLCO5Ykqk">The Board of Directors and the audit committee will receive
regular updates from management on cybersecurity matters and are promptly informed by management about any significant new threats or
incidents</span>. In the future, management and our third-party service providers will conduct reviews at least once annually of our cybersecurity
readiness to ensure continuous improvement in our cybersecurity strategies.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>We
have implemented mechanisms to monitor and manage cybersecurity threats and incidents, including utilization of tools for continuous
monitoring of our IT environment to detect and mitigate threats, a fundamental plan for responding to cyber incidents and training for
employees to recognize and report potential cybersecurity incidents and to foster a culture of cybersecurity awareness and vigilance.
Our Chief Administrative Officer, along with a third-party service provider, are responsible for operational oversight of our cybersecurity
strategy and policies. Any identified cybersecurity incident is reported to our Chief Administrative Officer who evaluates the severity
of the incident. Based on this assessment, further steps are taken involving other members of management and, depending on the severity,
the audit committee and the Board of Directors. We believe this structured approach allows us to effectively manage and mitigate cybersecurity
risks, safeguarding our systems and data against various digital threats. Additionally, our proactive stance is supported by cybersecurity
insurance, which further reinforces our preparedness against potential cyber threats.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Incident Reporting and Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>During
the years ended December 31, 2023 and 2024, we have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zEtOM1mwRRW3">not</span> identified any risks from cybersecurity threats that have materially affected
or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. However,
we remain vigilant and prepared to respond effectively to any incidents, should they arise.</span></span></p>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our
Board of Directors provides direct oversight of cybersecurity risk and has delegated to its audit committee the responsibility of reviewing
and discussing with management our risk exposures relating to cybersecurity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Board of Directors and the audit committee will receive
regular updates from management on cybersecurity matters and are promptly informed by management about any significant new threats or
incidents<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zHII7B87Rjee" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
1 &#8211; <span id="xdx_82C_ztVTq4A1fvoj">Organization</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Organization</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next
Generation <span style="background-color: white">Cancer therapy </span> <span style="background-color: white">(&#8220;NGC&#8221;) </span> drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing
FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known and established
existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our NGC treatments will
provide improved safety-efficacy profiles when compared to their currently marketed counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended with the Secretary of State of
Delaware that effected a <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20240122__20240122_zB3orY3QwZR4" title="Reverse stock split">1-for-20 reverse stock split</span> of our common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240122_zPTQ3p56BSo2" title="Common stock, par value">0.0001</span> per share (the &#8220;Reverse Stock Split&#8221;).
Pursuant to the Certificate of Amendment, our issued common stock decreased from <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20240121_zFd6vKWntT6i" title="Common stock shares issued">24,706,474</span> shares to <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20240122_ztMcbhUbOiNi" title="Common stock, shares issued">1,291,000</span> shares and our outstanding
common stock decreased from <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240121_zMReQH9Q8hel" title="Common stock shares outstanding">24,606,474</span> to <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20240122_zO1T4DtizU4d" title="Common stock, shares outstanding">1,286,000</span>. The Reverse Stock Split did not affect our authorized common stock of <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20240122_znzi3Hs2tYJ5" title="Common stock, shares authorized">100,000,000</span>
shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, and restricted
stock units, as well as exercise prices and per share information in these consolidated financial statements give retroactive effect
to the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization
of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception,
currently devoting substantially all of our efforts toward research and development of our NGC drug product
candidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated
deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zCBBEnE2a7bi" title="Accumulated deficit">87.2</span> million at December 31, 2024. During the year ended December 31, 2024, we generated a net loss of $<span id="xdx_903_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zpqInEsbLdr7" title="Net loss">11.9</span> million and
used $<span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zN2rqougPdF9" title="Net cash used in operating activities">11.2</span> million in net cash for operating activities from continuing operations. To date, none of our drug candidates have been approved
for sale, and therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have financed our operations primarily through public equity issuances, including an offering we sold on January 27, 2025 where we sold
<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250127__20250127__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIdsXD0naTpf" title="Number of shares sold">1,030,972</span> shares of our common stock, pre-funded warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zogXEA8VMUKl" title="Warrants to purchase">7,019,700</span> shares of our common stock, and accompanying Series
A warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0ydKH27MuKa" title="Warrants to purchase shares">8,050,672</span> shares of our common stock (the &#8220;Series A Warrants&#8221;) and Series B warrants to purchase
up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zS6kZ31q4Me7" title="Warrants to purchase common stock">4,025,336</span> shares of our common stock (the &#8220;Series B Warrants&#8221; and collectively with the Series A Warrants, the &#8220;Common
Warrants&#8221;) for net proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zr0lZ2YRTCba" title="Net proceeds">4.5</span> million, after deducting placement agent fees and offering-related expenses (see Note 14 for
additional details). On January 30, 2025, pre-funded warrants to purchase <span id="xdx_900_ecustom--ClassOfWarrantOrRightExercised_iI_c20250130__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0HyrCDWJfJa" title="Warrants exercised">525,700</span> shares of our common stock were exercised and, as of
March 12, 2025, pre-funded warrants for the purchase of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250312__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrFY2Q82gPZd" title="Warrants outstanding">6,494,000</span> remain outstanding. We will continue to be dependent upon equity
and/or debt financing until we are able to generate positive cash flows from its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, we had cash and cash equivalents totaling $<span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_z6OOfwSGf4z2" title="Cash and cash equivalents">1.2</span> million. Together with the $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zepT5e4MYsB8" title="Net proceeds">4.5</span> million net proceeds we raised in January
2025, and based on our current business plans, we believe these funds will satisfy our capital needs into mid-2025. Our ability to execute
our longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend on our ability
to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absent
additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year
or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our
projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial
doubt exists about our ability to continue as a going concern within one year after the date that these consolidated financial statements
are available to be issued. The accompanying consolidated financial statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might
be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zqtUGwYB1k1g" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
2 &#8211; <span id="xdx_829_zxnPYDg6pXh6">Basis of Presentation and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJwbA0ZS79Z8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zfmt3sv6MuK6">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange
Commission (the &#8220;SEC&#8221;), and reflect all of our activities, including those of our wholly-owned subsidiary. All material intercompany
accounts and transactions have been eliminated in consolidation. Operating results for the year ended December 31, 2024 are not necessarily
indicative of future results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_zvfbiAHSVea5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_z6qoGM74IBTa">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and regulations
of the SEC, we make estimates and judgments that affect the amounts reported in the consolidated financial statements and accompanying
notes. Estimates are used for, but not limited to stock-based compensation, intangible assets, future milestone payments and income taxes.
These estimates and assumptions are continuously evaluated and are based on management&#8217;s experience and knowledge of the relevant
facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates
and could impact future results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zKoo1C6jtf03" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z3lz7d9cpfM4">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash on hand and money market funds. We consider all highly liquid investments maturing within three months
from the date of purchase as cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_ecustom--PrepaidExpensesPolicyTextBlock_z3qevoN2fMUi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zVQDTR4r1B4k">Prepaid
Expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments made to third parties under
these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.
The majority of our prepaid expenses relate to advanced payments made to CROs and other vendors for our ongoing clinical trials. We allocate
the prepaid expenses between current and non-current assets based on the anticipated timing of utilizing the advances. At December 31,
2024, we determined that $<span id="xdx_90E_eus-gaap--PrepaidExpenseNoncurrent_iIP1custom--AccountingPoliciesLineItemsAbstract_pn5n6_c20241231_zE498icFARu7" title="Prepaid expense">1.3</span> million would not be applied until after December 31, 2025.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zS4wfLdYwof4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zvh4Vi9h7wea">Property
and Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
is stated at cost, less accumulated depreciation. Costs of renewals and improvements that extend the useful lives of the assets are capitalized.
Expenditures for maintenance and routine repairs are charged to expense as incurred. Depreciation is recognized on a straight-line basis
over the estimated useful lives of the assets, which generally range from <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iIP1us-gaap--PropertyPlantAndEquipmentLineItems_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_zoCtbnHRkXe8" title="Estimated useful lives of property plant and equipment">3</span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iIP1us-gaap--PropertyPlantAndEquipmentLineItems_dtY_c20241231__srt--RangeAxis__srt--MaximumMember_zLZpDmG39177" title="Estimated useful lives of property and equipment">5</span> years. We amortize leasehold improvements over the shorter
of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related
accumulated depreciation are removed from the accounts with the resulting net gain or loss, if any, reflected in the consolidated statement
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z1prFuGxIT3c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zkoqXS1iLQ5g">Impairment
of Long-Lived Assets and Intangibles Other Than Goodwill</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for the impairment of long-lived assets in accordance with ASC 360<i>, Property, Plant and Equipment</i> and ASC 350, <i>Intangibles
&#8211; Goodwill and Other,</i> which require that long-lived assets and certain identifiable intangibles be reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to its expected future undiscounted net cash flows
generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which
the carrying amounts of the assets exceed the fair value of the assets based on the present value of the expected future cash flows associated
with the use of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbm5AT6BEZh4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zL2TdenAtji6">Fair
Value Measurements and Disclosure</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
apply ASC 820, <i>Fair Value Measurements and Disclosures</i>, which expands disclosures for assets and liabilities that are measured
and reported at fair value on a recurring basis. Fair value is defined as an exit price, representing the amount that would be received
upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or
liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; Quoted market prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access
at the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; Quoted market prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or
liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Fair value determined
using models or other valuation methodologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; Significant unobservable inputs for assets or liabilities that cannot be corroborated by market data. Fair value is determined
by the reporting entity&#8217;s own assumptions utilizing the best information available and includes situations where there is little
market activity for the asset or liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
asset&#8217;s or liability&#8217;s fair value measurement within the fair value hierarchy is based upon the lowest level of any input
that is significant to the fair value measurement. Our policy is to recognize transfers between levels of the fair value hierarchy in
the period the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 1, 2, or 3 during
the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSwxTtKBlKua" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zDdSubbyF0yf">Stock-based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
measure compensation expense for stock options and other stock awards in accordance with ASC 718, <i>Compensation&#8212;Stock Compensation</i>.
Stock-based compensation is measured at fair value on grant date and recognized as compensation expense over the requisite service period.
Generally, we issue stock options and other stock awards with service-based and/or performance-based vesting conditions. For awards with
only service-based vesting conditions, we record compensation cost for these awards using the straight-line method over the service period.
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For awards that contain performance vesting conditions,
we do not recognize compensation expense until achieving the performance condition is probable. We estimate the fair value of stock option
and warrant grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based
awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.
We value restricted stock awards (RSAs) and restricted stock units (RSUs) based on the closing share price of our common stock on the
date of grant. Stock-based compensation costs are recorded as general and administrative or research and development costs in the statements
of operations based upon the underlying individual&#8217;s or entity&#8217;s role.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
of fair value are not intended to predict actual future events or the value ultimately realized by employees or consultants who receive
these awards, and subsequent events are not indicative of the reasonableness of our original estimates of fair value. We account for
forfeitures in the period in which they occur, rather than estimate expected forfeitures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z4qzW1m203ec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zsAvmqMEF221">Net
Loss Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average common stock outstanding (which excludes unvested RSAs) and
vested, but unissued RSUs. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted
weighted average number of shares of common stock outstanding during the period. Since we have experienced a net loss for all periods
presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the years ended December 31, 2024 and
2023 excludes the impact of potentially dilutive common shares related to outstanding stock options, unvested restricted stock awards
(RSAs), unvested RSUs and common stock purchase warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
diluted net loss per share for the years ended December 31, 2024 and 2023 excluded <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_iP1custom--AccountingPoliciesLineItemsAbstract_pid_c20240101__20241231_zjF4WhW5Lk6k" title="Antidilutive securities excluded from computation of earnings per share">2,013,154</span> and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_iP1custom--AccountingPoliciesLineItemsAbstract_pid_c20230101__20231231_zlt27ixgXgc1" title="Antidilutive securities excluded from computation of earnings per share">296,326</span> of potentially dilutive common
shares, respectively, related to outstanding stock options, unvested RSAs, unvested RSUs and warrants since those shares would have had
an anti-dilutive effect on loss per share during the years then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_znxOJ7ZTbKK4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_z342kDdpre2c">Segments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">We have one reportable segment, which is focused on discovering and developing a pipeline of Next Generation Cancer
therapy drugs. Our Chief Executive Officer, who is the chief operating decision maker (CODM), assesses segment performance and decides
how to allocate resources based on net loss that is also reported on the Consolidated Statements of Operations and Comprehensive Loss.
See Note 11 for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zNouNC8tTmg4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zjEuC6PXltOe">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, accounts receivable and accounts payable approximate their fair value because of the short-term
maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zW9LuNaeVIn9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zjxmExykSpx6">Research
and Development</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred and consist of direct and overhead-related expenses related primarily to clinical trials,
including development personnel salaries and related costs. Expenditures to acquire technologies, including licenses, which are utilized
in research and development and that have no alternative future use are expensed as the acquisition of in-process research and development
when incurred. Technology we develop for use in our products is expensed as incurred until technological feasibility has been established
after which it is capitalized and depreciated. No research and development costs were capitalized during the years ended December 31,
2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zHxivy8XX6Ub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zqu3ysScCQ1a">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. As of December 31, 2024 and 2023, we recorded a valuation allowance equal to the full recorded amount of our
net deferred tax assets since it is more-likely-than-not that benefits from our deferred tax assets will not be realized. The valuation
allowance is reviewed quarterly and is maintained until sufficient positive evidence exists to support its reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing
authority, based on the technical merits of the position. Our policy is to record interest and penalties related to income taxes as part
of its income tax provision. As of December 31, 2024, we had <span id="xdx_903_eus-gaap--UnrecognizedTaxBenefits_iIP1custom--AccountingPoliciesLineItemsAbstract_do_c20241231_zkuwbJhRSg02" title="Unrecognized tax benefits">no</span> unrecognized tax benefits and as such, no liability, interest or penalties
were required to be recorded. We do not expect this to change significantly in the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_ecustom--RecentAccountingPronouncementsPolicyPolicyTextBlock_zHPKtuk6v6Vb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i><span id="xdx_861_zB4GDa2ri0Oe">Recently Adopted Accounting Standard</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">In November 2023, the FASB issued ASU 2023-07 &#8211; Segment Reporting (Topic 280) &#8211; Improvements to Reportable
Segment Disclosures, which improves segment disclosure requirements, primarily through enhanced disclosure requirements for significant
segment expenses. The improved disclosure requirements apply to all public entities that are required to report segment information, including
those with only one reportable segment. We adopted this standard effective for the year ending December 31, 2024 and the primary impact
of which was the additional segment disclosures included in Note 11.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z51Qe2P6ysXl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_ztahQYnCPzBa">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our financial statements. We have <span style="background-color: white">considered
all recent accounting pronouncements issued since the last audit of our consolidated financial statements. We believe that these recent
pronouncements will not have a material effect on our consolidated financial statements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide
enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and
for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption
is permitted. We are evaluating this standard to determine if adoption will have a material impact on our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense
Disaggregation Disclosures (Subtopic 220-40), which requires disclosure, in the notes to the financial statements, of specified information
about certain costs and expenses. This ASU is effective for public entities for annual reporting periods beginning after December 15,
2026 and interim reporting periods beginning after December 15, 2027. We are currently evaluating the impact ASU 2024-03 will have on
our consolidated financial statements.</p>

<p id="xdx_858_zzQRomPClUQ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zpLYO7qj0VH" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
3 - <span id="xdx_82A_ztEoIkXfszYb">Stock-based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">T<span style="background-color: white">he
Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) allows us to make grants of stock options,
restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors.
The 2019 Plan originally provided for the aggregate issuance of <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220710__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember__us-gaap--AwardTypeAxis__custom--OriginalMember_zwuerPj2XEW5" title="Maximum equity available for issuance under the plan">150,000</span> shares of our common stock. </span>On June 28, 2024, our shareholders
approved an increase of shares available under the 2019 Plan, which now provides for the aggregate issuance of <span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240628__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zNbHqIt1mtCe" title="Maximum equity available for issuance under the plan">800,000</span> shares of our
common stock. At December 31, 2024, we have <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zkkZDKpzyOg3" title="Shares available for future grants">353,641</span> shares available for future grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Compensation Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zlEUr9SVxlF" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the years ended December 31, 2024 and 2023 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B0_zOokHVYXHBB1" style="display: none">Schedule of Stock-based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20240101__20241231_zVJKGeD5iRTc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zScrTcXsxnQj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended <br/> December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXsVE2UNk0g1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">169,414</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">363,956</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z42I0Er24F7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">460,100</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,007,258</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_zZPgq9e56vU3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">629,514</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,371,214</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zGvd0ZePmG9a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">No
tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for all net deferred
tax assets relating to this expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrAcclmb4UH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes our stock option activity during the years ended December 31, 2023 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_ziFTZbmuS8H9" style="display: none">Schedule
of Stock Option Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total
    options Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual life<br/>
    (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zrGZbbB4faIi" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">8,943</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zHUwAVbHUVUf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif">341.34</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_z9DN332ZIQxb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited
    or expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231_zAtzSQrUPqk6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, forfeited"><span style="font-family: Times New Roman, Times, Serif">(1,951</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zrbtHTTNqPji" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif">257.28</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTzQJ6MkYlG7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">6,992</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zhFKS0JEgZLf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif">364.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zbh8yDbnm0oi" title="Weighted average remaining contractual term, ending">2.1</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_zPTWYcH5toE3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0603">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited
    or expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231_zrTTPNrvRx55" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, forfeited or expired"><span style="font-family: Times New Roman, Times, Serif">(4,245</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zAqysptNg5W2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price,  forfeited or expired"><span style="font-family: Times New Roman, Times, Serif">336.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding and exercisable as of December
    31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zdrJ9top9x8i" title="Options outstanding, ending balance"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zTTIIMLMS9I6" title="Options exercisable, ending balance">2,747</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z2FPO341OJ92" title="Weighted average exercise price, ending balance"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zF0kKGejBLoh" title="Weighted average exercise price, exercisable">409.09</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zLQxr5HEKPZb" title="Weighted average remaining contractual term, outstanding"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zCMdEWqF3l1d" title="Weighted average remaining contractual term, exercisable">3.7</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AF_z7T4Ai5nuFcl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
forfeiture rate was applied to these stock options. The aggregate intrinsic value of outstanding options, all of which are exercisable,
was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDFKWPh4OO0k" title="Aggregate intrinsic value of outstanding options"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRzwHyeFJT63" title="Aggregate intrinsic value of outstanding options">0</span></span> at both December 31, 2023 and 2024. <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z028FAoYJ3b8" title="Stock option exercised"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhsWAfBbA6ub" title="Stock option exercised">No</span></span> stock options were exercised during the years ended December 31, 2023 or 2024 and there
is no unamortized expense at December 31, 2024 since the options are fully vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Awards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zTUUuDHmtpX6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes our restricted stock award (RSA) activity during the years ended December 31, 2023 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_z1gVx5R7HU79" style="display: none">Schedule
of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted-
    <br/> average <br/> grant-date fair <br/> value per share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Unvested as of January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zHpjhP2ZJb" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of restricted stock, shares outstanding"><span style="font-family: Times New Roman, Times, Serif">3,095</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zvDtXH6wKy01" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">94.44</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zBUNAWaUSTS2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"><span style="font-family: Times New Roman, Times, Serif">10,750</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zDiKjrXzSbK6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"><span style="font-family: Times New Roman, Times, Serif">14.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zG6Gh8y9hnE4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif">(1,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zcvkQywoHq93" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"><span style="font-family: Times New Roman, Times, Serif">133.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zYiyJ9hVSuic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, cancelled"><span style="font-family: Times New Roman, Times, Serif">(2,555</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zn1xW8o7KVYi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, cancelled"><span style="font-family: Times New Roman, Times, Serif">22.13</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vested and issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zj6DtCTV8uv6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and issued"><span style="font-family: Times New Roman, Times, Serif">(8,790</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zfzhoPcljnXc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and issued"><span style="font-family: Times New Roman, Times, Serif">24.44</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Unvested as of December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zjcDEBXwowyi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zilrWwqCxmWd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">9.26</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zideJL0eB3J5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zgIOp8FB0jg8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0657">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z5n5dSliOvqj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zR5gOnMVpmud" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0661">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zWpr9dJBfmAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0663">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z2C3Qvxl48o" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0665">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vested and issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z6eoJ079nVs4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and issued"><span style="font-family: Times New Roman, Times, Serif">(1,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zPK10SK2ydB3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and issued"><span style="font-family: Times New Roman, Times, Serif">9.26</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested as of December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z9tt9Iq8ImZd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zUXL4psXllCc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, outstanding"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0673">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AC_zOqgk4IXrrPe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zy3iLyAGdEYe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes our restricted stock unit (RSU) activity during the years ended December 31, 2023 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zaOCKzHQqr42" style="display: none">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted-
    <br/> average <br/> grant-date fair <br/> value per share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUh97PPNY936" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of shares, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">135,741</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4hMt2jDQga" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">73.81</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8lbwStdwJo8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"><span style="font-family: Times New Roman, Times, Serif">116,078</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOodBTN4AX85" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"><span style="font-family: Times New Roman, Times, Serif">14.18</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOHHyEcHKati" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif">(12,296</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaCdhNLohGXa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"><span style="font-family: Times New Roman, Times, Serif">21.69</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFzyblqRBRmi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, cancelled"><span style="font-family: Times New Roman, Times, Serif">(16,801</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyeq0B0XBxQj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, cancelled"><span style="font-family: Times New Roman, Times, Serif">71.36</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTxaoyJSVlec" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, issued"><span style="font-family: Times New Roman, Times, Serif">(17,093</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbUE9VovGPXc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, issued"><span style="font-family: Times New Roman, Times, Serif">110.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLGvR1SLePC5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">222,722</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0KgHqINrAj7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">45.82</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1x1hbnWfSC6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"><span style="font-family: Times New Roman, Times, Serif">192,026</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwSYF57PFWD1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"><span style="font-family: Times New Roman, Times, Serif">1.63</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdl41hLqzvnf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif">(14,019</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZoGrtkvNO1k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"><span style="font-family: Times New Roman, Times, Serif">71.68</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTA62TKWj5ah" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, issued"><span style="font-family: Times New Roman, Times, Serif">(17,093</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zf2oPqvFDvKc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, issued"><span style="font-family: Times New Roman, Times, Serif">110.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbNZUhfAXpS6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, ending balance"><span style="font-family: Times New Roman, Times, Serif">383,636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBIYi8aRsFZ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, ending balance"><span style="font-family: Times New Roman, Times, Serif">19.87</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vested and unissued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdSXGwQWf9Nl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and unissued"><span style="font-family: Times New Roman, Times, Serif">(149,013</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaTLvyHdpMG1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"><span style="font-family: Times New Roman, Times, Serif">43.10</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB626M0FokK2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, unvested"><span style="font-family: Times New Roman, Times, Serif">234,623</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJVlZu6FfKQi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, unvested"><span style="font-family: Times New Roman, Times, Serif">5.11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p id="xdx_8A7_zfnE5a5W7f9j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, we granted the following RSUs:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            June 28, 2024, we granted RSUs for the future issuance of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z2Ic12qVaul5" title="Number of shares, granted">39,202</span> shares of common stock to
                                            our employees which vest accordingly: RSUs for the future issuance of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockUnitsMember__us-gaap--VestingAxis__custom--JanuaryOneTwoThousandTwentyFiveVestingMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zTYANXC7WJL" title="Number of shares, granted">14,969</span> shares of common
                                            stock vest on January 1, 2025; RSUs for the future issuance of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240628__20240628__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockUnitsMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--VestingAxis__custom--ThreeYearVestingMember_z1KMfj5WnySk" title="Number of shares, granted">18,173</span> shares of common stock
                                            vest over a three-year period upon meeting service requirements; RSUs for the future issuance
                                            of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240628__20240628__us-gaap--AwardTypeAxis__custom--FirstPerformanceBasedRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z73xb1N8OkWe" title="Number of shares, granted">3,030</span> shares of common stock vested upon grant due to regaining Nasdaq compliance; and
                                            RSUs for the future issuance of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__custom--SecondPerformanceBasedRSUMember__us-gaap--TypeOfArrangementAxis__custom--NextGenerationCapecitabineCAPMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z4hvvWFRSRL9" title="Number of shares, granted">3,030</span> shares of common stock vested on October 2, 2024 when
                                            we dosed the first patient in our Phase 2 study in NGC-Cap.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            July 16, 2024, Russell Skibsted was appointed as our Chief Financial Officer (&#8220;CFO&#8221;).
                                            In addition to cash compensation, the Compensation Committee awarded RSUs for the future
                                            issuance of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zeGrUrOHlOsd" title="Number of shares, granted">28,000</span> shares of common stock to Mr. Skibsted, which vest accordingly: <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__custom--JulySixteenTwoThousandTwentyFiveVestingMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zRafHYryhzC1" title="Number of shares, granted">14,000</span>
                                            vest on July 16, 2025; <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--VestingAxis__custom--FirstPerformanceBasedRSUMember_zKN49MW9ovg4" title="Number of shares, granted">7,000</span> vest upon reaching a market capitalization (i.e. total value
                                            of Processa&#8217;s outstanding shares of stock at the then current market price) of at least
                                            $<span id="xdx_902_ecustom--MarketCapitalization_iI_pn6n6_c20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--VestingAxis__custom--FirstPerformanceBasedRSUMember_zk0qaH9a03r6" title="Market capitalization">30</span> million; and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--VestingAxis__custom--SecondPerformanceBasedRSUMember_z7JGgu9UBLV8" title="Number of shares, granted">7,000</span> vest upon receipt of cumulative financing(s) of at least $<span id="xdx_902_ecustom--PerformanceVestingCriteriaValue_iI_pn6n6_c20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--VestingAxis__custom--SecondPerformanceBasedRSUMember_zM9F8ODzd8f1" title="Performance vesting criteria">15</span> million.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            September 3, 2024, RSUs for the future issuance of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240903__20240903__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zuhaLftduwVh" title="Number of shares, granted">124,824</span> shares of common stock were granted
                                            to our independent directors and vest on the earlier of June 28, 2025 or the next annual
                                            shareholder meeting.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
                                            December 31, 2024, unrecognized stock-based compensation expense for RSUs of approximately
                                            $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLWIN50N7gRf" title="Unrecognized stock-based compensation expense">613,000</span> is expected to be fully recognized over a weighted average period of <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVogPNmBEA99" title="Weighted average period for recognition">0.7</span> years.
                                            The unrecognized expense excludes $<span style="background-color: white"><span id="xdx_90B_ecustom--UnrecognizedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zombOCEZmphe" title="Unrecognized share based compensation expense">432,060</span> </span>related
                                            to certain RSUs with a performance milestone that is not currently probable of occurring.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Holders
of our vested RSUs will be issued shares of our common stock upon the satisfaction of the distribution restrictions contained in their
Restricted Stock Unit Award Agreement. The distribution restrictions are typically different (longer) than the vesting schedule, imposing
an additional restriction on the holder. Unlike RSAs, while employees may hold fully vested RSUs, the individual does not hold any shares
or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts
into one share of our common stock. The RSUs contain dividend equivalent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_ecustom--ScheduleOfWarrantValuationAssumptionTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2Jl7pxRbsei" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes our warrant activity during the years ended December 31, 2023 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zRzQRMec8UTj" style="display: none">Schedule of Warrants Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total
    warrants outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual<br/>
    life (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGqRSYw9p3yb" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrants outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">14,283</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGJURedJKvch" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif">205.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCsQTmCVI6l7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, granted"><span style="font-family: Times New Roman, Times, Serif">173,007</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeIqhRO1dMv2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">19.27</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9NrC0pskkui" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, expired or cancelled"><span style="font-family: Times New Roman, Times, Serif">(6,783</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zC2GvJUrZnQd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, expired"><span style="font-family: Times New Roman, Times, Serif">266.96</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt">Not exercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zurrmhM9Fjgc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Not exercisable">(7,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNHnrmsmBqAf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, not exercisable">7.40</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zB77ppbgMXah" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, exercisable">7,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zb45yKNXNDXf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable">7.40</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding and exercisable as of December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpjNwCfzuASi" title="Warrants outstanding, beginning balance"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5tzx0izZMgl" title="Warrants, exercisable">173,007</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDVSyUcHtNr7" title="Weighted average exercise price, beginning balance">25.41</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zF7XqKZb5Bze" title="Weighted average remaining contractual term, ending"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zX4BhSkIDDK4" title="Weighted average remaining contractual term, exercisable">2.2</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6gNJTXjpyLh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, exercisable">7,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPQuxIhoW21f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable">7.40</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zHIALzkmJBX9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, granted"><span style="font-family: Times New Roman, Times, Serif">1,617,777</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWA7T7CXdLr1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">4.54</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Expired
    or cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4ai87IdmVWh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, expired or cancelled"><span style="font-family: Times New Roman, Times, Serif">(22,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYaY4v1ZICFj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, expired or cancelled"><span style="font-family: Times New Roman, Times, Serif">54.62</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding and exercisable as of December
    31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRvIcHK539f" title="Warrants outstanding, ending balance"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4jhRbRLuT55" title="Warrants, exercisable">1,775,784</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7rJNa6M9UAf" title="Weighted average exercise price, ending balance"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDndxQAR2JKj" title="Weighted average exercise price, exercisable">5.95</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGVC8ehhNS78" title="Weighted average remaining contractual term, outstanding"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zuS1NksCppE1" title="Weighted average remaining contractual term, exercisable">3.8</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_z2stNADCw70h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, we did not grant any warrants to purchase shares of our common stock other than warrants to purchase
<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__custom--OfferingMember_zfevzV3v7PQa" title="Warrants to purchase common stock">1,617,777</span> shares of common stock as part of the Offering (see Note 4). Warrants to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zrYpgHEgE61e" title="Warrants, expired unexercised">7,500</span> shares of our common stock expired
unexercised. We also repurchased a warrant issued to a consultant in 2023 for the purchase of <span id="xdx_902_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFPK6NQa2ug3" title="Warrants repurchased, shares">15,000</span> shares of our common stock in exchange
for a payment of $<span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodValue_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoNhqFqqryel" title="Payment for warrants repurchased">10,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, we amended our financial consulting agreement with Spartan Capital Securities, LLC (&#8220;Spartan&#8221;), our placement agent for our registered direct offering in February
2023, by extending the term until February 10, 2024. We compensated
Spartan for financial consulting services provided under the amendment by granting warrants to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230417__20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zUvZNAFHp7R8" title="Warrants, granted">158,007</span> shares of our common
stock on April 17, 2023, with an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zID4DcWFAuwf" title="Warrants exercise price">20.40</span>. The warrants expire on <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zCnI83kq7I0c" title="Warrants maturity date">April 17, 2026</span>, and contain both call and cashless
exercise provision. We also granted warrants to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20231118__20231118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zjQP6caa7y75" title="Warrants, granted">15,000</span> shares of our common stock to a consultant on November 18, 2023, of which
warrants to purchase <span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_c20231118__20231118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zPD1xtoKC8uj" title="Warrants, exercisable">7,500</span> shares of our common stock were exercisable, with an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zEamF6yt1VJa" title="Warrant exercise price">7.40</span>. These warrants expire on <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_dd_c20231118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zL3jW7ixPSVb" title="Warrant expiration date">November
18, 2025</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z187qcKGfGgk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
used the Black-Scholes option pricing model to calculate the grant date fair value of the two warrants granted in 2023 with the following
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zpzqMzlWJHif" style="display: none">Schedule
of Warrant Valuation Assumption</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Average risk-free rate of interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zFFa3YACrxN8" title="Warrants, measurement input">4.32</span>-<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zAKeD9yxN461" title="Warrants, measurement input">4.88</span>
                                            </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_z3cdHYYbNIi7" title="Expected term (years)">2.00</span>&#8211;<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zCgxZ3Mye4Wf" title="Expected term (years)">3.00</span>
                                            &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected stock price volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zvN0Na7wW7ph" title="Warrants, measurement input">82.85</span>-<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zpitNuAAUAad" title="Warrants, measurement input">108.47</span>
                                            </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zk12iZhMWC1a" title="Warrants, measurement input">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p id="xdx_8A1_zssuzqLdxQI2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zUrcz5lh6kPk" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
4 &#8211; <span id="xdx_828_znkqnzsR8Wmk">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Financings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, we issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJd7pqRHNTW5" title="Stock issued">2,356,549</span> shares of our common stock through several fundraising efforts described below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Public
    Offering &#8211; </i>On January 30, 2024, we closed a public offering (the &#8220;Offering&#8221;) for the sale of <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlVtb3XifXQh" title="Number of shares, sold">476,000</span> shares
    of common stock, P</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">re-Funded Warrants to purchase
    up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z031sVAES4j6" title="Warrants to purchase">1,079,555</span> shares of common stock in lieu of shares of common stock, and Common Warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zbXyJ3AXuhwb" title="Warrants to purchase">1,555,555</span> shares
    of our common stock. The Common Warrants have an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjafoz1qP2e9" title="Warrant exercise price">4.50</span>, are immediately exercisable and expire on <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrO0qwpZmoU6" title="Warrants, maturity date">January 30, 2029</span>.
    The shares of common stock were offered at a combined public offering price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zqKo0Wyz9Rv" title="Warrant exercise price">4.50</span> per share and accompanying Common Warrant and
    $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240130__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zzCU2Zym2Bgd" title="Warrants, price per share">4.4999</span> per Pre-Funded Warrant and accompanying Common Warrant. The Pre-Funded Warrants had an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240130__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zvlrk92jKLwk" title="Warrant exercise price">0.0001</span> and were
    exercised in full simultaneously with the closing of the Offering in exchange for <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesExercised_iI_c20240130__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlsdrklOLHMl" title="Warrants, exercised">1,079,555</span> shares of our common stock. Gross proceeds
    in connection with the Offering were $<span id="xdx_901_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zvVjzGumwdJh" title="Gross proceeds">7.0</span> million. We received $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zl8TrhpbuAR9" title="Net proceeds">6.3</span> million in net proceeds from the Offering, after deducting the
    fees of the placement agent and other offering-related expenses. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ATM
    Offering</i> &#8211; We sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zkBogvc6ePCk">800,994</span> shares at an average price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zPkN04OMsy9l">1.93</span> per share for aggregate net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z3346w7zcbt4" title="Net proceeds">1.5</span> million.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also issued to the placement agent warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zUr0bCKip20h">62,222</span> shares of common stock, exercisable at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zk14eQ3OsRY2">5.625</span> per share that expire on
<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zqqnB4wqbuze" title="Warrant expiration date">February 1, 2027</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, we issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2mIJnw4q8ac" title="Stock issued">421,611</span> shares of our common stock through several fundraising efforts described below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ATM
    Offering</i> &#8211; On February 5, 2023, in connection with our Registered Direct Offering discussed below, we terminated our ATM
    and suspended the Sales Agreement with Oppenheimer &amp; Co. Inc., but we may reinstate it in the future. During the year ended December
    31, 2023, we sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zuwk64KHNYMl">28,483</span> shares at an average price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zkOJarHcptNi">24.40</span> per share for aggregate gross proceeds of $<span id="xdx_905_ecustom--GrossProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zyZXoLwWd1e5">693,000</span> (net proceeds of
    $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z2lC1V4B6tkb">672,000</span>) prior to deducting sales commissions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Lincoln
    Park Capital Fund, LLC Purchase Agreement</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;
    <span style="background-color: white">During the year ended December 31, 2023, we sold <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zEq7FyfcsIu7">2,500</span> shares at an average price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zLLNVV8bf3l2">21.60</span>
    per share for aggregate gross proceeds of $<span id="xdx_905_ecustom--GrossProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zBNg3idhBHae" title="Gross proceeds from issuance of common stock">54,000</span> under the purchase agreement with Lincoln Park.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Registered
    Direct Offering &#8211; </i>On February 14, 2023, we closed a registered direct offering (the &#8220;Offering&#8221;) for the sale
    of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230214__20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_z3CjSM9w2bwf">390,628</span> shares of common stock at a purchase price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zFwNYLv0iO3a" title="Share price">16.00</span> per share for gross proceeds of $<span id="xdx_900_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20230214__20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zL886pzNPTA5">6.3</span> million (net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230214__20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zqjtW0CVP5vj">5.6</span>
    million).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
paid <span style="background-color: white">Spartan</span> a cash fee of <span id="xdx_908_ecustom--TransactionCostsPercentage_iI_pid_dp_uPure_c20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zxnR4dQUflil" title="Cash fee percentage">8.0</span>%
of the gross proceeds from the Offering, excluding proceeds received from our insiders, and reimbursed Spartan for legal fees of
$<span id="xdx_908_ecustom--ReimbursementFees_c20230214__20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_z9LargEDUAmj" title="Reimbursement fees">60,000</span>.
The engagement agreement with Spartan required us to indemnify Spartan and certain of its affiliates against certain customary
liabilities. On February 14, 2023, we amended the consulting agreement with Spartan originally entered into on August 24, 2022,
extending the term of the consulting agreement until February 10, 2024. As compensation for services under the agreement, on April
17, 2023, we granted Spartan warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zpR7kli7VJG2" title="Warrants, granted">158,007</span>
shares of our common stock with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zij7yQ6U1vAd" title="Warrant exercise price">20.40</span>.
The warrants will expire <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zjGnp0U8w2Ah" title="Warrant expiration date">April
17, 2026</span> and contain both call and cashless exercise provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share of Common Stock</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zpRHUrmyAeo4" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
5 &#8211; <span id="xdx_829_z0X4jL8t1nvg">Net Loss per Share of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average common stock outstanding (which excludes unvested RSAs) and
vested, but unissued RSUs. Diluted net loss per share is computed by dividing net loss by the diluted weighted average common stock outstanding,
which includes potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants. The treasury-stock method is
used to determine the dilutive effect of our stock options and warrants grants. Since we experienced a loss for both periods presented,
basic and diluted net loss per share are the same and, as they would have an anti-dilutive impact on diluted net loss per share, any
dilutive common shares outstanding were excluded from the computation shown below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ztC0TQL72M1g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the year ended December 31, 2024 and 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zof6YcQ0I1Ng" style="display: none">Schedule of Net Loss Per Share Basic and Diluted</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20240101__20241231_zD7hGGrZtbYb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230101__20231231_ztCaIABrWzKc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net loss
    per share:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zvISSDNk0s4g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss available to common shareholders</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,850,118</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,121,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number
    of common shares-basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zAXRoHMtpuKi" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zDAcUSp6rggj" title="Weighted average number of common shares-diluted">3,059,906</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_znY8l3lNV6C6" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z3UrPgxgOuO6" title="Weighted average number of common shares-diluted">1,311,572</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net
    loss per share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20240101__20241231_z4x0DgFmBZeh" title="Basic net loss per share"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_z74TIldS6lO4" title="Diluted net loss per share">(3.87</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zdM1LxYB6f4f" title="Basic net loss per share"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zPdcntEirbpf" title="Diluted net loss per share">(8.48</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number of common
    shares outstanding &#8211; basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuNa5O8XU0qc" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgRRORPEjkj" title="Weighted average number of common shares outstanding - diluted">2,912,539</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8kcd3MpdFAd" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXt8aX7sTIPg" title="Weighted average number of common shares outstanding - diluted">1,186,952</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number
    of vested RSUs&#8211; basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_ziUYKHxO80j4" title="Weighted average number of vested RSUs - basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zOz4sF7jb7G2" title="Weighted average number of vested RSUs - diluted">147,367</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_ze1IAvsJxQFc" title="Weighted average number of vested RSUs - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0KpRQcUpNk6" title="Weighted average number of vested RSUs - diluted">124,619</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number
    of common shares-basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z6MJcpcwggpe" title="Weighted average number of common shares-basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_z4zDITZyKKw7" title="Weighted average number of common shares-diluted">3,059,906</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_z7dvCnzjGdPb" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z7pUlJLy7xZh" title="Weighted average number of common shares-diluted">1,311,572</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A0_zwOrTfoFSMsa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 3, we issued various equity instruments during the years ended December 31, 2024 and 2023 which impact our EPS calculation.
All granted RSAs are considered issued and outstanding for purposes of our financial statements. Unvested RSAs are included as dilutive
securities, but are excluded from our denominator of basic EPS. At December 31, 2023, <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9IbvdijZrsa" title="Shares unvested">1,250</span> RSAs were not vested and were excluded from
the EPS calculation. We had <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zZTn5E4vXSU6" title="Shares unvested">no</span> unvested RSAs at December 31, 2024. Vested RSUs are included in our computation of the weighted average
shares for basic EPS and unvested RSUs are included as dilutive securities. At December 31, 2024 and 2023, <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwIu6txRUIB" title="Shares unvested">234,623</span> and <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfXZPYv89od9" title="Shares unvested">102,623</span> unvested
RSUs were excluded from the EPS calculation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zplRa7HBS542" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outstanding stock options, unvested RSAs, unvested RSUs and warrants to purchase common stock were excluded from the computation of diluted
net loss per share as their effect would have been anti-dilutive for the periods presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zy0gGxkf4Eia" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20240101__20241231_zvgAKxGK8DF6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230101__20231231_zzInmJVIHRGe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zUIMPvmE7EHk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options, unvested RSAs, unvested
    RSUs and purchase warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,013,154</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">296,326</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_z2DUNhfCbqO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LesseeOperatingAndFinancingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_806_ecustom--LesseeOperatingAndFinancingLeasesTextBlock_zVi78KPqPmPa" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
6 &#8211; <span id="xdx_822_z6yTFOVp4tVf">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under an operating lease. Our leases do not provide an
implicit rate and, as such, we have used our incremental borrowing rate of <span id="xdx_90F_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20241231_zoMaAm0GSjjf" title="Operating and financing lease borrowing rate">8</span>% to determine the present value of the lease payments based
on the information available at the lease commencement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs included in our consolidated statements of operations totaled approximately $<span id="xdx_904_eus-gaap--LeaseCost_c20240101__20241231_zhbK1hb52Yla" title="Lease cost">90,000</span> and $<span id="xdx_908_eus-gaap--LeaseCost_c20230101__20231231_zf6Jn2Goq64f" title="Lease cost">97,000</span> for the years ended December 31,
2024 and 2023, respectively. The weighted average remaining lease terms and discount rate for our operating leases at December 31, 2024
were as follows:</span></p>

<p id="xdx_894_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_znFw21XxbQ15" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B1_zL8HvYp8x371" style="display: none">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year Ended <br/> December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Remaining lease term (years) for our office lease</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_902_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zqXsky4jypj3" title="Remaining lease term (years)">0.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_z4vZEn4XDTn6" title="Remaining lease term (years)">1.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Remaining lease term (years) for our equipment lease</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zOaMetDFtdX2" title="Remaining lease term (years)">1.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z5zJxd4m6F1" title="Remaining lease term (years)">0.3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted average discount rate for our facility and equipment leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20241231_zUB8zwPiP7Fa" title="Weighted average discount rate for our facility and equipment leases">8.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20231231_zmEmpJsdLcsi" title="Weighted average discount rate for our facility and equipment leases">8.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A7_zKBHHoeqTpSj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMRYa9vAdA78" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the operating lease were as follows at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zeWKMtOwI9Af" style="display: none">Schedule of Annual Lease Liabilities for all Operating Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_490_20241231_zoEmIJPyAWFk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_ztLma9CsyeDh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">70,040</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zOEtXm9V4krb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">70,040</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z0N10jlv7Ldg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    Interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zT0heS5JvJ2f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,905</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zEeJVhEdNdeh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zDKtp7BckTHa" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl1001">Less:
    current maturities</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(66,905</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zeAKPPrOxFMb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zB1x3vZ13zq8" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityNoncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1004">Non-current
    lease liability</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A4_zcyoHwCUbVO9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zNGtCiTI2OZ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the financing lease were as follows at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_z4ICQeLz6p74" style="display: none">Schedule of Annual Lease Liabilities for all Financing Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_499_20241231_zFfHPZTHX9f7" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_zu77aSb5E7l8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,821</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzELQ_zMeY740iJsda" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">571</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_zJgKN8wrwWR5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,392</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_z3WtNPt2hZId" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    Interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(790</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zThN1ikNiGwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,602</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zoEv3801EW8d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zC8VrVM0EHMa" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl1019">Less:
    current maturities</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,115</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zNmJYSo5KRoi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_z0jUbRXiOgnb" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityNoncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1022">Non-current
    lease liability</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">487</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A7_z8umzddRKmZ4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_LesseeOperatingAndFinancingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating And Financing Leases [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_LesseeOperatingAndFinancingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLicenseAgreementsAbstract', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LicenseAgreementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><p id="xdx_80C_ecustom--LicenseAgreementDisclosureTextBlock_zO0cQGBZrDZe" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
7 &#8211; <span id="xdx_824_zkDXlM5abXlf">License Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into license agreements which allow us to develop, manufacture, and/or commercialize the following drug assets:</span></p>

<p id="xdx_89E_ecustom--LicenseAgreementsTableTextBlock_zuW2fUIKpKUd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B0_zDFwIjQmexUg" style="display: none">Schedule of License Agreements</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Licensor</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Drug
    Asset</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Agreement
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amendment
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elion
    Oncology, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Cap
    (PCS6422)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--ElionOncologyIncMember_zZHD3RtVvUGb" title="Agreement Date">August
    23, 2020</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--LicenseAgreementsAmendmentDate_c20240101__20241231__dei--LegalEntityAxis__custom--ElionOncologyIncMember_zPgIpyDVHN07" title="Amendment Date">May
    17, 2022</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ocuphire
    Pharma, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Gem
    (PCS3117)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--OcuphirePharmaIncMember_zArfmSPmtob2" title="Agreement Date">June
    16, 2021</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aposense,
    Ltd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Iri
    (PCS11T)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--AposenseLtdMember_zbMYJ3AAwpm5" title="Agreement Date">May
    24, 2020</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuhan
    Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS12852</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--YuhanCorporationMember_zpBvzCkuV2y5" title="Agreement Date">August
    19, 2020</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CoNCERT
    Pharmaceuticals, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS499</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--CoNCERTPharmaceuticalsIncMember_znHExZHEkPXg" title="Agreement Date">March
    19, 2018</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  </table>
<p id="xdx_8AD_z0YMxZkksEed" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"> For more information, you should
refer to the summaries described in the Business section of this Annual Report and the copies of such agreements, which have been filed
as exhibits to this Annual Report.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zfZapyG0kJb9" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
8 - <span id="xdx_823_zuZlvlWoD9ah">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred net operating losses since inception. At December 31, 2024 and 2023, we had available federal and state net operating loss
carryforwards of $<span id="xdx_901_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20241231_zu2k74JD3bHc" title="Deferred tax assets, capital loss carryforwards">36.0</span> million and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20231231_zwPyrmTyV034" title="Deferred tax assets, capital loss carryforwards">28.6</span> million, respectively. The federal net operating losses generated in 2018 and later of $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--TaxCreditCarryforwardAxis__custom--FederalMember_zbExmqLhP4wl" title="Net operating loss carryforwards">29.3</span>
million will carry forward indefinitely. Net operating losses generated prior to 2018 will expire <span id="xdx_907_ecustom--NetOperatingLossCarryforwardExpiryDate_c20240101__20241231_zXojIORC0Ovh" title="Net operating loss carryforward, expiration date">2037</span>. We have not recognized any deferred
tax assets related to the federal orphan drug or other research and development tax credits as of December 31, 2024 or 2023. The federal
research and development tax credits have a <span id="xdx_902_ecustom--NetOperatingLossCarryforwardTerm_dtY_c20240101__20241231_zurUtY1C19Lj" title="Net operating loss carryforward term">20</span>-year carryforward period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231_z8IRnB35ZVC" title="Income tax examination description">Pursuant
to Code Sec. 382 of the Internal Revenue Code (&#8220;the Code&#8221;), the utilization of our net operating loss carryforwards could
be limited as a result of a cumulative change in stock ownership of more than 50% over a three-year period. We have not completed a Sec.
382 study and as such our net operating loss carryforwards may be subject to such limitation.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwt2GrubCQIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of our effective income tax rate and statutory income tax rate for the years ended December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zJABXTlKqHO4" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zwtvD2OueJRd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20230101__20231231_zdLvUfSOZch4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_zfEZgCXxUCD6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Federal statutory income tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zAbAVBiqBEr3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State tax rate, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.58</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.77</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential_pid_dp_uPure_maEIT001_zJzhlselhuj4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.04</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msEIT001_z8lFLos2qbXc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Federal orphan drug tax credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.41</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zqt7BJVx8Hgf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Deferred tax asset valuation
    allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27.93</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zcOl9omLdlP7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Effective income tax
    rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p id="xdx_8A2_zjJJH1oc9f4f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zwQXe0HxRsVg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant components of our deferred tax assets and liabilities for Federal and state income taxes consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 21.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zw9z2aDyk6Sa" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20241231_zSzN8iRkrpXl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20231231_zn2bWa0RGskl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Non-current:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_maDTAGzhSD_zTh70Z6GDAH5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net operating
    loss carry forward &#8211; Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,566,071</span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,012,941</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_maDTAGzhSD_zW9YDjrfqMK5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carry
    forward &#8211; State</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,074,542&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,672,436</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzhSD_z4FqIL4VIpR6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,794,226</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,453,799</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzhSD_z7fRjgnCxBQf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation and other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">238</span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">999</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected_iI_maDTAGzhSD_zGfvk5GSnpIk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Purchased in-process R&amp;D</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,477,193&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,500,562</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsFederalOrphanDrugCredits_iI_maDTAGzhSD_zSfvfuU57t0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal orphan drug credits</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,209,202&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,202,955</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_iI_maDTAGzhSD_zbtbcRxTIGUd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Capitalized research and
    development costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,781,193&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,795,379</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsStartupExpenditures_iI_maDTAGzhSD_z0OVEdAjESwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Start-up
    expenditures and amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzhSD_maDTANzhKZ_zwKhCno95VK8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total non-current deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,902,665&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,639,071</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzhKZ_zuiwq3AZK1pd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance for
    deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(19,902,665</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(17,639,071</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzhKZ_msDTLznZn_zUpYY4GNVbXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1106">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred Tax Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Non-current:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzSHY_zWFnpWlHTZu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Intangible
    asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzSHY_maDTLznZn_z3jxlwImi8rj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total non-current deferred
    tax liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLznZn_zwMFvmmOLge9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax asset
    (liability)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AC_zTuvhC4Qy5Dk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in 2022, the Tax Cuts and Jobs Act of 2017 (TCJA) eliminated the option to deduct research and development expenditures in the current
year and requires taxpayers to amortize them over five or fifteen years pursuant to IRC Section 174. During 2024 and 2023, for income
tax purposes, we capitalized approximately $<span id="xdx_907_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization_iI_pn5n6_c20241231_z5GYIHJbIjb" title="Capitalized research and development net of amortization">3.8</span> million and $<span id="xdx_901_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization_iI_pn5n6_c20231231_zBoS4puIgsih" title="Capitalized research and development net of amortization">3.2</span> million of research and development expenditures, net of amortization
of these costs in each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation allowance generally reflects limitations on our ability to use the tax attributes and reduces the value of such attributes
to the more-likely-than-not realizable amount. We assessed the available positive and negative evidence to estimate if sufficient taxable
income will be generated to use the existing net deferred tax assets. Based on a weighing of the objectively verifiable negative evidence
primarily in the form of cumulative operating losses, we believe that it is not more-likely-than-not that the deferred tax assets will
be realized and, accordingly, a full valuation allowance has been established. The valuation allowance increased by $<span id="xdx_906_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zYtD407Q6euc" title="Valuation allowance deferred tax asset">2.3</span> million
and $<span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231_z7KaIjxstrdg" title="Valuation allowance deferred tax asset">3.1</span> million for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize potential liabilities for uncertain tax positions using a two-step process. The first step is to evaluate the tax position
for recognition by determining if the weight of available evidence indicates that it is more-likely-than-not that the position will be
sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit
as the largest amount that is more than 50% likely to be realized upon settlement. We have not recorded any uncertain tax positions.
As of December 31, 2024 and 2023, we had <span id="xdx_903_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20240101__20241231_zwcpn4NhdAR3" title="Penalties and interest expense"><span id="xdx_904_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20230101__20231231_zbE4XGrJwUE1" title="Penalties and interest expense">no</span></span> accrued penalties or interest related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file U.S. Federal income tax returns, as well as state tax returns for California, Florida and Maryland. There are currently no income
tax examinations underway for these jurisdictions. However, tax years from and including 2017 remain open for examination by federal
and state income tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zGbXBtfiGVWe" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
9 &#8211; <span id="xdx_820_zZjW4RWdDjyj">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CorLyst,
LLC (&#8220;CorLyst&#8221;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred,
which are recognized as a reduction of our general and administrative operating expenses in our consolidated statements of operations.
We recorded approximately $<span id="xdx_908_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20240101__20241231__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_z3AV2FCnoFU6" title="Rent and other costs reimbursements received">110,000</span> and $<span id="xdx_90C_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zxuogKjgmsUi" title="Rent and other costs reimbursements received">112,000</span> in reimbursements during the years ended December 31, 2024 and 2023, respectively. At
December 31, 2024, $<span id="xdx_902_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20241231__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_z5wEpLThZvYk" title="Due from related parties">47</span> was due from CorLyst and <span id="xdx_909_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zJuxQlB8JlEl" title="Due from related parties">no</span> amounts were due at December 31, 2023. Our President, Research and Development is
the CEO of CorLyst, and CorLyst is a shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLitigationAbstract', window );"><strong>Litigation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LitigationDisclosureTextBlock', window );">Litigation</a></td>
<td class="text"><p id="xdx_80E_ecustom--LitigationDisclosureTextBlock_zlbGTNK0EM71" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-style: normal"><b>Note 10
&#8211; <span id="xdx_82E_zfQbsmeXJKJf">Litigation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white">On
May 7, 2024, the Company received notification from Elion purporting to terminate the license agreement by and between the Company and
Elion as a result of the Company&#8217;s alleged breach thereof. The Company believes that Elion&#8217;s claims are without merit and
disputes that the license agreement has been validly terminated. On July 5, 2024, the Company filed a complaint in New York State Court
seeking monetary damages, declaratory judgement and injunctive relief. On August 14, 2024, the Company received Elion&#8217;s answer and
counterclaims. On October 10, 2024, the Company filed its response to Elion&#8217;s counterclaims. The Company intends to enforce its
rights under the license agreement and will pursue such other remedies as it determines are appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white">On
December 3, 2024, Jason Assad and Marc Gyimesi, two of the investors in our February 2021 private offering, filed a lawsuit in New York
County Court alleging fraud and negligent misrepresentation in connection therewith and seeking monetary damages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white">We
intend to vigorously defend ourselves in these lawsuits and cannot at this time predict the likely outcome of any litigation, reasonably
determine either the probability of a material adverse result or any estimated range of potential exposure, or reasonably determine how
these matters or any future matters might impact our business, our financial condition, or our results of operations, although such impact,
including the costs of defense, as well as any judgments or indemnification obligations, among other things, could be materially adverse
to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLitigationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLitigationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_LitigationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation [Disclosure Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_LitigationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_z3Ver1nv0cti" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 11 &#8211;
<span id="xdx_826_zJcrXtO9w3ab">Segment Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt">We
manage our operations as a single segment, focused on developing the next generation of cancer therapy drugs. As our CODM, our CEO manages
and allocates resources at a consolidated level. He assesses performance, monitors budget versus actual results, and decides how to allocate
resources based on net loss that also is reported on the consolidated statement of operations and comprehensive loss as consolidated net
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt">The
accounting policies of our single operating segment are the same as those described in the summary of significant accounting policies
in Note 2. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. In 2024 and 2023,
all our long-lived assets were held in the United States. Expenditures for the addition of long-lived assets are reported on the consolidated
statements of cash flows as purchases of property and equipment. We do not have intra-entity sales or transfers since our only subsidiary
is currently dormant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p id="xdx_89B_eus-gaap--ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_z25iEhybPU2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt">The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B0_zLIfRicpOYJb" style="display: none; font-family: Times New Roman, Times, Serif">Schedule
of Reportable Segment Profit and Loss, Including Significant Expense Categories</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zAnLjiL2NMwc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_z5DpZyRfuHSf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PreclinicalClinicalTrialAndOtherCosts_msNILzaqM_zJgImA2CqUx9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify">Preclinical, clinical trial and other costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">5,450,963</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,817,669</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_ze2sg5BHQyE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development personnel expense<sup id="xdx_F45_zI38usS3yZ05" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,818,183</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,981,849</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_msNILzaqM_zAxhz0moFkLb" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expense<span><sup></sup></span></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_z6WgPoxEZaN4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative personnel expense<sup id="xdx_F45_zgShVznxBUTa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,981,756</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,737,792</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_msNILzaqM_zh7jxUMLZp61" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expense<sup style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AdministrativeAndFacilitiesExpense_msNILzaqM_zAhzTBc9TFVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative and facilities expense<sup id="xdx_F4F_zwJTbuSjIAc2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,800,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,919,751</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InvestmentIncomeInterest_iN_di_maNILzaqM_zCkaNoOQbq32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Interest income, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(201,088</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(335,541</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtNILzaqM_zahXuwdY0E32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">11,850,118</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">11,121,520</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><sup id="xdx_F0B_zmU81x7sUVcd">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zPsqjYqgI5r5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Research
and development personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqBDe7kz9TZ2" title="Research and development personnel costs include employee stock-based compensation expense">169,414</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zZEE1TTtC5Ja" title="Research and development personnel costs include employee stock-based compensation expense">363,956</span> for the year ended December
31, 2024, and 2023, respectively.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><sup id="xdx_F07_zP9lRgsLHKZj">(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zJFW1grtFjYh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">General
and administrative personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_zCX8mmnoY3n6" title="General and administrative personnel costs include employee stock-based compensation expense">186,925</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_z490ruzWdrCi" title="General and administrative personnel costs include employee stock-based compensation expense">387,854</span> for the year ended December
31, 2024, and 2023, respectively, and are net of reimbursements received from CorLyst, LLC.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><sup id="xdx_F09_zEzn2b7zhIq6">(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zcOiJ6oVqRI7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Administrative
&amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and
other administrative costs.</span></td>
</tr></table>

<p id="xdx_8A8_zfSCKHyaa56f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zbNWT4PynzGb" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
12 &#8211; <span id="xdx_82B_z0d6S1detV75">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Purchase
Obligations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter contracts in the normal course of business with contract research organizations and subcontractors to further develop our products.
The contracts are cancellable, with varying provisions regarding termination. If we terminated a cancellable contract with a specific
vendor, we would only be obligated for products or services that we received as of the effective date of the termination and any applicable
cancellation fees. As of December 31, 2024, we are contractually obligated to pay up to approximately $<span id="xdx_90B_eus-gaap--PurchaseObligation_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--CROsMember_zuJLWgOG4oZ" title="Purchase obligation">12.2</span> million for future services
under the agreements with the CROs for our clinical trials in NGC-Cap. Our actual contractual obligations will also vary depending on
the progress and results of the remaining clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of Credit Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_805_eus-gaap--ConcentrationRiskDisclosureTextBlock_zrg4QKCv4zNh" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
13 &#8211; <span id="xdx_822_z5VupWP4iq48">Concentration of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at December 31, 2024, exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_z3L1q01Inzg8" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note
14 &#8211; <span id="xdx_82D_zqr7bkDBZ4j1">Subsequent Events</span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i><span style="text-decoration: underline">Public Offering</span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 27, 2025, we sold, pursuant to securities purchase agreements (the &#8220;Purchase Agreement&#8221;), <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zemSGCgLLC41" title="Number of shares, sold">1,030,972</span> shares of our
common stock and accompanying Series A warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z7esswsEqYbb" title="Warrants to purchase">8,050,672</span> shares of our common stock (the &#8220;Series A Warrants&#8221;)
and Series B warrants to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjdkB6fQqNg2" title="Warrants to purchase">4,025,336</span> shares of our common stock (the &#8220;Series B Warrants&#8221; and collectively with
the Series A Warrants, the &#8220;Common Warrants&#8221;) at a combined purchase price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zHff3iUiYJh3" title="Warrant exercise price">0.615</span> for institutional investors and $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndCertainBoardMembersMember_zEnldQHctb9d" title="Warrant exercise price">0.7975</span>
for the Company&#8217;s Chief Executive Officer and certain board members. The Series A and Series B Warrants both have an exercise price
of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAAndBMember_zSMNu24czw91" title="Warrant exercise price">0.65</span> per share of common stock, and will be exercisable beginning on the effective date of stockholder approval of the issuance of
the shares upon exercise of the warrants (&#8220;Warrant Stockholder Approval&#8221;). The Series A Warrants will expire on the <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zTeIE5PAYmcd" title="Warrants, exercisable term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1201">five</span></span>-year
anniversary date of stockholder approval and the Series B Warrants will expire on the eighteen-month anniversary date of stockholder
approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also sold pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zY046aFfT4Y2" title="Warrants to purchase">7,019,700</span>
shares of our common stock to a purchaser whose purchase of shares of common stock in the public offering would have resulted in the
purchaser beneficially owning more than <span id="xdx_90D_ecustom--OutstandingSharesPercentage_pid_dp_uPure_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zDaE3QiKW3O6" title="Outstanding shares percentage, maximum">9.99</span>%
of our outstanding common stock immediately following the consummation of the public offering. Each Pre-Funded Warrant is
exercisable for one share of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zK19Kj8JuNu" title="Warrant exercise price">0.0001</span>
per share of common stock. The public offering price per Pre-Funded Warrant, is equal to the public offering price per share and
Common Warrants less $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEyldy0iO96a" title="Warrant exercise price">0.0001</span>.
Each Pre-Funded Warrant will be exercisable upon issuance and will expire when exercised in full. On January 30, 2025, Pre-Funded
Warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zFkI624LWxrb" title="Warrants to purchase">525,700</span>
shares of our common stock were exercised and, as of March 12, 2025, Pre-Funded Warrants for the purchase of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250312__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zox4kV6cRIS6" title="Warrants outstanding">6,494,000</span> remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
proceeds in connection with this offering were $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_za3Ru8kSC2i8" title="Gross proceeds">5.0</span> million and we received $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMkAYfauTM7e" title="Net proceeds">4.5</span> million in net proceeds from the offering, after deducting
the fees of the placement agent and other offering-related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Amended
and Restated Bylaws</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2025, the Board of Directors (the &#8220;Board&#8221;) of the Company adopted the Amended and Restated Bylaws (as
amended, the &#8220;Bylaws&#8221;). The Bylaws, which became effective immediately, amended Section 2.4 to change the quorum requirements
for a stockholders meeting to be the holders of shares of outstanding capital stock of the Company representing one third (1/3) of the
voting power of all outstanding shares of capital stock of the Company except if business is to be voted on by a class or series of stock
voting as a class, then the holders of shares representing one third (1/3) of the voting power of the outstanding shares of such class
or series shall constitute a quorum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Executive
Employment Agreements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">On March 19, 2025, we entered into new or amended employment agreements with all members of our executive team
that continue until terminated or modified pursuant to the terms of the employment agreements. The agreements establish their base salaries,
target bonuses, eligibility to participate in our 2019 Omnibus Incentive Plan, and severance benefits, among other things.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJwbA0ZS79Z8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zfmt3sv6MuK6">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange
Commission (the &#8220;SEC&#8221;), and reflect all of our activities, including those of our wholly-owned subsidiary. All material intercompany
accounts and transactions have been eliminated in consolidation. Operating results for the year ended December 31, 2024 are not necessarily
indicative of future results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_zvfbiAHSVea5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_z6qoGM74IBTa">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and regulations
of the SEC, we make estimates and judgments that affect the amounts reported in the consolidated financial statements and accompanying
notes. Estimates are used for, but not limited to stock-based compensation, intangible assets, future milestone payments and income taxes.
These estimates and assumptions are continuously evaluated and are based on management&#8217;s experience and knowledge of the relevant
facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates
and could impact future results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zKoo1C6jtf03" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z3lz7d9cpfM4">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash on hand and money market funds. We consider all highly liquid investments maturing within three months
from the date of purchase as cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_PrepaidExpensesPolicyTextBlock', window );">Prepaid Expenses</a></td>
<td class="text"><p id="xdx_849_ecustom--PrepaidExpensesPolicyTextBlock_z3qevoN2fMUi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zVQDTR4r1B4k">Prepaid
Expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments made to third parties under
these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.
The majority of our prepaid expenses relate to advanced payments made to CROs and other vendors for our ongoing clinical trials. We allocate
the prepaid expenses between current and non-current assets based on the anticipated timing of utilizing the advances. At December 31,
2024, we determined that $<span id="xdx_90E_eus-gaap--PrepaidExpenseNoncurrent_iIP1custom--AccountingPoliciesLineItemsAbstract_pn5n6_c20241231_zE498icFARu7" title="Prepaid expense">1.3</span> million would not be applied until after December 31, 2025.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zS4wfLdYwof4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zvh4Vi9h7wea">Property
and Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
is stated at cost, less accumulated depreciation. Costs of renewals and improvements that extend the useful lives of the assets are capitalized.
Expenditures for maintenance and routine repairs are charged to expense as incurred. Depreciation is recognized on a straight-line basis
over the estimated useful lives of the assets, which generally range from <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iIP1us-gaap--PropertyPlantAndEquipmentLineItems_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_zoCtbnHRkXe8" title="Estimated useful lives of property plant and equipment">3</span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iIP1us-gaap--PropertyPlantAndEquipmentLineItems_dtY_c20241231__srt--RangeAxis__srt--MaximumMember_zLZpDmG39177" title="Estimated useful lives of property and equipment">5</span> years. We amortize leasehold improvements over the shorter
of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related
accumulated depreciation are removed from the accounts with the resulting net gain or loss, if any, reflected in the consolidated statement
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets and Intangibles Other Than Goodwill</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z1prFuGxIT3c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zkoqXS1iLQ5g">Impairment
of Long-Lived Assets and Intangibles Other Than Goodwill</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for the impairment of long-lived assets in accordance with ASC 360<i>, Property, Plant and Equipment</i> and ASC 350, <i>Intangibles
&#8211; Goodwill and Other,</i> which require that long-lived assets and certain identifiable intangibles be reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to its expected future undiscounted net cash flows
generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which
the carrying amounts of the assets exceed the fair value of the assets based on the present value of the expected future cash flows associated
with the use of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements and Disclosure</a></td>
<td class="text"><p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbm5AT6BEZh4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zL2TdenAtji6">Fair
Value Measurements and Disclosure</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
apply ASC 820, <i>Fair Value Measurements and Disclosures</i>, which expands disclosures for assets and liabilities that are measured
and reported at fair value on a recurring basis. Fair value is defined as an exit price, representing the amount that would be received
upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or
liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; Quoted market prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access
at the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; Quoted market prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or
liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Fair value determined
using models or other valuation methodologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; Significant unobservable inputs for assets or liabilities that cannot be corroborated by market data. Fair value is determined
by the reporting entity&#8217;s own assumptions utilizing the best information available and includes situations where there is little
market activity for the asset or liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
asset&#8217;s or liability&#8217;s fair value measurement within the fair value hierarchy is based upon the lowest level of any input
that is significant to the fair value measurement. Our policy is to recognize transfers between levels of the fair value hierarchy in
the period the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 1, 2, or 3 during
the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSwxTtKBlKua" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zDdSubbyF0yf">Stock-based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
measure compensation expense for stock options and other stock awards in accordance with ASC 718, <i>Compensation&#8212;Stock Compensation</i>.
Stock-based compensation is measured at fair value on grant date and recognized as compensation expense over the requisite service period.
Generally, we issue stock options and other stock awards with service-based and/or performance-based vesting conditions. For awards with
only service-based vesting conditions, we record compensation cost for these awards using the straight-line method over the service period.
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For awards that contain performance vesting conditions,
we do not recognize compensation expense until achieving the performance condition is probable. We estimate the fair value of stock option
and warrant grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based
awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.
We value restricted stock awards (RSAs) and restricted stock units (RSUs) based on the closing share price of our common stock on the
date of grant. Stock-based compensation costs are recorded as general and administrative or research and development costs in the statements
of operations based upon the underlying individual&#8217;s or entity&#8217;s role.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
of fair value are not intended to predict actual future events or the value ultimately realized by employees or consultants who receive
these awards, and subsequent events are not indicative of the reasonableness of our original estimates of fair value. We account for
forfeitures in the period in which they occur, rather than estimate expected forfeitures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z4qzW1m203ec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zsAvmqMEF221">Net
Loss Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average common stock outstanding (which excludes unvested RSAs) and
vested, but unissued RSUs. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted
weighted average number of shares of common stock outstanding during the period. Since we have experienced a net loss for all periods
presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the years ended December 31, 2024 and
2023 excludes the impact of potentially dilutive common shares related to outstanding stock options, unvested restricted stock awards
(RSAs), unvested RSUs and common stock purchase warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
diluted net loss per share for the years ended December 31, 2024 and 2023 excluded <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_iP1custom--AccountingPoliciesLineItemsAbstract_pid_c20240101__20241231_zjF4WhW5Lk6k" title="Antidilutive securities excluded from computation of earnings per share">2,013,154</span> and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_iP1custom--AccountingPoliciesLineItemsAbstract_pid_c20230101__20231231_zlt27ixgXgc1" title="Antidilutive securities excluded from computation of earnings per share">296,326</span> of potentially dilutive common
shares, respectively, related to outstanding stock options, unvested RSAs, unvested RSUs and warrants since those shares would have had
an anti-dilutive effect on loss per share during the years then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_znxOJ7ZTbKK4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_z342kDdpre2c">Segments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">We have one reportable segment, which is focused on discovering and developing a pipeline of Next Generation Cancer
therapy drugs. Our Chief Executive Officer, who is the chief operating decision maker (CODM), assesses segment performance and decides
how to allocate resources based on net loss that is also reported on the Consolidated Statements of Operations and Comprehensive Loss.
See Note 11 for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zNouNC8tTmg4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zjEuC6PXltOe">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, accounts receivable and accounts payable approximate their fair value because of the short-term
maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zW9LuNaeVIn9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zjxmExykSpx6">Research
and Development</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred and consist of direct and overhead-related expenses related primarily to clinical trials,
including development personnel salaries and related costs. Expenditures to acquire technologies, including licenses, which are utilized
in research and development and that have no alternative future use are expensed as the acquisition of in-process research and development
when incurred. Technology we develop for use in our products is expensed as incurred until technological feasibility has been established
after which it is capitalized and depreciated. No research and development costs were capitalized during the years ended December 31,
2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zHxivy8XX6Ub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zqu3ysScCQ1a">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. As of December 31, 2024 and 2023, we recorded a valuation allowance equal to the full recorded amount of our
net deferred tax assets since it is more-likely-than-not that benefits from our deferred tax assets will not be realized. The valuation
allowance is reviewed quarterly and is maintained until sufficient positive evidence exists to support its reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing
authority, based on the technical merits of the position. Our policy is to record interest and penalties related to income taxes as part
of its income tax provision. As of December 31, 2024, we had <span id="xdx_903_eus-gaap--UnrecognizedTaxBenefits_iIP1custom--AccountingPoliciesLineItemsAbstract_do_c20241231_zkuwbJhRSg02" title="Unrecognized tax benefits">no</span> unrecognized tax benefits and as such, no liability, interest or penalties
were required to be recorded. We do not expect this to change significantly in the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_RecentAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standard</a></td>
<td class="text"><p id="xdx_849_ecustom--RecentAccountingPronouncementsPolicyPolicyTextBlock_zHPKtuk6v6Vb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i><span id="xdx_861_zB4GDa2ri0Oe">Recently Adopted Accounting Standard</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">In November 2023, the FASB issued ASU 2023-07 &#8211; Segment Reporting (Topic 280) &#8211; Improvements to Reportable
Segment Disclosures, which improves segment disclosure requirements, primarily through enhanced disclosure requirements for significant
segment expenses. The improved disclosure requirements apply to all public entities that are required to report segment information, including
those with only one reportable segment. We adopted this standard effective for the year ending December 31, 2024 and the primary impact
of which was the additional segment disclosures included in Note 11.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z51Qe2P6ysXl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_ztahQYnCPzBa">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our financial statements. We have <span style="background-color: white">considered
all recent accounting pronouncements issued since the last audit of our consolidated financial statements. We believe that these recent
pronouncements will not have a material effect on our consolidated financial statements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide
enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and
for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption
is permitted. We are evaluating this standard to determine if adoption will have a material impact on our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense
Disaggregation Disclosures (Subtopic 220-40), which requires disclosure, in the notes to the financial statements, of specified information
about certain costs and expenses. This ASU is effective for public entities for annual reporting periods beginning after December 15,
2026 and interim reporting periods beginning after December 15, 2027. We are currently evaluating the impact ASU 2024-03 will have on
our consolidated financial statements.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_PrepaidExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_PrepaidExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_RecentAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_RecentAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zlEUr9SVxlF" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the years ended December 31, 2024 and 2023 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B0_zOokHVYXHBB1" style="display: none">Schedule of Stock-based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20240101__20241231_zVJKGeD5iRTc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zScrTcXsxnQj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended <br/> December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXsVE2UNk0g1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">169,414</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">363,956</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z42I0Er24F7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">460,100</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,007,258</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_zZPgq9e56vU3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">629,514</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,371,214</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Warrant Valuation Assumption</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z187qcKGfGgk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
used the Black-Scholes option pricing model to calculate the grant date fair value of the two warrants granted in 2023 with the following
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zpzqMzlWJHif" style="display: none">Schedule
of Warrant Valuation Assumption</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Average risk-free rate of interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zFFa3YACrxN8" title="Warrants, measurement input">4.32</span>-<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zAKeD9yxN461" title="Warrants, measurement input">4.88</span>
                                            </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_z3cdHYYbNIi7" title="Expected term (years)">2.00</span>&#8211;<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zCgxZ3Mye4Wf" title="Expected term (years)">3.00</span>
                                            &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected stock price volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zvN0Na7wW7ph" title="Warrants, measurement input">82.85</span>-<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zpitNuAAUAad" title="Warrants, measurement input">108.47</span>
                                            </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zk12iZhMWC1a" title="Warrants, measurement input">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrAcclmb4UH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes our stock option activity during the years ended December 31, 2023 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_ziFTZbmuS8H9" style="display: none">Schedule
of Stock Option Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total
    options Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual life<br/>
    (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zrGZbbB4faIi" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">8,943</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zHUwAVbHUVUf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif">341.34</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_z9DN332ZIQxb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited
    or expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231_zAtzSQrUPqk6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, forfeited"><span style="font-family: Times New Roman, Times, Serif">(1,951</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zrbtHTTNqPji" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif">257.28</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTzQJ6MkYlG7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">6,992</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zhFKS0JEgZLf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif">364.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zbh8yDbnm0oi" title="Weighted average remaining contractual term, ending">2.1</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_zPTWYcH5toE3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0603">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited
    or expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231_zrTTPNrvRx55" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, forfeited or expired"><span style="font-family: Times New Roman, Times, Serif">(4,245</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zAqysptNg5W2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price,  forfeited or expired"><span style="font-family: Times New Roman, Times, Serif">336.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding and exercisable as of December
    31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zdrJ9top9x8i" title="Options outstanding, ending balance"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zTTIIMLMS9I6" title="Options exercisable, ending balance">2,747</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z2FPO341OJ92" title="Weighted average exercise price, ending balance"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zF0kKGejBLoh" title="Weighted average exercise price, exercisable">409.09</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zLQxr5HEKPZb" title="Weighted average remaining contractual term, outstanding"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zCMdEWqF3l1d" title="Weighted average remaining contractual term, exercisable">3.7</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_RestrictedStockAwardMember', window );">Restricted Award [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zTUUuDHmtpX6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes our restricted stock award (RSA) activity during the years ended December 31, 2023 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_z1gVx5R7HU79" style="display: none">Schedule
of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted-
    <br/> average <br/> grant-date fair <br/> value per share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Unvested as of January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zHpjhP2ZJb" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of restricted stock, shares outstanding"><span style="font-family: Times New Roman, Times, Serif">3,095</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zvDtXH6wKy01" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">94.44</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zBUNAWaUSTS2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"><span style="font-family: Times New Roman, Times, Serif">10,750</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zDiKjrXzSbK6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"><span style="font-family: Times New Roman, Times, Serif">14.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zG6Gh8y9hnE4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif">(1,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zcvkQywoHq93" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"><span style="font-family: Times New Roman, Times, Serif">133.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zYiyJ9hVSuic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, cancelled"><span style="font-family: Times New Roman, Times, Serif">(2,555</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zn1xW8o7KVYi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, cancelled"><span style="font-family: Times New Roman, Times, Serif">22.13</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vested and issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zj6DtCTV8uv6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and issued"><span style="font-family: Times New Roman, Times, Serif">(8,790</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zfzhoPcljnXc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and issued"><span style="font-family: Times New Roman, Times, Serif">24.44</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Unvested as of December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zjcDEBXwowyi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zilrWwqCxmWd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">9.26</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zideJL0eB3J5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zgIOp8FB0jg8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0657">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z5n5dSliOvqj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zR5gOnMVpmud" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0661">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zWpr9dJBfmAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0663">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z2C3Qvxl48o" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0665">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vested and issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z6eoJ079nVs4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and issued"><span style="font-family: Times New Roman, Times, Serif">(1,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zPK10SK2ydB3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and issued"><span style="font-family: Times New Roman, Times, Serif">9.26</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested as of December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z9tt9Iq8ImZd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zUXL4psXllCc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, outstanding"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0673">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zy3iLyAGdEYe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes our restricted stock unit (RSU) activity during the years ended December 31, 2023 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zaOCKzHQqr42" style="display: none">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted-
    <br/> average <br/> grant-date fair <br/> value per share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUh97PPNY936" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of shares, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">135,741</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4hMt2jDQga" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">73.81</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8lbwStdwJo8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"><span style="font-family: Times New Roman, Times, Serif">116,078</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOodBTN4AX85" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"><span style="font-family: Times New Roman, Times, Serif">14.18</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOHHyEcHKati" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif">(12,296</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaCdhNLohGXa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"><span style="font-family: Times New Roman, Times, Serif">21.69</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFzyblqRBRmi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, cancelled"><span style="font-family: Times New Roman, Times, Serif">(16,801</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyeq0B0XBxQj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, cancelled"><span style="font-family: Times New Roman, Times, Serif">71.36</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTxaoyJSVlec" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, issued"><span style="font-family: Times New Roman, Times, Serif">(17,093</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbUE9VovGPXc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, issued"><span style="font-family: Times New Roman, Times, Serif">110.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLGvR1SLePC5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">222,722</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0KgHqINrAj7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">45.82</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1x1hbnWfSC6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"><span style="font-family: Times New Roman, Times, Serif">192,026</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwSYF57PFWD1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"><span style="font-family: Times New Roman, Times, Serif">1.63</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdl41hLqzvnf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif">(14,019</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZoGrtkvNO1k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"><span style="font-family: Times New Roman, Times, Serif">71.68</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTA62TKWj5ah" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, issued"><span style="font-family: Times New Roman, Times, Serif">(17,093</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zf2oPqvFDvKc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, issued"><span style="font-family: Times New Roman, Times, Serif">110.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbNZUhfAXpS6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, ending balance"><span style="font-family: Times New Roman, Times, Serif">383,636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBIYi8aRsFZ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, ending balance"><span style="font-family: Times New Roman, Times, Serif">19.87</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vested and unissued</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdSXGwQWf9Nl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and unissued"><span style="font-family: Times New Roman, Times, Serif">(149,013</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaTLvyHdpMG1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"><span style="font-family: Times New Roman, Times, Serif">43.10</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB626M0FokK2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, unvested"><span style="font-family: Times New Roman, Times, Serif">234,623</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJVlZu6FfKQi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, unvested"><span style="font-family: Times New Roman, Times, Serif">5.11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ScheduleOfWarrantValuationAssumptionTableTextBlock', window );">Schedule of Warrants Activity</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfWarrantValuationAssumptionTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2Jl7pxRbsei" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes our warrant activity during the years ended December 31, 2023 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zRzQRMec8UTj" style="display: none">Schedule of Warrants Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total
    warrants outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual<br/>
    life (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGqRSYw9p3yb" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrants outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">14,283</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGJURedJKvch" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif">205.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCsQTmCVI6l7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, granted"><span style="font-family: Times New Roman, Times, Serif">173,007</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeIqhRO1dMv2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">19.27</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9NrC0pskkui" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, expired or cancelled"><span style="font-family: Times New Roman, Times, Serif">(6,783</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zC2GvJUrZnQd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, expired"><span style="font-family: Times New Roman, Times, Serif">266.96</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt">Not exercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zurrmhM9Fjgc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Not exercisable">(7,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNHnrmsmBqAf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, not exercisable">7.40</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zB77ppbgMXah" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, exercisable">7,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zb45yKNXNDXf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable">7.40</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding and exercisable as of December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpjNwCfzuASi" title="Warrants outstanding, beginning balance"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5tzx0izZMgl" title="Warrants, exercisable">173,007</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDVSyUcHtNr7" title="Weighted average exercise price, beginning balance">25.41</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zF7XqKZb5Bze" title="Weighted average remaining contractual term, ending"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zX4BhSkIDDK4" title="Weighted average remaining contractual term, exercisable">2.2</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6gNJTXjpyLh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, exercisable">7,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPQuxIhoW21f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable">7.40</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zHIALzkmJBX9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, granted"><span style="font-family: Times New Roman, Times, Serif">1,617,777</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWA7T7CXdLr1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">4.54</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Expired
    or cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4ai87IdmVWh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, expired or cancelled"><span style="font-family: Times New Roman, Times, Serif">(22,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYaY4v1ZICFj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, expired or cancelled"><span style="font-family: Times New Roman, Times, Serif">54.62</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding and exercisable as of December
    31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRvIcHK539f" title="Warrants outstanding, ending balance"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4jhRbRLuT55" title="Warrants, exercisable">1,775,784</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7rJNa6M9UAf" title="Weighted average exercise price, ending balance"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDndxQAR2JKj" title="Weighted average exercise price, exercisable">5.95</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGVC8ehhNS78" title="Weighted average remaining contractual term, outstanding"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zuS1NksCppE1" title="Weighted average remaining contractual term, exercisable">3.8</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ScheduleOfWarrantValuationAssumptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ScheduleOfWarrantValuationAssumptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_RestrictedStockAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_RestrictedStockAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Basic and Diluted</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ztC0TQL72M1g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the year ended December 31, 2024 and 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zof6YcQ0I1Ng" style="display: none">Schedule of Net Loss Per Share Basic and Diluted</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20240101__20241231_zD7hGGrZtbYb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230101__20231231_ztCaIABrWzKc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net loss
    per share:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zvISSDNk0s4g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss available to common shareholders</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,850,118</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,121,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number
    of common shares-basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zAXRoHMtpuKi" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zDAcUSp6rggj" title="Weighted average number of common shares-diluted">3,059,906</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_znY8l3lNV6C6" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z3UrPgxgOuO6" title="Weighted average number of common shares-diluted">1,311,572</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net
    loss per share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20240101__20241231_z4x0DgFmBZeh" title="Basic net loss per share"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_z74TIldS6lO4" title="Diluted net loss per share">(3.87</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zdM1LxYB6f4f" title="Basic net loss per share"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zPdcntEirbpf" title="Diluted net loss per share">(8.48</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number of common
    shares outstanding &#8211; basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuNa5O8XU0qc" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgRRORPEjkj" title="Weighted average number of common shares outstanding - diluted">2,912,539</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8kcd3MpdFAd" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXt8aX7sTIPg" title="Weighted average number of common shares outstanding - diluted">1,186,952</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number
    of vested RSUs&#8211; basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_ziUYKHxO80j4" title="Weighted average number of vested RSUs - basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zOz4sF7jb7G2" title="Weighted average number of vested RSUs - diluted">147,367</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_ze1IAvsJxQFc" title="Weighted average number of vested RSUs - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0KpRQcUpNk6" title="Weighted average number of vested RSUs - diluted">124,619</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number
    of common shares-basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z6MJcpcwggpe" title="Weighted average number of common shares-basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_z4zDITZyKKw7" title="Weighted average number of common shares-diluted">3,059,906</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_z7dvCnzjGdPb" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z7pUlJLy7xZh" title="Weighted average number of common shares-diluted">1,311,572</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zplRa7HBS542" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outstanding stock options, unvested RSAs, unvested RSUs and warrants to purchase common stock were excluded from the computation of diluted
net loss per share as their effect would have been anti-dilutive for the periods presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zy0gGxkf4Eia" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20240101__20241231_zvgAKxGK8DF6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230101__20231231_zzInmJVIHRGe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zUIMPvmE7EHk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options, unvested RSAs, unvested
    RSUs and purchase warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,013,154</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">296,326</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</a></td>
<td class="text"><p id="xdx_894_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_znFw21XxbQ15" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B1_zL8HvYp8x371" style="display: none">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year Ended <br/> December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Remaining lease term (years) for our office lease</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_902_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zqXsky4jypj3" title="Remaining lease term (years)">0.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_z4vZEn4XDTn6" title="Remaining lease term (years)">1.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Remaining lease term (years) for our equipment lease</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zOaMetDFtdX2" title="Remaining lease term (years)">1.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z5zJxd4m6F1" title="Remaining lease term (years)">0.3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted average discount rate for our facility and equipment leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20241231_zUB8zwPiP7Fa" title="Weighted average discount rate for our facility and equipment leases">8.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20231231_zmEmpJsdLcsi" title="Weighted average discount rate for our facility and equipment leases">8.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Annual Lease Liabilities for all Operating Leases</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMRYa9vAdA78" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the operating lease were as follows at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zeWKMtOwI9Af" style="display: none">Schedule of Annual Lease Liabilities for all Operating Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_490_20241231_zoEmIJPyAWFk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_ztLma9CsyeDh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">70,040</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zOEtXm9V4krb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">70,040</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z0N10jlv7Ldg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    Interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zT0heS5JvJ2f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,905</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zEeJVhEdNdeh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zDKtp7BckTHa" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl1001">Less:
    current maturities</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(66,905</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zeAKPPrOxFMb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zB1x3vZ13zq8" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityNoncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1004">Non-current
    lease liability</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Annual Lease Liabilities for all Financing Leases</a></td>
<td class="text"><p id="xdx_894_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zNGtCiTI2OZ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the financing lease were as follows at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_z4ICQeLz6p74" style="display: none">Schedule of Annual Lease Liabilities for all Financing Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_499_20241231_zFfHPZTHX9f7" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_zu77aSb5E7l8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,821</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzELQ_zMeY740iJsda" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">571</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_zJgKN8wrwWR5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,392</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_z3WtNPt2hZId" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    Interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(790</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zThN1ikNiGwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,602</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zoEv3801EW8d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zC8VrVM0EHMa" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl1019">Less:
    current maturities</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,115</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zNmJYSo5KRoi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_z0jUbRXiOgnb" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityNoncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1022">Non-current
    lease liability</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">487</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operating and Financing Leases[Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLicenseAgreementsAbstract', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LicenseAgreementsTableTextBlock', window );">Schedule of License Agreements</a></td>
<td class="text"><p id="xdx_89E_ecustom--LicenseAgreementsTableTextBlock_zuW2fUIKpKUd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B0_zDFwIjQmexUg" style="display: none">Schedule of License Agreements</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Licensor</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Drug
    Asset</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Agreement
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amendment
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elion
    Oncology, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Cap
    (PCS6422)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--ElionOncologyIncMember_zZHD3RtVvUGb" title="Agreement Date">August
    23, 2020</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--LicenseAgreementsAmendmentDate_c20240101__20241231__dei--LegalEntityAxis__custom--ElionOncologyIncMember_zPgIpyDVHN07" title="Amendment Date">May
    17, 2022</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ocuphire
    Pharma, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Gem
    (PCS3117)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--OcuphirePharmaIncMember_zArfmSPmtob2" title="Agreement Date">June
    16, 2021</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aposense,
    Ltd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Iri
    (PCS11T)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--AposenseLtdMember_zbMYJ3AAwpm5" title="Agreement Date">May
    24, 2020</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuhan
    Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS12852</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--YuhanCorporationMember_zpBvzCkuV2y5" title="Agreement Date">August
    19, 2020</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CoNCERT
    Pharmaceuticals, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS499</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--CoNCERTPharmaceuticalsIncMember_znHExZHEkPXg" title="Agreement Date">March
    19, 2018</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_LicenseAgreementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreements [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_LicenseAgreementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwt2GrubCQIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of our effective income tax rate and statutory income tax rate for the years ended December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zJABXTlKqHO4" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zwtvD2OueJRd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20230101__20231231_zdLvUfSOZch4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_zfEZgCXxUCD6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Federal statutory income tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zAbAVBiqBEr3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State tax rate, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.58</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.77</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential_pid_dp_uPure_maEIT001_zJzhlselhuj4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.04</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msEIT001_z8lFLos2qbXc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Federal orphan drug tax credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.41</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zqt7BJVx8Hgf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Deferred tax asset valuation
    allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27.93</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zcOl9omLdlP7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Effective income tax
    rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zwQXe0HxRsVg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant components of our deferred tax assets and liabilities for Federal and state income taxes consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 21.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zw9z2aDyk6Sa" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20241231_zSzN8iRkrpXl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20231231_zn2bWa0RGskl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Non-current:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_maDTAGzhSD_zTh70Z6GDAH5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net operating
    loss carry forward &#8211; Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,566,071</span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,012,941</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_maDTAGzhSD_zW9YDjrfqMK5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carry
    forward &#8211; State</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,074,542&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,672,436</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzhSD_z4FqIL4VIpR6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,794,226</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,453,799</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzhSD_z7fRjgnCxBQf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation and other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">238</span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">999</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected_iI_maDTAGzhSD_zGfvk5GSnpIk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Purchased in-process R&amp;D</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,477,193&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,500,562</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsFederalOrphanDrugCredits_iI_maDTAGzhSD_zSfvfuU57t0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal orphan drug credits</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,209,202&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,202,955</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_iI_maDTAGzhSD_zbtbcRxTIGUd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Capitalized research and
    development costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,781,193&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,795,379</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsStartupExpenditures_iI_maDTAGzhSD_z0OVEdAjESwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Start-up
    expenditures and amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzhSD_maDTANzhKZ_zwKhCno95VK8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total non-current deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,902,665&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,639,071</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzhKZ_zuiwq3AZK1pd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance for
    deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(19,902,665</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(17,639,071</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzhKZ_msDTLznZn_zUpYY4GNVbXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1106">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred Tax Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Non-current:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzSHY_zWFnpWlHTZu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Intangible
    asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzSHY_maDTLznZn_z3jxlwImi8rj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total non-current deferred
    tax liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLznZn_zwMFvmmOLge9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax asset
    (liability)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock', window );">Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_z25iEhybPU2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt">The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B0_zLIfRicpOYJb" style="display: none; font-family: Times New Roman, Times, Serif">Schedule
of Reportable Segment Profit and Loss, Including Significant Expense Categories</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zAnLjiL2NMwc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_z5DpZyRfuHSf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PreclinicalClinicalTrialAndOtherCosts_msNILzaqM_zJgImA2CqUx9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify">Preclinical, clinical trial and other costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">5,450,963</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,817,669</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_ze2sg5BHQyE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development personnel expense<sup id="xdx_F45_zI38usS3yZ05" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,818,183</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,981,849</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_msNILzaqM_zAxhz0moFkLb" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expense<span><sup></sup></span></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_z6WgPoxEZaN4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative personnel expense<sup id="xdx_F45_zgShVznxBUTa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,981,756</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,737,792</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_msNILzaqM_zh7jxUMLZp61" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expense<sup style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AdministrativeAndFacilitiesExpense_msNILzaqM_zAhzTBc9TFVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative and facilities expense<sup id="xdx_F4F_zwJTbuSjIAc2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,800,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,919,751</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InvestmentIncomeInterest_iN_di_maNILzaqM_zCkaNoOQbq32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Interest income, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(201,088</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(335,541</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtNILzaqM_zahXuwdY0E32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">11,850,118</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">11,121,520</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><sup id="xdx_F0B_zmU81x7sUVcd">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zPsqjYqgI5r5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Research
and development personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqBDe7kz9TZ2" title="Research and development personnel costs include employee stock-based compensation expense">169,414</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zZEE1TTtC5Ja" title="Research and development personnel costs include employee stock-based compensation expense">363,956</span> for the year ended December
31, 2024, and 2023, respectively.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><sup id="xdx_F07_zP9lRgsLHKZj">(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zJFW1grtFjYh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">General
and administrative personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_zCX8mmnoY3n6" title="General and administrative personnel costs include employee stock-based compensation expense">186,925</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_z490ruzWdrCi" title="General and administrative personnel costs include employee stock-based compensation expense">387,854</span> for the year ended December
31, 2024, and 2023, respectively, and are net of reimbursements received from CorLyst, LLC.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><sup id="xdx_F09_zEzn2b7zhIq6">(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zcOiJ6oVqRI7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Administrative
&amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and
other administrative costs.</span></td>
</tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 27, 2025</div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 12, 2025</div></th>
<th class="th"><div>Jan. 30, 2025</div></th>
<th class="th"><div>Jan. 21, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-20 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,291,000<span></span>
</td>
<td class="nump">3,707,628<span></span>
</td>
<td class="nump">1,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,706,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,286,000<span></span>
</td>
<td class="nump">3,702,628<span></span>
</td>
<td class="nump">1,286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,606,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,219,199<span></span>
</td>
<td class="nump">$ 75,369,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,850,118<span></span>
</td>
<td class="nump">11,121,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,245,042<span></span>
</td>
<td class="nump">8,063,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,191,325<span></span>
</td>
<td class="nump">$ 4,706,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="nump">1,030,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Subsequent Event [Member] | Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="nump">8,050,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Subsequent Event [Member] | Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="nump">4,025,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Subsequent Event [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="nump">7,019,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ClassOfWarrantOrRightExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,494,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OrganizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OrganizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PCSA_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PCSA_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PCSA_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PCSA_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_AccountingPoliciesLineItemsAbstract', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expense</a></td>
<td class="nump">$ 1,274,442<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">2,013,154<span></span>
</td>
<td class="nump">296,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_AccountingPoliciesLineItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_AccountingPoliciesLineItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 629,514<span></span>
</td>
<td class="nump">$ 2,371,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">169,414<span></span>
</td>
<td class="nump">363,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 460,100<span></span>
</td>
<td class="nump">$ 2,007,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance</a></td>
<td class="nump">6,992<span></span>
</td>
<td class="nump">8,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance</a></td>
<td class="nump">$ 364.72<span></span>
</td>
<td class="nump">$ 341.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options, forfeited or expired</a></td>
<td class="num">(4,245)<span></span>
</td>
<td class="num">(1,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited or expired</a></td>
<td class="nump">$ 336.00<span></span>
</td>
<td class="nump">$ 257.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance</a></td>
<td class="nump">2,747<span></span>
</td>
<td class="nump">6,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, ending balance</a></td>
<td class="nump">2,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance</a></td>
<td class="nump">$ 409.09<span></span>
</td>
<td class="nump">$ 364.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 409.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity (Details) - Restricted Award [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares outstanding, Beginning balance</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">3,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, Beginning balance</a></td>
<td class="nump">$ 9.26<span></span>
</td>
<td class="nump">$ 94.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 133.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Number of shares, cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, vested and issued</a></td>
<td class="num">(1,250)<span></span>
</td>
<td class="num">(8,790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, vested and issued</a></td>
<td class="nump">$ 9.26<span></span>
</td>
<td class="nump">$ 24.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_RestrictedStockAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_RestrictedStockAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding', window );">Number of shares, Beginning balance</a></td>
<td class="nump">222,722<span></span>
</td>
<td class="nump">135,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, Beginning balance</a></td>
<td class="nump">$ 45.82<span></span>
</td>
<td class="nump">$ 73.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">192,026<span></span>
</td>
<td class="nump">116,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, granted</a></td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="nump">$ 14.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, forfeited</a></td>
<td class="num">(14,019)<span></span>
</td>
<td class="num">(12,296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, forfeited</a></td>
<td class="nump">$ 71.68<span></span>
</td>
<td class="nump">$ 21.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Number of shares, cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod', window );">Number of shares, issued</a></td>
<td class="num">(17,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, issued</a></td>
<td class="nump">$ 110.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding', window );">Number of shares, ending balance</a></td>
<td class="nump">383,636<span></span>
</td>
<td class="nump">222,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, ending balance</a></td>
<td class="nump">$ 19.87<span></span>
</td>
<td class="nump">$ 45.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued', window );">Number of shares, vested and unissued</a></td>
<td class="num">(149,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, vested and unissued</a></td>
<td class="nump">$ 43.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares outstanding, ending balance</a></td>
<td class="nump">234,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, outstanding</a></td>
<td class="nump">$ 5.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options issued in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options issued in period weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than option vested and unissued outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Activity (Details) - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, beginning balance</a></td>
<td class="nump">173,007<span></span>
</td>
<td class="nump">14,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance</a></td>
<td class="nump">$ 25.41<span></span>
</td>
<td class="nump">$ 205.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants, granted</a></td>
<td class="nump">1,617,777<span></span>
</td>
<td class="nump">173,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 4.54<span></span>
</td>
<td class="nump">$ 19.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Warrants, expired or cancelled</a></td>
<td class="num">(22,500)<span></span>
</td>
<td class="num">(6,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired', window );">Weighted average exercise price, expired or cancelled</a></td>
<td class="nump">$ 54.62<span></span>
</td>
<td class="nump">$ 266.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable', window );">Warrants, Not exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable', window );">Weighted average exercise price, not exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Warrants, exercisable</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Warrants, exercisable</a></td>
<td class="nump">1,775,784<span></span>
</td>
<td class="nump">173,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, outstanding</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, ending balance</a></td>
<td class="nump">1,775,784<span></span>
</td>
<td class="nump">173,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance</a></td>
<td class="nump">$ 5.95<span></span>
</td>
<td class="nump">$ 25.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 5.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments not exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding and exercisable number expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding and exercisable number granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments not exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Warrant Valuation Assumption (Details) - Warrant [Member]<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.0432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.0488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Measurement Input, Option Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.8285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Measurement Input, Option Volatility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">1.0847<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 03, 2024</div></th>
<th class="th"><div>Jul. 16, 2024</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
<th class="th"><div>Nov. 18, 2023</div></th>
<th class="th"><div>Apr. 17, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 10, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,617,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember', window );">Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants, expired unexercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="nump">$ 20.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 18,  2025<span></span>
</td>
<td class="text">Apr. 17,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Warrants, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Spartan Capital Securites LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 17,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=PCSA_ConsultantMember', window );">Consultant [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Warrants repurchased, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Payment for warrants repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,026<span></span>
</td>
<td class="nump">116,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_UnrecognizedShareBasedCompensationExpense', window );">Unrecognized share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 432,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member] | July 16, 2025 Vesting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member] | First Performance Based RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_MarketCapitalization', window );">Market capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member] | Second Performance Based RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_PerformanceVestingCriteriaValue', window );">Performance vesting criteria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">124,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_ServiceBasedRestrictedStockUnitsMember', window );">Service Based RSUs [Member] | Employees [Member] | January 1, 2025 Vesting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_ServiceBasedRestrictedStockUnitsMember', window );">Service Based RSUs [Member] | Employees [Member] | 3-Year Vesting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_FirstPerformanceBasedRSUMember', window );">First Performance Based RSUs [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_SecondPerformanceBasedRSUMember', window );">Second Performance Based RSUs [Member] | Employees [Member] | Next Generation Capecitabine - Cap [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember', window );">2019 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum equity available for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember', window );">2019 Plan [Member] | Original [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum equity available for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_MarketCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_MarketCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_PerformanceVestingCriteriaValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance vesting criteria value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_PerformanceVestingCriteriaValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_UnrecognizedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized share based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_UnrecognizedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=PCSA_OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=PCSA_OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_SpartanCapitalSecuritesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_SpartanCapitalSecuritesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=PCSA_JulySixteenTwoThousandTwentyFiveVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=PCSA_JulySixteenTwoThousandTwentyFiveVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=PCSA_FirstPerformanceBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=PCSA_FirstPerformanceBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=PCSA_SecondPerformanceBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=PCSA_SecondPerformanceBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=PCSA_ThreeYearVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=PCSA_ThreeYearVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_FirstPerformanceBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_FirstPerformanceBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_SecondPerformanceBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_SecondPerformanceBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_NextGenerationCapecitabineCAPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_NextGenerationCapecitabineCAPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_OriginalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_OriginalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 30, 2024</div></th>
<th class="th"><div>Feb. 14, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 18, 2023</div></th>
<th class="th"><div>Apr. 17, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,763,079<span></span>
</td>
<td class="nump">$ 6,321,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=PCSA_ATMOfferingMember', window );">ATM Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares, sold</a></td>
<td class="nump">476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  01,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 672,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Registered Direct Offering [Member] | Accredited Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Registered Direct Offering [Member] | Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_TransactionCostsPercentage', window );">Cash fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ReimbursementFees', window );">Reimbursement fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember', window );">Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="nump">$ 20.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 18,  2025<span></span>
</td>
<td class="text">Apr. 17,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,356,549<span></span>
</td>
<td class="nump">421,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=PCSA_PreFundedWarrantMember', window );">Pre-Funded Warrants [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants, granted</a></td>
<td class="nump">1,079,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="nump">$ 4.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_StockIssuedDuringPeriodSharesExercised', window );">Warrants, exercised</a></td>
<td class="nump">1,079,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants, granted</a></td>
<td class="nump">1,555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">Jan. 30,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ReimbursementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ReimbursementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_StockIssuedDuringPeriodSharesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_StockIssuedDuringPeriodSharesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_TransactionCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_TransactionCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=PCSA_ATMOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=PCSA_ATMOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=PCSA_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=PCSA_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=PCSA_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=PCSA_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_AccreditedInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_AccreditedInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=PCSA_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=PCSA_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Net Loss Per Share Basic and Diluted (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders</a></td>
<td class="num">$ (11,850,118)<span></span>
</td>
<td class="num">$ (11,121,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares-basic</a></td>
<td class="nump">3,059,906<span></span>
</td>
<td class="nump">1,311,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares-diluted</a></td>
<td class="nump">3,059,906<span></span>
</td>
<td class="nump">1,311,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="num">$ (8.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="num">$ (8.48)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares-basic</a></td>
<td class="nump">147,367<span></span>
</td>
<td class="nump">124,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares-diluted</a></td>
<td class="nump">147,367<span></span>
</td>
<td class="nump">124,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares-basic</a></td>
<td class="nump">2,912,539<span></span>
</td>
<td class="nump">1,186,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares-diluted</a></td>
<td class="nump">2,912,539<span></span>
</td>
<td class="nump">1,186,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options, unvested RSAs, unvested RSUs and purchase warrants</a></td>
<td class="nump">2,013,154<span></span>
</td>
<td class="nump">296,326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares unvested</a></td>
<td class="nump">2,013,154<span></span>
</td>
<td class="nump">296,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares unvested</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares unvested</a></td>
<td class="nump">234,623<span></span>
</td>
<td class="nump">102,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate', window );">Weighted average discount rate for our facility and equipment leases</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=PCSA_FacilityLeaseMember', window );">Facility Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Remaining lease term (years)</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term (years)</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=PCSA_FacilityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=PCSA_FacilityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Annual Lease Liabilities for all Operating Leases (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 70,040<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">70,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(3,135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">66,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current maturities</a></td>
<td class="num">$ (66,905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current maturities of lease liability<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease liability</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Non-current lease liability<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Annual Lease Liabilities for all Financing Leases (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 6,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">7,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(790)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">6,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current maturities</a></td>
<td class="num">$ (6,115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current maturities of lease liability<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current lease liability</a></td>
<td class="nump">$ 487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Non-current lease liability<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate', window );">Operating and financing lease borrowing rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 97,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of License Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=PCSA_ElionOncologyIncMember', window );">Elion Oncology Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LicenseAgreementsDate', window );">Agreement Date</a></td>
<td class="text">Aug. 23,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LicenseAgreementsAmendmentDate', window );">Amendment Date</a></td>
<td class="text">May 17,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=PCSA_OcuphirePharmaIncMember', window );">Ocuphire Pharma Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LicenseAgreementsDate', window );">Agreement Date</a></td>
<td class="text">Jun. 16,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=PCSA_AposenseLtdMember', window );">Aposense, Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LicenseAgreementsDate', window );">Agreement Date</a></td>
<td class="text">May 24,  2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=PCSA_YuhanCorporationMember', window );">Yuhan Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LicenseAgreementsDate', window );">Agreement Date</a></td>
<td class="text">Aug. 19,  2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=PCSA_CoNCERTPharmaceuticalsIncMember', window );">CoNCERT Pharmaceuticals, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LicenseAgreementsDate', window );">Agreement Date</a></td>
<td class="text">Mar. 19,  2018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_LicenseAgreementsAmendmentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreements amendment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_LicenseAgreementsAmendmentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_LicenseAgreementsDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreements date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_LicenseAgreementsDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_ElionOncologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_ElionOncologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_OcuphirePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_OcuphirePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_AposenseLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_AposenseLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_YuhanCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_YuhanCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_CoNCERTPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_CoNCERTPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Deferred tax assets, capital loss carryforwards</a></td>
<td class="nump">$ 36,000,000.0<span></span>
</td>
<td class="nump">$ 28,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_NetOperatingLossCarryforwardExpiryDate', window );">Net operating loss carryforward, expiration date</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_NetOperatingLossCarryforwardTerm', window );">Net operating loss carryforward term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination description</a></td>
<td class="text">Pursuant
to Code Sec. 382 of the Internal Revenue Code (&#8220;the Code&#8221;), the utilization of our net operating loss carryforwards could
be limited as a result of a cumulative change in stock ownership of more than 50% over a three-year period. We have not completed a Sec.
382 study and as such our net operating loss carryforwards may be subject to such limitation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization', window );">Capitalized research and development net of amortization</a></td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance deferred tax asset</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Penalties and interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=PCSA_FederalMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development net of amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_NetOperatingLossCarryforwardExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforward, expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_NetOperatingLossCarryforwardExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_NetOperatingLossCarryforwardTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforward term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_NetOperatingLossCarryforwardTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=PCSA_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=PCSA_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net</a></td>
<td class="nump">5.58%<span></span>
</td>
<td class="nump">5.77%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential', window );">Permanent differences</a></td>
<td class="num">(0.04%)<span></span>
</td>
<td class="num">(0.25%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Federal orphan drug tax credit</a></td>
<td class="nump">0.05%<span></span>
</td>
<td class="nump">1.41%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Deferred tax asset valuation allowance</a></td>
<td class="num">(26.59%)<span></span>
</td>
<td class="num">(27.93%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, income tax rate permanent differential.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net operating loss carry forward &#8211; Federal</a></td>
<td class="nump">$ 7,566,071<span></span>
</td>
<td class="nump">$ 6,012,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carry forward &#8211; State</a></td>
<td class="nump">2,074,542<span></span>
</td>
<td class="nump">1,672,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation expense</a></td>
<td class="nump">2,794,226<span></span>
</td>
<td class="nump">3,453,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and other</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected', window );">Purchased in-process R&amp;D</a></td>
<td class="nump">2,477,193<span></span>
</td>
<td class="nump">2,500,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DeferredTaxAssetsFederalOrphanDrugCredits', window );">Federal orphan drug credits</a></td>
<td class="nump">1,209,202<span></span>
</td>
<td class="nump">1,202,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research and development costs</a></td>
<td class="nump">3,781,193<span></span>
</td>
<td class="nump">2,795,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DeferredTaxAssetsStartupExpenditures', window );">Start-up expenditures and amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total non-current deferred tax assets</a></td>
<td class="nump">19,902,665<span></span>
</td>
<td class="nump">17,639,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(19,902,665)<span></span>
</td>
<td class="num">(17,639,071)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total non-current deferred tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax asset (liability)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset acquired inprocess research and development tax effected.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DeferredTaxAssetsFederalOrphanDrugCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets federal orphan drug credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DeferredTaxAssetsFederalOrphanDrugCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DeferredTaxAssetsStartupExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets startup expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DeferredTaxAssetsStartupExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - CorLyst, LLC [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ProceedsFromRentAndOtherCostsReimbursements', window );">Rent and other costs reimbursements received</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related parties</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ProceedsFromRentAndOtherCostsReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent and other costs reimbursements received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ProceedsFromRentAndOtherCostsReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=PCSA_CorLystLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=PCSA_CorLystLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,269,146<span></span>
</td>
<td class="nump">$ 5,799,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,782,060<span></span>
</td>
<td class="nump">5,657,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(201,088)<span></span>
</td>
<td class="num">(335,541)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,850,118)<span></span>
</td>
<td class="num">(11,121,520)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember', window );">Reportable Segment, Aggregation before Other Operating Segment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_PreclinicalClinicalTrialAndOtherCosts', window );">Preclinical, clinical trial and other costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,450,963<span></span>
</td>
<td class="nump">3,817,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_AdministrativeAndFacilitiesExpense', window );">Administrative and facilities expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,800,304<span></span>
</td>
<td class="nump">3,919,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(201,088)<span></span>
</td>
<td class="num">(335,541)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,850,118<span></span>
</td>
<td class="nump">11,121,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember', window );">Reportable Segment, Aggregation before Other Operating Segment [Member] | Employees [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,818,183<span></span>
</td>
<td class="nump">1,981,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 1,981,756<span></span>
</td>
<td class="nump">$ 1,737,792<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Administrative
&amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and
other administrative costs.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Research
and development personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqBDe7kz9TZ2" title="Research and development personnel costs include employee stock-based compensation expense">169,414</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zZEE1TTtC5Ja" title="Research and development personnel costs include employee stock-based compensation expense">363,956</span> for the year ended December
31, 2024, and 2023, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">General
and administrative personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_zCX8mmnoY3n6" title="General and administrative personnel costs include employee stock-based compensation expense">186,925</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_z490ruzWdrCi" title="General and administrative personnel costs include employee stock-based compensation expense">387,854</span> for the year ended December
31, 2024, and 2023, respectively, and are net of reimbursements received from CorLyst, LLC.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_AdministrativeAndFacilitiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_AdministrativeAndFacilitiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_PreclinicalClinicalTrialAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_PreclinicalClinicalTrialAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">General and administrative personnel costs include employee stock-based compensation expense</a></td>
<td class="nump">$ 629,514<span></span>
</td>
<td class="nump">$ 2,371,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">General and administrative personnel costs include employee stock-based compensation expense</a></td>
<td class="nump">169,414<span></span>
</td>
<td class="nump">363,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">General and administrative personnel costs include employee stock-based compensation expense</a></td>
<td class="nump">460,100<span></span>
</td>
<td class="nump">2,007,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | CorLyst, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">General and administrative personnel costs include employee stock-based compensation expense</a></td>
<td class="nump">$ 186,925<span></span>
</td>
<td class="nump">$ 387,854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_CorLystLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_CorLystLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_CROsMember', window );">CROs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 12.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_CROsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_CROsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jan. 27, 2025</div></th>
<th class="th"><div>Jan. 30, 2024</div></th>
<th class="th"><div>Mar. 12, 2025</div></th>
<th class="th"><div>Jan. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="nump">7,019,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OutstandingSharesPercentage', window );">Outstanding shares percentage, maximum</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,494,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares, sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares, sold</a></td>
<td class="nump">1,030,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Subsequent Event [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, exercisable term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Subsequent Event [Member] | Chief Executive Officer and Certain Board Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.7975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Subsequent Event [Member] | Series A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="nump">8,050,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Subsequent Event [Member] | Series B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="nump">4,025,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Subsequent Event [Member] | SeriesA And B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OutstandingSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding shares percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OutstandingSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=PCSA_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=PCSA_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PCSA_SeriesAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PCSA_SeriesAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PCSA_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PCSA_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PCSA_SeriesAAndBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PCSA_SeriesAAndBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>98
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .F#=%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( .F#=%JL0NUG\0   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DE%+PS 0Q[^*Y+V]M,4AH<N+8T\*@@/%MY#<
MMF#3A.2DW;<WK5NGZ ?P,7?__.YW<*T.0ON(3]$'C&0QW8RNZY/08<V.1$$
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M%$^[%!N2;_/G/Y9<2A[E+S>,^DQD.\#G*\[E;B/[@OTS1Y/_ U!+ P04
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M)L2<IJI/!*X#U/4E8_)YH#N1IO.,_@)02P,$%     @ Z8-T6B#2OC_: P
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M1*NA&VVB)5;14EMH0]I[\0TMJF\SUI2EL$;(1LHSI)6M>(DMH/1LXL.G?KT
M1V8!;A(@9M<)5;<%M+(%E""- H<P\AWQ(3]/?(GIL/J]7D=FO7[VWE?D:['4
M(.;]P2Z(Z<$64G4_C*(XEFY_*W.^4PIL"2C59AZ?+NB'M3]YX&V6WM-K;YI@
MD"I35=6Q-*<T=7:QBI9814MMH0W)[94],BO[CMR&QRTI,L IV.$GP;)8O!/
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M? ".>6"%/:1PXG=P/X6](0#K.N 2%'$:TS09\*!5"<2_$Q]$C,;H@L]%6=I
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M.&5@NZ'I#&^:V*@;XZGMX[:F_PS:$$#G6V/\R0@$PY^K^ M02P,$%     @
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MI-_7^E9^7 .PW2209G>&! O#4+LO+Z&$@HZI_<IDUBOC3:E9=F!XJK[$XL[
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M2,D?;O>@%(,3PB+B%$,AK?5MRJY(68?>H9@F&-U?@%-!JBK&5%24[STX9HW
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M]N1(>7F[6[[ /_B-ZH5K6U?S1^H>C:<%>+YT\(?XA0Y(K]B_^5]02P,$%
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M=>!.-&?%P.F5Y10^P"D(V:^JZ=8M>].4HCQD< :U)MW"4;=7X5<YOA:%QZ+
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M-TQRYS?5@?0)2\.YFQ@VH1ME@1OB^KUR.OZ%+<!O*1&[K="(0P>D+'J""G!
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MG2%$^$F7/?=:?$H4%^RH:%8L%>@;U5EZWMP-'J<Q;(TQTSS25*%M<.UKJP5
MTLGJ&^XFM]0"WOM$X3J@&_8,H]XN$QPS$M2D&&'"[5H'F:I@NK!BC\' AL5
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MN<!'!;HL"J8."\SE_JX7]IJ.CWR3&=LQF-UNV0:7:)ZVCXI:@Q8EY04*S:4
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MGB0WR9Y^E.QZ&9 &Z$TD2N2GGY+)3#9*/YH"T<*V%-),@\+:ZBH,35I@R<Q
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MQ/IN/KN:OH>J#"DI,>64,$/)0G(<\-40"POQY:@"VT?>J"?@6L!B@;:MAV/
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MF/\'4O]O#OO[A%679,FCT7Z2R'BT!^5D2%G1V5J:E%@RIQ<["M_\PGKV@2;
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M,M?#&6<)%VH"/I^4I5Q=* 7M![OC?P%02P,$%     @ Z8-T6L]%X-K5 P
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M-/1F<,N<'FFH[ 4Z7TIIMANKH'OVS?X#4$L#!!0    ( .F#=%HQ+531; ,
M "H*   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;,U6VV[C-A!]]U<,
MU L2P&M=;,N.:QM(-EUT@6P;)&D7?:2ED4TL17I)*E[_?8>4K$T31S5Z ?I@
M611GSIQ#'E[F.Z4_F0VBA2^ED&81;*S=SL+09!LLF1FH+4KJ*90NF:6F7H=F
MJY'E/JD481)%:5@R+H/EW'^[U<NYJJS@$F\UF*HLF=Y?H5"[11 'AP]W?+VQ
M[D.XG&_9&N_1_KJ]U=0*6Y2<ER@-5Q(T%HO@,IY=I2[>!_S&<6>>O(-3LE+J
MDVN\SQ=!Y BAP,PZ!$9_C_@6A7! 1.-S@QFT)5WBT_<#^CNOG;2LF,&W2GSD
MN=TL@FD .1:L$O9.[7["1L_8X65*&/^$71,;!9!5QJJR228&)9?U/_O2C,,I
M"4F3D'C>=2'/\II9MIQKM0/MH@G-O7BI/IO(<>DFY=YJZN649Y<W2)(,G#VP
ME4!S/@\M@;JN,&L KFJ Y!6 .($/2MJ-@1]ECOF? 4)BTU)*#I2NDD[$:\P&
M,(S[D$3)J -OV$H<>KQAI\1CRNJ\T?$\MQQF9LLR7 3D=X/Z$8/E]]_$:?1#
M!ZM1RVK4A;Z\I^655P)!%?#1>P=SN'Q$34L![M"M)R[7X,G# ^K2 ),Y7'.3
MJ4I:N&,6@18E_+*E'.MB7?\[+IG,VLRCLO\7Q'J_(].U9WINHMUL#WM?\87'
MMX0/9WL*-><>5%7T*PJ>81,1#:80#Z:G9>+GBF]I2[%-4#R("6#8:W6R1F=^
M4*,/:EQZP3(NN-U[0<^P#$P'$7Q7/SO\,6[],3YY&BZEK)AHAOR&LY5CP:FD
M(\:$>#+4K\]Z9[GC9J_K]NJQ$L_JV@UQ:^O6,3O4",SU"]KMR1@6:#5CN4+=
MKN@9_"-ISBQC^!8F43\:1;T'92F]KKYE>S<?YM!W@\;,>N\E60&-A;-A/QZ.
MX;QWZP32O#TR47D2+P6F:?\B&C<(6:6UBZ<SH-)U_UD=0& _*_FF"7@V4'MB
M^08ZK)"V5DC_/2N<L@%TEON;5BC:NO^9%5YL(8T5TOXTB5TCA?$D?L42_>%%
M\L(1DXOH1#_TTRCILD,_CO_:#:/IY*@?PB?G=XEZ[6\I!OP.5!_E[=?V(G19
MG_]?P^M;U >FUUP:DE!0:C28T++7]<VD;EBU];>!E;)TM_"O&[K,H78!U%\H
M90\-5Z"]'B[_ %!+ P04    " #I@W1:A]H#-[@"    !@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6RE5&UOFS 0_LZOL)@T-5)7P*%IVB5(">VZ
M3GV)FF[3/CIP 52PF6V:]M_O; C+I#:JM"_@.]_SW'.V[R8;(1]5#J#)<U5R
M-75SK>LSSU-)#A531Z(&CCMK(2NFT929IVH)++6@JO2H[X^\BA7<C2;6MY#1
M1#2Z+#@L)%%-53'Y,H=2;*9NX&X=]T66:^/PHDG-,EB"_EXO)%I>SY(6%7!5
M"$XDK*?N+#B;AR;>!OPH8*-VUL14LA+BT1A7Z=3UC2 H(=&&@>'O"6(H2T.$
M,GYWG&Z?T@!WUUOV+[9VK&7%%,2B_%FD.I^Z8Y>DL&9-J>_%YBMT]1P;OD24
MRG[)IHT=8L:D45I4'1CMJN#MGSUWY[ #&/MO &@'H%9WF\BJ/&>:11,I-D2:
M:&0S"UNJ1:.X@IM+66J)NP7B='1=)'C"0&:9!,##UHH</+!5"6HP\30F,&%>
MTI'-6S+Z!EE R8W@.E?D@J>0_DO@H;)>'MW*F].]C.>0')%A<$BH3\,]?,.^
MW*'E&[Z[W->J;#G"USE,FYRIFB4P=;$/%,@G<*./'X*1_WF/PK!7&.YCCY;8
M=FE3 A%K\CZU_\/GM"XAR;EL,F>F%,Z!?MO!)X71N$Q[T[DHL9N<.XXO3V0O
MA^2*XQ7=7L:?8E8[!XMX.0HI'9!9D^'K=>C0WIU/;MB+$YQ8@SIW25/GA01G
MD3-LK1V22Z@LR3 (3@;D6\/!"486%9!;;^;,:J%,#8?.M4Y;R)4L+"0('@8V
M#0V[G ;PJ\D9=V(A:R&9'00FE(Z/Z59B<+H3'HO;^.+^H1.60*.+A)6J4XC0
M\/04D\@D[W#!V.!>NWAOIRLKD)F=/8HDHN&Z;=#>VX^W6=O5?\/;V8@)LX(K
M4L(:H?[1R;%+9#MO6D.+VO;X2FB<&':9XX@&:0)P?RV$WAHF03_THS]02P,$
M%     @ Z8-T6HNAY!NP!   0@L  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&ULG591;]LV$'[7KSBX:Y$ BBU1DA6GB8&D2;$ ZQ D68=AV ,MG6VB
M$JF25)STU^](V8K3N%ZQ!UND>/SN.]YWU)VNE/YBEH@6'NM*FK/!TMKF9#0R
MQ1)K;H:J04DK<Z5K;FFJ%R/3:.2EWU17(Q9%XU'-A1Q,3_V[&ST]5:VMA,0;
M#::M:ZZ?+K!2J[-!/-B\N!6+I74O1M/3AB_P#NT?S8VFV:A'*46-T@@E0>/\
M;' >GUQDSMX;?!:X,EMC<)',E/KB)M?EV2!RA+#"PCH$3H\'_(!5Y8"(QM<U
MYJ!WZ39NCS?H'WWL%,N,&_R@JC]%:9=G@^,!E#CG;65OU>I77,?C"1:J,OX?
M5IUME@R@:(U5]7HS,:B%[)[\<7T.6QN.HQ]L8.L-S//N''F6E]SRZ:E6*]#.
MFM#<P(?J=Q,Y(5U2[JRF54'[[/1:%JI&N.>/:.#@GL\J-(>G(TO0SF!4K&$N
M.ACV YB8P2<E[=+ E2RQ? DP(DX],;8A=L'V(EYB,80D#H%%+-V#E_2!)AXO
M^<] X5*8HE*FU0A_G\^,U22-?W;%W"&FNQ%=N9R8AA=X-J!Z,*@?<#!]]R8>
M1^_W\$U[OND^].D=E5_95@AJ#E?S.7KUPE84M]PBW&*A9"$JP9W&=\6PW\MY
MH%\@.&^JU8"]1]%YM.11.X]<EF LMZU5^NG5*MT28)<(3\BU 71: ,HDUC/4
M?38]!@T2$ :XH4T5W0WF!/Y/S(%'=&C!7^0TN'KE<\OB(Y:H>;4G !8/HPC>
M;I[!G75O-\LA2+HGLV%V3";9,,_)X@;I<I H+92".&N4A2NE:!BE</C6#5A&
M@]ZWTLV22RAUN_"XA<926"#[C$#C81H3Z"42$BUX"VX,>7W@5=M%S-UQ<7(#
M!VP\S";>#<N'D\3YN=J1NL#'%G6A=8\]$LUZB68_+=&>L$O3N2-L?)I_$WQ&
MJ;("S2YU[G6PN\+NEQ@8L9!B+@I.ITXQ-LJ=O]F(MWQU>!V7ZIF+%^HF(QM)
M;Y\8F9#*C#"6< C7B;K3J9"+ETK]B="W)+A19O!2F:\3;DZ"WY4\*EIZ+2U-
M2 /T+:9,$H. [B]BR#5)F$)9<5W"NS?'+([?]V'] GF8C<=AE,<TIF?,PDD:
MOP2"9Z#@>Z!.^XP TC!+&<3A.&=AFHRI*E3QQ9\\?9Z[BP,?W=B9YY,T9&P,
M29AF"<TF%!REKUC?,.YH%!VG!I8<PX26;UI=+.G+6M+Y'S5:4?T8N'W'Z^;]
M)>&E>1[&I&T69E%$$;&=I=25D2&2+)K0C_D119QEP0?>",LK\8U<.!UQ\N=X
M!"4^4%O2U.AU9&@[$3Z.U^[R218F^<3= =H>M4W@8R0O].7H4LQKI:WXU@5V
M!$?!O2(_()_SME.,\22<$+7Q.(,X#\?)Q.4H^+PI<'@N<$I)L OA8 OBD&8]
M"ARN.>S:Y1B^4.N61+]3V[6T7"X$M0-!=_WLCRYP7K;KZ]G\-9'@8&/Y=$C*
M//*_7??1:*NOJ5$O?/?F"K.5MFMQ^K=]@WC>]47/YEUW^8GKA9 &*IS3UFB8
MT\VCNXZMFUC5^"YIIBSU7'ZXI"87M3.@];E2=C-Q#OJV>?HO4$L#!!0    (
M .F#=%J]R=(H\@,  %H)   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;*U6VV[C-A!]UU<0ZF(1 VITM2UG;0-)=ML&Z )&G+8HBC[0TD@F0I%:DHJ3
MO^]0MSA;K[% ^V*3U,R9,T<S'"T/4CWJ/8 ASQ47>N7NC:FO?%]G>ZBHOI0U
M"'Q22%51@UM5^KI60//6J>)^% 0SOZ),N.ME>[91ZZ5L#&<"-HKHIJJH>KD!
M+@\K-W2'@WM6[HT]\-?+FI:P!?-;O5&X\T>4G%4@-)."*"A6[G5X=9-8^];@
M=P8'?;0F-I.=E(]V<Y>OW, 2 @Z9L0@4_Y[@%CBW0$CC2X_ICB&MX_%Z0/^I
MS1USV5$-MY+_P7*S7[FI2W(H:,/-O3S\ GT^4XN72:[;7W+H;0.79(TVLNJ=
MD4'%1/=/GWL=OL<AZAVBEG<7J&7YD1JZ7BIY(,I:(YI=M*FVWDB."?M2MD;A
M4X9^9KV%$B4VY!YJJ0P3);EXH#L.>K+T#>);*S_KL6XZK.@;6&%$/DMA]II\
M$CGD;P%\)#:RBP9V-]%9Q(^079(X]$@41,D9O'C,-F[QXN_.]J_KG38*:^/O
M4_EV:,EI--LO5[JF&:Q<; @-Z@G<]?L?PEGPX0S79.2:G$-?;['_\H8#D47/
MU[X7,J2P4;)@AE"1DU^EUAZY$QEO<IO3EI6"%2RC:/;I&=M7 [FE!DJI&.A3
M>9YG\K 'IY <^]>B=S3:A(71V)@C-=U3JU^I\98:&ZGI(VK04\M&:AZAQBBV
M:SH\(XELU%$$9XB EQ$Q>R O0)4F8*N-8*U M0,UUDM+ !?Q%1FT=/YG+9TV
MCHWA_(E43C YLM@HR%!:Q.(>&58$\\5?&UIB1HID4J.J[\C42Z:!MYC%N(Z]
M-)Q[L]G"N4?5J<KVK4,.3WBIUIWFH+04 O@HZT4X(2$ZIEZ8QKA:I+A+7B&<
MKR%Z1^=G$*!Z3C3'.X?9#K&7YZDHT:3'GD]GN)K'<V^^B,Z!#'&NWQY;RX)F
MC#.#RKX&B"<D\M(@\.(@0246X0)#A<Z=,( U:&QQR0H\(G""741!Z 5I2B;H
M%T^]:1*2B?,@#3)Y1T(4 #4-P[3;A%'H3:/ L4I]4Y77E+LWT]4R9E'57+X
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M=ZJU ZXWJ/\WC,FWB590-XOSOP%02P,$%     @ Z8-T6AW4_<?L P  A0\
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MZE2C';7[L-H'!VX2M(!3VTDF_[XV$ B!$++3SL.$C^OC<XX_[C7C/>/?Q!I
MHK<D3L7$6$NY>; L$:PAH<)D&TC5FR7C"97JEJ\LL>% PZQ1$EO$MCTKH5%J
M3,?9LQ<^';.MC*,47C@2VR2A_/ (,=M/#&P<'WR*5FNI'UC3\8:NX!7D7YL7
MKNZL$B6,$DA%Q%+$83DQ9OAACD>Z01;Q=P1[<7*-M)0%8]_TS<=P8MB:$<00
M2 U!U<\.YA#'&DGQ^*< -<H^=</3ZR/ZATR\$K.@ N8L_AR%<CTQA@8*84FW
ML?S$]K]#(<C5> &+1?8?[?-8?V2@8"LD2XK&BD$2I?DO?2N,.&E W L-2-&
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M*Z )2+O W%\(H5\&]D2C.I":_@=02P,$%     @ Z8-T6HXK)*(B#@  A\D
M !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULQ=WO3]M( L;Q?V7$G4Z[
M4EL2.S^@1Y&ZV#.>U;9;%757I].],&$ JTF<M1THJ_[Q9P>#,XD9XM-W+_MB
M"VGF8Z<\-A,_L7UREV9?\QMC"O%M-IWG[PYNBF+Q]O PG]R869R_21=F7O[-
M59K-XJ+\-KL^S!>9B2]7@V;30Z_7&QW.XF1^<'JR>NQ3=GJ2+HMI,C>?,I$O
M9[,XN__)3-.[=P?]@\<'/B?7-T7UP.'IR2*^-N>F^++XE)7?'3XIE\G,S/,D
MG8O,7+T[>-]_J\>K :MG_):8NWSM:U&]E(LT_5I]HR_?'?2J-3)3,RDJ(B[_
MN#5G9CJMI'(]_JC1@Z=E5@/7OW[4Y>K%ER_F(L[-63K]/;DL;MX='!V(2W,5
M+Z?%Y_0N,O4+&E;>))WFJ_^+N_JYO0,Q6>9%.JL'EVLP2^8/?\;?ZG^(M0']
MP3,#O'J M^L OQ[@[SI@4 \8; X8/C-@6 \8[CI@5 \8;0X8/S-@7 \8[_H:
MCNH!1[L..*X''*_B\/#S6_WP@[B(3T^R]$YDU;-+K?IBE:#5Z/)GGLRKL)\7
M6?FW23FN.#TOTLG7UU5<+L59.BNWH3Q>I?"'P!1Q,LW%QSC+XBJ1/XK7XLMY
M('[X^X\GAT6Y[$HXG-3+40_+\9Y93M\3'])Y<9.+<'YI+FW@L%SIIS7W'M?\
M)\\IGIO%&]'S7PFOYPU:5NC,/?SGY?2-Z(^>'1Z\-'S^1GA'SPX/W<,_IK?E
MTA^&^RW#I7OX^T56#A\_.URYAP=F\D;X_6=7/MI]>-O2]2[_\KW5<,\1!/\I
MPO[*&SSC_5X%=%Z(?W\PLPN3_4=\%[]>79DLF5\_/=:REC\YU>J7S-M\$4_,
MNX/RMTANLEMS</J/O_5'O7^VA8W$ A(+24R2F"*QB,0TA%EQ'CS%>;#2_>?V
M:S=Q9E[_M+U'?E_%_-J4,XU"7-R+]>=]BN]7#[^_B[-+\>]?2E+HPLSRUN /
MR."36$!B(8E)$E,D%I&8AC K^,.GX ]WV8_GHDC%8IE-;LIHBTDZFY79SZMI
M2EN6G637+)-80&(AB4D24P_8:(55[ZQN3_NC_KC\[^3P=CVFY$(UA%DQ'3W%
M=.2,Z5DZS\MW4M7LXOUU9A[VQZYYAI/K&E$2"T@L)#%)8HK$(A+3$&;E>/R4
MX_&>YQEC,O@D%I!82&*2Q!2)122F(<P*_M%3\(_X>8:3[)IE$@M(+"0Q>;0]
M-1@>]7H;,P-%+C,B,0UA5DJ/GU)ZO%-*7PGS;9%DY<YW.3??3#9)\LW#9P\)
M=7)=$TIB 8F%)"9)3!UOQ7T\[/4VIL'D$C6$6?GL]YHCQ[T=$WI=_=F>2K?1
M-9:H%J!:6&OV[JZW&0")+E2A6H1JFM+L>*X5&_V=#@L_[C3%(DLFIC6C3JAS
M1DDM0+6PUH[7]U%O!IL)W7Z2U]M\ED)7+$(U36EV\KPF>=Z.R2M_<3^\I[J,
MB_;H.:7.T2.U -7"%_[-G@JQJA4:MOVN?@%XJL0J8-2ZKR1?3X1JFM+LQ#8-
M6G^G"FTUV5SM+>.+:7M>T=(,U0)4"VO-/9V3Z#(5JD6HIBG-3FA3BO6=U8/[
MJ*OX+LX7<5;$<W$6+Y(BGHIS,UEF26%R\<LO9\[#L^X%=XXTVH>A6HAJ$M44
MJD6HIBG-CGY3B_6'>SY0VT=;-%0+4"U$-8EJ"M4B5-.49F\"3>76=W=NNQUJ
M0(LV5 M0+40U66LO'J=%EQJAFJ8T.Y]-E=9W%A9=CC6@I1BJ!:@6HIJLM9<.
M2J"-%ZII2K,CVI1>_9U:KYT.2J!E%ZH%J!:BFGSA)[##$0JT"D,U36EV?)LV
MK.^NP^KW?QN?\]W\Z&]KFM%B#-4"5 M13:*:0K4(U32EV:<Q-#V:U]OS^SL/
M+>%0+4"U$-4DJBE4BU!-4YJ]"31=G;=35Y>+S#Q^(N?RE<BKP.>M@48;.U0+
M4"U$-8EJJM9>:+PC=*&:TNRD-MV>YZZ9'G>\5VDF[EI2VYI6M.1#M0#50E23
MJ*9J;;R>UEY+6M%>C]+LM#:]GN?N]5JG#,VLXI7X=;&::;CFS^Y%=$XO6OFA
M6HAJ$M44JD6HIBG-#GE3#7J#?<^?T8H0U0)4"U%-HII"M0C5-*79FT!3$7KN
M4^?>7U]GYCHNC$CF19;,\V0B;N/ITHCT2J3+(B_B^675G:>K_7W[G!HM 5$M
M0+40U22JJ5I;GZ5LS5!>?(JFULF.8U/7>>ZZ;G51B3IKPOFA=3?4.71H9X=J
M(:I)5%/>=@.X%;H7GZ*I=;)#UW1PGKN#^VSR<M<W*<K?[@_Y^S)/RO=F/WP^
M_Y+_Z)[AHIT<J@6H%J*:1#6%:A&J:4JSH]UT=][1OF>X:.6':@&JA:@F44VA
M6H1JFM+L3:#I_SQW__=Q6>V^J^GLPU%AYR>!W%;G-*.5'ZJ%J"9137G;)\3U
MCQ^J;WMJT?*\TAP?;<XO_HJ:SF]J.M]]NMN7>68FZ?4\^;/<N^9KETV;K.^1
MS;?JZ]:/5;C]KJE$M0#50E23J*9J;?W=TZCO;Q\'1I>J*<W.;M.O^2_T:ZMK
M/I99C6]-%E\;L3!9DEZN6HPZU55Z6U.+5FVH%J!:B&H2U=0+/]\C,7NXN&+?
M$Y?Q?=OQG0A=(4UI=J";&LYWUW#VSKB:$8B..V.TDT.U -5"5).HIOSM3F[@
M>[W1ULX8+>4HS<[NVN4JW:7<;@<JQ'<1SA;3]-Z8W'T92_8ZENR%+-DK6;*7
MLF2O9<E>S)*]FN5?T<_Y33_G[[N?\]%^#M4"5 M13:*:0K4(U32EV9M T\_Y
M[GZNT]$+M]4YS6@1YV]?[M&OWM/;OZ]#=*$2U12J1:BF*<V.:=/;^>[>;N>9
MR=E-8JZ$3.;Q?)+$T^IZV\FD#+ASGH)6?:@6H%J(:A+5%*I%J*8IS4Y_4R#Z
M^[X@IH\6C:@6H%J(:A+5%*I%J*8IS=X$FJ+1=Y^BUFV>@G:&_O;5(KVCK<.R
M ;K0$-4DJBE4BU!-4YH=TZ8,]-UE(#9/*9_R\W)Z_W@?F*'XK91?O&\(VBZB
M6H!J(:I)5%.H%J&:IC3[_B%-4SG8]PF% [3*1+4 U4)4DZBF4"U"-4UI]B;0
M%)X#=R'6:2+CMCJGN>6LN,'V1 9=:(AJ$M44JD6HIBG-CFE38P[<-28YD9%)
MEA?BD\E6=\"<3XQXV+-7EG,^XU['SO%'JU!4"U%-HII"M0C5-*796TE3F [\
M?<]GT X5U0)4"U%-HII"M0C5-*79F\#:/0&=!57'^0Q:A]::=2'<END,6G.B
MFD0UA6H1JFE*LU/:U)P#=\WY(<Z^FD),'J[!F_P9/_>A0K?3.:';)\15'^C<
M/KD_0)<;HII$-85J$:II2K-3VK2<@_]3RUE==MI,TOGE_S3K1NM05 M0+40U
MB6H*U2)4TY1F;R9-'3K8=QTZ0.M05 M0+40UB6H*U2)4TY1F;P)-'3H ZU"W
MU3G-VW5HVZP;;4-13:*:0K4(U32EV2EMVM"!NPU=GWS<UOWEI+KW19;$K4%%
M^\M:LRZK-6R??*/=)*I)5%.H%J&:IC3[%N]--SETGT6Y\^0[2#(S*5+W9PK=
M"^L:950+4"U$-8EJ"M4B5-.49L>]Z2&'_3U/HH=H>8EJ :J%J"913:%:A&J:
MTNQ-H.DXAR_<V:_+)+JVK/+<&QQY&S=Z.',OLW-.T981U22J*52+4$U3FIW3
MIF4<OG"MU%),VH_?M9Z+67UV,)XOX^Q>]#M\>M"]%IWWUVC5B&HAJDE44Z@6
MH9JF-'L[:*K&X6#?4Q:TGT2U -5"5).HIE M0C5-:?8FT/280_!T3;?5.<WH
MZ9K#[=,U^X/CT?'&Z9KH0B6J*52+4$U3FAW3IL@<OG"9U>XS%O_UOTR<[391
M00M*5 M0+40UB6H*U2)4TY1FQ[\I*(?[+BB':$&):@&JA:@F44VA6H1JFM+L
M3: I*(=@0>FV.J<9O<;K<+ON[!_UQ_[F1 5M*%%-H5J$:IK2[)@V#>70W5#N
M=&K"SA>\<B^L<X[1\R]1+40UB6H*U2)4TY1FQ7W4=)RC?9]_.4)[3U0+4"U$
M-8EJ"M4B5-.49F\"3>\Y L^_=%N=TXQ6F*/MLSG]GK_QT9807:9$-85J$:II
M2K-3VE23(W<UN=NGMY\[EO+1?"N$,G-3WT[]+%Z825+$%]6^^W7UK7,:XUZW
MSJE'"U%4"U%-HII"M0C5-*796T=3B([V?=KE".U"42U M1#5)*HI5(M035.:
MO0DT7>C(631UG,:@M2:J!;7VTC0&K2M13:%:A&J:TNR4-G7ER%U7>KW^L?@T
MC=WW\74CG>.)]I2H%J*:1#6%:A&J:4JS8]S4F:/1ON<;:*6):@&JA:@F44VA
M6H1JFM+L3:"I-$?N>UA^B+\EL^5,F#^627$OXMLXF<874[.Z44^2Y\O5>]3E
M_+*<E!0W1BS*G7YKT-'B$M6"6EN?BARUG"X4HDN5J*90+4(U36EVA)M*<N2N
M)%=[YWPCNE?+8IF9A\ESZ\VGW6CGP*+=)*J%J"9138VV6UA_Z(\&_8W;\:!+
MU91F![8I)T?N<G)[]BR^BU^SY#J9QU/WC!HM(E$M0+40U22J*52+4$U3FA7M
M<5-$CO==1([1(A+5 E0+44VBFD*U"-4TI=F;0%-$CMU%)#6C=B^F<]#1CA+5
M0E23J*90+4(U/6ZY[N_0>E_S$.'#_,:8(HB+^/1D9K)K<V:FTUQ,TN6\'%AU
MET^/BLQ<E:^Z_S;J'QQN/?Z^__:]5SU^V#"G)XOXVGR(LW+VDHNIN2K)WIOQ
M\$!DU1U@'[\ITL6[@W)]+]*B2&>K+V],7&X#U1/*O[]*T^+QFVH!=VGV=;7:
MI_\%4$L#!!0    ( .F#=%K1^"Q-RPH  -U_   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;+6=76_;.!:&_PKA60QF@(ZM;]N9Q$!JD9PNVF[0[.Q<
M#/9"D1E;J"UY)#GI /OC5Y(54Y05RD+>YJ+QA\Y#N>>->/B:%*^?D_1KMA$B
M)]]VVSB[&6WR?'\UF63A1NR";)SL15R\\YBDNR OGJ;K2;9/1;"J@G;;B648
MWF071/%H<5V]=I<NKI-#OHUB<9>2[+#;!>G?[\4V>;X9F:.7%[Y$ZTU>OC!9
M7.^#M;@7^>_[N[1X-CE15M%.Q%F4Q"05CS>C6_.*>T894!WQGT@\9XW'I/PH
M#TGRM7SR874S,LHS$EL1YB4B*'X]B:78;DM2<1Y_U=#1J<TRL/GXA<ZJ#U]\
MF(<@$\MD^T>TRC<WH]F(K,1C<-CF7Y+GWT3]@=R2%R;;K/J7/-?'&B,2'K(\
MV=7!Q1GLHOCX._A6_T<T @I.=X!5!UCM .>5 +L.L-L!WBL!3AW@7-J"6P>X
MEWX&KP[P+@V8U@'3*EG'_]TJ-7Z0!XOK-'DF:7ET02L?5/FMHHN,1'$IQ?L\
M+=Z-BKA\<9\GX==-LEV)-/OQAYEE3G\E]*]#E/]-?O)%'D3;C'P.TC0H%?,S
M^87\?N^3G_[Q\_4D+UHO&9.P;LD_MF2]TI)ID4])G&\R0N.56*F 27':IW.W
M7L[]O:4E_C.(Q\0VWA'+L)R.$UKJPYEX&!/3J<+MKL^C#_=%6+1NOMHZO3R\
MJW6F#_^</!4G/WLUG.O#;_=I$3[M"E=289]D9%<\^Q7><AMD&4D>2:4G\N?'
MXGWR(1>[[+\=)_?^"'.Z8>75]RK;!Z&X&167UTRD3V*T^/$'TS-^[<HR$N8C
M810)8T@8!\$4K3@GK3@Z^N)ST<'NTR048I5UB4,;/50<2)A_A$TK6-G'/RVF
M4\\VIO/KR5,S[^?'>;9E.E-#/8XA3XZ#8$I*W5-*76U*;__]B?SK\5&D4;PF
M?WX2NP>1=O[A:S%#<XN$^4@81<(8$L9!,$4EWDDE'K*3\)!:0<)\)(PB80P)
MXR"8HI7I22M3[17E*)$HRP[M4O$H#FWT4'$@8?X1YC4N_C/#F,^=5A^!;),A
M81P$4](^.Z5]ID_[)DA%41U$H>C*NC9X:-:1,/\(FS>R;H[G=BOGR!89$L9!
M,"7G\U/.YV^J![710Y..A/GSLSK/=(WRIY5W9*,,">,@F))WTY#>@Z'-_-TA
M#3=!)LCM.A5B)^)<6SSJ:4.5 *7Y4!J%TAB4QE$T53,-O\I$%I$U#:49),V'
MTBB4QJ TCJ*IFK&D9BQ]#W,HKRFE:+*ROLC>D2S9=I:5-:A9O3E3[^R*OM0W
M.%@(2!J%TAB4QE$T50C2I32UQM;BC]+)+GH9\4VD891I*LT:U"SHG+';5@'4
M>H32*)3&H#2.HJDJD/ZCJ3<@>9H47<A+R4D>TV17C32#.!3E12),=KLD)EG9
MP71JH\,'-#KJOJ7^/ ;K TFC4!J#TCB*INI#FIFFWLWL&Y#4X:J_VYE_J$,)
MI5$HC4%I'$53\R]M2E/K;.F&)>1_I"@XPV0;D[L@_4J6P3[*@RUAAWA%/GY<
MZL<O4$<32O.A- JE,2B-HVBJN*2O:4ZAXQ>HT0FE^5 :A=(8E,91-%4STA0U
M>US1'C-<'SY8)%!C%$JC-:TY/K/<=K_+H&UR%$U-OG1'3;T]VF.)ZZ,'YQ[J
MCT)IM*8UAV26.?;:N8?ZHRB:.K])&J26WB!]ZTA%CQ\J#BC-A])H36O6Y*YS
M5I$S:*,<15/5(:U02VN;]=2I=]NBY>K%VW6?LZYO:+!.H"XIE$:A- :E<11-
ME9-T22T+69E:2&-P":7Y4!J%TAB4QE$T53/24+4N,E2S=V1=_NXN3_6,P4J!
MFJXUK5E0>E;QT_H&%]HH@](XBJ9*0+JIEMY-O=Q3UX,&ZP!JKM8TTVP6$&//
M<MM"@-JF4!I'T50A2-O4TMNF4@C[J%PO4!2FJR#O5@)T'BB4YO=\RFK5 #',
M=Z2<.S_M["^@UBJ4QE$T52/26K7TUNI]L!79A=,]]*C!(H':I5 :A=(8E,91
M-%4PTBZUH':I!;5+H30?2J-0&H/2.(JF:D;:I=;;[%)]^&"10.U2*(U:'7;I
MS)G9;5<$ZI>B:&KVI5]JO<DOU4</3C[4+X72J-7AESICIYU[J%^*HJF+$*5?
M:G]?OU2/'RH.*,V'TJA][I=Z<_O<,(6VRE$T51[2,+7UAFG?Q Y]^.#T0VU0
M*(W6-"7]4ZLC_5"#$T53TR\-3EL_#?1>A(<TRJ-B!**WSK^(=93E(A4KXD>I
M"//SQ8W%4;=A6!P1Y<51'^(G45Q44NUX1G]V@]4%-4RA- JE,2B-HVBJ!AOK
MY+$+Y;$KY;%+Y;%KY;&+Y;&KY;^'PVI+A]76.ZQ]XQE]^&"1.&=C!GMN>-9,
M[1I\:*L42F-0&D?1U/1+7]76.XX] QI]].#LG\]M-;UVYJ$34:$T!J5Q%$W-
MO'1+;;U;^N;A#-1!K6F]TYY]:+,42F-0&D?15'U(<]36+Y+O'<] W=":IDRQ
M\3KS#S4ZH30&I7$43<V_-#KM'J,3.Z 9,F-(?V:#I07U4*$T"J4Q*(VC:*K^
MI-5JSZ&#&:CU"J7Y4!J%TAB4QE$T]=Y?TJ)U]!;M,L@VY%$4!:U(P^(J$ZP[
MJUH]9:A6:III-?HN8VRTAS301BF4QJ TCJ*I(I!&K*,W8K^(:/=P2+-C;U.H
MH?M&<% [UNFP/#N*%VBC%$IC4!I'T50-2#?6T;NQRR3.#MN\K$$NFP^BYPV6
M ]0_A=(HE,:@-(ZBJ:J1_JD#]4\=J'\*I?E0&H72&)3&4315,XW[C>K]TXLF
M*>L9@Y6"I/E0&H72&)3&G7/SV71GAC$]]=*J!J2)ZEPZ.;5OEK(>-%@(T+FI
M4!J%TEA-:TXWF;9GF_".@RRC<92:76F4.GJC=,#48SUI<'JALTJA- JEL9X,
MG.Y'7LZ*=CO_M/6 TQW)2X"GN^Y+>]31VZ/+HSU>5PJZRA+JDT)I/I1&H30&
MI7$4356+-%.=&;2RA!J@4)H/I5$HC4%I'$53-2,-4*=GKFG/-_/Z\,$B@3J>
M-4V9&VR[GNN<W<W^_$#',CW3;-_-'FI3HFCJ_>RE3>GVW)HT%;^4-_41*_(R
M?%"^*AEVYU)]8T-U *7Y4!J%TAB4QE$T55+2]'2A=RYUH>XGE.9#:11*8U :
M1]%4S4B3U-6;I!=9%^[Y34M-8SIWW?;]*O6-#18!U/.$TAB4QE$T5032\W11
M=RVM03/U:R[#,-M"@!J94!J%TAB4QE$T50C2R'3U1F;/3, ZNIE]9^S,Y_-V
M]J'F))1&H30&I7$43<U^8X^EBRS,HB]XN1!T]P;NI;T!=O\D[ 9*V!V4L%LH
M?8])H:[T.MW+O,XWC$:@%BB4YD-I%$IC4!I'T50927/4A2ZL=Z$6*93F0VD4
M2F-0&D?15,U(B]35SS>];#1RON;<=*N?=O\#]3RA- JE,2B-HVBJ"*3GZ>H]
MSP&CD?,%Z.=[*.A;&ZP"Z#1.*(U!:1Q%4W=RE/ZHI_='!WSCVD,Z[>)<?O$W
M[^HM]("A$H'2*)3&H#2.HATE,FEL,KX3Z;K:/SXC87*(\^.>W:=7CWO4^^85
MK;9R;[U^:U[=5CNV3R3FN/']IR!=1W%&MN*Q0!KC:5%II\>]Y(]/\F1?;67^
MD.1YLJL>;D2P$FEY0/'^8Y+D+T_*!IZ3]&MUVHO_ U!+ P04    " #I@W1:
M?030".D#  !0$   &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6S-6%&/
MVC@0_BM6[E1MI5T2)R' %B(5:'4K=4^KY;9]J/I@DH%$F]B<;:#]]V<G(036
MY'8ED/H"B3/S^?N&\62&X9;Q9Y$ 2/0SSZ@868F4JUO;%E$".1$=M@*JGBP8
MSXE4MWQIBQ4'$A=.>6:[CA/8.4FI%0Z+M0<>#ME:9BF%!X[$.L\)_S6&C&U'
M%K9V"X_I,I%ZP0Z'*[*$&<BGU0-7=W:-$J<Y4)$RBC@L1M9'?#O!@78H++ZF
ML!6-:Z2ES!E[UC=W\<AR-"/(()(:@JBO#4P@RS22XO%O!6K5>VK'YO4._7,A
M7HF9$P$3EGU+8YF,K+Z%8EB0=28?V?8OJ 1U-5[$,E%\HFUEZU@H6@O)\LI9
M,<A36GZ3GU4@&@Y*J-G!K1S<8P?_A(-7.7B%T))9(6M*) F'G&T1U]8*35\4
ML2F\E9J4ZI]Q)KEZFBH_&<Y47L3K#!!;H+]5UGQA0J 'X&B6$ YH3$0:(4)C
M-$VSM80874U!DC03[]$->II-T=6?[X>V5$PTGAU5NX[+7=T3NV(7W3,J$X$^
MT1CB0P!;2:AUN#L=8[<5<0I1!WGX&KF.ZQL(35[O[K70\>JP>@6>=P+O$^$T
MI<M&**_+6%ZC^2\T87FN4GB2$2&NT1V-LG6LK-$_6U8NHGN0"8O1]R\*%]U)
MR,4/4Y1+$KZ9A*X MV)%(AA9ZH@+X!NPPG=_X,#Y8(K0F< .XN77\?+;T$.=
M>IE./;)1R47F*B$E0U$9)Z'CE[ L!BY,42BA>P6T+EN;\ ;C?M=1'T-[TY1H
MM,0N[KI.;7G OUOS[[;R_U:4"W4\R :X*G^(KO.Y^NG5J6J*$#=SG00F$25^
MT*#F.=W!P F.)+RTPQ[&W9YK%A#4 H+S"(C+.F"2$+Q2PDN[5@F]6D*O54)9
MJ^@NDU:*?<'91+5$&C03P>OT>T=$#5;]CM\WT^S7-/NM-'>%]'5$^Z\B:K Z
M3710$QVT$GT$(7D:::XSR:)G]$13*=#5X^Q)5?_O]Z 3Q%B66G'?6I;.!'80
M NSL7X_.[U#(*Q9G"MFYT YCUF@I\(6+8;7!08GP>UYPG/<F.]</\,"<^=C=
M2W O7@ZK+?Y?A,&N3<2^!\&MK^RPRL[R\+:=UW:<-V??)1H)O.\DL/];G-C6
MAN;-,3L3VF',]MT+OG3[@E_V)>X NUUO<)SMA@8&]X-!]\3;'^\[&'SY%@:_
M[$U.R# T,489=F,VRX$OBY%5*$9K*LOQIEXMQ^*Q'HOU;'>TKL;EC\60:.]A
MREG[GO!E2@7*8*$@G4Y/A9B7XVMY(]FJF #G3*IYLKA,U,@/7!NHYPO&Y.Y&
M;U#_B1#^!U!+ P04    " #I@W1:SDF>[HT"   &!@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6RM5$UOVS ,_2N$!PP;T-9?:;9UB8$D[= ="@0U
MNAV&'12;B87*DB?)2??O1\F.EQ9)L<,NMC[X'ODHDI.=TH^F0K3P5 MIID%E
M;7,5AJ:HL&;F0C4HZ6:M=,TL;?4F-(U&5GI0+<(DBL9AS;@,LHD_6^ILHEHK
MN,2E!M/6-=._YRC4;AK$P?[@GF\JZP[";-*P#>9H'YJEIETXL)2\1FFXDJ!Q
M/0UF\=5BY.R]P3>..W.P!J=DI=2CVWPMIT'D D*!A74,C'Y;7* 0CHC"^-5S
M!H-+!SQ<[]F_>.VD9<4,+I3XSDM;38./ 92X9JVP]VIWB[V>2\=7*&'\%W:]
M;11 T1JKZAY,$=1<=G_VU.?A !"/3P"2'I"\!(Q. -(>D'JA761>UC6S+)MH
MM0/MK(G-+7QN/)K4<.E>,;>:;CGA;)93692M0%!KF$G+STLN6I=9R+%H-;<<
M#=P\%:(ML82U5C4L5-VTEOE7(-0-TY++C8$E:L@KIA'>7:-E7)CW< [&G9A)
M:"E8YS(L^L#F76#)B<#B!.Z4M!5YE^3Z.4%(*@>IR5[J/'F5\1J+"TCC,TBB
M9'0DH,6_P]-7PDF'S*>>+SW!=R1O/V8K8S55]L]C^>KH1L?I7+=?F885. VH
MG0WJ+0;9VS?Q./I\3.M_(GNF?#0H'[W&GN56%8^@&E=!Y@Q:N45CJ;KN\]GS
M[8,!)DMH6EU4U*JP8UHS:8]64^=R[%VZT;7-DBA.XTMZZ>VA\"-VG\9I,A[,
M.DGA04O5J#=^TA@H5"MM5W+#:3?,YC3,?-._.*<A-_.]'?ZEZ2;D'=,;+@T(
M7!-E=/'A,@#=39UN8U7C&W>E+(T!OZQH4*-V!G2_5LKN-\[!,/JS/U!+ P04
M    " #I@W1:MD$=6!$#  !J"P  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6S%5EUOVC 4_2M6)DVMM#9?$$H'D8!N:J6V0J!N#]4>3'(A46,[LPVT
M_WZV$U)" UI5I+Z [=Q[?.[Q<7)[:\:?1 (@T3/)J.A;B93YI6V+* &"Q3G+
M@:HG<\8)EFK*%[;(.>#8))',]APGL E.J17VS-J8ASVVE%E*8<R16!*"^<L0
M,K;N6ZZU69BDBT3J!3OLY7@!4Y /^9BKF5VAQ"D!*E)&$8=YWQJXER/7T0DF
MXE<*:[$U1KJ4&6-/>G(3]RU',X(,(JDAL/I;P0BR3",I'G]+4*O:4R=NCS?H
M/TWQJI@9%C!BV>\TEDG?NK!0#'.\S.2$K:^A+*BM\2*6"?.+UD5LIVNA:"DD
M(V6R8D!26OSCYU*(K00WV)/@E0G>;D)K3X)?)OBFT(*9*>L*2QSV.%LCKJ,5
MFAX8;4RVJB:E^ABGDJNGJ<J3X;URRBT3 N7 T33!'!";HQ$C1&D\E2QZ0B=7
M('&:"72/.<=:]5-TAH2.%3U;*A(:RH[*#8?%AMZ>#5T/W3$J$X%^T!CB.H"M
MV%<E>)L2AMY!Q"N(SI'O?D.>X[4:"(W^/]T_0,>O%/4-GK\'SXAX-E36BK6.
MZKX);!P[4.K1!:@[(-'L!6W'C?&+61ZL,8_1XZV"1#<2B/C3)'"Q?ZMY?WWO
M+T6.(^A;ZF(+X"NPPJ]?W,#YWB3.D<!J4K4JJ5J'T NI!%K2%0BYZX6BU@(@
M, #ZE;0*/<?UW;8ZZ-5V&0UQW<#W@BJL1K!=$6P?)#A1O'@:*6[E77B\ S(#
MWG@L!Z'>>RQ' JM5'515!Y_LX."84AT)K"95IY*J\U$'=]XXT]GQ[ML(UVL[
MS<Z]J(A=O,^Y#S25 IU,I@_B]*"-#^*^]VR.!%:3H%M)T/UD&W>/*=61P&I2
MN<YK&^!\U,@E0NT=Z[<"_=&LV;DASG6\[;B"H[W5M1#@"]/,"12Q)97%U[]:
M+1K&H6X8==>SLZX:R8%IG^Q7F*(+O<-\D5*!,I@K2.>\HUZKO&CLBHEDN>F-
M9DRJ3LL,$]4, ]<!ZOF<,;F9Z VJ]CK\!U!+ P04    " #I@W1:B*+"YOH"
M   ["P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6RU5N]OVC 0_5=.
MF31UTD1^ 84.(K6P:I5:#=%M_5#M@TD.L)K$J>U ^>]G.R$C$V2ME'Z!.+Y[
MOO?NQ;K1EO$GL4:4\)+$J1A;:RFS"]L6X1H3(CHLPU3M+!E/B%1+OK)%QI%$
M)BF);<]Q^G9":&H%(_-NQH,1RV5,4YQQ$'F2$+Z[PIAMQY9K[5_,Z6HM]0L[
M&&5DA?<H?V8SKE9VA1+1!%-!60H<EV/KTKV8#'6\"?A%<2L.GD$S63#VI!<W
MT=AR=$$88R@U E%_&YQ@'&L@5<9SB6E51^K$P^<]^K7AKK@LB, )BQ]H)-=C
M:V!!A$N2QW+.MM^PY-/3>"&+A?F%;1GK6!#F0K*D3%85)#0M_LE+J<-!@N>=
M2/#*!._?A.Z)!+],\ W1HC)#:THD"4:<;8'K:(6F'XPV)ENQH:GNXKWD:I>J
M/!G<*UM$>8S EO!@.&,$EQODJH4P1^T#FJ[@%I54\ -Y(H"D$4RI"%F>2I@3
MB:#,!-\SE2-UK-Z_IBE)PRI3P-D4):&Q^#2RI2I;'VZ'98E718G>B1*G&';
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MZX\0$&:!?K_D7!T&YEZL/FOB/U!+ P04    " #I@W1:D"T,464"   M!@
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M'GOAE6L!] ^-;Z0W3*VYT%CW%5*&HW-4IGQS\H&1C;O?2VFP6[AAB?T<E$W
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M@@61SDL\>DI3N'>I%R"SNG11*!$5U\W][D9=>73>% 6[Z4UM91;+*%>(P=I
MH^[0G,VR*5>:CA9E72*LA#8%1]W,38D'TDXPW]="Z&W'+N"*QND_4$L#!!0
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M$I[36O64R23CLA(4_7,WETI FOUK$M@@^F9$O?=N9$D2.K)@<TDJUM0:7WS
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M#>#]@G/U.M%7MO:*/OX?4$L#!!0    ( .F#=%KT?C.KF0(  ((&   9
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MM@#O+Z4TV\ ^H/OLI+\!4$L#!!0    ( .F#=%J5?&S9&04  #,3   9
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M>W+./3?F=I=2W>L9@"$/!1>ZY\V,*2]\7Z<S**@^ER4(?#*5JJ &ERKW=:F
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M')G<[0R'6E V )]/I33KA7U!/2;W_P%02P,$%     @ Z8-T6H)^+JXZ @
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M2\(PCMT(8&X%88@AL!MQ!%, &C D#*OWX,[[R%^]I_SU;Z2#OU!+ P04
M" #I@W1:EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
M4$L#!!0    ( .F#=%IH"1SY^00  '<F   /    >&PO=V]R:V)O;VLN>&UL
MQ9I+<]LV$(#_"D8G]Y!*?#F))\J,8KMM9E1;8[G.,0.1*PEC$E  4([]ZPN
ME;.TY)U>()]D/DQ]7 C[[8+\]*#T_4*I>_:SJ:49#];6;LZ&0U.NH>'F=[4!
MZ8XLE6ZX=9MZ-30;#;PR:P#;U,-T-#H=-ES(P>=/NVO-]!!O* NE%4JZG7['
MG8 '\^NXWV1;8<1"U,(^C@?A[QH&K!%2-.()JO%@-&!FK1[^4EH\*6EY/2^U
MJNOQ(.D.W(&VHMS;/?>0MWQAPA[+%S?<@8P'IR-WP:70QH8SPO6Y8]R".[G;
M:JWZ0]06] 6W\*=6[4;(E;^,NXLANHT0A]UG%\0S_7_"J)9+4<*%*ML&I.WB
MJ*'V@-*LQ<8,F.0-C ?G:@O:WX_[@J]5=V_60:%(Z3/A#NBO5<"+B2*-JD7E
MOKUB7WC-90DLA- @P)0 3-\,D)W,.(+,",CLB)!S#^'_P3"U9->;WE#G!&3^
M9I#G:RX19$% %F\'R<T:09X2D*=O"/D]19#O"<CW<2%G_)%M#9N!#O_NI\V%
M,&6M3*L!(7X@$#_$1?PJC:A LUO-*Y>+V41K+E==,!'A1X+PXW$)9V[82P&&
M<5FQ62^'CZ@D/HK\@WQ<@#90MMKYEMT(<\_^YI)WH60X22:D:R++YEJON!1/
MX0!FHO221/;+%VY$F+DS#<:=&LX(PSMOFZ87.DHP263#S*TJ[]\MN'$9YUPU
M[DIF+XR46Y+(<@E\:U6[R6*^L\L?K?LA8C9**4EDIURYZTZ5,<RIV)4.7$/(
MU*IIW$C/+<:DI))$MLH4W.CBO)=0]D@BZV/J3I,&V&2E82\C)Y0TDNC6*%4#
M[);_[$>+TD02V1,W?J>;FC.N70)VMG#3,W1(O2J:4D0:61%38<7J9<I(*1ND
MD6TPAU70TPULE.OUY J#D1U']):C:83M2CHO E?N>3R0WOP8DA)"&K_E<!/4
MZLY7/I]IJ(0-\L>,E!32V%)H%P9^M'Z0+[<O4DA*&2&-; 12^KT"/J6,D$8V
MPFO29R>W/)#\PJ14D496!>G7?C0I;Z21O='Y];_8F=\P%J6.-+(Z]D5["#&C
MW)%%=@<V[D$X2B/9L35RD)#R21;9)[CM82<78+FH#;OBVB?O+9[&&;F&%=DH
M=%+,,"8EE2RV5-PUJK8..>9 @L28E&*RR(K9PV37FQ#0B5^5%AB34DP66S$(
M\P:,U:+L%K4\\>0!8U**R2(KAL3\!Y>T&:68++)B,.8W/[]]-N\&W+4%)QB3
M4DX663D',-D=K]MNQD_P<C6EG3RR=EXO?T(.Q9B4@/+8 CJP]('2/,:D+)1'
MMA >].>*;?9<L6%,RD)Y[(4NA#EQ?=>[2M2MUR2;^_5-C$D^2XEL(;KFQ;+,
M*0OE1[30-Q"KM<^:DRUHO@*72#$F9:'\B!::2-GRFH5JG4T%7X@:8U(6RH]H
MH3W,7J.34Q;*C]3H[%6:N"+.*0'E1Q30@?X'/XJD!%0<M>^A"O>"$E 16T H
MFI?+)837'M@S/,:D!%0<44 7L 2M72YRL6438_JO&Q24@(K( GI]*3?\!# F
M):#BB&U0U_KZII?MNF&,23[./Z* ]C![*;.@!%1$?Z)/+/GV"O>"$E 16T O
M%U3[60EC4@(J@H"&NQ>=*E@*"=65^PKC]I>\+F>:^8_NZ6Q>^&<KR[:NS]V^
M:SE5O-J]-[5[Y^OSOU!+ P04    " #I@W1:$R?LNN\!  "E(@  &@   'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=J[3NM %(7A5XG\ $SV+< 1H:*A
M1;R %287D<26/0AX>Z)0A&51G ;-JJRQY>V_^F2-??>4]VW9=<=QN^O'V<=A
M?QR7S;:4_E]*XVJ;#^UXU?7Y>+JR[H9#6T[+89/Z=O7:;G+2^7R1AI\SFON[
MGS-GSY]]_I^)W7J]6^6';O5VR,?RR^#TW@VOXS;GTLR>VV&3R[))'_O+Z3&=
M#W)UFMS,'E^6S?#X(DVJ':00I/6##(*L?I!#D-</"@B*^D$+"%K4#[J&H.OZ
M03<0=%,_Z!:";NL'R1QEG!,D3; FT%J0:R'P6A!L(1!;D&PA,%L0;2%06Y!M
M(7!;$&XAD%N0;B&P6Q!O(=!;46\ET%M1;R706R<OVP1Z*^JM!'HKZJT$>BOJ
MK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM!'K;9+.$0&]#
MO8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U ;T>]G4!O1[V=0&]'
MO9U ;Y]L=A/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z!VH=Q#H':AW$.@=
MJ'<0Z!VH=Q#H':AW$.@=DX^5!'H'ZAT$>@?J'01Z!^H=?ZGW6#[W>;ST?*_Q
M^7])=3G=FR^//R^_3Z*$BS/."?Y*N?\"4$L#!!0    ( .F#=%IB(^<8V $
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MKYZZ5(A\K,<_\2,QE3[Z^Z@_[9+*7V:G[7VV?CV<1V##[?@]_GS&'_4/[$.
M]"%!^E @?6B0/N8@?9R"]'$&TL<Y2!]\AM((BJ@<A52.8BI'096CJ,I16.4H
MKG(46#F*K )%5H$BJT"15:#(*E!D%2BR"A19!8JL D56@2*K1)%5HL@J4625
M*+)*%%DEBJP215:)(JM$D56BR*I09%4HLBH4616*K I%5H4BJT*15:'(JE!D
M52BR:A19-8JL&D56C2*K1I%5H\BJ4635*++J_Y3UR=KU7__;T-_SUM3=>SX;
M?B"Y>@502P$"% ,4    " #I@W1:1L=-2)4   #-    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .F#=%JL0NUG\0
M "L"   1              "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( .F#=%J97)PC$ 8  )PG   3              "  >,!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ Z8-T6K&_FT[W!P  ?S0  !@
M             ("!) @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( .F#=%JP/HSY- 8  )H<   8              " @5$0  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #I@W1:#Z0;:?T"  "%
M"@  &               @(&[%@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ Z8-T6B#2OC_: P  * X  !@              ("![AD
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .F#=%IM?+2C
MJ@8   $L   8              " @?X=  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " #I@W1:*O? IS,'   +(   &
M@('>)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ Z8-T
M6E5]QZ$[ @  Q00  !@              ("!1RP  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( .F#=%J?;E8T3 (  *,%   8
M      " @;@N  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" #I@W1:WD5[$DP"  "2!@  &               @($Z,0  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ Z8-T6CRE,S@1 @  W00  !D
M             ("!O#,  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " #I@W1:E[(#;? &   [%@  &0              @($$-@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .F#=%I&\Q"!D@@
M -,3   9              " @2L]  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ Z8-T6L-.H'JR$0  ;B\  !D              ("!
M]$4  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #I@W1:
MIQ$'WEL*  !S&@  &0              @('=5P  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( .F#=%J9@!6Z>0,  *\'   9
M      " @6]B  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ Z8-T6D!8<LI&!0  RPT  !D              ("!'V8  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #I@W1:M7:5*=4$  "U"P
M&0              @(&<:P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( .F#=%I&6[F4>P,  &\'   9              " @:AP  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ Z8-T6A88KZ^_
M"   &A0  !D              ("!6G0  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " #I@W1:&B)<[,T"   R!@  &0
M@(%0?0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .F#
M=%K!JNOHZ00  -H*   9              " @52   !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ Z8-T6F#VD'W&!0  *PT  !D
M         ("!=(4  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " #I@W1:"JYRJR\#   @!P  &0              @(%QBP  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( .F#=%H2-+IG 0,  (X&
M   9              " @=>.  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ Z8-T6N"1,3W5!   I@H  !D              ("!#Y(
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #I@W1:U*:;
M>N(2  #]-P  &0              @($;EP  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( .F#=%H=V'D2-@<  +P;   9
M  " @32J  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
MZ8-T6L]%X-K5 P   @H  !D              ("!H;$  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " #I@W1:,2U4T6P#   J"@  &0
M            @(&MM0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( .F#=%J'V@,WN (    &   9              " @5"Y  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ Z8-T6HNAY!NP!
M0@L  !D              ("!/[P  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " #I@W1:O<G2*/(#  !:"0  &0              @($F
MP0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .F#=%K.
M"4OL;@<  )-(   9              " @4_%  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ Z8-T6N*V5)R5 P  ?@T  !D
M     ("!],P  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M" #I@W1:SU+1D"D#  !J"P  &0              @(' T   >&PO=V]R:W-H
M965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( .F#=%H"\3DKQ@,  #@.   9
M              " @2#4  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L!
M A0#%     @ Z8-T6AW4_<?L P  A0\  !D              ("!'=@  'AL
M+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #I@W1:^IHZS&8$
M  #,$@  &0              @(% W   >&PO=V]R:W-H965T<R]S:&5E=#,X
M+GAM;%!+ 0(4 Q0    ( .F#=%J; T>5300  "@2   9              "
M@=W@  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ Z8-T
M6KPF;HB2 P  G!(  !D              ("!8>4  'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " #I@W1:CBLDHB(.  "'R0  &0
M        @($JZ0  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( .F#=%K1^"Q-RPH  -U_   9              " @8/W  !X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ Z8-T6GT$T CI P  4!
M !D              ("!A0(! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " #I@W1:SDF>[HT"   &!@  &0              @(&E!@$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( .F#=%JV01U8
M$0,  &H+   9              " @6D) 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ Z8-T6HBBPN;Z @  .PL  !D
M ("!L0P! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #I
M@W1:N46<X^$"  "A"   &0              @('B#P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( .F#=%H[-*"@^ (  .((   9
M          " @?H2 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#
M%     @ Z8-T6I M#%%E @  +08  !D              ("!*18! 'AL+W=O
M<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #I@W1:-):2W.$"  !
M"@  &0              @('%& $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM
M;%!+ 0(4 Q0    ( .F#=%HSTVLB;@0   D/   9              " @=T;
M 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ Z8-T6JO+
M6^4< P  70D  !D              ("!@B ! 'AL+W=O<FMS:&5E=',O<VAE
M970U,BYX;6Q02P$"% ,4    " #I@W1:%"Z&M30$  "N#P  &0
M    @('5(P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M .F#=%KT?C.KF0(  ((&   9              " @4 H 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ Z8-T6I5\;-D9!0  ,Q,  !D
M             ("!$"L! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " #I@W1:F,D'L$L#   R"P  &0              @(%@, $ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( .F#=%J"?BZN.@(
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( .F#=%IH"1SY^00  '<F   /
M      "  0A" 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #I@W1:$R?L
MNN\!  "E(@  &@              @ $N1P$ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #I@W1:8B/G&-@!  !((@  $P
M    @ %520$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0@!"  42  !>
%2P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>145</ContextCount>
  <ElementCount>309</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Net Loss per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock</Role>
      <ShortName>Net Loss per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999021 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Concentration of Credit Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ConcentrationOfCreditRisk</Role>
      <ShortName>Concentration of Credit Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Stock-basedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Net Loss per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables</Role>
      <ShortName>Net Loss per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Leases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999033 - Disclosure - License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/LicenseAgreementsTables</Role>
      <ShortName>License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/LicenseAgreements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/SegmentReporting</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Organization (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OrganizationDetailsNarrative</Role>
      <ShortName>Organization (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Organization</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Schedule of Restricted Stock Awards (???RSAs???) Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails</Role>
      <ShortName>Schedule of Restricted Stock Awards (???RSAs???) Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Schedule of Restricted Stock Units (???RSUs???) Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails</Role>
      <ShortName>Schedule of Restricted Stock Units (???RSUs???) Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Schedule of Warrants Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails</Role>
      <ShortName>Schedule of Warrants Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Schedule of Warrant Valuation Assumption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails</Role>
      <ShortName>Schedule of Warrant Valuation Assumption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Stock-based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/StockholdersEquity</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails</Role>
      <ShortName>Schedule of Net Loss Per Share Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative</Role>
      <ShortName>Net Loss per Share of Common Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails</Role>
      <ShortName>Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails</Role>
      <ShortName>Schedule of Annual Lease Liabilities for all Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails</Role>
      <ShortName>Schedule of Annual Lease Liabilities for all Financing Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Schedule of License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails</Role>
      <ShortName>Schedule of License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/IncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/RelatedPartyTransactions</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails</Role>
      <ShortName>Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical</Role>
      <ShortName>Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/SubsequentEvents</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>pcsa-20241231.xsd</File>
    <File>pcsa-20241231_cal.xml</File>
    <File>pcsa-20241231_def.xml</File>
    <File>pcsa-20241231_lab.xml</File>
    <File>pcsa-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="518">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>105
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "PCSA",
   "nsuri": "http://processapharmaceuticals.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "pcsa-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pcsa-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pcsa-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pcsa-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pcsa-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 249,
   "keyCustom": 60,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 21,
   "memberCustom": 39,
   "hidden": {
    "total": 78,
    "http://fasb.org/us-gaap/2024": 60,
    "http://processapharmaceuticals.com/20241231": 15,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 145,
   "entityCount": 1,
   "segmentCount": 67,
   "elementCount": 586,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 518,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/cyd/2024": 9,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://processapharmaceuticals.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://processapharmaceuticals.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://processapharmaceuticals.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://processapharmaceuticals.com/role/Organization",
     "longName": "999015 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "999016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensation",
     "longName": "999017 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://processapharmaceuticals.com/role/StockholdersEquity",
     "longName": "999018 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock",
     "longName": "999019 - Disclosure - Net Loss per Share of Common Stock",
     "shortName": "Net Loss per Share of Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://processapharmaceuticals.com/role/Leases",
     "longName": "999020 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://processapharmaceuticals.com/role/LicenseAgreements",
     "longName": "999021 - Disclosure - License Agreements",
     "shortName": "License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "PCSA:LicenseAgreementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "PCSA:LicenseAgreementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://processapharmaceuticals.com/role/IncomeTaxes",
     "longName": "999022 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://processapharmaceuticals.com/role/RelatedPartyTransactions",
     "longName": "999023 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://processapharmaceuticals.com/role/Litigation",
     "longName": "999024 - Disclosure - Litigation",
     "shortName": "Litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "PCSA:LitigationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "PCSA:LitigationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://processapharmaceuticals.com/role/SegmentReporting",
     "longName": "999025 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://processapharmaceuticals.com/role/CommitmentsAndContingencies",
     "longName": "999026 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://processapharmaceuticals.com/role/ConcentrationOfCreditRisk",
     "longName": "999027 - Disclosure - Concentration of Credit Risk",
     "shortName": "Concentration of Credit Risk",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://processapharmaceuticals.com/role/SubsequentEvents",
     "longName": "999028 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999029 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensationTables",
     "longName": "999030 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables",
     "longName": "999031 - Disclosure - Net Loss per Share of Common Stock (Tables)",
     "shortName": "Net Loss per Share of Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://processapharmaceuticals.com/role/LeasesTables",
     "longName": "999032 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://processapharmaceuticals.com/role/LicenseAgreementsTables",
     "longName": "999033 - Disclosure - License Agreements (Tables)",
     "shortName": "License Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "PCSA:LicenseAgreementsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "PCSA:LicenseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "PCSA:LicenseAgreementsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "PCSA:LicenseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://processapharmaceuticals.com/role/IncomeTaxesTables",
     "longName": "999034 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://processapharmaceuticals.com/role/SegmentReportingTables",
     "longName": "999035 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
     "longName": "999036 - Disclosure - Organization (Details Narrative)",
     "shortName": "Organization (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-222024-01-22",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-222024-01-22",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999037 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidExpenseNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "longName": "999038 - Disclosure - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "999039 - Disclosure - Schedule of Stock Option Activity (Details)",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
     "longName": "999040 - Disclosure - Schedule of Restricted Stock Awards (\u201cRSAs\u201d) Activity (Details)",
     "shortName": "Schedule of Restricted Stock Awards (\u201cRSAs\u201d) Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_RestrictedStockAwardMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_custom_RestrictedStockAwardMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
     "longName": "999041 - Disclosure - Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity (Details)",
     "shortName": "Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails",
     "longName": "999042 - Disclosure - Schedule of Warrants Activity (Details)",
     "shortName": "Schedule of Warrants Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "PCSA:ScheduleOfWarrantValuationAssumptionTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "PCSA:ScheduleOfWarrantValuationAssumptionTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails",
     "longName": "999043 - Disclosure - Schedule of Warrant Valuation Assumption (Details)",
     "shortName": "Schedule of Warrant Valuation Assumption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999044 - Disclosure - Stock-based Compensation (Details Narrative)",
     "shortName": "Stock-based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_WarrantMember_custom_OfferingMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_WarrantMember_custom_OfferingMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999045 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_ATMOfferingMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
     "longName": "999046 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)",
     "shortName": "Schedule of Net Loss Per Share Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "999047 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
     "longName": "999048 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)",
     "shortName": "Net Loss per Share of Common Stock (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_RestrictedStockMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails",
     "longName": "999049 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)",
     "shortName": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_FacilityLeaseMember",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails",
     "longName": "999050 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)",
     "shortName": "Schedule of Annual Lease Liabilities for all Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails",
     "longName": "999051 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)",
     "shortName": "Schedule of Annual Lease Liabilities for all Financing Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://processapharmaceuticals.com/role/LeasesDetailsNarrative",
     "longName": "999052 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails",
     "longName": "999053 - Disclosure - Schedule of License Agreements (Details)",
     "shortName": "Schedule of License Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_ElionOncologyIncMember",
      "name": "PCSA:LicenseAgreementsDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "PCSA:LicenseAgreementsTableTextBlock",
       "PCSA:LicenseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_ElionOncologyIncMember",
      "name": "PCSA:LicenseAgreementsDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "PCSA:LicenseAgreementsTableTextBlock",
       "PCSA:LicenseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999054 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "999055 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999056 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999057 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_CorLystLLCMember",
      "name": "PCSA:ProceedsFromRentAndOtherCostsReimbursements",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_CorLystLLCMember",
      "name": "PCSA:ProceedsFromRentAndOtherCostsReimbursements",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
     "longName": "999058 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)",
     "shortName": "Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember",
      "name": "PCSA:PreclinicalClinicalTrialAndOtherCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
     "longName": "999059 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)",
     "shortName": "Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_custom_CorLystLLCMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999060 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_CROsMember",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_CROsMember",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999061 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2025-01-27_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-01-27_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "PCSA_ATMOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ATMOfferingMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM Offering [Member]",
        "documentation": "ATM Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_AccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "AccountingPoliciesLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AccountingPoliciesLineItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_AccountingPoliciesLineItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "AccountingPoliciesLineItemsAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Line Items]",
        "documentation": "Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r576"
     ]
    },
    "PCSA_AccreditedInvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "AccreditedInvestorMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accredited Investor [Member]",
        "documentation": "Accredited Investor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r710",
      "r711",
      "r712",
      "r713",
      "r761",
      "r811"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares withheld to pay income taxes on stock-based compensation",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of stock award",
        "documentation": "Adjustments to additional paid in capital settlement of stock awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant granted in connection with a consulting agreement",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r27",
      "r76"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_AdministrativeAndFacilitiesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "AdministrativeAndFacilitiesExpense",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Administrative and facilities expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r642",
      "r668"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r631",
      "r645",
      "r671"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r621",
      "r632",
      "r646",
      "r663",
      "r672",
      "r676",
      "r684"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "verboseLabel": "General and administrative personnel costs include employee stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r310"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive securities excluded from computation of earnings per share",
        "verboseLabel": "Stock options, unvested RSAs, unvested RSUs and purchase warrants",
        "terseLabel": "Shares unvested",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "PCSA_AposenseLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "AposenseLtdMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aposense, Ltd. [Member]",
        "documentation": "Aposense, Ltd. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r97",
      "r114",
      "r135",
      "r167",
      "r175",
      "r200",
      "r204",
      "r213",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r356",
      "r358",
      "r376",
      "r414",
      "r495",
      "r557",
      "r558",
      "r576",
      "r589",
      "r726",
      "r727",
      "r771"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r118",
      "r135",
      "r213",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r356",
      "r358",
      "r376",
      "r576",
      "r726",
      "r727",
      "r771"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-current Assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r213",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r356",
      "r358",
      "r376",
      "r726",
      "r727",
      "r771"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Assets",
        "label": "Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r601",
      "r603",
      "r624"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r601",
      "r603",
      "r624"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r601",
      "r603",
      "r624"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "PCSA_CROsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "CROsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CROs [Member]",
        "documentation": "CROs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r112",
      "r548"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents - Beginning of Year",
        "periodEndLabel": "Cash and Cash Equivalents - End of Year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r133"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Decrease in Cash and Cash Equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r64"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ChiefExecutiveOfficerAndCertainBoardMembersMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer and Certain Board Members [Member]",
        "documentation": "Chief Executive Officer and Certain Board Members [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r115",
      "r116",
      "r117",
      "r135",
      "r155",
      "r156",
      "r159",
      "r161",
      "r169",
      "r170",
      "r213",
      "r239",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r249",
      "r250",
      "r253",
      "r256",
      "r263",
      "r376",
      "r452",
      "r453",
      "r454",
      "r455",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r483",
      "r504",
      "r526",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r701",
      "r707",
      "r714"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r169",
      "r249",
      "r250",
      "r251",
      "r253",
      "r256",
      "r261",
      "r263",
      "r452",
      "r453",
      "r454",
      "r455",
      "r565",
      "r701",
      "r707"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "PCSA_ClassOfWarrantOrRightExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ClassOfWarrantOrRightExercised",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Class of warrant or right exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase common stock",
        "verboseLabel": "Warrants, granted",
        "terseLabel": "Warrants to purchase",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_CoNCERTPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "CoNCERTPharmaceuticalsIncMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CoNCERT Pharmaceuticals, Inc [Member]",
        "documentation": "CoNCERT Pharmaceuticals, Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r90",
      "r415",
      "r482"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r233",
      "r234",
      "r544",
      "r723",
      "r725"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum equity available for issuance under the plan",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r580",
      "r581",
      "r583",
      "r584",
      "r585",
      "r586",
      "r710",
      "r711",
      "r713",
      "r761",
      "r809",
      "r811"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r483"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r54",
      "r483",
      "r501",
      "r811",
      "r812"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.0001, 100,000,000 shares authorized; 3,707,628 issued and 3,702,628 outstanding at December 31, 2024 and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r417",
      "r576"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/ConcentrationOfCreditRisk"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "PCSA_ConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ConsultantMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultant [Member]",
        "documentation": "Consultant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement [Member]",
        "documentation": "Consulting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_CorLystLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "CorLystLLCMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CorLyst, LLC [Member]",
        "documentation": "CorLyst, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r611",
      "r694"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r611",
      "r694"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r696"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r696"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r606",
      "r689"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r607",
      "r690"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r607",
      "r690"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r605",
      "r688"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r608",
      "r691"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r610",
      "r693"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r610",
      "r693"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r611",
      "r694"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r612",
      "r695"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r609",
      "r692"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total non-current deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r89",
      "r331"
     ]
    },
    "PCSA_DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchased in-process R&amp;D",
        "documentation": "Deferred tax asset acquired inprocess research and development tax effected."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets, capital loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research and development costs",
        "documentation": "Deferred tax assets capitalized research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research and development net of amortization",
        "documentation": "Deferred tax assets capitalized research and development net of amortization."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_DeferredTaxAssetsFederalOrphanDrugCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "DeferredTaxAssetsFederalOrphanDrugCredits",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal orphan drug credits",
        "documentation": "Deferred tax assets federal orphan drug credits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carry forward \u2013 Federal",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carry forward \u2013 State",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and other",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "PCSA_DeferredTaxAssetsStartupExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "DeferredTaxAssetsStartupExpenditures",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Start-up expenditures and amortization",
        "documentation": "Deferred tax assets startup expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance for deferred tax assets",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax asset (liability)",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible asset",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r26"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r810"
     ]
    },
    "PCSA_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Annual Lease Liabilities For All Operating Leases",
        "terseLabel": "Schedule Of Annual Lease Liabilities For All Financing Leases"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_DisclosureLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "DisclosureLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_DisclosureLitigationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "DisclosureLitigationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r271",
      "r302",
      "r303",
      "r305",
      "r567"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r603",
      "r624"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r603",
      "r624",
      "r664"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "PCSA_DueToLicensor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "DueToLicensor",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to licensor",
        "documentation": "Due to licensor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share - Basic",
        "verboseLabel": "Basic net loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r152",
      "r155",
      "r159",
      "r160",
      "r161",
      "r166",
      "r351",
      "r354",
      "r368",
      "r369",
      "r410",
      "r425",
      "r549"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r159"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share - Diluted",
        "verboseLabel": "Diluted net loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r155",
      "r159",
      "r160",
      "r161",
      "r166",
      "r351",
      "r354",
      "r368",
      "r369",
      "r410",
      "r425",
      "r549"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r163"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share of Common Stock",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r162",
      "r164",
      "r165"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r569"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r318",
      "r342",
      "r569"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax asset valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r569",
      "r709",
      "r756"
     ]
    },
    "PCSA_EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences",
        "documentation": "Effective income tax rate reconciliation, income tax rate permanent differential."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax rate, net",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r569",
      "r709",
      "r756"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal orphan drug tax credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r323",
      "r709",
      "r756"
     ]
    },
    "PCSA_ElionOncologyIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ElionOncologyIncMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elion Oncology Inc [Member]",
        "documentation": "Elion Oncology Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized stock-based compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "EmployeesMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]",
        "documentation": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r107",
      "r122",
      "r123",
      "r124",
      "r137",
      "r138",
      "r139",
      "r141",
      "r146",
      "r148",
      "r150",
      "r168",
      "r214",
      "r215",
      "r226",
      "r265",
      "r340",
      "r341",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r396",
      "r424",
      "r442",
      "r443",
      "r444",
      "r461",
      "r526"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r642",
      "r668"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r614",
      "r625",
      "r639",
      "r665"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_FacilityLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "FacilityLeaseMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Facility Lease [Member]",
        "documentation": "Facility Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements and Disclosure",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "PCSA_FederalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "FederalMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal [Member]",
        "documentation": "Federal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Present value of lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r393"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current maturities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Annual Lease Liabilities for all Financing Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current lease liability",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of finance lease obligation",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r391"
     ]
    },
    "PCSA_FinancingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "FinancingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease liability",
        "documentation": "Financing lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_FirstPerformanceBasedRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "FirstPerformanceBasedRSUMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Performance Based RSUs [Member]",
        "documentation": "First Performance Based RSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r632",
      "r646",
      "r672"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r632",
      "r646",
      "r672"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r632",
      "r646",
      "r672"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r632",
      "r646",
      "r672"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r632",
      "r646",
      "r672"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "verboseLabel": "General and administrative expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r506"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "PCSA_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from issuance of common stock",
        "documentation": "Gross proceeds from issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r601",
      "r603",
      "r624"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets and Intangibles Other Than Goodwill",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Operating Loss Before Income Tax Benefit",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r92",
      "r96",
      "r411",
      "r422",
      "r551",
      "r557",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r229",
      "r230",
      "r373",
      "r374",
      "r375",
      "r439",
      "r441",
      "r511",
      "r547",
      "r570",
      "r780"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r373",
      "r374",
      "r375",
      "r439",
      "r441",
      "r511",
      "r547",
      "r570",
      "r780"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r313",
      "r318",
      "r324",
      "r325",
      "r326",
      "r328",
      "r335",
      "r343",
      "r345",
      "r346",
      "r347",
      "r457",
      "r569"
     ]
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationDescription",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax examination description",
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Penalties and interest expense",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income Tax Benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r105",
      "r149",
      "r150",
      "r167",
      "r183",
      "r204",
      "r317",
      "r318",
      "r344",
      "r426",
      "r569"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r315",
      "r316",
      "r328",
      "r329",
      "r334",
      "r339",
      "r451"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r132",
      "r336",
      "r337"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "PCSA_IncreaseDecreaseInDueFromToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "IncreaseDecreaseInDueFromToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Due from related parties",
        "documentation": "Due (from) to related parties.",
        "label": "IncreaseDecreaseInDueFromToRelatedParties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r706"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r632",
      "r646",
      "r663",
      "r672",
      "r676",
      "r684"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r604",
      "r687"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r604",
      "r687"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r604",
      "r687"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r130",
      "r131"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income, net",
        "negatedLabel": "Interest income, net",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r178",
      "r204",
      "r557",
      "r705"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued for consulting services",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "JanuaryOneTwoThousandTwentyFiveVestingMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 1, 2025 Vesting [Member]",
        "documentation": "January 1, 2025 Vesting [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_JulySixteenTwoThousandTwentyFiveVestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "JulySixteenTwoThousandTwentyFiveVestingMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 16, 2025 Vesting [Member]",
        "documentation": "July 16, 2025 Vesting [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r575"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Remaining lease term (years)",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r766"
     ]
    },
    "PCSA_LesseeOperatingAndFinancingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "LesseeOperatingAndFinancingLeasesTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "documentation": "Lessee Operating And Financing Leases [Text Block]",
        "label": "LesseeOperatingAndFinancingLeasesTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Annual Lease Liabilities for all Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining lease term (years)",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r52",
      "r135",
      "r213",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r357",
      "r358",
      "r359",
      "r376",
      "r481",
      "r550",
      "r589",
      "r726",
      "r771",
      "r772"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r91",
      "r419",
      "r576",
      "r708",
      "r722",
      "r765"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r111",
      "r135",
      "r213",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r357",
      "r358",
      "r359",
      "r376",
      "r576",
      "r726",
      "r771",
      "r772"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_LicenseAgreementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "LicenseAgreementDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/LicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "License Agreements",
        "documentation": "License Agreement Disclosure [Text Block]",
        "label": "LicenseAgreementDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_LicenseAgreementsAmendmentDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "LicenseAgreementsAmendmentDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Date",
        "documentation": "License agreements amendment date."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_LicenseAgreementsDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "LicenseAgreementsDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement Date",
        "documentation": "License agreements date."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_LicenseAgreementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "LicenseAgreementsTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/LicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of License Agreements",
        "documentation": "License Agreements [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_LincolnParkCapitalFundLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "LincolnParkCapitalFundLLCMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lincoln Park Capital Fund LLC [Member]",
        "documentation": "Lincoln Park Capital Fund LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_LitigationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "LitigationDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Litigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Litigation",
        "documentation": "Litigation [Disclosure Text Block]",
        "label": "Litigation [Disclosure Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_MarketCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "MarketCapitalization",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market capitalization",
        "documentation": "Market capitalization."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r636"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r637"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r638"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r638"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r638"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r638"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r267",
      "r311",
      "r372",
      "r408",
      "r438",
      "r440",
      "r447",
      "r473",
      "r474",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r545",
      "r546",
      "r563",
      "r565",
      "r566",
      "r571",
      "r572",
      "r573",
      "r574",
      "r577",
      "r728",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r571"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r571"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r267",
      "r311",
      "r372",
      "r408",
      "r438",
      "r440",
      "r447",
      "r473",
      "r474",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r545",
      "r546",
      "r563",
      "r565",
      "r566",
      "r571",
      "r572",
      "r573",
      "r577",
      "r728",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "verboseLabel": "Net Loss",
        "terseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r66",
      "r93",
      "r109",
      "r119",
      "r120",
      "r124",
      "r135",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r149",
      "r150",
      "r157",
      "r213",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r351",
      "r354",
      "r369",
      "r376",
      "r423",
      "r503",
      "r524",
      "r525",
      "r587",
      "r726"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common shareholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r142",
      "r143",
      "r144",
      "r145",
      "r152",
      "r153",
      "r158",
      "r161",
      "r354"
     ]
    },
    "PCSA_NetOperatingLossCarryforwardExpiryDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "NetOperatingLossCarryforwardExpiryDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforward, expiration date",
        "documentation": "Net operating loss carryforward, expiration date."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_NetOperatingLossCarryforwardTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "NetOperatingLossCarryforwardTerm",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforward term",
        "documentation": "Net operating loss carryforward term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_NextGenerationCapecitabineCAPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "NextGenerationCapecitabineCAPMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Next Generation Capecitabine - Cap [Member]",
        "documentation": "Next Generation Capecitabine - Cap [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_NonCashLeaseLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "NonCashLeaseLiabilityNet",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net",
        "documentation": "Non cash lease liability net."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OcuphirePharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "OcuphirePharmaIncMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ocuphire Pharma Inc [Member]",
        "documentation": "Ocuphire Pharma Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "OfferingMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Member]",
        "documentation": "Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OperatingAndFinanceLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "OperatingAndFinanceLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense for right-of-use assets",
        "documentation": "Operating and finance lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OperatingAndFinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "OperatingAndFinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current maturities of lease liability",
        "documentation": "Operating and finance lease liability current."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liability",
        "documentation": "Operating and finance lease liability noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "OperatingAndFinancingLeaseWeightedAverageDiscountRate",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate for our facility and equipment leases",
        "verboseLabel": "Operating and financing lease borrowing rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r551",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current maturities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current lease liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Organization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r86",
      "r448",
      "r449"
     ]
    },
    "PCSA_OrganizationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "OrganizationLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OrganizationLineItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OrganizationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "OrganizationTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OrganizationTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OriginalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "OriginalMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original [Member]",
        "documentation": "Original [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r113",
      "r413",
      "r558",
      "r589"
     ]
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to related parties",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r576"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due from related parties",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r619",
      "r630",
      "r644",
      "r670"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r633",
      "r647",
      "r673"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r633",
      "r647",
      "r673"
     ]
    },
    "PCSA_OutstandingSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "OutstandingSharesPercentage",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding shares percentage, maximum",
        "documentation": "Outstanding shares percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r651"
     ]
    },
    "PCSA_PaymentsForSettlementOfStockAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "PaymentsForSettlementOfStockAwards",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlement of stock award",
        "documentation": "Payments for settlement of stock awards.",
        "label": "Payments for settlement of stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares withheld to pay taxes on stock-based compensation",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "PCSA_PerformanceVestingCriteriaValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "PerformanceVestingCriteriaValue",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance vesting criteria",
        "documentation": "Performance vesting criteria value"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_PlacementAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "PlacementAgentMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent [Member]",
        "documentation": "Placement Agent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "PCSA_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_PreclinicalClinicalTrialAndOtherCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "PreclinicalClinicalTrialAndOtherCosts",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preclinical, clinical trial and other costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r249"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r483"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r249"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r483",
      "r501",
      "r811",
      "r812"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value $0.0001, 1,000,000 shares authorized; no shares issued or outstanding at December 31, 2024 or December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r416",
      "r576"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "verboseLabel": "Prepaid expense",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "PCSA_PrepaidExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "PrepaidExpensesPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses",
        "documentation": "Prepaid Expenses [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of stock",
        "verboseLabel": "Net proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r452"
     ]
    },
    "PCSA_ProceedsFromRentAndOtherCostsReimbursements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ProceedsFromRentAndOtherCostsReimbursements",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent and other costs reimbursements received",
        "documentation": "Rent and other costs reimbursements received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r394"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r394",
      "r412",
      "r421",
      "r576"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r101",
      "r104",
      "r420"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r394"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives of property and equipment",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r266",
      "r267",
      "r297",
      "r298",
      "r299",
      "r311",
      "r372",
      "r406",
      "r407",
      "r408",
      "r438",
      "r440",
      "r447",
      "r473",
      "r474",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r545",
      "r546",
      "r563",
      "r565",
      "r566",
      "r571",
      "r572",
      "r573",
      "r574",
      "r577",
      "r581",
      "r724",
      "r728",
      "r763",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails"
     ],
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r266",
      "r267",
      "r297",
      "r298",
      "r299",
      "r311",
      "r372",
      "r406",
      "r407",
      "r408",
      "r438",
      "r440",
      "r447",
      "r473",
      "r474",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r545",
      "r546",
      "r563",
      "r565",
      "r566",
      "r571",
      "r572",
      "r573",
      "r574",
      "r577",
      "r581",
      "r724",
      "r728",
      "r763",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "PCSA_RecentAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "RecentAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Standard"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories",
        "documentation": "Tabular disclosure of reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r614",
      "r625",
      "r639",
      "r665"
     ]
    },
    "PCSA_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Direct Offering [Member]",
        "documentation": "Registered Direct Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ReimbursementFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ReimbursementFees",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement fees",
        "documentation": "Reimbursement fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r770"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r507",
      "r508",
      "r511"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r458",
      "r459",
      "r460",
      "r509",
      "r510",
      "r511",
      "r530",
      "r532"
     ]
    },
    "us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReportableSegmentAggregationBeforeOtherOperatingSegmentMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reportable Segment, Aggregation before Other Operating Segment [Member]",
        "documentation": "Aggregation of reportable segments before other operating segment. Excludes intersegment elimination and reconciling item."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r558"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r615",
      "r626",
      "r640",
      "r666"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r616",
      "r627",
      "r641",
      "r667"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r634",
      "r648",
      "r674"
     ]
    },
    "PCSA_RestrictedStockAwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "RestrictedStockAwardMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Award [Member]",
        "documentation": "Restricted Stock Award [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r76",
      "r418",
      "r445",
      "r446",
      "r456",
      "r484",
      "r576"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r137",
      "r138",
      "r139",
      "r141",
      "r146",
      "r148",
      "r150",
      "r214",
      "r215",
      "r226",
      "r340",
      "r341",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r360",
      "r362",
      "r363",
      "r365",
      "r367",
      "r384",
      "r385",
      "r442",
      "r444",
      "r461",
      "r811"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use asset obtained in exchange for financing lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r575"
     ]
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, sold",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Agreement [Member]",
        "documentation": "Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Loss Per Share Basic and Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r17",
      "r155",
      "r156",
      "r159"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r569",
      "r756"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r394"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r507",
      "r508",
      "r511"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-based Compensation Expense",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r83"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Awards (\u201cRSAs\u201d) Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r78"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Valuation Assumption",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r72",
      "r74",
      "r75",
      "r76",
      "r115",
      "r116",
      "r117",
      "r169",
      "r249",
      "r250",
      "r251",
      "r253",
      "r256",
      "r261",
      "r263",
      "r452",
      "r453",
      "r454",
      "r455",
      "r565",
      "r701",
      "r707"
     ]
    },
    "PCSA_ScheduleOfWarrantValuationAssumptionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ScheduleOfWarrantValuationAssumptionTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Activity"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases",
        "documentation": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operating and Financing Leases[Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SecondPerformanceBasedRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "SecondPerformanceBasedRSUMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Performance Based RSUs [Member]",
        "documentation": "Second Performance Based RSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r167",
      "r172",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r211",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r231",
      "r232",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r554",
      "r557",
      "r558",
      "r564",
      "r578",
      "r779",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r167",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r187",
      "r189",
      "r190",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r211",
      "r552",
      "r555",
      "r556",
      "r557",
      "r559",
      "r561",
      "r562"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r207",
      "r210",
      "r553",
      "r554",
      "r560"
     ]
    },
    "PCSA_SeriesAAndBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "SeriesAAndBMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SeriesA And B [Member]",
        "documentation": "SeriesA And B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SeriesAWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "SeriesAWarrantMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrant [Member]",
        "documentation": "Series A Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants [Member]",
        "documentation": "Series A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SeriesBWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "SeriesBWarrantMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrant [Member]",
        "documentation": "Series B Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]",
        "documentation": "Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ServiceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Based RSUs [Member]",
        "documentation": "Service Based RSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, Beginning balance",
        "periodEndLabel": "Number of shares, ending balance",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-average grant-date fair value per share, Beginning balance",
        "periodEndLabel": "Weighted-average grant-date fair value per share, ending balance",
        "documentation": "Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, cancelled",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, cancelled",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, issued",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options issued in period.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, issued",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options issued in period weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares outstanding, Beginning balance",
        "periodEndLabel": "Number of shares outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-average grant-date fair value per share, Beginning balance",
        "periodEndLabel": "Weighted-average grant-date fair value per share, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285"
     ]
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, vested and unissued",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than option vested and unissued outstanding.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, vested and unissued",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, vested and issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, vested and issued",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ]
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants, exercisable",
        "label": "Warrants, exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Warrants, exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercisable number.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining contractual term, exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average remaining contractual term.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, expired unexercised",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants, expired or cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants, Not exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments not exercisable number.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants outstanding, beginning balance",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80"
     ]
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "documentation": "Number of warrants outstanding weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, expired or cancelled",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding and exercisable number expired."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding and exercisable number granted."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, not exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments not exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining contractual term, outstanding",
        "documentation": "Number of warrants outstanding weighted average remaining contractual term.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for future grants",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, forfeited or expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeited or expired",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value of outstanding options",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, beginning balance",
        "periodEndLabel": "Options outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r275",
      "r294",
      "r295",
      "r296",
      "r297",
      "r300",
      "r306",
      "r307",
      "r308",
      "r309"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term, exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term, outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares withheld to pay income taxes on stock-based compensation, shares",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "PCSA_SpartanCapitalSecuritesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "SpartanCapitalSecuritesLLCMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spartan Capital Securites LLC [Member]",
        "documentation": "Spartan Capital Securites LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r108",
      "r167",
      "r172",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r211",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r231",
      "r232",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r554",
      "r557",
      "r558",
      "r564",
      "r578",
      "r779",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r115",
      "r116",
      "r117",
      "r135",
      "r155",
      "r156",
      "r159",
      "r161",
      "r169",
      "r170",
      "r213",
      "r239",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r249",
      "r250",
      "r253",
      "r256",
      "r263",
      "r376",
      "r452",
      "r453",
      "r454",
      "r455",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r483",
      "r504",
      "r526",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r701",
      "r707",
      "r714"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r54",
      "r57",
      "r58",
      "r107",
      "r122",
      "r123",
      "r124",
      "r137",
      "r138",
      "r139",
      "r141",
      "r146",
      "r148",
      "r150",
      "r168",
      "r214",
      "r215",
      "r226",
      "r265",
      "r340",
      "r341",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r396",
      "r424",
      "r442",
      "r443",
      "r444",
      "r461",
      "r526"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r168",
      "r385",
      "r409",
      "r450",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r483",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r505",
      "r506",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r526",
      "r582"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r168",
      "r212",
      "r385",
      "r409",
      "r450",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r483",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r505",
      "r506",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r526",
      "r582"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r629",
      "r643",
      "r669"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with license agreement, shares",
        "verboseLabel": "Shares issued in connection with license agreement",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r76"
     ]
    },
    "PCSA_StockIssuedDuringPeriodSharesExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesExercised",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, exercised",
        "documentation": "Stock issued during period shares exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with capital raises, net of transaction costs, shares",
        "verboseLabel": "Number of shares sold",
        "terseLabel": "Stock issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r76",
      "r452",
      "r526",
      "r539"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, shares",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r76",
      "r281"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with license agreement",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r54",
      "r57",
      "r58",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with capital raises, net of transaction costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r76",
      "r461",
      "r526",
      "r539",
      "r588"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r53",
      "r54",
      "r76"
     ]
    },
    "PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of 5,000 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor",
        "documentation": "Stock issued in connection with licensing agreement which had previously been recorded as due to licensor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants repurchased, shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r76",
      "r455",
      "r526",
      "r541"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for warrants repurchased",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r76",
      "r461",
      "r526",
      "r541",
      "r588"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r57",
      "r58",
      "r69",
      "r485",
      "r501",
      "r527",
      "r528",
      "r576",
      "r589",
      "r708",
      "r722",
      "r765",
      "r811"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r134",
      "r248",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r265",
      "r366",
      "r529",
      "r531",
      "r543"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r404"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r404"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r404"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r404"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r404"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r405"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "PCSA_ThreeYearVestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "ThreeYearVestingMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "3-Year Vesting [Member]",
        "documentation": "3-Year Vesting [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r769"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_TransactionCostsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "TransactionCostsPercentage",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash fee percentage",
        "documentation": "Transaction costs percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, 5,000 shares",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r54",
      "r57"
     ]
    },
    "PCSA_TwoThousandAndNineteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "TwoThousandAndNineteenPlanMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2019 Plan [Member]",
        "documentation": "2019 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/OrganizationDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "PCSA_UnrecognizedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "UnrecognizedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized share based compensation expense",
        "documentation": "Unrecognized share based compensation expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r327",
      "r568"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://processapharmaceuticals.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r99",
      "r100",
      "r102",
      "r103"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance deferred tax asset",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantsActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r580",
      "r583",
      "r584",
      "r585",
      "r586"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expiration date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWarrantValuationAssumptionDetails",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (years)",
        "verboseLabel": "Warrants, exercisable term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted",
        "verboseLabel": "Weighted average number of common shares-diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r161"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic",
        "verboseLabel": "Weighted average number of common shares-basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r161"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "PCSA_YuhanCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20241231",
     "localname": "YuhanCorporationMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Yuhan Corporation [Member]",
        "documentation": "Yuhan Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>106
<FILENAME>0001641172-25-000070-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-000070-xbrl.zip
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M=)B6$E/QO6?FD2ABWW@H[+@QO-C:GR+Y^CTDW<Q63I ):84.OC9!_X:NK2;
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MP9+8UED7FIKLR41+E_WU5!#,IF]^#!GXM@O]$0C8NOP4"%H=97%.6*H+8WF
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M*W7IM_Y%XP^4AU("7+-YE=JQ(\TT">3**$CG,VE967! A48J#J*X4*@@P5'
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M22: 4*$<A@6[ =HPK%NZW8<R]>PXKUQ=&MS]ZYI\S&9D2]ED5>C7P,)3IEI
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MU;9EI\<]RC"]SNR,PL7DE?X#5-L2-B:Y;#;\. -]&[M5S!2:()S>A=JL0M=
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M[B;.!O]FM/+3BY-7OR-C^.F7BU_?/O__4$L#!!0    ( .F#=%J]+MG[6#P
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M+U-\BL)85-^/J.HU" $,U.>8<;DJ^W_0!/5T<QLV\/GMKE9PXW!K1QJE/>+
M;E(J*D:BA."F*N,ABPDB- NJNFP"48&<&>[%/4D)(7?!N81!*._E*LB"[)Y-
MVY^HXY>F&9(7@^$0JBJCM>WU+GH  .4MZ/-A18CA*['"$5.LQG4F\68 ! _
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MV.K@&L,]XQC$J0;#**8DLIB;B9KR-ERMJ_04]W6>%!7U/6FH?AT%Q":F)IM
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MS[$JZU17YO'ME:*R%;PXOWW8/]G?.P5BQ4,4$HD27:4EC .GK.E.T1%; HV
MN/ #N">3BB@T+O(D1:*KHDK7\)JR'@N!O, OK-2>K3P9N(/V"&&HA1;@]@^9
M( RY #E4#3#(+GI8<X [OJ3#H]_@V,^0 -X=G>P/0.[A\55IHD6.@ #$TYXT
M=:,R^-N%SE5>PY#3LIBD%0Z.9UX,8=ZJFPD,:(0I"X=(H0Q&P3$"V5)<5L]7
M:D-7CD;D@TN->O?S* <\J;(7T84N"8:8N0P!7&9I#@!S=QM-*[S^I<UA_NL
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M;4.^R"&^ '$EHL'[ (_14">,TZK,4AW&&B24*^SI3X24V/@;8C&NDRQ*[$V
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M,';M:[&8CGMEMU&OWV.-!_CA3!P &A$\?U>0.N,5(*O'&,J!81M^L$O$EN/
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MQ=;"RB0O9(O- S2D="*.J;2:MS8A(E+.0B>N= J@F7*_1T\+NY4M\?>#]/V
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M(JBXQ@_9L[CJCT3(8\V?FE>'KSC%;Q'>->MAOFU>W6$CJIKAQ%6/<AXB/WW
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MM_LGIV?PT&F$3_[[Z..GP[.]DP/XQO[A&?PM.C@\.X)1#DYYV%_AX^MF@,/
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M7&K4N)]%&2!)E3Z/+G1!,,3,I0^P,DTR@):[VVA4X?4O;0[S7P?0Y<7'EV?
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M'9.5A?:UW4XK%81F-<"(Z)+E,! "D*QXP_@@R) +P\0H$,R&A1FC2-OBC(U
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MQP%B/Q)XA9'UKX]>G>S9D&S]99(4NMQL2>J@9' *NL.N??C4@DQ=ZC]28';
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M\$\-)RM@VOCEU=&;/R@$X?W9;Q]>_G]02P,$%     @ Z8-T6MH&Q'XP/
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MX(&FK%FA5E)JWW5CM)V \L,OI(>VU^P.!#6TS6M."HZ"-(ZQ-HH,J;6E06W
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M ;K6E&S21YMZ?3E'Y$5@)I."E@NK9$K6)5]M2KT9H4+R]IB"V(_?>(C^$ C
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M7FCY8+LA[8N?65%/RZ(YX[TAEP*/^V++'Q.K#;4W7F55<=6..[UKXNH__E
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M&,^/<5'?FN#CDB8<TN[D$GMMPX@QS1R?G@<^_!TUU>[R8F2OM^3'M^+%-^/
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M!().J5[LAY;ITJHPY[JJA7X&<:OK!#L ?R,8Z?XN-+S(&X@&-IS3PH&5,1;
M0)07X3B_"@RW3</!0A!\\Q)U>*MJ:W!>]-(F)8*V.IUU,LA<<YVG'I(2T48,
MA3N,T0'8JHG0V'@.6MB+-\6WD 9=ZQR)]7G4KAO6\1 NYA#"/!Q87C).N:I(
MD7=F#VFY&A-Q@!U+)YBAJ<NR*/M;+/F&/0\FS^KL]='C@GM)$3?"&ZK.>QAE
M[FV%R1'M-*CUWS$=ZFHJVA\N_ZX"@+^AX/OMPP^7[HM]=MM6L\<:Y&PB84>4
M@E$S&N^9Q(.#(M\XH6JEG>:S#VKCOCTN+#ER\)ED9W4/F.-1/Y$EKU5N[E;1
MJ.T,?+(-"IT9^79M<KLUE5]3&94P8.*5^&=G\SJS_4W:83)('9&AS6=2@[1D
M[QFU<!Q%2:E04(&M@&UI5 8_9+J&E<$/P%NU_#,NBL_5:#@H-4H/\"%,>U:J
M&?[$/BS,02HJ&@#3I/.8"OT;&CL*4ZX<[<5Z:^;JH$*IN.^<K< :M#^%I_A[
M8O5]"F0,R $"($)OTZ0$0$"MSYKK6-7(\L^H@C!,CO*?+(# 8)!0F 9A<96Y
M<8\7]$P"QCTRZVZCT."*I#9 R%H:H#CQ(L8:SYE.SK17OF)1$EEE;09-QOP>
MY3Y%J@O7.2?C1>OZ@29"F5SDD1WKF(HR!IEQ%9?64!3$9M+Q+&"+#"54X@+W
MM'5'6+0!_$9W,+;/PT2L70J2FX[\M:.7H.IT5BYRO4'AJ59$[DEP1$I6TK)J
M8WXRQ,8L"JD6/ 6"X"P(6DF\TLKF>M*MAZ%<3<BKFX>.VB$)J *@@I5B.POR
ML*H:.QBR0B"?AMF([0)Z!39X"IMVBS..@F#%VN._P^V043?A:F,8[,$8* X9
M<J)6I*F1GZZD%#EI4T)9FNA][ =H173N\8*>29NS@Z)VB8UP?A\:LKF:WC!5
MF]R@GH^9RWSS .6PD\J$JTQ.^%UMWA4>1'?,-9.G+TRW4@E> .QR#7.X>P+W
MQ/Q=5VT<-TJ2BN#JG67:[W\V]3(_C3;Y+-#[G)&6"IQ0M_46V,/!FM>Z&POK
MH9DZ->35W"<R&&O]V83?T&=(BKISF7NTRJ#\-AF4SU?.R;MT3CY?.2=7%W&I
MO.FIJ*T8':K[*HB02\[TM4 C%I81T.2TX0^Q;4K*AF*,#00)%C_E.$'A82@%
ML^4L3RQ#,P)T#L(X#T7LB5]$>]I:6$>#BKC&15,23!CH9G5!V*PD)072-GA>
M;Z4I$@.A @U^0TO6+M6Y2C/2DTO9AQ&F4+JNULRD)-TSS7]M<JG#;&(CR0(L
M(V2IABT[4QA]QM+;5;O'E?$PXM"LC#RP9.C]%23<"A9&D7@BJ>.NS4#LQHHI
M,X6:" >3H5"K4,M/N&DGQJG5LJ!+&P?(&TZ.'ZF$6TVE;0WW_FJH7AD-S(93
MA60"!5S*CG(+1=6>5KJ<DPK/A6P(7G_1D70[L<=#6U"3#TZ@';G#<,>):HYT
M^$985S+!O38*/D=K*IE)=RNLP6A<N_OY.>,?TX]C#)2HK'GTTYLP&^8A[,2W
M/]PE8^MS,8_^7)2?T3**)K2>+AJAB:7-+!0YMA S8*9$DYP_PI9S%()JK'-L
MAV/S''R(1 )DRTE]0>V7I)HG$OC4HM4(PR! U]$SRZ2,P5&BH D4:XV\@%40
M66$:AJ$KT1H*E:Q]99=^YX=PR7XR+@P*1#VC?$MR*>+:-X >&RLC^I71)X=6
MV)S*;25DK:!9>XLV@1!-;?" SF*]<M,;C<"N1JZP>U-R>B>EY5@;AEAA0BWP
M3/.:38\U&%;32I%56!MH29>2X2QSDZ;EK_W&:VHUV0I25+&)"K42E/EHYVBV
MPD\HL-KNB(QN?%[DW9Q8VXIX#YT5MY4 ,AD.B'GSRV@O,D7L2QH45 H"'AGX
M*!)9IH9KT%UY6EV]>"].PR11C\3?C+L\'!C;%W7 U:I$VQRFL8"$EA7SGEZ)
MSMK$)?0)<"MJX)),,]X>-*)-PO]RX,Q3E4T\YWTPN@P?DTR3>!"9]!T<5IK<
M'7G7<=^ST6.W:&,,=%Z'JL&4!KS&$Q5+L]^1;[>$^VLL@Y7C_&8D6#"GI7B1
M7?S-_I&+.NGS"R,UR= ;C=7AI?*O;1;L!K%>E+9C@9/=6.I-2PZ\)M\X<;3(
M/$&WGE&8[V1:2B$J%*"E/;N1U^"XLH1%U]SE=C%>\NSV9"+)<>;I@'*N1)Y[
MO*#GZ(XX#8)XF-'U(!R*V2 4C_"V(L6R9D00KT=>Z>T>6C>*>JL&>^&,6&_;
M8:L6]*%G.\2AA>]"=VP,)TGK 8K#]*B$C:2W$5Q:B8SPL3D%98N9LJ/UT0*0
M)+)K 2/ RX<:A"'P84H0^4XH]@C?(Q5PC#Y"OK=%QBVY\ K!BJ)<86P8IQ(M
MYGH^AS)ZEI]"-4>-#[?!\[(@!YA?,A!4B%S*'L#0M39M'CD-10H8.JT&H&UC
M1Q_%6%W]>[R@Y^@4:,F^+5&7N;2($#8T:ZIG$OQ*5",G-]R5WJ^+*4MPADV+
MC-B^V.1VZI4:310Q!K-03I.XNM#"@:GOSK$8,/96\V83SH6M5%I$Y%4WELNG
M1X9[5LMDG^**".2T$*K5_;G'"WJ.ALO^^U-<$?R"B%35(6**R,2:I69_L(A/
M(S8<QHTH#"@SDQ>[ZV$?#M:D+)MDWO,(YNMU#U_I@0#QC'II>4)EN$85L@T*
M2ZD^,VV0$:WTZ_.HX:"MF@ET5W)-OB3NCE&L8MGJG$UWJL2N&[D1EZ4==TLN
MH+!2/QZ'%&LLG!J&!!B.7?N)CH;+2VZSZ.FVRJWII:WJ*4;<6N&@LK";/:GJ
MLI'B0:ZR1R@4H.CDA</;H$U$F/F<:E&7(U]0$"XM#4/L_H9O&HF?@D#.]65;
M5A^%U8CL,CB"&(0]-*:*4Q9IM@E,ST 9/-=6]B#AZDK9RLD)HRZFC=#B_C68
MUK$!]"&:L NJDTPEB<U3!@-)Z4<T:*MEDZ9DHV[H-0""[_S8E,! ;]#MY: 9
M;.AN\$DG3J9V&$%6:87>9R<12VD'YK!7A>,!YZWZ5<B6WZ%3G3L@3:8B-^R(
M2Y<G..=%56_XMAFF7=^^U??#Y$PW\&U_O_)MWZ5O^_N5;WMU$9<J(NX,!ZTZ
MP$&!GX9IL!3V[8DE:L8582%V"+4E?E$24G,5IQSY:\*RF3$R:0>52]55H26Z
MF@7(X0"-,-Q;3.0E?"]3%Y.&JT0Y"<1X'UP+BU 4*?49Y@*1E=8P/FXE4$O0
MMK$M.*>H)T>)G;\5D]F1%4*[3Y]1D[NBAG%C)(F@/-W@$R:V#-54ZN=FW#HL
MD:F*S95G3G2#2UGF^K("M-C :I$^<\<')FFF';S>LHS,DQ2>_,?;BX58T#E=
MDR00LRY@) N2R3!XSDB>M((*$Z9B:2,@\I$3S]V^RN\DO9A&YB2Q 743KS4<
M62S2&^5"8_X05JHSHDE;$U^Q]WN\H.?8N3&@*DZ7L($8J/WQ%>]1'A'A#=:$
MT=!XZ;"7A(SD1OFL]=QAE5@06WZRMH1\R<'.";4C*2\Q]_S,3U$#B1,)$G?V
M=JIQD)F:\IVT4=/6.\)/>%'DOB.N;9R4)B7V:G#Y.:-"2FP07K25X>7^+^@Y
M=CO<]_1<)JSMT&$J ^RA.:O>:=UNQ].38X DW.!9RZ@0..42JEYA$AN0PI*=
MWL:*>)Y%LI##M?"[ GW6E1@RR1%+?@N)8[O&B^X2#R@$FE+-0T=Z1UU<H?0]
M7M#SS>^' \R:#HW!B#!8/-(SO0>%5:A3_#7G'H:%<(4M(\Y5MHH(T4,7Y60\
MU" >E9HM/HGIH6L3M]F^[KOU.K$T?)V0;I-E+RY*#&?$-FLYSN_ZB_**;?0,
M7PN,4C!2CO,O^UN$Q3]:L*_P_!['E=UAM\7O-RF\:]>%;[G>EDONB'Y=R!C<
MFE: L<VM8I-@B95S^L*G.IFP7!%)19*11[)0DZ>@$F*I(XS40<-'3R-K+LLB
M!F.7FT>.WL\I1WSI<[] 8Z?B:P(8@6T39QHTJ(2BS1(N/FKRX'"TOAQ57-=Y
M6M94(*4E)/9D&AOGFRP"#<AE:@HV<2(DSR4U.2CI1ZS:B?3R[M B"3LR=DZ.
M7?:$SZ#VC+&FX_2@,<&8&-KC%FKMVO<HZ>T!AGS^=:C-"Z8V/V#8)\4:?E07
M+Z/_XT7+$X+^!TMGW1D-"IH=#@=D!\+"(K9CH=]=!%T.BULH9NJ"[M![4*(N
M*&!1HDA*?89-$CGM;9*E:+F0B'I0HO(XG6<8I[_+L?O<7%B2T35Y$EQNABFT
MK4K.K\.23VR86-12?$Q>="SMQMJBXA)*9/3BHDH2XX\EE6I>'4YQ@D^14&S6
MPR3;3-UC2*J:\<P5YW(^+C\!PM8HITE%,56IA/,D(%GE'&F(D@[*(REY36"-
M6'Y7*F II"6Y,>PX*Y)-Y_#VSGAJJ0+;0R(V#[KKLNW;<;T_Y\7*GW.7_IP7
M*W_.ZI;_[?=J>XN%E3UN,VSY[!W))9^X!7IO-^CA@&,O.O' -IB/_"8L*%"%
M0=,>NI)2;U)^D;U(("/4%UJW^Y^UXVY=$1X; &.*W\VP[D9) @%QXP3C_K$B
M8*(9%K84B[(AZ9BY+IJJ!=[(ZQ$V:L,Y$E$!6]1P'@%0BNEP8 S0I-M0B<BV
M5XS8?PAL*,K,&HR R:1(@U.BO*U5.75/]\]#!"\.-681BI;(C\94<A3;]9R+
M71/S(,F1Y(03VAY0E5#$D^3223CS0Q)85A3G5A1GFRG.3T7BZHT@@OV,TG)Y
M1X3G0,J%5#;V-ZV& W<13!2[U"VF #&$CZK?,LTB21R_-\%9,W\%Z(O"T1*V
M9OJ. /*J]QET\#N34&:L!@@IZ0WE8NU(= .7X$XI#K7-<8\D7%*>LY80T2#"
M77!WDI*%L#=$._6J9VBKADE>AS) &[U%$@8PZ2JMO/0!,WGI@64,8>@]Q*YL
M;/5-.<W+"W/ ]#7,O2YE>LJE4VDFM<$IP2M3EXLW#LY%?]%EG%8F<4I20,C-
M..+]2<]3H%V:V9%T&**,%DV5K<U":^$+9"'29 3W(BVHF@P[\&5&;=^06IOV
M<]DR?M'%;!JH1&D6L!X2X5S)@+<A8MN/V^4\;[DGMA4YAPH%E?E/V*<O_I9%
M% (O_!3T$.HC[M50Z*\)86)<69Z@8*9"ZHP;XFIZ6W5ZKO7;?'!NO(1-[@UJ
M*D^ V$6VX<\Z'_$UPH0I,C[3^U*"PIARSV%_DM1EUI8:S2^)(1J!_8P>&*O,
M6&;87=R.RN7EFG+ MCF.(3XV19E@"Y@'O8F5OK%Z'3SNRYRUY,5055\T><&6
MI8"2)*NY+E,2$.'QM% 6# *56WE\?([H*OR"HFD51D9A'6 $]M*]$.S_U2S%
M5<G@8N$V@'C1&%*J+T  & 3#4EP.C4D:HG9*AM42JX(#YOVW(V(R?J8YBEMR
M4#U%HO<%K/6!#$)*?H!L"T=_UJ@S;4M4>\A1$!PS]=FNC4FY?\14E3FMB5UB
M@!N+^[R[,?QR&9E\(#(!UJZZ@)\^;0X3Q>_9&(;7G,V;YLZ$^,4OHN_"RL84
MRQ?@Q'#@G;>O(82N$KA6A9.&1"1@E.G4P":DIU R[VQ-L1E/$9A1%1\*5#]G
M [4$%16Y9M&JM'7<[+GT.7(,4>"[E^9TJT=1FI%*0F<3(IJDD(@:-3)!]X8:
M8(XGOTO!E.'KW!2K0TV\4O0.5+[!DE4JIN% _/&>-87?[2:KBD+^N%NF[1_7
M3Q.=^9[C]OP%7;41/JR*X\+&J"X[DL*8]9 $C@<H%]REIO:$-;5W:DXD[(Y4
M,S.\U"90;$"PG>!,MC'%**H2")6:3Q?Y=(EX)BZ+5'H0LKM%HESS'E70YS7&
M$>\NEM^TSU94B!ELO%@"M-5]M//7&( ?TBU:B>WW8J^VG\KUQ"Q(72)3OZLK
M&KJ3;9"D1(B3D"<M&S4G90HX(\OS?8G9LQKD5ICET&(1S"034GU&\ZTI\=,I
M"X&R@C'GHNT X3#)<ZO[]O>\;W M=GK5Y+O8/:_5'?:Y\17JUI8NM4?*UHW;
M'C[]2S5)^8;-7P!IMH>#'W2.<2.L)(D>9GI*&PNB%[AG6UZ1'=?T?C:-AELN
MK-G<QFF70CQ-*^[(1R**3,'1^UL!]C39<[5D2GTFG>X8IK,FY5 >+ ?59&=D
M1ZB=6;._*)Q ,QP@.'Z'P9%$!V&Q[<O1=1KG8HV% N9 \13UE\MKFI[AL=A)
M<:M678;N>ETW"$/9WEK%H=QE',KVUBH0974Q[Y*S/<8>?K:ANG <BCE';V.-
ME-:$*J#^RJEX)L'.T6^C]Q;8X0!CO]FWZ/7C)<XF;-#TYG7LT'>W>BUZJY3#
MW?,B_ZV!S2$#6&(R48+Q>:R@M2 GPTH]&Z]9:=>(*0 -!]8PWPT[;W7 \C)G
M+/,RZR)/!@W5'488:=7:= GT%Y;:4\WTZA:\M-XUY=AT[Y&&#%MR&U5EHVRX
ME^W(VO(QQ&/!$<*FQF4ZYM!9"\7:>-TS@=*.I+CK=2H.V7127V[@W]-H;6>G
MGJY'B;KT>HAV]\LM93CPUQ*T9OR0EE5M6E52[QY;*O/AW=H'3(V> #7B<"/M
M.@M^'2%*VVW%B2)H+X+!YLRX.KA6T+X*'X.K)<*JO8&578;I>V3: J/9T43:
MMZ_PR,61U^0AHY@%)G4SY/RVB&3;)ZK=U;0IJ\&:;5V?7AKH]0,.*T%ABVAL
M*  D8IJ.*;XK2=&5.FX6D-V1J0$40-?=2 MO2# ,*>ITNZ:@#VMAU:K,4O;'
MF@;=^LL\=;5%R?"3?MF8 29,3=LOH)Q8\"MQ/;\22@NXY6'WD&=3L_CZ,1.M
M0'N1KHI$$Y%VV8RAD![VKTLJ1Q#'"C@ +Y/+?EH-U/++L)4N=:2..5\ (PY)
ML/186<HY'U'6S.9PI+/NB:Q)L$IGC<.!MOD6?,QQJK 6V[JKXL4N=?*M6D ;
MW9VD%UU#,(&#D8OM @-F+ +=K8=J1?_O@OX_'0[VN*Q8=.S7'L-R9?VUAH,2
M90L,+&'3ZA:QLG$+X4A86N[2](,.,3)$OL[7>1%A27QI ?X>KMAL#+\]V799
M@*!8ZCQ19<3]!X/;'GQ'UG-7^D]*KE%J=YI38SU0H0W&C_K2.3D]J5I B\("
M;Z;SLVVS:B'C,$2B:SX<J0-#BK[/T,!/XK&I#F>G8,:2MU??&W\CXVA P%2:
MH82PTL;PT=D(P&#<4>3U8<?.*_"M#Y1+9O?DU^VM'91@O9;D3*]Z-DY*,&/U
M$'\+>_'/UB 9!WB8I;^A#<Z(UB". ZQG6LHR,?C")%=4["^RKCMTQ[S^A!1R
M!S;I+OQX^SEP["PSQ+:?6IBZXR@W4*%C+FQBWW2LO.\>7%UKW$0C8[P<?U"I
M#+.L[9A,\TM?S>:<#)NNH2[+ NL&J3I(8O6BY%1G$9@;2AU8. I-')6^^;YE
MVB:OI2W'V5HYQBI1Z5=V5]9T"A(O(+8,Y6:AHK(@3<.^V!%('[>165WQ&MML
M&KW=DWK"-T*Q<$1A#3*\L_#;_<%^O!D%,4LC#"&.07"[>4:H%3^D,J^%E[3J
M\-IA82W?6GVA.$Z3".\+H<&Z5J3@?GAF[\91L+UR%-RIHV![Y2A8W?B_4"S&
M'0M*SS:!!=KRY,1HN3'?GQ0%E5;2&II88%M%I+POW^HE1?M[ZFE2@0PR%Y8L
MPBSN;F/Y>=YD7/ 'C7?6U(4J4TJM+GS[5-_0+/\9J0H#NJ0@?-?6*MHS[[-K
M/Q"MF2!\[AC/$@#_/*($$9@7U)U*8Y6@\@SSJU!$0E*ON/.,J=^%XLTZ395E
M)N6K5M2S T/37;"^M: Q%+JNG"(GZ7.GK?P#WC$0.%T/ %&XVBW5I BFR%A5
MB%E2^WX55O;W)&6/WFP___KLJP/J3Q_D7?%'[;80Z IH<ILZ8NV=$[IC:*E9
M%%D3YIVZ<,L,<Q9U8BD6UX^LA,B8@LVL',2X!O)KS%2:8<)ZW90Y*U-S:T+2
M"6<F8L,O*G2$.A>FLJ3L5@CR5<3DDR0EM;_TD@S('4EF9B]SQCVH;+$ 1SG-
MJ)C2DGX&HI?3)JZ_?% (UW^';B;\OCT\?K]W[,O!-]^!0"R^3B(G2!&LJX3E
M1T8J= *R3/)UF];9(Q""<:8%@K@]-[/"99_8Z[=O]B>VBD1D& MV57T9W0[(
M98+U;HI]L)T,<<B5SGV 2'6XQ3'^N2?V)R/(,O?^B$N6JNAHJH!!Q+JA7<56
M@E&TG\>;JU/X$T[A^9/OM^ VQEA3-E/1^Y+Z]IXT:4WW='OKV>H8_H1C^%'E
M*"F,HI_>1X^WMYZO=OU/F>[![JS/;QU_>XG\]MLA^4_E9G2DJ Y!]#'-_Q8'
M\0>GZUH4OP*&ISM W%4\O2B*)#I%OP5J6E9X_IL?P,W%_^4"=EB"?J1(VGFW
M&[UXNO/L2=^-$*/U<O.D2+FXD>JV2C'_EG;<[\F.6YZGYRJ[J[*#)A#/C[,K
MO9+A$O0M,:'=VB]2+L(UMN2R?+;%8]6NT!&4R:IH=9HM'-> 0 $G7A144(J\
MKU)(W^Q]KOF5Z?)O:[I\\?6FRU;K!$2X#^B"^.07N@PLFZ<_[D5[_[WW[M/I
M_G_VHMUW_SXX_/GCWOL?]DZ&@]V#]]'N#\=[>R?PV.YIZ]D?=T^B#Y\^?OPE
M.M[;?3^*/AV\WSL^.8673B)\\S^''S\=G.X>[\,3>P>G\%VT?W!Z"*/LG_"P
M/\''5T& PP 45T+PXR[ >! ='AT='I]^.M@__26".79/_AW]UZ>]D]/]PP.&
MYAW\\.GC:?3S_NF/^,+NZ>GA\<'>+]'AAW!4B;$YB=[]>+C_;B]ZN_?A\'@/
M:-_^#P?[!S^TP7]0*/AGWBKC<+\['G_E77F+U^7_'@.*# >  D>[/^PA>L*1
M LKL(E:__;A[\&^^*YZF\N#W!/%\]_33,1( N$D?#C]^//PY.CR(#O;^^Y3V
MZ?_]S3;%W(K.@J\)M'F\"K2YTT";QZM &_O_\K32)=_E9;*G_8/A /CWP=[)
M2?3SCWO'>X<?1GWB_%2=>SW;NSFF(H93\ 7G_%#Q-M-,\LYX^M(/R5U]_ZJW
M2<'7^1874HQ'8KTXOOT$UW@?WQWB>@[^]>BQ?\_N0J!:LE_QZ/CP'2#G+B^E
M_2>8BH"I2Y576,3Y9=3,Y[J,%6YKVPD5>J#^++:[#,/O\9W!ZL6Z&CO:G=@"
M_Y!Y[B^&M3\=;_8C[*(_1[NGQ_OO_AU]W#_HX"-MV5VOOF4IOA,J=%\PZ0Z@
M>'A+NTM$: 7#//G',J_?V\MNS$DPZW4ZPJVY^M/G?WP!\.+^F^^J[P3*SB#^
MRG[010F"[L&97=Y^S[176!^NV!19RN.O6<D-4'GY>__]LO8^\%WNO_FS[L)?
MFW+TW#_&4@;EX&P4W2 *ZX%LQM5DU+KZ_CJ2S#=P"=PPX^K)J^B0BR>_C#XJ
M4#=7UJ#E6X.>_%%KT+=IV[=L6P"K0F\/W_]"GOH?3W_Z^.9_ %!+ P04
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MIM$="^_!H'7QF&54NKS41FLZ 7"5XED-HE-=:5(S_ZTFTY>@T8'"54QI,!'
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MA9E">Q1C-A[X:T<K>S73"[;(]19%=UJ(W)&!AYRLI&75QOQDF(U9%'(M> J
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MR!1^<IC'=R64O]YZGSWZ<0?-/C$6(LQ4M%]2/\6S)@54M[OS=.46_+/*4=R
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M__.[T9]_A4USZCL< \UI\1]02P,$%     @ Z8-T6AF^P)+V<   6<L"  D
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MMD'&(UHEG041!4ZJ5HEI]<<CF,\"1-<,K370UZ.9G\BZ^;%$*S$>D6NGJ4'
M\]9:EVTKH;/811*:IO9"PK?H;JF*8JX6![\&K43LAEG1RV7-T^JM-!$1N-<6
M7=%$\G,[7>,B9I<Y-$E6J^Y3TUB&^UP7S_VV^# KX$JGE8IW%O^ SR%=,\6'
M#6T:=U@764U.!+XD^1J9%J P5.( #?HIFU</*041>7K< 9X6LWS;%O&!)TF:
M7RZVJQ6LBIKK#2BV%<QA,4>G;#B'<)IQ-FC.4P+;[]MIO:V<*-U@0+>8JSD=
MN\7@%S !8'=W[%6#FW*^=;Y3.H#PJR69BC"AM,+<MR&G<$X"P6YK^'EK?JZ;
M$H_*IJY4[)E-1:[&CVMTAON796E@I6_A3=FOVRGLZ.P%V-*KNMWBM0&-S(L%
M6?4P'>8V?GCR-9BT1V5)9NWQ>"1G*+K98/M<E/6VA</8SI;%?(OKB-O+;LJ#
M47S'AQ1JXH]/LO^[K9OMFA7Q,Q8HN97(SFV#?JS(A3=TTSY' W2!FC4=W9?5
MS#_D0K9X/;H+%/Y=S5DNP"'EJ[P?@$U@,G:\*5:)Q-7GG.$3=8*VZ 28C$=>
M:Z_IPB)]GV1CGC9*^@Y7D$P-7V[6[3K+-V4'&M60FQ7&+)8#BP1R>)5PEH\>
M?/GH6'\ RC VMJDO^9Y B18X=]V[KWU?RHSH:UQH(E6P*[LM/I']FW:*WBCQ
M5> #X5WZFB(7'MU5Y/E=E+BG]$=E*\H']H9<D[C=LMDJ1Q4<A8SS7/.@9#)@
M+\E3DX&EL%.;[3FS!)[IS2S+:AP:O3#SO>+[*#590[\8F$1Z5B>%5'C7DG-X
MHD+A#$TZ+_('GU$V4L49&FW48!/WMP5/X<QZS[4!/*;Y_%_UMJGLY^-1_Y!&
M)J"*C_C.>4H6X!;6914/DG47CLL&7=91TXF$"^C**1$@2$Q/X5/X]Y;[I,$U
MM]?DG3P:5/HG.*VH"+H%QP'@!_,&;*X5>28JC+F%W8'65P7B6\C&0^L)@P,\
ME,-%>,>'%%Z$3TZRWVL]*F_IN)_L!'U_CD.^AZN(\$D0*[QVX]'/9=NUC!1
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MBVGVQG,Z*$S2O$UNBEQ/8"Z2+1QTA#L^I!O$?1X?XCZW&?=Y?(C['$[WK5H
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MJ!(]KAV:8[HAQ+<#Z[^ZBGDZ0ZA/S*GPM7 J3,*TI3 3:CPJR%<7H"!(BJW
M IH+[$2P3>)NTUXD(#$P67W634>Z31M(KS(>$D(\TG,24Q8SS#=>:-V,3D3V
M1MCG""E< 10IQ)<0S=^-1T<?CH6WM;/G!4<5,8SP%]\*D<Z$6+*+O &YN\_O
M'CQT/RP#Y +[I*H*!]8: B<E(:4</)_8$DZ,6U%_C? AH@(@Q/^"I#^"2F>&
MVIX/TG3((1P^MD,2IC"SJ?3AQNNX9]LT+:9Q">%='?,U)Q2W&O]C@;>[N)E)
MN5'UQ[##5'7\<P3DXTP286:OG^2[_9@M$%+V)$IE#6U(6IZX67ZP7H!^]^ X
MV*/7ON?HX?$U7=:6?/X@[==%V<")5!KXOC"H?93(8Z^<"QHYYV7B!9 !SR8;
M05%@?-28?2 $PQR"D4?"D:$&R%0VY&5608;JET294<.%B[H0AN+^$\=\G]&2
M:Z(!C:DG?DGVCD>A^(^'$DE^&37&8@C[YD9,\6P\C1EG$S<%4CT5@@WRX<,7
M]67V?^J*M8<6%09,LD$>-,22G+9M/2N)6/;7ABJ-4F8&*HEY0V$DOG%ARBK\
MN>3H,"0!.U3/MC3=G%B;*!E@<VVW#2-/<#^=";!O/'J.6CAG7-C[2R?NP:-)
M]N Q=>S!$\3;RH8Q[6E;V2G?20^^??280CA*H-N_=NU/>E4"[I$B>.\TVQMX
MU9\<O.JWZ55_<O"J_[5/]FT1 [VU9IIQG#,Z0"_;T$PEZ[:7=SAHM X5LHNM
M/VPL\GW %22A8V^G9#O,E)[YP3=ZD"TJQ).,ZJ/!<964<RH@JQ3B3$(IE7()
M/,NJB]!K*D<F34Q1J $Z=_0VW"%!^X464#V;;3<N89%1S*Q&*?'FUK<L@#Y&
M"S#4@C31'OYP#\YU29% %>ZRHA1\-:8)#E=4!1AD9;[B?)=>5Z G"TK3/18(
MH?%J6@#HK(:9:@B<VF\#%(5+3?6TS)730A4NH3K5A&5DXJ?9D9QF0E0R\)&Y
M.F//</PZ7R*7VC5P4LQ)0/SOD5KAJ2_%.BNKBWIU4<R%PS^G+XSG<F@LF-&!
MC@RG83W&^(8LCE6,GA$(TN/._< %\CQ/+PK<D%5]B?R10G+K*G7R"142%3%
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M+&;O6\K61K$\;_)%UQK&$?)V>3"'T:K68-^F5 3OI&5TSB0#S:-N6OP7U6A
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MI\=K//U8O,:G1T\,KR%]EASR?^;4??GCZQ?__0/^XQ_O?OGYA_\?4$L#!!0
M   ( .F#=%J;"BU4YP<  (X\   *    97@S,2TQ+FAT;>U;;6_;.!+^7J#_
M@1=@BP20XZ1M#MC8&R")W5WCLJV1&@OL1UH:6;Q0I$I2=KR__F9(R2^QTR:
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M6MW"/V,*"   *SP   H   !E>#,Q+3(N:'1M[5MM3QNY%OZ.Q'_P(K4":4*
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M"B%":)M! H6"PN+XV,P]%RI%FO/J"O^/98$R@F WY_\((2N,G+ AHH8 3X&
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MZIH?0YV^[!N^_4M?$OX?4$L#!!0    ( .F#=%J)IG*MY00  ! G   *
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M[90->48>W+<(,Q4,A.N<B@,:0'YU7XCT-&7,-:R# & /);V*R)Z'X<P9E:V
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M^"I7]^RA&58$_7($W?EREJ=GJK$$:BE0T%G8!\ON[VJ_7GJ_+J;M%V+_4#/
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M#J9F!Q)39BF6QHF'XND2,DGIAD$8P]=54TN\!#HE/<.#2>U5+%(+8%AF"<8
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M8&ZJ_R/A>J"B+Q!3NKCF.6]5I%I>W 442QC4NF-IJ'Y3ID?AH,! ,V?#*@9
M1"8 <L-)Q\8F+5'J3$K:O^KJCART+ RF:R" U)>2L'\M!\&K=J9>W!65*9BS
M2K+N-,HEU'"MVLMHC)12!H<(G0H8:/EY^A*[E)*(=*41O!3U$,J0=1^@,YK
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M>I8PJ;M;ANP:L9RD*L+0;=?[.LF00L@1F,8RK8/9L+/S+E:&8X,82_5W)A0
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M.E9^"Y>S/&AP=@=<F&EK#[/#-H4"+](3;R7P[BD[QWY1<0+ +%=L<+BO5@!
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MMQ0VA^*<0=5IF#-2MSS^X);'!^@@<'KRH_QYZS?\Z=T?#Y-HW=5-IU0G(@3
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M@/.V043T!'MF)<7]26 G=\S_(-ZI6],+H_^\=WSB,*EK6A+WU<\!*I'\0U5
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M':?HG2>@]X7'@O -.SL,K:%?7_3(>?3IMEK<D_D$.@:G/V9575;ED3_IEC!
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M']D05W.1KYW?<I%JWY&9,6A":"ZQ;G!^4N:=P/TY(N<8X87!(Q@OJUET,7/
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MWH74JM?LU5VE.7(I7@D/WM2+6N[_C?I6),-;:UO# K<N1%X/W'H0^3UY_@;
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MYV)(K*K"S#E'0H8@H]>8"[MG.TG,S:I.?HVV_X5Q]KAS?3EZ6\YKGKAYP,K
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MLJI$ZTE^WN];L8Q@$(N:[+>KJGZ7N)X&5<>@O15LM:XPOB^Z[>W(\DJ3Y\Y
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MQBH.[Q\K]P1-RE>Y35[MLD?AN:M_"IX[!FH^C-+-'D/I?E $;F:/\M0(W,P
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M%,=H;;92HX2C>7)%NW+<OCAA@I7,#QPX^@$?[ 0\%_M043^EEMJ9R+_8]$:
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M5D2=P-'%='SZU?0QEQ/A8IX#Y"P_%DRYN?JQI=ALX\W$"X#;MQP6OL0JI+.
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M^<XQA%/Q[OK+OPP4":)M^2\T[<V!YND%^96^2>EQ=1U3Y( E3#J&;!JCB$]
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MGVVL)%,DFBTF*W/U+O]3Z7Y\^?D"%WJ/<*$O/U_@0A]U\'P5$<B+B@Y%\FK
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MV8>DA;C]>C_='@K2Q%7D@-2_]\":<@6 4T1ZVCVD(#/6)\NS<SHPA@#$>OJ
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M5INHQF0%OH=8]@P+_S+7CY!_\%/X=7HSP=V>QOXG^@.RPVF.>2%N["SF0M3
M[/U@<?.OZ(T1=,4F*'B\R4%JR6SU)KPD7&H>8?U%>@[%"$,?"//D<#%)N2[I
MK<*I;!+GJ=:8259CY+F&I ELH%5F8G[@/Y(O2(Q+TR0<U.VKNCT72GN:W+M
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M)V 92L0Q*VQ'M6FG)9?.M+L@*DU F44\;)24CN79)"YJ^"@VQ>[I,"1VXHI
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ML8KDJ,8&Z[" /3Y@_@1B)**]QQ39M$W8B4:J*%/( 0Y</I^:8S6L0+R)2(6
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MJWTR-MZ^,YU['_!\+."<>9WEY_A?C*6^19&"@<./YVE$%\./G\9P&);%)_C
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M,J+)0!"P&+H"3 !+3DL(8.27)K26#H@+[6\T7^J4<:'/P16Q#.J/HH=XM8>
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M%?"96-L$%E9>]JL\E>E&/3:=PJR4"@:1@*9,T,X"S4@F*XQ\M#@IH/]S__#
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MEX&+'<IQF++L[?[.?RH:#.3.&X*G@7*;@HXH"EQTV")]JL$,6<('(%IQ!)*
M?X$Q?P;)!.515/W?% I^YJ?51('+4O@5;(Z\Q(T2HUQ?XEY9>@K<&^,7Q<-8
M10'N<AA$3OO"58P@IR SY>+=DW#N]U'X$MS.6,;9A[]E*5:?E53328(85:S#
M<&RH^>!I0]CS6<[;#7:1_%/KB< #U4?5;%A(FL23F-5%X.L9PJT,B@,^#J:T
M"(>JG-/[_0&(]HBVI<Q.I&#VHWW_-?Q9A:A@6&TM?(J4O!6TFV!OQ5F$2B&9
M>V$!&JP@!5@,8IZK 5^/OR=U!->7!<^2?11^<Z1*E4_B%$8T)&47IY6*5I]
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MF6W-9(R^A9*Q1KGF(;>E1K<T;"$WB121OUEVN+ L\[A?E;IYQR)E<ON?)H9
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M*<A_"5-$:A_N]66)"UKBT%EB@CI70SC0-;;EU:L+/Z_:D^QAD!OSF X'[WP
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MKBX<?I!V9VF:RHL*7[ .0!2 S["2EPFZ001B_P(.)_EU0@Z[J2Q*<W0A$Z'
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M<Y..VXJF[-K@\7OEM?+CZ*F:#&47(BC;V\+!UY:,D8;/G>BFI:GRDN856;D
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MR?;0&DU&3BX](:QJ[;[MR>&[1[MQ^7KS4AUE>4!,(L+7 QO9HVO13[L.RO/
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M]N,YWVZ1X^C$C735)9[1^JMLJ79[?--Z+K0N6L[HC_(ADS)]N$ ZG0V0X60
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M[.:QY<7)MHT<%D#++%^Z;MS6/R^AGO6D<FV%=C?S.%6UPHO58M:8%2. CT
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M9C"-M4AAQ)4.XLJ$1X+A#L.=K7FS+DT#.CL&@^P-U6\-UG10W]Z+$,:&@,5
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MAIHC48H9,%8GP0C)Z=?4[:P>CNYLJ"R]HA1F/ 9=+Y?#^%*RGLWAX[5Z4IN
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M/P >O6 %A(INJ"_$^#.C<$[DX.+'ZH8*_SD.'JX[#4R$X"LAR<W _ *UTXV
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M,B>=N<H,_[R*C?;\F#$$?,8FUIVT2>,T^^5KP9N74?D1'LP+_JOK'S.ZX:'
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MSB3X)B]V= QPT8D_A$0N:@5G-#M>#1SO>_)#[T7Y$O^\[P%G%!)_""AEM:G
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M0UE3W(FLV8&]*%)?SU6I<O7TNCB0++B]F!0QE0PIM2N3,8(!Z72>*B1:E!U
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M,1[)2-9-JH:BE=$L=WE-<L>%RU+RJX;L7X2]-'/\5V[(LRP''@X.A>:_NK(
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M31EH,0K+?,*OC04>;NT7Q)JM=2O6U7[T'MFF@$G8)??%? #\[FW?MF[G@UJ
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MVRM\'C=D/;I@<(P09Q-"#^C'??4$C>5^__L_N1S1Y#F!_4FTF0'W"SSO4^/
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MYU"0T_!FV[9XQ1+@=*P"W-NX6K_5C$LX'U<JXW%W<//"##VCIC:)MG^B>Y5
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M"8%5H3\I*_IY!77ML<Q!KS3<\$NV,OZ\.V\]/%M%H/>XVP]:5*"F-BO7O^:
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MBN5P_3!G[<;Y?NAL.M;@> OVTL'+[GFH:J<<:F4K\U#Q0GP1(A6,>B!S=XQ
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M-NE U<UW%@[ 2F6I:CE;*VT?'[4U<;@7J*B=5VO86H3%Y\VE:.##0 /3,3F
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MUVL\I3-OG:D-_N&"OGT[J*[.*X%J[CZ7*5#-'ZA6[\R+%XT_W/6\/(;MLR(
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M&FNB&[5W^ O\@/ZLOWMCT#-QY+C.G2E]7WX<%"@P68D/YT476P=;<0P<Y*W
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MUM"=/P [P2C1$PP,\Y43NQ;#P^;'MXK"^7_,R"91RR.5@NWY\+!FM;FUQ"/
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M <<A]PUMF00!FA!D#8B'R#[XQA1#8GID?"N-L9ZB;<3L$%G9&2P+.N$)R+6
MQJJ=23#2"PLM@<O[V$_KU@DO+^7KQ$7!W7TF,^;R;JWUM;'?]OS]+QN)QHX;
M(1CYN)7DTM3-X%D9P,V>&H!]P.FF*>XI7Q<'N<R?(\?A'S\KMEXS:K7:1(=M
MH?.\_?CKS!M0?WR=M['?^_2K-PB_.,MWG6.6S(S7^?CNR_7&U.L$"L_!P>89
M,8]VQNNM2!O[L3&.,PU%<2 8GM$%H!L'^R:WN3*,Z1/2!3 ?_&C>[ V/+OH_
MKW]<)?BQ&S.N(TN^/(1%0;&]S[B=O.]IR2XSWOG&8^]\?7/B==^8>,'BL.+]
M=)'YV]E^Z.W,B7H_QK?_N#M;']T]]ZEOYV$4.6>?@V"NY-=#FQ)D.=Z3&8T1
MWEI5/P&9? I$A[[.R-#/U%P8)95'=T(-R;B]=X*B6NHM]#-Y]PYJ":2:]'T7
MK+T7:\JMZE&RAUBT9;B>6(8D[HX2%_;]AN!>J@-,?>SRSNT<7!Q_JNU]WJPO
MA>57H7]+^R\Q[F ;VB3K;N_RKOM/)QRP[Q\_?01[,#WQ<EAS:6AN^8RO\;JF
M&U[7=.)IG\V1OBE5!N)=_F"(00FIG6&XPNEB:(>R!E J[%$" >7H!F2^8 (6
M!8MD< EP"NT9W>P%C+0<=&XA%^RPZ :S>M0WX9![OJ2PH,+8C63"D_@1H<7F
MNQ#S-U@/\WP"RB%$@</\+H_NR 5%"I.(1-'2R?.6:SJ#D$RW&R?J^W&D(RF3
M3-9L)QS&20BK^"!)8M(U7(2-81]Y<AODA*=_C.&S9A%$T<$)=AHPC<$0=H'B
MPB.$^.$'5_HYN?O:8/U%6LC8%<)UX'LL,H.1;IL#LX?8 E+.-<'^\^'#7['=
MXWOBCL9?L4<J(4IMAW5I-ZVX!WBBU]>G7G$61* Z@#@D@%@H'5G @48+GEB1
MC[(1C):)1W1(N0^'/D(.<"-W ]DUU8M#I[YG\UBE!\(>PXI1J%&5B'#$3K@5
MA !%$2GWG/$406Y[!/ +FT)!(48E95R3<20@LWD8. #\YY3$J\H^4EU)HL-'
M,P1*;H6A:4N_NZ4?C'"WCH&1:DG9C@<D"HB<.#WV62>($=MAH;H.=W*-%.%W
MNPSM(R.A']>\"6,G0SU:&Y%JQ,F'\PBDGVY@QK9,YH1S(Z8,G#!@0\QF]GA&
M*JX#<MP310K$49 UT'.3*+'$E0?BRC=,CD7J1N*^=GH^_"AT1Y2%AVX"-(?=
MZZ0F)63RFGD(US(]#)L35\; /1P(,(1A#$9P! K! SNG<(E/,7\E(0!-9D1,
M,$M&6L("=.80BZ!DA,#OR)QD?%Q'3UJ V1BF?<U@=XE@"FAMF0ELZP'F_.$S
M:0('NQV2#F;HE%@AWYPR'[WOWVC\G+!(A!4V8MUNC)GTR:<#2KEP@#]B$1!0
M20>3/E@(UXE_=4'R>)9#+DI,PJ>CPDKX'=]OSFD(QHB+8J_7YSR2KVQH:9R*
M*H+(7P,/TO6$+!-WPUVB[!$N28S%VFS@I4J"WW$%V/%U0#H]P8HC3&6&ST $
MN*@+)# &T @H:Y0I_23DE:.DA6OZC7P,Z)P1#,^8T*,>%ON9X>G+N[6O+*A[
MUS7@;:M1!3B!@139:9VYF'O<\*C+L)*6-SPV+N\^6L'WZ&3[9LWLO'HOP*XG
M<%\.^V-.T) 4T7D!<:3940F$$SR/J9/(-U-FR0T23+)S,7>,+AYK%<'LYN$A
M40<EV:8'^Y=%'R($9&%@B21,8 Y!  1Q#Y1>3.R"-[5/=C]S/HX>([Z%D(+_
MF*;.L^DPZRT.L 8&A)^9C0RY^/JJ_B$I: EUV#MYR>"M!FHM#FE8'305(JP8
M">-0!K6$?#!$19?EV/ \R"6J]13OU]+7)S$QK%O!@A%N)9ENZ*-3*R!ZX+_@
M(J0HA)451ERT@_(?L#Z(&;1=:&$SS#X.;]3PBZ6I%I.XN<RJV&)(!8N^L(8'
MU&W$^B'<D44I63S:*6@EC6P*JB%;"]$B! FH4W*E'V(-1F@%3@=M1HXU83P8
MH)J-55YP8-(I\.GQ-V+1-/'N!K<A92(G/BG?R0N1[D/.CNE2]#?L,Q;1WJBE
M2N8WLC3KT,N%8C2@%#JYZV.[9C*G90$4^I3[S$T.]P6H$;XF2Q_6VE-+L64Y
M!F;?2]XQOB2/.$\^BY:-%5MFV->[KG]#) 6FL=4W0WY9:/4R3(S DV"Y]S!)
M4K5]2E&E7%70V0.S@EHM_#0T79Y\%V%XH8OJ*=RW);BF!TI<&'="QW;@!C6
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M+RW/PZ3J,^).&$;8!T8"RU0^R;3"@BZB6!Z02%K"1" .Y$"\P:G"7K24O5!
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MES0#+T^V8J39+SA/RW)<=ILG)BT%6(9B&_D7R1$_Y\QS !D+#GT I!+0!<:
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MWS$P$+HAR)/9DM1IDJN%@..@G*T!10(^LU#@)J"8*1K'D111+MZ,H[X? "!
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MARF4%,M$B8PR@=\I20+ETY"<L_QPR3$RF@:^[%_-ZB;(2=>%)ZI:"@3\H9+
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M<S'>BOQ A'"RR8+IEC*C-.]+%<PG22A95V5NX"K')T"!H')]C9?K)^-=47%
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M/.61))=^(%G-SS1;VGOR2P>=(BA# 6-=T;<=7A28%B@6/48]@  'DRQC/W
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M!T^XTMYDW!F2,VA[QFAI<]?I/B7[9/W-F7EJ+?'OZA&GYA;JQ6D<%G3:YD;
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M"76;03HXP:*$T,_DI4DEJCTQ'/M^P<RMTB-QUOB7!QESYW^4 &-JN929$5S
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M.RP$5"M=-"IGJ<L"8_?&N6ITN>4^:JE(7J4Q=FI$TT+Y5S28,?-/U+QAU3:
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M=1F(]%V[-\Z2<S%MH9 24UTN]^XY\+CZNON.E(3EIR'4Y5)Y<>J]GE 9_$U
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M^W/KD=_C!A8U*25RX'0ZNXM2(FWGX+!KE,C:$5VWPG@Y=)J[A_,3'1@OW[Q
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M;]\*7%XYJ+K 7TE75E<JLQQ_))*I=W8:]CE@X@+>YR%A.?9W&4LJSZ*$;PD
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MFV7GPOM DW=BE1?)[>;#"$NTKF0<>R&F],<J#1K+.UQ*F*4QBJ5\2 \K/H-
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MDU;3\,D+\TFKN]?N/. *[PXU<MY/1P,ODLKQ?[ >J4HBP0HFI3XVB2]:?]O
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M\O)2,@J*"G"+</#P<O\! O<$%14#'8,($Y.(FYJ,FOO_\0/[ <!Y E> ((,
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M7DQ6R#8G$Q7I@4)Y(^0='3"G%>)&4>,[-Q_@IQE2RJXR%8Z@Q9;[R0/,<PY
M^U1(\@U+U.9H7>KN@I5&@.#Y(=;VY.R'43I'_0$NVXK^EXCX1.J#/E)FS&/Z
MJ:V!NC.ES;3#UJ5ZO1>7$N-C4LT)I5]2%'0,97U-473F+TT$46I+AFK$[TXI
MTP59B?.<]O$5]H=@ )&N39FYS ?/J,$<BUF6I+]\C/J+', PJ\"G#@;83+[;
MNG5^/#]R70\C_?<4BOVY='>\Y/51:V12"B./:A@A_Y]ZJ:4'!ES'QT/J9&+7
M)>%LNQSGGJ;$.U\3;>Q5!/*N=G%<_3Z'4D,#]AQ*$T7>[M=J\4O58X'$7<9>
M9\WD6R_ BPE6#.#"V<# ->WWK)PJ<TI$YC! A:+U])77Z%"[]LT);^NI2JC
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M@-F7M1A:_IJMNY0]M9QJR[K+2.K6QGG)WQ(J;9))\V/"HHL/1H6[)\!PDLY
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M#ERNM="R'*:,A&PM6EH9TYO$%1,>=,AP[#30U5!E%TW=\)(:%2E;#FXV(79
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M6[D%XWX8^[540]--9-J!O&C[\/"TF3%M%O[@*VR"I!G+3WQ'1?:DI8X(W5#
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M(H75<O"X4-G'>SPV4@B+-8V_*>P8%[)R2D1&E[$F2#FPM0>_=Z3I[_K^HH]
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M+^C20;S/Z#?A!F'2;'6[ ^2=!=?OD_A+"R1L(O; /D3U#?5JVXDC$NFAPOG
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MV@F:Y$>LC.K7Y"D64VSP6W]#+6,?B8V$_<9O$D-'UD,QKJV&=+'I6K46;7$
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M=<1M]WOY)!AD\:#S6RG8;9-5S/W<)2Z]#I4=!V%3*8_JFFC >#*_:R##LL1
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MI3]8;D>N8S^J-A@(G#=?=W0%KA[^1?SGD56F_Z>-ZV#TOP!02P,$%     @
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MS',2IC!^C4W,"-W K$TAND\"WC.(\S9;U8<P?_'LAVF @TL:+[D%I4D^R[Y
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MNH@')FY4"F [#&H;>P?++FD'QB5-<6"B'P6(GH9.[6NHDVV7=%2B4BOY<"J
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MW5G!O<3FE-XCGV_OXW.<_>0+J^(N<5'EJ/6^NG*^TPN?GB7\X+ E["1(UY9
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M<O*A3&2%BM\6V>+J0Q.N2EF\?1IH?:K[-- ^#;1/ ^W30/LTT#X-M$\#[=-
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MPY27,EV+V<3=T[R;] H3+D]][9[ZXE46\+7W @^E)-CB ,Y/^1#.>HQFB7J
MK5.<J[3^[I@S0%N=IE=Q"BA_;9<4:Y+0!#(JVT8@I]9GAO$#E?M)83\7'SP
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MZO[C=P>*HX =",MWUF"Y4L+/^!G[*/2;++#P&*8.#K1]FP!+$*[O]>(:T;B
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M@THA.5KXJID%@\>=U':J]B@>J9L^/EE@?^-9Y,3P_SPQ8;#?_']02P,$%
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M#%%"&C.@$8*S3:B[SZ60<;E5J+S#)17P3@0=JC$7F@M\8*C KJK&41R0W6/
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MT DJ12M0<I $F.6BS-(4AXR5Z$M</#>Y*1$)XASG/#R%O8%8D("2MY(+LQS
MB\/:83J3O((R /8J*F1M;=\,?^5PCT9@,$9X$?U763_ZOLP4:6;_$A"*O]#>
MN9Y1CML,P3.K.4P8/+$0,*2?BUS8!JYDT)K]KWP$!.Q?\C+A<4S!FF"^?7.D
MQYALZO6(BR+A(.Y6?/ OO@0D&MOF_8MS]EC3 2K=/MZT1UG>R7V@"@@VOI5F
MEKNZ#!PP!>^V6N=Z\0CQ&2Y;K0? U1"K8>LD<R6G='S!Y"G+L7%[U0*P--0?
M*M7J_<#I7!LH B";I"+6/JU[NLWV9XU$L_%#X<18NCU'T;6Z')<LTBF!$&*I
M,T;\<F[.Y\TYNRU#=0!#6UDIV^FDKPN&<!,!3UZX5F_*X\-Y[,>=@N:35J8/
M@+7J:EG/2V^)MTK$^Q,7XM;* ^:O62RS9?#Z%XJ:';O3MKC*R*0#G+U*]+3=
M,K?JBHV7J<5!N[6S?U44(X0-AF><\#"\;;"K;WBB@MU-0TVZ-)#GFQP_6[#3
MFN\W/N85Y3XT9%YEQ>B1:>5 &PI[U.' 8\#S*FAV7-F/'F*&+E-]IZI1SH@J
M@Q>DY2.4S]3D2I#PP[3JZ,Z[U7F0/U\EV1=3CA*]BI<@7 UX:3BN1!Z0NVX$
MJ0[1S5:(*2&N!2GYX2TN&+![DKW$$8[.=NR^PG7:WK=?T/7$2_7VDYY]<PIR
M?&=Y9D5'FVX32P'#W]G0A23#'9%9"HA>;H:NB+>Q:>K62; X&9'# WL]?7#"
M^(!9!\4)'E1BF1W&O!SG4][B+ [<6,I0C -]!XP1.V+EQ/>AVT^Q11-I/L8#
ME]C1!?M7]N>0V<,RK_;@LM88!NV'_N1]H%[@+<4?ZS8(AB(N!X8,7)_0_=_!
M$%$":DR@OLB1@GPZ5J?159RR%<P-#G)%OE4[%6?!.I;@VX <@[QW:DP *<SH
M67K*S4C"9)N\JFB5$438[>+3;'5:LIW\/,<00GPG[SQ"V%NTWSWT>P?")H+F
M75S?86=?;( TH6=I5 =1YFR3$Y.7.,3Y'3E/@EAYWWAB&4[SJLVIWB#;VI0"
MO)N_?5 K@FG;PTUF"'NQLWE=BG\&IR%[&@5?X.J_/3^S#K TOTIB78#CG( 3
M*S9*$VBI#8>U4R'+%N7A,_T7=B0_6 ?P.9NG3T^ZQ]#]KPG$&M\3O WBZ*)^
MU+-V6>@ YO%P"UX/Z^:S*\POIZ=46,]OFY*@'3+N50O)4[!,M7T2@/,] Q&P
MJQG:W#6_J4?E;KII&.L#,='R:EE:Z*'R6S#04L3J5PBJ-59CBW< ^;D(PZRD
M[L]]L-/D7[+0\\M'137T/!PI05MYV0(6=A-K*19\P<2.M"$DPKLH,3NE8;NE
M/*;J/B#,_Y#M74Q0=K9)-+E"[7:1M2:4>7D6:F'3L<2(-1\BE31["=MT(.?/
MRA&ZN+OIG.(I8TY0]6[K%)4QFKN1WINP>'+,$J/'!.&\$V5_!K[W(3K4Z(;]
MHAK Y7*?AENZ:#<=WT%E;?7 S0%B=+0% 6"Q144MV*PI!<PB9S9T4XQ.6X)E
MC(X37E./N;F=7KV"2>M-QU^QNZ=U*=@38/1?^0N7BN::4H!+'D^O6)^_]MI0
M/-?9R(5=) KJF:W.LQ7:UKI\)PDWBMY):S]$]Q[C4(WO?D;W3;@0:MQ&%R)N
M32U\%Z**4#B "Z$M" "++2IJP69-*=!="#-TDPO1E@#*A6"/9N.(OT77'3Q7
M:?7Y\;-JIC+K.748;*LQ\!-,2F X:8M49ENWM6ZUJQ77VFW^(?\,K'V> ]UC
MGE^<#P?W$#>8YY8%U?D][MWEHU]:5APL-+7C,3S66>-LM)P=)=A7H3U#,*M
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M5Q!,D$(2O-;UFO#G*U [[0"XE]7 IL[T+H]S[0T&I:ACOT0)=N2;"'(@R&(
MI_111F2IU1W3Y;'X[9Z$=V29D\N\B*MWF#[AXCF+=-2Q4W-%HRF5:"AEHP."
M7A. "HEZ^5,']R1F#R(0M'Q\0%T1J"K#]=%=6= 9,XWXPP^&Z4HCZ^P8SP2W
M/<Q3"8+@D F=<+#7R2.8TURO&K=9\5?<>FQ8:[?LU#SX1<9*2+PEI0X(SDT
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M%]5HYW*29<P\)B_#7<U+^H>.E_0OOY[OGMB#M%4HS$.<__8I2(/*(W@LJ$.
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M33!K<,B+?'NC0UL/87@4]+=3/J!0OU3O@^'R;V5<[ QF?RSDDJIR@'WF#27
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M5TT3.?J6/:OQ\8<_/SPN^ L;'S_\^7>H^0KX0=35BE?J<QH7.:_804?4Y*]
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MXB6<H*<=J@JIS@U.T'4:)B6_-;S\DIU6>\*?</&<16".$J2-<6,X4S I.;T
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MJ;AHYA@O8ZE]?(7%8,<IF^5N,*U"D\QE)[E7/$D1%B,GHA8V8MJ'9GC@>54
M2E@);6ZD':I3)WGISXL2+[.;.*2#+1-WP@:_PNH9&339I>\BHRU=27EIX,LZ
MW#E7;#:.?H?5R')PPC-YC93?35W34&4A?'.-4Z<+JX.F Y]GHM*V&#\>'"8O
M=!#S>7^T'?B9SHBJL66G!JM')V$6;UISY7I_\^'QL]\A^1]!6@9D=Y?BWG'1
M\@NM_NXJ?L$_LY<*T[6B\Z8HP^K"&<C''5D7@3Z<H(\_?/P]JG6\]N;RF6#\
M5QP0?;_)Q6#UD!;CN"]^/&62(+K@*B9Y05<B/'M"VEB)Q\^*KM"+P^H2*ZS"
M2S),"?6TH%B^1_: =F3?4P9Y6%UE!U:<FY@6Q,ZZQ:]%=9&1OU<8;'$8%]3S
M2?'YXE[1818ZL#K-'K#X8NIK@3I5U-=%I^RO?IV,,MD]QJ\L_&2.ES%%&U:/
MSH$N^!FT#/3A#X"\C$\!^0T7[8-+PE4=I1"LSM$@'/=!)8K"@:R795;/-M=4
M."=Q@4D<R+>P#?*P>L0.K&3;MYVN7NKA$=9ZU5ZOCX[ZG!(ZFZY3]B"9=:J"
M:9JP.F\J['$W]O4'1URRQ /:L7?$<+DV?O]@(7*F$L&$Q=E5W3H43E\<+&H?
MI"ZS0M[:"SKO)<CM-JO/^\3S0.4!X&5UXP7?DS@\X"'MWE" D=1W.PB+$GX_
MC9VS?FE8W LS$$-MZHM-&&U9H6\K#&'O-N2'W))GL;TC^F^2RYKC\*$[:=8&
MZ,BB>'H#AQT"]2\!IM4X6U< O[)Q0WU*EFP2T+BI$?WWN)$U!\!Q@RN [W_<
M/.!-$*=L49VE!0G"H@P2=N?X@]_!HX3U%8\@4YOLZVJ1IGPZZ-H/\-OD?B+6
MZINBJLM^@Y]AT4**30C@J(6\[MI2*N5EP@-1U@1SRBK:6RD)J^E-,,7$7HT\
M:A6\]DAM)?*KC#SBHD@XHKM5=X5.DB?>J *KCZSQ"INZM2)_>3IO59F)XTE)
MJ]G?3X#M(WN8)DCKDX,Z_0K.;V[.54?'!@58?6:)5G#E*C54ZZ%6$5%-K^-L
M$?U76:4[SI?9(HIB5O,@N0_BZ+JKIMT W*,L6+V\?T7$/-YMB2RD-VC+I!Y[
MS"]9U>=GT,9SDX[/-"\JY&#UJQZD,A-A &-&)/B*W;R(ZGUO54=(Q8#U@PZC
MY%T45$DW._Y^0Z/8B&0Y77!T43+'M;K0664A:E;WDCT7*S58W30)LS#E<<L5
M<VT4<?7F(FF=?JG9T_:SO<!3[,CR]+ DUIM-EO(*"/UHIP:K'R=AUJ<BJAXA
MC&M]-D.%O(1JHO(S0R5!R*WS8JV9GB1"L#I)@U"PB(THXK)>S>$->_4B2>\#
M\EOM&#%;K7;W#?*P^L0.[+A[:BWV*/%OK<?/%+T[^X]!@G.3)R<3@M4M&H3"
M+,1$@6QI=+E(;9UJHP:P?K&$*PFMKO50ZW/#Z+('O(YS]KQ/=!$3'!:&S5B]
M.*S.LL(JODC7**%*"X'8OEV$(844%RR_"HMRS(BB@U2"L+K&@%+86VC%42/O
M]Z)5]Z $?^]2DV=6+0JK1XPXQWW24ZC?C^J2S7KQD@>OV5]A+.[>"1*PND %
M3S11/3FTHH*@$DVH IL-\K#ZP@[LE*O:-J'+Q^JJZY3:3PKB E?_O4XO2LR6
MR<OL 2?L<3GJR3/O1.@T:TU8W3<5MBPOQ;>L 7_']K))I8*VE<ZQHL];]@P2
M!/1Z14I04=A=OG438''LCR5AT<8$4SW>A^D83"0Y5H?<LGN#^?,HP006TVFH
M!&%UAP&E$ ;#/!$J+^;&P)Z28G2[R]?4JTI3S-VEO\3%<Y47IQ^\\)?G.'S^
M]R"Z)_@ESLH\V9UAG#[@,",1CA:Y/@_0\3X%BQ)'KZ=VDY\=8K;?1%_H1^O4
M17S*;]?S7]AWT7- 9XSVR^B)?AJ1^MLHR%$$(/=1_4CSC@\Q58X"4086)]0
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MAN=)4&RZ:G[I@#OY )4RT^,$W74KV.Z?4>]+? YKOG6"^-?XO[7?\\HQ-3_
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M1("98=_WX'OW@/W'/-4@?VY\(W\>*C<LC8&Y3NLKR$V*^QI>DRM=O44_KR1
M';QG!23N;V6ROVT*_!U+@#"ZX<WW+:H3&Z]G!F+EZQ?2J#W;C2.AK)5 ]ZX*
MJV5'-NJHUO<1]B%6ZJ+$;*F^S&K?Y#X@X^.(:9H %C\S :OZT5@"I"%(Z,K
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M1,);.FFHP <">+,U$/$_HQH>"AJ1(']X)E$D#G)!#)+RMO9 V/^"";N:3@^
MERZ**[ZUP+&O= '"_U=?X&]0B\2!*6$TF?,MG0&P;S0&HOX3)NH*"E'QOH[G
M4+1W3<'G'WRP:^0A07U#TS"(BAG=\']+]7"W-(="CG+F-)*)"OL_2<# H%<:
M0R%'.88:2!P8\,N<L8/):+6*NC44<I0#J(G(@3&_CC.:;40-FOM\];1WG!YB
MW6P%Q1CET*DB"@7;K:<ASD1I'1V^]990C%'.FCKB4'"^E#F)T6T\)Z__DVQT
M0#>:0I%&.6-JR4.!>LJH2%EYH*%9:33;0L%&.5GJ"41!^S%XO16U/F1@@@#)
M#+JR"Q1[E&,EB%P4%HBX,+9.*N[B2Q$CRS:7R5RKT@T=H>Q .6]:D(["E/%\
MSN%*R__<T9A\T+&BM3GXC@B/ 1HR/8']HQWL'^&PHYQ#C61Z OOW=K!_#X<=
MY2QJ)!,3]DO^XX0])E\4-]#*QE#(4<ZB!A(Q 9<[S81-6?)"BQJ=)M0;/:#0
M(QY1]<2B"GRQR4.D?=L2BC?B<;6=.$R<ITF:!='_IFN3)=G>'HHYXL%51^C0
M#L:"[\)IH0HEJC6!XHMR5FTE9VA(!8<9"=3B>]@""BC* ;2-F('QO$O$W<=S
M$FO]L<U64%Q13I(JHH96O"*N.%4N_<J?P1%L*&JU3L; ,/[*:,9G(')*\KCT
MT2ANQ11-H?"B'/^TY T,]8,,JQ?).MLJP.TXM[6#@HQRV%,3-C#"4T8$IPDW
MNV4<ET@\8)/%0J5Y=>VAB*.<]<R$XB)_FZ8Y8;;XM_2"<@'EV <E>F@]4Y85
M__#QZ5%DS"BT3*,5%&N4(Y^*J(&QO4_*'*F'S>HIB=3I(:T-H0BC'/ TI T,
M\L$\VN&M-8$"BW*R:R4'22=<OX;RA0YU]$)[2RC *"<]'7%HNG<)TKU+2]V+
M<N)3$86$[:X,ZN0IJM4J;X>YM0,XSP83<0VI0^?OR90?\:H86\EYW/ ?VF%7
M-(4"CI,BJ2-O:*CS.16%O>24RN)-0;1_^$>!NK$7E $X.91 HE'<^[^2*/J?
M<?(E?B!!FL1D7ICZ.@^_L@N4"XAWB 9R45CP2Q+E'"4F T&98@THFD(A1[P[
M5)"'$WM9!#7O]I[B^4@=XJH>4. 1+Q'UQ"+%IV5$S)F^D*L@"\H9ZO!7]8#B
MCWBAJ"<6+7Z>E:6BM'?FM890M!%#85M)0P'Y815$T46>TIBD6MU2:P@%&3'F
MM94T%)"O5X0MN5+[F25?LN<RMU,'MJ(#%'3$R%8MJ3C@O^[SR(O\-RWR+:W!
MU0D085<2B55V8_?8QH-\T9LI4->UA^*.FEBI)G1@Y"?9,V%5^TE.YI:?VW1!
M#^9>4"Z@'%>A1./LK95,?NW6>M .BC?BP;2-,)R<J?PIHN%-E 1:N_R@&11?
MQ%-H"UDH\%X$\>\L7V?A1I0@)$1<GZ2[U08X$ $'@+($\7QJ!06.NV#_%(-\
MG"&=Y%DJ%&+EF<Y6IX&V'Y0UF$F< ,*1K*!TG^A%YA>;F2@8+L(4'LEK=A%5
M7C5N-XH W:'\0:TH!(9A8#;=A@LF'=X)&V<920O8U,$$NO901J <B,V$HI4!
MX0MWE5TSEK#+A"O14,\!2#\H)U#K#9D)Q[CM2M@-9:M;Q5FMU@1<0@[M'JM.
M#@ZDZAB/@P90.''N99NDX(!YEX2:2(-&(RBH>'>M39):@/W/]XW9W_%_V/ZU
M]8\'HQU7_?LBB *^7?-C'ZG< !]4 ?\X>C?:W1++,N!QFD1T+G;\4=E_5 YP
MM+0L@O1)\B-/WRV#8%U64H^R=/LO>]DI_^&WW>0FB]VU]C0I/&::*N)E=UCO
MX]=!%\K*MV>,--3;894>MX+T<-$H*'&@D+HSHCP+0OG1:(Y6P5P/;AL'%*2B
M,^(R2)_%DRS\/^*IS9<@$H>0<789,+;AIT+Q'FK;EESV!W9'*X4.XD'2A21/
M^#=E9!W0>?E:$)^W=/,>T*OF'J@S6C7U#KRS0 .=<T >=>-&_Q[9#MPPX<[G
M7KP*=U=0K9RAG%Z69$$D6^*MM61-6+:9<A--/-TEU,-:;,OW1+O(=+W0RKG;
M;&$0PCU93_=)'-I9%6T]T$J^VQL6:H+1.7*HC?<3A6Y(U1YHU>"A8.LVHB;I
MZ+RITP-?)8BEX;OQ0D7J">]$%;/&K.9:&Z,5FK?1<!HRT1?0X;O<,_&R^63Q
MF1N=8KH:9NB[X=6D!T">V%#B"YOV](!6"&:->GL6-(E#![RN;>4<'Y^#>/]/
MM_$+27>OP2J-2_B6=,PW\.KC6[.[?VA/> LTK6G;Y>S8?P%B[1M@2^51=RYP
M,M+D.8DXQ*D0OFQC-E?@(^"] 7"\7]X6)W2]7IDPV&VOZX/WN$!7#B@9Z,BW
MWWQ^?'KY,-X;GGS6A=01:8%M)[11NQ1%?WAWO$<)X! G70CS9$65X?#I--@$
M3Q$Q>X(5[?'>,[#FDX$2I^OF*B>/R1T-29SN>]061ZT-WFL%G59 *X7H8BZM
MU"8AAM-86P>\UPJZ"KJ!=G3>\(7(<FY;6G!'TP7O,8,C%)&>?G0.V;#F&)XX
M\V;T;F:]K4.2S7V5H1O>ZPJ]L]K=I597HUI[4P(R/SO<H#AXE<$*:QOKVL,[
MK@J1H$6%^61#[TOH#:A)D:U$=\[,RT2F#I,XU/)3VPGOB8A^^ M !'W5=?'Y
M]>#E<_#$1#\\.P'?WG2K&.1<#2&?K8WQWJF H]R(T%#1C,Z/2IJF*?ZVT1+O
M@8NNG%!1B\Z&\7PN7?E!- WH_#:^#-:4[XF5^6J.R8"^>&]F=&45'!%TYCTR
M;I[F; -916UM\9[@Z,H<-<7V-N!/A0T8DZ7(2D*U F<D"VA,YM<!BT4E@7$8
MYJL\$O.Z(@OQBH.:L9"^>(^!=&4T'!'T5=BDS<8(Q'Q$I"MSU!2?\$G,9 )W
MO\W'?+7$_2V^$];[E.$ZE0 _$]EH1^U!NNOW\'37T9\.QON/<_JKRW,>QWK"
MY'3GTEJ8$B:+PD"/?NK^IYLN:X<0^O9Z.-VBI,\XSYX31O_8KV\3(YO]L!-K
M>^.@"A(O.2=KEEMR;=L'.\.V9XX=0N$EM_0UPS2T=2D:YJ/Q P0%G7D5[X3]
ME@?JC)V4>P03+<#QB9'PK4[;"3O[MA_&>;O)->9HVN&4'; 3<OMDE&=[FV4Q
M3!55778UA[=!_;'+QRWMP-5;SEA.%NCC/NR"G<][!+>,0/A7(6S_0-1D44;5
M5!]X/O"=_*#SG>P'&B6+464H%)$4=4M79#<GLZ-$V0$YG[?,V8<D5JN[('M
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MA"V#F/YQF!FP#;C_Z;L/C?)"!QU0RK579W#)SS5)1.>%(,7S:06IR>*&BJ!
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MN:$J3HF"PKR M45/;-H'T"M'IQ_U9)GVI%J=0H6?0]HZ.1& :]+1YIY^R,$
MZPLD,55DL/7^C'!SGX;\."DUXN>89NGLX;-I#S!TP[Y7@,IRC5T@,-"WB7N2
MW<9ALB+"0;![(_ QJ6QL9;TFJ=[43+0>"#G0!W:,J_&T(UKH7/Z5B/M(,A^_
M$!8LR6&02N66TL!CRV&P0W@ZL;@35"<=OJ&@N'0,-@BW%@_U0-B!/GT*B FN
MDQ:15J L75T>'.RZL%M+^IMB:BG!<+;N.F 'Z?3"V!KY/;/6FRLF8<V^.^+@
MHKF$^HON$NK@NZ/]AT?;+X\$6T>5;XM>VZ]7KJ[.%U6XGJ'Q*LEU3[SW-+QG
MQP/#35:OF+XMU5.[TSZ(28&4H_YK7:OLKK/7.YW -44Q:E&KVI^RU*>O+2JI
MEZ8JZJFJC#J\</6QG_##-]CY&OQH^O&OQ_NKX-_CNSMW_EZS][2J^GIKY\ZG
M*_J"3/X!PZW38;.O@\,UHM&OXKM3N:<DGD^C((;<$KGYFA^2TRKUMNN[$_V>
MW1]9WAOY4G;<Y4K0WS%Y=K>$>AV(]^:B,_9Z>H5X]B=@/H?FA^>AK4:!-R[/
MVHW-C(@EQT&X(QSL1\)6J8RQ3T,!Q2S(R$W")FLB' ?QDO_IAL9!'&X[I!H/
MZ$\Z#^AV&J-R'J/=1$9RX)&<2AF47TQF)&8S6B1LM)N/_/MN1D7/]$BGJ")/
M9$])\16-\T*T5S?']EQ,6<+ARS9"Z6:<H2+";RWK]D(=$Z81D"U'/?P&IX.)
M-GR?@G*& )\!I*\?=K^MO#83 (V$XA_IE;.\V)@/^J#.;YN954K1S_QJTOA'
M34=X4&<_F&DAM% ^5HET4]+N)@AI1+.-W VT%=5:6V*?HBUDJYKVJ:$:_:"T
M(\%T FXTQ#[S=F"&BA1/>'''SPZ$[*SJW5% 7$_&ABLZ2%_DXR;<8JKQ"XZ+
M)RPLCD*%S=L\V9F8:.KMK1:$\1$&CH<5(=3'[]IAOGIL5VQO'<?"#DZU9_T1
MQ"J7M#=.G'$<YT$D*;FCP9/8Y"E);Q(VCJ)#=:5QT/SXG3Y$37RB=,94/B(=
M,$$459PP9[>+U<ZZ!7-3>C;3JYS<<\EX_$*B%_*)[RS/FF-?]Q&Q=N$._IAC
M8?-D.S83<#R?$;=EAXP]W@>?9%Q!8D:4:TG]',_++8?,KU^%VC?=_'0<#FWC
M[ELX3(C92\I/A:3$9,EW_3FJK"AH5DN#L@/:X;@#OPU4HRMQQ?PN<R: L&;.
MKA]:ADA_/*IA\!877TGBKA+)9%$>(8)HFJ14,.M:F/,I?8IXK[2S0-A\ 2W]
MNW?1L<?55WUPG\1A1Y50[8I6J+8_UC:1..F<0".5#G5#MX^@5=9U(4.]:(B3
M<-F 8VI^_'"4R^8<*0-8]54W\7&N&ON13LA%TQ6FD]X13$3_DP3L\4O2721V
M YR24\<2%70[SC3?[NP[+7\+%(<3=L*UDFCO?+,<YI2<,)T0.NGS?BO%EKP_
M+2>.EN*WMR$;'73Z7J?D8X'0__86:X^NN;[&/R7O3;^8^FG.09QRQHZGY$X!
MHO#VM'V_[K@>/X'V8%+_TO,67'$'OC5=D9T?/]:=;#5OV;&%=+STFYU\["'J
M,NHSVO#T]+(D4CS;I0M?V34Y)==6@S+_]-K^BN&.AEP3D_&2D2+W7G.1\+WN
M(J$<:+0?R?E-07WJ<.6G[HG\E(XIG[;6SJ^L61,_5&_C>),FNYO1':"45DM;
M/Y+MVH5)!?Z=J^36E(3?+I.7]W-""^SY#WO(^2]\"U@&T77,5<Q&D;;*6S4:
MG0+(;?/N-=G4#&[Q:64.*6]RV (9UC;$&I@>SMA-UN=U),I\Q&$2)<O-;1QJ
M$S]5C=',E09(39-33^"QGAG5D2#,U\^4D:FT2$RP*ENCW90!<#60Z C8\9H;
M\GS7O<OF6DA;VJ'=. ' 5)+E",9_YL]!?)FP=<(D_5HL58W1KG< @.H)=(3J
M97)_>3U[G!X>0TRKW]@+[;(%@#.09$> -T]S:L^*HBUVF2^E"5Y%64OG4-B.
M^?_.Q4\V(-<Z8:='=X2[E73_W!S%4U./P2O,A_M#W;]1]!_) ?PIB;ZC:C]7
M<U5T;2?L4.DD32\YJ)M%PD3%/M/KWL:.?AP1 7Q2AC<K",-WD:BG"/"9@#K[
MP3R@<((9Z,S-TH6)7"8O&9G3K#I%?>4P39=39IB&+/3B8*US@]3V-G;T@V-&
M*83PJL?JVZHR8(2/&D3Z F"';;"K30$EYZ#L5QN5Z&$Z5^6M)B=HG*8DXPM[
M345\<'V-JQ>#Q1#(1Q^+K;6V,JQA0F>LFM8NU@/^.:H[[\Q(.#K/WI-,^>WK
MUS5E&\VY%MH9NP94![[8D(?&($5I-M/<K6JR.=N>'#!%48T-1[GM#G[7K\&*
MQA+7*Y*&C*[%CX!#NJHC]CNAW=4<$!-'2TFU0=(_R'S&(>0??!8E[,D+B1)9
M(TX(VV*\2EA&_P@47)/A#WV,C.;0/FY!]H@J^IK])8CR N\H2KZ(N-8Z=9?/
MXJ6)V]B4]V4_$EH>P-&KNBMJZ.QN4T=3$@>1R'WG,GL;9X1S(>.;O?!\VZEL
M[4!H^0%.5#@ ,_^N!?;1C]>+!0F%*W]'FXBOG9$PB445['*74@9$_J@+B-R-
M7;E&*)XC.1P?^SWFMW*= .'E."O]'.+>*^=SV!PT5M/;R^#(_@7[^X@>(477
M^!!:Y&THUV1W? 91Y?+P.+E0CXKMM7 C$284'=GXD*D=_&G*SXQ!+"ZQ*>\J
MX*)!I##S^QH<VQ]BP?$^R3XA';#SG1^YZJOC8#M<W*SS)E(GG34.(7E[FFF<
M?)L'H>.DQ^I#V%XA-^+5 6M/%8QX^(/&.3]SE8>O)+96+NUC8#N.^N*\#J%>
M*PEY<_)L2+4PF/;E]S2'SC_K#IW;8>5ALQA8OG=9K>QW/F^ZN9M6>U:N^-Q3
M+@L6M]20P4[N/'D$9.BJW6+N!P>@7GA>&_'TSHW'HN<?^P7UY;^5#L^#=ZGC
M^06)R8(;Q^T/5^LSW]U\[80.GTYQ\%6DE ]660B*9HS3.X7:(S30_?$XY!_F
MO]_&I<G7?MTI[DJDO;NW%PW7QUT&/J'C7U\D#QLL4#JX)XS;]?$5RY=J!U'K
MM;BZ_PF=WRPI\RR<0RA^,+^@HV'?VQ_+/3O4AN(EM_]8EJ_E]LYEB1,%9EQK
M5^P+]V.YI,'#/Q/F9\;->0MSI6R/5O:N/]/D@/(3KGY]E&N[3W?U3QXS&^2"
M/KTKD :=]\3F["%;@WT3'K.W0O;;6,D5]^_/23+_0J.H"-@*XJ6HPEF07?\=
MQ/JN0T/EQ$\GUG& O@DEL<.O@H598MI[087!0]>4#H9C^?SHJ0ZQ50QP!OOI
M?!J(M<B7DS,2B9E-^7%C\\B"..78B(M82.F,O]0O)<O!1G*T474X?PIIJ @V
M7T>:>R(5L-S=+ZMF>+$Y^(NAW&BWX?Q(+X=RMUX8LQO-^)4Y%-.],Y?E,/?T
M@Z-'27>-S6::\<MT*.:H+]2A[?35\-&3$AZ*V9D*>!BZ^<%%@'3">.6V?,=E
MPNXV:79W=VDH.EAOAAUD 9*=P]*#[90Z<MQ/A3U)YND-G_B,R.O82?9,F+PT
MF!&Z>LI96I2+4V!N-0)RL!-T=ZTRI -"Z!Y].<$9"0E]$5I7N,*,3Z/I^GBZ
MBI1\ Y"DY)0WP:4SLDY8)B;^0)9"OK@D+F@F@ZI248PTRN<T7C[094P7?)1X
MF[-YR;%:)DP?@/I770#J_M.C\MNCXN-%&"K__/\SVDU@5)G!J)S":#\'[$C5
MDH"")/%&B_%<J.Z!?1ZLS^PV7B1<C(087FS*/X)/@Q:#^6&KF#BI/ -:4(I_
M M1,%G *A/7VA)_=Y;K.:A#5^&?!7:'>BSSE\TK3<N*I_C1HZ/;FN*DG%_T\
M6$['=/ZK-?.$2Q );%]=/9WP>CB.U^RB\7+)A#]>R!?AHD:DW;>+32];*0^.
M.QOSJ&&Q3>16H6P<W7M SLWA)F59A??\MSW?^2^_/0K+=;*XC>?TA<[S(%(H
M3-Y6T=23Y7>\DE236(G\1^3,KS1[EN<UX0)\INO'Y%K_B%$;0:9!D+FIYH&9
M5R;2'#V(M%I'R8:05/\24KT56K9!%^2:OAL%U<Y\:23DK<2!_K+\[R.C073@
M,5)ZT4!]L=_UL#B;'/K0+)!!]YZUAU&7GHWKU]+ML<]XF!8^'7TRV%&#>F)<
M6/&]#[H; G%Z+^3^3&*17,')'\]77/2%RT)$2QAKTAD[8B<"'B$40% P&:]Z
MJ>U@ON*]YR L@XK4')5OH0$Z8N?V=57O<%#0=?MM_$+23%!9Q))MRQVJUZ&Z
M!W;*WA$+T 3#2<>VWI.2JCMM&DNM&786WQ'<;"7X;59<Z>]2;"J9\DSDM]IN
MR'X:_H9L]*>#69UOS+ZNE]@[WG.=7V!WZRK'?8&]>W6F_=S$1XPQA]I.)\02
M+1WHET>*V9DNDPS=_& /0.Q@O/+GJDGCO#!?* $Z8WMV0.)HX]+Q[.TQ@Z?!
MQ$-@=^R#>Q<N6B'3*Q]3$GZ[3%[>SPDM6,A_V'..__+;'3]%1H5S7[%G\5:-
M1GXH0?T>U3;O7N_MS. :KN,:SZ,CP]J&6 /3(:[07,>@]Z\=0"_=NPDW/UIQ
MBYH,H7 EM=> ,[K/H?VQ;]2,3[=;TN/$<X[L_N&$KFA6A"G%\Z+,\)+$(06]
M"/_G[^J.G,IXTEUS,*(_F:TZLBVJ[EH.@QWC?)E$G(:DO$O@'."3W4[^/N&&
M3ON?JXEGX!#H_K[EA^W126*48=/]H8/ODNJ!%H SJ]^O^"%3[E9F3?#Z!0_?
M"??(QYXL*C/5N]\4S;\R(5"@@.ZV:U(:M!-G\BA8#^2' &B%N6ZJVI+HZ+PV
MF^BC':L-L/UP'>7KX"C7H!?]$#?-6?C,CRJ3IX@68>;JA='6%OEPYL)HJ*T5
M-4(>IJ;F3RGY5RY\O2\"!<C9ZT/C$GTWR*@8Q9_S5IT^P+VWL@?2*>IP/J9S
M4&MK/_8;$R_JAY964O"/';5Y 8X0ZAY>,D9[-ZXDY6R<(['D;%Z?S>N>S.NM
MY3)>,D*T"98R T35^@T8W@8DT*WPNG[@GS+DFZLZ^+%8NF]!>TK<Y$H>QQ1C
M0KFZBY^,J0F:F3>^Q/W4IF;:=!3-L56;4<3T#/%-BVUO2B^C($TGBX<L"7\'
MULUH=O%SP4 "39NT5.('D"Y7*E,R*;&VMIXPPR1@]?N*%DK<F%H/1*0)C'^5
MEHG>SFIOBITJJ!:0JAVE(]-1RG;QR0LXLO6FV)%_-LBVD^D4V;%XS!$BL-5V
MV"]R64EKD\!S@13'.Z*Q LH/YPHHKMEU>A50+I\I65R_DC 75PR3Q8*&A(DH
M&<(R_MF+)&#S8B$;;@WMQT%++>VGBDIGY/PY,X@G9K.-")A,8@*OM]?>[70T
M)8R>BOCAL*DV+=,10M'<$[9 1*[&'P5!V%X0DU5<MNMF$3M[J5,K3#7@AS2(
MIXS<Y.+R'7+84#4&@NOLB4T0N#H"?-D8 EF#3UCX][F8&?]%Q-6GMVF:BS)$
M%<^_9I^P&@4[T\!P%5W?,SH@A,[6\N16RMR$S>CR.=M-GQLP3!:EN0RBB,PO
M-F6[M&RH"^P]=F#/?,$F[O<$9/<:)-R6Q*W;U8H -X)92%,R9=P$WOUQ1_8'
M2P$R#X?MN.M#;*"@H6N/[<SXT::8VB3/TBR(10F71\)61A-(TQ/;3VC)2"@4
M'E9HJ\RTV+"F7/P$U$M5:39M#_0B7T#&&0GQ9)&UJHC*Q"U5Z$%/]!)>/6C+
M%BC0>59] DF8?^*I]-N86P!!-,V?(AI.%GSI:YEG,02V^]^2B];@>,G."2L,
M_N* 9\?'>E]L#T /#&R'PRHDO_R+^)^G("7\7_Y_4$L! A0#%     @ Z8-T
M6F)SQL8Z/   DXX!  L              ( !     &5X,3 M,3$N:'1M4$L!
M A0#%     @ Z8-T6KTNV?M8/   M'@!  L              ( !8SP  &5X
M,3 M,3(N:'1M4$L! A0#%     @ Z8-T6J0^F5'&.P  &&\!  L
M     ( !Y'@  &5X,3 M,3,N:'1M4$L! A0#%     @ Z8-T6FXSE^[ .P
M1V\!  L              ( !T[0  &5X,3 M,30N:'1M4$L! A0#%     @
MZ8-T6MH&Q'XP/   RGT!  L              ( !O/   &5X,3 M,34N:'1M
M4$L! A0#%     @ Z8-T6K&-87/$.P  5F\!  L              ( !%2T!
M &5X,3 M,38N:'1M4$L! A0#%     @ Z8-T6F#V5:LO @  #R$   @
M         ( ! FD! &5X,3DN:'1M4$L! A0#%     @ Z8-T6E:CN8^) @
MK1(   H              ( !5VL! &5X,C$M,2YH=&U02P$"% ,4    " #I
M@W1:SCNI;AP#  ! #@  "@              @ $(;@$ 97@R,RTQ+FAT;5!+
M 0(4 Q0    ( .F#=%I9O[(210,  #0.   *              "  4QQ 0!E
M>#(S+3(N:'1M4$L! A0#%     @ Z8-T6AF^P)+V<   6<L"  D
M     ( !N70! &5X,RTR+FAT;5!+ 0(4 Q0    ( .F#=%J;"BU4YP<  (X\
M   *              "  =;E 0!E>#,Q+3$N:'1M4$L! A0#%     @ Z8-T
M6MW"/V,*"   *SP   H              ( !Y>T! &5X,S$M,BYH=&U02P$"
M% ,4    " #I@W1:B:9RK>4$   0)P  "@              @ $7]@$ 97@S
M,BTQ+FAT;5!+ 0(4 Q0    ( .F#=%K6GY22$F # +PJ(0 ,
M  "  23[ 0!F;W)M,3 M:RYH=&U02P$"% ,4    " #I@W1:+RH1%<"1  "3
MO@  $               @ %@6P4 9F]R;3$P+6M?,# Q+FIP9U!+ 0(4 Q0
M   ( .F#=%I<3':3<A(  'C9   1              "  4[M!0!P8W-A+3(P
M,C0Q,C,Q+GAS9%!+ 0(4 Q0    ( .F#=%KLKD5@?1,  $;M   5
M      "  >__!0!P8W-A+3(P,C0Q,C,Q7V-A;"YX;6Q02P$"% ,4    " #I
M@W1:[S=7940R  #5>@, %0              @ &?$P8 <&-S82TR,#(T,3(S
M,5]D968N>&UL4$L! A0#%     @ Z8-T6JN?=/<,>P   EX' !4
M     ( !%D8& '!C<V$M,C R-#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( .F#
M=%KE]4B4M%4  .[4!0 5              "  57!!@!P8W-A+3(P,C0Q,C,Q
>7W!R92YX;6Q02P4&     !4 %0#6!   /!<'

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:PCSA="http://processapharmaceuticals.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pcsa-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="AsOf2025-03-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2025-03-12</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-222024-01-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="AsOf2024-01-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2024-01-21</instant>
        </period>
    </context>
    <context id="From2025-01-272025-01-27_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-27</startDate>
            <endDate>2025-01-27</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-27_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="AsOf2025-01-27_custom_SeriesAWarrantsMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="AsOf2025-01-27_custom_SeriesBWarrantsMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="AsOf2025-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-12_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-12</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-10_custom_TwoThousandAndNineteenPlanMember_custom_OriginalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:OriginalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-10</instant>
        </period>
    </context>
    <context id="AsOf2024-06-28_custom_TwoThousandAndNineteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandAndNineteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-06-282024-06-28_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_JanuaryOneTwoThousandTwentyFiveVestingMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:JanuaryOneTwoThousandTwentyFiveVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_EmployeesMember_custom_ThreeYearVestingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:ThreeYearVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="From2024-06-282024-06-28_custom_FirstPerformanceBasedRSUMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:FirstPerformanceBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="From2024-06-282024-06-28_custom_SecondPerformanceBasedRSUMember_custom_NextGenerationCapecitabineCAPMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SecondPerformanceBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:NextGenerationCapecitabineCAPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-16</startDate>
            <endDate>2024-07-16</endDate>
        </period>
    </context>
    <context id="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySixteenTwoThousandTwentyFiveVestingMember_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:JulySixteenTwoThousandTwentyFiveVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-16</startDate>
            <endDate>2024-07-16</endDate>
        </period>
    </context>
    <context id="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_FirstPerformanceBasedRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:FirstPerformanceBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-16</startDate>
            <endDate>2024-07-16</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_FirstPerformanceBasedRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:FirstPerformanceBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-16</instant>
        </period>
    </context>
    <context id="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_SecondPerformanceBasedRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:SecondPerformanceBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-16</startDate>
            <endDate>2024-07-16</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_SecondPerformanceBasedRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:SecondPerformanceBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-16</instant>
        </period>
    </context>
    <context id="From2024-09-032024-09-03_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_custom_OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ConsultantMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-172023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:SpartanCapitalSecuritesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-17</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:SpartanCapitalSecuritesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-17</instant>
        </period>
    </context>
    <context id="From2023-11-182023-11-18_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-18</startDate>
            <endDate>2023-11-18</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-18_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-18</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RestrictedStockAwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:RestrictedStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember417832562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_RestrictedStockAwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:RestrictedStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RestrictedStockAwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:RestrictedStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RestrictedStockAwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:RestrictedStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RestrictedStockAwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:RestrictedStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-292024-01-30_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-29</startDate>
            <endDate>2024-01-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="AsOf2024-01-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="AsOf2024-01-30_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PurchaseAgreementMember_custom_PlacementAgentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-02-142023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-14</startDate>
            <endDate>2023-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-14</instant>
        </period>
    </context>
    <context id="AsOf2023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-14</instant>
        </period>
    </context>
    <context id="From2023-02-142023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-14</startDate>
            <endDate>2023-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-17_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-17</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember417833750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember417833750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FacilityLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">PCSA:FacilityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FacilityLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">PCSA:FacilityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ElionOncologyIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:ElionOncologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OcuphirePharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:OcuphirePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AposenseLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:AposenseLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_YuhanCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:YuhanCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CoNCERTPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CoNCERTPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">PCSA:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CROsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:CROsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-10-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_SeriesAWarrantMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesAWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_SeriesBWarrantMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesBWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_ChiefExecutiveOfficerAndCertainBoardMembersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ChiefExecutiveOfficerAndCertainBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_SeriesAAndBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesAAndBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_us-gaap_WarrantMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="From2025-01-272025-01-27_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-27</startDate>
            <endDate>2025-01-27</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-27_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="AsOf2025-01-30_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-12_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-12</instant>
        </period>
    </context>
    <context id="From2025-01-272025-01-27_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-27</startDate>
            <endDate>2025-01-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>PCSA:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0001533743</dei:EntityCentralIndexKey>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0087"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0090"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:DueToLicensor
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0119"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0140"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0141"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0146"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0147"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0259"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:FinancingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:NonCashLeaseLiabilityNet
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:NonCashLeaseLiabilityNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0591"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0603"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember"
      id="xdx2ixbrl0655"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember"
      id="xdx2ixbrl0657"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember"
      id="xdx2ixbrl0659"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember"
      id="xdx2ixbrl0661"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember"
      id="xdx2ixbrl0663"
      unitRef="Shares"
      xsi:nil="true"/>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember"
      id="xdx2ixbrl0665"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_RestrictedStockAwardMember"
      id="xdx2ixbrl0671"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_custom_RestrictedStockAwardMember"
      id="xdx2ixbrl0673"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="AsOf2024-12-31" id="xdx2ixbrl1001">http://processapharmaceuticals.com/20241231#OperatingAndFinanceLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1003"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="AsOf2024-12-31" id="xdx2ixbrl1004">http://processapharmaceuticals.com/20241231#OperatingAndFinanceLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="AsOf2024-12-31" id="xdx2ixbrl1019">http://processapharmaceuticals.com/20241231#OperatingAndFinanceLeaseLiabilityCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="AsOf2024-12-31" id="xdx2ixbrl1022">http://processapharmaceuticals.com/20241231#OperatingAndFinanceLeaseLiabilityNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <PCSA:DeferredTaxAssetsStartupExpenditures
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1097"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:DeferredTaxAssetsStartupExpenditures
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1098"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1106"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1107"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1109"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1110"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1115"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_us-gaap_WarrantMember_custom_PurchaseAgreementMember"
      id="xdx2ixbrl1201">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000013">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000014">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000015">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000016">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000017">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000019">001-39531</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000020">Processa Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000022">45-1539785</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000023">7380 Coca Cola Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000024">Suite 106</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000025">Hanover</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000026">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000027">21076</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000028">(443)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000029">776-3133</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-12-31" id="Fact000030">Common     Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-12-31" id="Fact000031">PCSA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-12-31" id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000033">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000034">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000035">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000036">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000037">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000038">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000039">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000040">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000041">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000042">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-28"
      decimals="-5"
      id="Fact000043"
      unitRef="USD">5800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-12"
      decimals="INF"
      id="Fact000044"
      unitRef="Shares">5269240</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000045">None.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000049">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cybersecurity
Risk Management and Strategy&lt;/b&gt;&lt;/span&gt;&#160;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zlQ1SODAGDP3"&gt;We
have established processes to assess, identify, and manage cybersecurity risks. These processes are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zODYREMUV9F4"&gt;integrated&lt;/span&gt; into our overall risk
management program and are designed to protect our information assets from internal and external cyber threats&lt;/span&gt; and include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify; width: 0.25in"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;implementing
    physical, procedural, and technical safeguards;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;developing
    and maintaining comprehensive response plans;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;engaging
    with &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zkxK7PJMcqs3"&gt;external cybersecurity experts to enhance our oversight and keep pace with evolving threats&lt;/span&gt;; and&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;considering
    the cybersecurity capabilities of partners and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zTEDx5rvv61k"&gt;third-party service providers&lt;/span&gt;, both prior to engaging them and on an ongoing basis.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&#160;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000050">We
have established processes to assess, identify, and manage cybersecurity risks. These processes are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zODYREMUV9F4"&gt;integrated&lt;/span&gt; into our overall risk
management program and are designed to protect our information assets from internal and external cyber threats</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000051">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2024-01-01to2024-12-31" id="Fact000052">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000053">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000057">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cybersecurity
Governance and Oversight&lt;/b&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zL4l5kD4iNy2"&gt;Our
Board of Directors provides direct oversight of cybersecurity risk and has delegated to its audit committee the responsibility of reviewing
and discussing with management our risk exposures relating to cybersecurity&lt;/span&gt;. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_ztIFLCO5Ykqk"&gt;The Board of Directors and the audit committee will receive
regular updates from management on cybersecurity matters and are promptly informed by management about any significant new threats or
incidents&lt;/span&gt;. In the future, management and our third-party service providers will conduct reviews at least once annually of our cybersecurity
readiness to ensure continuous improvement in our cybersecurity strategies.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;We
have implemented mechanisms to monitor and manage cybersecurity threats and incidents, including utilization of tools for continuous
monitoring of our IT environment to detect and mitigate threats, a fundamental plan for responding to cyber incidents and training for
employees to recognize and report potential cybersecurity incidents and to foster a culture of cybersecurity awareness and vigilance.
Our Chief Administrative Officer, along with a third-party service provider, are responsible for operational oversight of our cybersecurity
strategy and policies. Any identified cybersecurity incident is reported to our Chief Administrative Officer who evaluates the severity
of the incident. Based on this assessment, further steps are taken involving other members of management and, depending on the severity,
the audit committee and the Board of Directors. We believe this structured approach allows us to effectively manage and mitigate cybersecurity
risks, safeguarding our systems and data against various digital threats. Additionally, our proactive stance is supported by cybersecurity
insurance, which further reinforces our preparedness against potential cyber threats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cybersecurity
Incident Reporting and Management&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;During
the years ended December 31, 2023 and 2024, we have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zEtOM1mwRRW3"&gt;not&lt;/span&gt; identified any risks from cybersecurity threats that have materially affected
or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. However,
we remain vigilant and prepared to respond effectively to any incidents, should they arise.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&#160;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000058">Our
Board of Directors provides direct oversight of cybersecurity risk and has delegated to its audit committee the responsibility of reviewing
and discussing with management our risk exposures relating to cybersecurity</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000059">The Board of Directors and the audit committee will receive
regular updates from management on cybersecurity matters and are promptly informed by management about any significant new threats or
incidents</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000060">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000061">677</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000062">Cherry Bekaert LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000063">Tampa, Florida</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">1191325</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">4706197</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">682294</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">926300</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">1873619</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">5632497</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">5016</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">2554</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">1274442</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">1274442</us-gaap:AssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000095"
      unitRef="USD">70677</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">146057</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">5535</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">5535</us-gaap:OtherAssets>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">76212</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">151592</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">3229289</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">5786643</us-gaap:Assets>
    <PCSA:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000113"
      unitRef="USD">73020</PCSA:OperatingAndFinanceLeaseLiabilityCurrent>
    <PCSA:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">83649</PCSA:OperatingAndFinanceLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000116"
      unitRef="USD">880880</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">311617</us-gaap:AccountsPayableCurrent>
    <PCSA:DueToLicensor
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">189000</PCSA:DueToLicensor>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">39</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">578731</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">146274</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000128"
      unitRef="USD">1532631</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000129"
      unitRef="USD">730579</us-gaap:LiabilitiesCurrent>
    <PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000134"
      unitRef="USD">487</PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000135"
      unitRef="USD">66905</PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000137"
      unitRef="USD">1533118</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000138"
      unitRef="USD">797484</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000149"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000151"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000153"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000155"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000157"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000159"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000161"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000163"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000168"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000170"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000172"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000174"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">3707628</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000178"
      unitRef="Shares">3702628</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000180"
      unitRef="Shares">1291000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000182"
      unitRef="Shares">1286000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">371</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">129</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000184"
      unitRef="USD">89214999</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000185"
      unitRef="USD">80658111</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000190"
      unitRef="Shares">5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000192"
      unitRef="Shares">5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000187"
      unitRef="USD">300000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">300000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000194"
      unitRef="USD">-87219199</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">-75369081</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">1696171</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">4989159</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">3229289</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">5786643</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000206"
      unitRef="USD">7269146</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">5799518</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000209"
      unitRef="USD">4782060</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">5657543</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000212"
      unitRef="USD">-12051206</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000213"
      unitRef="USD">-11457061</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000218"
      unitRef="USD">201088</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">335541</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000221"
      unitRef="USD">-11850118</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000222"
      unitRef="USD">-11121520</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">-11850118</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000228"
      unitRef="USD">-11121520</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000230"
      unitRef="USDPShares">-3.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000232"
      unitRef="USDPShares">-3.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000234"
      unitRef="USDPShares">-8.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000236"
      unitRef="USDPShares">-8.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000238"
      unitRef="Shares">3059906</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000240"
      unitRef="Shares">3059906</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000242"
      unitRef="Shares">1311572</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000244"
      unitRef="Shares">1311572</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000252"
      unitRef="Shares">806774</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000246"
      unitRef="USD">80</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000247"
      unitRef="USD">72018222</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000254"
      unitRef="Shares">-5000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000248"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000249"
      unitRef="USD">-64247561</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000250"
      unitRef="USD">7470741</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000262"
      unitRef="Shares">6945</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000256"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000257"
      unitRef="USD">1060338</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000260"
      unitRef="USD">1060339</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000270"
      unitRef="Shares">421611</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000264"
      unitRef="USD">42</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000265"
      unitRef="USD">6352035</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000268"
      unitRef="USD">6352077</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000273"
      unitRef="USD">1310875</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">1310875</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">-52746</PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000282"
      unitRef="USD">-52746</PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000290"
      unitRef="Shares">55670</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000284"
      unitRef="USD">6</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">-30613</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000288"
      unitRef="USD">-30607</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000295"
      unitRef="USD">-11121520</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000296"
      unitRef="USD">-11121520</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000304"
      unitRef="Shares">1291000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000298"
      unitRef="USD">129</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000299"
      unitRef="USD">80658111</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000306"
      unitRef="Shares">-5000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000300"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000301"
      unitRef="USD">-75369081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000302"
      unitRef="USD">4989159</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000314"
      unitRef="Shares">1291000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000308"
      unitRef="USD">129</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000309"
      unitRef="USD">80658111</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000310"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000311"
      unitRef="USD">-75369081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000312"
      unitRef="USD">4989159</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000322"
      unitRef="Shares">62502</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000316"
      unitRef="USD">6</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000317"
      unitRef="USD">629508</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000320"
      unitRef="USD">629514</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000330"
      unitRef="Shares">2356549</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000324"
      unitRef="USD">236</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000325"
      unitRef="USD">7762843</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000328"
      unitRef="USD">7763079</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000338"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000332"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000333"
      unitRef="USD">188999</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000336"
      unitRef="USD">189000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000341"
      unitRef="USD">-8561</PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000344"
      unitRef="USD">-8561</PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000352"
      unitRef="Shares">7423</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000346"
      unitRef="USD">1</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000347"
      unitRef="USD">15901</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000350"
      unitRef="USD">15902</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000357"
      unitRef="USD">-11850118</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000358"
      unitRef="USD">-11850118</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000366"
      unitRef="Shares">3707628</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000360"
      unitRef="USD">371</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">89214999</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000368"
      unitRef="Shares">-5000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000362"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000363"
      unitRef="USD">-87219199</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000364"
      unitRef="USD">1696171</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000376"
      unitRef="Shares">3707628</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000370"
      unitRef="USD">371</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">89214999</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000372"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">-87219199</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000374"
      unitRef="USD">1696171</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000381"
      unitRef="USD">-11850118</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000382"
      unitRef="USD">-11121520</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000387"
      unitRef="USD">782</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000388"
      unitRef="USD">222</us-gaap:Depreciation>
    <PCSA:OperatingAndFinanceLeaseExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000390"
      unitRef="USD">87184</PCSA:OperatingAndFinanceLeaseExpense>
    <PCSA:OperatingAndFinanceLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000391"
      unitRef="USD">81530</PCSA:OperatingAndFinanceLeaseExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000393"
      unitRef="USD">629514</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000394"
      unitRef="USD">1060339</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000397"
      unitRef="USD">1310875</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000402"
      unitRef="USD">1030436</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000403"
      unitRef="USD">-956834</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000405"
      unitRef="USD">-83649</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000406"
      unitRef="USD">-78896</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000408"
      unitRef="USD">569263</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000409"
      unitRef="USD">-15931</us-gaap:IncreaseDecreaseInAccountsPayable>
    <PCSA:IncreaseDecreaseInDueFromToRelatedParties
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000411"
      unitRef="USD">39</PCSA:IncreaseDecreaseInDueFromToRelatedParties>
    <PCSA:IncreaseDecreaseInDueFromToRelatedParties
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000412"
      unitRef="USD">12</PCSA:IncreaseDecreaseInDueFromToRelatedParties>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000414"
      unitRef="USD">432457</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000415"
      unitRef="USD">-256787</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000417"
      unitRef="USD">-11245042</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000418"
      unitRef="USD">-8063346</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000423"
      unitRef="USD">3244</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000424"
      unitRef="USD">2776</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000426"
      unitRef="USD">-3244</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000427"
      unitRef="USD">-2776</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000432"
      unitRef="USD">7763079</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000433"
      unitRef="USD">6321470</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000435"
      unitRef="USD">15902</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <PCSA:PaymentsForSettlementOfStockAwards
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000438"
      unitRef="USD">8561</PCSA:PaymentsForSettlementOfStockAwards>
    <PCSA:PaymentsForSettlementOfStockAwards
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000439"
      unitRef="USD">52746</PCSA:PaymentsForSettlementOfStockAwards>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000441"
      unitRef="USD">5202</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000444"
      unitRef="USD">7733414</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000445"
      unitRef="USD">6268724</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000447"
      unitRef="USD">-3514872</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000448"
      unitRef="USD">-1797398</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000450"
      unitRef="USD">4706197</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000451"
      unitRef="USD">6503595</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000453"
      unitRef="USD">1191325</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000454"
      unitRef="USD">4706197</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000459"
      unitRef="USD">1204</us-gaap:InterestPaidNet>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000471"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000468"
      unitRef="USD">189000</PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000473"
      unitRef="USD">11804</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <PCSA:FinancingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000476"
      unitRef="USD">-11804</PCSA:FinancingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000482">&lt;p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zHII7B87Rjee" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_82C_ztVTq4A1fvoj"&gt;Organization&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next
Generation &lt;span style="background-color: white"&gt;Cancer therapy &lt;/span&gt; &lt;span style="background-color: white"&gt;(&#x201c;NGC&#x201d;) &lt;/span&gt; drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing
FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known and established
existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our NGC treatments will
provide improved safety-efficacy profiles when compared to their currently marketed counterparts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended with the Secretary of State of
Delaware that effected a &lt;span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20240122__20240122_zB3orY3QwZR4" title="Reverse stock split"&gt;1-for-20 reverse stock split&lt;/span&gt; of our common stock, par value $&lt;span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240122_zPTQ3p56BSo2" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share (the &#x201c;Reverse Stock Split&#x201d;).
Pursuant to the Certificate of Amendment, our issued common stock decreased from &lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20240121_zFd6vKWntT6i" title="Common stock shares issued"&gt;24,706,474&lt;/span&gt; shares to &lt;span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20240122_ztMcbhUbOiNi" title="Common stock, shares issued"&gt;1,291,000&lt;/span&gt; shares and our outstanding
common stock decreased from &lt;span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240121_zMReQH9Q8hel" title="Common stock shares outstanding"&gt;24,606,474&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20240122_zO1T4DtizU4d" title="Common stock, shares outstanding"&gt;1,286,000&lt;/span&gt;. The Reverse Stock Split did not affect our authorized common stock of &lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20240122_znzi3Hs2tYJ5" title="Common stock, shares authorized"&gt;100,000,000&lt;/span&gt;
shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, and restricted
stock units, as well as exercise prices and per share information in these consolidated financial statements give retroactive effect
to the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization
of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception,
currently devoting substantially all of our efforts toward research and development of our NGC drug product
candidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated
deficit of $&lt;span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zCBBEnE2a7bi" title="Accumulated deficit"&gt;87.2&lt;/span&gt; million at December 31, 2024. During the year ended December 31, 2024, we generated a net loss of $&lt;span id="xdx_903_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zpqInEsbLdr7" title="Net loss"&gt;11.9&lt;/span&gt; million and
used $&lt;span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zN2rqougPdF9" title="Net cash used in operating activities"&gt;11.2&lt;/span&gt; million in net cash for operating activities from continuing operations. To date, none of our drug candidates have been approved
for sale, and therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable
future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have financed our operations primarily through public equity issuances, including an offering we sold on January 27, 2025 where we sold
&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250127__20250127__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIdsXD0naTpf" title="Number of shares sold"&gt;1,030,972&lt;/span&gt; shares of our common stock, pre-funded warrants to purchase up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zogXEA8VMUKl" title="Warrants to purchase"&gt;7,019,700&lt;/span&gt; shares of our common stock, and accompanying Series
A warrants to purchase up to &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0ydKH27MuKa" title="Warrants to purchase shares"&gt;8,050,672&lt;/span&gt; shares of our common stock (the &#x201c;Series A Warrants&#x201d;) and Series B warrants to purchase
up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zS6kZ31q4Me7" title="Warrants to purchase common stock"&gt;4,025,336&lt;/span&gt; shares of our common stock (the &#x201c;Series B Warrants&#x201d; and collectively with the Series A Warrants, the &#x201c;Common
Warrants&#x201d;) for net proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zr0lZ2YRTCba" title="Net proceeds"&gt;4.5&lt;/span&gt; million, after deducting placement agent fees and offering-related expenses (see Note 14 for
additional details). On January 30, 2025, pre-funded warrants to purchase &lt;span id="xdx_900_ecustom--ClassOfWarrantOrRightExercised_iI_c20250130__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0HyrCDWJfJa" title="Warrants exercised"&gt;525,700&lt;/span&gt; shares of our common stock were exercised and, as of
March 12, 2025, pre-funded warrants for the purchase of &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250312__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrFY2Q82gPZd" title="Warrants outstanding"&gt;6,494,000&lt;/span&gt; remain outstanding. We will continue to be dependent upon equity
and/or debt financing until we are able to generate positive cash flows from its operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024, we had cash and cash equivalents totaling $&lt;span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_z6OOfwSGf4z2" title="Cash and cash equivalents"&gt;1.2&lt;/span&gt; million. Together with the $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zepT5e4MYsB8" title="Net proceeds"&gt;4.5&lt;/span&gt; million net proceeds we raised in January
2025, and based on our current business plans, we believe these funds will satisfy our capital needs into mid-2025. Our ability to execute
our longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend on our ability
to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#x2019; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Absent
additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year
or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our
projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial
doubt exists about our ability to continue as a going concern within one year after the date that these consolidated financial statements
are available to be issued. The accompanying consolidated financial statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might
be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-01-222024-01-22" id="Fact000484">1-for-20 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-01-22"
      decimals="INF"
      id="Fact000486"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-01-21"
      decimals="INF"
      id="Fact000488"
      unitRef="Shares">24706474</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-01-22"
      decimals="INF"
      id="Fact000490"
      unitRef="Shares">1291000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-01-21"
      decimals="INF"
      id="Fact000492"
      unitRef="Shares">24606474</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-01-22"
      decimals="INF"
      id="Fact000494"
      unitRef="Shares">1286000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-01-22"
      decimals="INF"
      id="Fact000496"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000498"
      unitRef="USD">-87200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000500"
      unitRef="USD">-11900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000502"
      unitRef="USD">-11200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-272025-01-27_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000504"
      unitRef="Shares">1030972</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-27_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000506"
      unitRef="Shares">7019700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-27_custom_SeriesAWarrantsMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000508"
      unitRef="Shares">8050672</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-27_custom_SeriesBWarrantsMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000510"
      unitRef="Shares">4025336</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-272025-01-27_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000512"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <PCSA:ClassOfWarrantOrRightExercised
      contextRef="AsOf2025-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000514"
      unitRef="Shares">525700</PCSA:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-03-12_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000516"
      unitRef="Shares">6494000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000518"
      unitRef="USD">1200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-272025-01-27_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000520"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000522">&lt;p id="xdx_805_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zqtUGwYB1k1g" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_829_zxnPYDg6pXh6"&gt;Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJwbA0ZS79Z8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zfmt3sv6MuK6"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange
Commission (the &#x201c;SEC&#x201d;), and reflect all of our activities, including those of our wholly-owned subsidiary. All material intercompany
accounts and transactions have been eliminated in consolidation. Operating results for the year ended December 31, 2024 are not necessarily
indicative of future results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zvfbiAHSVea5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_z6qoGM74IBTa"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing our consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and regulations
of the SEC, we make estimates and judgments that affect the amounts reported in the consolidated financial statements and accompanying
notes. Estimates are used for, but not limited to stock-based compensation, intangible assets, future milestone payments and income taxes.
These estimates and assumptions are continuously evaluated and are based on management&#x2019;s experience and knowledge of the relevant
facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates
and could impact future results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zKoo1C6jtf03" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_z3lz7d9cpfM4"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash on hand and money market funds. We consider all highly liquid investments maturing within three months
from the date of purchase as cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--PrepaidExpensesPolicyTextBlock_z3qevoN2fMUi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zVQDTR4r1B4k"&gt;Prepaid
Expenses&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments made to third parties under
these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.
The majority of our prepaid expenses relate to advanced payments made to CROs and other vendors for our ongoing clinical trials. We allocate
the prepaid expenses between current and non-current assets based on the anticipated timing of utilizing the advances. At December 31,
2024, we determined that $&lt;span id="xdx_90E_eus-gaap--PrepaidExpenseNoncurrent_iIP1custom--AccountingPoliciesLineItemsAbstract_pn5n6_c20241231_zE498icFARu7" title="Prepaid expense"&gt;1.3&lt;/span&gt; million would not be applied until after December 31, 2025.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zS4wfLdYwof4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zvh4Vi9h7wea"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
is stated at cost, less accumulated depreciation. Costs of renewals and improvements that extend the useful lives of the assets are capitalized.
Expenditures for maintenance and routine repairs are charged to expense as incurred. Depreciation is recognized on a straight-line basis
over the estimated useful lives of the assets, which generally range from &lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iIP1us-gaap--PropertyPlantAndEquipmentLineItems_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_zoCtbnHRkXe8" title="Estimated useful lives of property plant and equipment"&gt;3&lt;/span&gt; to &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iIP1us-gaap--PropertyPlantAndEquipmentLineItems_dtY_c20241231__srt--RangeAxis__srt--MaximumMember_zLZpDmG39177" title="Estimated useful lives of property and equipment"&gt;5&lt;/span&gt; years. We amortize leasehold improvements over the shorter
of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related
accumulated depreciation are removed from the accounts with the resulting net gain or loss, if any, reflected in the consolidated statement
of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z1prFuGxIT3c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zkoqXS1iLQ5g"&gt;Impairment
of Long-Lived Assets and Intangibles Other Than Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for the impairment of long-lived assets in accordance with ASC 360&lt;i&gt;, Property, Plant and Equipment&lt;/i&gt; and ASC 350, &lt;i&gt;Intangibles
&#x2013; Goodwill and Other,&lt;/i&gt; which require that long-lived assets and certain identifiable intangibles be reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to its expected future undiscounted net cash flows
generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which
the carrying amounts of the assets exceed the fair value of the assets based on the present value of the expected future cash flows associated
with the use of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbm5AT6BEZh4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zL2TdenAtji6"&gt;Fair
Value Measurements and Disclosure&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
apply ASC 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, which expands disclosures for assets and liabilities that are measured
and reported at fair value on a recurring basis. Fair value is defined as an exit price, representing the amount that would be received
upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or
liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 &#x2013; Quoted market prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access
at the measurement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 &#x2013; Quoted market prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or
liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Fair value determined
using models or other valuation methodologies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 &#x2013; Significant unobservable inputs for assets or liabilities that cannot be corroborated by market data. Fair value is determined
by the reporting entity&#x2019;s own assumptions utilizing the best information available and includes situations where there is little
market activity for the asset or liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
asset&#x2019;s or liability&#x2019;s fair value measurement within the fair value hierarchy is based upon the lowest level of any input
that is significant to the fair value measurement. Our policy is to recognize transfers between levels of the fair value hierarchy in
the period the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 1, 2, or 3 during
the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSwxTtKBlKua" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zDdSubbyF0yf"&gt;Stock-based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
measure compensation expense for stock options and other stock awards in accordance with ASC 718, &lt;i&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt;.
Stock-based compensation is measured at fair value on grant date and recognized as compensation expense over the requisite service period.
Generally, we issue stock options and other stock awards with service-based and/or performance-based vesting conditions. For awards with
only service-based vesting conditions, we record compensation cost for these awards using the straight-line method over the service period.
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For awards that contain performance vesting conditions,
we do not recognize compensation expense until achieving the performance condition is probable. We estimate the fair value of stock option
and warrant grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based
awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment.
We value restricted stock awards (RSAs) and restricted stock units (RSUs) based on the closing share price of our common stock on the
date of grant. Stock-based compensation costs are recorded as general and administrative or research and development costs in the statements
of operations based upon the underlying individual&#x2019;s or entity&#x2019;s role.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimates
of fair value are not intended to predict actual future events or the value ultimately realized by employees or consultants who receive
these awards, and subsequent events are not indicative of the reasonableness of our original estimates of fair value. We account for
forfeitures in the period in which they occur, rather than estimate expected forfeitures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z4qzW1m203ec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zsAvmqMEF221"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted average common stock outstanding (which excludes unvested RSAs) and
vested, but unissued RSUs. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted
weighted average number of shares of common stock outstanding during the period. Since we have experienced a net loss for all periods
presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the years ended December 31, 2024 and
2023 excludes the impact of potentially dilutive common shares related to outstanding stock options, unvested restricted stock awards
(RSAs), unvested RSUs and common stock purchase warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
diluted net loss per share for the years ended December 31, 2024 and 2023 excluded &lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_iP1custom--AccountingPoliciesLineItemsAbstract_pid_c20240101__20241231_zjF4WhW5Lk6k" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,013,154&lt;/span&gt; and &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_iP1custom--AccountingPoliciesLineItemsAbstract_pid_c20230101__20231231_zlt27ixgXgc1" title="Antidilutive securities excluded from computation of earnings per share"&gt;296,326&lt;/span&gt; of potentially dilutive common
shares, respectively, related to outstanding stock options, unvested RSAs, unvested RSUs and warrants since those shares would have had
an anti-dilutive effect on loss per share during the years then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_znxOJ7ZTbKK4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_z342kDdpre2c"&gt;Segments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;We have one reportable segment, which is focused on discovering and developing a pipeline of Next Generation Cancer
therapy drugs. Our Chief Executive Officer, who is the chief operating decision maker (CODM), assesses segment performance and decides
how to allocate resources based on net loss that is also reported on the Consolidated Statements of Operations and Comprehensive Loss.
See Note 11 for additional information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zNouNC8tTmg4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_zjEuC6PXltOe"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash and cash equivalents, accounts receivable and accounts payable approximate their fair value because of the short-term
maturity of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zW9LuNaeVIn9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_zjxmExykSpx6"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred and consist of direct and overhead-related expenses related primarily to clinical trials,
including development personnel salaries and related costs. Expenditures to acquire technologies, including licenses, which are utilized
in research and development and that have no alternative future use are expensed as the acquisition of in-process research and development
when incurred. Technology we develop for use in our products is expensed as incurred until technological feasibility has been established
after which it is capitalized and depreciated. No research and development costs were capitalized during the years ended December 31,
2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zHxivy8XX6Ub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zqu3ysScCQ1a"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes.&lt;/i&gt; Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. As of December 31, 2024 and 2023, we recorded a valuation allowance equal to the full recorded amount of our
net deferred tax assets since it is more-likely-than-not that benefits from our deferred tax assets will not be realized. The valuation
allowance is reviewed quarterly and is maintained until sufficient positive evidence exists to support its reversal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
recognize the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing
authority, based on the technical merits of the position. Our policy is to record interest and penalties related to income taxes as part
of its income tax provision. As of December 31, 2024, we had &lt;span id="xdx_903_eus-gaap--UnrecognizedTaxBenefits_iIP1custom--AccountingPoliciesLineItemsAbstract_do_c20241231_zkuwbJhRSg02" title="Unrecognized tax benefits"&gt;no&lt;/span&gt; unrecognized tax benefits and as such, no liability, interest or penalties
were required to be recorded. We do not expect this to change significantly in the next twelve months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--RecentAccountingPronouncementsPolicyPolicyTextBlock_zHPKtuk6v6Vb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_861_zB4GDa2ri0Oe"&gt;Recently Adopted Accounting Standard&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;In November 2023, the FASB issued ASU 2023-07 &#x2013; Segment Reporting (Topic 280) &#x2013; Improvements to Reportable
Segment Disclosures, which improves segment disclosure requirements, primarily through enhanced disclosure requirements for significant
segment expenses. The improved disclosure requirements apply to all public entities that are required to report segment information, including
those with only one reportable segment. We adopted this standard effective for the year ending December 31, 2024 and the primary impact
of which was the additional segment disclosures included in Note 11.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z51Qe2P6ysXl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_ztahQYnCPzBa"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#x201c;ASU&#x201d;).
We have implemented all new accounting pronouncements that are in effect and that may impact our financial statements. We have &lt;span style="background-color: white"&gt;considered
all recent accounting pronouncements issued since the last audit of our consolidated financial statements. We believe that these recent
pronouncements will not have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="background-color: white"&gt;In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide
enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and
for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption
is permitted. We are evaluating this standard to determine if adoption will have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense
Disaggregation Disclosures (Subtopic 220-40), which requires disclosure, in the notes to the financial statements, of specified information
about certain costs and expenses. This ASU is effective for public entities for annual reporting periods beginning after December 15,
2026 and interim reporting periods beginning after December 15, 2027. We are currently evaluating the impact ASU 2024-03 will have on
our consolidated financial statements.&lt;/p&gt;

&lt;p id="xdx_858_zzQRomPClUQ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000524">&lt;p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJwbA0ZS79Z8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zfmt3sv6MuK6"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange
Commission (the &#x201c;SEC&#x201d;), and reflect all of our activities, including those of our wholly-owned subsidiary. All material intercompany
accounts and transactions have been eliminated in consolidation. Operating results for the year ended December 31, 2024 are not necessarily
indicative of future results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000526">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zvfbiAHSVea5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_z6qoGM74IBTa"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing our consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and regulations
of the SEC, we make estimates and judgments that affect the amounts reported in the consolidated financial statements and accompanying
notes. Estimates are used for, but not limited to stock-based compensation, intangible assets, future milestone payments and income taxes.
These estimates and assumptions are continuously evaluated and are based on management&#x2019;s experience and knowledge of the relevant
facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates
and could impact future results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000528">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zKoo1C6jtf03" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_z3lz7d9cpfM4"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash on hand and money market funds. We consider all highly liquid investments maturing within three months
from the date of purchase as cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <PCSA:PrepaidExpensesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000530">&lt;p id="xdx_849_ecustom--PrepaidExpensesPolicyTextBlock_z3qevoN2fMUi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zVQDTR4r1B4k"&gt;Prepaid
Expenses&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments made to third parties under
these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.
The majority of our prepaid expenses relate to advanced payments made to CROs and other vendors for our ongoing clinical trials. We allocate
the prepaid expenses between current and non-current assets based on the anticipated timing of utilizing the advances. At December 31,
2024, we determined that $&lt;span id="xdx_90E_eus-gaap--PrepaidExpenseNoncurrent_iIP1custom--AccountingPoliciesLineItemsAbstract_pn5n6_c20241231_zE498icFARu7" title="Prepaid expense"&gt;1.3&lt;/span&gt; million would not be applied until after December 31, 2025.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PCSA:PrepaidExpensesPolicyTextBlock>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000532"
      unitRef="USD">1300000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000534">&lt;p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zS4wfLdYwof4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zvh4Vi9h7wea"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
is stated at cost, less accumulated depreciation. Costs of renewals and improvements that extend the useful lives of the assets are capitalized.
Expenditures for maintenance and routine repairs are charged to expense as incurred. Depreciation is recognized on a straight-line basis
over the estimated useful lives of the assets, which generally range from &lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iIP1us-gaap--PropertyPlantAndEquipmentLineItems_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_zoCtbnHRkXe8" title="Estimated useful lives of property plant and equipment"&gt;3&lt;/span&gt; to &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iIP1us-gaap--PropertyPlantAndEquipmentLineItems_dtY_c20241231__srt--RangeAxis__srt--MaximumMember_zLZpDmG39177" title="Estimated useful lives of property and equipment"&gt;5&lt;/span&gt; years. We amortize leasehold improvements over the shorter
of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related
accumulated depreciation are removed from the accounts with the resulting net gain or loss, if any, reflected in the consolidated statement
of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      id="Fact000536">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      id="Fact000538">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000540">&lt;p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z1prFuGxIT3c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zkoqXS1iLQ5g"&gt;Impairment
of Long-Lived Assets and Intangibles Other Than Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for the impairment of long-lived assets in accordance with ASC 360&lt;i&gt;, Property, Plant and Equipment&lt;/i&gt; and ASC 350, &lt;i&gt;Intangibles
&#x2013; Goodwill and Other,&lt;/i&gt; which require that long-lived assets and certain identifiable intangibles be reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to its expected future undiscounted net cash flows
generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which
the carrying amounts of the assets exceed the fair value of the assets based on the present value of the expected future cash flows associated
with the use of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000542">&lt;p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbm5AT6BEZh4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zL2TdenAtji6"&gt;Fair
Value Measurements and Disclosure&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
apply ASC 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, which expands disclosures for assets and liabilities that are measured
and reported at fair value on a recurring basis. Fair value is defined as an exit price, representing the amount that would be received
upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or
liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 &#x2013; Quoted market prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access
at the measurement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 &#x2013; Quoted market prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or
liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Fair value determined
using models or other valuation methodologies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 &#x2013; Significant unobservable inputs for assets or liabilities that cannot be corroborated by market data. Fair value is determined
by the reporting entity&#x2019;s own assumptions utilizing the best information available and includes situations where there is little
market activity for the asset or liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
asset&#x2019;s or liability&#x2019;s fair value measurement within the fair value hierarchy is based upon the lowest level of any input
that is significant to the fair value measurement. Our policy is to recognize transfers between levels of the fair value hierarchy in
the period the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 1, 2, or 3 during
the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000544">&lt;p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSwxTtKBlKua" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zDdSubbyF0yf"&gt;Stock-based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
measure compensation expense for stock options and other stock awards in accordance with ASC 718, &lt;i&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt;.
Stock-based compensation is measured at fair value on grant date and recognized as compensation expense over the requisite service period.
Generally, we issue stock options and other stock awards with service-based and/or performance-based vesting conditions. For awards with
only service-based vesting conditions, we record compensation cost for these awards using the straight-line method over the service period.
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For awards that contain performance vesting conditions,
we do not recognize compensation expense until achieving the performance condition is probable. We estimate the fair value of stock option
and warrant grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based
awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment.
We value restricted stock awards (RSAs) and restricted stock units (RSUs) based on the closing share price of our common stock on the
date of grant. Stock-based compensation costs are recorded as general and administrative or research and development costs in the statements
of operations based upon the underlying individual&#x2019;s or entity&#x2019;s role.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimates
of fair value are not intended to predict actual future events or the value ultimately realized by employees or consultants who receive
these awards, and subsequent events are not indicative of the reasonableness of our original estimates of fair value. We account for
forfeitures in the period in which they occur, rather than estimate expected forfeitures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000546">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z4qzW1m203ec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zsAvmqMEF221"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted average common stock outstanding (which excludes unvested RSAs) and
vested, but unissued RSUs. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted
weighted average number of shares of common stock outstanding during the period. Since we have experienced a net loss for all periods
presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the years ended December 31, 2024 and
2023 excludes the impact of potentially dilutive common shares related to outstanding stock options, unvested restricted stock awards
(RSAs), unvested RSUs and common stock purchase warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
diluted net loss per share for the years ended December 31, 2024 and 2023 excluded &lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_iP1custom--AccountingPoliciesLineItemsAbstract_pid_c20240101__20241231_zjF4WhW5Lk6k" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,013,154&lt;/span&gt; and &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_iP1custom--AccountingPoliciesLineItemsAbstract_pid_c20230101__20231231_zlt27ixgXgc1" title="Antidilutive securities excluded from computation of earnings per share"&gt;296,326&lt;/span&gt; of potentially dilutive common
shares, respectively, related to outstanding stock options, unvested RSAs, unvested RSUs and warrants since those shares would have had
an anti-dilutive effect on loss per share during the years then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000548"
      unitRef="Shares">2013154</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000550"
      unitRef="Shares">296326</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000552">&lt;p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_znxOJ7ZTbKK4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_z342kDdpre2c"&gt;Segments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;We have one reportable segment, which is focused on discovering and developing a pipeline of Next Generation Cancer
therapy drugs. Our Chief Executive Officer, who is the chief operating decision maker (CODM), assesses segment performance and decides
how to allocate resources based on net loss that is also reported on the Consolidated Statements of Operations and Comprehensive Loss.
See Note 11 for additional information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000554">&lt;p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zNouNC8tTmg4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_zjEuC6PXltOe"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash and cash equivalents, accounts receivable and accounts payable approximate their fair value because of the short-term
maturity of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000556">&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zW9LuNaeVIn9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_zjxmExykSpx6"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred and consist of direct and overhead-related expenses related primarily to clinical trials,
including development personnel salaries and related costs. Expenditures to acquire technologies, including licenses, which are utilized
in research and development and that have no alternative future use are expensed as the acquisition of in-process research and development
when incurred. Technology we develop for use in our products is expensed as incurred until technological feasibility has been established
after which it is capitalized and depreciated. No research and development costs were capitalized during the years ended December 31,
2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000558">&lt;p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zHxivy8XX6Ub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zqu3ysScCQ1a"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes.&lt;/i&gt; Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. As of December 31, 2024 and 2023, we recorded a valuation allowance equal to the full recorded amount of our
net deferred tax assets since it is more-likely-than-not that benefits from our deferred tax assets will not be realized. The valuation
allowance is reviewed quarterly and is maintained until sufficient positive evidence exists to support its reversal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
recognize the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing
authority, based on the technical merits of the position. Our policy is to record interest and penalties related to income taxes as part
of its income tax provision. As of December 31, 2024, we had &lt;span id="xdx_903_eus-gaap--UnrecognizedTaxBenefits_iIP1custom--AccountingPoliciesLineItemsAbstract_do_c20241231_zkuwbJhRSg02" title="Unrecognized tax benefits"&gt;no&lt;/span&gt; unrecognized tax benefits and as such, no liability, interest or penalties
were required to be recorded. We do not expect this to change significantly in the next twelve months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000560"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <PCSA:RecentAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000562">&lt;p id="xdx_849_ecustom--RecentAccountingPronouncementsPolicyPolicyTextBlock_zHPKtuk6v6Vb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_861_zB4GDa2ri0Oe"&gt;Recently Adopted Accounting Standard&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;In November 2023, the FASB issued ASU 2023-07 &#x2013; Segment Reporting (Topic 280) &#x2013; Improvements to Reportable
Segment Disclosures, which improves segment disclosure requirements, primarily through enhanced disclosure requirements for significant
segment expenses. The improved disclosure requirements apply to all public entities that are required to report segment information, including
those with only one reportable segment. We adopted this standard effective for the year ending December 31, 2024 and the primary impact
of which was the additional segment disclosures included in Note 11.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</PCSA:RecentAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000564">&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z51Qe2P6ysXl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_ztahQYnCPzBa"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#x201c;ASU&#x201d;).
We have implemented all new accounting pronouncements that are in effect and that may impact our financial statements. We have &lt;span style="background-color: white"&gt;considered
all recent accounting pronouncements issued since the last audit of our consolidated financial statements. We believe that these recent
pronouncements will not have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="background-color: white"&gt;In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide
enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and
for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption
is permitted. We are evaluating this standard to determine if adoption will have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense
Disaggregation Disclosures (Subtopic 220-40), which requires disclosure, in the notes to the financial statements, of specified information
about certain costs and expenses. This ASU is effective for public entities for annual reporting periods beginning after December 15,
2026 and interim reporting periods beginning after December 15, 2027. We are currently evaluating the impact ASU 2024-03 will have on
our consolidated financial statements.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000566">&lt;p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zpLYO7qj0VH" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
3 - &lt;span id="xdx_82A_ztEoIkXfszYb"&gt;Stock-based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;T&lt;span style="background-color: white"&gt;he
Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) allows us to make grants of stock options,
restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors.
The 2019 Plan originally provided for the aggregate issuance of &lt;span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220710__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember__us-gaap--AwardTypeAxis__custom--OriginalMember_zwuerPj2XEW5" title="Maximum equity available for issuance under the plan"&gt;150,000&lt;/span&gt; shares of our common stock. &lt;/span&gt;On June 28, 2024, our shareholders
approved an increase of shares available under the 2019 Plan, which now provides for the aggregate issuance of &lt;span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240628__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zNbHqIt1mtCe" title="Maximum equity available for issuance under the plan"&gt;800,000&lt;/span&gt; shares of our
common stock. At December 31, 2024, we have &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zkkZDKpzyOg3" title="Shares available for future grants"&gt;353,641&lt;/span&gt; shares available for future grants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Compensation Expense&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zlEUr9SVxlF" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
recorded stock-based compensation expense for the years ended December 31, 2024 and 2023 as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B0_zOokHVYXHBB1" style="display: none"&gt;Schedule of Stock-based Compensation Expense&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231_zVJKGeD5iRTc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zScrTcXsxnQj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended &lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXsVE2UNk0g1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;169,414&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;363,956&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z42I0Er24F7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;460,100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,007,258&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_zZPgq9e56vU3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;629,514&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,371,214&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zGvd0ZePmG9a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;No
tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for all net deferred
tax assets relating to this expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrAcclmb4UH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table summarizes our stock option activity during the years ended December 31, 2023 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_ziFTZbmuS8H9" style="display: none"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average remaining contractual life&lt;br/&gt;
    (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zrGZbbB4faIi" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,943&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zHUwAVbHUVUf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;341.34&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_z9DN332ZIQxb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0591"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited
    or expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231_zAtzSQrUPqk6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,951&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zrbtHTTNqPji" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;257.28&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTzQJ6MkYlG7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,992&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zhFKS0JEgZLf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;364.72&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zbh8yDbnm0oi" title="Weighted average remaining contractual term, ending"&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_zPTWYcH5toE3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0603"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited
    or expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231_zrTTPNrvRx55" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, forfeited or expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,245&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zAqysptNg5W2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price,  forfeited or expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;336.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and exercisable as of December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zdrJ9top9x8i" title="Options outstanding, ending balance"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zTTIIMLMS9I6" title="Options exercisable, ending balance"&gt;2,747&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z2FPO341OJ92" title="Weighted average exercise price, ending balance"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zF0kKGejBLoh" title="Weighted average exercise price, exercisable"&gt;409.09&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zLQxr5HEKPZb" title="Weighted average remaining contractual term, outstanding"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zCMdEWqF3l1d" title="Weighted average remaining contractual term, exercisable"&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z7T4Ai5nuFcl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
forfeiture rate was applied to these stock options. The aggregate intrinsic value of outstanding options, all of which are exercisable,
was $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDFKWPh4OO0k" title="Aggregate intrinsic value of outstanding options"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRzwHyeFJT63" title="Aggregate intrinsic value of outstanding options"&gt;0&lt;/span&gt;&lt;/span&gt; at both December 31, 2023 and 2024. &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z028FAoYJ3b8" title="Stock option exercised"&gt;&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhsWAfBbA6ub" title="Stock option exercised"&gt;No&lt;/span&gt;&lt;/span&gt; stock options were exercised during the years ended December 31, 2023 or 2024 and there
is no unamortized expense at December 31, 2024 since the options are fully vested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Awards&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zTUUuDHmtpX6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table summarizes our restricted stock award (RSA) activity during the years ended December 31, 2023 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_z1gVx5R7HU79" style="display: none"&gt;Schedule
of Restricted Stock Awards (&#x201c;RSAs&#x201d;) Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-
    &lt;br/&gt; average &lt;br/&gt; grant-date fair &lt;br/&gt; value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zHpjhP2ZJb" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of restricted stock, shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,095&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zvDtXH6wKy01" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;94.44&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zBUNAWaUSTS2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,750&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zDiKjrXzSbK6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.59&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zG6Gh8y9hnE4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zcvkQywoHq93" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;133.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zYiyJ9hVSuic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,555&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zn1xW8o7KVYi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22.13&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zj6DtCTV8uv6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,790&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zfzhoPcljnXc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24.44&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zjcDEBXwowyi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zilrWwqCxmWd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.26&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zideJL0eB3J5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zgIOp8FB0jg8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0657"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z5n5dSliOvqj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zR5gOnMVpmud" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0661"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zWpr9dJBfmAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0663"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z2C3Qvxl48o" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0665"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z6eoJ079nVs4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zPK10SK2ydB3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.26&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z9tt9Iq8ImZd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zUXL4psXllCc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0673"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zOqgk4IXrrPe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zy3iLyAGdEYe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table summarizes our restricted stock unit (RSU) activity during the years ended December 31, 2023 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zaOCKzHQqr42" style="display: none"&gt;Schedule of Restricted Stock Units (&#x201c;RSUs&#x201d;) Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-
    &lt;br/&gt; average &lt;br/&gt; grant-date fair &lt;br/&gt; value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUh97PPNY936" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of shares, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135,741&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4hMt2jDQga" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73.81&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8lbwStdwJo8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;116,078&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOodBTN4AX85" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOHHyEcHKati" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(12,296&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaCdhNLohGXa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.69&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFzyblqRBRmi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(16,801&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyeq0B0XBxQj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;71.36&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTxaoyJSVlec" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(17,093&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbUE9VovGPXc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;110.59&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLGvR1SLePC5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;222,722&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0KgHqINrAj7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45.82&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1x1hbnWfSC6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192,026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwSYF57PFWD1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdl41hLqzvnf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14,019&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZoGrtkvNO1k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;71.68&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTA62TKWj5ah" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(17,093&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zf2oPqvFDvKc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;110.59&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbNZUhfAXpS6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;383,636&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBIYi8aRsFZ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19.87&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and unissued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdSXGwQWf9Nl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and unissued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(149,013&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaTLvyHdpMG1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43.10&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB626M0FokK2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;234,623&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJVlZu6FfKQi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_8A7_zfnE5a5W7f9j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, we granted the following RSUs:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            June 28, 2024, we granted RSUs for the future issuance of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z2Ic12qVaul5" title="Number of shares, granted"&gt;39,202&lt;/span&gt; shares of common stock to
                                            our employees which vest accordingly: RSUs for the future issuance of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockUnitsMember__us-gaap--VestingAxis__custom--JanuaryOneTwoThousandTwentyFiveVestingMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zTYANXC7WJL" title="Number of shares, granted"&gt;14,969&lt;/span&gt; shares of common
                                            stock vest on January 1, 2025; RSUs for the future issuance of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240628__20240628__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockUnitsMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--VestingAxis__custom--ThreeYearVestingMember_z1KMfj5WnySk" title="Number of shares, granted"&gt;18,173&lt;/span&gt; shares of common stock
                                            vest over a three-year period upon meeting service requirements; RSUs for the future issuance
                                            of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240628__20240628__us-gaap--AwardTypeAxis__custom--FirstPerformanceBasedRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z73xb1N8OkWe" title="Number of shares, granted"&gt;3,030&lt;/span&gt; shares of common stock vested upon grant due to regaining Nasdaq compliance; and
                                            RSUs for the future issuance of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__custom--SecondPerformanceBasedRSUMember__us-gaap--TypeOfArrangementAxis__custom--NextGenerationCapecitabineCAPMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z4hvvWFRSRL9" title="Number of shares, granted"&gt;3,030&lt;/span&gt; shares of common stock vested on October 2, 2024 when
                                            we dosed the first patient in our Phase 2 study in NGC-Cap.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            July 16, 2024, Russell Skibsted was appointed as our Chief Financial Officer (&#x201c;CFO&#x201d;).
                                            In addition to cash compensation, the Compensation Committee awarded RSUs for the future
                                            issuance of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zeGrUrOHlOsd" title="Number of shares, granted"&gt;28,000&lt;/span&gt; shares of common stock to Mr. Skibsted, which vest accordingly: &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__custom--JulySixteenTwoThousandTwentyFiveVestingMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zRafHYryhzC1" title="Number of shares, granted"&gt;14,000&lt;/span&gt;
                                            vest on July 16, 2025; &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--VestingAxis__custom--FirstPerformanceBasedRSUMember_zKN49MW9ovg4" title="Number of shares, granted"&gt;7,000&lt;/span&gt; vest upon reaching a market capitalization (i.e. total value
                                            of Processa&#x2019;s outstanding shares of stock at the then current market price) of at least
                                            $&lt;span id="xdx_902_ecustom--MarketCapitalization_iI_pn6n6_c20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--VestingAxis__custom--FirstPerformanceBasedRSUMember_zk0qaH9a03r6" title="Market capitalization"&gt;30&lt;/span&gt; million; and &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--VestingAxis__custom--SecondPerformanceBasedRSUMember_z7JGgu9UBLV8" title="Number of shares, granted"&gt;7,000&lt;/span&gt; vest upon receipt of cumulative financing(s) of at least $&lt;span id="xdx_902_ecustom--PerformanceVestingCriteriaValue_iI_pn6n6_c20240716__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--VestingAxis__custom--SecondPerformanceBasedRSUMember_zM9F8ODzd8f1" title="Performance vesting criteria"&gt;15&lt;/span&gt; million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            September 3, 2024, RSUs for the future issuance of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240903__20240903__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zuhaLftduwVh" title="Number of shares, granted"&gt;124,824&lt;/span&gt; shares of common stock were granted
                                            to our independent directors and vest on the earlier of June 28, 2025 or the next annual
                                            shareholder meeting.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
                                            December 31, 2024, unrecognized stock-based compensation expense for RSUs of approximately
                                            $&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLWIN50N7gRf" title="Unrecognized stock-based compensation expense"&gt;613,000&lt;/span&gt; is expected to be fully recognized over a weighted average period of &lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVogPNmBEA99" title="Weighted average period for recognition"&gt;0.7&lt;/span&gt; years.
                                            The unrecognized expense excludes $&lt;span style="background-color: white"&gt;&lt;span id="xdx_90B_ecustom--UnrecognizedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zombOCEZmphe" title="Unrecognized share based compensation expense"&gt;432,060&lt;/span&gt; &lt;/span&gt;related
                                            to certain RSUs with a performance milestone that is not currently probable of occurring.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Holders
of our vested RSUs will be issued shares of our common stock upon the satisfaction of the distribution restrictions contained in their
Restricted Stock Unit Award Agreement. The distribution restrictions are typically different (longer) than the vesting schedule, imposing
an additional restriction on the holder. Unlike RSAs, while employees may hold fully vested RSUs, the individual does not hold any shares
or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts
into one share of our common stock. The RSUs contain dividend equivalent rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfWarrantValuationAssumptionTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2Jl7pxRbsei" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table summarizes our warrant activity during the years ended December 31, 2023 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zRzQRMec8UTj" style="display: none"&gt;Schedule of Warrants Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average remaining contractual&lt;br/&gt;
    life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGqRSYw9p3yb" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrants outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,283&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGJURedJKvch" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;205.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCsQTmCVI6l7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;173,007&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeIqhRO1dMv2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19.27&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9NrC0pskkui" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, expired or cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6,783&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zC2GvJUrZnQd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;266.96&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt"&gt;Not exercisable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zurrmhM9Fjgc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Not exercisable"&gt;(7,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNHnrmsmBqAf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, not exercisable"&gt;7.40&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercisable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zB77ppbgMXah" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, exercisable"&gt;7,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zb45yKNXNDXf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"&gt;7.40&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and exercisable as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpjNwCfzuASi" title="Warrants outstanding, beginning balance"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5tzx0izZMgl" title="Warrants, exercisable"&gt;173,007&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDVSyUcHtNr7" title="Weighted average exercise price, beginning balance"&gt;25.41&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zF7XqKZb5Bze" title="Weighted average remaining contractual term, ending"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zX4BhSkIDDK4" title="Weighted average remaining contractual term, exercisable"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercisable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6gNJTXjpyLh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, exercisable"&gt;7,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPQuxIhoW21f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"&gt;7.40&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zHIALzkmJBX9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,617,777&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWA7T7CXdLr1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.54&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired
    or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4ai87IdmVWh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, expired or cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(22,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYaY4v1ZICFj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, expired or cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54.62&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and exercisable as of December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRvIcHK539f" title="Warrants outstanding, ending balance"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4jhRbRLuT55" title="Warrants, exercisable"&gt;1,775,784&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7rJNa6M9UAf" title="Weighted average exercise price, ending balance"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDndxQAR2JKj" title="Weighted average exercise price, exercisable"&gt;5.95&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGVC8ehhNS78" title="Weighted average remaining contractual term, outstanding"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zuS1NksCppE1" title="Weighted average remaining contractual term, exercisable"&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z2stNADCw70h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, we did not grant any warrants to purchase shares of our common stock other than warrants to purchase
&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__custom--OfferingMember_zfevzV3v7PQa" title="Warrants to purchase common stock"&gt;1,617,777&lt;/span&gt; shares of common stock as part of the Offering (see Note 4). Warrants to purchase &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zrYpgHEgE61e" title="Warrants, expired unexercised"&gt;7,500&lt;/span&gt; shares of our common stock expired
unexercised. We also repurchased a warrant issued to a consultant in 2023 for the purchase of &lt;span id="xdx_902_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFPK6NQa2ug3" title="Warrants repurchased, shares"&gt;15,000&lt;/span&gt; shares of our common stock in exchange
for a payment of $&lt;span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodValue_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoNhqFqqryel" title="Payment for warrants repurchased"&gt;10,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2023, we amended our financial consulting agreement with Spartan Capital Securities, LLC (&#x201c;Spartan&#x201d;), our placement agent for our registered direct offering in February
2023, by extending the term until February 10, 2024. We compensated
Spartan for financial consulting services provided under the amendment by granting warrants to purchase &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230417__20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zUvZNAFHp7R8" title="Warrants, granted"&gt;158,007&lt;/span&gt; shares of our common
stock on April 17, 2023, with an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zID4DcWFAuwf" title="Warrants exercise price"&gt;20.40&lt;/span&gt;. The warrants expire on &lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zCnI83kq7I0c" title="Warrants maturity date"&gt;April 17, 2026&lt;/span&gt;, and contain both call and cashless
exercise provision. We also granted warrants to purchase &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20231118__20231118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zjQP6caa7y75" title="Warrants, granted"&gt;15,000&lt;/span&gt; shares of our common stock to a consultant on November 18, 2023, of which
warrants to purchase &lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_c20231118__20231118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zPD1xtoKC8uj" title="Warrants, exercisable"&gt;7,500&lt;/span&gt; shares of our common stock were exercisable, with an exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zEamF6yt1VJa" title="Warrant exercise price"&gt;7.40&lt;/span&gt;. These warrants expire on &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_dd_c20231118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zL3jW7ixPSVb" title="Warrant expiration date"&gt;November
18, 2025&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z187qcKGfGgk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
used the Black-Scholes option pricing model to calculate the grant date fair value of the two warrants granted in 2023 with the following
assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zpzqMzlWJHif" style="display: none"&gt;Schedule
of Warrant Valuation Assumption&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 0.5in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average risk-free rate of interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zFFa3YACrxN8" title="Warrants, measurement input"&gt;4.32&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zAKeD9yxN461" title="Warrants, measurement input"&gt;4.88&lt;/span&gt;
                                            &lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_z3cdHYYbNIi7" title="Expected term (years)"&gt;2.00&lt;/span&gt;&#x2013;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zCgxZ3Mye4Wf" title="Expected term (years)"&gt;3.00&lt;/span&gt;
                                            &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zvN0Na7wW7ph" title="Warrants, measurement input"&gt;82.85&lt;/span&gt;-&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zpitNuAAUAad" title="Warrants, measurement input"&gt;108.47&lt;/span&gt;
                                            &lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zk12iZhMWC1a" title="Warrants, measurement input"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zssuzqLdxQI2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-07-10_custom_TwoThousandAndNineteenPlanMember_custom_OriginalMember"
      decimals="INF"
      id="Fact000568"
      unitRef="Shares">150000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-06-28_custom_TwoThousandAndNineteenPlanMember"
      decimals="INF"
      id="Fact000570"
      unitRef="Shares">800000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_custom_TwoThousandAndNineteenPlanMember"
      decimals="INF"
      id="Fact000572"
      unitRef="Shares">353641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000574">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zlEUr9SVxlF" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
recorded stock-based compensation expense for the years ended December 31, 2024 and 2023 as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B0_zOokHVYXHBB1" style="display: none"&gt;Schedule of Stock-based Compensation Expense&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231_zVJKGeD5iRTc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zScrTcXsxnQj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended &lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXsVE2UNk0g1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;169,414&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;363,956&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z42I0Er24F7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;460,100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,007,258&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_zZPgq9e56vU3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;629,514&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,371,214&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000576"
      unitRef="USD">169414</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000577"
      unitRef="USD">363956</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000579"
      unitRef="USD">460100</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000580"
      unitRef="USD">2007258</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000582"
      unitRef="USD">629514</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000583"
      unitRef="USD">2371214</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact000585">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrAcclmb4UH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table summarizes our stock option activity during the years ended December 31, 2023 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_ziFTZbmuS8H9" style="display: none"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average remaining contractual life&lt;br/&gt;
    (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zrGZbbB4faIi" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,943&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zHUwAVbHUVUf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;341.34&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_z9DN332ZIQxb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0591"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited
    or expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231_zAtzSQrUPqk6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,951&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zrbtHTTNqPji" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;257.28&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTzQJ6MkYlG7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,992&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zhFKS0JEgZLf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;364.72&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zbh8yDbnm0oi" title="Weighted average remaining contractual term, ending"&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_zPTWYcH5toE3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0603"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited
    or expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231_zrTTPNrvRx55" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, forfeited or expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,245&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zAqysptNg5W2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price,  forfeited or expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;336.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and exercisable as of December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zdrJ9top9x8i" title="Options outstanding, ending balance"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zTTIIMLMS9I6" title="Options exercisable, ending balance"&gt;2,747&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z2FPO341OJ92" title="Weighted average exercise price, ending balance"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zF0kKGejBLoh" title="Weighted average exercise price, exercisable"&gt;409.09&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zLQxr5HEKPZb" title="Weighted average remaining contractual term, outstanding"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zCMdEWqF3l1d" title="Weighted average remaining contractual term, exercisable"&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000587"
      unitRef="Shares">8943</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000589"
      unitRef="USDPShares">341.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000593"
      unitRef="Shares">1951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000595"
      unitRef="USDPShares">257.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000597"
      unitRef="Shares">6992</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000599"
      unitRef="USDPShares">364.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31" id="Fact000601">P2Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000605"
      unitRef="Shares">4245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000607"
      unitRef="USDPShares">336.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000609"
      unitRef="Shares">2747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000611"
      unitRef="Shares">2747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000613"
      unitRef="USDPShares">409.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000615"
      unitRef="USDPShares">409.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-01to2024-12-31" id="Fact000617">P3Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact000619">P3Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000621"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000623"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000625"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000627"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember"
      id="Fact000629">&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zTUUuDHmtpX6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table summarizes our restricted stock award (RSA) activity during the years ended December 31, 2023 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_z1gVx5R7HU79" style="display: none"&gt;Schedule
of Restricted Stock Awards (&#x201c;RSAs&#x201d;) Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-
    &lt;br/&gt; average &lt;br/&gt; grant-date fair &lt;br/&gt; value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zHpjhP2ZJb" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of restricted stock, shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,095&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zvDtXH6wKy01" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;94.44&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zBUNAWaUSTS2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,750&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zDiKjrXzSbK6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.59&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zG6Gh8y9hnE4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zcvkQywoHq93" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;133.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zYiyJ9hVSuic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,555&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zn1xW8o7KVYi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22.13&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zj6DtCTV8uv6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,790&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zfzhoPcljnXc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24.44&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zjcDEBXwowyi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zilrWwqCxmWd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.26&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zideJL0eB3J5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zgIOp8FB0jg8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0657"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z5n5dSliOvqj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zR5gOnMVpmud" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0661"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zWpr9dJBfmAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0663"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z2C3Qvxl48o" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0665"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z6eoJ079nVs4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zPK10SK2ydB3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.26&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_z9tt9Iq8ImZd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardMember_zUXL4psXllCc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0673"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000631"
      unitRef="Shares">3095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000633"
      unitRef="USDPShares">94.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">10750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000637"
      unitRef="USDPShares">14.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000639"
      unitRef="Shares">1250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000641"
      unitRef="USDPShares">133.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000643"
      unitRef="Shares">2555</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000645"
      unitRef="USDPShares">22.13</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000647"
      unitRef="Shares">8790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000649"
      unitRef="USDPShares">24.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000651"
      unitRef="Shares">1250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000653"
      unitRef="USDPShares">9.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000667"
      unitRef="Shares">1250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardMember"
      decimals="INF"
      id="Fact000669"
      unitRef="USDPShares">9.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact000675">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zy3iLyAGdEYe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table summarizes our restricted stock unit (RSU) activity during the years ended December 31, 2023 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zaOCKzHQqr42" style="display: none"&gt;Schedule of Restricted Stock Units (&#x201c;RSUs&#x201d;) Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-
    &lt;br/&gt; average &lt;br/&gt; grant-date fair &lt;br/&gt; value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUh97PPNY936" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of shares, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135,741&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4hMt2jDQga" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73.81&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8lbwStdwJo8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;116,078&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOodBTN4AX85" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOHHyEcHKati" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(12,296&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaCdhNLohGXa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.69&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFzyblqRBRmi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(16,801&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyeq0B0XBxQj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;71.36&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTxaoyJSVlec" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(17,093&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbUE9VovGPXc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;110.59&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLGvR1SLePC5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;222,722&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0KgHqINrAj7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45.82&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1x1hbnWfSC6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192,026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwSYF57PFWD1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdl41hLqzvnf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14,019&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZoGrtkvNO1k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;71.68&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTA62TKWj5ah" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(17,093&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zf2oPqvFDvKc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;110.59&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbNZUhfAXpS6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;383,636&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBIYi8aRsFZ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19.87&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and unissued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdSXGwQWf9Nl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and unissued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(149,013&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaTLvyHdpMG1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43.10&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB626M0FokK2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;234,623&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJVlZu6FfKQi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000677"
      unitRef="Shares">135741</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000679"
      unitRef="USDPShares">73.81</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000681"
      unitRef="Shares">116078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000683"
      unitRef="USDPShares">14.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000685"
      unitRef="Shares">12296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000687"
      unitRef="USDPShares">21.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000689"
      unitRef="Shares">16801</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000691"
      unitRef="USDPShares">71.36</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000693"
      unitRef="Shares">17093</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000695"
      unitRef="USDPShares">110.59</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000697"
      unitRef="Shares">222722</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000699"
      unitRef="USDPShares">45.82</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000701"
      unitRef="Shares">192026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000703"
      unitRef="USDPShares">1.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000705"
      unitRef="Shares">14019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000707"
      unitRef="USDPShares">71.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000709"
      unitRef="Shares">17093</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000711"
      unitRef="USDPShares">110.59</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000713"
      unitRef="Shares">383636</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000715"
      unitRef="USDPShares">19.87</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000717"
      unitRef="Shares">149013</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000719"
      unitRef="USDPShares">43.10</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000721"
      unitRef="Shares">234623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000723"
      unitRef="USDPShares">5.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-06-282024-06-28_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact000725"
      unitRef="Shares">39202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_JanuaryOneTwoThousandTwentyFiveVestingMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact000727"
      unitRef="Shares">14969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_EmployeesMember_custom_ThreeYearVestingMember"
      decimals="INF"
      id="Fact000729"
      unitRef="Shares">18173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-06-282024-06-28_custom_FirstPerformanceBasedRSUMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact000731"
      unitRef="Shares">3030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-06-282024-06-28_custom_SecondPerformanceBasedRSUMember_custom_NextGenerationCapecitabineCAPMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact000733"
      unitRef="Shares">3030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      id="Fact000735"
      unitRef="Shares">28000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySixteenTwoThousandTwentyFiveVestingMember_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      id="Fact000737"
      unitRef="Shares">14000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_FirstPerformanceBasedRSUMember"
      decimals="INF"
      id="Fact000739"
      unitRef="Shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <PCSA:MarketCapitalization
      contextRef="AsOf2024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_FirstPerformanceBasedRSUMember"
      decimals="-6"
      id="Fact000741"
      unitRef="USD">30000000</PCSA:MarketCapitalization>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-07-162024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_SecondPerformanceBasedRSUMember"
      decimals="INF"
      id="Fact000743"
      unitRef="Shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <PCSA:PerformanceVestingCriteriaValue
      contextRef="AsOf2024-07-16_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember_custom_SecondPerformanceBasedRSUMember"
      decimals="-6"
      id="Fact000745"
      unitRef="USD">15000000</PCSA:PerformanceVestingCriteriaValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-09-032024-09-03_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember"
      decimals="INF"
      id="Fact000747"
      unitRef="Shares">124824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000749"
      unitRef="USD">613000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact000751">P0Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <PCSA:UnrecognizedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000753"
      unitRef="USD">432060</PCSA:UnrecognizedShareBasedCompensationExpense>
    <PCSA:ScheduleOfWarrantValuationAssumptionTableTextBlock
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      id="Fact000755">&lt;p id="xdx_897_ecustom--ScheduleOfWarrantValuationAssumptionTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2Jl7pxRbsei" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table summarizes our warrant activity during the years ended December 31, 2023 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zRzQRMec8UTj" style="display: none"&gt;Schedule of Warrants Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average remaining contractual&lt;br/&gt;
    life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGqRSYw9p3yb" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Warrants outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,283&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGJURedJKvch" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;205.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCsQTmCVI6l7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;173,007&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeIqhRO1dMv2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19.27&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9NrC0pskkui" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, expired or cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6,783&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zC2GvJUrZnQd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;266.96&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt"&gt;Not exercisable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zurrmhM9Fjgc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Not exercisable"&gt;(7,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNHnrmsmBqAf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, not exercisable"&gt;7.40&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercisable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zB77ppbgMXah" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, exercisable"&gt;7,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zb45yKNXNDXf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"&gt;7.40&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and exercisable as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpjNwCfzuASi" title="Warrants outstanding, beginning balance"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5tzx0izZMgl" title="Warrants, exercisable"&gt;173,007&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDVSyUcHtNr7" title="Weighted average exercise price, beginning balance"&gt;25.41&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zF7XqKZb5Bze" title="Weighted average remaining contractual term, ending"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zX4BhSkIDDK4" title="Weighted average remaining contractual term, exercisable"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercisable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6gNJTXjpyLh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, exercisable"&gt;7,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPQuxIhoW21f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"&gt;7.40&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zHIALzkmJBX9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,617,777&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWA7T7CXdLr1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.54&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired
    or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4ai87IdmVWh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, expired or cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(22,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYaY4v1ZICFj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, expired or cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54.62&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and exercisable as of December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRvIcHK539f" title="Warrants outstanding, ending balance"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4jhRbRLuT55" title="Warrants, exercisable"&gt;1,775,784&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7rJNa6M9UAf" title="Weighted average exercise price, ending balance"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDndxQAR2JKj" title="Weighted average exercise price, exercisable"&gt;5.95&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGVC8ehhNS78" title="Weighted average remaining contractual term, outstanding"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zuS1NksCppE1" title="Weighted average remaining contractual term, exercisable"&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</PCSA:ScheduleOfWarrantValuationAssumptionTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000757"
      unitRef="Shares">14283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000759"
      unitRef="USDPShares">205.01</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000761"
      unitRef="Shares">173007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000763"
      unitRef="USDPShares">19.27</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000765"
      unitRef="Shares">6783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000767"
      unitRef="USDPShares">266.96</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000769"
      unitRef="Shares">7500</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotExercisable>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000771"
      unitRef="USDPShares">7.40</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceNotExercisable>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000773"
      unitRef="Shares">-7500</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000775"
      unitRef="USDPShares">7.40</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000777"
      unitRef="Shares">173007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000779"
      unitRef="Shares">173007</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000781"
      unitRef="USDPShares">25.41</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact000783">P2Y2M12D</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact000785">P2Y2M12D</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000787"
      unitRef="Shares">-7500</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000789"
      unitRef="USDPShares">7.40</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000791"
      unitRef="Shares">1617777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000793"
      unitRef="USDPShares">4.54</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000795"
      unitRef="Shares">22500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000797"
      unitRef="USDPShares">54.62</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000799"
      unitRef="Shares">1775784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000801"
      unitRef="Shares">1775784</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000803"
      unitRef="USDPShares">5.95</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000805"
      unitRef="USDPShares">5.95</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      id="Fact000807">P3Y9M18D</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      id="Fact000809">P3Y9M18D</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_custom_OfferingMember"
      decimals="INF"
      id="Fact000811"
      unitRef="Shares">1617777</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-01-012024-12-31_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact000813"
      unitRef="Shares">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-01-012024-12-31_custom_ConsultantMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000815"
      unitRef="Shares">15000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-01-012024-12-31_custom_ConsultantMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000817"
      unitRef="USD">10000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-04-172023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember"
      decimals="INF"
      id="Fact000819"
      unitRef="Shares">158007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember"
      decimals="INF"
      id="Fact000821"
      unitRef="USDPShares">20.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember"
      id="Fact000823">2026-04-17</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-11-182023-11-18_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact000825"
      unitRef="Shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="From2023-11-182023-11-18_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact000827"
      unitRef="Shares">7500</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-11-18_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact000829"
      unitRef="USDPShares">7.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-11-18_custom_ConsultingAgreementMember"
      id="Fact000831">2025-11-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember417832562"
      id="Fact000833">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z187qcKGfGgk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
used the Black-Scholes option pricing model to calculate the grant date fair value of the two warrants granted in 2023 with the following
assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zpzqMzlWJHif" style="display: none"&gt;Schedule
of Warrant Valuation Assumption&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 0.5in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average risk-free rate of interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zFFa3YACrxN8" title="Warrants, measurement input"&gt;4.32&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zAKeD9yxN461" title="Warrants, measurement input"&gt;4.88&lt;/span&gt;
                                            &lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_z3cdHYYbNIi7" title="Expected term (years)"&gt;2.00&lt;/span&gt;&#x2013;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zCgxZ3Mye4Wf" title="Expected term (years)"&gt;3.00&lt;/span&gt;
                                            &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zvN0Na7wW7ph" title="Warrants, measurement input"&gt;82.85&lt;/span&gt;-&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zpitNuAAUAad" title="Warrants, measurement input"&gt;108.47&lt;/span&gt;
                                            &lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zk12iZhMWC1a" title="Warrants, measurement input"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000835"
      unitRef="Pure">0.0432</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000837"
      unitRef="Pure">0.0488</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember"
      id="Fact000839">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember"
      id="Fact000841">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000843"
      unitRef="Pure">0.8285</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000845"
      unitRef="Pure">1.0847</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact000847"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000849">&lt;p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zUrcz5lh6kPk" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_828_znkqnzsR8Wmk"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Financings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, we issued &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJd7pqRHNTW5" title="Stock issued"&gt;2,356,549&lt;/span&gt; shares of our common stock through several fundraising efforts described below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Public
    Offering &#x2013; &lt;/i&gt;On January 30, 2024, we closed a public offering (the &#x201c;Offering&#x201d;) for the sale of &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlVtb3XifXQh" title="Number of shares, sold"&gt;476,000&lt;/span&gt; shares
    of common stock, P&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;re-Funded Warrants to purchase
    up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z031sVAES4j6" title="Warrants to purchase"&gt;1,079,555&lt;/span&gt; shares of common stock in lieu of shares of common stock, and Common Warrants to purchase up to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zbXyJ3AXuhwb" title="Warrants to purchase"&gt;1,555,555&lt;/span&gt; shares
    of our common stock. The Common Warrants have an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjafoz1qP2e9" title="Warrant exercise price"&gt;4.50&lt;/span&gt;, are immediately exercisable and expire on &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrO0qwpZmoU6" title="Warrants, maturity date"&gt;January 30, 2029&lt;/span&gt;.
    The shares of common stock were offered at a combined public offering price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zqKo0Wyz9Rv" title="Warrant exercise price"&gt;4.50&lt;/span&gt; per share and accompanying Common Warrant and
    $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240130__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zzCU2Zym2Bgd" title="Warrants, price per share"&gt;4.4999&lt;/span&gt; per Pre-Funded Warrant and accompanying Common Warrant. The Pre-Funded Warrants had an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240130__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zvlrk92jKLwk" title="Warrant exercise price"&gt;0.0001&lt;/span&gt; and were
    exercised in full simultaneously with the closing of the Offering in exchange for &lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesExercised_iI_c20240130__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlsdrklOLHMl" title="Warrants, exercised"&gt;1,079,555&lt;/span&gt; shares of our common stock. Gross proceeds
    in connection with the Offering were $&lt;span id="xdx_901_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zvVjzGumwdJh" title="Gross proceeds"&gt;7.0&lt;/span&gt; million. We received $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zl8TrhpbuAR9" title="Net proceeds"&gt;6.3&lt;/span&gt; million in net proceeds from the Offering, after deducting the
    fees of the placement agent and other offering-related expenses. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;ATM
    Offering&lt;/i&gt; &#x2013; We sold &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zkBogvc6ePCk"&gt;800,994&lt;/span&gt; shares at an average price of $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zPkN04OMsy9l"&gt;1.93&lt;/span&gt; per share for aggregate net proceeds of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z3346w7zcbt4" title="Net proceeds"&gt;1.5&lt;/span&gt; million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
also issued to the placement agent warrants to purchase &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zUr0bCKip20h"&gt;62,222&lt;/span&gt; shares of common stock, exercisable at $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zk14eQ3OsRY2"&gt;5.625&lt;/span&gt; per share that expire on
&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zqqnB4wqbuze" title="Warrant expiration date"&gt;February 1, 2027&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, we issued &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2mIJnw4q8ac" title="Stock issued"&gt;421,611&lt;/span&gt; shares of our common stock through several fundraising efforts described below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;ATM
    Offering&lt;/i&gt; &#x2013; On February 5, 2023, in connection with our Registered Direct Offering discussed below, we terminated our ATM
    and suspended the Sales Agreement with Oppenheimer &amp;amp; Co. Inc., but we may reinstate it in the future. During the year ended December
    31, 2023, we sold &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zuwk64KHNYMl"&gt;28,483&lt;/span&gt; shares at an average price of $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zkOJarHcptNi"&gt;24.40&lt;/span&gt; per share for aggregate gross proceeds of $&lt;span id="xdx_905_ecustom--GrossProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zyZXoLwWd1e5"&gt;693,000&lt;/span&gt; (net proceeds of
    $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z2lC1V4B6tkb"&gt;672,000&lt;/span&gt;) prior to deducting sales commissions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Lincoln
    Park Capital Fund, LLC Purchase Agreement&lt;/i&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;
    &lt;span style="background-color: white"&gt;During the year ended December 31, 2023, we sold &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zEq7FyfcsIu7"&gt;2,500&lt;/span&gt; shares at an average price of $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zLLNVV8bf3l2"&gt;21.60&lt;/span&gt;
    per share for aggregate gross proceeds of $&lt;span id="xdx_905_ecustom--GrossProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zBNg3idhBHae" title="Gross proceeds from issuance of common stock"&gt;54,000&lt;/span&gt; under the purchase agreement with Lincoln Park.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Registered
    Direct Offering &#x2013; &lt;/i&gt;On February 14, 2023, we closed a registered direct offering (the &#x201c;Offering&#x201d;) for the sale
    of &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230214__20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_z3CjSM9w2bwf"&gt;390,628&lt;/span&gt; shares of common stock at a purchase price of $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zFwNYLv0iO3a" title="Share price"&gt;16.00&lt;/span&gt; per share for gross proceeds of $&lt;span id="xdx_900_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20230214__20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zL886pzNPTA5"&gt;6.3&lt;/span&gt; million (net proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230214__20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zqjtW0CVP5vj"&gt;5.6&lt;/span&gt;
    million).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
paid &lt;span style="background-color: white"&gt;Spartan&lt;/span&gt; a cash fee of &lt;span id="xdx_908_ecustom--TransactionCostsPercentage_iI_pid_dp_uPure_c20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zxnR4dQUflil" title="Cash fee percentage"&gt;8.0&lt;/span&gt;%
of the gross proceeds from the Offering, excluding proceeds received from our insiders, and reimbursed Spartan for legal fees of
$&lt;span id="xdx_908_ecustom--ReimbursementFees_c20230214__20230214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_z9LargEDUAmj" title="Reimbursement fees"&gt;60,000&lt;/span&gt;.
The engagement agreement with Spartan required us to indemnify Spartan and certain of its affiliates against certain customary
liabilities. On February 14, 2023, we amended the consulting agreement with Spartan originally entered into on August 24, 2022,
extending the term of the consulting agreement until February 10, 2024. As compensation for services under the agreement, on April
17, 2023, we granted Spartan warrants to purchase &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zpR7kli7VJG2" title="Warrants, granted"&gt;158,007&lt;/span&gt;
shares of our common stock with an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zij7yQ6U1vAd" title="Warrant exercise price"&gt;20.40&lt;/span&gt;.
The warrants will expire &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zjGnp0U8w2Ah" title="Warrant expiration date"&gt;April
17, 2026&lt;/span&gt; and contain both call and cashless exercise provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000851"
      unitRef="Shares">2356549</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-292024-01-30_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000853"
      unitRef="Shares">476000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000855"
      unitRef="Shares">1079555</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-01-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000857"
      unitRef="Shares">1555555</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000859"
      unitRef="USDPShares">4.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-01-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember"
      id="Fact000861">2029-01-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-30_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000863"
      unitRef="USDPShares">4.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000865"
      unitRef="USDPShares">4.4999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000867"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <PCSA:StockIssuedDuringPeriodSharesExercised
      contextRef="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000869"
      unitRef="Shares">1079555</PCSA:StockIssuedDuringPeriodSharesExercised>
    <PCSA:GrossProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-292024-01-30_custom_PurchaseAgreementMember"
      decimals="-5"
      id="Fact000871"
      unitRef="USD">7000000.0</PCSA:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-292024-01-30_custom_PurchaseAgreementMember"
      decimals="-5"
      id="Fact000873"
      unitRef="USD">6300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_custom_ATMOfferingMember"
      decimals="INF"
      id="Fact000874"
      unitRef="Shares">800994</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31_custom_ATMOfferingMember"
      decimals="INF"
      id="Fact000875"
      unitRef="USDPShares">1.93</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_custom_ATMOfferingMember"
      decimals="-5"
      id="Fact000877"
      unitRef="USD">1500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_PurchaseAgreementMember_custom_PlacementAgentMember"
      decimals="INF"
      id="Fact000878"
      unitRef="Shares">62222</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_PurchaseAgreementMember_custom_PlacementAgentMember"
      decimals="INF"
      id="Fact000879"
      unitRef="USDPShares">5.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_PurchaseAgreementMember_custom_PlacementAgentMember"
      id="Fact000881">2027-02-01</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000883"
      unitRef="Shares">421611</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact000884"
      unitRef="Shares">28483</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-31_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact000885"
      unitRef="USDPShares">24.40</us-gaap:SharesIssuedPricePerShare>
    <PCSA:GrossProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31_custom_SalesAgreementMember"
      decimals="0"
      id="Fact000886"
      unitRef="USD">693000</PCSA:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31_custom_SalesAgreementMember"
      decimals="0"
      id="Fact000887"
      unitRef="USD">672000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000888"
      unitRef="Shares">2500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000889"
      unitRef="USDPShares">21.60</us-gaap:SharesIssuedPricePerShare>
    <PCSA:GrossProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      id="Fact000891"
      unitRef="USD">54000</PCSA:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-142023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember"
      decimals="INF"
      id="Fact000892"
      unitRef="Shares">390628</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember"
      decimals="INF"
      id="Fact000894"
      unitRef="USDPShares">16.00</us-gaap:SharesIssuedPricePerShare>
    <PCSA:GrossProceedsFromIssuanceOfCommonStock
      contextRef="From2023-02-142023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember"
      decimals="-5"
      id="Fact000895"
      unitRef="USD">6300000</PCSA:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-02-142023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember"
      decimals="-5"
      id="Fact000896"
      unitRef="USD">5600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <PCSA:TransactionCostsPercentage
      contextRef="AsOf2023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember"
      decimals="INF"
      id="Fact000898"
      unitRef="Pure">0.080</PCSA:TransactionCostsPercentage>
    <PCSA:ReimbursementFees
      contextRef="From2023-02-142023-02-14_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember"
      decimals="0"
      id="Fact000900"
      unitRef="USD">60000</PCSA:ReimbursementFees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact000902"
      unitRef="Shares">158007</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact000904"
      unitRef="USDPShares">20.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember"
      id="Fact000906">2026-04-17</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000908">&lt;p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zpRHUrmyAeo4" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_829_z0X4jL8t1nvg"&gt;Net Loss per Share of Common Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted average common stock outstanding (which excludes unvested RSAs) and
vested, but unissued RSUs. Diluted net loss per share is computed by dividing net loss by the diluted weighted average common stock outstanding,
which includes potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants. The treasury-stock method is
used to determine the dilutive effect of our stock options and warrants grants. Since we experienced a loss for both periods presented,
basic and diluted net loss per share are the same and, as they would have an anti-dilutive impact on diluted net loss per share, any
dilutive common shares outstanding were excluded from the computation shown below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ztC0TQL72M1g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of net loss per share for the year ended December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zof6YcQ0I1Ng" style="display: none"&gt;Schedule of Net Loss Per Share Basic and Diluted&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zD7hGGrZtbYb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_ztCaIABrWzKc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic and diluted net loss
    per share:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zvISSDNk0s4g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,850,118&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,121,520&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average number
    of common shares-basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zAXRoHMtpuKi" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zDAcUSp6rggj" title="Weighted average number of common shares-diluted"&gt;3,059,906&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_znY8l3lNV6C6" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z3UrPgxgOuO6" title="Weighted average number of common shares-diluted"&gt;1,311,572&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic and diluted net
    loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20240101__20241231_z4x0DgFmBZeh" title="Basic net loss per share"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_z74TIldS6lO4" title="Diluted net loss per share"&gt;(3.87&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zdM1LxYB6f4f" title="Basic net loss per share"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zPdcntEirbpf" title="Diluted net loss per share"&gt;(8.48&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average number of common
    shares outstanding &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuNa5O8XU0qc" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgRRORPEjkj" title="Weighted average number of common shares outstanding - diluted"&gt;2,912,539&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8kcd3MpdFAd" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXt8aX7sTIPg" title="Weighted average number of common shares outstanding - diluted"&gt;1,186,952&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average number
    of vested RSUs&#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_ziUYKHxO80j4" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zOz4sF7jb7G2" title="Weighted average number of vested RSUs - diluted"&gt;147,367&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_ze1IAvsJxQFc" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0KpRQcUpNk6" title="Weighted average number of vested RSUs - diluted"&gt;124,619&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average number
    of common shares-basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z6MJcpcwggpe" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_z4zDITZyKKw7" title="Weighted average number of common shares-diluted"&gt;3,059,906&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_z7dvCnzjGdPb" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z7pUlJLy7xZh" title="Weighted average number of common shares-diluted"&gt;1,311,572&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zwOrTfoFSMsa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
described in Note 3, we issued various equity instruments during the years ended December 31, 2024 and 2023 which impact our EPS calculation.
All granted RSAs are considered issued and outstanding for purposes of our financial statements. Unvested RSAs are included as dilutive
securities, but are excluded from our denominator of basic EPS. At December 31, 2023, &lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9IbvdijZrsa" title="Shares unvested"&gt;1,250&lt;/span&gt; RSAs were not vested and were excluded from
the EPS calculation. We had &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zZTn5E4vXSU6" title="Shares unvested"&gt;no&lt;/span&gt; unvested RSAs at December 31, 2024. Vested RSUs are included in our computation of the weighted average
shares for basic EPS and unvested RSUs are included as dilutive securities. At December 31, 2024 and 2023, &lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwIu6txRUIB" title="Shares unvested"&gt;234,623&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfXZPYv89od9" title="Shares unvested"&gt;102,623&lt;/span&gt; unvested
RSUs were excluded from the EPS calculation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zplRa7HBS542" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
outstanding stock options, unvested RSAs, unvested RSUs and warrants to purchase common stock were excluded from the computation of diluted
net loss per share as their effect would have been anti-dilutive for the periods presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zy0gGxkf4Eia" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_zvgAKxGK8DF6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zzInmJVIHRGe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zUIMPvmE7EHk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options, unvested RSAs, unvested
    RSUs and purchase warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,013,154&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;296,326&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z2DUNhfCbqO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000910">&lt;p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ztC0TQL72M1g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of net loss per share for the year ended December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zof6YcQ0I1Ng" style="display: none"&gt;Schedule of Net Loss Per Share Basic and Diluted&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zD7hGGrZtbYb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_ztCaIABrWzKc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic and diluted net loss
    per share:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zvISSDNk0s4g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,850,118&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,121,520&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average number
    of common shares-basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zAXRoHMtpuKi" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zDAcUSp6rggj" title="Weighted average number of common shares-diluted"&gt;3,059,906&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_znY8l3lNV6C6" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z3UrPgxgOuO6" title="Weighted average number of common shares-diluted"&gt;1,311,572&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic and diluted net
    loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20240101__20241231_z4x0DgFmBZeh" title="Basic net loss per share"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_z74TIldS6lO4" title="Diluted net loss per share"&gt;(3.87&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zdM1LxYB6f4f" title="Basic net loss per share"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zPdcntEirbpf" title="Diluted net loss per share"&gt;(8.48&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average number of common
    shares outstanding &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuNa5O8XU0qc" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgRRORPEjkj" title="Weighted average number of common shares outstanding - diluted"&gt;2,912,539&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8kcd3MpdFAd" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXt8aX7sTIPg" title="Weighted average number of common shares outstanding - diluted"&gt;1,186,952&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average number
    of vested RSUs&#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_ziUYKHxO80j4" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zOz4sF7jb7G2" title="Weighted average number of vested RSUs - diluted"&gt;147,367&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_ze1IAvsJxQFc" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0KpRQcUpNk6" title="Weighted average number of vested RSUs - diluted"&gt;124,619&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average number
    of common shares-basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z6MJcpcwggpe" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_z4zDITZyKKw7" title="Weighted average number of common shares-diluted"&gt;3,059,906&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_z7dvCnzjGdPb" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z7pUlJLy7xZh" title="Weighted average number of common shares-diluted"&gt;1,311,572&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000912"
      unitRef="USD">-11850118</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000913"
      unitRef="USD">-11121520</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000915"
      unitRef="Shares">3059906</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000917"
      unitRef="Shares">3059906</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000919"
      unitRef="Shares">1311572</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000921"
      unitRef="Shares">1311572</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000923"
      unitRef="USDPShares">-3.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000925"
      unitRef="USDPShares">-3.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000927"
      unitRef="USDPShares">-8.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000929"
      unitRef="USDPShares">-8.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000931"
      unitRef="Shares">2912539</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000933"
      unitRef="Shares">2912539</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000935"
      unitRef="Shares">1186952</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000937"
      unitRef="Shares">1186952</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember417833750"
      decimals="INF"
      id="Fact000939"
      unitRef="Shares">147367</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember417833750"
      decimals="INF"
      id="Fact000941"
      unitRef="Shares">147367</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember417833750"
      decimals="INF"
      id="Fact000943"
      unitRef="Shares">124619</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember417833750"
      decimals="INF"
      id="Fact000945"
      unitRef="Shares">124619</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000947"
      unitRef="Shares">3059906</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000949"
      unitRef="Shares">3059906</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000951"
      unitRef="Shares">1311572</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000953"
      unitRef="Shares">1311572</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact000955"
      unitRef="Shares">1250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact000957"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000959"
      unitRef="Shares">234623</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000961"
      unitRef="Shares">102623</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000963">&lt;p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zplRa7HBS542" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
outstanding stock options, unvested RSAs, unvested RSUs and warrants to purchase common stock were excluded from the computation of diluted
net loss per share as their effect would have been anti-dilutive for the periods presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zy0gGxkf4Eia" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_zvgAKxGK8DF6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zzInmJVIHRGe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zUIMPvmE7EHk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options, unvested RSAs, unvested
    RSUs and purchase warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,013,154&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;296,326&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000965"
      unitRef="Shares">2013154</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000966"
      unitRef="Shares">296326</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <PCSA:LesseeOperatingAndFinancingLeasesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000968">&lt;p id="xdx_806_ecustom--LesseeOperatingAndFinancingLeasesTextBlock_zVi78KPqPmPa" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_822_z6yTFOVp4tVf"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under an operating lease. Our leases do not provide an
implicit rate and, as such, we have used our incremental borrowing rate of &lt;span id="xdx_90F_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20241231_zoMaAm0GSjjf" title="Operating and financing lease borrowing rate"&gt;8&lt;/span&gt;% to determine the present value of the lease payments based
on the information available at the lease commencement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
costs included in our consolidated statements of operations totaled approximately $&lt;span id="xdx_904_eus-gaap--LeaseCost_c20240101__20241231_zhbK1hb52Yla" title="Lease cost"&gt;90,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--LeaseCost_c20230101__20231231_zf6Jn2Goq64f" title="Lease cost"&gt;97,000&lt;/span&gt; for the years ended December 31,
2024 and 2023, respectively. The weighted average remaining lease terms and discount rate for our operating leases at December 31, 2024
were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_znFw21XxbQ15" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B1_zL8HvYp8x371" style="display: none"&gt;Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Remaining lease term (years) for our office lease&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zqXsky4jypj3" title="Remaining lease term (years)"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_z4vZEn4XDTn6" title="Remaining lease term (years)"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Remaining lease term (years) for our equipment lease&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zOaMetDFtdX2" title="Remaining lease term (years)"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z5zJxd4m6F1" title="Remaining lease term (years)"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted average discount rate for our facility and equipment leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20241231_zUB8zwPiP7Fa" title="Weighted average discount rate for our facility and equipment leases"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20231231_zmEmpJsdLcsi" title="Weighted average discount rate for our facility and equipment leases"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A7_zKBHHoeqTpSj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMRYa9vAdA78" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for the operating lease were as follows at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zeWKMtOwI9Af" style="display: none"&gt;Schedule of Annual Lease Liabilities for all Operating Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20241231_zoEmIJPyAWFk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_ztLma9CsyeDh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70,040&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zOEtXm9V4krb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70,040&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z0N10jlv7Ldg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    Interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zT0heS5JvJ2f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66,905&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zEeJVhEdNdeh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zDKtp7BckTHa" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityCurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;Less:
    current maturities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(66,905&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zeAKPPrOxFMb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zB1x3vZ13zq8" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityNoncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;Non-current
    lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zcyoHwCUbVO9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zNGtCiTI2OZ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for the financing lease were as follows at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_z4ICQeLz6p74" style="display: none"&gt;Schedule of Annual Lease Liabilities for all Financing Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20241231_zFfHPZTHX9f7" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_zu77aSb5E7l8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,821&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzELQ_zMeY740iJsda" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;571&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_zJgKN8wrwWR5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,392&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_z3WtNPt2hZId" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    Interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(790&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zThN1ikNiGwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,602&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zoEv3801EW8d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zC8VrVM0EHMa" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityCurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1019"&gt;Less:
    current maturities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6,115&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zNmJYSo5KRoi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_z0jUbRXiOgnb" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityNoncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1022"&gt;Non-current
    lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;487&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_z8umzddRKmZ4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PCSA:LesseeOperatingAndFinancingLeasesTextBlock>
    <PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000970"
      unitRef="Pure">0.08</PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000972"
      unitRef="USD">90000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000974"
      unitRef="USD">97000</us-gaap:LeaseCost>
    <PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000976">&lt;p id="xdx_894_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_znFw21XxbQ15" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B1_zL8HvYp8x371" style="display: none"&gt;Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Remaining lease term (years) for our office lease&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zqXsky4jypj3" title="Remaining lease term (years)"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_z4vZEn4XDTn6" title="Remaining lease term (years)"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Remaining lease term (years) for our equipment lease&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zOaMetDFtdX2" title="Remaining lease term (years)"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z5zJxd4m6F1" title="Remaining lease term (years)"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted average discount rate for our facility and equipment leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20241231_zUB8zwPiP7Fa" title="Weighted average discount rate for our facility and equipment leases"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20231231_zmEmpJsdLcsi" title="Weighted average discount rate for our facility and equipment leases"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2024-12-31_custom_FacilityLeaseMember"
      id="Fact000978">P0Y9M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2023-12-31_custom_FacilityLeaseMember"
      id="Fact000980">P1Y9M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="AsOf2024-12-31_us-gaap_EquipmentMember"
      id="Fact000982">P1Y1M6D</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="AsOf2023-12-31_us-gaap_EquipmentMember"
      id="Fact000984">P0Y3M18D</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000986"
      unitRef="Pure">0.080</PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate>
    <PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000988"
      unitRef="Pure">0.080</PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000990">&lt;p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMRYa9vAdA78" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for the operating lease were as follows at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zeWKMtOwI9Af" style="display: none"&gt;Schedule of Annual Lease Liabilities for all Operating Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20241231_zoEmIJPyAWFk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_ztLma9CsyeDh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70,040&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zOEtXm9V4krb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70,040&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z0N10jlv7Ldg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    Interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zT0heS5JvJ2f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66,905&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zEeJVhEdNdeh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zDKtp7BckTHa" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityCurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;Less:
    current maturities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(66,905&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zeAKPPrOxFMb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zB1x3vZ13zq8" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityNoncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;Non-current
    lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000992"
      unitRef="USD">70040</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000994"
      unitRef="USD">70040</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000996"
      unitRef="USD">3135</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000998"
      unitRef="USD">66905</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001000"
      unitRef="USD">66905</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001006">&lt;p id="xdx_894_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zNGtCiTI2OZ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for the financing lease were as follows at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_z4ICQeLz6p74" style="display: none"&gt;Schedule of Annual Lease Liabilities for all Financing Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20241231_zFfHPZTHX9f7" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_zu77aSb5E7l8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,821&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzELQ_zMeY740iJsda" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;571&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_zJgKN8wrwWR5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,392&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_z3WtNPt2hZId" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    Interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(790&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zThN1ikNiGwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,602&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zoEv3801EW8d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zC8VrVM0EHMa" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityCurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1019"&gt;Less:
    current maturities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6,115&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zNmJYSo5KRoi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_z0jUbRXiOgnb" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20241231%23OperatingAndFinanceLeaseLiabilityNoncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1022"&gt;Non-current
    lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;487&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001008"
      unitRef="USD">6821</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001010"
      unitRef="USD">571</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001012"
      unitRef="USD">7392</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001014"
      unitRef="USD">790</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001016"
      unitRef="USD">6602</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001018"
      unitRef="USD">6115</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001021"
      unitRef="USD">487</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <PCSA:LicenseAgreementDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001024">&lt;p id="xdx_80C_ecustom--LicenseAgreementDisclosureTextBlock_zO0cQGBZrDZe" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_824_zkDXlM5abXlf"&gt;License Agreements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have entered into license agreements which allow us to develop, manufacture, and/or commercialize the following drug assets:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--LicenseAgreementsTableTextBlock_zuW2fUIKpKUd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B0_zDFwIjQmexUg" style="display: none"&gt;Schedule of License Agreements&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Licensor&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Drug
    Asset&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Agreement
    Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amendment
    Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Elion
    Oncology, Inc.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NGC-Cap
    (PCS6422)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--ElionOncologyIncMember_zZHD3RtVvUGb" title="Agreement Date"&gt;August
    23, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--LicenseAgreementsAmendmentDate_c20240101__20241231__dei--LegalEntityAxis__custom--ElionOncologyIncMember_zPgIpyDVHN07" title="Amendment Date"&gt;May
    17, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ocuphire
    Pharma, Inc.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NGC-Gem
    (PCS3117)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--OcuphirePharmaIncMember_zArfmSPmtob2" title="Agreement Date"&gt;June
    16, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Aposense,
    Ltd.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NGC-Iri
    (PCS11T)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--AposenseLtdMember_zbMYJ3AAwpm5" title="Agreement Date"&gt;May
    24, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Yuhan
    Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PCS12852&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--YuhanCorporationMember_zpBvzCkuV2y5" title="Agreement Date"&gt;August
    19, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CoNCERT
    Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PCS499&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--CoNCERTPharmaceuticalsIncMember_znHExZHEkPXg" title="Agreement Date"&gt;March
    19, 2018&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_z0YMxZkksEed" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt; For more information, you should
refer to the summaries described in the Business section of this Annual Report and the copies of such agreements, which have been filed
as exhibits to this Annual Report.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</PCSA:LicenseAgreementDisclosureTextBlock>
    <PCSA:LicenseAgreementsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001026">&lt;p id="xdx_89E_ecustom--LicenseAgreementsTableTextBlock_zuW2fUIKpKUd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B0_zDFwIjQmexUg" style="display: none"&gt;Schedule of License Agreements&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Licensor&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Drug
    Asset&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Agreement
    Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amendment
    Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Elion
    Oncology, Inc.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NGC-Cap
    (PCS6422)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--ElionOncologyIncMember_zZHD3RtVvUGb" title="Agreement Date"&gt;August
    23, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--LicenseAgreementsAmendmentDate_c20240101__20241231__dei--LegalEntityAxis__custom--ElionOncologyIncMember_zPgIpyDVHN07" title="Amendment Date"&gt;May
    17, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ocuphire
    Pharma, Inc.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NGC-Gem
    (PCS3117)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--OcuphirePharmaIncMember_zArfmSPmtob2" title="Agreement Date"&gt;June
    16, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Aposense,
    Ltd.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NGC-Iri
    (PCS11T)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--AposenseLtdMember_zbMYJ3AAwpm5" title="Agreement Date"&gt;May
    24, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Yuhan
    Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PCS12852&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--YuhanCorporationMember_zpBvzCkuV2y5" title="Agreement Date"&gt;August
    19, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CoNCERT
    Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PCS499&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--LicenseAgreementsDate_c20240101__20241231__dei--LegalEntityAxis__custom--CoNCERTPharmaceuticalsIncMember_znHExZHEkPXg" title="Agreement Date"&gt;March
    19, 2018&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</PCSA:LicenseAgreementsTableTextBlock>
    <PCSA:LicenseAgreementsDate
      contextRef="From2024-01-012024-12-31_custom_ElionOncologyIncMember"
      id="Fact001028">2020-08-23</PCSA:LicenseAgreementsDate>
    <PCSA:LicenseAgreementsAmendmentDate
      contextRef="From2024-01-012024-12-31_custom_ElionOncologyIncMember"
      id="Fact001030">2022-05-17</PCSA:LicenseAgreementsAmendmentDate>
    <PCSA:LicenseAgreementsDate
      contextRef="From2024-01-012024-12-31_custom_OcuphirePharmaIncMember"
      id="Fact001032">2021-06-16</PCSA:LicenseAgreementsDate>
    <PCSA:LicenseAgreementsDate
      contextRef="From2024-01-012024-12-31_custom_AposenseLtdMember"
      id="Fact001034">2020-05-24</PCSA:LicenseAgreementsDate>
    <PCSA:LicenseAgreementsDate
      contextRef="From2024-01-012024-12-31_custom_YuhanCorporationMember"
      id="Fact001036">2020-08-19</PCSA:LicenseAgreementsDate>
    <PCSA:LicenseAgreementsDate
      contextRef="From2024-01-012024-12-31_custom_CoNCERTPharmaceuticalsIncMember"
      id="Fact001038">2018-03-19</PCSA:LicenseAgreementsDate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001040">&lt;p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zfZapyG0kJb9" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
8 - &lt;span id="xdx_823_zuZlvlWoD9ah"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have incurred net operating losses since inception. At December 31, 2024 and 2023, we had available federal and state net operating loss
carryforwards of $&lt;span id="xdx_901_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20241231_zu2k74JD3bHc" title="Deferred tax assets, capital loss carryforwards"&gt;36.0&lt;/span&gt; million and $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20231231_zwPyrmTyV034" title="Deferred tax assets, capital loss carryforwards"&gt;28.6&lt;/span&gt; million, respectively. The federal net operating losses generated in 2018 and later of $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--TaxCreditCarryforwardAxis__custom--FederalMember_zbExmqLhP4wl" title="Net operating loss carryforwards"&gt;29.3&lt;/span&gt;
million will carry forward indefinitely. Net operating losses generated prior to 2018 will expire &lt;span id="xdx_907_ecustom--NetOperatingLossCarryforwardExpiryDate_c20240101__20241231_zXojIORC0Ovh" title="Net operating loss carryforward, expiration date"&gt;2037&lt;/span&gt;. We have not recognized any deferred
tax assets related to the federal orphan drug or other research and development tax credits as of December 31, 2024 or 2023. The federal
research and development tax credits have a &lt;span id="xdx_902_ecustom--NetOperatingLossCarryforwardTerm_dtY_c20240101__20241231_zurUtY1C19Lj" title="Net operating loss carryforward term"&gt;20&lt;/span&gt;-year carryforward period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231_z8IRnB35ZVC" title="Income tax examination description"&gt;Pursuant
to Code Sec. 382 of the Internal Revenue Code (&#x201c;the Code&#x201d;), the utilization of our net operating loss carryforwards could
be limited as a result of a cumulative change in stock ownership of more than 50% over a three-year period. We have not completed a Sec.
382 study and as such our net operating loss carryforwards may be subject to such limitation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwt2GrubCQIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of our effective income tax rate and statutory income tax rate for the years ended December 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zJABXTlKqHO4" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zwtvD2OueJRd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zdLvUfSOZch4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_zfEZgCXxUCD6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zAbAVBiqBEr3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State tax rate, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.58&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.77&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential_pid_dp_uPure_maEIT001_zJzhlselhuj4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.04&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msEIT001_z8lFLos2qbXc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal orphan drug tax credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.05&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.41&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zqt7BJVx8Hgf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax asset valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(26.59&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(27.93&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zcOl9omLdlP7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Effective income tax
    rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zjJJH1oc9f4f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zwQXe0HxRsVg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
significant components of our deferred tax assets and liabilities for Federal and state income taxes consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 21.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zw9z2aDyk6Sa" style="display: none"&gt;Schedule of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zSzN8iRkrpXl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_zn2bWa0RGskl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_maDTAGzhSD_zTh70Z6GDAH5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating
    loss carry forward &#x2013; Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,566,071&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,012,941&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_maDTAGzhSD_zW9YDjrfqMK5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating loss carry
    forward &#x2013; State&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,074,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,672,436&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzhSD_z4FqIL4VIpR6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,794,226&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,453,799&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzhSD_z7fRjgnCxBQf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation and other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;238&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;999&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected_iI_maDTAGzhSD_zGfvk5GSnpIk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Purchased in-process R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,477,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,500,562&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsFederalOrphanDrugCredits_iI_maDTAGzhSD_zSfvfuU57t0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal orphan drug credits&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,209,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,202,955&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_iI_maDTAGzhSD_zbtbcRxTIGUd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Capitalized research and
    development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,781,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,795,379&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsStartupExpenditures_iI_maDTAGzhSD_z0OVEdAjESwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Start-up
    expenditures and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1097"&gt;-&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1098"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzhSD_maDTANzhKZ_zwKhCno95VK8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total non-current deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,902,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,639,071&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzhKZ_zuiwq3AZK1pd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation allowance for
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(19,902,665&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(17,639,071&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzhKZ_msDTLznZn_zUpYY4GNVbXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1106"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1107"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzSHY_zWFnpWlHTZu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
    asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1109"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1110"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzSHY_maDTLznZn_z3jxlwImi8rj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total non-current deferred
    tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLznZn_zwMFvmmOLge9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred tax asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1115"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zTuvhC4Qy5Dk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beginning
in 2022, the Tax Cuts and Jobs Act of 2017 (TCJA) eliminated the option to deduct research and development expenditures in the current
year and requires taxpayers to amortize them over five or fifteen years pursuant to IRC Section 174. During 2024 and 2023, for income
tax purposes, we capitalized approximately $&lt;span id="xdx_907_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization_iI_pn5n6_c20241231_z5GYIHJbIjb" title="Capitalized research and development net of amortization"&gt;3.8&lt;/span&gt; million and $&lt;span id="xdx_901_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization_iI_pn5n6_c20231231_zBoS4puIgsih" title="Capitalized research and development net of amortization"&gt;3.2&lt;/span&gt; million of research and development expenditures, net of amortization
of these costs in each year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
valuation allowance generally reflects limitations on our ability to use the tax attributes and reduces the value of such attributes
to the more-likely-than-not realizable amount. We assessed the available positive and negative evidence to estimate if sufficient taxable
income will be generated to use the existing net deferred tax assets. Based on a weighing of the objectively verifiable negative evidence
primarily in the form of cumulative operating losses, we believe that it is not more-likely-than-not that the deferred tax assets will
be realized and, accordingly, a full valuation allowance has been established. The valuation allowance increased by $&lt;span id="xdx_906_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zYtD407Q6euc" title="Valuation allowance deferred tax asset"&gt;2.3&lt;/span&gt; million
and $&lt;span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231_z7KaIjxstrdg" title="Valuation allowance deferred tax asset"&gt;3.1&lt;/span&gt; million for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
recognize potential liabilities for uncertain tax positions using a two-step process. The first step is to evaluate the tax position
for recognition by determining if the weight of available evidence indicates that it is more-likely-than-not that the position will be
sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit
as the largest amount that is more than 50% likely to be realized upon settlement. We have not recorded any uncertain tax positions.
As of December 31, 2024 and 2023, we had &lt;span id="xdx_903_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20240101__20241231_zwcpn4NhdAR3" title="Penalties and interest expense"&gt;&lt;span id="xdx_904_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20230101__20231231_zbE4XGrJwUE1" title="Penalties and interest expense"&gt;no&lt;/span&gt;&lt;/span&gt; accrued penalties or interest related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
file U.S. Federal income tax returns, as well as state tax returns for California, Florida and Maryland. There are currently no income
tax examinations underway for these jurisdictions. However, tax years from and including 2017 remain open for examination by federal
and state income tax authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001042"
      unitRef="USD">36000000.0</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001044"
      unitRef="USD">28600000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_custom_FederalMember"
      decimals="-5"
      id="Fact001046"
      unitRef="USD">29300000</us-gaap:OperatingLossCarryforwards>
    <PCSA:NetOperatingLossCarryforwardExpiryDate contextRef="From2024-01-01to2024-12-31" id="Fact001048">2037</PCSA:NetOperatingLossCarryforwardExpiryDate>
    <PCSA:NetOperatingLossCarryforwardTerm contextRef="From2024-01-01to2024-12-31" id="Fact001050">P20Y</PCSA:NetOperatingLossCarryforwardTerm>
    <us-gaap:IncomeTaxExaminationDescription contextRef="From2024-01-01to2024-12-31" id="Fact001052">Pursuant
to Code Sec. 382 of the Internal Revenue Code (&#x201c;the Code&#x201d;), the utilization of our net operating loss carryforwards could
be limited as a result of a cumulative change in stock ownership of more than 50% over a three-year period. We have not completed a Sec.
382 study and as such our net operating loss carryforwards may be subject to such limitation.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001054">&lt;p id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwt2GrubCQIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of our effective income tax rate and statutory income tax rate for the years ended December 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zJABXTlKqHO4" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zwtvD2OueJRd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zdLvUfSOZch4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_zfEZgCXxUCD6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zAbAVBiqBEr3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State tax rate, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.58&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.77&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential_pid_dp_uPure_maEIT001_zJzhlselhuj4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.04&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msEIT001_z8lFLos2qbXc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal orphan drug tax credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.05&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.41&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zqt7BJVx8Hgf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax asset valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(26.59&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(27.93&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zcOl9omLdlP7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Effective income tax
    rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001056"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001057"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001059"
      unitRef="Pure">0.0558</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001060"
      unitRef="Pure">0.0577</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <PCSA:EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001062"
      unitRef="Pure">-0.0004</PCSA:EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential>
    <PCSA:EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001063"
      unitRef="Pure">-0.0025</PCSA:EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001065"
      unitRef="Pure">-0.0005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001066"
      unitRef="Pure">-0.0141</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001068"
      unitRef="Pure">-0.2659</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001069"
      unitRef="Pure">-0.2793</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001071"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001072"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001074">&lt;p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zwQXe0HxRsVg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
significant components of our deferred tax assets and liabilities for Federal and state income taxes consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 21.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zw9z2aDyk6Sa" style="display: none"&gt;Schedule of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zSzN8iRkrpXl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_zn2bWa0RGskl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_maDTAGzhSD_zTh70Z6GDAH5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating
    loss carry forward &#x2013; Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,566,071&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,012,941&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_maDTAGzhSD_zW9YDjrfqMK5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating loss carry
    forward &#x2013; State&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,074,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,672,436&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzhSD_z4FqIL4VIpR6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,794,226&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,453,799&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzhSD_z7fRjgnCxBQf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation and other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;238&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;999&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected_iI_maDTAGzhSD_zGfvk5GSnpIk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Purchased in-process R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,477,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,500,562&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsFederalOrphanDrugCredits_iI_maDTAGzhSD_zSfvfuU57t0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal orphan drug credits&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,209,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,202,955&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_iI_maDTAGzhSD_zbtbcRxTIGUd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Capitalized research and
    development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,781,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,795,379&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsStartupExpenditures_iI_maDTAGzhSD_z0OVEdAjESwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Start-up
    expenditures and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1097"&gt;-&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1098"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzhSD_maDTANzhKZ_zwKhCno95VK8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total non-current deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,902,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,639,071&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzhKZ_zuiwq3AZK1pd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation allowance for
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(19,902,665&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(17,639,071&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzhKZ_msDTLznZn_zUpYY4GNVbXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1106"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1107"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzSHY_zWFnpWlHTZu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
    asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1109"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1110"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzSHY_maDTLznZn_z3jxlwImi8rj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total non-current deferred
    tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLznZn_zwMFvmmOLge9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred tax asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1115"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001076"
      unitRef="USD">7566071</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001077"
      unitRef="USD">6012941</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001079"
      unitRef="USD">2074542</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001080"
      unitRef="USD">1672436</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001082"
      unitRef="USD">2794226</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001083"
      unitRef="USD">3453799</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001085"
      unitRef="USD">238</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001086"
      unitRef="USD">999</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <PCSA:DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001088"
      unitRef="USD">2477193</PCSA:DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected>
    <PCSA:DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001089"
      unitRef="USD">2500562</PCSA:DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected>
    <PCSA:DeferredTaxAssetsFederalOrphanDrugCredits
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001091"
      unitRef="USD">1209202</PCSA:DeferredTaxAssetsFederalOrphanDrugCredits>
    <PCSA:DeferredTaxAssetsFederalOrphanDrugCredits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001092"
      unitRef="USD">1202955</PCSA:DeferredTaxAssetsFederalOrphanDrugCredits>
    <PCSA:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001094"
      unitRef="USD">3781193</PCSA:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <PCSA:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001095"
      unitRef="USD">2795379</PCSA:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001100"
      unitRef="USD">19902665</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001101"
      unitRef="USD">17639071</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001103"
      unitRef="USD">19902665</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001104"
      unitRef="USD">17639071</us-gaap:DeferredTaxAssetsValuationAllowance>
    <PCSA:DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001118"
      unitRef="USD">3800000</PCSA:DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization>
    <PCSA:DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001120"
      unitRef="USD">3200000</PCSA:DeferredTaxAssetsCapitalizedResearchAndDevelopmentNetOfAmortization>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001122"
      unitRef="USD">2300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact001124"
      unitRef="USD">3100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001126"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001128"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001130">&lt;p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zGbXBtfiGVWe" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_820_zZjW4RWdDjyj"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CorLyst,
LLC (&#x201c;CorLyst&#x201d;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred,
which are recognized as a reduction of our general and administrative operating expenses in our consolidated statements of operations.
We recorded approximately $&lt;span id="xdx_908_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20240101__20241231__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_z3AV2FCnoFU6" title="Rent and other costs reimbursements received"&gt;110,000&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zxuogKjgmsUi" title="Rent and other costs reimbursements received"&gt;112,000&lt;/span&gt; in reimbursements during the years ended December 31, 2024 and 2023, respectively. At
December 31, 2024, $&lt;span id="xdx_902_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20241231__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_z5wEpLThZvYk" title="Due from related parties"&gt;47&lt;/span&gt; was due from CorLyst and &lt;span id="xdx_909_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zJuxQlB8JlEl" title="Due from related parties"&gt;no&lt;/span&gt; amounts were due at December 31, 2023. Our President, Research and Development is
the CEO of CorLyst, and CorLyst is a shareholder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <PCSA:ProceedsFromRentAndOtherCostsReimbursements
      contextRef="From2024-01-012024-12-31_custom_CorLystLLCMember"
      decimals="0"
      id="Fact001132"
      unitRef="USD">110000</PCSA:ProceedsFromRentAndOtherCostsReimbursements>
    <PCSA:ProceedsFromRentAndOtherCostsReimbursements
      contextRef="From2023-01-012023-12-31_custom_CorLystLLCMember"
      decimals="0"
      id="Fact001134"
      unitRef="USD">112000</PCSA:ProceedsFromRentAndOtherCostsReimbursements>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-12-31_custom_CorLystLLCMember"
      decimals="0"
      id="Fact001136"
      unitRef="USD">47</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31_custom_CorLystLLCMember"
      decimals="0"
      id="Fact001138"
      unitRef="USD">0</us-gaap:OtherReceivablesNetCurrent>
    <PCSA:LitigationDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001140">&lt;p id="xdx_80E_ecustom--LitigationDisclosureTextBlock_zlbGTNK0EM71" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;&lt;b&gt;Note 10
&#x2013; &lt;span id="xdx_82E_zfQbsmeXJKJf"&gt;Litigation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="background-color: white"&gt;On
May 7, 2024, the Company received notification from Elion purporting to terminate the license agreement by and between the Company and
Elion as a result of the Company&#x2019;s alleged breach thereof. The Company believes that Elion&#x2019;s claims are without merit and
disputes that the license agreement has been validly terminated. On July 5, 2024, the Company filed a complaint in New York State Court
seeking monetary damages, declaratory judgement and injunctive relief. On August 14, 2024, the Company received Elion&#x2019;s answer and
counterclaims. On October 10, 2024, the Company filed its response to Elion&#x2019;s counterclaims. The Company intends to enforce its
rights under the license agreement and will pursue such other remedies as it determines are appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="background-color: white"&gt;On
December 3, 2024, Jason Assad and Marc Gyimesi, two of the investors in our February 2021 private offering, filed a lawsuit in New York
County Court alleging fraud and negligent misrepresentation in connection therewith and seeking monetary damages.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="background-color: white"&gt;We
intend to vigorously defend ourselves in these lawsuits and cannot at this time predict the likely outcome of any litigation, reasonably
determine either the probability of a material adverse result or any estimated range of potential exposure, or reasonably determine how
these matters or any future matters might impact our business, our financial condition, or our results of operations, although such impact,
including the costs of defense, as well as any judgments or indemnification obligations, among other things, could be materially adverse
to us.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</PCSA:LitigationDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001142">&lt;p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_z3Ver1nv0cti" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 11 &#x2013;
&lt;span id="xdx_826_zJcrXtO9w3ab"&gt;Segment Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt"&gt;We
manage our operations as a single segment, focused on developing the next generation of cancer therapy drugs. As our CODM, our CEO manages
and allocates resources at a consolidated level. He assesses performance, monitors budget versus actual results, and decides how to allocate
resources based on net loss that also is reported on the consolidated statement of operations and comprehensive loss as consolidated net
loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt"&gt;The
accounting policies of our single operating segment are the same as those described in the summary of significant accounting policies
in Note 2. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. In 2024 and 2023,
all our long-lived assets were held in the United States. Expenditures for the addition of long-lived assets are reported on the consolidated
statements of cash flows as purchases of property and equipment. We do not have intra-entity sales or transfers since our only subsidiary
is currently dormant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_z25iEhybPU2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt"&gt;The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B0_zLIfRicpOYJb" style="display: none; font-family: Times New Roman, Times, Serif"&gt;Schedule
of Reportable Segment Profit and Loss, Including Significant Expense Categories&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zAnLjiL2NMwc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_z5DpZyRfuHSf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--PreclinicalClinicalTrialAndOtherCosts_msNILzaqM_zJgImA2CqUx9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"&gt;Preclinical, clinical trial and other costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;5,450,963&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;3,817,669&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_ze2sg5BHQyE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development personnel expense&lt;sup id="xdx_F45_zI38usS3yZ05" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,818,183&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,981,849&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_msNILzaqM_zAxhz0moFkLb" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expense&lt;span&gt;&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_z6WgPoxEZaN4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General and administrative personnel expense&lt;sup id="xdx_F45_zgShVznxBUTa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,981,756&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,737,792&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_msNILzaqM_zh7jxUMLZp61" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General and administrative expense&lt;sup style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--AdministrativeAndFacilitiesExpense_msNILzaqM_zAhzTBc9TFVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Administrative and facilities expense&lt;sup id="xdx_F4F_zwJTbuSjIAc2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,800,304&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,919,751&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InvestmentIncomeInterest_iN_di_maNILzaqM_zCkaNoOQbq32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Interest income, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(201,088&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(335,541&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtNILzaqM_zahXuwdY0E32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,850,118&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,121,520&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;sup id="xdx_F0B_zmU81x7sUVcd"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_zPsqjYqgI5r5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Research
and development personnel costs include employee stock-based compensation expense of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqBDe7kz9TZ2" title="Research and development personnel costs include employee stock-based compensation expense"&gt;169,414&lt;/span&gt; and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zZEE1TTtC5Ja" title="Research and development personnel costs include employee stock-based compensation expense"&gt;363,956&lt;/span&gt; for the year ended December
31, 2024, and 2023, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;sup id="xdx_F07_zP9lRgsLHKZj"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_zJFW1grtFjYh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;General
and administrative personnel costs include employee stock-based compensation expense of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_zCX8mmnoY3n6" title="General and administrative personnel costs include employee stock-based compensation expense"&gt;186,925&lt;/span&gt; and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_z490ruzWdrCi" title="General and administrative personnel costs include employee stock-based compensation expense"&gt;387,854&lt;/span&gt; for the year ended December
31, 2024, and 2023, respectively, and are net of reimbursements received from CorLyst, LLC.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;sup id="xdx_F09_zEzn2b7zhIq6"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_zcOiJ6oVqRI7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Administrative
&amp;amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and
other administrative costs.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A8_zfSCKHyaa56f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001144">&lt;p id="xdx_89B_eus-gaap--ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_z25iEhybPU2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt"&gt;The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B0_zLIfRicpOYJb" style="display: none; font-family: Times New Roman, Times, Serif"&gt;Schedule
of Reportable Segment Profit and Loss, Including Significant Expense Categories&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zAnLjiL2NMwc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_z5DpZyRfuHSf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--PreclinicalClinicalTrialAndOtherCosts_msNILzaqM_zJgImA2CqUx9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"&gt;Preclinical, clinical trial and other costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;5,450,963&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;3,817,669&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_ze2sg5BHQyE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development personnel expense&lt;sup id="xdx_F45_zI38usS3yZ05" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,818,183&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,981,849&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_msNILzaqM_zAxhz0moFkLb" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expense&lt;span&gt;&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_z6WgPoxEZaN4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General and administrative personnel expense&lt;sup id="xdx_F45_zgShVznxBUTa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,981,756&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,737,792&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_msNILzaqM_zh7jxUMLZp61" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General and administrative expense&lt;sup style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--AdministrativeAndFacilitiesExpense_msNILzaqM_zAhzTBc9TFVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Administrative and facilities expense&lt;sup id="xdx_F4F_zwJTbuSjIAc2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,800,304&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,919,751&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InvestmentIncomeInterest_iN_di_maNILzaqM_zCkaNoOQbq32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Interest income, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(201,088&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(335,541&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtNILzaqM_zahXuwdY0E32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,850,118&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,121,520&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;sup id="xdx_F0B_zmU81x7sUVcd"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_zPsqjYqgI5r5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Research
and development personnel costs include employee stock-based compensation expense of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqBDe7kz9TZ2" title="Research and development personnel costs include employee stock-based compensation expense"&gt;169,414&lt;/span&gt; and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zZEE1TTtC5Ja" title="Research and development personnel costs include employee stock-based compensation expense"&gt;363,956&lt;/span&gt; for the year ended December
31, 2024, and 2023, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;sup id="xdx_F07_zP9lRgsLHKZj"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_zJFW1grtFjYh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;General
and administrative personnel costs include employee stock-based compensation expense of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_zCX8mmnoY3n6" title="General and administrative personnel costs include employee stock-based compensation expense"&gt;186,925&lt;/span&gt; and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_z490ruzWdrCi" title="General and administrative personnel costs include employee stock-based compensation expense"&gt;387,854&lt;/span&gt; for the year ended December
31, 2024, and 2023, respectively, and are net of reimbursements received from CorLyst, LLC.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;sup id="xdx_F09_zEzn2b7zhIq6"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_zcOiJ6oVqRI7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Administrative
&amp;amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and
other administrative costs.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock>
    <PCSA:PreclinicalClinicalTrialAndOtherCosts
      contextRef="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact001146"
      unitRef="USD">5450963</PCSA:PreclinicalClinicalTrialAndOtherCosts>
    <PCSA:PreclinicalClinicalTrialAndOtherCosts
      contextRef="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact001147"
      unitRef="USD">3817669</PCSA:PreclinicalClinicalTrialAndOtherCosts>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact001149"
      unitRef="USD">1818183</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact001150"
      unitRef="USD">1981849</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact001155"
      unitRef="USD">1981756</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact001156"
      unitRef="USD">1737792</us-gaap:GeneralAndAdministrativeExpense>
    <PCSA:AdministrativeAndFacilitiesExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact001161"
      unitRef="USD">2800304</PCSA:AdministrativeAndFacilitiesExpense>
    <PCSA:AdministrativeAndFacilitiesExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact001162"
      unitRef="USD">3919751</PCSA:AdministrativeAndFacilitiesExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact001164"
      unitRef="USD">201088</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact001165"
      unitRef="USD">335541</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact001167"
      unitRef="USD">11850118</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact001168"
      unitRef="USD">11121520</us-gaap:NetIncomeLoss>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001171"
      unitRef="USD">169414</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001173"
      unitRef="USD">363956</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_custom_CorLystLLCMember"
      decimals="0"
      id="Fact001176"
      unitRef="USD">186925</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_custom_CorLystLLCMember"
      decimals="0"
      id="Fact001178"
      unitRef="USD">387854</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001181">&lt;p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zbNWT4PynzGb" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
12 &#x2013; &lt;span id="xdx_82B_z0d6S1detV75"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Purchase
Obligations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
enter contracts in the normal course of business with contract research organizations and subcontractors to further develop our products.
The contracts are cancellable, with varying provisions regarding termination. If we terminated a cancellable contract with a specific
vendor, we would only be obligated for products or services that we received as of the effective date of the termination and any applicable
cancellation fees. As of December 31, 2024, we are contractually obligated to pay up to approximately $&lt;span id="xdx_90B_eus-gaap--PurchaseObligation_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--CROsMember_zuJLWgOG4oZ" title="Purchase obligation"&gt;12.2&lt;/span&gt; million for future services
under the agreements with the CROs for our clinical trials in NGC-Cap. Our actual contractual obligations will also vary depending on
the progress and results of the remaining clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="AsOf2024-12-31_custom_CROsMember"
      decimals="-5"
      id="Fact001183"
      unitRef="USD">12200000</us-gaap:PurchaseObligation>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001185">&lt;p id="xdx_805_eus-gaap--ConcentrationRiskDisclosureTextBlock_zrg4QKCv4zNh" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
13 &#x2013; &lt;span id="xdx_822_z5VupWP4iq48"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at December 31, 2024, exceeded FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001187">&lt;p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_z3L1q01Inzg8" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
14 &#x2013; &lt;span id="xdx_82D_zqr7bkDBZ4j1"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Public Offering&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 27, 2025, we sold, pursuant to securities purchase agreements (the &#x201c;Purchase Agreement&#x201d;), &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zemSGCgLLC41" title="Number of shares, sold"&gt;1,030,972&lt;/span&gt; shares of our
common stock and accompanying Series A warrants to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z7esswsEqYbb" title="Warrants to purchase"&gt;8,050,672&lt;/span&gt; shares of our common stock (the &#x201c;Series A Warrants&#x201d;)
and Series B warrants to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjdkB6fQqNg2" title="Warrants to purchase"&gt;4,025,336&lt;/span&gt; shares of our common stock (the &#x201c;Series B Warrants&#x201d; and collectively with
the Series A Warrants, the &#x201c;Common Warrants&#x201d;) at a combined purchase price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zHff3iUiYJh3" title="Warrant exercise price"&gt;0.615&lt;/span&gt; for institutional investors and $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndCertainBoardMembersMember_zEnldQHctb9d" title="Warrant exercise price"&gt;0.7975&lt;/span&gt;
for the Company&#x2019;s Chief Executive Officer and certain board members. The Series A and Series B Warrants both have an exercise price
of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAAndBMember_zSMNu24czw91" title="Warrant exercise price"&gt;0.65&lt;/span&gt; per share of common stock, and will be exercisable beginning on the effective date of stockholder approval of the issuance of
the shares upon exercise of the warrants (&#x201c;Warrant Stockholder Approval&#x201d;). The Series A Warrants will expire on the &lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zTeIE5PAYmcd" title="Warrants, exercisable term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1201"&gt;five&lt;/span&gt;&lt;/span&gt;-year
anniversary date of stockholder approval and the Series B Warrants will expire on the eighteen-month anniversary date of stockholder
approval.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
also sold pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zY046aFfT4Y2" title="Warrants to purchase"&gt;7,019,700&lt;/span&gt;
shares of our common stock to a purchaser whose purchase of shares of common stock in the public offering would have resulted in the
purchaser beneficially owning more than &lt;span id="xdx_90D_ecustom--OutstandingSharesPercentage_pid_dp_uPure_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zDaE3QiKW3O6" title="Outstanding shares percentage, maximum"&gt;9.99&lt;/span&gt;%
of our outstanding common stock immediately following the consummation of the public offering. Each Pre-Funded Warrant is
exercisable for one share of common stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zK19Kj8JuNu" title="Warrant exercise price"&gt;0.0001&lt;/span&gt;
per share of common stock. The public offering price per Pre-Funded Warrant, is equal to the public offering price per share and
Common Warrants less $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEyldy0iO96a" title="Warrant exercise price"&gt;0.0001&lt;/span&gt;.
Each Pre-Funded Warrant will be exercisable upon issuance and will expire when exercised in full. On January 30, 2025, Pre-Funded
Warrants to purchase &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zFkI624LWxrb" title="Warrants to purchase"&gt;525,700&lt;/span&gt;
shares of our common stock were exercised and, as of March 12, 2025, Pre-Funded Warrants for the purchase of &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250312__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zox4kV6cRIS6" title="Warrants outstanding"&gt;6,494,000&lt;/span&gt; remain outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gross
proceeds in connection with this offering were $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_za3Ru8kSC2i8" title="Gross proceeds"&gt;5.0&lt;/span&gt; million and we received $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250127__20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMkAYfauTM7e" title="Net proceeds"&gt;4.5&lt;/span&gt; million in net proceeds from the offering, after deducting
the fees of the placement agent and other offering-related expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Amended
and Restated Bylaws&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 18, 2025, the Board of Directors (the &#x201c;Board&#x201d;) of the Company adopted the Amended and Restated Bylaws (as
amended, the &#x201c;Bylaws&#x201d;). The Bylaws, which became effective immediately, amended Section 2.4 to change the quorum requirements
for a stockholders meeting to be the holders of shares of outstanding capital stock of the Company representing one third (1/3) of the
voting power of all outstanding shares of capital stock of the Company except if business is to be voted on by a class or series of stock
voting as a class, then the holders of shares representing one third (1/3) of the voting power of the outstanding shares of such class
or series shall constitute a quorum.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Executive
Employment Agreements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;On March 19, 2025, we entered into new or amended employment agreements with all members of our executive team
that continue until terminated or modified pursuant to the terms of the employment agreements. The agreements establish their base salaries,
target bonuses, eligibility to participate in our 2019 Omnibus Incentive Plan, and severance benefits, among other things.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-272025-01-27_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001189"
      unitRef="Shares">1030972</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_SeriesAWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001191"
      unitRef="Shares">8050672</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_SeriesBWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001193"
      unitRef="Shares">4025336</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001195"
      unitRef="USDPShares">0.615</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_ChiefExecutiveOfficerAndCertainBoardMembersMember"
      decimals="INF"
      id="Fact001197"
      unitRef="USDPShares">0.7975</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_SeriesAAndBMember"
      decimals="INF"
      id="Fact001199"
      unitRef="USDPShares">0.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember"
      decimals="INF"
      id="Fact001203"
      unitRef="Shares">7019700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <PCSA:OutstandingSharesPercentage
      contextRef="From2025-01-272025-01-27_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember"
      decimals="INF"
      id="Fact001205"
      unitRef="Pure">0.0999</PCSA:OutstandingSharesPercentage>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember"
      decimals="INF"
      id="Fact001207"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001209"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-30_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember"
      decimals="INF"
      id="Fact001211"
      unitRef="Shares">525700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-03-12_us-gaap_SubsequentEventMember_custom_PreFundedWarrantMember"
      decimals="INF"
      id="Fact001213"
      unitRef="Shares">6494000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-01-272025-01-27_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001215"
      unitRef="USD">5000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-272025-01-27_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001217"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact001218">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact001219">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact001220">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact001221">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2024-01-01to2024-12-31" id="Fact001222">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001149"
          xlink:label="Fact001149"
          xlink:type="locator"/>
        <link:footnote id="Footnote001169" xlink:label="Footnote001169" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Research
and development personnel costs include employee stock-based compensation expense of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqBDe7kz9TZ2"
  title="Research and development personnel costs include employee stock-based compensation expense">169,414</xhtml:span> and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zZEE1TTtC5Ja"
  title="Research and development personnel costs include employee stock-based compensation expense">363,956</xhtml:span> for the year ended December
31, 2024, and 2023, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001149"
          xlink:to="Footnote001169"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001150"
          xlink:label="Fact001150"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001150"
          xlink:to="Footnote001169"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001155"
          xlink:label="Fact001155"
          xlink:type="locator"/>
        <link:footnote id="Footnote001174" xlink:label="Footnote001174" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">General
and administrative personnel costs include employee stock-based compensation expense of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_zCX8mmnoY3n6"
  title="General and administrative personnel costs include employee stock-based compensation expense">186,925</xhtml:span> and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__dei--LegalEntityAxis__custom--CorLystLLCMember_z490ruzWdrCi"
  title="General and administrative personnel costs include employee stock-based compensation expense">387,854</xhtml:span> for the year ended December
31, 2024, and 2023, respectively, and are net of reimbursements received from CorLyst, LLC.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001155"
          xlink:to="Footnote001174"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001156"
          xlink:label="Fact001156"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001156"
          xlink:to="Footnote001174"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001161"
          xlink:label="Fact001161"
          xlink:type="locator"/>
        <link:footnote id="Footnote001179" xlink:label="Footnote001179" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Administrative
&amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and
other administrative costs.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001161"
          xlink:to="Footnote001179"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001162"
          xlink:label="Fact001162"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001162"
          xlink:to="Footnote001179"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
